FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Khandpur, U
   Huntoon, K
   Smith-Cohn, M
   Shaw, A
   Elder, JB
AF Khandpur, Umang
   Huntoon, Kristin
   Smith-Cohn, Matthew
   Shaw, Andrew
   Elder, James Bradley
TI Bilateral Recurrent Dysplastic Cerebellar Gangliocytoma
   (Lhermitte-Duclos Disease) in Cowden Syndrome: A Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebellum neoplasia; Cowden syndrome; Dysplastic gangliocytoma;
   Hamartoma; Lhermitte-Duclos disease
ID CENTRAL-NERVOUS-SYSTEM; PTEN; HAMARTOMA; TUMORS; MRI; CT;
   CLASSIFICATION; HYPERTROPHY; EXPERIENCE
AB BACKGROUND: Dysplastic gangliocytoma (Lhermitte-Duclos disease [LDD]) typically presents as a PTEN (phosphatase and tensin homolog)-positive, insidious unilateral mass of the cerebellar cortex. Patients can present with symptoms of increased intracranial pressure. Magnetic resonance imaging (MRI) will reveal a characteristic laminar/tigroid appearance. Surgical management has been superior to conservative measures for symptomatic lesions. The outcomes for bilateral craniotomy have not yet been described.
   CASE DESCRIPTION: A 50-year-old patient with Cowden syndrome had initially presented with vertigo and imbalance. T2-weighted MRI showed a striated pattern of hypointensity and hyperintensity in bilateral cerebellar hemispheres consistent with Lhermitte-Duclos disease. He underwent right posterior fossa craniotomy with near total surgical resection and achieved symptom resolution. However, 3 years later, asymptomatic recurrence of the right-sided LDD and progression of left-sided LDD were noted. These were managed with a 1-year course of temozolomide. Both lesions remained stable until 4 years after completion of temozolomide. MRI demonstrated progression in the left hemisphere requiring a second surgical resection. PTEN analysis of the resected lesion was negative for mutation.
   CONCLUSIONS: To the best of our knowledge, the present case is the first reported case of bilateral cerebellar hemisphere LDD ultimately managed by temporally dissociated bilateral surgical resections. Our patient was unique in that he had undergone surgery for resection of LDD, followed by a second surgery for contralateral progression 8 years later. The therapeutic options to prevent recurrence are limited, although temozolomide did seem to impede progression. Symptomatic patients will typically benefit most from surgical intervention. Given the strong association between adult LDD and Cowden syndrome, maintaining close follow-up care and possible surveillance imaging will be essential.
C1 [Khandpur, Umang; Huntoon, Kristin; Shaw, Andrew; Elder, James Bradley] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Smith-Cohn, Matthew] Univ Utah, Dept Neurol, Salt Lake City, UT USA.
RP Elder, JB (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
EM James.Elder@osumc.edu
OI Smith-Cohn, Matthew/0000-0002-9102-0802
CR Abel TW, 2005, J NEUROPATH EXP NEUR, V64, P341, DOI 10.1093/jnen/64.4.341
   Afshar-Oromieh A, 2010, NEUROSURG REV, V33, P401, DOI 10.1007/s10143-010-0278-1
   Amagasa M, 1997, Brain Tumor Pathol, V14, P63, DOI 10.1007/BF02478871
   AWWAD EE, 1995, AM J NEURORADIOL, V16, P1719
   Bayat MRH, 2005, SA J RADIOL, V9, P30, DOI 10.4102/sajr.v9i1.95
   BELLAMY JC, 1963, AM J CLIN PATHOL, V40, P395
   BEUCHE W, 1983, CLIN NEUROPATHOL, V2, P163
   Bhatia J K, 2016, Med J Armed Forces India, V72, pS147, DOI 10.1016/j.mjafi.2016.03.012
   Biswas SN, 2016, BMJ CASE REP, V2016
   Bozbuga M, 2010, NEUROL INDIA, V58, P309, DOI 10.4103/0028-3886.63799
   Capone MA, 2003, NEUROPEDIATRICS, V34, P30
   Carlson JJ, 2006, J NEUROIMAGING, V16, P157, DOI 10.1111/j.1552-6569.2006.00020.x
   DILORENZO N, 1984, J NEUROSURG, V60, P644, DOI 10.3171/jns.1984.60.3.0644
   Dubey A, 2009, SURG NEUROL, V72, P369, DOI 10.1016/j.surneu.2009.04.001
   El-Bahy K, 2005, ACTA NEUROCHIR, V147, P137, DOI 10.1007/s00701-004-0407-0
   Fernandes-Cabral DT, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.04.128
   Gama I, 2017, BMJ CASE REP, V2017
   Govindan A, 2012, INDIAN J PATHOL MICR, V55, P107, DOI 10.4103/0377-4929.94875
   HAIR LS, 1992, ACTA NEUROPATHOL, V84, P570, DOI 10.1007/BF00304477
   Hashimoto Hiroyuki, 1997, Neurologia Medico-Chirurgica, V37, P692
   Inoue T, 2007, BRAIN TUMOR PATHOL, V24, P25, DOI 10.1007/s10014-006-0211-z
   Jain N, 2015, J CLIN DIAGNOSTIC RE, V9
   Jiang T, 2017, WORLD NEUROSURG, V104, P398, DOI 10.1016/j.wneu.2017.04.147
   Klisch J, 2001, AM J NEURORADIOL, V22, P824
   Koeller KK, 2001, RADIOGRAPHICS, V21, P1533, DOI 10.1148/radiographics.21.6.g01nv051533
   Kuper M, 2013, BRAIN LANG, V127, P327, DOI 10.1016/j.bandl.2013.01.001
   Kulkantrakorn K, 1997, NEUROLOGY, V48, P725, DOI 10.1212/WNL.48.3.725
   Kumar N, 2016, NEUROL INDIA, V64, P162, DOI 10.4103/0028-3886.173658
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   MARANO SR, 1988, J NEUROSURG, V69, P599, DOI 10.3171/jns.1988.69.4.0599
   Matsumoto H, 2015, TURK NEUROSURG, V25, P783, DOI 10.5137/1019-5149.JTN.9835-13.2
   MILBOUW G, 1988, NEUROSURGERY, V22, P124, DOI 10.1227/00006123-198801000-00020
   Murata J, 1999, J NEURO-ONCOL, V41, P129, DOI 10.1023/A:1006167421100
   Nayil K, 2011, TURK NEUROSURG, V21, P651, DOI [10.5137/1019-5149.JTN .2989-10.1, 10.5137/1019-5149.JTN.2989-10.1]
   Nielson C, 2016, DERMATOL ONLINE J, V22
   Nowak DA, 2002, ACTA NEUROL SCAND, V105, P137, DOI 10.1034/j.1600-0404.2002.1r127.x
   Perez-Nunez A, 2004, ACTA NEUROCHIR, V146, P679, DOI 10.1007/s00701-004-0264-x
   Pilarski R, 2013, JNCI-J NATL CANCER I, V105, P1607, DOI 10.1093/jnci/djt277
   Pilarski R, 2011, J MED GENET, V48, P505, DOI 10.1136/jmg.2011.088807
   PRITCHETT PS, 1978, ACTA NEUROPATHOL, V42, P1
   Puri A S, 2007, Neuroradiol J, V19, P717
   Robinson S, 2000, NEUROSURGERY, V46, P371, DOI 10.1097/00006123-200002000-00021
   Robinson Shenandoah, 2006, Neurosurg Focus, V20, pE6
   Schmid GL, 2014, PEDIATR RES, V75, P527, DOI 10.1038/pr.2013.246
   Shin JH, 2002, RADIOGRAPHICS, V22, P1177, DOI 10.1148/radiographics.22.5.g02se051177
   Spaargaren L, 2003, NEURORADIOLOGY, V45, P381, DOI 10.1007/s00234-003-0984-2
   Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922
   STAPLETON SR, 1992, BRIT J NEUROSURG, V6, P153, DOI 10.3109/02688699209002919
   Tan TC, 2007, J CLIN NEUROSCI, V14, P801, DOI 10.1016/j.jocn.2006.06.007
   Turgut M, 2008, J NEUROS-PEDIATR, V1, P262, DOI 10.3171/PED/2008/1/3/262
   Pinto WBVD, 2014, ARQ NEURO-PSIQUIAT, V72, P645, DOI 10.1590/0004-282X20140091
   Wang QG, 2017, CLIN NEUROL NEUROSUR, V162, P53, DOI 10.1016/j.clineuro.2017.09.007
   Wei GQ, 2014, MOL CLIN ONCOL, V2, P415, DOI 10.3892/mco.2014.258
   WILLIAMS DW, 1992, AM J NEURORADIOL, V13, P287
   Zak M, 2017, J CHILD NEUROL, V32, P322, DOI 10.1177/0883073816681340
   Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 319
EP 325
DI 10.1016/j.wneu.2019.03.131
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300218
PM 30905649
DA 2020-05-12
ER

PT J
AU Yi, L
   Zhao, WY
   Krings, T
   Wang, W
   Chen, JC
AF Yi, Lei
   Zhao, Wenyuan
   Krings, Timo
   Wang, Wei
   Chen, Jincao
TI High-Flow Extracranial-to-Intracranial Bypass for Treatment of
   Thrombotic Parent Vessel Occlusion After Stent-Assisted Aneurysm Coiling
   as a Potential Rescue Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE HF EC-IC bypass; In-stent thrombosis; Stent-assisted coiling; Tirofiban
ID OUTCOMES; PREDICTORS; RISK
AB INTRODUCTION: Stent thrombosis (ST) is a known complication after intracranial stent implantation. The pathophysiology of ST is multifactorial, and standardized treatments for ST remain uncertain.
   CASE DESCRIPTION: A patient harboring an unruptured aneurysm of the posterior communicating segment of the left internal carotid artery was treated with stent-assisted coil embolization while on dual antiaggregation therapy. Despite adherence to medication, ST occurred 8 days after the intervention. Following tirofiban infusion, the thrombus dissolved and clinical symptoms improved However, after tirofiban was stopped, the patient experienced again ischemic symptoms. The patient underwent high-flow extracranial-to-intracranial bypass with good patency of the graft and resolution of symptoms.
   CONCLUSIONS: In case of refractory ST, high-flow extracranial-to-intracra- bypass proved to be in this case a feasible and effective rescue option.
C1 [Yi, Lei; Zhao, Wenyuan; Wang, Wei; Chen, Jincao] Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Krings, Timo] Univ Toronto, Toronto Western Hosp, Div Neuroradiol, Toronto, ON, Canada.
RP Zhao, WY (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM doczhaowy@163.com
OI Krings, Timo/0000-0001-6321-5787; Xu, Shuangxiang/0000-0001-8864-9653
CR Aggour M, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f8d1db
   Armstrong EJ, 2012, JACC-CARDIOVASC INTE, V5, P131, DOI 10.1016/j.jcin.2011.10.013
   Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313
   Fujii K, 2005, J AM COLL CARDIOL, V45, P995, DOI 10.1016/j.jacc.2004.12.066
   Hesstermans AACM, 2010, J THROMB HAEMOST, V8, P2385, DOI 10.1111/j.1538-7836.2010.04046.x
   Kanemaru K, 2013, J STROKE CEREBROVASC, V22, P1196, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.015
   Katsaridis V, 2008, AM J NEURORADIOL, V29, P1414, DOI 10.3174/ajnr.A1068
   Mega JL, 2010, JAMA-J AM MED ASSOC, V304, P1821, DOI 10.1001/jama.2010.1543
   Nomura M, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019917739448
   Ong DS, 2015, NAT REV CARDIOL, V12, P325, DOI 10.1038/nrcardio.2015.32
   Riedel CH, 2009, STROKE, V40, P1310, DOI 10.1161/STROKEAHA.108.531400
   Sun X, 2017, STROKE, V48, P784, DOI 10.1161/STROKEAHA.116.015538
   Tamura A, 2006, AM J CARDIOL, V97, P195, DOI 10.1016/j.amjcard.2005.07.132
   Uren NG, 2002, EUR HEART J, V23, P124, DOI 10.1053/euhj.2001.2707
   Zwart Bastiaan, 2010, Curr Treat Options Cardiovasc Med, V12, P46, DOI 10.1007/s11936-009-0055-z
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 326
EP 329
DI 10.1016/j.wneu.2019.03.039
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300219
PM 30878756
DA 2020-05-12
ER

PT J
AU Sato, H
   Wada, H
   Noro, S
   Saga, T
   Kamada, K
AF Sato, Hirotaka
   Wada, Hajime
   Noro, Shohei
   Saga, Takehiro
   Kamada, Kyousuke
TI Subarachnoid Hemorrhage with Concurrent Dural and Perimedullary
   Arteriovenous Fistulas at Craniocervical Junction: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniocervical junction; dAVF; Perimedullary AVF
AB BACKGROUND: The association between a dural arteriovenous fistula (dAVF) perimedullary arteriovenous fistula (AVF) is rarely observed at the cranio-cervical junction (CCJ). We present a case of subarachnoid hemorrhage (SAH) with concurrent dAVF and perimedullary AVF at the CCJ. Here, we describe the cause of bleeding and the process of determining whether it was a varix or an arterial aneurysm.
   CASE DESCRIPTION: A 69-year-old man with SAH visited the emergency department. A dAVF at the CCJ was detected on digital subtraction angiography (DSA). However, after 3 weeks, when the DSA was repeated, a perimedullary AVF and varix were identified. We performed an endovascular treatment, but because the perimedullary AVF remained, we performed a direct surgery. The patient was discharged without weakness, but this left abducens nerve palsy remained.
   CONCLUSIONS: In recent reports, SAH caused by concurrent dAVF and perimedullary AVF raised the possibility of an arterial aneurysm. However, in this case, the possibility of venous bleeding was high and a varix rather than an aneurysm was observed, On the basis of the reported cases, concurrent dAVF and perimedullary AVF at the CCJ is a "middle-flow arteriovenous shunt" that may induce a varix or an arterial aneurysm.
C1 [Sato, Hirotaka; Wada, Hajime; Noro, Shohei; Saga, Takehiro; Kamada, Kyousuke] Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan.
RP Sato, H (reprint author), Asahikawa Med Univ, Dept Neurosurg, Asahikawa, Hokkaido, Japan.
EM kyoukui080021@gmail.com
CR Aviv RI, 2004, AM J NEURORADIOL, V25, P854
   Ito A, 2017, WORLD NEUROSURG, V101, DOI 10.1016/j.wneu.2017.03.032
   Jeon JP, 2015, INTERV NEURORADIOL, V21, P733, DOI 10.1177/1591019915609128
   Kai Y, 2005, AM J NEURORADIOL, V26, P1949
   Nambu Iku, 2017, Surg Neurol Int, V8, P2, DOI 10.4103/2152-7806.198729
   Onda K, 2014, J NEUROSURG-SPINE, V20, P256, DOI 10.3171/2013.11.SPINE13402
   Sato K, 2013, J NEUROSURG, V118, P451, DOI 10.3171/2012.10.JNS121028
   van Beijnum J, 2007, J NEUROL, V254, P1044, DOI 10.1007/s00415-006-0485-4
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 331
EP 334
DI 10.1016/j.wneu.2019.02.079
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300221
PM 30825618
DA 2020-05-12
ER

PT J
AU Voisin, MR
   Ovenden, C
   Tsang, DS
   Gupta, AA
   Huang, A
   Gao, AF
   Diamandis, P
   Almeida, JP
   Gentili, F
AF Voisin, Mathew R.
   Ovenden, Chris
   Tsang, Derek S.
   Gupta, Abha A.
   Huang, Annie
   Gao, Andrew F.
   Diamandis, Phedias
   Almeida, Joao P.
   Gentili, Fred
TI Atypical Teratoid/Rhabdoid Sellar Tumor it an Adult with a Familial
   History of a Germline SMARCB1 Mutation: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE ATRT; hSNF5; INI1; RTPS; Sellar; SMARCB1
ID MALIGNANT RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; TURCICA;
   PREDISPOSITION; CHILDREN; THERAPY; PROTEIN; INFANCY; VARIANT; REGION
AB BACKGROUND: Adult sellar atypical teratoid/rhabdoid tumor (ATRT) is a rare diagnosis that has recently been shown to be a clinicopathologically and genetically distinct variant of ATRT occurring almost exclusively in middle-aged women. Although up to one third of pediatric ATRT is caused by a familial syndrome, no previous cases of a familial adult sellar ATRT have been reported. We present the first case report of a familial germline mutation causing adult sellar ATRT and a literature review of 29 previously reported cases of sporadic adult sellar ATRT.
   CASE DESCRIPTION: A 51-year-old woman with a family history of brain tumors spanning 3 generations presented with visual decline and was diagnosed with an adult sellar ATRT. Genetic studies showed a heterozygous splice-site loss-of-function mutation of the INI1 gene in exon 7. Treatment included endoscopic endonasal biopsy, craniospinal irradiation, and focal tumor boost, followed by adjuvant chemotherapy.
   CONCLUSIONS: This is the first case report of a familial germline mutation causing adult sellar ATRT. This article highlights the importance of a thorough family history and genetic testing in these individuals and reviews the current genetics, histopathology, and multidisciplinary treatment approach in this rare condition.
C1 [Voisin, Mathew R.; Almeida, Joao P.; Gentili, Fred] Univ Toronto, Toronto Western Hosp, Dept Neurosurg, Toronto, ON, Canada.
   [Ovenden, Chris] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Gupta, Abha A.] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada.
   [Gao, Andrew F.; Diamandis, Phedias] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Pathol, Toronto, ON, Canada.
   [Tsang, Derek S.] Univ Hlth Network, Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada.
   [Huang, Annie] Hosp Sick Children, Pediat Brain Tumor Program, Toronto, ON, Canada.
RP Voisin, MR (reprint author), Univ Toronto, Toronto Western Hosp, Dept Neurosurg, Toronto, ON, Canada.
EM mvoisin@qmed.ca
RI Tsang, Derek S./I-3007-2019
OI Tsang, Derek S./0000-0002-9762-6901
CR Alfonso-Perez T, 2014, ONCOGENE, V33, P3064, DOI 10.1038/onc.2013.276
   Almalki Mussa Hussain, 2017, J Clin Med Res, V9, P216, DOI 10.14740/jocmr2922w
   Arita K, 2008, ACTA NEUROCHIR, V150, P491, DOI 10.1007/s00701-008-1500-y
   Barresi V, 2018, NEUROPATHOLOGY, V38, P260, DOI 10.1111/neup.12440
   BIEGEL JA, 2006, NEUROSURG FOCUS, V20, P1, DOI DOI 10.3171/foc.2006.20.1.12
   Biswas S, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00236
   Brown AP, 2013, INT J RADIAT ONCOL, V86, P277, DOI 10.1016/j.ijrobp.2013.01.014
   Bruggers CS, 2011, PEDIATR BLOOD CANCER, V56, P1026, DOI 10.1002/pbc.22757
   Burger PC, 1998, AM J SURG PATHOL, V22, P1083, DOI 10.1097/00000478-199809000-00007
   Chhabda S, 2016, QUANT IMAGING MED SU, V6, P486, DOI 10.21037/qims.2016.10.01
   Chi SN, 2009, J CLIN ONCOL, V27, P385, DOI 10.1200/JCO.2008.18.7724
   Chou SQH, 2013, HONG KONG J RADIOL, V16, P65, DOI 10.12809/hkjr1311034
   Haberler C, 2006, AM J SURG PATHOL, V30, P1462, DOI 10.1097/01.pas.0000213329.71745.ef
   Hasselblatt M, 2014, ACTA NEUROPATHOL, V128, P453, DOI 10.1007/s00401-014-1323-x
   Heras FL, 2010, PATHOL RES PRACT, V206, P788, DOI 10.1016/j.prp.2010.07.004
   Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073
   Janson K, 2006, PEDIATR BLOOD CANCER, V47, P279, DOI 10.1002/pbc.20622
   Johann PD, 2018, AM J SURG PATHOL, V42, P506, DOI 10.1097/PAS.0000000000001023
   Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001
   Kuge A, 2000, NEUROL SURG TOKYO, V28, P351
   Larran-Escandon L, 2016, ENDOCRINOL NUTR, V63, P364, DOI 10.1016/j.endonu.2016.05.004
   Lev I, 2015, AACE CLIN CASE REP, V1, pe2, DOI DOI 10.4158/EP14337.CR
   Moretti C, 2013, CLIN MED INSIGHT-CAS, V6, P177, DOI 10.4137/CCRep.S12834
   Nakata S, 2017, AM J SURG PATHOL, V41, P932, DOI 10.1097/PAS.0000000000000845
   Nishikawa A, 2018, J CLIN NEUROSCI, V49, P16, DOI 10.1016/j.jocn.2017.12.010
   Nobusawa S, 2016, VIRCHOWS ARCH, V469, P711, DOI 10.1007/s00428-016-2017-7
   Paolini MA, 2018, J NEUROPATH EXP NEUR, V77, P1115, DOI 10.1093/jnen/nly091
   Park Hae Gi, 2014, Brain Tumor Res Treat, V2, P108, DOI 10.14791/btrt.2014.2.2.108
   Proust F, 1999, J NEURO-ONCOL, V43, P63, DOI 10.1023/A:1006114732613
   Raisanen J, 2005, BRAIN PATHOL, V15, P23
   Schneiderhan TM, 2011, NEUROPATH APPL NEURO, V37, P326, DOI 10.1111/j.1365-2990.2010.01111.x
   Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639
   Shitara Satoshi, 2014, Surg Neurol Int, V5, P75, DOI 10.4103/2152-7806.133105
   Slavc I, 2014, CANCER MED-US, V3, P91, DOI 10.1002/cam4.161
   Sredni ST, 2015, PEDIATR DEVEL PATHOL, V18, P49, DOI 10.2350/14-07-1531-MISC.1
   Swensen JJ, 2009, J MED GENET, V46, P68, DOI 10.1136/jmg.2008.060152
   Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833
   Torchia J, 2016, CANCER CELL, V30, P891, DOI 10.1016/j.ccell.2016.11.003
   Warren KS, 2014, CUAJ-CAN UROL ASSOC, V8, pE260, DOI 10.5489/cuaj.1633
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 336
EP 345
DI 10.1016/j.wneu.2019.04.083
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300223
PM 31004861
DA 2020-05-12
ER

PT J
AU O'Connor, KP
   Strickland, AE
   Bohnstedt, BN
AF O'Connor, Kyle P.
   Strickland, Allison E.
   Bohnstedt, Bradley N.
TI PulseRider Use in Ruptured Basilar Apex Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case series; PulseRider; Ruptured basilar apex aneurysm; Ruptured
   basilar tip aneurysm
ID UNRUPTURED INTRACRANIAL ANEURYSMS; NATURAL-HISTORY; MANAGEMENT;
   GUIDELINES; SAFETY
AB BACKGROUND: The PulseRider (Pulsar Vascular, Inc, Los Gatos, California, USA) device was developed to treat wide-neck aneurysms, and the Adjunctive Neurovascular Support of Wide-neck aneurysm Embolization and Reconstruction (ANSWER) Trial showed efficacy in the treatment of unruptured wide-neck aneurysms. Our case series demonstrates the use of the PulseRider device in the treatment of ruptured wide-neck aneurysms.
   CASE DESCRIPTION: The 2 patients in our series presented with subarachnoid hemorrhage secondary to ruptured basilar apex aneurysms. The patients were taken to the neurointervention suite for embolization of their aneurysms with the PulseRider and platinum microcoils.
   CONCLUSIONS: In both cases, a Roy Raymond class III embolization was achieved. The patients recovered from their subarachnoid hemorrhage and were discharged with resolution of their symptoms. The presented cases document the safety and efficacy of treating ruptured aneurysms with the PulseRider device.
C1 [O'Connor, Kyle P.; Strickland, Allison E.; Bohnstedt, Bradley N.] Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73104 USA.
RP Bohnstedt, BN (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73104 USA.
EM bbohnste@gmail.com
CR Aguilar-Salinas P, 2018, WORLD NEUROSURG, V115, P288, DOI 10.1016/j.wneu.2018.04.102
   Binz DD, 2009, NEUROCRIT CARE, V10, P253, DOI 10.1007/s12028-009-9193-0
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Gory B, 2016, AM J NEURORADIOL, V37, P130, DOI 10.3174/ajnr.A4506
   Gory B, 2017, WORLD NEUROSURG, V99, P605, DOI 10.1016/j.wneu.2016.12.065
   Harada K, 2013, ACTA NEUROCHIR, V155, P2037, DOI 10.1007/s00701-013-1841-7
   Hudson JS, 2019, NEUROSURGERY, V84, P479, DOI 10.1093/neuros/nyy127
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Mukherjee S, 2017, J NEUROSURG, V127, P61, DOI 10.3171/2016.2.JNS152334
   Sheth Sunil A, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-011836
   Sheth SA, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011836.rep
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spiotta AM, 2018, AM J NEURORADIOL, V39, P848, DOI 10.3174/ajnr.A5599
   Spiotta AM, 2017, NEUROSURGERY, V81, P56, DOI 10.1093/neuros/nyx085
   Spiotta AM, 2016, J NEUROINTERV SURG, V8, P186, DOI 10.1136/neurintsurg-2014-011531
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Valente I, 2018, WORLD NEUROSURG, V110, P158, DOI 10.1016/j.wneu.2017.11.024
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 346
EP 349
DI 10.1016/j.wneu.2019.04.042
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300224
PM 30980983
DA 2020-05-12
ER

PT J
AU Barkley, AS
   Susarla, SM
   Lee, A
AF Barkley, Ariana S.
   Susarla, Srinivas M.
   Lee, Amy
TI Frontotemporal Dermal Sinus Tract with 2 Connected Intradiploic Dermoid
   Cysts: A Rare Case and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Abscess; Dermoid cyst; Frontotemporal tract; Intradiploic
AB BACKGROUND: Frontotemporal dermal sinus tracts with associated dermoid cysts are very rare, with only 1 found in the largest series to date and 10 total documented case reports.
   CASE DESCRIPTION: We present the first case to our knowledge of a dermal sinus tract associated with 2 intradiploic dermoid cysts in the rare location of the pterion and sphenosquamosal suture. The patient was a 15-month-old girl presenting with periorbital cellulitis who was found to have 2 connected intradiploic cysts on radiographic imaging. The mass was excised, and pathology was consistent with a ruptured dermoid cyst.
   CONCLUSIONS: We review of the literature and argue for early identification and prophylactic surgical resection to avoid complications associated with infection and to mitigate risk of subtotal resection.
C1 [Barkley, Ariana S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
   [Susarla, Srinivas M.] Univ Washington, Dept Surg, Med Ctr, Div Plast Surg, Seattle, WA 98195 USA.
   [Lee, Amy] Seattle Childrens Hosp, Dept Pediat Neurosurg, Seattle, WA USA.
RP Barkley, AS (reprint author), Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA.
EM arianab@uw.edu
RI Susarla, Srinivas/P-1051-2019
OI Susarla, Srinivas/0000-0003-0155-8260
CR BARTLETT SP, 1993, PLAST RECONSTR SURG, V91, P1208, DOI 10.1097/00006534-199306000-00005
   Bliss M, 2016, J NEUROSURG-PEDIATR, V18, P471, DOI 10.3171/2016.5.PEDS1687
   BONAVOLONTA G, 1995, OPHTHALMIC PLAST REC, V11, P187, DOI 10.1097/00002341-199509000-00005
   CULLEN JF, 1974, BRIT J OPHTHALMOL, V58, P105, DOI 10.1136/bjo.58.2.105
   Green M F, 1973, Br J Plast Surg, V26, P298, DOI 10.1016/0007-1226(73)90019-2
   Hong SW, 1998, BRIT J PLAST SURG, V51, P255, DOI 10.1054/bjps.1997.0236
   Naderi S, 2012, PEDIATR NEUROSURG, V48, P86, DOI 10.1159/000342681
   NEBLETT CR, 1970, J NEUROSURG, V33, P103, DOI 10.3171/jns.1970.33.1.0103
   Nocini PF, 1996, J ORAL MAXIL SURG, V54, P357, DOI 10.1016/S0278-2391(96)90761-2
   Parag P, 2001, PEDIATR SURG INT, V17, P77, DOI 10.1007/s003830000396
   PENSLER JM, 1988, PLAST RECONSTR SURG, V82, P953, DOI 10.1097/00006534-198812000-00003
   POLLARD ZF, 1975, AM J OPHTHALMOL, V79, P310, DOI 10.1016/0002-9394(75)90087-2
   Scolozzi P, 2005, HEAD NECK-J SCI SPEC, V27, P429, DOI 10.1002/hed.20174
   SMIRNIOTOPOULOS JG, 1995, RADIOGRAPHICS, V15, P1437, DOI 10.1148/radiographics.15.6.8577967
   Wells TS, 2004, OPHTHAL PLAST RECONS, V20, P465, DOI 10.1097/01.IOP.0000144789.04263.19
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 350
EP 353
DI 10.1016/j.wneu.2019.03.222
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300225
PM 30930322
DA 2020-05-12
ER

PT J
AU Li, QF
   Gao, YL
   Xin, WQ
   Zhou, ZW
   Rong, HT
   Qin, YF
   Li, K
   Zhou, Y
   Wang, JW
   Xiong, JH
   Dong, XL
   Yang, MC
   Liu, YX
   Shen, J
   Wang, GE
   Song, AG
   Zhang, JN
AF Li, Qifeng
   Gao, Yalong
   Xin, Wenqiang
   Zhou, Ziwei
   Rong, Hongtao
   Qin, Yafei
   Li, Ke
   Zhou, Yuan
   Wang, Jiwei
   Xiong, Jianhua
   Dong, Xinlong
   Yang, Mengchen
   Liu, Yixin
   Shen, Jun
   Wang, Guangen
   Song, Aiguo
   Zhang, Jianning
TI Meta-Analysis of Prognosis of Different Treatments for Symptomatic
   Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Review
DE Conservative treatment; Moyamoya disease; Stroke; Surgical treatment
ID EXTRACRANIAL-INTRACRANIAL BYPASS; LONG-TERM OUTCOMES; ADULT MOYAMOYA;
   SURGICAL-TREATMENT; CLINICAL-FEATURES; CONSERVATIVE TREATMENT; INDIRECT
   REVASCULARIZATION; FOLLOW-UP; HEMORRHAGE; SURGERY
AB OBJECTIVE: The purpose of this study was to evaluate the efficacy of surgical revascularization versus conservative treatment and different surgical modalities, in order to provide evidence for the patient with moyamoya disease (MMD) to choose the appropriate treatment.
   METHODS: We comprehensively searched PubMed, Embase, Web of Science, and the Cochrane Library for articles published regarding MMD treatment. If the I-2 value, which evaluated the heterogeneity, was <50%, a fixed-effect model was used; if not, a random effect model was applied.
   RESULTS: Twenty-seven articles were included in the meta-analysis. The surgery group is more advantageous in reducing the risk of future stroke events than conservative treatment in MMD patients (odds ratio [OR] 0.26, 95% confidence interval [CI] 0.20-0.33, P < 0.001). In addition, the surgical group also had an advantage in terms of increased cerebral perfusion (OR 7.16, 95% CI 3.28-15.64, P < 0.001) and death due to rebleeding (OR 0.27, 95% CI 0.10-0.72, P < 0.01). Direct surgery showed a significant efficacy over indirect surgery (OR 2.03, 95% CI 1.32-3.13, P < 0.01). No obvious difference was found between the direct and indirect bypass subset (OR 0.76, 95% CI 0.51-1.14, P = 0185). Angiographic results in patients undergoing direct bypass surgery are more pronounced (OR 0.20, 95% CI 0.06-0.67, P < 0.01).
   CONCLUSIONS: In patients with symptomatic moyamoya disease, bypass surgery is more effective than conservative treatment to prevent future strokes. In surgical patients, direct bypass seems to reduce the risk of stroke more than an indirect bypass.
C1 [Li, Qifeng; Gao, Yalong; Xin, Wenqiang; Zhou, Ziwei; Rong, Hongtao; Li, Ke; Zhou, Yuan; Wang, Jiwei; Xiong, Jianhua; Dong, Xinlong; Yang, Mengchen; Shen, Jun; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Li, Qifeng; Gao, Yalong; Xin, Wenqiang; Zhou, Ziwei; Rong, Hongtao; Qin, Yafei; Li, Ke; Zhou, Yuan; Wang, Jiwei; Xiong, Jianhua; Dong, Xinlong; Yang, Mengchen; Shen, Jun; Zhang, Jianning] Tianjin Neurol Inst, Minist Educ China & Tianjin, Key Lab Postneurotrauma Neurorepair & Regenerat C, Tianjin, Peoples R China.
   [Wang, Jiwei] Tianjin Huanhu Hosp, Dept Neurol, Tianjin, Peoples R China.
   [Liu, Yixin] Tianjin Huanhu Hosp, Sch Med Lab, Dept Clin Immunol, Tianjin, Peoples R China.
   [Wang, Guangen] Shexian Hosp, Dept Intens Care Unit, Handan, Hebei, Peoples R China.
   [Song, Aiguo] Shexian Hosp, Dept Neurol, Handan, Hebei, Peoples R China.
   [Shen, Jun] Yijishan Hosp, Wannan Med Coll, Dept Neurosurg, Wuhu, Peoples R China.
RP Zhang, JN (reprint author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.; Zhang, JN (reprint author), Tianjin Neurol Inst, Minist Educ China & Tianjin, Key Lab Postneurotrauma Neurorepair & Regenerat C, Tianjin, Peoples R China.
EM jianningzhang@hotmail.com
FU Tianjin Research Program [15ZXJZSY00040]
FX This work was supported by Tianjin Research Program (grant
   15ZXJZSY00040).
CR Ahn IM, 2014, STROKE, V45, P1090, DOI 10.1161/STROKEAHA.113.004273
   [Anonymous], 1965, No To Shinkei, V17, P750
   Bang JS, 2012, NEUROSURGERY, V70, P625, DOI 10.1227/NEU.0b013e3182333c47
   Cho WS, 2015, J NEUROSURG, V122, P82, DOI 10.3171/2014.9.JNS132281
   Cho WS, 2014, STROKE, V45, P3025, DOI 10.1161/STROKEAHA.114.005624
   Choi In Jae, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P216, DOI 10.7461/jcen.2012.14.3.216
   Choi Won-Seo, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P191, DOI 10.7461/jcen.2013.15.3.191
   Czabanka M, 2011, CEREBROVASC DIS, V32, P361, DOI 10.1159/000330351
   Ding JY, 2018, WORLD NEUROSURG, V117, pE557, DOI 10.1016/j.wneu.2018.06.076
   Fung LWE, 2005, CHILD NERV SYST, V21, P358, DOI 10.1007/s00381-004-1118-9
   Ge PC, 2018, J STROKE CEREBROVASC, V27, P1517, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.047
   Ge PC, 2018, J CLIN NEUROSCI, V50, P277, DOI 10.1016/j.jocn.2017.12.004
   Ge PC, 2017, WORLD NEUROSURG, V103, P283, DOI 10.1016/j.wneu.2017.03.101
   Ge PC, 2017, WORLD NEUROSURG, V100, P459, DOI 10.1016/j.wneu.2017.01.055
   Gross BA, 2013, ACTA NEUROCHIR, V155, P247, DOI 10.1007/s00701-012-1545-4
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hallemeier CL, 2006, STROKE, V37, P1490, DOI 10.1161/01.STR.0000221787.70503.ca
   Han JS, 2011, STROKE, V42, P3047, DOI 10.1161/STROKEAHA.111.615955
   Huang Z, 2015, NEUROL RES, V37, P886, DOI 10.1179/1743132815Y.0000000073
   Jeon JP, 2018, J NEUROSURG, V128, P793, DOI 10.3171/2016.11.JNS161688
   Jiang HQ, 2018, WORLD NEUROSURG, V116, pE1032, DOI 10.1016/j.wneu.2018.05.153
   Kawaguchi S, 2000, J NEUROSURG, V93, P397, DOI 10.3171/jns.2000.93.3.0397
   Kazumata K, 2014, J NEUROSURG, V121, P432, DOI 10.3171/2014.1.JNS13946
   Kim DS, 2012, NEUROL MED-CHIR, V52, P333, DOI 10.2176/nmc.52.333
   Kim H, 2016, WORLD NEUROSURG, V94, P273, DOI 10.1016/j.wneu.2016.07.009
   Kim T, 2016, J NEUROSURG, V124, P1788, DOI 10.3171/2015.6.JNS151105
   Kleinloog R, 2012, J NEUROL NEUROSUR PS, V83, P531, DOI 10.1136/jnnp-2011-301387
   Kuroda S, 2005, STROKE, V36, P2148, DOI 10.1161/01.STR.0000182256.32489.99
   Lee SB, 2012, ACTA NEUROCHIR, V154, P1179, DOI 10.1007/s00701-012-1325-1
   Lee SU, 2018, CURR TREAT OPTION NE, V20, DOI 10.1007/s11940-018-0511-8
   Liu XJ, 2015, J NEUROSURG, V122, P392, DOI 10.3171/2014.10.JNS132369
   Liu XJ, 2013, J NEUROL NEUROSUR PS, V84, P258, DOI 10.1136/jnnp-2012-302236
   Luo RT, 2017, WORLD NEUROSURG, V108, P683, DOI 10.1016/j.wneu.2017.09.056
   Mesiwala AH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E15
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Ohue S, 2008, SURG NEUROL, V69, P281, DOI 10.1016/j.surneu.2007.01.047
   Oyama H, 2013, NAGOYA J MED SCI, V75, P37
   Porras JL, 2018, WORLD NEUROSURG, V110, pE928, DOI 10.1016/j.wneu.2017.11.113
   Qian C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002218
   Research Committee on the Pathology Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, NEUROL MED CHIR TOKY, V52, P245, DOI DOI 10.2176/NMC.52.245
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Shang Shuling, 2020, Neurosurg Rev, V43, P371, DOI 10.1007/s10143-018-0994-5
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sundaram S, 2014, J NEUROL SCI, V336, P99, DOI 10.1016/j.jns.2013.10.014
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Yoshida Y, 1999, STROKE, V30, P2272, DOI 10.1161/01.STR.30.11.2272
   Zhang WG, 2016, WORLD NEUROSURG, V93, P365, DOI 10.1016/j.wneu.2016.06.063
NR 47
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 354
EP 361
DI 10.1016/j.wneu.2019.04.062
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300226
PM 30995556
DA 2020-05-12
ER

PT J
AU Sweid, A
   Hauge, J
   Gooch, MR
   Jabbour, P
   Rosenwasser, RH
   Tjoumakaris, S
AF Sweid, Ahmad
   Hauge, Julie
   Gooch, Michael R.
   Jabbour, Pascal
   Rosenwasser, Robert H.
   Tjoumakaris, Stavropoula
TI Safety and Efficacy of Mechanical Thrombectomy in 2 Cases of Acute
   Ischemic Stroke in Centennial Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Centennials; Eldest patient; Mechanical
   thrombectomy
AB BACKGROUND: Mechanical thrombectomy (MT) became a standard of care L. stroke patients after the positive results of 5 randomized trials in 2015. However, elderly patients >65 were excluded from those trials. Recent studies and clinical trials examining the efficacy of MT in patients older than the age of 85 have shown that good outcomes can be achieved with careful patient selection.
   CASE DESCRIPTION: Two patients older than the age of 100 who presented with stroke were treated with MT. Although the cases were different in baseline neurologic status, surgical history, and gender, both achieved successful procedures.
   CONCLUSION: We believe that MT in centennials is technically safe and effective and should be considered. In this age group a careful assessment of existing medical condition and a thorough discussion with the family about goals of care is of paramount importance to optimize clinical outcomes.
C1 [Sweid, Ahmad; Gooch, Michael R.; Jabbour, Pascal; Rosenwasser, Robert H.; Tjoumakaris, Stavropoula] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Sweid, Ahmad; Gooch, Michael R.; Jabbour, Pascal; Rosenwasser, Robert H.; Tjoumakaris, Stavropoula] Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
   [Hauge, Julie] Univ Penn, Philadelphia, PA 19104 USA.
RP Tjoumakaris, S (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.; Tjoumakaris, S (reprint author), Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
EM stavropoula.tjoumakaris@jefferson.edu
OI Sweid, Ahmad/0000-0002-2652-2451
CR Alawieh A, 2018, J NEUROINTERV SURG, V10, P1209, DOI 10.1136/neurintsurg-2018-013787
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Cummings CL, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2011-010082
   Denti L, 2010, J AM GERIATR SOC, V58, P12, DOI 10.1111/j.1532-5415.2009.02616.x
   Fonarow GC, 2010, CIRCULATION, V121, P879, DOI 10.1161/CIRCULATIONAHA.109.892497
   Forti P, 2013, NEUROLOGY, V80, P29, DOI 10.1212/WNL.0b013e31827b1a41
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Murphy Sherry L, 2017, Natl Vital Stat Rep, V66, P1
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Russo Tommasina, 2011, J Aging Res, V2011, P108785, DOI 10.4061/2011/108785
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Slawski DE, 2018, INTERV NEUROL, V7, P246, DOI 10.1159/000487333
   Tonetti DA, 2018, WORLD NEUROSURG, V119, pE941, DOI 10.1016/j.wneu.2018.08.008
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 362
EP 365
DI 10.1016/j.wneu.2019.04.123
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300227
PM 31009787
DA 2020-05-12
ER

PT J
AU Bhatjiwale, MM
   Bhatjiwale, MG
   Chandorkar, SS
AF Bhatjiwale, Mrudul M.
   Bhatjiwale, Mohinish G.
   Chandorkar, Salila S.
TI Transtentorial Brain Herniation After Lumbar Drainage in Patient Planned
   for Cranioplastic Reconstruction: Catastrophic Play Between Atmospheric
   and Intracranial Pressure
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF diversion; Intracranial pressure; Lumbar cerebrospinal fluid
   drainage; Persistent brain herniation; Sinking craniotomy flap syndrome;
   Trephination syndrome
AB BACKGROUND: The sinking skin flap syndrome, also known as the syndrome of the trephined or the trephination syndrome, occurs in patients who have undergone a decompressive craniectomy. As opposed to this, persistent brain herniation also occurs in patients after a decompressive craniectomy and a cerebrospinal fluid (CSF) drainage procedure is one of the therapies used to reduce it. A continuous lumbar CSF drainage procedure can upset the pressure dynamics of the atmosphere versus intracranial pressures to a point of fatal clinical deterioration and hence needs to be closely monitored.
   CASE DESCRIPTION: Our case report speaks of persistent brain herniation in which drainage of CSF led to a trephination syndrome, which was reversed once again, by measures to increase CSF production and intracranial pressure.
   CONCLUSIONS: Timely intervention eventually led to a favorable outcome and avoidance of a catastrophy.
C1 [Bhatjiwale, Mrudul M.] Narayana Hlth City, Dept Neurosurg, Bengaluru, India.
   [Bhatjiwale, Mohinish G.] Navneet Hi Tech & Bhagwatie BDBA Hosp, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Chandorkar, Salila S.] Neuro Hlth Fdn, Mumbai, Maharashtra, India.
RP Bhatjiwale, MM (reprint author), Narayana Hlth City, Dept Neurosurg, Bengaluru, India.
EM mbhatjiwale@gmail.com
OI Bhatjiwale, Mrudul/0000-0001-5339-3774
CR Fraioli MF, OPEN ACCESS LIB J, V3, pe2346
   Giese H, 2018, J CLIN NEUROSCI, V52, P88, DOI 10.1016/j.jocn.2018.03.008
   Han PY, 2008, J KOREAN NEUROSURG S, V43, P51, DOI 10.3340/jkns.2008.43.1.51
   Kelley GR, 2004, NEUROLOGY, V62, P157, DOI 10.1212/WNL.62.1.157
   Liao CC, 2002, J CLIN NEUROSCI, V9, P553, DOI 10.1054/jocn.2002.1116
   Wang QP, 2014, NEUROL INDIA, V62, P79, DOI 10.4103/0028-3886.128337
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 366
EP 369
DI 10.1016/j.wneu.2019.04.090
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300228
PM 31004859
DA 2020-05-12
ER

PT J
AU Kikuta, S
   Iwanaga, J
   Kusukawa, J
   Tubbs, RS
AF Kikuta, Shogo
   Iwanaga, Joe
   Kusukawa, Jingo
   Tubbs, R. Shane
TI Carotid Sinus Nerve: A Comprehensive Review of Its Anatomy, Variations,
   Pathology, and Clinical Applications
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid sinus nerve; Glossopharyngeal nerve; Intercarotid plexus;
   Sympathetic ganglion; Vagus nerve
ID BAROREFLEX FAILURE; EPILEPSY CONTROL; SYNCOPE; HYPERSENSITIVITY;
   MANAGEMENT; VASODEPRESSOR; STIMULATION; GUIDELINES; REFLEX; COMMON
AB The carotid sinus nerve branches off the glossopharyngeal nerve just after its appearance from the jugular foramen, descends along the internal carotid artery, and enters the carotid sinus. There have been many studies of the pathway and the course of the carotid sinus nerve and its communications with surrounding nerves. The intercommunication is exceedingly complicated. Acknowledgment of its anatomic diversity can be important in specific operations dealing with this area. Herein we review the anatomy, variations, pathology, and clinical applications of the carotid sinus nerve.
C1 [Kikuta, Shogo; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA USA.
   [Kikuta, Shogo; Iwanaga, Joe; Kusukawa, Jingo] Kurume Univ, Sch Med, Dent & Oral Med Ctr, Kurume, Fukuoka, Japan.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dent & Oral Med Ctr, Kurume, Fukuoka, Japan.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
OI Kikuta, Shogo/0000-0002-2236-2884
CR Andrew K, 2018, CUREUS, V10, P4
   ARENBERG IK, 1971, LARYNGOSCOPE, V81, P253, DOI 10.1288/00005537-197102000-00006
   Boyd JD, 1937, ANAT ANZEIGER, V84, P386
   Braeucker W, 1923, ANAT ANZEIGER, V56, P225
   Brignole M, 2004, EUROPACE, V6, P467, DOI 10.1016/j.eupc.2004.08.008
   BRIGNOLE M, 1990, PACE, V13, P2071, DOI 10.1111/j.1540-8159.1990.tb06944.x
   Brignole M, 2013, EUROPACE, V15, P1070, DOI 10.1093/europace/eut206
   Cordier P, 1932, C R ASS ANAT, V27, P161
   Davies AJ, 2001, AGE AGEING, V30, P289, DOI 10.1093/ageing/30.4.289
   De Toma G, 2000, J VASC SURG, V31, P806, DOI 10.1067/mva.2000.103789
   DECASTRO F, 1928, [No title captured], V25, P331
   Druener L., 1925, DEUT MED WOCHENSCHR, V14, P559, DOI DOI 10.1055/S-0028-1136629
   FUSE SCHOZO, 1950, FOLIA PSYCHIATR ET NEUROL JAP, V4, P1
   GAGGIOLI G, 1995, AM J CARDIOL, V75, P518, DOI 10.1016/S0002-9149(99)80596-7
   Healey J, 2004, CLIN AUTON RES, V14, P80, DOI 10.1007/s10286-004-1012-2
   Hemmy D C, 1975, Wis Med J, V74, P73
   Hering H., 1924, MUNCHEN MED WOCHEN, V71, P1265
   HONDA Y, 1979, J APPL PHYSIOL, V46, P632
   HOVELACQUE A., 1930, PRESSE MED, V38, P449
   Humm AM, 2006, J NEUROL NEUROSUR PS, V77, P1267, DOI 10.1136/jnnp.2006.093518
   Loftus C, 1995, CAROTID ENDARTERECTO
   MALONEY JD, 1994, AM HEART J, V127, P1030, DOI 10.1016/0002-8703(94)90083-3
   Mathias CJ, 2001, LANCET, V357, P348, DOI 10.1016/S0140-6736(00)03642-4
   MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53
   MCINTOSH SJ, 1993, AM J MED, V95, P203, DOI 10.1016/0002-9343(93)90261-M
   Miller VM, 2008, NEUROPATH APPL NEURO, V34, P403, DOI 10.1111/j.1365-2990.2007.00903.x
   MORLEY CA, 1984, INT J CARDIOL, V6, P287, DOI 10.1016/0167-5273(84)90188-8
   O'Dwyer C, 2011, EUROPACE, V13, P1040, DOI 10.1093/europace/eur069
   Patwardhan RV, 2002, PEDIATR NEUROSURG, V36, P236, DOI 10.1159/000058426
   Ray BS, 1942, SURGERY, V11, P915
   Seong J, 2005, J BIOMECH, V38, P453, DOI 10.1016/j.jbiomech.2004.04.022
   Sheehan D, 1941, ANAT REC, V80, P431, DOI 10.1002/ar.1090800405
   Sigaudo-Roussel D, 2002, J VASC SURG, V36, P793, DOI 10.1067/mva.2002.126564
   SIMPSON RK, 1987, J NEUROSURG, V67, P757, DOI 10.3171/jns.1987.67.5.0757
   Solari D, 2014, EUROPACE, V16, P928, DOI 10.1093/europace/eut283
   Standring S, 2015, GRAYS ANATOMY E BOOK
   STRASBERG B, 1989, PROG CARDIOVASC DIS, V31, P379, DOI 10.1016/0033-0620(89)90032-7
   Sutton Richard, 2014, Glob Cardiol Sci Pract, V2014, P1, DOI 10.5339/gcsp.2014.18
   Tang TY, 2007, EUR J VASC ENDOVASC, V34, P304, DOI 10.1016/j.ejvs.2007.02.024
   Tchibukmacher NB., 1938, SURG GYNECOL OBSTET, V67, P740
   Timmers HJLM, 2003, J HYPERTENS, V21, P591, DOI 10.1097/00004872-200303000-00026
   Timmers HJLM, 2004, NETH J MED, V62, P151
   Toorop RJ, 2010, EUR J VASC ENDOVASC, V39, P146, DOI 10.1016/j.ejvs.2009.09.009
   Toorop RJ, 2009, ANN VASC SURG, V23, P538, DOI 10.1016/j.avsg.2008.11.008
   Toorop RJ, 2009, J VASC SURG, V50, P177, DOI 10.1016/j.jvs.2009.03.029
   Tubbs RS, 2002, PEDIATR NEUROSURG, V36, P244, DOI 10.1159/000058427
   Tubbs RS, 2015, NERVE NERVE INJURIES, V1
   WHIPP BJ, 1994, THORAX, V49, P1081, DOI 10.1136/thx.49.11.1081
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 370
EP 374
DI 10.1016/j.wneu.2019.04.064
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300229
PM 30995553
DA 2020-05-12
ER

PT J
AU Agnoletto, GJ
   Imbarrato, GJ
   Granja, MF
   Monteiro, A
   Aldana, PR
   Hanel, RA
AF Agnoletto, Guilherme J.
   Imbarrato, Gregory J.
   Granja, Manuel F.
   Monteiro, Andre
   Aldana, Philipp R.
   Hanel, Ricardo A.
TI A De Novo Sphenoparietal Dural Arteriovenous Fistula: Unveiling the
   Deceitful Culprit
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Brain; Carotid cavernous fistula; Dural
   arteriovenous fistula; Transvenous embolization
ID MIDDLE MENINGEAL ARTERY
AB INTRODUCTION: Intracranial dural arteriovenous fistulas (DAVFs) are an uncommon pathology, and a sphenoparietal drainage pattern is certainly rare. We present a case of a de novo sphenoparietal DAVF in a prepubescent patient previously treated for a cerebellar arteriovenous malformation (AVM) 10 years before.
   CASE DESCRIPTION: A 10-year-old boy presented with worsening headaches for the past few weeks, swelling of the right side of face and eye, and chemosis and proptosis of the right eye. Of note, the patient had been treated successfully for a cerebellar AVM at 6 weeks of age with advanced imaging follow-up until 4 years previously demonstrating resolution of AVM and no other abnormalities whatsoever. Suspecting a carotid cavernous fistula, we performed angiography, which revealed a sphenoparietal DAVF with feeders from both the external and internal carotid artery. Despite sudden onset of symptoms and recent previously negative imaging, bony erosion was noted on computed tomography of the head and orbits. Successful treatment was achieved via transvenous embolization.
   CONCLUSIONS: This case highlights the different array of presentations that sphenoparietal fistulas may display. Even though most DAVFs are acquired, secondary lesions and spontaneous malformations must be considered in a differential diagnosis.
C1 [Agnoletto, Guilherme J.; Imbarrato, Gregory J.; Granja, Manuel F.; Monteiro, Andre; Hanel, Ricardo A.] Lyerly Neurosurg, Baptist Neurol Inst, Dept Cerebrovasc Neurosurg, Jacksonville, FL 32207 USA.
   [Aldana, Philipp R.] Univ Florida, Wolfson Childrens Hosp, Dept Pediat Neurosurg, Jacksonville, FL USA.
RP Agnoletto, GJ (reprint author), Lyerly Neurosurg, Baptist Neurol Inst, Dept Cerebrovasc Neurosurg, Jacksonville, FL 32207 USA.
EM guilherme.agnoletto@bmcjax.com
OI Monteiro, Andre/0000-0001-6827-6650
CR Davies M A, 1997, Interv Neuroradiol, V3, P303
   Davies M A, 1997, Interv Neuroradiol, V3, P295
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Gross BA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.12.FOCUS11336
   Macdonald A, 2015, J NEUROINTERV SURG, V7, DOI 10.1136/neurintsurg-2014-011103.rep
   Osbun JW, 2013, WORLD NEUROSURG, V80, pE381, DOI 10.1016/j.wneu.2013.02.022
   PAKARINEN S, 1965, J NEUROSURG, V23, P438, DOI 10.3171/jns.1965.23.4.0438
   Robert T, 2016, AM J NEURORADIOL, V37, P1870, DOI 10.3174/ajnr.A4831
   Smith J E, 1981, J Natl Med Assoc, V73, P274
   TSUTSUMI K, 1990, NEUROSURGERY, V26, P869, DOI 10.1227/00006123-199005000-00023
   Tubbs RS, 2007, NEUROSURGERY, V60, P9, DOI 10.1227/01.NEU.0000249241.35731.C6
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 375
EP 380
DI 10.1016/j.wneu.2019.04.120
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300230
PM 31009777
DA 2020-05-12
ER

PT J
AU Zhang, S
   Zhao, HG
   Sa, R
   Qin, XW
   Qu, LM
   Wang, YB
   Deng, SL
   Yu, H
   Xu, SB
AF Zhang, Shuai
   Zhao, Hongguang
   Sa, Ri
   Qin, Xiaowei
   Qu, Limei
   Wang, Yubo
   Deng, Shuanglin
   Yu, Hong
   Xu, Songbai
TI Bilateral Internal Auditory Canal Metastasis of Colon Carcinoma
   Mimicking Neurofibromatosis Type II: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Cerebellopontine angle; Colon carcinoma; Internal auditory
   canal; Metastasis; Neurofibromatosis
ID CEREBELLOPONTINE ANGLE; TUMORS; ADENOCARCINOMA
AB BACKGROUND: The vast majority of cerebellopontine angle tumors are benign with a favorable prognosis. Metastatic tumors occurring in the cerebellopontine angle are extremely rare. Herein, we report a case of colon carcinoma metastasis to the bilateral internal auditory canals.
   CASE DESCRIPTION: A 59-year-old man presented with a 2-week history of binaural hearing loss. One year before admission, he was diagnosed with colon carcinoma and underwent surgical resection combined with chemotherapy. Physical examination showed complete hearing loss in bilateral ears and bilateral facial palsy. Magnetic resonance imaging of the brain revealed nodules in the bilateral internal auditory canals. Middle-ear computed tomography demonstrated soft-tissue masses extending into the bilateral internal auditory canals. A diagnosis of neurofibromatosis type II was suspected. A unilateral surgical resection of the cerebellopontine angle tumor was performed. Postoperatively, the hearing loss and facial palsy remained unchanged. Pathologic examination showed metastatic, poorly differentiated carcinoma. The patient was diagnosed with metastatic colon carcinoma in the bilateral internal auditory canals. The patient refused radiotherapy and chemotherapy. The tumor progressed rapidly, and the patient developed dysphagia and choking 1 month later. The patient died of respiratory and circulatory failure 2 months after the surgery.
   CONCLUSIONS: Clinicians should be aware of metastatic tumors in the internal auditory canals. Comprehensive clinicoradiologic evaluation should be highlighted. A history of malignancy and rapidly progressive hearing loss and facial palsy may suggest the diagnosis of metastasis to the internal auditory canal. The definitive diagnosis still depends on histopathologic examination.
C1 [Zhang, Shuai; Qin, Xiaowei; Wang, Yubo; Deng, Shuanglin; Xu, Songbai] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Zhao, Hongguang; Sa, Ri] Jilin Univ, Hosp 1, Dept Nucl Med, Changchun, Jilin, Peoples R China.
   [Qu, Limei] Jilin Univ, Hosp 1, Dept Pathol, Changchun, Jilin, Peoples R China.
   [Yu, Hong] Jilin Univ, Hosp 1, Dept Otolaryngol, Changchun, Jilin, Peoples R China.
RP Xu, SB (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM xusongbai@jlu.edu.cn
CR BRACKMANN DE, 1980, OTOLARYNG HEAD NECK, V88, P555, DOI 10.1177/019459988008800508
   Brackmann DE, 2007, OTOL NEUROTOL, V28, P529, DOI 10.1097/mao.0b013e3180383694
   Chang MT, 2015, AM J OTOLARYNG, V36, P798, DOI 10.1016/j.amjoto.2015.06.002
   Christensen TD, 2017, ACTA ONCOL, V56, P639, DOI 10.1080/0284186X.2017.1290272
   Christensen TD, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2290-5
   HILL BA, 1976, ARCH OTOLARYNGOL, V102, P568
   Huang TW, 2002, OTOL NEUROTOL, V23, P975, DOI 10.1097/00129492-200211000-00027
   Jariengprasert C, 2006, AM J OTOLARYNG, V27, P143, DOI 10.1016/j.amjoto.2005.07.019
   LITTLE JR, 1974, ARCH NEUROL-CHICAGO, V30, P138, DOI 10.1001/archneur.1974.00490320026003
   MOFFAT DA, 1993, J LARYNGOL OTOL, V107, P1087, DOI 10.1017/S0022215100125393
   Nozawa H, 2017, ONCOLOGY-BASEL, V93, P309, DOI 10.1159/000478661
   Samii M, 1985, Clin Neurosurg, V32, P242
   Springborg JB, 2008, SKULL BASE-INTERD AP, V18, P217, DOI 10.1055/s-2007-1016959
   Wang CP, 2000, TZU CHI MED J, V12, P277
NR 14
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 381
EP 386
DI 10.1016/j.wneu.2019.02.166
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300231
PM 30862585
DA 2020-05-12
ER

PT J
AU Monteiro, A
   Agnoletto, GJ
   Granja, MF
   Andrade, MR
   Hanel, RA
AF Monteiro, Andre
   Agnoletto, Guilherme Jose
   Granja, Manuel F.
   Andrade, Manuella R.
   Hanel, Ricardo A.
TI Stent-Assisted Coiling of Pseudoaneurysm After Vertebro-Carotid
   Transposition: Harmonious Combination of Open and Endovascular
   Neurosurgical Techniques
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular therapy; Pseudoaneurysm; Vertebral artery stenosis;
   Vertebral artery stenting; Vertebral artery transposition;
   Vertebro-carotid transposition
ID MEDICAL-TREATMENT; ARTERY-STENOSIS; REVASCULARIZATION; ANGIOPLASTY;
   MANAGEMENT; DIAGNOSIS
AB BACKGROUND: Most cases of vertebral artery stenosis are treated either conservatively or surgically. When non-conservative treatment is chosen, whether to treat it with open surgery or endovascular intervention remains a topic of divergence. In the setting of endovascular therapy failure, the vertebral to common carotid artery transposition certainly is an appropriate choice to recover the posterior circulation. Like any other open surgery, it is not devoid of soft-tissue-related complications. A pseudoaneurysm following this procedure and at this particular location is a rare but lethal complication and, to the best of our knowledge, has not yet been reported.
   CASE DESCRIPTION: We present the case of an 80-year-old man with previous ischemic stroke who presented to the emergency department with aphasia, right-sided weakness, and dysarthria. Invasive imaging revealed right vertebral stenosis and hypoplastic left vertebral artery that failed endovascular therapy. The patient was then treated with a right vertebral to common carotid artery transposition. During follow-up, a pseudoaneurysm was found and treated with a stent-assisted coiling.
   CONCLUSIONS: Pseudoaneurysms at the extracranial carotid and vertebral circulation are rare and have potential for deadly outcomes. Despite several treatments available, this anatomical location requires endovascular therapy due to efficacy and promptitude of this treatment. This is an interesting case where the patient's management required open and endovascular procedures. The pseudoaneurysm was a rare complication that, to the best of our knowledge, has not previously been reported. This case is an illustration of complementary work between open surgery and endovascular intervention.
C1 [Monteiro, Andre; Agnoletto, Guilherme Jose; Granja, Manuel F.; Andrade, Manuella R.; Hanel, Ricardo A.] Baptist Neurol Inst, Baptist Hlth, Lyerly Neurosurg, Jacksonville, FL 32217 USA.
RP Hanel, RA (reprint author), Baptist Neurol Inst, Baptist Hlth, Lyerly Neurosurg, Jacksonville, FL 32217 USA.
EM rhanel@lyerlyneuro.com
OI Monteiro, Andre/0000-0001-6827-6650
CR Albuquerque FC, 2003, NEUROSURGERY, V53, P607, DOI 10.1227/01.NEU.0000079494.87390.28
   Bernik Thomas R, 2002, Vasc Endovascular Surg, V36, P461, DOI 10.1177/153857440203600607
   Compter A, 2015, LANCET NEUROL, V14, P606, DOI 10.1016/S1474-4422(15)00017-4
   Coward LJ, 2007, STROKE, V38, P1526, DOI 10.1161/STROKEAHA.106.471862
   Franklin JA, 2003, J AM COLL SURGEONS, V197, P293, DOI 10.1016/S1072-7515(03)00375-2
   Hanel RA, 2009, NEUROSURGERY, V64, P1043, DOI 10.1227/01.NEU.0000347099.17437.64
   Keeling AN, 2009, CARDIOVASC INTER RAD, V32, P2, DOI 10.1007/s00270-008-9440-3
   Lee CJ, 2011, EXPERT REV CARDIOVAS, V9, P575, DOI [10.1586/erc.11.54, 10.1586/ERC.11.54]
   Lee JH, 2019, J VASC ACCESS, V20, P224, DOI 10.1177/1129729818788803
   Lutsep HL, 2004, STROKE, V35, P1388, DOI 10.1161/01.STR.0000128708.86762.d6
   Mahmoud MZ, 2015, WORLD J RADIOL, V7, P89, DOI 10.4329/wjr.v7.i5.89
   McConnell PI, 2000, SURGERY, V127, P716, DOI 10.1067/msy.2000.105293
   Nadig S, 2009, HEAD NECK-J SCI SPEC, V31, P136, DOI 10.1002/hed.20855
   Rangel-Castilla L, 2015, J NEUROSURG, V122, P671, DOI 10.3171/2014.9.JNS14194
   Sasada S, 2010, BREAST CANCER-TOKYO, V17, P75, DOI 10.1007/s12282-009-0095-y
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 387
EP 390
DI 10.1016/j.wneu.2019.04.114
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300232
PM 31009786
DA 2020-05-12
ER

PT J
AU Xu, RS
   Xia, YX
   Passias, PG
   Protopsaltis, T
   Sciubba, DM
AF Xu, Risheng
   Xia, Yuanxuan
   Passias, Peter G.
   Protopsaltis, Themistocles
   Sciubba, Daniel M.
TI Occipitocervical Osteotomies and Interfacet Grafts for Reduction of
   Occipitocervical Kyphosis and Basilar Invagination
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alagille syndrome; Atlantoaxial instability; Basilar invagination;
   Fusion; Intrafacetal spacer; Oc-C2
ID ATLANTOAXIAL JOINT DISTRACTION; POSTERIOR CERVICAL FUSION; CANAL
   STENOSIS REPORT; TRANSNASAL ODONTOIDECTOMY; ALAGILLE SYNDROME;
   EXPERIENCE; FIXATION; MASS; COMPLICATIONS; DECOMPRESSION
AB BACKGROUND: Occipitocervicai congenital pathologies involving instability of the atlantoaxial joint and basilar invagination are challenging to treat owing to the complex anatomy involving neurovascular structures at the skull base and the high-risk nature of surgery close to the brainstem.
   CASE DESCRIPTION: A patient presented with Alagille syndrome with multiple segmentation/fusion anomalies of the cervical spine and craniocervical junction, including fusion of the skull base and occipital condyles and partial assimilation of the Cl anterior ring and C2 dens. The head was anteriorly displaced, with C2 located immediately below the foramen magnum. There was significant kyphotic angulation due to nonunion of the base of the dens and the body of C2. The patient underwent occipitocervical osteotomies and occiput-C2 interfacet grafts for reduction of occipitocervical kyphosis along with foramen magnum decompression and occiput-C6 fusion. The patient had significant neurologic improvement and sustained improved craniocervical alignment on last follow-up.
   CONCLUSIONS: In patients with atlantoaxial instability with basilar invagination, posterior facet release, local distraction, and placement of cortical bone interbody grafts with occipitocervical fusion may be instrumental in reducing craniocervical kyphosis and compression by allowing anterior translation of the upper cervical spine relative to the skull. This method may be a safe and effective posterior-only approach for brainstem/spinal cord decompression for patients with complex craniocervical congenital malformations.
C1 [Xu, Risheng; Xia, Yuanxuan; Sciubba, Daniel M.] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.
   [Passias, Peter G.; Protopsaltis, Themistocles] NYU, Dept Orthopaed Surg, New York, NY USA.
RP Sciubba, DM (reprint author), Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.
EM dsciubb1@jhmi.edu
CR Adams JM, 2018, GASTROENTEROLOGY, V154, P803, DOI 10.1053/j.gastro.2018.02.007
   Andersson ER, 2018, GASTROENTEROLOGY, V154, P1080, DOI 10.1053/j.gastro.2017.11.002
   Bissonnette MLZ, 2017, KIDNEY INT REP, V2, P493, DOI 10.1016/j.ekir.2016.11.002
   Carpenter CD, 2018, PEDIATR RADIOL, V48, P602, DOI 10.1007/s00247-017-4043-2
   Dickson I, 2018, NAT REV GASTRO HEPAT, V15, P4, DOI 10.1038/nrgastro.2017.161
   Gilbert MA, 2017, CURR PATHOBIOL REP, V5, P233, DOI 10.1007/s40139-017-0144-8
   Goel A, 2005, SPINE, V30, pE551, DOI 10.1097/01.brs.0000179414.64741.7b
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   Goel A, 2008, NEUROL INDIA, V56, P144, DOI 10.4103/0028-3886.41991
   Goel A, 2007, J NEUROSURG-SPINE, V7, P90, DOI 10.3171/SPI-07/07/090
   Goel A, 2007, SURG NEUROL, V67, P135, DOI 10.1016/j.surneu.2006.05.059
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P127, DOI 10.4103/0974-8237.188417
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P15, DOI 10.4103/0974-8237.135210
   Goel A, 2013, J CRANIOVERTEBRAL JU, V4, P56, DOI 10.4103/0974-8237.128527
   Goel A, 2013, J NEUROSURG-SPINE, V19, P672, DOI 10.3171/2011.8.SPINE11249
   Goel A, 2011, J NEUROSURG-SPINE, V14, P3, DOI 10.3171/2010.9.SPINE1010
   Goel A, 2009, J NEUROSURG-SPINE, V11, P9, DOI 10.3171/2009.3.SPINE08927
   Grochowski CM, 2016, GENE, V576, P381, DOI 10.1016/j.gene.2015.10.065
   Hannoush ZC, 2017, J CLIN ENDOCR METAB, V102, P350, DOI 10.1210/jc.2016-3171
   Huang DG, 2015, SPINE J, V15, P2271, DOI 10.1016/j.spinee.2015.07.008
   Kamath BM, 2018, J PEDIATR GASTR NUTR, V67, P148, DOI 10.1097/MPG.0000000000001958
   MAILLEFERT JF, 1995, REV RHUM, V62, P537
   McCormack BM, 2013, J NEUROSURG-SPINE, V18, P245, DOI 10.3171/2012.12.SPINE12477
   Olsen IE, 2005, J PEDIATR GASTR NUTR, V40, P76, DOI 10.1097/00005176-200501000-00014
   Ozaras N, 2015, J PHYS THER SCI, V27, P3601, DOI 10.1589/jpts.27.3601
   Park J, 2011, J NEUROSURG-SPINE, V14, P639, DOI 10.3171/2011.1.SPINE10446
   Saleh M, 2016, APPL CLIN GENET, V9, DOI 10.2147/TACG.S86420
   Satoskar SR, 2014, J CRANIOVERTEBRAL JU, V5, P157, DOI 10.4103/0974-8237.147079
   Shriver MF, 2016, CLIN NEUROL NEUROSUR, V148, P121, DOI 10.1016/j.clineuro.2016.07.019
   Siemionow K, 2016, J NEUROL SURG PART A, V77, P482, DOI 10.1055/s-0036-1584210
   Tan LA, 2015, J NEUROSURG-SPINE, V22, P466, DOI 10.3171/2014.10.SPINE14192
   Teng CS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02574-7
   Tubbs RS, 2016, CHILD NERV SYST, V32, P55, DOI 10.1007/s00381-015-2864-6
NR 33
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 391
EP 396
DI 10.1016/j.wneu.2019.03.271
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300233
PM 30954738
DA 2020-05-12
ER

PT J
AU ElJalby, M
   Pannullo, SC
   Schwartz, TH
   Parashar, B
   Wernicke, AG
AF ElJalby, Mahmoud
   Pannullo, Susan C.
   Schwartz, Theodore H.
   Parashar, Bhupesh
   Wernicke, A. Gabriella
TI Optimal Timing and Sequence of Immunotherapy When Combined with
   Stereotactic Radiosurgery in the Treatment of Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain metastasis; Concurrent; Immunotherapy; Radiation; Sequential;
   Stereotactic radiosurgery; Timing
ID ANTITUMOR IMMUNITY; RADIATION-THERAPY; TUMOR-CELLS; MELANOMA;
   IPILIMUMAB; IRRADIATION; RADIOTHERAPY; SURVIVAL; PATIENT; COSTIMULATION
AB Checkpoint immunotherapy (CIT) is an emerging and exciting treatment modality for the treatment of cancer. Much excitement has ensued in the potential of CIT to revolutionize the treatment and prognosis of brain metastases. The combination of stereotactic radiosurgery (SRS) and CIT has also been studied and showed promise compared with either treatment modality alone. However, several questions have arisen, in particular, the timing at which SRS and CIT should be administered relative to each other. We reviewed the reported data and attempted to offer a potential answer to this question.
C1 [ElJalby, Mahmoud] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
   [Pannullo, Susan C.; Schwartz, Theodore H.; Wernicke, A. Gabriella] Cornell Univ, Weill Med Coll, Dept Neurosurg, New York, NY 10021 USA.
   [Parashar, Bhupesh; Wernicke, A. Gabriella] Cornell Univ, Weill Med Coll, Dept Radiat Oncol, New York, NY 10021 USA.
RP Wernicke, AG (reprint author), Cornell Univ, Weill Med Coll, Dept Neurosurg, New York, NY 10021 USA.; Wernicke, AG (reprint author), Cornell Univ, Weill Med Coll, Dept Radiat Oncol, New York, NY 10021 USA.
EM gaw9008@med.cornell.edu
RI Schwartz, Theodore/AAK-3320-2020
CR Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239
   Burnette B, 2013, SEMIN RADIAT ONCOL, V23, P273, DOI 10.1016/j.semradonc.2013.05.009
   Burnette Byron, 2012, Front Oncol, V2, P143, DOI 10.3389/fonc.2012.00143
   Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820
   Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073
   Chakraborty M, 2003, J IMMUNOL, V170, P6338, DOI 10.4049/jimmunol.170.12.6338
   Chen L, 2015, INT J RADIAT ONCOL, V93, pE102, DOI 10.1016/j.ijrobp.2015.07.807
   CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5
   CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1
   Cohen JV, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00049
   Cohen-Inbar O, 2017, J NEUROSURG, V127, P1007, DOI 10.3171/2016.9.JNS161585
   D'Andrea G, 2017, WORLD NEUROSURG, V97, P169, DOI 10.1016/j.wneu.2016.09.054
   Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012
   Demaria S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00128
   Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313
   Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265
   Di Giacomo AM, 2015, ANN ONCOL, V26, P798, DOI 10.1093/annonc/mdu577
   Di Giacomo AM, 2017, CYTOKINE GROWTH F R, V36, P33, DOI 10.1016/j.cytogfr.2017.07.002
   Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158
   Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258
   Formenti SC, 2013, JNCI-J NATL CANCER I, V105, P256, DOI 10.1093/jnci/djs629
   Foulds GA, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00014
   Frey B, 2012, CURR MED CHEM, V19, P1751, DOI 10.2174/092986712800099811
   Garnett CT, 2004, CANCER RES, V64, P7985, DOI 10.1158/0008-5472.CAN-04-1525
   Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0
   Gerber SA, 2013, AM J PATHOL, V182, P2345, DOI 10.1016/j.ajpath.2013.02.041
   Golden EB, 2013, CANCER IMMUNOL RES, V1, P365, DOI 10.1158/2326-6066.CIR-13-0115
   Goldman JW, 2016, J THORAC ONCOL, V11, pS238
   Hiniker SM, 2012, NEW ENGL J MED, V366, P2035, DOI 10.1056/NEJMc1203984
   Hutter A, 2003, NEUROIMAG CLIN N AM, V13, P237, DOI 10.1016/S1052-5149(03)00016-9
   Iorgulescu JB, 2018, CANCER IMMUNOL RES, V6, P1039, DOI 10.1158/2326-6066.CIR-18-0067
   Kiess AP, 2015, INT J RADIAT ONCOL, V92, P368, DOI 10.1016/j.ijrobp.2015.01.004
   Knisely JPS, 2012, J NEUROSURG, V117, P227, DOI 10.3171/2012.5.JNS111929
   Kroeze SGC, 2019, STRAHLENTHER ONKOL, V195, P199, DOI 10.1007/s00066-018-01422-5
   Kroeze SGC, 2017, CANCER TREAT REV, V53, P25, DOI 10.1016/j.ctrv.2016.11.013
   Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503
   Liu C, 2011, INT J BIOL SCI, V7, P168, DOI 10.7150/ijbs.7.168
   Manda K, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00102
   Margolin K, 2012, LANCET ONCOL, V13, P459, DOI 10.1016/S1470-2045(12)70090-6
   Martin AM, 2018, JAMA ONCOL, V4, P1123, DOI 10.1001/jamaoncol.2017.3993
   Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-48
   Morgensztern D, 2010, J THORAC ONCOL, V5, P29, DOI 10.1097/JTO.0b013e3181c5920c
   National Cancer Institute, AD CENTR NERV SYST T
   Odorizzi PM, 2015, J EXP MED, V212, P1125, DOI 10.1084/jem.20142237
   Oliva ICG, 2018, ANN ONCOL, V29, P1509, DOI 10.1093/annonc/mdy185
   Park B, 2014, INT J MOL SCI, V15, P927, DOI 10.3390/ijms15010927
   Patchell RA, 2003, CANCER TREAT REV, V29, P533, DOI 10.1016/S0305-7372(03)00105-1
   Patel KR, 2017, AM J CLIN ONCOL-CANC, V40, P444, DOI 10.1097/COC.0000000000000199
   Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824
   Qian JM, 2016, CANCER-AM CANCER SOC, V122, P3051, DOI 10.1002/cncr.30138
   Rahman R, 2017, INT J RADIAT ONCOL, V99, pE101, DOI 10.1016/j.ijrobp.2017.06.833
   Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494
   Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086
   Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8
   Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108
   Shoukat S, 2013, J CLIN ONCOL, V31
   Silk AW, 2013, CANCER MED-US, V2, P899, DOI 10.1002/cam4.140
   Skrepnik T, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1283461
   Sneed PK, 2012, INT J RADIAT ONCOL, V84, pS118, DOI 10.1016/j.ijrobp.2012.07.208
   Sperduto PW, 2008, INT J RADIAT ONCOL, V70, P510, DOI 10.1016/j.ijrobp.2007.06.074
   Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527
   Spiotto M, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1266
   Stamell EF, 2013, INT J RADIAT ONCOL, V85, P293, DOI 10.1016/j.ijrobp.2012.03.017
   Stewart BW, 2014, WORLD CANC REPORT 20
   TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351
   Van Limbergen EJ, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20170157
   Weichselbaum RR, 2017, NAT REV CLIN ONCOL, V14, P365, DOI 10.1038/nrclinonc.2016.211
   Young KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157164
NR 69
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 397
EP 404
DI 10.1016/j.wneu.2019.04.093
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300234
PM 31004856
DA 2020-05-12
ER

PT J
AU Ogasawara, Y
   Kashimura, H
   Akamatsu, Y
   Aso, K
   Oshida, S
AF Ogasawara, Yasushi
   Kashimura, Hiroshi
   Akamatsu, Yosuke
   Aso, Kenta
   Oshida, Sotaro
TI Fenestrated Mini-Clip Application to Preserve a Tightly Adhering Branch
   Artery to a Middle Cerebral Artery Aneurysm: Technical Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adhered artery; Clipping; Fenestrated mini-clip; Narrow blade
AB BACKGROUND: Fenestrated mini-clips have been reported as useful for treating dog ear-shaped remnant aneurysms, the small aneurysms to which the efferent artery adheres or is impeded by the surrounding neurovascular structure in the restricted operative corridor, because of the smaller clip head. Here, the alternative utility of fenestrated mini-clip was reported by mentioning the narrower clip blade.
   METHODS: We report a case of middle cerebral artery aneurysm tightly adhered by the anterior temporal artery (ATA) as well as the efferent arteries and demonstrate the utility of fenestrated mini-clip.
   RESULTS: During aneurysm dissection, the superior division of the M2 segment of the middle cerebral artery and the ATA adhered tightly to the aneurysm, thereby restricting meticulous aneurysm dissection, To preserve the efferent artery and the ATA, a fenestrated standard clip was applied, transmitting the efferent artery, and the clip blade was applied in the restricted space between the adhering ATA and the aneurysm neck. However, because kinking of the ATA was observed following first clip application, the fenestrated mini-clip was applied in similar fashion to avoid kinking of the ATA instead of a standard clip, thereby preserving the ATA without further aneurysm dissection. Finally, successful obliteration of the aneurysm and preservation of the ATA were achieved with the subsequent clip application.
   CONCLUSIONS: In selected cases, application of a narrower bladed fenestrated mini-clip in the restricted space may be useful to preserve tightly adhering branch arteries, as well as efferent arteries.
C1 [Ogasawara, Yasushi; Kashimura, Hiroshi; Aso, Kenta; Oshida, Sotaro] Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
   [Akamatsu, Yosuke] Iwate Med Univ, Sch Med, Dept Neurosurg, Morioka, Iwate, Japan.
RP Kashimura, H (reprint author), Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
EM h-kashimura@pref.iwate.jp
CR Akamatsu Y, 2019, WORLD NEUROSURG, V122, P240, DOI 10.1016/j.wneu.2018.10.222
   FUJITA S, 1986, J NEUROSURG, V65, P122, DOI 10.3171/jns.1986.65.1.0122
   Ota Nakao, 2015, Surg Neurol Int, V6, pS553, DOI 10.4103/2152-7806.168072
   SUGITA K, 1982, J NEUROSURG, V57, P240, DOI 10.3171/jns.1982.57.2.0240
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 405
EP 408
DI 10.1016/j.wneu.2019.02.179
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300235
PM 30862572
DA 2020-05-12
ER

PT J
AU Meidert, AS
   Kinzinger, J
   Mohnle, P
   Pekrul, I
   Spiekermann, K
   Thorsteinsdottir, J
   Briegel, J
   Huge, V
AF Meidert, Agnes S.
   Kinzinger, Johannes
   Moehnle, Patrick
   Pekrul, Isabell
   Spiekermann, Karsten
   Thorsteinsdottir, Jun
   Briegel, Josef
   Huge, Volker
TI Perioperative Management of a Patient with Severe Factor V Deficiency
   Presenting with Chronic Subdural Hematoma: A Clinical Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bleeding disorder; Chronic subdural hematoma; Critical care; Factor V
   deficiency
AB BACKGROUND: Severe factor V deficiency is an extremely rare coagulation disorder. Patients with factor V activity <5% usually become symptomatic in early childhood.
   CASE DESCRIPTION: We report the case of an 82-year-old woman with incidentally diagnosed severe factor V deficiency, who developed a symptomatic chronic subdural hematoma, requiring burr hole craniostomy. Successful management was achieved by a multidisciplinary approach. Preoperatively, factor V activity was increased from 2% to 50% by administration of 25 mL/kg body weight of fresh frozen plasma over 30 minutes under close cardiopulmonary monitoring in the intensive care unit. Straight afterward, the patient was transferred to the operating room where surgery was performed under general anesthesia. Burr hole craniostomy could be performed without perioperative complications. In the postoperative days, there was no relevant recurrence of the subdural hematoma in the follow-up computed tomography scans tinder frequent control of coagulation parameters. However, despite further transfusion of fresh frozen plasma, factor V activity did not increase >16%. The patient was discharged without any neurologic deficits. In a hemostaseologic follow-up 2 months after surgery, factor V activity < 1% was confirmed with evidence of a factor V inhibitor in the modified Bethesda assay. Most likely, the patient suffered from an acquired form of factor V deficiency with preformed antibodies that had been boosted by the initial treatment with fresh frozen plasma.
   CONCLUSIONS: We conclude that in this rare bleeding disorder, intracranial surgery was successfully managed because of a thoroughly planned perioperative therapeutic strategy. However, if there is time prior to surgery, a full checkup of the bleeding disorder is advisable.
C1 [Meidert, Agnes S.; Kinzinger, Johannes; Moehnle, Patrick; Pekrul, Isabell; Briegel, Josef; Huge, Volker] Univ Hosp Munich LMU, Dept Anaesthesiol, Munich, Germany.
   [Moehnle, Patrick; Pekrul, Isabell] Univ Hosp Munich LMU, Dept Transfus Med Cellular Therapeut & Hemostaseo, Munich, Germany.
   [Spiekermann, Karsten] Univ Hosp Munich LMU, Dept Internal Med Hematol & Oncol 3, Munich, Germany.
   [Thorsteinsdottir, Jun] Univ Hosp Munich LMU, Dept Neurosurg, Munich, Germany.
RP Meidert, AS (reprint author), Univ Hosp Munich LMU, Dept Anaesthesiol, Munich, Germany.
EM agnes_meidert@web.de
RI Briegel, Josef/AAG-3774-2019
CR Ang AL, 2009, THROMB HAEMOSTASIS, V101, P852, DOI 10.1160/TH08-11-0767
   Asselta R, 2009, SEMIN THROMB HEMOST, V35, P382, DOI 10.1055/s-0029-1225760
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Huang JN, 2008, HAEMOPHILIA, V14, P1164, DOI 10.1111/j.1365-2516.2008.01785.x
   Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290
   Mannucci PM, 2004, BLOOD, V104, P1243, DOI 10.1182/blood-2004-02-0595
   Martinaud C, 2012, ANESTHESIOLOGY, V117, P339, DOI 10.1097/ALN.0b013e3182608cdd
   Peyvandi F, 2016, HEMATOL-AM SOC HEMAT, P663, DOI 10.1182/asheducation-2016.1.663
   Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2
   Yoneoka Y, 1999, ACTA NEUROCHIR, V141, P667, DOI 10.1007/s007010050359
NR 12
TC 0
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 409
EP 413
DI 10.1016/j.wneu.2019.04.080
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300236
PM 30999086
DA 2020-05-12
ER

PT J
AU Zolnourian, A
   Borg, N
   Akhigbe, T
   Macdonald, J
   Bulters, D
AF Zolnourian, Ardalan
   Borg, Nicholas
   Akhigbe, Taiwo
   Macdonald, Jason
   Bulters, Diederik
TI Vessel Wall Imaging After Subarachnoid Hemorrhage in Patients with
   Multiple Intracranial Aneurysms: A Cautionary Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial aneurysm; Subarachnoid hemorrhage; Vessel wall imaging
ID CEREBRAL VASOCONSTRICTION SYNDROME; MRI; ENHANCEMENT
AB BACKGROUND: Almost 30% of patients with subarachnoid hemorrhage (SAH) are found to have multiple aneurysms. This can potentially present a serious management dilemma when planning treatment. Magnetic resonance imaging vessel wall imaging (VWI) has been proposed as a reliable technique in differentiating between ruptured and unruptured aneurysms in patients with multiple intracranial aneurysms who present with SAH. Expert consensus now supports this as a possible use for the technique.
   CASE DESCRIPTION: Here we present a patient presenting a particular clinical dilemma with SAH and a left third nerve palsy and transient speech disturbance who had circumferential enhancement in the left larger 3.5-mm irregular middle cerebral artery aneurysm and no detectable enhancement in what was angiographically either a 1.5-mm smooth noncompressive left posterior communicating artery aneurysm or infundibulum, but was proved at surgery to be the culprit aneurysm.
   CONCLUSION: Although a case of concurrent false positive and false negative in the same patient has not previously been reported, the positive predictive value of VWI for rupture status is known to be much lower than its negative predictive value, and a case like this might be expected to occur in 0.6% of patients. Therefore, whereas VWI is a valuable tool, it should be used in conjunction with, and not in lieu of, traditional indicators of aneurysm rupture.
C1 [Zolnourian, Ardalan; Borg, Nicholas; Akhigbe, Taiwo; Bulters, Diederik] Wessex Neurol Ctr, Dept Neurosurg, Southampton, Hants, England.
   [Macdonald, Jason] Wessex Neurol Ctr, Dept Neuroradiol, Southampton, Hants, England.
RP Zolnourian, A (reprint author), Wessex Neurol Ctr, Dept Neurosurg, Southampton, Hants, England.
EM a.zolnourian@soton.ac.uk
OI Zolnourian, Ardalan H/0000-0002-0428-179X
CR Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84
   Edjlali M, 2014, STROKE, V45, P3704, DOI 10.1161/STROKEAHA.114.006626
   ENDO S, 1995, J NEUROSURG, V83, P421, DOI 10.3171/jns.1995.83.3.0421
   Hu P, 2016, NEURORADIOLOGY, V58, P979, DOI 10.1007/s00234-016-1729-3
   Juvela S, 2000, STROKE, V31, P392, DOI 10.1161/01.STR.31.2.392
   Kim SC, 2009, J KOREAN NEUROSURG S, V45, P240, DOI 10.3340/jkns.2009.45.4.240
   Mandell DM, 2017, AM J NEURORADIOL, V38, P218, DOI 10.3174/ajnr.A4893
   Mandell DM, 2012, STROKE, V43, P860, DOI 10.1161/STROKEAHA.111.626184
   Matouk CC, 2013, NEUROSURGERY, V72, P492, DOI 10.1227/NEU.0b013e31827d1012
   Nagahata S, 2016, CLIN NEURORADIOL, V26, P277, DOI 10.1007/s00062-014-0353-z
   Natori T, 2014, J STROKE CEREBROVASC, V23, P2419, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.019
   Obusez EC, 2014, AM J NEURORADIOL, V35, P1527, DOI 10.3174/ajnr.A3909
   Vergouwen MDI, 2011, ARCH NEUROL-CHICAGO, V68, P676, DOI 10.1001/archneurol.2011.89
NR 13
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 414
EP 417
DI 10.1016/j.wneu.2019.04.130
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300237
PM 31026656
DA 2020-05-12
ER

PT J
AU Dai, LM
   Qiu, Y
   Cen, B
   Lv, J
AF Dai, Li Ming
   Qiu, Yong
   Cen, Bo
   Lv, Jing
TI Intramedullary Schwannoma of Cervical Spinal Cord Presenting
   Inconspicuous Enhancement with Gadolinium
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intramedullary schwannomas; Magnetic resonance imaging; Spinal cord;
   Surgical resection
ID FEATURES; OUTCOMES; TUMORS
AB BACKGROUND: Intramedullary schwannomas of the spinal cord are extremely rare. Most previous studies are case reports, which have found that intramedullary schwannomas could be homogeneous or asymmetrically enhanced with gadolinium. However, intramedullary schwannomas with minimal enhancement have not been reported.
   CASE DESCRIPTION: This article describes a 34-year-old patient who presented with nonradiative neck pain, progressive weakness of the left limbs, and sensory deficit of both lower extremities. Preoperative examinations such as magnetic resonance imaging (MRI) were performed, and the patient underwent surgical treatment MRI showed that the lesion presented unsharp enhancement with gadolinium on T1-weighted images. Histopathologic findings were consistent with the diagnosis of schwannoma.
   CONCLUSIONS: We report a case of intramedullary schwannoma that presented inconpicuous enhancement with gadolinium. MRI is useful but cannot be used to differentiate schwannomas from other intramedullary spinal tumours. Surgical resection is the most vital factor for the treatment of intramedullary schwannoma.
C1 [Dai, Li Ming; Qiu, Yong; Cen, Bo] Wuhan Brain Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Lv, Jing] Wuhan Brain Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China.
RP Qiu, Y (reprint author), Wuhan Brain Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM 1248204814@qq.com
OI Dai, li ming/0000-0002-9656-9984
CR Brotchi J, 2002, NEUROSURGERY, V50, P1059
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Fanburg-Smith JC, 2006, MODERN PATHOL, V19, P115, DOI 10.1038/modpathol.3800489
   Gao L, 2017, J COMPUT ASSIST TOMO, V41, P137, DOI 10.1097/RCT.0000000000000493
   Hayashi F, 2009, SPINE J, V9, P19
   Ho T, 2006, ASIAN J SURG, V29, P306, DOI 10.1016/S1015-9584(09)60108-1
   Kim SD, 2005, SURG NEUROL, V63, P389, DOI 10.1016/j.surneu.2004.03.023
   Kodama Y, 2001, NEURORADIOLOGY, V43, P567, DOI 10.1007/s002340100540
   Kyoshima K, 2005, J CLIN NEUROSCI, V12, P481, DOI 10.1016/j.jocn.2004.06.015
   Lee SE, 2013, J NEURO-ONCOL, V113, P75, DOI 10.1007/s11060-013-1091-9
   Nicacio JM, 2009, RARE TUMORS, V1, DOI 10.4081/rt.2009.e44
   Ohtonari T, 2009, NEUROL MED-CHIR, V49, P536, DOI 10.2176/nmc.49.536
   Patel NP, 2017, MED GAS RES, V7, P133, DOI 10.4103/2045-9912.208520
   Raco A, 2005, NEUROSURGERY, V56, P972, DOI 10.1227/01.NEU.0000158318.66568.CC
   Riffaud L, 2000, NEURORADIOLOGY, V42, P275, DOI 10.1007/s002340050885
   Ryu KS, 2011, J KOREAN NEUROSURG S, V49, P302, DOI 10.3340/jkns.2011.49.5.302
   Verla T, 2016, WORLD NEUROSURG, V95, P108, DOI 10.1016/j.wneu.2016.07.066
   Wang SJ, 2003, NEUROL RES, V25, P516, DOI 10.1179/016164103101201751
   WOLTMAN HW, 1951, AMA ARCH NEUROL PSY, V65, P378, DOI 10.1001/archneurpsyc.1951.02320030115010
   Wu L, 2011, NEUROL MED-CHIR, V51, P630, DOI 10.2176/nmc.51.630
   Yang T, 2014, ACTA NEUROCHIR, V156, P1789, DOI 10.1007/s00701-014-2168-8
   Zhang Q, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.126
NR 22
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 418
EP 422
DI 10.1016/j.wneu.2019.04.118
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300238
PM 31028978
DA 2020-05-12
ER

PT J
AU Hou, K
   Li, GC
   Wang, X
   Xu, K
   Yu, JL
AF Hou, Kun
   Li, Guichen
   Wang, Xin
   Xu, Kan
   Yu, Jinlu
TI Endovascular Treatment for Peripheral Superior Cerebellar Artery
   Aneurysms: Current State and Future Considerations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Collateral circulation; Dissecting aneurysm; Endovascular treatment;
   Parent artery occlusion; Superior cerebellar artery aneurysm
ID POSTERIOR CIRCULATION; DISSECTING ANEURYSMS; PARENT ARTERY; INJECTION;
   MANAGEMENT; OCCLUSION; FEATURES; PATIENT
AB BACKGROUND: Superior cerebellar artery (SCA) aneurysms can be divided into 2 types: basilar artery (BA)-SCA junction aneurysms and peripheral SCA aneurysms. The peripheral SCA aneurysm is a distinct entity from its BA-SCA counterpart. No comprehensive literature review for endovascular management of peripheral SCA aneurysms has been conducted.
   METHODS: A PubMed search of the published articles written in English was performed on February 13, 2019 for patients who underwent endovascular treatment for peripheral SCA aneurysms. Segmentation of SCA was in accordance with the proposed nomenclature by Rodriguez-Hernandez et al. A modified Rankin Scale score <= 1 was defined as good recovery.
   RESULTS: Thirty-five articles reporting 55 patients including 2 cases in our center were included in the final analysis. The affected patients (28 females, 50.9%) were aged from 3 months to 79 years (46.22 +/- 13.51 years). Forty-five patients (81.8%) presented with spontaneous subarachnoid hemorrhage with or without cerebellar hematoma. Forty-six patients (83.6%) experienced good recovery. Permanent or transient procedure-related complications occurred in 17/49 patients (34.7%) during endovascular treatment (EVT). However, no fatal or server procedure-related complication occurred in the long-term.
   CONCLUSIONS: Peripheral SCA aneurysms are rare cerebrovascular lesions and should be treated as a specific entity. EVT is an efficient and safe option in peripheral SCA aneurysms. Permanent and fatal procedure-related complications are rare. Further prospective and larger-scale studies are warranted to better elucidate the role of EVT in peripheral SCA aneurysms.
C1 [Hou, Kun; Wang, Xin; Xu, Kan; Yu, Jinlu] Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Li, Guichen] Jilin Univ, Hosp 1, Dept Neurol, Changchun, Jilin, Peoples R China.
RP Yu, JL (reprint author), Jilin Univ, Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM jlyu@jlu.edu.cn
RI ; Yu, Jinlu/G-7719-2019
OI Hou, Kun/0000-0001-7112-7883; Yu, Jinlu/0000-0003-2329-7946
FU Second Round Scientific Research Funding of The First Hospital of Jilin
   University (Eastern Division)
FX This research received funding support from the Second Round Scientific
   Research Funding of The First Hospital of Jilin University (Eastern
   Division) (B2).
CR Alurkar A, 2012, J CLIN IMAG SCI, V2, DOI 10.4103/2156-7514.99181
   Andreou A, 2007, AM J NEURORADIOL, V28, P355
   Baek JW, 2014, J KOREAN NEUROSURG S, V56, P257, DOI 10.3340/jkns.2014.56.3.257
   Biondi A, 2006, NEUROIMAG CLIN N AM, V16, P453, DOI 10.1016/j.nic.2006.05.006
   Chaloupka JC, 1996, AM J NEURORADIOL, V17, P1338
   Chen JCT, 2017, J CLIN NEUROSCI, V38, P87, DOI 10.1016/j.jocn.2016.12.026
   Cognard C, 1999, AM J NEURORADIOL, V20, P780
   Danet M, 2001, AM J NEURORADIOL, V22, P717
   Del Santo MA, 2016, BMJ CASE REP, V2016
   Di Stefano G, 2017, WORLD NEUROSURG, V101, DOI 10.1016/j.wneu.2017.03.082
   Eckard DA, 2000, AM J NEURORADIOL, V21, P137
   Gjertsen O, 2007, INTERV NEURORADIOL, V13, P167, DOI 10.1177/159101990701300207
   Gotoh H, 2004, J CLIN NEUROSCI, V11, P196, DOI 10.1016/S0967-5868(03)00136-X
   HARDY DG, 1980, NEUROSURGERY, V6, P10, DOI 10.1227/00006123-198001000-00002
   Haw C, 2004, CAN J NEUROL SCI, V31, P53, DOI 10.1017/S0317167100002833
   Jankowitz BT, 2011, J NEUROIMAGING, V21, P56, DOI 10.1111/j.1552-6569.2009.00429.x
   Jeon Joon Bok, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P276, DOI 10.7461/jcen.2016.18.3.276
   Jin Sung-Chul, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P29, DOI 10.7461/jcen.2012.14.1.29
   Kamat AS, 2012, J CLIN NEUROSCI, V19, P464, DOI 10.1016/j.jocn.2011.07.028
   Kang Min-Cheol, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P243, DOI 10.7461/jcen.2012.14.3.243
   Kim CH, 2014, NEURORADIOLOGY, V56, P647, DOI 10.1007/s00234-014-1375-6
   Komotar RJ, 2005, NEUROSURGERY, V56, P836, DOI 10.1227/01.NEU.0000156467.05456.9D
   Leonardi M, 2001, INTERV NEURORADIOL, V7, P343, DOI 10.1177/159101990100700411
   Lubicz B, 2003, AM J NEURORADIOL, V24, P1208
   LUHAN JA, 1953, NEUROLOGY, V3, P77, DOI 10.1212/WNL.3.2.77
   Matouk CC, 2011, INTERV NEURORADIOL, V17, P371, DOI 10.1177/159101991101700315
   Mitsos AP, 2008, NEURORADIOLOGY, V50, P161, DOI 10.1007/s00234-007-0315-0
   Mou KJ, 2016, J CRANIOFAC SURG, V27, pE244, DOI 10.1097/SCS.0000000000002439
   Nakai Y, 2000, SURG NEUROL, V54, P73, DOI 10.1016/S0090-3019(00)00261-5
   Ong CK, 2010, J CLIN NEUROSCI, V17, P515, DOI 10.1016/j.jocn.2009.06.041
   Onishi S, 2019, WORLD NEUROSURG, V122, P102, DOI 10.1016/j.wneu.2018.10.137
   Oran I, 2009, DIAGN INTERV RADIOL, V15, P159
   Paiva WS, 2012, J TRAUMA ACUTE CARE, V72, pE115, DOI 10.1097/TA.0b013e318238bee5
   Patra DP, 2016, WORLD NEUROSURG, V94, P229, DOI 10.1016/j.wneu.2016.07.007
   Peluso JPP, 2007, AM J NEURORADIOL, V28, P1573, DOI 10.3174/ajnr.A0607
   Rodriguez-Hernandez A, 2017, NEUROSURGERY, V80, P908, DOI 10.1093/neuros/nyw111
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Szajner M, 2003, INTERV NEURORADIOL, V9, P193, DOI 10.1177/159101990300900209
   Tahir R, 2018, CUREUS, V10, DOI 10.7759/cureus.2918
   Takeshima Y, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.052
   Uchikawa H, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.11.069
   Velioglu M, 2015, TURK NEUROSURG, V25, P526, DOI 10.5137/1019-5149.JTN.8611-13.0
   Wang C, 2015, J CRANIOFAC SURG, V26, P1270, DOI 10.1097/SCS.0000000000001758
   Yamakawa H, 2008, SURG NEUROL, V70, P421, DOI 10.1016/j.surneu.2007.02.061
   Zenteno M, 2007, J NEUROSURG, V107, P860, DOI 10.3171/JNS-07/10/0860
   Zicherman J, 2004, AM J NEURORADIOL, V25, P1077
NR 46
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 423
EP 433
DI 10.1016/j.wneu.2019.04.145
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300239
PM 31028980
DA 2020-05-12
ER

PT J
AU Liby, P
   Lomachinsky, V
   Petrak, B
AF Liby, Petr
   Lomachinsky, Victor
   Petrak, Borek
TI Jugular Bulb Dysmaturation in Torcular Dural Sinus Malformation:
   Clinical Images and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dural sinus malformation; Jugular bulb dysmaturation; Torcular
AB We present unique clinical images of jugular bulb dysmaturation (JBD) in an infant with torcular dural sinus malformation (tDSM). Lasjaunias et al hypothesized that the former possess a pivoting role for development of the latter. However, reports about tDSM are extremely rare and lack focus on JBD presence. In this paper we focused on JBD depiction. The combination of magnetic resonance imaging angiography, computed tomography angiography, and digital subtraction angiography imaging of JBD is unique. Moreover, we reviewed current tDSM literature and showed that the presence of JBD in tDSMs correlates significantly with a higher mortality.
C1 [Liby, Petr] Charles Univ Prague, Fac Med 2, Dept Neurosurg, Prague, Czech Republic.
   [Petrak, Borek] Charles Univ Prague, Fac Med 2, Dept Pediat Neurol, Prague, Czech Republic.
   [Petrak, Borek] Motol Univ Hosp, Prague, Czech Republic.
   [Lomachinsky, Victor] Univ Pernambuco, Fac Ciencias Med, Recife, PE, Brazil.
RP Liby, P (reprint author), Charles Univ Prague, Fac Med 2, Dept Neurosurg, Prague, Czech Republic.
EM petr.liby@fnmotol.cz
OI Liby, Petr/0000-0001-8392-795X
CR Barbosa M, 2003, INTERV NEURORADIOL, V9, P407, DOI 10.1177/159101990300900413
   Lasjaunias P, 1996, INTERV NEURORADIOL, V30, P179
   Merzoug V, 2008, EUR RADIOL, V18, P692, DOI 10.1007/s00330-007-0783-y
   OKUDERA T, 1994, AM J NEURORADIOL, V15, P1871
NR 4
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 434
EP 435
DI 10.1016/j.wneu.2019.04.129
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300240
PM 31026653
DA 2020-05-12
ER

PT J
AU Bartek, J
   Alattar, A
   Jensdottir, M
   Chen, CC
AF Bartek, Jiri, Jr.
   Alattar, Ali
   Jensdottir, Margret
   Chen, Clark C.
TI Biopsy and Ablation of H3K27 Glioma Using Skull-Mounted Smartframe
   Device: Technical Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clearpoint Smartframe; Glioblastoma; Laser interstitial thermal therapy;
   Neurosurgery; Skull mount; Stereotactic biopsy; Stereotactic laser
   ablation
ID INTRACRANIAL LESIONS; STEREOTACTIC BIOPSY; FRAMELESS; EFFICACY; SAFETY
AB BACKGROUND: Clearpoint Smartframe is a magnetic resonance imaging - compatible stereotactic system often used to perform magnetic resonance imaging - guided biopsies. The system is typically mounted on the scalp through screws that pierce the skin and penetrate the outer table of the cranium. However, the frame can also be configured to be mounted directly onto the skull.
   CASE DESCRIPTION: Here, we describe the clinical context well suited Tor a skull-mount Clearpoint Smartframe surgery. The patient suffered from a subcentimeter right parafourth ventricular contrast-enhancing lesion with hydrocephalus and underwent a right suboccipital needle biopsy followed by an occipital ventriculoperitoneal shunt. Although the hydrocephalus resolved with the ventriculoperitoneal shunt, the biopsy sample proved nondiagnostic. The patient underwent a second procedure during which the Clearpoint Smartframe was mounted onto the skull through space dissected free during the previous surgery. Diagnostic biopsy (H3K27 glioma) was performed followed by stereotactic laser ablation of the lesion.
   CONCLUSIONS: We describe a case in which the skull mount Cleat, oint Smartframe was used to biopsy and ablate a midline H3K27 glioma.
C1 [Bartek, Jiri, Jr.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Bartek, Jiri, Jr.; Jensdottir, Margret] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Rigshosp, Copenhagen Univ Hosp, Dept Neurosurg, Copenhagen, Denmark.
   [Alattar, Ali] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Chen, Clark C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Chen, CC (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM ccchen@umn.edu
CR Dammers R, 2008, ACTA NEUROCHIR, V150, P23, DOI 10.1007/s00701-007-1473-x
   Hall WA, 1998, CANCER, V82, P1749, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1756::AID-CNCR23>3.0.CO;2-2
   Hawasli AH, 2013, NEUROSURGERY, V73, P1007, DOI 10.1227/NEU.0000000000000144
   Kamath AA, 2017, STEREOT FUNCT NEUROS, V95, P417, DOI 10.1159/000485387
   Larson PS, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822f4a91
   Lu Y, 2015, WORLD NEUROSURG, V83, P261, DOI 10.1016/j.wneu.2014.07.043
   Malone H, 2015, WORLD NEUROSURG, V84, P1084, DOI 10.1016/j.wneu.2015.05.025
   Rennert RC, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16217
   Sanai N, 2008, NEUROSURGERY, V63, P460, DOI 10.1227/01.NEU.0000324731.68843.74
   Scheer JK, 2017, OPER NEUROSURG, V13, P329, DOI 10.1093/ons/opw035
   Zabramski Joseph M, 2012, Surg Neurol Int, V3, P81, DOI 10.4103/2152-7806.99171
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 436
EP 441
DI 10.1016/j.wneu.2019.04.029
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300241
PM 30974271
DA 2020-05-12
ER

PT J
AU Miki, K
   Natori, Y
   Kai, Y
   Mori, M
   Yamada, T
   Noguchi, N
AF Miki, Kenji
   Natori, Yoshihiro
   Kai, Yasutoshi
   Mori, Megumu
   Yamada, Tetsuhisa
   Noguchi, Naoki
TI How to Remove a Penetrating Intracranial Large Nail
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial; Penetrating foreign body; Superior sagittal sinus
ID INJURY
AB BACKGROUND: The incidence of penetrating intracranial foreign bodies is and to date, not many relevant studies have been published worldwide. In particular, a nail penetrating intracranially, just near the superior sagittal sinus (SSS), is extremely rare. We treated the case of a large nail that penetrated the middle of the head and strategized its removal.
   CASE DESCRIPTION: A 70-year-old man had experienced headache lasting a day. Computed tomography of the brain revealed a nail penetrating the middle of his head; in particular, the tip of the nail had penetrated the right ventricle, causing a slight subarachnoid hemorrhage. Angiography showed that the nail was very close to the SSS and that the venous flow was normal. However, there was a risk of the nail penetrating through the SSS or injuring other arteries, and we removed the nail directly from the intracranial view to stop bleeding from the SSS or other vessels. Fortunately, there was no bleeding, and we washed the hole created by the nail penetration and concluded the surgery.
   CONCLUSIONS: Our technique is useful and safe for removing large nails penetrating the head.
C1 [Miki, Kenji; Natori, Yoshihiro; Kai, Yasutoshi; Mori, Megumu; Yamada, Tetsuhisa; Noguchi, Naoki] Aso Iizuka Hosp, Dept Neurosurg, Iizuka, Fukuoka, Japan.
RP Miki, K (reprint author), Aso Iizuka Hosp, Dept Neurosurg, Iizuka, Fukuoka, Japan.
EM mickeydreamk@yahoo.co.jp
CR Birk DM, 2015, J NEUROSURG, V123, P81, DOI 10.3171/2014.10.JNS141349
   Chan SK, 2014, HONG KONG MED J, V20, P67, DOI 10.12809/hkmj134028
   GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002
   HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019
   Kazim Syed Faraz, 2011, J Emerg Trauma Shock, V4, P395, DOI 10.4103/0974-2700.83871
   Kim PE, 2002, NEUROIMAG CLIN N AM, V12, P229, DOI 10.1016/S1052-5149(02)00007-2
   Paiva WS, 2010, CLIN OPHTHALMOL, V4, P1103, DOI 10.2147/OPTH.S9638
   Riley JP, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.09.083
   Rosenfeld JV, 2015, WORLD J SURG, V39, P1352, DOI 10.1007/s00268-014-2874-7
   Sani S, 2005, J NEUROSURG, V103, P567, DOI 10.3171/jns.2005.103.3.0567
   Shin TH, 2012, J KOREAN NEUROSURG S, V52, P414, DOI 10.3340/jkns.2012.52.4.414
   Skoch J, 2013, J NEUROL SURG REP, V74, P23, DOI 10.1055/s-0033-1346976
   Su YM, 2016, J SURG CASE REP, V3, P1
   Vakil MT, 2017, EMERG RADIOL, V24, P301, DOI 10.1007/s10140-016-1477-z
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 442
EP 445
DI 10.1016/j.wneu.2019.04.161
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300242
PM 31029823
DA 2020-05-12
ER

PT J
AU Watanabe, J
   Okamoto, K
   Ohashi, T
   Natsumeda, M
   Hasegawa, H
   Oishi, M
   Miyatake, S
   Matsumoto, N
   Fujii, Y
AF Watanabe, Jun
   Okamoto, Kouichirou
   Ohashi, Tsukasa
   Natsumeda, Manabu
   Hasegawa, Hitoshi
   Oishi, Makoto
   Miyatake, Satoko
   Matsumoto, Naomichi
   Fujii, Yukihiko
TI Malignant Hyperthermia and Cerebral Venous Sinus Thrombosis After
   Ventriculoperitoneal Shunt in Infant with Schizencephaly and COL4A1
   Mutation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous thrombosis; COL4A1; Malignant hyperthermia;
   Schizencephaly; Ventriculoperitoneal shunt
ID HEMORRHAGE
AB Background: Schizencephaly is a rare congenital central nervous system malformation characterized by linear, thickened clefts of the cerebral mantle. Recently, germline mutations in collagen type IV alpha 1 (COL4A1) have been reported to be a genetic cause of schizencephaly as a result of prenatal stroke. Patients with COL4A1 mutation demonstrate a variety of disease phenotypes. However, little is known about the potential complications of patients with COL4A1 mutations before and after neurologic surgery.
   Case Description: A 9-month-old boy with schizencephaly and a congenital cataract underwent a ventriculoperitoneal shunt for progressive hydrocephalus. Postoperatively, he developed malignant hyperthermia and cerebral venous thrombosis. Early treatment with dantrolene sodium and hydration was effective. Genetic testing revealed a germline COL4A1 mutation.
   CONCLUSIONS: To our knowledge, malignant hyperthermia and cerebral venous thrombosis have not been reported in the literature in patients with COL4A1 mutations after surgery. Schizencephaly arising from COL4A1 mutations might be a disease prone to these adverse effects because this mutation is known to be associated with venous tortuosity, venous vulnerability, and muscle spasms due to basement membrane protein abnormalities. We need to better understand the wide spectrum of clinical phenotypes of COL4A1 mutations and potential complications in order to better manage surgery of patients with schizencephaly.
C1 [Watanabe, Jun; Natsumeda, Manabu; Hasegawa, Hitoshi; Oishi, Makoto; Fujii, Yukihiko] Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan.
   [Okamoto, Kouichirou] Niigata Univ, Brain Res Inst, Dept Translat Res, Niigata, Japan.
   [Ohashi, Tsukasa] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat, Niigata, Japan.
   [Miyatake, Satoko; Matsumoto, Naomichi] Yokohama City Univ, Grad Sch Med, Dept Human Genet, Yokohama, Kanagawa, Japan.
RP Watanabe, J (reprint author), Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata, Japan.
EM jwatanabe@bri.niigata-u.ac.jp
RI Natsumeda, Manabu/Z-2072-2019
OI Natsumeda, Manabu/0000-0003-3098-8323; Watanabe, Jun/0000-0001-9474-2483
FU AMEDJapan Agency for Medical Research and Development (AMED)
   [JP18ek0109280, JP18dm0107090, JP18ek0109301, JP18ek0109348,
   JP18kk020500]; JSPS KAKENHIMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP17K10080,
   JP17H01539]
FX This work was supported by AMED under grants JP18ek0109280,
   JP18dm0107090, JP18ek0109301, JP18ek0109348, and JP18kk020500 and by
   JSPS KAKENHI under grants JP17K10080 and JP17H01539.
CR Abe Y, 2017, EUR J MED GENET, V60, P169, DOI 10.1016/j.ejmg.2016.12.008
   Braga VL, 2018, PEDIATR NEUROL, V87, P23, DOI 10.1016/j.pediatrneurol.2018.08.001
   Cavallin M, 2018, EUR J MED GENET, V61, P765, DOI 10.1016/j.ejmg.2018.10.004
   de Vries LS, 2009, ANN NEUROL, V65, P12, DOI 10.1002/ana.21525
   Gould DB, 2005, SCIENCE, V308, P1167, DOI 10.1126/science.1109418
   Gould DB, 2006, NEW ENGL J MED, V354, P1489, DOI 10.1056/NEJMoa053727
   Iwama K, 2018, J HUM GENET, V63, P1049, DOI 10.1038/s10038-018-0488-x
   Meuwissen MEC, 2011, NEUROLOGY, V76, P844, DOI 10.1212/WNL.0b013e31820e7751
   Meuwissen MEC, 2015, GENET MED, V17, P843, DOI 10.1038/gim.2014.210
   Niwa T, 2015, MAGN RESON MED SCI, V14, P223, DOI 10.2463/mrms.2014-0060
   Packard AM, 1997, NEUROLOGY, V48, P1427, DOI 10.1212/WNL.48.5.1427
   Petrov D, 2017, CHILD NERV SYST, V33, P491, DOI 10.1007/s00381-016-3329-2
   Plaisier E, 2007, NEW ENGL J MED, V357, P2687, DOI 10.1056/NEJMoa071906
   Sato Yota, 2018, Hum Genome Var, V5, P4, DOI 10.1038/s41439-018-0005-y
   Sebire G, 2005, BRAIN, V128, P477, DOI 10.1093/brain/awh412
   Shah S, 2012, DEV MED CHILD NEUROL, V54, P569, DOI 10.1111/j.1469-8749.2011.04198.x
   YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P116, DOI 10.1097/00005072-194604000-00003
   Yoneda Y, 2013, ANN NEUROL, V73, P48, DOI 10.1002/ana.23736
NR 18
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 446
EP 450
DI 10.1016/j.wneu.2019.04.156
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300244
PM 31029817
DA 2020-05-12
ER

PT J
AU Xin, WQ
   Xin, QQ
   Ming, HL
   Gao, YL
   Zhao, Y
   Gao, YK
   Yang, XY
AF Xin, Wen-Qiang
   Xin, Qi-Qiang
   Ming, Hao-Lang
   Gao, Ya-Long
   Zhao, Yan
   Gao, Yi-Kuan
   Yang, Xinyu
TI Predictable Risk Factors of Spontaneous Venous Thromboembolism in
   Patients Undergoing Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Review
DE Meta-analysis; Risk factors; Spinal surgery; Venous thromboembolism
   (VTE)
ID DEEP-VEIN THROMBOSIS; ACUTE PULMONARY THROMBOEMBOLISM; PREVALENCE;
   EMBOLISM; PREVENTION; RATES; COMPLICATIONS; INFECTION; OUTCOMES; EVENTS
AB OBJECTIVE: The purpose of this study was to conduct a meta-analysis to identify the risk factors for formation of venous thromboembolism (VTE) in patients after spine surgery.
   METHODS: This study retrieved potential academic articles on the related factors for VTE formation in patients after spine surgery from MEDLINE, PubMed, EMBASE, and the Cochrane Library. The reference articles for the identified studies were carefully reviewed to ensure that all available documents were represented in the study.
   RESULTS: A total of 21 articles (20 retrospective studies and 1 prospective study) involving 2,870,105 patients were identified in the analysis, including 7829 patients who presented with VIE after spine surgery; the incidence of VTE was 0.273%. Our meta-analysis showed that compared with patients who did not have VTE after spine surgery, there was significantly more blood loss (weighted mean difference [WMD], 93.295; 95% confidence interval [CI], 60.521-126.069; P< 0.001), higher age (WMD, 6.011; 95% CI, 3.647-9.376; P < 0.001), thoracolumbar surgery (odds ratio [013], 0233; 95% CI, 0.198-0.274; P < 0.001), and longer duration of surgery (WMD, 45.672; 95% CI, 10.433 to -80.911; P = 0.011) among the patients with VTE. Patients with a history of hypertension (OR, 1.785; 95% CI, 1.516-2.103; P < 0.001), diabetes (OR, 1.535; 95% CI, 1.286-1.832; P < 0.001), and preoperative walking disability (OR, 4.882; 95% CI, 2.044-11.663; P < 0.001) showed a significantly higher rate of VTE after spine surgery. However, no significant differences were found in gender (P = 0.289), fusion surgery (P = 0.979), body mass index (P = 0.157), history of heart disease (P = 0.397), and level of D-dimer (P = 0.220).
   CONCLUSIONS: A higher rate of postoperative VTE is closely associated with the elderly, longer duration of surgery, thoracolumbar surgery, greater blood loss, and patients with a history of hypertension, preoperative walking disability, or diabetes after spinal surgery; these risk factors should be guarded against.
C1 [Xin, Wen-Qiang; Ming, Hao-Lang; Gao, Ya-Long; Zhao, Yan; Gao, Yi-Kuan; Yang, Xinyu] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Xin, Qi-Qiang] Nanchang Univ, Sch Publ Hlth, Dept Prevent Med, Nanchang, Jiangxi, Peoples R China.
RP Yang, XY (reprint author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM tumeduxinyu@yeah.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570507]; Natural Science Foundation of Tianjin
   CityNatural Science Foundation of Tianjin [16JCZDJC35700]
FX Our work was supported by funding from the National Natural Science
   Foundation of China (number 81570507, X. Y. Y.) and the Project of the
   Natural Science Foundation of Tianjin City (grant number 16JCZDJC35700).
CR Akhigbe T, 2017, J CLIN NEUROSCI, V39, P45, DOI 10.1016/j.jocn.2017.02.016
   ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933
   Arnold PM, 2014, SPINE J, V14, P65, DOI 10.1016/j.spinee.2013.06.016
   Bono CM, 2009, SPINE J, V9, P1046, DOI 10.1016/j.spinee.2009.09.005
   Browne JA, 2007, SPINE, V32, P2214, DOI 10.1097/BRS.0b013e31814b1bc0
   FERREE BA, 1994, ORTHOPEDICS, V17, P35
   FERREE BA, 1993, SPINE, V18, P1079, DOI 10.1097/00007632-199306150-00019
   Geerts W, 2005, CHEST, V128, P3775, DOI 10.1378/chest.128.5.3775
   GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401
   Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656
   Glassman Steven D, 2003, Spine J, V3, P496, DOI 10.1016/S1529-9430(03)00426-1
   Glotzbecker MP, 2009, SPINE, V34, P291, DOI 10.1097/BRS.0b013e318195601d
   Golinvaux NS, 2014, SPINE, V39, P1809, DOI 10.1097/BRS.0000000000000506
   Guzman JZ, 2014, SPINE, V39, P1596, DOI 10.1097/BRS.0000000000000482
   Hohl JB, 2015, J SPINAL DISORD TECH, V28, pE310, DOI 10.1097/BSD.0b013e31828b7d82
   Ikeda T, 2017, J ORTHOP SCI, V22, P197, DOI 10.1016/j.jos.2016.11.014
   Inoue Hirokazu, 2018, JB JS Open Access, V3, pe0015, DOI 10.2106/JBJS.OA.18.00015
   Jameson SS, 2011, J SHOULDER ELB SURG, V20, P764, DOI 10.1016/j.jse.2010.11.034
   Johanson NA, 2009, J AM ACAD ORTHOP SUR, V17, P183, DOI 10.5435/00124635-200903000-00007
   JONES EW, 1983, DIABETOLOGIA, V25, P502
   Kahn SR, 2005, ARCH INTERN MED, V165, P1173, DOI 10.1001/archinte.165.10.1173
   Linnemann B, 2014, J VASC SURG-VENOUS L, V2, P131, DOI 10.1016/j.jvsv.2013.09.006
   Monti Manuel, 2016, Recenti Progressi in Medicina, V107, P480, DOI 10.1701/2354.25228
   Mosenthal WP, 2018, SPINE, V43, pE474, DOI 10.1097/BRS.0000000000002379
   Mukubo Yukiko, 2006, J Anesth, V20, P51, DOI 10.1007/s00540-005-0368-3
   Nakamura M, 2001, CLIN CARDIOL, V24, P132, DOI 10.1002/clc.4960240207
   NEGUS D, 1969, LANCET, V2, P645
   Nicol M, 2009, EUR SPINE J, V18, P1548, DOI 10.1007/s00586-009-1035-4
   Nourian AA, 2016, SPINE, V41, pE73, DOI 10.1097/BRS.0000000000001160
   Oda T, 2000, SPINE, V25, P2962, DOI 10.1097/00007632-200011150-00019
   Ota M, 2002, HEART VESSELS, V17, P7, DOI 10.1007/s003800200036
   Righini M, 2008, CURR OPIN PULM MED, V14, P408, DOI 10.1097/MCP.0b013e32830460ea
   Rojas-Tomba F, 2016, Rev Esp Cir Ortop Traumatol, V60, P133, DOI 10.1016/j.recot.2015.10.002
   Schoenfeld AJ, 2013, SPINE, V38, P1892, DOI 10.1097/BRS.0b013e31829fc3a0
   Sebastian AS, 2016, GLOB SPINE J, V6, P738, DOI 10.1055/s-0036-1579553
   Smith JS, 2011, SPINE, V36, P556, DOI 10.1097/BRS.0b013e3181eadd41
   Strom RG, 2013, SPINE, V38, pE1498, DOI 10.1097/BRS.0b013e3182a4408d
   Takahashi H, 2012, J ORTHOP SCI, V17, P114, DOI 10.1007/s00776-011-0188-2
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Tominaga H, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000466
   Wang TY, 2015, WORLD NEUROSURG, V84, P1605, DOI 10.1016/j.wneu.2015.07.008
   Watanabe H, 2018, JB JS OPEN ACCESS, V3
   Wei JC, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0403-0
   Xing KH, 2008, THROMB RES, V123, P24, DOI 10.1016/j.thromres.2008.05.005
   Yang SD, 2015, SCI REP-UK, V5, DOI 10.1038/srep11834
   Yoshioka K, 2015, SPINE, V40, pE301, DOI 10.1097/BRS.0000000000000727
   Yuan L, 2017, NEUROSCI LETT, V666, P24
NR 47
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 451
EP 463
DI 10.1016/j.wneu.2019.04.126
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300245
PM 31026651
DA 2020-05-12
ER

PT J
AU Bureta, CA
   Yamamoto, T
   Ishidou, Y
   Abematsu, M
   Tominaga, H
   Horinouchi, S
   Yone, K
   Komiya, S
   Taniguchi, N
AF Bureta, Costansia A.
   Yamamoto, Takuya
   Ishidou, Yasuhiro
   Abematsu, Masahiko
   Tominaga, Hiroyuki
   Horinouchi, Suguru
   Yone, Kazunori
   Komiya, Setsuro
   Taniguchi, Noboru
TI Extraforaminal L5 Nerve Root Compression Caused by Intervertebral
   Osteophyte Accompanied by Lumbosacral Transitional Vertebra: A Case
   Treated by Anterior Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior decompression; Case report; Castellvi Type Ila; Extraforaminal
   L5 nerve root compression; Intervertebral osteophyte; Lumbosacral
   transitional vertebrae
ID OUT FORAMINAL STENOSIS; LUMBAR SPINAL NERVE; POSTERIOR DECOMPRESSION;
   ENTRAPMENT; COMPLICATIONS; SURGERY
AB BACKGROUND: Several authors have reported the occurrence of extra-foraminal L5 nerve root compression between lumbosacral transitional vertebrae (LSTV) and sacral ala, but reports on a lesion caused by an intervertebral osteophyte on the ventral and contralateral side of a unilateral abnormality by LSTV are hardly available.
   CASE DESCRIPTION: A 67-year-old woman presented with pain along the distribution of the L5 nerve root; straight leg raise test, femoral nerve stretch test, and Kemp test were positive on the left. Following plain radiographs, computerized tomography, magnetic resonance imaging, and selective nerve root block, an osteophyte bridging the L5 and S1 vertebral bodies in the ventral side was identified compressing the L5 nerve root. On account of resistance to conservative therapy and the delicate position of the lesion, surgical treatment was performed by an anterior decompression. Subsequently, the patient attained adequate relief from pain and could walk normally.
   CONCLUSION: We herein present a very rare case of extraforaminal L5 nerve root compression caused by an intervertebral osteophyte on the ventral and contralateral side of a unilateral abnormality by LSTV, which was managed by anterior decompression.
C1 [Bureta, Costansia A.; Abematsu, Masahiko; Tominaga, Hiroyuki; Horinouchi, Suguru; Yone, Kazunori; Komiya, Setsuro; Taniguchi, Noboru] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Orthopaed Surg, Kagoshima, Japan.
   [Bureta, Costansia A.] Muhimbili Orthopaed & Neurosurg Inst, Dept Neurosurg, Dar Es Salaam, Tanzania.
   [Yamamoto, Takuya] Kagoshima Univ, Japanese Red Cross Kagoshima Hosp, Dept Orthopaed Surg, Kagoshima, Japan.
   [Ishidou, Yasuhiro] Kagoshima Univ, Grad Sch Med & Dent Sci, Near Future Locomotor Organ Med Creat Course Kusu, Kagoshima, Japan.
RP Yamamoto, T (reprint author), Kagoshima Univ, Japanese Red Cross Kagoshima Hosp, Dept Orthopaed Surg, Kagoshima, Japan.
EM tyamamo@m2.kufm.kagoshima-u.ac.jp
CR Abe E, 1997, SPINE, V22, P823, DOI 10.1097/00007632-199704010-00023
   Bron JL, 2007, ACTA ORTHOP BELG, V73, P687
   CASTELLVI AE, 1984, SPINE, V9, P493, DOI 10.1097/00007632-198407000-00014
   Delport Elva G, 2006, Pain Physician, V9, P53
   ELSTER AD, 1989, SPINE, V14, P1373, DOI 10.1097/00007632-198912000-00015
   Fischer CR, 2014, ADV ORTHOP, V2014, DOI 10.1155/2014/142604
   Ichihara K, 2004, J SPINAL DISORD TECH, V17, P154, DOI 10.1097/00024720-200404000-00013
   Jancuska JM, 2015, INT J SPINE SURG, V9, DOI 10.14444/2042
   Jenis L G, 2001, Am J Orthop (Belle Mead NJ), V30, P205
   Kang BU, 2009, J NEUROSURG-SPINE, V10, P60, DOI 10.3171/2008.10.SPI08215
   Konin GP, 2010, AM J NEURORADIOL, V31, P1778, DOI 10.3174/ajnr.A2036
   Matsumoto M, 2002, SPINE, V27, pE169, DOI 10.1097/00007632-200203150-00020
   Matsumoto M, 2010, J NEUROSURG-SPINE, V12, P72, DOI 10.3171/2009.7.SPINE09344
   Miyoshi Y, 2011, NEUROL MED-CHIR, V51, P153, DOI 10.2176/nmc.51.153
   Otani K, 2001, J BONE JOINT SURG BR, V83B, P1137, DOI 10.1302/0301-620X.83B8.11736
   Park YK, 2003, J NEUROSURG, V98, P264, DOI 10.3171/spi.2003.98.3.0264
   Porter NA, 2014, SKELETAL RADIOL, V43, P55, DOI 10.1007/s00256-013-1750-0
   Rajaraman V, 1999, J NEUROSURG, V91, P60, DOI 10.3171/spi.1999.91.1.0060
   STROMQVIST B, 1988, ACTA ORTHOP SCAND, V59, P615
   TRANSFELDT EE, 1993, J SPINAL DISORD, V6, P507, DOI 10.1097/00002517-199306060-00006
   WILTSE LL, 1984, SPINE, V9, P31, DOI 10.1097/00007632-198401000-00008
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 464
EP 468
DI 10.1016/j.wneu.2019.04.104
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300246
PM 31009779
DA 2020-05-12
ER

PT J
AU Zhang, YL
   Huang, JS
   Zhang, CL
   Jiang, CZ
   Ding, CY
   Lin, YX
   Wu, XY
   Wang, CY
   Kang, DZ
   Lin, ZY
AF Zhang, Yuanlong
   Huang, Jinsheng
   Zhang, Chunlin
   Jiang, Changzhen
   Ding, Chenyu
   Lin, Yuanxiang
   Wu, Xiyue
   Wang, Chenyang
   Kang, Dezhi
   Lin, Zhangya
TI An Extended Endoscopic Endonasal Approach for Sellar Area
   Chondrosarcoma: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chondrosarcoma; Neuroendoscopy; Sellar area
ID SKULL BASE; INTRACRANIAL CHONDROSARCOMA
AB BACKGROUND: Chondrosarcoma is a malignant tumor that originates from mesenchymal cells that have differentiated into chondrocytes, often growing laterally, rarely seen in the cranium, and seldom seen in the saddle area. We believe that only a few cases have been reported in the literature. We report a case of pituitary fossa chondrosarcoma, which was completely resected by an extended endoscopic endonasal approach, and a literature review.
   CASE DESCRIPTION: A 20-year-old man was admitted to hospital with bilateral temporal headache and blurred vision, without any history of sexual dysfunction or diabetes insipidus. Endocrine function was normal. Computed tomography of the head showed calcified sellar lesions and sellar bone destruction, which were closely associated with the right cavernous sinus. Magnetic resonance imaging showed saddle area space-occupying lesions, with low signal on the T1-weighted image and high signal on the T2-weighted image, uneven enhancement by enhanced scanning, and unclear pituitary display. The tumor was completely resected by an extended endoscopic endonasal approach and confirmed by magnetic resonance imaging. Postoperative pathology revealed conventional chondrosarcoma (World Health Organization grade II). Postsurgical visual acuity also improved. The patient did not receive radiotherapy or chemotherapy. No recurrence was found at 10-month follow-up.
   CONCLUSIONS: Sellar region chondrosarcoma is rare. For space-occupying lesions in this area, chondrosarcoma should be considered and not necessarily pituitary adenoma, craniopharyngioma, meningioma, and chordoma. The extended endoscopic endonasal approach represents a good treatment option for sellar area chondrosarcoma.
C1 [Zhang, Yuanlong; Jiang, Changzhen; Ding, Chenyu; Lin, Yuanxiang; Wu, Xiyue; Wang, Chenyang; Kang, Dezhi; Lin, Zhangya] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Huang, Jinsheng; Zhang, Chunlin] First Hosp Nanping City, Dept Neurosurg, Nanping, Fujian, Peoples R China.
RP Jiang, CZ (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
EM 893416880@qq.com
FU Key Clinical Specialty Discipline Construction Program of Fujian;
   Guiding Projects of Fujian Science and Technology Plan Project, People's
   Republic of China [2016Y0035]
FX This work was sponsored by the Key Clinical Specialty Discipline
   Construction Program of Fujian and the Guiding Projects of Fujian
   Science and Technology Plan Project (2016Y0035), People's Republic of
   China.
CR Abele TA, 2012, CLIN RADIOL, V67, P821, DOI 10.1016/j.crad.2012.01.001
   Aksoy S, 2005, J NEURO-ONCOL, V71, P333, DOI 10.1007/s11060-004-1725-z
   Allan CA, 2001, J CLIN ENDOCR METAB, V86, P386, DOI 10.1210/jc.86.1.386
   Amichetti M, 2010, NEUROSURG REV, V33, P155, DOI 10.1007/s10143-009-0235-z
   Brackmann DE, 2006, OTOL NEUROTOL, V27, P981, DOI 10.1097/01.mao.0000233812.48800.b4
   Cao JG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011274
   Ceylan S, 2009, NEUROSURG REV, V32, P309, DOI 10.1007/s10143-009-0201-9
   Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013
   Dutta Gautam, 2018, Surg Neurol Int, V9, P76, DOI 10.4103/sni.sni_455_17
   Freda PU, 1996, J CLIN ENDOCR METAB, V81, P3455, DOI 10.1210/jc.81.10.3455
   Freda PU, 1999, ENDOCRIN METAB CLIN, V28, P81, DOI 10.1016/S0889-8529(05)70058-X
   Gunes M, 2009, MINIM INVAS NEUROSUR, V52, P238, DOI 10.1055/s-0028-1128117
   Hasegawa H, 2018, J NEUROSURG, V128, P1438, DOI 10.3171/2017.1.JNS162000
   Inenaga C, 2003, ACTA NEUROCHIR, V145, P593, DOI 10.1007/s00701-003-0059-5
   Korten AGGC, 1998, J NEUROL NEUROSUR PS, V65, P88, DOI 10.1136/jnnp.65.1.88
   Li D, 2018, WORLD NEUROSURG, V109, pE517, DOI 10.1016/j.wneu.2017.10.013
   MEYERS SP, 1992, RADIOLOGY, V184, P103, DOI 10.1148/radiology.184.1.1609064
   Murphey MD, 2003, RADIOGRAPHICS, V23, P1245, DOI 10.1148/rg.235035134
   Raza SM, 2017, NEUROSURGERY, V81, P520, DOI 10.1093/neuros/nyx042
   Sadashiva N, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.049
   Schwartz TH, 2019, J NEUROSURG, V130, P337, DOI 10.3171/2018.10.JNS182154
   Sharma Manisha, 2016, Iran J Pathol, V11, P161
NR 22
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 469
EP 477
DI 10.1016/j.wneu.2019.04.075
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300247
PM 30995554
DA 2020-05-12
ER

PT J
AU Aso, K
   Kashimura, H
   Akamatsu, Y
   Ogasawara, Y
   Oshida, S
AF Aso, Kenta
   Kashimura, Hiroshi
   Akamatsu, Yosuke
   Ogasawara, Yasushi
   Oshida, Sotaro
TI Cerebral Aneurysm Arising from Variant Posterior Communicating Artery
   Lying Lateral to Oculomotor Nerve
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Oculomotor nerve; Subarachnoid hemorrhage; True
   posterior communicating artery aneurysm
ID MICROSURGICAL ANATOMY
AB BACKGROUND: In most cases, the posterior communicating artery (PCoA) lies medial to the oculomotor nerve. In this report, a rare case of a ruptured cerebral aneurysm arising from a variant PCoA lying lateral to the oculomotor nerve is described.
   CASE DESCRIPTION: A 41-year-old woman who had a history of surgical clipping of a right PCoA aneurysm 13 years earlier developed a subarachnoid hemorrhage due to a ruptured left true PCoA aneurysm. Three-dimensional computed tomography angiography showed a small saccular aneurysm arising from the PCoA itself. She underwent surgical clipping via a left frontotemporal craniotomy. Interestingly, the PCoA lay lateral to the oculomotor nerve, and the aneurysm dome projected medially and compressed the oculomotor nerve medially. A slightly angled fenestrated miniclip was applied across the PCoA, followed by reconstruction of the PCoA medial wall and simultaneous obliteration of the aneurysm. Complete aneurysm obliteration and good patency of both the PCoA and perforating arteries were confirmed intraoperatively by indocyanine green videoangiography. The patient's postoperative course was uneventful, and the patient was discharged with no neurologic deficits.
   CONCLUSIONS: Recognizing this anatomic variant is helpful in minimizing the potential complications in microsurgical management around the PCoA and oculomotor nerve. Lateral localization of the P1-2 junction might affect this rare anatomic variant.
C1 [Aso, Kenta; Kashimura, Hiroshi; Ogasawara, Yasushi; Oshida, Sotaro] Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
   [Akamatsu, Yosuke] Iwate Med Univ, Sch Med, Dept Neurosurg, Morioka, Iwate, Japan.
RP Kashimura, H (reprint author), Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
EM h-kashimura@pref.iwate.jp
CR SAEKI N, 1977, J NEUROSURG, V46, P563, DOI 10.3171/jns.1977.46.5.0563
   Sorimachi T, 2004, J NEUROSURG, V100, P353, DOI 10.3171/jns.2004.100.2.0353
   Takahashi S, 2010, NEUROVASCULAR IMAGING: MRI & MICROANGIOGRAPHY, P1, DOI 10.1007/978-1-84882-134-7
   Uchino A, 2015, SURG RADIOL ANAT, V37, P565, DOI 10.1007/s00276-014-1413-4
   VINCENTELLI F, 1990, NEUROSURGERY, V26, P824, DOI 10.1227/00006123-199005000-00015
   YASARGIL MG, 1984, MICRONEUROSURGERY, V2
   ZEAL AA, 1978, J NEUROSURG, V48, P534, DOI 10.3171/jns.1978.48.4.0534
NR 7
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 478
EP 480
DI 10.1016/j.wneu.2019.03.022
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300248
PM 30876995
DA 2020-05-12
ER

PT J
AU Zheng, XD
   Wu, XH
AF Zheng, Xiaodan
   Wu, Xinghuo
TI Diagnosis and Management of Intraspinal Tuberculoma with Giant
   Paraspinal Abscesses
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraspinal tuberculoma; Magnetic resonance imaging; Spinal cord;
   Tuberculosis
ID SPINAL MENINGITIDES; RADICULOMYELOPATHY; MEDULLARIS; INFECTIONS
AB BACKGROUND: Although tuberculosis is rare in the west, in recent years, it's becoming more and more common in China. Intraspinal tuberculoma is extremely rare, but it's an important cause of morbidity. Magnetic resonance imaging scanning is an effective method for the diagnosis of intraspinal tuberculoma.
   CASE DESCRIPTION: This case report shows an intraspinal tuberculoma with paraspinal abscesses in a 28-year-old female patient with subacute progressing neurologic deficit. L1-L5 laminectomy was performed, followed by extensively excision of intraspinal and paraspinal lesion. Antituberculous treatment was carried out after pathologic diagnosis. An excellent clinical outcome was obtained. Within 24 hours of the surgical procedure, muscle weakness in both lower extremities started to improve. Three days later, the patient felt muscle strength recovered significantly, with grade 4/5 in the lower limbs in 2 weeks. Six weeks later, the patient was able to walk without assistance.
   CONCLUSIONS: The case was treated by surgical excision of an intraspinal a paraspinal lesion followed by normal quadruple antituberculous therapy. Although intraspinal tuberculoma is a rare entity, it can be effectively diagnosed on the basis of magnetic resonance imaging scanning and treated by the combination of medical and surgical treatments.
C1 [Zheng, Xiaodan] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Stomatol, Wuhan, Hubei, Peoples R China.
   [Wu, Xinghuo] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Orthopaed Surg, Wuhan, Hubei, Peoples R China.
RP Wu, XH (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Union Hosp, Dept Orthopaed Surg, Wuhan, Hubei, Peoples R China.
EM wuxinghuo@163.com
CR CAMPILLO VALERO D, 1961, Rev Clin Esp, V81, P44
   DASTUR DK, 1969, J NEUROL SCI, V8, P261, DOI 10.1016/0022-510X(69)90113-0
   GUPTA RK, 1994, NEURORADIOLOGY, V36, P39, DOI 10.1007/BF00599194
   Jaiswal Manish, 2017, Asian J Neurosurg, V12, P331, DOI 10.4103/1793-5482.143461
   Jaiswal Manish, 2015, Korean J Spine, V12, P5, DOI 10.14245/kjs.2015.12.1.5
   JENA A, 1991, BRIT J RADIOL, V64, P555, DOI 10.1259/0007-1285-64-762-555
   JOHNSTON JD, 1962, NEW ENGL J MED, V266, P703, DOI 10.1056/NEJM196204052661405
   Kemaloglu S, 2001, SPINAL CORD, V39, P498, DOI 10.1038/sj.sc.3101187
   Kumar S, 2007, CLIN ORTHOP RELAT R, P62, DOI 10.1097/BLO.0b013e318065b73c
   Ledermann HP, 2003, RADIOLOGY, V228, P506, DOI 10.1148/radiol.2282020752
   SHARIF HS, 1990, RADIOLOGY, V177, P101, DOI 10.1148/radiology.177.1.2399306
   SMITH AS, 1991, RADIOL CLIN N AM, V29, P809
   Sree Harsha C K, 2006, J Orthop Surg (Hong Kong), V14, P71
   Tureyen K, 2002, NEUROSURGERY, V50, P651
   WADIA NH, 1969, J NEUROL SCI, V8, P239, DOI 10.1016/0022-510X(69)90112-9
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 481
EP 484
DI 10.1016/j.wneu.2019.04.157
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300249
PM 31029821
DA 2020-05-12
ER

PT J
AU De Bonis, P
   Visani, J
   Zauli, G
   Mongardi, L
   Zamboni, P
   Cavallo, MA
AF De Bonis, Pasquale
   Visani, Jacopo
   Zauli, Giorgio
   Mongardi, Lorenzo
   Zamboni, Paolo
   Cavallo, Michele Alessandro
TI A Brain Hidden in the Ferrara Cathedral: A Novel Interpretation of a
   Renaissance Masterpiece
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bastianino; Dissection; Neuroanatomy; Renaissance; Universal Judgement
AB The aim of present report was to briefly review the history of the anatomical studies during the Italian Renaissance and to outline their relationship to the figurative arts, focusing, in particular, on neuroanatomical studies that have been at the center of the medical and philosophical debate from the 14th to 16th centuries. Therefore, we have presented the interpretation of different Renaissance masterpieces for which some references to brain anatomy have been previously reported. We propose a new interpretation, in neuroanatomical key, of the fresco of the universal judgment in the vault of San Giorgio's Cathedral in Ferrara, Italy, painted around the end of the 16th century.
C1 [De Bonis, Pasquale; Visani, Jacopo; Mongardi, Lorenzo; Cavallo, Michele Alessandro] St Anna Univ Hosp, Dept Neurosurg, Ferrara, Italy.
   [Zauli, Giorgio] St Anna Univ Hosp, Div Anat & Histol, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Zamboni, Paolo] St Anna Univ Hosp, Dept Vasc Surg, Ferrara, Italy.
RP Visani, J (reprint author), St Anna Univ Hosp, Dept Neurosurg, Ferrara, Italy.
EM jacopo.visani@gmail.com
RI de bonis, pasquale/K-8200-2016; mongardi, lorenzo/AAI-2247-2020
OI de bonis, pasquale/0000-0002-9879-8940; 
CR Finger Stanley, 2000, MINDS BRAIN HIST PIO
   Kemp M, 1972, J Warburg Courtauld Inst, V35, P200
   Kemp M, 1970, Med Hist, V14, P277
   MESHBERGER FL, 1990, JAMA-J AM MED ASSOC, V264, P1837, DOI 10.1001/jama.264.14.1837
   Paluzzi A, 2007, J ROY SOC MED, V100, P540, DOI 10.1258/jrsm.100.12.540
   Suk I, 2010, NEUROSURGERY, V66, P851, DOI 10.1227/01.NEU.0000368101.34523.E1
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 486
EP 489
DI 10.1016/j.wneu.2019.03.285
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300251
PM 30954742
DA 2020-05-12
ER

PT J
AU Decramer, T
   Wouters, A
   Kiekens, C
   Theys, T
AF Decramer, Thomas
   Wouters, Anke
   Kiekens, Carlotte
   Theys, Tom
TI Froin Syndrome After Spinal Cord Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Froin syndrome; Intrathecal drug therapy; Spinal cord injury;
   Xanthochromia
AB BACKGROUND: Froin syndrome is characterized by xanthochromia and hy-percoagulability of the cerebrospinal fluid (CSF) due to elevated protein levels. This entity results from blockage of the spinal canal by a mass lesion leading to an isolated caudal CSF space.
   CASE DESCRIPTION: A 48-year-old male, who developed spasticity after a C6 Spinal cord injury (SCI) 20 years earlier, presented with subobstruction of his intrathecal baclofen pump. A catheter access port aspiration revealed an extremely high protein concentration (38 g/L) with no signs of infection. Froin syndrome was confirmed when magnetic resonance imaging showed a complete obstruction of the spinal canal at the SCI level.
   CONCLUSIONS: We report the first case of Froin syndrome after SCI. Froin syndrome can impact intrathecal drug delivery and CSF diagnostics.
C1 [Decramer, Thomas; Theys, Tom] Univ Hosp, Dept Neurosurg, Leuven, Belgium.
   [Wouters, Anke] Univ Hosp, Dept Neurol, Leuven, Belgium.
   [Kiekens, Carlotte] Univ Hosp, Dept Phys & Rehabil Med, Leuven, Belgium.
RP Decramer, T (reprint author), Univ Hosp, Dept Neurosurg, Leuven, Belgium.
EM thomas.decramer@uzleuven.be
RI Kiekens, Carlotte/V-7545-2018; Theys, Tom/AAG-4536-2019
OI Kiekens, Carlotte/0000-0001-8500-7751; Decramer,
   Thomas/0000-0002-2585-581X
CR Dancel R, 2016, NEW ENGL J MED, V374, P1076, DOI 10.1056/NEJMicm1509557
   Froin G., 1903, GAZETTE HOPITAUX, V76, P1005
   Greenfield JG, 1921, J NEUROL PSYCHOPATHO, V2, P105
   Kwon SK, 2014, KOREAN J ANESTHESIOL, V67, pS58, DOI 10.4097/kjae.2014.67.S.S58
   Mirza S, 2008, CLIN RADIOL, V63, P600, DOI 10.1016/j.crad.2007.07.027
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 490
EP 491
DI 10.1016/J.WNEU.2019.04.198
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300252
PM 31048043
DA 2020-05-12
ER

PT J
AU Ren, ZG
   Mokin, M
   Bauer, CT
   Miao, ZR
   Burgin, WS
   Wang, YJ
AF Ren, Zeguang
   Mokin, Maxim
   Bauer, Clayton T.
   Miao, Zhongrong
   Burgin, W. Scott
   Wang, Yongjun
TI Indications for Mechanical Thrombectomy-Too Wide or Too Narrow?
SO WORLD NEUROSURGERY
LA English
DT Review
DE Indication; Mechanical; Stroke; Thrombectomy
ID MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC-STROKE; LARGE VESSEL OCCLUSION;
   HEALTH-CARE PROFESSIONALS; INTRAVENOUS THROMBOLYSIS; ANTERIOR
   CIRCULATION; M2 OCCLUSIONS; ENDOVASCULAR THROMBECTOMY;
   PLASMINOGEN-ACTIVATOR; MEDICAL-MANAGEMENT
AB The indications for mechanical thrombectomy (MT) have expanded since the American Heart Association/American Stroke Association reported its first guidelines for MT in 2013. Multiple subsequent randomized clinical trials of MT have proved its efficacy, including the DAWN (DWI [diffusion weighted imaging] or CTP [computed tomography perfusion] Assessment with Clinical Mismatch in the Triage of Wake-ttp and Late Presenting Strokes Undergoing Neuro-intervention with Trevo) and DEFUSE-3 (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke-3) trials. The current guidelines from the American Heart Association/American Stroke Association provide class I support for the use of MT for the following indications: 1) internal carotid artery (ICA)/M1 middle cerebral artery (MCA) occlusion, symptom onset <6 hours, National Institutes of Health Stroke Scale score of >= 6, Alberta Stroke Program Early Computed Tomography Score of >= 6; and 2) large vessel occlusions in the anterior circulation, symptom onset 6-16 hours, and meeting the DAWN or DEFUSE-3 eligibility criteria. Class Ila evidence is also available for the use of MT for large vessel occlusions in the anterior circulation, symptom onset 16-24 hours, and meeting other DAWN eligibility criteria. In clinical practice, these class I and Ila indications for MT have been well followed. However, many other potential indications are available, including 1) M2 or M3 MCA occlusion, symptom onset <6 hours; 2) Alberta Stroke Program Early Computed Tomography Score <6, ICA or M1 MCA occlusion, symptom onset <6 hours; 3) National Institutes of Health Stroke Scale score <6, ICA or M1 occlusion, symptom onset <6 hours; 4) tandem occlusions; and 5) posterior circulation occlusion <6 hours. The present review analyzed the available data to provide support for further prospective clinical trials regarding these potential indications.
C1 [Ren, Zeguang; Mokin, Maxim; Bauer, Clayton T.] Univ S Florida, Dept Neurosurg, Tampa, FL 33620 USA.
   [Burgin, W. Scott] Univ S Florida, Dept Neurol, Tampa, FL USA.
   [Miao, Zhongrong] Capital Med Univ, Beijing Tiantan Hosp, Dept Intervent Neurol, Beijing, Peoples R China.
   [Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.
   [Ren, Zeguang] Taihe Hosp, Ctr Cerebrovasc Dis, Shiyan, Hubei, Peoples R China.
RP Ren, ZG (reprint author), Univ S Florida, Dept Neurosurg, Tampa, FL 33620 USA.; Ren, ZG (reprint author), Taihe Hosp, Ctr Cerebrovasc Dis, Shiyan, Hubei, Peoples R China.
EM renzem@gmail.com
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Ali SF, 2016, STROKE, V47, P2986, DOI 10.1161/STROKEAHA.116.014871
   Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Baumann CR, 2006, STROKE, V37, P1332, DOI 10.1161/01.STR.0000217272.38455.a2
   Bhogal P, 2016, STROKE VASC NEUROL, V1, P165, DOI 10.1136/svn-2016-000052
   Bhogal P, 2017, INTERV NEUROL, V6, P191, DOI 10.1159/000475535
   Bhole R, 2017, J NEUROINTERV SURG, V9, P225, DOI 10.1136/neurintsurg-2015-012206
   Bowen MT, 2018, INTERV NEUROL, V7, P91, DOI 10.1159/000481205
   Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6
   Chen CJ, 2017, WORLD NEUROSURG, V107, P684, DOI 10.1016/j.wneu.2017.08.108
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Dargazanli C, 2017, STROKE, V48, P3274, DOI 10.1161/STROKEAHA.117.018113
   Dargazanli C, 2017, CEREBROVASC DIS, V43, P305, DOI 10.1159/000468995
   DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113
   Desilles JP, 2017, STROKE, V48, P963, DOI 10.1161/STROKEAHA.116.015202
   Dhamoon MS, 2009, STROKE, V40, P2805, DOI 10.1161/STROKEAHA.109.549576
   Dorn F, 2015, J STROKE CEREBROVASC, V24, P1465, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.013
   El Tawil S, 2016, EUR STROKE J, V1, P264, DOI 10.1177/2396987316667176
   Flores A, 2015, J NEUROINTERV SURG, V7, P234, DOI 10.1136/neurintsurg-2014-011100
   Frank RA, 2018, NEURORADIOL J, V31, P464, DOI 10.1177/1971400918770898
   Gautheron V, 2018, STROKE, V49, P750, DOI 10.1161/STROKEAHA.117.020244
   Ghandehari K, 2013, J RES MED SCI, V18, P906
   Gilgen MD, 2015, STROKE, V46, P2510, DOI 10.1161/STROKEAHA.115.010250
   Gory B, 2018, STROKE, V49, P461, DOI 10.1161/STROKEAHA.117.019598
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Greisenegger S, 2014, STROKE, V45, P765, DOI 10.1161/STROKEAHA.113.003827
   Han M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004702
   Haussen DC, 2018, J NEUROINTERV SURG, V10, P325, DOI 10.1136/neurintsurg-2017-013243
   Haussen DC, 2017, J NEUROINTERV SURG, V9, P917, DOI 10.1136/neurintsurg-2016-012633
   Heldner MR, 2015, J NEUROL NEUROSUR PS, V86, P755, DOI 10.1136/jnnp-2014-308401
   Heldner MR, 2013, STROKE, V44, P1153, DOI 10.1161/STROKEAHA.111.000604
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Kaschner MG, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918760747
   Khatri P, 2012, STROKE, V43, P560, DOI 10.1161/STROKEAHA.110.593897
   Kim YW, 2017, J NEUROINTERV SURG, V9, P626, DOI 10.1136/neurintsurg-2016-012466
   Kohrmann M, 2009, CEREBROVASC DIS, V27, P160, DOI 10.1159/000185607
   Kranz PG, 2009, AM J NEURORADIOL, V30, P1206, DOI 10.3174/ajnr.A1547
   Logallo N, 2014, ACTA NEUROL SCAND, V129, P37, DOI 10.1111/ane.12235
   Maas MB, 2009, STROKE, V40, P2988, DOI 10.1161/STROKEAHA.109.555664
   Manceau PF, 2018, EUR J NEUROL, V25, P105, DOI 10.1111/ene.13460
   Mendez B, 2018, STROKE, V49, P2723, DOI 10.1161/STROKEAHA.118.021989
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Mourand I, 2018, J NEUROINTERV SURG, V10, P5, DOI 10.1136/neurintsurg-2017-013358
   Munich SA, 2016, NEUROSURGERY, V79, P428, DOI 10.1227/NEU.0000000000001182
   Nacu A, 2016, ACTA NEUROL SCAND, V133, P25, DOI 10.1111/ane.12418
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Ohta T, 2018, NEUROL MED-CHIR, V58, P156, DOI 10.2176/nmc.oa.2017-0203
   Park JS, 2016, J KOREAN NEUROSURG S, V59, P352, DOI 10.3340/jkns.2016.59.4.352
   Porelli S, 2013, INTERV NEURORADIOL, V19, P87, DOI 10.1177/159101991301900114
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Protto S, 2016, CARDIOVASC INTER RAD, V39, P988, DOI 10.1007/s00270-016-1315-4
   Rajajee V, 2006, NEUROLOGY, V67, P980, DOI 10.1212/01.wnl.0000237520.88777.71
   Ribo M, 2018, J NEUROINTERV SURG, V10, P221, DOI 10.1136/neurintsurg-2017-013038
   Riedel CH, 2011, STROKE, V42, P1775, DOI 10.1161/STROKEAHA.110.609693
   Romano JG, 2015, JAMA NEUROL, V72, P423, DOI 10.1001/jamaneurol.2014.4354
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Salahuddin H, 2018, J NEUROINTERV SURG, V10, P330, DOI 10.1136/neurintsurg-2017-013159
   Salahuddin H, 2017, INTERV NEUROL, V6, P242, DOI 10.1159/000477589
   Sarraj A, 2016, JAMA NEUROL, V73, P1291, DOI 10.1001/jamaneurol.2016.2773
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Smith EE, 2011, STROKE, V42, P3110, DOI 10.1161/STROKEAHA.111.613208
   Spokoyny I, 2015, J STROKE CEREBROVASC, V24, P1276, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.037
   Steffenhagen N, 2009, CEREBROVASC DIS, V28, P201, DOI 10.1159/000226579
NR 63
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 492
EP 499
DI 10.1016/j.wneu.2019.04.116
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300253
PM 31009772
DA 2020-05-12
ER

PT J
AU Shimizu, A
   Ishikawa, T
   Yamaguchi, K
   Funatsu, T
   Ryu, B
   Nagahara, A
   Ikeda, S
   Kawamata, T
AF Shimizu, Atsushi
   Ishikawa, Tatsuya
   Yamaguchi, Koji
   Funatsu, Takayuki
   Ryu, Bikei
   Nagahara, Ayumi
   Ikeda, Shigeru
   Kawamata, Takakazu
TI Brainstem Venous Congestion Caused by Perimedullary Drainage in Anterior
   Cranial Fossa Dural Arteriovenous Fistula
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cranial fossa; Dural arteriovenous fistula; Myelopathy;
   Perimedullary vein
ID DIFFUSE MR ENHANCEMENT; SPINAL-CORD; CRANIOCERVICAL JUNCTION; CERVICAL
   MYELOPATHY; THORACOLUMBAR CORD; BRIDGING VEINS; ANATOMY
AB BACKGROUND: Myelopathy develops relatively rarely in intracranial dural arteriovenous fistula (DAVF); it has only been reported in posterior cranial fossa DAVE Herein, we report the first, to our knowledge, case of anterior cranial fossa (ACF) DAVF with myelopathy.
   CASE DESCRIPTION: A 75-year-old man presented with dizziness, nausea, and gait disturbance. T2-weighted magnetic resonance imaging revealed a hyperintense area in the left cerebellum and medulla; a flow void was also detected around the medulla. The patient was first diagnosed with spinal DAVF, but the shunt point was detected at the anterior ethmoidal artery, flowing from the olfactory vein to the basal vein of Rosenthal and anterior/posterior spinal veins. The shunt point was clipped during craniotomy, and neurologic symptoms improved.
   CONCLUSIONS: Myelopathy because of intracranial DAVF potentially involves diagnostic pitfalls. Even in ACF DAVF, there is a possibility of myelopathy caused by perimedullary venous drainage.
C1 [Shimizu, Atsushi; Ishikawa, Tatsuya; Yamaguchi, Koji; Funatsu, Takayuki; Ryu, Bikei; Nagahara, Ayumi; Ikeda, Shigeru; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
RP Ishikawa, T (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Shinjuku Ku, Tokyo, Japan.
EM tishikawa@twmu.ac.jp
OI Ishikawa, Tatsuya/0000-0003-3553-6510; Bikei, Ryu/0000-0003-0323-6628
CR Akkoc Y, 2006, J KOREAN MED SCI, V21, P958, DOI 10.3346/jkms.2006.21.5.958
   Asakawa H, 2002, SURG NEUROL, V58, P251, DOI 10.1016/S0090-3019(02)00861-3
   Baltsavias G, 2015, NEUROSURG REV, V38, P253, DOI 10.1007/s10143-014-0590-2
   Baltsavias G, 2015, NEUROSURG REV, V38, P265, DOI 10.1007/s10143-014-0594-y
   Bousson V, 1999, J NEUROL NEUROSUR PS, V67, P227, DOI 10.1136/jnnp.67.2.227
   BRET P, 1994, NEUROSURGERY, V35, P965, DOI 10.1227/00006123-199411000-00026
   Brunereau L, 1996, AM J NEURORADIOL, V17, P1549
   Chen CJ, 1998, NEURORADIOLOGY, V40, P393, DOI 10.1007/s002340050609
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   GOBIN YP, 1992, J NEUROSURG, V77, P718, DOI 10.3171/jns.1992.77.5.0718
   Hahnel S, 1998, NEUROLOGY, V51, P1131, DOI 10.1212/WNL.51.4.1131
   Kim NH, 2011, J NEUROSURG, V114, P830, DOI 10.3171/2010.5.JNS10128
   Kiyosue H, 2008, NEURORADIOLOGY, V50, P1013, DOI 10.1007/s00234-008-0433-3
   Li J, 2004, NEUROL MED-CHIR, V44, P24, DOI 10.2176/nmc.44.24
   Mascalchi M, 1996, AM J NEURORADIOL, V17, P1137
   Narvid J, 2008, NEUROSURGERY, V62, P159, DOI 10.1227/01.NEU.0000311073.71733.C4
   Pannu Y, 2004, SURG NEUROL, V62, P463, DOI 10.1016/j.surneu.2004.01.017
   PARTINGTON MD, 1992, J NEUROSURG, V76, P615, DOI 10.3171/jns.1992.76.4.0615
   PISKE RL, 1988, NEURORADIOLOGY, V30, P426, DOI 10.1007/BF00404108
   Renner C, 2006, SURG NEUROL, V65, P506, DOI 10.1016/j.surneu.2005.06.022
   Ricolfi F, 1999, NEURORADIOLOGY, V41, P803, DOI 10.1007/s002340050846
   Satoh M, 2005, SURG NEUROL, V64, P341, DOI 10.1016/j.surneu.2004.12.029
   TERADA T, 1984, NEUROSURGERY, V14, P578, DOI 10.1227/00006123-198405000-00011
   Trop I, 1998, AM J NEURORADIOL, V19, P583
   VERSARI PP, 1993, NEUROSURGERY, V33, P914
   Wiesmann M, 2000, EUR RADIOL, V10, P1606, DOI 10.1007/s003300000382
   Yoshida S, 1999, NEUROL MED-CHIR, V39, P376, DOI 10.2176/nmc.39.376
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 503
EP 508
DI 10.1016/j.wneu.2019.04.204
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300256
PM 31048058
DA 2020-05-12
ER

PT J
AU Larijani, A
   Karvigh, SA
   Nadri, S
   Shirani, M
   Alimohamadi, M
AF Larijani, Amirhossein
   Karvigh, Sanaz Ahmadi
   Nadri, Sattar
   Shirani, Mohammad
   Alimohamadi, Maysam
TI Total Corpus Callosotomy for Medically Refractory Status Epilepticus Due
   to Progressive Myoclonic Epilepsy: A Clinically Challenging Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Corpus callosotomy; Epilepsy surgery; Progressive myoclonic epilepsy;
   Status epilepticus
ID MULTIPLE SUBPIAL TRANSECTION; DEEP-BRAIN-STIMULATION; NEUROSURGICAL
   TREATMENT; LENNOX-GASTAUT; ANTERIOR; SECTION
AB BACKGROUND: Progressive myoclonic epilepsy (PME) is a syndrome characterized by development of progressive myoclonus, cognitive impairment, and other neurologic deficits. Despite major advances in medical treatment of epilepsy, some PME patients remain refractory to antiepileptic drugs. This may further accentuate cognitive impairment and deteriorate functional capacity. Corpus callosotomy (CC) is used in patients with drug-resistant epilepsy who are not candidates for either excisional epilepsy surgery or neurostimulation. We report the application of the standard complete callosotomy to control medically refractory status epilepticus in a patient with PME.
   CASE DESCRIPTION: A 16-year-old boy was referred to the emergency department with generalized tonic-clonic seizures. He was known to have PME since 5 years earlier, with frequent generalized seizures requiring hospitalization and reloading of the drugs. The patient was discussed by the epilepsy surgery working group, and corpus callosotomy was considered as a last resort to control the refractory status epilepticus. The patient experienced no generalized seizures during the 3-month postoperative period (Engel class IIIB).
   CONCLUSIONS: Inasmuch as surgery was the last resort to control severe disabling status epilepticus, because most of the epileptogenic discharges were originating from the parieto-occipital regions and profound cognitive impairment was present, we decided to perform a complete rather than just an anterior callosotomy. CC may be considered to prevent secondary generalized seizures as the most disabling attacks in patients with certain epilepsy syndromes. Nevertheless, the impact of palliative surgical intervention on the overall disease course of patients with an underlying diffuse pathologic state remains to be determined.
C1 [Larijani, Amirhossein; Alimohamadi, Maysam] Univ Tehran Med Sci, Brain & Spinal Injury Res Ctr, Neurosci Inst, Sina Hosp, Tehran, Iran.
   [Larijani, Amirhossein; Nadri, Sattar; Shirani, Mohammad; Alimohamadi, Maysam] Univ Tehran Med Sci, Dept Neurosurg, Sina Hosp, Tehran, Iran.
   [Karvigh, Sanaz Ahmadi] Univ Tehran Med Sci, Sina Hosp, Dept Neurol, Tehran, Iran.
RP Alimohamadi, M (reprint author), Univ Tehran Med Sci, Brain & Spinal Injury Res Ctr, Neurosci Inst, Sina Hosp, Tehran, Iran.; Alimohamadi, M (reprint author), Univ Tehran Med Sci, Dept Neurosurg, Sina Hosp, Tehran, Iran.
EM alimohamadi59@gmail.com
RI Alimohamadi, Maysam/AAB-5498-2020
OI Alimohamadi, Maysam/0000-0002-8556-3181
CR Acharya JN, 1992, NEUROL INDIA, V40, P145
   Alexopoulos A, 2005, NEUROLOGY, V64, P567, DOI 10.1212/01.WNL.0000150580.40019.63
   Asadi-Pooya AA, 2008, EPILEPSY BEHAV, V13, P271, DOI 10.1016/j.yebeh.2008.04.020
   Asadi-Pooya AA, 2013, EPILEPSY BEHAV, V29, P285, DOI 10.1016/j.yebeh.2013.08.011
   BERKOVIC SF, 1986, NEW ENGL J MED, V315, P296, DOI 10.1056/NEJM198607313150506
   BERKOVIC SF, 1993, EPILEPSIA, V34, pS19
   Berkovic SF, 1997, EPILEPSY COMPREHENSI, P2455
   Cukiert A, 2006, EPILEPSIA, V47, P371, DOI 10.1111/j.1528-1167.2006.00430.x
   D'Giano CH, 2001, SEIZURE-EUR J EPILEP, V10, P382, DOI 10.1053/seiz.2001.0521
   ENGEL J, 1987, SURG TREATMENT EPILE
   FIOL ME, 1993, EPILEPSIA, V34, P74, DOI 10.1111/j.1528-1157.1993.tb02378.x
   GATES JR, 1987, EPILEPSIA, V28, P28, DOI 10.1111/j.1528-1157.1987.tb03618.x
   GORMAN DG, 1992, EPILEPSIA, V33, P546, DOI 10.1111/j.1528-1157.1992.tb01707.x
   Irwin K, 2001, DEV MED CHILD NEUROL, V43, P248, DOI 10.1017/S0012162201000470
   Janszky J, 2000, CLIN NEUROPHARMACOL, V23, P86, DOI 10.1097/00002826-200003000-00005
   Jenssen S, 2006, SEIZURE-EUR J EPILEP, V15, P621, DOI 10.1016/j.seizure.2006.09.003
   Kasasbeh AS, 2014, NEUROSURGERY, V74, P17, DOI 10.1227/NEU.0000000000000197
   Leppik IE, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s11.4.x
   Lhatoo SD, 2007, EPILEPSIA, V48, P61, DOI 10.1111/j.1528-1167.2007.01353.x
   MAMELAK AN, 1993, J NEUROSURG, V79, P688, DOI 10.3171/jns.1993.79.5.0688
   Michelucci R, 2016, EPILEPTIC DISORD, V18, pS145, DOI 10.1684/epd.2016.0861
   Molyneaux PD, 1998, J NEUROL NEUROSUR PS, V65, P137
   Morrell F, 1995, BRAIN, V118, P1529, DOI 10.1093/brain/118.6.1529
   Ng YT, 2006, J NEUROSURG, V105, P378, DOI 10.3171/ped.2006.105.5.378
   Okumura E, 2013, CLIN NEUROPHYSIOL, V124, P2091, DOI 10.1016/j.clinph.2013.05.004
   Shorvon SD, 2000, HDB EPILEPSY TREATME, P71
   Smith B, 2000, EPILEPSIA, V41, P1046, DOI 10.1111/j.1528-1157.2000.tb00293.x
   SPENCER SS, 1993, EPILEPSIA, V34, P561, DOI 10.1111/j.1528-1157.1993.tb02596.x
   Spencer SS, 1995, ADV BEHAV BIOL, V45, P145
   Vesper J, 2007, EPILEPSIA, V48, P1984, DOI 10.1111/j.1528-1167.2007.01166.x
   Wille C, 2011, EPILEPSIA, V52, P489, DOI 10.1111/j.1528-1167.2010.02884.x
   Wong TT, 2006, CHILD NERV SYST, V22, P999, DOI 10.1007/s00381-006-0133-4
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 509
EP 513
DI 10.1016/j.wneu.2019.04.162
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300257
PM 31042603
DA 2020-05-12
ER

PT J
AU Qian, H
   Wang, L
   Brooks, KS
   Zhao, XC
   Liu, FJ
   Sun, YM
   Shi, XE
   Lei, T
AF Qian, Hai
   Wang, Long
   Brooks, Kenneth Scott
   Zhao, Xiaochun
   Liu, Fangjun
   Sun, Yuming
   Shi, Xiang'en
   Lei, Ting
TI Intraoperative Finding of an Anterior Communicating Artery Blister-Like
   Aneurysm During a Primary Craniopharyngioma Resection: Accidental or
   Incidental?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm suturing; Anterior communicating artery; Blister-like aneurysm;
   Craniopharyngioma; Pathogeny
ID INFLAMMATION; INTERLEUKIN-6
AB BACKGROUND: The presence of an anterior communicating artery blister-like aneurysm in the setting of a craniopharyngioma has never been reported to our knowledge.
   CASE DESCRIPTION: This patient was admitted to our service for an untreated craniopharyngioma resection. An anterior interhemispheric approach with right frontal craniotomy was performed and a blister-like aneurysm of the anterior communicating artery was found during the surgery. After the tumor was completely resected, a suturing technique was used for the aneurysm. In this article, we are going to present this rare case and discuss the potential pathogeny of the aneurysm.
   CONCLUSIONS: We hypothesized that cystic craniopharyngioma may rupture spontaneously. The cystic fluid accumulated in the lower subarachnoid space due to gravity, and it may lead to local vascular cytotoxic and inflammatory reactions which may result in the vascular wall remodeling and lead to the reconstructed vascular wall weakness.
C1 [Qian, Hai; Wang, Long; Zhao, Xiaochun; Liu, Fangjun; Sun, Yuming; Shi, Xiang'en; Lei, Ting] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Brooks, Kenneth Scott] Univ Arizona, Coll Med, Tucson, AZ USA.
   [Wang, Long] Sapporo Teishinkai Hosp, Stroke Ctr, Dept Neurosurg, Sapporo, Hokkaido, Japan.
RP Lei, T (reprint author), Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xiaobailt@hotmail.com
RI WANG, LONG/AAI-5029-2020
OI LEI, TING/0000-0002-4407-5253
CR Carbone F, 2015, IUBMB LIFE, V67, P18, DOI 10.1002/iub.1344
   Elliott RE, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09296
   Hakizimana D, 2018, ACTA NEUROCHIR, V160, P1203, DOI 10.1007/s00701-018-3530-z
   Harrison SC, 2013, EUR HEART J, V34, P3707, DOI 10.1093/eurheartj/ehs354
   Hoffmann A, 2016, PITUITARY, V19, P422, DOI 10.1007/s11102-016-0722-5
   Hosaka K, 2014, TRANSL STROKE RES, V5, P190, DOI 10.1007/s12975-013-0313-y
   Kulkarni V, 2000, SURG NEUROL, V54, P249, DOI 10.1016/S0090-3019(00)00288-3
   Lee SU, 2018, J CLIN NEUROSCI, V58, P181, DOI 10.1016/j.jocn.2018.08.002
   Tena-Suck ML, 2014, ACTA HISTOCHEM, V116, P448, DOI 10.1016/j.acthis.2013.10.002
   Massimi L, 2017, BRAIN PATHOL, V27, P370, DOI 10.1111/bpa.12502
   Mori M, 2004, INT J MOL MED, V14, P505
   Penn DL, 2014, J CLIN NEUROSCI, V21, P28, DOI 10.1016/j.jocn.2013.07.004
   Pereira P, 2002, NEUROSURGERY, V50, P885, DOI 10.1097/00006123-200204000-00042
   Rajput D, 2012, TURK NEUROSURG, V22, P233, DOI 10.5137/1019-5149.JTN.2958-10.2
   Takeuchi S, 2013, BRIT J NEUROSURG, V27, P102, DOI 10.3109/02688697.2012.701677
   Vakharia Kunal, 2017, Int J Crit Illn Inj Sci, V7, P126, DOI 10.4103/IJCIIS.IJCIIS_121_16
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 514
EP 517
DI 10.1016/j.wneu.2019.04.067
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300258
PM 30986581
DA 2020-05-12
ER

PT J
AU O'Connor, KP
   Pelargos, PE
   Palejwala, AH
   Shi, H
   Villeneuve, L
   Glenn, CA
AF O'Connor, Kyle P.
   Pelargos, Panayiotis E.
   Palejwala, Ali H.
   Shi, Helen
   Villeneuve, Lance
   Glenn, Chad A.
TI Resection of Pediatric Trigeminal Schwannoma Using Minimally Invasive
   Approach: Case Report, Literature Review, and Operative Video
SO WORLD NEUROSURGERY
LA English
DT Review
DE Mini-pterional; Operative video; Pediatric; Trigeminal schwannoma
ID NEURINOMAS; REMOVAL; TUMORS; CAVE
AB BACKGROUND: Trigeminal schwannomas are fifth cranial nerve tumors that originate from the nerve sheath. They rarely occur within the pediatric population and can cause dysfunction of the trigeminal nerve and surrounding structures. When patients become symptomatic, neurosurgeons should consider resection.
   CASE DESRIPTION: We report the case of a 14-year-old adolescent boy who presented with an isolated sixth nerve palsy manifested by diplopia. The patient was found to have a trigeminal schwannoma involving the ophthalmic and maxillary branches of the trigeminal nerve. A modified mini-pterional craniotomy was performed for an extended middle fossa approach with an anterior petrosectomy to gain access to the inferior aspect of the posterior fossa tumor component. Intraoperatively, the sixth nerve was compressed within Dorello's canal. Postoperatively, the patient's sixth nerve palsy resolved, and magnetic resonance imaging demonstrated near-total resection with residual enhancement along the superior orbital fissure near the oculomotor nerve entry zone and foramen rotundum.
   CONSLUSIONS: We present a rare case of pediatric trigeminal schwannoma Mp treated surgically with a near-total resection via a novel mini-pterional approach and use of cranial nerve diffusion tensor imaging.
C1 [O'Connor, Kyle P.; Pelargos, Panayiotis E.; Palejwala, Ali H.; Shi, Helen; Villeneuve, Lance; Glenn, Chad A.] Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73106 USA.
RP Glenn, CA (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK 73106 USA.
EM chad-glenn@ouhsc.edu
CR Agarwal A, 2015, NEURORADIOL J, V28, P36, DOI 10.15274/NRJ-2014-10117
   Agrawal Aviral, 2017, Natl J Maxillofac Surg, V8, P149, DOI 10.4103/njms.NJMS_82_14
   Al-Mefty O, 2002, J NEUROSURG, V96, P453, DOI 10.3171/jns.2002.96.3.0453
   Avci E, 2011, SURG RADIOL ANAT, V33, P569, DOI 10.1007/s00276-011-0782-1
   Doddamani Ramesh Sharanappa, 2018, Asian J Neurosurg, V13, P136, DOI 10.4103/1793-5482.175633
   Fukaya R, 2011, NEUROSURG REV, V34, P159, DOI 10.1007/s10143-010-0289-y
   Goel A, 2010, J NEUROSURG, V113, P1079, DOI 10.3171/2009.10.JNS091149
   Gwak HS, 2003, SURG NEUROL, V60, P39, DOI 10.1016/S0090-3019(03)00069-7
   Iaconetta G, 2010, CRANIAL, CRANIOFACIAL AND SKULL BASE SURGERY, P39, DOI 10.1007/978-88-470-1167-0_5
   JEFFERSON G, 1953, Clin Neurosurg, V1, P11
   Kawase T, 2009, PRACTICAL HDB NEUROS, P233
   Kim Ji Hyun, 2018, Arch Craniofac Surg, V19, P94, DOI 10.7181/acfs.2018.01781
   Koyye Ravindranath Tagore, 2003, Brain Tumor Pathol, V20, P79, DOI 10.1007/BF02483451
   LESOIN F, 1986, ACTA NEUROCHIR, V82, P118, DOI 10.1007/BF01456371
   Liu HL, 2011, EUR ARCH OTO-RHINO-L, V268, P1343, DOI 10.1007/s00405-011-1491-4
   MacNally SP, 2008, BRIT J NEUROSURG, V22, P729, DOI 10.1080/02688690802272172
   MCCORMICK PC, 1988, J NEUROSURG, V69, P850, DOI 10.3171/jns.1988.69.6.0850
   Muto J, 2010, NEUROSURGERY, V67, P291, DOI 10.1227/01.NEU.0000382967.84940.52
   Ostergard TA, 2018, WORLD NEUROSURG, V119, P176, DOI 10.1016/j.wneu.2018.07.259
   PerezDiaz CJ, 1996, CHILD NERV SYST, V12, P283
   POLLACK IF, 1989, J NEUROSURG, V70, P737, DOI 10.3171/jns.1989.70.5.0737
   ROSS DL, 1984, NEUROSURGERY, V15, P108, DOI 10.1227/00006123-198407000-00021
   Ruzevick J, 2015, CLIN NEUROL NEUROSUR, V134, P24, DOI 10.1016/j.clineuro.2015.04.005
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Samii M, 2012, NEUROSURG REV, V35, P277, DOI 10.1007/s10143-011-0361-2
   Shi W, 2011, BRIT J NEUROSURG, V25, P714, DOI 10.3109/02688697.2011.562991
   Sun DQ, 2018, OTOL NEUROTOL, V39, P82, DOI 10.1097/MAO.0000000000001602
   Tsuboi K, 1999, ACTA NEUROCHIR, V141, P429, DOI 10.1007/s007010050320
   Tsuboi K, 1999, ACTA NEUROCHIR, V141, P433
   Tullos HJ, 2018, WORLD NEUROSURG, V117, pE637, DOI 10.1016/j.wneu.2018.06.103
   VANLOVEREN HR, 1991, J NEUROSURG, V74, P837, DOI 10.3171/jns.1991.74.5.0837
   Verstappen CCP, 2005, CHILD NERV SYST, V21, P1008, DOI 10.1007/s00381-004-1091-3
   Yoshida K, 1999, J NEUROSURG, V91, P202, DOI 10.3171/jns.1999.91.2.0202
NR 33
TC 7
Z9 7
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 518
EP 524
DI 10.1016/j.wneu.2019.04.113
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300259
PM 31009782
DA 2020-05-12
ER

PT J
AU Takahashi, Y
   Wanibuchi, M
   Kimura, Y
   Akiyama, Y
   Mikami, T
   Mikuni, N
AF Takahashi, Yasuhiro
   Wanibuchi, Masahiko
   Kimura, Yusuke
   Akiyama, Yukinori
   Mikami, Takeshi
   Mikuni, Nobuhiro
TI Meningioma Originating from the Hypoglossal Canal: Case Report and
   Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Extracranial meningioma; Hypoglossal canal; Transcondylar approach
ID CRANIOVERTEBRAL JUNCTION; MORPHOMETRIC-ANALYSIS
AB BACKGROUND: Primary extracranial meningiomas are uncommon neoplasms. In particular, meningioma involving the hypoglossal canal is extremely rare, with only 4 cases reported in the literature so far. Given that each of these meningiomas originated in the juxtacondyle region with involvement of the hypoglossal canal, to the best of our knowledge, a meningioma that exists only within the hypoglossal canal has yet to be reported.
   CASE DESCRIPTION: We present a case of primary extracranial meningioma arising solely From the hypoglossal canal. A 62-year-old woman presented with long-term difficulty in tongue movement Her tongue was deviated to the right, and neurologic examination revealed fasciculation and muscle wasting on the right side of the tongue. Computed tomography revealed a calcification in the right hypoglossal canal. Magnetic resonance imaging further demonstrated a hypointense tumor on both T1-weighted and T2-weighted images, with contrast enhancement in the right condyle. Total tumor removal was performed via a transcondylar approach, and histopathologic examination confirmed the presence of a transitional meningioma. No recurrence was observed at 14 months of follow-up. The patient's tongue atrophy was slightly improved, and the deviation completely disappeared.
   CONCLUSIONS: In this extremely rare case of hypoglossal canal meningioma total tumor removal via a transcondylar approach resulted in the recovery of hypoglossal nerve function.
C1 [Takahashi, Yasuhiro; Wanibuchi, Masahiko; Kimura, Yusuke; Akiyama, Yukinori; Mikami, Takeshi; Mikuni, Nobuhiro] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido, Japan.
RP Wanibuchi, M (reprint author), Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido, Japan.
EM wanibuti@sapmed.ac.jp
OI Mikami, Takeshi/0000-0002-8608-1037; Wanibuchi,
   Masahiko/0000-0002-1856-7123
CR Barut N, 2009, BRIT J NEUROSURG, V23, P276, DOI 10.1080/02688690902814725
   Calzada G, 2007, SKULL BASE-INTERD AP, V17, P187, DOI 10.1055/s-2007-977466
   Dobrowolski S, 2016, J SURG CASE REP, DOI 10.1093/jscr/rjw039
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Kshettry VR, 2017, J NEUROSURG, V127, P829, DOI 10.3171/2016.7.JNS16293
   Muthukumar N, 2005, ACTA NEUROCHIR, V147, P889, DOI 10.1007/s00701-005-0555-x
   Naderi S, 2005, CLIN NEUROL NEUROSUR, V107, P191, DOI 10.1016/j.clineuro.2004.07.014
   Neeff M, 2007, SKULL BASE-INTERD AP, V17, P325, DOI 10.1055/s-2007-986437
   Rushing EJ, 2009, HEAD NECK PATHOL, V3, P116, DOI 10.1007/s12105-009-0118-1
   Schick U, 2004, J NEUROSURG, V101, P951, DOI 10.3171/jns.2004.101.6.0951
   Turbin RE, 2002, OPHTHALMOLOGY, V109, P890, DOI 10.1016/S0161-6420(02)01017-5
   Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091
   von Eckardstein KL, 2010, NEUROSURGERY, V67, P1236, DOI 10.1227/NEU.0b013e3181efe412
   Wanibuchi M, 2009, PHOTOATLAS SKULL BAS
   WHICKER JH, 1973, AM J SURG, V126, P452, DOI 10.1016/S0002-9610(73)80029-7
   Yoshida Kazunari, 2010, No Shinkei Geka, V38, P17
   Zulkiflee Abu Bakar, 2012, Ear Nose Throat J, V91, pE26
NR 17
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 525
EP 529
DI 10.1016/j.wneu.2019.04.084
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300260
PM 31004855
DA 2020-05-12
ER

PT J
AU Timmers, AAC
   Bos, EM
   Dammers, R
AF Timmers, Annelieve A. C.
   Bos, Eelke M.
   Dammers, Ruben
TI A Case of Spontaneous Third Ventriculocisternostomy to the
   Interpeduncular Fossa
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; Shunt; Spontaneous third ventriculocisternostomy;
   Triventricular hydrocephalus
ID 3-DIMENSIONAL SAMPLING PERFECTION; SPONTANEOUS VENTRICULOSTOMY;
   OBSTRUCTIVE HYDROCEPHALUS; DIVERTICULA; VENTRICLE; SEQUENCE; MRI
AB BACKGROUND: Triventricular hydrocephalus is caused by an obstruction of cerebrospinal fluid flow causing increased intracranial pressure (ICP). Common treatment options include ventricular shunting or endoscopic third ventriculocisternostomy. Spontaneous third ventriculocisternostomy is a rare phenomenon in patients with obstructive triventricular hydrocephalus. We present the case of a patient with triventricular hydrocephalus and evidence of spontaneous third ventriculocisternostomy.
   CASE DESCRIPTION: A 33-year-old female patient was referred to our outpatient clinic for triventricular hydrocephalus diagnosed on imaging. Magnetic resonance imaging (MRI) of her brain showed a triventricular obstructive hydrocephalus owing to a possible aqueductal stenosis. No clinical or diagnostic signs of elevated ICP were present. Repeat imaging showed no changes in cerebral ventricular size and MRI flow imaging demonstrated flow voids in the third ventricle extending through the floor of the third ventricle to the prepontine cistern. We concluded that the cause of hydrocephalus was likely to be a compensated aqueductal stenosis.
   CONCLUSIONS: Spontaneous third ventriculocisternostomy is seen in patients with chronic hydrocephalus. MRI sensitive to flow artefacts can be useful in the diagnosis of patients with apparent compensated hydrocephalus, and phase-contrast imaging can prove cerebrospinal fluid flow across the stoma. Resolution of symptoms owing to elevated ICP is regularly observed in patients with a spontaneous ventriculocisternostomy.
C1 [Timmers, Annelieve A. C.; Bos, Eelke M.; Dammers, Ruben] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands.
RP Dammers, R (reprint author), Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands.
EM r.dammers@erasmusmc.nl
OI Bos, Eelke/0000-0003-3647-6740; Dammers, Ruben/0000-0001-7033-0644
CR Al Abdulsalam H, 2018, OPER NEUROSURG, V14, pE26, DOI 10.1093/ons/opx268
   Algin O, 2010, AM J NEURORADIOL, V31, P26
   Algin O, 2013, J NEURORADIOLOGY, V40, P11, DOI 10.1016/j.neurad.2011.12.003
   Algin O, 2010, NEURORADIOLOGY, V52, P99, DOI 10.1007/s00234-009-0592-x
   ALONSO A, 1979, RADIOLOGY, V133, P651, DOI 10.1148/133.3.651
   Bailey A, 2010, CLIN NEUROL NEUROSUR, V112, P817, DOI 10.1016/j.clineuro.2010.06.010
   BHATIA R, 1977, ACTA NEUROCHIR, V39, P159, DOI 10.1007/BF01406725
   Daniel RT, 2004, J NEUROSURG, V101, P518, DOI 10.3171/jns.2004.101.3.0518
   Deniz FE, 2008, CHILD NERV SYST, V24, P633, DOI 10.1007/s00381-007-0542-z
   Fujita K, 2001, CHILD NERV SYST, V17, P750, DOI 10.1007/s003810100502
   Gallia GL, 2008, J NEUROSURG-PEDIATR, V1, P477, DOI 10.3171/PED/2008/1/6/477
   Jabaudon D, 2003, NEUROSURGERY, V52, P209, DOI 10.1097/00006123-200301000-00026
   KAPILA A, 1981, J NEUROSURG, V54, P101, DOI 10.3171/jns.1981.54.1.0101
   Kartal MG, 2015, J COMPUT ASSIST TOMO, V39, P321, DOI 10.1097/RCT.0000000000000206
   Kim LJ, 2005, ACTA NEUROCHIR, V147, P219, DOI 10.1007/s00701-004-0401-6
   LESLIE EV, 1964, RADIOLOGY, V83, P683, DOI 10.1148/83.4.683
   Miyasaka Y, 1977, No Shinkei Geka, V5, P81
   NAIDICH TP, 1982, AM J NEURORADIOL, V3, P257
   Ogrenci A, 2016, CHILD NERV SYST, V32, P1727, DOI 10.1007/s00381-016-3096-0
   Osuka S, 2007, CHILD NERV SYST, V23, P897, DOI 10.1007/s00381-007-0315-8
   Parmar A, 2009, J NEUROSURG, V111, P628, DOI 10.3171/2008.5.JNS08286
   Rovira A, 1999, AM J NEURORADIOL, V20, P1647
   Stachura K, 2010, NEUROL NEUROCHIR POL, V44, P87
   WAKAI S, 1984, J NEUROL NEUROSUR PS, V47, P514, DOI 10.1136/jnnp.47.5.514
   Yuen A, 2008, J CLIN NEUROSCI, V15, P587, DOI 10.1016/j.jocn.2007.05.015
   ZILKHA A, 1974, RADIOLOGY, V111, P633, DOI 10.1148/111.3.633
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 530
EP 533
DI 10.1016/j.wneu.2019.02.142
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300261
PM 30851465
DA 2020-05-12
ER

PT J
AU Yao, AH
   Jia, LY
   Wang, BH
   Zhang, JS
   Zhang, J
   Xu, BN
AF Yao, Anhui
   Jia, Liyun
   Wang, Benhan
   Zhang, Jiashu
   Zhang, Jun
   Xu, Bainan
TI Idiopathic Hypertrophic Pachymeningitis Mimicking Meningioma with
   Occlusion of Superior Sagittal Sinus: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Idiopathic hypertrophic pachymeningitis; Meningioma
ID LYMPHOPLASMACYTE-RICH MENINGIOMA; CLINICORADIOLOGICAL SPECTRUM; CRANIAL
   PACHYMENINGITIS
AB BACKGROUND: Idiopathic hypertrophic pachymeningitis is a rare inflammatory condition with diffuse thickening of the dura mater, which may cause a compressive effect or vascular compromise.
   CASE DESCRIPTION: A 40-year-old Chinese man presented with persistent headache for 5 months and a sudden epileptic seizure 2 days ago. Magnetic resonance imaging demonstrated a large (71 x 34 x 27 mm) extra-axial mass at the right frontal convexity with severe edema mimicking meningioma. The lesion and peripheral dura mater showed contrast enhancement. Additionally, the skull near the lesion was eroded. Meningioma was diagnosed, and the patient underwent surgery. During the operation, we found the lesion texture was very tough, and the superior sagittal sinus was occluded. Histopathologic findings revealed a large number of infiltrated lymphocytes with fibrosis and microabscess formation; intracranial idiopathic hypertrophic pachymeningitis was diagnosed. Follow-up magnetic resonance imaging performed 3 months after surgery demonstrated the enhancement was notably alleviated.
   CONCLUSIONS: Idiopathic hypertrophic pachymeningitis should be part of the differential diagnosis of some cases of meningioma.
C1 [Yao, Anhui; Zhang, Jiashu; Zhang, Jun; Xu, Bainan] Gen Hosp PLA, Dept Neurosurg, Beijing, Peoples R China.
   [Yao, Anhui; Wang, Benhan] PLA, Hosp 988, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
   [Jia, Liyun] Zhengzhou Univ, Sch Basic Med Sci, Dept Med Genet & Cell Biol, Zhengzhou, Henan, Peoples R China.
RP Zhang, J (reprint author), Gen Hosp PLA, Dept Neurosurg, Beijing, Peoples R China.
EM zjun_301@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81402455]
FX This study was funded by the National Natural Science Foundation of
   China (Grant No. 81402455).
CR Arrese T, 2005, NEUROCIRUGIA, V16, P63
   Barbieri FR, 2018, WORLD NEUROSURG, V119, P183, DOI 10.1016/j.wneu.2018.07.194
   Cha YJ, 2016, BRAIN TUMOR PATHOL, V33, P216, DOI 10.1007/s10014-016-0254-8
   Chan JW, 2006, JCR-J CLIN RHEUMATOL, V12, P30, DOI 10.1097/01.rhu.0000200423.12270.18
   Christakis PG, 2012, CLIN NEUROL NEUROSUR, V114, P176, DOI 10.1016/j.clineuro.2011.10.011
   Dash GK, 2015, J NEUROL SCI, V350, P51, DOI 10.1016/j.jns.2015.02.013
   Hamada J, 2000, NEUROSURGERY, V47, P1230, DOI 10.1097/00006123-200011000-00043
   Hatano N, 1999, NEUROSURGERY, V45, P1336, DOI 10.1097/00006123-199912000-00014
   Hirunwiwatkul P, 2007, J NEURO-OPHTHALMOL, V27, P91, DOI 10.1097/WNO.0b013e31806773a5
   Hosler MR, 2007, J NEURO-OPHTHALMOL, V27, P95, DOI 10.1097/WNO.0b013e318064c53a
   Huang YY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007549
   Jang Y, 2017, J CLIN NEUROL, V13, P155, DOI 10.3988/jcn.2017.13.2.155
   Kupersmith MJ, 2004, NEUROLOGY, V62, P686, DOI 10.1212/01.WNL.0000113748.53023.B7
   Lee Young-Sub, 2014, Brain Tumor Res Treat, V2, P87, DOI 10.14791/btrt.2014.2.2.87
   Lin CK, 2013, BMC SURG, V13, DOI 10.1186/1471-2482-13-37
   Lok JYC, 2015, HONG KONG MED J, V21, P360, DOI 10.12809/hkmj144295
   Noda D, 2008, NEUROL SURG TOKYO, V36, P717
   Oku T, 1995, No To Shinkei, V47, P569
   Russo A, 2018, CEPHALALGIA, V38, P804, DOI 10.1177/0333102417708773
   Uchida H, 2018, CLIN NEUROL NEUROSUR, V168, P30, DOI 10.1016/j.clineuro.2018.02.035
   Ueda Akihiro, 2011, Rinsho Shinkeigaku, V51, P243
   Umegaki Sho, 2018, No Shinkei Geka, V46, P147, DOI 10.11477/mf.1436203691
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 534
EP 537
DI 10.1016/j.wneu.2019.04.006
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300262
PM 30965168
DA 2020-05-12
ER

PT J
AU Tran, HM
   Karras, CL
   Yerneni, K
   Trybula, SJ
   Vo, ST
   Nguyen, P
   Huynh, PL
   Nguyen, CK
   Nguyen, TV
   Tran, PH
   Tran, BHH
   Vo, TT
   Tran, KT
   Tran, TK
   Le, TK
   Le, SMT
   Nguyen, TM
   Prevedello, DM
AF Huy Minh Tran
   Karras, Constantine L.
   Yerneni, Ketan
   Trybula, Siting J.
   Son Tan Vo
   Phong Nguyen
   Phuong Le Huynh
   Chung Kim Nguyen
   Tan Van Nguyen
   Phong Hung Tran
   Bao Hoan Huy Tran
   Tung Thanh Vo
   Khiem Thien Tran
   Tuyen Kim Tran
   Tuan Kham Le
   Su Minh Tran Le
   Tan Minh Nguyen
   Prevedello, Daniel M.
TI Neurosurgical Oncology in Vietnam
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Cho ray; Global neurosurgery; Meningioma; Neuro-oncology;
   Tumor; Vietnam
AB BACKGROUND: In conjunction with Vietnam's unparaleled economic growth over the past 20 years, our scope of neurosurgical interventions has considerably diversified throughout this time period.
   METHODS: Although still appreciably limited, health-resources and infrastructure have expanded and shifted the focus within neurosurgery at Ho Chi Minh City's Cho Ray Hospital from head trauma (which remains highly prevalent) to an equal proportion of elective cases for vascular lesions, tumors, and degenerative spine disease. Arguably the most significant progress throughout the new millennium has been achieved in the realm of neurosurgical oncology.
   RESULTS: About 1000 craniotomies are performed annually for brain tumors at our institution, most of which are for lower-grade lesions that result in excellent surgical outcomes. We continue to strive to improve the standard of care for patients with malignant brain tumors, as the first multidisciplinary neuro-oncology care team was founded recently in 2016.
   CONCLUSIONS: This article is the first in the English nerosurgical literature to report on the current state and outcomes of neuro-oncology in Vietnam, as we highlight our experiences in caring for patients with brain tumors at Cho Ray Hospital.
C1 [Huy Minh Tran; Son Tan Vo; Tuan Kham Le; Su Minh Tran Le] Univ Med & Pharm, Dept Neurol Surg, Ho Chi Minh City, Vietnam.
   [Huy Minh Tran] Taipei Med Univ, Coll Med, PhD Program Med, Taipei, Taiwan.
   [Karras, Constantine L.; Yerneni, Ketan; Trybula, Siting J.] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Phong Nguyen; Phuong Le Huynh; Chung Kim Nguyen; Tan Van Nguyen; Phong Hung Tran; Bao Hoan Huy Tran; Tung Thanh Vo; Khiem Thien Tran; Tuyen Kim Tran; Tuan Kham Le; Su Minh Tran Le; Tan Minh Nguyen] Cho Ray Hosp, Dept Neurol Surg, Ho Chi Minh City, Vietnam.
   [Prevedello, Daniel M.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
RP Karras, CL (reprint author), Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA.
EM constantine.karras@northwestern.edu
OI Prevedello, Daniel/0000-0003-0214-2339; Tran, Huy
   Minh/0000-0003-3145-1325
FU Ohio State University Office of Global Health
FX Supported by the Ohio State University Office of Global Health.
CR ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840
   Karras CL, 2017, WORLD NEUROSURG, V105, P122, DOI 10.1016/j.wneu.2017.05.141
   Rosenfeld JV, 1997, SURG NEUROL, V48, P307, DOI 10.1016/S0090-3019(96)00397-7
   World Health Organization, VIETN COUNTR STAT
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 541
EP 548
DI 10.1016/j.wneu.2019.03.078
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300264
PM 30902769
DA 2020-05-12
ER

PT J
AU Ghali, GZ
   Ghali, MGZ
   Ghali, EZ
   Srinivasan, VM
   Wagner, KM
   Rothermel, A
   Taylor, J
   Johnson, J
   Kan, P
   Lam, S
   Britz, G
AF Ghali, George Zaki
   Ghali, Michael George Zaki
   Ghali, Emil Zaki
   Srinivasan, Visish M.
   Wagner, Kathryn M.
   Rothermel, Alexis
   Taylor, Jesse
   Johnson, Jeremiah
   Kan, Peter
   Lam, Sandi
   Britz, Gavin
TI Intracranial Venous Hypertension in Craniosynostosis: Mechanistic
   Underpinnings and Therapeutic Implications
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniosynostosis; Hydrocephalus; ICP; Intracranial hypertension;
   Jugular; Transverse sinus; Venous
ID CHRONIC TONSILLAR HERNIATION; CRANIAL VAULT EXPANSION; GROWTH-FACTOR
   RECEPTORS; CHIARI-I MALFORMATION; CINE PHASE-CONTRAST; SYNDROMIC
   CRANIOSYNOSTOSIS; JUGULAR FORAMEN; POSTERIOR-FOSSA; COMPLEX
   CRANIOSYNOSTOSIS; SINUS PERICRANII
AB Patients with complex, multisutural, and syndromic craniosynostosis (CSO) frequently exhibit intracranial hypertension. The intracranial hypertension cannot be entirely attributed to the craniocephalic disproportion with calvarial restriction because cranial vault expansion has not consistently alleviated elevated intracranial pressure. Evidence has most strongly supported a multi-factorial interaction, including venous hypertension along with other pathogenic processes. Patients with CSO exhibit marked venous anomalies, including stenosis of the jugular-sigmoid complex, transverse sinuses, and extensive transosseous venous collaterals. These abnormal intracranial-extracranial occipital venous collaterals might represent anomalous development, with persistence and subsequent enlargement of channels normally present in the fetus, either as a primary defect or as nonregression in response to failure of the development of the jugular-sigmoid complexes. It has been suggested by some investigators that venous hypertension in patients with CSO could be treated directly via jugular foraminoplasty, venous stenting, or jugular venous bypass, although these options are not in common clinical practice. Obstructive sleep apnea, occurring as a consequence of midface hypoplasia, can also contribute to intracranial hypertension in patients with syndromic CSO. Thus, correction of facial deformities, as well as posterior fossa decompression, could also play important roles in the treatment of intracranial hypertension. Determining the precise mechanistic underpinnings underlying intracranial hypertension in any given patient with CSO requires individualized evaluation and management.
C1 [Ghali, George Zaki] US EPA, Arlington, VA USA.
   [Ghali, George Zaki] Purdue Univ, Dept Toxicol, W Lafayette, IN 47907 USA.
   [Ghali, Michael George Zaki; Britz, Gavin] Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.
   [Ghali, Michael George Zaki; Srinivasan, Visish M.; Wagner, Kathryn M.; Johnson, Jeremiah; Kan, Peter; Lam, Sandi] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
   [Ghali, Emil Zaki] Inova Alexandria Hosp, Dept Med, Alexandria, VA USA.
   [Ghali, Emil Zaki] El Gomhoureya Gen Hosp, Dept Urol Surg, Alexandria, Egypt.
   [Rothermel, Alexis] Penn State Hershey Med Ctr, Div Plast & Reconstruct Surg, Hershey, PA USA.
   [Taylor, Jesse] Univ Penn, Childrens Hosp Philadelphia, Div Plast & Reconstruct Surg, Philadelphia, PA 19104 USA.
RP Ghali, MGZ (reprint author), Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.; Ghali, MGZ (reprint author), Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
EM mgzghali@gmail.com
OI Britz, Gavin/0000-0002-2358-3005
CR Al-Otibi M, 2007, J NEUROSURG, V107, P508, DOI 10.3171/PED-07/12/508
   Anderson PJ, 2004, PEDIATR NEUROSURG, V40, P161, DOI 10.1159/000081933
   Anderson PJ, 1997, CHILD NERV SYST, V13, P97, DOI 10.1007/s003810050052
   ANDEWEG J, 1989, CHILD NERV SYST, V5, P318, DOI 10.1007/BF00274522
   Aydin S, 2005, SURG NEUROL, V64, P237, DOI 10.1016/j.surneu.2005.02.021
   BALLER FRIEDRICH, 1950, ZEITSCHRIFT MENSCHL VERERBUNGS U KONSTITUTIONSLEHRE, V29, P782
   Bannink N, 2008, J CRANIOFAC SURG, V19, P121, DOI 10.1097/SCS.0b013e31815f4015
   Bansal R, 2003, DEV NEUROSCI-BASEL, V25, P83, DOI 10.1159/000072258
   Bedford THB, 1942, J PHYSIOL-LONDON, V101, P362, DOI 10.1113/jphysiol.1942.sp003991
   BENABID AL, 1974, NEUROCHIRURGIE, V20, P623
   BERING EA, 1959, ARCH NEURO PSYCHIATR, V81, P693, DOI 10.1001/archneurpsyc.1959.02340180027004
   Blaser SI, 2015, PEDIATR RADIOL, V45, P485, DOI 10.1007/s00247-015-3320-1
   BLOMQUIST HKS, 1986, J NEUROL NEUROSUR PS, V49, P536, DOI 10.1136/jnnp.49.5.536
   Booth CD, 2011, J CRANIOFAC SURG, V22, P285, DOI 10.1097/SCS.0b013e3181f7b738
   Britto JA, 1998, PLAST RECONSTR SURG, V101, P540, DOI 10.1097/00006534-199802000-00052
   Cinalli G, 1998, J NEUROSURG, V88, P209, DOI 10.3171/jns.1998.88.2.0209
   Cinalli G, 2005, CHILD NERV SYST, V21, P889, DOI 10.1007/s00381-004-1115-z
   CINALLI G, 1995, J NEUROSURG, V83, P575, DOI 10.3171/jns.1995.83.4.0575
   Collmann H, 2005, CHILD NERV SYST, V21, P902, DOI 10.1007/s00381-004-1116-y
   COLLMANN H, 1988, CHILD NERV SYST, V4, P279
   Costa MA, 2015, J NEUROSURG-PEDIATR, V16, P80, DOI 10.3171/2014.12.PEDS14604
   CRONQVIST S, 1972, J NEUROSURG, V36, P249, DOI 10.3171/jns.1972.36.3.0249
   Dagtekin A, 2011, CLIN NEUROL NEUROSUR, V113, P399, DOI 10.1016/j.clineuro.2010.12.020
   de Lange SA, 1970, DEV MED CHILD NE S22, V12, P28
   Di Rocco C, 2011, CHILD NERV SYST, V27, P1653, DOI 10.1007/s00381-011-1545-3
   DICHIRO GD, 1964, J NEUROSURG, V21, P447, DOI 10.3171/jns.1964.21.6.0447
   Driessen C, 2013, ARCH DIS CHILD, V98, P538, DOI 10.1136/archdischild-2012-302745
   Driessen C, 2013, CHILD NERV SYST, V29, P289, DOI 10.1007/s00381-012-1922-6
   FISHMAN MA, 1971, J NEUROSURG, V34, P621, DOI 10.3171/jns.1971.34.5.0621
   Flanagan MF, 2015, NEUROL RES INT, V2015, DOI 10.1155/2015/794829
   Florisson JMG, 2015, J CRANIO MAXILL SURG, V43, P312, DOI 10.1016/j.jcms.2014.11.023
   FOK H, 1992, BRIT J PLAST SURG, V45, P394, DOI 10.1016/0007-1226(92)90013-N
   FRANCIS PM, 1992, PEDIATR NEUROSURG, V18, P202, DOI 10.1159/000120663
   GEROLD M, 1959, Zentralbl Chir, V84, P831
   GIRARD N, 1994, CHILD NERV SYST, V10, P141, DOI 10.1007/BF00301078
   GOLABI M, 1987, NEUROSURGERY, V21, P63, DOI 10.1227/00006123-198707000-00013
   Gong SG, 2012, CHILD NERV SYST, V28, P1495, DOI 10.1007/s00381-012-1792-y
   Gonsalez S, 1997, EUR RESPIR J, V10, P367, DOI 10.1183/09031936.97.10020367
   Gosain AK, 1996, PLAST RECONSTR SURG, V97, P292, DOI 10.1097/00006534-199602000-00004
   GRAY JL, 1994, J SURG RES, V57, P596, DOI 10.1006/jsre.1994.1189
   GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385
   GUTHRIE TC, 1970, J NEUROSURG, V33, P407, DOI 10.3171/jns.1970.33.4.0407
   HAAR FL, 1975, J NEUROSURG, V42, P597, DOI 10.3171/jns.1975.42.5.0597
   Hayward R, 2005, CHILD NERV SYST, V21, P880, DOI 10.1007/s00381-004-1114-0
   Hayward R, 2005, J NEUROSURG, V102, P16, DOI 10.3171/ped.2005.102.1.0016
   Hirabuki N, 2000, AM J NEURORADIOL, V21, P1497
   Hopkins TE, 2003, J NEUROSURG, V98, P1113, DOI 10.3171/jns.2003.98.5.1113
   Hyre MA, 2007, 2007 AM ASS OR MAX S
   Inagaki T, 2007, CHILD NERV SYST, V23, P1455, DOI 10.1007/s00381-007-0436-0
   JANNY P, 1981, NEUROCHIRURGIE, V27, P79
   Jeevan D, 2008, CHILD NERV SYST, V24, P1413, DOI 10.1007/s00381-008-0667-8
   Kimiwada T, 2013, NEUROL MED-CHIR, V53, P121, DOI 10.2176/nmc.53.121
   KINAL ME, 1962, J NEUROSURG, V19, P195, DOI 10.3171/jns.1962.19.3.0195
   KINAL ME, 1966, J NEUROSURG, V25, P395, DOI 10.3171/jns.1966.25.4.0395
   Kollar CD, 2001, CHILD NERV SYST, V17, P117, DOI 10.1007/s003810000269
   KUROSU A, 1994, NEUROSURGERY, V34, P1090, DOI 10.1227/00006123-199406000-00025
   LAMAS E, 1977, J NEUROSURG, V46, P804, DOI 10.3171/jns.1977.46.6.0804
   Langfitt T W, 1966, Acta Neurochir (Wien), V15, P212, DOI 10.1007/BF01406783
   LASJAUNIAS P, 1997, VASCULAR DIS NEONATE
   Levitt MR, 2012, J NEUROSURG-PEDIATR, V9, P111, DOI 10.3171/2011.11.PEDS11268
   Liasis A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1119, DOI 10.1001/archopht.124.8.1119
   LO WWM, 1984, RADIOLOGY, V150, P743, DOI 10.1148/radiology.150.3.6320256
   LUNDAR T, 1990, J NEUROSURG, V73, P138, DOI 10.3171/jns.1990.73.1.0138
   LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1
   Martinez-Abadias N, 2013, DEV DYNAM, V242, P80, DOI 10.1002/dvdy.23903
   MartinezPerez D, 1996, PEDIATR NEUROSURG, V25, P252, DOI 10.1159/000121134
   MARTINS AN, 1974, J NEUROSURG, V40, P603, DOI 10.3171/jns.1974.40.5.0603
   Marucci DD, 2008, PLAST RECONSTR SURG, V122, P1162, DOI 10.1097/PRS.0b013e31818458f0
   McLaughlin JF, 1997, CHILD NERV SYST, V13, P59, DOI 10.1007/s003810050042
   MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44
   Mulliken JB, 1999, PLAST RECONSTR SURG, V104, P1603, DOI 10.1097/00006534-199911000-00001
   Mursch K, 1999, CHILD NERV SYST, V15, P110, DOI 10.1007/s003810050344
   Mursch K, 1998, PEDIATR NEUROSURG, V29, P320, DOI 10.1159/000028746
   Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233
   Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049
   Nishikawa M, 1997, J NEUROSURG, V86, P40, DOI 10.3171/jns.1997.86.1.0040
   NIWA J, 1988, Neurological Surgery, V16, P1273
   NOLTE J, 2002, HUMAN BRAIN INTRO IT
   OKUDERA T, 1994, AM J NEURORADIOL, V15, P1871
   OSTERHOLM JL, 1970, J NEUROSURG, V32, P654, DOI 10.3171/jns.1970.32.6.0654
   Padget DH, 1957, CONTRIB EMBRYOL, V247, P81
   Pagnoni M, 2014, J CRANIO MAXILL SURG, V42, P513, DOI 10.1016/j.jcms.2013.07.018
   Park SC, 2009, J NEUROSURG-PEDIATR, V4, P536, DOI 10.3171/2009.7.PEDS0994
   Perlyn CA, 2006, CLEFT PALATE-CRAN J, V43, P740, DOI 10.1597/05-212
   PIERREKAHN A, 1980, CHILD BRAIN, V7, P205
   Pollack IF, 1996, PEDIATR NEUROSURG, V24, P202, DOI 10.1159/000121038
   Ranger A, 2010, J CRANIOFAC SURG, V21, P427, DOI 10.1097/SCS.0b013e3181cfa792
   RAYNOR RB, 1986, SPINE, V11, P343, DOI 10.1097/00007632-198605000-00009
   RENIER D, 1982, J NEUROSURG, V57, P370, DOI 10.3171/jns.1982.57.3.0370
   Rich PM, 2003, AM J NEURORADIOL, V24, P45
   Rijken BFM, 2015, J CRANIO MAXILL SURG, V43, P813, DOI 10.1016/j.jcms.2015.04.001
   RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963
   Robson CD, 2000, AM J NEURORADIOL, V21, P1707
   Rollins N, 2000, CHILD NERV SYST, V16, P569, DOI 10.1007/PL00007299
   Rollins N, 2005, AM J NEURORADIOL, V26, P50
   Rollins N, 2000, PEDIATR NEUROSURG, V32, P308, DOI 10.1159/000028959
   ROSMAN NP, 1978, ANN NEUROL, V3, P445, DOI 10.1002/ana.410030516
   SAINTEROSE C, 1984, J NEUROSURG, V60, P727, DOI 10.3171/jns.1984.60.4.0727
   SALDINO RM, 1972, AM J ROENTGENOL, V116, P609, DOI 10.2214/ajr.116.3.609
   Sandberg DI, 2007, J NEUROSURG, V106, P490, DOI 10.3171/ped.2007.106.6.490
   Sankey EW, 2015, J CLIN NEUROSCI, V22, P1507, DOI 10.1016/j.jocn.2015.03.027
   Savarirayan R, 1998, J MED GENET, V35, P767, DOI 10.1136/jmg.35.9.767
   Schaller B, 2004, BRAIN RES REV, V46, P243, DOI 10.1016/j.brainresrev.2004.04.005
   Sgouros S, 2005, CHILD NERV SYST, V21, P861, DOI 10.1007/s00381-004-1112-2
   SHAPIRO K, 1976, J NEUROSURG, V45, P20, DOI 10.3171/jns.1976.45.1.0020
   Shillito JJ, 1982, ATLAS PEDIAT NEUROSU
   SHIROYAMA Y, 1991, CHILD NERV SYST, V7, P382, DOI 10.1007/BF00304202
   SHULMAN K, 1964, ARCH NEUROL-CHICAGO, V10, P575, DOI 10.1001/archneur.1964.00460180041003
   SINDOU M, 1980, SURG NEUROL, V13, P215
   STEINBOK P, 1989, J NEUROSURG, V71, P42, DOI 10.3171/jns.1989.71.1.0042
   STEWART DR, 1975, J PEDIATR SURG, V10, P771, DOI 10.1016/0022-3468(75)90383-8
   Tamburrini G, 2005, CHILD NERV SYST, V21, P913, DOI 10.1007/s00381-004-1117-x
   Tamburrini G, 2012, CHILD NERV SYST, V28, P1511, DOI 10.1007/s00381-012-1819-4
   TAYLOR GA, 1992, RADIOLOGY, V183, P449, DOI 10.1148/radiology.183.2.1561348
   Taylor WJ, 2001, J NEUROSURG, V94, P377, DOI 10.3171/jns.2001.94.3.0377
   Thompson DNP, 1997, PEDIATR NEUROSURG, V26, P288, DOI 10.1159/000121208
   Thompson DNP, 1997, PEDIATR NEUROSURG, V26, P296, DOI 10.1159/000121209
   THOMPSON DNP, 1995, J NEUROSURG, V82, P1071, DOI 10.3171/jns.1995.82.6.1071
   THOMPSON DNP, 1995, CHILD NERV SYST, V11, P269, DOI 10.1007/BF00301758
   Tokumaru AM, 1996, AM J NEURORADIOL, V17, P619
   Trigylidas T, 2008, CHILD NERV SYST, V24, P329, DOI 10.1007/s00381-007-0432-4
   Tuite GF, 1996, NEUROSURGERY, V38, P272, DOI 10.1097/00006123-199602000-00009
   Walshe J, 2000, MECH DEVELOP, V90, P103, DOI 10.1016/S0925-4773(99)00225-7
   Weber J, 2008, NEUROSURG REV, V31, P179, DOI 10.1007/s10143-007-0100-x
   Weed LH, 1933, AM J PHYSIOL, V105, P266
   YOUNG B, 1979, CHILD BRAIN, V5, P73
   Zakhary GM, 2014, J CRANIO MAXILL SURG, V42, P1684, DOI 10.1016/j.jcms.2014.05.014
NR 127
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 549
EP 558
DI 10.1016/j.wneu.2018.07.260
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300265
PM 30092478
DA 2020-05-12
ER

PT J
AU Zhang, XX
   Zhou, Y
   Zuo, Q
   Duan, GL
   Tang, HS
   Yang, PF
   Xu, Y
   Hong, B
   Huang, QH
   Liu, JM
AF Zhang, Xiaoxi
   Zhou, Yu
   Zuo, Qiao
   Duan, Guoli
   Tang, Haishuang
   Yang, Pengfei
   Xu, Yi
   Hong, Bo
   Huang, Qinghai
   Liu, Jianmin
TI Endovascular Treatment of Ruptured Middle Cerebral Artery Aneurysms: A
   Single-Arm Meta-Analysis and Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endovascular treatment; Middle cerebral aneurysms; Ruptured; Single-arm
ID INTRACRANIAL ANEURYSMS; COILING; OUTCOMES
AB OBJECTIVE: The use of endovascular treatment for ruptured middle cerebral artery (MCA) aneurysms, which have been more likely to be recommended for neurosurgical clipping because of the complex anatomic configuration, remains controversial. In the present study, the angiographic and clinical outcomes of endovascularly treated ruptured MCA aneurysms were systematically reviewed.
   METHODS: Online databases, including Cochrane, Medline, Web of Science, and Embase, were retrospectively and systematically searched. The primary outcomes were the immediate complete occlusion rate, mortality, complication-related mortality, and procedure-related complication rate. Meta-analysis was performed using a random or fixed effect model based on heterogeneity.
   RESULTS: A total of 14 studies with 1004 ruptured MCA aneurysms were included. The procedure-related mortality rate at discharge was 1.8% (95% confidence interval [CI], 0.9%-2.7%; I-2 = 0.0%; P = 0.623). The favorable clinical outcome rate at discharge was 65.4% (95% CI, 54.8%-76.0%; I-2 = 94.2%; P < 0.001) and had progressively increased to 73.2% (95% CI, 59.9%-86.5%; I-2 = 80.9%; P < 0.001). The overall complication rate was 22.7% (95% CI, 15.1%-30.3%; I-2 = 75.5%; P < 0.001).
   CONCLUSION: Endovascular treatment of MCA aneurysms was related to a high incidence of procedure-related complications but a low rate of procedure-related mortality. The overall angiographic and clinical outcomes were comparable and warrant further investigation comparing clipping versus coiling for ruptured MCA aneurysms.
C1 [Zhang, Xiaoxi; Zhou, Yu; Zuo, Qiao; Duan, Guoli; Tang, Haishuang; Yang, Pengfei; Xu, Yi; Hong, Bo; Huang, Qinghai; Liu, Jianmin] Naval Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Liu, JM (reprint author), Naval Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM chstroke@163.com
OI Zuo, Qiao/0000-0003-4512-6363
FU National Key R&D Program of China [2016YFC1300700]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81701136]
FX The present study was supported by the National Key R&D Program of China
   (grant 2016YFC1300700) and the National Natural Science Foundation of
   China (grant 81701136).
CR Bracard S, 2010, J NEUROSURG, V112, P703, DOI 10.3171/2009.6.JNS09483
   Brinjikji W, 2011, NEUROSURGERY, V68, P397, DOI 10.1227/NEU.0b013e318201d7f4
   Calvacante T, 2013, NEUROCHIRURGIE, V59, P121, DOI 10.1016/j.neuchi.2013.04.007
   Chung J, 2015, WORLD NEUROSURG, V83, P666, DOI 10.1016/j.wneu.2015.01.023
   Doerfler A, 2006, AM J NEURORADIOL, V27, P513
   Guresir E, 2011, ACTA NEUROCHIR, V153, P1247, DOI 10.1007/s00701-011-1008-3
   Hirota N, 2007, NEURORADIOL J, V20, P89, DOI 10.1177/197140090702000116
   Horowitz M, 2006, SURG NEUROL, V66, P167, DOI 10.1016/j.surneu.2005.12.022
   Iijima A, 2005, RADIOLOGY, V237, P611, DOI 10.1148/radiol.2372041015
   Jin SC, 2013, NEURORADIOLOGY, V55, P321, DOI 10.1007/s00234-012-1119-4
   Kadkhodayan Y, 2015, NEUROSURGERY, V76, P54, DOI 10.1227/NEU.0000000000000562
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Li H, 2013, STROKE, V44, P29, DOI 10.1161/STROKEAHA.112.663559
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Mortimer AM, 2014, AM J NEURORADIOL, V35, P706, DOI 10.3174/ajnr.A3776
   Quintana EM, 2016, INTERV NEURORADIOL, V22, P649, DOI 10.1177/1591019916662383
   Oishi H, 2009, NEUROL MED-CHIR, V49, P287, DOI 10.2176/nmc.49.287
   Quadros RS, 2007, AM J NEURORADIOL, V28, P1567, DOI 10.3174/ajnr.A0595
   Suzuki S, 2009, NEUROSURGERY, V64, P876, DOI 10.1227/01.NEU.0000343534.05655.37
   Vehmeijer JT, 2016, EUR HEART J, V37, P1439, DOI 10.1093/eurheartj/ehv735
   Vendrell JF, 2009, RADIOLOGY, V253, P191, DOI 10.1148/radiol.2531082092
   Zhao XT, 2017, INT J NEUROSCI, V127, P433, DOI 10.1080/00207454.2016.1190923
   Zijlstra IA, 2016, J NEUROINTERV SURG, V8, P24, DOI 10.1136/neurintsurg-2014-011478
NR 23
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 559
EP 566
DI 10.1016/j.wneu.2019.01.066
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300266
PM 30685370
DA 2020-05-12
ER

PT J
AU Kinaci, A
   Moayeri, N
   van der Zwan, A
   van Doormaal, TPC
AF Kinaci, Ahmet
   Moayeri, Nizar
   van der Zwan, Albert
   van Doormaal, Tristan P. C.
TI Effectiveness of Sealants in Prevention of Cerebrospinal Fluid Leakage
   after Spine Surgery: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid leakage; Dural sealant; Durotomy; Spinal surgery
ID POLYGLYCOLIC ACID MESH; INCIDENTAL DUROTOMY; DURAL REPAIR; FIBRIN GLUE;
   COLLAGEN MATRIX; BED REST; UNINTENDED DUROTOMY; INTRADURAL TUMORS;
   TISSUE ADHESIVE; RISK-FACTORS
AB BACKGROUND: Sealants are often used in spine surgery to prevent postoperative cerebrospinal fluid (CSF) leakage.
   OBJECTIVE: To investigate the efficacy of sealants in preventing postoperative CSF leakage in spine surgery.
   METHODS: The PubMed, Embase, and Cochrane databases were searched for articles reporting the outcome of patients treated with a sealant for spinal dural repair. The number of patients, indication of surgery, surgical site, applied technique, type of sealant used, and outcome in terms of postoperative CSF leakage were noted for each study. The primary outcome was CSF leakage in general and secondary outcome infection.
   RESULTS: Forty-one articles were selected with a total of 2542 cases; there were 4 comparative studies with 540 sealed cases and 343 cases with primary suture closure only. The quantity of CSF leakage did not differ between the sealant group (50 of 540, 9.1%) and the group treated with sutures only (48 of 343, 13.8%) (risk ratio [RR], 0.58 [confidence interval [CI], 0.18-1.82]). The infection rate did also not differ between the sealant and primary suture groups (RR, 0.94 [Cl, 0.55-1.60. This result was found in both the intended and the unintended durotomy subgroups. Secondary analysis of all cases showed that endoscopic or minimally invasive surgery had lower CSF leakage rates compared with open surgery regardless of sealant use (RR, 0.18 [CI, 0.05-0.75]).
   CONCLUSIONS: Currently available sealants seem not to reduce the rate of CSF leakage in spine surgery. In endoscopic and minimally invasive surgery, the CSF leakage rate is less frequent compared with open, conventional surgery regardless of sealant use.
C1 [Kinaci, Ahmet; Moayeri, Nizar; van der Zwan, Albert; van Doormaal, Tristan P. C.] Univ Med Ctr Utrecht, Brain Ctr Rudolph Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.
   [Kinaci, Ahmet; van der Zwan, Albert] Brain Technol Inst, Utrecht, Netherlands.
RP Kinaci, A (reprint author), Univ Med Ctr Utrecht, Brain Ctr Rudolph Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands.; Kinaci, A (reprint author), Brain Technol Inst, Utrecht, Netherlands.
EM akinaci@outlook.com
FU Polyganics B.V.
FX This work was partially funded by Polyganics B.V.
CR Arnautovic Kenan I, 2016, Med Arch, V70, P460, DOI 10.5455/medarh.2016.70.460-465
   Baker GA, 2012, SPINE J, V12, P121, DOI 10.1016/j.spinee.2012.01.012
   Black P, 2002, J NEUROSURG, V96, P250, DOI 10.3171/spi.2002.96.2.0250
   Bono F, 2005, J NEUROL, V252, P237, DOI 10.1007/s00415-005-0623-4
   Bouten PJM, 2014, PROG POLYM SCI, V39, P1375, DOI 10.1016/j.progpolymsci.2014.02.001
   Brown LD, 2001, STAT SCI, V16, P101, DOI 10.1214/ss/1009213286
   Chauvet D, 2011, ACTA NEUROCHIR, V153, P2465, DOI 10.1007/s00701-011-1197-9
   El-Mahdy W, 1999, BRIT J NEUROSURG, V13, P550, DOI 10.1080/02688699943042
   Epstein NE, 2007, J SPINAL DISORD TECH, V20, P380, DOI 10.1097/BSD.0b013e31802dabd2
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS301, DOI 10.4103/2152-7806.111427
   Epstein NE, 2010, SPINE J, V10, P1065, DOI 10.1016/j.spinee.2010.09.017
   Ferroli P, 2013, WORLD NEUROSURG, V79, P551, DOI 10.1016/j.wneu.2011.09.022
   Galarza M, 2018, J CLIN NEUROSCI, V50, P177, DOI 10.1016/j.jocn.2018.01.008
   Graziano Francesca, 2016, Surg Neurol Int, V7, pS77, DOI 10.4103/2152-7806.174894
   Guerin P, 2012, INJURY, V43, P397, DOI 10.1016/j.injury.2010.12.014
   Haji FA, 2011, SPINE, V36, pE1018, DOI 10.1097/BRS.0b013e31820019f9
   Hida K, 2006, SURG NEUROL, V65, P136, DOI 10.1016/j.surneu.2005.07.059
   Hodges SD, 1999, SPINE, V24, P2062, DOI 10.1097/00007632-199910010-00017
   Ito K, 2015, J NEUROSURG-SPINE, V23, P812, DOI 10.3171/2015.3.SPINE141215
   Jankowitz BT, 2009, EUR SPINE J, V18, P1169, DOI 10.1007/s00586-009-0928-6
   Jenkinson MD, 2006, EUR SPINE J, V15, P203, DOI 10.1007/s00586-005-0902-x
   Jeon SH, 2017, CLIN SPINE SURG, V30, pE702, DOI 10.1097/BSD.0000000000000249
   Kane PJ, 1999, BRIT J NEUROSURG, V13, P558, DOI 10.1080/02688699943051
   Khalatbari MR, 2012, EUR SPINE J, V21, P2091, DOI 10.1007/s00586-012-2187-1
   Kim KD, 2011, SPINE, V36, P1906, DOI 10.1097/BRS.0b013e3181fdb4db
   Koechlin NO, 2013, J NEUROL SURG PART A, V74, P216, DOI 10.1055/s-0032-1304809
   Kogias E, 2017, CLIN SPINE SURG, V30, pE1333, DOI 10.1097/BSD.0000000000000279
   Lee G, 2010, SPINE, V35, pE1522, DOI 10.1097/BRS.0b013e3181edfe2c
   Lee Si-Hoon, 2013, Korean J Spine, V10, P44, DOI 10.14245/kjs.2013.10.1.44
   Lei Tao, 2012, Orthop Surg, V4, P247, DOI 10.1111/os.12007
   Low JCM, 2013, BRIT J NEUROSURG, V27, P800, DOI 10.3109/02688697.2013.798858
   Mannion RJ, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e318207b3c7
   Masuda S, 2016, J ORTHOP SCI, V21, P586, DOI 10.1016/j.jos.2016.07.016
   McMahon P, 2012, J NEUROSURG-SPINE, V17, P30, DOI 10.3171/2012.3.SPINE11939
   Miscusi M, 2014, EUR SPINE J, V23, P1761, DOI 10.1007/s00586-013-3138-1
   Montano N, 2019, J CLIN NEUROSCI, V61, P88, DOI 10.1016/j.jocn.2018.10.138
   Mulder M, 2009, SPINE, V34, pE144, DOI 10.1097/BRS.0b013e31818d5427
   Nakamura H, 2005, SPINE, V30, pE347, DOI 10.1097/01.brs.0000167820.54413.8e
   Nandyala SV, 2014, SPINE, V39, pE1042, DOI 10.1097/BRS.0000000000000425
   Narotam PK, 2004, SPINE, V29, P2861, DOI 10.1097/01.brs.0000148049.69541.ad
   Narotam PK, 2007, J NEUROSURG, V106, P45, DOI 10.3171/jns.2007.106.1.45
   Parihar VS, 2017, J NEUROL SURG PART A, V78, P219, DOI 10.1055/s-0036-1594014
   Parlato C, 2011, ACTA NEUROCHIR, V153, P142, DOI 10.1007/s00701-010-0718-2
   PATIN DJ, 1993, ANESTH ANALG, V76, P535
   Radcliff KE, 2016, CLIN SPINE SURG, V29, P281, DOI 10.1097/BSD.0b013e31827d7ad8
   Reddy K, 2017, CAN J NEUROL SCI, V44, pS37
   Reddy M, 2002, ACTA NEUROCHIR, V144, P265, DOI 10.1007/s007010200034
   Ruban D, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11122
   SHAFFREY CI, 1990, NEUROSURGERY, V26, P207, DOI 10.1227/00006123-199002000-00004
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Shimada Y, 2006, J ORTHOP SCI, V11, P454, DOI 10.1007/s00776-006-1044-7
   Sin AH, 2006, J NEUROSURG-SPINE, V5, P224, DOI 10.3171/spi.2006.5.3.224
   Sohn S, 2013, EUR SPINE J, V22, P577, DOI 10.1007/s00586-012-2504-8
   Stendel R, 2008, J NEUROSURG, V109, P215, DOI 10.3171/JNS/2008/109/8/0215
   Sugawara T, 2005, NEUROSURGERY, V57, P290, DOI 10.1227/01.NEU.0000176410.65750.C0
   Takahashi Y, 2013, J NEUROSURG-SPINE, V18, P165, DOI 10.3171/2012.10.SPINE12271
   Tan LA, 2014, J NEUROSURG-SPINE, V21, P279, DOI 10.3171/2014.3.SPINE13719
   Telera S, 2015, J NEUROSURG SCI, V59, P195
   Teli M, 2010, EUR SPINE J, V19, P443, DOI 10.1007/s00586-010-1290-4
   van Doormaal T, 2018, OPER NEUROSURG, V15, P425, DOI 10.1093/ons/opx260
   Wang Hui-ren, 2012, Orthop Surg, V4, P233, DOI 10.1111/os.12005
   Weber C, 2015, EUR SPINE J, V24, P2065, DOI 10.1007/s00586-014-3504-7
   Williams BJ, 2011, NEUROSURGERY, V68, P117, DOI 10.1227/NEU.0b013e3181fcf14e
   Wolff S, 2012, ORTHOP TRAUMATOL-SUR, V98, P879, DOI 10.1016/j.otsr.2012.06.016
   Won Young Il, 2016, Korean J Spine, V13, P24, DOI 10.14245/kjs.2016.13.1.24
   Wright NM, 2015, SPINE, V40, P505, DOI 10.1097/BRS.0000000000000810
   Yokogawa N, 2018, SPINE J, V18, P381, DOI 10.1016/j.spinee.2017.07.169
NR 67
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 567
EP +
DI 10.1016/j.wneu.2019.02.236
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300267
PM 30928579
OA Other Gold
DA 2020-05-12
ER

PT J
AU Siccoli, A
   Klukowska, AM
   Schroder, ML
   Staartjes, VE
AF Siccoli, Alessandro
   Klukowska, Anita M.
   Schroder, Marc L.
   Staartjes, Victor E.
TI A Systematic Review and Meta-Analysis of Perioperative Parameters in
   Robot-Guided, Navigated, and Freehand Thoracolumbar Pedicle Screw
   Instrumentation
SO WORLD NEUROSURGERY
LA English
DT Review
DE Instrumentation; Navigation; Outcome; Perioperative; Robot; Spinal
   fusion
ID INTRAOPERATIVE COMPUTED-TOMOGRAPHY; FLUOROSCOPY-BASED NAVIGATION;
   CONVENTIONAL FLUOROSCOPY; LEARNING-CURVE; PLACEMENT ACCURACY; LUMBAR
   FUSION; SPINE; INSERTION; SURGERY; ASSISTANCE
AB BACKGROUND: Robotic guidance (RG) and navigation (NV) have been shown to reduce radiologic and clinically relevant pedicle screw malpositions. It remains unknown if there are any additional benefits to these techniques in intraoperative and perioperative end points.
   METHODS: We conducted a systematic review in MEDLINE, Embase, Scopus, and the Cochrane Library and identified controlled studies comparing RG, NV, and freehand (FH) thoracolumbar pedicle screw insertion and carried out random-effects meta-analyses.
   RESULTS: Thirty-two studies (24,008 patients) were included. Only 8 studies (26%) were randomized, and study quality was rated as very low or low in 24 cases (77%). Compared with NV, FH procedures showed longer length of hospital stay (Delta, 0.7 days; 95% confidence interval, 0.2-1.2; P = 0.006) and more overall complications (odds ratio, 1.6; 95% confidence interval, 1.3-1.9; P < 0.001). No statistically significant differences among RG and FH were identified, likely because of lack in statistical power (all P> 0.05). In particular, both RG and NV did not show increased intraoperative radiation use, as determined by seconds of fluoroscopy, compared with FH (both P > 0.05).
   CONCLUSIONS: It seems that navigation may offer potential benefits in perioperative outcomes such as length of hospital stay and overall complications, without significant increase in intraoperative radiation, which cannot yet be said for robotic guidance. The findings must be interpreted with caution, because the evidence is severely limited in both quantity and quality. Further evaluation will establish any demonstrable intraoperative or perioperative benefits to computer assistance, which may warrant the high costs often associated with these devices.
C1 [Siccoli, Alessandro; Klukowska, Anita M.; Schroder, Marc L.; Staartjes, Victor E.] Bergman Clin, Dept Neurosurg, Amsterdam, Netherlands.
   [Siccoli, Alessandro; Staartjes, Victor E.] Univ Zurich, Fac Med, Zurich, Switzerland.
   [Klukowska, Anita M.] Univ Nottingham, Sch Med, Nottingham, England.
   [Staartjes, Victor E.] Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Movement Sci, Neurosurg, Amsterdam, Netherlands.
RP Staartjes, VE (reprint author), Bergman Clin, Dept Neurosurg, Amsterdam, Netherlands.; Staartjes, VE (reprint author), Univ Zurich, Fac Med, Zurich, Switzerland.; Staartjes, VE (reprint author), Vrije Univ Amsterdam, Amsterdam UMC, Amsterdam Movement Sci, Neurosurg, Amsterdam, Netherlands.
EM victor.staartjes@gmail.com
OI Staartjes, Victor/0000-0003-1039-2098
CR Alaid A, 2018, NEUROSURG REV, V41, P489, DOI 10.1007/s10143-017-0877-1
   Bovonratwet P, 2018, SPINE, V43, P447, DOI 10.1097/BRS.0000000000002327
   Chang PY, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.2.FocusVid.1694
   Chenin L, 2017, WORLD NEUROSURG, V105, P86, DOI 10.1016/j.wneu.2017.05.118
   Chenin L, 2016, ACTA NEUROCHIR, V158, P1125, DOI 10.1007/s00701-016-2799-z
   Cui G, 2012, SPINE, V37, P891, DOI 10.1097/BRS.0b013e31823aff81
   Du JP, 2018, WORLD NEUROSURG, V109, P24, DOI 10.1016/j.wneu.2017.07.154
   Fichtner J, 2018, WORLD NEUROSURG, V109, pE24, DOI 10.1016/j.wneu.2017.09.091
   Fraser J, 2010, MINIM INVAS NEUROSUR, V53, P184, DOI 10.1055/s-0030-1267926
   Fu TS, 2008, INT ORTHOP, V32, P517, DOI 10.1007/s00264-007-0358-1
   Gaines RW, 2000, J BONE JOINT SURG AM, V82A, P1458, DOI 10.2106/00004623-200010000-00013
   Gao ST, 2018, EUR SPINE J, V27, P921, DOI 10.1007/s00586-017-5333-y
   Gautschi OP, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11168
   Guedes Vinícius de Paula, 2015, Coluna/Columna, V14, P181, DOI 10.1590/S1808-185120151403122410
   Hartl R, 2013, WORLD NEUROSURG, V79, P162, DOI 10.1016/j.wneu.2012.03.011
   Hu XB, 2014, CLIN ORTHOP RELAT R, V472, P1839, DOI 10.1007/s11999-013-3291-1
   Hyun SJ, 2017, SPINE, V42, P353, DOI 10.1097/BRS.0000000000001778
   Jin B, 2016, CHINESE MED J-PEKING, V129, P2552, DOI 10.4103/0366-6999.192777
   Jin MR, 2016, EUR SPINE J, V25, P1729, DOI 10.1007/s00586-015-4012-0
   Kaoudi A, 2018, WORLD NEUROSURG, V116, P226, DOI 10.1016/j.wneu.2018.05.060
   Kepler CK, 2014, SPINE, V39, P1584, DOI 10.1097/BRS.0000000000000486
   Keric N, 2017, J ROBOT SURG, V11, P17, DOI 10.1007/s11701-016-0597-5
   Khan A, 2019, WORLD NEUROSURG, V123, pE474, DOI 10.1016/j.wneu.2018.11.190
   Khan A, 2019, OPER NEUROSURG, V17, P61, DOI 10.1093/ons/opy280
   Khanna R, 2016, WORLD NEUROSURG, V94, P255, DOI 10.1016/j.wneu.2016.07.014
   Kim HJ, 2017, INT J MED ROBOT COMP, V13, DOI 10.1002/rcs.1779
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   Kotani Y, 2007, SPINE, V32, P1543, DOI 10.1097/BRS.0b013e318068661e
   Laine T, 2000, EUR SPINE J, V9, P235, DOI 10.1007/s005860000146
   Le XF, 2018, WORLD NEUROSURG, V120, pE745, DOI 10.1016/j.wneu.2018.08.157
   Liu Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003581
   Lonjon N, 2016, EUR SPINE J, V25, P947, DOI 10.1007/s00586-015-3758-8
   Luther N, 2015, J SPINAL DISORD TECH, V28, pE298, DOI 10.1097/BSD.0b013e31828af33e
   Marcus HJ, 2014, EUR SPINE J, V23, P291, DOI 10.1007/s00586-013-2879-1
   Miller JA, 2017, WORLD NEUROSURG, V105, P412, DOI 10.1016/j.wneu.2017.06.016
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Molliqaj G, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS179
   NOLTE LP, 1995, CLIN BIOMECH, V10, P293, DOI 10.1016/0268-0033(95)00004-5
   Nooh A, 2017, GLOB SPINE J, V7, P617, DOI 10.1177/2192568217699193
   Overley SC, 2017, NEUROSURGERY, V80, pS86, DOI 10.1093/neuros/nyw077
   Park SM, 2018, WORLD NEUROSURG, V118, pE550, DOI 10.1016/j.wneu.2018.06.236
   Rajasekaran S, 2007, SPINE, V32, pE56, DOI 10.1097/01.brs.0000252094.64857.ab
   Ringel F, 2012, SPINE, V37, pE496, DOI 10.1097/BRS.0b013e31824b7767
   Roser F, 2013, NEUROSURGERY, V72, pA12, DOI 10.1227/NEU.0b013e318270d02c
   Ryang YM, 2015, SPINE J, V15, P467, DOI 10.1016/j.spinee.2014.10.003
   Schatlo B, 2015, ACTA NEUROCHIR, V157, P1819, DOI 10.1007/s00701-015-2535-0
   Schatlo B, 2014, J NEUROSURG-SPINE, V20, P636, DOI 10.3171/2014.3.SPINE13714
   Schroder ML, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16534
   Schroerlucke SR, 2017, SPINE J, V17, pS254, DOI DOI 10.1016/J.SPINEE.2017.08.177
   Shin BJ, 2012, J NEUROSURG-SPINE, V17, P113, DOI 10.3171/2012.5.SPINE11399
   Shin MH, 2015, J SPINAL DISORD TECH, V28, pE347, DOI 10.1097/BSD.0b013e31829047a7
   Shin MH, 2012, J KOREAN NEUROSURG S, V52, P204, DOI 10.3340/jkns.2012.52.3.204
   Silbermann J, 2011, EUR SPINE J, V20, P875, DOI 10.1007/s00586-010-1683-4
   Solomiichuk V, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1710
   Staartjes VE, 2018, WORLD NEUROSURG, V116, P433, DOI 10.1016/j.wneu.2018.05.159
   Ughwanogho E, 2012, SPINE, V37, pE473, DOI 10.1097/BRS.0b013e318238bbd9
   Wang Y, 2016, ORTHOPEDICS, V39, pE857, DOI 10.3928/01477447-20160517-01
   Wang Y, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-015-0338-x
   Wolterink Jelmer M., 2017, Simulation and Synthesis in Medical Imaging. Second International Workshop, SASHIMI 2017. Held in Conjunction with MICCAI 2017. Proceedings: LNCS 10557, P14, DOI 10.1007/978-3-319-68127-6_2
   Woo EJ, 2018, SPINE J, V18, P1166, DOI 10.1016/j.spinee.2017.11.006
   Wu MH, 2017, SPINE J, V17, P1082, DOI 10.1016/j.spinee.2017.04.002
   Xiao R, 2017, J NEUROSURG-SPINE, V26, P628, DOI 10.3171/2016.10.SPINE16373
   Yang BP, 2012, SPINE, V37, P2055, DOI 10.1097/BRS.0b013e31825c05cd
   Zygourakis Corinna C, 2018, Neurosurg Focus, V45, pV6, DOI 10.3171/2018.7.FocusVid.18123
NR 64
TC 1
Z9 1
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 576
EP +
DI 10.1016/j.wneu.2019.03.196
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300268
PM 30954747
DA 2020-05-12
ER

PT J
AU Goyal, A
   Akhras, A
   Wahood, W
   Alvi, MA
   Nassr, A
   Bydon, M
AF Goyal, Anshit
   Akhras, Aya
   Wahood, Waseem
   Alvi, Mohammed Ali
   Nassr, Ahmad
   Bydon, Mohamad
TI Should Multilevel Posterior Cervical Fusions Involving C7 Cross the
   Cervicothoracic Junction? A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE C7; Cervical; Cervicothoracic junction; Crossing; Fusion; Posterior;
   Reoperation
ID ADJACENT SEGMENT DEGENERATION; ANTERIOR; SPINE; INSTRUMENTATION;
   DECOMPRESSION; COMPLICATIONS; DISKECTOMY; GUIDELINES; MYELOPATHY;
   DISEASE
AB BACKGROUND: Current literature remains inconclusive as to whether multilevel posterior cervical fusions (PCFs) involving the C7 vertebra should cross the cervicothoracic junction (CTJ). The objective of this systematic review was to assess the differences in clinical outcomes, fusion, and reoperation rates, between patients undergoing multilevel PCFs ending at C7 and those undergoing PCF crossing the CTJ.
   METHODS: A systematic review of literature from 4 databases on crossing the CTJ was conducted. Inclusion criteria consisted of 1) patients undergoing multilevel PCF or combined anterior and PCF involving C7, 2) diagnosis for surgery being degenerative disk or deformity.
   RESULTS: Six studies consisting of 530 patients were included in this review. Two were 1-arm studies and 4 were comparative studies. There were 305 patients (58%) in the noncrossing group and 225 patients (42%) in the crossing group. Among the 3 comparative studies that recorded fusion rate, patients in the crossing group were more likely to achieve fusion (odds ratio, 2.75; 95% confidence interval, 1.61-4.09; P < 0.001) and were less likely to undergo a reoperation (odds ratio, 0.42; 95% confidence interval, 0.25-0.73; P = 0.002) compared with patients in the noncrossing group. In our indirect analyses, fusion rate and reoperation rate were comparable between the 2 groups (P = 0.689 and P = 0.714, respectively).
   CONCLUSIONS: Our results indicate that based on current evidence, multilevel PCFs that cross the CTJ may have higher fusion rates and lower reoperation rates compared with fusions that stop at C7. These results are important to assist the surgeon in decision making regarding the lower instrumented level when performing a multilevel PCF.
C1 [Goyal, Anshit; Akhras, Aya; Wahood, Waseem; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.
   [Goyal, Anshit; Wahood, Waseem; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Nassr, Ahmad] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
   [Akhras, Aya] Mohammed Bin Rashid Univ Med & Hlth Sci, Dubai, U Arab Emirates.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Wahood,
   Waseem/0000-0002-2963-4096; Akhras, Aya/0000-0002-1019-4377
CR Ahn SS, 2016, WORLD NEUROSURG, V89, P42, DOI [10.1016/J.WNEU.2016.01.013, 10.1016/j.wneu.2016.01.013]
   AN HS, 1994, SPINE, V19, P2557, DOI 10.1097/00007632-199411001-00011
   Bambakidis NC, 2005, SPINE, V30, pS2, DOI 10.1097/01.brs.0000174509.31291.26
   Bechara BP, 2012, SPINE, V37, pE23, DOI 10.1097/BRS.0b013e31821c3275
   Carrier CS, 2013, SPINE J, V13, P1370, DOI 10.1016/j.spinee.2013.05.050
   Chapman JR, 1996, J NEUROSURG, V84, P552, DOI 10.3171/jns.1996.84.4.0552
   Cheng I, 2015, GLOB SPINE J, V5, P282, DOI 10.1055/s-0035-1546418
   Cheung JPY, 2016, ASIAN SPINE J, V10, P385, DOI 10.4184/asj.2016.10.2.385
   Demura S, 2013, SPINE, V38, P1764, DOI 10.1097/BRS.0b013e31829eca52
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Elsawaf A, 2009, NEUROSURG REV, V32, P215, DOI 10.1007/s10143-008-0164-2
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Hart RA, 2008, SPINE, V33, P2887, DOI 10.1097/BRS.0b013e318190affe
   Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009
   Ishihara Hirokazu, 2004, Spine J, V4, P624, DOI 10.1016/j.spinee.2004.04.011
   Kretzer RM, 2010, J NEUROSURG-SPINE, V13, P435, DOI 10.3171/2010.4.SPINE09995
   Lapsiwala Samir, 2006, Spine J, V6, p268S, DOI 10.1016/j.spinee.2006.05.008
   Lawrence BD, 2012, SPINE, V37, pS52, DOI 10.1097/BRS.0b013e31826d60fb
   Litrico S, 2014, ORTHOP TRAUMATOL-SUR, V100, P305, DOI 10.1016/j.otsr.2014.07.004
   Louie PK, 2017, SPINE J, V17, P1264, DOI 10.1016/j.spinee.2017.04.027
   Marquez-Lara A, 2014, SPINE, V39, P476, DOI 10.1097/BRS.0000000000000165
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Myhre SL, 2017, GLOB SPINE J, V7, P334, DOI 10.1177/2192568217699188
   Osterhoff G, 2017, WORLD NEUROSURG, V103, P419, DOI 10.1016/j.wneu.2017.04.029
   Schroeder GD, 2016, SPINE, V41, P1845, DOI 10.1097/BRS.0000000000001864
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Truumees E, 2018, SPINE J, V18, P782, DOI 10.1016/j.spinee.2017.09.010
   Wang VY, 2007, NEUROSURG CLIN N AM, V18, P365, DOI 10.1016/j.nec.2007.02.012
   Wells G, 2014, NEWCASTLE OTTAWA QUA
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
NR 31
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 588
EP +
DI 10.1016/j.wneu.2019.03.283
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300269
PM 30954754
DA 2020-05-12
ER

PT J
AU Alvi, MA
   Kurian, SJ
   Wahood, W
   Goyal, A
   Elder, BD
   Bydon, M
AF Alvi, Mohammed Ali
   Kurian, Shyam J.
   Wahood, Waseem
   Goyal, Anshit
   Elder, Benjamin D.
   Bydon, Mohamad
TI Assessing the Difference in Clinical and Radiologic Outcomes Between
   Expandable Cage and Nonexpandable Cage Among Patients Undergoing
   Minimally Invasive Transforaminal Interbody Fusion: A Systematic Review
   and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Expandable cage; Lumbar fusion; Minimally invasive surgery;
   Nonexpandable cage; Spine surgery; Transforaminal lumbar interbody
   fusion
ID CERVICAL DISC REPLACEMENT; ADJACENT SEGMENT DISEASE; LUMBAR LORDOSIS;
   POSTERIOR; RESTORATION; ARTHROPLASTY; ALIGNMENT
AB BACKGROUND: Minimally invasive transforaminal interbody fusion (MIS-TLIF) has been shown to have excellent outcomes for surgical management of degenerative disc disease. However, the challenge is in addressing coronal imbalance and restoring lumbar lordosis and sagittal alignment. Use of expandable cages in MIS-TLIF has been hypothesized to circumvent this disadvantage. An indirect meta-analysis of the evidence is presented comparing outcomes from expandable cages with those from nonexpandable cages, in patients undergoing MIS-TLIF.
   METHODS: PRISMA guidelines were used to conduct a systematic review and meta-analysis to compare the clinical and radiologic outcomes of expandable cages and nonexpandable cages in patients undergoing MIS-TLIF.
   RESULTS: Twelve studies (706 patients) were included in the meta-analysis. The mean increase in disc height was found to be significantly greater for the nonexpandable cages group than for the expandable cages group (1.33 mm; 95% confidence interval [CI], 1.28-1.38 vs. 1.14 mm,; 95% CI, 1.06-1.23; P < 0.001). No significant difference was found regarding change in lumbar lordosis at last follow-up between the 2 groups (P = 0.34). The mean change in segmental lordosis was found to be significantly higher for the expandable cage group (5.04 , 95% CI, 3.89-6.20 vs. 2.08', 95% Cl, 1.93-2.22; P < 0.001). We did not detect any significant difference in fusion rate (P = 0.33), subsidence rate (P = 0.41) or in reoperations (P = 0.56) at last follow-up between the 2 groups.
   CONCLUSIONS: Our results indicate that there may not be a significant difference in clinical and radiologic parameters between expandable cages and nonexpandable cages among patients undergoing MIS-TLIF, and it is unclear if the higher cost of the expandable cages is justified.
C1 [Alvi, Mohammed Ali; Wahood, Waseem; Goyal, Anshit; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.
   [Alvi, Mohammed Ali; Wahood, Waseem; Goyal, Anshit; Elder, Benjamin D.; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Kurian, Shyam J.] Mayo Clin, Alix Sch Med, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Wahood,
   Waseem/0000-0002-2963-4096
CR Alimi M, 2015, GLOB SPINE J, V5, P169, DOI 10.1055/s-0035-1552988
   Audat Z, 2012, SINGAP MED J, V53, P183
   Barrey C, 2015, WORLD J ORTHOP, V6, P117, DOI 10.5312/wjo.v6.i1.117
   Choi WS, 2018, NEUROSURGERY, V82, P289, DOI 10.1093/neuros/nyx212
   Choi WS, 2016, BIOMED RES INT, DOI 10.1155/2016/2518394
   Coe JD, 2016, MED DEVICES-EVID RES, V9, P341, DOI 10.2147/MDER.S112523
   de Kunder SL, 2017, SPINE J, V17, P1712, DOI 10.1016/j.spinee.2017.06.018
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fujimori T, 2015, GLOB SPINE J, V5, P102, DOI 10.1055/s-0034-1396432
   Guanciale AF, 1996, SPINE, V21, P964, DOI 10.1097/00007632-199604150-00012
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   HARMS J, 1982, Z ORTHOP GRENZGEB, V120, P343, DOI 10.1055/s-2008-1051624
   Harms J G, 1998, Oper Orthop Traumatol, V10, P90, DOI 10.1007/s00064-006-0112-7
   Hawasli AH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17197
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsieh PC, 2007, J NEUROSURG-SPINE, V7, P379, DOI 10.3171/SPI-07/10/379
   Humphreys SC, 2001, SPINE, V26, P567
   Jagannathan J, 2009, NEUROSURGERY, V64, P955, DOI 10.1227/01.NEU.0000343544.77456.46
   Kepler Christopher K, 2012, Orthop Surg, V4, P15, DOI 10.1111/j.1757-7861.2011.00165.x
   Kim CW, 2016, WORLD NEUROSURG, V90, P228, DOI 10.1016/j.wneu.2016.02.075
   Kim JS, 2009, J SPINAL DISORD TECH, V22, P114, DOI 10.1097/BSD.0b013e318169bff5
   Lee DY, 2008, J NEUROSURG-SPINE, V9, P137, DOI 10.3171/SPI/2008/9/8/137
   Li XC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171546
   Liang Y, 2015, EUR SPINE J, V24, P2560, DOI 10.1007/s00586-015-3933-y
   Massie LW, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.10.FOCUS17562
   McAfee PC, 2005, SPINE, V30, pS60, DOI 10.1097/01.brs.0000155578.62680.dd
   Min SH, 2013, EUR SPINE J, V22, P1164, DOI 10.1007/s00586-012-2619-y
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Moher D, 2009, J CHIN INTEGR MED, V7, P889, DOI DOI 10.3736/JCIM20090918
   Morningstar Mark W, 2003, J Chiropr Med, V2, P137, DOI 10.1016/S0899-3467(07)60077-9
   Phan K, 2015, BRIT J NEUROSURG, V29, P705, DOI 10.3109/02688697.2015.1036838
   Rouben D, 2011, J SPINAL DISORD TECH, V24, P288, DOI 10.1097/BSD.0b013e3181f9a60a
   Sakeb N, 2013, INDIAN J ORTHOP, V47, P255, DOI 10.4103/0019-5413.111484
   Shriver MF, 2016, SPINE J, V16, P168, DOI 10.1016/j.spinee.2015.10.032
   Sorensen CJ, 2015, MANUAL THER, V20, P553, DOI 10.1016/j.math.2015.01.001
   Tassemeier T, 2018, J CRANIOVERTEBRAL JU, V9, P196, DOI 10.4103/jcvjs.JCVJS_56_18
   Tuli SK, 2004, J NEUROSURG-SPINE, V1, P47, DOI 10.3171/spi.2004.1.1.0047
   Verma K, 2013, SPINE, V38, P2253, DOI 10.1097/BRS.0000000000000052
   Wang MY, 2014, J NEUROSURG-SPINE, V21, P861, DOI 10.3171/2014.8.SPINE13841
   Wells G, 2004, NEWCASTLE OTTAWA SCA
   Xie L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2851-8
   Yang Y, 2017, INT J CLIN EXP MED, V10, P11314
   Yee TJ, 2017, NEUROSURGERY, V81, P69, DOI 10.1093/neuros/nyw177
   Yee TJ, 2014, J CLIN NEUROSCI, V21, P1796, DOI 10.1016/j.jocn.2014.03.010
   Zhao H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010005
   박재성, 2005, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V37, P340
NR 46
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 596
EP +
DI 10.1016/j.wneu.2019.03.284
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300270
PM 30954733
DA 2020-05-12
ER

PT J
AU Dhawan, S
   He, YY
   Bartek, J
   Alattar, AA
   Chen, CC
AF Dhawan, Sanjay
   He, Yuyu
   Bartek, Jiri, Jr.
   Alattar, Ali A.
   Chen, Clark C.
TI Comparison of Frame-Based Versus Frameless Intracranial Stereotactic
   Biopsy: Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Biopsy; Frame-based; Frameless; Neurosurgery; Stereotactic
ID BRAIN BIOPSY; DIAGNOSTIC YIELD; ACCURACY; EFFICACY; SAFETY;
   COMPLICATIONS; ADVANTAGES; MORBIDITY; LESS; BIAS
AB BACKGROUND: Frame-based stereotaxy has generally been considered the reference standard for brain biopsies. However, frameless stereotaxy might expedite the efficiency of the clinical work flow. Conflicting findings have been reported regarding the relative efficacy and safety of frame-based and frameless needle biopsy of brain lesions. We performed a meta-analysis of the reported data to compare the relative efficacy, safety, and time efficiency of frame-based and frameless stereotactic needle biopsy.
   METHODS: The PubMed database was searched for studies comparing frame-based and frameless biopsy. Of the 5248 reports found, 15 were included in the present meta-analysis.
   RESULTS: The 15 studies included in the present meta-analysis included 2400 patients. Our analysis found no statistically significant differences between frame-based and frameless biopsy in the diagnostic yield (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.71-1.41), morbidity (OR, 1.13; 95% CI, 0.76-1.66), mortality (OR, 0.94; 95% CI, 0.40-2.17), postbiopsy hemorrhage (OR, 1.16; 95% CI, 0.68-1.96), and postbiopsy neurological deficit (OR, 1.01; 95% CI, 0.62-1.65). The results from our integrated analysis indicated that frameless biopsies are associated with a shorter procedural time relative to frame-based biopsy (standard difference in the mean, 0.64; 95% CI, 0.24-1.04; P = 0.002; I-2 [Higgins inconsistency index] = 86.66%).
   CONCLUSIONS: The results from our meta-analysis suggest no significant differences exist between frame-based and frameless biopsy in diagnostic yield, morbidity, and mortality. Frameless biopsy is associated with shorter procedural times relative to frame-based biopsy. We have also discussed the relative merits of frame-based and frameless biopsies.
C1 [Dhawan, Sanjay; He, Yuyu; Chen, Clark C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
   [Bartek, Jiri, Jr.] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Copenhagen Univ Hosp, Rigshosp, Dept Neurosurg, Copenhagen, Denmark.
   [Alattar, Ali A.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
RP Chen, CC (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM ccchen@umn.edu
CR Air EL, 2009, J NEUROSURG, V111, P820, DOI 10.3171/2009.3.JNS081695
   Barnett GH, 1999, J NEUROSURG, V91, P569, DOI 10.3171/jns.1999.91.4.0569
   Bradac O, 2017, WORLD NEUROSURG, V104, P831, DOI 10.1016/j.wneu.2017.04.104
   Dammers R, 2008, ACTA NEUROCHIR, V150, P23, DOI 10.1007/s00701-007-1473-x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dorward NL, 2002, BRIT J NEUROSURG, V16, P110, DOI 10.1080/02688690220131705
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Lobao CAF, 2009, ARQ NEURO-PSIQUIAT, V67, P876, DOI 10.1590/S0004-282X2009000500018
   Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545
   Georgiopoulos M, 2018, J NEUROL SURG PART A, V79, P31, DOI 10.1055/s-0037-1602697
   Grossman R, 2005, ACTA NEUROCHIR, V147, P627, DOI 10.1007/s00701-005-0495-5
   Grunert P, 2002, MINIM INVAS NEUROSUR, V45, P11, DOI 10.1055/s-2002-23576
   Hall WA, 1998, CANCER, V82, P1749, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1756::AID-CNCR23>3.0.CO;2-2
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jain D, 2006, NEUROL INDIA, V54, P394
   Kim JE, 2003, ACTA NEUROCHIR, V145, P547, DOI 10.1007/s00701-003-0048-8
   Kitchen Neil D., 1993, Stereotactic and Functional Neurosurgery, V61, P195, DOI 10.1159/000100637
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Livermore LJ, 2014, BRIT J NEUROSURG, V28, P637, DOI 10.3109/02688697.2014.887657
   Lu Y, 2015, WORLD NEUROSURG, V83, P261, DOI 10.1016/j.wneu.2014.07.043
   McGirt MJ, 2005, J NEUROSURG, V102, P897, DOI 10.3171/jns.2005.102.5.0897
   Nishihara Masamitsu, 2014, Surg Neurol Int, V5, pS421, DOI 10.4103/2152-7806.140211
   Owen CM, 2009, J NEURO-ONCOL, V93, P139, DOI 10.1007/s11060-009-9871-y
   Pan HC, 2003, J CLIN NEUROSCI, V10, P602, DOI 10.1016/S0967-5868(03)00130-9
   Parney IF, 2012, HAND CLINIC, V104, P187, DOI 10.1016/B978-0-444-52138-5.00015-3
   Poca MA, 2017, ACTA NEUROCHIR, V159, P1939, DOI 10.1007/s00701-017-3191-3
   Raabe A, 2003, ZBL NEUROCHIR, V64, P1, DOI 10.1055/s-2003-37150
   Sawin PD, 1998, SURG NEUROL, V49, P640, DOI 10.1016/S0090-3019(97)00435-7
   Smith JS, 2005, J NEURO-ONCOL, V73, P173, DOI 10.1007/s11060-004-4208-3
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Swart R, 2018, SOUTH AFR J ANAESTH, V24, P90, DOI 10.1080/22201181.2018.1487633
   Tsermoulas G, 2013, BRIT J NEUROSURG, V27, P207, DOI 10.3109/02688697.2012.722239
   Waters J Dawn, 2013, Surg Neurol Int, V4, pS176, DOI 10.4103/2152-7806.110677
   Woodworth G, 2005, NEUROL RES, V27, P358, DOI 10.1179/016164105X40057
   Woodworth GF, 2006, J NEUROSURG, V104, P233, DOI 10.3171/jns.2006.104.2.233
   Yamada K, 2004, J CLIN NEUROSCI, V11, P263, DOI 10.1016/j.jocn.2003.03.004
NR 37
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 607
EP +
DI 10.1016/j.wneu.2019.04.016
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300271
PM 30974279
DA 2020-05-12
ER

PT J
AU Incekara, F
   Koene, S
   Vincent, AJPE
   van den Bent, MJ
   Smits, M
AF Incekara, Fatih
   Koene, Stephan
   Vincent, Arnaud J. P. E.
   van den Bent, Martin J.
   Smits, Marion
TI Association Between Supratotal Glioblastoma Resection and Patient
   Survival: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Glioblastoma; Gross total resection; Supratotal resection; Survival
ID AGGRESSIVE RESECTION; VOLUMETRIC-ANALYSIS; NONELOQUENT AREAS; SURGERY;
   CONTRAST; EXTENT; GRADE; GLIOMAS; FLUORESCENCE; PREDICTION
AB BACKGROUND: Gross total resection (GTR) of the contrast enhancing (CE) area will improve the survival of patients with glioblastoma (GBM). However, GBM can infiltrate into the brain parenchyma, beyond the CE margins. It remains unclear whether resection beyond the CE area (supratotal resection [SPTR]) can improve survival without causing additional neurological deficits. The aim of the present meta-analysis was to study the association between SPTR and overall survival of patients of GBM.
   METHODS: Embase, PubMed, and other literature databases were searched for eligible studies until August 2018. Studies involving patients with GBM that had compared SPTR with GTR were included in the present study. The main outcome was overall survival, presented as hazard ratios (HRs) with 95% confidence intervals (Cis) and median overall survival differences with the 95% CIs.
   RESULTS: The meta-analysis, which included 6 studies and 1168 unique patients with GBM, showed that compared with GTR, SPTR of GBM resulted in a 53% lower risk of mortality at any time during follow-up (HR, 0.47; 95% CI, 0.31-0.72; P = 0.0005). The median overall survival of the SPTR group was 6.4 months (95% CI, 3.2-9.7) longer than the GTR group (P = 0.0001). Reports on postoperative deficits were limited, and the quality of evidence was moderate to very low.
   CONCLUSIONS: Compared with GTR, SPTR of GBM resulted in a lower risk of mortality and longer median overall survival. However, the quality of evidence of the available studies was poor. Therefore, it remains unclear whether SPTR is safe and actually improves the survival of patients with GBM. Future prospective trials and a standardized definition of SPTR are needed.
C1 [Incekara, Fatih; Vincent, Arnaud J. P. E.] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.
   [Incekara, Fatih; Koene, Stephan; Smits, Marion] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Radiol, Rotterdam, Netherlands.
   [van den Bent, Martin J.] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Brain Canc Inst, Rotterdam, Netherlands.
RP Incekara, F (reprint author), Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.; Incekara, F (reprint author), Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Radiol, Rotterdam, Netherlands.
EM f.incekara@erasmusmc.nl
RI Smits, Marion/AAB-3985-2019; Smits, Marion/E-4795-2011
OI Smits, Marion/0000-0001-5563-2871; 
CR Abd-El-Barr MM, 2014, WORLD NEUROSURG, V82, pE109, DOI 10.1016/j.wneu.2014.05.006
   Aldave G, 2013, NEUROSURGERY, V72, P915, DOI 10.1227/NEU.0b013e31828c3974
   Bahrami N, 2018, AM J NEURORADIOL, V39, P1017, DOI 10.3174/ajnr.A5620
   Brown TJ, 2016, JAMA ONCOL, V2, P1460, DOI 10.1001/jamaoncol.2016.1373
   Catapano G, 2017, WORLD NEUROSURG, V104, P239, DOI 10.1016/j.wneu.2017.05.022
   Coburger J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131872
   Coburger J, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13463
   Valle RD, 2011, J NEURO-ONCOL, V102, P105, DOI 10.1007/s11060-010-0296-4
   Duffau H, 2013, NEUROCHIRURGIE, V59, P2, DOI 10.1016/j.neuchi.2012.11.001
   Duffau H, 2014, WORLD NEUROSURG, V82, pE101, DOI 10.1016/j.wneu.2014.02.015
   Eidel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169292
   Elson A, 2015, J NEURO-ONCOL, V122, P549, DOI 10.1007/s11060-015-1743-z
   Esquenazi Y, 2017, NEUROSURGERY, V81, P275, DOI 10.1093/neuros/nyw174
   Eyupoglu IY, 2016, ONCOTARGET, V7, P25755, DOI 10.18632/oncotarget.8367
   Gessler F, 2019, NEUROSURGERY, V84, P190, DOI 10.1093/neuros/nyy049
   Gessler F, 2015, NEUROSURGERY, V77, P16, DOI 10.1227/NEU.0000000000000729
   Glenn CA, 2018, WORLD NEUROSURG, V114, pE747, DOI 10.1016/j.wneu.2018.03.072
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Grossman R, 2017, ANN SURG ONCOL, V24, P794, DOI 10.1245/s10434-016-5635-z
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Jenkinson MD, 2018, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD012788
   John F, NEURO-ONCOLOGY, DOI [10.1093/neuroonc/noy169, DOI 10.1093/NEUROONC/NOY169]
   Li YM, 2016, J NEUROSURG, V124, P977, DOI 10.3171/2015.5.JNS142087
   Mampre D, 2018, BRIT J NEUROSURG, V32, P528, DOI 10.1080/02688697.2018.1498450
   Marko NF, 2014, J CLIN ONCOL, V32, P774, DOI 10.1200/JCO.2013.51.8886
   Meyer RB, 2001, MAYO CLIN PROC, V76, P677, DOI 10.4065/76.7.677
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Neira JA, 2017, J NEUROSURG, V127, P111, DOI 10.3171/2016.7.JNS16232
   Pessina F, 2017, J NEURO-ONCOL, V135, P129, DOI 10.1007/s11060-017-2559-9
   Quan GM, 2018, J NEURO-ONCOL, V137, P631, DOI 10.1007/s11060-018-2758-z
   Riley RD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d549
   Roh TH, 2020, J NEUROSURG, V132, P895, DOI 10.3171/2018.12.JNS182558
   Schucht P, 2014, ACTA NEUROCHIR, V156, P305, DOI 10.1007/s00701-013-1906-7
   Smits M, 2017, RADIOLOGY, V284, P316, DOI 10.1148/radiol.2017151930
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Yan JL, 2017, J NEUROSURG, V126, P234, DOI 10.3171/2016.1.JNS152153
   Yordanova YN, 2017, NEUROCHIRURGIE, V63, P243, DOI 10.1016/j.neuchi.2016.09.006
   Yordanova YN, 2011, J NEUROSURG, V115, P232, DOI 10.3171/2011.3.JNS101333
NR 38
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 617
EP +
DI 10.1016/j.wneu.2019.04.092
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300272
PM 31004858
OA Green Published
DA 2020-05-12
ER

PT J
AU Chen, FL
   Guo, HG
   Mao, CL
   Jiang, XM
   Liu, SC
   Huang, L
   Wei, XJ
   Liang, ZL
   Zhou, D
   Li, WY
AF Chen, Feili
   Guo, Hanguo
   Mao, Chengliang
   Jiang, Xinmiao
   Liu, Sichu
   Huang, Ling
   Wei, Xiaojuan
   Liang, Zhanli
   Zhou, Dong
   Li, Wenyu
TI Unusual Relapse of Primary Central Nervous System Lymphoma Both Inside
   and Outside Central Nervous System in Patient with Ventriculoperitoneal
   Shunt
SO WORLD NEUROSURGERY
LA English
DT Article
DE Primary central nervous system lymphoma; Relapse; Ventriculoperitoneal
   shunt
ID PRIMARY CNS LYMPHOMA
AB BACKGROUND: Relapse of primary central nervous system (CNS) lymphoma (PCNSL) occurs primarily at the initial site. Relapse outside the CNS is rare.
   CASE DESCRIPTION: We present the case of a 62-year-old immunocompetent man who underwent a stereotactic biopsy to diagnose PCNSL and subsequent placement of ventriculoperitoneal shunt (VPS) for symptom relief in November 2012. He got complete remission after 6 cycles of high-dose methotrexate-based chemotherapy. In August 2017, relapse of lymphoma occurred in the abdomen, left basal ganglia, and bilateral ventricle with the largest lesion being around the VPS in the abdomen. He got complete remission after 6 cycles of R-CHOP (rituximab, cyclophosphamide, epirubicin, vincristine and prednisolone) plus 8 cycles of high-dose methotrexate chemotherapy.
   CONCLUSIONS: Here we report the first case of extra-CNS relapse of PCNSL around the site of VPS in the abdomen after intensive chemotherapy. Neuro-surgeons should be aware of a potential risk of PCNSL spread along the VPS.
C1 [Chen, Feili; Guo, Hanguo; Jiang, Xinmiao; Liu, Sichu; Huang, Ling; Wei, Xiaojuan; Liang, Zhanli; Li, Wenyu] Guangdong Acad Med Sci, Guangdong Gen Hosp, Lymphoma Div, Guangzhou, Guangdong, Peoples R China.
   [Mao, Chengliang; Zhou, Dong] Guangdong Acad Med Sci, Guangdong Gen Hosp, Neurosurg Div, Guangzhou, Guangdong, Peoples R China.
RP Li, WY (reprint author), Guangdong Acad Med Sci, Guangdong Gen Hosp, Lymphoma Div, Guangzhou, Guangdong, Peoples R China.
EM lwy80411@163.com
CR Ahmed Z, 2014, CASE REP HEMATOL, DOI 10.1155/2014/161952
   Ambady P, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987-017-0064-3
   Ferreri AJM, 2017, HEMATOL-AM SOC HEMAT, P565, DOI 10.1182/asheducation-2017.1.565
   Garcia-Reyero Julia, 2018, Appl Immunohistochem Mol Morphol, DOI 10.1097/PAI.0000000000000655
   Jahnke K, 2005, ANN ONCOL, V16, P445, DOI 10.1093/annonc/mdi075
   Ko JH, 2011, J CLIN ONCOL, V29, pE823, DOI 10.1200/JCO.2011.37.3233
   Langner-Lemercier S, 2016, NEURO-ONCOLOGY, V18, P1297, DOI 10.1093/neuonc/now033
   Whiting AC, 2018, NEUROSURGERY, V83, pE16, DOI 10.1093/neuros/nyx373
   Zenz T, 2017, INT J CANCER, V141, P1381, DOI 10.1002/ijc.30838
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 625
EP 628
DI 10.1016/j.wneu.2019.01.277
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300274
PM 30794971
DA 2020-05-12
ER

PT J
AU Wang, K
   Li, SJ
   Xiang, W
   Ming, Y
   Peng, T
   Wang, HR
   Chen, LG
   Zhou, J
AF Wang, Ke
   Li, Shenjie
   Xiang, Wei
   Ming, Yang
   Peng, Tao
   Wang, Haorun
   Chen, Ligang
   Zhou, Jie
TI Cerebral Granuloma Mimicking Malignant Neoplasm in Patient with Seizures
   21 Years After Head Trauma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Granuloma; Neoplasm; Surgery; Trauma
ID BRAIN-INJURY
AB BACKGROUND: Chronic posttraumatic cerebral granuloma is a rare, delayed complication of traumatic brain injury. Because of its late onset of symptoms and atypical appearance, the correct diagnosis of this rare lesion is difficult.
   CASE DESCRIPTION: A 49-year-old man presented with seizures, which occurred 21 years after open right forehead trauma. Imaging techniques, such as magnetic resonance imaging and magnetic resonance spectroscopy, which indicated a malignant neoplasm, revealed a mass lesion on the right frontal lobe, invading the dura and partial frontal bone. The patient underwent total removal of the lesion and titanium mesh cranioplasty, simultaneously, due to invasion of the mass lesion into the skull. However, the postoperative histopathologic diagnosis was chronic inflammatory granuloma. At 1-year follow-up, he did not have any discomfort and epilepsy did not recur.
   CONCLUSIONS: Chronic cerebral granuloma should be considered in the differential diagnosis of a novel or recurrent mass detected in patients with a history of traumatic brain injury or prior surgery. Moreover, the retained foreign bodies in the superficial or nonfunctional area of the brain should be thoroughly examined and removed at the time of injury, particularly in open brain trauma.
C1 [Wang, Ke; Li, Shenjie; Xiang, Wei; Ming, Yang; Peng, Tao; Wang, Haorun; Chen, Ligang; Zhou, Jie] Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou, Sichuan, Peoples R China.
RP Chen, LG (reprint author), Southwest Med Univ, Affiliated Hosp, Dept Neurosurg, Luzhou, Sichuan, Peoples R China.
EM chengligang.cool@163.com
OI Zhou, Jie/0000-0003-0755-4818; wang, ke/0000-0001-9865-0877
CR Akhaddar A, 2018, WORLD NEUROSURG, V120, P457, DOI 10.1016/j.wneu.2018.09.143
   Akiyama K, 2012, LARYNGOSCOPE, V122, P2382, DOI 10.1002/lary.23490
   Chunhua Qian, 2014, J Craniofac Surg, V25, pe109, DOI 10.1097/SCS.0000000000000439
   Hourani R, 2008, AM J NEURORADIOL, V29, P366, DOI 10.3174/ajnr.A0810
   Jang SW, 2010, KOREAN J RADIOL, V11, P359, DOI 10.3348/kjr.2010.11.3.359
   Kirkman MA, 2012, J NEUROTRAUM, V29, P2365, DOI 10.1089/neu.2012.2485
   Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002
   Podolsky-Gondim GG, 2018, CUREUS, V10, DOI 10.7759/cureus.2836
   Shandra O, 2019, J NEUROSCI, V39, P1944, DOI 10.1523/JNEUROSCI.1067-18.2018
NR 9
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 629
EP +
DI 10.1016/j.wneu.2019.01.286
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300275
PM 30794983
DA 2020-05-12
ER

PT J
AU Liu, BC
   Sun, C
   Xing, Y
   Zhou, F
   Tian, Y
   Yang, ZW
   Hou, GJ
AF Liu, Bingchuan
   Sun, Chuan
   Xing, Yong
   Zhou, Fang
   Tian, Yun
   Yang, Zhongwei
   Hou, Guojin
TI Intervertebral Bridging Ossification After Percutaneous Kyphoplasty in
   Osteoporotic Vertebral Compression Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Intervertebral bridging ossification; Osteoporotic
   vertebral compression fracture; Percutaneous kyphoplasty
ID RISK-FACTORS; CALCIUM-PHOSPHATE; SULFATE
AB BACKGROUND: Percutaneous kyphoplasty (PKP) is effective in treating osteoprotic vertebral compression fractures (OVCFs). Intervertebral bridging ossification can sometimes be detected after surgery, but studies related to its formation mechanism and its influence on outcome are few.
   CASE DESCRIPTION: We reviewed patients' radiologic images and found 7 patients in whom intervertebral bridging ossification developed after PKP Their personal and clinical information was recorded. The 7 patients had an average age of 63.43 +/- 4.79 years. Injured levels included L1 (1 patients) and L2 (1 patient). GeneX and PMMA cement were respectively applied. Both the Cobb angle and the VAS scores were significantly improved after surgery, but all surgical vertebrae showed recollapse combined with larger Cobb angle at the last follow-up visits. In 1 patient the new-onset T11 fracture developed 29 months after surgery.
   CONCLUSIONS: We deemed that spinal degeneration, mechanical instability, bone cement, and fracture pattern are all potential promoting factors for intervertebral bridging ossification. Solid bridging ossification may increase local spinal stability, but it also increases the risk of adjacent vertebral fractures.
C1 [Liu, Bingchuan; Sun, Chuan; Xing, Yong; Zhou, Fang; Tian, Yun; Yang, Zhongwei; Hou, Guojin] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.
RP Tian, Y (reprint author), Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.
EM tiany@bjmu.edu.cn
OI Bingchuan, Liu/0000-0003-4738-9239
FU Beijing Municipal Science and Technology CommissionBeijing Municipal
   Science & Technology Commission [Z161100000516226]
FX Supported by Beijing Municipal Science and Technology Commission, Grant
   Number: Z161100000516226.
CR Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198-017-3909-3
   Cheng C, 2019, CURR OSTEOPOROS REP, V17, P36, DOI 10.1007/s11914-019-00501-5
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Garg Bhavuk, 2017, J Clin Orthop Trauma, V8, P131, DOI 10.1016/j.jcot.2017.02.001
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Heo DH, 2010, WORLD NEUROSURG, V73, P207, DOI 10.1016/j.surneu.2009.07.038
   Hu GF, 2010, J MATER SCI-MATER M, V21, P627, DOI 10.1007/s10856-009-3885-z
   Kang SK, 2011, ANN REHABIL MED-ARM, V35, P844, DOI 10.5535/arm.2011.35.6.844
   Kimura A, 2016, EUR SPINE J, V25, P3456, DOI 10.1007/s00586-015-4064-1
   Laratta Joseph L, 2017, J Spine Surg, V3, P364, DOI 10.21037/jss.2017.08.02
   Lee JK, 2018, SPINE J, V18, P962, DOI 10.1016/j.spinee.2017.10.006
   Ma CH, 2017, INJURY, V48, P2847, DOI 10.1016/j.injury.2017.10.037
   McBride-Gagyi S, 2018, J ORTHOP RES, V36, P2228, DOI 10.1002/jor.23866
   Sakai Y, 2007, SPINE, V32, P1279, DOI 10.1097/BRS.0b013e318059af8a
   Sivakumar R, 2016, J Orthop Case Rep, V6, P59, DOI 10.13107/jocr.2250-0685.508
   Smirnov VV, 2018, DOKL CHEM, V483, P279, DOI 10.1134/S0012500818110083
   Tang Q, 2018, AM J TRANSL RES, V10, P1211
   Tang Q, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0062-9
   Toyone T, 2010, SPINE, V35, P1915, DOI 10.1097/BRS.0b013e3181dc846c
   Urban RM, 2007, CLIN ORTHOP RELAT R, P110, DOI 10.1097/BLO.0b013e318059b902
   Yang HL, 2016, SPINE, V41, pB52, DOI 10.1097/BRS.0000000000001804
   Yu WB, 2018, WORLD NEUROSURG, V111, P119, DOI 10.1016/j.wneu.2017.12.019
   Zhang ZT, 2013, J SPINAL DISORD TECH, V26, pE150, DOI 10.1097/BSD.0b013e31827412a5
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 633
EP +
DI 10.1016/j.wneu.2019.04.014
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300276
PM 30965166
DA 2020-05-12
ER

PT J
AU Cavallo, LM
   Somma, T
   Solari, D
   Iannuzzo, G
   Frio, F
   Baiano, C
   Cappabianca, P
AF Cavallo, Luigi M.
   Somma, Teresa
   Solari, Domenico
   Iannuzzo, Gianpiero
   Frio, Federico
   Baiano, Cinzia
   Cappabianca, Paolo
TI Endoscopic Endonasal Transsphenoidal Surgery: History and Evolution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic pituitary surgery; Endoscopic skull base surgery; History
   transsphenoidal surgery; Transsphenoidal surgery
ID OPEN TRANSCRANIAL RESECTION; SKULL BASE RECONSTRUCTION;
   PITUITARY-ADENOMAS; TUBERCULUM SELLAE; SUPRASELLAR CRANIOPHARYNGIOMAS;
   PTERYGOPALATINE FOSSA; TRANSNASAL APPROACH; TRANSORBITAL ROUTE; SURGICAL
   APPROACH; CAVERNOUS SINUS
AB In previous decades, extensive and disfiguring transfacial and/or transcranial approaches were used to reach the sellar and parasellar areas. However, these surgical routes were burdened by severe complications and high mortality rates. Recently, the development of endoscopic endonasal techniques has revolutionized the surgical strategies for approaching the sella and adjacent areas and increased the development of transsphenoidal surgery. With these techniques, surgeons have been able to overcome the visual limitations of the open surgical approaches and access areas previously hidden from view. After the contributions of the Pittsburgh duo, Carrau and Jho, pioneers of pure endoscopic surgery, our school began to implement this technique, introducing technical innovations and variations, describing the anatomical details and defining new routes, and playing a key role in its widespread clinical application.
C1 [Cavallo, Luigi M.; Somma, Teresa; Solari, Domenico; Iannuzzo, Gianpiero; Frio, Federico; Baiano, Cinzia; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
RP Cavallo, LM (reprint author), Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
EM lcavallo@unina.it
OI Frio, Federico/0000-0002-0010-2942
CR APUZZO MLJ, 1977, J NEUROSURG, V46, P398, DOI 10.3171/jns.1977.46.3.0398
   Artico M, 1998, NEUROSURGERY, V42, P909, DOI 10.1097/00006123-199804000-00121
   Bander ED, 2018, J NEUROSURG, V128, P40, DOI 10.3171/2016.9.JNS16823
   Barkhoudarian G, 2013, NEUROSURGERY, V73, P74, DOI 10.1227/NEU.0b013e31828ba962
   Cappabianca P, 1999, SKULL BASE SURG, V9, P109, DOI 10.1055/s-2008-1058157
   Cappabianca P, 1998, MINIM INVAS NEUROSUR, V41, P66, DOI 10.1055/s-2008-1052019
   Cappabianca P, 2000, MINIM INVAS NEUROSUR, V43, P38, DOI 10.1055/s-2000-8814
   Cappabianca P, 2004, NEUROSURGERY, V54, P1043, DOI 10.1227/01.NEU.0000119325.14116.9C
   Cappabianca P, 2002, MINIM INVAS NEUROSUR, V45, P193, DOI 10.1055/s-2002-36197
   Cappabianca P, 2002, J NEUROSURG, V97, P293, DOI 10.3171/jns.2002.97.2.0293
   Cappabianca P, 1999, NEUROSURGERY, V45, P392, DOI 10.1097/00006123-199908000-00041
   Cappabianca P, 2008, ADV TECHNICAL STANDA, P152
   Cappabianca P, 2008, PITUITARY, V11, P385, DOI 10.1007/s11102-008-0087-5
   Cappabianca P, 2014, WORLD NEUROSURG, V82, pS3, DOI 10.1016/j.wneu.2014.07.019
   Cappabianca P, 2014, ACTA NEUROCHIR, V156, P2217, DOI 10.1007/s00701-014-2213-7
   Cappabianca P, 2012, PROG NEUROL SURG, V26, P1
   Carrau RL, 1996, LARYNGOSCOPE, V106, P914, DOI 10.1097/00005537-199607000-00025
   Castelnuovo P, 2006, RHINOLOGY, V44, P2
   Castelnuovo P, 2014, WORLD NEUROSURG, V82, pS22, DOI 10.1016/j.wneu.2014.07.021
   Castelnuovo P, 2010, EUR ARCH OTO-RHINO-L, V267, P649, DOI 10.1007/s00405-009-1196-0
   Castelnuovo PG, 2006, SKULL BASE-INTERD AP, V16, P15, DOI 10.1055/s-2005-922095
   Cavallo LM, 2008, NEUROSURGERY, V62, P1202, DOI [10.1227/01.neu.0000333786.98596.33, 10.1227/01.NEU.0000325689.30097.E7, 10.1227/01.NEU.000028005.26449.2D]
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE5
   Cavallo LM, 2009, J NEUROSURG, V111, P578, DOI 10.3171/2009.2.JNS081026
   Cavallo LM, 2007, J NEUROSURG, V107, P713, DOI 10.3171/JNS-07/10/0713
   Cavallo Luigi Maria, 2005, Neurosurgery, V56, P379, DOI 10.1227/01.NEU.0000156548.30011.D4
   Cavallo LM, 2015, WORLD NEUROSURG, V84, P267, DOI 10.1016/j.wneu.2015.03.007
   Cavallo LM, 2014, WORLD NEUROSURG, V82, pS32, DOI 10.1016/j.wneu.2014.07.023
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Cavallo LM, 2013, NEUROSURG REV, V36, P27, DOI 10.1007/s10143-012-0403-4
   Ceylan S, 2009, NEUROSURG REV, V32, P309, DOI 10.1007/s10143-009-0201-9
   Chibbaro S, 2014, NEUROSURG REV, V37, P224
   Chibbaro S, 2014, NEUROSURG REV, V37, P217, DOI 10.1007/s10143-013-0503-9
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Cohen-Gadol AA, 2005, J NEUROSURG, V103, P372, DOI 10.3171/jns.2005.103.2.0372
   Colao A, 1998, J ENDOCRINOL INVEST, V21, P284, DOI 10.1007/BF03350330
   Cushing H, 1932, AM J SURG, V16, P348
   Dallan I, 2017, J NEUROSURG, V127, P622, DOI 10.3171/2016.8.JNS16465
   Dallan I, 2014, EUR ARCH OTO-RHINO-L, V271, P2197, DOI 10.1007/s00405-013-2854-9
   Dallan I, 2013, EUR ARCH OTO-RHINO-L, V270, P1643, DOI 10.1007/s00405-012-2281-3
   De Caro MD, 2017, NEUROSURG REV, V40, P105, DOI 10.1007/s10143-016-0740-9
   de Divitiis E, 2002, NEUROSURGERY, V51, P699, DOI 10.1097/00006123-200209000-00016
   de Divitiis E, 2002, NEUROSURGERY, V51, P705
   de Divitiis E, 2008, NEUROSURGERY, V62, P556, DOI 10.1227/01.neu.0000317303.93460.24
   de Divitiis E, 2007, NEUROSURGERY, V61, P229, DOI 10.1227/01.neu.0000303221.63016.f2
   de Divitiis E, 2007, NEUROSURGERY, V60, P46, DOI 10.1227/01.NEU.0000249211.89096.25
   de Divitiis E, 2006, NEUROSURGERY, V59, P512, DOI 10.1227/01.NEU.0000227475.69682.77
   de Divitiis O, 2007, NEUROSURGERY, V61, P239, DOI 10.1227/01.neu.0000303222.40145.1a
   de Notaris M, 2014, LARYNGOSCOPE, V124, P2231, DOI 10.1002/lary.24693
   de Notaris M, 2011, WORLD NEUROSURG, V75, P106, DOI 10.1016/j.wneu.2010.09.033
   Dhandapani S, 2017, J NEUROSURG, V126, P418, DOI 10.3171/2016.1.JNS152238
   Di Maio S, 2011, J NEUROSURG, V114, P345, DOI 10.3171/2010.9.JNS10262
   Di Somma A, 2018, J NEUROSURG, V129, P1203, DOI 10.3171/2017.4.JNS162749
   Di Somma A, 2018, ACTA NEUROCHIR, V160, P707, DOI 10.1007/s00701-017-3448-x
   Di Somma A, 2017, J NEUROSURG, V127, P199, DOI 10.3171/2016.8.JNS16566
   DOTT NM, 1925, BRIT J SURG, V13, P314, DOI DOI 10.1002/BJS.1800135009
   Esposito F, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.033
   Fernandez-Miranda JC, 2012, NEUROSURGERY, V71, P146, DOI 10.1227/NEU.0b013e3182438915
   Frank G, 2002, NEUROSURGERY, V50, P675, DOI 10.1097/00006123-200203000-00059
   Frank G, 2001, J NEUROSURG, V95, P917
   Frank G, 2006, NEUROENDOCRINOLOGY, V83, P240, DOI 10.1159/000095534
   Frank G, 2006, NEUROSURGERY, V59, P50, DOI 10.1227/01.NEU.0000219914.17221.55
   Fraser JF, 2009, MINIM INVAS NEUROSUR, V52, P25, DOI 10.1055/s-0028-1104567
   Fraser JF, 2010, NEUROSURGERY, V67, P150, DOI 10.1227/01.NEU.0000383130.80179.41
   Fraser JF, 2010, J NEUROSURG, V112, P1061, DOI 10.3171/2009.7.JNS081504
   Gardner PA, 2008, J NEUROSURG, V109, P6, DOI 10.3171/JNS/2008/109/7/0006
   Gondim JA, 2014, WORLD NEUROSURG, V82, pE281, DOI 10.1016/j.wneu.2013.08.028
   GUIOT G, 1963, PRESSE MED, V71, P1225
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hajdari S, 2018, WORLD NEUROSURG, V119, pE80, DOI 10.1016/j.wneu.2018.07.018
   Halstead AE, 1910, T AM SURG ASS, V28, P73
   Hanna E, 2009, ARCH OTOLARYNGOL, V135, P1219, DOI 10.1001/archoto.2009.173
   HARDY J, 1971, J NEUROSURG, V34, P582, DOI 10.3171/jns.1971.34.4.0582
   Hirsch O, 1910, J AMER MED ASSOC, V55, P772, DOI 10.1001/jama.1910.04330090046014
   Hirsch O, 1910, WIEN MED WSCHR, V60, P749
   Hirsch O, 1910, VERH DTSCH GES CHIR, V39, P51
   Horsley V, 1906, BMJ-BRIT MED J, V2, P411
   Jahangiri A, 2014, J CLIN NEUROSCI, V21, P779, DOI 10.1016/j.jocn.2013.07.023
   JAMES JA, 1967, ARCHIV OTOLARYNGOL, V86, P256
   JANKOWSKI R, 1992, LARYNGOSCOPE, V102, P198, DOI 10.1288/00005537-199202000-00016
   Jho H.D., 1996, NEUROSURGICAL OPERAT, P1
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Jho HD, 2001, MINIM INVAS NEUROSUR, V44, P190, DOI 10.1055/s-2001-19927
   Juraschka K, 2014, J NEUROSURG, V121, P75, DOI 10.3171/2014.3.JNS131679
   Kanter AS, 2005, NEUROSURG FOCUS, V18, P1
   Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kassam AB, 2008, NEUROSURGERY, V63, P57, DOI [10.1227/01.NEU.0000297013.35469.37, 10.1227/01.neu.0000317374.30443.23]
   Kassam AB, 2008, J NEUROSURG, V108, P715, DOI 10.3171/JNS/2008/108/4/0715
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Kim SK, 2014, ACTA NEUROCHIR, V156, P1917, DOI 10.1007/s00701-014-2150-5
   Kocher T, 1909, DTSCH Z CHIR, V100, P13
   Komotar RJ, 2012, PITUITARY, V15, P150, DOI 10.1007/s11102-011-0359-3
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Koutourousiou M, 2014, J NEUROSURG, V120, P1326, DOI 10.3171/2014.2.JNS13767
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Koutourousiou M, 2012, NEUROSURGERY, V71, P614, DOI 10.1227/NEU.0b013e31825ea3e0
   Lanzino G, 2001, J NEUROSURG, V95, P1097, DOI 10.3171/jns.2001.95.6.1097
   Laufer I, 2007, J NEUROSURG, V106, P400, DOI 10.3171/jns.2007.106.3.400
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Liu JK, 2001, J NEUROSURG, V95, P1083, DOI 10.3171/jns.2001.95.6.1083
   Lombardi D, 2008, ANN OTO RHINOL LARYN, V117, P653, DOI 10.1177/000348940811700904
   LUFT R, 1953, J NEUROSURG, V10, P301, DOI 10.3171/jns.1953.10.3.0301
   Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17753
   Magro F, 2006, NEUROSURGERY, V59, P237, DOI 10.1227/01.NEU.0000233977.79721.17
   Mason RB, 1997, J NEUROSURG, V87, P343, DOI 10.3171/jns.1997.87.3.0343
   McLaughlin N, 2013, J NEUROSURG, V118, P613, DOI 10.3171/2012.11.JNS112020
   Nicolai P, 2008, AM J RHINOL, V22, P308, DOI 10.2500/ajr.2008.22.3170
   Patel SK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12125
   Pinheiro-Neto CD, 2007, LARYNGOSCOPE, V117, P1560, DOI 10.1097/MLG.0b013e31806db514
   Rivera-Serrano CM, 2011, LARYNGOSCOPE, V121, P990, DOI 10.1002/lary.21419
   Schloffer H, 1907, WIEN KLIN WSCHR, V20, P621
   Schloffer H, 1906, BEITR KLIN CHIR, V50, P767
   Schwartz TH, 2008, NEUROSURGERY, V62, P991, DOI [10.1227/01.NEU.0000313231.81129.66, 10.1227/01.neu.0000325861.06832.06]
   SETHI DS, 1995, J LARYNGOL OTOL, V109, P956, DOI 10.1017/S0022215100131755
   Solari D, 2007, J NEUROSURG, V106, P157, DOI 10.3171/jns.2007.106.1.157
   Solari D, 2016, J NEUROSURG SCI, V60, P454
   Solari D, 2014, WORLD NEUROSURG, V82, pS164, DOI 10.1016/j.wneu.2014.08.005
   Solari D, 2014, HAND CLINIC, V124, P291, DOI 10.1016/B978-0-444-59602-4.00019-8
   Stippler M, 2009, NEUROSURGERY, V64, P268, DOI 10.1227/01.NEU.0000338071.01241.E2
   Tabaee A, 2009, J NEUROSURG, V111, P545, DOI 10.3171/2007.12.17635
   Tabaee APD, 2007, PRACTICAL ENDOSCOPIC, P191
   Wang AJ, 2016, J NEUROSURG SCI, V60, P441
   Wannemuehler TJ, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16314
   WEISS MH, 1987, SURG 3 VENTRICLE, P476
   Zacharia BE, 2016, OTOLARYNG CLIN N AM, V49, P201, DOI 10.1016/j.otc.2015.09.013
   Zada G, 2011, J NEUROSURG, V114, P286, DOI 10.3171/2010.8.JNS10520
   Zada G, 2010, WORLD NEUROSURG, V74, P452, DOI 10.1016/j.wneu.2010.09.028
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P419, DOI 10.1016/j.wneu.2015.10.004
NR 135
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 686
EP 694
DI 10.1016/j.wneu.2019.03.048
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300312
PM 31266131
DA 2020-05-12
ER

PT J
AU Solari, D
   Pivonello, R
   Caggiano, C
   Guadagno, E
   Chiaramonte, C
   Miccoli, G
   Cavallo, LM
   De Caro, MD
   Colao, A
   Cappabianca, P
AF Solari, Domenico
   Pivonello, Rosario
   Caggiano, Chiara
   Guadagno, Elia
   Chiaramonte, Carmela
   Miccoli, Giovanni
   Cavallo, Luigi M.
   De Caro, Marialaura Del Basso
   Colao, Annamaria
   Cappabianca, Paolo
TI Pituitary Adenomas: What Are the Key Features? What Are the Current
   Treatments? Where Is the Future Taking Us?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adenomas; Endocrinology; Endoscopic endonasal surgery; Multidisciplinary
   team; Pituitary/hypothalamus; Radiation oncology; Targeted drugs
ID ENDONASAL TRANSSPHENOIDAL APPROACH; GAMMA-KNIFE SURGERY; ENDOSCOPIC
   TRANSORBITAL ROUTE; TRANS-SPHENOIDAL SURGERY; EVIDENCE-BASED GUIDELINE;
   LONG-TERM TREATMENT; CUSHINGS-DISEASE; MEDICAL-TREATMENT; CAVERNOUS
   SINUS; FOLLOW-UP
AB Pituitary tumors are a heterogeneous group of lesions (usually benign) and proper understanding of the anatomy, physiology, and pathology of the hypothalamic/pituitary region is essential to make an accurate diagnosis and define the essential treatment options (i.e., surgery, medical therapies, and radiotherapy, alone or in combination). Surgery is the primary treatment for acromegaly, Cushing disease, thyroid-stimulating hormone-secreting adenomas, resistant prolactinomas, and nonfunctioning pituitary adenomas causing mass effect, Medical and radiation therapy are reserved in cases in which surgery is not possible or does not provide a complete cure. In the last decades, tremendous innovations (i.e., targeted drugs and refined surgical tools and techniques) have expanded the treatment strategies for pituitary adenomas. We herein report the current indications for and depiction of the surgical techniques in pituitary surgery, review current medical treatments, and provide a glimpse of future possibilities.
C1 [Solari, Domenico; Caggiano, Chiara; Chiaramonte, Carmela; Miccoli, Giovanni; Cavallo, Luigi M.; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
   [Pivonello, Rosario; Colao, Annamaria] Univ Napoli Federico II, Div Endocrinol, Naples, Italy.
   [Guadagno, Elia; De Caro, Marialaura Del Basso] Univ Napoli Federico II, Dept Adv Biomed Sci, Sect Pathol, Naples, Italy.
RP Solari, D (reprint author), Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
EM domenico.solari@unina.it
CR Afargan M, 2001, ENDOCRINOLOGY, V142, P477, DOI 10.1210/en.142.1.477
   Alband N, 2014, HAND CLINIC, V124, P339, DOI 10.1016/B978-0-444-59602-4.00023-X
   Alexandraki KI, 2010, FRONT HORM RES, V38, P165, DOI 10.1159/000318507
   Amlashi FG, 2016, ENDOCRINE, V52, P427, DOI 10.1007/s12020-016-0863-3
   Andereggen L, 2017, WORLD NEUROSURG, V97, P595, DOI 10.1016/j.wneu.2016.10.059
   Badie B, 2000, SURG NEUROL, V53, P168, DOI 10.1016/S0090-3019(99)00195-0
   Barbot M, 2014, PITUITARY, V17, P109, DOI 10.1007/s11102-013-0475-3
   Barkhoudarian G, 2013, NEUROSURGERY, V73, P74, DOI 10.1227/NEU.0b013e31828ba962
   Beckers A, 2007, EUR J ENDOCRINOL, V157, P371, DOI 10.1530/EJE-07-0348
   Bengtsson D, 2015, J CLIN ENDOCR METAB, V100, P1689, DOI 10.1210/jc.2014-4350
   Bertagna X, 2014, J CLIN ENDOCR METAB, V99, P1375, DOI 10.1210/jc.2013-2117
   BEVAN JS, 1992, ENDOCR REV, V13, P220, DOI 10.1210/er.13.2.220
   Biller BMK, 2008, J CLIN ENDOCR METAB, V93, P2454, DOI 10.1210/jc.2007-2734
   BOCHICCHIO D, 1995, J CLIN ENDOCR METAB, V80, P3114, DOI 10.1210/jc.80.11.3114
   Boscaro M, 2009, J CLIN ENDOCR METAB, V94, P115, DOI 10.1210/jc.2008-1008
   Bostrom JP, 2015, STRAHLENTHER ONKOL, V191, P477, DOI 10.1007/s00066-014-0802-2
   Briceno LG, 2014, HORM RES PAEDIAT, V82, P364, DOI 10.1159/000368401
   Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042
   Briet C, 2015, ENDOCRIN METAB CLIN, V44, P199, DOI 10.1016/j.ecl.2014.10.016
   BRIGNER WL, 1994, PERCEPT MOTOR SKILL, V78, P1385, DOI 10.2466/pms.1994.78.3c.1385
   Bronstein MD, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0096-8
   Bruns C, 2002, EUR J ENDOCRINOL, V146, P707, DOI 10.1530/eje.0.1460707
   Bush ZM, 2008, REV ENDOCR METAB DIS, V9, P83, DOI 10.1007/s11154-007-9061-1
   Cappabianca P, 1998, MINIM INVAS NEUROSUR, V41, P66, DOI 10.1055/s-2008-1052019
   Cappabianca P, 2004, NEUROSURGERY, V55, P933, DOI 10.1227/01.NEU.0000137330.02549.0D
   Cappabianca P, 2004, NEUROSURGERY, V54, P1043, DOI 10.1227/01.NEU.0000119325.14116.9C
   Cappabianca P, 2002, NEUROSURGERY, V51, P1365, DOI 10.1227/01.NEU.0000035904.77559.9F
   Cappabianca P, 2008, ADV TECHNICAL STANDA, P152
   Cappabianca P, 2004, NEUROSURGERY, V55, P940
   Cappabianca P, 2010, ENDOCRINOLOGY, P358
   Cappabianca P, 2008, PITUITARY, V11, P385, DOI 10.1007/s11102-008-0087-5
   Cappabianca P, 2015, NEUROSURG CLIN N AM, V26, P323, DOI 10.1016/j.nec.2015.03.007
   Cappabianca P, 2014, WORLD NEUROSURG, V82, pS3, DOI 10.1016/j.wneu.2014.07.019
   Cappabianca P, 2014, ACTA NEUROCHIR, V156, P2217, DOI 10.1007/s00701-014-2213-7
   Carrau RL, 2013, HEAD NECK-J SCI SPEC, V35, pE351, DOI 10.1002/hed.23238
   Carrau RL, 1996, LARYNGOSCOPE, V106, P914, DOI 10.1097/00005537-199607000-00025
   Carrau RL, 2001, OTOLARYNG CLIN N AM, V34, P1143, DOI 10.1016/S0030-6665(05)70371-6
   Casanueva FF, 2006, CLIN ENDOCRINOL, V65, P265, DOI 10.1111/j.1365-2265.2006.02562.x
   Castelnuovo P, 2006, RHINOLOGY, V44, P2
   Castinetti F, 2008, EUR J ENDOCRINOL, V158, P91, DOI 10.1530/EJE-07-0514
   Castinetti F, 2009, EUR J ENDOCRINOL, V160, P1003, DOI 10.1530/EJE-09-0098
   Castinetti F, 2014, J CLIN ENDOCR METAB, V99, P1623, DOI 10.1210/jc.2013-3628
   Catargi B, 2003, J CLIN ENDOCR METAB, V88, P5808, DOI 10.1210/jc.2003-030254
   Cavallo LM, 2007, NEUROSURGERY S, V61, P33, DOI DOI 10.1227/01.NEU.0000289708.49684.47
   Cavallo LM, 2007, NEUROSURGERY, V61, P24, DOI 10.1227/01.NEU.0000280005.26449.2D
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2
   Cavallo LM, 2014, ACTA NEUROCHIR, V156, P1631, DOI 10.1007/s00701-014-2128-3
   Cavallo LM, 2007, J NEUROSURG, V107, P713, DOI 10.3171/JNS-07/10/0713
   Cavallo Luigi Maria, 2005, Neurosurgery, V56, P379, DOI 10.1227/01.NEU.0000156548.30011.D4
   Ceccato F, 2015, J NEURO-ONCOL, V122, P189, DOI 10.1007/s11060-014-1702-0
   Chang EF, 2008, J NEUROSURG, V108, P736, DOI 10.3171/JNS/2008/108/4/0736
   Chanson P, 2004, Minerva Endocrinol, V29, P241
   Chen LK, 2011, J NEURO-ONCOL, V102, P129, DOI 10.1007/s11060-010-0302-x
   Chen Y, 2013, EUR J ENDOCRINOL, V169, P487, DOI 10.1530/EJE-13-0400
   Cohen-Inbar O, 2017, J NEURO-ONCOL, V135, P67, DOI 10.1007/s11060-017-2520-y
   Colao A, 2006, J ENDOCRINOL INVEST, V29, P1017, DOI 10.1007/BF03349217
   Colao A, 1998, J ENDOCRINOL INVEST, V21, P284, DOI 10.1007/BF03350330
   Colao A, 2014, J CLIN ENDOCR METAB, V99, P791, DOI 10.1210/jc.2013-2480
   Colao A, 2004, ENDOCR REV, V25, P102, DOI 10.1210/er.2002-0022
   Colao A, 2003, NEW ENGL J MED, V349, P2023, DOI 10.1056/NEJMoa022657
   Colao A, 1997, J CLIN ENDOCR METAB, V82, P876, DOI 10.1210/jc.82.3.876
   Colao A, 2007, CLIN ENDOCRINOL, V67, P426, DOI 10.1111/j.1365-2265.2007.02905.x
   Colao A, 2016, PITUITARY, V19, P235, DOI 10.1007/s11102-015-0684-z
   Colao A, 2014, PITUITARY, V17, P180, DOI 10.1007/s11102-013-0483-3
   Colao A, 2012, NEW ENGL J MED, V366, P914, DOI 10.1056/NEJMoa1105743
   Colao A, 2011, ENDOCR REV, V32, P247, DOI 10.1210/er.2010-0002
   Colao A, 2009, BEST PRACT RES CL EN, V23, P575, DOI 10.1016/j.beem.2009.05.003
   Dallan I, 2017, J NEUROSURG, V127, P622, DOI 10.3171/2016.8.JNS16465
   Dallan I, 2013, EUR ARCH OTO-RHINO-L, V270, P1643, DOI 10.1007/s00405-012-2281-3
   Dallapiazza RF, 2015, NEUROSURGERY, V76, P42, DOI 10.1227/NEU.0000000000000563
   Das K, 2001, NEUROL RES, V23, P51, DOI 10.1179/016164101101198280
   Davies BM, 2016, ACTA NEUROCHIR, V158, P677, DOI 10.1007/s00701-015-2699-7
   De Caro MD, 2017, NEUROSURG REV, V40, P105, DOI 10.1007/s10143-016-0740-9
   de Castro LF, 2017, HORM RES PAEDIAT
   de Divitiis E, 2003, ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL SURGERY, P91
   de Divitiis E, 2002, NEUROSURGERY, V51, P699, DOI 10.1097/00006123-200209000-00016
   de Divitiis E, 2002, ADV TECH STAND NEUR, V27, P137
   de Divitiis E, 2002, NEUROSURGERY, V51, P705
   de Divitiis E, 2007, NEUROSURGERY, V60, P46, DOI 10.1227/01.NEU.0000249211.89096.25
   Neto MAD, 2010, CLIN ENDOCRINOL, V72, P512, DOI 10.1111/j.1365-2265.2009.03665.x
   Dehdashti AR, 2009, NEUROSURGERY, V64, P677, DOI 10.1227/01.NEU.0000339121.20101.85
   Di Maio S, 2011, J NEUROSURG, V114, P345, DOI 10.3171/2010.9.JNS10262
   Di Somma A, 2018, J NEUROSURG, V129, P1203, DOI 10.3171/2017.4.JNS162749
   Di Somma A, 2019, J NEUROSURG, V130, P848, DOI 10.3171/2017.9.JNS171406
   Di Somma A, 2018, ACTA NEUROCHIR, V160, P707, DOI 10.1007/s00701-017-3448-x
   Dias N, 2002, MOL CANCER THER, V1, P347
   Ding D, 2014, J NEURO-ONCOL, V119, P513, DOI 10.1007/s11060-014-1501-7
   Doglietto Francesco, 2005, Neurosurg Focus, V19, pE3
   Donoho DA, 2017, PITUITARY, V20, P169, DOI 10.1007/s11102-016-0781-7
   ELIAS WJ, 2000, SCHMIDEK SWEET OPERA, P373
   Eschler DC, 2018, ENDOCRINE, V59, P16, DOI 10.1007/s12020-017-1438-7
   Esposito F, 2007, NEUROSURGERY, V60, P295, DOI 10.1227/01.NEU.0000255354.64077.66
   Even-Zohar N, 2018, PITUITARY, V21, P168, DOI 10.1007/s11102-018-0865-7
   FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504
   Feelders RA, 2010, NEUROENDOCRINOLOGY, V92, P111, DOI 10.1159/000314292
   Feelders RA, 2010, NEW ENGL J MED, V362, P1846, DOI 10.1056/NEJMc1000094
   FELDMAN D, 1986, ENDOCR REV, V7, P409, DOI 10.1210/edrv-7-4-409
   Ferrari CI, 1997, CLIN ENDOCRINOL, V46, P409, DOI 10.1046/j.1365-2265.1997.1300952.x
   Fleseriu M, 2016, PITUITARY, V19, P138, DOI 10.1007/s11102-015-0692-z
   Fleseriu M, 2015, ENDOCRIN METAB CLIN, V44, P51, DOI 10.1016/j.ecl.2014.10.006
   Fleseriu M, 2012, J CLIN ENDOCR METAB, V97, P2039, DOI 10.1210/jc.2011-3350
   Frank G, 2002, NEUROSURGERY, V50, P675, DOI 10.1097/00006123-200203000-00059
   Frank G, 2006, FRONT HORM RES, V34, P64, DOI 10.1159/000091573
   Fraser JF, 2009, MINIM INVAS NEUROSUR, V52, P25, DOI 10.1055/s-0028-1104567
   FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520
   Fukuoka H, 2011, J CLIN INVEST, V121, P4712, DOI 10.1172/JCI60417
   Gadelha MR, 2014, LANCET DIABETES ENDO, V2, P875, DOI 10.1016/S2213-8587(14)70169-X
   Gheorghiu ML, 2017, PITUITARY, V20, P154, DOI 10.1007/s11102-016-0783-5
   Gillam MP, 2006, ENDOCR REV, V27, P485, DOI 10.1210/er.2005-9998
   Gittleman H, 2014, J NEUROSURG, V121, P527, DOI 10.3171/2014.5.JNS131819
   Giustina A, 2014, NAT REV ENDOCRINOL, V10, P243, DOI 10.1038/nrendo.2014.21
   Godbout A, 2010, EUR J ENDOCRINOL, V163, P709, DOI 10.1530/EJE-10-0382
   Guelho D, 2015, EXPERT OPIN EMERG DR, V20, P463, DOI 10.1517/14728214.2015.1047762
   Gueorguiev M, 2011, NAT REV ENDOCRINOL, V7, P71, DOI 10.1038/nrendo.2010.233
   Hamrahian AH, 2014, ENDOCR PRACT, V20, P746, DOI 10.4158/EP14147.RA
   Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887
   Heaney AP, 1999, CLIN ENDOCRINOL, V51, P293, DOI 10.1046/j.1365-2265.1999.00766.x
   Hirohata T, 2014, NEUROL MED-CHIR, V54, P966, DOI 10.2176/nmc.ra.2014-0178
   Hofmann BM, 2006, NEUROSURGERY, V58, P1108, DOI 10.1227/01.NEU.0000215945.26764.92
   Horvath Zsolt, 2013, Magy Onkol, V57, P251, DOI MagyOnkol.2013.57.4.251
   Huang WY, 2012, AM FAM PHYSICIAN, V85, P1073
   Iglesias P, 2017, EUR J INTERN MED, V41, P62, DOI 10.1016/j.ejim.2017.03.023
   Jane Jr JA, 2000, ENDOTEXT
   Jenkins PJ, 2001, CLIN ENDOCRINOL, V55, P727, DOI 10.1046/j.1365-2265.2001.01418.x
   Jho H.D., 1996, NEUROSURGICAL OPERAT, P1
   Ji Y, 2016, NEURO-ONCOL PRACT, V3, P188, DOI 10.1093/nop/npv059
   Jung TY, 2009, J NEUROSURG, V111, P572, DOI 10.3171/2008.10.JNS0880
   Juraschka K, 2014, J NEUROSURG, V121, P75, DOI 10.3171/2014.3.JNS131679
   Kamenicky P, 2011, J CLIN ENDOCR METAB, V96, P2796, DOI 10.1210/jc.2011-0536
   Kanter Adam S, 2005, Neurosurg Focus, V18, pe6
   Karavitaki N, 2005, CLIN ENDOCRINOL, V62, P397, DOI 10.1111/j.1365-2265.2005.02231.x
   Kari E, 2012, INT FORUM ALLERGY RH, V2, P2, DOI 10.1002/alr.20036
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
   Kelly Daniel F, 2007, Neurosurg Focus, V23, pE5, DOI 10.3171/foc.2007.23.3.7
   Lacroix A, 2018, LANCET DIABETES ENDO, V6, P17, DOI 10.1016/S2213-8587(17)30326-1
   Langlois F, 2017, ENDOCRINOL METAB, V32, P162, DOI 10.3803/EnM.2017.32.2.162
   Lau SKM, 2017, J NEURO-ONCOL, V132, P307, DOI 10.1007/s11060-017-2370-7
   Laufer I, 2007, J NEUROSURG, V106, P400, DOI 10.3171/jns.2007.106.3.400
   Laws E R, 2001, Clin Neurosurg, V48, P306
   Laws ER, 2005, J NEUROSURG, V102, P825, DOI 10.3171/jns.2005.102.5.0825
   Laws ER, 2010, TRANSSPHENOIDAL SURG
   LAWS ER, 1993, BRAIN SURG COMPLICAT, P357
   Laws ERJ, 1985, PROLACTIN BASIC CLIN, P849
   Leonhard M, 2003, ENDOSCOPIC ENDONASAL TRANSSPHENOIDAL SURGERY, P9
   Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611
   Li K, 2015, CLIN NEUROL NEUROSUR, V136, P20, DOI 10.1016/j.clineuro.2015.05.019
   Lila AR, 2010, ENDOCR PRACT, V16, P968, DOI 10.4158/EP10031.OR
   Liu JK, 2001, J NEUROSURG, V95, P1083, DOI 10.3171/jns.2001.95.6.1083
   Liu NA, 2011, P NATL ACAD SCI USA, V108, P8414, DOI 10.1073/pnas.1018091108
   Lloyd RV, 2004, WHO CLASSIFICATION T, P9
   Lobo Bjorn, 2015, Surg Neurol Int, V6, P82, DOI 10.4103/2152-7806.157442
   LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903
   Losa M, 2004, J NEUROSURG, V100, P438, DOI 10.3171/jns.2004.100.3.0438
   Lucas JW, 2016, NEUROSURGERY, V79, pE533, DOI 10.1227/NEU.0000000000001389
   Maiter D, 2016, ANN ENDOCRINOL-PARIS, V77, P128, DOI 10.1016/j.ando.2016.04.001
   Manojlovic-Gacic E, 2018, PITUITARY, V21, P119, DOI 10.1007/s11102-017-0855-1
   MANTERO F, 1992, J STEROID BIOCHEM, V43, P409, DOI 10.1016/0960-0760(92)90077-V
   Mather G, 2000, VISION RES, V40, P3501, DOI 10.1016/S0042-6989(00)00178-4
   McLaughlin N, 2013, WORLD NEUROSURG, V80, P569, DOI 10.1016/j.wneu.2012.07.034
   McLaughlin N, 2012, NEUROSURGERY, V71, P916, DOI 10.1227/NEU.0b013e31826d5d06
   Melmed S, 2009, J CLIN ENDOCR METAB, V94, P1509, DOI 10.1210/jc.2008-2421
   Melmed S, 2001, J CLIN ENDOCR METAB, V86, P2929, DOI 10.1210/jc.86.7.2929
   MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405
   Melmed S, 2016, NAT REV ENDOCRINOL, V12, P90, DOI 10.1038/nrendo.2015.196
   Melmed S, 2015, J CLIN ENDOCR METAB, V100, P1699, DOI 10.1210/jc.2014-4113
   Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692
   Melmed S, 2009, J CLIN INVEST, V119, P3189, DOI 10.1172/JCI39375
   Milano Michael T, 2018, Int J Radiat Oncol Biol Phys, DOI 10.1016/j.ijrobp.2018.01.053
   Minniti G, 2005, EUR J ENDOCRINOL, V153, P723, DOI 10.1530/eje.1.02030
   Minniti G, 2005, CLIN ENDOCRINOL, V62, P210, DOI 10.1111/j.1365-2265.2005.02199.x
   Minniti G, 2007, J NEURO-ONCOL, V84, P79, DOI 10.1007/s11060-007-9344-0
   Minniti G, 2007, NEUROSURG REV, V30, P167, DOI 10.1007/s10143-007-0072-x
   Minniti G, 2018, PITUITARY, V21, P154, DOI 10.1007/s11102-018-0868-4
   Minniti G, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0841-9
   Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-36
   Mohan N, 2017, BMJ CASE REP, V2017
   Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699
   MOLITCH ME, 1992, ENDOCRIN METAB CLIN, V21, P597, DOI 10.1016/S0889-8529(18)30204-4
   MOLITCH ME, 1985, J CLIN ENDOCR METAB, V60, P698, DOI 10.1210/jcem-60-4-698
   Moncet D, 2007, MEDICINA-BUENOS AIRE, V67, P26
   Morgan FH, 2013, PHARMACOTHERAPY, V33, P319, DOI 10.1002/phar.1202
   Much JW, 2009, J NEURO-OPHTHALMOL, V29, P136, DOI 10.1097/WNO.0b013e3181a57d19
   NABARRO JDN, 1987, CLIN ENDOCRINOL, V26, P481, DOI 10.1111/j.1365-2265.1987.tb00805.x
   Netea-Maier RT, 2006, J ENDOCRINOL INVEST, V29, P1001, DOI 10.1007/BF03349214
   Nieman LK, 2015, J CLIN ENDOCR METAB, V100, P2807, DOI 10.1210/jc.2015-1818
   Nishioka H, 2015, ENDOCR PATHOL, V26, P349, DOI 10.1007/s12022-015-9398-z
   O'Malley BW, 2007, ARCH OTOLARYNGOL, V133, P1215, DOI 10.1001/archotol.133.12.1215
   O'Malley BW, 2007, INT J RADIAT ONCOL, V69, pS125, DOI 10.1016/j.ijrobp.2007.06.028
   Oldfield EH, 2006, J NEUROSURG, V104, P7, DOI 10.3171/jns.2006.104.1.7
   Oldfield EH, 2003, J NEUROSURG, V98, P948, DOI 10.3171/jns.2003.98.5.0948
   Osamura RY, 2017, WHO CLASSIFICATION T, P14
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Ozer E, 2013, LARYNGOSCOPE, V123, P2176, DOI 10.1002/lary.24034
   Pereira AM, 2010, NEUROENDOCRINOLOGY, V92, P65, DOI 10.1159/000314317
   Pereira AM, 2004, J CLIN ENDOCR METAB, V89, P71, DOI 10.1210/jc.2003-030849
   PERNECZKY A, 1999, KEYHOLE CONCEPT NEUR
   Petersenn S, 2017, ENDOCRINE, V57, P156, DOI 10.1007/s12020-017-1316-3
   Petrossians P, 2017, ENDOCR-RELAT CANCER, V24, P505, DOI 10.1530/ERC-17-0253
   PIRPIRIS M, 1993, AM J HYPERTENS, V6, P287, DOI 10.1093/ajh/6.4.287
   Pivonello R, 2017, PITUITARY, V20, P46, DOI 10.1007/s11102-017-0797-7
   Pivonello R, 2015, ENDOCR REV, V36, P385, DOI 10.1210/er.2013-1048
   Pivonello R, 2014, CLIN ENDOCRINOL, V81, P408, DOI 10.1111/cen.12431
   Pivonello R, 2009, J CLIN ENDOCR METAB, V94, P223, DOI 10.1210/jc.2008-1533
   Plockinger U, 2012, EUR J ENDOCRINOL, V166, P223, DOI 10.1530/EJE-11-0737
   PRINCEN HMG, 1986, J CLIN INVEST, V78, P1064, DOI 10.1172/JCI112662
   REINA IJ, 1989, ACTA ENDOCRINOL-COP, V121, P185
   Reitmeyer M, 2002, MOL CELL ENDOCRINOL, V197, P73, DOI 10.1016/S0303-7207(02)00281-2
   Renehan AG, 2000, J CLIN ENDOCR METAB, V85, P3417, DOI 10.1210/jc.85.9.3417
   Rizzoli P, 2016, NEUROSURGERY, V78, P316, DOI 10.1227/NEU.0000000000001067
   Rockall AG, 2003, EUR J ENDOCRINOL, V149, P561, DOI 10.1530/eje.0.1490561
   Rogers B, 2009, PERCEPTION, V38, P907, DOI 10.1068/pmkrog
   ROTSTEIN DM, 1992, J MED CHEM, V35, P2818, DOI 10.1021/jm00093a015
   Sandstrom H, 2016, RADIOTHER ONCOL, V121, P180, DOI 10.1016/j.radonc.2016.10.014
   Sathyapalan T, 2012, EXPERT REV ANTICANC, V12, P669, DOI [10.1586/ERA.12.27, 10.1586/era.12.27]
   SATO A, 1994, HYPERTENSION, V23, P25, DOI 10.1161/01.HYP.23.1.25
   Schmidek HH, 2000, SCHMIDEK SWEET OPERA, P385
   Schopohl J, 2015, PITUITARY, V18, P604, DOI 10.1007/s11102-014-0618-1
   Sebastian P, 2016, REP PRACT ONCOL RADI, V21, P466, DOI 10.1016/j.rpor.2016.06.002
   Shahlaie K, 2010, CURR OPIN ENDOCRINOL, V17, P369, DOI 10.1097/MED.0b013e32833abcba
   Sheehan J, 2016, NEUROSURGERY, V79, pE539, DOI 10.1227/NEU.0000000000001385
   Sheehan JP, 2011, J NEUROSURG, V114, P303, DOI 10.3171/2010.5.JNS091635
   Sheehan JP, 2005, J NEUROSURG, V102, P678, DOI 10.3171/jns.2005.102.4.0678
   Shimon I, 2004, J ENDOCRINOL INVEST, V27, P721, DOI 10.1007/BF03347512
   SHIPLEY JE, 1992, SLEEP, V15, P514, DOI 10.1093/sleep/15.6.514
   Simeoli C, 2015, ENDOCRINE, V50, P725, DOI 10.1007/s12020-015-0557-2
   Sitruk-Ware R, 2003, CONTRACEPTION, V68, P409, DOI 10.1016/S0010-7824(03)00171-9
   Solari D, 2014, HAND CLINIC, V124, P291, DOI 10.1016/B978-0-444-59602-4.00019-8
   SONINO N, 1987, NEW ENGL J MED, V317, P812, DOI 10.1056/NEJM198709243171307
   SONINO N, 1991, CLIN ENDOCRINOL, V35, P347, DOI 10.1111/j.1365-2265.1991.tb03547.x
   Stafford SL, 2003, INT J RADIAT ONCOL, V55, P1177, DOI 10.1016/S0360-3016(02)04380-8
   Swearingen B, 2012, J CLIN ENDOCR METAB, V97, P1073, DOI 10.1210/jc.2011-3237
   Tabaee A, 2009, NEUROSURGERY, V64, P288, DOI 10.1227/01.NEU.0000338069.51023.3C
   Terzolo M, 2005, J CLIN ENDOCR METAB, V90, P84, DOI 10.1210/jc.2004-0240
   Thaler ER, 1999, AM J RHINOL, V13, P303, DOI 10.2500/105065899782102827
   Thapar K, 2001, BRAIN TUMORS, P804
   Theodoropoulou M, 2004, J ENDOCRINOL, V183, P385, DOI 10.1677/joe.1.05616
   Tichomirowa MA, 2009, J INTERN MED, V266, P5, DOI 10.1111/j.1365-2796.2009.02109.x
   TISHLER RB, 1993, INT J RADIAT ONCOL, V27, P215, DOI 10.1016/0360-3016(93)90230-S
   Trementino L, 2016, HORM METAB RES, V48, P290, DOI 10.1055/s-0042-101347
   Trevillot V, 2013, EUR ANN OTORHINOLARY, V130, P201, DOI 10.1016/j.anorl.2012.03.010
   Trifiletti DM, 2018, INT J RADIAT ONCOL, V101, P610, DOI 10.1016/j.ijrobp.2018.02.023
   Trouillas J, 2013, ACTA NEUROPATHOL, V126, P123, DOI 10.1007/s00401-013-1084-y
   Turcu AF, 2013, J CLIN ENDOCR METAB, V98, P1812, DOI 10.1210/jc.2012-4171
   Tuvia S, 2014, PHARM RES-DORDR, V31, P2010, DOI 10.1007/s11095-014-1303-9
   van den Bosch OFC, 2014, CLIN ENDOCRINOL, V80, P184, DOI 10.1111/cen.12286
   Vandeva S, 2010, BEST PRACT RES CL EN, V24, P461, DOI 10.1016/j.beem.2010.03.001
   Varsavsky M, 2013, ENDOCRINOL NUTR, V60, P154, DOI 10.1016/j.endonu.2012.02.009
   Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518
   Vilar L, 2010, PITUITARY, V13, P123, DOI 10.1007/s11102-009-0209-8
   Vitale G, 2004, Minerva Endocrinol, V29, P77
   Vitale Giovanni, 2004, Treat Endocrinol, V3, P309, DOI 10.2165/00024677-200403050-00004
   WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403
   Whitelaw BC, 2012, CLIN ENDOCRINOL, V76, P877, DOI 10.1111/j.1365-2265.2012.04373.x
   Wilson PJ, 2014, J CLIN NEUROSCI, V21, P100, DOI 10.1016/j.jocn.2013.04.007
   Wilson PJ, 2018, J NEUROSURG, V128, P429, DOI 10.3171/2016.11.JNS162286
   Xekouki P, 2012, J CLIN ENDOCR METAB, V97, pE357, DOI 10.1210/jc.2011-1179
   Yasargil MG, 1984, MICRONEUROSURGERY, V1, P215
   Yasargil MG, 1996, MICRONEUROSURGERY MI, VIV, P200
   Zaidi HA, 2017, NEUROSURGERY, V81, P659, DOI 10.1093/neuros/nyx073
   Zhao K, 2016, CLIN NEUROL NEUROSUR, V150, P139, DOI 10.1016/j.clineuro.2016.09.009
NR 263
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 695
EP 709
DI 10.1016/j.wneu.2019.03.049
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300313
PM 31266132
DA 2020-05-12
ER

PT J
AU de Divitiis, O
   d'Avella, E
   de Notaris, M
   Di Somma, A
   De Rosa, A
   Solari, D
   Cappabianca, P
AF de Divitiis, Oreste
   d'Avella, Elena
   de Notaris, Matteo
   Di Somma, Alberto
   De Rosa, Andrea
   Solari, Domenico
   Cappabianca, Paolo
TI The (R)evolution of Anatomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Cadaver laboratory; Cultural nomadism; Endoscopy; Skull base
ID ENDOSCOPIC ENDONASAL APPROACH; OPTIC-NERVE DECOMPRESSION; SUPERIOR
   ORBITAL FISSURE; INTERNAL CAROTID-ARTERY; ASSISTED BRAIN SURGERY;
   COMPUTER-BASED MODEL; SKULL BASE LESIONS; ANGLE-OF-ATTACK;
   TRANSSPHENOIDAL APPROACH; PTERYGOPALATINE FOSSA
AB In the study and practice of neurosurgery at the "Federico II" University of Naples, a central role has always been reserved for anatomy. Based on worldwide cooperation, the meaning of anatomical research has evolved from methodological investigation to an educational and communication tool. The contribution of our school to the anatomical data on the sellar region has been chronologically reviewed in the present report. The path that brought us to focus on the endoscopic endonasal anatomy has been presented, together with the evolution of anatomical investigation. The confidence achieved with decades of cadaveric laboratory studies has changed the profile of our anatomical investigations. The quantification and comparison became essential in these studies owing to their effect on surgical application and advanced imaging techniques entered the field of anatomical dissection. Anatomy at our school is an evolving science Our efforts in anatomical scientific publications and organization of participatory courses have made us a center of reference for endoscopic endonasal surgery and have allowed us to share our knowledge with other specialists in this field.
C1 [de Divitiis, Oreste; d'Avella, Elena; Di Somma, Alberto; De Rosa, Andrea; Solari, Domenico; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
   [de Notaris, Matteo] Hosp G Rummo, Dept Neurosurg, Benevento, Italy.
RP d'Avella, E (reprint author), Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
EM elenadavella@gmail.com
RI Di Somma, Alberto/AAG-5690-2020
OI Di Somma, Alberto/0000-0002-3253-3448
CR Adawi MM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.058
   Alfieri A, 2003, NEUROSURGERY, V52, P374, DOI 10.1227/01.NEU.0000044562.73763.00
   Alfieri A, 2001, NEUROSURGERY, V49, P354, DOI 10.1097/00006123-200108000-00017
   Alfieri A, 2001, NEUROSURGERY, V48, P827, DOI 10.1097/00006123-200104000-00027
   Almeida JP, 2018, J NEUROSURG, V128, P1885, DOI 10.3171/2017.3.JNS163110
   AlQahtani A, 2015, ACTA OTORHINOLARYNGO, V35, P173
   ANDERSON RL, 1981, ARCH OPHTHALMOL-CHIC, V99, P120
   Aoun SG, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2012.05.024
   Aydin S, 2007, J Neurosurg Sci, V51, P129
   Bernardo A, 2003, NEUROSURGERY, V52, P499, DOI 10.1227/01.NEU.0000047813.32607.68
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1015, DOI 10.1016/j.wneu.2017.06.140
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1030, DOI [10.1016/J.WNEU.2017.06.158, 10.1016/j.wneu.2017.06.158]
   Biroli Francesco, 2008, Neurosurgery, V62, P273, DOI 10.1227/01.neu.0000317404.31336.69
   Bly RA, 2014, J NEUROL SURG PART B, V75, P11, DOI 10.1055/s-0033-1353363
   Cappabianca P, 1999, SKULL BASE SURG, V9, P109, DOI 10.1055/s-2008-1058157
   Cappabianca P, 1998, MINIM INVAS NEUROSUR, V41, P66, DOI 10.1055/s-2008-1052019
   Cappabianca P, 2004, CHILD NERV SYST, V20, P796, DOI 10.1007/s00381-004-0933-3
   Cappabianca P, 2004, NEUROSURGERY, V54, P1043, DOI 10.1227/01.NEU.0000119325.14116.9C
   Cappabianca P, 2002, CLIN NEUROL NEUROSUR, V104, P387, DOI 10.1016/S0303-8467(02)00022-7
   Cappabianca P, 2001, NEUROSURGERY, V49, P473, DOI 10.1097/00006123-200108000-00042
   Cappabianca P, 1999, NEUROSURGERY, V45, P392, DOI 10.1097/00006123-199908000-00041
   Cappabianca P, 2017, TRANSSPHENOIDAL SURG, P213
   Cappabianca P, 2016, ENDOSCOPIC PITUITARY
   CAPPABIANCA P, 2001, ATLAS ENDOSCOPIC ANA
   Cappabianca P, 2008, NEUROSURGERY, V63, P240, DOI 10.1227/01.NEU.0000327038.09638.37
   Cappabianca P, 2015, NEUROSURG CLIN N AM, V26, P323, DOI 10.1016/j.nec.2015.03.007
   Cappabianca P, 2010, ACTA NEUROCHIR, V152, P897, DOI 10.1007/s00701-009-0580-2
   Cappabianca P, 2009, SURG NEUROL, V71, P597, DOI 10.1016/j.surneu.2008.03.015
   Cappabianca P, 2009, ACTA NEUROCHIR, V151, P69, DOI 10.1007/s00701-008-0172-6
   Carrau RL, 1996, LARYNGOSCOPE, V106, P914, DOI 10.1097/00005537-199607000-00025
   Castelnuovo P, 2013, SURG ANATOMY INTERNA
   Cavallo LM, 2007, CHILD NERV SYST, V23, P665, DOI 10.1007/s00381-007-0332-7
   Cavallo LM, 2007, NEUROSURGERY S, V61, P33, DOI DOI 10.1227/01.NEU.0000289708.49684.47
   Cavallo LM, 2016, ATLAS SELLAR PARASEL, P3
   Cavallo LM, 2011, TRANSNASAL ENDOSCOPI, P265
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE2
   Cavallo Luigi M, 2005, Neurosurg Focus, V19, pE5
   Cavallo LM, 2015, WORLD NEUROSURG, V83, P160, DOI 10.1016/j.wneu.2014.10.018
   Cavallo LM, 2010, WORLD NEUROSURG, V73, P301, DOI 10.1016/j.wneu.2010.02.021
   Cavallo Luigi Maria, 2005, Neurosurgery, V56, P379, DOI 10.1227/01.NEU.0000156548.30011.D4
   Cavallo LM, 2015, WORLD NEUROSURG, V84, P267, DOI 10.1016/j.wneu.2015.03.007
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   Cebula N, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.021
   Chen HI, 2014, J NEUROSURG, V120, P1428, DOI 10.3171/2014.2.JNS131060
   Chen JCT, 1999, NEUROSURGERY, V45, P883, DOI 10.1097/00006123-199910000-00031
   d'Avella E, 2008, NEUROSURGERY, V62, P305, DOI 10.1227/01.NEU.0000310691.25061.8C
   d'Avella E, 2015, ACTA NEUROCHIR, V157, P1495, DOI 10.1007/s00701-015-2497-2
   d'Avella E, 2014, NEUROSURG REV, V37, P253, DOI 10.1007/s10143-014-0526-x
   Dallan I, 2010, MINIM INVAS NEUROSUR, V53, P261, DOI 10.1055/s-0030-1263105
   Dallan I, 2017, J NEUROSURG, V127, P622, DOI 10.3171/2016.8.JNS16465
   Dallan I, 2015, EUR ARCH OTO-RHINO-L, V272, P3851, DOI 10.1007/s00405-015-3556-2
   Dallan I, 2015, WORLD NEUROSURG, V84, P97, DOI 10.1016/j.wneu.2015.02.034
   Dallan I, 2014, EUR ARCH OTO-RHINO-L, V271, P2197, DOI 10.1007/s00405-013-2854-9
   Dallan I, 2013, EUR ARCH OTO-RHINO-L, V270, P1643, DOI 10.1007/s00405-012-2281-3
   Dallan I, 2010, NEUROSURGERY, V67, P1, DOI 10.1227/01.NEU.0000354351.00684.B9
   Dallan L, 2018, OPER NEUROSURG, V14, P243, DOI 10.1093/ons/opx100
   de Divitiis E, 2002, NEUROSURGERY, V51, P699, DOI 10.1097/00006123-200209000-00016
   de Divitiis E, 2003, ENDOSCOPIC ENDONASAL
   de Divitiis E, 2002, NEUROSURGERY, V51, P705
   de Divitiis O, 2002, NEUROSURGERY, V50, P563, DOI 10.1097/00006123-200203000-00026
   de Notaris M, 2013, WORLD NEUROSURG S, V79
   de Notaris M, 2008, NEUROSURG REV, V31, P309, DOI 10.1007/s10143-008-0130-z
   de Notaris M, 2014, WORLD NEUROSURG, V82, pS41, DOI 10.1016/j.wneu.2014.07.024
   de Notaris M, 2014, LARYNGOSCOPE, V124, P2231, DOI 10.1002/lary.24693
   de Notaris M, 2014, WORLD NEUROSURG, V82, pE387, DOI 10.1016/j.wneu.2012.10.071
   de Notaris M, 2012, J NEUROSURG, V116, P622, DOI 10.3171/2011.11.JNS111162
   de Notaris M, 2011, WORLD NEUROSURG, V75, P106, DOI 10.1016/j.wneu.2010.09.033
   de Notaris M, 2010, CHILD NERV SYST, V26, P621, DOI 10.1007/s00381-010-1107-0
   de Notaris M, 2009, NEUROSURGERY, V65, P42, DOI [10.1227/01.NEU.000034/001.62158.57, 10.1227/01.NEU.0000347001.62158.57]
   Di Somma A, 2018, J NEUROSURG, V129, P1203, DOI 10.3171/2017.4.JNS162749
   Di Somma A, 2018, OPER NEUROSURG, V15, P567, DOI 10.1093/ons/opx256
   Di Somma A, 2018, ACTA NEUROCHIR, V160, P707, DOI 10.1007/s00701-017-3448-x
   Di Somma A, 2017, J NEUROSURG, V127, P199, DOI 10.3171/2016.8.JNS16566
   Di Somma A, 2017, WORLD NEUROSURG, V101, P227, DOI 10.1016/j.wneu.2017.01.117
   Di Somma A, 2014, RHINOLOGY, V52, P195, DOI 10.4193/Rhin13.165
   Di Somma A, 2014, BIOMED RES INT, DOI 10.1155/2014/703792
   Esposito F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151533
   Evans CH, 2016, SURG CLIN N AM, V96, P71, DOI 10.1016/j.suc.2015.09.005
   Fortes FSG, 2012, LARYNGOSCOPE, V122, P445, DOI 10.1002/lary.22395
   Frati P, 2006, J NEUROSURG, V105, P789, DOI 10.3171/jns.2006.105.5.789
   FREEMAN W, 1948, LANCET, V252, P371, DOI 10.1016/S0140-6736(48)90947-7
   Fries G, 1998, NEUROSURGERY, V42, P226, DOI 10.1097/00006123-199802000-00008
   Goel A, 2013, WORLD NEUROSURG, V80, P813, DOI 10.1016/j.wneu.2012.10.029
   Gonzalez LF, 2002, NEUROSURGERY, V50, P550, DOI 10.1097/00006123-200203000-00023
   HAKUBA A, 1989, J NEUROSURG, V71, P699, DOI 10.3171/jns.1989.71.5.0699
   Hechl PS, 1997, ENDOSCOPIC ANATOMY P
   Holland JP, 2011, J SURG EDUC, V68, P110, DOI 10.1016/j.jsurg.2010.10.002
   Iaconetta G, 2007, NEUROSURGERY, V61, P7, DOI 10.1227/01.NEU.0000280037.32286.F2
   Iaconetta G, 2018, WORLD NEUROSURG, V109, pE486, DOI 10.1016/j.wneu.2017.10.006
   Iaconetta G, 2013, NEUROSURG REV, V36, P227, DOI 10.1007/s10143-012-0426-x
   Iaconetta G, 2010, NEUROSURGERY, V66, P593, DOI 10.1227/01.NEU.0000365422.36441.C8
   Jane Jr JA, 2002, OPER TECHN NEUROSURG, V5, P226
   Jho HD, 1996, ACTA NEUROCHIR, V138, P1416, DOI 10.1007/BF01411120
   Kaptain GJ, 2001, NEUROSURGERY, V49, P94, DOI 10.1097/00006123-200107000-00014
   Kassam A, 2007, J NEUROSURG, V106, P75, DOI 10.3171/ped.2007.106.2.75
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   Koppe M, 2013, J CRANIOFAC SURG, V24, P1616, DOI 10.1097/SCS.0b013e3182a2d635
   LAWS ER, 1980, J NEUROSURG, V52, P661, DOI 10.3171/jns.1980.52.5.0661
   Lim JH, 2012, J NEUROL SURG PART B, V73, P394, DOI 10.1055/s-0032-1329617
   LINBERG JV, 1981, ARCH OPHTHALMOL-CHIC, V99, P113, DOI 10.1001/archopht.1981.03930010115015
   Magro F, 2006, NEUROSURGERY, V59, P237, DOI 10.1227/01.NEU.0000233977.79721.17
   Mason RB, 1997, J NEUROSURG, V87, P343, DOI 10.3171/jns.1997.87.3.0343
   Messina A, 2007, NEUROSURG REV, V30, P189, DOI 10.1007/s10143-007-0084-6
   Moe KS, 2010, NEUROSURGERY, V67, P16, DOI 10.1227/01.NEU.0000373431.08464.43
   Moon K, 2010, NEUROSURGERY, V67, P799, DOI 10.1227/01.NEU.0000383135.92953.A3
   O'BRIEN M D, 1973, Stroke, V4, P201
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Prosser JD, 2011, LARYNGOSCOPE, V121, P1601, DOI 10.1002/lary.21863
   Ramakrishna R, 2016, J CLIN NEUROSCI, V24, P99, DOI 10.1016/j.jocn.2015.07.021
   Reisch R, 2003, SURG NEUROL, V59, P223, DOI 10.1016/S0090-3019(02)01037-6
   Robison RA, 2013, WORLD NEUROSURG, V80, pS2, DOI 10.1016/j.wneu.2013.08.002
   Snyderman C, 2007, LARYNGOSCOPE, V117, P699, DOI 10.1097/mlg.0b013e318031c817
   Solari D, 2007, J NEUROSURG, V106, P157, DOI 10.3171/jns.2007.106.1.157
   Solari D, 2016, J NEUROSURG SCI, V60, P454
   Solari D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139609
   Solari D, 2014, WORLD NEUROSURG, V82, pS164, DOI 10.1016/j.wneu.2014.08.005
   Solari D, 2014, WORLD NEUROSURG, V81, P279, DOI 10.1016/j.wneu.2013.02.078
   Solari D, 2012, TRANSL MED UNISA, V2, P36
   Urgun K, 2016, TURK NEUROSURG, V26, P568, DOI 10.5137/1019-5149.JTN.12293-14.1
   WEISS MH, 1987, SURG 3 VENTRICLE, P476
   Wilson DA, 2014, WORLD NEUROSURG, V82, pE487, DOI 10.1016/j.wneu.2013.02.003
   Wilson SR, 2007, AM J EMERG MED, V25, P208, DOI 10.1016/j.ajem.2006.08.008
NR 124
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP 710
EP 735
DI 10.1016/j.wneu.2019.03.050
PG 26
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300314
PM 31266133
DA 2020-05-12
ER

PT J
AU Akamatsu, Y
   Kashimura, H
   Suzuki, T
   Aso, K
   Oshida, S
   Fujiwara, S
   Kubo, Y
   Ogasawara, K
AF Akamatsu, Yosuke
   Kashimura, Hiroshi
   Suzuki, Taro
   Aso, Kenta
   Oshida, Sotaro
   Fujiwara, Shunrou
   Kubo, Yoshitaka
   Ogasawara, Kuniaki
TI Impact of the Intracranial Course of Internal Carotid Artery on Optimal
   Surgical Approach for Posterior Communicating Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior temporal approach; Internal carotid artery; Low-lying;
   Posterior communicating artery aneurysms; Transsylvian approach
ID FENESTRATED CLIPS; COMPLEX
AB BACKGROUND: The anterior temporal approach (ATA) has been reported as suitable for surgical clipping of posteriorly projecting internal carotid artery (ICA) aneurysms. As the ICA follows a variable course, tortuosity of the ICA may affect visualization of the aneurysm. The aim of this study was to investigate the impact of the intracranial course of the ICA and aneurysm projection on surgical approach.
   METHODS: Consecutive patients with posterior communicating artery aneurysms treated with clipping at our hospital between May 2015 and April 2018 were retrospectively reviewed. When the transsylvian approach (TSA) could not achieve adequate exposure of the aneurysm, the ATA was subsequently performed. Distance between the ICA and the anterior and posterior clinoid line, angle between the midline and the C1 segment of the ICA, and aneurysm projection were compared between ATA and TSA groups.
   RESULTS: Of 52 patients (40 ruptured, 12 unruptured), 12 were in the ATA group, and 40 were in the TSA group. Mean ICAeanterior and posterior clinoid distance was significantly shorter in the ATA group than in the TSA group (P = 0.002), and mean midline-C1 angle was significantly larger in the ATA group than in the TSA group (P < 0.0001). The ATA group was associated with a greater frequency of posteriorly projecting aneurysms (12 of 12; 100%) than the TSA group (9 of 40; 22.5%) (P < 0.00001).
   CONCLUSIONS: A low-lying, laterally projecting intracranial ICA and posteriorly projecting aneurysm are predictors of the necessity for the ATA in the surgical clipping of posterior communicating artery aneurysms.
C1 [Akamatsu, Yosuke; Kashimura, Hiroshi; Suzuki, Taro; Aso, Kenta; Oshida, Sotaro] Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
   [Akamatsu, Yosuke; Fujiwara, Shunrou; Kubo, Yoshitaka; Ogasawara, Kuniaki] Iwate Med Univ, Dept Neurosurg, Morioka, Iwate, Japan.
RP Kashimura, H (reprint author), Iwate Prefectural Chubu Hosp, Dept Neurosurg, Kitakami, Iwate, Japan.
EM h-kashimura@pref.iwate.jp
CR Anan M, 2014, CLIN NEUROL NEUROSUR, V123, P169, DOI 10.1016/j.clineuro.2014.05.006
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Fischer E, 1938, ZENTRALBL NEUROCHIR, V3, P300
   FUJITA S, 1986, J NEUROSURG, V65, P122, DOI 10.3171/jns.1986.65.1.0122
   Fukuda H, 2016, NEUROSURGERY, V78, P381, DOI 10.1227/NEU.0000000000001131
   HEROS RC, 1993, NEUROSURGERY, V33, P244
   Katsuno Makoto, 2015, Surg Neurol Int, V6, P10, DOI 10.4103/2152-7806.149843
   Kazumata K, 2003, SURG CEREBRAL STROKE, V31, P431
   Kim JH, 2009, SURG NEUROL, V72, P142, DOI 10.1016/j.surneu.2008.03.045
   Kinouchi H, 2004, J NEUROSURG, V101, P989, DOI 10.3171/jns.2004.101.6.0989
   Nathal Edgar, 2005, Neurosurgery, V56, P178
   OCHIAI C, 1989, ACTA NEUROCHIR, V99, P117, DOI 10.1007/BF01402319
   Oshida S, 2018, WORLD NEUROSURG, V116, P230, DOI 10.1016/j.wneu.2018.05.135
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   SANO K, 1994, ACTA NEUROCHIR, V130, P14, DOI 10.1007/BF01405498
   Saura H, 2018, WORLD NEUROSURG, V117, P1, DOI 10.1016/j.wneu.2018.05.215
   SUGITA K, 1981, J NEUROSURG, V54, P346, DOI 10.3171/jns.1981.54.3.0346
   SUGITA K, 1982, J NEUROSURG, V57, P240, DOI 10.3171/jns.1982.57.2.0240
   Yang I, 2008, NEUROSURGERY, V62, P371, DOI 10.1227/01.NEU.0000312719.93685.9A
   Yasargil MG, 1984, MICRONEUROSURGERY, VI, P299
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E142
EP E148
DI 10.1016/j.wneu.2019.03.002
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300020
PM 30872191
DA 2020-05-12
ER

PT J
AU Akinduro, OO
   Izzo, A
   Lu, VM
   Ricciardi, L
   Trifiletti, D
   Peterson, JL
   Bernet, V
   Donaldson, A
   Eggenberger, E
   Olomu, O
   Reimer, R
   Wharen, R
   Quinones-Hinojosa, A
   Chaichana, KL
AF Akinduro, Oluwaseun O.
   Izzo, Alessandro
   Lu, Victor M.
   Ricciardi, Luca
   Trifiletti, Daniel
   Peterson, Jennifer L.
   Bernet, Victor
   Donaldson, Angela
   Eggenberger, Eric
   Olomu, Osarenoma
   Reimer, Ronald
   Wharen, Robert
   Quinones-Hinojosa, Alfredo
   Chaichana, Kaisorn L.
TI Endocrine and Visual Outcomes Following Gross Total Resection and
   Subtotal Resection of Adult Craniopharyngioma: Systematic Review end
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniopharyngioma; Gross total resection; Panhypopituitarism; Subtotal
   resection
ID QUALITY-OF-LIFE; CHILDHOOD CRANIOPHARYNGIOMA; ENDONASAL RESECTION;
   DIABETES-INSIPIDUS; SURGICAL-TREATMENT; PITUITARY-STALK; MANAGEMENT;
   CHILDREN; SURGERY; RECURRENCE
AB OBJECTIVE: The optimal surgical strategy for management of adult patients with craniopharyngioma remains controversial. To analyze the functional outcomes of adult patients with gross total resection (GTR) and subtotal resection (STR) of craniopharyngioma.
   METHODS: MEDLINE, EMBASE, Scopus, and Cochrane databases were searched from inception to July 19, 2018, for articles comparing postoperative endocrine function, vision, complications, and recurrence rates for adult patients with GTR and STR of craniopharyngioma. The articles were analyzed by meta-analysis of proportions using a random-effects model to calculate summary odds ratios (ORs).
   RESULTS: The initial search resulted in 2468 studies and 540 studies selected for full text review. Seventeen studies were included in the final analyses with 748 patients in the GTR cohort and 559 patients in the STR cohort. GTR resulted in a significantly lower likelihood of recurrence when compared with STR (OR, 0.106; 95% confidence interval [CI], 0.067-0.168; P < 0.001), hut a significantly greater likelihood of panhypopituitarism (OR, 2.063; 95% CI, 1.058-4.024; P = 0.034) and permanent diabetes insipidus (OR, 2.776; 95% CI, 1.321-5.832; P = 0.007). There was no significant difference between the groups for postoperative worsened vision (P = 0.868), improved vision (P = 0.876), pathologic weight gain (P = 0.724), cerebrospinal fluid leak (P = 0.788), complications (P = 0.656), or death (P = 0.261).
   CONCLUSIONS: This is the first systematic review of functional outcomes of adult patients with craniopharyngioma. GTR results in decreased likelihood of recurrence, but increased likelihood of postoperative panhypopituitarsm and permanent diabetes insipidus. Surgeons should be aware of these associations when determining the optimal operative strategy for adult patients with craniopharyngioma.
C1 [Akinduro, Oluwaseun O.; Reimer, Ronald; Wharen, Robert; Quinones-Hinojosa, Alfredo; Chaichana, Kaisorn L.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Trifiletti, Daniel; Peterson, Jennifer L.] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL 32224 USA.
   [Bernet, Victor] Mayo Clin, Dept Endocrinol, Jacksonville, FL 32224 USA.
   [Eggenberger, Eric] Mayo Clin, Dept Neuroopthalmol, Jacksonville, FL 32224 USA.
   [Donaldson, Angela; Olomu, Osarenoma] Mayo Clin, Dept Otolaryngol, Jacksonville, FL 32224 USA.
   [Lu, Victor M.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Izzo, Alessandro; Ricciardi, Luca] Catholic Univ, Dept Neurosurg, Rome, Italy.
RP Chaichana, KL (reprint author), Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
EM chaichana.kaisorn@mayo.edu
RI Ricciardi, Luca/L-5405-2019
OI Ricciardi, Luca/0000-0001-5110-8386; Trifiletti,
   Daniel/0000-0002-9150-2916
FU Mayo Professorship; Mayo Clinic Clinician Investigator Award; RACER
   Clinical Investigator's award
FX The authors would like to thank Tara Brigham of the Mayo Clinic library
   for her gracious assistance with the search strategy. Dr.
   Quinones-Hinojosa was supported by the Mayo Professorship and the Mayo
   Clinic Clinician Investigator Award. Dr. Chaichana was supported by the
   RACER Clinical Investigator's award.
CR Abe T, 1997, Neurosurg Focus, V3, pe4
   AMENDOLA BE, 1985, J CLIN ONCOL, V3, P252, DOI 10.1200/JCO.1985.3.2.252
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Barua Kanak Kanti, 2003, Kobe Journal of Medical Sciences, V49, P123
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bosnjak R, 2013, RADIOL ONCOL, V47, P266, DOI 10.2478/raon-2013-0036
   Buttner M, 2017, ENDOCRINE, V58, P14, DOI 10.1007/s12020-017-1377-3
   Bunin GR, 1998, J NEUROSURG, V89, P547, DOI 10.3171/jns.1998.89.4.0547
   Castro DC, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00090
   Cheng J, 2017, J CRANIOFAC SURG, V28, pE591, DOI 10.1097/SCS.0000000000003920
   Dandurand C, 2018, NEUROSURGERY, V83, P631, DOI 10.1093/neuros/nyx570
   De Bucy C, 2017, EUR J ENDOCRINOL, V177, P1, DOI 10.1530/EJE-17-0048
   Dekkers OM, 2006, EUR J ENDOCRINOL, V154, P483, DOI 10.1530/eje.1.02114
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duff JM, 2000, NEUROSURGERY, V46, P291, DOI 10.1097/00006123-200002000-00007
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Elowe-Gruau E, 2013, J CLIN ENDOCR METAB, V98, P2376, DOI 10.1210/jc.2012-3928
   Erfurth EM, 2013, PITUITARY, V16, P46, DOI 10.1007/s11102-012-0428-2
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Frank G, 2006, NEUROSURGERY, V59, P75, DOI 10.1227/01.NEU.0000219897.98238.A3
   Gardner PA, 2008, J NEUROSURG, V109, P6, DOI 10.3171/JNS/2008/109/7/0006
   Gerganov V, 2014, J NEUROSURG, V120, P559, DOI 10.3171/2013.9.JNS122133
   Guo FY, 2018, CLIN NEUROL NEUROSUR, V167, P162, DOI 10.1016/j.clineuro.2018.02.034
   Hardesty DA, 2018, J NEUROSURG SCI, V62, P310, DOI 10.23736/S0390-5616.18.04331-X
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Karavitaki N, 2005, CLIN ENDOCRINOL, V62, P397, DOI 10.1111/j.1365-2265.2005.02231.x
   Kim Ja Hye, 2013, Ann Pediatr Endocrinol Metab, V18, P161, DOI 10.6065/apem.2013.18.4.161
   Kim YH, 2012, NEUROSURGERY, V71, P715, DOI 10.1227/NEU.0b013e318262146b
   Lamas C, 2014, ENDOCRINOL NUTR, V61, pE15, DOI 10.1016/j.endonu.2014.01.005
   LAWS ER, 1977, J NEUROSURG, V46, P717, DOI 10.3171/jns.1977.46.6.0717
   Lee MH, 2012, J CLIN NEUROSCI, V19, P1005, DOI 10.1016/j.jocn.2011.09.033
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Li K, 2015, CLIN NEUROL NEUROSUR, V136, P20, DOI 10.1016/j.clineuro.2015.05.019
   Lin Y, 2017, PEDIATR NEUROSURG, V52, P155, DOI 10.1159/000455919
   Liu JK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16284
   Marchetti M, 2016, NEUROSURGERY, V78, P638, DOI 10.1227/NEU.0000000000001073
   Merchant TE, 2002, INT J RADIAT ONCOL, V53, P533, DOI 10.1016/S0360-3016(02)02799-2
   Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1
   Moussazadeh N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16299
   Muller HL, 2011, EUR J ENDOCRINOL, V165, P17, DOI 10.1530/EJE-11-0158
   Ozgural O, 2018, J CRANIOFAC SURG, V29, pE572, DOI 10.1097/SCS.0000000000004592
   Park HR, 2017, WORLD NEUROSURG, V103, P465, DOI 10.1016/j.wneu.2017.04.047
   Rao YJ, 2017, J NEURO-ONCOL, V132, P109, DOI 10.1007/s11060-016-2342-3
   Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221
   Roth CL, 2015, OBESITY, V23, P1226, DOI 10.1002/oby.21067
   Schoenfeld A, 2012, J NEURO-ONCOL, V108, P133, DOI 10.1007/s11060-012-0806-7
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Stripp DCH, 2004, INT J RADIAT ONCOL, V58, P714, DOI 10.1016/S0360-3016(03)01570-0
   Tang B, 2018, CLIN NEUROL NEUROSUR, V168, P38, DOI 10.1016/j.clineuro.2018.02.002
   Taussky P, 2011, J NEUROSURG, V115, P55, DOI 10.3171/2011.2.JNS10566
   Tavangar SM, 2004, ENDOCR PATHOL, V15, P339, DOI 10.1385/EP:15:4:339
   THOMSETT MJ, 1980, J PEDIATR-US, V97, P728, DOI 10.1016/S0022-3476(80)80254-X
   Wang GQ, 2018, J SURG RES, V226, P131, DOI 10.1016/j.jss.2018.01.029
   WEINER HL, 1994, NEUROSURGERY, V35, P1001, DOI 10.1227/00006123-199412000-00001
   Wijnen M, 2017, EUR J ENDOCRINOL, V176, P755, DOI 10.1530/EJE-17-0044
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhao XT, 2012, CLIN NEUROL NEUROSUR, V114, P149, DOI 10.1016/j.clineuro.2011.10.004
   Zoli M, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16317
NR 60
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E656
EP E668
DI 10.1016/j.wneu.2019.03.239
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300082
PM 30947004
DA 2020-05-12
ER

PT J
AU Akkaya, E
   Evran, S
   Calis, F
   Cevik, S
   Hanimoglu, H
   Seyithanoglu, MH
   Katar, S
   Karatas, E
   Kocyigit, A
   Saglam, MY
   Hatiboglu, MA
   Kaynar, MY
AF Akkaya, Enes
   Evran, Sevket
   Calis, Fatih
   Cevik, Serdar
   Hanimoglu, Hakan
   Seyithanoglu, Mehmet Hakan
   Katar, Salim
   Karatas, Ersin
   Kocyigit, Abdurrahim
   Saglam, Mustafa Yasin
   Hatiboglu, Mustafa Aziz
   Kaynar, Mehmet Yasar
TI Effects of Intrathecai Verapamil on Cerebral Vasospasm in Experimental
   Rat Study
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT 16th World Congress of Neurosurgery of the
   World-Federation-of-Neurosurgical-Societies (WFNS)
CY AUG 20-25, 2017
CL Istanbul, TURKEY
SP World Federat Neurosurg Soc
DE Aneurysm; Apoptosis; Endothelin-1; Intrathecal verapamil; Oxidative
   stress; Subarachnoid hemorrhage; Vasospasm
ID ANEURYSMAL SUBARACHNOID HEMORRHAGE; CISTERNAL IRRIGATION; MODEL;
   NIMODIPINE; PREVENTION; MANAGEMENT; MECHANISMS; INFUSION; RELEASE
AB BACKGROUND: Verapamil a calcinarn channel blacker, has shown promising results on cerebral vasospasm. However, it has not yet been accepted for treatment or prevention purposes because of the associated side effects, Although the effective results of nimodipine and nicardipine's intrathecal administration are well known, intrathecal verapamil has not been considered earlier. We used an experimental subarachnoid hemorrhage induced vasospasm model for the evaluation of vasodilator and neuroprotective effects of intrathecal verapamil,
   METHODS: A total of 24 Sprague-Davvley rats were randomly divided into the following 3 groups: group 1 (sham), group 2 (subarachnoid hemorrhage), and group 3 {verapamil). A double hemorrhage method was used. Group 2 did not receive any treatment. Verapamil (Eporon, Hem Ilac, Turkey) at a dose of 1000 mu g/kg was given intrathecally to group 3 rats. The animals were euthanized on day 7 of the procedure. Arterial wall thickness and lumen diameter in the basilar arterial cross-sectional areas, endothelin-1 serum level, oxidative stress index, and apoptosis were measured in all groups.
   RESULTS: In the verapamil group, wall thickness, endothelin-1 level, oxidative stress index, and apoptosis were found to be significantly lower than the subarachnoid hemorrhage group, but the lumen diameter was found to be greater, Intrathecal verapamil was found to decrease vasospasm parameters and apoptosis and increase the antioxidant and antiapoptotic pathways.
   CONCLUSIONS: Our findings suggest that intrathecal verapamil can prevent vasospasnt oxidative stress, and apoptosis after experimental subarachnoid hemorrhage.
C1 [Akkaya, Enes] Univ Hlth Sci, Sisli Hamidiye Etfal Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Evran, Sevket] Univ Hlth Sci, Haseki Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Calis, Fatih] Medeniyet Univ, Goztepe Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Cevik, Serdar] Istinye Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Hanimoglu, Hakan] Koc Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Seyithanoglu, Mehmet Hakan; Hatiboglu, Mustafa Aziz] Bezmialem Univ Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Karatas, Ersin; Kocyigit, Abdurrahim] Bezmialem Univ Hosp, Dept Biochem, Istanbul, Turkey.
   [Katar, Salim] Selahaddin Eyyubi State Hosp, Dept Neurosurg, Diyarbakir, Turkey.
   [Saglam, Mustafa Yasin] Agri State Hosp, Dept Pathol, Agri, Turkey.
   [Kaynar, Mehmet Yasar] Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
RP Akkaya, E (reprint author), Univ Hlth Sci, Sisli Hamidiye Etfal Educ & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM drenesnrs@gmail.com
RI Kocyigit, Abdurrahim/P-8685-2019; Cevik, Serdar/G-7161-2018; akkaya,
   enes/AAA-2182-2020; KARATAS, Ersin/G-1852-2016; Kaynar, Mehmet
   Yasar/AAA-3180-2020; EVRAN, Sevket/AAG-3284-2019
OI Kocyigit, Abdurrahim/0000-0003-2335-412X; KARATAS,
   Ersin/0000-0001-6848-7618; Kaynar, Mehmet Yasar/0000-0001-7327-836X;
   Akkaya, Enes/0000-0003-2503-754X
FU Bezmialem Vakif University FundBezmialem Vakif University [3.2015/40]
FX This work was supported by the Bezmialem Vakif University Fund (Project
   Number: 3.2015/40).
CR Baggott CD, 2014, NEUROSURG CLIN N AM, V25, P497, DOI 10.1016/j.nec.2014.04.008
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   Bele S, 2015, ACTA NEUROCHIR, V157, P2041, DOI 10.1007/s00701-015-2597-z
   Borel CO, 2003, STROKE, V34, P427, DOI 10.1161/01.STR.0000053848.06436.AB
   Cahill J, 2006, STROKE, V37, P1868, DOI 10.1161/01.STR.0000226995.27230.96
   Cossu G, 2014, BIOMED RES INT, DOI 10.1155/2014/628597
   Dabus G, 2013, INTERV NEUROL, V2, P30, DOI 10.1159/000354755
   Dudhani RV, 2013, JOVE-J VIS EXP, DOI 10.3791/4157
   Findlay JM, 2016, CAN J NEUROL SCI, V43, P15, DOI 10.1017/cjn.2015.288
   Gules I, 2002, AM J PHYSIOL-HEART C, V283, pH2551, DOI 10.1152/ajpheart.00616.2002
   Kasuya H, 2002, STROKE, V33, P1011, DOI 10.1161/01.STR.0000014563.75483.22
   Kim JH, 2014, NEUROL SCI, V35, P715, DOI 10.1007/s10072-013-1589-0
   Marbacher S, 2008, INTENS CARE MED, V34, P932, DOI 10.1007/s00134-008-0995-x
   Mazumdar Avi, 2006, Neurosurg Focus, V21, pE15
   Meguro T, 2001, NEUROL RES, V23, P761, DOI 10.1179/016164101101199144
   Miller CA, 2006, NEUROCRIT CARE, V5, P215, DOI 10.1385/NCC:5:3:215
   Nishuchi M, 2010, NEUROSURGERY, V66, P158, DOI 10.1227/01.NEU.0000363153.62579.FF
   Raabe A, 2002, NEUROSURGERY, V50, P1006, DOI 10.1097/00006123-200205000-00013
   Rothoerl RD, 2007, NEUROL RES, V29, P636, DOI 10.1179/016164107X240224
   Sasaki T, 2000, STROKE, V31, P1256, DOI 10.1161/01.STR.31.6.1256
   Sayama Christina M, 2006, Neurosurg Focus, V21, pE12, DOI 10.3171/foc.2006.21.3.12
   Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684
   Scott JA, 2006, ANESTH ANALG, V103, P742, DOI 10.1213/01.ane.0000228861.80314.22
   Sorkin LS, 2008, EUR J PHARMACOL, V587, P118, DOI 10.1016/j.ejphar.2008.03.033
   Takasusuki T, 2011, ANESTHESIOLOGY, V115, P153, DOI 10.1097/ALN.0b013e31821950c2
   Vatter H, 2006, NEUROSURGERY, V58, P1190, DOI 10.1227/01.NEU.0000199346.74649.66
NR 26
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1104
EP E1111
DI 10.1016/j.wneu.2019.04.050
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300136
PM 30980985
DA 2020-05-12
ER

PT J
AU Amagasaki, K
   Watanabe, S
   Naemura, K
   Shono, N
   Hosono, A
   Nakaguchi, H
AF Amagasaki, Kenichi
   Watanabe, Saiko
   Naemura, Kazuaki
   Shono, Naoyuki
   Hosono, Atushi
   Nakaguchi, Hiroshi
TI Transposition of the Culprit Artery Passing Between the Facial Nerve and
   Auditory Nerve in Microvascular Decompression Surgery for Hemifacial
   Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Facial and auditory nerve complex;
   Hemifacial spasm; Microvascular decompression
AB BACKGROUND: Decompression of the culprit artery causing hemifacial spasm (HFS), which passes between the facial nerve (cranial nerve [CN] VII) and the auditory nerve (CN VIII), can he difficult, especially if the artery compresses CN VII right after passing between the 2 nerves. Perforators or small arteries branching from near the compression site to adjacent structures can hinder the decompression process because such vessels can anchor the passing condition. The effect of such perforators or small arteries on the decompression process in such cases was investigated.
   METHODS: The culprit artery passed between any part of CN VII and VIII in 59 of 396 consecutive patients with HFS who underwent microvascular decompression. The culprit artery compressed CN VII right after passing between the 2 nerves in 22 of the 59 cases. Direction of the perforators or small arteries from near the compression site and direction of decompression of the culprit artery were analyzed in these 22 cases.
   RESULTS: Perforators or small arteries were observed in 20 cases, predominantly in the medial direction. The culprit artery was mobilized toward the petrous bone direction in most cases. No clear relationship was found between the 2 factors.
   CONCLUSIONS: Variation of curvature or tortuosity of the culprit artery and length of perforators or small branches may also have affected the decompression process and the directions. Adequate dissection near the compression site to obtain maximum mobilization of the culprit artery is necessary to achieve successful decompression in such cases.
C1 [Amagasaki, Kenichi; Watanabe, Saiko; Naemura, Kazuaki; Shono, Naoyuki; Hosono, Atushi; Nakaguchi, Hiroshi] Mitsui Mem Hosp, Dept Neurosurg, Tokyo, Japan.
RP Amagasaki, K (reprint author), Mitsui Mem Hosp, Dept Neurosurg, Tokyo, Japan.
EM amagasaki@mitsuihosp.or.jp
CR Amagasaki Kenichi, 2017, Surg Neurol Int, V8, P67, DOI 10.4103/sni.sni_8_17
   Amagasaki K, 2015, BRIT J NEUROSURG, V29, P347, DOI 10.3109/02688697.2014.1003033
   Attabib N, 2007, J NEUROSURG, V106, P929, DOI 10.3171/jns.2007.106.5.929
   Bejjani GK, 1997, J NEUROSURG, V86, P728, DOI 10.3171/jns.1997.86.4.0728
   Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   Khoo HM, 2012, NEUROSURGERY, V71, P25, DOI 10.1227/NEU.0b013e318246aa74
   Lee JM, 2018, J NEUROSURG, V129, P299, DOI 10.3171/2017.3.JNS162869
   LISTER JR, 1982, NEUROSURGERY, V10, P170
   MARTIN RG, 1980, NEUROSURGERY, V6, P483, DOI 10.1227/00006123-198005000-00001
   Masuoka J, 2011, NEUROSURG REV, V34, P373, DOI 10.1007/s10143-011-0310-0
   Ohtani K, 2016, WORLD NEUROSURG, V92, P171, DOI 10.1016/j.wneu.2016.05.005
   Otani N, 2018, J NEUROSURG, V128, P1522, DOI 10.3171/2017.1.JNS161243
   Rawlinson J N, 1988, Br J Neurosurg, V2, P173, DOI 10.3109/02688698808992667
   Shigeno T, 2002, NEUROL MED-CHIR, V42, P184, DOI 10.2176/nmc.42.184
   Sindou M, 2008, NEUROSURGERY, V63, P341, DOI 10.1227/01.NEU.0000327022.79171.D6
   Tanaka Y, 2014, NEUROL MED-CHIR, V54, P483, DOI 10.2176/nmc.tn2012-0296
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E996
EP E1002
DI 10.1016/j.wneu.2019.04.020
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300124
PM 30974269
DA 2020-05-12
ER

PT J
AU Bae, IS
   Yi, HJ
   Ko, Y
   Kim, YS
   Chun, HJ
   Choi, KS
AF Bae, In-Suk
   Yi, Hyeong-Joong
   Ko, Yong
   Kim, Young Soo
   Chun, Hyoung-Joon
   Choi, Kyu-Sun
TI Practical Incidence of Complications and Degree of Patient Satisfaction
   After Endovascular Coil Embolization for Unruptured Intracranial
   Saccular Aneurysm Based on Patients' Surveys
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Endovascular coil embolization; Questionnaire;
   Satisfaction; Unruptured intracranial aneurysms (UIAs)
ID GUGLIELMI DETACHABLE COILS; RETROPERITONEAL HEMATOMA; CLOSURE DEVICES;
   TRIAL ISAT; ANGIOSEAL; RISK; INTERVENTION; EFFICACY; PUNCTURE; THERAPY
AB OBJECTIVE: Endovascular treatment for unruptured intracranial aneurysms (UIAs) has been regarded as second to none management nowadays as the result of its proven efficacy and need for less-invasive treatment. Most researchers have focused on the anatomical outcome after endovascular treatment, so in this study we estimated the real incidence of untoward effect and degree of patients' satisfaction based on s survey.
   METHODS: This retrospective study was approved by the institutional review board, and 112 patients treated for saccular UIAs were evaluated among a total of 135 patients. After informed consentwas obtained, these patientswere sent a questionnaire regarding treatment effectiveness, complications, and patient satisfaction. These data were collected and compared with angiographic and clinical outcome.
   RESULTS: The response rate was 87.5% (98/112). Intracranial complications occurred in 10 aneurysms (10.2%): 7 ischemic and 3 hemorrhagic strokes. Other complications occurred in 30 patients (30.6%): 17 alopecia, 15 bleeding tendency, and 3 puncture-site complications. Overall, 89 (90.8%) patients reported being satisfied with their treatment. Patient satisfaction was closely correlated with clinically successful outcome of treatment.
   CONCLUSIONS: Ninety percent of patients were satisfied with the results after endovascular treatment of UIAs. Endovascular coil embolization was effective and safe procedure, with high clinical success rate and degree of satisfaction.
C1 [Bae, In-Suk; Yi, Hyeong-Joong; Ko, Yong; Kim, Young Soo; Chun, Hyoung-Joon; Choi, Kyu-Sun] Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul, South Korea.
RP Yi, HJ (reprint author), Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul, South Korea.
EM hyji8499@hanyang.ac.kr
OI Bae, In-Suk/0000-0002-0738-9253
CR Abando A, 2004, J VASC SURG, V40, P287, DOI 10.1016/j.jvs.2004.05.007
   Bos JJ, 1996, J VASC INTERV RADIOL, V7, P479, DOI 10.1016/S1051-0443(96)70788-1
   Farouque HMO, 2005, J AM COLL CARDIOL, V45, P363, DOI 10.1016/j.jacc.2004.10.042
   GRIER D, 1990, BRIT J RADIOL, V63, P602, DOI 10.1259/0007-1285-63-752-602
   GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008
   Johansson M, 2001, STROKE, V32, P2845, DOI 10.1161/hs1201.099416
   Lubavin BV, 2004, AM J EMERG MED, V22, P236, DOI 10.1016/j.ajem.2004.02.025
   Lubicz B, 2004, AM J NEURORADIOL, V25, P592
   Michalis LK, 2002, CARDIOVASC INTER RAD, V25, P423, DOI 10.1007/s00270-002-1942-9
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Mukhopadhyay K, 2005, EUR J RADIOL, V56, P409, DOI 10.1016/j.ejrad.2005.03.025
   Oishi H, 2012, AM J NEURORADIOL, V33, P958, DOI 10.3174/ajnr.A2858
   Park HK, 2005, AM J NEURORADIOL, V26, P506
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Raymond J, 2012, NEUROCHIRURGIE, V58, P103, DOI 10.1016/j.neuchi.2012.02.020
   Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251
   Sawada M, 2000, INTERV NEURORADIOL, V6, P85, DOI 10.1177/15910199000060S111
   Silber S, 1999, HERZ, V24, P620, DOI 10.1007/BF03044486
   Silber S, 2000, Z KARDIOL, V89, P383, DOI 10.1007/s003920050502
   Sluzewski M, 2001, J NEUROSURG, V94, P238, DOI 10.3171/jns.2001.94.2.0238
   Standhardt H, 2008, STROKE, V39, P899, DOI 10.1161/STROKEAHA.107.496372
   Vaitkus Paul T, 2004, J Invasive Cardiol, V16, P243
   Vinuela F, 2008, J NEUROSURG, V108, P832, DOI 10.3171/JNS/2008/108/4/0832
   Wardlaw JM, 2000, BRAIN, V123, P205, DOI 10.1093/brain/123.2.205
   Weir RU, 2003, AM J NEURORADIOL, V24, P585
   Yamada NK, 2007, AM J NEURORADIOL, V28, P1778, DOI 10.3174/ajnr.A0641
   Zuccarello M, 2001, NEUROL MED-CHIR, V41, P571, DOI 10.2176/nmc.41.571
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E76
EP E85
DI 10.1016/j.wneu.2019.02.093
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300011
PM 30831292
DA 2020-05-12
ER

PT J
AU Bender, MT
   Zarrin, DA
   Campos, JK
   Lin, LM
   Huang, J
   Caplan, J
   Tamargo, RJ
   Colby, GP
   Coon, AL
AF Bender, Matthew T.
   Zarrin, David A.
   Campos, Jessica K.
   Lin, Li-Mei
   Huang, Judy
   Caplan, Justin M.
   Tamargo, Rafael J.
   Colby, Geoffrey P.
   Coon, Alexander L.
TI Tiny Pipes: 67 Cases of Flow Diversion for Aneurysms in Distal Vessels
   Measuring Less Than 2.0 mm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Distal circulation aneurysms; Flow diversion; Pipeline embolization
   device; Sub-2.0 mm vessels
ID EMBOLIZATION DEVICE; CEREBRAL ANEURYSMS; CATHETER NUANCES; PIPELINE
   FLEX; EXPERIENCE; ACCESS
AB BACKGROUND: Flow diversion is increasingly used for off-label treatments of distal circulation aneurysms. Reports of use in sub-2.0-mm vessels are scant.
   METHODS: A prospectively collected, institutional review board-approved cerebral aneurysm database was reviewed to identify patients who underwent flow diversion with a 2.5-mm diameter Pipeline embolization device.
   RESULTS: Sixty-seven aneurysms were treated in 67 procedures (66 [99%] successful, 64 [96%] single device, 2 [3%] with 2 devices) in 57 patients. Average age was 56 years and 60% were female. Aneurysm location was 51 (76%) anterior cerebral artery, 14 (21%) middle cerebral artery, and 2 (3%) posterior cerebral artery. Aneurysm size was 4.1 +/- 3.0 mm (1-20 mm). Safety outcomes included 3 major strokes (4.5%) resulting in permanent neurologic deficit (modified Rankin Scale score 6,4,4), including 1 mortality (1.5%). Acute stent thrombosis was observed intraprocedurally or within 24 hours of each stroke. There were 2 small-volume (< 10 cm(3), 40 cm(3)) dependent intracerebral hemorrhage (3.0%) that resolved without permanent neurologic deficit. For effectiveness, 71% of patients underwent follow-up angiography. Complete occlusion was achieved by 88% at 6 months, 86% at 12 months, and 89% at last follow-up. A slight vessel diameter reduction was apparent on average 6.9 months after the procedure, which was statistically significant at the proximal (P = 0.001) but not distal (P = 0.317) device end. Preoperative average parent vessel diameter was 1.9 mm proximally (range, 1.1-2.6 mm) and 1.7 mm distally (range, 1.0-2.3 mm) of the Pipeline embolization device. Follow-up average vessel diameter was 1.7 mm proximally (range, 0.7-2.4 mm) and 1.6 mm distally (range, 0.6-2.1 mm). Flow delay associated with vessel diameter reduction occurred once. There were no cases of asymptomatic vessel occlusion.
   CONCLUSIONS: Flow diversion can be safe and effective for aneurysms originating from vessels 2.0 mm in diameter. Heightened vigilance for the prevention and management of acute stent and vessel thrombosis is warranted in these cases.
C1 [Bender, Matthew T.; Zarrin, David A.; Campos, Jessica K.; Huang, Judy; Caplan, Justin M.; Tamargo, Rafael J.; Coon, Alexander L.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Colby, Geoffrey P.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
   [Lin, Li-Mei] Univ Calif Irvine, Dept Neurosurg, Orange, CA 92668 USA.
RP Coon, AL (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dralexandercoon@gmail.com
OI Huang, Judy/0000-0002-0675-1935
CR Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Bender MT, 2019, NEUROSURGERY, V84, P206, DOI 10.1093/neuros/nyy076
   Bender MT, 2019, NEUROSURGERY, V85, P543, DOI 10.1093/neuros/nyy395
   Bender MT, 2018, J NEUROINTERV SURG, V10, P843, DOI 10.1136/neurintsurg-2017-013739
   Bender MT, 2019, J NEUROSURG, V130, P259, DOI 10.3171/2017.11.JNS171738
   Bender MT, 2018, NEUROSURGERY, V83, P692, DOI 10.1093/neuros/nyx484
   Bender MT, 2017, J NEUROINTERV SURG, V9, P978, DOI 10.1136/neurintsurg-2016-012618
   Briganti F, 2016, J NEUROINTERV SURG, V8, P287, DOI 10.1136/neurintsurg-2014-011460
   Chalouhi N, 2015, J NEUROSURG, V122, P1498, DOI 10.3171/2014.12.JNS14411
   Colby GP, 2018, J NEUROSURG-PEDIATR, V22, P532, DOI 10.3171/2018.6.PEDS18165
   Colby GP, 2018, J NEUROSURG, V129, P1475, DOI 10.3171/2017.7.JNS171289
   Colby GP, 2017, J NEUROINTERV SURG, V9, P679, DOI 10.1136/neurintsurg-2016-012946
   Colby GP, 2017, INTERV NEUROL, V6, P90, DOI 10.1159/000456086
   Dornbos D, 2018, NEUROSURGERY, V82, P268, DOI 10.1093/neuros/nyx170
   Griessenauer CJ, 2017, NEUROSURGERY, V80, P579, DOI 10.1227/NEU.0000000000001377
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kallmes DF, 2016, INTERV NEUROL, V5, P89, DOI 10.1159/000446503
   KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018
   Lin LM, 2018, INTERV NEUROL, V7, P218, DOI 10.1159/000486458
   Lin LM, 2018, INTERV NEUROL, V7, P153, DOI 10.1159/000486538
   Lin LM, 2018, J NEUROINTERV SURG, V10, P137, DOI 10.1136/neurintsurg-2017-013184
   Lin LM, 2017, J NEUROINTERV SURG, V9, P689, DOI 10.1136/neurintsurg-2016-012971
   Lin LM, 2015, J NEUROINTERV SURG, V7, P628, DOI 10.1136/neurintsurg-2014-011298
   Lin Li-Mei, 2013, Surg Neurol Int, V4, P114, DOI 10.4103/2152-7806.117711
   Martin AR, 2015, AM J NEURORADIOL, V36, P557, DOI 10.3174/ajnr.A4170
   Mazaris P, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.04.037
   Nossek E, 2017, J CLIN NEUROSCI, V35, P133, DOI 10.1016/j.jocn.2016.10.041
   Puri AS, 2016, NEURORADIOLOGY, V58, P267, DOI 10.1007/s00234-015-1630-5
NR 28
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E193
EP E201
DI 10.1016/j.wneu.2019.02.204
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300027
PM 30878751
DA 2020-05-12
ER

PT J
AU Bergeron, D
   Iorio-Morin, C
   Bigder, M
   Dakson, A
   Eagles, ME
   Elliott, CA
   Honey, CM
   Kameda-Smith, MM
   Persad, ARL
   Touchette, CJ
   Tso, MK
   Fortin, D
AF Bergeron, David
   Iorio-Morin, Christian
   Bigder, Mark
   Dakson, Ayoub
   Eagles, Matthew E.
   Elliott, Cameron A.
   Honey, C. Michael
   Kameda-Smith, Michelle Masayo
   Persad, Amit R. L.
   Touchette, Charles J.
   Tso, Michael K.
   Fortin, David
CA Canadian Neurosurg Res Collabor
TI Mobile Applications in Neurosurgery: A Systematic Review, Quality Audit,
   and Survey of Canadian Neurosurgery Residents
SO WORLD NEUROSURGERY
LA English
DT Review
DE Apps; Mobile applications; Neurosurgery
ID SUPRATENTORIAL LESIONS; HEALTH APPLICATIONS; SMARTPHONE; APP; SURGERY;
   CARE; TOOL
AB BACKGROUND: In the past decade, smartphone applications (Apps) have experienced remarkable development across all fields of medicine, including neurosurgery . However, owing to a lack of regulatory oversight and peer review, a clear need exists for a comprehensive review and audit of the existing available Apps. In the present study, we systematically reviewed the existing mobile Apps in neurosurgery, evaluated their clinical use by neurosurgery residents in Canada, and performed a quality audit of the most popular Apps.
   METHODS: Indexed Apps were identified from either the Google Play Store or the iOS App Store using a comprehensive list of keywords related to neurosurgery. A subsequent cross-sectional survey of 76 Canadian neurosurgery residents was conducted, including a section on smartphone App use. We next evaluated the most popular Apps among the residents using the Healthcare Smartphone App Evaluation Tool and performed a quality audit of their content using established medical references.
   RESULTS: The survey identified 118 mobile Apps related to neurosurgery. The 3 most used Apps used by the current cohort of Canadian neurosurgery residents were Neurosurgery Survival Guide, Neuromind, and the Journal of Neurosurgery App. Each of these 3 Apps received an excellent score on the Healthcare Smartphone App Evaluation Tool. A quality audit of 30 pages of the Neurosurgery Survival Guide and 40 clinical scores of the Neuromind App, performed by 10 neurosurgery residents, failed to reveal inaccurate or false statements.
   CONCLUSION: The present study has highlighted the current landscape of neurosurgery mobile Apps and their use among neurosurgery residents.
C1 [Bergeron, David] Univ Montreal, Div Neurosurg, Montreal, PQ, Canada.
   [Iorio-Morin, Christian; Touchette, Charles J.; Fortin, David] Univ Sherbrooke, Div Neurosurg, Sherbrooke, PQ, Canada.
   [Bigder, Mark; Honey, C. Michael] Univ Manitoba, Div Neurosurg, Winnipeg, MB, Canada.
   [Dakson, Ayoub] Univ Dalhousie, Div Neurosurg, Halifax, NS, Canada.
   [Eagles, Matthew E.; Tso, Michael K.] Univ Calgary, Div Neurosurg, Calgary, AB, Canada.
   [Elliott, Cameron A.] Univ Alberta, Div Neurosurg, Edmonton, AB, Canada.
   [Kameda-Smith, Michelle Masayo] McMaster Univ, Div Neurosurg, Hamilton, ON, Canada.
   [Persad, Amit R. L.] Univ Saskatchewan, Div Neurosurg, Saskatoon, SK, Canada.
RP Iorio-Morin, C (reprint author), Univ Sherbrooke, Div Neurosurg, Sherbrooke, PQ, Canada.
EM Christian.Iorio-Morin@USherbrooke.ca
RI Kameda-Smith, Michelle/AAK-5181-2020; Iorio-Morin, Christian/I-8696-2019
OI Kameda-Smith, Michelle/0000-0003-0904-9946; Iorio-Morin,
   Christian/0000-0003-2995-7255; Honey, Michael/0000-0002-2960-6255
CR Ahmad F, 2013, WORLD NEUROSURG, V80, P446, DOI 10.1016/j.wneu.2013.09.011
   Bellei EA, 2018, TELEMED E-HEALTH, V24, P839, DOI 10.1089/tmj.2017.0230
   Boulos Maged N Kamel, 2014, Online J Public Health Inform, V5, P229, DOI 10.5210/ojphi.v5i3.4814
   Buijink Arthur Willem Gerard, 2013, Evid Based Med, V18, P90, DOI 10.1136/eb-2012-100885
   Cenydd Llyr Ap, 2013, Stud Health Technol Inform, V184, P20
   Chan SR, 2014, JAMA-J AM MED ASSOC, V312, P1155, DOI 10.1001/jama.2014.9002
   Chen JG, 2017, WORLD NEUROSURG, V106, P193, DOI [10.1016/j.WNEU.2017.06.146, 10.1016/j.wneu.2017.06.146]
   Cortez NG, 2014, NEW ENGL J MED, V371, P372, DOI 10.1056/NEJMhle1403384
   Dakson A, 2017, CAN J NEUROL SCI, V44, P204, DOI 10.1017/cjn.2016.437
   Debono B, 2016, EUR SPINE J, V25, P3536, DOI 10.1007/s00586-016-4680-4
   Eftekhar B, 2017, J NEUROL SURG PART A, V78, P502, DOI 10.1055/s-0037-1598049
   Eftekhar B, 2016, J NEUROSURG, V125, P754, DOI 10.3171/2015.6.JNS1588
   Eftekhar B, 2016, WORLD NEUROSURG, V85, P359, DOI 10.1016/j.wneu.2015.09.091
   Farzandipour M, 2017, APPL CLIN INFORM, V8, P1068, DOI [10.4338/ACI-2017-07-R-0116, 10.4338/ACI-2017-07-R0116]
   Felbaum DR, 2018, OPER NEUROSURG, V14, P303, DOI 10.1093/ons/opx112
   Gagnon L, 2014, CAN MED ASSOC J, V186, pE247, DOI 10.1503/cmaj.109-4772
   Guo Y, 2019, J CLIN NEUROSCI, V62, P277, DOI 10.1016/j.jocn.2018.12.023
   Iorio-Morin C, 2018, CAN J NEUROL SCI, V45, P214, DOI 10.1017/cjn.2017.263
   Iorio-Morin C, 2016, CLIN NEUROL NEUROSUR, V142, P48, DOI 10.1016/j.clineuro.2016.01.021
   Jin M, 2015, TELEMED E-HEALTH, V21, P831, DOI 10.1089/tmj.2014.0151
   Kameda-Smith MM, 2018, WORLD NEUROSURG, V111, pE465, DOI 10.1016/j.wneu.2017.12.089
   Kubben P L, 2011, Surg Neurol Int, V2, P32, DOI 10.4103/2152-7806.78238
   Kubben Pieter, 2012, Surg Neurol Int, V3, P109, DOI 10.4103/2152-7806.101781
   Kubben Pieter L, 2017, Surg Neurol Int, V8, P216, DOI 10.4103/sni.sni_129_17
   Kubben PL, 2016, STEREOT FUNCT NEUROS, V94, P182, DOI 10.1159/000446610
   Kubben Pieter L, 2012, Surg Neurol Int, V3, P30, DOI 10.4103/2152-7806.93852
   Kulendran M, 2014, SURG INNOV, V21, P427, DOI 10.1177/1553350614525670
   Meyer TD, 2018, J AFFECT DISORDERS, V226, P169, DOI 10.1016/j.jad.2017.09.012
   Mobasheri MH, 2015, SURGERY, V158, P1352, DOI 10.1016/j.surg.2015.03.029
   Mosa AM, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-67
   Ozdalga E, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1994
   Payne KFB, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-121
   Piquer J, 2015, J NEUROSURG-PEDIATR, V15, P552, DOI 10.3171/2014.10.PEDS14318
   Powell AC, 2014, JAMA-J AM MED ASSOC, V311, P1851, DOI 10.1001/jama.2014.2564
   Rat C, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9392
   Thomale Ulrich-W, 2015, Methods Mol Biol, V1256, P405, DOI 10.1007/978-1-4939-2172-0_27
   Tripathi M, 2014, TURK NEUROSURG, V24, P828, DOI 10.5137/1019-5149.JTN.11840-14.0
   Visser BJ, 2012, J TELEMED TELECARE, V18, P124, DOI 10.1258/jtt.2011.110205
   Yang YT, 2014, HEALTH AFFAIR, V33, P222, DOI 10.1377/hlthaff.2013.0958
   Zaki Michael, 2014, Surg Neurol Int, V5, P113, DOI 10.4103/2152-7806.137534
NR 40
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1026
EP E1038
DI 10.1016/j.wneu.2019.04.035
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300128
PM 30980978
DA 2020-05-12
ER

PT J
AU Berra, LV
   Armocida, D
   Pesce, A
   Di Rita, A
   Santoro, A
AF Berra, Luigi Valentino
   Armocida, Daniele
   Pesce, Alessandro
   Di Rita, Andrea
   Santoro, Antonio
TI Herpes Simplex Reactivation After Surgical Treatment of Trigeminal
   Neuralgia: A Retrospective Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Herpes labialis; Herpes simplex; Microvascular decompression;
   Percutaneous balloon compression; Treatment; Trigeminal neuralgia
ID DORSAL-ROOT GANGLION; MICROVASCULAR DECOMPRESSION; VIRUS REACTIVATION;
   GENE-EXPRESSION; COMPRESSION; INFECTION; NEURONS; LATENCY; TYPE-1; MODEL
AB BACKGROUND: Herpes simplex virus (HSV) reactivation after surgery for trigeminal neuralgia has long been recognized. Only a few studies to date have focused on this complication, and its actual incidence remains unknown. The aim of this study was to investigate the incidence of postoperative herpes labialis (HL) in a cohort of patients treated with either percutaneous balloon compression or microvascular decompression to identify potentially significant differences between different treatments.
   METHODS: A total of 92 patients who were operated on for TN with microvascular decompression (group A) or percutaneous balloon compression (group B) in the period 2010-2017 were retrospectively evaluated. The 2 subgroups of patients were compared according to history of previous HL and incidence of postoperative HL.
   RESULTS: The final cohort comprised 56 male and 36 female patients. Average age was 58.50 years; 30 male patients belonged to group A and 26 male patients belonged to group B. Lifetime incidence of episodes of HL before surgery in 18/58 patients in group A (31.0%) and 12/34 patients in group B (35.3%), with no statistically significant difference among subgroups. Postoperatively, 1/56 patients in group A (1.7%) experienced HL compared 5/34 patients in group B (14.7%), with a strongly statistically significant difference between the 2 subgroups.
   CONCLUSIONS: In our clinical experience, herpes simplex virus reactivation after surgery for trigeminal neuralgia is not so rare and is still not completely understood. Postoperative herpes simplex virus reactivation could be due to a direct mechanical injury on gasserian ganglion neurons, which is more common after percutaneous balloon compression.
C1 [Berra, Luigi Valentino; Armocida, Daniele; Santoro, Antonio] Sapienza Univ Rome, Div Neurosurg, Human Neurosci Dept, Rome, Italy.
   [Pesce, Alessandro] Sapienza Univ Rome, Div Neurosurg, NESMOS Dept, Rome, Italy.
   [Pesce, Alessandro] Azienda Univ Osped St Andrea, Rome, Italy.
   [Di Rita, Andrea] San Carlo Borromeo Hosp, Div Neurosurg, Milan, Italy.
RP Armocida, D (reprint author), Sapienza Univ Rome, Div Neurosurg, Human Neurosci Dept, Rome, Italy.
EM danielearmocida@yahoo.it
RI Pesce, Alessandro/AAC-2223-2020
OI berra, luigi/0000-0003-2605-9089
CR Athanasiou TC, 2005, BRIT J NEUROSURG, V19, P463, DOI 10.1080/02688690500495067
   Baechli H, 2007, EUR SURG RES, V39, P51, DOI 10.1159/000098436
   Bergenheim AT, 2013, WORLD NEUROSURG, V79, P359, DOI 10.1016/j.wneu.2012.03.014
   Bick SKB, 2017, NEUROSURG CLIN N AM, V28, P429, DOI 10.1016/j.nec.2017.02.009
   BURCHIEL KJ, 1988, J NEUROSURG, V69, P361, DOI 10.3171/jns.1988.69.3.0361
   Chen FM, 2017, J ORAL PATHOL MED, V46, P561, DOI 10.1111/jop.12534
   CROEN KD, 1987, NEW ENGL J MED, V317, P1427, DOI 10.1056/NEJM198712033172302
   Cushing H., 1905, JAMA-J AM MED ASSOC, V44, P1002
   Dandy WE, 1932, ANN SURG, V96, P787, DOI 10.1097/00000658-193210000-00026
   Devor M, 2002, CLIN J PAIN, V18, P4, DOI 10.1097/00002508-200201000-00002
   El Hayderi L, 2013, CLIN ORAL INVEST, V17, P1961, DOI 10.1007/s00784-013-0986-3
   Feldman LT, 2002, P NATL ACAD SCI USA, V99, P978, DOI 10.1073/pnas.022301899
   Garber DA, 1997, J VIROL, V71, P5885, DOI 10.1128/JVI.71.8.5885-5893.1997
   Ives AM, 2017, J VIROL, V91, DOI 10.1128/JVI.00582-17
   Jalloh I, 2009, SURG NEUROL, V72, P502, DOI 10.1016/j.surneu.2008.11.002
   Kennedy PGE, 2015, J GEN VIROL, V96, P1581, DOI 10.1099/vir.0.000128
   Ma ZX, 2009, CLIN J PAIN, V25, P44, DOI 10.1097/AJP.0b013e31817e138e
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   MELLERICK DM, 1987, VIROLOGY, V158, P265, DOI 10.1016/0042-6822(87)90198-X
   Miller CS, 2005, J CLIN MICROBIOL, V43, P2173, DOI 10.1128/JCM.43.5.2173-2180.2005
   MULLAN S, 1983, J NEUROSURG, V59, P1007, DOI 10.3171/jns.1983.59.6.1007
   PAZIN GJ, 1978, J INFECT DIS, V138, P405, DOI 10.1093/infdis/138.3.405
   PAZIN GJ, 1979, NEW ENGL J MED, V301, P225, DOI 10.1056/NEJM197908023010501
   Pickett GE, 2005, NEUROSURGERY, V56, P537, DOI 10.1227/01.NEU.0000153907.43563.FF
   Ploner M, 2005, NEUROLOGY, V65, P1674, DOI 10.1212/01.wnl.0000184491.21252.9b
   Revuelta-Gutierrez R, 2013, WORLD NEUROSURG, V80, P385, DOI 10.1016/j.wneu.2012.07.030
   SCHADELIN J, 1988, AM J MED, V85, P46
   SHELDEN CH, 1955, J NEUROSURG, V12, P123, DOI 10.3171/jns.1955.12.2.0123
   Tanaka S, 2013, WORLD NEUROSURG, V80, P371, DOI 10.1016/j.wneu.2012.01.057
   TENSER RB, 1985, BRAIN RES, V332, P386, DOI 10.1016/0006-8993(85)90610-9
   Tenser RB, 2015, WORLD NEUROSURG, V84, P279, DOI 10.1016/j.wneu.2015.03.022
   Wang HJ, 2011, PAIN, V152, P1649, DOI 10.1016/j.pain.2011.03.010
   Xiao HS, 2002, P NATL ACAD SCI USA, V99, P8360, DOI 10.1073/pnas.122231899
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E16
EP E21
DI 10.1016/j.wneu.2019.01.226
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300004
PM 30771541
DA 2020-05-12
ER

PT J
AU Bickerton, R
   Ahmed, S
   Kholief, A
   Nassimizadeh, AK
AF Bickerton, Robert
   Ahmed, Shahzada
   Kholief, Amr
   Nassimizadeh, Abdul-Karim
TI Breadth and Depth. Three-Dimensional Endoscopic Field of View:
   Two-Dimensional Versus Three-Dimensional Endoscopic Field of View
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3-Dimensional; Endoscopy; Skull base
ID PITUITARY SURGERY; TRANSITION
AB BACKGROUND: Three-dimensional (3D) endoscopy is emerging tool in ear-nose-throat (ENT) and skull base surgery with the benefit of providing real-time depth perception. Several investigators have reported that the field of view (FOV) is reduced in 3D endoscopes compared with regular 2-dimensional (2D) endoscopes. Thus, we objectively compared the FOV of 2D and 3D endoscopes.
   METHODS: Using a standard 2D and 2 different 3D ENT endoscopes, images were captured of 1-mm graph paper from a set distance of 6 cm. The FOV was calculated from these images and compared among the endoscopes.
   RESULTS: The VisionSense 3D endoscope had a slightly ...duller FOV (9.1 cm vs. 10.1 cm; - 9.9%), and the Karl Storz 3D endoscope showed a slightly larger FOV (10.4 cm vs. 10.1 cm; +3.0%). However, the results were complicated by the different-shaped images produced by the 3D endoscopes.
   CONCLUSION: The differences in the FOV between the 2D and 3D endoscopes used in ENT surgery were not clinically significant. Thus, the FOV should not be considered a limitation of 3D technology.
C1 [Bickerton, Robert] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Ahmed, Shahzada; Kholief, Amr] Univ Hosp Birmingham NHS Fdn, Dept Ear Nose & Throat ENT Surg, Birmingham, W Midlands, England.
   [Kholief, Amr] Alexandria Univ, Dept Otolaryngol Head & Neck Surg, Alexandria, Egypt.
   [Nassimizadeh, Abdul-Karim] Walsall Healthcare Natl Hlth Serv Trust, Dept Ear Nose & Throat ENT Surg, Walsall, W Midlands, England.
RP Bickerton, R (reprint author), Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England.
EM rxb451@student.bham.ac.uk
OI Bickerton, Robert/0000-0002-4188-9833
CR Bickerton R, 2019, LARYNGOSCOPE, V129, P1280, DOI 10.1002/lary.27812
   Chamoun R, 2011, J NEUROSURG SCI, V55, P265
   Charalampaki Patra, 2013, Asian J Neurosurg, V8, P125, DOI 10.4103/1793-5482.121681
   Cote M, 2013, ACTA NEUROCHIR, V155, P2299, DOI 10.1007/s00701-013-1889-4
   Di Ieva A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.005
   Goudakos JK, 2011, CLIN OTOLARYNGOL, V36, P212, DOI 10.1111/j.1749-4486.2011.02331.x
   Jho HD, 1997, SURG NEUROL, V47, P213, DOI 10.1016/S0090-3019(96)00452-1
   Laws ER, 2014, WORLD NEUROSURG, V82, pS152, DOI 10.1016/j.wneu.2014.07.035
   Lee SC, 2008, CLIN EXP OTORHINOLAR, V1, P53, DOI 10.3342/ceo.2008.1.2.53
   Nassimizadeh A, 2015, J NEUROL SURG REP, V76, pE200, DOI 10.1055/s-0035-1547368
   Rampinelli V, 2017, WORLD NEUROSURG, V105, P223, DOI 10.1016/j.wneu.2017.05.130
   Schaberg MR, 2010, CURR OPIN OTOLARYNGO, V18, P8, DOI 10.1097/MOO.0b013e328334db5b
   Szold A, 2005, SURG ENDOSC, V19, P730, DOI 10.1007/s00464-004-8272-8
   Van Gompel JJ, 2014, LARYNGOSCOPE, V124, P387, DOI 10.1002/lary.24222
   Wang QZ, 2017, BIOMED OPT EXPRESS, V8, P1441, DOI 10.1364/BOE.8.001441
   Yang I, 2010, NEUROSURG CLIN N AM, V21, P643, DOI 10.1016/j.nec.2010.07.008
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P419, DOI 10.1016/j.wneu.2015.10.004
   김창훈, 2016, Journal of Rhinology, V23, P102
NR 18
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E717
EP E721
DI 10.1016/j.wneu.2019.03.247
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300089
PM 30947003
DA 2020-05-12
ER

PT J
AU Bohoun, CA
   Goto, T
   Morisako, H
   Nagahama, A
   Tanoue, Y
   Ohata, K
AF Bohoun, Christian A.
   Goto, Takeo
   Morisako, Hiroki
   Nagahama, Atsufumi
   Tanoue, Yuta
   Ohata, Kenji
TI Skull Base Dural Repair Using Autologous Fat as a Dural Substitute: An
   Efficient Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autologous fat graft; Dural repair; Dural substitute; Skull base surgery
AB BACKGROUND: Dural repair during skull base approaches remains challenging, especially in the presence of significant defects. The autologous fat has become an alternative to various substitute materials being used previously. We report here our experience and technique for the repair of notable skull base dural defects using autologous fat as a dural substitute.
   METHODS: Over a period of 5 years, 71 consecutive patients operated on for skull base pathologies with an important intraoperative dural defect repaired using autologous fat tissue as replacement material were reviewed. The graft, withdrawn from the abdomen or thigh, was flattened and applied to the defect. The clinical findings and outcomes were assessed.
   RESULTS: Main pathologies included schwannomas (45%) and meningiomas (35.21%), with no side predilection. Surgical approaches such as transcondylar fossa, suboccipital, and frontotemporal approaches were used. Dural defects were mainly located in the posterior (73.2%) and middle cranial fossae (25.4%). No harvesting site-related complication occurred. In 7 cases, transitory subcutaneous fluid collection spontaneously resorbing after 8 days to 2 months was observed. No external cerebrospinal fluid leakage, infection, or other complication was noted during the following period.
   CONCLUSIONS: Dural repair can be effectively and durably achieved using autologous fat graft as a dural substitute during skull base approaches, even in cases of extended defects. The observed characteristics of the fat graft along with the achieved outcome make it an ideal dural substitute.
C1 [Bohoun, Christian A.; Goto, Takeo; Morisako, Hiroki; Nagahama, Atsufumi; Tanoue, Yuta; Ohata, Kenji] Osaka City Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan.
RP Bohoun, CA (reprint author), Osaka City Univ, Grad Sch Med, Dept Neurosurg, Osaka, Japan.
EM chbohoun@gmail.com
OI Nagahama, Atsufumi/0000-0002-8975-513X
CR Di Vitantonio Hambra, 2016, Surg Neurol Int, V7, pS463, DOI 10.4103/2152-7806.185777
   Jeong W, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0378-0
   Kato H, 2014, PLAST RECONSTR SURG, V133, p303E, DOI 10.1097/PRS.0000000000000066
   Ludwig CA, 2015, INT J SURG CASE REP, V7, P1, DOI 10.1016/j.ijscr.2014.12.008
   Metwali H, 2018, WORLD NEUROSURG, V110, P249, DOI 10.1016/j.wneu.2017.11.084
   Sekhar LN, 2013, WORLD NEUROSURG, V79, P440, DOI 10.1016/j.wneu.2011.12.062
   Taha ANM, 2011, WORLD NEUROSURG, V75, P692, DOI 10.1016/j.wneu.2011.01.023
NR 7
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E896
EP E900
DI 10.1016/j.wneu.2019.03.293
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300111
PM 30959259
DA 2020-05-12
ER

PT J
AU Boyaci, MG
   Rakip, U
   Aslan, A
   Koca, HB
   Aslan, E
   Korkmaz, S
   Yildizhan, S
AF Boyaci, Mehmet Gazi
   Rakip, Usame
   Aslan, Adem
   Koca, Halit Bugra
   Aslan, Esra
   Korkmaz, Serhat
   Yildizhan, Serhat
TI Effects of 2-Aminoethyl Diphenylborinate, a Modulator of Transient
   Receptor Potential and Orai Channels in Subarachnoid Hemorrhage: An
   Experimental Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE 2-Aminoethyl diphenylborate; Ca2+ channels; Cerebral vasospasm; Orai
   channels; Subarachnoid hemorrhage; TRP channels
ID EARLY BRAIN-INJURY; DELAYED CEREBRAL-ISCHEMIA; 2-AMINOETHOXYDIPHENYL
   BORATE; NITRIC-OXIDE; CELL-DEATH; VASOSPASM; DAMAGE; 2-APB; CA2+;
   INFLAMMATION
AB BACKGROUND: Cerebral vasospasm remains a serious problem affecting morbidity and mortality in patients with subarachnoid hemorrhage (SAH) during neurosurgery. We aimed to demonstrate the role of the transient receptor potential channel and other channels for Ca2+ in the etiology of cerebral vasospasm using 2-aminoethyl diphenylborinate (2-APB) and the effective dose range of an unstudied pharmacological agent, which can limit vasospasm.
   METHODS: We performed an experimental study using 32 Sprague-Dawley rats divided into 4 groups: sham group (n = 8), SAH group (n = 8), 2-APB group (SAH rats intraperitoneally administered with 0.5 mg/kg 2-APB; n = 8), and 2-APB-2 group (SAH rats intraperitoneally administered with 2 mg/kg 2-APB; n = 8). The rats were sacrificed after 24 hours, and superoxide dismutase, glutathione peroxidase, malondialdehyde, tumor necrosis factor-alpha, and interleukin-1 beta in the brain tissue and serum were measured. The histopathological investigation of brain tissue included measurement of the luminal diameter and wall thickness of the basilar artery (BA), and apoptotic cells in the hippocampus were counted after caspase staining.
   RESULTS: Autologous arterial blood injection into the cisterna magna caused vasospasm in rats. 2-APB treatment increased the BA wall thickness and reduced the BA lumen diameter, inducing significant vascular changes. 2-APB also alleviated cell apoptosis at 24 hours after SAH.
   CONCLUSION: In experimental SAH in rats, 2-APB treatment increased the BA wall thickness and reduced the BA lumen diameter, inducing significant vascular changes. 2-APB also alleviated cell apoptosis at 24 hours after SAH.
C1 [Boyaci, Mehmet Gazi; Aslan, Adem; Korkmaz, Serhat; Yildizhan, Serhat] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Neurosurg, Afyon, Turkey.
   [Koca, Halit Bugra] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Biochem, Afyon, Turkey.
   [Aslan, Esra] Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Histol & Embryol, Afyon, Turkey.
   [Rakip, Usame] TCSB Nigde Omer Halisdemir Univ Hosp, Dept Neurosurg, Nigde, Turkey.
RP Boyaci, MG (reprint author), Afyonkarahisar Hlth Sci Univ, Fac Med, Dept Neurosurg, Afyon, Turkey.
EM mgazibyc@hotmail.com
OI Boyaci, Mehmet Gazi/0000-0001-7329-2102
CR Ali S, 2017, J PHYSIOL-LONDON, V595, P3085, DOI 10.1113/JP273130
   Alkan T., 2001, Archives of Physiology and Biochemistry, V109, P145
   Ansari N, 2014, J BIOMOL STRUCT DYN, V32, P1211, DOI 10.1080/07391102.2013.812520
   Atangana E, 2017, TRANSL STROKE RES, V8, P144, DOI 10.1007/s12975-016-0485-3
   Aydin Hasan Emre, 2015, Acta Neurochir Suppl, V120, P255, DOI 10.1007/978-3-319-04981-6_43
   Baggott CD, 2014, NEUROSURG CLIN N AM, V25, P497, DOI 10.1016/j.nec.2014.04.008
   Basbug M, 2017, EUR SURG, V49, P32, DOI 10.1007/s10353-016-0452-y
   Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091
   Berna-Erro A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000522
   Boulouis G, 2017, EUR RADIOL, V27, P3333, DOI 10.1007/s00330-016-4702-y
   Brayden JE, 2008, CLIN EXP PHARMACOL P, V35, P1116, DOI 10.1111/j.1440-1681.2007.04855.x
   Brown TE, 2013, HIPPOCAMPUS, V23, P662, DOI 10.1002/hipo.22125
   Chen ZQ, 2017, MED GAS RES, V7, P194, DOI 10.4103/2045-9912.215750
   Manoel ALD, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00292
   de Rooij NK, 2013, STROKE, V44, P43, DOI 10.1161/STROKEAHA.112.674291
   Earley S, 2015, PHYSIOL REV, V95, P645, DOI 10.1152/physrev.00026.2014
   Emmez H, 2017, TURK NEUROSURG, V27, P374, DOI 10.5137/1019-5149.JTN.16101-15.1
   Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210
   Fleig A, 2017, J PHYSIOL-LONDON, V595, P2997, DOI 10.1113/JP274289
   Fliniaux I, 2018, CELL CALCIUM, V69, P4, DOI 10.1016/j.ceca.2017.07.002
   Grimm S, 2012, BBA-MOL CELL RES, V1823, P327, DOI 10.1016/j.bbamcr.2011.11.018
   Harr MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005579
   Hayman EG, 2017, MOLECULES, V22, DOI 10.3390/molecules22050724
   Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200
   Hu N, 2014, BRAIN RES, V1585, P63, DOI 10.1016/j.brainres.2014.08.012
   Hu WY, 2015, BRIT J PHARMACOL, V172, P2273, DOI 10.1111/bph.13048
   Huang JB, 2017, ADV EXP MED BIOL, V976, P61, DOI 10.1007/978-94-024-1088-4_6
   HUBSCHMANN O R, 1987, Neurological Research, V9, P265
   Ilik MK, 2014, TURK NEUROSURG, V24, P873, DOI 10.5137/1019-5149.JTN.9371-13.5
   Inagawa T, 2016, WORLD NEUROSURG, V85, P56, DOI 10.1016/j.wneu.2015.08.052
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Kertmen H, 2014, ACTA NEUROCHIR, V156, P951, DOI 10.1007/s00701-014-2008-x
   Kraft R, 2015, CHANNELS, V9, P244, DOI 10.1080/19336950.2015.1071747
   Kumar G, 2016, J NEUROSURG, V124, P1257, DOI 10.3171/2015.4.JNS15428
   Leon-Aparicio D, 2017, CELL CALCIUM, V65, P80, DOI 10.1016/j.ceca.2017.01.013
   Lilla N, 2018, WORLD NEUROSURG, V116, pE57, DOI 10.1016/j.wneu.2018.03.205
   Lilla N, 2016, J NEUROL SCI, V370, P312, DOI 10.1016/j.jns.2016.09.032
   Longden TA, 2016, J CEREBR BLOOD F MET, V36, P492, DOI 10.1177/0271678X15616138
   Mulier M, 2017, CELL CALCIUM, V66, P19, DOI 10.1016/j.ceca.2017.04.007
   Nilius B, 2014, PHARMACOL REV, V66, P676, DOI 10.1124/pr.113.008268
   ORDY JM, 1993, EXP NEUROL, V119, P128, DOI 10.1006/exnr.1993.1014
   PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636
   Popugaeva E, 2018, NEURODEGENER DIS MAN, V8, P5, DOI 10.2217/nmt-2017-0053
   Prunell GF, 2005, NEUROSURGERY, V56, P1082, DOI 10.1227/01.NEU.0000157966.76590.39
   Reading SA, 2005, AM J PHYSIOL-HEART C, V288, pH2055, DOI 10.1152/ajpheart.00861.2004
   Rothoerl RD, 2007, NEUROL RES, V29, P636, DOI 10.1179/016164107X240224
   Sehba Fatima A, 2015, Acta Neurochir Suppl, V120, P23, DOI 10.1007/978-3-319-04981-6_4
   Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003
   Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z
   Smani T, 2015, BBA-MOL CELL RES, V1853, P1772, DOI 10.1016/j.bbamcr.2015.04.016
   SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58
   Takahashi K, 2014, EXP CELL RES, V323, P337, DOI 10.1016/j.yexcr.2014.03.001
   Togashi K, 2008, BRIT J PHARMACOL, V153, P1324, DOI 10.1038/sj.bjp.0707675
   Xu HL, 2018, NEUROCHEM INT, V112, P197, DOI 10.1016/j.neuint.2017.07.010
   Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730
   Zhang ZY, 2015, CELL MOL NEUROBIOL, V35, P147, DOI 10.1007/s10571-014-0106-1
NR 56
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E376
EP E388
DI 10.1016/j.wneu.2019.03.129
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300047
PM 30905651
DA 2020-05-12
ER

PT J
AU Bretonnier, M
   Henaux, PL
   Gaberel, T
   Roualdes, V
   Kerdiles, G
   Le Reste, PJ
   Morandi, X
AF Bretonnier, Maxime
   Henaux, Pierre-Louis
   Gaberel, Thomas
   Roualdes, Vincent
   Kerdiles, Gaelle
   Le Reste, Pierre-Jean
   Morandi, Xavier
TI Spinal Dural Arteriovenous Fistulas: Clinical Outcome After Surgery
   Versus Embolization: A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical outcome; Embolization; Initial occlusion; Late recurrence;
   Spinal dural arteriovenous fistula; Surgery
ID INDOCYANINE GREEN ANGIOGRAPHY; ENDOVASCULAR TREATMENT;
   SURGICAL-MANAGEMENT; MALFORMATIONS; EXPERIENCE; SERIES
AB OBJECTIVE: Spinal dural arteriovenous fistulas (SDAVFs) are rare vascular spinal malformations. According to the reported data, surgery seems to result in better occlusion rates than endovascular treatment. However, the post-treatment evolution of neurological symptoms stratified by the treatment remains unknown. The main objective of the present study was to compare the clinical outcomes for patients according to the treatment method.
   METHODS: The data from 63 patients with SDAVFs from 2000 to 2017 at 4 academic neurosurgical departments were retrospectively analyzed. Preoperative and postoperative examination neurological status was assessed using the Aminoff-Logue scale (ALS), which evaluates gait and micturition disturbances. Initial occlusion, late recurrence, and complications of the 2 techniques were also reviewed.
   RESULTS: Patients who had undergone surgery and embolization improved clinically on the ALS (P = 0.0009), and no significant differences were found between the 2 techniques. Subgroup analysis using the ALS showed that patients who had undergone surgery and embolization without late recurrence improved (P < 0.0001 and P = 0.0334, respectively) and that patients who had undergone surgery or embolization with late recurrence did not improve. The initial occlusion rate was in favor of surgery, with 91.3% versus 70% for endovascular treatment (P = 0.050). The late recurrence rate was higher for embolization (21.4% vs. 9.1% for surgery; P = 0.28).
   CONCLUSIONS: Surgery can be proposed as first-line treatment of SDAVFs after multidisciplinary discussion between neurosurgeons and neuroradiologists. The development of late recurrence negatively affects the neurological outcome of patients.
C1 [Bretonnier, Maxime; Henaux, Pierre-Louis; Le Reste, Pierre-Jean; Morandi, Xavier] Rennes Univ Hosp, Dept Neurosurg, Rennes, France.
   [Bretonnier, Maxime; Henaux, Pierre-Louis; Morandi, Xavier] Univ Rennes, Univ Hosp Rennes, French Natl Inst Hlth & Med Res, Rennes, France.
   [Gaberel, Thomas] Caen Univ Hosp, Dept Neurosurg, Caen, France.
   [Roualdes, Vincent] Nantes Univ Hosp, Nord Laennec, Dept Neurosurg, St Herblain, France.
   [Kerdiles, Gaelle] Tours Univ Hosp, Dept Neurosurg, Tours, France.
RP Bretonnier, M (reprint author), Rennes Univ Hosp, Dept Neurosurg, Rennes, France.; Bretonnier, M (reprint author), Univ Rennes, Univ Hosp Rennes, French Natl Inst Hlth & Med Res, Rennes, France.
EM maxime.bretonnier@chu-rennes.fr
OI Bretonnier, Maxime/0000-0002-9703-7285; Le Reste,
   Pierre-Jean/0000-0003-4673-5697
CR AMINOFF MJ, 1974, J NEUROL SCI, V23, P255, DOI 10.1016/0022-510X(74)90229-9
   AMINOFF MJ, 1974, BRAIN, V97, P197, DOI 10.1093/brain/97.1.197
   Bakker NA, 2015, NEUROSURGERY, V77, P137, DOI 10.1227/NEU.0000000000000727
   Bretonnier M, 2018, J CLIN NEUROSCI, V52, P37, DOI 10.1016/j.jocn.2018.02.015
   Cenzato M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1218
   Fusco MR, 2014, OPER NEUROSURG, V10, P251, DOI 10.1227/NEU.0000000000000318
   Gemmete JJ, 2013, AM J NEURORADIOL, V34, P1974, DOI 10.3174/ajnr.A3522
   HASSLER W, 1989, J NEUROSURG, V70, P360, DOI 10.3171/jns.1989.70.3.0360
   Hessler C, 2010, CENT EUR NEUROSURG, V71, P8, DOI 10.1055/s-0029-1224195
   Jellema K, 2006, BRAIN, V129, P3150, DOI 10.1093/brain/awl220
   KENDALL BE, 1977, NEURORADIOLOGY, V13, P181, DOI 10.1007/BF00344211
   Kim LJ, 2006, NEUROSURGERY, V59, P53, DOI 10.1227/01.NEU.0000219219.97287.91
   Kirsch M, 2013, NEURORADIOLOGY, V55, P337, DOI 10.1007/s00234-013-1134-0
   Marquardt G, 2009, EUR SPINE J, V18, P1117, DOI 10.1007/s00586-009-0946-4
   Muralidharan R, 2013, SPINE, V38, P1188, DOI 10.1097/BRS.0b013e31828b2e10
   Nagata S, 2006, SURG NEUROL, V65, P563, DOI 10.1016/j.surneu.2005.09.018
   Patel NP, 2013, WORLD NEUROSURG, V80, pE267, DOI 10.1016/j.wneu.2012.04.003
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Ropper AE, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11344
   ROSENBLUM B, 1987, J NEUROSURG, V67, P795, DOI 10.3171/jns.1987.67.6.0795
   Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821
   Schuette AJ, 2010, NEUROSURGERY, V67, P658, DOI 10.1227/01.NEU.0000374721.84406.7F
   Spiotta AM, 2011, J NEUROINTERV SURG, V3, P182, DOI 10.1136/jnis.2010.003210
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   van Dijk JMC, 2002, STROKE, V33, P1578, DOI 10.1161/01.STR.0000018009.83713.06
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
NR 26
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E943
EP E949
DI 10.1016/j.wneu.2019.04.005
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300117
PM 30974280
DA 2020-05-12
ER

PT J
AU Bucklitsch, J
   Muller, A
   Weitner, A
   Filmann, N
   Patriciu, A
   Behmanesh, B
   Seifert, V
   Marquardt, G
   Quick-Weller, J
AF Bucklitsch, Joern
   Mueller, Andreas
   Weitner, Albert
   Filmann, Natalie
   Patriciu, Andrei
   Behmanesh, Bedjan
   Seifert, Volker
   Marquardt, Gerhard
   Quick-Weller, Johanna
TI Significant Impact of Implantable Functional Electrical Stimulation on
   Gait Parameters: A Kinetic Analysis in Foot Drop Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE ActiGait; Foot drop; Functional electrical stimulation; Gait; Neurologic
   drop foot; Stroke
ID PERONEAL NERVE-STIMULATION; STROKE PATIENTS; WALKING; TRIAL
AB OBJECTIVE: Neurogenic drop foot is a common result of acquired damage of the central nervous system and can cause severe restriction of mobility. ActiGait, an implantable functional electrical stimulation device, restores ankle dorsiflexion by active peroneal nerve stimulation. The aim of our study was to evaluate its effect on foot contact pattern during normal walk.
   METHODS: Eight patients with drop foot who used ActiGait in everyday life performed a 20-meter comfortable walk test. Gait parameters were evaluated with an insole system (Medilogic). Percentage of biped stance in a double-step, effective foot length, width of gait, and overall plantar load were measured in comparison with and without activated drop foot stimulation.
   RESULTS: Effective foot length increased in all patients on average from 46.0% to 60.2% (P = 0.038). However, percentage of biped stance in a double-step showed no significant difference (31.2% vs. 27.8% on average, P = 0.063), nor did width of gait (2.6% vs. 2.4% on average, P = 0.73) and overall plantar load (3.51 N/cm(2)vs. 3.39 N/cm(2), P = 0.25).
   CONCLUSION: The ActiGait implantable drop foot stimulator significantly improves effective foot length during normal walk of patients with neurogenic drop foot. Further investigation is needed to confirm whether ActiGait has no effect on the other parameters or whether it facilitates permanent gait adaptations that persist without the activated device.
C1 [Mueller, Andreas] Goethe Univ, ProFuss GmbH, Frankfurt, Germany.
   [Weitner, Albert] Goethe Univ, Orthopad Tech Weitner, Frankfurt, Germany.
   [Filmann, Natalie] Goethe Univ, Klinikum & Fachbereich Med, Inst Biostat & Math Modellierung, Frankfurt, Germany.
   [Bucklitsch, Joern; Behmanesh, Bedjan; Seifert, Volker; Marquardt, Gerhard; Quick-Weller, Johanna] Goethe Univ, Klin & Poliklin Neurochirurg, Frankfurt, Germany.
   [Patriciu, Andrei] Nstim Serv GmbH, Vienna, Austria.
RP Quick-Weller, J (reprint author), Goethe Univ, Klin & Poliklin Neurochirurg, Frankfurt, Germany.
EM johanna.quick@gmx.de
CR Blazkiewicz M, 2017, CLIN BIOMECH, V42, P14, DOI 10.1016/j.clinbiomech.2016.12.014
   Burridge J, 2007, J REHABIL MED, V39, P212, DOI 10.2340/16501977-0039
   Ernst J, 2013, RESTOR NEUROL NEUROS, V31, P557, DOI 10.3233/RNN-120283
   Everaert DG, 2010, NEUROREHAB NEURAL RE, V24, P168, DOI 10.1177/1545968309349939
   Hegewald D., 1999, GANGANALYTISCHE BEST, P1
   Kottink AIR, 2004, ARTIF ORGANS, V28, P577, DOI 10.1111/j.1525-1594.2004.07310.x
   Kottink AI, 2007, ARCH PHYS MED REHAB, V88, P971, DOI 10.1016/j.apmr.2007.05.002
   Martin KD, 2016, J NEUROSURG, V124, P70, DOI 10.3171/2014.12.JNS142110
   Schiemanck S, 2015, RESTOR NEUROL NEUROS, V33, P795, DOI 10.3233/RNN-150501
   Sheffler LR, 2006, NEUROREHAB NEURAL RE, V20, P355, DOI 10.1177/1545968306287925
   Wong AM, 2004, ARCH PHYS MED REHAB, V85, P1625, DOI 10.1016/j.apmr.2003.11.039
   Yao D, 2017, ORTHOPADE, V46, P227, DOI 10.1007/s00132-016-3371-5
   Yao D, 2016, Musculoskelet Surg, V100, P223
NR 13
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E236
EP E241
DI 10.1016/j.wneu.2019.03.064
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300032
PM 30954755
DA 2020-05-12
ER

PT J
AU Caplan, IF
   Sullivan, PZ
   Kung, D
   O'Rourke, DM
   Choudhri, O
   Glauser, G
   Osiemo, B
   Goodrich, S
   McClintock, SD
   Malhotra, NR
AF Caplan, Ian F.
   Sullivan, Patricia Zadnik
   Kung, David
   O'Rourke, Donald M.
   Choudhri, Omar
   Glauser, Gregory
   Osiemo, Benjamin
   Goodrich, Stephen
   McClintock, Scott D.
   Malhotra, Neil R.
TI LACE plus Index as Predictor of 30-Day Readmission in Brain Tumor
   Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumors; Discharge predictive tool; Hospital readmissions; LACE
   plus index
ID CRANIOTOMY; PERFORMANCE; CARE; HOME
AB BACKGROUND: The LACE+ index (Length of stay, Acuity of admission, Charlson Comorbidity Index score, and Emergency department [ED] visits in the past 6 months) is a tool used to predict 30-day readmissions. We sought to examine this predictive tool in patients undergoing brain tumor surgery.
   METHODS: Admissions and readmissions for patients undergoing craniotomy for supratentorial neoplasm at a single multihospital academic medical center were analyzed. All brain tumor cases for which the patient was alive at 30 days after surgery were included (n = 352). Simple logistic regression analyses were used to assess the ability of the LACE+ index and subsequent single variables to accurately predict the outcome measures of 30-day readmission, reoperation, and ED visit. Analysis of the model's or variable's discrimination was determined by the receiver operating characteristic curve as represented by the C-statistic.
   RESULTS: The sample included admissions for craniotomy for supratentorial neoplasm (n = 352). Assessment of the LACE+ index demonstrates a 1.02x increased odds of 30-day readmission for every 1-unit increase in LACE+ score (P = 0.031, CI = 1.00-1.03). Despite this, analysis of the receiver operating characteristic curve indicates that LACE+ index has poor specificity in predicting 30-day readmission (C-statistic = 0.58). A 1-unit increase in LACE+ score also predicts a 0.98x reduction in odds of home discharge (P < 0.001, CI = 0.97-0.99, C-statistic = 0.70). But LAC+ index does not predict 30-day reoperation (P = 0.945) or 30-day ED visits (P = 0.218).
   CONCLUSIONS: The results of this study demonstrate that the LACE+ index is not yet suitable as a prediction model for 30-day readmission in a brain tumor population.
C1 [Caplan, Ian F.; Sullivan, Patricia Zadnik; Kung, David; O'Rourke, Donald M.; Choudhri, Omar; Glauser, Gregory; Malhotra, Neil R.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Osiemo, Benjamin; Goodrich, Stephen; Malhotra, Neil R.] Univ Penn, Populat Hlth, Philadelphia, PA 19104 USA.
   [Osiemo, Benjamin; Goodrich, Stephen; McClintock, Scott D.] West Chester Univ, West Chester Stat Inst, W Chester, PA USA.
   [Osiemo, Benjamin; Goodrich, Stephen; McClintock, Scott D.] West Chester Univ, Dept Math, W Chester, PA USA.
RP Malhotra, NR (reprint author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.; Malhotra, NR (reprint author), Univ Penn, Populat Hlth, Philadelphia, PA 19104 USA.
EM NRM@uphs.upenn.edu
OI Goodrich, Stephen/0000-0001-9225-3627
CR Ansari SF, 2018, NEUROSURGERY, V82, P173, DOI 10.1093/neuros/nyx160
   Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72
   Cotter PE, 2012, AGE AGEING, V41, P784, DOI 10.1093/ageing/afs073
   Damery S, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016921
   Dasenbrock HH, 2017, NEUROSURGERY, V80, P551, DOI 10.1093/neuros/nyw062
   Dickinson H, 2015, J NEUROSURG, V122, P61, DOI 10.3171/2014.8.JNS1498
   Donoho DA, 2018, J NEURO-ONCOL, V136, P87, DOI 10.1007/s11060-017-2625-3
   El Morr C, 2017, INTERACT J MED RES, V6, DOI 10.2196/ijmr.7183
   El Morr C, 2016, STUD HEALTH TECHNOL, V223, P25, DOI 10.3233/978-1-61499-645-3-25
   Hakim MA, 2018, CLIN EPIDEMIOL, V10, P51, DOI 10.2147/CLEP.S149574
   HOSMER DW, 2000, WILEY PS TX, P1
   Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563
   Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561
   Lonjaret L, 2017, ANAESTH CRIT CARE PA, V36, P213, DOI 10.1016/j.accpm.2016.06.012
   Marcus LP, 2014, J NEUROSURG, V120, P1201, DOI 10.3171/2014.1.JNS131264
   Missios S, 2017, J NEUROSURG, V127, P1213, DOI 10.3171/2016.9.JNS161575
   Moghavem N, 2015, J NEUROSURG, V123, P189, DOI 10.3171/2014.12.JNS14447
   Nuno M, 2014, NEUROSURGERY, V74, P196, DOI 10.1227/NEU.0000000000000243
   Pace A, 2012, J PALLIAT MED, V15, P225, DOI 10.1089/jpm.2011.0306
   Piazza M, 2019, NEUROSURGERY, V85, P50, DOI 10.1093/neuros/nyy197
   Robinson R, 2017, PEERJ, V5, DOI 10.7717/peerj.3137
   Senders JT, 2018, NEUROSURGERY, V83, P1249, DOI 10.1093/neuros/nyy001
   Society AC, 2018, KEY STAT BRAIN SPIN
   Teh R, 2018, INT J EVID-BASED HEA, V16, P174, DOI 10.1097/XEB.0000000000000142
   van Walraven Carl, 2012, Open Med, V6, pe80
   van Walraven C, 2010, CAN MED ASSOC J, V182, P551, DOI 10.1503/cmaj.091117
   Wang H, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-97
NR 27
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E443
EP E448
DI 10.1016/j.wneu.2019.03.169
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300243
PM 30926557
DA 2020-05-12
ER

PT J
AU Ceylan, S
   Anik, I
   Cabuk, B
   Caklili, M
   Anik, Y
AF Ceylan, Savas
   Anik, Ihsan
   Cabuk, Burak
   Caklili, Melih
   Anik, Yonca
TI Extension Pathways of Pituitary Adenomas with Cavernous Sinus
   Involvement and Its Surgical Approaches
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Endoscopic; Invasion; Lateral corridor; Medial corridor
ID TRANSSPHENOIDAL APPROACH; INVASION; SURGERY; CLASSIFICATION; CRITERIA;
   DIAGNOSIS; OUTCOMES; ANATOMY; TUMORS; SPACE
AB BACKGROUND: Resection and remission rates are low in pituitary adenomas that invade the cavernous sinus (CS) because of the complexity of the region. In this study, the authors describe the invasion patterns and surgical approaches for these corridors.
   METHODS: Endoscopic transsphenoidal surgery was performed in 1849 patients between August 1997 and 2017; 381 of these patients were included in the study because of the presence of CS invasion. CS invasion pathways and CS compartments were defined, and these patients were divided into 3 groups according to their invasion corridors. The cases were also categorized according to the Knosp classification.
   RESULTS: A total of 381 patients were included, 199 of whom were men. The mean follow-up duration was 34 months. In preoperative magnetic resonance imaging measurements, 2 of 381 patients had microadenoma, 350 of 381 had macroadenoma, and 29 of 381 had giant adenoma. When the early postoperative magnetic resonance images were compared with the preoperative images, 91 of 381 (23.9%) patients had subtotal tumor resection, 83 of 381 (21.8%) had near-total tumor resection, and 207 of 381 (54.3%) had gross total tumor resection. Considering the invasion classification with endoscopic confirmation, there were 168 of 381 (44.1%) cases of isolated medial corridor involvement, 74 of 381 (19.4%) cases of isolated lateral corridor involvement, and 139 of 381 (36.5%) cases of total involvement cases.
   CONCLUSIONS: Medial wall defect has no importance in the invasion. Similarly, seeing the existence of pitholes is not an invasion criterion. Pituitary adenomas invade 4 compartments: the superior, anteroinferior, posterior, and lateral compartments of the CS via 2 corridors. Increased experience, novel approaches, and endoscopic developments have contributed immensely to this field.
C1 [Ceylan, Savas; Anik, Ihsan; Cabuk, Burak; Caklili, Melih] Kocaeli Univ, Neurosurg & Pituitary Res Ctr, Kocaeli, Turkey.
   [Anik, Yonca] Kocaeli Univ, Radiol & Pituitary Res Ctr, Kocaeli, Turkey.
RP Ceylan, S (reprint author), Kocaeli Univ, Neurosurg & Pituitary Res Ctr, Kocaeli, Turkey.
EM ssceylan@yahoo.com
RI Caklili, Melih/G-2721-2018; Caklili, Melih/AAG-3063-2019; Ceylan,
   Savas/H-1308-2018; Cabuk, Burak/G-9285-2018
OI Caklili, Melih/0000-0002-4405-0566; Caklili, Melih/0000-0002-4405-0566;
   Cabuk, Burak/0000-0003-1198-3869
CR Ajlan A, 2017, J NEUROL SURG PART B, V78, P273, DOI 10.1055/s-0036-1598022
   Alfieri A, 2001, NEUROSURGERY, V49, P354, DOI 10.1097/00006123-200108000-00017
   Anik I, 2018, WORLD NEUROSURG, V112, pE691, DOI 10.1016/j.wneu.2018.01.134
   Campero A, 2010, J CLIN NEUROSCI, V17, P746, DOI 10.1016/j.jocn.2009.10.015
   Cavallo Luigi Maria, 2005, Neurosurgery, V56, P379, DOI 10.1227/01.NEU.0000156548.30011.D4
   Ceylan S, 2011, ACTA NEUROCHIR, V153, P2435, DOI 10.1007/s00701-011-1182-3
   Ceylan S, 2011, TURK NEUROSURG, V21, P330, DOI 10.5137/1019-5149.JTN.4149-11.0
   Ceylan S, 2010, J NEUROSURG, V112, P99, DOI 10.3171/2009.4.JNS09182
   CHI JG, 1980, J NEUROSURG, V52, P667, DOI 10.3171/jns.1980.52.5.0667
   CIRIC I, 1977, J NEUROSURG, V46, P596, DOI 10.3171/jns.1977.46.5.0596
   Cottier JP, 2000, ANN ENDOCRINOL-PARIS, V61, P269
   Neto MAD, 2010, CLIN ENDOCRINOL, V72, P512, DOI 10.1111/j.1365-2265.2009.03665.x
   Doglietto F, 2009, NEUROSURGERY, V64, P413, DOI 10.1227/01.NEU.0000338943.08985.73
   Dolenc VV, 1997, NEUROSURGERY, V41, P542, DOI 10.1097/00006123-199709000-00007
   DOLENC VV, 1989, ANATOMY SURG CAVERNO, P3
   FAHLBUSCH R, 1988, ACTA NEUROCHIR, V92, P93, DOI 10.1007/BF01401978
   Fernandez-Miranda JC, 2014, J NEUROL SURG PART B, V75
   Fernandez-Miranda JC, 2018, J NEUROSURG, V129, P430, DOI 10.3171/2017.2.JNS162214
   Frank G, 2006, FRONT HORM RES, V34, P64, DOI 10.1159/000091573
   HARRIS FS, 1976, J NEUROSURG, V45, P169, DOI 10.3171/jns.1976.45.2.0169
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P9, DOI 10.1055/s-2004-818346
   Kassam A, 2005, NEUROSURG FOCUS, V19, P1, DOI DOI 10.3171/foc.2005.19.1.4
   Kitano M, 2008, J NEUROSURG, V108, P26, DOI 10.3171/JNS/2008/108/01/0026
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Koutourousiou M, 2017, WORLD NEUROSURG, V103, P713, DOI 10.1016/j.wneu.2017.04.096
   Li AJ, 2017, WORLD NEUROSURG, V101, P236, DOI 10.1016/j.wneu.2017.01.022
   Little AS, 2018, NEUROSURGERY, V65, P95, DOI 10.1093/neuros/nyy303.142
   Micko ASG, 2015, J NEUROSURG, V122, P803, DOI 10.3171/2014.12.JNS141083
   Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
   Nishioka Hiroshi, 2014, J Neurosurg, V121, P505, DOI 10.3171/2014.3.JNS132214
   Park HH, 2018, WORLD NEUROSURG, V117, pE280, DOI 10.1016/j.wneu.2018.06.012
   Sol YL, 2014, J NEUROIMAGING, V24, P498, DOI 10.1111/j.1552-6569.2012.00710.x
   Tao YX, 2010, CHINESE MED J-PEKING, V123, P3519, DOI 10.3760/cma.j.issn.0366-6999.2010.24.003
   Trouillas J, 2013, ACTA NEUROPATHOL, V126, P123, DOI 10.1007/s00401-013-1084-y
   Truong HQ, 2019, J NEUROSURG, V131, P122, DOI 10.3171/2018.3.JNS18596
   Vieira JO, 2006, SURG NEUROL, V65, P130, DOI 10.1016/j.surneu.2005.05.021
   Woodworth GF, 2014, J NEUROSURG, V120, P1086, DOI 10.3171/2014.1.JNS131228
   Yokoyama S, 2001, NEUROSURGERY, V49, P857, DOI 10.1097/00006123-200110000-00014
   Zhao B, 2010, J NEUROSURG, V112, P108, DOI 10.3171/2009.3.JNS0929
   Zoli M, 2016, J NEUROSURG SCI, V60, P485
NR 40
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E986
EP E995
DI 10.1016/j.wneu.2019.04.013
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300123
PM 30965171
DA 2020-05-12
ER

PT J
AU Chen, C
   Wei, L
   Li, MT
   Ling, C
   Luo, L
   Guo, YF
   Li, ZY
   Guo, Y
   Wang, H
AF Chen, Chuan
   Wei, Lei
   Li, Manting
   Ling, Cong
   Luo, Lun
   Guo, Yuefei
   Li, Zhangyu
   Guo, Ying
   Wang, Hui
TI Superficial Temporal Artery Trunk-to-Middle Cerebral Artery Bypass with
   Short Radial Artery Interposition Graft for Symptomatic Internal Carotid
   Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE High-flow bypass; Interposition graft; Ischemic stroke; Radial artery;
   Superficial temporal artery trunk; Symptomatic internal carotid artery
   occlusion
ID MOYAMOYA-DISEASE; SURGERY; ISCHEMIA; STROKE; ANEURYSMS; OUTCOMES; RISK
AB OBJECTIVE: We investigated the use of high-flow superficial temporal artery trunk-to-radial artery-to-middle cerebral artery (STAt-RA-MCA) bypass to prevent ischemic stroke in patients with symptomatic internal carotid artery occlusion (SICAO).
   METHODS: We retrospectively analyzed the data from patients with SICAO who had undergone high-flow STAt-RA-MCA bypass in our center from October 2014 to November 2017. The incidence of ischemic stroke, changes in cerebral blood flow, characteristics of perioperative complications, and related factors determining the blood flow rate in the graft were analyzed.
   RESULTS: From October 2014 to November 2017, we treated 21 patients with SICAO using high-flow STAt-RA-MCA bypass. A total of 42 ischemic stroke events had been reported within 6 months before surgery. The ipsilateral/ contralateral mean transit time (I/C MTT) ratio before surgery was 1.24 +/- 0.10 (range, 1.14-1.51). During a median follow-up period of 692 days (range, 212-1114), 3 transient ischemic attacks occurred in 3 patients; 18 patients (85.7%) did not experience recurrent stroke. The patency rate of the bypass graft was 95.2% (20 of 21). The I/C MTT ratio was 1.06 +/- 0.11 on postoperative day 1 in all patients and was significantly different from the preoperative I/C MTT ratio P < 0.001). The surgical complication rate was 9.5% (2 of 21), and no reoperation was required.
   CONCLUSION: Our results suggest that high-flow STAt-RA-MCA bypass can effectively reduce the risk of stroke in patients with SICAO. Moreover, the surgical procedure is a highly safe procedure. Further randomized controlled studies are required to draw more precise conclusions.
C1 [Chen, Chuan; Li, Manting; Ling, Cong; Luo, Lun; Li, Zhangyu; Guo, Ying; Wang, Hui] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
   [Wei, Lei] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou, Guangdong, Peoples R China.
   [Guo, Yuefei] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiol, Guangzhou, Guangdong, Peoples R China.
RP Wang, H (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurosurg, Guangzhou, Guangdong, Peoples R China.
EM 33691681@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571202]; Natural Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2014A030313055]
FX The present study was supported by the National Natural Science
   Foundation of China (grant 81571202) and the Natural Science Foundation
   of Guangdong Province (grant 2014A030313055).
CR Abla AA, 2015, WORLD NEUROSURG, V83, P145, DOI 10.1016/j.wneu.2014.08.027
   Alaraj A, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E7
   Balogh B, 2002, J HAND SURG-AM, V27A, P1073, DOI 10.1053/jhsu.2002.35887
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Fischer U, 2010, STROKE, V41, P661, DOI 10.1161/STROKEAHA.109.572883
   Galkin P, 2017, J NEUROSURG SCI, V61, P22, DOI 10.23736/S0390-5616.16.03234-3
   Grubb Robert L Jr, 2004, Curr Neurol Neurosci Rep, V4, P23, DOI 10.1007/s11910-004-0007-7
   Hanggi D, 2009, J NEUROSURG, V111, P181, DOI 10.3171/2009.2.JNS081388
   Ishishita Y, 2014, WORLD NEUROSURG, V82, P130, DOI 10.1016/j.wneu.2013.02.063
   Kaku Y, 2014, ACTA NEUROCHIR SUPPL, V119, P79, DOI 10.1007/978-3-319-02411-0_14
   Klijn CJM, 2002, STROKE, V33, P2451, DOI 10.1161/01.STR.0000030319.78212.51
   Klijn CJM, 2000, NEUROLOGY, V55, P1806
   Maselli Giuliano, 2011, Surg Neurol Int, V2, P46, DOI 10.4103/2152-7806.79764
   Matsukawa H, 2017, NEUROSURGERY, V81, P672, DOI 10.1093/neuros/nyx075
   MATSUSHIMA T, 1992, NEUROSURGERY, V31, P401, DOI 10.1227/00006123-199209000-00003
   Neff KW, 2004, NEURORADIOLOGY, V46, P730, DOI 10.1007/s00234-004-1252-9
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Ramanathan D, 2012, NEUROSURGERY, V70, P1442, DOI 10.1227/NEU.0b013e31824c046f
   Roh SW, 2011, J KOREAN NEUROSURG S, V50, P185, DOI 10.3340/jkns.2011.50.3.185
   Santoro A, 1999, J Neurosurg Sci, V43, P237
   Santoro A, 1999, J NEUROSURG SCI, V43, P250
   Santoro A, 1999, J NEUROSURG SCI, V43, P231
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   Sia SF, 2013, J CLIN NEUROSCI, V20, P1, DOI 10.1016/j.jocn.2012.05.007
   van Doormaal TPC, 2011, NEUROSURGERY, V68, P1687, DOI 10.1227/NEU.0b013e318214e2e7
   Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD
   Yang K, 2015, WORLD NEUROSURG, V83, P197, DOI 10.1016/j.wneu.2014.06.008
   Zhu FP, 2014, J BIOMECH, V47, P1800, DOI 10.1016/j.jbiomech.2014.03.032
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E268
EP E279
DI 10.1016/j.wneu.2019.03.086
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300036
PM 30898742
DA 2020-05-12
ER

PT J
AU Chen, SH
   McCarthy, DJ
   Sheinberg, D
   Hanel, R
   Sur, S
   Jabbour, P
   Atallah, E
   Chalouhi, N
   Dumont, A
   Amenta, P
   Hasan, D
   Raper, D
   Liu, K
   Jane, JA
   Crowley, RW
   Aguilar-Salinas, P
   Bentley, J
   Monteith, S
   Mitchell, BD
   Yavagal, DR
   Peterson, EC
   Starke, RM
AF Chen, Stephanie H.
   McCarthy, David J.
   Sheinberg, Dallas
   Hanel, Ricardo
   Sur, Samir
   Jabbour, Pascal
   Atallah, Elias
   Chalouhi, Nohra
   Dumont, Aaron
   Amenta, Peter
   Hasan, David
   Raper, Daniel
   Liu, Kenneth
   Jane, John A., Jr.
   Crowley, R. Webster
   Aguilar-Salinas, Pedro
   Bentley, Josh
   Monteith, Stephen
   Mitchell, Bartley D.
   Yavagal, Dileep R.
   Peterson, Eric C.
   Starke, Robert M.
TI Pipeline Embolization Device for the Treatment of Intracranial
   Pseudoaneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Bypass; Clipping; Endovascular; Flow diversion; Iatrogenic;
   Infection; Pipeline; Pseudoaneurysm; Sacrifice; Subarachnoid hemorrhage;
   Trauma
ID ARTERY PSEUDOANEURYSM; FLOW DIVERSION; ANEURYSMS; SECONDARY
AB BACKGROUND: Intracranial pseudoaneurysms (PSAs) are associated with high rupture and mortality rates and have traditionally been treated by parent vessel sacrifice. There has been recent interest in using flow-diverting devices for treatment of these complex lesions while preserving flow through the parent artery. The objective of this study is to examine the safety and efficacy of these devices in the treatment of intracranial PSA.
   METHODS: We performed a multi-institutional retrospective study of intracranial PSAs treated with the Pipeline Embolization Device (PED) between 2014 and 2017 at 7 institutions. Complications and clinical and radiographic outcomes were reviewed.
   RESULTS: A total of 19 patients underwent PED placement for intracranial PSA. Iatrogenic injury and trauma comprised most etiologies in our series. The mean pseudoaneurysm diameter was 8.8 mm, and 18 of 19 PSAs (95%) involved the internal carotid artery (ICA). Multiple PEDs were deployed in a telescoping fashion in 7 patients (37%). Of the 18 patients with follow up imaging, 14 (78%) achieved complete pseudoaneurysm obliteration and 2 achieved near-complete obliteration (11%). Two patients (11%) were found to have significant pseudoaneurysm progression on short-term follow-up and required ICA sacrifice. No patients experienced new neurologic deficits or deterioration secondary to PED placement. No patients experienced bleeding or rebleeding from PSA.
   CONCLUSIONS: In well-selected patients, the use of flow-diverting stents may be a feasible alternative to parent vessel sacrifice. Given the high morbidity and mortality associated with PSA, we recommend short-and long-term radiographic follow-up for patients treated with flow-diverting stents.
C1 [Chen, Stephanie H.; McCarthy, David J.; Sheinberg, Dallas; Hanel, Ricardo; Sur, Samir; Yavagal, Dileep R.; Peterson, Eric C.; Starke, Robert M.] Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA.
   [Hanel, Ricardo; Aguilar-Salinas, Pedro] Baptist Hlth, Dept Neurol Surg, Miami, FL USA.
   [Jabbour, Pascal; Atallah, Elias; Chalouhi, Nohra] Jefferson Univ, Dept Neurol Surg, Philadelphia, PA USA.
   [Dumont, Aaron; Amenta, Peter] Tulane Univ Med Ctr Hosp & Clin, Dept Neurol Surg, New Orleans, LA USA.
   [Hasan, David] Univ Iowa, Dept Neurol Surg, Iowa City, IA USA.
   [Raper, Daniel; Liu, Kenneth; Jane, John A., Jr.] Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA.
   [Crowley, R. Webster] Rush Univ, Dept Neurol Surg, Med Ctr, Chicago, IL 60612 USA.
   [Bentley, Josh; Monteith, Stephen] Swedish Hlth, Dept Neurol Surg, Seattle, WA USA.
   [Mitchell, Bartley D.] Methodist Inst, Dept Neurol Surg, Houston, TX USA.
RP McCarthy, DJ (reprint author), Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA.
EM djm77@med.miami.edu
RI Aguilar-Salinas, Pedro/AAJ-4444-2020
OI Aguilar-Salinas, Pedro/0000-0002-5268-6548; Hanel,
   Ricardo/0000-0001-7195-5806
CR Amenta Peter S, 2012, Surg Neurol Int, V3, P160, DOI 10.4103/2152-7806.105099
   Caroff J, 2018, J NEUROINTERV SUR S2, V10, pA55
   Chiu AHY, 2017, J NEUROINTERV SURG, V9, pE18, DOI 10.1136/neurintsurg-2016-012657.rep
   Giorgianni A, 2015, INTERV NEURORADIOL, V21, P23, DOI [10.11771591019915575441, 10.1177/1591019915575441]
   Griauzde J, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1735
   Gupta R, 2016, WORLD NEUROSURG, V96, P285, DOI 10.1016/j.wneu.2016.09.013
   Hagen MW, 2017, J NEUROINTERV SURG, V9, P1006, DOI 10.1136/neurintsurg-2016-012612
   HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009
   Kabbasch Christoph, 2016, J Vasc Interv Neurol, V9, P14
   Kadkhodayan Y, 2013, J NEUROINTERV SURG, V5, DOI 10.1136/neurintsurg-2012-010394
   Kallmes DF, 2009, AM J NEURORADIOL, V30, P1153, DOI 10.3174/ajnr.A1530
   Kim JD, 2013, J NEURO-OPHTHALMOL, V33, P359, DOI 10.1097/WNO.0b013e3182a30427
   Larson P S, 2000, Neurosurg Focus, V8, pe4
   Lerat Justine, 2011, Skull Base Rep, V1, P133, DOI 10.1055/s-0031-1284209
   Maras D, 2006, CARDIOVASC INTER RAD, V29, P958, DOI 10.1007/s00270-005-0367-7
   Moon Tae Hun, 2015, Korean J Neurotrauma, V11, P124, DOI 10.13004/kjnt.2015.11.2.124
   Natarajan SK, 2017, NEUROSURG CLIN N AM, V28, P375, DOI 10.1016/j.nec.2017.02.011
   Nerva JD, 2015, J NEUROINTERV SURG, V7, P210, DOI 10.1136/neurintsurg-2013-011047
   Prasad V, 2014, J NEUROINTERV SURG, V6, pE48, DOI 10.1136/neurintsurg-2013-010899.rep
   Sami MT, 2018, CLIN NEUROL NEUROSUR, V169, P154, DOI 10.1016/j.clineuro.2018.04.012
   Sweid A, 2018, J CLIN NEUROSCI, V58, P20, DOI 10.1016/j.jocn.2018.10.081
   Sylvester PT, 2016, J NEUROSURG, V125, P1256, DOI 10.3171/2015.6.JNS142483
   Tsang ACO, 2015, J NEUROINTERV SURG, V7, P603, DOI 10.1136/neurintsurg-2014-011154
   Wan WS, 2013, EUR J RADIOL, V82, P95, DOI 10.1016/j.ejrad.2011.01.061
NR 24
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E86
EP E93
DI 10.1016/j.wneu.2019.02.135
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300012
PM 30849553
DA 2020-05-12
ER

PT J
AU Cho, YH
   Yang, IC
   Kim, YS
   Kim, TS
   Joo, SP
AF Cho, Yong-Hwan
   Yang, In-Chul
   Kim, You-Sub
   Kim, Tae-Sun
   Joo, Sung-Pil
TI Bifrontal Interhemispheric Approach Involving Cutting the Superior
   Sagittal Sinus for Distal Anterior Cerebral Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Distal anterior cerebral artery; Modified bifrontal
   interhemispheric approach; Unilateral anterior interhemispheric approach
ID ENDOVASCULAR TREATMENT; SACCULAR ANEURYSMS; SURGICAL-TREATMENT;
   MENINGIOMAS; EXPERIENCE; LIGATION; BRAIN
AB BACKGROUND: The unilateral interhemispheric approach for distal anterior cerebral artery aneurysms presents several risks, such as postoperative venous infarction due to occasional sacrifice of parasagittal bridging vein and postoperative frontal lobe damage due to retraction force. To overcome these risks, we used a bifrontal craniotomy with straight dural incision and cutting of the superior sagittal sinus.
   METHODS: We retrospectively reviewed 61 patients (42 unruptured and 19 ruptured A2 and A3 aneurysms) who under aneurysm clipping through bifrontal interhemispheric approach between March 2007 and December 2017. There were 35 A2 aneurysms and 27 A3 aneurysms, and mean size of aneurysms was 5.45 mm. The modified bifrontal interhemispheric approach involved 3 steps: bifrontal craniotomy of centrobasal portion of the frontal bone, ligation and division of anterior one third of the superior sagittal sinus, and approaching the aneurysm via the interhemispheric space. All patients underwent computed tomography on postoperative days 3 and 7 for evaluation of brain retraction damage or venous infarction.
   RESULTS: Among patients with ruptured aneurysms, 79% had a favorable outcome (Glasgow Outcome Scale score 4 or 5) 6 months after primary subarachnoid hemorrhage; all patients with unruptured aneurysms had favorable outcomes. Surgical outcome was strongly related to preoperative neurologic Hunt and Hess grade. Three patients had poor outcomes due to poor Hunt and Hess grade on admission (grade 3 in 2 patients, grade 4 in 1 patient). Follow-up CT showed that venous infarction did not occur in any of the patients.
   CONCLUSIONS: Modified bifrontal interhemispheric approach may be a safe and effective method for treating A2 and A3 aneurysms with relatively good clinical outcome and no surgery-related complications.
C1 [Cho, Yong-Hwan; Yang, In-Chul; Kim, You-Sub; Kim, Tae-Sun; Joo, Sung-Pil] Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
RP Joo, SP (reprint author), Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
EM nsjsp@hanmail.net
FU Basic Science Research Program through the National Research Foundation
   of Korea - Ministry of Education [2018R1D1A1B07048483]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea funded by the Ministry
   of Education (Grant No. 2018R1D1A1B07048483).
CR Aboukais R, 2015, NEUROCHIRURGIE, V61, P244, DOI 10.1016/j.neuchi.2015.03.010
   Acerbi F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18120
   Bakac G, 1997, NEURORADIOLOGY, V39, P566, DOI 10.1007/s002340050468
   BAPTISTA AG, 1963, NEUROLOGY, V13, P825, DOI 10.1212/WNL.13.10.825
   BECKER DH, 1979, NEUROSURGERY, V4, P495, DOI 10.1227/00006123-197906000-00001
   Cavalcanti DD, 2013, AM J NEURORADIOL, V34, P1593, DOI 10.3174/ajnr.A3408
   Chhabra R, 2005, SURG NEUROL, V64, P315, DOI 10.1016/j.surneu.2005.03.038
   de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X
   DiMeco F, 2008, NEUROSURGERY, V62, P1124, DOI [10.1227/01.NEU.0000143373.74160.F2, 10.1227/01.neu.0000333779.73940.c4]
   Ferroli P, 2011, WORLD NEUROSURG, V75, P122, DOI 10.1016/j.wneu.2010.09.011
   Hayashi N, 2011, NEUROL MED-CHIR, V51, P160, DOI 10.2176/nmc.51.160
   HERNESNIEMI J, 1992, NEUROSURGERY, V31, P994, DOI 10.1227/00006123-199212000-00002
   Huang QH, 2010, NEUROL INDIA, V58, P259, DOI 10.4103/0028-3886.63809
   Inci S, 1998, SURG NEUROL, V50, P130, DOI 10.1016/S0090-3019(97)00344-3
   Kawashima M, 2003, J NEUROSURG, V99, P517, DOI 10.3171/jns.2003.99.3.0517
   Kubota M, 2001, ACTA NEUROCHIR, V143, P321, DOI 10.1007/s007010170085
   Kurtsoy A, 2005, MINIM INVAS NEUROSUR, V48, P264, DOI 10.1055/s-2005-915596
   LAITINEN L, 1960, J NEUROSURG, V17, P447, DOI 10.3171/jns.1960.17.3.0447
   Lehecka M, 2008, NEUROSURGERY, V62, P590, DOI 10.1227/01.neu.0000317307.16332.03
   MANN KS, 1984, SURG NEUROL, V21, P261, DOI 10.1016/0090-3019(84)90199-X
   Miyazawa N, 2000, ACTA NEUROCHIR, V142, P1241, DOI 10.1007/s007010070020
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Nakamura M, 2007, NEUROSURGERY, V60, P844, DOI 10.1227/01.NEU.0000255453.20602.80
   Ng PY, 1998, BRIT J NEUROSURG, V12, P209
   OHNO K, 1990, NEUROSURGERY, V27, P907, DOI 10.1227/00006123-199012000-00008
   Park Hyun Seok, 2013, Neurointervention, V8, P87, DOI 10.5469/neuroint.2013.8.2.87
   Park J, 2004, ACTA NEUROCHIR, V146, P973, DOI 10.1007/s00701-004-0304-6
   PERLMUTTER D, 1978, J NEUROSURG, V49, P204, DOI 10.3171/jns.1978.49.2.0204
   Petr O, 2017, WORLD NEUROSURG, V100, P557, DOI 10.1016/j.wneu.2016.11.134
   Proust F, 1997, STROKE, V28, P2405, DOI 10.1161/01.STR.28.12.2405
   Salunke P, 2013, CLIN NEUROL NEUROSUR, V115, P1998, DOI 10.1016/j.clineuro.2013.06.003
   Schaller B, 2003, SWISS MED WKLY, V133, P412
   Schaller B, 2003, AM J NEURORADIOL, V24, P1876
   SINDOU M, 1988, SURG NEUROL, V30, P434, DOI 10.1016/0090-3019(88)90027-4
   Steven DA, 2007, NEUROSURGERY, V60, P227, DOI 10.1227/01.NEU.0000249267.33945.E7
   Suzuki S, 2011, INTERV NEURORADIOL, V17, P49, DOI 10.1177/159101991101700108
   TRAYNELIS VC, 1992, J NEUROSURG, V77, P481, DOI 10.3171/jns.1992.77.3.0481
   WISOFF JH, 1987, NEUROSURGERY, V20, P735, DOI 10.1227/00006123-198705000-00011
   YASARGIL MG, 1974, J NEUROSURG, V40, P218
   YASUI N, 1992, ACTA NEUROCHIR, V118, P91, DOI 10.1007/BF01401292
   YOSHIMOTO T, 1979, J NEUROSURG, V50, P40, DOI 10.3171/jns.1979.50.1.0040
NR 41
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1057
EP E1063
DI 10.1016/j.wneu.2019.04.041
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300132
PM 30980976
DA 2020-05-12
ER

PT J
AU Choi, SH
   Lee, DH
   Hwang, CJ
   Son, SM
   Woo, Y
   Goh, TS
   Kang, SW
   Lee, JS
AF Choi, Sung Hoon
   Lee, Dong-Ho
   Hwang, Chang Ju
   Son, Seung Min
   Woo, Youngha
   Goh, Tae Sik
   Kang, Sang Woo
   Lee, Jung Sub
TI Effectiveness of C2 Incidence Angle for Evaluating Global Spinopelvic
   Alignment in Patients with Mild Degenerative Spondylosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE C2 incidence; Geometric sum; Incidence angle of inflection point; L1
   incidence; Pelvic incidence and lumbar lordosis mismatch; Spinopelvic
   alignment
ID CERVICAL SAGITTAL ALIGNMENT; COMPENSATORY ALIGNMENT; DEFORMITY; BALANCE;
   IMPROVEMENT; IMPACT
AB OBJECTIVE: To analyze the correlation between C2 incidence (C2I) and cervical and thoracolumbar sagittal parameters and determine the effectiveness of C2I for evaluating global spinopelvic sagittal alignment.
   METHODS: Whole spine standing lateral radiographs of 226 patients (mean age, 47.8 +/- 11.3 years; 63% women) were analyzed. Spinopelvic parameters and incidence angles of inflection point were evaluated. The correlation between each parameter was analyzed using Pearson correlation coefficient and linear regression. Using C2I quartiles, 3 groups were compared to distinguish different alignment patterns by analysis of variance.
   RESULTS: C2I correlated significantly with C0-2 lordosis (CO2L), C2-7 lordosis (C27L), C0-7 lordosis , C2 slope (C2S), T1 slope-C27L C2-7 sagittal vertical axis, and chin brow vertical angle (CBVA) in cervical parameters (r = - 0.378, r = 0.533, r = 0.251, r = 0.688, r = 0.681, r = 0.278, and r = 0.351, respectively; P < 0.01) and with T1 incidence (T1I), pelvic incidence-lumbar lordosis mismatch, L1 incidence (L1I), pelvic tilt (PT), and pelvic incidence (PI) (r = 0.480, r = 0.516, r = 0.518, r = 0.635, and r = 0.392, respectively; P < 0.01) in thoracolumbar alignment parameters. C2I was estimated by the 2 following equations: C2I = 1.00C2S + 1.0PT and C2I = 0.98PI - 0.99LL + 0.98 thoracic kyphosis - 1.0C271 (R-2 = 0.97, P < 0.001, respectively), with an excellent coefficient of determination. PI, PT, L1I, T1I, and C2S were increased significantly between groups using C2I quartiles. In the high C2I group, C27L and C0-7 lordosis had less lordosis; however, C02L had more lordosis and C2-7 sagittal vertical axis and CBVA showed higher than low C2I group.
   CONCLUSIONS: C2I was significantly correlated with both cervical and thoracolumbar sagittal parameters, and different sagittal alignment patterns were presented regarding the amount of C2I. As the geometric summation from the pelvis to C2 vertebra, C2I would be a beneficial clue to connect correlation chains of spinal sagittal alignment.
C1 [Choi, Sung Hoon; Son, Seung Min; Kang, Sang Woo] Pusan Natl Univ, Yangsan Hosp, Biomed Res Inst, Dept Orthopaed Surg, Yangsan, South Korea.
   [Lee, Dong-Ho; Hwang, Chang Ju] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Orthoped Surg, Seoul, South Korea.
   [Woo, Youngha] Daedong Hosp, Dept Orthoped Surg, Busan, South Korea.
   [Goh, Tae Sik; Lee, Jung Sub] Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
RP Lee, JS (reprint author), Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
EM jungsublee@pusan.ac.kr
OI Choi, Sung Hoon/0000-0003-3328-2043
FU National Research Foundation of Korea - Korean governmentNational
   Research Foundation of KoreaKorean Government [2018R1D1A1B07051146]
FX This work was supported by a National Research Foundation of Korea grant
   funded by the Korean government (2018R1D1A1B07051146).
CR Ailon T, 2015, NEUROSURGERY, V77, pS75, DOI 10.1227/NEU.0000000000000938
   Ames CP, 2015, J NEUROSURG-SPINE, V23, P673, DOI 10.3171/2014.12.SPINE14780
   Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Barrey C, 2007, EUR SPINE J, V16, P1459, DOI 10.1007/s00586-006-0294-6
   Choi SH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011668
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Khaleel ZL, 2014, J NEUROSURG-SPINE, V20, P172, DOI 10.3171/2013.10.SPINE13405
   Mizutani J, 2018, NEUROSURGERY, V82, P686, DOI 10.1093/neuros/nyx288
   Oh T, 2015, J NEUROSURG-SPINE, V22, P658, DOI 10.3171/2014.10.SPINE14829
   Protopsaltis TS, 2017, CLIN SPINE SURG, V30, pE959, DOI 10.1097/BSD.0000000000000554
   Protopsaltis TS, 2015, J NEUROSURG-SPINE, V23, P153, DOI 10.3171/2014.11.SPINE1441
   Protopsaltis TS, 2016, SPINE, V16, pS154
   Ramchandran S, 2018, EUR SPINE J, V27, P416, DOI 10.1007/s00586-017-5395-x
   Roussouly P, 2010, EUR SPINE J, V19, P1824, DOI 10.1007/s00586-010-1476-9
   Scheer JK, 2013, J NEUROSURG-SPINE, V19, P141, DOI 10.3171/2013.4.SPINE12838
   Smith JS, 2014, SPINE, V39, pE1001, DOI 10.1097/BRS.0000000000000432
   Smith JS, 2012, J NEUROSURG-SPINE, V17, P300, DOI 10.3171/2012.6.SPINE1250
   Tan LA, 2017, NEUROSURGERY, V81, P197, DOI 10.1093/neuros/nyx249
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E826
EP E834
DI 10.1016/j.wneu.2019.03.274
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300103
PM 30954734
DA 2020-05-12
ER

PT J
AU Chou, D
   Mundis, G
   Wang, M
   Fu, KM
   Shaffrey, C
   Okonkwo, D
   Kanter, A
   Eastlack, R
   Nguyen, S
   Deviren, V
   Uribe, J
   Fessler, R
   Nunley, P
   Anand, N
   Park, P
   Mummaneni, P
AF Chou, Dean
   Mundis, Gregory
   Wang, Michael
   Fu, Kai-Ming
   Shaffrey, Christopher
   Okonkwo, David
   Kanter, Adam
   Eastlack, Robert
   Nguyen, Stacie
   Deviren, Vedat
   Uribe, Juan
   Fessler, Richard
   Nunley, Pierce
   Anand, Neel
   Park, Paul
   Mummaneni, Praveen
CA Int Spine Study Grp
TI Minimally Invasive Surgery for Mild-to-Moderate Adult Spinal
   Deformities: Impact on Intensive Care Unit and Hospital Stay
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deformity; Length of stay; Minimally invasive; MIS; Scoliosis; Spinal
   deformity
ID PEDICLE SUBTRACTION OSTEOTOMY; PERIOPERATIVE COMPLICATIONS; MAJOR
   COMPLICATIONS; SAGITTAL BALANCE; SCOLIOSIS; FUSION; PARAMETERS;
   OUTCOMES; COST
AB OBJECTIVE: To compare circumferential minimally invasive (cMIS) versus open surgeries for mild-to-moderate adult spinal deformity (ASD) with regard to intensive care unit (ICU) and hospital lengths of stay (LOS).
   METHODS: A retrospective review of 2 multicenter ASD databases with 426 ASD (sagittal vertical axis <6 cm) surgery patients with 4 or more fusion levels and 2-year follow-up was conducted. ICU stay, LOS, and estimated blood loss (EBL) were compared between open and cMIS surgeries.
   RESULTS: Propensity matching resulted in 88 patients (44 cMIS, 44 open). cMIS were older (61 vs. 53 years, P = 0.005). Mean levels fused were 6.5 in cMIS and 7.1 in open (P = 0.368). Preoperative lordosis was higher in open than in cMIS (42.7 degrees vs. 40.9 degrees, P = 0.016), and preoperative visual analog score back pain was greater in open than in cMIS (7 vs. 6.2, P = 0.033). Preoperative and postoperative spinopelvic parameters and coronal Cobb angles were not different. EBL was 534 cc in cMIS and 1211 cc in open (P < 0.001). Transfusions were less in cMIS (27.3% vs. 70.5%, P < 0.001). ICU stay was 0.6 days for cMIS and days for open (P = 0.009). Hospital LOS was 7.9 days for cMIS versus 9.6 for open (P = 0.804).
   CONCLUSIONS: For patients with mild-to-moderate ASD, cMIS surgery had a significantly lower EBL and shorter ICU stay. Major and minor complication rates were lower in cMIS patients than open patients. Overall LOS was shorter in cMIS patients, but did not reach statistical significance.
C1 [Chou, Dean; Mummaneni, Praveen] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
   [Deviren, Vedat] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94143 USA.
   [Mundis, Gregory; Eastlack, Robert] Scripps Clin Torrey Pines, Dept Orthoped Surg, La Jolla, CA USA.
   [Nguyen, Stacie] San Diego Ctr Spinal Disorders, Dept Orthoped Surg, La Jolla, CA USA.
   [Anand, Neel] Cedars Sinai Med Ctr, Dept Orthoped Surg, Los Angeles, CA USA.
   [Wang, Michael] Univ Miami, Dept Neurosurg, Coral Gables, FL 33124 USA.
   [Fu, Kai-Ming] Weill Cornell Med Coll, Dept Neurosurg, New York, NY USA.
   [Shaffrey, Christopher] Duke Univ, Dept Neurosurg, Durham, NC USA.
   [Okonkwo, David; Kanter, Adam] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA.
   [Uribe, Juan] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Fessler, Richard] Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
   [Nunley, Pierce] Spine Inst Louisiana, Orthoped Surg, Shreveport, LA USA.
   [Park, Paul] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Chou, D (reprint author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
EM dean.chou@ucsf.edu
CR Acosta FL, 2011, J NEUROSURG-SPINE, V15, P92, DOI 10.3171/2011.3.SPINE10425
   Akbarnia BA, 2014, J SPINAL DISORD TECH, V27, P29, DOI 10.1097/BSD.0b013e318287bdc1
   Anand N, 2008, J SPINAL DISORD TECH, V21, P459, DOI 10.1097/BSD.0b013e318167b06b
   Anand N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09278
   Asai Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178697
   Auerbach JD, 2012, SPINE, V37, P1198, DOI 10.1097/BRS.0b013e31824fffde
   Buchowski JM, 2007, SPINE, V32, P2245, DOI 10.1097/BRS.0b013e31814b2d52
   Cho SK, 2012, SPINE, V37, P489, DOI 10.1097/BRS.0b013e3182217ab5
   Chou D, 2016, OPER NEUROSURG, V12, P309, DOI 10.1227/NEU.0000000000001167
   Daubs MD, 2007, SPINE, V32, P2238, DOI 10.1097/BRS.0b013e31814cf24a
   Deukmedjian AR, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13173
   Deukmedjian AR, 2012, SCI WORLD J, DOI 10.1100/2012/789698
   Dhall SS, 2008, J NEUROSURG-SPINE, V9, P560, DOI 10.3171/SPI.2008.9.08142
   Eck K R, 2001, Spine (Phila Pa 1976), V26, pE182, DOI 10.1097/00007632-200105010-00012
   Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Haque RM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1424
   Hofstetter CP, 2015, WORLD J ORTHOP, V6, P190, DOI 10.5312/wjo.v6.i2.190
   Kanter AS, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS14112
   Kelly MP, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS1419
   KOSTUIK JP, 1988, ORTHOP CLIN N AM, V19, P371
   Lafage V, 2008, SPINE, V33, P1572, DOI 10.1097/BRS.0b013e31817886a2
   Mummaneni PV, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1413
   MUNDIS GM, 2010, SPINE PHILA PA 197 S, V35, pS31
   NORRIS C, 1995, CAN J ANAESTH, V42, P192, DOI 10.1007/BF03010674
   Park P, 2015, J NEUROSURG-SPINE, V22, P374, DOI 10.3171/2014.9.SPINE131004
   Passias PG, 2012, SPINE, V37, P247, DOI 10.1097/BRS.0b013e31821350d0
   Putzier M, 2016, SPINE J, V16, P811, DOI 10.1016/j.spinee.2015.07.460
   Scheer JK, 2015, SPINE, V40, P1505, DOI 10.1097/BRS.0000000000001062
   Schwab FJ, 2013, SPINE, V38, pE803, DOI 10.1097/BRS.0b013e318292b7b9
   Schwab FJ, 2012, EUR SPINE J, V21, P2603, DOI 10.1007/s00586-012-2370-4
   Smith JS, 2013, SPINE, V38, P1663, DOI 10.1097/BRS.0b013e31829ec563
   Smith JS, 2013, EUR SPINE J, V22, P402, DOI 10.1007/s00586-012-2547-x
   Smith JS, 2011, SPINE, V36, P556, DOI 10.1097/BRS.0b013e3181eadd41
   Stevens KJ, 2006, J SPINAL DISORD TECH, V19, P77, DOI 10.1097/01.bsd.0000193820.42522.d9
   Uribe JS, 2012, J NEUROSURG-SPINE, V17, P476, DOI 10.3171/2012.8.SPINE111121
   Uribe JS, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS13534
   Wang MY, 2014, WORLD NEUROSURG, V81, DOI 10.1016/j.wneu.2012.10.002
   Wang MY, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1423
   Wang MY, 2013, J NEUROSURG-SPINE, V18, P4, DOI 10.3171/2012.9.SPINE111081
   Wang MY, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09286
   Wang XH, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.11.FOCUS12373
   Zilberberg MD, 2010, SEMIN RESP CRIT CARE, V31, P13, DOI 10.1055/s-0029-1246282
NR 43
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E649
EP E655
DI 10.1016/j.wneu.2019.03.237
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300081
PM 30947010
DA 2020-05-12
ER

PT J
AU Churi, ON
   Gupta, S
   Misra, BK
AF Churi, Omkar N.
   Gupta, Santosh
   Misra, Basant K.
TI Correlation of Preoperative Cranial Nerve Diffusion Tensor Tractography
   with Intraoperative Findings in Surgery of Cerebellopontine Angle Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle tumors; Cranial nerves; Diffusion tensor
   tractography; Fiber tracking; Vestibular schwannoma
ID SCHWANNOMAS ACOUSTIC NEUROMAS; IN-VIVO VISUALIZATION; VESTIBULAR
   SCHWANNOMAS; FACIAL-NERVE; FIBER TRACKING; CONSTRUCTIVE INTERFERENCE;
   PREDICTION; POSITION; TRACT
AB OBJECTIVE: Imaging to visualize nerves around tumors preoperatively could help the surgeon to plan the surgery and excise the tumor with preservation or improvement in patients' quality of life. In the present prospective study, we attempted to correlate the preoperative cranial nerves (i.e., trigeminal, abducens, facial, and vestibulocochlear diffusion tensor tractography and anatomic magnetic resonance imaging [MRI] findings) with intraoperative findings during cerebellopontine angle (CPA) tumor surgery.
   METHODS: The 40 enrolled patients had CPA tumors (31 vestibular schwannomas, 5 epidermoid tumors, 2 meningiomas, 2 trigeminal schwannomas). All the patients were undergoing microsurgery for the first time. They underwent preoperative MRI for anatomic and diffusion tensor imaging (DTI) data. The imaging series were postprocessed, and 3-dimensional images were obtained. The location of the involved nerves around the tumors was recorded during surgery by the senior surgeon, who was kept unaware of the results of the fiber tracking, and a correlation was performed.
   RESULTS: We evaluated the correlation between the DTI and intraoperative findings for the nerve location in relation to the tumor in the CPA. The correlation between the DTI and intraoperative findings for the facial, trigeminal, and vestibulocochlear nerves was 85% (34 of 40), 85% (34 of 40), and 75% (12 of 16), respectively.
   CONCLUSIONS: The modified technical parameters proposed could lead to better preservation of cranial nerve function, especially for patients with large tumors. To the best of our knowledge, the present study is the first systematic study of relevant cranial nerves in 40 patients with demonstration of the vestibulocochlear bundle by preoperative MRI in the most common CPA tumors using advanced MRI sequences such as diffusion tensor tractography and capturing the data in a multiplanar format.
C1 [Churi, Omkar N.; Misra, Basant K.] PD Hinduja Natl Hosp & MRC, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Gupta, Santosh] PD Hinduja Natl Hosp & MRC, Dept Radiol, Mumbai, Maharashtra, India.
RP Misra, BK (reprint author), PD Hinduja Natl Hosp & MRC, Dept Neurosurg, Mumbai, Maharashtra, India.
EM basantkmisra@gmail.com
CR Bagadia A, 2011, J CLIN NEUROSCI, V18, P633, DOI 10.1016/j.jocn.2010.08.026
   Bammer R, 2003, EUR J RADIOL, V45, P223, DOI 10.1016/S0720-048X(02)00311-X
   Borkar SA, 2016, NEUROL INDIA, V64, P965, DOI 10.4103/0028-3886.190270
   Burmeister HP, 2009, J COMPUT ASSIST TOMO, V33, P782, DOI 10.1097/RCT.0b013e31818da6bb
   CASSELMAN JW, 1993, AM J NEURORADIOL, V14, P47
   Chen DQ, 2011, NEUROSURGERY, V68, P1077, DOI 10.1227/NEU.0b013e31820c6cbe
   Everton KL, 2008, AM J NEURORADIOL, V29, P1344, DOI 10.3174/ajnr.A1089
   Gerganov VM, 2011, J NEUROSURG, V115, P1087, DOI 10.3171/2011.7.JNS11495
   Gjuric M, 2008, SKULL BASE-INTERD AP, V18, P317, DOI 10.1055/s-0028-1086056
   GUPTA S, 2008, INDIAN J RADIOL IMAG, V18, P37, DOI DOI 10.4103/0971-3026.35818
   Hodaie M, 2010, NEUROSURGERY, V66, P788, DOI 10.1227/01.NEU.0000367613.09324.DA
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   Kakizawa Y, 2008, J NEUROSURG, V108, P483, DOI 10.3171/JNS/2008/108/3/0483
   LALWANI AK, 1992, OTOLARYNG CLIN N AM, V25, P707
   Matthies C, 1997, NEUROSURGERY, V40, P1
   Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781
   Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052
   Nagae-Poetscher LM, 2004, AM J NEURORADIOL, V25, P1325
   Naganawa S, 2001, AM J NEURORADIOL, V22, P1179
   Nimsky C, 2005, NEUROSURGERY, V56, P130, DOI 10.1227/01.NEU.0000144842.18771.30
   Nimsky C, 2007, NEUROSURGERY, V61, P306, DOI [10.1227/01.NEU.0000204726.00088.6D, 10.1227/01.neu.0000279224.83998.7d]
   Nimsky C, 2006, NEUROIMAGE, V30, P1219, DOI 10.1016/j.neuroimage.2005.11.001
   Roundy N, 2012, J NEUROSURG, V116, P697, DOI 10.3171/2011.12.JNS111404
   Samii M, 2006, J NEUROSURG, V105, P527, DOI 10.3171/jns.2006.105.4.527
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Sampath P, 2000, J NEUROSURG, V92, P70, DOI 10.3171/jns.2000.92.1.0070
   Sartoretti-Schefer S, 2000, AM J NEURORADIOL, V21, P810
   Savardekar AR, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.12.FOCUS17672
   Song F, 2016, J NEUROSURG, V125, P787, DOI 10.3171/2015.7.JNS142922
   Taoka T, 2006, J MAGN RESON IMAGING, V24, P1005, DOI 10.1002/jmri.20725
   Thomas B, 2005, RIV NEURORADIOL, V18, P419, DOI 10.1177/197140090501800403
   Yoshino M, 2015, J NEUROSURG, V123, P1480, DOI 10.3171/2014.11.JNS14988
   Youssef AS, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09144
   Zhang YY, 2017, WORLD NEUROSURG, V99, P70, DOI 10.1016/j.wneu.2016.11.110
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E509
EP E516
DI 10.1016/j.wneu.2019.03.190
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300063
PM 30928584
DA 2020-05-12
ER

PT J
AU Clifton, W
   Edwards, S
   Dove, C
   Damon, A
   Simon, L
   Rosenbush, K
   Nottmeier, E
   Quinones-Hinojosa, A
   Pichelmann, M
AF Clifton, William
   Edwards, Steve
   Dove, Conrad
   Damon, Aaron
   Simon, Leslie
   Rosenbush, Kristin
   Nottmeier, Eric
   Quinones-Hinojosa, Alfredo
   Pichelmann, Mark
TI Finding the "Sweet Spot" for C2 Root Transection in C1 Lateral Mass
   Exposure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlas; C1; C2 nerve; Dorsal root ganglion; Fusion; Lateral mass;
   Preganglionic segment
ID NERVE ROOT; SCREW PLACEMENT; ATLANTOAXIAL FIXATION; ANATOMIC
   CONSIDERATIONS; POSTERIOR ARCH; ENTRY POINT; INSERTION; ATLAS; C-2
AB BACKGROUND: Atlantoaxiai fusion often requires C2 nerve transection for complete C1 lateral mass exposure. Nerve transection is made ideally at the preganglionic segment proximal to the dorsal root ganglion to minimize the risk of postoperative dysesthesias. If the nerve is transected too proximally, cerebrospinal fluid leak may be encountered by violation of the dura and arachnoid where the sensory and motor nerve rootlets exit the subarachnoid space. In this study we aimed to quantify the length of the C2 nerve preganglionic segment using cadaveric specimens and develop a method for reliable intraoperative localization for sectioning during C1-2 arthrodesis.
   METHODS: Using microsurgical techniques, 16 C2 nerves from 8 frozen and injected cadaveric cervical spine specimens were dissected. Two key measurements were taken to establish a reliable method of preganglionic segment identification. The "sweet spot" for nerve transection was based on the approximate location of the midpoint of the preganglionic segment.
   RESULTS: The final determination of the ideal spot for C2 nerve transection using these calculations was 3 mm lateral to the medial border of the lateral mass.
   CONCLUSIONS: This anatomic study found remarkable consistency in the preganglionic segment length. The medial border of the lateral mass appeared to be a consistently reliable landmark for identification of the preganglionic segment of the C2 nerve root. By using relationships between known anatomic structures intraoperatively, safety of atlantoaxial fixation can be optimized to maximize complication avoidance and satisfactory patient outcomes.
C1 [Clifton, William; Edwards, Steve; Nottmeier, Eric; Quinones-Hinojosa, Alfredo; Pichelmann, Mark] Mayo Clin Florida, Dept Neurol Surg, Jacksonville, FL 32224 USA.
   [Simon, Leslie] Mayo Clin Florida, Dept Emergency Med, Jacksonville, FL USA.
   [Dove, Conrad; Damon, Aaron; Rosenbush, Kristin] Mayo Clin Florida, Coll Med, Jacksonville, FL USA.
RP Clifton, W (reprint author), Mayo Clin Florida, Dept Neurol Surg, Jacksonville, FL 32224 USA.
EM Clifton.william@mayo.edu
RI Clifton, William/AAA-6109-2019
OI Clifton, William/0000-0003-3533-8776
CR Acar F, 2008, STEREOT FUNCT NEUROS, V86, P106, DOI 10.1159/000113872
   Al-Habib AF, 2017, J CRANIOVERTEBRAL JU, V8, P97, DOI 10.4103/jcvjs.JCVJS_36_17
   Badhiwala JH, 2017, SPINE, V42, pE1067, DOI 10.1097/BRS.0000000000002069
   Bilge O, 2004, SPINE, V29, P495, DOI 10.1097/01.BRS.0000113872.18219.7B
   Dong Y, 2003, SPINE, V28, P860, DOI 10.1097/00007632-200305010-00004
   Du JY, 2015, J NEUROSURG-SPINE, V22, P151, DOI 10.3171/2014.10.SPINE13805
   Elliott RE, 2015, J SPINAL DISORD TECH, V28, P171, DOI 10.1097/BSD.0b013e3182898aa9
   Elliott RE, 2012, WORLD NEUROSURG, V78, P697, DOI 10.1016/j.wneu.2011.10.035
   Fisahn C, 2017, WORLD NEUROSURG, V97, P221, DOI 10.1016/j.wneu.2016.10.007
   Hu Y, 2017, CLIN SPINE SURG, V30, pE662, DOI 10.1097/BSD.0000000000000280
   Huang DG, 2015, SPINE J, V15, P2271, DOI 10.1016/j.spinee.2015.07.008
   Huang DG, 2014, ORTHOP SURG, V6, P269, DOI 10.1111/os.12136
   Ishak B, 2017, WORLD NEUROSURG, V107, P194, DOI [10.1016/J.WNEU.2017.07.159, 10.1016/j.wneu.2017.07.159]
   Jacobson ME, 2012, ORTHOP CLIN N AM, V43, P11, DOI 10.1016/j.ocl.2011.09.004
   Janjua MB, 2017, CUREUS, V9, DOI 10.7759/cureus.1074
   Kang MM, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.07.010
   Lee SH, 2013, J CLIN NEUROSCI, V20, P162, DOI 10.1016/j.jocn.2012.01.045
   Lu DC, 2010, NEUROSURGERY, V66, pA141, DOI 10.1227/01.NEU.0000365744.54102.B9
   Lu J, 1998, SPINE, V23, P649, DOI 10.1097/00007632-199803150-00001
   Ma XY, 2005, SPINE, V30, P1519, DOI 10.1097/01.brs.0000168546.17788.49
   Salunke P, 2018, WORLD NEUROSURG, V118, pE925, DOI 10.1016/j.wneu.2018.07.101
   Stulik J, 2005, Acta Chir Orthop Traumatol Cech, V72, P22
   Wang Michael Y, 2002, Neurosurg Focus, V12, pE14
   Wang SL, 2011, SPINE, V36, P3, DOI 10.1097/BRS.0b013e3181c97dc7
   Xia H, 2004, SPINE, V29, P500, DOI 10.1097/01.BRS.0000113874.82587.33
   Yabuki S, 1996, SPINE, V21, P1513, DOI 10.1097/00007632-199607010-00004
   Yamagata T, 2013, NEUROL MED-CHIR, V53, P914, DOI 10.2176/nmc.tn2012-0288
   Yeom JS, 2013, SPINE J, V13, P786, DOI 10.1016/j.spinee.2013.04.006
   Yeom JS, 2012, SPINE J, V12, P476, DOI 10.1016/j.spinee.2012.06.010
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E738
EP E744
DI 10.1016/j.wneu.2019.03.256
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300092
PM 30951909
DA 2020-05-12
ER

PT J
AU Cunningham, M
   Azimi, S
   Zhang, GZ
AF Cunningham, Miles
   Azimi, Sina
   Zhang, GuangZhu
TI Intracerebral Delivery in Complex 3D Arrays: The Intracerebral
   Microinjection Instrument
SO WORLD NEUROSURGERY
LA English
DT Article
DE Functional neurosurgery; Intracerebral microinjection instrument;
   Restorative therapeutics; Stereotactic surgery
ID CELL TRANSPLANTATION; STEM-CELLS; MICROTRANSPLANTATION; BRAIN
AB OBJECTIVE: This video article describes and illustrates the function and application of the intracerebral microinjection instrument (IMI). This newly developed technology allows delivery of therapeutic agents within the human brain in complex 3-dimensional arrays using a single pass or minimal overlying penetrations through brain tissue.
   METHODS: The IMI uses a delivery microcannula with a reduced diameter that minimizes local trauma and is capable of delivering precise volumes of therapeutic agents to discrete brain substructures. The IMI also permits simultaneous recording of neural activity during the delivery procedure, enabling extreme precision using electrophysiologic mapping. Surgical planning software designed specifically for the IMI enables strategic placement of multiple injections.
   RESULTS: This technology platform is presently being --A successfully to deliver therapeutic stem cells to restore function in stroke patients.
   CONCLUSIONS: Additional applications of the IMI include delivery of viral vectors for gene therapy, infusion of neurotrophic factors, targeted delivery of chemotherapeutic agents, and delivery of antiretroviral medications.
C1 [Cunningham, Miles; Azimi, Sina] Harvard Med Sch, McLean Hosp, Lab Neural Reconstruct, Belmont, MA 02478 USA.
   [Zhang, GuangZhu] PLA, Army Gen Hosp, Affiliated BaYi Brain Hosp, Beijing, Peoples R China.
RP Cunningham, M (reprint author), Harvard Med Sch, McLean Hosp, Lab Neural Reconstruct, Belmont, MA 02478 USA.
EM mcunningham@mclean.harvard.edu
CR Bartus RT, 2015, NEUROBIOL DIS, V78, P162, DOI 10.1016/j.nbd.2015.03.023
   Bartus RT, 2014, MOL THER, V22, P487, DOI 10.1038/mt.2013.281
   Bjarkam CR, 2010, STEREOT FUNCT NEUROS, V88, P56, DOI 10.1159/000268743
   Cunningham MG, 2004, NEUROSURGERY, V54, P1497, DOI 10.1227/01.NEU.0000125007.03145.00
   FINSEN BR, 1990, PROG BRAIN RES, V82, P111
   FINSEN BR, 1991, J NEUROIMMUNOL, V32, P159, DOI 10.1016/0165-5728(91)90008-U
   Glud AN, 2016, NEUROMODULATION, V19, P708, DOI 10.1111/ner.12484
   Kondziolka D, 2004, CELL TRANSPLANT, V13, P749, DOI 10.3727/000000004783983350
   Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038
   Marin G, 2001, J NEUROSCI METH, V106, P121, DOI 10.1016/S0165-0270(01)00332-6
   Mendez I, 2000, J NEUROSURG, V92, P493, DOI 10.3171/jns.2000.92.3.0493
   NIKKHAH G, 1994, NEUROSCIENCE, V63, P57, DOI 10.1016/0306-4522(94)90007-8
   NIKKHAH G, 1994, BRAIN RES, V633, P133, DOI 10.1016/0006-8993(94)91532-6
   Silvestrini MT, 2015, MOL THER, V23, P119, DOI 10.1038/mt.2014.155
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1172
EP E1175
DI 10.1016/j.wneu.2019.04.081
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300146
PM 31003027
DA 2020-05-12
ER

PT J
AU De Vilalta, A
   Kournoutas, I
   Ojeda, PL
   Canals, AG
   Vigo, V
   Rutledge, CW
   Chae, R
   Abla, AA
   Rubio, RR
AF De Vilalta, Alex
   Kournoutas, Ioannis
   Lopez Ojeda, Pablo
   Gabarros Canals, Andreu
   Vigo, Vera
   Rutledge, Caleb W.
   Chae, Ricky
   Abla, Adib A.
   Rubio, Roberto Rodriguez
TI Revascularization of the Anterior Inferior Cerebellar Artery Using
   Extracranial and Intracranial Donors: A Morphometric Cadaveric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; End-to-side; Occipital artery;
   Posterior inferior cerebellar artery; Revascularization; Side-to-side
ID MEDULLA-OBLONGATA; ANEURYSMS; BYPASS; ANATOMY; VARIANT; OPTIONS
AB INTRODUCTION: Anterior inferior cerebellar artery (AICA) aneurysms are rare, accounting for 0.2%-1.3% of all intracranial aneurysms. The standard treatment is often endovascular embolization or neck clipping; however, sacrifice of the parent vessel is sometimes necessary. Addition of revascularization procedures is a subject of controversy. The occipital artery (OA) has been used as a donor for bypass, but recently there has been a trend toward intracranial-intracranial approaches. The posterior inferior cerebellar artery (PICA)-AICA side-to-side bypass may serve as a safe alternative.
   OBJECTIVE: To characterize the PICA-AICA side-to-side bypass and the OA-AICA end-to-side bypass and review the literature relevant to AICA revascularization.
   METHODS: We performed a far-lateral approach on 12 cadaveric specimens and analyzed the regional anatomy. On this basis, we performed either an OA-AICA or a PICA-AICA bypass and took morphometric measurements relevant to the technique.
   RESULTS: PICA-AICA bypass was successful in 6/12 specimens. The length of the flocculopeduncular segment was 42.6 +/- 15.8 mm in the specimens in which the bypass was feasible and 26.2 +/- 7.2 mm in those in which the bypass was not feasible (P = 0.04). Mean distance between AICA and PICA was 5.3 +/- 4 mm in the specimens in which side-to-side bypass was feasible and 11.6 +/- 4.2 mm in the specimens in which it was not (P = 0.02). OA-AICA end-to-side bypass was feasible in all the specimens (75% in the flocculopeduncular segment; 25% in the cortical segment).
   CONCLUSIONS: This is the first cadaveric study analyzing the PICA-AICA side-to-side bypass for AICA revascularization. Our analyses provide evidence for the feasibility of this bypass and document the anatomic variations that may indicate its use.
C1 [Rutledge, Caleb W.; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [De Vilalta, Alex; Kournoutas, Ioannis; Vigo, Vera; Chae, Ricky; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
   [De Vilalta, Alex; Lopez Ojeda, Pablo; Gabarros Canals, Andreu] Hosp Univ Bellvitge, Dept Neurosurg, Barcelona, Spain.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM luis.rodriguezrubio@ucsf.edu
OI Chae, Ricky/0000-0001-5014-9303; Rodriguez-Rubio,
   Roberto/0000-0002-7206-309X
CR Abla AA, 2016, J NEUROSURG, V124, P1275, DOI 10.3171/2015.5.JNS15368
   Abla AA, 2014, J NEUROSURG, V120, P1364, DOI 10.3171/2014.3.JNS132219
   AKAR ZC, 1995, J NEUROSURG, V82, P97, DOI 10.3171/jns.1995.82.1.0097
   Akhtar S, 2016, INT J SURG CASE REP, V22, P23, DOI 10.1016/j.ijscr.2016.03.006
   Amin-Hanjani S, 2007, SURG NEUROL, V68, pS4, DOI 10.1016/j.surneu.2007.07.051
   Amin-Hanjani S, 2010, ACTA NEUROCHIR, V152, P1021, DOI 10.1007/s00701-010-0635-4
   Andaluz N, 2005, ACTA NEUROCHIR, V147, P419, DOI 10.1007/s00701-004-0453-7
   Ashley WW, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E20
   Ates O, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E9
   AUSMAN JI, 1990, J NEUROSURG, V72, P554, DOI 10.3171/jns.1990.72.4.0554
   Bambakidis NC, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.1.FOCUS0915
   Ban Seung Pil, 2017, Oper Neurosurg (Hagerstown), V13, P679, DOI 10.1093/ons/opx039
   Baskaya Mustafa K, 2006, Neurosurgery, V58, pE388
   Benet A, 2019, J NEUROSURG, V130, P207, DOI 10.3171/2017.6.JNS17518
   Crowley RW, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0911
   Evans JJ, 2004, NEUROSURGERY, V55, P1036, DOI 10.1227/01.NEU.0000140822.64362.C6
   Fujimura M, 2012, NEUROL MED-CHIR, V52, P435, DOI 10.2176/nmc.52.435
   Gandhi S, 2019, OPER NEUROSURG, V16, pE119, DOI 10.1093/ons/opy201
   Gonzalez LF, 2004, NEUROSURGERY, V55, P1025, DOI 10.1227/01.NEU.0000141083.00866.82
   Gopalakrishnan CV, 2009, BRIT J NEUROSURG, V23, P554, DOI 10.1080/02688690902987778
   Kanamori F, 2016, NAGOYA J MED SCI, V78, P517, DOI 10.18999/nagjms.78.4.517
   Kawashima M, 2005, J NEUROSURG, V102, P132, DOI 10.3171/jns.2005.102.1.0132
   Koizumi H, 2012, RADIOL CASE REPORTS, V7, P2
   Lee BS, 2018, OPER NEUROSURG, V15, P418, DOI 10.1093/ons/opx275
   Li X, 2012, NEUROSURG REV, V35, P111, DOI 10.1007/s10143-011-0338-1
   Lv XL, 2016, INTERV NEURORADIOL, V22, P643, DOI 10.1177/1591019916656474
   Meybodi AT, 2018, J NEUROSURG, V129, P691, DOI 10.3171/2017.4.JNS163195
   Meybodi AT, 2016, J NEUROSURG, V125, P909, DOI 10.3171/2015.8.JNS151411
   NISHIMOTO A, 1983, J NEUROSURG, V59, P697, DOI 10.3171/jns.1983.59.4.0697
   Ooigawa H, 2015, INTERDISCIP NEUROSUR, V2, P123, DOI 10.1016/j.inat.2015.04.003
   Oyama H, 2010, NEUROL MED-CHIR, V50, P571, DOI 10.2176/nmc.50.571
   RHOTON AL, NEUROSURGERY S, V47, pS2
   Rodriguez-Hernandez A, 2013, WORLD NEUROSURG, V80, P103, DOI 10.1016/j.wneu.2012.09.010
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Sanmillan JL, 2016, WORLD NEUROSURG, V89, P368, DOI 10.1016/j.wneu.2016.01.081
   Suzuki K, 1999, SURG NEUROL, V51, P509, DOI 10.1016/S0090-3019(97)00462-X
   Thines L, 2016, NEUROCHIRURGIE, V62, P1, DOI 10.1016/j.neuchi.2015.03.008
   Tokimura H, 2012, NEUROSURG REV, V35, P497, DOI 10.1007/s10143-012-0390-5
   Umekawa M, 2018, WORLD NEUROSURG, V116, P209, DOI 10.1016/j.wneu.2018.04.161
   Vigo V, 2018, WORLD NEUROSURG, V136, P23
   Wang L, 2018, WORLD NEUROSURG, V115, P357, DOI 10.1016/j.wneu.2018.04.173
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E768
EP E778
DI 10.1016/j.wneu.2019.03.260
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300096
PM 30951912
DA 2020-05-12
ER

PT J
AU Denadai, R
   Raposo-Amaral, CA
   Buzzo, CL
   Ghizoni, E
   Cendes, F
   Raposo-Amaral, CE
AF Denadai, Rafael
   Raposo-Amaral, Cesar Augusto
   Buzzo, Celso Luiz
   Ghizoni, Enrico
   Cendes, Fernando
   Raposo-Amaral, Cassio Eduardo
TI Anatomical Fat Grafting for Reconstruction of Frontotemporal Contour
   Deformities After Neurosurgical and Craniofacial Surgical Interventions:
   A Symmetry Outcome Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deformities; Fat grafting; Frontal; Frontotemporal; Symmetry; Temporal
ID FACIAL TISSUE DEPTH; DECOMPRESSIVE CRANIECTOMY; CLINICAL-IMPLICATIONS;
   RECIPIENT SITE; CRANIOPLASTY; COMPARTMENTS; CRANIOTOMY; ASYMMETRY;
   CHILDREN; FACE
AB BACKGROUND: Fait grafting has been described as an option to repair frontotemporal contour deformities (volumetric deficiency of bone and/or soft tissues) after neurosurgical/craniofacial surgical interventions. However, technical surgical descriptions have varied, with reports describing the bolus fat injection or the classical multi-layer injection, but with no detailed descriptions concerning how and where the fat should be grafted. The purpose of this study was to assess the frontotemporal symmetry outcomes after a single fat-grafting procedure for postoperative frontotemporal contour deformity reconstructions using the anatomical fat-grafting approach.
   METHODS: A prospective analysis was conducted of consecutive patients (n = 106) who underwent anatomical fat grafting (Coleman's structural fat grafting technique using anatomical facial subunit and fat compartment principles) to reconstruct frontotemporal contour deformities after neurosurgical/craniofacial surgical interventions. A subjective assessment by a panel of external surgical professionals and laypersons was obtained to grade the frontotemporal symmetry. Objective ultrasound symmetry assessment was blindly performed preoperatively and at 3 and 12-month follow-up.
   RESULTS: There were significant (all P < 0.05) post-operative subjective and objective frontotemporal symmetry enhancements (preoperative < postoperative) after anatomical fat grafting, with no differences (all P > 0.05) between the 3- and 12-month postoperative comparisons. Thirty-seven percent of patients required an additional fat grafting session for residual asymmetry after 12 months of follow-up.
   CONCLUSIONS: Patients with frontotemporal contour deformities presented improved subjective and objective frontotemporal symmetry after an anatomical fat grafting session.
C1 [Denadai, Rafael; Raposo-Amaral, Cesar Augusto; Buzzo, Celso Luiz; Raposo-Amaral, Cassio Eduardo] SOBRAPAR Hosp, Inst Plast & Craniofacial Surg, Sao Paulo, Brazil.
   [Ghizoni, Enrico] Univ Campinas UNICAMP, Dept Neurol, Div Neurosurg, Sao Paulo, Brazil.
   [Cendes, Fernando] Univ Campinas UNICAMP, BRAINN Brazilian Inst Neurosci, Sao Paulo, Brazil.
   [Cendes, Fernando] Univ Campinas UNICAMP, Dept Neurol, Neuroimaging Lab, Neurotechnol Res Innovat & Disseminat Ctr, Sao Paulo, Brazil.
RP Denadai, R (reprint author), SOBRAPAR Hosp, Inst Plast & Craniofacial Surg, Sao Paulo, Brazil.
EM denadai.rafael@hotmail.com
RI Cendes, Fernando/C-1301-2012; Denadai, Rafael/A-8038-2013
OI Cendes, Fernando/0000-0001-9336-9568; Denadai,
   Rafael/0000-0003-0525-3480; Ghizoni, Enrico/0000-0001-8684-1780
CR Asemota A, 2018, J CRANIOFAC SURG, V29, P130, DOI 10.1097/SCS.0000000000004107
   Aspinall CL, 2010, J CRANIOFAC SURG, V21, P1330, DOI 10.1097/SCS.0b013e3181ef2a5b
   Castro-Govea Y, 2018, ARCH PLAST SURG-APS, V45, P128, DOI 10.5999/aps.2017.00997
   Chen X, 2019, ANN PLAS SURG, V82, P110, DOI 10.1097/SAP.0000000000001683
   Choi J, 2018, ARCH PLAST SURG-APS, V45, P69, DOI 10.5999/aps.2017.01088
   Coleman SR, 2006, PLAST RECONSTR SURG, V118, p108S, DOI 10.1097/01.prs.0000234610.81672.e7
   Cotofana S, 2017, PLAST RECONSTR SURG, V139, DOI 10.1097/PRS.0000000000003174
   De Greef S, 2006, FORENSIC SCI INT, V159, pS126, DOI 10.1016/j.forsciint.2006.02.034
   Denadai R, 2019, PLAST RECONSTR SURG, V143, P823, DOI 10.1097/PRS.0000000000005389
   Denadai R, 2019, PLAST RECONSTR SURG, V143, P544, DOI 10.1097/PRS.0000000000005220
   Denadai R, 2017, PLAST RECONSTR SURG, V140, p50E, DOI 10.1097/PRS.0000000000003440
   Ettorre G, 2006, J CRANIO MAXILL SURG, V34, P65, DOI 10.1016/j.jcms.2005.11.002
   Gabbay JS, 2013, PLAST RECONSTR SURG, V131, P1329, DOI 10.1097/PRS.0b013e31828bd70c
   Gordon CR, 2018, J CRANIOFAC SURG, V29, P4, DOI 10.1097/SCS.0000000000004063
   Gordon CR, 2014, OPER NEUROSURG, V10, P179, DOI 10.1227/NEU.0000000000000296
   Guo XS, 2019, AESTHET SURG J, V39, P1071, DOI 10.1093/asj/sjy233
   Haddock NT, 2012, PLAST RECONSTR SURG, V130, P1235, DOI 10.1097/PRS.0b013e31826d16a6
   Halani SH, 2017, NEUROSURGERY, V81, P204, DOI 10.1093/neuros/nyx054
   Huang RL, 2018, JAMA FACIAL PLAST SU, V20, P387, DOI 10.1001/jamafacial.2018.0165
   Huang RL, 2017, AESTHET SURG J, V37, P855, DOI 10.1093/asj/sjw257
   Jackson TH, 2013, AM J ORTHOD DENTOFAC, V144, P663, DOI 10.1016/j.ajodo.2013.06.020
   Jiang TR, 2016, J PLAST RECONSTR AES, V69, P1621, DOI 10.1016/j.bjps.2016.06.027
   Kato H, 2014, PLAST RECONSTR SURG, V133, p303E, DOI 10.1097/PRS.0000000000000066
   Kaufman MR, 2007, PLAST RECONSTR SURG, V119, P2287, DOI 10.1097/01.prs.0000260712.44089.e7
   Khouri RK, 2017, PLAST RECONSTR SURG, V140, p466E, DOI 10.1097/PRS.0000000000003648
   Khouri RK, 2014, PRS-GLOB OPEN, V2, DOI 10.1097/GOX.0000000000000183
   Krastev TK, 2018, JAMA FACIAL PLAST SU, V20, P351, DOI 10.1001/jamafacial.2018.0102
   Laurent F, 2006, Ann Chir Plast Esthet, V51, P512, DOI 10.1016/j.anplas.2006.02.008
   LEFEBVRE A, 1982, CAN J PSYCHIAT, V27, P579, DOI 10.1177/070674378202700712
   Legnani FG, 2013, ACTA NEUROCHIR, V155, P2281, DOI 10.1007/s00701-013-1882-y
   Lin CW, 2018, INT J ORAL MAX SURG, V47, P48, DOI 10.1016/j.ijom.2017.06.031
   Manheim MH, 2000, J FORENSIC SCI, V45, P48
   Menick FJ, 1998, OPER TECH PLAST RECO, V5, P12
   Mojallal A, 2009, PLAST RECONSTR SURG, V124, P471, DOI 10.1097/PRS.0b013e3181af023a
   Muresan C, 2012, J RECONSTR MICROSURG, V28, P319, DOI 10.1055/s-0032-1311690
   Peckmann TR, 2013, J FORENSIC SCI, V58, P1429, DOI 10.1111/1556-4029.12211
   Pessa JE, 2017, AESTHET SURG J, V37, P969, DOI 10.1093/asj/sjx089
   Reisch R, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.024
   Rohrich RJ, 2007, PLAST RECONSTR SURG, V119, P2219, DOI 10.1097/01.prs.0000265403.66886.54
   Rychen J, 2018, WORLD NEUROSURG, V113, P163, DOI 10.1016/j.wneu.2018.02.016
   Santiago GF, 2018, J CRANIOFAC SURG, V29, P1723, DOI 10.1097/SCS.0000000000004639
   Schaverien MV, 2009, PLAST RECONSTR SURG, V123, P695, DOI 10.1097/PRS.0b013e31817d53fc
   Scheuer JF, 2017, PLAST RECONSTR SURG, V139, p50E, DOI 10.1097/PRS.0000000000002913
   Shi Y, 2016, DERMATOL SURG, V42, P535, DOI 10.1097/DSS.0000000000000615
   SILVA RAFAEL DENADAI PIGOZZI DA, 2017, Rev. Col. Bras. Cir., V44, P154, DOI 10.1590/0100-69912017002008
   Ueland HO, 2019, J PLAST RECONSTR AES, V72, P973, DOI 10.1016/j.bjps.2018.12.031
   Vaca EE, 2017, J PLAST RECONSTR AES, V70, P401, DOI 10.1016/j.bjps.2016.10.008
   van Veen MM, 2018, J PLAST RECONSTR AES, V71, P1181, DOI 10.1016/j.bjps.2018.04.007
   Vetrano IG, 2019, WORLD NEUROSURG, V122, pE1398, DOI 10.1016/j.wneu.2018.11.064
   Wang TT, 2017, AESTHET SURG J, V37, P375, DOI 10.1093/asj/sjw271
NR 50
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1064
EP E1082
DI 10.1016/j.wneu.2019.04.044
PG 19
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300133
PM 30980984
DA 2020-05-12
ER

PT J
AU Deng, L
   Zhang, G
   Wei, X
   Yang, WS
   Li, R
   Shen, YQ
   Xie, XF
   Lv, XN
   Li, YL
   Zhao, LB
   Lv, FJ
   Qin, XY
   Xie, P
   Li, Q
AF Deng, Lan
   Zhang, Gang
   Wei, Xiao
   Yang, Wen-Song
   Li, Rui
   Shen, Yi-Qing
   Xie, Xiong-Fei
   Lv, Xin-Ni
   Li, Yu-Lun
   Zhao, Li-Bo
   Lv, Fa-Jin
   Qin, Xin-Yue
   Xie, Peng
   Li, Qi
TI Comparison of Satellite Sign and Island Sign in Predicting Hematoma
   Growth and Poor Outcome in Patients with Primary Intracerebral
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Hematoma growth; Intracerebral hemorrhage; Island
   sign; Satellite sign
ID NONCONTRAST COMPUTED-TOMOGRAPHY; BLACK-HOLE SIGN; IMAGING PREDICTOR;
   SPOT SIGN; EXPANSION; DENSITY; SHAPE; ENLARGEMENT; ARTICLE
AB OBJECTIVE: Satellite sign (SS) and island sign (IS) are novel noncontrast computed tomography (CT) predictors of hematoma growth. The aim of this study was to compare diagnostic performance of IS and SS in predicting hematoma growth and functional outcome in patients with intracerebral hemorrhage (ICH).
   METHODS: The study included patients with ICH who underwent baseline CT scan within 6 hours of symptom onset and follow-up CT scan within 36 hours after initial CT between July 2012 and April 2017. Sensitivity, specificity, positive predictive value, and negative predictive value of IS and SS in predicting hematoma growth and functional outcome were assessed. Accuracy of the 2 signs in predicting hematoma growth and functional outcome was analyzed using receiver operating characteristic analysis. Association between the presence of IS and SS and ICH growth was assessed using multivariate logistic regression.
   RESULTS: Of 307 patients with ICH, IS was observed in 46 patients (15.0%), and SS was observed in 151 patients (49.2%). Rates of hematoma growth were 40.4% in SS+ patients, 91.3% in IS+ patients, 18.4% in SS-IS- patients, 21.1% in SS+IS- patients, 100% in SS-IS+ patients, and 90.5% in SS+ IS+ patients. After adjusting for potential confounders, IS remained an independent predictor for hematoma growth and poor functional outcome. The area under the curve of IS was significantly larger than the area under the curve of SS in predicting hematoma growth (P = 0.001).
   CONCLUSIONS: IS seems to be an optimal shape irregularity imaging marker for predicting hematoma growth and functional outcome in patients with ICH.
C1 [Deng, Lan; Yang, Wen-Song; Li, Rui; Lv, Xin-Ni; Qin, Xin-Yue; Xie, Peng; Li, Qi] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.
   [Shen, Yi-Qing; Xie, Xiong-Fei; Li, Yu-Lun; Lv, Fa-Jin] Chongqing Med Univ, Affiliated Hosp 1, Dept Radiol, Chongqing, Peoples R China.
   [Zhang, Gang] First Peoples Hosp Zunyi, Dept Cerebrovasc Dis, Zunyi, Peoples R China.
   [Wei, Xiao] Chongqing Med & Pharmaceut Coll, Dept Med Technol, Chongqing, Peoples R China.
   [Zhao, Li-Bo] Chongqing Med Univ, Dept Neurol, Yongchuan Hosp, Chongqing, Peoples R China.
RP Li, Q (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China.
EM qili_md@126.com
RI Li, Qi/AAG-3893-2020
FU National Key R&D Program of China [2018YFC1312200, 2018YFC1312203];
   Young Elite Scientist Sponsorship Program by China Association of
   Science and Technology [2017QNRC001]; Health and Family Planning
   Commission of Chongqing [2017MSXM014]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [81200899]
FX This study was supported by grants from the National Key R&D Program of
   China (No. 2018YFC1312200, 2018YFC1312203), Young Elite Scientist
   Sponsorship Program by China Association of Science and Technology (No.
   2017QNRC001), Health and Family Planning Commission of Chongqing (No.
   2017MSXM014), and National Natural Science Foundation of China (No.
   81200899).
CR Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Blacquiere D, 2015, STROKE, V46, P3111, DOI 10.1161/STROKEAHA.115.010566
   Boulouis G, 2017, STROKE, V48, P1120, DOI 10.1161/STROKEAHA.116.015062
   Boulouis G, 2016, JAMA NEUROL, V73, P961, DOI 10.1001/jamaneurol.2016.1218
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Delcourt C, 2016, STROKE, V47, P1227, DOI 10.1161/STROKEAHA.116.012921
   Delcourt C, 2012, NEUROLOGY, V79, P314, DOI 10.1212/WNL.0b013e318260cbba
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Dowlatshahi D, 2011, NEUROLOGY, V76, P1238, DOI 10.1212/WNL.0b013e3182143317
   Fujii Y, 1998, STROKE, V29, P1160, DOI 10.1161/01.STR.29.6.1160
   FUJII Y, 1994, J NEUROSURG, V80, P51, DOI 10.3171/jns.1994.80.1.0051
   Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21
   Huang YW, 2018, BIOSCI TRENDS, V12, P193, DOI 10.5582/bst.2018.01061
   Li Q, 2019, NEUROCRIT CARE, V30, P601, DOI 10.1007/s12028-018-0644-3
   Li Q, 2018, STROKE, V49, pE35, DOI 10.1161/STROKEAHA.117.020016
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Shimoda Y, 2017, CEREBROVASC DIS, V44, P105, DOI 10.1159/000477179
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Xiong X, 2018, MED SCI MONITOR, V24, DOI 10.12659/MSM.906708
   Yu ZY, 2018, STROKE, V49, pE34, DOI 10.1161/STROKEAHA.117.019992
   Yu ZY, 2017, WORLD NEUROSURG, V108, P347, DOI 10.1016/j.wneu.2017.09.022
   Yu ZY, 2017, CLIN NEUROL NEUROSUR, V162, P67, DOI 10.1016/j.clineuro.2017.09.008
   Zhang F, 2018, WORLD NEUROSURG, V120, pE304, DOI 10.1016/j.wneu.2018.08.056
   Zheng J, 2018, WORLD NEUROSURG, V117, pE167, DOI 10.1016/j.wneu.2018.05.221
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E818
EP E825
DI 10.1016/j.wneu.2019.03.273
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300102
PM 30954737
DA 2020-05-12
ER

PT J
AU Deng, LH
   Qiu, S
   Wang, L
   Li, YX
   Wang, DR
   Liu, M
AF Deng, Linghui
   Qiu, Shi
   Wang, Lu
   Li, Yuxiao
   Wang, Deren
   Liu, Ming
TI Comparison of Four Food and Drug Administratione-Approved Mechanical
   Thrombectomy Devices for Acute Ischemic Stroke: A Network Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Mechanical thrombectomy devices; Network
   meta-analysis
ID STENT-RETRIEVER THROMBECTOMY; TISSUE-PLASMINOGEN ACTIVATOR; ENDOVASCULAR
   TREATMENT; MERCI RETRIEVER; THERAPY; REVASCULARIZATION; RECANALIZATION;
   INCONSISTENCY; GENERATION; MANAGEMENT
AB BACKGROUND: The use of mechanical thrombectomy for the treatment of acute ischemic stroke (AIS) is rapidly increasing. However, there are limited data on the comparative effects of the various devices approved by the U. S. Food and Drug Administration for the treatment of AIS. We aimed to perform a network meta-analysis to assess the relative efficacy and safety of 4 thrombectomy devices.
   METHODS: We searched PubMed, the Cochrane Library Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) and parallel group observational studies that assessed thrombectomy devices in patients with AIS. Primary efficacy outcomes included functional independence (90-day modified Rankin Scale score) and recanalization rate (thrombolysis in cerebral infarction score). Safety outcomes included incidence of symptomatic intracranial hemorrhages and 90-day mortality.
   RESULTS: Five RCTs and 5 observational studies, including 1659 participants, were included. According to GRADE (Grading of Recommendations, Assessment, Development and Evaluations), most of the studies are of moderate quality of evidence. Compared with Penumbra, Solitaire and Trevo were associated with higher rates of functional independence (3.75 [1.44-7.66] and 4.68 [1.42-11.50], respectively). For revascularization, Solitaire and Trevo had higher rates of successful recanalization than Merci (2.99 [1.15-6.53] and 3.34 [1.20-8.01], respectively). In terms of safety outcomes (symptomatic intracerebral hemorrhage and mortality), there was no significant difference between any comparators.
   CONCLUSIONS: We concluded that stent retriever devices were superior to nonestent retriever devices in functional outcomes and recanalization without significant increases in death or symptomatic hemorrhage. We found no evidence for a differential therapy effect by stent type. Further high-quality RCTs assessing efficacy difference between these 2 stent retrievers are justified.
C1 [Deng, Linghui; Wang, Lu; Li, Yuxiao; Wang, Deren; Liu, Ming] Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, Dept Neurol, Chengdu, Sichuan, Peoples R China.
   [Qiu, Shi] Sichuan Univ, West China Hosp, Dept Urol, Inst Urol, Chengdu, Sichuan, Peoples R China.
   [Qiu, Shi] Sichuan Univ, West China Hosp, Ctr Biomed Big Data, Chengdu, Sichuan, Peoples R China.
RP Liu, M (reprint author), Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, Dept Neurol, Chengdu, Sichuan, Peoples R China.
EM wyplmh@hotmail.com
OI D, L/0000-0003-2153-6421; Wang, Deren/0000-0002-2388-3585
FU Major International (Regional) Joint Research Project, National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81620108009]; National Key Research and Development Program of China,
   Ministry of Science and Technology of China [2016YFC1300500-505]; Key
   Research and Development Program, Science and Technology Department of
   Sichuan Province [2017SZ0007]
FX This study was supported by Major International (Regional) Joint
   Research Project, National Natural Science Foundation of China (grant
   number 81620108009), The National Key Research and Development Program
   of China, Ministry of Science and Technology of China
   (2016YFC1300500-505), and Key Research and Development Program, Science
   and Technology Department of Sichuan Province (grant number 2017SZ0007).
CR Badhiwala JH, 2015, JAMA-J AM MED ASSOC, V314, P1832, DOI 10.1001/jama.2015.13767
   Broussalis E, 2013, AM J NEURORADIOL, V34, P366, DOI 10.3174/ajnr.A3195
   Bush CK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147287
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Deshaies EM, 2014, J NEUROSURG, V121, P12, DOI 10.3171/2014.2.JNS131372
   Dippel DW, 2016, STROKE, V47, P2574, DOI 10.1161/STROKEAHA.116.013929
   Elgendy IY, 2015, J AM COLL CARDIOL, V66, P2498, DOI 10.1016/j.jacc.2015.09.070
   Friedrich B, 2016, ROFO-FORTSCHR RONTG, V188, P259, DOI 10.1055/s-0041-106899
   Furie KL, 2018, STROKE, V49, P509, DOI 10.1161/STROKEAHA.118.020176
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Grech R, 2016, CLIN RADIOL, V71, P48, DOI 10.1016/j.crad.2015.09.011
   Hentschel KA, 2017, J NEUROSURG, V126, P1123, DOI 10.3171/2016.2.JNS152086
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2012, RES SYNTH METHODS, V3, P98, DOI 10.1002/jrsm.1044
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jang MU, 2014, J STROKE CEREBROVASC, V23, pE339, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.027
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kang DH, 2017, J KOREAN NEUROSURG S, V60, P335, DOI 10.3340/jkns.2016.0809.005
   Khatri P, 2009, NEUROLOGY, V73, P1066, DOI 10.1212/WNL.0b013e3181b9c847
   Leker RR, 2012, STROKE, V43, P3389, DOI 10.1161/STROKEAHA.112.673665
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Marmagkiolis K, 2015, JACC-CARDIOVASC INTE, V8, P1758, DOI 10.1016/j.jcin.2015.07.021
   Mazighi M, 2009, LANCET NEUROL, V8, P802, DOI 10.1016/S1474-4422(09)70182-6
   Mendonca N, 2014, J NEUROIMAGING, V24, P167, DOI 10.1111/j.1552-6569.2012.00730.x
   Nogueira RG, 2012, LANCET, V380, P1231, DOI 10.1016/S0140-6736(12)61299-9
   Punal-Rioboo J, 2014, INTERV NEUROL, V3, P149, DOI 10.1159/000430474
   Ribo M, 2014, J NEUROINTERV SURG, V6, P265, DOI 10.1136/neurintsurg-2013-010748
   Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643
   Salanti G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099682
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Saver JL, 2012, LANCET, V380, P1241, DOI 10.1016/S0140-6736(12)61384-1
   Smith WS, 2008, STROKE, V39, P1205, DOI 10.1161/STROKEAHA.107.497115
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Touma L, 2016, JAMA NEUROL, V73, P275, DOI 10.1001/jamaneurol.2015.4441
   van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167
   Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7
   Zangerle A, 2007, NEUROLOGY, V68, P39, DOI 10.1212/01.wnl.0000250341.38014.d2
NR 38
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E49
EP E57
DI 10.1016/j.wneu.2019.02.011
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300008
PM 30802552
DA 2020-05-12
ER

PT J
AU Desai, SM
   Mehta, A
   Morrison, AA
   Gross, BA
   Jankowitz, BT
   Jovin, TG
   Jadhav, AP
AF Desai, Shashvat M.
   Mehta, Amol
   Morrison, Andrew A.
   Gross, Bradley A.
   Jankowitz, Brian T.
   Jovin, Tudor G.
   Jadhav, Ashutosh P.
TI Endovascular Thrombectomy, Platelet Count, and Intracranial Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial hemorrhage; Ischemic stroke; Large vessel occlusion;
   Platelet count; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; THROMBOLYSIS; ALTEPLASE
AB BACKGROUND: Intracranial hemorrhage can be a devastating complication of endovascular thrombectomy (ET) after acute ischemic stroke increasing disability and mortality. Patients with low platelet count were excluded from major ET trials. This study explores the association between platelet count and intracranial hemorrhage after ET.
   METHODS: A retrospective review of patients undergoing ET for anterior circulation large vessel occlusions at a single comprehensive stroke center between January 2015 and February 2018 was performed. Demographic and clinical information including National Institutes of Health Stroke Scale score, intravenous tissue plasminogen activator administration, ASPECTS, platelet count, international normalized ratio, time from symptom onset to recanalization, and modified thrombolysis in cerebral infarction score were analyzed. Radiological imaging and clinical course in the hospital was evaluated to identify parenchymal hemorrhage and symptomatic intracranial hemorrhage (sICH). Univariable and multivariable analyses were conducted.
   RESULTS: A total of 555 patients underwent ET and 43% were male. The mean age and National Institutes of Health Stroke Scale score were 71 +/- 14 years and 17 +/- 6, respectively. Parenchymal hemorrhage-2 and sICH (European-Australian Cooperative Acute Stroke Study-III criteria) were noted in 9.7% and 5.8% patients, respectively. Rates of sICH in patients with platelet count <100,000 (n = 15), 100,000 to <150,000 (n = 59), and >= 150,000 (n = 481) were 6.7% (n = 1), 10.1% (n = 6), and 5.2% (n = 25), respectively (P = 0.25), and rates of modified Rankin Scale 0-2 at 90 days were 26.7%, 23.7%, and 36.4%, respectively (P = 0.12). Low ASPECTS was a significant predictor of sICH per European-Australian Cooperative Acute Stroke Study-III definition (P value = 0.046). Platelet count was not a predictor (P = 0.386) of sICH.
   CONCLUSIONS: Risk of sICH after ET is low and comparable in patients with low and normal platelet counts. Low platelets should not exclude patients from undergoing intra-arterial therapy.
C1 [Desai, Shashvat M.; Jadhav, Ashutosh P.] Univ Pittsburgh, Sch Med, Med Ctr, Dept Neurol, Pittsburgh, PA 15260 USA.
   [Gross, Bradley A.; Jankowitz, Brian T.; Jadhav, Ashutosh P.] Univ Pittsburgh, Sch Med, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
   [Mehta, Amol; Morrison, Andrew A.] Univ Pittsburgh, Sch Med, Med Ctr, Pittsburgh, PA USA.
   [Jovin, Tudor G.] Cooper Univ Hosp, Neurol Inst, Camden, NJ USA.
RP Jadhav, AP (reprint author), Univ Pittsburgh, Sch Med, Med Ctr, Dept Neurol, Pittsburgh, PA 15260 USA.; Jadhav, AP (reprint author), Univ Pittsburgh, Sch Med, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
EM jadhavap@upmc.edu
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Hao YG, 2017, INTERV NEUROL, V6, P57, DOI 10.1159/000454721
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   L'Allinec V, 2018, J NEUROINTERV SURG, V10, pE29, DOI 10.1136/neurintsurg-2017-013714
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Nogueira RG, 2009, STROKE, V40, P516, DOI 10.1161/STROKEAHA.108.525089
   Peng F, 2018, J NEUROINTERV SURG, V10, P25, DOI 10.1136/neurintsurg-2016-012849
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Raphael CE, 2016, MAYO CLIN PROC, V91, P1035, DOI 10.1016/j.mayocp.2016.05.008
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4
   Zhang J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.08
NR 17
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1039
EP E1043
DI 10.1016/j.wneu.2019.04.036
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300129
PM 30980980
DA 2020-05-12
ER

PT J
AU Di, GF
   Fang, XY
   Hu, QX
   Zhou, W
   Jiang, XC
AF Di, Guangfu
   Fang, Xinyun
   Hu, Qianxin
   Zhou, Wei
   Jiang, Xiaochun
TI A Microanatomical Study of the Far Lateral Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniocervical junction; Far lateral approach; Microanatomy; Occipital
   condyle; Vertebral artery
ID INFERIOR CEREBELLAR ARTERY; VERTEBRAL ARTERY; CRANIOVERTEBRAL JUNCTION;
   MICROSURGICAL ANATOMY; OCCIPITAL ARTERY; FORAMEN MAGNUM;
   OCCIPITOCERVICAL FUSION; QUANTITATIVE ANATOMY; EXTRADURAL ORIGIN;
   TRANSCONDYLAR
AB OBJECTIVE: The far-lateral approach (FLA) remains a challenge for neurosurgeons due to the complex anatomy of this region, especially in patients with anatomical variations. There is therefore an urgent need for better quantitative knowledge of the microsurgical anatomy of the FLA.
   METHODS: The study was performed using the dried skulls and atlas vertebrae of 50 Chinese adults, in which significant clinical parameters were measured. We further used 12 cadaveric heads to simulate the FLA to explore the step-by-step anatomy entailed by this procedure, enabling us to obtain key images and related information.
   RESULTS: Limited to hypoglossal canal, the occipital condyle posterior was abraded by roughly 10 mm, which provided good exposure to the ventral front of the foramen magnum. When occipital artery exits the occipital groove, the mean diameter was 2.20 mm. The average occipital artery suboccipital segment length was 65.26 mm. The posterior spinal artery (PSA) and posterior inferior cerebellar artery (PICA) generally originated from the fourth vertebral artery segment intradurally, and the mean distances from the PSA and PICA to the dural entry point of the vertebral artery were 2.62 mm and 8.71 mm, respectively. The incidence of PSA and PICA arising from the third vertebral artery segment was 16.67% and 4.17%, respectively.
   CONCLUSIONS: Understanding the important anatomic structures of the CVJ region and developing improved knowledge of the microsurgical anatomy of the FLA offer an opportunity to ensure safe exposure and treatment of lesions in the ventral and ventrolateral regions of the CVJ.
C1 [Di, Guangfu; Fang, Xinyun; Hu, Qianxin; Zhou, Wei; Jiang, Xiaochun] Yijishan Hosp, Wannan Med Coll, Dept Neurosurg, Wuhu, Peoples R China.
RP Jiang, XC (reprint author), Yijishan Hosp, Wannan Med Coll, Dept Neurosurg, Wuhu, Peoples R China.
EM jiangxiaochun2001@hotmail.com
OI Di, Guangfu/0000-0001-9856-2025
FU Key Research and Development Plan Project of Anhui Province
   [1804h0802023]
FX This study was supported by the Key Research and Development Plan
   Project of Anhui Province (1804h0802023).
CR Alvernia JE, 2006, NEUROSURGERY, V58, P114, DOI 10.1227/01.NEU.0000193519.00443.34
   Ates O, 2008, NEUROSURG FOCUS, V24, P9
   Barut N, 2009, BRIT J NEUROSURG, V23, P276, DOI 10.1080/02688690902814725
   Bejjani GK, 2000, SURG NEUROL, V54, P109, DOI 10.1016/S0090-3019(00)00255-X
   Campero A, 2018, WORLD NEUROSURG, V113, P188, DOI 10.1016/j.wneu.2018.02.090
   Ebraheim NA, 1998, SPINE, V23, P320, DOI 10.1097/00007632-199802010-00007
   Fine AD, 1999, J NEUROSURG, V91, P645, DOI 10.3171/jns.1999.91.4.0645
   Fukuda H, 2014, WORLD NEUROSURG, V82, pE459, DOI 10.1016/j.wneu.2013.09.015
   Gupta T, 2008, SURG RADIOL ANAT, V30, P239, DOI 10.1007/s00276-008-0313-x
   Isaji T, 2018, J NEUROSURG-SPINE, V28, P154, DOI 10.3171/2017.5.SPINE161286
   Kawashima M, 2005, J NEUROSURG, V102, P132, DOI 10.3171/jns.2005.102.1.0132
   Keser N, 2018, WORLD NEUROSURG, V112, pE534, DOI 10.1016/j.wneu.2018.01.073
   Kshettry VR, 2017, J NEUROSURG, V127, P829, DOI 10.3171/2016.7.JNS16293
   La Rocca G, 2017, ACTA NEUROCHIR, V159, P1887, DOI 10.1007/s00701-017-3300-3
   Lanzino G, 2005, NEUROSURGERY, V57, P367, DOI 10.1227/01.NEU.0000176848.05925.80
   Le Minor JM, 2004, AM J PHYS ANTHROPOL, V125, P16, DOI 10.1002/ajpa.10270
   Mao Y, 2014, WORLD NEUROSURG, V82, pE415, DOI 10.1016/j.wneu.2013.10.040
   Mazur MD, 2017, NEUROSURGERY, V80, P140, DOI 10.1093/neuros/nyw002
   Muthukumar N, 2005, ACTA NEUROCHIR, V147, P889, DOI 10.1007/s00701-005-0555-x
   Niklaus K, 2005, NEUROSURG FOCUS, V19, P4
   Park HH, 2016, WORLD NEUROSURG, V88, P154, DOI 10.1016/j.wneu.2015.12.073
   Park W, 2014, WORLD NEUROSURG, V82, P714, DOI 10.1016/j.wneu.2014.06.053
   Rhoton AL, 2000, NEUROSURGERY, V47, pS195, DOI 10.1097/00006123-200009001-00020
   Russo VM, 2012, WORLD NEUROSURG, V77, P704, DOI 10.1016/j.wneu.2011.03.024
   Seckin H, 2009, J NEUROSURG-SPINE, V10, P228, DOI 10.3171/2008.12.SPINE08289
   Sen C, 2010, NEUROSURGERY, V66, pA104, DOI 10.1227/01.NEU.0000365930.95389.60
   Shiban E, 2016, J NEUROSURG, V125, P196, DOI 10.3171/2015.5.JNS15176
   Shin H, 2006, J NEUROSURG-SPINE, V4, P137, DOI 10.3171/spi.2006.4.2.137
   Singh H, 2017, WORLD NEUROSURG, V100, P167, DOI 10.1016/j.wneu.2016.12.095
   Slam C, 2007, CLIN ANAT, V20, P886, DOI 10.1002/ca.20541
   Sorenson TJ, 2017, ACTA NEUROCHIR, V159, P1489, DOI 10.1007/s00701-017-3200-6
   Spektor S, 2000, J NEUROSURG, V92, P824, DOI 10.3171/jns.2000.92.5.0824
   Vanek P, 2017, NEUROSURG REV, V40, P369, DOI 10.1007/s10143-016-0784-x
   Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
   Winking M, 2013, OPER TECH ORTHOP, V23, P9, DOI 10.1053/j.oto.2013.04.001
   Xiao XR, 2013, J NEUROSURG, V118, P657, DOI 10.3171/2012.9.JNS12176
NR 37
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E932
EP E942
DI 10.1016/j.wneu.2019.04.004
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300116
PM 30995558
DA 2020-05-12
ER

PT J
AU Dinc, N
   Won, SY
   Eibach, M
   Gessler, F
   Konczalla, J
   Quick-Weller, J
   Seifert, V
   Marquardt, G
AF Dinc, Nazife
   Won, Sae-Yeon
   Eibach, Michael
   Gessler, Florian
   Konczalla, Juergen
   Quick-Weller, Johanna
   Seifert, Volker
   Marquardt, Gerhard
TI The Extent of Neurologic Improvement and Social Life in Young Patients
   with Ruptured and Unruptured Brain AVM: A Lona-Term Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterioyenous malformation; Brain AVM; Intracerebral hemorrhage in young
   patients; Long-term follow-up
ID INTERNATIONAL MULTICENTER COHORT; ARTERIOVENOUS-MALFORMATIONS;
   PEDIATRIC-PATIENTS; OUTCOMES; CHILDREN; HEMORRHAGE; AGE; EXPERIENCE;
   MANAGEMENT; STROKE
AB BACKGROUND: Intracerebral hemorrhage, seizures, neurologic deficits, and cognitive impairments due to brain AVM in childhood are incriminating for brain and executive function with sequelae for further social life. Long-term follow-up data on brain AVM in young patients are rare, making it difficult to compare and evaluate treatment risks and outcomes.
   METHODS: We studied young patients with brain AVM who were referred to our institution between 2005 and 2012 and for whom follow-up data were available. We stratified the patients into those with ruptured AVM (rAVM) and unruptured AVM (uAVM) and compared treated and nontreated patients. Differences in outcome and social participation were assessed.
   RESULTS: A total of 29 young patients with brain AVM, median age 16 years, were included in our study with complete follow-up data of over 5 years (mean, 6 years). In 18 (62.1%) patients rAVM and in 11 (37.9%) patients uAVM were found. Twenty (69%) patients received treatment (rAVM 70% vs. uAVM 30%). Among treatment methods, microsurgery was most frequently used (rAVM 33.3% vs. uAVM 36.4%). In rAVM, 16 of 18 (88.9%) patients returned to work or school, and in uAVM, 11 (100%) patients did so. Concerning cognitive problems, no statistically significant difference was found in the 2 groups comparing treated and nontreated patients (P> 0.05). A favorable outcome was achieved in 13 (72.2%) patients with rAVM and in 11 (100%) patients with uAVM.
   CONCLUSION: Favorable outcome was achieved in the majority of patients. The rate of neurologic improvement and participation in social life was very high in the 2 groups.
C1 [Dinc, Nazife; Won, Sae-Yeon; Eibach, Michael; Gessler, Florian; Konczalla, Juergen; Quick-Weller, Johanna; Seifert, Volker; Marquardt, Gerhard] Goethe Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
RP Dinc, N (reprint author), Goethe Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
EM nazife.dinc@kgu.de
RI Won, Sae-Yeon/AAK-3408-2020
CR Abecassis IJ, 2016, J NEUROSURG-PEDIATR, V18, P611, DOI 10.3171/2016.6.PEDS16103
   Beslow LA, 2010, STROKE, V41, P313, DOI 10.1161/STROKEAHA.109.568071
   Blauwblomme T, 2014, STROKE, V45, P1664, DOI 10.1161/STROKEAHA.113.004292
   Broderick JP, 2017, STROKE, V48, P2007, DOI 10.1161/STROKEAHA.117.017866
   Capitanio Jody Filippo, 2016, Neurosurgery, V63 Suppl 1, P180, DOI 10.1227/01.neu.0000489773.66889.56
   Darsaut TE, 2011, NEUROSURGERY, V69, P540, DOI 10.1227/NEU.0b013e3182181c00
   de Ribanpierre S, 2008, SWISS MED WKLY, V138, P59, DOI 2008/05/smw-11958
   Di Rocco C, 2000, ACTA NEUROCHIR, V142, P145, DOI 10.1007/s007010050017
   Dinc N, 2017, ANN VASE MED RES, V4, P1055
   Dinc N, 2018, J CLIN NEUROSCI, V53, P171, DOI 10.1016/j.jocn.2018.04.010
   Ding D, 2017, J NEUROSURG-PEDIATR, V19, P127, DOI 10.3171/2016.9.PEDS16283
   Ding DL, 2015, J CLIN NEUROSCI, V22, P1857, DOI 10.1016/j.jocn.2015.06.014
   Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045
   Fullerton HJ, 2005, STROKE, V36, P2099, DOI 10.1161/01.STR.0000181746.77149.2b
   Gross BA, 2016, J NEUROSURG-PEDIATR, V17, P123, DOI 10.3171/2015.2.PEDS14541
   Hetts SW, 2014, AM J NEURORADIOL, V35, P1376, DOI 10.3174/ajnr.A3886
   Ismail FY, 2017, EUR J PAEDIATR NEURO, V21, P23, DOI 10.1016/j.ejpn.2016.07.007
   Jordan LC, 2009, STROKE, V40, P400, DOI 10.1161/STROKEAHA.108.518761
   Josephson CB, 2015, SEMIN NEUROL, V35, P223, DOI 10.1055/s-0035-1552621
   Kim H, 2014, NEUROLOGY, V83, P590, DOI 10.1212/WNL.0000000000000688
   Lazar R M, 2001, Neurosurg Focus, V11, pe4
   Ma L, 2017, EUR RADIOL, V27, P2868, DOI 10.1007/s00330-016-4645-3
   Ma L, 2017, CEREBROVASC DIS, V43, P231, DOI 10.1159/000458731
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Nerva JD, 2016, NEUROSURGERY, V78, P695, DOI 10.1227/NEU.0000000000001076
   Sanchez-Mejia RO, 2006, J NEUROSURG, V105, P82, DOI 10.3171/ped.2006.105.2.82
   Shtaya A, 2017, CHILD NERV SYST, V33, P573, DOI 10.1007/s00381-017-3383-4
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stapf C, 2003, STROKE, V34, P2664, DOI 10.1161/01.STR.0000094824.03372.9B
   Starke RM, 2017, J NEUROSURG-PEDIATR, V19, P136, DOI 10.3171/2016.9.PEDS16284
   Tong XZ, 2016, WORLD NEUROSURG, V87, P598, DOI 10.1016/j.wneu.2015.10.060
   Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD
   Yang HB, 2017, WORLD NEUROSURG, V105, P37, DOI 10.1016/j.wneu.2017.05.031
   Zeiler FA, 2016, CAN J NEUROL SCI, V43, P82, DOI 10.1017/cjn.2015.267
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E503
EP E508
DI 10.1016/j.wneu.2019.03.187
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300062
PM 30928578
DA 2020-05-12
ER

PT J
AU Elsamadicy, AA
   Camara-Quintana, J
   Kundishora, AJ
   Lee, M
   Freedman, IG
   Long, A
   Qureshi, T
   Laurans, M
   Tomak, P
   Karikari, IO
AF Elsamadicy, Aladine A.
   Camara-Quintana, Joaquin
   Kundishora, Adam J.
   Lee, Megan
   Freedman, Isaac G.
   Long, Aaron
   Qureshi, Tariq
   Laurans, Maxwell
   Tomak, Patrick
   Karikari, Isaac O.
TI Reduced Impact of Obesity on Short-Term Surgical Outcomes,
   Patient-Reported Pain Scores, and 30-Day Readmission Rates After Complex
   Spinal Fusion (>= 7 Levels) for Adult Deformity Correction
SO WORLD NEUROSURGERY
LA English
DT Article
DE 30-day readmission rates; Adult deformity correction; Complex spine
   fusion; Obesity; Patient-reported pain scores; Postoperative
   complications; Postoperative pain
ID BODY-MASS INDEX; MORBID-OBESITY; SURGERY; COMPLICATIONS; THORACOLUMBAR;
   COSTS
AB OBJECTIVE: In the past decade, prevalence of obesity in the United States have been soaring at a disparaging rate. Previous spine studies have associated obesity with inferior surgical outcomes, increased complication and 30-day readmission rates, and worsening patient-reported outcomes. However, there is a paucity of data identifying whether the impact of obesity is sustained in patients undergoing complex deformity correction involving 7 levels or greater. The aim of this study was to determine whether obesity impacts surgical outcomes, patient-reported pain scores, and 30-day readmission rates after complex spinal fusions >= 7 levels.
   METHODS: The medical records of 112 adult patients (>= 18 years old) with spine deformity undergoing elective, primary complex spinal fusion (>= 7 levels) for deformity correction at a major academic institution from 2010 to 2015 were reviewed. Preoperative body mass index greater than or equal to 30 kg/m(2) was classified as obese. Patient demographics, comorbidities, and intraoperative and postoperative complication rates were collected for each patient. Inpatient patient-reported pain scores and ambulatory status also were collected. The primary outcomes of this study were surgical outcomes, patient-reported pain scores, and 30-day readmission rates.
   RESULTS: Of the 112 patients, 33 (29.5%) were obese (obese: n = 33 vs. non-obese: n [79). Patient demographics and comorbidities were similar between both cohorts, including age, sex, diabetes, hypertension, and home narcotic use. The median number of fusion levels operated, length of surgery, estimated blood loss, transfusion, and complication rates were similar between both cohorts. Moreover, the postoperative complication profiles between the cohorts also were similar, with a comparable length of hospital stay (obese: 6.5 +/- 4.6 days vs. non-obese: 7.0 +/- 3.9 days, P = 0.5833) and 30-day readmission rates (obese: 12.1% vs. non-obese: 13.9%, P = 0.7984). Baseline (P = 0.6826), first (P = 0.9691), and last (P = 0.9583) postoperative patient-reported pain scores were similar between cohorts. Analogously, ambulatory status was similar between the cohorts, including days from operating room to ambulation (P = 0.3471) and number of steps on first (P = 0.9173) and last (P = 0.1634) ambulatory day before discharge.
   CONCLUSIONS: Our study suggests that obesity does not significantly affect surgical outcomes, patient-reported pain scores, and 30-day readmission rates after complex spinal surgery requiring >= 7 levels of fusion. Further studies are necessary to corroborate our findings.
C1 [Elsamadicy, Aladine A.; Camara-Quintana, Joaquin; Kundishora, Adam J.; Lee, Megan; Freedman, Isaac G.; Long, Aaron; Qureshi, Tariq; Laurans, Maxwell; Tomak, Patrick] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
   [Karikari, Isaac O.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
RP Elsamadicy, AA (reprint author), Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
EM aladine.elsamadicy@yale.edu
CR Amin RM, 2018, SPINE, V43, P693, DOI 10.1097/BRS.0000000000002407
   Auffinger B, 2014, WORLD NEUROSURG, V82, pE345, DOI 10.1016/j.wneu.2013.09.053
   Biener Adam I, 2018, JAMA, V319, P218, DOI 10.1001/jama.2017.21063
   Cowan JA, 2006, NEUROSURGERY, V59, P15, DOI 10.1227/01.NEU.0000219836.54861.CD
   De la Garza-Ramos R, 2015, SPINE, V40, P56, DOI 10.1097/BRS.0000000000000655
   Di Capua J, 2018, GLOB SPINE J, V8, P615, DOI 10.1177/2192568218761361
   Elsamadicy AA, 2019, NEUROSURGERY, V84, P758, DOI 10.1093/neuros/nyy215
   Elsamadicy AA, 2016, WORLD NEUROSURG, V96, P148, DOI 10.1016/j.wneu.2016.08.097
   Hales CM, 2018, JAMA-J AM MED ASSOC, V319, P1723, DOI 10.1001/jama.2018.3060
   Hannan EL, 2011, JACC-CARDIOVASC INTE, V4, P569, DOI 10.1016/j.jcin.2011.01.010
   Higgins DM, 2016, NEUROSURGERY, V78, P127, DOI 10.1227/NEU.0000000000001018
   Kaffarnik M, 2009, ZBL CHIR, V134, P43, DOI 10.1055/s-0028-1098806
   Kalanithi PA, 2012, SPINE, V37, P982, DOI 10.1097/BRS.0b013e31823bbeef
   Lim S, 2018, SPINE, V43, P215, DOI 10.1097/BRS.0000000000000608
   Manson NA, 2016, GLOB SPINE J, V6, P108, DOI 10.1055/s-0035-1556585
   Martin BI, 2019, SPINE, V44, P369, DOI 10.1097/BRS.0000000000002822
   Onyekwelu I, 2017, J NEUROSURG-SPINE, V26, P158, DOI 10.3171/2016.7.SPINE16448
   Owens RK, 2016, SPINE J, V16, P1178, DOI 10.1016/j.spinee.2016.06.005
   Pereira BJA, 2014, CLIN NEUROL NEUROSUR, V127, P112, DOI 10.1016/j.clineuro.2014.09.016
   Planchard RF, 2015, GLOB SPINE J, V5, P287, DOI 10.1055/s-0035-1546819
   Puvanesarajah V, 2017, SPINE, V42, P122, DOI 10.1097/BRS.0000000000001692
   Rajaee SS, 2014, BONE JOINT J, V96B, P807, DOI 10.1302/0301-620X.96B6.31149
   Shamji MF, 2009, NEUROSURGERY, V65, P490, DOI 10.1227/01.NEU.0000350863.69524.8E
   Sharma A, 2019, NEUROSURGERY, V84, P733, DOI 10.1093/neuros/nyy190
   Sood A, 2015, WORLD J SURG, V39, P2376, DOI 10.1007/s00268-015-3112-7
   Vaidya R, 2009, SPINE, V34, P495, DOI 10.1097/BRS.0b013e318198c5f2
   Walid MS, 2011, J NEUROSURG-SPINE, V14, P318, DOI 10.3171/2010.11.SPINE10139
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E108
EP E113
DI 10.1016/j.wneu.2019.02.165
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300015
PM 30876992
DA 2020-05-12
ER

PT J
AU Faramand, A
   Kano, H
   Niranjan, A
   Park, KJ
   Flickinger, JC
   Lunsford, LD
AF Faramand, Andrew
   Kano, Hideyuki
   Niranjan, Ajay
   Park, Kyung-Jae
   Flickinger, John C.
   Lunsford, L. Dade
TI Tumor Control and Cranial Nerve Outcomes After Adjuvant Radiosurgery for
   Low-Grade Skull Base Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial nerve; Meningioma; Radiation; Radiosurgery; Skull base
ID GAMMA-KNIFE RADIOSURGERY; CAVERNOUS SINUS MENINGIOMAS; STEREOTACTIC
   RADIOSURGERY; PETROCLIVAL MENINGIOMAS; SURGICAL OUTCOMES; EXPERIENCE;
   RECURRENCE; SURGERY; SYSTEM
AB OBJECTIVE: We evaluated the tumor control and cranial nerve (CN) outcomes after adjuvant stereotactic radiosurgery (SRS) for petroclival, cavernous sinus, and cerebellopontine angle meningiomas.
   METHODS: From our prospectively maintained database of 2022 patients with meningioma who had undergone Leksell SRS during a 30-year interval, we found 43 patients with petroclival, 94 with cavernous sinus, and 13 patients with cerebellopontine angle meningiomas who had undergone adjuvant SRS after surgical resection of the meningioma. The patients included in the present report had had >= 1 CN deficit at the initial presentation and a minimum follow-up period of 12 months. The median age at SRS was 54 years (range, 22-81). SRS was performed for residual tumor in 104 patients (69%) and recurrent tumor in 46 patients (31%). The median tumor volume treated with SRS was 8.1 cm(3) (range, 0.3-42), and the median margin dose was 13 Gy (range, 10-20).
   RESULTS: Tumor control was achieved in 135 patients (90%) at a median follow-up point of 75 months. The progression-free survival rate after SRS was 99.5% at 1 year, 98% at 3 years, 95% at 5 years, and 90% at 10 years. Overall, 29 of the 150 patients (19%) reported improvement in CN function. Deterioration in CN function after SRS developed in 15 patients (10%). The rate of deterioration was 3.5% at 1 year, 5.5% at 3 years, and 7% at 5 years.
   CONCLUSIONS: Adjuvant SRS provides effective tumor control and a low rate of new or worsening CN deficits.
C1 [Faramand, Andrew; Kano, Hideyuki; Niranjan, Ajay; Flickinger, John C.; Lunsford, L. Dade] Univ Pittsburgh, Med Ctr, Dept Neurol Surg & Radiat Oncol, Pittsburgh, PA 15260 USA.
   [Park, Kyung-Jae] Korea Univ, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Kano, H (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg & Radiat Oncol, Pittsburgh, PA 15260 USA.
EM kanoh@upmc.edu
CR ALMEFTY O, 1988, NEUROSURGERY, V22, P510, DOI 10.1227/00006123-198803000-00010
   Azar M, 2017, STEREOT FUNCT NEUROS, V95, P259, DOI 10.1159/000478024
   Bambakidis NC, 2008, NEUROSURGERY, V62, P1182, DOI [10.1227/01.NEU.0000280119.36270.BA, 10.1227/01.neu.0000333784.04435.65]
   Bindal R, 2003, SURG NEUROL, V59, P87, DOI 10.1016/S0090-3019(02)00995-3
   Chung LK, 2017, J CLIN NEUROSCI, V36, P1, DOI 10.1016/j.jocn.2016.10.009
   Couldwell WT, 2011, NEUROSURG FOCUS, V30
   CUSIMANO MD, 1995, NEUROSURGERY, V37, P1
   DeJesus O, 1996, NEUROSURGERY, V39, P915, DOI 10.1097/00006123-199611000-00005
   DEMONTE F, 1994, J NEUROSURG, V81, P245, DOI 10.3171/jns.1994.81.2.0245
   Ding D, 2014, NEUROSURGERY, V75, P398, DOI 10.1227/NEU.0000000000000480
   Faramand A, 2018, J NEURO-ONCOL, V139, P341, DOI 10.1007/s11060-018-2866-9
   Flannery TJ, 2017, J NEUROSURG, V127, P67, DOI 10.3171/2009.8.JNS09695
   GARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55, DOI 10.1177/000348948809700110
   Hasegawa T, 2007, J NEUROSURG, V107, P745, DOI 10.3171/JNS-07/10/0745
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   Kano H, 2013, NEUROSURGERY, V73, P401, DOI 10.1227/01.neu.0000431471.64289.3d
   Kim JW, 2017, STEREOT FUNCT NEUROS, V95, P209, DOI 10.1159/000475763
   Lee JYK, 2002, J NEUROSURG, V97, P65, DOI 10.3171/jns.2002.97.1.0065
   Magill ST, 2019, J NEUROSURG, V131, P1179, DOI 10.3171/2018.6.JNS18118
   Morisako H, 2015, J NEUROSURG, V122, P373, DOI 10.3171/2014.8.JNS132406
   Morita A, 1999, J NEUROSURG, V90, P42, DOI 10.3171/jns.1999.90.1.0042
   Nanda A, 2011, J NEUROSURG, V114, P1268, DOI 10.3171/2010.11.JNS10326
   Natarajan SK, 2007, NEUROSURGERY, V60, P965, DOI 10.1227/01.NEU.0000255472.52882.D6
   Nicolato A, 2002, NEUROSURGERY, V51, P1153, DOI 10.1097/00006123-200211000-00009
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   OSullivan MG, 1997, NEUROSURGERY, V40, P238, DOI 10.1097/00006123-199702000-00003
   Park SH, 2014, J NEUROSURG, V120, P708, DOI 10.3171/2013.11.JNS131607
   Pollock BE, 2005, INT J RADIAT ONCOL, V62, P1427, DOI 10.1016/j.ijrobp.2004.12.067
   Pomeraniec IJ, 2018, J NEUROSURG, V129, P648, DOI 10.3171/2017.5.JNS163069
   Reinert M, 2006, ACTA NEUROCHIR, V148, P1257, DOI 10.1007/s00701-006-0909-z
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Sheehan JP, 2015, J NEUROSURG, V122, P1479, DOI 10.3171/2014.10.JNS14139
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Spiegelmann R, 2010, J NEURO-ONCOL, V98, P195, DOI 10.1007/s11060-010-0173-1
   Starke R, 2014, J NEURO-ONCOL, V119, P169, DOI 10.1007/s11060-014-1470-x
   Sughrue ME, 2010, J NEUROSURG, V113, P1087, DOI 10.3171/2010.3.JNS091807
   Tahara A, 2009, J CLIN NEUROSCI, V16, P655, DOI 10.1016/j.jocn.2008.08.011
   Zentner J, 1997, J NEUROL NEUROSUR PS, V62, P341, DOI 10.1136/jnnp.62.4.341
NR 38
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E221
EP E229
DI 10.1016/j.wneu.2019.03.052
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300030
PM 30880202
DA 2020-05-12
ER

PT J
AU Muoio, VMF
   Uno, M
   Oba-Shinjo, S
   da Silva, R
   Pereira, BJA
   Clara, C
   Matushita, H
   Marie, SNK
AF Figueira Muoio, Valeria Marques
   Uno, Miyuki
   Oba-Shinjo, Sueli
   da Silva, Roseli
   Araujo Pereira, Benedito Jamilson
   Clara, Carlos
   Matushita, Hamilton
   Marie, Suely N. K.
TI OTX1 and OTX2 Genes in Medulloblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Classic; Desmoplastic; Medulloblastoma; OTX1 gene; OTX2 gene
ID MOLECULAR SUBGROUPS; INDUCED APOPTOSIS; HEDGEHOG; EXPRESSION; WNT;
   CLASSIFICATION; TUMORS; CELLS; MORPHOGENESIS; SIMILARITIES
AB OBJECTIVE: To study the prevalence of OTX1 and OTX2 gene expression in 60 medulloblastoma specimen samples and to establish correlations between gene expression and clinical and histopathological aspects.
   METHODS: We performed a retrospective analysis of 60 patients with a diagnosis of medulloblastoma at the Clinicas Hospital of the School of Medicine, University of Sao Paulo, and the Cancer Hospital of Barretos. We created a database of the 60 patients containing information on the gene expression of OTX1 and OTX2 (obtained using realtime polymerase chain reaction) and clinical and epidemiological data. Statistical tests were performed to verify potential correlations of clinicopathological data and follow-up aspects with gene expression.
   RESULTS: The OTX1 gene was expressed in 52% of the study population. Expression varied with age (higher in adults), location (predominantly by hemisphere), and histological type (desmoplastic). The OTX2 gene was expressed in 62% of the study population. Expression varied with age (higher in younger age groups), location (predominantly vermis), and histological type (classic and anaplastic). A statistical correlation between OTX2 gene expression and the development of leptomeningeal metastases was observed.
   CONCLUSIONS: The relative expression of OTX1 and OTX2 was dependent on patient age, tumor location, and histological variant. In addition, OTX2 expression might be a predictive factor for leptomeningeal metastases of medulloblastoma. The OTX pathway should be consider as an important venue for medulloblastomas development.
C1 [Figueira Muoio, Valeria Marques; Uno, Miyuki; Oba-Shinjo, Sueli; da Silva, Roseli; Araujo Pereira, Benedito Jamilson; Matushita, Hamilton; Marie, Suely N. K.] Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil.
   [Clara, Carlos] Canc Hosp Barretos, Fundacao Pio XII, Barretos, Brazil.
RP Pereira, BJA (reprint author), Univ Sao Paulo, Dept Neurol, Sao Paulo, Brazil.
EM benedito.jamilson@hotmail.com
RI Oba-Shinjo, Sueli M./C-4017-2012
OI Oba-Shinjo, Sueli M./0000-0002-1650-5973
FU Fundacao de Amparo a Pesquisa de Sao PauloFundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [04/12133-6]; Ludwig Institute for
   Cancer Research
FX The present study was supported by grants from the Fundacao de Amparo a
   Pesquisa de Sao Paulo (process number 04/12133-6) and Ludwig Institute
   for Cancer Research.
CR Abacioglu U, 2002, INT J RADIAT ONCOL, V54, P855, DOI 10.1016/S0360-3016(02)02986-3
   Acampora D, 1997, DEVELOPMENT, V124, P3639
   Adamson DC, 2010, CANCER RES, V70, P181, DOI 10.1158/0008-5472.CAN-09-2331
   Ajeawung NF, 2012, CLIN INVEST MED, V35, pE246
   Akay KM, 2004, PEDIATR NEUROSURG, V40, P220, DOI 10.1159/000082295
   Albright AL, 1996, NEUROSURGERY, V38, P265, DOI 10.1097/00006123-199602000-00007
   Ayrault O, 2010, CANCER RES, V70, P5618, DOI 10.1158/0008-5472.CAN-09-3740
   Bai RY, 2010, NEURO-ONCOLOGY, V12, P655, DOI 10.1093/neuonc/nop062
   Bertrand FE, 2012, CELL CYCLE, V11, P4344, DOI 10.4161/cc.22134
   Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2
   Boncinelli E, 2001, TRENDS GENET, V17, P633, DOI 10.1016/S0168-9525(01)02418-0
   Boon K, 2005, CANCER RES, V65, P703
   Boulay G, 2017, CANCER DISCOV, V7, P288, DOI 10.1158/2159-8290.CD-16-0844
   BOURGOUIN PM, 1992, AM J ROENTGENOL, V159, P609, DOI 10.2214/ajr.159.3.1503035
   Buhren J, 2000, J NEUROPATH EXP NEUR, V59, P229
   Bunt J, 2010, MOL CANCER RES, V8, P1344, DOI 10.1158/1541-7786.MCR-09-0546
   Chang Q, 2007, J NEURO-ONCOL, V84, P263, DOI 10.1007/s11060-007-9380-9
   Crossley PH, 2001, NEUROSCIENCE, V108, P183, DOI 10.1016/S0306-4522(01)00411-0
   Danesin C, 2009, DEV CELL, V16, P576, DOI 10.1016/j.devcel.2009.03.007
   de Haas T, 2006, J NEUROPATH EXP NEUR, V65, P176, DOI 10.1097/01.jnen.0000199576.70923.8a
   Di CH, 2005, CANCER RES, V65, P919
   Dubuc AM, 2012, ACTA NEUROPATHOL, V123, P485, DOI 10.1007/s00401-012-0959-7
   Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189
   Fiorilli P, 2008, LAB INVEST, V88, P1143, DOI 10.1038/labinvest.2008.89
   Gumireddy K, 2003, CLIN CANCER RES, V9, P4052
   Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904
   Han C, 2005, MOL CELL, V17, P321, DOI 10.1016/j.molcel.2005.01.009
   Hinman VF, 2000, DEV GENES EVOL, V210, P129, DOI 10.1007/s004270050019
   Ho DM, 2002, CANCER, V95, P2578
   Ho DMT, 2002, CANCER, V95, P2577, DOI 10.1002/cncr.11003
   Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268
   Insan MB, 2014, MINI-REV MED CHEM, V14, P20, DOI 10.2174/13895575113136660107
   Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284
   Kalderon D, 2002, TRENDS CELL BIOL, V12, P523, DOI 10.1016/S0962-8924(02)02388-7
   Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570
   Kobayashi T, 2010, DEV GROWTH DIFFER, V52, P351, DOI 10.1111/j.1440-169X.2010.01170.x
   Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8
   Kortmann R D, 2003, Forum (Genova), V13, P99
   Li KKW, 2013, INT J CLIN EXP PATHO, V6, P1211
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83
   Min HS, 2006, ACTA NEUROPATHOL, V112, P13, DOI 10.1007/s00401-006-0073-9
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Northcott PA, 2012, EXPERT REV NEUROTHER, V12, P871, DOI [10.1586/ERN.12.66, 10.1586/ern.12.66]
   Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327
   Northcott PA, 2012, NAT REV NEUROL, V8, P340, DOI 10.1038/nrneurol.2012.78
   Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821
   Omodei D, 2009, AM J PATHOL, V175, P2609, DOI 10.2353/ajpath.2009.090542
   Ramaswamy V, 2013, LANCET ONCOL, V14, P1200, DOI 10.1016/S1470-2045(13)70449-2
   Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213
   Salsano E, 2004, NEUROSCI LETT, V370, P180, DOI 10.1016/j.neulet.2004.08.053
   Salsano E, 2007, NEURO-ONCOLOGY, V9, P298, DOI 10.1215/15228517-2007-014
   Simeone A, 2002, CURR OPIN GENET DEV, V12, P409, DOI 10.1016/S0959-437X(02)00318-0
   SZYMAS J, 1987, CHILD NERV SYST, V3, P74, DOI 10.1007/BF00271127
   Wortham M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107156
   Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192
   Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052
NR 58
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E58
EP E64
DI 10.1016/j.wneu.2019.02.013
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300009
PM 30797919
DA 2020-05-12
ER

PT J
AU Florman, JE
   Cushing, DA
   England, EC
   White, E
AF Florman, Jeffrey E.
   Cushing, Deborah A.
   England, Emma C.
   White, Elbert
TI How to Transect the C2 Root for Cl Lateral Mass Screw Placement: Case
   Series and Review of an Underappreciated Variable in Outcome
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlantoaxial fusion; C1-2 fusion; C1 lateral mass screw; C2
   ganglionectomy; C2 transection; Occipital neuralgia; Spinal fusion
ID NERVE ROOT; AFFECT FUNCTIONALITY; OCCIPITAL NEURALGIA; PAIN RELIEF;
   FIXATION; GANGLIONECTOMY; C-2
AB BACKGROUND: The techniques for atlantoaxial arthrodesis have been modified over the years, and placing C1 lateral mass screws is a modern approach. C2 neuropathy is a complication of concern; however, sacrifice of the C2 nerve is an accepted and often favored adjunct. The impact of the technique for cutting the C2 nerve is not adequately addressed in the literature. The aim of this study was to evaluate the clinical outcomes from a series of roots sacrificed during C1-2 fusion with attention to the C2 transection method.
   METHODS: Clinical data were collected from trauma patients who underwent C1 screw fixation for atlantoaxial fusion. Chart review was performed and outcome assessed through telephone surveys to patients who were at least 6 months postoperative. Quality of life, C2 nerve function, neck pain, and head pain were assessed.
   RESULTS: Sixty-six roots were divided in 35 patients. There were no cases of occipital neuralgia at routine 3month follow-up. Delayed telephone surveys were completed in 17 patients and exposed 4 cases of severe head/neck pain but none consistent with occipital neuralgia.
   CONCLUSIONS: C2 neuralgia is rare when sharply dividing the C2 root with the aid of bipolar electrocautery at the midportion of the ganglion where it overlies the C1-2 joint. A literature review suggests the impact of the root sacrifice method is an underappreciated modifiable factor in outcome. In future reports, description of the root transection technique is imperative and trials comparing ganglionectomy versus transection proximal to the ganglion or through the ganglion should be considered.
C1 [Florman, Jeffrey E.; Cushing, Deborah A.; England, Emma C.; White, Elbert] Maine Med Ctr, Dept Neurosurg, Portland, ME 04102 USA.
RP Florman, JE (reprint author), Maine Med Ctr, Dept Neurosurg, Portland, ME 04102 USA.
EM FLORMJ@mmc.org
CR Acar F, 2008, STEREOT FUNCT NEUROS, V86, P106, DOI 10.1159/000113872
   Aryan HE, 2008, J NEUROSURG-SPINE, V8, P222, DOI 10.3171/SPI/2008/8/3/222
   Badhiwala JH, 2017, SPINE, V42, pE1067, DOI 10.1097/BRS.0000000000002069
   Dewan MC, 2014, NEUROSURGERY, V74, P475, DOI 10.1227/NEU.0000000000000306
   Ducic I, 2014, ANN PLAS SURG, V72, P184, DOI 10.1097/SAP.0b013e3182898736
   Elliott RE, 2012, WORLD NEUROSURG, V78, P697, DOI 10.1016/j.wneu.2011.10.035
   Goal A, 2002, NEUROSURGERY, V51, P1356
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Guan Q, 2018, NEUROSURG REV, V41, P779, DOI 10.1007/s10143-017-0923-z
   Hamilton DK, 2011, J NEUROSURG-SPINE, V15, P3, DOI 10.3171/2011.1.SPINE10417
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Hong JT, 2016, SPINE J, V16, P1055, DOI 10.1016/j.spinee.2016.04.019
   Kang MM, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.07.010
   Larsen AMG, 2018, OPER NEUROSURG, V14, P647, DOI 10.1093/ons/opx164
   Mixter SJ, 1910, ANN SURG, V51, P193, DOI 10.1097/00000658-191002000-00004
   Moisi M, 2017, J NEUROSURG-SPINE, V26, P679, DOI 10.3171/2016.11.SPINE16769
   Patel AJ, 2013, CHILD NERV SYST, V29, P93, DOI 10.1007/s00381-012-1899-1
   Pisapia JM, 2012, WORLD NEUROSURG, V77, P362, DOI 10.1016/j.wneu.2011.06.062
   Salunke P, 2018, WORLD NEUROSURG, V118, pE925, DOI 10.1016/j.wneu.2018.07.101
   Simsek S, 2009, SURG NEUROL, V72, P676, DOI 10.1016/j.surneu.2009.06.015
   Squires J, 2010, EUR SPINE J, V19, P1318, DOI 10.1007/s00586-010-1452-4
   Wang Michael Y, 2002, Neurosurg Focus, V12, pE14
   Witiw CD, 2015, NEUROSURGERY, V76, P638, DOI 10.1227/NEU.0000000000000711
   Yamagata T, 2013, NEUROL MED-CHIR, V53, P914, DOI 10.2176/nmc.tn2012-0288
   Yeom JS, 2013, SPINE J, V13, P786, DOI 10.1016/j.spinee.2013.04.006
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1210
EP E1214
DI 10.1016/j.wneu.2019.04.100
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300151
PM 31004854
DA 2020-05-12
ER

PT J
AU Folzenlogen, Z
   Seinfeld, J
   Kubes, S
   Kumpe, D
   Case, D
   Roark, C
AF Folzenlogen, Zach
   Seinfeld, Joshua
   Kubes, Sheila
   Kumpe, David
   Case, David
   Roark, Christopher
TI Use of the PulseRider Device in the Treatment of Ruptured Intracranial
   Aneurysms: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Coiling; Devices; PulseRider; Stent; Subarachnoid hemorrhage
ID CLOPIDOGREL RESPONSE VARIABILITY; ASSISTED COIL EMBOLIZATION; BASILAR
   TIP ANEURYSMS; ANTICOAGULATION; RISK
AB BACKGROUND: Wide-necked intracranial aneurysms present unique treatment challenges in the setting of subarachnoid hemorrhage. New generations of endoluminal devices (stents) have expanded our ability to treat complex aneurysms. The PulseRider Aneurysm Neck Reconstruction Device (PulseRider [Cerenovus, Irvine, California, USA]) is new to the U. S. market after receiving Food and Drug Administration approval in June 2017. Official recommendation for use of the PulseRider is with dual antiplatelet therapy (DAPT). Its design has been hypothesized to carry a lower risk of thromboembolic complications in the circumstance that DAPT needs to be discontinued.
   METHODS: Between March and June 2018, we treated 4 cases of ruptured wide-necked basilar tip aneurysms at the University of Colorado Hospital, Aurora, Colorado, with PulseRider-assisted coil embolization. Imaging and chart reviews were performed retrospectively on each of these patients.
   RESULTS: All 4 aneurysms were successfully treated with PulseRider-assisted coil embolization. There were no periprocedural hemorrhages and no postprocedural reruptures. Two patients developed nonocclusive thrombi in the posterior cerebral arteries at the time of coiling, which was resolved with intra-arterial glycoprotein IIb/ IIIa receptor antagonists. Two patients developed external ventricular draineassociated hemorrhages, only one of which developed after the administration of DAPT. All patients were eventually discharged to home.
   CONCLUSIONS: The PulseRider device represents a novel design for stent-assisted coil embolization. We report a small but promising series of its successful use in the acute treatment of wide-necked, ruptured basilar artery aneurysms. Additional experience is needed to determine if this device has a place in our armamentarium for treatment of ruptured aneurysms.
C1 [Folzenlogen, Zach] Univ Colorado, Dept Neurosurg, Aurora, CO 80309 USA.
   [Seinfeld, Joshua; Kubes, Sheila; Kumpe, David; Case, David; Roark, Christopher] Univ Colorado, Dept Neurosurg & Radiol, Aurora, CO USA.
RP Folzenlogen, Z (reprint author), Univ Colorado, Dept Neurosurg, Aurora, CO 80309 USA.
EM Zach.folzenlogen@ucdenver.edu
CR [Anonymous], ENGLISH INSTRUCTIONS
   Barton CA, 2012, J TRAUMA ACUTE CARE, V72, P815, DOI 10.1097/TA.0b013e31824fbadf
   Bechan RS, 2016, AM J NEURORADIOL, V37, P502, DOI 10.3174/ajnr.A4542
   Ben-Dor I, 2009, AM J CARDIOL, V104, P227, DOI 10.1016/j.amjcard.2009.03.022
   Bruder M, 2015, WORLD NEUROSURG, V84, P1653, DOI 10.1016/j.wneu.2015.07.003
   Chung J, 2014, J NEUROSURG, V121, P4, DOI 10.3171/2014.4.JNS131662
   Ferguson AD, 2008, TEX HEART I J, V35, P313
   Gory B, 2016, AM J NEURORADIOL, V37, P130, DOI 10.3174/ajnr.A4506
   Gurbel PA, 2009, CIRCULATION, V120, P2577, DOI 10.1161/CIRCULATIONAHA.109.912550
   Kang HS, 2010, AM J NEURORADIOL, V31, P1206, DOI 10.3174/ajnr.A2051
   Kim KS, 2018, J NEUROSURG, V129, P890, DOI 10.3171/2017.5.JNS162307
   Kung DK, 2011, J NEUROSURG, V114, P1021, DOI 10.3171/2010.9.JNS10445
   Lawson A, 2018, J NEUROSURG, V128, P144, DOI 10.3171/2016.9.JNS152849
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Muto M, 2017, RADIOL MED, V122, P43, DOI 10.1007/s11547-016-0686-6
   Ramchand P, 2013, NEUROCRIT CARE, V19, pS265
   Sekhar LN, 2013, NEUROSURGERY, V72, P284, DOI 10.1227/NEU.0b013e3182797952
   Skukalek SL, 2016, J NEUROINTERV SURG, V8, P58, DOI 10.1136/neurintsurg-2014-011145
   Sohail U, 2016, WORLD J GASTRO ENDOS, V8, P553, DOI 10.4253/wjge.v8.i16.553
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spiessberger A, 2018, WORLD NEUROSURG, V114, P305, DOI 10.1016/j.wneu.2018.03.141
   Tantry US, 2014, ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE, P285
   Uchiyama S, 2011, CARDIOVASC THER, V29, pE100, DOI 10.1111/j.1755-5922.2010.00202.x
   van Eijck M, 2015, AM J NEURORADIOL, V36, P2108, DOI 10.3174/ajnr.A4410
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E149
EP E154
DI 10.1016/j.wneu.2019.03.003
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300021
PM 30862588
DA 2020-05-12
ER

PT J
AU Gan, YJ
   Zhou, XW
   Niu, XD
   Li, JM
   Wang, TW
   Zhang, HDF
   Yang, Y
   Liu, YH
   Mao, Q
AF Gan, Youjun
   Zhou, Xingwang
   Niu, Xiaodong
   Li, Jiaoming
   Wang, Tianwei
   Zhang, Haodongfang
   Yang, Yuan
   Liu, Yanhui
   Mao, Qing
TI Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in
   Elderly Patients with High-Grade Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Elderly patients; Glioblastoma; High-grade glioma;
   Neutrophil/lymphocyte ratio; NLR; Prognostic factor
ID TO-LYMPHOCYTE RATIO; PRETREATMENT NEUTROPHIL; GLIOBLASTOMA; SURVIVAL;
   ASSOCIATION; TARGETS
AB OBJECTIVE: The present study was performed to investigate the prognostic role of the preoperative neutrophil/lymphocyte ratio (NLR) in elderly patients with high-grade glioma.
   METHODS: We collected the data from elderly patients (age >= 65 years) who had been diagnosed with high-grade glioma in our hospital from December 2014 to January 2018. The preoperative NLR was evaluated in univariate and multivariate models to examine their effect on overall survival (OS).
   RESULTS: The study included 135 elderly patients (World Health Organization grade III, n = 22; grade IV, n = 113) with a mean age 70.61 +/- 4.60 years. The mean NLR was 3.98 +/- 3.28. The optimal NLR cutoff for predicting OS was 3. Of the 135 patients, 65 (48.1%) had a baseline NLR of >= 3 and 70 (51.9%) a baseline NLR <3. For patients with an NLR of >= 3 and NLR <3, the mean OS was 9.6 months and 17.1 months, respectively. The results showed that age, gender, tumor location, preoperative Karnofsky performance scale score, extent of resection (EOR), and postoperative adjuvant therapy were not associated with the NLR. The tumor grade, neutrophil count, and lymphocyte count were significantly associated with the NLR (P < 0.001). On univariate analysis, tumor grade, preoperative Karnofsky performance scale score >= 80, EOR, frontal tumor, adjuvant radiotherapy plus temozolomide, NLR of >= 3, and lymphocyte count of >= 1.6 x 10(9)/L were significantly associated with OS. On multivariate analysis, tumor grade, EOR, adjuvant radiotherapy plus temozolomide, NLR of >= 3, and lymphocyte count of >= 1.6 x 10(9)/L were still associated with OS after excluded related parameters.
   CONCLUSIONS: A high NLR was an unfavorable predictor of prognosis for elderly patients with high-grade glioma.
C1 [Gan, Youjun; Zhou, Xingwang; Niu, Xiaodong; Li, Jiaoming; Zhang, Haodongfang; Yang, Yuan; Liu, Yanhui; Mao, Qing] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Wang, Tianwei] Xi An Jiao Tong Univ, Xian Cent Hosp, Sch Med, Dept Neurosurg, Xian, Shaanxi, Peoples R China.
RP Mao, Q (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM maoqing20000@163.com
FU Key Research and Development Project from the Department of Science and
   Technology of Sichuan Province, China [2017SZ0006]; Department of
   Science and Technology of Sichuan Province, China [2016TJPT0012]
FX The present research was funded by the Key Research and Development
   Project from the Department of Science and Technology of Sichuan
   Province, China (grant 2017SZ0006) and infrastructure platform from the
   Department of Science and Technology of Sichuan Province, China (grant
   2016TJPT0012).
CR Arbel Y, 2012, ATHEROSCLEROSIS, V225, P456, DOI 10.1016/j.atherosclerosis.2012.09.009
   Arvold ND, 2014, CLIN INTERV AGING, V9, P357, DOI 10.2147/CIA.S44259
   Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9
   Barberis I, 2016, J Prev Med Hyg, V57, pE41
   Belen E, 2015, J CLIN HYPERTENS, V17, P532, DOI 10.1111/jch.12533
   Curbelo J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173947
   de Jager CPC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046561
   Deng QW, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0409-0
   Gondo T, 2012, UROLOGY, V79, P1085, DOI 10.1016/j.urology.2011.11.070
   Gorlia T, 2008, LANCET ONCOL, V9, P29, DOI 10.1016/S1470-2045(07)70384-4
   Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583
   Han S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1629-7
   Hau P, 2004, ONKOLOGE S1, V10, pS26
   Keizman D, 2012, ONCOLOGIST, V17, P1508, DOI 10.1634/theoncologist.2012-0125
   Lanca T, 2012, ONCOIMMUNOLOGY, V1, P717, DOI 10.4161/onci.20068
   Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557
   Lopes M, 2018, J NEURO-ONCOL, V136, P173, DOI 10.1007/s11060-017-2641-3
   Mantovani A, 2010, ANN MED, V42, P161, DOI 10.3109/07853890903405753
   McNamara MG, 2014, J NEURO-ONCOL, V117, P147, DOI 10.1007/s11060-014-1366-9
   Mirzaei R, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1478647
   Murphy J, 2000, AM J GASTROENTEROL, V95, P3607
   Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824
   Sasaki T, 2018, J NEURO-ONCOL, V140, P329, DOI 10.1007/s11060-018-2957-7
   Tamura Y, 2018, THER RES, V39, P67
   Toro-Moreno A. C., 2017, REV ECUAT NEUROL, V26, P283
   Wainwright DA, 2011, NEURO-ONCOLOGY, V13, P1308, DOI 10.1093/neuonc/nor134
   Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329
   Weng WJ, 2018, NEUROL RES, V40, P917, DOI 10.1080/01616412.2018.1497271
   Yasar Z, 2015, EUR REV MED PHARMACO, V19, P956
NR 29
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E261
EP E267
DI 10.1016/j.wneu.2019.03.085
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300035
PM 30898756
DA 2020-05-12
ER

PT J
AU Ge, HJ
   Yang, HC
   Ren, H
   Li, W
   Lv, XL
   Jin, HW
   Liu, D
   Liu, XK
   He, HW
   Miao, ZR
   Li, YX
AF Ge, Huijian
   Yang, Hongchao
   Ren, Hui
   Li, Wei
   Lv, Xianli
   Jin, Hengwei
   Liu, Dong
   Liu, Xinke
   He, Hongwei
   Miao, Zhongrong
   Li, Youxiang
TI Association of Thrombelastographic Parameters with Complications in
   Patients with Intracranial Aneurysm After Stent Placement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet drug resistance; Intracranial aneurysms; Stent;
   Thrombelastographic parameters
ID THROMBOEMBOLIC EVENTS; COIL EMBOLIZATION; CLOT STRENGTH; CLOPIDOGREL
   RESISTANCE; ENDOVASCULAR TREATMENT; ASSISTED EMBOLIZATION; VARIABILITY;
   NEUROFORM; STANDARD; THERAPY
AB OBJECTIVE: A prospective trial was conducted to investigate the platelet function and association between thrombelastographic (TEG) parameters and embolic or hemorrhagic complications in patients with intracranial aneurysm undergoing stent treatment.
   METHODS: Between September 2013 and June 2016, we prospectively recruited patients with intracranial aneurysm who were treated with stent-assisted coiling. TEG parameters were used to assess the platelet function before stenting procedures. The primary study end point was the onset of ischemic stroke, transient ischemic attack, or silent ischemic events in the territory of the stented artery within 6 months after the procedure. The secondary end point was assessed by bleeding events.
   RESULTS: Four hundred and thirty-one patients with 453 intracranial aneurysms were enrolled. A total of 519 neurovascular stents were implanted. During the follow-up, a total of 70 primary end points (16.2%) and 59 secondary end points (13.7%) were detected. Thromboembolic complications such as symptomatic and slient ischemic complications were more frequently observed in patients with large aneurysms (> 10 mm, P [0.01), lower adenosine diphosphate (ADP) inhibition rate (P < 0.0001), and higher ADPinduced platelet-fibrin clot strength (maximum amplitude of adenosine diphosphate [MA-ADP]) (P < 0.0001). Besides, based on multivariate analysis, a higher ADP inhibition ratio was identified as a significant independent predictor of subsequent bleeding events ( P < 0.0001). According to the receiver operating characteristic curve analysis, the safe range of the ADP inhibition ratio and MA-ADP of the TEG analysis were identified as 29.45%-55.4% and < 46.15, respectively.
   CONCLUSIONS: The ADP inhibition ratio and MA-ADP of TEG analysis were associated with subsequent cerebral ischemic events and intracranial or extracranial bleeding events in patients with intracranial aneurysm after stent treatment.
C1 [Ge, Huijian; Jin, Hengwei; Liu, Xinke; He, Hongwei; Miao, Zhongrong; Li, Youxiang] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Ge, Huijian; Jin, Hengwei; Liu, Xinke; He, Hongwei; Miao, Zhongrong; Li, Youxiang] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Ge, Huijian; Li, Wei; Jin, Hengwei; Liu, Xinke; He, Hongwei; Li, Youxiang] Beijing Engn Res Ctr Intervent Neuroradiol, Beijing, Peoples R China.
   [Yang, Hongchao] Capital Med Univ, Beijing Chaoyang Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Ren, Hui] Capital Med Univ, Beijing Luhe Hosp, Lab Diag Ctr, Beijing, Peoples R China.
   [Li, Wei] Xingtai Med Coll, Affiliated Hosp 2, Dept Neurosurg, Xingtai, Hebei, Peoples R China.
   [Lv, Xianli] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Liu, Dong] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Li, YX (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Li, YX (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
EM liyouxiang@263.net
RI Liu, Xinke/X-7189-2019
OI Liu, Xinke/0000-0003-3918-0814
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81471166, 81171078]
FX This work was supported by the National Natural Science Foundation of
   China (81471166 and 81171078).
CR Alexander M, 2014, J NEUROINTERV SUR S1, V6, pA68, DOI [10.1136/neurintsurg-2014-011343.129, DOI 10.1136/NEURINTSURG-2014-011343.129]
   Almandoz JED, 2014, J NEUROINTERV SURG, V6, P767, DOI 10.1136/neurintsurg-2013-010976
   Almandoz JED, 2013, J NEUROINTERV SURG, V5, pIII3, DOI 10.1136/neurintsurg-2012-010582
   Bendok BR, 2003, NEUROSURGERY, V52, P1125, DOI 10.1227/01.NEU.0000057833.50219.25
   Brooks NP, 2008, J NEUROSURG, V108, P1095, DOI 10.3171/JNS/2008/108/6/1095
   Chalouhi N, 2013, STROKE, V44, P1348, DOI 10.1161/STROKEAHA.111.000641
   Fifi JT, 2013, AM J NEURORADIOL, V34, P716, DOI 10.3174/ajnr.A3405
   Gasparyan AY, 2010, VASC HEALTH RISK MAN, V6, P109
   Ge HJ, 2017, J NEUROINTERV SURG, V9, P958, DOI 10.1136/neurintsurg-2016-012635
   Gentric JC, 2013, AM J NEURORADIOL, V34, P1203, DOI 10.3174/ajnr.A3379
   Gurbel PA, 2005, J AM COLL CARDIOL, V46, P1820, DOI 10.1016/j.jacc.2005.07.041
   Gurbel PA, 2010, AM HEART J, V160, P346, DOI 10.1016/j.ahj.2010.05.034
   Heller RS, 2013, J NEUROSURG, V119, P1603, DOI 10.3171/2013.7.JNS122178
   Hwang G, 2015, JAMA NEUROL, V72, P764, DOI 10.1001/jamaneurol.2015.0654
   Jeong YH, 2013, PLATELETS, V24, P166, DOI 10.3109/09537104.2012.675108
   Johnson AK, 2015, J NEUROSURG, V123, P453, DOI 10.3171/2014.10.JNS141361
   Kang HS, 2010, AM J NEURORADIOL, V31, P1206, DOI 10.3174/ajnr.A2051
   Lanterna LA, 2004, NEUROSURGERY, V55, P767, DOI 10.1227/01.NEU.0000137653.93173.1C
   Lee SJ, 2013, CLIN RADIOL, V68, P256, DOI 10.1016/j.crad.2012.07.017
   Lu DS, 2013, THROMB RES, V132, pE94, DOI 10.1016/j.thromres.2013.07.012
   Muto M, 2017, RADIOL MED, V122, P43, DOI 10.1007/s11547-016-0686-6
   Rafiq S, 2012, EUR J CARDIO-THORAC, V41, P550, DOI 10.1093/ejcts/ezr001
   Song J, 2015, CLIN NEUROL NEUROSUR, V135, P73, DOI 10.1016/j.clineuro.2015.05.013
   Tavassoli N, 2010, AM J CARDIOVASC DRUG, V10, P29, DOI 10.2165/11318260-000000000-00000
   Wang B, 2017, J NEUROINTERV SURG, V9, P192, DOI 10.1136/neurintsurg-2015-011687
   Yahia AM, 2010, J NEUROIMAGING, V20, P113, DOI 10.1111/j.1552-6569.2009.00390.x
   Yang HC, 2016, J NEUROSURG, V125, P247, DOI 10.3171/2015.6.JNS1511
   Yang HC, 2015, INTERV NEURORADIOL, V21, P61, DOI 10.15274/INR-2014-10094
   Yao XY, 2014, CEREBROVASC DIS, V38, P182, DOI 10.1159/000365652
NR 29
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E30
EP E38
DI 10.1016/j.wneu.2019.02.007
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300006
PM 30790737
DA 2020-05-12
ER

PT J
AU Georgiou, I
   Georgiou, S
   Bhatt, P
AF Georgiou, Ioannis
   Georgiou, Sotiris
   Bhatt, Pragnesh
TI Harvey Cushing's Influence on Norman Dott's Work on Acromegaly:
   Pituitary Research, Treatment Modalities, and Research Dissemination c.
   1900-c. 1960
SO WORLD NEUROSURGERY
LA English
DT Article
DE Harvey Cushing; Norman Dott; Pituitary adenoma; Trans-sphenoidal
ID SURGERY; HISTORY
AB OBJECTIVE: To review Dr. Harvey Cushing's influence on Mr. Norman Dott's work on acromegaly and other subjects surrounding the pituitary gland such as pituitary research, treatment modalities, and research dissemination. Dott was the first Professor of Neurosurgery in Scotland during 1947 and was considered a pioneer of the understanding and treatment modalities for pituitary disorders such as acromegaly. During 1923, he published an article regarding pituitary physiology that won him the award for the Rockefeller Fellowship Trust, to travel to Boston Massachusetts, giving him the opportunity to train under Cushing's supervision for the years of 1923-1924. However, similarities can be seen between Dott's physiology project that was completed before he ever met Cushing, as well as his treatment suggestions for acromegaly, after he had finished his training under Cushing's supervision.
   METHODS: This was a historical perspective based on literature review. We reviewed Norman Dott's archives held by University of Edinburgh Library or online sources and we compared these with the work Cushing had previously performed in a chronological fashion. Cushing's work on the pituitary gland and acromegaly can be largely found online, in biographical books, and in other secondary sources. The search included words such as "transsphenoidal surgery," "x-ray," "Harvey Cushing," "Norman Dott," "Acromegaly," "Annual Meetings," and "Pituitary physiology." We excluded any primary sources that were not published between 1900 and 1960 regarding either pituitary physiology or the treatments for acromegaly.
   CONCLUSIONS: Sir Norman Dott was the first Professor of Neurosurgery in Scotland during 1947 and is well known for his pioneering work on intracranial aneurysms. Although less well known for his contribution to pituitary pathologies, we would like to share his contribution in this regard and correlate it with Cushing's influence.
C1 [Georgiou, Ioannis] Univ Aberdeen, Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland.
   [Georgiou, Sotiris] Univ Manchester, Manchester, Lancs, England.
   [Bhatt, Pragnesh] NHS Grampian, Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland.
RP Georgiou, I (reprint author), Univ Aberdeen, Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland.
EM i.georgiou.15@aberdeen.ac.uk
OI Georgiou, Ioannis/0000-0002-0820-322X
CR [Anonymous], 1925, BRIT J SURG, V13, P314
   Bliss M., 2007, HARVEY CUSHING LIFE
   Casper Stephen T, 2014, NEUROLOGISTS HIST ME
   Chanson P, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-17
   Cushing H., 1912, PITUITARY BODY ITS D, P295
   Cushing H., 1912, PITUITARY BODY ITS D, P12
   de Herder WW, 2016, NEUROENDOCRINOLOGY, V103, P7, DOI 10.1159/000371808
   Dott NM, 1923, Q J EXP PHYSIOL, V13, P241, DOI 10.1113/expphysiol.1923.sp000293
   Dott NM, GEN 2085 8 D117
   Dott NM, GEN 2085 26 H14
   Dott NM, ROYAL INFIRMARY EDIN
   Dott NM, GEN 2085 8 D25
   Dott NM, GEN 2085 8 D118
   Dott NM, GEN 2085 8 D1
   Dott NM, GEN 2085 26 H1
   Dott NM, ROYAL INFIRMPATENTY
   Guilford E., 1926, BMJ-BRIT MED J, P158
   Lanzino G, 2001, J NEUROSURG, V95, P1097, DOI 10.3171/jns.2001.95.6.1097
   MOULD RF, 1995, PHYS MED BIOL, V40, P1741, DOI 10.1088/0031-9155/40/11/001
   Patel SK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12125
   Prieto R, 2017, J NEUROSURG, V127, P927, DOI 10.3171/2016.9.JNS16702
   Rush C, 1990, SHARP COMPASSION NOR
   Stone JL, 2005, J AM COLL SURGEONS, V201, P784, DOI 10.1016/j.jamcollsurg.2005.04.010
   Thomas A, 2013, HIST RADIOLOGY
   Wang AJ, 2016, J NEUROSURG SCI, V60, P441
   Watts W, 1957, BMJ-BRIT MED J, P133
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E8
EP E15
DI 10.1016/j.wneu.2019.01.038
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300003
PM 30928575
DA 2020-05-12
ER

PT J
AU Goel, A
   Dhar, A
   Shah, A
   Rai, S
   Bakale, N
   Vaja, T
AF Goel, Atul
   Dhar, Arjun
   Shah, Abhidha
   Rai, Survendra
   Bakale, Nilesh
   Vaja, Tejas
TI Revision for Failed Craniovertebral Junction Stabilization: A Report of
   30 Treated Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial stabilization; Craniovertebral instability;
   Occipitocervical fixation
ID ATLANTOAXIAL DISLOCATION; SPINOUS PROCESS; FIXATION; INSTABILITY;
   FACETAL; PLATE
AB OBJECTIVE: To analyze the probable causes of failed craniovertebral junction stabilization procedures, and to evaluate the advantages of the Goel technique in revision surgery and the positive factors that lead to reduction of the instability and achieve ultimate arthrodesis.
   METHODS: During the period from January 2010 to June 2018, we treated 30 cases where previous attempt at craniovertebral stabilization with various fixation techniques had failed and the patients presented with progressively worsening neurologic deficits. All patients were re-operated by lateral mass fixation techniques described by the senior author. The technique involved opening of the atlantoaxial joint, denuding the articular cartilage, introduction of bone graft within the articular cavity, and plate and screw fixation. No bone decompression was done.
   RESULTS: Fixation of multiple subaxial spinal segments (n = 9), inclusion of occipital bone in the fixation construct (n = 21), and dependence on metal stabilization rather than bone fusion (n = 19) appear to be important causes of implant failure. All patients improved in clinical symptoms after revision surgery. Postoperative images of all patients demonstrated significant reduction of the atlantoaxial dislocation and craniovertebral junction realignment. During the average follow-up period of 32 months, all reoperated patients continued to show clinical recovery. No further surgery was necessary.
   CONCLUSIONS: Although relatively difficult, when indicated, reoperation and direct stabilization of the atlantoaxial joint can result in significant and enduring clinical recovery.
C1 [Goel, Atul; Shah, Abhidha; Rai, Survendra; Bakale, Nilesh; Vaja, Tejas] KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Dhar, Arjun] Dept Neurosurg, Mumbai, Maharashtra, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
OI Dhar, Arjun/0000-0003-2044-8796
CR Ahmed R, 2013, NEUROSURGERY S, V72
   Ahmed R, 2013, NEUROSURGERY, V72, P214
   Fujiwara A, 2003, SPINE, V28, P1601, DOI 10.1097/00007632-200307150-00023
   Goel A, 2004, J CLIN NEUROSCI, V11, P735, DOI 10.1016/j.jocn.2004.03.021
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A, 2007, J NEUROSURG-SPINE, V7, P90, DOI 10.3171/SPI-07/07/090
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P85, DOI 10.4103/jcvjs.JCVJS_38_17
   Goel A, 2017, NEUROSURGERY, V80, pE263, DOI 10.1093/neuros/nyx036
   Goel A, 2017, WORLD NEUROSURG, V100, P236, DOI 10.1016/j.wneu.2017.01.015
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P141, DOI 10.4103/0974-8237.147070
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P3, DOI 10.4103/0974-8237.135206
   Goel A, 2010, J CLIN NEUROSCI, V17, P1345, DOI 10.1016/j.jocn.2010.03.012
   Goel A, 2010, J NEUROSURG-SPINE, V13, P1, DOI 10.3171/2009.10.SPINE09761
   Goel A, 2009, J NEUROSURG-SPINE, V11, P9, DOI 10.3171/2009.3.SPINE08927
   Haher TR, 1999, SPINE, V24, P5, DOI 10.1097/00007632-199901010-00003
   Huang M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14810
   Moskovich R, 2000, J BONE JOINT SURG AM, V82A, P349, DOI 10.2106/00004623-200003000-00006
   Sindgikar P, 2016, NEUROL INDIA, V64, P1220, DOI 10.4103/0028-3886.193781
   Tang C, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010441
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E856
EP E863
DI 10.1016/j.wneu.2019.03.286
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300106
PM 30954741
DA 2020-05-12
ER

PT J
AU Guo, R
   Wu, YX
   Chen, RQ
   Yu, ZY
   You, C
   Ma, L
   Tian, M
AF Guo, Rui
   Wu, Yixuan
   Chen, Ruiqi
   Yu, Zhiyuan
   You, Chao
   Ma, Lu
   Tian, Meng
TI Clinical Value of Neutrophil-to-Lymphocyte Ratio in Primary
   Intraventricular Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neutrophil-to-lymphocyte ratio; Outcome; Pneumonia; Primary
   intraventricular hemorrhage
ID RISK-FACTORS; ETIOLOGY; PNEUMONIA; MORTALITY; FEATURES; PREDICTS;
   OUTCOMES; ADULTS; YIELD
AB OBJECTIVES: The neutrophil-to-lymphocyte ratio (NLR) reflects the balance between innate and adaptive inflammatory responses. This study intended to evaluate parameters associated with admission high NLR and its impact on clinical outcome in patients with primary intraventricular hemorrhage (PIVH).
   METHODS: This study retrospectively analyzed consecutive patients with PIVH without a history of head trauma or parenchymal/subarachnoid hemorrhage on computed tomography scan between 2010 and 2016 in a single center. Clinical outcomes at discharge and 90 days were assessed with the modified Rankin Score (mRS) and dichotomized as good (mRS 0-2) and poor (mRS 3-6) outcomes. Associations were estimated using multivariable logistic regression.
   RESULTS: We had 171 patients with PIVH included in the present study. There were 94 male (55.0%) and 77 female (45.0%) patients, with an average age of 46.1 +/- 17.2 years. Multivariable logistic analyses revealed independent associations of high NLR (>= 8.25) with higher Graeb score, Moyamoya disease, higher admission blood glucose level, and lower platelet count. The patients with high NLR had poorer outcome at discharge and 90 days. After adjustment, the patients with high NLR tended to be associated with poor outcome both at discharge and 90 days. In addition, NLR exhibited a superior predictive power of pneumonia in PIVH than absolute neutrophil count and white blood cell count.
   CONCLUSIONS: NLR tended to be associated with 90-day clinical outcomes of patients with PIVH and exhibited independent predictive power for pneumonia in PIVH.
C1 [Guo, Rui; Chen, Ruiqi; Yu, Zhiyuan; You, Chao; Ma, Lu; Tian, Meng] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Wu, Yixuan] Sichuan Univ, West China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.
RP Tian, M (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM huaxitianmeng@163.com
CR Akirov A, 2016, J DIABETES COMPLICAT, V30, P845, DOI 10.1016/j.jdiacomp.2016.03.021
   Angelopoulos M, 1995, SURG NEUROL, V44, P433, DOI 10.1016/0090-3019(95)00261-8
   Brooks SD, 2014, J NEUROINTERV SURG, V6, P578, DOI 10.1136/neurintsurg-2013-010780
   Chang Dyi-Sheng, 1998, Kaohsiung Journal of Medical Sciences, V14, P633
   DARBY DG, 1988, NEUROLOGY, V38, P68, DOI 10.1212/WNL.38.1.68
   Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   GATES PC, 1986, STROKE, V17, P872, DOI 10.1161/01.STR.17.5.872
   Gibson PH, 2010, AM J CARDIOL, V105, P186, DOI 10.1016/j.amjcard.2009.09.007
   Giede-Jeppe A, 2017, CEREBROVASC DIS, V44, P26, DOI 10.1159/000468996
   Giray S, 2009, TURK NEUROSURG, V19, P338
   GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795
   Han XL, 2018, BMC PUBLIC HEALTH, V18, DOI [10.1186/s12889-018-5417-6, 10.1186/s12879-018-3098-5]
   Ji RJ, 2013, STROKE, V44, P1303, DOI 10.1161/STROKEAHA.111.000598
   Jiang CY, 2020, J REAL-TIME IMAGE PR, V17, P197, DOI 10.1007/s11554-018-0757-0
   Kim S, 2018, JAMA CARDIOL, V3, P455, DOI 10.1001/jamacardio.2018.1042
   Lattanzi S, 2018, J NEUROL SCI, V387, P98, DOI 10.1016/j.jns.2018.01.038
   Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627
   Lee SH, 2017, MED SCI MONITOR, V23, P1401, DOI 10.12659/MSM.899309
   Marti-Fabregas J, 1999, J NEUROL, V246, P287, DOI 10.1007/s004150050348
   Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801
   Nam KW, 2018, STROKE, V49, P1886, DOI 10.1161/STROKEAHA.118.021228
   Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098
   Srivastava T, 2014, NEUROL INDIA, V62, P144, DOI 10.4103/0028-3886.132333
   Tao CY, 2017, BIOMARK MED, V11, P33, DOI 10.2217/bmm-2016-0187
   Tembl J, 1997, REV NEUROLOGIA, V25, P215
   Wang F, 2016, J STROKE CEREBROVASC, V25, P182, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.013
   Weinstein R, 2017, J STROKE CEREBROVASC, V26, P995, DOI 10.1016/j.jstrokecerebrovasdis.2016.11.114
   Zahorec R, 2001, Bratisl Lek Listy, V102, P5
   Zhang F, 2018, WORLD NEUROSURG, V119, pE956, DOI 10.1016/j.wneu.2018.08.010
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1051
EP E1056
DI 10.1016/j.wneu.2019.04.040
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300131
PM 30980971
DA 2020-05-12
ER

PT J
AU Guo, R
   Yang, JK
   Yu, ZY
   Chen, RQ
   You, C
   Li, H
   Ma, L
AF Guo, Rui
   Yang, Jinkun
   Yu, Zhiyuan
   Chen, Ruiqi
   You, Chao
   Li, Hao
   Ma, Lu
TI Risk Factors and Outcomes of Pneumonia After Primary Intraventricular
   Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Outcome; Pneumonia; Primary intraventricular hemorrhage; Risk factors
ID ACUTE STROKE; CLINICAL-FEATURES; INFECTION; ETIOLOGY; ADULTS; YIELD;
   CARE
AB OBJECTIVES: To investigate the risk factors in the development of pneumonia and its impact on outcome after primary intraventricular hemorrhage (PIVH).
   METHODS: This is a single-center retrospective study including consecutive patients with PIVH admitted to West China Hospital from 2010 to 2016. Pneumonia was defined according to the modified Centers for Disease Control and Prevention criteria within 7 days after PIVH onset. Poor outcome (modified Rankin score >= 3) and mortality at discharge and at 90 days were analyzed.
   RESULTS: Among the included 174 patients, pneumonia occurred in 13 (7.5%) patients. Patients with pneumonia had lower Glasgow Coma Scale (GCS) score (P = 0.001) and greater Graeb score (P = 0.001) at admission, presented more often with acute hydrocephalus (P = 0.04) and greater rates with stroke history (P = 0.002), and harbored greater admission blood glucose (P = 0.01) and absolute neutrophil counts (P = 0.02). In a multivariable analysis, only GCS score and stroke history were independent predictors of pneumonia after PIVH. The patients with pneumonia had longer duration of hospital stay (P = 0.002) and poorer outcome (P = 0.02) at 90 days. However, after adjustment for confounders, pneumonia after PIVH was not an independent predictor of poor outcome at 90 days.
   CONCLUSIONS: GCS score and stroke history were independent predictors of pneumonia development after PIVH. Pneumonia after PIVH was associated with longer duration of hospital stay and poorer outcome at 90 days.
C1 [Guo, Rui; Yu, Zhiyuan; Chen, Ruiqi; You, Chao; Li, Hao; Ma, Lu] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Yang, Jinkun] Sichuan Univ, West China Hosp, Dept Anesthesiol, Chengdu, Sichuan, Peoples R China.
RP Ma, L (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM huaxi_malu@163.com
CR Angelopoulos M, 1995, SURG NEUROL, V44, P433, DOI 10.1016/0090-3019(95)00261-8
   Badve MS, 2019, INT J STROKE, V14, P125, DOI 10.1177/1747493018806196
   Chang Dyi-Sheng, 1998, Kaohsiung Journal of Medical Sciences, V14, P633
   DARBY DG, 1988, NEUROLOGY, V38, P68, DOI 10.1212/WNL.38.1.68
   Ding RY, 2000, DYSPHAGIA, V15, P51, DOI 10.1007/s004550010001
   Finlayson O, 2011, NEUROLOGY, V77, P1338, DOI 10.1212/WNL.0b013e31823152b1
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   GATES PC, 1986, STROKE, V17, P872, DOI 10.1161/01.STR.17.5.872
   Giray S, 2009, TURK NEUROSURG, V19, P338
   Ji RJ, 2013, STROKE, V44, P1303, DOI 10.1161/STROKEAHA.111.000598
   Kammersgaard L P, 2001, J Stroke Cerebrovasc Dis, V10, P217, DOI 10.1053/jscd.2001.30366
   Katzan IL, 2003, NEUROLOGY, V60, P620, DOI 10.1212/01.WNL.0000046586.38284.60
   Kwan J, 2007, ACTA NEUROL SCAND, V115, P331, DOI 10.1111/j.1600-0404.2006.00783.x
   Lee SH, 2017, MED SCI MONITOR, V23, P1401, DOI 10.12659/MSM.899309
   Marti-Fabregas J, 1999, J NEUROL, V246, P287, DOI 10.1007/s004150050348
   Nam KW, 2018, STROKE, V49, P1886, DOI 10.1161/STROKEAHA.118.021228
   Saposnik G, 2008, STROKE, V39, P2318, DOI 10.1161/STROKEAHA.107.510362
   Sellars C, 2007, STROKE, V38, P2284, DOI 10.1161/STROKEAHA.106.478156
   Smith CJ, 2015, STROKE, V46, P2335, DOI 10.1161/STROKEAHA.115.009617
   Smith CJ, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001307
   Srivastava T, 2014, NEUROL INDIA, V62, P144, DOI 10.4103/0028-3886.132333
   Tembl J, 1997, REV NEUROLOGIA, V25, P215
   Vargas M, 2006, STROKE, V37, P461, DOI 10.1161/01.STR.0000199138.73365.b3
   Vermeij FH, 2009, CEREBROVASC DIS, V27, P465, DOI 10.1159/000210093
   Walter U, 2007, J NEUROL, V254, P1323, DOI 10.1007/s00415-007-0520-0
   Weinstein R, 2017, J STROKE CEREBROVASC, V26, P995, DOI 10.1016/j.jstrokecerebrovasdis.2016.11.114
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E979
EP E985
DI 10.1016/j.wneu.2019.04.012
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300122
PM 30965165
DA 2020-05-12
ER

PT J
AU Hadley, C
   Sheth, S
   Fargen, KM
   Srinivasan, VM
   Cherian, J
   Chen, S
   Johnson, J
   Kan, P
AF Hadley, Caroline
   Sheth, Sunil
   Fargen, Kyle M.
   Srinivasan, Visish M.
   Cherian, Jacob
   Chen, Stephen
   Johnson, Jeremiah
   Kan, Peter
TI Mechanical Thrombectomy for Acute Stroke in Patients with Target and
   Unrelated Vessel AVMs and AVFs: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE AVM; Dural AVF; Stroke; Thrombectomy
ID TISSUE-PLASMINOGEN-ACTIVATOR; ACUTE ISCHEMIC-STROKE; UNRUPTURED
   INTRACRANIAL ANEURYSMS; HEALTH-CARE PROFESSIONALS; MIDDLE
   CEREBRAL-ARTERY; ARTERIOVENOUS MALFORMATION; THROMBOLYSIS; THERAPY;
   EMBOLUS; SAFETY
AB BACKGROUND: Advances in acute and long-term post-stroke care have resulted in improved survival and functional outcomes for patients who have suffered large vessel ischemic strokes. For years, tissue plasminogen activator was the mainstay of treatment for acute stroke. Its use was previously limited to patients without known comorbid intracranial vascular pathology because of concern for bleeding risk. More recently, however, the use of tissue plasminogen activator in select patients with vascular anomalies has increased and is now largely thought to be safe. With the safety and efficacy of mechanical thrombectomy now proven for large vessel occlusions (LVOs), similar investigation is needed to assess procedural safety in patients with concomitant arteriovenous (AV) malformations or fistulae.
   METHODS: We reviewed patients treated for LVOs at our institution and those of our collaborators and identified 6 patients who were treated for LVO with either known or incidentally identified concomitant AV malformations or dural AV fistulae.
   RESULTS: We present a case series of 6 patients with nonaneurysmal intracranial vascular lesions who underwent mechanical thrombectomy for LVO without complications related to these lesions.
   CONCLUSIONS: Although limited by small size, our series adds to the literature evidence that mechanical thrombectomy for LVO can safely be performed with concomitant dural AV fistulae and AV malformations.
C1 [Hadley, Caroline; Srinivasan, Visish M.; Cherian, Jacob; Johnson, Jeremiah; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Chen, Stephen] Baylor Coll Med, Dept Intervent Radiol, Houston, TX 77030 USA.
   [Sheth, Sunil] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA.
   [Fargen, Kyle M.] Wake Forest Univ, Dept Neurosurg, Winston Salem, NC 27109 USA.
RP Kan, P (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM peter.kan@bcm.edu
OI Chen, Stephen/0000-0002-5580-831X; Fargen, Kyle/0000-0001-8979-1993
CR Abla Adib A, 2013, J Neurointerv Surg, V5, pe10, DOI 10.1136/neurintsurg-2011-010164
   Demaerschalk BM, 2016, STROKE, V47, P581, DOI 10.1161/STR.0000000000000086
   Edwards NJ, 2012, STROKE, V43, P412, DOI 10.1161/STROKEAHA.111.634147
   Henninger N, 2010, AM J EMERG MED, V28, p117e1
   JAFAR JJ, 1991, J NEUROSURG, V74, P808, DOI 10.3171/jns.1991.74.5.0808
   Kane I, 2005, CEREBROVASC DIS, V20, P51, DOI 10.1159/000086282
   Katz BS, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.10.027
   Kuhn Anna Luisa, 2014, J Vasc Interv Neurol, V7, P47
   Matsumaru Y, 1998, INTERV NEURORADIOL, V4, P165, DOI 10.1177/159101999800400209
   Matsuzaki T, 2011, J STROKE CEREBROVASC, V20, P269, DOI 10.1016/j.jstrokecerebrovasdis.2010.01.008
   MAWAD ME, 1984, RADIOLOGY, V153, P401, DOI 10.1148/radiology.153.2.6484172
   Oh YS, 2008, CEREBROVASC DIS, V26, P650, DOI 10.1159/000166842
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   PRONER J, 1990, ARCH NEUROL-CHICAGO, V47, P105, DOI 10.1001/archneur.1990.00530010131032
   Ritter MA, 2003, J NEUROL, V250, P1255, DOI 10.1007/s00415-003-0177-2
   Saito N, 2000, AM J NEURORADIOL, V21, P546
   Singh J, 2016, INTERV NEURORADIOL, V22, P544, DOI 10.1177/1591019916653257
   Smith WS, 2006, AM J NEURORADIOL, V27, P1177
   Sumner CJ, 2002, CRIT CARE MED, V30, P2359, DOI 10.1097/00003246-200210000-00028
   Zibold F, 2016, J NEUROINTERV SURG, V8, P1016, DOI 10.1136/neurintsurg-2015-012079
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1255
EP E1261
DI 10.1016/j.wneu.2019.04.019
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300159
PM 30986580
DA 2020-05-12
ER

PT J
AU Hamilton, K
   Josiah, DT
   Tierney, M
   Brooks, N
AF Hamilton, Kimberly
   Josiah, Darnell T.
   Tierney, Mark
   Brooks, Nathaniel
TI Surgical Practice in Traumatic Spinal Fracture Treatment with Regard to
   the Subaxial Cervical Injury Classification and Severity and the
   Thoracolumbar Injury Classification and Severity Systems: A Review of 58
   Patients at the University of Wisconsin
SO WORLD NEUROSURGERY
LA English
DT Review
DE Spine fracture; Spinal injury; Spinal Injury Classification System;
   Spinal surgery; Tree stand fall
ID POSTERIOR LIGAMENTOUS COMPLEX; SCORING SYSTEM; INTEGRITY; VALIDITY
AB OBJECTIVES: Spine surgeons at a Level 1 Trauma Center have observed a high incidence of spine and spinal cord injuries owing to falls from tree stands. These injuries have been retrospectively reviewed in the context of the Thoracolumbar Injury Classification and Severity (TLICS) and the Subaxial Cervical Injury Classification and Severity (SLICS) classification systems to assess inter-user reliability and validity. We hypothesize that the inter-rater reliability will be similar between neuroradiology and neurosurgery raters and validity of the scoring system will be maintained at our institution.
   METHODS: The University of Wisconsin Hospital and Clinics' trauma database was reviewed for tree stande related injuries from 1999 to 2013, with a focus on patients suffering from spine and spinal cord injuries. The TLICS and SLICS scores were then independently determined for these injuries by a neurosurgeon and a neuroradiologist.
   RESULTS: When cases were grouped by management recommendation (operative, equivocal, and nonoperative) reviewer agreement was 12/15 (80%) of SLICS and 38/52 (73%) of TLICS scores. Operative SLICS positive predictive value reached 100%, however, with a wide confidence interval. Conversely, the SLICS negative predictive value was poor at 54% e60%, with frequent operative treatment for patients assigned nonoperative scores. TLICS scores reached 77.8% and 93.3% positive predictive value per reviewer, whereas negative predictive values reached 93.9% and 89.2%, respectively.
   CONCLUSIONS: The TLICS and SLICS systems provide good-to-excellent inter-rater reliability. SLICS validity was poor, whereas TLICS was reasonable for nonoperative cases and moderate for operative cases. Systems such as the TLICS and the SLICS may be best applied in the educational setting to confirm the fracture morphology and presence or absence of ligamentous injury between surgeons and radiologists.
C1 [Hamilton, Kimberly; Josiah, Darnell T.; Brooks, Nathaniel] Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
   [Tierney, Mark] Univ Michigan, Metro Hlth, Dept Radiol, Wyoming, MI USA.
RP Hamilton, K (reprint author), Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
EM k.hamilton@neurosurgery.wisc.edu
CR ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017
   BUCHOLZ RW, 1986, ORTHOP CLIN N AM, V17, P67
   DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003
   Do Koh Y, 2010, ASIAN SPINE J, V4, P109, DOI 10.4184/asj.2010.4.2.109
   Dodwad SNM, 2015, J SPINAL DISORD TECH, V28, pE410, DOI 10.1097/BSD.0b013e3182a14743
   FERGUSON RL, 1984, CLIN ORTHOP RELAT R, P77
   Hamilton Kimberly, 2017, WMJ, V116, P201
   Harrop JS, 2006, J NEUROSURG-SPINE, V4, P118, DOI 10.3171/spi.2006.4.2.118
   HOLDSWORTH F, 1970, J BONE JOINT SURG AM, VA 52, P1534, DOI 10.2106/00004623-197052080-00002
   Joaquim AF, 2014, J SPINAL CORD MED, V37, P420, DOI 10.1179/2045772313Y.0000000143
   Joaquim AF, 2013, SPINE J, V13, P1760, DOI 10.1016/j.spinee.2013.03.014
   KELLY RP, 1968, ANN SURG, V167, P705, DOI 10.1097/00000658-196805000-00009
   Lee JY, 2005, J ORTHOP SCI, V10, P671, DOI 10.1007/s00776-005-0956-y
   Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591
   Mattei TA, 2014, EUR SPINE J, V23, P2255, DOI 10.1007/s00586-014-3312-0
   MCCORMACK T, 1994, SPINE, V19, P1741, DOI 10.1097/00007632-199408000-00014
   Mirza Sohail K, 2002, J Am Acad Orthop Surg, V10, P364
   Rampersaud YR, 2006, J SPINAL DISORD TECH, V19, P477, DOI 10.1097/01.bsd.0000211237.14211.21
   Samuel S, 2015, SPINE, V40, P137, DOI 10.1097/BRS.0000000000000666
   Shen JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139995
   Stone Addison T, 2010, Evid Based Spine Care J, V1, P19, DOI 10.1055/s-0030-1267064
   Vaccaro AR, 2007, SPINE, V32, P2365, DOI 10.1097/BRS.0b013e3181557b92
   Vaccaro AR, 2005, SPINE, V30, P2325, DOI 10.1097/01.brs.0000182986.43345.cb
   Vaccaro AR, 2005, J SPINAL DISORD TECH, V18, P209
   van Middendorp JJ, 2010, EUR SPINE J, V19, P1238, DOI 10.1007/s00586-010-1415-9
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E101
EP E107
DI 10.1016/j.wneu.2019.02.141
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300014
PM 30851463
DA 2020-05-12
ER

PT J
AU Hayashi, K
   Uekawa, K
   Kawano, T
   Ohmori, Y
   Amadatsu, T
   Takemoto, Y
   Mukasa, A
AF Hayashi, Kenyu
   Uekawa, Ken
   Kawano, Takayuki
   Ohmori, Yuki
   Amadatsu, Toshihiro
   Takemoto, Yushin
   Mukasa, Akitake
TI Cortical Venous Reddening Predicts Remote Cerebral Infarction Post
   Superficial Temporal Artery-Middle Cerebral Artery Bypass in
   Atherosclerotic Occlusive Cerebrovascular Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bypass surgery; Red vein; Selective neuronal loss
ID MISERY-PERFUSION; ISCHEMIC-STROKE; NEURONAL DAMAGE; SURGERY
AB BACKGROUND: The superficial temporal artery (STA)-middle cerebral artery (MCA) anastomosis (STA-MCA bypass) currently is performed to prevent atherosclerotic occlusive cerebrovascular disease. However, the benefits of the bypass surgery remain controversial. To ensure consistent surgical benefits, understanding the mechanisms of perioperative cerebral infarction (CI) is required. Moreover, appropriate patient selection procedures must be determined to decrease the rate of perioperative stroke. We retrospectively investigated patients who underwent bypass surgery at our institution and determined that the patients who presented with cortical venous reddening after anastomosis during the surgery developed perioperative CI.
   METHODS: A total of 45 consecutive patients who underwent bypass surgery were retrospectively investigated. Twenty-five of the 45 patients underwent bypass for atherosclerotic occlusion or stenosis of the internal carotid artery or middle cerebral artery. Preoperative iodine-123-N-isopropyl-iodoamphetamine single-photon emission computed tomography was performed with and without acetazolamide administration. Change in color of the cortical veins was observed on recorded surgical videos, and its correlation with perioperative CI was investigated.
   RESULTS: We experienced 2 cases of perioperative extensive CI at a region remote from the site of anastomosis. In both cases, retrospective investigation of surgical videos demonstrated reddening of cortical veins soon after the anastomosis procedure. Of all 45 patients, postoperative CI and venous reddening were observed in only these 2 cases.
   CONCLUSIONS: We determined that patients presenting with cortical venous reddening after anastomosis developed perioperative CI. Cortical venous reddening may be an important predictor for the occurrence of CI after STA-MCA bypass surgery for patients with atherosclerotic occlusive cerebrovascular disease.
C1 [Hayashi, Kenyu; Kawano, Takayuki; Ohmori, Yuki; Amadatsu, Toshihiro; Takemoto, Yushin; Mukasa, Akitake] Kumamoto Univ, Sch Med, Dept Neurosurg, Honjo, Kumamoto, Japan.
   [Uekawa, Ken] Saiseikai Kumamoto Hosp, Dept Neurosurg, Kumamoto, Japan.
RP Kawano, T (reprint author), Kumamoto Univ, Sch Med, Dept Neurosurg, Honjo, Kumamoto, Japan.
EM tkawano-nsu@umin.net
OI Takemoto, Yushin/0000-0002-5302-9291; Hayashi,
   Kenyu/0000-0001-8207-5652; Kawano, Takayuki/0000-0002-6885-4542
CR Baron J-C, 2005, Cerebrovasc Dis, V20 Suppl 2, P25, DOI 10.1159/000089354
   BARON JC, 1981, STROKE, V12, P454, DOI 10.1161/01.STR.12.4.454
   Baron JC, 2014, J CEREBR BLOOD F MET, V34, P2, DOI 10.1038/jcbfm.2013.188
   Carrera E, 2013, BRAIN, V136, P1816, DOI 10.1093/brain/awt112
   Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761
   Grubb RL, 2013, J NEUROSURG, V118, P25, DOI 10.3171/2012.9.JNS12551
   Hanggi D, 2012, ACTA NEUROCHIR, V154, P1943, DOI 10.1007/s00701-012-1480-4
   Igarashi H, 2015, MAGN RESON MED SCI, V14, P13, DOI 10.2463/mrms.2014-0039
   *JET STUD GROUP, 2002, SURG CEREB STROKE, V30, P434, DOI DOI 10.2335/SCS.30.434
   Kataoka H, 2015, NEUROL MED-CHIR, V55, P460, DOI 10.2176/nmc.oa.2014-0424
   Kuroda S, 2006, STROKE, V37, P393, DOI 10.1161/01.STR.0000198878.66000.4e
   Machida T, 2014, NEUROL MED-CHIR, V54, P827, DOI 10.2176/nmc.cr.2013-0261
   Miura M, 2018, J NEUROIMAGING, V28, P206, DOI 10.1111/jon.12489
   Nakagawara J, 1997, STROKE, V28, P124, DOI 10.1161/01.STR.28.1.124
   Nakagawara Jyoji, 2016, Acta Neurochir Suppl, V123, P99, DOI 10.1007/978-3-319-29887-0_14
   Nakamizo A, 2009, AM J NEURORADIOL, V30, P900, DOI 10.3174/ajnr.A1468
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Reynolds MR, 2013, J NEUROSURG, V119, P988, DOI 10.3171/2013.6.JNS13312
   Tsuda K, 2018, INTERACT CARDIOV TH, V27, P75, DOI 10.1093/icvts/ivy049
   Yamauchi H, 2017, AM J NEURORADIOL, V38, P935, DOI 10.3174/ajnr.A5110
   Yamauchi H, 2016, STROKE, V47, P1534, DOI 10.1161/STROKEAHA.116.013093
   Yamauchi H, 2012, BRAIN, V135, P2515, DOI 10.1093/brain/aws131
   Yasargil MG, 1969, MICROSURGERY APPLIED, P105
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E864
EP E872
DI 10.1016/j.wneu.2019.03.287
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300107
PM 30954735
DA 2020-05-12
ER

PT J
AU Helmers, AK
   Birkenfeld, F
   Deuschl, G
   Paschen, S
   Cohrs, G
   Mehdorn, HM
   Falk, D
AF Helmers, Ann-Kristin
   Birkenfeld, Falk
   Deuschl, Gunther
   Paschen, Steffen
   Cohrs, Gesa
   Mehdorn, Hubertus Maximilian
   Falk, Daniela
TI Do Adaptors Shorten the Battery Life of Nonrechargeable Generators for
   Deep Brain Stimulation?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Activa-PC; Adaptor; Battery life; Deep brain stimulation; IPG; Kinetra
ID LUMBAR SPINAL STENOSIS; DYNAMIC STABILIZATION; COMPUTED-TOMOGRAPHY;
   AXIAL LOAD; FUSION; MRI; COMPRESSION
AB OBJECTIVE: Generators implanted for deep brain stimulation must be replaced after several years. If a Kinetra generator is replaced by the Activa-PC, an adaptor will be required to attach it to the original extension cables. On the basis of our clinical impression that the battery life of the Active-PC generator was shorter when an adaptor was used, we performed this retrospective study.
   METHODS: We determined the battery lifetimes of deep brain stimulation generators that had been implanted in our department. The inclusion criterion was the initial implantation of a Kinetra generator that was later replaced by an Activa-PC with adaptor, which itself was subsequently also replaced. These patients were compared with an Activa-PC control group without an adaptor but identical with regard to number of battery exchanges, disease, and target.
   RESULTS: There were 28 patients in the study group and 14 in the control group. Battery lifetime of the Activa-PC with adaptor (32.4 +/- 7.7 months) was significantly shorter than that of the Kinetra (53.5 +/- 15.7 months, P = 0.000006). The battery life of Activa-PC without an adaptor (35.3 +/- 8.2 months) did not differ significantly from that of the Activa-PC with an adaptor (P = 0.333).
   CONCLUSIONS: The battery lifetime in a replacement Activa-PC is shorter than that in the original Kinetra generator. Adaptors have no significant effect on battery life. Patients should be informed that the battery in their new generator must be checked more frequently than before.
C1 [Helmers, Ann-Kristin; Cohrs, Gesa; Mehdorn, Hubertus Maximilian; Falk, Daniela] Christian Albrechts Univ Kiel, Dept Neurosurg, Univ Med Ctr Schleswig Holstein, Kiel, Germany.
   [Birkenfeld, Falk] Christian Albrechts Univ Kiel, Dept Oral & Maxillofacial Surg, Univ Med Ctr Schleswig Holstein, Kiel, Germany.
   [Deuschl, Gunther; Paschen, Steffen] Christian Albrechts Univ Kiel, Dept Neurol, Univ Med Ctr Schleswig Holstein, Kiel, Germany.
RP Helmers, AK (reprint author), Christian Albrechts Univ Kiel, Dept Neurosurg, Univ Med Ctr Schleswig Holstein, Kiel, Germany.
EM ann-kristin.helmers@uksh.de
RI Helmers, Ann-Kristin AH/M-2040-2017; Deuschl, Gunther/A-7986-2010
OI Deuschl, Gunther/0000-0002-4176-9196
CR Alyas F, 2008, CLIN RADIOL, V63, P1035, DOI 10.1016/j.crad.2007.11.022
   Comer CM, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-121
   Danielson B, 2001, SPINE, V26, P2601, DOI 10.1097/00007632-200112010-00015
   Danielson BI, 1998, ACTA RADIOL, V39, P604, DOI 10.3109/02841859809175484
   Eun SS, 2012, J NEURORADIOLOGY, V39, P104, DOI 10.1016/j.neurad.2011.02.008
   Felix ZF, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-89
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Gardner A, 2011, EUR SPINE J, V20, P690, DOI 10.1007/s00586-010-1668-3
   Genevay S, 2010, BEST PRACT RES CL RH, V24, P253, DOI 10.1016/j.berh.2009.11.001
   GRIEVE GP, 1981, COMMON VERTEBRAL JOI
   HAMANISHI C, 1994, J SPINAL DISORD, V7, P388
   Kanno H, 2012, SPINE, V37, P207, DOI 10.1097/BRS.0b013e3182134e73
   Kanno H, 2012, SPINE, V37, pE985, DOI 10.1097/BRS.0b013e31821038f2
   Kimura S, 2001, SPINE, V26, P2596, DOI 10.1097/00007632-200112010-00014
   Madsen R, 2008, SPINE, V33, P61, DOI 10.1097/BRS.0b013e31815e395f
   Mariconda M, 2002, J SPINAL DISORD TECH, V15, P39, DOI 10.1097/00024720-200202000-00006
   Masciocchi C, 1997, EUR J RADIOL, V26, P46, DOI 10.1016/S0720-048X(97)00082-X
   Moon ES, 2005, YONSEI MED J, V46, P806, DOI 10.3349/ymj.2005.46.6.806
   NOWICKI BH, 1990, RADIOLOGY, V176, P433, DOI 10.1148/radiology.176.2.2367657
   Ozer AF, 2017, CLIN ORTHOP SURG, V9, P310, DOI 10.4055/cios.2017.9.3.310
   Pfahler M, 1998, ARCH ORTHOP TRAUM SU, V118, P121, DOI 10.1007/s004020050330
   Ricart O, 2008, REV CHIR ORTHOP, V94, P619, DOI 10.1016/j.rco.2008.04.015
   Riel KA, 1999, KNEE SURG SPORT TR A, V7, P37, DOI 10.1007/s001670050118
   Sirvanci M, 2008, EUR SPINE J, V17, P679, DOI 10.1007/s00586-008-0646-5
   Skelly AC, 2007, COMPREHENSIVE EVIDEN
   Wang YC, 2008, J FORMOS MED ASSOC, V107, P334, DOI 10.1016/S0929-6646(08)60095-9
   Wassenaar M, 2012, EUR SPINE J, V21, P220, DOI 10.1007/s00586-011-2019-8
   Willen J, 2001, SPINE, V26, P2607, DOI 10.1097/00007632-200112010-00016
   Yavin D, 2017, NEUROSURGERY, V80, P701, DOI 10.1093/neuros/nyw162
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E65
EP E75
DI 10.1016/j.wneu.2019.02.064
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300010
PM 30974267
DA 2020-05-12
ER

PT J
AU Hirono, S
   Kawauchi, D
   Kobayashi, M
   Orimoto, R
   Ikegami, S
   Horiguchi, K
   Iwadate, Y
AF Hirono, Seiichiro
   Kawauchi, Daisuke
   Kobayashi, Masayoshi
   Orimoto, Ryosuke
   Ikegami, Shiro
   Horiguchi, Kentaro
   Iwadate, Yasuo
TI Mechanism of Corpus Callosum Infarction Associated with Acute
   Hydrocephalus: Clinical, Surgical, and Radiological Evaluations for
   Pathophysiology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute hydrocephalus; Corpus callosum; Infarction; Pathophysiology
ID LESIONS
AB BACKGROUND: Corpus callosum (CC) infarction has been reported to be rare because of the rich blood supply in the CC. The pathophysiology of CC infarction associated with acute hydrocephalus is unknown. The aim of the present study was to clarify the characteristics and mechanism of CC infarction associated with acute noncommunicating hydrocephalus (ANCH).
   METHODS: We reviewed clinical the data from all patients who had undergone surgical intervention for ANCH at Chiba University Hospital from January 2008 to March 2018. Patients with vascular lesions, a history of hydrocephalus, and lacking magnetic resonance imaging studies were excluded. The clinical, surgical, and radiological parameters were obtained retrospectively for pathophysiological analysis.
   RESULTS: A total of 23 patients with ANCH who had undergone surgical intervention and had met the inclusion criteria were included in the present study. Of the 23 patients, 6 (23%) had developed CC infarction. All CC infarctions were located in the splenium. Although no clinical or surgical features were associated with splenial infarction, the radiological parameters of lateral ventricle enlargement and a narrower callosal angle at the posterior commissure and the foramen of Monro were significantly associated with splenial infarction.
   CONCLUSION: The present study has presented evidence that increased intraventricular pressure by ANCH applied transversely in the splenium will directly induce compression of the superior branch of the posterior callosal artery and pericallosal pial plexus, resulting in splenium-specific infarction in patients with ANCH.
C1 [Hirono, Seiichiro; Kawauchi, Daisuke; Kobayashi, Masayoshi; Orimoto, Ryosuke; Ikegami, Shiro; Horiguchi, Kentaro; Iwadate, Yasuo] Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan.
RP Hirono, S (reprint author), Chiba Univ, Grad Sch Med, Dept Neurol Surg, Chiba, Japan.
EM s-hirono@umin.ac.jp
OI Horiguchi, Kentaro/0000-0002-4400-3006; Kawauchi,
   Daisuke/0000-0002-7679-173X
CR ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C
   Catani M., 2012, ATLAS HUMAN BRAIN CO
   Chrysikopoulos H, 1997, EUR J RADIOL, V25, P2, DOI 10.1016/S0720-048X(96)01155-2
   Kaymakamzade B, 2016, NEUROL NEUROCHIR POL, V50, P280, DOI 10.1016/j.pjnns.2016.03.005
   Lane JI, 2001, AM J NEURORADIOL, V22, P158
   Li S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120409
   Park MK, 2014, NEUROL ASIA, V19, P79
   Spreer J, 1996, ACTA NEUROCHIR, V138, P174, DOI 10.1007/BF01411357
   Suh DY, 1997, NEUROSURGERY, V41, P488, DOI 10.1097/00006123-199708000-00037
   Ture U, 1996, NEUROSURGERY, V39, P1075
   WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799
NR 11
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E873
EP E880
DI 10.1016/j.wneu.2019.03.288
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300108
PM 30954745
DA 2020-05-12
ER

PT J
AU Hopkins, BS
   Weber, KA
   Kesavabhotla, K
   Paliwal, M
   Cantrell, DR
   Smith, ZA
AF Hopkins, Benjamin S.
   Weber, Kenneth A., II
   Kesavabhotla, Kartik
   Paliwal, Monica
   Cantrell, Donald R.
   Smith, Zachary A.
TI Machine Learning for the Prediction of Cervical Spondylotic Myelopathy:
   A Post Hoc Pilot Study of 28 Participants
SO WORLD NEUROSURGERY
LA English
DT Article
DE Artificial intelligence; Cervical myelopathy; Cervical spondylotic
   myelopathy; CSM; Machine learning; Spine
ID COMPUTER-AIDED DETECTION; SPINAL-CORD-INJURY; ATRIAL-FIBRILLATION; RISK;
   CLASSIFICATION; SYSTEM
AB BACKGROUND: Cervical spondylotic myelopathy (CSM) severity and presence of symptoms are often difficult to predict based simply on clinical imaging alone. Similarly, improved machine learning techniques provide new tools with immense clinical potential.
   METHODS: A total of 14 patients with CSM and 14 controls underwent imaging of the cervical spine. Two different artificial neural network models were trained; 1) to predict CSM diagnosis; and 2) to predict CSM severity. Model 1 consisted of 6 inputs including 3 common imaging scales for the evaluation of cord compression, alongside 3 objective magnetic resonance imaging measurements. The outcome for model 1 was binary to predict CSM diagnosis. Model 2 consisted of 23 input variables derived from probabilistic volume mapping measurements of white matter tracts in the region of compression. The outcome of model 2 was linear, to predict the modified Japanese Orthopedic Association (mJOA) score.
   RESULTS: Model 1 was used in predicting CSM. The mean cross-validated accuracy of the trained model was 86.50% (95% confidence interval, 85.16%-87.83%) with a median accuracy of 90.00%. Area under the curve (AUC) was calculated for each repetition. Average AUC for each repetition was 0.947 with a median AUC of 1.0. Average sensitivity, specificity, positive predictive value, and negative predictive value were 90.25%, 85.05%, 81.58%, and 91.94%, respectively. Model 2 was used in modeling mJOA. The mJOA model predicted scores, with a mean and median error of -0.29 mJOA points and -0.08 mJOA points, respectively, mean error per batch was 0.714 mJOA points.
   CONCLUSIONS: Machine learning provides a promising method for prediction, diagnosis, and even prognosis in patients with CSM.
C1 [Hopkins, Benjamin S.; Kesavabhotla, Kartik; Paliwal, Monica; Smith, Zachary A.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Cantrell, Donald R.] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL USA.
   [Weber, Kenneth A., II] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA USA.
RP Smith, ZA (reprint author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
EM zsmith1@nm.org
OI Weber, Kenneth/0000-0002-0916-9174
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [T32DA035165]; National Institute of
   Neurological Disorders and StrokeUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [K23NS104211];
   Neurosurgical Research Education Fund Summer Student Research Fellowship
FX Funding contributing to this manuscript has been received by the
   National Institute on Drug Abuse (grant number T32DA035165), the
   National Institute of Neurological Disorders and Stroke (grant number
   K23NS104211), and the Neurosurgical Research Education Fund Summer
   Student Research Fellowship. The authors otherwise have nothing to
   disclose and no further conflicts of interest.
CR Ames CP, 2013, SPINE, V38, pS149, DOI 10.1097/BRS.0b013e3182a7f449
   Bauer C, 2012, COMPUT MED IMAG GRAP, V36, P601, DOI 10.1016/j.compmedimag.2012.08.001
   Ben-Nun T.H., 2018, 1802 ARXIV, P1802
   BENZEL EC, 1991, J SPINAL DISORD, V4, P286, DOI 10.1097/00002517-199109000-00005
   Chang V, 2015, NEUROSURGERY, V77, P561, DOI 10.1227/NEU.0000000000000888
   Cloney M, 2018, J CLIN NEUROSCI, V57, P208, DOI 10.1016/j.jocn.2018.03.028
   Cloney MB, 2018, SPINE, V43, P675, DOI 10.1097/BRS.0000000000002470
   Cui JL, 2015, EUR SPINE J, V24, P41, DOI 10.1007/s00586-014-3522-5
   Davatzikos C, 2008, NEUROBIOL AGING, V29, P514, DOI 10.1016/j.neurobiolaging.2006.11.010
   De Leener B, 2018, NEUROIMAGE, V165, P170, DOI 10.1016/j.neuroimage.2017.10.041
   De Leener B, 2017, NEUROIMAGE, V145, P24, DOI 10.1016/j.neuroimage.2016.10.009
   Dundar MM, 2008, IEEE T BIO-MED ENG, V55, P1015, DOI 10.1109/TBME.2007.909544
   Durand WM, 2018, SPINE, V43, P1058, DOI 10.1097/BRS.0000000000002515
   Ellingson BM, 2015, EUR SPINE J, V24, pS197, DOI 10.1007/s00586-013-2915-1
   Erickson BJ, 2017, J DIGIT IMAGING, V30, P391, DOI 10.1007/s10278-017-9994-1
   Gao SJ, 2013, EUR J RADIOL, V82, P1940, DOI 10.1016/j.ejrad.2013.06.011
   Giger ML, 2018, J AM COLL RADIOL, V15, P512, DOI 10.1016/j.jacr.2017.12.028
   Guan XF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117707
   Hopkins BS, 2018, SPINE, V43, pE1204, DOI 10.1097/BRS.0000000000002667
   Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278
   Kang Y, 2011, AM J ROENTGENOL, V197, pW134, DOI 10.2214/AJR.10.5560
   Kim JS, 2018, SPINE, V43, P853, DOI 10.1097/BRS.0000000000002442
   Klineberg E, 2010, ORTHOP CLIN N AM, V41, P193, DOI 10.1016/j.ocl.2009.12.010
   Koh J, 2012, INT J COMPUT ASS RAD, V7, P861, DOI 10.1007/s11548-012-0674-9
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Marr B., 2018, FORBES, V27
   Mitchell TM, 2008, SCIENCE, V320, P1191, DOI 10.1126/science.1152876
   Muoio D., 2018, REALISTIC LOOK HYPE
   NAGATA K, 1990, SPINE, V15, P1088, DOI 10.1097/00007632-199011010-00002
   NURICK S, 1972, BRAIN, V95, P87
   Oktay AB, 2014, COMPUT MED IMAG GRAP, V38, P613, DOI 10.1016/j.compmedimag.2014.04.006
   Oktay AB, 2011, LECT NOTES COMPUT SC, V6893, P158, DOI 10.1007/978-3-642-23626-6_20
   PAVLOV H, 1987, RADIOLOGY, V164, P771, DOI 10.1148/radiology.164.3.3615879
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Schoepf UJ, 2007, J THORAC IMAG, V22, P319, DOI 10.1097/RTI.0b013e31815842a9
   Suleiman LI, 2018, J CLIN NEUROSCI, V51, P57, DOI 10.1016/j.jocn.2018.02.023
   Summers Ronald M, 2010, Gastrointest Endosc Clin N Am, V20, P245, DOI 10.1016/j.giec.2010.02.004
   Uda T, 2013, SPINE, V38, P407, DOI 10.1097/BRS.0b013e31826f25a3
   Wang SQ, 2015, J MAGN RESON IMAGING, V41, P1682, DOI 10.1002/jmri.24709
   Wei J, 2007, ACAD RADIOL, V14, P659, DOI 10.1016/j.acra.2007.02.017
   Wong KKL, 2017, COMPUT MED IMAG GRAP, V57, P1, DOI 10.1016/j.compmedimag.2017.04.001
   You JY, 2015, RADIOLOGY, V276, P553, DOI 10.1148/radiol.2015142384
   Zhu XJ, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0146-5
NR 43
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E436
EP E442
DI 10.1016/j.wneu.2019.03.165
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300054
PM 30922901
DA 2020-05-12
ER

PT J
AU Hosoo, H
   Tsuruta, W
   Nakai, Y
   Shiigai, M
   Sato, M
   Ito, Y
   Takigawa, T
   Marushima, A
   Ishikawa, E
   Yamamoto, T
   Matsumaru, Y
   Matsumura, A
AF Hosoo, Hisayuki
   Tsuruta, Wataro
   Nakai, Yasunobu
   Shiigai, Masanari
   Sato, Masayuki
   Ito, Yoshiro
   Takigawa, Tomoji
   Marushima, Aiki
   Ishikawa, Eiichi
   Yamamoto, Tetsuya
   Matsumaru, Yuji
   Matsumura, Akira
TI The Visualization Methods of Occluded Dural Sinus for Safe Transvenous
   Embolization of Dural AVFs
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D FFE T1Gd; dAVFs; Occluded sinus; Sinus thrombus; T1 VISTA BB; TVE
ID INFERIOR PETROSAL SINUS; ARTERIOVENOUS-FISTULAS; CAVERNOUS SINUS;
   BLACK-BLOOD; CAUDAL END; MRI; CLASSIFICATION; DIAGNOSIS
AB BACKGROUND: Transvenous embolization (TVE) via occluded sinus is one option for the treatment of dural arteriovenous fistulas. Understanding of the anatomical characteristics of the occluded sinus is difficult. It is often hard to reach the shunt point because of some risk of vessel perforation.
   METHODS: We assessed usefulness of T1 Volumetric Isotropic TSE Acquisition (VISTA) Black Blood (BB) and 3D-T1 Fast Field Echo (FFE) for the evaluation and visualization of an occluded sinus. Evaluation of T1 VISTA BB and 3D-T1 FFE was performed preoperatively. TVE was performed via the occluded sinus while referring to the visualized reconstruction image.
   RESULTS: Fourteen cases of TVE were performed between 2009 and 2015. The entire occluded sinus, including both thrombus and blood flow, was seen as the high-intensity region on 3D FFE T1 gadlinium (Gd). On the other hand, thrombus was seen as the iso- or high-intensity region and blood flow as the low-intensity region on T1 VISTA BB. The maximum intensity projection reconstruction image of 3D FFE T1Gd could visualize the whole occluded sinus and was useful for microcatheter maneuver. Total shunt obliteration was achieved in 13 cases (92.8%) except for one.
   CONCLUSIONS: Magnetic resonance imaging evaluation of the occluded sinus using both T1 VISTA BB and 3D FFE T1Gd gives us valuable information of the occluded sinus regarding the development and the course of the occluded sinus, the length of the thrombotic occlusion, and leads to safer catheter maneuvers in TVE.
C1 [Hosoo, Hisayuki; Tsuruta, Wataro; Sato, Masayuki; Ito, Yoshiro; Takigawa, Tomoji; Marushima, Aiki; Ishikawa, Eiichi; Matsumaru, Yuji; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Ibaraki, Japan.
   [Hosoo, Hisayuki; Tsuruta, Wataro] Toranomon Gen Hosp, Dept Endovasc Neurosurg, Tokyo, Japan.
   [Nakai, Yasunobu] Tsukuba Med Ctr Hosp, Dept Neurosurg, Ibaraki, Japan.
   [Shiigai, Masanari] Tsukuba Med Ctr Hosp, Dept Radiol, Ibaraki, Japan.
   [Yamamoto, Tetsuya] Yokohama City Univ Med, Dept Neurosurg, Yokohama, Kanagawa, Japan.
RP Tsuruta, W (reprint author), Univ Tsukuba, Fac Med, Dept Neurosurg, Ibaraki, Japan.; Tsuruta, W (reprint author), Toranomon Gen Hosp, Dept Endovasc Neurosurg, Tokyo, Japan.
EM wataro@cf6.so-net.ne.jp
OI Hosoo, Hisayuki/0000-0002-0392-6808
CR Benndorf G, 2000, SURG NEUROL, V54, P42, DOI 10.1016/S0090-3019(00)00260-3
   Chaudhary N, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31823fcc6e
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Kim Myeong Jin, 2013, Neurointervention, V8, P15, DOI 10.5469/neuroint.2013.8.1.15
   Klisch J, 2003, NEUROSURGERY, V53, P836, DOI 10.1227/01.NEU.0000083551.26295.AB
   LALWANI AK, 1993, J NEUROSURG, V79, P11, DOI 10.3171/jns.1993.79.1.0011
   Lekkhong E, 2011, AM J NEURORADIOL, V32, P1738, DOI 10.3174/ajnr.A2566
   Luo CB, 2015, J CHIN MED ASSOC, V78, P526, DOI 10.1016/j.jcma.2015.05.008
   Luo CB, 2014, J CHIN MED ASSOC, V77, P610, DOI 10.1016/j.jcma.2014.08.011
   Lv XL, 2010, WORLD NEUROSURG, V74, P297, DOI 10.1016/j.wneu.2010.02.063
   Matsushima K, 2014, OPER NEUROSURG, V10, P357, DOI 10.1227/NEU.0000000000000323
   MILLER DL, 1993, AM J NEURORADIOL, V14, P1075
   Mitsuhashi Y, 2007, AM J NEURORADIOL, V28, P1179, DOI 10.3174/ajnr.A0489
   Naito I, 2001, NEURORADIOLOGY, V43, P672, DOI 10.1007/s002340100550
   NISHIJIMA M, 1992, J NEUROSURG, V76, P600, DOI 10.3171/jns.1992.76.4.0600
   Nishijima M, 1998, J Clin Neurosci, V5 Suppl, P42, DOI 10.1016/S0967-5868(98)90010-8
   Okuchi S, 2014, ACAD RADIOL, V21, P812, DOI 10.1016/j.acra.2014.03.007
   Qiao Y, 2011, J MAGN RESON IMAGING, V34, P22, DOI 10.1002/jmri.22592
   Saito A, 2012, NEURORADIOLOGY, V54, P1187, DOI 10.1007/s00234-012-1025-9
   Srivatanakul K, 2015, INTERV NEURORADIOL, V21, P362, DOI 10.1177/1591019915581945
   Takano K, 2013, NEURORADIOLOGY, V55, P845, DOI 10.1007/s00234-013-1183-4
   Takemoto K, 2011, ACTA NEUROCHIR SUPPL, V112, P59, DOI 10.1007/978-3-7091-0661-7_11
   Tomak PR, 2003, NEUROSURGERY, V52, P750, DOI 10.1227/01.NEU.0000053221.22954.85
   Treitl KM, 2015, INVEST RADIOL, V50, P401, DOI 10.1097/RLI.0000000000000142
   Wajnberg E, 2012, INTERV NEURORADIOL, V18, P60, DOI 10.1177/159101991201800108
   WATANABE A, 1984, NEURORADIOLOGY, V26, P375, DOI 10.1007/BF00327490
   Yamauchi S, 2015, NEURORADIOLOGY, V57, P799, DOI 10.1007/s00234-015-1530-8
   Yilmaz SG, 2013, OPHTHAL PLAST RECONS, V29, P272, DOI 10.1097/IOP.0b013e3182916571
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E337
EP E345
DI 10.1016/j.wneu.2019.02.250
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300043
PM 30904803
DA 2020-05-12
ER

PT J
AU Howie, BA
   Witek, AM
   Hussain, MS
   Bain, MD
   Toth, G
AF Howie, Benjamin A.
   Witek, Alex M.
   Hussain, M. Shazam
   Bain, Mark D.
   Toth, Gabor
TI Carotid Endarterectomy and Carotid Artery Stenting in a Predominantly
   Symptomatic Real-World Patient Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid; Endarterectomy; Outcomes; Restenosis; Stenting
ID ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; PREVENTION; ANGIOPLASTY;
   STENOSIS; PLACEBO; STROKE
AB BACKGROUND: Carotid endarterectomy (CEA) and carotid artery stenting (CAS) are well-established treatments that have been shown to decrease stroke recurrence in patients with underlying carotid artery disease. We assessed clinical outcome, safety, and restenosis rates for patients who underwent standardized CEA or CAS at our tertiary care center using patient selection criteria based on available scientific evidence.
   METHODS: Retrospective chart review of patients who underwent CEA or CAS between 2009 and 2016.
   RESULTS: In total, 314 cases (204 with CEA and 110 with CAS) were analyzed. Patients were predominantly white (84.4%), men (61.1%) with hypertension (86.9%) and hyperlipidemia (81.8%). Most patients (84.5%) had symptomatic carotid disease. No significant differences were observed in median postoperative National Institutes of Health Stroke Scale and modified Rankin scale (mRS) scores based on pretreatment symptomatic status or treatment modality (CEA vs. CAS). Most patients (85.9%) had favorable outcomes (mRS score 0-2) at a median follow-up of 11.7 months (interquartile range, 1.8-28.8). The perioperative complication rate was low (3.2%), and permanent neurologic deficit was seen in only 3 patients (1%). Restenosis was found in 7.3%, without significant difference between CEA and CAS at last follow-up. Restenosis was asymptomatic in most patients.
   CONCLUSIONS: Our findings in a real-world predominantly symptomatic cohort demonstrate that favorable patient outcomes and low restenosis and complication rates can be achieved with both CEA and CAS by the utilization of a consistent institutional patient selection and treatment process.
C1 [Howie, Benjamin A.; Witek, Alex M.; Hussain, M. Shazam; Bain, Mark D.; Toth, Gabor] Cleveland Clin, Cerebrovasc Ctr, Cleveland, OH 44106 USA.
   [Witek, Alex M.; Bain, Mark D.] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
   [Howie, Benjamin A.] Northeast Ohio Med Univ, Rootstown, OH USA.
RP Toth, G (reprint author), Cleveland Clin, Cerebrovasc Ctr, Cleveland, OH 44106 USA.
EM tothg@ccf.org
RI Toth, Gabor/Z-3778-2019
CR Avgerinos K, 2017, WORLD J DIABETES, V8, P270, DOI 10.4239/wjd.v8.i6.270
   Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485
   Blann AD, 2015, THROMB HAEMOSTASIS, V114, P403, DOI 10.1160/TH15-05-0383
   Brooks WH, 2001, J AM COLL CARDIOL, V38, P1589, DOI 10.1016/S0735-1097(01)01595-9
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Brown MM, 2001, LANCET, V357, P1729
   Das RR, 2008, STROKE, V39, P2929, DOI 10.1161/STROKEAHA.108.516575
   Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1
   Guimaraes PO, 2017, CARDIOVASC DRUG THER, V31, P295, DOI 10.1007/s10557-017-6728-z
   Halliday A, 2004, LANCET, V363, P1491
   Han TS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016581
   HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401
   Mantese VA, 2010, STROKE, V41, pS31, DOI 10.1161/STROKEAHA.110.595330
   Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046
   Sheffet AJ, 2010, INT J STROKE, V5, P40, DOI 10.1111/j.1747-4949.2009.00405.x
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035
   World Health Organization, 2017, TOP 10 CAUS DEATH
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
NR 19
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E722
EP E726
DI 10.1016/j.wneu.2019.03.254
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300090
PM 30951917
DA 2020-05-12
ER

PT J
AU Huang, ZF
   Chen, LY
   Yang, JF
   Deng, YL
   Sui, WY
   Yang, JL
AF Huang, Zi-fang
   Chen, Liuyun
   Yang, Jing-fan
   Deng, Yao-long
   Sui, Wen-yuan
   Yang, Jun-lin
TI Multimodality Intraoperative Neuromonitoring in Severe Thoracic
   Deformity Posterior Vertebral Column Resection Correction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Correction; Neuromonitoring; Paraplegia; Posterior vertebral column
   resection; Spinal deformity
ID PEDIATRIC SPINAL DEFORMITY; CORD-INJURY; NEUROMUSCULAR BLOCKADE;
   SURGERY; METHYLPREDNISOLONE; COMPLICATIONS; OSTEOTOMY; SERIES
AB BACKGROUND: Multimodal intraoperative neuro-monitoring (IONM) has been proposed as an effective way to reduce permanent neurologic injury during spinal deformity surgery. However, few studies have reported evoked potential changes at different surgical stages of thoracic posterior vertebral column resection (PVCR).
   METHODS: A total of 82 cases with severe thoracic deformity (Yang's A type) treated by PVCR in a single institution between January 2010 and March 2015 were reviewed. Multimodal IONM including somatosensory evoked potential, motor evoked potential, and descending neurogenic evoked potential was performed for real-time assessment of spinal cord function during surgery. The risk factors of neuromonitoring events at different surgical stages were documented and analyzed.
   RESULTS: Multimodal IONM was successfully performed in all 82 cases. Thirty-nine neuromonitoring events presented in 27 (32.9%) cases. Neurologic monitoring events were more likely to occur in patients with larger scoliosis and kyphosis, longer osteotomy closure distance, more Halo gravity traction, more screw insertion, and higher PVCR segments. The reasons for monitoring changes included 6 events during screw insertion, 20 during osteotomy, 9 during osteotomy gap closure, and 4 during deformity correction. New postoperative neurologic deficits were observed in 11 (13.4%) cases including 1 incomplete paraplegia, 8 transient cord deficits, and 2 nerve root injuries.
   CONCLUSIONS: Multimodal IONM can effectively identify neurologic deficits throughout surgery. Osteotomy and osteotomy gap closure are the surgical stages with the highest neurologic risks during PVCR procedures. It is imperative to improve dexterity since the majority of neuromonitoring events are caused by surgical techniques.
C1 [Huang, Zi-fang; Chen, Liuyun] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
   [Yang, Jing-fan; Deng, Yao-long; Sui, Wen-yuan; Yang, Jun-lin] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Spine Ctr, Shanghai, Peoples R China.
RP Yang, JL (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Spine Ctr, Shanghai, Peoples R China.
EM yangjunlin@xinhuamed.com.cn
FU National Key Research and Development Program [2018YFC0116500]; Chinese
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2016M592578]; Guangdong Science and Technology Planning Project, China
   [2014B020212021, 2015A070710007]; Guangzhou Science and Technology
   Planning Project, China [201508020031]
FX This work was supported by grants from the National Key Research and
   Development Program (2018YFC0116500), Chinese Postdoctoral Science
   Foundation (2016M592578), Guangdong Science and Technology Planning
   Project, China (2014B020212021 and 2015A070710007), Guangzhou Science
   and Technology Planning Project, China (201508020031). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Accadbled F, 2006, SPINE, V31, P2614, DOI 10.1097/01.brs.0000240642.28495.99
   BLAIR EA, 1994, AM J OTOL, V15, P161
   BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001
   Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597
   Cheh G, 2008, SPINE, V33, P1093, DOI 10.1097/BRS.0b013e31816f5f73
   Cho Samuel K, 2015, Spine Deform, V3, P73, DOI 10.1016/j.jspd.2014.06.013
   COBB JR, 1948, AM ACADEMY ORTHOPAED, V5, P261
   Deletis V, 2008, CLIN NEUROPHYSIOL, V119, P248, DOI 10.1016/j.clinph.2007.09.135
   Eggspuehler A, 2007, EUR SPINE J, V16, pS188, DOI 10.1007/s00586-007-0427-6
   Krassioukov AV, 2004, J NEUROSURG-SPINE, V1, P243, DOI 10.3171/spi.2004.1.3.0243
   Lenke LG, 2013, SPINE, V38, P119, DOI 10.1097/BRS.0b013e318269fab1
   Lenke LG, 2010, CLIN ORTHOP RELAT R, V468, P687, DOI 10.1007/s11999-009-1037-x
   Lenke LG, 2009, SPINE, V34, P2213, DOI 10.1097/BRS.0b013e3181b53cba
   Minahan RE, 2000, SPINE, V25, P2526, DOI 10.1097/00007632-200010010-00016
   Norton J, 2009, CAN J NEUROL SCI, V36, P47, DOI 10.1017/S0317167100006302
   Sala F, 2007, EUR SPINE J, V16, pS130, DOI 10.1007/s00586-007-0423-x
   Schwab F, 2014, NEUROSURGERY, V74, P112, DOI 10.1227/NEU.0000000000000182o
   Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476
   Sloan TB, 2007, J CLIN NEUROPHYSIOL, V24, P316
   Sloan TB, 2008, CURR OPIN ANESTHESIO, V21, P560, DOI 10.1097/ACO.0b013e32830f1fbd
   Sui WY, 2017, WORLD NEUROSURG, V104, P723, DOI 10.1016/j.wneu.2017.05.063
   Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/00007632-200211010-00012
   Suk SI, 2005, SPINE, V30, P1682, DOI 10.1097/01.brs.0000170590.21071.c1
   Sutter M, 2007, EUR SPINE J, V16, pS153, DOI 10.1007/s00586-007-0417-8
   Thuet ED, 2010, SPINE, V35, P1880, DOI 10.1097/BRS.0b013e3181e53434
   Wang SJ, 2017, SPINE J, V17, P76, DOI 10.1016/j.spinee.2016.08.002
   Wang XB, 2016, SPINE, V41, P1447, DOI 10.1097/BRS.0000000000001547
   Weinzierl MR, 2007, NEUROSURG REV, V30, P109, DOI 10.1007/s10143-006-0061-5
   Yang JL, 2016, EUR SPINE J, V25, P1821, DOI 10.1007/s00586-015-4367-2
   Zhang BB, 2017, EUR SPINE J, V26, P1871, DOI 10.1007/s00586-017-5061-3
   Zhang JG, 2005, SPINE, V30, P218, DOI 10.1097/01.brs.0000150486.60895.a1
NR 31
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E416
EP E426
DI 10.1016/J.WNEU.2019.03.140
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300052
PM 30981802
DA 2020-05-12
ER

PT J
AU Iannaccone, S
   Spina, A
   Alemanno, F
   Della Rosa, PA
   Houdayer, E
   Raggi, A
   Riccio, L
   Brugliera, L
   Mortini, P
AF Iannaccone, Sandro
   Spina, Alfio
   Alemanno, Federica
   Della Rosa, Pasquale Anthony
   Houdayer, Elise
   Raggi, Alberto
   Riccio, Lucia
   Brugliera, Luigia
   Mortini, Pietro
TI Uncertain Effectiveness of Prophylactic Anticonvulsive Medication in
   Predicting Cognitive Outcome of Neurosurgical Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiepileptic drugs; Cognitive outcome; Levetiracetam; Neurosurgery;
   Side effects
ID HIGH-GRADE GLIOMA; QUALITY-OF-LIFE; PRIMARY BRAIN-TUMOR; EPILEPSY;
   LEVETIRACETAM; REHABILITATION; EFFICACY; DEFICITS; THERAPY
AB OBJECTIVES: To evaluate the influence of prophylactic anticonvulsive medication, above all levetiracetam monotherapy, in predicting the cognitive outcome of neurosurgical patients with post-traumatic brain injury, intracerebral hemorrhage, and encephalic tumors.
   METHODS: We examined data concerning 232 of 327 adult patients admitted to the Neurorehabilitation Department of the San Raffaele Hospital (Milan, Italy) after discharge from the Neurosurgery Department. Cognitive status was evaluated by means of the "Mini-Mental State" examination and the Functional Independence Measure at baseline and at the end of a rehabilitation care with an average duration of about four weeks.
   RESULTS: The vast majority of the patients were treated with levetiracetam. Our data showed a negative role of antiepileptic drugs on cognitive recovery in a cohort of neurosurgical patients.
   CONCLUSIONS: Knowing thoroughly the effects of anti-epileptic drugs in rehabilitation outcome is of fundamental importance. This study represents the only large series analyzing these aspects in the rehabilitation of neurosurgical patients. Antiepileptic drugs should be managed to ensure patients the best possible cognitive outcome. Further evidence from good-quality trials is required to assess the clinical effectiveness of prophylactic anticonvulsive medication in predicting the cognitive outcome of neurosurgical patients who are treated with rehabilitation.
C1 [Iannaccone, Sandro; Alemanno, Federica; Della Rosa, Pasquale Anthony; Houdayer, Elise; Brugliera, Luigia] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Rehabil & Funct Recovery, Milan, Italy.
   [Spina, Alfio; Riccio, Lucia; Mortini, Pietro] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
   [Raggi, Alberto] GB Morgagni L Pierantoni Hosp, Unit Neurol, Forli, Italy.
RP Spina, A (reprint author), Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
EM spina.alfio@hsr.it
RI Rosa, Pasquale Anthony Della/AAC-3459-2019; Spina, Alfio/AAA-2175-2019;
   Luigia, Brugliera/AAN-3430-2020; mortini, pietro/AAB-1292-2019
OI Rosa, Pasquale Anthony Della/0000-0002-3137-1731; Luigia,
   Brugliera/0000-0001-6355-7437; 
CR Bernett A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00099
   BROOK P, 1975, BRIT J PSYCHIAT, V127, P42, DOI 10.1192/bjp.127.1.42
   de Groot M, 2013, NEURO-ONCOLOGY, V15, P216, DOI 10.1093/neuonc/nos288
   de Oliveira JA, 2014, J NEURO-ONCOL, V120, P399, DOI 10.1007/s11060-014-1564-5
   DEUTSCHMAN CS, 1985, NEUROSURGERY, V17, P510, DOI 10.1227/00006123-198509000-00021
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Gehring K, 2009, J CLIN ONCOL, V27, P3712, DOI 10.1200/JCO.2008.20.5765
   Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886
   Greenhalgh J, 2018, COCHRANE DB SYST REV, V5
   Hassler MR, 2010, J NEURO-ONCOL, V97, P109, DOI 10.1007/s11060-009-0006-2
   Helmstaedter C, 2008, EPILEPSY BEHAV, V13, P642, DOI 10.1016/j.yebeh.2008.07.012
   Helmstaedter C, 2017, SEIZURE-EUR J EPILEP, V49, P83, DOI 10.1016/j.seizure.2017.02.017
   Helmstaedter C, 2016, SEIZURE-EUR J EPILEP, V36, P63, DOI 10.1016/j.seizure.2016.02.001
   Keith R A, 1987, Adv Clin Rehabil, V1, P6
   Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5
   Klein M, 2003, NEUROLOGY, V61, P1796, DOI 10.1212/01.WNL.0000098892.33018.4C
   Klein M, 2001, J CLIN ONCOL, V19, P4037, DOI 10.1200/JCO.2001.19.20.4037
   Klein M, 2003, ANN NEUROL, V54, P514, DOI 10.1002/ana.10712
   Kwan P, 2001, LANCET, V357, P216, DOI 10.1016/S0140-6736(00)03600-X
   Locke Dona E C, 2008, J Support Oncol, V6, P383
   Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9
   Maschio M, 2015, J NEURO-ONCOL, V125, P419, DOI 10.1007/s11060-015-1933-8
   Meador KJ, 2007, EPILEPSY BEHAV, V11, P292, DOI 10.1016/j.yebeh.2007.08.009
   Motamedi G, 2003, EPILEPSY BEHAV, V4, pS25, DOI 10.1016/j.yebeh.2003.07.004
   Ortinski P, 2004, EPILEPSY BEHAV, V5, pS60, DOI 10.1016/j.yebeh.2003.11.008
   Piazzini A, 2006, EPILEPSY RES, V68, P181, DOI 10.1016/j.eplepsyres.2005.10.006
   Pourzitaki C, 2016, BRIT J CLIN PHARMACO, V82, P315, DOI 10.1111/bcp.12926
   Reijneveld JC, 2001, NEUROLOGY, V56, P618, DOI 10.1212/WNL.56.5.618
   Rossetti AO, 2010, CURR OPIN NEUROL, V23, P603, DOI 10.1097/WCO.0b013e32833e996c
   Siomin V, 2005, J NEURO-ONCOL, V74, P211, DOI 10.1007/s11060-004-6912-4
   Spina A, 2017, WORLD NEUROSURG, V103, P220, DOI 10.1016/j.wneu.2017.03.126
   Taphoorn MJB, 2004, LANCET NEUROL, V3, P159, DOI 10.1016/S1474-4422(04)00680-5
   Vermeulen J, 1995, EPILEPSY RES, V22, P65, DOI 10.1016/0920-1211(95)00047-X
   Wen PY, 2002, CURR OPIN ONCOL, V14, P299, DOI 10.1097/00001622-200205000-00008
   Wu T, 2009, EPILEPSY BEHAV, V16, P468, DOI 10.1016/j.yebeh.2009.08.026
   Zhou B, 2008, EPILEPSY BEHAV, V12, P305, DOI 10.1016/j.yebeh.2007.10.003
   Zucchella C, 2013, J NEURO-ONCOL, V114, P93, DOI 10.1007/s11060-013-1153-z
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E692
EP E696
DI 10.1016/j.wneu.2019.03.243
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300086
PM 30947008
DA 2020-05-12
ER

PT J
AU Imamura, H
   Sakai, N
   Ito, Y
   Sakai, C
   Hyodo, A
   Miyachi, S
   Matsumaru, Y
   Yoshimura, S
   Abe, T
   Yamagami, H
   Hayakawa, M
   Sato, H
   Fujinaka, T
   Tanabe, K
   Haraguchi, K
   Sakamoto, M
   Morimoto, M
   Higashi, T
   Sugiu, K
   Ishii, A
   Nakahara, I
   Oishi, H
   Matsumoto, Y
   Niimi, Y
   Yonaha, H
   Enomoto, Y
   Iinoshi, T
   Kawanishi, M
   Hyodo, A
   Ushikoshi, S
   Toma, N
   Kiura, S
   Mase, M
   Izumi, T
AF Imamura, Hirotoshi
   Sakai, Nobuyuki
   Ito, Yasushi
   Sakai, Chiaki
   Hyodo, Akio
   Miyachi, Shigeru
   Matsumaru, Yuji
   Yoshimura, Shinichi
   Abe, Toshi
   Yamagami, Hiroshi
   Hayakawa, Mikito
   Sato, Hiroaki
   Fujinaka, Toshiyuki
   Tanabe, Kenichiro
   Haraguchi, Koichi
   Sakamoto, Makoto
   Morimoto, Masashi
   Higashi, Toshio
   Sugiu, Kenji
   Ishii, Akira
   Nakahara, Ichiro
   Oishi, Hidenori
   Matsumoto, Yasushi
   Niimi, Yasunari
   Yonaha, Hirokatsu
   Enomoto, Yukiko
   Iinoshi, Tomoshi
   Kawanishi, Masahiko
   Hyodo, Akio
   Ushikoshi, Satoshi
   Toma, Naoki
   Kiura, Sadanori
   Mase, Mitshuhito
   Izumi, Takashi
CA JHSR Collaborators
TI Prospective Registry of Embolization of Intracranial Aneurysms Using
   HydroSoft Coils: Results of the Japanese HydroSoft Registry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Coil embolization; Hydrogel-coated coil;
   Recanalization
ID BARE PLATINUM COILS; ENDOVASCULAR TREATMENT; COMPARING
   HYDROSOFT/HYDROFRAME; CEREBRAL ANEURYSMS; HYDROGEL; HYDROCEPHALUS;
   MULTICENTER; PACKING; SAFETY
AB BACKGROUND: The effect of HydroSoft coils on the prevention of recanalization and thrombosis after embolization is unclear. We herein report the results of the single-armed prospective Japanese HydroSoft Registry.
   METHODS: Aneurysms with a diameter of <10 mm that were treated with a >= 50% length of HydroSoft coils were registered. We evaluated the safety and recanalization rate and analyzed the factors related to their recanalization and thrombosis 1 year later.
   RESULTS: In total, 122 aneurysms were registered. Their mean maximum diameter and neck length were 6.4 and 3.9 mm, respectively. The mean length of the HydroSoft coils was 84.3%. No intracranial hemorrhage occurred, but 2 patients developed minor ischemic strokes. Angiographic examination immediately after the procedure showed complete obliteration, neck remnant (NR), and body filling (BF) in 20 (16.4%), 32 (26.2%), and 67 (54.9%) cases, respectively. One-year follow-up angiography showed complete obliteration, NR, and BF in 68 (55.7%), 15 (12.3%), and 15 (12.3%) cases, respectively, and 5 aneurysms (4.1%) were recanalized (4 and 1 with BF and NR as their initial angiographic result, respectively). Another 11 aneurysms still showed BF, although their thrombosis was promoted. No significant factors related to recanalization were identified. A high volume embolization ratio and small neck were significantly associated with thrombosis 1 year after embolization with HydroSoft coils.
   CONCLUSIONS: The safety and prevention of recanalization 1 year after the treatment appeared acceptable. The high volume embolization ratio associated with HydroSoft coils could induce progression of thrombosis for aneurysms characterized by NR and BF during the follow-up period.
C1 [Imamura, Hirotoshi; Sakai, Nobuyuki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Ito, Yasushi] Shinrakuen Hosp, Dept Neurosurg, Niigata, Japan.
   [Sakai, Chiaki; Yoshimura, Shinichi] Hyogo Coll Med Hosp, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
   [Hyodo, Akio] Dokkyo Med Univ, Saitama Med Ctr, Dept Neurosurg, Saitama, Japan.
   [Miyachi, Shigeru] Aichi Med Univ, Dept Neurol Surg, Nagakute, Aichi, Japan.
   [Matsumaru, Yuji; Hayakawa, Mikito] Univ Tsukuba, Fac Med, Div Stroke Prevent & Treatment, Ibaraki, Japan.
   [Abe, Toshi] Kurume Univ, Sch Med, Dept Radiol, Fukuoka, Fukuoka, Japan.
   [Yamagami, Hiroshi] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Osaka, Japan.
   [Sato, Hiroaki] Tokyo Metropolitan Police Hosp, Dept Neuroendovasc Therapy, Tokyo, Japan.
   [Fujinaka, Toshiyuki] Natl Hosp Org Osaka Natl Hosp, Dept Neurosurg, Osaka, Japan.
   [Tanabe, Kenichiro] Translat Res Ctr Med Innovat, Div Med Stat, Kobe, Hyogo, Japan.
   [Imamura, Hirotoshi; Sakai, Nobuyuki] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan.
   [Sakai, Chiaki] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan.
   [Matsumaru, Yuji] Toranomon Gen Hosp, Tokyo, Japan.
   [Sato, Hiroaki] Tokyo Metropolitan Hosp, Tokyo, Japan.
   [Fujinaka, Toshiyuki] Osaka Univ Hosp, Osaka, Japan.
   [Haraguchi, Koichi] Hakodate Shintoshi Hosp, Hakodate, Hokkaido, Japan.
   [Sakamoto, Makoto] Tottori Univ Hosp, Tottori, Japan.
   [Morimoto, Masashi] Yokohama Shintoshi Neurosurg Hosp, Yokohama, Kanagawa, Japan.
   [Higashi, Toshio] Fukuoka Univ Hosp, Fukuoka, Fukuoka, Japan.
   [Sugiu, Kenji] Okayama Univ Hosp, Okayama, Japan.
   [Ishii, Akira] Kyoto Univ Hosp, Kyoto, Japan.
   [Nakahara, Ichiro] Kokura Mem Hosp, Kitakyushu, Fukuoka, Japan.
   [Oishi, Hidenori] Juntendo Univ Hosp, Tokyo, Japan.
   [Matsumoto, Yasushi] Konan Hosp, Kumamoto, Japan.
   [Niimi, Yasunari] St Lukes Int Hosp, Tokyo, Japan.
   [Yonaha, Hirokatsu] Okinawa Red Cross Hosp, Naha, Okinawa, Japan.
   [Enomoto, Yukiko] Gifu Univ Hosp, Gifu, Japan.
   [Iinoshi, Tomoshi] Sapporo Med Univ Hosp, Sapporo, Hokkaido, Japan.
   [Kawanishi, Masahiko] Kagawa Univ Hosp, Miki, Kagawa, Japan.
   [Hyodo, Akio] Dokkyo Med Univ, Koshigaya Hosp, Mibu, Tochigi, Japan.
   [Ushikoshi, Satoshi] Natl Hosp Org Hokkaido Med Ctr, Sapporo, Hokkaido, Japan.
   [Toma, Naoki] Mie Univ Hosp, Tsu, Mie, Japan.
   [Kiura, Sadanori] Hiroshima Univ Hosp, Hiroshima, Japan.
   [Mase, Mitshuhito] Nagoya City Med Univ Hosp, Nagoya, Aichi, Japan.
   [Izumi, Takashi] Nagoya Univ Hosp, Nagoya, Aichi, Japan.
RP Imamura, H (reprint author), Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
EM i-hiro@zg7.so-net.ne.jp
OI Sakai, Nobuyuki/0000-0002-3289-1210
CR Bandeira A, 2010, NEURORADIOLOGY, V52, P141, DOI 10.1007/s00234-009-0607-7
   Brinjikji W, 2018, J NEUROINTERV SURG, V10, P83, DOI 10.1136/neurintsurg-2016-012915
   Griessenauer CJ, 2016, WORLD NEUROSURG, V94, P157, DOI 10.1016/j.wneu.2016.06.127
   Kallmes DF, 2012, AM J NEURORADIOL, V23, P1580
   Marchan EM, 2008, J NEUROSURG, V109, P186, DOI 10.3171/JNS/2008/109/8/0186
   McDougall CG, 2014, AM J NEURORADIOL, V35, P935, DOI 10.3174/ajnr.A3857
   Meyers PM, 2004, NEUROSURGERY, V55, P1222, DOI 10.1227/01.NEU.0000140987.71791.DF
   Molyneux AJ, 2012, STROKE, V43, P2544, DOI 10.1161/STROKEAHA.112.657254
   Park JH, 2011, AM J NEURORADIOL, V32, P1756, DOI 10.3174/ajnr.A2633
   Raymond J, 2017, AM J NEURORADIOL, V38, P432, DOI 10.3174/ajnr.A5101
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Sluzewski M, 2004, RADIOLOGY, V231, P653, DOI 10.1148/radiol.2313030460
   Taschner C, 2015, NEURORADIOLOGY, V57, P599, DOI 10.1007/s00234-015-1501-0
   Taschner CA, 2016, NEURORADIOLOGY, V58, P777, DOI 10.1007/s00234-016-1693-y
   Tsumoto T, 2009, J NEUROSURG, V111, P11, DOI 10.3171/2008.10.JNS08855
   Turner RD, 2013, J NEUROINTERV SURG, V5, P207, DOI 10.1136/neurintsurg-2011-010194
   White PM, 2011, LANCET, V377, P1655, DOI 10.1016/S0140-6736(11)60408-X
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E631
EP E637
DI 10.1016/j.wneu.2019.03.234
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300078
PM 30947007
DA 2020-05-12
ER

PT J
AU Ishak, B
   Jenkins, S
   Bordes, S
   Mehta, K
   Iwanaga, J
   Loukas, M
   Tubbs, RS
AF Ishak, Basem
   Jenkins, Skyler
   Bordes, Stephen
   Mehta, Karishma
   Iwanaga, Joe
   Loukas, Marios
   Tubbs, R. Shane
TI A Contralateral Transfalcine Approach to the Mesial Frontoparietal
   Region and Cingulate Gyrus: A Cadaveric Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contralateral approach; Interhemispheric approach; Medial lesion;
   Surgical technique; Transfalcine approach
ID TRANSPRECUNEUS APPROACH; INTERHEMISPHERIC APPROACH; LATERAL VENTRICLE;
   MENINGIOMAS; RESECTION; TRIGONE
AB BACKGROUND: Neurosurgery for lesions located the mesial frontoparietal region and cingulate gyrus may need significant brain retraction, which may cause neural injury. Therefore, the goal of this anatomic study was to evaluate a contralateral transfalcine approach to these regions.
   METHODS: Eight adult cadaver heads were used in this study. An 8 x 8 cm craniotomy was performed, and bilateral longitudinal incisions were made into the dura mater adjacent to the superior sagittal sinus. Measurements were then taken to see how much retraction was necessary for an ipsilateral approach to the mesial frontoparietal region down to the cingulate gyrus and compared with measurements using a contralateral transfalcine approach to this same region.
   RESULTS: Ipsilateral approaches required 1.5 to 3 cm of lateral retraction (40-50 degrees) from the midline, whereas contralateral transfalcine approaches required 0.5 to 1 cm of lateral retraction (10-20 degrees).
   CONCLUSION: In comparison with the traditional ipsilateral interhemispheric approach to lesions of the mesial frontoparietal region and cingulate gyrus, the contralateral transfalcine approach was found to necessitate less hemispheric retraction and provided a better working angle. Clinical validation of this technique is now necessary.
C1 [Ishak, Basem; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Jenkins, Skyler; Bordes, Stephen; Mehta, Karishma; Loukas, Marios; Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Ishak, Basem] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.
EM joei@seattlesciencefoundation.org
RI Bordes, Stephen/AAF-8704-2019; Jenkins, skyler/AAF-9237-2019
OI Bordes, Stephen/0000-0002-7507-0674; Jenkins, skyler/0000-0001-9594-3869
CR Barkhoudarian G, 2017, OPER NEUROSURG, V13, P528, DOI 10.1093/ons/opx067
   Bohnstedt BN, 2015, J NEUROSURG, V123, P1045, DOI 10.3171/2015.3.JNS14847
   Briggs RG, 2019, CLIN ANAT, V32, P546, DOI 10.1002/ca.23349
   Burkhardt JK, 2018, J NEUROSURG, V129, P198, DOI 10.3171/2017.2.JNS162750
   Dandy WE, 1915, J EXP MED, V22, P237, DOI 10.1084/jem.22.2.237
   DEALMEIDA GM, 1984, NEUROSURGERY, V14, P744, DOI 10.1227/00006123-198406000-00018
   Ferroli P, 2007, ACTA NEUROCHIR, V149, P1147, DOI 10.1007/s00701-007-1116-2
   Gilsbach J M, 1985, Acta Neurochir Suppl (Wien), V35, P84
   Giussani C, 2017, CLIN ANAT, V30, P1017, DOI 10.1002/ca.22919
   GOEL A, 1995, ACTA NEUROCHIR, V135, P210, DOI 10.1007/BF02187772
   Hendrix P, 2019, CLIN ANAT, V32, P524, DOI 10.1002/ca.23346
   Lawton MT, 1996, NEUROSURGERY, V39, P729, DOI 10.1097/00006123-199610000-00016
   Little AS, 2010, NEUROSURGERY, V67, P277, DOI 10.1227/01.NEU.0000374699.12150.0
   Malekpour M, 2015, J CLIN NEUROSCI, V22, P383, DOI 10.1016/j.jocn.2014.07.017
   Shrivastava RK, 2003, J NEUROSURG, V99, P787, DOI 10.3171/jns.2003.99.4.0787
   Sun CJ, 2014, J CLIN NEUROSCI, V21, P1968, DOI 10.1016/j.jocn.2014.03.030
   Wang S, 2010, J NEUROSURG, V113, P949, DOI 10.3171/2010.1.JNS091169
   Zaidi HA, 2014, NEUROSURGERY, V75, P80, DOI 10.1227/NEU.0000000000000339
   Zhu W, 2013, WORLD NEUROSURG, V80, P167, DOI 10.1016/j.wneu.2012.08.010
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1127
EP E1131
DI 10.1016/j.wneu.2019.04.053
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300139
PM 30981799
DA 2020-05-12
ER

PT J
AU Ishihara, H
   Oka, F
   Goto, H
   Nishimoto, T
   Okazaki, K
   Sadahiro, H
   Kawano, R
   Suzuki, M
AF Ishihara, Hideyuki
   Oka, Fumiaki
   Goto, Hisaharu
   Nishimoto, Takuma
   Okazaki, Koki
   Sadahiro, Hirokazu
   Kawano, Reo
   Suzuki, Michiyasu
TI Impact of Frailty on Medium-Term Outcome in Asymptomatic Patients After
   Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angioplasty; Complication; Frailty; Stent; Stroke
ID OLDER-ADULTS; HEALTH; PREVENTION; RISK
AB OBJECTIVE: There are few reports on the relationship between carotid artery stenting (CAS) and frailty. In this study, medium-term outcome after CAS in patients with asymptomatic carotid artery stenosis was examined to see the effect of frailty itself.
   METHODS: A retrospective study was performed in 71 consecutive patients who were treated with CAS for asymptomatic lesions from January 2007 to June 2014. In this study, only patients without neurologic symptoms before treatment were included. Frailty was defined on the basis of the presence of >= 2 of the 5 items on the Cardiovascular Health Study (CHS) Index. The relationship of frailty with a composite endpoint of the incidence of stroke, disease requiring hospital admission, and death for 3 years after CAS was examined.
   RESULTS: There were 23 cases (average age 73.9 years, median CHS index 3) with frailty and 48 (average age 70.9 years, median CHS index 0) without frailty. There were no differences in comorbidities or CAS perioperative complications between these groups. However, there was a significantly higher incidence of the composite endpoint in patients with frailty (13/23 vs. 4/48, P < 0.001), and in multivariate analysis, frailty was strongly associated with this endpoint (odds ratio 28.24, 95% confidence interval 4.62-172.71).
   CONCLUSIONS: In CAS conducted for asymptomatic lesions, perioperative complications had no relationship with frailty. However, frailty is likely to be associated with lower activity of daily life in the medium term after CAS, and consideration of underlying diseases is required in patients with frailty.
C1 [Ishihara, Hideyuki; Oka, Fumiaki; Goto, Hisaharu; Nishimoto, Takuma; Okazaki, Koki; Sadahiro, Hirokazu; Suzuki, Michiyasu] Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi, Japan.
   [Kawano, Reo] Hiroshima Univ Hosp, Ctr Integrated Med Res, Minami Ku, Hiroshima, Japan.
RP Ishihara, H (reprint author), Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi, Japan.
EM hishi@yamaguchi-u.ac.jp
RI Kawano, Reo/M-2661-2018
OI Kawano, Reo/0000-0001-8699-3768; Ishihara, Hideyuki/0000-0002-0208-2412
CR Ambler GK, 2015, BRIT J SURG, V102, P638, DOI 10.1002/bjs.9785
   Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Halliday A, 2004, LANCET, V363, P1491
   Melin AA, 2015, J VASC SURG, V61, P683, DOI 10.1016/j.jvs.2014.10.009
   Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046
   Morley JE, 2013, J AM MED DIR ASSOC, V14, P392, DOI 10.1016/j.jamda.2013.03.022
   Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]
   Seino S, 2017, GERIATR GERONTOL INT, V17, P2034, DOI 10.1111/ggi.13016
   Soysal P, 2017, AGEING RES REV, V36, P78, DOI 10.1016/j.arr.2017.03.005
   Veronese N, 2017, AGEING RES REV, V35, P63, DOI 10.1016/j.arr.2017.01.003
NR 11
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E396
EP E399
DI 10.1016/j.wneu.2019.03.135
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300049
PM 30910751
DA 2020-05-12
ER

PT J
AU Janjua, MB
   Reddy, S
   Samdani, AF
   Welch, WC
   Ozturk, AK
   Price, AV
   Weprin, BE
   Swift, DM
AF Janjua, M. Burhan
   Reddy, Sumanth
   Samdani, Amer F.
   Welch, William C.
   Ozturk, Ali K.
   Price, Angela V.
   Weprin, Bradley E.
   Swift, Dale M.
TI Predictors of 90-Day Readmission in Children Undergoing Spinal Cord
   Tumor Surgery: A Nationwide Readmissions Database Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE 30-Day and 90-day readmission rates; Complications and revisions; NRD;
   Payor status; Pediatric spinal tumor surgery
ID HOSPITAL READMISSIONS; DEFORMITY; RESECTION; FUSION; LASSO
AB OBJECTIVE: A fair number of hospital admissions occur after 30 days; thus, the true readmission rate could have been underestimated. Therefore, we hypothesized that the 90-day readmission rate might better characterize the factors contributing to readmission for pediatric patients undergoing spinal tumor resection.
   METHODS: The Nationwide Readmissions Database was used to study the patient demographic data, comorbidities, admissions, hospital course, spinal tumor behavior (malignant vs. benign), complications, revisions, and 30-and 90-day readmissions.
   RESULTS: Of the 397 patients included in the 30-day cohort, 43 (10.8%) had been readmitted. In comparison, the 90-day readmission rate was significantly greater; 52 of 325 patients were readmitted (16.0%; P < 0.04). Patients aged 16-20 constituted the largest subgroup. However, the highest readmission rate was observed for patients aged <5 years (30-day, 21.7%; 90-day, 26.4%). Medicaid patients were more likely to be readmitted than were private insurance patients (30-day odds ratio [OR], 3.3 [P < 0.001]; 90-day OR, 2.29 [P < 0.02]). In both cohorts, patients with malignant tumors required readmission more often than did those with benign tumors (30-day OR, 2.78 [P < 0.02]; 90-day OR, 1.92 [P = 0.08]). In the 90-day cohort, the patients had been readmitted 26.4 days after discharge versus 10.6 days in the 30-day cohort. Within the 90-day cohort, 18.6% of the readmissions were tot spinal reoperation, 28.3% for chemotherapy or hematologic complications, and 25.6% for other central nervous system disorders. The median charges for each readmission were similar to$50,000 and similar to$40,000 for the 30- and 90-day cohorts, respectively. Medicaid insurance, malignant tumors, and younger age were significant predictors of readmission in the 90-day cohort.
   CONCLUSIONS: The prevalence and charges associated with unplanned hospital readmissions after spinal tumor resection were remarkably high. Younger age, Medicaid insurance, malignant tumors, and complications during the initial admission were significant predictors of 90-day readmission.
C1 [Janjua, M. Burhan; Reddy, Sumanth; Price, Angela V.; Weprin, Bradley E.; Swift, Dale M.] UT Southwestern Med Ctr, Dept Pediat Neurosurg, Dallas, TX 75390 USA.
   [Janjua, M. Burhan; Welch, William C.; Ozturk, Ali K.] Univ Penn Hosp, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Samdani, Amer F.] Shriners Hosp Children Philadelphia, Dept Neurosurg, Div Pediat Spine, Philadelphia, PA USA.
RP Janjua, MB (reprint author), UT Southwestern Med Ctr, Dept Pediat Neurosurg, Dallas, TX 75390 USA.; Janjua, MB (reprint author), Univ Penn Hosp, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM mburhanj@gmail.com
OI Reddy, Sumanth/0000-0002-6275-6001
CR Ahmed R, 2014, J NEUROSURG-PEDIATR, V13, P600, DOI [10.3171/2014.1.PEDS13317, 10.3171/2014.1.PEDS13316]
   Aldebeyan S, 2016, SPINE, V41, P1535, DOI 10.1097/BRS.0000000000001575
   Anakwenze OA, 2011, J PEDIATR ORTHOPED, V31, P475, DOI 10.1097/BPO.0b013e318220bb46
   Auguste KI, 2006, NEUROSURG CLIN N AM, V17, P51, DOI 10.1016/j.nec.2005.10.004
   Azad TD, 2018, J NEUROSURG-PEDIATR, V22, P404, DOI 10.3171/2018.4.PEDS17587
   Bai G, 2015, HEALTH AFFAIR, V34, P922, DOI 10.1377/hlthaff.2014.1414
   Basques BA, 2014, SPINE, V39, P497, DOI 10.1097/BRS.0000000000000184
   Bhimani AD, 2019, WORLD NEUROSURG, V121, pE389, DOI 10.1016/j.wneu.2018.09.113
   Chotai S, 2017, J NEUROSURG-PEDIATR, V20, P542, DOI 10.3171/2017.6.PEDS17117
   Elsamadicy Aladine A, 2018, J Spine Surg, V4, P304, DOI 10.21037/jss.2018.05.14
   Epstein F J, 1990, Neurosurg Clin N Am, V1, P569
   Gephart MGH, 2012, J NEUROSURG-PEDIATR, V10, P555, DOI 10.3171/2012.9.PEDS1272
   Hersh DS, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17329
   Hsu S, 2011, J NEUROSURG-SPINE, V14, P742, DOI 10.3171/2011.1.SPINE10351
   Huisman Thierry A G M, 2009, Cancer Imaging, V9 Spec No A, pS45, DOI 10.1102/1470-7330.2009.9012
   Jain A, 2015, SPINE, V40, P856, DOI 10.1097/BRS.0000000000000857
   Jovanovic M, 2016, ARTIF INTELL MED, V72, P12, DOI 10.1016/j.artmed.2016.07.003
   Karhade AV, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16168
   Kim Y, 2015, ANN SURG, V262, P502, DOI 10.1097/SLA.0000000000001429
   Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561
   McCormick PJ, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0936-3
   McGirt MJ, 2008, CHILD NERV SYST, V24, P735, DOI 10.1007/s00381-007-0513-4
   McGirt MJ, 2008, J NEUROS-PEDIATR, V1, P57, DOI 10.3171/PED-08/01/057
   McIlvennan CK, 2015, CIRCULATION, V131, P1796, DOI 10.1161/CIRCULATIONAHA.114.010270
   Parker SL, 2018, J NEUROSURG-SPINE, V29, P327, DOI 10.3171/2018.1.SPINE17505
   Ranstam J, 2018, BRIT J SURG, V105, P1348, DOI 10.1002/bjs.10895
   Ribbing J, 2007, J PHARMACOKINET PHAR, V34, P485, DOI 10.1007/s10928-007-9057-1
   Sahu RK, 2015, J PEDIATR NEUROSCI, V10, P214, DOI 10.4103/1817-1745.165660
   Simon SL, 2008, J PEDIATR ORTHOPED, V28, P244, DOI 10.1097/BPO.0b013e3181623819
   Yao KC, 2007, J NEUROSURG, V107, P463, DOI 10.3171/PED-07/12/463
   Zhang ZH, 2017, ONCOTARGET, V8, P49637, DOI 10.18632/oncotarget.17870
NR 31
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E697
EP E706
DI 10.1016/j.wneu.2019.03.245
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300087
PM 30947001
DA 2020-05-12
ER

PT J
AU Jenkins, S
   Bordes, S
   Aly, I
   Jeyamohan, S
   Ishak, B
   Iwanaga, J
   Loukas, M
   Tubbs, RS
AF Jenkins, Skyler
   Bordes, Stephen
   Aly, Islam
   Jeyamohan, Shiveindra
   Ishak, Basem
   Iwanaga, Joe
   Loukas, Marios
   Tubbs, R. Shane
TI Internal Morphology of the Odontoid Process: Anatomic and Imaging Study
   with Application to C2 Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Computed tomography; Fracture; Magnetic resonance imaging;
   Odontoid process
ID SURFACE ANATOMY; DENS
AB OBJECTIVE: Fracture of the odontoid process is a critical injury to diagnose and often treat. The aim of this anatomic study was to present a comprehensive understanding of this part of the C2 vertebra.
   METHODS: We used 20 C2 vertebrae. Samples underwent imaging (computed tomography [CT] with and without three-dimensional reconstruction, micro-CT, 1.5T magnetic resonance imaging) and sagittal and coronal sectioning using a bone saw. Sectioned specimens were imaged under a digital handheld microscope, and transillumination of the bone was used to highlight its internal trabecular pattern. Three samples underwent infusion of the odontoid process with a hardening substance and were then decalcified.
   RESULTS: Internal trabecular patterns of the odontoid process of all specimens were discernible. In sagittal and coronal sections, trabecular patterns were highlighted with transillumination, but the patterns were much clearer using the digital microscope. Magnetic resonance imaging and CT provided the least detail of the imaging methods, but the trabecular patterns could he identified. Three-dimensional reconstruction of CT data was the preferred imaging method over magnetic resonance imaging and CT without three-dimensional reconstruction. The most distinct trabecular and cortical patterns were seen using micro-CT. Osteoporosis was seen in 2 specimens (10%). Five specimens (25%) were found to have a subdental synchondrosis. For most specimens, the trabeculae were found throughout the odontoid process.
   CONCLUSIONS: Improved knowledge of the anatomy, structural composition, and variations within the C2 vertebra may allow for better treatment options and patient care.
C1 [Aly, Islam; Jeyamohan, Shiveindra; Ishak, Basem; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Jenkins, Skyler; Bordes, Stephen; Loukas, Marios] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.
EM joei@seattlesciencefoundation.org
RI Bordes, Stephen/AAF-8704-2019; Jenkins, skyler/AAF-9237-2019
OI Bordes, Stephen/0000-0002-7507-0674; Jenkins, skyler/0000-0001-9594-3869
CR ALTHOFF B, 1977, ACTA ORTHOP SCAND, V48, P622, DOI 10.3109/17453677708994808
   ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017
   Badshah M, 2017, CLIN ANAT, V30, P781, DOI 10.1002/ca.22907
   DOHERTY BJ, 1995, SPINE, V20, P513, DOI 10.1097/00007632-199503010-00002
   Ezra D, 2019, CLIN ANAT, V32, P84, DOI 10.1002/ca.23269
   Gebauer M, 2007, UNFALLCHIRURG, V110, P97, DOI 10.1007/s00113-006-1201-7
   GRAHAM RS, J NEUROSURG S, V93, P117
   Greiner TM, 2017, CLIN ANAT, V30, P894, DOI 10.1002/ca.22948
   HELLER JG, 1992, SPINE, V17, P861, DOI 10.1097/00007632-199208000-00001
   Henry AD, 1999, J BONE JOINT SURG BR, V81B, P472, DOI 10.1302/0301-620X.81B3.9109
   KOEBKE J, 1979, ANAT EMBRYOL, V155, P197, DOI 10.1007/BF00305752
   Korres DS, 2004, CLIN ORTHOP RELAT R, P134
   NUCCI RC, 1995, SPINE, V20, P264, DOI 10.1097/00007632-199502000-00002
   Okada K, 2000, SPINE, V25, P1303, DOI 10.1097/00007632-200005150-00020
   Puttlitz CM, 2000, SPINE, V25, P2868, DOI 10.1097/00007632-200011150-00006
   Sharif K, 2018, CLIN ANAT, V31, P216, DOI 10.1002/ca.22980
   Shen XH, 2017, CLIN ANAT, V30, P330, DOI 10.1002/ca.22847
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Shoja MM, 2018, CLIN ANAT, V31, P202, DOI 10.1002/ca.22939
   Tardieu GG, 2017, CLIN ANAT, V30, P811, DOI 10.1002/ca.22923
   Yoon SY, 2018, CLIN ANAT, V31, P710, DOI 10.1002/ca.23074
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1120
EP E1126
DI 10.1016/j.wneu.2019.04.052
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300138
PM 30980977
DA 2020-05-12
ER

PT J
AU Jiang, L
   Xia, WQ
   Huang, H
   Liu, KQ
   Si, XL
   Zhao, XY
   Yin, CG
AF Jiang, Lin
   Xia, Wen-Qing
   Huang, Huan
   Liu, Ke-Qin
   Si, Xiao-Li
   Zhao, Xin-Yi
   Yin, Cong-Guo
TI Mechanical Thrombectomy Outcome Predictors in Stroke Patients with M2
   Occlusion: A Single-Center Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Middle cerebral artery; Stroke; Thrombectomy
ID MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT;
   PROACT-II; THROMBOLYSIS; REPERFUSION; THERAPY; SITE
AB BACKGROUND: Mechanical thrombectomy (MT) has demonstrated benefit in patients with acute ischemic stroke due to proximal large-vessel occlusion. However, it is unclear whether these results can be extrapolated to patients with an occlusion of the second segment (M2) of the middle cerebral artery (MCA). We sought to study outcomes in patients with M2 occlusion treated with MT and to better understand clinical predictors of these outcomes.
   METHODS: We performed a single-center retrospective analysis of consecutive patients with acute MCA M2 segment occlusion who underwent stent retriever MT. We correlated clinical and radiographic outcomes with demographic, clinical, and technical characteristics.
   RESULTS: Thirty-seven patients were included in the analysis (median admission National Institutes of Health Stroke Scale [NIHSS] score, 15 [12-19], mean age 74 [67-80] years, 48.6% women). Good clinical outcome at 3 months (modified Rankin Scale <= 2) was achieved in 48.6% of patients. Baseline NIHSS was a predictor of clinical outcomes, based on modified Rankin Scale distribution at 3 months after MT (P = 0.015, odds ratio 1.63, 95% confidence interval 1.01-2.43).
   CONCLUSIONS: The results of our single-institution experience suggest that MT-based endovascular therapy for M2 occlusions is safe and effective. Baseline NIHSS was a predictor of outcomes in patients treated with MT for M2 segment occlusion of the MCA.
C1 [Jiang, Lin; Xia, Wen-Qing; Huang, Huan; Liu, Ke-Qin; Si, Xiao-Li; Yin, Cong-Guo] Zhejiang Univ, Sch Med, Hangzhou Peoples Hosp 1, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
   [Zhao, Xin-Yi] Zhejiang Univ, Affiliated Hosp 1, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis,Sch Med, Hangzhou, Zhejiang, Peoples R China.
RP Yin, CG (reprint author), Zhejiang Univ, Sch Med, Hangzhou Peoples Hosp 1, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
EM yincg716@aliyun.com
OI Jiang, Lin/0000-0002-7796-3820
FU Zhejiang Provincial Natural Science Foundation, ChinaNatural Science
   Foundation of Zhejiang Province [GF18H090036]
FX This study was supported by Zhejiang Provincial Natural Science
   Foundation, China (GF18H090036).
CR Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Bluhmki E, 2009, LANCET NEUROL, V8, P1095, DOI 10.1016/S1474-4422(09)70264-9
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Daou B, 2015, NEUROSURGERY, V77, P355, DOI 10.1227/NEU.0000000000000830
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Lemmens R, 2016, NEUROLOGY, V86, P762, DOI 10.1212/WNL.0000000000002399
   Lucke-Wold B, 2017, J NEUROINTERV SURG, V9, pA25
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Munich SA, 2016, NEUROSURGERY, V79, P428, DOI 10.1227/NEU.0000000000001182
   Navia P, 2016, J NEUROINTERV SURG, V8, P787, DOI 10.1136/neurintsurg-2015-011798
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Rahme R, 2014, J NEUROSURG, V121, P1354, DOI 10.3171/2014.7.JNS131430
   Rahme R, 2013, STROKE, V44, P240, DOI 10.1161/STROKEAHA.112.671495
   Raoult H, 2013, J NEURORADIOLOGY, V40, P252, DOI 10.1016/j.neurad.2013.04.001
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Salahuddin H, 2018, J NEUROINTERV SURG, V10, P330, DOI 10.1136/neurintsurg-2017-013159
   Saqqur M, 2007, STROKE, V38, P948, DOI 10.1161/01.STR.0000257304.21967.ba
   Sarraj A, 2016, JAMA NEUROL, V73, P1291, DOI 10.1001/jamaneurol.2016.2773
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Shi ZS, 2014, STROKE, V45, P1977, DOI 10.1161/STROKEAHA.114.005603
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E155
EP E161
DI 10.1016/j.wneu.2019.03.013
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300022
PM 30872195
DA 2020-05-12
ER

PT J
AU Joshi, ND
   Lieber, B
   Wong, K
   Al-Alam, E
   Agarwal, N
   Diaz, V
AF Joshi, Neil D.
   Lieber, Bryan
   Wong, Karren
   Al-Alam, Eliana
   Agarwal, Nitin
   Diaz, Vicki
TI Social Media in Neurosurgery: Using ResearchGate
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometrics; Neurosurgery; Research collaboration; ResearchGate;
   Social media
ID JOURNALS
AB BACKGROUND: Neurosurgery is a unique field, which would benefit greatly from increased global collaboration, furthering research efforts. ResearchGate is a social media platform geared toward scientists and researchers.
   OBJECTIVE: This study evaluated the use of ResearchGate for neurosurgical research collaboration and compared the ResearchGate score with more classic bibliometrics. ResearchGate is a unifying social platform that can strengthen global research collaboration (e.g., data sharing) in the neurosurgery community.
   METHODS: Publicly available metrics on 3718 neurosurgery clinical faculty and residents in Canada and the United States were obtained from the American Association of Neurological Surgeons Web site. The following metrics were collected: program name, clinician name, sex, attending (yes or no), resident (yes or no), postgraduate year (if resident), and ResearchGate profile (yes or no). ResearchGate score and its components and h index excluding self-citations were collected. Fellows were not included.
   RESULTS: Of the 3718 total individuals included, 1338 (36.0%) were present on ResearchGate, comprising 181 women (13.5%) and 1157 men (86.5%). Women and men were present in similar proportions (33.8% of women and 36.3% of men) (chi(2) [1, N = 3718] = 126; P = 026). More faculty were present on ResearchGate than residents (62.4%) (chi(2) [1, N = 3718] = 11.42; P = 0.001). A strong positive monotonic correlation between h index and ResearchGate score was shown (r(s) [1292] = 0.93; P < 0.0005). More than 400 international departments were determined.
   CONCLUSIONS: ResearchGate may be a useful platform to increase neurosurgical networking and research collaboration. Its novel bibliometrics are strongly correlated with more classic platforms.
C1 [Joshi, Neil D.; Wong, Karren] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
   [Agarwal, Nitin; Diaz, Vicki] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
   [Al-Alam, Eliana] Michigan State Univ, Coll Commun Arts & Sci, E Lansing, MI 48824 USA.
   [Lieber, Bryan] Wayne State Univ, Dept Neurosurg, Detroit, MI USA.
RP Agarwal, N (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
EM agarwaln@upmc.edu
OI Agarwal, Nitin/0000-0003-0256-3897
CR Agarwal N, 2019, WORLD NEUROSURG, V122, pE307, DOI 10.1016/j.wneu.2018.10.027
   Alotaibi NM, 2016, WORLD NEUROSURG, V93, P449, DOI 10.1016/j.wneu.2016.06.134
   Alotaibi NM, 2016, WORLD NEUROSURG, V90, P574, DOI 10.1016/j.wneu.2016.01.087
   Alotaibi NM, 2016, WORLD NEUROSURG, V88, P619, DOI 10.1016/j.wneu.2015.11.011
   [Anonymous], 2017, Nature, V550, P162, DOI 10.1038/550162a
   Ban VS, 2016, WORLD NEUROSURG, V91, P609, DOI 10.1016/j.wneu.2016.02.117
   Citrome L, 2015, INT J CLIN PRACT, V69, P623, DOI 10.1111/ijcp.12681
   Hoffmann CP, 2016, J ASSOC INF SCI TECH, V67, P765, DOI 10.1002/asi.23423
   Kim C, 2018, WORLD NEUROSURG, V113, pE172, DOI 10.1016/j.wneu.2018.01.210
   Memon AR, 2017, J PAK MED ASSOC, V67, P488
   Memon AR, 2016, J PAK MED ASSOC, V66, P1643
   Perrin Andrew, 2015, SOCIAL MEDIA USAGE 2
   Prabhu AV, 2017, INT J RADIAT ONCOL, V99, P1083, DOI 10.1016/j.ijrobp.2017.08.015
   ResearchGate, 2018, RESEARCHGATE RECRUIT
   Scott M., 2014, NY TIMES
   Thelwall M, 2016, J AM SOC INF SCI TEC, V68, P468
   Thelwall M, 2015, J ASSOC INF SCI TECH, V66, P876, DOI 10.1002/asi.23236
NR 17
TC 3
Z9 3
U1 6
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E950
EP E956
DI 10.1016/j.wneu.2019.04.007
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300118
PM 30965167
DA 2020-05-12
ER

PT J
AU Kanaya, K
   Goto, T
   Horiuchi, T
   Hongo, K
AF Kanaya, Kohei
   Goto, Tetsuya
   Horiuchi, Tetsuyoshi
   Hongo, Kazuhiro
TI Comparison of Intraoperative Motor Evoked Potentials Monitoring with
   Direct Cranial Stimulation by Peg-Screw and Transcranial Stimulation by
   Corkscrew for Supratentorial Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Corkscrew electrode; Motor evoked potentials; Motor threshold; Peg-screw
   electrode; Transcranial electrical stimulation
ID ELECTRICAL-STIMULATION; ANEURYSM SURGERY; TUMOR SURGERY; ELECTRODE;
   RESECTION
AB OBJECTIVE: Corkscrew (CS) electrodes are usually used for transcranial electrical stimulation (TES) in the intraoperative monitoring of motor evoked potentials (MEP). Direct cranial stimulation with peg-screw (PS) electrodes can elicit MEP. The present study investigated the difference in the initial threshold between PS and CS electrodes for intraoperative MEP monitoring.
   METHODS: We retrospectively analyzed TES-MEP monitoring for supratentorial surgery in 72 patients. Of these 72 patients, 44 were monitored with PS and CS electrodes (PS/CS group) and 28 were monitored with CS and CS electrodes (CS/CS group). TES was used to deliver electrical stimulation by a train of 4-pulse anodel constant current stimulation. The initial threshold in each electrode was checked and analyzed.
   RESULTS: In the PS/CS group, the initial threshold with the PS electrode was 38.3 +/- 15.1 mA (mean +/- standard deviation) on the affected side, and the initial threshold with the CS electrode was 51.4 +/- 13.9 mA on the unaffected side. The initial threshold with the PS electrode was significantly lower than that with the CS electrode (P = 0.0001). In the CS/CS group, the initial threshold was 56.2 +/- 16.5 mA on the affected side and 62.1 +/- 18.6 mA on the unaffected side, with no statistically significant difference (P = 0.23).
   CONCLUSION: The initial threshold to elicit MEP was significantly lower with the PS electrode than with the CS electrode. A PS electrode can be used as a feasible stimulation electrode for TES-MEP.
C1 [Kanaya, Kohei; Goto, Tetsuya; Horiuchi, Tetsuyoshi; Hongo, Kazuhiro] Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano, Japan.
RP Goto, T (reprint author), Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano, Japan.
EM tegotou@shinshu-u.ac.jp
OI GOTO, TETSUYA/0000-0002-9878-1057; Kanaya, Kohei/0000-0001-9667-9828
CR Abboud T, 2019, J NEUROSURG, V131, P740, DOI 10.3171/2018.4.JNS172468
   Calancie B, 1998, J NEUROSURG, V88, P457, DOI 10.3171/jns.1998.88.3.0457
   Goto T, 2018, SHINSHU MED J, V66, P333
   Goto T, 2010, SKULL BASE-INTERD AP, V20, P429, DOI 10.1055/s-0030-1261270
   Hardian RF, 2020, J NEUROSURG, V132, P265, DOI 10.3171/2018.8.JNS181199
   Hemmer LB, 2014, WORLD NEUROSURG, V81, P99, DOI 10.1016/j.wneu.2012.05.034
   Kombos T, 2001, J NEUROSURG, V95, P608, DOI 10.3171/jns.2001.95.4.0608
   Kombos T, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09141
   Landazuri P, 2013, J CLIN NEUROPHYSIOL, V30, P623, DOI 10.1097/01.wnp.0000436891.39727.80
   Langeloo DD, 2003, SPINE, V28, P1043, DOI 10.1097/00007632-200305150-00017
   Legatt AD, 2016, J CLIN NEUROPHYSIOL, V33, P42, DOI 10.1097/WNP.0000000000000253
   Li Fenghua, 2011, Am J Electroneurodiagnostic Technol, V51, P191
   MacDonald DB, 2013, CLIN NEUROPHYSIOL, V124, P2291, DOI 10.1016/j.clinph.2013.07.025
   MacDonald DB, 2007, EUR SPINE J, V16, pS171, DOI 10.1007/s00586-007-0426-7
   Macdonald David B, 2006, J Clin Monit Comput, V20, P347, DOI 10.1007/s10877-006-9033-0
   MacDonald DB, 2008, INTRAOPERATIVE MONIT, V8, P882
   Moiyadi A, 2018, WORLD NEUROSURG, V120, pE259, DOI 10.1016/j.wneu.2018.08.046
   Morota N, 1997, NEUROSURGERY, V41, P1327, DOI 10.1097/00006123-199712000-00017
   Motoyama Y, 2011, NEUROL MED-CHIR, V51, P15, DOI 10.2176/nmc.51.15
   Oinuma M, 2007, NEUROSURGERY, V60, P189, DOI 10.1227/01.NEU.0000249204.81472.88
   Quinones-Hinojosa A, 2005, NEUROSURGERY, V56, P982, DOI 10.1277/01.NEU.0000158203.29369.37
   Sala F, 2006, NEUROSURGERY, V58, P1129, DOI 10.1227/01.NEU.0000215948.97195.58
   Seidel K, 2013, J NEUROSURG, V118, P287, DOI 10.3171/2012.10.JNS12895
   Shiban E, 2015, J NEUROSURG, V123, P711, DOI 10.3171/2014.10.JNS141289
   Stecker Mark M, 2012, Surg Neurol Int, V3, pS174, DOI 10.4103/2152-7806.98579
   Sutter MA, 2007, EUR SPINE J, V16, pS221, DOI 10.1007/s00586-007-0432-9
   Szelenyi A, 2007, NEUROPHYSIOL CLIN, V37, P391, DOI 10.1016/j.neucli.2007.09.006
   Szelenyi A, 2003, J NEUROSURG, V99, P575, DOI 10.3171/jns.2003.99.3.0575
   Szelenyi A, 2007, CLIN NEUROPHYSIOL, V118, P1586, DOI 10.1016/j.clinph.2007.04.008
   Szelenyi A, 2006, J NEUROSURG, V105, P675, DOI 10.3171/jns.2006.105.5.675
   Szelenyi A, 2013, BRAIN STIMUL, V6, P482, DOI 10.1016/j.brs.2012.10.002
   Szelenyi A, 2010, NEUROSURGERY, V67, P302, DOI 10.1227/01.NEU.0000371973.46234.46
   Tanaka Y, 2016, J ANESTH, V30, P1037, DOI 10.1007/s00540-016-2242-x
   Tomio Ryosuke, 2016, Surg Neurol Int, V7, pS791
   van Dongen EP, 1999, BRIT J ANAESTH, V82, P323, DOI 10.1093/bja/82.3.323
   Watanabe K, 2004, J NEUROSURG, V100, P155, DOI 10.3171/jns.2004.100.1.0155
   Weigang E, 2005, THORAC CARDIOV SURG, V53, P28, DOI 10.1055/s-2004-830431
   Williams Aparna, 2014, J Anaesthesiol Clin Pharmacol, V30, P439, DOI 10.4103/0970-9185.137297
NR 38
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1044
EP E1050
DI 10.1016/j.wneu.2019.04.039
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300130
PM 30980975
DA 2020-05-12
ER

PT J
AU Kawaguchi, T
   Ogawa, Y
   Tominaga, T
AF Kawaguchi, Tomohiro
   Ogawa, Yoshikazu
   Tominaga, Teiji
TI Retinal Nerve Fiber Layer Thickness Measurement for Predicting Visual
   Outcome after Transsphenoidal Surgery: Optic Disc Atrophy Is Not the
   Deciding Indicator
SO WORLD NEUROSURGERY
LA English
DT Article
DE Optic disc atrophy; Optical coherence tomography; Retinal nerve fiber
   layer thickness; Transsphenoidal surgery; Visual outcome
ID COHERENCE TOMOGRAPHY; PITUITARY-ADENOMA; RECOVERY; VISION; POTENTIALS;
   SYSTEM
AB BACKGROUND: Postoperative visual recovery is a major concern after transsphenoidal surgery. Optical coherence tomography (OCT) can visualize the anatomy of the retina, and retinal nerve fiber layer (RNFL) thinning reflects loss of optic nerve axons. Visual-evoked potential (VEP) is an electrophysiological response that confirms the nerve conductance. Therefore, these factors reflecting the optic nerve condition may be closely associated with the visual outcome after transsphenoidal surgery.
   METHODS: A total of 124 eyes in 62 patients with sellar tumor who underwent transsphenoidal surgery were included. The following variables were retrospectively analyzed: age, sex, tumor diameter, histology, symptom duration, history of rapid deterioration, optic disc atrophy on fundoscopy, peripapillary RNFL thickness on OCT, and latency and reproducibility of the VEP waveform.
   RESULTS: Four eyes were excluded for no visual disturbance in 3 and glaucoma aggravation in 1. Eighty-three eyes manifested visual improvement, 37 revealed no change, and none showed postoperative deterioration. Univariate analysis demonstrated that thick RNFL of the inferior and temporal quadrants, reproducible VEP waveform, short symptom duration, histologic diagnosis of pituitary adenoma, and small tumor diameter were associated with good visual recovery. Multivariate analysis showed RNFL thickness of the temporal quadrant had significant association with visual recovery (P = 0.03).
   CONCLUSIONS: OCT is a useful diagnostic modality to assess optic nerve condition, and RNFL thickness of the temporal quadrant is correlated with visual outcome after transsphenoidal surgery. Patients with severe visual disturbance may still achieve visual recovery, so surgery should be considered even if optic disc atrophy is evident.
C1 [Kawaguchi, Tomohiro; Ogawa, Yoshikazu] Kohnan Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi, Japan.
RP Ogawa, Y (reprint author), Kohnan Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
EM yogawa@kohnan-sendai.or.jp
RI Kawaguchi, Tomohiro/AAD-9616-2019
OI Kawaguchi, Tomohiro/0000-0001-7622-1270
CR Anik I, 2011, ACTA NEUROCHIR, V153, P831, DOI 10.1007/s00701-011-0942-4
   Budenz DL, 2005, INVEST OPHTH VIS SCI, V46, P2440, DOI 10.1167/iovs.04-1174
   Carrim ZI, 2007, ACTA NEUROCHIR, V149, P255, DOI 10.1007/s00701-006-1108-7
   CEDZICH C, 1987, NEUROSURGERY, V21, P709, DOI 10.1227/00006123-198711000-00018
   Chacko AG, 1996, BRIT J NEUROSURG, V10, P275, DOI 10.1080/02688699650040133
   Chung SB, 2012, ACTA NEUROCHIR, V154, P1505, DOI 10.1007/s00701-012-1426-x
   CIRIC I, 1983, J NEUROSURG, V59, P395, DOI 10.3171/jns.1983.59.3.0395
   COHEN AR, 1985, NEUROSURGERY, V17, P446, DOI 10.1227/00006123-198509000-00008
   DeLellis AR, 2004, PATHOLOGY GENETICS T
   Dhasmana Renu, 2011, J Ophthalmic Vis Res, V6, P187
   FINDLAY G, 1983, ACTA NEUROCHIR, V68, P175, DOI 10.1007/BF01401176
   Gnanalingham KK, 2005, J NEUROL NEUROSUR PS, V76, P415, DOI 10.1136/jnnp.2004.035576
   HARDING GFA, 1990, J NEUROL NEUROSUR PS, V53, P890, DOI 10.1136/jnnp.53.10.890
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X
   Kamada K, 2005, NEUROSURGERY, V57, P121, DOI 10.1227/01.NEU.0000163526.60240.B6
   Kawaguchi Tomohiro, 2015, No Shinkei Geka, V43, P323, DOI 10.11477/mf.1436203015
   King AJW, 2000, AM J OPHTHALMOL, V129, P599, DOI 10.1016/S0002-9394(99)00464-X
   Kitano M, 2007, J NEUROSURG, V107, P337, DOI 10.3171/JNS-07/08/0337
   LENNERSTRAND G, 1983, ACTA OPHTHALMOL, V61, P1104
   Louis ND, 2007, WHO CLASSIFICATION T
   MARCUS M, 1991, AUST NZ J OPHTHALMOL, V19, P111, DOI 10.1111/j.1442-9071.1991.tb00637.x
   Moon CH, 2011, INVEST OPHTH VIS SCI, V52, P8527, DOI 10.1167/iovs.11-8034
   Ogawa Y, 2013, ACTA NEUROCHIR, V155, P1879, DOI 10.1007/s00701-013-1817-7
   POWELL M, 1995, BRIT J NEUROSURG, V9, P367, DOI 10.1080/02688699550041377
   Sasaki T, 2010, J NEUROSURG, V112, P273, DOI 10.3171/2008.9.JNS08451
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2353, DOI 10.1167/iovs.12-11103
   SMITH KJ, 1981, BRAIN, V104, P383, DOI 10.1093/brain/104.2.383
   SULLIVAN LJ, 1991, J CLIN NEURO-OPHTHAL, V11, P262
   SYMON L, 1979, J NEUROL NEUROSUR PS, V42, P973, DOI 10.1136/jnnp.42.11.973
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Wilson W B, 1976, Surg Neurol, V5, P323
NR 34
TC 1
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E427
EP E435
DI 10.1016/j.wneu.2019.03.143
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300053
PM 30910754
DA 2020-05-12
ER

PT J
AU Kerschbaumer, J
   Pinggera, D
   Steiger, R
   Rietzler, A
   Wohrer, A
   Riedmann, M
   Grams, AE
   Thome, C
   Freyschlag, CF
AF Kerschbaumer, Johannes
   Pinggera, Daniel
   Steiger, Ruth
   Rietzler, Andreas
   Wohrer, Adelheid
   Riedmann, Marina
   Grams, Astrid Ellen
   Thome, Claudius
   Freyschlag, Christian Franz
TI Results of Phosphorus Magnetic Resonance Spectroscopy for Brain
   Metastases Correlate with Histopathologic Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE 31-P-MRS; Biopsy; Brain metastases; Infiltration; Spectroscopy
ID SODIUM-GUIDED RESECTION; CELL LUNG-CANCER; CEREBRAL METASTASES; SURGICAL
   RESECTION; ENERGY-METABOLISM; MANAGEMENT; TUMORS; RADIOSURGERY;
   RADIOTHERAPY; CHEMOTHERAPY
AB BACKGROUND: Brain metastases (BMs) are classically well-circumscribed lesions. Still, the amount of edema in these neoplasms suggests either mechanisms of infiltration or defense. A better understanding of the mechanisms within the edema of BMs seems reasonable to preoperatively identify areas of potential infiltration and resect them. BMs represent tumors with high energy demand and cell turnover; therefore, they qualify for preoperative investigation with phosphorus-31 magnetic resonance spectroscopy (31PMRS), which reveals information about those characteristics.
   METHODS: Ten patients with BMs were included in this trial. All underwent preoperative standard magnetic resonance imaging with additional 31PMRS. In all patients, 1 voxel within the contrast-enhancing tumor (CE+), 1 voxel at the border (including CE+ areas and surrounding T2-hyperintensive [T2+] areas), and 1 distant voxel purely including T2+ areas were determined by a neuroradiologist and a neurosurgeon. A frameless stereotactic biopsy was performed after craniotomy. Subsequently, the metabolites of the 31PMRS were analyzed and compared with the histopathologic results.
   RESULTS: Ratios, reflecting resynthesis (CE+/border/T2+: 1.109 +/- 0.192/1.112 +/- 0.158/1.083 +/- 0.097), hydrolysis (0.303 +/- 0.089/0.360 +/- 0.122/0.321 +/- 0.089), energy demand (4.227 +/- 2.35/3.453 +/- 1.284/3.599 +/- 0.833), and membrane turnover (1.239 +/- 0.2611/3.453 +/- 1.284/3.599 +/- 0.283) were calculated and compared intraindividually with a voxel from the contralateral side (resynthesis/hydrolysis/energy demand/membrane turnover: 1.063 +/- 0.085/0.335 +/- 0.073/3.317 +/- 0.7573/0.784 +/- 0.186), respectively. Resynthesis showed a trend toward higher ratios in CE+ and border biopsies without reaching statistical significances. This trend was also seen concerning energy demand. Membrane turnover was significantly higher in CE+, border zone, and also in the T2+ areas compared with controls (P > 0.001).
   CONCLUSIONS: 31PMRS in BMs provides information on metabolic changes in tumor and surrounding edema. There is proof of enhanced metabolism in tissue without histologic tumor manifestation.
C1 [Kerschbaumer, Johannes; Pinggera, Daniel; Thome, Claudius; Freyschlag, Christian Franz] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
   [Steiger, Ruth; Rietzler, Andreas; Grams, Astrid Ellen] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria.
   [Riedmann, Marina] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   [Wohrer, Adelheid] Med Univ Vienna, Inst Neurol, Vienna, Austria.
RP Kerschbaumer, J (reprint author), Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
EM johannes.kerschbaumer@tirol-kliniken.at
RI Grams, Astrid/AAH-6325-2019
CR Berghoff AS, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.06.03
   Berghoff AS, 2013, NEURO-ONCOLOGY, V15, P1664, DOI 10.1093/neuonc/not112
   Berghoff AS, 2016, J NEURO-ONCOL, V130, P19, DOI 10.1007/s11060-016-2216-8
   Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Chiang IC, 2004, NEURORADIOLOGY, V46, P619, DOI 10.1007/s00234-004-1246-7
   Ciminera AK, 2017, CLIN EXP METASTAS, V34, P6
   Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58
   Gaspar LE, 2010, J NEURO-ONCOL, V96, P17, DOI 10.1007/s11060-009-0060-9
   Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5
   Hattingen E, 2009, MAGN RESON MATER PHY, V22, P43, DOI 10.1007/s10334-008-0148-9
   Hattingen E, 2011, NEURO-ONCOLOGY, V13, P1349, DOI 10.1093/neuonc/nor132
   Hattingen E, 2011, NMR BIOMED, V24, P536, DOI 10.1002/nbm.1621
   Hohne J, 2017, ACTA NEUROCHIR, V159, P363, DOI 10.1007/s00701-016-3054-3
   Kalkanis SN, 2010, J NEURO-ONCOL, V96, P33, DOI 10.1007/s11060-009-0061-8
   Kamp MA, 2016, ONCOTARGET, V7, P66776, DOI 10.18632/oncotarget.11488
   Kamp MA, 2012, ACTA NEUROCHIR, V154, P1981, DOI 10.1007/s00701-012-1463-5
   Kamp MA, 2012, ACTA NEUROCHIR, V154, P223, DOI 10.1007/s00701-011-1200-5
   Kerschbaumer J, 2017, ANTICANCER RES, V37, P871, DOI 10.21873/anticanres.11392
   Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655
   Lehnhardt FG, 2001, NMR BIOMED, V14, P307, DOI 10.1002/nbm.708
   Lin QT, 2010, NEOPLASIA, V12, P748, DOI 10.1593/neo.10602
   Linskey ME, 2010, J NEURO-ONCOL, V96, P45, DOI 10.1007/s11060-009-0073-4
   Mehta MP, 2010, J NEURO-ONCOL, V96, P71, DOI 10.1007/s11060-009-0062-7
   PAGET S, 1989, CANCER METAST REV, V8, P98
   PARIZEL PM, 1989, J COMPUT ASSIST TOMO, V13, P378, DOI 10.1097/00004728-198905000-00002
   Patchell RA, 1998, JAMA-J AM MED ASSOC, V280, P1485, DOI 10.1001/jama.280.17.1485
   Preusser M, 2012, ACTA NEUROPATHOL, V123, P205, DOI 10.1007/s00401-011-0933-9
   Schebesch KM, 2016, TURK NEUROSURG, V26, P185, DOI 10.5137/1019-5149.JTN.16952-16.0
   Schebesch KM, 2015, ACTA NEUROCHIR, V157, P899, DOI 10.1007/s00701-015-2395-7
   Siam L, 2015, ONCOTARGET, V6, P29254, DOI 10.18632/oncotarget.4201
   Sierra A, 1997, LAB INVEST, V77, P357
   Soffietti R, 2013, J CLIN ONCOL, V31, P65, DOI 10.1200/JCO.2011.41.0639
   Spanberger T, 2013, CLIN EXP METASTAS, V30, P357, DOI 10.1007/s10585-012-9542-9
   Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Widhalm G, 2014, CLIN NEUROPATHOL, V33, P260, DOI 10.5414/NP300798
   Yoo H, 2009, J NEUROSURG, V110, P730, DOI 10.3171/2008.8.JNS08448
NR 38
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E172
EP E178
DI 10.1016/j.wneu.2019.03.041
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300024
PM 30878742
DA 2020-05-12
ER

PT J
AU Kikuta, S
   Iwanaga, J
   Watanabe, K
   Tubbs, RS
AF Kikuta, Shogo
   Iwanaga, Joe
   Watanabe, Koichi
   Tubbs, R. Shane
TI Revisiting the Middle Cluneal Nerves: An Anatomic Study with Application
   to Pain Syndromes and Invasive Procedures Around the Sacrum
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Cadaver; Middle cluneal nerve; Posterior sacrococcygeal plexus;
   Sacral dorsal rami
ID ENTRAPMENT NEUROPATHY; SUPERIOR
AB OBJECTIVE: The middle cluneal nerves (MCNs) are stated to arise from the sacral dorsal rami of S1 to S3 and supply the gluteal skin, but their detailed anatomy is unclear and often variably depicted and described. Therefore, the goal of this study was to revisit the anatomy of the MCNs and provide a clearer picture of their morphology.
   METHODS: Five fresh-frozen Caucasian cadavers (10 sides) (2 men and 3 women) were dissected for this study. The sacral dorsal rami from each posterior sacral foramen were identified and traced laterally to identify the MCNs. The contribution, pathway, and distribution of the MCNs were investigated.
   RESULTS: Each sacral dorsal ramus joined to form the posterior sacrococcygeal plexus. A total of 25 MCNs were identified. The MCNs were formed by the sacral dorsal rami of S1-2 in 48% (12/25), S1-3 in 4% (1/25), S1-4 in 20% (5/25), S2-3 in 8% (2/25), and S2-4 in 20% (5/25). The MCNs pierced the gluteus maximus by 2 different pathways and supplied the gluteal skin or the gluteus maximus muscle.
   CONCLUSIONS: We clarified the anatomy and variations of the MCNs and revisited its current nomenclature. Such knowledge might improve diagnoses and invasive procedure outcomes in patients with pathology in the region of the MCNs.
C1 [Kikuta, Shogo; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA USA.
   [Kikuta, Shogo; Iwanaga, Joe] Kurume Univ, Dent & Oral Med Ctr, Sch Med, Kurume, Fukuoka, Japan.
   [Iwanaga, Joe; Watanabe, Koichi] Kurume Univ, Div Gross & Clin Anat, Dept Anat, Sch Med, Kurume, Fukuoka, Japan.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA USA.; Iwanaga, J (reprint author), Kurume Univ, Dent & Oral Med Ctr, Sch Med, Kurume, Fukuoka, Japan.; Iwanaga, J (reprint author), Kurume Univ, Div Gross & Clin Anat, Dept Anat, Sch Med, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
OI Kikuta, Shogo/0000-0002-2236-2884
CR Abdul-Jabbar A, 2018, WORLD NEUROSURG, V116, pE108, DOI 10.1016/j.wneu.2018.04.095
   Aota Y, 2016, WORLD J ORTHOP, V7, P167, DOI 10.5312/wjo.v7.i3.167
   Berthelot JM, 1996, J RHEUMATOL, V23, P2179
   Darnis B, 2008, SURG RADIOL ANAT, V30, P177, DOI 10.1007/s00276-008-0306-9
   GROB KR, 1995, Z RHEUMATOL, V54, P117
   Henry Brandon Michael, 2017, Folia Med Cracov, V57, P105
   Horwitz MT, 1939, ANAT REC, V74, P91, DOI 10.1002/ar.1090740110
   Isu T, 2018, NEUROSPINE, V15, P25, DOI 10.14245/ns.1836024.012
   Iwanaga J, 2018, CLIN ANAT, V31, P937, DOI 10.1002/ca.23232
   Iwanaga J, 2018, WORLD NEUROSURG, V116, pE766, DOI 10.1016/j.wneu.2018.05.087
   Kim K, 2018, EUR SPINE J, V27, pS309, DOI 10.1007/s00586-017-5208-2
   Konno T, 2017, J PAIN RES, V10, P1431, DOI 10.2147/JPR.S135382
   Kraus MD, 2010, CLIN ORTHOP RELAT R, V468, P2419, DOI 10.1007/s11999-010-1393-6
   Mahli Ahmet, 2002, Spine (Phila Pa 1976), V27, pE478, DOI 10.1097/00007632-200211150-00018
   Maigne JY, 1997, SPINE, V22, P1156, DOI 10.1097/00007632-199705150-00017
   Matsumoto J, 2018, J NEUROSURG-SPINE, V29, P208, DOI 10.3171/2017.12.SPINE17991
   McGrath C, 2009, JOINT BONE SPINE, V76, P57, DOI 10.1016/j.jbspin.2008.02.015
   Netter F, 2014, ATLAS HUMAN ANATOMY
   Routt MLC, 1997, J ORTHOP TRAUMA, V11, P584
   Sciulli RL, 2007, AM J ROENTGENOL, V188, pW181, DOI 10.2214/AJR.05.0479
   Sittitavornwong S, 1950, J ORAL MAXILLOFAC SU, V71, P1777
   Standring S, 2015, GRAYS ANATOMY E BOOK
   Tomaszewski KA, 2017, CLIN ANAT, V30, P14, DOI 10.1002/ca.22800
   Tubbs RS, 2010, J NEUROSURG-SPINE, V13, P356, DOI 10.3171/2010.3.SPINE09747
   WILLARD FH, 1998, P 3 INT WORLD C LOW, P207
   Yilmaz E, 2018, WORLD NEUROSURG, V113, pE296, DOI 10.1016/j.wneu.2018.02.009
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1228
EP E1231
DI 10.1016/J.WNEU.2019.04.109
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300154
PM 31009778
DA 2020-05-12
ER

PT J
AU Kim, J
   Li, YP
   Ahmed, A
AF Kim, Jason
   Li, Yiping
   Ahmed, Azam
TI Predictors of Impaired Cerebral Perfusion After How Diversion Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Flow diversion therapy; Hyperperfusion; Hypoperfusion
ID SMOKING; STENTS
AB BACKGROUND: Flow-diverting stents (FDS) are relatively safe and highly efficacious in treating cerebral aneurysms; however, a small subset of patients experience devastating hemorrhagic complications owing to presumed alterations in local aneurysm and distal cerebral blood flow. The downstream effects of FDS on distal cerebral blood flow is not well understood, but isolated reports of hyperperfusion injury have been described in the literature. We investigate the incidence and clinical factors contributing to abnormal cerebral blood flow after FDS placement.
   METHODS: A retrospective analysis of patients undergoing FDS for elective aneurysm treatment between 2014-2017 was performed. Patients who underwent perfusion imaging within 24-hours posttreatment were included for further analysis. Univariate and multivariate analyses were performed to assess the impact of multiple variables on the postoperative perfusion changes.
   RESULTS: A total of 69 patients underwent FDS therapy to treat unruptured intracranial aneurysms. Thirteen patients (18.8%) developed abnormal perfusion changes. A significant difference of the median was found in aneurysm projection width, depth, neck width, calculated approximate volume, and size ratio between the hypoperfused, normal, and hyperperfusion cases. On multivariate analysis, history of smoking (P = 0.0117), and approximate calculated volume (P = 0.0145) were significant predictors of hyperperfusion identified on posttreatment imaging.
   CONCLUSIONS: This study yielded several novel findings. We demonstrate that cerebral blood flow alterations will occur in a significant subset of patients undergoing FDS treatment. We also provide new evidence that aneurysm volume and history of smoking may predict the developing of postoperative perfusion anomalies. Future studies are needed to evaluate the clinical ramifications of cerebral blood flow disruption in large prospective studies.
C1 [Kim, Jason] Univ Wisconsin, Dept Neurol Surg, Sch Med, Madison, WI 53706 USA.
   [Li, Yiping; Ahmed, Azam] Univ Wisconsin, Sch Med, Dept Neurol Surg, Madison, WI 53706 USA.
RP Kim, J (reprint author), Univ Wisconsin, Dept Neurol Surg, Sch Med, Madison, WI 53706 USA.
EM jjkim28@wisc.edu
OI Li, Yiping/0000-0002-2333-7736; Ahmed, Azam/0000-0001-7293-496X
CR Adhiyaman V, 2007, QJM-INT J MED, V100, P239, DOI 10.1093/qjmed/hcm009
   Brunozzi D, 2018, J NEUROINTERV SURG, V10, P249, DOI 10.1136/neurintsurg-2017-013042
   Chiu AHY, 2012, BMJ CASE REP, V2012
   Dalman JE, 1999, EUR J VASC ENDOVASC, V18, P222, DOI 10.1053/ejvs.1999.0846
   Fischer S, 2012, NEURORADIOLOGY, V54, P369, DOI 10.1007/s00234-011-0948-x
   Giacomini L, 2015, INTERV NEURORADIOL, V21, P292, DOI 10.1177/1591019915582153
   Hirai Sakyo, 2015, J Vasc Surg Cases, V1, P46, DOI 10.1016/j.jvsc.2014.11.004
   Ho AL, 2015, NEUROSURGERY, V77, P59, DOI 10.1227/NEU.0000000000000735
   Hussein AE, 2017, INTERV NEURORADIOL, V23, P137, DOI 10.1177/1591019916685892
   Iida M, 1998, STROKE, V29, P1656, DOI 10.1161/01.STR.29.8.1656
   Levitt MR, 2014, AM J NEURORADIOL, V35, P143, DOI 10.3174/ajnr.A3624
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E556
EP E560
DI 10.1016/j.wneu.2019.03.203
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300069
PM 30928588
DA 2020-05-12
ER

PT J
AU Kim, MK
   Lim, YC
AF Kim, Mi Kyung
   Lim, Yong Cheol
TI Aneurysms of the Proximal (A1) Segment of the Anterior Cerebral Artery:
   A Clinical Analysis of 31 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Anterior cerebral artery; Ruptured aneurysm; Subarachnoid
   hemorrhage
ID ENDOVASCULAR TREATMENT; INTRACRANIAL ANEURYSMS; COIL EMBOLIZATION;
   MANAGEMENT; CLASSIFICATION; HYPOPLASIA
AB OBJECTIVE: This study aimed to investigate the characteristics of A1 aneurysms according to their locations and to compare their imaging appearances so as to identify factors associated with their rupture.
   METHODS: We retrospectively reviewed the medical records of 31 patients harboring 32 A1 aneurysms diagnosed and treated between March 2009 and September 2018 at our institute.
   RESULTS: Thirteen (41.9%) of the patients had vascular abnormalities, and multiple aneurysms were found in 13 (41.9%) patients. A total of 16 (53.3%) aneurysms were located on the proximal A1 segment, whereas the middle segments were affected in 7 (23.3%) and the distal segments in 7 (23.3%). Altogether, 93.8% of proximal A1 aneurysms projected posteriorly, 85.7% of middle aneurysms projected superiorly, and 85.7% of distal aneurysms projected inferiorly (P = 0.000). Four (33.3%) of the 12 total ruptured aneurysms were located on the distal A1 segment. Nine (69.2%) ruptured aneurysms were elongated or irregular in shape (P = 0.004). The aspect and height-width ratios of the ruptured aneurysms were higher than those of the unruptured aneurysms (P = 0.001, P = 0.018, respectively).
   CONCLUSIONS: Most A1 aneurysms showed a directional predilection according to the location of the A1 segment. Additionally, A1 aneurysms with elongated or irregular shapes, high aspect or height-width ratios, and distal locations of the A1 segment showed high risks of rupture. Therefore, a thorough assessment of the characteristics of A1 aneurysms can enhance the selection of proper treatment strategies.
C1 [Kim, Mi Kyung; Lim, Yong Cheol] Ajou Univ Hosp, Dept Neurosurg, Suwon, South Korea.
RP Lim, YC (reprint author), Ajou Univ Hosp, Dept Neurosurg, Suwon, South Korea.
EM nsyclim@gmail.com
OI Kim, Mi Kyung/0000-0002-8824-0505
CR Bhaisora KS, 2014, NEUROL INDIA, V62, P410, DOI 10.4103/0028-3886.141284
   Chang HW, 2011, ACTA NEUROCHIR, V153, P279, DOI 10.1007/s00701-010-0804-5
   Cho YD, 2014, NEURORADIOLOGY, V56, P219, DOI 10.1007/s00234-014-1319-1
   CROMPTON MR, 1962, LANCET, V2, P421
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   Ding XM, 2017, WORLD NEUROSURG, V104, P291, DOI 10.1016/j.wneu.2017.04.106
   Gupta R, 2006, J NEUROIMAGING, V16, P117, DOI 10.1111/j.1552-6569.2006.00033.x
   Hassan T, 2011, ACTA NEUROCHIR, V153, P305, DOI 10.1007/s00701-010-0824-1
   Kwon WK, 2013, J KOREAN NEUROSURG S, V53, P293, DOI 10.3340/jkns.2013.53.5.293
   Lee Ha Young, 2011, Neurointervention, V6, P95, DOI 10.5469/neuroint.2011.6.2.95
   Lee JM, 2010, WORLD NEUROSURG, V74, P478, DOI 10.1016/j.wneu.2010.06.040
   Lubicz B, 2006, AM J NEURORADIOL, V27, P142
   Lubicz B, 2009, NEURORADIOLOGY, V51, P99, DOI 10.1007/s00234-008-0474-7
   Maiti TK, 2016, WORLD NEUROSURG, V85, P85, DOI 10.1016/j.wneu.2015.07.022
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Park Hyun-Seok, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P13, DOI 10.7461/jcen.2013.15.1.13
   PIA HW, 1978, ACTA NEUROCHIR, V40, P5, DOI 10.1007/BF01773112
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Rinaldo L, 2017, WORLD NEUROSURG, V108, P662, DOI 10.1016/j.wneu.2017.09.092
   Rinaldo L, 2017, J NEUROSURG, V127, P89, DOI 10.3171/2016.7.JNS16736
   SUZUKI M, 1992, J NEUROSURG, V76, P455, DOI 10.3171/jns.1992.76.3.0455
   van Rooij WJ, 2008, NEURORADIOLOGY, V50, P583, DOI 10.1007/s00234-008-0375-9
   WAKABAYASHI T, 1985, SURG NEUROL, V24, P31, DOI 10.1016/0090-3019(85)90059-X
   Wanibuchi M, 2001, SURG NEUROL, V55, P148, DOI 10.1016/S0090-3019(01)00396-2
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Xu LY, 2012, J COMPUT ASSIST TOMO, V36, P421, DOI 10.1097/RCT.0b013e3182574dea
   Yasargil MG, 1984, MICRONEUROSURGERY, VII, P165
NR 27
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E488
EP E496
DI 10.1016/J.WNEU.2019.03.178
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300060
PM 30928587
DA 2020-05-12
ER

PT J
AU Kondo, K
   Nemoto, M
   Harada, N
   Masuda, H
   Ando, S
   Kubota, S
   Sugo, N
AF Kondo, Kosuke
   Nemoto, Masaaki
   Harada, Naoyuki
   Masuda, Hiroyuki
   Ando, Syunpei
   Kubota, Shuuhei
   Sugo, Nobuo
TI Three-Dimensional Printed Model for Surgical Simulation of Combined
   Transpetrosal Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D Printed model; Combined transpetrosal approach; Mastoidectomy;
   Petrosectomy; Skull base surgery
ID RAPID PROTOTYPING MODEL; TEMPORAL BONE; SKULL BASE; SURGERY
AB BACKGROUND: The combined transpetrosal approach is a complicated skull base surgery with a high degree of difficulty. Herein, we made a 3-dimensional (3D) printed petrous bone with color-coded anatomic sites and evaluated its usefulness as a model to practice drilling associated with combined transpetrosal surgery.
   METHODS: To design a 3D model of the petrous bone, we chose a representative epidermoid petroclival tumor case who underwent combined transpetrosal surgery at our hospital. A 3D image of the petrous bone embedded with color-coded anatomic sites, including cranial nerves, brainstem, and internal carotid and vertebrobasilar arteries, was created based on preoperative computed tomography scan, magnetic resonance, and digital subtraction angiography images and was then 3D printed. Thirteen neurosurgeons from our department evaluated the anatomic reproducibility and estimated distance between each anatomic site of the 3D image and model and the usefulness of the model for drilling practice.
   RESULTS: The anatomic reproducibility of both the 3D image and model was high, and the 3D model was considered good for drilling practice (P < 0.05). The error in the estimated distance between anatomic sites in the 3D model was significantly smaller than that of the 3D image (P< 0.0001).
   CONCLUSIONS: These results indicate that our 3D printed model is very useful for practice with craniotomy and petrosectomy drilling, necessary in the combined transpetrosal approach.
C1 [Kondo, Kosuke; Nemoto, Masaaki; Harada, Naoyuki; Masuda, Hiroyuki; Ando, Syunpei; Kubota, Shuuhei; Sugo, Nobuo] Toho Univ, Fac Med, Sch Med, Dept Neurosurg Omori,Ota Ku, Tokyo, Japan.
RP Sugo, N (reprint author), Toho Univ, Fac Med, Sch Med, Dept Neurosurg Omori,Ota Ku, Tokyo, Japan.
EM nsugo@med.toho-u.ac.jp
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [JP16K10800]
FX This work was supported by a Grant-in-Aid for Scientific Research
   (KAKENHI) from the Japan Society for the Promotion of Science
   (JP16K10800).
CR Adachi K, 2018, WORLD NEUROSURG, V116, pE611, DOI 10.1016/j.wneu.2018.05.052
   Adachi K, 2016, WORLD NEUROSURG, V92, P339, DOI 10.1016/j.wneu.2016.05.019
   Bohl MA, 2018, WORLD NEUROSURG, V116, pE1075, DOI 10.1016/j.wneu.2018.05.167
   Garling RJ, 2018, J NEUROSURG-PEDIATR, V22, P137, DOI 10.3171/2018.2.PEDS17671
   Grau S, 2018, WORLD NEUROSURG, V110, P315, DOI 10.1016/j.wneu.2017.11.083
   Harada N, 2011, NEUROL MED-CHIR, V51, P567, DOI 10.2176/nmc.51.567
   Janjua MB, 2017, J CLIN NEUROSCI, V41, P36, DOI 10.1016/j.jocn.2017.03.015
   Kimura T, 2009, NEUROSURGERY, V65, P719, DOI 10.1227/01.NEU.0000354350.88899.07
   Kondo K, 2016, ACTA NEUROCHIR, V158, P1213, DOI 10.1007/s00701-016-2781-9
   Kondo K, 2015, NEUROL MED-CHIR, V55, P592, DOI 10.2176/nmc.oa.2014-0436
   Lin QS, 2018, WORLD NEUROSURG, V113, pE222, DOI 10.1016/j.wneu.2018.01.215
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   Morales-Gomez JA, 2019, J NEUROSURG, V130, P1721, DOI 10.3171/2017.12.JNS172574
   Morisako H, 2015, J NEUROSURG, V122, P373, DOI 10.3171/2014.8.JNS132406
   Mowry SE, 2015, OTOL NEUROTOL, V36, P1562, DOI 10.1097/MAO.0000000000000848
   Oishi M, 2013, J NEUROSURG, V119, P94, DOI 10.3171/2013.3.JNS121109
   Okonogi S, 2017, ACTA NEUROCHIR, V159, P1619, DOI 10.1007/s00701-017-3202-4
   Orabona GD, 2018, SURG ONCOL, V27, P200, DOI 10.1016/j.suronc.2018.03.007
   Pakzaban P, 2018, NEUROSPINE, V15, P242, DOI 10.14245/ns.1836068.034
   PUERTA AM, 1989, J OPT SOC AM A, V6, P309, DOI 10.1364/JOSAA.6.000309
   Suzuki R, 2018, ANAT SCI INT, V93, P154, DOI 10.1007/s12565-017-0417-7
   van de Belt TH, 2018, WORLD NEUROSURG, V117, pE99, DOI 10.1016/j.wneu.2018.05.190
   Wang L, 2018, J CLIN NEUROSCI, V50, P77, DOI 10.1016/j.jocn.2018.01.074
   Wanibuchi M, 2016, WORLD NEUROSURG, V91, P66, DOI [10.1016/J.WNEU.2016.03.084, 10.1016/j.wneu.2016.03.084]
   Woldegiorgis BH, 2018, ERGONOMICS, V8, P1
NR 25
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E609
EP E616
DI 10.1016/j.wneu.2019.03.219
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300076
PM 30930318
DA 2020-05-12
ER

PT J
AU Kumar, K
   Das, KK
   Singh, S
   Khatri, D
   Deora, H
   Singh, J
   Bhaisora, K
   Srivastava, AK
   Jaiswal, AK
   Behari, S
AF Kumar, Krishna
   Das, Kuntal Kanti
   Singh, Suyash
   Khatri, Deepak
   Deora, Harsh
   Singh, Jaskaran
   Bhaisora, Kamlesh
   Srivastava, Arun K.
   Jaiswal, Awadhesh K.
   Behari, Sanjay
TI Vascular Offenders in Trigeminal Neuralgia: A Unified Classification and
   Assessment of the Outcome of Microvascular Decompression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical pain; Microvascular decompression; Outcome; Primary trigeminal
   neuralgia; Unusual offenders
ID NEUROVASCULAR COMPRESSION; SURGERY; NERVE; RATES
AB BACKGROUND: Vascular loop compression remains the most accepted theory for trigeminal neuralgia (TN). Apart from the normal adjoining vascular loops, certain unusual vascular loops incriminated in TN such as vertebrobasilar dolichoectasia and pure venous compressions do not truly fit into the traditional classification. Moreover, vascular diseases such as cavernoma and aneurysms causing TN are considered as secondary TNs. There is a lack of unified classification for TN with underlying vascular offenders, otherwise amenable to microvascular decompression.
   METHODS: We classified vascular offenders in TN (n = 53) into the usual offenders such as superior cerebellar artery or anterior inferior cerebellar artery loop with (n = 4) or without (n = 34) superior petrosal vein loop (n = 38, group I). The unusual vascular offenders (n = 15, group II) comprised unusual arterial loops (n = 4, IIa), pure venous compressions (n = 8, IIb) and vascular diseases (n = 3, IIc). The clinical symptoms, pain severity scores, and surgical outcomes were compared.
   RESULTS: A right-sided preference and male predominance typified the unusual group. The incidence of atypical pain and sensory impairment was higher in group II. Group II also showed a less favorable immediate pain outcome, particularly the patients in group IIb. Group IIb also showed a higher incidence of postoperative hemorrhagic complications. However, long-term outcomes did not differ significantly.
   CONCLUSIONS: Unusual vascular offenders in TN do constitute a significant population. They differ from the usual group with respect to the type of pain, gender, and side of involvement and tend to have more complications with similar pain outcomes after microvascular decompression.
C1 [Kumar, Krishna; Das, Kuntal Kanti; Singh, Suyash; Khatri, Deepak; Deora, Harsh; Singh, Jaskaran; Bhaisora, Kamlesh; Srivastava, Arun K.; Jaiswal, Awadhesh K.; Behari, Sanjay] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM kkdas@sgpgi.ac.in
RI DEORA, HARSH/A-5817-2019; Khatri, Deepak/C-3554-2019
OI DEORA, HARSH/0000-0003-3247-1117; Khatri, Deepak/0000-0003-1902-9623
CR ADAMS CBT, 1982, J NEUROL NEUROSUR PS, V45, P1020, DOI 10.1136/jnnp.45.11.1020
   Broggi G, 2000, J NEUROL NEUROSUR PS, V68, P59, DOI 10.1136/jnnp.68.1.59
   Chen GQ, 2014, NEUROL SCI, V35, P61, DOI 10.1007/s10072-013-1518-2
   Cruccu G, 2016, NEUROLOGY, V87, P220, DOI 10.1212/WNL.0000000000002840
   Dandy W., 1934, AM J SURG, V24, P445
   DeSouza DD, 2016, FRONT NEUROANAT, V10, DOI 10.3389/finana.2016.0095
   Devor M, 2002, CLIN J PAIN, V18, P4, DOI 10.1097/00002508-200201000-00002
   Docampo J, 2015, NEURORADIOL J, V28, P28, DOI 10.15274/NRJ-2014-10116
   FRITZ W, 1988, J NEUROSURG, V69, P367, DOI 10.3171/jns.1988.69.3.0367
   Guclu B, 2011, ACTA NEUROCHIR, V153, P2365, DOI 10.1007/s00701-011-1168-1
   Haller S, 2016, AM J NEURORADIOL, V37, P1384, DOI 10.3174/ajnr.A4683
   Inoue T, 2017, ACTA NEUROCHIR, V159, P2127, DOI 10.1007/s00701-017-3325-7
   Kalkanis SN, 2003, NEUROSURGERY, V52, P1251, DOI 10.1227/01.NEU.0000065129.25359.EE
   Lee A, 2014, J NEUROSURG, V120, P1048, DOI 10.3171/2014.1.JNS131410
   Liebelt BD, 2017, WORLD NEUROSURG, V104, P788, DOI 10.1016/j.wneu.2017.05.098
   Lutz J, 2011, RADIOLOGY, V258, P524, DOI 10.1148/radiol.10100477
   Moreno NEM, 2016, NEUROSURGERY, V79, P879, DOI 10.1227/NEU.0000000000001404
   Miller JP, 2009, J NEUROSURG, V110, P627, DOI 10.3171/2008.6.17620
   Obermann Mark, 2010, Ther Adv Neurol Disord, V3, P107, DOI 10.1177/1756285609359317
   PETTY PG, 1980, MED J AUSTRALIA, V1, P166, DOI 10.5694/j.1326-5377.1980.tb134736.x
   Regis J, 2016, J NEUROSURG, V124, P1079, DOI 10.3171/2015.2.JNS142144
   Riesenburger RI, 2010, J NEUROSURG, V112, P766, DOI 10.3171/2009.8.JNS081706
   Sabalys Gintautas, 2013, J Oral Maxillofac Res, V3, pe2, DOI 10.5037/jomr.2012.3402
   Shi L, 2017, ONCOTARGET, V8, P44819, DOI 10.18632/oncotarget.14765
   Slavin Konstantin V, 2007, Head Face Med, V3, P30, DOI 10.1186/1746-160X-3-30
   Thomas KL, 2014, CLIN ANAT, V27, P89, DOI 10.1002/ca.22157
NR 26
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E366
EP E375
DI 10.1016/j.wneu.2019.03.128
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300046
PM 30905645
DA 2020-05-12
ER

PT J
AU Kuo, KL
   Lin, CL
   Wu, CH
   Chang, CH
   Tsai, HP
   Loh, JK
   Lieu, AS
   Su, YF
AF Kuo, Keng-Liang
   Lin, Chih-Lung
   Wu, Chieh-Hsin
   Chang, Chih-Hui
   Tsai, Hung-Pei
   Loh, Joon-Khim
   Lieu, Ann-Shung
   Su, Yu-Feng
TI Meningeal Melanocytoma Associated with Nevus of Ota: Analysis of Twelve
   Reported Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case series; Ipsilateral; Meningeal melanocytoma; Nevus of Ota;
   Supratentorial
ID INTRACRANIAL MELANOMA; MALIGNANT-MELANOMA; IPSILATERAL NEVUS
AB BACKGROUND: Primary melanocytic neoplasms (PMNs) are rare neoplasms, especially within the central nervous system. Meningeal melanocytomas, a subtype of PMN, are even rarer. Nevus of Ota results from the incomplete migration of melanocytes from the neural crest Synchronous nevus of Ota and meningeal melanocytoma are infrequently encountered in clinical practice.
   OBJECTIVE: To evaluate and elucidate 12 cases of synchronous meningeal melanocytoma and nevus of Ota, thereby improving the understanding of the relationship between these 2 diseases.
   METHODS: We reviewed cases and searched the English-language literature from the PubMed database and collected clinical parameters of 12 cases of synchronously occurring nevus of Ota and meningeal melanocytoma.
   RESULTS: Among the 12 cases, 90.90% and 91.66% of the lesion were located ipsilaterally and supratentorially, respectively.
   CONCLUSIONS: Our findings indicated a trend for both types of lesion to be located ipsilaterally and supratentorially. When a patient with nevus of Ota is found to harbor an intracranial neoplasm, the most likely diagnosis is PMN.
C1 [Kuo, Keng-Liang; Lin, Chih-Lung; Chang, Chih-Hui; Loh, Joon-Khim; Su, Yu-Feng] Kaohsiung Med Univ, Coll Med, Sch Med, Grad Inst Med, Kaohsiung, Taiwan.
   [Lin, Chih-Lung; Loh, Joon-Khim] Kaohsiung Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, Kaohsiung, Taiwan.
   [Wu, Chieh-Hsin; Loh, Joon-Khim; Lieu, Ann-Shung; Su, Yu-Feng] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Surg, Kaohsiung, Taiwan.
   [Kuo, Keng-Liang; Lin, Chih-Lung; Wu, Chieh-Hsin; Chang, Chih-Hui; Tsai, Hung-Pei; Loh, Joon-Khim; Lieu, Ann-Shung; Su, Yu-Feng] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Neurosurg, Kaohsiung, Taiwan.
   [Su, Yu-Feng] Kaohsiung Municipal Tatung Hosp, Dept Surg, Div Neurosurg, Kaohsiung, Taiwan.
RP Su, YF (reprint author), Kaohsiung Med Univ, Coll Med, Sch Med, Grad Inst Med, Kaohsiung, Taiwan.; Su, YF (reprint author), Kaohsiung Med Univ, Coll Med, Sch Med, Dept Surg, Kaohsiung, Taiwan.; Su, YF (reprint author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Neurosurg, Kaohsiung, Taiwan.; Su, YF (reprint author), Kaohsiung Municipal Tatung Hosp, Dept Surg, Div Neurosurg, Kaohsiung, Taiwan.
EM suyufeng2000@gmail.com
OI Kuo, Keng-Liang/0000-0001-7353-0967; Su, Yu-feng/0000-0003-0355-3981
CR Adeeb N, 2012, CHILD NERV SYST, V28, P827, DOI 10.1007/s00381-012-1744-6
   Arunkumar MJ, 2001, CLIN ONCOL-UK, V13, P52, DOI 10.1053/clon.2001.9215
   BALMACEDA CM, 1993, NEUROLOGY, V43, P381, DOI 10.1212/WNL.43.2.381
   BOTTICELLI AR, 1983, CANCER, V51, P2304, DOI 10.1002/1097-0142(19830615)51:12<2304::AID-CNCR2820511223>3.0.CO;2-U
   Chen HX, 2015, NEUROLOGY, V85, P555, DOI 10.1212/WNL.0000000000001837
   Cichorek M, 2013, POSTEP DERM ALERGOL, V30, P30, DOI 10.5114/pdia.2013.33376
   Das A, 2001, INTERN MED J, V31, P562, DOI 10.1046/j.1445-5994.2001.00119.x
   DORSEY CS, 1954, J INVEST DERMATOL, V22, P225, DOI 10.1038/jid.1954.28
   Hino K, 2005, NEUROSURGERY, V56, P1376, DOI 10.1227/01.NEU.0000159716.45457.BC
   HORSEY WJ, 1980, CAN J NEUROL SCI, V7, P101, DOI 10.1017/S0317167100023477
   Hulke JW, 1861, OPHTHALMIC HOSP REP, V3, P279
   KABUTO M, 1988, Neurological Surgery, V16, P875
   KOCA MR, 1992, KLIN MONATSBL AUGENH, V200, P665, DOI 10.1055/s-2008-1045854
   Konstantinov Nikifor K, 2018, Cutis, V102, pE2
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Matsumoto S, 1998, J NEUROSURG, V88, P890, DOI 10.3171/jns.1998.88.5.0890
   Munoz-Hidalgo L, 2014, J CLIN ONCOL, V32, pE72, DOI 10.1200/JCO.2013.48.8718
   Navas M, 2009, J NEURO-ONCOL, V95, P105, DOI 10.1007/s11060-009-9907-3
   Nitta K, 2014, MELANOMA RES, V24, P286, DOI 10.1097/CMR.0000000000000069
   Ota M, 1939, TOKYO MED J, V63, P1243
   Pan H, 2011, J CLIN NEUROSCI, V18, P1548, DOI 10.1016/j.jocn.2011.01.040
   Patterson CRS, 2009, AUSTRALAS J DERMATOL, V50, P294, DOI 10.1111/j.1440-0960.2009.00562.x
   Piercecchi-Marti MD, 2002, J NEUROSURG, V96, P619, DOI 10.3171/jns.2002.96.3.0619
   Rahimi-Movaghar V, 2003, SURG NEUROL, V59, P200, DOI 10.1016/S0090-3019(02)01052-2
   Rivers JK, 2001, J CUTAN MED SURG, V5, P381, DOI 10.1007/s10227-001-0004-2
   Rutten I, 2005, ACTA NEUROCHIR, V147, P313, DOI 10.1007/s00701-004-0457-3
   SAGAR HJ, 1983, J NEUROSURG, V58, P280, DOI 10.3171/jns.1983.58.2.0280
   Samadian M, 2015, WORLD NEUROSURG, V84, P567, DOI 10.1016/j.wneu.2015.03.061
   SANG DN, 1977, ARCH OPHTHALMOL-CHIC, V95, P1820
   Shin D, 2015, MELANOMA RES, V25, P273, DOI 10.1097/CMR.0000000000000163
   TYNDEL FJ, 1994, NEUROLOGY, V44, P586, DOI 10.1212/WNL.44.3_Part_1.586
   Zembowicz A, 2004, AM J SURG PATHOL, V28, P31, DOI 10.1097/00000478-200401000-00002
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E311
EP E320
DI 10.1016/j.wneu.2019.03.113
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300040
PM 30904806
DA 2020-05-12
ER

PT J
AU Kuroda, H
   Toyota, S
   Kumagai, T
   Iwata, T
   Kobayashi, M
   Mori, K
   Taki, T
AF Kuroda, Hideki
   Toyota, Shingo
   Kumagai, Tetsuya
   Iwata, Takamitsu
   Kobayashi, Maki
   Mori, Kanji
   Taki, Takuyu
TI Feasibility of Smart Metal Artifact Reduction Algorithm on Computed
   Tomography Angiography for Clipping of Recurrent Aneurysms After Coil
   Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping after coil embolization; Metal artifact reduction; Recurrent
   aneurysms
ID TREATED CEREBRAL ANEURYSMS; INTRACRANIAL ANEURYSMS; FOLLOW-UP; CT
   ANGIOGRAPHY; IMPACT; TISSUE
AB BACKGROUND: The number of patients with a history of clipping of recurrent aneurysms after coil embolization has increased. The aim of this article was to report the feasibility of CT angiography using a commercial metal artifact reduction algorithm (Smart Metal Artifact Reduction [MAR]) for patients who underwent clipping of recurrent aneurysms after coil embolization.
   METHODS: Six cases of clipping of recurrent aneurysms after coil embolization were examined with CT angiography using MAR between 2015 and 2018 at a single institution. Conventional CT angiography and three-dimensional digital subtraction angiography data were compared, and depiction of the status of treated aneurysms using MAR was estimated.
   RESULTS: Conventional CT angiography was unable to depict the status of treated aneurysms in the patients with a history of clipping of recurrent aneurysms after coil embolization because of metal artifacts. With MAR, metal artifacts were greatly reduced, and the status of treated aneurysms was able to be depicted, although depiction was inferior to three-dimensional digital subtraction angiography.
   CONCLUSIONS: For patients with a history of clipping of recurrent aneurysms after coil embolization, CT angiography using MAR is feasible, although further development of imaging techniques is needed.
C1 [Kuroda, Hideki; Toyota, Shingo; Kumagai, Tetsuya; Iwata, Takamitsu; Kobayashi, Maki; Mori, Kanji; Taki, Takuyu] Kansai Rosai Hosp, Dept Neurosurg, Amagasaki, Hyogo, Japan.
RP Toyota, S (reprint author), Kansai Rosai Hosp, Dept Neurosurg, Amagasaki, Hyogo, Japan.
EM strokect@aol.com
CR Barrett JF, 2004, RADIOGRAPHICS, V24, P1679, DOI 10.1148/rg.246045065
   Bier G, 2017, NEURORADIOLOGY, V59, P649, DOI 10.1007/s00234-017-1855-6
   Brown JH, 1999, AM J NEURORADIOL, V20, P694
   Daou B, 2016, J NEUROSURG, V125, P1337, DOI 10.3171/2015.10.JNS151544
   Dorfer C, 2012, NEUROSURGERY, V70, P537, DOI 10.1227/NEU.0b013e3182350da5
   El Beltagy M, 2010, WORLD NEUROSURG, V74, P472, DOI 10.1016/j.wneu.2010.06.036
   Friedrich B, 2016, CLIN NEURORADIOL, V26, P31, DOI 10.1007/s00062-014-0324-4
   Gonner F, 2002, NEURORADIOLOGY, V44, P755, DOI 10.1007/s00234-002-0825-8
   Guilfoile C, 2017, AUSTRALAS PHYS ENG S, V40, P385, DOI 10.1007/s13246-017-0543-5
   Huang JY, 2015, PHYS MED BIOL, V60, P1047, DOI 10.1088/0031-9155/60/3/1047
   Izumo T, 2015, WORLD NEUROSURG, V83, P211, DOI 10.1016/j.wneu.2014.08.013
   Kang HS, 2006, NEUROSURGERY, V58, P60, DOI 10.1227/01.NEU.0000194188.51731.13
   Kidoh M, 2016, EUR RADIOL, V26, P1378, DOI 10.1007/s00330-015-3950-6
   Mennecke A, 2017, EUR RADIOL, V27, P88, DOI 10.1007/s00330-016-4351-1
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Pjontek R, 2016, J NEUROINTERV SURG, V8, P824, DOI 10.1136/neurintsurg-2015-011787
   Prell D, 2010, AM J NEURORADIOL, V31, P634, DOI 10.3174/ajnr.A1883
   Psychogios MN, 2013, NEURORADIOLOGY, V55, P813, DOI 10.1007/s00234-013-1165-6
   Shigematsu T, 2013, STROKE, V44, P2735, DOI 10.1161/STROKEAHA.111.000609
   SILVERMAN PM, 1986, COMPUT RADIOL, V10, P37, DOI 10.1016/0730-4862(86)90017-X
   Sunwoo L, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e158
   Toyota S, 2018, ACTA NEUROCHIR SUPPL, V129, P53, DOI 10.1007/978-3-319-73739-3_8
   Toyota S, 2015, NEUROL MED-CHIR, V55, P838, DOI 10.2176/nmc.oa.2015-0037
   van Rooij WJ, 2007, NEURORADIOLOGY, V49, P343, DOI 10.1007/s00234-006-0200-2
   Wallace RC, 2007, AM J NEURORADIOL, V28, P1207, DOI 10.3174/ajnr.A0664
   Wallace RC, 2007, AM J NEURORADIOL, V28, P1001, DOI 10.3174/ajnr.A0662
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1249
EP E1254
DI 10.1016/j.wneu.2019.04.133
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300158
PM 31026660
DA 2020-05-12
ER

PT J
AU Laeke, T
   Tirsit, A
   Debebe, F
   Girma, B
   Gere, D
   Park, KB
   Azazh, A
AF Laeke, Tsegazeab
   Tirsit, Abenezer
   Debebe, Finot
   Girma, Biruk
   Gere, Desalegn
   Park, Kee B.
   Azazh, Aklilu
TI Profile of Head Injuries: Prehospital Care, Diagnosis, and Severity in
   an Ethiopian Tertiary Hospital
SO WORLD NEUROSURGERY
LA English
DT Article
DE Head injury; Interhospital transfer; Mortality; Prehospital care;
   Resource limited setup; Vital signs
ID TRAUMATIC BRAIN-INJURY; MORTALITY; EPIDEMIOLOGY
AB BACKGROUND: Consistent data on head injury is lacking especially in the low-and middle-income countries. Our study tries to characterize patients with head injury at the emergency department of one of the few tertiary public hospitals giving neurosurgical care in the country.
   METHODS: A retrospective cross-sectional study was performed from May 2015 to October 2015 in one of the neurosurgical teaching hospitals, Black Lion Specialized Hospital. All adult patients with head injury who visited the emergency department during the study period were included. Data on patients' sociodemographic, mechanism of trauma, clinical presentation, imaging findings, and presence of polytrauma were collected by a pretested questionnaire. The source of data was emergency department logbooks and patient charts.
   RESULTS: A total of 390 patients with head injury who visited the emergency department were included during the study period. There were 335 males (85.9%) and 55 females (14.1%) with the mean age (standard deviation) of 35.4 (15.6) years. Majority of patients came by taxi constituting 149 (38.2%) of all patients, whereas 147 patients (37.7%) used ambulance. Of 147 patients brought by ambulances, 133 (90.4%) were referred from other hospitals. The majority, 26 (45.6%), of patientswho came directly to the emergency department used taxis. It is shown that the mode of arrival and origin of arrival are significantly related, P = 0.000. Mortality of severe head injury at the emergency department was 50.8%.
   CONCLUSIONS: Prehospital care coverage was low and ambulances were used mainly for interhospital transfers. Mortality of severe head injury at the emergency department is high and significantly associated with preventable causes like vital sign derangement.
C1 [Laeke, Tsegazeab; Tirsit, Abenezer] Addis Ababa Univ, Coll Hlth Sci, Neurosurg Unit, Addis Ababa, Ethiopia.
   [Laeke, Tsegazeab; Tirsit, Abenezer] Univ Bergen, Dept Clin Med, Fac Med, Bergen, Norway.
   [Laeke, Tsegazeab; Tirsit, Abenezer] Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.
   [Debebe, Finot; Girma, Biruk; Gere, Desalegn; Azazh, Aklilu] Addis Ababa Univ, Dept Emergency Med, Coll Hlth Sci, Addis Ababa, Ethiopia.
   [Park, Kee B.] Harvard Med Sch, Boston, MA 02115 USA.
RP Laeke, T (reprint author), Addis Ababa Univ, Coll Hlth Sci, Neurosurg Unit, Addis Ababa, Ethiopia.; Laeke, T (reprint author), Univ Bergen, Dept Clin Med, Fac Med, Bergen, Norway.; Laeke, T (reprint author), Univ Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England.
EM tselaeke@gmail.com
CR Adeleye A O, 2017, Ann Ib Postgrad Med, V15, P34
   Azaj A., 2013, East and Central African Journal of Surgery, V18, P108
   Bank W, 2018, WORLD BANK LIST EC
   Boniface R, 2016, PAN AFR MED J, V23, DOI 10.11604/pamj.2016.23.46.7487
   Boschini LP, 2016, INJURY, V47, P1118, DOI 10.1016/j.injury.2016.01.015
   Dinh MM, 2013, INJURY, V44, P606, DOI 10.1016/j.injury.2012.01.011
   Djientcheu V, 2016, J NEUROL SCI, V371, P100, DOI 10.1016/j.jns.2016.10.016
   Hunchak Cheryl, 2015, BMC Res Notes, V8, P605, DOI 10.1186/s13104-015-1592-z
   Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362
   Kesinger MR, 2014, INJURY, V45, P1350, DOI 10.1016/j.injury.2014.04.037
   Kraus J, 2000, EPIDEMIOLOGY BRAIN I
   Kuenzler M, 2015, EMERG MED LOS ANGEL, V5, P1, DOI [10.4172/2165-7548.1000226, DOI 10.4172/2165-7548.1000226]
   Kuo BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182285
   Maier D, 2014, WORLD NEUROSURG, V81, P478, DOI 10.1016/j.wneu.2013.08.014
   Meskere Yehune, 2015, Ethiop Med J, V53, P141
   Murad MK, 2012, PREHOSP DISASTER MED, V27, P36, DOI 10.1017/S1049023X11006819
   Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8
   Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343
   Peeters S, 2017, WORLD NEUROSURG, V97, P580, DOI 10.1016/j.wneu.2016.09.127
   Qureshi JS, 2013, INT J SURG, V11, P265, DOI 10.1016/j.ijsu.2013.01.011
   Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035
   Seedat M, 2009, LANCET, V374, P1011, DOI 10.1016/S0140-6736(09)60948-X
   Sultan M, 2018, BMC HEALTH SERV RES, V18, P1
   Thanni L O A, 2006, Afr Health Sci, V6, P104
   Tiska MA, 2004, EMERG MED J, V21, P237, DOI 10.1136/emj.2002.002097
   Wolde A., 2008, East and Central African Journal of Surgery, V13, P14
   World Health Organization, 2008, GLOB BURD DIS 2004 U
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E186
EP E192
DI 10.1016/j.wneu.2019.03.044
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300026
PM 30878740
DA 2020-05-12
ER

PT J
AU Lamanna, A
   Maingard, J
   Kok, HK
   Barras, C
   Jhamb, A
   Thijs, V
   Chandra, R
   Brooks, DM
   Asadi, H
AF Lamanna, Anthony
   Maingard, Julian
   Kok, Hong Kuan
   Barras, Christen
   Jhamb, Ashu
   Thijs, Vincent
   Chandra, Ronil
   Brooks, Duncan Mark
   Asadi, Hamed
TI Carotid Artery Stenting in Acute Stroke Using a Microporous Stent
   Device: A Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery atherosclerosis; Carotid artery stenosis; Carotid artery
   stenting; Casper stent; Stroke
ID ACUTE ISCHEMIC-STROKE; RETRIEVER THROMBECTOMY; ENDOVASCULAR THERAPY;
   MICROMESH STENT; OCCLUSION; THROMBOLYSIS; METAANALYSIS; BENEFITS
AB BACKGROUND: Carotid artery stenting (CAS) is an established treatment for carotid artery stenosis, typically in a semielective or elective setting. The growth of mechanical thrombectomy for acute stroke has led to an increased use of emergent carotid artery stenting (eCAS). This single-center retrospective case series evaluates the safety and efficacy of eCAS using a dual-layer micromesh nitinol stent to treat carotid artery stenosis in the acute stroke setting.
   METHODS: Ethics approval was granted by the institutional review board. Clinical data of all patients who underwent CAS using the Casper dual-layer micromesh nitinol stent system (MicroVention, Terumo, Tustin, California, USA) at a tertiary level 24-hour endovascular thrombectomy service over a 2-year period (June 2016-June 2018) were retrospectively obtained and reviewed.
   RESULTS: Twenty eCAS procedures were performed in 19 patients over the study period. Most patients had tandem lesions (12/20; 60%). Median National Institute of Health Stroke Scale score on admission was 17 (interquartile range 9-22). Stent deployment was technically successful in all patients. Recanalization rate was 95%. Symptomatic intracranial hemorrhage occurred in 2 patients (10%), both resulting in death. No other procedure-related deaths occurred. Stent thrombosis occurred in 2 patients. One delayed embolic stroke occurred. No other stent-related complications occurred. Median National Institute of Health Stroke Scale score at 24 hours postprocedure was 3 (interquartile range 1-12). Six patients had a good clinical outcome (modified Rankin Scale score between 0 and 2) at 3- to 6-month follow-up (38%).
   CONCLUSIONS: eCAS using the Casper stenting system is effective and technically feasible in the acute stroke setting, although the ideal antiplatelet and anticoagulation regime is not clearly established.
C1 [Lamanna, Anthony; Brooks, Duncan Mark; Asadi, Hamed] Austin Hosp, Dept Radiol, Intervent Radiol Serv, Melbourne, Vic, Australia.
   [Brooks, Duncan Mark; Asadi, Hamed] Austin Hosp, Dept Radiol, Intervent Neuroradiol Serv, Melbourne, Vic, Australia.
   [Kok, Hong Kuan] Northern Hosp Radiol, Intervent Radiol Serv, Melbourne, Vic, Australia.
   [Barras, Christen] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Barras, Christen] Univ Adelaide, Adelaide, SA, Australia.
   [Jhamb, Ashu] St Vincents Hosp, Dept Radiol, Melbourne, Vic, Australia.
   [Thijs, Vincent] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Stroke Div, Melbourne, Vic, Australia.
   [Thijs, Vincent] Univ Melbourne, Melbourne, Vic, Australia.
   [Thijs, Vincent; Asadi, Hamed] Austin Hlth, Dept Neurol, Melbourne, Vic, Australia.
   [Chandra, Ronil; Asadi, Hamed] Monash Hlth, Dept Imaging, Melbourne, Vic, Australia.
   [Maingard, Julian; Chandra, Ronil] Monash Hlth, Intervent Neuroradiol Unit Monash Imaging, Melbourne, Vic, Australia.
   [Maingard, Julian; Asadi, Hamed] Deakin Univ, Fac Hlth, Sch Med, Waurn Ponds, Australia.
RP Lamanna, A (reprint author), Austin Hosp, Dept Radiol, Intervent Radiol Serv, Melbourne, Vic, Australia.
EM anton.lamanna92@gmail.com
OI Chandra, Ronil/0000-0001-7555-2297; Thijs, Vincent/0000-0002-6614-8417;
   Lamanna, Anthony/0000-0003-0705-2252
CR Akbari SH, 2013, J NEUROINTERV SURG, V5, P337, DOI 10.1136/neurintsurg-2012-010334
   Barkat M, 2017, EUR J VASC ENDOVASC, V53, P53, DOI 10.1016/j.ejvs.2016.10.011
   Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002
   Bartolini B, 2018, J NEUROINTERV SURG, P1
   Broussalis E, 2019, J NEUROINTERV SURG, V11, P62, DOI 10.1136/neurintsurg-2018-013869
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Casana R, 2017, EUR J VASC ENDOVASC, V54, P681, DOI 10.1016/j.ejvs.2017.09.015
   Christou I, 2002, J NEUROIMAGING, V12, P119, DOI 10.1111/j.1552-6569.2002.tb00107.x
   Dalainas I, 2006, CARDIOVASC INTER RAD, V29, P519, DOI 10.1007/s00270-005-5288-y
   Diaz O, 2018, J NEUROINTERV SURG, V10, P133, DOI 10.1136/neurintsurg-2016-012913
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524
   Jadhav A, 2018, J NEUROINTERV SURG, V10, P1155, DOI 10.1136/neurintsurg-2018-013810
   Kappelhof M, 2015, J NEUROINTERV SURG, V7, P8, DOI 10.1136/neurintsurg-2013-011004
   Kim YS, 2005, STROKE, V36, P869, DOI 10.1161/01.STR.0000160007.57787.4c
   Mbabuike N, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.1.FOCUS16521
   McKevitt FM, 2005, EUR J VASC ENDOVASC, V29, P522, DOI 10.1016/j.ejvs.2005.01.012
   Mokin M, 2012, STROKE, V43, P2362, DOI 10.1161/STROKEAHA.112.655621
   Mutzenbach SJ, 2018, J NEUROINTERV SURG, V10, DOI 10.1136/neurintsurg-2017-013583
   Rubiera M, 2006, STROKE, V37, P2301, DOI 10.1161/01.STR.0000237070.80133.1d
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schonholz C, 2014, J ENDOVASC THER, V21, P601, DOI 10.1583/14-4735R.1
   Sivan-Hoffmann R, 2017, EUR RADIOL, V27, P247, DOI 10.1007/s00330-016-4338-y
   Steglich-Arnholm H, 2015, J NEUROL, V262, P2668, DOI 10.1007/s00415-015-7895-0
   Trouillas P, 2006, STROKE, V37, P556, DOI 10.1161/01.STR.0000196942.84707.71
   WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P
   Wilson MP, 2018, J NEUROINTERV SURG, V10, P721, DOI 10.1136/neurintsurg-2017-013707
   Wissgott C, 2015, J ENDOVASC THER, V22, P634, DOI 10.1177/1526602815593490
   Yamada K, 2017, WORLD NEUROSURG, V105, P321, DOI 10.1016/j.wneu.2017.05.171
   Yilmaz U, 2017, STROKE, V48, P2171, DOI 10.1161/STROKEAHA.116.015965
NR 30
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1003
EP E1012
DI 10.1016/j.wneu.2019.04.024
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300125
PM 30974278
DA 2020-05-12
ER

PT J
AU Lastikka, M
   Oksanen, H
   Helenius, L
   Pajulo, O
   Helenius, I
AF Lastikka, Markus
   Oksanen, Hanna
   Helenius, Linda
   Pajulo, Olli
   Helenius, Ilkka
TI Comparison of Circular and Sagittal Reinforced Rod Options on Sagittal
   Balance Restoration in Adolescents Undergoing Pedicle Screw
   Instrumentation for Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Cobalt-chromium rod; Pedicle screw
   instrumentation; Posterior spinal fusion; Thoracic kyphosis
ID HYBRID INSTRUMENTATION; MULTICENTER; OUTCOMES; PARAMETERS; POSTERIOR;
   PROVIDES; SURGERY; SPINE
AB OBJECTIVE: Pedicle screw instrumentation is widely used for spinal deformity correction and fusion in adolescents for idiopathic scoliosis. The goal is to achieve and sustain good alignment in all 3 planes. We compared 2 different cobalt-chromium (CoCr) rod designs with different stiffnesses with regard to the restoration of coronal and sagittal balance in adolescents operated on for idiopathic scoliosis.
   MATERIAL AND METHODS: A prospective comparative study was made of 90 consecutive adolescents, mean age (standard deviation) 15.6 years (2.1 years), with idiopathic scoliosis who underwent posterior spinal fusion by the use of bilateral segmental pedicle screw instrumentation (PSI) with 6.0 Co-Cr rods. Fifty-four adolescents (43 girls) were operated on by the use of circular rods and 36 (27 girls) by the use of sagittal reinforced rods, with a 2-year follow-up.
   RESULTS: Preoperative major coronal curves were similar and at 2 years: 11 degrees (5.0) and 17 degrees (7.2) with correction percentages of 78% (10) and 69% (12) in the circular and reinforced rod groups (P < 0.01). Thoracic kyphosis at 2 years measured 16 degrees (7) and 21 degrees (6) in the circular and reinforced rod groups (P < 0.01). The number of patients with hypokyphosis was lower in the reinforced rod group at 2 years (P = 0.02). In the reinforced rod group, there was a negative correlation between coronal correction and thoracic kyphosis (r = - 0.52, P < 0.01).
   CONCLUSIONS: Both circular and sagittal reinforced 6.0-mm CoCr rods provide adequate coronal correction for adolescents with idiopathic scoliosis. The use of sagittal reinforced rods provided better thoracic kyphosis restoration and a lower risk for postoperative hypokyphosis.
C1 [Lastikka, Markus; Oksanen, Hanna; Helenius, Linda; Pajulo, Olli; Helenius, Ilkka] Univ Turku, Turku Univ Hosp, Dept Paediat Orthopaed Surg, Turku, Finland.
   [Helenius, Linda] Univ Turku, Turku Univ Hosp, Dept Anaesthesia & Crit Care, Turku, Finland.
RP Lastikka, M (reprint author), Univ Turku, Turku Univ Hosp, Dept Paediat Orthopaed Surg, Turku, Finland.
EM mphlas@utu.fi
RI Helenius, Ilkka/AAM-5803-2020
OI Helenius, Ilkka/0000-0001-5200-3279
FU Medtronic InternationalMedtronic; Baxter International; K2M via
   Innosurge
FX This study was supported by grants from University Hospital,
   Foundations, and Industry. Dr. I. Helenius is a consultant for Medtronic
   and the recipient of grants and research funding from Medtronic
   International, Baxter International, and K2M via Innosurge. Dr. Pajulo
   is the recipient of grants and research funding from Medtronic
   International and Baxter International.
CR Cheng I, 2005, SPINE, V30, P2104, DOI 10.1097/01.brs.0000179261.70845.b7
   Crawford AH, 2013, SPINE, V38, P1199, DOI 10.1097/BRS.0b013e31828ce597
   Fletcher ND, 2012, SPINE, V37, P200, DOI 10.1097/BRS.0b013e318216106c
   Geck MJ, 2007, J SPINAL DISORD TECH, V20, P586, DOI 10.1097/BSD.0b013e31803d3b16
   GRAY JM, 1991, SPINE, V16, pS391
   Haher TR, 1999, SPINE, V24, P1435, DOI 10.1097/00007632-199907150-00008
   Hwang SW, 2012, J NEUROSURG-SPINE, V17, P212, DOI 10.3171/2012.6.SPINE1215
   Johnston CE, 2011, SPINE, V36, P1096, DOI 10.1097/BRS.0b013e3181f8c931
   Kim YJ, 2006, SPINE, V31, P291, DOI 10.1097/01.brs.0000197865.20803.d4
   Kim YJ, 2004, SPINE, V29, P333, DOI 10.1097/01.BRS.0000109983.12113.9B
   Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219
   Lamerain M, 2014, EUR SPINE J, V23, P1190, DOI 10.1007/s00586-014-3168-3
   Lenke LG, 2007, J BONE JOINT SURG AM, V89A, P55, DOI 10.2106/JBJS.F.00644
   Lenke LG, 2001, J BONE JOINT SURG AM, V83A, P1169, DOI 10.2106/00004623-200108000-00006
   Liu H, 2015, J NEUROSURG-SPINE, V22, P259, DOI 10.3171/2014.10.SPINE1496
   Matsumoto T, 1997, J SPINAL DISORD, V10, P125
   Mattila M, 2013, SPINE, V38, P1576, DOI 10.1097/BRS.0b013e31829a6d37
   Merola AA, 2002, SPINE, V27, P2046, DOI 10.1097/00007632-200209150-00015
   Monazzam Shafagh, 2013, Spine Deform, V1, P359, DOI 10.1016/j.jspd.2013.06.002
   Newton PO, 2005, J BONE JOINT SURG AM, V87A, P1937, DOI 10.2106/JBJS.D.02209
   Ohrt-Nissen S, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17351
   Prince DE, 2014, J PEDIATR ORTHOPED, V34, P22, DOI 10.1097/BPO.0b013e318288b3c1
   Sarwahi V, 2014, SPINE J S, V154
   Schwab FJ, 2013, SPINE, V38, pE803, DOI 10.1097/BRS.0b013e318292b7b9
   Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3
   Yagi M, 2011, SPINE, V36, pE60, DOI 10.1097/BRS.0b013e3181eeaee2
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1020
EP E1025
DI 10.1016/j.wneu.2019.04.028
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300127
PM 30995548
DA 2020-05-12
ER

PT J
AU Lau, BL
   Othman, MIC
   Fathil, MFMD
   Liew, DNS
   Lim, SS
   Bujang, MA
   Wong, ASH
AF Lau, Bik Liang
   Othman, Mohd Iryan Che
   Fathil, Mohd Fakhri M. D.
   Liew, Donald Ngian San
   Lim, Swee San
   Bujang, Mohamad Adam
   Wong, Albert Sii Hieng
TI Does Putting Back Hyperostotic Bone Flap in Meningioma Surgery Cause
   Tumor Recurrence? An Observational Prospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranioplasty; Hyperostosis; Meningioma; Recurrence; Simpson
ID SIMPSON GRADE; UNITED-STATES; PRIMARY BRAIN; RESECTION; SYSTEM
AB BACKGROUND: Replacing the skull defect with synthetic materials for hyperostotic bone secondary to meningioma is recommended owing to the possibility of tumor invasion. In our institution, neurosurgeons have been putting back the refashioned hyperostotic bone flap after meningioma excision because of budget constraints. The aim of this study was to review the long-term meningioma recurrence rate in these patients.
   METHODS: This was a nonrandomized, prospective observational study conducted from September 2011 to January 2015 on patients with intracranial convexity and parasagittal meningiomas. Preoperative computed tomography brain scans were obtained in all patients to confirm bony hyperostosis. Intraoperatively, part of the hyperostotic bone was sent for histopathologic examination. The rest of the bone flap was refashioned by drilling off the hyperostotic part. The bone flap was put back over the craniotomy site after soaking in distilled water. All patients were followed up for tumor recurrence.
   RESULTS: The study included 34 patients with convexity or parasagittal meningioma World Health Organization grade I-II who underwent Simpson grade Ia and IIa excision. Median follow-up was 63.5 months (mean 64.9 +/- 9.4 months). The hyperostotic hone flap showed presence of tumor in 35% of patients. There were 2 patients with parasagittal meningiomas after Simpson grade IIa resections who developed tumor recurrences.
   CONCLUSIONS: Our study found that meningioma recurrence was unlikely when autologous cranioplasty was done with refashioned hyperostotic bone. This could be done in the same setting with meningioma excision. There was no recurrence in convexity meningiomas at mean 5-year follow-up.
C1 [Lau, Bik Liang; Othman, Mohd Iryan Che; Fathil, Mohd Fakhri M. D.; Liew, Donald Ngian San; Lim, Swee San; Wong, Albert Sii Hieng] Jalan Hosp, Sarawak Gen Hosp, Minist Hlth, Dept Neurosurg, Kuching, Malaysia.
   [Bujang, Mohamad Adam] Jalan Hosp, Sarawak Gen Hosp, Minist Hlth, Clin Res Ctr, Kuching, Malaysia.
RP Lau, BL (reprint author), Jalan Hosp, Sarawak Gen Hosp, Minist Hlth, Dept Neurosurg, Kuching, Malaysia.
EM laubikliang@gmail.com
OI Lau, Bik Liang/0000-0002-2846-3408
CR BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587
   CASTELLANO F, 1952, J NEUROSURG, V9, P188, DOI 10.3171/jns.1952.9.2.0188
   Davis FG, 2001, NEURO-ONCOLOGY, V3, P152, DOI 10.1093/neuonc/3.3.152
   Derome P J, 1978, Clin Neurosurg, V25, P435
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Echlin F, 1934, ARCH SURG-CHICAGO, V28, P357, DOI 10.1001/archsurg.1934.01170140137009
   Globus JH, 1937, RES PUBL ASSOC RES N, V16, P210
   Gousias K, 2016, J NEUROSURG, V125, P551, DOI 10.3171/2015.9.JNS15754
   Goyal N, 2012, NEUROL INDIA, V60, P50, DOI 10.4103/0028-3886.93589
   Hasseleid BF, 2012, J NEUROSURG, V117, P999, DOI 10.3171/2012.9.JNS12294
   Heald JB, 2014, ACTA NEUROCHIR, V156, P383, DOI 10.1007/s00701-013-1923-6
   Ito F, 2011, ANN SURG ONCOL, V18, P2357, DOI 10.1245/s10434-011-1588-4
   Kamitani H, 2001, SURG NEUROL, V56, P228, DOI 10.1016/S0090-3019(01)00582-1
   KIM KS, 1983, AM J ROENTGENOL, V141, P1217, DOI 10.2214/ajr.141.6.1217
   LUIS DN, 1997, PATHOLOGY GENETICS T, P134
   MAROON JC, 1994, J NEUROSURG, V80, P202, DOI 10.3171/jns.1994.80.2.0202
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Oya S, 2012, J NEUROSURG, V117, P121, DOI 10.3171/2012.3.JNS111945
   Pieper DR, 1999, NEUROSURGERY, V44, P742, DOI 10.1097/00006123-199904000-00028
   POMPILI A, 1982, SURG NEUROL, V17, P411, DOI 10.1016/S0090-3019(82)80006-2
   Samra MK, 2011, EGYPT J NEUROL SURG, V26, P139
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Talacchi A, 2011, ACTA NEUROCHIR, V153, P53, DOI 10.1007/s00701-010-0838-8
   Violaris K, 2012, OPEN J MOD NEUROSURG, V2, P6, DOI DOI 10.4236/0JMN.2012.21002
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E497
EP E502
DI 10.1016/j.wneu.2019.03.183
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300061
PM 30926555
DA 2020-05-12
ER

PT J
AU Li, C
   Sun, N
   Li, L
   Duan, JZ
   Zhang, YK
AF Li, Cheng
   Sun, Na
   Li, Lei
   Duan, Jingzhu
   Zhang, Yingkai
TI Transposterior Arch Lateral Mass Screw for C1 Fixation: Application of a
   3.5-mm-Diameter Screw in the Vertebral Artery Groove with a Height of <=
   3.5 mm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial instability; Atlas; Pedicle screw
ID POSTERIOR ARCH; PEDICLE; PLACEMENT; ATLAS; ANATOMY; CT
AB OBJECTIVE: To explore the feasibility and effectiveness of C1 lateral mass fixation via the posterior arch using pedicle screws of 3.5-mm diameter in patients whose atlas in the vertebral artery groove (C1 pedicle) was <= 3.5 mm in height.
   METHODS: A total of 14 patients who underwent trans-posterior arch lateral mass screw fixation between 2014 and 2017 due to atlantoaxial instability were retrospectively studied. The height of the atlas pedicle was <= 3.5 mm on one or both sides. The position of the screw and damage of the screw trajectory were assessed using the postoperative 3-dimensional computed tomography. The patients were regularly followed up to observe the fracture union and bone graft fusion.
   RESULTS: In total, 27 atlas pedicle heights were <= 3.5 mm and 22 screws were successfully inserted without any nenrovascular complications. However, the pedicle wall was found to have a certain degree of damage with damaged superior/inferior wall in 4 of 6 pedicles respectively. Clinical symptoms were relieved to varying degrees, and patients demonstrated bony fusion during the postoperative follow-up.
   CONCLUSIONS: Pedicle screws of 3.5-mm diameter could be fixed with a high success rate using the viscoelasticity and expansivity of the bone tissue even if the atlas pedicles were <= 3.5 mm in height. Although the screws had a certain probability of breaking the superior/inferior wall, they provided sufficient stability and enabled fracture or bone graft healing. Extraverted atlas pedicle screws should be considered in some cases.
C1 [Li, Cheng; Li, Lei; Duan, Jingzhu; Zhang, Yingkai] China Med Univ, Shengjing Hosp, Dept Orthopaed Surg, Shenyang, Liaoning, Peoples R China.
   [Sun, Na] China Med Univ, Shengjing Hosp, Dept Radiol, Shenyang, Liaoning, Peoples R China.
RP Li, L (reprint author), China Med Univ, Shengjing Hosp, Dept Orthopaed Surg, Shenyang, Liaoning, Peoples R China.
EM 18940258679@163.com
FU Shenyang Science and Technology Bureau
FX This study was supported by Shenyang Science and Technology Bureau.
CR Christensen DM, 2007, SPINE, V32, P844, DOI 10.1097/01.brs.0000259833.02179.c0
   Duan SY, 2010, SURG RADIOL ANAT, V32, P39, DOI 10.1007/s00276-009-0552-5
   Fensky F, 2014, EUR SPINE J, V23, P724, DOI 10.1007/s00586-013-3143-4
   Gebauer M, 2010, EUR SPINE J, V19, P85, DOI 10.1007/s00586-009-1181-8
   Huang DG, 2014, EUR SPINE J, V23, P1109, DOI 10.1007/s00586-014-3217-y
   Joaquim AF, 2010, WORLD NEUROSURG, V74, P359, DOI 10.1016/j.wneu.2010.05.010
   Kim JH, 2013, J KOREAN NEUROSURG S, V54, P25, DOI 10.3340/jkns.2013.54.1.25
   Lee SH, 2010, J CLIN NEUROSCI, V17, P886, DOI 10.1016/j.jocn.2009.10.008
   Lin JM, 2013, SPINE J, V13, P1549, DOI 10.1016/j.spinee.2013.06.006
   Ma XY, 2005, SPINE, V30, P1519, DOI 10.1097/01.brs.0000168546.17788.49
   Padua MRA, 2013, SPINE, V38, P1146, DOI 10.1097/BRS.0b013e31828aadf5
   Qian LX, 2013, EUR SPINE J, V22, P1142, DOI 10.1007/s00586-013-2662-3
   Resnick DK, 2002, NEUROSURGERY, V50, P426, DOI 10.1097/00006123-200202000-00039
   Tan MS, 2003, SPINE, V28, P888, DOI 10.1097/00007632-200305010-00010
   Xie WG, 2017, EXP THER MED, V14, P1467, DOI 10.3892/etm.2017.4710
NR 15
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E480
EP E487
DI 10.1016/j.wneu.2019.03.175
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300059
PM 30922900
DA 2020-05-12
ER

PT J
AU Li, JQ
   Wang, XZ
   Sun, YP
   Zhang, F
   Gao, Y
   Li, ZY
   Ding, WY
   Shen, Y
   Zhang, W
AF Li, Jiaqi
   Wang, Xianzheng
   Sun, Yapeng
   Zhang, Fei
   Gao, Yuan
   Li, Zeyang
   Ding, Wenyuan
   Shen, Yong
   Zhang, Wei
TI Safety Analysis of Two Anterior Lateral Lumbar lnterbody Fusions at the
   Initial Stage of Learning Curve
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Extreme lateral interbody fusion; Lumbar degenerative
   disease; Oblique lumbar interbody fusion
ID INTERBODY FUSION; POSTOPERATIVE COMPLICATIONS; ANATOMICAL RELATIONSHIP;
   PREVENTION; OUTCOMES; INJURY; SPINE
AB OBJECTIVE: Until now, there were few studies on the analysis of oblique lumbar interbody fusion (OLIF) and extreme lateral interbody fusion (XLIF) in the initial stage of learning curve. The purpose of this study was to find out the safety differences between the 2 minimally invasive fusion methods in the initial stage of learning curve and to provide reference for beginners.
   METHODS: We retrospectively collected the first 30 cases of lumbar degenerative disease with OLIF or XLIF in our center since June 2014. Patients were divided into group OLIF and group XLIF according to different operative methods. The clinical efficacy and complications of the 2 groups were compared. A P <0.05 was statistically significant.
   RESULTS: Group XLIF were aged 37-74 years (mean 58.4 years) and group OLIF were aged 39-71 years (mean 56.1 years). There were no significant differences between the 2 groups in age, sex, operation time, intraoperative bleeding volume, operation segment, and follow-up time. The incidence of complications in group XLIF was significantly lower than that in group OLIF (10% vs. 33.3%; P = 0.028).
   CONCLUSIONS: OLIF has a higher risk of neurovascular in the initial stage of learning. By contrast, the XLIF approach is simple and the incidence of complications is relatively low. Therefore, we believed that XLIF is more acceptable in the initial stage of anterolateral lumbar interbody fusion.
C1 [Li, Jiaqi; Wang, Xianzheng; Sun, Yapeng; Zhang, Fei; Gao, Yuan; Li, Zeyang; Ding, Wenyuan; Shen, Yong; Zhang, Wei] Hebei Med Univ, Hosp 3, Dept Spinal Surg, Shijiazhuang, Hebei, Peoples R China.
RP Zhang, W (reprint author), Hebei Med Univ, Hosp 3, Dept Spinal Surg, Shijiazhuang, Hebei, Peoples R China.
EM zhangweiat430@sina.com
OI Zhang, Wei/0000-0001-5972-4087
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Alimi M, 2014, J NEUROSURG-SPINE, V20, P623, DOI 10.3171/2014.1.SPINE13569
   Berjano P, 2015, EUR SPINE J, V24, pS369, DOI 10.1007/s00586-015-3929-7
   Chithriki M, 2002, SURG RADIOL ANAT, V24, P308, DOI 10.1007/s00276-002-0036-3
   Clement M, 2012, CLIOMETRICA, V6, P89, DOI 10.1007/s11698-011-0065-4
   Dakwar E, 2011, J NEUROSURG-SPINE, V14, P290, DOI 10.3171/2010.10.SPINE10395
   DEYO RA, 1993, SPINE, V18, P1463
   Grimm BD, 2016, CLIN SPINE SURG, V29, pE151, DOI 10.1097/BSD.0000000000000121
   Launay O, 2016, INSTRUMENTED PLIF LU
   Mahan MA, 2017, CLIN ANAT, V30, P479, DOI 10.1002/ca.22879
   Malham GM, 2012, THESCIENTIFICWORLDJO, V2012, DOI DOI 10.1100/2012/246989
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Mehren C, 2016, CLIN ORTHOP RELAT R, V474, P2020, DOI 10.1007/s11999-016-4883-3
   Miscusi M, 2018, EUR SPINE J, V27, P222, DOI 10.1007/s00586-018-5596-y
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Narita W, 2016, J NEUROSURG-SPINE, V25, P456, DOI 10.3171/2016.1.SPINE151069
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Okuda S, 2006, J BONE JOINT SURG AM, V88A, P2714, DOI 10.2106/JBJS.F.00186
   Orita S, 2017, SPINE, V42, P135, DOI 10.1097/BRS.0000000000001700
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Park SC, 2008, APPL SOIL ECOL, V48, P185
   Pirro N, 2005, SURG RADIOL ANAT, V27, P137, DOI 10.1007/s00276-004-0301-8
   Potter BK, 2005, J SPINAL DISORD TECH, V18, P337, DOI 10.1097/01.bsd.0000166642.69189.45
   Rodgers W B, 2010, SAS J, V4, P63, DOI 10.1016/j.esas.2010.03.001
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Rodgers WB, 2008, SPINE J S, V8, p112S
   Satake K, 2016, ASIAN SPINE J, V10, P907, DOI 10.4184/asj.2016.10.5.907
   Tohmeh AG, 2014, SPINE, V39, pE1582, DOI 10.1097/BRS.0000000000000645
   Williams AL, 2005, AM J NEURORADIOL, V26, P2057
   Woods K, 2017, CUREUS, V9, DOI 10.7759/cureus.1980
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
   Zeng ZY, 2018, ORTHOP SURG, V10, P98, DOI 10.1111/os.12380
NR 32
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E901
EP E909
DI 10.1016/j.wneu.2019.03.294
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300112
PM 30959256
DA 2020-05-12
ER

PT J
AU Li, YW
   Wang, B
   Lu, GH
   Li, L
   Dai, YL
   Tu, ZM
   Gu, HW
AF Li, Yawei
   Wang, Bing
   Lu, Guohua
   Li, Lei
   Dai, Yuliang
   Tu, Zhiming
   Gu, Haowen
TI Effects of Ho:YAG Laser Ablation on Postoperative Low Back Pain and
   Functional Status After Transforaminal Endoscopic Lumbar Discectomy:
   Minimum of 2-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic discectomy; Functional status; Ho:YAG laser; Low back pain;
   Lumbar disc herniation
ID DISC HERNIATION; INTERVERTEBRAL DISC; SURGERY; COMPLICATIONS;
   ANNULOPLASTY; OUTCOMES
AB OBJECTIVE: To evaluate effects of holmium:yttrium-aluminum-garnet (Ho:YAG) laser ablation on postoperative low back pain and improving functional status in patients with lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy (TELD).
   METHODS: The study enrolled 220 patients with lumbar disc herniation who underwent TELD or TELD with Ho:YAG laser from August 2015 to September 2016. Parameters including operative time, hospitalization, complications, and recurrence were recorded. Clinical outcomes were assessed according to visual analog scale for back pain and leg pain, Oswestry Disability Index for functional status, and modified MacNab criteria for patient satisfaction.
   RESULTS: Minimal 2-year follow-up was completed by 186 patients: 76 patients who underwent TELD and 110 patients who underwent TELD with Ho:YAG laser. In the group undergoing TELD, clinical outcomes of back pain and functional status exhibited a V-shaped upward trend after surgery; there were no statistically significant differences in visual analog scale for back pain and Oswestry Disability Index scores at final follow-up compared with preoperatively (P > 0.05). In the group undergoing TELD with Ho:YAG laser, postoperative visual analog scale for hack pain and Oswestry Disability Index scores significantly improved compared with preoperatively (P < 0.05) exhibiting relatively consistent improvement after surgery. The only laser-related complication was a burning sensation in the ipsilateral lower limb during the thermal procedure in 2 cases.
   CONCLUSIONS: Performing Ho:YAG laser ablation with TELD prolonged low back pain relief and improved functional outcome during 2-year follow-up compared with TELD alone in patients with symptomatic lumbar disc herniation.
C1 [Li, Yawei; Wang, Bing; Lu, Guohua; Li, Lei; Dai, Yuliang; Tu, Zhiming; Gu, Haowen] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
RP Wang, B (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
EM xywb801@csu.edu.cn
CR Abrishamkar Saeid, 2010, Middle East Journal of Anesthesiology, V20, P839
   Ahn Y, 2018, EXPERT REV MED DEVIC, V15, P423, DOI 10.1080/17434440.2018.1483236
   Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Choi KC, 2015, NEUROSURGERY, V76, P372, DOI 10.1227/NEU.0000000000000628
   Erdem Mehmet Nuri, 2018, J Spine Surg, V4, P414, DOI 10.21037/jss.2018.04.02
   Farrokhi MR, 2016, J NEUROSURG-SPINE, V24, P7, DOI 10.3171/2015.3.SPINE141172
   Fritsch EW, 1996, SPINE, V21, P626, DOI 10.1097/00007632-199603010-00017
   FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506
   Kim CH, 2013, SPINE, V38, P581, DOI 10.1097/BRS.0b013e318274f9a7
   Knight MTN, 2001, J CLIN LASER MED SUR, V19, P73, DOI 10.1089/104454701750285395
   Kreiner DS, 2014, SPINE J, V14, P180, DOI 10.1016/j.spinee.2013.08.003
   Lee GW, 2014, EUR J ORTHOP SURG TR, V24, P231
   Lee MH, 2016, J KOREAN NEUROSURG S, V59, P559, DOI 10.3340/jkns.2016.59.6.559
   Lee SH, 2010, WORLD NEUROSURG, V73, P198, DOI 10.1016/j.surneu.2009.01.023
   Lurie JD, 2014, SPINE, V39, P3, DOI 10.1097/BRS.0000000000000088
   Maliszewski Mariusz, 2004, Neurol Neurochir Pol, V38, P271
   Matsumoto M, 2010, J ORTHOP SCI, V15, P92, DOI 10.1007/s00776-009-1428-6
   MCCARRON RF, 1987, SPINE, V12, P760, DOI 10.1097/00007632-198710000-00009
   McGirt MJ, 2009, NEUROSURGERY, V64, P338, DOI 10.1227/01.NEU.0000337574.58662.E2
   Ozgencil E, 2011, SINGAP MED J, V52, P883
   PARKE WW, 1990, SPINE, V15, P300, DOI 10.1097/00007632-199004000-00010
   Ross JS, 1996, NEUROSURGERY, V38, P855, DOI 10.1227/00006123-199604000-00053
   Ruetten S, 2007, J NEUROSURG-SPINE, V6, P521, DOI 10.3171/spi.2007.6.6.521
   Shahbandar L, 2005, OPER TECHN SPORT MED, V13, P114, DOI 10.1053/j.otsm.2005.08.002
   Singh Vijay, 2006, Pain Physician, V9, P139
   Tsou Paul M, 2004, Spine J, V4, P564
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   Yeung AT, 2000, MT SINAI J MED, V67, P327
   Yeung AT, 2014, INT J SPINE SURG, V8, P1, DOI DOI 10.14444/1022.EC0LLECTI0N
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E793
EP E798
DI 10.1016/J.WNEU.2019.03.265
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300099
PM 30951910
DA 2020-05-12
ER

PT J
AU Liang, F
   Zhang, YP
   Yan, P
   Ma, C
   Liang, SK
   Jiang, CH
AF Liang, Fei
   Zhang, Yupeng
   Yan, Peng
   Ma, Chao
   Liang, Shikai
   Jiang, Chuhan
TI Outcomes and Complications After the Use of the Pipeline Embolization
   Device in the Treatment of Intracranial Aneurysms of the Posterior
   Circulation: A Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm obliteration; Pipeline embolization device; Posterior
   circulation aneurysm; Aneurysm obliteration; Pipeline embolization
   device; Posterior circulation aneurysm
ID ASSISTED COIL EMBOLIZATION; CEREBRAL ANEURYSMS; ARTERY ANEURYSMS; FLOW
   DIVERTOR; FUSIFORM; OCCLUSION
AB OBJECTIVE: The use of the Pipeline embolization device (PED) for posterior circulation aneurysms is controversial. The aim of this study was to explore the safety and efficacy of PED for these aneurysms in a meta-analysis. Meta-regression was used to identify predictors for incomplete aneurysm occlusion and procedure-related complications.
   METHODS: PubMed, Web of Science, and OVID data-bases were searched to identify all published references evaluating the treatment effect of PED for posterior circulation aneurysms. Only studies written in English that reported original data and included >10 cases were considered for inclusion. Patient demographics, aneurysm characteristics, angiographic outcomes, and clinical outcomes were extracted. A random-effects model was adopted to pool the obliteration rates and complication rates across selected studies. Finally, we conducted meta-regression analysis to identify predictors of angiographic outcomes.
   RESULTS: 12 studies including 358 patients with 365 aneurysms were included. The pooled complete aneurysm obliteration rate was 82% (95% confidence interval 73%-90%), and pooled procedure-related complication rate was 18% (95% confidence interval 14%-22%). Increasing age predicted incomplete obliteration of aneurysms after PED treatment in these patients (P = 0.01).
   CONCLUSIONS: PED is an alternative to treat intracranial aneurysms of the posterior circulation, achieving high complete occlusion rates, but it is less effective in elderly patients. The risk of procedure-related complications is not negligible. Further larger, long-term follow-up studies are needed before definitive conclusions can be drawn.
C1 [Liang, Fei; Zhang, Yupeng; Yan, Peng; Ma, Chao; Jiang, Chuhan] Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.
   [Liang, Fei; Zhang, Yupeng; Yan, Peng; Ma, Chao; Jiang, Chuhan] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Liang, Shikai] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
RP Jiang, CH (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Intervent Neuroradiol, Beijing, Peoples R China.; Jiang, CH (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
EM jiangchuhan126@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81371314]; High-level Personnel Training Program of
   Beijing Health System [2013-2-016]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81371314) and High-level Personnel Training Program of
   Beijing Health System (Grant No. 2013-2-016).
CR Adeeb N, 2017, AM J NEURORADIOL, V38, P2295, DOI 10.3174/ajnr.A5375
   Albuquerque FC, 2015, J NEUROINTERV SURG, V7, P641, DOI 10.1136/neurintsurg-2014-011340
   Almandoz JED, 2017, NEURORADIOLOGY, V59, P1291, DOI 10.1007/s00234-017-1930-z
   Bender MT, 2019, NEUROSURGERY, V84, P206, DOI 10.1093/neuros/nyy076
   Cognard C, 1999, RADIOLOGY, V212, P348, DOI 10.1148/radiology.212.2.r99jl47348
   Corley JA, 2018, OPER NEUROSURG, V15, P1, DOI 10.1093/ons/opx180
   Daou B, 2019, J NEUROSURG, V130, P1376, DOI 10.3171/2017.12.JNS163090
   Faria MD, 2011, AM J NEURORADIOL, V32, P2192, DOI 10.3174/ajnr.A2671
   Debette S, 2015, LANCET NEUROL, V14, P640, DOI 10.1016/S1474-4422(15)00009-5
   Fischer S, 2014, NEUROSURGERY, V75, P364, DOI 10.1227/NEU.0000000000000431
   Griessenauer CJ, 2019, J NEUROSURG, V130, P923, DOI 10.3171/2017.9.JNS171376
   Gupta R, 2018, J NEUROSURG, P1
   Kallmes DF, 2015, AM J NEURORADIOL, V36, P108, DOI 10.3174/ajnr.A4111
   Kiyofuji S, 2018, J NEUROINTERV SURG, V10, P500, DOI 10.1136/neurintsurg-2017-013312
   Klisch J, 2009, NEUROSURGERY, V65, P258, DOI 10.1227/01.NEU.0000348295.44970.C8
   Liang F, 2018, WORLD NEUROSURG, V112, pE683, DOI 10.1016/j.wneu.2018.01.129
   Lopes DK, 2018, NEUROSURGERY, V83, P488, DOI 10.1093/neuros/nyx467
   Maus V, 2018, WORLD NEUROSURG, V111, pE424, DOI 10.1016/j.wneu.2017.12.095
   Mazur MD, 2016, J NEUROINTERV SURG, V8, P1041, DOI 10.1136/neurintsurg-2015-012040
   Munich SA, 2014, J NEUROSURG, V121, P1077, DOI 10.3171/2014.7.JNS132595
   Natarajan SK, 2016, J NEUROSURG, V125, P111, DOI 10.3171/2015.6.JNS1565
   Phillips TJ, 2012, AM J NEURORADIOL, V33, P1225, DOI 10.3174/ajnr.A3166
   Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531
   Rho MH, 2013, ACTA NEUROCHIR, V155, P2009, DOI 10.1007/s00701-013-1866-y
   Shapiro M, 2012, AM J NEURORADIOL, V33, P159, DOI 10.3174/ajnr.A2719
   Srinivasan VM, 2018, J NEUROINTERV SURG, V10, P666, DOI 10.1136/neurintsurg-2017-013427
   STEINBERG GK, 1993, J NEUROSURG, V79, P161, DOI 10.3171/jns.1993.79.2.0161
   Wallace AN, 2018, WORLD NEUROSURG, V114, pE581, DOI 10.1016/j.wneu.2018.03.036
   Wallace AN, 2018, NEUROSURGERY, V83, P790, DOI 10.1093/neuros/nyx561
   Wang CB, 2016, NEURORADIOLOGY, V58, P391, DOI 10.1007/s00234-016-1649-2
   Wang J, 2018, J NEUROINTERV SURG, V10, P687, DOI 10.1136/neurintsurg-2017-013272
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 32
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E888
EP E895
DI 10.1016/j.wneu.2019.03.291
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300110
PM 30959253
DA 2020-05-12
ER

PT J
AU Liang, L
   Qu, LH
   Chu, X
   Liu, Q
   Lin, GX
   Wang, F
   Xu, SC
AF Liang, Liang
   Qu, Lianghua
   Chu, Xuan
   Liu, Qiang
   Lin, Guoxiong
   Wang, Feng
   Xu, Shengchun
TI Meningeal Architecture of the Jugular Foramen: An Anatomic Study Using
   Plastinated Histologic Sections
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnid; Dura mater; Jugular foramen; Skull base
ID MICROSURGICAL ANATOMY; VEIN
AB OBJECTIVE: This 3-dimensional histologic study aimed to provide a precise description of the meningeal structures in the jugular foramen.
   METHODS: 22 posterior skull base tissue blocks containing the jugular foramen region were obtained from 11 human cadaveric heads. These blocks were plastinated and cut into serial sections. After staining, these sections were examined under an optical microscope and used to reconstruct a 3-dimensional visualization model.
   RESULTS: At the intracranial orifice of the jugular foramen, the meningeal dura formed 2 separate dural perforations: the glossopharyngeal meatus and the vagal meatus. The arachnoid extended into 2 dural meatuses and terminated at the inferior ganglion of the glossopharyngeal nerve in the glossopharyngeal meatus and the superior ganglion of the vagus nerve in the vagal meatus. At the intraforaminal part of the jugular foramen, the meningeal dura encased the glossopharyngeal nerve to form a dural sheath while encasing the vagus and accessory nerves to form a dural network. At the extracranial orifice of the jugular foramen, the dural wall of the jugular bulb extended downward to form a dense connective tissue sheath. The initial end of the internal jugular vein invaginated into this sheath and fused with the jugular bulb.
   CONCLUSIONS: Knowledge of the anatomy of the meningeal architecture of the jugular foramen can be helpful in avoiding surgical complications of the lower cranial nerves when this complex area is approached.
C1 [Liang, Liang; Qu, Lianghua; Chu, Xuan; Liu, Qiang; Lin, Guoxiong; Wang, Feng; Xu, Shengchun] Anhui Med Univ, Dept Anat, Hefei, Anhui, Peoples R China.
   [Liang, Liang; Wang, Feng; Xu, Shengchun] Anhui Med Univ, Chinese Brain Bank, Hefei, Anhui, Peoples R China.
RP Xu, SC (reprint author), Anhui Med Univ, Dept Anat, Hefei, Anhui, Peoples R China.; Xu, SC (reprint author), Anhui Med Univ, Chinese Brain Bank, Hefei, Anhui, Peoples R China.
EM xsc@ahmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31500967, 81671368]; Grants for Scientific Research
   of BSKY from Anhui Medical University [XJ201501]
FX This study was supported by the National Natural Science Foundation of
   China (Reference Nos. 31500967, 81671368) and the Grants for Scientific
   Research of BSKY (Reference No. XJ201501) from Anhui Medical University.
CR Aydin H, 2011, DIAGN INTERV RADIOL, V17, P3, DOI 10.4261/1305-3825.DIR.2744-09.3
   AYENI SA, 1995, J NEUROSURG, V83, P903, DOI 10.3171/jns.1995.83.5.0903
   Bernard F, 2018, J NEUROSURG, V129, P770, DOI 10.3171/2017.1.JNS161890
   DODO Y, 1986, J ANAT, V144, P153
   Feng H, 2012, J CRANIOFAC SURG, V23, P1181, DOI 10.1097/SCS.0b013e3182565ba4
   Griessenauer CJ, 2016, J NEUROL SURG PART B, V77, P260, DOI 10.1055/s-0035-1567863
   Katsuta T, 1997, NEUROSURGERY, V41, P149, DOI 10.1097/00006123-199707000-00030
   Komune N, 2019, WORLD NEUROSURG, V126, pE500, DOI 10.1016/j.wneu.2019.02.078
   KVETON JF, 1988, AM J OTOL, V9, P109
   Manjila S, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18106
   Matsushima K, 2015, OPER NEUROSURG, V11, P135, DOI 10.1227/NEU.0000000000000570
   Matsushima K, 2014, J NEUROSURG, V121, P397, DOI 10.3171/2014.3.JNS132419
   Matsushima K, 2014, NEUROSURG REV, V37, P115, DOI 10.1007/s10143-013-0493-7
   Mizutani K, 2018, WORLD NEUROSURG, V120, P405, DOI 10.1016/j.wneu.2018.09.067
   Noble DJ, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160392
   Ota N, 2017, OPER NEUROSURG, V13, P382, DOI 10.1093/ons/opw038
   Papini Giacomo Davide Edoardo, 2017, Eur Radiol Exp, V1, P4, DOI 10.1186/s41747-017-0008-3
   Qian ZH, 2018, J CRANIOFAC SURG, V29, P787, DOI 10.1097/SCS.0000000000004234
   Rhoton AL, 2000, NEUROSURGERY, V47, pS267, DOI 10.1097/00006123-200009001-00026
   RHOTON AL, 1975, J NEUROSURG, V42, P541, DOI 10.3171/jns.1975.42.5.0541
   Sen C, 2001, NEUROSURGERY, V48, P838, DOI 10.1097/00006123-200104000-00029
   SHAPIRO R, 1972, J NEUROSURG, V36, P340, DOI 10.3171/jns.1972.36.3.0340
   Sutiono AB, 2011, NEUROSURGERY, V69, P230, DOI 10.1227/NEU.0b013e31822a19a3
   Tanoue S, 2010, BRIT J RADIOL, V83, P831, DOI 10.1259/bjr/85248833
   Tubbs RS, 2015, J NEUROL SURG PART B, V76, P214, DOI 10.1055/s-0034-1543973
   Tummala RP, 2005, OPER TECH NEUROSURG, V8, P2
   Van Osch K, 2019, J OTOLARYNGOL-HEAD N, V48, DOI 10.1186/s40463-019-0324-0
   Vlajkovic S, 2010, MED SCI MONITOR, V16, pBR140
NR 28
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E809
EP E817
DI 10.1016/j.wneu.2019.03.272
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300101
PM 30954756
DA 2020-05-12
ER

PT J
AU Lin, D
   Wang, Y
   Zhou, ZQ
   Lin, ZX
AF Lin, Da
   Wang, Ye
   Zhou, Zhongqing
   Lin, Zhixiong
TI Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A
   Study of the Differences and Clinical Significance
SO WORLD NEUROSURGERY
LA English
DT Article
DE CD8+T cell; Craniopharyngioma; Immune microenvironment; Ki67; M2
   macrophages; Programmed cell death 1 ligand 1
ID TUMOR-ASSOCIATED MACROPHAGES; SURGICAL-TREATMENT; NIVOLUMAB; REVEALS;
   PD-1
AB OBJECTIVE: This study explored the differences between the immune microenvironments of primary and recurrent craniopharyngiomas (CPs). In addition, we investigated the relationship between the immune microenvironment and clinical characteristics of CP.
   METHODS: We collected 52 specimens from 26 patients with CPs. For each patient, specimens for both primary and recurrent CPs were obtained. We performed an immunohistochemical analysis of these specimens to determine the distributions of M2 macrophages, CD8+ T cells, programmed cell death 1 ligand 1 (PD-L1), and Ki67.
   RESULTS: In recurrent CP specimens, the distributions of M2 macrophages, Ki67, and PD-L1 increased compared with primary CP specimens (P = 0.019, P = 0.0084, and P = 0.0319, respectively). Moreover, the distributions of M2 macrophages, CD8+ Tcells, and PD-L1 in papillary CPswere higher than those observed in adamantinomatous craniopharyngiomas (ACPs) (P = 0.0317, P = 0.0359, and P < 0.0001, respectively). In the adult ACP group, M2 macrophages, CD8+ Tcells, and PD-L1weremore abundant/expressed than in the child ACP group (P = 0.0159, P = 0.0215, and P < 0.0088, respectively). A positive correlation was found between M2 macrophages and CD8+ T cells (r = 0.4079; P = 0.0027). Correspondingly, M2 macrophages and CD8+ T cells were both positively correlated with PD-L1 (r = 0.4564; P = 0.0007 and r = 0.3987; P = 0.0034, respectively). The observed high expression of M2 macrophages in primary CPs suggests a shortened time for tumor recurrence (P = 0.0131).
   CONCLUSIONS: The microenvironment of recurrent CP varies from that of primary CP. The abundance of M2 macrophages in primary CP may indicate a risk of early recurrence. Therefore, it is recommended to increase the frequency of follow-up examinations in these patients.
C1 [Lin, Da; Lin, Zhixiong] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Wang, Ye; Zhou, Zhongqing; Lin, Zhixiong] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Lin, ZX (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.; Lin, ZX (reprint author), Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM LIN_ZX1967@163.com
CR ADAMSON TE, 1990, J NEUROSURG, V73, P12, DOI 10.3171/jns.1990.73.1.0012
   Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310
   Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, P1
   Bunin GR, 1998, J NEUROSURG, V89, P547, DOI 10.3171/jns.1998.89.4.0547
   Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493
   Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670
   Coy S, 2018, NEURO-ONCOLOGY, V20, P1101, DOI 10.1093/neuonc/noy035
   Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
   Donson AM, 2017, J NEUROPATH EXP NEUR, V76, P779, DOI 10.1093/jnen/nlx061
   Fahlbusch R, 1999, J NEUROSURG, V90, P237, DOI 10.3171/jns.1999.90.2.0237
   Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104
   Jeong TS, 2017, J KOREAN NEUROSURG S, V60, P108, DOI 10.3340/jkns.2015.0707.022
   Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5
   Karavitaki N, 2008, ENDOCRIN METAB CLIN, V37, P173, DOI 10.1016/j.ecl.2007.10.012
   Kim SK, 2001, CHILD NERV SYST, V17, P531, DOI 10.1007/s003810100458
   Losa M, 2004, J NEUROL NEUROSUR PS, V75, P889, DOI 10.1136/jnnp.2003.012781
   Muller HL, 2017, NAT REV ENDOCRINOL, V13, P299, DOI 10.1038/nrendo.2016.217
   Munhoz RR, 2018, CANCER J, V24, P7, DOI 10.1097/PPO.0000000000000299
   Nishi T, 1999, INT J MOL MED, V3, P157
   Parra ER, 2017, SCI REP, V7, P1, DOI DOI 10.3174/AJNR.A2906
   Prieto R, 2013, WORLD NEUROSURG, V79, P733, DOI 10.1016/j.wneu.2012.07.033
   Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016
   Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9
   Robinson LC, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16308
   Shi XE, 2017, WORLD NEUROSURG, V102, P167, DOI 10.1016/j.wneu.2017.02.095
   Turel MK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16315
   Zhu WC, 2017, CHILD NERV SYST, V33, P1491, DOI 10.1007/s00381-017-3473-3
NR 31
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E212
EP E220
DI 10.1016/j.wneu.2019.02.212
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300029
PM 30880197
DA 2020-05-12
ER

PT J
AU Lin, GX
   Kim, JS
   Sharma, S
   Sun, LW
   Wu, HH
   Chang, KS
   Chen, YC
   Chen, CM
AF Lin, Guang-Xun
   Kim, Jin-Sung
   Sharma, Sagar
   Sun, Li-Wei
   Wu, Hsuan-Han
   Chang, Kai-Sheng
   Chen, Ying-Chieh
   Chen, Chien-Min
TI Full Endoscopic Discectomy, Debridement, and Drainage for High-Risk
   Patients with Spondylodiscitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic debridement; Infectious spondylodiscitis; Minimally invasive
   surgery; Percutaneous endoscopic drainage
ID PYOGENIC SPONDYLODISCITIS; ANTERIOR DEBRIDEMENT; MANAGEMENT; FUSION;
   FIXATION; BIOPSY
AB OBJECTIVE: To evaluate the efficacy and clinical results of full endoscopic debridement and drainage (FEDD) for high-risk patients with spondylodiscitis.
   METHODS: Fourteen patients who underwent FEDD at our institution between November 2015 and September 2017 were retrospectively reviewed. All patients had single-level infectious spondylodiscitis and were high- risk candidates for surgery. Their general condition was evaluated according to the American Society of Anesthesiologists grading system. The Charlson Comorbidity Index was used for comprehensive assessment of comorbidity status. Outcomes were evaluated by numeric rating scale (NRS) pain score, Oswestry Disability Index, modified Macnab criteria, and radiographic images at follow-up.
   RESULTS: All 14 patients experienced immediate relief of back pain after FEDD, with no procedure-related complications. The causative bacteria were identified in 10 of the 14 patients (71.5%). Half of the 14 patients had an American Society of Anesthesiologists score of >= 3. The average Charlson Comorbidity Index was 5.1 +/- 1.6 points. Compared with the preoperative NRS score of 8.2 +/- 0.9, the NRS scores at 1 week and 12 months after surgery were 3.4 +/- 1.1 and 1.4 +/- 1.2, respectively. A significant improvement in Oswestry Disability Index was observed after surgery (preoperative, 30.1 +/- 3.9; 12 months postoperatively, 17.6 +/- 6.2; P < 0.05). Satisfaction rate was 85.7% based on the Macnab criteria (excellent or good outcome). None of the patients developed any significant kyphotic deformity after FEDD.
   CONCLUSIONS: FEDD may be an effective alternative to extensive open surgery in patients with infectious spondylodiscitis, especially those who are high-risk candidates for surgery (elderly patients with multiple comorbidities and patients in poor general condition).
C1 [Lin, Guang-Xun; Kim, Jin-Sung; Sharma, Sagar] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Lin, Guang-Xun] Xiamen Univ, Dept Orthoped, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China.
   [Sun, Li-Wei; Wu, Hsuan-Han; Chang, Kai-Sheng; Chen, Ying-Chieh; Chen, Chien-Min] Changhua Christian Hosp, Div Neurosurg, Dept Surg, Changhua, Taiwan.
   [Chen, Chien-Min] Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.
   [Chen, Chien-Min] Dayeh Univ, Coll Nursing & Hlth Sci, Dacun, Changhua, Taiwan.
RP Chen, CM (reprint author), Changhua Christian Hosp, Div Neurosurg, Dept Surg, Changhua, Taiwan.; Chen, CM (reprint author), Kaohsiung Med Univ, Sch Med, Kaohsiung, Taiwan.; Chen, CM (reprint author), Dayeh Univ, Coll Nursing & Hlth Sci, Dacun, Changhua, Taiwan.
EM 96015@cch.org.tw
RI Kim, Jin-Sung/Y-2904-2019; Sharma, Sagar/AAG-5911-2020
OI Kim, Jin-Sung/0000-0001-5086-0875; Sharma, Sagar/0000-0002-2559-6010
FU China Scholarship Council (CSC)China Scholarship Council [[2016]3100]
FX The author Gaung-Xun Lin would like to give thanks for China Scholarship
   Council (CSC, number [2016]3100).
CR Ahn Y, 2012, BRIT J NEUROSURG, V26, P482, DOI 10.3109/02688697.2011.650739
   Bavinzski G, 2003, NEUROSURG REV, V26, P102, DOI 10.1007/s10143-002-0241-x
   Chen HC, 2015, BIOMED RES INT, V2015
   Dimar JR, 2004, SPINE, V29, P326, DOI 10.1097/01.BRS.0000109410.46538.74
   Frangen TM, 2006, UNFALLCHIRURG, V109, P743, DOI 10.1007/s00113-006-1084-7
   Fu TS, 2010, MINIM INVASIV THER, V19, P42, DOI 10.3109/13645700903384450
   Guerado E, 2012, INT ORTHOP, V36, P413, DOI 10.1007/s00264-011-1441-1
   Haaker R G, 1997, Eur Spine J, V6, P98, DOI 10.1007/BF01358740
   Hadjipavlou AG, 2000, SPINE, V25, P1668, DOI 10.1097/00007632-200007010-00010
   Herren C, 2017, DTSCH ARZTEBL INT, V114, P875, DOI 10.3238/arztebl.2017.0875
   Ito M, 2007, SPINE, V32, P200, DOI 10.1097/01.brs.0000251645.58076.96
   Kim BJ, 2013, AM J NEURORADIOL, V34, P233, DOI 10.3174/ajnr.A3120
   Korovessis Panagiotis, 2008, Spine (Phila Pa 1976), V33, pE759, DOI 10.1097/BRS.0b013e318187875e
   Lin CP, 2012, SPINE, V37, pE1572, DOI 10.1097/BRS.0b013e31827399b8
   Lin Y, 2015, J NEUROSURG-SPINE, V23, P747, DOI 10.3171/2015.5.SPINE14876
   Michiels I, 2017, ORTHOPADE, V46, P785, DOI 10.1007/s00132-017-3436-0
   Paulson EK, 2001, RADIOLOGY, V220, P161, DOI 10.1148/radiology.220.1.r01jl29161
   Rankine JJ, 2004, POSTGRAD MED J, V80, P607, DOI 10.1136/pgmj.2003.017863
   Rezai AR, 1999, NEUROSURGERY, V44, P1018, DOI 10.1097/00006123-199905000-00047
   Rutges JPHJ, 2016, EUR SPINE J, V25, P983, DOI 10.1007/s00586-015-4318-y
   Sobottke R, 2009, Spine (Phila Pa 1976), V34, pE452, DOI 10.1097/BRS.0b013e3181a0aa5b
   Yang SC, 2007, INT ORTHOP, V31, P367, DOI 10.1007/s00264-006-0188-6
   Yang SC, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-105
   Yang SC, 2014, EUR SPINE J, V23, P846, DOI 10.1007/s00586-013-3157-y
   Yang SC, 2008, CLIN ORTHOP RELAT R, V466, P3086, DOI 10.1007/s11999-008-0441-y
   Zarghooni K, 2012, INT ORTHOP, V36, P405, DOI 10.1007/s00264-011-1425-1
NR 26
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E202
EP E211
DI 10.1016/j.wneu.2019.02.206
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300028
PM 30878748
DA 2020-05-12
ER

PT J
AU Lin, MH
   Hu, TT
   Yan, L
   Xiao, DD
   Zhao, HY
   Yan, PF
AF Lin, Minhua
   Hu, Tingting
   Yan, Ling
   Xiao, Dongdong
   Zhao, Hongyang
   Yan, Pengfei
TI Can Systemic Inflammatory Markers Be Used to Predict the Pathological
   Grade of Meningioma Before Surgery?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningioma; Neurosurgery; Preoperative diagnosis; Systemic inflammatory
   marker
ID MODULATORY MOLECULE PD-L1; REGULATORY T-CELLS; PATHODIAGNOSTIC
   PARAMETERS; PROGNOSTIC-FACTORS; MRI; EXPRESSION; SURVIVAL; ASSOCIATION;
   DIAGNOSIS; IMPACT
AB BACKGROUND: We sought to determine whether systemic inflammatory markers (SIMs) can be used to predict the pathological grade of meningioma before surgery.
   METHODS: Patients with histopathologically proven intracranial meningiomas who had undergone surgery from January 2014 to April 2018 were identified. The 14 most recent SIM levels measured before surgery were retrieved. The Mann-Whitney U test was used to determine the statistically significant differences between groups. Receiver operating characteristic curves were constructed, and the areas under the curve (AUC) were calculated to assess the diagnostic value of each biomarker. Predictive models built with biomarker pairs using logistic regression or support vector machine classifiers were used to assess their combined performance.
   RESULTS: A total of 672 patients with 575 and 97 low-grade and high-grade meningiomas, respectively, were investigated. Of the 14 SIMS, 7 differed significantly between the 2 meningioma groups. However, receiver operating characteristic analysis showed that none of these 7 SIMs alone could predict for the meningioma grade; the highest AUC was 0.61. Two biomarkers (erythrocyte and neutrophil/lymphocyte ratio) were incorporated into the logistic regression model; the corresponding AUC was 0.64. Moreover, 21 biomarker pairs were used to train the support vector machine classifiers; the AUCs of 6 pairs were >0.55; the maximum AUC was 0.60.
   CONCLUSIONS: SIMs obtained from routine preoperative laboratory testing had a limited ability to differentiate low- and high-grade meningioma in our cohort of 672 patients. Further prospective, multicenter studies with larger sample sizes are warranted to confirm this finding.
C1 [Lin, Minhua; Hu, Tingting; Xiao, Dongdong; Zhao, Hongyang; Yan, Pengfei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Yan, Ling] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
RP Yan, PF (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM yanpfei@hust.edu.cn
CR Aizer AA, 2015, CANCER-AM CANCER SOC, V121, P4376, DOI 10.1002/cncr.29639
   Akai T, 2004, NEUROL MED-CHIR, V44, P600, DOI 10.2176/nmc.44.600
   Alexiou GA, 2010, CLIN NEUROL NEUROSUR, V112, P177, DOI 10.1016/j.clineuro.2009.12.011
   Aziz MH, 2018, ANN SURG, DOI [10.1097/SLA, DOI 10.1097/SLA]
   Chen M, 2018, J NEURO-ONCOL, V138, P113, DOI 10.1007/s11060-018-2776-x
   Choi ES, 2014, ANN SURG ONCOL, V21, P778, DOI 10.1245/s10434-013-3418-3
   Cornelius JF, 2012, NEUROSURGERY, V70, P1033, DOI 10.1227/NEU.0b013e31823bcd87
   Crane CA, 2012, NEURO-ONCOLOGY, V14, P584, DOI 10.1093/neuonc/nos014
   Czyz M, 2017, NEUROSURGERY, V80, P300, DOI 10.1093/neuros/nyw030
   Domingues PH, 2012, AM J PATHOL, V181, P1749, DOI 10.1016/j.ajpath.2012.07.033
   Du ZM, 2015, ONCOTARGET, V6, P4704, DOI 10.18632/oncotarget.3082
   Fang LJ, 2013, NEURO-ONCOLOGY, V15, P1479, DOI 10.1093/neuonc/not110
   Fankhauser CD, 2018, BRIT J CANCER, V118, P825, DOI 10.1038/bjc.2017.467
   Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004
   Han SJ, 2016, J NEURO-ONCOL, V130, P543, DOI 10.1007/s11060-016-2256-0
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320
   Jabini R, 2014, GENE, V538, P348, DOI 10.1016/j.gene.2013.12.039
   Jensen RL, 2009, J NEURO-ONCOL, V92, P317, DOI 10.1007/s11060-009-9827-2
   Kawahara Y, 2012, J NEURO-ONCOL, V108, P147, DOI 10.1007/s11060-012-0809-4
   Lin BJ, 2014, J NEUROSURG, V121, P1201, DOI 10.3171/2014.7.JNS132359
   Mangubat EZ, 2010, SKULL BASE-INTERD AP, V20, P469, DOI 10.1055/s-0030-1261266
   Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2
   Moradi A, 2008, J CLIN NEUROSCI, V15, P1370, DOI 10.1016/j.jocn.2007.12.005
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Park BK, 2016, J SURG ONCOL, V114, P216, DOI 10.1002/jso.24299
   Polyzoidis S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0388-3
   Qi Q, 2015, PANCREATOLOGY, V15, P145, DOI 10.1016/j.pan.2014.12.004
   Rassouli A, 2015, HEAD NECK-J SCI SPEC, V37, P103, DOI 10.1002/hed.23567
   Reszec J, 2013, J NEURO-ONCOL, V115, P119, DOI 10.1007/s11060-013-1208-1
   Surov A, 2016, WORLD NEUROSURG, V88, P598, DOI 10.1016/j.wneu.2015.10.049
   Surov A, 2015, TRANSL ONCOL, V8, P517, DOI 10.1016/j.tranon.2015.11.012
   Wulaningsih W, 2015, CARCINOGENESIS, V36, P1121, DOI 10.1093/carcin/bgv096
   Xu WS, 2018, J NEURO-ONCOL, V137, P279, DOI 10.1007/s11060-017-2714-3
   Yan PF, 2017, TRANSL ONCOL, V10, P570, DOI 10.1016/j.tranon.2017.04.006
   Yan PF, 2016, INT J SURG, V36, P109, DOI 10.1016/j.ijsu.2016.10.023
   Zheng SH, 2018, J NEUROSURG, V129, P583, DOI 10.3171/2017.3.JNS161648
   Zikou A, 2016, CLIN NEUROL NEUROSUR, V146, P109, DOI 10.1016/j.clineuro.2016.05.005
NR 38
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E677
EP E684
DI 10.1016/j.wneu.2019.03.241
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300084
PM 30947006
DA 2020-05-12
ER

PT J
AU Liu, JG
   Gao, GZ
   Zhang, SM
   Huang, YB
   Wu, J
   Hu, XH
   Lu, J
   Zhang, Q
   Zhou, L
   Huang, YL
AF Liu, Jiangang
   Gao, Guangzhong
   Zhang, Shiming
   Huang, Yabo
   Wu, Jiang
   Hu, Xiaohui
   Lu, Jun
   Zhang, Qin
   Zhou, Lei
   Huang, Yulun
TI Cotton-Assisted Surgical Clipping of Very Small Aneurysms: A Two-Center
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Cotton pads; Treatment outcome; Very small aneurysm
ID BLISTER-LIKE ANEURYSMS; CEREBRAL ANEURYSMS; FOLLOW-UP; EMBOLIZATION;
   OUTCOMES
AB OBJECTIVE: Very small intracranial aneurysms (VSIAs) are challenging to treat because aneurysm tearing and clip slippage can occur during neurosurgical clipping. In this study, we introduce and share our experience with cotton-assisted clipping of VSIAs.
   METHODS: We retrospectively analyzed the data of 20 patients with 24 VSIAs treated with cotton-assisted clipping between February 2008 and December 2014 in the Neurosurgery Departments of the First Affiliated Hospital, Soochow University and Taizhou People's Hospital. During surgery, 2 aneurysm necks were torn. To treat the tears, we wrapped rectangular cotton pads around the parental arteries at the site of rupture. The remaining 22 aneurysms were clipped after being wrapped in cotton pads.
   RESULTS: The 2 aneurysm ruptures were successfully repaired with cotton-assisted clipping. In the remaining 22 aneurysms, no cases of aneurysm clip slippage or aneurysm rupture occurred. Patients were followed up on average for 59.0 months (range, 30-113 months). Of the 20 patients, the 16 patients with preoperative Hunt-Hess grades of 1-3 recovered well after the surgery (Glasgow Outcome Scale [GOS] score, 5). Of the 4 patients with Hunt-Hess grades of 4-5, 3 had a good recovery (GOS scores, 4-5), and 1 patient died of heart disease 6 months after being discharged from the hospital; this patient had a GOS score of 4 at the time of discharge.
   CONCLUSIONS: Cotton-assisted clipping could prevent aneurysm clip slipping and aneurysm rupture and facilitate the repair of aneurysm neck tears. This technique is a useful alternative therapy for VSIAs.
C1 [Liu, Jiangang; Zhang, Shiming; Huang, Yabo; Wu, Jiang; Hu, Xiaohui; Zhou, Lei; Huang, Yulun] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China.
   [Gao, Guangzhong; Lu, Jun; Zhang, Qin] Taizhou Peoples Hosp, Dept Neurosurg, Taizhou, Jiangsu, Peoples R China.
RP Zhang, SM (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China.
EM shmzhang2004@aliyun.com
OI Huang, Yabo/0000-0001-8372-1492
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China [HX12201118]; Scientific Research of Jiangsu Commission of
   Health [H2018065]; Suzhou Basic Research on Science and Technology
   [SYS201535]
FX The present study was supported by the National Science Foundation of
   China (No. HX12201118), Scientific Research of Jiangsu Commission of
   Health (No. H2018065), and Suzhou Basic Research on Science and
   Technology (No. SYS201535).
CR Barrow DL, 2011, NEUROSURGERY, V68, P294, DOI 10.1227/NEU.0b013e31821343c6
   Brinjikji W, 2010, STROKE, V41, P116, DOI 10.1161/STROKEAHA.109.566356
   Bruneau M, 2016, NEUROSURGERY, V78, P47, DOI 10.1227/NEU.0000000000000991
   Chalouhi N, 2014, NEUROSURGERY, V74, P527, DOI 10.1227/NEU.0000000000000309
   David CA, 1999, J NEUROSURG, V91, P396, DOI 10.3171/jns.1999.91.3.0396
   Feng YG, 2013, CLIN NEUROL NEUROSUR, V115, P2284, DOI 10.1016/j.clineuro.2013.07.034
   Hwang JH, 2011, NEURORADIOLOGY, V53, P349, DOI 10.1007/s00234-010-0735-0
   Kalani MYS, 2013, NEUROSURGERY, V73, P1026, DOI 10.1227/NEU.0000000000000147
   Lim YC, 2008, NEURORADIOLOGY, V50, P423, DOI 10.1007/s00234-008-0365-y
   Lim YC, 2013, NEUROSURGERY, V73, P480, DOI 10.1227/NEU.0000000000000005
   Lin FX, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.070
   Malinova V, 2015, CLIN NEUROL NEUROSUR, V137, P79, DOI 10.1016/j.clineuro.2015.06.021
   Mizoi K, 1995, SURG NEUROL, V44, P114, DOI 10.1016/0090-3019(95)00035-6
   Mooney MA, 2015, OPER NEUROSURG, V11, P387, DOI 10.1227/NEU.0000000000000866
   Pierot L, 2010, STROKE, V41, P2855, DOI 10.1161/STROKEAHA.110.588830
   Safavi-Abbasi S, 2015, NEUROSURG FOCUS, V38
   Safavi-Abbasi S, 2016, J NEUROSURG, V125, P720, DOI 10.3171/2015.7.JNS151165
   Schuette AJ, 2011, NEUROSURGERY, V68, P731, DOI 10.1227/NEU.0b013e3182077373
   Strickland BA, 2016, J CLIN NEUROSCI, V34, P6, DOI 10.1016/j.jocn.2016.05.009
   van Rooij WJ, 2009, AM J NEURORADIOL, V30, P835, DOI 10.3174/ajnr.A1429
   Yoon JW, 2014, NEUROSURGERY, V75, P419, DOI 10.1227/NEU.0000000000000487
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E242
EP E250
DI 10.1016/j.wneu.2019.02.227
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300033
PM 30885863
DA 2020-05-12
ER

PT J
AU Lochte, BC
   Carroll, KT
   Hirshman, B
   Lanman, T
   Carter, B
   Chen, CC
AF Lochte, Bryson C.
   Carroll, Kate T.
   Hirshman, Brian
   Lanman, Tyler
   Carter, Bob
   Chen, Clark C.
TI Smoking As a Risk Factor for Postcraniotomy 30-Day Mortality
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Risk factors; Smoking
ID CIGARETTE-SMOKING; POSTOPERATIVE COMPLICATIONS; BLOOD-FLOW; CESSATION
   INTERVENTION; THORACIC SURGEONS; FACE LIFT; IMPACT; CHILDREN;
   INFLAMMATION; REPLACEMENT
AB BACKGROUND: There is limited information on the impact of smoking on postcraniotomy mortality. In this study we used the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) to examine this issue.
   METHODS: We identified 16,280 postcraniotomy patients in the ACS-NSQIP database. Indications for surgery were categorized by vascular, trauma, epilepsy, malignant tumor, and benign tumor. Univariate and multivariable logistic regression analyses were used to identify risk factors associated with mortality.
   RESULTS: In the ACS-NSQIP dataset, postcraniotomy mortality within 30 days of surgery was 5.03%. An area under the curve analysis indicated 30 pack-years as the optimal discriminating threshold for risk stratification in terms of 30-day postcraniotomy mortality. Using this threshold, multivariate analyses revealed 3 variables that were closely associated with 30-day post-craniotomy mortality: male gender (P = 0.002), indication for operation (P< 0.001), and a smoking history of >= 30 pack-years (P < 0.001). In subsequent stratified analyses, smoking-associated mortality risk was observed only in males (odds ratio of 2.33 comparing males with <= 30 and <30 pack-years of smoking history; 97.5% confidence interval 1.36-4.03). When the analysis was further stratified by surgical indications, the mortality association with smoking was found only in male patients who underwent craniotomy as treatment for neurovascular diseases (odds ratio 3.88, 97.5% confidence interval 1.39-11.65). Such an association was not seen in patients who underwent craniotomy for traumatic brain injury, malignant tumors, benign tumors, or epilepsy.
   CONCLUSIONS: This study identified >= 30 pack-years as a risk factor for male patients undergoing craniotomy as treatment for neurovascular diseases.
C1 [Lochte, Bryson C.; Carroll, Kate T.; Hirshman, Brian; Lanman, Tyler; Carter, Bob; Chen, Clark C.] Univ Calif San Diego, Dept Neurosurg, La Jolla, CA 92093 USA.
RP Chen, CC (reprint author), Univ Calif San Diego, Dept Neurosurg, La Jolla, CA 92093 USA.
EM clarkchen@ucsd.edu
CR Bilimoria KY, 2013, J AM COLL SURGEONS, V217, P833, DOI 10.1016/j.jamcollsurg.2013.07.385
   Bluman LG, 1998, CHEST, V113, P883, DOI 10.1378/chest.113.4.883
   Boms N, 2010, J VASC RES, V47, P214, DOI 10.1159/000255964
   Chu H, 2014, ONCOL LETT, V8, P1477, DOI 10.3892/ol.2014.2374
   Dinc N, 2017, WORLD NEUROSURG, V99, P566, DOI 10.1016/j.wneu.2016.12.079
   Drannik AG, 2004, AM J RESP CRIT CARE, V170, P1164, DOI 10.1164/rccm.200311-1521OC
   Drongowski RA, 2003, PAEDIATR ANAESTH, V13, P304, DOI 10.1046/j.1460-9592.2003.01100.x
   Esmon CT, 2009, BLOOD REV, V23, P225, DOI 10.1016/j.blre.2009.07.002
   Garey KW, 2004, CHEST, V125, P22, DOI 10.1378/chest.125.1.22
   Gastaldelli A, 2010, CURR PHARM DESIGN, V16, P2526, DOI 10.2174/138161210792062858
   JENSEN JA, 1991, ARCH SURG-CHICAGO, V126, P1131
   Johans SJ, 2017, WORLD NEUROSURG, V107, P216, DOI [10.1016/j.wneu.2017.07.177, 10.1016/J.WNEU.2017.07.177]
   Khullar D, 2012, J AM COLL SURGEONS, V215, P418, DOI 10.1016/j.jamcollsurg.2012.05.023
   Krishnamurthy S, 2007, NEUROSURGERY, V61, P475, DOI 10.1227/01.NEU.0000290892.46954.12
   Krueger JK, 2001, PLAST RECONSTR SURG, V108, P1063, DOI 10.1097/00006534-200109150-00042
   Lau D, 2012, J NEUROSURG, V116, P1204, DOI 10.3171/2012.3.JNS111783
   Lindstrom D, 2008, ANN SURG, V248, P739, DOI 10.1097/SLA.0b013e3181889d0d
   Litvack ZN, 2009, NEUROSURGERY, V65, P890, DOI 10.1227/01.NEU.0000356970.22315.BC
   Lyons B, 1996, ANAESTHESIA, V51, P324, DOI 10.1111/j.1365-2044.1996.tb07740.x
   Mason DP, 2009, ANN THORAC SURG, V88, P362, DOI 10.1016/j.athoracsur.2009.04.035
   Mills E, 2011, AM J MED, V124, P144, DOI 10.1016/j.amjmed.2010.09.013
   Monfrecola G, 1998, DERMATOLOGY, V197, P115, DOI 10.1159/000017980
   Nasell H, 2010, J BONE JOINT SURG AM, V92A, P1335, DOI 10.2106/JBJS.I.00627
   O'Rourke JM, 2006, PEDIATR ANESTH, V16, P560, DOI 10.1111/j.1460-9592.2005.01821.x
   Owen D, 2007, INT J CLIN PRACT, V61, P2002, DOI 10.1111/j.1742-1241.2007.01565..x
   PEARCE AC, 1984, ANESTHESIOLOGY, V61, P576, DOI 10.1097/00000542-198411000-00018
   Peolsson A, 2006, ACTA NEUROCHIR, V148, P167, DOI 10.1007/s00701-005-0660-x
   REES TD, 1984, PLAST RECONSTR SURG, V73, P911, DOI 10.1097/00006534-198406000-00009
   RIEFKOHL R, 1986, PLAST RECONSTR SURG, V77, P592, DOI 10.1097/00006534-198604000-00013
   Rosenberger PH, 2006, J AM ACAD ORTHOP SUR, V14, P397, DOI 10.5435/00124635-200607000-00002
   Sanden B, 2011, SPINE, V36, P1059, DOI 10.1097/BRS.0b013e3181e92b36
   SARIN CL, 1974, JAMA-J AM MED ASSOC, V229, P1327, DOI 10.1001/jama.229.10.1327
   Shi Y, 2011, ANESTHESIOLOGY, V115, P12, DOI 10.1097/ALN.0b013e3182207bde
   Shi Y, 2010, ANESTHESIOLOGY, V112, P102, DOI 10.1097/ALN.0b013e3181c61cf9
   Shroyer ALW, 2003, ANN THORAC SURG, V75, P1856, DOI 10.1016/S0003-4975(03)00179-6
   Singh JA, 2011, ARTHRIT CARE RES, V63, P1365, DOI 10.1002/acr.20555
   Sorensen LT, 2012, ARCH SURG-CHICAGO, V147, P373, DOI 10.1001/archsurg.2012.5
   Stevenson JC, 2007, MATURITAS, V57, P31, DOI 10.1016/j.maturitas.2007.02.007
   Teede HJ, 1999, J AM COLL CARDIOL, V34, P131, DOI 10.1016/S0735-1097(99)00155-2
   Theadom A, 2006, TOB CONTROL, V15, P352, DOI 10.1136/tc.2005.015263
   Tonnesen H, 2011, ANESTHESIOLOGY, V115, P1, DOI 10.1097/ALN.0b013e31822085f3
   Turan A, 2011, ANESTHESIOLOGY, V114, P837, DOI 10.1097/ALN.0b013e318210f560
   Walcott BP, 2014, J NEUROSURG, V120, P278, DOI 10.3171/2013.8.JNS13703
   Warner DO, 2005, MAYO CLIN PROC, V80, P252, DOI 10.4065/80.2.252
   WEBSTER RC, 1986, PLAST RECONSTR SURG, V77, P596, DOI 10.1097/00006534-198604000-00014
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E400
EP E406
DI 10.1016/j.wneu.2019.03.138
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300050
PM 30910752
DA 2020-05-12
ER

PT J
AU Luo, W
   Xu, YL
   Yang, J
   Liu, ZM
   Liu, H
AF Luo, Wei
   Xu, Yulun
   Yang, Jun
   Liu, Zhongmin
   Liu, Hai
TI Fourth Ventricular Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical features; Fourth ventricle; Imaging features; Meningiomas;
   Treatment
ID CLEAR-CELL MENINGIOMA; INTRAVENTRICULAR MENINGIOMAS; SINGLE-INSTITUTION;
   4TH-VENTRICLE; DIAGNOSIS; SERIES; TUMORS; ADULT
AB OBJECTIVE: Fourth ventricular meningiomas (FVMs) are extremely rare. Here, we report a series of 11 patients at a single institution. A comprehensive literature analysis is conducted.
   METHODS: Information about 11 patient was extracted from the patient data. Reports of cases in English were obtained from the literature. Including our 11 patients, 71 patients were analyzed in this study.
   RESULTS: The most common age of onset was from the third decade to sixth decade of life. The female/male ratio was about 1.16:1. The most frequent subtype of meningioma was fibrous meningioma. FVMs had specific imaging features, such as calcification (20%), peritumoral edema (30.3%), heterogeneous enhancement (22.5%), cystic formation (4.3%), and hydrocephalus (52.8%). The proportion of total tumor resection was about 94.9%, with 15.3% of postoperative complications. During follow-up, the recurrent rate of FVMs was about 6.8%. There was no significant difference in the analysis of correlation between hydrocephalus and the maximum diameter of tumors, correlation between hydrocephalus and the volume of tumor, or correlation between peritumoral edema and the volume of tumor, as well as correlation between heterogeneous enhancement and the grade of meningiomas.
   CONCLUSIONS: FVMs have their own characteristics in age of onset, gender ratio, histologic types, and imaging features. The recommended treatment is surgical treatment via the telovelar approach with suboccipital craniotomy/craniectomy. Adjuvant therapy is needed in some high-grade meningiomas and in patients undergoing partial resection. The prognosis is relatively good, with fewer postoperative complications and a higher rate of total resection.
C1 [Luo, Wei; Liu, Zhongmin] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Surg, Shanghai, Peoples R China.
   [Xu, Yulun; Yang, Jun; Liu, Hai] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Dept Neurosurg, Beijing, Peoples R China.
RP Liu, H (reprint author), Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Dept Neurosurg, Beijing, Peoples R China.
EM 110784809@qq.com
CR Adeli Alborz, 2018, Oncotarget, V9, P35974, DOI 10.18632/oncotarget.26313
   Akimoto J, 2001, NEUROL MED-CHIR, V41, P402, DOI 10.2176/nmc.41.402
   Alver I, 2011, TURK NEUROSURG, V21, P249, DOI 10.5137/1019-5149.JTN.2869-09.0
   Berhouma M, 2019, NEUROSURG REV, V42, P59, DOI 10.1007/s10143-017-0897-x
   Bertalanffy A, 2006, NEUROSURG REV, V29, P30, DOI 10.1007/s10143-005-0414-5
   Bhatoe Harjinder S, 2006, Neurosurg Focus, V20, pE9, DOI 10.3171/foc.2006.20.3.10
   Buerki RA, 2018, FUTURE ONCOL, V14, P2161, DOI 10.2217/fon-2018-0006
   Burgan OT, 2010, PEDIATR NEUROSURG, V46, P462, DOI 10.1159/000325072
   Carlotti CG, 2003, AM J SURG PATHOL, V27, P131, DOI 10.1097/00000478-200301000-00015
   CEYLAN S, 1992, CLIN NEUROL NEUROSUR, V94, P181, DOI 10.1016/0303-8467(92)90080-M
   Chaskis C, 2001, J CLIN NEUROSCI, V8, P59, DOI 10.1054/jocn.2001.0879
   Cummings TJ, 1999, CLIN NEUROPATHOL, V18, P265
   da Costa LB, 2007, SKULL BASE-INTERD AP, V17, P347, DOI 10.1055/s-2007-986440
   DELFINI R, 1992, NEUROSURG REV, V15, P147, DOI 10.1007/BF00313514
   DIAZ P, 1990, NEUROSURGERY, V26, P1057, DOI 10.1227/00006123-199006000-00024
   Dudley RWR, 2018, J NEURO-ONCOL, V137, P621, DOI 10.1007/s11060-018-2756-1
   Epari S, 2006, J NEURO-ONCOL, V78, P263, DOI 10.1007/s11060-005-9092-y
   Euskirchen P, 2018, PRESSE MED, V47, pE247, DOI 10.1016/j.lpm.2018.05.016
   Fathi AR, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0337-4
   Ferguson SD, 2018, J NEUROSURG, V128, P339, DOI 10.3171/2016.11.JNS161167
   Go Kyeong O, 2018, Brain Tumor Res Treat, V6, P13, DOI 10.14791/btrt.2018.6.e3
   GOKALP HZ, 1981, ACTA NEUROCHIR, V57, P115, DOI 10.1007/BF01665122
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   Grujicic D, 2017, WORLD NEUROSURG, V97, P178, DOI 10.1016/j.wneu.2016.09.068
   HAAS A, 1954, AM J SURG, V88, P346, DOI 10.1016/S0002-9610(54)90527-9
   HOFFMAN JC, 1972, AM J ROENTGENOL, V115, P100, DOI 10.2214/ajr.115.1.100
   Huang RY, 2019, NEURO-ONCOLOGY, V21, pI44, DOI 10.1093/neuonc/noy143
   Iseda Tsutomu, 1997, Neurologia Medico-Chirurgica, V37, P36, DOI 10.2176/nmc.37.36
   JOHNSON MD, 1989, NEUROSURGERY, V24, P587, DOI 10.1227/00006123-198904000-00017
   Liu M, 2006, NEUROSURG REV, V29, P36, DOI 10.1007/s10143-005-0418-1
   Lyngdoh BT, 2007, J CLIN NEUROSCI, V14, P442, DOI 10.1016/j.jocn.2006.01.005
   Marx S, 2018, ACTA NEUROCHIR, V160, P1063, DOI 10.1007/s00701-018-3496-x
   Matsumura M, 1988, Neurol Med Chir (Tokyo), V28, P996, DOI 10.2176/nmc.28.996
   Nagata K, 1988, Neurol Med Chir (Tokyo), V28, P86, DOI 10.2176/nmc.28.86
   Nakamura M, 2003, SURG NEUROL, V59, P491, DOI 10.1016/S0090-3019(03)00082-X
   Nakano S, 1989, Neurol Med Chir (Tokyo), V29, P52, DOI 10.2176/nmc.29.52
   Nanda A, 2016, WORLD NEUROSURG, V88, P526, DOI 10.1016/j.wneu.2015.10.071
   Odegaard KM, 2013, NEUROSURG REV, V36, P57, DOI 10.1007/s10143-012-0410-5
   Ooigawa H, 2004, NEUROL MED-CHIR, V44, P660, DOI 10.2176/nmc.44.660
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Payabyash S, 2018, NEURORADIOL J, V31, P554, DOI 10.1177/1971400918800803
   Pereira BJA, 2018, NEUROSURG REV
   PERRY RD, 1990, J COMPUT ASSIST TOMO, V14, P276, DOI 10.1097/00004728-199003000-00022
   Pichierri A, 2011, BRIT J NEUROSURG, V25, P454, DOI 10.3109/02688697.2011.555019
   Qin Y, 2012, CLIN IMAG, V36, P379, DOI 10.1016/j.clinimag.2011.11.034
   Ramraje S, 2012, AUSTRALAS MED J, V5, P126, DOI 10.4066/AMJ.2012.993
   RODRIGUE.J, 1974, AM J ROENTGENOL, V120, P27, DOI 10.2214/ajr.120.1.27
   Salehpour Firooz, 2018, Asian J Neurosurg, V13, P428, DOI 10.4103/1793-5482.228551
   SCHAERER JP, 1960, J NEUROSURG, V17, P337, DOI 10.3171/jns.1960.17.2.0337
   Shah Ankit S, 2018, Surg Neurol Int, V9, P237, DOI 10.4103/sni.sni_277_18
   Shibuya M, 1999, J CLIN NEUROSCI, V6, P50, DOI 10.1016/S0967-5868(99)90605-7
   Takeuchi S, 2012, ACTA NEUROL BELG, V112, P97, DOI 10.1007/s13760-012-0040-2
   Tomasello F, 2015, WORLD NEUROSURG, V83, P1141, DOI 10.1016/j.wneu.2015.01.039
   TSUBOI K, 1983, NEUROSURGERY, V13, P163, DOI 10.1097/00006123-198308000-00010
   VOGEL FS, 1950, J NEUROPATH EXP NEUR, V9, P443, DOI 10.1097/00005072-195010000-00010
   Watts J, 2014, INSIGHTS IMAGING, V5, P113, DOI 10.1007/s13244-013-0302-4
   Wind JJ, 2010, J CLIN NEUROSCI, V17, P1301, DOI 10.1016/j.jocn.2010.03.013
   Zhang BY, 2012, CLIN RADIOL, V67, P455, DOI 10.1016/j.crad.2011.10.017
   Zhang J, 2013, CLIN NEUROL NEUROSUR, V115, P1567, DOI 10.1016/j.clineuro.2012.11.007
   Zhang J, 2007, SURG NEUROL, V67, P535, DOI 10.1016/j.surneu.2006.07.011
NR 60
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1201
EP E1209
DI 10.1016/j.wneu.2019.04.097
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300150
PM 31004862
DA 2020-05-12
ER

PT J
AU Ma, XJ
   Zhang, GJ
   Wang, W
   Li, D
   Wu, Z
   Zhang, JT
AF Ma, Xiu-Jian
   Zhang, Gui-Jun
   Wang, Wei
   Li, Da
   Wu, Zhen
   Zhang, Jun-Ting
TI Proposed Treatment for Intracranial Transitional Meningioma: A
   Single-Center Series of 298 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gross total resection; Proposed treatment; Transitional meningioma
ID RADIOSURGERY
AB OBJECTIVE: We retrospectively assessed the surgical outcomes of transitional meningioma (TM) in a relatively large series to evaluate the long-term outcomes and propose an appropriate treatment strategy for TM.
   METHODS: We included 298 patients who had undergone surgery from September 2011 to August 2013. The clinical characteristics, surgical record, and follow-up data for these patients were retrieved.
   RESULTS: The 298 enrolled patients included 213 women (71.5%). The mean and median age of the 298 patients was 50.7 +/- 0.6 years and 52.0 years (range, 6.0-74.0), respectively. Radiologically, 144 tumors (48.3%) were located in the skull base. Gross total resection (GTR) was achieved in 266 patients (89.3%); 7 patients (2.6%) received adjuvant radiotherapy. After a median follow-up of 61.8 months, 23 patients (8.6%) had developed recurrence and 2 patients (0.8%) had died. The results from univariate analysis indicated that GTR was associated with better progression-free survival (hazard ratio, 0.165; 95% confidence interval, 0.071-0.382; P < 0.001)1 Skull base tumors tended to predict for poor progression-free survival (hazard ratio, 2.169; 95% confidence interval, 0.919-5.118; P = 0.077). For the first tumor recurrence, 11 patients (47.8%) underwent gamma knife radiosurgery, and only 2 patients developed a second recurrence.
   CONCLUSION: The results from the present study have shown that GTR should be achieved during the first surgery for TM. Gamma knife radiosurgery might be an effective therapy for patients with tumor recurrence.
C1 [Ma, Xiu-Jian; Zhang, Gui-Jun; Wang, Wei; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Xiu-Jian; Zhang, Gui-Jun; Wang, Wei; Li, Da; Wu, Zhen; Zhang, Jun-Ting] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Ma, Xiu-Jian; Zhang, Gui-Jun; Wang, Wei; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.
   [Ma, Xiu-Jian; Zhang, Gui-Jun; Wang, Wei; Li, Da; Wu, Zhen; Zhang, Jun-Ting] Tianjin Fifth Ctr Hosp, Beijing Key Lab Brain Tumor, Tianjin, Peoples R China.
   [Wang, Wei] Tianjin Fifth Ctr Hosp, Dept Neurosurg, Tianjin, Peoples R China.
RP Zhang, GJ (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, GJ (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.; Zhang, GJ (reprint author), Beijing Inst Brain Disorders, Ctr Brain Tumor, Beijing, Peoples R China.; Zhang, GJ (reprint author), Tianjin Fifth Ctr Hosp, Beijing Key Lab Brain Tumor, Tianjin, Peoples R China.
EM zhangjunting2003@aliyun.com
CR Ayerbe J, 1999, ACTA NEUROCHIR, V141, P921, DOI 10.1007/s007010050398
   BABU RP, 1994, J NEUROSURG, V81, P49, DOI 10.3171/jns.1994.81.1.0049
   Bassiouni H, 2006, NEUROSURGERY, V59, P1177, DOI 10.1227/01.NEU.0000245629.77968.37
   Bledsoe JM, 2010, J NEUROSURG, V112, P951, DOI 10.3171/2009.8.JNS09703
   Bloch O, 2012, J NEURO-ONCOL, V107, P13, DOI 10.1007/s11060-011-0720-4
   Cudlip SA, 1998, ACTA NEUROCHIR, V140, P1007, DOI 10.1007/s007010050208
   De Salles AAF, 2001, STEREOT FUNCT NEUROS, V76, P218, DOI 10.1159/000066722
   Deinsberger R, 2004, MINIM INVAS NEUROSUR, V47, P333, DOI 10.1055/s-2004-830126
   Hug EB, 2000, J NEURO-ONCOL, V48, P151, DOI 10.1023/A:1006434124794
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   SALPIETRO FM, 1994, NEUROSURGERY, V35, P638, DOI 10.1227/00006123-199410000-00009
   Samii M, 1996, NEUROSURGERY, V39, P1086, DOI 10.1097/00006123-199612000-00003
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Zhang GJ, 2018, WORLD NEUROSURG, V117, pE57, DOI 10.1016/j.wneu.2018.04.226
NR 14
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E280
EP E287
DI 10.1016/j.wneu.2019.03.104
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300037
PM 30902770
DA 2020-05-12
ER

PT J
AU Martin, M
   Lobo, D
   Bitot, V
   Couffin, S
   Escalard, S
   Mounier, R
   Cook, F
AF Martin, Mathieu
   Lobo, David
   Bitot, Valerie
   Couffin, Severine
   Escalard, Simon
   Mounier, Roman
   Cook, Fabrice
TI Prediction of Early Intracranial Hypertension After Severe Traumatic
   Brain Injury: A Prospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Intracranial pressure; Optic nerve sheath diameter;
   Transcranial Doppler; Traumatic brain injury
ID OPTIC-NERVE SHEATH; PRESSURE; MANAGEMENT; DIAMETER; ULTRASONOGRAPHY;
   GUIDELINES; CARE
AB OBJECTIVE: This study aimed to assess the reliability of clinical features, noninvasive transcranial Doppler-related pulsatility index (PI) calculation, and optic nerve sheath diameter (ONSD) measured by ultrasound (US) and initial computed tomography (CT) scan (Marshall CT scan classification) in predicting the occurrence of early (<24 hours) high intracranial pressure (EHICP) (>20 mm Hg) after severe traumatic brain injury (TBI).
   METHODS: We conducted an observational prospective study in a level 1 trauma center. Patients were measured simultaneously for PI and US ONSD in the triage zone. Patients were categorized into 2 groups: those who had EHICP after TBI (EHICP+) and those who did not (EHICP-).
   RESULTS: Fifty-four patients were included; 32 were categorized as EHICP+ and 22 as EHICP-. PI >1.4 did not correlate with EHICP+ patients (69% vs. 46%, P = 0.09). US ONSD measurement was higher in the EHICP+ group (6.25; range, 6-6.95 vs. 5.7; range, 5.2-6.4; P = 0.005). The area under the receiver operating characteristic curve for US ONSD as a predictor of developing EHICP was 0.73 (95% confidence interval [CI], 0.59-0.86). CT ONSD measurement was higher in the EHICP+ group (6.71; range, 6.35-7.87 vs. 6.25; range, 5.8-6.93; P = 0.04). The area under the receiver operating characteristic curve for CT ONSD measurement as a predictor for EHICP+ was 0.67 (95% CI, 0.53-0.81). The diffuse injury III and IV categories in the Marshall CT scan classification were associated with the occurrence of EHICP (P = 0.004).
   CONCLUSIONS: None of the clinical features or noninvasive tools assessed in this study enabled clinicians to strictly ascertain EHICP. Further studies are needed to establish their potential role before intracranial pressure probe insertion.
C1 [Martin, Mathieu; Lobo, David; Bitot, Valerie; Couffin, Severine; Mounier, Roman; Cook, Fabrice] Paris Est Creteil Univ, Surg Intens Care Unit, Trauma Ctr, Dept Anaesthesiol & Crit Care Med, Creteil, France.
   [Escalard, Simon] Paris Est Creteil Univ, Dept Neuroradiol, Creteil, France.
   [Escalard, Simon] Henri Mondor Univ Hosp, AP HP, Creteil, France.
RP Martin, M (reprint author), Paris Est Creteil Univ, Surg Intens Care Unit, Trauma Ctr, Dept Anaesthesiol & Crit Care Med, Creteil, France.
EM mathieu.martin@aphp.fr
OI Bitot, Valerie/0000-0002-8447-2296
CR Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802
   Bauerle J, 2012, J NEUROIMAGING, V22, P42, DOI 10.1111/j.1552-6569.2010.00546.x
   Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8
   Bremmer R, 2010, NEUROCRIT CARE, V12, P362, DOI 10.1007/s12028-009-9329-2
   Cardim D, 2016, J NEUROTRAUM, V33, P792, DOI 10.1089/neu.2015.4134
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2
   Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816
   Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6
   Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006
   Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276
   Glaser J, 2016, TRAUMA SURG ACUTE CA, V1, P1
   Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1
   Marion DW, 2006, NEUROSURGERY, V58, P655
   MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287
   Meyfroidt G, 2017, NEUROSURGERY, V81, pE1, DOI 10.1093/neuros/nyx144
   Moretti R, 2011, ACTA ANAESTH SCAND, V55, P644, DOI 10.1111/j.1399-6576.2011.02432.x
   Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X
   Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7
   Potgieter DW, 2011, ANAESTH INTENS CARE, V39, P95, DOI 10.1177/0310057X1103900116
   Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6
   Robba C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002356
   Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7
   Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3
   Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738
   Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825
   Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300
   Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255
   Wang LJ, 2018, JAMA OPHTHALMOL, V136, P250, DOI 10.1001/jamaophthalmol.2017.6560
NR 29
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1242
EP E1248
DI 10.1016/j.wneu.2019.04.121
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300157
PM 31009774
DA 2020-05-12
ER

PT J
AU Matsushige, T
   Shimonaga, K
   Mizoue, T
   Hosogai, M
   Hashimoto, Y
   Kaneko, M
   Ono, C
   Ishii, D
   Sakamoto, S
   Kurisu, K
AF Matsushige, Toshinori
   Shimonaga, Koji
   Mizoue, Tatsuya
   Hosogai, Masahiro
   Hashimoto, Yukishige
   Kaneko, Mayumi
   Ono, Chiaki
   Ishii, Daizo
   Sakamoto, Shigeyuki
   Kurisu, Kaoru
TI Focal Aneurysm Wall Enhancement on Magnetic Resonance Imaging Indicates
   Intraluminal Thrombus and the Rupture Point
SO WORLD NEUROSURGERY
LA English
DT Article
DE Histopathology; Intraluminal thrombus; Magnetic resonance imaging;
   Ruptured intracranial aneurysm
ID INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSMS; MRI
AB BACKGROUND: w to precise mechanism of aneurysm wall enhancement (AWE) in ruptured intracranial anewrysms on magnetic resonance vessel wall imaging (VWI) remains unclear. We explored patterns of VWI findings and correlations with intraoperative or histopathologic aneurysm wall architecture.
   METHODS: Twenty-four patients were evaluated by VWI before microsurgical clipping or endovascular coiling. The patterns of AWE were categorized, and the contrast ratio of AWE area was measured relative to the pituitary stalk. A total of 13 aneurysms were microsurgically inspected of the aneurysm wall and 4 were available for histopathologic evaluation.
   RESULTS: AWE was identified in 20 of 24 ruptured aneurysms. Among these 20 aneurysms, AWE was focal in 15 and circumferential in 5. Focal AWE showed significantly higher contrast ratio than circumferential AWE (P = 0.002). Histopathologic studies suggested that focal AWE indicating contrast ratio over 0.1 could be associated with fresh intraluminal thrombus at the rupture site. On the contrary, circumferential AWE suggested potential wall thickening with abundant neovascularization and inflammatory cells.
   CONCLUSIONS: Two AWE patterns were seen in ruptured intracranial aneurysms. Focal AWE on magnetic resonance imaging might indicate the presence of intraluminal thrombus, and detection of this sign could be useful for identification of the rupture point before treatment.
C1 [Matsushige, Toshinori; Shimonaga, Koji; Mizoue, Tatsuya; Hosogai, Masahiro; Hashimoto, Yukishige] Hiroshima City Asa Citizens Hosp, Dept Neurosurg & Intervent Neuroradiol, Hiroshima, Japan.
   [Kaneko, Mayumi] Hiroshima City Asa Citizens Hosp, Dept Pathol, Hiroshima, Japan.
   [Ono, Chiaki] Hiroshima City Asa Citizens Hosp, Dept Radiol, Hiroshima, Japan.
   [Matsushige, Toshinori; Shimonaga, Koji; Ishii, Daizo; Sakamoto, Shigeyuki; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
RP Matsushige, T (reprint author), Hiroshima City Asa Citizens Hosp, Dept Neurosurg & Intervent Neuroradiol, Hiroshima, Japan.; Matsushige, T (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM teruteru728@hiroshima-u.ac.jp
OI Sakamoto, Shigeyuki/0000-0003-3683-4771; Ishii,
   Daizo/0000-0002-7139-695X; Hosogai, Masahiro/0000-0001-7217-4446
CR Bhogal P, 2016, J NEUROINTERV SURG, V8, P1160, DOI 10.1136/neurintsurg-2015-012130
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Darbousset R, 2012, BLOOD, V120, P2133, DOI 10.1182/blood-2012-06-437772
   Edjlali M, 2014, STROKE, V45, P3704, DOI 10.1161/STROKEAHA.114.006626
   Frosen J, 2004, STROKE, V35, P2287, DOI 10.1161/01.STR.0000140636.30204.da
   Frosen J, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-71
   Hu P, 2016, NEURORADIOLOGY, V58, P979, DOI 10.1007/s00234-016-1729-3
   Ishikawa T, 2012, SURG CEREB STROKE JP, V40, P223
   Ishikawa T, 2006, SURG NEUROL, V66, P269, DOI 10.1016/j.surneu.2006.03.030
   Kataoka K, 1999, STROKE, V30, P1396, DOI 10.1161/01.STR.30.7.1396
   Kim J, 2016, J STROKE, V18, P286, DOI 10.5853/jos.2016.00906
   Krings T, 2011, NAT REV NEUROL, V7, P547, DOI 10.1038/nrneurol.2011.136
   Kumar V, 2018, ROBBINS BASIC PATHOL, P97
   Larsen N, 2018, AM J NEURORADIOL, V39, P1617, DOI 10.3174/ajnr.A5731
   Lehman VT, 2018, J NEUROSURG, V128, P969, DOI 10.3171/2016.12.JNS162262
   Mandell DM, 2017, AM J NEURORADIOL, V38, P218, DOI 10.3174/ajnr.A4893
   Matouk CC, 2013, NEUROSURGERY, V72, P492, DOI 10.1227/NEU.0b013e31827d1012
   Nagahata S, 2016, CLIN NEURORADIOL, V26, P277, DOI 10.1007/s00062-014-0353-z
   Nakagawa D, 2019, J NEUROSURG, V130, P1391, DOI 10.3171/2018.2.JNS1884
   Omodaka S, 2016, AM J NEURORADIOL, V37, P1262, DOI 10.3174/ajnr.A4722
   Omodaka S, 2019, J NEUROSURG, V131, P1262, DOI 10.3171/2018.5.JNS18322
   Omodaka S, 2018, NEUROSURGERY, V82, P638, DOI 10.1093/neuros/nyx267
   Shimonaga K, 2018, STROKE, V49, P2516, DOI 10.1161/STROKEAHA.118.021819
   Texakalidis P, 2018, WORLD NEUROSURG, V117, P453, DOI 10.1016/j.wneu.2018.06.008
   Wang GX, 2018, J NEUROINTERV SURG, V10, P566, DOI 10.1136/neurintsurg-2017-013308
   Wang XR, 2019, ACAD RADIOL, V26, P664, DOI 10.1016/j.acra.2018.05.005
   Xiang JP, 2011, STROKE, V42, P144, DOI 10.1161/STROKEAHA.110.592923
NR 27
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E578
EP E584
DI 10.1016/j.wneu.2019.03.209
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300072
PM 30928597
DA 2020-05-12
ER

PT J
AU Mirone, G
   Cicala, D
   Meucci, C
   d'Amico, A
   Santoro, C
   Muto, M
   Cinalli, G
AF Mirone, Giuseppe
   Cicala, Domenico
   Meucci, Chiara
   d'Amico, Alessandra
   Santoro, Claudia
   Muto, Mario
   Cinalli, Giuseppe
TI Multiple Burr-Hole Surgery for the Treatment of Moyamoya Disease and
   Quasi-Moyamoya Disease in Chilrirnn: Preliminary Surgical and Imaging
   Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Advent calendar technique; Indirect revascularization; Moyamoya disease;
   Multiple burr-hole technique; Neurofibromatosis; PWI MRI; Quasi-moyamoya
   disease
ID INVERSION-RECOVERY IMAGES; LEPTOMENINGEAL IVY SIGN; SINGLE-CENTER
   EXPERIENCE; CEREBRAL HEMODYNAMICS; ADULT PATIENTS; FLUID;
   REVASCULARIZATION; OPERATION; CHILDREN
AB OBJECTIVE: Moyamoya disease (MMD) is characterized by a progressive spontaneous occlusion of distal internal carotid arteries and its main branches. It is necessary to promptly diagnose and treat this condition, especially in children, because of the high risk of stroke and consequent severe disability. In this study, we examine the role of multiple burr-hole surgery (MBHS) in the treatment of pediatric patients with MMD and quasi-MMD and the role of perfusion magnetic resonance imaging (MRI) in the surgical indication and during follow-up.
   METHODS: We reviewed preoperative, early postoperative, and late postoperative MRI perfusion and digital subtraction angiography images together with clinical and surgical outcomes in 10 children with MMD treated by MBHS.
   RESULTS: Fourteen MBHS procedures (6 unilateral, 2 bilateral, and 2 single-setting bilateral) were performed in 10 children. Clinical and radiologic follow-up for all patients ranges from 16 months to 7 years. No ischemic events (transient ischemic attacks or stroke) occurred during the follow-up period. Postoperative digital subtraction angiography showed good revascularization around the burr-hole sites in all patients. The functional efficacy of the surgery was confirmed by dynamic susceptibility contrast perfusion MRI studies in 8 patients.
   CONCLUSIONS: Our data underline the good rate of success of MBHS in pediatric MMD and quasi-MMD. This technique results in good collateral revascularization, improved cerebral perfusion and excellent short and long-term symptoms control, with low perioperative risk. Postoperative changes of perfusion parameters and ivy sign MRI finding seem to show a positive correlation and mainly occur in posterior middle cerebral artery territory.
C1 [Mirone, Giuseppe; Meucci, Chiara; Cinalli, Giuseppe] Santobono Pausilipon Childrens Hosp, Dept Pediat Neurosurg, Naples, Italy.
   [Cicala, Domenico] Santobono Pausilipon Childrens Hosp, Dept Pediat Neuroradiol, Naples, Italy.
   [d'Amico, Alessandra] Federico II Univ Naples, Sch Med, Dept Neuroradiol, Naples, Italy.
   [Santoro, Claudia] Luigi Vanvitelli Univ Campania, Sch Med, Dept Woman Child Gen & Specialist Surg, Naples, Italy.
   [Muto, Mario] AORN Cardarelli, Dept Neuroradiol, Naples, Italy.
RP Mirone, G (reprint author), Santobono Pausilipon Childrens Hosp, Dept Pediat Neurosurg, Naples, Italy.
EM peppemirone@fastwebnet.it
RI santoro, claudia/V-8578-2019
OI santoro, claudia/0000-0003-4547-0500; D'Amico,
   Alessandra/0000-0002-9952-7288
CR Ball  W S Jr, 2001, Magn Reson Imaging Clin N Am, V9, P207
   Blauwblomme T, 2016, AM J NEURORADIOL, V37, P706, DOI 10.3174/ajnr.A4592
   Blauwblomme T, 2017, NEUROSURGERY, V80, P950, DOI 10.1093/neuros/nyw161
   Calamante F, 2001, STROKE, V32, P2810, DOI 10.1161/hs1201.099893
   Currie S, 2011, PEDIATR NEUROL, V44, P401, DOI 10.1016/j.pediatrneurol.2011.02.007
   ENDO M, 1989, J NEUROSURG, V71, P180, DOI 10.3171/jns.1989.71.2.0180
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Ikeda H, 1999, AM J HUM GENET, V64, P533, DOI 10.1086/302243
   Inoue TK, 2000, J CHILD NEUROL, V15, P179, DOI 10.1177/088307380001500307
   Kaku Y, 2013, CEREBROVASC DIS, V36, P19, DOI 10.1159/000351143
   Kawaguchi T, 1996, J NEUROSURG, V84, P468, DOI 10.3171/jns.1996.84.3.0468
   Kawaguchi T, 1998, NEUROL SURG TOKYO, V26, P217
   Kawashima M, 2010, AM J NEURORADIOL, V31, P1713, DOI 10.3174/ajnr.A2124
   Kim SK, 2003, PEDIATR NEUROSURG, V38, P68, DOI 10.1159/000068050
   Lee JK, 2013, J KOREAN NEUROSURG S, V54, P302, DOI 10.3340/jkns.2013.54.4.302
   Lee S, 2017, J CHILD NEUROL, V32, P924, DOI 10.1177/0883073817718730
   Lee SK, 2003, AM J NEURORADIOL, V24, P741
   Lim M, 2006, CURR NEUROVASC RES, V3, P237, DOI 10.2174/156720206778018730
   Liu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022542
   MATSUSHIMA Y, 1984, CHILD BRAIN, V11, P155
   McLaughlin N, 2014, WORLD NEUROSURG, V81, P91, DOI 10.1016/j.wneu.2013.05.010
   Mineharu Y, 2008, NEUROLOGY, V70, P2357, DOI 10.1212/01.wnl.0000291012.49986.f9
   Miyatake S, 2012, NEUROLOGY, V78, P803, DOI 10.1212/WNL.0b013e318249f71f
   Mori N, 2009, AM J NEURORADIOL, V30, P930, DOI 10.3174/ajnr.A1504
   Phi JH, 2015, J KOREAN NEUROSURG S, V57, P408, DOI 10.3340/jkns.2015.57.6.408
   Quintana LM, 2016, J VASC MED SURG, V4, P250
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Sainte-Rose C, 2006, J NEUROSURG, V105, P437, DOI 10.3171/ped.2006.105.6.437
   Scott RM, 2004, J NEUROSURG, V100, P142, DOI 10.3171/ped.2004.100.2.0142
   Seo KD, 2015, YONSEI MED J, V56, P1322, DOI 10.3349/ymj.2015.56.5.1322
   Suzuki H, 2017, J NEUROSURG-PEDIATR, V19, P560, DOI 10.3171/2017.1.PEDS16541
   SUZUKI J, 1975, CHILD BRAIN, V1, P193
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Togao O, 2006, AM J NEURORADIOL, V27, P391
   Uyttenboogaart M, 2005, STROKE, V36, P1984, DOI 10.1161/01.STR.0000177872.87960.61
   Yamada I, 1999, RADIOLOGY, V212, P340, DOI 10.1148/radiology.212.2.r99au08340
   Yonekawa Y, 1997, CLIN NEUROL NEUROSUR, V99, pS58, DOI 10.1016/S0303-8467(97)00042-5
   Yoshimoto T, 1997, CLIN NEUROL NEUROSUR, V99, pS218
   Yun TJ, 2009, RADIOLOGY, V251, P216, DOI 10.1148/radiol.2511080654
   Zhao M, 2018, ACTA NEUROL BELG, V118, P227, DOI 10.1007/s13760-017-0844-1
   Zhao X, 2015, BRIT J NEUROSURG, V29, P811, DOI 10.3109/02688697.2015.1071318
NR 41
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E843
EP E855
DI 10.1016/j.wneu.2019.03.282
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300105
PM 30954732
DA 2020-05-12
ER

PT J
AU Miura, M
   Yoshimura, S
   Yamada, K
   Kanamaru, T
   Matsumoto, K
   Shindo, S
   Uchida, K
   Shirakawa, M
   Kawasaki, M
   Ando, Y
AF Miura, Masatomo
   Yoshimura, Shinichi
   Yamada, Kiyofumi
   Kanamaru, Takuya
   Matsumoto, Kazuma
   Shindo, Seigo
   Uchida, Kazutaka
   Shirakawa, Manabu
   Kawasaki, Masanori
   Ando, Yukio
TI Presence of Plaque Neovascularization on Optical Frequency Domain
   Imaging Predicts Progression of Carotid Artery Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenosis; Carotid artery stenting; Optical frequency
   domain imaging; Neovascularization
ID CONTRAST-ENHANCED ULTRASOUND; ADVENTITIAL VASA VASORUM; ATHEROSCLEROTIC
   PLAQUES; COHERENCE TOMOGRAPHY; ENDARTERECTOMY; VISUALIZATION; RUPTURE;
   STENT
AB BACKGROUND AND PURPOSE: Neovascularization (NV) is regarded to be one of the important features of vulnerable plaque. The purpose of this study was to evaluate associations between the presence of NV, detected using optical frequency domain imaging (OFDI), and ischemic events and the progress of carotid artery stenosis.
   MATERIALS AND METHODS: Carotid artery plaques were evaluated using an OFDI system before angioplasty. NV was defined as no-signal tubuloluminal structures recognized on at least 3 consecutive images. The total number of NVs was compared between symptomatic and asymptomatic plaques and between progressive and nonprogressive plaques. Carotid plaque was diagnosed as "progressive" when peak systolic velocity increased between serial carotid duplex scans.
   RESULTS: A total of 36 patients (17 symptomatic, 16 progressive) were included. The percentage of patients with smoking habits was significantly higher with progressive carotid plaque than with nonprogressive carotid plaque (P = 0.003). NV was detected in 34 patients (94%), and the total number of NVs was significantly higher with progressive carotid plaque (10.2 +/- 4.8 vs. 3.7 +/- 2.8; P < 0.0001). There was no relationship between the number of NVs and ischemic events (symptomatic 6.0 +/- 5.1 vs. asymptomatic 7.1 +/- 5.0; P = 0.47). In multivariate logistic regression analysis, the number of NVs was an independent predictor of progressive carotid plaque (odds ratio 1.64 per 1 increase [95% confidence interval 1.19-2.64]; P = 0.0005).
   CONCLUSIONS: NV was more frequently observed in progressive carotid plaques. Evaluation of NV using OFDI may be useful in predicting progressive carotid plaques.
C1 [Miura, Masatomo; Yoshimura, Shinichi; Yamada, Kiyofumi; Uchida, Kazutaka; Shirakawa, Manabu] Hyogo Coll Med, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
   [Matsumoto, Kazuma] Hyogo Coll Med, Dept Clin Radiol, Nishinomiya, Hyogo, Japan.
   [Miura, Masatomo; Ando, Yukio] Kumamoto Univ, Grad Sch Med Sci, Dept Neurol, Kumamoto, Japan.
   [Kanamaru, Takuya] Nippon Med Sch, Neurol Sci, Dept Neurol, Bunkyo Ku, Tokyo, Japan.
   [Miura, Masatomo; Shindo, Seigo] Japanese Red Cross Kumamoto Hosp, Dept Neurol, Kumamoto, Japan.
   [Kawasaki, Masanori] Gifu Univ, Grad Sch Med, Dept Cardiol, Gifu, Japan.
RP Yoshimura, S (reprint author), Hyogo Coll Med, Dept Neurosurg, Nishinomiya, Hyogo, Japan.
EM hyogoneuro@yahoo.co.jp
FU Japan Heart Foundation Research Grant; Smoking Research Foundation
   Grant; JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP18K15568]
FX This work was supported by Japan Heart Foundation Research Grant,
   Smoking Research Foundation Grant, JSPS KAKENHI Grant Number JP18K15568.
CR Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Doyle B, 2007, J AM COLL CARDIOL, V49, P2073, DOI 10.1016/j.jacc.2007.01.089
   Huang PT, 2010, WORLD J CARDIOL, V2, P89, DOI 10.4330/wjc.v2.i4.89
   Huang RQ, 2016, J AM SOC ECHOCARDIOG, V29, P491, DOI 10.1016/j.echo.2016.02.012
   Kakkos SK, 2014, J VASC SURG, V59, P956, DOI 10.1016/j.jvs.2013.10.073
   Kerwin WS, 2008, MAGN RESON MED, V59, P507, DOI 10.1002/mrm.21532
   King A, 2009, STROKE, V40, P3711, DOI 10.1161/STROKEAHA.109.563056
   Lee J, 2012, LIFE SCI, V91, P1058, DOI 10.1016/j.lfs.2012.06.032
   Miura M, 2018, WORLD NEUROSURG, V119, P54, DOI 10.1016/j.wneu.2018.07.005
   Nishimiya K, 2015, CIRC J, V79, P1323, DOI 10.1253/circj.CJ-15-0078
   Nishimiya K, 2014, CIRC J, V78, P2516, DOI 10.1253/circj.CJ-14-0485
   Pelisek J, 2012, CIRC J, V76, P1274, DOI 10.1253/circj.CJ-11-0768
   Rafailidis V, 2017, J ULTRASOUND, V20, P97, DOI 10.1007/s40477-017-0239-4
   Saito K, 2014, STROKE, V45, P3073, DOI 10.1161/STROKEAHA.114.006483
   Shindo S, 2015, AM J NEURORADIOL, V36, P2140, DOI 10.3174/ajnr.A4404
   Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025
   Takarada S, 2010, CATHETER CARDIO INTE, V75, P202, DOI 10.1002/ccd.22273
   ten Kate GL, 2013, J VASC SURG, V57, P539, DOI 10.1016/j.jvs.2012.07.028
   Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18
   Xiong L, 2009, RADIOLOGY, V251, P583, DOI 10.1148/radiol.2512081829
   Yamada K, 2017, WORLD NEUROSURG, V105, P321, DOI 10.1016/j.wneu.2017.05.171
   Yoshimura S, 2012, AM J NEURORADIOL, V33, P308, DOI 10.3174/ajnr.A2740
   Yoshimura S, 2011, JACC-CARDIOVASC IMAG, V4, P432, DOI 10.1016/j.jcmg.2011.01.013
   Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953
NR 25
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E330
EP E336
DI 10.1016/j.wneu.2019.02.249
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300042
PM 30904795
DA 2020-05-12
ER

PT J
AU Miyachi, S
   Nagano, Y
   Hironaka, T
   Kawaguchi, R
   Ohshima, T
   Matsuo, N
   Maejima, R
   Takayasu, M
AF Miyachi, Shigeru
   Nagano, Yoshitaka
   Hironaka, Takahide
   Kawaguchi, Reo
   Ohshima, Tomotaka
   Matsuo, Naoki
   Maejima, Ryuya
   Takayasu, Masakazu
TI Novel Operation Support Robot with Sensory-Motor Feedback System for
   Neuroendovascular Intervention
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neuroendovascular intervention; Sensory-motor feedback; Support robot;
   Telesurgery
ID PERCUTANEOUS CORONARY INTERVENTION; COIL EMBOLIZATION;
   CLINICAL-APPLICATION; CATHETER SYSTEM; FEASIBILITY; NAVIGATION; SAFETY;
   FORCE
AB BACKGROUND: Robotic technology is rapidly developing in the medical field, particularly contributing to support operative intervention using the da Vinci system during endoscopic surgery. Neuroendovascular intervention robot surgery is preferred when aiming to reduce radiation exposure among surgeons.
   METHODS: We developed a prototype of a support robot with 2 independent slaves manipulating both the microcatheter and microguidewire connected with the remote master driver with 2 joysticks. This design simulates usual catheterization with both hands. The slave manipulator has a sufficient output force >1 N to reproduce the exact master intervention without slip and delay. This machine has a unique function that indicates the reaction force of the resistance on wire stuck using the sensor system. We investigated the master-slave response, reliability of the force gauge, and degree of slippage of the slave motion on the table and checked the controllability, safety, and reproducibility of microcatheterization and insertion maneuver into the experimental aneurysm in the in vivo silicone vessel model.
   RESULTS: We realized the well master-slave response with a stable driving speed of the microguidewire at approximately 1 mm/s and with linear correlation between the output voltage and driving force. Also, we confirmed the well safety function to avoid the overloading to the vascular wall with the slippage of the slave roller on loading >1 N pushing force. Successful microcatheterization and insertion into the aneurysm model was performed in the wet vascular model corresponding to the 3-dimensional handling without excessive stress to the vascular or aneurysmal wall.
   CONCLUSIONS: Neuroendovascular intervention requires delicate power adjustment with fine finger control. Our support robot for neuroendovascular interventions demonstrated the accurate reproducibility of the operator's maneuver and safe operation in the vascular model using the sensor system. This system will realize the neurointervention without human operators in the AngioSuite and may facilitate telesurgery with remote control in the near future.
C1 [Miyachi, Shigeru; Kawaguchi, Reo; Ohshima, Tomotaka; Matsuo, Naoki; Maejima, Ryuya; Takayasu, Masakazu] Aichi Med Univ, Dept Neurosurg & Neuroendovasc Therapy, Nagakute, Aichi, Japan.
   [Nagano, Yoshitaka] Aichi Univ Technol, Dept Elect Control & Robot Engn, Gamagori, Aichi, Japan.
   [Hironaka, Takahide] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan.
RP Miyachi, S (reprint author), Aichi Med Univ, Dept Neurosurg & Neuroendovasc Therapy, Nagakute, Aichi, Japan.
EM miyachi.shigeru.752@mail.aichi-med-u.ac.jp
CR Antoniou GA, 2011, J VASC SURG, V53, P493, DOI 10.1016/j.jvs.2010.06.154
   Goto Tetsuya, 2009, J Brain Dis, V1, P45
   Guiatni M, 2013, IEEE-ASME T MECH, V18, P1170, DOI 10.1109/TMECH.2012.2197862
   Guo J, 2015, 2015 IEEE INTERNATIONAL CONFERENCE ON INFORMATION AND AUTOMATION, P609, DOI 10.1109/ICInfA.2015.7279359
   Guo J, 2016, INT J MED ROBOT COMP, V12, P32, DOI 10.1002/rcs.1642
   Haraguchi K, 2013, INTERV NEURORADIOL, V19, P159, DOI 10.1177/159101991301900203
   Ji C, 2011, IEEE ENG MED BIO, P6680, DOI 10.1109/IEMBS.2011.6091647
   Lumsden AB, 2010, J ENDOVASC THER, V17, P612, DOI 10.1583/10-3208R.1
   Mahmud E, 2017, JACC-CARDIOVASC INTE, V10, P1320, DOI 10.1016/j.jcin.2017.03.050
   Matsubara N, 2017, WORLD NEUROSURG, V105, P857, DOI 10.1016/j.wneu.2017.06.092
   Matsubara N, 2011, NEURORADIOLOGY, V53, P169, DOI 10.1007/s00234-010-0722-5
   Matsubara N, 2009, J NEUROSURG, V111, P41, DOI 10.3171/2009.1.JNS081181
   Meng C, 2013, INT J MED ROBOT COMP, V9, P230, DOI 10.1002/rcs.1494
   Nagano Y, 2010, J JPN SOC COMP AID S, V12, P101
   Negoro M, 2001, INTERV NEURORADIOL, V7, P111, DOI 10.1177/15910199010070S116
   Ota T, 2009, ANN THORAC SURG, V87, P1253, DOI 10.1016/j.athoracsur.2008.10.026
   Riga C, 2009, J ENDOVASC THER, V16, P149, DOI 10.1583/08-2651.1
   Tanimoto M, 1998, IEEE ROBOT AUTOM LET, V1998, P1728
   Thomas D, 2012, J ELECTROCARDIOL, V45, P95, DOI 10.1016/j.jelectrocard.2011.05.005
   Weisz G, 2013, J AM COLL CARDIOL, V61, P1596, DOI 10.1016/j.jacc.2012.12.045
   Xiao Nan, 2012, P 2012 IEEE INT C AU, P645
NR 21
TC 0
Z9 0
U1 7
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E617
EP E623
DI 10.1016/j.wneu.2019.03.221
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300077
PM 30930317
DA 2020-05-12
ER

PT J
AU Mohammed, N
   Narayan, V
   Patra, D
   Savardekar, AR
   Riaz, M
   Nanda, A
AF Mohammed, Nasser
   Narayan, Vinayak
   Patra, Devi
   Savardekar, Amey R.
   Riaz, Muhammad
   Nanda, Anil
TI Management of Meningiomas Involving the Major Venous Sinuses: A
   Single-Institution Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meningiomas; Parasagittal; Surgery; Venous sinus
ID SUPERIOR SAGITTAL SINUS; GROSS-TOTAL RESECTION; ATYPICAL MENINGIOMAS;
   RECURRENCE; RADIOTHERAPY; SURGERY
AB BACKGROUND: In the management of meningiomas invading the major venous sinuses, balance between tumor control and complication prevention is desirable. The aim of this study was to describe an institutional experience in management of meningiomas involving major venous sinuses.
   METHODS: A retrospective study was carried out over 18 years, between 1999 and 2017, in patients with meningiomas involving major venous sinuses. Clinical features, operative strategy, histology, postoperative complications, adjuvant therapy, and long-term follow-up were studied.
   RESULTS: The study included 84 patients. Neurologic deficits were seen in 26 (31%) patients at presentation. The recurrence rates in Simpson grade I, II, and III excision were 7.6%, 25%, and 29.4% at a mean follow-up of 45.4 months (range, 1-192 months). No intervention of the involved sinus was done in 64 (76%) cases, venotomy was done in 3 (3.5%) cases, sinus resection without graft was done in 14 (16.6%) cases, and sinus reconstruction with patch was done in 3 (3.5%) cases. There were 53 (67.0%) patients with World Health Organization grade I histology and 25 (31.6%) patients with World Health Organization grade II histology. Fifteen recurrences were treated with Gamma Knife radiosurgery. In univariate analysis using Cox proportional hazards model, World Health Organization grade (P = 0.036, hazard ratio 2.90, 95% confidence interval = 1.07-7.87) and Simpson grade (P = 0.017, hazard ratio 2.90, 95% confidence interval [1.18-5.29) were found to be significant factors to predict tumor recurrence.
   CONCLUSIONS: Management of meningiomas involving major venous sinus with microsurgical techniques and adjuvant Gamma Knife radiosurgery achieves a good tumor control rate with an acceptable complication rate.
C1 [Mohammed, Nasser] Univ Virginia, Sch Med, Dept Neurol Surg, Charlottesville, VA 22908 USA.
   [Narayan, Vinayak; Nanda, Anil] Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08901 USA.
   [Patra, Devi] Mayo Clin, Dept Neurosurg, Phoenix, AZ USA.
   [Savardekar, Amey R.] Louisiana State Univ, Dept Neurosurg, Hlth Ctr, Shreveport, LA 71105 USA.
   [Riaz, Muhammad] Childrens Hosp Colorado, Dept Pediat Neurosurg, Aurora, CO USA.
RP Nanda, A (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08901 USA.
EM an651@rwjms.rutgers.edu
RI mohammed, nasser/AAG-1525-2019
OI mohammed, nasser/0000-0002-3811-3559; Patra, Devi/0000-0003-0912-2226;
   Savardekar, Amey/0000-0002-9305-7457
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Alvernia JE, 2009, MENINGIOMAS, P309
   BONNAL J, 1978, J NEUROSURG, V48, P935, DOI 10.3171/jns.1978.48.6.0935
   Caroli E, 2006, NEUROSURG REV, V29, P236, DOI 10.1007/s10143-006-0020-1
   Colli BO, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.08.023
   CROMPTON MR, 1970, J NEUROL NEUROSUR PS, V33, P80, DOI 10.1136/jnnp.33.1.80
   DiMeco F, 2004, NEUROSURGERY, V55, P1263, DOI 10.1227/01.NEU.0000143373.74160.F2
   Ding DL, 2017, J NEUROSURG, V127, P117, DOI 10.3171/2013.6.JNS13110
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   Hasegawa T, 2011, J NEUROSURG, V114, P1392, DOI 10.3171/2010.11.JNS10112
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Kondziolka D, 1998, NEUROSURGERY, V43, P405, DOI 10.1097/00006123-199809000-00001
   Kondziolka D, 2008, NEUROSURGERY, V62, P53, DOI 10.1227/01.NEU.0000311061.72626.0D
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Mantovani A, 2014, WORLD NEUROSURG, V82, P455, DOI 10.1016/j.wneu.2013.06.024
   MARKS SM, 1986, SURG NEUROL, V25, P436, DOI 10.1016/0090-3019(86)90081-9
   Raza SM, 2010, NEUROSURGERY, V67, P885, DOI 10.1227/NEU.0b013e3181ef2a18
   SchmidElsaesser R, 1997, NEUROSURGERY, V41, P1005, DOI 10.1097/00006123-199711000-00001
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou MP, 2006, J NEUROSURG, V105, P514, DOI 10.3171/jns.2006.105.4.514
   Sughrue ME, 2011, J NEUROSURG, V114, P731, DOI 10.3171/2010.9.JNS10646
   Tomasello F, 2013, J NEUROSURG, V119, P74, DOI 10.3171/2012.11.JNS112011
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E179
EP E185
DI 10.1016/j.wneu.2019.03.043
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300025
PM 30878750
DA 2020-05-12
ER

PT J
AU Morris, SAL
   Zhu, P
   Rao, M
   Martir, M
   Zhu, JJ
   Hsu, S
   Ballester, LY
   Day, AL
   Tandon, N
   Kim, DH
   Shepard, S
   Blanco, A
   Esquenazi, Y
AF Morris, Saint-Aaron L.
   Zhu, Ping
   Rao, Mayank
   Martir, Magda
   Zhu, Jay J.
   Hsu, Sigmund
   Ballester, Leomar Y.
   Day, Arthur L.
   Tandon, Nitin
   Kim, Dong H.
   Shepard, Scott
   Blanco, Angel
   Esquenazi, Yoshua
TI Gamma Knife Stereotactic Radiosurgery in Combination with Bevacizumab
   for Recurrent Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bevacizumab; Gamma knife; Radiosurgery; Recurrent glioblastoma;
   Stereotactic radiosurgery
ID SINGLE-AGENT BEVACIZUMAB; HIGH-GRADE GLIOMA; ADJUSTED SURVIVAL CURVES;
   PRIMARY BRAIN-TUMORS; RADIATION-THERAPY; ADJUVANT TEMOZOLOMIDE;
   MALIGNANT GLIOMAS; TREATMENT OPTION; MULTIFORME; REIRRADIATION
AB BACKGROUND: Prior retrospective and prospective studies suggest improved survival with the use of stereotactic radiosurgery (SRS) and bevacizumab in the treatment of limited-volume glioblastoma (GBM) recurrences.
   METHODS: We retrospectively reviewed our experience with gamma knife SRS in combination with bevacizumab for the treatment of focal GBM recurrence during 2009-2015. Outcomes include overall survival, progression free survival (PFS), and radiation-related adverse events. Kaplan-Meier methods and multivariable Cox proportional hazards models were performed for survival analysis.
   RESULTS: Within a median of 13.7 months after diagnosis, a total of 45 patients with GBM underwent gamma knife SRS and bevacizumab treatment. Median age was 57 years (range: 20-78 years) and 63.3% were women. The median Karnofsky Performance Score (KPS) at recurrence was 80 (range: 40-100). Sixty-four percent of patients had single radiosurgery target (range: 1-4) and median target volume and margin dose were 2.2 cm(3) (range: 0.1-25.2 cm(3)) and 17.0 gray (Gy) (range: 13-24 Gy), respectively. Median PFS and overall survival were 9.3, 31.0 months following diagnosis, and 5.2, 13.3 months after SRS, respectively. Factors associated with poor outcomes were KPS <= 70, SRS dose <18 Gy, and use of <2 chemotherapy agents prior to SRS. No radiation-related adverse events occurred.
   CONCLUSIONS: SRS in combination with bevacizumab can be safely used to treat focal GBM recurrence. KPS, radiation dose, and multi-agent chemotherapy usage prior to SRS demonstrated significant impact on PFS. Bevacizumah may provide clinically relevant radioprotection.
C1 [Morris, Saint-Aaron L.; Zhu, Ping; Rao, Mayank; Martir, Magda; Zhu, Jay J.; Hsu, Sigmund; Day, Arthur L.; Tandon, Nitin; Kim, Dong H.; Blanco, Angel; Esquenazi, Yoshua] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
   [Ballester, Leomar Y.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pathol & Lab Med, Houston, TX 77030 USA.
   [Shepard, Scott] Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA 19122 USA.
RP Esquenazi, Y (reprint author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.
EM Yoshua.EsquenaziLevy@uth.tmc.edu
OI Tandon, Nitin/0000-0002-2752-2365
CR Abbassy M, 2018, NEUROSURGERY, V83, P385, DOI 10.1093/neuros/nyx369
   Bir SC, 2015, NEUROSURG REV, V38, P705, DOI 10.1007/s10143-015-0632-4
   Bokstein F, 2016, J NEURO-ONCOL, V126, P551, DOI 10.1007/s11060-015-1997-5
   Cabrera AR, 2013, INT J RADIAT ONCOL, V86, P873, DOI 10.1016/j.ijrobp.2013.04.029
   Chamberlain MC, 2010, J NEURO-ONCOL, V96, P259, DOI 10.1007/s11060-009-9957-6
   Clarke J, 2017, INT J RADIAT ONCOL, V99, P797, DOI 10.1016/j.ijrobp.2017.06.2466
   Cohen MH, 2009, ONCOLOGIST, V14, P1131, DOI 10.1634/theoncologist.2009-0121
   Combs SE, 2005, J CLIN ONCOL, V23, P8863, DOI 10.1200/JCO.2005.03.4157
   Combs SE, 2005, CANCER, V104, P2168, DOI 10.1002/cncr.21429
   Cuneo KC, 2012, INT J RADIAT ONCOL, V82, P2018, DOI 10.1016/j.ijrobp.2010.12.074
   Elliott RE, 2011, WORLD NEUROSURG, V76, P128, DOI 10.1016/j.wneu.2010.12.053
   Fetcko K, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008293
   Fogh SE, 2010, J CLIN ONCOL, V28, P3048, DOI 10.1200/JCO.2009.25.6941
   Ghali WA, 2001, JAMA-J AM MED ASSOC, V286, P1494, DOI 10.1001/jama.286.12.1494
   Giglio P, 2003, NEUROLOGIST, V9, P180, DOI 10.1097/01.nrl.0000080951.78533.c4
   Goldman DA, 2018, J NEUROSURG, V129, P1231, DOI 10.3171/2017.6.JNS17393
   Gonzalez J, 2007, INT J RADIAT ONCOL, V67, P323, DOI 10.1016/j.ijrobp.2006.10.010
   Gorski DH, 1999, CANCER RES, V59, P3374
   Gutin PH, 2009, INT J RADIAT ONCOL, V75, P156, DOI 10.1016/j.ijrobp.2008.10.043
   Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52
   Hsieh PC, 2005, NEUROSURGERY, V57, P684, DOI 10.1227/01.NEU.0000175550.96901.A3
   Imber BS, 2017, NEUROSURGERY, V80, P129, DOI 10.1227/NEU.0000000000001344
   Kida Y, 2009, PROG NEUROL, V22, P122, DOI 10.1159/000163387
   Koga T, 2012, CANCER-AM CANCER SOC, V118, P4193, DOI 10.1002/cncr.27372
   Kohshi K, 2007, J NEURO-ONCOL, V82, P297, DOI 10.1007/s11060-006-9283-1
   Kong DS, 2008, CANCER-AM CANCER SOC, V112, P2046, DOI 10.1002/cncr.23402
   Kozin SV, 2001, CANCER RES, V61, P39
   Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055
   Larson EW, 2014, WORLD J CLIN ONCOL, V5, P142, DOI 10.5306/wjco.v5.i2.142
   Lederman G, 2000, AM J CLIN ONCOL-CANC, V23, P155, DOI 10.1097/00000421-200004000-00010
   Lubelski D, 2013, J NEURO-ONCOL, V115, P317, DOI 10.1007/s11060-013-1233-0
   Maranzano E, 2011, TUMORI, V97, P56
   Martinez-Carrillo M, 2014, BIOMED RES INT, DOI 10.1155/2014/657953
   Minniti G, 2011, J NEURO-ONCOL, V103, P683, DOI 10.1007/s11060-010-0446-8
   Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1
   Nahum AE, 2015, CLIN ONCOL-UK, V27, P260, DOI 10.1016/j.clon.2015.02.001
   Niranjan A, 2015, J NEUROSURG, V122, P757, DOI 10.3171/2014.11.JNS13295
   Niyazi M, 2011, RADIOTHER ONCOL, V98, P1, DOI 10.1016/j.radonc.2010.11.006
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Park KJ, 2012, J NEURO-ONCOL, V107, P323, DOI 10.1007/s11060-011-0744-9
   Pinzi V, 2015, NEUROL SCI, V36, P1431, DOI 10.1007/s10072-015-2172-7
   Pouratian N, 2009, J NEURO-ONCOL, V94, P409, DOI 10.1007/s11060-009-9873-9
   Raizer JJ, 2010, CANCER-AM CANCER SOC, V116, P5297, DOI 10.1002/cncr.25462
   Schaub C, 2016, J CANCER RES CLIN, V142, P1825, DOI 10.1007/s00432-016-2187-3
   Schmidt Benjamin, 2012, Curr Angiogenes, V1, P169
   Shaw E, 1996, INT J RADIAT ONCOL, V34, P647, DOI 10.1016/0360-3016(95)02106-X
   Sirin S, 2011, VOJNOSANIT PREGL, V68, P961, DOI 10.2298/VSP1111961S
   Skeie BS, 2012, WORLD NEUROSURG, V78, P658, DOI 10.1016/j.wneu.2012.03.024
   SNEED PK, 1994, INT J RADIAT ONCOL, V29, P719, DOI 10.1016/0360-3016(94)90559-2
   Souhami L, 2004, INT J RADIAT ONCOL, V60, P853, DOI 10.1016/j.ijrobp.2004.04.011
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Veninga T, 2001, RADIOTHER ONCOL, V59, P127, DOI 10.1016/S0167-8140(01)00299-7
   Villavicencio AT, 2009, NEUROSURG REV, V32, P417, DOI 10.1007/s10143-009-0212-6
   Vordermark D, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-55
   Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541
   Yazici G, 2014, J NEURO-ONCOL, V120, P117, DOI 10.1007/s11060-014-1524-0
   Zhang X, 2007, COMPUT METH PROG BIO, V88, P95, DOI 10.1016/j.cmpb.2007.07.010
NR 58
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E523
EP E533
DI 10.1016/j.wneu.2019.03.193
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300065
PM 30954746
DA 2020-05-12
ER

PT J
AU Mutlu, O
   Olcay, AB
   Bilgin, C
   Hakyemez, B
AF Mutlu, Onur
   Olcay, Ali Bahadir
   Bilgin, Cem
   Hakyemez, Bahattin
TI Evaluating the Effectiveness of 2 Different Flow Diverter Stents Based
   on the Stagnation Region Formation in an Aneurysm Sac Using Lagrangian
   Coherent Structure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lagrangian coherent structure; Computational fluid dynamics; Flow
   diverter stent effectiveness; Stagnated fluid flow zones
ID INTERNAL CAROTID-ARTERY; NEWTONIAN BLOOD-FLOW; INTRACRANIAL ANEURYSMS;
   ENDOVASCULAR TREATMENT; CEREBRAL ANEURYSM; FOLLOW-UP; DIVERSION;
   RECONSTRUCTION; SIMULATION; OCCLUSION
AB BACKGROUND: Flow diverter stents are often used in the treatment of giant aneurysms at carotid arteries. Although these stents promise to decrease blood flow into the aneurysm sac, little is known about hemodynamics inside the aneurysm once the stent is planted into the aneurysm neck. To further explore this, computational fluid dynamics and Lagrangian coherent structure (LCS) techniques were used to evaluate the time evolution mechanism of stagnation regions inside an aneurysm. The purpose of this work is to provide a quantitative effectiveness comparison of 2 different flow diverter stents placed into the aneurysm neck based on their stagnation zone formations in the sac.
   METHODS: In numerical modeling, Womersley function, and fluidsolid interaction were defined as the 3 cardiac cycles for blood velocity and the aneurysm wall, respectively. Moreover, blood was accepted as a non-Newtonian fluid, and mean arterial blood pressure of the patient was entered into the computational domain to accurately mimic the hemodynamics inside the aneurysm sac accurately.
   RESULTS: The numerical analyses revealed that the use of a Fred-type stent in the aneurysm neck causes fluid flow zone formations yielding to sequenced stagnated regions. Time evolution of stagnation regions in an aneurysm sac was shown just after a flow diverter stent was employed at a patient's aneurysm neck. Furthermore, the stagnation field in the Fred stent-fitted aneurysm was nearly 4.8 times the stagnation area of the Surpass brand stent-attached aneurysm.
   CONCLUSIONS: Finite time Lyapunov exponent fields obtained from the LCS techniques demonstrated a good agreement with the patient's digital subtraction angiography images obtained just after treatment.
C1 [Mutlu, Onur; Olcay, Ali Bahadir] Yeditepe Univ, Dept Mech Engn, Fac Engn, Istanbul, Turkey.
   [Bilgin, Cem; Hakyemez, Bahattin] Uludag Univ, Dept Radiol, Sch Med, Gorukle, Bursa, Turkey.
RP Olcay, AB (reprint author), Yeditepe Univ, Dept Mech Engn, Fac Engn, Istanbul, Turkey.
EM bahadir.olcay@yeditepe.edu.tr
FU Scientific and Technological Research Council of Turkey under the 1001
   Program [117M491]
FX This work was supported by The Scientific and Technological Research
   Council of Turkey under the 1001 Program (Project no. 117M491).
CR Alderazi YJ, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/415653
   Annesi SM, 2014, TXB MED SURG NURSING
   Augsburger L, 2011, ANN BIOMED ENG, V39, P850, DOI 10.1007/s10439-010-0200-6
   Azer Karim, 2007, Cardiovasc Eng, V7, P51, DOI 10.1007/s10558-007-9031-y
   Baldewsing RA, 2004, ULTRASONICS, V42, P723, DOI 10.1016/j.ultras.2003.11.017
   Berg P, 2018, INT J ARTIF ORGANS, V41, P698, DOI 10.1177/0391398818775521
   Beydoun HA, 2018, WORLD NEUROSURG, V114, pE938, DOI 10.1016/j.wneu.2018.03.120
   Brasiliense LBC, 2017, WORLD NEUROSURG, V107, P641, DOI 10.1016/j.wneu.2017.08.099
   Castro MA, 2006, ACAD RADIOL, V13, P811, DOI 10.1016/j.acra.2006.03.011
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Chapin JC, 2015, BLOOD REV, V29, P17, DOI 10.1016/j.blre.2014.09.003
   Chien A, 2008, MED BIOL ENG COMPUT, V46, P1113, DOI 10.1007/s11517-008-0400-5
   Cognard C, 1999, RADIOLOGY, V212, P348, DOI 10.1148/radiology.212.2.r99jl47348
   Colby GP, 2012, NEUROSURGERY, V71, P944, DOI 10.1227/NEU.0b013e3182690b8b
   Connolly ES, 2004, MANAGEMENT CEREBRAL, P271
   Damiano RJ, 2017, AM J NEURORADIOL, V38, P603, DOI 10.3174/ajnr.A5062
   Dholakia R, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4034932
   Doost SN, 2016, COMPUT METH PROG BIO, V127, P232, DOI 10.1016/j.cmpb.2015.12.020
   El-Chalouhi N, 2014, WORLD NEUROSURG, V82, P696, DOI 10.1016/j.wneu.2013.02.089
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Feng X, 2017, WORLD NEUROSURG, V103, P576, DOI 10.1016/j.wneu.2017.04.017
   Fiorella D, 2008, NEUROSURGERY, V62, P1115, DOI 10.1227/01.neu.0000325873.44881.6e
   Fiorella D, 2009, NEUROSURGERY, V64, P212, DOI 10.1227/01.NEU.0000337576.98984.E4
   Haller G, 2000, PHYSICA D, V147, P352, DOI 10.1016/S0167-2789(00)00142-1
   Jing LK, 2016, WORLD NEUROSURG, V89, P199, DOI 10.1016/j.wneu.2016.01.079
   Johnston BM, 2004, J BIOMECH, V37, P709, DOI 10.1016/j.jbiomech.2003.09.016
   Lanzino G, 2012, AM J NEURORADIOL, V33, P2158, DOI 10.3174/ajnr.A3207
   Larrabide I, 2012, MED IMAGE ANAL, V16, P721, DOI 10.1016/j.media.2010.04.009
   Lee CJ, 2014, JSM NEUROSURG SPINE, V2, P1043
   Levitt MR, 2014, AM J NEURORADIOL, V35, P143, DOI 10.3174/ajnr.A3624
   Liu J, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.002
   Liu X, 2011, J BIOMECH, V44, P1123, DOI 10.1016/j.jbiomech.2011.01.024
   Lubicz B, 2010, STROKE, V41, P2247, DOI 10.1161/STROKEAHA.110.589911
   Nabaei M, 2014, J THEOR BIOL, V354, P60, DOI 10.1016/j.jtbi.2014.03.020
   Narracott AJ, 2003, DEV MODEL INVESTIGAT
   Ngoepe MN, 2016, J THROMB HAEMOST, V14, P262, DOI 10.1111/jth.13220
   Ohta M, 2005, CARDIOVASC INTER RAD, V28, P768, DOI 10.1007/s00270-004-7148-6
   Olcay AB, 2018, J APPL FLUID MECH, V11, P375, DOI 10.18869/acadpub.jafm.73.245.28185
   Olcay AB, 2008, EXP FLUIDS, V44, P235, DOI [10.1007/s00348-007-0397-9, 10.1007/S00348-007-0397-9]
   Olcay AB, 2016, PROG COMPUT FLUID DY, V16, P126, DOI 10.1504/PCFD.2016.075159
   PENINGTON DG, 1976, BRIT J HAEMATOL, V34, P365, DOI 10.1111/j.1365-2141.1976.tb03583.x
   Qian XQ, 2011, COMPUT CARDIOL, V38, P29
   Ravindran K, 2018, WORLD NEUROSURG, V120, pE1031, DOI 10.1016/j.wneu.2018.08.225
   RILEY WA, 1992, STROKE, V23, P952, DOI 10.1161/01.STR.23.7.952
   Saatci I, 2004, AM J NEURORADIOL, V25, P1742
   Seibert Brad, 2011, Front Neurol, V2, P45, DOI 10.3389/fneur.2011.00045
   Shadden SC, 2005, PHYSICA D, V212, P271, DOI 10.1016/j.physd.2005.10.007
   Shadden SC, 2008, ANN BIOMED ENG, V36, P1152, DOI 10.1007/s10439-008-9502-3
   Shadden SC, 2015, ANN BIOMED ENG, V43, P41, DOI 10.1007/s10439-014-1070-0
   Shadden SC, 2010, CHAOS, V20, DOI 10.1063/1.3272780
   Silva MA, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1718
   Sindeev S, 2019, WORLD NEUROSURG, V122, pE577, DOI 10.1016/j.wneu.2018.10.107
   Spiegel M, 2011, COMPUT METHOD BIOMEC, V14, P9, DOI 10.1080/10255842.2010.518565
   Steinman DA, 2003, AM J NEURORADIOL, V24, P559
   Streyer W, 2016, MRS COMMUN, V6, P1, DOI 10.1557/mrc.2015.81
   Stryker Neurovascular, 2015, SURP STREAML PROD PR, P1
   Sun WB, 2018, WORLD NEUROSURG, V120, pE1301, DOI 10.1016/j.wneu.2018.09.057
   Tang AYS, 2013, J BIOMEDICAL SCI ENG, V6, P812
   Toger J, 2012, ANN BIOMED ENG, V40, P2652, DOI 10.1007/s10439-012-0615-3
   Ugron A, 2014, INTERV MED APPL SCI, V6, P61, DOI 10.1556/IMAS.6.2014.2.2
   van Beekvelt MCP, 2001, J APPL PHYSIOL, V90, P511
   Vetel J, 2009, EXP FLUIDS, V46, P1067, DOI 10.1007/s00348-009-0615-8
   WOMERSLEY JR, 1955, J PHYSIOL-LONDON, V127, P553, DOI 10.1113/jphysiol.1955.sp005276
   Zammar SG, 2018, WORLD NEUROSURG, V115, pE200, DOI 10.1016/j.wneu.2018.04.012
   Zanaty M, 2014, STROKE, V45, P2656, DOI 10.1161/STROKEAHA.114.006247
NR 65
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E727
EP E737
DI 10.1016/j.wneu.2019.03.255
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300091
PM 30951913
DA 2020-05-12
ER

PT J
AU Nakano, Y
   Kitagawa, T
   Osada, Y
   Tanaka, T
   Nishizawa, S
   Yamamoto, J
AF Nakano, Yoshiteru
   Kitagawa, Takehiro
   Osada, Yoshio
   Tanaka, Tohru
   Nishizawa, Shigeru
   Yamamoto, Junkoh
TI 5-Aminolevulinic Acid Suppresses Prostaglandin E2 Production by Murine
   Macrophages and Enhances Macrophage Cytotoxicity Against Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE 5-Aminolevulinic acid; COX-2; Glioma; mPGES-1; Prostaglandin E-2
ID INDUCED PROTOPORPHYRIN IX; PHOTODYNAMIC THERAPY; E-2 SYNTHESIS; TUMOR;
   EXPRESSION; BRAIN; INDUCTION; MECHANISM; ABILITY; IL-10
AB BACKGROUND: 5-Aminolevulinic acid (5-ALA) induces the accumulation of a large amount of protoporphyrin IX (PpIX) in tumors, which has been used in the treatment of several cancers. 5-ALA is commonly used for fluorescence-guided tumor resection in clinical neurosurgery and for photodynamic therapy based on the generation of cytotoxic oxygen.
   OBJECTIVE: The purpose of this study was to identify the mechanisms of 5-ALA-induced immune response in macrophages in malignant glioma.
   METHODS: Intracellular levels of 5-ALA-induced PpIX in C3H/HeN murine peritoneal macrophages were measured by the median fluorescence intensity using flow cytometry and confocal laser scanning microscopy. Macrophages were cultured in vitro with or without 0.5 mM 5-ALA, 0.1 tg/mL lipopolysaccharide, and 20% glioma-conditioned medium. Levels of immunosuppressive prostaglandin E-2 (PGE(2)), interleukin-10, and transforming growth factor beta were measured using enzyme immunoassay in the culture supernatant. In addition, macrophages and RSV-M mouse glioma cells were co-cultured in vitro with cell culture inserts with or without 5-ALA (0.1 and 0.5 mM) and lipopolysaccharide (0.1 mu g/mL).
   RESULTS: We found that 5-ALA-induced PpIX accumulated in macrophages and significantly suppressed PGE(2) production and expression of both cyclooxygenase-2 and microsomal prostaglandin E synthase-1. 5-ALA treatment also suppressed PGE(2) production by glioma-conditioned medium. 5-ALA suppressed RSV-M glioma cell proliferation in a concentration-dependent manner.
   CONCLUSIONS: These results indicate that 5-ALA suppressed PGE(2) production by macrophages via the down-regulation of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression levels. This is a novel mechanism to induce effective immune response against glioma in macrophages.
C1 [Nakano, Yoshiteru; Kitagawa, Takehiro; Nishizawa, Shigeru; Yamamoto, Junkoh] Univ Occupat & Environm Hlth, Sch Med, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
   [Osada, Yoshio] Univ Occupat & Environm Hlth, Sch Med, Dept Immunol & Parasitol, Kitakyushu, Fukuoka, Japan.
   [Tanaka, Tohru] SBI Pharmaceut Co Ltd, Minato Ku, Tokyo, Japan.
RP Nakano, Y (reprint author), Univ Occupat & Environm Hlth, Sch Med, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
EM yo-naka@med.uoeh-u.ac.jp
FU JSPS (Japan Society for the Promotion of Science) KAKENHIMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [26861170]
FX This work was supported by JSPS (Japan Society for the Promotion of
   Science) KAKENHI grant number 26861170.
CR CSERR HF, 1992, IMMUNOL TODAY, V13, P507, DOI 10.1016/0167-5699(92)90027-5
   Demidova TN, 2004, INT J IMMUNOPATH PH, V17, P117, DOI 10.1177/039463200401700203
   EVANS S, 1990, J NATL CANCER I, V82, P34, DOI 10.1093/jnci/82.1.34
   Hebeda KM, 1998, ACTA NEUROCHIR, V140, P495, DOI 10.1007/s007010050131
   KAMBAYASHI T, 1995, J IMMUNOL, V154, P3383
   KATAMURA K, 1995, J IMMUNOL, V155, P4604
   Korbelik M, 2006, CANCER IMMUNOL IMMUN, V55, P900, DOI 10.1007/s00262-005-0088-4
   Korbelik M, 1997, BRIT J CANCER, V75, P202, DOI 10.1038/bjc.1997.34
   Korbelik M, 2006, LASER SURG MED, V38, P500, DOI 10.1002/lsm.20337
   KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775
   Kuroda E, 2000, J IMMUNOL, V164, P2386, DOI 10.4049/jimmunol.164.5.2386
   Kuroda E, 2003, J IMMUNOL, V170, P757, DOI 10.4049/jimmunol.170.2.757
   Loercher AE, 1999, J IMMUNOL, V163, P6251
   MAEDA H, 1995, J IMMUNOL, V155, P4926
   Mimura S, 1996, LASER SURG MED, V19, P168
   Mlkvy P, 1996, BRIT J CANCER, V73, P1473, DOI 10.1038/bjc.1996.279
   Muller P J, 1996, J Clin Laser Med Surg, V14, P263
   Nakano Y, 2006, J NEUROSURG, V104, P574, DOI 10.3171/jns.2006.104.4.574
   Nakano Y, 2008, J NEUROSURG, V108, P311, DOI 10.3171/JNS/2008/108/2/0311
   Parney IF, 2000, NEUROSURGERY, V46, P778, DOI 10.1097/00006123-200004000-00002
   SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Wang S, 2014, ULTRASOUND MED BIOL, V40, P2125, DOI 10.1016/j.ultrasmedbio.2014.05.007
   Wu CY, 1998, J IMMUNOL, V161, P2723
   Xiao H, 2009, CHINESE MED J-PEKING, V122, P1316, DOI 10.3760/cma.j.issn.0366-6999.2009.11.015
   Yamamoto J, 2005, INT J ONCOL, V27, P1207
   Yamamoto J, 2006, CLIN CANCER RES, V12, P7132, DOI 10.1158/1078-0432.CCR-06-0786
   Yamamoto J, 2015, MOL MED REP, V11, P1813, DOI 10.3892/mmr.2014.2991
   Yamamoto J, 2012, ONCOL REP, V27, P1748, DOI 10.3892/or.2012.1699
NR 29
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E669
EP E676
DI 10.1016/j.wneu.2019.03.240
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300083
PM 30947012
DA 2020-05-12
ER

PT J
AU Neufeld, EA
   Menacho, ST
   Shah, LM
AF Neufeld, Ethan A.
   Menacho, Sarah T.
   Shah, Lubdha M.
TI Craniocervical Junction and Posterior Fossa Dimensions can Affect Need
   for Decompressive Craniectomy in Posterior Cranial Fossa Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the American-Society-of-Neuroradiology
CY JUN 06, 2018
CL Vancouver, CANADA
SP Amer Soc Neuroradiol
DE Cerebellum; Cerebrovascular disorders; Posterior cranial fossa; Stroke
ID CEREBELLAR HEMORRHAGE; MANAGEMENT; MORTALITY
AB BACKGROUND: Posterior fossa hemorrhage (PFH) of the cerebellum is managed by decompressive craniectomy when there is clinical deterioration. There is no current consensus on an objective imaging method to determine which patients need surgery before clinical deterioration. We developed an imaging scoring tool by assessing initial hemorrhage diameter and posterior fossa (PF) measurements to determine which patients will benefit from early surgical intervention.
   METHODS: For this case-control study, we reviewed the electronic medical record to identify adults who presented with PFH over a 10-year period at our institution. Chart review for clinical findings and inciting factors were documented. The average diameter of PFH and the surrogate PF volume on initial imaging studies were measured. These measurements were correlated with surgical intervention. A scoring tool was developed based on radiographic and clinical data.
   RESULTS: Fifty-one patients met the inclusion criteria. The average hemorrhage diameter and the surrogate PF volume measurements were statistically different between surgical and nonsurgical cases (P < 0.001 and P = 0.019, respectively). The scoring system was created by dividing average hemorrhage diameter by surrogate PF volume and multiplying by 1000. The median score of nonsurgical patients was 9.1, and the median score of surgical patients was 15.6.
   CONCLUSIONS: Patients presenting with PFH with smaller PF volumes may be more likely to require surgery as determined by clinical standards. The proposed scoring system based on simple measurements on initial computed tomography and magnetic resonance imaging may help surgeons consider early surgical intervention in those patients with PFH with smaller PF volumes.
C1 [Neufeld, Ethan A.; Shah, Lubdha M.] Univ Utah, Dept Neuroradiol, Salt Lake City, UT 84112 USA.
   [Menacho, Sarah T.] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA.
RP Neufeld, EA (reprint author), Univ Utah, Dept Neuroradiol, Salt Lake City, UT 84112 USA.
EM ethan.neufeld@hsc.utah.edu
CR Aguilar MI, 2011, NEUROHOSPITALIST, V1, P148, DOI 10.1177/1941875211409050
   Alperin N, 2014, NEUROSURGERY, V75, P515, DOI 10.1227/NEU.0000000000000507
   Amar AP, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS11369
   Arnone GD, 2017, WORLD NEUROSURG, V106, P543, DOI 10.1016/j.wneu.2017.07.041
   Dastur CK, 2017, STROKE VASC NEUROL, V2, P21, DOI 10.1136/svn-2016-000047
   DINSDALE HB, 1964, ARCH NEUROL-CHICAGO, V10, P200, DOI 10.1001/archneur.1964.00460140086011
   Karadan U, 2018, J STROKE CEREBROVASC, V27, pE73, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.007
   Kirollos RW, 2001, NEUROSURGERY, V49, P1378, DOI 10.1097/00006123-200112000-00015
   KOBAYASHI S, 1994, NEUROSURGERY, V34, P246, DOI 10.1227/00006123-199402000-00006
   Luney MS, 2016, NEUROCRIT CARE, V25, P365, DOI 10.1007/s12028-015-0217-7
   MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287
   Puffer RC, 2016, WORLD NEUROSURG, V92, P166, DOI 10.1016/j.wneu.2016.05.003
   Rojas CA, 2007, AM J NEURORADIOL, V28, P1819, DOI 10.3174/ajnr.A0660
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   Salvetti M, 2018, HIGH BLOOD PRESS CAR, V25, P191, DOI 10.1007/s40292-018-0262-3
   Sekula Jr. R.F., 2005, CEREBROSPINAL FLUID, V2, P11, DOI [DOI 10.1186/1743-8454-2-11, 10.1186/1743-8454-2-11]
   SMOKER WRK, 1994, RADIOGRAPHICS, V14, P255, DOI 10.1148/radiographics.14.2.8190952
   TANEDA M, 1987, J NEUROSURG, V67, P545, DOI 10.3171/jns.1987.67.4.0545
   VANLOON J, 1993, ACTA NEUROCHIR, V122, P187, DOI 10.1007/BF01405527
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E570
EP E577
DI 10.1016/j.wneu.2019.03.208
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300071
PM 30928591
DA 2020-05-12
ER

PT J
AU Niknejad, HR
   Stockx, L
   Wuyts, J
AF Niknejad, Hamid Reza
   Stockx, Luc
   Wuyts, Jan
TI Minimally Invasive Aneurysm Clipping: The Extent of the Supraorbital
   Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Clipping; Supraorbital approach
AB BACKGROUND: The supraorbital keyhole craniotomy is a well-established minimally invasive approach for the treatment of intracranial aneurysms. However, the surgical range of exposure using this technique for treatment of intracranial aneurysms has not been studied.
   METHODS: We retrospectively reviewed the data of all clipped aneurysm cases using the supraorbital approach (SO) between 2006 and 2016 in our center. Most importantly, we determined the location of the treated aneurysms in the axial 2-dimensional plane, with the anterior clinoid process (ACP) as the point of reference: the ACP to aneurysm distance. Finally, we extracted data on patient age, aneurysm size, size of the craniotomy, length of hospital stay, and surgery-related complications.
   RESULTS: We included 142 patients for this series. A total of 170 aneurysms were clipped by means of the SO, and in 18 cases multiple aneurysms were treated during the same surgery. The mean aneurysm size was 7 mm (3.5-22 mm) and the mean craniotomy size was 28 mm (19-41 mm). The aneurysm location ranged from 14.4 mm medially to 35 mm laterally, measured with the ipsilateral ACP as the zero reference.
   CONCLUSIONS: Although the SO is conventionally used in the treatment of anterior circulation aneurysms, we were able to treat aneurysms over a range of 50 mm over the skull base. With its low complication risk, relatively short hospital stay, and excellent cosmetic results, SO remains a valuable treatment option for both young and aged patients.
C1 [Wuyts, Jan] Ziekenhuis Oost Limburg, Dept Neurosurg, Genk, Belgium.
   [Stockx, Luc] Ziekenhuis Oost Limburg, Dept Intervent Neuroradiol, Genk, Belgium.
   [Niknejad, Hamid Reza] Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium.
RP Niknejad, HR (reprint author), Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium.
EM hamidreza.niknejad@uzleuven.be
CR Acciarri N, 2016, J NEUROSURG SCI, V60, P83
   Cheng Y, 2013, J CRANIOFAC SURG, V24, P2098, DOI 10.1097/SCS.0b013e31829ae3af
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   DELASHAW JB, 1992, NEUROSURGERY, V30, P954, DOI 10.1227/00006123-199206000-00028
   Figueiredo EG, 2006, NEUROSURGERY, V59, P212, DOI 10.1227/01.NEU.0000223365.55701.F2
   Madhugiri VS, 2013, WORLD NEUROSURG, V80, P836, DOI 10.1016/j.wneu.2013.02.072
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Mori Kentaro, 2014, Asian J Neurosurg, V9, P14, DOI 10.4103/1793-5482.131059
   Pierot L, 2017, AM J NEURORADIOL, V38, P1151, DOI 10.3174/ajnr.A5178
   Reisch R, 2003, SURG NEUROL, V59, P223, DOI 10.1016/S0090-3019(02)01037-6
   ROSEGAY H, 1992, J NEUROSURG, V76, P1032, DOI 10.3171/jns.1992.76.6.1032
   Steiger HJ, 2001, NEUROSURGERY, V48, P347, DOI 10.1097/00006123-200102000-00021
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Yasa Y, 2017, J CRANIOFAC SURG, V28, pE70, DOI 10.1097/SCS.0000000000003223
   Zumofen DW, 2017, WORLD NEUROSURG, V98, P614, DOI 10.1016/j.wneu.2016.10.110
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1132
EP E1136
DI 10.1016/j.wneu.2019.04.068
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300140
PM 30986584
DA 2020-05-12
ER

PT J
AU Nomura, S
   Akagawa, H
   Yamaguchi, K
   Ishikawa, T
   Kawashima, A
   Kasuya, H
   Mukawa, M
   Nariai, T
   Maehara, T
   Okada, Y
   Kawamata, T
AF Nomura, Shunsuke
   Akagawa, Hiroyuki
   Yamaguchi, Koji
   Ishikawa, Tatsuya
   Kawashima, Akitsugu
   Kasuya, Hidetoshi
   Mukawa, Maki
   Nariai, Tadashi
   Maehara, Taketoshi
   Okada, Yoshikazu
   Kawamata, Takakazu
TI Rare and Low-Frequency Variants in RNF213 Confer Susceptibility to
   Moyamoya Syndrome Associated with Hyperthyroidism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hyperthyroidism; Moyamoya syndrome; Next-generation sequencing; RNF213
ID MAGNETIC-RESONANCE ANGIOGRAPHY; MICE LACKING RNF213; TEMPORAL PROFILE;
   P.R4810K POLYMORPHISM; GENETIC-VARIATION; MEDICAL PROGRESS; DISEASE
AB BACKGROUND: Moyamoya syndrome (MMS), distinguished from definite moyamoya disease (MMD), is characterized by moyamoya vasculopathy thought to develop secondary to underlying conditions (e.g., hyperthyroidism). Recent studies have shown that a proportion of East Asian (EAS) patients with MMS possess the p.R4810K variant of RNF213 (rs112735431), the foremost susceptibility variant among EAS patients with MMD. We evaluated the association between hyperthyroidism-associated MMS (hMMS) and sequence variants in RNF213.
   METHODS: We performed next-generation sequencing of RNF213 in 15 patients with hMMS. Candidate coding variants for the association analysis were defined by allelic frequencies of <1%, based on the p.R4810K frequency in the Japanese population. The association with hMMS was tested using a collapsing method, and 260 unrelated EAS women from the 1000 Genomes Project served as population-based controls.
   RESULTS: All patients were female, reflecting female predominance in both moyamoya and hyperthyroid conditions. Five candidate missense variants in RNF213 were identified in 8 of 15 patients (53.3%): p.C118R, p.R4062Q, and p.R4810K as heterozygous; and p.A3468V and p.S3986N as compound heterozygous with p.R4810K. Among 260 EAS female controls, 36 (13.8%) had putatively functional variants. All identified variants were missense variants and were significantly overrepresented among patients compared with EAS controls (permuted P = 0.00010; odds ratio = 7.03; 95% confidence interval, 2.09-24.3).
   CONCLUSIONS: Rare and low-frequency missense variants in RNF213 confer susceptibility to both MMD and hMMS. This finding indicates that susceptibility variants in RNF213 may require additional clinical factors with an effect equivalent to hyperthyroidism in order to develop moyamoya vasculopathy.
C1 [Nomura, Shunsuke; Yamaguchi, Koji; Ishikawa, Tatsuya; Okada, Yoshikazu; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
   [Akagawa, Hiroyuki] Tokyo Womens Med Univ, Inst Integrated Med Sci TIIMS, Tokyo, Japan.
   [Kawashima, Akitsugu] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Neurosurg, Chiba, Japan.
   [Akagawa, Hiroyuki; Kasuya, Hidetoshi] Tokyo Womens Med Univ, Med Ctr, Dept Neurosurg, Tokyo, Japan.
   [Mukawa, Maki; Nariai, Tadashi; Maehara, Taketoshi] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan.
RP Akagawa, H (reprint author), Tokyo Womens Med Univ, Inst Integrated Med Sci TIIMS, Tokyo, Japan.; Akagawa, H (reprint author), Tokyo Womens Med Univ, Med Ctr, Dept Neurosurg, Tokyo, Japan.
EM akagawa.hiroyuki@twmu.ac.jp
OI Ishikawa, Tatsuya/0000-0003-3553-6510; Nariai,
   Tadashi/0000-0001-8819-4855
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16K10740,
   17K16629]
FX The authors report no conflict of interest regarding the materials or
   methods used in this study or the findings specified in this paper. This
   work was supported by JSPS KAKENHI grant numbers 16K10740 (H. Akagawa)
   and 17K16629 (M. Mukawa).
CR Akagawa Hiroyuki, 2018, Hum Genome Var, V5, P17060, DOI 10.1038/hgv.2017.60
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   [Anonymous], 2012, NEUROL MED CHIR TOKY, V52, P245, DOI DOI 10.2176/NMC.52.245
   Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987
   Carithers LJ, 2015, BIOPRESERV BIOBANK, V13, P311, DOI 10.1089/bio.2015.0032
   Cecchi AC, 2014, STROKE, V45, P3200, DOI 10.1161/STROKEAHA.114.006244
   Colleran Kathleen M, 2003, Endocr Pract, V9, P290
   De Leo S, 2016, LANCET, V388, P906, DOI 10.1016/S0140-6736(16)00278-6
   Fujimura M, 2014, J STROKE, V16, P65, DOI 10.5853/jos.2014.16.2.65
   Guey S, 2017, EUR J HUM GENET, V25, P995, DOI 10.1038/ejhg.2017.92
   Kamada F, 2011, J HUM GENET, V56, P34, DOI 10.1038/jhg.2010.132
   Kanoke A, 2016, BRAIN RES, V1642, P1, DOI 10.1016/j.brainres.2016.03.009
   Kanoke A, 2015, BRAIN RES, V1624, P497, DOI 10.1016/j.brainres.2015.07.039
   Kim JS, 2016, J STROKE, V18, P2, DOI 10.5853/jos.2015.01627
   Kim SJ, 2010, STROKE, V41, P173, DOI 10.1161/STROKEAHA.109.562264
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Kobayashi H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164759
   Koizumi A, 2016, ENVIRON HEALTH PREV, V21, P55, DOI 10.1007/s12199-015-0498-7
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024
   Li DS, 2013, CLIN NEUROL NEUROSUR, V115, P1647, DOI 10.1016/j.clineuro.2013.02.018
   Liu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022542
   Miyawaki S, 2015, J STROKE CEREBROVASC, V24, P1075, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.005
   Morimoto T, 2016, J STROKE CEREBROVASC, V25, P2632, DOI 10.1016/j.jstrokecerebrovasdis.2016.07.004
   Morris AP, 2010, GENET EPIDEMIOL, V34, P188, DOI 10.1002/gepi.20450
   Moteki Y, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001862
   Mukawa M, 2017, J STROKE CEREBROVASC, V26, P150, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.003
   Nomura S, 2018, J NEUROSURG, V129, P563, DOI 10.3171/2018.1.JNS173211
   Phi JH, 2016, J NEUROSURG-PEDIATR, V17, P717, DOI 10.3171/2015.10.PEDS15537
   Price AL, 2010, AM J HUM GENET, V86, P832, DOI 10.1016/j.ajhg.2010.04.005
   Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407
   Ryu B, 2015, ACTA NEUROCHIR, V157, P1095, DOI 10.1007/s00701-015-2422-8
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   SIEGERT CEH, 1995, STROKE, V26, P496, DOI 10.1161/01.STR.26.3.496
   Sonobe S, 2014, BRAIN RES, V1552, P64, DOI 10.1016/j.brainres.2014.01.011
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   VANDIEMENSTEENVOORDE R, 1990, NEUROPEDIATRICS, V21, P110, DOI 10.1055/s-2008-1071474
   Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707
   Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105
   Zhang Q, 2017, WORLD NEUROSURG, V99, P701, DOI 10.1016/j.wneu.2016.12.119
   Zhou SR, 2016, AM J HUM GENET, V99, P1072, DOI 10.1016/j.ajhg.2016.09.001
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E460
EP E466
DI 10.1016/j.wneu.2019.03.172
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300056
PM 30922903
DA 2020-05-12
ER

PT J
AU Ohba, S
   Murayama, K
   Abe, M
   Hasegawa, M
   Hirose, Y
AF Ohba, Shigeo
   Murayama, Kazuhiro
   Abe, Masato
   Hasegawa, Mitsuhiro
   Hirose, Yuichi
TI Magnetic Resonance Imaging and Proton Magnetic Resonance Spectroscopy
   for Differentiating Between Enhanced Gliomas and Malignant Lymphomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE ADC; Glioma; Malignant lymphoma; MRS
ID NERVOUS-SYSTEM LYMPHOMA; MR SPECTROSCOPY; GLIOBLASTOMA-MULTIFORME;
   DIFFUSION; GRADE
AB BACKGROUND: Although the treatment strategies for malignant lymphomas and gliomas differ, it is usually difficult to preoperatively distinguish between them. Magnetic resonance spectroscopy (MRS) was recently reported to be useful for preoperative diagnoses; however, MRS data analysis using LCModel, which is a quantitative and objective method, was performed in only a few of the existing reports.
   METHODS: The clinical characteristics, conventional magnetic resonance imaging findings, and MRS parameters using LCModel were evaluated to identify the factors that can help distinguish between malignant lymphomas and enhanced gliomas.
   RESULTS: In total, 59 cases were evaluated, including 13 cases of malignant lymphoma, 1 case of pilocytic astrocytoma, 5 cases of grade II glioma, 5 cases of grade III glioma, and 35 cases of glioblastoma. There was no correlation between clinical characteristics (sex and age) and diagnosis. Neither T1- nor T2-weighted image was useful for differentiation between the 2 forms of tumors, but the apparent diffusion coefficient minimum value was useful for distinguishing malignant lymphomas from gliomas, with an area under the curve (AUC) value of 0.852. MRS analysis using LCModel revealed differences in glutamate (Glu), N-acetylaspartate (NAA) + N-acetylaspartylglutamate NAAG), Glu + glutamine, and Lipid (Lip) 13a + Lip13b between malignant lymphomas and gliomas. The largest AUC was 0.904, which was obtained for the Glu level, followed by 0.883 and 0.866 for NAA + NAAG and Lip13a + Lip13b, respectively.
   CONCLUSIONS: Quantitative analysis of proton-MRS using LCModel is considered to be a valuable method for distinguishing between gliomas and malignant lymphomas.
C1 [Ohba, Shigeo; Hasegawa, Mitsuhiro; Hirose, Yuichi] Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan.
   [Murayama, Kazuhiro] Fujita Hlth Univ, Dept Radiol, Toyoake, Aichi, Japan.
   [Abe, Masato] Fujita Hlth Univ, Dept Pathol, Toyoake, Aichi, Japan.
RP Ohba, S (reprint author), Fujita Hlth Univ, Dept Neurosurg, Toyoake, Aichi, Japan.
EM shigeo.ohba@gmail.com
CR Aburano H, 2015, JPN J RADIOL, V33, P392, DOI 10.1007/s11604-015-0430-5
   ASARI S, 1994, NEURORADIOLOGY, V36, P308, DOI 10.1007/BF00593267
   Calli C, 2006, EUR J RADIOL, V58, P394, DOI 10.1016/j.ejrad.2005.12.032
   Chawla S, 2010, J COMPUT ASSIST TOMO, V34, P836, DOI 10.1097/RCT.0b013e3181ec554e
   Citterio G, 2017, CRIT REV ONCOL HEMAT, V113, P97, DOI 10.1016/j.critrevonc.2017.03.019
   Di Carlo DT, 2019, NEUROSURG REV, V42, P263, DOI 10.1007/s10143-017-0928-7
   Harting I, 2003, NEUROSCI LETT, V342, P163, DOI 10.1016/S0304-3940(03)00272-6
   Ko CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162565
   Lehmann C, 2009, BRAIN RES, V1297, P1, DOI 10.1016/j.brainres.2009.08.070
   Lin X, 2017, AM J NEURORADIOL, V38, P485, DOI 10.3174/ajnr.A5023
   Lolli V, 2010, NEURORADIOL J, V23, P680, DOI 10.1177/197140091002300606
   Lu SS, 2017, J COMPUT ASSIST TOMO, V41, P898, DOI 10.1097/RCT.0000000000000622
   Mansour A, 2014, CANCER IMAGING, V14, DOI 10.1186/1470-7330-14-22
   Mohan S, 2010, NEURORADIOL J, V23, P269, DOI 10.1177/197140091002300302
   Mora P, 2014, EUR RADIOL, V24, P2895, DOI 10.1007/s00330-014-3308-5
   MOUNTFORD CE, 1988, TRENDS BIOCHEM SCI, V13, P172, DOI 10.1016/0968-0004(88)90145-4
   Nagashima H, 2018, J NEURO-ONCOL, V136, P317, DOI 10.1007/s11060-017-2655-x
   Oz G, 2014, RADIOLOGY, V270, P658, DOI 10.1148/radiol.13130531
   POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6
   Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698
   Toh CH, 2008, AM J NEURORADIOL, V29, P471, DOI 10.3174/ajnr.A0872
   Toh CH, 2006, J NEUROSURG, V105, P132, DOI 10.3171/jns.2006.105.1.132
   Verma A, 2016, BBA CLIN, V5, P170, DOI 10.1016/j.bbacli.2016.04.002
   Wen JB, 2017, J COMPUT ASSIST TOMO, V41, P904, DOI 10.1097/RCT.0000000000000636
   Yamasaki F, 2015, J NEUROSURG, V122, P1370, DOI 10.3171/2014.9.JNS14106
   Zhang SH, 2016, PAK J MED SCI, V32, P389, DOI 10.12669/pjms.322.9013
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E779
EP E787
DI 10.1016/j.wneu.2019.03.261
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300097
PM 30951915
DA 2020-05-12
ER

PT J
AU Otero-Rodriguez, A
   Sousa-Casasnovas, P
   Cruz-Terron, H
   Arandia-Guzman, DA
   Garcia-Martin, A
   Pascual-Argente, D
   Munoz-Martin, MC
AF Otero-Rodriguez, Alvaro
   Sousa-Casasnovas, Pablo
   Cruz-Terron, Helena
   Angel Arandia-Guzman, Daniel
   Garcia-Martin, Andoni
   Pascual-Argente, Daniel
   Cristina Munoz-Martin, Maria
TI Utility of Radiologic Variables to Predict the Result of Lumbar Infusion
   Test in the Diagnosis of Idiopathic Normal Pressure Hydrocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Callosal angle; Cingulate sulcus sign; DESH; Idiopathic normal pressure
   hydrocephalus; Lumbar infusion test; Rout; Temporal horn
ID CALLOSAL ANGLE; MANAGEMENT; MRI; GUIDELINES; SHUNT
AB BACKGROUND: Diagnosis of idiopathic normal pressure hydrocephalus is based in clinical data, radiologic variables, and invasive cerebrospinal fluid (CSF) testing, such as the lumbar infusion test. Several neuroimaging findings are inconclusively related to improvement after CSF shunt surgery. CSF tests are invasive and have complications. The aim of this study was to select radiologic variables related to a positive lumbar infusion test so as to avoid this test in patients.
   METHODS: Patients with possible idiopathic normal pressure hydrocephalus were reviewed. The collected radiologic data were cingulate sulcus sign, disproportionately enlarged subarachnoid space, callosal angle, and width of temporal horns. Two groups were established: group 1, comprising patients with resistance to CSF outflow <12 mm Hg/ml/minute, and group 2, comprising patients with resistance to CSF outflow >12 mm Hg/ml/minute. Negative and positive predictive values were determined.
   RESULTS: The study included 43 patients in group 1 and 64 patients in group 2. Group 2 significantly showed more acute callosal angle with higher accuracy cutoff value of 90.6 degrees, lower width of temporal horns with higher accuracy cutoff value of 8 mm, and higher percentage of cingulate sulcus sign and disproportionately enlarged subarachnoid space. Matching the radiologic variables, positive predictive values were >80%; however, negative predictive values were low.
   CONCLUSIONS: Owing to high positive predictive values of matched radiological variables, the lumbar infusion test could be avoided in the diagnosis of idiopathic normal pressure hydrocephalus. However, when 1 or 2 of the variables are negative, this invasive test should be performed.
C1 [Otero-Rodriguez, Alvaro; Sousa-Casasnovas, Pablo; Angel Arandia-Guzman, Daniel; Garcia-Martin, Andoni; Pascual-Argente, Daniel] Complejo Asistencial Univ Salamanca, Dept Neurosurg, Salamanca, Spain.
   [Cruz-Terron, Helena] Univ Salamanca, Dept Surg, Salamanca, Spain.
   [Cristina Munoz-Martin, Maria] Gerencia Atenc Primaria Salamanca, Salamanca, Spain.
RP Otero-Rodriguez, A (reprint author), Complejo Asistencial Univ Salamanca, Dept Neurosurg, Salamanca, Spain.
EM aoteror@saludcastillayleon.es
CR Adachi Michito, 2006, Radiat Med, V24, P568, DOI 10.1007/s11604-006-0074-6
   BRADLEY WG, 1991, RADIOLOGY, V178, P459, DOI 10.1148/radiology.178.2.1987609
   Brean A, 2008, EUR J NEUROL, V15, P605, DOI 10.1111/j.1468-1331.2008.02134.x
   Craven CL, 2016, J CLIN NEUROSCI, V34, P294, DOI 10.1016/j.jocn.2016.09.004
   Halperin JJ, 2015, NEUROLOGY, V85, P2063, DOI 10.1212/WNL.0000000000002193
   Hashimoto M, 2010, FLUIDS BARRIERS CNS, V7, P2, DOI 10.1186/1743-8454-7-18
   Holodny AI, 1998, J NEUROSURG, V89, P742, DOI 10.3171/jns.1998.89.5.0742
   Ishii K, 2008, EUR RADIOL, V18, P2678, DOI 10.1007/s00330-008-1044-4
   Klassen BT, 2011, NEUROLOGY, V77, P1119, DOI 10.1212/WNL.0b013e31822f02f5
   LEMAY M, 1970, RADIOLOGY, V96, P347, DOI 10.1148/96.2.347
   Marmarou A, 2005, NEUROSURGERY, V57, P17, DOI 10.1227/01.NEU.0000168184.01002.60
   Marmarou A, 2005, NEUROSURGERY, V57, pI, DOI 10.1097/00006123-200509001-00001
   Marmarou A, 2005, J NEUROSURG, V102, P987, DOI 10.3171/jns.2005.102.6.0987
   Mori E, 2012, NEUROL MED-CHIR, V52, P775, DOI 10.2176/nmc.52.775
   Relkin Norman, 2005, Neurosurgery, V57, pS4
   Tanaka N, 2009, NEUROEPIDEMIOLOGY, V277, P54
   Virhammar J, 2014, AM J NEURORADIOL, V35, P2311, DOI 10.3174/ajnr.A4046
   Virhammar J, 2014, J NEUROSURG, V120, P178, DOI 10.3171/2013.8.JNS13575
   Wikkelso C, 2013, J NEUROL NEUROSUR PS, V84, P562, DOI 10.1136/jnnp-2012-303314
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E957
EP E964
DI 10.1016/j.wneu.2019.04.009
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300119
PM 30965169
DA 2020-05-12
ER

PT J
AU Park, J
   Kwak, Y
   Kim, CH
   Lee, Y
   Choi, YJ
   Kang, DH
   Ohk, B
AF Park, Jaechan
   Kwak, Youngseok
   Kim, Chang-Hyun
   Lee, Youngseop
   Choi, Yeon-Ju
   Kang, Dong-Hun
   Ohk, Boram
TI Intraoperative Mannitol Administration Increases the Risk of
   Postoperative Chronic Subdural Hemorrhage After Unruptured Aneurysm
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hemorrhage; Craniotomy; Intracranial aneurysm; Mannitol
ID HYPERTONIC SALINE; CRANIOTOMY; HEMATOMA; BRAIN
AB OBJECTIVE: Although mannitol is used widely to facilitate brain retraction in cases of ruptured aneurysms, there is no consensus about the intraoperative administration of mannitol in the case of unruptured aneurysms. Accordingly, this study was conducted to identify an intraoperative mannitol administration strategy.
   METHODS: Mannitol was administered routinely to patients (n = 90) from January 2015 to April 2016 and not administered to patients (n = 97) from May 2016 to June 2017. The patient groups with and without mannitol administration were then compared based on the patient medical records, radiologic data, and digital recordings from an intraoperative microscope.
   RESULTS: The patient groups with and without mannitol administration were comparable regarding patient age, number of elderly patients, sex, and aneurysm locations. No between-group difference was identified in terms of the intradural procedural time, retraction-induced cortical injury, postoperative electrolyte imbalance, symptomatic infarction, and postoperative epidural hematomas. However, the patient group without mannitol administration showed a significantly lower incidence of chronic subdural hematomas (CSDHs) >50 ml (13.3% vs. 3.1%, P = 0.010). Moreover, a multivariate analysis revealed that an advanced age (P = 0.019), male sex (P <0.001), and mannitol administration (P = 0.040) were all statistically significant risk factors for a postoperative CSDH >50 mL following unruptured aneurysm surgery.
   CONCLUSIONS: Withholding the administration of mannitol during a pterional or modified procedure for unruptured aneurysms was found to reduce the postoperative occurrence of a CSDH without increasing the operative difficulties or other postoperative complications.
C1 [Park, Jaechan; Lee, Youngseop; Choi, Yeon-Ju; Kang, Dong-Hun] Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Daegu, South Korea.
   [Park, Jaechan; Lee, Youngseop; Choi, Yeon-Ju; Kang, Dong-Hun] Kyungpook Natl Univ, Sch Med, Biomed Res Inst, Daegu, South Korea.
   [Kwak, Youngseok] Catholic Univ Daegu, Sch Med, Dept Neurosurg, Daegu, South Korea.
   [Kim, Chang-Hyun] Keimyung Univ, Sch Med, Dept Neurosurg, Daegu, South Korea.
   [Ohk, Boram] Kyungpook Natl Univ Hosp, Clin Trial Ctr, Daegu, South Korea.
RP Park, J (reprint author), Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Daegu, South Korea.; Park, J (reprint author), Kyungpook Natl Univ, Sch Med, Biomed Res Inst, Daegu, South Korea.
EM jparkmd@hotmail.com
OI Kim, Chang-Hyun/0000-0001-5401-5660
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI15C0001]
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (HI15C0001).
CR Barrow DL, 2004, NEUROL INDIA, V52, P156
   Beritashvili N, 1997, CLIN HEMORHEOL MICRO, V17, P285
   Chatterjee N, 2012, J NEUROSURG ANESTH, V24, P25, DOI 10.1097/ANA.0b013e3182338b11
   Cho WS, 2018, J KOREAN NEUROSURG S, V61, P127, DOI 10.3340/jkns.2017.0404.005
   Diringer MN, 2012, NEUROSURGERY, V70, P1215, DOI 10.1227/NEU.0b013e3182417bc2
   Fanous AA, 2016, WORLD NEUROSURG, V91, DOI 10.1016/j.wneu.2016.04.021
   Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007
   Hassan ZU, 2007, J CLIN ANESTH, V19, P307, DOI 10.1016/j.jclinane.2006.09.005
   Hirota Kiichi, 2005, J Anesth, V19, P75, DOI 10.1007/s00540-004-0270-4
   Inamasu J, 2013, J CLIN NEUROSCI, V20, P1095, DOI 10.1016/j.jocn.2012.09.024
   JAFAR JJ, 1986, J NEUROSURG, V64, P754, DOI 10.3171/jns.1986.64.5.0754
   Kaneda K, 2010, J CLIN PHARMACOL, V50, P536, DOI 10.1177/0091270009348973
   Kwon MY, 2016, J KOREAN NEUROSURG S, V59, P458, DOI 10.3340/jkns.2016.59.5.458
   Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359
   Lee WJ, 2018, J KOREAN NEUROSURG S, V61, P761, DOI 10.3340/jkns.2017.0242
   MANNINEN PH, 1987, CAN J ANAESTH, V34, P442, DOI 10.1007/BF03014345
   Mori K, 2003, ACTA NEUROCHIR, V145, P533, DOI 10.1007/s00701-003-0026-1
   Moroi J, 2005, NEUROSURGERY, V56, P224, DOI 10.1227/01.neu.0000148897.28828.85
   Nolte J., 2009, HUMAN BRAIN INTRO IT, P80
   Ogilvy CS, 1996, J NEUROSURG, V84, P785, DOI 10.3171/jns.1996.84.5.0785
   Ohno T, 2013, WORLD NEUROSURG, V80, P534, DOI 10.1016/j.wneu.2012.09.025
   Park J, 2016, J NEUROSURG, V124, P310, DOI 10.3171/2015.1.JNS14309
   Park J, 2011, J NEUROSURG, V115, P700, DOI 10.3171/2011.5.JNS102087
   Park J, 2014, J KOREAN NEUROSURG S, V56, P371, DOI 10.3340/jkns.2014.56.5.371
   Park J, 2011, NEUROSURGERY, V68, P300, DOI 10.1227/NEU.0b013e3182124810
   RAVUSSIN P, 1993, NEUROSURGERY, V32, P236, DOI 10.1227/00006123-199302000-00013
   Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94
   Seo H, 2017, J NEUROSURG, V126, P1839, DOI 10.3171/2016.6.JNS16537
   TANAKA Y, 1987, SURG NEUROL, V27, P353, DOI 10.1016/0090-3019(87)90010-3
   Tuffiash E, 2003, STROKE, V34, P2195, DOI 10.1161/01.STR.0000087787.38080.B8
   Yoshimoto Y, 1998, J NEUROSURG, V88, P485, DOI 10.3171/jns.1998.88.3.0485
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E919
EP E924
DI 10.1016/j.wneu.2019.03.296
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300114
PM 30959258
DA 2020-05-12
ER

PT J
AU Pasarikovski, CR
   Tanner, BK
   Marques, AJP
   da Costa, L
   Howard, P
   Dyer, EE
   Yang, VXD
AF Pasarikovski, Christopher R.
   Tanner, Breah K.
   Marques, Andrew J. P.
   da Costa, Leodante
   Howard, Peter
   Dyer, Erin E.
   Yang, Victor X. D.
TI Neurointerventional Procedural Complications in a Growing Canadian
   Regional Stroke Center: Single Hospital Experience Analysis in the
   Context of Recommended Case Volumes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Carotid; Case volume; Complications; Neurointerventional;
   Stroke
ID RUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; SUBARACHNOID
   HEMORRHAGE; THROMBECTOMY; STATEMENT; ENDARTERECTOMY; ASSOCIATION;
   COMPETENCE; MORTALITY; OUTCOMES
AB BACKGROUND: Evidence continues to emerge regarding the inverse relationship between high neurointerventional case volume and complication rates, leading several medical/surgical societies to recommend minimum volumes for specific procedures. Recent data suggest few centers are meeting these requirements. We report a single center's neurointerventional complication rates with associated case volumes, along with a review of the literature.
   METHODS: A retrospective cohort review of all consecutive patients undergoing diagnostic catheter cerebral angiography and/or neurointerventional procedures between January 1, 2013, and March 1, 2018, was undertaken. No diagnostic or interventional procedures were excluded. All major and minor complications were recorded.
   RESULTS: A total of 1000 procedures (463 diagnostic cerebral angiograms and 537 neurointerventional procedures) were completed. Of the neurointerventional procedures, 216 (40%) were endovascular thrombectomy, 170 (32%) were aneurysmal embolization, and 48 (9%) were carotid stenting. The mean and median age was 60 years. There were 460 women and 540 men. The total number of major complications for diagnostic angiography, endovascular thrombectomy, ruptured aneurysm embolization, unruptured aneurysm embolization, and carotid artery stenting were 4 (0.9%), 4 (1.9%), 10 (11%), 4 (5.4%), and 3 (6.3%), respectively.
   CONCLUSIONS: We provided a single-center experience of the relationship between neurointerventional procedural case volume and complication rates in the growth phase of our center's establishment. We demonstrated that as our center was being developed, specific procedural staffing measures allowed proficiency maintenance, acquisition of new techniques, and complication avoidance, whereas specific case volumes crossed the suggested thresholds as defined in the literature.
C1 [Pasarikovski, Christopher R.; da Costa, Leodante; Yang, Victor X. D.] Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
   [Tanner, Breah K.; Marques, Andrew J. P.; Howard, Peter] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
   [da Costa, Leodante; Dyer, Erin E.; Yang, Victor X. D.] Univ Toronto, Sunnybrook Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Tanner, Breah K.; Marques, Andrew J. P.; Yang, Victor X. D.] Ryerson Univ, Bioengn & Biophoton Lab, Toronto, ON, Canada.
   [Howard, Peter] Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Div Neuroradiol, Toronto, ON, Canada.
RP Pasarikovski, CR (reprint author), Univ Toronto, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
EM cpasarikovski2015@meds.uwo.ca
CR Alberts MJ, 2005, STROKE, V36, P1597, DOI 10.1161/01.STR.0000170622.07210.b4
   Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Citron Steven J, 2003, J Vasc Interv Radiol, V14, pS257
   Cognard C, 2011, NEUROSURGERY, V69, P837, DOI 10.1227/NEU.0b013e3182257b30
   Connors JJ, 2005, NEUROLOGY, V64, P190, DOI 10.1212/01.WNL.0000148958.34025.09
   Cross DT, 2003, J NEUROSURG, V99, P810, DOI 10.3171/jns.2003.99.5.0810
   DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997
   Fargen KM, 2017, J NEUROINTERV SURG, V9, P717, DOI 10.1136/neurintsurg-2017-013209
   Gallas S, 2005, AM J NEURORADIOL, V26, P1723
   Gonzales NR, 2014, STROKE, V45, P3320, DOI 10.1161/STROKEAHA.114.006228
   Grigoryan M, 2012, STROKE, V43, P1309, DOI 10.1161/STROKEAHA.111.636076
   Hassan AE, 2012, STROKE, V43, P3012, DOI 10.1161/STROKEAHA.112.658781
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982
   Qureshi AI, 2011, J NEUROSURG, V114, P834, DOI 10.3171/2010.6.JNS091486
   Renowden SA, 2009, CLIN NEUROL NEUROSUR, V111, P179, DOI 10.1016/j.clineuro.2008.09.026
   Rinaldo L, 2017, STROKE, V48, P1316, DOI 10.1161/STROKEAHA.116.016360
   Rosenfield KM, 2005, J VASC SURG, V41, P160, DOI 10.1016/j.jvs.2004.12.009
   Sarzetto F, 2017, WORLD NEUROSURG, V99, P593, DOI 10.1016/j.wneu.2016.12.054
   van Rooij WJ, 2006, AM J NEURORADIOL, V27, P1498
NR 22
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E94
EP E100
DI 10.1016/j.wneu.2019.02.137
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300013
PM 30851466
DA 2020-05-12
ER

PT J
AU Pennington, Z
   Lubelski, D
   D'Sa, A
   Westbroek, E
   Ahmed, AK
   Goodwin, ML
   Witham, TF
   Bydon, A
   Theodore, N
   Sciubba, DM
AF Pennington, Zach
   Lubelski, Daniel
   D'Sa, Adam
   Westbroek, Erick
   Ahmed, A. Karim
   Goodwin, Matthew L.
   Witham, Timothy F.
   Bydon, Ali
   Theodore, Nicholas
   Sciubba, Daniel M.
TI Preoperative Clinical and Radiographic Variables Predict Postoperative
   C5 Palsy
SO WORLD NEUROSURGERY
LA English
DT Article
DE C5 palsy; Cervical spine; Degenerative spine disease; Posterior cervical
   decompression
ID OPEN-DOOR LAMINOPLASTY; NERVE ROOT PALSY; MULTIVARIATE-ANALYSIS;
   CERVICAL LAMINECTOMY; DECOMPRESSION; FUSION; SPINE; SURGERY
AB BACKGROUND: Postoperative C5 palsy affects 8% of patients undergoing posterior cervical decompression. It is associated with a period functional disability that may exceed 12 months and increase direct care costs > $2000.
   METHODS: All patients undergoing posterior cervical decompression at a single tertiary-care facility for degenerative conditions were evaluated for preoperative imaging, clinical presentation, surgical operation, and postoperative course. We sought to identify those variables predictive of postoperative C5 palsy.
   RESULTS: Of 221 included patients (mean age, 63 years; 54% male), 12.2% experienced C5 palsy. On univariate analysis, C5 palsy was associated with foraminal diameter (P = 0.0005), spinal cord cross-sectional area (P = 0.11), number of levels undergoing laminectomy (P = 0.14), and clinical presentation of dropping objects (P = 0.07), hand clumsiness (P = 0.13), or paresthesias in the upper extremities (P = 0.08). Foramina! diameter (odds ratio, 0.31 per mm increase; 95% confidence interval, 0.16-0.60; P < 0.001) and patient report of gait disturbance (odds ratio, 0.53; 95% confidence interval, 0.33-0.85; P = 0.008) were the only significant predictors on multivariate analysis. A foraminal diameter <2 mm had 2-fold greater odds of postoperative C5 palsy. A receiver operating curve for the multivariate logistic model had an associated C-statistic of 0.7818. The absolute error of this model was 9.3% on internal validation.
   CONCLUSIONS: Foraminal stenosis most strongly predicted postoperative C5 palsy. A proof-of-concept model incorporating foramen size, as well as clinical complaints of paresthesias, hand clumsiness, and gait abnormality, successfully predicts the occurrence of postoperative palsy with an overall accuracy of 78%.
C1 [Pennington, Zach; Lubelski, Daniel; D'Sa, Adam; Westbroek, Erick; Ahmed, A. Karim; Goodwin, Matthew L.; Witham, Timothy F.; Bydon, Ali; Theodore, Nicholas; Sciubba, Daniel M.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Sciubba, DM (reprint author), Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dsciubb1@jhmi.edu
OI Pennington, Zachary/0000-0001-8012-860X
CR Acharya S, 2016, INDIAN J NEUROSURG, V5, P69, DOI 10.1055/s-0036-1586742
   Baba S, 2016, ASIAN SPINE J, V10, P298, DOI 10.4184/asj.2016.10.2.298
   Bydon M, 2014, SPINE J, V14, P2861, DOI 10.1016/j.spinee.2014.03.040
   Bydon M, 2014, NEUROSURGERY, V74, P595, DOI 10.1227/NEU.0000000000000322
   Chen GD, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0715-3
   Daniel JW, 2018, SPINE, V43, P1154, DOI 10.1097/BRS.0000000000002575
   Deutsch Harel, 2003, Neurosurg Focus, V15, pE5
   Dombrowski ME, 2019, SPINE J, V19, P253, DOI 10.1016/j.spinee.2018.05.031
   Gutkowska Olga, 2020, Neurosurg Rev, V43, P407, DOI 10.1007/s10143-018-1001-x
   Guzman JZ, 2014, BONE JOINT J, V96B, P950, DOI 10.1302/0301-620X.96B7.33665
   Hwang JC, 2010, J KOREAN NEUROSURG S, V47, P358, DOI 10.3340/jkns.2010.47.5.358
   Imagama S, 2010, J BONE JOINT SURG BR, V92B, P393, DOI 10.1302/0301-620X.92B3.22786
   Kang KC, 2017, CLIN SPINE SURG, V30, P419, DOI 10.1097/BSD.0000000000000505
   Kang Y, 2011, AM J ROENTGENOL, V197, pW134, DOI 10.2214/AJR.10.5560
   Kato S, 2017, J BONE JOINT SURG AM, V99, P1013, DOI 10.2106/JBJS.16.00882
   Katsumi K, 2013, J SPINAL DISORD TECH, V26, P177, DOI 10.1097/BSD.0b013e31823db346
   Knapik DM, 2018, GLOB SPINE J, V8, P600, DOI 10.1177/2192568218758085
   Komagata Masashi, 2004, Spine J, V4, P650, DOI 10.1016/j.spinee.2004.03.022
   Kratzig T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188338
   Lee HJ, 2016, CLIN NEUROL NEUROSUR, V143, P9, DOI 10.1016/j.clineuro.2016.02.007
   Lee S- H, 2014, BMJ-BRIT MED J, V41, P574
   Lubelski D, 2014, SPINE J, V14, P1895, DOI 10.1016/j.spinee.2013.10.038
   McCormick Z, 2015, J NAT SCI, V1, pe140
   Miller JA, 2014, SPINE J, V14, P2854, DOI 10.1016/j.spinee.2014.03.038
   Nakashima H, 2012, J NEUROSURG-SPINE, V17, P103, DOI 10.3171/2012.4.SPINE11255
   Nassr A, 2012, SPINE, V37, P174, DOI 10.1097/BRS.0b013e318219cfe9
   Nori S, 2017, EUR SPINE J, V26, P2393, DOI 10.1007/s00586-017-5202-8
   Palejwala Sheri K, 2017, Surg Neurol Int, V8, P92, DOI 10.4103/sni.sni_471_16
   Planchard RF, 2016, GLOB SPINE J, V6, P571, DOI 10.1055/s-0035-1570084
   Radcliff KE, 2014, J SPINAL DISORD TECH, V27, P86, DOI 10.1097/BSD.0b013e31824e53af
   Sasai K, 2003, SPINE, V28, P1972, DOI 10.1097/01.BRS.0000083237.94535.46
   Savage NJ, 2015, EUR SPINE J, V24, P434, DOI 10.1007/s00586-014-3469-6
   Sciubba DM, 2008, J NEUROSURG-SPINE, V8, P413, DOI 10.3171/SPI/2008/8/5/413
   Tetreault L, 2015, WORLD NEUROSURG, V83, P679, DOI 10.1016/j.wneu.2015.01.021
   Thompson SE, 2017, GLOB SPINE J S, V7, P708
   Vonck CE, 2018, GLOB SPINE J, V8, P244, DOI 10.1177/2192568217722562
   Zhang H, 2015, J SPINAL DISORD TECH, V28, P89, DOI 10.1097/BSD.0b013e3182695295
NR 37
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E585
EP E592
DI 10.1016/j.wneu.2019.03.211
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300073
PM 30928589
DA 2020-05-12
ER

PT J
AU Perry, A
   Kerezoudis, P
   Graffeo, CS
   Carlstrom, LP
   Peris-Celda, M
   Meyer, FB
   Bydon, M
   Link, MJ
AF Perry, Avital
   Kerezoudis, Panagiotis
   Graffeo, Christopher S.
   Carlstrom, Lucas P.
   Peris-Celda, Maria
   Meyer, Fredric B.
   Bydon, Mohamad
   Link, Michael J.
TI Little Insights from Big Data: Cerebrospinal Fluid Leak After Skull Base
   Surgery and the Limitations of Database Research
SO WORLD NEUROSURGERY
LA English
DT Article
DE Big data; Cerebrospinal fluid leak; Meningioma; NSQIP; Pituitary
   adenoma; Schwannoma; Skull base surgery; Trigeminal neuralgia
ID TRANSSPHENOIDAL SURGERY; RECONSTRUCTION; MENINGITIS; MANAGEMENT;
   RESECTION; TRANSLABYRINTHINE; COMPLICATIONS; NEUROSURGERY; MORBIDITY;
   OUTCOMES
AB BACKGROUND: Cerebrospinal fluid (CSF) leak is a frustrating complication of skull base surgery. Published methodologies using national surgical databases to assess CSF leak have not accounted for variability between skull base operations.
   OBJECTIVE: Our goal was to attempt the development of a novel framework for adapting big data techniques to skull base surgery and assess the reliability of corresponding data manipulations.
   METHODS: A retrospective nested case-control analysis was performed using patients from the National Surgical Quality Improvement Program (NSQIP) registry, 2012-2015. Current Procedural Terminology and International Classification of Diseases, Ninth Revision codes identified possible skull base operations, which were systematically grouped by anatomic location. Meningioma, schwannoma, pituitary adenoma, and trigeminal neuralgia (TN) were included.
   RESULTS: Of 2918 patients, 84 (2.9%) were readmitted/ reoperated on within 30 days for CSF leak. Operations involving the anterior fosse, both middle/posterior fosses in 1 approach, or the orbitocranial zygomatic approach were significantly associated with CSF leak, as were schwan-nomas and meningiomas in any location (8.5%, 3.1%, 10.2%, 4.1%, and 3.0%; all P< 0.0001). Multivariate analysis of only middle/posterior fossa lesions identified schwannoma (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.3-5.6; P = 0.008), TN (OR, 5.4; 95% CI, 2-14.7; P = 0.008), chronic obstructive pulmonary disease (OR, 3.9; 95% CI, 1.1-14; P = 0.03), and increased operative time (OR, 4.0; 95% CI, 1.7-9.5; P = 0.009) as significant CSF leak risk factors.
   CONCLUSIONS: Based on NSQIP data analyzed using a rational skull base/anatomic framework, risk factors for postoperative CSF leak include chronic obstructive pulmonary disease, operative time, anterior fossa meningioma, and middle/posterior fosse schwannoma or TN. Although databases such as NSQIP can be extensively manipulated to generate surrogate results that may provide limited insight, applications beyond their design should be approached carefully.
C1 [Perry, Avital; Kerezoudis, Panagiotis; Graffeo, Christopher S.; Carlstrom, Lucas P.; Peris-Celda, Maria; Meyer, Fredric B.; Bydon, Mohamad; Link, Michael J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55902 USA.
   [Link, Michael J.] Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN 55902 USA.
   [Kerezoudis, Panagiotis; Bydon, Mohamad] Mayo Clin, Mayo Clin Neuroinformat Lab, Rochester, MN USA.
RP Link, MJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55902 USA.; Link, MJ (reprint author), Mayo Clin, Dept Otolaryngol Head & Neck Surg, Rochester, MN 55902 USA.
EM link.michael@mayo.edu
CR Alattar AA, 2018, NEUROSURGERY, V82, P630, DOI 10.1093/neuros/nyx197
   Babadjouni R, 2019, NEUROSURGERY, V84, P726, DOI 10.1093/neuros/nyy187
   Bani A, 2002, ACTA NEUROCHIR, V144, P979, DOI 10.1007/s00701-002-0981-y
   Becker SS, 2003, OTOL NEUROTOL, V24, P107, DOI 10.1097/00129492-200301000-00021
   Bi WL, 2019, J NEUROL SURG PART B, V80, P96, DOI 10.1055/s-0038-1667124
   BLACK PM, 1987, NEUROSURGERY, V20, P920, DOI 10.1227/00006123-198706000-00017
   Bloomfield GL, 1997, CRIT CARE MED, V25, P496, DOI 10.1097/00003246-199703000-00020
   Brackmann DE, 2000, AM J OTOL, V21, P417, DOI 10.1016/S0196-0709(00)80054-X
   BRYCE GE, 1991, OTOLARYNG HEAD NECK, V104, P81, DOI 10.1177/019459989110400115
   Calverley Peter Ma, 2013, Cough, V9, P17, DOI 10.1186/1745-9974-9-17
   CARTER CC, 1957, NEUROLOGY, V7, P169, DOI 10.1212/WNL.7.3.169
   Ciric I, 1997, NEUROSURGERY, V40, P225, DOI 10.1097/00006123-199702000-00001
   Copeland WR, 2015, J NEUROSURG, V122, P312, DOI 10.3171/2014.10.JNS14432
   Faciszewski T, 2003, SPINE, V28, P502, DOI 10.1097/00007632-200303010-00017
   Kessler R, 2011, EUR RESPIR J, V37, P264, DOI 10.1183/09031936.00051110
   McCutcheon BA, 2013, OTOLARYNG HEAD NECK, V149, P931, DOI 10.1177/0194599813508539
   Mehta GU, 2012, J NEUROSURG, V116, P1299, DOI 10.3171/2012.3.JNS112160
   Murphy M, 2016, J NEUROL SURG PART B, V77, P350, DOI 10.1055/s-0036-1572508
   Murphy ME, 2016, CLIN NEUROL NEUROSUR, V148, P105, DOI 10.1016/j.clineuro.2016.06.020
   Oravec CS, 2018, NEUROSURGERY, V82, pE188, DOI 10.1093/neuros/nyy102
   Owens RL, 2010, RESP CARE, V55, P1333
   Perry A, 2017, WORLD NEUROSURG, V100, P201, DOI 10.1016/j.wneu.2017.01.001
   RADHAKRISHNAN K, 1993, ARCH NEUROL-CHICAGO, V50, P78, DOI 10.1001/archneur.1993.00540010072020
   RODGERS GK, 1993, LARYNGOSCOPE, V103, P959
   Rolston JD, 2017, J CLIN NEUROSCI, V37, P44, DOI 10.1016/j.jocn.2016.10.045
   Samii M, 1997, NEUROSURGERY, V40, P248, DOI 10.1097/00006123-199702000-00005
   SAMII M, 1997, NEUROSURGERY, V40, P260, DOI DOI 10.1227/01.NEU.0000023603.90705.6B
   Seiler RW, 2000, J NEUROSURG, V93, P762, DOI 10.3171/jns.2000.93.5.0762
   Selesnick SH, 2004, OTOL NEUROTOL, V25, P387, DOI 10.1097/00129492-200405000-00030
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   SNYDERMAN CH, 1990, LARYNGOSCOPE, V100, P607
   Zanation AM, 2009, AM J RHINOL ALLERGY, V23, P518, DOI 10.2500/ajra.2009.23.3378
NR 32
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E561
EP E569
DI 10.1016/j.wneu.2019.03.207
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300070
PM 30928599
DA 2020-05-12
ER

PT J
AU Prabhuraj, AR
   Yeole, U
   Arimappamagan, A
   Rao, KVLN
   Bhat, DI
   Dwarakanath, S
   Govindswamy, B
   Somanna, S
AF Prabhuraj, A. R.
   Yeole, Ujwal
   Arimappamagan, Arivazhagan
   Rao, K. V. L. Narasinga
   Bhat, Dhananjaya I.
   Dwarakanath, Srinivas
   Govindswamy, Bhanumathi
   Somanna, Sampath
TI Effect of Gamma Knife Radiosurgery on Vestibular Schwannoma with
   Serviceable Hearing: A Single-Center Indian Study
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT 16th World Congress of Neurosurgery of the
   World-Federation-of-Neurosurgical-Societies (WFNS)
CY AUG 20-25, 2017
CL Istanbul, TURKEY
SP World Federat Neurosurg Soc
DE GKRS; Hearing preservation; Tumor control; Vestibular Schwannoma
ID RADIATION-THERAPY; PRESERVATION; SURGERY; MANAGEMENT; RADIOTHERAPY
AB OBJECTIVE: Gamma Knife radiosurgery (GKRS) is an established treatment modality for vestibular schwannomas (VSs). The tumor control and hearing preservation rates suggest that GKRS is a good alternative treatment for small-and medium-size VS. Data are lacking from India regarding GKRS for VSs. Our aim was to find the hearing preservation and tumor control rates and the factors contributing to these.
   METHODS: In a retrospective 9-year study period, 87 patients had undergone GKRS for unilateral VS with Gardner-Robertson (GR) class I or II serviceable hearing. All 87 had been evaluated with magnetic resonance imaging and audiometry before GKRS and during follow-up to assess for the factors influencing tumor control and hearing preservation.
   RESULTS: Of the 87 patients, 77 with a minimum followup of 2 years and magnetic resonance imaging and audiometry evaluations available were included in the present study. The median follow-up period was 30 months. The tumor control rate and hearing preservation rate was 96.1% and 79.2%, respectively. Hearing preservation was not affected by the tumor volume. However, age > 40 years, pre-GKRS pure tone average < 30 decibels, speech discrimination score > 85%, pre-GKRS Gardner-Robertson grade I hearing, mean cochlear dose < 4 Gy, and pre-GKRS Ohata class of laterality C, D, E were significant on univariate analysis. The multivariate analysis revealed that age > 40 years (P = 0.017), pre-GKRS pure tone average < 30 decibels (P = 0.002), and Gardner-Robertson class I (P = 0.001) were significant factors. No patient developed cranial nerve dysfunction, hydrocephalus, or malignant degeneration.
   CONCLUSION: For most patients with small VSs, GKRS will be an effective alternative treatment to microsurgery with retained serviceable hearing and good tumor control.
C1 [Prabhuraj, A. R.; Yeole, Ujwal; Arimappamagan, Arivazhagan; Rao, K. V. L. Narasinga; Bhat, Dhananjaya I.; Dwarakanath, Srinivas; Somanna, Sampath] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bengaluru, India.
   [Govindswamy, Bhanumathi] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Div Radiat Oncol, Bengaluru, India.
RP Prabhuraj, AR (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bengaluru, India.
EM drprabhuraj@yahoo.co.in
OI Kandregula, Sandeep/0000-0001-9392-3143; Yeole,
   Ujwal/0000-0002-5848-5384; Bhat, Dhananjaya/0000-0001-8595-8311
CR Ambett R, 2009, J LARYNGOL OTOL, V123, P502, DOI 10.1017/S0022215108003575
   Anaizi AN, 2016, J NEUROL SURG PART B, V77, P212, DOI 10.1055/s-0035-1564591
   Apicella G, 2016, REP PRACT ONCOL RADI, V21, P399, DOI 10.1016/j.rpor.2016.02.002
   Baschnagel AM, 2013, J NEUROSURG, V118, P571, DOI 10.3171/2012.10.JNS12880
   Bennion NR, 2016, PRACT RADIAT ONCOL, V6, pE155, DOI 10.1016/j.prro.2015.11.015
   Boari N, 2014, J NEUROSURG, V121, P123, DOI 10.3171/2014.8.GKS141506
   Carlson ML, 2015, OTOLARYNG HEAD NECK, V153, P440, DOI 10.1177/0194599815590105
   Doherty Joni K, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P305, DOI 10.1097/01.moo.0000244186.72645.d4
   Doris L, 2005, ARCH OTOLARYNGOL, V131, P241, DOI 10.1001/archotol.131.3.241
   Friedman William A, 2003, Neurosurg Focus, V14, pe2
   Frischer JM, 2019, J NEUROSURG, V130, P388, DOI 10.3171/2017.8.JNS171281
   Hasegawa T, 2011, J NEUROSURG, V115, P1078, DOI 10.3171/2011.7.JNS11749
   Jain VK, 2005, NEUROL INDIA, V53, P41, DOI 10.4103/0028-3886.15052
   Kano Hideyuki, 2013, J Neurosurg, V119 Suppl, P863
   Lassaletta L, 2003, OTOLARYNG HEAD NECK, V129, P397, DOI 10.1016/S0194-5998(03)00628-4
   Misra BK, 2009, NEUROL INDIA, V57, P257, DOI 10.4103/0028-3886.53263
   Muacevic A, 2004, ACT NEUR S, V91, P75
   Muzevic D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009897.pub2
   Myrseth E, 2005, NEUROSURGERY, V56, P927, DOI 10.1227/01.NEU.0000158315.64079.0A
   Myrseth E, 2009, NEUROSURGERY, V64, P654, DOI 10.1227/01.NEU.0000340684.60443.55
   Ohata K, 2002, J Postgrad Med, V48, P253
   Paek SH, 2005, CANCER-AM CANCER SOC, V104, P580, DOI 10.1002/cncr.21190
   Patnaik U, 2015, OTOL NEUROTOL, V36, P638, DOI 10.1097/MAO.0000000000000657
   Ruess D, 2018, WORLD NEUROSURG, V116, pE194, DOI 10.1016/j.wneu.2018.04.149
   Smith MC, 2006, NEUROSURG CLIN N AM, V17, P169, DOI 10.1016/j.nec.2006.04.002
   Stangerup SE, 2006, OTOL NEUROTOL, V27, P547, DOI 10.1097/00129492-200606000-00018
   Tamura M, 2009, NEUROSURGERY, V64, P289, DOI 10.1227/01.NEU.0000338256.87936.7C
   Yang I, 2010, J NEUROSURG, V112, P851, DOI 10.3171/2009.8.JNS0985
   Yang I, 2009, J CLIN NEUROSCI, V16, P742, DOI 10.1016/j.jocn.2008.09.023
   Yomo S, 2012, J NEUROSURG, V117, P877, DOI 10.3171/2012.7.JNS10672
NR 30
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E114
EP E123
DI 10.1016/j.wneu.2019.02.169
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300017
PM 30862586
DA 2020-05-12
ER

PT J
AU Qian, WQ
   Shan, TK
   Qiu, QQ
   Zhang, JG
   Xia, CC
   Liu, Y
   You, C
AF Qian Weiqiang
   Shan Tikun
   Qiu Qiongqiong
   Zhang Jinge
   Xia Chunchao
   Liu Yi
   You Chao
TI Asymmetric Cortical Vessel Sign Indicates Hemodynamic Deficits in Adult
   Patients with Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Asymmetric cortical vessel sign; CT perfusion; Hypoperfusion; Moyamoya
   disease; Susceptibility-weighted imaging
ID CEREBRAL-BLOOD-FLOW; CLINICAL-FEATURES; ISCHEMIC FINDINGS;
   REVASCULARIZATION; HYPERPERFUSION; METABOLISM; BRAIN
AB BACKGOUND: Asymmetric cortical vessel sign (ACVS) on susceptibility-weighted imaging (SWI) indicates elevated concentration of deoxyhemoglobin and elevated oxygen extraction fraction in patients with cerebral ischemia. This study aimed to clarify whether ACVS is associated with impaired hemodynamics and hyperperfusion syndrome in patients with moyamoya disease (MMD).
   METHODS: Consecutive adult patients with MMD were enrolled. ACVS data on SWI and perfusion data using dynamic perfusion computed tomography were obtained and evaluated preoperatively and on postoperative days 2 and 180.
   RESULTS: A total of 24 patients with MMD were enrolled. Of 11 (45.83%) patients showing positive ACVS before surgery, 8 turned negative on postoperative day 2 and 9 showed absence of ACVS 180 days after surgery. Regions of interest showing positive ACVS had lower cerebral blood flow (CBF, P< 0.001), increased cerebral blood volume (P = 0.021), prolonged time to peak (P< 0.001), and mean transit time (P = 0.009). No patients with hemorrhagic symptoms showed positive ACVS(P = 0.041) and patients with positive ACVS showed more increase in CBF (P< 0.004).
   CONCLUSIONS: In patients with MMD, ACVS on SWI indicates severe impairment in hemodynamics and is associated with more increase in CBF after bypass surgery. Hence, ACVS on SWI might be considered as a neuroimaging marker for the evaluation of hemodynamics in patients with MMD.
C1 [Qian Weiqiang; Shan Tikun; Liu Yi; You Chao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Zhang Jinge; Xia Chunchao] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China.
   [Qiu Qiongqiong] Capital Med Univ, Innovat Ctr Neurol Disorders, Dept Neurol, Xuanwu Hosp, Beijing, Peoples R China.
RP Liu, Y (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM huaxily7978@126.com
FU Key Research and Development Projects in Sichuan province [2018sz0208]
FX This research was supported by the Key Research and Development Projects
   in Sichuan province (grant number: 2018sz0208).
CR An HY, 2012, TRANSL STROKE RES, V3, P65, DOI 10.1007/s12975-011-0141-x
   Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148
   Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96
   Horie N, 2011, AM J NEURORADIOL, V32, P1697, DOI 10.3174/ajnr.A2568
   Hsu CCT, 2017, NEURORADIOL J, V30, DOI 10.1177/1971400917690166
   Kaku Y, 2012, J CEREBR BLOOD F MET, V32, P2066, DOI 10.1038/jcbfm.2012.110
   Kawai N, 2014, J STROKE CEREBROVASC, V23, pE55, DOI 10.1016/j.jstrokecerebrovasdis.2013.08.012
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Li ZL, 2014, EUR RADIOL, V24, P1906, DOI 10.1007/s00330-014-3247-1
   Liu XJ, 2015, J NEUROSURG, V122, P392, DOI 10.3171/2014.10.JNS132369
   Morita N, 2008, CEREBROVASC DIS, V26, P367, DOI 10.1159/000151640
   Noshiro S, 2016, NEUROL RES, V38, P110, DOI 10.1080/01616412.2015.1136117
   OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Sun W, 2014, EUR J NEUROL, V21, P1411, DOI 10.1111/ene.12510
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Tada Y, 2010, NEUROL MED-CHIR, V50, P1006, DOI 10.2176/nmc.50.1006
   Tamura H, 2002, STROKE, V33, P967, DOI 10.1161/01.STR.0000013672.70986.E2
   Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786
   Uchino H, 2012, STROKE, V43, P2610, DOI 10.1161/STROKEAHA.112.654723
NR 20
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E137
EP E141
DI 10.1016/j.wneu.2019.02.187
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300019
PM 30862600
DA 2020-05-12
ER

PT J
AU Qin, H
   Huang, SB
   Xu, L
   Wei, PG
   Jiang, JZ
   Xie, ZL
   Luo, X
   Tan, HT
   Huang, WH
AF Qin, Hao
   Huang, Shengbin
   Xu, Lin
   Wei, Pingou
   Jiang, Jianzhong
   Xie, Zhaolin
   Luo, Xiang
   Tan, Haitao
   Huang, Wenhua
TI Radiation Exposure and Operation Time in Percutaneous Endoscopic Lumbar
   Discectomy Using Fluoroscopy-Based Navigation System
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printed; Fluoroscopy; Navigation; Operation time; Percutaneous
   endoscopic lumbar discectomy
ID PEDICLE SCREW PLACEMENT; COMPUTER-ASSISTED NAVIGATION; DISC HERNIATION;
   MICROENDOSCOPIC DISKECTOMY; CLINICAL-OUTCOMES; LEARNING-CURVE; THORACIC
   SPINE; MICRODISCECTOMY; ACCURACY; IMPROVES
AB OBJECTIVE: This study evaluated radiation exposure and operation time of percutaneous endoscopic lumbar discectomy (PELD) by using a fluoroscopy-based navigation system for access and localization.
   METHODS: Eighty-six PELDs performed by a single surgeon were retrospectively analyzed. Patients were separated into 2 groups: group A (using a three-dimensional [3D]-printed navigation instrument and fluoroscopy-based navigation system) and group B (with conventional fluoroscopy and standard instrumentation). The operation, fluoroscopy, and total access time were collected, as well as fluoroscopy and access times.
   RESULTS: The operative time for group A was 59 minutes (standard deviation [SD], 6 minutes) and 106 minutes (SD, 15 minutes) in group B (P < 0.001). In group A, fluoroscopy was used an average of 5 times (SD, 0.7) and 29 times (SD, 8) in group B (P < 0.001). The fluoroscopy time was 9 minutes (SD, 2 minutes) in group A and 40 minutes (SD, 8 minutes) in group B (P < 0.001). The number of access attempts was 1.3 (SD, 0.5) in group A and 8 (SD, 2 times) in group B (P < 0.001). The total access time was 11 minutes (SD, 2 minutes) in group A and 28 minutes (SD, 5 minutes) in group B (P < 0.001).
   CONCLUSIONS: PELD using the fluoroscopy-based navigation system showed lower operative, fluoroscopy, and access time compared with conventional techniques. In addition, fewer fluoroscopy images and access attempts were made in the navigation group. These data suggest that this novel technique reduces fluoroscopy and operation time and may reduce risks of repeated surgical access attempts.
C1 [Qin, Hao; Tan, Haitao; Huang, Wenhua] Guangxi Med Univ, Nanning, Guangxi, Peoples R China.
   [Qin, Hao; Huang, Shengbin; Xu, Lin; Wei, Pingou; Jiang, Jianzhong; Xie, Zhaolin; Luo, Xiang; Tan, Haitao] Guigang Peoples Hosp, Dept Orthopaed, Guigang, Guangxi, Peoples R China.
   [Huang, Wenhua] Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
RP Huang, WH (reprint author), Guangxi Med Univ, Nanning, Guangxi, Peoples R China.; Huang, WH (reprint author), Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
EM 13822232749@139.com
FU National Natural Science Foundation Project of ChinaNational Natural
   Science Foundation of China [81760401]; National Key R&D Program of
   China [2017YFC1103403]; South Wisdom Valley Innovative Research Team
   Program [2015CXTD05]; Science and Technology Project of Guangdong
   Province [2015B010125005, 2016B090917001, 2016B090913004,
   2017B090912006]; Guangxi Science and Technology Base and Talent
   Specialization [AD17129017, AD17195042]; Science and Technology Project
   of Guigang City [1803002]
FX This work is supported by the National Natural Science Foundation
   Project of China (81760401), National Key R&D Program of China
   (2017YFC1103403), South Wisdom Valley Innovative Research Team Program
   (2015CXTD05), the Science and Technology Project of Guangdong Province
   (2015B010125005, 2016B090917001, 2016B090913004, 2017B090912006),
   Guangxi Science and Technology Base and Talent Specialization
   (AD17129017, AD17195042), and the Science and Technology Project of
   Guigang City (1803002).
CR Ahn SS, 2015, J KOREAN NEUROSURG S, V58, P539, DOI 10.3340/jkns.2015.58.6.539
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Aizawa T, 2016, J ORTHOP SCI, V21, P579, DOI 10.1016/j.jos.2016.07.012
   Allam Y, 2013, EUR SPINE J, V22, P648, DOI 10.1007/s00586-012-2505-7
   Amelot A, 2018, SPINE J, V18, P892, DOI 10.1016/j.spinee.2018.01.019
   Chen XJ, 2016, INT J COMPUT ASS RAD, V11, P613, DOI 10.1007/s11548-015-1282-2
   Chen ZH, 2018, J NEUROSURG-SPINE, V28, P300, DOI 10.3171/2017.7.SPINE161434
   Choi G, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-14
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE291
   Eun SS, 2018, SPINE J, V18, P1286, DOI 10.1016/j.spinee.2018.02.021
   Fan GX, 2017, WORLD NEUROSURG, V103, P899, DOI 10.1016/j.wneu.2017.04.034
   Fan GX, 2017, INT ORTHOP, V41, P323, DOI 10.1007/s00264-016-3281-5
   Fan GX, 2016, PAIN PHYSICIAN, V19, pE1123
   GUAN X, 2015, J SPINAL DISORD TECH, V28, P78, DOI DOI 10.1097/BSD.0000000000000145
   Han W, 2010, ORTHOPEDICS, V33
   Hincapie CA, 2018, EUR SPINE J, V27, P1526, DOI 10.1007/s00586-017-5325-y
   Hu ZY, 2017, INT J SURG, V41, P97, DOI 10.1016/j.ijsu.2017.03.059
   Kaminski L, 2017, EUR SPINE J, V26, P2811, DOI 10.1007/s00586-017-4968-z
   Kim MH, 2017, EVID-BASED COMPL ALT, DOI 10.1155/2017/5239719
   Lee S, 2007, EUR SPINE J, V16, P431, DOI 10.1007/s00586-006-0219-4
   Li HY, 2018, WORLD NEUROSURG, V112, pE255, DOI 10.1016/j.wneu.2018.01.030
   Ling JM, 2014, J CLIN NEUROSCI, V21, P493, DOI 10.1016/j.jocn.2013.02.034
   Liu C, 2017, PAIN PHYSICIAN, V20, pE75
   Liu XY, 2018, J NEUROSURG-SPINE, V28, P317, DOI 10.3171/2017.6.SPINE172
   Lurie JD, 2016, SPINE, V41, P803, DOI 10.1097/BRS.0000000000001333
   Madhok R, 2010, J NEUROSURG-SPINE, V12, P347, DOI 10.3171/2009.10.SPINE08932
   Maroulakos M, 2019, J DENT, V80, P1, DOI 10.1016/j.jdent.2018.11.004
   Nakamura J, 2017, PAIN PHYSICIAN, V20, pE507
   Ohnsorge JAK, 2013, EUR SPINE J, V22, P642, DOI 10.1007/s00586-012-2495-5
   Park SH, 2018, ARTHROSCOPY, V34, P166, DOI 10.1016/j.arthro.2017.04.016
   Passacantilli E, 2016, J NEUROSURG SCI, V60, P410
   Patton AG, 2015, SPINE, V40, pE404, DOI 10.1097/BRS.0000000000000786
   Peng Chan Wb, 2009, J Orthop Surg Res, V4, P20, DOI 10.1186/1749-799X-4-20
   Peul WC, 2008, BRIT MED J, V336, P1355, DOI 10.1136/bmj.a143
   Plastaras C, 2013, PAIN PHYSICIAN, V16, pE731
   Prasarn ML, 2013, SPINE, V38, P1401, DOI 10.1097/BRS.0b013e318294e27d
   Quinones-Hinojosa A, 2006, J SPINAL DISORD TECH, V19, P109
   Ricles LM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan6521
   Siasios Ioannis D, 2017, J Spine Surg, V3, P657, DOI 10.21037/jss.2017.12.05
   Veresciagina K, 2010, EUR SPINE J, V19, P1450, DOI 10.1007/s00586-010-1431-9
   Wang L, 2017, WORLD NEUROSURG, V103, P671, DOI 10.1016/j.wneu.2017.04.098
   Wei S, 2015, VIDEOSURGERY MINIINV, V10, P555, DOI 10.5114/wiitm.2015.55845
   Wood MJ, 2014, INT J SPINE SURG, V8, DOI 10.14444/1027
   Wu H, 2010, CHIN J TRAUMATOL, V13, P201, DOI 10.3760/cma.j.issn.1008-1275.2010.04.002
   Wu JL, 2016, WORLD NEUROSURG, V92, P142, DOI 10.1016/j.wneu.2016.04.127
   Wu XB, 2016, BIOMED RES INT, DOI 10.1155/2016/4924013
   Yang BP, 2012, SPINE, V37, P2055, DOI 10.1097/BRS.0b013e31825c05cd
   Yokosuka Junichi, 2016, J Spine Surg, V2, P158
   Yoon Sang Mok, 2012, Korean J Spine, V9, P215, DOI 10.14245/kjs.2012.9.3.215
   Zeng YD, 2017, EXP THER MED, V14, P2960, DOI 10.3892/etm.2017.4917
   Zhang Hong-lei, 2011, Orthop Surg, V3, P52, DOI 10.1111/j.1757-7861.2010.00110.x
   Zhao YZ, 2018, WORLD NEUROSURG, V119, P77, DOI 10.1016/j.wneu.2018.07.185
NR 52
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E39
EP E48
DI 10.1016/j.wneu.2019.01.289
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300007
PM 30802551
DA 2020-05-12
ER

PT J
AU Radwanski, RE
   Winston, G
   Younus, I
   ElJalby, M
   Yuan, M
   Oh, Y
   Gucer, SB
   Hoffman, CE
   Stieg, PE
   Greenfield, JP
   Pannullo, SC
AF Radwanski, Ryan E.
   Winston, Graham
   Younus, Iyan
   ElJalby, Mahmoud
   Yuan, Melissa
   Oh, Yuna
   Gucer, Sadiye Buse
   Hoffman, Caitlin E.
   Stieg, Philip E.
   Greenfield, Jeffrey P.
   Pannullo, Susan C.
TI Neurosurgery Training Camp for Sub-Internship Preparation: Lessons From
   the Inaugural Course
SO WORLD NEUROSURGERY
LA English
DT Article
DE Education; Neurosurgery; Sub-internship; Training camp
ID BOOT CAMP; MEDICAL-STUDENTS; SKILLS; RESIDENTS; SOCIETY
AB OBJECTIVE: Historically, medical student education in neurological surgery has generally limited student involvement to assisting in research projects with minimal formal clinical exposure before starting sub-internships and application for the neurosurgery match. Consequently, students have generally had little opportunity to acquire exposure to clinical neurosurgery and attain minimal proficiency. A medical student training camp was created to improve the preparation of medical students for the involvement in neurological surgery activities and sub-internships.
   METHODS: A 1-day course was held at Weill Cornell Medicine, which consisted of a series of morning lectures, an interactive resident lunch panel, and afternoon hands- on laboratory sessions. Students completed self-assessment questionnaires regarding their confidence in several areas of clinical neurosurgery before the start of the course and again at its end.
   RESULTS: A significant increase in self-assessed confidence was observed in all skill areas surveyed. Overall, rising fourth year students who were starting sub-internships in the subsequent weeks reported a substantial increase in their preparedness for the elective rotations in neurosurgery.
   CONCLUSIONS: The preparation of medical students for clinical neurosurgery can be improved. Single-day courses such as the described training camp are an effective method for improving knowledge and skill gaps in medical students entering neurosurgical careers. Initiatives should be developed, in addition to this annual program, to increase the clinical and research skills throughout medical student education.
C1 [Radwanski, Ryan E.; Winston, Graham; Younus, Iyan; ElJalby, Mahmoud; Yuan, Melissa; Oh, Yuna; Gucer, Sadiye Buse; Hoffman, Caitlin E.; Stieg, Philip E.; Greenfield, Jeffrey P.; Pannullo, Susan C.] Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
RP Younus, I (reprint author), Weill Cornell Med, Dept Neurol Surg, New York, NY 10065 USA.
EM iyy2001@med.cornell.edu
OI Yuan, Melissa/0000-0002-5097-110X; Greenfield,
   Jeffrey/0000-0003-1904-1040
FU Neurosurgery Research and Education Foundation-the philanthropic arm of
   the American Association of Neurological Surgeons; Weill Cornell
   Medicine's Department of Neurological Surgery, Office of Academic
   Affairs, Medical Student Executive Committee; Clinical and Translational
   Science Center; Brainlab (Munich, Germany); Your Design Medical
   (Brooklyn, New York, USA)
FX Funding for the present study was provided by the Neurosurgery Research
   and Education Foundation-the philanthropic arm of the American
   Association of Neurological Surgeons, and Weill Cornell Medicine's
   Department of Neurological Surgery, Office of Academic Affairs, Medical
   Student Executive Committee, and Clinical and Translational Science
   Center. Additional support for this program was provided by Brainlab
   (Munich, Germany) and Your Design Medical (Brooklyn, New York, USA).
CR Agarwal Nitin, 2013, World Neurosurg, V80, P745, DOI 10.1016/j.wneu.2013.08.027
   Antonoff Mara B, 2009, J Surg Educ, V66, P248, DOI 10.1016/j.jsurg.2009.09.002
   Esterl Robert M Jr, 2006, Curr Surg, V63, P264, DOI 10.1016/j.cursur.2006.03.004
   Fox BD, 2011, J NEUROSURG, V114, P27, DOI 10.3171/2010.5.JNS10245
   Kashkoush A, 2017, WORLD NEUROSURG, V108, P101, DOI 10.1016/j.wneu.2017.08.125
   Klingensmith ME, 2010, SURG CLIN N AM, V90, P505, DOI 10.1016/j.suc.2010.02.004
   Neylan CJ, 2017, J SURG EDUC, V74, P384, DOI 10.1016/j.jsurg.2016.10.014
   O'Herrin JK, 2003, AM J SURG, V186, P125, DOI 10.1016/S0002-9610(03)00188-0
   Okusanya OT, 2012, J SURG EDUC, V69, P536, DOI 10.1016/j.jsurg.2012.04.001
   Parent RJ, 2010, J AM COLL SURGEONS, V210, P984, DOI 10.1016/j.jamcollsurg.2010.03.006
   Selden NR, 2013, J NEUROSURG, V119, P796, DOI 10.3171/2013.3.JNS122114
   Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45
   Selden NR, 2011, NEUROSURGERY, V68, P759, DOI 10.1227/NEU.0b013e3182077969
   Wayne DB, 2014, SIMUL HEALTHC, V9, P33, DOI 10.1097/SIH.0000000000000001
   Zuckerman SL, 2016, WORLD NEUROSURG, V86, P120, DOI 10.1016/j.wneu.2015.08.081
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E707
EP E716
DI 10.1016/j.wneu.2019.03.246
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300088
PM 30947014
DA 2020-05-12
ER

PT J
AU Razek, AAKA
   Talaat, M
   El-Serougy, L
   Abdelsalam, M
   Gaballa, G
AF Razek, Ahmed Abdel Khalek Abdel
   Talaat, Mona
   El-Serougy, Lamiaa
   Abdelsalam, Mohamed
   Gaballa, Gada
TI Differentiating Glioblastomas from Solitary Brain Metastases Using
   Arterial Spin Labeling Perfusion- and Diffusion Tensor Imaging-Derived
   Metrics
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffusion; Glioblastoma; Metastasis
ID HIGH-GRADE GLIOMAS; MAGNETIC-RESONANCE-SPECTROSCOPY; PROGNOSTIC
   PARAMETERS; MULTIFORME; TUMORS; COEFFICIENT; REGION; VOLUME; HEAD
AB OBJECTIVE: We sought to differentiate glioblastomas from solitary brain metastasis using arterial spin labeling perfusion (ASL)- and diffusion tensor imaging (DTI)-derived metrics.
   METHODS: A prospective study was done on 36 patients with provisional diagnosis of glioblastomas versus brain metastasis who underwent ASL and DTI of the brain. The tumor blood flow (TBF) and DTI metrics (fractional anisotropy [FA] and mean diffusivity [MD]) of the enhancing tumoral and peritumoral parts were measured.
   RESULTS: There was a significant difference of TBF (P = 0. 001) and MD (P = 0.001) of the tumoral and peritumoral parts of glioblastoma and metastasis (P = 0.001). There was a significant difference of FA of peritumoral part (P = 0.001) and insignificant difference of tumoral part (P = 0.06) between glioblastomas and metastasis. The cutoff of TBF of tumoral and peritumoral parts used for differentiation were 29.7 and 17.8 (mL/100 g/minute) revealed an area under the curve (AUC) of 0.943 and 0.937 with accuracy of 91.7% and 88.9%. The cutoff of MD of tumoral and peritumoral parts were 1.27 and 1.33 (10(-3) mm(2)/second) revealed AUC of 0.840 and 0.987 and accuracy of 83.3% and 91.7%, respectively. Combined TBF, MD, and FA of the peritumoral part revealed AUC of 0.984 and accuracy of 91.7%.
   CONCLUSIONS: A combination of ASL- and DTI-derived metrics of the peritumoral part can be used for differentiation of glioblastomas from solitary brain metastasis.
C1 [Razek, Ahmed Abdel Khalek Abdel; El-Serougy, Lamiaa; Gaballa, Gada] Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt.
   [Abdelsalam, Mohamed] Mansoura Fac Med, Dept Neurol, Mansoura, Egypt.
   [Talaat, Mona] Kafr Elsheikh Fac Med, Diagnost Radiol, Kafr Al Sheikh, Egypt.
RP Razek, AAKA (reprint author), Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt.
EM arazek@mans.edu.eg
RI Abdel Razek, Ahmed/J-6737-2016
OI Abdel Razek, Ahmed/0000-0002-9613-5932
CR Bauer AH, 2015, NEURORADIOLOGY, V57, P697, DOI 10.1007/s00234-015-1524-6
   Bette S, 2016, EUR J RADIOL, V85, P2182, DOI 10.1016/j.ejrad.2016.10.002
   Blanchet L, 2011, AM J NEURORADIOL, V32, P67, DOI 10.3174/ajnr.A2269
   Byrnes TJD, 2011, NMR BIOMED, V24, P54, DOI 10.1002/nbm.1555
   El-Serougy L, 2016, NEURORADIOL J, V29, P400, DOI 10.1177/1971400916665382
   El-Serougy LG, 2015, EGYPT J RADIOL NUC M, V46, P1099, DOI 10.1016/j.ejrnm.2015.08.005
   Ganbold M, 2017, J MED INVESTIG, V64, P58, DOI 10.2152/jmi.64.58
   Hsu CCT, 2016, J NEUROIMAGING, V26, P383, DOI 10.1111/jon.12360
   Jiang R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112550
   Lee EJ, 2013, CLIN RADIOL, V68, pE689, DOI 10.1016/j.crad.2013.06.021
   Ma JH, 2010, AM J NEURORADIOL, V31, P1699, DOI 10.3174/ajnr.A2161
   Mabray Marc C, 2015, Brain Tumor Res Treat, V3, P8, DOI 10.14791/btrt.2015.3.1.8
   Maurer MH, 2013, ROFO-FORTSCHR RONTG, V185, P235, DOI 10.1055/s-0032-1330318
   Mohammadzadeh A, 2016, NEUROIMAG CLIN N AM, V26, P567, DOI 10.1016/j.nic.2016.06.006
   Mouthuy N, 2012, J NEURORADIOLOGY, V39, P301, DOI 10.1016/j.neurad.2011.11.002
   Razek AAKA, 2018, J LARYNGOL OTOL, V132, P923, DOI 10.1017/S0022215118001743
   Razek AAKA, 2012, AM J NEURORADIOL, V33, P944, DOI 10.3174/ajnr.A2892
   Razek AA, 2011, RADIOL MED, V116, P125, DOI 10.1007/s11547-010-0588-y
   Razek AAKA, 2019, J COMPUT ASSIST TOMO
   Razek AAKA, 2019, EUR J RADIOL, V111, P76, DOI 10.1016/j.ejrad.2018.12.022
   Razek AAKA, 2019, WORLD NEUROSURG, V123, pE303, DOI 10.1016/j.wneu.2018.11.155
   Razek AAKA, 2018, MAGN RESON IMAGING, V54, P84, DOI 10.1016/j.mri.2018.08.009
   Razek AAKA, 2018, NEUROIMAG CLIN N AM, V28, P303, DOI 10.1016/j.nic.2018.01.009
   Razek AAKA, 2018, EUR ARCH OTO-RHINO-L, V275, P1301, DOI 10.1007/s00405-018-4950-3
   Razek AAKA, 2018, NEURORADIOLOGY, V60, P169, DOI 10.1007/s00234-017-1955-3
   Razek AAKA, 2017, J COMPUT ASSIST TOMO, V41, P131, DOI 10.1097/RCT.0000000000000486
   Razek AAKA, 2016, NMR BIOMED, V29, P483, DOI 10.1002/nbm.3472
   Razek AAKA, 2014, RADIOGRAPHICS, V34, P873, DOI 10.1148/rg.344135028
   Razek AAKA, 2013, EUR J RADIOL, V82, P1885, DOI 10.1016/j.ejrad.2013.07.007
   Razek AAKA, 2013, RADIOL MED, V118, P534, DOI 10.1007/s11547-012-0890-x
   Razek AAKA, 2010, EUR J RADIOL, V76, P52, DOI 10.1016/j.ejrad.2009.05.021
   Server A, 2011, NEURORADIOLOGY, V53, P319, DOI 10.1007/s00234-010-0740-3
   Sunwoo L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166662
   Toh CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109172
   Tsougos I, 2012, CANCER IMAGING, V12, P423, DOI 10.1102/1470-7330.2012.0038
   Wang Q, 2017, TUMOR BIOL, V39
   Wijnen JP, 2012, J MAGN RESON IMAGING, V36, P1072, DOI 10.1002/jmri.23737
   Yamashita K, 2012, NEURORADIOLOGY, V54, P809, DOI 10.1007/s00234-011-0977-5
NR 38
TC 10
Z9 10
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E593
EP E598
DI 10.1016/j.wneu.2019.03.213
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300074
PM 30928596
DA 2020-05-12
ER

PT J
AU Rbia, N
   Bulstra, LF
   Saffari, TM
   Hovius, SER
   Shin, AY
AF Rbia, Nadia
   Bulstra, Liselotte F.
   Saffari, Tiam M.
   Hovius, Steven E. R.
   Shin, Alexander Y.
TI Collagen Nerve Conduits and Processed Nerve Allografts for the
   Reconstruction of Digital Nerve Gaps: A Single-Institution Case Series
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Collagen conduit; Digital nerve; Peripheral nerve; Processed nerve
   allograft
ID POLYGLYCOLIC ACID; RAT MODEL; REPAIR; INJURIES; REGENERATION; RECOVERY
AB OBJECTIVE: A single-institution case series is reported and a review of the literature on the outcomes of digital nerve gap reconstruction with the NeuraGen type 1 collagen nerve conduit (Integra Life Sciences, Plainsboro New Jersey, USA) and the Avance Nerve Graft (Axogen Inc., Alachua, Florida, USA) is presented.
   METHODS: Thirty-seven patients were included with a minimal follow-up of 12 months. Primary outcome was postoperative sensory recovery measured by static 2-point discrimination test or the Semmes-Weinstein monofilament test. Secondary outcome measurements were perioperative or postoperative complications. Final outcome data were stratified to grade results as excellent, good, or poor.
   RESULTS: The mean nerve gap length was 14 +/- 4.9 mm for the collagen conduits versus 18.4 +/- 9.3 for nerve allografts. After 12 months, outcomes were graded as excellent sensory recovery in 48% of the collagen conduit repairs and 39% of the nerve allografts (P = 0.608), good in 26% of the conduits and 55% of the allografts (P = 0.074), and poor in 26% of the conduits versus 6% of the allografts (P = 0.091). One neuroma and 1 infection were reported. Graft rejection or extrusion was not observed.
   CONCLUSIONS: Nerve conduits and processed nerve allografts offer convenient off-the-shelf options for digital nerve gap repair. Both techniques offer effective means of reconstructing a digital nerve gap <2.5 cm at a minimum of 12 months of follow-up. Future prospective randomized large sample size studies comparing nerve conduits with allografts are needed to perform subgroup analyses and to define their exact role in digital nerve injuries.
C1 [Rbia, Nadia; Bulstra, Liselotte F.; Saffari, Tiam M.; Shin, Alexander Y.] Mayo Clin, Div Hand & Microvasc Surg, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Rbia, Nadia; Bulstra, Liselotte F.; Saffari, Tiam M.; Hovius, Steven E. R.] Erasmus MC, Dept Plast Reconstruct & Hand Surg, Rotterdam, Netherlands.
RP Shin, AY (reprint author), Mayo Clin, Div Hand & Microvasc Surg, Dept Orthoped Surg, Rochester, MN 55905 USA.
EM shin.alexander@mayo.edu
CR Bushnell BD, 2008, J HAND SURG-AM, V33A, P1081, DOI 10.1016/j.jhsa.2008.03.015
   DELLON AL, 1987, J HAND SURG-AM, V12A, P693, DOI 10.1016/S0363-5023(87)80049-7
   DEMEDINACELI L, 1993, MICROSURG, V14, P244, DOI 10.1002/micr.1920140406
   Duncan SFM, 2015, OCHSNER J, V15, P191
   Giusti G, 2012, J BONE JOINT SURG AM, V94A, P410, DOI 10.2106/JBJS.K.00253
   Guo Y, 2013, J PLAST SURG HAND SU, V47, P451, DOI 10.3109/2000656X.2013.778862
   Haug A, 2013, J HAND SURG-AM, V38A, P90, DOI 10.1016/j.jhsa.2012.10.017
   HIRASAWA Y, 1985, J BONE JOINT SURG BR, V67, P814
   Huber JL, 2017, J HAND SURG-EUR VOL, V42, P720, DOI 10.1177/1753193417699777
   Isaacs Jonathan, 2014, Hand (N Y), V9, P131, DOI 10.1007/s11552-014-9601-6
   Johnson PJ, 2011, J RECONSTR MICROSURG, V27, P83, DOI 10.1055/s-0030-1267834
   Karabekmez Furkan E, 2009, Hand (N Y), V4, P245, DOI 10.1007/s11552-009-9195-6
   Kim JS, 2018, ANN PLAS SURG, V80, pS311, DOI 10.1097/SAP.0000000000001440
   Krarup C, 2002, ANN NEUROL, V51, P69, DOI 10.1002/ana.10054
   LI S-T, 1992, Clinical Materials, V9, P195, DOI 10.1016/0267-6605(92)90100-8
   Lohmeyer JA, 2009, J RECONSTR MICROSURG, V25, P55, DOI 10.1055/s-0028-1103505
   Lundborg G, 2004, J HAND SURG-BRIT EUR, V29B, P418, DOI 10.1016/j.jhsb.2004.02.008
   MACKINNON SE, 1990, PLAST RECONSTR SURG, V85, P419, DOI 10.1097/00006534-199003000-00015
   Means Kenneth R Jr, 2016, Hand (N Y), V11, P144, DOI 10.1177/1558944715627233
   Mermans Joline F, 2012, Hand (N Y), V7, P233, DOI 10.1007/s11552-012-9433-1
   Moore AM, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00040
   Moore AM, 2011, MUSCLE NERVE, V44, P221, DOI 10.1002/mus.22033
   Noble J, 1998, J TRAUMA, V45, P116, DOI 10.1097/00005373-199807000-00025
   Paprottka Felix J, 2013, Plast Surg Int, V2013, P704589, DOI 10.1155/2013/704589
   Poppler Louis H, 2015, Hand (N Y), V10, P68, DOI 10.1007/s11552-014-9699-6
   Renner A, 2004, Handchir Mikrochir Plast Chir, V36, P13
   Rinker BD, 2015, J RECONSTR MICROSURG, V31, P384, DOI 10.1055/s-0035-1549160
   Saunders RA, 2016, HAND UPPER EXTREMITY
   Schmauss D, 2014, J RECONSTR MICROSURG, V30, P561, DOI 10.1055/s-0034-1375237
   Silva JB, 2017, HAND SURG REHABIL, V36, P71, DOI 10.1016/j.hansur.2016.10.212
   Stang F, 2013, ARCH ORTHOP TRAUM SU, V133, P875, DOI 10.1007/s00402-013-1731-8
   Taras JS, 2013, J HAND SURG-AM, V38A, P1965, DOI 10.1016/j.jhsa.2013.07.008
   Taras JS, 2011, J HAND SURG-AM, V36A, P1441, DOI 10.1016/j.jhsa.2011.06.009
   Waitayawinyu T, 2007, J HAND SURG-AM, V32A, P1521, DOI 10.1016/j.jhsa.2007.07.015
   Wangensteen Kirk J, 2010, Hand (N Y), V5, P273, DOI 10.1007/s11552-009-9245-0
   Weinstein SJ., 1960, SOMATOSENSORY CHANGE, V60, P62
   Whitlock EL, 2009, MUSCLE NERVE, V39, P787, DOI 10.1002/mus.21220
   Yan Ying, 2016, J Hand Surg Am, V41, pe113, DOI 10.1016/j.jhsa.2016.01.009
NR 38
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1176
EP E1184
DI 10.1016/j.wneu.2019.04.087
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300147
PM 31003028
DA 2020-05-12
ER

PT J
AU Rinaldo, L
   Brinjikji, W
   Cloft, H
   Lanzino, G
   Gonzalez, LF
   Kan, P
   Castilla, LR
AF Rinaldo, Lorenzo
   Brinjikji, Waleed
   Cloft, Harry
   Lanzino, Giuseppe
   Gonzalez, L. Fernando
   Kan, Peter
   Castilla, Leonardo Rangel
TI & para;Effect of Fetal Posterior Circulation on Efficacy of Flow
   Diversion for Treatment of Posterior Communicating Artery Aneurysms: A
   Multi-Institutional Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Circle of Willis; Flow diverter; Intracranial aneurysm
ID PIPELINE EMBOLIZATION; ORIGIN
AB BACKGROUND: Flow diversion (FD) has emerged as an effective treatment modality for aneurysms of the posterior communicating artery (PCOM). Whether or not a fetal posterior circulation (FPC) affects PCOM aneurysm occlusion rates after FD remains undetermined.
   METHODS: We performed a retrospective cohort study in which treatment outcomes for FD of PCOM aneurysms from multiple institutions were reviewed. The primary outcome of interest was complete aneurysm occlusion at last follow-up. The presence of a FPC, defined as a PCOM diameter larger than that of the P1 segment, was noted and its relationship to complete aneurysm occlusion was investigated using a Cox proportional hazards model.
   RESULTS: There were 49 patients with 49 PCOM aneurysms treated with FD who met inclusion criteria for analysis. A FPC was present in 16 patients (32.7%). Complete aneurysm occlusion was observed in 34 patients (69.4%). Complete occlusion was less common for patients with a FPC (43.7% vs. 81.8%; P = 0.007). For patients with and without a FPC, median time to occlusion was 51 and 6 months, respectively (P = 0.002). Using a multivariable Cox proportional hazards model, a FPC was associated with reduced odds of complete occlusion on last follow-up (risk ratio 0.35, 95% confidence interval 0.14-0.89; P = 0.029).
   CONCLUSIONS: Our results indicate reduced efficacy of FD for the treatment of PCOM aneurysms associated with a FPC. These findings may influence treatment selection for aneurysms at this location.
C1 [Rinaldo, Lorenzo; Brinjikji, Waleed; Cloft, Harry; Lanzino, Giuseppe; Castilla, Leonardo Rangel] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
   [Brinjikji, Waleed; Cloft, Harry; Lanzino, Giuseppe; Castilla, Leonardo Rangel] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Gonzalez, L. Fernando] Duke Univ, Dept Cerebrovasc & Endovasc Neurosurg, Durham, NC USA.
   [Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Rinaldo, L (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
EM Rinaldo.Lorenzo@Mayo.Edu
CR Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Brinjikji W, 2014, CLIN NEUROL NEUROSUR, V120, P84, DOI 10.1016/j.clineuro.2014.02.018
   Daou B, 2017, J NEUROSURG, V126, P564, DOI 10.3171/2016.2.JNS152544
   Kadirvel R, 2014, RADIOLOGY, V270, P394, DOI 10.1148/radiol.13130796
   Kan P, 2016, J NEUROINTERV SURG, V8, P945, DOI 10.1136/neurintsurg-2015-011959
   Kuhn AL, 2018, INTERV NEURORADIOL, V24, DOI 10.1177/1591019918759735
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Roy AK, 2018, NEUROSURGERY, V82, P695, DOI 10.1093/neuros/nyx293
   Szikora I, 2015, AM J NEURORADIOL, V36, P1716, DOI 10.3174/ajnr.A4336
   Tsang Anderson Chun On, 2015, Neurointervention, V10, P60, DOI 10.5469/neuroint.2015.10.2.60
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Wallace AN, 2017, CLIN NEUROL NEUROSUR, V160, P83, DOI 10.1016/j.clineuro.2017.06.014
   Zada G, 2008, NEUROSURGERY, V63, P55, DOI [10.1227/01.neu.0000335012.37875.7d, 10.1227/01.NEU.0000320383.15473.39]
   Zanaty M, 2016, CASE REP VASC MED, V469, P1275
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1232
EP E1236
DI 10.1016/J.WNEU.2019.04.112
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300155
PM 31009780
DA 2020-05-12
ER

PT J
AU Sato, K
   Endo, H
   Fujimura, M
   Endo, T
   Shimizu, H
   Tominaga, T
AF Sato, Kanako
   Endo, Hidenori
   Fujimura, Miki
   Endo, Toshiki
   Shimizu, Hiroaki
   Tominaga, Teiji
TI Tailor-Made Branch Reconstruction by Intracranial to Intracranial Bypass
   During Clipping Surgery for Middle Cerebral Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Clipping; IC-IC bypass; Middle cerebral artery
AB BACKGROUND: In dipping surgery, it can be advantageous to dissect an adherent artery from the aneurysmal dome to achieve complete clipping. Bypass surgery can be useful to reconstruct an adherent artery when dissection of the artery is technically difficult or risky. We report the effectiveness of tailor-made intracranial (IC)-IC bypass to reconstruct an adherent artery in clipping surgery for middle cerebral artery (MCA) aneurysms.
   METHODS: A retrospective review of 384 consecutive patients who had presented with MCA aneurysms from 2008 to 2016 had identified 4 patients who had undergone an IC-IC bypass during clipping surgery for reconstruction of an adherent artery. We analyzed the preoperative radiological findings, methods of bypass surgery, surgical complications, and clinical outcomes in the present study.
   RESULTS: Preoperative angiography showed that the temporal cortical artery coursed along the aneurysmal dome in all cases. These cortical arteries exhibited tight adherence to the aneurysmal body intraoperatively, proving them to be difficult to dissect from the aneurysm. The adherent artery was injured during dissection in 2 cases. These arteries were reconstructed by IC-IC bypass, after which neck clipping was completed. The methods of IC-IC bypass included end-to-end anastomosis in 2 patients, end-to-side anastomosis in 1, and side-to-side anastomosis in 1 patient. Postoperative computed tomography and magnetic resonance imaging revealed neither hemorrhagic nor ischemic complications. The postoperative course was uneventful in all the patients.
   CONCLUSIONS: During clipping surgery for MCA aneurysms, tailor-made IC-IC bypass is one of the useful options to reconstruct tightly adherent branch arteries, especially when an external carotid artery graft has not been prepared in advance.
C1 [Sato, Kanako; Endo, Hidenori; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Sato, Kanako; Fujimura, Miki; Endo, Toshiki] Kohnan Hosp, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Shimizu, Hiroaki] Akita Univ, Grad Sch Med, Dept Neurosurg, Akita, Japan.
RP Endo, H (reprint author), Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi, Japan.
EM hideendo@gmail.com
OI Endo, Hidenori/0000-0003-1472-6032
CR Abla AA, 2016, J NEUROSURG, V124, P1275, DOI 10.3171/2015.5.JNS15368
   Endo H, 2015, J STROKE CEREBROVASC, V24, P2358, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.028
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Meybodi AT, 2017, J NEUROSURG, V127, P463, DOI 10.3171/2016.7.JNS16772
   Quinones-Hinojosa Alfredo, 2008, Neurosurgery, V62, P1442, DOI 10.1227/01.neu.0000333808.64530.dd
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   SUNDT TM, 1978, J NEUROSURG, V48, P916, DOI 10.3171/jns.1978.48.6.0916
   YASARGIL MG, 1969, [No title captured]
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1152
EP E1158
DI 10.1016/j.wneu.2019.04.074
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300143
PM 30995550
DA 2020-05-12
ER

PT J
AU Shah, A
   Patil, A
   Vutha, R
   Thakar, K
   Goel, A
AF Shah, Abhidha
   Patil, Abhinandan
   Vutha, Ravikiran
   Thakar, Khevana
   Goel, Atul
TI Recovery of Transcranial Motor Evoked Potentials After Atlantoaxial
   Stabilization for Chiari Formation: Report of 20 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial fixation; Chiari formation; Transcranial motor evoked
   potentials
ID I MALFORMATION; FIXATION; IMPROVEMENT; PLATE
AB BACKGROUND: The outcome of neurophysiologic motor evoked potential (MEP) monitoring during surgery for Chiari formation by atlantoaxial fixation and without any bone or dural foramen magnum decompression is analyzed.
   METHODS: During the period August 2017 to October 2018, 20 patients having Chiari formation with or without syringomyelia were surgically treated by atlantoaxial fixation. Apart from other forms of monitoring, MEP monitoring formed the basis of study. MEP monitoring was done during various phases of surgery that included monitoring immediately after screw tightening for atlantoaxial fixation.
   RESULTS: It was observed that there was positive improvement in MEP in 100% of the patients when measured in the surgical stage immediately after the procedure of screw tightening for atlantoaxial fixation. The improvement in MEP correlated with parallel improvement in neurologic function.
   CONCLUSIONS: Improvement in MEP adds credence to the hypothesis that atlantoaxial instability forms the nodal point of pathogenesis of Chiari formation.
C1 [Shah, Abhidha; Patil, Abhinandan; Vutha, Ravikiran; Goel, Atul] KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Thakar, Khevana] Shiv Surg Neurophysiol, Intraoperat Neurophysiol, Ahmadabad, Gujarat, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Mumbai, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Anderson RC, 2001, J CHILD NEUROL, V16, P936, DOI 10.1177/088307380101601214
   Anderson RCE, 2003, J CLIN NEUROPHYSIOL, V20, P65, DOI 10.1097/00004691-200302000-00009
   Anderson RCE, 2003, J NEUROSURG, V98, P459, DOI 10.3171/jns.2003.98.3.0459
   Barzilai O, 2016, ACTA NEUROCHIR, V158, P335, DOI 10.1007/s00701-015-2664-5
   Fujiwara A, 2003, SPINE, V28, P1601, DOI 10.1097/00007632-200307150-00023
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel Atul, 2019, Acta Neurochir Suppl, V125, P101, DOI 10.1007/978-3-319-62515-7_15
   Goel A, 2018, WORLD NEUROSURG, V111, pE668, DOI 10.1016/j.wneu.2017.12.137
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P1, DOI 10.4103/0974-8237.199881
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P107, DOI 10.4103/0974-8237.142302
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P3, DOI 10.4103/0974-8237.135206
   Kawasaki Y, 2017, J CRANIOFAC SURG, V28, P1837, DOI 10.1097/SCS.0000000000003926
   Moncho D, 2017, J NEUROSURG, V126, P606, DOI 10.3171/2015.11.JNS151764
   Zamel K, 2009, J CLIN NEUROPHYSIOL, V26, P70, DOI 10.1097/WNP.0b013e31819f9058
NR 16
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E644
EP E648
DI 10.1016/j.wneu.2019.03.236
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300080
PM 30947011
DA 2020-05-12
ER

PT J
AU Shao, B
   Wang, JY
   Chen, Y
   He, XJ
   Chen, HH
   Peng, YJ
   Yang, PX
   Duan, HY
   Yang, F
   Teng, LF
AF Shao, Bo
   Wang, Junyou
   Chen, Yu
   He, Xijun
   Chen, Huihui
   Peng, Yujiang
   Yang, Pengxiang
   Duan, Hongyu
   Yang, Fan
   Teng, Lingfang
TI Clipping versus Coiling for Ruptured Intracranial Aneurysms: A
   Meta-Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Coiling; Meta-analysis; Ruptured intracranial aneurysms
ID CEREBRAL ANEURYSMS; ENDOVASCULAR COILING; FOLLOW-UP
AB BACKGROUND: Hie treatment strategies of ruptured intracranial aneurysms (RIAs) include surgical clipping and endovascular coiling, and the efficacy and safety of clipping versus coiling are yet controversial.
   OBJECTIVE: To summarize the available randomized controlled trials to determine the optimal treatment method for patients with RIA.
   METHODS: PubMed, Embase, and the Cochrane Library were systematically searched for randomized controlled trials published up to September 5, 2017. The summary analysis was performed using a random-effects model. The primary outcomes included poor outcome, mortality, and rebleeding, whereas the secondary outcomes included complete occlusion, incomplete occlusion, severe disability, and vegetative state.
   RESULTS: We identified 5 trials with data collected from 2883 patients. The summary results indicated that surgical clipping in patients was associated with a high incidence of poor outcome (relative risk [RR], 1.34; 95% confidence interval [CI], 1.18-1.51; P < 0.001), whereas no significant effect was observed on mortality (RR, 1.09; 95% CI, 0.79-1.49; P = 0.608) and rebleeding (RR, 0.65; 95% CI, 0.20-2.06; P = 0.460) compared with endovascular coiling. Furthermore, we noted that surgical clipping significantly increased the incidence of complete occlusion compared with endovascular coiling (RR, 1.30; 95% CI, 1.09 1.55; P = 0.004). Conversely, surgical clipping was associated with a low incidence of incomplete occlusion (RR, 0.67; 95% CI, 0.45-0.99; P = 0.044). No significant differences were noted between surgical clipping and endovascular coiling with respect to the outcomes of severe disability (RR, 1.39; 95% CI, 0.90-2.16; P = 0.140) and vegetative state (RR, 1.35; 95% CI, 0.84-2.17; P = 0.213).
   CONCLUSIONS: This meta-analysis provides moderate evidence that surgical clipping has few benefits than endovascular coiling for the treatment of RIA.
C1 [Shao, Bo; Wang, Junyou; Chen, Yu; He, Xijun; Chen, Huihui; Peng, Yujiang; Yang, Pengxiang; Duan, Hongyu; Yang, Fan; Teng, Lingfang] First Peoples Hosp Wenling, Dept Neurosurg, Wenling, Zhejiang, Peoples R China.
RP Teng, LF (reprint author), First Peoples Hosp Wenling, Dept Neurosurg, Wenling, Zhejiang, Peoples R China.
EM tenglingfang0866@163.com
FU Zhejiang Medical and Health Science and Technology Plan [2017KY721];
   Taizhou Science and Technology Plan Project [1601KY42]; Zhejiang
   Provincial Science and Technology Plan of Traditional Chinese Medicine
   [2018ZB139]
FX This study was supported by the Zhejiang Medical and Health Science and
   Technology Plan (grant number 2017KY721), Taizhou Science and Technology
   Plan Project (grant number 1601KY42), and Zhejiang Provincial Science
   and Technology Plan of Traditional Chinese Medicine (grant number
   2018ZB139).
CR Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643
   Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bodily KD, 2011, AM J NEURORADIOL, V32, P1232, DOI 10.3174/ajnr.A2478
   Brilstra EH, 2000, NEUROLOGY, V55, P1656, DOI 10.1212/WNL.55.11.1656
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Deeks JJ, 2008, COCHRANE HDB SYSTEMA, V501, P28
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   GRAVES VB, 1995, NEUROSURGERY, V37, P640, DOI 10.1227/00006123-199510000-00006
   GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jeong Hae Woong, 2014, Neurointervention, V9, P63, DOI 10.5469/neuroint.2014.9.2.63
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Kondoh T, 1988, Neurol Med Chir (Tokyo), V28, P1107, DOI 10.2176/nmc.28.1107
   Lanzino G, 2013, AM J NEURORADIOL, V34, P1764, DOI 10.3174/ajnr.A3515
   Latchaw RE, 1999, RADIOLOGY, V211, P306, DOI 10.1148/radiology.211.2.r99ma33306
   Li H, 2013, STROKE, V44, P29, DOI 10.1161/STROKEAHA.112.663559
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Raper DMS, 2016, J NEUROSURG SCI, V60, P104
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Ryu CW, 2015, AM J NEURORADIOL, V36, P1682, DOI 10.3174/ajnr.A4365
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187
   Thornton J, 2002, NEUROSURGERY, V50, P239, DOI 10.1097/00006123-200202000-00003
   Tobias A, 1999, STATA TECH B, V47, P15
   Wadd IH, 2015, JCPSP-J COLL PHYSICI, V25, P798, DOI 11.2015/JCPSP.798801
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Xia ZW, 2017, WORLD NEUROSURG, V98, P411, DOI 10.1016/j.wneu.2016.11.032
NR 35
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E353
EP E365
DI 10.1016/j.wneu.2019.03.123
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300045
PM 30928577
OA Bronze
DA 2020-05-12
ER

PT J
AU Sharkey, P
   Pinilla-Monsalve, G
   Rigamonti, A
   Carson, K
   Robison, J
   Vivas-Buitrago, T
   Jusue-Torres, I
   Clemens, G
   Sanyal, A
   Hoffberger, J
   Sankey, EW
   Lu, J
   Adams, A
   Rigamonti, D
AF Sharkey, Phoebe
   Pinilla-Monsalve, Gabriel
   Rigamonti, Alessandra
   Carson, Kathryn
   Robison, Jamie
   Vivas-Buitrago, Tito
   Jusue-Torres, Ignacio
   Clemens, Gwendolyn
   Sanyal, Abanti
   Hoffberger, Jamie
   Sankey, Eric W.
   Lu, Jennifer
   Adams, Atif
   Rigamonti, Daniele
TI Health Care Expenditures of Medicare Beneficiaries with Normal Pressure
   Hydrocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Health expenditures; Medicare; Normal pressure hydrocephalus
ID SHUNT SURGERY; PREVALENCE; EPIDEMIOLOGY; MODELS; DEATH
AB BACKGROUND: Normal pressure hydrocephalus (NPH) is an underdiagnosed and undertreated condition affecting the elderly population and with costs associated with its surgical management reported to be less than those associated with conservative management.
   OBJECTIVE: To determine if the rate of diagnosis of NPH has improved over the last decade, the rate of treatment has increased, and if surgical treatment costs and socioeconomic factors related to receipt of treatment have changed over time compared with conservative therapy.
   METHODS: A retrospective study based on data from a nationally representative random sample of 2,378,637 Medicare beneficiaries (2006-2010) was performed. Shunt surgery, shunt revision, replacement, and removal were analyzed as independent variables.
   RESULTS: A total of 2321 patients with NPH were included, with 580 (24.99%) receiving a first shunt procedure. The adjusted effect of the procedure is that total 5-year expenditures are $11,676 more per patient (P < 0.001) than expenditures associated with nonsurgical management. Shunt revision ($22,715, P < 0.01) and/or replacement ($46,607, P< 0.001) add significantly to 5-year expenditures. Socioeconomic factors including African American race (P = 0.006); age 75-79 years (P = 0.024), 80-84 years (P< 0.001), and >= 85 years (P< 0.001); and Medicaid (P< 0.001) have significant negative associations with shunt surgery.
   CONCLUSIONS: There was a 1.66-fold increase in the rate of diagnosis of NPH, from 0.12% in 1999 to 0.2% in 2008 The total costs per surgical patient rose by approximately 145% to 160% comparing 2001 and 2010. This increase was mainly due to hospital (by 167% to 168%) and home health costs (by 118% to 148%). Providing appropriate care across the socioeconomic spectrum warrants further study and requires identifying the factors that limit access to care.
C1 [Sharkey, Phoebe] Loyola Univ Maryland, Sellinger Sch Business, Dept Neurosurg, Baltimore, MD USA.
   [Pinilla-Monsalve, Gabriel; Robison, Jamie; Hoffberger, Jamie; Lu, Jennifer; Adams, Atif; Rigamonti, Daniele] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21218 USA.
   [Rigamonti, Alessandra] Cornell Univ, Dept Neurosurg, Ithaca, NY USA.
   [Carson, Kathryn; Clemens, Gwendolyn; Sanyal, Abanti] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Neurosurg, Baltimore, MD USA.
   [Vivas-Buitrago, Tito] Univ Santander UDES, Sch Med, Fac Hlth Sci, Bucaramanga, Colombia.
   [Vivas-Buitrago, Tito] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Jusue-Torres, Ignacio] Loyola Univ Chicago, Dept Neurosurg, Maywood, IL USA.
   [Sankey, Eric W.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
RP Rigamonti, D (reprint author), Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD 21218 USA.
EM daniele.rigamonti@jhah.com
RI Jusue-Torres, Ignacio/C-5979-2013
OI Jusue-Torres, Ignacio/0000-0002-9749-1912
FU Salisbury Family Foundation Endowed Professorship
FX This work was funded by the Salisbury Family Foundation Endowed
   Professorship.
CR Brean A, 2008, ACTA NEUROL SCAND, V118, P48, DOI 10.1111/j.1600-0404.2007.00982.x
   Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125
   FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428
   Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870
   Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X
   Hiraoka K, 2008, NEUROL MED-CHIR, V48, P197, DOI 10.2176/nmc.48.197
   Iseki C, 2009, J NEUROL SCI, V277, P54, DOI 10.1016/j.jns.2008.10.004
   Jaraj D, 2014, NEUROLOGY, V82, P1449, DOI 10.1212/WNL.0000000000000342
   Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
   Kahlon B, 2007, NEUROSURGERY, V60, P327, DOI 10.1227/01.NEU.0000249273.41569.6E
   Kameda M, 2017, ACTA NEUROCHIR, V159, P995, DOI 10.1007/s00701-017-3115-2
   Martin-Laez R, 2015, WORLD NEUROSURG, V84, P2002, DOI 10.1016/j.wneu.2015.07.005
   McGirt MJ, 2005, NEUROSURGERY, V57, P699, DOI 10.1227/01.NEU.0000175724.00147.10
   Michels KB, 2002, JAMA-J AM MED ASSOC, V287, P3130, DOI 10.1001/jama.287.23.3130
   Mori E, 2012, NEUROL MED-CHIR, V52, P775, DOI 10.2176/nmc.52.775
   Resnic FS, 2000, J AM MED INFORM ASSN, P690
   Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064
   Smith EE, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.005207
   Stein SC, 2006, J NEUROSURG, V105, P815, DOI 10.3171/jns.2006.105.6.815
   Tanaka N, 2009, NEUROEPIDEMIOLOGY, V32, P171, DOI 10.1159/000186501
   TRENKWALDER C, 1995, ARCH NEUROL-CHICAGO, V52, P1017, DOI 10.1001/archneur.1995.00540340109020
   Wikkelso C, 2013, J NEUROL NEUROSUR PS, V84, P562, DOI 10.1136/jnnp-2012-303314
   Williams MA, 2007, J NEUROSURG, V107, P21, DOI 10.3171/JNS-07/07/0021
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E548
EP E555
DI 10.1016/J.WNEU.2019.03.201
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300068
PM 30928595
DA 2020-05-12
ER

PT J
AU Shen, HK
   Fogel, GR
   Zhu, J
   Liao, ZH
   Liu, WQ
AF Shen, Hangkai
   Fogel, Guy R.
   Zhu, Jia
   Liao, Zhenhua
   Liu, Weiqiang
TI Biomechanical Analysis of Different Lumbar Interspinous Process Devices:
   A Finite Element Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Facet joint force; Finite element method; Interspinous process device;
   Intradiscal pressure; Lumbar biomechanics
ID SPINE; INSTABILITY; IMPLANTS; SEGMENTS; FRACTURE; FUSION; LOAD
AB BACKGROUND: Recently, interspinous stabilization with the interspinous process device (IPD) has become an alternative to treat lumbar spinal stenosis. The biomechanical influence of different design features of IPDs on intradiscal pressure (IDP) and facet joint force (FJF) has not been fully understood. The aim of this study was to investigate the biomechanical performance of different IPDs using finite element (FE) method.
   METHODS: A FE model of the L1 -5 segments was developed and validated. Four surgical FE models were constructed by inserting different implants at the L3-4 segment (Coflex-F, DIAM, Wallis, and pedicle screw system). The 4 motion modes were simulated.
   RESULTS: The IPDs decreased range of motion (ROM) at the surgical level substantially in flexion and extension, hut little influence was found in lateral bending and torsion. Compared with the DIAM and Wallis devices, the Coflex-F device showed advantages in stabilizing the surgical level, especially in flexion and extension, while it increased FJF at adjacent levels by 26%-27% in extension. Among the 3 IPDs, the DIAM device exhibited the most comparable ROM, IDP, and FJF at adjacent levels compared with the intact lumbar spine. The influence of the Wallis device was between that of the Coflex-F and DIAM devices.
   CONCLUSIONS: Compared with rigid fixation, the IPDs demonstrated less compensation at adjacent levels in terms of ROM, IDP, and FJF, which may lower the incidence of adjacent segment degeneration in the long term.
C1 [Shen, Hangkai; Liu, Weiqiang] Tsinghua Univ, Dept Mech Engn, Beijing, Peoples R China.
   [Shen, Hangkai; Zhu, Jia; Liao, Zhenhua; Liu, Weiqiang] Tsinghua Univ Shenzhen, Biomech & Biotechnol Lab, Res Inst, Shenzhen, Peoples R China.
   [Fogel, Guy R.] Spine Pain Begone Clin, San Antonio, TX USA.
RP Liu, WQ (reprint author), Tsinghua Univ, Dept Mech Engn, Beijing, Peoples R China.; Liu, WQ (reprint author), Tsinghua Univ Shenzhen, Biomech & Biotechnol Lab, Res Inst, Shenzhen, Peoples R China.
EM weiqiangliu19@163.com
FU National Key Research and Development Plan [2016YFC1102002]; Application
   Demonstration Project of Shenzhen [KJYY20170405161248988]
FX This study was supported by the National Key Research and Development
   Plan (2016YFC1102002) and the Application Demonstration Project of
   Shenzhen (KJYY20170405161248988).
CR Ayturk UM, 2011, COMPUT METHOD BIOMEC, V14, P695, DOI 10.1080/10255842.2010.493517
   Bellini CM, 2007, J SPINAL DISORD TECH, V20, P423, DOI 10.1097/BSD.0b013e318031af6f
   BERKSON MH, 1979, J BIOMECH ENG-T ASME, V101, P53, DOI 10.1115/1.3426225
   BRINCKMANN P, 1991, SPINE, V16, P641, DOI 10.1097/00007632-199106000-00008
   Chen CS, 2018, MED BIOL ENG COMPUT, V56, P1333, DOI 10.1007/s11517-017-1767-y
   Choi J, 2017, SPINE, V42, pE332, DOI 10.1097/BRS.0000000000001789
   Christie SD, 2005, SPINE, V30, pS73, DOI 10.1097/01.brs.0000174532.58468.6c
   Chung KJ, 2009, SPINE, V34, pE380, DOI 10.1097/BRS.0b013e31819fd3a0
   Esses SI, 1996, SPINE, V21, P676, DOI 10.1097/00007632-199603150-00003
   Fabrizi AP, 2011, EUR SPINE J, V20, P20, DOI 10.1007/s00586-011-1753-2
   Fan W, 2018, WORLD NEUROSURG, V114, pE1086, DOI 10.1016/j.wneu.2018.03.150
   Fan W, 2017, COMPUT BIOL MED, V86, P75, DOI 10.1016/j.compbiomed.2017.05.004
   Guo LX, 2019, MED BIOL ENG COMPUT, V57, P89, DOI 10.1007/s11517-018-1838-8
   Hilibrand Alan S, 2004, Spine J, V4, p190S, DOI 10.1016/j.spinee.2004.07.007
   Kettler A, 2008, CLIN BIOMECH, V23, P242, DOI 10.1016/j.clinbiomech.2007.09.004
   Kim DH, 2007, J AM ACAD ORTHOP SUR, V15, P200, DOI 10.5435/00124635-200704000-00003
   Liu X, 2017, BMC MUSCULOSKELET DI, V18
   Lo CC, 2011, COMPUT METHOD BIOMEC, V14, P969, DOI 10.1080/10255842.2010.502894
   Mo ZM, 2018, CLIN NEUROL NEUROSUR, V172, P74, DOI 10.1016/j.clineuro.2018.06.030
   Panjabi MM, 2007, CLIN BIOMECH, V22, P257, DOI 10.1016/j.clinbiomech.2006.08.006
   Park WM, 2014, INT J PRECIS ENG MAN, V15, P2597, DOI 10.1007/s12541-014-0632-2
   Renner SM, 2007, J BIOMECH, V40, P1326, DOI 10.1016/j.jbiomech.2006.05.019
   Richards JC, 2005, SPINE, V30, P744, DOI 10.1097/01.brs.0000157483.28505.e3
   Schilling C, 2014, EUR SPINE J, V23, P762, DOI 10.1007/s00586-014-3237-7
   SHIRAZIADL A, 1986, SPINE, V11, P914, DOI 10.1097/00007632-198611000-00012
   Sobottke R, 2009, EUR SPINE J, V18, P1494, DOI 10.1007/s00586-009-1081-y
   Tamburrelli FC, 2011, EUR SPINE J, V20, P27, DOI 10.1007/s00586-011-1763-0
   Wilke HJ, 2008, EUR SPINE J, V17, P1049, DOI 10.1007/s00586-008-0657-2
   Wu AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100498
   Zhang ZJ, 2018, WORLD NEUROSURG, V111, pE581, DOI 10.1016/j.wneu.2017.12.127
   Zhong ZC, 2006, MED ENG PHYS, V28, P90, DOI 10.1016/j.medengphy.2005.03.007
   Zhu ZQ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011140
NR 32
TC 0
Z9 0
U1 5
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1112
EP E1119
DI 10.1016/j.wneu.2019.04.051
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300137
PM 30980982
DA 2020-05-12
ER

PT J
AU Shen, J
AF Shen, Jian
TI Fully Endoscopic Lumbar Laminectomy and Transforaminal Lumbar Interbody
   Fusion Under Local Anesthesia with Conscious Sedation: A Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fully endoscopic; Interbody fusion; Lumbar laminectomy
ID INJURY
AB OBJECTIVE: To evaluate clinical outcomes of a case series of 18 patients who underwent fully endoscopic foraminotomy, laminectomy, and transforaminal lumbar interbody fusion combined with percutaneous screw fixation.
   METHODS: This was a retrospective case series of a single surgeon. Average age of patients was 66 years (range, 51-82 years). All patients had grade I or grade II spondylolisthesis and severe central canal stenosis. Patients underwent endoscopic transforaminal access through Kambin triangle for foraminotomy, discectomy, endplate preparation, and interbody fusion, which was followed by fully endoscopic unilateral laminectomy and bilateral decompression and percutaneous pedicle screw and connecting rod placement.
   RESULTS: All procedures were successful without conversion to open surgery. Mean operative time was 168 minutes, and average estimated blood loss was 36 mL. Mean length of hospital stay was 1.2 days. There were no intraoperative or postoperative complications. Comparison of preoperative and final clinical metrics demonstrated that average Oswestry Disability Index score improved from 48 +/- 14 (range, 37-61) to 13 +/- 11 (range, 0-27) (P < 0.001). Average visual analog scale back pain score improved from 8.1 +/- 2.0 (range, 6.8-10.0) to 1.8 +/- 0.9 (range, 0.0-3.5) (P < 0.001). Oswestry Disability Index and visual analog scale back pain scores at last follow-up showed 73% and 78% improvement, respectively, from the preoperative period. There were no cases of nonunion clinically or radiographically on final follow-up of >12 months.
   CONCLUSIONS: Fully endoscopic laminectomy and interbody fusion under conscious sedation is an effective treatment with minimal complications for patients with lumbar spondylolisthesis and severe spinal stenosis.
C1 [Shen, Jian] Mohawk Valley Orthoped, Amsterdam, Netherlands.
   [Shen, Jian] Ctr Spine Regenerat Surg, New York, NY 10075 USA.
RP Shen, J (reprint author), Mohawk Valley Orthoped, Amsterdam, Netherlands.; Shen, J (reprint author), Ctr Spine Regenerat Surg, New York, NY 10075 USA.
EM james2173@yahoo.com
OI Shen, Jian/0000-0001-6283-9715
CR BAGBY GW, 1988, ORTHOPEDICS, V11, P931
   Chang PY, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.2.FocusVid.1694
   Choi I, 2013, EUR SPINE J, V22, P2481, DOI 10.1007/s00586-013-2849-7
   FOLEY KT, 2003, [No title captured], V28, pS2
   Harms J G, 1998, Oper Orthop Traumatol, V10, P90, DOI 10.1007/s00064-006-0112-7
   KAWAGUCHI Y, 1994, SPINE, V19, P2598, DOI 10.1097/00007632-199411001-00018
   Kim CW, 2010, SPINE, V35, pS281, DOI 10.1097/BRS.0b013e3182022d32
   Lee SH, 2017, BIOMED RES INT, DOI 10.1155/2017/3731983
   Malham GM, 2015, EUR SPINE J, V24, pS339, DOI 10.1007/s00586-015-3807-3
   Morgenstern R, 2015, INT J SPINE SURG, V9, DOI 10.14444/2041
   Syed H, 2016, J NEUROL SURG PART A, V77, P344, DOI 10.1055/s-0035-1558821
NR 11
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E745
EP E750
DI 10.1016/j.wneu.2019.03.257
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300093
PM 30951914
DA 2020-05-12
ER

PT J
AU Shen, J
   Huang, KY
   Shen, J
   Zhu, Y
   Jiang, H
   Pan, JW
   Zhan, RY
AF Shen, Jie
   Huang, Kaiyuan
   Shen, Jian
   Zhu, Yu
   Jiang, Hao
   Pan, Jianwei
   Zhan, Renya
TI Clinical Efficacy Between Microsurgical Clipping and Endovascular
   Coiling in the Treatment of Ruptured Poor-Grade Anterior Circulation
   Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cerebral circulation; Clipping; Coiling; Poor-grade aneurysms;
   Short-term mortality
ID DELAYED CEREBRAL-ISCHEMIA; UNRUPTURED INTRACRANIAL ANEURYSMS;
   SHUNT-DEPENDENT HYDROCEPHALUS; SUBARACHNOID HEMORRHAGE; ANGIOGRAPHIC
   VASOSPASM; TRIAL ISAT; PREDICTORS; SERIES
AB BACKGROUND: The treatment for patients with poor-grade aneurysms defined as World Federation of Neurosurgical Societies (WFNS) grade IV - V is still unclear and controversial. In this research, we compared the clinical efficacy and safety between clipping and coiling in the treatment of ruptured poor-grade anterior circulation aneurysms.
   METHODS: We conducted a retrospective analysis of a hospital database. From January 2013 to May 2018, 94 patients who presented with poor-grade anterior circulation aneurysms were included. Preoperative baseline, post-procedure complications, and outcome (3-month and 6-month modified Rankin Scale scores) were analyzed. Multivariate logistic regression analysis was conducted to identify risk factors of short-term (in-hospital, 30-day) mortality.
   RESULTS: A total of 21 (22%) patients died during short-term follow-up; there was a greater short-term mortality in coiling group (38% vs. 15%, P = 0.015). The incidence of delayed cerebral ischemia and intracranial infection in the clipping group was significantly greater than the coiling group: (33% vs. 14%, P = 0.045) and (68% vs. 41%, P = 0.016). However, coiling group had a greater rate of shunt-dependent hydrocephalus (21% vs. 6%, P = 0.035). Multivariate logistic regression analysis revealed cerebral vasospasm (odds ratio [OR], 9.22; P < 0.01), admission WFNS grade V (OR, 15.43; P < 0.01), coiling (OR, 5.92; P = 0.013), and postoperative aneurysm rebleeding (OR, 40.04; P = 0.01) would influence the mortality.
   CONCLUSIONS: Patients with ruptured poor-grade anterior circulation aneurysms who undergo microsurgical clipping seem to have a lower short-term mortality. Cerebral vasospasm, WFNS grade V, and postoperative aneurysm rebleeding are associated with short-term mortality.
C1 [Shen, Jie; Huang, Kaiyuan; Shen, Jian; Zhu, Yu; Jiang, Hao; Pan, Jianwei; Zhan, Renya] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
RP Zhan, RY (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Neurosurg, Hangzhou, Zhejiang, Peoples R China.
EM 1196057@zju.edu.cn
OI Huang, Kaiyuan/0000-0002-4301-7676
FU Key Research & Development (R& D) Plan of Zhejiang Province [2019C03095]
FX This research was funded by "Key Research & Development (R& D) Plan of
   Zhejiang Province (2019C03095)."
CR Bradac O, 2012, ACTA NEUROCHIR, V154, P971, DOI 10.1007/s00701-012-1340-2
   Budohoski KP, 2014, J NEUROL NEUROSUR PS, V85, P1343, DOI 10.1136/jnnp-2014-307711
   Cagnazzo F, 2018, AM J NEURORADIOL, V39, P852, DOI 10.3174/ajnr.A5591
   Darsaut TE, 2013, J NEUROSURG, V119, P1642, DOI 10.3171/2013.5.JNS13917
   de Gans K, 2002, NEUROSURGERY, V50, P336, DOI 10.1097/00006123-200202000-00018
   de Oliveira JG, 2007, NEUROSURGERY, V61, P924, DOI 10.1227/01.neu.0000303188.72425.24
   DRAKE CG, 1988, J NEUROSURG, V68, P985
   Etminan N, 2013, ACTA NEUROCHIR SUPPL, V115, P33, DOI 10.1007/978-3-7091-1192-5_8
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700
   Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9
   Han YY, 2018, WORLD NEUROSURG, V115, pE160, DOI 10.1016/j.wneu.2018.03.219
   Kreiter KT, 2002, STROKE, V33, P200, DOI 10.1161/hs0102.101080
   Kumar G, 2016, J NEUROSURG, V124, P1257, DOI 10.3171/2015.4.JNS15428
   Leclerc JL, 2015, P NATL ACAD SCI USA, V112, P1155, DOI 10.1073/pnas.1412833112
   Li H, 2013, STROKE, V44, P29, DOI 10.1161/STROKEAHA.112.663559
   Marbacher S, 2010, ACTA NEUROCHIR, V152, P501, DOI 10.1007/s00701-009-0521-0
   Mees SMD, 2012, J NEUROL, V259, P679, DOI 10.1007/s00415-011-6243-2
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Phan K, 2017, WORLD NEUROSURG, V102, P632, DOI 10.1016/j.wneu.2017.03.057
   Raymond J, 2012, NEUROCHIRURGIE, V58, P103, DOI 10.1016/j.neuchi.2012.02.020
   Schuss P, 2016, WORLD NEUROSURG, V85, P125, DOI 10.1016/j.wneu.2015.08.046
   Schuss P, 2013, J NEUROSURG, V118, P984, DOI 10.3171/2012.11.JNS121435
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Taki W, 2011, WORLD NEUROSURG, V76, P437, DOI 10.1016/j.wneu.2011.04.026
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Xia ZW, 2017, WORLD NEUROSURG, V98, P411, DOI 10.1016/j.wneu.2016.11.032
   Xie ZY, 2017, WORLD NEUROSURG, V106, P844, DOI 10.1016/j.wneu.2017.06.119
   Zhao B, 2016, AM J NEURORADIOL, V37, P873, DOI 10.3174/ajnr.A4649
   Zhao B, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-86
NR 34
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E321
EP E329
DI 10.1016/j.wneu.2019.02.248
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300041
PM 30904812
DA 2020-05-12
ER

PT J
AU Spena, G
   Guerrini, F
   Grimod, G
   Salmaggi, A
   Mazzeo, LA
AF Spena, Giannantonio
   Guerrini, Francesco
   Grimod, Gianluca
   Salmaggi, Andrea
   Mazzeo, Lucio Aniello
TI Polymethyl Methacrylate Cranioplasty Is an Effective Ultrasound Window
   to Explore Intracranial Structures: Preliminary Experience and Future
   Perspectives
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranioplasty; PMMA; Transcranial; Ultrasound
ID REAL-TIME SONOGRAPHY
AB OBJECTIVE: To evaluate the feasibility of transcranial sonography in patients harboring polymethylmethacrylate cranioplasties (PMMA-CP) and explore whether this material is a valid sonic window to explore intracerebral structures.
   METHODS: In 6 patients, we performed transcranial sonography (TCS), using the PMMA-CP as sonic window. To test the reliability of ultrasound images, we collected several quantitative and qualitative measurements of intracranial structures and compared these sonographic images with standard computed tomography (CT) scan images.
   RESULTS: We found that PMMA-CP is a very good sonic window and allowed us to obtain very good quality echographic images of intracranial structures, as shown by the comparison of measurements with CT scan, which were very reliable. The main drawback was related to the shape (i.e., the curvature) of the cranial flap, which hindered the ultrasound probe from correctly adhering to the scalp.
   CONCLUSIONS: Although limited by the restricted number of cases, this preliminary experience represents the first available data about the serial use of TCS using PMMA-CP as window. These results open the path to the routine use of TCS to longitudinally control patients already harboring PMMA-CP. More, we here discuss its potential role in globally reducing the number of follow-up CT and magnetic resonance imaging scans required in different type of patients and pathologies.
C1 [Spena, Giannantonio; Guerrini, Francesco; Grimod, Gianluca; Mazzeo, Lucio Aniello] A Manzoni Hosp, Dept Neurosci, Unit Neurosurg, Lecce, Italy.
   [Guerrini, Francesco] Univ Pavia, Dept Surg Diagnost & Pediat Sci, Unit Neurosurg, Pavia, Italy.
   [Salmaggi, Andrea] A Manzoni Hosp, Dept Neurosci, Unit Neurol, Lecce, Italy.
RP Guerrini, F (reprint author), A Manzoni Hosp, Dept Neurosci, Unit Neurosurg, Lecce, Italy.; Guerrini, F (reprint author), Univ Pavia, Dept Surg Diagnost & Pediat Sci, Unit Neurosurg, Pavia, Italy.
EM frague21@gmail.com
RI Salmaggi, Andrea/S-7154-2017
OI Salmaggi, Andrea/0000-0001-6925-3434
CR AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769
   Andrabi Syed M, 2017, Surg Neurol Int, V8, P91, DOI 10.4103/sni.sni_45_17
   BECKER G, 1994, NEURORADIOLOGY, V36, P585, DOI 10.1007/BF00600414
   BECKER G, 1991, ULTRASCHALL MED, V12, P211, DOI 10.1055/s-2007-1005932
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Lochab J, 2004, INDIAN J PURE AP PHY, V42, P595
   Malcolm JG, 2018, WORLD NEUROSURG, V116, P60, DOI 10.1016/j.wneu.2018.05.009
   Malcolm JG, 2016, J CLIN NEUROSCI, V33, P39, DOI 10.1016/j.jocn.2016.04.017
   Marchac D, 2008, J PLAST RECONSTR AES, V61, P744, DOI 10.1016/j.bjps.2007.10.055
   Mattei L, 2016, CHILD NERV SYST, V32, P1907, DOI 10.1007/s00381-016-3186-z
   Mursch K, 2018, WORLD NEUROSURG, V117, P142, DOI 10.1016/j.wneu.2018.06.064
   Prada F, 2015, ULTRASCHALL MED, V36, P174, DOI 10.1055/s-0034-1385347
   Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033
   van de Vijfeijken SECM, 2018, WORLD NEUROSURG, V117, P443, DOI 10.1016/j.wneu.2018.05.193
   Wijnhoud AD, 2008, ULTRASOUND MED BIOL, V34, P923, DOI 10.1016/j.ultrasmedbio.2007.11.022
NR 15
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1013
EP E1019
DI 10.1016/j.wneu.2019.04.026
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300126
PM 30974273
DA 2020-05-12
ER

PT J
AU Styczen, H
   Tsogkas, I
   Liman, J
   Maus, V
   Psychogios, MN
AF Styczen, Hanna
   Tsogkas, Ioannis
   Liman, Jan
   Maus, Volker
   Psychogios, Marios Nikos
TI Endovascular Mechanical Thrombectomy for Cerebral Venous Sinus
   Thrombosis: A Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous sinus thrombosis; Cerebral venous thrombosis; Mechanical
   thrombectomy; Stroke
ID VEIN; PATHOPHYSIOLOGY; DIAGNOSIS; STROKE
AB BACKGROUND: Cerebral venous thrombosis (CVT) is a entity with a potentially fatal outcome. Patients who do not respond to standard medical therapy alone may benefit from endovascular treatment options. We evaluate the angiographic and clinical results of mechanical thrombectomy in patients with severe CVT.
   METHODS: Endovascular procedures were performed in patients with CVT in addition to standard anticoagulation therapy between 2011 and 2018. Clinical and radiologic parameters, procedure details, and angiographic and clinical outcomes were reviewed retrospectively.
   RESULTS: In total, 14 thrombectomy procedures were executed. Successful recanalization of the occluded sinus was achieved in 86% of cases (12/14); of those, 29% were recanalized completely. Procedural complications included perforation of the transverse sinus in 1 case (7%). Worsening of intracranial hemorrhage occurred in 14% (2/14) of cases. Favorable clinical outcome (modified Rankin Scale score 0-2) was achieved in 12 of 13 patients (92%).
   CONCLUSIONS: Transvenous mechanical thrombectomy is feasible, sate, and effective, leading to a high degree of successful recanalization rate of occluded dural sinus. It may be a salvage treatment for selected patients with severe CVT refractory to standard medical treatment.
C1 [Styczen, Hanna; Tsogkas, Ioannis; Maus, Volker; Psychogios, Marios Nikos] Univ Med Ctr Goettingen, Dept Diagnost & Intervent Neuroradiol, Gottingen, Germany.
   [Liman, Jan] Univ Med Ctr Goettingen, Dept Neurol, Gottingen, Germany.
   [Maus, Volker] Univ Hosp Bochum, Inst Diagnost & Intervent Radiol, Neuroradiol & Nucl Med, Bochum, Germany.
   [Psychogios, Marios Nikos] Univ Hosp Basel, Dept Neuroradiol, Clin Radiol & Nucl Med, Basel, Switzerland.
RP Styczen, H (reprint author), Univ Med Ctr Goettingen, Dept Diagnost & Intervent Neuroradiol, Gottingen, Germany.
EM hanna.styczen@med.uni-goettingen.de
OI Maus, Volker/0000-0001-5097-2631; Styczen, Hanna/0000-0002-9623-4156
CR Borhani Haghighi A, 2014, CLIN APPL THROMB-HEM, V20, P507
   Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7
   Coutinho JM, 2017, 3 EUR STROK ORG C PR
   Coutinho JM, 2013, INT J STROKE, V8, P135, DOI 10.1111/j.1747-4949.2011.00753.x
   Dentali F, 2006, BLOOD, V108, P1129, DOI 10.1182/blood-2005-12-4795
   Ferro JM, 2017, EUR J NEUROL, V24, P1203, DOI 10.1111/ene.13381
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   Ferro JM, 2009, CEREBROVASC DIS, V28, P39, DOI 10.1159/000215942
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Ilyas A, 2017, J NEUROINTERV SURG, V9, P1086, DOI 10.1136/neurintsurg-2016-012938
   Itrat Ahmed, 2006, JPMA Journal of the Pakistan Medical Association, V56, P506
   Khealani BA, 2008, STROKE, V39, P2707, DOI 10.1161/STROKEAHA.107.512814
   Konakondla S, 2017, AGING DIS, V8, P136, DOI 10.14336/AD.2016.0915
   Mascitelli JR, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011782.rep
   Maus V, 2019, CLIN NEURORADIOL, V29, P669, DOI 10.1007/s00062-018-0702-4
   Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364
   Siddiqui FM, 2015, STROKE, V46, P1263, DOI 10.1161/STROKEAHA.114.007465
   Silvis SM, 2019, STROKE, V50, P501, DOI 10.1161/STROKEAHA.118.023017
   Silvis SM, 2016, SEMIN THROMB HEMOST, V42, P622, DOI 10.1055/s-0036-1584132
   Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354
   VILLRINGER A, 1994, J NEURORADIOLOGY, V21, P72
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1097
EP E1103
DI 10.1016/j.wneu.2019.04.049
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300135
PM 30980969
DA 2020-05-12
ER

PT J
AU Suehiro, E
   Fujiyama, Y
   Kiyohira, M
   Haji, K
   Ishihara, H
   Nomura, S
   Suzuki, M
AF Suehiro, Eiichi
   Fujiyama, Yuichi
   Kiyohira, Miwa
   Haji, Kouhei
   Ishihara, Hideyuki
   Nomura, Sadahiro
   Suzuki, Michiyasu
CA Japan Neurotrauma Data Bank Comm
TI Risk of Deterioration of Geriatric Traumatic Brain Injury in Patients
   Treated with Antithrombotic Drugs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antithrombotic drugs; Deterioration; Geriatric traumatic brain injury;
   Reversal of antithrombotic drugs
ID PROTHROMBIN COMPLEX CONCENTRATE; PLATELET TRANSFUSION; INTRACRANIAL
   HEMORRHAGE; ANTICOAGULATED PATIENTS; ANTIPLATELET; REVERSAL;
   COAGULOPATHY; THERAPY
AB OBJECTIVE: Developed countries have rapidly aging populations and the use of antithrombotic drugs is increasing. We investigated the effects of antithrombotic drugs and reversal of these drugs in patients with geriatric traumatic brain injury (TBI).
   METHODS: Age, sex, mechanism of injury, Glasgow Coma Scale on admission, head computed tomography findings, antithrombotic therapy, acute exacerbation, and outcomes at discharge were examined in 711 patients with geriatric TBI, complicated with traumatic intracranial hemorrhage using data from the Japan Neurotrauma Data Bank Project 2015 (JNTDB P2015). These items were compared between patients who did and did not receive antithrombotic therapy. We also conducted a questionnaire survey of reversal of antithrombotic therapy at hospitals participating in the JNTDB P2015. Acute exacerbation was compared in hospitals that did and did not regularly use reversal of this therapy.
   RESULTS: The major cause of injury was a fall. In head computed tomography, acute subdural hematoma was found in 65.7% of the subjects. Antithrombotic therapy was performed in 30.4% of subjects, and these subjects were significantly older than those who did not receive this therapy; many had a fall as the mechanism of injury, and the level of consciousness was significantly exacerbated with this therapy. In hospitals that performed regular reversal, late exacerbation of the level of consciousness was suppressed.
   CONCLUSIONS: Patients with geriatric TBI who are given antithrombotic drugs have a risk for late exacerbation, even if initially diagnosed with mild TBI. Therefore, there is a possibility that reversal of antithrombotic drugs is important to suppress the risk of deterioration of patients with TBI.
C1 [Suehiro, Eiichi; Fujiyama, Yuichi; Kiyohira, Miwa; Haji, Kouhei; Ishihara, Hideyuki; Nomura, Sadahiro; Suzuki, Michiyasu] Yamaguchi Univ, Dept Neurosurg, Sch Med, Ube, Yamaguchi, Japan.
   [Suehiro, Eiichi; Suzuki, Michiyasu; Japan Neurotrauma Data Bank Comm] Japan Neurotrauma Data Bank Comm, Japan Soc Neurotraumatol, Tokyo, Japan.
RP Suehiro, E (reprint author), Yamaguchi Univ, Dept Neurosurg, Sch Med, Ube, Yamaguchi, Japan.; Suehiro, E (reprint author), Japan Neurotrauma Data Bank Comm, Japan Soc Neurotraumatol, Tokyo, Japan.
EM suehiro-nsu@umin.ac.jp
OI Ishihara, Hideyuki/0000-0002-0208-2412
CR Akamatsu Yosuke, 2017, No Shinkei Geka, V45, P771, DOI 10.11477/mf.1436203591
   Altman J., 2015, ACAD EMERG MED, V22, pS255
   Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0
   Bershad EM, 2008, J NEUROSURG, V109, P664, DOI 10.3171/JNS/2008/109/10/0664
   Cabinet Office Japan, 2017, ANN REP AG SOC
   Campiglio L, 2017, NEUROL-CLIN PRACT, V7, P296, DOI 10.1212/CPJ.0000000000000375
   Chauny JM, 2016, J EMERG MED, V51, P519, DOI 10.1016/j.jemermed.2016.05.045
   Chenoweth JA, 2018, JAMA SURG, V153, P570, DOI 10.1001/jamasurg.2017.6159
   Choi PA, 2017, NEUROSURGERY, V80, P98, DOI 10.1227/NEU.0000000000001401
   Cohn B, 2014, J EMERG MED, V46, P410, DOI 10.1016/j.jemermed.2013.08.107
   Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x
   Hawley C, 2017, EMERG MED J, V34, P509, DOI 10.1136/emermed-2016-206506
   Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204
   Holzmacher JL, 2018, BRAIN INJURY, V32, P325, DOI 10.1080/02699052.2018.1425804
   Jehan F, 2019, J SURG RES, V236, P224, DOI 10.1016/j.jss.2018.11.050
   NAGATA K, 1987, NEURORADIOLOGY, V29, P327, DOI 10.1007/BF00348909
   Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567
   Shabani S, 2016, WORLD NEUROSURG, V96, P66, DOI 10.1016/j.wneu.2016.08.075
   Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014
   Steiner T, 2016, LANCET NEUROL, V15, P566, DOI 10.1016/S1474-4422(16)00110-1
   Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X
   Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266
   Suehiro Eiichi, 2018, No Shinkei Geka, V46, P1127, DOI 10.11477/mf.1436203880
   Toyoda K, 2009, CEREBROVASC DIS, V27, P151, DOI 10.1159/000177924
   Uccella L, 2018, WORLD NEUROSURG, V110, pE339, DOI 10.1016/j.wneu.2017.10.173
   van den Brand CL, 2017, J NEUROTRAUM, V34, P1, DOI 10.1089/neu.2015.4393
   Verschoof MA, 2018, J NEUROL, V265, P315, DOI 10.1007/s00415-017-8701-y
   Watson VL, 2017, NEUROSURGERY, V81, P899, DOI 10.1093/neuros/nyx072
   Yanamadala V, 2014, J CLIN NEUROSCI, V21, P1881, DOI 10.1016/j.jocn.2014.05.001
   Yokobori S, 2016, WORLD NEUROSURG, V86, P127, DOI 10.1016/j.wneu.2015.09.105
NR 30
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1221
EP E1227
DI 10.1016/j.wneu.2019.04.108
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300153
PM 31009773
DA 2020-05-12
ER

PT J
AU Sun, KQ
   Wang, SM
   Sun, JC
   Wang, HB
   Huan, L
   Sun, XF
   Lv, HD
   Wang, ZQ
   Zou, WG
   Shi, JG
AF Sun, Kaiqiang
   Wang, Shunmin
   Sun, Jingchuan
   Wang, Haibo
   Huan, Le
   Sun, Xiaofei
   Lv, Hongdi
   Wang, Ziqin
   Zou, Weiguo
   Shi, Jiangang
TI Surgical Outcomes After Anterior Controllable Antedisplacement and
   Fusion Compared with Single Open-Door Laminoplasty: Preliminary Analysis
   of Postoperative Changes of Spinal Cord Displacements on T2-Weighted
   Magnetic Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior controllable antedisplacement and fusion; Shift; Spinal cord
   displacement; C5 palsy; Deviation angle; Spinal cord rotation
ID POSTERIOR LONGITUDINAL LIGAMENT; NERVE ROOT PALSY; C5 PALSY; CERVICAL
   DECOMPRESSION; RISK-FACTORS; SURGERY; OSSIFICATION; COMPLICATIONS;
   MYELOPATHY; STENOSIS
AB OBJECTIVE: This retrospective cohort study aimed to investigate the change of spinal cord displacements and the occurrence of C5 palsy between anterior controllable antedisplacement and fusion (ACAF) (group A) and single open-door laminoplasty (group L).
   METHODS: From January 2016 to December 2017, a total of 80 patients with cervical ossification of the posterior longitudinal ligament (OPLL) were enrolled. All patients underwent computed tomography and magnetic resonance imaging. The types and extent of OPLL, spinal cord rotation, deviation angle, and distance between the vertebral arteries line and spinal cord (DVS) were measured. Patients with postoperative C5 palsy were recorded. Neurologic function was evaluated by Japanese Orthopaedic Association (JOA) score.
   RESULTS: Three days after surgery, patients in group A had better recovery (6.7 degrees +/- 2.4 degrees) of spinal cord rotation than group L (3.1 degrees +/- 0.8 degrees; P < 0.05). Deviation angle showed similar changes to spinal cord rotation. At the final follow-up, patients in group A had decreased DVS (11.0 +/- 0.7 mm), whereas patients in group L had increased DVS (15.1 +/- 0.8 mm) compared with preoperation (P < 0.05). Five patients (1 in group A and 4 in group 1) developed postoperative C5 palsy (P> 0.05). Patients in group A had a higher JOA score at the final follow-up than those in group L (P < 0.05).
   CONCLUSIONS: ACAF could achieve in situ decompression in terms of spinal cord rotation, deviation angle, and spinal cord shift with better clinical outcomes and relatively lower incidence of C5 palsy compared with single open-door laminoplasty.
C1 [Sun, Kaiqiang; Wang, Shunmin; Sun, Jingchuan; Wang, Haibo; Huan, Le; Sun, Xiaofei; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Lv, Hongdi] 990th Hosp Peoples Liberat Army, Zhumadian, Henan, Peoples R China.
   [Wang, Ziqin] Henan Prov Corps Hosp Chinese Peoples Armed Polic, Zhengzhou, Henan, Peoples R China.
   [Zou, Weiguo] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS Ctr Excellence Mol Cell Sci, Inst Biochem & Cell Biol,State Key Lab Cell Biol, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
EM changzhengspine@smmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81271828, 81702141]
FX The study is supported by the National Natural Science Foundation of
   China (Grant/Award numbers: 81271828, and 81702141).
CR Alleyne CH, 1998, SURG NEUROL, V50, P213, DOI 10.1016/S0090-3019(97)00315-7
   Bydon M, 2014, NEUROSURGERY, V74, P595, DOI 10.1227/NEU.0000000000000322
   Chiba K, 2002, SPINE, V27, P2108, DOI 10.1097/00007632-200210010-00006
   Chugh AJ, 2015, SPINE J, V15, pS229
   Currier BL, 2012, SPINE, V37, pE328, DOI 10.1097/BRS.0b013e3182417276
   Eskander MS, 2012, J BONE JOINT SURG AM, V94A, P1605, DOI 10.2106/JBJS.K.00664
   Guzman JZ, 2014, BONE JOINT J, V96B, P950, DOI 10.1302/0301-620X.96B7.33665
   Houten John K, 2018, J Neurosurg Sci, DOI 10.23736/S0390-5616.18.04563-0
   Imagama S, 2010, J BONE JOINT SURG BR, V92B, P393, DOI 10.1302/0301-620X.92B3.22786
   Jiang YQ, 2017, EUR SPINE J, V26, P1162, DOI 10.1007/s00586-016-4878-5
   Kaneyama S, 2010, SPINE, V35, pE1553, DOI 10.1097/BRS.0b013e3181ce873d
   Kim S, 2014, J SPINAL DISORD TECH, V27, P436, DOI 10.1097/BSD.0b013e31826a10b0
   Kratzig T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188338
   Kurakawa T, 2016, EUR SPINE J, V25, P2060, DOI 10.1007/s00586-016-4548-7
   Lee HJ, 2017, EUR SPINE J, V26, P2340, DOI 10.1007/s00586-017-5077-8
   Lim CH, 2017, EUR SPINE J, V26, P1101, DOI 10.1007/s00586-016-4664-4
   Liu XW, 2017, EUR SPINE J, V26, P1173, DOI 10.1007/s00586-016-4912-7
   Liu Y, 2012, EUR SPINE J, V21, P2428, DOI 10.1007/s00586-012-2323-y
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   Odate S, 2017, J NEUROSURG-SPINE, V26, P466, DOI 10.3171/2016.9.SPINE16430
   Odate S, 2013, SPINE, V38, P2184, DOI 10.1097/BRS.0000000000000019
   Qin RQ, 2018, EUR SPINE J, V27, P1375, DOI 10.1007/s00586-017-5451-6
   Radcliff KE, 2014, J SPINAL DISORD TECH, V27, P86, DOI 10.1097/BSD.0b013e31824e53af
   Shiozaki T, 2009, SPINE, V34, P274, DOI 10.1097/BRS.0b013e318194e275
   Shou FY, 2015, EUR SPINE J, V24, P2724, DOI 10.1007/s00586-015-4186-5
   Sun JC, 2018, EUR SPINE J, V27, P1469, DOI 10.1007/s00586-017-5437-4
   Takase H, 2018, WORLD NEUROSURG, V120, pE1107, DOI 10.1016/j.wneu.2018.08.240
   Tsuzuki N, 1993, Eur Spine J, V2, P191, DOI 10.1007/BF00299445
   Wang HY, 2015, INT J CLIN EXP MED, V8, P3983
   Wang T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008560
   Yamanaka K, 2014, J NEUROSURG-SPINE, V20, P1, DOI 10.3171/2013.9.SPINE12952
   Yang HS, 2018, WORLD NEUROSURG, V115, pE501, DOI 10.1016/j.wneu.2018.04.078
   Yang HL, 2013, J SPINAL DISORD TECH, V26, pE13, DOI 10.1097/BSD.0b013e31827844cd
   Zhang H, 2015, J SPINAL DISORD TECH, V28, P89, DOI 10.1097/BSD.0b013e3182695295
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E288
EP E298
DI 10.1016/J.WNEU.2019.03.108
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300038
PM 30902779
DA 2020-05-12
ER

PT J
AU Talamonti, G
   Nichelatti, M
   Picano, M
   Marcati, E
   D'Aliberti, G
   Cenzato, M
AF Talamonti, Giuseppe
   Nichelatti, Michele
   Picano, Marco
   Marcati, Eleonora
   D'Aliberti, Giuseppe
   Cenzato, Marco
TI Endoscopic Third Ventriculostomy in Cases of Ventriculoperitoneal Shunt
   Malfunction: Does Shunt Duration Play a Role?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic third ventriculostomy; Hydrocephalus; Shunt malfunction;
   Ventriculoperitoneal shunt
ID FOLLOW-UP; HYDROCEPHALUS; OUTCOMES; CHILDREN; 3RD-VENTRICULOSTOMY;
   MANAGEMENT; REMOVAL; FAILURE; RISK
AB BACKGROUND: Endoscopic third ventriculostomy (ETV) is now widely used to manage ventriculoperitoneal shunt (VPS) malfunctions, but outcome predictors are still debated. Different opinions exist about the prognostic factors, but shunt duration is generally considered unimportant although its influence remains poorly investigated.
   METHODS: A total of 139 patients undergoing EN for VPS malfunction were reviewed. Successful ETV was defined as shunt independence. There were 56 children and 83 adults; hydrocephalus had different causes. The mean VPS-ETV interval was 8.1 years.
   RESULTS: Ninety patients (64.7%) became shunt free. Children and adults achieved comparable success rates (64.3% and 65.1%, respectively). Age, gender, and cause of shunt malfunction were scarcely significant. The success rates were 86.8% (33/38 patients) in obstructive hydrocephalus (OH), 55.2% (36/67) in communicating hydrocephalus, and 58.8% (21/34) in myelomeningocele-related hydrocephalus, which was significant (P = 0.02). History of multiple revisions was a negative predictor (P < 0.001): success rate, 39% (16/48) versus 81.3% (74/91). Any individual time step increase reduced the odds of ETV success by 34% (P = 0.014). In OH, the results were good regardless of any other factor, including shunt duration. In communicating hydrocephalus, short VPS-ETV intervals correlated with better outcome (P = 0.021), although they were irrelevant in perinatal posthemorrhagic hydrocephalus. In myelomeningocele-related hydrocephalus, shunt duration had intermediate effects.
   CONCLUSIONS: EN is the first option for shunt malfunctions in OH and perinatal posthemorrhagic hydrocephalus, regardless of other factors. Conversely, in other types of hydrocephalus, the chances of shunt independence are lower and shunt duration and history of multiple shunt revisions are significant.
C1 [Talamonti, Giuseppe; Picano, Marco; Marcati, Eleonora; D'Aliberti, Giuseppe; Cenzato, Marco] ASST Niguarda Hosp, Dept Neurosurg, Milan, Italy.
   [Nichelatti, Michele] ASST Niguarda Hosp, Serv Biostat, Milan, Italy.
RP Talamonti, G (reprint author), ASST Niguarda Hosp, Dept Neurosurg, Milan, Italy.
EM tala_nch@yahoo.it
RI Marcati, Eleonora/Y-5073-2019; Talamonti, Giuseppe/AAC-2760-2019
OI Talamonti, Giuseppe/0000-0002-9164-3292; Marcati,
   Eleonora/0000-0002-6302-235X
CR Baldauf J, 2010, MINIM INVAS NEUROSUR, V53, P159, DOI 10.1055/s-0030-1268415
   Baskin JJ, 1998, J NEUROSURG, V88, P478, DOI 10.3171/jns.1998.88.3.0478
   Boschert J, 2003, J NEUROSURG, V98, P1032, DOI 10.3171/jns.2003.98.5.1032
   Brichtova E, 2013, MINIM INVASIVE SURG, V2013, DOI 10.1155/2013/584567
   Buxton N, 2003, SURG NEUROL, V60, P201, DOI 10.1016/S0090-3019(03)00317-3
   Chhun V, 2015, WORLD NEUROSURG, V83, P970, DOI 10.1016/j.wneu.2015.01.058
   Cinalli G, 1998, NEUROSURGERY, V43, P1323, DOI 10.1097/00006123-199812000-00030
   Cinalli G, 1999, CHILD NERV SYST, V15, P718, DOI 10.1007/s003810050461
   Cinalli G, 2014, NEUROENDOSCOPY CURRE, P47, DOI 10.1007/978-3-642-39085-2_4.
   Deopujari CE, 2018, CHILD NERV SYST, V34, P1905, DOI 10.1007/s00381-018-3901-z
   Fukuhara T, 2000, NEUROSURGERY, V46, P1100, DOI 10.1097/00006123-200005000-00015
   Grand W, 2016, NEUROSURGERY, V78, P109, DOI 10.1227/NEU.0000000000000994
   Hader WJ, 2008, NEUROSURGERY, V63, P168, DOI 10.1227/01.NEU.0000310762.26035.B0
   Kita D, 2016, CHILD NERV SYST, V32, P1543, DOI 10.1007/s00381-016-3055-9
   Kulkarni AV, 2009, J PEDIATR-US, V155, P254, DOI 10.1016/j.jpeds.2009.02.048
   Lam S, 2016, J CLIN NEUROSCI, V31, P166, DOI 10.1016/j.jocn.2016.03.004
   Lee SH, 2011, J KOREAN NEUROSURG S, V49, P217, DOI 10.3340/jkns.2011.49.4.217
   Marton E, 2010, CHILD NERV SYST, V26, P937, DOI 10.1007/s00381-010-1130-1
   Melikian A, 2010, WORLD NEUROSURG, V74, P532, DOI 10.1016/j.wneu.2010.08.005
   Neils David M, 2013, Surg Neurol Int, V4, P3, DOI 10.4103/2152-7806.106116
   Nishiyama K, 2003, J NEUROSURG, V98, P1027, DOI 10.3171/jns.2003.98.5.1027
   O'Brien DF, 2005, J NEUROSURG, V103, P393, DOI 10.3171/ped.2005.103.5.0393
   Rei J, 2017, WORLD NEUROSURG, V105, P163, DOI 10.1016/j.wneu.2017.05.107
   Siomin V, 2002, J NEUROSURG, V97, P519, DOI 10.3171/jns.2002.97.3.0519
   Spennato P, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.005
   Talamonti G, 2007, J NEUROSURG, V107, P368, DOI 10.3171/PED-07/11/368
   Teo C, 1996, PEDIATR NEUROSURG, V25, P57, DOI 10.1159/000121098
   Waqar M, 2018, J CLIN NEUROSCI, V51, P6, DOI 10.1016/j.jocn.2018.02.012
   Waqar M, 2016, WORLD NEUROSURG, V94, P386, DOI 10.1016/j.wneu.2016.07.028
   Woodworth G, 2007, NEUROL RES, V29, P27, DOI 10.1179/016164106X119914
   Woodworth GF, 2012, WORLD NEUROSURG, V78, P312, DOI 10.1016/j.wneu.2011.09.018
   Xu R, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.037
   Zhao R, 2016, WORLD NEUROSURG, V88, P92, DOI 10.1016/j.wneu.2015.12.047
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E799
EP E808
DI 10.1016/j.wneu.2019.03.268
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300100
PM 30954740
DA 2020-05-12
ER

PT J
AU Tang, Y
   Xu, XP
   Zhu, F
   Chen, CW
   Wang, FS
   Lu, M
   Huang, X
AF Tang, Yong
   Xu, Xingping
   Zhu, Feng
   Chen, Changwei
   Wang, Fusheng
   Lu, Min
   Huang, Xing
TI Incidence and Risk Factors of Cervical Kyphosis in Patients with
   Adolescent Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Apical vertebral translation; Cervical
   kyphosis; Incidence; Lumbar pelvic relationship; Risk factor; T1 coronal
   tilt
ID SAGITTAL ALIGNMENT; DEFORMITY; SPINE; PREVALENCE; BALANCE; ANGLE
AB BACKGROUND: Cervical kyphosis (CK) has been reported in patients with adolescent idiopathic scoliosis (AIS). The report about the incidence of CK between patients with AIS and normal populations was little. Patients included in previous studies often required scoliosis surgery (Cobb angle >= 40 degrees), which does not represent all patients with MS. The aims of this study were to compare incidence of CK between patients with AIS (Cobb angle >10) and an age-matched normal population and to identify risk factors related to CK, especially coronal parameters that have rarely been studied in current literature.
   METHODS: Patients with MS (n = 112) and asymptomatic subjects from the general population (control group; = 40) were retrospectively analyzed. Radiographic parameters of coronal and sagittal plane were measured on full-length spine x-rays. Patients with MS were divided into 2 groups based on cervical lordosis angle: cervical lordosis and CK.
   RESULTS: CK was observed in 14 of 40 (35%) subjects in the control group and 68 of 112 (60.7%) patients with AIS. Several parameters were related to CK, including major curve, proximal thoracic, and main thoracic Cobb angle; proximal thoracic kyphosis angle; main thoracic kyphosis angle; T1 slope; sagittal vertical axis; vertical distance between C7 plumb line and center sacral vertical line; apical vertebral translation; T1 coronal tilt; and lumbar pelvic relationship. Logistic regression identified main thoracic Cobb angle, main thoracic kyphosis angle, sagittal vertical axis, lumbar pelvic relationship, and apical vertebral translation as independent risk factors of CK.
   CONCLUSIONS: Incidence of CK increases in patients with AIS relative to normal subjects. Coronal parameters of the spine could influence cervical sagittal alignment.
C1 [Tang, Yong; Xu, Xingping; Zhu, Feng; Chen, Changwei; Wang, Fusheng; Lu, Min; Huang, Xing] Yinzhou Peoples Hosp Ningbo City, Dept Orthoped, Ningbo, Zhejiang, Peoples R China.
RP Tang, Y (reprint author), Yinzhou Peoples Hosp Ningbo City, Dept Orthoped, Ningbo, Zhejiang, Peoples R China.
EM 2494995973@qq.com
CR Akbar M, 2018, J NEUROSURG-SPINE, V29, P506, DOI 10.3171/2018.3.SPINE171263
   Canavese F, 2011, EUR SPINE J, V20, P1141, DOI 10.1007/s00586-011-1837-z
   HILIBRAND AS, 1995, J PEDIATR ORTHOPED, V15, P627, DOI 10.1097/01241398-199509000-00015
   Hiyama A, 2016, EUR SPINE J, V25, P3226, DOI 10.1007/s00586-016-4701-3
   Hu XB, 2018, INT J SPINE SURG, V12, P22, DOI 10.14444/5004
   Ito K, 2016, EUR SPINE J, V25, P3220, DOI 10.1007/s00586-016-4699-6
   Jiang J, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1730-y
   Katz DE, 2001, SPINE, V26, P2354, DOI 10.1097/00007632-200111010-00012
   Knott PT, 2010, SPINE J, V10, P994, DOI 10.1016/j.spinee.2010.08.031
   La Maida GA, 2018, EUR SPINE J, V27, P157, DOI 10.1007/s00586-018-5626-9
   Lang CD, 2019, SPINE J, V19, P1041, DOI 10.1016/j.spinee.2018.12.002
   Lang CD, 2019, WORLD NEUROSURG, V123, pE597, DOI 10.1016/j.wneu.2018.11.228
   Lowenstein JE, 2007, SPINE, V32, P448, DOI 10.1097/01.brs.0000255030.78293.fd
   Matsubayashi Y, 2017, SPINE J, V17, P622, DOI 10.1016/j.spinee.2016.11.007
   Norheim Elizabeth P, 2015, Spine Deform, V3, P327, DOI 10.1016/j.jspd.2014.11.008
   Pesenti S, 2016, EUR SPINE J, V25, P424, DOI 10.1007/s00586-015-4244-z
   Protopsaltis T, 2018, INT J SPINE SURG, V12, P362, DOI 10.14444/5042
   Protopsaltis TS, 2018, SPINE, V43, P681, DOI 10.1097/BRS.0000000000002346
   Protopsaltis TS, 2015, J NEUROSURG-SPINE, V23, P153, DOI 10.3171/2014.11.SPINE1441
   Smith JS, 2014, SPINE, V39, pE1001, DOI 10.1097/BRS.0000000000000432
   STOKES IAF, 1994, SPINE, V19, P236, DOI 10.1097/00007632-199401001-00020
   Sucato DJ, 2008, SPINE, V33, P2630, DOI 10.1097/BRS.0b013e3181880498
   Tamai K, 2018, SPINE J, V18, P1505, DOI 10.1016/j.spinee.2018.01.012
   Wang LL, 2017, J ORTHOP SCI, V22, P254, DOI 10.1016/j.jos.2016.12.006
   Yagi Mitsuru, 2014, Spine Deform, V2, P122, DOI 10.1016/j.jspd.2013.11.002
   Youn MS, 2016, EUR SPINE J, V25, P3114, DOI 10.1007/s00586-016-4488-2
   Yu M, 2013, EUR SPINE J, V22, P2372, DOI 10.1007/s00586-013-2753-1
   Zhu C, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1590-5
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E788
EP E792
DI 10.1016/j.wneu.2019.03.264
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300098
PM 30951919
DA 2020-05-12
ER

PT J
AU Telera, S
   Gorgoglione, N
   Raus, L
   Vidiri, A
   Villani, V
   Pace, A
   Fabi, A
   Crispo, F
   Castiglione, M
   Sperduti, I
   Boccaletti, R
AF Telera, Stefano
   Gorgoglione, Nicola
   Raus, Laura
   Vidiri, Antonello
   Villani, Veronica
   Pace, Andrea
   Fabi, Alessandra
   Crispo, Francesco
   Castiglione, Melina
   Sperduti, Isabella
   Boccaletti, Riccardo
TI Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical
   Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidural compression; Metastatic spine disease; Mini-invasive approach;
   Open kyphoplasty; PMMA; VK100
ID VERTEBROPLASTY; MANAGEMENT; SURGERY; DECOMPRESSION; EFFICACY; CANCER;
   TUMOR
AB OBJECTIVE: Symptomatic metastatic spine disease (MSD), is a challenging disease involving 3%-20% of patients with bone metastases. Different surgical options are available and must be tailored to the general and neurologic conditions of the patients. Open kyphoplasty (OKP) refers to decompressive hemilaminectomy, associated with a contralateral percutaneous kyphoplasty, and in some cases, to a posterior stabilization. The aim of the study was to critically review our experience during the last decade with OKP in patients with cancer.
   METHODS: Fifty-three patients with cancer underwent OKP for symptomatic MSD. The Tokuhashi score and Spinal Instability Neoplastic Score were calculated for each patient. Length of hospital stay, perioperative complications, incidence of adjacent-level fractures, and median survival after surgery were evaluated. Karnofsky Performance Status, visual analog scale, and Dennis Pain Score were calculated preoperatively, postoperatively, and at last follow-up.
   RESULTS: Median Tokuhashi score and Spinal Instability Neoplastic Score were 10 and 10, respectively. The mean volume of filling material inserted was 3.6 mL. Median operative time was 180 minutes. Complications included 8 leakages (15%), 2 permanent motor deficits (3.8%), and 2 asymptomatic pulmonary embolisms (3.8%). Mean length of hospital stay was 7 days. A significant improvement was observed in Karnofsky Performance Status, visual analog scale score, and Dennis Pain Score (P < 0.0001). Median follow-up was 16 months and overall survival 22 months.
   CONCLUSIONS: OKP was an effective treatment of symptomatic MSDs in selected oncologic patients with low Tokuhashi scores. It relieved lateral epidural compressions, expanded indications of palliative surgery in patients who were not otherwise surgical candidates, and rapidly dealt with cement leakages.
C1 [Telera, Stefano; Raus, Laura; Crispo, Francesco; Castiglione, Melina; Boccaletti, Riccardo] IRCSS Natl Canc Inst Regina Elena, Dept Neurosurg, Rome, Italy.
   [Vidiri, Antonello] IRCSS Natl Canc Inst Regina Elena, Dept Radiol, Rome, Italy.
   [Villani, Veronica; Pace, Andrea] IRCSS Natl Canc Inst Regina Elena, Dept Neurol, Rome, Italy.
   [Fabi, Alessandra] IRCSS Natl Canc Inst Regina Elena, Dept Clin Oncol A, Rome, Italy.
   [Sperduti, Isabella] IRCSS Natl Canc Inst Regina Elena, Dept Biostat, Rome, Italy.
   [Gorgoglione, Nicola] Messina Univ, Div Neurosurg, Messina, Italy.
RP Telera, S (reprint author), IRCSS Natl Canc Inst Regina Elena, Dept Neurosurg, Rome, Italy.
EM stefano.telera@ifo.gov.it
RI villani, veronica/K-9339-2016; Fabi, Alessandra/AAC-1021-2019; Sperduti,
   Isabella/K-8902-2016
OI /0000-0002-1239-7143; Sperduti, Isabella/0000-0001-5115-3099; pace,
   andrea/0000-0002-9407-6916; villani, veronica/0000-0001-8769-9966;
   BOCCALETTI, Riccardo/0000-0002-9327-6393
CR Barzilai O, 2018, NEUROSURGERY, V82, P757, DOI 10.1093/neuros/nyx567
   Berenson J, 2011, LANCET ONCOL, V12, P225, DOI 10.1016/S1470-2045(11)70008-0
   Boszczyk BM, 2004, J NEUROSURG, V100, P32, DOI 10.3171/spi.2004.100.1.0032
   Bouras T, 2018, WORLD NEUROSURG, V111, pE573, DOI 10.1016/j.wneu.2017.12.107
   Bouza Carmen, 2009, BMC Palliat Care, V8, P12, DOI 10.1186/1472-684X-8-12
   Choi D, 2017, NEUROSURGERY, V80, pS131, DOI 10.1093/neuros/nyw084
   Donnelly DJ, 2015, WORLD NEUROSURG, V84, P1484, DOI 10.1016/j.wneu.2015.06.018
   Drakhshandeh D, 2018, WORLD NEUROSURG, V111, pE396, DOI 10.1016/j.wneu.2017.12.081
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Fuentes S, 2007, NEUROCHIRURGIE, V53, P49, DOI 10.1016/j.neuchi.2007.04.001
   Fuentes S, 2009, NEUROSURGERY, V64, P350, DOI 10.1227/01.NEU.0000337066.59130.61
   Gerszten Peter C, 2005, Neurosurg Focus, V18, pe8
   Gokaslan ZL, 1998, J NEUROSURG, V89, P599, DOI 10.3171/jns.1998.89.4.0599
   Guzik G, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0288-9
   Hsiang John, 2003, Spine J, V3, P520, DOI 10.1016/S1529-9430(03)00154-2
   Jacobs W B, 2001, Neurosurg Focus, V11, pe10
   Klimo P, 2004, ONCOLOGIST, V9, P188, DOI 10.1634/theoncologist.9-2-188
   Kumar N, 2017, EJSO-EUR J SURG ONC, V43, P1784, DOI 10.1016/j.ejso.2017.05.006
   La Maida GA, 2011, ASIAN SPINE J, V5, P162, DOI 10.4184/asj.2011.5.3.162
   Laufer I, 2013, J NEUROSURG-SPINE, V18, P207, DOI 10.3171/2012.11.SPINE12111
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Marco RAW, 2010, J BONE JOINT SURG AM, V92A, P67, DOI 10.2106/JBJS.I.01236
   Moulding HD, 2010, J NEUROSURG-SPINE, V13, P87, DOI 10.3171/2010.3.SPINE09639
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Santiago FR, 2014, WORLD J RADIOL, V6, P329, DOI 10.4329/wjr.v6.i6.329
   Singh K, 2005, J SPINAL DISORD TECH, V18, P413, DOI 10.1097/01.bsd.0000173840.59099.06
   Stefano T, 2018, CLIN NEUROL NEUROSUR, V171, P184, DOI 10.1016/j.clineuro.2018.06.018
   Steinmann J, 2005, SPINE, V30, P201, DOI 10.1097/01.brs.0000150831.46856.87
   Sundaresan N, 1996, J NEUROSURG, V85, P438, DOI 10.3171/jns.1996.85.3.0438
   Tancioni F, 2012, EUR SPINE J, V21, pS146, DOI 10.1007/s00586-012-2232-0
   Tancioni F, 2012, ANN SURG ONCOL, V19, P294, DOI 10.1245/s10434-011-1894-x
   Telera S, 2016, WORLD NEUROSURG, V90, P133, DOI 10.1016/j.wneu.2016.02.065
   Tohmeh AG, 1999, SPINE, V24, P1772, DOI 10.1097/00007632-199909010-00004
   Virk MS, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.10.FOCUS16359
   Wenger M, 1999, ACTA NEUROCHIR, V141, P625, DOI 10.1007/s007010050352
   Wise JJ, 1999, SPINE, V24, P1943, DOI 10.1097/00007632-199909150-00014
   Yao WT, 2012, CLIN NEUROL NEUROSUR, V114, P307, DOI 10.1016/j.clineuro.2011.10.032
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E751
EP E760
DI 10.1016/j.wneu.2019.03.258
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300094
PM 30951918
DA 2020-05-12
ER

PT J
AU Teng, L
   Chen, WG
   Yin, CY
   Zhang, HT
   Zhao, QP
AF Teng, Lu
   Chen, Weiguang
   Yin, Changyou
   Zhang, Hongtao
   Zhao, Qingping
TI Dexmedetomidine Improves Cerebral Ischemia-Reperfusion Injury in Rats
   via Extracellular Signal-Regulated Kinase/Cyclic Adenosine Monophosphate
   Response Element Binding Protein Signaling Pathway
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain injury; Cerebral ischemia reperfusion; Dexmedetomidine; ERK/CREB
   pathway
ID BRAIN-INJURY; ERK; ACTIVATION; CREB; INCREASES; SEVOFLURANE; MECHANISM;
   KINASES; NEURONS; SYSTEM
AB OBJECTIVE: To investigate the mechanism of dexmede- which may provide new ways for clinical treatment of tomidine (Dex) in improving brain damage induced by cerebral ischemia-reperfusion injury. cerebral ischemia-reperfusion injury in rats.
   METHODS: Rats were randomly divided into a sham operation group, ischemia-reperfusion group, Dex group, piracetam group, and yohimbine + Dex group, with 12 rats per group. 2,3,5-Triphenyltetrazolium chloride staining was used to analyze cerebral infarct size. Hematoxylin-eosin staining and immunohistochemistry were used to observe brain damage caused by ischemia-reperfusion. Cognitive and memory functions was detected by Morris water maze test, and the expression of phosphorylated extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phosphorylated cyclic adenosine monophosphate response element binding protein (CREB) were measured by Western blot.
   RESULTS: Cognitive dysfunction was improved in the Dex group and the piracetam group compared with the ischemia-reperfusion group. Compared with the ischemiareperfusion group, infarct size and neuronal cell death rates were decreased in the Dex group and the piracetam group. The expression of phosphorylated ERK1/2 and phosphorylated CREB in the Dex group was increased, whereas the expression of phosphorylated ERK1/2 and phosphorylated CREB in the yohimbine + Dex group was lower than in the Dex group (P < 0.05).
   CONCLUSIONS: Dex improved ischemic brain damage by promoting signal transduction of the ERK/CREB pathway, which may provide new ways for clinical treatment of cerebral ischemia-reperfusion injury.
C1 [Teng, Lu; Yin, Changyou; Zhang, Hongtao; Zhao, Qingping] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Peoples R China.
   [Chen, Weiguang] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Emergency Neurosurg, Yantai, Peoples R China.
RP Zhao, QP (reprint author), Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, Yantai, Peoples R China.
EM zhaoqingping247@163.com
CR Al-Mufti F, 2018, NEUROSURGERY, V82, P781, DOI 10.1093/neuros/nyx341
   Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a
   Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064
   Barry RMD, 2010, DRUG DEVELOP RES, V2, P475
   Cao H, 2012, NEUROSCI BULL, V28, P77, DOI 10.1007/s12264-012-1060-x
   Cruz CD, 2007, CURR NEUROPHARMACOL, V5, P244, DOI 10.2174/157015907782793630
   DeDeyn PP, 1997, STROKE, V28, P2347, DOI 10.1161/01.STR.28.12.2347
   Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553
   Guo J, 2006, NEUROSCIENCE, V143, P827, DOI 10.1016/j.neuroscience.2006.08.031
   Hou G, 2013, JIANGSU MED J, V39, P1508
   Hu SP, 2017, HUM EXP TOXICOL, V36, P474, DOI 10.1177/0960327116652458
   Huang SY, 2018, INT J MOL MED, V41, P2252, DOI 10.3892/ijmm.2018.3387
   Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49
   [金哲 Jin Zhe], 2016, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V36, P1216
   Jung HY, 2018, NEUROCHEM INT, V118, P265, DOI 10.1016/j.neuint.2018.05.005
   Kida Satoshi, 2012, Exp Neurobiol, V21, P136, DOI 10.5607/en.2012.21.4.136
   LI Jinfeng, 2016, CHINA HLTH STANDARD, V7, P174
   Liu GY, 2016, ACTA CIR BRAS, V31, P8, DOI 10.1590/S0102-865020160010000002
   Lyu M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00312
   Ma WY, 2001, PAIN, V93, P295, DOI 10.1016/S0304-3959(01)00335-9
   Marinelli PW, 2007, PSYCHOPHARMACOLOGY, V195, P345, DOI 10.1007/s00213-007-0905-x
   Nagy Z, 2017, BRAIN RES BULL, V134, P30, DOI 10.1016/j.brainresbull.2017.06.011
   [彭晓红 Peng Xiaohong], 2014, [中国医院药学杂志, Chinese Journal of Hospital Pharmacy], V34, P2107
   Qi XL, 2008, NEUROBIOL DIS, V31, P278, DOI 10.1016/j.nbd.2008.05.003
   Qian XL, 2015, EUR J PHARMACOL, V746, P206, DOI 10.1016/j.ejphar.2014.11.017
   Riquelme JA, 2016, PHARMACOL RES, V103, P318, DOI 10.1016/j.phrs.2015.11.004
   Shi YM, 2014, MED RECAPITULATE, V20, P2507
   Song Z, 2016, SHANGHAI MED J, V2, P112
   Tetsuro S, 2007, ANESTHESIOLOGY, V107, P605
   Trifilieff P, 2006, LEARN MEMORY, V13, P349, DOI 10.1101/lm.80206
   Wang WX, 2018, NEUROSCI LETT, V677, P110, DOI 10.1016/j.neulet.2018.03.043
   Wang ZQ, 2004, BRAIN RES, V996, P55, DOI 10.1016/j.brainres.2003.09.074
   Weeber EJ, 2002, NEURON, V33, P845, DOI 10.1016/S0896-6273(02)00634-7
   [韦祎 Wei Yi], 2014, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V34, P1309
   Wen XR, 2016, MOL NEUROBIOL, V53, P1661, DOI 10.1007/s12035-015-9111-8
   Wu H, 2018, BIOSCI REP
   Xie GL, 2013, EXP THER MED, V5, P1593, DOI 10.3892/etm.2013.1030
   Yan M, 2011, NEUROCHEM INT, V58, P549, DOI 10.1016/j.neuint.2011.01.013
   Yang GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078355
   Zhang C, 2014, BRAIN RES, V1555, P1, DOI 10.1016/j.brainres.2014.01.051
   Zhang HZ, 2016, J NEUROCHEM, V137, P618, DOI 10.1111/jnc.13613
   Zhang J, 2015, J STROKE CEREBROVASC, V24, P1471, DOI 10.1016/j.jstrokecerebrovasdis.2015.02.008
   Zhang YP, 2018, J MOL MED, V96, P611, DOI 10.1007/s00109-018-1649-2
   [张正洪 Zhang Zhenghong], 2007, [解剖学杂志, Chinese Journal of Anatomy], V30, P174
   Zhou XB, 2008, MED RECAPITULATE, V14, P3784
   Zou S, 2017, EXP THER MED, V14, P6012, DOI 10.3892/etm.2017.5268
NR 46
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E624
EP E630
DI 10.1016/j.wneu.2019.03.232
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300273
PM 30930327
DA 2020-05-12
ER

PT J
AU Torne, R
   Garcia, S
   Sanroman, L
   Rodriguez-Hernandez, A
   Reyes, L
   Tercero, J
   Ensenat, J
AF Torne, Ramon
   Garcia, Sergio
   Sanroman, Luis
   Rodriguez-Hernandez, Ana
   Reyes, Luis
   Tercero, Javier
   Ensenat, Joaquim
TI Safety and Feasibility Assessment of the O-Arm as an Intraoperative
   Angiography Device in Aneurysm Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D reconstruction; Aneurysm clipping; Intraoperative angiography; O-arm
   fluoroscopy
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   SURGICAL-TREATMENT; ARTERIOVENOUS-MALFORMATIONS; ROTATIONAL ANGIOGRAPHY;
   MICRO-DOPPLER; PLACEMENT; EFFICACY; ROUTINE
AB OBJECTIVE: To describe the technique and initial experience of using a rotational 3-dimensional (3D) fluoroscopy system (O-arm; Medtronic) as intraoperative angiography (IA) in the surgery of cerebral aneurysms.
   METHODS: The 3D IA with O-arm (IAWOA) was performed in a consecutive cohort of patients with unruptured intracranial aneurysms. Conventional microsurgical clipping was performed with the assistance of indocyanine green videoangiography. Then the O-arm chassis was brought in, the ipsilateral internal carotid artery was catheterized, and contrasted images were acquired. Resulting datasets were exported in Digital Imaging and Communications in Medicine and processed using the Osirix software in an accessory computer. The 3D image reconstruction was evaluated intraoperatively to confirm aneurysm occlusion and parent vessel patency. Afterward, agreement among IAWOA, indocyanine green videoangiography, and standard postoperative angiography was analyzed.
   RESULTS: The initial pilot study was performed in 6 patients with 7 unruptured aneurysms. The aneurysm occlusion rate was 100%. The concordance of the IAWOA and the standard postoperative angiography was complete, both in terms of occlusion and parent vessel patency. No complications derived from the IAWOA were observed except in 1 patient, who presented a retroperitoneal hematoma without clinical consequences.
   CONCLUSIONS: The 3D rotational fluoroscopy (O-arm) device could be safely and effectively used as an IA system in selected patients. To the best of our knowledge, this is the first study reporting its use as an IA device. This technique seems to offer excellent image quality that could be compared with that of the gold standard 3D digital subtraction angiography but with a lower cost and versatility of use for other subspecialties.
C1 [Torne, Ramon; Garcia, Sergio; Reyes, Luis; Ensenat, Joaquim] Univ Barcelona, Hosp Clin Barcelona, Dept Neurol Surg, Barcelona, Spain.
   [Sanroman, Luis] Univ Barcelona, Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain.
   [Tercero, Javier] Univ Barcelona, Hosp Clin Barcelona, Dept Anestiol, Barcelona, Spain.
   [Rodriguez-Hernandez, Ana] Germans Trias & Pujol Univ Hosp, Dept Neurol Surg, Barcelona, Spain.
RP Torne, R (reprint author), Univ Barcelona, Hosp Clin Barcelona, Dept Neurol Surg, Barcelona, Spain.
EM ramtorne@hotmail.com
OI Torne, Ramon/0000-0001-7932-2528; Garcia Garcia,
   Sergio/0000-0003-2356-5306
CR Alexander TD, 1996, NEUROSURGERY, V39, P10, DOI 10.1097/00006123-199607000-00004
   BARROW DL, 1992, NEUROSURGERY, V30, P153, DOI 10.1227/00006123-199202000-00001
   Burkhardt T, 2015, J NEUROL SURG PART A, V76, P451, DOI 10.1055/s-0035-1551829
   Chalouhi N, 2012, NEUROSURGERY, V71, P1162, DOI 10.1227/NEU.0b013e318271ebfc
   Chiang VL, 2002, J NEUROSURG, V96, P988, DOI 10.3171/jns.2002.96.6.0988
   David CA, 1999, J NEUROSURG, V91, P396, DOI 10.3171/jns.1999.91.3.0396
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   Dehdashti AR, 2009, J NEUROSURG, V111, P188, DOI 10.3171/2008.12.JNS081018
   DERDEYN CP, 1995, AM J NEURORADIOL, V16, P307
   Epstein Nancy E, 2014, Surg Neurol Int, V5, pS517, DOI 10.4103/2152-7806.148001
   Fredrickson VL, 2017, NEUROSURG CLIN N AM, V28, P603, DOI 10.1016/j.nec.2017.05.011
   GROSSART KW, 1974, CLIN RADIOL, V25, P279, DOI 10.1016/S0009-9260(74)80151-0
   Gruber A, 2011, NEUROSURGERY, V68, P657, DOI 10.1227/NEU.0b013e31820777ee
   Hardesty DA, 2014, J CLIN NEUROSCI, V21, P1377, DOI 10.1016/j.jocn.2014.02.006
   Holloway K, 2013, NEUROSURGERY, V72, P47, DOI 10.1227/NEU.0b013e318273a090
   Houten JK, 2012, NEUROSURGERY, V70, P990, DOI 10.1227/NEU.0b013e318237a829
   Klopfenstein JD, 2004, J NEUROSURG, V100, P230, DOI 10.3171/jns.2004.100.2.0230
   Kotowski M, 2013, ACTA NEUROCHIR, V155, P2071, DOI 10.1007/s00701-013-1873-z
   Lee DJ, 2015, J NEUROSURG, V122, P526, DOI 10.3171/2014.9.JNS13919
   Marbacher S, 2019, J NEUROSURG, V131, P64, DOI 10.3171/2018.1.JNS172253
   MARTIN NA, 1990, J NEUROSURG, V73, P526, DOI 10.3171/jns.1990.73.4.0526
   Murayama Y, 2011, NEUROSURGERY, V68, P1427, DOI 10.1227/NEU.0b013e31820b4f1c
   Narvaez-Martinez Y, 2016, NEUROCIRUGIA, V27, P277, DOI 10.1016/j.neucir.2016.05.002
   Origitano TC, 1999, SURG NEUROL, V51, P117, DOI 10.1016/S0090-3019(97)00529-6
   Pai BS, 2010, NEUROL INDIA, V58, P571, DOI 10.4103/0028-3886.68681
   Payner TD, 1998, J NEUROSURG, V88, P441, DOI 10.3171/jns.1998.88.3.0441
   Raabe A, 2005, J NEUROSURG, V103, P982, DOI 10.3171/jns.2005.103.6.0982
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Riva M, 2018, NEUROSURGERY, V83, P166, DOI 10.1093/neuros/nyx387
   Rodriguez-Hernandez A, 2013, NEUROSURGERY, V72, P415, DOI 10.1227/NEU.0b013e3182804aa2
   Roessler K, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13475
   Siasios I, 2012, NEURORADIOLOGY, V54, P1109, DOI 10.1007/s00234-012-1023-y
   Stellar S, 1997, NEUROSURGERY, V40, P1108, DOI 10.1097/00006123-199705000-00063
   Tang G, 2002, J NEUROSURG, V96, P993, DOI 10.3171/jns.2002.96.6.0993
   Washington CW, 2013, J NEUROSURG, V118, P420, DOI 10.3171/2012.10.JNS11818
   Westermaier T, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0133-0
   Westermaier T, 2015, EMERG RADIOL, V22, P97, DOI 10.1007/s10140-014-1252-y
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1159
EP E1165
DI 10.1016/j.wneu.2019.04.076
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300144
PM 30995551
DA 2020-05-12
ER

PT J
AU Troude, L
   Boucekine, M
   Montava, M
   Lavieille, JP
   Regis, JM
   Roche, PH
AF Troude, Lucas
   Boucekine, Mohamed
   Montava, Marion
   Lavieille, Jean-Pierre
   Regis, Jean-Marie
   Roche, Pierre-Hugues
TI Predictive Factors of Early Postoperative and Long-Term Facial Nerve
   Function After Large Vestibular Schwannoma Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Facial nerve; Gamma Knife surgery; Large vestibular schwannoma;
   Predictive factors; Subtotal resection
ID GAMMA-KNIFE SURGERY; ACOUSTIC NEUROMA; SUBTOTAL RESECTION;
   CEREBELLOPONTINE ANGLE; LEARNING-CURVE; TUMOR; RADIOSURGERY; MANAGEMENT;
   PARALYSIS; REMOVAL
AB OBJECTIVE: The preservation of acceptable facial nerve (FN) function after surgery is the key concern for most patients with vestibular schwannomas (VS). To assess predictive factors of early postoperative and long-term FN function in patients harboring large VS operated with a FN-sparing technique.
   METHODS: Single-center retrospective cohort study with 169 consecutive large VS operated on between January 2003 and May 2015. Clinical, radiologic, and intraoperative factors were assessed according to FN function.
   RESULTS: At last follow-up examination, among the 145 patients without preoperative FN palsy, FN function was good (House-Brackmann [HB] grades I or II) in 84% and moderate (HB grade III) in 15% of patients. Only 1 patient presented with poor HB grade IV function. Multivariate logistic regression model showed the mean preoperative VS extrameatal diameter as being an independent predictor of an unfavorable initial FN outcome (odds ratio [OR], 1.062; P = 0.038). Surgical anatomic preservation of the cochlear nerve was associated with better FN outcomes (OR, 0.237; P = 0.012). A history of previous surgery seemed to be related to long-term impaired FN function (OR, 71.405; P = 0.042), as well as early postoperative FN function (OR, 19.068; P = 0.000). No correlation was found between a history of previous Gamma Knife surgery treatment (P = 0.225) or the extent of resection (P = 0.438) and impaired FN outcomes. History of previous surgery was identified as an unfavorable predictive recovery factor of impaired postoperative FN function (P = 0.034).
   CONCLUSIONS: As long as the extent of resection or additional Gamma Knife surgery have not been identified as predictive risk factors of postoperative FN palsy, we suggest that optimal resection is the main option for patients harboring large VS.
C1 [Troude, Lucas; Boucekine, Mohamed; Montava, Marion; Lavieille, Jean-Pierre; Regis, Jean-Marie; Roche, Pierre-Hugues] North Univ Hosp, AP HM, AMU, Dept Neurosurg, Marseille, France.
RP Troude, L (reprint author), North Univ Hosp, AP HM, AMU, Dept Neurosurg, Marseille, France.
EM lucas.troude@ap-hm.fr
OI MONTAVA, Marion/0000-0003-1347-9412
CR Betchen SA, 2003, J NEUROSURG, V99, P818, DOI 10.3171/jns.2003.99.5.0818
   Bloch DC, 2004, OTOLARYNG HEAD NECK, V130, P104, DOI 10.1016/S0194-5998(03)01598-5
   BRIGGS RJS, 1994, NEUROSURGERY, V34, P785, DOI 10.1227/00006123-199405000-00001
   Buchman CA, 1996, LARYNGOSCOPE, V106, P1406, DOI 10.1097/00005537-199611000-00019
   Chen ZN, 2014, J NEUROSURG, V120, P1278, DOI 10.3171/2014.2.JNS131497
   Daniel RT, 2017, ACTA NEUROCHIR, V159, P1197, DOI 10.1007/s00701-017-3194-0
   Dobel C, 2013, LARYNGO RHINO OTOL, V92, P9, DOI 10.1055/s-0032-1327624
   El-Kashlan HK, 2000, AM J OTOL, V21, P389, DOI 10.1016/S0196-0709(00)80049-6
   Falcioni M, 2011, J NEUROSURG, V115, P820, DOI 10.3171/2011.5.JNS101597
   Fenton JE, 2002, OTOL NEUROTOL, V23, P388, DOI 10.1097/00129492-200205000-00027
   Freeman SRM, 2007, OTOL NEUROTOL, V28, P1076, DOI 10.1097/MAO.0b013e318159e76a
   Fuentes Stephane, 2008, Prog Neurol Surg, V21, P79, DOI 10.1159/000156709
   GARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55, DOI 10.1177/000348948809700110
   Gerganov VM, 2009, ACTA NEUROCHIR, V151, P581, DOI 10.1007/s00701-009-0288-3
   Haque R, 2011, J NEUROSURG, V115, P917, DOI 10.3171/2011.7.JNS101921
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   Iwai Y, 2003, SURG NEUROL, V59, P283, DOI 10.1016/S0090-3019(03)00025-9
   Iwai Y, 2007, NEUROSURGERY, V60, P75, DOI 10.1227/01.NEU.0000249251.78794.45
   Jeltema HR, 2015, LARYNGOSCOPE, V125, P1703, DOI 10.1002/lary.25115
   Jung S, 2000, SURG NEUROL, V53, P370, DOI 10.1016/S0090-3019(00)00196-8
   KAMEYAMA S, 1994, ACTA NEUROCHIR, V129, P127, DOI 10.1007/BF01406491
   Koos WT, 1998, J NEUROSURG, V88, P506, DOI 10.3171/jns.1998.88.3.0506
   Kunihiro T, 1999, ORL-J OTO-RHIN-LARYN, V61, P98, DOI 10.1159/000027649
   Lanman TH, 1999, J NEUROSURG, V90, P617, DOI 10.3171/jns.1999.90.4.0617
   Lee J, 2007, ARCH OTOLARYNGOL, V133, P56, DOI 10.1001/archotol.133.1.56
   Mamikoglu B, 2002, OTOL NEUROTOL, V23, P224, DOI 10.1097/00129492-200203000-00020
   Monfared A, 2016, NEUROSURGERY, V79, P194, DOI 10.1227/NEU.0000000000001162
   Nicoucar K, 2006, J NEUROSURG, V105, P205, DOI 10.3171/jns.2006.105.2.205
   Ohta S, 1998, BRIT J NEUROSURG, V12, P419, DOI 10.1080/02688699844619
   Pan HC, 2012, J NEUROSURG, V117, P69, DOI 10.3171/2012.6.GKS12697
   Regis Jean, 2013, J Neurosurg, V119 Suppl, P1091
   Regis Jean, 2007, Prog Neurol Surg, V20, P129, DOI 10.1159/000100100
   Roche Pierre-Hugues, 2008, Prog Neurol Surg, V21, P158, DOI 10.1159/000156903
   Roche Pierre-Hugues, 2008, Prog Neurol Surg, V21, P152, DOI 10.1159/000156902
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Sampath P, 2000, J NEUROSURG, V92, P70, DOI 10.3171/jns.2000.92.1.0070
   Stripf T, 2007, J NEUROSURG, V107, P927, DOI 10.3171/JNS-07/11/0927
   Torres R, 2017, OTOLARYNG HEAD NECK, V156, P525, DOI 10.1177/0194599816677711
   Troude L, 2018, WORLD NEUROSURG, V118, pE895, DOI 10.1016/j.wneu.2018.07.093
   van de Langenberg R, 2011, J NEUROSURG, V115, P875, DOI 10.3171/2011.6.JNS101958
   Welling DB, 1999, AM J OTOL, V20, P644
   Zaouche S, 2005, ACTA OTO-LARYNGOL, V125, P363, DOI 10.1080/00016480410025216
NR 42
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E599
EP E608
DI 10.1016/j.wneu.2019.03.218
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300075
PM 30930324
DA 2020-05-12
ER

PT J
AU Vasquez, CA
   Moen, SL
   Juliano, MJ
   Jagadeesan, BD
   Pluhar, GE
   Chen, CC
   Grande, AW
AF Vasquez, Ciro A.
   Moen, Sean L.
   Juliano, Mario J.
   Jagadeesan, Bharathi D.
   Pluhar, G. Elizabeth
   Chen, Clark C.
   Grande, Andrew W.
TI Development of a Novel Canine Model of Ischemic Stroke: Skull Base
   Approach with Transient Middle Cerebral Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Animal stroke; Canine; Canine stroke; Experimental stroke; Middle
   cerebral artery; Stroke model
ID ANIMAL-MODELS; B-VIRUS; VOLUME
AB OBJECTIVE: Although canine stroke models have several intrinsic advantages, establishing consistent and reproducible territorial stroke in these models has been challenging because of the abundance of collateral circulation. We have described a skull-base surgical approach that yields reproducible stroke volumes.
   METHODS: Ten male beagles were studied. In all 10 dogs, a craniectomy was performed to expose the circle of Willis. Cerebral aneurysm clips were temporarily applied to the middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery, and/or ophthalmic artery (OA) for 1 hour, followed by cauterization of the distal MCA pial collateral vessels. Indocyanine green angiography was performed to assess the local blood flow to the intended area of infarction. The dogs' neurologic examination was evaluated, and the stroke burden was quantified using magnetic resonance imaging.
   RESULTS: High mortality was observed after 1-hour clip occlusion of the posterior cerebral artery, MCA, ACA, and OA (n = 4). Without coagulation of the MCA collateral vessels, 1-hour occlusion of the MCA and/or ACA and OA yielded inconsistent stroke volumes (n = 2). In contrast, after coagulation of the distal MCA pial collateral vessels, 1-hour occlusion of the MCA, ACA, and OA yielded consistent territorial stroke volumes (n = 4; average stroke volume, 9.13 +/- 0.90 cm(3) ; no surgical mortalities), with reproducible neurologic deficits.
   CONCLUSION: Consistent stroke volumes can be achieved in male beagles using a skull base surgical approach with temporary occlusion of the MCA, ACA, and OA when combined with cauterization of the distal MCA pial collateral vessels.
C1 [Vasquez, Ciro A.; Moen, Sean L.; Chen, Clark C.; Grande, Andrew W.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
   [Jagadeesan, Bharathi D.; Grande, Andrew W.] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA.
   [Juliano, Mario J.; Grande, Andrew W.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Pluhar, G. Elizabeth] Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, Minneapolis, MN 55455 USA.
RP Grande, AW (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.; Grande, AW (reprint author), Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA.; Grande, AW (reprint author), Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
EM grande@umn.edu
OI Grande, Andrew/0000-0002-6474-7969
CR Atchaneeyasakul K, 2016, BRAIN RES BULL, V127, P134, DOI 10.1016/j.brainresbull.2016.07.006
   Bley T, 2010, AM J NEURORADIOL, V31, P536, DOI 10.3174/ajnr.A1851
   Boulos AS, 2011, J NEUROSURG, V114, P1117, DOI 10.3171/2010.8.JNS09352
   Cheng Yu Dennis, 2004, NeuroRx, V1, P36, DOI 10.1007/BF03206566
   Christoforidis GA, 2011, INVEST RADIOL, V46, P34, DOI 10.1097/RLI.0b013e3181f0cbc7
   Chung DJ, 2009, J NEUROSCI RES, V87, P3554, DOI 10.1002/jnr.22162
   DELZOPPO GJ, 1995, J INTERN MED, V237, P79
   DIAZ FG, 1981, SURG NEUROL, V15, P458, DOI 10.1016/S0090-3019(81)80040-7
   Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128
   Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51
   Green AR, 2003, TRENDS PHARMACOL SCI, V24, P402, DOI 10.1016/S0165-6147(03)00192-5
   Harris AD, 2009, J MAGN RESON IMAGING, V29, P1262, DOI 10.1002/jmri.21763
   Kang BT, 2007, J VET SCI, V8, P369, DOI 10.4142/jvs.2007.8.4.369
   Kang BT, 2009, COMPARATIVE MED, V59, P459
   Kang BT, 2009, RES VET SCI, V87, P300, DOI 10.1016/j.rvsc.2009.01.010
   Liebeskind DS, 2001, CNS DRUGS, V15, P165, DOI 10.2165/00023210-200115030-00001
   MULLAN JC, 1993, NEUROSURGERY, V32, P967, DOI 10.1227/00006123-199306000-00015
   O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741
   PALMER AE, 1987, J MED PRIMATOL, V16, P99
   Pearson H, 2006, NATURE, V444, P532, DOI 10.1038/444532a
   PURDY PD, 1989, STROKE, V20, P1368, DOI 10.1161/01.STR.20.10.1368
   Qureshi AI, 2004, NEURORADIOLOGY, V46, P988, DOI 10.1007/s00234-004-1180-8
   Rink C, 2008, P NATL ACAD SCI USA, V105, P14100, DOI 10.1073/pnas.0806678105
   Rink C, 2011, J CEREBR BLOOD F MET, V31, P2218, DOI 10.1038/jcbfm.2011.85
   Shaibani A, 2006, AM J NEURORADIOL, V27, P1788
   Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85
   van der Born IMJ, 2012, AM J NEURORADIOL, V33, P353, DOI 10.3174/ajnr.A2944
   WEIGLER BJ, 1992, CLIN INFECT DIS, V14, P555, DOI 10.1093/clinids/14.2.555
   Zhang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142251
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E251
EP E260
DI 10.1016/J.WNEU.2019.03.082
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300034
PM 30898757
DA 2020-05-12
ER

PT J
AU Wang, DL
   Lin, P
   Lin, ZY
   Zheng, SF
   Shang-Guan, HC
   Kang, DZ
   Chen, GR
   Zhang, YB
   Wen, CS
   Lin, YX
   Yao, PS
AF Wang, Deng-Liang
   Lin, Peng
   Lin, Zhang-Ya
   Zheng, Shu-Fa
   Shang-Guan, Huang-Cheng
   Kang, De-Zhi
   Chen, Guo-Rong
   Zhang, Yi-Bin
   Wen, Chun-Shui
   Lin, Yuan-Xiang
   Yao, Pei-Sen
TI Lower Hemoglobin Levels Are Associated with Acute Seizures in Patients
   with Ruptured Cerebral Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Epilepsy; Hemoglobin; Risk factors
ID SUBARACHNOID HEMORRHAGE; MEDICAL PROGRESS; EPILEPSY; HYPERTENSION;
   CYTOKINES; ANEMIA; RATIO
AB OBJECTIVE: We tested the hypothesis that low hemoglobin levels are associated with acute seizures after aneurysmal subarachnoid hemorrhage (aSAH).
   METHODS: Patients with ruptured intracranial aneurysms were enrolled in the observational cohort study that prospectively collected age, sex, symptom onset, history of diabetes and hypertension, history of coronary artery disease, temperature, Hunt-Hess grade, Fisher grade, aneurysm location, hemoglobin, hematocrit, serum potassium, sodium, calcium, phosphorus, iron, and modified Rankin Scale. Acute seizures were determined as seizures within 1 week after aSAH.
   RESULTS: We included 554 patients with requisite data for analysis in the prospective study. Incidence of acute seizures following aSAH was 3.61%. In the univariate analysis, significant differences were detected in admission Hunt-Hess grade, Fisher grade, hemoglobin, and serum iron between epilepsy and nonepilepsy groups. Furthermore, acute seizures were associated with higher modified Rankin Scale score and poor outcome (P = 0.004). Serum hemoglobin levels were 114.30 +/- 20.08 g/L in the epilepsy group, which were lower than those in the nonepilepsy group (128.64 +/- 17.94 mmol/L, P = 0.001). Serum iron levels were 8.89 +/- 5.03 g/L in the epilepsy group, which were also lower than those in the nonepilepsy group (13.71 +/- 6.70 mmol/L, P = 0.002). The hemoglobin level was positively correlated with serum iron on admission (p = 0.321, P = 0.000). In the multivariate logistic regression model, lower hemoglobin was considered as an independent risk factor of acute seizures (odds ratio 4.286, 95% confidence interval 1.492-12.315, P = 0.007). The optimal cutoff value for hemoglobin level as a predictor for acute epilepsy after aSAH was determined as 119 g/L in the receiver operating characteristic curve (sensitivity was 75.00%, and specificity was 69.48%).
   CONCLUSIONS: These data support the hypothesis that hemoglobin was inversely associated with acute seizures following aSAH.
C1 [Wang, Deng-Liang; Lin, Peng; Lin, Zhang-Ya; Zheng, Shu-Fa; Kang, De-Zhi; Chen, Guo-Rong; Lin, Yuan-Xiang; Yao, Pei-Sen] Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
   [Shang-Guan, Huang-Cheng] Fujian Med Univ, Affiliated Hosp 1, Dept Crit Med, Fuzhou, Fujian, Peoples R China.
   [Zhang, Yi-Bin] Dehua Cty Hosp, Neurosurg, Quanzhou, Fujian, Peoples R China.
   [Wen, Chun-Shui] Datian Cty Hosp, Neurol, Sanming, Peoples R China.
RP Yao, PS (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Neurosurg, Fuzhou, Fujian, Peoples R China.
EM peisen.yao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81802492]; Young and Middle-aged Backbone Key
   Research Project of National Health and Family Planning Commission of
   Fujian Province [2017-ZQN-46]; Natural Science Funding of Fujian
   Province [2018J01175, 2018J01176]; special fund for public health of
   Fujian Province Department of Finance (BPB-LZY2013); key clinical
   specialty discipline construction program of Fujian, P. R.C; major
   project of Fujian Provincial Department of Science and Technology
   [2014YZ0003, 2014YZ01]
FX The study was supported by National Natural Science Foundation of China
   (81802492 to Pei-Sen Yao), the Young and Middle-aged Backbone Key
   Research Project of National Health and Family Planning Commission of
   Fujian Province (2017-ZQN-46 to Pei-Sen Yao), Natural Science Funding of
   Fujian Province (2018J01175 to Pei-Sen Yao and 2018J01176 to Shu-Fa
   Zheng), special fund for public health of Fujian Province Department of
   Finance (BPB-LZY2013 to Zhang-Ya Lin), key clinical specialty discipline
   construction program of Fujian, P. R.C, and major project of Fujian
   Provincial Department of Science and Technology (2014YZ0003 and 2014YZ01
   to DeZhi Kang).
CR Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Choi KS, 2009, J KOREAN NEUROSURG S, V46, P93, DOI 10.3340/jkns.2009.46.2.93
   deUngria M, 2000, PEDIATR RES, V48, P169, DOI 10.1203/00006450-200008000-00009
   Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303
   ECHLIN F, 1971, J NEUROSURG, V35, P646, DOI 10.3171/jns.1971.35.6.0646
   Ertas G, 2013, J NEUROL SCI, V324, P49, DOI 10.1016/j.jns.2012.09.032
   HART RG, 1981, NEUROSURGERY, V8, P417, DOI 10.1227/00006123-198104000-00002
   HASAN D, 1993, ANN NEUROL, V33, P286
   Hulkkonen J, 2004, EPILEPSY RES, V59, P199, DOI 10.1016/j.eplepsyres.2004.04.007
   Huttunen J, 2015, NEUROLOGY, V84, P2229, DOI 10.1212/WNL.0000000000001643
   Ibrahim GM, 2013, J NEUROSURG, V119, P347, DOI 10.3171/2013.3.JNS122097
   Idro R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014001
   Ishikawa M, 2016, ACTA NEUROCHIR, V158, P1057, DOI 10.1007/s00701-016-2792-6
   Juvela S, 2005, J NEUROSURG, V102, P998, DOI 10.3171/jns.2005.102.6.0998
   Lin CL, 2003, J NEUROSURG, V99, P978, DOI 10.3171/jns.2003.99.6.0978
   Ludwiczek S, 2003, BLOOD, V101, P4148, DOI 10.1182/blood-2002-08-2459
   Madan N, 2011, INDIAN J PEDIATR, V78, P58, DOI 10.1007/s12098-010-0192-0
   OHMAN J, 1990, NEUROSURGERY, V27, P578
   Ozaydin E, 2012, SEIZURE-EUR J EPILEP, V21, P211, DOI 10.1016/j.seizure.2011.12.014
   Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258
   Taki W, 2011, WORLD NEUROSURG, V76, P437, DOI 10.1016/j.wneu.2011.04.026
   Tokgoz S, 2013, J STROKE CEREBROVASC, V22, P1169, DOI 10.1016/j.jstrokecerebrovasdis.2013.01.011
   Tombini M, 2013, EPILEPSY RES, V107, P244, DOI 10.1016/j.eplepsyres.2013.09.010
   UKKOLA V, 1990, ACTA NEUROCHIR, V106, P115, DOI 10.1007/BF01809452
   Virta M, 2002, EPILEPSIA, V43, P920, DOI 10.1046/j.1528-1157.2002.02002.x
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Zipfel GJ, 2015, J NEUROSURG, V122, P381, DOI 10.3171/2014.8.JNS141613
NR 27
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1237
EP E1241
DI 10.1016/j.wneu.2019.04.115
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300156
PM 31009781
DA 2020-05-12
ER

PT J
AU Wang, HB
   Li, X
   Wang, YJ
   Sun, JC
   Wang, Y
   Xu, XM
   Zhang, B
   Shi, JG
AF Wang, Haibo
   Li, Xin
   Wang, Yingjie
   Sun, Jingchuan
   Wang, Yuan
   Xu, Ximing
   Zhang, Bin
   Shi, Jiangang
TI Assessing Spinal Cord Injury Area in Patients with Tethered Cord
   Syndrome by Diffusion Tensor Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apparent diffusion coefficient; Diffusion tensor imaging; Fractional
   anisotropy; Tethered cord syndrome; Urinary incontinence
ID TRACTOGRAPHY; VALUES; ADULTS; YOUNG
AB OBJECTIVE: We evaluated the spinal cord injury range in patients with tethered cord syndrome (TCS) who had urinary incontinence.
   METHODS: We included 30 subjects in the present study, 15 with tethered cord syndrome and urinary incontinence and 15 normal volunteers. All 30 subjects underwent magnetic resonance diffusion tensor imaging (DTI). Apparent diffusion coefficient (ADC) and fractional anisotropy (FA) were calculated from a region of interest). All the patients and volunteers were measured 4 segments above the conus medullaris.
   RESULTS: All the FA values and ADC values could be measured from the DTI scans in the normal volunteers and patients. The average ADC value was 1.244 +/- 0.061 in the control group and 1.052 +/- 0.045 in the TCS group. The difference was statistically significant (P < 0.05). The average FA value was 0.866 +/- 0.030 in the control group and 1.079 +/- 0.049 in the TCS group, with a statistically significant difference (P < 0.05). The differences in the ADC values in each segment were statistically significant in the 2 groups, although only the difference in the FA value of the fourth segment above the conus medullaris was statistically significant in the 2 groups.
   CONCLUSION: DTI can detect the spinal cord damage range in patients with TCS. In the patients with urinary incontinence, the spinal cord damage was widespread, and the most severe lesion was at the fourth segment above the conus medullaris. This might indicate that decompression of the spinal cord should at least include the fourth segment above the conus medullaris.
C1 [Wang, Haibo; Li, Xin; Wang, Yingjie; Sun, Jingchuan; Wang, Yuan; Xu, Ximing; Zhang, Bin; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Spine Ctr, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Spine Ctr, Shanghai, Peoples R China.
EM czyyshijiangang@163.com
CR Ahn S, 2011, KOREAN J RADIOL, V12, P651, DOI 10.3348/kjr.2011.12.6.651
   Alahmari DM, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00070
   Aldave G, 2017, J NEUROSURG-PEDIATR, V19, P703, DOI 10.3171/2017.1.PEDS16533
   Bertrand MM, 2016, SURG RADIOL ANAT, V38, P963, DOI 10.1007/s00276-016-1655-4
   Chan TY, 2015, EUR SPINE J, V24, P2991, DOI 10.1007/s00586-015-4144-2
   Chen P, 2018, BIOMED RES INT, V2018, P1
   Dong FL, 2018, EUR SPINE J, V27, P1839, DOI 10.1007/s00586-018-5579-z
   Filippi CG, 2010, EUR RADIOL, V20, P2194, DOI 10.1007/s00330-010-1797-4
   Hotta H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135185
   Hsieh PC, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.4.FOCUS1070
   Jiang J, 2017, J PSYCHIATR NEUROSCI, V42, P150, DOI 10.1503/jpn.150341
   Jones JGA, 2013, AM J NEURORADIOL, V34, P471, DOI 10.3174/ajnr.A3199
   Klekamp J, 2011, J NEUROSURG-SPINE, V15, P258, DOI 10.3171/2011.4.SPINE10504
   Kokubun S, 2011, J NEUROSURG-SPINE, V15, P21, DOI 10.3171/2011.2.SPINE10114
   Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076
   Lee GYF, 2006, J NEUROSURG-SPINE, V4, P123, DOI 10.3171/spi.2006.4.2.123
   Lee SK, 2005, RADIOGRAPHICS, V25, P68
   Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085
   Li X, 2014, SPINE, V39, pE615, DOI 10.1097/BRS.0000000000000288
   Miyagi R, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0576-4
   Nakashima H, 2016, GLOB SPINE J, V6, P535, DOI 10.1055/s-0035-1569004
   Sakai T, 2014, J MED INVESTIG, V61, P197, DOI 10.2152/jmi.61.197
   Schatlo B, 2019, CLIN NEURORADIOL, V29, P523, DOI 10.1007/s00062-018-0686-0
   Taylor WD, 2004, BIOL PSYCHIAT, V55, P201, DOI 10.1016/j.biopsych.2003.07.001
   Tsuchiya K, 2008, NEURORADIOLOGY, V50, P221, DOI 10.1007/s00234-007-0335-9
   Walker L, 2016, NEUROIMAGE, V124, P1125, DOI 10.1016/j.neuroimage.2015.05.083
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E542
EP E547
DI 10.1016/j.wneu.2019.03.195
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300067
PM 30928592
DA 2020-05-12
ER

PT J
AU Wang, HB
   Sun, JC
   Wang, Y
   Sun, KQ
   Xu, XM
   Zhang, B
   Shi, JG
AF Wang, Haibo
   Sun, Jingchuan
   Wang, Yuan
   Sun, Kaiqiang
   Xu, Ximing
   Zhang, Bin
   Shi, Jiangang
TI Homogeneous Spinal-Shortening Axial Decompression for Tethered Cord
   Syndrome: Modified Spinal Column Shortening
SO WORLD NEUROSURGERY
LA English
DT Article
DE Homogeneous spinal-shortening axial decompression; Surgical outcome;
   Tethered cord syndrome
ID SURGICAL-MANAGEMENT; ADULTS; MYELOMENINGOCELE; CHILDREN
AB OBJECTIVE: Tethered cord syndrome is a rare and intractable disease. The aim of this study was to investigate surgical outcome of homogeneous spinal-shortening axial decompression (HSAD) for tethered cord syndrome through a minimum 3-year follow-up.
   METHODS: Patients who underwent HSAD for tethered cord syndrome in our institution between May 2011 and July 2015 were included in this study. After a minimum 3-year follow-up, radiologic and clinical data were collected. Surgical outcome was evaluated with Japanese Orthopaedic Association, visual analog scale, International Consultation on Incontinence Questionnaire- Short Form, and Rintala scores and urodynamics.
   RESULTS: The study included 64 patients (28 men and 36 women) with a mean age of 35.7 +/- 18.1 years. Significant improvement of visual analog scale and Japanese Orthopaedic Association scores was noted postoperatively and at a minimum 3-year follow-up. At the final follow-up, Japanese Orthopaedic Association and visual analog scale scores in all patients were improved compared with preoperatively. The International Consultation on Incontinence Questionnaire-Short Form score was decreased from 14.94 +/- 4.15 preoperatively to 7.63 +/- 4.40 at final follow-up (P < 0.01). Rintala score was improved from 5.26 +/- 3.45 preoperatively to 12.32 +/- 3.43 at final follow-up (P < 0.01). All urodynamic parameters improved compared with preoperatively.
   CONCLUSIONS: HSAD was effective and safe. The results were satisfactory with a minimum 3-year follow-up. HSAD could be an alternative surgical treatment of TCS.
C1 [Wang, Haibo; Sun, Jingchuan; Wang, Yuan; Sun, Kaiqiang; Xu, Ximing; Zhang, Bin; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Spine Ctr, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Surg, Spine Ctr, Shanghai, Peoples R China.
EM czyyshijiangang@163.com
FU Shanghai Science and Technology Commission Technology Support Project
   [18441905800]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [81802218, 81871828]
FX This study was supported by grants from the Shanghai Science and
   Technology Commission Technology Support Project (Grant No. 18441905800)
   and National Natural Science Foundation of China (Grant Nos. 81802218
   and 81871828).
CR Aldave G, 2017, J NEUROSURG-PEDIATR, V19, P703, DOI 10.3171/2017.1.PEDS16533
   Archibeck MJ, 1997, J PEDIATR ORTHOPED, V17, P773, DOI 10.1097/00004694-199711000-00014
   DAVIDOFF AM, 1991, J PEDIATR SURG, V26, P1001, DOI 10.1016/0022-3468(91)90851-J
   George TM, 2005, J NEUROSURG, V102, P150, DOI 10.3171/jns.2005.102.2.0150
   Grande AW, 2006, J NEUROSURG-SPINE, V4, P478, DOI 10.3171/spi.2006.4.6.478
   Huttmann S, 2001, J NEUROSURG, V95, P173, DOI 10.3171/spi.2001.95.2.0173
   Iskandar BJ, 1998, J NEUROSURG, V88, P958, DOI 10.3171/jns.1998.88.6.0958
   Klekamp J, 2011, J NEUROSURG-SPINE, V15, P258, DOI 10.3171/2011.4.SPINE10504
   Kokubun S, 2011, J NEUROSURG-SPINE, V15, P21, DOI 10.3171/2011.2.SPINE10114
   Lee GYF, 2006, J NEUROSURG-SPINE, V4, P123, DOI 10.3171/spi.2006.4.2.123
   PANG D, 1982, J NEUROSURG, V57, P32, DOI 10.3171/jns.1982.57.1.0032
   Safain MG, 2015, J NEUROSURG-SPINE, V23, P120, DOI 10.3171/2014.11.SPINE14877
   Samuels R, 2009, CHILD NERV SYST, V25, P1085, DOI 10.1007/s00381-009-0895-6
   Steinbok P, 2016, J UROLOGY, V195, P1183, DOI 10.1016/j.juro.2015.09.082
   Sun JC, 2018, WORLD NEUROSURG, V116, pE66, DOI 10.1016/j.wneu.2018.03.221
   Sysoev K, 2018, CHILD NERV SYST, V34, P305, DOI 10.1007/s00381-017-3630-8
NR 16
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E517
EP E522
DI 10.1016/j.wneu.2019.03.192
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300064
PM 30928585
DA 2020-05-12
ER

PT J
AU Wang, HW
   Xue, Z
   Ma, YD
   Sun, ZH
   Wu, C
AF Wang, Hua-wei
   Xue, Zhe
   Ma, Yu-dong
   Sun, Zheng-hui
   Wu, Chen
TI The Special Considerations in the Surgical Management of Proximal
   Anterior Cerebral Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Anterior cerebral artery; Clipping; Proximal; Subarachnoid
   hemorrhage
ID RUPTURED INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; MICROSURGICAL
   ANATOMY; FUSIFORM ANEURYSM; A1 SEGMENT
AB BACKGROUND: Proximal anterior cerebral artery (A1) aneurysms are difficult to clip because of their frequent proximity to perforators, location behind the parent artery, or adherence to surrounding structures.
   METHODS: We retrospectively reviewed a consecutive series of patients with A1 aneurysms and report the clinical status, radiologic findings, treatment methods, and outcome.
   RESULTS: This series included 19 male and 12 female patients with a mean age of 50 years. The morphology of the A1 aneurysms was fusiform in 2 patients and saccular in the remaining 29 patients. Multiple aneurysms were presented in 9 patients (29.0%). On admission, 26 patients (83.9%) presented with subarachnoid hemorrhage, 3 of whom had an additional intracerebral hematoma. All surgeries were performed with a standard pteriomal craniotomy. The mean Glasgow Outcome Scale score at final follow-up was 4.8 (interquartile range, 5, 5), with 26 patients (83.9%) rated as 5. The mean follow-up time was 38.5 months (range, 12-60 months).
   CONCLUSIONS: A1 aneurysms are rare but have their own complex characteristics and are difficult to treat. Meticulous analysis of the relevant angiographs is needed for their diagnosis. An important consideration in surgery is the preservation of perforators and prevention of rupture. Wide opening of the sylvian fissure and temporary control of the parent artery can facilitate dissection of the A1 aneurysms dome. Multiple intraoperative monitoring methods, such as microvascular Doppler ultrasonography and somatosensory and motor evoked potential monitoring, can reduce the relevant complications of surgery.
C1 [Wang, Hua-wei; Xue, Zhe; Ma, Yu-dong; Sun, Zheng-hui; Wu, Chen] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Yu-dong; Sun, Zheng-hui] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Hainan Hosp, Sanya, Peoples R China.
RP Sun, ZH (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.; Sun, ZH (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Hainan Hosp, Sanya, Peoples R China.
EM szh_301@126.com
CR Aoki Y, 2007, NEUROL MED-CHIR, V47, P351, DOI 10.2176/nmc.47.351
   Bhaisora KS, 2014, NEUROL INDIA, V62, P410, DOI 10.4103/0028-3886.141284
   Chang HW, 2011, ACTA NEUROCHIR, V153, P279, DOI 10.1007/s00701-010-0804-5
   COSSU M, 1993, NEUROSURGERY, V32, P344, DOI 10.1227/00006123-199303000-00002
   Czepko R, 2005, J Neurosurg Sci, V49, P85
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   DUNKER RO, 1976, J NEUROSURG, V44, P359, DOI 10.3171/jns.1976.44.3.0359
   HANDA J, 1984, SURG NEUROL, V22, P486, DOI 10.1016/0090-3019(84)90308-2
   Hino A, 2002, ACTA NEUROCHIR, V144, P1291, DOI 10.1007/s00701-002-1014-6
   Huo XC, 2013, INTERV NEURORADIOL, V19, P186
   Kedia S, 2013, NEUROL INDIA, V61, P117, DOI 10.4103/0028-3886.111113
   Ko JK, 2013, J KOREAN NEUROSURG S, V54, P75, DOI 10.3340/jkns.2013.54.2.75
   Lee JM, 2010, WORLD NEUROSURG, V74, P478, DOI 10.1016/j.wneu.2010.06.040
   Lehecka M, 2010, WORLD NEUROSURG, V74, P439, DOI 10.1016/j.wneu.2010.07.032
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219
   Lubicz B, 2009, NEURORADIOLOGY, V51, P99, DOI 10.1007/s00234-008-0474-7
   Mariniello G, 2010, CENT EUR NEUROSURG, V71, P96, DOI 10.1055/s-0029-1202358
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Park Hyun-Seok, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P13, DOI 10.7461/jcen.2013.15.1.13
   PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259
   ROSNER SS, 1984, J NEUROSURG, V61, P468, DOI 10.3171/jns.1984.61.3.0468
   SHIGEMORI M, 1988, J NEUROL NEUROSUR PS, V51, P451, DOI 10.1136/jnnp.51.3.451
   SUZUKI M, 1992, J NEUROSURG, V76, P455, DOI 10.3171/jns.1992.76.3.0455
   TAMURA M, 1985, Neurological Surgery, V13, P1337
   TEAL JS, 1973, RADIOLOGY, V106, P123, DOI 10.1148/106.1.123
   WAKABAYASHI T, 1985, SURG NEUROL, V24, P31, DOI 10.1016/0090-3019(85)90059-X
   Yilmaz M, 2014, BOSNIAN J BASIC MED, V14, P8
NR 27
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E761
EP E767
DI 10.1016/j.wneu.2019.03.259
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300095
PM 30951911
DA 2020-05-12
ER

PT J
AU Wang, HW
   Ma, LP
   Yin, YH
   Yu, XG
   Meng, CL
AF Wang, Hua-wei
   Ma, Li-peng
   Yin, Yi-heng
   Yu, Xin-guang
   Meng, Chun-ling
TI Biomechanical Rationale for the Development of Atlantoaxial Instability
   and Basilar Invagination in Patients with Occipitalization of the Atlas:
   A Finite Element Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial dislocation; Atlantoaxial instability; Basilar
   invagination; Craniocervical junction; Finite element analysis;
   Occipitalization of the atlas
ID UPPER CERVICAL-SPINE; FACET JOINT RELEASE; CRANIOVERTEBRAL JUNCTION;
   POSTERIOR REDUCTION; DISLOCATION; CLASSIFICATION; FIXATION; ANATOMY;
   ALAR; MICE
AB OBJECTIVE: Occipitalization of the atlas (OA) often is associated with atlantoaxial dislocation and basilar invagination. The purpose of this study is to determine the biomechanical difference between normal and OA conditions in the craniovertebral junction and to further explore the rationale for development of atlantoaxial dislocation and basilar invagination using the finite element model (FEM).
   METHODS: A ligamentous, nonlinear, sliding-contact, 3-dimensional FEM of the occipitoatlantoaxial complex was generated. Validation of the model was accomplished by comparing kinematic predictions with experimental data. We defined the atlantooccipital joint as a tie contact to simulate the OA deformity. The range of motion and the value of the maximum Von Mises stress were compared between the intact and OA models.
   RESULTS: We found all of the predicted data in the intact FEM fell within 1 standard deviation of the cadaver data for all 6 loadings. The OA simulation significantly reduced the overall range of motion of the occipitoatlantoaxial complex at all loadings. The maximum Von Mises stress was predicted to increase at the transverse ligament and the superior articular facet of the axis for all the flexion, extension, lateral bending, and axial rotation loadings.
   CONCLUSIONS: The OA could result in hypermobility of the atlantoaxial segment and cause overstress in the transverse ligament and the lateral atlantoaxial joints. These changes explain the pathogenesis of atlantoaxial dislocation and basilar invagination associated with OA. Follow-up should be scheduled regularly due to the nature of the dynamic development of atlantoaxial dislocation and basilar invagination.
C1 [Wang, Hua-wei; Yin, Yi-heng; Yu, Xin-guang] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Li-peng; Meng, Chun-ling] Beijing Technol & Business Univ, Sch Mat Sci & Mech Engn, Beijing, Peoples R China.
RP Yu, XG (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xinguang_yu@263.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571350]; Beijing Science and Technology Nova
   Program Project [Z171100001117106]; National Key R&D Program of China
   [2018YFC1002500]
FX This work was supported by the National Natural Science Foundation of
   China (No: 81571350), the Beijing Science and Technology Nova Program
   Project (No: Z171100001117106), and the National Key R&D Program of
   China (No: 2018YFC1002500).
CR Al-Motabagani MA, 2006, ANAT SCI INT, V81, P173, DOI 10.1111/j.1447-073x.2006.00129.x
   Brolin K, 2004, SPINE, V29, P376, DOI 10.1097/01.BRS.0000090820.99182.2D
   Chandra PS, 2016, NEUROSURGERY, V78, P400
   Chandra PS, 2014, OPER NEUROSURG, V10, P621, DOI 10.1227/NEU.0000000000000470
   CONDIE BG, 1993, DEVELOPMENT, V119, P579
   CONDIE BG, 1994, NATURE, V370, P304, DOI 10.1038/370304a0
   DVORAK J, 1988, J ORTHOP RES, V6, P452, DOI 10.1002/jor.1100060317
   FIELDING JW, 1957, J BONE JOINT SURG AM, V39, P1280, DOI 10.2106/00004623-195739060-00005
   Gholve PA, 2007, J BONE JOINT SURG AM, V89A, P571, DOI 10.2106/JBJS.F.00527
   Jian FZ, 2010, NEUROSURGERY, V66, P678, DOI 10.1227/01.NEU.0000367632.45384.5A
   LIND B, 1989, ARCH PHYS MED REHAB, V70, P692
   Lopez AJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14807
   Menezes AH, 2008, CHILD NERV SYST, V24, P1091, DOI 10.1007/s00381-008-0606-8
   Menezes AH, 2008, CHILD NERV SYST, V24, P1109, DOI 10.1007/s00381-008-0600-1
   Menezes AH, 2008, CHILD NERV SYST, V24, P1101, DOI 10.1007/s00381-008-0605-9
   Mudaliar RP, 2013, J CLIN DIAGN RES, V7, P1835, DOI 10.7860/JCDR/2013/6611.3327
   Netter F, 2014, ATLAS HUMAN ANATOMY
   Pang D, 2011, CHILD NERV SYST, V27, P523, DOI 10.1007/s00381-010-1358-9
   PANJABI M, 1991, J SPINAL DISORD, V4, P157, DOI 10.1097/00002517-199106000-00005
   PANJABI M, 1991, J ORTHOPAED RES, V9, P584, DOI 10.1002/jor.1100090415
   PANJABI MM, 1991, J SPINAL DISORD, V4, P270
   Puttlitz CM, 2000, SPINE, V25, P1607, DOI 10.1097/00007632-200007010-00003
   Puttlitz CM, 2001, SPINE, V26, P2449, DOI 10.1097/00007632-200111150-00011
   Salunke P, 2011, J NEUROSURG-SPINE, V15, P678, DOI 10.3171/2011.7.SPINE1152
   Wang C, 2006, SPINE, V31, pE306, DOI 10.1097/01.brs.0000217686.80327.e4
   Wang HW, 2019, WORLD NEUROSURG, V121, pE1, DOI 10.1016/j.wneu.2018.08.016
   Wang SL, 2013, SPINE, V38, pE1348, DOI 10.1097/BRS.0b013e3182a1e5e4
   Wang SL, 2009, SPINE, V34, P2838, DOI 10.1097/BRS.0b013e3181b4fb8b
   Yin YH, 2016, NEUROSURGERY, V78, P391, DOI 10.1227/NEU.0000000000001026
   Yin YH, 2012, SPINE, V37, pE170, DOI 10.1097/BRS.0b013e318227efe7
   Ferreira EDZ, 2015, SPINE, V40, P1763, DOI 10.1097/BRS.0000000000001045
   Zong R, 2017, WORLD NEUROSURG, V99, P96, DOI 10.1016/j.wneu.2016.11.062
NR 32
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E474
EP E479
DI 10.1016/j.wneu.2019.03.174
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300058
PM 30922907
DA 2020-05-12
ER

PT J
AU Wang, JC
   Liu, CC
   Wang, C
   Li, J
   Lv, GH
   A, JC
   Deng, YW
   Wang, WJ
AF Wang, Jingcheng
   Liu, Congcong
   Wang, Cheng
   Li, Jing
   Lv, Guohua
   A, Jiancuo
   Deng, Youwen
   Wang, Wenjun
TI Early and Midterm Outcomes of Surgical Correction for Severe Dystrophic
   Cervical Kyphosis in Patients with Neurofibromatosis Type 1: A
   Retrospective Multicenter Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical kyphosis; Dystrophic change; Neurofibromatosis; Surgical
   correction
ID BONE-MINERAL-DENSITY; SPINAL DEFORMITIES; FOLLOW-UP; RELIABILITY;
   CHILDREN; OSTEOPOROSIS; SCOLIOSIS; CURVES; FUSION; ROD
AB OBJECTIVE: To evaluate the early and midterm outcomes of surgical correction for severe dystrophic cervical kyphosis in patients with neurofibromatosis type 1 (NF-1) and analyze the pathomechanics and the influence on surgical efficacy of related systemic skeletal dystrophy.
   METHODS: Ten patients who underwent surgical correction for NF-1-related severe dystrophic cervical kyphosis were reviewed. Radiographic parameters, including local and global Cobb angle, sagittal vertical axis, and T-1 slope, were measured. The visual analog scale score, Japanese Orthopaedic Association score, Neck Disability Index, Patient Satisfaction Index, and complications were evaluated.
   RESULTS: The average follow-up was 50.6 months. The local and global Cobb angle improved from the preoperative average of 82.0 degrees and 54.9 degrees to an average of 35.6 degrees and 29.8 degrees, respectively, at the time of final follow-up. The C2-7 sagittal vertical axis averaged 5.8 mm before surgery and 8.9 mm at the final follow-up. The average T1 slope was -12.3 degrees before surgery and -1.6 degrees at the final follow-up. The visual analog scale score, Japanese Orthopaedic Association score, and Neck Disability Index improved significantly, and the overall satisfaction rate was 90.0%. One death and 4 instrumentation failures occurred, 3 patients showed progression of the kyphosis, and 2 fusion failures were observed.
   CONCLUSIONS: Surgical correction, specifically the combined anteroposterior procedure, is essential and effective for management of NF-1-related severe dystrophic cervical kyphosis. However, high incidences of instrumentation failure, kyphosis progression, and fusion failure were observed. NF-1-related continuous skeletal dystrophy caused by multiple metabolic factors remarkably affected the midterm outcomes. Early prevention and targeted pharmacotherapy may be necessary.
C1 [Wang, Jingcheng; Liu, Congcong] Cent S Univ, Xiangya Hosp 2, Dept Orthoped, Changsha, Hunan, Peoples R China.
   [Liu, Congcong; Deng, Youwen] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Lv, Guohua; Deng, Youwen] Cent S Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha, Hunan, Peoples R China.
   [Wang, Cheng; Wang, Wenjun] Univ South China, Affiliated Hosp 1, Dept Spine Surg, Hengyang, Hunan, Peoples R China.
   [Li, Jing; A, Jiancuo] Qinghai Red Cross Hosp, Dept Orthoped, Xining, Qinghai, Peoples R China.
RP Deng, YW (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.; Deng, YW (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha, Hunan, Peoples R China.
EM drywdeng@csu.edu.cn
CR AKBARNIA BA, 1992, SPINE, V17, pS244
   Benlidayi IC, 2015, ACTA CLIN BELG, V70, P130, DOI 10.1179/2295333714Y.0000000094
   Brunetti-Pierri N, 2008, MOL GENET METAB, V94, P105, DOI 10.1016/j.ymgme.2007.12.004
   CALVERT PT, 1989, J BONE JOINT SURG BR, V71, P246
   Chen H, 2008, ANN CLIN LAB SCI, V38, P25
   Cnossen MH, 1998, ARCH DIS CHILD, V78, P408, DOI 10.1136/adc.78.5.408
   Crawford A H, 1999, J Am Acad Orthop Surg, V7, P217
   CRAWFORD AH, 1989, CLIN ORTHOP RELAT R, P29
   Daltroy LH, 1996, SPINE, V21, P741, DOI 10.1097/00007632-199603150-00017
   Durrani AA, 2000, SPINE, V25, P69, DOI 10.1097/00007632-200001010-00013
   Etame Arnold B, 2010, Neurosurg Focus, V28, pE14, DOI 10.3171/2010.1.FOCUS09272
   FUNASAKI H, 1994, J BONE JOINT SURG AM, V76A, P692, DOI 10.2106/00004623-199405000-00010
   George-Abraham JK, 2013, AM J MED GENET A, V161A, P921, DOI 10.1002/ajmg.a.35541
   Halmai V, 2002, J NEUROSURG, V97, P310, DOI 10.3171/spi.2002.97.3.0310
   Heerva E, 2014, CALCIFIED TISSUE INT, V94, P608, DOI 10.1007/s00223-013-9835-2
   Heerva E, 2013, CALCIFIED TISSUE INT, V92, P23, DOI 10.1007/s00223-012-9661-y
   Helenius IJ, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.16.00096
   Illes T, 2001, OSTEOPOROSIS INT, V12, P823, DOI 10.1007/s001980170032
   Knott PT, 2010, SPINE J, V10, P994, DOI 10.1016/j.spinee.2010.08.031
   Lammert M, 2005, OSTEOPOROSIS INT, V16, P1161, DOI 10.1007/s00198-005-1940-2
   Lin T, 2018, WORLD NEUROSURG, V111, pE62, DOI 10.1016/j.wneu.2017.11.174
   Ma JM, 2011, J NEUROSURG-SPINE, V14, P93, DOI 10.3171/2010.9.SPINE091015
   Mummaneni PV, 2008, J NEUROSURG-SPINE, V9, P515, DOI 10.3171/SPI.2008.10.08226
   Nottmeier EW, 2009, J SPINAL DISORD TECH, V22, P385, DOI 10.1097/BSD.0b013e318180e672
   O'Shaughnessy BA, 2008, SPINE, V33, P771, DOI 10.1097/BRS.0b013e3181695082
   Parisini P, 1999, SPINE, V24, P2247, DOI 10.1097/00007632-199911010-00013
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Petramala L, 2012, ARCH DERMATOL RES, V304, P325, DOI 10.1007/s00403-011-1191-3
   Rodari G, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657-018-0507-8
   Schnabel C, 2013, JOINT BONE SPINE, V80, P315, DOI 10.1016/j.jbspin.2012.07.010
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198-009-0933-y
   SIROIS JL, 1990, J PEDIATR ORTHOPED, V10, P522
   Stevenson DA, 2007, J PEDIATR-US, V150, P83, DOI 10.1016/j.jpeds.2006.10.048
   Taleb FS, 2011, J NEUROSURG-SPINE, V14, P356, DOI 10.3171/2010.9.SPINE09242
   Topsakal C, 2001, NEUROL MED-CHIR, V41, P551, DOI 10.2176/nmc.41.551
   VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409
   Vitale MG, 2002, CLIN ORTHOP RELAT R, P107, DOI 10.1097/01.blo.0000022199.37246.c9
   Watanabe K, 2016, CLIN SPINE SURG, V29, pE428, DOI 10.1097/BSD.0000000000000127
   Winter R B, 1988, J Spinal Disord, V1, P39
   WINTER RB, 1984, J BONE JOINT SURG AM, V66A, P1102, DOI 10.2106/00004623-198466070-00019
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yifei Gu, 2019, Int Orthop, V43, P639, DOI 10.1007/s00264-018-4050-4
   Yonenobu K, 2001, SPINE, V26, P1890, DOI 10.1097/00007632-200109010-00014
   YONGHING K, 1979, J BONE JOINT SURG AM, V61, P695, DOI 10.2106/00004623-197961050-00007
NR 44
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1190
EP E1200
DI 10.1016/j.wneu.2019.04.096
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300149
PM 31004860
DA 2020-05-12
ER

PT J
AU Wang, MH
   Chae, R
   Shehata, J
   Vigo, V
   Winkler, E
   McDermott, MW
   El-Sayed, IH
   Abla, AA
   Rubio, RR
AF Wang, Minghao
   Chae, Ricky
   Shehata, Joseph
   Vigo, Vera
   Winkler, Ethan
   McDermott, Michael W.
   El-Sayed, Ivan H.
   Abla, Adib A.
   Rubio, Roberto Rodriguez
TI Comparative Analysis of the Subtonsillar, Far-Lateral, Extreme-Lateral,
   and Endoscopic Far-Medial Approaches to the Lower Clivus An Anatornienl
   Cadaver Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior portion of foramen magnum; Extreme-lateral approach;
   Far-lateral approach; Far-medial approach; Foramen magnum; Hypoglossal
   canal; Jugular foramen; Lower clivus; Subtonsillar approach
ID FORAMEN MAGNUM MENINGIOMAS; TRANSCONDYLAR APPROACH; ENDONASAL APPROACH;
   CRANIOVERTEBRAL JUNCTION; TRANSORAL APPROACH; SURGICAL ANATOMY;
   CEREBELLOMEDULLARY CISTERN; CRANIOCERVICAL JUNCTION; MICROSURGICAL
   ANATOMY; SUBOCCIPITAL APPROACH
AB BACKGROUND: The lower dim (LC) is one of the most difficult areas to access in neurosurgery. Several microsurgical approaches to the LC have been reported, including the subtonsillar, far-lateral (FL), extreme-lateral (EL), and endoscopic far-medial (Endo-FM). However, no consensus has been reached regarding the optimal approach. We aimed to quantify and compare the surgical exposure and freedom (angle of attack) for various targets at the LC using these 4 surgical approaches.
   METHODS: The subtonsillar, FL, EL, and Endo-FM approaches were performed on 5 cadaveric specimens (total 10 sides). Surgical exposure and freedom were measured using the neuronavigation system.
   RESULTS: At the LC, the Endo-FM approach provided the greatest area of exposure (459.3 +/- 82.2 mm(2)). For surgical freedom, the EL approach provided the greatest angle of attack at the jugular foramen (98.1 degrees +/- 9.2 degrees) and hypoglossal canal (128.8 degrees +/- 26.1 degrees). The Endo-FM was the only approach that provided access to the midline of the LC in all specimens. However, the surgical freedom at the midline (20.9 degrees +/- 2.4 degrees at the level of the jugular foramen; 24.2 degrees +/- 2.9 degrees at the level of hypoglossal canal) was limited by its deep surgical corridor (104.3 +/- 11.2 mm) compared with the EL and FL approaches.
   CONCLUSION: The Endo-FM approach provided the greatest surgical freedom at the ventral aspect but the least freedom at the lateral aspect. The EL approach provided maximal values for most parameters among the open approaches; however, the craniotomy with the EL approach was the most complicated. Our quantitative results could guide neurosurgeons in preoperative planning for LC lesions, including awareness of the maximum exposure limits and the advantages and disadvantages of each surgical approach.
C1 [Wang, Minghao] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Shenyang, Liaoning, Peoples R China.
   [Wang, Minghao; Chae, Ricky; Shehata, Joseph; Vigo, Vera; El-Sayed, Ivan H.; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Chae, Ricky; Shehata, Joseph; Vigo, Vera; Winkler, Ethan; McDermott, Michael W.; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [El-Sayed, Ivan H.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
OI Wang, Minghao/0000-0003-1705-0891; Chae, Ricky/0000-0001-5014-9303;
   Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR Alfieri A, 2002, ACTA NEUROCHIR, V144, P219, DOI 10.1007/s007010200029
   AlMefty O, 1996, J NEUROSURG, V84, P1, DOI 10.3171/jns.1996.84.1.0001
   Alzhrani G, 2019, J NEUROSURG, V131, P920, DOI 10.3171/2018.4.JNS172935
   Arnautovic KI, 1997, J NEUROSURG, V86, P252, DOI 10.3171/jns.1997.86.2.0252
   Arnautovic KI, 2000, J NEUROSURG, V92, P71, DOI 10.3171/spi.2000.92.1.0071
   BABU RP, 1994, J NEUROSURG, V81, P49, DOI 10.3171/jns.1994.81.1.0049
   Banerji D, 1999, NEUROL INDIA, V47, P22
   Benet A, 2014, WORLD NEUROSURG, V81, P385, DOI 10.1016/j.wneu.2013.01.091
   Bernard F, 2016, NEUROCHIRURGIE, V62, P86, DOI 10.1016/j.neuchi.2015.10.010
   Bertalanffy H, 1996, Acta Neurochir Suppl, V65, P82
   Bruneau M, 2010, J CRANIOVERTEBRAL JU, V1, P10, DOI 10.4103/0974-8237.65476
   Ruiz-Valdepenas EC, 2018, ACTA NEUROCHIR, V160, P741, DOI 10.1007/s00701-018-3483-2
   Cavalheiro S, 2015, CHILD NERV SYST, V31, P1815, DOI 10.1007/s00381-015-2799-y
   Chandra PS, 2003, NEUROL INDIA, V51, P193
   Chibbaro S, 2014, NEUROSURG REV, V37, P224
   Chibbaro S, 2014, NEUROSURG REV, V37, P217, DOI 10.1007/s10143-013-0503-9
   Colasanti R, 2015, OPER NEUROSURG, V11, P181, DOI 10.1227/NEU.0000000000000632
   CROCKARD HA, 1991, NEUROSURGERY, V28, P88
   DEOLIVEIRA E, 1985, SURG NEUROL, V24, P293, DOI 10.1016/0090-3019(85)90042-4
   Di Somma A, 2018, WORLD NEUROSURG, V117, P301, DOI 10.1016/j.wneu.2018.06.019
   Dobrowolski S, 2016, CLIN NEUROL NEUROSUR, V145, P28, DOI 10.1016/j.clineuro.2016.02.027
   Dobrowolski S, 2016, J SURG CASE REP, DOI 10.1093/jscr/rjw039
   Doglietto F, 2018, WORLD NEUROSURG, V113, pE659, DOI 10.1016/j.wneu.2018.02.118
   Elhadi AM, 2015, OPER NEUROSURG, V11, P69, DOI 10.1227/NEU.0000000000000601
   Elhammady M, 2012, FAR LATERAL APPROACH
   Fric R, 2011, BRIT J NEUROSURG, V25, P86, DOI 10.3109/02688697.2010.525266
   Funaki T, 2013, NEUROSURGERY, V73, P155, DOI 10.1227/01.neu.0000431469.82215.93
   GEORGE B, 1988, SURG NEUROL, V29, P484, DOI 10.1016/0090-3019(88)90145-0
   Goel A, 2001, NEUROSURGERY, V49, P102, DOI 10.1097/00006123-200107000-00016
   HAMMON WM, 1972, J NEUROSURG, V37, P339, DOI 10.3171/jns.1972.37.3.0339
   Herlan S, 2017, ACTA NEUROCHIR, V159, P1613, DOI 10.1007/s00701-017-3270-5
   Herlan S, 2014, CLIN NEUROL NEUROSUR, V125, P98, DOI 10.1016/j.clineuro.2014.07.029
   HEROS RC, 1986, J NEUROSURG, V64, P559, DOI 10.3171/jns.1986.64.4.0559
   JACKLER RK, 1995, AM J OTOL, V16, P39
   Jhawar SS, 2016, J CRANIOVERTEBRAL JU, V7, P204, DOI 10.4103/0974-8237.193270
   Jho HD, 1997, J NEUROSURG, V87, P44, DOI 10.3171/jns.1997.87.1.0044
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P1, DOI 10.1055/S-2003-812538
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P16, DOI 10.1088/s-2004-818347
   Jho HD, 1997, SURG NEUROL, V47, P213, DOI 10.1016/S0090-3019(96)00452-1
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kawashima M, 2003, NEUROSURGERY, V53, P662, DOI 10.1227/01.NEU.0000080070.16099.BB
   Khattar N, 2018, OPER NEUROSURG, V14, P503, DOI 10.1093/ons/opx160
   Kooshkabadi A, 2015, NEUROSURGERY, V77, P888, DOI 10.1227/NEU.0000000000000922
   Koutourousiou M, 2017, WORLD NEUROSURG, V99, P500, DOI 10.1016/j.wneu.2016.12.001
   Leon-Ariza DS, 2017, WORLD NEUROSURG, V106, P477, DOI 10.1016/j.wneu.2017.07.029
   Liu James K, 2012, Neurosurg Focus, V33, P1, DOI [10.3171/2012.V2.FOCUS12142, 10.3171/2012.V2.FOCUS12143]
   Locatelli Davide, 2019, Acta Neurochir Suppl, V125, P209, DOI 10.1007/978-3-319-62515-7_30
   Margalit Nevo S, 2005, Neurosurgery, V56, P324, DOI 10.1227/01.NEU.0000156796.28536.6D
   Menezes A H, 1994, Clin Neurosurg, V41, P187
   Morera VA, 2010, NEUROSURGERY, V66, pONS211, DOI 10.1227/01.NEU.0000369926.01891.5D
   Moscovici S, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.2.FOCUS14784
   Pillai P, 2009, NEUROSURGERY, V64, P437, DOI 10.1227/01.NEU.0000334050.45750.C9
   Rabadan AT, 2016, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00072
   RHOTON AL, NEUROSURGERY S, V47, pS19
   ROHDE V, 1994, SKULL BASE SURG, V4, P177, DOI 10.1055/s-2008-1058952
   Salas E, 1999, J NEUROSURG, V90, P206, DOI 10.3171/spi.1999.90.2.0206
   Scheithauer MO, 2010, GMS CURR TOP OTORHIN, V9
   SEEGER W, 1978, ATLAS TOPOGRAPHICAL
   SEN CN, 1990, NEUROSURGERY, V27, P197, DOI 10.1227/00006123-199008000-00004
   SEN CN, 1991, ACTA NEUROCHIR, V108, P70, DOI 10.1007/BF01407670
   Seoane P, 2017, NEUROSURGERY, V81, P268, DOI 10.1093/neuros/nyw136
   Spektor S, 2000, J NEUROSURG, V92, P824, DOI 10.3171/jns.2000.92.5.0824
   Spencer WR, 1999, LARYNGOSCOPE, V109, P791, DOI 10.1097/00005537-199905000-00020
   Steinberger J, 2016, SPINE, V41, pE535, DOI 10.1097/BRS.0000000000001320
   Suhardja Agustinus, 2003, Neurosurg Focus, V14, pe9
   Tatagiba M, 2006, ACTA NEUROCHIR, V148, P965, DOI 10.1007/s00701-006-0816-3
   Visocchi M, 2017, WORLD NEUROSURG, V101, P122, DOI 10.1016/j.wneu.2017.01.099
   Wang WH, 2016, OPER NEUROSURG, V12, P153, DOI 10.1227/NEU.0000000000001102
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
   Wu AH, 2010, NEUROSURGERY, V66, pONS191, DOI [10.1227/01.NEU.0000369704.49958.5B, 10.1227/10.NEU.0000369704.49958.5B]
   Wu PF, 2018, ACTA NEUROCHIR, V160, P695, DOI 10.1007/s00701-018-3502-3
   Wu Z, 2009, SURG NEUROL, V72, P376, DOI 10.1016/j.surneu.2009.05.006
   Yamahata H, 2016, WORLD NEUROSURG, V87, P1, DOI 10.1016/j.wneu.2015.09.022
   Ziyal IM, 1999, CRIT REV NEUROSURG, V9, P107, DOI 10.1007/s003290050117
NR 74
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1083
EP E1096
DI 10.1016/j.wneu.2019.04.048
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300134
PM 30980974
DA 2020-05-12
ER

PT J
AU Wang, TH
   Zheng, GQ
   Wang, Y
   Zhang, XS
   Hu, FQ
   Wang, Y
AF Wang, Tianhao
   Zheng, Guoquan
   Wang, Yao
   Zhang, Xuesong
   Hu, Fanqi
   Wang, Yan
TI Comparison of 2 Surgeries in Correction of Severe Kyphotic Deformity
   Caused by Ankylosing Spondylitis: Vertebral Column Decancellation and
   Pedicle Subtraction Osteotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; Deformity; Osteotomy; Pedicle subtraction
   osteotomy; Thoracolumbar kyphosis; Vertebral column decancellation
ID WEDGE OSTEOTOMY; THORACOLUMBAR KYPHOSIS; SPINE; ANGLE
AB OBJECTIVE: To compare the treatment results between 1-level vertebral column decancellation (VCD) and pedicle subtraction osteotomy (PSO) for correcting severe kyphotic deformity in ankylosing spondylitis (AS). VCD and PSO have been used to correct AS-related kyphotic deformity, but the differences on correcting results between VCD and PSO are not clear.
   METHODS: Between 2013 and 2015, 57 patients underwent 1-level spinal osteotomy (VCD: n = 30; PSO: n = 27) for correcting kyphotic deformity. Sagittal parameters, fusion results, surgical information, and clinical outcomes were documented and compared. All data were obtained before and 1 week after surgery, 6 months after surgery, and at final follow-up (at least 2 years).
   RESULTS: VCD provided significantly greater osteotomy angle (50.8 degrees +/- 9.7 degrees ) than PSO (38.5 degrees +/- 6.1 degrees ). In the VCD group, the change of the anterior column was 5.0 +/- 1.3 mm, which was larger than the PSO group. The middle column was shortened by 9.9 +/- 2.0 mm and 19.1 +/- 3.3 mm in the VCD group and PSO group, respectively. There was no significant difference in operating time and blood loss between the 2 groups. All cases had solid fusion. Between the 2 groups, Scoliosis Research Society Outcomes Instrument-22 scores were similar at the final follow-up. No major acute complications occurred in both groups.
   CONCLUSIONS: VCD is a safe and effective method in treating rigid kyphotic deformity secondary to AS. VCD provides a larger correction angle in one segment and preserves more height of osteotomized vertebrae than PSO.
C1 [Wang, Tianhao] Third Mil Med Univ, Southwest Hosp, Chongqing, Peoples R China.
   [Wang, Tianhao; Zheng, Guoquan; Wang, Yao; Zhang, Xuesong; Hu, Fanqi; Wang, Yan] Gen Hosp Chinese Peoples Liberat Army, Dept Orthopaed, Beijing, Peoples R China.
RP Wang, Y (reprint author), Gen Hosp Chinese Peoples Liberat Army, Dept Orthopaed, Beijing, Peoples R China.
EM yanwang_301@126.com
CR Arun R, 2011, EUR SPINE J, V20, P2252, DOI 10.1007/s00586-011-1894-3
   BRANTIGAN JW, 1993, SPINE, V18, P2106, DOI 10.1097/00007632-199310001-00030
   Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   Bridwell KH, 2003, J BONE JOINT SURG AM, V85A, P454, DOI 10.2106/00004623-200303000-00009
   Chang KW, 2011, SPINE, V36, pE186, DOI 10.1097/BRS.0b013e3181ef6828
   Chang KW, 2005, SPINE, V30, P1584, DOI 10.1097/01.brs.0000170300.17082.49
   GERTZBEIN SD, 1992, SPINE, V17, P374, DOI 10.1097/00007632-199203000-00025
   Gupta S, 2018, NEUROSURG CLIN N AM, V29, P355, DOI 10.1016/j.nec.2018.03.001
   Lafage V, 2011, J NEUROSURG-SPINE, V14, P184, DOI 10.3171/2010.9.SPINE10129
   Liu C, 2017, CLIN SPINE SURG, V30, pE942, DOI 10.1097/BSD.0000000000000519
   Ponte A, 2018, SPINE DEFORM, V6, P2
   Qiao M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1834-4
   Sengupta DK, 2001, SPINE, V26, P1068, DOI 10.1097/00007632-200105010-00016
   Sengupta R, 2007, NAT CLIN PRACT RHEUM, V3, P496, DOI 10.1038/ncprheum0591
   Smith-Petersen M N, 1969, Clin Orthop Relat Res, V66, P6
   Song K, 2013, SPINE, V38, pE616, DOI 10.1097/BRS.0b013e31828b3299
   THOMASEN E, 1985, CLIN ORTHOP RELAT R, P142, DOI 10.1097/00003086-198504000-00019
   Wang TH, 2018, J NEUROSURG-SPINE, V29, P75, DOI 10.3171/2017.11.SPINE17228
   Wang Y, 2018, SPINE DEFORM, V6, P366
   Wang Y, 2011, EUR SPINE J, V20, P1703, DOI 10.1007/s00586-011-1771-0
   Wang Y, 2010, J SPINAL DISORD TECH, V23, P186, DOI 10.1097/BSD.0b013e3181a5abde
   Wang Y, 2009, EUR SPINE J, V18, P1436, DOI 10.1007/s00586-009-1067-9
   Xu H, 2015, SPINE J, V15, P290, DOI 10.1016/j.spinee.2014.09.014
   Zhang X, 2016, BONE JOINT J, V98B, P672, DOI 10.1302/0301-620X.98B5.35726
   Zhao YF, 2017, CLIN SPINE SURG, V30, pE454, DOI 10.1097/BSD.0000000000000216
   Zhu ZZ, 2012, J SPINAL DISORD TECH, V25, P383, DOI 10.1097/BSD.0b013e318224b199
NR 26
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E972
EP E978
DI 10.1016/j.wneu.2019.04.011
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300121
PM 30965170
DA 2020-05-12
ER

PT J
AU Wang, XJ
   Yang, RZ
   Sun, HH
   Zhang, YY
AF Wang, Xiji
   Yang, Ruize
   Sun, Honghui
   Zhang, Yongyuan
TI Different Effects of Intravenous, Topical, and Combined Application of
   Tranexamic Acid on Patients with Thoracolumbar Fracture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hidden blood loss; Minimally invasive surgery; Percutaneous pedicle
   screw; Thoracolumbar fracture; Tranexamic acid
ID PEDICLE SCREW FIXATION; HIDDEN BLOOD-LOSS; FUSION; METAANALYSIS; HIP
AB OBJECTIVE: To observe the efficacy of intravenous, topical, and combined application of tranexamic acid (TXA) in patients with thoracolumbar fracture fixed with percutaneous pedicle screw, and to identify the optimal application method of TXA.
   METHODS: A total of 181 patients with thoracolumbar fracture treated with percutaneous pedicle screw fixation were enrolled in this randomized controlled trial and were randomly classified into 3 groups, including group A (intravenous group), group B (topical group), and group C (combined group). The total blood loss (TBL), hidden blood loss (HBL), intraoperative blood loss (IBL), preoperative D-dimer, postoperative D-dimer, incidence of deep vein thrombosis (DVT), and incidence of other complications were compared and analyzed among the 3 groups.
   RESULTS: TBL, HBL, and IBL in the topical group 24 hours after operation were higher (P < 0.05) than those in the intravenous group and combined group, whereas the difference between the intravenous group and combined group was not statistically significant. Meanwhile, there was no statistically significant difference in operation time, preoperative D-dimer, and postoperative D-dimer among the 3 groups (P> 0.05), but D-dimer in all groups at 72 hours after surgery was higher than that before surgery. No DVT or other complication was observed in the patients.
   CONCLUSIONS: Preoperative intravenous drip of TXA can remarkably reduce intraoperative HBL and IBL in patients with thoracolumbar fracture fixed with percutaneous pedicle screw. Nonetheless, intraoperative topical application of TXA before wound closure is not recommended.
C1 [Wang, Xiji; Yang, Ruize; Sun, Honghui; Zhang, Yongyuan] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
RP Zhang, YY (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM forever1987qt@163.com
OI Zhang, Yongyuan/0000-0003-4017-397X
CR Cao DG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010435
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   Duncan CM, 2015, J ARTHROPLASTY, V30, P272, DOI 10.1016/j.arth.2014.08.022
   Ker K, 2013, BRIT J SURG, V100, P1271, DOI 10.1002/bjs.9193
   Kim KT, 2017, EUR SPINE J, V26, P2851, DOI 10.1007/s00586-017-5230-4
   Kocis J, 2020, EUR J TRAUMA EMERG S, V46, P147, DOI 10.1007/s00068-018-0998-4
   Korovessis PG, 2020, J INVEST SURG, V33, P263, DOI [10.1080/08941939.2018.1493163, 10.1080/08941939.2018.1425780]
   Luo W, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0815-0
   Phan K, 2015, CLIN NEUROL NEUROSUR, V135, P85, DOI 10.1016/j.clineuro.2015.05.016
   Pradhan RL, 2015, J NEPAL MED ASSOC, V53, P169, DOI 10.31729/jnma.2785
   Ren ZN, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008233
   Shakeri M, 2018, ASIAN SPINE J, V12, P484, DOI 10.4184/asj.2018.12.3.484
   Smorgick Y, 2013, SPINE J, V13, P877, DOI 10.1016/j.spinee.2013.02.008
   Urrutia J, 2015, SPINE, V40, pE54, DOI 10.1097/BRS.0000000000000656
   Wang WT, 2018, SPINE, V43, pE734, DOI 10.1097/BRS.0000000000002491
   Winter SF, 2016, GLOB SPINE J, V6, P284, DOI 10.1055/s-0035-1563609
   Wong J, 2008, ANESTH ANALG, V107, P1479, DOI 10.1213/ane.0b013e3181831e44
   Wu YS, 2017, EUR SPINE J, V26, P1878, DOI 10.1007/s00586-017-4950-9
   Xu DR, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0672-2
   Yang M, 2019, INT ORTHOP, V43, P1749, DOI 10.1007/s00264-018-4012-x
   Yang Y, 2015, INT J SURG, V23, P82, DOI 10.1016/j.ijsu.2015.09.053
   Zou Wei, 2017, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V31, P830, DOI 10.7507/1002-1892.201702089
   Zufferey PJ, 2010, BRIT J ANAESTH, V104, P23, DOI 10.1093/bja/aep314
NR 23
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1185
EP E1189
DI 10.1016/j.wneu.2019.04.095
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300148
PM 31004853
DA 2020-05-12
ER

PT J
AU Wang, X
   Bao, YH
   Chen, G
   Guo, HC
   Li, MC
   Liang, JT
   Bai, XS
   Ling, F
AF Wang, Xu
   Bao, Yuhai
   Chen, Ge
   Guo, Hongchuan
   Li, Mingchu
   Liang, Jiantao
   Bai, Xuesong
   Ling, Feng
TI Trigeminal Schwannomas in Middle Fossa Could Breach into Subdural Space:
   Report of 4 Cases and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic endonasal approach; Epidural approach; Interdural approach;
   Pial artery; Trigeminal schwannomas; Tumor recurrence
ID ENDOSCOPIC ENDONASAL APPROACH; SURGICAL-TREATMENT; NEURINOMAS; NERVE;
   EXPERIENCE; REMOVAL
AB OBJECTIVE: The objectives of this study were to report 4 cases diagnosed with trigeminal schwannomas (TS), among whom tumor in epidural space of middle fossa broke through dura mater into subdural space, and to analyze the potential reason for recurrence of TS in middle fossa after surgical removal by endoscopic endonasal approach (EEA) or interdural approach.
   METHODS: The information of 4 patients diagnosed with TS who were surgically treated was retrospectively analyzed and the selection of approaches, surgical strategies, and potential reason for recurrence after middle fossa TS removal by EEA and interdural approach were discussed.
   RESULTS: During last 10 years, 43 patients with TS received surgical treatment at Xuan Wu Hospital of Capital Medical University, among whom 1 patient with TS extending from middle fossa to infratemporal fossa was first treated by EEA, then the tumor recurred and the patient underwent a second operation via a frontotemporal subdural approach. During the second operation, we found part of tumor had broken through the dura mater into subdural space. Moreover, this phenomenon was detected in another 3 patients with middle-posterior fossa TS.
   CONCLUSIONS: TS in middle fossa has been widely believed to be totally located at epidural space, whereas we found that it could occasionally breach into subdural space and accept blood supply from the pial artery. We believe this could be the potential reason for recurrence after tumor resection by EEA and interdural approach.
C1 [Wang, Xu; Bao, Yuhai; Chen, Ge; Guo, Hongchuan; Li, Mingchu; Liang, Jiantao; Bai, Xuesong; Ling, Feng] Capital Med Univ, XuanWu Hosp, Dept Skull Base Surg Ctr, Dept Neurosurg, Beijing, Peoples R China.
RP Ling, F (reprint author), Capital Med Univ, XuanWu Hosp, Dept Skull Base Surg Ctr, Dept Neurosurg, Beijing, Peoples R China.
EM ling-feng@vip.163.com
RI Bai, Xuesong/AAK-4058-2020
OI Bai, Xuesong/0000-0003-4324-1181
CR Akimoto J, 2000, ACTA NEUROCHIR, V142, P591, DOI 10.1007/s007010050475
   Al-Mefty O, 2002, J NEUROSURG, V96, P453, DOI 10.3171/jns.2002.96.3.0453
   Bresson D, 2014, NEUROCHIRURGIE, V60, P174, DOI 10.1016/j.neuchi.2014.03.009
   Champ CE, 2012, NEUROSURGERY, V71, P270, DOI 10.1227/NEU.0b013e318256bbc5
   Fukaya R, 2011, NEUROSURG REV, V34, P159, DOI 10.1007/s10143-010-0289-y
   Goel A, 2003, NEUROSURGERY, V52, P783, DOI 10.1227/01.NEU.0000053365.05795.03
   Jacquesson T, 2015, ACTA NEUROCHIR, V157, P935, DOI 10.1007/s00701-015-2409-5
   Jeong Seong Kyun, 2014, Brain Tumor Res Treat, V2, P62, DOI 10.14791/btrt.2014.2.2.62
   Komatsu F, 2012, J NEUROSURG, V117, P690, DOI 10.3171/2012.7.JNS11730
   Kouyialis AT, 2007, ACTA NEUROCHIR, V149, P959, DOI 10.1007/s00701-007-1173-6
   MacNally SP, 2008, BRIT J NEUROSURG, V22, P729, DOI 10.1080/02688690802272172
   MCCORMICK PC, 1988, J NEUROSURG, V69, P850, DOI 10.3171/jns.1988.69.6.0850
   Pamir MN, 2007, NEUROSURG REV, V30, P329, DOI 10.1007/s10143-007-0093-5
   Raza SM, 2015, NEUROSURG CLIN N AM, V26, P473, DOI 10.1016/j.nec.2015.03.010
   Raza SM, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14341
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Samii M, 2014, OPER NEUROSURG, V10, P565, DOI 10.1227/NEU.0000000000000478
   Shin SS, 2011, NEUROSURGERY, V69, P1046, DOI 10.1227/NEU.0b013e3182287bb9
   Tanriover N, 2009, SURG NEUROL, V71, P586, DOI 10.1016/j.surneu.2008.04.009
   Wanibuchi M, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822efb21
   YASUI T, 1989, J NEUROSURG, V71, P506, DOI 10.3171/jns.1989.71.4.0506
   Yoshida K, 1999, J NEUROSURG, V91, P202, DOI 10.3171/jns.1999.91.2.0202
   Zhou LF, 2007, SURG NEUROL, V68, P594, DOI 10.1016/j.surneu.2006.12.065
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E534
EP E541
DI 10.1016/j.wneu.2019.03.194
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300066
PM 30928581
DA 2020-05-12
ER

PT J
AU Wang, ZP
   Wang, K
   Qian, ZQ
   Zeng, L
   Gao, L
AF Wang, Zhanpeng
   Wang, Ke
   Qian, Zhouqi
   Zeng, Li
   Gao, Liang
TI Lumboperitoneal and Ventriculoperitoneal Shunt Surgery for
   Posthemorrhagic Communicating Hydrocephalus: A Comparison
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Lumboperitoneal shunt; Posthemorrhagic communicating
   hydrocephalus; Ventriculoperitoneal shunt
ID NORMAL-PRESSURE HYDROCEPHALUS; IDIOPATHIC INTRACRANIAL HYPERTENSION;
   LONG-TERM OUTCOMES; COMPLICATIONS; MANAGEMENT; DIAGNOSIS; ADULT;
   HEMORRHAGE; EXPERIENCE; DRAINAGE
AB OBJECTIVE: This study aimed to compare the efficacy and complications of lumboperitoneal (LP) and ven-triculoperitoneal (VP) shunt surgeries in patients with posthemorrhagic communicating hydrocephalus.
   METHODS: Retrospective analysis of the records of patients who were admitted to the Shanghai Tenth People's Hospital Affiliated to Tongji University between February 2012 and January 2018 was performed. The efficacy of the LP and VP shunt surgeries and their associated complications were compared. The evaluation of the efficacy of these surgeries involved both clinical and radiologic aspects. The evaluated complications included hemorrhage, infection, excessive drainage, seizure disorder, shunt obstruction, and migration. Revision and mortality were regarded as the consequence of complications and were collected.
   RESULTS: One-hundred and fifty-eight (115 males and 43 females) patients were treated with VP or LP shunt (102 vs. 56, respectively) for posthemorrhagic communicating hydrocephalus. The percentage of patients with a Glasgow Coma Scale (GCS) score between 3.00 and 12.00 was 79.11%. There was no significant difference in the observed clinical (P = 0.097) or radiologic (P = 0.360) improvements between the LP and VP shunt groups. The total rate of complications (P = 0.009) and hemorrhage (P = 0.03) were lower in the LP shunt group than in the VP shunt group.
   CONCLUSIONS: In the treatment of moderate and severe coma patients with posthemorrhagic communicating hydrocephalus, LP shunt surgery is equally as effective as the VP shunt surgery and is associated with fewer complications.
C1 [Wang, Zhanpeng; Gao, Liang] Anhui Med Univ, Shanghai Clin Med Coll, Dept Neurosurg, Hefei, Anhui, Peoples R China.
   [Wang, Ke; Qian, Zhouqi; Zeng, Li] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Neurosurg, Shanghai, Peoples R China.
RP Gao, L (reprint author), Anhui Med Univ, Shanghai Clin Med Coll, Dept Neurosurg, Hefei, Anhui, Peoples R China.
EM lianggaoh@126.com
CR Abubaker K, 2011, BRIT J NEUROSURG, V25, P94, DOI 10.3109/02688697.2010.544781
   ADEGBITE AB, 1982, J NEUROSURG, V57, P423, DOI 10.3171/jns.1982.57.3.0423
   AHMANN PA, 1980, ANN NEUROL, V7, P118, DOI 10.1002/ana.410070205
   Al-Schameri AR, 2016, WORLD NEUROSURG, V94, P345, DOI 10.1016/j.wneu.2016.07.002
   Alkherayf F, 2015, CLIN NEUROL NEUROSUR, V136, P5, DOI 10.1016/j.clineuro.2015.05.018
   AOKI N, 1990, NEUROSURGERY, V26, P998, DOI 10.1227/00006123-199006000-00013
   Aoki N., 1990, NEUROSURGERY, P1003
   Bayar MA, 2018, TURK NEUROSURG, V28, P62, DOI 10.5137/1019-5149.JTN.18702-16.1
   Bir SC, 2017, J NEUROL SURG PART B, V78, P30, DOI 10.1055/s-0036-1584309
   Bloch O, 2012, J CLIN NEUROSCI, V19, P1107, DOI 10.1016/j.jocn.2011.11.019
   Bondurant CP, 1995, PEDIATR NEUROSURG, V23, P254, DOI 10.1159/000120968
   Boon AJW, 1998, J NEUROSURG, V88, P490, DOI 10.3171/jns.1998.88.3.0490
   CHAPLIN ER, 1980, PEDIATRICS, V65, P901
   Chen QW, 2017, J NEUROL SCI, V375, P220, DOI 10.1016/j.jns.2017.01.072
   Eide PK, 2010, NEUROSURGERY, V66, P80, DOI 10.1227/01.NEU.0000363408.69856.B8
   Farahmand D, 2009, J NEUROL NEUROSUR PS, V80, P1248, DOI 10.1136/jnnp.2007.141416
   Hashimoto M, 2010, FLUIDS BARRIERS CNS, V7, P2, DOI 10.1186/1743-8454-7-18
   Hebb AO, 2001, NEUROSURGERY, V49, P1166, DOI 10.1097/00006123-200111000-00028
   Jaraj D, 2017, EUR J NEUROL, V24, P468, DOI 10.1111/ene.13226
   Jia L, 2011, J ZHEJIANG UNIV-SC B, V12, P293, DOI 10.1631/jzus.B1000248
   Kaestner S, 2013, J NEUROL SURG PART A, V74, P279, DOI 10.1055/s-0033-1342929
   Kang S, 2000, ACTA NEUROCHIR, V142, P45, DOI 10.1007/s007010050006
   Kiefer M, 2012, DTSCH ARZTEBL INT, V109, P15, DOI 10.3238/arztebl.2012.0015
   Klinge P, 2012, ACTA NEUROL SCAND, V126, P145, DOI 10.1111/j.1600-0404.2012.01676.x
   Korinek AM, 2011, NEUROSURGERY, V68, P985, DOI 10.1227/NEU.0b013e318208f360
   LUNDJOHANSEN M, 1994, NEUROSURGERY, V35, P839, DOI 10.1227/00006123-199411000-00006
   MALM J, 1995, ARCH NEUROL-CHICAGO, V52, P783, DOI 10.1001/archneur.1995.00540320059013
   McGirt MJ, 2005, NEUROSURGERY, V57, P699, DOI 10.1227/01.NEU.0000175724.00147.10
   Menger RP, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14436
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Miyajima M, 2016, J NEUROSURG, V125, P1483, DOI 10.3171/2015.10.JNS151894
   Mori E, 2012, NEUROL MED-CHIR, V52, P775, DOI 10.2176/nmc.52.775
   Moza K, 2005, OTOLARYNG CLIN N AM, V38, P577, DOI 10.1016/j.otc.2005.01.001
   NORNES H, 1973, J NEUROSURG, V39, P226, DOI 10.3171/jns.1973.39.2.0226
   PARE L, 1992, J NEUROSURG, V76, P422, DOI 10.3171/jns.1992.76.3.0422
   PUCA A, 1991, NEUROSURGERY, V29, P822, DOI 10.1227/00006123-199112000-00003
   Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096
   Reddy GK, 2011, WORLD NEUROSURG, V76, P176, DOI 10.1016/j.wneu.2011.01.032
   Reddy GK, 2011, J NEURO-ONCOL, V103, P333, DOI 10.1007/s11060-010-0393-4
   Singh A, 2013, NEUROL INDIA, V61, P513, DOI 10.4103/0028-3886.121932
   Sood S, 2005, J NEUROSURG, V103, P119, DOI 10.3171/ped.2005.103.2.0119
   Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6
   THEODORE J, 1976, AM REV RESPIR DIS, V113, P405
   Widenka D C, 2000, Neurol Neurochir Pol, V34, P56
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
   Yadav YR, 2004, NEUROL INDIA, V52, P188
   Zemack G, 2002, NEUROSURGERY, V51, P1392, DOI 10.1097/00006123-200212000-00009
   Zhang JQ, 2009, SURG NEUROL, V72, pS29, DOI 10.1016/j.surneu.2008.03.040
NR 48
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E638
EP E643
DI 10.1016/J.WNEU.2019.03.235
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300079
PM 30947009
DA 2020-05-12
ER

PT J
AU Wei, LJ
   Zhang, JB
   Geng, JJ
   Lin, C
   Zhang, Y
   Zhang, B
   Tan, Q
   Tao, YH
   Ye, DP
   Chen, Z
   Feng, H
   Zhu, G
AF Wei, Linjie
   Zhang, Jianbo
   Geng, Junjun
   Lin, Chi
   Zhang, Yu
   Zhang, Bo
   Tan, Qiang
   Tao, Yihao
   Ye, Dongping
   Chen, Zhi
   Feng, Hua
   Zhu, Gang
TI Hemoglobin Concentration Affects Hypertensive Basal Ganglia Hemorrhage
   After Surgery: Correlation Analysis in a High-Altitude Region
SO WORLD NEUROSURGERY
LA English
DT Article
DE Correlation; Hemoglobin; High altitude; Hypertensive cerebral hemorrhage
ID INTRACEREBRAL HEMORRHAGE; ELEVATED HEMOGLOBIN; PRESSURE; EDEMA
AB OBJECTIVE: Hypertensive cerebral hemorrhage leads to greater mortality and worse functional outcomes at high altitudes. Experimental studies have suggested that hemoglobin can lead to increased perihemorrhagic edema after intracerebral hemorrhage.
   METHODS: Patients were divided into a high-hemoglobin (H-H) group (>180 g/L) and a low-hemoglobin (L-H) group (<= 180 g/L). The distance from the cortex to the midline was used to indicate the degree of edema. At 1, 7, 14, and 21 days, the patients' status was scored using the Glasgow coma scale, and survival was plotted using Kaplan-Meier survival curves. Pearson correlation analysis showed that the difference between the postoperative and preoperative Glasgow coma scale score correlated with the hemoglobin concentration. The Glasgow outcome scale was used to assess neurological recovery after 6 months.
   RESULTS: On days 7, 14, and 21, the edema of the H-H group was significantly greater than that of the L-H group (P< 0.01 and P < 0.001, respectively). The edema of the H-H group peaked at 14 and 21 days, but that of the L-H group peaked at 7 days. The hemoglobin concentration and postoperative neurological recovery had a linear relationship in the H-H group. The L-H group had greater survival compared with the H-H group (P < 0.05). The L-H group had higher Glasgow outcome scale scores compared with the H-H group (P < 0.05).
   CONCLUSION: The hemoglobin concentration affects the mortality and morbidity from hypertensive cerebral hemorrhage in high-altitude regions, and a linear relationship exists between hemoglobin concentration and neurological recovery in the H-H group.
C1 [Wei, Linjie; Zhang, Jianbo; Geng, Junjun; Zhang, Bo; Tan, Qiang; Tao, Yihao; Chen, Zhi; Feng, Hua; Zhu, Gang] Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.
   [Lin, Chi] First Peoples Hosp Honghe City, Dept Neurosurg, Kunming, Yunnan, Peoples R China.
   [Zhang, Yu; Ye, Dongping] Peoples Liberat Army 956th Hosp, Peoples Liberat Army 115 Hosp, Dept Neurosurg, Linzhi, Tibet, Peoples R China.
RP Zhu, G (reprint author), Army Med Univ, Mil Med Univ 3, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.
EM zhugang6666@126.com
FU First Affiliated Hospital of Army Medical University's Science and
   Technology Innovation Program [SWH2017JSZD03]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [81571116]; National Key Basic Research Development Program (973
   Program) of China [2014CB541606]
FX The present study was supported by the First Affiliated Hospital of Army
   Medical University's Science and Technology Innovation Program (grant
   SWH2017JSZD03 to Z.C.), National Natural Science Foundation of China
   (grant 81571116 to Z.G.), and National Key Basic Research Development
   Program (973 Program) of China (grant 2014CB541606 to H.F.).
CR Chen RQ, 2017, CLIN NEUROL NEUROSUR, V157, P46, DOI 10.1016/j.clineuro.2017.03.025
   Dunatov S, 2011, ACTA NEUROL SCAND, V124, P343, DOI 10.1111/j.1600-0404.2010.01481.x
   GROTTA J, 1982, STROKE, V13, P296, DOI 10.1161/01.STR.13.3.296
   Hintsala H, 2014, AM J HYPERTENS, V27, P656, DOI 10.1093/ajh/hpt136
   Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287
   Jha SK, 2002, HIGH ALT MED BIOL, V3, P21, DOI 10.1089/152702902753639513
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Li Q, 2013, BRIT J NEUROSURG, V27, P617, DOI 10.3109/02688697.2013.765938
   Lim-Hing K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00074
   Lucking EF, 2014, EXP PHYSIOL, V99, P1312, DOI 10.1113/expphysiol.2014.080556
   Luneva O G, 2005, Dokl Biochem Biophys, V405, P465, DOI 10.1007/s10628-005-0141-4
   Nanduri J, 2015, J MOL MED, V93, P473, DOI 10.1007/s00109-015-1274-2
   Ponjoan A, 2014, ENVIRON RES, V132, P190, DOI 10.1016/j.envres.2014.03.039
   Wagner I, 2012, EUR J NEUROL, V19, P525, DOI 10.1111/j.1468-1331.2011.03526.x
   Wei LJ, 2016, WORLD NEUROSURG, V86, P181, DOI 10.1016/j.wneu.2015.09.070
   Zhu HT, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0976-8
   Zhu HT, 2013, ACTA NEUROCHIR, V155, P655, DOI 10.1007/s00701-013-1618-z
   Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005
NR 18
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E835
EP E842
DI 10.1016/j.wneu.2019.03.281
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300104
PM 30954736
DA 2020-05-12
ER

PT J
AU Westbroek, EM
   Ahmed, AK
   Pennington, Z
   Goodwin, ML
   Xia, YX
   Boone, C
   Gailloud, P
   Sciubba, DM
AF Westbroek, Erick M.
   Ahmed, A. Karim
   Pennington, Zach
   Goodwin, Matthew L.
   Xia, Yuanxuan
   Boone, Christine
   Gailloud, Philippe
   Sciubba, Daniel M.
TI Atypical Vertebral Hemangiomas Are Frequently Associated with
   Radiculomedullary Arteries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypervascular tumors; Preoperative embolization; Spine oncology;
   Vascular anatomy
ID PREOPERATIVE EMBOLIZATION; TUMORS; DIAGNOSIS; SPINE
AB BACKGROUND: Preoperative endovascular embolization of atypical hemangiomas of the spine can reduce intraoperative blood loss. One frequent concern raised about embolizing these tumors is a possible association with arteries feeding the spinal cord, such as the artery of Adamkiewicz. This study aimed to elucidate a relationship between spinal levels affected by atypical spinal hemangiomas and radiculomedullary arteries.
   METHODS: This was a retrospective review of 8 patients undergoing preoperative embolization of atypical spinal hemangiomas. We evaluated 54 spinal levels by angiography during embolization procedures. Each spinal level was categorized on the basis of the presence or absence of tumor and radiculomedullary artery.
   RESULTS: Six of 15 (40%) affected levels had an associated radiculomedullary artery. Four of 39 (10.2%) unaffected levels had an associated cord feeding artery. The relative risk of affected spinal levels having an associated radiculomedullary artery was 3.9 (95% confidence interval 1.28-11.91). The attributable risk was 0.40 (95% CI 0.12-0.76). The chi-squared statistic was 6.35, with a P value of 0.01. Six of 8 patients (75%) had a radiculomedullary artery at a level of disease and embolization.
   CONCLUSIONS: In this study, spinal levels affected by atypical hemangiomas requiring surgery were associated with radiculomedullary arteries. When performing preoperative embolization, great care must be taken to identify and preserve arteries supplying the spinal cord.
C1 [Westbroek, Erick M.; Ahmed, A. Karim; Pennington, Zach; Goodwin, Matthew L.; Xia, Yuanxuan; Sciubba, Daniel M.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Gailloud, Philippe] Johns Hopkins Univ, Sch Med, Div Intervent Neuroradiol, Baltimore, MD USA.
   [Boone, Christine] Univ Calif San Diego, Sch Med, Div Intervent Radiol, La Jolla, CA 92093 USA.
RP Westbroek, EM (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM erickw@jhmi.edu
OI Pennington, Zachary/0000-0001-8012-860X; Boone,
   Christine/0000-0002-7204-8666
CR Alexander J, 2010, SPINE, V35, pE917, DOI 10.1097/BRS.0b013e3181ddfb24
   Bender YY, 2017, CLIN RADIOL, V72, P692, DOI 10.1016/j.crad.2017.02.018
   Cross JJ, 2000, EUR RADIOL, V10, P997, DOI 10.1007/s003300051051
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Gaudino S, 2015, SKELETAL RADIOL, V44, P25, DOI 10.1007/s00256-014-2035-y
   GRUNDY BL, 1982, CAN ANAESTH SOC J, V29, P452, DOI 10.1007/BF03009408
   Guzman R, 2005, EUR SPINE J, V14, P263, DOI 10.1007/s00586-004-0757-6
   Hong CG, 2017, WORLD J SURG ONCOL, V15, P1, DOI 10.1186/s12957-017-1118-3
   James JM, 2009, DEVELOPMENT, V136, P833, DOI 10.1242/dev.028845
   Jiang L, 2014, SPINE J, V14, P944, DOI 10.1016/j.spinee.2013.07.450
   Kato S, 2013, SPINE, V38, P1964, DOI 10.1097/BRS.0b013e3182a46576
   Kilic K, 2017, CASE REP SURG, V2017, P1
   Luksanapruksa P, 2018, J NEUROINTERV SURG, V10, P596, DOI 10.1136/neurintsurg-2017-013350
   Nair S, 2013, INTERV NEURORADIOL, V19, P377, DOI 10.1177/159101991301900317
   Ozkan E, 2011, TECH VASC INTERV RAD, V14, P129, DOI 10.1053/j.tvir.2011.02.005
   Persad AR, 2018, INT J SPINE SURG, V12, P415, DOI 10.14444/5049
   PICARD L, 1989, NEUROCHIRURGIE, V35, P289
   Prabhu VC, 2003, J NEUROSURG, V98, P156, DOI 10.3171/spi.2003.98.2.0156
   Rodallec MH, 2008, RADIOGRAPHICS, V28, P1019, DOI 10.1148/rg.284075156
   Sciubba DM, 2010, J NEUROSURG-SPINE, V13, P94, DOI 10.3171/2010.3.SPINE09202
   Slon V, 2016, SPINE, V41, pE481, DOI 10.1097/BRS.0000000000001464
   SUNDARESAN N, 1986, J CLIN ONCOL, V4, P1851, DOI 10.1200/JCO.1986.4.12.1851
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   Zaborovskii Nikita, 2018, Eur J Orthop Surg Traumatol, V28, P1047, DOI 10.1007/s00590-018-2162-6
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1215
EP E1220
DI 10.1016/j.wneu.2019.04.101
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300152
PM 31004857
DA 2020-05-12
ER

PT J
AU Winkler-Schwartz, A
   Marwa, I
   Bajunaid, K
   Mullah, M
   Alotaibi, FE
   Bugdadi, A
   Sawaya, R
   Sabbagh, AJ
   Del Maestro, R
AF Winkler-Schwartz, Alexander
   Marwa, Ibrahim
   Bajunaid, Khalid
   Mullah, Muhammad
   Alotaibi, Fahad E.
   Bugdadi, Abdulgadir
   Sawaya, Robin
   Sabbagh, Abdulrahman J.
   Del Maestro, Rolando
TI A Comparison of Visual Rating Scales and Simulated Virtual Reality
   Metrics in Neurosurgical Training: A Generalizability Theory Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Assessment; Education; Neurosurgery; Resident; Simulation; Surgery
ID OPERATIVE SKILLS; PERFORMANCE; PROFICIENCY; NEUROTOUCH; RESIDENTS
AB BACKGROUND: Adequate assessment and feedback remains a cornerstone of psychomotor skills acquisition, particularly within neurosurgery where the consequence of adverse operative events is significant. However, a critical appraisal of the reliability of visual rating scales in neurosurgery is lacking. Therefore, we sought to design a study to compare visual rating scales with simulated metrics in a neurosurgical virtual reality task.
   METHODS: Neurosurgical faculty rated anonymized participant video recordings of the removal of simulated brain tumors using a visual rating scale made up of seven composite elements. Scale reliability was evaluated using generalizability theory, and scale subcomponents were compared with simulated metrics using Pearson correlation analysis.
   RESULTS: Four staff neurosurgeons evaluated 16 medical student neurosurgery applicants. Overall scale reliability and internal consistency were 0.73 and 0.90, respectively. Reliability of 0.71 was achieved with two raters. Individual participants, raters, and scale items accounted for 27%, 11%, and 0.6% of the data variability. The hemostasis scale component related to the greatest number of simulated metrics, whereas respect for no-go zones and tissue was correlated with none. Metrics relating to instrument force and patient safety (brain volume removed and blood loss) were captured by the fewest number of rating scale components.
   CONCLUSIONS: To our knowledge, this is the first study comparing participant's ratings with simulated performance. Given rating scales capture less well instrument force, quantity of brain volume removed, and blood loss, we suggest adopting a hybrid educational approach using visual rating scales in an operative environment, supplemented by simulated sessions to uncover potentially problematic surgical technique.
C1 [Winkler-Schwartz, Alexander; Marwa, Ibrahim; Bajunaid, Khalid; Alotaibi, Fahad E.; Bugdadi, Abdulgadir; Sawaya, Robin; Del Maestro, Rolando] McGill Univ, Dept Neurol & Neurosurg, Neurosurg Simulat & Artificial Intelligence Learn, Montreal, PQ, Canada.
   [Mullah, Muhammad] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.
   [Bajunaid, Khalid; Sabbagh, Abdulrahman J.] Univ Jeddah, Fac Med, Dept Surg, Div Neurosurg, Jeddah, Saudi Arabia.
   [Alotaibi, Fahad E.] King Fahad Med City, Natl Neurosci Inst, Neurosurg Dept, Riyadh, Saudi Arabia.
   [Bugdadi, Abdulgadir] Umm Al Qura Univ, Fac Med, Dept Surg, Mecca, Saudi Arabia.
   [Sabbagh, Abdulrahman J.] King Abdulaziz Univ, Clin Skills & Simulat Ctr, Jeddah, Saudi Arabia.
RP Winkler-Schwartz, A (reprint author), McGill Univ, Dept Neurol & Neurosurg, Neurosurg Simulat & Artificial Intelligence Learn, Montreal, PQ, Canada.
EM manuscriptinquiry@gmail.com
RI Bajunaid, Khalid/P-8499-2019
OI Bajunaid, Khalid/0000-0002-7925-5959; Sabbagh, Abdulrahman
   J/0000-0003-4849-2166
FU Di Giovanni Foundation; Colannini Foundation; Montreal Neurological
   Institute and Hospital; Montreal English School Board; Fonds de
   recherche du Quebec - SanteFonds de la Recherche en Sante du Quebec
FX This work was supported by the Di Giovanni Foundation, Montreal English
   School Board, Colannini Foundation, and Montreal Neurological Institute
   and Hospital. A. Winkler-Schwartz is supported by a doctoral training
   grant for applicants with a professional degree issued by the Fonds de
   recherche du Quebec - Sante. R. Del Maestro is the William Feindel
   Emeritus Professor in Neuro-Oncology at McGill University.
CR Aggarwal R, 2008, ANN SURG, V247, P372, DOI 10.1097/SLA.0b013e318160b371
   Aldave G, 2017, J NEUROSURG-PEDIATR, V19, P377, DOI 10.3171/2016.10.PEDS16471
   Alotaibi FE, 2015, OPER NEUROSURG, V11, P89, DOI 10.1227/NEU.0000000000000631
   Alotaibi FE, 2015, SURG INNOV, V22, P636, DOI 10.1177/1553350615579729
   AlZhrani G, 2015, J SURG EDUC, V72, P685, DOI 10.1016/j.jsurg.2014.12.014
   Azarnoush H, 2017, J NEUROSURG, V127, P171, DOI 10.3171/2016.7.JNS16322
   Azarnoush H, 2015, INT J COMPUT ASS RAD, V10, P603, DOI 10.1007/s11548-014-1091-z
   Bajunaid K, 2017, J NEUROSURG, V126, P71, DOI 10.3171/2015.5.JNS15558
   Feldman M, 2012, J CONTIN EDUC HEALTH, V32, P279, DOI 10.1002/chp.21156
   Gelinas-Phaneuf N, 2014, INT J COMPUT ASS RAD, V9, P1, DOI 10.1007/s11548-013-0905-8
   Hadley C, 2015, J NEUROSURG-PEDIATR, V16, P497, DOI 10.3171/2015.1.PEDS14511
   Jensen RL, 2017, J NEUROSURG, V127, P949, DOI 10.3171/2017.3.JNS17242
   Pang P, 2018, QUALITY AND SAFETY IN NEUROSURGERY, P213, DOI 10.1016/B978-0-12-812898-5.00017-5
   Sarkiss CA, 2016, WORLD NEUROSURG, V89, P1, DOI 10.1016/j.wneu.2015.12.052
   Sawaya R, 2019, J NEUROSURG, V131, P192, DOI 10.3171/2018.2.JNS172327
   Sawaya R, 2018, OPER NEUROSURG, V14, P686, DOI 10.1093/ons/opx189
   Streiner DL, 2015, HLTH MEASUREMENT SCA
   Sugiyama T, 2018, JAMA SURG, V153, P234, DOI 10.1001/jamasurg.2017.4516
   Winkler-Schwartz A, 2016, J SURG EDUC, V73, P942, DOI 10.1016/j.jsurg.2016.04.013
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E230
EP E235
DI 10.1016/j.wneu.2019.03.059
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300031
PM 30880209
DA 2020-05-12
ER

PT J
AU Xia, C
   Xue, BC
   Wang, YW
   Qin, XD
   Qiu, Y
   Zhu, ZZ
   Xu, LL
AF Xia, Chao
   Xue, Bingchuan
   Wang, Yuwen
   Qin, Xiaodong
   Qiu, Yong
   Zhu, Zezhang
   Xu, Leilei
TI Investigating Role of IRX Family in Development of Female Adolescent
   Idiopathic Scoliosis: Which One Is Real Cause?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; IRX1; SNP
ID GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; SUSCEPTIBILITY;
   POLYMORPHISMS; POC5; IL-6
AB BACKGROUND: Previous studies showed that several variants located around the IRX family may have functional roles in the development of adolescent idiopathic scoliosis (AIS). However, there was lack of knowledge concerning the target gene of the region on 5p13.3 and the role of IRX genes in the etiology of AIS. This study aimed to validate the relationship between the IRX family and AIS in a large-scale general population and to further investigate the target gene of the region, which was associated with AIS.
   METHODS: SNP rs12517904 and rs117273909 were gen-otyped in 1323 patients and 1670 age-matched healthy controls. Paraspinal muscle was collected from 70 AIS patients and 20 congenital scoliosis patients. Student's t-test was used to compare the IRX1 expression between AIS patients and controls. The 1-way analysis of variance test was used to compare the expression of the IRX genes among different genotypes.
   RESULTS: For rs12517904, patients were found to have a significantly higher frequency of allele T than the controls (37.6% vs. 34.7%, P = 0.02). Allele T can significantly add to the risk of AIS with an odds ratio of 1.14. AIS patients were found to have significantly lower IRX1 expression than the controls. Patients with genotype TT were found to have significantly lower IRX1 expression than those with genotype GG.
   CONCLUSIONS: Our large-scale case control study validated that the IRX1 gene could be the disease-associated gene of AIS. The variant rs12517904 of the IRX1 gene is functionally associated with the development of AIS in the Chinese population. The role of IRX1 in the onset of AIS is worthy of further investigation.
C1 [Xia, Chao; Xue, Bingchuan; Wang, Yuwen; Qin, Xiaodong; Qiu, Yong; Zhu, Zezhang; Xu, Leilei] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
RP Xu, LL (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Spine Surg, Nanjing, Jiangsu, Peoples R China.
EM peterxu_drumtower@163.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81661168013, 81772304, 81871747]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [N_CUHK416/16]; Research Grants Council of the Hong Kong Special
   Administrative RegionHong Kong Research Grants Council [N_CUHK416/16]
FX This work was supported by the Natural Science Foundation of China
   (81661168013, 81772304, 81871747) and Joint Research Scheme sponsored by
   the National Natural Science Foundation of China and the Research Grants
   Council of the Hong Kong Special Administrative Region (N_CUHK416/16).
CR Altaf F, 2013, BMJ-BRIT MED J, V346, pf2508, DOI DOI 10.1136/BMJ.F2508
   Andersen MR, 2017, SPINE, V42, pE702, DOI 10.1097/BRS.0000000000001927
   Buchan JG, 2014, HUM MOL GENET, V23, P5271, DOI 10.1093/hmg/ddu224
   Cavodeassi F, 2001, DEVELOPMENT, V128, P2847
   Chen ZJ, 2009, EUR J HUM GENET, V17, P525, DOI 10.1038/ejhg.2008.203
   Haller G, 2015, J BONE JOINT SURG AM, V97A, P1411, DOI 10.2106/JBJS.O.00290
   Justice CM, 2016, G3-GENES GENOM GENET, V6, P1707, DOI 10.1534/g3.116.029975
   Kou I, 2013, NAT GENET, V45, P676, DOI 10.1038/ng.2639
   Li W, 2016, J MED GENET, V53, P488, DOI 10.1136/jmedgenet-2015-103684
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Nelson LM, 2011, SPINE, V36, P37, DOI 10.1097/BRS.0b013e3181e8755b
   Nikolova ST, 2016, SPINE, V41, P785, DOI 10.1097/BRS.0000000000001360
   Ogura Y, 2015, AM J HUM GENET, V97, P337, DOI 10.1016/j.ajhg.2015.06.012
   Patten SA, 2015, J CLIN INVEST, V125, P1124, DOI 10.1172/JCI77262
   Ryzhkov II, 2013, SPINE, V38, pE699, DOI 10.1097/BRS.0b013e31828de9e1
   Sharma S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7452
   Sharma S, 2011, HUM MOL GENET, V20, P1456, DOI 10.1093/hmg/ddq571
   Sui WY, 2017, J BACK MUSCULOSKELET, V30, P559, DOI 10.3233/BMR-150309
   Takahashi Y, 2011, NAT GENET, V43, P1237, DOI 10.1038/ng.974
   Takahashi Y, 2011, J ORTHOP RES, V29, P1055, DOI 10.1002/jor.21347
   Takahashi Y, 2011, J ORTHOP RES, V29, P834, DOI 10.1002/jor.21322
   Xu LL, 2018, SPINE, V43, pE683, DOI 10.1097/BRS.0000000000002490
   Xu LL, 2018, SPINE, V43, pE580, DOI 10.1097/BRS.0000000000002497
   Xu LL, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1731-x
   Zhu ZZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9355
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E132
EP E136
DI 10.1016/j.wneu.2019.02.184
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300185
PM 30862593
DA 2020-05-12
ER

PT J
AU Xu, S
   Liang, Y
   Zhu, ZQ
   Wang, KF
   Liu, HY
AF Xu, Shuai
   Liang, Yan
   Zhu, Zhenqi
   Wang, Kaifeng
   Liu, Haiying
TI Position of the Aorta Relative to Vertebrae in Patients with
   Degenerative Thoracolumbar or Lumbar Scoliosis: A Case-Control Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Abdominal aorta; Aorta-vertebrae angle; Aorta-vertebrae distance; De
   novo lumbar scoliosis; Rotation angle
ID ALTERED BODY POSITION; IDIOPATHIC SCOLIOSIS; THORACIC AORTA; SPINE;
   INSTRUMENTATION; CLASSIFICATION; COMPLICATIONS; SCREW
AB OBJECTIVE: To investigate the position of the aorta relative to the spine in patients with de novo lumbar scoliosis (DLS).
   METHODS: This study enrolled 142 patients with DLS, including 80 cases of left thoracolumbar/ lumbar scoliosis (left group) and 62 cases of right scoliosis (right group). In addition, 132 cases free of deformity were allocated to the control group. Parameters of the Cobb angle and apical vertebrae were measured by radiograph, whereas the left pedicle-vertebrae angle (alpha), rotation angle (gamma), and left pedicle-vertebrae distance (d) of T12-L4 were obtained by magnetic resonance imaging. Independent sample t test was performed to compare alpha, gamma, and d between the DLS and control groups, followed by a Pearson correlation analysis to study the correlation between Cobb angle and alpha, gamma, and d.
   RESULTS: No difference was found between the right group and control group (P [0.554). The value of mean d (4.62 +/- 0.57 cm) gradually increased from T12 to L4 in the left group and showed significant difference with the corresponding value in the control group (4.44 +/- 0.43 cm; P < 0.001). There was no significant difference between the right group and control group (P [0.762). The value of mean d (4.54 +/- 1.84 cm) showed no significant difference between the right group and control group (P [0.530). The correlation analysis showed a significant correlation between rotation angle g and Cobb angle (P < 0.001), but not in a and d with Cobb angle.
   CONCLUSIONS: Although the position of the aorta relative to the spine showed no significant difference between patients with DLS and normal subjects, great attention should still be paid to prevent DLS-induced aorta injury.
C1 [Xu, Shuai; Liang, Yan; Zhu, Zhenqi; Wang, Kaifeng; Liu, Haiying] Peking Univ, Peoples Hosp, Dept Spinal Surg, Beijing, Peoples R China.
RP Liu, HY (reprint author), Peking Univ, Peoples Hosp, Dept Spinal Surg, Beijing, Peoples R China.
EM liuhaiying1131@sina.com
CR Ailon T, 2015, NEUROSURGERY, V77, pS75, DOI 10.1227/NEU.0000000000000938
   Ayca B, 2016, VASCULAR, V24, P315, DOI 10.1177/1708538115597371
   Bekki H, 2016, SPINE, V41, P585, DOI 10.1097/BRS.0000000000001257
   Bullmann V, 2006, SPINE, V31, P1706, DOI 10.1097/01.brs.0000224183.68795.a5
   Chang DG, 2017, SPINE, V42, pE890, DOI 10.1097/BRS.0000000000001998
   Cho KJ, 2014, ASIAN SPINE J, V8, P371, DOI 10.4184/asj.2014.8.3.371
   Feng F, 2013, SPINE, V38, pE1235, DOI 10.1097/BRS.0b013e31829ef890
   Grauers A, 2012, EUR SPINE J, V21, P1069, DOI 10.1007/s00586-011-2074-1
   Ha KY, 2016, SPINE, V41, pE282, DOI 10.1097/BRS.0000000000001229
   Huitema GC, 2007, SPINE, V32, P1259, DOI 10.1097/BRS.0b013e3180592c4a
   Inamasu J, 2006, ACTA NEUROCHIR, V148, P375, DOI 10.1007/s00701-005-0669-1
   Jiang H, 2012, SPINE, V37, pE1054, DOI 10.1097/BRS.0b013e3182600a7d
   Kebaish KM, 2011, SPINE, V36, P731, DOI 10.1097/BRS.0b013e3181e9f120
   Khamanarong Kimaporn, 2009, Journal of the Medical Association of Thailand, V92, P47
   Kulkarni SS, 2003, EUR SPINE J, V12, P48, DOI 10.1007/s00586-002-0460-4
   Liang Y, 2018, J ORTHOP SCI, V23, P289, DOI 10.1016/j.jos.2017.11.003
   Liljenqvist UR, 2002, J BONE JOINT SURG AM, V84A, P359, DOI 10.2106/00004623-200203000-00005
   Liu JM, 2012, J SPINAL DISORD TECH, V25, pE82, DOI 10.1097/BSD.0b013e31824a7bc3
   Maruyama T, 2004, SPINE, V29, P2067, DOI 10.1097/01.brs.0000138409.14577.f0
   MATSUZAKI H, 1993, SPINE, V18, P2327, DOI 10.1097/00007632-199311000-00033
   Milbrandt TA, 2007, SPINE, V32, pE348, DOI 10.1097/BRS.0b013e318059aeda
   Munoz JJ, 2010, LEARN IMAGING, P147, DOI 10.1007/978-3-540-87997-8_7
   Pasha S, 2016, EUR SPINE J, V25, P3137, DOI 10.1007/s00586-016-4582-5
   Pichaisak Witchate, 2015, Journal of the Medical Association of Thailand, V98, P373
   Qiao J, 2012, EUR SPINE J, V21, P2043, DOI 10.1007/s00586-012-2315-y
   Qu Z, 2017, CLIN SPINE SURG, V30, P328, DOI 10.1097/BSD.0000000000000304
   Sadat-Ali M, 2008, EUR SPINE J, V17, P944, DOI 10.1007/s00586-008-0671-4
   Schwab F, 2006, SPINE, V31, P2109, DOI 10.1097/01.brs.0000231725.38943.ab
   Sevastik B, 1996, SURG RADIOL ANAT, V18, P51, DOI 10.1007/BF03207763
   Sucato DJ, 2003, J BONE JOINT SURG AM, V85A, P1461, DOI 10.2106/00004623-200308000-00006
   Szolar DH, 1996, NEURORADIOLOGY, V38, P521, DOI 10.1007/BF00626086
   Takeshita K, 2011, SPINE, V36, pE1519, DOI 10.1097/BRS.0b013e31820f8e6b
   Takeshita K, 2010, SPINE, V35, pE1571, DOI 10.1097/BRS.0b013e3181cf0cb6
   Wang GH, 2015, EUR SPINE J, V24, P1792, DOI 10.1007/s00586-015-3942-x
   WOOLSEY RM, 1986, SURG NEUROL, V25, P267, DOI 10.1016/0090-3019(86)90237-5
   Xu LL, 2013, EUR SPINE J, V22, P1326, DOI 10.1007/s00586-013-2678-8
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1
EP E7
DI 10.1016/j.wneu.2019.01.036
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300002
PM 30851468
DA 2020-05-12
ER

PT J
AU Yagi, K
   Tao, Y
   Hara, K
   Hirai, S
   Takai, H
   Kinoshita, K
   Oyama, N
   Yagita, Y
   Matsubara, S
   Uno, M
AF Yagi, Kenji
   Tao, Yoshifumi
   Hara, Keijirou
   Hirai, Satoshi
   Takai, Hiroki
   Kinoshita, Keita
   Oyama, Naoki
   Yagita, Yoshiki
   Matsubara, Shunji
   Uno, Masaaki
TI Does Noncontrast Computed Tomography Scan Predict Rebleeding After
   Endoscopic Surgery for Spontaneous Intracerebral Hemorrhage?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blend sign; Intracerebral hemorrhage; Noncontrasted computed tomography
   scan; Radiographic marker; Rebleeding; Surgery
ID ANGIOGRAPHY SPOT SIGN; HEMATOMA EXPANSION; BLEND SIGN; CT; MARKERS;
   GROWTH
AB BACKGROUND: The relationship between noncontrast computed tomography (CT) markers, which predict the expansion of spontaneous intracerebral hemorrhage (sICH) under conservative treatment, and postoperative rebleeding (PR) after treatment by directly removing the sICH is unknown. This study investigated the relationship between noncontrast CT markers and PR in patients with sICH treated by endoscopic surgery.
   METHODS: The study population included 92 patients with available data who underwent endoscopic surgery for sICH at our institution from January 2010 to September 2018. The correlations between PR and preoperative noncontrast CT markers, including the blend sign, hypodensities, black hole sign, heterogeneous density, and island signs, were retrospectively evaluated.
   RESULTS: In 5 of the 18 patients (27.8%) with the blend sign, PR developed, whereas only 5 of 74 patients (6.8%) without the blend sign developed PR. In the univariate regression analyses, manifestation of hydrocephalus (odds ratio [OR], 8.75; 95%) confidence interval [CI], 2.15-35.68; P = 0.002), presence of the blend sign (OR, 5.31; 95% CI, 1.34-20.97; P = 0.02), and insertion of external ventricular drainage (OR, 13.88; 95% CI, 3.22-59.77; P < 0.001) were significant risk factors. The other radiographic markers were not associated with PR. In a multivariate analysis, the presence of the blend sign (OR, 22.07; 95% CI, 2.18-773.60; P = 0.009) was the only independent predictor of PR.
   CONCLUSIONS: The blend sign is likely to he a strong predictor for PR in patients who undergo endoscopic surgery for sICH. To improve the prognosis of patients with sICH, further studies are needed to establish new treatment strategies and surgical procedures.
C1 [Yagi, Kenji; Tao, Yoshifumi; Hara, Keijirou; Hirai, Satoshi; Takai, Hiroki; Kinoshita, Keita; Matsubara, Shunji; Uno, Masaaki] Kawasaki Med Sch, Dept Neurosurg, Kurashiki, Okayama, Japan.
   [Oyama, Naoki; Yagita, Yoshiki] Kawasaki Med Sch, Dept Stroke Med, Kurashiki, Okayama, Japan.
RP Yagi, K (reprint author), Kawasaki Med Sch, Dept Neurosurg, Kurashiki, Okayama, Japan.
EM kenji-yagi@mail.goo.ne.jp
CR AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Boulouis G, 2016, JAMA NEUROL, V73, P961, DOI 10.1001/jamaneurol.2016.1218
   Brouwers HB, 2014, NEUROLOGY, V83, P883, DOI 10.1212/WNL.0000000000000747
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Gregson BA, 2012, STROKE, V43, P1496, DOI 10.1161/STROKEAHA.111.640284
   Kuo LT, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10313
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Miki K, 2019, J NEUROSURG, V130, P1485, DOI 10.3171/2017.12.JNS172335
   Miki K, 2018, WORLD NEUROSURG, V116, pE513, DOI 10.1016/j.wneu.2018.05.022
   Morgenstern LB, 2001, NEUROLOGY, V56, P1294, DOI 10.1212/WNL.56.10.1294
   Morotti A, 2017, NEUROLOGY, V89, P548, DOI 10.1212/WNL.0000000000004210
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800
   Seifman MA, 2011, NEUROSURG REV, V34, P393, DOI 10.1007/s10143-010-0304-3
   Shen ZK, 2018, WORLD NEUROSURG, V120, pE153, DOI 10.1016/j.wneu.2018.07.256
   Sporns PB, 2018, STROKE, V49, P2317, DOI 10.1161/STROKEAHA.118.021625
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Wu GF, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0910-6
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Zhang F, 2018, MED SCI MONITOR, V24, P6237, DOI 10.12659/MSM.910024
NR 23
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E965
EP E971
DI 10.1016/j.wneu.2019.04.010
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300120
PM 30965164
DA 2020-05-12
ER

PT J
AU Yang, J
   Wu, H
   Kong, QQ
   Wang, Y
   Peng, ZY
   Zhang, LF
   Yan, YQ
   Guo, C
   Zhang, DF
AF Yang, Jin
   Wu, Hao
   Kong, Qingquan
   Wang, Yu
   Peng, Zhiyu
   Zhang, Lifeng
   Yan, Yuqing
   Guo, Chuan
   Zhang, Dongfeng
TI Full Endoscopic Transforaminal Decompression Surgery for Symptomatic
   Lumbar Spinal Stenosis in Geriatric Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Full endoscopic lumbar surgery; Geriatric patients; Preoperative
   assessment; Preoperative preparation; Symptomatic lumbar spinal
   stenosis; Transforaminal decompression
ID SURGICAL OUTCOMES; COMPLICATIONS; TRENDS; OLDER; FUSION; AGE
AB OBJECTIVE: Recently, full endoscopic transforaminal decompression surgery (FETDS) under local anesthesia has been used to treat symptomatic lumbar spinal stenosis (SLSS) in selective patients. Considering the minimal injury associated with this technique, it has a potential advantage for geriatric patients. In addition, combining thorough preoperative assessments and preparations with this technique to achieve a safer and more effective outcome for geriatric patients with SLSS is necessary.
   METHODS: Between June 2015 and September 2016, after thorough preoperative assessments and preparations, 56 geriatric patients who underwent FETDS with a median 18 months follow-up were enrolled in this study. Clinical results were assessed using the Oswestry Disability Index, visual analog scale (VAS), and the modified Macnab criteria.
   RESULTS: The median duration of surgery was 75 minutes. The mean VAS score for preoperative leg pain was 6.54 +/- 0.66, which improved to 1.79 +/- 0.80, 1.50 +/- 0.79, 1.43 +/- 0.85, and 1.39 +/- 0.97 after surgery, at 3 months, at 6 months, and at the last follow-up, respectively. The mean VAS score for preoperative low back pain was 2.00 +/- 1.01, which changed to 2.09 +/- 0.79, 2.07 +/- 0.83, 2.09 +/- 0.92, and 2.23 +/- 0.76 at the same evaluation times, respectively. The mean preoperative Oswestry Disability Index was 69.30 +/- 6.07, which improved to 22.36 +/- 8.35, 22.32 +/- 8.47, 22.21 +/- 6.61, and 24.57 +/- 8.23, respectively. The modified Macnab criteria were consistent with excellent or good outcomes in 91.1% of patients. Three patients (5.4%) developed complications.
   CONCLUSIONS: FETDS was effective and safe in the treatment of SLSS in geriatric patients, with minimal physiologic impact, taking advantage of the current protocol of thorough assessments and appropriate preoperative preparation.
C1 [Yang, Jin; Wu, Hao; Kong, Qingquan; Wang, Yu; Peng, Zhiyu; Zhang, Lifeng; Yan, Yuqing; Guo, Chuan; Zhang, Dongfeng] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
   [Yang, Jin] Southwest Med Univ, Affiliated Hosp, Dept Spine Surg, Luzhou, Sichuan, Peoples R China.
RP Kong, QQ (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu, Sichuan, Peoples R China.
EM kqqspine@126.com
OI Wang, Yu/0000-0002-0939-5606
CR Airaksinen O, 1997, SPINE, V22, P2278, DOI 10.1097/00007632-199710010-00016
   Best NM, 2007, SPINE, V32, P1135, DOI 10.1097/01.brs.0000261486.51019.4a
   Chen XQ, 2019, INT ORTHOP, V43, P1263, DOI 10.1007/s00264-018-4051-3
   Ciol MA, 1996, J AM GERIATR SOC, V44, P285, DOI 10.1111/j.1532-5415.1996.tb00915.x
   Deyo RA, 2005, SPINE, V30, P1441, DOI 10.1097/01.brs.0000166503.37969.8a
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Finlayson E V, 2001, Eff Clin Pract, V4, P172
   Fredman B, 2002, EUR SPINE J, V11, P571, DOI 10.1007/s00586-002-0409-7
   Galiano K, 2005, SPINE, V30, P332, DOI 10.1097/01.brs.0000152381.20719.50
   Jakola AS, 2010, BMC SURG, V10, DOI 10.1186/1471-2482-10-34
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Katz JN, 1999, SPINE, V24, P2229, DOI 10.1097/00007632-199911010-00010
   Li ZZ, 2016, CLIN NEUROL NEUROSUR, V143, P90, DOI 10.1016/j.clineuro.2016.02.008
   Massarweh NN, 2009, ARCH SURG-CHICAGO, V144, P1108, DOI 10.1001/archsurg.2009.204
   Morgalla MH, 2011, J NEUROSURG-SPINE, V14, P305, DOI 10.3171/2010.10.SPINE09708
   Nanjo Y, 2013, ARCH ORTHOP TRAUM SU, V133, P1243, DOI 10.1007/s00402-013-1808-4
   Okuda S, 2006, J BONE JOINT SURG AM, V88A, P2714, DOI 10.2106/JBJS.F.00186
   Oresanya LB, 2014, JAMA-J AM MED ASSOC, V311, P2110, DOI 10.1001/jama.2014.4573
   Rosen DS, 2007, NEUROSURGERY, V60, P503, DOI 10.1227/01.NEU.0000255332.87909.58
   Saleh A, 2017, SPINE J, V17, P1106, DOI 10.1016/j.spinee.2017.03.019
   Schizas C, 2010, SPINE, V35, P1919, DOI 10.1097/BRS.0b013e3181d359bd
   Shabat S, 2002, ARCH GERONTOL GERIAT, V35, P143, DOI 10.1016/S0167-4943(02)00016-X
   Shabat S, 2008, EUR SPINE J, V17, P193, DOI 10.1007/s00586-007-0514-8
   Shin SH, 2018, WORLD NEUROSURG, V114, pE873, DOI 10.1016/j.wneu.2018.03.107
   Sobottke R, 2017, EUR SPINE J, V26, P462, DOI 10.1007/s00586-015-4078-8
   Ulrich NH, 2015, SPINE, V40, P415, DOI 10.1097/BRS.0000000000000765
   Wang Y, 2018, WORLD NEUROSURG, V119, pE276, DOI 10.1016/j.wneu.2018.07.133
   Xiong CJ, 2019, EUR SPINE J, V28, P78, DOI 10.1007/s00586-018-5655-4
NR 28
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E449
EP E459
DI 10.1016/j.wneu.2019.03.171
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300055
PM 30922895
DA 2020-05-12
ER

PT J
AU Yang, XG
   Wang, F
   Feng, JT
   Hu, YC
   Lun, DX
   Hua, KC
   Liu, YH
   Zhang, H
   Yang, L
AF Yang, Xiong-gang
   Wang, Feng
   Feng, Jiang-tao
   Hu, Yong-cheng
   Lun, Deng-xing
   Hua, Kun-chi
   Liu, Yong-heng
   Zhang, Hao
   Yang, Li
TI Recursive Partitioning Analysis (RPA) of Prognostic Factors for Overall
   Survival in Patients with Spinal Metastasis: A New System for Stratified
   Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decision tree model; Prognostic factor; Recursive partitioning analysis;
   Spinal metastasis; Survival
ID CORD COMPRESSION; PREOPERATIVE EVALUATION; TOKUHASHI SCORE; SURGERY;
   RADIOTHERAPY
AB BACKGROUND: Accurate survival estimate is necessary when determining the most appropriate treatment modality for metastatic spinal tumor. The main purpose of this study was to identify the prognostic factors of spinal metastasis and establish a decision tree model.
   METHODS: A consecutive cohort of 507 patients from 3 institutional clinical centers who were treated for metastatic spinal tumor between 2005 and 2015 were retrospectively reviewed. In total, 70% of the participants were randomly selected as a "training sample." The prognostic effect of preoperative factors was evaluated using the "training sample," and a decision tree model was established. Then, the accuracy of the new model, as well as the Tokuhashi and Tomita score, was tested by the "test sample," which consisted of the remaining 30% of participants.
   RESULTS: A decision tree model was generated based on the significant factors with an order of descending importance on predicting the prognosis. According to the new model, patients were classified into 3 groups, mean survival times of less than 6 months, 6-12 months, and more than 12 months, who were indicated for conservative therapy/palliative operation, palliative operation, and invasive excision, respectively. The newly established model was confirmed to be of high accuracy in predicting overall survival, whereas the Tokuhashi and Tomita scores were of modest accuracy and consistency.
   CONCLUSIONS: A new decision tree model for prognosis prediction in spinal metastasis was established with a satisfactory accuracy and consistency. However, the Tokuhashi and Tomita systems were presented to be less correlated between the scores and actual survival.
C1 [Yang, Xiong-gang; Wang, Feng; Feng, Jiang-tao; Hua, Kun-chi; Liu, Yong-heng; Zhang, Hao; Yang, Li] Tianjin Med Univ, Grad Sch, Tianjin, Peoples R China.
   [Hu, Yong-cheng] Tianjin Hosp, Dept Orthoped Oncol, Tianjin, Peoples R China.
   [Lun, Deng-xing] Weifang Peoples Hosp, Dept Spine Surg, Weifang, Shandong, Peoples R China.
RP Hu, YC (reprint author), Tianjin Hosp, Dept Orthoped Oncol, Tianjin, Peoples R China.
EM yongchenghu@126.com
CR BARRON KD, 1959, NEUROLOGY, V9, P91, DOI 10.1212/WNL.9.2.91
   Bartels RHMA, 2007, CANCER-AM CANCER SOC, V110, P2042, DOI 10.1002/cncr.23002
   BAUER HCF, 1995, ACTA ORTHOP SCAND, V66, P143, DOI 10.3109/17453679508995508
   Bollen L, 2014, NEURO-ONCOLOGY, V16, P991, DOI 10.1093/neuonc/not318
   BYRNE TN, 1992, NEW ENGL J MED, V327, P614
   Chen HJ, 2010, SPINE, V35, pE1339, DOI [10.1155/2010/174528, 10.1097/BRS.0b013e3181e574f5]
   Chen YJ, 2007, SPINE, V32, pE413, DOI 10.1097/BRS.0b013e318074d6c7
   Enkaoua EA, 1997, SPINE, V22, P2293, DOI 10.1097/00007632-199710010-00020
   Gakhar H, 2013, EUR SPINE J, V22, P565, DOI 10.1007/s00586-012-2480-z
   HARRINGTON KD, 1986, J BONE JOINT SURG AM, V68A, P1110, DOI 10.2106/00004623-198668070-00025
   Hessler C, 2011, SPINE, V36, P983, DOI 10.1097/BRS.0b013e3181e8f7f8
   Hirabayashi H, 2003, CANCER-AM CANCER SOC, V97, P476, DOI 10.1002/cncr.11039
   Jacobs W B, 2001, Neurosurg Focus, V11, pe10
   Lei MX, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1852-2
   Leithner A, 2008, EUR SPINE J, V17, P1488, DOI 10.1007/s00586-008-0763-1
   MCQUAY HJ, 2000, COCHRANE DB SYST REV, V2
   North RB, 2005, J NEUROSURG-SPINE, V2, P564, DOI 10.3171/spi.2005.2.5.0564
   Ogihara S, 2006, SPINE, V31, P1585, DOI 10.1097/01.brs.0000222146.91398.c9
   Park JH, 2011, J KOREAN NEUROSURG S, V50, P434, DOI 10.3340/jkns.2011.50.5.434
   Park SJ, 2016, SPINE J, V16, P322, DOI 10.1016/j.spinee.2015.11.005
   Prasad D, 2005, LANCET ONCOL, V6, P15, DOI 10.1016/S1470-2045(04)01709-7
   Quraishi NA, 2013, EUR SPINE J, V22, pS27, DOI 10.1007/s00586-012-2648-6
   Rades D, 2012, STRAHLENTHER ONKOL, V188, P424, DOI 10.1007/s00066-011-0058-z
   Rades D, 2006, J CLIN ONCOL, V24, P3388, DOI 10.1200/JCO.2005.05.0542
   Rades D, 2013, CANCER-AM CANCER SOC, V119, P897, DOI 10.1002/cncr.27849
   Rades D, 2011, INT J RADIAT ONCOL, V81, pE861, DOI 10.1016/j.ijrobp.2010.11.056
   SCHABERG J, 1985, SPINE, V10, P19, DOI 10.1097/00007632-198501000-00003
   SUNDARESAN N, 1991, NEUROSURGERY, V29, P645, DOI 10.1227/00006123-199111000-00001
   Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5
   TOKUHASHI Y, 1990, SPINE, V15, P1110, DOI 10.1097/00007632-199011010-00005
   Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016
   Ulmar B, 2007, ANN SURG ONCOL, V14, P998, DOI 10.1245/s10434-006-9000-5
   van der Linden YM, 2005, CANCER-AM CANCER SOC, V103, P320, DOI 10.1002/cncr.20756
   Vanek P, 2015, SPINE, V40, P1824, DOI 10.1097/BRS.0000000000001141
   White BD, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2538
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E124
EP E131
DI 10.1016/j.wneu.2019.02.183
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300018
PM 30862584
DA 2020-05-12
ER

PT J
AU Yin, MC
   Wang, HS
   Ma, JM
   Huang, Q
   Sun, ZW
   Yan, WJ
   Ye, J
   Mo, W
AF Yin, Mengchen
   Wang, Hongshen
   Ma, Junming
   Huang, Quan
   Sun, Zhengwang
   Yan, Wangjun
   Ye, Jie
   Mo, Wen
TI Radiological Characteristics and Surgical Outcome of Patients with Long
   Ossification of the Posterior Longitudinal Ligament Resulting in
   Ossified Lesions in the Upper Cervical Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE OPLL; Ossified lesions; Radiological characteristics; Surgical outcomes;
   Upper cervical spine
ID AXIAL SYMPTOMS; EXPANSIVE LAMINOPLASTY; MYELOPATHY; LAMINECTOMY; FUSION;
   CORD; DECOMPRESSION; MUSCULATURE; CORPECTOMY; MOTION
AB OBJECTIVE: Designing surgical strategies for ossified lesions in the upper cervical spine is challenging owing to the complex anatomic structures. The present study aimed to clarify the prevalence of ossified lesions in the upper cervical spine in patients with ossification in the posterior longitudinal ligament and illustrate the clinical features, radiological findings, and surgical outcomes of this abnormality.
   METHODS: Demographic and clinical data were collected for all patients preoperatively and included age, gender, body mass index, alcohol and tobacco use, history of diabetes, visual analog score, and Japanese Orthopaedic Association score. The cervical angle, morphology of ossification in the posterior longitudinal ligament, K-line, occupation ratio, space available for the spinal cord, high-intensity zone, and compression ratio of the spinal cord were calculated. The operative approach, technique used, and complications were recorded.
   RESULTS: A total of 38 patients were enrolled. The upper cervical segment in 23 patients was not surgically addressed. In the group with the upper cervical segment addressed surgically, 10 patients were treated with C3-C6 open-door laminoplasty and C2 partial laminectomy, 1 with C1-C7 laminoplasty, 1 with C2-C7 laminoplasty, 2 with C3-C6 total and C2 partial laminectomy, and 1 with C1-C5 laminectomy and occipitocervical fusion.
   CONCLUSIONS: The development of ossified lesions in the upper cervical spine has a high incidence. Decompressive surgery for upper cervical spine segments should be recommended for patients with severe narrowing of the spinal canal and a high signal intensity that extends to the upper cervical segment of the spinal cord. We hope that the findings from the present study will aid in clinical decision-making and provide useful information that can be incorporated into future guidelines.
C1 [Yin, Mengchen; Ma, Junming; Ye, Jie; Mo, Wen] Shanghai Univ Tradit Chinese Med, LongHua Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Wang, Hongshen] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Div Spine Ctr, Guangzhou, Guangdong, Peoples R China.
   [Wang, Hongshen] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Huang, Quan] Second Mil Med Univ, Changzheng Hosp, Dept Bone Tumor Surg, Shanghai, Peoples R China.
   [Sun, Zhengwang; Yan, Wangjun] Fudan Univ, Canc Ctr, Dept Musculoskeletal Oncol, Shanghai, Peoples R China.
RP Mo, W (reprint author), Shanghai Univ Tradit Chinese Med, LongHua Hosp, Dept Orthopaed, Shanghai, Peoples R China.
EM mw2218@126.com
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [81603635, 81403419]; Research Project of Shanghai
   Health and Family Planning Commission [20164Y0081, ZYKC201701003,
   201840010]; Research Project of Shanghai Science and Technology
   Commission [16401930600, 17401934400]; Research Project of Shanghai
   Shenkang Hospital Development Center [16CR3074B, 16CR4011A]; Research
   Project of National TCM Clinical Research Base of Longhua Hospital
   [LYTD- 60]; "Sailing Program" of the Shanghai Science and Technology
   Committee [19YF1449600]
FX The present study was sponsored by research grants from the National
   Nature Science Foundation of China (grants 81603635 and 81403419),
   Research Project of Shanghai Health and Family Planning Commission
   (grants 20164Y0081, ZYKC201701003, and 201840010), Research Project of
   Shanghai Science and Technology Commission (grants 16401930600 and
   17401934400), Research Project of Shanghai Shenkang Hospital Development
   Center (grants 16CR3074B and 16CR4011A), Research Project of National
   TCM Clinical Research Base of Longhua Hospital (grant LYTD- 60), and the
   "Sailing Program" of the Shanghai Science and Technology Committee
   (grant 19YF1449600).
CR CAMPBELL WI, 1990, ULSTER MED J, V59, P149
   Choi BW, 2011, ASIAN SPINE J, V5, P267, DOI 10.4184/asj.2011.5.4.267
   Duetzmann S, 2015, J NEUROSURG-SPINE, V23, P24, DOI 10.3171/2014.11.SPINE14427
   Fujimori T, 2014, SPINE, V39, P58, DOI 10.1097/BRS.0000000000000054
   Fujimura Y, 1996, ARCH ORTHOP TRAUM SU, V115, P203, DOI 10.1007/BF00434554
   Fujiyoshi T, 2008, SPINE, V33, pE990, DOI 10.1097/BRS.0b013e318188b300
   Gu YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136042
   Hida Kazutoshi, 2008, Clin Neurosurg, V55, P126
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   Iizuka H, 2001, SPINE, V26, P2220, DOI 10.1097/00007632-200110150-00013
   Kalb S, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10265
   Kawaguchi Y, 2003, J SPINAL DISORD TECH, V16, P497, DOI 10.1097/00024720-200312000-00002
   Kawaguchi Y, 2008, J BONE JOINT SURG AM, V90A, P748, DOI 10.2106/JBJS.G.00037
   Kim P, 2007, J NEUROSURG-SPINE, V7, P293, DOI 10.3171/SPI-07/09/293
   Kimura H, 2014, EUR SPINE J, V23, P1491, DOI 10.1007/s00586-014-3253-7
   Koda M, 2016, EUR SPINE J, V25, P2294, DOI 10.1007/s00586-016-4555-8
   Kovalova I, 2016, SPINE, V41, P1908, DOI 10.1097/BRS.0000000000001842
   Lee SE, 2016, WORLD NEUROSURG, V90, P51, DOI 10.1016/j.wneu.2015.11.074
   Lee SE, 2013, J NEUROSURG-SPINE, V18, P465, DOI 10.3171/2013.1.SPINE12779
   Liu YB, 2016, MED SCI MONITOR, V22, P3746, DOI 10.12659/MSM.900954
   Machino M, 2012, SPINE, V37, pE1243, DOI 10.1097/BRS.0b013e3182659d3e
   MATSUZAKI H, 1989, SPINE, V14, P1198, DOI 10.1097/00007632-198911000-00011
   Miao JH, 2018, WORLD NEUROSURG, V113, P212, DOI 10.1016/j.wneu.2018.02.076
   Oda Takenori, 2009, Spine (Phila Pa 1976), V34, P1395, DOI 10.1097/BRS.0b013e3181a2b486
   Qin RQ, 2018, EUR SPINE J, V27, P1375, DOI 10.1007/s00586-017-5451-6
   Takeuchi K, 2005, SPINE, V30, P2544, DOI 10.1097/01.brs.0000186332.66490.ba
   TSUYAMA N, 1984, CLIN ORTHOP RELAT R, P71
   WACKENHEIM A, 1978, J RADIOL ELEC MED N, V59, P413
   Wang L, 2019, SPINE, V44, pE150, DOI 10.1097/BRS.0000000000002807
   YONE K, 1992, SPINE, V17, pS388, DOI 10.1097/00007632-199210001-00008
   Yukawa Y, 2007, SPINE, V32, P1980, DOI 10.1097/BRS.0b013e318133fbce
   Yusof MI, 2011, SURG RADIOL ANAT, V33, P109, DOI 10.1007/s00276-010-0704-7
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E299
EP E310
DI 10.1016/j.wneu.2019.03.112
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300039
PM 30954753
DA 2020-05-12
ER

PT J
AU Yolcu, Y
   Wahood, W
   Alvi, MA
   Kerezoudis, P
   Okuno, SH
   Foote, RL
   Bydon, M
AF Yolcu, Yagiz
   Wahood, Waseem
   Alvi, Mohammed Ali
   Kerezoudis, Panagiotis
   Okuno, Scott H.
   Foote, Robert L.
   Bydon, Mohamad
TI Evaluating the Role of Adjuvant Radiotherapy in the Management of Sacral
   and Vertebral Chordoma: Results from a National Database
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; National cancer database; Radiotherapy; Surgery; Survival
ID RADIATION-THERAPY; UNILATERAL SACRIFICE; MAJOR RESECTIONS; SPINE;
   OUTCOMES; CHONDROSARCOMAS; SACRECTOMY; SERIES; TUMORS
AB BACKGROUND: Chordomas are slow-growing but locally invasive tumors. The standard of care consists of surgical resection and radiotherapy (RT) when complete resection is not possible. The reported data has reached equivocal results regarding the effect of adding RT to increase patient survival. We investigated the effect of adjuvant RT on patient survival.
   METHODS: The National Cancer Database was queried for patients with a diagnosis of sacral and vertebral column chordoma from 2004 to 2010. The primary outcome was overall survival, which was assessed using Kaplan-Meier plots. Cox proportional hazards were performed to evaluate the effect of each treatment modality on survival after adjusting for an array of patient demographics, facility type, and tumor characteristics.
   RESULTS: The data from 282 patients with chordoma were analyzed; 209 patients (74.1%) had undergone gross total resection (GTR) alone. The median follow-up period for the GTR alone and GTR plus RT groups was 63.4 and 67.6 months, respectively. The mean survival was comparable between patients receiving GTR alone and those receiving adjuvant RT, for both sacral (7.7 and 6.9 years, respectively; P = 0.56) and vertebral chordoma (8.8 and 6.2 years, respectively; P = 0.59). Using Cox proportional hazards, we found that compared with GTR alone, GTR plus adjuvant RT did not add any significant survival benefit, for patients with either sacral chordoma (hazard ratio, 0.55; P = 0.43) or vertebral chordoma (hazard ratio, 7.29; P = 0.23).
   CONCLUSION: Using data from d urge national cancer registry, we found that the available evidence is not enough to suggest that the addition of RT offers a survival benefit for patients with sacral and spinal chordoma after GTR. Given the non-negligible complications associated with RT, the balance of benefits and risks must be considered during preoperative tailoring of the treatment decisions.
C1 [Yolcu, Yagiz; Wahood, Waseem; Alvi, Mohammed Ali; Kerezoudis, Panagiotis; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Neuroinformat Lab, Rochester, MN 55905 USA.
   [Yolcu, Yagiz; Wahood, Waseem; Alvi, Mohammed Ali; Kerezoudis, Panagiotis; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Okuno, Scott H.] Mayo Clin, Dept Med Oncol, Rochester, MN USA.
   [Foote, Robert L.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Neuroinformat Lab, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Wahood,
   Waseem/0000-0002-2963-4096
CR AMENDOLA BE, 1986, RADIOLOGY, V158, P839, DOI 10.1148/radiology.158.3.3945761
   Breteau N, 1996, B CANC RADIOTHER S, V83, p142s
   Catton C, 1996, RADIOTHER ONCOL, V41, P67, DOI 10.1016/S0167-8140(96)91805-8
   Jullien-Petrelli AC, 2018, SPINE J, V18, P632, DOI 10.1016/j.spinee.2017.08.255
   Dhawale AA, 2014, SPINE, V39, pE353, DOI 10.1097/BRS.0000000000000173
   Fuchs B, 2005, J BONE JOINT SURG AM, V87A, P2211, DOI 10.2106/JBJS.D.02693
   GUNTERBERG B, 1976, FERTIL STERIL, V27, P1146
   GUNTERBERG B, 1976, BRIT J SURG, V63, P546, DOI 10.1002/bjs.1800630713
   Hanna SA, 2008, CLIN ORTHOP RELAT R, V466, P2217, DOI 10.1007/s11999-008-0356-7
   Hsieh PC, 2009, SPINE, V34, P2233, DOI 10.1097/BRS.0b013e3181b61b90
   Hsu W, 2009, CURR TREAT OPTION ON, V10, P107, DOI 10.1007/s11864-009-0102-8
   Imai R, 2016, INT J RADIAT ONCOL, V95, P322, DOI 10.1016/j.ijrobp.2016.02.012
   Indelicato DJ, 2016, INT J RADIAT ONCOL, V95, P297, DOI 10.1016/j.ijrobp.2016.01.057
   Jiang BW, 2012, J CLIN NEUROSCI, V19, P1101, DOI 10.1016/j.jocn.2012.01.005
   Kabolizadeh P, 2017, INT J RADIAT ONCOL, V97, P254, DOI 10.1016/j.ijrobp.2016.10.006
   Kayani B, 2014, EJSO-EUR J SURG ONC, V40, P1412, DOI 10.1016/j.ejso.2014.04.008
   Lockney DT, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.9.FOCUS16373
   Lu JJ, 2008, RAD ONCOLOGY EVIDENC
   Mukherjee D, 2011, J NEUROSURG-SPINE, V14, P143, DOI 10.3171/2010.10.SPINE10189
   Pennicooke B, 2016, SPINE, V41, pS186, DOI 10.1097/BRS.0000000000001831
   Prabhakaran P S, 1998, Australas Radiol, V42, P42, DOI 10.1111/j.1440-1673.1998.tb00563.x
   Radaelli S, 2016, SPINE, V41, P1049, DOI 10.1097/BRS.0000000000001604
   Ropper AE, 2012, NEUROSURGERY, V70, P211, DOI 10.1227/NEU.0b013e31822d5f17
   Rotondo RL, 2015, J NEUROSURG-SPINE, V23, P788, DOI 10.3171/2015.3.SPINE14716
   Sanusi O, 2018, WORLD NEUROSURG, V115, pE13, DOI 10.1016/j.wneu.2018.02.127
   Sciubba DM, 2008, NEUROSURG CLIN N AM, V19, P5, DOI 10.1016/j.nec.2007.09.006
   Uhl M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-100
   Wagner TD, 2009, INT J RADIAT ONCOL, V73, P259, DOI 10.1016/j.ijrobp.2008.03.074
   Yamada Y, 2013, NEUROSURGERY, V73, P673, DOI 10.1227/NEU.0000000000000083
   Zhou JH, 2017, NEUROSURGERY, V81, P812, DOI 10.1093/neuros/nyx081
NR 30
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1137
EP E1144
DI 10.1016/j.wneu.2019.04.070
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300141
PM 30995559
DA 2020-05-12
ER

PT J
AU Zeng, JK
   Sun, XJ
   Sun, ZY
   Guan, J
   Han, C
   Zhao, X
   Zhang, P
   Xie, YZ
   Zhao, J
AF Zeng, Junkai
   Sun, Xiaojiang
   Sun, Zhenyu
   Guan, Jie
   Han, Chen
   Zhao, Xin
   Zhang, Pu
   Xie, Youzhuan
   Zhao, Jie
TI Negative Pressure Wound Therapy Versus Closed Suction Irrigation System
   in the Treatment of Deep Surgical Site Infection After Lumbar Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Closed suction irrigation system; Lumbar; Negative pressure wound
   therapy; Spine; Surgical site infection
ID POSTERIOR SPINAL-FUSION; VACUUM-ASSISTED-CLOSURE; RISK-FACTORS;
   INSTRUMENTATION; MANAGEMENT; RETENTION; IMPACT
AB OBJECTIVE: We compared the efficacy of a closed suction irrigation system (CSIS) and negative pressure wound therapy (NPWT) for deep surgical site infection (SSI) after lumbar surgery with instrumentation.
   METHODS: We included 31 patients (NPWT group, n =16; CSIS group, n = 15) with deep SS's after lumbar surgery with instrumentation from 2007 to 2017. The medical records were reviewed and patient characteristics, laboratory results, infection details, and treatment interventions were recorded. The Japanese Orthopaedic Association score and Oswestry disability index were used to assess pain and functional outcomes preoperatively and 3 and 12 months postoperatively. The cost of SSIs were compared between the NPWT and CSIS groups.
   RESULTS: No significant differences were found in the baseline characteristic data between the NPWT and CSIS groups. Implants were retained in all patients in the CSIS group, but required removal from 2 patients with late infections in the NPWT group. The average hospital stay was 36.8 +/- 10.5 days and 33.4 +/- 18.9 days in the NPWT and CSIS groups, respectively. The cost was greater in the NPWT group than in the CSIS group. Both NPWT and CSIS significantly reduced the Oswestry disability index and improved the Japanese Orthopaedic Association scores, but no significant difference was found between the 2 groups.
   CONCLUSIONS: Our results have shown that both NPWT and CSIS are efficient techniques for the management of deep SSI after lumbar surgery with instrumentation. CSIS was more economical and the NPWT system was portable and easier for postoperative nursing care.
C1 [Zeng, Junkai; Sun, Xiaojiang; Sun, Zhenyu; Guan, Jie; Han, Chen; Zhao, Xin; Zhang, Pu; Xie, Youzhuan; Zhao, Jie] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Sch Med,Dept Orthopaed Surg, Shanghai, Peoples R China.
RP Xie, YZ (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Sch Med,Dept Orthopaed Surg, Shanghai, Peoples R China.
EM drxie_miss@163.com
FU National Key Research and Development Program of China [2018YFC2002303];
   Ninth People's Hospital affiliated to Shanghai Jiao Tong University,
   School of Medicine "Multi-Disciplinary Team" Clinical Research Project
   [201701010]; Shanghai Clinical Medical Centre [2017ZZ01023]; Shanghai
   Municipal Key Clinical Specialty
FX The present study was supported by the National Key Research and
   Development Program of China (grant 2018YFC2002303), Ninth People's
   Hospital affiliated to Shanghai Jiao Tong University, School of Medicine
   "Multi-Disciplinary Team" Clinical Research Project (grant 201701010),
   Shanghai Clinical Medical Centre (grant 2017ZZ01023), and the Shanghai
   Municipal Key Clinical Specialty.
CR Atkinson RA, 2017, J HOSP INFECT, V95, P148, DOI 10.1016/j.jhin.2016.11.016
   Awad T, 2013, J WOUND CARE, V22, P162, DOI 10.12968/jowc.2013.22.3.162
   Cabo J, 1995, Eur J Orthop Surg Traumatol, V5, P75, DOI 10.1007/BF02716223
   Canavese F, 2008, J BONE JOINT SURG BR, V90B, P377, DOI 10.1302/0301-620X.90B3.19890
   Chen YC, 2018, WORLD NEUROSURG, V116, pE18, DOI 10.1016/j.wneu.2018.02.142
   CRUSE PJE, 1980, SURG CLIN N AM, V60, P27
   Darden BV, 2006, ORTHOPEDICS, V29, P425, DOI 10.3928/01477447-20060501-12
   De la Garza-Ramos R, 2016, NEUROL RES, V38, P117, DOI 10.1080/01616412.2016.1138669
   Dryden M, 2017, CURR OPIN INFECT DIS, V30, P143, DOI [10.1097/QCO.0000000000000350, 10.1097/qco.0000000000000350]
   Fernandez-Moure JS, 2019, SURG INFECT, V20, P167, DOI 10.1089/sur.2018.237
   Garner BH, 2016, INFECT DIS CLIN N AM, V30, P909, DOI 10.1016/j.idc.2016.07.010
   Ge DM, 2018, ADV SKIN WOUND CARE, V31, P421, DOI 10.1097/01.ASW.0000542530.71686.5c
   Glass GE, 2014, BRIT J SURG, V101, P1627, DOI 10.1002/bjs.9636
   Gu WF, 2018, AM J INFECT CONTROL, V46, P8, DOI 10.1016/j.ajic.2017.09.025
   Hedequist D, 2009, SPINE, V34, P60, DOI 10.1097/BRS.0b013e31818ed75e
   Hong HS, 2008, SPINE, V33, P2473, DOI 10.1097/BRS.0b013e3181894ff0
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Iheozor-Ejiofor Z, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012522.pub2
   Janssen Daniel M C, 2018, J Bone Jt Infect, V3, P94, DOI 10.7150/jbji.23832
   Jeffery S, 2018, J WOUND CARE, V27, pS5, DOI 10.12968/jowc.2018.27.Sup3.S5
   Jones GA, 2007, J NEUROSURG-SPINE, V6, P407, DOI 10.3171/spi.2007.6.5.407
   Kale Maya, 2017, J Orthop Case Rep, V7, P95, DOI 10.13107/jocr.2250-0685.706
   Kirkland KB, 1999, INFECT CONT HOSP EP, V20, P725, DOI 10.1086/501572
   Kowalski TJ, 2007, CLIN INFECT DIS, V44, P913, DOI 10.1086/512194
   Labler L, 2006, EUR SPINE J, V15, P1388, DOI 10.1007/s00586-006-0164-2
   Laratta Joseph L, 2018, J Spine Surg, V4, P471, DOI 10.21037/jss.2018.04.03
   Lian XF, 2014, J SPINAL DISORD TECH, V27, pE315, DOI 10.1097/BSD.0000000000000122
   Liu X, 2018, INT J SURG, V53, P72, DOI 10.1016/j.ijsu.2018.02.064
   Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620
   Maruo K, 2014, J ORTHOP SCI, V19, P398, DOI 10.1007/s00776-014-0545-z
   Miyazaki S, 2016, INT ORTHOP, V40, P1171, DOI 10.1007/s00264-015-3073-3
   Mok JM, 2009, SPINE, V34, P578, DOI 10.1097/BRS.0b013e31819a827c
   Muschik M, 2004, EUR SPINE J, V13, P645, DOI 10.1007/s00586-004-0694-4
   Ploumis A, 2008, J SPINAL DISORD TECH, V21, P320, DOI 10.1097/BSD.0b013e318141f99d
   Rohmiller MT, 2010, SPINE, V35, P642, DOI 10.1097/BRS.0b013e3181b616eb
   Stannard JP, 2012, J ORTHOP TRAUMA, V26, P37, DOI 10.1097/BOT.0b013e318216b1e5
   Tamai K, 2019, SPINE, V44, pE157, DOI 10.1097/BRS.0000000000002790
   Taylor A R, 1970, J Bone Joint Surg Br, V52, P88
   ter Gunne AFP, 2010, EUR SPINE J, V19, P982, DOI 10.1007/s00586-009-1269-1
   van den Bulck R, 2013, INT WOUND J, V10, P145, DOI 10.1111/j.1742-481X.2012.00954.x
   Webb LX, 2017, ORTHOP CLIN N AM, V48, P167, DOI 10.1016/j.ocl.2016.12.004
   Weinstein MA, 2000, J SPINAL DISORD, V13, P422, DOI 10.1097/00002517-200010000-00009
   WOLFGANG GL, 1985, CLIN ORTHOP RELAT R, P162
   Yuan W, 2018, SPINE, V43, pE1089, DOI 10.1097/BRS.0000000000002615
NR 44
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E389
EP E395
DI 10.1016/j.wneu.2019.03.130
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300048
PM 30905647
DA 2020-05-12
ER

PT J
AU Zhang, DD
   Zhuang, Z
   Wei, YX
   Liu, XY
   Li, W
   Gao, YY
   Li, JS
   Hang, CH
AF Zhang, Dingding
   Zhuang, Zong
   Wei, Yongxiang
   Liu, Xiangyu
   Li, Wei
   Gao, Yongyue
   Li, Jinsong
   Hang, Chunhua
TI Association of Admission Serum Glucose-Phosphate Ratio with Severity and
   Prognosis of Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Biomarker; Glucose; Phosphate;
   Prognosis
ID DELAYED CEREBRAL-ISCHEMIA; PHOSPHATE LEVELS; HYPERGLYCEMIA;
   HYPOPHOSPHATEMIA; MANAGEMENT; VASOSPASM; RISK
AB BACKGROUND AND PURPOSE: Serum hyperglycemia and hypophosphatemia have been reported to be common in patients with aneurysmal subarachnoid hemorrhage (aSAH). This study aimed to explore whether admission serum glucose-phosphate ratio was associated with the severity and prognosis of aSAH.
   METHODS: We retrospectively analyzed 198 patients with aSAH who were admitted within 24 hours of hemorrhage to a single academic hospital from June 2016 to September 2017. The following determinations were recorded: aSAH severity on admission, assessment by the World Federation of Neurosurgical Societies grading scale (WFNS), Fisher score defined according to the computed tomography results, and 3-month outcome assessed by the Glasgow Outcome Scale. A statistical analysis of the clinical and laboratory risk factors of poor outcome was conducted.
   RESULTS: Admission serum glucose-phosphate ratio was increased in a WFNS grade-dependent manner and was higher in patients who had a poor outcome than in those who had a good outcome 3 months after aSAH. Multiple binomial logistic regression analysis showed that serum glucose-phosphate ratio, along with age, WFNS grade, and intraventricular hemorrhage, was associated with 3-month poor outcome after aSAH when we controlled for Fisher score, acute hydrocephalus, delayed cerebral ischemia, symptomatic cerebral vasospasm, serum glucose and phosphate levels, and glucose-potassium ratio. Receiver operating characteristic analysis showed that the area under the curve for glucose-phosphate ratio was significantly higher than age and intraventricular hemorrhage.
   CONCLUSIONS: The study shows that the glucose-phosphate ratio is a potential biomarker that can reflect disease severity and prognosis in aSAH patients.
C1 [Zhang, Dingding; Zhuang, Zong; Wei, Yongxiang; Liu, Xiangyu; Li, Wei; Gao, Yongyue; Li, Jinsong; Hang, Chunhua] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
RP Hang, CH (reprint author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
EM hang_neurosurgery@163.com
FU Natural Science Foundation of Jiangsu Province, ChinaNatural Science
   Foundation of Jiangsu Province [BK20180126]; National Natural Science
   Foundation, ChinaNational Natural Science Foundation of China [81771291]
FX This study was supported by the Natural Science Foundation of Jiangsu
   Province, China (Grants NO. BK20180126), and the National Natural
   Science Foundation, China (NO. 81771291).
CR Al-Mufti F, 2018, J NEUROL SCI, V390, P44, DOI 10.1016/j.jns.2018.02.039
   Al-Mufti F, 2019, NEUROSURGERY, V84, P397, DOI 10.1093/neuros/nyy045
   Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Fujiki Y, 2018, J NEUROSURG, V129, P870, DOI 10.3171/2017.5.JNS162799
   Geerse DA, 2010, CRIT CARE, V14, DOI 10.1186/cc9215
   Haap M, 2006, EUR J CLIN NUTR, V60, P734, DOI 10.1038/sj.ejcn.1602375
   Huang YH, 2017, NEUROSURGERY, V80, P809, DOI 10.1093/neuros/nyx016
   Junttila E, 2017, ACTA ANAESTH SCAND, V61, P641, DOI 10.1111/aas.12903
   Khattab M, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0101-5
   Kruyt ND, 2010, J CEREBR BLOOD F MET, V30, P1577, DOI 10.1038/jcbfm.2010.102
   Kruyt ND, 2009, STROKE, V40, pE424, DOI 10.1161/STROKEAHA.108.529974
   Larsen VH, 1996, SCAND J CLIN LAB INV, V56, P83, DOI 10.3109/00365519609088626
   Latorre JGS, 2009, STROKE, V40, P1644, DOI 10.1161/STROKEAHA.108.535534
   Paleologos M, 2000, CLIN SCI, V98, P619, DOI 10.1042/CS19990172
   Park W, 2009, DIABETES RES CLIN PR, V83, P119, DOI 10.1016/j.diabres.2008.08.018
   Przybycien-Szymanska MM, 2015, J STROKE CEREBROVASC, V24, P1453, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.047
   Rodriguez-Rodriguez A, 2014, J NEUROL SCI, V341, P119, DOI 10.1016/j.jns.2014.04.020
   Schmutzhard E, 2011, NEUROCRIT CARE, V15, P281, DOI 10.1007/s12028-011-9601-0
   Sharma S, 2019, HYPOPHOSPHATEMIA
   Thiele RH, 2009, ANESTHESIOLOGY, V110, P603, DOI 10.1097/ALN.0b013e318198006a
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Williamson CA, 2015, NEUROCRIT CARE, V23, P330, DOI 10.1007/s12028-015-0138-5
NR 24
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1145
EP E1151
DI 10.1016/j.wneu.2019.04.071
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300142
PM 30995552
DA 2020-05-12
ER

PT J
AU Zhang, HQ
   Li, M
   Wang, YX
   Tang, MX
   Guo, CF
   Liu, SH
   Deng, A
   Gao, QL
AF Zhang, Hong-Qi
   Li, Min
   Wang, Yu-Xiang
   Tang, Ming-Xing
   Guo, Chao-Feng
   Liu, Shao-Hua
   Deng, Ang
   Gao, Qile
TI Minimum 5-Year Follow-Up Outcomes for Comparison Between Titanium Mesh
   Cage and Allogeneic Bone Graft to Reconstruct Anterior Column Through
   Posterior Approach for the Surgical treatment of Thoracolumbar Spinal
   Tuberculosis with Kyphosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Allogeneic bone graft; Kyphosis; Posterior approach; Spinal
   tuberculosis; Thoracolumbar; Titanium mesh cage
ID RETROSPECTIVE ANALYSIS; INSTRUMENTATION; DEBRIDEMENT; FUSION;
   MANAGEMENT; ALLOGRAFTS; DEFORMITY; DISCITIS; FIXATION
AB OBJECTIVE: We aimed to compare the clinical efficacy of titanium mesh cage with that of allogeneic bone graft to reconstruct the anterior column through posterior approach for the surgical management of patients with thoracolumbar spinal tuberculosis with kyphosis.
   METHODS: From January 2011 to March 2013, 57 patients with single-segment or two-segments thoracolumbar spinal tuberculosis with kyphosis were treated by debridement, interbody graft, posterior instrumentation, and fusion via a posterior-only procedure. Twenty-four patients in group A were treated with allogeneic bone graft to reconstruct the anterior column, whereas 33 patients in group B were treated with titanium mesh cage. The clinical efficacy was evaluated by visual analog scale WAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), neurologic function recovery, kyphotic Cobb angle, and postoperative complications.
   RESULTS: The mean follow-up was 72.4 months. Neurologic function was significantly improved after surgery in all cases. There were significant differences of VAS, ESR, and CRP between preoperation and postoperation at the final follow-up, with no significant difference between the two groups. The kyphotic Cobb correction was significantly improved when compared with those in preoperation, but there was no significant difference between the two groups. One patient in group A with two segments involved experienced graft fracture. He had anterior bone graft with titanium mesh cage.
   CONCLUSIONS: Minimum 5-year follow-up outcomes showed that one-stage posterior focus debridement, interbody graft using titanium mesh cages, posterior instrumentation, and fusion is an effective treatment for patients with thoracolumbar spinal tuberculosis accompanied by kyphosis. It may obtain better clinical efficacy than allogeneic bone graft for treating two-segments thoracolumbar spinal tuberculosis.
C1 [Zhang, Hong-Qi; Wang, Yu-Xiang; Tang, Ming-Xing; Guo, Chao-Feng; Liu, Shao-Hua; Deng, Ang; Gao, Qile] Cent S Univ, Xiangya Spinal Surg Ctr, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Li, Min] Cent S Univ, Xiangya Stomatol Hosp, Changsha, Hunan, Peoples R China.
RP Wang, YX (reprint author), Cent S Univ, Xiangya Spinal Surg Ctr, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China.
EM wangyuxiang201808@163.com
FU Hunan Province Natural Science Foundation, China [2017JJ3489]; Youth
   Research Fund of XiangYa Hospital of Central South University [2017Q16];
   Key Research and Development Project of Hunan Province [2017SK2062]
FX This work was supported by the Hunan Province Natural Science
   Foundation, China (2017JJ3489), Youth Research Fund of XiangYa Hospital
   of Central South University (2017Q16) and Key Research and Development
   Project of Hunan Province (2017SK2062).
CR BRIDWELL KH, 1995, SPINE, V20, P1410, DOI 10.1097/00007632-199506000-00014
   Cavusoglu H, 2008, J NEUROSURG-SPINE, V8, P30, DOI 10.3171/SPI-08/01/030
   CHACKO AG, 2004, SPINE, V29, P363
   Chen Yi-Cheng, 2003, J Chin Med Assoc, V66, P411
   Chiriano J, 2009, J VASC SURG, V50, P148, DOI 10.1016/j.jvs.2009.01.007
   DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003
   Gong K, 2011, ARCH ORTHOP TRAUM SU, V131, P217, DOI 10.1007/s00402-010-1138-8
   Govender S, 2003, INT ORTHOP, V27, P244, DOI 10.1007/s00264-003-0446-9
   Govender S, 1999, J BONE JOINT SURG BR, V81B, P106, DOI 10.1302/0301-620X.81B1.9316
   Guzey FK, 2005, J NEUROSURG-SPINE, V3, P450, DOI 10.3171/spi.2005.3.6.0450
   Hirakawa A, 2010, J SPINAL DISORD TECH, V23, P133, DOI 10.1097/BSD.0b013e31819a870f
   Jain AK, 2002, CLIN ORTHOP RELAT R, P75
   Lee SH, 2006, J SPINAL DISORD TECH, V19, P595, DOI 10.1097/01.bsd.0000211241.06588.7b
   Lonnroth K, 2008, SEMIN RESP CRIT CARE, V29, P481, DOI 10.1055/s-0028-1085700
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Pigrau-Serrallach C, 2013, EUR SPINE J, V22, P556, DOI 10.1007/s00586-012-2331-y
   Przybylski GJ, 2001, J NEUROSURG, V94, P1, DOI 10.3171/spi.2001.94.1.0001
   Rajasekaran S, 2002, CLIN ORTHOP RELAT R, P85
   Rajasekaran S, 2012, INT ORTHOP, V36, P359, DOI 10.1007/s00264-011-1469-2
   Rath SA, 1996, NEUROSURGERY, V38, P926, DOI 10.1097/00006123-199605000-00013
   Sundararaj GD, 2011, ASIAN SPINE J, V5, P155, DOI 10.4184/asj.2011.5.3.155
   Talu U, 2006, J SPINAL DISORD TECH, V19, P554, DOI 10.1097/01.bsd.0000211202.93125.c7
   Tosun B, 2014, EUR SPINE J, V23, P2299, DOI 10.1007/s00586-014-3565-7
   Zevallos M, 2003, CLIN GERIATR MED, V19, P121, DOI 10.1016/S0749-0690(02)00057-5
   Zhang HQ, 2012, ARCH ORTHOP TRAUM SU, V132, P1677, DOI 10.1007/s00402-012-1604-6
   Zhang HQ, 2011, CHILD NERV SYST, V27, P735, DOI 10.1007/s00381-010-1319-3
   Zhang HW, 2016, REC NAT PROD, V10, P1
NR 27
TC 2
Z9 2
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E407
EP E415
DI 10.1016/j.wneu.2019.03.139
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300051
PM 30910755
DA 2020-05-12
ER

PT J
AU Zhang, HJ
   Wang, SL
   Li, ZC
   Shen, RK
   Lin, RQ
   Wu, WC
   Lin, JH
AF Zhang, Hongjie
   Wang, Shenglin
   Li, Zhechen
   Shen, Rongkai
   Lin, Renqin
   Wu, Wence
   Lin, Jianhua
TI Anterior Cervical Surgery for the Treatment of Hirayama Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical surgery; Cold paralysis; Grip strength; Hirayama
   disease; Imaging indicators; Tremor
ID JUVENILE MUSCULAR-ATROPHY; FUSION PROCEDURES; MYELOPATHY; MRI;
   DECOMPRESSION; EXPERIENCE
AB OBJECTIVE: To provide a quantitative assessment of clinical outcomes of anterior cervical surgery for patients with Hirayama disease.
   METHODS: Nineteen patients undergoing anterior cervical surgery were retrospectively collected, and preoperative and postoperative clinical and radiographic data were compared.
   RESULTS: All patients had a mean follow-up time of 72.5 +/- 30.6 months. Tremor in 6 of 14 patients and cold paralysis in 8 patients were resolved after operation. Grip strength of upper extremities was significantly improved (preoperative 15.67 +/- 2.74 kg vs. postoperative 19.82 +/- 2.89 kg, P < 0.001). Postoperative cervical lordosis was significantly increased to 6.41 +/- 4.39 mm from 2.70 +/- 4.61 mm (P < 0.001). The overall range of cervical flexed motion was significantly decreased (preoperative 33.10 degrees +/- 10.60 degrees vs. postoperative 13.55 degrees +/- 6.69 degrees, P < 0.001), with segmental range of C5-6 (preoperative 12.52 degrees +/- 7.13 degrees vs. postoperative 7.04 degrees +/- 3.75 degrees, P = 0.002) and C6-7 (preoperative 9.01 degrees +/- 5.01 degrees vs. postoperative 5.73 degrees +/- 2.74 degrees, P = 0.014) contributing significantly to the improvement. Postoperative angle mobility of C3-4 to C6-7 was significantly decreased (P < 0.001). Postoperative neutral magnetic resonance imaging showed the transverse area of spinal cord of C6 (P = 0.016) and C7 (P = 0.021) was significantly increased.
   CONCLUSIONS: Anterior cervical surgery can provide clinical efficacy and imaging improvement, including reduced range of cervical flexed motion and angle mobility of lower cervical spine and increased cervical lordosis and spinal cord area.
C1 [Zhang, Hongjie; Wang, Shenglin; Li, Zhechen; Lin, Renqin; Wu, Wence; Lin, Jianhua] Fujian Med Univ, Affiliated Hosp 1, Dept Spinal Surg, Fuzhou, Fujian, Peoples R China.
   [Shen, Rongkai] Fujian Med Univ, Affiliated Hosp 1, Dept Bone Tumor & Joint Surg, Fuzhou, Fujian, Peoples R China.
RP Lin, JH (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Spinal Surg, Fuzhou, Fujian, Peoples R China.
EM 710489558@qq.com
CR Agundez M, 2015, NEUROLOGIA, V30, P502, DOI 10.1016/j.nrl.2013.05.005
   BORDEN AGB, 1960, RADIOLOGY, V74, P806, DOI 10.1148/74.5.806
   Boruah DK, 2018, AM J NEURORADIOL, V39, P974, DOI 10.3174/ajnr.A5577
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   Gourie-Devi M, 2003, ACTA NEUROL SCAND, V107, P215, DOI 10.1034/j.1600-0404.2003.02142.x
   Guigui P, 1998, SPINE, V23, P440, DOI 10.1097/00007632-199802150-00006
   Guo X, 2014, J SPINAL DISORD TECH, V27, pE241, DOI 10.1097/BSD.0000000000000098
   HIRAYAMA K, 1963, NEUROLOGY, V13, P373, DOI 10.1212/WNL.13.5.373
   Hirayama K, 2000, INTERNAL MED, V39, P283, DOI 10.2169/internalmedicine.39.283
   Hou C, 2012, NEUROL SCI, V33, P1101, DOI 10.1007/s10072-011-0912-x
   Huang YL, 2011, NEUROIMAG CLIN N AM, V21, P939, DOI 10.1016/j.nic.2011.07.009
   Koutsis G, 2016, J NEUROL SCI, V364, P42, DOI 10.1016/j.jns.2016.03.012
   Lin MS, 2010, J NEUROSURG-SPINE, V12, P629, DOI 10.3171/2009.12.SPINE09431
   Lu FZ, 2013, J NEUROSURG-SPINE, V19, P412, DOI 10.3171/2013.4.SPINE12575
   Martinez-Cayuelas E, 2015, REV NEUROLOGIA, V60, P309, DOI 10.33588/rn.6007.2014525
   Misra UK, 2005, ARCH NEUROL-CHICAGO, V62, P120, DOI 10.1001/archneur.62.1.120
   Paredes I, 2014, J NEUROSURG-SPINE, V20, P191, DOI 10.3171/2013.10.SPINE13508
   PEIRIS JB, 1989, J NEUROL NEUROSUR PS, V52, P314, DOI 10.1136/jnnp.52.3.314
   Preethish-Kumar V, 2015, AMYOTROPH LAT SCL FR, V16, P338, DOI 10.3109/21678421.2015.1039546
   Schroder R, 1999, J NEUROL, V246, P1069, DOI 10.1007/s004150050514
   Song J, 2018, WORLD NEUROSURG, V114, pE1094, DOI 10.1016/j.wneu.2018.03.152
   Song J, 2017, WORLD NEUROSURG, V105, P69, DOI 10.1016/j.wneu.2017.05.097
   Tashiro K, 2006, AMYOTROPH LATERAL SC, V7, P38, DOI 10.1080/14660820500396877
   Tokumaru Y, 2001, Rinsho Shinkeigaku, V41, P173
   TOMA S, 1995, J NEUROL NEUROSUR PS, V58, P56, DOI 10.1136/jnnp.58.1.56
   Vitale V, 2016, QUANT IMAGING MED SU, V6, P364, DOI 10.21037/qims.2016.07.08
   Wang HL, 2018, WORLD NEUROSURG, V116, pE588, DOI 10.1016/j.wneu.2018.05.045
   Watanabe K, 2005, J NEUROSURG-SPINE, V3, P86, DOI 10.3171/spi.2005.3.2.0086
   Xu XJ, 2011, EUR J RADIOL, V78, P82, DOI 10.1016/j.ejrad.2010.08.012
   Yang G, 2014, J CHILD NEUROL, V29, P509, DOI 10.1177/0883073813482770
   Zheng CJ, 2018, CLIN NEUROPHYSIOL, V129, P2341, DOI 10.1016/j.clinph.2018.08.024
   Zou F, 2019, WORLD NEUROSURG, V122, pE296, DOI 10.1016/j.wneu.2018.10.025
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E910
EP E918
DI 10.1016/j.wneu.2019.03.295
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300113
PM 30959255
DA 2020-05-12
ER

PT J
AU Zhang, K
   Wang, ZL
   Gao, BL
   Xue, JY
   Li, TX
   Zhao, TY
   Cai, DY
   He, YK
AF Zhang, Kun
   Wang, Zi-Liang
   Gao, Bu-Lang
   Xue, Jiang-Yu
   Li, Tian-Xiao
   Zhao, Tong-Yuan
   Cai, Dong-Yang
   He, Ying-Kun
TI Use of a First Large-Sized Coil Versus Conventional Coils for
   Embolization of Cerebral Aneurysms: Effects on Packing Density, Coil
   Length, and Durable Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysms; Conventional coil; Embolization; Large-sized coils;
   Percent packing volume
ID INTRACRANIAL ANEURYSMS; ENDOVASCULAR TREATMENT; CLASSIFICATION
AB OBJECTIVE: To investigate effects of using a large-sized coil first on embolizing cerebral aneurysms compared with conventional coils.
   MATERIALS AND METHODS: Forty-six patients with 51 saccular intracranial aneurysms who underwent embolization with a large-sized coil first were enrolled as the large-sized coil group. There were 33 female and 13 male patients with a mean age of 56.9 +/- 8.8 years. The treatment modality was coiling alone in 30 aneurysms and stent-assisted coiling in 21. Meanwhile, 50 patients with 53 intracranial aneurysms who were treated with conventional-sized coils were selected as the control conventional-sized coil group, including 36 female and 14 male patients with a mean age of 54.6 +/- 5.8 years. The treatment modality was coiling alone in 29 aneurysms and stent-assisted coiling in 24 aneurysms. The occlusion rate, percent packing volume, total coil number and length, and follow-up occlusion rate were compared between the 2 groups.
   RESULTS: Significantly (P < 0.001) decreased percent packing volume (19.54% +/- 6.44% vs. 27.39% +/- 5.68%), decreased coil number (2.98 +/- 1.09 vs. 6.38 +/- 1.65), and length (26.20 +/- 26.57 vs. 44.35 +/- 35.88 cm) were achieved in the large versus the conventional coil group. At angiographic follow-up of 8 months, only 1 aneurysm (2.2%) recurred in the large coil group compared with 5 aneurysms recurrent (11.1%) in the conventional coil group.
   CONCLUSIONS: The use of a large-sized coil as the first one for embolizing cerebral aneurysms may be a better embolization strategy because it achieves similar initial occlusion rates, decreased packing density, decreased coil numbers and lengths, and reduced recurrence prevalence at follow-up.
C1 [Zhang, Kun; Wang, Zi-Liang; Gao, Bu-Lang; Xue, Jiang-Yu; Li, Tian-Xiao; Zhao, Tong-Yuan; Cai, Dong-Yang; He, Ying-Kun] Zhengzhou Univ, Henan Prov Peoples Hosp, Henan Prov Cerebrovasc Hosp, Zhengzhou, Henan, Peoples R China.
RP Xue, JY (reprint author), Zhengzhou Univ, Henan Prov Peoples Hosp, Henan Prov Cerebrovasc Hosp, Zhengzhou, Henan, Peoples R China.
EM 58079422@qq.com
RI Gao, Bu-Lang/N-3669-2015
OI Gao, Bu-Lang/0000-0003-4668-0737
FU 2018 Henan Provincial Scientific and Technological Development Plan
   [182102310530]
FX This study was funded by 2018 Henan Provincial Scientific and
   Technological Development Plan (182102310530).
CR Chalouhi N, 2012, NEUROSURGERY, V71, P381, DOI 10.1227/NEU.0b013e31825c36dd
   Darflinger R, 2016, J NEUROINTERV SURG, V8, P507, DOI 10.1136/neurintsurg-2015-011668
   Deshaies EM, 2007, J NEUROSURG, V106, P226, DOI 10.3171/jns.2007.106.2.226
   Giacomini L, 2015, INTERV NEURORADIOL, V21, P292, DOI 10.1177/1591019915582153
   Goertz L, 2019, WORLD NEUROSURG, V126, pE965, DOI 10.1016/j.wneu.2019.02.198
   Kakalis NMP, 2008, IEEE T MED IMAGING, V27, P814, DOI 10.1109/TMI.2008.915549
   Kawanabe Y, 2001, ACTA NEUROCHIR, V143, P451, DOI 10.1007/s007010170073
   Li YJ, 2018, J BIOMECH, V80, P88, DOI 10.1016/j.jbiomech.2018.08.026
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Mitsos AP, 2008, NEURORADIOLOGY, V50, P341, DOI 10.1007/s00234-007-0334-x
   Morales HG, 2011, AM J NEURORADIOL, V32, P1935, DOI 10.3174/ajnr.A2635
   Murayama Y, 2003, J NEUROSURG, V98, P959, DOI 10.3171/jns.2003.98.5.0959
   Raymond J, 2003, STROKE, V34, P2801, DOI 10.1161/01.STR.0000098651.14384.AB
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Ryttlefors M, 2008, STROKE, V39, P2720, DOI 10.1161/STROKEAHA.107.506030
   Sluzewski M, 2004, RADIOLOGY, V231, P653, DOI 10.1148/radiol.2313030460
   Stapleton CJ, 2016, J NEUROINTERV SURG, V8, P927, DOI 10.1136/neurintsurg-2015-012035
   Zhu DY, 2018, WORLD NEUROSURG, V118, pE79, DOI 10.1016/j.wneu.2018.06.123
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E685
EP E691
DI 10.1016/j.wneu.2019.03.242
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300085
PM 30946999
DA 2020-05-12
ER

PT J
AU Zhang, S
   Zhang, X
   Ling, Y
   Li, AM
AF Zhang, Sheng
   Zhang, Xin
   Ling, Ying
   Li, Aimin
TI Predicting Recurrent Hypertensive Intracerebral Hemorrhage: Derivation
   and Validation of a Risk-Scoring Model Based on Clinical Characteristics
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypertensive intracerebral hemorrhage; Recurrent; Risk-scoring model;
   Secondary prevention
ID STROKE; DEEP; HOMOCYSTEINE; MICROBLEEDS; MORTALITY; DISEASE; INJURY;
   ADULTS; LOBAR
AB OBJECTIVE: To develop and validate a risk-scoring model for predicting recurrent hypertensive cerebral hemorrhage (RHCH) occurring within 1 year after initial hypertensive cerebral hemorrhage and to facilitate preemptive clinical intervention for the prevention of secondary hemorrhage.
   METHODS: Patient gender, age, blood pressure, Glasgow Coma Scale (GCS) score, location of cerebral hemorrhage, surgery, past medical history, blood biochemical parameters, and Glasgow Outcome Scale score were analyzed using logistic regression analysis to determine independent predictors of RHCH. A risk-scoring model was constructed by assigning coefficients to each predictor and validating it in another independent cohort. The accuracy of the model was then assessed by the area under the receiver operating characteristic curve (AUC), and the calibration ability of the model was assessed by the Hosmer-Lemeshow test.
   RESULTS: Of 520 patients in the derivation cohort, 38 developed RHCH within 1 year after discharge. Independent risk factors of RHCH were age > 60 years; stage 3 hypertension at admission; GCS score 9-12 (admission); GCS score 3-8 (discharge); history of cerebral ischemic stroke, smoking, alcoholism; and plasma homocysteine (Hcy) level >= 10 mu mol/L. The recurrence rates for the low-risk (0-13 points), intermediate-risk (14-26 points), and high-risk (27-39 points) groups were 1.73%, 6.11%, and 57.14%, respectively (P < 0.001). The corresponding rates in the validation cohort, of whom 10/ 107 (9.35%) developed RHCH, were 3.45%, 7.14%, and 71.43%, respectively (P < 0.001). The risk-scoring model showed good discrimination in both the derivation and validation cohorts, with an AUC of 0.802 versus 0.863. The model also showed good calibration ability (the Hosmer-Lemeshow P values of the two cohorts were 0.532 vs. 0.724).
   CONCLUSIONS: This model will help identify high- risk groups for RHCH in order to facilitate and improve preemptive clinical intervention.
C1 [Zhang, Sheng] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Xin] Nanjing Med Univ, Lianyungang Clin Coll, Lianyungang, Peoples R China.
   [Ling, Ying] Shanghai Yangpu Dist Cent Hosp, Shanghai, Peoples R China.
   [Li, Aimin] Nanjing Med Univ, Lianyungang Clin Coll, Peoples Hosp Lianyungang 1, Dept Neurosurg, Lianyungang, Peoples R China.
RP Li, AM (reprint author), Nanjing Med Univ, Lianyungang Clin Coll, Peoples Hosp Lianyungang 1, Dept Neurosurg, Lianyungang, Peoples R China.
EM 1127595015@qq.com
OI Sheng, Zhang/0000-0001-7658-9825
FU Science and Technology Project of Jiangsu Province, China [BE2015657]
FX This work was supported by the Science and Technology Project of Jiangsu
   Province, China (grant number BE2015657).
CR Biffi A, 2010, NEUROLOGY, V75, P693, DOI 10.1212/WNL.0b013e3181eee40f
   Chen HH, 2017, J WUHAN UNIV TECHNOL, V32, P1, DOI 10.1007/s11595-017-1547-4
   Chinese Medical Association Neurology Branch Department of Cerebrovascular Diseases of Chinese Medical Association Neurology Branch, 2015, CHIN J NEUROL, V48, P435
   Cui H, 2011, CHINESE MED J-PEKING, V124, P3676, DOI 10.3760/cma.j.issn.0366-6999.2011.22.014
   Department of Neurosurgery of Chinese Medical Association Emergency Physician Branch of Chinese Medical Association Stroke Screening and Prevention Engineering Committee in National Committee of Health and Family Planning, 2015, CHIN J EMERG MED, V24, P1319
   Dmewoski J, 2010, DIABETES NUTR METAB, V164, P319
   [窦文波 DOU Wenbo], 2007, [中国现代医学杂志, China Journal of Modern Medicine], V17, P1002
   EIKhairy L, 2001, JAMA-J AM MED ASSOC, V103, P2544
   Grunwald Z, 2017, NEUROCRIT CARE, V26, P205, DOI 10.1007/s12028-016-0321-3
   Han LY, 2015, STROKE, V46, P1777, DOI 10.1161/STROKEAHA.115.009111
   Hanger HC, 2007, J NEUROL NEUROSUR PS, V78, P836, DOI 10.1136/jnnp.2006.106500
   Hannibal L, 2017, MOL ASPECTS MED, V53, P36, DOI 10.1016/j.mam.2016.11.003
   Hansen BM, 2013, J NEUROL NEUROSUR PS, V84, P1150, DOI 10.1136/jnnp-2013-305200
   Hao L, 2007, J NUTR, V137, P407
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hu Da-yi, 2008, Zhonghua Nei Ke Za Zhi, V47, P976
   Hu X, 2011, ACTA NEUROCHIR SUPPL, V111, P387, DOI 10.1007/978-3-7091-0693-8_66
   Huo Y, 2015, JAMA-J AM MED ASSOC, V313, P1325, DOI 10.1001/jama.2015.2274
   Imaizumi T, 2004, J NEUROSURG, V101, P915, DOI 10.3171/jns.2004.101.6.0915
   Imaizumi T, 2013, J STROKE CEREBROVASC, V22, P869, DOI 10.1016/j.jstrokecerebrovasdis.2012.08.003
   Jeon SB, 2007, J NEUROL, V254, P508, DOI 10.1007/s00415-006-0406-6
   Joint committee issued Chinese guideline for the management of dyslipidemia in adults, 2007, CHIN J CARDIOL, V19, P4
   Kang DW, 2012, NEUROLOGY, V79, P848, DOI 10.1212/WNL.0b013e3182648a79
   Kase Carlos S, 2011, Continuum (Minneap Minn), V17, P1304, DOI 10.1212/01.CON.0000410037.64971.e3
   Kim KH, 2013, WORLD NEUROSURG, V79, P489, DOI 10.1016/j.wneu.2012.03.026
   Kim KH, 2009, J KOREAN NEUROSURG S, V45, P341, DOI 10.3340/jkns.2009.45.6.341
   Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P190, DOI 10.1080/08037050152669684
   Li Xinhui, 2011, CHIN J CLIN RATIONAL, V4, P96
   Liu Hanwei, 2007, CHINA PRACT MED, V2, P65
   Liu Qin, 2009, CHIN J PRACT NERVOUS, V12, P28
   Lu XQ, 2013, PROC INT CONF DOC, P240, DOI 10.1109/ICDAR.2013.55
   McLean E, 2008, FOOD NUTR BULL, V29, pS38, DOI 10.1177/15648265080292S107
   Naka H, 2006, AM J NEURORADIOL, V27, P830
   National Health and Family Planning Commission Neurology Medical Quality Control Center, 2015, CHIN J STROKE, V10, P499
   Qi Zhanning, 2016, MED J W CHINA, V28, P1684
   Sorimachi T, 2007, J NEUROSURG, V106, P250, DOI 10.3171/jns.2007.106.2.250
   Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587
   Weimar C, 2011, CEREBROVASC DIS, V32, P283, DOI 10.1159/000330643
   Wolf ME, 2016, EUR NEUROL, V76, P295, DOI 10.1159/000452659
   Yang Jianming, 2008, MED J NATL DEFENDING, V18, P227
   Yuan F, 2012, J NEUROTRAUM, V29, P2137, DOI 10.1089/neu.2011.2233
NR 41
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E162
EP E171
DI 10.1016/j.wneu.2019.03.024
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300023
PM 30876994
DA 2020-05-12
ER

PT J
AU Zhang, YP
   Hai, Y
   Tao, LM
   Yang, JC
   Zhou, LJ
   Yin, P
   Pan, AX
   Zhang, YS
   Liu, C
AF Zhang, Yangpu
   Hai, Yong
   Tao, Luming
   Yang, Jincai
   Zhou, Lijin
   Yin, Peng
   Pan, Aixing
   Zhang, Yaoshen
   Liu, Chang
TI Posterior Multiple-Level Asymmetrical Ponte Osteotomies for Rigid Adult
   Idiopathic Scoliosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult idiopathic scoliosis; Ponte osteotomy; Posterior spine surgery;
   Severe spine deformity; Vertebral column resection
AB OBJECTIVE: To evaluate the efficacy and safety of posterior multiple-level asymmetrical Ponte osteotomies for rigid adult idiopathic scoliosis.
   METHODS: A retrospective study was conducted for adult patients with rigid idiopathic scoliosis (flexibility of main curve <25%) who underwent one-stage multiple-level asymmetrical Ponte osteotomies with a minimum of 2-year follow-up between February 2009 and November 2015. The demographic data and surgical issues were collected, and the improvement of clinical function scores and radiologic parameters were obtained after surgery and during the follow-up to assess deformity correction, spinal balance, and clinical outcome.
   RESULTS: A total of 49 patients were included (10 male and 39 female) in this study, with an average age of 26.53 years old. The average follow-up was 28.37 +/- 6.98 months. All the cases presented a significant improvement of the main curve and focal kyphosis from 85.62 +/- 19.80 degrees to 36.19 +/- 16.74 degrees and 53.98 +/- 26.80 degrees to 30.88 +/- 18.69 degrees, with a mean correction rate of 57.73% and 41.23%. The postoperative coronal and sagittal parameters were all significantly improved, except coronal balance. The mean operative time and blood loss were 267.86 +/- 54.49 minutes and 838.78 +/- 538.93 mL. All the clinical function scores of patients were significantly improved at the final follow-up. Only one patient had a complication related to surgical incision, with no neurologic complications occurring.
   CONCLUSIONS: he surgical procedure of multiple-level asymmetrical Ponte osteotomy is a safe and effective technique, with reduced operation time, blood loss, and complications, and may offer an appropriate option to address the problems of rigid adult idiopathic scoliosis.
C1 [Zhang, Yangpu; Hai, Yong; Tao, Luming; Yang, Jincai; Zhou, Lijin; Yin, Peng; Pan, Aixing; Zhang, Yaoshen; Liu, Chang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
RP Hai, Y (reprint author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
EM yong.hai@ccmu.edu.cn
RI Hai, Yong/L-6987-2019
OI Hai, Yong/0000-0002-7206-325X
CR Angevine PD, 2008, NEUROSURGERY, V63, pA86, DOI 10.1227/01.NEU.0000320427.28377.F7
   Chen ZQ, 2011, J ORTHOP SCI, V16, P133, DOI 10.1007/s00776-011-0034-6
   Cho KJ, 2005, SPINE, V30, P2030, DOI 10.1097/01.brs.0000179085.92998.ee
   Dorward IG, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09259
   Geck MJ, 2007, J SPINAL DISORD TECH, V20, P586, DOI 10.1097/BSD.0b013e31803d3b16
   Halanski MA, 2013, J SPINAL DISORD TECH, V26, P252, DOI 10.1097/BSD.0b013e318241e3cf
   Hasler CC, 2010, EUR SPINE J, V19, P732, DOI 10.1007/s00586-010-1320-2
   Lee SM, 2004, SPINE, V29, P343, DOI 10.1097/01.BRS.0000109991.88149.19
   Lehman RA, 2008, SPINE, V33, P1598, DOI 10.1097/BRS.0b013e318178872a
   Liu RW, 2010, SPINE, V35, P416, DOI 10.1097/BRS.0b013e3181b3564a
   Lonner BS, 2019, SPINE DEFORMITY, V7, P84
   Newton PO, 2010, SPINE, V35, P1365, DOI 10.1097/BRS.0b013e3181dccd63
   Pizones Javier, 2016, Spine Deform, V4, P439, DOI 10.1016/j.jspd.2016.05.004
   Ponte A, 2018, SPINE DEFORM, V6, P2
   Ponte A, 1984, PROGR SPINAL PATHOLO, P75
   Samdani Amer F, 2015, Spine Deform, V3, P483, DOI 10.1016/j.jspd.2015.03.002
   Sangiorgio Sophia N, 2013, Spine Deform, V1, P171, DOI 10.1016/j.jspd.2013.01.006
   Shah Suken A, 2013, Spine Deform, V1, P196, DOI 10.1016/j.jspd.2013.03.002
   Shufflebarger HL, 2004, SPINE, V29, P269, DOI 10.1097/01.BRS.0000109881.63411.48
   SMITHPETERSEN MN, 1945, J BONE JOINT SURG, V27, P1
   Sugar O., 1978, JAMA-J AM MED ASSOC, V240, P2776
   Suk S, 2002, SPINE, V27, P2374, DOI 10.1097/00007632-200211010-00012
   Sun XF, 2018, WORLD NEUROSURG, V119, pE174, DOI 10.1016/j.wneu.2018.07.086
   Verla T, 2016, WORLD NEUROSURG, V87, P591, DOI 10.1016/j.wneu.2015.10.061
   Wiemann J, 2011, J CHILD ORTHOP, V5, P109, DOI 10.1007/s11832-011-0327-5
   Zhu F, 2017, SPINE, V42, pE1133, DOI 10.1097/BRS.0000000000002106
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E467
EP E473
DI 10.1016/j.wneu.2019.03.173
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300057
PM 30922897
DA 2020-05-12
ER

PT J
AU Zhang, ZB
   Yang, K
   Xia, YR
   Meng, XH
   Yu, XG
AF Zhang, Zhibin
   Yang, Kai
   Xia, Yirong
   Meng, Xianghui
   Yu, Xinguang
TI High-Field Intraoperative Magnetic Resonance Imaging Increases Extent of
   Resection and Progression-Free Survival for Nonfunctioning Pituitary
   Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope; Extent of resection; Intraoperative MRI; Nonfunctioning
   pituitary adenoma; Progression-free survival
ID TRANSSPHENOIDAL SURGERY; TUMOR RESECTION; MACROADENOMAS; EXPERIENCE;
   MRI; IMPLEMENTATION; IMPROVE; SUITE
AB BACKGROUND: The effect of intraoperative magnetic resonance imaging (iMRI) on tumor control during endoscopic transsphenoidal surgery (TSS) for nonfunctioning pituitary adenomas (NFPAs) has not yet been completely characterized. The present study assessed the effect of the iMRI findings on gross total resection (GTR) and progression-free survival at a mean follow-up of 62 +/- 9.4 months.
   METHODS: Retrospective analyses were performed on the data from 133 consecutive patients with NFPA who had undergone endoscopic TSS with iMRI using a 1.5T scanner.
   RESULTS: Compared with the first and final iMRI scans, the GTR rate increased from 42.9% to 63.9%. Multivariate logistic regression analysis revealed that a lower GTR rate was associated with a higher Knosp score (odds ratio [OR], 3.612; 95% confidence interval [CI], 1.568-8.321; P = 0.003), an increased tumor volume (OR, 0.926; 95% CI, 0.866-0.991; P = 0.025), and a history of surgery (OR, 0.376; 95% CI, 0.155-0.917; P = 0.031). During follow-up, 8 tumors (9.4%) recurred, and 29 remnants (60.4%) regenerated. The recurrence and regeneration rates were 0.019 and 0.121 patient/year, respectively. Kaplan-Meier analysis revealed that the tumor recurrence rates were lower for patients who had undergone GTR (P < 0.01) compared with those who had not. Univariate Cox regression analysis suggested that the presence of tumor remnants (hazard ratio, 1.546; 95% CI, 1.071-2.232; P = 0.02) was the influencing factor associated with tumor progression.
   CONCLUSIONS: High-field iMRI can increase the GTR rate in endoscopic TSS for NPFAs. The increased GTR rate was associated with longer progression-free survival. Cavernous sinus invasion, tumor size, and surgical history were important predictors of GTR in patients with NFPA.
C1 [Zhang, Zhibin; Yu, Xinguang] Nankai Univ, Sch Medcine, Tianjin, Peoples R China.
   [Zhang, Zhibin; Xia, Yirong; Meng, Xianghui; Yu, Xinguang] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Yang, Kai] Dongying Peoples Hosp, Dept Neurosurg, Dongying, Shandong, Peoples R China.
RP Yu, XG (reprint author), Nankai Univ, Sch Medcine, Tianjin, Peoples R China.; Yu, XG (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM zhangjuren102@163.com
CR Baumann F, 2010, NEUROSURG REV, V33, P83, DOI 10.1007/s10143-009-0230-4
   Berkmann S, 2014, ACTA NEUROCHIR, V156, P2233, DOI 10.1007/s00701-014-2210-x
   Berkmann S, 2014, J NEUROSURG, V121, P1166, DOI 10.3171/2014.6.JNS131994
   Berkmann S, 2012, ACTA NEUROCHIR, V154, P639, DOI 10.1007/s00701-012-1285-5
   Black PM, 1997, NEUROSURGERY, V41, P831, DOI 10.1097/00006123-199710000-00013
   Bohinski RJ, 2001, NEUROSURGERY, V49, P1133
   Brochier S, 2010, EUR J ENDOCRINOL, V163, P193, DOI 10.1530/EJE-10-0255
   Chang EF, 2008, J NEUROSURG, V108, P736, DOI 10.3171/JNS/2008/108/4/0736
   Chen XL, 2012, NEUROSURG REV, V35, P95, DOI 10.1007/s10143-011-0336-3
   Chen Y, 2012, NEUROENDOCRINOLOGY, V96, P333, DOI 10.1159/000339823
   Coburger J, 2014, J NEUROSURG, V120, P346, DOI 10.3171/2013.9.JNS122207
   Colao A, 2008, ENDOCR-RELAT CANCER, V15, P905, DOI 10.1677/ERC-08-0181
   Dallapiazza RF, 2015, NEUROSURGERY, V76, P42, DOI 10.1227/NEU.0000000000000563
   De Witte O, 2005, NEUROCHIRURGIE, V51, P577, DOI 10.1016/S0028-3770(05)83632-X
   Famini P, 2011, J CLIN ENDOCR METAB, V96, P1633, DOI 10.1210/jc.2011-0168
   Ferrante E, 2006, EUR J ENDOCRINOL, V155, P823, DOI 10.1530/eje.1.02298
   Garcia S, 2017, WORLD NEUROSURG, V102, P102, DOI 10.1016/j.wneu.2017.02.094
   Gong J, 2007, J CLIN NEUROSCI, V14, P758, DOI 10.1016/j.jocn.2006.07.004
   Hwang JM, 2013, J KOREAN NEUROSURG S, V54, P317, DOI 10.3340/jkns.2013.54.4.317
   JANKOWSKI R, 1992, LARYNGOSCOPE, V102, P198, DOI 10.1288/00005537-199202000-00016
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Losa M, 2008, J NEUROSURG, V108, P525, DOI 10.3171/JNS/2008/108/3/0525
   Nimsky C, 2006, NEUROSURGERY, V59, P105, DOI 10.1227/01.NEU.0000219198.38423.1E
   Pal'a A, 2017, WORLD NEUROSURG, V102, P144, DOI 10.1016/j.wneu.2017.02.132
   Paterno' V, 2014, ACTA NEUROCHIR, V156, P463, DOI 10.1007/s00701-013-1978-4
   Qiu TM, 2012, CHINESE MED J-PEKING, V125, P4328, DOI 10.3760/cma.j.issn.0366-6999.2012.24.002
   Ramm-Pettersen J, 2011, ACTA NEUROCHIR, V153, P1367, DOI 10.1007/s00701-011-1004-7
   Roelfsema F, 2012, PITUITARY, V15, P71, DOI 10.1007/s11102-011-0347-7
   Serra C, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.12.FOCUS15564
   Shou XF, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0767-0
   Sylvester PT, 2015, PITUITARY, V18, P72, DOI 10.1007/s11102-014-0560-2
   Tabakow P, 2012, ADV CLIN EXP MED, V21, P495
   Theodosopoulos PV, 2010, J NEUROSURG, V112, P736, DOI 10.3171/2009.6.JNS08916
   Thorp BD, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14350
   Vargas G, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/756069
   Vitaz TW, 2011, CLIN NEUROL NEUROSUR, V113, P731, DOI 10.1016/j.clineuro.2011.07.025
   Wang FY, 2015, SURG ENDOSC, V29, P1270, DOI 10.1007/s00464-014-3815-0
   Woollons AC, 2000, CLIN ENDOCRINOL, V53, P713, DOI 10.1046/j.1365-2265.2000.01153.x
   Wu JS, 2009, NEUROSURGERY, V65, P63, DOI 10.1227/01.NEU.0000348549.26832.51
   Zada G, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10155
   Zaidi HA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15515
   Zhang HP, 2017, WORLD NEUROSURG, V104, P802, DOI 10.1016/j.wneu.2017.04.056
   Zhang ZB, 2019, TURK NEUROSURG, V29, P635, DOI 10.5137/1019-5149.JTN.22603-18.2
NR 43
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E925
EP E931
DI 10.1016/j.wneu.2019.04.001
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300115
PM 30974275
DA 2020-05-12
ER

PT J
AU Zhao, M
   Wang, XF
   Deng, JH
   Guan, YG
   Zhou, J
   Li, TF
   Luan, GM
AF Zhao, Meng
   Wang, Xiongfei
   Deng, Jiahui
   Guan, Yuguang
   Zhou, Jian
   Li, Tianfu
   Luan, Guoming
TI Globus Pallidus Internus Electric High-Frequency Stimulation Modulates
   Dopaminergic Activity in the Striatum of a Rat Model of Tourette
   Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Dopamine; Dopamine transporter; Tourette
   syndrome
ID DEEP BRAIN-STIMULATION
AB OBJECTIVE: The purpose of this study was to investigate the role of deep brain stimulation (DBS) of the globus pallidus internus (GPi) in dopamine and dopamine transporter metabolism and to explore the regulatory role of DBS on dopaminergic neurons in Tourette syndrome by constructing an autoimmune model.
   METHODS: Serum with high concentrations of antinuclear antibodies or phosphate-buffered saline solution was injected into the striatum of rats by a stereotactic technique and micropump. Then, electrodes were planted in the rats' globus pallidus internus. Concentrations of dopamine and dopamine transporter in the striatum were detected by enzyme-linked immunosorbent assay, immunohistochemistry, and Western blot analysis after 7 days of high-frequency stimulation (130 Hz).
   RESULTS: The tic behavior score of rats in the Tourette syndrome group was higher than that of rats in the control group (P< 0.01). After high-frequency stimulation, the scores of the Tourette syndrome model group and the control group significantly decreased. The concentration of dopamine in the Tourette syndrome model group and the control group also significantly decreased after electric stimulation (P< 0.05). In addition, immunohistochemical analysis and Western blot test results showed that dopamine transporter in the Tourette syndrome model nonstimulation group was lower than in the Tourette syndrome model stimulation group, and that dopamine transporter in the control nonstimulation group was lower than in the control stimulation group (P < 0.05).
   CONCLUSIONS: The results of this study show that the mechanism of DBS of the GPi in the treatment of Tourette syndrome involved monoamine neurotransmitters, especially the dopamine system, that affected the metabolism and transport of corresponding neurotransmitters, playing an important role in regulating the concentration of synaptic neurotransmitters and changing the biologic activity of basal ganglia nerve circuits.
C1 [Zhao, Meng; Wang, Xiongfei; Deng, Jiahui; Guan, Yuguang; Zhou, Jian; Luan, Guoming] Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Li, Tianfu] Capital Med Univ, Sanbo Brain Hosp, Dept Neurol, Beijing, Peoples R China.
   [Zhao, Meng; Wang, Xiongfei; Deng, Jiahui; Guan, Yuguang; Zhou, Jian; Li, Tianfu; Luan, Guoming] Beijing Key Lab Epilepsy, Beijing, Peoples R China.
   [Zhao, Meng; Wang, Xiongfei; Deng, Jiahui; Guan, Yuguang; Zhou, Jian; Li, Tianfu; Luan, Guoming] Beijing Inst Brain Disorders, Epilepsy Inst, Beijing, Peoples R China.
RP Luan, GM (reprint author), Capital Med Univ, Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.; Luan, GM (reprint author), Beijing Key Lab Epilepsy, Beijing, Peoples R China.; Luan, GM (reprint author), Beijing Inst Brain Disorders, Epilepsy Inst, Beijing, Peoples R China.
EM luangm3@163.com
FU National Natural Science Foundation of China ProjectNational Natural
   Science Foundation of China [81790654]; Beijing Postdoctoral Research
   FoundationChina Postdoctoral Science Foundation [2017-122-ZZ]
FX This research was supported by National Natural Science Foundation of
   China Project (81790654) and Beijing Postdoctoral Research Foundation
   (2017-122-ZZ).
CR Ackermans L, 2013, NEUROSURGERY, V80, pe15
   Akbarian-Tefaghi L, 2017, STEREOT FUNCT NEUROS, V95, P251, DOI 10.1159/000478273
   Albin RL, 2006, TRENDS NEUROSCI, V29, P175, DOI 10.1016/j.tins.2006.01.001
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   DICKSON PR, 1994, NEUROSCIENCE, V61, P81, DOI 10.1016/0306-4522(94)90062-0
   Jankovic J, 2011, MOVEMENT DISORD, V26, P1149, DOI 10.1002/mds.23618
   Kuhn J, 2012, BIOL PSYCHIAT, V71, pE11, DOI 10.1016/j.biopsych.2011.09.035
   Leckman JF, 2016, BIOL PSYCHIAT, V79, P343, DOI 10.1016/j.biopsych.2015.11.028
   Luigjes J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.03.009
   McCairn KW, 2013, J NEUROSCI, V33, P6581, DOI 10.1523/JNEUROSCI.4874-12.2013
   Muller-Vahl K, 2010, MOVEMENT DISORD, V25, P309, DOI 10.1002/mds.22900
   Servello D, 2011, ACTA NEUROCHIR, V153, P629, DOI 10.1007/s00701-010-0851-y
   SINGER HS, 1982, ANN NEUROL, V12, P361, DOI 10.1002/ana.410120408
   SINGER HS, 1991, ANN NEUROL, V30, P558, DOI 10.1002/ana.410300408
   Taylor JR, 2002, AM J PSYCHIAT, V159, P657, DOI 10.1176/appi.ajp.159.4.657
   Wong DF, 2008, NEUROPSYCHOPHARMACOL, V33, P1239, DOI 10.1038/sj.npp.1301528
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E881
EP E887
DI 10.1016/j.wneu.2019.03.290
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300109
PM 30959252
DA 2020-05-12
ER

PT J
AU Zhao, W
   Li, HX
   Hou, Y
   Jin, YC
   Zhang, LS
AF Zhao, Wei
   Li, Hongxing
   Hou, Yun
   Jin, Yinchuan
   Zhang, Lianshuang
TI Combined Administration of Poly-ADP-Ribose Polymerase-1 and Caspase-3
   Inhibitors Alleviates Neuronal Apoptosis After Spinal Cord Injury in
   Rats
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Apoptosis-inducing factor; Caspase-3; Poly-ADP-ribose
   polymerase-1; Spinal cord injury
ID CELL-DEATH; STEM-CELLS; ACTIVATION; MECHANISMS; DAMAGE; TRANSLOCATION;
   DEPLETION; ISCHEMIA
AB BACKGROUND: Neuronal apoptosis plays a pivotal role in spinal cord injury (SCI)-induced secondary cellular events. Caspase-dependent and -independent pathways are involved in neuronal apoptosis. Caspase-3 is the final effector of caspase-dependent apoptosis, whereas polyADP-ribose polymerase-1 (PARP-1) and apoptosis-inducing factor (AIF) are key executors of caspase-independent apoptosis. However, it remains unclear whether simultaneous inhibition of the 2 apoptosis pathways will be more beneficial for neuronal survival. Therefore, this study investigated the ability of coadministration of the PARP-1 inhibitor 3-aminobenzamide (3-AB) and caspase-3 inhibitor z-DEVD-fmk to attenuate apoptosis in a rat SCI model.
   METHODS: The rats were subjected to moderate contusive SCI. Locomotor function was measured using the Basso, Beattie, and Bresnahan rating scales; neuronal apoptosis was detected using transferase-mediated deoxyuridine triphosphate-biotin nick end labeling; and immunohistochemistry and Western blotting were used to measure protein expression.
   RESULTS: We found the locomotor function of rats was weakened within 7 days post-SCI. At day 7 post-SCI, neuronal apoptosis dramatically increased and the expression of PARP-1, AIF, and cleaved caspase-3 was significantly upregulated. Further, Bcl-2 expression was significantly downregulated. The highest locomotor function recovery was recorded after the combined administration of 3-AB and z-DEVD-fmk for 7 days post-SCI when compared with 3-AB or z-DEVD-fmk administered alone. In addition, this combination therapy significantly reduced neuronal apoptosis by preventing upregulation of PARP-1 and AIF, inhibiting caspase-3 activation, and elevating Bcl-2 expression.
   CONCLUSIONS: These results suggest that combination therapy is beneficial for neuronal function recovery in rats with SCI. The underlying mechanism may be associated with cosuppression of caspase-dependent and caspase-independent apoptosis pathways.
C1 [Zhao, Wei; Li, Hongxing; Hou, Yun; Jin, Yinchuan; Zhang, Lianshuang] Binzhou Med Univ, Dept Histol & Embryol, Yantai, Shandong, Peoples R China.
RP Zhang, LS (reprint author), Binzhou Med Univ, Dept Histol & Embryol, Yantai, Shandong, Peoples R China.
EM lshzh999@163.com
FU Key Research and Development Program of Shandong Province, China
   [2018GSF118129]; Science and Technology Development Plan of Chinese
   Medicine of Shandong Province, China [2017-234]
FX This work was supported by financial grants from the Key Research and
   Development Program of Shandong Province, China (2018GSF118129); and the
   Science and Technology Development Plan of Chinese Medicine of Shandong
   Province, China (2017-234).
CR Ahuja CS, 2017, NEUROSURGERY, V80, pS9, DOI 10.1093/neuros/nyw080
   Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010
   ALLEN AR, 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008
   Anilkumar U, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00281
   [Anonymous], 2016, J Spinal Cord Med, V39, P493, DOI 10.1080/10790268.2016.1210925
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Bayrakdar ET, 2014, CELL BIOCHEM FUNCT, V32, P557, DOI 10.1002/cbf.3049
   Beckham JD, 2010, J NEUROVIROL, V16, P306, DOI 10.3109/13550284.2010.499890
   Cieslik M, 2013, NEUROCHEM INT, V62, P626, DOI 10.1016/j.neuint.2013.02.016
   D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709
   Fan J, 2017, ADV NEUROBIOL, V15, P403, DOI 10.1007/978-3-319-57193-5_16
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416
   Hangen E, 2010, TRENDS BIOCHEM SCI, V35, P278, DOI 10.1016/j.tibs.2009.12.008
   Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833
   Maier C, 2007, INTENS CARE MED, V33, P845, DOI 10.1007/s00134-007-0585-3
   Nasrabady SE, 2011, CELL MOL NEUROBIOL, V31, P503, DOI 10.1007/s10571-011-9661-x
   Nicola FD, 2017, BRAIN RES, V1663, P95, DOI 10.1016/j.brainres.2017.03.015
   Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281
   Pacher P, 2008, AM J PATHOL, V173, P2, DOI 10.2353/ajpath.2008.080019
   Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576
   Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014
   Selvarajah S, 2015, JAMA-J AM MED ASSOC, V314, P1643, DOI 10.1001/jama.2015.11194
   Smart AD, 2017, P NATL ACAD SCI USA, V114, pE8174, DOI 10.1073/pnas.1705064114
   Sousa FG, 2012, CARCINOGENESIS, V33, P1433, DOI 10.1093/carcin/bgs132
   Srivastava SK, 2015, BRIT J CANCER, V113, P660, DOI 10.1038/bjc.2015.252
   Sweis R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0715-4
   Tallis M, 2014, CHROMOSOMA, V123, P79, DOI 10.1007/s00412-013-0442-9
   Uchiyama T, 2002, J MOL CELL CARDIOL, V34, P1049, DOI 10.1006/jmcc.2002.2045
   Wang SJ, 2013, BRAIN RES, V1535, P14, DOI 10.1016/j.brainres.2013.08.038
   Wang Y, 2014, NEUROSCIENCE, V266, P91, DOI 10.1016/j.neuroscience.2014.02.007
   Wang YF, 2016, SCIENCE, V354, DOI 10.1126/science.aad6872
   Wu KLH, 2009, J NEUROTRAUM, V26, P965, DOI 10.1089/neu.2008.0692
   Yi JH, 2016, BEHAV BRAIN RES, V308, P75, DOI 10.1016/j.bbr.2016.04.019
   Zhang YH, 2005, J CEREBR BLOOD F MET, V25, P868, DOI 10.1038/sj.jcbfm.9600081
   Zhao H, 2004, J CEREBR BLOOD F MET, V24, P681, DOI 10.1097/01.WCB.0000127161.89708.A5
NR 35
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E346
EP E352
DI 10.1016/j.wneu.2019.03.116
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300044
PM 30904799
DA 2020-05-12
ER

PT J
AU Zheng, WJ
   Li, LM
   Hu, ZH
   Liao, W
   Lin, QC
   Zhu, YH
   Lin, SH
AF Zheng, Wen-Jian
   Li, Liang-Ming
   Hu, Zi-Hui
   Liao, Wei
   Lin, Qi-Chang
   Zhu, Yong-Hua
   Lin, Shao-Hua
TI Complications in Staged Late Titanium Cranioplasty and
   Ventriculoperitoneal Shunting for Patients with Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral hemorrhage; Cranioplasty; Extradural collection; Sunken skin
   flap; Ventriculoperitoneal shunt
ID DECOMPRESSIVE CRANIECTOMY; HYDROCEPHALUS; PREDICTION; INFECTION;
   COLLAPSE; OUTCOMES; RISK
AB BACKGROUND: Hydrocephalus is a common complication following decompressive craniectomy. Ventriculoperitoneal shunt (VPS) is required for some patients before receiving a cranioplasty (CP). The presence of a VPS is regarded as a risk factor for overall CP complications.
   METHODS: A retrospective survey was conducted on 176 patients with traumatic brain injury who underwent late (>3 months) titanium CP (Ti-CP) in our hospital from April 2014 to July 2018. Thirteen patients (7.4%) had preoperative VPS. Propensity score matching was performed for these 13 patients with a ratio of 1:5. A total of 78 patients were selected. Preoperative clinical parameters and postoperative complications were analyzed. The period of postoperative follow-up ranged from 3 to 63 months (mean 21.3 +/- 17.0 months).
   RESULTS: The overall complication rate was greater in the VPS group (P = 0.010). These patients were more likely to develop a sunken skin flap (P < 0.001). The rate of postoperative cerebral hemorrhage was greater in the VPS group. Logistic analysis showed that preoperative VPS was an independent risk factor for postoperative extradural collection (odds ratio 17.714, P < 0.001). VPS was not related to postoperative infection and seizure. Post-operative drainage duration longer than 2.5 days significantly increased the risk of postoperative infection (odds ratio 7.715, P = 0.023).
   CONCLUSIONS: The presence of a VPS significantly increased the risk of extradural collection in patients with traumatic brain injury who underwent late Ti-CP. It also was related to postoperative hemorrhage. The sunken skin flap in patients with VPS increased surgical difficulty and the likelihood of extradural accumulation. Preoperative VPS was not related to postoperative infection and seizure in Ti-CP.
C1 [Zheng, Wen-Jian; Li, Liang-Ming; Hu, Zi-Hui; Liao, Wei; Lin, Qi-Chang; Zhu, Yong-Hua; Lin, Shao-Hua] Zhongshan City Peoples Hosp, Dept Neurosurg, Zhongshan, Guangdong, Peoples R China.
RP Zheng, WJ (reprint author), Zhongshan City Peoples Hosp, Dept Neurosurg, Zhongshan, Guangdong, Peoples R China.
EM 297229614@qq.com
RI zheng, wenjian/W-2471-2019
OI zheng, wenjian/0000-0001-5490-3852
CR Al-Jishi A, 2011, CAN J NEUROL SCI, V38, P612, DOI 10.1017/S0317167100012154
   Centers for Disease Control and Prevention, 2017, NAT HEALTHC SAF NETW
   Gordon CR, 2014, OPER NEUROSURG, V10, P179, DOI 10.1227/NEU.0000000000000296
   Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839
   Honeybul S, 2018, ACTA NEUROCHIR, V160, P885, DOI 10.1007/s00701-018-3514-z
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Honeybul S, 2014, INJURY, V45, P1332, DOI 10.1016/j.injury.2014.03.007
   Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65
   Jeong Se Ho, 2016, Korean J Neurotrauma, V12, P6, DOI 10.13004/kjnt.2016.12.1.6
   Jung Young Taek, 2015, Korean J Neurotrauma, V11, P93, DOI 10.13004/kjnt.2015.11.2.93
   Kim SP, 2014, J KOREAN NEUROSURG S, V56, P410, DOI 10.3340/jkns.2014.56.5.410
   Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7
   Lai CH, 2016, J DIABETES COMPLICAT, V30, P426, DOI 10.1016/j.jdiacomp.2015.12.026
   Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359
   Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313
   Malcolm JG, 2016, J CLIN NEUROSCI, V33, P39, DOI 10.1016/j.jocn.2016.04.017
   Morton RP, 2018, J NEUROSURG, V128, P1648, DOI 10.3171/2016.11.JNS161917
   Mustroph CM, 2017, WORLD NEUROSURG, V103, P686, DOI 10.1016/j.wneu.2017.04.066
   Randolph J. J., 2014, PRACT ASSESS RES EVA, V19, P18
   Roth J, 2011, NEUROSURGERY, V68, pE271, DOI 10.1227/NEU.0b013e3181fe6165
   Shibahashi K, 2017, WORLD NEUROSURG, V101, P20, DOI 10.1016/j.wneu.2017.01.106
   Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026
   Wang HF, 2017, J CRANIOFAC SURG, V28, pE560, DOI 10.1097/SCS.0000000000003863
   Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3
   Yang NR, 2018, WORLD NEUROSURG, V110, pE160, DOI 10.1016/j.wneu.2017.10.117
   Yoshioka N, 2018, WORLD NEUROSURG, V119, P311, DOI 10.1016/j.wneu.2018.08.076
   Zanaty M, 2015, J NEUROSURG, V123, P182, DOI 10.3171/2014.9.JNS14405
   Zheng WJ, 2018, WORLD NEUROSURG, V120, pE811, DOI 10.1016/j.wneu.2018.08.172
   Zhu HF, 2018, WORLD NEUROSURG, V113, P198, DOI 10.1016/j.wneu.2018.02.080
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E1166
EP E1171
DI 10.1016/j.wneu.2019.04.079
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300145
PM 30995562
DA 2020-05-12
ER

PT J
AU Zhu, Q
   Qian, K
   Jia, GJ
   Lv, G
   Wang, JS
   Zhong, LY
   Yu, SQ
AF Zhu, Qiang
   Qian, Ke
   Jia, Guijun
   Lv, Gang
   Wang, Jisheng
   Zhong, Liyong
   Yu, Shuqing
TI Clinical Features, Magnetic Resonance Imaging, and Treatment Experience
   of 20 Patients with Lymphocytic Hypophysitis in a Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diabetes insipidus; Lymphocytic hypophysitis; Stalk thickening; Steroid
   pulse therapy
ID AUTOIMMUNE HYPOPHYSITIS; GLUCOCORTICOIDS; AZATHIOPRINE; MANAGEMENT
AB OBJECTIVE: Lymphocytic hypophysitis (LYH) is a rare autoimmune inflammatory disease of the pituitary gland. In this study, we aim to characterize LYH at presentation and focus on the management and prognosis of LYH.
   METHODS: A retrospective study of patients with LYH was conducted between 2011 and 2018 at a single institute. The patients were included by pathologic conformation and strict exclusion criteria. Clinical profile, imaging, and management data were collected.
   RESULTS: Twenty patients with LYH (16 women and 4 men) were included. Ten patients were diagnosed histologically and the remaining 10 patients were confirmed clinically of exclusion criteria. The median age at diagnosis was 37 years (range, 16-58 years). Presenting symptoms were followed by polyuria/polydipsia (11, 55%), vision changes (10, 50%), headache (8, 40%), menstrual irregularities and amenorrhea (4, 20%), diplopia (1, 5%), or sexual dysfunction (1, 5%). Eight patients had partial anterior pituitary hormone dysfunction. The thyroidstimulating hormone axis was most involved. Ten patients received transsphenoidal surgery, 5 patients experienced steroid pulse therapy, and observation was performed on 5 patients. Only 5 patients (25%) showed improvement of anterior pituitary dysfunction after initial management. Recovery of diabetes insipidus occurred in 2 patients (18%). The overall recurrence rate was 22.2%.
   CONCLUSIONS: Nonoperative treatment is a better option for most patients with LYH because it is effective and noninvasive. Surgery is recommended for definitive diagnosis, severe or rapid progression of neurologic impairment, and glucocorticoid insensitivity. Periodic follow-up is mandatory in a patient's long-term management.
C1 [Zhu, Qiang; Qian, Ke; Jia, Guijun; Lv, Gang; Wang, Jisheng; Yu, Shuqing] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhong, Liyong] Capital Med Univ, Beijing Tiantan Hosp, Dept Endocrinol, Beijing, Peoples R China.
RP Yu, SQ (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM yushuqingttyy@163.com
OI zhu, qiang/0000-0002-8253-1811
CR Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011
   Caturegli P, 2008, AUTOIMMUN REV, V7, P631, DOI 10.1016/j.autrev.2008.04.016
   Chiloiro S, 2018, EUR J ENDOCRINOL, V178, pL1, DOI 10.1530/EJE-17-0910
   De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007
   GOUDIE RB, 1962, J PATHOL BACTERIOL, V83, P584, DOI 10.1002/path.1700830241
   Gutenberg A, 2009, AM J NEURORADIOL, V30, P1766, DOI 10.3174/ajnr.A1714
   Gutenberg A, 2006, EUR J ENDOCRINOL, V155, P101, DOI 10.1530/eje.1.02183
   Higham CE, 2016, LANCET, V388, P2403, DOI 10.1016/S0140-6736(16)30053-8
   Honegger J, 1997, NEUROSURGERY, V40, P713, DOI 10.1097/00006123-199704000-00010
   Honegger J, 2015, J CLIN ENDOCR METAB, V100, P3841, DOI 10.1210/jc.2015-2152
   Honegger J, 2015, J CLIN ENDOCR METAB, V100, P3460, DOI 10.1210/jc.2015-2146
   Howlett TA, 2010, CLIN ENDOCRINOL, V73, P18, DOI 10.1111/j.1365-2265.2009.03765.x
   Imber BS, 2015, PITUITARY, V18, P630, DOI 10.1007/s11102-014-0622-5
   Khare S, 2015, PITUITARY, V18, P16, DOI 10.1007/s11102-013-0550-9
   Kyriacou A, 2017, PITUITARY, V20, P241, DOI 10.1007/s11102-016-0769-3
   Leung GKK, 2004, J NEUROSURG, V101, P262, DOI 10.3171/jns.2004.101.2.0262
   Papanastasiou L, 2011, PITUITARY, V14, P16, DOI 10.1007/s11102-010-0252-5
   Park SM, 2014, ENDOCRINOL METAB, V29, P470, DOI 10.3803/EnM.2014.29.4.470
   Perez-Nunez A, 2005, ACTA NEUROCHIR, V147, P1297, DOI 10.1007/s00701-005-0641-0
   Wang SC, 2017, CLIN ENDOCRINOL, V87, P177, DOI 10.1111/cen.13354
   Yang GQ, 2011, ENDOCR J, V58, P675, DOI 10.1507/endocrj.K10E-334
NR 21
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD JUL
PY 2019
VL 127
BP E22
EP E29
DI 10.1016/j.wneu.2019.01.250
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IF5NH
UT WOS:000473128300005
PM 30790734
DA 2020-05-12
ER

PT J
AU Ndlela, LL
   Oberholster, PJ
   Van Wyk, JH
   Cheng, PH
AF Ndlela, L. L.
   Oberholster, P. J.
   Van Wyk, J. H.
   Cheng, P. H.
TI A laboratory based exposure of Microcystis and Oscillatoria
   cyanobacterial isolates to heterotrophic bacteria
SO TOXICON
LA English
DT Article
DE Biological control; Microcystis; Oscillatoria; Cyanotoxin reduction;
   Pseudomonas rhodesiae; Bacillus sp
ID BIOLOGICAL-CONTROL; TOXIC CYANOBACTERIUM; ALGICIDAL BACTERIA;
   CROSS-REACTIVITY; CHLOROPHYLL-A; TWEEN 80; BIODEGRADATION; DEGRADATION;
   RR; POPULATIONS
AB Biological control of cyanobacteria is a viable means of controlling nuisance bloom occurrences; however the majority of studies done are against Microcystis sp., with a commonly lytic effect caused. Filamentous cyanobacteria such as Oscillatoria are not as extensively studied in this area of biological control and are often part of Microcystis dominated blooms. This study employed heterotrophic bacteria] isolates selected from bloom waters that indicated potential predatory behaviour against both filamentous and colonial cyanobacterial isolates. In comparison to a known Bacillus isolate, which is often reported among bacterial control agents, three other bacteria isolates were tested as control agents against non-axenic Oscillatoria and Microcystis cyanobacterial cultures. Assessments of cyanobacterial cell responses to the bacteria were conducted through water chemistry, chlorophyll a, alkaline phosphatase activity, microscopy and cyanotoxin measurements. The changes in these parameters were compared to untreated cyanobacterial cultures where no bacteria were added. The study found that at ratios of bacteria half that of Microcystis, minimal changes in chlorophyll a were observed, whilst Oscillatoria showed a decreased chlorophyll a more in the presence of isolates 1 and 3w. The assessment of alkaline phosphatase activity showed decreased activity in both cyanobacterial isolates exposed to the bacteria, relative to the untreated control sample. Microscopy analysis through fluorescence indicated that the attachment of the bacteria to the surface of the cyanobacteria hampered with the fluorescence and scanning electron microscopy indicated that the cells were damaged by the addition of the bacterial isolates. Cyanotoxin detection through the ELISA kit testing indicated that there was toxin reduction in samples treated with the bacterial isolates, with the highest reduction being close to 60% in the case of Microcystis sp. treated with isolate 3w. Similar reductions were noted in the filamentous cyanobacterium Oscillatoria, in the presence of isolate 1.
C1 [Ndlela, L. L.; Oberholster, P. J.; Cheng, P. H.] CSIR, 11 Jan Celliers Rd, ZA-7600 Stellenbosch, South Africa.
   [Ndlela, L. L.; Oberholster, P. J.; Van Wyk, J. H.] Stellenbosch Univ, Dept Bot & Zool, Fac Sci, ZA-7600 Matieland, South Africa.
RP Ndlela, LL (reprint author), CSIR, 11 Jan Celliers Rd, ZA-7600 Stellenbosch, South Africa.
EM LNdlela@csir.co.za
OI Ndlela, Luyanda/0000-0002-3233-1942; van Wyk, JH/0000-0002-3500-4496
CR Alamri SA, 2012, SAUDI J BIOL SCI, V19, P435, DOI 10.1016/j.sjbs.2012.06.006
   Antunes JT, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00473
   Beaz-Hidalgo R, 2015, SYST APPL MICROBIOL, V38, P161, DOI 10.1016/j.syapm.2015.02.005
   Berry C, 2012, J INVERTEBR PATHOL, V109, P1, DOI 10.1016/j.jip.2011.11.008
   BoekeMa BKHL, 2007, APPL ENVIRON MICROB, V73, P3838, DOI 10.1128/AEM.00097-07
   Boyer JN, 2009, ECOL INDIC, V9, pS56, DOI 10.1016/j.ecolind.2008.11.013
   Campinas M, 2010, SEP PURIF TECHNOL, V70, P345, DOI 10.1016/j.seppur.2009.10.021
   Chen J, 2010, INT J MOL SCI, V11, P896, DOI 10.3390/ijms11030896
   Crater JS, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny138
   Demeke A., 2016, INT J FAUNA BOIL STU, V3, P32
   Flaherty KW, 2007, LAKE RESERV MANAGE, V23, P255, DOI 10.1080/07438140709354014
   FRALEIGH PC, 1988, LIMNOL OCEANOGR, V33, P476, DOI 10.4319/lo.1988.33.3.0476
   Gumbo JR, 2014, PHYS CHEM EARTH, V72-75, P24, DOI 10.1016/j.pce.2014.09.004
   Gumbo JR, 2011, PHYS CHEM EARTH, V36, P881, DOI 10.1016/j.pce.2011.07.050
   Gumbo JR, 2010, AFR J BIOTECHNOL, V9, P663
   Guo HJ, 2010, BIORESOURCE TECHNOL, V101, P8599, DOI 10.1016/j.biortech.2010.06.085
   Harke MJ, 2016, HARMFUL ALGAE, V54, P4, DOI 10.1016/j.hal.2015.12.007
   He XX, 2017, WATER RES, V126, P515, DOI 10.1016/j.watres.2017.09.037
   Ho LN, 2007, TOXICON, V50, P438, DOI 10.1016/j.toxicon.2007.03.021
   Holland A, 2013, MAR DRUGS, V11, P2239, DOI 10.3390/md11072239
   Hotto AM, 2007, APPL ENVIRON MICROB, V73, P4570, DOI 10.1128/AEM.00318-07
   JACQUES NA, 1980, J GEN MICROBIOL, V119, P195
   Janda JM, 2010, CLIN MICROBIOL REV, V23, P35, DOI 10.1128/CMR.00039-09
   Kahng HY, 2002, APPL MICROBIOL BIOT, V60, P475, DOI 10.1007/s00253-002-1137-y
   Kamande GM, 2000, J DAIRY SCI, V83, P536, DOI 10.3168/jds.S0022-0302(00)74913-7
   Kansole MMR, 2016, WATER-SUI, V8, DOI 10.3390/w8110508
   Kim BH, 2008, LIMNOL OCEANOGR-METH, V6, P513, DOI 10.4319/lom.2008.6.513
   Kohl J, 2011, BIOL CONTROL, V57, P1, DOI 10.1016/j.biocontrol.2010.12.004
   Korsten L, 2004, S AFR J BOT, V70, P128, DOI 10.1016/S0254-6299(15)30273-8
   Kotut K, 2010, LIMNOLOGICA, V40, P47, DOI 10.1016/j.limno.2009.01.003
   Lemes GAF, 2015, J VENOM ANIM TOXINS, V21, DOI 10.1186/s40409-015-0001-3
   Lenneman EM, 2014, FEMS MICROBIOL LETT, V354, P102, DOI 10.1111/1574-6968.12436
   Maruyama T, 2003, MICROBIAL ECOL, V46, P279, DOI 10.1007/s00248-002-3007-7
   Mayali X, 2004, J EUKARYOT MICROBIOL, V51, P139, DOI 10.1111/j.1550-7408.2004.tb00538.x
   McLeod C, 2017, ENERGY RES SOC SCI, V30, P35, DOI 10.1016/j.erss.2017.06.017
   Mowe M. A. D, 2014, J LIMNOL, V74, DOI [10.4081/jlimno1.2014.1005, DOI 10.4081/JLIMNO1.2014.1005]
   Ndlela LL, 2018, APPL MICROBIOL BIOT, V102, P9911, DOI 10.1007/s00253-018-9391-9
   Oberholster PJ, 2009, ECOTOX ENVIRON SAFE, V72, P1177, DOI 10.1016/j.ecoenv.2008.12.014
   Paerl HW, 2016, HARMFUL ALGAE, V54, P213, DOI 10.1016/j.hal.2015.09.009
   Paerl HW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113123
   PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0
   Preece EP, 2017, HARMFUL ALGAE, V61, P31, DOI 10.1016/j.hal.2016.11.006
   Qian SS, 2015, ENVIRON SCI TECHNOL, V49, P14221, DOI 10.1021/acs.est.5b03029
   Rahimnejad M, 2015, ALEX ENG J, V54, P745, DOI 10.1016/j.aej.2015.03.031
   Ren HQ, 2010, WORLD J MICROB BIOT, V26, P465, DOI 10.1007/s11274-009-0192-2
   Sakthipriya N, 2015, PROCEDIA ENGINEER, V116, P213, DOI 10.1016/j.proeng.2015.08.284
   Samdal IA, 2014, ENVIRON SCI TECHNOL, V48, P8035, DOI 10.1021/es5012675
   Schmidt JR, 2014, TOXINS, V6, P3354, DOI 10.3390/toxins6123354
   Sengco MR, 2009, HARMFUL ALGAE, V8, P623, DOI 10.1016/j.hal.2008.11.005
   Sigee DC, 1999, HYDROBIOLOGIA, V395, P161, DOI 10.1023/A:1017097502124
   Sitoki L, 2012, HYDROBIOLOGIA, V691, P109, DOI 10.1007/s10750-012-1062-8
   Su JF, 2016, CHEM ENG J, V293, P139, DOI 10.1016/j.cej.2016.02.044
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tian B, 2007, FEMS MICROBIOL ECOL, V61, P197, DOI 10.1111/j.1574-6941.2007.00349.x
   Van Wichelen J, 2016, HARMFUL ALGAE, V55, P97, DOI 10.1016/j.hal.2016.02.009
   Verschuere L, 2000, MICROBIOL MOL BIOL R, V64, P655, DOI 10.1128/MMBR.64.4.655-671.2000
   Wang J, 2006, B ENVIRON CONTAM TOX, V76, P999, DOI 10.1007/s00128-006-1017-8
   Wang L, 2017, SAUDI J BIOL SCI, V24, P556, DOI 10.1016/j.sjbs.2017.01.026
   WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991
   Wu LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101837
   Zhang BH, 2016, APPL ENVIRON MICROB, V82, P5132, DOI 10.1128/AEM.01198-16
   Zhang ML, 2010, J ENVIRON SCI, V22, P168, DOI 10.1016/S1001-0742(09)60089-9
   Zhu L, 2014, APPL ENVIRON MICROB, V80, P1874, DOI 10.1128/AEM.02972-13
NR 63
TC 0
Z9 0
U1 9
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 1
EP 12
DI 10.1016/j.toxicon.2019.04.002
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700001
PM 31004611
DA 2020-05-12
ER

PT J
AU Del Fabbro, L
   Jesse, CR
   de Gomes, MG
   Borges, C
   Donato, F
   Souza, LC
   Goes, AR
   Furian, AF
   Boeira, SP
AF Del Fabbro, Lucian
   Jesse, Cristiano Ricardo
   de Gomes, Marcelo Gomes
   Borges Filho, Carlos
   Donato, Franciele
   Souza, Leandro Cattelan
   Goes, Andre Rossito
   Furian, Ana Flavia
   Boeira, Silvana Peterini
TI The flavonoid chrysin protects against zearalenone induced reproductive
   toxicity in male mice
SO TOXICON
LA English
DT Article
DE Mycotoxin; Glutathione; Apoptosis; Inflammation; Spermatozoa
ID OXIDATIVE STRESS; ANTIOXIDANT ACTIVITY; IN-VITRO; GLUTATHIONE;
   MYCOTOXINS; EXPRESSION; RATS; QUANTITATION; ATTENUATION; REACTIVITY
AB The mycotoxin zearalenone (ZEA) has strong estrogenic effects and elicits reproductive toxicity. Chrysin is a natural flavonoid found in many plant and has a broad range of pharmacological activities, including anticancer, antioxidant and anti-inflammatory. The present study aimed to investigate the potential protective effects of chrysin against ZEA toxicity. Mice received chrysin (5 or 20 mg/kg; i.g.) for ten days, and then received a single injection of ZEA (40 mg/kg). Two days thereafter, blood and testes were collected. ZEA decreased number and motility of sperm, plasma testosterone levels, enzymatic (glutathione peroxidase, glutathione reductase, glutathione-S-transferase) and non-enzimatic defenses (reduced glutathione). Moreover, ZEA increased 4-hydroxynonenal and 8-hydroxy-2'-deoxyguanosine levels, myeloperoxidase activity and levels of proinflammatory cytokines (interleukins-1 beta and 6, tumor necrosis factor alpha). ZEA also decreased levels of anti-inflammatory cytokine interleukin-10 and increased activity of caspases 3 and 9. Chrysin treatment increased the number and motility of sperm, testosterone levels, restored antioxidant defenses and reduced the inflammation and apoptosis process. In summary, chrysin attenuated the toxic effects caused by ZEA in blood and testes of mice, suggesting a potential preventive treatment against the deleterious effects of ZEA.
C1 [Del Fabbro, Lucian; Jesse, Cristiano Ricardo; de Gomes, Marcelo Gomes; Borges Filho, Carlos; Donato, Franciele; Souza, Leandro Cattelan; Goes, Andre Rossito; Boeira, Silvana Peterini] Univ Fed Pampa, Lab Avaliacoes Farmacol & Toxicol Aplicadas Mol, Campus Itaqui, BR-97650000 Itaqui, RS, Brazil.
   [Furian, Ana Flavia] Univ Fed Santa Maria, Lab Farmacol Micotoxinas & Toxicol Lafarmt, BR-97105900 Santa Maria, RS, Brazil.
RP Furian, AF (reprint author), Univ Fed Santa Maria, Dept Tecnol & Ciencia Alimentos, Predio 43,Sala 4217, BR-97105900 Santa Maria, RS, Brazil.
EM ana.furian@ufsm.br
RI Del Fabbro, Lucian/AAD-6683-2020; de Gomes, Marcelo Gomes/AAA-2432-2019
OI de Gomes, Marcelo Gomes/0000-0001-9017-5979; Del Fabbro,
   Lucian/0000-0003-3613-4134
FU Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS)Foundation
   for Research Support of the State of Rio Grande do Sul (FAPERGS)
   [16/2551-0000526-5, 16/2251-0000183-9]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)CAPES [001]
FX This work was supported by Fundacao de Amparo a Pesquisa do Rio Grande
   do Sul (FAPERGS) [#16/2551-0000526-5] (PRONUPEQ) and
   [#16/2251-0000183-9] (ARD/PPP) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). This study was financed in part by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) - Finance Code 001".
CR Aebi H, 1984, METHOD ENZYMOL, V6, P105, DOI DOI 10.1016/S0076-6879(84)05016-3
   Aitken RJ, 2001, REPRODUCTION, V122, P497, DOI 10.1530/rep.0.1220497
   Anand KV, 2012, GERIATR GERONTOL INT, V12, P741, DOI 10.1111/j.1447-0594.2012.00843.x
   Assuncao R, 2018, FOOD CHEM TOXICOL, V118, P399, DOI 10.1016/j.fct.2018.05.040
   Banerjee A, 2005, FOOD CHEM, V90, P727, DOI 10.1016/j.foodchem.2004.04.033
   Boeira SP, 2015, CHEM-BIOL INTERACT, V230, P50, DOI 10.1016/j.cbi.2015.02.003
   Boeira SP, 2014, EXP TOXICOL PATHOL, V66, P179, DOI 10.1016/j.etp.2014.01.002
   Boeira SP, 2012, TOXICON, V60, P358, DOI 10.1016/j.toxicon.2012.04.353
   Borges C, 2016, CHEM-BIOL INTERACT, V260, P154, DOI 10.1016/j.cbi.2016.11.005
   Borges Filho C, 2016, EUR J PHARMACOL, V791, P284, DOI 10.1016/j.ejphar.2016.09.005
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CARLBERG I, 1975, J BIOL CHEM, V250, P5475
   Choi BK, 2012, TOX RESEARCH, V28, P279, DOI 10.5487/TR.2012.28.4.279
   Ciftci O, 2012, ANDROLOGIA, V44, P181, DOI 10.1111/j.1439-0272.2010.01127.x
   Ciftci O, 2010, IMMUNOPHARM IMMUNOT, V32, P99, DOI 10.3109/08923970903164318
   Dhawan Kamaldeep, 2002, Journal of Medicinal Food, V5, P43
   di Menna ME, 1997, MYCOPATHOLOGIA, V139, P165, DOI 10.1023/A:1006863908275
   Eldutar E, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21960
   Filho CB, 2015, NEUROSCIENCE, V289, P367, DOI 10.1016/j.neuroscience.2014.12.048
   Fleck Stefanie C, 2012, Mycotoxin Res, V28, P267, DOI 10.1007/s12550-012-0143-x
   Fraeyman S, 2017, TOXINS, V9, DOI 10.3390/toxins9070228
   FREUND M, 1964, J REPROD FERTIL, V8, P149
   Gao X, 2018, J NUTR, V148, P1209, DOI 10.1093/jn/nxy114
   Goes ATR, 2018, CHEM-BIOL INTERACT, V279, P111, DOI 10.1016/j.cbi.2017.10.019
   GROSS VJ, 1975, ANN APPL BIOL, V80, P211, DOI 10.1111/j.1744-7348.1975.tb01624.x
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Hadjmohammadi MR, 2010, J SEP SCI, V33, P3144, DOI 10.1002/jssc.201000326
   Hayes R, 1996, J ANDROL, V17, P41
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Hougee S, 2005, BIOCHEM PHARMACOL, V69, P241, DOI 10.1016/j.bcp.2004.10.002
   Jana K, 2008, J ENDOCRINOL, V197, P315, DOI 10.1677/JOE-07-0282
   Kalogeropoulos N, 2013, FOOD CHEM TOXICOL, V55, P378, DOI 10.1016/j.fct.2013.01.010
   Koppen R, 2012, J AGR FOOD CHEM, V60, P11733, DOI 10.1021/jf3037775
   Lauren DR, 1997, FOOD ADDIT CONTAM, V14, P435, DOI 10.1080/02652039709374549
   Lee HJ, 2017, J AGR FOOD CHEM, V65, P7034, DOI 10.1021/acs.jafc.6b04847
   LISSI E, 1995, FREE RADICAL BIO MED, V18, P153, DOI 10.1016/0891-5849(94)00117-3
   Marin DE, 2013, FOOD CHEM TOXICOL, V58, P408, DOI 10.1016/j.fct.2013.05.033
   Marin DE, 2012, TOXIN REV, V31, P32, DOI 10.3109/15569543.2012.730092
   Mate G, 2014, TOXICON, V90, P155, DOI 10.1016/j.toxicon.2014.08.005
   Meinhardt U, 2002, SEMIN REPROD MED, V20, P277, DOI 10.1055/s-2002-35374
   Mike N, 2013, TOXICON, V73, P130, DOI 10.1016/j.toxicon.2013.07.015
   MISRA HP, 1972, J BIOL CHEM, V247, P3170
   MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4
   Nabavi SF, 2015, NEUROCHEM INT, V90, P224, DOI 10.1016/j.neuint.2015.09.006
   Pfeiffer E, 2010, J AGR FOOD CHEM, V58, P12055, DOI 10.1021/jf1022498
   Pichichero E, 2010, INT J ONCOL, V37, P973, DOI 10.3892/ijo_00000748
   Pittet A, 1998, REV MED VET-TOULOUSE, V149, P479
   Pushpavalli G, 2010, FOOD CHEM TOXICOL, V48, P1654, DOI 10.1016/j.fct.2010.03.040
   Rani N, 2016, CHEM-BIOL INTERACT, V250, P59, DOI 10.1016/j.cbi.2016.03.015
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Sathiavelu J, 2009, J PHARM PHARMACOL, V61, P809, DOI [10.1211/jpp/61.06.0015, 10.1211/jpp.61.06.0015]
   Souza LC, 2015, PHARMACOL BIOCHEM BE, V134, P22, DOI 10.1016/j.pbb.2015.04.010
   Speaker KJ, 2014, BRAIN BEHAV IMMUN, V39, P87, DOI 10.1016/j.bbi.2013.10.028
   TOREL J, 1986, PHYTOCHEMISTRY, V25, P383, DOI 10.1016/S0031-9422(00)85485-0
   Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004
   Venkataramana M, 2014, FOOD CHEM TOXICOL, V65, P335, DOI 10.1016/j.fct.2013.12.042
   VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x
   Wang DF, 2010, ANIM REPROD SCI, V122, P317, DOI 10.1016/j.anireprosci.2010.10.002
   Wang HW, 2014, FOOD CHEM TOXICOL, V71, P217, DOI 10.1016/j.fct.2014.05.032
   Wang XD, 2007, DRUG METAB DISPOS, V35, P268, DOI 10.1124/dmd.106.011684
   Wang YJ, 2014, TOXICOL LETT, V226, P182, DOI 10.1016/j.toxlet.2014.02.003
   Wendel A, 1981, Methods Enzymol, V77, P325
   Zatecka E, 2014, REPROD TOXICOL, V45, P20, DOI 10.1016/j.reprotox.2014.01.003
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
NR 64
TC 2
Z9 2
U1 6
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 13
EP 21
DI 10.1016/j.toxicon.2019.04.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700002
PM 31004610
DA 2020-05-12
ER

PT J
AU Suntravat, M
   Cromer, WE
   Marquez, J
   Galan, JA
   Zawieja, DC
   Davies, P
   Salazar, E
   Sanchez, EE
AF Suntravat, Montamas
   Cromer, Walter E.
   Marquez, Jessenia
   Galan, Jacob A.
   Zawieja, David C.
   Davies, Peter
   Salazar, Emelyn
   Sanchez, Elda E.
TI The isolation and characterization of a new snake venom cysteine-rich
   secretory protein (svCRiSP) from the venom of the Southern Pacific
   rattlesnake and its effect on vascular permeability
SO TOXICON
LA English
DT Article
DE Snake venom; Southern pacific rattlesnake; Snake venom cysteine-rich
   secretory protein (svCRiSP); Vascular permeability; Vasculature;
   Lymphatic cells
ID ANTI-ANGIOGENIC ACTIVITIES; CYTOSKELETON; NEUTROPHILS; HISTAMINE;
   TARGETS; CLONING; NATRIN; CANCER
AB A novel snake venom cysteine-rich secretory protein (svCRiSP), Hellerin, was purified from C. o. helleri venom using sequential reverse phase and cation-exchange chromatography. Gel electrophoresis, N-terminal sequencing, and LC-MS/MS sequencing identified a single protein with a molecular mass of approximately 24.8 kDa and confirmed its identity as a svCRiSP. Hellerin had cytotoxic effects on human umbilical vein endothelial cells (HUVECs) in a dose-dependent manner but not in human dermal lymphatic endothelial cells (HDLECs) and human dermal blood endothelial cells (HDBECs). Hellerin produced a dramatic increase in both blood vascular permeability in vivo, and in the trans-epithelial permeability of cultured HDLEC and HDBEC cells. This is the first study that describes the effect of a svCRiSP on vascular, blood and lymphatic permeability.
C1 [Suntravat, Montamas; Marquez, Jessenia; Galan, Jacob A.; Salazar, Emelyn; Sanchez, Elda E.] Texas A&M Univ, Natl Nat Toxins Res Ctr, 975 W Ave B, Kingsville, TX 78363 USA.
   [Cromer, Walter E.; Zawieja, David C.] Texas A&M Hlth Sci Ctr, Dept Med Physiol, Temple, TX USA.
   [Davies, Peter] Texas A&M Univ, Inst Biosci & Technol, Houston, TX USA.
   [Sanchez, Elda E.] Texas A&M Univ, Dept Chem, Kingsville, TX USA.
RP Suntravat, M (reprint author), Texas A&M Univ, Natl Nat Toxins Res Ctr, 975 W Ave B, Kingsville, TX 78363 USA.
EM montamas.suntravat@tamuk.edu
FU National Heart, Lung, and Blood Institute (NHLBI) of the National
   Institutes of Health (MD, USA) under Academic Research Enhancement
   awards (AREA) (Texas A&M University-Kingsville (TAMUK), USA)
   [R15HL137134-01]; Office of Research Infrastructure Programs (ORIP) of
   the National Institutes of Health (MD, USA) under Viper Resource Center
   (VRC)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P40OD010960-14]; Texas A&M
   University's Presidential Undergraduate Research Program (TAMUK); Robert
   A. Welch Foundation Department (Department of Chemistry, TAMUK)
   [AC-0006]
FX Funding for the project was granted by the National Heart, Lung, and
   Blood Institute (NHLBI) of the National Institutes of Health (MD, USA)
   under Academic Research Enhancement awards (AREA) grant#R15HL137134-01
   (Texas A&M University-Kingsville (TAMUK), USA, Dr. M. Suntravat), the
   Office of Research Infrastructure Programs (ORIP) of the National
   Institutes of Health (MD, USA) under Viper Resource Center (VRC)
   grant#P40OD010960-14 (NNTRC, TAMUK, Dr. E.E. Sanchez), the Texas A&M
   University's Presidential Undergraduate Research Program (TAMUK), and
   the Robert A. Welch Foundation Department, grant#AC-0006 (Department of
   Chemistry, TAMUK). We would also like to thank, Nora Diaz DeLeon and
   Mark Hockmuller (NNTRC Serpentarium curator) and all the NNTRC
   personnel.
CR ALNAZHAN S, 1990, J ENDODONT, V16, P129, DOI 10.1016/S0099-2399(06)81589-X
   Banan A, 2001, AM J PHYSL GASTROINT, V280
   Bernardes-Oliveira E, 2016, EVID-BASED COMPL ALT, DOI 10.1155/2016/1574971
   Bogatcheva NV, 2008, MICROVASC RES, V76, P202, DOI 10.1016/j.mvr.2008.06.003
   Bradshaw MJ, 2016, CYTOTECHNOLOGY, V68, P687, DOI 10.1007/s10616-014-9820-2
   Brown RL, 1999, P NATL ACAD SCI USA, V96, P754, DOI 10.1073/pnas.96.2.754
   Cromer WE, 2014, ANGIOGENESIS, V17, P395, DOI 10.1007/s10456-013-9393-2
   EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283
   Estrella A, 2011, ARCH TOXICOL, V85, P305, DOI 10.1007/s00204-010-0597-6
   Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005
   Gibbs GM, 2008, ENDOCR REV, V29, P865, DOI 10.1210/er.2008-0032
   Gutierrez-Praena D, 2019, ENVIRON TOXICOL, V34, P240, DOI 10.1002/tox.22679
   Heyborne William H., 2010, P325
   Ikeda K, 1999, INFLAMMATION, V23, P87, DOI 10.1023/A:1020295718728
   Lecht S, 2015, BBA-GEN SUBJECTS, V1850, P1169, DOI 10.1016/j.bbagen.2015.02.002
   Lucena SE, 2014, TOXICON, V78, P10, DOI 10.1016/j.toxicon.2013.11.005
   MA TY, 1995, J CELL PHYSIOL, V164, P533, DOI 10.1002/jcp.1041640311
   Martin HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088338
   Matsunaga Y, 2009, J BIOCHEM, V145, P365, DOI 10.1093/jb/mvn174
   Niall H D, 1973, Methods Enzymol, V27, P942
   Phillips PG, 1985, J APPL PHYSIOL, V64, P1196
   Richard J F, 1999, Int Microbiol, V2, P185
   ROTROSEN D, 1986, J CELL BIOL, V103, P2379, DOI 10.1083/jcb.103.6.2379
   SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657
   Sunagar K, 2015, VENOMOUS REPTILES TH, P241
   Sunagar K, 2014, J PROTEOMICS, V99, P68, DOI [10.1016/j.jprot.2014.01.013, 10.1016]
   Tasoulis T, 2017, TOXINS, V9, DOI 10.3390/toxins9090290
   Udby L, 2004, BIOCHEMISTRY-US, V43, P12877, DOI 10.1021/bi048823e
   Udby L, 2002, J IMMUNOL METHODS, V263, P43, DOI 10.1016/S0022-1759(02)00033-9
   Udby L, 2002, J LEUKOCYTE BIOL, V72, P462
   Wang F, 2006, BIOCHEM BIOPH RES CO, V351, P443, DOI 10.1016/j.bbrc.2006.10.067
   Wang J, 2005, BIOCHEMISTRY-US, V44, P10145, DOI 10.1021/bi050614m
   Wang YL, 2010, J BIOL CHEM, V285, P37872, DOI 10.1074/jbc.M110.146290
   Wu WB, 2003, EXP CELL RES, V288, P143, DOI 10.1016/S0014-4827(03)00183-6
   Yamazaki Y, 2004, TOXICON, V44, P227, DOI 10.1016/j.toxicon.2004.05.023
   Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6
   Yamazaki Y, 2002, BIOCHEMISTRY-US, V41, P11331, DOI 10.1021/bi026132h
NR 37
TC 2
Z9 2
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 22
EP 30
DI 10.1016/j.toxicon.2019.04.006
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700003
PM 31014961
DA 2020-05-12
ER

PT J
AU Green, BT
   Keele, JW
   Bennett, GL
   Gardner, DR
   Stonecipher, CA
   Cook, D
   Pfister, JA
AF Green, Benedict T.
   Keele, John W.
   Bennett, Gary L.
   Gardner, Dale R.
   Stonecipher, Clint A.
   Cook, Daniel
   Pfister, James A.
TI Animal and plant factors which affect larkspur toxicosis in cattle: Sex,
   age, breed, and plant chemotype
SO TOXICON
LA English
DT Article
DE Cattle; Delphinium; Methyllycaconitine; Diterpenoid alkaloid; Larkspur;
   Poisoning/toxicity; Sex-dependent
ID NICOTINIC ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN BINDING; MIXED
   EFFECTS MODELS; NORDITERPENOID ALKALOIDS; DELPHINIUM-BARBEYI; DEPENDENT
   PHARMACOKINETICS; DITERPENOID ALKALOIDS; GENE-EXPRESSION;
   METHYLLYCACONITINE; TOXICITY
AB Larkspur (Delphinium spp.) poisoning is a long-term problem for cattle grazing on rangelands of western North America. Recent research has shown that both plant and animal-based factors are critical in understanding and mitigating larkspur poisoning in cattle. Non-toxicological factors including sex, age, cattle breed, and plant chemotype affect cattle responses to larkspur. For example, Angus heifers are more susceptible to larkspur intoxication than are steers or bulls. Young cattle appear to be more susceptible to larkspur poisoning than mature animals. Beef breeds of cattle are more susceptible to larkspur intoxication than dairy breeds. In addition to animal factors, plant alkaloid composition (chemotype) affects the potential toxicity for cattle because of differences in the ratios and concentrations of highly toxic N-(methylsuccinimido) anthranoyllycoctonine (MSAL)-type alkaloids compared to less lethal non-MSAL-type alkaloids. Animal- and plant-based factors can provide substantial information to inform livestock producers on management to reduce risk and cattle losses to various larkspur species in western North America.
C1 [Green, Benedict T.; Gardner, Dale R.; Stonecipher, Clint A.; Cook, Daniel; Pfister, James A.] USDA ARS, Poisonous Plant Res Lab, Logan, UT 84341 USA.
   [Keele, John W.; Bennett, Gary L.] USDA ARS, Meat Anim Res Ctr, Clay Ctr, NE 68933 USA.
RP Green, BT (reprint author), USDA ARS, Poisonous Plant Res Lab, Logan, UT 84341 USA.
EM Ben.Green@ars.usda.gov
FU United States Department of Agriculture, Agricultural Research
   ServiceUnited States Department of Agriculture (USDA)
   [2080-32630-014-00-D]
FX The authors wish to thank Isabelle McCollum, Rex Probst, Jessie Roper,
   Kermit Price, Ed Knoppel, Chuck Hailes and Scott Larsen for their expert
   technical support of this research. This research was supported by
   United States Department of Agriculture, Agricultural Research Service,
   Project Number: 2080-32630-014-00-D.
CR Ahlberg CM, 2016, J ANIM SCI, V94, P1857, DOI 10.2527/jas.2015-0161
   AIYAR VN, 1979, EXPERIENTIA, V35, P1367, DOI 10.1007/BF01964013
   ALKONDON M, 1992, MOL PHARMACOL, V41, P802
   Andrade C, 2015, J CLIN PSYCHIAT, V76, pE857, DOI 10.4088/JCP.15f10150
   ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001
   Ashwell MS, 2011, RES VET SCI, V90, P235, DOI 10.1016/j.rvsc.2010.05.029
   Bailey K, 1983, Regul Toxicol Pharmacol, V3, P389, DOI 10.1016/0273-2300(83)90009-0
   BENN MH, 1983, ALKALOIDS CHEM BIOL, V1, P153
   Cook D, 2017, BIOCHEM SYST ECOL, V75, P1, DOI 10.1016/j.bse.2017.09.002
   Cook D, 2015, TOXICON, V99, P36, DOI 10.1016/j.toxicon.2015.03.005
   Cook D, 2011, AM J VET RES, V72, P706, DOI 10.2460/ajvr.72.5.706
   Cook D, 2009, J CHEM ECOL, V35, P643, DOI 10.1007/s10886-009-9637-1
   Dacasto M, 2005, VET RES, V36, P179, DOI 10.1051/vetres:2004066
   Dobelis P, 1999, J PHARMACOL EXP THER, V291, P538
   Ewan Joseph, 1945, UNIV COLO STUDIES SERIES D, V2, P55
   FINKGREMMELS J, 1994, ANALYST, V119, P2521, DOI 10.1039/an9941902521
   Gardner DR, 2009, PHYTOCHEM ANALYSIS, V20, P104, DOI 10.1002/pca.1104
   Gardner DR, 2002, BIOCHEM SYST ECOL, V30, P77, DOI 10.1016/S0305-1978(01)00120-X
   Gardner DR, 1997, PHYTOCHEM ANALYSIS, V8, P55, DOI 10.1002/(SICI)1099-1565(199703)8:2<55::AID-PCA338>3.0.CO;2-Q
   Gardner DR, 1999, J AGR FOOD CHEM, V47, P5049, DOI 10.1021/jf990615j
   Giantin M, 2008, DRUG METAB DISPOS, V36, P885, DOI 10.1124/dmd.107.019042
   Green BT, 2018, TOXICON, V152, P57, DOI 10.1016/j.toxicon.2018.07.020
   Green B. T., 2014, Rangelands, V36, P10, DOI 10.2111/RANGELANDS-D-13-00031.1
   Green BT, 2019, J ANIM SCI, V97, P1424, DOI 10.1093/jas/skz002
   Green BT, 2019, J ANIM SCI, V97, P1415, DOI 10.1093/jas/skz004
   Green BT, 2013, CHEM RES TOXICOL, V26, P1129, DOI 10.1021/tx400166f
   Green BT, 2013, RES VET SCI, V95, P612, DOI 10.1016/j.rvsc.2013.04.018
   Green BT, 2012, AM J VET RES, V73, P1318, DOI 10.2460/ajvr.73.8.1318
   Green BT, 2011, J APPL TOXICOL, V31, P20, DOI 10.1002/jat.1563
   Green BT, 2009, AM J VET RES, V70, P926, DOI 10.2460/ajvr.70.7.926
   Green BT, 2009, AM J VET RES, V70, P539, DOI 10.2460/ajvr.70.4.539
   Greene W. H., 2008, ECONOMETRIC ANAL, P871
   Hammond AC, 1996, J ANIM SCI, V74, P295
   Heaton MP, 2001, MAMM GENOME, V12, P219, DOI 10.1007/s003350010269
   Holloway MG, 2006, MOL ENDOCRINOL, V20, P647, DOI 10.1210/me.2005-0328
   Hughes HD, 2014, INNATE IMMUN-LONDON, V20, P888, DOI 10.1177/1753425913508993
   Janus K, 1999, J VET PHARMACOL THER, V22, P163, DOI 10.1046/j.1365-2885.1999.00203.x
   Janus K, 2000, RES VET SCI, V69, P33, DOI 10.1053/rvsc.2000.0381
   KINGSBURY JM, 1964, POISONOUS PLANTS US
   Kleiber C, 2008, USE R, P1, DOI 10.1007/978-0-387-77318-6_1
   Knight AP, 2001, GUIDE PLANT POISONIN
   KUKEL CF, 1994, CAN J PHYSIOL PHARM, V72, P104, DOI 10.1139/y94-016
   MANNERS GD, 1992, J RANGE MANAGE, V45, P63, DOI 10.2307/4002527
   MANNERS GD, 1995, J NAT PRODUCTS, V58, P863, DOI 10.1021/np50120a007
   MANNERS GD, 1993, J AGR FOOD CHEM, V41, P96, DOI 10.1021/jf00025a020
   Marsh C. D, 1916, LARKSPUR POISONING L, V365
   NATION PN, 1982, CAN VET J, V23, P264
   NOUWS JFM, 1983, J VET PHARMACOL THER, V6, P59, DOI 10.1111/j.1365-2885.1983.tb00455.x
   Pfister J. A., 2011, Journal of Agricultural Science (Toronto), V3, P36
   Pfister JA, 2003, VET HUM TOXICOL, V45, P137
   Pfister JA, 2002, J RANGE MANAGE, V55, P350, DOI 10.2307/4003471
   Pfister JA, 2002, BIOCHEM SYST ECOL, V30, P129, DOI 10.1016/S0305-1978(01)00124-7
   Pfister JA, 1999, J RANGE MANAGE, V52, P378, DOI 10.2307/4003549
   Pfister JA, 1999, J NAT TOXINS, V8, P81
   Pfister JA, 2011, RANGELAND ECOL MANAG, V64, P664, DOI 10.2111/REM-D-11-00001.1
   R Core Team, 2013, R LANG ENV STAT COMP
   Ralphs MH, 2000, J CHEM ECOL, V26, P1595, DOI 10.1023/A:1005530627792
   Ralphs MH, 2002, J CHEM ECOL, V28, P2327, DOI 10.1023/A:1021013719206
   Retallick KJ, 2017, J ANIM SCI, V95, P1444, DOI 10.2527/jas.2016.1260
   Sallovitz J, 2002, VET J, V164, P47, DOI 10.1053/tvjl.2002.0715
   SECHSEROVA M, 1979, ARZNEIMITTELFORSCH, V29-1, P650
   Snelling WM, 2015, J ANIM SCI, V93, P5128, DOI 10.2527/jas.2015-9356
   Stegelmeier B. L., 1998, P205
   TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382
   Vaida F, 2007, COMPUT STAT DATA AN, V51, P5718, DOI 10.1016/j.csda.2006.09.036
   Vaida F, 2009, J COMPUT GRAPH STAT, V18, P797, DOI 10.1198/jcgs.2009.07130
   Voisinet BD, 1997, J ANIM SCI, V75, P892
   VOLNER Z, 1990, VET QUART, V12, P98, DOI 10.1080/01652176.1990.9694251
   WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C
   WARNOCK M.J, 1997, FLORA N AM N MEXICO, V3, P196
   Warnock Michael J., 1995, Phytologia, V78, P73
   Waxman DJ, 2009, MOL PHARMACOL, V76, P215, DOI 10.1124/mol.109.056705
   Welch KD, 2008, J ANIM SCI, V86, P2761, DOI 10.2527/jas.2008-1025
   Welch KD, 2017, TOXICON, V133, P91, DOI 10.1016/j.toxicon.2017.05.008
   Welch KD, 2017, TOXICON, V128, P46, DOI 10.1016/j.toxicon.2017.01.020
   Welch KD, 2015, J ANIM SCI, V93, P4181, DOI 10.2527/jas.2015-9101
   Welch KD, 2013, J APPL TOXICOL, V33, P1017, DOI 10.1002/jat.2894
   Welch KD, 2012, J ANIM SCI, V90, P2394, DOI 10.2527/jas.2011-4560
   Welch KD, 2009, J ANIM SCI, V87, P1558, DOI 10.2527/jas.2008-1577
   Welch KD, 2013, TOXICOL APPL PHARM, V266, P366, DOI 10.1016/j.taap.2012.11.024
   Welch KD, 2010, AM J VET RES, V71, P487, DOI 10.2460/ajvr.71.4.487
   Wink M, 1999, FUNCTIONS SECONDARY, V3
   WONNACOTT S, 1993, METHODS NEUROSCIENCE, V12, P263
   Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007
   Ziska LH, 2005, GLOBAL CHANGE BIOL, V11, P1798, DOI 10.1111/j.1365-2486.2005.001029.x
NR 85
TC 0
Z9 0
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 31
EP 39
DI 10.1016/j.toxicon.2019.04.013
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700004
PM 31029637
DA 2020-05-12
ER

PT J
AU Villalta, M
   Sampaio, TL
   de Menezes, RRPPB
   Lima, DB
   Jorge, ARC
   Alves, RS
   Monteiro, HSA
   Gawarammana, I
   Maduwage, K
   Malleappah, R
   Leon, G
   Martins, AMC
   Gutierrez, JM
AF Villalta, Mauren
   Sampaio, Tiago Lima
   Pessoa Bezerra de Menezes, Ramon Rose Paula
   Lima, Danya Bandeira
   Coelho Jorge, Antonio Rafael
   Alves, Renata Sousa
   Azul Monteiro, Helena Serra
   Gawarammana, Indika
   Maduwage, Kalana
   Malleappah, Roy
   Leon, Guillermo
   Martins, Alice M. C.
   Maria Gutierrez, Jose
TI Nephrotoxicity induced by the venom of Hypnale hypnale from Sri Lanka:
   Studies on isolated perfused rat kidney and renal tubular cell lines
SO TOXICON
LA English
DT Article
DE Hypnale hypnale; Hump-nosed pit viper; Nephrotoxicity; Cytotoxicity;
   Renal tubular cells
ID NOSED PIT-VIPER; SNAKE-VENOM; ANTIVENOM; INJURY; CLEARANCE; TOXICITY;
   EFFICACY; BITE
AB The hump-nosed pit viper Hypnale hypnale is responsible for a high number of snakebite cases in southwestern India and Sri Lanka. Although most patients only develop local signs and symptoms of envenoming, there is a growing body of evidence indicating that these envenomings may be associated with systemic alterations, including acute kidney injury. In this study we evaluated the renal toxicity of H. hypnale venom by using a perfused isolated rat kidney system and by assessing cytotoxicity in two different renal tubular cell lines in culture. The venom caused alterations in several renal functional parameters, such as reduction on perfusion pressure, renal vascular resistance, and sodium and chloride tubular transport, whereas glomerular filtration rate and urinary flow initially decreased and then increased after venom perfusion. In addition, this venom was cytotoxic to proximal and distal renal tubular cells in culture, with predominance of necrosis over apoptosis. Moreover, the venom affected the mitochondrial membrane potential and induced an increment in reactive oxygen species in these cells. Taken together, our results demonstrate a nephrotoxic activity of H. hypnale venom in these experimental models, in agreement with clinical observations.
C1 [Villalta, Mauren; Leon, Guillermo; Maria Gutierrez, Jose] Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose, Costa Rica.
   [Sampaio, Tiago Lima; Pessoa Bezerra de Menezes, Ramon Rose Paula; Lima, Danya Bandeira; Alves, Renata Sousa; Martins, Alice M. C.] Univ Fed Ceara, Dept Clin & Toxicol Anal, Fortaleza, Ceara, Brazil.
   [Coelho Jorge, Antonio Rafael; Azul Monteiro, Helena Serra] Univ Fed Ceara, Dept Physiol & Pharmacol, Fortaleza, Ceara, Brazil.
   [Gawarammana, Indika; Maduwage, Kalana] Univ Peradeniya, Fac Med, Peradeniya, Sri Lanka.
   [Malleappah, Roy] AVRI, Moreno Valley, CA USA.
RP Gutierrez, JM (reprint author), Univ Costa Rica, Inst Clodomiro Picado, Fac Microbiol, San Jose, Costa Rica.
EM jose.gutierrez@ucr.ac.cr
OI Maduwage, Kalana/0000-0001-5351-808X; Menezes,
   Ramon/0000-0003-3109-9683; Leon, Guillermo/0000-0002-8217-4068
FU Vicerrectoria de Investigacion, Universidad de Costa Rica [741-B4-102];
   Graduate Studies System of this university
FX This study was supported by Vicerrectoria de Investigacion, Universidad
   de Costa Rica (project No. 741-B4-102), and by the Graduate Studies
   System of this university for supporting a research stay of M. Villalta
   at the Federal University of Ceara. Thanks are due to Daniel Keyler for
   fruitful discussions. This work was carried out by Mauren Villalta in
   partial fulfillment of the requirements for the PhD degree at the
   University of Costa Rica.
CR Albuquerque PLMM, 2014, NEPHROLOGY, V19, P764, DOI 10.1111/nep.12327
   Ali SA, 2013, J PROTEOMICS, V91, P338, DOI 10.1016/j.jprot.2013.07.020
   Ariaratnam CA, 2008, T ROY SOC TROP MED H, V102, P1120, DOI 10.1016/j.trstmh.2008.03.023
   Ariaratnam CA, 2009, AM J TROP MED HYG, V81, P725, DOI 10.4269/ajtmh.2009.09-0225
   Baracca A, 2003, BBA-BIOENERGETICS, V1606, P137, DOI 10.1016/S0005-2728(03)00110-5
   Barbosa PSF, 2002, TOXICON, V40, P1427, DOI 10.1016/S0041-0101(02)00156-3
   Bernardi P., 2007, V45, P481
   de Silva Umesh, 2018, J Med Case Rep, V12, P213, DOI 10.1186/s13256-018-1756-2
   DESILVA A, 1994, T ROY SOC TROP MED H, V88, P209, DOI 10.1016/0035-9203(94)90301-8
   Evangelista IL, 2010, TOXICON, V55, P1061, DOI 10.1016/j.toxicon.2009.12.004
   FONTELES MC, 1983, AM J PHYSIOL, V244, pF235
   Gunatilake M., 2003, Ceylon Journal of Medical Science, V46, P61
   Havt A, 2001, TOXICON, V39, P1841, DOI 10.1016/S0041-0101(01)00146-5
   Herath N, 2012, TOXICON, V60, P61, DOI 10.1016/j.toxicon.2012.03.015
   Joseph JK, 2007, T ROY SOC TROP MED H, V101, P85, DOI 10.1016/j.trstmh.2006.03.008
   Karunarathne S, 2013, Indian J Nephrol, V23, P294, DOI 10.4103/0971-4065.114476
   Keyler DE, 2013, TOXICON, V69, P90, DOI 10.1016/j.toxicon.2013.01.022
   Kularatne K, 2011, ASIAN PAC J TROP MED, V4, P564, DOI 10.1016/S1995-7645(11)60147-8
   Kularatne S. A. M., 1999, Ceylon Medical Journal, V44, P169
   Maduwage K, 2013, TOXICON, V61, P11, DOI 10.1016/j.toxicon.2012.10.013
   Maduwage Kalana, 2011, J Venom Res, V2, P17
   Maduwage K, 2009, ZOOTAXA, P1
   Marinho AD, 2015, TOXICON, V108, P126, DOI 10.1016/j.toxicon.2015.09.031
   MARTINEZMALDONA.M, 1978, J PHYSL, V280, P487
   Mello CP, 2014, TOXICON, V88, P107, DOI 10.1016/j.toxicon.2014.05.009
   Mora R, 2005, TOXICON, V45, P651, DOI 10.1016/j.toxicon.2005.01.008
   Morais ICO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132569
   de Morais ICO, 2013, TOXICON, V61, P38, DOI 10.1016/j.toxicon.2012.10.005
   Rathnayaka RMMKN, 2019, WILD ENVIRON MED, V30, P66, DOI 10.1016/j.wem.2018.10.003
   Rathnayaka RMMKN, 2019, T ROY SOC TROP MED H, V113, P131, DOI 10.1093/trstmh/try120
   Rathnayaka RMMKN, 2018, WILD ENVIRON MED, V29, P94, DOI 10.1016/j.wem.2017.11.003
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   SELLAHEWA KH, 1995, AM J TROP MED HYG, V53, P260, DOI 10.4269/ajtmh.1995.53.260
   Shivanthan MC, 2014, J VENOM ANIM TOXINS, V20, DOI 10.1186/1678-9199-20-24
   Silva Anjana, 2012, BMC Res Notes, V5, P471, DOI 10.1186/1756-0500-5-471
   Sitprija V, 2012, TOXICON, V60, P943, DOI 10.1016/j.toxicon.2012.06.012
   Tan CH, 2015, TOXICON, V93, P164, DOI 10.1016/j.toxicon.2014.11.231
   Tan CH, 2012, TOXICON, V60, P1259, DOI 10.1016/j.toxicon.2012.08.012
   Vanuopadath M, 2018, INT J BIOL MACROMOL, V118, P1736, DOI 10.1016/j.ijbiomac.2018.07.016
   Villalta M, 2016, TOXICON, V122, P152, DOI 10.1016/j.toxicon.2016.10.007
   WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204
   Warrell David A., 1995, P493
NR 42
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 40
EP 46
DI 10.1016/j.toxicon.2019.04.014
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700005
PM 31034846
DA 2020-05-12
ER

PT J
AU Gault, G
   Lefebvre, S
   Benoit, E
   Lattard, V
   Grancher, D
AF Gault, Gilbert
   Lefebvre, Sebastien
   Benoit, Etienne
   Lattard, Virginie
   Grancher, Denis
TI Variability of ferulenol and ferprenin concentration in French giant
   fennel (Ferula sp.) leaves
SO TOXICON
LA English
DT Article
DE Ferula communis; Ferula glauca; Distribution; Prenylated coumarins;
   Ferulenol concentration; Ferprenin concentration
ID PRENYLATED COUMARINS; COMMUNIS; SESQUITERPENOIDS; CHEMOTYPE
AB Few studies have reported quantitative data about the levels of prenylated coumarins in Ferula sp. Yet, the toxicity of Ferula sp. is only due to the presence of prenylated coumarins and to their concentrations and all studies suggest the existence of several chemotypes within the same species or even within the same variety. The aim of this study was to investigate the hypothesis of different chemotypes in french Ferula sp. in relationship with the botanical species. In this objective, the species of giant fennels and their concentrations in prenylated coumarins were explored. Three different species or subspecies of giant fennel were detected in continental France: F. communis communis communis L., F. communis catalaunica microcarpa Cauwet-Marc and F. glauca L. Surprisingly, the three species/subspecies of giant fennels were found to be located in exclusive and well separated geographical areas. In French giant fennels, ferulenol and ferprenin were detected. Distribution of ferulenol and ferprenin were found to be different between botanical varieties, but also according to the season, the soil and the altitude. Our study seems to suggest that among F. communis species, the same plant can be regarded as poisonous at one point and another as non-poisonous.
C1 [Gault, Gilbert; Lefebvre, Sebastien; Benoit, Etienne; Lattard, Virginie; Grancher, Denis] INRA VetAgro Sup, USC 1233, RS2GP, 1 Ave Bourgelat, F-69280 Marcy Letoile, France.
RP Grancher, D (reprint author), INRA VetAgro Sup, USC 1233, RS2GP, 1 Ave Bourgelat, F-69280 Marcy Letoile, France.
EM denis.grancher@vetagro-sup.fr
FU Bpi France [I1301001W]
FX This work was supported by grants ISI noI1301001W "NEORAMUS" from Bpi
   France.
CR Appendino G, 2001, J NAT PROD, V64, P393, DOI 10.1021/np000468f
   APPENDINO G, 1988, PHYTOCHEMISTRY, V27, P944, DOI 10.1016/0031-9422(88)84130-X
   APPENDINO G, 1988, PHYTOCHEMISTRY, V27, P3619, DOI 10.1016/0031-9422(88)80778-7
   Arnoldi L, 2004, FITOTERAPIA, V75, P342, DOI 10.1016/j.fitote.2004.03.001
   Benkhalti F., 1994, ACT 1 C INT PHARM AR, P215
   CARBONI S, 1964, TETRAHEDRON LETT, P2783
   Cauwet-Marc A. M, 1988, ACTES S INT BOT PIUS, V2, P129
   Cauwet-Marc A.M., 1990, REV RES AMELIOR AGR, V2, P1
   CAUWETMARC AM, 1981, [No title captured], V8, P101
   Cornevin C, 1887, PLANTES VENENEUSES E, P380
   Fraigui O, 2001, VET HUM TOXICOL, V43, P327
   Gault G., 2015, P 9 C INT SOC POIS P, V15, P95
   Gebauer M, 2007, BIOORGAN MED CHEM, V15, P2414, DOI 10.1016/j.bmc.2007.01.014
   Hu HJ, 2004, J ORG CHEM, V69, P3782, DOI 10.1021/jo049703f
   Infante M, 1965, ARCH ZOOTEC, V14, P25
   Jung EJ, 2010, GREEN CHEM, V12, P2003, DOI 10.1039/c0gc00265h
   Kurzyna-Mlynik R, 2008, PLANT SYST EVOL, V274, P47, DOI 10.1007/s00606-008-0022-2
   Lamnaouer D, 1987, THESIS
   Lannehoa Y, 1998, PRESSE MED, V27, P1579
   Louvet MS, 2015, PHYTOCHEMISTRY, V118, P124, DOI 10.1016/j.phytochem.2015.08.012
   Maggi F, 2009, BIOCHEM SYST ECOL, V37, P432, DOI 10.1016/j.bse.2009.05.011
   MISKI M, 1985, PHYTOCHEMISTRY, V24, P1735, DOI 10.1016/S0031-9422(00)82543-1
   Oldenburg J, 2008, VITAM HORM, V78, P35, DOI 10.1016/S0083-6729(07)00003-9
   Pimenov M.G., 2004, TURK J BOT, V28, P139
   Reduron J. P, 2007, B SOC BOT CTR OUEST, V3, P1260
   Rubiolo P, 2006, J AGR FOOD CHEM, V54, P7556, DOI 10.1021/jf061592t
   Sacchetti G, 2003, BIOCHEM SYST ECOL, V31, P527, DOI 10.1016/S0305-1978(02)00199-0
   Shlosberg A, 2011, ISR J VET MED, V66, P171
   SHLOSBERG A, 1985, ZBL VET MED A, V32, P778
   VALLE MG, 1987, PHYTOCHEMISTRY, V26, P253
NR 30
TC 1
Z9 1
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 47
EP 55
DI 10.1016/j.toxicon.2019.04.010
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700006
PM 31034847
DA 2020-05-12
ER

PT J
AU Micheloud, JF
   Aguirre, LS
   Marioni, J
   Mugas, ML
   Cabrera, JL
   Martinez, OG
   Gallardo, SC
   Gimeno, EJ
   Nunez-Montoya, SC
AF Francisco Micheloud, Juan
   Aguirre, Laura S.
   Marioni, Juliana
   Laura Mugas, Maria
   Luis Cabrera, Jose
   Gladys Martinez, Olga
   Carola Gallardo, Silvina
   Juan Gimeno, Eduardo
   Carolina Nunez-Montoya, Susana
TI Experimental poisoning by Heterophyllaea pustulata Hook. f. (Rubiaceae)
   in goats. Clinical, biochemical and toxicological aspects
SO TOXICON
LA English
DT Article
DE Poisonous plants; Anthraquinone derivatives; Phototoxicity; Primary
   photosensitization; Dermatitis
ID EXPRESSION
AB The aim of this study was to investigate the clinical, biochemical and toxicological findings of the experimentally poisoning induced by Heterophyllaea pustulata in goats. Ten healthy adult female Saanen breed goats were used in the experiment. The goats were randomly assigned to two groups of five individuals: control and experimental group (CG and EG). Both groups were kept in the same enclosure devoid of shade for 8 h daily. The EG received only H. pustulata samples (leaves and thin steam) and water ad libitum. The CG received lucerne hay. Blood samples were taken at different times after oral administration of vegetal samples, and level of hepatic enzymes, total bilirubin, conjugated and non-conjugated bilirubin was measured, together with the detection of anthraquinones (AQs) and phylloerythrin by High Performance Liquid Chromatography with Diode-Array Detector and Mass Spectrometry with Electron Spray Ionization and Quadrupole Time Of Fly analysis. At the same time, skin biopsy samples were collected for AQs determinations. For histopathological examination, hepatic biopsy samples were collected on day 8. Clinically, all goats of the EG revealed photophobia, dermatitis and photosensitization. None of these goats developed jaundice or died during the experiment (15 days). In addition, affected goats exhibited a significant elevation in the serum levels of glutamic oxaloacetic transaminase, direct bilirubin, and total bilirubin. Microscopic examination of the liver samples revealed slight degenerative lesions. Although phylloerythrin was not detected in sera, a high level of two predominant AQs in H. pustulata (rubiadin/soranjidiol) were noted between 24 and 72 h after plant consumption, which coincided with the period in which the clinical signs were more obvious. Since those AQs were not identified in skin samples, the clinical findings were supported by the presence of AQs in sera. Finally, toxicological studies of the AQs are important, since many current works suggest their potential use in the photodynamic therapy.
C1 [Francisco Micheloud, Juan] Inst Nacl Tecnol Agr, Grp Trabajo Patol Epidemiol & Invest Diagraist Ar, Buenos Aires, DF, Argentina.
   [Francisco Micheloud, Juan; Aguirre, Laura S.] Univ Catolica Salta, Fac Ciencias Vet, Praict Hosp Grandes Anim, Salta, Argentina.
   [Marioni, Juliana; Laura Mugas, Maria; Luis Cabrera, Jose; Carolina Nunez-Montoya, Susana] Consejo Nacl Invest Cient & Tecn, IMBIV, Consejo Nacl Invest Cient & Tecn, Inst Multidisciplinario Biol Vegetal, Buenos Aires, DF, Argentina.
   [Marioni, Juliana; Laura Mugas, Maria; Luis Cabrera, Jose; Carolina Nunez-Montoya, Susana] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Ciencias Farmaceut, Farmacognosia, Edificio Ciencias 2,Ciudad Univ,X5000HUA, Cordoba, Argentina.
   [Gladys Martinez, Olga; Carola Gallardo, Silvina] Univ Nacl Salta, IBIGEO, Fac Ciencias Nat, Herbario MCNS, Av Bolivia 5150, Salta, Argentina.
   [Juan Gimeno, Eduardo] Univ Nacl La Plata, Fac Ciencias Vet, Catedra Patol Gen, La Plata, Buenos Aires, Argentina.
RP Micheloud, JF (reprint author), Inst Nacl Tecnol Agr, Grp Trabajo Patol Epidemiol & Invest Diagraist Ar, Buenos Aires, DF, Argentina.
EM micheloud.juan@inta.gob.ar
OI MARIONI, JULIANA/0000-0002-4404-0800
FU INTA; Consejo de Investigacion de la Universidad Catolica de Salta
FX This study was supported by grants from INTA and Consejo de
   Investigacion de la Universidad Catolica de Salta. SCNM, JLC and EJG are
   members of the Research Career of CONICET, Dr. Victor Suarez for his
   contribution to statistical analysis and to Dr. Romina Di Paola (ICYTAC
   - CONICET and Universidad Nacional de Cordoba) for performing
   HPLC-DAD-ESI-QTOF experiments.
CR Aguirre D. H., 2001, Medicina Veterinaria, V18, P487
   Aslani MR, 2004, SMALL RUMINANT RES, V51, P261, DOI 10.1016/S0921-4488(03)00195-0
   Aslani MR, 2003, VET RES COMMUN, V27, P53, DOI 10.1023/A:1022010707704
   Bacigalupo N.M., 1993, FLORA PROVINCIA JUJU, VIII, P375
   Comini LR, 2007, J PHOTOCH PHOTOBIO A, V188, P185, DOI 10.1016/j.jphotochem.2006.12.011
   Di Rienzo J.A., 2008, INFOSTAT VERSION 200
   GLENN BL, 1964, PATHOL VET, V1, P469, DOI 10.1177/030098586400100601
   HANSEN EDUARDO W., 1967, REV INVEST AGROPECUAR SER 4 PATOL ANIM, V4, P81
   Jackson J. V, 1978, BERLE ISOLATION IDEN, P16
   Jeschke MG, 2007, SHOCK, V28, P172, DOI 10.1097/shk.0b013e318047b9e2
   Jeschke MG, 2009, MOL MED, V15, P337, DOI 10.2119/molmed.2009.00005
   Jeschke MG, 2001, AM J PHYSIOL-GASTR L, V280, pG1314
   KELLERMAN TS, 1988, PLANT POISONINGS MYC
   Kelly W. R, 1993, PATHOLOGY DOMESTIC A, V2
   Klein D, 2003, SHOCK, V20, P536, DOI 10.1097/01.shk.0000093345.68755.98
   Marioni J, 2016, PHARM BIOL, V54, P2791, DOI 10.1080/13880209.2016.1183683
   Mauldin EA, 2016, JUBB KENNEDY PALMERS, P509
   Melo CH, 2015, GENET MOL RES, V14, P8672, DOI 10.4238/2015.July.31.16
   Montoya SCN, 2005, J PHOTOCH PHOTOBIO B, V78, P77, DOI 10.1016/j.jphotobiol.2004.09.009
   Montoya SCN, 2003, PHYTOMEDICINE, V10, P569, DOI 10.1078/094471103322331854
   Montoya SC, 2008, TOXICON, V51, P1409, DOI 10.1016/j.toxicon.2008.03.011
   Montoya SCN, 2006, J NAT PROD, V69, P801, DOI 10.1021/np050181o
   Radostits O. M, 2007, VET MED TXB DIS CATT, P264
   ROWE LD, 1989, VET CLIN N AM-FOOD A, V5, P301, DOI 10.1016/S0749-0720(15)30978-6
   SMITH BL, 1991, NEW ZEAL VET J, V39, P18, DOI 10.1080/00480169.1991.35650
   Suarez V. H, 2017, VET ARG, VXXXIV, P1
   Taylor I, 2004, BRAIN, V127, P1878, DOI 10.1093/brain/awh211
   Tokarnia C.H., 2012, PLANTAS TOXICAS BRAS, P305
NR 28
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 56
EP 61
DI 10.1016/j.toxicon.2019.04.015
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700007
PM 31029636
DA 2020-05-12
ER

PT J
AU Zhao, JQ
   Lv, QY
   Liu, P
   Guo, LY
   Zhang, LW
   Zheng, YL
   Ming, LH
   Kong, DC
   Jiang, H
   Jiang, YQ
AF Zhao, Junqing
   Lv, Qingyu
   Liu, Peng
   Guo, Liyuan
   Zhang, Liwen
   Zheng, Yuling
   Ming, Lihua
   Kong, Decong
   Jiang, Hua
   Jiang, Yongqiang
TI AlphaLISA for detection of staphylococcal enterotoxin B free from
   interference by protein A
SO TOXICON
LA English
DT Article
DE Staphylococcus enterotoxin B; AlphaLISA; Immunoassay
ID AUREUS; ELISA; ASSAY
AB Staphylococcal enterotoxin B (SEB) is an important enterotoxin which is a major reason for food poisoning and a potential biologic agent. Hence, rapid and accurate detection is very important. An amplified luminescent proximity homogeneous assay (AlphaLISA) for SEB detection was established here. Its performance was evaluated on mock specimen and culture supernatant. Its free from the effect of protein A was compared with ELISA. Results showed that the linear range for SEB detection was 25 pg/mL to 25 ng/mL. The detection limitation is 25 pg/mL in buffer and 50 pg/mL in specimen respectively. There was no cross-reaction with other classical SEs or botulinum toxin. AlphaLISA was also tolerant to the matrix of sample and showed good repeatability. The inter-assay coefficient of variation (CV) and intra-assay CV were < 10% for buffer and mock specimens, respectively. Besides AlphaLISA detection was free of the interference of protein A (which is the obstacle for immune-based detection of SEs in Staphylococcus aureus culture supernatants): this feature is very important for food-poisoning confirmation caused by SEB contamination. These data suggest that the AlphaLISA established here is well suited for SEB detection in food samples and S. aureus culture supernatants.
C1 [Zhao, Junqing; Lv, Qingyu; Liu, Peng; Zheng, Yuling; Kong, Decong; Jiang, Hua; Jiang, Yongqiang] Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Zhang, Liwen] Anhui Med Univ, Hefei 230032, Anhui, Peoples R China.
   [Ming, Lihua] Chest Hosp Xinjiang, Urumqi 830049, Peoples R China.
   [Guo, Liyuan] Malden Catholic High Sch, 99 Crystal St, Malden, MA 02148 USA.
RP Jiang, H; Jiang, YQ (reprint author), Acad Mil Med Sci, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
EM jhua76@126.com; jiangyq@bmi.ac.cn
RI Liu, Peng/V-9305-2019
FU Chinese State Key Project Specialized for Infectious Disease
   [2018ZX10712001-015, AWS15J006, 2018ZX10711001-003-001,
   2018ZX10732401-001-008]; Chinese State Key Project Specialized for new
   drugs [2016ZX09J16105-002-002]; National Key RD Plan [2017YFC1200904];
   State Key Laboratory of Pathogen and Biosecurity (Academy of Military
   Medical Science) [SKLPBS1816]; Beijing Natural Science FoundationBeijing
   Natural Science Foundation [7172155]
FX This work was supported by research grants from the Chinese State Key
   Project Specialized for Infectious Disease (Grant No.:
   2018ZX10712001-015, AWS15J006, 2018ZX10711001-003-001, and
   2018ZX10732401-001-008), Chinese State Key Project Specialized for new
   drugs (Grant No.: 2016ZX09J16105-002-002), National Key R&D Plan (Grant
   No.: 2017YFC1200904), the State Key Laboratory of Pathogen and
   Biosecurity (Academy of Military Medical Science, Grant No.:
   SKLPBS1816), Beijing Natural Science Foundation (Grant No.: 7172155).
CR Alam SI, 2017, LETT APPL MICROBIOL, V64, P217, DOI 10.1111/lam.12706
   Andjelkovic M, 2016, TOXINS, V8, DOI 10.3390/toxins8040118
   Armstrong CM, 2018, TOXINS, V10, DOI 10.3390/toxins10110422
   Chen XY, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3236-9
   DeGrasse JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033410
   Denayer S, 2017, TOXINS, V9, DOI 10.3390/toxins9120407
   Dutta K, 2015, J BIOL CHEM, V290, P6715, DOI 10.1074/jbc.M114.630715
   EDWIN C, 1989, J CLIN MICROBIOL, V27, P1496, DOI 10.1128/JCM.27.7.1496-1501.1989
   Eglen Richard M, 2008, Curr Chem Genomics, V1, P2, DOI 10.2174/1875397300801010002
   Gu LW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055892
   Hait JM, 2018, J AOAC INT, V101, P1482, DOI 10.5740/jaoacint.17-0501
   Lassabe G, 2018, ANAL CHEM, V90, P6187, DOI 10.1021/acs.analchem.8b00657
   Ler SG, 2006, J CHROMATOGR A, V1133, P1, DOI 10.1016/j.chroma.2006.08.078
   MAH RA, 1967, APPL MICROBIOL, V15, P866, DOI 10.1128/AEM.15.4.866-870.1967
   McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77
   Mondal B, 2018, J AGR FOOD CHEM, V66, P1516, DOI 10.1021/acs.jafc.7b04820
   Nagaraj S, 2016, INT J FOOD MICROBIOL, V237, P136, DOI 10.1016/j.ijfoodmicro.2016.08.009
   Nia Y, 2016, TOXINS, V8, DOI 10.3390/toxins8090268
   Nodoushan SM, 2019, BIOSENS BIOELECTRON, V127, P221, DOI 10.1016/j.bios.2018.12.021
   NYCHAS GJ, 1991, J APPL BACTERIOL, V70, P344, DOI 10.1111/j.1365-2672.1991.tb02947.x
   Park CE, 1996, INT J FOOD MICROBIOL, V29, P281, DOI 10.1016/0168-1605(95)00046-1
   Reddy P, 2014, J IMMUNOL METHODS, V408, P114, DOI 10.1016/j.jim.2014.05.012
   Reddy PK, 2013, J IMMUNOL METHODS, V391, P31, DOI 10.1016/j.jim.2013.02.004
   Reddy PN, 2015, ANN MICROBIOL, V65, P1915, DOI 10.1007/s13213-014-1029-2
   ROGEMOND V, 1991, LETT APPL MICROBIOL, V13, P175, DOI 10.1111/j.1472-765X.1991.tb00601.x
   Rusnak JM, 2004, EMERG INFECT DIS, V10, P1544, DOI 10.3201/eid1009.040250
   Smith M. E, 2018, TOXICITY BIOL WARFAR
   Temur E, 2012, ANAL CHEM, V84, P10600, DOI 10.1021/ac301924f
   Tonacini J, 2019, TOXINS, V11, DOI 10.3390/toxins11020101
   Yu ZTF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11339
NR 30
TC 1
Z9 2
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 62
EP 68
DI 10.1016/j.toxicon.2019.04.016
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700008
PM 31047932
DA 2020-05-12
ER

PT J
AU Najafi, S
   Sanati, E
   Khademi, M
   Abdorrazaghi, F
   Mofrad, RK
   Rezasoltani, Z
AF Najafi, Sharif
   Sanati, Ehsan
   Khademi, Mahsa
   Abdorrazaghi, Fateme
   Mofrad, Reza Kazempoor
   Rezasoltani, Zahra
TI Intra-articular botulinum toxin type A for treatment of knee
   osteoarthritis: Clinical trial
SO TOXICON
LA English
DT Article
DE Botulinum toxins; Type A; abobotulinumtoxinA; Osteoarthritis; Knee;
   Aged; Pain
ID HIP OSTEOARTHRITIS; AQUATIC EXERCISE; JOINT PAIN; METAANALYSIS;
   MANAGEMENT
AB In recent years, there is a growing interest in new medical applications of botulinum toxin, including pain control, osteoarthritis treatment, and wound healing. While clinical applications of botulinum toxin seem promising, existing evidence regarding the therapeutic effects is still inadequate. The aim was to assess the efficacy of a single injection of abobotulinumtoxin A into the knee joint cavity to reduce pain in elderly people. We carried out a single group clinical trial in a University Hospital. Thirty participants (24 women) more than 50 years of age with knee osteoarthritis were included. Diagnosis of osteoarthritis was based on clinical and radiologic findings. We gave a single injection containing 250 units of Dysport (= 100 units of botulinum neurotoxin type A) diluted with 5 ml of normal saline. The primary outcome measure was knee pain. The secondary outcome was the patients' opinion about their knee and associated problems measured with the Knee injury and Osteoarthritis Outcome Score. The outcomes were measured at the baseline and at 4 weeks after the intervention. Within-group comparisons based on the Knee injury and Osteoarthritis Outcome Scores showed favorable results for joint pain and stiffness, sports, severity of symptoms, quality of life, and daily activities (all p-values < 0.001). Also, pain intensity, joint effusion, knee clicking and locking, and flexion-extension scores showed significant beneficial results (all p-values <= 0.005). We concluded that botulinum neurotoxin type A is an effective and safe initial treatment of knee osteoarthritis with clear clinical advantages. Patients' satisfaction, minimum adverse effects in addition to single-dose prescription make the toxin as a choice for the first-line therapy of osteoarthritis at least at the short-term in elderly people. The symptom relief increases the patient's compliance and willing to participate in other therapeutic programs.
C1 [Najafi, Sharif; Sanati, Ehsan; Khademi, Mahsa; Abdorrazaghi, Fateme; Rezasoltani, Zahra] Aja Univ Med Sci, Fac Med, Dept Phys Med & Rehabil, Etemadzadeh St, Tehran 1411718541, Iran.
   [Mofrad, Reza Kazempoor] Shahid Beheshti Univ Med Sci, Fac Med, Tehran, Iran.
RP Rezasoltani, Z (reprint author), Aja Univ Med Sci, Fac Med, Dept Phys Med & Rehabil, Etemadzadeh St, Tehran 1411718541, Iran.
EM sh.najafi@ajaums.ac.ir; ehsanati@ajaums.ac.ir; m_khademii@yahoo.com;
   f.m.abdorrazaghi@gmail.com; rezakazempoor@sbmu.ac.ir;
   Z.Rezasoltani@ajaums.ac.ir
RI Rezasoltani, Zahra/AAM-2569-2020; najafi, sharif/AAJ-4598-2020
OI rezasoltani, zahra/0000-0003-1864-9388
CR Altman R, 2018, SEMIN ARTHRITIS RHEU, V48, P168, DOI 10.1016/j.semarthrit.2018.01.009
   Bao X, 2018, J REHABIL MED, V50, P534, DOI 10.2340/16501977-2340
   Bastos R, 2018, KNEE SURG SPORT TR A, V26, P3342, DOI 10.1007/s00167-018-4883-9
   Batifol D, 2018, J STOMATOL ORAL MAXI, V119, P319, DOI 10.1016/j.jormas.2018.06.002
   Bowman EN, 2018, INT ORTHOP, V42, P733, DOI 10.1007/s00264-017-3731-8
   Braun HJ, 2012, BONE, V51, P278, DOI 10.1016/j.bone.2011.11.019
   Briani RV, 2018, BRIT J SPORT MED, V52, P1031, DOI 10.1136/bjsports-2017-098099
   Courseau M, 2018, CLIN J PAIN, V34, P383, DOI 10.1097/AJP.0000000000000538
   da Costa BR, 2017, LANCET, V390, pE21, DOI 10.1016/S0140-6736(17)31744-0
   Fonfria E, 2018, TOXINS, V10, DOI [10.3390/toxins10050208, DOI 10.3390/T0XINS10050208.[REVIEW]]
   Franco MR, 2017, PHYS THER, V97, P693, DOI 10.1093/ptj/pzx043
   Goh SL, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0321-6
   Hassan F, 2018, SPORTS MED ARTHROSC, V26, P79, DOI 10.1097/JSA.0000000000000190
   Heikkila HM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191043
   Hsieh LF, 2016, PM&R, V8, P1127, DOI 10.1016/j.pmrj.2016.05.009
   Hurley M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010842.pub2
   Khenioui H, 2016, JOINT BONE SPINE, V83, P149, DOI 10.1016/j.jbspin.2015.10.001
   Kuntz AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195653
   Matsumoto H, 2017, CLIN RHEUMATOL, V36, P1839, DOI 10.1007/s10067-017-3592-y
   McAlindon TE, 2018, NAT REV RHEUMATOL, V14, P73, DOI 10.1038/nrrheum.2017.219
   Mills K, 2019, SCHMERZ, V33, P22, DOI 10.1007/s00482-018-0275-9
   Nielsen FK, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1871-z
   O'Neil J, 2018, CLIN REHABIL, V32, P980, DOI 10.1177/0269215518763714
   Ogata T, 2018, CLIN RHEUMATOL, V37, P2479, DOI 10.1007/s10067-018-4106-2
   Peeler J, 2018, KNEE, V25, P135, DOI 10.1016/j.knee.2017.12.003
   Runhaar J, 2017, ANN RHEUM DIS, V76, P1862, DOI 10.1136/annrheumdis-2017-211149
   Safarpour Y, 2018, TOXICON, V147, P120, DOI 10.1016/j.toxicon.2018.01.017
   Shukla Divya, 2018, Anesth Essays Res, V12, P47, DOI 10.4103/aer.AER_210_17
   Simental-Mendia M, 2018, RHEUMATOL INT, V38, P1413, DOI 10.1007/s00296-018-4077-2
   Sliepen M, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1980-3
   Tian KW, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010240
   Waller B, 2017, OSTEOARTHR CARTILAGE, V25, P1238, DOI 10.1016/j.joca.2017.02.800
   Waller B, 2014, PHYS THER, V94, P1383, DOI 10.2522/ptj.20130417
   Ware JK, 2018, AM J SPORT MED, V46, P869, DOI 10.1177/0363546517751661
   Wyszynska J, 2018, PHOTOMED LASER SURG, V36, P343, DOI 10.1089/pho.2017.4425
NR 35
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 69
EP 77
DI 10.1016/j.toxicon.2019.04.003
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700009
PM 30995453
DA 2020-05-12
ER

PT J
AU Thakur, R
   Chattopadhyay, P
   Mukherjee, AK
AF Thakur, Rupamoni
   Chattopadhyay, Pronobesh
   Mukherjee, Ashis K.
TI The wound healing potential of a pro-angiogenic peptide purified from
   Indian Russell's viper (Daboia russelii) venom
SO TOXICON
LA English
DT Article
DE Aloe vera; antibacterial; Pro-angiogenic venom peptide; Wound healing
ID ANTICOAGULANT ACTIVITY; GROWTH-FACTORS; INHIBITION; DAMAGE
AB The cutaneous wound healing property of a pro-angiogenic venom peptide (RVVAP) in a cream-based formulation was evaluated using the excision wound healing model on Wistar strain rats. The wound healing potency and modest antibacterial activity of RVVAP was enhanced significantly (p < 0.05) when combined with Aloe vera extract. RVVAP was also found to be non-toxic at the tested dose of 1.0 mg/kg. Nevertheless, the release of inflammatory cytokines such as IL-1, IL-6, IL-10, and TNF-alpha in RVVAP-treated mice was suppressed, compared to the untreated controls. This is the first report assessing the wound healing potential of a low-molecular mass, non-enzymatic, pro-angiogenic peptide purified from snake venom.
C1 [Thakur, Rupamoni; Mukherjee, Ashis K.] Tezpur Univ, Dept Mol Biol & Biotechnol, Microbial Biotechnol & Prot Res Lab, Sch Sci, Tezpur 784028, Assam, India.
   [Thakur, Rupamoni] Dibrugarh Univ, Dept Life Sci, Dibrugarh 786004, Assam, India.
   [Chattopadhyay, Pronobesh] Def Res Lab, Div Pharmaceut Technol, Tezpur 784001, Assam, India.
RP Mukherjee, AK (reprint author), Tezpur Univ, Dept Mol Biol & Biotechnol, Tezpur 784028, Assam, India.
EM akm@tezu.ernet.in
FU DST-INSPIRE Fellowship [DST/INSPIRE fellowship/2010/[122]/IF10136]
FX The authors thank Dr. Glen Wheeler, Owl Editing, Canada, for editing the
   manuscript. RT was the recipient of DST-INSPIRE Fellowship (DST/INSPIRE
   fellowship/2010/[122]/IF10136).
CR Aravinthan A, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1497-3
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3
   Sant'Ana EMC, 2011, INT WOUND J, V8, P245, DOI 10.1111/j.1742-481X.2011.00776.x
   Daniels J. C, 2002, BOOK INDIAN REPTILES
   DAVIS RH, 1994, J AM PODIAT MED ASSN, V84, P77, DOI 10.7547/87507315-84-2-77
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Gosain A, 2004, WORLD J SURG, V28, P321, DOI 10.1007/s00268-003-7397-6
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Herrera C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004599
   Hochreiter-Hufford A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008748
   Kalita B, 2018, J PROTEOME RES, V17, P2819, DOI 10.1021/acs.jproteome.8b00291
   Koh DCI, 2006, CELL MOL LIFE SCI, V63, P3030, DOI 10.1007/s00018-006-6315-0
   Lopes JA, 2012, J VENOM ANIM TOXINS, V18, P73, DOI 10.1590/S1678-91992012000100009
   Menke NB, 2007, CLIN DERMATOL, V25, P19, DOI 10.1016/j.clindermatol.2006.12.005
   Mukherjee AK, 2000, TOXICON, V38, P163, DOI 10.1016/S0041-0101(99)00125-7
   Mukherjee AK, 2011, J PROTEINS PROTEOMIC, V2, P31
   Mukherjee AK, 2007, BBA-GEN SUBJECTS, V1770, P187, DOI 10.1016/j.bbagen.2006.09.021
   Mukherjee AK, 2014, THROMB RES, V134, P1150, DOI 10.1016/j.thromres.2014.09.009
   Mukherjee AK, 2014, INT J BIOL MACROMOL, V67, P154, DOI 10.1016/j.ijbiomac.2014.02.058
   Mukherjee AK, 2014, TOXICON, V77, P26, DOI 10.1016/j.toxicon.2013.10.024
   Nejatzadeh-Barandozi F, 2013, ORG MED CHEM LETT, V3, P1
   Samy RP, 2011, CURR MED CHEM, V18, P5104
   Samy RP, 2016, BIOCHEM PHARMACOL, V115, P1, DOI 10.1016/j.bcp.2016.03.006
   Samy RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080199
   Serra R, 2015, EXPERT REV ANTI-INFE, V13, P605, DOI 10.1586/14787210.2015.1023291
   Tang J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092082
   Thakur R, 2017, TOXICON, V131, P37, DOI 10.1016/j.toxicon.2017.03.011
   Thakur R, 2015, COMP BIOCHEM PHYS C, V168, P55, DOI 10.1016/j.cbpc.2014.12.001
   Thakur R, 2014, BIOCHIMIE, V105, P149, DOI 10.1016/j.biochi.2014.07.006
   Upadhyay A, 2013, J ETHNOPHARMACOL, V146, P490, DOI 10.1016/j.jep.2013.01.012
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835
NR 33
TC 0
Z9 0
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 78
EP 82
DI 10.1016/j.toxicon.2019.04.009
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700010
PM 31054289
DA 2020-05-12
ER

PT J
AU Aupanun, S
   Poapolathep, S
   Phuektes, P
   Giorgi, M
   Zhang, ZW
   Oswald, IP
   Poapolathep, A
AF Aupanun, Sawinee
   Poapolathep, Saranya
   Phuektes, Patchara
   Giorgi, Mario
   Zhang, Zhaowei
   Oswald, Isabelle P.
   Poapolathep, Amnart
TI Individual and combined mycotoxins deoxynivalenol, nivalenol, and
   fusarenon-X induced apoptosis in lymphoid tissues of mice after oral
   exposure
SO TOXICON
LA English
DT Article
DE Deoxynivalenol; Nivalenol; Fusarenon-X; Mycotoxin combination; Lymphoid
   tissues
ID TRICHOTHECENE VOMITOXIN DEOXYNIVALENOL; HUMAN T-CELLS; GENE-EXPRESSION;
   IN-SITU; MITOCHONDRIA; INDUCTION; TRANSPORT; GLYCOPROTEIN; INVOLVEMENT;
   HISTOLOGY
AB Lymphocytes are involved in the adaptive immune response and are highly sensitive to type B trichothecenes. In grains and their products, deoxynivalenol (DON) is the most widely distributed trichothecene. It usually co-occurs with other type B members, such as nivalenol (NIV) and fusarenon-X (FX), because they are all produced by the same Fusarium fungi. However, the combined effects of mycotoxins are complex and cannot be predicted based on individual toxicity. Thus, the adverse effects of combined toxins are of increasing concern. The aim of this study was to compare the toxicity to lymphoid tissues of mice of DON alone or mixed with NIV or FX. Forty, 3-week-old male ICR mice were given a single oral administration of a vehicle control, one toxin, binary, or ternary mixtures and then sacrificed at 12 h after exposure. Mice treated with FX alone showed marked nuclear condensation and fragmentation of lymphocytes in the cortical thymus and germinal center of Peyer's patches and spleen. Similarly, these animals clearly displayed TUNEL- and Caspase-3-positive cells in the regions. In contrast, minimal changes were noticed in the lymphoid tissues of mice receiving combined toxins when compared to this toxin alone. In addition, oral exposure to FX alone significantly up-regulated the relative expression of Bax, Caspase-3, Caspase-9, and Trp53. These data increase our understanding of the toxic actions of DON, NIV, and FX alone or in combination to lymphocytes and can be used to assess the possible risk associated with their co-occurrences in foodstuffs to human and animal health.
C1 [Aupanun, Sawinee; Poapolathep, Saranya; Poapolathep, Amnart] Kasetsart Univ, Fac Vet Med, Dept Pharmacol, Bangkok 10900, Thailand.
   [Aupanun, Sawinee; Poapolathep, Saranya; Poapolathep, Amnart] KU, NRU, CASAF, KU Inst Adv Studies, Bangkok 10900, Thailand.
   [Phuektes, Patchara] Khonkaen Univ, Fac Vet Med, Dept Pathobiol, Khon Kaen 40002, Thailand.
   [Giorgi, Mario] Univ Pisa, Dept Vet Sci, Via Livornese, I-56122 Pisa, Italy.
   [Zhang, Zhaowei] Chinese Acad Agr Sci, Oil Crops Res Inst, Wuhan 430062, Hubei, Peoples R China.
   [Oswald, Isabelle P.] Univ Toulouse, Toxalim Res Ctr Food Toxicol, INRA, ENVT,INP Purpan,UPS, Toulouse, France.
RP Poapolathep, A (reprint author), Kasetsart Univ, Fac Vet Med, Dept Pharmacol, Chatuchak Bangkok 10900, Thailand.
EM fvetamp@ku.ac.th
RI OSWALD, Isabelle P/A-8497-2013; OSWALD, Isabelle/W-9852-2019
OI OSWALD, Isabelle P/0000-0001-9918-277X; OSWALD,
   Isabelle/0000-0001-9918-277X; Poapolathep, Amnart/0000-0001-5322-3281
FU Center for Advanced Studies for Agriculture and Food Institute for
   Advanced Studies, Kasetsart University under the Higher Education
   Research Promotion; National Research University Project of Thailand,
   Office of the Higher Education Commission, Ministry of Education,
   Thailand
FX This work was partially supported by the Center for Advanced Studies for
   Agriculture and Food Institute for Advanced Studies, Kasetsart
   University under the Higher Education Research Promotion and National
   Research University Project of Thailand, Office of the Higher Education
   Commission, Ministry of Education, Thailand. Authors acknowledge the
   English editing of the manuscript to Dr. H. Owen (University of
   Queensland, Australia).
CR Alassane-Kpembi I, 2015, ARCH TOXICOL, V89, P1337, DOI 10.1007/s00204-014-1309-4
   Alassane-Kpembi I, 2013, TOXICOL APPL PHARM, V272, P191, DOI 10.1016/j.taap.2013.05.023
   ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102
   Aupanun S, 2019, TOXICON, V160, P29, DOI 10.1016/j.toxicon.2019.02.006
   Aupanun S, 2016, TOXICON, V123, P15, DOI 10.1016/j.toxicon.2016.10.012
   Aupanun S, 2015, RES VET SCI, V102, P217, DOI 10.1016/j.rvsc.2015.08.012
   Avantaggiato G, 2004, FOOD CHEM TOXICOL, V42, P817, DOI 10.1016/j.fct.2004.01.004
   AZCONAOLIVERA JI, 1995, TOXICOL APPL PHARM, V133, P109, DOI 10.1006/taap.1995.1132
   Bensassi F, 2012, FOOD CHEM TOXICOL, V50, P1680, DOI 10.1016/j.fct.2012.01.015
   Bensassi F, 2009, TOXICOLOGY, V264, P104, DOI 10.1016/j.tox.2009.07.020
   Berthiller F, 2007, INT J FOOD MICROBIOL, V119, P33, DOI 10.1016/j.ijfoodmicro.2007.07.022
   BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1
   Bracarense APFL, 2017, WORLD MYCOTOXIN J, V10, P89, DOI 10.3920/WMJ2016.2094
   Cavaliere C, 2005, RAPID COMMUN MASS SP, V19, P2085, DOI 10.1002/rcm.2030
   Cavret S, 2006, FOOD CHEM TOXICOL, V44, P444, DOI 10.1016/j.fct.2005.08.021
   Cesta MF, 2006, TOXICOL PATHOL, V34, P455, DOI 10.1080/01926230600867743
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Gerez JR, 2015, EXP TOXICOL PATHOL, V67, P89, DOI 10.1016/j.etp.2014.10.001
   Hussein HS, 2001, TOXICOLOGY, V167, P101, DOI 10.1016/S0300-483X(01)00471-1
   International Agency for Research on Cancer (IARC), 1993, IARC MONOGRAPHS EVAL, V56
   Ivanova L, 2018, TOXICOL LETT, V284, P21, DOI 10.1016/j.toxlet.2017.11.021
   Jung Camille, 2010, Int J Inflam, V2010, P823710, DOI 10.4061/2010/823710
   Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757
   Katika MR, 2015, J IMMUNOTOXICOL, V12, P206, DOI 10.3109/1547691X.2014.925995
   Kovalsky P, 2016, TOXINS, V8, DOI 10.3390/toxins8120363
   Ma YN, 2012, TOXICOL IN VITRO, V26, P414, DOI 10.1016/j.tiv.2012.01.010
   Marzocco S, 2009, TOXICOL LETT, V189, P21, DOI 10.1016/j.toxlet.2009.04.024
   Mazumder P M, 2001, Anc Sci Life, V20, P1
   Miura K, 1998, TOXICOLOGY, V127, P195, DOI 10.1016/S0300-483X(98)00023-7
   Pearse G, 2006, TOXICOL PATHOL, V34, P504, DOI 10.1080/01926230600865549
   Pestka JJ, 2005, TOXICOLOGY, V206, P207, DOI 10.1016/j.tox.2004.08.020
   Pestka JJ, 2004, TOXICOL LETT, V153, P61, DOI 10.1016/j.toxlet.2004.04.023
   Poapolathep A, 2002, EXP TOXICOL PATHOL, V53, P441, DOI 10.1078/0940-2993-00211
   Poapolathep A, 2003, TOXICON, V41, P1047, DOI 10.1016/S0041-0101(03)00089-8
   Rodrigues I, 2012, TOXINS, V4, P663, DOI 10.3390/toxins4090663
   Rodriguez-Carrasco Y, 2013, CHEMOSPHERE, V93, P2297, DOI 10.1016/j.chemosphere.2013.07.086
   Rodriguez-Carrasco Y, 2014, FOOD CHEM, V146, P212, DOI 10.1016/j.foodchem.2013.09.053
   Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523
   Schollenberger M, 2012, TOXINS, V4, P778, DOI 10.3390/toxins4100778
   Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x
   Sobrova Pavlina, 2010, Interdiscip Toxicol, V3, P94, DOI 10.2478/v10102-010-0019-x
   Streit E, 2013, J SCI FOOD AGR, V93, P2892, DOI 10.1002/jsfa.6225
   Streit E, 2012, TOXINS, V4, P788, DOI 10.3390/toxins4100788
   Sutjarit S, 2014, TOXICOL LETT, V229, P292, DOI 10.1016/j.toxlet.2014.06.843
   Tep J, 2007, TOXICOL LETT, V170, P248, DOI 10.1016/j.toxlet.2007.03.012
   Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5
   UENO Y, 1983, TRICHOTHECENES CHEM
   van Krieken J. H. J. M, 1997, CURR DIAGN PATHOL, V4, P100
   Videmann B, 2007, FOOD CHEM TOXICOL, V45, P1938, DOI 10.1016/j.fct.2007.04.011
   WILS P, 1994, J PHARMACOL EXP THER, V269, P654
   Wu Wen-liang, 2013, SCI J ELECT ENG, V3, P8, DOI DOI 10.1371/J0URNAL.P0NE.0082679
   Wu WD, 2012, FOOD CHEM TOXICOL, V50, P2056, DOI 10.1016/j.fct.2012.03.055
   Zhou HR, 2000, TOXICOL SCI, V53, P253, DOI 10.1093/toxsci/53.2.253
NR 54
TC 1
Z9 1
U1 6
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 83
EP 94
DI 10.1016/j.toxicon.2019.04.017
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700011
PM 31054920
DA 2020-05-12
ER

PT J
AU Shafee, T
   Mitchell, ML
   Norton, RS
AF Shafee, Thomas
   Mitchell, Michela L.
   Norton, Raymond S.
TI Mapping the chemical and sequence space of the ShKT superfamily
SO TOXICON
LA English
DT Article
DE ShKT; Cysteine-rich peptide; Disulfide-rich protein; Peptide evolution;
   Peptide structure; Sequence analysis
ID POTASSIUM-CHANNEL TOXIN; CRYSTAL-STRUCTURE; R PACKAGE; PROTEIN; DOMAIN;
   PEPTIDE; INHIBITOR; METALLOPROTEINASE; EVOLUTION; GENOME
AB The ShKT superfamily is widely distributed throughout nature and encompasses a wide range of documented functions and processes, from modulation of potassium channels to involvement in morphogenesis pathways. Cysteine-rich secretory proteins (CRISPs) contain a cysteine-rich domain (CRD) at the C-terminus that is similar in structure to the ShK fold. Despite the structural similarity of the CRD and ShK-like domains, we know little of the sequence-function relationships in these families. Here, for the first time, we examine the evolution of the biophysical properties of sequences within the ShKT superfamily in relation to function, with a focus on the ShK-like superfamily. ShKT data were sourced from published sequences in the protein family database, in addition to new ShK-like sequences from the Australian speckled anemone (Oulactis sp.). Our analysis clearly delineates the ShK-like family from the CRDs of CRISP proteins. The four CRISP subclusters separate out into the main phyla of Mammalia, Insecta and Reptilia. The ShK-like family is in turn composed of seven subclusters, the largest of which contains members from across the eukaryotes, with a continuum of intermediate properties. Smaller sub-clusters contain specialised members such as nematode ShK-like sequences. Several of these ShKT sub-clusters contain no functionally characterised sequences. This chemical space analysis should be useful as a guide to select sequences for functional studies and to gain insight into the evolution of these highly divergent sequences with an ancient conserved fold.
C1 [Shafee, Thomas] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia.
   [Shafee, Thomas] La Trobe Univ, AgriBio, Dept Anim Plant & Soil Sci, Melbourne, Vic 3086, Australia.
   [Mitchell, Michela L.; Norton, Raymond S.] Monash Univ, Monash Inst Pharmaceut Sci, Med Chem, Parkville, Vic 3052, Australia.
   [Mitchell, Michela L.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia.
   [Mitchell, Michela L.] Museum Victoria, Marine Invertebrates, GPO Box 666, Melbourne, Vic 3001, Australia.
   [Mitchell, Michela L.] Queensland Museum, Biodivers & Geosci, POB 3300, South Brisbane, Qld 4101, Australia.
RP Shafee, T (reprint author), La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Melbourne, Vic 3086, Australia.
EM T.Shafee@LaTrobe.edu.au
OI Mitchell, Michela/0000-0001-6331-534X; Shafee,
   Thomas/0000-0002-2298-7593; Norton, Raymond/0000-0001-8893-0584
FU ARCFondation ARC pour la Recherche sur le CancerAustralian Research
   Council [LP150100621]; Australian Government Research Training Program
   ScholarshipAustralian GovernmentDepartment of Industry, Innovation and
   Science; Monash Medicinal Chemistry Faculty Scholarship; Australian
   National Health and Medical Research CouncilNational Health and Medical
   Research Council of Australia; Monash University - Museum Victoria
   Scholarship
FX The authors acknowledge Dr. Rodrigo A. V. Morales and Edward Airey for
   their contribution to the preparation of sequences used in the analysis.
   This project was funded in part by ARC linkage grant LP150100621. M.L.M
   acknowledges an Australian Government Research Training Program
   Scholarship, Monash Medicinal Chemistry Faculty Scholarship and Monash
   University - Museum Victoria Scholarship top-up. R.S.N acknowledges
   fellowship support from the Australian National Health and Medical
   Research Council.
CR Atchley WR, 2005, P NATL ACAD SCI USA, V102, P6395, DOI 10.1073/pnas.0408677102
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Campen A, 2008, PROTEIN PEPTIDE LETT, V15, P956, DOI 10.2174/092986608785849164
   CASTANEDA O, 1995, TOXICON, V33, P603, DOI 10.1016/0041-0101(95)00013-C
   Chandy KG, 2017, CURR OPIN CHEM BIOL, V38, P97, DOI 10.1016/j.cbpa.2017.02.015
   Chang S. C, 2018, WIKIJ SCI, V1, DOI [10.15347/wjs/2018.003, DOI 10.15347/WJS/2018.003]
   Chhabra S, 2014, FASEB J, V28, P3952, DOI 10.1096/fj.14-251967
   Chi V, 2012, TOXICON, V59, P529, DOI 10.1016/j.toxicon.2011.07.016
   Columbus-Shenkar YY, 2018, ELIFE, V7, DOI [10.7554/e.Life.35014.001, 10.7554/eLife.35014]
   Cotton J, 1997, EUR J BIOCHEM, V244, P192, DOI 10.1111/j.1432-1033.1997.00192.x
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Csardi G, 2006, INT J COMPLEX SYST, V1695, P1, DOI [10.3724/SP.J.1087.2009.02191, DOI 10.3724/SP.J.1087.2009.02191]
   Dash TS, 2019, STRUCTURE, V27, P315, DOI 10.1016/j.str.2018.10.022
   DeLano W.L., 2002, CCP4 NEWSLETTER PROT, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Development Core Team R, 2011, R LANG ENV STAT COMP
   Fautin D. G, 1998, ENCY REPROD, P645
   Fraley C, 2012, MCLUST VERSION 4 R N, V597, P1
   Galea CA, 2014, CELL MOL LIFE SCI, V71, P1191, DOI 10.1007/s00018-013-1431-0
   Garcia-Fernandez R, 2016, TOXINS, V8, DOI 10.3390/toxins8040110
   Gibbs GM, 2008, ENDOCR REV, V29, P865, DOI 10.1210/er.2008-0032
   Gibbs GM, 2006, J BIOL CHEM, V281, P4156, DOI 10.1074/jbc.M506849200
   Guo M, 2005, J BIOL CHEM, V280, P12405, DOI 10.1074/jbc.M413566200
   Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181
   Inkpen SA, 2016, J MOL EVOL, V83, P184, DOI 10.1007/s00239-016-9766-4
   Jackson MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04669-9
   Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697
   Krishnarjuna B, 2018, TOXICON, V150, P50, DOI 10.1016/j.toxicon.2018.05.006
   Krishnarjuna B, 2018, PEPTIDES, V99, P169, DOI 10.1016/j.peptides.2017.10.001
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lanigan M.D., 2002, ACTINIA EQUINA, V41, P11963, DOI [10.1021/bi026400b, DOI 10.1016/50014-5793(98)00403-7]
   Lanigan MD, 2002, BIOCHEMISTRY-US, V41, P11963, DOI 10.1021/bi026400b
   Mitchell ML, 2019, PROTEINS, V87, P551, DOI 10.1002/prot.25679
   Moran Y, 2013, MAR BIOTECHNOL, V15, P329, DOI 10.1007/s10126-012-9491-y
   Nguyen HM, 2013, J BIOL CHEM, V288, P6451, DOI 10.1074/jbc.M112.421495
   Ovchinnikova TV, 2006, BIOCHEM BIOPH RES CO, V348, P514, DOI 10.1016/j.bbrc.2006.07.078
   Oxley PR, 2014, CURR BIOL, V24, P451, DOI 10.1016/j.cub.2014.01.018
   Pan TL, 1998, DEV GENES EVOL, V208, P259, DOI 10.1007/s004270050180
   Pearson WR, 2005, CURR OPIN STRUC BIOL, V15, P254, DOI 10.1016/j.sbi.2005.05.005
   Peigneur S, 2011, BIOCHEM PHARMACOL, V82, P81, DOI 10.1016/j.bcp.2011.03.023
   Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g
   Ponce D, 2016, TOXINS, V8, DOI 10.3390/toxins8040102
   PRENTIS PJ, 2018, TOXINS, V10, DOI DOI 10.3390/TOXINS8040102
   Punta M, 2012, NUCLEIC ACIDS RES, V40, pD290, DOI 10.1093/nar/gkr1065
   Rangaraju S, 2010, J BIOL CHEM, V285, P9124, DOI 10.1074/jbc.M109.071266
   Rashid MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078712
   Revell LJ, 2012, METHODS ECOL EVOL, V3, P217, DOI 10.1111/j.2041-210X.2011.00169.x
   Richards S, 2008, NATURE, V452, P949, DOI 10.1038/nature06784
   Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85
   Shafee T, 2019, BIOINFORMATICS, V35, P743, DOI 10.1093/bioinformatics/bty697
   Shafee T, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1300-6
   Shafee TMA, 2017, CELL MOL LIFE SCI, V74, P663, DOI 10.1007/s00018-016-2344-5
   SHAFEE TMA, 2016, SPRINGERPLUS, V5, DOI DOI 10.1007/S00018-016-2344-5
   Shikamoto Y, 2005, J MOL BIOL, V350, P735, DOI 10.1016/j.jmb.2005.05.020
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Sunagar K, 2012, MOL BIOL EVOL, V29, P1807, DOI 10.1093/molbev/mss058
   Sunanda P, 2018, PEPTIDE SCI, V110, DOI 10.1002/pep2.24073
   Tarcha EJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180762
   Tsang SW, 2007, DEV BIOL, V312, P353, DOI 10.1016/j.ydbio.2007.09.037
   Tudor J.E., 1996, BIOL REPROD, V3, P317, DOI [10.1038/nsb0496-317, DOI 10.1095/BIOLREPROD.111.092403]
   Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317
   van der Burg CA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3204-2
   WAKE DB, 1991, AM NAT, V138, P543, DOI 10.1086/285234
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Yan L, 2000, DEVELOPMENT, V127, P129
NR 64
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 95
EP 102
DI 10.1016/j.toxicon.2019.04.008
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700012
PM 31063742
DA 2020-05-12
ER

PT J
AU Ling, SM
   Li, XL
   Zhang, DP
   Wang, K
   Zhao, WW
   Zhao, Q
   Wang, RZ
   Yuan, J
   Xin, SJ
   Wang, SH
AF Ling, Sumei
   Li, Xiulan
   Zhang, Danping
   Wang, Ke
   Zhao, Wenwen
   Zhao, Qiang
   Wang, Rongzhi
   Yuan, Jun
   Xin, Sijie
   Wang, Shihua
TI Detection of okadaic acid (OA) and tetrodotoxin (TTX) simultaneously in
   seafood samples using colloidal gold immunoassay
SO TOXICON
LA English
DT Article
DE Monoclonal antibody; Colloidal gold immunoassay; Okadaic acid;
   Tetrodotoxin
ID LINKED-IMMUNOSORBENT-ASSAY; PERFORMANCE LIQUID-CHROMATOGRAPHY;
   MONOCLONAL-ANTIBODY; IMMUNOCHROMATOGRAPHIC ASSAY; RAPID DETECTION;
   FUMONISIN B-1; STRIP TEST; SHELLFISH; IDENTIFICATION; ZEARALENONE
AB Tetrodotoxin (TTX) is a neurotoxin mainly responsible for severe neurological illness, and okadaic acid (OA) is another important lipophilic toxin to humans. In this study, we developed a gold strip for simultaneous detection of OA and TTX in real seafood samples. In the assay, the prepared nanoparticles (about 40 nm) was applied to conjugate with specific monoclonal antibodies against OA and TTX, and the resulted mixtures were used to capture its corresponding toxin in test strip. OA and TTX conjugates were coated as two test lines on the nitrocellulose membrane, and goat anti-mouse IgG was used to form the control line, forming three lines on the test strip. The visual detection limits (vLOD) of this immunoassay for OA and TTX were 0.75 and 15 ng/mL, respectively, and no cross reactions were observed in the process of detection. The visual assay for OA and TTX detection could be finished within 10 min. This study might provide a feasible method and good understanding for rapidly simultaneous detection for toxins based on immunoassay.
C1 [Wang, Shihua] Fujian Agr & Forestry Univ, Educ Minist, Key Lab Biopesticide & Chem Biol, Key Lab Pathogen Fungi & Mycotoxins Fujian Prov, Fuzhou 350002, Fujian, Peoples R China.
   Fujian Agr & Forestry Univ, Sch Life Sci, Fuzhou 350002, Fujian, Peoples R China.
RP Wang, SH (reprint author), Fujian Agr & Forestry Univ, Educ Minist, Key Lab Biopesticide & Chem Biol, Key Lab Pathogen Fungi & Mycotoxins Fujian Prov, Fuzhou 350002, Fujian, Peoples R China.
EM wshhhy@sina.com
FU Science and Technology Project in Fujian Province [2017Y4002,
   2018N0002]; Department of Education Project in Fujian Province
   [JAT170205]; Project of Fujian Marine and fishery Department; Fujian
   Provincial Development and Reform Commission
FX This work was supported by the Science and Technology Project in Fujian
   Province (2017Y4002, 2018N0002), Department of Education Project in
   Fujian Province (JAT170205), Project of Fujian Marine and fishery
   Department (Fujian marine hi-tech [2015] 26), and Fujian Provincial
   Development and Reform Commission (the study and invention of a new type
   of marine biotoxin detection kit, [2013] 229).
CR Amada T, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-87
   An TY, 2010, TOXICON, V55, P653, DOI 10.1016/j.toxicon.2009.08.018
   Bane V, 2016, FOOD ADDIT CONTAM A, V33, P1728, DOI 10.1080/19440049.2016.1235801
   Du W, 2014, FOOD CHEM, V145, P789, DOI 10.1016/j.foodchem.2013.08.094
   Foubert A, 2017, ANAL CHIM ACTA, V955, P48, DOI 10.1016/j.aca.2016.11.042
   Garcia C, 2010, J TOXICOL SCI, V35, P335, DOI 10.2131/jts.35.335
   Jin N, 2014, TOXICON, V90, P226, DOI 10.1016/j.toxicon.2014.08.057
   Kawatsu K, 2014, FOOD CHEM, V162, P94, DOI [10.1016/, 10.1016/j.foodchem.2014.04.038]
   Le T, 2013, FOOD CHEM, V138, P1610, DOI 10.1016/j.foodchem.2012.11.077
   Li X, 2013, BIOSENS BIOELECTRON, V49, P426, DOI 10.1016/j.bios.2013.05.039
   Lin T, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-418
   Ling SM, 2015, TOXICON, V108, P210, DOI 10.1016/j.toxicon.2015.10.014
   Ling SM, 2015, BIOSENS BIOELECTRON, V71, P256, DOI 10.1016/j.bios.2015.04.049
   Ling SM, 2014, TOXICON, V80, P64, DOI 10.1016/j.toxicon.2013.12.008
   Liu BH, 2014, J AGR FOOD CHEM, V62, P1254, DOI 10.1021/jf404827s
   Lu SY, 2012, ANAL BIOCHEM, V422, P59, DOI 10.1016/j.ab.2011.12.039
   O'Leary MA, 2004, TOXICON, V44, P549, DOI 10.1016/j.toxicon.2004.07.008
   Paz B, 2008, MAR DRUGS, V6, P489, DOI 10.3390/md20080024
   Smienk HGF, 2012, TOXINS, V4, P339, DOI 10.3390/toxins4050339
   Stokes AN, 2012, BIOL PROCED ONLINE, V14, DOI 10.1186/1480-9222-14-3
   Suzuki T, 2011, ANAL SCI, V27, P571, DOI 10.2116/analsci.27.571
   Tao J, 2010, FOOD ADDIT CONTAM A, V27, P1589, DOI 10.1080/19440049.2010.504237
   Tsao ZJ, 2007, J AGR FOOD CHEM, V55, P4921, DOI 10.1021/jf0708140
   Vdovenko MM, 2013, TALANTA, V116, P343, DOI 10.1016/j.talanta.2013.05.057
   Wang RZ, 2017, J HAZARD MATER, V339, P154, DOI 10.1016/j.jhazmat.2017.06.030
   Wang YK, 2013, J AGR FOOD CHEM, V61, P5031, DOI 10.1021/jf400803q
   Zhou Y, 2009, FOOD CHEM, V112, P582, DOI 10.1016/j.foodchem.2008.06.022
   Zhou Y, 2010, SENSOR ACTUAT B-CHEM, V146, P368, DOI 10.1016/j.snb.2010.02.049
NR 28
TC 1
Z9 1
U1 8
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 103
EP 109
DI 10.1016/j.toxicon.2019.04.011
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700013
PM 31029635
DA 2020-05-12
ER

PT J
AU Liu, YM
   Ming, W
   Wang, Y
   Liu, SH
   Qiu, YF
   Xiang, YX
   Hu, LL
   Fan, LJ
   Peng, X
   Wang, H
   Kong, TH
   Dong, WH
   Guo, QF
AF Liu, Yamin
   Ming, Wei
   Wang, Yan
   Liu, Sihong
   Qiu, Yanfen
   Xiang, Yongxin
   Hu, Lili
   Fan, Lingjie
   Peng, Xiang
   Wang, Han
   Kong, Tianhan
   Dong, Weihua
   Guo, Qifeng
TI Cytotoxin 1 from Naja atra Cantor venom induced necroptosis of leukemia
   cells
SO TOXICON
LA English
DT Article
DE CTX1; Necroptosis; Lysosome cell death; Leukemia
ID LYSOSOMAL MEMBRANE PERMEABILIZATION; ACUTE MYELOID-LEUKEMIA; RIP1
   KINASE; CANCER; DEATH; CASPASES; HEALTH; COBRA
AB Background: Cytotoxin 1 (CTX1) purified from Naja atra Cantor venom could inhibit cancer cell proliferation, but the mechanism is not clear. This study aimed to investigate the mechanism by which leukemia cells are killed by CTX1.
   Materials and methods: HL-60 and KG1 a cells were treated with CTX1 and the cell death was detected.
   Results: The viability of HL-60 and KG1 a cells decreased in a dose- and time-dependent manner after treatment with CTX1. CTX1 mainly induced late apoptosis and necrosis. The cell death induced by CTX1 could be rescued by specific necroptosis inhibitor Nec-1 but not by caspase inhibitor Z-VAD-fmk in HL-60 cells. In addition, CTX1 increased lysosome membrane permeability (LMP) and release of cathepsin B.
   Conclusion: CTX1 could induce necroptosis in leukemia cells, and it is related to LMP increase and cathepsin release. CTX1 could be a promising anti-cancer drug for leukemia therapy.
C1 [Liu, Yamin; Wang, Yan; Liu, Sihong; Guo, Qifeng] South China Univ Technol, Sch Med, Guangzhou Peoples Hosp 1, Dept Orthopaed, Guangzhou 510180, Guangdong, Peoples R China.
   [Ming, Wei] Hetao Coll, Med Humanities Teaching & Res Off, Bayannur City 015000, Inner Mongolia, Peoples R China.
   [Qiu, Yanfen; Xiang, Yongxin; Hu, Lili; Fan, Lingjie; Peng, Xiang; Wang, Han; Kong, Tianhan; Dong, Weihua] Guangzhou Med Univ, Dept Pathophysiol, Guangzhou 510182, Guangdong, Peoples R China.
RP Dong, WH (reprint author), Guangzhou Med Univ, Dept Pathophysiol, Guangzhou 510182, Guangdong, Peoples R China.; Guo, QF (reprint author), South China Univ Technol, Guangzhou Peoples Hosp 1, Sch Med, Dept Orthoped, 1 Panfu Rd, Guangzhou 510180, Guangdong, Peoples R China.
EM dong_gz@163.com; guoqifenggz@163.com
CR Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Chen DS, 2016, BBA-REV CANCER, V1865, P228, DOI 10.1016/j.bbcan.2016.03.003
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Dubovskii PV, 2005, BIOCHEM J, V387, P807, DOI 10.1042/BJ20041814
   Feofanov AV, 2005, BIOCHEM J, V390, P11, DOI 10.1042/BJ20041892
   Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9
   Grootjans S, 2017, CELL DEATH DIFFER, V24, P1184, DOI 10.1038/cdd.2017.65
   Groth-Pedersen L, 2013, CANCER LETT, V332, P265, DOI 10.1016/j.canlet.2010.05.021
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HAYASHI K, 1975, BIOCHEM BIOPH RES CO, V64, P360, DOI 10.1016/0006-291X(75)90262-4
   Marquez M, 2004, ANTICANCER RES, V24, P1347
   Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852
   Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003
   Sachet M, 2017, APOPTOSIS, V22, P1189, DOI 10.1007/s10495-017-1413-z
   Serrano-Puebla A, 2016, ANN NY ACAD SCI, V1371, P30, DOI 10.1111/nyas.12966
   Su Z, 2016, CELL DEATH DIFFER, V23, P748, DOI 10.1038/cdd.2016.8
   Sukhai MA, 2013, J CLIN INVEST, V123, P315, DOI 10.1172/JCI64180
   Suzuki-Matsubara M, 2016, COMP BIOCHEM PHYS C, V179, P158, DOI 10.1016/j.cbpc.2015.09.015
   Wang Z, 2015, INT J BIOCHEM CELL B, V64, P126, DOI 10.1016/j.biocel.2015.03.018
   Wu MY, 2013, AM J CHINESE MED, V41, P643, DOI 10.1142/S0192415X13500456
   Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047
   Zhong J, 2018, BIOCELL, V42, P99, DOI 10.32604/biocell.2018.04915
   Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013
NR 25
TC 0
Z9 0
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUL
PY 2019
VL 165
BP 110
EP 115
DI 10.1016/j.toxicon.2019.04.012
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IF1BS
UT WOS:000472812700014
PM 31029638
DA 2020-05-12
ER

PT J
AU Cupo, KL
   Beckstead, RB
AF Cupo, Katherine L.
   Beckstead, Robert B.
TI PCR detection of Heterakis gallinarum in environmental samples
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Diagnostic PCR; Heterakis gallinarum; Histomonas meleagridis; Earthworm;
   Darkling beetle
ID HISTOMONAS-MELEAGRIDIS; TRANSMISSION; CHICKEN; TURKEYS
AB Heterakis gallinarum is a widely distributed cecal nematode that parasitizes gallinaceous birds including chickens and turkeys. H. gallinarum infection poses a problem for the poultry industry as the nematode egg serves as a vector for the protozoan parasite, Histomonas meleagridis, the causative agent of histomonosis. The only means of detecting H. gallinarum in the environment is microscopic identification of the eggs in soil or feces; however, H. gallinarum eggs are often mistaken for those of Ascaridia gall. Three primer sets were designed from sequences cloned from the H. gallinarum genome to develop a diagnostic PCR. Each of these primer sets amplified a single product from H. gallinarum, but were unable to amplify DNA from H. meleagridis, Ascaridia gall, or Cestode sp. H. gallinarum DNA was amplified from Lumbricus sp. (earthworms) and Alphitobius diaperinus (darkling beetles), confirming that the earthworm acts as a paratenic host for H. gallinarum and suggesting that the darkling beetle may be a carrier for this nematode.
C1 [Cupo, Katherine L.; Beckstead, Robert B.] North Carolina State Univ, Prestage Dept Poultry Sci, Box 7608, Raleigh, NC 27695 USA.
RP Beckstead, RB (reprint author), North Carolina State Univ, Prestage Dept Poultry Sci, Box 7608, Raleigh, NC 27695 USA.
EM beckstead@ncsu.edu
OI Beckstead, Robert/0000-0001-6827-0515
FU US Poultry and Egg Association
FX Funding for this project was provided by the US Poultry and Egg
   Association.
CR Amor N, 2018, TURK J VET ANIM SCI, V42, P388, DOI 10.3906/vet-1803-28
   Boubaker G, 2016, MOL CELL PROBE, V30, P211, DOI 10.1016/j.mcp.2016.05.004
   Das G, 2011, VET PARASITOL, V176, P208, DOI 10.1016/j.vetpar.2010.11.004
   FARR MM, 1961, CORNELL VET, V51, P3
   Gu XB, 2018, MITOCHONDRIAL DNA A, V29, P629, DOI 10.1080/24701394.2017.1334771
   Gu XB, 2016, MITOCHONDRIAL DNA A, V27, P3612, DOI 10.3109/19401736.2015.1079825
   Huber K, 2007, AVIAN PATHOL, V36, P279, DOI 10.1080/03079450701447317
   Ibanez-Escribano A, 2014, PARASITOL INT, V63, P427, DOI 10.1016/j.parint.2013.12.017
   Jimenez FA, 2012, J PARASITOL, V98, P1166, DOI 10.1645/GE-3045.1
   KAUSHIK R K, 1969, Journal of Helminthology, V43, P69, DOI 10.1017/S0022149X0000393X
   LUND E E, 1974, International Journal for Parasitology, V4, P455, DOI 10.1016/0020-7519(74)90061-7
   LUND EE, 1974, J PARASITOL, V60, P683, DOI 10.2307/3278739
   LUND EE, 1966, J PARASITOL, V52, P899, DOI 10.2307/3276528
   Permin A, 1999, BRIT POULTRY SCI, V40, P439, DOI 10.1080/00071669987179
   Powell FL, 2009, PARASITE IMMUNOL, V31, P312, DOI 10.1111/j.1365-3024.2009.01113.x
   Sigmon CS, 2019, J APPL POULTRY RES, V28, P755, DOI 10.3382/japr/pfz029
   Smith T., 1895, USDA B, V8, P7
   Smythe AB, 2006, SYST BIOL, V55, P972, DOI 10.1080/10635150601089001
   Tyzzer EE, 1934, P AM ACAD ARTS SCI, V69, P189, DOI 10.2307/20023041
   Tyzzer EE, 1926, P SOC EXP BIOL MED, V23, P708
   Tyzzer EF, 1920, J INFECT DIS, V27, P207, DOI 10.1093/infdis/27.3.207
   Wang BJ, 2016, INFECT GENET EVOL, V40, P228, DOI 10.1016/j.meegid.2016.03.012
NR 22
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 1
EP 6
DI 10.1016/j.vetpar.2019.05.011
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400001
PM 31303197
DA 2020-05-12
ER

PT J
AU Ceballos, L
   Canton, C
   Pruzzo, C
   Sanabria, R
   Moreno, L
   Sanchis, J
   Suarez, G
   Ortiz, P
   Fairweather, I
   Lanusse, C
   Alvarez, L
   Martinez-Valladares, M
AF Ceballos, Laura
   Canton, Candela
   Pruzzo, Cesar
   Sanabria, Rodrigo
   Moreno, Laura
   Sanchis, Jaime
   Suarez, Gonzalo
   Ortiz, Pedro
   Fairweather, Ian
   Lanusse, Carlos
   Alvarez, Luis
   Martinez-Valladares, Maria
TI The egg hatch test: A useful tool for albendazole resistance diagnosis
   in Fasciola hepatica
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola hepatica; Albendazole; Resistance; Egg hatch test
ID ANTHELMINTIC RESISTANCE; IN-VIVO; SULFOXIDE METABOLITE; DRUG-RESISTANCE;
   LIVER FLUKE; TRICLABENDAZOLE; EFFICACY; NEMATODES; SHEEP; SURFACE
AB In the current study, the egg hatch test (EHT) has been evaluated as an in vitro technique to detect albendazole (ABZ) resistance in Fasciola hepatica. The intra- and inter-assay variations of the EHT were measured by means of the coefficient of variation in different fluke isolates and over time; then, the results of the EHT were compared with the "gold standard" controlled efficacy test, which assesses the in vivo anthelmintic efficacy. The EHT was used later to evaluate the intra-herd variability regarding the level of ABZ resistance in calves infected by the same fluke isolate. Finally, several factors of the initial protocol were modified to improve the simplicity of the assay, including the incubation time of eggs with the drug and the use of eggs collected from faeces. The greatest uniformity between results within the assay and over time until 8 weeks after gallbladder collection (the deadline proposed for egg analysis) was obtained with an ABZ concentration of 0.5 mu M. The length of exposure to ABZ was shown to be critical, as prolonged incubation (15 days) led to a change of ovicidal activity. The ABZ concentration of 0.5 mu M is suggested as a possible discriminating dose to predict ABZ resistance, due to the close agreement between the results of the EHT at an ABZ concentration of 0.5 mu M and those of the in vivo assays.
C1 [Ceballos, Laura; Canton, Candela; Moreno, Laura; Lanusse, Carlos; Alvarez, Luis] UNCPBA CICPBA CONICET, Ctr Invest Vet Tandil CIVETAN, Lab Farmacol, Fac Ciencias Vet, Campus Univ, Tandil, Argentina.
   [Pruzzo, Cesar; Sanabria, Rodrigo] UNLP, Fac Ciencias Vet, La Plata, Buenos Aires, Argentina.
   [Sanabria, Rodrigo] CONICET UNSAM, INTECH, Chascomus, Argentina.
   [Sanchis, Jaime] Univ Republ Reg Norte, Dept Parasitol, Salto, Uruguay.
   [Suarez, Gonzalo] Univ Republ UDELAR, Fac Vet, Area Farmacol, Montevideo, Uruguay.
   [Ortiz, Pedro] UNC, Fac Ciencias Vet, Cajamarca, Peru.
   [Fairweather, Ian] Queens Univ Belfast, Sch Biol Sci, Belfast, Antrim, North Ireland.
   [Martinez-Valladares, Maria] Univ Leon, CSIC, Inst Ganaderia Montana, Dept Anim Hlth, Leon, Spain.
RP Alvarez, L (reprint author), UNCPBA CICPBA CONICET, Ctr Invest Vet Tandil CIVETAN, Lab Farmacol, Fac Ciencias Vet, Campus Univ, Tandil, Argentina.
EM lalvarez@vet.unicen.edu.ar
RI Martinez-Valladares, Maria/K-6847-2019
OI Martinez-Valladares, Maria/0000-0002-3723-1895
FU CONICET from ArgentinaConsejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); Agencia Nacional de PromociOn Cientifica y Tecnica
   (ANPCyT), from Argentina; Spanish "Ramon y Cajal" Programme, Ministry of
   Economy and Competitiveness (Ministerio de Economia y Competitividad)
   [RYC-2015-18368]
FX This study was partially supported by CONICET and Agencia Nacional de
   PromociOn Cientifica y Tecnica (ANPCyT), from Argentina, and by the
   Spanish "Ramon y Cajal" Programme, Ministry of Economy and
   Competitiveness (Ministerio de Economia y Competitividad) (MMV,
   RYC-2015-18368).
CR Alvarez L, 2009, VET PARASITOL, V164, P211, DOI 10.1016/j.vetpar.2009.05.014
   Alvarez-Sanchez MA, 2006, VET REC, V159, P424, DOI 10.1136/vr.159.13.424
   BORAY JC, 1983, VET REC, V113, P315, DOI 10.1136/vr.113.14.315
   Buchanan JF, 2003, PARASITOLOGY, V126, P141, DOI 10.1017/S0031182002002664
   Canevari J, 2014, J HELMINTHOL, V88, P286, DOI 10.1017/S0022149X13000163
   Coles GC, 2006, VET PARASITOL, V136, P167, DOI 10.1016/j.vetpar.2005.11.019
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   COLES GC, 1978, VET REC, V103, P360, DOI 10.1136/vr.103.16.360
   Devine C, 2012, VET PARASITOL, V184, P37, DOI 10.1016/j.vetpar.2011.08.006
   Devine C, 2010, PARASITOLOGY, V137, P871, DOI 10.1017/S003118200999148X
   Fairweather I, 2011, VET PARASITOL, V176, P1, DOI 10.1016/j.vetpar.2010.12.011
   Fairweather I, 2005, J HELMINTHOL, V79, P227, DOI 10.1079/JOH2005298
   Fairweather I, 2011, VET PARASITOL, V180, P133, DOI 10.1016/j.vetpar.2011.05.034
   Flanagan A, 2011, VET PARASITOL, V176, P170, DOI 10.1016/j.vetpar.2010.10.057
   Flanagan AM, 2011, VET PARASITOL, V176, P34, DOI 10.1016/j.vetpar.2010.10.037
   Hanna REB, 2010, VET PARASITOL, V168, P240, DOI 10.1016/j.vetpar.2009.11.014
   Kaplan RM, 2004, TRENDS PARASITOL, V20, P477, DOI 10.1016/j.pt.2004.08.001
   Kelley JM, 2016, TRENDS PARASITOL, V32, P458, DOI 10.1016/j.pt.2016.03.002
   Kotze AC, 2014, INT J PARASITOL-DRUG, V4, P164, DOI 10.1016/j.ijpddr.2014.07.007
   MAFF (Ministry of Agriculture Fisheries and Food), 1986, MAN VET PAR LAB TECH
   Martinez-Valladares M, 2013, VET PARASITOL, V191, P177, DOI 10.1016/j.vetpar.2012.08.009
   Mas-Coma S, 2018, PARASITOLOGY, V145, P1665, DOI [10.1017/S0031182018000914, 10.1017/s0031182018000914]
   McConville M, 2006, PARASITOLOGY, V133, P195, DOI 10.1017/S0031182006000114
   McConville M, 2009, VET PARASITOL, V162, P75, DOI 10.1016/j.vetpar.2009.02.004
   MCKELLAR QA, 1990, J VET PHARMACOL THER, V13, P223, DOI 10.1111/j.1365-2885.1990.tb00773.x
   Mooney L, 2009, VET PARASITOL, V164, P201, DOI 10.1016/j.vetpar.2009.05.017
   Novobilsky A, 2016, INT J PARASITOL-DRUG, V6, P141, DOI 10.1016/j.ijpddr.2016.06.004
   Ortiz P, 2013, VET PARASITOL, V195, P118, DOI 10.1016/j.vetpar.2013.01.001
   Robles-Perez D, 2014, VET PARASITOL, V203, P217, DOI 10.1016/j.vetpar.2013.11.020
   Sanabria R, 2013, VET PARASITOL, V193, P105, DOI 10.1016/j.vetpar.2012.11.033
   Sutherland IA, 2011, TRENDS PARASITOL, V27, P176, DOI 10.1016/j.pt.2010.11.008
   Toner E, 2010, PARASITOLOGY, V137, P855, DOI 10.1017/S0031182009991247
   Ueno H., 1988, MANUAL LAB DIAGNOSTI
   Walker SM, 2004, PARASITOL RES, V94, P427, DOI 10.1007/s00436-004-1222-5
   Wolstenholme AJ, 2004, TRENDS PARASITOL, V20, P469, DOI 10.1016/j.pt.2004.07.010
   WOOD IB, 1995, VET PARASITOL, V58, P181, DOI 10.1016/0304-4017(95)00806-2
NR 36
TC 2
Z9 2
U1 5
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 7
EP 13
DI 10.1016/j.vetpar.2019.06.001
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400002
PM 31303208
DA 2020-05-12
ER

PT J
AU Costes-Thire, M
   Laurent, P
   Ginane, C
   Villalba, JJ
AF Costes-Thire, Morgane
   Laurent, Pauline
   Ginane, Cecile
   Villalba, Juan J.
TI Diet selection and trade-offs between condensed tannins and nutrients in
   parasitized sheep
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Condensed tannins; Gastrointestinal nematodes; Self-medication;
   Foraging; Sheep
ID SHORT-TERM CONSUMPTION; NEMATODE INFECTION; GEOMETRIC ANALYSIS;
   SELF-MEDICATION; PREFERENCE; FOOD; SUPPLEMENTATION; NUTRITION; ANOREXIA;
   PROTEIN
AB Foraging behavior by parasitized herbivores can be interpreted as a decision-making process where individuals are faced with trading-off the ingestion of nutrients with the ingestion of potentially medicinal -and toxic- plant secondary compounds. We determined how parasitized sheep prioritize selection of crude protein, energy and a medicinal plant secondary compound (quebracho tannins-QT). Foraging preferences were tested in 40 lambs before experiencing a parasitic infection (Phase 1), during an infection (Phase 2; 10,000 L-3 Haemonchus contortus per lamb) and after chemotherapy (Phase 3). Lambs were assigned to four groups (10 lambs/group) such that animals in Group 1 (Control) could choose between foods of high (HEP) or low (LEP) energy to protein ratios. The other groups received the same choice, but QT were added (4%) to HEP (Group 2), to LEP (Group 3) or to both foods (Group 4). All groups under a parasitic infection (Phase 2) increased their preference for HEP (from 0.44 to 0.66 +/- 0.042; P < 0.05) and intake of digestible energy (from 0.106 to 0.126 +/- 0.007 Mcal/kg BW; P < 0.05) relative to Phase 1, a pattern that remained during Phase 3. Only lambs receiving QT in HEP increased their intake of QT from Phase 1 to Phase 2 (P < 0.05). Fecal egg counts and blood parameters revealed a parasitic infection (P < 0.05) in Phase 2 that subsided in Phase 3, although no differences were detected among groups (P > 0.05). The importance of protein nutrition on parasitized animals has been highlighted before, but these results suggest that lambs prioritized the ingestion of energy-dense over protein-dense foods or medicinal condensed tannins when challenged by gastrointestinal parasitism. Consumption of medicinal tannins represented a side-effect of the preference manifested for energy-dense foods during testing.
C1 [Costes-Thire, Morgane; Ginane, Cecile] Univ Clermont Auvergne, INRA, VetAgro Sup, UMR Herbivores, F-63122 St Genes Champanelle, France.
   [Laurent, Pauline] Inst Natl Agron Paris Grignon, AgroParisTech, UFR Nutr Anim Qual Prod & Bien Etre, Dept Sci Anim, F-75005 Paris, France.
   [Villalba, Juan J.] Utah State Univ, Dept Wildland Resources, Logan, UT 84322 USA.
RP Villalba, JJ (reprint author), Utah State Univ, Dept Wildland Resources, Logan, UT 84322 USA.
EM juan.villalba@usu.edu
FU Utah Agricultural Experiment Station [UTA01321]; Fulbright-France
   Scholarship
FX This research was supported by grants from the Utah Agricultural
   Experiment Station (Grant UTA01321). This paper is published with the
   approval of the Director, Utah Agricultural Experiment Station, and Utah
   State University, as journal paper number 9183. We acknowledge R. Stott
   for veterinary services, J. Hall for parasitological services and
   Elizabeth Stewart for technical support. Financial support for M.C.T.
   from a Fulbright-France Scholarship is acknowledged.
CR Mendez-Ortiz FA, 2012, ANIM FEED SCI TECH, V176, P185, DOI 10.1016/j.anifeedsci.2012.07.022
   ARBOUR KJ, 1988, J COMP PSYCHOL, V102, P177, DOI 10.1037/0735-7036.102.2.177
   Association of the Official Analytical Chemists (AOAC), 1995, OFFICIAL METHODS ANA
   Chartier C, 2000, VET PARASITOL, V92, P1, DOI 10.1016/S0304-4017(00)00268-5
   Coop RL, 1999, VET PARASITOL, V84, P187, DOI 10.1016/S0304-4017(99)00070-9
   Costes-Thire M, 2018, APPL ANIM BEHAV SCI, V203, P11, DOI 10.1016/j.applanim.2018.02.015
   Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a
   Garate-Gallardo L, 2015, PARASITE, V22, DOI 10.1051/parasite/2015019
   Ginane C, 2005, ANIM BEHAV, V69, P541, DOI 10.1016/j.anbehav.2004.06.008
   Goering H. K., 1970, USDA AGR HDB FORAGE
   Harris JA, 2004, J EXP PSYCHOL-ANIM B, V30, P177, DOI 10.1037/0097-7403.30.3.177
   Hoste H, 2008, PARASITE IMMUNOL, V30, P79, DOI 10.1111/j.1365-3024.2007.00987.x
   Hoste H, 2015, VET PARASITOL, V212, P5, DOI 10.1016/j.vetpar.2015.06.026
   Hoste H, 2012, VET PARASITOL, V186, P18, DOI 10.1016/j.vetpar.2011.11.042
   Hoste H, 2006, TRENDS PARASITOL, V22, P253, DOI 10.1016/j.pt.2006.04.004
   Houdijk JGM, 2000, VET PARASITOL, V91, P43, DOI 10.1016/S0304-4017(00)00255-7
   Juhnke J, 2012, VET PARASITOL, V188, P104, DOI 10.1016/j.vetpar.2012.02.015
   Knox MR, 2006, VET PARASITOL, V139, P385, DOI 10.1016/j.vetpar.2006.04.026
   Kyriazakis I, 1998, ANIM BEHAV, V56, P265, DOI 10.1006/anbe.1998.0761
   Kyriazakis I, 1996, VET PARASITOL, V61, P297, DOI 10.1016/0304-4017(95)00824-1
   KYRIAZAKIS I, 1994, BRIT J NUTR, V72, P665, DOI 10.1079/BJN19940070
   Kyriazakis I, 2014, ANIM PROD SCI, V54, P1190, DOI 10.1071/AN14431
   Kyriazakis I, 2010, ANIM FEED SCI TECH, V156, P1, DOI 10.1016/j.anifeedsci.2010.01.001
   Lisonbee LD, 2009, BEHAV PROCESS, V82, P184, DOI 10.1016/j.beproc.2009.06.009
   Lobley GE, 1997, P NUTR SOC, V56, P547, DOI 10.1079/PNS19970057
   Lozano GA, 1998, ADV STUD BEHAV, V27, P291
   Mendez-Ortiz FA, 2019, VET PARASITOL, V265, P1, DOI 10.1016/j.vetpar.2018.11.008
   Min BR, 2004, SMALL RUMINANT RES, V51, P279, DOI 10.1016/S0921-4488(03)00204-9
   Mir RA, 2007, J AGR SCI, V3, P562
   Mueller-Harvey I, 2006, J SCI FOOD AGR, V86, P2010, DOI 10.1002/jsfa.2577
   Nnadi PA, 2009, VET PARASITOL, V161, P232, DOI 10.1016/j.vetpar.2009.01.014
   NRC, 1985, NUTR REQ SHEEP, P2
   Provenza FD, 2006, FEEDING IN DOMESTIC VERTEBRATES: FROM STRUCTURE TO BEHAVIOUR, P210, DOI 10.1079/9781845930639.0210
   Provenza FD, 2003, SMALL RUMINANT RES, V49, P257, DOI 10.1016/S0921-4488(03)00143-3
   PROVENZA FD, 1995, J RANGE MANAGE, V48, P2, DOI 10.2307/4002498
   Retama-Flores C, 2012, ANIMAL, V6, P145, DOI 10.1017/S1751731111001339
   Sahin A, 2003, LIVEST PROD SCI, V82, P163, DOI 10.1016/S0301-6226(03)00030-7
   SILANIKOVE N, 1994, J AGR FOOD CHEM, V42, P2844, DOI 10.1021/jf00048a035
   SIMPSON SJ, 1995, J INSECT PHYSIOL, V41, P545, DOI 10.1016/0022-1910(95)00006-G
   Simpson SJ, 2001, ECOLOGY, V82, P422
   SYKES AR, 1976, J AGR SCI, V86, P507, DOI 10.1017/S0021859600061049
   Sykes AR, 2001, NEW ZEAL VET J, V49, P222, DOI 10.1080/00480169.2001.36236
   Van Soest P. J, 2018, NUTR ECOLOGY RUMINAN
   Ventura-Cordero J, 2018, ANIMAL, V12, P1269, DOI 10.1017/S1751731117002634
   Villalba JJ, 2010, J ANIM SCI, V88, P2189, DOI 10.2527/jas.2009-2272
   Villalba JJ, 1997, BRIT J NUTR, V77, P287, DOI 10.1079/BJN19970030
   Villalba JJ, 2017, P NUTR SOC, V76, P113, DOI 10.1017/S0029665116000719
   Villalba JJ, 2009, RANGELAND ECOL MANAG, V62, P399, DOI 10.2111/08-076.1
   Waghorn G, 2008, ANIM FEED SCI TECH, V147, P116, DOI 10.1016/j.anifeedsci.2007.09.013
   Walker HK, 1990, CLIN METHODS HIST PH
   WALLACE DS, 1995, RES VET SCI, V58, P232, DOI 10.1016/0034-5288(95)90108-6
   Wang J, 1996, J CHEM ECOL, V22, P2011, DOI 10.1007/BF02040092
NR 52
TC 0
Z9 0
U1 2
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 14
EP 21
DI 10.1016/j.vetpar.2019.05.013
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400003
PM 31303198
DA 2020-05-12
ER

PT J
AU Leisewitz, AL
   Goddard, A
   Clift, S
   Thompson, PN
   de Gier, J
   Van Engelshoven, JMAJAJ
   Schoeman, JP
AF Leisewitz, Andrew L.
   Goddard, Amelia
   Clift, Sarah
   Thompson, Peter N.
   de Gier, Jill
   Van Engelshoven, Jessica M. A. J. A. J.
   Schoeman, Johan P.
TI A clinical and pathological description of 320 cases of naturally
   acquired Babesia rossi infection in dogs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Haemoprotozoa; Dog; Multisystemic; Morbidity; Mortality
ID INFLAMMATORY RESPONSE SYNDROME; RESPIRATORY-DISTRESS-SYNDROME;
   CRITICALLY-ILL PUPPIES; CANINE BABESIOSIS; THYROXINE CONCENTRATIONS;
   LABORATORY FINDINGS; SOUTH-AFRICA; MORTALITY; PREDICTORS; CORTISOL
AB Babesia rossi causes the most severe clinical disease in dogs of all the babesia parasites. We included 320 naturally-infected dogs that presented for care at the Onderstepoort Veterinary Academic Hospital between 2006 and 2016. All dogs had mono-infections confirmed by multiplex PCR. The data allowed more accurate clinical classification of the disease and identified parameters that were associated with disease severity and death. Odds ratios for dying were significant (P < 0.05) for increased band neutrophil count, collapse at presentation; presence of cerebral signs; hypoglycaemia; hyperlactatemia; high urea, high creatinine; hyperbilirubinaemia; hypercortisolaemia; and hypothyroxinaemia. Joint component analysis confirmed that the variables with significant odds ratios grouped together with death. Yet, multivariate logistic regression was unable to identify a group of significant independent predictors of death. Receiver Operator Characteristic curves indicated that low total thyroid hormone, high bilirubin, high serum urea and high cortisol concentrations were the variables with the highest sensitivity and specificity for death. These data provide both the clinician and researcher with a set of easily-measured laboratory and clinical assessments to classify cases into those that are uncomplicated and those that are complicated. The disease is complex and multisystemic and probably involves mechanisms more proximal in the pathogenesis than those that have been evaluated.
C1 [Leisewitz, Andrew L.; Goddard, Amelia; de Gier, Jill; Van Engelshoven, Jessica M. A. J. A. J.; Schoeman, Johan P.] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Private Bag X04, ZA-0110 Ondertspoort, South Africa.
   [Clift, Sarah] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Private Bag X04, ZA-0110 Ondertspoort, South Africa.
   [Thompson, Peter N.] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, Private Bag X04, ZA-0110 Ondertspoort, South Africa.
RP Leisewitz, AL (reprint author), Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Private Bag X04, ZA-0110 Ondertspoort, South Africa.
EM Andrew.leisewitz@up.ac.za
RI Schoeman, Johan/J-6765-2013
OI Schoeman, Johan/0000-0002-5057-311X; Goddard,
   Amelia/0000-0002-8415-4802; Leisewitz, Andrew/0000-0001-8432-9425;
   Thompson, Peter/0000-0002-2268-9748
FU National Research Foundation (South Africa)National Research Foundation
   - South Africa [CPRR13080726333]
FX This work was supported by funding provided by the National Research
   Foundation (South Africa); Grant number CPRR13080726333 held by A
   Leisewitz. The funding agency played no role in the research project or
   preparation of the manuscript for publication.
CR ANDREIS PG, 1991, ENDOCRINOLOGY, V129, P53, DOI 10.1210/endo-129-1-53
   Balk RA, 2014, VIRULENCE, V5, P20, DOI 10.4161/viru.27135
   Basson P. A., 1965, Journal of the South African Veterinary Medical Association, V36, P333
   Boonen E, 2013, NEW ENGL J MED, V368, P1477, DOI 10.1056/NEJMoa1214969
   Botha H., 1964, Journal of the South African Veterinary Medical Association, V35, P27
   Brady CA, 2001, VET CLIN N AM-SMALL, V31, P1147, DOI 10.1016/S0195-5616(01)50097-2
   BUTTON C, 1979, J AM VET MED ASSOC, V175, P475
   Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008
   Clark IA, 1998, ANN TROP MED PARASIT, V92, P483, DOI 10.1080/00034989859456
   Collett MG, 2000, J S AFR VET ASSOC, V71, P180
   Cray C, 2009, COMPARATIVE MED, V59, P517
   Daste T, 2013, J VET EMERG CRIT CAR, V23, P615, DOI 10.1111/vec.12114
   de Scally MP, 2006, J S AFR VET ASSOC, V77, P175
   Defauw P, 2018, VET PARASITOL, V260, P22, DOI 10.1016/j.vetpar.2018.07.012
   Defauw P., 2017, OCCURANCE RENAL AZOT
   Dvir E, 2019, ONDERSTEPOORT J VET, V86, DOI 10.4102/ojvr.v86i1.1644
   Dvir Eran, 2004, J Vet Cardiol, V6, P15, DOI 10.1016/S1760-2734(06)70060-1
   Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101
   GILLES HM, 1953, ANN TROP MED PARASIT, V47, P426, DOI 10.1080/00034983.1953.11685588
   Goddard A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150113
   Goddard A, 2015, VET CLIN PATH, V44, P493, DOI 10.1111/vcp.12306
   Goddard A, 2015, VET J, V205, P387, DOI 10.1016/j.tvjl.2015.05.008
   Goddard A, 2013, VET J, V196, P213, DOI 10.1016/j.tvjl.2012.09.009
   Happel KI, 2004, AM J MED SCI, V328, P230, DOI 10.1097/00000441-200410000-00006
   HOROWITZ ML, 1994, CHEST, V106, P1299, DOI 10.1378/chest.106.4.1299
   HORSTMANN RD, 1981, BLUT, V42, P157, DOI 10.1007/BF01026385
   Ince C, 2016, SHOCK, V45, P259, DOI 10.1097/SHK.0000000000000473
   Jacobson LS, 2006, VET PARASITOL, V138, P126, DOI 10.1016/j.vetpar.2006.01.047
   Jacobson LS, 1996, J SMALL ANIM PRACT, V37, P286, DOI 10.1111/j.1748-5827.1996.tb02381.x
   JACOBSON LS, 1994, J S AFR VET ASSOC, V65, P134
   Jacobson LS, 2005, AM J VET RES, V66, P244, DOI 10.2460/ajvr.2005.66.244
   Kantrowitz LB, 2001, J AM VET MED ASSOC, V219, P765, DOI 10.2460/javma.2001.219.765
   Keller N, 2004, J VET INTERN MED, V18, P265, DOI 10.1892/0891-6640(2004)18&lt;265:PARFOH&gt;2.0.CO;2
   Kettner F, 2003, J S AFR VET ASSOC, V74, P63
   Kilpatrick S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146560
   Koster LS, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1297, 10.4102/JSAVA.V86I1.1297]
   Krause PJ, 2007, TRENDS PARASITOL, V23, P605, DOI 10.1016/j.pt.2007.09.005
   Lehr HA, 2000, J PATHOL, V190, P373, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;373::AID-PATH593&gt;3.0.CO;2-3
   Leisewitz AL, 2001, J VET INTERN MED, V15, P445, DOI 10.1892/0891-6640(2001)015&lt;0445:TMADOS&gt;2.3.CO;2
   Leisewitz A, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12630
   Liebenberg C, 2013, J VET INTERN MED, V27, P150, DOI 10.1111/jvim.12016
   Lobetti R, 2002, J VET INTERN MED, V16, P63, DOI 10.1892/0891-6640(2002)016&lt;0063:CTICB&gt;2.3.CO;2
   Lobetti RG, 2001, J S AFR VET ASSOC, V72, P23
   Lobetti RG, 1996, J S AFR VET ASSOC, V67, P188
   Maegraith B., 1957, Zeitschrift fuer Tropenmedizin und Parasitologie, V8, P485
   MALHERBE W. D., 1951, Journal of the South African Veterinary Medical Association, V22, P25
   Matijatko V, 2012, TRENDS PARASITOL, V28, P99, DOI 10.1016/j.pt.2011.11.003
   Matjila PT, 2009, J CLIN MICROBIOL, V47, P3586, DOI 10.1128/JCM.01110-08
   Matjila PT, 2008, VET PARASITOL, V155, P152, DOI 10.1016/j.vetpar.2008.04.012
   McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8
   McDevitt Michael A, 2004, Curr Hematol Rep, V3, P97
   Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9
   Mooney CT, 2008, J SMALL ANIM PRACT, V49, P11, DOI 10.1111/j.1748-5827.2007.00418.x
   Nel M, 2004, J VET INTERN MED, V18, P471, DOI 10.1892/0891-6640(2004)18&lt;471:PVOBLB&gt;2.0.CO;2
   Okano S, 2002, VET REC, V150, P245, DOI 10.1136/vr.150.8.245
   Paim CB, 2012, VET PARASITOL, V185, P131, DOI 10.1016/j.vetpar.2011.09.039
   Pashmakova MB, 2014, J VET EMERG CRIT CAR, V24, P264, DOI 10.1111/vec.12172
   Penzhorn BL, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-51
   Philipose Cheryl Sarah, 2016, Trop Parasitol, V6, P147
   Piercy S. E., 1947, Veterinary Record London, V59, P612
   PURCHASE H S, 1947, Vet Rec, V59, P269
   Rau S, 2007, VET CLIN PATH, V36, P253, DOI 10.1111/j.1939-165X.2007.tb00220.x
   Rautenbach Y, 2017, VET PARASITOL, V241, P26, DOI 10.1016/j.vetpar.2017.05.001
   Rees P, 2008, VET PARASITOL, V152, P60, DOI 10.1016/j.vetpar.2007.11.017
   Reyers F, 1998, ANN TROP MED PARASIT, V92, P503, DOI 10.1080/00034989859474
   Scheepers E, 2011, J S AFR VET ASSOC, V82, P136
   Schetters TPM, 2009, VET PARASITOL, V162, P7, DOI 10.1016/j.vetpar.2009.02.012
   Schetters TPM, 1998, ANN TROP MED PARASIT, V92, P513, DOI 10.1080/00034989859483
   Schnittger L, 2012, INFECT GENET EVOL, V12, P1788, DOI 10.1016/j.meegid.2012.07.004
   Schoeman JP, 2007, J S AFR VET ASSOC, V78, P215
   Schoeman JP, 2009, ONDERSTEPOORT J VET, V76, P59
   Schoeman JP, 2008, VET PARASITOL, V154, P205, DOI 10.1016/j.vetpar.2008.03.023
   Schoeman JP, 2008, MICROBES INFECT, V10, P203, DOI 10.1016/j.micinf.2007.11.002
   Schoeman JP, 2007, VET PARASITOL, V148, P75, DOI 10.1016/j.vetpar.2007.06.010
   Schoeman JP, 2007, JAVMA-J AM VET MED A, V231, P1534, DOI 10.2460/javma.231.10.1534
   Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1596-0
   Sudhakara Reddy B, 2016, J Parasit Dis, V40, P268, DOI 10.1007/s12639-014-0491-x
   Taylor WRJ, 2012, CHEST, V142, P492, DOI 10.1378/chest.11-2655
   Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1
   Turrin NP, 2004, EXP BIOL MED, V229, P996
   Vannier EG, 2015, INFECT DIS CLIN N AM, V29, P357, DOI 10.1016/j.idc.2015.02.008
   Weltan SM, 2008, VET CLIN PATH, V37, P164, DOI 10.1111/j.1939-165X.2008.00037.x
   Welzl C, 2001, J S AFR VET ASSOC, V72, P158
   White NJ, 2014, LANCET, V383, P723, DOI 10.1016/S0140-6736(13)60024-0
NR 84
TC 2
Z9 2
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 22
EP 30
DI 10.1016/j.vetpar.2019.06.005
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400004
PM 31303199
DA 2020-05-12
ER

PT J
AU Muchiut, SM
   Fernandez, AS
   Lloberas, M
   Steffan, PE
   Luque, SE
   Cardozo, PA
   Bernat, GA
   Riva, E
   Fiel, CA
AF Manuel Muchiut, Sebastian
   Silvina Fernandez, Alicia
   Lloberas, Mercedes
   Eduardo Steffan, Pedro
   Elisabet Luque, Sonia
   Alejandra Cardozo, Patricia
   Anahi Bernat, Gisele
   Riva, Eliana
   Alberto Fiel, Cesar
TI Recovery of fenbendazole efficacy on resistant Haemonchus contortus by
   management of parasite refugia and population replacement
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Parasite population; Refugia; Haemonchus contortus; Sheep; Anthelmintic
   resistance
ID ANTHELMINTIC RESISTANCE; SHEEP; EPIDEMIOLOGY; INFECTIONS; RUMINANTS;
   AUSTRALIA; NEMATODES; ECOLOGY
AB The recovery of fenbendazole efficacy against Haemonchus contortus was attempted in a sheep intensive production system, using a strategy of population replacement in which the initial absolute efficacy of fenbendazole was 0%. The strategy was based on managing the parasite populations in refugia. Firstly, the resistant parasite population was reduced by means of anthelmintic treatments with efficacious drugs (Phase I), then a new, susceptible population was introduced in summer by way of artificially infected lambs at weaning, which were left to graze on the experimental pasture for eleven months (Phase II). Lastly, the impact of the replacement strategy, in terms of benzimidazole efficacy, was measured (Phase III). Faecal egg counts from permanent lambs and worm burdens as a measure of pasture infectivity from tracer lambs were determined throughout the study. During Phase I, faecal egg counts diminished from a peak of 2968 (300-7740) epg to 0 epg at the end, while adult worm burdens of H. contortus were reduced from 2625 (800-5100) to 0, which showed that the treatment strategy used in Phase I was effective in reducing the resistant population. These parameters also showed that good levels of pasture contamination and infectivity were achieved in Phase II, as faecal egg counts of up to 7275 (3240-13080) epg and adult worm burdens of 500 (200-800) H. contortus were reached. The absolute benzimidazole efficacy on H. contortus estimated at 16 months post-population replacement (Phase III) was 97.58%. The results lead to the conclusion that the recovery of anthelmintic efficacy of fenbendazole against a resistant population of H. contortus may be achieved by means of a strategy based on management of refugia and a subsequent introduction of a susceptible population. This strategy might be translatable to other resistant nematode genera.
C1 [Manuel Muchiut, Sebastian; Silvina Fernandez, Alicia; Eduardo Steffan, Pedro; Anahi Bernat, Gisele; Riva, Eliana; Alberto Fiel, Cesar] Univ Natl Ctr Prov Buenos Aires, Area Parasitol & Enfermedades Parasitarias, Ctr Invest Vet Tandil CIVETAN, Fac Ciencias Vet, Pje Arroyo Seco S-N,B7000, Tandil, Argentina.
   [Silvina Fernandez, Alicia; Elisabet Luque, Sonia] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Lloberas, Mercedes; Alejandra Cardozo, Patricia] EEA INTA, Lab Parasitol, Balcarce, Argentina.
   [Anahi Bernat, Gisele; Riva, Eliana] CICPBA, La Plata, Buenos Aires, Argentina.
RP Muchiut, SM (reprint author), Univ Natl Ctr Prov Buenos Aires, Area Parasitol & Enfermedades Parasitarias, Ctr Invest Vet Tandil CIVETAN, Fac Ciencias Vet, Pje Arroyo Seco S-N,B7000, Tandil, Argentina.
EM smuchiut@vet.unicen.edu.ar
FU Agencia Nacional de Promotion Cientifica y Tecnologica, Ministerio de
   Ciencia, Tecnologia e Innovation Productiva [PICT 2012-1048]
FX Sergio Dinino and Carlos Nieto, from EEA Balcarce-INTA, are thanked for
   their on -farm technical assistance. Professor Peter Purslow is thanked
   for his helpful assistance correcting the manuscript. This study was
   supported the Agencia Nacional de Promotion Cientifica y Tecnologica,
   Ministerio de Ciencia, Tecnologia e Innovation Productiva (grant No PICT
   2012-1048).
CR ARMOUR J, 1980, VET PARASITOL, V6, P7, DOI 10.1016/0304-4017(80)90037-0
   Aumont G., 2002, SUBSTITUTION PEUPLEM, P1
   Balbi A, 1993, APORTES PARASITOLOGI, VII, P121
   Besier RB, 2016, ADV PARASIT, V93, P181, DOI 10.1016/bs.apar.2016.02.024
   Besier RB, 2003, AUST J EXP AGR, V43, P1383, DOI 10.1071/EA02229
   BESIER RB, 1993, VET PARASITOL, V45, P293, DOI 10.1016/0304-4017(93)90083-Y
   Bird J, 2001, VET PARASITOL, V97, P219, DOI 10.1016/S0304-4017(01)00406-X
   Coles GC, 2006, VET PARASITOL, V136, P167, DOI 10.1016/j.vetpar.2005.11.019
   Entrocasso C, 2008, VET PARASITOL, V155, P249, DOI 10.1016/j.vetpar.2008.04.015
   Guzmán M., 2012, InVet, V14, P25
   Guzman M, 2014, TRANSMISION HAEMONCH
   HENRIKSEN SA, 1983, NORD VET MED, V35, P429
   HOSTE H, 1993, AM J VET RES, V54, P1886
   Muchiut SM, 2018, VET PARASITOL, V254, P43, DOI 10.1016/j.vetpar.2018.03.004
   Miller M., 2015, 25 INT C WORLD ASS A
   Moussavou-Boussougou MN, 2007, PARASITOLOGY, V134, P553, DOI 10.1017/S0031182006001697
   Niec R, 1968, MANUAL TECNICO
   O'Connor LJ, 2006, VET PARASITOL, V142, P1, DOI 10.1016/j.vetpar.2006.08.035
   Pereira D., 2006, 34 JORN UR BUIATR PA, P61
   ROBERTS FHS, 1950, AUST J AGR RES, V1, P99, DOI 10.1071/AR9500099
   Romero J., 2018, INTA EDICIONES, V560, P1
   Sanchez R. O., 2005, Revista de Medicina Veterinaria (Buenos Aires), V86, P17
   Sissay MM, 2006, VET PARASITOL, V135, P337, DOI 10.1016/j.vetpar.2005.09.005
   SUAREZ VH, 1995, INT J PARASITOL, V25, P489, DOI 10.1016/0020-7519(94)00122-5
   Suarez VH, 2017, ONDERSTEPOORT J VET, V84, DOI 10.4102/ojvr.v84i1.1240
   van Wyk JA, 2002, VET RES, V33, P509, DOI 10.1051/vetres:2002036
   VANWYK JA, 1990, VET PARASITOL, V35, P61, DOI 10.1016/0304-4017(90)90116-S
   Vercruysse J, 2001, VET PARASITOL, V96, P171, DOI 10.1016/S0304-4017(00)00443-X
   Vlassoff A, 2001, NEW ZEAL VET J, V49, P213, DOI 10.1080/00480169.2001.36235
   WOOD IB, 1995, VET PARASITOL, V58, P181, DOI 10.1016/0304-4017(95)00806-2
NR 30
TC 1
Z9 1
U1 5
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 31
EP 37
DI 10.1016/j.vetpar.2019.06.003
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400005
PM 31303200
DA 2020-05-12
ER

PT J
AU Maia, ACRG
   Porcino, GN
   Faria-Pinto, P
   Mendes, TV
   Antinarelli, LMR
   Coimbra, ES
   Reis, AB
   Juliano, L
   Juliano, MA
   Marques, MJ
   Vasconcelos, EG
AF Ribeiro Gomes Maia, Ana Carolina
   Porcino, Gabriane Nascimento
   Faria-Pinto, Priscila
   Mendes, Tulio Vieira
   Ribeiro Antinarelli, Luciana Maria
   Coimbra, Elaine Soares
   Reis, Alexandre Barbosa
   Juliano, Luiz
   Juliano, Maria Aparecida
   Marques, Marcos Jose
   Vasconcelos, Eveline Gomes
TI Leishmania infantum nucleoside triphosphate diphosphohydrolase 1
   (NTPDase 1) B-domain: Antibody antiproliferative effect on the
   promastigotes and IgG subclass responses in canine visceral
   leishmaniasis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE NTPDase; ATP diphosphohydrolase; Apyrase; Leishmania infantum;
   Leishmaniasis; Antibody; Peptides
ID ATP-DIPHOSPHOHYDROLASE; ANTIGENIC DOMAIN; PARASITE DENSITY; POTATO
   APYRASE; HYDROLASE-II; LOCALIZATION; PATTERNS; ISOFORM
AB A nucleoside triphosphate diphosphohydrolase-1 (NTPDase 1) was identified on the surface, flagellum and kinetoplast from L. infantum promastigotes by immunocytochemistry and confocal laser scanning microscopy, using immune sera that recognized specifically the B domain of NTPDase 1 and produced against synthetic peptides (LbB1LJ and LbB2LJ) derived from this domain. The polyclonal antibodies had effective antileishmanial effect, reducing significantly in vitro promastigotes growth (21-25%), an antiproliferative effect also demonstrated by immune sera produced against recombinant r-pot B domain, and two other synthetic peptides (potB1LJ and potB2LJ). In addition, using these biomolecules in ELISA technique, IgG1 and IgG2 subclasses reactivities of either healthy dogs or infected by L. infantum and classified clinically as asymptomatic, oligo-symptomatic and symptomatic were tested. Analysis of distinct IgG1 and IgG2 seropositivities patterns suggested antibody subclasses binding epitopes along B domain for protection against infection, indicating this domain as a new tool for prophylactic and immunotherapeutic investigations.
C1 [Ribeiro Gomes Maia, Ana Carolina; Porcino, Gabriane Nascimento; Faria-Pinto, Priscila; Vasconcelos, Eveline Gomes] Univ Fed Juiz de Fora, Inst Ciencias Biol, Lab Estrutura & Funcao Prot, Dept Bioquim, Rua Jose Lourenco Kelmer S-N,Campus Univ, BR-36036900 Juiz De Fora, MG, Brazil.
   [Mendes, Tulio Vieira] Marinha Brasil, Hosp Naval Marcilio Dias, Doencas Infecciosas & Parasitarias, Rio De Janeiro, RJ, Brazil.
   [Ribeiro Antinarelli, Luciana Maria; Coimbra, Elaine Soares] Univ Fed Juiz de Fora, Inst Ciencias Biol, Dept Parasitol Microbiol & Imunol, Juiz De Fora, MG, Brazil.
   [Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Lab Imunopatol, Nucleo Pesquisas Ciencias Biol, Escola Farm, Ouro Preto, MG, Brazil.
   [Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Escola Farm, Dept Anal Clin, Ouro Preto, MG, Brazil.
   [Juliano, Luiz; Juliano, Maria Aparecida] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, Sao Paulo, SP, Brazil.
   [Marques, Marcos Jose] Univ Fed Alfenas, Inst Ciencias Biomed, Dept Ciencias Biol, Alfenas, MG, Brazil.
RP Maia, ACRG (reprint author), Univ Fed Juiz de Fora, Inst Ciencias Biol, Lab Estrutura & Funcao Prot, Dept Bioquim, Rua Jose Lourenco Kelmer S-N,Campus Univ, BR-36036900 Juiz De Fora, MG, Brazil.
EM anacarolina.maia@ufjf.edu.br
RI Marques, Marcos Jose/G-8384-2012
OI Faria-Pinto, Priscila/0000-0002-9011-2027
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas
   Gerais State Research Foundation (FAPEMIG) [CBB-APQ-2008-12]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [471340/2011-1, 470388/2010-2]; Fundacao de Amparo a Pesquisa do Estado
   Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [12/50191-4R]; PROQUALI/UFJF; CAPES/REUNICAPES; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX This work was supported in part by grants from the Fundacao de Amparo a
   Pesquisa do Estado de Minas Gerais (FAPEMIG; CBB-APQ-2008-12), Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   471340/2011-1 and 470388/2010-2) and Fundacao de Amparo a Pesquisa do
   Estado Sao Paulo (FAPESP;12/50191-4R). All the authors contributed
   equally to this work. Antinarelli LMR, Maia ACRG and Porcino GN were
   recipients of Doctoral Degree fellowships from the PROQUALI/UFJF and
   CAPES/REUNI. Coimbra ES, Reis AB, Juliano L, Juliano MA and Marques MJ
   are recipients of fellowships from the CNPq.
CR Coimbra ES, 2008, PARASITOLOGY, V135, P327, DOI 10.1017/S0031182007003927
   De Brito RCF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01043
   de Figueiredo AB, 2016, BIOMED J, V39, P244, DOI 10.1016/j.bj.2016.08.004
   Detoni ML, 2013, PARASITOL RES, V112, P2773, DOI 10.1007/s00436-013-3445-9
   Faria-Pinto P, 2008, PARASITOLOGY, V135, P943, DOI 10.1017/S0031182008004538
   Gradoni L, 2015, VET PARASITOL, V208, P94, DOI 10.1016/j.vetpar.2015.01.003
   Iborra S, 2018, EXPERT REV VACCINES, V17, P323, DOI 10.1080/14760584.2018.1459191
   Korkmaz B, 2008, NAT PROTOC, V3, P991, DOI 10.1038/nprot.2008.63
   Luo FJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00605
   Marconato DG, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12487
   Paes-Vieira L, 2018, CELL BIOL INT, V42, P670, DOI 10.1002/cbin.10944
   Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053
   Mendes RGPR, 2011, MEM I OSWALDO CRUZ, V106, P808, DOI 10.1590/S0074-02762011000700005
   Porcino GN, 2012, EXP PARASITOL, V132, P293, DOI 10.1016/j.exppara.2012.08.009
   Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001
   Reis AB, 2010, TRENDS PARASITOL, V26, P341, DOI 10.1016/j.pt.2010.04.005
   Rezende-Soares FA, 2010, PARASITOLOGY, V137, P773, DOI 10.1017/S0031182009991661
   Maia ACRG, 2019, EXP PARASITOL, V200, P1, DOI 10.1016/j.exppara.2019.03.003
   Maia ACRG, 2013, PARASITOL INT, V62, P44, DOI 10.1016/j.parint.2012.09.004
   Maia ACRG, 2011, DEV COMP IMMUNOL, V35, P1057, DOI 10.1016/j.dci.2011.03.026
   Ribeiro RR, 2018, BIOMED RES INT, DOI 10.1155/2018/3296893
   Rodrigues V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1412-x
   Santos RF, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000387
   Araujo MSS, 2009, VACCINE, V27, P1008, DOI 10.1016/j.vaccine.2008.11.104
   Tan F, 2011, VACCINE, V29, P2742, DOI 10.1016/j.vaccine.2011.01.089
   Tan F, 2010, PARASITOL INT, V59, P141, DOI 10.1016/j.parint.2009.12.007
   Neto RGT, 2010, VET PARASITOL, V169, P248, DOI 10.1016/j.vetpar.2010.01.023
   Vasconcellos RD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003309
NR 28
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 38
EP 44
DI 10.1016/j.vetpar.2019.06.004
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400006
PM 31303201
DA 2020-05-12
ER

PT J
AU Elguero, ME
   Tomazic, ML
   Montes, MG
   Florin-Christensen, M
   Schnittger, L
   Nusblat, AD
AF Elguero, Maria E.
   Tomazic, Mariela L.
   Montes, Maria G.
   Florin-Christensen, Monica
   Schnittger, Leonhard
   Nusblat, Alejandro D.
TI The Cryptosporidium parvum gp60 glycoprotein expressed in the ciliate
   Tetrahymena thermophila is immunoreactive with sera of calves infected
   with Cryptosporidium oocysts
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Gp60; Cryptosporidiosis; Tetrahymena thermophila; Cryptosporidium
   parvum; Heterologous expression; Immunoreactivity
ID SDS-PAGE MIGRATION; SURFACE DISPLAY; CELL-SURFACE; PROTEINS; ANTIGEN;
   CLONING; GP40/15
AB Cryptosporidium parvum is a protozoan parasite of the phylum Apicomplexa responsible for cryptosporidiosis in calves, a disease that causes significant diarrhea and impairs gain of body weight, generating important production losses. As to now, no effective drugs or vaccines are available for the treatment or prevention of bovine cryptosporidiosis. Several reports suggest that development of a vaccine to prevent cryptosporidiosis is feasible, but relatively few vaccine candidates have been characterized and tested. The most prominent C. parvum antigen is gp60, an O-glycosylated mucin-like protein tethered to the parasite membrane by a glycosylphosphatidylinositol (GPI) anchor. Gp60 has been shown to be involved in essential mechanisms for the survival of C. parvum, such as recognition, adhesion to, and invasion of host cells. This work was aimed at expressing gp60 in Tetrahymena thermophila, a ciliated protozoon with numerous advantages for the heterologous expression of eukaryotic proteins, as a first approach for the development of a recombinant vaccine for bovine cryptosporidiosis. T. thermophila-expressed gp60 localized to the protozoon cell surface and oral apparatus, and partitioned into the Triton X-114 detergent phase. This indicates that the protein entered the reticuloendothelial system of the ciliate, and suggests it contains a GPI-anchor. Homogenates of gp60-expressing T. thermophila cells were recognized by sera from calves naturally infected with C. parvum demonstrating their immunoreactivity. In summary, the heterologous expression of gp60, a C. parvum-encoded GPI-anchored protein, has been successfully demonstrated in the ciliate T. thermophila.
C1 [Elguero, Maria E.; Montes, Maria G.; Nusblat, Alejandro D.] Univ Buenos Aires, CONICET, Inst Nanobiotecnol NANOBIOTEC, Fac Farm & Bioquim, Junin,956 C1113AAD, Buenos Aires, DF, Argentina.
   [Tomazic, Mariela L.; Florin-Christensen, Monica; Schnittger, Leonhard] Consejo Nacl Invest Cient & Tecn, Inst Patobiol Vet IPVET, CICVyA, Inst Natl Tecnol Agr, Hurlingham, Buenos Aires, Argentina.
   [Tomazic, Mariela L.; Florin-Christensen, Monica; Schnittger, Leonhard] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
RP Nusblat, AD (reprint author), Univ Buenos Aires, CONICET, Inst Nanobiotecnol NANOBIOTEC, Fac Farm & Bioquim, Junin,956 C1113AAD, Buenos Aires, DF, Argentina.
EM anusblat@ffyb.uba.ar
OI Florin-Christensen, Monica/0000-0003-0456-3970
FU Secretarla de Ciencia, Tecnologia e Innovation Productiva, Argentina
   [PICT 2013-1708]
FX We acknowledge Douglas Chalker, Department of Biology, Washington
   University in St. Luis for kindly providing the pICY-GTW vector, to
   Joaquin Lombardelli and Karina Tiranti, Departamento de Patologia
   Animal, Universidad Nacional de Rio Cuarto, CONICET, Cordoba, Argentina
   for the collection of calf sera. MFC, LS, MLT, and ADN are members of
   "Carrera del Investigador Cientifico", CONICET, Argentina. This work was
   financially supported by a grant of the Secretarla de Ciencia,
   Tecnologia e Innovation Productiva, Argentina (PICT 2013-1708).
CR Adl SM, 2012, J EUKARYOT MICROBIOL, V59, P429, DOI 10.1111/j.1550-7408.2012.00644.x
   Aldag I, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-11
   BOLIVAR I, 1989, J CELL SCI, V94, P343
   Calow J, 2016, MABS-AUSTIN, V8, P1498, DOI 10.1080/19420862.2016.1228504
   CALZONE FJ, 1982, EXP CELL RES, V140, P471, DOI 10.1016/0014-4827(82)90144-6
   Cevallos AM, 2000, INFECT IMMUN, V68, P5167, DOI 10.1128/IAI.68.9.5167-5175.2000
   Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831
   Cole ES, 2008, J EUKARYOT MICROBIOL, V55, P245, DOI 10.1111/j.1550-7408.2008.00337.x
   Colussi P., 2011, Production of Glycoproteins in Genetically Modified Ciliates, Patent No. [W02011119498, 2011119498]
   De Waele V, 2010, PREV VET MED, V96, P143, DOI 10.1016/j.prevetmed.2010.06.017
   Elguero ME, 2019, CRIT REV BIOTECHNOL, V39, P220, DOI 10.1080/07388551.2018.1530188
   GAERTIG J, 1992, P NATL ACAD SCI USA, V89, P9196, DOI 10.1073/pnas.89.19.9196
   Gaertig J, 1999, NAT BIOTECHNOL, V17, P462, DOI 10.1038/8638
   Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29
   GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E
   Jayaram J, 2010, BIOPHARM INT, P6
   Jenkins M, 2004, J PARASITOL, V90, P1178, DOI 10.1645/GE-3333RN
   JENKINS MC, 1993, INFECT IMMUN, V61, P2377, DOI 10.1128/IAI.61.6.2377-2382.1993
   KO YG, 1995, ANAL BIOCHEM, V224, P166, DOI 10.1006/abio.1995.1024
   Kondo A, 2004, APPL MICROBIOL BIOT, V64, P28, DOI 10.1007/s00253-003-1492-3
   Lazar I., 2010, GEL ANAL 2010A FREEW
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Lynn D.H., 2010, CILIATED PROTOZOA
   Mead JR, 2014, HUM VACC IMMUNOTHER, V10, P1505, DOI 10.4161/hv.28485
   O'Connor RM, 2003, INFECT IMMUN, V71, P6027, DOI 10.1128/IAI.71.10.6027-6034.2003
   O'Connor RM, 2007, MOL BIOCHEM PARASIT, V152, P149, DOI 10.1016/j.molbiopara.2007.01.003
   OIE, 2012, OIE MAN DIAGN TEST V
   Olson ME, 2004, TRENDS PARASITOL, V20, P185, DOI 10.1016/j.pt.2004.01.015
   Peterson DS, 2002, MOL BIOCHEM PARASIT, V122, P119, DOI 10.1016/S0166-6851(02)00079-8
   Priest JW, 2001, MOL BIOCHEM PARASIT, V113, P117, DOI 10.1016/S0166-6851(00)00386-8
   Rath A, 2009, P NATL ACAD SCI USA, V106, P1760, DOI 10.1073/pnas.0813167106
   Ruehle MD, 2016, GENETICS, V203, P649, DOI 10.1534/genetics.114.169748
   Sagodira S, 1999, PARASITE IMMUNOL, V21, P507, DOI 10.1046/j.1365-3024.1999.00247.x
   Shang YH, 2002, P NATL ACAD SCI USA, V99, P3734, DOI 10.1073/pnas.052016199
   Shi YH, 2012, PROTEIN SCI, V21, P1197, DOI 10.1002/pro.2107
   Slapeta J, 2013, INT J PARASITOL, V43, P957, DOI 10.1016/j.ijpara.2013.07.005
   Strong WB, 2000, INFECT IMMUN, V68, P4117, DOI 10.1128/IAI.68.7.4117-4134.2000
   Tomazic ML, 2018, VET PARASITOL, V264, P74, DOI 10.1016/j.vetpar.2018.11.007
   Tomazic ML, 2013, VET PARASITOL, V198, P382, DOI 10.1016/j.vetpar.2013.09.022
   TOURANCHEAU AB, 1995, EMBO J, V14, P3262, DOI 10.1002/j.1460-2075.1995.tb07329.x
   Tzipori S, 2002, MICROBES INFECT, V4, P1047, DOI 10.1016/S1286-4579(02)01629-5
   Wanyiri JW, 2007, INFECT IMMUN, V75, P184, DOI 10.1128/IAI.00944-06
NR 42
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 45
EP 50
DI 10.1016/j.vetpar.2019.06.008
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400007
PM 31303202
DA 2020-05-12
ER

PT J
AU Rodrigues, FT
   Moreira, FA
   Coutinho, T
   Dubey, JP
   Cardoso, L
   Lopes, AP
AF Rodrigues, Filipa T.
   Moreira, Fernando A.
   Coutinho, Teresa
   Dubey, Jitender P.
   Cardoso, Luis
   Lopes, Ana Patricia
TI Antibodies to Toxoplasma gondii in slaughtered free-range and broiler
   chickens
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Modified agglutination test; Portugal; Poultry; Serology; Zoonosis
ID INFECTION; TRANSMISSION; PREVALENCE; STORES
AB The consumption of undercooked infected chicken can be a source of infection for humans and carnivores regarding the zoonotic protozoan parasite Toxoplasma gondii. Furthermore, free-range chickens are sentinels for the presence of T. gondii oocysts in the environment because they feed from the ground. By using the modified agglutination test (MAT), we investigated the presence of antibodies to T. gondii in 178 free-range and 170 broiler chickens raised indoors and slaughtered in Portugal. Prevalence of specific antibodies was 5.6% in free-range and 0.0% in broiler chickens raised indoors (p = 0.002).
C1 [Rodrigues, Filipa T.; Coutinho, Teresa; Cardoso, Luis; Lopes, Ana Patricia] Univ Tras Os Montes & Alto Douro UTAD, Sch Agr & Vet Sci, Dept Vet Sci, Vila Real, Portugal.
   [Rodrigues, Filipa T.; Cardoso, Luis; Lopes, Ana Patricia] UTAD, Anim & Vet Res Ctr CECAV, Vila Real, Portugal.
   [Moreira, Fernando A.] UP, Inst Biomed Sci Abel Salazar ICBAS, Dept Vet Clin, Porto, Portugal.
   [Moreira, Fernando A.] UP, Food & Agr Sci & Technol Inst ICETA, Anim Sci & Study Ctr CECA, Porto, Portugal.
   [Dubey, Jitender P.] ARS, Anim Parasit Dis Lab, Beltsville Agr Res Ctr, USDA, Beltsville, MD USA.
RP Cardoso, L (reprint author), UTAD, Dept Vet Sci, P-5000801 Vila Real, Portugal.
EM lcarcdoso@utad.pt
RI Cardoso, Luis/J-8310-2013
OI Cardoso, Luis/0000-0002-6145-7560; Lopes, Ana
   Patricia/0000-0002-8182-5674; Moreira, Fernando A./0000-0002-6781-6800;
   Teixeira Rodrigues, Filipa/0000-0003-1495-1635
FU Portuguese Science and Technology Foundation (FCT)Portuguese Foundation
   for Science and Technology [UID/CVT/00772/2019]
FX This study was funded by project UID/CVT/00772/2019 supported by the
   Portuguese Science and Technology Foundation (FCT).
CR Casartelli-Alves L, 2014, VET PARASITOL, V204, P346, DOI 10.1016/j.vetpar.2014.05.039
   Chumpolbanchorn K, 2013, VET PARASITOL, V196, P209, DOI 10.1016/j.vetpar.2013.01.009
   Dubey JP, 2007, VET PARASITOL, V148, P207, DOI 10.1016/j.vetpar.2007.06.033
   Dubey JP, 2016, PARASITOLOGY, V143, P314, DOI 10.1017/S0031182015001316
   Dubey JP, 2010, ZOONOSES PUBLIC HLTH, V57, P60, DOI 10.1111/j.1863-2378.2009.01274.x
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL, P313, DOI DOI 10.3855/JIDC.2797
   Dubey JP, 2006, J PARASITOL, V92, P184, DOI 10.1645/GE-652R.1
   Dubey JP, 2005, J PARASITOL, V91, P1082, DOI 10.1645/GE-683.1
   Esteves A., 2012, ACTA PARASITOL PORT, V19, P182
   Graczyk TK, 2005, CLIN MICROBIOL REV, V18, P128, DOI 10.1128/CMR.18.1.128-132.2005
   Hamilton CM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2019-6
   Lopes AP, 2014, PARASITOLOGY, V141, P1699, DOI 10.1017/S0031182014001413
   Matsuo K, 2014, PARASITOL INT, V63, P638, DOI 10.1016/j.parint.2014.04.003
   Millar PR, 2012, PESQUI VET BRASIL, V32, P231, DOI 10.1590/S0100-736X2012000300009
   Pereira KS, 2010, ADV FOOD NUTR RES, V60, P1, DOI 10.1016/S1043-4526(10)60001-0
   Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11
   Rodrigues FT, 2019, REV BRAS PARASITOL V, V28, P172, DOI [10.1590/S1984-296120180091, 10.1590/s1984-296120180091]
   RUIZ A, 1980, AM J TROP MED HYG, V29, P1161, DOI 10.4269/ajtmh.1980.29.1161
   Yang N, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-237
   Ying YQ, 2017, PARASITOL RES, V116, P1591, DOI 10.1007/s00436-017-5420-3
NR 20
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 51
EP 53
DI 10.1016/j.vetpar.2019.06.007
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400008
PM 31303203
DA 2020-05-12
ER

PT J
AU Carreton, E
   Falcon-Cordon, Y
   Falcon-Cordon, S
   Morchon, R
   Matos, JI
   Montoya-Alonso, JA
AF Carreton, E.
   Falcon-Cordon, Y.
   Falcon-Cordon, S.
   Morchon, R.
   Matos, J. I.
   Montoya-Alonso, J. A.
TI Variation of the adulticide protocol for the treatment of canine
   heartworm infection: Can it be shorter?
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Heartworm; Adulticide treatment; Melarsomine dihydrochloride; Canine
   dirofilariosis
ID DIROFILARIA-IMMITIS; DOXYCYCLINE; IVERMECTIN; PATHOLOGY; CLIMATE;
   DISEASE
AB The treatment of canine heartworm has been modified over the years, adding improvements for greater efficacy, safeness and better prognosis. Currently, the recommended adulticidal protocol consists of the administration of three doses of melarsomine dihydrochloride, preceded by the administration of macrocyclic lactones over two to three months. The objective of this study was to evaluate a variation of the adulticide protocol of heartworm in 76 dogs infected by Dirofilaria immitis, which consists of the pre-administration of macrocyclic lactones (ivermectin) during a single month. On the day of diagnosis, presence of circulating microfilariae was determined and an echocardiography was performed to assess the parasite burden. Treatment began on day 0, with doxycycline for 30 days (10 mg/kg BID) and monthly ivermectin (6mcg/kg). On day 30, the first dose of melarsomine dihydrochloride was administered, followed by a second and third dose on days 60 and 61, respectively. On day 90, the dogs were examined and discharged. Six months after the last dose, all dogs were negative to the presence of antigens and amicrofilaremic. Also, 38.1% of animals were evaluated by echocardiography, showing absence of adult parasites. It is considered that the ineffectiveness of melarsomine against worms < 4 months should be avoided by the previous administration of macrocyclic lactones for two to three months, killing larvae < 2 months while older filariae are allowed to mature to be susceptible to melarsomine dihydrochloride. With this protocol, this gap would be covered for the 2nd and 3rd injections, when worms would be four months and older. In addition, there is evidence that melarsomine is effective against worms under four months and macrocyclic lactones have some efficacy against heartworms older than two months. This modification allows a faster elimination of heartworms and a better compliance from the owners of the infected dogs.
C1 [Carreton, E.; Falcon-Cordon, Y.; Falcon-Cordon, S.; Matos, J. I.; Montoya-Alonso, J. A.] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Fac Vet Med, Internal Med, Las Palmas Gran Canaria, Spain.
   [Morchon, R.] Univ Salamanca, Fac Pharm, Lab Parasitol, Grp GIR Anim & Human Dirofilariosis, Salamanca, Spain.
RP Carreton, E (reprint author), Univ Las Palmas Gran Canaria, Fac Vet Med, Internal Med, Arucas 35413, Las Palmas, Spain.
EM elena.carreton@ulpgc.es
RI Montoya-Alonso, Jose Alberto/M-2567-2014; Morchon,
   Rodrigo/AAH-6170-2019; Carreton, Elena/F-5722-2010
OI Montoya-Alonso, Jose Alberto/0000-0002-2683-7592; Morchon,
   Rodrigo/0000-0003-2699-1482; Carreton, Elena/0000-0001-6509-910X
CR American Heartworm Society, 2018, CURR CAN GUID PREV D
   Bazzocchi C, 2008, INT J PARASITOL, V38, P1401, DOI 10.1016/j.ijpara.2008.03.002
   Bowman DD, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2433-9
   Bowman DD, 2009, VET CLIN N AM-SMALL, V39, P1127, DOI 10.1016/j.cvsm.2009.06.003
   Carreton E, 2014, VET PARASITOL, V206, P55, DOI 10.1016/j.vetpar.2014.08.015
   Carreton E, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2448-2
   European Society of Dirofilariosis and Angiostrongylosis, 2017, GUID CLIN MAN CAN HE
   Genchi C, 2011, VET PARASITOL, V176, P295, DOI 10.1016/j.vetpar.2011.01.012
   Kramer L, 2008, VET PARASITOL, V158, P191, DOI 10.1016/j.vetpar.2008.09.014
   Kramer L, 2011, VET PARASITOL, V176, P357, DOI 10.1016/j.vetpar.2011.01.021
   Maksimowich DS, 1997, AM J VET RES, V58, P389
   McCall J. W., 2010, STAT HEARTW 2010 S 1
   McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2
   McCall JW, 2005, VET PARASITOL, V133, P197, DOI 10.1016/j.vetpar.2005.04.005
   Miterpakova M, 2018, PARASITOL RES, V117, P2347, DOI 10.1007/s00436-018-5912-9
   Montoya-Alonso JA, 2016, VET PARASITOL, V216, P66, DOI 10.1016/j.vetpar.2015.12.005
   Morchon R, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00196
   RAWLINGS CA, 1993, AM J VET RES, V54, P920
   Simon F, 2012, CLIN MICROBIOL REV, V25, P507, DOI 10.1128/CMR.00012-12
   Venco L, 2003, RECENT ADV HEARTWORM, P111
NR 20
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 54
EP 56
DI 10.1016/j.vetpar.2019.06.006
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400009
PM 31303204
DA 2020-05-12
ER

PT J
AU Wang, CW
   Huang, Y
   Zhao, JY
   Ma, YY
   Xu, XL
   Wan, Q
   Li, H
   Yu, H
   Pan, BL
AF Wang, Chuanwen
   Huang, Yu
   Zhao, Jiayi
   Ma, Yuyun
   Xu, Xiaolin
   Wan, Qiang
   Li, Hao
   Yu, He
   Pan, Baoliang
TI First record of Aspergillus oryzae as an entomopathogenic fungus against
   the poultry red mite Dermanyssus gallinae
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Dermanyssus gallinae; Poultry red mite; Entomopathogenic fungus;
   Aspergillus oryzae; Biological control
ID BEAUVERIA-BASSIANA; LABORATORY EVALUATION; ACARI; IDENTIFICATION;
   TRANSMISSION; INFECTION; STRAINS; LOCUST; GEER; SEX
AB The poultry red mite, Dennanyssus gallinae, is a blood-feeding ectoparasite that affects egg-laying hens worldwide. Strategies to control this parasite have focused in the use of entomopathogenic fungi, such as Metarhizium anisopliae. However, only a few studies have evaluated the use of Aspergillus oryzae to control D. gallinae and none of them have employed native strains. In the work presented here, a novel entomopathogenic fungus was isolated from a dead D. gallinae. The results of phylogenetic analysis showed 100% similarity between the isolated strain and those of two species, A. oryzae and Aspergillus flavus, and 99.82% similarity with A. parviscler-otigenus, which were in the same branch of the Flavi section of the genus Aspergillus. This entomopathogenic fungus was a non-aflatoxin B1 producer, as shown by the presence of aflatoxin B1 in the conidial infection suspension. Morphological features of fungus in comparison with A. oryzae and A. flavus indicated that the isolated strain belonged to A. oryzae, and was named Aspergillus sp. Dg-1. The pathogenicity of Aspergillus sp. Dg-1 on D. gallinae at different life stages was then assessed under laboratory conditions. The experiments showed that the isolated strain significantly increased the mortality rate in adult mites, up to 24.83 +/- 2.25, compared to the mortality rates in the control group, which were 15.17 +/- 2.75 (P < 0.05). However, Aspergillus sp. Dg-1 did not have pathogenic effects on the second nymph stage of D. gallinae. Our findings demonstrate that Aspergillus sp. Dg-1 has pathogenic effects on D. gallinae in their adult stage, presenting biocontrol potential against D. gallinae.
C1 [Wang, Chuanwen; Huang, Yu; Zhao, Jiayi; Ma, Yuyun; Xu, Xiaolin; Wan, Qiang; Li, Hao; Yu, He; Pan, Baoliang] China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
RP Pan, BL (reprint author), China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
EM baoliang@cau.edu.cn
FU National Key Research and Development Program of China [2017YFD0501200];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31873008]
FX This work was supported by the "National Key Research and Development
   Program of China" (Grant No. 2017YFD0501200) and the "National Natural
   Science Foundation of China" (Grant No. 31873008).
CR Balajee SA, 2007, STUD MYCOL, P39, DOI 10.3114/sim.2007.59.05
   Beugnet F, 1997, VET REC, V140, P577, DOI 10.1136/vr.140.22.577
   Bidochka M. J., 2012, MEM ENTOMOL SOC CAN, V129, P213
   Cafarchia C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0693-9
   Chauve C, 1998, VET PARASITOL, V79, P239, DOI 10.1016/S0304-4017(98)00167-8
   Cosoroaba I., 2001, REV MED VET TOULOUSE
   Dimbi S, 2003, ANZ SCHADL-J PEST SC, V76, P113, DOI 10.1007/s10340-003-0006-5
   Flochlay AS, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2292-4
   Geiser DM, 2007, STUD MYCOL, P1, DOI 10.3114/sim.2007.59.01
   Gokce A, 2003, J INVERTEBR PATHOL, V84, P83, DOI 10.1016/j.jip.2003.09.004
   Gupta A, 2002, WORLD J MICROB BIOT, V18, P325, DOI 10.1023/A:1015231209695
   Immediato D, 2016, VET PARASITOL, V229, P159, DOI 10.1016/j.vetpar.2016.10.018
   Immediato D, 2015, VET PARASITOL, V212, P478, DOI 10.1016/j.vetpar.2015.07.004
   Jenkins N. E., 1998, J OBSTET GYNECOL NEO, V13, P243
   Kaoud H. A., 2010, International Journal of Poultry Science, V9, P259
   Klich M, 2001, SYST APPL MICROBIOL, V24, P131, DOI 10.1078/0723-2020-00007
   Kulshrestha V, 1997, MYCOPATHOLOGIA, V139, P75, DOI 10.1023/A:1006859620780
   Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733
   Maniania NK, 1998, BIOCONTROL, V43, P311, DOI 10.1023/A:1009939711555
   Moro C. V., 2011, TRENDS ACAROLOGY
   Moro CV, 2009, EXP APPL ACAROL, V48, P93, DOI 10.1007/s10493-009-9248-0
   Mul M, 2009, WORLD POULTRY SCI J, V65, P589, DOI 10.1017/S0043933909000403
   Pritchard J, 2015, AVIAN PATHOL, V44, P143, DOI 10.1080/03079457.2015.1030589
   Samish M, 2001, J PARASITOL, V87, P1355, DOI 10.1645/0022-3395(2001)087[1355:POEFTD]2.0.CO;2
   SAMSON RA, 1985, ADV PENICILLIUM ASPE
   SCHLEIN Y, 1985, PARASITOLOGY, V90, P57, DOI 10.1017/S0031182000049015
   Shah PA, 2003, APPL MICROBIOL BIOT, V61, P413, DOI 10.1007/s00253-003-1240-8
   Sommer D, 2016, TIERAERZTL PRAX G N, V44, P26, DOI 10.15653/TPG-150413
   Sparagano OAE, 2014, ANNU REV ENTOMOL, V59, P447, DOI 10.1146/annurev-ento-011613-162101
   Steenberg T, 2014, EXP APPL ACAROL, V62, P511, DOI 10.1007/s10493-013-9757-8
   Tavassoli M, 2008, AVIAN PATHOL, V37, P259, DOI 10.1080/03079450802043718
   Tavassoli M, 2011, VET PARASITOL, V178, P374, DOI 10.1016/j.vetpar.2011.01.031
   VANEMOUS R, 2005, POULT INT, V44, P26
   Varga J, 2011, STUD MYCOL, P57, DOI 10.3114/sim.2011.69.05
   VENKATESH MV, 1975, MYCOPATHOLOGIA, V57, P135, DOI 10.1007/BF00551419
   Wang CW, 2018, VET PARASITOL, V258, P38, DOI 10.1016/j.vetpar.2018.06.003
   Wang FF, 2010, VET REC, V167, P934, DOI 10.1136/vr.c6212
   Wu SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090107
   ZEMAN P, 1985, Experimental and Applied Acarology, V1, P17, DOI 10.1007/BF01262196
   Zhang PF, 2015, BIOCONTROL SCI TECHN, V25, P1285, DOI 10.1080/09583157.2015.1049977
NR 40
TC 1
Z9 1
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 57
EP 63
DI 10.1016/j.vetpar.2019.06.011
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400010
PM 31303205
DA 2020-05-12
ER

PT J
AU dos Santos, IB
   Maciel, WG
   Felippelli, G
   Toscano, JHB
   Cruz, BC
   Chagas, ACD
   Soares, VE
   Lopes, WDZ
   da Costa, AJ
   de Oliveira, GP
AF dos Santos, Isabella Barbosa
   Maciel, Willian Giquelin
   Felippelli, Gustavo
   Barbosa Toscano, Joao Henrique
   Cruz, Breno Cayeiro
   De Souza Chagas, Ana Carolina
   Soares, Vando Edesio
   Zanetti Lopes, Welber Daniel
   da Costa, Alvimar Jose
   de Oliveira, Gilson Pereira
TI Viability of Haemonchus placei parasitism in experimentally infected
   young goats
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Small ruminants; Haemoncosis; H. placei; Goat breeding
ID DOMESTIC RUMINANTS; HOST-SPECIFICITY; CONTORTUS; SHEEP; DIFFERENTIATION;
   MORPHOMETRICS; PCR
AB The present study aimed to evaluate the viability of Haemonchus placei parasitism in experimentally infected goats. For that, 14 75 days old kids male Saanen kids were placed in one of the four experimental groups: GI - infected with 5000 H. placei L3 (n = 4); Gil infected with 5000 H. contortus L3 (n = 4); GIII infected with 2500 H. contortus L3 + 2500 H. placei L3 (n = 4), and GIV - control, inoculated with distilled water (n = 2). Each kid received, orally, the infective dose in a single inoculum. Based on daily fecal egg counts, the average pre-patent period was determined as 24 days for H. contortus, and 31 days for H. placei. Regarding the Haemonchus spp. recovered at necropsy, the experimental groups GI, GII, and GIII had, respectively, an average of 25.5, 619.5, and 724.75 (120 H. placei, and 604.75 H. contortus) adult specimens, and no immature forms. Under the conditions of this study, the viability of goat infection by H. placei was confirmed, although, with low susceptibility. Nevertheless, the parasitism of this helminth species was more intense when associated with H. contortus. This fact indicates that in common grazing between cattle and young goats, when the latter end up ingesting both Haemonhcus species, especially in a mixed infection, H. placei may also parasitize them.
C1 [dos Santos, Isabella Barbosa; Maciel, Willian Giquelin; Felippelli, Gustavo; Barbosa Toscano, Joao Henrique; Cruz, Breno Cayeiro; De Souza Chagas, Ana Carolina; Soares, Vando Edesio; Zanetti Lopes, Welber Daniel; da Costa, Alvimar Jose; de Oliveira, Gilson Pereira] UNESP CPPAR, Fac Ciencias Agr & Vet, Via Acesso Prof Paulo Donatto Castellani S-N, BR-14884900 Jaboticabal, SP, Brazil.
   [De Souza Chagas, Ana Carolina] Empresa Brasileira Pesquisa Agr EMBRAPA, Embrapa Pecuaria Sudeste, Rodovia Washington Luis,Km 234, BR-15379970 Sao Carlos, SP, Brazil.
   [Zanetti Lopes, Welber Daniel] Univ Fed Goias, Inst Patol Trop & Saude Publ, BR-74605050 Goiania, Go, Brazil.
RP dos Santos, IB; Lopes, WDZ (reprint author), UNESP CPPAR, Fac Ciencias Agr & Vet, Via Acesso Prof Paulo Donatto Castellani S-N, BR-14884900 Jaboticabal, SP, Brazil.
EM isabellabs853@hotmail.com; wdzlopes@hotmail.com
RI Toscano, Joao Henrique Barbosa/J-9147-2019
OI Toscano, Joao Henrique Barbosa/0000-0002-5501-6099
CR Achi YL, 2003, VET PARASITOL, V116, P151, DOI 10.1016/S0304-4017(03)00258-9
   Akkari H, 2013, VET PARASITOL, V193, P118, DOI 10.1016/j.vetpar.2012.12.014
   Amarante AFT, 1997, VET PARASITOL, V73, P89, DOI 10.1016/S0304-4017(97)00036-8
   Amarante MRV, 2017, J HELMINTHOL, V91, P757, DOI 10.1017/S0022149X16000882
   Bichuette MA, 2015, SMALL RUMINANT RES, V133, P93, DOI 10.1016/j.smallrumres.2015.09.009
   dos Santos MC, 2014, REV BRAS PARASITOL V, V23, P495, DOI 10.1590/S1984-29612014085
   Favero FC, 2016, VET PARASITOL, V217, P25, DOI 10.1016/j.vetpar.2015.12.017
   Gordon H. McL., 1939, Journal of the Council for Scientific and Industrial Research Australia, V12, P50
   Jacquiet P, 1997, PARASITOL RES, V83, P82, DOI 10.1007/s004360050213
   LICHTENFELS JR, 1994, J PARASITOL, V80, P107, DOI 10.2307/3283353
   Reiniger RCP, 2017, RES VET SCI, V114, P136, DOI 10.1016/j.rvsc.2017.02.017
   Riggs NL, 2001, VET PARASITOL, V94, P191, DOI 10.1016/S0304-4017(00)00381-2
   ROBERTS FHS, 1950, AUST J AGR RES, V1, P99, DOI 10.1071/AR9500099
   Santipap M, 2018, J OBSTET GYNAECOL, V38, P1054, DOI 10.1080/01443615.2018.1446422
   Santos MC, 2014, VET PARASITOL, V203, P127, DOI 10.1016/j.vetpar.2014.02.048
   STATISTICAL ANALYSIS SYSTEM INSTITUTE-SAS Institute, 2001, SAS US GUID EST
   WOOD IB, 1995, VET PARASITOL, V58, P181, DOI 10.1016/0304-4017(95)00806-2
NR 17
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 64
EP 67
DI 10.1016/j.vetpar.2019.06.012
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400011
PM 31303206
DA 2020-05-12
ER

PT J
AU Sears, KP
   Kappmeyer, LS
   Wise, LN
   Silva, M
   Ueti, MW
   White, S
   Reif, KE
   Knowles, DP
AF Sears, Kelly P.
   Kappmeyer, Lowell S.
   Wise, Lauren N.
   Silva, Marta
   Ueti, Massaro W.
   White, Stephen
   Reif, Kathryn E.
   Knowles, Donald P.
TI Infection dynamics of Theileria equi and Theileria haneyi, a newly
   discovered apicomplexan of the horse
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Equine theileriosis; Apicomplexan; Superinfection; T. equi; T. haneyi;
   Piroplasmosis
ID BABESIA-EQUI; PROTECTIVE IMMUNITY; CROSS-PROTECTION; SURFACE PROTEIN;
   MALARIA; PIROPLASMOSIS; ANTIGENS; SUPERINFECTION; COMPETITION; VIRULENCE
AB Theileria equi infection, exotic to the United States has reemerged through intravenous (iatrogenic) and tick borne transmission. Surveillance at the US-Mexico border identified a new species, Theileria haneyi, (T. haneyi(EP)) (EP = Eagle Pass, Texas) which warranted additional investigation due to inability to detect by PCR targeting of T. equi ema-1 and EMA-1-cELISA validated for T. equi. Infection dynamics of T. haneyi(EP) were evaluated, including ability to superinfect in the presence of T. equi-Texas (T. equil(TN)), the isolate responsible for the re-emergence of T. equi in the U S. Experimental infection with T. equi(TX) or T. haneyi(EP) revealed minimal clinical disease however, T. equi(TX) infection led to significantly greater neutropenia. Comparison of time to antibody detection following inoculation revealed significantly greater time to detectable anti-T. haneyi(EP) antibody (26.67 days post-inoculation (DPI)) than T. equi(TX) (11.67 DPI). Regardless of initial infection with either T. equi(TX) or T. haneyi(EP), superinfection was established. Comparative analysis of antibody responses from a splenectomized horse infected with T. haneyi(EP) to that of a spleen intact horse infected with T. equi(FL) revealed a different antibody binding profile to T. haneyi(EP), T. equi(TX) and T. equi(FL) merozoite antigen and limited shared antigen/cross-reactive antibody(s). Affinity purified T. equi EMA-1 and EMA-2 from T. equi(FL) were shown as targets for horse antibodies against T. haneyi. Data presented here show (1) T. haneyi(EP) can superinfect in the presence of T. equi(TX) infection and co-persists for minimally 25 months, (2) intravenous challenge with T. haneyi is subclinical, and (3) limited cross-reactive antibody between T. haneyi(EP) and T. equi includes reactivity to EMA-1 and EMA-2.
C1 [Sears, Kelly P.] Washington State Univ, Vet Clin Sci, Pullman, WA 99164 USA.
   [Kappmeyer, Lowell S.; Wise, Lauren N.; Ueti, Massaro W.; White, Stephen; Reif, Kathryn E.] ARS, Anim Dis Res Unit, USDA, Pullman, WA 99164 USA.
   [Wise, Lauren N.] St Georges Univ, Sch Vet Med, True Blue Campus, St Georges, Grenada.
   [Silva, Marta; White, Stephen; Reif, Kathryn E.; Knowles, Donald P.] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.
   [Reif, Kathryn E.] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Ctr Excellence Vector Borne Dis Res, Manhattan, KS 66506 USA.
RP Sears, KP (reprint author), Washington State Univ, Vet Clin Sci, Pullman, WA 99164 USA.
EM kellyp.sears@wsu.edu
RI Kappmeyer, Lowell/AAF-2115-2020
FU Agricultural Research Service (ARS), USA, CRIS [2090-320000-034-00D]
FX We thank Shelby Beckner, Nancy Kumpula-Mc Whirter, Ralph Horn, and James
   Allison for their excellent technical assistance. We thank Tiffany
   Sheely for her assistance with the graphical abstract design. This work
   was supported by the Agricultural Research Service (ARS), USA,
   CRIS#2090-320000-034-00D.
CR Akinosoglou KS, 2012, HEMATOLOGY, V17, P106, DOI 10.1179/102453312X13221316477336
   Ambawat HK, 1999, VET PARASITOL, V85, P319, DOI 10.1016/S0304-4017(99)00110-7
   Atkinson CT, 2001, J WILDLIFE DIS, V37, P20, DOI 10.7589/0090-3558-37.1.20
   Beard LA, 2013, JAVMA-J AM VET MED A, V242, P992, DOI 10.2460/javma.242.7.992
   Bell AS, 2006, EVOLUTION, V60, P1358, DOI 10.1111/j.0014-3820.2006.tb01215.x
   BENACH JL, 1979, AM J TROP MED HYG, V28, P643, DOI 10.4269/ajtmh.1979.28.643
   Bruce MC, 2002, CURR OPIN MICROBIOL, V5, P431, DOI 10.1016/S1369-5274(02)00348-X
   COX FEG, 1970, B WORLD HEALTH ORGAN, V43, P325
   DALE DC, 1973, BLOOD, V41, P197, DOI 10.1182/blood.V41.2.197.197
   DALGLIESH RJ, 1981, AUST VET J, V57, P8, DOI 10.1111/j.1751-0813.1981.tb07075.x
   de Roode JC, 2005, P NATL ACAD SCI USA, V102, P7624, DOI 10.1073/pnas.0500078102
   DEWAAL DT, 1988, ONDERSTEPOORT J VET, V55, P33
   DEWAAL DT, 1992, BRIT VET J, V148, P6, DOI 10.1016/0007-1935(92)90061-5
   DEWAAL DT, 1987, ONDERSTEPOORT J VET, V54, P561
   Fairlie-Clarke KJ, 2013, INFECT GENET EVOL, V20, P270, DOI 10.1016/j.meegid.2013.09.013
   Giha HA, 1999, INFECT IMMUN, V67, P4092, DOI 10.1128/IAI.67.8.4092-4098.1999
   Guimaraes AM, 1997, J EQUINE VET SCI, V17, P211, DOI 10.1016/S0737-0806(97)80563-1
   Hall CM, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-35
   KAPPMEYER LS, 1993, MOL BIOCHEM PARASIT, V62, P121, DOI 10.1016/0166-6851(93)90185-Z
   Knowles DP, 2018, INT J PARASITOL, V48, P679, DOI 10.1016/j.ijpara.2018.03.010
   KNOWLES DP, 1991, INFECT IMMUN, V59, P2412, DOI 10.1128/IAI.59.7.2412-2417.1991
   KUTTLER KL, 1986, AM J VET RES, V47, P1668
   Portugal S, 2011, NAT MED, V17, P732, DOI 10.1038/nm.2368
   RAY P, 1994, INFECT IMMUN, V62, P2354, DOI 10.1128/IAI.62.6.2354-2361.1994
   Scoles GA, 2011, EMERG INFECT DIS, V17, P1903, DOI 10.3201/eid1710.101182
   Sedegah M, 2007, PARASITE IMMUNOL, V29, P559, DOI 10.1111/j.1365-3024.2007.00976.x
   SEDEGAH M, 1982, ANN TROP MED PARASIT, V76, P219, DOI 10.1080/00034983.1982.11687529
   Short MA, 2012, JAVMA-J AM VET MED A, V240, P588, DOI 10.2460/javma.240.5.588
   Silva MG, 2013, MOL BIOCHEM PARASIT, V188, P109, DOI 10.1016/j.molbiopara.2013.03.002
   Singh B., 1980, Indian Journal of Parasitology, V4, P77
   Sitali L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0935-7
   TENTER AM, 1986, VET PARASITOL, V20, P49, DOI 10.1016/0304-4017(86)90092-0
   Terkawi MA, 2007, VACCINE, V25, P2027, DOI 10.1016/j.vaccine.2006.11.041
   Ueti MW, 2008, INFECT IMMUN, V76, P3525, DOI 10.1128/IAI.00251-08
   Ueti MW, 2012, INFECT IMMUN, V80, P2354, DOI 10.1128/IAI.00341-12
   Wise LN, 2013, J VET INTERN MED, V27, P1334, DOI 10.1111/jvim.12168
   WRIGHT IG, 1987, INFECT IMMUN, V55, P364, DOI 10.1128/IAI.55.2.364-368.1987
   Zobba R, 2008, J EQUINE VET SCI, V28, P301, DOI 10.1016/j.jevs.2008.03.005
NR 38
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 68
EP 75
DI 10.1016/j.vetpar.2019.06.009
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400012
PM 31303207
DA 2020-05-12
ER

PT J
AU Peng, ZW
   Shen, DD
   Zhang, DY
   Li, XY
   Wang, LX
   Zhai, Q
   Hou, ZJ
   Li, HP
AF Peng, Zhiwei
   Shen, Dongdong
   Zhang, Danyu
   Li, Xiuyun
   Wang, Lixing
   Zhai, Qian
   Hou, Zhijun
   Li, Heping
TI Genetic characteristics and phylogenetic relationship of Parascaris spp.
   from Equus zebra, E. caballus, and E. asinus
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Parascaris spp.; E. zebra; E. caballus; E. caballus; Phylogeny; Genetic
   characteristics
ID MULTIPLE SEQUENCE ALIGNMENT; POPULATION-GENETICS; MAXIMUM-LIKELIHOOD;
   INFECTION; UNIVALENS
AB The equine Parascaris spp. is large, parasitic nematodes, and predominantly focuses on the intestine of foals and young weanlings. There are two roundworms, Parascaris equorum and Parascaris univalens, recognized among equine hosts. In this study, all fifty-nine Parascaris worms were harvested from three different equine hosts (twenty specimens from Equus zebra, twenty specimens from E. caballus, and nineteen specimens from E. asinus). The ribosomal gene (ITS) and mitochondrial genes (cox1 and nadh1) were amplified to identify and genetically characterize these worms. Analysis of ITS sequences revealed five genotypes among the fifty-nine worms, and the sequence similarity among the worms from E. zebra and E. caballus was at a high level (99.87%), while the one of E. asinus worms showed an apparent difference from the worms either from the E. zebra or from the E. caballus (sequence similarity ranging from 93.04 to 93.42%). Analysis of mitochondrial genes revealed that twenty-one (cox1 gene) and thirteen (nadh1 gene) unique haplotypes were defined among the fifty-nine worms. The shared haplotypes (four cox1 haplotypes and one nadh1 haplotype) only occurred between the worm populations from E. zebra and E. caballus. The cox1 and nadh1 haplotype sequences were respectively applied to construct phylogenetic trees. Although the topologies showed that E. asinus worm population had an obvious boundary with the worm populations of the E. zebra and the E. caballus, however, no noticeable boundary was found within the two later worm populations. Meanwhile, the E. asinus worm population showed an obvious genetic differentiation and an extremely low gene flow (close to zero) with the worm populations from E. zebra and E. caballus, indicating that the genetic characteristics of the worms from the E. asinus have an obvious difference with the one from E. zebra and E. caballus.
C1 [Peng, Zhiwei; Shen, Dongdong; Zhang, Danyu; Wang, Lixing; Zhai, Qian; Hou, Zhijun; Li, Heping] Northeast Forestry Univ, Coll Wildlife Resources, Harbin 150040, Heilongjiang, Peoples R China.
   [Li, Xiuyun] Harbin Northern Forest Zoo, Harbin, Heilongjiang, Peoples R China.
   [Hou, Zhijun] China State Forestry Adm, Key Lab Wildlife Conservat, Harbin 150040, Heilongjiang, Peoples R China.
RP Hou, ZJ (reprint author), Northeast Forestry Univ, Coll Wildlife Resources, Harbin 150040, Heilongjiang, Peoples R China.; Li, HP (reprint author), China State Forestry Adm, Key Lab Wildlife Conservat, Harbin 150040, Heilongjiang, Peoples R China.
EM houzhijundz@163.com; lihepinghrb2002@yahoo.com.cn
FU National Key Research and Development Program [2017YFD0501702];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2572018AA29]; Surveillance
   of Wildlife Diseases from the State Forestry Administration of China
FX This study was supported by the following Grants: National Key Research
   and Development Program (project 2017YFD0501702), Fundamental Research
   Funds for the Central Universities (No.2572018AA29) and Surveillance of
   Wildlife Diseases from the State Forestry Administration of China.
CR Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Excoffier L, 2010, MOL ECOL RESOUR, V10, P564, DOI 10.1111/j.1755-0998.2010.02847.x
   Franssen F, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-124
   Gao JF, 2019, J HELMINTHOL, V93, P383, DOI 10.1017/S0022149X18000330
   GODAY C, 1984, SCIENCE, V224, P411, DOI 10.1126/science.224.4647.411
   Guindon S, 2009, METHODS MOL BIOL, V537, P113, DOI 10.1007/978-1-59745-251-9_6
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Hussain T, 2014, VET PARASITOL, V206, P188, DOI 10.1016/j.vetpar.2014.10.026
   Jabbar A., 2014, PARASITE VECTOR, V7, P1
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Martin F, 2018, VET PARASITOL, V264, P69, DOI 10.1016/j.vetpar.2018.11.003
   Nielsen MK, 2014, PARASITOL RES, V113, P4485, DOI 10.1007/s00436-014-4135-y
   Pawar RM, 2012, ACTA PARASITOL, V57, P67, DOI 10.2478/s11686-012-0012-y
   Peng ZW, 2016, VET PARASITOL, V226, P74, DOI 10.1016/j.vetpar.2016.06.031
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   SRIHAKIM S, 1978, AM J VET RES, V39, P1155
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Tyden E, 2013, INFECT GENET EVOL, V13, P236, DOI 10.1016/j.meegid.2012.09.022
   WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x
   Yin FY, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-279
   Zhu XQ, 2002, PARASITOLOGY, V124, P615, DOI 10.1017/S0031182002001579
NR 22
TC 0
Z9 0
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 76
EP 79
DI 10.1016/j.vetpar.2019.06.013
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400013
PM 31303209
DA 2020-05-12
ER

PT J
AU Gharieb, RMA
   Bowman, DD
   Liotta, JL
   Xiao, LH
AF Gharieb, Rasha M. A.
   Bowman, Dwight D.
   Liotta, Janice L.
   Xiao, Lihua
TI Isolation, genotyping and subtyping of single Cryptosporidium oocysts
   from calves with special reference to zoonotic significance
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cryptosporidium; Single oocyst; PCR-RFLP; gp60; Zoonoses
ID DAIRY CALVES; GENETIC DIVERSITY; MOLECULAR CHARACTERIZATION; PARVUM
   SUBTYPES; SPORADIC CRYPTOSPORIDIOSIS; RISK-FACTORS; CATTLE; HUMANS;
   PREVALENCE; SPP.
AB The ability of the small-subunit ribosomal RNA (SSU rRNA) based nested PCR and Restriction Fragment Length Polymorphism (PCR-RFLP) to identify and genotype a single Cryptosporidium oocyst isolated from bovine faecal samples was evaluated in this study. In addition, subtyping was carried out by sequencing the 60 kDa glycoprotein (gp60) gene from the same single oocyst. Faecal samples were collected from 40 pre-weaned calves (5-20 days old) from 7 dairy farms located in 3 different counties within the Finger Lakes region of Upstate New York. All the samples were microscopically positive for Cryptosporidium spp. A total of 400 Cryptosporidium oocysts (10 single oocysts from each calf sample) were individually isolated and analyzed using a nested PCR targeting the SSU rRNA gene. The SSU rRNA gene was amplified in 324 (81%) individual oocysts. All SSU rRNA amplified individual oocysts DNA was genotyped using PCR-RFLP. C. parvum was the only identified species; 107 single oocysts generated PCR products from the A gene, 18 generated PCR products from the B gene and 199 generated PCR products from both. Sequence analysis of the gp60 gene in 99 individual oocysts revealed the presence of only subtype IIaA15G2R1 with 99.4-100% and 99.1-100% identity of nucleotides and amino acids, respectively. These sequences were identical (100%) in oocysts from 35 calves and exhibited mutations in the non-repeat region of the 12)60 gene in those of 5 other calves. The examination of DNA from individual oocysts with gen-otyping and subtyping tools provides methodology to more clearly define the genetic characteristics of Cryptosporidium spp. on farms and within individual animals.
C1 [Gharieb, Rasha M. A.; Bowman, Dwight D.; Liotta, Janice L.] Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.
   [Xiao, Lihua] South China Agr Univ, Coll Vet Med, Guangzhou, Guangdong, Peoples R China.
   [Gharieb, Rasha M. A.] Zagazig Univ, Fac Vet Med, Dept Zoonoses, Zagazig 44511, Egypt.
RP Bowman, DD (reprint author), Cornell Univ, Coll Vet Med, Dept Microbiol & Immunol, Ithaca, NY 14853 USA.
EM ddb3@cornell.edu
RI Xiao, Lihua/B-1704-2013
OI Xiao, Lihua/0000-0001-8532-2727
CR Aita J, 2015, J VET MED SCI, V77, P997, DOI 10.1292/jvms.15-0082
   Alves M, 2003, J CLIN MICROBIOL, V41, P2744, DOI 10.1128/JCM.41.6.2744-2747.2003
   Amer S, 2013, EXP PARASITOL, V135, P518, DOI 10.1016/j.exppara.2013.09.002
   Amer S, 2010, VET PARASITOL, V169, P382, DOI 10.1016/j.vetpar.2010.01.017
   Avendano C, 2018, PARASITOL RES, V117, P1317, DOI 10.1007/s00436-018-5818-6
   Cai M, 2017, VET PARASITOL, V241, P14, DOI 10.1016/j.vetpar.2017.05.005
   Chalmers RM, 2013, TRENDS PARASITOL, V29, P237, DOI 10.1016/j.pt.2013.03.001
   Diaz P, 2018, PARASITOL RES, V117, P3081, DOI 10.1007/s00436-018-6000-x
   Fayer R, 2006, VET PARASITOL, V135, P105, DOI 10.1016/j.vetpar.2005.08.003
   Feltus DC, 2006, J CLIN MICROBIOL, V44, P4303, DOI 10.1128/JCM.01067-06
   Feng YY, 2018, TRENDS PARASITOL, V34, P997, DOI 10.1016/j.pt.2018.07.009
   Feng YY, 2013, INT J PARASITOL, V43, P1141, DOI 10.1016/j.ijpara.2013.09.002
   Glaberman S, 2002, EMERG INFECT DIS, V8, P631, DOI 10.3201/eid0806.010368
   Grinberg A, 2013, INFECT GENET EVOL, V15, P18, DOI 10.1016/j.meegid.2012.08.017
   Guo YQ, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1517-1
   Hunter PR, 2004, EMERG INFECT DIS, V10, P1241, DOI 10.3201/eid1007.030582
   Ichikawa-Seki M, 2015, PARASITOL INT, V64, P161, DOI 10.1016/j.parint.2014.11.007
   Ikarashi M, 2013, VET PARASITOL, V196, P220, DOI 10.1016/j.vetpar.2012.12.053
   Jiang JL, 2003, J EUKARYOT MICROBIOL, V50, P542, DOI 10.1111/j.1550-7408.2003.tb00623.x
   Jiang JL, 2005, APPL ENVIRON MICROB, V71, P4446, DOI 10.1128/AEM.71.8.4446-4454.2005
   Kaupke A, 2015, PARASITOL RES, V114, P4709, DOI 10.1007/s00436-015-4719-1
   Le Blancq SM, 1997, MOL BIOCHEM PARASIT, V90, P463, DOI 10.1016/S0166-6851(97)00181-3
   do Couto MCM, 2014, ACTA TROP, V130, P117, DOI 10.1016/j.actatropica.2013.11.002
   Matsubara R, 2017, PARASITOL INT, V66, P588, DOI 10.1016/j.parint.2017.05.004
   Meganck V, 2015, PREV VET MED, V118, P64, DOI 10.1016/j.prevetmed.2014.11.007
   Naguib D, 2018, PARASITOL INT, V67, P736, DOI 10.1016/j.parint.2018.07.012
   Ng J, 2011, VET PARASITOL, V176, P145, DOI 10.1016/j.vetpar.2010.10.056
   Peng MM, 2001, J EUKARYOT MICROBIOL, p28S
   Peng MM, 2003, PARASITOL RES, V90, P175, DOI 10.1007/s00436-003-0834-5
   Quilez J, 2008, PARASITOLOGY, V135, P1613, DOI 10.1017/S0031182008005088
   Rahmouni I, 2014, AM J TROP MED HYG, V90, P346, DOI 10.4269/ajtmh.13-0522
   Roy SL, 2004, J CLIN MICROBIOL, V42, P2944, DOI 10.1128/JCM.42.7.2944-2951.2004
   Ryan U, 2016, PARASITE IMMUNOL, V38, P535, DOI 10.1111/pim.12350
   Santin M, 2004, VET PARASITOL, V122, P103, DOI 10.1016/j.vetpar.2004.03.020
   Santin M, 2008, VET PARASITOL, V155, P15, DOI 10.1016/j.vetpar.2008.04.018
   Shirley DAT, 2012, CURR OPIN INFECT DIS, V25, P555, DOI 10.1097/QCO.0b013e328357e569
   Shirley MW, 1996, PARASITOLOGY, V112, P523, DOI 10.1017/S0031182000066099
   Shrivastava Arpit Kumar, 2017, Trop Parasitol, V7, P8, DOI 10.4103/2229-5070.202290
   Soba B, 2008, PARASITOLOGY, V135, P1263, DOI 10.1017/S0031182008004800
   Sulaiman IM, 2005, J CLIN MICROBIOL, V43, P2805, DOI 10.1128/JCM.43.6.2805-2809.2005
   Szonyi B, 2010, PARASITOL RES, V107, P317, DOI 10.1007/s00436-010-1864-4
   Tanriverdi S, 2002, J CLIN MICROBIOL, V40, P3237, DOI 10.1128/JCM.40.9.3237-3244.2002
   Taylan-Ozkan A, 2016, EXP PARASITOL, V170, P16, DOI 10.1016/j.exppara.2016.06.014
   Tomazic ML, 2013, VET PARASITOL, V198, P382, DOI 10.1016/j.vetpar.2013.09.022
   Trotz-Williams LA, 2006, PARASITOL RES, V99, P346, DOI 10.1007/s00436-006-0157-4
   Trotz-Williams LA, 2007, PREV VET MED, V82, P12, DOI 10.1016/j.prevetmed.2007.05.003
   Wang YZ, 2014, EXP PARASITOL, V144, P96, DOI 10.1016/j.exppara.2014.06.019
   Wu ZL, 2003, APPL ENVIRON MICROB, V69, P4720, DOI 10.1128/AEM.69.8.4720-4726.2003
   Xiao L, 2008, CRYPTOSPORIDIUM CRYP, P164
   Xiao LH, 2001, J INFECT DIS, V183, P492, DOI 10.1086/318090
   Xiao LH, 1999, APPL ENVIRON MICROB, V65, P3386
   Xiao LH, 2007, PARASITOL RES, V100, P701, DOI 10.1007/s00436-006-0337-2
   Xiao LH, 2010, EXP PARASITOL, V124, P80, DOI 10.1016/j.exppara.2009.03.018
   Zahedi A, 2017, INT J PARASITOL, V47, P601, DOI 10.1016/j.ijpara.2017.03.003
NR 54
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 80
EP 86
DI 10.1016/j.vetpar.2019.05.003
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400014
PM 31303210
DA 2020-05-12
ER

PT J
AU Giunchetti, RC
   Silveira, P
   Resende, LA
   Leite, JC
   Melo, OAD
   Rodrigues-Alves, ML
   Costa, LM
   Lair, DF
   Chaves, VR
   Soares, ID
   de Mendonca, LZ
   Lanna, MF
   Ribeiro, HS
   Maia-Goncalves, AA
   Santos, TAP
   Roatt, BM
   Aguiar-Soares, RDO
   Vitoriano-Souza, J
   Moreira, ND
   Mathias, FAS
   Cardoso, JMD
   Coura-Vital, W
   Galdino, AS
   Viana, KF
   Martins, OA
   da Silveira-Lemos, D
   Dutra, WO
   Reis, AB
AF Giunchetti, Rodolfo Cordeiro
   Silveira, Patricia
   Resende, Lucilene Aparecida
   Leite, Jaqueline Costa
   de Oliveira Melo-Junior, Otoni Alves
   Rodrigues-Alves, Marina Luiza
   Costa, Lais Moreira
   Lair, Daniel Ferreira
   Chaves, Vinicius Rossi
   Soares, Ingrid dos Santos
   de Mendonca, Ludmila Zanandreis
   Lanna, Mariana Ferreira
   Ribeiro, Helen Silva
   Maia-Goncalves, Ana Alice
   Pereira Santos, Thaiza Aline
   Roatt, Bruno Mendes
   Oliveira Aguiar-Soares, Rodrigo Dian
   Vitoriano-Souza, Juliana
   Moreira, Nadia das Dores
   Siqueira Mathias, Fernando Augusto
   de Oliveira Cardoso, Jamille Mirelle
   Coura-Vital, Wendel
   Galdino, Alexsandro Sobreira
   Viana, Kelvinson Fernandes
   Martins-Filho, Olindo Assis
   da Silveira-Lemos, Denise
   Dutra, Walderez Ornelaz
   Reis, Alexandre Barbosa
TI Canine visceral leishmaniasis biomarkers and their employment in
   vaccines
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Canine visceral leishmaniasis; Immunopathology; Vaccine; Immunogenicity;
   Biomarkers
ID EXCRETED-SECRETED ANTIGENS; IGG2 ANTIBODY-RESPONSES; LONG-LASTING
   PROTECTION; PARASITE DENSITY; IMMUNE-RESPONSE; ENDEMIC AREAS;
   RECOMBINANT ANTIGENS; PERIPHERAL-BLOOD; SAPONIN ADJUVANT;
   INTERFERON-GAMMA
AB The natural history of canine visceral leishmaniasis (CVL) has been well described, particularly with respect to the parasite load in different tissues and immunopathological changes according to the progression of clinical forms. The biomarkers evaluated in these studies provide support for the improvement of the tools used in developing vaccines against CVL. Thus, we describe the major studies using the dog model that supplies the rationale for including different biomarkers (tissue parasitism, histopathology, hematological changes, leuco-cytes immunophenotyping, cytokines patterns, and in vitro co-culture systems using purified T-cells subsets and macrophages infected with L. infantum) for immunogenicity and protection evaluations in phases I and II applied to pre-clinical and clinical vaccine trials against CVL. The search for biomarkers related to resistance or susceptibility has revealed a mixed cytokine profile with a prominent proinflammatory immune response as relevant for Leishmania replication at low levels as observed in asymptomatic dogs (highlighted by high levels of IFN-gamma and TNF-alpha and decreased levels in IL-4, TGF-beta and IL-10). Furthermore, increased levels in CD4(+) and CD8(+) T-cell subsets, presenting intracytoplasmic proinflammatory cytokine balance, have been associated with a resistance profile against CVL. In contrast, a polyclonal B-cell expansion towards plasma cell differentiation contributes to high antibody production, which is the hallmark of symptomatic dogs associated with high susceptibility in CVL. Finally, the different studies used to analyze biomarkers have been incorporated into vaccine immunogenicity and protection evaluations. Those biomarkers identified as resistance or susceptibility markers in CVL have been used to evaluate the vaccine performance against L. infantum in a kennel trial conducted before the field trial in an area known to be endemic for visceral leishmaniasis. This rationale has been a guiding force in the testing and selection of the best vaccine candidates against CVL and provides a way for the veterinary industry to register commercial immunobiological products.
C1 [Giunchetti, Rodolfo Cordeiro; Silveira, Patricia; Resende, Lucilene Aparecida; Leite, Jaqueline Costa; de Oliveira Melo-Junior, Otoni Alves; Rodrigues-Alves, Marina Luiza; Costa, Lais Moreira; Lair, Daniel Ferreira; Chaves, Vinicius Rossi; Soares, Ingrid dos Santos; de Mendonca, Ludmila Zanandreis; Lanna, Mariana Ferreira; Ribeiro, Helen Silva; Maia-Goncalves, Ana Alice; Pereira Santos, Thaiza Aline; Dutra, Walderez Ornelaz] Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Lab Biol Cell Interact, Av Pres Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
   [Roatt, Bruno Mendes; Oliveira Aguiar-Soares, Rodrigo Dian; Vitoriano-Souza, Juliana; Moreira, Nadia das Dores; Siqueira Mathias, Fernando Augusto; de Oliveira Cardoso, Jamille Mirelle; Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Nucleus Res Biol Sci, Lab Immunopathol, BR-35400000 Ouro Preto, MG, Brazil.
   [Coura-Vital, Wendel; Reis, Alexandre Barbosa] Univ Fed Ouro Preto, Sch Pharm, Dept Clin Anal, BR-35400000 Ouro Preto, MG, Brazil.
   [Galdino, Alexsandro Sobreira] Univ Fed Sao Joao del Rei, Microbial Biotechnol Lab, BR-35501296 Divinopolis, MG, Brazil.
   [Viana, Kelvinson Fernandes] Fed Univ Latin Amer Integrat, Latin Amer Inst Life & Nat Sci, Lab Biochem & Mol Biol, BR-85870901 Foz Do Iguacu, PR, Brazil.
   [Martins-Filho, Olindo Assis; da Silveira-Lemos, Denise] FIOCRUZ Minas, Rene Rachou Inst, Lab Diagnost & Monitoring Biomarkers, BR-30190002 Belo Horizonte, MG, Brazil.
RP Giunchetti, RC (reprint author), Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Lab Biol Cell Interact, Av Pres Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM giunchetti@icb.ufmg.br
RI Viana, Kelvinson/Y-4325-2019
OI Cordeiro Giunchetti, Rodolfo/0000-0003-4181-7546; Siqueira Mathias,
   Fernando Augusto/0000-0003-2071-0344
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais, BrazilMinas
   Gerais State Research Foundation (FAPEMIG); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, CNPq, BrazilNational Council
   for Scientific and Technological Development (CNPq); Departamento de
   Ciencia e Tecnologia (DECIT/Ministerio da Satide); CAPESCAPES;
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Minas Gerais, Brazil, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, CNPq, Brazil, Departamento de Ciencia e Tecnologia
   (DECIT/Ministerio da Satide) and CAPES. RCG, ASG, OAMF, WOD are grateful
   to CNPq for fellowships. We are also grateful to Randall Hope Johnson
   for assistance in preparing the manuscript.
CR ABRANCHES P, 1991, J PARASITOL, V77, P557, DOI 10.2307/3283159
   Aguiar-Soares RDDO, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-61
   Ali N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00660
   Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X
   Alves CF, 2009, VET IMMUNOL IMMUNOP, V128, P349, DOI 10.1016/j.vetimm.2008.11.020
   da Silva AVA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006445
   Barbosa MAG, 2011, J COMP PATHOL, V145, P336, DOI 10.1016/j.jcpa.2011.03.001
   Borj-Cabrera GP, 2002, VACCINE, V20, P3277, DOI 10.1016/S0264-410X(02)00294-3
   Borja LS, 2016, VET PARASITOL, V229, P110, DOI 10.1016/j.vetpar.2016.10.004
   Borja-Cabrera GP, 2008, VACCINE, V26, P4991, DOI 10.1016/j.vaccine.2008.07.029
   Carcelen J, 2009, VACCINE, V27, P5964, DOI 10.1016/j.vaccine.2009.07.069
   de Freitas JCC, 2012, RES VET SCI, V93, P705, DOI 10.1016/j.rvsc.2011.12.009
   Carrera L, 1996, EXP PARASITOL, V82, P139, DOI 10.1006/expr.1996.0018
   Carvalho CG, 2017, PARASITOL RES, V116, P987, DOI 10.1007/s00436-017-5375-4
   Cavalcanti AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123009
   Chaabouni A, 2018, VET PARASITOL, V261, P9, DOI 10.1016/j.vetpar.2018.07.011
   COOPER GR, 1946, P SOC EXP BIOL MED, V61, P179, DOI 10.3181/00379727-61-15265
   Abbehusen MMC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15651-8
   Costa-Pereira C, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0397-6
   Coura-Vital W, 2011, Vet J, V190, pe43, DOI 10.1016/j.tvjl.2011.04.005
   D'Amico G, 2003, KIDNEY INT, V63, P809, DOI 10.1046/j.1523-1755.2003.00840.x
   Da Costa RT, 2003, T ROY SOC TROP MED H, V97, P678
   da Silva VO, 2000, VACCINE, V19, P1082, DOI 10.1016/S0264-410X(00)00339-X
   Day MJ, 2007, VET PARASITOL, V147, P2, DOI 10.1016/j.vetpar.2007.03.037
   de Amorim IFG, 2010, VET PARASITOL, V173, P55, DOI 10.1016/j.vetpar.2010.06.021
   de Mendonca LZ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1752-6
   Deane LM., 1962, REV INST MED TROP SP, V4, P149
   DEPLAZES P, 1995, PARASITE IMMUNOL, V17, P451, DOI 10.1111/j.1365-3024.1995.tb00914.x
   dos-Santos WLC, 2004, PARASITOL RES, V92, P89, DOI 10.1007/s00436-003-1016-1
   Elliott J., 2013, CHRONIC KIDNEY DIS I, VXV, P857
   de Lima VMF, 2010, VET PARASITOL, V173, P330, DOI 10.1016/j.vetpar.2010.07.012
   Fernandes AP, 2008, VACCINE, V26, P5888, DOI 10.1016/j.vaccine.2008.05.095
   Fernandes CB, 2014, VACCINE, V32, P1287, DOI 10.1016/j.vaccine.2013.12.046
   Cotrina JF, 2018, VACCINE, V36, P1972, DOI 10.1016/j.vaccine.2018.02.111
   Fernandez J. C., 2018, VACCINE, V15, P972
   Ferri R. G., 1996, REV INST MED TROP SP, V8, P225
   Fiuza JA, 2015, VACCINE, V33, P280, DOI 10.1016/j.vaccine.2014.11.039
   Garcia-Martinez JD, 2015, RES VET SCI, V99, P204, DOI 10.1016/j.rvsc.2015.01.002
   Ghosh S, 2002, INFECT IMMUN, V70, P6828, DOI 10.1128/IAI.70.12.6828-6838.2002
   Ginel PJ, 2008, RES VET SCI, V85, P510, DOI 10.1016/j.rvsc.2008.01.007
   Giunchetti RC, 2006, J COMP PATHOL, V135, P100, DOI 10.1016/j.jcpa.2006.06.005
   Giunchetti RC, 2008, VACCINE, V26, P623, DOI 10.1016/j.vaccine.2007.11.057
   Giunchetti RC, 2008, VET IMMUNOL IMMUNOP, V121, P23, DOI 10.1016/j.vetimm.2007.07.009
   Giunchetti RC, 2008, RES VET SCI, V84, P269, DOI 10.1016/j.rvsc.2007.04.020
   Giunchetti RC, 2007, VACCINE, V25, P7674, DOI 10.1016/j.vaccine.2007.08.009
   Gomes De Almeida Leal C, 2014, VET PARASITOL, V205, P472, DOI DOI 10.1016/J.VETPAR.2014.08.022
   Grimaldi G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185438
   Holzmuller P, 2005, VET IMMUNOL IMMUNOP, V106, P247, DOI 10.1016/j.vetimm.2005.03.001
   Hosein S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140325
   Koutinas AF, 2014, VET PATHOL, V51, P527, DOI 10.1177/0300985814521248
   Lemesre JL, 2007, VACCINE, V25, P4223, DOI 10.1016/j.vaccine.2007.02.083
   Lemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
   Lima LVD, 2017, PARASITE, V24, DOI 10.1051/parasite/2017039
   Lima V.M.F., 2010, VET IMMUNOL IMMUNOP, V135, P296
   Correa APFL, 2007, VET PARASITOL, V143, P267, DOI 10.1016/j.vetpar.2006.08.023
   Madeira IMVM, 2016, INT J EXP PATHOL, V97, P139, DOI 10.1111/iep.12179
   Maia C, 2012, J TROP MED, DOI 10.1155/2012/541571
   MANCIANTI F, 1988, T ROY SOC TROP MED H, V82, P566, DOI 10.1016/0035-9203(88)90510-X
   Martin V, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-69
   MARTINEZMORENO A, 1995, VET IMMUNOL IMMUNOP, V48, P209, DOI 10.1016/0165-2427(95)05434-8
   Matralis D, 2016, PARASITE IMMUNOL, V38, P510, DOI 10.1111/pim.12335
   Menezes-Souza D, 2011, VET PARASITOL, V177, P39, DOI 10.1016/j.vetpar.2010.11.025
   Molano I, 2003, VET IMMUNOL IMMUNOP, V92, P1, DOI 10.1016/S0165-2427(02)00315-X
   Moreira ML, 2016, VET PARASITOL, V220, P33, DOI 10.1016/j.vetpar.2016.02.009
   Moreno J, 2014, VET IMMUNOL IMMUNOP, V158, P199, DOI 10.1016/j.vetimm.2014.01.011
   Moreno J, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001683
   Nascimento MSL, 2015, J COMP PATHOL, V153, P197, DOI 10.1016/j.jcpa.2015.10.174
   Nascimento MSL, 2013, VET IMMUNOL IMMUNOP, V153, P202, DOI 10.1016/j.vetimm.2013.02.015
   Nieto CG, 1999, VET IMMUNOL IMMUNOP, V67, P117, DOI 10.1016/S0165-2427(98)00213-X
   Oliva G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003213
   OLIVEIRA GGS, 1993, MEM I OSWALDO CRUZ, V88, P243, DOI 10.1590/S0074-02761993000200011
   Ordeix L., 2017, INFECT DIS, V158, P56
   PATERAKI E, 1983, INFECT IMMUN, V42, P496, DOI 10.1128/IAI.42.2.496-500.1983
   Jacintho APP, 2018, PARASITOL RES, V117, P1819, DOI 10.1007/s00436-018-5868-9
   Quinnell RJ, 2003, VET IMMUNOL IMMUNOP, V91, P161, DOI 10.1016/S0165-2427(02)00311-2
   Regina-Silva S, 2016, VACCINE, V34, P2233, DOI 10.1016/j.vaccine.2016.03.019
   Reis AB, 2006, CLIN EXP IMMUNOL, V146, P303, DOI 10.1111/j.1365-2249.2006.03206.x
   Reis AB, 2006, VET IMMUNOL IMMUNOP, V112, P102, DOI 10.1016/j.vetimm.2006.02.001
   Reis AB, 2006, RES VET SCI, V81, P68, DOI 10.1016/j.rvsc.2005.09.011
   Reis AB, 2010, TRENDS PARASITOL, V26, P341, DOI 10.1016/j.pt.2010.04.005
   Reis AB, 2009, VET IMMUNOL IMMUNOP, V128, P87, DOI 10.1016/j.vetimm.2008.10.307
   Resende LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161169
   Resende LA, 2013, VET PARASITOL, V198, P371, DOI 10.1016/j.vetpar.2013.09.011
   Roatt B. M., 2012, PLOS ONE, V11, P1
   Rodriguez-Cortes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155224
   Sant'Ana JAP, 2007, ARQ BRAS MED VET ZOO, V59, P1137, DOI 10.1590/S0102-09352007000500008
   Santos-Gomes GM, 2002, VET IMMUNOL IMMUNOP, V88, P21, DOI 10.1016/S0165-2427(02)00134-4
   Silva LC, 2013, INT J EXP PATHOL, V94, P133, DOI 10.1111/iep.12010
   Smith BE, 2004, J VET INTERN MED, V18, P47, DOI 10.1892/0891-6640(2004)18&lt;47:AACBDI&gt;2.0.CO;2
   Solano-Gallego L, 2001, VET PARASITOL, V96, P265, DOI 10.1016/S0304-4017(00)00446-5
   Solca MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep32619
   Souza CC, 2014, INT J EXP PATHOL, V95, P260, DOI 10.1111/iep.12080
   Strauss-Ayali D, 2007, VET RES, V38, P547, DOI 10.1051/vetres:2007015
   Tafuri Wagner Luiz, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P81, DOI 10.1590/S0036-46651996000200001
   Tafuri WL, 2001, VET PARASITOL, V96, P203, DOI 10.1016/S0304-4017(00)00436-2
   Bagues NCT, 2018, COMP IMMUNOL MICROB, V56, P14, DOI 10.1016/j.cimid.2017.11.003
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Tonin AA, 2016, COMP IMMUNOL MICROB, V44, P61, DOI 10.1016/j.cimid.2015.09.004
   Torrecilha RBP, 2016, PREV VET MED, V132, P83, DOI 10.1016/j.prevetmed.2016.08.006
   TRYPHONAS L, 1977, CAN J COMP MED, V41, P1
   Venturin GL, 2016, PARASITE IMMUNOL, V38, P698, DOI 10.1111/pim.12353
   Viana KF, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1528-z
   Viana KF, 2015, VET PARASITOL, V211, P124, DOI 10.1016/j.vetpar.2015.05.025
   Viana KF, 2013, VET PARASITOL, V198, P62, DOI 10.1016/j.vetpar.2013.08.014
   Vitoriano-Souza J, 2008, VACCINE, V26, P3922, DOI 10.1016/j.vaccine.2008.04.084
   Vitoriano-Souza J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040745
   Zafra R, 2008, VET IMMUNOL IMMUNOP, V123, P353, DOI 10.1016/j.vetimm.2008.02.022
   Zatelli A, 2003, AM J VET RES, V64, P558, DOI 10.2460/ajvr.2003.64.558
NR 108
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUL
PY 2019
VL 271
BP 87
EP 97
DI 10.1016/j.vetpar.2019.05.006
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IM0NV
UT WOS:000477686400015
PM 31303211
DA 2020-05-12
ER

PT J
AU Najjar, Z
   Quinn, E
   Anderson, T
   Sheppeard, V
   Gupta, L
AF Najjar, Zeina
   Quinn, Emma
   Anderson, Teresa
   Sheppeard, Vicky
   Gupta, Leena
TI Surveillance methods to detect the impact of a significant cold chain
   breach
SO VACCINE
LA English
DT Article
DE Cold chain breach; Vaccination; Vaccine-preventable disease
   surveillance; Evaluation
ID VACCINE
AB In January 2015, a significant cold chain breach on a postnatal ward in a tertiary hospital in Sydney, Australia was noted to have been occurring since August 2013. Surveillance, amongst the 1178 mothers and 1178 babies affected, for vaccine-preventable diseases (VPDs) and adverse events following immunisation (AEFIs) using linkage with a notifiable diseases database was subsequently undertaken; no directly related instances of VPDs or AEFIs were detected. We evaluate this novel systematic surveillance method which has not been previously reported to determine whether it is effective in determining the impact of cold chain breaches on an individual and population level. The recommendation for revaccination of the affected mothers and subsequent surveillance was resource-intensive and future studies related to such incidents should focus on detailing the resources used to allow the costs versus benefits of such systematic surveillance to be determined. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Najjar, Zeina; Quinn, Emma; Anderson, Teresa; Gupta, Leena] Sydney Local Hlth Dist, Level 11 KGV Bldg,Missenden Rd, Camperdown, NSW 2050, Australia.
   [Sheppeard, Vicky] Hlth Protect NSW, 73 Miller St, Sydney, NSW 2060, Australia.
RP Najjar, Z (reprint author), Sydney Local Hlth Dist, Publ Hlth Unit, Level 9 KGV Bldg,Missenden Rd, Camperdown, NSW 2050, Australia.
EM zeina.najjar@health.nsw.gov.au; emma.quinn@health.nsw.gov.au;
   teresa.anderson@health.nsw.gov.au; vicky.sheppeard@health.nsw.gov.au;
   leena.gupta@health.nsw.gov
CR [Anonymous], 2013, WHO GLOB VACC ACT PL
   [Anonymous], 2017, PERT VACC
   [Anonymous], 2013, NAT VACC STOR GUID S
   [Anonymous], 2016, NATIONAL PARTNERSHIP
   Breakwell L, 2015, MMWR-MORBID MORTAL W, V64, P1088, DOI 10.15585/mmwr.mm6438a7
   Craig L, 2010, VACCINE, V29, P65, DOI 10.1016/j.vaccine.2010.10.014
   Davaalkham D, 2007, J EPIDEMIOL COMMUN H, V61, P578, DOI 10.1136/jech.2006.051375
   McColloster P, 2011, AM J PUBLIC HEALTH, V101, P46, DOI 10.2105/AJPH.2009.179853
   NSW Health, A Z INF DIS PERT NOT
   NSW Health, VACC STOR COLD CHAIN
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3950
EP 3952
DI 10.1016/j.vaccine.2019.05.091
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700011
PM 31227356
OA Other Gold
DA 2020-05-12
ER

PT J
AU German, EL
   Solorzano, C
   Sunny, S
   Dunne, F
   Gritzfeld, JF
   Mitsi, E
   Nikolaou, E
   Hyder-Wright, AD
   Collins, AM
   Gordon, SB
   Ferreira, DM
AF German, E. L.
   Solorzano, C.
   Sunny, S.
   Dunne, F.
   Gritzfeld, J. F.
   Mitsi, E.
   Nikolaou, E.
   Hyder-Wright, A. D.
   Collins, A. M.
   Gordon, S. B.
   Ferreira, D. M.
TI Protective effect of PCV vaccine against experimental pneumococcal
   challenge in adults is primarily mediated by controlling colonisation
   density
SO VACCINE
LA English
DT Article
DE Pneumococcus; PCV; Colonisation; Density; QPCR
ID NASOPHARYNGEAL CARRIAGE; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE;
   CHILDREN; GENES
AB Widespread use of Pneumococcal Conjugate Vaccines (PCV) has reduced vaccine-type nasopharyngeal colonisation and invasive pneumococcal disease. In a double-blind, randomised controlled trial using the Experimental Human Pneumococcal Challenge (EHPC) model, PCV-13 (Prevenar-13) conferred 78% protection against colonisation acquisition and reduced bacterial intensity (AUC) as measured by classical culture. We used a multiplex qPCR assay targeting lytA and pneumococcal serotype 6A/B cpsA genes to reassess the colonisation status of the same volunteers. Increase in detection of low-density colonisation resulted in reduced PCV efficacy against colonisation acquisition (29%), compared to classical culture (83%). For experimentally colonised volunteers, PCV had a pronounced effect on decreasing colonisation density. These results obtained in adults suggest that the success of PCV vaccination could primarily be mediated by the control of colonisation density. Studies assessing the impact of pneumococcal vaccines should allow for density measurements in their design. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [German, E. L.; Solorzano, C.; Sunny, S.; Dunne, F.; Gritzfeld, J. F.; Mitsi, E.; Nikolaou, E.; Collins, A. M.; Gordon, S. B.; Ferreira, D. M.] Univ Liverpool Liverpool Sch Trop Med, 1 Daulby St, Liverpool L7 8XZ, Merseyside, England.
   [Hyder-Wright, A. D.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England.
   [Sunny, S.] Royal Liverpool Univ Hosp, Med Microbiol, Liverpool, Merseyside, England.
   [Dunne, F.] Univ Birmingham, IIA, Birmingham, W Midlands, England.
   [Gritzfeld, J. F.] Univ Liverpool, Alder Hey Childrens NHS Fdn Trust Hosp, Inst Translat Med Child Hlth, Liverpool, Merseyside, England.
   [Gordon, S. B.] Malawi Liverpool Wellcome Trust, Blantyre, Malawi.
RP Ferreira, DM (reprint author), Univ Liverpool Liverpool Sch Trop Med, 1 Daulby St, Liverpool L7 8XZ, Merseyside, England.
EM Esther.German@lstmed.ac.uk; Carla.SolorzanoGonzalez@lstmed.ac.uk;
   syba.sunny@rlbuht.nhs.uk; f.j.dunne@bham.ac.uk;
   j.gritzfeld@liverpool.ac.uk; Elena.Mitsi@lstmed.ac.uk;
   Elissavet.Nikolaou@lstmed.ac.uk; Angela.Hyder-Wright@lstmed.ac.uk;
   Andrea.Collins@lstmed.ac.uk; sgordon@mlw.mw;
   Daniela.Ferreira@lstmed.ac.uk
OI Gordon, Stephen/0000-0001-6576-1116; collins,
   andrea/0000-0002-4094-1572; Mitsi, Elena/0000-0001-7586-6050; Ferreira,
   Daniela M/0000-0002-0594-0902
FU Medical Research Council/FAPESP [MR/M011569/1]; Medical Research
   CouncilMedical Research Council UK (MRC) [MR/M01156911]; Bill & Melinda
   Gates FoundationGates Foundation [OPP1035281, OPP1117728]; National
   Institute for Health Research (NIHR) Local Clinical Research
   NetworkNational Institute for Health Research (NIHR)
FX This work was supported by the Medical Research Council/FAPESP (grant
   number MR/M011569/1), Medical Research Council (grant number
   MR/M01156911), the Bill & Melinda Gates Foundation, (grant numbers
   OPP1035281 and OPP1117728); and the National Institute for Health
   Research (NIHR) Local Clinical Research Network. The funders were not
   involved in the design, data processing or publication of this work.
CR Adler H, 2019, J INFECT DIS
   Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Collins AM, 2015, AM J RESP CRIT CARE, V192, P853, DOI 10.1164/rccm.201503-0542OC
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8
   Gritzfeld JF, 2014, CLIN MICROBIOL INFEC, V20, pO1145, DOI 10.1111/1469-0691.12752
   Gritzfeld JF, 2013, JOVE-J VIS EXP, P72
   Hanke CR, 2016, PEDIATR INFECT DIS J, V35, P432, DOI 10.1097/INF.0000000000001030
   Huong TTV, 2011, PEDIATR INFECT DIS J, V30, P11, DOI 10.1097/INF.0b013e3181f111a2
   Johnston C, 2010, J CLIN MICROBIOL, V48, P2762, DOI 10.1128/JCM.01746-09
   Lessa FC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35921-3
   Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071
   Pimenta F, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03199
   Rudan I, 2013, J GLOBAL HLTH, V3
   Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Thors V, 2016, HUM VACC IMMUNOTHER, V12, P375, DOI 10.1080/21645515.2015.1090069
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3953
EP 3956
DI 10.1016/j.vaccine.2019.05.080
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700012
PM 31176540
OA Green Accepted, Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Granadillo, M
   Batte, A
   Alfonso, AB
   Blanco, A
   Urquiza, D
   Varas, L
   Soler, D
   Miyares, M
   Limonta, M
   Torrens, I
AF Granadillo, Milaid
   Batte, Aileen
   Alfonso, Alain B.
   Blanco, Aracelys
   Urquiza, Dioslaida
   Varas, Laura
   Soler, Dayana
   Miyares, Maelys
   Limonta, Miladys
   Torrens, Isis
TI Impact on antitumor response using a new adjuvant preparation as a
   component of a human papillomavirus type 16 therapeutic vaccine
   candidate
SO VACCINE
LA English
DT Article
DE LALF(32-51)-E7; CiGB550-E7; fusion protein; VSSP; HPV vaccine
ID EFFICACY
AB Cervical cancer is a global public health problem and human papillomavirus (HPV) 16 accounts for approximately 50% of cases worldwide. Although there are several types of HPV therapeutic vaccines in clinical research, there are currently not approved for use in humans. We developed the fusion protein LALF(32)(-51)-E7 (hereafter denominated CIGB550-E7) defined by a cell-penetrating peptide linked to an E7 mutein for the treatment of HPV16-associated tumors. We have demonstrated previously the benefit on antitumor response induced by the immunization with CIGB550-E7 admixed with very small size proteoliposomes (VSSP) adjuvant compared with the adjuvant-free immunization. In this study, we obtained a similar antitumor response in mice immunized with CIGB550-E7 admixed with the new adjuvant sVSSP that does not contain any animal-derived product. Also, the immunization with the above mentioned vaccine preparation induced a cell-mediated immune response. Our results are encouraging for the future clinical trials with the vaccine candidate C1GB550-E7+sVSSP. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Granadillo, Milaid; Batte, Aileen; Alfonso, Alain B.; Torrens, Isis] Ctr Genet Engn & Biotechnol, Pharmaceut Dept, POB 6162, Havana 10600, Cuba.
   [Blanco, Aracelys; Urquiza, Dioslaida] Ctr Genet Engn & Biotechnol, Direct Preclin Invest & Anim Expt, POB 6162, Havana 10600, Cuba.
   [Varas, Laura; Soler, Dayana; Miyares, Maelys; Limonta, Miladys] Ctr Genet Engn & Biotechnol, Direct Technol Dev, POB 6162, Havana 10600, Cuba.
RP Granadillo, M (reprint author), Ctr Genet Engn & Biotechnol, Pharmaceut Dept, POB 6162, Havana 10600, Cuba.
EM milaid.granadillo@cigb.edu.cu
OI Alfonso, Alain/0000-0003-3540-5270
FU Center for Genetic Engineering and Biotechnology, Cuba
FX This work was supported by the Center for Genetic Engineering and
   Biotechnology, Cuba.
CR Bray F., 2018, CA CANC J CLIN
   Chabeda A, 2018, PAPILLOMAVIRUS RES, V5, P46, DOI 10.1016/j.pvr.2017.12.006
   Dillner J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3493
   Estevez F, 1999, VACCINE, V18, P190, DOI 10.1016/S0264-410X(99)00219-4
   Fernandez A, 2014, WORLD J IMMUNOL, V4, P98
   Granadillo M, 2016, J CELL IMMUNOTHER, V2, P44
   Granadillo M, 2017, CLIN EXP METASTAS, V34, P241, DOI 10.1007/s10585-017-9846-x
   Granadillo M, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-12
   Granadillo M, 2011, VACCINE, V29, P920, DOI 10.1016/j.vaccine.2010.11.083
   Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4
   Lin KY, 1996, CANCER RES, V56, P21
   NAITO S, 1986, CANCER RES, V46, P4109
   Temizoz B, 2016, INT IMMUNOL, V28, P329, DOI 10.1093/intimm/dxw015
   Wheeler CM, 2012, LANCET ONCOL, V13, P100, DOI 10.1016/S1470-2045(11)70287-X
   Bosch FX, 2013, VACCINE, V31, P1, DOI 10.1016/j.vaccine.2013.07.026
NR 15
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3957
EP 3960
DI 10.1016/j.vaccine.2019.05.060
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700013
PM 31155419
DA 2020-05-12
ER

PT J
AU Teixeira, AF
   Fernandes, LGV
   Cavenague, MF
   Takahashi, MB
   Santos, JC
   Passalia, FJ
   Daroz, BB
   Kochi, LT
   Vieira, ML
   Nascimento, ALTO
AF Teixeira, Aline F.
   Fernandes, Luis G., V
   Cavenague, Maria F.
   Takahashi, Maria B.
   Santos, Jademilson C.
   Passalia, Felipe J.
   Daroz, Brenda B.
   Kochi, Leandro T.
   Vieira, Monica L.
   Nascimento, Ana L. T. O.
TI Adjuvanted leptospiral vaccines: Challenges and future development of
   new leptospirosis vaccines
SO VACCINE
LA English
DT Review
DE Leptospira; Leptospirosis; Vaccine; Adjuvant
ID IMMUNOGLOBULIN-LIKE PROTEIN; HUMORAL IMMUNE-RESPONSE; OUTER-MEMBRANE
   PROTEINS; DENDRITIC CELLS; B-SUBUNIT; PROTECTIVE IMMUNITY; CARBON
   NANOTUBES; CPG OLIGODEOXYNUCLEOTIDES; RESPIRATORY CHALLENGE; RECOMBINANT
   LIPL32
AB Leptospirosis is a neglected infectious disease of global importance. Vaccination is the most viable strategy for the control of leptospirosis, but in spite of efforts for the development of an effective vaccine against the disease, few advances have been made, and to date, bacterin is the only option for prevention of leptospirosis. Bacterins are formulations based on inactivated leptospires that present a series of drawbacks, such as serovar-dependence and short-term immunity. Therefore, bacterins are not widely used in humans, and only Cuba, France and China have these vaccines licensed for at-risk populations. The development of recombinant DNA technology emerges as an alternative to solve the problem. Recombinant protein-based vaccines or DNA vaccines seem to be an attractive strategy, but the use of adjuvants is critical for achievement of a protective immune response. Adjuvants are capable of enhancing and/or modulating immune responses by exposing antigens to antigen-presenting cells. In the last years, several components have been tested as adjuvants, such as aluminum salts, oil based-emulsion adjuvants, bacteria-derived components and liposomes. This review highlights the use of adjuvants in the multiple vaccine approaches that have been used for leptospirosis and their most important immunological aspects. Immune response data generated by these strategies can contribute to the understanding of the immune mechanisms involved in protection against leptospirosis, and consequently, the development of effective vaccines against this disease. This is the first review on leptospiral vaccines focusing on adjuvant aspects. (C) 2019 Published by Elsevier Ltd.
C1 [Teixeira, Aline F.; Fernandes, Luis G., V; Cavenague, Maria F.; Takahashi, Maria B.; Santos, Jademilson C.; Passalia, Felipe J.; Daroz, Brenda B.; Kochi, Leandro T.; Vieira, Monica L.; Nascimento, Ana L. T. O.] Inst Butantan, Ctr Biotecnol, Lab Especial Desenvolvimento Vacinas, Ave Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
   [Cavenague, Maria F.; Takahashi, Maria B.; Passalia, Felipe J.; Daroz, Brenda B.; Kochi, Leandro T.] Univ Sao Paulo, Inst Ciencias Biomed, Programa Posgrad Interunidades Biotecniol, Sao Paulo, Brazil.
RP Nascimento, ALTO (reprint author), Inst Butantan, Ctr Biotecnol, Lab Especial Desenvolvimento Vacinas, Ave Vital Brazil 1500, BR-05503900 Sao Paulo, SP, Brazil.
EM ana.nascimento@butantan.gov.br
RI Vieira, Monica L/L-6757-2018; Virgilio Fernandes, Luis
   Guilherme/G-1712-2017
OI Vieira, Monica L/0000-0002-4162-8086; Passalia, Felipe
   Jose/0000-0003-0305-7160; Takahashi, Maria Beatriz/0000-0001-5841-7085;
   Daroz, Brenda/0000-0002-1069-5681; Virgilio Fernandes, Luis
   Guilherme/0000-0001-8794-9021
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2016/11541-0, 2017/01102-2, 2017/01411-5, 2017/26223-7, 2017/00236-5,
   2017/25167-6, 2016/01384-5, 2017/06731-8, 14/50981-0]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
   [301229/2017-1, 441449/2014-0]; Fundacao Butantan; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior -Brazil (CAPES)CAPES [001]
FX The following Brazilian agencies: FAPESP (grant 14/50981-0), CNPq
   (grants 301229/2017-1 and 441449/2014-0) and Fundacao Butantan,
   financially supported this work; AFT, FJP, BBD, MBT, MLV, JCS, LTK LGVF
   have fellowships from FAPESP (2016/11541-0, 2017/01102-2, 2017/01411-5,
   2017/26223-7, 2017/00236-5, 2017/25167-6, 2016/01384-5 and 2017/06731-8,
   respectively); This study was also financed in part by the Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior -Brazil (CAPES) -
   Finance Code 001 (MFC). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ADLER B, 1977, INFECT IMMUN, V17, P67, DOI 10.1128/IAI.17.1.67-72.1977
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   ALLISON AC, 1974, NATURE, V252, P252, DOI 10.1038/252252a0
   Arenas Jesus, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P221
   Atzingen Marina V, 2012, Open Microbiol J, V6, P79, DOI 10.2174/1874285801206010079
   Atzingen MV, 2010, J MED MICROBIOL, V59, P1005, DOI 10.1099/jmm.0.021485-0
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Bacelo KL, 2014, BIOMED RES INT, DOI 10.1155/2014/636491
   Bastola R, 2017, ARCH PHARM RES, V40, P1238, DOI 10.1007/s12272-017-0969-z
   Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2
   Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   Branger C, 2001, INFECT IMMUN, V69, P6831, DOI 10.1128/IAI.69.11.6831-6838.2001
   Branger C, 2005, INFECT IMMUN, V73, P4062, DOI 10.1128/IAI.73.7.4062-4069.2005
   BRAZOLOT MCL, 1998, P NATL ACAD SCI USA, V95, P15553, DOI DOI 10.1073/PNAS.95.26.15553
   Brewer JM, 1996, EUR J IMMUNOL, V26, P2062, DOI 10.1002/eji.1830260915
   BRODERSON JR, 1989, LAB ANIM SCI, V39, P400
   Brunner R, 2010, IMMUNOL LETT, V128, P29, DOI 10.1016/j.imlet.2009.10.005
   Caimano MJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004004
   Cao YG, 2011, VACCINE, V29, P7379, DOI 10.1016/j.vaccine.2011.07.070
   Chiou CJ, 2009, BIOMATERIALS, V30, P5862, DOI 10.1016/j.biomaterials.2009.06.046
   Chu RS, 2000, INFECT IMMUN, V68, P1450, DOI 10.1128/IAI.68.3.1450-1456.2000
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Confer AW, 2013, VET MICROBIOL, V163, P207, DOI 10.1016/j.vetmic.2012.08.019
   Cong YZ, 1997, J IMMUNOL, V159, P5301
   Conrad NL, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005441
   Costa F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003898
   Coutinho ML, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001422
   Cui BF, 2018, EXPERT REV VACCINES, V17, P335, DOI 10.1080/14760584.2018.1457443
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Delaney KN, 2010, VIRAL IMMUNOL, V23, P201, DOI 10.1089/vim.2009.0107
   Dupuis M, 1998, CELL IMMUNOL, V186, P18, DOI 10.1006/cimm.1998.1283
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   El Sahly H, 2010, EXPERT REV VACCINES, V9, P1135, DOI [10.1586/erv.10.111, 10.1586/ERV.10.111]
   ELOIT M, 1995, VET RES, V26, P207
   Evangelista IN, 2017, PLOS ONE, V12
   FAINE S, 1974, AUST J EXP BIOL MED, V52, P301, DOI 10.1038/icb.1974.28
   FAINE S, 1999, LEPTOSPIRA LEPTOSPIR
   Faisal SM, 2009, VACCINE, V27, P6537, DOI 10.1016/j.vaccine.2009.08.051
   Faisal SM, 2009, VACCINE, V27, P6129, DOI 10.1016/j.vaccine.2009.08.029
   Faisal SM, 2009, VACCINE, V27, P378, DOI 10.1016/j.vaccine.2008.10.089
   Farsani Hassan Heydari, 2015, World J Methodol, V5, P230, DOI 10.5662/wjm.v5.i4.230
   Felix SR, 2011, CLIN VACCINE IMMUNOL, V18, P2026, DOI 10.1128/CVI.05297-11
   Fernandes LGV, 2017, INT J INFECT DIS, V57, P61, DOI 10.1016/j.ijid.2017.01.032
   Forster KM, 2015, MEM I OSWALDO CRUZ, V110, P989, DOI 10.1590/0074-02760150222
   Forster KM, 2013, CLIN VACCINE IMMUNOL, V20, P725, DOI 10.1128/CVI.00601-12
   Gandhapudi SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056855
   Garba B, 2018, MICROB PATHOGENESIS, V124, P136, DOI 10.1016/j.micpath.2018.08.028
   Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723
   Garcon N, 2012, EXPERT REV VACCINES, V11, P349, DOI [10.1586/ERV.11.192, 10.1586/erv.11.192]
   Ghimire TR, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0972-0
   Grassmann AA, 2012, CLIN VACCINE IMMUNOL, V19, P740, DOI 10.1128/CVI.05720-11
   Guerreiro H, 2001, INFECT IMMUN, V69, P4958, DOI 10.1128/IAI.69.8.4958-4968.2001
   Haake DA, 1999, INFECT IMMUN, V67, P6572
   HAAKE DA, 1993, J BACTERIOL, V175, P4225, DOI 10.1128/JB.175.13.4225-4234.1993
   Haake DA, 2002, INFECT IMMUN, V70, P4936, DOI 10.1128/IAI.70.9.4936-4945.2002
   Hagan JE, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004275
   Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291
   Hartwig DD, 2015, MEM I OSWALDO CRUZ, V110, P134, DOI 10.1590/0074-02760140276
   Hartwig DD, 2014, CURR MICROBIOL, V68, P524, DOI 10.1007/s00284-013-0505-4
   Hartwig DD, 2013, CLIN VACCINE IMMUNOL, V20, P747, DOI 10.1128/CVI.00034-13
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hensel MT, 2017, J VIROL, P91
   Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Humphryes PC, 2014, CLIN VACCINE IMMUNOL, V21, P546, DOI 10.1128/CVI.00719-13
   ISHIZAKA S, 1983, EUR J IMMUNOL, V13, P225, DOI 10.1002/eji.1830130309
   Ismaili J, 2002, J IMMUNOL, V168, P926, DOI 10.4049/jimmunol.168.2.926
   Izurieta P, 2015, VACCINE, V33, P2800, DOI 10.1016/j.vaccine.2015.04.027
   JOHNSON AG, 1987, REV INFECT DIS, V9, pS512
   Jones T, 2009, CURR OPIN MOL THER, V11, P337
   JOST BH, 1989, J MED MICROBIOL, V29, P115, DOI 10.1099/00222615-29-2-115
   Kam NWS, 2005, P NATL ACAD SCI USA, V102, P11600, DOI 10.1073/pnas.0502680102
   Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001
   Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475
   Klumpp C, 2006, BBA-BIOMEMBRANES, V1758, P404, DOI 10.1016/j.bbamem.2005.10.008
   Koizumi N, 2004, VACCINE, V22, P1545, DOI 10.1016/j.vaccine.2003.10.007
   Konduru NV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004398
   Kotton CN, 2004, INFECT IMMUN, V72, P5535, DOI 10.1128/IAI.72.10.5535-5547.2004
   Kovarik J, 2001, IMMUNOLOGY, V102, P67, DOI 10.1046/j.1365-2567.2001.01158.x
   Laurichesse H, 2007, CLIN MICROBIOL INFEC, V13, P395, DOI 10.1111/j.1469-0691.2007.01662.x
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Lenz LL, 1996, IMMUNITY, V5, P63, DOI 10.1016/S1074-7613(00)80310-6
   Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001
   Lin X, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0852-y
   Lin XA, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-21
   Lourdault K, 2014, INFECT IMMUN, V82, P893, DOI 10.1128/IAI.01533-13
   Lucas DSD, 2011, VACCINE, V29, P3413, DOI 10.1016/j.vaccine.2011.02.084
   Malmstrom J, 2009, NATURE, V460, P762, DOI 10.1038/nature08184
   Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403
   Martinez R, 2004, REV PANAM SALUD PUBL, V15, P249, DOI 10.1590/S1020-49892004000400005
   Matsunaga J, 2003, MOL MICROBIOL, V49, P929, DOI 10.1046/j.1365-2958.2003.03619.x
   Miki H, 2015, J IMMUNOL, V194, P5069, DOI 10.4049/jimmunol.1402915
   Mishra V, 2018, CRIT REV THER DRUG, V35, P293, DOI 10.1615/CritRevTherDrugCarrierSyst.2018014419
   Monaris D, 2015, CLIN VACCINE IMMUNOL, V22, P965, DOI 10.1128/CVI.00285-15
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   Morgan J, 2002, CLIN INFECT DIS, V34, P1593, DOI 10.1086/340615
   Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487
   Munks MW, 2010, BLOOD, V116, P5191, DOI 10.1182/blood-2010-03-275529
   Nashar TO, 1997, IMMUNOLOGY, V91, P572, DOI 10.1046/j.1365-2567.1997.00291.x
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/erv.12.140, 10.1586/ERV.12.140]
   Oleszycka E, 2016, FEBS J, V283, P9, DOI 10.1111/febs.13546
   Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007
   Oliveira TL, 2016, MEM I OSWALDO CRUZ, V111, P712, DOI 10.1590/0074-02760160214
   Oliveira TL, 2018, VACCINE, V36, P2574, DOI 10.1016/j.vaccine.2018.03.078
   Oliveira TL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142821
   Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI 10.1586/ERV.10.89
   Palaniappan RUM, 2006, INFECT IMMUN, V74, P1745, DOI 10.1128/IAI.74.3.1745-1750.2006
   Palaniappan RUM, 2004, J MED MICROBIOL, V53, P975, DOI 10.1099/jmm.0.45568-0
   Palaniappan RUM, 2002, INFECT IMMUN, V70, P5924, DOI 10.1128/IAI.70.11.5924-5930.2002
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.0818-9641.2004.01272.x
   Ptak CP, 2019, BIOTECHNOL BIOENG, V116, P260, DOI 10.1002/bit.26864
   Ptak CP, 2014, BIOCHEMISTRY-US, V53, P5249, DOI 10.1021/bi500669u
   Raja V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24674-8
   Rocha ADR, 2008, CAN J MICROBIOL, V54, P677, DOI [10.1139/W08-056, 10.1139/w08-056]
   Raw I, 2008, Method to obtain monophosphoryl lipid a from bordetella pertussis as a by-product of the cellular pertussis vaccine production, Patent No. [WO 2008134830 A1, 2008134830]
   Reeman S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120378
   Reynales H, 2012, VACCINE, V30, P6436, DOI 10.1016/j.vaccine.2012.08.005
   Riese P, 2013, CURR TOP MED CHEM, V13, P2562, DOI 10.2174/15680266113136660183
   Rosenkrands I, 2005, INFECT IMMUN, V73, P5817, DOI 10.1128/IAI.73.9.5817-5826.2005
   Schmidt ST, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8010007
   Schwendener Reto A, 2014, Ther Adv Vaccines, V2, P159, DOI 10.1177/2051013614541440
   Seixas FK, 2007, VACCINE, V26, P88, DOI 10.1016/j.vaccine.2007.10.052
   SEPPALA IJT, 1984, IMMUNOLOGY, V53, P827
   Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402
   Silva EF, 2007, VACCINE, V25, P6277, DOI 10.1016/j.vaccine.2007.05.053
   Silva LA, 2016, REV SOC BRAS MED TRO, V49, P628, DOI 10.1590/0037-8682-0115-2016
   Sindoni D, 2009, J Prev Med Hyg, V50, P121
   Sivakumar SM, 2011, SAUDI PHARM J, V19, P197, DOI 10.1016/j.jsps.2011.06.003
   Sprott GD, 2004, INFECT IMMUN, V72, P5235, DOI 10.1128/IAI.72.9.5235-5246.2004
   Stern EJ, 2010, CLIN INFECT DIS, V50, P843, DOI 10.1086/650578
   Stills HF, 2005, ILAR J, V46, P280, DOI 10.1093/ilar.46.3.280
   Sutherland IW, 1998, TRENDS BIOTECHNOL, V16, P41, DOI 10.1016/S0167-7799(97)01139-6
   Teixeira AF, 2018, BIOMED RES INT, DOI 10.1155/2018/1813745
   Thompson BS, 2005, J LEUKOCYTE BIOL, V78, P1273, DOI 10.1189/jlb.0305172
   Verdier F, 2005, VACCINE, V23, P1359, DOI 10.1016/j.vaccine.2004.09.012
   Vogel FR, 2000, CLIN INFECT DIS, V30, pS266, DOI 10.1086/313883
   Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7
   Weimer ET, 2009, INFECT IMMUN, V77, P2356, DOI 10.1128/IAI.00054-09
   Weltzin R, 2000, INFECT IMMUN, V68, P2775, DOI 10.1128/IAI.68.5.2775-2782.2000
   World Health Organization, 2018, ASS REP GLOB VACC AC
   Yamamoto M, 2000, J INFECT DIS, V182, P180, DOI 10.1086/315694
   Yan WW, 2010, VACCINE, V28, P2277, DOI 10.1016/j.vaccine.2009.12.071
   Yan WW, 2009, MICROBES INFECT, V11, P230, DOI 10.1016/j.micinf.2008.11.008
   Yanagihara Y, 2007, COMP IMMUNOL MICROB, V30, P399, DOI 10.1016/j.cimid.2007.05.003
   Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618
   Zhang J, 2016, VACCINE, V34, P622, DOI 10.1016/j.vaccine.2015.12.039
NR 147
TC 2
Z9 2
U1 4
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3961
EP 3973
DI 10.1016/j.vaccine.2019.05.087
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700014
PM 31186193
DA 2020-05-12
ER

PT J
AU Thomas, LF
   Bellet, C
   Rushton, J
AF Thomas, Lian F.
   Bellet, Camille
   Rushton, Jonathan
TI Using economic and social data to improve veterinary vaccine
   development: Learning lessons from human vaccinology
SO VACCINE
LA English
DT Review
DE Social data; Economic data; Socio-economic analysis; Cost-effectiveness;
   Post-introduction studies; Pharmacovigilance; Disease burden
ID BOVINE NEONATAL PANCYTOPENIA; PATHOGENIC AVIAN INFLUENZA; MONOVALENT
   ROTAVIRUS VACCINATION; COST-EFFECTIVENESS; GLOBAL BURDEN; ANIMAL HEALTH;
   RETROSPECTIVE EVALUATION; SYSTEMATIC ANALYSIS; CONTROL STRATEGIES;
   DISEASE
AB The drivers of vaccine development are many and varied. They include, for example, recognition of the burden of a vaccine-targeted disease, prioritisation of the multiple problems associated with a disease, consideration of the differing socio-economic situations under which vaccines are used, the influence of advocacy groups, and assessment of the feasibility of large-scale vaccine manufacture and distribution. In the field of human health, data-driven development of vaccines is becoming increasingly common through the availability of reliable information on the Global Burden of Disease (GBD) and stringent evaluations of vaccination programmes utilising empirical data on costing and effectiveness, and standardised cost-effectiveness thresholds. The data generated from such analyses allow policymakers, implementing partners, industries and researchers to make decisions based on the best, and most contextually relevant, available evidence. In this paper, we wish to explore the current use of economic and social data for the development of veterinary vaccines. Through comparison with the development of human vaccines, we will look for opportunities in animal health sciences to better integrate socioeconomic data and analyses into the process of veterinary vaccine selection, development, and field implementation. We believe that more robust animal health impact assessments could add value to veterinary vaccine development by improving resource allocation and animal disease management. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Thomas, Lian F.; Bellet, Camille; Rushton, Jonathan] Univ Liverpool, Inst Infect & Global Hlth, IC2 Bldg,146 Brownlow Hill, Liverpool L3 5RF, Merseyside, England.
   [Thomas, Lian F.] Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya.
RP Thomas, LF (reprint author), Univ Liverpool, Inst Infect & Global Hlth, IC2 Bldg,146 Brownlow Hill, Liverpool L3 5RF, Merseyside, England.
EM Lian.thomas@liverpool.ac.uk; Camillle.Bellet@liverpool.ac.uk;
   j.rushton@liverpool.ac.uk
OI Thomas, Lian/0000-0001-8447-1210
FU Biotechnology and Biological Sciences Research CouncilBiotechnology and
   Biological Sciences Research Council (BBSRC); Department for
   International Development; Economic & Social Research CouncilEconomic &
   Social Research Council (ESRC); Medical Research CouncilMedical Research
   Council UK (MRC); Natural Environment Research CouncilNERC Natural
   Environment Research Council; Defence Science & Technology Laboratory,
   under the Zoonoses and Emerging Livestock Systems (ZELS) programme
   [BB/L019019/1]; SAPHIR Project (Strengthening Animal Production & Health
   through the Immune Response) of the Horizon 2020 Programme of the
   European Union [633184]; CGIAR Research Program on Agriculture for
   Nutrition and Health (A4NH)
FX The authors are supported by the Biotechnology and Biological Sciences
   Research Council, the Department for International Development, the
   Economic & Social Research Council, the Medical Research Council, the
   Natural Environment Research Council and the Defence Science &
   Technology Laboratory, under the Zoonoses and Emerging Livestock Systems
   (ZELS) programme, grant reference BB/L019019/1, the SAPHIR Project
   (Strengthening Animal Production & Health through the Immune Response)
   of the Horizon 2020 Programme of the European Union (Project ID 633184)
   and the CGIAR Research Program on Agriculture for Nutrition and Health
   (A4NH), led by the International Food Policy Research Institute (IFPRI).
   We also acknowledge the CGIAR Fund Donors
   (http://www.cgiar.org/funders/).The funders had no role in the decision
   to publish or the preparation of this manuscript.
CR Atherly DE, 2012, VACCINE, V30, pA7, DOI 10.1016/j.vaccine.2011.12.096
   Backer JA, 2015, PREV VET MED, V121, P142, DOI 10.1016/j.prevetmed.2015.06.006
   Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS220, DOI 10.1093/cid/civ1025
   Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS213, DOI 10.1093/cid/civ1183
   Bar-Zeev N, 2015, VACCINE, V33, P2637, DOI 10.1016/j.vaccine.2015.04.053
   Benedictus L, 2016, VACCINE, V34, P1002, DOI 10.1016/j.vaccine.2016.01.013
   Boklund A, 2013, PREV VET MED, V111, P206, DOI 10.1016/j.prevetmed.2013.05.008
   Bujok M., 2013, DEP, V23, P32
   Buyer TR, 2017, GLOBAL VET VACCINES
   Carvalho N, 2017, PHARMACOECONOMICS, P1
   Chiarlone C., 2016, Revue Veterinaire Clinique, V51, P23, DOI 10.1016/j.anicom.2016.02.001
   Clarivate, WEB SCI
   Clark A, 2013, VACCINE, V31, pC19, DOI 10.1016/j.vaccine.2013.05.045
   De Briyne N, 2017, VET REC OPEN, V4
   de la Fuente J, 1998, VACCINE, V16, P366, DOI 10.1016/S0264-410X(97)00208-9
   Demasius W, 2014, RES VET SCI, V96, P537, DOI 10.1016/j.rvsc.2014.03.019
   Fitzpatrick MC, 2014, ANN INTERN MED, V160, P91, DOI 10.7326/M13-0542
   Harmer A, 2011, HDB TRANSNATIONAL GO, P384
   Heldens JGM, 2008, VET J, V178, P7, DOI 10.1016/j.tvjl.2007.11.009
   Hinrichs J, 2010, ANIM SCI REV, V2011, P73
   Hinrichs J, 2006, P 11 INT SOC VET EP
   Jarvis LS, 2018, J AGR ECON, V69, P201, DOI 10.1111/1477-9552.12131
   Kasonta R, 2012, VACCINE, V30, P6649, DOI 10.1016/j.vaccine.2012.08.069
   Khazeni N, 2009, ANN INTERN MED, V151, P829, DOI 10.7326/0003-4819-151-12-200912150-00157
   Kimani T, 2016, ECOHEALTH, V13, P729, DOI 10.1007/s10393-016-1192-y
   Knight-Jones T, 2014, P R SOC B
   Knight-Jones TJD, 2014, VACCINE, V32, P1848, DOI 10.1016/j.vaccine.2014.01.071
   Leach M, 2010, GLOBAL ENVIRON CHANG, V20, P369, DOI 10.1016/j.gloenvcha.2009.11.008
   Longworth N, 2014, TRANSBOUND EMERG DIS, V61, P217, DOI 10.1111/tbed.12034
   Marseille E., 2014, B WORLD HEALTH ORGAN, V93, P118
   Marsh TL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601410
   Maure CG, 2014, B WORLD HEALTH ORGAN, V92, P695, DOI 10.2471/BLT.14.138875
   McLeod A, 2007, DEV BIOLOGICALS, V130, P63
   McLeod A, 2007, REV SCI TECH OIE, V26, P313, DOI 10.20506/rst.26.2.1745
   McReynolds SW, 2014, PREV VET MED, V117, P487, DOI 10.1016/j.prevetmed.2014.10.005
   Murray CJL, 2017, LANCET, V390, P1460, DOI 10.1016/S0140-6736(17)32367-X
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
   Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Pfeiffer DU, 2007, VET J, V174, P302, DOI 10.1016/j.tvjl.2007.05.010
   Porphyre T, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00047
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Reichmann F, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0857-7
   Roth F, 2003, B WORLD HEALTH ORGAN, V81, P867
   Roth JA, 2011, PROCEDIA VACCINOL, V5, P127, DOI 10.1016/j.provac.2011.10.009
   Rushton J, 2005, WORLD POULTRY SCI J, V61, P491, DOI 10.1079/WPS200570
   Rushton J, 2018, LANCET, V392, P538, DOI 10.1016/S0140-6736(18)31472-7
   Rushton J, 2018, J AGR ECON, V69, P199, DOI 10.1111/1477-9552.12265
   Rushton J, 2017, PREV VET MED, V137, P130, DOI 10.1016/j.prevetmed.2016.11.020
   Rushton J, 2017, PARASITOLOGY, V144, P15, DOI 10.1017/S0031182016000196
   Santuccio C, 2015, PHARMACOL RES, V92, P2, DOI 10.1016/j.phrs.2014.10.011
   Schroeder T. C., 2015, Journal of Agricultural and Applied Economics, V47, P47
   Shaw APM, 2017, REV SCI TECH OIE, V36, P147, DOI 10.20506/rst.36.1.2618
   Stoll A, 2016, VET J, V216, P59, DOI 10.1016/j.tvjl.2016.07.003
   Sun Z, 2017, SCI REP-UK, V7, DOI 10.1038/srep46441
   Torgerson PR, 2017, ONE HLTH
   Tran C. C., 2016, Veterinary Sciences, V3, P6, DOI 10.3390/vetsci3010006
   Uema D, 2018, METHODS BIOSTATISTIC, P217
   W. H. Organization, 2002, IMP PHARM
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Walker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035
   WHO, 2010, CHOOS INT AR COST EF
   Woodward KN, 2005, J VET PHARMACOL THER, V28, P149, DOI 10.1111/j.1365-2885.2005.00646.x
   Woodward KN, 2005, J VET PHARMACOL THER, V28, P131, DOI 10.1111/j.1365-2885.2005.00645.x
   World Health Organization, 2014, PRINC CONS ADD VACC, V27
NR 65
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3974
EP 3980
DI 10.1016/j.vaccine.2018.10.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700015
PM 30340883
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hou, HH
   Liu, XF
   Peng, QS
AF Hou, Huanhuan
   Liu, Xiaofeng
   Peng, Qisheng
TI The advances in brucellosis vaccines
SO VACCINE
LA English
DT Review
DE Brucellosis; Vaccine
ID ZN SUPEROXIDE-DISMUTASE; SUIS STRAIN-2 VACCINE; IMMUNE-RESPONSE; DNA
   VACCINE; CONFERS PROTECTION; BALB/C MICE; MELITENSIS REV-1; ABORTUS
   VACCINE; CONJUNCTIVAL VACCINATION; RESIDUAL VIRULENCE
AB Brucellosis is a worldwide zoonosis affecting animal and human health. Till now, there is no effective vaccine licensed for brucellosis in humans. Although M5, H38 and 45/20 vaccines were used to prevent animal brucellosis in the early stages, the currently used animal vaccines are S19, Rev.1, S2, RB51 and SR82. However, these vaccines still have several drawbacks such as residual virulence and interfering conventional serological tests. With the development of DNA recombination technologies and the completion of the sequence of Brucella genome, much research focuses on the search for potential safer and more effective vaccines. Preliminary studies have demonstrated that new vaccines, including genetically engineered attenuated vaccines, subunit vaccines and other potential vaccines, have higher levels of protection, but there are still some problems. In this paper, we briefly review the main vaccines that have been used in controlling the brucellosis for decades and the progress in the development of new brucellosis vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hou, Huanhuan; Peng, Qisheng] Jilin Univ, Inst Zoonosis, Key Lab Zoonosis, Minist Educ, Changchun 130062, Jilin, Peoples R China.
   [Liu, Xiaofeng] Tumor Hosp Jilin Prov, Changchun 130021, Jilin, Peoples R China.
RP Peng, QS (reprint author), Jilin Univ, Inst Zoonosis, Key Lab Zoonosis, Minist Educ, Changchun 130062, Jilin, Peoples R China.
EM Qishengpeng@yahoo.com
OI Peng, Qisheng/0000-0002-6971-6774
FU NSFC (Natural Science Foundation of China)National Natural Science
   Foundation of China [31870121]
FX We thank Professor M.B. Humphrey (University of Oklahoma Health Sciences
   Center and Department of Veterans Affairs, Oklahoma City, Oklahoma,
   United States of America) for critically reading this manuscript. This
   work was supported by NSFC (Natural Science Foundation of China)
   (31870121) to Qjsheng Peng
CR Abkar M, 2019, IMMUNOL LETT, V207, P28, DOI 10.1016/j.imlet.2019.01.010
   Adams LG, 2002, VET MICROBIOL, V90, P553, DOI 10.1016/S0378-1135(02)00235-3
   Al-Mariri A, 2001, INFECT IMMUN, V69, P6264, DOI 10.1128/IAI.69.10.6264-6270.2001
   Alcantara RB, 2004, INFECT IMMUN, V72, P4911, DOI 10.1128/IAI.72.8.4911-4917.2004
   Almiron M, 2001, INFECT IMMUN, V69, P6225, DOI 10.1128/IAI.69.10.6225-6230.2001
   Arenas-Gamboa AM, 2009, INFECT IMMUN, V77, P877, DOI 10.1128/IAI.01017-08
   Ashford DA, 2004, VACCINE, V22, P3435, DOI 10.1016/j.vaccine.2004.02.041
   Baloglu S, 2005, VET MICROBIOL, V109, P11, DOI 10.1016/j.vetmic.2005.04.011
   Banai M, 2002, VET MICROBIOL, V90, P497, DOI 10.1016/S0378-1135(02)00231-6
   Bardenstein S, 2002, J CLIN MICROBIOL, V40, P1475, DOI 10.1128/JCM.40.2.1475-1480.2002
   Blasco JM, 1997, PREV VET MED, V31, P275, DOI 10.1016/S0167-5877(96)01110-5
   BLASCO JM, 1993, VACCINE, V11, P1291, DOI 10.1016/0264-410X(93)90097-H
   BOSSERAY N, 1990, VACCINE, V8, P462, DOI 10.1016/0264-410X(90)90247-J
   BOSSERAY N, 1978, BRIT J EXP PATHOL, V59, P354
   Briones G, 2001, INFECT IMMUN, V69, P4528, DOI 10.1128/IAI.69.7.4528-4535.2001
   Cassataro J, 2005, INFECT IMMUN, V73, P8079, DOI 10.1128/IAI.73.12.8079-8088.2005
   Cespedes S, 2000, J MED MICROBIOL, V49, P165, DOI 10.1099/0022-1317-49-2-165
   Cheville NF, 1996, AM J VET RES, V57, P1153
   Clapp B, 2011, J WILDLIFE DIS, V47, P501, DOI 10.7589/0090-3558-47.3.501
   Crasta OR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002193
   CUNNINGHAM B, 1977, VET REC, V101, P283, DOI 10.1136/vr.101.14.283
   Martins RD, 2012, J CONTROL RELEASE, V162, P553, DOI 10.1016/j.jconrel.2012.07.030
   Martins RD, 2010, VACCINE, V28, P3038, DOI 10.1016/j.vaccine.2009.10.073
   Avila-Calderon ED, 2013, BIOMED RES INT, DOI 10.1155/2013/743509
   Dean AS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001865
   Delpino MV, 2007, VACCINE, V25, P6721, DOI 10.1016/j.vaccine.2007.07.002
   den Hartigh AB, 2004, INFECT IMMUN, V72, P5143, DOI 10.1128/IAI.72.9.5143-5149.2004
   Di DD, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3076-5
   Dorneles EMS, 2015, VET RES, V46, DOI 10.1186/s13567-015-0199-7
   Edwards SJ, 1945, VET REC
   ELBERG SS, 1957, J BACTERIOL, V73, P211, DOI 10.1128/JB.73.2.211-217.1957
   Ferguson GP, 2004, P NATL ACAD SCI USA, V101, P5012, DOI 10.1073/pnas.0307137101
   Florentino MA, 2008, VET MICROBIOL, V132, P302, DOI 10.1016/j.vetmic.2008.05.003
   Golshani M, 2016, VET MICROBIOL, V197, P47, DOI 10.1016/j.vetmic.2016.10.027
   Gomez G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059751
   Gonzalez-Smith A, 2006, IMMUNOBIOLOGY, V211, P65, DOI 10.1016/j.imbio.2005.09.004
   group R, 1991, CHINESE J CONTROL EN
   Gupta VK, 2012, VACCINE, V30, P4017, DOI 10.1016/j.vaccine.2012.04.036
   Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7
   He YQ, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/297505
   He Yongqun, 2010, Immunome Res, V6 Suppl 1, pS5, DOI 10.1186/1745-7580-6-S1-S5
   Hisham Y, 2018, J IMMUNOL RES, DOI 10.1155/2018/1474517
   Hop HT, 2015, FEMS MICROBIOL LETT, P362
   Hu XD, 2009, DNA CELL BIOL, V28, P191, DOI 10.1089/dna.2008.0790
   Ingolotti M, 2010, EXPERT REV VACCINES, V9, P747, DOI 10.1586/ERV.10.57
   Ivanov Arkady V., 2011, Animal Health Research Reviews, V12, P113, DOI 10.1017/S1466252311000028
   Jalava K, 2002, J CONTROL RELEASE, V85, P17, DOI 10.1016/S0168-3659(02)00267-5
   Jiang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070852
   Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773
   Lalsiamthara J, 2018, VACCINE, V36, P1837, DOI 10.1016/j.vaccine.2018.02.069
   Lalsiamthara J, 2017, J VET SCI, V18, P281, DOI 10.4142/jvs.2017.18.S1.281
   Lalsiamthara J, 2015, VACCINE, V33, P2577, DOI 10.1016/j.vaccine.2015.04.004
   LeVier K, 2000, SCIENCE, V287, P2492, DOI 10.1126/science.287.5462.2492
   Leya M, 2018, J VET SCI, V19, P643, DOI 10.4142/jvs.2018.19.5.643
   Lin Y, 2011, J BIOMED SEMANT, V2, DOI 10.1186/2041-1480-2-9
   Liu J, 2015, VET IMMUNOL IMMUNOP, V166, P138, DOI 10.1016/j.vetimm.2015.04.008
   Lopez-Goni I, 2008, J CLIN MICROBIOL, V46, P3484, DOI 10.1128/JCM.00837-08
   Lord VR, 1998, AM J VET RES, V59, P1016
   Luo D, 2006, INFECT IMMUN, V74, P2734, DOI 10.1128/IAI.74.5.2734-2741.2006
   Mailybayeva A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186484
   Manthei CA, SUMMARY CONTROLLED R
   Mcewen AD, 1940, VET REC
   Memish ZA, 2004, J TRAVEL MED, V11, P49, DOI 10.2310/7060.2004.13551
   Monreal D, 2003, INFECT IMMUN, V71, P3261, DOI 10.1128/IAI.71.6.3261-3271.2003
   MONTARAZ JA, 1986, INFECT IMMUN, V53, P245, DOI 10.1128/IAI.53.2.245-251.1986
   Munoz PM, 2008, VACCINE, V26, P2562, DOI 10.1016/j.vaccine.2008.03.030
   MUSTAFA AA, 1993, VET RES, V24, P422
   Nicoletti P, 1990, Adv Biotechnol Processes, V13, P147
   Oliveira SC, 1996, VACCINE, V14, P959, DOI 10.1016/0264-410X(96)00018-7
   Oliveira SC, 2011, EXPERT REV VACCINES, V10, P1291, DOI [10.1586/erv.11.110, 10.1586/ERV.11.110]
   Olsen SC, 2005, EXPERT REV VACCINES, V4, P915, DOI 10.1586/14760584.4.6.915
   Onate AA, 2005, INFECT IMMUN, V73, P3294, DOI 10.1128/IAI.73.6.3294-3300.2005
   Osman AEF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123374
   Palmer MV, 1997, AM J VET RES, V58, P472
   Pappas G, 2010, INT J ANTIMICROB AG, V36, pS8, DOI 10.1016/j.ijantimicag.2010.06.013
   Pasquevich KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016203
   Pasquevich KA, 2010, J IMMUNOL, V184, P5200, DOI 10.4049/jimmunol.0902209
   Pasquevich KA, 2009, INFECT IMMUN, V77, P436, DOI 10.1128/IAI.01151-08
   Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224
   Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816
   RADWAN AI, 1995, REV SCI TECH OIE, V14, P719, DOI 10.20506/rst.14.3.860
   Saez D, 2008, VET MICROBIOL, V129, P396, DOI 10.1016/j.vetmic.2007.11.015
   Saez D, 2012, VACCINE, V30, P1283, DOI 10.1016/j.vaccine.2011.12.088
   Salmakov KM, 2010, VACCINE, V28, pF35, DOI 10.1016/j.vaccine.2010.03.050
   SCHURIG GG, 1984, AM J VET RES, V45, P967
   Schurig GG, 2002, VET MICROBIOL, V90, P479, DOI 10.1016/S0378-1135(02)00255-9
   SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S
   Seleem MN, 2010, VET MICROBIOL, V140, P392, DOI 10.1016/j.vetmic.2009.06.021
   Shang DQ, 2002, VET MICROBIOL, V90, P165, DOI 10.1016/S0378-1135(02)00252-3
   Singh D, 2015, MOL IMMUNOL, V68, P272, DOI 10.1016/j.molimm.2015.09.011
   Singha H, 2008, MICROBES INFECT, V10, P1089, DOI 10.1016/j.micinf.2008.05.007
   Sislema-Egas F, 2012, VACCINE, V30, P7286, DOI 10.1016/j.vaccine.2012.09.039
   Soh SH, 2019, VACCINE, V37, P1554, DOI 10.1016/j.vaccine.2019.02.005
   STEVENS MG, 1994, VET MICROBIOL, V41, P383, DOI 10.1016/0378-1135(94)90034-5
   TABATABAI LB, 1994, VACCINE, V12, P919, DOI 10.1016/0264-410X(94)90035-3
   Tabynov K, 2016, VET MICROBIOL, V197, P15, DOI 10.1016/j.vetmic.2016.11.001
   Tabynov K, 2016, VACCINE, V34, P438, DOI 10.1016/j.vaccine.2015.12.028
   Tabynov K, 2015, VACCINE, V33, P3619, DOI 10.1016/j.vaccine.2015.06.045
   Tabynov K, 2014, VACCINE, V32, P5889, DOI 10.1016/j.vaccine.2014.08.073
   Tabynov K, 2014, VACCINE, V32, P2034, DOI 10.1016/j.vaccine.2014.02.058
   Taylor A.W., 1949, VET REC
   THOMAS EL, 1981, VET REC, V108, P90, DOI 10.1136/vr.108.5.90
   Tibor A, 1998, INFECT IMMUN, V66, P5561, DOI 10.1128/IAI.66.11.5561-5564.1998
   TOTH TE, 1995, VET MICROBIOL, V45, P171, DOI 10.1016/0378-1135(95)00047-E
   Trant CGMC, 2010, INFECT IMMUN, V78, P2283, DOI 10.1128/IAI.01433-09
   Ugalde JE, 2003, INFECT IMMUN, V71, P6264, DOI 10.1128/IAI.71.11.6264-6269.2003
   Velikovsky CA, 2003, INFECT IMMUN, V71, P5750, DOI 10.1128/IAI.71.10.5750-5755.2003
   Velikovsky CA, 2002, INFECT IMMUN, V70, P2507, DOI 10.1128/IAI.70.5.2507-2511.2002
   Vemulapalli R, 1999, CLIN DIAGN LAB IMMUN, V6, P760, DOI 10.1128/CDLI.6.5.760-764.1999
   VERGER JM, 1995, VACCINE, V13, P191, DOI 10.1016/0264-410X(95)93135-V
   Vishnu US, 2015, OMICS, V19, P722, DOI 10.1089/omi.2015.0105
   WAGHELA S, 1983, VET REC, V112, P476, DOI 10.1136/vr.112.20.476
   Wallach JC, 2008, CLIN MICROBIOL INFEC, V14, P805, DOI 10.1111/j.1469-0691.2008.02029.x
   Wang FK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028485
   Wang Z, 2013, CURR PHARM BIOTECHNO, V14, P887
   Winter AJ, 1996, AM J VET RES, V57, P677
   WOODARD LF, 1983, AM J VET RES, V44, P907
   Xiang ZS, 2008, NUCLEIC ACIDS RES, V36, pD923, DOI 10.1093/nar/gkm1039
   Xiang ZS, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S4-S2
   XIE X, 1986, VACCINE, V4, P212, DOI 10.1016/0264-410X(86)90131-3
   Yang Xinghong, 2013, Front Biol (Beijing), V8, P60
NR 121
TC 5
Z9 5
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3981
EP 3988
DI 10.1016/j.vaccine.2019.05.084
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700016
PM 31176541
DA 2020-05-12
ER

PT J
AU Loh, FK
   Nathan, S
   Chow, SC
   Fang, CM
AF Loh, Fei-Kean
   Nathan, Sheila
   Chow, Sek-Chuen
   Fang, Chee-Mun
TI Vaccination challenges and strategies against long-lived Toxoplasma
   gondii
SO VACCINE
LA English
DT Review
DE Toxoplasma gondii; Vaccination; Life cycle; Cross-protection
ID PROTECTIVE IMMUNE-RESPONSE; DNA VACCINES; INTRANASAL IMMUNIZATION;
   BIPOLAR DISORDER; RHOPTRY PROTEINS; T. GONDII; MICE; INFECTION;
   ADENOVIRUS; NANOPARTICLES
AB Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Loh, Fei-Kean; Fang, Chee-Mun] Univ Nottingham, Sch Pharm, Div Biomed Sci, Malaysia Campus, Semenyih 43500, Selangor, Malaysia.
   [Nathan, Sheila] Univ Kebangsaan Malaysia, Fac Sci & Technol, Sch Biosci & Biotechnol, Bangi 43600, Selangor, Malaysia.
   [Chow, Sek-Chuen] Monash Univ Malaysia, Sch Sci, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
RP Fang, CM (reprint author), Univ Nottingham, Sch Pharm, Div Biomed Sci, Malaysia Campus, Semenyih 43500, Selangor, Malaysia.
EM CheeMun.Fang@nottingham.edu.my
RI Nathan, Sheila/C-1182-2011
OI Nathan, Sheila/0000-0002-2132-2346; Fang, Chee-Mun/0000-0002-4934-5697
FU Ministry of Science, Technology, and Innovation Malaysia (MOSTI)Ministry
   of Energy, Science, Technology, Environment and Climate Change
   (MESTECC), Malaysia [06-02-12-SF0314]
FX This work was funded by Ministry of Science, Technology, and Innovation
   Malaysia (MOSTI) [eScience grant 06-02-12-SF0314].
CR Abdelbaset AE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173745
   Alarcon JB, 1999, ADV PARASIT, V42, P343, DOI 10.1016/S0065-308X(08)60152-9
   Azegami T, 2014, INT IMMUNOL, V26, P517, DOI 10.1093/intimm/dxu063
   Benson A, 2009, CELL HOST MICROBE, V6, P187, DOI 10.1016/j.chom.2009.06.005
   Blythe MJ, 2005, PROTEIN SCI, V14, P246, DOI 10.1110/ps.041059505
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X
   Capobiango JD, 2016, J PEDIAT-BRAZIL, V92, P616, DOI 10.1016/j.jped.2016.02.014
   Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113
   CHATFIELD SN, 1992, VACCINE, V10, P53, DOI 10.1016/0264-410X(92)90420-O
   Chen J, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-487
   Chen J, 2015, ANAL BIOCHEM, V486, P81, DOI 10.1016/j.ab.2015.06.035
   Chen Y, 2018, ANAL BIOCHEM, V540, P38, DOI 10.1016/j.ab.2017.11.003
   CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455
   Chirmule N, 1999, GENE THER, V6, P1574, DOI 10.1038/sj.gt.3300994
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Cong H, 2005, PARASITE IMMUNOL, V27, P29, DOI 10.1111/j.1365-3024.2005.00738.x
   Cong H, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-145
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   Dicks MDJ, 2012, PLOS ONE, P7, DOI [10.1371/journal.pone.00403115, DOI 10.1371/JOURNAL.PONE.00403115]
   Dimier-Poisson I, 2015, BIOMATERIALS, V50, P164, DOI 10.1016/j.biomaterials.2015.01.056
   Dubey JP, 2008, INT J PARASITOL, V38, P1257, DOI 10.1016/j.ijpara.2008.03.007
   Dunay IR, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00057-17
   El Bissati K, 2014, VACCINE, V32, P3243, DOI 10.1016/j.vaccine.2014.03.092
   El Temsahy Mona M, 2016, J Parasit Dis, V40, P611, DOI 10.1007/s12639-014-0546-z
   EL-Malky MA, 2014, PARASITOL RES, V113, P2277, DOI 10.1007/s00436-014-3882-0
   Ferguson DJP, 2009, ACTA PATHOL MICROB B, V82B, P167, DOI [10.1111/j.1699-0463.1974tb02309.x, DOI 10.1111/J.1699-0463.1974TB02309.X]
   Flegr J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090203
   Fox BA, 2015, INFECT IMMUN, V83, P2148, DOI 10.1128/IAI.02756-14
   Fox BA, 2011, EUKARYOT CELL, V10, P1193, DOI 10.1128/EC.00297-10
   Garcia J, 2014, VACCINE DEV THER, V4, P23, DOI DOI 10.2147/VDT.S57474
   Gedik Y., 2016, Trials in Vaccinology, V5, P15, DOI 10.1016/j.trivac.2015.11.002
   Gigley JP, 2009, INFECT IMMUN, V77, P5380, DOI 10.1128/IAI.00649-09
   Gigley JP, 2009, J IMMUNOL, V182, P1069, DOI 10.4049/jimmunol.182.2.1069
   Grzybek M, 2015, PARASITOL RES, V114, P523, DOI 10.1007/s00436-014-4214-0
   GUSTAFSON GL, 1992, RES IMMUNOL, V143, P483, DOI 10.1016/0923-2494(92)80058-S
   Han YL, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2104-z
   Harms JS, 1999, BRAZ J MED BIOL RES, P32
   HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561
   Hutchinson W M, 1966, Trans Ophthalmol Soc U K, V86, P185
   ITOH Y, 2007, J BIOL-LONDON, V6, pNIL4
   Jongert E, 2009, MEM I OSWALDO CRUZ, V104, P252, DOI 10.1590/S0074-02762009000200019
   Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062
   Lagal V, 2015, INFECT IMMUN, V83, P2475, DOI 10.1128/IAI.02606-14
   Lakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317
   Lee DH, 2016, ACTA TROP, V164, P77, DOI 10.1016/j.actatropica.2016.08.025
   Lee SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175644
   da Cunha IAL, 2012, VET PARASITOL, V186, P216, DOI 10.1016/j.vetpar.2011.11.034
   Letscher-Bru V, 2003, INFECT IMMUN, V71, P6615, DOI 10.1128/IAI.71.11.6615-6619.2003
   Li X, 2018, PARASITOL INT, V67, P351, DOI 10.1016/j.parint.2018.02.002
   Li XZ, 2016, INFECT GENET EVOL, V45, P447, DOI 10.1016/j.meegid.2016.10.006
   Li XZ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0815-1
   Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x
   Liu ZZ, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0173-9
   Lu G, 2017, PARASITOL INT, V66, P596, DOI 10.1016/j.parint.2017.06.002
   Lu G, 2015, ACTA TROP, V146, P66, DOI 10.1016/j.actatropica.2015.03.013
   Luo FJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00605
   Lyons RE, 2002, TRENDS PARASITOL, V18, P198, DOI 10.1016/S1471-4922(02)02248-1
   Marc MA, 2015, EXPERT OPIN DRUG DEL, V12, P1851, DOI 10.1517/17425247.2015.1077559
   Mendes EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063201
   Mevelec MN, 2010, VET RES, V41, DOI 10.1051/vetres/2010021
   Montazeri N, 2017, FRONT MICROBIOL, V8, DOI [10.3389/fmicb.2017.01031, 10.3389/fmicb.2017.00025]
   Page DT, 2001, DRUG DISCOV TODAY, V6, P92, DOI 10.1016/S1359-6446(00)01600-7
   Penarete-Vargas DM, 2010, INFECT IMMUN, V78, P651, DOI 10.1128/IAI.00703-09
   Rashid A, 2016, 2016 INTERNATIONAL CONFERENCE ON OPEN SOURCE SYSTEMS AND TECHNOLOGIES (ICOSST), P1, DOI 10.1109/ICOSST.2016.7838328
   Rueckert C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003001
   Sanchez VR, 2015, ACTA TROP, V150, P159, DOI 10.1016/j.actatropica.2015.07.013
   Sardinha-Silva A, 2017, BIORXIV
   SCHLUTER D, 1991, J NEUROIMMUNOL, V31, P185, DOI 10.1016/0165-5728(91)90040-E
   Sher A, 2017, CELL MOL IMMUNOL, V14, P36, DOI 10.1038/cmi.2016.12
   Sinai AP, 2016, CURR CLIN MICROBIOL, V3, P175, DOI 10.1007/s40588-016-0045-3
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   SOETE M, 1994, EXP PARASITOL, V78, P361, DOI 10.1006/expr.1994.1039
   Soete Martine, 1993, NATO ASI (Advanced Science Institute) Series Series H Cell Biology, V78, P93
   Song PX, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2147-1
   Stanford MR, 2009, MEM I OSWALDO CRUZ, V104, P312, DOI 10.1590/S0074-02762009000200027
   Subauste CS, 2000, J IMMUNOL, V165, P1498, DOI 10.4049/jimmunol.165.3.1498
   Suhrbier A, 1997, IMMUNOL CELL BIOL, V75, P402, DOI 10.1038/icb.1997.63
   Sung RS, 2001, MOL THER, V3, P757, DOI 10.1006/mthe.2001.0318
   Sutterland AL, 2015, ACTA PSYCHIAT SCAND, V132, P161, DOI 10.1111/acps.12423
   SUZUKI Y, 1991, IMMUNOLOGY, V74, P732
   Szatraj K, 2017, J APPL MICROBIOL, V123, P325, DOI 10.1111/jam.13446
   Tanaka S, 2014, VACCINE, V32, P1781, DOI 10.1016/j.vaccine.2014.01.095
   Tang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29379
   Tassi I, 2015, EUR J IMMUNOL, V45, P1972, DOI 10.1002/eji.201445045
   Trovato Maria, 2015, World J Virol, V4, P156, DOI 10.5501/wjv.v4.i3.156
   Vanniasinkam T, 2006, VIROLOGY, V344, P412, DOI 10.1016/j.virol.2005.08.040
   Verma R, 2013, HUM VACC IMMUNOTHER, V9, P291, DOI 10.4161/hv.22474
   de Barros JLVM, 2017, J AFFECT DISORDERS, V209, P59, DOI [10.1016/j.jad.2016.11.016, 10.1016/j.jad.201]
   Wang H., 2014, J PLOS, V9, P10, DOI DOI 10.13746/J.NJKJ.2014.0212
   Wang HL, 2016, PARASITE, V23, DOI 10.1051/parasite/2016012
   Wang HL, 2014, ACTA TROP, V137, P58, DOI 10.1016/j.actatropica.2014.05.001
   Wang JL, 2018, J INFECT DIS, V218, P768, DOI 10.1093/infdis/jiy211
   Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730
   Wang T, 2017, PARASITE, V24, DOI 10.1051/parasite/2017013
   Wang ZD, 2017, LANCET HIV, V4, pE177, DOI 10.1016/S2352-3018(17)30005-X
   WILKINS MF, 1988, NEW ZEAL VET J, V36, P86, DOI 10.1080/00480169.1988.35489
   Xu Y, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-525
   Xu Y, 2015, PARASITOL RES, V114, P4195, DOI 10.1007/s00436-015-4652-3
   Yin HQ, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1108-7
   Zhang NZ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1496-0
   Zhang NZ, 2015, EXPERT REV VACCINES, V14, P1289, DOI 10.1586/14760584.2015.1061938
   Zheng LN, 2017, ACTA TROP, V166, P336, DOI 10.1016/j.actatropica.2016.12.004
   Zorgi NE, 2016, MED MICROBIOL IMMUN, V205, P297, DOI 10.1007/s00430-015-0447-5
   Zorgi NE, 2011, IMMUNOL LETT, V138, P187, DOI 10.1016/j.imlet.2011.04.007
NR 105
TC 0
Z9 0
U1 4
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 3989
EP 4000
DI 10.1016/j.vaccine.2019.05.083
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700017
PM 31186188
DA 2020-05-12
ER

PT J
AU Murti, M
   Otterstatter, M
   Orth, A
   Balshaw, R
   Halani, K
   Brown, PD
   Hejazi, S
   Thompson, D
   Allison, S
   Bharmal, A
   Dawar, M
   Hoyano, D
   Lee, V
   Naus, M
   Pollock, S
   Bevanda, J
   Coughlin, S
   Fitzgerald, J
   Keen, D
   Maracle, M
   Sprague, S
   Henry, B
AF Murti, Michelle
   Otterstatter, Michael
   Orth, Alison
   Balshaw, Robert
   Halani, Khalif
   Brown, Paul D.
   Hejazi, Samar
   Thompson, Darby
   Allison, Sandra
   Bharmal, Aamir
   Dawar, Meena
   Hoyano, Dee
   Lee, Victoria
   Naus, Monika
   Pollock, Sue
   Bevanda, John
   Coughlin, Sandy
   Fitzgerald, John
   Keen, Dave
   Maracle, Melanie
   Sprague, Stacy
   Henry, Bonnie
TI Measuring the impact of influenza vaccination on healthcare worker
   absenteeism in the context of a province-wide mandatory
   vaccinate-or-mask policy
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Healthcare worker; Absenteeism; Organizational
   policy; Public health
ID IMMUNIZATION
AB Objectives: In 2012, British Columbia (BC) implemented a province-wide vaccinate-or-mask influenza prevention policy for healthcare workers (HCWs) with the aim of improving HCW coverage, and reducing illness in patients and staff. We assess post-policy impacts of HCW vaccination status on their absenteeism.
   Methods: We matched individual HCW payroll data from December 1, 2012 to March 31, 2017 with annually self-reported vaccination status for BC health authority employees to assess sick rates (sick time as a proportion of sick time and productive time). We modelled adjusted odds ratios (OR) of taking any sick time, relative rates (RR) of sick time taken, and predicted mean sick rates by vaccination status in influenza (December 1-March 31) and non-influenza seasons (April 1 to November 30). We used two methods to assess changes in influenza season sick rates for HCWs who had a change in their vaccination status over the five years.
   Results: HCWs who reported 'early' vaccination (before December 1 when the policy is in effect) were less likely to take sick time (OR 0.874, 95%CI: 0.866-0.881) and took less sick time (RR 0.907, 95%CI: 0.901-0.912) in influenza season compared to HCWs who did not report vaccination: whereas HCWs who reported 'late' (between December 1 and March 31, and subject to masking until vaccinated) had similar sick rates to HCWs who did not report vaccination. These trends were also observed in non-influenza season. Influenza season sick rates were similar for HCWs that had at least one year of 'early' vaccination and one year where vaccination was not reported over the five year period.
   Conclusions: Overall absenteeism is lower among HCWs who report vaccination versus those who do not report. However, absenteeism behaviours appear to be influenced by individual level factors other than vaccination status. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Murti, Michelle; Orth, Alison; Brown, Paul D.; Hejazi, Samar; Bharmal, Aamir; Lee, Victoria; Keen, Dave] Fraser Hlth Author, 13450 102nd Ave,Suite 400, Surrey, BC V3T 0H1, Canada.
   [Murti, Michelle; Otterstatter, Michael; Allison, Sandra; Bharmal, Aamir; Dawar, Meena; Hoyano, Dee; Lee, Victoria; Naus, Monika; Pollock, Sue; Henry, Bonnie] Univ British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
   [Murti, Michelle] Publ Hlth Ontario, 480 Univ Ave,Suite 300, University, ON M5G 1V2, Canada.
   [Otterstatter, Michael; Balshaw, Robert; Naus, Monika] BC Ctr Dis Control, 655W 12th Ave, Vancouver, BC V5Z 4R4, Canada.
   [Balshaw, Robert] Univ Manitoba, 753 McDermot Ave,Third Floor, Winnipeg, MB R3E 0T6, Canada.
   [Halani, Khalif; Thompson, Darby] Emmes Canada, 4664 Lougheed Hwy,Suite 200, Burnaby, BC V5C 3Y2, Canada.
   [Allison, Sandra; Maracle, Melanie] Northern Hlth Author, 299 Victoria St,Suite 600, Prince George, BC V2L 5B8, Canada.
   [Dawar, Meena; Sprague, Stacy] Vancouver Coastal Hlth Author, 601 West Broadway,11th Floor, Vancouver, BC V5Z 4C2, Canada.
   [Hoyano, Dee; Fitzgerald, John] Isl Hlth Author, 1952 Bay St, Victoria, BC V8R 1J8, Canada.
   [Pollock, Sue; Bevanda, John] Interior Hlth Author, 505 Doyle Ave, Kelowna, BC V1Y 0C5, Canada.
   [Coughlin, Sandy] Providence Hlth Care, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   [Henry, Bonnie] Off Prov Hlth Officer, POB 9648 STN PROV GOVT, Victoria, BC V8W 9P4, Canada.
RP Murti, M (reprint author), Publ Hlth Ontario, 480 Univ Ave,Suite 300, University, ON M5G 1V2, Canada.
EM michelle.murti@oahpp.ca; Michael.otterstatter@bccdc.ca;
   alison.orth@fraserhealth.ca; Roberthalshaw@umanitoba.ca;
   khalani@emmes.com; paul.brown@fraserhealth.ca;
   samar.hejazi@fraserhealth.ca; dthompson@emmes.com;
   Sandra.allison@northernhealth.ca; aamir.bharmal@fraserhealth.ca;
   meena.dawar@vch.ca; dee.hoyano@viha.ca; Victoria.lee@fraserhealth.ca;
   monika.naus@bccdc.ca; sue.pollock@interiorhealth.ca;
   john.bevanda@interiorhealth.ca; scoughlin@providence.bc.ca;
   john.fitzgerald@viha.ca; dave.keen@fraserhealth.ca;
   melanie.maracle@northernhealth.ca; stacy.sprague2@vch.ca;
   bonnie.henry@gov.bc.ca
OI Murti, Michelle/0000-0003-4649-6913
FU Michael Smith Foundation for Health ResearchMichael Smith Foundation for
   Health Research [PJ IVP 00002 156]
FX Support for this evaluation was provided by the Michael Smith Foundation
   for Health Research, Award Number: PJ IVP 00002 156. We would also like
   to thank Nicole Miller for her assistance with the data used in this
   evaluation.
CR [Anonymous], 2012, INFL PREV POL
   [Anonymous], 2018, INFL CONTR PROGR FRE
   Balshaw R, 2016, CAN IMM C OTT CAN
   BC Centre for Disease Control, 2017, EV BCS INFL PREV POL
   BC Centre for Disease Control, 2018, AC HCWS 2017 18 INFL
   BC Centre for Disease Control, 2015, BRIT COL INFL SURV B
   BC Centre for Disease Control, 2019, CAN SENT PRACT SURV
   BC Centre for Disease Control, 2013, BC INFL PREV POL DIS
   Buchan Sarah A, 2016, CMAJ Open, V4, pE479
   Chhetri B, 2015, USING ADM DATA UNPUB
   Chiu S, 2017, AM J INFECT CONTROL, V45, P1254, DOI 10.1016/j.ajic.2017.04.008
   De Serres G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0163586
   Frederick J, 2018, INFECT CONT HOSP EP, P1
   Gianino MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182510
   Henry B, 2016, B C MED J, V58, P555
   Kidd F, 2012, AM J INFECT CONTROL, V40, P188, DOI 10.1016/j.ajic.2011.02.022
   National Advisory Committee on Immunizations, 2018, CAN IMM GUID CHAPT I
   Nunn A, 2018, VACCINE, V36, P395, DOI 10.1016/j.vaccine.2017.11.072
   Pereira M, 2017, CLIN MED, V17, P484, DOI 10.7861/clinmedicine.17-6-484
   Public Health Agency of Canada, 2016, VACC UPT CAN AD RES
   R Core Team, 2018, R LANG ENV STAT COMP
   Rakita RM, 2010, INFECT CONT HOSP EP, V31, P881, DOI 10.1086/656210
   Saxen H, 1999, PEDIATR INFECT DIS J, V18, P779, DOI 10.1097/00006454-199909000-00007
   Turnberg W, 2010, AM J INFECT CONTROL, V38, P486, DOI 10.1016/j.ajic.2009.12.006
   Van Buynder PG, 2015, VACCINE, V33, P1625, DOI 10.1016/j.vaccine.2015.01.048
   WEINGARTEN S, 1988, J GEN INTERN MED, V3, P32, DOI 10.1007/BF02595754
   Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908
   Wilson KE, 2018, AM J INFECT CONTROL, P1
   Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08
NR 29
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4001
EP 4007
DI 10.1016/j.vaccine.2019.06.014
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700018
PM 31204156
OA Other Gold
DA 2020-05-12
ER

PT J
AU Murti, M
   Otterstatter, M
   Orth, A
   Balshaw, R
   Halani, K
   Brown, PD
   Hejazi, S
   Thompson, D
   Allison, S
   Bharmal, A
   Dawar, M
   Hoyano, D
   Lee, V
   Naus, M
   Pollock, S
   Bevanda, J
   Coughlin, S
   Fitzgerald, J
   Keen, D
   Maracle, M
   Sprague, S
   Henry, B
AF Murti, Michelle
   Otterstatter, Michael
   Orth, Alison
   Balshaw, Robert
   Halani, Khalif
   Brown, Paul D.
   Hejazi, Samar
   Thompson, Darby
   Allison, Sandra
   Bharmal, Aamir
   Dawar, Meena
   Hoyano, Dee
   Lee, Victoria
   Naus, Monika
   Pollock, Sue
   Bevanda, John
   Coughlin, Sandy
   Fitzgerald, John
   Keen, Dave
   Maracle, Melanie
   Sprague, Stacy
   Henry, Bonnie
TI Measuring the impact of a mandatory province-wide vaccinate-or-mask
   policy on healthcare worker absenteeism in British Columbia, Canada
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Healthcare worker; Absenteeism; Organizational
   policy; Public health
ID INFLUENZA VACCINATION; STAFF; PERSONNEL
AB Objectives: Vaccinate-or-mask (VOM) policies aim to improve influenza vaccine coverage among healthcare workers (HCW) and reduce influenza-related illness among patients and staff. In 2012, British Columbia (BC) implemented a province-wide VOM influenza prevention policy. This study describes an evaluation of policy impacts on HCW absenteeism rates from before to after policy implementation.
   Methods: Using payroll data from regional and provincial Health Authorities (HA), we assessed all-cause sick rates (sick time as a proportion of sick time and productive time) before (2007-2011, excluding 2009-2010) and after (2012-2017) policy implementation, and during influenza season (December 1-March 31) and non-influenza season (April 1-November 30). We used a two-part negative binomial hurdle model to calculate odds ratios (OR) of taking any sick time, relative rates (RR) of sick time taken, and predicted mean sick rates, adjusting for age group, sex, job type, job classification, HA, year and vaccine effectiveness.
   Results: During influenza season, HCWs in the post-policy period were less likely to take any sick time (OR 0.989, 95%CI: 0.979-0.999) but had higher rates of sick time (RR 1.038, 95%CI: 1.030-1.045). However, during non-influenza season, HCWs in the post-policy period were more likely to take any sick time (OR 1.015, 95%CI: 1.008-1.022) but had lower rates of sick time (RR 0.971, 95%CI: 0.966-0.976). There was an overall increase in predicted mean sick rate from pre to post-policy in influenza season (4.392% to 4.508%) and non-influenza season (3.815% to 3.901%).
   Conclusions: The observed year-round increase in sick rates from pre-to-post policy was likely influenced by other factors; however, opposite trends in how HCWs took sick time in the influenza and non-influenza seasons may reflect policy influences and need further research to explore reasons for these differences. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Murti, Michelle; Orth, Alison; Brown, Paul D.; Hejazi, Samar; Bharmal, Aamir; Lee, Victoria; Keen, Dave] Fraser Hlth Author, 13450 102nd Ave,Suite 400, Surrey, BC V3T 041, Canada.
   [Murti, Michelle; Otterstatter, Michael; Allison, Sandra; Bharmal, Aamir; Dawar, Meena; Hoyano, Dee; Lee, Victoria; Naus, Monika; Pollock, Sue; Henry, Bonnie] Univ British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
   [Murti, Michelle] Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
   [Otterstatter, Michael; Balshaw, Robert; Naus, Monika] BC Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.
   [Balshaw, Robert] Univ Manitoba, 753 McDermot Ave,Third Floor, Winnipeg, MB R3E 0T6, Canada.
   [Halani, Khalif; Thompson, Darby] Emmes Canada, 4664 Lougheed Hwy,Suite 200, Burnaby, BC V5C 3Y2, Canada.
   [Allison, Sandra; Maracle, Melanie] Northern Hlth Author, 299 Victoria St,Suite 600, Prince George, BC V2L 5B8, Canada.
   [Dawar, Meena; Sprague, Stacy] Vancouver Coastal Hlth Author, 601 West Broadway,11th Floor, Vancouver, BC V5Z 4C2, Canada.
   [Hoyano, Dee; Fitzgerald, John] Isl Hlth Author, 1952 Bay St, Victoria, BC V8R 1J8, Canada.
   [Pollock, Sue; Bevanda, John] Interior Hlth Author, 505 Doyle Ave, Kelowna, BC V1Y 0C5, Canada.
   [Coughlin, Sandy] Providence Hlth Care, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   [Henry, Bonnie] Off Prov Hlth Officer, POB 9648 STN PROV GOVT, Victoria, BC V8W 9P4, Canada.
RP Murti, M (reprint author), Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
EM michelle.murti@oahpp.ca; Michael.otterstatter@bccdc.ca;
   alison.orth@fraserhealth.ca; Robert.balshaw@umanitoba.CA;
   khalani@emmes.com; paul.brown@fraserhealth.ca;
   samar.hejazi@fraserhealth.ca; dthompson@emmes.com;
   Sandra.allison@northernhealth.ca; aamir.bharmal@fraserhealth.ca;
   meena.dawar@vch.ca; dee.hoyano@viha.ca; Victoria.lee@fraserhealth.ca;
   monika.naus@bccdc.ca; sue.pollock@interiorhealth.ca;
   john.bevanda@interiorhealth.ca; scoughlin@providence.bc.ca;
   john.fitzgerald@viha.ca; dave.keen@fraserhealth.ca;
   melanie.maracle@northernhealth.ca; stacy.sprague2@vch.ca;
   bonnie.henry@gov.bc.ca
OI Murti, Michelle/0000-0003-4649-6913
FU Michael Smith Foundation for Health ResearchMichael Smith Foundation for
   Health Research [PJ IVP 00002 156]
FX Support for this evaluation was provided by the Michael Smith Foundation
   for Health Research, Award Number: PJ IVP 00002 156.
CR Babcock HM, 2010, CLIN INFECT DIS, V50, P459, DOI 10.1086/650752
   BC Centre for Disease Control, INFL PREV POL
   BC Centre for Disease Control, 2019, CAN SENT PRACT SURV
   BC Centre for Disease Control, 2017, EV BCS INFL PREV POL
   BC Centre for Disease Control, 2014, INFL VACC COV STAFF
   BC Centre for Disease Control, INFL VACC COV STAFF
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P1009, DOI 10.15585/mmwr.mm6638a1
   Buchan Sarah A, 2016, CMAJ Open, V4, pE479
   CDC (Centers for Disease Control and Prevention), 2019, DIS BURD INFL
   Centers for Disease Control and Prevention, 2017, 2016 17 INFL SEAS HL
   Chiu S, 2017, AM J INFECT CONTROL, V45, P1254, DOI 10.1016/j.ajic.2017.04.008
   Frederick J, 2018, INFECT CONT HOSP EP, P1
   Gianino MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182510
   HAMMOND GW, 1984, CAN MED ASSOC J, V131, P449
   Henry B, 2016, B C MED J, V58, P555
   Kidd F, 2012, AM J INFECT CONTROL, V40, P188, DOI 10.1016/j.ajic.2011.02.022
   National Advisory Committee on Immunizations, 2018, CAN IMM GUID CHAPT I
   Nguyen-Van-Tam J, 1999, INFECT CONT HOSP EP, V20, P691, DOI 10.1086/501568
   Ofstead CL, 2017, VACCINE, V35, P2390, DOI 10.1016/j.vaccine.2017.03.041
   Pitts SI, 2014, AM J PREV MED, V47, P330, DOI 10.1016/j.amepre.2014.05.035
   *PUBL HLTH AG CAN, 2007, [No title captured], P1
   Public Health Agency of Canada, 2016, VACC UPT CAN AD RES
   R Core Team, 2018, R LANG ENV STAT COMP
   Rakita RM, 2010, INFECT CONT HOSP EP, V31, P881, DOI 10.1086/656210
   Rantanen I, 2011, INT ARCH OCC ENV HEA, V84, P225, DOI 10.1007/s00420-010-0604-5
   The Canadian Press, 2017, THE CANADIAN PRESS
   Turnberg W, 2010, AM J INFECT CONTROL, V38, P486, DOI 10.1016/j.ajic.2009.12.006
   Van Buynder PG, 2015, VACCINE, V33, P1625, DOI 10.1016/j.vaccine.2015.01.048
   Widera E, 2010, J GEN INTERN MED, V25, P1244, DOI 10.1007/s11606-010-1422-x
   Wilson KE, 2018, AM J INFECT CONTROL, P1
   World Health Organization, 2017, NEW REL 650OOO PEOPL
   Yassi A, 1991, Can J Infect Dis, V2, P101
   Zeileis A, 2008, J STAT SOFTW, V27, P1, DOI 10.18637/jss.v027.i08
NR 33
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4008
EP 4014
DI 10.1016/j.vaccine.2019.06.007
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700019
PM 31204158
OA Other Gold
DA 2020-05-12
ER

PT J
AU DeMarcus, L
   Shoubaki, L
   Federinko, S
AF DeMarcus, Laurie
   Shoubaki, Lisa
   Federinko, Susan
TI Comparing influenza vaccine effectiveness between cell-derived and
   egg-derived vaccines, 2017-2018 influenza season
SO VACCINE
LA English
DT Article
DE Vaccine effectiveness; Influenza; Cell-derived; Egg-derived; Influenza
   A(H3N2); Mutation
AB The Department of Defense Global Respiratory Pathogen Surveillance Program conducted a study to compare the differences in vaccine effectiveness (VE) of the cell-derived and egg-derived vaccines. DoD healthcare beneficiaries, excluding service members, that presented with influenza-like illness for the period of 1 October 2017 through 28 April 2018 were included in a test-negative case-control study examining laboratory confirmed influenza infections. Three VE analyses were performed (1) influenza infection among those vaccinated with cell-derived vaccines (2) influenza infection among those vaccinated with egg-derived vaccines and a (3) relative VE which directly compared the odds of influenza infection with cell-derived vaccine against those with egg-derived vaccines. The cell-derived and egg-derived vaccines were moderately protective against all influenza types with significant VE estimates for all dependents at 46% (95% confidence interval, 33, 56) and 53% (45, 60), respectively. Of the subtype analyses, influenza A(H1N1)pdm09 performed the best. In the cell-derived vaccine, the adult age group was moderate to high at 71% (44, 85) and children moderate at 56% (15, 75). In the egg-derived vaccine, the children age group was at a high 88% (80, 93) effectiveness and adults at 81% (56, 92). When comparing cell-derived vaccine directly to the egg-derived vaccine, the relative VE found significant results only for influenza A(H1N1)pdm09 which favored the egg-derived vaccine with odds ratios of 2.0 (1.1, 3.6) for all dependents and 2.9 (1.3, 6.3) for children. In the influenza A(H3N2) analysis, statistical significance was not gained; however, the odds favored the cell-derived vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [DeMarcus, Laurie; Shoubaki, Lisa; Federinko, Susan] Def Hlth Agcy, Air Force Hlth Surveillance Branch Air Force Sate, 2510 5th St, Wright Patterson AFB, OH 45433 USA.
   [DeMarcus, Laurie; Shoubaki, Lisa] STS Syst Integrat LLC, San Antonio, TX USA.
RP DeMarcus, L (reprint author), Def Hlth Agcy, Air Force Hlth Surveillance Branch Air Force Sate, 2510 5th St, Wright Patterson AFB, OH 45433 USA.
EM Laurie.DeMarcus.ctr@us.af.mil
FU DoD Global Emerging Infections Surveillance (DoD-GEIS) Respiratory Focus
   Area
FX DoD Global Emerging Infections Surveillance (DoD-GEIS) Respiratory Focus
   Area funds the Department of Defense Global Respiratory Pathogen
   Surveillance Program at the US Air Force School of Aerospace Medicine at
   Wright-Patterson Air Force Base in Dayton, Ohio.
CR [Anonymous], 2016, CELL BAS FLU VACC S
   Department of the Air Force, 2017, AIR FORC 2017 2018 S
   Flannery B, 2018, MMWR-MORBID MORTAL W, V67, P180, DOI 10.15585/mmwr.mm6706a2
   Frey S, 2010, CLIN INFECT DIS, V51, P997, DOI 10.1086/656578
   Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Paules C, 2018, NEW ENGL J MED
   Rajao DS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00123
   Remschmidt C, 2015, BMC INFECT DIS, V15
   Shoubaki Lisa, 2018, MSMR, V25, P26
   Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153
   Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682
NR 12
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4015
EP 4021
DI 10.1016/j.vaccine.2019.06.004
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700020
PM 31201055
DA 2020-05-12
ER

PT J
AU Zhang, T
   Chen, X
   Liu, HY
   Bao, QF
   Wang, ZR
   Liao, GY
   Xu, XM
AF Zhang, Ting
   Chen, Xue
   Liu, Hongyang
   Bao, Qifeng
   Wang, Zhirong
   Liao, Guoyang
   Xu, Xuemei
TI A rationally designed flagellin-L2 fusion protein induced serum and
   mucosal neutralizing antibodies against multiple HPV types
SO VACCINE
LA English
DT Article
DE Papillomavirus; L2; Flagellin; Neutralizing antibody; Mucosal
   immunization
ID CROSS-PROTECTIVE EFFICACY; MINOR CAPSID PROTEIN; HUMAN-PAPILLOMAVIRUS;
   IMMUNE-RESPONSES; INTRANASAL IMMUNIZATION; VACCINES PROTECT; N-TERMINUS;
   CHALLENGE; VIRUS; EPITOPE
AB The amino terminus of human papillomavirus (HPV) minor capsid protein L2 harbors several conserved neutralizing epitopes, including aa.17-36 (RG-1 epitope) and aa.65-85 consensus epitope (cL2 epitope), which are considered to be promising for the construction of cost-effective pan-HPV vaccine candidates. However, the immunogenicity of L2 epitope/peptide is rather weak, and the neutralizing spectrum induced by single type of L2 antigen is suboptimal. In this study, we constructed L2 concatemer with HPV18/33/58/59 RG-1 epitopes and 16L2 aa.11-88 peptide, and fused it with flagellin, a strong systemic and mucosal adjuvant, by hypervariable region replacement. A copy of cL2 epitope was also introduced to the C-terminus of the recombinant protein. The resultant Fla-5PcL2 protein can be produced in E. coli expression system with high yield and good stability. We assessed the immunogenicity of Fla-5PcL2 in mouse model via systemic and mucosal route, and found that subcutaneous immunization with Fla-5PcL2 induced robust serum neutralizing antibodies against divergent HPV types, while intranasal immunization with Fla-5PcL2 induced remarkable L2-specific IgA and cross-neutralizing antibodies in mucosal secretions, and medium titers of cross-neutralizing antibodies in sera. Moreover, Fla-5PcL2 induced full protection against vaginal HPV challenges. As mucosal antibodies provide the first-line defense at infection sites, and needle-free immunizations may increase vaccine compliance and require less public health resources, our results demonstrate that Fla-5PcL2 is a promising vaccine candidate which possibly meet the need in low-resource regions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Ting; Chen, Xue; Liu, Hongyang; Bao, Qifeng; Wang, Zhirong; Xu, Xuemei] Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Dept Biophys & Struct Biol,Inst Basic Med Sci, Beijing, Peoples R China.
   [Liao, Guoyang] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Dept Biol Prod 5, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.
RP Liao, GY (reprint author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Biol, Dept Biol Prod 5, 935 Jiaoling Rd, Kunming 650118, Yunnan, Peoples R China.; Xu, XM (reprint author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biophys & Struct Biol, Room 151,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Xu, XM (reprint author), Peking Union Med Coll, Room 151,5 Dong Dan San Tiao, Beijing 100005, Peoples R China.
EM liaogy@imbcams.com.cn; xuemeixu@vip.sina.com
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [5162025]; CAMS Innovation Fund for Medical Sciences (CIFMS)
   [2016-12M-3-026]; International Science & Technology Cooperation Program
   of China [2013DFA32430]
FX This work was supported by Beijing Natural Science Foundation (5162025),
   CAMS Innovation Fund for Medical Sciences (CIFMS, 2016-12M-3-026) and
   International Science & Technology Cooperation Program of China
   (2013DFA32430). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Alphs HH, 2008, P NATL ACAD SCI USA, V105, P5850, DOI 10.1073/pnas.0800868105
   Arbyn M, 2014, J PATHOL, V234, P431, DOI 10.1002/path.4424
   Biedma ME, 2019, VACCINE, V37, P652, DOI 10.1016/j.vaccine.2018.12.009
   Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775
   Bruni L, 2016, HUMAN PAPILLOMAVIRUS
   Buck CB, 2005, METH MOLEC MED, V119, P445
   Bzhalava D, 2015, VIROLOGY, V476, P341, DOI 10.1016/j.virol.2014.12.028
   Cardoso JC, 2011, ACTA DERMATOVEN ALP, V20, P145
   Chen XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105100
   Chen X, 2018, HUM VACC IMMUNOTHER, V14, P2025, DOI 10.1080/21645515.2018.1464355
   Chen X, 2017, ONCOTARGET, V8, P63333, DOI 10.18632/oncotarget.19327
   Nguyen CT, 2011, VACCINE, V29, P5731, DOI 10.1016/j.vaccine.2011.05.095
   Cubie HA, 2013, VIROLOGY, V445, P21, DOI 10.1016/j.virol.2013.06.007
   de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023
   Delaney KN, 2010, VIRAL IMMUNOL, V23, P201, DOI 10.1089/vim.2009.0107
   Dell K, 2006, VACCINE, V24, P2238, DOI 10.1016/j.vaccine.2005.11.060
   Deng L, 2017, VIROLOGY, V509, P82, DOI 10.1016/j.virol.2017.06.001
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Gambhira R, 2007, J VIROL, V81, P13927, DOI 10.1128/JVI.00936-07
   Gambhira R, 2007, J VIROL, V81, P11585, DOI 10.1128/JVI.01577-07
   Handisurya A, 2016, BRIT J CANCER, V114, P409, DOI 10.1038/bjc.2015.462
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Hong SH, 2012, VACCINE, V30, P466, DOI 10.1016/j.vaccine.2011.10.058
   Huber B, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0120152e0120152, DOI 10.1371/JOURNAL.PONE.0120152E0120152]
   Jagu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055538
   Jagu S, 2009, JNCI-J NATL CANCER I, V101, P782, DOI 10.1093/jnci/djp106
   Kalnin K, 2017, VACCINE, V35, P4942, DOI 10.1016/j.vaccine.2017.07.086
   Kalnin K, 2014, VACCINE, V32, P3540, DOI 10.1016/j.vaccine.2014.04.032
   Kemp TJ, 2011, VACCINE, V29, P2011, DOI 10.1016/j.vaccine.2011.01.001
   Khanal S, 2015, EXP MOL PATHOL, V99, P330, DOI 10.1016/j.yexmp.2015.06.021
   Liu F, 2010, BIOCHEM BIOPH RES CO, V392, P582, DOI 10.1016/j.bbrc.2010.01.077
   Liu G, 2012, VACCINE, V30, P6833, DOI 10.1016/j.vaccine.2012.09.013
   Liu G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020928
   Longet S, 2011, J VIROL, V85, P13253, DOI 10.1128/JVI.06093-11
   Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1
   Mardanova ES, 2016, BIOENGINEERED, V7, P28, DOI 10.1080/21655979.2015.1126017
   McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613
   Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156
   Nakao S, 2012, VIROLOGY, V434, P110, DOI 10.1016/j.virol.2012.09.006
   Nempont C, 2008, J IMMUNOL, V181, P2036, DOI 10.4049/jimmunol.181.3.2036
   Nieto K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039741
   Parker KH, 2019, VACCINE, V37, P2864, DOI 10.1016/j.vaccine.2019.03.064
   Pastrana DV, 2004, VIROLOGY, V321, P205, DOI 10.1016/j.virol.2003.12.027
   Pryde JG, 1998, METH MOL B, V88, P23
   Puth S, 2019, MUCOSAL IMMUNOL, V12, P565, DOI 10.1038/s41385-018-0104-6
   Puth S, 2017, HUM VACC IMMUNOTHER, V13, P2794, DOI 10.1080/21645515.2017.1327109
   Roden RBS, 2000, VIROLOGY, V270, P254, DOI 10.1006/viro.2000.0272
   Rubio I, 2011, VIROLOGY, V409, P348, DOI 10.1016/j.virol.2010.10.017
   Rubio I, 2009, VACCINE, V27, P1949, DOI 10.1016/j.vaccine.2009.01.102
   Schellenbacher C, 2013, J INVEST DERMATOL, V133, P2706, DOI 10.1038/jid.2013.253
   Seitz H, 2014, VACCINE, V32, P2610, DOI 10.1016/j.vaccine.2014.03.033
   Seitz H, 2013, CLIN VACCINE IMMUNOL, V20, P1061, DOI 10.1128/CVI.00195-13
   Senger T, 2010, VACCINE, V28, P1583, DOI 10.1016/j.vaccine.2009.11.048
   Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011
   Smith ML, 2006, VIROLOGY, V348, P475, DOI 10.1016/j.virol.2005.12.039
   Song LZ, 2014, VACCINE, V32, P4317, DOI 10.1016/j.vaccine.2014.06.013
   Song L, 2009, VACCINE, V27, P5875, DOI 10.1016/j.vaccine.2009.07.060
   Song L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00326
   Stepanova LA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119520
   Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016
   Sun Y, 2012, J DENT RES, V91, P941, DOI 10.1177/0022034512457684
   Talbot HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014442
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tumban E, 2013, VACCINE, V31, P4647, DOI 10.1016/j.vaccine.2013.07.052
   Tyler M, 2014, VACCINE, V32, P4267, DOI 10.1016/j.vaccine.2014.06.054
   Varga Janos, 2018, J Invest Surg, P1, DOI 10.1080/08941939.2018.1442532
   Wang D, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0123944e0123944, DOI 10.1371/JOURNAL.PONE.0123944E0123944]
   Weimer ET, 2009, VACCINE, V27, P6762, DOI 10.1016/j.vaccine.2009.08.080
   Wheeler CM, 2012, LANCET ONCOL, V13, P100, DOI 10.1016/S1470-2045(11)70287-X
   WHO/ICO Information Centre on HPV and Cervical Cancer, 2007, Vaccine, V25 Suppl 3, pC1
   Yang JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10247-8
   Yang JY, 2013, HUM VACC IMMUNOTHER, V9, P1084, DOI 10.4161/hv.23809
   Yoon SI, 2012, SCIENCE, V335, P859, DOI 10.1126/science.1215584
   Zhang T, 2016, VACCINE, V34, P5531, DOI 10.1016/j.vaccine.2016.10.009
   Zhang T, 2010, VACCINE, V28, P3479, DOI 10.1016/j.vaccine.2010.02.057
NR 75
TC 2
Z9 2
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4022
EP 4030
DI 10.1016/j.vaccine.2019.06.002
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700021
PM 31213378
DA 2020-05-12
ER

PT J
AU Muralidharan, A
   Russell, MS
   Larocque, L
   Gravel, C
   Sauve, S
   Chen, Z
   Li, CG
   Chen, WX
   Cyr, T
   Rosu-Myles, M
   Wang, LS
   Li, XG
AF Muralidharan, Abenaya
   Russell, Marsha S.
   Larocque, Louise
   Gravel, Caroline
   Sauve, Simon
   Chen, Ze
   Li, Changgui
   Chen, Wangxue
   Cyr, Terry
   Rosu-Myles, Michael
   Wang, Lisheng
   Li, Xuguang
TI Chitosan alters inactivated respiratory syncytial virus vaccine elicited
   immune responses without affecting lung histopathology in mice
SO VACCINE
LA English
DT Article
DE Respiratory syncytial virus; Vaccine; Immunopathology; Vaccine safety
ID REGULATORY T-CELLS; TRANSLATIONAL MINIREVIEW SERIES; RSV VACCINE;
   INFECTION; IMMUNIZATION; DISEASE; TISSUE; DELIVERY; PROTECTION;
   CHALLENGE
AB Chitosan is a polysaccharide capable of augmenting immune responses with a proven safety record in animals and humans. These properties make it a potentially attractive agent for the prevention and treatment of infectious disease. Infection by respiratory syncytial virus (RSV) is the leading cause of serious lower respiratory disease in young children throughout the world. There is no licensed vaccine available against RSV whereas inactivated vaccine is known to cause enhanced respiratory disease instead of protection. Here, we investigated whether chitosan administered one or three days post-infection could protect animals against RSV infection and whether it could alter immune responses or immunopathology induced by inactivated RSV vaccine when administered twice before RSV infection. We found chitosan could modestly protect animals against RSV infection when given post-infection, while, in conjunction with inactivated RSV vaccine when given pre-infection, it could significantly reduce RSV infection in mice. Further mechanistic investigation revealed that chitosan enhanced antigen-specific immune responses through augmenting the induction of regulatory T cells, lung resident T cells and neutralizing antibodies while reversing Th2-skewed immune responses induced by inactivated RSV vaccine but, surprisingly, failing to reverse lung histopathology. Overall, this study sheds more light on the molecular mechanisms underlying inactivated RSV vaccine-induced disease. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Muralidharan, Abenaya; Russell, Marsha S.; Larocque, Louise; Gravel, Caroline; Sauve, Simon; Cyr, Terry; Rosu-Myles, Michael; Li, Xuguang] Hlth Canada, Sir Frederick G Banting Res Ctr, Ctr Biol Evaluat, Biol & Genet Therapies Directorate, AL 2201E,251 Sir Frederick Banting Driveway, Ottawa, ON K1A 0K9, Canada.
   [Chen, Ze] Shanghai Inst Biol Prod, 1262 Yanan W Rd, Shanghai 200052, Peoples R China.
   [Li, Changgui] Natl Inst Food & Drug Control, 2 Tiantan Xili, Beijing, Peoples R China.
   [Li, Changgui] Who Collaborating Ctr Standardizat & Evaluat Biol, 2 Tiantan Xili, Beijing, Peoples R China.
   [Chen, Wangxue] Natl Res Council Canada, Human Therapeut Portfolio, 100 Sussex Dr, Ottawa, ON K1N 5A2, Canada.
   [Muralidharan, Abenaya; Rosu-Myles, Michael; Wang, Lisheng; Li, Xuguang] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Roger Guindon Campus, Ottawa, ON K1N 8M5, Canada.
RP Li, XG (reprint author), Hlth Canada, Sir Frederick G Banting Res Ctr, Ctr Biol Evaluat, Biol & Genet Therapies Directorate, AL 2201E,251 Sir Frederick Banting Driveway, Ottawa, ON K1A 0K9, Canada.
EM Sean.Li@canada.ca
FU Genomics Research and Development Initiative Grant, Government of Canada
FX This work was funded by Genomics Research and Development Initiative
   Grant, Government of Canada.
CR Afzali B, 2010, CLIN EXP IMMUNOL, V159, P120, DOI 10.1111/j.1365-2249.2009.04038.x
   Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005
   Arca HC, 2009, EXPERT REV VACCINES, V8, P937, DOI 10.1586/ERV.09.47
   Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803
   Aspden TJ, 1997, J PHARM SCI, V86, P509, DOI 10.1021/js960182o
   Atmar RL, 2011, NEW ENGL J MED, V365, P2178, DOI 10.1056/NEJMoa1101245
   Boelen A, 2000, VACCINE, V19, P982, DOI 10.1016/S0264-410X(00)00213-9
   Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303
   Bruck WM, 2006, CHITIN CHITOSAN OLIG
   Calvo C, 2007, PEDIATR INFECT DIS J, V26, P904, DOI 10.1097/INF.0b013e31812e52e6
   CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957
   DORNISH M, 1997, ADV CHITIN SCI, V2, P664
   Durant LR, 2013, J VIROL, V87, P10946, DOI 10.1128/JVI.01295-13
   El-Kamary SS, 2010, J INFECT DIS, V202, P1649, DOI 10.1086/657087
   Falsey A R, 2005, Exp Lung Res, V31 Suppl 1, P77
   Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894
   FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956
   Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423
   Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718
   Harding S., CHITIN HDB EUR CHITI, P457
   Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010
   Jaberolansar N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10415-w
   Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851
   Johnson TR, 2004, J VIROL, V78, P6024, DOI 10.1128/JVI.78.11.6024-6032.2004
   Kamphuis T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036812
   KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954
   Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004
   Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Knezevic-Jugovic Z, 2011, CHITIN CHITOSAN OLIG, P25
   Knudson CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004757
   Lee DCP, 2010, J VIROL, V84, P8790, DOI 10.1128/JVI.00796-10
   Liu J, 2014, EUR J IMMUNOL, V44, P1058, DOI 10.1002/eji.201343766
   Mann AJ, 2014, PLOS ONE, P9, DOI [10.1371/journalpone.0093761e93761, DOI 10.1371/JOURNALPONE.0093761E93761]
   McMaster SR, 2015, J IMMUNOL, V195, P203, DOI 10.4049/jimmunol.1402975
   Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003
   Morabito KM, 2017, MUCOSAL IMMUNOL, V10, P545, DOI 10.1038/mi.2016.48
   Morris GA, 2010, BIOTECHNOL GENET ENG, V27, P257, DOI 10.1080/02648725.2010.10648153
   Muralidharan A, 2017, EXPERT REV VACCINES, V16, P351, DOI 10.1080/14760584.2017.1260452
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Newman SP, 2004, RESPIRATORY DRUG DEL, P617
   Nwe N, 2011, CHITIN CHITOSAN OLIG, P3
   O'Connor RA, 2010, CLIN EXP IMMUNOL, V159, P137, DOI 10.1111/j.1365-2249.2009.04040.x
   Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781
   Power UF, 2001, J VIROL, V75, P12421, DOI 10.1128/JVI.75.24.12421-12430.2001
   Prince GA, 2001, J GEN VIROL, V82, P2881, DOI 10.1099/0022-1317-82-12-2881
   Raiden S, 2014, AM J RESP CRIT CARE, V189, P865, DOI 10.1164/rccm.201311-1977LE
   Roon KI, 1999, BRIT J CLIN PHARMACO, V47, P285, DOI 10.1046/j.1365-2125.1999.00894.x
   Ruckwardt TJ, 2009, J VIROL, V83, P3019, DOI 10.1128/JVI.00036-09
   Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007
   Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536
   Schmidt ME, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006810
   Shalev I, 2011, SEMIN IMMUNOL, V23, P282, DOI 10.1016/j.smim.2011.04.003
   Smith A, 2014, HUM VACC IMMUNOTHER, V10, P797, DOI 10.4161/hv.27449
   Stoker DG, 2008, PAIN MED, V9, P3, DOI 10.1111/j.1526-4637.2007.00300.x
   Sui ZW, 2010, VACCINE, V28, P7690, DOI 10.1016/j.vaccine.2010.09.019
   Sui ZW, 2010, ARCH VIROL, V155, P535, DOI 10.1007/s00705-010-0621-4
   Waris ME, 1996, J VIROL, V70, P2852, DOI 10.1128/JVI.70.5.2852-2860.1996
   Weiss KA, 2011, J IMMUNOL, V187, P3145, DOI 10.4049/jimmunol.1100764
   Wen ZS, 2011, MAR DRUGS, V9, P1038, DOI 10.3390/md9061038
   Zaharoff DA, 2007, VACCINE, V25, P2085, DOI 10.1016/j.vaccine.2006.11.034
   Zheng M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28729
NR 62
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4031
EP 4039
DI 10.1016/j.vaccine.2019.06.003
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700022
PM 31186190
DA 2020-05-12
ER

PT J
AU Hirth, JM
   Kuo, YF
   Starkey, JM
   Rupp, RE
   Laz, TH
   Rahman, M
   Berenson, AB
AF Hirth, Jacqueline M.
   Kuo, Yong-Fang
   Starkey, Jonathan M.
   Rupp, Richard E.
   Laz, Tabassum H.
   Rahman, Mahbubur
   Berenson, Abbey B.
TI Regional variations in human papillomavirus prevalence across time in
   NHANES (2003-2014)
SO VACCINE
LA English
DT Article
DE HPV prevalence; Vaginal HPV; HPV vaccination; Geographic disparities;
   Cancer prevention
ID UNITED-STATES; HPV VACCINATION; NATIONAL-HEALTH; CERVICAL-CANCER; WOMEN;
   UPDATE; RECOMMENDATIONS; REDUCTION; BARRIERS; COVERAGE
AB Introduction: The consequences of low human papillomavirus (HPV) vaccination in Census regions with higher incidence of cervical cancer may contribute to continued disparities. Our purpose was to evaluate regional variations in HPV prevalence across time.
   Methods: Repeated cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 2003-2014 were examined. Participants included females 14 to 34 years old who provided adequate vaginal samples for HPV DNA typing (N = 6387). Region of residence and HPV vaccination status associations with HPV prevalence were examined using chi-square and multivariable logistic regression. HPV types were grouped according to vaccine-type HPV (types 6, 11, 16, 18) and risk (high or low-risk). Time and vaccination status were included in subsequent models for post-licensure survey cycles (2007-2014) to assess their effects on observed associations.
   Results: No decreases in vaccine-type HPV prevalence were found between the prevaccine cycles (20032006) and early post-licensure cycles (2007-2010, p > 0.05). Vaccine-type HPV prevalence decreased in late post-licensure years (2011-2014) compared to prevaccine years (2003-2006, p = 0.001). The highest prevalence of vaccine-type HPV occurred in the South (8.6%) and Midwest (8.6%), followed by the West (4.8%), and the Northeast (3.5%) in late post-licensure years. Lower odds of vaccine-type HPV across time in post-licensure survey cycles were found to be attributable to time, and more strongly to HPV vaccination.
   Conclusions: There were regional variations in vaccine-type HPV prevalence between prevaccine and post-licensure years. These decreases appeared to be at least partially attributable to HPV vaccination. Programs are needed to address geographical disparities in HPV vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hirth, Jacqueline M.; Berenson, Abbey B.] Univ Texas Med Branch, Dept Obstet & Gynecol, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA.
   [Kuo, Yong-Fang] Univ Texas Med Branch, Dept Biostat & Epidemiol, Galveston, TX 77555 USA.
   [Starkey, Jonathan M.] Univ Texas Med Branch, Inst Translat Sci, Galveston, TX 77555 USA.
   [Rupp, Richard E.] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA.
   [Laz, Tabassum H.] St Lukes Int Hosp, Dept Radiol, Tokyo, Japan.
   [Rahman, Mahbubur] St Lukes Int Univ, Grad Sch Publ Hlth, Div Epidemiol, Tokyo, Japan.
RP Hirth, JM (reprint author), 301 Univ Blvd, Galveston, TX 77555 USA.
EM jmhirth@utmb.edu
FU Institute for Translational Sciences at the University of Texas Medical
   Branch; Clinical and Translational Science Award from the National
   Center for Advancing Translational Sciences, National Institutes of
   Health [UL1 TR001439]; Office of Research on Women's Health (ORWH), the
   Office of the Director (OD), the Eunice Kennedy Shriver National
   Institute of Child Health and Human Development (NICHD) at the National
   Institutes of Health [K12HD052023]
FX This study was conducted with the support of the Institute for
   Translational Sciences at the University of Texas Medical Branch,
   supported in part by a Clinical and Translational Science Award (UL1
   TR001439) from the National Center for Advancing Translational Sciences,
   National Institutes of Health. J.M. Hirth was a Scholar supported by a
   research career development award (K12HD052023: Building
   Interdisciplinary Research Careers in Women's Health Program - BIRCWH;
   Principal Investigator: Berenson) from the Office of Research on Women's
   Health (ORWH), the Office of the Director (OD), the Eunice Kennedy
   Shriver National Institute of Child Health and Human Development (NICHD)
   at the National Institutes of Health during data analyses for this
   study. The findings and conclusions in this paper are those of the
   authors and do not necessarily represent the views of the Research Data
   Center, the National Center for Health Statistics, or the Centers for
   Disease Control and Prevention. The sponsors did not have any role in
   the study design, collection, analysis, and interpretation of the data
   or any other aspect of this study or manuscript.
CR Banister CE, 2015, J INFECT DIS, V211, P100, DOI 10.1093/infdis/jiu394
   Baussano I, 2017, J INFECT DIS, V216, P336, DOI 10.1093/infdis/jix299
   Berenson AB, 2017, OBSTET GYNECOL, V130, P693, DOI 10.1097/AOG.0000000000002193
   Berenson AB, 2016, J INFECT DIS, V214, P1961, DOI 10.1093/infdis/jiw515
   Berenson AB, 2015, EXPERT REV VACCINES, V14, P1377, DOI 10.1586/14760584.2015.1078240
   Bratic JS, 2016, CURR OPIN PEDIATR, V28, P407, DOI 10.1097/MOP.0000000000000353
   Brotherton JML, 2011, LANCET, V377, P2085, DOI 10.1016/S0140-6736(11)60551-5
   Bureau USC, 2011, AM COMM SURV 5 YEAR
   Centers for Disease Control and Prevention, 2013, CANC PREV CONTR
   de Sanjose S, 2014, PRESSE MED, V43, pE423, DOI 10.1016/j.lpm.2014.10.001
   De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116
   Erickson BK, 2014, CLIN THER, V36, P8, DOI 10.1016/j.clinthera.2013.11.003
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Garland SM, 2014, CLIN THER, V36, P17, DOI 10.1016/j.clinthera.2013.12.005
   Hirth J, 2016, VACCINE, V34, P4415, DOI 10.1016/j.vaccine.2016.07.014
   Hirth JM, 2014, HUM VACC IMMUNOTHER, V10, P3475, DOI 10.4161/21645515.2014.980202
   Institution NC, 2015, SEER STAT FACT SHEET
   Kasting ML, 2016, HUM VACC IMMUNOTHER, V12, P1435, DOI 10.1080/21645515.2016.1141158
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   Lewis RM, 2018, VACCINE, V36, P2567, DOI 10.1016/j.vaccine.2018.03.083
   Markowitz Lauri E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   Markowitz LE, 2013, J INFECT DIS, V208, P385, DOI 10.1093/infdis/jit192
   Mesher D, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009915
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   National Center for Health Statistics (NCHS), NAT HLTH NUTR EX SUR
   Oliver SE, 2017, J INFECT DIS, V216, P594, DOI 10.1093/infdis/jix244
   Oltean HN, 2016, PUBLIC HEALTH REP, V131, P474, DOI 10.1177/003335491613100313
   Petrosky EY, 2017, CLIN PEDIATR, V56, P363, DOI 10.1177/0009922816660541
   Rahman M, 2015, J COMMUN HEALTH, V40, P404, DOI 10.1007/s10900-015-9995-2
   Rahman M, 2014, VACCINE, V32, P2394, DOI 10.1016/j.vaccine.2014.02.097
   Reagan-Steiner S, 2016, MMWR-MORBID MORTAL W, V65, P850, DOI 10.15585/mmwr.mm6533a4
   Saraiya M, 2007, OBSTET GYNECOL, V109, P360, DOI 10.1097/01.AOG.0000254165.92653.e8
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006
   U.S. Cancer Statistics Working Group, 2016, US CANC STAT 1999 20
   U. S. Food & Drug Administration Gruber MF, 2014, APPR LETT GARDASIL 9
   United States Census Bureau, CENS DIV CENS REG
   Vadaparampil ST, 2016, CANCER EPIDEM BIOMAR, V25, P1435, DOI 10.1158/1055-9965.EPI-15-1294
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
NR 40
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4040
EP 4046
DI 10.1016/j.vaccine.2019.06.001
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700023
PM 31182324
DA 2020-05-12
ER

PT J
AU Shinjoh, M
   Sugaya, N
   Furuichi, M
   Araki, E
   Maeda, N
   Isshiki, K
   Ohnishi, T
   Nakamura, S
   Yamada, G
   Narabayashi, A
   Nishida, M
   Taguchi, N
   Nakata, Y
   Yoshida, M
   Tsunematsu, K
   Shibata, M
   Munenaga, T
   Hirano, Y
   Ookawara, I
   Sekiguchi, S
   Kobayashi, Y
   Yamaguchi, Y
   Yoshida, N
   Mitamura, K
   Takahashi, T
AF Shinjoh, Masayoshi
   Sugaya, Norio
   Furuichi, Munehiro
   Araki, Eriko
   Maeda, Naonori
   Isshiki, Kyohei
   Ohnishi, Takuma
   Nakamura, Shoko
   Yamada, Go
   Narabayashi, Atsushi
   Nishida, Mitsuhiro
   Taguchi, Nobuhiko
   Nakata, Yuji
   Yoshida, Makoto
   Tsunematsu, Kenichiro
   Shibata, Meiwa
   Munenaga, Takeshi
   Hirano, Yasuhiro
   Ookawara, Ichiro
   Sekiguchi, Shinichiro
   Kobayashi, Yasuaki
   Yamaguchi, Yoshio
   Yoshida, Naoko
   Mitamura, Keiko
   Takahashi, Takao
CA Keio Pediat Influenza Res Grp
TI Effectiveness of inactivated influenza vaccine in children by vaccine
   dose, 2013-18
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Children; Effectiveness; Hospitalization;
   Test-negative case control; Vaccine dose
ID LABORATORY-CONFIRMED INFLUENZA; IMMUNOGENICITY; CANDIDATE; SEASON;
   TRIAL; AGE
AB Objectives: We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses.
   Methods: VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever >= 38 degrees C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed.
   Results: In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505-0.621], 0.550 [95% CI, 0.516-0.586]), 0.549 [95% CI, 0.517-0.583], and 1.014 [95% Cl, 0.907-1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1-12 years, especially among those aged 1-5 years. in the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A.
   Conclusions: Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shinjoh, Masayoshi; Furuichi, Munehiro; Sekiguchi, Shinichiro; Takahashi, Takao] Keio Univ, Dept Pediat, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Sugaya, Norio] Keiyu Hosp, Dept Pediat, Nishi Ku, 3-7-3 Minatomirai, Yokohama, Kanagawa 2200012, Japan.
   [Sugaya, Norio] Keiyu Hosp, Dept Infect Control, Nishi Ku, 3-7-3 Minatomirai, Yokohama, Kanagawa 2200012, Japan.
   [Araki, Eriko] Yokohama City Municipal Hosp, Pediat, Hodogaya Ku, 56 Okazawacho, Yokohama, Kanagawa 2408555, Japan.
   [Maeda, Naonori] Natl Hosp Org Tokyo Med Ctr, Dept Pediat, Meguro Ku, 2-5-1 Higashigaoka, Tokyo 1520021, Japan.
   [Isshiki, Kyohei] Saitama City Hosp, Dept Pediat, Midori Ku, 2460 Mimuro, Saitama, Saitama 3368522, Japan.
   [Ohnishi, Takuma] Natl Hosp Org Saitama Natl Hosp, Dept Pediat, 2-1 Suwa, Wako, Saitama 3210102, Japan.
   [Nakamura, Shoko] Tokyo Metropolitan Otsuka Hosp, Dept Pediat, Toshima Ku, 2-8-1 Minamiohtsuka, Tokyo 1708476, Japan.
   [Yamada, Go] Saiseikai Utsunomiya Hosp, Pediat, 201,3-9-11 Nishiki, Utsunomiya, Tochigi 3210967, Japan.
   [Narabayashi, Atsushi] Kawasaki Municipal Hosp, Dept Pediat, Kawasaki Ku, 12-1 Shinkawadori, Kawasaki, Kanagawa 2100013, Japan.
   [Nishida, Mitsuhiro] Shizuoka City Shimizu Hosp, Dept Pediat, Shimizu Ku, 1231 Miyakami, Shizuoka, Shizuoka 4248636, Japan.
   [Taguchi, Nobuhiko] Keiyu Hosp, Dept Pediat, Nishi Ku, 3-7-3 Minatomirai, Yokohama, Kanagawa 2208581, Japan.
   [Nakata, Yuji] Nippon Koukan Hosp, Dept Pediat, 1-2-1 Koukandori, Kawasaki, Kanagawa 2100852, Japan.
   [Yoshida, Makoto] Sano Kousei Gen Hosp, Dept Pediat, 1728 Horigome Cho, Sano City, Tochigi 3278511, Japan.
   [Tsunematsu, Kenichiro] Hino Municipal Hosp, Dept Pediat, 4-3-1 Tamadaira, Hino, Tokyo 1910062, Japan.
   [Shibata, Meiwa] Yokohama Rosai Hosp, Div Pediat, Kohoku Ku, 3211 Kozukue Cho, Yokohama, Kanagawa 2220036, Japan.
   [Munenaga, Takeshi] Ota Mem Hosp, Dept Pediat, 455-1 Oshima Chou, Ota, Gumma 3738585, Japan.
   [Hirano, Yasuhiro] Hiratsuka City Hosp, Dept Pediat, 1-19-1 Minamihara, Hiratsuka, Kanagawa 2540065, Japan.
   [Ookawara, Ichiro] Japanese Red Cross Shizuoka Hosp, Dept Pediat, Aoi Ku, 8-2 Outemachi, Shizuoka 4200853, Japan.
   [Kobayashi, Yasuaki] Japanese Red Cross Ashikaga Hosp, Dept Pediat, 284-1 Yobecho, Ashikaga, Tochigi 3260843, Japan.
   [Yamaguchi, Yoshio] Natl Hosp Org Tochigi Med Ctr, Inst Clin Res, Dept Infect & Allergy, 1-10-37 Nakatomatsuri, Utsunomiya, Tochigi 3208580, Japan.
   [Yoshida, Naoko] Keio Univ, Dept Infect Dis, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
   [Mitamura, Keiko] Eiju Gen Hosp, Dept Pediat, Taito Ku, 2-23-16 Higashi Ueno, Tokyo 1108645, Japan.
RP Shinjoh, M (reprint author), Keio Univ, Dept Pediat, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
CR Allison MA, 2006, J PEDIATR-US, V149, P755, DOI 10.1016/j.jpeds.2006.06.036
   Bai YH, 2015, HUM VACC IMMUNOTHER, V11, P1648, DOI 10.1080/21645515.2015.1037998
   Coleman LA, 2011, VACCINE, V29, P387, DOI 10.1016/j.vaccine.2010.10.082
   De Smedt T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199180
   Domachowske JB, 2013, J INFECT DIS, V207, P1878, DOI 10.1093/infdis/jit091
   Eisenberg KW, 2008, PEDIATRICS, V122, P911, DOI 10.1542/peds.2007-3304
   Flannery B, 2018, MMWR-MORBID MORTAL W, V67, P180, DOI 10.15585/mmwr.mm6706a2
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Hoberman A, 2003, JAMA-J AM MED ASSOC, V290, P1608, DOI 10.1001/jama.290.12.1608
   Katayose M, 2011, VACCINE, V29, P1844, DOI 10.1016/j.vaccine.2010.12.049
   Kawai S, 2011, CLIN INFECT DIS, V53, P130, DOI 10.1093/cid/cir336
   Kelly H, 2011, PEDIATR INFECT DIS J, V30, P107, DOI 10.1097/INF.0b013e318201811c
   Kimiya T, 2018, EUR J PEDIATR, V177, P1009, DOI 10.1007/s00431-018-3145-7
   Langley JM, 2013, J INFECT DIS, V208, P544, DOI 10.1093/infdis/jit263
   Maldonado YA, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-2367
   Merckx J, 2017, ANN INTERN MED, V167, P394, DOI 10.7326/M17-0848
   Neuzil KM, 2006, J INFECT DIS, V194, P1032, DOI 10.1086/507309
   Pebody RG, 2018, EURO SURVEILL, V23
   Pharmaceuticals and Medical Devices Agency (PMDA), JAP INT IN INFL VACC
   Ritzwoller DP, 2005, PEDIATRICS, V116, P153, DOI 10.1542/peds.2005-0049
   Rondy M, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.9.18-00086
   Sakai-Tagawa Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14536-0
   Sakai-Tagawa Y, 2014, MICROBIOL IMMUNOL, V58, P600, DOI 10.1111/1348-0421.12185
   Seki Y, 2018, J INFECT CHEMOTHER
   Shinjoh M, 2018, VACCINE, V36, P5510, DOI 10.1016/j.vaccine.2018.07.065
   Shinjoh M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136539
   Skowronski DM, 2007, VACCINE, V25, P2842, DOI 10.1016/j.vaccine.2006.10.002
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Sugaya N, 2016, EURO SURVEILL, V21
   Sugaya N, 2018, VACCINE, V36, P1063, DOI 10.1016/j.vaccine.2018.01.024
   The National Institute of Infectious Diseases, INFL VACC COV RAT AG
   The National Institute of Infectious Diseases, SUMM REP INFL SURV
   World Health Organization, INFL LAB SURV INF
   World Health Ornaization, WHO PUBL HLTH RES AG
NR 35
TC 1
Z9 3
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4047
EP 4054
DI 10.1016/j.vaccine.2019.05.090
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700024
PM 31186191
DA 2020-05-12
ER

PT J
AU Nordin, JD
   Vazquez-Benitez, G
   Olsen, A
   Kuckler, LC
   Gao, AY
   Kharbanda, EO
AF Nordin, James D.
   Vazquez-Benitez, Gabriela
   Olsen, Avalow
   Kuckler, Leslie C.
   Gao, Ashley Y.
   Kharbanda, Elyse O.
TI Safety of guidelines recommending live attenuated influenza vaccine for
   routine use in children and adolescents with asthma
SO VACCINE
LA English
DT Article
DE Vaccine safety; Asthma; Pediatrics; Immunization guidelines; Influenza
   vaccine
ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; COST-EFFECTIVENESS;
   VIRUS VACCINE; UNITED-STATES; PREVENTION; TRIVALENT; EFFICACY; ADULTS
AB Objective: Evaluate whether a guideline recommending Live Attenuated Influenza Vaccine (LAIV) for children 2 years and older with asthma increased risks for lower respiratory events (LREs), within 21 or 42 days of vaccination, as compared to standard guidelines to administer Inactivated Influenza Vaccine (IIV) in children with asthma.
   Methods: This was a pre/post guideline retrospective cohort study of children ages 2-17 years with asthma and receiving one or more influenza vaccines in two large medical groups from 2007 to 2016. Both groups recommended IIV in the pre-period; in 2010, one group implemented a guideline recommending LAIV for all children, including those with asthma. Main outcomes were medically attended LREs within 21 and 42 days after influenza immunization. Analysis used a generalized estimating equation regression to estimate the ratio of rate ratios (RORs) comparing pre/post events between LAIV guideline and control group.
   Results: The cohort included 7851 influenza vaccinations in 4771 children with asthma. Among patients in the LAIV guideline group, the proportion receiving LAIV increased from 23% to 68% post-guideline implementation, versus an increase from 7 to 11% in the control group. Age and baseline asthma severity adjusted ROR showed no increase in LREs, primarily asthma exacerbations, following implementation of the LAIV guideline: overall aROR (95% Confidence Interval): 0.74 (0.43-1.29) for LRE within 21 days of vaccination, 0.77 (0.53-1.14) for LRE within 42 days of vaccination. For the subset of children ages 2-4 years aROR: 0.92 (0.34-2.53) for LRE within 21 days of vaccination and 0.94 (0.49-1.82) for LRE within 42 days of vaccination; for children 5-18 years aROR (95% CI): 0.58 (0.26-1.30) for LRE within 21 days of vaccination and 0.67 (0.37-1.23) for LRE within 42 days.
   Conclusion: In a large cohort of children with asthma, a guideline recommending LAIV rather than IIV did not increase LREs following vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nordin, James D.; Vazquez-Benitez, Gabriela; Olsen, Avalow; Kuckler, Leslie C.; Gao, Ashley Y.; Kharbanda, Elyse O.] HealthPartners Inst, Mail Stop 23301A,8170 33rd Ave South, Minneapolis, MN 55425 USA.
RP Nordin, JD (reprint author), HealthPartners Inst, Mail Stop 23301A,8170 33rd Ave South, Minneapolis, MN 55425 USA.
EM James.D.Nordin@healthpartners.com
OI Kharbanda, Elyse/0000-0003-1806-6502; Nordin, James/0000-0002-3359-5843
FU National Institute of Allergy and Infectious Diseases/NII-I/DHHS
   [R21AI122141]
FX This study was funded by National Institute of Allergy and Infectious
   Diseases/NII-I/DHHS, Grant R21AI122141.
CR Ashkenazi S, 2006, PEDIATR INFECT DIS J, V25, P870, DOI 10.1097/01.inf.0000237829.66310.85
   Barnighausen T, 2017, J CLIN EPIDEMIOL, V89, P4, DOI 10.1016/j.jclinepi.2017.02.020
   Baxter R, 2012, VACCINE, V30, P3053, DOI 10.1016/j.vaccine.2012.02.080
   Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368
   Bergen R, 2004, PEDIATR INFECT DIS J, V23, P138, DOI 10.1097/01.inf.0000109392.96411.4f
   Birnbaum HG, 2009, J ASTHMA, V46, P67, DOI 10.1080/02770900802503099
   BURNEY L E, 1960, J Okla State Med Assoc, V53, P830
   Dawood FS, 2011, PEDIATRICS, V128, pE27, DOI 10.1542/peds.2010-3343
   Duffy J, 2017, ANN ALLERG ASTHMA IM, V118, P439, DOI 10.1016/j.anai.2017.01.030
   Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf
   Groenwold RHH, 2010, INT J EPIDEMIOL, V39, P107, DOI 10.1093/ije/dyp332
   Grohskopf LA, 2018, MMWR-MORBID MORTAL W, V67, P643, DOI 10.15585/mmwr.mm6722a5
   Haber P, 2015, VACCINE, V33, P1987, DOI 10.1016/j.vaccine.2015.01.080
   Leidy KN, 1999, VALUE HLTH, V2
   MDH. MN Public Health Data Access, 2014, ASTHM HOSP ALL AG 20
   NHS, 2014, GREEN BOOK INFL
   Nichol KL, 2011, VACCINE, V29, P7554, DOI 10.1016/j.vaccine.2011.08.015
   Nordin JD, 2018, 24 ANN HLTH CAR SYST
   Piedra PA, 2005, PEDIATRICS, V116, pE397, DOI 10.1542/peds.2004-2258
   Prosser LA, 2011, ARCH PEDIAT ADOL MED, V165, P112, DOI 10.1001/archpediatrics.2010.182
   Quach C, 2014, PAEDIATR RESPIR REV, V15, P340, DOI 10.1016/j.prrv.2014.06.002
   Ray GT, 2017, VACCINE, V35, P2668, DOI 10.1016/j.vaccine.2017.03.082
   Redding G, 2002, PEDIATR INFECT DIS J, V21, P44, DOI 10.1097/00006454-200201000-00010
   Toback SL, 2013, VACCINE, V31, P1812, DOI 10.1016/j.vaccine.2013.01.055
NR 26
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4055
EP 4060
DI 10.1016/j.vaccine.2019.05.081
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700025
PM 31196683
DA 2020-05-12
ER

PT J
AU Yang, H
   Luo, GX
   Zeng, YJ
   Li, YJ
   Yu, SY
   Zhao, BY
   An, R
   Zhang, SY
   Wang, YB
   Li, TD
   Ge, SX
   Xia, NS
AF Yang, Han
   Luo, Guoxing
   Zeng, Yuanjun
   Li, Yijian
   Yu, Siyuan
   Zhao, Biyan
   An, Ran
   Zhang, Shiyin
   Wang, Yingbin
   Li, Tingdong
   Ge, Shengxiang
   Xia, Ningshao
TI The distinct impact of maternal antibodies on the immunogenicity of live
   and recombinant rotavirus vaccines
SO VACCINE
LA English
DT Article
DE Rotavirus vaccine; Maternal antibody; Recombinant VP4*; Neutralizing
   antibody; IgA
ID ATTENUATED HUMAN ROTAVIRUS; INFANT IMMUNE-RESPONSES; B-CELL RESPONSES;
   EFFICACY; IMMUNIZATION; PROTECTION; VIRUS; SERUM; IGG; MONOVALENT
AB A high titre of maternal antibodies is one of the possible factors associated with decreased rotavirus vaccine efficacy in low-income countries where rotavirus-associated morbidity and mortality are high. Although some studies show a negative correlation between maternal antibody levels and seroconversion after vaccination, withholding breastfeeding does not improve rotavirus vaccine efficacy. Different types of recombined vaccines were developed as an alternative to produce higher protection in developing areas. In previous studies, we found that recombinantly expressed, truncated VP4* can stimulate high titres of neutralizing antibodies and can confer protection against rotavirus infections and rotavirus-induced diarrhoea. In this study, the impact of maternal antibodies on live and recombinant rotavirus vaccines (VP4*) was evaluated in a mouse model. Dams were infected orally with murine rotavirus 7 days after delivery to mimic a natural rotavirus infection in infants and to evaluate the separate effects of trans-placentally acquired and milk-acquired maternal antibodies, pups were half exchanged. After immunization with live rotavirus, both the neutralizing antibody and IgA antibody responses were inhibited by maternal antibodies, especially by milk antibodies; however, the neutralizing antibody responses after immunization with recombinant VP4* were enhanced. In addition, the in vitro incubation of VP4* with immune sera of rotavirus could also enhance the immune responses could also enhance the immune responses. Our finding provides a basis for the development of non-replicating vaccines to address the problem of live attenuated vaccines in low- and middle-income countries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Han; Luo, Guoxing; Zeng, Yuanjun; Li, Yijian; Yu, Siyuan; Zhao, Biyan; An, Ran; Zhang, Shiyin; Wang, Yingbin; Li, Tingdong; Ge, Shengxiang; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Strait Collaborat Innovat Ctr Biomed & Pharmaceut, State Key Lab Mol Vaccinol & Mol Diagnost,Natl In, Xiamen 361102, Fujian, Peoples R China.
RP Li, TD; Ge, SX (reprint author), Xiamen Univ, Sch Publ Hlth, Xiamen 361102, Fujian, Peoples R China.
EM litingdong@xmu.edu.cn; sxge@xmu.edu.cn
FU Scientific Research Foundation of the State Key Laboratory of Molecular
   Vaccinology and Molecular Diagnostics [2016ZY005]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [81501741]
FX This work was supported by the Scientific Research Foundation of the
   State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics
   (Grant No. 2016ZY005). Financial support was provided by the National
   Natural Science Foundation of China (81501741).
CR Aaby P, 2012, BMJ OPEN, V2
   Ali A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127622
   [Anonymous], 2013, VACCINE, V31, P6170, DOI 10.1016/j.vaccine.2013.05.037
   Anwari P, 2018, VACCINE, V36, P7765, DOI 10.1016/j.vaccine.2017.06.072
   Appaiahgari MB, 2014, VACCINE, V32, P651, DOI 10.1016/j.vaccine.2013.12.017
   Becker-Dreps S, 2015, PEDIATR INFECT DIS J, V34, P115, DOI 10.1097/INF.0000000000000481
   Chan J, 2011, VACCINE, V29, P1242, DOI 10.1016/j.vaccine.2010.11.087
   Chen MY, 2017, HUM VACC IMMUNOTHER, V13, P1126, DOI 10.1080/21645515.2016.1274474
   Chilengi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150100
   Coste A, 2000, J VIROL, V74, P8966, DOI 10.1128/JVI.74.19.8966-8971.2000
   Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085
   Franco MA, 2006, VACCINE, V24, P2718, DOI 10.1016/j.vaccine.2005.12.048
   Gaensbauer JT, 2018, CLIN INFECT DIS, V67, pS57, DOI 10.1093/cid/ciy649
   Glass RI, 2018, VACCINE, V36, P2233, DOI 10.1016/j.vaccine.2018.03.008
   Groome MJ, 2014, LANCET INFECT DIS, V14, P1096, DOI 10.1016/S1473-3099(14)70940-5
   HJELT K, 1987, J MED VIROL, V21, P39, DOI 10.1002/jmv.1890210106
   Jiang BM, 2002, CLIN INFECT DIS, V34, P1351, DOI 10.1086/340103
   Johansson E, 2008, VACCINE, V26, P778, DOI 10.1016/j.vaccine.2007.11.089
   Kirkwood CD, 2017, VACCINE
   Li TD, 2014, J VIROL METHODS, V209, P7, DOI 10.1016/j.jviromet.2014.08.012
   Li YJ, 2018, VACCINE, V36, P2086, DOI 10.1016/j.vaccine.2018.03.011
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Magwira CA, 2018, VACCINE, V36, P3427, DOI 10.1016/j.vaccine.2018.04.091
   MICKLESON KNP, 1982, J PEDIATR GASTR NUTR, V1, P381, DOI 10.1097/00005176-198201030-00018
   Moon SS, 2016, CLIN INFECT DIS, V62, P157, DOI 10.1093/cid/civ828
   Moon SS, 2010, PEDIATR INFECT DIS J, V29, P919, DOI 10.1097/INF.0b013e3181e232ea
   Nemoto M, 2018, VACCINE, V36, P5551, DOI 10.1016/j.vaccine.2018.07.057
   Nguyen TV, 2006, CLIN VACCINE IMMUNOL, V13, P475, DOI 10.1128/CVI.13.4.475-485.2006
   Nguyen TV, 2006, VACCINE, V24, P2302, DOI 10.1016/j.vaccine.2005.11.043
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Nordgren J, 2014, CLIN INFECT DIS, V59, P1567, DOI 10.1093/cid/ciu633
   OFFIT PA, 1985, J VIROL, V54, P58, DOI 10.1128/JVI.54.1.58-64.1985
   Patel M, 2012, VACCINE, V30, pA30, DOI 10.1016/j.vaccine.2011.11.093
   Perez-Schael I, 2007, J INFECT DIS, V196, P537, DOI 10.1086/519687
   Rongsen-Chandola T, 2014, VACCINE, V32, pA134, DOI 10.1016/j.vaccine.2014.04.078
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Steele AD, 2010, VACCINE, V28, P6542, DOI 10.1016/j.vaccine.2008.08.034
   Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Vesikari T, 2012, PEDIATR INFECT DIS J, V31, P509, DOI 10.1097/INF.0b013e3182489cac
   Wen Y M, 1999, Int Rev Immunol, V18, P251, DOI 10.3109/08830189909043028
   Wilson E, 2004, J EXP MED, V200, P805, DOI 10.1084/jem.20041069
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
   Zhang L, 2014, VACCINE, V32, P6091, DOI 10.1016/j.vaccine.2014.08.078
   Zhang W, 2013, J VIRAL HEPATITIS, V20, P875, DOI 10.1111/jvh.12103
NR 46
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4061
EP 4067
DI 10.1016/j.vaccine.2019.05.086
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700026
PM 31182323
DA 2020-05-12
ER

PT J
AU von Mollendorf, C
   Dunne, EM
   La Vincente, S
   Ulziibayar, M
   Suuri, B
   Luvsantseren, D
   Narangerel, D
   Ortika, BD
   Pell, CL
   Nation, ML
   Alamrousi, A
   Hinds, J
   Demberelsuren, S
   Nguyen, C
   Mungun, T
   Mulholland, EK
   Satzke, C
AF von Mollendorf, Claire
   Dunne, Eileen M.
   La Vincente, Sophie
   Ulziibayar, Mukhchuluun
   Suuri, Bujinlkham
   Luvsantseren, Dashtseren
   Narangerel, Dorj
   Ortika, Belinda D.
   Pell, Casey L.
   Nation, Monica L.
   Alamrousi, Ahmed
   Hinds, Jason
   Demberelsuren, Sodbayar
   Nguyen, Cattram
   Mungun, Tuya
   Mulholland, E. Kim
   Satzke, Catherine
TI Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and
   one year after the introduction of the 13-valent pneumococcal conjugate
   vaccine
SO VACCINE
LA English
DT Article
DE 13-valent pneumococcal conjugate vaccine impact; Pneumococcal carriage;
   Children; Mongolia; Herd immunity; Antimicrobial resistance
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   HAEMOPHILUS-INFLUENZAE; SEROTYPE REPLACEMENT; DISEASE; PCV13;
   RESISTANCE; DENSITY; IMPACT; ERA
AB Background: Nasopharyngeal carriage of Streptococcus pneumoniae precedes disease, is the source of pneumococcal community spread, and the mechanism for herd protection provided by pneumococcal conjugate vaccines (PCVs). There are few PCV impact studies in low- and middle-income countries, particularly in Asia. In 2016, Mongolia introduced the 13-valent PCV (PCV13) in a phased manner using a 2 + 1 schedule, with catch-up. We aimed to assess the impact of PCV13 introduction on nasopharyngeal pneumococcal carriage and density in children in Mongolia.
   Methods: We conducted two cross-sectional carriage surveys (pre- and one year post-PCV) at community health clinics in two districts of the capital city, Ulaanbaatar in both May July 2015 and 2017. The study analysis included 961 children too young to be vaccinated (5-8 weeks old) and 989 children eligible for vaccination (12-23 months old). Pneumococci were detected by quantitative real-time PCR and molecular serotyping performed using DNA microarray.
   Findings: One year post-PCV introduction, PCV13 serotype carriage reduced by 52% in 12-23 month olds (adjusted prevalence ratio [aPR] 0.48 [95% confidence interval [CI] 0.39-0.59]), with evidence of non-PCV13 serotype replacement (aPR 1.55 [95% CI 130-1.85]), compared with the pre-PCV period. In 5-8 week olds, PCV13 serotype carriage reduced by 51% (aPR 0.49 [95% Cl 0.33-0.73]) with no significant change in non-PCV13 serotype carriage (aPR 1.10 [95% CI 0.83-1.46]). An increase was observed in both PCV13 and non-PCV13 pneumococcal density post-PCV introduction. Antimicrobial resistance (AMR) genes were common, with 82.3% of samples containing at least one of the 10 AMR genes assessed.
   Conclusion: This study demonstrates substantive PCV13 impact on pneumococcal carriage one year post-vaccine introduction in Mongolia. The reductions in PCV13 serotype carriage are likely to result in reductions in pneumococcal disease including indirect effects. Increases in non-PCV13 serotypes require further monitoring. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [von Mollendorf, Claire; Dunne, Eileen M.; La Vincente, Sophie; Ortika, Belinda D.; Pell, Casey L.; Nation, Monica L.; Alamrousi, Ahmed; Nguyen, Cattram; Mulholland, E. Kim; Satzke, Catherine] Royal Childrens Hosp, Murdoch Childrens Res Inst, New Vaccines, Parkville, Vic, Australia.
   [von Mollendorf, Claire; Dunne, Eileen M.; Nguyen, Cattram; Mulholland, E. Kim; Satzke, Catherine] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Ulziibayar, Mukhchuluun; Suuri, Bujinlkham; Luvsantseren, Dashtseren; Mungun, Tuya] Minist Hlth, NCCD, Ulaanbaatar, Mongolia.
   [Narangerel, Dorj] Minist Hlth, Ulaanbaatar, Mongolia.
   [Hinds, Jason] St Georges Univ London, Inst Infect & Immun, London, England.
   [Hinds, Jason] London Biosci Innovat Ctr, BUGS Biosci, London, England.
   [Demberelsuren, Sodbayar] WHO, Expanded Programme Immunizat, Ulaanbaatar, Mongolia.
   [Mulholland, E. Kim] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Satzke, Catherine] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia.
   [La Vincente, Sophie] RhEACH, Level 1,Rue Cite 1, Geneva, Switzerland.
RP von Mollendorf, C (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, 50 Flemington Rd, Parkville, Vic 3052, Australia.
EM claire.vonmollendorf@mcri.edu.au
RI Satzke, Catherine/D-6501-2013
OI Satzke, Catherine/0000-0003-3164-8849; Dunne, Eileen/0000-0001-5542-0780
FU Gavi Alliance [PP61690717A2]; Victorian Government's Operational
   Infrastructure Support Program; NHMRC Career Development
   FellowshipNational Health and Medical Research Council of Australia
   [1087957]; veski Inspiring Women Fellowship
FX The project was funded by the Gavi Alliance (contract number
   PP61690717A2), with support from the Victorian Government's Operational
   Infrastructure Support Program. CS was supported by a NHMRC Career
   Development Fellowship (1087957) and a veski Inspiring Women Fellowship.
CR Bataar Otgon, 2013, Middle East Journal of Anesthesiology, V22, P293
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Brugger SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011638
   Chan J, 2017, WEST PAC SURVEILL RE, V8, DOI 10.5365/wpsar.2016.7.4.006
   Collins AM, 2015, AM J RESP CRIT CARE, V192, P853, DOI 10.1164/rccm.201503-0542OC
   Dagan R, 2017, VACCINE, V35, P945, DOI 10.1016/j.vaccine.2016.12.052
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   Desai AP, 2015, PEDIATR INFECT DIS J, V34, P1168, DOI 10.1097/INF.0000000000000849
   Dorj G, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-379
   Dunne EM, 2018, LANCET GLOB HEALTH, V6, pE1375, DOI 10.1016/S2214-109X(18)30383-8
   Egere U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049143
   Ginsburg AS, 2017, LANCET GLOB HEALTH, V5, pE1176, DOI 10.1016/S2214-109X(17)30364-9
   Grant LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074906
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   International Vaccine Access Center (IVAC), 2018, VIEW HUB REP GLOB VA
   Kaur R, 2016, PEDIATR INFECT DIS J, V35, P901, DOI 10.1097/INF.0000000000001206
   Kim SH, 2012, ANTIMICROB AGENTS CH, V56, P1418, DOI 10.1128/AAC.05658-11
   Klugman KP, 2014, LANCET GLOB HEALTH, V2, pE365, DOI 10.1016/S2214-109X(14)70241-4
   Koliou MG, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1119-6
   Lee GM, 2014, J PEDIATR INFECT DIS, V3, P23, DOI 10.1093/jpids/pit057
   Loughlin AM, 2014, PEDIATR INFECT DIS J, V33, P504, DOI 10.1097/INF.0000000000000279
   Manna S, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.06.031
   Mulholland K, 2012, LANCET, V379, P1387, DOI 10.1016/S0140-6736(12)60588-1
   Navne JE, 2017, INT J CIRCUMPOL HEAL, V76, DOI 10.1080/22423982.2017.1309504
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   Okike IO, 2014, CLIN INFECT DIS, V59, pE150, DOI 10.1093/cid/ciu514
   Roca A, 2012, CLIN INFECT DIS, V55, P816, DOI 10.1093/cid/cis554
   Salter SJ, 2012, MICROBIOL-SGM, V158, P1560, DOI 10.1099/mic.0.056580-0
   Satzke C, 2019, VACCINE, V37, P296, DOI 10.1016/j.vaccine.2018.10.077
   Satzke C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001903
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Sigauque B, 2018, PEDIATR INFECT DIS J, V37, P1054, DOI 10.1097/INF.0000000000002134
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Turner P, 2012, CLIN MICROBIOL INFEC, V18, P970, DOI 10.1111/j.1469-0691.2011.03711.x
   van der Linden M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0941-9
   van Selm S, 2003, INFECT IMMUN, V71, P6192, DOI 10.1128/IAI.71.11.6192-6198.2003
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Weinberger DM, 2013, AM J EPIDEMIOL, V178, P1488, DOI 10.1093/aje/kwt156
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   World Health Organization, 2018, WHO UNICEF EST NAT I
NR 40
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4068
EP 4075
DI 10.1016/j.vaccine.2019.05.078
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700027
PM 31174939
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Nosan, G
   Paro-Panjan, D
   Ihan, A
   Kopitar, AN
   Cucnik, S
   Avcin, T
AF Nosan, Gregor
   Paro-Panjan, Darja
   Ihan, Alojz
   Kopitar, Andreja Natasa
   Cucnik, Sasa
   Avcin, Tadej
TI Vaccine immune response, autoimmunity and morbidity after neonatal blood
   exchange transfusion
SO VACCINE
LA English
DT Article
DE Exchange transfusion; Vaccination; Diphtheria-tetanus vaccine;
   Immunomodulation; Newborn
ID GLYCOPROTEIN-I ANTIBODIES; CELL STORAGE; LEUKOREDUCTION; VARICELLA;
   CHILDREN; IMMUNOMODULATION; ANTICARDIOLIPIN; MICROCHIMERISM; CANCER;
   RISK
AB Introduction: A blood exchange transfusion (BET) is most commonly performed to treat severe neonatal haemolytic disease. A distinct form of blood transfusion adverse reaction is transfusion-related immunomodulation. The purpose of our retrospective single-centre case-control cohort study was to investigate whether a blood exchange transfusion in the neonatal period provokes immunomodulation and affects humoral immune response to vaccination, morbidity and occurrence of autoantibodies.
   Methods: Study subjects were 74 apparently healthy children, who were born at term as appropriate for gestational age and received four doses of diphtheria and tetanus toxoid vaccine. Forty-one received BET due to neonatal hemolytic disease and no other blood product afterwards, while 33 did not receive any blood products. Analysis of diphtheria, tetanus and autoimmune antibodies was performed and their medical records were analyzed for infectious, allergic, cancerous and autoimmune diseases.
   Results: A clearly exaggerated immune response to diphtheria (1.016 IU/mL, 95% confidence interval (CI) 0.662-1.369 IU/mL vs. 0.515 IU/mL, 95% CI 0.363 to 0.626 P = 0.011) and slightly exaggerated immune response to tetanus vaccine (1.798 IU/mL, 95% CI 1.180-2.416 IU/mL vs. 1.036 95% CI 0.398-1.673 IU/mL, P = non-specific) were observed in BET subjects. A propensity towards autoimmunity (25.8% vs. 12.5%, P = non-specific) was observed in BET subjects. However, BET in the neonatal period did not influence the occurrence of bacterial, childhood viral diseases with exception of varicella (43.9% vs. 21.2%, P = 0.040), autoimmune and cancer diseases.
   Conclusion: BET impacted humoral immune response to diphtheria and tetanus vaccine and occurrence of autoimmune antibodies, but did not affect morbidity and the occurrence of autoimmune diseases. These effects could be related to massive antigenic load of BET and an accelerated priming of immune cells and consequent immunomodulation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nosan, Gregor; Paro-Panjan, Darja] Univ Med Ctr Ljubljana, Dept Neonatol, Div Paediat, Bohoriceva Ul 20, Ljubljana 1525, Slovenia.
   [Paro-Panjan, Darja; Avcin, Tadej] Univ Ljubljana, Fac Med, Dept Paediat, Ljubljana, Slovenia.
   [Ihan, Alojz; Kopitar, Andreja Natasa] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
   [Cucnik, Sasa] Univ Med Ctr Ljubljana, Dept Rheumatol, Div Internal Med, Ljubljana, Slovenia.
   [Cucnik, Sasa] Univ Ljubljana, Fac Pharm, Chair Clin Biochem, Ljubljana, Slovenia.
   [Avcin, Tadej] Univ Med Ctr Ljubljana, Dept Allergol Rheumatol & Clin Immunol, Div Paediat, Ljubljana, Slovenia.
RP Nosan, G (reprint author), Univ Med Ctr Ljubljana, Dept Neonatol, Div Paediat, Bohoriceva Ul 20, Ljubljana 1525, Slovenia.
EM gregor.nosan@kclj.si
OI Nosan, Gregor/0000-0002-7306-6719
FU Slovenian Research AgencySlovenian Research Agency - Slovenia [L7-8274];
   University Medical Centre Ljubljana research grant [20180093]
FX This work was partially supported by the Slovenian Research Agency grant
   [grant number L7-8274] and the University Medical Centre Ljubljana
   research grant [grant number 20180093].
CR Almizraq RJ, 2016, TRANSFUS APHER SCI, V55, P281, DOI 10.1016/j.transci.2016.10.018
   Avcin T, 2002, CLIN EXP RHEUMATOL, V20, P101
   Avcin T, 2001, RHEUMATOLOGY, V40, P565, DOI 10.1093/rheumatology/40.5.565
   Banbury MK, 2006, J AM COLL SURGEONS, V202, P131, DOI 10.1016/j.jamcollsurg.2005.08.028
   Bloch EM, 2013, TRANSFUS MED REV, V27, P10, DOI 10.1016/j.tmrv.2012.08.002
   Bunn C, MANUAL OF BIOLOGICAL
   Cata JP, 2013, BRIT J ANAESTH, V110, P690, DOI 10.1093/bja/aet068
   Llamas JMC, 2012, REV EDUC-MADRID, P537, DOI 10.4438/1988-592X-RE-2010-357-072
   Danesh A, 2014, BLOOD, V123, P687, DOI 10.1182/blood-2013-10-530469
   Dasararaju R, 2015, CANCER CONTROL, V22, P16, DOI 10.1177/107327481502200104
   DAVEY RJ, 1995, IMMUNOL INVEST, V24, P431, DOI 10.3109/08820139509062791
   FELDMAN S, 1975, PEDIATRICS, V56, P388
   Friedman R, 2014, J BONE JOINT SURG AM, V96A, P272, DOI 10.2106/JBJS.L.01268
   Fu XY, 2016, TRANSFUSION, V56, P2560, DOI 10.1111/trf.13748
   Garcia-Roa M, 2017, BLOOD TRANSFUS-ITALY, V15, P222, DOI 10.2450/2017.0345-16
   GERSHON AA, 2015, NAT REV DIS PRIMERS, V1, DOI DOI 10.1038/NRDP201516
   Ghio M, 2011, TRANSFUSION, V51, P1567, DOI 10.1111/j.1537-2995.2010.03000.x
   Gilliss BM, 2011, ANESTHESIOLOGY, V115, P635, DOI 10.1097/ALN.0b013e31822a22d9
   Goubran H, 2017, TRANSFUS APHER SCI, V56, P336, DOI 10.1016/j.transci.2017.05.019
   Jean-Philippe P, 2007, PEDIATRICS, V120, pE1345, DOI 10.1542/peds.2004-1681
   Jy W, 2011, TRANSFUSION, V51, P886, DOI 10.1111/j.1537-2995.2011.03099.x
   Karsten E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21387-w
   Kveder T, PROCEEDINGS OF THE S
   Long K, 2014, TRANSFUSION, V54, P1340, DOI 10.1111/trf.12472
   Muszynski JA, 2017, TRANSFUSION, V57, P195, DOI 10.1111/trf.13855
   Novakova L, 2011, CELL IMMUNOL, V269, P78, DOI 10.1016/j.cellimm.2011.04.008
   Qu LR, 2005, TRANSFUSION, V45, P591, DOI 10.1111/j.0041-1132.2005.04303.x
   Refaai MA, 2013, EXPERT REV HEMATOL, V6, P653, DOI 10.1586/17474086.2013.850026
   Remy KE, 2018, TRANSFUSION, V58, P804, DOI 10.1111/trf.14488
   Ruhl H, 2009, TRANSFUS MED REV, V23, P62, DOI 10.1016/j.tmrv.2008.09.006
   Sparrow RL, 2010, BLOOD TRANSFUS-ITALY, V8, pS26, DOI 10.2450/2010.005S
   TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236
   Utter GH, 2007, VOX SANG, V93, P188, DOI 10.1111/j.1423-0410.2007.00954.x
   Utter GH, 2006, TRANSFUSION, V46, P1863, DOI 10.1111/j.1537-2995.2006.00991.x
   VAMVAKAS E, 1993, TRANSFUSION, V33, P111, DOI 10.1046/j.1537-2995.1993.33293158041.x
   Wiegering V, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-31
   Young PP, 2004, TRANSFUSION, V44, P67, DOI 10.1046/j.0041-1132.2003.00589.x
   Zigon P, 2011, CROAT MED J, V52, P694, DOI 10.3325/cmj.2011.52.694
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4076
EP 4080
DI 10.1016/j.vaccine.2019.05.077
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700028
PM 31160098
DA 2020-05-12
ER

PT J
AU Zhang, J
   Liu, NH
   Lu, Y
   Huang, Z
   Zang, YH
   Chen, JN
   Zhang, JF
   Ding, Z
AF Zhang, Jin
   Liu, Ninghua
   Lu, Yang
   Huang, Zhen
   Zang, Yuhui
   Chen, Jiangning
   Zhang, Junfeng
   Ding, Zhi
TI Phosphorothioated antisense oligodeoxynucleotide suppressing
   interleukin-10 is a safe and potent vaccine adjuvant
SO VACCINE
LA English
DT Article
DE Cytotoxicity; Adjuvant; IL-10; Antisense oligodeoxynucleotide; Antibody
   titer
ID HUMAN DENDRITIC CELLS; T-HELPER-CELL; PROTECTIVE IMMUNITY;
   OLIGONUCLEOTIDES; INDUCTION; DELIVERY; POLYETHYLENEIMINE; STIMULATION;
   CYTOKINES; ANTIGEN
AB While vaccination is highly effective for the prevention of many infectious diseases, the number of adjuvants licensed for human use is currently very limited. The aim of this study was to evaluate the safety, efficacy, and to clarify the mechanism of a phosphorothioated interleukin (IL)-10-targeted antisense oligonucleotide (ASO) as an immune adjuvant in intradermal vaccination. The cytotoxicity of IL-10 ASO and its ability to promote T cell proliferation were assessed by Cell Counting Kit-8 (CCK-8) assay. The contents of IL-6, IL-8, TNF-alpha, IL-1 beta, and IL-10 in inoculated local tissue and the antigen-specific antibody titers in mouse serum samples were determined by ELISA. The target cells of IL-10 ASO were observed using immunofluorescent staining. The results showed that the specific antibody titer of ovalbumin (OVA), a model antigen, was increased 100-fold upon addition of IL-10 ASO as an adjuvant compared to that of OVA alone. IL-10 ASO showed an immunopotentiation efficacy similar to that of Freund's incomplete adjuvant, with no detectable cell or tissue toxicity. In vitro and in vivo experiments confirmed that IL-10 ASO enhances immune responses by temporarily suppressing IL-10 expression from local dendritic cells and consequently promoting T cell proliferation. In conclusion, IL-10 ASO significantly enhances immune responses against co-delivered vaccine antigens with high efficacy and low toxicity. It has the potential to be developed into a safe and efficient immune adjuvant. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Jin; Liu, Ninghua; Lu, Yang; Huang, Zhen; Zang, Yuhui; Chen, Jiangning; Zhang, Junfeng; Ding, Zhi] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Xianlin Ave 163, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhang, Junfeng] Nanjing Univ, Collaborat Innovat Ctr Chem Life Sci, Nanjing 210023, Jiangsu, Peoples R China.
   [Ding, Zhi] Nanjing Univ, Changzhou High Tech Res Inst, Changzhou 213164, Peoples R China.
RP Zhang, JF; Ding, Z (reprint author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Xianlin Ave 163, Nanjing 210023, Jiangsu, Peoples R China.
EM jfzhang@nju.edu.cn; dingzhi@nju.edu.cn
OI Ding, Zhi/0000-0002-2112-1835
FU Natural Science Foundation, Jiangsu Province [BK20161478]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities; State Key Laboratory of Pharmaceutical
   Biotechnology Independent Research Grant [ZZYJ-SN-201405]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81673380]
FX This study was funded by the Natural Science Foundation, Jiangsu
   Province (grant number BK20161478), the Fundamental Research Funds for
   the Central Universities, State Key Laboratory of Pharmaceutical
   Biotechnology Independent Research Grant (grant number ZZYJ-SN-201405),
   and the National Natural Science Foundation of China (grant number
   81673380).
CR Aguilar JC, 2007, VACCINE, V25, P3752, DOI 10.1016/j.vaccine.2007.01.111
   [Anonymous], 2018, WORLD HLTH STAT
   Arima H, 1998, ANTISENSE NUCLEIC A, V8, P319, DOI 10.1089/oli.1.1998.8.319
   Baek KH, 2001, J IMMUNOL, V167, P2847, DOI 10.4049/jimmunol.167.5.2847
   Boyaka PN, 2001, ADV DRUG DELIVER REV, V51, P71, DOI 10.1016/S0169-409X(01)00170-3
   Ding Z, 2009, PHARM RES-DORDR, V26, P1635, DOI 10.1007/s11095-009-9874-6
   Elias F, 2003, J IMMUNOL, V171, P3697, DOI 10.4049/jimmunol.171.7.3697
   *EMEA, 2005, GUID ADJ VACC HUM US
   Fallon J, 2014, ONCOTARGET, V5, P1869, DOI 10.18632/oncotarget.1853
   FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081
   He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026
   Huang Z, 2012, J CONTROL RELEASE, V158, P286, DOI 10.1016/j.jconrel.2011.11.013
   Hunter AC, 2006, ADV DRUG DELIVER REV, V58, P1523, DOI 10.1016/j.addr.2006.09.008
   Igietseme JU, 2000, J IMMUNOL, V164, P4212, DOI 10.4049/jimmunol.164.8.4212
   Kayamuro H, 2010, J VIROL, V84, P12703, DOI 10.1128/JVI.01182-10
   Liu Y, 2017, ADV DRUG DELIVER REV, V115, P98, DOI 10.1016/j.addr.2017.03.004
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004
   Min WP, 2000, J IMMUNOL, V164, P161, DOI 10.4049/jimmunol.164.1.161
   Monteith DK, 1997, ANTI-CANCER DRUG DES, V12, P421
   Moreira D, 2018, CLIN CANCER RES, V24, P5948, DOI 10.1158/1078-0432.CCR-18-1277
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ni R, 2016, ADV DRUG DELIVER REV, V106, P3, DOI 10.1016/j.addr.2016.07.005
   Perrie Y, 2008, INT J PHARMACEUT, V364, P272, DOI 10.1016/j.ijpharm.2008.04.036
   PISETSKY DS, 1993, MOL BIOL REP, V18, P217, DOI 10.1007/BF01674433
   Pradhan P, 2014, BIOMATERIALS, V35, P5491, DOI 10.1016/j.biomaterials.2014.03.039
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183
   Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002
   Sakamoto T, 2004, GENE THER, V11, P317, DOI 10.1038/sj.gt.3302171
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/ERV.11.21, 10.1586/erv.11.21]
   Sharma N, 2017, CYTOKINE, V90, P169, DOI 10.1016/j.cyto.2016.11.010
   Sharma VK, 2014, MEDCHEMCOMM, V5, P1454, DOI 10.1039/c4md00184b
   Sheppard NC, 2014, INT IMMUNOL, V26, P531, DOI 10.1093/intimm/dxu055
   Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593
   Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507
   Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993
   Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344
NR 39
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4081
EP 4088
DI 10.1016/j.vaccine.2019.05.076
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700029
PM 31164303
DA 2020-05-12
ER

PT J
AU Beissbarth, J
   Smith-Vaughan, HC
   Harris, TM
   Binks, MJ
   Leach, AJ
AF Beissbarth, Jemima
   Smith-Vaughan, Heidi Carol
   Harris, Tegan Maree
   Binks, Michael John
   Leach, Amanda Jane
TI Use of the 10-valent pneumococcal Haemophilus influenzae protein D
   conjugate vaccine (PHiD-CV10) in an Australian Indigenous paediatric
   population does not alter the prevalence of nontypeable Haemophilus
   influenzae without the protein D gene
SO VACCINE
LA English
DT Article
DE Haemophilus influenzae; NTHi; Hpd; Otitis media
ID COVERAGE ANNUAL-REPORT; IMMUNIZATION COVERAGE; OTITIS-MEDIA; CARRIAGE;
   ASSAY
AB Background: Nontypeable Haemophilus influenzae (NTHi) is one of the main respiratory pathogens associated with otitis media and lung infections in Australian Indigenous children. PHiD-CV10, the 10-valent pneumococcal conjugate vaccine containing H. influenzae protein D was used in the Northern Territory infant vaccination schedule for two years from October 2009.
   Methods: NTHi isolates from nasopharyngeal and ear discharge samples collected before, during and after the PHiD-CV10 era were screened for the hpd gene by PCR. Target amplicon sequence, extracted from available genomic sequence data, was analysed to identify variability in this region.
   Results: There was no statistically significant difference in the proportion of hpd#3-PCR negative isolates from each era; overall 7% and 6% of nasopharyngeal and ear discharge isolates were negative, respectively. The nucleotide sequence data supported the hpd-PCR findings; truncations of the hpd gene precluding amplification and presumably expression of protein D were observed in approximately 7% of available genomes.
   Conclusions: In the Northern Territory of Australia, a population at high risk of NTHi-associated infection, PHiD-CV10 use did not select for hpd-PCR negative isolates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Beissbarth, Jemima; Smith-Vaughan, Heidi Carol; Harris, Tegan Maree; Binks, Michael John; Leach, Amanda Jane] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia.
RP Beissbarth, J (reprint author), Menzies Sch Hlth Res, John Matthews Bldg 58,Royal Darwin Hosp Campus, Casuarina, NT 0810, Australia.
EM jemima.beissbarth@menzies.edu.au
FU Centre for Research Excellence in Ear and Hearing Health of Aboriginal
   and Torres Strait Islander Children [GNT 1078557]; NHMRCNational Health
   and Medical Research Council of Australia [GNT 545232, GNT 436023, ECF:
   1159905]; GlaxoSmithKlineGlaxoSmithKline [116164]; PfizerPfizer
   [WI172145]; NHMRC CRE-LungNational Health and Medical Research Council
   of Australia [GNT 1040830]
FX This study was funded by the Centre for Research Excellence in Ear and
   Hearing Health of Aboriginal and Torres Strait Islander Children (GNT
   1078557), the original studies from which the isolates were selected
   were supported by NHMRC (GNT 545232, GNT 436023), GlaxoSmithKline
   (Protocol code 116164), and Pfizer (Ref#WI172145). The funding bodies
   had no input into study design or the manuscript preparation. MJB is
   supported by NHMRC (ECF: 1159905), HCSV and TMH are supported by NHMRC
   CRE-Lung (GNT 1040830).
CR Ahren IL, 2001, MICROB PATHOGENESIS, V31, P151, DOI 10.1006/mpat.2001.0456
   Akkoyunlu M, 1996, INFECT IMMUN, V64, P4586, DOI 10.1128/IAI.64.11.4586-4592.1996
   AKKOYUNLU M, 1991, INFECT IMMUN, V59, P1231, DOI 10.1128/IAI.59.4.1231-1238.1991
   Clarke C, 2017, EXPERT REV VACCINES, V16, P751, DOI 10.1080/14760584.2017.1333905
   de Gier C, 2016, J CLIN MICROBIOL, V54, P2380, DOI 10.1128/JCM.00982-16
   Hogg JS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r103
   Hull B, 2011, COMMUN DIS INTELL, V35, P132
   Hull B, 2009, COMMUN DIS INTELL, V33, P170
   Hull BP, 2014, COMMUN DIS INTELL, V38, pE208
   Hull BP, 2013, COMMUN DIS INTELL, V37, pE291
   Hunt M, 2017, MICROB GENOMICS, V3, DOI 10.1099/mgen.0.000131
   Leach AJ, 2016, INT J PEDIATR OTORHI, V86, P224, DOI 10.1016/j.ijporl.2016.05.011
   Leach AJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-121
   Leach AJ, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0483-8
   Leach AJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007247
   Leach AJ, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-200
   Mackenzie GA, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-14
   Morris Peter S, 2005, BMC Pediatr, V5, P27, DOI 10.1186/1471-2431-5-27
   Pickering J, 2014, J CLIN MICROBIOL, V52, P663, DOI 10.1128/JCM.02191-13
   Poolman JT, 2000, VACCINE, V19, pS108, DOI 10.1016/S0264-410X(00)00288-7
   Price EP, 2017, FUTURE MICROBIOL, V12, P585, DOI 10.2217/fmb-2016-0215
   Price EP, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1857-x
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Smith-Vaughan HC, 2014, CLIN VACCINE IMMUNOL, V21, P250, DOI 10.1128/CVI.00632-13
   Van Eldere J, 2014, LANCET INFECT DIS, V14, P1281, DOI 10.1016/S1473-3099(14)70734-0
   Wang X, 2011, INT J MED MICROBIOL, V301, P303, DOI 10.1016/j.ijmm.2010.11.004
NR 26
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4089
EP 4093
DI 10.1016/j.vaccine.2019.05.079
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700030
PM 31164306
DA 2020-05-12
ER

PT J
AU New, RRC
   Moore, BD
   Butcher, W
   Mahood, R
   Lever, MS
   Smither, S
   O'Brien, L
   Weller, SA
   Bayliss, M
   Gibson, LCD
   Macleod, C
   Bogu, M
   Harvey, R
   Almond, N
   Williamson, ED
AF New, R. R. C.
   Moore, B. D.
   Butcher, W.
   Mahood, R.
   Lever, M. S.
   Smither, S.
   O'Brien, L.
   Weller, S. A.
   Bayliss, M.
   Gibson, L. C. D.
   Macleod, C.
   Bogu, M.
   Harvey, R.
   Almond, N.
   Williamson, E. D.
TI Antibody-mediated protection against MERS-CoV in the murine model
SO VACCINE
LA English
DT Article
DE MERS; Coronavirus; Vaccination; Mucosal immunity; Systemic immunity;
   Respiratory infection; Neutralising antibody; Novel vaccine formulation
ID RECEPTOR-BINDING DOMAIN; FC-FUSION PROTEINS; MIDDLE-EAST; SPIKE PROTEIN;
   VACCINES; IMMUNITY
AB Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed subcutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Butcher, W.; Mahood, R.; Lever, M. S.; Smither, S.; O'Brien, L.; Weller, S. A.; Bayliss, M.; Williamson, E. D.] Def Sci & Technol Lab, Salisbury, Wilts, England.
   [Moore, B. D.; Macleod, C.] Univ Strathclyde, Pure & Appl Chem, Glasgow, Lanark, Scotland.
   [New, R. R. C.; Bogu, M.] Vaxcine UK Ltd, London Biosci Innovat Ctr, London, England.
   [Gibson, L. C. D.] Scottish Biomed Drug Discovery, West Scotland Sci Pk, Glasgow, Lanark, Scotland.
   [Harvey, R.; Almond, N.] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England.
   [New, R. R. C.] Middlesex Univ, Fac Sci & Technol, London, England.
RP Williamson, ED (reprint author), Def Sci & Technol Lab, Salisbury, Wilts, England.
EM dewilliamson@dstl.gov.uk
RI MacLeod, Clair/G-8981-2017
OI MacLeod, Clair/0000-0001-7036-1790; Almond, Neil/0000-0001-6105-0616
FU SBRI awards from Innovate UK [972228, 971527]; NIHR Policy Research
   Programme [971527]
FX This work was supported by SBRI awards 972228 and 971527 from Innovate
   UK to RRCN and NA, respectively and on independent research commissioned
   from NA and funded by the NIHR Policy Research Programme, [971527]. The
   views expressed in the publication are those of the author(s) and not
   necessarily those of the NHS, the NIHR, the Department of Health, 'arms'
   length bodies or other government departments.
CR Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Bosch BJ, 2013, CELL RES, V23, P1069, DOI 10.1038/cr.2013.108
   Chen YQ, 2013, J VIROL, V87, P10777, DOI 10.1128/JVI.01756-13
   Czajkowsky DM, 2012, EMBO MOL MED, V4, P1015, DOI 10.1002/emmm.201201379
   Domingos M de O', 2008, OPEN DRUG DELIVERY J, V9, P52
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Du LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081587
   Excler JL, 2016, EMERG INFECT DIS, V22, pE1, DOI 10.3201/eid2208.160229
   Guo XJ, 2015, IMMUNOLOGY, V145, P476, DOI 10.1111/imm.12462
   Haagmans BL, 2016, SCIENCE, V351, P77, DOI 10.1126/science.aad1283
   Jones S, 2014, VACCINE, V32, P4234, DOI 10.1016/j.vaccine.2013.09.061
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lu XY, 2014, J CLIN MICROBIOL, V52, P67, DOI 10.1128/JCM.02533-13
   Ma F, 2010, CELL MOL IMMUNOL, V7, P381, DOI 10.1038/cmi.2010.30
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Moore BD, 2018, VACCINE, V36, P5210, DOI 10.1016/j.vaccine.2018.06.039
   Omrani AS, 2015, PATHOG GLOB HEALTH, V109, P354, DOI 10.1080/20477724.2015.1122852
   Prabakaran M, 2010, ANTIVIR RES, V86, P180, DOI 10.1016/j.antiviral.2010.02.315
   Rath T, 2015, CRIT REV BIOTECHNOL, V35, P235, DOI 10.3109/07388551.2013.834293
   Raviprakash K, 2008, J VIROL, V82, P6927, DOI 10.1128/JVI.02724-07
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Schoenen H, 2010, J IMMUNOL, V184, P2756, DOI 10.4049/jimmunol.0904013
   Tai WB, 2017, J VIROL, V91, DOI 10.1128/JVI.01651-16
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   van Endert P, 2016, IMMUNOL REV, V272, P80, DOI 10.1111/imr.12424
   Wang C, 2017, ANTIVIR RES, V140, P55, DOI 10.1016/j.antiviral.2016.12.019
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang QH, 2016, ANTIVIR RES, V133, P165, DOI 10.1016/j.antiviral.2016.07.015
   Wang YF, 2017, HUM VACC IMMUNOTHER, V13, P1615, DOI 10.1080/21645515.2017.1296994
   Woo PCY, 2014, EMERG INFECT DIS, V20, P560, DOI 10.3201/eid2004.131769
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
NR 34
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4094
EP 4102
DI 10.1016/j.vaccine.2019.05.074
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700031
PM 31178378
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Xia, M
   Huang, PW
   Jiang, X
   Tan, M
AF Xia, Ming
   Huang, Pengwei
   Jiang, Xi
   Tan, Ming
TI Immune response and protective efficacy of the S particle presented
   rotavirus VP8*vaccine in mice
SO VACCINE
LA English
DT Article
DE Nanoparticle; Vaccine platform; S particle; Subunit vaccine; Rotavirus;
   Norovirus; Subviral particle
ID CAPSID PROTEIN FORMS; INTUSSUSCEPTION RISK; VACCINE CANDIDATE; DUAL
   VACCINE; P-DOMAIN; NOROVIRUS; VIRUS; VP8(STAR); EPITOPES; DIARRHEA
AB Rotaviruses cause severe diarrhea in infants and young children, leading to significant morbidity and mortality. Despite implementation of current rotavirus vaccines, severe diarrhea caused by rotaviruses still claims similar to 200,000 lives of children with great economic loss worldwide each year. Thus, new prevention strategies with high efficacy are highly demanded. Recently, we have developed a polyvalent protein nanoparticle derived from norovirus VP1, the S particle, and applied it to display rotavirus neutralizing antigen VP8* as a vaccine candidate (S-VP8*) against rotavirus, which showed promise as a vaccine based on mouse immunization and in vitro neutralization studies. Here we further evaluated this S-VP8* nanoparticle vaccine in a mouse rotavirus challenge model. S-VP8* vaccines containing the murine rotavirus (EDIM strain) VP8* antigens (S-mVP8*) were constructed and immunized mice, resulting in high titers of anti-EDIM VP8* IgG. The S-mVP8* nanoparticle vaccine protected immunized mice against challenge of the homologous murine EDIM rotavirus at a high efficacy of 97% based on virus shedding reduction in stools compared with unimmunized controls. Our study further supports the polyvalent S-VP8* nanoparticles as a promising vaccine candidate against rotavirus and warrants further development. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xia, Ming; Huang, Pengwei; Jiang, Xi; Tan, Ming] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   [Jiang, Xi; Tan, Ming] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
RP Jiang, X; Tan, M (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM Jason.jiang@cchmc.org; Ming.Tan@cchmc.org
FU National Institute of Health, National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [5R01 AI089634-01, R21
   AI092434-01A1]; Cincinnati Children's Hospital Medical Center
FX We thank Dr. Monica M. McNeal at Cincinnati Children's Hospital Medical
   Center for providing EDIM rotavirus and necessary reagents for detection
   of EDIM antigens in the mouse stool samples. The research described in
   this article was supported by the National Institute of Health, the
   National Institute of Allergy and Infectious Diseases (5R01 AI089634-01
   to X.J. and R21 AI092434-01A1 to M.T.) and an institutional Innovation
   Fund of Cincinnati Children's Hospital Medical Center to M.T.
CR Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Bauchau V, 2015, PHARMACOEPIDEM DR S, V24, P765, DOI 10.1002/pds.3800
   Choi AHC, 2003, VACCINE, V21, P761, DOI 10.1016/S0264-410X(02)00595-9
   Choi AHC, 2000, J VIROL, V74, P11574, DOI 10.1128/JVI.74.24.11574-11580.2000
   Desai R, 2013, PEDIATR INFECT DIS J, V32, P1, DOI 10.1097/INF.0b013e318270362c
   Glass RI, 2001, NOVART FDN SYMP, V238, P5
   Glass RI, 2014, NEW ENGL J MED, V370, P568, DOI 10.1056/NEJMe1315836
   Hu LY, 2012, NATURE, V485, P256, DOI 10.1038/nature10996
   Huang PW, 2012, J VIROL, V86, P4833, DOI 10.1128/JVI.05507-11
   Imbert-Marcille BM, 2014, J INFECT DIS, V209, P1227, DOI 10.1093/infdis/jit655
   Liu Y, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006707
   Liu Y, 2016, J VIROL, V90, P9983, DOI 10.1128/JVI.01494-16
   Liu Y, 2012, J VIROL, V86, P9899, DOI 10.1128/JVI.00979-12
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   McNeal MM, 1999, J VIROL, V73, P7565, DOI 10.1128/JVI.73.9.7565-7573.1999
   Trang NV, 2014, J CLIN MICROBIOL, V52, P1366, DOI 10.1128/JCM.02927-13
   Nordgren J, 2014, CLIN INFECT DIS, V59, P1567, DOI 10.1093/cid/ciu633
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Prasad BVV, 1999, SCIENCE, V286, P287, DOI 10.1126/science.286.5438.287
   Rosillon D, 2015, PEDIATR INFECT DIS J, V34, P763, DOI 10.1097/INF.0000000000000715
   Tan M, 2005, J VIROL, V79, P14017, DOI 10.1128/JVI.79.22.14017-14030.2005
   Tan M, 2004, J VIROL, V78, P6233, DOI 10.1128/JVI.78.12.6233-6242.2004
   Tan M, 2018, EMERG MICROBES INFEC, P7
   Tan M, 2008, VIROLOGY, V382, P115, DOI 10.1016/j.virol.2008.08.047
   Tan M, 2014, EXPERT REV MOL MED, V16, DOI 10.1017/erm.2014.2
   Tan M, 2011, PROCEDIA VACCINOL, V4, DOI 10.1016/j.provac.2011.07.004
   Tan M, 2011, VIROLOGY, V410, P345, DOI 10.1016/j.virol.2010.11.017
   Tan M, 2011, J VIROL, V85, P753, DOI 10.1128/JVI.01835-10
   Tate JE, 2012, LANCET INFECT DIS, V12, P136, DOI 10.1016/S1473-3099(11)70253-5
   Vesikari T, 2007, INT J INFECT DIS, V11, pS29, DOI 10.1016/S1201-9712(07)60019-8
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Wang LY, 2014, BIOMATERIALS, V35, P8427, DOI 10.1016/j.biomaterials.2014.06.021
   Wang LY, 2014, VACCINE, V32, P445, DOI 10.1016/j.vaccine.2013.11.064
   Wang LY, 2013, BIOMATERIALS, V34, P4480, DOI 10.1016/j.biomaterials.2013.02.041
   Weintraub ES, 2014, NEW ENGL J MED, V370, P513, DOI 10.1056/NEJMoa1311738
   Xia M, 2018, ACS NANO
   Xia M, 2018, ACS NANO, V12, P10665, DOI 10.1021/acsnano.8b02776
   Xia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep25735
   Xia M, 2016, VACCINE, V34, P905, DOI 10.1016/j.vaccine.2015.12.068
   Xia M, 2011, VACCINE, V29, P7670, DOI 10.1016/j.vaccine.2011.07.139
   Yen C, 2011, HUM VACCINES, V7, P1282, DOI 10.4161/hv.7.12.18321
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
   Yung C-F, 2015, J PEDIAT, V167, pe1
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 44
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4103
EP 4110
DI 10.1016/j.vaccine.2019.05.075
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700032
PM 31201052
DA 2020-05-12
ER

PT J
AU Narayanan, N
   Elsaid, MI
   NeMoyer, RE
   Trivedi, N
   Zeb, U
   Rustgi, VK
AF Narayanan, Navaneeth
   Elsaid, Mohamed, I
   NeMoyer, Rachel E.
   Trivedi, Niti
   Zeb, Uroosa
   Rustgi, Vinod K.
TI Disparities in hepatitis A virus (HAV) vaccination coverage among adult
   travelers to intermediate or high-risk countries: The role of birthplace
   and race/ethnicity
SO VACCINE
LA English
DT Article
DE Hepatitis A; Hepatitis A virus; Vaccination; Liver disease; Travel
   medicine; Healthcare disparities
ID NATIONAL-HEALTH; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; ETHNIC
   DISPARITIES; UNITED-STATES; POPULATIONS; RECOMMENDATIONS; PROPHYLAXIS;
   IMMUNITY
AB Background: While the hepatitis A virus (HAV) vaccine is recommended for United States (US) travelers to endemic regions, vaccination rates are lower among non-US-born adults and some racial minority groups.
   Purpose: We aimed to examine the relationship between birthplace, race and their interaction as predictors of self-reported HAV vaccination among adult travelers to high-risk countries (HRCs) through analysis of the National Health Interview Survey (NHIS), 2012-2015.
   Methods: The study included 36,872 US adult participants in the 2012-2015 NHIS who traveled to countries where HAV is endemic. The main outcome was self-reported HAV vaccination (>= 2 doses). Complex survey methods were applied to all models to provide statistical estimates that were representative of US adults. Multivariable logistic regression models adjusting for demographic, socioeconomic, medical, and access-to-care characteristics were fitted to examine the association between birthplace, race, race-by-birthplace (for interaction) and vaccination status.
   Results: For adult travelers to HRCs, the adjusted odds ratio (AOR) of HAV vaccination was lower for non-US-born compared to US-born adults, AOR 0.86 (95% CI; 0.76, 0.98). For Hispanics, the AOR of HAV vaccination was 0.80 (95% CI; 0.70, 0.91) as compared to non-Hispanic-Whites. Furthermore, a significant qualitative interaction between birthplace and race was found (P-value 0.0005). Among non-Hispanic Blacks, the adjusted odds of HAV vaccination for non-US-born adults were 1.35 (95% CI; 1.06, 1.72) times the odds for US-born adults. In contrast, the AORs of HAV vaccination of non-US-born versus US-born adults were 36% (95% CI; 17%, 51%) and 30% (95% CI; 12%, 44%), lower for Asians and Hispanics, respectively.
   Conclusions: The association between birthplace and HAV vaccination status differs by race among travelers to HRCs, with US-born non-Hispanic Black and non-US-born Asian and Hispanic adults having lower odds of vaccination. Health care resources should be focused on these target populations to improve travel vaccination compliance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Narayanan, Navaneeth; Elsaid, Mohamed, I; NeMoyer, Rachel E.; Trivedi, Niti; Zeb, Uroosa] Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Piscataway, NJ 08854 USA.
   [Narayanan, Navaneeth] Rutgers State Univ, Ernest Mario Sch Pharm, Piscataway, NJ USA.
   [Narayanan, Navaneeth] Rutgers Robert Wood Johnson Med Sch, Div Infect Dis, New Brunswick, NJ USA.
   [Elsaid, Mohamed, I; Rustgi, Vinod K.] Rutgers Robert Wood Johnson Med Sch, Div Gastroenterol & Hepatol, New Brunswick, NJ USA.
   [NeMoyer, Rachel E.] Rutgers Robert Wood Johnson Med Sch, Div Gen Surg, New Brunswick, NJ USA.
RP Narayanan, N (reprint author), Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Piscataway, NJ 08854 USA.
EM navan12@pharmacy.rutgers.edu
RI Elsaid, Mohamed I/AAG-4082-2019
OI Elsaid, Mohamed I/0000-0001-7963-2438; Narayanan,
   Navaneeth/0000-0001-5071-9193
CR [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   [Anonymous], 1996, MMWR Recomm Rep, V45, P1
   Bacaner N, 2004, JAMA-J AM MED ASSOC, V291, P2856, DOI 10.1001/jama.291.23.2856
   Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822
   Cofie LE, 2018, AM J PREV MED, V54, P20, DOI 10.1016/j.amepre.2017.08.017
   Curran D, 2016, HUM VACC IMMUNOTHER, V12, P2765, DOI 10.1080/21645515.2016.1203495
   Denniston MM, 2015, VACCINE, V33, P3887, DOI 10.1016/j.vaccine.2015.06.063
   Doshani M, 2019, MMWR-MORBID MORTAL W, V68, P153, DOI 10.15585/mmwr.mm6806a6
   Egede LE, 2003, AM J PUBLIC HEALTH, V93, P2074, DOI 10.2105/AJPH.93.12.2074
   Foster MA, 2019, MMWR-MORBID MORTAL W, V68, P413, DOI 10.15585/mmwr.mm6818a2
   Grieco E.M., 2012, SIZE PLACE BIRTH GEO
   Klevens RM, 2015, VACCINE, V33, P6192, DOI 10.1016/j.vaccine.2015.10.009
   Liu SJ, 2015, J TRAVEL MED, V22, P174, DOI 10.1111/jtm.12186
   Lu PJ, 2015, VACCINE, V33, pD83, DOI 10.1016/j.vaccine.2015.09.031
   Lu PJ, 2015, AM J PREV MED, V49, pS412, DOI 10.1016/j.amepre.2015.03.005
   Lu PJ, 2014, AM J PREV MED, V47, P722, DOI 10.1016/j.amepre.2014.08.009
   Lu PJ, 2013, VACCINE, V31, P2348, DOI 10.1016/j.vaccine.2013.03.011
   Moorman AC, 2018, GASTROENTEROLOGY, V154, P2015, DOI 10.1053/j.gastro.2018.04.031
   Nelson NP, 2018, MMWR-MORBID MORTAL W, V67, P1216, DOI 10.15585/mmwr.mm6743a5
   Noonan AS, 2016, PUBLIC HEALTH REV, V37, DOI 10.1186/s40985-016-0025-4
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Wilson E, 2019, MMWR-MORBID MORTAL W, V68, P330, DOI 10.15585/mmwr.mm6814a4
   Wooten Darcy A, 2019, Top Antivir Med, V26, P117
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4111
EP 4117
DI 10.1016/j.vaccine.2019.05.071
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700033
PM 31196682
DA 2020-05-12
ER

PT J
AU Fawole, OA
   Srivastava, T
   Feemster, KA
AF Fawole, Oluwatunmise A.
   Srivastava, Tuhina
   Feemster, Kristen A.
TI Student health administrator perspectives on college vaccine policy
   development and implementation
SO VACCINE
LA English
DT Article
DE Vaccine; College; Vaccine policy; College health; Administrators;
   School-entry; Vaccine perceptions; Vaccine hesitancy; Vaccines;
   Immunizations; University health; Vaccine requirements
ID IMMUNIZATION REQUIREMENTS; US COLLEGES; OUTBREAK; CAMPUS
AB Background: Immunization policies at colleges and universities differ greatly for many reasons, including prior experience with disease outbreaks and state immunization requirements. Few studies comprehensively explore the range of factors that influence the development of college vaccine policies or facilitators and barriers to their implementation.
   Objective: To explore the perceptions and decision-making process that influence college vaccine policy development and implementation from the perspective of student health administrators.
   Methods: This qualitative study used semi-structured interviews with student health administrators (N =10) from ten U.S. colleges and universities purposefully sampled by school type (public vs. private) and geographic region. A descriptive codebook was developed from the interview guide, and each interview was double-coded using NVivo 11 software (kappa = 0.87; inter-observer reliability = 99.4%).
   Results: We coded 5785 phrases. Administrators positively viewed their institutions' vaccine requirements, but some expressed concerns about the acceptance of philosophical and religious exemptions. They noted that students were generally ambivalent towards vaccine requirements, and while students recognized the benefits of vaccination, they did not prioritize immunizations. All administrators cited reliance on governmental and professional organizations as well as state regulations for decisions regarding vaccine requirements and recommendations at their institutions. Partnerships with other school departments, pharmaceutical companies, immunization coalitions, and healthcare providers were frequently cited as facilitators of college vaccine programs. Costs of purchasing, storing, and tracking vaccines were identified as major barriers.
   Conclusions: We identified key themes that can be evaluated in subsequent studies to identify factors associated with successful implementation of university immunization programs and inform initiatives to increase vaccine acceptance and optimize immunization rates on college and university campuses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fawole, Oluwatunmise A.; Srivastava, Tuhina; Feemster, Kristen A.] Childrens Hosp Philadelphia, Vaccine Educ Ctr, 3615 Civ Ctr Blvd,Suite 1202 ARC, Philadelphia, PA 19104 USA.
   [Feemster, Kristen A.] Univ Penn, Philadelphia, PA 19104 USA.
   [Feemster, Kristen A.] Philadelphia Dept Publ Hlth, 1101 Market St, Philadelphia, PA 19107 USA.
RP Feemster, KA (reprint author), Childrens Hosp Philadelphia, Vaccine Educ Ctr, 3615 Civ Ctr Blvd,Suite 1202 ARC, Philadelphia, PA 19104 USA.
EM fawole@email.chop.edu; srivastavt@email.chop.edu;
   feemster@email.chop.edu
OI Feemster, Kristen/0000-0003-0822-5688; Srivastava,
   Tuhina/0000-0002-9684-9759
FU Vaccine Education Center at the Children's Hospital of Philadelphia
FX We would like to acknowledge: Charlotte Moser for study design input and
   manuscript review; Caitlin Fasano for study design input; and the
   Vaccine Education Center at the Children's Hospital of Philadelphia for
   support of this project.
CR Advisory Committee for Immunization Practices, 2018, BIRTH 18 YEARS CATCH
   [Anonymous], 2017, MENINGOCOCCAL DIS US
   Benjamin SM, 2016, INFLUENZA RES TREAT, V2016, DOI [10.1155/201614248071, DOI 10.1155/201614248071]
   Board of Regents legal definition, FREE DICT
   Centers for Disease Control and Prevention, 2012, CDC STD SURV 2011 CE
   Centers for Disease Control and Prevention, 2017, MEN COMM SETT RISK F
   Ellis R., 2019, NPR SHOTS HLTH NEWS
   Fawole OA, 2018, J ADOLESCENT HEALTH, V63, P286, DOI 10.1016/j.jadohealth.2018.06.013
   Feemster KA, 2017, PED AC SOC ANN M SAN
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   IMREY PB, 1995, J CLIN MICROBIOL, V33, P3133, DOI 10.1128/JCM.33.12.3133-3137.1995
   Jewett A, 2016, J AM COLL HEALTH, V64, P409, DOI 10.1080/07448481.2015.1117465
   Kumar A, 2005, PEDIATR CLIN N AM, V52, P229, DOI 10.1016/j.pcl.2004.10.009
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lefkowitz ES, 2014, WOMEN HEALTH, V54, P487, DOI 10.1080/03630242.2014.903552
   Leung J, 2016, J AM COLL HEALTH, V64, P490, DOI 10.1080/07448481.2016.1138481
   MacDougall DM, 2017, VACCINE, V35, P2520, DOI 10.1016/j.vaccine.2017.02.011
   Mandal S, 2013, CLIN INFECT DIS, V57, P344, DOI 10.1093/cid/cit243
   McNamara LA, 2015, PEDIATRICS, V135, P798, DOI 10.1542/peds.2014-4015
   Milistein SG, 2003, J RES ADOLESCENCE, V12, P399, DOI [10.1111/1532-779500039, DOI 10.1111/1532-779500039]
   Noesekabel A, 2017, VACCINE, V35, P3661, DOI 10.1016/j.vaccine.2017.05.038
   Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1
   Sandler K, 2019, J AM COLL HEALTH, DOI 10.1080/07448481.2019.1583660
   Schaffner W, 2014, INFECT DIS CLIN PRAC
   Thompson EL, 2016, PREV MED, V86, P92, DOI 10.1016/j.ypmed.2016.02.003
   Zipprich Jennifer, 2012, Morbidity and Mortality Weekly Report, V61, P986
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4118
EP 4123
DI 10.1016/j.vaccine.2019.05.073
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700034
PM 31164307
DA 2020-05-12
ER

PT J
AU Liao, QY
   Lam, WWT
   Wong, CKH
   Lam, C
   Chen, J
   Fielding, R
AF Liao, Qiuyan
   Lam, Wendy Wing Tak
   Wong, Carlos King Ho
   Lam, Cherry
   Chen, Jing
   Fielding, Richard
TI The relative effects of determinants on Chinese adults' decision for
   influenza vaccination choice: What is the effect of priming?
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Preference; Priming; Risk judgment
ID SEASONAL INFLUENZA; ELDERLY-PEOPLE; BEHAVIOR; IMPACT; RISK; FOOD;
   METAANALYSIS; PREFERENCES; ACCEPTANCE; EMOTION
AB Objectives: To assess the relative effects of altering different factors (attributes) related to adults' decision for influenza vaccination choice, and whether priming modifies these relative effects.
   Methods: Chinese adults were randomly allocated to either a control condition (non-risk related video), or one of the three health risk-priming conditions (disease (influenza) risk video, intervention (vaccine) risk video, or non-specific (air pollution) risk video), each comprising similar to 200 participants, prior to a discrete choice experiment survey. Mixed logit modelling estimated the relative effects of predetermined attributes influencing vaccination choice.
   Results: Across all four conditions, for determining vaccination choice, Vaccine Efficacy had a greater effect than social cues (community vaccination coverage rate (CVCR) and doctors' advice) but social cues can compensate for the effect of "uncertain" vaccine safety; influenza case-fatality ratio (CFR) became dominantly important among all included attributes when it reached 20%; vaccination preference increased when a CVCR changed incrementally from 5% to 60% but declined thereafter when the CVCR reached 80%. Compared with Control participants, a CVCR increased by 80% had a smaller effect for participants primed by intervention risk on vaccination choice, while the effect of influenza risk relative to vaccine risk increased following disease risk priming.
   Conclusion: While increasing confidence on vaccine efficacy is more important for influenza with less severe consequences, highlighting disease consequences becomes increasingly important when its CFR increases, for promoting vaccination uptake. For a new vaccine with uncertain safety, involving doctors and early vaccine takers to validate vaccine safety should be important. Brief exposure to influenza/vaccine risk didn't increase the effect of specific risk on vaccination choice but may change the relative weight of disease versus intervention risk when individuals make trade-off for vaccination decision. Free riding on herd immunity may increase when community vaccination coverage is high particularly following intervention risk priming. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liao, Qiuyan; Lam, Wendy Wing Tak; Lam, Cherry; Fielding, Richard] Univ Hong Kong, Sch Publ Hlth, Div Behav Sci, Hong Kong, Peoples R China.
   [Wong, Carlos King Ho] Univ Hong Kong, Dept Family Med & Primary Care, Hong Kong, Peoples R China.
   [Chen, Jing] Univ Hong Kong, Sch Nursing, Hong Kong, Peoples R China.
RP Liao, QY (reprint author), Univ Hong Kong, Sch Publ Hlth, Pokfulam, 7 Sassoon Rd, Hong Kong, Peoples R China.
EM qyliao11@hku.hk; wwtlam@hku.hk; carlosho@hku.hk; cylam1@hku.hk;
   pianogal@hku.hk; fielding@hku.hk
RI Lam, Wendy Wing Tak/C-4319-2009
OI Lam, Wendy Wing Tak/0000-0003-2383-0149; , Qiuyan/0000-0002-1105-6857
FU Health Medical Research Funding, Food and Health Bureau, Government of
   Hong Kong [14130942]
FX This work was supported by the Health Medical Research Funding, Food and
   Health Bureau, Government of Hong Kong [grant number 14130942, 2015].
CR Asllani A, 2011, J MED SYST, V35, P1465, DOI 10.1007/s10916-009-9423-1
   Bar-Haim Y, 2007, PSYCHOL BULL, V133, P1, DOI 10.1037/0033-2909.133.1.1
   Bargh JA, 2008, PERSPECT PSYCHOL SCI, V3, P73, DOI 10.1111/j.1745-6916.2008.00064.x
   Barsalou LW, 2009, PHILOS T R SOC B, V364, P1281, DOI 10.1098/rstb.2008.0319
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Bhattacharyya S, 2011, VACCINE, V29, P5519, DOI 10.1016/j.vaccine.2011.05.028
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9
   Cohen J., 1988, STAT POWER ANAL BEHA
   CONNER M, 2005, PREDICTING HLTH BEHA
   de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054
   Determann D, 2016, EUROSURVEILLANCE, V21, P20, DOI 10.2807/1560-7917.ES.2016.21.22.30247
   Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505
   Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343
   Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146
   EDWARDS W, 1961, ANNU REV PSYCHOL, V12, P473, DOI 10.1146/annurev.ps.12.020161.002353
   Eilers R, 2017, VACCINE, V35, P2823, DOI 10.1016/j.vaccine.2017.04.014
   Falagas ME, 2006, CRIT CARE, V10, DOI 10.1186/cc4910
   Fu F, 2011, P ROY SOC B-BIOL SCI, V278, P42, DOI 10.1098/rspb.2010.1107
   Fu LDY, 2017, VACCINE, V35, P802, DOI 10.1016/j.vaccine.2016.12.045
   Gaillet-Torrent M, 2014, APPETITE, V76, P17, DOI 10.1016/j.appet.2014.01.009
   Garske T, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2840
   Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004
   Hollands GJ, 2016, HEALTH PSYCHOL, V35, P847, DOI 10.1037/hea0000293
   Hong Kong Census and Statistics Department, 2016, 2016 POP BY CENS
   Houlihan S, 2018, PUBLIC HEALTH, V156, P52, DOI 10.1016/j.puhe.2017.11.002
   Husemann S, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1742-1
   Jefferson T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub4
   KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185
   Kahneman D, 2011, THINKING FAST SLOW
   Kan T, 2018, PUBLIC HEALTH, V156, P67, DOI 10.1016/j.puhe.2017.12.007
   King D, 2016, HEALTH PSYCHOL, V35, P96, DOI 10.1037/hea0000239
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233
   Li FCK, 2008, J EPIDEMIOL COMMUN H, V62, P555, DOI 10.1136/jech.2007.064030
   Liao Q, 2013, VACCINE, V31, P4084, DOI 10.1016/j.vaccine.2013.07.009
   Liao QY, 2016, INT J BEHAV MED, V23, P621, DOI 10.1007/s12529-016-9551-1
   Liao QY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017713
   Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267
   Lu PJ, 2017, VACCINE, V35, P4346, DOI 10.1016/j.vaccine.2017.06.074
   Mason BW, 2000, J EPIDEMIOL COMMUN H, V54, P473, DOI 10.1136/jech.54.6.473
   MATHEWS A, 1993, COGNITION EMOTION, V7, P517, DOI 10.1080/02699939308409203
   Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080
   Merz B, 2009, NAT HAZARD EARTH SYS, V9, P1033, DOI 10.5194/nhess-9-1033-2009
   Papies EK, 2008, J EXP SOC PSYCHOL, V44, P1283, DOI 10.1016/j.jesp.2008.04.008
   Papies EK, 2016, HEALTH PSYCHOL REV, V10, P408, DOI 10.1080/17437199.2016.1183506
   Parker AM, 2013, AM J PREV MED, V45, P118, DOI 10.1016/j.amepre.2013.02.016
   Reintjes R, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0151258, 10.1371/journal.pone.0]
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Ryan M, 2008, ECON NON-MARK GOOD, V11, P1, DOI 10.1007/978-1-4020-5753-3
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Slovic P, 2004, RISK ANAL, V24, P311, DOI 10.1111/j.0272-4332.2004.00433.x
   SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559
   Wang LDL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-133
   Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249
   Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506
   Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459
NR 59
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4124
EP 4132
DI 10.1016/j.vaccine.2019.05.072
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700035
PM 31186189
DA 2020-05-12
ER

PT J
AU Chang, J
   Hou, ZY
   Fang, H
   Meng, QY
AF Chang, Jie
   Hou, Zhiyuan
   Fang, Hai
   Meng, Qingyue
TI Are providers' recommendation and knowledge associated with uptake of
   optional vaccinations among children? A multilevel analysis in three
   provinces of China
SO VACCINE
LA English
DT Article
ID MIDDLE-INCOME COUNTRIES; PARENTAL MIGRATION; ROTAVIRUS VACCINE;
   HEALTH-WORKERS; IMMUNIZATION; DETERMINANTS; COVERAGE; BELIEFS; YOUNGER;
   DISEASE
AB Background: Immunization services providers play a crucial role in the successful implementation of immunization, particularly for new vaccines. Several childhood vaccinations that are important for public health are not included in the National Immunization Programme in China, although they are available as optional and self-paid vaccines. Their coverage remains low.
   Objective: To examine the association between providers' knowledge and recommendations of optional vaccines, as well as other supply- and demand-side factors, and their uptake among children.
   Methods: A cross-sectional study, that included an in-person questionnaire survey for parents of children under-3 years and a self-administrative questionnaire survey for their vaccination services providers, was conducted in 36 townships or sub-districts in three provinces of China in 2013. Using a sample of 1791 household from 30 townships or sub-districts, we applied multilevel logistic analyses to examine the factors associated with the uptake of optional vaccines based on a hierarchal framework that combined demand-side and supply-side factors.
   Results: Coverage of optional childhood vaccinations varied across small areas. Supply- and demand-side factors were both associated with the uptake of these vaccines. Immunization services providers' recommendations and their knowledge about optional vaccination were positively and significantly associated with uptake. Children were more likely to receive the vaccines if they lived in communities with higher immunization worker density or larger immunization clinics. Several demand-side psychological factors about childhood vaccination were also associated with optional vaccinations.
   Conclusions: Promoting immunization services providers to conduct evidence-based recommendations about some important childhood optional vaccinations and enhancing their knowledge regarding optional vaccinations and communication skills are useful strategies to increase the coverage of these vaccinations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chang, Jie] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian 710061, Shaanxi, Peoples R China.
   [Chang, Jie] Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian 710061, Shaanxi, Peoples R China.
   [Hou, Zhiyuan] Fudan Univ, Collaborat Innovat Ctr Social Risks Governance Hl, Natl Key Lab Hlth Technol Assessment, Natl Hlth Commiss,Sch Publ Hlth, Shanghai 200032, Peoples R China.
   [Fang, Hai; Meng, Qingyue] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China.
RP Meng, QY (reprint author), Peking Univ, China Ctr Hlth Dev Studies, Beijing 100191, Peoples R China.
EM qmeng@bjmu.edu.cn
RI Chang, Jie/AAE-5797-2019
OI Chang, Jie/0000-0001-7296-8641
FU National Health Commission of P. R. China; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [71503196]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2015M580862, 2016T90935]
FX This study was supported by the National Health Commission of P. R.
   China. Jie Chang acknowledges support from the National Natural Science
   Foundation of China (71503196) and the China Postdoctoral Science
   Foundation (2015M580862, 2016T90935). The authors also thank Quanle Li,
   Yun Feng, Jingshan Zheng, Dahai Yue, Qiong Wu, Yang Sun, and Qing Wang
   for their invaluable effort and support that made this study possible.
CR Abebe DS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1075
   Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Center for Health Statistics and Information, 2008, AN REP NAT HLTH SERV
   Center for Health Statistics and Information of National Health and Family Planning Committee, 2013, AN REP 5 NAT HLTH SE
   Connors JT, 2017, J PEDIATR NURS, V33, P10, DOI 10.1016/j.pedn.2016.11.002
   Cui SH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2013-1
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   Fu CX, 2010, PEDIATR INFECT DIS J, V29, P690, DOI 10.1097/INF.0b013e3181d7380e
   Ghosh A, 2017, VACCINE, V35, P1087, DOI 10.1016/j.vaccine.2016.12.024
   He Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068169
   Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047
   Hu Y., 2016, E CHINA INT J ENV RE, V13, P560
   Hu Y, 2015, HUM VACC IMMUNOTHER, V11, P761, DOI 10.1080/21645515.2015.1012015
   Hu Y, 2014, INT J ENV RES PUB HE, V11, P5555, DOI 10.3390/ijerph110505555
   Kaddar M, 2013, VACCINE, V31, pB81, DOI 10.1016/j.vaccine.2012.11.085
   Li Y, 2018, HUM VACC IMMUNOTHER, V14, P894, DOI 10.1080/21645515.2017.1420447
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Makinen M, 2012, HEALTH POLICY PLANN, V27, pII39, DOI 10.1093/heapol/czs036
   Malosh R, 2014, VACCINE, V32, P1841, DOI 10.1016/j.vaccine.2014.01.075
   Mergler MJ, 2013, VACCINE, V31, P4591, DOI 10.1016/j.vaccine.2013.07.039
   Morin A, 2012, VACCINE, V30, P5921, DOI 10.1016/j.vaccine.2012.07.050
   National Bureau of Statistics, 2017, CHIN STAT YB
   National Bureau of Statistics of China, CHIN STAT YB 2014
   Ni ZL, 2017, EPIDEMIOL INFECT, V145, P1763, DOI 10.1017/S0950268817000589
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Pandolfi E, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-984
   Phillips DE, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2626-0
   Phillips N, 2018, NATURE, V560, P14, DOI 10.1038/d41586-018-05835-1
   Qiu J, 2016, LANCET, V387, P2382, DOI 10.1016/S0140-6736(16)30737-1
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   State Council, REG VACC SUPPL VACC
   Streng A, 2010, VACCINE, V28, P5738, DOI 10.1016/j.vaccine.2010.06.007
   Sturm LA, 2005, J DEV BEHAV PEDIATR, V26, P441, DOI 10.1097/00004703-200512000-00009
   Tang XY, 2016, TROP MED INT HEALTH, V21, P886, DOI 10.1111/tmi.12719
   The Asia Pacific Observatory on Health Systems and Policies. People's Republic of China Health System Review, 2015, HLTH SYSTEMS TRANSIT, V5
   van Lier A, 2014, EUR J PUBLIC HEALTH, V24, P304, DOI 10.1093/eurpub/ckt042
   Wagner AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097800
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   WHO UNICEF World-Bank., 2009, STATE WORLD VACCINES
   Wu D, 2016, PEDIATR INFECT DIS J, V35, pE392, DOI 10.1097/INF.0000000000001327
   Yu HJ, 2012, HEALTH AFFAIR, V31, P2545, DOI 10.1377/hlthaff.2011.1272
   Yu WZ, 2016, INT J EPIDEMIOL, V45, P441, DOI 10.1093/ije/dyv349
   Zhang SK, 2013, VACCINE, V31, P3244, DOI 10.1016/j.vaccine.2013.05.046
   Zhang XY, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0802-4
   Zheng J-s, 2012, CHIN J VACCINES IMMU, P233
   Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039
   Zhou CC, 2015, HEALTH AFFAIR, V34, P1964, DOI 10.1377/hlthaff.2015.0150
NR 51
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4133
EP 4139
DI 10.1016/j.vaccine.2019.05.070
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700036
PM 31174935
DA 2020-05-12
ER

PT J
AU Bell, CA
   Russell, ML
   Drews, SJ
   Simmonds, KA
   Svenson, LW
   Schwartz, KL
   Kwong, JC
   Mahmud, SM
   Crowcroft, NS
AF Bell, Christopher A.
   Russell, Margaret L.
   Drews, Steven J.
   Simmonds, Kimberley A.
   Svenson, Lawrence W.
   Schwartz, Kevin L.
   Kwong, Jeffrey C.
   Mahmud, Salaheddin M.
   Crowcroft, Natasha S.
TI Acellular pertussis vaccine effectiveness and waning immunity in
   Alberta, Canada: 2010-2015, a Canadian Immunization Research Network
   (CIRN) study
SO VACCINE
LA English
DT Article
DE Acellular pertussis vaccine; Whooping cough; Vaccine effectiveness;
   Waning immunity; Epidemiology; Canada
ID BORDETELLA-PERTUSSIS; TIME
AB Background: Pertussis is still frequently reported in Canada. In Alberta, pertussis incidence ranged from 1.8 to 20.5 cases per 100,000 persons for 2004-2015. Most cases occurred in those aged <15 years. In Alberta, acellular formulations replaced whole-cell in 1997. We investigated pertussis vaccine effectiveness (VE) using a test-negative design (TND) study.
   Methods: We included all persons who had a real-time PCR laboratory test for Bordetella pertussis between January 1, 2010 and August 31, 2015, in the province of Alberta, Canada. Vaccination history was obtained from Alberta's immunization repository. Vaccination status was classified as complete, incomplete, or unvaccinated, based on the province's vaccination schedule. Persons who had received >= one dose of whole cell vaccine were excluded from analysis. Multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for pertussis infection by time since last vaccination. We adjusted for vaccination status, age, sex, neighbourhood income, urban/rural status, and the presence of a co-morbid condition. VE was calculated as [(1 - aOR) * 100].
   Results: Of the 12,149 tests available, 936 (7.7%) were positive for Bordetella pertussis. Among the full cohort, VE was 90% (95% CI 87-92%) at 1 year, 81% (95% CI 77-85%) at 1-3 years, 76% (95% CI 68-82%) at 4-7 years, and 37% (95% CI 11-56%) at 8 or more years since a last dose of acellular pertussis vaccine.
   Conclusions: Pertussis VE was highest in the first year after vaccination, then declined noticeably as years since a last vaccination increased. Our results suggest that a large number of adolescents and adults are susceptible to infection with Bordetella pertussis. Regular boosters throughout childhood, adolescence, and during pregnancy may be needed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bell, Christopher A.; Russell, Margaret L.; Simmonds, Kimberley A.; Svenson, Lawrence W.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, 3280 Hosp Dr NW, Calgary, AB T2N 3Z6, Canada.
   [Drews, Steven J.] Univ Alberta Hosp, Alberta Hlth Serv, ProvLab Alberta, Diagnost Virol, 2B1-03 WMC,8440-112 St, Edmonton, AB T6G 2J2, Canada.
   [Drews, Steven J.] Univ Alberta, Dept Lab Med & Pathol, 4B1-19 WMC, Edmonton, AB T6G 2J2, Canada.
   [Simmonds, Kimberley A.; Svenson, Lawrence W.] Alberta Minist Hlth, 10025 Jasper Ave, Edmonton, AB T5J 1S6, Canada.
   [Svenson, Lawrence W.] Univ Alberta, Fac Med & Dent, Div Prevent Med, 22F Univ Terrace,8303 112 ST NW, Edmonton, AB T6G 2T4, Canada.
   [Svenson, Lawrence W.] Univ Alberta, Sch Publ Hlth, 3-300 Edmonton Clin Hlth Acad,11405 87 Ave NE, Edmonton, AB T6G 1C9, Canada.
   [Schwartz, Kevin L.; Kwong, Jeffrey C.; Crowcroft, Natasha S.] Univ Toronto, Dalla Lana Sch Publ Hlth, 155 Coll St,6th Floor, Toronto, ON M5T 3M7, Canada.
   [Schwartz, Kevin L.; Kwong, Jeffrey C.; Crowcroft, Natasha S.] Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
   [Schwartz, Kevin L.; Kwong, Jeffrey C.; Crowcroft, Natasha S.] ICES, 2075 Bayview Ave,Room G1-06, Toronto, ON M4N 3M5, Canada.
   [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, 500 Univ Ave,5th Floor, Toronto, ON M5G 1V7, Canada.
   [Mahmud, Salaheddin M.] Univ Manitoba, Vaccine & Drug Evaluat Ctr, Fac Hlth Sci, Room 5113-750 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.
   [Crowcroft, Natasha S.] Univ Toronto, Lab Med & Pathobiol, 1 Kings Coll Circle,6th Floor, Toronto, ON M5S 1A8, Canada.
RP Russell, ML (reprint author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, 3280 Hosp Dr NW, Calgary, AB T2N 3Z6, Canada.
EM mlrussel@ucalgary.ca
OI Crowcroft, Natasha/0000-0002-6761-8783
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [137470]; Canadian Immunization Research Network [PC01
   AB03]; Alberta Ministry of Health [RSO 1026380]; University of Calgary
   [RSO 1026380]
FX This work was supported by the Canadian Institutes of Health Research
   (grant #137470; Canadian Immunization Research Network, sub grant PC01
   AB03), and a research agreement between the Alberta Ministry of Health
   and the University of Calgary (RSO 1026380).
CR Ad Hoc Group for the Study of Pertussis Vaccines, 1988, LANCET, V1, P955
   *ALB HLTH, 2017, OV ADM HLTH DAT
   Alberta Health, 2017, HIST BIOL ADM ALB
   Alberta Health, 2017, IMM DAT SUBM RESP GU
   Alberta Health, 2018, INT HLTH DAT APPL
   Alberta Health, 2015, NOT DIS DIS SURV LIS
   Canadian Immunization Research Network (CIRN), 2018, MULT APPR EV PERT VA
   Centers for Disease Control and Prevention (CDC), 2017, PERT SURV REP
   Cherry JD, 2015, CURR EPIDEMIOL REV, V2, P120
   CODY CL, 1981, PEDIATRICS, V68, P650
   Crowcroft NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195984
   Fathima S, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-48
   Feudtner C, 2000, PEDIATRICS, V106, P205
   Fisman DN, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-694
   Gilbert NL, 2017, HUM VACC IMMUNOTHER, V13, P1447, DOI 10.1080/21645515.2016.1277847
   Government of Alberta, 2000, PUBL HLTH ACT
   Guiso N, 2014, J INFECTION, V68, pS119, DOI 10.1016/j.jinf.2013.09.022
   Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850
   Liu XFC, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4468-4
   Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939
   National Advisory Committee on Immunization (NACI), 2018, UPD IMM PREGN TET TO
   Palmer CM, 2007, COMMUN DIS INTELL, V31, P202
   PHAC, 2010, PATH SAF DAT SHEETS
   Public Health Agency of Canada (PHAC), 2013, VACC COV CAN CHILDR
   Public Health Agency of Canada (PHAC), 2018, CAN PROV TERR ROUT C
   Public Health Agency of Canada (PHAC), 2018, VACC COV GOALS VACC
   Public Health Agency of Canada (PHAC), 2018, CAN NOT DIS SURV SYS
   Public Health Agency of Canada (PHAC), 2014, PERT WHOOP COUGH
   Reischl U, 2001, J CLIN MICROBIOL, V39, P1963, DOI 10.1128/JCM.39.5.1963-1966.2001
   Riolo MA, 2013, VACCINE, V31, P5903, DOI 10.1016/j.vaccine.2013.09.020
   Schwartz KL, 2016, CAN MED ASSOC J, V188, pE399, DOI 10.1503/cmaj.160193
   Simmonds K, 2014, INT J INFECT DIS, V29, P223, DOI 10.1016/j.ijid.2014.10.028
   Tartof SY, 2013, PEDIATRICS, V131, pE1047, DOI 10.1542/peds.2012-1928
   World Health Organization, 2015, PERT VACC WHO POS PA, V90, P433
NR 34
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4140
EP 4146
DI 10.1016/j.vaccine.2019.05.067
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700037
PM 31164304
DA 2020-05-12
ER

PT J
AU Gessner, BD
   Jiang, Q
   Van Werkhoven, CH
   Sings, HL
   Webber, C
   Scott, D
   Gruber, WC
   Grobbee, DE
   Bonten, MJM
   Jodar, L
AF Gessner, Bradford D.
   Jiang, Qin
   Van Werkhoven, Cornelis H.
   Sings, Heather L.
   Webber, Chris
   Scott, Daniel
   Gruber, William C.
   Grobbee, Diederick E.
   Bonten, Marc J. M.
   Jodar, Luis
TI A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent
   pneumococcal conjugate vaccine against clinical community acquired
   pneumonia from a randomized clinical trial in the Netherlands
SO VACCINE
LA English
DT Article
DE Community acquired pneumonia; Pneumococcal conjugate vaccine; Randomized
   controlled trial; Serotype; Vaccine efficacy
ID SEQUENTIAL INTRODUCTION; DISEASE; CHILDREN; ENGLAND; ADULTS; WALES;
   OLDER
AB Background: Serotype-specific vaccine efficacy (VE) against adult community acquired pneumonia (CAP) remains poorly defined, yet such data are important for assessing the utility of adult pneumococcal conjugate vaccine (PCV) programs.
   Methods: We evaluated the Community Acquired Pneumonia Immunization Trial in Adults to assess serotype-specific VE for CAP. This parallel-arm randomized clinical trial assessed 13-valent PCV (PCV13) VE among community dwelling persons aged >= 65 years in The Netherlands. In the original analysis, PCV13 VE against first episodes of vaccine-type (VT) chest radiology confirmed CAP was 45.6% (95% confidence interval [CI] 21.8-62.5%). Unlike the original analysis, we included any subject that met a clinical definition of CAP regardless of radiographic findings. VT-CAP was identified by culture (sterile or nonsterile) or serotype-specific urinary antigen detection (SSUAD) test. Only the five serotypes with at least 10 episodes in the control arm, based on the original analysis, were included for VE assessment.
   Results: Of 272 clinical CAP visits with VT serotypes identified, 253 (93%) were identified by SSUAD including 210 (77%) by SSUAD alone. VE was determined for serotypes 1, 3, 6A, 7F, and 19A, with total first episodes of, respectively, 27, 36, 25, 38, and 48. VE (95%C1) for the five evaluated serotypes against first clinical CAP episodes were: serotype 1, 20.0% (-83.1% to 65.8%); serotype 3, 61.5% (17.6-83.4%); serotype 6A, 33.3% (-58.6% to 73.2%); serotype 7F, 73.3% (40.5-89.4%); and serotype 19A, 45.2% (-2.2% to 71.5%).
   Discussion: Statistically significant VE was observed for serotypes 3 and 7F for clinical CAP among elderly community dwelling adults. The VE point estimates and Cls for serotypes 1, 6A, and 19A were lower but consistent with the overall VT-CAP VE of 45.6% previously reported. These findings may be relevant in models to accurately account for the potential impact of adult PCV13 immunization. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Gessner, Bradford D.; Jiang, Qin; Sings, Heather L.; Jodar, Luis] Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
   [Van Werkhoven, Cornelis H.; Grobbee, Diederick E.; Bonten, Marc J. M.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Webber, Chris; Scott, Daniel; Gruber, William C.] Pfizer Vaccines, Clin Res & Dev, Hurley, England.
   [Grobbee, Diederick E.] Acad Contract Res Org, Fulius Clin, Zeist, Netherlands.
   [Bonten, Marc J. M.] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands.
RP Gessner, BD (reprint author), Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM Bradford.gessner@Pfizer.com
FU Pfizer Inc.Pfizer
FX This study was sponsored by Pfizer Inc. The sponsor was involved with
   study concept and design, conduct, analysis and interpretation of the
   data, drafting of the manuscript, and the decision to submit the
   manuscript for publication. The corresponding author had full access to
   the study data and had final responsibility for the decision to submit
   for publication.
CR [Anonymous], 2015, 1253241196 STN PFIZ
   Azarian T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006966
   Ben-Shimol S, 2014, CLIN INFECT DIS, V59, P1724, DOI 10.1093/cid/ciu683
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   Gessner BD, 2018, VACCINE
   Hak E, 2008, NETH J MED, V66, P378
   Hanquet G, 2018, THORAX
   Huijts SM, 2013, EUR RESPIR J, V42, P1283, DOI 10.1183/09031936.00137412
   KUNDEL HL, 1989, SEMIN RESPIR MED, V10, P203, DOI 10.1055/s-2007-1006173
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Mackenzie G, 2016, PNEUMONIA, V8, DOI 10.1186/s41479-016-0012-z
   MELBYE H, 1992, ACTA RADIOL, V33, P79
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Patterson S., 2016, Trials in Vaccinology, V5, P92, DOI 10.1016/j.trivac.2016.04.004
   Regev-Yochay G, 2015, VACCINE, V33, P1135, DOI 10.1016/j.vaccine.2015.01.030
   Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]
   Sings HL, 2018, CLIN INFECT DIS
   Suzuki M, 2017, LANCET INFECT DIS, V17, P313, DOI [10.1016/S1473-3099(17)30049-X, 10.1016/s1473-3099(17)30049-x]
   von Mollendorf C, 2016, EMERG INFECT DIS, V22, P261, DOI 10.3201/eid2202.150967
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Wunderink RG, 2018, CLIN INFECT DIS, V66, P1504, DOI 10.1093/cid/cix1066
NR 22
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4147
EP 4154
DI 10.1016/j.vaccine.2019.05.065
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700038
PM 31155413
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Hwang, CS
   Smith, LC
   Wenthur, CJ
   Ellis, B
   Zhou, B
   Janda, KD
AF Hwang, Candy S.
   Smith, Lauren C.
   Wenthur, Cody J.
   Ellis, Beverly
   Zhou, Bin
   Janda, Kim D.
TI Heroin vaccine: Using titer, affinity, and antinociception as metrics
   when examining sex and strain differences
SO VACCINE
LA English
DT Article
DE Heroin; Sex differences; Strain; Mouse; Conjugate vaccine
ID EFFICACY; MORPHINE; COCAINE; HAPTEN; INTERLEUKIN-1-BETA; METABOLITES;
   ANTIBODIES; TOLERANCE; ANALGESIA; MICE
AB Anti-drug vaccines have potential as new interventions against substance use disorder (SUD). However, given the challenges seen with inter-individual variability in SUD vaccine trials to date, new interventions should ensure a robust immune response and safety profile among a diverse population. This requires accounting for sex and heritable genetic differences in response to both abused substances as well as the vaccination itself. To test response variability to our heroin-tetanus toxoid (Her-TT) immunoconjugate vaccine, we vaccinated male and female mice from several mouse strains including Swiss Webster (SW), BALB/c, and Jackson diversity mice (J:DO). Previous studies with vaccinated male SW mice demonstrated a rare hypersensitivity resulting in mice rapidly expiring with exposure to a low dose of heroin. Our results indicate that this response is limited to only male SW mice, and not to any other strain or female SW mice. Our data suggest that this hypersensitivity is not the result of an overactive cytokine or IgE response. Vaccination was similarly effective among the sexes for each strain and against repeated heroin challenge. Inbred BALB/c and J:DO mice were found to have the best vaccine response against heroin in antinociception behavioral assay. These results highlight the importance of incorporating both male and female subjects, along with different strains to mimic diverse human populations, as new SUD vaccines are being tested. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hwang, Candy S.; Smith, Lauren C.; Wenthur, Cody J.; Ellis, Beverly; Zhou, Bin; Janda, Kim D.] Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem Immunol & Microbial Sci, La Jolla, CA 92037 USA.
   [Hwang, Candy S.] Southern Connecticut State Univ, Dept Chem, 501 Crescent St, New Haven, CT 06515 USA.
   [Wenthur, Cody J.] Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
RP Janda, KD (reprint author), Scripps Res Inst, Dept Chem, BCC 582,10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM kdjanda@scripps.edu
OI Smith, Lauren/0000-0002-4290-3262; Wenthur, Cody/0000-0001-6043-3842;
   Hwang, Candy/0000-0003-2826-4078
FU National Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [UH3DA041146]
FX This work was supported by the National Institute of Health under grant
   UH3DA041146.
CR Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654
   Bremer PT, 2014, MOL PHARMACEUT, V11, P1075, DOI 10.1021/mp400631w
   Bremer PT, 2017, J AM CHEM SOC
   Brimijoin S, 2013, EXPERT REV VACCINES, V12, P323, DOI [10.1586/ERV.13.1, 10.1586/erv.13.1]
   Bugelski PJ, 2009, EXPERT REV CLIN IMMU, V5, P499, DOI 10.1586/ECI.09.31
   Centers for Disease Control and Prevention, 2018, ANN SURV REP DRUG RE
   Claycomb RJ, 2012, NEUROBIOL DIS, V45, P234, DOI 10.1016/j.nbd.2011.08.007
   French JE, 2015, ENVIRON HEALTH PERSP, V123, P237, DOI 10.1289/ehp.1408202
   Gooyit M, 2017, ACS CHEM NEUROSCI, V8, P468, DOI 10.1021/acschemneuro.6b00389
   Greenspan JD, 2007, PAIN, V132, pS26, DOI 10.1016/j.pain.2007.10.014
   Hoogsteder PHJ, 2014, ADDICTION, V109, P1252, DOI 10.1111/add.12573
   Hoozemans JJM, 2001, EXP GERONTOL, V36, P559, DOI 10.1016/S0531-5565(00)00226-6
   Hwang CS, 2019, BIOORGAN MED CHEM, V27, P125, DOI 10.1016/j.bmc.2018.11.027
   Hwang CS, 2018, ACS CHEM NEUROSCI, V9, P1269, DOI 10.1021/acschemneuro.8b00079
   Hwang CS, 2018, MOL PHARMACEUT, V15, P1062, DOI 10.1021/acs.molpharmaceut.7b00933
   Jalah R, 2015, BIOCONJUGATE CHEM, V26, P1041, DOI 10.1021/acs.bioconjchem.5b00085
   Karinen R, 2009, J ANAL TOXICOL, V33, P345, DOI 10.1093/jat/33.7.345
   Kest B, 1999, J PHARMACOL EXP THER, V289, P1370
   Kimishima A, 2016, ACS CHEM BIOL
   Kosten T, 2014, BRIT J CLIN PHARMACO, V77, P368, DOI 10.1111/bcp.12115
   Kosten TR, 2002, VACCINE, V20, P1196, DOI 10.1016/S0264-410X(01)00425-X
   Matyas GR, 2013, VACCINE, V31, P2804, DOI 10.1016/j.vaccine.2013.04.027
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689
   Negus SS, 2003, NEUROPSYCHOPHARMACOL, V28, P919, DOI 10.1038/sj.npp.1300096
   Ohia-Nwoko O, 2016, INT REV NEUROBIOL, V126, P263, DOI 10.1016/bs.irn.2016.02.009
   Ponce R, 2008, J IMMUNOTOXICOL, V5, P33, DOI 10.1080/15476910801897920
   Pravetoni M, 2016, HUM VACC IMMUNOTHER, V12, P3005, DOI 10.1080/21645515.2016.1212785
   Schlosburg JE, 2013, P NATL ACAD SCI USA, V110, P9036, DOI 10.1073/pnas.1219159110
   Smith LC, 2018, CHEM RES TOXICOL
   Sulima A, 2018, J MED CHEM, V61, P329, DOI 10.1021/acs.jmedchem.7b01427
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   YOBURN BC, 1989, PHARMACOL BIOCHEM BE, V32, P727, DOI 10.1016/0091-3057(89)90025-7
   YOBURN BC, 1990, BRAIN RES, V529, P143, DOI 10.1016/0006-8993(90)90821-R
   Yuill MB, 2016, NEUROREPORT, V27, P392, DOI 10.1097/WNR.0000000000000551
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4155
EP 4163
DI 10.1016/j.vaccine.2019.05.061
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700039
PM 31176539
DA 2020-05-12
ER

PT J
AU Cilleruelo, MJ
   Fernandez-Garcia, A
   Villaverde, S
   Echevarria, J
   Marin, MA
   Sanz, JC
   Lopez, A
   Royuela, A
   Antoran, BR
   de Ory, F
AF Jose Cilleruelo, Maria
   Fernandez-Garcia, Aurora
   Villaverde, Serena
   Echevarria, Juan
   Angel Marin, Miguel
   Carlos Sanz, Juan
   Lopez, Agustin
   Royuela, Ana
   Ruiz Antoran, Belen
   de Ory, Fernando
TI Duration of immunity to measles, rubella and mumps during the first year
   of life
SO VACCINE
LA English
DT Article
DE Measles; Rubella; Mumps; Passive antibodies; MMR vaccine; ELISA
ID MATERNAL ANTIBODIES; IMMUNOGLOBULIN-G; VACCINE IMMUNOGENICITY; INFANTS
   BORN; CORD BLOOD; VIRUS; 6-MONTH-OLD; PERSISTENCE; VARICELLA; MOTHERS
AB Introduction and objectives: The MMR vaccine was included in the official vaccination schedule in Spain in 1981. Currently, most women of childbearing age are vaccinated and have not been naturally infected. Several studies have shown that vaccinated women have a lower antibody concentration than that achieved after natural infection, and a shorter duration of transplacentally acquired antibodies in their children. The objective of this study was to determine the antibody titer in mothers and their infants at birth and throughout the first year of life under current epidemiological circumstances.
   Material and methods: Single-center, observational, descriptive and prospective study conducted between October 2013 and December 2014. One sample of serum and another of a dried blood spot on filter paper were taken from each mother. Dried blood spot samples on filter paper were taken from the children at birth, and at 3, 6, 9 and 12 months. In all the samples, levels of antibodies to the measles, rubella and mumps viruses were measured using standardized quantitative assays.
   Results: 146 mother-child pairs were included. 78.4%, 86.9% and 67.1% of mothers had antibodies to measles, rubella and mumps, respectively. A decrease in the antibody titer in children was observed after 3 months, and no antibodies against the three diseases were detected by the age of 6 months. Comparisons revealed no statistically significant differences between the antibody titers of children of mothers born before or after 1981 during the first year of their life.
   Discussion: The rapid loss of transplacentally acquired antibodies against measles, rubella and mumps, under current epidemiological conditions, suggests that bringing the MMR vaccination forward to 9 months might be justified. Larger population studies are needed to confirm these results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jose Cilleruelo, Maria; Villaverde, Serena; Angel Marin, Miguel; Lopez, Agustin; Royuela, Ana; Ruiz Antoran, Belen] Hosp Univ Puerta Hierro, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Serv Pediat, Majadahonda 28222, Spain.
   [Fernandez-Garcia, Aurora; Echevarria, Juan; de Ory, Fernando] Inst Hlth Carlos III, Natl Ctr Microbiol, Natl Reference Lab Measles & Rubella Eliminat, Majadahonda 28220, Spain.
   [Carlos Sanz, Juan] Comunidad Madrid, Lab Reg Salud Publ, Madrid 28052, Spain.
   [Fernandez-Garcia, Aurora; Echevarria, Juan; Carlos Sanz, Juan; Royuela, Ana; de Ory, Fernando] CIBERESP, Madrid, Spain.
RP de Ory, F (reprint author), Inst Hlth Carlos III, Natl Ctr Microbiol, Majadahonda 28220, Spain.
EM fory@isciii.es
RI Echevarria, Juan E./F-7913-2016
OI Echevarria, Juan E./0000-0001-7522-850X
FU Fondo de Investigacion Sanitaria [FIS PI12/02006]; CIBER de
   Epidemiologia y Salud Publica [ESPG13]
FX The study was funded by the Fondo de Investigacion Sanitaria (FIS
   PI12/02006), AF-G was funded by CIBER de Epidemiologia y Salud Publica
   (ESPG13).
CR Asamblea Mundial de la Salud, 1998, SAL TOD SIGL 21, V51
   Brugha R, 1996, EPIDEMIOL INFECT, V117, P519, DOI 10.1017/S0950268800059203
   CARSON MM, 1995, PEDIATR INFECT DIS J, V14, P17, DOI 10.1097/00006454-199501000-00003
   Choudhury SA, 2008, J NATL MED ASSOC, V100, P1445, DOI 10.1016/S0027-9684(15)31545-5
   Consejo Interterritorial del Sistema Nacional de Salud, 2018, CAL VAC REC 2018
   DOPATKA HD, 1992, J CLIN LAB ANAL, V6, P417, DOI 10.1002/jcla.1860060614
   Epidemiologia del Sarampion, 2017, RUB SINDR RUB CONG E
   European Centre for Disease Prevention and Control, 2018, MONTHL MEASL RUB MON
   Gagneur A, 2010, EXPERT REV ANTI-INFE, V8, P1339, DOI [10.1586/eri.10.126, 10.1586/ERI.10.126]
   Gans HA, 2013, J INFECT DIS, V208, P1, DOI 10.1093/infdis/jit144
   Glezen WP, 2003, VACCINE, V21, P3389, DOI 10.1016/S0264-410X(03)00339-6
   Goncalves G, 2016, VACCINE, V34, P2750, DOI 10.1016/j.vaccine.2016.04.007
   Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002
   Hogrefe WR, 2002, CLIN DIAGN LAB IMMUN, V9, P1338, DOI 10.1128/CDLI.9.6.1338-1342.2002
   JOHNSON CE, 1994, PEDIATRICS, V93, P939
   Johnson CE, 2000, VACCINE, V18, P2411, DOI 10.1016/S0264-410X(99)00574-5
   Klinge J, 2000, VACCINE, V18, P3134, DOI 10.1016/S0264-410X(00)00096-7
   Kumar ML, 1998, VACCINE, V16, P2047, DOI 10.1016/S0264-410X(98)00083-8
   Leineweber B, 2004, PEDIATR INFECT DIS J, V23, P361, DOI 10.1097/00006454-200404000-00019
   Leuridan E, 2007, VACCINE, V25, P6296, DOI 10.1016/j.vaccine.2007.06.020
   Leuridan E, 2012, EUR J PEDIATR, V171, P1167, DOI 10.1007/s00431-012-1691-y
   Leuridan E, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1626
   Calles JM, 2015, REV ESP SALUD PUBLIC, V89, P365, DOI 10.4321/S1135-57272015000400005
   Mercader S, 2006, J VIROL METHODS, V137, P140, DOI 10.1016/j.jviromet.2006.06.018
   Plans P, 2015, EUR J CLIN MICROBIOL, V34, P1161, DOI 10.1007/s10096-015-2339-4
   Sanz JC, 2006, APMIS, V114, P788, DOI 10.1111/j.1600-0463.2006.apm_463.x
   Sanz-Moreno JC, 2005, VACCINE, V23, P4921, DOI 10.1016/j.vaccine.2005.05.018
   Smetana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170257
   Viana PO, 2015, VACCINE, V33, P3104, DOI 10.1016/j.vaccine.2015.04.104
   Waaijenborg S, 2013, J INFECT DIS, V208, P10, DOI 10.1093/infdis/jit143
   Zhang XW, 2012, VACCINE, V30, P752, DOI 10.1016/j.vaccine.2011.11.078
NR 31
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4164
EP 4171
DI 10.1016/j.vaccine.2019.05.056
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700040
PM 31151799
DA 2020-05-12
ER

PT J
AU Kawai, AT
   Martin, D
   Henrickson, SE
   Goff, A
   Reidy, M
   Santiago, D
   Selvam, N
   Selvan, M
   McMahill-Walraven, C
   Lee, GM
AF Kawai, Alison Tse
   Martin, David
   Henrickson, Sarah E.
   Goff, Ashleigh
   Reidy, Megan
   Santiago, Diana
   Selvam, Nandini
   Selvan, Mano
   McMahill-Walraven, Cheryl
   Lee, Grace M.
TI Validation of febrile seizures identified in the Sentinel Post-Licensure
   Rapid Immunization Safety Monitoring Program
SO VACCINE
LA English
DT Article
DE Febrile seizures; Algorithm validation; Vaccine safety
ID VACCINE
AB Background: The Sentinel Initiative was established in 2008 to monitor the safety of FDA-regulated medical products. We evaluated the positive predictive value (PPV) of ICD-9 codes for post-vaccination febrile seizures to identify optimal algorithms for use in post-market safety surveillance.
   Methods: We identified ICD-9 diagnosis codes for fever and seizures in the emergency department or inpatient setting after vaccinations of interest from July 1, 2010 to June 30, 2011. Medical record review was conducted to verify febrile seizure events.
   Results: Of 216 potential febrile seizures identified with one or more seizure codes (the broadest algorithm), 152 were chart-confirmed (i.e., documentation of fever within 24 h of seizure or clinician diagnosis of febrile seizure; PPV 70%, 95% CI 64, 76%). Two codes specific for febrile seizures produced the highest PPV (PPV 91%, 95% CI 85, 95%) and accounted for 140 confirmed febrile seizures. In the absence of febrile seizure codes, other seizure codes yielded much lower PPVs, regardless of the presence of fever codes.
   Conclusions: Our results indicate that ICD-9 diagnosis codes in the inpatient and emergency department settings have high predictive value for identifying febrile seizures within the Sentinel Distributed Database. While the PPV of the algorithm based on any diagnosis code for seizure is moderate, the algorithm limited to febrile seizure codes has a high PPV (>90%) and captures the vast majority of confirmed cases identified by the broadest algorithm, suggesting that the narrower algorithm limited to febrile seizure,codes may be preferred. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kawai, Alison Tse; Goff, Ashleigh; Reidy, Megan; Santiago, Diana; Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.
   [Kawai, Alison Tse; Goff, Ashleigh; Reidy, Megan; Santiago, Diana; Lee, Grace M.] Harvard Med Sch, Boston, MA 02115 USA.
   [Martin, David] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
   [Henrickson, Sarah E.] Childrens Hosp Philadelphia, Div Allergy Immunol, Philadelphia, PA 19104 USA.
   [Selvam, Nandini] HealthCore, Alexandria, VA USA.
   [Selvan, Mano] Humana, Comprehens Hlth Insight, Louisville, KY USA.
   [McMahill-Walraven, Cheryl] Aetna, Blue Bell, PA USA.
   [Lee, Grace M.] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94304 USA.
   [Kawai, Alison Tse] RTI Hlth Solut, 307 Waverley Oaks Rd,Suite 101, Waltham, MA 02452 USA.
RP Kawai, AT (reprint author), RTI Hlth Solut, 307 Waverley Oaks Rd,Suite 101, Waltham, MA 02452 USA.
EM akawai@rti.org
OI Henrickson, Sarah/0000-0001-5569-4132
FU FDA through the Department of Health and Human Services (HHS)
   [HHSF2232009100061]
FX This work was funded by the FDA through the Department of Health and
   Human Services (HHS) Contract number HHSF2232009100061.
CR Baker MA, 2013, VACCINE, V31, pK98, DOI 10.1016/j.vaccine.2013.04.088
   Curtis LH, 2012, PHARMACOEPIDEM DR S, V21, P23, DOI 10.1002/pds.2336
   Hodgson ES, 2008, PEDIATRICS, V121, P1281, DOI 10.1542/peds.2008-0939
   Kawai AT, 2015, PEDIATRICS, V136, pE848, DOI 10.1542/peds.2015-0635
   Klein NP, 2010, PEDIATRICS, V126, pE1, DOI 10.1542/peds.2010-0665
   Nguyen M, 2012, PHARMACOEPIDEM DR S, V21, P291, DOI 10.1002/pds.2323
   Quantin C, 2013, AM J EPIDEMIOL, V178, P1731, DOI 10.1093/aje/kwt207
   Shui IM, 2009, VACCINE, V27, P5307, DOI 10.1016/j.vaccine.2009.06.092
   Sukumaran L, 2015, VACCINE, V33, P4446, DOI 10.1016/j.vaccine.2015.07.037
   Thyagarajan V, 2013, VACCINE, V31, P5997, DOI 10.1016/j.vaccine.2013.10.026
   Tse A, 2012, VACCINE, V30, P2024, DOI 10.1016/j.vaccine.2012.01.027
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4172
EP 4176
DI 10.1016/j.vaccine.2019.05.042
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700041
PM 31186192
DA 2020-05-12
ER

PT J
AU Mansour, Z
   Brandt, L
   Said, R
   Fahmy, K
   Riedner, G
   Danovaro-Holliday, MC
AF Mansour, Ziad
   Brandt, Lina
   Said, Racha
   Fahmy, Kamal
   Riedner, Gabriele
   Danovaro-Holliday, M. Carolina
TI Home-based records' quality and validity of caregivers' recall of
   children's vaccination in Lebanon
SO VACCINE
LA English
DT Article
DE Vaccination; Survey; Bias; Home-based record; Recall
AB Introduction: Home-based records (HBRs) (also known as vaccination cards) and caregivers' recall are the main means to ascertain vaccination status; however, data on the quality of HBRs and the validity of recall vaccination data compared to HBRs is scarce. This manuscript presents results from two analyses related to HBRs, one on HBR pictures taken during a vaccination coverage survey, including an assessment of the HBR quality and legibility, and an evaluation of the agreement between caregivers' recall and the vaccination information in the HBRs.
   Methods: Using pictures from 500 randomly selected HBRs collected during the 2016 district-based immunization coverage evaluation survey in Lebanon, two independent researchers assessed the quality of the picture and then of the HBR itself against a pre-defined set of criteria. HBRs were classified into three types: private, public and all others. In addition, caregivers' recall was compared to data found in vaccination HBRs to assess measures of vaccination status agreement for 5713 children for whom both sources of data were available.
   Results: Over 90% of the 500 HBR pictures reviewed were considered adequate to assess the HBR quality. In the sample, most cards were type 1 (41%), followed by type 2 (34%). Most HBRs met the set criteria for quality in terms of physical condition and legibility, while, among the 28 different types of cards, vaccination cards' content and design met a moderate level of quality. Concordance, sensitivity, specificity, positive and negative predictive values, and the Kappa statistic showed diverse levels of agreement for vaccination status per vaccine dose between caregivers' recall and vaccination HBRs.
   Conclusion: This study illustrates that taking pictures of HBRs in a coverage survey is feasible and useful to conduct secondary analyses related to HBRs, such as assessing their quality and comparing recall with HBRs when both sources of data are available. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Mansour, Ziad; Brandt, Lina; Said, Racha] Connecting Res Dev, Beirut, Lebanon.
   [Danovaro-Holliday, M. Carolina] WHO, Geneva, Switzerland.
   [Fahmy, Kamal] World Hlth Org, Eastern Mediterranean Reg Off, Cairo, Egypt.
   [Riedner, Gabriele] World Hlth Org, Lebanon Country Off, Beirut, Lebanon.
RP Said, R (reprint author), Connecting Res Dev, 8th Floor,8115 Tower,POB 50-540, Bauchrieh, Lebanon.
EM saidr@crdconsultancy.org
OI Said, Racha/0000-0003-0885-7984
FU Bill & Melinda Gates Foundation through the World Health Organization
   [OPP1115427, OPP1055811]
FX This study would not have been possible without the financial support of
   Bill & Melinda Gates Foundation through the World Health Organization
   (OPP1115427 and OPP1055811).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1
   Bolivian Ministry of Public Health Population Development and Environment United Nations Children's Fund, 2013, BOL NAT IMM COV SURV
   Brown DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201538
   Brown DW, 2014, VACCINE, V32, P1775, DOI 10.1016/j.vaccine.2014.01.098
   Brown DW, 2012, OPEN VACCINE J, V5, P1, DOI DOI 10.2174/1875035401205010001
   Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404
   Danovaro-Holliday MC, 2018, VACCINE, V36, P5150, DOI 10.1016/j.vaccine.2018.07.019
   Dansereau Emily, 2019, Gates Open Res, V3, P923, DOI 10.12688/gatesopenres.12916.1
   Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060762
   Mansour Z, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6418-9
   Miles MG, 2012, VACCINE, V30, pA131, DOI 10.1016/j.vaccine.2011.10.002
   Ministry of Public Health, 2017, NAT IMM CAL
   Ministry of Public Health World Health Organization, 2016, EXP PROGR IMM DISTR
   Modi RN, 2018, VACCINE, V36, P4161, DOI 10.1016/j.vaccine.2018.05.089
   Roberton T, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030022
   Rossi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168145
   Sinno DD, 2009, PEDIATR INT, V51, P520, DOI 10.1111/j.1442-200X.2008.02769.x
   World Health Organization, 2015, PRACT GUID DES US PR
   World Health Organization, 2018, WHOIVB1809
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4177
EP 4183
DI 10.1016/j.vaccine.2019.05.032
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700042
PM 31221562
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mulama, DH
   Mutsvunguma, LZ
   Totonchy, J
   Ye, P
   Foley, J
   Escalante, GM
   Rodriguez, E
   Nabiee, R
   Muniraju, M
   Wussow, F
   Barasa, AK
   Ogembo, JG
AF Mulama, David H.
   Mutsvunguma, Lorraine Z.
   Totonchy, Jennifer
   Ye, Peng
   Foley, Joslyn
   Escalante, Gabriela M.
   Rodriguez, Esther
   Nabiee, Ramina
   Muniraju, Murali
   Wussow, Felix
   Barasa, Anne K.
   Ogembo, Javier Gordon
TI A multivalent Kaposi sarcoma-associated herpesvirus-like particle
   vaccine capable of eliciting high titers of neutralizing antibodies in
   immunized rabbits
SO VACCINE
LA English
DT Article
DE Kaposi sarcoma-associated human herpesvirus; Kaposi sarcoma;
   Prophylactic vaccine; Glycoproteins; Neutralizing antibody titers;
   Rabbits
ID INFLUENZA HEMAGGLUTININ STEM; DNA-SEQUENCES; VIRUS; GLYCOPROTEINS;
   FUSION; VIRION; KSHV; HUMAN-HERPESVIRUS-8; INFECTION; PROTEINS
AB Kaposi sarcoma-associated herpesvirus (KSHV) is an emerging pathogen and the causative agent of multiple cancers in immunocompromised patients. To date, there is no licensed prophylactic KSHV vaccine. In this study, we generated a novel subunit vaccine that incorporates four key KSHV envelope glycoproteins required for viral entry in diverse cell types (gpK8.1, gB, and gH/gL) into a single multivalent KSHV-like particle (KSHV-LP). Purified KSHV-LPs were similar in size, shape, and morphology to KSHV virions. Vaccination of rabbits with adjuvanted KSHV-LPs generated strong glycoprotein-specific antibody responses, and purified immunoglobulins from KSHV-LP-immunized rabbits neutralized KSHV infection in epithelial, endothelial, fibroblast, and B cell lines (60-90% at the highest concentration tested). These findings suggest that KSHV-LPs may be an ideal platform for developing a safe and effective prophylactic KSHV vaccine. We envision performing future studies in animal models that are susceptible to KSHV infection, to determine correlates of immune protection in vivo. (C) 2019 Published by Elsevier Ltd.
C1 [Mulama, David H.; Mutsvunguma, Lorraine Z.; Ye, Peng; Foley, Joslyn; Rodriguez, Esther; Muniraju, Murali; Wussow, Felix; Barasa, Anne K.; Ogembo, Javier Gordon] City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunooncol, Duarte, CA 91010 USA.
   [Mulama, David H.] Masinde Muliro Univ Sci & Technol, Biol Sci Dept, Kakamega, Kenya.
   [Totonchy, Jennifer; Nabiee, Ramina] Chapman Univ, Sch Pharm, Irvine, CA USA.
   [Escalante, Gabriela M.] City Hope Natl Med Ctr, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA.
   [Barasa, Anne K.] Univ Nairobi, Dept Human Pathol, Nairobi, Kenya.
RP Ogembo, JG (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, 1500 East Duarte Rd, Duarte, CA 91010 USA.
EM jogembo@coh.org
OI Ogembo, Javier/0000-0001-6949-8693; Nabiee, Ramina/0000-0001-9806-8481
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [K01
   CA184388-02]; St. Baldrick's International Scholar grant; National
   Cancer Institute of the NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA033572]
FX This work was supported by the National Institutes of Health (NIH) K01
   CA184388-02 (J.G.O.) and St. Baldrick's International Scholar grant
   (D.H.M.). Research reported in this publication included work performed
   in City of Hope Core Facilities including Analytical Cytometry, Electron
   Microscopy, Integrative Genomics, Bioinformatics, Small Animal Studies,
   and Drug Discovery & Structural Biology supported by the National Cancer
   Institute of the NIH under award number P30CA033572. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH. The funding agencies had no
   role in study design, data collection and analysis, preparation of the
   manuscript, or decision to publish. We thank Ms. Supriya Bautista for
   her help with the organization of figures and Dr. Sarah T. Wilkinson for
   editing the manuscript and offering insightful feedback and discussion.
CR Barasa AK, 2017, ONCOTARGET, V8, P34481, DOI 10.18632/oncotarget.15605
   Bechtel JT, 2005, J VIROL, V79, P4952, DOI 10.1128/JVI.79.8.4952-4964.2005
   Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Bootz A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006601
   Bray F., 2018, CA CANC J CLIN
   Broering TJ, 2009, J VIROL, V83, P12473, DOI 10.1128/JVI.01138-09
   CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802
   Chang H, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000606
   CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
   Cheeseman HM, 2017, J VIROL, V91, DOI 10.1128/JVI.01762-16
   Cheru L, 2010, VACCINE, V28, P4423, DOI 10.1016/j.vaccine.2010.04.036
   Chiuppesi F, 2018, J VIROL, V92, DOI 10.1128/JVI.01012-18
   CLARKE BE, 1987, NATURE, V330, P381, DOI 10.1038/330381a0
   Connolly SA, 2011, NAT REV MICROBIOL, V9, P369, DOI 10.1038/nrmicro2548
   Descamps D, 2009, HUM VACCINES, V5, P332, DOI 10.4161/hv.5.5.7211
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dittmer DP, 2016, J CLIN INVEST, V126, P3165, DOI 10.1172/JCI84418
   Gantt S, 2016, J INFECT DIS, V214, P36, DOI 10.1093/infdis/jiw076
   Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299
   Gibson DG, 2009, NAT METHODS, V6, P343, DOI [10.1038/NMETH.1318, 10.1038/nmeth.1318]
   Hahn A, 2009, J VIROL, V83, P396, DOI 10.1128/JVI.01170-08
   Hahn AS, 2012, NAT MED, V18, P961, DOI 10.1038/nm.2805
   Hesse F, 2000, TRENDS BIOTECHNOL, V18, P173, DOI 10.1016/S0167-7799(99)01420-1
   Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263
   Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556
   Krishnan HH, 2005, J VIROL, V79, P10952, DOI 10.1128/JVI.79.17.10952-10967.2005
   Kundi M, 2007, EXPERT REV VACCINES, V6, P133, DOI 10.1586/14760584.6.2.133
   Labo N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004046
   Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110
   Luna RE, 2004, J VIROL, V78, P6389, DOI 10.1128/JVI.78.12.6389-6398.2004
   McHugh D, 2017, CELL HOST MICROBE, V22, P61, DOI 10.1016/j.chom.2017.06.009
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888
   Metz SW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002124
   Minhas V, 2008, AM J EPIDEMIOL, V168, P311, DOI 10.1093/aje/kwn125
   Minhas V, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-115
   Morrison TG, 2003, BBA-BIOMEMBRANES, V1614, P73, DOI 10.1016/S0005-2736(03)00164-0
   Murali Muniraju, 2019, J VIROL, DOI [10.1128/JV1/L00630-19, DOI 10.1128/JV1/L00630-19]
   Myoung J, 2011, J VIROL METHODS, V174, P12, DOI 10.1016/j.jviromet.2011.03.012
   Ogembo JG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0415-2
   Pantua HD, 2006, J VIROL, V80, P11062, DOI 10.1128/JVI.00726-06
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   RYAN MD, 1994, EMBO J, V13, P928, DOI 10.1002/j.1460-2075.1994.tb06337.x
   Sashihara J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002308
   Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301
   SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276
   Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798
   Urbanowicz RA, 2016, J VIROL, V90, P3288, DOI 10.1128/JVI.02700-15
   WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106
   Walsh G, 2006, NAT BIOTECHNOL, V24, P769, DOI 10.1038/nbt0706-769
   Wang LX, 2014, P NATL ACAD SCI USA, V111, P3146, DOI 10.1073/pnas.1318175111
   Weed DJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01034-18
   Wu TT, 2012, CURR OPIN VIROL, V2, P482, DOI 10.1016/j.coviro.2012.06.005
   Zhao BC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00932
   Zhu FX, 2005, J VIROL, V79, P800, DOI 10.1128/JVI.79.2.800-811.2005
   Zhu LJ, 1999, VIROLOGY, V262, P237, DOI 10.1006/viro.1999.9900
NR 57
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4184
EP 4194
DI 10.1016/j.vaccine.2019.04.071
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700043
PM 31201053
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Muller, C
   Ulrich, R
   Schinkothe, J
   Muller, M
   Kollner, B
AF Mueller, Claudia
   Ulrich, Reiner
   Schinkoethe, Jan
   Mueller, Marcus
   Koellner, Bernd
TI Characterization of protective humoral and cellular immune responses
   against RHDV2 induced by a new vaccine based on recombinant baculovirus
SO VACCINE
LA English
DT Article
DE RHDV; Recombinant vaccine; Protection; Immune response
ID RABBIT HEMORRHAGIC-DISEASE; VIRUS-LIKE PARTICLES; BOOST VACCINATION;
   INFECTION; IMMUNOGENICITY; IMMUNIZATION; ANTIGEN; YOUNG; PCR
AB Rabbit hemorrhagic disease (RHD) is a lethal disease in rabbits caused by RHD virus (RHDV). Protection is only possible through vaccination. A new virus variant (RHDV2) which emerged in 2010 in France differed from the classical RHDV1 variant in certain aspects and vaccines against RHDV1 induced limited cross protection only. In a previous study, we designed a recombinant baculovirus based RHDV2-VP1 vaccine, which provided a protective immunity in rabbits against RHDV2. In the present study this newly created vaccine is characterized with regard to onset and duration of protection, and possible cross protection against classical RHDV1. Furthermore, humoral and cellular immune mechanisms in vaccinated and infected rabbits were analyzed. In all experiments, the recombinant vaccine was compared to a conventional liver-based RHDV2 vaccine.
   The RHDV2-VP1 vaccine induced a protective immune response already seven days after single vaccination and fully protected for at least 14 months. A booster vaccination 21 days after the first had a negative influence on long-term protection. The cross protection provided by the RHDV2-VP1 vaccine against classical RHDV1 was limited since only 50% of vaccinated rabbits survived the infection. Conclusively, the new, baculovirus-based RHDV2-VP1 vaccine has the potential to protect rabbits against the infection with RHDV2, blocks completely the disease progression and prevents the spread of RHDV2 at the population level. (C) 2019 Published by Elsevier Ltd.
C1 [Mueller, Claudia; Ulrich, Reiner; Schinkoethe, Jan; Mueller, Marcus; Koellner, Bernd] Friedrich Loeffler Inst, Inst Mol Virol & Cell Biol, Dept Expt Anim Facil & Bior Management, Inst Immunol, Greifswald, Germany.
   [Mueller, Marcus] IDT Biol Riems, Greifswald, Germany.
RP Kollner, B (reprint author), Friedrich Loeffler Inst, Inst Immunol, Greifswald, Germany.
EM bernd.koellner@fli.de
FU IDT Biologika Insel Riems
FX This work was funded by IDT Biologika Insel Riems.
CR Abrantes J, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-12
   Arguello Villares J L, 1991, Rev Sci Tech, V10, P459
   Baily JL, 2014, VET REC, V174, DOI 10.1136/vr.g2781
   Barcena J, 2015, VET RES, V46, DOI 10.1186/s13567-015-0245-5
   Camarda A, 2014, RES VET SCI, V97, P642, DOI 10.1016/j.rvsc.2014.10.008
   Duarte M, 2015, INFECT GENET EVOL, V35, P163, DOI 10.1016/j.meegid.2015.08.005
   Duarte M, 2015, VET REC, V176, DOI 10.1136/vr.h497
   Farnos O, 2009, ANTIVIR RES, V81, P25, DOI 10.1016/j.antiviral.2008.08.007
   Fernandez E, 2011, VET IMMUNOL IMMUNOP, V142, P179, DOI 10.1016/j.vetimm.2011.05.007
   Fernandez-Fernandez MR, 2001, VIROLOGY, V280, P283, DOI 10.1006/viro.2000.0762
   Ferreira PG, 2006, RES VET SCI, V80, P218, DOI 10.1016/j.rvsc.2005.05.007
   Ferreira PG, 2005, VET IMMUNOL IMMUNOP, V103, P217, DOI 10.1016/j.vetimm.2004.09.028
   Gall A, 2007, VET MICROBIOL, V120, P17, DOI 10.1016/j.vetmic.2006.10.006
   Gronowski AM, 1999, J VIROL, V73, P9944, DOI 10.1128/JVI.73.12.9944-9951.1999
   Guo HM, 2016, ANTIVIR RES, V131, P85, DOI 10.1016/j.antiviral.2016.04.011
   Hall RN, 2015, EMERG INFECT DIS, V21, P2276, DOI 10.3201/eid2112.151210
   Hoffmann B, 2006, J VIROL METHODS, V136, P200, DOI 10.1016/j.jviromet.2006.05.020
   LAURENT S, 1994, J VIROL, V68, P6794, DOI 10.1128/JVI.68.10.6794-6798.1994
   Le Gall-Recule G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-81
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Vidal J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140039
   Marin MS, 1995, VIRUS RES, V39, P119, DOI 10.1016/0168-1702(95)00074-7
   Marques RM, 2012, VET IMMUNOL IMMUNOP, V150, P181, DOI 10.1016/j.vetimm.2012.09.038
   Muller C, 2019, ARCH VIROL, V164, P137, DOI 10.1007/s00705-018-4032-2
   NAGESHA HS, 1995, ARCH VIROL, V140, P1095, DOI 10.1007/BF01315418
   OHLINGER VF, 1993, VET RES, V24, P103
   Patton NM, 1989, RABBIT RES, V12, P64
   PlanaDuran J, 1996, ARCH VIROL, V141, P1423, DOI 10.1007/BF01718245
   Prieto JM, 2000, RES VET SCI, V68, P181, DOI 10.1053/rvsc.1999.0357
   Puggioni G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-96
   Radaelli A, 2003, VACCINE, V21, P2052, DOI 10.1016/S0264-410X(02)00773-9
   SMID B, 1991, VET MICROBIOL, V26, P77, DOI 10.1016/0378-1135(91)90043-F
   Stearns-Kurosawa DJ, 2011, ANNU REV PATHOL-MECH, V6, P19, DOI 10.1146/annurev-pathol-011110-130327
   Strive T, 2009, VIROLOGY, V384, P97, DOI 10.1016/j.virol.2008.11.004
   Vaine M, 2008, J VIROL, V82, P7369, DOI 10.1128/JVI.00562-08
   West DJ, 1996, VACCINE, V14, P1019, DOI 10.1016/0264-410X(96)00062-X
   Westcott DG, 2014, VET REC, V174, DOI 10.1136/vr.g2345
   XU ZJ, 1989, VET RES COMMUN, V13, P205, DOI 10.1007/BF00142046
NR 38
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4195
EP 4203
DI 10.1016/j.vaccine.2019.04.061
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700044
PM 31182325
DA 2020-05-12
ER

PT J
AU Manara, C
   Brazzoli, M
   Piccioli, D
   Taccone, M
   D'Oro, U
   Maione, D
   Frigimelica, E
AF Manara, Cristina
   Brazzoli, Michela
   Piccioli, Diego
   Taccone, Marianna
   D'Oro, Ugo
   Maione, Domenico
   Frigimelica, Elisabetta
TI Co-administration of GM-CSF expressing RNA is a powerful tool to enhance
   potency of SAM-based vaccines
SO VACCINE
LA English
DT Article
DE Self-amplifying mRNA; Protective immunity; Vaccine; Influenza; GM-CSF
ID COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; IMMUNE-RESPONSES;
   DENDRITIC CELLS; PROTECTIVE EFFICACY; NONVIRAL DELIVERY; POTENTIAL ROLE;
   T-CELLS; IMMUNOGENICITY; RECRUITMENT
AB Self-amplifying mRNAs (SAM)-based vaccines have been shown to induce a robust immune response in various animal species against both viral and bacterial pathogens. Due to their synthetic nature and to the versatility of the manufacturing process, SAM technology may represent an attractive solution for rapidly producing novel vaccines, which is particularly critical in case of pandemic infections or diseases mediated by newly emerging pathogens. Recent published data support the hypothesis that Antigen Presenting Cells (APCs) are responsible for CD8+ T-cell priming after SAM vaccination, suggesting cross-priming as the key mechanism for antigen presentation by SAM vaccines. In our study we investigated the possibility to enhance the immune response induced in mice by a single immunization with SAM by increasing the recruitment of APCs at the site of injection. To enhance SAM immunogenicity, we selected murine granulocyte-macrophage colony-stimulating factor (GM-CSF) as a model chemoat-tractant for APCs, and developed a SAM-GM-CSF vector. We evaluated whether the use of SAM-GM-CSF in combination with a SAM construct encoding the Influenza A virus nucleoprotein (NP) would lead to an increase of APC recruitment and NP-specific immune response. We indeed observed that the administration of SAM-GM-CSF enhances the recruitment of APCs at the injection site. Consistently with our hypothesis, co-administration of SAM-GM-CSF with SAM-NP significantly improved the magnitude of NP-specific CD8+ T-cell response both in terms of frequency of cytotoxic antigen-specific CD8+ T-cells and their functional activity in vivo. Furthermore, co-immunization with SAM-GM-CSF and SAM-NP provided an increase in protection against a lethal challenge with influenza virus. In conclusion, we demonstrated that increased recruitment of APCs at the site of injection is associated with an enhanced effectiveness of SAM vaccination and might be a powerful tool to potentiate the efficacy of RNA vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Manara, Cristina; Brazzoli, Michela; Piccioli, Diego; Taccone, Marianna; D'Oro, Ugo; Maione, Domenico; Frigimelica, Elisabetta] GSK Vaccines Srl, Via Fiorentina 1, I-53100 Siena, Italy.
RP Frigimelica, E (reprint author), GSK Vaccines Srl, Via Fiorentina 1, I-53100 Siena, Italy.
EM elisabetta.x.frigimelica@gsk.com
CR Barouch DH, 2006, J PATHOL, V208, P283, DOI 10.1002/path.1874
   BODEY GP, 1994, EUR J CLIN MICROBIOL, V13, P363, DOI 10.1007/BF01971991
   Bogers WM, 2015, J INFECT DIS, V211, P947, DOI 10.1093/infdis/jiu522
   Brazzoli M, 2016, J VIROL, V90, P332, DOI 10.1128/JVI.01786-15
   Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133
   Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090
   Cho JH, 1999, VACCINE, V17, P1136, DOI 10.1016/S0264-410X(98)00333-8
   Cu Y, 2013, VACCINES, V1, P367, DOI 10.3390/vaccines1030367
   Curiel-Lewandrowski C, 1999, J IMMUNOL, V163, P174
   Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308
   Disis ML, 1996, BLOOD, V88, P202
   ESTEY EH, 1991, BRIT J HAEMATOL, V77, P291, DOI 10.1111/j.1365-2141.1991.tb08573.x
   Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Geissler M, 1997, J IMMUNOL, V158, P1231
   Gerloni M, 1998, EUR J IMMUNOL, V28, P1832, DOI 10.1002/(SICI)1521-4141(199806)28:06<1832::AID-IMMU1832>3.0.CO;2-J
   Heidenreich R, 2015, INT J CANCER, V137, P372, DOI 10.1002/ijc.29402
   Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54
   Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245
   Iwasaki A, 1997, J IMMUNOL, V158, P4591
   Jager E, 1996, INT J CANCER, V67, P54, DOI 10.1002/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C
   JONES T, 1994, EUR J CLIN MICROBIOL, V13, pS47, DOI 10.1007/BF01973602
   Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181
   Kim JJ, 1997, J IMMUNOL, V158, P816
   Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046
   KURZROCK R, 1992, AM J MED, V93, P41, DOI 10.1016/0002-9343(92)90678-5
   Labeur MS, 1999, J IMMUNOL, V162, P168
   Lazzaro S, 2015, IMMUNOLOGY, V146, P312, DOI 10.1111/imm.12505
   Lee SJ, 2015, VACCINE, V33, P1549, DOI 10.1016/j.vaccine.2015.02.019
   Lee SW, 1998, J VIROL, V72, P8430, DOI 10.1128/JVI.72.10.8430-8436.1998
   Liu JY, 2008, J VIROL, V82, P5643, DOI 10.1128/JVI.02564-07
   Liu YR, 2014, BIOMACROMOLECULES, V15, P3836, DOI 10.1021/bm501166j
   Magini D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161193
   Maruggi G, 2017, VACCINE, V35, P361, DOI 10.1016/j.vaccine.2016.11.040
   McKay PF, 2004, EUR J IMMUNOL, V34, P1011, DOI 10.1002/eji.200324840
   McNeel DG, 1999, BLOOD, V93, P2653, DOI 10.1182/blood.V93.8.2653.408k07_2653_2659
   MEROPOL NJ, 1992, J BIOL CHEM, V267, P14266
   Morens DM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003467
   Moskophidis D, 1998, J EXP MED, V188, P223, DOI 10.1084/jem.188.2.223
   Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328
   Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285
   Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436
   Stambas J, 2007, J IMMUNOL, V178, P1285, DOI 10.4049/jimmunol.178.3.1285
   Sumida SM, 2004, J CLIN INVEST, V114, P1334, DOI 10.1172/JCI200422608
   Taglietti M, 1995, ADV EXP MED BIOL, V378, P565
   Tarr PE, 1996, VACCINE, V14, P1199, DOI 10.1016/S0264-410X(96)00031-X
   Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998
   Ulmer JB, 2016, CURR OPIN IMMUNOL, V41, P18, DOI 10.1016/j.coi.2016.05.008
   Ulmer JB, 2015, EXPERT OPIN DRUG DIS, V10, P101, DOI 10.1517/17460441.2015.996128
   Ulmer JB, 2012, VACCINE, V30, P4414, DOI 10.1016/j.vaccine.2012.04.060
   Warren TL, 2000, CURR OPIN HEMATOL, V7, P168, DOI 10.1097/00062752-200005000-00007
   Weiss WR, 1998, J IMMUNOL, V161, P2325
   XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8
   Yasen A, 2018, VIROLOGY, V515, P92, DOI 10.1016/j.virol.2017.12.012
NR 54
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4204
EP 4213
DI 10.1016/j.vaccine.2019.04.028
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700045
PM 31227353
DA 2020-05-12
ER

PT J
AU Quintel, BK
   Thomas, A
   DeRaad, DEP
   Slifka, MK
   Amanna, IJ
AF Quintel, Benjamin K.
   Thomas, Archana
   DeRaad, Danae E. Poer
   Slifka, Mark K.
   Amanna, Ian J.
TI Advanced oxidation technology for the development of a next-generation
   inactivated West Nile virus vaccine
SO VACCINE
LA English
DT Article
DE West Nile virus; Hydrogen peroxide; Advanced oxidation; Vaccine;
   Vaccination; Antibody
ID ISATIN-BETA-THIOSEMICARBAZONE; UNITED-STATES; COPPER; DNA; ENHANCEMENT;
   DEGRADATION; INFECTION; RADICALS; KINETICS; IMMUNITY
AB West Nile virus (WNV) is the most frequent mosquito-borne disease reported in the continental United States and although an effective veterinary vaccine exists for horses, there is still no commercial vaccine approved for human use. We have previously tested a 3% hydrogen peroxide (H2O2)-based WNV inactivation approach termed, HydroVax, in Phase I clinical trials and the vaccine was found to be safe and modestly immunogenic. Here, we describe an advanced, next-generation oxidation approach (HydroVax-II) for the development of inactivated vaccines that utilizes reduced concentrations of H2O2 in combination with copper (cupric ions, Cu2+) complexed with the antiviral compound, methisazone (MZ). Further enhancement of this oxidative approach included the addition of a low percentage of formaldehyde, a cross-linking reagent with a different mechanism of action that, together with H2O2/Cu/MZ, provides a robust two-pronged approach to virus inactivation. Together, this new approach results in rapid virus inactivation while greatly improving the maintenance of WNV-specific neutralizing epitopes mapped across the three structural domains of the WNV envelope protein. In combination with more refined manufacturing techniques, this inactivation technology resulted in vaccine-mediated WNV-specific neutralizing antibody responses that were 130-fold higher than that observed using the first generation,H2O2-only vaccine approach and provided 100% protection against lethal WNV infection. This new approach to vaccine development represents an important area for future investigation with the potential not only for improving vaccines against WNV, but other clinically relevant viruses as well. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Quintel, Benjamin K.; DeRaad, Danae E. Poer; Amanna, Ian J.] Najit Technol Inc, 505 NW 185th Ave, Beaverton, OR 97006 USA.
   [Thomas, Archana; Slifka, Mark K.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Dept Mol Microbiol & Immunol, Div Neurosci, Beaverton, OR USA.
RP Amanna, IJ (reprint author), Najit Technol Inc, 505 NW 185th Ave, Beaverton, OR 97006 USA.
EM iamanna@najittech.com
OI Amanna, Ian/0000-0001-7545-4013; DeRaad, Danae/0000-0003-1099-0514
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01AI082196, R44AI079898]; Oregon National Primate Research Center
   [8P51OD011092-53]
FX This work was supported by the National Institute of Allergy and
   Infectious Diseases [grant numbers U01AI082196 and R44AI079898] and the
   Oregon National Primate Research Center [grant number 8P51OD011092-53].
CR Amanna IJ, 2014, EXPERT REV VACCINES, V13, P589, DOI 10.1586/14760584.2014.906309
   Amanna IJ, 2012, NAT MED, V18, P974, DOI 10.1038/nm.2763
   Amanna IJ, 2018, CURR TOP MICROBIOL I
   ARMSTRONG ME, 1993, J HEPATOL, V18, pS20, DOI 10.1016/S0168-8278(05)80373-3
   Bakonyi T, 2013, VET MICROBIOL, V165, P61, DOI 10.1016/j.vetmic.2013.03.005
   Barbusinski K, 2009, ECOL CHEM ENG S, V16, P347
   Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471
   BAUER DJ, 1963, LANCET, V2, P494
   BAUER DJ, 1965, ANN NY ACAD SCI, V130, P110, DOI 10.1111/j.1749-6632.1965.tb12545.x
   Bauer DJ, 1977, SPECIFIC TREATMENT V
   Beigel JH, 2010, ANTIMICROB AGENTS CH, V54, P2431, DOI 10.1128/AAC.01178-09
   Burakoff A, 2018, MMWR-MORBID MORTAL W, V67, P13, DOI 10.15585/mmwr.mm6701a3
   *CDCP, [No title captured]
   Chabierski S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066507
   Cherrier MV, 2009, EMBO J, V28, P3269, DOI 10.1038/emboj.2009.245
   Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442
   Feng Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005767
   Food and Drug Administration, VACC LIC US US
   FOX MP, 1977, ANN NY ACAD SCI, V284, P533, DOI 10.1111/j.1749-6632.1977.tb21986.x
   Furuya Y, 2010, J GEN VIROL, V91, P1450, DOI 10.1099/vir.0.018168-0
   GOLDSTEI.MA, 1970, APPL MICROBIOL, V19, P290, DOI 10.1128/AEM.19.2.290-294.1970
   GOMEZ CP, 1966, LANCET, V2, P233
   GREENWAY TE, 1995, VACCINE, V13, P1411, DOI 10.1016/0264-410X(95)00076-D
   HIATT CW, 1964, BACTERIOL REV, V28, P150, DOI 10.1128/MMBR.28.2.150-163.1964
   Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09
   Kocha T, 1997, BBA-PROTEIN STRUCT M, V1337, P319, DOI 10.1016/S0167-4838(96)00180-X
   Lindsey NP, 2014, AM J TROP MED HYG, V90, P163, DOI 10.4269/ajtmh.13-0432
   LOGAN JC, 1975, J GEN VIROL, V28, P271, DOI 10.1099/0022-1317-28-3-271
   MASSIE HR, 1972, BIOCHIM BIOPHYS ACTA, V272, P539, DOI 10.1016/0005-2787(72)90509-6
   MIKELENS PE, 1976, BIOCHEM PHARMACOL, V25, P821, DOI 10.1016/0006-2952(76)90153-2
   Nieto-Juarez JI, 2010, ENVIRON SCI TECHNOL, V44, P3351, DOI 10.1021/es903739f
   Oliphant T, 2007, J VIROL, V81, P11828, DOI 10.1128/JVI.00643-07
   Petersen LR, 2013, EPIDEMIOL INFECT, V141, P591, DOI 10.1017/S0950268812001070
   Pinto AK, 2013, J VIROL, V87, P1926, DOI 10.1128/JVI.02903-12
   Polack FP, 2007, PEDIATR RES, V62, P111, DOI 10.1203/PDR.0b013e3180686ce0
   Poore EA, 2017, VACCINE, V35, P283, DOI 10.1016/j.vaccine.2016.11.080
   PORRO M, 1980, J INFECT DIS, V142, P716, DOI 10.1093/infdis/142.5.716
   Ramirez DC, 2005, J BIOL CHEM, V280, P27402, DOI 10.1074/jbc.M504241200
   RAPPUOLI R, 1994, VACCINE, V12, P579, DOI 10.1016/0264-410X(94)90259-3
   RODRIGUEZ H, 1995, J BIOL CHEM, V270, P17633, DOI 10.1074/jbc.270.29.17633
   SAGRIPANTI JL, 1993, APPL ENVIRON MICROB, V59, P4374, DOI 10.1128/AEM.59.12.4374-4376.1993
   Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2
   Walker JM, 2012, J VIROL, V86, P13735, DOI 10.1128/JVI.02178-12
   Woods CW, 2019, VACCINE, V37, P4222, DOI 10.1016/j.vaccine.2018.12.026
NR 44
TC 4
Z9 4
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4214
EP 4221
DI 10.1016/j.vaccine.2018.12.020
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700046
PM 30606462
DA 2020-05-12
ER

PT J
AU Woods, CW
   Sanchez, AM
   Swamy, GK
   McClain, MT
   Harrington, L
   Freeman, D
   Poore, EA
   Slifka, DK
   DeRaad, DEP
   Amanna, IJ
   Slifka, MK
   Cai, S
   Shahamatdar, V
   Wierzbicki, MR
   Amegashie, C
   Walter, EB
AF Woods, Christopher W.
   Sanchez, Ana M.
   Swamy, Geeta K.
   McClain, Micah T.
   Harrington, Lynn
   Freeman, Debra
   Poore, Elizabeth A.
   Slifka, Dawn K.
   DeRaad, Danae E. Poer
   Amanna, Ian J.
   Slifka, Mark K.
   Cai, Shu
   Shahamatdar, Venus
   Wierzbicki, Michael R.
   Amegashie, Cyrille
   Walter, Emmanuel B.
TI An observer blinded, randomized, placebo-controlled, phase I dose
   escalation trial to evaluate the safety and immunogenicity of an
   inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults
SO VACCINE
LA English
DT Article
DE West Nile virus; Vaccine; Phase 1
ID NEUTRALIZING ANTIBODY; WN-VAX; IMMUNITY; INFECTION; EFFICACY; MICE; LIVE
AB Background: West Nile virus (WNV) is the most common mosquito-borne infection in the United States. HydroVax-001 WNV is a hydrogen peroxide inactivated, whole virion (WNV-Kunjin strain) vaccine adjuvanted with aluminum hydroxide.
   Methods: We performed a phase 1, randomized, placebo-controlled, double-blind (within dosing group), dose escalation clinical trial of the HydroVax-001 WNV vaccine administered via intramuscular injection. This trial evaluated 1 mcg and 4 mcg dosages of HydroVax-001 WNV vaccine given intramuscularly on day 1 and day 29 in healthy adults. The two dosing groups of HydroVax-001 were enrolled sequentially and each group consisted of 20 individuals who received HydroVax-001 and 5 who received placebo. Safety was assessed at all study days (days 1, 2, 4 and 15 post dose 1, and days 1, 2, 4, 15, 29, 57, 180 and 365 post dose 2), and reactogenicity was assessed for 14 days after administration of each dose. Immunogenicity was measured by WNV-specific plaque reduction neutralization tests (PRNT50) in the presence or absence of added complement or by WNV-specific enzyme-linked immunosorbent assays (ELISA).
   Results: HydroVax-001 was safe and well-tolerated as there were no serious adverse events or concerning safety signals. At the 1 mcg dose, HydroVax-001 was not immunogenic by PRNT50 but elicited up to 41% seroconversion by WNV-specific ELISA in the per-protocol population (PP) after the second dose. At the 4 mcg dose, HydroVax-001 elicited neutralizing antibody responses in 31% of the PP following the second dose. In the presence of added complement, PRNT50 seroconversion rates increased to 50%, and 75% seroconversion was observed by WNV-specific ELISA.
   Conclusions: The HydroVax-001 WNV vaccine was found to be modestly immunogenic and well-tolerated at all dose levels. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Woods, Christopher W.; McClain, Micah T.] Duke Univ, Sch Med, Duke Dept Med, Durham, NC USA.
   [Sanchez, Ana M.; Harrington, Lynn; Walter, Emmanuel B.] Duke Univ, Sch Med, Duke Human Vaccine Inst, Durham, NC USA.
   [Swamy, Geeta K.] Duke Univ, Sch Med, Duke Dept Gynecol & Obstet, Durham, NC USA.
   [Freeman, Debra] Duke Univ, Sch Med, Duke Early Phase Res Unit, Durham, NC USA.
   [Poore, Elizabeth A.; Slifka, Dawn K.; DeRaad, Danae E. Poer; Amanna, Ian J.] Najit Technol Inc, Beaverton, OR USA.
   [Slifka, Mark K.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR USA.
   [Cai, Shu; Shahamatdar, Venus] NIH, Div Microbiol & Infect Dis, Bldg 10, Bethesda, MD 20892 USA.
   [Wierzbicki, Michael R.; Amegashie, Cyrille] Emmes Corp, Rockville, MD USA.
RP Woods, CW (reprint author), 310 Trent Dr,Duke Box 90519, Durham, NC 27708 USA.
EM chris.woods@duke.edu
OI Amanna, Ian/0000-0001-7545-4013; DeRaad, Danae/0000-0003-1099-0514
FU Division of Microbiology and Infectious Diseases (DMID), National
   Institute of Allergy and Infectious Diseases (NIAID) of NIH through the
   Vaccine and Treatment Evaluation Units (VTEU); US Department of Health
   and Human Services under HHS (Duke University) [HHSN272201300017I]; US
   Department of Health and Human Services under HHS (Emmes Corporation)
   [HHSN272201500002C]; Clinical and Translational Science Awards (CTSA)
   Program from the National Center for Advancing Translational Sciences
   [A03-0077]
FX This project was supported by the Division of Microbiology and
   Infectious Diseases (DMID), National Institute of Allergy and Infectious
   Diseases (NIAID) of NIH through the Vaccine and Treatment Evaluation
   Units (VTEU), and the US Department of Health and Human Services under
   contracts HHS (Duke University HHSN272201300017I) and HHS (Emmes
   Corporation HHSN272201500002C). This work was also supported by the
   Clinical and Translational Science Awards (CTSA) Program from the
   National Center for Advancing Translational Sciences #A03-0077 (Duke
   University - Early Phase Research Unit). The authors and participating
   faculty and staff were compensated for their work on this project
   through the US government contracts to their institutions listed above.
   The vaccine was provided by Najit Technologies, Inc.
CR Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092
   Amanna IJ, 2014, EXPERT REV VACCINES, V13, P589, DOI 10.1586/14760584.2014.906309
   Amanna IJ, 2012, NAT MED, V18, P974, DOI 10.1038/nm.2763
   Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471
   Barzon L, 2013, EXPERT REV ANTI-INFE, V11, P479, DOI [10.1586/ERI.13.34, 10.1586/eri.13.34]
   Biedenbender R, 2011, J INFECT DIS, V203, P75, DOI 10.1093/infdis/jiq003
   Dayan GH, 2012, VACCINE, V30, P6656, DOI 10.1016/j.vaccine.2012.08.063
   Diamond MS, 2008, IMMUNOL REV, V225, P212, DOI 10.1111/j.1600-065X.2008.00676.x
   Dubischar-Kastner K, 2010, VACCINE, V28, P5197, DOI 10.1016/j.vaccine.2010.05.069
   Durbin AP, 2013, VACCINE, V31, P5772, DOI 10.1016/j.vaccine.2013.07.064
   Emig M, 2004, CLIN INFECT DIS, V38, P289, DOI 10.1086/380458
   Gessner BD, 2017, VACCINE, V35, P3452, DOI 10.1016/j.vaccine.2017.05.003
   Ledgerwood JE, 2011, J INFECT DIS, V203, P1396, DOI 10.1093/infdis/jir054
   Lieberman MM, 2009, CLIN VACCINE IMMUNOL, V16, P1332, DOI 10.1128/CVI.00119-09
   Lim CK, 2008, VIROLOGY, V374, P60, DOI 10.1016/j.virol.2007.12.021
   Lyons A, 2007, VACCINE, V25, P3445, DOI 10.1016/j.vaccine.2006.12.046
   Martin JE, 2007, J INFECT DIS, V196, P1732, DOI 10.1086/523650
   Mehlhop E, 2005, J VIROL, V79, P7466, DOI 10.1128/JVI.79.12.7466-7477.2005
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Monath TP, 2006, P NATL ACAD SCI USA, V103, P6694, DOI 10.1073/pnas.0601932103
   Muraki Y, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0282-8
   Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401
   Nelson S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000060
   Ng T, 2003, Dev Biol (Basel), V114, P221
   Orlinger KK, 2010, VACCINE, V28, P3318, DOI 10.1016/j.vaccine.2010.02.092
   Petersen LR, 2013, JAMA-J AM MED ASSOC, V310, P308, DOI 10.1001/jama.2013.8042
   Petersen LR, 2008, MED CLIN N AM, V92, P1307, DOI 10.1016/j.mcna.2008.07.004
   Pinto AK, 2013, J VIROL, V87, P1926, DOI 10.1128/JVI.02903-12
   Poore EA, 2017, VACCINE, V35, P283, DOI 10.1016/j.vaccine.2016.11.080
   Posadas-Herrera G, 2010, VACCINE, V28, P7939, DOI 10.1016/j.vaccine.2010.09.076
   Quintel BK, 2019, VACCINE, V37, P4214, DOI 10.1016/j.vaccine.2018.12.020
   Sejvar JJ, 2007, CLIN INFECT DIS, V44, P1617, DOI 10.1086/518281
   Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511
   Whiteman MC, 2010, VACCINE, V28, P1075, DOI 10.1016/j.vaccine.2009.10.112
   Widman DG, 2008, VACCINE, V26, P2762, DOI 10.1016/j.vaccine.2008.03.009
   Widman DG, 2010, AM J TROP MED HYG, V82, P1160, DOI 10.4269/ajtmh.2010.09-0310
NR 36
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 9
PY 2019
VL 37
IS 30
BP 4222
EP 4230
DI 10.1016/j.vaccine.2018.12.026
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IJ6EU
UT WOS:000475995700047
PM 30661836
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Deceuninck, G
   Lefebvre, B
   Tsang, R
   Betala-Belinga, JF
   De Serres, G
   De Wals, P
AF Deceuninck, G.
   Lefebvre, B.
   Tsang, R.
   Betala-Belinga, J. F.
   De Serres, G.
   De Wals, P.
TI Impact of a mass vaccination campaign against Serogroup B meningococcal
   disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after
   its launch
SO VACCINE
LA English
DT Article
DE Meningococcal disease; Meningococcal vaccine; Effectiveness; Mass
   campaign; Immunization
ID IMMUNOGENICITY; CARRIAGE; 4CMENB; SAFETY
AB In the Saguenay-Lac-Saint-Jean region of Quebec, 83% of the population <= 20 years (n congruent to 59,500) was immunized in 2014 with the four-component Serogroup B meningococcal vaccine to control a long-lasting outbreak caused by a virulent ST-269 Serogroup B Neisseria meningitidis clone. Following the campaign, invasive meningococcal B disease (B-IMD) incidence fell sharply in the target population from 11.4/100,000 in 2006-2014 to 0.4/100,000 in 2014-2018 (p < 0.0001). Five B-IMD cases occurred in the region from July 2014 to June 2018, including one vaccinated child, one unvaccinated young adult and 3 unvaccinated elderly adults. Estimate of direct vaccine protection was 79% [95%CI:-231%;99%]. The overall campaign impact in the region taking into account the decrease in B-IMD incidence at provincial level was a 86% [95%CI:-2%;98%] decrease in B-IMD risk. The campaign impact was mostly seen in the target age-group suggesting no herd effect among unvaccinated older adults. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Deceuninck, G.; De Serres, G.; De Wals, P.] Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech, Quebec City, PQ, Canada.
   [Lefebvre, B.] Inst Natl Sante Publ Quebec, Lab Sante Publ Quebec, Ste Anne De Bellevue, PQ, Canada.
   [Tsang, R.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Vaccine Preventable Bacterial Dis, Winnipeg, MB, Canada.
   [Betala-Belinga, J. F.] Ctr Integre Univ Sante & Serv Sociaux Saguenay La, Direct Sante Publ Reg Sociosanit Saguenay Lac St, Chicoutimi, PQ, Canada.
   [De Serres, G.; De Wals, P.] Inst Natl Sante Publ Quebec, Direct Risques Biol & Sante Travail, Quebec City, PQ, Canada.
   [De Serres, G.; De Wals, P.] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada.
RP Deceuninck, G; De Wals, P (reprint author), Univ Laval, Dept Med Sociale & Prevent, CRIUCPQ, 2725 Chemin Ste Foy, Quebec City, PQ G1V 4G5, Canada.
EM genevieve.deceuninck.ciussscn@ssss.gouv.qc.ca;
   philippe.dewals@criucpq.ulaval.ca
FU Minitere de la sante et des Sercices sociaux du Quebec
FX The study was supported by a grant from the "Minitere de la sante et des
   Sercices sociaux du Quebec". The sponsor had no role in the design and
   conduct of the study, data collection, management and analysis, final
   interpretation, preparation, review, and approval of the manuscript.
CR Bettinger JA, 2013, VACCINE, V32, P124, DOI 10.1016/j.vaccine.2013.03.063
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   De Serres G, 2018, VACCINE, V36, P8039, DOI 10.1016/j.vaccine.2018.10.095
   De Wals P, 2018, IMPACT EPIDEMIOLOGIQ
   De Wals P, 2017, CLIN INFECT DIS, V64, P1263, DOI 10.1093/cid/cix154
   Falconer M, 2018, HUM VACC IMMUNOTHER, V14, P225, DOI 10.1080/21645515.2017.1394535
   Flacco ME, 2018, LANCET INFECT DIS, V18, P461, DOI 10.1016/S1473-3099(18)30048-3
   Gilca R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050659
   Law DKS, 2006, J CLIN MICROBIOL, V44, P2743, DOI 10.1128/JCM.00601-06
   Nolan T, 2019, PEDIATR INFECT DIS J, V38, P643, DOI 10.1097/INF.0000000000002334
   Nolan T, 2019, VACCINE, V37, P1209, DOI 10.1016/j.vaccine.2018.12.059
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Read RC, 2014, LANCET, V384, P2123, DOI 10.1016/S0140-6736(14)60842-4
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4243
EP 4245
DI 10.1016/j.vaccine.2019.06.021
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700004
PM 31239214
DA 2020-05-12
ER

PT J
AU Hauser, MI
   Muscatello, DJ
   Soh, ACY
   Dwyer, DE
   Turner, RM
AF Hauser, Michael I.
   Muscatello, David J.
   Soh, Annabel C. Y.
   Dwyer, Dominic E.
   Turner, Robin M.
TI An indirect comparison meta-analysis of AS03 and MF59 adjuvants in
   pandemic influenza A(H1N1)pdm09 vaccines
SO VACCINE
LA English
DT Review
DE Influenza vaccines; Adjuvants; Immunologic; Influenza A virus; H1N1
   subtype; Pandemics; Meta-analysis
ID IMMUNE-RESPONSE; OBSERVER-BLIND; MULTICENTER TRIAL; LESS-THAN-9 YEARS;
   H1N1 INFLUENZA; HEALTHY-ADULTS; VIRUS VACCINE; DOSE-RANGE;
   IMMUNOGENICITY; SAFETY
AB Background: Although oil-in-water adjuvants improve pandemic influenza vaccine efficacy, AS03 versus MF59 adjuvant comparisons in A(H1N1)pdm09 pandemic vaccines are lacking.
   Methods: We conducted an indirect-comparison meta-analysis extracting published data from randomised controlled trials in literature databases (01/01/2009-09/09/2018), evaluating immunogenicity and safety of AS03- or MF59-adjuvanted vaccines. We conducted comparisons of log-transformed haemagglutination inhibition geometric mean titre ratio (GMTR; primary outcome) of different regimens of each adjuvant versus unadjuvanted counterparts. Then via test of subgroup differences, we indirectly compared different AS03 versus MF59 regimens.
   Results: We identified 22 publications with 10,734 participants. In adults, AS03-adjuvanted vaccines (3.75 mu g haemagglutinin) achieved superior GMTR versus unadjuvanted vaccines (all four comparisons); MD = 0.56 (95%CI 0.33 to 0.80, p < 0.001) to 1.18 (95%CI 0.72 to 1.65, p < 0.001). MF59 (full-dose)-adjuvanted vaccines (7.5 mu g haemagglutinin) were superior to unadjuvanted vaccines (three of four comparisons); MD = 0.47 (95%CI 0.19 to 0.75, p = 0.001) to 0.80 (95%CI 0.44 to 1.16, p < 0.001). Adult indirect comparisons favoured AS03 over MF59 (six of eight comparisons; p < 0.001 to p = 0.088).
   Paediatric indirect comparisons favoured MF59-adjuvanted vaccines (two of seven comparisons; p = 0.011, 0.079). However, unadjuvanted control group seroconversion rate was lower in MF59 than AS03 studies (p < 0.001 to p = 0.097).
   There was substantial heterogeneity, and adult AS03 studies had lower risk of bias.
   Conclusions: Despite limited studies, in adults, AS03-adjuvanted vaccines allow antigen sparing versus MF59-adjuvanted and unadjuvanted vaccines, with similar immunogenicity, but higher risk of pain and fatigue (secondary outcomes) than unadjuvanted vaccines. In children, adjuvanted vaccines are also superior, but the better adjuvant is uncertain. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hauser, Michael I.; Soh, Annabel C. Y.] Univ New South Wales, Sydney, NSW, Australia.
   [Muscatello, David J.] Univ New South Wales, Sch Publ Hlth & Community Med, Bot St, Sydney, NSW 2052, Australia.
   [Dwyer, Dominic E.] Westmead Hosp, New South Wales Hlth Pathol Inst Clin Pathol & Me, Ctr Infect Dis & Microbiol Lab Serv, Sydney, NSW, Australia.
   [Dwyer, Dominic E.] Univ Sydney, Sydney, NSW, Australia.
   [Turner, Robin M.] Univ Otago, Div Hlth Sci, Ctr Biostat, Dunedin 9016, New Zealand.
RP Muscatello, DJ (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, Bot St, Sydney, NSW 2052, Australia.; Turner, RM (reprint author), Univ Otago, Div Hlth Sci, Ctr Biostat, Dunedin 9016, New Zealand.
EM david.muscatello@unsw.edu.au; robin.turner@otago.ac.nz
RI Muscatello, David/AAD-9134-2019
OI Muscatello, David/0000-0002-2391-4396
CR Ahmed SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2354
   Arguedas A, 2011, HUM VACCINES, V7, P58, DOI 10.4161/hv.7.1.13411
   Atmar RL, 2009, CURR TOP MICROBIOL, V333, P323, DOI 10.1007/978-3-540-92165-3_16
   Block SL, 2012, PEDIATR INFECT DIS J, V31, pE92, DOI 10.1097/INF.0b013e318257644f
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Bowater RJ, 2013, J APPL STAT, V40, P2, DOI 10.1080/02664763.2012.700448
   CHAN M, 2009, WORLD NOW START 2009
   Cheong HJ, 2011, CLIN VACCINE IMMUNOL, V18, P1358, DOI 10.1128/CVI.05111-11
   Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650
   Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001269.pub6
   Eccleston-Turner M, 2017, MED LAW INT, V17, P227, DOI [10.1177/0968533217723683, DOI 10.1177/0968533217723683]
   Ferguson M, 2012, J INFECT DIS, V205, P733, DOI 10.1093/infdis/jir641
   Guo Q, 2016, CELL PHYSIOL BIOCHEM, V40, P921, DOI 10.1159/000453150
   Hatz C, 2012, VACCINE, V30, P4820, DOI 10.1016/j.vaccine.2012.05.013
   Hatz C, 2012, VACCINE, V30, P3470, DOI 10.1016/j.vaccine.2012.03.017
   Hauser M, INDIRECT COMP METAAN
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Jackson LA, 2015, JAMA-J AM MED ASSOC, V314, P237, DOI 10.1001/jama.2015.7916
   Jackson LA, 2012, J INFECT DIS, V206, P811, DOI 10.1093/infdis/jis427
   Jester B, 2018, AM J EPIDEMIOL, V187, P2596, DOI 10.1093/aje/kwy165
   Kirkwood B, 2003, ESSENTIAL MED STAT, P71
   Knuf M, 2006, VACCINE, V24, P2043, DOI 10.1016/j.vaccine.2005.11.024
   Knuf M, 2015, HUM VACC IMMUNOTHER, V11, P358, DOI 10.4161/21645515.2014.987014
   Knuf M, 2014, PEDIATR INFECT DIS J, V33, pE320, DOI 10.1097/INF.0000000000000462
   Langley JM, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-279
   Langley JM, 2012, PEDIATR INFECT DIS J, V31, P848, DOI 10.1097/INF.0b013e31825e6cd6
   Manzoli L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024384
   McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019
   Montplaisir J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108489
   Nassim C, 2012, PEDIATR INFECT DIS J, V31, pE59, DOI 10.1097/INF.0b013e31824b9545
   Nauta JJP, 2009, BIOLOGICALS, V37, P216, DOI 10.1016/j.biologicals.2009.02.002
   Nicholson KG, 2011, LANCET INFECT DIS, V11, P91, DOI 10.1016/S1473-3099(10)70296-6
   Nolan T, 2014, J INFECT DIS, V210, P545, DOI 10.1093/infdis/jiu173
   Partinen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033723
   Poder A, 2014, VACCINE, V32, P1121, DOI 10.1016/j.vaccine.2013.11.031
   R Core Team, 2017, R LANG ENV STAT COMP
   Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409
   Reisinger KS, 2014, HUM VACC IMMUNOTHER, V10, P2395, DOI 10.4161/hv.29393
   Roman F, 2011, CLIN VACCINE IMMUNOL, V18, P835, DOI 10.1128/CVI.00480-10
   Roman F, 2010, VACCINE, V28, P1740, DOI 10.1016/j.vaccine.2009.12.014
   Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006
   Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.3389/FPSYG.2014.01521
   Taubenberger JK, 2009, REV SCI TECH OIE, V28, P187, DOI 10.20506/rst.28.1.1879
   Vaarala O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114361
   Waddington CS, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2649
   Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108
   Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008
   World Health Organization, 2016, INFL VACC RESP START
   World Health Organization, 2016, 2009 PAND VACC NARC
   World Health Organization, 2018, CHECKL PAND INFL RIS
   Yang WH, 2013, VACCINE, V31, P4389, DOI 10.1016/j.vaccine.2013.07.007
   Yin JK, 2011, INFLUENZA OTHER RESP, V5, P299, DOI 10.1111/j.1750-2659.2011.00229.x
NR 53
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4246
EP 4255
DI 10.1016/j.vaccine.2019.06.039
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700005
PM 31253447
DA 2020-05-12
ER

PT J
AU Ramanathan, R
   Stibitz, S
   Pratt, D
   Roberts, J
AF Ramanathan, Roshan
   Stibitz, Scott
   Pratt, Douglas
   Roberts, Jeff
TI Use of controlled human infection models (CHIMs) to support vaccine
   development: US regulatory considerations
SO VACCINE
LA English
DT Review
DE Regulation; Controlled human infection models; Vaccine; Clinical
   development; Vaccine licensure
AB In 2016, the United States (U.S.) Food and Drug Administration (FDA) licensed Vaxchora (R) for active immunization against disease caused by Vibrio cholerae serogroup 01 in adults. Vaxchora was the first US-licensed vaccine for which the primary evidence supporting effectiveness was derived from human challenge studies. Following this precedent, FDA has received numerous inquiries from manufacturers, academic researchers, funders and other stakeholders regarding how controlled human infection models (CHIMs) can be used to support the development of safe and effective vaccines to address public health needs. The aims of this article are to discuss: (1) Chemistry, Manufacturing and Controls (CMC) for challenge inocula, (2) conduct of controlled human infection studies under US IND and (3) use of CHIMs to support vaccine development. General concepts and regulatory considerations for the safe conduct of CHIMs and use of CHIMs to evaluate vaccine effectiveness are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ramanathan, Roshan; Stibitz, Scott; Pratt, Douglas; Roberts, Jeff] US FDA, Off Vaccines Res & Review, CBER, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
RP Roberts, J (reprint author), US FDA, Off Vaccines Res & Review, CBER, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM jeff.roberts@fda.hhs.gov
CR [Anonymous], 2012, GUID IND INV SAF REP
   Butler D, 2017, NATURE, V545, P396, DOI 10.1038/545396a
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7
   Endy TP, 2014, J INFECT DIS, V209, P556, DOI 10.1093/infdis/jiu112
   Falsey AR, 2015, AM J RESP CRIT CARE, V191, P975, DOI 10.1164/rccm.201503-0471ED
   FDA, 2016, VAXCHORA SUMM BAS RE
   FDA, 2017, GUID IND FORM M FDA
   FDA, DRUG MAST FIL CBER R
   FDA, 2010, GUID IND CHAR QUAL C
   FDA, 2013, GUID CLIN INV SPONS
   *FDA, 2007, [No title captured]
   FDA (Food and Drug Administration), 1998, GUID IND PROV CLIN E
   Gunn JS, 2014, TRENDS MICROBIOL, V22, P648, DOI 10.1016/j.tim.2014.06.007
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   IABS, 2017, 2 HUM CHALL TRIALS V
   *ICH, 1996, GUID GOOD CLIN PRACT
   Reber AJ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv052
   Selgelid Michael J, 2018, Indian J Med Ethics, V3, P263, DOI 10.20529/IJME.2018.073
   Wright PF, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw108
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4256
EP 4261
DI 10.1016/j.vaccine.2019.06.009
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700006
PM 31235375
DA 2020-05-12
ER

PT J
AU Russ, SM
   Brackney, M
   Meek, J
   Niccolai, LM
AF Russ, Savanah M.
   Brackney, Monica
   Meek, James
   Niccolai, Linda M.
TI Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women
   with High Grade Cervical Lesions
SO VACCINE
LA English
DT Article
DE Vaccination; Human papillomavirus; Barriers; Vaccine eligibility
ID UNITED-STATES; PAPILLOMAVIRUS; COMMUNICATION
AB Background: Incidence of high-grade cervical lesions (HGCL) has declined in the U.S following the introduction of the human papillomavirus (HPV) vaccine in 2006. However, many women continue to be diagnosed with HGCLs, including those eligible to receive the vaccine but did not. We determined self-reported barriers to and correlates of HPV vaccination in vaccine-eligible women diagnosed with cervical intraepithelial neoplasia grades 2, 2/3, 3 and adenocarcinoma in situ (CIN2+).
   Methods: Data from a statewide surveillance system in Connecticut for CIN2+ during 2008-2015 were used for this analysis. Enhanced surveillance data were collected for women residing in New Haven County, including HPV vaccine history and demographic factors, through chart review and patient interviews. Women who reported being unvaccinated were asked why they did not receive the vaccine. We evaluated trends in reasons for not receiving the vaccine using a two-sided Cochran Armitage trend test. Log-binomial analysis was used to assess associations between sociodemographic characteristics and vaccination status.
   Results: Between 2008 and 2015, 1625 vaccine-eligible women were diagnosed with CIN2+, with 882 of these women reporting never receiving the HPV vaccine. The proportion of unvaccinated vaccine-eligible women did not significantly change from 2008 to 2015 (p = 0.18, range 49.1% to 60.0%). The most commonly reported reason for being unvaccinated was age/too old, followed by previous HPV diagnosis and no provider recommendation. Women who had public or no insurance were significantly more likely than privately insured women to report being unvaccinated (p = <0.001, p = 0.0034).
   Conclusions: Commonly cited barriers to vaccination, such as age/too old and previous HPV diagnosis, are not contraindications for vaccination. Furthermore, frequent reporting of no provider recommendation underscores the important role providers play in the immunization of their patients. These results indicate the need for greater efforts by providers to dispel myths about HPV vaccine eligibility and to promote vaccination for all of their eligible patients. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Russ, Savanah M.; Brackney, Monica; Meek, James; Niccolai, Linda M.] Yale Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA.
RP Russ, SM (reprint author), Connecticut Emerging Infect Program, 1 Church St,7th Floor, New Haven, CT 06520 USA.
EM savanah.russ@yale.edu; monica.brackney@yale.edu; james.meek@yale.edu;
   linda.niccolai@yale.edu
FU CDCCentre National de la Recherche Scientifique (CNRS)United States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA [5 NU50CK000488-02-00]; Connecticut Emerging Infections
   Program
FX This work was supported by a CDC cooperative agreement [5
   NU50CK000488-02-00] with the Connecticut Emerging Infections Program.
CR [Anonymous], 2016, VACCINATION COVERAGE
   [Anonymous], SEARCH DATA HLTH PEO
   Connecticut Department of Public Health, 2008, CONN EPIDEMIOLOGIST, V28, P1
   Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023
   Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1673, DOI 10.1158/1055-9965.EPI-15-0326
   Krieger N, 2005, AM J PUBLIC HEALTH, V95, P312, DOI 10.2105/AJPH.2003.032482
   Mehta NR, 2012, OBSTET GYNECOL, V119, P575, DOI 10.1097/AOG.0b013e3182460d9f
   Niccolai LM, 2017, CLIN INFECT DIS, V65, P884, DOI 10.1093/cid/cix455
   Research C. for B. E. Approved Products, 2006, RES C B E APPROVED P
   Roberts MC, 2018, AM J PUBLIC HEALTH, V108, P493, DOI [10.2105/AJPH.2017.304263, 10.2105/ajph.2017.304263]
   Satterwhite CL, 2013, SEX TRANSM DIS, V40, P187, DOI 10.1097/OLQ.0b013e318286bb53
   Thompson KM, 2018, PUBLIC HEALTH REP, V133, P543, DOI 10.1177/0033354918793629
   U. S. Census Bureau, QUICKFACTS NEW HAV C
   Walker TY, 2018, MMWR-MORBID MORTAL W, V67, P909, DOI 10.15585/mmwr.mm6733a1
NR 14
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4262
EP 4267
DI 10.1016/j.vaccine.2019.06.061
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700007
PM 31248688
DA 2020-05-12
ER

PT J
AU Bernardo, CD
   Gonzalez-Chica, DA
   Chilver, M
   Stocks, N
AF Bernardo, Carla De Oliveira
   Gonzalez-Chica, David Alejandro
   Chilver, Monique
   Stocks, Nigel
TI Influenza immunisation coverage from 2015 to 2017: A national study of
   adult patients from Australian general practice
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Vaccination coverage; General practice; Electronic
   health records
ID VACCINATION; IMPACT
AB Objectives: To assess influenza immunisation rates and coverage in adult patients from Australian general practice and identify whether practice or patients' characteristics are associated with vaccination uptake.
   Design: Open cohort study.
   Setting: 550 Australian general practices included in the MedicineInsight database.
   Participants: Patients aged 18+ years who had at least one consultation during influenza season between 2015 and 2017. Two samples were considered: (1) 'active' patients (at least three consultations in any two consecutive years) and (2) 'every year' patients (at least one consultation per year).
   Main outcome measures: Influenza vaccination rates per 1,000 consultations and coverage (% vaccinated among those who consulted) from 2015 to 2017.
   Results: Between 2015 and 2017 the influenza vaccine rate changed from 57.4 to 51.7 and 67.0 per 1,000 consultations, while correspondent values for coverage were 29.3%, 25.2% and 27.6% (in 'active' patients). Vaccine coverage was at least 30% higher in inner regional areas, among patients aged 65+ years or those with comorbidities. Similar associations were found among 'every year' patients, but average coverage across the three years was higher (41% vs 27%). Aboriginal and Torres Strait Islander people, either with or without comorbidity, showed a vaccine coverage 10-30% higher than non-Indigenous people for those aged less than 65 years (p-value for interaction < 0.001).
   Conclusion: Medicinelnsight data is a useful and low-cost method to monitor influenza immunisation coverage. Independent of the sample used, vaccination coverage among Indigenous people or patients with comorbidities could be improved. Targeted strategies for high-risk groups need to be developed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bernardo, Carla De Oliveira; Gonzalez-Chica, David Alejandro; Stocks, Nigel] Univ Adelaide, Adelaide Med Sch, Discipline Gen Practice, Adelaide, SA, Australia.
   [Gonzalez-Chica, David Alejandro] Univ Adelaide, Adelaide Rural Clin Sch, Adelaide, SA, Australia.
   [Chilver, Monique] Univ Adelaide, Australian Sentinel Practices Res Network ASPREN, Adelaide, SA, Australia.
   [Stocks, Nigel] NHMRC, Australian Partnership Preparedness Res Infect Di, Canberra, ACT, Australia.
RP Bernardo, CD (reprint author), Univ Adelaide, Discipline Gen Practice, Helen Mayo North Bldg,Frome Rd,Level 1, Adelaide, SA 5005, Australia.
EM carla.bernardo@adelaide.edu.au
OI Gonzalez-Chica, David/0000-0002-7153-2878; Stocks,
   Nigel/0000-0002-9018-0361
CR Australian Bureau of Statistics (ABS), 2015, NAT HLTH SURV 1 RES
   Australian Bureau of Statistics (ABS), CENS POP HOUS SOC EC
   Australian Bureau of Statistics (ABS), TABL BUILD
   Australian Government. Department of Health, US AUSTR IMM REG
   Australian Government. Department of health, 2017 INFL SEAS AUSTR
   Australian Government. Department of Health, NAT IMM RES QUAL 201
   Australian Government Department of Health, 2018, NAT NOT DIS SURV SYS
   Australian Institute of Health and Welfare 2011, 2011, 2009 AD VACC SURV SU
   Australian Sentinel Practices Research Network (ASPREN), 2018, SYNDR SURV RES
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885
   Britt H., 2016, GEN PRACTICE SERIES, V40
   Cheng AC, 2017, COMMUN DIS INTELL, V41, pE337
   Damiani G, 2007, PREV MED, V45, P373, DOI 10.1016/j.ypmed.2007.07.007
   de Bekker-Grob EW, 2018, VACCINE, V36, P1467, DOI 10.1016/j.vaccine.2018.01.054
   Dyda A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1820-8
   Dyda A, 2015, PUBLIC HEALTH RES PR, V25, DOI 10.17061/phrp2541543
   Dyda A, 2015, VACCINE, V33, P3299, DOI 10.1016/j.vaccine.2015.05.046
   European Centre for Disease Prevention and Control, 2016, SEAS INFL VACC ANT U
   Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014
   Gonzalez-Chica DA, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1941-x
   Horby PW, 2005, AUST NZ J PUBL HEAL, V29, P35, DOI 10.1111/j.1467-842X.2005.tb00745.x
   Li-Kim-Moy J, 2016, COMMUN DIS INTELL, V40, pE482
   Medicinelnsight, 2018, MED DAT BOOK VERS 2
   Naidu L, 2013, COMMUN DIS INTELL, V37, pS1
   Public Health Agency, SURV INFL NO IR 2017
   Public Health England, 2018, SEAS INFL VACC UPT G
   Regan AK, 2018, VACCINE, V36, P3195, DOI 10.1016/j.vaccine.2018.04.076
   Santibanez TA, FLU VACCINATION COVE
   The Royal Australian College of General Practitioners, 2015, STAND GEN PRACT
   World Health Organization, 2018, INFL SEAS
   World Health Organization (WHO), 2016, METH ASS INFL VACC C
   Wu SS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-636
NR 33
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4268
EP 4274
DI 10.1016/j.vaccine.2019.06.057
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700008
PM 31253446
DA 2020-05-12
ER

PT J
AU Zaman, K
   Kingma, R
   Yunus, M
   van Straaten, I
   Mekkes, D
   Bouwstra, X
   Gunale, B
   Kulkarni, PS
AF Zaman, Khalequ
   Kingma, Robert
   Yunus, Md
   van Straaten, Ineke
   Mekkes, Dirk
   Bouwstra, Xandra
   Gunale, Bhagwat
   Kulkarni, Prasad S.
TI Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral
   Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III,
   observer blind, randomized, controlled clinical study
SO VACCINE
LA English
DT Article
DE Bivalent Oral Polio Vaccine; Safety; Immunogenicity lot-to-lot
   consistency; Children; Infants
ID OPEN-LABEL; NON-INFERIORITY; SCHEDULES
AB Background: Poliomyelitis infection continues to be endemic in few countries despite rigorous efforts for eradication. A new Bivalent Oral Polio Vaccine (BBio bOPV) was tested in a Phase Ill Clinical study.
   Methods: An observer blind, randomized, controlled clinical study was conducted comparing BBio bOPV with a licensed bOPV (511 bOPV). Initially in Part 1, 40 children 5-6 years of age were given a single dose of either vaccine in 1:1 ratio. In Part 2, 1080 infants of 6-8 weeks of age were received in 1:1:1:1 ratio one of the 3 lots of BBio bOPV or SII bOPV at 6, 10 and 14 weeks of age. Blood samples were collected to assess neutralizing antibody responses against Polio Type 1 and 3 viruses. Safety of the vaccines were recorded.
   Results: All children were seroprotected against both Type 1 and Type 3 polioviruses post-vaccination. More than 96% of the infants demonstrated seroconversion as well as seroprotection against both types of polioviruses. The geometric mean titres (GMT) for Type 1 and Type 3 antibodies were comparable between the groups. The 3 lots of BBio bOPV generated similar GMTs of Type 1 and Type 3 antibodies. In total 387 participants reported at least one adverse event and 18 serious adverse events. None of these events were vaccine related.
   Conclusions: The new bOPV vaccine demonstrated immunogenicity that was non-inferior to a licensed bOPV vaccine. Consistency in immune response by 3 consecutively manufactured lots was also demonstrated. The vaccine did not cause any adverse event. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zaman, Khalequ; Yunus, Md] Int Ctr Diarrhoea Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.
   [Kingma, Robert; van Straaten, Ineke; Mekkes, Dirk; Bouwstra, Xandra] Bilthoven Biol, Bilthoven, Netherlands.
   [Gunale, Bhagwat; Kulkarni, Prasad S.] Serum Inst India Pvt Ltd, Pune, Maharashtra, India.
RP Zaman, K (reprint author), Int Ctr Diarrhoea Dis Res, GPO Box 128, Dhaka 1000, Bangladesh.
EM kzaman@icddrb.org
FU Bithoven Biologicals, Netherlands
FX The study was funded by Bithoven Biologicals, Netherlands.
CR Anand A, 2015, VACCINE, V33, P6816, DOI 10.1016/j.vaccine.2015.09.039
   [Anonymous], 2014, WHO TECHN REP SER, V980
   [Anonymous], 2017, OR POL VACC SUPPL OU
   Asturias EJ, 2016, LANCET, V388, P158, DOI 10.1016/S0140-6736(16)00703-0
   Estivariz CF, 2015, LANCET INFECT DIS, V15, P898, DOI 10.1016/S1473-3099(15)00094-8
   Hampton LM, 2017, J INFECT DIS, V216, pS217, DOI 10.1093/infdis/jix105
   Mir F, 2015, LANCET INFECT DIS, V15, P889, DOI 10.1016/S1473-3099(15)00093-6
   Saleem AF, 2018, J INFECT DIS, V217, P443, DOI 10.1093/infdis/jix577
   Sutter RW, 2015, LANCET, V386, P2413, DOI 10.1016/S0140-6736(15)00237-8
   Sutter RW, 2010, LANCET, V376, P1682, DOI 10.1016/S0140-6736(10)61230-5
   World Health Organisation, 1993, GUID WHO EPI COLL ST
NR 11
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4275
EP 4280
DI 10.1016/j.vaccine.2019.06.048
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700009
PM 31235374
DA 2020-05-12
ER

PT J
AU Li, AJ
   Peiris, TSR
   Sanderson, C
   Lochlainn, LN
   Mausiry, M
   da Silva, RBJBM
   Ogbuanu, IU
AF Li, Anyie J.
   Peiris, Thelge Sudath Rohana
   Sanderson, Colin
   Lochlainn, Laura Nic
   Mausiry, Manuel
   da Silva, Rosye Bela Joana Benevides Moniz
   Ogbuanu, Ikechukwu Udo
TI Opportunities to improve vaccination coverage in a country with a
   fledgling health system: Findings from an assessment of missed
   opportunities for vaccination among health center attendees-Timor Leste,
   2016
SO VACCINE
LA English
DT Article
DE Missed opportunities for vaccination; Immunization; Vaccination
   coverage; Coverage and equity; Healthcare utilization; Timor Leste
ID IMMUNIZATION
AB Introduction: Since its independence in 2002, Timor Leste has made significant strides in improving childhood vaccination coverage. However, coverage is still below national targets, and children continue to have missed opportunities for vaccination (MOV), when eligible children have contact with the health system but are not vaccinated. Timor Leste implemented the updated World Health Organization methodology for assessing MOV in 2016.
   Methods: The MOV data collection included quantitative (caregiver exit interviews and health worker knowledge, attitudes, practices surveys (KAP)) and qualitative arms (focus group discussions (FGDs) with caregivers and health workers and in-depth interviews (IDIs) with health administrators). During a four-day period, health workers and caregivers with children <24 months of age attending the selected eight facilities in Dili Municipality were invited to participate. The researchers calculated the proportion of MOV and timeliness of vaccine doses among children with documented vaccination histories (i.e., from a home-based record or facility register) and thematically analyzed the qualitative data.
   Results: Researchers conducted 365 caregiver exit interviews, 169 health worker KAP surveys, 4 FGDs with caregivers, 2 FGDs with health workers, and 2 IDIs with health administrators. Among eligible children with documented vaccination histories (n = 199), 41% missed an opportunity for vaccination. One-third of health workers (33%) believed their knowledge of immunization practices to be insufficient. Qualitative results showed vaccines were not available at all selected health facilities, and some facilities reported problems with their cold chain equipment.
   Conclusion: This study demonstrates that many children in Timor Leste miss opportunities for vaccination during health service encounters. Potential interventions to reduce MOV include training of health workers, improving availability of vaccines at more health facilities, and replacing unusable cold chain equipment. Timor Leste should continue to scale up successful MOV interventions beyond Dili Municipality to improve vaccination coverage nationally and strengthen the health system overall. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Li, Anyie J.; Ogbuanu, Ikechukwu Udo] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Peiris, Thelge Sudath Rohana] WHO, Country Off, Dili, Timor-Leste.
   [Sanderson, Colin] London Sch Hyg & Trop Med, London, England.
   [Lochlainn, Laura Nic] WHO, Geneva, Switzerland.
   [Mausiry, Manuel; da Silva, Rosye Bela Joana Benevides Moniz] Minist Hlth, Dili, Timor-Leste.
RP Li, AJ (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop H24-2, Atlanta, GA 30329 USA.
EM yrw5@cdc.gov
OI Nic Lochlainn, Laura/0000-0001-8095-9892
FU World Health OrganizationWorld Health Organization [001]; CDC HHS
   [NU2GGH002093]; None [NU2GGH002093]; OSELS CDC HHS [U36 OE000002]
CR Amin R, 2013, GLOB HEALTH-SCI PRAC, V1, P417, DOI 10.9745/GHSP-D-13-00115
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P266
   Brown DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201538
   Bucens IK, 2006, J PAEDIATR CHILD H, V42, P28, DOI 10.1111/j.1440-1754.2006.00784.x
   Cabral J, 1982, SOC SCI MED, V2013, P285
   Central Intelligence Agency, 2018, WORLD FACTB TIM LEST
   Cutilli CC, 2010, ORTHOP NURS, V29, P214, DOI 10.1097/NOR.0b013e3181db5471
   Gavi, 2018, TRANS TWINS SRI LANK
   Gavi, 2017, JOINT APPR REP 2017
   Gavi, 2017, TWINN IS WINN LANDM
   HUTCHINS SS, 1993, B WORLD HEALTH ORGAN, V71, P549
   John Snow Inc, 2015, TIM LEST HLTH IMPR P
   Laryea DO, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-90
   Magadzire Bvudzai Priscilla, 2017, Gates Open Res, V1, P5, DOI 10.12688/gatesopenres.12761.1
   Morris K, 2001, LANCET, V357, P873, DOI 10.1016/S0140-6736(00)04203-3
   Ogbuanu IU, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210648
   Restrepo-Mendez MC, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30963
   Sadoh AE, 2009, J HEALTH POPUL NUTR, V27, P391
   Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063
   Tulloch J, 2003, INITIAL STEPS REBUIL
   World Health Organization, 2016, GLOBAL IMMUNIZATION
   World Health Organization, 2017, PLANN GUID RED MISS
   World Health Organization, 2017, METH ASS MISS OPP VA
   World Health Organization UNICEF, 2017, TIM LEST WHO UNICEF
NR 24
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4281
EP 4290
DI 10.1016/j.vaccine.2019.06.041
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700010
PM 31239213
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Singh, G
   Zholobko, O
   Pillatzki, A
   Webb, B
   Nelson, E
   Voronov, A
   Ramamoorthy, S
AF Singh, Gagandeep
   Zholobko, Oksana
   Pillatzki, Angela
   Webb, Brett
   Nelson, Eric
   Voronov, Andriy
   Ramamoorthy, Sheela
TI An amphiphilic invertible polymer as a delivery vehicle for a
   M2e-HA2-HA1 peptide vaccine against an Influenza A virus in pigs
SO VACCINE
LA English
DT Article
DE M2e; HA2; HA1; Influenza; Vaccine; Peptide; Amphiphilic invertible
   polymer; Micellar assemblies; H1N1; Swine influenza virus
ID UNIVERSAL ANTIBODIES; FUSION PEPTIDE; HEMAGGLUTININ; DESIGN; MICE;
   PROTECTION; ECTODOMAIN; CIRCOVIRUS; CHALLENGE; ADJUVANTS
AB Influenza A viruses (IAVs) are a group of genetically diverse and economically important zoonotic pathogens. Despite decades of research, effective and broadly protective vaccines are yet to be developed. Recent breakthroughs in epitope-based immunization for influenza viruses identify certain conserved regions of the HA2 and M2e proteins as capable of inducing broad protection against multiple influenza strains. The M2e and HA2 peptides have been evaluated in mice but not as a combination in pigs, which play an important role in the transmission and evolution of IAV. Peptides are inherently weak immunogens; and effective delivery of peptide antigens is challenging. To enhance the delivery and immunogenicity of peptide-based vaccines, the conserved M2e and HA2 and a strain-specific HAl epitope of Influenza A (H1N1) pdm09 were expressed as a chain in a bacterial expression system and entrapped in a novel amphiphilic invertible polymer made from polyethyelene glycol (PEG, molecular weight 600 g/mol) and polytetrahydrofuran (PTHF, molecular weight 650 g/mol), PEG600PTHF650. Piglets vaccinated with polymeric peptide vaccine mounted significantly stronger antibody responses against the peptide construct when compared to piglets immunized with the multi-epitope peptide alone. When vaccinated pigs were challenged with Influenza A (H1N1) pdm09, viral shedding in nasal secretions and lung lesion scores were significantly reduced when compared to the unvaccinated controls and pigs vaccinated with the peptide alone at six days post-challenge. Thus, the combination of the PEG(600)PTHF(650) polymer and trimeric peptide construct enhanced delivery of the peptide antigen, acted as an adjuvant in stimulating strong antibody responses, reduced the effects of viral infection in vaccinated pigs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Singh, Gagandeep; Ramamoorthy, Sheela] N Dakota State Univ, Dept Microbiol Sci, Fargo, ND 58105 USA.
   [Zholobko, Oksana; Voronov, Andriy] N Dakota State Univ, Dept Coatings & Polymer Mat, Fargo, ND 58105 USA.
   [Pillatzki, Angela; Nelson, Eric] S Dakota State Univ, Anim Dis Res & Diagnost Lab, Brookings, SD USA.
   [Webb, Brett] N Dakota State Univ, Vet Diagnost Lab, Fargo, ND 58105 USA.
RP Ramamoorthy, S (reprint author), N Dakota State Univ, Dept Microbiol Sci, Fargo, ND 58105 USA.
EM sheela.ramamoorthy@ndsu.edu
OI Ramamoorthy, Sheela/0000-0001-5906-5974
FU Agricultural Products Utilization Committee (APUC) of N. Dakota, the N.
   Dakota State Board of Agricultural Research (SBARE)
FX The authors disclose receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   supported by the Agricultural Products Utilization Committee (APUC) of
   N. Dakota, the N. Dakota State Board of Agricultural Research (SBARE).
CR Adams JR, 2015, ACTA BIOMATER, V14, P104, DOI 10.1016/j.actbio.2014.11.050
   Adar Y, 2009, VACCINE, V27, P2099, DOI 10.1016/j.vaccine.2009.02.011
   Ameghi A, 2016, VIRAL IMMUNOL, V29, P228, DOI 10.1089/vim.2015.0050
   Bommakanti G, 2010, P NATL ACAD SCI USA, V107, P13701, DOI 10.1073/pnas.1007465107
   Chun S, 2008, VACCINE, V26, P6068, DOI 10.1016/j.vaccine.2008.09.015
   DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6
   De Filette M, 2006, VACCINE, V24, P544, DOI 10.1016/j.vaccine.2005.08.061
   De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004
   De Filette M, 2006, VACCINE, V24, P6597, DOI 10.1016/j.vaccine.2006.05.082
   Du LY, 2010, MICROBES INFECT, V12, P280, DOI 10.1016/j.micinf.2010.01.001
   Dutry I, 2011, BMC P, V5, pP62, DOI [10.1186/1753-6561-5-S1-P62, DOI 10.1186/1753-6561-5-S1-P62]
   El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147
   Ellis J, 1998, CAN VET J, V39, P44
   Fan JA, 2004, VACCINE, V22, P2993, DOI 10.1016/j.vaccine.2004.02.021
   Feng JQ, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-102
   Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Gauger PC, 2012, VET PATHOL, V49, P900, DOI 10.1177/0300985812439724
   Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Hashem AM, 2010, BIOCHEM BIOPH RES CO, V403, P247, DOI 10.1016/j.bbrc.2010.11.030
   Heinen PP, 2002, J GEN VIROL, V83, P1851, DOI 10.1099/0022-1317-83-8-1851
   Hevus I, 2012, BIOMACROMOLECULES, V13, P2537, DOI 10.1021/bm3007924
   Hevus I, 2011, POLYM CHEM-UK, V2, P2767, DOI 10.1039/c1py00399b
   Horvath A, 1998, IMMUNOL LETT, V60, P127, DOI 10.1016/S0165-2478(97)00137-5
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Imai M, 1998, VIRUS RES, V53, P129, DOI 10.1016/S0168-1702(97)00143-3
   Imai M, 2012, CURR OPIN VIROL, V2, P160, DOI 10.1016/j.coviro.2012.03.003
   Jang YH, 2014, VIRUSES-BASEL, V6, P3159, DOI 10.3390/v6083159
   Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366
   Kim YJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01730
   Kohut A, 2017, MACROMOL CHEM PHYS, V218, DOI 10.1002/macp.201700344
   Ma W, 2009, ZOONOSES PUBLIC HLTH, V56, P326, DOI 10.1111/j.1863-2378.2008.01217.x
   Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mozdzanowska K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-118
   NAGY Z, 1994, SCAND J IMMUNOL, V40, P281, DOI 10.1111/j.1365-3083.1994.tb03464.x
   Neirynck S, 1999, NAT MED, V5, P1157
   Newman MJ, 1998, J PHARM SCI, V87, P1357, DOI 10.1021/js980072c
   Opriessnig T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191739
   Opriessnig T, 2010, VET MICROBIOL, V142, P177, DOI 10.1016/j.vetmic.2009.09.056
   Pan Y, 2018, J PHYS CHEM C
   Price GE, 2018, VACCINE, V36, P4910, DOI 10.1016/j.vaccine.2018.06.051
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reese Kaleb A, 2013, Vet Med Int, V2013, P316926, DOI 10.1155/2013/316926
   Schepens B, 2018, CURR OPIN IMMUNOL, V53, P22, DOI 10.1016/j.coi.2018.03.024
   Shakya AK, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0536
   Stanekova Z, 2011, ACTA VIROL, V55, P61, DOI 10.4149/av_2011_01_61
   Stanekova Z, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-351
   Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10
   Voronov A, 2008, LANGMUIR, V24, P12587, DOI 10.1021/la801769v
   Voronov A, 2006, LANGMUIR, V22, P1946, DOI 10.1021/la052225z
   Wang TT, 2010, P NATL ACAD SCI USA, V107, P18979, DOI 10.1073/pnas.1013387107
   Wen F, 2016, J VET SCI, V17, P71, DOI 10.4142/jvs.2016.17.1.71
   Wolf AI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028445
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   Wu KW, 2012, GENOMICS, V100, P102, DOI 10.1016/j.ygeno.2012.06.003
   Zhang XT, 2011, INTERVIROLOGY, V54, P290, DOI 10.1159/000319440
   Zhao GY, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-9
NR 59
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4291
EP 4301
DI 10.1016/j.vaccine.2019.06.030
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700011
PM 31235376
DA 2020-05-12
ER

PT J
AU Sobey, KG
   Jamieson, SE
   Walpole, AA
   Rosatte, RC
   Donovan, D
   Fehlner-Gardiner, C
   Nadin-Davis, SA
   Davies, JC
   Kyle, CJ
AF Sobey, Kirk G.
   Jamieson, Sarah E.
   Walpole, Aaron A.
   Rosatte, Rick C.
   Donovan, Dennis
   Fehlner-Gardiner, Christine
   Nadin-Davis, Susan A.
   Davies, J. Chris
   Kyle, Christopher J.
TI ONRAB (R) oral rabies vaccine is shed from, but does not persist in,
   captive mammals
SO VACCINE
LA English
DT Article
DE Safety; Quantitative PCR; Captive trials; Non-target; Rabies vector
ID STRIPED SKUNKS; FIELD TRIAL; RED FOXES; RACCOONS; ONTARIO; BAITS;
   WILDLIFE; PROTECTION; RESPONSES; PATHOGENICITY
AB ONRAB (R) is a human adenovirus rabies glycoprotein recombinant vaccine developed to control rabies in wildlife. To support licensing and widespread use of the vaccine, safety studies are needed to assess its potential residual impact on wildlife populations. We examined the persistence of the ONRAB (R) vaccine virus in captive rabies vector and non-target mammals. This research complements work on important rabies vector species (raccoon, striped skunk, and red fox) but also adds to previous findings with the addition of some non-target species (Virginia opossum, Norway rats, and cotton rats) and a prolonged period of post vaccination monitoring (41 days). Animals were directly inoculated orally with the vaccine and vaccine shedding was monitored using quantitative real-time PCR applied to oral and rectal swabs. ONRAB (R) DNA was detected in both oral and rectal swabs from 6 h to 3 days post-inoculation in most animals, followed by a resurgence of shedding between days 17 and 34 in some species. Overall, the duration over which ONRAB (R) DNA was detectable was shorter for non-target mammals, and by day 41, no animal had detectable DNA in either oral or rectal swabs. All target species, as well as cotton rats and laboratory-bred Norway rats, developed robust humoral immune responses as measured by competitive ELISA, with all individuals being seropositive at day 31. Similarly, opossums showed good response (89% seropositive; 8/9), whereas only one of nine wild caught Norway rats was seropositive at day 31. These results support findings of other safety studies suggesting that ONRAB (R) does not persist in vector and non-target mammals exposed to the vaccine. As such, we interpret these data to reflect a low risk of adverse effects to wild populations following distribution of ONRAB (R) to control sylvatic rabies. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Sobey, Kirk G.; Jamieson, Sarah E.; Rosatte, Rick C.; Donovan, Dennis; Davies, J. Chris] Trent Univ, Ontario Minist Nat Resources & Forestry, Wildlife Res & Monitoring Sect, 2140 East Bank Dr, Peterborough, ON K9L 0G2, Canada.
   [Walpole, Aaron A.] Ontario Minist Nat Resources & Forestry, Wildlife Sect, 300 Water St, Peterborough, ON K9J 8M5, Canada.
   [Fehlner-Gardiner, Christine; Nadin-Davis, Susan A.] Canadian Food Inspect Agcy, Ottawa Lab Fallowfield, POB 11300,Stn H, Nepean, ON K2H 8P9, Canada.
   [Kyle, Christopher J.] Trent Univ, Nat Resources DNA Profiling & Forens Ctr, 2140 East Bank Dr,DNA Bldg, Peterborough, ON K9J 7B8, Canada.
RP Jamieson, SE (reprint author), Trent Univ, Ontario Minist Nat Resources & Forestry, Wildlife Res & Monitoring Sect, 2140 East Bank Dr, Peterborough, ON K9L 0G2, Canada.
EM sarah.jamieson@ontario.ca; aaron.walpole@on-tario.ca; rcr99@nexicom.net;
   ddonovan2421@gmail.com; Gardiner@canada.ca;
   susan.nadin-davis@-canada.ca; jchris.davies@bell.net;
   christopherkyle@-trentu.ca
FU Ontario's Ministry of Natural Resources and Forestry
FX This research benefitted from valuable discussions with the Rabies
   Advisory Committee (J. Broadfoot, Chair). We are grateful to the staff
   at Artemis Technologies Inc. for the preparation of the baits and the
   sage advice they provided and to Dr. A. Kamen (NRC, BRI) and the staff
   of the Animal Cell Technology Section at BRI for their assistance in
   producing the vaccine. We gratefully acknowledge Drs. L Prevec, O.
   Yarosh, A. Wandeler, F. Graham, and J. Campbell for their work on the
   development of the AdRG1.3 vaccine virus construct and M. Harnden and T.
   Khan for their work in Trent University's Natural Resource DNA Profiling
   and Forensic Centre. Finally, we thank Dr. B. White (Trent U) for
   helpful discussions about laboratory techniques and B. Stevenson (OMNRF)
   and L. Bruce (OMNRF) for valuable discussions and comments on early
   versions of the manuscript. This work was funded by Ontario's Ministry
   of Natural Resources and Forestry.
CR Anderson A, 2015, TRANSBOUND EMERG DIS, V62, P446, DOI 10.1111/tbed.12168
   Arnberg N, 2013, P NATL ACAD SCI USA, V110, P19976, DOI 10.1073/pnas.1319937110
   ARTOIS M, 1992, VACCINE, V10, P524, DOI 10.1016/0264-410X(92)90351-J
   Borkow G, 2008, TRENDS PARASITOL, V24, P243, DOI 10.1016/j.pt.2008.02.009
   Brown LJ, 2014, VACCINE, V32, P3675, DOI 10.1016/j.vaccine.2014.04.029
   Brown LJ, 2014, VACCINE, V32, P984, DOI 10.1016/j.vaccine.2013.12.015
   Brown LJ, 2012, J WILDLIFE DIS, V48, P1010, DOI 10.7589/2012-01-023
   CHARLTON KM, 1992, ARCH VIROL, V123, P169, DOI 10.1007/BF01317147
   Cross ML, 2007, VET J, V174, P472, DOI 10.1016/j.tvjl.2006.10.005
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   European Medicins Agency, 2017, RAB EUR PUBL ASS REP, V44
   Fehlner-Gardiner C, 2015, CURR LAB TECH RABIES, V2, P145
   Fehlner-Gardiner C, 2013, J WILDLIFE DIS, V44, P71
   Fehlner-Gardiner C, 2012, J WILDLIFE DIS, V48, P157, DOI 10.7589/0090-3558-48.1.157
   Freuling CM, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0142
   Fry TL, 2013, VACCINE, V31, P3839, DOI 10.1016/j.vaccine.2013.06.069
   Ghebremedhin B, 2014, EUR J MICROBIOL IMMU, V4, P26, DOI 10.1556/EuJMI.4.2014.1.2
   Gilbert A, 2018, J WILDLIFE DIS, V54, P122, DOI 10.7589/2017-04-073
   Gilbert AT, 2018, J WILDLIFE DIS, V54, P790, DOI 10.7589/2017-09-242
   Hamada K, 2005, GYNECOL ONCOL, V99, pS177, DOI 10.1016/j.ygyno.2005.07.078
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Henderson H, 2009, VACCINE, V27, P7194, DOI 10.1016/j.vaccine.2009.09.030
   Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008
   Kellogg F, 2013, MMWR-MORBID MORTAL W, V62, P267
   Knowles MK, 2009, VACCINE, V27, P6619, DOI 10.1016/j.vaccine.2009.08.005
   MacInnes CD, 2001, J WILDLIFE DIS, V37, P119, DOI 10.7589/0090-3558-37.1.119
   Mainguy J, 2012, J WILDLIFE DIS, V48, P979, DOI 10.7589/2011-12-316
   Maki J, 2017, VET RES, V48, DOI 10.1186/s13567-017-0459-9
   Muller TF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003953
   Murray DL, 1999, ANIM CONSERV, V2, P241, DOI 10.1111/j.1469-1795.1999.tb00070.x
   Musher DM, 2003, NEW ENGL J MED, V348, P1256, DOI 10.1056/NEJMra021771
   Oldham JN, 1967, HELMINTHS ECTOPARASI, P641
   Olson CA, 1999, J WILDLIFE DIS, V35, P687, DOI 10.7589/0090-3558-35.4.687
   PACINI DL, 1984, J INFECT DIS, V150, P92, DOI 10.1093/infdis/150.1.92
   Pedersen K, 2019, J WILDLIFE DIS, V55, P399, DOI 10.7589/2018-05-138
   Pedersen K, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00754
   Pimentel D, 2005, ECOL ECON, V52, P273, DOI 10.1016/j.ecolecon.2004.10.002
   PREVEC L, 1990, J INFECT DIS, V161, P27, DOI 10.1093/infdis/161.1.27
   Radke JR, 2018, CURR OPIN INFECT DIS, V31, P251, DOI [10.1097/QCO.0000000000000451, 10.1097/qco.0000000000000451]
   Rosatte R, 2013, J WILDLIFE DIS, V44, P946
   Rosatte RC, 2011, J WILDLIFE DIS, V47, P459, DOI 10.7589/0090-3558-47.2.459
   Rosatte RC, 2009, J WILDLIFE DIS, V45, P772, DOI 10.7589/0090-3558-45.3.772
   Rosatte RC, 2009, J WILDLIFE DIS, V45, P363, DOI 10.7589/0090-3558-45.2.363
   Rosatte RC, RABIES SCI BASIS DIS, P617
   Rupprecht CE, 2001, NEW ENGL J MED, V345, P582, DOI 10.1056/NEJMoa010560
   RUPPRECHT CE, 1990, J WILDLIFE DIS, V26, P99, DOI 10.7589/0090-3558-26.1.99
   RUPPRECHT CE, 1992, VACCINE, V10, P368, DOI 10.1016/0264-410X(92)90065-R
   Russell WC, 2009, J GEN VIROL, V90, P1, DOI 10.1099/vir.0.003087-0
   Shen CF, 2012, VACCINE, V30, P300, DOI 10.1016/j.vaccine.2011.10.095
   Slate D, 2014, J WILDLIFE DIS, V50, P582, DOI 10.7589/2013-08-207
   Slate D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000549
   Smyser TJ, 2013, J WILDLIFE MANAGE, V77, P1372, DOI 10.1002/jwmg.585
   Sobey KG, 2013, VACCINE, V31, P2207, DOI 10.1016/j.vaccine.2013.02.057
   Stevenson B, 2016, Can Commun Dis Rep, V42, P125
   Szanto AG, 2011, EPIDEMICS-NETH, V3, P76, DOI 10.1016/j.epidem.2011.02.002
   THOMAS I, 1990, J GEN VIROL, V71, P37, DOI 10.1099/0022-1317-71-1-37
   Vos A, 2018, VACCINE, V36, P811, DOI 10.1016/j.vaccine.2017.12.076
   Walsh LL, 2018, CAN J ZOOL, V96, P107, DOI 10.1139/cjz-2017-0071
   Wilkerson JA, 2000, WILD ENVIRON MED, V11, P31, DOI 10.1580/1080-6032(2000)011[0031:RU]2.3.CO;2
   Wold WSM, 2007, FIELDS VIROLOGY, pp2395
   Xiang ZQ, 2003, J IMMUNOL, V171, P4287, DOI 10.4049/jimmunol.171.8.4287
   Xiang ZQ, 2003, J VIROL, V77, P10780, DOI 10.1128/JVI.77.20.10780-10789.2003
   Yang YP, 1996, HUM MOL GENET, V5, P1703, DOI 10.1093/hmg/5.11.1703
   Yarosh OK, 1996, VACCINE, V14, P1257, DOI 10.1016/S0264-410X(96)00012-6
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4310
EP 4317
DI 10.1016/j.vaccine.2019.06.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700013
PM 31248686
DA 2020-05-12
ER

PT J
AU Renson, P
   Fablet, C
   Andraud, M
   Normand, V
   Lebret, A
   Paboeuf, F
   Rose, N
   Bourry, O
AF Renson, Patricia
   Fablet, Christelle
   Andraud, Mathieu
   Normand, Valerie
   Lebret, Arnaud
   Paboeuf, Frederic
   Rose, Nicolas
   Bourry, Olivier
TI Maternally-derived neutralizing antibodies reduce vaccine efficacy
   against porcine reproductive and respiratory syndrome virus infection
SO VACCINE
LA English
DT Article
DE PRRS virus; Modified live virus vaccine; Maternally derived antibody;
   Neutralizing antibody; IFNa; Interference
ID MODIFIED-LIVE VACCINE; IMMUNE-RESPONSES; FARM; TRANSMISSION;
   PERFORMANCE; PROTECTION; PIGLETS; DISEASE; INNATE; STRAIN
AB Modified live virus (MLV) vaccines are commonly used to reduce the impact of porcine reproductive and respiratory syndrome (PRRS) but limited efficacy is achieved in field conditions. Here, we evaluated the impact of maternally-derived neutralizing antibodies (MDNAs) on vaccine efficacy after PRRS virus (PRRSV) challenge. Piglets with low (A-) or high (A+) MDNA levels derived from a commercial pig herd were moved to experimental facilities to be vaccinated (V+) or not (V-) with a PRRSV-1 MLV vaccine at 3 weeks of age (woa). Because of unexpectedly low vaccine detection in A-V+ piglets post-vaccination (pv), all V+ piglets received a second vaccination at 4 woa. Five weeks (W5) pv, piglets were inoculated with a PRRSV-1 field strain to evaluate vaccine protection, and were mingled 24 h later with non-inoculated piglets of similar immune status to assess viral transmission. Vaccine strain was detected at W2 pv in 69% and 6% of A-V+ and A+V+ piglets, and at W5 pv in 50% and 25% of A-V+ and A+V+ piglets, respectively. At W5 pv, 94% of A-V+ and 44% of A+V+ piglets seroconverted, with a significant IFNg response induction in the A-V+ group only. After challenge, compared to the V- inoculated group, viremia was 100-fold lower at 10 days post-infection in A-V+ whereas viremia was not significantly reduced in A+V+ piglets. A lower transmission rate was estimated for the A-V+ group: 0.15 [0.07-0.29] versus 0.44 [0.18-1.76] and 0.32 [0.14-0.68] for the A+V+ and V- groups, respectively. Investigations about the low vaccine strain detection after the first vaccination suggested a relationship between IFNa levels and vaccine strain detection in A-V+ piglets. We showed that MDNAs impair vaccine efficacy against PRRSV both in inoculated and contact piglets, probably by reducing vaccine replication. IFNa may also interfere with PRRSV vaccination. These new data could help improving vaccination protocols. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Renson, Patricia; Bourry, Olivier] Agence Natl Securite Sanitaire Alimentat Environm, Unite Virol Immunol Porcines, BP 53, F-22440 Ploufragan, France.
   [Fablet, Christelle; Andraud, Mathieu; Rose, Nicolas] Anses, Unite Epidemiol, BP 53, F-22440 Ploufragan, France.
   [Paboeuf, Frederic] Anses, Serv Prod Pores Assainis & Expt, BP 53, F-22440 Ploufragan, France.
   [Renson, Patricia] UGPVB, 104 Rue Eugene Pottier, F-35065 Rennes, France.
   [Renson, Patricia; Fablet, Christelle; Andraud, Mathieu; Paboeuf, Frederic; Rose, Nicolas; Bourry, Olivier] Univ Bretagne Loire, 1 Pl Paul Ricoeur,CS 54417, F-35044 Rennes, France.
   [Normand, Valerie; Lebret, Arnaud] ZA Goheleve, Grp Vet Chene Vert Conseil, Porc Spect, F-56920 Noyal Pontivy, France.
RP Bourry, O (reprint author), Anses, Unite Virol Immunol Porcines, BP 53, F-22440 Ploufragan, France.
EM olivier.bourry@anses.fr
OI BOURRY, Olivier/0000-0003-0220-0922
FU European PRRS Research Award 2015; Conseil Regional de BretagneRegion
   Bretagne; Union des Groupements de Producteurs de Viande de Bretagne
FX The authors are grateful to Virginie Dorenlor, Eric Eveno and Florent
   Eono for their involvement in pig sampling in the field. We are also
   thankful to Sophie Mahe and Mireille Le Dimna for their contribution to
   sample analysis. We thank Yann Bailly and Gerald Le Diguerher for animal
   care and Jennifer Richardson from the Anses-Inra-ENVA Virology
   laboratory for access to the Elispot reader. This work was supported by
   the European PRRS Research Award 2015, the "Conseil Regional de
   Bretagne" and the "Union des Groupements de Producteurs de Viande de
   Bretagne".
CR Alexopoulos C, 2005, VET MICROBIOL, V111, P151, DOI 10.1016/j.vetmic.2005.10.007
   Balasch M, 2018, PORCINE HEALTH MANAG, V4, DOI 10.1186/s40813-018-0101-x
   Balka G, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0037-y
   Barbe F, 2011, VET J, V187, P48, DOI 10.1016/j.tvjl.2009.12.012
   Brockmeier SL, 2017, VET MICROBIOL, V212, P48, DOI 10.1016/j.vetmic.2017.11.004
   Charley B, 2006, ANN NY ACAD SCI, V1081, P130, DOI 10.1196/annals.1373.014
   Dokland T, 2010, VIRUS RES, V154, P86, DOI 10.1016/j.virusres.2010.07.029
   Fablet C, 2016, VET MICROBIOL, V192, P175, DOI 10.1016/j.vetmic.2016.07.014
   Fablet C, 2012, VET MICROBIOL, V157, P152, DOI 10.1016/j.vetmic.2011.12.015
   Feng H, 2016, VACCINE, V34, P3044, DOI 10.1016/j.vaccine.2016.04.088
   Fernandez-Sainz I, 2015, VIROLOGY, V483, P284, DOI 10.1016/j.virol.2015.04.024
   Geldhof MF, 2013, VET MICROBIOL, V167, P260, DOI 10.1016/j.vetmic.2013.08.017
   Jamin A, 2006, VET IMMUNOL IMMUNOP, V114, P224, DOI 10.1016/j.vetimm.2006.08.009
   Jeong J, 2018, VET MICROBIOL, V214, P113, DOI 10.1016/j.vetmic.2017.12.023
   LABONNARDIERE C, 1981, INFECT IMMUN, V32, P28, DOI 10.1128/IAI.32.1.28-31.1981
   Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06
   Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003
   Martelli P, 2009, VACCINE, V27, P3788, DOI 10.1016/j.vaccine.2009.03.028
   Murtaugh MP, 2011, VACCINE, V29, P8192, DOI 10.1016/j.vaccine.2011.09.013
   Nathues H, 2017, PREV VET MED, V142, P16, DOI 10.1016/j.prevetmed.2017.04.006
   Neumann EJ, 2005, JAVMA-J AM VET MED A, V227, P385, DOI 10.2460/javma.2005.227.385
   Pileri E, 2015, VET MICROBIOL, V175, P7, DOI 10.1016/j.vetmic.2014.11.007
   Prieto C, 2008, VET J, V175, P356, DOI 10.1016/j.tvjl.2007.01.021
   Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040
   Vandeputte J, 2001, AM J VET RES, V62, P1805, DOI 10.2460/ajvr.2001.62.1805
NR 25
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4318
EP 4324
DI 10.1016/j.vaccine.2019.06.045
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700014
PM 31248683
OA Green Published
DA 2020-05-12
ER

PT J
AU Yi, XY
   Huang, ZX
   Hou, XR
   Zhu, P
   Wang, XY
   Luo, HB
   Liu, BY
AF Yi, Xia-Yu
   Huang, Zhao-Xia
   Hou, Xiao-Rui
   Zhu, Ping
   Wang, Xiang-Yu
   Luo, Hai-Bo
   Liu, Bei-Yi
TI Immunization with a peptide mimicking Lipoteichoic acid protects mice
   against Staphylococcus aureus infection
SO VACCINE
LA English
DT Article
DE Staphylococcus aureus; Lipoteichoic acid; Vaccine candidate; Multiple
   antigenic peptides; Immune response
ID BIOFILM FORMATION; ADHESION; ANTIBODY
AB Lipoteichoic acid (LTA), a major component of the cell wall of Staphylococcus aureus (S. aureus), is not generally considered as an ideal vaccine candidate since it is a thymus-independent antigen. In this study, we screened a 12-mer phage peptide library and identified a series of peptide sequences that can mimic the epitope of LTA. A tetra-branched multiple antigenic peptide, named MAP2-3, comprising one of the positive peptide sequences (GHKEDRQWCQHS), was synthesized. Immunization with MAP2-3 induced LTA-specific IgG antibodies, prolonged the survival time, and decreased the bacterial burden in organs of mice infected with S. aureus. Moreover, passive immunization with polyclonal anti-MAP2-3 sera reduced bacterial load in organs of mice with bacteremia, alleviated acute lung injury in mice with pneumonia, and decreased the size of lesions in mice with skin infection. The number of LTA-specific antibody-secreting cells in the spleen of MAP2-3 immunized mice were significantly higher than that in the control mice. In summary, as a surrogate of LTA, vaccination with MAP2-3 elicited humoral immune response and protected mice from S. aureus infection. This study provides a new option to design vaccines against S. aureus. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yi, Xia-Yu; Huang, Zhao-Xia; Hou, Xiao-Rui; Zhu, Ping; Wang, Xiang-Yu; Liu, Bei-Yi] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, 1023-1063 Shatai Rd, Guangzhou 510515, Guangdong, Peoples R China.
   [Luo, Hai-Bo] Seventy Fourth Mil Hosp PLA, Clin Lab, Guangzhou, Guangdong, Peoples R China.
   [Huang, Zhao-Xia] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai, Guangdong, Peoples R China.
   [Wang, Xiang-Yu] Cent S Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Hunan, Peoples R China.
   [Wang, Xiang-Yu] Cent S Univ, Xiangya Hosp 3, Inst Infect & Computat Med, Changsha, Hunan, Peoples R China.
RP Liu, BY (reprint author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, 1023-1063 Shatai Rd, Guangzhou 510515, Guangdong, Peoples R China.
EM lbydodo@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31270980]; Guangdong Natural Science
   FoundationNational Natural Science Foundation of Guangdong Province
   [S2012010009562]; Guangdong Medical Science and Technology Research
   [A2016533]
FX This work was supported by grants from National Natural Science
   Foundation of China (31270980) to BY Liu, Guangdong Natural Science
   Foundation (S2012010009562) to BY Liu and Guangdong Medical Science and
   Technology Research (A2016533) to XR Hou. The funders had no role in
   study design, data collection and analysis, and decision to publish or
   preparation of the manuscript.
CR Abachin E, 2002, MOL MICROBIOL, V43, P1, DOI 10.1046/j.1365-2958.2002.02723.x
   Acree ME, 2017, INFECT CONT HOSP EP, V38, P1226, DOI 10.1017/ice.2017.177
   Bagnoli F, 2015, P NATL ACAD SCI USA, V112, P3680, DOI 10.1073/pnas.1424924112
   Broecker F, 2016, CELL CHEM BIOL
   Chen QY, 2013, INFECT IMMUN, V81, P2554, DOI 10.1128/IAI.00271-13
   DeLeo FR, 2010, LANCET, V375, P1557, DOI 10.1016/S0140-6736(09)61999-1
   DIJOHN D, 1989, LANCET, V2, P1415
   Fabretti F, 2006, INFECT IMMUN, V74, P4164, DOI 10.1128/IAI.00111-06
   Foster TJ, 2009, VET DERMATOL, V20, P456, DOI 10.1111/j.1365-3164.2009.00825.x
   Fujita Y, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-48
   Fukuda MN, 2012, GLYCOBIOLOGY, V22, P318, DOI 10.1093/glycob/cwr140
   Hou YC, 2003, J IMMUNOL, V170, P4373, DOI 10.4049/jimmunol.170.8.4373
   Huang ZX, 2017, BIOMED PHARMACOTHER, V95, P1684, DOI 10.1016/j.biopha.2017.09.058
   Laverde D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110953
   Lebeer S, 2007, APPL ENVIRON MICROB, V73, P6768, DOI 10.1128/AEM.01393-07
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806
   Mahajan B, 2010, INFECT IMMUN, V78, P4613, DOI 10.1128/IAI.00533-10
   Menendez T, 2011, INT J MED MICROBIOL, V301, P16, DOI 10.1016/j.ijmm.2010.04.020
   Mishra RPN, 2012, J INFECT DIS, V206, P1041, DOI 10.1093/infdis/jis463
   Oscherwitz J, 2010, J IMMUNOL, V185, P3661, DOI 10.4049/jimmunol.1001749
   Percy MG, 2014, ANNU REV MICROBIOL, V68, P81, DOI 10.1146/annurev-micro-091213-112949
   Ramanathan A, 2015, LYMPHAT RES BIOL, V13, P120, DOI 10.1089/lrb.2014.0034
   Schneewind O, 2014, J BACTERIOL, V196, P1133, DOI 10.1128/JB.01155-13
   Sheen TR, 2010, J MOL MED, V88, P633, DOI 10.1007/s00109-010-0630-5
   Su CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071055
   Theilacker C, 2012, J INFECT DIS, V205, P1076, DOI 10.1093/infdis/jis022
   Thiemermann C, 2002, MICROBES INFECT, V4, P927, DOI 10.1016/S1286-4579(02)01620-9
   Umair S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162016
   Wang XY, 2015, PLOS ONE, V10
   Yu RK, 2016, GLYCOBIOLOGY, V26, P63, DOI 10.1093/glycob/cwv080
   Zhang F, 2017, VACCINE, V35, P3834, DOI 10.1016/j.vaccine.2017.05.085
NR 31
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4325
EP 4335
DI 10.1016/j.vaccine.2019.06.024
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700015
PM 31230882
DA 2020-05-12
ER

PT J
AU Nandi, A
   Shet, A
   Behrman, JR
   Black, MM
   Bloom, DE
   Laxminarayan, R
AF Nandi, Arindam
   Shet, Anita
   Behrman, Jere R.
   Black, Maureen M.
   Bloom, David E.
   Laxminarayan, Ramanan
TI Anthropometric, cognitive, and schooling benefits of measles
   vaccination: Longitudinal cohort analysis in Ethiopia, India, and
   Vietnam
SO VACCINE
LA English
DT Article
DE Measles; India; Ethiopia, Vietnam; Young Lives; Long term effects
ID PROPENSITY SCORE; IMMUNIZATION; ATTAINMENT; VACCINES; COVERAGE; PROGRESS
AB Objective: To estimate the associations between measles vaccination and child anthropometry, cognition, and schooling outcomes in Ethiopia, India, and Vietnam.
   Methods: Longitudinal survey data from Young Lives were used to compare outcomes at ages 7-8 and 11-12 years between children who reported receipt or non-receipt of measles vaccine at 6-18 months-of-life (n = similar to 2000/country). Z-scores of height-for-age (HAZ), BMI-for-age (BMIZ), weight-for-age (WAZ), Peabody Picture Vocabulary Test (PPVT), early grade reading assessment (EGRA), language and mathematics tests, and attained schooling grade were examined. Propensity score matching was used to control for systematic differences between measles-vaccinated and measles-unvaccinated children.
   Findings: Using age- and country-matched measles-unvaccinated children as comparisons, measles-vaccinated children had better anthropometrics, cognition, and schooling. Measles-vaccinated children had 0.1 higher HAZ in India and 0.2 higher BMIZ and WAZ in Vietnam at age 7-8 years, and 0.2 higher BMIZ at age 11-12 years in Vietnam. At ages 7-8 years, they scored 4.5 and 2.9 percentage points (pp) more on PPVF and mathematics, and 2.3 points more on EGRA in Ethiopia, 2.5 points more on EGRA in India, and 2.6 pp, 4 pp, and 2.7 points more respectively on PPVT, mathematics, and EGRA in Vietnam. At ages 11-12 years, they scored 3 pp more on English and PPVT in India, and 1.7 pp more on PPVT in Vietnam. They also attained 0.2-0.3 additional schooling grades across all ages and countries.
   Conclusion: Our findings suggest that measles vaccination may have benefits on cognitive gains and school-grade attainment that can have broad educational and economic consequences which extend beyond early childhood. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Nandi, Arindam] Ctr Dis Dynam Econ & Policy, 1400 Eye St NW,Suite 500, Washington, DC 20005 USA.
   [Shet, Anita] Johns Hopkins Bloomberg Sch Publ Hlth, 415 N Washington St, Baltimore, MD 21231 USA.
   [Behrman, Jere R.] Univ Penn, Perelman Ctr Polit Sci & Econ, Econ Dept, 133 South 36th St, Philadelphia, PA 19104 USA.
   [Black, Maureen M.] RTI Int, Res Triangle Pk, NC 27709 USA.
   [Black, Maureen M.] Univ Maryland, Sch Med, Dept Pediat, 737 W Lombard St,Suite 161, Baltimore, MD 21201 USA.
   [Bloom, David E.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, 665 Huntington Ave,Bldg 1,12th Floor,Suite 1202, Boston, MA 02115 USA.
   [Laxminarayan, Ramanan] Ctr Dis Dynam Econ & Policy, B-25,Lajpat Nagar 2, Delhi 110024, India.
   [Laxminarayan, Ramanan] Princeton Univ, Princeton Environm Inst, Princeton, NJ 08544 USA.
RP Nandi, A (reprint author), Ctr Dis Dynam Econ & Policy, 1400 Eye St NW,Suite 500, Washington, DC 20005 USA.
EM nandi@cddep.org; ashet1@jhu.edu; jbehrman@econ.upenn.edu;
   mblack@som.umaryland.edu; dbloom@hsph.harvard.edu; ramanan@cddep.org
OI Nandi, Arindam/0000-0002-3967-2424; Laxminarayan,
   Ramanan/0000-0002-1390-9016
FU Bill & Melinda Gates FoundationGates Foundation [OPP1183738]
FX This work was supported by the Bill & Melinda Gates Foundation
   [OPP1183738]. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Anekwe TD, 2015, VACCINE, V33, P5020, DOI 10.1016/j.vaccine.2015.04.072
   Awofeso N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-358
   Barnett I, 2013, INT J EPIDEMIOL, V42, P701, DOI 10.1093/ije/dys082
   Beraud G, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.25.1700796
   Bhalotra S.R., 2011, CAPTAIN MEN DEATH HI
   Black MM, 2017, LANCET, V389, P77, DOI 10.1016/S0140-6736(16)31389-7
   Bloom DE, 2012, APPL ECON, V44, P2777, DOI 10.1080/00036846.2011.566203
   Boyden J., 2016, YOUNG LIVES INT STUD
   Canning D, 2011, SOC SCI MED, V72, P1429, DOI 10.1016/j.socscimed.2011.02.043
   CDC, 2018, MEASL CAS OUTBR
   Ceccarelli G, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tax080
   Centers for Disease Control and Prevention, 2018, COMPL MEASL
   Crookston BT, 2013, AM J CLIN NUTR, V98, P1555, DOI 10.3945/ajcn.113.067561
   Cueto S., 2012, PSYCHOMETRIC CHARACT
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   An DTM, 2016, GLOBAL HEALTH ACTION, V9, P38, DOI 10.3402/gha.v9.29189
   de Onis Mercedes, 2004, Food Nutr Bull, V25, pS15
   Dehejia RH, 1999, J AM STAT ASSOC, V94, P1053, DOI 10.2307/2669919
   Dehejia RH, 2002, REV ECON STAT, V84, P151, DOI 10.1162/003465302317331982
   Phan D, 2013, J COMP ECON, V41, P1106, DOI 10.1016/j.jce.2013.04.001
   Driessen J, 2015, APPL ECON, V47, P6019, DOI 10.1080/00036846.2015.1061647
   ecdc, 2018, MEASL OUTBR STILL ON
   Evans DK, 2016, WORLD BANK RES OBSER, V31, P242, DOI 10.1093/wbro/lkw004
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Gelman A, 2012, J RES EDUC EFF, V5, P189, DOI 10.1080/19345747.2011.618213
   Gensowski M, 2018, CHILDHOOD HLTH SHOCK, DOI [10.3386/w24753, DOI 10.3386/W24753]
   Gessner BD, 2017, VACCINE, V35, P6255, DOI 10.1016/j.vaccine.2017.09.048
   Glewwe P., 1991, SCH SKILLS RETURNS G
   Heckman JJ, 1997, REV ECON STUD, V64, P605, DOI 10.2307/2971733
   Heywood AE, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay118
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hsu J. C., 1996, MULTIPLE COMP THEORY
   Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9
   Lahariya C, 2014, INDIAN J MED RES, V139, P491
   Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6
   Leong WY, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay080
   Loken KV, 2018, REV ECON STAT, DOI [10.1162/rest.a.00790, DOI 10.1162/REST.A.00790]
   Lu CL, 2016, LANCET GLOB HEALTH, V4, pE916, DOI [10.1016/S2214-109X(16)30266-2, 10.1016/s2214-109x(16)30266-2]
   Massad E, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay091
   Mina MJ, 2017, J INFECTION, V74, pS10, DOI 10.1016/S0163-4453(17)30185-8
   Mina MJ, 2015, SCIENCE, V348, P694, DOI 10.1126/science.aaa3662
   Montenegro CE, WPS7020 WORLD BANK, P1
   Nandi A, 2019, ANN NY ACAD SCI, V1449, P70, DOI 10.1111/nyas.14127
   Oster E, 2009, DEMOGRAPHY, V46, P325, DOI 10.1353/dem.0.0055
   Pande RP, 2003, DEMOGRAPHY, V40, P395, DOI 10.1353/dem.2003.0029
   Pavli A, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax016
   Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Saadatian-Elahi M, 2016, VACCINE, V34, P1139, DOI 10.1016/j.vaccine.2016.01.021
   Semba RD, 2004, SURV OPHTHALMOL, V49, P243, DOI 10.1016/j.survophthal.2003.12.005
   Singh PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073102
   Sorup S, 2014, JAMA-J AM MED ASSOC, V311, P826, DOI 10.1001/jama.2014.470
   Thang NM, 2007, J BIOSOC SCI, V39, P41, DOI 10.1017/S0021932006001234
   Nguyen TD, 2015, HUM VACC IMMUNOTHER, V11, P1526, DOI 10.1080/21645515.2015.1032487
   Tuite AR, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay077
   Vashishtha VM, 2013, INDIAN PEDIATR, V50, P111, DOI 10.1007/s13312-013-0025-0
   Kien VD, 2017, INT J PUBLIC HEALTH, V62, pS41, DOI 10.1007/s00038-016-0899-4
   WESTFALL P, 1993, RESAMPLING BASED MUL
   Wilder-Smith A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0911-8
   World Health Organization, 2016, PROGR GLOB IMM GOALS
   World Health Organization, 2017, WHO VACC PREV DIS MO
   World Health Organization United Nations Children's Fund World Bank Group, 2018, NURT CAR EARL CHILDH
   Young Lives, 2016, YOUNG LIV SURV SAMPL
NR 63
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4336
EP 4343
DI 10.1016/j.vaccine.2019.06.025
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700016
PM 31227354
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Tambyah, PA
   Oon, J
   Asli, R
   Kristanto, W
   Hwa, SH
   Vang, F
   Karvval, L
   Fuchs, J
   Santangelo, JD
   Gordon, GS
   Thomson, C
   Rao, R
   Dean, H
   Das, SC
   Stinchcomb, DT
AF Tambyah, Paul A.
   Oon, Jolene
   Asli, Rosmonaliza
   Kristanto, William
   Hwa, Shi-Hsia
   Vang, Fue
   Karvval, Lovkesh
   Fuchs, Jeremy
   Santangelo, Joseph D.
   Gordon, Gilad S.
   Thomson, Cynthia
   Rao, Raman
   Dean, Hansi
   Das, Subash C.
   Stinchcomb, Dan T.
TI An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy
   adults: A phase I, double blind, randomized, placebo-controlled, study
   of two dosages
SO VACCINE
LA English
DT Article
DE Enterovirus 71 vaccine; B2 sub-genotype; Phase I clinical trial;
   Immunogenicity; Seroconversion; Cross-neutralization
ID BINARY ETHYLENIMINE; MOUTH-DISEASE; ANTIBODY-RESPONSES; VIRUS; FOOT;
   HAND; ANTIGENICITY; INFECTION; MICE; IMMUNIZATION
AB Background: Hand, foot and mouth disease (HFMD), especially that caused by enterovirus 71 (EV71) infection, is a public health concern in the Asia-Pacific region. We report a phase I clinical trial of an EV71 candidate vaccine (INV21) based on a binary ethylenimine inactivated B2 sub-genotype formulated with aluminum hydroxide.
   Methods: In this double-blind, placebo-controlled, randomized, dose escalation study adult volunteers received two vaccinations 28 days apart of low or high dose formulations of the candidate vaccine and were then monitored for safety and reactogenicity for four weeks after each dose, and for their immune responses up to 28 weeks.
   Results: Of 36 adults enrolled, 35 completed the study as planned. Either no or mild adverse events were observed, mainly injection site pain and tiredness. Seroconversion was 100% after two vaccinations. High geometric mean neutralizing antibody titers (GMT) were observed 14 days post first dose, peaking 14 days post second dose (at Day 42) in both high and low dose groups; GMTs on days 14, 28, 42, and 56 were 128, 81, 323, 203 and 144, 100, 451, 351 in low-and high-dose groups, respectively. Titers for both doses declined gradually to Day 196 but remained higher than baseline and the placebo groups, which had low GMTs throughout the duration of the study. Cross-neutralizing antibody activity against heterologous sub-genotypes was demonstrated.
   Conclusion: These data show that the EV71 candidate vaccine is safe and immunogenic in adults and supports further clinical development as a potential pediatric vaccine by initiating a dose-escalation study for determining the dose-dependent safety and immunogenicity of the vaccine in young naive children. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Tambyah, Paul A.; Oon, Jolene; Asli, Rosmonaliza; Kristanto, William] Natl Univ Singapore, Yong Loo Lin Sch Med, NUN Invest Med Unit, Dept Med, 1E Kent Ridge Rd,NUHS Tower Block,Level 10, Singapore 119228, Singapore.
   [Hwa, Shi-Hsia; Thomson, Cynthia; Rao, Raman] Takeda Pharmaceut Asia Pacific Pte Ltd, Vaccine Business Unit, 21 Biopolis Rd,Nucleos South Tower,Level 4, Singapore 138567, Singapore.
   [Gordon, Gilad S.; Stinchcomb, Dan T.] Takeda Vaccines Inc, Takeda Pharmaceut USA, Ft Collins, CO USA.
   [Vang, Fue; Karvval, Lovkesh; Fuchs, Jeremy; Santangelo, Joseph D.; Dean, Hansi; Das, Subash C.] Takeda Pharmaceut USA, Vaccine Business Unit, 40 Landsdowne St, Cambridge, MA 02139 USA.
RP Das, SC (reprint author), Takeda Pharmaceut USA, Vaccine Business Unit, 40 Landsdowne St, Cambridge, MA 02139 USA.
EM subash.das@takeda.com
OI Hwa, Shi-Hsia/0000-0002-5648-9808
FU Inviragen Inc.
FX This study was initially funded by Inviragen Inc., which was acquired by
   Takeda Vaccines, Inc. in May 2013.
CR Aaskov J, 1997, VACCINE, V15, P1396, DOI 10.1016/S0264-410X(97)00051-0
   Arita M, 2007, J VIROL, V81, P9386, DOI 10.1128/JVI.02856-06
   Awad Manal, 2003, Egypt J Immunol, V10, P67
   BAHNEMANN HG, 1975, ARCH VIROL, V47, P47, DOI 10.1007/BF01315592
   BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X
   Berhane Y, 2006, J VIROL METHODS, V132, P59, DOI 10.1016/j.jviromet.2005.09.005
   Chan YF, 2010, INFECT GENET EVOL, V10, P404, DOI 10.1016/j.meegid.2009.05.010
   Chang HW, 2011, J VIROL METHODS, V173, P189, DOI 10.1016/j.jviromet.2011.02.003
   Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1
   Chang PC, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090890
   Chen HF, 2006, VACCINE, V24, P2944, DOI 10.1016/j.vaccine.2005.12.047
   Cheng A, 2013, VACCINE, V31, P2471, DOI 10.1016/j.vaccine.2013.03.015
   Cheng LW, 2012, J VIROL METHODS, V182, P43, DOI 10.1016/j.jviromet.2012.03.004
   Chia MY, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003044
   Chong P, 2012, HUM VACC IMMUNOTHER, V8, P1775, DOI 10.4161/hv.21739
   Chou AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079783
   Chou AH, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831282
   Chung YC, 2008, VACCINE, V26, P1855, DOI 10.1016/j.vaccine.2008.01.058
   Diedrich S, 2009, ARCH VIROL, V154, P1139, DOI 10.1007/s00705-009-0413-x
   Fan C, 2017, J VIROL, V91, DOI 10.1128/JVI.00038-17
   Foo DGW, 2007, MICROBES INFECT, V9, P1299, DOI 10.1016/j.micinf.2007.06.002
   Grund S, 2011, J VIROL METHODS, V171, P369, DOI 10.1016/j.jviromet.2010.11.024
   Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301
   Hu YM, 2018, HUM VACC IMMUNOTHER, V14, P1517, DOI 10.1080/21645515.2018.1442997
   Huang CC, 1999, NEW ENGL J MED, V341, P936, DOI 10.1056/NEJM199909233411302
   Huang SW, 2009, J CLIN MICROBIOL, V47, P3653, DOI 10.1128/JCM.00630-09
   Hwa SH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002538
   Koh W. M., 2018, BMJ GLOB HLTH, V3, P1
   Koh WM, 2016, PEDIATR INFECT DIS J, V35, pE285, DOI 10.1097/INF.0000000000001242
   Kung SH, 2007, CLIN MICROBIOL INFEC, V13, P782, DOI 10.1111/j.1469-0691.2007.01745.x
   LARGHI OP, 1980, J CLIN MICROBIOL, V11, P120, DOI 10.1128/JCM.11.2.120-122.1980
   Lee MS, 2010, EXPERT REV VACCINES, V9, P149, DOI [10.1586/erv.09.152, 10.1586/ERV.09.152]
   Li YP, 2012, VACCINE, V30, P3295, DOI 10.1016/j.vaccine.2012.03.010
   Lin CL, 2018, J INFECT DIS THER, V6, P370, DOI [10.4172/2332-0877.1000370, DOI 10.4172/2332-0877.1000370]
   Liu CC, 2011, VACCINE, V29, P4362, DOI 10.1016/j.vaccine.2011.04.010
   Liu JN, 2010, VACCINE, V28, P7444, DOI 10.1016/j.vaccine.2010.08.080
   Lyu K, 2015, SCI BULL, V60, P1305, DOI 10.1007/s11434-015-0847-3
   Mao QY, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.73
   Mao QY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079599
   Meng FY, 2012, HUM VACC IMMUNOTHER, V8, P669, DOI 10.4161/hv.19521
   Meng T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021757
   Mizuta K, 2009, VACCINE, V27, P3153, DOI 10.1016/j.vaccine.2009.03.060
   Ong KC, 2010, J VIROL, V84, P661, DOI 10.1128/JVI.00999-09
   RACE E, 1995, VACCINE, V13, P54, DOI 10.1016/0264-410X(95)80011-2
   Sabanathan S, 2014, J EPIDEMIOL COMMUN H, V68, P500, DOI 10.1136/jech-2014-203836
   Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8
   Tung Wong Siew, 2007, Genet Vaccines Ther, V5, P6, DOI 10.1186/1479-0556-5-6
   Vanhee M, 2009, VET RES, V40, DOI 10.1051/vetres/2009046
   Wang YR, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-539
   Yee PTI, 2017, VIROLOGY, V506, P121, DOI 10.1016/j.virol.2017.03.017
   Zhang W, 2016, HUM VACC IMMUNOTHER, V12, P922, DOI 10.1080/21645515.2015.1115934
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 53
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4344
EP 4353
DI 10.1016/j.vaccine.2019.06.023
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700017
PM 31230881
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tshilwane, SI
   Thema, N
   Steyn, HC
   van Kleef, M
   Pretorius, A
AF Tshilwane, S. I.
   Thema, N.
   Steyn, H. C.
   van Kleef, M.
   Pretorius, A.
TI A multi-epitope DNA vaccine co-administered with monophosphoryl lipid A
   adjuvant provides protection against tick transmitted Ehrlichia
   ruminantium in sheep
SO VACCINE
LA English
DT Article
DE Multi-epitope DNA vaccine; Monophosphoryl lipid A; E. ruminantium; Tick
   challenge
ID T-CELL RESPONSES; IN-VITRO; IMMUNE-RESPONSES; IMMUNIZATION;
   OPTIMIZATION; LYMPHOCYTES; HEARTWATER; CHALLENGE; SPACERS; ANTIGEN
AB Previously, a heartwater experimental DNA vaccine provided 100% protection following laboratory challenge with Ehrlichia ruminantium administered by needle but not against an E. ruminantium tick challenge in the field. A multi-epitope DNA vaccine incorporating both CD4(+) and CD8(+) cytotoxic T lymphocytes epitopes could provide a better alternative. In this study, we investigated the use of multi-epitope DNA vaccines against an E. ruminantium experimental tick challenge in sheep. The multi-epitope DNA vaccines were delivered via the intramuscular route and intradermal route using the gene gun in the presence of monophosphoryl lipid A (MPL) adjuvant, which was either applied topically to the gene gun inoculation site or co-administered with the vaccine via the intramuscular route. Initially two constructs namely, pSignal plus and pLamp were tested with MPL applied topically only and no protection was obtained in this formulation. However, when pLamp was co-administered with MPL via the intramuscular route in addition to topical application, its protective efficiency improved to protect 60% of the sheep against tick challenge. In this formulation, the vaccine induced enhanced activation of memory T cell responses both before and after challenge with variations amongst the different sheep possibly due to their different genetic backgrounds. In conclusion, this study showed that a heartwater multi-epitope DNA vaccine, co-administered with MPL adjuvant can protect sheep following a laboratory E. ruminantium tick challenge. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tshilwane, S. I.; Thema, N.; Steyn, H. C.; van Kleef, M.; Pretorius, A.] Agr Res Council Onderstepoort Vet Res, Private Bag X5, ZA-0110 Onderstepoort, South Africa.
   [Thema, N.; van Kleef, M.; Pretorius, A.] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, Private Bag X04, ZA-0110 Onderstepoort, South Africa.
RP Tshilwane, SI (reprint author), Univ KwaZulu Natal, Sch Life Sci, Univ Rd, ZA-4000 Durban, South Africa.
EM TshilwaneS@ukzn.ac.za
RI Tshilwane, Ivy/AAK-8970-2020
OI Tshilwane, Ivy/0000-0002-3549-4675
FU NRF [IFR2011040500039]; THRIP [TP2010070900014]; RMRDT [09/25/c224];
   ARC-OVR, South Africa; ECSP [30/01/V011]; OBP
FX The authors acknowledge financial support received from the NRF
   (IFR2011040500039), THRIP (TP2010070900014) and RMRDT (09/25/c224) in
   collaboration with OBP and ECSP (30/01/V011) and the ARC-OVR, South
   Africa.
CR Aksular M, 2018, VACCINE, V36, P7003, DOI 10.1016/j.vaccine.2018.09.065
   Allsopp BA, 2009, ONDERSTEPOORT J VET, V76, P81
   Alves-Silva MV, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00100
   Babiuk S, 2003, MOL THER, V8, P992, DOI 10.1016/j.ymthe.2003.09.008
   Bal SM, 2010, J CONTROL RELEASE, V148, P266, DOI 10.1016/j.jconrel.2010.09.018
   Capriotti Kara, 2012, J Clin Aesthet Dermatol, V5, P24
   Chappell P, 2015, ELIFE, V4, DOI 10.7554/eLife.05345
   Coelho-dos-Reis JG, 2016, CLIN IMMUNOL, V168, P6, DOI 10.1016/j.clim.2016.04.014
   Godinho RMD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099887
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   El Bissati K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85955
   Esteves I, 2002, ANN NY ACAD SCI, V969, P126, DOI 10.1111/j.1749-6632.2002.tb04363.x
   Faber FE, 2016, VIRUS RES, V220, P12, DOI 10.1016/j.virusres.2016.04.007
   Fougeroux C, 2019, J IMMUNOL, V202, P2320, DOI 10.4049/jimmunol.1801210
   Himes R, 2011, VACCINE, V29, P5393, DOI 10.1016/j.vaccine.2011.05.085
   Kara PD, 2018, VACCINE, V36, P4708, DOI 10.1016/j.vaccine.2018.06.017
   Katou F, 2000, AM J PATHOL, V156, P519, DOI 10.1016/S0002-9440(10)64756-6
   Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976
   Livingston BD, 2001, VACCINE, V19, P4652, DOI 10.1016/S0264-410X(01)00233-X
   Malik A, 2019, INT J NANOMED, V14, P3129, DOI 10.2147/IJN.S172391
   Montomoli E, 2011, EXPERT REV VACCINES, V10, P1053, DOI [10.1586/erv.11.48, 10.1586/ERV.11.48]
   Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487
   Mwangi W, 2007, CLIN VACCINE IMMUNOL, V14, P304, DOI 10.1128/CVI.00363-06
   Nagaoka Y, 1999, CANCER RES, V59, P975
   Olafsdottir T, 2015, VACCINE, V33, P5302, DOI 10.1016/j.vaccine.2015.04.099
   Pontarollo RA, 2002, VET IMMUNOL IMMUNOP, V84, P43, DOI 10.1016/S0165-2427(01)00379-8
   Pouliot K, 2014, VACCINE, V32, P5049, DOI 10.1016/j.vaccine.2014.07.010
   Pretorius A, 2008, VACCINE, V26, P4363, DOI 10.1016/j.vaccine.2008.06.006
   Pretorius A, 2007, VACCINE, V25, P2316, DOI 10.1016/j.vaccine.2006.11.061
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Rodriguez F, 1998, J VIROL, V72, P5174, DOI 10.1128/JVI.72.6.5174-5181.1998
   Sabet LP, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.22215
   Sebatjane SI, 2010, VET IMMUNOL IMMUNOP, V137, P217, DOI 10.1016/j.vetimm.2010.05.011
   Starodubova ES, 2010, ACTA NATURAE, V2, P53, DOI 10.32607/20758251-2010-2-1-53-59
   Steyn HC, 2008, VET MICROBIOL, V131, P258, DOI 10.1016/j.vetmic.2008.04.002
   Stoecklinger A, 2011, J IMMUNOL, V186, P1377, DOI 10.4049/jimmunol.1002557
   Thema N, 2019, MOL IMMUNOL, V107, P106, DOI 10.1016/j.molimm.2018.12.012
   Thema N, 2019, VET IMMUNOL IMMUNOP, V207, P1, DOI 10.1016/j.vetimm.2018.11.012
   Thema N, 2016, ONDERSTEPOORT J VET, V83, DOI 10.4102/ojvr.v83i1.1170
   Tian MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00310
   Todorova B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04547-2
   Totte P, 1999, PARASITOL TODAY, V15, P286, DOI 10.1016/S0169-4758(99)01467-2
   Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084
   Vachiery N, 2006, VACCINE, V24, P4747, DOI 10.1016/j.vaccine.2006.03.031
   van der Laan JW, 2015, VACCINE, V33, P1507, DOI 10.1016/j.vaccine.2015.01.073
   Vatakis D, 2011, CLIN VACCINE IMMUNOL, V18, P1776, DOI 10.1128/CVI.05179-11
   Velders MP, 2001, J IMMUNOL, V166, P5366, DOI 10.4049/jimmunol.166.9.5366
   Wang QM, 2004, SCAND J IMMUNOL, V60, P219, DOI 10.1111/j.0300-9475.2004.01442.x
   Weber CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128722
NR 49
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4354
EP 4363
DI 10.1016/j.vaccine.2019.06.027
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700018
PM 31248684
DA 2020-05-12
ER

PT J
AU Song, SS
   Li, PF
   Zhang, RH
   Chen, JH
   Lan, JJ
   Lin, SL
   Guo, GJ
   Xie, ZJ
   Jiang, SJ
AF Song, Shasha
   Li, Pengfei
   Zhang, Ruihua
   Chen, Junhao
   Lan, Jingjing
   Lin, Shaoli
   Guo, Guanjie
   Xie, Zhijing
   Jiang, Shijin
TI Oral vaccine of recombinant Lactococcus lactis expressing the VP1
   protein of duck hepatitis A virus type 3 induces mucosal and systemic
   immune responses
SO VACCINE
LA English
DT Article
DE Duck hepatitis A virus type 3 (DHAV-3); VP1; Lactococcus lactis (L.
   lactis); Oral vaccination
ID IMMUNIZATION; PROTECTION; POLYSACCHARIDE; INTERLEUKIN-10; CELLS; GENE
AB Duck hepatitis A virus (DHAV) is the major pathogen of duck viral hepatitis, which has caused great economic losses to duck breeding industry. As an effective delivery tool for protein antigens, Lactococcus lactis (L. lactis) has been successfully used to stimulate mucosal and systemic immune response. In this study, a recombinant L lactis named NZ3900-VP1 was constructed, which could express VP1 protein of DHAV type 3 (DHAV-3) by using a nisin-controlled expression (NICE) system. The animal experiment in both mice and ducklings were performed to detect the immune response and protection effect of oral vaccination by the recombinant L lactis. The results showed that oral vaccination with L. lactis NZ3900-VP1 significantly induced specific anti-VP1 IgG antibodies and mucosal secretory immunoglobulin A (slgA) of DHAV-3 in mice and ducklings, and cytokines including interleukin-2 (IL-2), interferon gamma (IFN-gamma), interleukin-10 (IL-10) and interleukin-4 (IL-4). Notably, the ducklings vaccinated with L. lactis NZ3900-VP1 were effectively protected when facing natural infestation of DHAV-3, which indicated that the recombinant L. lactis could serve as an effective vaccine to prevent DHAV-3 infection in ducklings. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Song, Shasha; Li, Pengfei; Zhang, Ruihua; Chen, Junhao; Lan, Jingjing; Lin, Shaoli; Guo, Guanjie; Xie, Zhijing; Jiang, Shijin] Shandong Agr Univ, Coll Vet Med, Dept Prevent Vet Med, Tai An 271018, Shandong, Peoples R China.
   [Song, Shasha; Zhang, Ruihua; Chen, Junhao; Lan, Jingjing; Xie, Zhijing; Jiang, Shijin] Shandong Prov Key Lab Anim Biotechnol & Dis Contr, Tai An 271018, Shandong, Peoples R China.
   [Song, Shasha; Zhang, Ruihua; Chen, Junhao; Lan, Jingjing; Xie, Zhijing; Jiang, Shijin] Shandong Prov Engn Technol Res Ctr Anim Dis Contr, Tai An 271018, Shandong, Peoples R China.
RP Jiang, SJ (reprint author), Shandong Agr Univ, Coll Vet Med, Dept Prevent Vet Med, Tai An 271018, Shandong, Peoples R China.
EM sjjiang@sdau.edu.cn
OI Jiang, Shijin/0000-0002-4747-8410
FU National Key Research and Development Program of China [2017YFD0500800];
   Funds of Shandong "Double Tops" Program, China [SYL2017YSTD11]; Shandong
   Modern Agricultural Technology & Industry System, China [SDAIT-11-15]
FX This work was funded by grants from the National Key Research and
   Development Program of China (2017YFD0500800), Funds of Shandong "Double
   Tops" Program, China (SYL2017YSTD11) and Shandong Modern Agricultural
   Technology & Industry System, China (SDAIT-11-15).
CR Chen LL, 2013, J VIROL METHODS, V192, P12, DOI 10.1016/j.jviromet.2013.04.012
   Chen Linlin, 2014, Virologica Sinica, V29, P196, DOI 10.1007/s12250-014-3444-8
   Chen Y, 2014, CARBOHYD POLYM, V102, P333, DOI 10.1016/j.carbpol.2013.11.065
   Gao SY, 2015, INT IMMUNOPHARMACOL, V24, P140, DOI 10.1016/j.intimp.2014.10.032
   Hickey RM, 2004, APPL ENVIRON MICROB, V70, P1744, DOI 10.1128/AEM.70.3.1744-1748.2004
   Doan HTT, 2016, J INFECT DEV COUNTR, V10, P988, DOI 10.3855/jidc.7239
   Kim MC, 2007, ARCH VIROL, V152, P2059, DOI 10.1007/s00705-007-1023-0
   Kim MC, 2009, VACCINE, V27, P6688, DOI 10.1016/j.vaccine.2009.08.092
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311
   Lan RY, 2008, J AUTOIMMUN, V31, P7, DOI 10.1016/j.jaut.2008.03.002
   Levine MM, 2000, J PEDIATR GASTR NUTR, V31, P336, DOI 10.1097/00005176-200010000-00003
   LEVINE PP, 1950, CORNELL VET, V40, P71
   Li CF, 2013, J VIROL METHODS, V191, P69, DOI 10.1016/j.jviromet.2013.04.004
   Lin SL, 2016, ARCH VIROL, V161, P405, DOI 10.1007/s00705-015-2648-z
   Liu GQ, 2008, VIRUS RES, V137, P137, DOI 10.1016/j.virusres.2008.04.030
   Meager A, 2005, CYTOKINE, V31, P109, DOI 10.1016/j.cyto.2005.04.003
   Mierau I, 2005, APPL MICROBIOL BIOT, V68, P705, DOI 10.1007/s00253-005-0107-6
   Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791
   Rudge EU, 2002, J EXP MED, V195, P1079, DOI 10.1084/jem.20011435
   Shen YL, 2015, J VIROL METHODS, V225, P30, DOI 10.1016/j.jviromet.2015.08.016
   Soliman M, 2015, ARCH VIROL, V160, P493, DOI 10.1007/s00705-014-2264-3
   Wang AP, 2019, POULTRY SCI, V98, P112, DOI 10.3382/ps/pey325
   Wang ZS, 2012, FUTURE MICROBIOL, V7, P1003, DOI [10.2217/FMB.12.69, 10.2217/fmb.12.69]
   Wei CY, 2012, J VIROL, V86, P10247, DOI 10.1128/JVI.01643-12
   WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x
   Wen CH, 2006, 2006 7TH INTERNATIONAL SYMPOSIUM ON ANTENNAS, PROPAGATION AND EM THEORY, VOLS 1 AND 2, PROCEEDINGS, P288
   Wilke CM, 2011, CANCER IMMUNOL IMMUN, V60, P1529, DOI 10.1007/s00262-011-1104-5
   Yam KK, 2008, VACCINE, V26, P2689, DOI 10.1016/j.vaccine.2008.03.024
   Zhang RH, 2015, VET MICROBIOL, V180, P196, DOI 10.1016/j.vetmic.2015.09.008
   Zhao L, 2017, VACCINE, V35, P4010, DOI 10.1016/j.vaccine.2017.05.076
   Zhou J, 2017, ALLERGOL IMMUNOPATH, V45, P496, DOI 10.1016/j.aller.2017.04.005
NR 32
TC 0
Z9 0
U1 4
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4364
EP 4369
DI 10.1016/j.vaccine.2019.06.026
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700019
PM 31227355
DA 2020-05-12
ER

PT J
AU Mungwira, RG
   Maure, CG
   Zuber, PLP
AF Mungwira, Randy G.
   Maure, Christine Guillard
   Zuber, Patrick L. P.
TI Economic and immunisation safety surveillance characteristics of
   countries implementing no-fault compensation programmes for vaccine
   injuries
SO VACCINE
LA English
DT Article
DE Vaccine injury; No-fault compensation programmes; Country profiles
AB Improvements in vaccine safety surveillance and investigative capacity lead to identification of rare reactions attributable to vaccination. As a result, the issue of fair compensation for those who experience vaccine injuries is gaining growing attention. Although vaccine injury compensation programmes (VICP) have been developed in a few countries for more than 50 years, no global policy guidance to guide vaccine injury compensation in all countries wishing to adopt such compensation schemes is currently available. To update the landscape analysis of no-fault compensation programmes and characterize VICP implementing countries, we conducted a survey of all 194 Member States from the World Health Organization and received feedback from 151. This analysis describes the economic and vaccine safety surveillance characteristics of Member States implementing VICPs. This analysis describes the characteristics of 25 Member States implementing a compensation programmes. Characteristics examined include economic, vaccination and safety surveillance indicators. Twenty of the 25 Member States (80%) with compensation programmes are categorized as high-income countries, 20/25 (80%) met the Global Vaccine Action Plan (GVAP) safety indicator of reporting at least ten annual reports of adverse events following immunization per 100,000 population, 21/25 (84%) met the GVAP coverage indicator by achieving greater than 90% third dose of Diphtheria, Tetanus and Pertussis vaccine (DTP3) and 17/25 (68%) assessed vaccine hesitancy in 2017. All Member States with VICP have a national immunization technical advisory group. This study identified growing interest in the implementation of no-fault compensation programs beyond high-income countries. Global policies guiding compensation should be developed for countries regardless of the maturity of their immunization programmes.
   Research in context: As a result of improved vaccine safety surveillance, World Health Organization (WHO) Member States are facing situations where known untoward serious vaccine reactions are documented, including in low-and middle-income settings. This has led to increased interest for the development of national no-fault compensation policies for vaccine injuries. As of 2010, compensation schemes for vaccine related injuries had been identified and characterized in 19 out of 194 WHO member states. All these programmes were in the industrialized world with none in low-and middle-income countries. Previous reviews have described the characteristics of the existing programmes based on the six common elements identified by Evans in 1999 with less emphasis on characteristics from countries implementing these no-fault compensation programmes.
   This manuscript aimed to identify predictors of countries implementing no-fault compensation programmes for vaccine injuries and update the inventory of existing programmes as part of a more comprehensive global landscape evaluation of existing programmes. This information will be useful for country self-evaluation and future compensation policy formulation as discussion to develop policies guiding the implementation of vaccine injury compensation continues to gain growing attention. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mungwira, Randy G.] Univ Siena, Siena, Italy.
   [Maure, Christine Guillard; Zuber, Patrick L. P.] WHO, Dept Essential Med & Hlth Prod, Global Vaccine Safety Grp, Geneva, Switzerland.
RP Mungwira, RG (reprint author), Univ Malawi, Coll Med, Private Bag 360, Blantyre, Malawi.
EM rgmungwira@gmail.com; maurec@who.int; zuberp@who.int
OI Mungwira, Randy/0000-0003-2505-0904
FU World Health OrganizationWorld Health Organization [001]
CR [Anonymous], 2017, WHO UNICEF JOINT REP
   [Anonymous], 2018, INT C DRUG REG AUTH
   Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7
   Cook KM, 2011, PEDIATRICS, V127, pS74, DOI 10.1542/peds.2010-1722K
   Evans G, 1999, VACCINE, V17, pS25, DOI 10.1016/S0264-410X(99)00291-1
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Halabi SF, 2017, JAMA-J AM MED ASSOC, V317, P471, DOI 10.1001/jama.2016.19492
   Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063
   Lateef TM, 2015, J PEDIATR-US, V166, P576, DOI 10.1016/j.jpeds.2014.10.054
   Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012
   LEVINE C, 1984, HASTINGS CENT REP, V14, P2
   Levine EM, 2017, PLOTKINS VACCINES, P1601
   Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901
   MacDonald NE, 2017, VACCINE, V35, P6925, DOI 10.1016/j.vaccine.2017.10.048
   Mallory ML, 2018, VACCINATION INDUCED
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048
   Wilson K, 2007, CAN MED ASSOC J, V176, P1681, DOI 10.1503/cmaj.070610
   World Health O, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, 2018, GLOB IMM M SUCC NAV
   World Health Organization, 2018, IMM VACC BIOL OFF CO
NR 21
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4370
EP 4375
DI 10.1016/j.vaccine.2019.06.018
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700020
PM 31213377
DA 2020-05-12
ER

PT J
AU Bellan, SE
   Eggo, RM
   Gsell, PS
   Kucharski, AJ
   Dean, NE
   Donohue, R
   Zook, M
   Edmunds, WJ
   Odhiambo, F
   Longini, IM
   Brisson, M
   Mahon, BE
   Henao-Restrepo, AM
AF Bellan, Steven E.
   Eggo, Rosalind M.
   Gsell, Pierre-Stephane
   Kucharski, Adam J.
   Dean, Natalie E.
   Donohue, Richard
   Zook, Matt
   Edmunds, W. John
   Odhiambo, Frank
   Longini, Ira M., Jr.
   Brisson, Marc
   Mahon, Barbara E.
   Henao-Restrepo, Ana Maria
TI An online decision tree for vaccine efficacy trial design during
   infectious disease epidemics: The InterVax-Tool
SO VACCINE
LA English
DT Article
DE Vaccine trial design; Outbreaks; Epidemics; Vaccines; Public Health
   Emergency; Emerging infectious diseases; Scientific communication; Phase
   III trial; Decision support system
AB Background: Licensed vaccines are urgently needed for emerging infectious diseases, but the nature of these epidemics causes challenges for the design of phase III trials to evaluate vaccine efficacy. Designing and executing rigorous, fast, and ethical, vaccine efficacy trials is difficult, and the decisions and limitations in the design of these trials encompass epidemiological, logistical, regulatory, statistical, and ethical dimensions.
   Results: Trial design decisions are complex and interrelated, but current guidance documents do not lend themselves to efficient decision-making. We created InterVax-Tool (http://vaxeval.com), an online, interactive decision-support tool, to help diverse stakeholders navigate the decisions in the design of phase Ill vaccine trials.
   InterVax-Tool offers high-level visual and interactive assistance through a set of four decision trees, guiding users through selection of the: (1) Primary Endpoint, (2) Target Population, (3) Randomization Scheme, and, (4) Comparator. We provide guidance on how key considerations-grouped as Epidemiological, Vaccine-related, Infrastructural, or Sociocultural-inform each decision in the trial design process.
   Conclusions: InterVax-Tool facilitates structured, transparent, and collaborative discussion of trial design, while recording the decision-making process. Users can save and share their decisions, which is useful both for comparing proposed trial designs, and for justifying particular design choices.
   Here, we describe the goals and features of InterVax-Tool as well as its application to the design of a Zika vaccine efficacy trial. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Bellan, Steven E.] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA.
   [Bellan, Steven E.] Univ Georgia, Ctr Ecol Infect Dis, Athens, GA 30602 USA.
   [Eggo, Rosalind M.; Kucharski, Adam J.; Edmunds, W. John] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
   [Gsell, Pierre-Stephane; Henao-Restrepo, Ana Maria] WHO, Geneva, Switzerland.
   [Dean, Natalie E.; Longini, Ira M., Jr.] Univ Florida, Dept Biostat, Gainesville, FL USA.
   [Donohue, Richard; Zook, Matt] Univ Kentucky, Dept Geog, Lexington, KY USA.
   [Odhiambo, Frank] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya.
   [Brisson, Marc] CHU Quebec, Ctr Rech, Quebec City, PQ, Canada.
   [Brisson, Marc] Univ Laval, Dept Med Sociale & Prevent, Quebec City, PQ, Canada.
   [Brisson, Marc] Imperial Coll, Dept Infect Dis Epidemiol, London, England.
   [Mahon, Barbara E.] Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Bellan, SE; Eggo, RM (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
EM steve.bellan@uga.edu; r.eggo@lshtm.ac.uk
OI Eggo, Rosalind M/0000-0002-0362-6717
FU National Institute of Health (NIH) National Institute of Allergy and
   Infectious Diseases [K01A1125830]; National Institute for Health
   Research through the Health Protection Research Unit in Immunisation at
   the London School of Hygiene & Tropical Medicine; HDR UK Innovation
   Fellowship [MR/S003975/1]; Innovative Medicines Initiative 2 (IMI2)
   Joint Undertaking under grant agreement EBOVAC1 [115854]; European
   UnionEuropean Union (EU); European Federation of Pharmaceutical
   Industries and Associations; National Institutes of Health (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [U54 GM111274, R37-A1032042]; WHOWorld Health
   Organization; VEEPED (Vaccine Efficacy Evaluation for Priority Emerging
   Diseases); National Institute for Health Research using Official
   Development Assistance (ODA); Public Health England; Sir Henry Dale
   Fellowship - Wellcome Trust [206250/Z/17/Z]; Sir Henry Dale Fellowship -
   Royal Society [206250/Z/17/Z]
FX SEB was supported by National Institute of Health (NIH) National
   Institute of Allergy and Infectious Diseases grant K01A1125830. RME
   acknowledges funding from the National Institute for Health Research
   through the Health Protection Research Unit in Immunisation at the
   London School of Hygiene & Tropical Medicine in partnership with Public
   Health England, from an HDR UK Innovation Fellowship (grant
   MR/S003975/1), and from the Innovative Medicines Initiative 2 (IMI2)
   Joint Undertaking under grant agreement EBOVAC1 (grant 115854). The IMI2
   is supported by the European Union Horizon 2020 Research and Innovation
   Programme and the European Federation of Pharmaceutical Industries and
   Associations. AJK was supported by a Sir Henry Dale Fellowship jointly
   funded by the Wellcome Trust and the Royal Society (grant
   206250/Z/17/Z). NED and IML were supported by National Institutes of
   Health (NIH) grants U54 GM111274 and R37-A1032042, and WHO funding. WJE
   acknowledges VEEPED (Vaccine Efficacy Evaluation for Priority Emerging
   Diseases) for funding. VEEPED is funded by the National Institute for
   Health Research using Official Development Assistance (ODA) funding.;
   The views expressed are those of the authors and not necessarily those
   of the funders. The funders had no role in study design; in the writing
   of the report; or in the decision to submit the paper for publication.
   The findings and conclusions in this report are those of the authors and
   do not necessarily represent the official position of the US Centers for
   Disease Control and Prevention.
CR Afzal S, 2011, 2011 IEEE C VIS AN S, P189
   [Anonymous], 2017, INTEGRATING CLIN RES
   [Anonymous], 2015, BMJ
   Baden LR, 2017, NEW ENGL J MED, V377, P1482, DOI 10.1056/NEJMe1712330
   Bellan SE, QUANTIFYING ETHICAL
   Bellan SE, 2015, LANCET INFECT DIS, V3099, P1
   Bowles Kathryn H, 2012, NI 2012 (2012), V2012, P41
   Camacho A, 2017, VACCINE, V35, P544, DOI 10.1016/j.vaccine.2016.12.019
   Camacho A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009346
   Dean NE, 2018, BIORXIV, DOI [10.1021/bi0121656, DOI 10.1021/BI0121656]
   Ebola ca Suffit ring vaccination trial consortium, BMJ
   Eyal N., 2017, J MED ETHICS
   Fogli D, 2013, DECIS SUPPORT SYST, V55, P336, DOI 10.1016/j.dss.2013.01.022
   Geoghegan JL, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170189
   Halloran ME, 2017, INFECT DIS
   Halloran ME, 2010, DESIGN ANAL VACCINE
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Kieny MP, 2017, LANCET, V389, P2469, DOI 10.1016/S0140-6736(17)31635-5
   Rid A, 2016, AM J PUBLIC HEALTH, pe1
   von Winterfeldt D, 2013, P NATL ACAD SCI USA, V110, P14055, DOI 10.1073/pnas.1213532110
   WHO, 2017, EFF TRIALS ZIKV VACC
NR 21
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4376
EP 4381
DI 10.1016/j.vaccine.2019.06.019
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700021
PM 31242963
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Geng, F
   Guo, J
   Guo, QQ
   Xie, Y
   Dong, L
   Zhou, Y
   Liu, CL
   Yu, B
   Wu, H
   Wu, JX
   Zhang, HH
   Kong, W
   Yu, XH
AF Geng, Fei
   Guo, Jie
   Guo, Qian-Qian
   Xie, Yu
   Dong, Ling
   Zhou, Yi
   Liu, Chen-Lu
   Yu, Bin
   Wu, Hui
   Wu, Jia-Xin
   Zhang, Hai-Hong
   Kong, Wei
   Yu, Xiang-Hui
TI A DNA vaccine expressing an optimized secreted FAP alpha induces
   enhanced anti-tumor activity by altering the tumor microenvironment in a
   murine model of breast cancer
SO VACCINE
LA English
DT Article
DE FAP alpha; Cancer-associated fibroblast; Tumour microenvironment;
   Myeloid-derived suppressor cell; DNA vaccine; Cancer immunotherapy
ID FIBROBLAST ACTIVATION PROTEIN; CLINICAL-IMPLICATIONS; STROMAL
   FIBROBLASTS; SUPPRESSOR-CELLS; IMMUNE-RESPONSES; BOOST IMMUNITY;
   IMMUNOTHERAPY; INTERFACE; INDUCTION; SURVIVAL
AB Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAP alpha, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAP alpha-targeted vaccine containing only the extracellular domain of human FAP alpha with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8(+) T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAP alpha-targeted vaccine expressing an optimized secreted human FAP alpha induced enhanced anti-tumor activity by reducing the number of FAP alpha(+) CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Geng, Fei; Guo, Jie; Guo, Qian-Qian; Xie, Yu; Dong, Ling; Zhou, Yi; Liu, Chen-Lu; Yu, Bin; Wu, Hui; Wu, Jia-Xin; Zhang, Hai-Hong; Kong, Wei; Yu, Xiang-Hui] Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun 130012, Jilin, Peoples R China.
RP Zhang, HH; Kong, W; Yu, XH (reprint author), Jilin Univ, Sch Life Sci, 2699 St Qianjin, Changchun 130012, Jilin, Peoples R China.
EM Zhanghh@jlu.edu.cn
FU Specialized Research Fund for the National Natural Science Foundation of
   China [31300765]; National Science, Technology Major Project of the
   Ministry of Science and Technology of China [2018ZX09301050-003,
   2014ZX09304314-001]; Jilin Province Science and Technology Program
   [20180201001YY, 20160519018JH]; Changchun City Science and Technology
   Plan Project [1711002]
FX We are grateful for the support of the Specialized Research Fund for the
   National Natural Science Foundation of China (No. 31300765), the
   National Science, Technology Major Project of the Ministry of Science
   and Technology of China (No. 2018ZX09301050-003 and 2014ZX09304314-001),
   Jilin Province Science and Technology Program (No. 20180201001YY and
   20160519018JH), and Changchun City Science and Technology Plan Project
   (No. 1711002).
CR Acharya PS, 2006, HUM PATHOL, V37, P352, DOI 10.1016/j.humpath.2005.11.020
   Adachi K, 2018, NAT BIOTECHNOL, V36, P346, DOI 10.1038/nbt.4086
   Amini MA, 2018, JNCI-J NATL CANCER I, P14
   Bagley SJ, 2018, NEURO-ONCOLOGY, V20, P1429, DOI 10.1093/neuonc/noy032
   Becker JC, 2013, CANCER IMMUNOL IMMUN, V62, P1137, DOI 10.1007/s00262-013-1434-6
   Bianchi G, 2011, HISTOL HISTOPATHOL, V26, P941, DOI 10.14670/HH-26.941
   Chen MH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14421
   Delogu G, 2002, INFECT IMMUN, V70, P292, DOI 10.1128/IAI.70.1.292-302.2002
   Elkhattouti A, 2015, FRONT ONCOL, V27, P5
   Fassnacht M, 2005, CLIN CANCER RES, V11, P5566, DOI 10.1158/1078-0432.CCR-05-0699
   Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235
   Gottschalk S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082658
   Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746
   Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006
   Huang Y, 2011, CLIN EXP METASTAS, V28, P567, DOI 10.1007/s10585-011-9392-x
   Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204
   Jung YY, 2015, TUMOR BIOL, V36, P8685, DOI 10.1007/s13277-015-3594-9
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kou YM, 2017, IMMUNOL LETT, V190, P51, DOI 10.1016/j.imlet.2017.07.007
   Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300
   Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Luo MC, 2008, J VIROL METHODS, V154, P121, DOI 10.1016/j.jviromet.2008.08.011
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Mentlein R, 2011, BIOL CHEM, V392, P199, DOI 10.1515/BC.2010.119
   Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417
   Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Ostrand-Rosenberg S, 2018, J IMMUNOL, V200, P422, DOI 10.4049/jimmunol.1701019
   Ouyang LQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep39541
   Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849
   Pure E, 2018, ONCOGENE, V37, P4343, DOI 10.1038/s41388-018-0275-3
   RETTIG WJ, 1993, CANCER RES, V53, P3327
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Tang HD, 2016, CANCER LETT, V370, P85, DOI 10.1016/j.canlet.2015.10.009
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Wang YQ, 2013, INT IMMUNOPHARMACOL, V17, P9, DOI 10.1016/j.intimp.2013.04.015
   Wen YA, 2010, CANCER SCI, V101, P2325, DOI 10.1111/j.1349-7006.2010.01695.x
   Williams SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-250
   Wonganu B, 2016, BBA-BIOMEMBRANES, V1858, P1876, DOI 10.1016/j.bbamem.2016.05.001
   Xia Q, 2016, VACCINE, V34, P4526, DOI 10.1016/j.vaccine.2016.07.054
   Xia Q, 2016, CANCER IMMUNOL IMMUN, V65, P613, DOI 10.1007/s00262-016-1827-4
   Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973
   Yuan DT, 2013, J SURG ONCOL, V108, P157, DOI 10.1002/jso.23368
NR 46
TC 1
Z9 1
U1 4
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4382
EP 4391
DI 10.1016/j.vaccine.2019.06.012
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700022
PM 31202521
DA 2020-05-12
ER

PT J
AU Blom, K
   Yin, L
   Arnheim-Dahlstrom, L
AF Blom, Kim
   Yin, Li
   Arnheim-Dahlstrom, Lisen
TI Effectiveness of the herpes zoster vaccine Zostavax (R) in Stockholm
   County, Sweden
SO VACCINE
LA English
DT Article
DE Herpes zoster; Vaccination; Zostavax; Effectiveness; Cohort;
   Population-based
ID POSTHERPETIC NEURALGIA; POPULATION; OLDER; IMPACT; COMPLICATIONS;
   SAFETY; STROKE; RISK; LIFE; PAIN
AB Objective: The objective of this study was to estimate the effectiveness of the herpes zoster vaccine Zostavax in a cohort of vaccinated individuals in Sweden.
   Methods: The study is a retrospective population-based matched cohort study conducted with data from health care registers in Stockholm Country. Primary endpoints were new diagnosis of HZ after administration of Zostavax. Individuals above the age of 50 years and living in Stockholm County in 2013 were included into the study. Ten non-vaccinated individuals per vaccinated were included and randomized into the cohort. The non-vaccinated were matched on age at index date and gender.
   Results: Zostavax had an overall effectiveness (VE) of 34% (HR = 0.66, 95% Cl: 0.55-0.78). When stratifying by age, 61-75 years was the only age group that showed a reduced risk of HZ (HR = 0.57; CI 0.44-0.73) compared to those that were non-vaccinated. As compared to the unvaccinated group, the VE was significant at days 180-359 (HR = 0.53; 95% CI 0.33-0.88), 360-539 (HR = 0.46; 95% CI 0.27-0.80) and at days 540-719 (HR = 0.56; 95% CI 0.35-0.90) after vaccination.
   Conclusion: This is the first population-based study in Sweden studying the effectiveness of HZ vaccination. Our findings are well in-line with previous studies, however studies addressing the longitudinal efficacy and effectiveness of Zostavax are still required. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Blom, Kim] Karolinska Univ Hosp Huddinge, Dept Med, Karolinska Inst, Ctr Infect Med, Stockholm, Sweden.
   [Yin, Li; Arnheim-Dahlstrom, Lisen] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
RP Blom, K (reprint author), Karolinska Univ Hosp Huddinge, Dept Med, Karolinska Inst, Ctr Infect Med, Stockholm, Sweden.
EM kim.blom@ki.se
FU Sanofi Pasteur MSD
FX This study was funded by Sanofi Pasteur MSD. The funders had no role in
   the study design; collection, analysis and interpretation of data;
   writing the manuscript; or the decision to submit the manuscript for
   publication.
CR Betta M, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0054
   Bowsher D, 1999, EUR J PAIN-LONDON, V3, P335, DOI 10.1016/S1090-3801(99)90015-0
   Breuer J, 2014, NEUROLOGY, V83, pE27, DOI 10.1212/WNL.0000000000000584
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Damm O, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1861-8
   EMA, 2018, ZOST 2018
   Fogelberg S, 2018, PHARMACOEPIDEMIOL DR
   Fogelberg S, 2018, PHARMACOEPIDEM DR S, V27, P1159, DOI 10.1002/pds.4653
   Gabutti G, 2017, HUM VACC IMMUNOTHER, V13, P391, DOI 10.1080/21645515.2017.1264831
   Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16
   Izurieta HS, 2017, CLIN INFECT DIS, V64, P785, DOI 10.1093/cid/ciw854
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   Katz J, 2004, CLIN INFECT DIS, V39, P342, DOI 10.1086/421942
   Kawai K, 2016, CLIN INFECT DIS, V63, P221, DOI 10.1093/cid/ciw296
   Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107
   Landsting SL., HDB VALDATABASERNA
   Langan SM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001420
   Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y
   Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450
   Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y
   Mullooly JP, 2005, EPIDEMIOL INFECT, V133, P245, DOI 10.1017/S095026880400281X
   Nagel MA, 2014, CURR OPIN NEUROL, V27, P356, DOI 10.1097/WCO.0000000000000092
   Nilsson J, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0951-7
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003
   Schmader KE, 2007, CLIN J PAIN, V23, P490, DOI 10.1097/AJP.0b013e318065b6c9
   Schmader KE, 2012, CLIN INFECT DIS, V54, P922, DOI 10.1093/cid/cir970
   Statistiska centralbyran (SCB), LONG INT SJUKF OCH A
   Studahl M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-586
   Sundstrom K, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1170-y
   The national Board of Health and Welfare, 2017, HEALTHC REG SWED
   Tseng HF, 2016, CLIN INFECT DIS, V62, P462, DOI 10.1093/cid/civ930
   Tseng HF, 2012, J INFECT DIS, V206, P190, DOI 10.1093/infdis/jis334
   Tseng HF, 2011, VACCINE, V29, P3628, DOI 10.1016/j.vaccine.2011.03.018
   Tseng HF, 2011, JAMA-J AM MED ASSOC, V305, P160, DOI 10.1001/jama.2010.1983
   van Lier A, 2015, EBIOMEDICINE, V2, P1494, DOI 10.1016/j.ebiom.2015.08.017
   Vesikari T, 2013, HUM VACC IMMUNOTHER, V9, P858, DOI 10.4161/hv.23412
   Weinberg A, 2018, INFECT DIS
   Widgren K, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1957-5
   World Health Organization, 2017, ATC DDD IND 2017
   Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4401
EP 4406
DI 10.1016/j.vaccine.2019.06.008
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700024
PM 31230884
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ella, R
   Babji, S
   Ciarlet, M
   Blackwelder, WC
   Vadrevu, KM
AF Ella, Raches
   Babji, Sudhir
   Ciarlet, Max
   Blackwelder, William C.
   Vadrevu, Krishna Mohan
TI A randomized, open-labelled, non-inferiority phase 4 clinical trial to
   evaluate the immunogenicity and safety of the live, attenuated, oral
   rotavirus vaccine, ROTAVAC (R) in comparison with a licensed rotavirus
   vaccine in healthy infants
SO VACCINE
LA English
DT Article
DE Rotavirus vaccine; nHRV; ROTAVAC; Immunogenicity; Oral vaccine;
   Diarrhoea; Rotarix; RV1
ID 1ST 2 YEARS; IMMUNE-RESPONSE; DOUBLE-BLIND; EFFICACY; CHILDREN;
   GASTROENTERITIS; DIARRHEA; IGG; INFECTION; SERUM
AB Background: ROTAVAC (nHRV), derived naturally from the human 116E rotavirus (RV) neonatal strain, was licensed in India in 2015 based on promising results of a phase 3, safety and efficacy vaccine trial. As a pre-requisite for WHO prequalification, we compared the immunogenicity and safety of ROTAVAC (R) to those of a WHO-prequalified, Rotarix (R).
   Methods: We conducted a multicentre, open-labeled, randomized phase 4 clinical trial where 464 infants, 6-8 weeks of age were equally randomized to receive as licensed, the complete regimen of ROTAVAC (R) (3 doses; Group I) or Rotarix (R) (2 doses; Group II). Antibody responses (serum anti-RV Immunoglobulin A [IgA]) were measured by enzyme-linked immunosorbent assay (ELISA). The primary analysis was an assessment of non-inferiority of ROTAVAC (R) to Rotarix (R) for geometric mean concentration (GMC) for infants who received the complete regimen of either vaccine.
   Results: The GMC for Group I was 20.4 (95%Cl: 17.6, 23.6) and that for Group II was 24.8 (95%CI: 20.3, 30.3), the GMC ratio was 0.82 (95% CI: 0.64, 1.05), thus meeting the non-inferiority criterion. Site-wise analysis of GMC titres revealed that one site had a peculiar pre-vaccination titre affecting only ROTAVAC (R) post-vaccination GMCs. Seroconversion rates were 35.3% (95%Cl: 29.0, 41.9) and 31.0% (95%Cl: 25.1, 37.4) for Groups I and Group II, respectively. There was no substantive difference in safety profiles between both vaccines.
   Conclusions: The complete regimen of ROTAVAC (R) demonstrated immunological non-inferiority to the complete regimen of Rotarix (R) with a clinically acceptable safety profile. Because the demand for RV vaccines is increasing as more countries are expanding their immunization schedules, the lack of need of a buffering agent, low dose volume (0.5 mL), non-interference with other concomitantly administered vaccines, and conformance with WHO-prequalification requirements provide ROTAVAC (R) the potential for widespread global usage. Post completion of this study, ROTAVAC (R) is now a WHO-prequalified vaccine. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Ella, Raches; Vadrevu, Krishna Mohan] Bharat Biotech Int Ltd, Hyderabad 500078, Telangana, India.
   [Babji, Sudhir] Christian Med Coll & Hosp, Div Gastrointestinal Sci, Vellore, Tamil Nadu, India.
RP Vadrevu, KM (reprint author), Bharat Biotech Int Ltd, Hyderabad 500078, Telangana, India.
EM kmohan@bharatbiotech.com
CR Appaiahgari MB, 2014, VACCINE, V32, P651, DOI 10.1016/j.vaccine.2013.12.017
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Bahl R, 2005, J INFECT DIS, V192, pS114, DOI 10.1086/431497
   Becker-Dreps S, 2015, PEDIATR INFECT DIS J, V34, P115, DOI 10.1097/INF.0000000000000481
   BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282
   Bhandari N, 2014, VACCINE, V32, pA110, DOI 10.1016/j.vaccine.2014.04.079
   Bhandari N, 2014, LANCET, V383, P2136, DOI 10.1016/S0140-6736(13)62630-6
   Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016
   Chan J, 2011, VACCINE, V29, P1242, DOI 10.1016/j.vaccine.2010.11.087
   Chandola TR, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00302
   Chilengi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150100
   Cunliffe NA, 2012, VACCINE, V30, pA36, DOI 10.1016/j.vaccine.2011.09.120
   Donken R, 2015, VACCINE, V33, P1426, DOI 10.1016/j.vaccine.2015.01.072
   Ella R, 2018, HUM VACC IMMUNOTHER
   GART JJ, 1990, BIOMETRICS, V46, P637, DOI 10.2307/2532084
   Glass RI, 2014, J INFECT SUPPL 1, V68, P59, DOI [10.1016/jjjnf.2013.09.010, DOI 10.1016/JJJNF2013.09.010]
   GlaxoSmithKline, ROT PRESCR INF
   Haider P, 2018, 12 INT ROT S M AUSTR
   Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/nejmoa1609462, 10.1056/NEJMoa1609462]
   Kompithra RZ, 2014, VACCINE, V32, pA129, DOI 10.1016/j.vaccine.2014.03.002
   Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014
   Lazarus RP, 2018, VACCINE, V36, P273, DOI 10.1016/j.vaccine.2017.07.116
   Linhares AC, 2008, LANCET, V371, P1181, DOI 10.1016/S0140-6736(08)60524-3
   MacLennan CA, 2014, P NATL ACAD SCI USA, V111, P12307, DOI 10.1073/pnas.1400473111
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Matthijnssens J, 2010, VIROLOGY, V403, P111, DOI 10.1016/j.virol.2010.04.004
   Merck & CO. I, ROTATEQ PRESCR INF
   Moon SS, 2016, CLIN INFECT DIS, V62, P157, DOI 10.1093/cid/civ828
   Nelson EAS, 2010, LANCET, V376, P568, DOI 10.1016/S0140-6736(10)60896-3
   Organization WH, 2009, ROT VACC UPD REL EP, V84, P533
   Patel M, 2009, J INFECT DIS, V200, pS39, DOI 10.1086/605035
   Paul A, 2014, VACCINE, V32, pA49, DOI 10.1016/j.vaccine.2014.03.039
   Rongsen-Chandola T, 2014, VACCINE, V32, pA134, DOI 10.1016/j.vaccine.2014.04.078
   Shetty RS, 2017, CLIN EPIDEMIOL GLOB, V5, P28, DOI 10.1016/j.cegh.2016.06.002
   Sinha A, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00519
   Vesikari T, 2010, EUR J PEDIATR, V169, P1379, DOI 10.1007/s00431-010-1242-3
   Vethanayagam RR, 2004, J INFECT DIS, V189, P2282, DOI 10.1086/420889
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
   2009, [No title captured], V84, P220
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4407
EP 4413
DI 10.1016/j.vaccine.2019.05.069
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700025
PM 31178377
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hewitt, JS
   Karuppannan, AK
   Tan, S
   Gauger, P
   Halbur, PG
   Gerber, PF
   De Groot, AS
   Moise, L
   Opriessnig, T
AF Hewitt, Joshua S.
   Karuppannan, Anbu K.
   Tan, Swan
   Gauger, Phillip
   Halbur, Patrick G.
   Gerber, Priscilla F.
   De Groot, Anne S.
   Moise, Leonard
   Opriessnig, Tanja
TI A prime-boost concept using a T-cell epitope-driven DNA vaccine followed
   by a whole virus vaccine effectively protected pigs in the pandemic H1N1
   pig challenge model
SO VACCINE
LA English
DT Article
DE Influenza A virus; Pigs; DNA vaccine; Prime boosting; Intradermal
   vaccination; T cell epitope; Immunoinformatics
ID SWINE INFLUENZA-VIRUS; IMMUNE-RESPONSES; EVOLUTION; INFECTION;
   NUCLEOPROTEIN; IMMUNIZATION; SELECTION; MICE
AB Influenza A virus (IAV) vaccines in pigs generally provide homosubtypic protection but fail to prevent heterologous infections. In this pilot study, the efficacy of an intradermal pDNA vaccine composed of conserved SLA class I and class H T cell epitopes (EPITOPE) against a homosubtypic challenge was compared to an intramuscular commercial inactivated whole virus vaccine (INACT) and a heterologous prime boost approach using both vaccines. Thirty-nine IAV-free, 3-week-old pigs were randomly assigned to one of five groups including NEG-CONTROL (unvaccinated, sham-challenged), INACT-INACT-IAV (vaccinated with FluSure XP (R) at 4 and 7 weeks, pH] N1 challenged), EPITOPE-INACT-IAV (vaccinated with PigMatrix EDV at 4 and FluSure XP (R) at 7 weeks, pH1N1 challenged), EPITOPE-EPITOPE-IAV (vaccinated with PigMatrix EDV at 4 and 7 weeks, pH1N1 challenged), and a POS-CONTROL group (unvaccinated, pH1N1 challenged). The challenge was done at 9 weeks of age and pigs were necropsied at day post challenge (dpc) 5. At the time of challenge, all INACT-INACT-IAV pigs, and by dpc 5 all EPITOPE-INACT-IAV pigs were IAV seropositive. IFN gamma secreting cells, recognizing vaccine epitope-specific peptides and pH1N1 challenge virus were highest in the EPITOPE-INACT-IAV pigs at challenge. Macroscopic lung lesion scores were reduced in all EPITOPE-INACT-IAV pigs while INACT-INACT-IAV pigs exhibited a bimodal distribution of low and high scores akin to na ve challenged animals. No IAV antigen in lung tissues was detected at necropsy in the EPITOPE-INACT-IAV group, which was similar to na ve unchallenged pigs and different from all other challenged groups. Results suggest that the heterologous prime boost approach using an epitope-driven DNA vaccine followed by an inactivated vaccine was effective against a homosubtypic challenge, and further exploration of this vaccine approach as a practical control measure against heterosubtypic IAV infections is warranted. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hewitt, Joshua S.; Karuppannan, Anbu K.; Gauger, Phillip; Halbur, Patrick G.; Opriessnig, Tanja] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA.
   [Tan, Swan; De Groot, Anne S.; Moise, Leonard] Univ Rhode Isl, Dept Cell & Mol Biol, Inst Immunol & Informat, 825 Chalkstone Ave, Providence, RI 02908 USA.
   [Gerber, Priscilla F.] Univ New England, Sch Environm & Rural Sci, Anim Sci, Armidale, NSW, Australia.
   [De Groot, Anne S.; Moise, Leonard] EpiVax Inc, Providence, RI USA.
   [Opriessnig, Tanja] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
RP Opriessnig, T (reprint author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.; Opriessnig, T (reprint author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
EM Tanja.Opriessnig@roslin.ed.ac.uk
RI Gerber, Priscilla/U-9385-2019; Opriessnig, Tanja/F-2984-2012; De Groot,
   Annie/B-6221-2013
OI Gerber, Priscilla/0000-0002-8343-8299; Opriessnig,
   Tanja/0000-0001-9642-0904; De Groot, Annie/0000-0001-5911-1459;
   Karuppannan, Anbu Kumar/0000-0003-3020-4867; Tan,
   Swan/0000-0002-0658-3396
FU Iowa State University College of Veterinary Medicine Summer Scholars
   Research Program; Biotechnology and Biological Sciences Research Council
   (BBSRC) Institute Strategic Programme GrantBiotechnology and Biological
   Sciences Research Council (BBSRC) [BBS/E/D/20002173, BBS/E/D/20002174];
   Iowa Pork Producers Association
FX Joshua Hewitt was supported through the Iowa State University College of
   Veterinary Medicine Summer Scholars Research Program. The study was
   funded by the Iowa Pork Producers Association. Support was also received
   by the Biotechnology and Biological Sciences Research Council (BBSRC)
   Institute Strategic Programme Grant awarded to the Roslin Institute
   Strategic Programme: Control of Infectious Disease (BBS/E/D/20002173 and
   BBS/E/D/20002174).
CR Anderson TK, 2013, INFLUENZA OTHER RESP, V7, P42, DOI 10.1111/irv.12193
   Borggren M, 2016, VACCINE, V34, P3634, DOI 10.1016/j.vaccine.2016.05.030
   Broderick KE, 2014, METHODS MOL BIOL, V1143, P123, DOI 10.1007/978-1-4939-0410-5_8
   Brown IH, 2000, VET MICROBIOL, V74, P29, DOI 10.1016/S0378-1135(00)00164-4
   Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168
   de Jong JC, 1999, VACCINE, V17, P1321, DOI 10.1016/S0264-410X(98)00392-2
   Ferrari L, 2011, RES VET SCI, V90, P64, DOI 10.1016/j.rvsc.2010.04.026
   Gao CX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00282
   Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003
   Gauger PC, 2011, VACCINE, V29, P2712, DOI 10.1016/j.vaccine.2011.01.082
   Giese M, 1998, VIRUS GENES, V17, P219, DOI 10.1023/A:1008013720032
   Gutierrez AH, 2016, PLOS ONE, P11
   Gutierrez AH, 2017, INFLUENZA OTHER RESP, V11, P531, DOI 10.1111/irv.12513
   Gutierrez AH, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0724-8
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Hause BM, 2012, CLIN VACCINE IMMUNOL, V19, P1457, DOI 10.1128/CVI.00096-12
   Heinen PP, 2001, J GEN VIROL, V82, P2697, DOI 10.1099/0022-1317-82-11-2697
   Janke BH, 2013, CURR TOP MICROBIOL, V370, P69, DOI 10.1007/82_2013_308
   Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366
   Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141
   Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780
   Kreijtz JHCM, 2007, VACCINE, V25, P612, DOI 10.1016/j.vaccine.2006.08.036
   LaMere MW, 2011, J IMMUNOL, V186, P4331, DOI 10.4049/jimmunol.1003057
   Lange E, 2009, J GEN VIROL, V90, P2119, DOI 10.1099/vir.0.014480-0
   Larsen DL, 2001, VACCINE, V19, P2842, DOI 10.1016/S0264-410X(01)00014-7
   Li WF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-183
   Machkovech HM, 2015, J VIROL, V89, P11275, DOI 10.1128/JVI.01571-15
   Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159
   Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1577, DOI 10.4161/hv.24615
   Okuda K, 2001, VACCINE, V19, P3681, DOI 10.1016/S0264-410X(01)00078-0
   Olson ZF, 2017, VET IMMUNOL IMMUNOP, V185, P57, DOI 10.1016/j.vetimm.2017.01.009
   Rajao DS, 2018, VIROLOGY, V518, P45, DOI 10.1016/j.virol.2018.02.006
   Rajao DS, 2014, VACCINE, V32, P5170, DOI 10.1016/j.vaccine.2014.07.059
   Rajao DS, INFLUENZA PATHOGENES, V12014, P307
   Sheng ZY, 2016, VACCINE, V34, P5751, DOI 10.1016/j.vaccine.2016.10.001
   Shope RE, 1931, SCIENCE, V73, P214, DOI 10.1126/science.73.1886.214
   Stincarelli M, 2013, VIRUS RES, V175, P151, DOI 10.1016/j.virusres.2013.04.012
   Tan GS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005578
   Vincent AL, 2008, VET MICROBIOL, V126, P310, DOI 10.1016/j.vetmic.2007.07.011
   Vincent LL, 1997, J VET DIAGN INVEST, V9, P191, DOI 10.1177/104063879700900214
   Wang B, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-127
   WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992
   Wei HL, 2014, VIRAL IMMUNOL, V27, P14, DOI 10.1089/vim.2013.0080
NR 43
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4302
EP 4309
DI 10.1016/j.vaccine.2019.06.044
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700012
PM 31248687
DA 2020-05-12
ER

PT J
AU Kwong, JC
   Buchan, SA
   Chung, H
   Campitelli, MA
   Schwartz, KL
   Crowcroft, NS
   Jackson, ML
   Karnauchow, T
   Katz, K
   McGeer, AJ
   McNally, JD
   Richardson, DC
   Richardson, SE
   Rosella, LC
   Simor, A
   Smieja, M
   Zahariadis, G
   Campigotto, A
   Gubbay, JB
AF Kwong, Jeffrey C.
   Buchan, Sarah A.
   Chung, Hannah
   Campitelli, Michael A.
   Schwartz, Kevin L.
   Crowcroft, Natasha S.
   Jackson, Michael L.
   Karnauchow, Timothy
   Katz, Kevin
   McGeer, Allison J.
   McNally, J. Dayre
   Richardson, David C.
   Richardson, Susan E.
   Rosella, Laura C.
   Simor, Andrew
   Smieja, Marek
   Zahariadis, George
   Campigotto, Aaron
   Gubbay, Jonathan B.
TI Can routinely collected laboratory and health administrative data be
   used to assess influenza vaccine effectiveness? Assessing the validity
   of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort
SO VACCINE
LA English
DT Article
DE Influenza; Human; Epidemiology; Influenza Vaccines; Data Linkage; Bias
ID TEST-NEGATIVE DESIGN; HEMISPHERE INFLUENZA; HOSPITALIZATION;
   SENSITIVITY; SURVIVAL; OUTCOMES; REGISTRY; NETWORK; DISEASE; A(H3N2)
AB Background: Linking data on laboratory specimens collected during clinical practice with health administrative data permits highly powered vaccine effectiveness (VE) studies to be conducted at relatively low cost, but bias from using convenience samples is a concern. We evaluated the validity of using such data for estimating VE.
   Methods: We created the Flu and Other Respiratory Viruses Research (FOREVER) Cohort by linking individual-level data on respiratory virus laboratory tests, hospitalizations, emergency department visits, and physician services. For community-dwelling adults aged > 65 years, we assessed the presence and magnitude of information and selection biases, generated VE estimates under various conditions, and compared our VE estimates with those from other studies.
   Results: We included 65,648 unique testing episodes obtained from 54,434 individuals during the 2010-11 to 2015-16 influenza seasons. To examine information bias, we found the proportion testing positive for influenza for patients with unknown interval from illness onset to specimen collection was more similar to patients for whom illness onset date was < 7 days before specimen collection than to patients for whom illness onset was > 7 days before specimen collection. To assess the presence of selection bias, we found the likelihood of influenza testing was comparable between vaccinated and unvaccinated individuals, although the adjusted odds ratios were significantly greater than 1 for some healthcare settings and during some influenza seasons. Over 6 seasons, VE estimates ranged between 36% (95%Cl, 27-44%) in 2010-11 and 5% (95%Cl,-2, 11%) in 2014-15. VE estimates were similar under a range of conditions, but were consistently higher when accounting for misclassification of vaccination status through a quantitative sensitivity analysis. VE estimates from the FOREVER Cohort were comparable to those from other studies.
   Conclusions: Routinely collected laboratory and health administrative data contained in the FOREVER Cohort can be used to estimate influenza VE in community-dwelling older adults. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Kwong, Jeffrey C.; Buchan, Sarah A.; Chung, Hannah; Campitelli, Michael A.; Schwartz, Kevin L.; Crowcroft, Natasha S.; Rosella, Laura C.] ICES, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
   [Kwong, Jeffrey C.; Buchan, Sarah A.; Schwartz, Kevin L.; Crowcroft, Natasha S.; Rosella, Laura C.; Gubbay, Jonathan B.] Publ Hlth Ontario, Toronto, ON, Canada.
   [Kwong, Jeffrey C.; Buchan, Sarah A.; Schwartz, Kevin L.; Crowcroft, Natasha S.; McGeer, Allison J.; Rosella, Laura C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.
   [Kwong, Jeffrey C.] Univ Hlth Network, Toronto, ON, Canada.
   [Crowcroft, Natasha S.; McGeer, Allison J.; Richardson, Susan E.; Simor, Andrew; Gubbay, Jonathan B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
   [Jackson, Michael L.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA.
   [Karnauchow, Timothy; McNally, J. Dayre] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada.
   [Karnauchow, Timothy] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada.
   [Katz, Kevin] North York Gen Hosp, Toronto, ON, Canada.
   [McGeer, Allison J.] Sinai Hlth Syst, Toronto, ON, Canada.
   [Richardson, David C.] William Osler Hlth Syst, Brampton, ON, Canada.
   [Richardson, Susan E.; Campigotto, Aaron; Gubbay, Jonathan B.] Hosp Sick Children, Toronto, ON, Canada.
   [Simor, Andrew] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
   [Smieja, Marek] McMaster Univ, Hamilton, ON, Canada.
   [Zahariadis, George; Campigotto, Aaron] London Hlth Sci Ctr, London, ON, Canada.
   [Zahariadis, George] Newfoundland & Labrador Publ Hlth Lab, St John, NF, Canada.
RP Kwong, JC (reprint author), ICES, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM jeff.kwong@utoronto.ca
RI McGeer, Allison/AAB-6885-2020
OI McGeer, Allison/0000-0001-5647-6137; Crowcroft,
   Natasha/0000-0002-6761-8783
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [CIHR MOP 130568]; CIHRCanadian Institutes of Health
   Research (CIHR); University of Toronto Department of Family and
   Community Medicine; Public Health Ontario (PHO); ICES - Ontario Ministry
   of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term
   Care, Ontario
FX This work was supported by an operating grant from the Canadian
   Institutes of Health Research (CIHR MOP 130568). JCK is supported by a
   New Investigator Award from CIHR and a Clinician Scientist Award from
   the University of Toronto Department of Family and Community Medicine.
   This study was also supported by Public Health Ontario (PHO) and ICES,
   which is funded by an annual grant from the Ontario Ministry of Health
   and Long-Term Care (MOHLTC). The study sponsors did not participate in
   the design and conduct of the study; collection, management, analysis
   and interpretation of the data; preparation, review or approval of the
   manuscript; or the decision to submit the manuscript for publication.
CR Antoniou T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021748
   Barr IG, 2014, VACCINE, V32, P4713, DOI 10.1016/j.vaccine.2014.02.014
   Belongia EA, 2016, LANCET INFECT DIS
   Blyth CC, 2014, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917
   Buchan SA, 2017, CAN MED ASSOC J, V189, pE146, DOI 10.1503/cmaj.151027
   Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375
   Ferdinands JM, 2011, VACCINE, V29, P1935, DOI 10.1016/j.vaccine.2010.12.098
   Fleet JL, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-81
   Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026
   Fox MP, 2005, INT J EPIDEMIOL, V34, P1370, DOI 10.1093/ije/dyi184
   Gershon AS, 2009, COPD, V6, P388, DOI 10.1080/15412550903140865
   Gershon AS, 2009, CAN RESPIR J, V16, P183, DOI 10.1155/2009/963098
   Gill SS, 2009, ARCH INTERN MED, V169, P867, DOI 10.1001/archinternmed.2009.43
   Gurevich Y, 2010, CAN J CARDIOL, V26, pE249, DOI 10.1016/S0828-282X(10)70416-5
   Hall S, 2006, J CLIN EPIDEMIOL, V59, P67, DOI 10.1016/j.jclinepi.2005.05.001
   Huang QS, 2015, INFLUENZA OTHER RESP, V9, P179, DOI 10.1111/irv.12315
   Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512
   Jaakkimainen RL, 2016, J ALZHEIMERS DIS, V54, P337, DOI 10.3233/JAD-160105
   Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Jackson ML, 2019, VACCINE X, V1
   Juurlink D.N., 2006, CANADIAN I HLTH INFO
   Kissling E, 2009, EUROSURVEILLANCE, V14, P2008
   Kwong JC, 2013, CLIN INFECT DIS, V57, P820, DOI 10.1093/cid/cit404
   Lam Ngan N, 2015, Can J Kidney Health Dis, V2, P20, DOI 10.1186/s40697-015-0054-9
   Lane CR, 2016, VACCINE, V34, P1070, DOI 10.1016/j.vaccine.2016.01.002
   Lau LLH, 2010, J INFECT DIS, V201, P1509, DOI 10.1086/652241
   Lee DS, 2007, J AM COLL CARDIOL, V49, P2408, DOI 10.1016/j.jacc.2007.02.058
   McNeil SA, 2015, EUROSURVEILLANCE, V20, P21, DOI 10.2807/1560-7917.ES2015.20.5.21024
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Quinn RR, 2010, MED CARE, V48, P745, DOI 10.1097/MLR.0b013e3181e419fd
   Rondy M, 2016, HUM VACC IMMUNOTHER, V12, P1217, DOI 10.1080/21645515.2015.1126013
   Schultz SE, 2013, CHRON DIS INJ CAN, V33, P160
   Schwartz Kevin L, 2016, CMAJ Open, V4, pE463
   Serres G. de, 2013, Eurosurveillance, V18, P20585
   Skowronski DM, 2007, VACCINE, V25, P2842, DOI 10.1016/j.vaccine.2006.10.002
   Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695
   The Canadian Stroke Strategy, 2010, CAN STROK STRAT COR
   Urquhart R, 2017, CAN J AGING, V36, P514, DOI 10.1017/S0714980817000393
NR 41
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4392
EP 4400
DI 10.1016/j.vaccine.2019.06.011
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700023
PM 31221563
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wilkinson, TA
   Dixon, BE
   Xiao, S
   Tu, WZ
   Lindsay, B
   Sheley, M
   Dugan, T
   Church, A
   Downs, SM
   Zimet, G
AF Wilkinson, Tracey A.
   Dixon, Brian E.
   Xiao, Shan
   Tu, Wanzhu
   Lindsay, Brianna
   Sheley, Meena
   Dugan, Tamara
   Church, Abby
   Downs, Stephen M.
   Zimet, Gregory
TI Physician clinical decision support system prompts and administration of
   subsequent doses of HPV vaccine: A randomized clinical trial
SO VACCINE
LA English
DT Article
DE Vaccine; Human papillomavirus; Computer assisted decision making;
   Clinical decision support system; Adolescent
ID PAPILLOMAVIRUS; INITIATION; RATES
AB Background: HPV vaccine is effective in preventing several cancers and anogenital warts, yet rates of HPV vaccination series completion in the United States are low. A primary reason identified by parents for vaccinating children against HPV is a health care provider's recommendation. Although most clinicians embrace vaccine recommendations, they are not always carried out evenly and subsequent HPV vaccines are missed.
   Methods: Using an electronic health records-based decision support system (CHICA) clinicians were randomized to either usual practice or to receive an automated reminder to recommend the 2nd or 3rd dose of HPV vaccine. The reminder was delivered to clinicians of all intervention group eligible adolescents who had already initiated the vaccine series. Logistic regression models with generalized estimating equations were used for data analysis.
   Results: A total of 1285 clinical encounters were observed across 29 randomized pediatric providers over a 13-month time frame (50.7% control group, 49.3% intervention group). Overall, patients were 44.9% female, 59.4% Black, 22.1% Hispanic, and 48.8% were ages 11-12 yrs. Within the control group, 421 (64.7%) received a subsequent HPV vaccine, compared to 481 (75.9%) (OR: 1.72, (95% CI 1.35-2.19)). Adjusted analysis showed no difference between the groups (aOR 1.52 (95% CI 0.88-2.62)) or when examined by age (11-12yrs aOR 1.66, (95% CI 0.79-3.48)) and 13-17yrs (aOR 1.19, (95% CI 0.76-1.85)) or gender female (aOR 1.39 (95% CI 0.71-2.72)) and males (aOR 1.67 (95% CI 0.95-2.92)). When results were stratified by both age and gender, there was similarly no statistically significant effect between the two groups.
   Conclusions: Automated physician reminders for subsequent 2nd and 3rd doses of HPV vaccination were used. Despite increased rates of vaccination in the intervention group, the differences did not reach the level of statistical significance. Future studies with multifaceted approaches may be needed to examine the efficacy of computer-based reminders. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wilkinson, Tracey A.; Sheley, Meena; Dugan, Tamara; Downs, Stephen M.] Indiana Univ Sch Med, Dept Pediat, Childrens Hlth Serv Res, 410 W 10th St,Suite 2000, Indianapolis, IN 46202 USA.
   [Dixon, Brian E.] Indiana Univ, Fairbanks Sch Publ Hlth, Dept Epidemiol, 1050 Wishard Blvd,RG5, Inpolis, IN 46202 USA.
   [Dixon, Brian E.; Tu, Wanzhu; Church, Abby] Regenstreif Inst, Ctr Biomed Informat, 1101 W 10th St, Indianapolis, IN 46202 USA.
   [Xiao, Shan; Tu, Wanzhu] Indiana Univ Sch Med, Dept Biostat, 410 W 10th St,Suite 3000, Indianapolis, IN 46202 USA.
   [Lindsay, Brianna] Merck & Co Inc, Ctr Observat & Real World Evidence, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
   [Zimet, Gregory] Indiana Univ Sch Med, Dept Pediat Adolescent Med, 410 W 10th St,Suite 1001, Indianapolis, IN 46202 USA.
   [Xiao, Shan] Biogen, Dept Biometr, Cambridge, MA 02142 USA.
   [Lindsay, Brianna] Univ Penn, Sch Arts & Sci, 433 S Univ Ave, Philadelphia, PA 19104 USA.
   [Church, Abby] Indiana Univ, Fairbanks Sch Publ Hlth, Dept Hlth Policy & Management, 1050 Wishard Blvd,RG5, Indianapolis, IN 46204 USA.
RP Wilkinson, TA (reprint author), Indiana Univ Sch Med, Childrens Hlth Serv Res, Dept Pediat, 410 West 10th St,HS 2000, Indianapolis, IN 46202 USA.
EM tracwilk@iu.edu; bedixon@regenstrief.org; wtu1@iu.edu;
   lindsabr@sas.upenn.edu; msheley@iu.edu; tmdugan@iu.edu;
   akchurch@iupui.edu; stmdowns@iu.edu; gzimet@iu.edu
RI Dixon, Brian E./A-9494-2013
OI Dixon, Brian E./0000-0002-1121-0607; Lindsay,
   Brianna/0000-0001-6116-3864
FU Merck-Regenstrief Program in Personalized Health Care Research and
   Innovation [21]
FX This study was supported by the Merck-Regenstrief Program in
   Personalized Health Care Research and Innovation (Project #21). Its
   contents are the sole responsibility of the authors and do not reflect
   the official view of Merck & Co., Inc.
CR [Anonymous], 2008, LANG ENV STAT COMP
   [Anonymous], 2013, HUM PAP VACC COV AD
   Arbyn M, 2011, COCHRANE DATABASE SY, V2011
   Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450
   Carroll AE, 2012, APPL CLIN INFORM, V3, P309, DOI 10.4338/ACI-2012-04-RA-0013
   Daley EM, 2017, PAPILLOMAVIRUS RES, V3, P142, DOI 10.1016/j.pvr.2017.04.004
   Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366
   Dixon BE, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0521-6
   EL Walker TYE, 2017, NATL REGIONAL STATE
   Embi PJ, 2012, J AM MED INFORM ASSN, V19, pE145, DOI 10.1136/amiajnl-2011-000743
   Fiks AG, 2013, PEDIATRICS, V131, P1114, DOI 10.1542/peds.2012-3122
   Francis DB, 2017, PATIENT ED COUNS
   Garcini LM, 2012, VACCINE, V30, P4588, DOI 10.1016/j.vaccine.2012.04.096
   Gilkey MB, 2014, PEDIATRICS
   IKENBERG H, 1983, INT J CANCER, V32, P563, DOI 10.1002/ijc.2910320507
   Iversen OE, 2016, JAMA-J AM MED ASSOC, V316, P2411, DOI 10.1001/jama.2016.17615
   Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
   Kharbanda EO, 2011, VACCINE, V29, P2537, DOI 10.1016/j.vaccine.2011.01.065
   Krist AH, 2015, J AM BOARD FAM MED, V28, P299, DOI 10.3122/jabfm.2015.03.150097
   Markowitz LE, 2016, JAMA-J AM MED ASSOC, V316, P2370, DOI 10.1001/jama.2016.16393
   Mayne SL, 2014, AM J PREV MED, V47, P734, DOI 10.1016/j.amepre.2014.08.010
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   Moss JL, 2012, CANCER EPIDEM BIOMAR, V21, P1913, DOI 10.1158/1055-9965.EPI-12-0509
   Reagan-Steiner S, 2016, MMWR-MORBID MORTAL W, V65, P850, DOI 10.15585/mmwr.mm6533a4
   Ruffin MT, 2015, J AM BOARD FAM MED, V28, P324, DOI 10.3122/jabfm.2015.03.140082
   SCHEURLEN W, 1986, INT J CANCER, V38, P671, DOI 10.1002/ijc.2910380509
   Szilagyi PG, 2015, ACAD PEDIATR, V15, P149, DOI 10.1016/j.acap.2014.10.006
   Zimet G, 2018, ACAD PEDIATR, V18, pS66, DOI 10.1016/j.acap.2017.11.002
NR 28
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 18
PY 2019
VL 37
IS 31
BP 4414
EP 4418
DI 10.1016/j.vaccine.2019.05.004
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IL0CM
UT WOS:000476963700026
PM 31201057
DA 2020-05-12
ER

PT J
AU Chen, Z
   Xu, JH
   Wang, YD
AF Chen, Zhuo
   Xu, Jianhong
   Wang, Yundong
TI Gas-liquid-liquid multiphase flow in microfluidic systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Gas-liquid-liquid; Multiphase; Microfluidics; Application; Scale-up
ID DOUBLE-EMULSION FORMATION; RARE-EARTH-ELEMENTS; MASS-TRANSFER; 3-PHASE
   FLOW; WATER; DROPLETS; SINGLE; INTENSIFICATION; MICROBUBBLES;
   FABRICATION
AB Gas-liquid-liquid (G/L/L) multiphase flow in microfluidic system has been a vital part of microfluidics, micro-chemical and micro-analysis in recent years. Microfluidics has emerged as a useful tool to prepare G/L/L that affords improved control over the micro-scale structure. With the aid of clever and efficient device designs, precise regulation of the size, shape and components can be realized. Existing results have shown that G/L/L multiphase micro-flow exhibits more complicated laws and unique characteristics in flow, transport and reactions compared with liquid-liquid or gas-liquid two-phase flow, allowing the optimal and more efficient control of the process. In this review, focused on the G/L/L multiphase flow in microfluidic systems, we recount the historical development of this system and approach, along with the state-of-the-art, including discussion of microfluidic devices (lithographically defined devices and capillary/needle-based devices) and microchannel type (cross-junction, flow-focusing, dual-coaxial, etc.) used to form and prepare G/L/L multiphase mixtures. Discussion is also extended to scaling laws and numerical simulations used to predict the size of microbubbles or droplets. In addition, flow and mass transfer characteristics, as well as applications and scale-up, are also discussed. Finally, the future trends in the development of G/L/L multiphase flow are addressed, emphasizing some directions worth detailed study and remaining challenges in the field. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Zhuo; Xu, Jianhong; Wang, Yundong] Tsinghua Univ, State Key Lab Chem Engn, Dept Chem Engn, Beijing 100084, Peoples R China.
RP Xu, JH; Wang, YD (reprint author), Tsinghua Univ, State Key Lab Chem Engn, Dept Chem Engn, Beijing 100084, Peoples R China.
EM xujianhong@mail.tsinghua.edu.cn; wangyd@mail.tsinghua.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21636004]; National Safety Academy Foundation
   [U1530107]; National Key Basic Research Program of China in the State
   Key Laboratory of Chemical Engineering of Tsinghua University, Beijing,
   China [2012CBA01203]
FX This research was carried out under the National Natural Science
   Foundation of China (21636004), the National Safety Academy Foundation
   (U1530107), the National Key Basic Research Program of China (No.
   2012CBA01203) in the State Key Laboratory of Chemical Engineering of
   Tsinghua University, Beijing, China. The authors gratefully acknowledge
   these grants.
CR Adamson DN, 2006, LAB CHIP, V6, P1178, DOI 10.1039/b604993a
   Arnold MM, 2007, J CONTROL RELEASE, V121, P100, DOI 10.1016/j.jconrel.2007.05.039
   Assmann N, 2013, CHEM ENG TECHNOL, V36, P921, DOI 10.1002/ceat.201200557
   Assmann N, 2011, CHEM ENG PROCESS, V50, P822, DOI 10.1016/j.cep.2011.05.009
   Atencia J, 2005, NATURE, V437, P648, DOI 10.1038/nature04163
   Brugarolas T, 2011, ADV FUNCT MATER, V21, P3924, DOI 10.1002/adfm.201100954
   Chen DLL, 2007, LANGMUIR, V23, P2255, DOI 10.1021/la062152z
   Chen R, 2012, LAB CHIP, V12, P3858, DOI 10.1039/c2lc40387k
   Chen YP, 2015, INT J HEAT MASS TRAN, V82, P42, DOI 10.1016/j.ijheatmasstransfer.2014.11.027
   Chen Z, 2018, CHEM ENG PROCESS, V127, P127, DOI 10.1016/j.cep.2018.03.004
   Chen Z, 2017, SEP PURIF TECHNOL, V174, P352, DOI 10.1016/j.seppur.2016.10.059
   Chlon C, 2009, BIOMACROMOLECULES, V10, P1025, DOI 10.1021/bm801243u
   Choi HJ, 2002, J VISUAL-JAPAN, V5, P145, DOI 10.1007/BF03182423
   Cristini V, 2004, LAB CHIP, V4, P257, DOI 10.1039/b403226h
   De Menech M, 2008, J FLUID MECH, V595, P141, DOI 10.1017/S002211200700910X
   Ding SK, 2019, J CONTROL RELEASE, V295, P31, DOI 10.1016/j.jconrel.2018.12.037
   Edwards D. A., 1998, J APPL PHYSL
   Ferrara KW, 2009, ACCOUNTS CHEM RES, V42, P881, DOI 10.1021/ar8002442
   Fu Y. H., 2014, CIESC J, V65, P2536
   Fu YH, 2016, CHEM ENG SCI, V146, P126, DOI 10.1016/j.ces.2016.02.036
   Garstecki P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.164501
   Hardt S, 2012, LAB CHIP, V12, P434, DOI 10.1039/c1lc20569b
   Hashimoto M, 2007, SMALL, V3, P1792, DOI 10.1002/smll.200700238
   Illg T, 2010, BIOORGAN MED CHEM, V18, P3707, DOI 10.1016/j.bmc.2010.03.073
   Jeong HH, 2015, LAB CHIP, V15, P4387, DOI 10.1039/c5lc01025j
   Kashid MN, 2011, CHEM ENG SCI, V66, P3876, DOI 10.1016/j.ces.2011.05.015
   Khan SA, 2009, LAB CHIP, V9, P1840, DOI 10.1039/b904119b
   Koster S, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/11/110301
   Koushik K, 2004, PHARM RES-DORDR, V21, P1119, DOI 10.1023/B:PHAM.0000032997.96823.88
   Kovarik ML, 2012, ANAL CHEM, V84, P516, DOI 10.1021/ac202611x
   Lee MH, 2010, LANGMUIR, V26, P2227, DOI 10.1021/la904425v
   Lee W, 2011, MACROMOL MATER ENG, V296, P203, DOI 10.1002/mame.201000302
   Lin PL, 2009, ADV MATER, V21, P3949, DOI 10.1002/adma.200901096
   Lou XW, 2008, ADV MATER, V20, P3987, DOI 10.1002/adma.200800854
   Muhlfriedel K, 2000, EXP FLUIDS, V28, P279, DOI 10.1007/s003480050388
   Mulligan MK, 2012, MICROFLUID NANOFLUID, V13, P65, DOI 10.1007/s10404-012-0941-7
   Nguyen NT, 2012, MICROFLUID NANOFLUID, V12, P1, DOI 10.1007/s10404-011-0903-5
   Nie ZH, 2008, MICROFLUID NANOFLUID, V5, P585, DOI 10.1007/s10404-008-0271-y
   Nightingale AM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4777
   Nisisako T, 2012, LAB CHIP, V12, P3426, DOI 10.1039/c2lc40245a
   Onal Y, 2005, CHEM ENG TECHNOL, V28, P972, DOI 10.1002/ceat.200500147
   Park JM, 2012, LAB CHIP, V12, P2672, DOI 10.1039/c2lc21235h
   Rajesh VM, 2012, CHEM ENG J, V207, P832, DOI 10.1016/j.cej.2012.07.082
   Romanowsky MB, 2012, LAB CHIP, V12, P802, DOI 10.1039/c2lc21033a
   Sang FN, 2018, AICHE J, V64, P730, DOI 10.1002/aic.15930
   Shah RK, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369-7021(08)70053-1
   Shao HW, 2012, MICROFLUID NANOFLUID, V12, P705, DOI 10.1007/s10404-011-0914-2
   Shih R, 2013, LAB CHIP, V13, P4816, DOI 10.1039/c3lc51016f
   Shui L, 2007, ADV COLLOID INTERFAC, V133, P35, DOI 10.1016/j.cis.2007.03.001
   Shui LL, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.3000624
   Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554
   Su YH, 2009, AICHE J, V55, P1948, DOI 10.1002/aic.11787
   Tan J, 2012, IND ENG CHEM RES, V51, P1834, DOI 10.1021/ie2010302
   Tan J, 2011, CHEM ENG J, V171, P1406, DOI 10.1016/j.cej.2011.05.060
   Tan J, 2011, SEP PURIF TECHNOL, V80, P225, DOI 10.1016/j.seppur.2011.04.030
   Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163
   Utada AS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.094502
   van der Graaf S, 2006, LANGMUIR, V22, P4144, DOI 10.1021/la052682f
   Wan J, 2008, ADV MATER, V20, P3314, DOI 10.1002/adma.200800628
   Wan JD, 2012, LANGMUIR, V28, P37, DOI 10.1021/la203824f
   Wan JD, 2010, SOFT MATTER, V6, P4677, DOI 10.1039/c002158j
   Wang K, 2010, MICROFLUID NANOFLUID, V8, P813, DOI 10.1007/s10404-009-0514-6
   Wang K, 2009, LANGMUIR, V25, P2153, DOI 10.1021/la803049s
   Wang K, 2013, CHEM ENG TECHNOL, V36, P1047, DOI 10.1002/ceat.201200561
   Wang WT, 2015, RSC ADV, V5, P82056, DOI 10.1039/c5ra15769b
   Wang WT, 2014, RSC ADV, V4, P16444, DOI 10.1039/c4ra01526f
   Xu JH, 2006, LANGMUIR, V22, P7943, DOI 10.1021/la0605743
   Xu JH, 2012, LAB CHIP, V12, P2029, DOI 10.1039/c2lc21193a
   Yang L, 2013, LAB CHIP, V13, P3355, DOI 10.1039/c3lc50652e
   Yue J, 2007, CHEM ENG SCI, V62, P2096, DOI 10.1016/j.ces.2006.12.057
   Yue J, 2014, LAB CHIP, V14, P1632, DOI 10.1039/c3lc51307f
   Zeng Y, 2010, ANAL CHEM, V82, P3183, DOI 10.1021/ac902683t
   Zhang JS, 2014, AICHE J, V60, P2724, DOI 10.1002/aic.14450
   Zhang SB, 2017, CHEM ENG SCI, V172, P100, DOI 10.1016/j.ces.2017.06.031
   Zhao CX, 2011, CHEM ENG SCI, V66, P1394, DOI 10.1016/j.ces.2010.08.038
   Zheng B, 2005, ANGEW CHEM INT EDIT, V44, P2520, DOI 10.1002/anie.200462857
   Zhou CF, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2353116
   Zuniga RN, 2008, TRENDS FOOD SCI TECH, V19, P176, DOI 10.1016/j.tifs.2007.11.012
NR 78
TC 7
Z9 7
U1 34
U2 150
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 1
EP 14
DI 10.1016/j.ces.2019.03.016
PG 14
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900001
DA 2020-05-12
ER

PT J
AU Ma, XK
   Li, P
   Ma, TX
   Chu, GW
   Luo, Y
   Zou, HK
   Sun, BC
   Chen, JF
AF Ma, Xiaoke
   Li, Peng
   Ma, Tian-Xiang
   Chu, Guang-Wen
   Luo, Yong
   Zou, Hai-Kui
   Sun, Baochang
   Chen, Jian-Feng
TI Study on phenol sulfonation by concentrated sulfuric acid: Kinetics and
   process optimization
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE p-Hydroxybenzenesulfonic acid (p-HBSA); Rotating packed bed (RPB);
   Stirred tank reactor (STR); Yield; Reaction rate constant; Activation
   energy
ID ROTATING PACKED-BED; AROMATIC SULFONATION; TECHNOLOGY; WATER
AB Sulfonation process usually exhibit high reaction rate and low yield and selectivity of product in common reactors for its insufficient micromixing. This work employed a rotating packed bed (RPB) to intensify the micromixing of the phenol sulfonation process to improve the yield and selectivity of p-hydroxybenzenesulfonic acid (p-HBSA). Experiments and kinetic study on the sulfonation of phenol by concentrated sulfuric acid were carried out in a stirred tank reactor (STR). The reaction rate constant k and activation energy E at certain temperature was tested. The values of pre-exponential factor and activation energy were obtained as follows: k(1) = 5.74 x 10(3), E-1 = 8.17 kJ/mol, k(-1) = 6.95 x 10(3), E-1 = 6.18 kJ/mol, k(2) = 1.43 x 10(10), E-2 = 69.35 kJ/mol, k(-2) = 0.05 x 10(3), E-2 = 14.17 kJ/mol. The effects of various operating conditions including reaction temperature (T), sulfuric acid/phenol molar ratio (eta), solvent/phenol molar ratio (zeta), concentrated sulfuric acid feeding rate (Q'), stirring speed (P), ageing time (tau), on the content of p-HBSA were investigated in an attempt to obtain the optimal operating conditions in the STR. The yield of p-HBSA is 89.85% at the optimal operating conditions. On the basis of the results in STR, further experiments were performed in a rotating packed bed (RPB) to improve the sulfonation reaction selectivity and p-HBSA yield. The effects of rotation speed (N), cycle time (t) and concentrated sulfuric acid feeding rate (Q) were investigated. Results show that the yield of p-HBSA can reach up to 96.52% in RPB at the optimal operating conditions of N = 2250 rpm, Q = 300 mL/min, T = 100 degrees C, eta = 1.1, tau = 25 min, zeta = 1.25 and t = 3 min. The yield of p-HBSA obtained in the RPB is 6.67% higher than that in the STR. The research exhibits that RPB can obviously improve the yield of p-HBSA. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chu, Guang-Wen; Luo, Yong; Zou, Hai-Kui; Sun, Baochang; Chen, Jian-Feng] Beijing Univ Chem Technol, Minist Educ High Grav Engn & Technol, Res Ctr, Beijing 100029, Peoples R China.
   [Ma, Xiaoke; Li, Peng; Chu, Guang-Wen; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
   [Ma, Tian-Xiang] PetroChina Co Ltd, Daqing Refining & Chem Co, Daqing 163411, Peoples R China.
RP Sun, BC (reprint author), POB 35,15 Bei San Huan Dong Rd, Beijing 100029, Peoples R China.
EM sunbc@mail.buct.edu.cn
RI Luo, Yong/E-7522-2016
OI Luo, Yong/0000-0001-8300-5277
FU National Key R&D Program of China [2016YFB0301500]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [U1607114]
FX This work was financially supported by National Key R&D Program of China
   (No. 2016YFB0301500) and National Natural Science Foundation of China
   (U1607114).
CR Abdolmaleki A, 2015, POLYMER, V75, P17, DOI 10.1016/j.polymer.2015.08.021
   Ansink H. R. W, 2010, CHEMINFORM, V23
   CERFONTAIN H, 1985, J CHEM SOC PERK T 2, P659, DOI 10.1039/p29850000659
   Chen J. F., 2003, CHINA PART, V1, P64, DOI DOI 10.1016/S1672-2515(07)60110-9
   Chen JF, 2000, IND ENG CHEM RES, V39, P948, DOI 10.1021/ie990549a
   Fernandes S. A, 2012, CHEMINFORM, V43, P1630
   Goossens H. D, 2015, RECL TRAV CHIM PAY B, V107, P426
   Guo K, 2000, CHEM ENG SCI, V55, P1699, DOI 10.1016/S0009-2509(99)00369-3
   Hai JY, 2006, CHEM ENG J, V121, P147, DOI 10.1016/j.cej.2006.04.010
   HAWASH S, 1993, IND ENG CHEM RES, V32, P1066, DOI 10.1021/ie00018a012
   Hongchang, 2017, COMPUT THEOR CHEM, V1112, P111, DOI 10.1016/j.comptc.2017.04.012
   Kaandorp A. W, 2015, RECL TRAV CHIM PAY B, V82, P113
   KENYON RL, 1950, IND ENG CHEM, V42, P1446, DOI 10.1021/ie50488a004
   Koleva G, 2011, J AM CHEM SOC, V133, P19094, DOI 10.1021/ja201866h
   Kucera F, 1998, POLYM ENG SCI, V38, P783, DOI 10.1002/pen.10244
   Li X., 1994, ACTA MECH SINICA, V26, P266
   Lin C. C, 2010, CHEM ENG PROCESS, V49, P76
   Moors SLC, 2017, CHEM SCI, V8, P680, DOI 10.1039/c6sc03500k
   NARDILLO AM, 1988, CHROMATOGRAPHIA, V25, P618, DOI 10.1007/BF02327658
   Natalino R, 2014, CATAL SCI TECHNOL, V4, P1369, DOI 10.1039/c3cy01081c
   Roberts DW, 2003, ORG PROCESS RES DEV, V7, P172, DOI 10.1021/op020088w
   Russo V, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.11.162
   Shang NC, 2006, J ENVIRON SCI HEAL A, V41, P2299, DOI 10.1080/10934520600873043
   SHIBUYA N, 1994, POLYMER, V35, P3237, DOI 10.1016/0032-3861(94)90128-7
   Speight J. G, 2017, ORG CHEM
   Sun BC, 2012, IND ENG CHEM RES, V51, P10949, DOI 10.1021/ie202983x
   Wang DG, 2007, COLLOID SURFACE A, V293, P201, DOI 10.1016/j.colsurfa.2006.07.030
   Wang ZY, 2016, CHEM ENG PROCESS, V110, P123, DOI 10.1016/j.cep.2016.10.010
   Weiser J, 1994, US, Patent No. [US5342916[P], 5342916]
   Weng Z, 2015, CHINA PET PROCESS PE, V17, P59
   Wu J, 2010, J CHEM TECHNOL BIOT, V76, P619
   Yang HJ, 2005, IND ENG CHEM RES, V44, P7730, DOI 10.1021/ie0503646
   Zhao H, 2010, CHEM ENG J, V156, P588, DOI 10.1016/j.cej.2009.04.053
NR 33
TC 1
Z9 1
U1 8
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 15
EP 25
DI 10.1016/j.ces.2019.03.002
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900002
DA 2020-05-12
ER

PT J
AU Svinterikos, E
   Zuburtikudis, I
   Al-Marzouqi, M
AF Svinterikos, Efstratios
   Zuburtikudis, Ioannis
   Al-Marzouqi, Mohamed
TI The nanoscale dimension determines the carbonization outcome of
   electrospun lignin/recycled-PET fibers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon nanofibers; Diameter; Carbonization; Electrospinning; Lignin;
   Recycled PET
ID CARBON NANOFIBERS; THERMAL-DEGRADATION; CO-PYROLYSIS; KINETICS; SHELL
AB The impact of the nanoscale dimension on the carbonization of electrospun fibers is usually overlooked. In this study, we prove that it is a decisive factor in the outcome of the carbonization process. Six electrospun fibrous mats, each with a different average fiber diameter ranging from 80 nm to 781 nm were fabricated from a lignin/recycled-PET blend of mass ratio 1/1, and their weight loss and decomposition profile were monitored via thermogravimetry. The nano-size effect is evident for those electrospun mats with average diameter lower than 121 nm. These mats exhibit a significantly higher decomposition rate at the 180-260 degrees C temperature range, which leads to a considerable degree of fusion of the precursor nanofibers. Thus, the carbon structures formed from these mats do not retain the geometrical integrity of their precursor nanofibers. In contrast, no size-effects are manifested to the electrospun samples of average fiber diameter larger than 387 nm, as they decompose at a similar and lower rate between 180 and 260 degrees C and yield infusible carbon fibers with similar geometry as their corresponding precursor fibers. These results highlight the determinant role of the nano-dimension when carbon fibers are produced through the carbonization of precursor fibers at the sub-micron scale and point out its significance in processes controlled by heat and mass transfer phenomena, as in the case of carbonization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Svinterikos, Efstratios; Al-Marzouqi, Mohamed] UAEU, Dept Chem & Petr Engn, POB 15551, Al Ain, U Arab Emirates.
   [Zuburtikudis, Ioannis] ADU, Dept Chem Engn, POB 59911, Abu Dhabi, U Arab Emirates.
RP Zuburtikudis, I (reprint author), ADU, Dept Chem Engn, POB 59911, Abu Dhabi, U Arab Emirates.
EM ioannis.zuburtikudis@adu.ac.ae
OI Svinterikos, Efstratios/0000-0001-6303-8944
FU Emirates Center for Energy and Environment Research (ECEER)
FX The authors would like to acknowledge the financial support provided by
   the Emirates Center for Energy and Environment Research (ECEER).
CR Brems A, 2011, RESOUR CONSERV RECY, V55, P772, DOI 10.1016/j.resconrec.2011.03.003
   Chen TJ, 2016, BIORESOURCE TECHNOL, V211, P502, DOI 10.1016/j.biortech.2016.03.091
   Chin BLF, 2014, ENERG CONVERS MANAGE, V87, P746, DOI 10.1016/j.enconman.2014.07.043
   Compere A. L., 2005, EVALUATION LIGNIN AL, V118
   Correa CR, 2017, ACS SUSTAIN CHEM ENG, V5, P8222, DOI 10.1021/acssuschemeng.7b01895
   Dallmeyer I, 2010, J WOOD CHEM TECHNOL, V30, P315, DOI 10.1080/02773813.2010.527782
   Frank E, 2014, ANGEW CHEM INT EDIT, V53, P5262, DOI 10.1002/anie.201306129
   Garcia A, 2009, SEP PURIF TECHNOL, V68, P193, DOI 10.1016/j.seppur.2009.05.001
   Inagaki M, 2012, ADV MATER, V24, P2547, DOI 10.1002/adma.201104940
   Kim J, 2016, ENERGY, V100, P51, DOI 10.1016/j.energy.2016.01.075
   Ko F, 2014, INTRO NANOFIBER MAT
   Ko KH, 2014, ENERG CONVERS MANAGE, V86, P154, DOI 10.1016/j.enconman.2014.04.060
   Kubo S, 2005, J POLYM ENVIRON, V13, P97, DOI 10.1007/s10924-005-2941-0
   Mohabeer C, 2017, J ANAL APPL PYROL, V127, P269, DOI 10.1016/j.jaap.2017.07.025
   Ogale A., 2016, J APPL POLYM SCI, V133, DOI [10.1002/APP.44212, DOI 10.1002/APP.44212]
   Peng SJ, 2016, NANO ENERGY, V22, P361, DOI 10.1016/j.nanoen.2016.02.001
   Przepiorski J, 2009, IND ENG CHEM RES, V48, P7110, DOI 10.1021/ie801694t
   Ruiz-Rosas R, 2010, CARBON, V48, P696, DOI 10.1016/j.carbon.2009.10.014
   Svinterikos E, 2017, J POLYM ENVIRON, V25, P465, DOI 10.1007/s10924-016-0806-3
   Svinterikos E, 2016, J APPL POLYM SCI, V133, DOI 10.1002/app.43936
   Ye JS, 2016, CHEM ENG J, V283, P304, DOI 10.1016/j.cej.2015.07.071
   Zhang BA, 2016, PROG MATER SCI, V76, P319, DOI 10.1016/j.pmatsci.2015.08.002
NR 22
TC 2
Z9 2
U1 5
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 26
EP 35
DI 10.1016/j.ces.2019.03.013
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900003
DA 2020-05-12
ER

PT J
AU Grigorov, PI
   Muzzio, FJ
   Glasser, BJ
AF Grigorov, Plamen, I
   Muzzio, Fernando J.
   Glasser, Benjamin J.
TI Modeling fluidized bed impregnation of active pharmaceutical ingredients
   onto porous excipients
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pharmaceutical; Fluidized bed; Impregnation; Modeling; Impregnation
   profile; Neusilin
ID SUPPORTED CATALYSTS; CAPILLARY-PRESSURE; NONUNIFORM DISTRIBUTION;
   CONCENTRATION PROFILES; INTERFACIAL AREA; SATURATION; FENOFIBRATE;
   STRENGTH; KINETICS; IMPACT
AB Impregnation of active pharmaceutical ingredients (APIs) onto porous excipients offers several advantages to solid dosage pharmaceutical preparation over conventional formulation methods. Previous work has successfully introduced fluidized bed (FB) impregnation of APIs onto porous carriers as a robust manufacturing process with numerous benefits (easy to implement, excellent blend uniformity and dissolution kinetics, stabilization of amorphous APIs). This study aims to develop a simple, multi-scale modeling approach to FB impregnation. The model consists of three main parts: (1) an energy/mass balance on the FB and an evaporative flux calculation, (2) an impregnation model for a single particle and (3) a drying model for a single particle. The model allows the calculation of some important process parameters (e.g. product temperature, maximum liquid spray rate) for given drying conditions. These are important process parameters needed to achieve successful impregnation. The model accounts for convection, diffusion and crystallization within the particle. The main characteristic is the 2D modeling of the liquid and API distributions within the particle during impregnation and drying. Several cases are presented to illustrate the effect of some material properties (fast crystallization, slow diffusion, low porosity) on the final API profile. Simulation results regarding API profiles of impregnation are in a very good agreement with experimental measurements carried out in our previous work. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Grigorov, Plamen, I; Muzzio, Fernando J.; Glasser, Benjamin J.] Rutgers State Univ, Dept Chem & Biochem Engn, 98 Brett Rd, Piscataway, NJ 08854 USA.
RP Glasser, BJ (reprint author), Rutgers State Univ, Dept Chem & Biochem Engn, 98 Brett Rd, Piscataway, NJ 08854 USA.
EM bglasser@scarletmail.rutgers.edu
CR Allgeier MC, 2016, J PHARM SCI-US, V105, P3105, DOI 10.1016/j.xphs.2016.06.019
   BECKER ER, 1977, J CATAL, V46, P372, DOI 10.1016/0021-9517(77)90221-4
   BECKER ER, 1977, J CATAL, V46, P365, DOI 10.1016/0021-9517(77)90220-2
   BENESI HA, 1968, J CATAL, V10, P328, DOI 10.1016/0021-9517(68)90147-4
   Bentsen R. G, 1976, NEW DISPLACEMENT CAP
   Bird BR, 2002, TRANSPORT PHENOMENA
   Bouledjouidja A, 2016, INT J PHARMACEUT, V499, P1, DOI 10.1016/j.ijpharm.2015.12.049
   Brooks R.H., 1964, HYDROL PAP
   Cha KH, 2012, INT J NANOMED, V7, P5565, DOI 10.2147/IJN.S36939
   Chen YH, 2009, POWDER TECHNOL, V191, P206, DOI 10.1016/j.powtec.2008.10.010
   Chevalier E, 2010, ACTA BIOMATER, V6, P266, DOI 10.1016/j.actbio.2009.07.040
   CHILDS EC, 1948, DISCUSS FARADAY SOC, V3, P78, DOI 10.1039/df9480300078
   Choudhari Y., 2014, MESOPOR BIOMATER
   CONSTANTINIDES A, 1999, NUMERICAL METHODS CH
   Cosijns A, 2009, DRUG DEV IND PHARM, V35, P655, DOI 10.1080/03639040802578103
   CUSSLER EL, 1997, DIFFUSION
   DENESUK M, 1993, J COLLOID INTERF SCI, V158, P114, DOI 10.1006/jcis.1993.1235
   Dullien F. A. L., 1992, POROUS MEDIA FLUID T
   Fatt I., 1956, NETWORK MODEL POROUS
   Finn R., 1999, NOT AM MATH SOC, V46, P770
   Fogler S.H., 1999, ELEMENTS CHEM REACTI
   Galarraga C, 2001, CHEM ENG J, V82, P13, DOI 10.1016/S1385-8947(00)00352-1
   GAVRIILIDIS A, 1993, CATAL REV, V35, P399, DOI 10.1080/01614949308013912
   Glasstone S., 1941, THEORY RATE PROCESSE
   Grigorov PI, 2018, POWDER TECHNOL, V332, P197, DOI 10.1016/j.powtec.2018.03.062
   Grigorov PI, 2016, AICHE J, V62, P4201, DOI 10.1002/aic.15312
   Grigorov PI, 2013, AICHE J, V59, P4538, DOI 10.1002/aic.14209
   HORVATH C, 1973, IND ENG CHEM FUND, V12, P229, DOI 10.1021/i160046a015
   Innocentini M. D. M., 1999, MAT RES, V2, P283, DOI DOI 10.1590/S1516-14391999000400008
   Joekar-Niasar V, 2008, TRANSPORT POROUS MED, V74, P201, DOI 10.1007/s11242-007-9191-7
   KOMIYAMA M, 1980, J CATAL, V63, P35, DOI 10.1016/0021-9517(80)90058-5
   KYLE BG, 1999, CHEM PROCESS THERMOD
   LEE SY, 1985, CATAL REV, V27, P207, DOI 10.1080/01614948508064737
   Lekhal A, 2004, CHEM ENG SCI, V59, P1063, DOI 10.1016/j.ces.2003.12.009
   Lekhal A, 2001, IND ENG CHEM RES, V40, P3989, DOI 10.1021/ie010126k
   Lekhal A, 2001, CHEM ENG SCI, V56, P4473, DOI 10.1016/S0009-2509(01)00120-8
   Lenormand R., 1988, NUMERICAL MODELS EXP
   Leverett M. C, 1941, CAPILLARY BEHAV PORO
   Li K, 2004, P 29 WORKSH GEOTH RE
   Li KW, 2001, SPE RESERV EVAL ENG, V4, P477, DOI 10.2118/75294-PA
   Liu X, 2008, CHEM ENG SCI, V63, P4517, DOI 10.1016/j.ces.2008.06.013
   Liu X, 2012, CHEM ENG SCI, V79, P187, DOI 10.1016/j.ces.2012.05.046
   Liu X, 2010, IND ENG CHEM RES, V49, P2649, DOI 10.1021/ie9014606
   Lopez-Periago A, 2009, J SUPERCRIT FLUID, V48, P56, DOI 10.1016/j.supflu.2008.09.015
   Markicevic B, 2010, TRANSPORT POROUS MED, V85, P953, DOI 10.1007/s11242-010-9603-y
   Mellaerts R, 2008, LANGMUIR, V24, P8651, DOI 10.1021/la801161g
   Metzger T, 2005, DRY TECHNOL, V23, P1797, DOI 10.1080/07373930500209830
   Mullin J. W, 2001, CRYSTALLIZATION CRYS
   NEIMARK AV, 1976, REACT KINET CATAL L, V5, P67, DOI 10.1007/BF02067435
   NEIMARK AV, 1981, IND ENG CHEM PROD RD, V20, P439, DOI 10.1021/i300003a006
   O'Carroll DM, 2005, J CONTAM HYDROL, V77, P247, DOI 10.1016/j.jconhyd.2005.01.004
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   PRAT M, 1993, INT J MULTIPHAS FLOW, V19, P691, DOI 10.1016/0301-9322(93)90096-D
   Purcell W. R, 1949, CAPILLARY PRESSURES
   Reeves PC, 1996, WATER RESOUR RES, V32, P2345, DOI 10.1029/96WR01105
   Rengarajan GT, 2008, J MATER CHEM, V18, P2537, DOI 10.1039/b804266g
   Roth J, 1972, J RES I CAT HOKKAIDO, V20, P85
   SANTHANAM N, 1994, CATAL TODAY, V21, P141, DOI 10.1016/0920-5861(94)80040-5
   SHYR YS, 1980, J CATAL, V63, P425, DOI 10.1016/0021-9517(80)90096-2
   Thomeer J. H. M, 1960, INTRO PORE GEOMETRIC
   VINCENT RC, 1974, J CATAL, V35, P206, DOI 10.1016/0021-9517(74)90199-7
   Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273
   WHITAKER S, 1977, ADV HEAT TRANSFER, V13, P119
   Yiotis AG, 2001, ADV WATER RESOUR, V24, P439, DOI 10.1016/S0309-1708(00)00066-X
NR 64
TC 0
Z9 0
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 36
EP 54
DI 10.1016/j.ces.2019.02.029
PG 19
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900004
DA 2020-05-12
ER

PT J
AU Liao, YX
   Ma, T
   Krepper, E
   Lucas, D
   Frohlich, J
AF Liao, Yixiang
   Ma, Tian
   Krepper, Eckhard
   Lucas, Dirk
   Froehlich, Jochen
TI Application of a novel model for bubble-induced turbulence to bubbly
   flows in containers and vertical pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Baseline model; Bubbly flow; Bubble-induced turbulence; Euler-Euler
   modelling
ID 2-PHASE FLOW; CLOSURE-MODEL; WATER FLOW; SIMULATION; COALESCENCE;
   PREDICTION; DIAMETER; BEHAVIOR; COLUMN; LIFT
AB The baseline model for the CFD-simulation of turbulent bubbly flows in the Euler-Euler framework was proposed several years ago. It defines a fixed set of closures including all constants to avoid case by case tuning and to have a basis for sustainable model development. The present paper extends the baseline model by improving the modelling of bubble-induced turbulence. The closure terms in the transport equations of the k-omega SST model are revisited and replaced with the model recently proposed by Ma et al. (Ma et al., 2017. Physical Review Fluids 2, 034301) which is based on an analysis of the turbulent kinetic energy budget obtained from direct numerical simulation data. Detailed validation results for various flow configurations with a wide range of gas and liquid volumetric fluxes are presented. In case of vertical pipe flow significant improvements in the predicted gas volume fraction and velocity profiles are obtained, especially in high gas volume fraction cases where bubble-induced turbulence is dominant. Simulations of other configurations, such as uniform and non-uniform bubble columns, show that the model of Ma et al. (2017) results in an also for these cases overall improvement. Therefore, the baseline model is now updated to include the new model for bubble-induced turbulence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liao, Yixiang; Ma, Tian; Krepper, Eckhard; Lucas, Dirk] Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Dresden, Germany.
   [Froehlich, Jochen] Tech Univ Dresden, Inst Fluid Mech, Dresden, Germany.
RP Liao, YX (reprint author), Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Dresden, Germany.
EM y.liao@hzdr.de
RI Liao, Yixiang/L-7630-2019; Frohlich, Jochen/B-4275-2010
OI Liao, Yixiang/0000-0002-1277-3938; Frohlich, Jochen/0000-0003-1653-5686;
   Lucas, Dirk/0000-0003-0463-2278
CR ANSYS Inc., 2012, ANSYS CFX SOLV THEOR
   bin Mohd Akbar Mohd Hatta, 2012, Multiphase Science and Technology, V24, P197
   Bove S, 2004, INT J CHEM REACT ENG, V2
   Burns A.D., 2004, P ICMF 98 5 INT C MU
   Crowe C.T., 2011, MULTIPHASE FLOWS DRO
   Deen NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4
   Hosokawa S., 2002, P ASME JOINT US EUR
   Hosokawa S., 2010, 7 INT C MULT FLOW TA
   Hosokawa S., 2007, 6 INT C MULT FLOW IC
   Ilic M., 2006, TECHNICAL REPORT
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   KATAOKA I, 1993, NUCL ENG DES, V141, P145, DOI 10.1016/0029-5493(93)90099-U
   KATAOKA I, 1989, INT J MULTIPHAS FLOW, V15, P843, DOI 10.1016/0301-9322(89)90045-1
   Koncar B., 2005, INT C NUCL EN NEW EU
   Krepper E., 2017, 17 INT TOP M NUCL RE
   Krepper E, 2008, NUCL ENG DES, V238, P1690, DOI 10.1016/j.nucengdes.2008.01.004
   Krepper E, 2018, NUCL ENG DES, V340, P388, DOI 10.1016/j.nucengdes.2018.09.042
   Krepper E, 2009, NUCL ENG DES, V239, P2372, DOI 10.1016/j.nucengdes.2009.06.015
   Kriebitzsch S, 2016, FLUIDS, V1, DOI 10.3390/fluids1030029
   Liao J, 2016, J CHEM TECHNOL BIOT, V91, P2904, DOI 10.1002/jctb.4917
   Liao Y, 2018, INT J NUMER METH FL, V87, P202, DOI 10.1002/fld.4491
   Liao Y., 2012, P 20 INT C NUCL ENG
   Liao YX, 2018, NUCL ENG DES, V337, P450, DOI 10.1016/j.nucengdes.2018.07.021
   Liao YX, 2016, INT J THERM SCI, V104, P194, DOI 10.1016/j.ijthermalsci.2016.01.016
   Liao YX, 2015, CHEM ENG SCI, V122, P336, DOI 10.1016/j.ces.2014.09.042
   Liao YX, 2011, NUCL ENG DES, V241, P1024, DOI 10.1016/j.nucengdes.2010.04.025
   Liu T. J., 1998, P 3 INT C MULT FLOW
   Lopez de Bertodano M., 1992, THESIS
   Lucas D, 2007, CHEM ENG SCI, V62, P4146, DOI 10.1016/j.ces.2007.04.035
   Lucas D, 2005, INT J MULTIPHAS FLOW, V31, P1304, DOI 10.1016/j.ijmultiphaseflow.2005.07.004
   Lucas D, 2016, NUCL ENG DES, V299, P2, DOI 10.1016/j.nucengdes.2015.07.007
   Lucas D, 2011, INT J MULTIPHAS FLOW, V37, P1178, DOI 10.1016/j.ijmultiphaseflow.2011.05.009
   Ma T, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.034301
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Ohnuki A, 2001, J NUCL SCI TECHNOL, V38, P1074, DOI 10.1080/18811248.2001.9715138
   Ohnuki A, 2000, INT J MULTIPHAS FLOW, V26, P367, DOI 10.1016/S0301-9322(99)00024-5
   Pan Y, 1999, CHEM ENG SCI, V54, P2481, DOI 10.1016/S0009-2509(98)00453-9
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Politano MS, 2003, INT J MULTIPHAS FLOW, V29, P1153, DOI 10.1016/S0301-9322(03)00065-X
   Prasser H.-M., 2003, TECHNICAL REPORT
   Rabha S, 2013, CHEM ENG SCI, V93, P401, DOI 10.1016/j.ces.2013.02.034
   Rzehak R, 2017, CHEM ENG SCI, V157, P147, DOI 10.1016/j.ces.2016.04.056
   Rzehak R, 2015, CHEM ENG TECHNOL, V38, P1972, DOI 10.1002/ceat.201500118
   Rzehak R, 2013, INT J MULTIPHAS FLOW, V55, P138, DOI 10.1016/j.ijmultiphaseflow.2013.04.007
   Santarelli C, 2016, INT J MULTIPHAS FLOW, V81, P27, DOI 10.1016/j.ijmultiphaseflow.2016.01.004
   Santarelli C, 2016, CHEM ENG SCI, V141, P46, DOI 10.1016/j.ces.2015.10.013
   Santarelli C, 2015, INT J MULTIPHAS FLOW, V75, P174, DOI 10.1016/j.ijmultiphaseflow.2015.05.007
   Sato Y., 1975, International Journal of Multiphase Flow, V2, P79, DOI 10.1016/0301-9322(75)90030-0
   Scott D, 2014, IOP C SER EARTH ENV, V22, DOI 10.1088/1755-1315/22/6/062008
   Shawkat ME, 2008, INT J MULTIPHAS FLOW, V34, P767, DOI 10.1016/j.ijmultiphaseflow.2008.01.007
   Shi PY, 2018, CHEM ENG SCI, V190, P419, DOI 10.1016/j.ces.2018.06.001
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Troshko AA, 2001, INT J MULTIPHAS FLOW, V27, P1965, DOI 10.1016/S0301-9322(01)00043-X
   Vaidheeswaran A, 2017, INT J HEAT MASS TRAN, V115, P741, DOI 10.1016/j.ijheatmasstransfer.2017.08.075
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   Yao W, 2004, INT J HEAT MASS TRAN, V47, P307, DOI 10.1016/j.ijheatmasstransfer.2003.06.004
   Ziegenhein T, 2015, CHEM ENG SCI, V122, P1, DOI 10.1016/j.ces.2014.09.022
   Ziegenhein T, 2017, CAN J CHEM ENG, V95, P170, DOI 10.1002/cjce.22647
NR 58
TC 9
Z9 9
U1 10
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 55
EP 69
DI 10.1016/j.ces.2019.03.007
PG 15
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900005
DA 2020-05-12
ER

PT J
AU Jia, CS
   Zhang, LH
   Peng, XL
   Luo, JX
   Zhao, YL
   Liu, JY
   Guo, JJ
   Tang, LD
AF Jia, Chun-Sheng
   Zhang, Lie-Hui
   Peng, Xiao-Long
   Luo, Jian-Xin
   Zhao, Yu-Long
   Liu, Jian-Yi
   Guo, Jing-Jing
   Tang, Lian-Dong
TI Prediction of entropy and Gibbs free energy for nitrogen
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Entropy; Gibbs free energy; Closed-form representation; Nitrogen;
   Nitrogen injection
ID THERMODYNAMIC PROPERTIES; METHANE RECOVERY; GAS DRAINAGE; PURE N-2;
   ADSORPTION; INJECTION; COAL; CO2; SIMULATION; ENTHALPY
AB Nitrogen (N-2) is widely used in oil and gas industry. We report two new efficient closed-form representations for the molar entropy and Gibbs free energy of pure gaseous substances. A comparison of the predicted and experimental values shows that the molar entropies and Gibbs free energies of N-2 can be excellently predicted in the temperature range of 100-6000 K. The present entropy and Gibbs free energy prediction models only require the experimental values of three molecular constants and are away from the utilization of a great number of experimental spectroscopy data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jia, Chun-Sheng; Zhang, Lie-Hui; Peng, Xiao-Long; Luo, Jian-Xin; Zhao, Yu-Long; Liu, Jian-Yi; Guo, Jing-Jing; Tang, Lian-Dong] Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
RP Jia, CS (reprint author), Southwest Petr Univ, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610500, Sichuan, Peoples R China.
EM chshjia@263.net
FU Key Program of National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [51534006]; Sichuan Province
   Foundation of China for Fundamental Research Projects [2018JY0468]
FX We would like to thank the kind referees for positive and invaluable
   suggestions which have greatly improved the manuscript. This work was
   supported by the Key Program of National Natural Science Foundation of
   China under Grant No. 51534006 and the Sichuan Province Foundation of
   China for Fundamental Research Projects under Grant No. 2018JY0468.
CR Buchowiecki M, 2018, CHEM PHYS LETT, V692, P236, DOI 10.1016/j.cplett.2017.12.051
   Chase  M. W, 1621, J PHYS CHEM REF DATA, P1621
   Corless RM, 1996, ADV COMPUT MATH, V5, P329, DOI 10.1007/BF02124750
   Deng M, 2018, EUR PHYS J PLUS, V133, DOI 10.1140/epjp/i2018-12090-2
   DONOHOE CW, 1981, J PETROL TECHNOL, V33, P263, DOI 10.2118/7494-PA
   Ghafoori A, 2012, PETROL SCI TECHNOL, V30, P1071, DOI 10.1080/10916461003681745
   Jia CS, 2019, CHEM PHYS LETT, V717, P16, DOI 10.1016/j.cplett.2019.01.001
   Jia CS, 2018, CHEM ENG SCI, V190, P1, DOI 10.1016/j.ces.2018.06.009
   Jia CS, 2018, CHEM ENG SCI, V183, P26, DOI 10.1016/j.ces.2018.03.009
   Jia CS, 2018, CHEM PHYS LETT, V692, P57, DOI 10.1016/j.cplett.2017.12.013
   Jia CS, 2017, INT J QUANTUM CHEM, V117, DOI 10.1002/qua.25383
   Jia CS, 2017, CHEM PHYS LETT, V676, P150, DOI 10.1016/j.cplett.2017.03.068
   Jia CS, 2017, CHEM PHYS LETT, V667, P211, DOI 10.1016/j.cplett.2016.11.059
   Jia CS, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4731340
   Kang JQ, 2018, J NAT GAS SCI ENG, V57, P21, DOI 10.1016/j.jngse.2018.06.041
   Khordad R, 2019, CHEM PHYS, V517, P30, DOI 10.1016/j.chemphys.2018.09.038
   Lin J, 2018, J NAT GAS SCI ENG, V55, P30, DOI 10.1016/j.jngse.2018.04.016
   Lin J, 2018, FUEL, V215, P665, DOI 10.1016/j.fuel.2017.11.129
   Liu JF, 2015, FUEL, V157, P151, DOI 10.1016/j.fuel.2015.04.070
   Liu Y, 2009, J CHEM ENG DATA, V54, P1981, DOI 10.1021/je800661q
   Mustafa O, 2015, J PHYS B-AT MOL OPT, V48, DOI 10.1088/0953-4075/48/6/065101
   National Institute of Standards and Technology (NIST), 2017, NIST CHEM WEBBOOK, V69
   Neron A, 2012, CHEM ENG SCI, V82, P260, DOI 10.1016/j.ces.2012.07.041
   Ocak Z, 2018, CHEM PHYS, V513, P252, DOI 10.1016/j.chemphys.2018.08.015
   Peng XL, 2018, CHEM ENG SCI, V190, P122, DOI 10.1016/j.ces.2018.06.027
   Perera MSA, 2015, J GEOPHYS ENG, V12, P90, DOI 10.1088/1742-2132/12/1/90
   Raganati F, 2018, CHEM ENG RES DES, V134, P540, DOI 10.1016/j.cherd.2018.04.037
   Sanger P, 1998, SPE J, V3, P26, DOI DOI 10.2118/30795-PA
   Schwabl F., 2006, STAT MECH
   Sherman BJ, 2016, CHEM ENG SCI, V153, P295, DOI 10.1016/j.ces.2016.07.019
   Song XQ, 2017, CHEM PHYS LETT, V673, P50, DOI 10.1016/j.cplett.2017.02.010
   Span R, 2000, J PHYS CHEM REF DATA, V29, P1361, DOI 10.1063/1.1349047
   STEELE D, 1962, REV MOD PHYS, V34, P239, DOI 10.1103/RevModPhys.34.239
   Tas A, 2017, ANN PHYS-NEW YORK, V379, P67, DOI 10.1016/j.aop.2017.02.010
   Telis VRN, 2000, THERMOCHIM ACTA, V343, P49, DOI 10.1016/S0040-6031(99)00379-2
   Wang JF, 2017, CHEM PHYS LETT, V686, P131, DOI 10.1016/j.cplett.2017.08.047
   Wang LG, 2015, J NAT GAS SCI ENG, V23, P363, DOI 10.1016/j.jngse.2015.02.002
   Winitzki S, 2003, LECT NOTES COMPUT SC, V2667, P780
   Zhang GD, 2012, PHYS REV A, V86, DOI 10.1103/PhysRevA.86.062510
   Zhang JF, 2015, FUEL, V160, P309, DOI 10.1016/j.fuel.2015.07.092
   Zhou FD, 2013, INT J COAL GEOL, V116, P53, DOI 10.1016/j.coal.2013.06.004
NR 41
TC 18
Z9 18
U1 4
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 70
EP 74
DI 10.1016/j.ces.2019.03.033
PG 5
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900006
DA 2020-05-12
ER

PT J
AU Jia, H
   Leng, X
   Wang, QX
   Han, YG
   Wang, SY
   Ma, A
   Guo, MZ
   Yan, H
   Lv, KH
AF Jia, Han
   Leng, Xu
   Wang, Qiuxia
   Han, Yugui
   Wang, Shaoyan
   Ma, An
   Guo, Muzhi
   Yan, Hui
   Lv, Kaihe
TI Controllable emulsion phase behaviour via the selective host-guest
   recognition of mixed surfactants at the water/octane interface
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE beta-cyclodextrin; Mixed surfactants; Controllable emulsion; Phase
   inversion; Selective host-guest recognition
ID ENHANCED-OIL-RECOVERY; GEMINI SURFACTANT; CRUDE-OIL; PHYSICOCHEMICAL
   PROPERTIES; SILICA NANOPARTICLES; HIGH-TEMPERATURE; TENSION; WATER;
   SYSTEM; STABILITY
AB Emulsions are deeply involved in almost all aspects of the petroleum industry, especially in enhanced oil recovery. Supramolecular chemistry proposes a facile and controllable method to construct target assemblies. In this report, we investigated the effects of beta-cyclodextrin (beta-CD) on the emulsions stabilized by the mixed N-dodecyl-N-methylpyrrolidinium bromide (L12) and sodium dodecyl sulfate (SDS). The additional beta-CD exerted strong influences on the water/n-octane interfacial tension (IFT) between n-octane and the mixed L12/SDS aqueous solutions, which should be attributed to its selective host-guest recognition. Interestingly, the additional beta-CD in moderate concentrations could selectively remove the major surfactant molecules at the interface to adjust the hydrophilic-lipophilic balance of the mixed adsorption layers, thereby causing the transformation of the emulsion type from O/W to W/O. The addition of excess beta-CD would generate the construction of n-octane/beta-CD complexes to enhance the hydrophilicity of the interfacial layers, which leads again to phase inversion. Emulsions and their types were characterized and confirmed by the measurements of their conductivities, average droplet radii and rheological properties. To verify the proposed mechanism for the multiple phase inversion, the effects of L12/SDS molar ratios and beta-CD concentrations were studied in depth in the control experiments. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jia, Han; Leng, Xu; Wang, Shaoyan; Ma, An; Guo, Muzhi; Lv, Kaihe] China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
   [Wang, Qiuxia; Han, Yugui] CNOOC China Ltd, Tianjin Branch, Bohai Oilfield Res Inst, Tianjin 300459, Peoples R China.
   [Yan, Hui] Liaocheng Univ, Sch Pharm, Liaocheng 252000, Shandong, Peoples R China.
RP Jia, H; Lv, KH (reprint author), China Univ Petr East China, Sch Petr Engn, Shandong Key Lab Oilfield Chem, Qingdao 266580, Shandong, Peoples R China.
EM jiahan@upc.edu.cn; 19930006@upc.edu.cn
OI Jia, Han/0000-0001-9204-2774
FU Key Project of the National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [U1762106]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21403301]; National Training Program of Innovation and Entrepreneurship
   for Undergraduates [20181032, 20181034]
FX The authors are grateful for funding from the Key Project of the
   National Natural Science Foundation of China (No. U1762106), the
   National Natural Science Foundation of China (No. 21403301) and the
   National Training Program of Innovation and Entrepreneurship for
   Undergraduates (20181032 and 20181034).
CR Bera A, 2015, J PET EXPLOR PROD TE, V5, P255, DOI 10.1007/s13202-014-0139-5
   Bera A, 2014, J CHEM ENG DATA, V59, P2490, DOI 10.1021/je500274r
   Bera A, 2014, FUEL, V121, P198, DOI 10.1016/j.fuel.2013.12.051
   Bera A, 2014, J CHEM ENG DATA, V59, P89, DOI 10.1021/je400850c
   Bera A, 2012, J CHEM ENG DATA, V57, P1000, DOI 10.1021/je2013796
   Bera A, 2011, COLLOID SURFACE A, V383, P114, DOI 10.1016/j.colsurfa.2011.03.035
   Bouchama F, 2003, COLLOID SURFACE A, V231, P11, DOI 10.1016/j.colsurfa.2003.08.011
   Bryan J, 2008, SPE DOE IMPR OIL REC
   Cao J, 2018, ENERG FUEL, V32, P246, DOI 10.1021/acs.energyfuels.7b03053
   Chen H, 2004, SURF SCI, V552, pL53, DOI 10.1016/j.susc.2004.01.018
   Dai CL, 2018, CHEM ENG SCI, V179, P73, DOI 10.1016/j.ces.2018.01.005
   Derguine-Mecheri L, 2018, J PETROL SCI ENG, V162, P712, DOI 10.1016/j.petrol.2017.10.088
   Dong MZ, 2009, FUEL, V88, P1049, DOI 10.1016/j.fuel.2008.11.014
   Feng HS, 2018, J PETROL SCI ENG, V171, P974, DOI 10.1016/j.petrol.2018.08.011
   Feng HS, 2018, COLLOID SURFACE A, V554, P74, DOI 10.1016/j.colsurfa.2018.06.028
   Fletcher PDI, 2015, LANGMUIR, V31, P3076, DOI 10.1021/la5049612
   Gao B, 2013, SPE J, V18, P829, DOI 10.2118/159700-PA
   Gernon MD, 2009, TRIBOL T, V52, P405, DOI 10.1080/10402000802687882
   Hanamertani AS, 2018, J PETROL SCI ENG, V162, P480, DOI 10.1016/j.petrol.2017.09.077
   Hirasaki GJ, 2011, SPE J, V16, P889, DOI 10.2118/115386-PA
   HOLMBERG K, 2003, SURFACTANTS POLYM AQ
   Iglauer S, 2010, J PETROL SCI ENG, V71, P23, DOI 10.1016/j.petrol.2009.12.009
   Inoue M, 2009, J OLEO SCI, V58, P85, DOI 10.5650/jos.58.85
   Jia H, 2018, J MOL LIQ, V268, P266, DOI 10.1016/j.molliq.2018.07.068
   Jia H, 2018, ENERG FUEL, V32, P154, DOI 10.1021/acs.energyfuels.7b02746
   Jia H, 2017, COLLOID SURFACE A, V529, P621, DOI 10.1016/j.colsurfa.2017.06.055
   Jia H, 2017, COLLOID SURFACE A, V513, P292, DOI 10.1016/j.colsurfa.2016.10.057
   Kamal MS, 2014, J SURFACTANTS DETERG, V17, P985, DOI 10.1007/s11743-014-1600-7
   Kamal MS, 2013, J CHEM-NY, DOI 10.1155/2013/801570
   Kittisrisawai S, 2015, J SURFACTANTS DETERG, V18, P603, DOI 10.1007/s11743-015-1688-4
   Kumar A, 2015, IND ENG CHEM RES, V54, P8375, DOI 10.1021/acs.iecr.5b01122
   Kumar N, 2018, EUR POLYM J, V109, P265, DOI 10.1016/j.eurpolymj.2018.09.058
   Kumar N, 2018, J MOL LIQ, V266, P147, DOI 10.1016/j.molliq.2018.06.069
   Kumar N, 2018, ENERG FUEL, V32, P6452, DOI 10.1021/acs.energyfuels.8b00043
   Kumar N, 2017, J IND ENG CHEM, V54, P304, DOI 10.1016/j.jiec.2017.06.005
   Lake L.W., 2014, ENHANCED OIL RECOVER
   Li ZQ, 2009, ACTA PHYS-CHIM SIN, V25, P6, DOI 10.3866/PKU.WHXB20090102
   Liu HL, 2016, J DISPER SCI TECHNOL, V37, P89, DOI 10.1080/01932691.2015.1029583
   Llamas S, 2018, LANGMUIR, V34, P5978, DOI 10.1021/acs.langmuir.8b00358
   Lv GJ, 2014, COLLOID SURFACE A, V447, P8, DOI 10.1016/j.colsurfa.2014.01.066
   Martinez-Magadan JM, 2018, J MOL GRAPH MODEL, V80, P264, DOI 10.1016/j.jmgm.2018.01.017
   Nan YQ, 2015, COLLOID SURFACE A, V482, P125, DOI 10.1016/j.colsurfa.2015.04.030
   Pal N, 2018, J PETROL SCI ENG, V168, P283, DOI 10.1016/j.petrol.2018.05.026
   Perazzo A, 2015, ADV COLLOID INTERFAC, V222, P581, DOI 10.1016/j.cis.2015.01.001
   Radi M, 2013, J DISPER SCI TECHNOL, V34, P582, DOI 10.1080/01932691.2012.681607
   Rajkhowa S, 2017, J SOLUTION CHEM, V46, P11, DOI 10.1007/s10953-016-0552-0
   Salager JL, 2013, J SURFACTANTS DETERG, V16, P449, DOI 10.1007/s11743-013-1470-4
   Salager JL, 2005, J SURFACTANTS DETERG, V8, P3, DOI 10.1007/s11743-005-0328-4
   Salager JL, 2004, ADV COLLOID INTERFAC, V108, P259, DOI 10.1016/j.cis.2003.10.008
   Seo S, 2018, FUEL, V234, P48, DOI 10.1016/j.fuel.2018.06.111
   Shah A, 2010, ENERG ENVIRON SCI, V3, P700, DOI 10.1039/b918960b
   SHINODA K, 1968, J COLLOID INTERF SCI, V26, P70, DOI 10.1016/0021-9797(68)90273-7
   Sun HQ, 2011, SOFT MATTER, V7, P7601, DOI 10.1039/c1sm05234a
   Tian MZ, 2013, J PHYS CHEM B, V117, P433, DOI 10.1021/jp310065y
   Wang C, 2017, SOFT MATTER, V13, P8636, DOI 10.1039/c7sm02025b
   Wang D, 2015, RSC ADV, V5, P95604, DOI 10.1039/c5ra18441j
   Wei B, 2019, FUEL, V236, P1321, DOI 10.1016/j.fuel.2018.09.105
   Woodward RT, 2009, CHEM COMMUN, P3554, DOI 10.1039/b904320a
   Wu YN, 2018, LANGMUIR, V34, P8015, DOI 10.1021/acs.langmuir.8b01187
   Wu YN, 2017, J PETROL SCI ENG, V153, P283, DOI 10.1016/j.petrol.2017.04.015
   Xie K, 2018, SPE PROD OPER, V33, P596, DOI 10.2118/189970-PA
   Xie K, 2016, SPE J, V21, P1, DOI 10.2118/174553-PA
   Xu HN, 2015, LANGMUIR, V31, P9061, DOI 10.1021/acs.langmuir.5b02111
   Xu XJ, 2006, FOOD HYDROCOLLOID, V20, P723, DOI 10.1016/j.foodhyd.2005.06.012
   Yu L, 2018, CHEM ENG SCI, V189, P165, DOI 10.1016/j.ces.2018.05.033
   Zhang L, 2008, COLLOID SURFACE A, V320, P111, DOI 10.1016/j.colsurfa.2008.01.035
NR 66
TC 19
Z9 20
U1 24
U2 83
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 75
EP 83
DI 10.1016/j.ces.2019.03.036
PG 9
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900007
DA 2020-05-12
ER

PT J
AU Bensabath, T
   Le, MD
   Monnier, H
   Glaude, PA
AF Bensabath, Tsilla
   Minh Duy Le
   Monnier, Hubert
   Glaude, Pierre-Alexandre
TI Polycyclic aromatic hydrocarbon (PAH) formation during acetylene
   pyrolysis in tubular reactor under low pressure carburizing conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pyrolysis; Acetylene; PAHs; Benzo[a]pyrene; Low-pressure gas carburizing
ID CHEMICAL-VAPOR-DEPOSITION; GAS-PHASE REACTIONS; SOOT; GROWTH; METHANE;
   CARBON; FLOW; VINYLACETYLENE; POLYMERIZATION; COMBUSTION
AB Low-pressure carburizing involves hydrocarbon pyrolysis, which leads to a fast gas-phase formation of polycyclic aromatic hydrocarbons (PAHs), some of which, such as benzo[a]pyrene, are carcinogenic. Workers can be exposed to these PAHs during maintenance and cleaning operations of carburizing furnaces. Experiments of acetylene pyrolysis were carried out in conditions close to low-pressure gas carburizing processes, at 1173 K and 8 kPa, in tubular reactors. At the outlet of the reaction zone, the reactant and the reaction products were analyzed by gas chromatography (TCD, FID and MS). Amongst other products, 16 PAHs classified as priority pollutants by the United States Environmental Protection Agency (US EPA) were observed and quantified. The study of the influence of residence time and of inlet reactant concentration shows that amounts of PAHs increase with residence time at low acetylene concentration but slightly decrease with pure acetylene due to the conversion of PAHs into soot. Results were compared to simulation results obtained with a detailed kinetic model of light hydrocarbon pyrolysis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bensabath, Tsilla; Glaude, Pierre-Alexandre] Univ Lorraine, CNRS, Lab React & Genie Proc, 1 Rue Grandville, F-54001 Nancy, France.
   [Bensabath, Tsilla; Minh Duy Le; Monnier, Hubert] INRS, 1 Rue Morvan, F-54519 Vandoeuvre Les Nancy, France.
RP Monnier, H (reprint author), INRS, 1 Rue Morvan, F-54519 Vandoeuvre Les Nancy, France.
EM hubert.monnier@inrs.fr
OI MONNIER, HUBERT/0000-0002-6175-3247
CR [Anonymous], 2017, IARC MONOGRAPHS EVAL
   Bensabath T, 2019, CHEM ENG SCI, V195, P810, DOI 10.1016/j.ces.2018.10.028
   Bensabath T, 2016, J ANAL APPL PYROL, V122, P342, DOI 10.1016/j.jaap.2016.09.007
   Berthelot M., 1866, ANN CHIM PHYS, V9, P469
   Buchholz D, 2010, IND ENG CHEM RES, V49, P1130, DOI 10.1021/ie900996h
   Champmartin C, 2017, ANN WORK EXPOS HEAL, V61, P321, DOI 10.1093/annweh/wxw024
   Dai B, 1999, CHEM ENG SCI, V54, P957, DOI 10.1016/S0009-2509(98)00312-1
   Dimitrijevic ST, 2000, J ANAL APPL PYROL, V53, P107, DOI 10.1016/S0165-2370(99)00060-1
   Frenklach M., 1984, 20TH S INT COMB PITT, P887, DOI DOI 10.1016/S0082-0784(85)80578-6
   Herbinet O, 2015, CHEM ENG SCI, V131, P49, DOI 10.1016/j.ces.2015.03.026
   Hiblot H, 2016, INT J HYDROGEN ENERG, V41, P18329, DOI 10.1016/j.ijhydene.2016.07.226
   Hooker W. J., 1958, S INT COMBUST, V7, P949, DOI [10.1016/S0082-0784(58)80142-3, DOI 10.1016/S0082-0784(58)80142-3]
   HOU KC, 1963, J PHYS CHEM-US, V67, P1579, DOI 10.1021/j100802a004
   Krestinin AV, 2000, KINET CATAL+, V41, P90, DOI 10.1007/BF02756146
   Kuwana K, 2006, CHEM ENG SCI, V61, P6718, DOI 10.1016/j.ces.2006.07.006
   Lacroix R, 2010, CARBON, V48, P132, DOI 10.1016/j.carbon.2009.08.041
   Li CE, 2018, CHEM ENG SCI, V187, P189, DOI 10.1016/j.ces.2018.04.070
   MATRAS D, 1973, CHEM ENG SCI, V28, P129, DOI 10.1016/0009-2509(73)85093-6
   MUNSON MSB, 1963, CARBON, V1, P51, DOI 10.1016/0008-6223(63)90009-5
   Norinaga K, 2007, IND ENG CHEM RES, V46, P3547, DOI 10.1021/ie061207p
   Norinaga K, 2006, CARBON, V44, P1790, DOI 10.1016/j.carbon.2005.12.050
   Norinaga K, 2009, J ANAL APPL PYROL, V86, P148, DOI 10.1016/j.jaap.2009.05.001
   OGURA H, 1977, B CHEM SOC JPN, V50, P1044, DOI 10.1246/bcsj.50.1044
   Pease RN, 1929, J AM CHEM SOC, V51, P3470, DOI 10.1021/ja01386a042
   Richter H, 2000, PROG ENERG COMBUST, V26, P565, DOI 10.1016/S0360-1285(00)00009-5
   Rokstad OA, 2014, INT J CHEM KINET, V46, P104, DOI 10.1002/kin.20830
   ROTA R, 1994, CHEM ENG SCI, V49, P4211
   Sanchez NE, 2012, ENERGY, V43, P30, DOI 10.1016/j.energy.2011.12.009
   Sanchez NE, 2013, GREEN ENERGY TECHNOL, P283, DOI 10.1007/978-1-4471-5307-8_11
   Sanchez NE, 2013, J ANAL APPL PYROL, V103, P126, DOI 10.1016/j.jaap.2012.10.027
   Sanchez NE, 2012, ENERG FUEL, V26, P4823, DOI 10.1021/ef300749q
   Sanchez NE, 2010, CHEM ENGINEER TRANS, V22, P131, DOI 10.3303/CET1022021
   Shukla B, 2007, J PHYS CHEM A, V111, P8308, DOI 10.1021/jp071813d
   Shukla B, 2012, COMBUST FLAME, V159, P3589, DOI 10.1016/j.combustflame.2012.08.007
   Shukla M, 2008, J PHYS CHEM A, V112, P2362, DOI 10.1021/jp7098398
   SILCOCKS CG, 1957, PROC R SOC LON SER-A, V242, P411, DOI 10.1098/rspa.1957.0185
   Stehling F. C., 1961, S INT COMBUSTION PIT, P774, DOI [10.1016/S0082-0784(06)80572-2, DOI 10.1016/S0082-0784(06)80572-2]
   Stehling F. C., 1957, S INT COMBUSTION PIT, P247, DOI [10.1016/S0082-0784(57)80035-6, DOI 10.1016/S0082-0784(57)80035-6]
   Straif K, 2005, LANCET ONCOL, V6, P931, DOI 10.1016/S1470-2045(05)70458-7
   Violi A, 1999, CHEM ENG SCI, V54, P3433, DOI 10.1016/S0009-2509(98)00460-6
   WU CH, 1987, INT J CHEM KINET, V19, P975, DOI 10.1002/kin.550191104
   Xu XJ, 2005, PHYS CHEM CHEM PHYS, V7, P326, DOI 10.1039/b412585a
   Yada K, 2013, COMPUT FLUIDS, V79, P65, DOI 10.1016/j.compfluid.2013.03.005
   Yan BH, 2012, CHEM ENG SCI, V84, P31, DOI 10.1016/j.ces.2012.08.005
NR 44
TC 0
Z9 0
U1 3
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 84
EP 94
DI 10.1016/j.ces.2019.03.030
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900008
DA 2020-05-12
ER

PT J
AU Bhat, M
   Sakthikumar, R
   Sivakumar, D
AF Bhat, Maanasa
   Sakthikumar, R.
   Sivakumar, D.
TI Fuel drop impact on heated solid surface in film evaporation regime
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drop collision; Drop impact; Film evaporation; Drop spreading; Maximum
   spreading diameter
ID BOILING REGIMES; WATER DROPLETS; COLLISION; DYNAMICS
AB This study reports an experimental investigation on the dynamics of impacting hydrocarbon fuel drops on a heated stainless steel surface in the film evaporation regime. The analysis is focused on the description of maximum spreading diameter of the impacting fuel drops on the heated surface kept at different temperatures below the boiling point of the fuel. By considering four different fuels of varying physical properties and fuel drops with impact velocity in the range 0.6 - 3.5 m/sec, the study explores a wide range of Weber number (30 - 902), Reynolds number (372 - 13457) and Ohnesorge number (0.0022 - 0.0151). The drop morphology and spreading dynamics on the heated surface are quantified by studying high speed videos of drop impact captured during experiments. Data analysis suggests that, in addition to Weber number and surface temperature, dynamic viscosity of the fuel also plays a role in determining the quantified trends of maximum spreading diameter. Existing theoretical models for the prediction of maximum diameter on unheated flat surfaces can be extended for drop impact on heated surfaces in the film evaporation regime by using surface temperature dependent fuel viscosity. With the support of the present experimental data, an empirical model involving an explicit surface temperature term is proposed for the prediction of maximum diameter on a heated surface in the film evaporation regime. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bhat, Maanasa; Sivakumar, D.] Indian Inst Sci, Dept Aerosp Engn, Bengaluru 560012, India.
   [Sakthikumar, R.; Sivakumar, D.] Indian Inst Sci, Interdisciplinary Ctr Energy Res, Bengaluru 560012, India.
RP Sivakumar, D (reprint author), Indian Inst Sci, Dept Aerosp Engn, Bengaluru 560012, India.
EM dskumar@iisc.ac.in
FU National Centre for Combustion Research and Development (NCCRD), Indian
   Institute of Science
FX This work is carried out under the support of National Centre for
   Combustion Research and Development (NCCRD), Indian Institute of
   Science.
CR Alizadeh A, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3692598
   [Anonymous], 1983, HDB AV FUEL PROP
   Bernardin JD, 1997, INT J HEAT MASS TRAN, V40, P247, DOI 10.1016/0017-9310(96)00119-6
   Bertola V, 2015, INT J HEAT MASS TRAN, V85, P430, DOI 10.1016/j.ijheatmasstransfer.2015.01.084
   Bonn N.S., 2012, J FLUID MECH, V549, P307
   CHANDRA S, 1991, P R SOC-MATH PHYS SC, V432, P13, DOI 10.1098/rspa.1991.0002
   Chen RH, 2007, EXP THERM FLUID SCI, V32, P587, DOI 10.1016/j.expthermflusci.2007.07.002
   Clanet C, 2004, J FLUID MECH, V517, P199, DOI 10.1017/S0022112004000904
   Clavijo CE, 2017, INT J HEAT MASS TRAN, V108, P1714, DOI 10.1016/j.ijheatmasstransfer.2016.12.076
   Derby B, 2011, J EUR CERAM SOC, V31, P2543, DOI 10.1016/j.jeurceramsoc.2011.01.016
   Derby B, 2010, ANNU REV MATER RES, V40, P395, DOI 10.1146/annurev-matsci-070909-104502
   Dhiman R., 2009, THESIS
   Greco L.C., 2015, 8 IB C TRIB
   Green D.W., 2008, PERRYS CHEM ENG HDB
   Kandlikar SG, 2001, CHEM ENG RES DES, V79, P491, DOI 10.1205/026387601750282436
   KANDLIKAR SG, 2001, P 35 NAT HEAT TRANSF
   Kompinsky E, 2013, CHEM ENG SCI, V98, P186, DOI 10.1016/j.ces.2013.04.047
   Liang GT, 2017, INT J HEAT MASS TRAN, V115, P1174, DOI 10.1016/j.ijheatmasstransfer.2017.06.029
   Liang G, 2017, INT J HEAT MASS TRAN, V115, P1206, DOI 10.1016/j.ijheatmasstransfer.2017.06.022
   Liang GT, 2017, INT J HEAT MASS TRAN, V106, P103, DOI 10.1016/j.ijheatmasstransfer.2016.10.031
   Liang GT, 2016, EXP THERM FLUID SCI, V74, P73, DOI 10.1016/j.expthermflusci.2015.11.027
   Mahulkar AV, 2015, CHEM ENG SCI, V130, P275, DOI 10.1016/j.ces.2015.03.012
   Manzello SL, 2002, INT J HEAT MASS TRAN, V45, P3961, DOI 10.1016/S0017-9310(02)00103-5
   Massinon M, 2012, BIOSYST ENG, V112, P56, DOI 10.1016/j.biosystemseng.2012.02.005
   Mehdizadeh NZ, 2006, P R SOC A, V462, P3115, DOI 10.1098/rspa.2006.1722
   Mitrakusuma WH, 2017, HEAT MASS TRANSFER, V53, P3085, DOI 10.1007/s00231-017-2053-0
   Nakoryakov VE, 2012, INT J HEAT MASS TRAN, V55, P6609, DOI 10.1016/j.ijheatmasstransfer.2012.06.069
   Ogawa H., 1997, JSAE REV, V18, P95
   Pasandideh-Fard M, 2001, INT J HEAT FLUID FL, V22, P201, DOI 10.1016/S0142-727X(00)00086-2
   PICKNETT RG, 1977, J COLLOID INTERF SCI, V61, P336, DOI 10.1016/0021-9797(77)90396-4
   Roisman IV, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3129283
   Sen S, 2014, EXP THERM FLUID SCI, V54, P38, DOI 10.1016/j.expthermflusci.2014.01.014
   Sen S, 2017, INT J THERM SCI, V121, P99, DOI 10.1016/j.ijthermalsci.2017.07.006
   Smith DB, 2000, T ASAE, V43, P255, DOI 10.13031/2013.2700
   Srikar R, 2009, INT J HEAT MASS TRAN, V52, P5814, DOI 10.1016/j.ijheatmasstransfer.2009.07.021
   Staat HJJ, 2015, J FLUID MECH, V779, DOI 10.1017/jfm.2015.465
   Tan SB, 2012, POLYM ENG SCI, V52, P1069, DOI 10.1002/pen.22173
   Ukiwe C, 2005, LANGMUIR, V21, P666, DOI 10.1021/la0481288
   Wildeman S, 2016, J FLUID MECH, V805, P636, DOI 10.1017/jfm.2016.584
   YU J, 1995, IND ENG CHEM RES, V34, P404, DOI 10.1021/ie00040a045
NR 40
TC 4
Z9 4
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 95
EP 104
DI 10.1016/j.ces.2019.03.017
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900009
DA 2020-05-12
ER

PT J
AU Yang, LM
   Yu, Y
   Pei, HJ
   Gao, Y
   Hou, GX
AF Yang, Liuming
   Yu, Yang
   Pei, Huijie
   Gao, Yuan
   Hou, Guoxiang
TI Lattice Boltzmann simulations of liquid flows in microchannel with an
   improved slip boundary condition
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Slip velocity; Boundary condition; Channel flow; Lattice Boltzmann
   simulation
ID COPPER-WATER NANOFLUID; TEMPERATURE-JUMP; 2-PHASE FLOWS; VELOCITY;
   NONSLIP; MODEL
AB Flow characteristics in channels are critical in chemical engineering. Slip velocity has a great influence on the microchannel flows. The lattice Boltzmann simulations of some typical channel flows are conducted with an improved slip boundary condition. Through theoretical analysis, the defects of the existing slip boundary conditions are clarified. To solve these problems, the slip boundary condition of Kuo et al. is ameliorated by considering the tangential momentum change generated by the external force. Besides, the Navier's slip model is adopted to specify the improved slip boundary condition. With this improved scheme, we study five cases, namely the Couette flow, the force driven Poiseuille flow, the time-dependent force driven Womersley flow, the porous plate flow and the channel flow with a surface-mounted block. Our method is accurate and reliable enough even with a coarse grid. The mass leakage at the wall is avoided and the numerical error generated by the external force is eliminated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Liuming; Yu, Yang; Gao, Yuan; Hou, Guoxiang] Huazhong Univ Sci & Technol, Sch Naval Architecture & Ocean Engn, Wuhan 430074, Hubei, Peoples R China.
   [Pei, Huijie] Huazhong Univ Sci & Technol, Sch Chem & Chem Engn, Key Lab Mat Chem Energy Convers & Storage, Minist Educ, Wuhan 430074, Hubei, Peoples R China.
RP Hou, GX (reprint author), Huazhong Univ Sci & Technol, Sch Naval Architecture & Ocean Engn, Wuhan 430074, Hubei, Peoples R China.
EM houguoxiang@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51679099, 51475179]; Fundamental Research Funds for
   the Central Universities HUSTFundamental Research Funds for the Central
   Universities [2016JCTD207]
FX We acknowledge the financial support from the National Natural Science
   Foundation of China (Grant No. 51679099 and No. 51475179), and the
   Fundamental Research Funds for the Central Universities HUST.
   2016JCTD207.
CR Ahmed NK, 2009, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2009/09/P09017
   Ansumali S, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.026311
   Benzi R, 2006, J FLUID MECH, V548, P257, DOI 10.1017/S0022112005007512
   Berry JD, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4993298
   Chai ZH, 2008, J APPL PHYS, V104, DOI 10.1063/1.2949273
   Chao C, 2018, CHEM ENG SCI, V192, P114, DOI 10.1016/j.ces.2018.07.026
   Dauyeshova B, 2017, CHEM ENG T, V57, P1267, DOI [10.3303/CET1757212, DOI 10.3303/CET1757212]
   Dong HY, 2013, J MATER CHEM A, V1, P5886, DOI 10.1039/c3ta10225d
   Fu TT, 2016, CHEM ENG TECHNOL, V39, P987, DOI 10.1002/ceat.201500620
   Guo ZL, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.056704
   Guo ZL, 2011, COMPUT MATH APPL, V61, P3519, DOI 10.1016/j.camwa.2010.01.022
   Guo ZL, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.046308
   He XY, 1997, PHYS REV E, V56, P6811, DOI 10.1103/PhysRevE.56.6811
   He XY, 1997, J STAT PHYS, V87, P115, DOI 10.1007/BF02181482
   Hu HB, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1603288
   Karatay E, 2013, P NATL ACAD SCI USA, V110, P8422, DOI 10.1073/pnas.1304403110
   Karimipour A, 2015, INT J THERM SCI, V91, P146, DOI 10.1016/j.ijthermalsci.2015.01.015
   Karimipour A, 2015, EUR J MECH B-FLUID, V49, P89, DOI 10.1016/j.euromechflu.2014.08.004
   Karimipour A, 2014, PHYSICA A, V402, P150, DOI 10.1016/j.physa.2014.01.057
   Kuo LS, 2009, COMPUT FLUIDS, V38, P883, DOI 10.1016/j.compfluid.2008.09.008
   Lee T, 2014, ADV COLLOID INTERFAC, V210, P21, DOI 10.1016/j.cis.2014.02.015
   Lim CY, 2002, PHYS FLUIDS, V14, P2299, DOI 10.1063/1.1483841
   Liu H, 2016, SCI CHINA PHYS MECH, V59, DOI 10.1007/s11433-015-5750-z
   Liu ZU, 2018, CHEM ENG SCI, V191, P19, DOI 10.1016/j.ces.2018.06.047
   Maali A, 2012, PHILOS T R SOC A, V370, P2304, DOI 10.1098/rsta.2011.0505
   Mohebbi R, 2018, INT J HEAT MASS TRAN, V117, P425, DOI 10.1016/j.ijheatmasstransfer.2017.10.043
   Navier C. L. M. H., 1827, MEM ACAD SCI I FR, V6, P389, DOI DOI 10.1017/CBO9781107415324.004
   Neto C, 2005, REP PROG PHYS, V68, P2859, DOI 10.1088/0034-4885/68/12/R05
   Nie XB, 2002, J STAT PHYS, V107, P279, DOI 10.1023/A:1014523007427
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   Reis T, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4764514
   Riaud A, 2018, LANGMUIR, V34, P4980, DOI 10.1021/acs.langmuir.8b00123
   Riaud A, 2013, CHEM ENG SCI, V99, P238, DOI 10.1016/j.ces.2013.05.054
   Rothstein JP, 2010, ANNU REV FLUID MECH, V42, P89, DOI 10.1146/annurev-fluid-121108-145558
   Saint-Raymond L, 2003, ANN SCI ECOLE NORM S, V36, P271, DOI 10.1016/S0012-9593(03)00010-7
   Sbragaglia M, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2044829
   Schaffel D, 2016, PHYS REV LETT, V116, DOI 10.1103/PhysRevLett.116.134501
   Silva G, 2018, PHYS REV E, V98, DOI 10.1103/PhysRevE.98.023302
   Silva G, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.013311
   Succi S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.064502
   Svec O, 2013, J NON-NEWTON FLUID, V199, P61, DOI 10.1016/j.jnnfm.2013.06.003
   Tan W, 2018, CHEM ENG SCI, V184, P273, DOI 10.1016/j.ces.2018.03.042
   Tang GH, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1897010
   Tao S, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.043305
   Tian Z. W, 2012, PHYSICA A, V385, P59
   Verhaeghe F, 2009, J COMPUT PHYS, V228, P147, DOI 10.1016/j.jcp.2008.09.004
   Wang K, 2018, COMPUT FLUIDS, V161, P60, DOI 10.1016/j.compfluid.2017.11.009
   Zhang SS, 2015, LANGMUIR, V31, P587, DOI 10.1021/la504451k
   Zheng L, 2007, COMMUN COMPUT PHYS, V2, P1125
NR 49
TC 2
Z9 2
U1 5
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 105
EP 117
DI 10.1016/j.ces.2019.03.032
PG 13
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900010
DA 2020-05-12
ER

PT J
AU Line, H
   Steiner, H
   Brenn, G
AF Line, Hakon
   Steiner, Helfried
   Brenn, Guenter
TI Experimental validation of analytical models for liquid film breakup on
   rotating substrates
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wetting; Model validation; Film breakup; Rotating flow
ID PERFECTLY WETTING FLUID; SIMILARITY SOLUTIONS; MINIMUM THICKNESS; DRY
   PATCH; VERTICAL SUBSTRATE; SLENDER RIVULETS; SHEAR-STRESS; THIN RIVULET;
   SURFACE; FLOW
AB Many models for predicting the breakup of liquid films spreading over solid substrates have been proposed over the years, each taking a different approach to modelling the minimum stable film height. There is not a lot of reliable experimental data in the literature for validating these models, however, as previous measurement campaigns have generally relied on the relatively weak gravitational force as a wetting driver, making the results sensitive to minor flow disturbances and flaws in the substrate.
   The present work considers experimentally the breakup of films spreading radially over rapidly rotating substrates, where the much stronger centrifugal force takes the place of gravity. An empirical correlation has been derived from the presently generated data and compared with analytical predictions. The predictions of the analytical wetting models, appropriately modified, were additionally validated against the observed radial breakup locations.
   The models which considered an equilibrium of surface tension and inertia were found to give the best overall agreement with the data. However, it was also shown that the retarding effect of viscous shear needs to be taken into account in the modelling and that a blended approach incorporating both inertial and viscous length scales is necessary in order to obtain a generally valid model. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Line, Hakon; Steiner, Helfried; Brenn, Guenter] Graz Univ Technol, Inst Stromungslehre & Warmeithertragung, Inffeldgasse 25F, A-8010 Graz, Austria.
RP Line, H (reprint author), Graz Univ Technol, Inst Stromungslehre & Warmeithertragung, Inffeldgasse 25F, A-8010 Graz, Austria.
EM hakon.line@live.com
OI Dr. Brenn, Gunter/0000-0001-7576-0790
FU COMET K1 centre ASSIC (Austrian Smart Systems Integration Research
   Center); BMVIT; BMWFW; federal province of Carinthia; federal province
   of Styria
FX This project has been supported by the COMET K1 centre ASSIC (Austrian
   Smart Systems Integration Research Center). The COMET-Programme
   (Competence Centers for Excellent Technologies) is supported by BMVIT,
   BMWFW and the federal provinces of Carinthia and Styria.
CR BANKOFF SG, 1971, INT J HEAT MASS TRAN, V14, P2143, DOI 10.1016/0017-9310(71)90034-2
   BROCHARD F, 1995, CR ACAD SCI II B, V321, P367
   Buckingham E, 1914, PHYS REV, V4, P345, DOI 10.1103/PhysRev.4.345
   CULICK FEC, 1960, J APPL PHYS, V31, P1128, DOI 10.1063/1.1735765
   DONIEC A, 1991, CAN J CHEM ENG, V69, P198, DOI 10.1002/cjce.5450690123
   DONIEC A, 1988, CHEM ENG SCI, V43, P847, DOI 10.1016/0009-2509(88)80080-0
   El-Genk MS, 2001, INT J HEAT MASS TRAN, V44, P2809, DOI 10.1016/S0017-9310(00)00326-4
   Hartley D.E., 1964, INT J HEAT MASS TRAN, V7, P1003, DOI DOI 10.1016/0017-9310(64)90042-0
   HOBLER T, 1964, CHEM STOSOW B, V2, P145
   Holland D, 2003, Q J MECH APPL MATH, V56, P411, DOI 10.1093/qjmam/56.3.411
   Holland D, 2002, J ENG MATH, V44, P369, DOI 10.1023/A:1021262720914
   Maynes D, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3593460
   MIKIELEWICZ J, 1976, INT J HEAT MASS TRAN, V19, P771, DOI 10.1016/0017-9310(76)90130-7
   Munakata T., 1975, J CHEM ENG JPN, V8, P440
   Nafikov I, 1980, J ENG PHYS THERMOPH+, V39, P750
   Nusselt W, 1916, Z VER DTSCH ING, V60, P541
   Podgorski T, 1999, PHYS FLUIDS, V11, P845, DOI 10.1063/1.869956
   Podgorski T, 2001, CR ACAD SCI IV-PHYS, V2, P1361, DOI 10.1016/S1296-2147(01)01249-5
   PONTER AB, 1977, INT J HEAT MASS TRAN, V20, P575, DOI 10.1016/0017-9310(77)90105-3
   Prince JF, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4935498
   REDON C, 1991, PHYS REV LETT, V66, P715, DOI 10.1103/PhysRevLett.66.715
   Rio E, 2004, J COLLOID INTERF SCI, V269, P164, DOI 10.1016/j.jcis.2003.07.005
   Rio E, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2173183
   Sebilleau J, 2009, EUR PHYS J-SPEC TOP, V166, P139, DOI 10.1140/epjst/e2009-00894-x
   Sebilleau J, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4933264
   Sullivan JM, 2008, Q J MECH APPL MATH, V61, P25
   TAYLOR G, 1959, PROC R SOC LON SER-A, V253, P313, DOI 10.1098/rspa.1959.0196
   Wilson SK, 2011, J FLUID MECH, V674, P281, DOI 10.1017/S0022112010006518
   Wilson SK, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2100987
   Wilson SK, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1979521
   Wilson SK, 2001, EUR J APPL MATH, V12, P233, DOI 10.1017/S095679250100417X
   Yatim YM, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4803906
   Yatim YM, 2012, J ENG MATH, V73, P53, DOI 10.1007/s10665-011-9499-8
   Yatim YM, 2011, Q J MECH APPL MATH, V64, P455, DOI 10.1093/qjmam/hbr014
NR 34
TC 0
Z9 0
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 118
EP 129
DI 10.1016/j.ces.2019.03.014
PG 12
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900011
DA 2020-05-12
ER

PT J
AU Lee, B
   Jeong, HH
   Kang, KK
   Lee, CS
   Lee, SH
AF Lee, Byungjin
   Jeong, Heon-Ho
   Kang, Kyoung-Ku
   Lee, Chang-Soo
   Lee, Sang-Ho
TI Improvement of a diffusion-based microfluidic chemotaxis assay through
   stable formation of a chemical gradient
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Diffusion; Reproducibility; Liquid-liquid interface; Chemotaxis;
   Pseudomonas aeruginosa
ID INDUCTIVELY-COUPLED PLASMA; QUANTITATIVE-ANALYSIS; SILICON DIOXIDE;
   SELECTIVITY; GENERATION; MECHANISM; DEVICE; SIO2
AB Microfluidic chemotaxis analysis requires stable and reproducible formation of chemical gradient with low batch-to-batch variation. Dimensional uniformity of a junction channel plays a key role in diffusion-based gradient generation. Conventional methods for the analysis of bacterial chemotaxis are limited in stability and reproducibility of the chemical gradient. Here, we report a microfabrication method employing plasma enhanced chemical vapor deposition for silicon oxide deposition and consecutive reactive ion etching processes to reduce the experimental errors of chemotaxis analysis occurring from dimensional inaccuracy of the junction channel. This approach produces precise dimensional junction channels with below 1% variation. Thus, we confirm the reproducibility of chemotaxis analysis and obtain the chemotaxis index of Pseudomonas aeruginosa PAO1 with bacterial chemoeffectors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Byungjin; Kang, Kyoung-Ku; Lee, Chang-Soo] Chungnam Natl Univ, Dept Chem Engn, Daehak Ro 99, Daejeon 34134, South Korea.
   [Jeong, Heon-Ho] Chonnam Natl Univ, Dept Chem & Biomol Engn, Yeosu 59626, South Korea.
   [Lee, Sang-Ho] Korea Inst Ind Technol, Micro Nano Scale Mfg R&D Grp, Ansan 426173, South Korea.
RP Lee, CS (reprint author), Chungnam Natl Univ, Dept Chem Engn, Daehak Ro 99, Daejeon 34134, South Korea.; Lee, SH (reprint author), Korea Inst Ind Technol, Micro Nano Scale Mfg R&D Grp, Ansan 426173, South Korea.
EM rhadum@cnu.ac.kr; sholee7@kitech.re.kr
OI Lee, Chang-Soo/0000-0003-3789-2412
FU Korea Institute of Industrial Technology and Global Research Laboratory
   (GRL) Program through the National Research Foundation of Korea (NRF) -
   Ministry of Science and ICT [NRF-2015K1A1A2033054]
FX This research was supported by Korea Institute of Industrial Technology
   and Global Research Laboratory (GRL) Program through the National
   Research Foundation of Korea (NRF), which is funded by the Ministry of
   Science and ICT (NRF-2015K1A1A2033054).
CR Abhyankar VV, 2006, LAB CHIP, V6, P389, DOI 10.1039/b514133h
   ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708
   Ahmed T, 2010, INTEGR BIOL-UK, V2, P604, DOI 10.1039/c0ib00049c
   Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018
   Celani A, 2010, P NATL ACAD SCI USA, V107, P1391, DOI 10.1073/pnas.0909673107
   Cheng SY, 2007, LAB CHIP, V7, P763, DOI 10.1039/b618463d
   Dertinger SKW, 2001, ANAL CHEM, V73, P1240, DOI 10.1021/ac001132d
   Diao JP, 2006, LAB CHIP, V6, P381, DOI 10.1039/b511958h
   Englert DL, 2009, METHODS MOL BIOL, V571, P1, DOI 10.1007/978-1-60761-198-1_1
   EPHRATH LM, 1979, J ELECTROCHEM SOC, V126, P1419, DOI 10.1149/1.2129291
   HEDLUND C, 1994, J VAC SCI TECHNOL A, V12, P1962, DOI 10.1116/1.578990
   Huang CP, 2009, LAB CHIP, V9, P1740, DOI 10.1039/b818401a
   Hwang BH, 2017, BIOTECHNOL BIOPROC E, V22, P469, DOI 10.1007/s12257-017-0215-z
   Hwang JW, 2016, KOREAN J CHEM ENG, V33, P57, DOI 10.1007/s11814-015-0037-7
   Irimia D, 2010, ANNU REV BIOMED ENG, V12, P259, DOI 10.1146/annurev-bioeng-070909-105241
   Jensen S., 2003, INT SOC OPTICS PHOTO, P111
   Jeon H, 2009, BIOMED MICRODEVICES, V11, P1135, DOI 10.1007/s10544-009-9330-8
   Jeong GS, 2011, ANAL CHEM, V83, P8454, DOI 10.1021/ac202170e
   Jeong HH, 2016, KOREAN J CHEM ENG, V33, P1757, DOI 10.1007/s11814-016-0041-6
   Jeong HH, 2015, LAB CHIP, V15, P889, DOI 10.1039/c4lc01097c
   Jeong HH, 2014, ANAL BIOCHEM, V446, P90, DOI 10.1016/j.ab.2013.10.027
   Jeong HH, 2013, BIOSENS BIOELECTRON, V47, P278, DOI 10.1016/j.bios.2013.03.031
   Jeong HH, 2010, BIOSENS BIOELECTRON, V26, P351, DOI 10.1016/j.bios.2010.08.006
   Keenan TM, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2345914
   Kim GY, 2016, KOREAN CHEM ENG RES, V54, P223, DOI 10.9713/kcer.2016.54.2.223
   Kim KP, 2010, LAB CHIP, V10, P3296, DOI 10.1039/c0lc00154f
   Kirmse KHR, 1996, J VAC SCI TECHNOL B, V14, P710, DOI 10.1116/1.588702
   Kothapalli CR, 2011, LAB CHIP, V11, P497, DOI 10.1039/c01c00240b
   Laermer F, 1999, PROC IEEE MICR ELECT, P211, DOI 10.1109/MEMSYS.1999.746812
   Lai SL, 2006, J VAC SCI TECHNOL A, V24, P1283, DOI 10.1116/1.2172944
   Lee B, 2017, KOREAN CHEM ENG RES, V55, P791, DOI 10.9713/kcer.2017.55.6.791
   Li J, 2011, TRENDS CELL BIOL, V21, P489, DOI 10.1016/j.tcb.2011.05.002
   Mao HB, 2003, P NATL ACAD SCI USA, V100, P5449, DOI 10.1073/pnas.0931258100
   Mosadegh B, 2007, LANGMUIR, V23, P10910, DOI 10.1021/la7026835
   OEHRLEIN GS, 1987, J APPL PHYS, V62, P662, DOI 10.1063/1.339766
   Ottemann KM, 2002, INFECT IMMUN, V70, P1984, DOI 10.1128/IAI.70.4.1984-1990.2002
   Paliwal S, 2007, NATURE, V446, P46, DOI 10.1038/nature05561
   Rolland L, 2000, MICROELECTRON ENG, V53, P375, DOI 10.1016/S0167-9317(00)00337-3
   Rueger NR, 1999, J VAC SCI TECHNOL A, V17, P2492, DOI 10.1116/1.581987
   Saadi W, 2007, BIOMED MICRODEVICES, V9, P627, DOI 10.1007/s10544-007-9051-9
   Schaepkens M, 1999, J VAC SCI TECHNOL A, V17, P26, DOI 10.1116/1.582108
   Seymour JR, 2010, SCIENCE, V329, P342, DOI 10.1126/science.1188418
   Sim JH, 2017, KOREAN J CHEM ENG, V34, P1495, DOI 10.1007/s11814-017-0041-1
   SIMKO JP, 1991, J ELECTROCHEM SOC, V138, P2748, DOI 10.1149/1.2086048
   Standaert TEFM, 1998, J VAC SCI TECHNOL A, V16, P239, DOI 10.1116/1.580978
   Takayama S, 2001, NATURE, V411, P1016, DOI 10.1038/35082637
   Weibel DB, 2006, CURR OPIN CHEM BIOL, V10, P584, DOI 10.1016/j.cbpa.2006.10.016
   Wu H., 2002, IEEE P 9 INT S PHYS, P91
   Xu H, 2014, LAB CHIP, V14, P2047, DOI 10.1039/c4lc00162a
   You SG, 2017, BIOTECHNOL BIOPROC E, V22, P474, DOI 10.1007/s12257-017-0194-0
NR 50
TC 0
Z9 0
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 130
EP 137
DI 10.1016/j.ces.2019.03.025
PG 8
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900012
DA 2020-05-12
ER

PT J
AU Zhou, WJ
   Liu, F
   Liu, DJ
   Chen, F
   Wei, JJ
AF Zhou, Wenjing
   Liu, Fei
   Liu, Dongjie
   Chen, Fei
   Wei, Jinjia
TI Energy analysis of a surfactant micelle's deformation by coarse-grained
   molecular dynamics simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE MARTINI force field; Coarse-grained molecular dynamics simulation;
   Energy analysis; Viscoelasticity theory; Surfactant micelle; Turbulent
   drag reduction
ID VISCOELASTIC WORMLIKE MICELLES; DRAG REDUCTION; FLOW; BEHAVIORS;
   VESICLES; RHEOLOGY; MODEL
AB Surfactant molecules can self-assemble into micellar networks and be used as efficient additives in turbulent drag reduction in aqueous solutions. The mechanism of turbulent drag reduction by these percolating structures is still unclear. In particular, the "viscoelasticity theory" postulates that the micellar network structures are capable of absorbing and releasing stress from turbulent kinetic energy which results in the decrease of the energy dissipation. Here, we focus on the single wormlike surfactant micelle which consists of cetyltrimethylammonium chloride (CTAC) and counter ion salts to study the energy variation during its deformation processes using MARTINI force field coarse-grained molecular dynamics (CGMD) simulations. The Muller-Plathe method was used to generate the small and large deformation stretching statuses of the wormlike micelle through adjusting the momenta exchange frequency. The simulation results show that the micelle can transfer its potential energy to water during its relaxation stage after being stretched. It is also found that the flow field of water is significantly influenced by the recoil of micelle and a vortex is observed in the area semi-enclosed by the bending micelle. Overall, the present study supports the hypothesis of "viscoelasticity theory" and provides further insight into the mechanism of turbulent drag reduction by surfactant additives. (C) 2019 Published by Elsevier Ltd.
C1 [Zhou, Wenjing; Chen, Fei; Wei, Jinjia] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
   [Liu, Fei; Liu, Dongjie; Chen, Fei; Wei, Jinjia] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Chen, F; Wei, JJ (reprint author), Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
EM feichen@xjtu.edu.cn; jjwei@mail.xjtu.edu.cn
RI Wei, Jinjia/G-6529-2011
OI CHEN, FEI/0000-0002-5395-230X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51636006, 51225601, 21803040]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [cxtd2017004]
FX The present work is supported by National Natural Science Foundation of
   China (No. 51636006, No. 51225601, No. 21803040). The Fundamental
   Research Funds for the Central Universities (No. cxtd2017004). We also
   thank Dr. Dan Zhao from University of Minnesota for useful discussions.
CR Cappelaere E, 1997, PHYS REV E, V56, P1869, DOI 10.1103/PhysRevE.56.1869
   Chng CP, 2013, SOFT MATTER, V9, P7294, DOI 10.1039/c3sm51038g
   Davies TS, 2006, J AM CHEM SOC, V128, P6669, DOI 10.1021/ja060021e
   de Gennes P. G., 1990, INTRO POLYM DYNAMICS, P34
   DenToonder JMJ, 1997, J FLUID MECH, V337, P193, DOI 10.1017/S0022112097004850
   Dhakal S, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.012605
   Dhakal S, 2016, ACS MACRO LETT, V5, P108, DOI 10.1021/acsmacrolett.5b00761
   Dhakal S, 2015, J CHEM PHYS, V143, DOI 10.1063/1.4926422
   Fischer E, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011501
   Gonzalez O, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4789411
   Helgeson ME, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.084501
   Helgeson ME, 2010, LANGMUIR, V26, P8049, DOI 10.1021/la100026d
   Huang CH, 2018, AICHE J, V64, P2898, DOI 10.1002/aic.16156
   Huang CH, 2016, CHEM ENG SCI, V152, P267, DOI 10.1016/j.ces.2016.06.009
   Kelkar MS, 2007, FLUID PHASE EQUILIBR, V260, P218, DOI 10.1016/j.fluid.2007.06.033
   Li F., 2012, TURBULENT DRAG REDUC, P3
   Liu F, 2018, J MOL LIQ, V265, P572, DOI 10.1016/j.molliq.2018.06.025
   Liu F, 2018, IND ENG CHEM RES, V57, P9018, DOI 10.1021/acs.iecr.8b01490
   Liu ZB, 2016, COLLOID SURFACE A, V506, P276, DOI 10.1016/j.colsurfa.2016.06.049
   Magid LJ, 1997, J PHYS CHEM B, V101, P7919, DOI 10.1021/jp970864f
   Maitland GC, 2000, CURR OPIN COLLOID IN, V5, P301, DOI 10.1016/S1359-0294(00)00069-8
   Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f
   Marrink SJ, 2004, J PHYS CHEM B, V108, P750, DOI 10.1021/jp036508g
   Martinez L, 2009, J COMPUT CHEM, V30, P2157, DOI 10.1002/jcc.21224
   Mondal J, 2013, J PHYS CHEM B, V117, P4254, DOI 10.1021/jp304933k
   Muller-Plathe F, 1999, PHYS REV E, V59, P4894, DOI 10.1103/PhysRevE.59.4894
   PINHO FT, 1990, J NON-NEWTON FLUID, V34, P129, DOI 10.1016/0377-0257(90)80015-R
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Sangwai AV, 2012, LANGMUIR, V28, P1127, DOI 10.1021/la203745d
   Sangwai AV, 2011, LANGMUIR, V27, P6628, DOI 10.1021/la2006315
   Stukowski A, 2010, IEEE T FUZZY SYST, V18, P2154
   Vasudevan M, 2010, NAT MATER, V9, P436, DOI [10.1038/nmat2724, 10.1038/NMAT2724]
   VIRK PS, 1975, AICHE J, V21, P625, DOI 10.1002/aic.690210402
   Wang P, 2017, J COLLOID INTERF SCI, V494, P47, DOI 10.1016/j.jcis.2017.01.057
   Yang J, 2002, CURR OPIN COLLOID IN, V7, P276, DOI 10.1016/S1359-0294(02)00071-7
   Zhang CW, 2013, CHEM ENG SCI, V102, P544, DOI 10.1016/j.ces.2013.08.024
   Zheng Y, 2000, J PHYS CHEM B, V104, P5263, DOI 10.1021/jp0002998
NR 37
TC 1
Z9 1
U1 5
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 138
EP 145
DI 10.1016/j.ces.2019.03.047
PG 8
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900013
DA 2020-05-12
ER

PT J
AU Ye, JH
   Zhu, HC
   Yang, Y
   Huang, KM
   Raghavan, GSV
AF Ye, Jinghua
   Zhu, Huacheng
   Yang, Yang
   Huang, Kama
   Raghavan, G. S. Vijaya
TI Dynamic analysis of a continuous-flow microwave-assisted screw propeller
   system for biodiesel production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microwave heating; Heating uniformity; Multi-physics simulation; Screw
   propeller; Continuous-flow reactor; Biodiesel synthesis
ID NUMERICAL-SIMULATION; UNIFORMITY
AB In order to overcome the apparent limitations of large-scale microwave processing, a microwave heating system with a screw propeller was utilized for biodiesel synthesis. To elucidate the heating dynamics and reaction process in the reactor, a comprehensive physics-based model was developed. A step-by-step algorithm based on implicit function, level set methods, and Arbitrary Lagrangian-Eulerian Formulation (ALE) machinery was proposed to compute the microwave heating process with chemical reaction and stirring. Material properties applied in the simulation were expressed as bivariate functions of the reaction solution's component and temperature. The temperature and reactant concentration of the microwave reactor outlet were measured and compared to simulation results to validate the simulation model. By using the proposed model, the heating process with different rotating speeds, material composition (Teflon and metal), pitch, and blade widths of the screw propeller and inlet velocities were also calculated to determine their effect on the temperature distribution of the reactor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ye, Jinghua; Zhu, Huacheng; Yang, Yang; Huang, Kama] Sichuan Univ, Coll Elect & Informat Engn, Chengdu 610065, Sichuan, Peoples R China.
   [Ye, Jinghua; Raghavan, G. S. Vijaya] McGill Univ, Dept Bioresource Engn, Macdonald Campus,21111 Lakeshore Rd, Ste Anne De Bellevue, PQ H9X 3V9, Canada.
RP Zhu, HC (reprint author), Sichuan Univ, Coll Elect & Informat Engn, Chengdu 610065, Sichuan, Peoples R China.
EM hczhu@scu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [61601312, 60151311]; Department of Science and
   Technology in Sichuan Province [2016FZ0070]; China Scholarship
   CouncilChina Scholarship Council [201706240031]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 61601312, 60151311), Department of Science and
   Technology in Sichuan Province (Grant No. 2016FZ0070), and China
   Scholarship Council (Grant No. 201706240031).
CR Antonio C, 2005, J MATER PROCESS TECH, V169, P234, DOI 10.1016/j.jmatprotec.2005.03.024
   Barnard TM, 2007, ENERG FUEL, V21, P1777, DOI 10.1021/ef0606207
   Batchelor G. K., 2000, INTRO FLUID DYNAMICS
   Campanone LA, 2014, APPL THERM ENG, V73, P914, DOI 10.1016/j.applthermaleng.2014.08.048
   Choedkiatsakul I, 2015, RENEW ENERG, V83, P25, DOI 10.1016/j.renene.2015.04.012
   Damm M, 2010, ORG PROCESS RES DEV, V14, P215, DOI 10.1021/op900297e
   Geedipalli SSR, 2007, J FOOD ENG, V82, P359, DOI 10.1016/j.jfoodeng.2007.02.050
   Glasnov TN, 2007, MACROMOL RAPID COMM, V28, P395, DOI 10.1002/marc.200600665
   Gulati T, 2016, CHEM ENG SCI, V156, P206, DOI 10.1016/j.ces.2016.09.004
   Hernando J, 2007, FUEL, V86, P1641, DOI 10.1016/j.fuel.2006.11.003
   Horikoshi S, 2011, J PHYS CHEM C, V115, P23030, DOI 10.1021/jp2076269
   Kaye G., 1995, KAYE LABY TABLES PHY
   Leadbeater NE, 2006, ENERG FUEL, V20, P2281, DOI 10.1021/ef060163u
   Lertsathapornsuk V, 2008, FUEL PROCESS TECHNOL, V89, P1330, DOI 10.1016/j.fuproc.2008.05.024
   Leung DYC, 2010, APPL ENERG, V87, P1083, DOI 10.1016/j.apenergy.2009.10.006
   Lidstrom P, 2001, TETRAHEDRON, V57, P9225, DOI 10.1016/S0040-4020(01)00906-1
   Motasemi F, 2012, RENEW SUST ENERG REV, V16, P4719, DOI 10.1016/j.rser.2012.03.069
   Niu XJ, 2016, APPL THERM ENG, V106, P579, DOI 10.1016/j.applthermaleng.2016.05.167
   Obermayer D, 2013, ORG BIOMOL CHEM, V11, P4949, DOI 10.1039/c3ob40790j
   Pan F, 2019, CHEM ENG SCI, V197, P306, DOI 10.1016/j.ces.2018.12.021
   [彭宝祥 Peng Baoxiang], 2009, [化学反应工程与工艺, Chemical Reaction Engineering and Technology], V25, P250
   Santos T, 2011, APPL THERM ENG, V31, P3255, DOI 10.1016/j.applthermaleng.2011.06.006
   Sebera V, 2012, DRY TECHNOL, V30, P1388, DOI 10.1080/07373937.2012.664800
   Shahid EM, 2011, RENEW SUST ENERG REV, V15, P4732, DOI 10.1016/j.rser.2011.07.079
   Standardization I. O. f, 2009, AN VEG FATS OILS DET
   Strauss CR, 2009, ORG PROCESS RES DEV, V13, P915, DOI 10.1021/op900194z
   Tangy A, 2017, BIORESOURCE TECHNOL, V224, P333, DOI 10.1016/j.biortech.2016.10.068
   Wu L, 2013, BIORESOURCE TECHNOL, V133, P279, DOI 10.1016/j.biortech.2013.01.009
   Yang L, 2017, CHEM ENG SCI, V169, P106, DOI 10.1016/j.ces.2016.12.003
   Ye JH, 2017, IEEE T MICROW THEORY, V65, P4773, DOI 10.1109/TMTT.2017.2708104
   Zhang C, 2016, INT J APPL ELECTROM, V51, P199, DOI 10.3233/JAE-160007
   Zhu HC, 2012, J SOLUTION CHEM, V41, P1729, DOI 10.1007/s10953-012-9902-8
   Zhu HC, 2017, APPL THERM ENG, V123, P1456, DOI 10.1016/j.applthermaleng.2017.05.118
NR 33
TC 2
Z9 2
U1 10
U2 30
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 146
EP 156
DI 10.1016/j.ces.2019.03.022
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900014
DA 2020-05-12
ER

PT J
AU Zou, Z
   Liu, WM
   Yan, D
   Xie, ZH
   Li, HZ
   Zhu, QS
   He, SY
AF Zou, Zheng
   Liu, Wenming
   Yan, Dong
   Xie, Zhaohui
   Li, Hongzhong
   Zhu, Qingshan
   He, Shengyi
TI CFD simulations of tapered bubbling/turbulent fluidized beds
   with/without gas distributor based on the structure-based drag model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidization; Tapered fluidized bed; CFD; The structure-based drag model
ID SOLID FLOW; HYDRODYNAMIC CHARACTERISTICS; FRICTIONAL STRESS; SPOUTED
   BED; PARTICLES; SEGREGATION; COEFFICIENT; PENETRATION; BEHAVIOR; JET
AB The hydrodynamic characteristics of tapered bubbling/turbulent fluidized beds with/without gas distributor are simulated based on the structure-based drag model. Besides the only parameter of gas voidage (epsilon(g)) contained in the original drag model, the heterogeneous drag index (H-d) for the tapered fluidized bed (TFB) also includes the parameter of gas velocity (u(g)) for the axial velocity gradient along bed height. Both the simulations of tapered bubbling and turbulent fluidized beds achieve more accurate predictions than the traditional drag models. There exist dilute center and dense annular regions with solids cycle flow structure in the TFB. The simulation also gives reasonable prediction for TFB without gas distributor, the variation of gas voidage profile reveals gas converging toward bed center with axial location rising. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zou, Zheng; Yan, Dong; Xie, Zhaohui; Li, Hongzhong; Zhu, Qingshan] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   [Liu, Wenming] SINOPEC, Res Inst Petr Proc, Beijing 100083, Peoples R China.
   [Li, Hongzhong; Zhu, Qingshan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [He, Shengyi] BOE Technol Grp Co Ltd, Beijing 100016, Peoples R China.
RP Li, HZ; Zhu, QS (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.; Li, HZ; Zhu, QS (reprint author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
OI zou, zheng/0000-0002-0417-4986
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21736010, 21878304]; State Key Development Program
   for Basic Research of China (973 Program)National Basic Research Program
   of ChinaState Key Development Program for Basic Research of China
   [2015CB251402]
FX The authors are grateful to the National Natural Science Foundation of
   China under Grant No. 21736010 and 21878304, the State Key Development
   Program for Basic Research of China (973 Program) under Grant No.
   2015CB251402.
CR Chen HZ, 2018, POWDER TECHNOL, V323, P163, DOI 10.1016/j.powtec.2017.10.015
   Chen J, 2015, POWDER TECHNOL, V274, P112, DOI 10.1016/j.powtec.2015.01.010
   Chen Y, 1997, CHEM ENG J, V68, P7, DOI 10.1016/S1385-8947(97)00058-2
   Chyang CS, 1997, POWDER TECHNOL, V90, P71, DOI 10.1016/S0032-5910(96)03202-0
   Depypere F, 2009, J FOOD ENG, V93, P324, DOI 10.1016/j.jfoodeng.2009.01.042
   Depypere F, 2005, THESIS
   Du W, 2006, CHEM ENG SCI, V61, P1401, DOI 10.1016/j.ces.2005.08.013
   Du W, 2006, CHEM ENG SCI, V61, P4558, DOI 10.1016/j.ces.2006.02.028
   Duangkhamchan W, 2010, CHEM ENG SCI, V65, P3100, DOI 10.1016/j.ces.2010.02.008
   Gan L, 2014, ADV POWDER TECHNOL, V25, P824, DOI 10.1016/j.apt.2013.12.007
   Gao JS, 2008, CHEM ENG SCI, V63, P1827, DOI 10.1016/j.ces.2007.12.009
   Gernon TM, 2012, POWDER TECHNOL, V231, P88, DOI 10.1016/j.powtec.2012.07.053
   Gernon TM, 2008, J VOLCANOL GEOTH RES, V174, P49, DOI 10.1016/j.jvolgeores.2007.12.034
   He SY, 2017, POWDER TECHNOL, V313, P161, DOI 10.1016/j.powtec.2017.03.007
   HE YL, 1994, CAN J CHEM ENG, V72, P561, DOI 10.1002/cjce.5450720402
   Hong RY, 1997, POWDER TECHNOL, V92, P205, DOI 10.1016/S0032-5910(97)03238-5
   Hosseini SH, 2009, CHEM ENG PROCESS, V48, P1539, DOI 10.1016/j.cep.2009.09.004
   Hosseini SH, 2010, ENERG FUEL, V24, P6086, DOI 10.1021/ef100612r
   Hou BL, 2010, CHEM ENG J, V157, P509, DOI 10.1016/j.cej.2009.12.047
   Jing S, 2000, CHEM ENG PROCESS, V39, P379, DOI 10.1016/S0255-2701(99)00103-8
   Khodabandehlou R, 2018, PARTICUOLOGY, V38, P152, DOI 10.1016/j.partic.2017.05.013
   Kozin V. E, 1967, CHEM TECH FUELS OIL, V3, P155
   Li HZ, 2010, PARTICUOLOGY, V8, P631, DOI 10.1016/j.partic.2010.07.018
   Li TW, 2009, CHEM ENG SCI, V64, P4884, DOI 10.1016/j.ces.2009.07.024
   Liu WM, 2015, POWDER TECHNOL, V286, P516, DOI 10.1016/j.powtec.2015.08.049
   Lu HL, 2004, CHEM ENG SCI, V59, P865, DOI 10.1016/j.ces.2003.10.018
   Lv XL, 2014, CHEM ENG J, V236, P149, DOI 10.1016/j.cej.2013.09.067
   MERRY JMD, 1971, TRANS INST CHEM ENG, V49, P189
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Pannala S, 2010, CHEM VAPOR DEPOS, V13, P481
   Peng YM, 1997, CHEM ENG SCI, V52, P2277, DOI 10.1016/S0009-2509(97)00061-4
   Santos DA, 2013, CAN J CHEM ENG, V91, P1776, DOI 10.1002/cjce.21866
   Sarkar A, 2014, CHEM ENG SCI, V114, P144, DOI 10.1016/j.ces.2014.04.018
   Sau DC, 2007, CHEM ENG J, V132, P151, DOI 10.1016/j.cej.2007.01.036
   Sau DC, 2011, APPL MATH MODEL, V35, P2265, DOI 10.1016/j.apm.2010.11.037
   Schaafsma SH, 2006, CHEM ENG SCI, V61, P4467, DOI 10.1016/j.ces.2006.01.040
   Setarehshenas N, 2017, KOREAN J CHEM ENG, P1
   Shakhova N. A, 1968, J ENG PHYS THERMOPH+, V14, P32
   Shan J, 2001, POWDER TECHNOL, V118, P271, DOI 10.1016/S0032-5910(00)00385-5
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   Sun LY, 2012, CHEM ENG SCI, V84, P170, DOI 10.1016/j.ces.2012.08.002
   TOYOHARA H, 1991, KAGAKU KOGAKU RONBUN, V17, P172, DOI 10.1252/kakoronbunshu.17.172
   Wang YC, 2014, PARTICUOLOGY, V15, P151, DOI 10.1016/j.partic.2013.07.003
   Wang Z, 2006, DISS ABSTR INT, V67-12, P7230
   Wang ZG, 2010, IND ENG CHEM RES, V49, P5053, DOI 10.1021/ie901119v
   Wiens J, 2006, POWDER TECHNOL, V169, P49, DOI 10.1016/j.powtec.2006.07.022
   Wormsbecker M, 2009, POWDER TECHNOL, V194, P115, DOI 10.1016/j.powtec.2009.03.036
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Zenz F. A., 1968, I CHEM ENG S SER, V30, P136
   Zhang J., 2017, THESIS
   Zhao ZG, 2014, POWDER TECHNOL, V256, P300, DOI 10.1016/j.powtec.2014.02.037
   [祝小龙 Zhu Xiaolong], 2014, [化工进展, Chemical Industry and Engineering Progress], V33, P328
NR 52
TC 1
Z9 1
U1 7
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 157
EP 168
DI 10.1016/j.ces.2019.03.034
PG 12
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900015
DA 2020-05-12
ER

PT J
AU Kong, XJ
   Li, ZJ
   Shen, BX
   Wu, Y
   Zhang, YK
   Cai, D
AF Kong, Xiangjin
   Li, Zhijun
   Shen, Boxi
   Wu, Yue
   Zhang, Yanke
   Cai, Dong
TI Simulation of flow and soot particle distribution in wall-flow DPF based
   on lattice Boltzmann method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Lattice Boltzmann method; Cell automation probabilistic model;
   Lagrangian model; Diesel particulate filter; Soot distribution; Porous
   media
ID NUMERICAL-SIMULATION; FILTRATION EFFICIENCY; PARTICULATE FILTERS;
   PRESSURE-DROP; DEPOSITION; MODEL; COMBUSTION; DIFFUSION; TRANSPORT;
   AUTOMATA
AB A two-dimensional mesoscopic gas-solid two-phase flow model has been developed to investigate the flow and soot loading in the micro-channel of diesel particulate filters. Soot particle size examined is in the range of 10 nm-1 mu m. The flow is solved by an incompressible lattice Boltzmann model and the transport of solid particles is described by the cell automation probabilistic model. The lattice Boltzmann-cell automation probabilistic model (LB-CA model) is validated with the results of previous studies. The effects of different upstream velocities on the flow field in channels are investigated. The distribution and deposition of soot particles with different sizes in clean channels are simulated based on the LB-CA method and the LB-Lagrangian method respectively. The effects of deposited soot particles on flow field are evaluated in real soot particle capture process. The results show that the distributions of velocity field and pressure field in the channel are significantly affected by the upstream velocity. Compared with the effect of the particle size, the upstream velocity is more influential on the particle deposition distributions. The profiles of deposition distribution from the LB-CA method are in close agreement with those from the LB-Lagrangian method. The deposition distributions of particles with different diameters at the top of the porous wall are similar to the distributions of wall velocity along the channel length. Generally, the deposited soot particles increase the axial pressure and decrease the axial velocity in the inlet channel. The evolution trend of the areas where wall velocity undergoes changes is consistent with that of the solid nodes made of the captured soot particles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kong, Xiangjin; Li, Zhijun; Shen, Boxi; Wu, Yue; Zhang, Yanke; Cai, Dong] Tianjin Univ, State Key Lab Engines, 92 Weijin Rd, Tianjin 300072, Peoples R China.
RP Li, ZJ (reprint author), Tianjin Univ, State Key Lab Engines, 92 Weijin Rd, Tianjin 300072, Peoples R China.
EM zhijunli@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51576140, 51276128]; Special Fund for Development
   of Small and Medium Enterprises [SQ2013ZOA100012]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 51576140, 51276128]; the Special Fund for
   Development of Small and Medium Enterprises [grant number
   SQ2013ZOA100012].
CR Afrouzi HH, 2015, COMPUT MATH APPL, V70, P1136, DOI 10.1016/j.camwa.2015.07.008
   Ansari V, 2015, COMPUT FLUIDS, V108, P170, DOI 10.1016/j.compfluid.2014.11.022
   Bensaid S, 2009, CHEM ENG J, V154, P211, DOI 10.1016/j.cej.2009.03.043
   Bensaid S, 2010, CHEM ENG SCI, V65, P357, DOI 10.1016/j.ces.2009.06.051
   Bollerhoff T, 2012, CATAL TODAY, V188, P24, DOI 10.1016/j.cattod.2011.12.017
   Brandon DJ, 2001, AEROSOL SCI TECH, V34, P340, DOI 10.1080/02786820151092496
   Breuer M, 2000, INT J HEAT FLUID FL, V21, P186, DOI 10.1016/S0142-727X(99)00081-8
   Choi S, 2013, 2013010528 SAE
   Chopard B, 2000, COMPUT PHYS COMMUN, V129, P167, DOI 10.1016/S0010-4655(00)00104-1
   CHOPARD B, 1994, INT J MOD PHYS C, V5, P47, DOI 10.1142/S0129183194000052
   Chopard B, 1999, FUTURE GENER COMP SY, V16, P249, DOI 10.1016/S0167-739X(99)00050-3
   Gong J, 2017, ENVIRON SCI TECHNOL, V51, P11196, DOI 10.1021/acs.est.7b02535
   Gong J, 2015, ENVIRON SCI TECHNOL, V49, P4963, DOI 10.1021/acs.est.5b00329
   Guan B, 2015, J ENVIRON MANAGE, V154, P225, DOI 10.1016/j.jenvman.2015.02.027
   Guo ZL, 2008, J COMPUT PHYS, V227, P4955, DOI 10.1016/j.jcp.2008.01.024
   Guo ZL, 2000, J COMPUT PHYS, V165, P288, DOI 10.1006/jcph.2000.6616
   Guo ZL, 2002, CHINESE PHYS, V11, P366, DOI 10.1088/1009-1963/11/4/310
   He XY, 1997, PHYS REV E, V56, P6811, DOI 10.1103/PhysRevE.56.6811
   Jafari S, 2010, J AEROSOL SCI, V41, P198, DOI 10.1016/j.jaerosci.2009.10.005
   Torregrosa AJ, 2017, ENERGY, V119, P887, DOI 10.1016/j.energy.2016.11.051
   Konstandopoulos A. G., 2000, 2000011016 SAE
   Konstandopoulos A. G., 2003, 200301898 SAE, DOI [10.1016/j.energy.2016.06.121, DOI 10.1016/J.ENERGY.2016.06.121]
   Konstandopoulos A. G., 1989, 890405 SAE, DOI [10.4271/890405, DOI 10.4271/890405]
   Liu YQ, 2009, J AEROSOL SCI, V40, P307, DOI 10.1016/j.jaerosci.2008.12.001
   Masselot A, 1998, EUROPHYS LETT, V42, P259, DOI 10.1209/epl/i1998-00239-3
   Meng ZW, 2016, J COMBUST, DOI 10.1155/2016/9612856
   Mohammed H., 2006, 2006010467 SAE
   Mohankumar S, 2017, RENEW SUST ENERG REV, V80, P1227, DOI 10.1016/j.rser.2017.05.133
   Orihuela MP, 2018, APPL THERM ENG, V131, P41, DOI 10.1016/j.applthermaleng.2017.11.149
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   Serrano JR, 2016, ENERGY, V112, P883, DOI 10.1016/j.energy.2016.06.121
   Roy S, 2003, J APPL PHYS, V93, P4870, DOI 10.1063/1.1559936
   Sanui R, 2016, SAE INT J FUELS LUBR, V9, P725, DOI 10.4271/2016-01-9079
   Sbrizzai F, 2005, CHEM ENG SCI, V60, P6551, DOI 10.1016/j.ces.2005.05.038
   Swanson J, 2013, AEROSOL SCI TECH, V47, P452, DOI 10.1080/02786826.2012.763087
   Tandon P, 2010, CHEM ENG SCI, V65, P4751, DOI 10.1016/j.ces.2010.05.020
   Tong ZX, 2017, APPL ENERG, V185, P2181, DOI 10.1016/j.apenergy.2016.01.043
   Wang HM, 2013, J COMPUT PHYS, V239, P57, DOI 10.1016/j.jcp.2012.12.032
   Wang HM, 2012, POWDER TECHNOL, V227, P111, DOI 10.1016/j.powtec.2011.12.057
   Wang MR, 2007, J COLLOID INTERF SCI, V311, P562, DOI 10.1016/j.jcis.2007.03.038
   Wu GJ, 2011, J AEROSOL SCI, V42, P447, DOI 10.1016/j.jaerosci.2011.04.003
   Wurzenberger J. C, 2007, 2007011137 SAE
   Yamamoto K, 2009, EUR PHYS J-SPEC TOP, V171, P205, DOI 10.1140/epjst/e2009-01030-x
   Yamamoto K, 2007, INT J MOD PHYS C, V18, P528, DOI 10.1142/S0129183107010760
   Yamamoto K, 2006, MATH COMPUT SIMULAT, V72, P257, DOI 10.1016/j.matcom.2006.05.021
   Yamamoto K, 2016, COMPUTATION, V4, DOI 10.3390/computation4040046
   Yamamoto K, 2015, CATAL TODAY, V242, P357, DOI 10.1016/j.cattod.2014.07.022
   Yamamoto K, 2013, P COMBUST INST, V34, P3083, DOI 10.1016/j.proci.2012.06.117
   Yuan JL, 2014, INT J HEAT MASS TRAN, V69, P358, DOI 10.1016/j.ijheatmasstransfer.2013.10.032
NR 49
TC 6
Z9 6
U1 10
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 169
EP 185
DI 10.1016/j.ces.2019.03.039
PG 17
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900016
DA 2020-05-12
ER

PT J
AU Su, HP
   Lian, C
   Liu, JC
   Liu, HL
AF Su, Haiping
   Lian, Cheng
   Liu, Jichuan
   Liu, Honglai
TI Machine learning models for solvent effects on electric double layer
   capacitance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solvent effects; Electric double layer capacitance; Machine learning;
   Classical density functional theory
ID DENSITY-FUNCTIONAL THEORY; ENERGY-STORAGE; IONIC LIQUIDS;
   ELECTROCHEMICAL-BEHAVIOR; ORGANIC ELECTROLYTES; PORE-SIZE;
   SUPERCAPACITORS; TEMPERATURE; PERFORMANCE; ADSORPTION
AB The role of solvent molecules in electrolytes for supercapacitors, representing a fertile ground for improving the capacitive performance of supercapacitors, is complicated and has not been well understood. Here, a combined method is applied to study the solvent effects on capacitive performance. To identify the relative importance of each solvent variable to the capacitance, five machine learning (ML) models were tested for a set of collected experimental data, including support vector regression (SVR), multilayer perceptions (MLP), M5 model tree (M5P), M5 rule (M5R) and linear regression (LR). The performances of these ML models are ranked as follows: M5P > M5R > MLP > SVR > LR. Moreover, the classical density functional theory (CDFT) is introduced to yield more microscopic insights into the conclusion derived from ML models. This method, by combining machine learning, experimental and molecular modeling, could potentially be useful for predicting and enhancing the performance of electric double layer capacitors (EDLCs). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Su, Haiping; Lian, Cheng; Liu, Honglai] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Su, Haiping; Lian, Cheng; Liu, Honglai] East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
   [Liu, Jichuan] UCL, Dept Chem Engn, London WC1E 7JE, England.
RP Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
EM liancheng@ecust.edu.cn; hlliu@ecust.edu.cn
RI QIAN, LIU/S-1353-2019
OI Lian, Cheng/0000-0002-9016-832X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834301, 21808055]; National Natural Science
   Foundation of China for Innovative Research GroupsNational Natural
   Science Foundation of China [51621002]; 111 Project of China [B08021];
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2017M620137]; Shanghai Sailing Program [18YF1405400,
   19YF1411700]; National Postdoctoral Program for Innovative Talents
   [BX201700076]
FX This work was sponsored by the National Natural Science Foundation of
   China (No. 91834301, 21808055), National Natural Science Foundation of
   China for Innovative Research Groups (No. 51621002), the 111 Project of
   China (No. B08021), the China Postdoctoral Science Foundation
   (2017M620137), Shanghai Sailing Program (18YF1405400, 19YF1411700), and
   the National Postdoctoral Program for Innovative Talents (BX201700076).
CR Amin H., 2016, J PHYS CONDENS MATT, V28
   Arulepp M, 2004, J POWER SOURCES, V133, P320, DOI 10.1016/j.jpowsour.2004.03.026
   Bishop CM, 1995, NEURAL NETWORKS PATT
   Bozym DJ, 2015, J PHYS CHEM LETT, V6, P2644, DOI 10.1021/acs.jpclett.5b00899
   Breiman L, 1984, CLASSIFICATION REGRE
   Burt R, 2014, PHYS CHEM CHEM PHYS, V16, P6519, DOI 10.1039/c3cp55186e
   Chakraborty S, 2014, WASTE MANAGE, V34, P623, DOI 10.1016/j.wasman.2013.12.010
   Chmiola J, 2006, SCIENCE, V313, P1760, DOI [10.1126/science.1132195, 10.1126/science/1132195]
   Decaux C, 2014, J POWER SOURCES, V263, P130, DOI 10.1016/j.jpowsour.2014.04.024
   Di J, 2018, ADV MATER, V30, DOI 10.1002/adma.201704740
   Dou QY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02152-5
   EVANS R, 1979, ADV PHYS, V28, P143, DOI 10.1080/00018737900101365
   Fedorov MV, 2008, ELECTROCHIM ACTA, V53, P6835, DOI 10.1016/j.electacta.2008.02.065
   Fedorov MV, 2014, CHEM REV, V114, P2978, DOI 10.1021/cr400374x
   Feng G, 2015, AICHE J, V61, P3022, DOI 10.1002/aic.14927
   Flake GW, 2002, MACH LEARN, V46, P271, DOI 10.1023/A:1012474916001
   Frackowiak E, 2013, J ENERGY CHEM, V22, P226, DOI 10.1016/S2095-4956(13)60028-5
   Garson G. D., 1991, AI EXPERT, V6, P46, DOI DOI 10.1207/S15327752JPA8502
   Haykin S., 1999, NEURAL NETWORKS COMP
   Henderson D, 2012, J PHYS CHEM B, V116, P11356, DOI 10.1021/jp305400z
   Hou YD, 2014, J PHYS CHEM C, V118, P10153, DOI 10.1021/jp5018289
   Inal F, 2006, FUEL PROCESS TECHNOL, V87, P1031, DOI 10.1016/j.fuproc.2006.08.002
   Janes A, 2004, J ELECTROANAL CHEM, V569, P257, DOI 10.1016/j.jelechem.2004.03.008
   Jiang DE, 2014, NANOSCALE, V6, P5545, DOI 10.1039/c4nr00046c
   Jiang DE, 2013, J PHYS CHEM LETT, V4, P1260, DOI 10.1021/jz4002967
   Jiang DE, 2012, J PHYS CHEM LETT, V3, P1727, DOI 10.1021/jz3004624
   Kim IT, 2010, ELECTROCHIM ACTA, V55, P6632, DOI 10.1016/j.electacta.2010.06.011
   Kondrat S, 2016, NANOSCALE HORIZ, V1, P45, DOI 10.1039/c5nh00004a
   Kornyshev AA, 2007, J PHYS CHEM B, V111, P5545, DOI 10.1021/jp067857o
   Largeot C, 2008, J AM CHEM SOC, V130, P2730, DOI 10.1021/ja7106178
   Li S, 2014, J PHYS-CONDENS MAT, V26, DOI 10.1088/0953-8984/26/28/284105
   Li Z, 2015, J PHYS CHEM B, V119, P3085, DOI 10.1021/jp510644k
   Lian C, 2016, ACS ENERGY LETT, V1, P21, DOI 10.1021/acsenergylett.6b00010
   Lian C., 2018, AICHE J
   Lian C., 2016, J PHYS-CONDENS MAT, V28, DOI DOI 10.1088/0953-8984/28/41/414005
   Lian C, 2018, J PHYS CHEM C, V122, P18304, DOI 10.1021/acs.jpcc.8b05148
   Lian C, 2018, J PHYS CHEM C, V122, P14402, DOI 10.1021/acs.jpcc.8b04464
   Lian C, 2017, J PHYS CHEM C, V121, P14066, DOI 10.1021/acs.jpcc.7b04869
   Lian C, 2016, J PHYS CHEM C, V120, P8704, DOI 10.1021/acs.jpcc.6b00964
   Lian C, 2014, MACROMOL THEOR SIMUL, V23, P575, DOI 10.1002/mats.201400033
   Liu K, 2017, MOL PHYS, V115, P454, DOI 10.1080/00268976.2016.1271154
   Liu K, 2016, J PHYS CHEM C, V120, P24041, DOI 10.1021/acs.jpcc.6b09161
   Liu WW, 2012, J MATER CHEM, V22, P8853, DOI 10.1039/c2jm15537k
   Lust E, 2004, J ELECTROANAL CHEM, V562, P33, DOI 10.1016/j.jelechem.2003.07.034
   MORITA M, 1992, J APPL ELECTROCHEM, V22, P901, DOI 10.1007/BF01024137
   NEWMAN J, 1975, AICHE J, V21, P25, DOI 10.1002/aic.690210103
   Osti NC, 2017, PHYS REV MATER, V1, DOI 10.1103/PhysRevMaterials.1.035402
   Osti NC, 2017, J PHYS CHEM LETT, V8, P167, DOI 10.1021/acs.jpclett.6b02587
   Pilon L, 2015, J ELECTROCHEM SOC, V162, pA5158, DOI 10.1149/2.0211505jes
   Robert E., 2016, J PHYS CONDENS MATT, V28
   Rochester CC, 2016, J PHYS CHEM C, V120, P16042, DOI 10.1021/acs.jpcc.5b12730
   Shao YL, 2015, CHEM SOC REV, V44, P3639, DOI 10.1039/c4cs00316k
   Simon P, 2013, ACCOUNTS CHEM RES, V46, P1094, DOI 10.1021/ar200306b
   Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88
   Su H., 2017, ANGEW CHEM, V129, P10920, DOI DOI 10.1002/ange.201705200
   Sui H, 2016, CHEMOSPHERE, V144, P1950, DOI 10.1016/j.chemosphere.2015.10.053
   Turan NG, 2011, CHEM ENG J, V173, P98, DOI 10.1016/j.cej.2011.07.042
   Uralcan B, 2016, J PHYS CHEM LETT, V7, P2333, DOI 10.1021/acs.jpclett.6b00859
   Uysal A, 2015, J PHYS-CONDENS MAT, V27, DOI 10.1088/0953-8984/27/3/032101
   Vatamanu J, 2015, J PHYS CHEM LETT, V6, P3594, DOI 10.1021/acs.jpclett.5b01199
   Wu GZ, 2013, CHEM ENG J, V223, P747, DOI 10.1016/j.cej.2013.02.122
   Wu JZ, 2007, ANNU REV PHYS CHEM, V58, P85, DOI 10.1146/annurev.physchem.58.032806.104650
   YATES DE, 1974, J CHEM SOC FARAD T 1, V70, P1807, DOI 10.1039/f19747001807
   Zhan C, 2017, ADV SCI, V4, DOI 10.1002/advs.201700059
   Zhong C, 2015, CHEM SOC REV, V44, P7484, DOI 10.1039/c5cs00303b
NR 65
TC 4
Z9 5
U1 16
U2 70
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 186
EP 193
DI 10.1016/j.ces.2019.03.037
PG 8
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900017
DA 2020-05-12
ER

PT J
AU Qin, CZ
   Guo, B
   Celia, M
   Wu, R
AF Qin, Chao-Zhong
   Guo, Bo
   Celia, Michael
   Wu, Rui
TI Dynamic pore-network modeling of air-water flow through thin porous
   layers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thin porous media; Pore-network modeling; Two-phase flow; polymer
   electrolyte fuel cell (PEFC); Water and heat management; Phase change
ID GAS-DIFFUSION LAYERS; LIQUID WATER; 2-PHASE FLOW; MULTIPHASE FLOW;
   MICROPOROUS LAYER; FUEL-CELL; TRANSPORT; MEDIA; CAPILLARITY; WETTABILITY
AB Thin porous layers, that have large aspect ratios, are seen in many applications such as hydrogen fuel cells and hygiene products, in which air-water immiscible flow is of great interest. Direct numerical simulations based on Navier-Stokes equation are computationally expensive, and even prohibitive for low capillary number flow such as water flooding in low-temperature polymer electrolyte fuel cells. Alternatively, the pore-network modeling needs much less computational resources, while still retaining essentials of the pore-structure information. In this work, a dynamic pore-network model of air-water flow with phase change has been developed. We focus on drainage processes through thin porous layers, in which liquid water is the nonwetting phase. Three test cases are conducted, namely, air-water flow through a thin porous layer, air-water flow through a bilayer of fine and coarse thin porous layers, and water flooding in the gas diffusion layer of a polymer electrolyte fuel cell with phase change between water and its vapor. Using these test cases, we aim to demonstrate the application of dynamic pore-network modeling in thin porous media studies. In particular, we discuss the challenge of modeling thin porous media at the average scale, and highlight the role of phase change in removing liquid water from the cathode gas diffusion layer. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qin, Chao-Zhong] Eindhoven Univ Technol, Dept Mech Engn, Off GEM Z 3-135,POB 513, NL-5600 MB Eindhoven, Netherlands.
   [Guo, Bo] Univ Arizona, Dept Hydrol & Atmospher Sci, Tucson, AZ 85721 USA.
   [Celia, Michael] Princeton Univ, Dept Civil & Environm Engn, Princeton, NJ 08544 USA.
   [Wu, Rui] Shanghai Jiao Tong Univ, Dept Mech Engn, Shanghai, Peoples R China.
RP Qin, CZ (reprint author), Eindhoven Univ Technol, Dept Mech Engn, Off GEM Z 3-135,POB 513, NL-5600 MB Eindhoven, Netherlands.
EM chaozhong.qin@gmail.com
RI QIAN, LIU/S-1353-2019; Guo, Bo/M-1996-2016
OI Guo, Bo/0000-0002-8825-7331
FU Darcy Center of Utrecht University; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China [51776122];
   Eindhoven University of Technology
FX C.Z.Q. and M.C. acknowledge the support of Darcy Center of Utrecht
   University and Eindhoven University of Technology. R.W. acknowledges the
   support of National Natural Science Foundation of China (No. 51776122).
CR Basu S, 2009, J ELECTROCHEM SOC, V156, pB748, DOI 10.1149/1.3115470
   Belgacem N, 2016, TRANSPORT POROUS MED, V115, P449, DOI 10.1007/s11242-016-0630-1
   Berg S, 2013, P NATL ACAD SCI USA, V110, P3755, DOI 10.1073/pnas.1221373110
   Blunt MJ, 2002, ADV WATER RESOUR, V25, P1069, DOI 10.1016/S0309-1708(02)00049-0
   Deevanhxay P, 2013, J POWER SOURCES, V230, P38, DOI 10.1016/j.jpowsour.2012.11.140
   Diersch HJG, 2011, TRANSPORT POROUS MED, V86, P753, DOI 10.1007/s11242-010-9650-4
   Fazeli M, 2015, J ELECTROCHEM SOC, V162, pF661, DOI 10.1149/2.0191507jes
   Garcia-Salaberri PA, 2015, INT J HEAT MASS TRAN, V86, P319, DOI 10.1016/j.ijheatmasstransfer.2015.02.073
   Gostick JT, 2007, J POWER SOURCES, V173, P277, DOI 10.1016/j.jpowsour.2007.04.059
   HASSANIZADEH SM, 1990, ADV WATER RESOUR, V13, P169, DOI 10.1016/0309-1708(90)90040-B
   Huang XW, 2016, TRANSPORT POROUS MED, V111, P123, DOI 10.1007/s11242-015-0584-8
   Ji Y, 2010, J ELECTROCHEM SOC, V157, pB1753, DOI 10.1149/1.3491359
   Joekar-Niasar V, 2010, J FLUID MECH, V655, P38, DOI 10.1017/S0022112010000704
   Kunz P, 2016, TRANSPORT POROUS MED, V114, P581, DOI 10.1007/s11242-015-0599-1
   Lee J, 2015, J ELECTROCHEM SOC, V162, pF669, DOI 10.1149/2.0221507jes
   Lee KJ, 2009, ELECTROCHIM ACTA, V54, P1166, DOI 10.1016/j.electacta.2008.08.068
   Ma SX, 1996, COLLOID SURFACE A, V117, P273, DOI 10.1016/0927-7757(96)03702-8
   Medici EF, 2013, INT J HEAT MASS TRAN, V65, P779, DOI 10.1016/j.ijheatmasstransfer.2013.06.035
   Morgan JM, 2014, J POWER SOURCES, V251, P269, DOI 10.1016/j.jpowsour.2013.09.090
   Mukherjee PP, 2009, ELECTROCHIM ACTA, V54, P6861, DOI 10.1016/j.electacta.2009.06.066
   Nam JH, 2009, INT J HEAT MASS TRAN, V52, P2779, DOI 10.1016/j.ijheatmasstransfer.2009.01.002
   Owejan JP, 2010, J ELECTROCHEM SOC, V157, pB1456, DOI 10.1149/1.3468615
   Park J, 2015, APPL ENERG, V155, P866, DOI 10.1016/j.apenergy.2015.06.068
   Patzek TW, 2001, SPE J, V6, P144, DOI 10.2118/71310-PA
   Pinder GF, 2008, ESSENTIALMULTIPHAS
   Prat M, 2015, HDB POROUS MEDIA
   Qin CZ, 2015, INT J HYDROGEN ENERG, V40, P3348, DOI 10.1016/j.ijhydene.2015.01.035
   Qin CZ, 2014, INT J HEAT MASS TRAN, V70, P693, DOI 10.1016/j.ijheatmasstransfer.2013.11.059
   Qin CZ, 2016, COMPUTATION, V4, DOI 10.3390/computation4020021
   Qin CZ, 2015, J ELECTROCHEM SOC, V162, pF1036, DOI 10.1149/2.0861509jes
   Qin CZ, 2012, J ELECTROCHEM SOC, V159, pB737, DOI 10.1149/2.092206jes
   Qin CZ, 2012, J ELECTROCHEM SOC, V159, pB434, DOI 10.1149/2.004205jes
   Qin CZ, 2012, J POWER SOURCES, V197, P136, DOI 10.1016/j.jpowsour.2011.08.095
   Raeini AQ, 2014, ADV WATER RESOUR, V74, P116, DOI 10.1016/j.advwatres.2014.08.012
   RANSOHOFF TC, 1988, J COLLOID INTERF SCI, V121, P392, DOI 10.1016/0021-9797(88)90442-0
   Rebai M, 2009, J POWER SOURCES, V192, P534, DOI 10.1016/j.jpowsour.2009.02.090
   Riasi MS, 2016, TRANSPORT POROUS MED, V115, P519, DOI 10.1007/s11242-016-0720-0
   Roudbari MS, 2016, COMPUT FLUIDS, V141, P212, DOI 10.1016/j.compfluid.2016.07.006
   Ryan O'hayre W. G. C, 2016, FUEL CELLS, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Sadeghifar H, 2014, J POWER SOURCES, V248, P632, DOI 10.1016/j.jpowsour.2013.09.136
   Sinha PK, 2007, ELECTROCHIM ACTA, V52, P7936, DOI 10.1016/j.electacta.2007.06.061
   Sinha PK, 2007, J MATER CHEM, V17, P3089, DOI 10.1039/b703485g
   Straubhaar B, 2016, INT J HEAT MASS TRAN, V102, P891, DOI 10.1016/j.ijheatmasstransfer.2016.06.078
   Sweijen T, 2016, TRANSPORT POROUS MED, V113, P207, DOI 10.1007/s11242-016-0689-8
   Tavangarrad AH, 2018, TRANSPORT POROUS MED, V122, P203, DOI 10.1007/s11242-018-0999-0
   Thompson KE, 2002, AICHE J, V48, P1369, DOI 10.1002/aic.690480703
   Valvatne PH, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002627
   Wang Y, 2008, FUEL CELLS, DOI [10.1149/1.2193403, DOI 10.1149/1.2193403]
   Wang ZY, 2009, INT J MULTIPHAS FLOW, V35, P227, DOI 10.1016/j.ijmultiphaseflow.2008.11.004
   Wargo EA, 2013, ELECTROCHIM ACTA, V87, P201, DOI 10.1016/j.electacta.2012.09.008
   Wu R, 2016, INT J HEAT MASS TRAN, V94, P81, DOI 10.1016/j.ijheatmasstransfer.2015.11.004
   Wu R, 2012, INT J HEAT MASS TRAN, V55, P6363, DOI 10.1016/j.ijheatmasstransfer.2012.06.019
   Wu R, 2012, INT J HEAT MASS TRAN, V55, P2581, DOI 10.1016/j.ijheatmasstransfer.2012.01.002
   Yang JH, 2017, COMPUTAT GEOSCI, V21, P849, DOI 10.1007/s10596-017-9630-7
   Zhuang LW, 2017, WATER RESOUR RES, V53, P9078, DOI 10.1002/2017WR020895
NR 55
TC 1
Z9 1
U1 7
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 194
EP 207
DI 10.1016/j.ces.2019.03.038
PG 14
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900018
DA 2020-05-12
ER

PT J
AU Wang, T
   Xia, ZH
   Chen, CX
AF Wang, Teng
   Xia, Zihong
   Chen, Caixia
TI Coupled CFD-PBM simulation of bubble size distribution in a 2D gas-solid
   bubbling fluidized bed with a bubble coalescence and breakup model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-solid bubbling fluidized bed; Bubble size distribution; CFD-PBM;
   Bubble coalescence and breakup model; Pseudo bubble-emulsion drag model
ID DIGITAL IMAGE-ANALYSIS; PHASE MASS-TRANSFER; BEHAVIOR; HYDRODYNAMICS;
   COEFFICIENT; FREQUENCY; DIAMETER; GELDART; FLOWS
AB A coupled model of computational fluid dynamics and population balance model (CFD-PBM) scheme was developed to simulate bubble size distribution in gas-solid bubbling fluidized beds. The bubbling gas fluidized bed was divided into a discrete bubble phase and a dense emulsion including a pseudo solids continua modeled by the kinetic theory of granular flow (KTGF). A modified bubble coalescence and breakup model was proposed and implemented in the population balance model. A pseudo bubble-emulsion drag force model was derived based on the bubble size distribution and used for simulating the gas-solid momentum exchanges between gas bubbles and the solids belong to the emulsion phase. By taking into account the effects of bubble coalescence and breakup, the coupled CFD-PBM model was capable of predicting the hydrodynamic behavior of a bubbling gas-solid fluidized bed. A benchmark simulation showed good agreements between the computation results and the literature experimental data. Particularly, the predicted time-averaged bubble local hold-up maps, bubble size distributions and their evolution agreed well with the measurement data. Grid convergence simulation results demonstrated that the present model is able to predict the major hydrodynamic behavior of a 2D bubbling fluidized bed using coarse computational grids, which makes the present model a promising tool for applications in large-scale fluidized bed reactors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Teng; Xia, Zihong; Chen, Caixia] East China Univ Sci & Technol, Minist Educ, Key Lab Coal Gasificat & Energy Chem Engn, Shanghai 200237, Peoples R China.
RP Xia, ZH; Chen, CX (reprint author), East China Univ Sci & Technol, Minist Educ, Key Lab Coal Gasificat & Energy Chem Engn, Shanghai 200237, Peoples R China.
EM zihxia@ecust.edu.cn; cxchen@ecust.edu.cn
RI QIAN, LIU/S-1353-2019
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [21276085]; Yankuang Energy R&D Co., Ltd,
   Shanghai
FX This work is supported by National Natural Science Foundation of China
   (NSFC) under Grant No. 21276085, and Yankuang Energy R&D Co., Ltd,
   Shanghai.
CR Abbasi M, 2015, CAN J CHEM ENG, V93, P1838, DOI 10.1002/cjce.22269
   Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Bakshi A, 2018, POWDER TECHNOL, V332, P114, DOI 10.1016/j.powtec.2018.03.048
   Bakshi A, 2016, CHEM ENG J, V293, P355, DOI 10.1016/j.cej.2016.02.058
   Benyahia S, 2012, POWDER TECHNOL, V220, P2, DOI 10.1016/j.powtec.2011.10.052
   Busciglio A, 2010, CHEM ENG SCI, V65, P4782, DOI 10.1016/j.ces.2010.05.016
   Busciglio A, 2008, CHEM ENG J, V140, P398, DOI 10.1016/j.cej.2007.11.015
   Busciglio A, 2009, CHEM ENG J, V148, P145, DOI 10.1016/j.cej.2008.11.010
   CHOI JH, 1988, J CHEM ENG JPN, V21, P171, DOI 10.1252/jcej.21.171
   Choi JH, 1998, IND ENG CHEM RES, V37, P2559, DOI 10.1021/ie970915v
   CLIFT R, 1972, CHEM ENG SCI, V27, P2309, DOI 10.1016/0009-2509(72)85111-X
   Clift R., 1978, BUBBLES DROPS PARTIC
   Clift R., 1985, FLUIDIZATION, P73
   Cloete S, 2013, POWDER TECHNOL, V239, P21, DOI 10.1016/j.powtec.2013.01.036
   DARTON RC, 1977, T I CHEM ENG-LOND, V55, P274
   DARTON RC, 1974, T I CHEM ENG-LOND, V52, P301
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   GLICKSMAN LR, 1987, CHEM ENG SCI, V42, P479, DOI 10.1016/0009-2509(87)80010-6
   GRACE JR, 1969, CHEM ENG SCI, V24, P497, DOI 10.1016/0009-2509(69)85021-9
   GRACE JR, 1974, CAN J CHEM ENG, V52, P417, DOI 10.1002/cjce.5450520319
   Hagesaether L, 2002, CHEM ENG SCI, V57, P3251, DOI 10.1016/S0009-2509(02)00197-5
   Hamidipour M, 2012, CHEM ENG SCI, V78, P167, DOI 10.1016/j.ces.2012.05.016
   Harrison D, 1962, S INTERACTION BETWEE, P127
   Hilligardt K., 1987, CHEM ENG TECHNOL, V10, P272
   Hong K, 2018, ADV POWDER TECHNOL, V29, P488, DOI 10.1016/j.apt.2018.02.024
   Hong K, 2013, CHEM ENG SCI, V99, P191, DOI 10.1016/j.ces.2013.05.050
   Hong K, 2012, CHEM ENG SCI, V75, P376, DOI 10.1016/j.ces.2012.03.022
   HORIO M, 1987, AICHE J, V33, P1865, DOI 10.1002/aic.690331113
   Igci Y, 2012, IND ENG CHEM RES, V51, P2094, DOI 10.1021/ie2007278
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   Kobayashi H., 1965, CHEM ENGNG TOKYO, V29, P885
   KRISHNA R, 1993, CHEM ENG J BIOCH ENG, V53, P89, DOI 10.1016/0923-0467(93)80010-T
   Kunii D., 1991, FLUIDIZATION ENG
   Laverman J. A., 2006, INVESTIGATION INFLUE
   Lehr F, 2001, CHEM ENG SCI, V56, P1159, DOI 10.1016/S0009-2509(00)00335-3
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li JG, 2017, POWDER TECHNOL, V313, P369, DOI 10.1016/j.powtec.2017.03.031
   Liao YX, 2015, CHEM ENG SCI, V122, P336, DOI 10.1016/j.ces.2014.09.042
   Liu XH, 2014, IND ENG CHEM RES, V53, P2800, DOI 10.1021/ie4029335
   Lu BN, 2009, CHEM ENG SCI, V64, P3437, DOI 10.1016/j.ces.2009.04.024
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Medrano JA, 2017, CHEM ENG J, V325, P404, DOI 10.1016/j.cej.2017.05.089
   Miwa K., 1971, KAGAKU KOGAKU, V35, P770
   MORI S, 1975, AICHE J, V21, P109, DOI 10.1002/aic.690210114
   MOROOKA S, 1972, INT CHEM ENG, V12, P168
   Movahedirad S, 2012, IND ENG CHEM RES, V51, P6571, DOI 10.1021/ie300027p
   Movahedirad S, 2014, CHEM ENG TECHNOL, V37, P2096, DOI 10.1002/ceat.201300565
   Movahedirad S, 2014, CHEM ENG TECHNOL, V37, P103, DOI 10.1002/ceat.201300432
   Movahedirad S, 2012, CHEM ENG TECHNOL, V35, P929, DOI 10.1002/ceat.201100383
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Penn A, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701879
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Shen LH, 2004, CHEM ENG SCI, V59, P2607, DOI 10.1016/j.ces.2004.01.063
   Shi WB, 2018, CHEM ENG SCI, V187, P391, DOI 10.1016/j.ces.2018.05.013
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   Taghipour F, 2005, CHEM ENG SCI, V60, P6857, DOI 10.1016/j.ces.2005.05.044
   Tan LH, 2017, PARTICUOLOGY, V33, P80, DOI 10.1016/j.partic.2016.09.008
   THOMAS DG, 1965, J COLL SCI IMP U TOK, V20, P267, DOI 10.1016/0095-8522(65)90016-4
   Toei R., 1967, KAGAKU KOGAKU, V31, P1238
   Toei R., 1975, J CHEM ENG JPN, V7, P451
   Verma V, 2014, AICHE J, V60, P1632, DOI 10.1002/aic.14393
   Briongos JV, 2011, AICHE J, V57, P1733, DOI 10.1002/aic.12375
   Wang JW, 2010, CHEM ENG SCI, V65, P2125, DOI 10.1016/j.ces.2009.12.004
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang SY, 2008, CHEM ENG SCI, V63, P5653, DOI 10.1016/j.ces.2008.08.010
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Wang TF, 2003, CHEM ENG SCI, V58, P4629, DOI 10.1016/j.ces.2003.07.009
   Werther J, 1984, P 4 INT C FLUID KASH
   Werther J., 1973, INT J MULTIPHASE FLO, V1, P103
   Werther J., 1974, AICHE S SER, V70, P53
   Werther J., 1976, FLUID TECHNOL
NR 72
TC 1
Z9 1
U1 6
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 208
EP 221
DI 10.1016/j.ces.2019.03.045
PG 14
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900019
DA 2020-05-12
ER

PT J
AU O'Neill, KT
   Brancato, L
   Stanwix, PL
   Fridjonsson, EO
   Johns, ML
AF O'Neill, Keelan T.
   Brancato, Lorenzo
   Stanwix, Paul L.
   Fridjonsson, Einar O.
   Johns, Michael L.
TI Two-phase oil/water flow measurement using an Earth's field nuclear
   magnetic resonance flow meter
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flow metering; Multiphase flow; NMR; 2D regularisation; Flow regimes
ID GAMMA-RAY ATTENUATION; WATER-IN-OIL; MULTIPHASE FLOW; REGIME
   IDENTIFICATION; FRACTION PREDICTION; DROPLET SIZES; NMR SIGNAL;
   EMULSIONS; RELAXATION; DIFFUSION
AB We present a novel multiphase flow metering technique for simultaneous measurement of oil and water volumetric flowrates. An Earth's field nuclear magnetic resonance (NMR) detection coil is applied to measure free induction decay (FID) signals of two-phase oil/water flows. A dual polarisation technique is introduced utilising an upstream permanent magnet as well as an electromagnetic prepolarising coil. FID signals with variable pre-polarising conditions are acquired and fit with a model for the NMR fluid signal using a 2D Tikhonov regularisation algorithm, allowing determination of a joint 2D velocity-T-1 probability distribution. Appropriate analysis of the measured velocity-T-1 distributions allows calculation of individual phase flowrates. The performance of the NMR flow measurement technique is examined for oil/water flows which are visually observed to be in three different flow regimes: stratified flow with mixing, dispersion of oil-in-water and water, and full oil-in-water emulsions. Two-phase flow characteristic features such as velocity slip are examined for each flow regime. Finally the accuracy of the measurement system in each flow regime is validated against in-line rotameter measurements. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [O'Neill, Keelan T.; Brancato, Lorenzo; Stanwix, Paul L.; Fridjonsson, Einar O.; Johns, Michael L.] Univ Western Australia, Sch Engn, Dept Chem Engn, Crawley, WA 6009, Australia.
RP Johns, ML (reprint author), Univ Western Australia, Sch Engn, Dept Chem Engn, Crawley, WA 6009, Australia.
EM michael.johns@uwa.edu.au
RI Fridjonsson, Einar/H-9226-2014
OI Fridjonsson, Einar/0000-0001-8365-6002
CR Abro E, 1999, FLOW MEAS INSTRUM, V10, P99, DOI 10.1016/S0955-5986(98)00043-0
   Allsopp K, 2001, J CAN PETROL TECHNOL, V40, P58
   ANDREW ER, 1987, J MAGN RESON, V73, P268, DOI 10.1016/0022-2364(87)90198-3
   Angeli P, 1998, INT J MULTIPHAS FLOW, V24, P1183
   Angeli P, 2000, INT J MULTIPHAS FLOW, V26, P1117, DOI 10.1016/S0301-9322(99)00081-6
   ARIRACHAKARAN S, 1989, SPE PROD OP S OKL, P155, DOI DOI 10.2118/18836-MS
   Arvoh BK, 2012, FLOW MEAS INSTRUM, V23, P56, DOI 10.1016/j.flowmeasinst.2011.11.002
   Blaney S, 2008, FLOW MEAS INSTRUM, V19, P57, DOI 10.1016/j.flowmeasinst.2007.09.002
   Bruvik EM, 2016, FLOW MEAS INSTRUM, V47, P10, DOI 10.1016/j.flowmeasinst.2015.10.013
   CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630
   CHARLES ME, 1961, CAN J CHEM ENG, V39, P27
   Connolly PRJ, 2017, WATER RESOUR RES, V53, P7917, DOI 10.1002/2017WR020829
   Corneliussen S., 2005, HDB MULTIPHASE FLOW
   Falcimaigne J, 2008, MULTIPHASE PRODUCTION: PIPELINE TRANSPORT, PUMPING AND METERING, P1
   Falcone G, 2002, J PETROL TECHNOL, V54, P77, DOI 10.2118/74689-JPT
   Falcone G, 2009, DEV PET SCI, V54, P19
   Folgero K., 2013, INT N SEA FLOW MEAS
   Freedman R., 2004, PETROPHYSICS, V45, P241
   Fridjonsson EO, 2013, MINER ENG, V53, P144, DOI 10.1016/j.mineng.2013.07.017
   Fridjonsson EO, 2014, J MAGN RESON, V245, P110, DOI 10.1016/j.jmr.2014.06.004
   Fridjonsson EO, 2014, ENERG FUEL, V28, P1756, DOI 10.1021/ef402117k
   Fridjonsson EO, 2012, J MAGN RESON, V221, P97, DOI 10.1016/j.jmr.2012.05.012
   Gladden LF, 1996, MEAS SCI TECHNOL, V7, P423, DOI 10.1088/0957-0233/7/3/026
   GLADDEN LF, 1994, CHEM ENG SCI, V49, P3339, DOI 10.1016/0009-2509(94)00129-4
   Gladden LF, 2017, ANNU REV CHEM BIOMOL, V8, P227, DOI 10.1146/annurev-chembioeng-061114-123222
   Gladden LF, 2013, J MAGN RESON, V229, P2, DOI 10.1016/j.jmr.2012.11.022
   Godefroy S, 2003, ROY SOC CH, P85, DOI 10.1039/9781847551269-00085
   GOLUB GH, 1979, TECHNOMETRICS, V21, P215, DOI 10.1080/00401706.1979.10489751
   Grombacher D, 2014, GEOPHYSICS, V79, pE11, DOI 10.1190/GEO2012-0488.1
   Grunewald E, 2012, GEOPHYSICS, V77, pEN1, DOI [10.1190/GEO2011-0160.1, 10.1190/geo2011-0160.1]
   Hills B., 2004, APPL MAGN RESON, V26, DOI [10.1016/j.jmr.2011.07.02010.1007/bf03166582, DOI 10.1016/J.JMR.2011.07.02010.1007/BF03166582]
   Hogendoorn J., 2013, INT N SEA FLOW MEAS
   Hogendoorn J., 2015, MAGNETIC RESONANCE M
   Hollingsworth KG, 2004, J COLLOID INTERF SCI, V274, P244, DOI 10.1016/j.jcis.2004.02.074
   Hollingsworth KG, 2003, J COLLOID INTERF SCI, V258, P383, DOI 10.1016/S0021-9797(02)00131-5
   HOULT DI, 1984, J MAGN RESON, V57, P394, DOI 10.1016/0022-2364(84)90256-7
   Hurlimann M. D., 2015, MOBILE NMR AND MRI, P11, DOI DOI 10.1039/9781782628095
   Hurlimann MD, 2002, J MAGN RESON, V157, P31, DOI 10.1006/jmre.2002.2567
   Istratov AA, 1999, REV SCI INSTRUM, V70, P1233, DOI 10.1063/1.1149581
   Kantzas Apostolos, 2009, Journal of Physics: Conference Series, V147, DOI 10.1088/1742-6596/147/1/012029
   Klaus A, 2012, LANGMUIR, V28, P8318, DOI 10.1021/la300435t
   Kleinberg R.L., 1996, LOG ANAL, V37, P20, DOI DOI 10.1016/S0730-725X(03)00135-8
   Kruger G. J., 1984, MEASURING TECHNIQUES, DOI [10.1007/978-3-642-82112-7_22, DOI 10.1007/978-3-642-82112-7_22]
   Kruger GJ, 1996, FLOW MEAS INSTRUM, V7, P25, DOI 10.1016/0955-5986(96)00005-2
   Lakshmanan S, 2017, FLOW MEAS INSTRUM, V53, P161, DOI 10.1016/j.flowmeasinst.2016.04.001
   Ling NNA, 2017, CHEM ENG SCI, V160, P362, DOI 10.1016/j.ces.2016.11.045
   Ling NNA, 2014, COLLOID SURFACE A, V462, P244, DOI 10.1016/j.colsurfa.2014.08.031
   Lovick J, 2004, INT J MULTIPHAS FLOW, V30, P139, DOI 10.1016/j.ijmultiphaseflow.2003.11.011
   Mailhiot SE, 2017, APPL MAGN RESON, V48, P407, DOI 10.1007/s00723-017-0869-x
   MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296
   Mitchell J, 2014, PROG NUCL MAG RES SP, V76, P1, DOI 10.1016/j.pnmrs.2013.09.001
   Mitchell J, 2012, PROG NUCL MAG RES SP, V62, P34, DOI 10.1016/j.pnmrs.2011.07.002
   Mitchell J, 2011, J MAGN RESON, V212, P394, DOI 10.1016/j.jmr.2011.07.020
   Mitchell J, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3446805
   Mitchell J, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.026101
   MUELLER E, 1986, MAGNET RESON MED, V3, P331, DOI 10.1002/mrm.1910030219
   Nadler M, 1997, INT J MULTIPHAS FLOW, V23, P55, DOI 10.1016/S0301-9322(96)00055-9
   O'Neill KT, 2017, FLOW MEAS INSTRUM, V58, P104, DOI 10.1016/j.flowmeasinst.2017.10.004
   O'Neill KT, 2016, J MAGN RESON, V269, P179, DOI 10.1016/j.jmr.2016.06.008
   Osan TM, 2011, J MAGN RESON, V209, P116, DOI 10.1016/j.jmr.2010.07.011
   PENDLEBURY JM, 1979, REV SCI INSTRUM, V50, P535, DOI 10.1063/1.1135904
   Piela K, 2008, INT J MULTIPHAS FLOW, V34, P665, DOI 10.1016/j.ijmultiphaseflow.2007.12.004
   Pinguet B., 2010, INT N SEA FLOW MEAS
   Pinguet B., 2006, SPE ANN TECHN C EXH, DOI [10.2118/103223-ms, DOI 10.2118/103223-MS]
   Pinguet B., 2010, FUNDAMENTALS MULTIPH
   RAJAN VSV, 1993, J ENERG RESOUR-ASME, V115, P151, DOI 10.1115/1.2905987
   Roshani GH, 2015, MEASUREMENT, V62, P25, DOI 10.1016/j.measurement.2014.11.006
   Roshani GH, 2014, MEASUREMENT, V51, P34, DOI 10.1016/j.measurement.2014.01.030
   Saetre C, 2010, FLOW MEAS INSTRUM, V21, P454, DOI 10.1016/j.flowmeasinst.2010.06.002
   Salgado CM, 2010, PROG NUCL ENERG, V52, P555, DOI 10.1016/j.pnucene.2010.02.001
   Song YQ, 2009, PROG NUCL MAG RES SP, V55, P324, DOI 10.1016/j.pnmrs.2009.07.001
   Song YQ, 2002, J MAGN RESON, V154, P261, DOI 10.1006/jmre.2001.2474
   Sukstanskii AL, 2001, J MAGN RESON, V151, P107, DOI 10.1006/jmre.2001.2363
   Thorn R, 2013, MEAS SCI TECHNOL, V24, DOI 10.1088/0957-0233/24/1/012003
   Tikhonov AN, 1995, NUMERICAL METHODS SO
   Tjugum SA, 2002, MEAS SCI TECHNOL, V13, P1319, DOI 10.1088/0957-0233/13/8/321
   Trallero JL, 1997, SPE PROD FACIL, V12, P165, DOI 10.2118/36609-PA
   Vogt SJ, 2013, BIOTECHNOL BIOENG, V110, P1366, DOI 10.1002/bit.24803
   Wagner L, 2016, MEAS SCI TECHNOL, V27, DOI 10.1088/0957-0233/27/10/105501
   WAHBA G, 1977, SIAM J NUMER ANAL, V14, P651, DOI 10.1137/0714044
   WAHBA G, 1982, [No title captured], V2, P383
   Wu HJ, 2001, INT J MULTIPHAS FLOW, V27, P459, DOI 10.1016/S0301-9322(00)00022-7
   Xu XX, 2007, J PETROL SCI ENG, V59, P43, DOI 10.1016/j.petrol.2007.03.002
   Zhen JZ, 2018, J MAGN RESON, V287, P33, DOI 10.1016/j.jmr.2017.12.006
   Zolfaghari R, 2016, SEP PURIF TECHNOL, V170, P377, DOI 10.1016/j.seppur.2016.06.026
NR 85
TC 1
Z9 1
U1 2
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 222
EP 237
DI 10.1016/j.ces.2019.03.018
PG 16
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900020
DA 2020-05-12
ER

PT J
AU Lapidot, T
   Matar, OK
   Heng, JYY
AF Lapidot, Tomer
   Matar, Omar K.
   Heng, Jerry Y. Y.
TI Calcium sulphate crystallisation in the presence of mesoporous silica
   particles: Experiments and population balance modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mesoporous silica particles; Population balance equation; Heterogeneous
   nucleation; Calcium sulphate crystallisation
ID SCALE FORMATION; CRYSTAL-GROWTH; HETEROGENEOUS NUCLEATION;
   GROWING-CRYSTALS; INITIAL PERIOD; AGGREGATION; PRECIPITATION; DIHYDRATE;
   EQUATIONS; GYPSUM
AB A population balance model is used to investigate the effect of mesoporous silica particles on calcium sulphate crystallisation in a stirred batch crystalliser. The model accounts for nucleation, growth, agglomeration, breakage, and particle-assisted nucleation, and the model equations are solved numerically using the method of classes over a logarithmic, non-uniform mesh. The crystallisation process is characterized experimentally using electrical conductivity to track the ion concentration and laser diffraction to measure the steady-state crystal size distribution obtained at the end of the experiments. The experiments are carried out over a range of temperatures, initial supersaturations, particle pore diameters, and particle loadings. The model is first fitted to experimental data obtained in the absence of particles to determine kinetic parameters of the nucleation, growth, agglomeration, and breakage for pure calcium sulphate crystallisation. Varying pore diameter did not influence the catalytic effect of the particles, however, particle loading was found to significantly decrease the nucleation induction time. The model was extended to account for the presence of particles by fitting two additional mechanisms. The first proposed a particle-assisted nucleation where nuclei are produced via heterogeneous crystallisation, then detach by particle-particle collision that is second-order with respect to particle loading. The second proposed that the crystal breakage frequency increases linearly with particle loading. Good agreement with the experimental data is demonstrated over the range of conditions examined. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lapidot, Tomer; Matar, Omar K.; Heng, Jerry Y. Y.] Imperial Coll London, Dept Chem Engn, South Kensington Campus, London SW7 2AZ, England.
RP Heng, JYY (reprint author), Imperial Coll London, Dept Chem Engn, South Kensington Campus, London SW7 2AZ, England.
EM jerry.heng@imperial.ac.uk
RI Heng, Jerry/E-7761-2015
OI Heng, Jerry/0000-0003-2659-5500
FU Energy Future Lab; Alan Howard Scholarships
FX The authors would like to acknowledge the Alan Howard Scholarships and
   the Energy Future Lab for generously sponsoring this work.
CR Allahyarov E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8110
   Alopaeus V, 2006, CHEM ENG SCI, V61, P6732, DOI 10.1016/j.ces.2006.07.010
   AMJAD Z, 1988, J COLLOID INTERF SCI, V123, P523, DOI 10.1016/0021-9797(88)90274-3
   Antonius Kusters K., 1991, THESIS
   Badens E, 1999, J CRYST GROWTH, V198, P704, DOI 10.1016/S0022-0248(98)01206-8
   Bansal B, 1997, J HEAT TRANS-T ASME, V119, P568, DOI 10.1115/1.2824143
   Bansal B, 2008, CHEM ENG PROCESS, V47, P1201, DOI 10.1016/j.cep.2007.03.016
   BOCK E, 1961, CAN J CHEM, V39, P1746, DOI 10.1139/v61-228
   Bott T. R., 1995, FOULING HEAT EXCHANG
   Bove S, 2005, CHEM ENG SCI, V60, P1449, DOI 10.1016/j.ces.2004.10.021
   Buffo A, 2012, CHEM ENG SCI, V70, P31, DOI 10.1016/j.ces.2011.04.042
   Cacciuto A, 2004, NATURE, V428, P404, DOI 10.1038/nature02397
   Charnay C, 2004, EUR J PHARM BIOPHARM, V57, P533, DOI 10.1016/j.ejpb.2003.12.007
   Chayen NE, 2006, P NATL ACAD SCI USA, V103, P597, DOI 10.1073/pnas.0504860102
   Chien WC, 2007, IND ENG CHEM RES, V46, P6435, DOI 10.1021/ie061416+
   CHRISTOFFERSEN MR, 1982, J CRYST GROWTH, V58, P585, DOI 10.1016/0022-0248(82)90145-2
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   DAVID R, 1991, CHEM ENG SCI, V46, P1129, DOI 10.1016/0009-2509(91)85105-7
   GILRON J, 1987, CHEM ENG SCI, V42, P2351, DOI 10.1016/0009-2509(87)80109-4
   HASSON D, 1970, IND ENG CHEM FUND, V9, P1, DOI 10.1021/i160033a001
   Hounslow MJ, 2013, CHEM ENG SCI, V101, P731, DOI 10.1016/j.ces.2013.06.058
   HOUNSLOW MJ, 1988, AICHE J, V34, P1821, DOI 10.1002/aic.690341108
   Kashchiev D., 2000, NUCLEATION
   Kim S, 2005, ORG PROCESS RES DEV, V9, P894, DOI 10.1021/op050091q
   Kim WT, 2001, INT COMMUN HEAT MASS, V28, P671
   Kumar J, 2008, POWDER TECHNOL, V182, P81, DOI 10.1016/j.powtec.2007.05.028
   Kumar S, 1997, CHEM ENG SCI, V52, P4659, DOI 10.1016/S0009-2509(97)00307-2
   Kwon JSI, 2014, CHEM ENG SCI, V107, P47, DOI 10.1016/j.ces.2013.12.005
   Lapidot T, 2016, IND ENG CHEM RES, V55, P11475, DOI 10.1021/acs.iecr.6b02914
   Lian GP, 2006, CHEM ENG SCI, V61, P7819, DOI 10.1016/j.ces.2006.08.075
   Linnikov OD, 2003, DESALINATION, V157, P235, DOI 10.1016/S0011-9164(03)00402-8
   Linnikov OD, 1999, DESALINATION, V122, P1, DOI 10.1016/S0011-9164(99)00023-5
   Linnikov OD, 2000, DESALINATION, V128, P35, DOI 10.1016/S0011-9164(00)00021-7
   LITSTER JD, 1995, AICHE J, V41, P591
   LIU ST, 1975, J COLLOID INTERF SCI, V52, P593, DOI 10.1016/0021-9797(75)90285-4
   Ma CY, 2008, AICHE J, V54, P209, DOI 10.1002/aic.11365
   Ma CY, 2007, ADV POWDER TECHNOL, V18, P707, DOI 10.1163/156855207782514932
   Ma DL, 2002, COMPUT CHEM ENG, V26, P1103, DOI 10.1016/S0098-1354(02)00033-9
   MARCHAL P, 1988, CHEM ENG SCI, V43, P59, DOI 10.1016/0009-2509(88)87126-4
   Marchisio DL, 2005, J AEROSOL SCI, V36, P43, DOI 10.1016/j.jaerosci.2004.07.009
   Mumtaz HS, 1997, CHEM ENG RES DES, V75, P152, DOI 10.1205/026387697523615
   Price SL, 2014, CHEM SOC REV, V43, P2098, DOI 10.1039/c3cs60279f
   Puel F, 1997, CHEM ENG RES DES, V75, P193, DOI 10.1205/026387697523444
   Ramachandran R, 2009, CHEM ENG RES DES, V87, P598, DOI 10.1016/j.cherd.2008.11.007
   RAMKRISHNA D, 2000, POPULATION BALANCES
   SMITH BR, 1971, J COLLOID INTERF SCI, V37, P612, DOI 10.1016/0021-9797(71)90339-0
   Sung-Tsuen Liu, 1970, Journal of Crystal Growth, V6, P281
   XIAO RF, 1988, PHYS REV A, V38, P2447, DOI 10.1103/PhysRevA.38.2447
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao Q, 2002, SURF COAT TECH, V155, P279, DOI 10.1016/S0257-8972(02)00116-0
NR 50
TC 0
Z9 0
U1 5
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 238
EP 249
DI 10.1016/j.ces.2019.02.045
PG 12
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900021
DA 2020-05-12
ER

PT J
AU Xue, K
   Liu, JQ
   Feng, C
   Gan, YX
   Bai, CH
AF Xue, Kun
   Liu, Jiaqi
   Feng, Chun
   Gan, Yixiang
   Bai, Chunhua
TI Explosively driven hierarchical particle jetting
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hierarchical particle jetting; Explosive dispersal; Coupled DEM and FEM;
   Shear bands; Particle packing structure
ID DYNAMIC FRAGMENTATION; CONSTITUTIVE MODEL; DEFORMATION; SYSTEMS;
   STRENGTH; FLOWS
AB When particle rings/shells are subjected to divergent explosive loadings, a dual overlapping particle jetting structure emerges during the shock interaction timescale which consists of a large number of minor jets initiated from the external interface at very early instants and a much reduced number of major jets formed from the internal interface at delayed times but overtaking the minor jets in later times. In the present work, the formation of the hierarchical particle jetting pattern is investigated numerically by discrete element method (DEM) coupled with finite element method (FEM), which execute the mechanical calculations of particles and the explosive/detonation gases, respectively. The numerical results find that the external jetting arises from the spallation of an outer layer pulled away by inward propagating rarefaction waves. Meanwhile an inner compact band re-compressed by a secondary shock remains densely packed while expanding outward. The fragmentation of the inner compact particle band, preceding the internal particle jetting, is caused by the profuse spiral shear failures expanding from the inner radius to the outer radius. The resultant jetting structure depends on the shear-band spacing and the grouping of the clockwise and counterclockwise shear bands as well. The former is a function of the bulk characteristics of the inner compact band, especially the resistance to the shear flows. The latter markedly varies with the microstructure of particle packing, especially the structural order. In the highly ordered extreme, the particle ring with global crystalline structure exhibits six groups of shear bands, probably giving rise to around six fragments. By contrast, the grouping of shear bands in the amorphous packing is far from definite, suggesting an increased number of much smaller fragments to be generated. The dual jetting structure would degenerate into a single jetting pattern if the inner compact band manages to entrain all the spall particles before the shear failure occurs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xue, Kun; Liu, Jiaqi; Bai, Chunhua] Beijing Inst Technol, State Key Lab Explos Sci & Technol, Beijing 100081, Peoples R China.
   [Feng, Chun] Chinese Acad Sci, Inst Mech, Key Lab Mech Fluid Solid Coupling Syst, Beijing 100190, Peoples R China.
   [Gan, Yixiang] Univ Sydney, Sch Civil Engn, Sydney, NSW, Australia.
RP Xue, K (reprint author), Beijing Inst Technol, State Key Lab Explos Sci & Technol, Beijing 100081, Peoples R China.
EM xuekun@bit.edu.cn
RI Gan, Yixiang/B-1551-2008
OI Gan, Yixiang/0000-0002-9621-0277
CR ALSINY A, 1992, GEOTECHNIQUE, V42, P395, DOI 10.1680/geot.1992.42.3.395
   Bai CH, 2018, SHOCK WAVES, V28, P599, DOI 10.1007/s00193-017-0795-8
   Balakrishnan K, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4873175
   Bohloli B, 2006, J PETROL SCI ENG, V53, P1, DOI 10.1016/j.petrol.2006.01.009
   Boisson J, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3694804
   Borg JP, 2009, AIP CONF PROC, V1195, P1331
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Desmond KW, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.022204
   Dobratz B. M., 1985, LLNL EXPLOSIVES HDB
   Fan YB, 2016, GEOTECH GEOL ENG, V34, P425, DOI 10.1007/s10706-015-9954-9
   Feng C, 2014, J ROCK MECH GEOTECH, V6, P26, DOI 10.1016/j.jrmge.2013.12.001
   Frost DL, 2018, SHOCK WAVES, V28, P439, DOI 10.1007/s00193-018-0825-1
   Frost D. L, 2011, 23 INT C DYN EXPL RE
   Frost DL, 2017, AIP CONF PROC, V1793, DOI 10.1063/1.4971702
   Frost DL, 2017, AIP CONF PROC, V1793, DOI 10.1063/1.4971701
   Fu PC, 2011, INT J NUMER ANAL MET, V35, P1918, DOI 10.1002/nag.988
   Grady D. E, 2009, DYNAMIC FRAGMENTATIO, P1
   Gregoire Y, 2011, AIP C P, V1426, P1623
   Guo P, 2007, CAN GEOTECH J, V44, P579, DOI 10.1139/T07-010
   Guo Y, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4812386
   Hanifpour M, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.062202
   Huang JY, 2016, SCRIPTA MATER, V111, P114, DOI 10.1016/j.scriptamat.2015.08.028
   Huang YJ, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.031307
   KIEFFER SW, 1981, NATURE, V291, P568, DOI 10.1038/291568a0
   Loiseau J, 2018, SHOCK WAVES, V28, P473, DOI 10.1007/s00193-018-0822-4
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   MacMinn CW, 2015, PHYS REV X, V5, DOI 10.1103/PhysRevX.5.011020
   Marr BJ, 2018, AIP CONF PROC, V1979, DOI 10.1063/1.5044930
   Milne AM, 2014, SHOCK WAVES, V24, P501, DOI 10.1007/s00193-014-0511-x
   Milne A, 2010, SHOCK WAVES, V20, P41, DOI 10.1007/s00193-009-0235-5
   Milne AM, 2016, PROPELL EXPLOS PYROT, V41, P665, DOI 10.1002/prep.201600016
   Mo H, 2018, SHOCK WAVES, V28, P559, DOI 10.1007/s00193-017-0741-9
   Oda M., 1982, SOILS FOUND, V22, P96, DOI DOI 10.3208/SANDF1972.22.4_96
   Oda M., 1985, SOILS FOUND, V25, P85, DOI [DOI 10.3208/SANDF1972.25.3_85, 10.3208/sandf1972.25.3_85]
   Omidvar M, 2012, INT J IMPACT ENG, V49, P192, DOI 10.1016/j.ijimpeng.2012.03.004
   Osnes AN, 2018, SHOCK WAVES, V28, P451, DOI 10.1007/s00193-017-0778-9
   Ouellet F, 2017, AIP CONF PROC, V1793, DOI 10.1063/1.4971740
   Pontalier Q, 2018, SHOCK WAVES, V28, P489, DOI 10.1007/s00193-018-0821-5
   Price MA, 2015, COMPUT FLUIDS, V111, P76, DOI 10.1016/j.compfluid.2015.01.006
   Rigby SE, 2018, SHOCK WAVES, V28, P613, DOI 10.1007/s00193-017-0727-7
   Ripley RC, 2014, J PHYS CONF SER, V500, DOI 10.1088/1742-6596/500/15/152012
   Ripley R.C., 2011, AIP C P, P1615
   Ritzel DV, 2009, SHOCK WAVES, VOL 1, PROCEEDINGS, P305, DOI 10.1007/978-3-540-85168-4_48
   Schreck CF, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.011305
   Shi ZH, 2017, CHEM ENG SCI, V162, P1, DOI 10.1016/j.ces.2016.12.044
   Shih CJ, 1998, ACTA MATER, V46, P4037, DOI 10.1016/S1359-6454(98)00040-8
   STEINHARDT PJ, 1983, PHYS REV B, V28, P784, DOI 10.1103/PhysRevB.28.784
   Sun J, 2011, J FLUID MECH, V682, P590, DOI 10.1017/jfm.2011.251
   Vidyapati V, 2016, IND ENG CHEM RES, V55, P10178, DOI 10.1021/acs.iecr.6b01171
   Vogler TJ, 2007, INT J SOLIDS STRUCT, V44, P636, DOI 10.1016/j.ijsolstr.2006.05.001
   Wang LX, 2013, MATH PROBL ENG, DOI 10.1155/2013/618980
   Xu N, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061306
   Xu T, 2013, SHOCK WAVES, V23, P619, DOI 10.1007/s00193-013-0472-5
   Xue K, 2014, EUR PHYS J E, V37, DOI 10.1140/epje/i2014-14088-y
   Xue K, 2013, EUR PHYS J E, V36, DOI 10.1140/epje/i2013-13008-1
   Yang LT, 2016, ACTA GEOTECH, V11, P1111, DOI 10.1007/s11440-015-0423-7
   Yuan RF, 2017, INT J ROCK MECH MIN, V93, P54, DOI 10.1016/j.ijrmms.2017.01.010
   Zheng QJ, 2017, POWDER TECHNOL, V314, P480, DOI 10.1016/j.powtec.2016.09.070
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 59
TC 0
Z9 0
U1 5
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 250
EP 269
DI 10.1016/j.ces.2019.03.043
PG 20
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900022
OA Green Published
DA 2020-05-12
ER

PT J
AU Liu, LF
   Yuan, Y
   Deng, W
   Li, SX
AF Liu, Lufeng
   Yuan, Ye
   Deng, Wei
   Li, Shuixiang
TI Determining random packing density and equivalent packing size of
   superballs via binary mixtures with spheres
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Superball; Maximally dense random packing; Binary mixture; Equivalent
   packing size
ID RANDOM CLOSE PACKING; PARTICLE-SHAPE; POROSITY; DYNAMICS; CUBES
AB We propose a new approach to determining the random packing densities of superballs via binary mixtures with spheres. The main idea of the approach is to suppress order formations in non-spherical particle packings via the polydispersity of particle shapes, which avoids using order metrics. The packing density of superballs in a mixture can be segregated using a linear fitting method with the concept of equivalent packing size (or size ratio with unit spheres) which represents the effective size (or volume) of a non-spherical particle in a binary mixture with spheres. We systemically study the packing properties of binary mixtures consisting of spheres and superballs and obtain the equivalent packing sizes of superballs. Our results show that the equivalent packing size ratio always corresponds to the minimal packing density or specific volume (reciprocal of packing densities) variation, and is independent of the solid volume fraction. The specific volumes of mixtures with the equivalent packing size ratio are always the upper bound for all the solid volume fractions. The linear relationship between the specific volume and solid volume fraction is only observed in the mixtures with superballs of small surface shape parameters (shapes close to a sphere), which results from the highly disordered nature in the mixtures. Moreover, the ideal random packing densities of mono-sized superballs obtained via the linear fitting method are surprisingly close to those of the MDRPs (maximally dense random packings), further verifying that the MDRPs of non-spherical particles correspond to the ideal random packings whose degrees of order are at the same level with that of the random close packing of spheres. Our work leads to a better understanding towards the random and binary packings and sheds new light on the essence of the MDRP. Our work also guides the optimal particle size distributions of powders in chemical engineering process. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Lufeng; Yuan, Ye; Deng, Wei; Li, Shuixiang] Peking Univ, Coll Engn, Dept Mech & Engn Sci, Beijing 100871, Peoples R China.
RP Li, SX (reprint author), Peking Univ, Coll Engn, Dept Mech & Engn Sci, Beijing 100871, Peoples R China.
EM lsx@pku.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11272010, 11572004, U1630112]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 11272010, 11572004 and U1630112) and the
   High-performance Computing Platform of Peking University.
CR Audus DJ, 2015, SOFT MATTER, V11, P3360, DOI 10.1039/c4sm02869d
   Batten RD, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.061105
   Baule A, 2018, REV MOD PHYS, V90, DOI 10.1103/RevModPhys.90.015006
   BERRYMAN JG, 1983, PHYS REV A, V27, P1053, DOI 10.1103/PhysRevA.27.1053
   Chen DY, 2014, J PHYS CHEM B, V118, P7981, DOI 10.1021/jp5010133
   Damasceno PF, 2012, SCIENCE, V337, P453, DOI 10.1126/science.1220869
   Delaney GW, 2010, EPL-EUROPHYS LETT, V89, DOI 10.1209/0295-5075/89/34002
   Donev A, 2005, J COMPUT PHYS, V202, P737, DOI 10.1016/j.jcp.2004.08.014
   Donev A, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2775928
   Jiao Y, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.041304
   Jiao Y, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.041309
   Jiao Y, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.041309
   John BS, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2819091
   Li CX, 2018, POWDER TECHNOL, V333, P286, DOI 10.1016/j.powtec.2018.04.035
   Li SX, 2013, SOFT MATTER, V9, P9298, DOI 10.1039/c3sm51710a
   Lin JJ, 2018, POWDER TECHNOL, V335, P388, DOI 10.1016/j.powtec.2018.05.015
   Liu AJ, 2010, ANNU REV CONDEN MA P, V1, P347, DOI 10.1146/annurev-conmatphys-070909-104045
   Liu LF, 2018, J CHEM PHYS, V149, DOI 10.1063/1.5049562
   Liu LF, 2017, SOFT MATTER, V13, P748, DOI 10.1039/c6sm02065h
   Liu LF, 2016, PHYSICA A, V444, P870, DOI 10.1016/j.physa.2015.10.101
   LUBACHEVSKY BD, 1990, J STAT PHYS, V60, P561, DOI 10.1007/BF01025983
   Meng LY, 2016, POWDER TECHNOL, V292, P176, DOI 10.1016/j.powtec.2016.01.036
   Moran J, 2018, POWDER TECHNOL, V330, P67, DOI 10.1016/j.powtec.2018.02.008
   Ni R, 2012, SOFT MATTER, V8, P8826, DOI 10.1039/c2sm25813g
   O'Hern CS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.075507
   Parisi G, 2010, REV MOD PHYS, V82, P789, DOI 10.1103/RevModPhys.82.789
   Royer JR, 2015, SOFT MATTER, V11, P5656, DOI 10.1039/c5sm00729a
   Schreck CF, 2010, SOFT MATTER, V6, P2960, DOI 10.1039/c001085e
   Smith KC, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.042203
   Torquato S, 2018, J CHEM PHYS, V149, DOI 10.1063/1.5036657
   Torquato S, 2000, PHYS REV LETT, V84, P2064, DOI 10.1103/PhysRevLett.84.2064
   Torquato S, 2010, REV MOD PHYS, V82, P2633, DOI 10.1103/RevModPhys.82.2633
   Torquato S, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.041104
   Torquato S, 2009, NATURE, V460, P876, DOI 10.1038/nature08239
   VanderWerf K, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.012909
   Xu N, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061306
   Xu WX, 2018, SOFT MATTER, V14, DOI 10.1039/c8sm01488d
   Yu AB, 1996, IND ENG CHEM RES, V35, P3730, DOI 10.1021/ie950616a
   YU AB, 1993, POWDER TECHNOL, V74, P205, DOI 10.1016/0032-5910(93)85029-9
   Yu AB, 1997, POWDER TECHNOL, V92, P185, DOI 10.1016/S0032-5910(97)03219-1
   YU AB, 1993, IND ENG CHEM RES, V32, P2179, DOI 10.1021/ie00021a043
   YU AB, 1993, J AM CERAM SOC, V76, P2813, DOI 10.1111/j.1151-2916.1993.tb04021.x
   Yuan Y, 2018, PHYS REV E, V98, DOI 10.1103/PhysRevE.98.042903
   Zhao SW, 2017, POWDER TECHNOL, V310, P175, DOI 10.1016/j.powtec.2016.12.094
   Zhong WQ, 2016, POWDER TECHNOL, V302, P108, DOI 10.1016/j.powtec.2016.07.010
   Zou RP, 2011, CHEM ENG SCI, V66, P4711, DOI 10.1016/j.ces.2011.06.037
   Zou RP, 1996, POWDER TECHNOL, V88, P71, DOI 10.1016/0032-5910(96)03106-3
NR 47
TC 4
Z9 4
U1 3
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 270
EP 281
DI 10.1016/j.ces.2019.03.041
PG 12
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900023
DA 2020-05-12
ER

PT J
AU Kong, XJ
   Li, ZJ
   Cai, D
   Shen, BX
   Zhang, YK
AF Kong, Xiangjin
   Li, Zhijun
   Cai, Dong
   Shen, Boxi
   Zhang, Yanke
TI Numerical simulation of the particle filtration process inside porous
   walls using lattice Boltzmann method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Lattice Boltzmann method; Cellular automation probabilistic model;
   Porous walls; Particulate filter; Soot particle deposition; Soot
   particle distribution
ID PARTICULATE FILTERS; MICROSCOPIC VISUALIZATION; DEPOSITION; MODEL;
   REGENERATION; TRANSPORT; AUTOMATA; MOTION; DPF
AB A domain decomposition-based lattice Boltzmann-cell automation probabilistic model (DDLB-CA model) has been developed to investigate soot particle filtration process in wall-flow diesel particulate filters. In order to obtain useful information for optimization of the porous structure, non-virtual porous walls are considered. Nine different porous walls are generated by a self-developed reconstruction scheme based on the pore size distribution (PSD) and porosity. The DDLB-CA model is validated with the results of previous studies. A clear pressure gradient and a spatial inhomogeneous velocity distribution can be seen for each porous wall. For the porous wall with the smallest mean pore size and the largest porosity, a lower initial pressure gradient and a better initial homogeneous velocity distribution can be achieved. Particles tend to deposit at the front of the porous wall with a PSD of a smaller mean pore size. Besides, particles also have an obvious tendency of depositing on the surface of narrow porous channels. Particle capture probability is obviously affected by the PSD. Therefore, adjustment of the PSD is recommended for optimization of the particle distribution and filtration efficiency. The solid nodes composed of deposited soot particles appear on the surface of narrow porous channels first and then form dendritic structures. Finally, the dendrite structures construct a bridge and block the narrow porous channel. The distributions of solid nodes are affected obviously by the structure of porous media. The locations of solid nodes affect the distribution of pressure and the uniformity of velocity distribution. The subsequent particles are more inclined to deposit at the front of the porous wall and the particle deposition efficiency eta increases after the formation of solid nodes. For the porous wall with a PSD of a smaller mean pore size, the solid nodes in front of porous walls (x/L-w < 0) are more concentrated, which means the cake layer will form more easily. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kong, Xiangjin; Li, Zhijun; Cai, Dong; Shen, Boxi; Zhang, Yanke] Tianjin Univ, State Key Lab Engines, 92 Weijin Rd, Tianjin 300072, Peoples R China.
RP Li, ZJ (reprint author), Tianjin Univ, State Key Lab Engines, 92 Weijin Rd, Tianjin 300072, Peoples R China.
EM zhijunli@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51576140, 51276128]; Special Fund for Development
   of Small and Medium Enterprises [SQ2013ZOA100012]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 51576140, 51276128]; the Special Fund for
   Development of Small and Medium Enterprises [grant number
   SQ2013ZOA100012].
CR Adler J., 2017, ADV CERAM ARMOR BIOC, V608, P139, DOI [10.1002/9781119321682.ch15, DOI 10.1002/9781119321682.CH15]
   Afrouzi HH, 2015, COMPUT MATH APPL, V70, P1136, DOI 10.1016/j.camwa.2015.07.008
   Ansari V, 2015, COMPUT FLUIDS, V108, P170, DOI 10.1016/j.compfluid.2014.11.022
   Bensaid S, 2009, CHEM ENG J, V154, P211, DOI 10.1016/j.cej.2009.03.043
   Bollerhoff T, 2012, CATAL TODAY, V188, P24, DOI 10.1016/j.cattod.2011.12.017
   Breuer M, 2000, INT J HEAT FLUID FL, V21, P186, DOI 10.1016/S0142-727X(99)00081-8
   Chopard B, 2000, COMPUT PHYS COMMUN, V129, P167, DOI 10.1016/S0010-4655(00)00104-1
   CHOPARD B, 1994, INT J MOD PHYS C, V5, P47, DOI 10.1142/S0129183194000052
   Chopard B, 1999, FUTURE GENER COMP SY, V16, P249, DOI 10.1016/S0167-739X(99)00050-3
   Furuta Y., 2009, 2009010292 SAE, DOI [10.4271/2009-01-0292, DOI 10.4271/2009-01-0292]
   Giesche H, 2006, PART PART SYST CHAR, V23, P9, DOI 10.1002/ppsc.200601009
   Gong J, 2018, CHEM ENG J, V338, P15, DOI 10.1016/j.cej.2018.01.006
   Gong J, 2015, ENVIRON SCI TECHNOL, V49, P4963, DOI 10.1021/acs.est.5b00329
   Guan B, 2015, J ENVIRON MANAGE, V154, P225, DOI 10.1016/j.jenvman.2015.02.027
   Guo Z. L., 2001, CHINESE J COMPUT PHY, V18, P184, DOI [10.19596/j.cnki.1001-246x.2001.02.018, DOI 10.19596/J.CNKI.1001-246X.2001.02.018]
   Guo ZL, 2008, J COMPUT PHYS, V227, P4955, DOI 10.1016/j.jcp.2008.01.024
   Guo ZL, 2000, J COMPUT PHYS, V165, P288, DOI 10.1006/jcph.2000.6616
   Guo ZL, 2002, CHINESE PHYS, V11, P366, DOI 10.1088/1009-1963/11/4/310
   Hanamura K, 2015, 2015011018 SAE, DOI [10.4271/2015-01-1018, DOI 10.4271/2015-01-1018]
   Hayashi H, 2008, COMPUT MATH APPL, V55, P1450, DOI 10.1016/j.camwa.2007.08.012
   He XY, 1997, PHYS REV E, V56, P6811, DOI 10.1103/PhysRevE.56.6811
   Iwasaki S, 2011, SAE INT J ENGINES, V4, P527, DOI 10.4271/2011-01-0603
   Jafari S, 2010, J AEROSOL SCI, V41, P198, DOI 10.1016/j.jaerosci.2009.10.005
   Torregrosa AJ, 2017, ENERGY, V119, P887, DOI 10.1016/j.energy.2016.11.051
   Karin P, 2009, SAE INT J FUELS LUBR, V2, P661, DOI 10.4271/2009-01-1476
   Koci P, 2019, CATAL TODAY, V320, P165, DOI 10.1016/j.cattod.2017.12.025
   Kong H, 2019, CATAL TODAY, V332, P89, DOI 10.1016/j.cattod.2018.07.022
   Kong X. J., 2018, 2018010955 SAE, DOI [10.4271/2018-01-0955, DOI 10.4271/2018-01-0955]
   Konstandopoulos A. G., 2000, 2000011016 SAE, DOI [10.4271/2000-01-1016, DOI 10.4271/2000-01-1016]
   Konstandopoulos A.G., 2003, 2003010846 SAE, DOI [10.4271/2003-01-0846, DOI 10.4271/2003-01-0846]
   Liu YQ, 2009, J AEROSOL SCI, V40, P307, DOI 10.1016/j.jaerosci.2008.12.001
   Masselot A, 1998, EUROPHYS LETT, V42, P259, DOI 10.1209/epl/i1998-00239-3
   Meng ZW, 2016, J COMBUST, DOI 10.1155/2016/9612856
   Merkel G. A., 2001, SAE TECH PAP SER, DOI [10.4271/2001-01-0193, DOI 10.4271/2001-01-0193]
   Mey D., 2009, 2009010288 SAE, DOI [10.4271/2009-01-0288, DOI 10.4271/2009-01-0288]
   Mey D., 2010, 2010010539 SAE, DOI [10.4271/2010-01-0539, DOI 10.4271/2010-01-0539]
   Mizuno Y., 2008, 2008010618 SAE, DOI [10.4271/2008-01-0618, DOI 10.4271/2008-01-0618]
   Mohankumar S, 2017, RENEW SUST ENERG REV, V80, P1227, DOI 10.1016/j.rser.2017.05.133
   Nakamura K., 2012, 2012010842 SAE, DOI [10.4271/2012-01-0842, DOI 10.4271/2012-01-0842]
   Ohara E., 2007, 2007010921 SAE, DOI [10.4271/2007-01-0921, DOI 10.4271/2007-01-0921]
   Orihuela MP, 2018, APPL THERM ENG, V131, P41, DOI 10.1016/j.applthermaleng.2017.11.149
   QIAN YH, 1992, EUROPHYS LETT, V17, P479, DOI 10.1209/0295-5075/17/6/001
   Serrano JR, 2016, ENERGY, V112, P883, DOI 10.1016/j.energy.2016.06.121
   Rutland C. J., 2014, ASME 2014 INT COMB E, DOI [10.1115/ICEF2014-5590, DOI 10.1115/ICEF2014-5590]
   Sanui R, 2016, SAE INT J FUELS LUBR, V9, P725, DOI 10.4271/2016-01-9079
   Sbrizzai F, 2005, CHEM ENG SCI, V60, P6551, DOI 10.1016/j.ces.2005.05.038
   Sugino T, 2017, SAE INT J FUELS LUBR, V10, P593, DOI 10.4271/2017-01-0925
   Talebizadeh P, 2016, J NANOPART RES, V18, DOI 10.1007/s11051-016-3667-8
   Tong ZX, 2017, APPL ENERG, V185, P2181, DOI 10.1016/j.apenergy.2016.01.043
   Wang HM, 2012, POWDER TECHNOL, V227, P111, DOI 10.1016/j.powtec.2011.12.057
   Yamamoto K, 2018, COMPUTATION, V6, DOI 10.3390/computation6040052
   Yamamoto K, 2016, COMPUTATION, V4, DOI 10.3390/computation4040046
   Yamamoto K, 2013, INT J ENGINE RES, V14, P333, DOI 10.1177/1468087412456687
   Yu MT, 2013, CHEM ENG J, V226, P68, DOI 10.1016/j.cej.2013.04.026
NR 54
TC 1
Z9 1
U1 13
U2 38
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 282
EP 299
DI 10.1016/j.ces.2019.03.040
PG 18
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900024
DA 2020-05-12
ER

PT J
AU Liu, QL
   Zhang, L
   Liu, LL
   Du, J
   Meng, QW
   Gani, R
AF Liu, Qilei
   Zhang, Lei
   Liu, Linlin
   Du, Jian
   Meng, Qingwei
   Gani, Rafiqul
TI Computer-aided reaction solvent design based on transition state theory
   and COSMO-SAC
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computer-aided molecular design; Reaction solvent; COSMO-SAC; Solvation
   effect; Decomposition-based algorithm
ID DIELS-ALDER REACTION; IONIC LIQUID DESIGN; MOLECULAR/MIXTURE DESIGN;
   VAPOR-LIQUID; PREDICTION; MODEL; SELECTION; SUBSTITUTION; METHODOLOGY;
   PERFORMANCE
AB Solvents have been widely used in chemical manufacturing processes. When involved in liquid homogeneous-phase kinetic reactions, they can have significant impacts on the reaction product yield. In this paper, an optimization-based framework is developed for reaction solvent design. The framework first identifies a reaction kinetic model using a hybrid method consisting of three steps. In step one, a rigorous thermodynamic derivation based on CTST (Conventional Transition State Theory) is performed to formulate a primary reaction kinetic model. In step two, a knowledge-based method is used to select additional solvent properties as supplementary descriptors to account for quantitative correction to the model and thereby improving the prediction accuracy. In step three, model identification is performed to obtain the best regressed reaction kinetic model. This hybrid modelling method is tested through two case studies, namely Diels-Alder and Menschutkin reactions, and an impressive consistency of the results is observed when the infinite dilution activity coefficients (calculated by COSMO-SAC model), hydrogen-bond donor, hydrogen-bond acceptor and solvent surface tension are selected as descriptors in the final reaction kinetic model. The GC-COSMO and GC (Group Contribution) methods are combined for the prediction of these descriptors. Finally, the Computer-Aided Molecular Design (CAMD) technique is integrated with the derived kinetic model for reaction solvent design by formulating and solving a Mixed-Integer Non-Linear Programming (MINLP) model. A decomposition-based solution algorithm is employed to manage the complexity involved with the nonlinear COSMO-SAC equations. Promising reaction solvents are identified and compared with those reported by others, indicating wide applicability and high accuracy of the developed optimization-based framework. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Qilei; Zhang, Lei; Liu, Linlin; Du, Jian] Dalian Univ Technol, Sch Chem Engn, Inst Chem Proc Syst Engn, Dalian 116024, Peoples R China.
   [Meng, Qingwei] Dalian Univ Technol, Sch Pharmaceut Sci & Technol, State Key Lab Fine Chem, Dalian 116024, Peoples R China.
   [Gani, Rafiqul] PSE SPEED, Skyttemosen 6, DK-3450 Allerod, Denmark.
   [Gani, Rafiqul] Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
RP Zhang, L (reprint author), Dalian Univ Technol, Sch Chem Engn, Inst Chem Proc Syst Engn, Dalian 116024, Peoples R China.
EM keleiz@dlut.edu.cn
RI Zhang, Lei/E-6294-2019; Zhang, Lei/W-4446-2019; Gani,
   Rafiqul/A-4865-2011
OI Zhang, Lei/0000-0002-7519-2858; Zhang, Lei/0000-0002-7519-2858; Gani,
   Rafiqul/0000-0002-6719-9283
FU NSFCNational Natural Science Foundation of China [21808025]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities [DUT17RC(3)008]
FX The authors are grateful for the financial support of NSFC (21808025)
   and "the Fundamental Research Funds for the Central Universities
   DUT17RC(3)008". The authors are also grateful for the help of Dr. Jun
   Liu and Dr. Nick Austin at SCM company. Most importantly, the author
   Qilei Liu appreciates his fiancee Yujing Zhao for her five-year company.
CR ABRAHAM MH, 1988, J CHEM SOC PERK T 2, P1717, DOI 10.1039/p29880001717
   ABRAHAM MH, 1987, J CHEM SOC PERK T 2, P913, DOI 10.1039/p29870000913
   Achenie L. E. K., 2003, COMPUTER AIDED MOL D
   Austin N.D., 2017, THESIS
   Austin ND, 2018, AICHE J, V64, P104, DOI 10.1002/aic.15871
   Austin ND, 2017, CHEM ENG SCI, V159, P93, DOI 10.1016/j.ces.2016.05.025
   Bini R, 2008, ORG BIOMOL CHEM, V6, P2522, DOI 10.1039/b802194e
   BLANKENBURG B, 1974, J PRAKT CHEM, V316, P804, DOI 10.1002/prac.19743160513
   BRIGNOLE EA, 1986, FLUID PHASE EQUILIBR, V29, P125, DOI 10.1016/0378-3812(86)85016-6
   Bussieck MR, 2001, SBB NEW SOLVER MIXED
   Carlson R, 2005, DATA HANDL SCI TECHN, V24, P1
   CATIVIELA C, 1994, J CHEM SOC PERK T 2, P847, DOI 10.1039/p29940000847
   Cativiela C, 1996, CHEM SOC REV, V25, P209, DOI 10.1039/cs9962500209
   Chen WL, 2016, IND ENG CHEM RES, V55, P9312, DOI 10.1021/acs.iecr.6b02345
   CONSTANTINOU L, 1995, FLUID PHASE EQUILIBR, V103, P11, DOI 10.1016/0378-3812(94)02593-P
   Conte E, 2011, AICHE J, V57, P2431, DOI 10.1002/aic.12458
   Cramer CJ, 1999, CHEM REV, V99, P2161, DOI 10.1021/cr960149m
   Datta S, 2017, COMPUT CHEM ENG, V106, P690, DOI 10.1016/j.compchemeng.2017.02.022
   Evans M.G., 1935, PROG THEOR PHYS, V56, P1965
   Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604
   Ferrarini F, 2018, AICHE J
   Folic M, 2008, IND ENG CHEM RES, V47, P5190, DOI 10.1021/ie0714549
   Folic M, 2007, AICHE J, V53, P1240, DOI 10.1002/aic.11146
   FREDENSLUND AA, 1977, VAPOR LIQUID EQUILIB
   Gani R, 2005, COMPUT CHEM ENG, V29, P1661, DOI 10.1016/j.compchemeng.2005.02.021
   GANI R, 1991, AICHE J, V37, P1318, DOI 10.1002/aic.690370905
   Gani R, 2008, COMPUT CHEM ENG, V32, P2420, DOI 10.1016/j.compchemeng.2008.01.006
   Giovanoglou A, 2003, AICHE J, V49, P3095, DOI 10.1002/aic.690491211
   GMEHLING J, 1993, IND ENG CHEM RES, V32, P178, DOI 10.1021/ie00013a024
   Grossmann IE, 2002, GAMS DICOPT DISCRETE, P0885
   Harel O, 2009, J APPL STAT, V36, P1109, DOI 10.1080/02664760802553000
   Harper PM, 2000, COMPUT CHEM ENG, V24, P677, DOI 10.1016/S0098-1354(00)00410-5
   Hsieh CM, 2010, FLUID PHASE EQUILIBR, V297, P90, DOI 10.1016/j.fluid.2010.06.011
   Hukkerikar AS, 2012, FLUID PHASE EQUILIBR, V321, P25, DOI 10.1016/j.fluid.2012.02.010
   Jimenez-Gonzalez C, 2011, ORG PROCESS RES DEV, V15, P900, DOI 10.1021/op100327d
   KAMLET MJ, 1976, J AM CHEM SOC, V98, P377, DOI 10.1021/ja00418a009
   Karunanithi AT, 2005, IND ENG CHEM RES, V44, P4785, DOI 10.1021/ie049328h
   KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Klamt A., 2005, COSMO RS QUANTUM CHE
   Kode SRL, 2016, DRAG SOFTW MOL DESCR
   KOENHEN DM, 1975, J APPL POLYM SCI, V19, P1163, DOI 10.1002/app.1975.070190423
   LAIDLER KJ, 1988, J CHEM EDUC, V65, P540, DOI 10.1021/ed065p540
   Lapkin AA, 2010, GREEN CHEM, V12, P241, DOI 10.1039/b922001a
   LASSAU C, 1968, B SOC CHIM FR, P2678
   Lee S, 2000, COMPUT CHEM ENG, V24, P2125, DOI 10.1016/S0098-1354(00)00581-0
   Lennard-Jones JE, 1940, T FARADAY SOC, V36, P1156, DOI 10.1039/tf9403601156
   Lin ST, 2004, J PHYS CHEM A, V108, P7429, DOI 10.1021/jp048813n
   Lin ST, 2002, IND ENG CHEM RES, V41, P899, DOI 10.1021/ie001047w
   Marenich AV, 2007, J CHEM THEORY COMPUT, V3, P2011, DOI 10.1021/ct7001418
   Marenich AV, 2009, J PHYS CHEM B, V113, P6378, DOI 10.1021/jp810292n
   Marenich AV, 2009, J PHYS CHEM B, V113, P4538, DOI 10.1021/jp809094y
   Marrero J, 2001, FLUID PHASE EQUILIBR, V183, P183, DOI 10.1016/S0378-3812(01)00431-9
   Misener R, 2014, J GLOBAL OPTIM, V59, P503, DOI 10.1007/s10898-014-0166-2
   Mu TC, 2007, AICHE J, V53, P3231, DOI 10.1002/aic.11338
   Mullins E, 2006, IND ENG CHEM RES, V45, P4389, DOI 10.1021/ie060370h
   Nobuoka K, 2013, RSC ADV, V3, P19632, DOI 10.1039/c3ra43523g
   OCHTERSKI JW, 2000, THERMOCHEMISTRY GAUS
   ODELE O, 1993, FLUID PHASE EQUILIBR, V82, P47, DOI 10.1016/0378-3812(93)87127-M
   Ortega J, 2008, IND ENG CHEM RES, V47, P3253, DOI 10.1021/ie071467m
   Otto R, 2012, NAT CHEM, V4, P534, DOI [10.1038/nchem.1362, 10.1038/NCHEM.1362]
   Palm V., 1993, ORG REACT TARTU, V28, P125
   Reichardt C., 1988, SOLVENTS SOLVENT EFF
   Reichardt C., 2003, SOLVENTS SOLVENT EFF
   RIHANI DN, 1965, IND ENG CHEM FUND, V4, P17, DOI 10.1021/i160013a003
   Struebing H, 2011, THESIS
   Struebing H, 2013, NAT CHEM, V5, P952, DOI [10.1038/NCHEM.1755, 10.1038/nchem.1755]
   SUTTER JM, 1993, MICROCHEM J, V47, P60, DOI 10.1006/mchj.1993.1012
   TAFT RW, 1985, J SOLUTION CHEM, V14, P153, DOI 10.1007/BF00647061
   Tawarmalani M, 2005, MATH PROGRAM, V103, P225, DOI 10.1007/s10107-005-0581-8
   te Velde G, 2001, J COMPUT CHEM, V22, P931, DOI 10.1002/jcc.1056
   Tomasi J, 1999, J MOL STRUC-THEOCHEM, V464, P211, DOI 10.1016/S0166-1280(98)00553-3
   Wang S, 2007, IND ENG CHEM RES, V46, P7275, DOI 10.1021/ie070465z
   Wittig R, 2003, IND ENG CHEM RES, V42, P183, DOI 10.1021/ie020506l
   Zhang JA, 2017, CHEM ENG SCI, V162, P364, DOI 10.1016/j.ces.2016.12.023
   Zhang JA, 2017, CHEM ENG SCI, V162, P355, DOI 10.1016/j.ces.2016.12.022
   Zhang L, 2016, ANNU REV CHEM BIOMOL, V7, P557, DOI 10.1146/annurev-chembioeng-080615-034439
   Zhang L, 2015, COMPUT CHEM ENG, V78, P79, DOI 10.1016/j.compchemeng.2015.04.022
   Zhou T, 2015, CHEM ENG SCI, V137, P613, DOI 10.1016/j.ces.2015.07.010
   Zhou T, 2014, CHEM ENG SCI, V115, P177, DOI 10.1016/j.ces.2013.11.020
NR 80
TC 3
Z9 3
U1 13
U2 1339
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 300
EP 317
DI 10.1016/j.ces.2019.03.023
PG 18
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900025
DA 2020-05-12
ER

PT J
AU Muilwijk, C
   Van den Akker, HEA
AF Muilwijk, Corne
   Van den Akker, Harry E. A.
TI Experimental investigation on the bubble formation from needles with and
   without liquid co-flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble formation; Liquid co-flow; Image analysis; Acoustic signal;
   Orifice constant; Period-2 bubbling
ID NUMERICAL SIMULATIONS; COHERENT STRUCTURES; SUBMERGED ORIFICES; GROWTH;
   DETACHMENT; DYNAMICS; COLUMN; VOLUME; QUIESCENT; BEHAVIOR
AB We report experiments on bubble formation from needles with and without liquid co-flow, carried out with needles in the range of 0.79 < d(n) < 2.06 mm, for gas flow rates up to 4.5 cm(3)/s per needle, and with liquid co-flow velocities up to 0.4 m/s. Bubble sizes and frequencies were obtained by means measuring an acoustic signal in the pressurized chamber upstream, which is validated by high-speed imaging analysis. Bubble contours, bubble growth curves and time return plots were obtained to analyse the bubble formation process. Different bubbling regimes are distinguished and a novel dimensionless pressure ratio is proposed to forecast the emergence of weeping and the transition from constant flow rate bubbling to constant chamber pressure bubbling. A single correlation for the non-dimensional bubble size with and without liquid co-flow was developed and validated with the experimental data obtained in the present study. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Muilwijk, Corne; Van den Akker, Harry E. A.] Univ Limerick, Bernal Inst, Limerick V94 T9PX, Ireland.
   [Van den Akker, Harry E. A.] Delft Univ Technol, Dept Chem Engn, Transport Phenomena Lab, Van der Maasweg 9, NL-2629 HZ Delft, Netherlands.
RP Muilwijk, C (reprint author), Univ Limerick, Bernal Inst, Limerick V94 T9PX, Ireland.
EM Corne.Muilwijk@ul.ie; Harry.VanDenAkker@ul.ie
OI Muilwijk, Corne/0000-0002-8750-9218
FU Bernal Project at the University of Limerick
FX This research was made possible through a start-up fund in the context
   of the Bernal Project at the University of Limerick. We acknowledge
   Niall Gogging BEng. for carrying out some of the experiments.
CR Abbassi W, 2017, EUR J MECH B-FLUID, V65, P284, DOI 10.1016/j.euromechflu.2017.04.001
   AKITA K, 1974, IND ENG CHEM PROC DD, V13, P84, DOI 10.1021/i260049a016
   Albadawi A, 2013, CHEM ENG SCI, V90, P77, DOI 10.1016/j.ces.2012.12.004
   Badam VK, 2007, CAN J CHEM ENG, V85, P257
   BHAVARAJU SM, 1978, AICHE J, V24, P454, DOI 10.1002/aic.690240310
   Buwa VV, 2007, CHEM ENG SCI, V62, P7119, DOI 10.1016/j.ces.2007.08.061
   Cano-Lozano JC, 2017, INT J MULTIPHAS FLOW, V97, P23, DOI 10.1016/j.ijmultiphaseflow.2017.07.016
   Chakraborty I, 2011, INT J HEAT MASS TRAN, V54, P4673, DOI 10.1016/j.ijheatmasstransfer.2011.06.010
   Chen WB, 2002, J CHEM ENG JPN, V35, P952, DOI 10.1252/jcej.35.952
   Chuang S. C., 1970, Transactions of the ASME. Series D, Journal of Basic Engineering, V92, P705
   Clift R., 1978, BUBBLES DROPS PARTIC
   Corchero G, 2012, INT J HEAT MASS TRAN, V55, P5044, DOI 10.1016/j.ijheatmasstransfer.2012.05.002
   Davidson J., 1960, T I CHEM ENGRS, V38, P335
   Di Bari S, 2013, EXP THERM FLUID SCI, V44, P124, DOI 10.1016/j.expthermflusci.2012.06.005
   Dietrich N, 2013, CHEM PAP, V67, P313, DOI 10.2478/s11696-012-0277-5
   GADDIS ES, 1986, CHEM ENG SCI, V41, P97, DOI 10.1016/0009-2509(86)85202-2
   Gerlach D, 2005, INT J HEAT MASS TRAN, V48, P425, DOI 10.1016/j.ijheatmasstransfer.2004.09.002
   Groen JS, 1996, CHEM ENG SCI, V51, P2511, DOI 10.1016/0009-2509(96)00110-8
   GROEN JS, 1995, CHEM ENG RES DES, V73, P615
   Harteveld WK, 2003, CAN J CHEM ENG, V81, P389
   Islam MT, 2015, CAN J CHEM ENG, V93, P1869, DOI 10.1002/cjce.22282
   Jamialahmadi M, 2001, CHEM ENG RES DES, V79, P523, DOI 10.1205/02638760152424299
   Kulkarni AA, 2005, IND ENG CHEM RES, V44, P5873, DOI 10.1021/ie049131p
   Kumar R., 1970, ADVANCES CHEMICAL EN, V8, P255, DOI DOI 10.1016/S0065-2377(08)60186-6
   Kupferberg K., 1969, T AM I CHEM ENG, V47, P241
   Kyriakides NK, 1997, CAN J CHEM ENG, V75, P684, DOI 10.1002/cjce.5450750405
   Lesage FJ, 2013, CHEM ENG SCI, V104, P742, DOI 10.1016/j.ces.2013.10.009
   Liu JT, 2018, APPL ACOUST, V130, P34, DOI 10.1016/j.apacoust.2017.09.005
   MIYAHARA T, 1984, J CHEM ENG JPN, V17, P597, DOI 10.1252/jcej.17.597
   Mosdorf R, 2003, CHEM ENG SCI, V58, P3837, DOI 10.1016/S0009-2509(03)00299-9
   Mudde RF, 2001, J FLUID MECH, V437, P203, DOI 10.1017/S0022112001004335
   OGUZ HN, 1993, J FLUID MECH, V257, P111, DOI 10.1017/S0022112093003015
   Ohta M, 2011, INT J MULTIPHAS FLOW, V37, P1059, DOI 10.1016/j.ijmultiphaseflow.2011.05.012
   Qu C, 2017, INT J HEAT MASS TRAN, V111, P17, DOI 10.1016/j.ijheatmasstransfer.2017.03.088
   Ruzicka MC, 2009, CHEM ENG RES DES, V87, P1349, DOI 10.1016/j.cherd.2009.03.001
   SADA E, 1978, CAN J CHEM ENG, V56, P669, DOI 10.1002/cjce.5450560603
   Simmons JA, 2015, EUR J MECH B-FLUID, V53, P24, DOI 10.1016/j.euromechflu.2015.01.003
   TAKAHASHI T, 1980, KAGAKU KOGAKU RONBUN, V6, P563, DOI 10.1252/kakoronbunshu.6.563
   TAKAHASHI T, 1976, [No title captured], V2, P138, DOI DOI 10.1252/KAKORONBUNSHU.2.138
   Terasaka K, 1999, CAN J CHEM ENG, V77, P458, DOI 10.1002/cjce.5450770304
   TRITTON DJ, 1993, PHYS FLUIDS A-FLUID, V5, P503, DOI 10.1063/1.858874
   Tufaile A, 2000, PHYS LETT A, V275, P211, DOI 10.1016/S0375-9601(00)00585-5
   Tufaile A, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056204
   Tufaile A, 2002, PHYSICA A, V308, P15, DOI 10.1016/S0378-4371(02)00571-X
   Tufaile A, 2001, PHYS LETT A, V287, P74, DOI 10.1016/S0375-9601(01)00460-1
   Tufaile A, 2000, PHYSICA A, V275, P336, DOI 10.1016/S0378-4371(99)00440-9
   Vafaei S, 2011, COLLOID SURFACE A, V384, P240, DOI 10.1016/j.colsurfa.2011.03.066
   Vafaei S, 2010, COLLOID SURFACE A, V369, P11, DOI 10.1016/j.colsurfa.2010.07.009
   Van den Akker H.E., 2015, ADV CHEM ENG, V46, P281, DOI DOI 10.1016/BS.ACHE.2015.10.010
   Van den Akker HEA, 1998, POWDER TECHNOL, V100, P123, DOI 10.1016/S0032-5910(98)00133-8
   Van den Akker HEA, 2006, ADV CHEM ENG, V31, P151
   Vazquez A, 2010, CHEM ENG SCI, V65, P4046, DOI 10.1016/j.ces.2010.03.041
   Vobecka L, 2012, EPJ WEB CONF, V25, DOI 10.1051/epjconf/20122502029
   Yang GQ, 2007, CHEM ENG SCI, V62, P2, DOI 10.1016/j.ces.2006.08.021
   Zhang J, 2017, CHEM ENG SCI, V168, P1, DOI 10.1016/j.ces.2017.04.012
   Zhang L, 2001, CHEM ENG SCI, V56, P5371, DOI 10.1016/S0009-2509(01)00241-X
   Zhang WX, 2000, CHEM ENG SCI, V55, P6243, DOI 10.1016/S0009-2509(00)00215-3
NR 57
TC 2
Z9 2
U1 4
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 318
EP 335
DI 10.1016/j.ces.2019.03.026
PG 18
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900026
DA 2020-05-12
ER

PT J
AU Shi, Y
   Ye, GH
   Yang, CF
   Tang, YQ
   Peng, C
   Qian, G
   Yuan, WK
   Duan, XZ
   Zhou, XG
AF Shi, Yao
   Ye, Guanghua
   Yang, Changfeng
   Tang, Yanqiang
   Peng, Chong
   Qian, Gang
   Yuan, Weikang
   Duan, Xuezhi
   Zhou, Xinggui
TI Pore engineering of hierarchically structured hydrodemetallization
   catalyst pellets in a fixed bed reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrodemetallization; Hierarchically structured catalyst; Pore
   engineering; Random spheres model; Optimization
ID HEAVY OIL; NANOPOROUS CATALYSTS; VANADIUM PORPHYRINS; DEACTIVATION;
   HYDRODEMETALATION; SIZE; OPTIMIZATION; DIFFUSION; KINETICS; DEPOSITION
AB Probing the effects of hydrodemetallization (HDM) catalyst pore structures is of great importance. In this work, the pore structures of hierarchically structured HDM catalyst pellets are optimized based on a Random Spheres Model at the reactor scale. Understanding of the metal deposition behaviors and the concentration profiles along the reactor indicates strong macropore-dependent catalyst pellet utilization and mesopore-dependent bed utilization, respectively. Subsequently, relationships of the effective diffusivity with the macropore structure and the concentration gradient along the reactor with the mesopore structure are proposed, and the effects of the macro-/mesopore diameters and porosity are studied to maximize the exit conversion and catalyst lifetime. Our optimized results not only are superior to previously optimized results, but also provide rational interpretations for previous experimental observations. The insights revealed here could shed new light on the rational pore engineering of the hierarchical structured HDM catalysts. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Yao; Ye, Guanghua; Yang, Changfeng; Tang, Yanqiang; Peng, Chong; Qian, Gang; Yuan, Weikang; Duan, Xuezhi; Zhou, Xinggui] East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
RP Duan, XZ (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM xzduan@ecust.edu.cn
RI QIAN, LIU/S-1353-2019
FU National Key R&D Program of China [2018YFB0604500]; Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21776077]; Shanghai Natural Science FoundationNatural Science
   Foundation of Shanghai [17ZR1407300, 17ZR1407500]; Program for Professor
   of Special Appointment (Eastern Scholar) at Shanghai Institutions of
   Higher Learning; Shanghai Rising-Star Program [17QA1401200]; Open
   Project of SKLOCE [SKL-Che-15C03]; State Key Laboratory of
   Organic-Inorganic Reaction Chemistry & Engineering Composites
   [oic-201801007]; 111 Project of the Ministry of Education of China
   [B08021]
FX This work was supported by the National Key R&D Program of China
   (2018YFB0604500), the Natural Science Foundation of China (21776077),
   the Shanghai Natural Science Foundation (17ZR1407300 and 17ZR1407500),
   the Program for Professor of Special Appointment (Eastern Scholar) at
   Shanghai Institutions of Higher Learning, the Shanghai Rising-Star
   Program (17QA1401200), the Open Project of SKLOCE (SKL-Che-15C03), the
   State Key Laboratory of Organic-Inorganic Reaction Chemistry &
   Engineering Composites (oic-201801007) and the 111 Project of the
   Ministry of Education of China (B08021). Also the authours would like to
   thank Prof. Marc-Olivier Coppens for the valuable suggestions in the
   modeling part of the research.
CR AGRAWAL R, 1984, IND ENG CHEM PROC DD, V23, P515, DOI 10.1021/i200026a018
   AGRAWAL R, 1984, IND ENG CHEM PROC DD, V23, P505, DOI 10.1021/i200026a017
   Ancheyta J, 2005, CATAL TODAY, V109, P3, DOI 10.1016/j.cattod.2005.08.025
   Ancheyta J, 2001, APPL CATAL A-GEN, V216, P195, DOI 10.1016/S0926-860X(01)00556-7
   Bartholomew C., 2000, KIRK OTHMER ENCY CHE, V5, P255
   Boualleg M., 2018, U.S. Patent, Patent No. 10125327
   Callejas MA, 2001, APPL CATAL A-GEN, V220, P93, DOI 10.1016/S0926-860X(01)00719-0
   Chang J, 1998, CATAL TODAY, V43, P233, DOI 10.1016/S0920-5861(98)00152-7
   Chen AC, 2013, CHEM ENG J, V231, P420, DOI 10.1016/j.cej.2013.07.035
   CYBULSKI A, 2006, STRUCTURED CATALYSTS
   Dong Y, 2016, CHEM ENG SCI, V142, P299, DOI 10.1016/j.ces.2015.12.004
   Froment G.F., 2010, CHEM REACTOR ANAL DE
   Furimsky E, 1999, CATAL TODAY, V52, P381, DOI 10.1016/S0920-5861(99)00096-6
   Furimsky E., 2007, CATALYSTS UPGRADING
   KEIL FJ, 1994, CHEM ENG SCI, V49, P4811
   KEIL FJ, 1993, HUNG J IND CHEM, V21, P277
   KHANG SJ, 1986, IND ENG CHEM PROC DD, V25, P437, DOI 10.1021/i200033a015
   KOBAYASHI S, 1987, IND ENG CHEM RES, V26, P2241, DOI 10.1021/ie00071a012
   Liu TT, 2016, CATAL TODAY, V271, P179, DOI 10.1016/j.callod.2015.07.045
   Marafi A, 2003, ENERG FUEL, V17, P661, DOI 10.1021/ef020177+
   Marchal C, 2010, ENERG FUEL, V24, P4290, DOI 10.1021/ef1000979
   MEARS DE, 1971, CHEM ENG SCI, V26, P1361, DOI 10.1016/0009-2509(71)80056-8
   Mederos FS, 2009, APPL CATAL A-GEN, V355, P1, DOI 10.1016/j.apcata.2008.11.018
   MELKOTE RR, 1989, CHEM ENG SCI, V44, P649, DOI 10.1016/0009-2509(89)85041-9
   OELDERIK JM, 1989, APPL CATAL, V47, P1, DOI 10.1016/S0166-9834(00)83258-3
   PEREIRA CJ, 1989, IND ENG CHEM RES, V28, P422, DOI 10.1021/ie00088a008
   RAJAGOPALAN K, 1979, IND ENG CHEM PROC DD, V18, P459, DOI 10.1021/i260071a019
   Rana MS, 2007, FUEL, V86, P1216, DOI 10.1016/j.fuel.2006.08.004
   Rana MS, 2004, CATAL TODAY, V98, P151, DOI 10.1016/j.cattod.2004.07.029
   Rao SM, 2012, CHEM ENG SCI, V83, P66, DOI 10.1016/j.ces.2011.11.044
   Rao SM, 2010, IND ENG CHEM RES, V49, P11087, DOI 10.1021/ie1009487
   Rieckmann C, 1997, HUNG J IND CHEM, V25, P137
   Rodriguez E, 2018, FUEL, V225, P118, DOI 10.1016/j.fuel.2018.02.085
   Seader J., 2006, SEPARATION PROCESS P
   Semeykina VS, 2016, IND ENG CHEM RES, V55, P3535, DOI 10.1021/acs.iecr.5b04730
   SHIMURA M, 1986, IND ENG CHEM FUND, V25, P330, DOI 10.1021/i100023a005
   SMITH BJ, 1991, J CATAL, V132, P21, DOI 10.1016/0021-9517(91)90244-X
   SMITH BJ, 1991, J CATAL, V132, P41, DOI 10.1016/0021-9517(91)90245-Y
   SMITH BJ, 1991, J CATAL, V132, P1, DOI 10.1016/0021-9517(91)90243-W
   Solsvik J, 2011, CHEM ENG SCI, V66, P1986, DOI 10.1016/j.ces.2011.01.060
   Spry J. C., 1975, 68 AICHE ANN M LOS A
   Toulhoat H, 2005, CATAL TODAY, V109, P135, DOI 10.1016/j.cattod.2005.08.023
   TOULHOAT H., 1990, CATAL TODAY, V7, P531
   Verstraete JJ, 2007, CHEM ENG SCI, V62, P5402, DOI 10.1016/j.ces.2007.03.020
   Wang G, 2008, IND ENG CHEM RES, V47, P3847, DOI 10.1021/ie071550+
   Wang G, 2007, CHEM ENG SCI, V62, P5110, DOI 10.1016/j.ces.2007.01.046
   Wang J, 2007, CHEM COMMUN, P4653, DOI 10.1039/b708822a
NR 47
TC 3
Z9 3
U1 12
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 336
EP 346
DI 10.1016/j.ces.2019.03.049
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900027
DA 2020-05-12
ER

PT J
AU Raun, KV
   Thorhauge, M
   Hoj, M
   Jensen, AD
AF Raun, Kristian Viegaard
   Thorhauge, Max
   Hoj, Martin
   Jensen, Anker Degn
TI Modeling of molybdenum transport and pressure drop increase in fixed bed
   reactors used for selective oxidation of methanol to formaldehyde using
   iron molybdate catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methanol; Formaldehyde; Molybdenum oxide; Selective oxidation; Reactor
   modeling
ID SURFACE; DEACTIVATION; PHASE
AB A dynamic model was developed for a single reactor tube, in which methanol oxidation to formaldehyde over an iron molybdate/molybdenum oxide catalyst takes place simultaneously with transport of MoO3 from the catalyst through the reactor. A previously developed dynamic 1D mathematical model for a single ring-shaped cylindrical catalyst pellet, in which volatilization of MoO3 takes place, was implemented in the reactor model. Known axial profiles in a pilot scale reactor with respect to MeOH and H2O concentration and temperature were used as input to the model. MeOH forms volatile Mo-species with solid MoO3 in the catalyst pellets, which diffuses to the bulk gas phase and is transported through the reactor, leading to MoO3 depleted pellets. Volatilization of MoO3 from the pellets occur at the inlet of the reactor. As MeOH is oxidized down the reactor, the volatile Mo-species decomposes via the reverse reaction that formed them. Deposition of MoO3 downstream in the reactor decreases the void space between the catalyst pellets leading to increased pressure drop. The hydraulic diameter of the catalyst pellets and the porosity of the deposited MoO3 were fitted to experimental data obtained in a pilot plant unit containing a single reactor tube. Furthermore, the model was used to simulate a tube under industrial conditions for up to two years (feed composition 8.4% MeOH, 4% H2O, 10% O-2 in N-2, bed length = 100 cm and a temperature of 190-346 degrees C). Finally, two cases where catalyst pellets with no excess MoO3 or shaped as filled cylinders are used in the initial 21 cm of the catalyst bed were simulated. The simulations show that this significantly decreases the rate at which the pressure drop increases. This model is a first step towards a useful tool to predict MoO3 transport, pressure drop increase and estimation of process life time at varying reaction conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Raun, Kristian Viegaard; Hoj, Martin; Jensen, Anker Degn] Tech Univ Denmark, DTU Chem Engn, DK-2800 Lyngby, Denmark.
   [Thorhauge, Max] Haldor Topsoe Res Labs, DK-2800 Lyngby, Denmark.
RP Jensen, AD (reprint author), Tech Univ Denmark, DTU Chem Engn, DK-2800 Lyngby, Denmark.
EM aj@kt.dtu.dk
OI Jensen, Anker Degn/0000-0002-7341-4859; Hoj, Martin/0000-0002-8482-3359
FU Independent Research Fund Denmark [DFF - 4184-00336]
FX This work is a collaboration between the CHEC research center at The
   Department of Chemical and Biochemical Engineering at Technical
   University of Denmark (DTU) and Haldor Topsoe A/S. We thank the
   Independent Research Fund Denmark for the financial support (DFF -
   4184-00336).
CR Adkins H, 1931, J AM CHEM SOC, V53, P1512, DOI 10.1021/ja01355a050
   Andersson A, 2006, CATAL TODAY, V112, P40, DOI 10.1016/j.cattod.2005.11.052
   Bahmanpour AM, 2014, REV CHEM ENG, V30, P583, DOI 10.1515/revce-2014-0022
   BHATTACHARYYA SK, 1967, J CATAL, V8, P128, DOI 10.1016/0021-9517(67)90295-3
   Brookes C, 2014, J PHYS CHEM C, V118, P26155, DOI 10.1021/jp5081753
   Burriesci N., 1980, STUD SURF SCI CATAL, V6, P115
   Cheng WH, 1996, J CATAL, V158, P477, DOI 10.1006/jcat.1996.0047
   CHUNG JS, 1988, J CATAL, V114, P398, DOI 10.1016/0021-9517(88)90043-7
   Gunther R, 2012, ULLMANNS ENCY IND CH
   Ivanov KI, 2010, CATAL TODAY, V154, P250, DOI 10.1016/j.cattod.2010.03.051
   Li LX, 2011, TRANSPORT POROUS MED, V89, P35, DOI 10.1007/s11242-011-9757-2
   Ma Y. H, 1988, DEACTIVATION KINETIC, V142, P132
   Partopour B, 2019, CHEM ENG J, V377, DOI 10.1016/j.cej.2018.08.124
   POPOV BI, 1976, KINET CATAL+, V17, P322
   POPOV BI, 1981, REACT KINET CATAL L, V18, P101
   Raun KV, 2019, CHEM ENG J, V361, P1285, DOI 10.1016/j.cej.2018.12.142
   Raun KV, 2018, CATAL SCI TECHNOL, V8, DOI 10.1039/c8cy01109e
   Smith RL, 1998, J CATAL, V180, P270, DOI 10.1006/jcat.1998.2280
   Soares APV, 2005, CATAL REV, V47, P125, DOI 10.1081/CR-200049088
   Soderhjelm E, 2008, TOP CATAL, V50, P145, DOI 10.1007/s11244-008-9112-1
   Tatibouet JM, 1997, APPL CATAL A-GEN, V148, P213, DOI 10.1016/S0926-860X(96)00236-0
   Yeo BR, 2016, SURF SCI, V648, P163, DOI 10.1016/j.susc.2015.11.010
NR 22
TC 3
Z9 3
U1 4
U2 34
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 347
EP 356
DI 10.1016/j.ces.2019.03.020
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900028
DA 2020-05-12
ER

PT J
AU Zhang, X
   Zhang, L
   Fung, KY
   Ng, KM
AF Zhang, Xiang
   Zhang, Lei
   Fung, Ka Yip
   Ng, Ka Ming
TI Product design: Incorporating make-or-buy analysis and supplier
   selection
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Product design; Make-or-buy analysis; Supplier selection; Light duty
   liquid detergent; Controlled release granular herbicide
ID CHEMICAL-PRODUCT; MODEL; FRAMEWORK; DETERGENT; QUALITY
AB A new product design framework is presented with the simultaneous consideration of make-or-buy analysis and supplier selection. Consumer preferences are first identified. Product ingredients are classified into different types based on their functionalities. For each ingredient type, potential ingredient candidates are generated from material databases or predictions using computer-aided tools. Heuristics and models (e.g., statistical, empirical, and mechanistic) are used to screen the ingredients and to design a process to manufacture a product with the desired product quality. Then, product price and market demand are determined by using a pricing model. After this, make-or-buy decisions are made through heuristics and suppliers are selected to maximize the profit. Two case studies consisting of light duty liquid detergent and controlled release granular herbicide are provided to illustrate the framework. (C) 2019 Published by Elsevier Ltd.
C1 [Zhang, Xiang; Zhang, Lei; Fung, Ka Yip; Ng, Ka Ming] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Clear Water Bay, Hong Kong, Peoples R China.
   [Zhang, Lei] Dalian Univ Technol, Sch Chem Engn, Inst Proc Syst Engn, Dalian 116012, Peoples R China.
RP Ng, KM (reprint author), Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Clear Water Bay, Hong Kong, Peoples R China.
EM kekmng@ust.hk
RI Zhang, Lei/E-6294-2019; Zhang, Lei/W-4446-2019
OI Zhang, Lei/0000-0002-7519-2858; Zhang, Lei/0000-0002-7519-2858
CR Amorim P, 2016, EUR J OPER RES, V252, P801, DOI 10.1016/j.ejor.2016.02.005
   Bagajewicz MJ, 2007, AICHE J, V53, P3155, DOI 10.1002/aic.11332
   Baki G, 2015, INTRO COSMETIC FORMU
   Bernardo FP, 2015, AICHE J, V61, P802, DOI 10.1002/aic.14681
   Calfa BA, 2015, COMPUT CHEM ENG, V82, P330, DOI 10.1016/j.compchemeng.2015.07.015
   CHAN KY, 1988, J AM OIL CHEM SOC, V65, P1971, DOI 10.1007/BF02546020
   Chan YC, 2018, AICHE J, V64, P2462, DOI 10.1002/aic.16153
   Cheng YS, 2009, COMPUT CHEM ENG, V33, P1097, DOI 10.1016/j.compchemeng.2008.10.010
   Conte E, 2012, AICHE J, V58, P173, DOI 10.1002/aic.12582
   Conte E, 2011, AICHE J, V57, P2431, DOI 10.1002/aic.12458
   Costa R, 2006, AICHE J, V52, P1976, DOI 10.1002/aic.10880
   Dahmen M, 2017, ENERG FUEL, V31, P4096, DOI 10.1021/acs.energyfuels.7b00118
   Davis G.A., 1992, HOUSEHOLD CLEANERS E
   Edwards MF, 2006, CHEM ENG RES DES, V84, P255, DOI [10.1205/cherd05030, 10.1205/cherd.05030]
   ENNIS BJ, 1991, POWDER TECHNOL, V65, P257, DOI 10.1016/0032-5910(91)80189-P
   Fishburn A. G., 1965, INTRO PHARM FORMULAT
   Fung HK, 2007, COMPUT-AIDED CHEM EN, V23, P239, DOI 10.1016/S1570-7946(07)80011-3
   Fung KY, 2006, AICHE J, V52, P3189, DOI 10.1002/aic.10940
   Fung KY, 2016, COMPUT CHEM ENG, V91, P15, DOI 10.1016/j.compchemeng.2016.03.009
   Fung KY, 2003, AICHE J, V49, P1193, DOI 10.1002/aic.690490512
   Gambogi J., 2006, LIQUID DETERGENTS, P171
   Geyskens I, 2006, ACAD MANAGE J, V49, P519, DOI 10.5465/AMJ.2006.21794670
   Hill M, 2009, COMPUT CHEM ENG, V33, P947, DOI 10.1016/j.compchemeng.2008.11.013
   Kalakul S, 2017, COMPUT-AIDED CHEM EN, V40A, P979, DOI 10.1016/B978-0-444-63965-3.50165-3
   Knowles A, 2012, CHEM TECHNOLOGY AGRO
   Leach R.H., 1993, PRINTING INK MANUAL
   Li J, 2007, AICHE J, V53, P2841, DOI 10.1002/aic.11311
   Magdassi S., 2010, CHEM INKJET INKS
   Maravelias CT, 2009, COMPUT CHEM ENG, V33, P1919, DOI 10.1016/j.compchemeng.2009.06.007
   Mata VG, 2005, AICHE J, V51, P2834, DOI 10.1002/aic.10530
   Mattei M, 2013, COMPUT-AIDED CHEM EN, V32, P817
   Mortier RM, 2010, CHEMISTRY AND TECHNOLOGY OF LUBRICANTS, THIRD EDITION, P1, DOI 10.1023/b105569
   Moschuris SJ, 2008, IND MARKET MANAG, V37, P143, DOI 10.1016/j.indmarman.2006.11.002
   Muller B, 2011, COATINGS FORMULATION
   Omidbakhsh N, 2012, IND ENG CHEM RES, V51, P14925, DOI 10.1021/ie300644f
   Omidbakhsh N, 2010, IND ENG CHEM RES, V49, P204, DOI 10.1021/ie900196u
   Petrie EM, 2000, HDB ADHESIVES SEALAN
   Platts KW, 2002, INT J PROD ECON, V77, P247, DOI 10.1016/S0925-5273(00)00177-8
   Sahinidis NV, 2003, AICHE J, V49, P1761, DOI 10.1002/aic.690490714
   Seider W.D., 2017, PRODUCT PROCESS DESI
   Showell M., 2006, HDB DETERGENTS D
   Smith BV, 2010, COMPUT CHEM ENG, V34, P857, DOI 10.1016/j.compchemeng.2010.02.039
   Smith BV, 2009, IND ENG CHEM RES, V48, P8566, DOI 10.1021/ie900377e
   Sundaram A, 2001, AICHE J, V47, P1387, DOI 10.1002/aic.690470615
   Tam SK, 2016, AICHE J, V62, P2740, DOI 10.1002/aic.15271
   Teixeira MA, 2012, AICHE J, V58, P1939, DOI 10.1002/aic.12715
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u
   van de Water H., 2006, Journal of Purchasing and Supply Management, V12, P258, DOI 10.1016/j.pursup.2007.01.003
   Ware N.R., 2012, MANAG SCI LETT, V2, P1465, DOI DOI 10.5267/j.msl.2012.05.007
   Wibowo C, 2002, AICHE J, V48, P1212, DOI 10.1002/aic.690480609
   Wibowo C, 2001, AICHE J, V47, P2746, DOI 10.1002/aic.690471214
   Xiao J, 2009, AICHE J, V55, P132, DOI 10.1002/aic.11651
   Zhang L, 2016, ANNU REV CHEM BIOMOL, V7, P557, DOI 10.1146/annurev-chembioeng-080615-034439
   Zhang X, 2018, COMPUT CHEM ENG, V118, P118, DOI 10.1016/j.compchemeng.2018.06.026
NR 54
TC 1
Z9 1
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 357
EP 372
DI 10.1016/j.ces.2019.03.021
PG 16
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900029
DA 2020-05-12
ER

PT J
AU Aminian, A
   ZareNezhad, B
AF Aminian, Ali
   ZareNezhad, Bahman
TI Oil-detachment from the calcium carbonate surfaces via the actions of
   surfactant, nanoparticle and low salinity brine: An insight from
   molecular dynamic simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE EOR; Molecular simulation; Nanoparticle; Surfactant; Low salinity; Oil
ID SILICA NANOPARTICLES; WETTABILITY; WATER; TEMPERATURE; RECOVERY; AOT
AB The molecular dynamic simulation of oil detachment from the calcium carbonate solid surface employing nanoparticles, an ionic surfactant and low salinity brine at petroleum reservoir operating conditions is investigated in this work. All molecular, atomic and ionic force fields and fluids-rock surface interactions are rigorously simulated in the present work. The simulation results indicate that both nanoparticle sand surfactant are adsorbed at the interface between oil and aqueous brine solution such that a reduction of interfacial tension and an increase in total surface pressure lead to the oil detachment. Synergetic effect of nanoparticle, surfactant and ionic species on the alteration of rock surface wettability from oil-wet to water condition is also demonstrated by the proposed approach. The proposed molecular simulation is quite useful for assessment of the performance of complex injecting fluids regarding the oil detachment from calcium carbonate surface at reservoir operating conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Aminian, Ali; ZareNezhad, Bahman] Semnan Univ, Fac Chem Petr & Gas Engn, POB 35195-363, Semnan, Iran.
RP ZareNezhad, B (reprint author), Semnan Univ, Fac Chem Petr & Gas Engn, POB 35195-363, Semnan, Iran.
EM bzarenezhad@semnan.ac.ir
CR Abel S, 2004, J PHYS CHEM B, V108, P19458, DOI 10.1021/jp047138e
   AI-Khafaji A, 2017, ENERG FUEL, V31, P11892, DOI 10.1021/acs.energyfuels.7b02182
   Al-Anssari S, 2018, FUEL, V211, P405, DOI 10.1016/j.fuel.2017.08.111
   Alejandre J, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3124184
   Atalay S, 2014, J PHYS CHEM C, V118, P10927, DOI 10.1021/jp5023554
   Chen GX, 2011, LANGMUIR, V27, P5393, DOI 10.1021/la200251v
   Chen H, 2015, LANGMUIR, V31, P2407, DOI 10.1021/la504595g
   de Lara LS, 2017, J PHYS CHEM C, V121, P20266, DOI 10.1021/acs.jpcc.7b05130
   Fletcher PDI, 2015, LANGMUIR, V31, P3076, DOI 10.1021/la5049612
   Harikrishnan AR, 2017, LANGMUIR, V33, P12180, DOI 10.1021/acs.langmuir.7b02123
   Harikrishnan AR, 2017, J PHYS CHEM B, V121, P6081, DOI 10.1021/acs.jpcb.7b02723
   Hensel JK, 2017, P NATL ACAD SCI USA, V114, P13351, DOI 10.1073/pnas.1700099114
   Jang H, 2018, COLLOID SURFACE A, V554, P261, DOI 10.1016/j.colsurfa.2018.06.045
   Lu YD, 2017, ENERG FUEL, V31, P4989, DOI 10.1021/acs.energyfuels.7b00370
   Mahani H, 2015, ENERG FUEL, V29, P1352, DOI 10.1021/ef5023847
   Maurya NK, 2018, CHEM ENG RES DES, V132, P370, DOI 10.1016/j.cherd.2018.01.049
   Nwidee LN, 2017, J PETROL SCI ENG, V149, P782, DOI 10.1016/j.petrol.2016.11.017
   Okeke G, 2013, J NANOSCI NANOTECHNO, V13, P1047, DOI 10.1166/jnn.2013.6121
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Ranatunga RJKU, 2011, SOFT MATTER, V7, P6942, DOI 10.1039/c1sm05145h
   Ranka M, 2015, ACS APPL MATER INTER, V7, P19651, DOI 10.1021/acsami.5b04200
   Son H., 2017, EXPT ANAL EOR EFFECT
   Wang FC, 2013, SOFT MATTER, V9, P7974, DOI 10.1039/c3sm51425k
   Wu YN, 2017, J PETROL SCI ENG, V153, P283, DOI 10.1016/j.petrol.2017.04.015
   Xiao SJ, 2011, J PHYS CHEM C, V115, P20067, DOI 10.1021/jp202743v
   Zhao MW, 2018, J MOL LIQ, V261, P373, DOI 10.1016/j.molliq.2018.04.034
NR 26
TC 2
Z9 2
U1 17
U2 50
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 373
EP 382
DI 10.1016/j.ces.2019.03.031
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900030
DA 2020-05-12
ER

PT J
AU Yang, JC
   Guo, Y
   Buettner, KE
   Curtis, JS
AF Yang, Jiecheng
   Guo, Yu
   Buettner, Kevin E.
   Curtis, Jennifer S.
TI DEM investigation of shear flows of binary mixtures of non-spherical
   particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shear flow; Binary; Non-spherical; Discrete element method
ID KINETIC-THEORY; NON-EQUIPARTITION; SMOOTH; SIZE; SIMULATIONS; DENSE;
   SHAPE; BED
AB Discrete element method (DEM) simulations of shear flows of binary mixtures of large non-spherical glued-sphere particles and small spheres are conducted in order to investigate the effect of particle shape and solid volume fraction ratio on the behavior of binary granular flows. The shear stresses first decrease and then increase with total solid volume fraction. The shear stresses increase with the increasing solid volume fraction ratio of large particles. The orientation distributions of large particles show that, in dense regions, the binary system with a higher solid fraction ratio of small spheres exhibits a more uniform alignment in the shear flow direction for large particles. By incorporating the effective particle projected area in the plane perpendicular to the flow plane, the conventional kinetic theory for binary spherical systems is found capable of predicting the stresses for binary systems of non-spherical particles. Stresses for binary systems with various solid volume fraction ratios collapse into a single line by further incorporating the root-mean-cubed diameter, but this scaling is not adequate for dense flows. Comparing the shear stresses for different large particle shapes shows that shear stresses can be affected by the particle shape and particle aspect ratio, but the differences between different particle shapes and aspect ratios are minimized by increasing the solid volume fraction ratio of small spheres. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Jiecheng; Curtis, Jennifer S.] Univ Calif Davis, Dept Chem Engn, Davis, CA 95616 USA.
   [Guo, Yu] Zhejiang Univ, Key Lab Soft Machines & Smart Devices Zhejiang Pr, Dept Engn Mech, Hangzhou 310027, Zhejiang, Peoples R China.
   [Buettner, Kevin E.] Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA.
RP Yang, JC (reprint author), Univ Calif Davis, Dept Chem Engn, Davis, CA 95616 USA.
EM yjcyang@ucdavis.edu
RI Buettner, Kevin/Z-5120-2019
OI Buettner, Kevin/0000-0002-7253-666X
FU CFD Research Corporation via a NASA-STTR Phase II [NNX14CK11C]
FX . The authors are grateful for funding support from CFD Research
   Corporation via a NASA-STTR Phase II Contract NNX14CK11C.
CR Arnarson BO, 1998, PHYS FLUIDS, V10, P1324, DOI 10.1063/1.869658
   BAGSTER DF, 1985, POWDER TECHNOL, V43, P11, DOI 10.1016/0032-5910(85)80074-7
   Benyahia S, 2008, CHEM ENG SCI, V63, P5672, DOI 10.1016/j.ces.2008.08.016
   Chen YP, 2017, PHYSICA A, V469, P293, DOI 10.1016/j.physa.2016.11.104
   Cleary PW, 2002, APPL MATH MODEL, V26, P89, DOI 10.1016/S0307-904X(01)00050-6
   Clelland R, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031301
   FARRELL M, 1986, ACTA MECH, V63, P45, DOI 10.1007/BF01182539
   Galvin JE, 2005, J FLUID MECH, V528, P207, DOI 10.1017/S002211200400326X
   Garzo V, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.031303
   Garzo V, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.031304
   Gu YL, 2016, POWDER TECHNOL, V295, P322, DOI 10.1016/j.powtec.2016.03.035
   Guo Y, 2015, J FLUID MECH, V775, P24, DOI 10.1017/jfm.2015.289
   Guo Y, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4812386
   Guo Y, 2012, J FLUID MECH, V713, P1, DOI 10.1017/jfm.2012.423
   Guo Y, 2012, POWDER TECHNOL, V228, P193, DOI 10.1016/j.powtec.2012.05.015
   Guo Y, 2015, ANNU REV FLUID MECH, V47, P21, DOI 10.1146/annurev-fluid-010814-014644
   Hrenya CM, 2011, COMPUTATIONAL GAS-SOLIDS FLOWS AND REACTING SYSTEMS: THEORY, METHODS AND PRACTICE, P102, DOI 10.4018/978-1-61520-651-3.ch003
   Huilin L., 2003, J CHEM ENG SCI, V58, P1197, DOI DOI 10.1016/S0009-2509(02)00635-8
   JENKINS JT, 1989, PHYS FLUIDS A-FLUID, V1, P2050, DOI 10.1063/1.857479
   JENKINS JT, 1987, J APPL MECH-T ASME, V54, P27, DOI 10.1115/1.3172990
   LaMarche CQ, 2017, POWDER TECHNOL, V318, P68, DOI 10.1016/j.powtec.2017.05.008
   LaMarche CQ, 2015, CHEM ENG SCI, V138, P432, DOI 10.1016/j.ces.2015.08.030
   Liever PA, 2018, EARTH AND SPACE 2018: ENGINEERING FOR EXTREME ENVIRONMENTS, P39
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Rosato AD, 2002, CHEM ENG SCI, V57, P265, DOI 10.1016/S0009-2509(01)00380-3
   Tangri H, 2017, POWDER TECHNOL, V317, P72, DOI 10.1016/j.powtec.2017.03.058
   Ueda T, 2011, GRANUL MATTER, V13, P731, DOI 10.1007/s10035-011-0292-1
   Yang JC, 2015, CURR PHARM DESIGN, V21, P5915, DOI 10.2174/1381612821666151008150845
   Zhang Y, 2011, POWDER TECHNOL, V209, P147, DOI 10.1016/j.powtec.2011.01.019
NR 29
TC 2
Z9 2
U1 5
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 383
EP 391
DI 10.1016/j.ces.2019.03.027
PG 9
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900031
DA 2020-05-12
ER

PT J
AU Liu, W
   Bai, BF
AF Liu, Wen
   Bai, Bofeng
TI Transition from bubble flow to slug flow along the streamwise direction
   in a gas-liquid swirling flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Swirling flow; Gas column; Bubble; Decay; Slug flow
ID 2-PHASE FLOW; PRESSURE-DROP; DECAY; SEPARATION; SURFACE; SINGLE; TUBES;
   MODEL; CORE; FILM
AB Transition from bubbly to slug flow is a well-known phenomenon. In the channel with a swirler, a transition to slug flow at a lower gas superficial velocity than in the same channel without the swirler was observed in this work. The transition phenomenon from bubble flow to slug flow under the effect of swirl in a circular pipe was observed and investigated. Compared to the flow pattern (maintaining the bubble flow along a streamwise direction) in a non-swirling flow, we observe that bubble flow is transformed to a gas column downstream of the swirler, then broken up, and finally separated into gas slugs in the streamwise direction. The dynamic condition for the occurrence of a liquid bridge is proposed, then combined with a swirl decay model of a gas-liquid two-phase swirling flow; thus, the axial position for the transition from a gas column to a slug flow along the streamwise direction can be predicted. Whether slug flow always remains along the streamwise direction is closely related to its size. Under the effect of swirl, the void fraction is decreased and the pressure drop is increased compared with that in a non-swirling flow, and gradually approximates the values of a non-swirling flow along the streamwise direction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Wen] Changzhou Univ, Jiangsu Key Lab Oil Gas Storage & Transportat Tec, Changzhou 213000, Peoples R China.
   [Liu, Wen; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51706024, 51425603]
FX The financial support of the National Natural Science Foundation of
   China (No. 51706024 and 51425603) is appreciated.
CR Akhavan-Behabadi MA, 2009, INT J REFRIG, V32, P922, DOI 10.1016/j.ijrefrig.2008.11.004
   Ali A.J, 2003, SPE, P1
   Bluemink JJ, 2010, J FLUID MECH, V643, P1, DOI 10.1017/S0022112009991881
   Chen CI, 2007, COMMUN NONLINEAR SCI, V12, P760, DOI 10.1016/j.cnsns.2005.04.010
   Chen CI, 2004, INT J HEAT MASS TRAN, V47, P1937, DOI 10.1016/j.ijheatmasstransfer.2003.09.032
   Chen XT, 1997, CHEM ENG SCI, V52, P4373, DOI 10.1016/S0009-2509(97)80857-3
   Cloos FJ, 2017, J FLUID MECH, V811, P350, DOI 10.1017/jfm.2016.734
   Falcone G., 2003, 84504 SPE
   FRYER PJ, 1982, INT J MULTIPHAS FLOW, V8, P285, DOI 10.1016/0301-9322(82)90037-4
   Gomez L, 2004, J FLUID ENG-T ASME, V126, P943, DOI 10.1115/1.1849254
   Gomez L, 2004, J FLUID ENG-T ASME, V126, P935, DOI 10.1115/1.1849253
   Gupta R, 2008, CHEM ENG J, V144, P153, DOI 10.1016/j.cej.2008.01.010
   Hewitt G, 1970, ANNULAR 2 PHASE FLOW
   Hreiz R, 2014, INT J MULTIPHAS FLOW, V58, P15, DOI 10.1016/j.ijmultiphaseflow.2013.08.006
   Kanizawa FT, 2011, J BRAZ SOC MECH SCI, V33, P243, DOI 10.1590/S1678-58782011000500006
   Kanizawa FT, 2012, INT J MULTIPHAS FLOW, V47, P50, DOI 10.1016/j.ijmultiphaseflow.2012.07.003
   Kataoka H, 2009, J ENG GAS TURB POWER, V131, DOI 10.1115/1.3078701
   KREITH F, 1965, J FLUID MECH, V22, P257, DOI 10.1017/S0022112065000733
   Lim KY, 2017, APPL THERM ENG, V121, P652, DOI 10.1016/j.applthermaleng.2017.04.134
   Liu S., 2018, INT J MULTIPH FLOW
   Liu S, 2018, INT J MULTIPHAS FLOW, V107, P131, DOI 10.1016/j.ijmultiphaseflow.2018.05.025
   Liu W., 2014, P ASME FEDSM 2014 CH
   Liu W, 2015, EXP THERM FLUID SCI, V68, P187, DOI 10.1016/j.expthermflusci.2015.04.018
   Liu W, 2015, CASE STUD THERM ENG, V5, P134, DOI 10.1016/j.csite.2015.03.003
   Lucas GP, 2005, MEAS SCI TECHNOL, V16, P749, DOI 10.1088/0957-0233/16/3/018
   Magaud F, 2003, J FLUID ENG-T ASME, V125, P239, DOI 10.1115/1.1539870
   Manglik R.M., 2003, ADV HEAT TRANSFER, V36, P183
   Matsubayashi T, 2012, NUCL ENG DES, V249, P63, DOI 10.1016/j.nucengdes.2011.05.036
   Najafi AF, 2005, INT COMMUN HEAT MASS, V32, P627, DOI 10.1016/j.icheatmasstransfer.2004.10.014
   Rocha AD, 2015, INT J HEAT FLUID FL, V53, P81, DOI 10.1016/j.ijheatfluidflow.2015.02.003
   Shakutsui H., 2010, 7 INT C MULT FLOW IC
   SMITHBERG E, 1964, T ASME             C, V86, P39, DOI DOI 10.1016/0017-9310(84)90206-0
   WHALLEY PB, 1979, INT J MULTIPHAS FLOW, V5, P211, DOI 10.1016/0301-9322(79)90018-1
   Wu HY, 2000, J HEAT TRANS-T ASME, V122, P204, DOI 10.1115/1.521459
   Yin JL, 2018, ANN NUCL ENERGY, V114, P122, DOI 10.1016/j.anucene.2017.12.009
   Yin JL, 2017, NUCL ENG DES, V320, P133, DOI 10.1016/j.nucengdes.2017.05.015
   Zonta F, 2013, INT J MULTIPHAS FLOW, V56, P172, DOI 10.1016/j.ijmultiphaseflow.2013.06.002
NR 37
TC 4
Z9 4
U1 7
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 392
EP 402
DI 10.1016/j.ces.2019.03.058
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900032
DA 2020-05-12
ER

PT J
AU Wanderley, RR
   Yuan, Y
   Rochelle, GT
   Knuutila, HK
AF Wanderley, Ricardo R.
   Yuan, Ye
   Rochelle, Gary T.
   Knuutila, Hanna K.
TI CO2 solubility and mass transfer in water-lean solvents
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 absorption; Water lean solvents; Hybrid solvents; Mass transfer
   rates
ID CARBON-DIOXIDE; CHEMICAL-KINETICS; ORGANIC-SOLVENTS; ABSORPTION RATE;
   PLUS WATER; CAPTURE; PIPERAZINE; AMINES; MONOETHANOLAMINE; ALKANOLAMINES
AB Shifting from aqueous to water lean solvents has been evaluated as a mean for increasing the mass transfer rates in regular chemical solvents with amines. An array of amines (monoethanolamine, 2-methylpiperazine and N-methyl diethanolamine) and diluents (sulfolane, ethylene glycol, 1-methylimidazole, dimethyl sulfoxide, N-methyl-2-pyrrolidinone) has been analyzed. Addition of organic diluents seem to generally induce both a shift in chemical equilibrium and an increase in mass transfer rates for a fixed CO2 partial pressure, though not necessarily for a fixed CO2 loading. However, these relative advantages in terms of mass transfer rates decrease the more loaded the water lean solvent is. The equilibrium shift caused by organic diluents has been evaluated in terms of de-stabilization of the species in the solvent, which for monoethanolamine-based solvents can be easily related to a decrease in dielectric permittivity. However, this analysis indicates that such treatment is insufficient for other types of water-lean solvents, suggesting that different kinds of intermolecular interactions should also be considered in future studies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wanderley, Ricardo R.; Knuutila, Hanna K.] Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
   [Wanderley, Ricardo R.; Yuan, Ye; Rochelle, Gary T.] Univ Texas Austin, McKetta Dept Chem Engn, 200 E Dean Keeton St, Austin, TX 78712 USA.
RP Knuutila, HK (reprint author), Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
EM hanna.knuutila@ntnu.no
OI Knuutila, Hanna Katariina/0000-0003-2057-1743
FU Faculty of Natural Sciences of the Norwegian University of Science and
   Technology (NTNU); University of Texas at Austin; Research Council of
   Norway (RCN)Research Council of Norway [289346]
FX This research was funded by the Faculty of Natural Sciences of the
   Norwegian University of Science and Technology (NTNU), the University of
   Texas at Austin and the Research Council of Norway (RCN) under project
   number 289346.
CR Akhfash M, 2017, J CHEM ENG DATA, V62, P2578, DOI 10.1021/acs.jced.7b00072
   ALVAREZFUSTER C, 1981, CHEM ENG SCI, V36, P1513, DOI 10.1016/0009-2509(81)85112-3
   Bara, 2011, Patent No. [US8506914B2, 8506914]
   Bezuglaya E. P, 2009, VISN CHARK NACL U C, V870, P199
   Bhown AS, 2011, ENVIRON SCI TECHNOL, V45, P8624, DOI 10.1021/es104291d
   Bishnoi S, 2000, CHEM ENG SCI, V55, P5531, DOI 10.1016/S0009-2509(00)00182-2
   Chen X, 2013, IND ENG CHEM RES, V52, P4239, DOI 10.1021/ie3023737
   Du Y, 2016, CHEM ENG SCI, V155, P397, DOI 10.1016/j.ces.2016.08.017
   Dugas R. E., 2009, THESIS
   Hamborg ES, 2011, ENRGY PROCED, V4, P187, DOI 10.1016/j.egypro.2011.01.040
   Hamborg ES, 2010, FLUID PHASE EQUILIBR, V291, P32, DOI 10.1016/j.fluid.2009.12.007
   Hansen C. M., 2007, HANSEN SOLUBILITY PA
   IEA Bioenergy, 2016, PLANT LISTS IEA BIOE
   Jassim MS, 2006, IND ENG CHEM RES, V45, P2465, DOI 10.1021/ie050547s
   Kohl A. L., 1997, GAS PURIFICATION, P1187, DOI [10.1016/B978-088415220-0/50014-8, DOI 10.1016/B978-088415220-0/50014-8]
   Lail M, 2014, ENRGY PROCED, V63, P580, DOI 10.1016/j.egypro.2014.11.063
   Leites IL, 1998, ENERG CONVERS MANAGE, V39, P1665, DOI 10.1016/S0196-8904(98)00076-4
   Li L, 2013, ENRGY PROCED, V37, P370, DOI 10.1016/j.egypro.2013.05.122
   Liu F., 2016, P IEEE INT C COMM IC, P1, DOI DOI 10.1109/ICC.2016.7510739
   Maryott A. A, 1951, ADA278956 NAT BUR ST
   Plowas I, 2013, J CHEM ENG DATA, V58, P1741, DOI 10.1021/je400149j
   REYNOLDS JA, 1957, P PHYS SOC LOND B, V70, P769, DOI 10.1088/0370-1301/70/8/306
   RIVAS OR, 1979, AICHE J, V25, P975, DOI 10.1002/aic.690250608
   ROBERTS BE, 1988, CHEM ENG COMMUN, V72, P201, DOI 10.1080/00986448808940017
   Rochelle G, 2011, CHEM ENG J, V171, P725, DOI 10.1016/j.cej.2011.02.011
   Ryckebosch E, 2011, BIOMASS BIOENERG, V35, P1633, DOI 10.1016/j.biombioe.2011.02.033
   SADA E, 1986, CHEM ENG J BIOCH ENG, V33, P87, DOI 10.1016/0300-9467(86)80038-7
   SADA E, 1985, AICHE J, V31, P1297, DOI 10.1002/aic.690310808
   Semenova T. A, 1977, PURIFICATION TECHNOL, P236
   Shannon MS, 2011, IND ENG CHEM RES, V50, P8665, DOI 10.1021/ie200259h
   Song JH, 1997, J CHEM ENG DATA, V42, P143, DOI 10.1021/je960203w
   Svensson H, 2014, ENRGY PROCED, V63, P750, DOI 10.1016/j.egypro.2014.11.083
   Tilstam U, 2012, ORG PROCESS RES DEV, V16, P1273, DOI 10.1021/op300108w
   TUV, 2012, IEE10130 TUV I CHEM
   VERSTEEG GF, 1988, CHEM ENG SCI, V43, P573, DOI 10.1016/0009-2509(88)87017-9
   WOERTZ BB, 1972, CAN J CHEM ENG, V50, P425, DOI 10.1002/cjce.5450500321
   Wu SL, 2017, FUEL PROCESS TECHNOL, V161, P162, DOI 10.1016/j.fuproc.2017.03.022
   Yamamoto S, 2014, ENRGY PROCED, V63, P1963, DOI 10.1016/j.egypro.2014.11.209
   Yuan Y, 2018, THESIS
   Yuan Y, 2018, CHEM ENG SCI, V182, P56, DOI 10.1016/j.ces.2018.02.026
NR 40
TC 6
Z9 6
U1 7
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 403
EP 416
DI 10.1016/j.ces.2019.03.052
PG 14
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900033
DA 2020-05-12
ER

PT J
AU Lim, AE
   Lim, CY
   Lam, YC
   Lim, YH
AF Lim, An Eng
   Lim, Chun Yee
   Lam, Yee Cheong
   Lim, Yee Hwee
TI Effect of microchannel junction angle on two-phase liquid-gas Taylor
   flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidics; Multiphase flow; Liquid-gas flow; Taylor flow;
   Blocking-squeezing mechanism
ID SEGMENTED FLOW; DROP FORMATION; MICRODROPLETS; CHEMISTRY; REACTORS;
   BUBBLE; SIZE
AB Two-phase liquid-gas Taylor flow triggered by blocking-squeezing mechanism was studied with different junction angle theta microchannels, i.e. 20 degrees, 45 degrees, 90 degrees, 135 degrees and 160 degrees, at various liquid (ethanol) and gas (He) flow rates. We experimentally investigated the effects of flow rates and theta on the gas bubble V-B and liquid slug V-S volumes. A theoretical model was formulated for the quantitative predictions of bubble and slug sizes for different theta and flow rates. Good agreements were obtained between theoretical predictions and experimental observations. The unit cell volume V-U (V-B + V-S) decreased pronouncedly for the 20 degrees channel with decreasing liquid or increasing gas flow rate, due to the slight increase in V-B and large decrease in V-S. In comparison, for the 45 degrees, 90 degrees, 135 degrees and 160 degrees channels with increasing liquid or decreasing gas flow rate, V-U were less sensitive to fluid flow rate changes, due to the approximate cancellation between V-B decrease and V-S increase. For the 20 degrees and 45 degrees channels, it produced larger V-U, due to larger V-B and V-S, when compared to the 90 degrees channel. This is caused by the larger gas bubble throat width D-N at the junction when theta < 90 degrees. As for the 135 degrees and 160 degrees channels (theta > 90 degrees), D-N is approximately equal to the gas channel width, with V-B, V-S and V-U approximately the same as the 90 degrees channel. With theta >= 90 degrees (i.e. 90 degrees, 135 degrees and 160 degrees channels), as evident from the smaller V-U, higher gas bubble density can be obtained when compared to theta < 90 degrees (i.e. 20 degrees and 45 degrees channels). Hitherto, this observation has not been realized, and the mechanics is first investigated here with the employment of extreme theta (i.e. 20 degrees and 160 degrees). A thorough understanding of the underlying mechanics affecting Taylor flow can facilitate its exploitation for controlled gas bubble and liquid slug generation. Our theoretical model facilitates the tuning of the channel designs and fluid flow rates to achieve the desired gas bubble and liquid slug sizes for specific applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lim, An Eng; Lam, Yee Cheong] Nanyang Technol Univ, Sch Mech & Aerosp Engn, 50 Nanyang Ave, Singapore 639798, Singapore.
   [Lim, Chun Yee] Singapore Inst Technol, Engn Cluster, 10 Dover Dr, Singapore 138682, Singapore.
   [Lim, Yee Hwee] ASTAR, Inst Chem & Engn Sci, Div Organ Chem, 8 Biomed Grove Neuros Bldg,07-01-02-03, Singapore 138665, Singapore.
RP Lam, YC (reprint author), Nanyang Technol Univ, Sch Mech & Aerosp Engn, 50 Nanyang Ave, Singapore 639798, Singapore.
EM myclam@ntu.edu.sg
RI Lam, Yee Cheong/F-8899-2010
OI Lam, Yee Cheong/0000-0002-5764-8380; Lim, An Eng/0000-0002-7805-643X
FU National Medical Research CouncilMedical Research Council UK (MRC)
   [NMRC/CBRG/0071/2014]
FX The authors would like to acknowledge the financial support of National
   Medical Research Council (NMRC/CBRG/0071/2014) for this work. C.Y. Lim
   acknowledges that the work was performed in Nanyang Technological
   University (NTU).
CR Abadie T, 2012, MICROFLUID NANOFLUID, V12, P355, DOI 10.1007/s10404-011-0880-8
   Abate AR, 2013, LAB CHIP, V13, P4864, DOI 10.1039/c3lc50905b
   Abate AR, 2012, LAB CHIP, V12, P1516, DOI 10.1039/c2lc21263c
   Anna SL, 2003, APPL PHYS LETT, V82, P364, DOI 10.1063/1.1537519
   Bolivar JM, 2013, GREEN PROCESS SYNTH, V2, P541, DOI 10.1515/gps-2013-0091
   Cabeza VS, 2012, LANGMUIR, V28, P7007, DOI 10.1021/la205131e
   Cramer C, 2004, CHEM ENG SCI, V59, P3045, DOI 10.1016/j.ces.2004.04.006
   Cubaud T, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3693591
   Dahl K, 2015, RSC ADV, V5, P88886, DOI 10.1039/c5ra20646d
   de Mas N, 2001, MICROREATION TECHNOLOGY, P60
   De Menech M, 2008, J FLUID MECH, V595, P141, DOI 10.1017/S002211200700910X
   Dietrich N, 2008, LANGMUIR, V24, P13904, DOI 10.1021/la802008k
   Fries D, 2009, MICROFLUID NANOFLUID, V6, P27, DOI 10.1007/s10404-008-0292-6
   Garstecki P, 2006, LAB CHIP, V6, P693
   Gunther A, 2004, LAB CHIP, V4, P278, DOI 10.1039/b403982c
   Guo F, 2009, MICROGRAVITY SCI TEC, V21, P51, DOI 10.1007/s12217-009-9146-4
   Haase S, 2017, INT J MULTIPHAS FLOW, V88, P251, DOI 10.1016/j.ijmultiphaseflow.2016.09.002
   Huebner A, 2008, LAB CHIP, V8, P1244, DOI 10.1039/b806405a
   Inoue T, 2007, IND ENG CHEM RES, V46, P1153, DOI 10.1021/ie061277w
   Jahnisch K, 2004, ANGEW CHEM INT EDIT, V43, P406, DOI 10.1002/anie.200300577
   Jahnisch K, 2000, J FLUORINE CHEM, V105, P117, DOI 10.1016/S0022-1139(00)00300-6
   Kashid MN, 2007, IND ENG CHEM RES, V46, P8420, DOI 10.1021/ie070077x
   Khan W, 2018, CHEM PAP, V72, P2921, DOI 10.1007/s11696-018-0522-7
   Kiwi-Minsker L, 2005, CATAL TODAY, V110, P2, DOI 10.1016/j.cattod.2005.09.011
   Leclerc A, 2010, CHEM ENG J, V165, P290, DOI 10.1016/j.cej.2010.08.021
   Li W, 2012, J AM CHEM SOC, V134, P3127, DOI 10.1021/ja2101278
   Lim AE, 2018, MICROMACHINES-BASEL, V9, DOI 10.3390/mi9050229
   Lim AE, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa734f
   Miller PW, 2011, CHEM-EUR J, V17, P460, DOI 10.1002/chem.201002644
   Musterd M, 2015, RSC ADV, V5, P16042, DOI 10.1039/c4ra15163a
   Nekouei M, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4978801
   Ngo IL, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031881
   Nunes P, 2010, MICROFLUID NANOFLUID, V9, P2
   Rahman MT, 2013, RSC ADV, V3, P2897, DOI 10.1039/c2ra23216b
   Sauzade M, 2013, PHYS REV E, V88, DOI 10.1103/PhysRevE.88.051001
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   Soh GY, 2016, CHEM ENG SCI, V139, P99, DOI 10.1016/j.ces.2015.09.025
   Tan J, 2009, CHEM ENG J, V146, P428, DOI 10.1016/j.cej.2008.10.024
   Tan J, 2010, IND ENG CHEM RES, V49, P10040, DOI 10.1021/ie1011504
   TeGrotenhuis WE, 2000, MICROREACTION TECHNOLOGY: INDUSTRIAL PROSPECTS, P541
   Teh SY, 2008, LAB CHIP, V8, P198, DOI 10.1039/b715524g
   Theberge AB, 2010, ANGEW CHEM INT EDIT, V49, P5846, DOI 10.1002/anie.200906653
   Thorsen T, 2001, PHYS REV LETT, V86, P4163, DOI 10.1103/PhysRevLett.86.4163
   van Steijn V, 2007, CHEM ENG SCI, V62, P7505, DOI 10.1016/j.ces.2007.08.068
   van Steijn V, 2010, LAB CHIP, V10, P2513, DOI 10.1039/c002625e
   Ward T, 2005, ELECTROPHORESIS, V26, P3716, DOI 10.1002/elps.200500173
   Xu JH, 2006, AICHE J, V52, P2254, DOI 10.1002/aic.10824
   Yue J, 2008, CHEM ENG SCI, V63, P4189, DOI 10.1016/j.ces.2008.05.032
   Zhang SH, 2015, CHEM ENG SCI, V138, P128, DOI 10.1016/j.ces.2015.07.046
NR 49
TC 1
Z9 2
U1 9
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 417
EP 428
DI 10.1016/j.ces.2019.03.044
PG 12
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900034
DA 2020-05-12
ER

PT J
AU Kanbur, BB
   Xiang, LM
   Dubey, S
   Choo, FH
   Duan, F
AF Kanbur, Baris Burak
   Xiang, Liming
   Dubey, Swapnil
   Choo, Fook Hoong
   Duan, Fei
TI Sustainability and thermoenvironmental indicators on the multiobjective
   optimization of the liquefied natural gas fired micro-cogeneration
   systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sustainability analysis; Environmental analysis; Micro-cogeneration;
   Thermoeconomic analysis; Multiobjective optimization; LNG cold
   utilization
ID CYCLE POWER-PLANT; THERMOECONOMIC OPTIMIZATION; THERMODYNAMIC
   PROPERTIES; EXERGOECONOMIC ANALYSIS; ENVIRONMENTAL-ANALYSES; EXERGY;
   LNG; EQUATION; ENERGY; STATE
AB Liquefied natural gas (LNG), a clean fuel type mainly containing methane, has been becoming more popular amongst the other fuels for the power generation systems. Although there are a lot of thermodynamic and thermoeconomic assessments about the LNG fired power generation systems, the environmental and sustainability aspects have still lack investigation, especially on the optimization step. To minimize this gap, a multiobjective optimization study is performed for the LNG fired microcogeneration system. The current study considers various objective functions from thermodynamic, environmental, thermoeconomic, and sustainability aspects. A newly developed sustainability index is used as one of the objective functions in the study. The approach is defined as the complex multiobjective optimization procedure that constitutes different multiobjective optimization groups to better understand and evaluate the different objective functions together. The controllable air temperature and relative humidity are selected as the external decision variables. The best trade-off regions are identified between 300.00 K and 313.15 K at the relative humidity of 90% while they are found between 310.15 K and 313.15 K at the relative humidity of 50%. The high relative humidity and ambient air temperature present the best climatic conditions for the optimal operation of the small-scale system during the indoor operations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kanbur, Baris Burak; Dubey, Swapnil; Choo, Fook Hoong] Nanyang Technol Univ, Interdisciplinary Grad Sch, Energy Res Inst, Singapore 637141, Singapore.
   [Kanbur, Baris Burak; Duan, Fei] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
   [Xiang, Liming] Nanyang Technol Univ, Sch Phys & Math Sci, Singapore 6373, Singapore.
RP Duan, F (reprint author), Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
EM feiduan@ntu.edu.sg
RI Xiang, Liming/B-6966-2011
OI Xiang, Liming/0000-0003-0698-5173; Kanbur, Baris
   Burak/0000-0001-8181-0993
FU Energy Innovation Research Programme (EIRP) [NRF2013EWT-EIRP001-017];
   National Research Foundation (NRF)
FX The work was funded under the Energy Innovation Research Programme
   (EIRP, Award No. NRF2013EWT-EIRP001-017), administrated by the Energy
   Market Authority (EMA). The EIRP is a competitive grant call initiative
   driven by the Energy Innovation Programme Office, and funded by the
   National Research Foundation (NRF). In addition, we gratefully thank to
   Dr. Lu Qiu, Dr. Kai Wang, Dr. Chenzhen Ji and Mr. Zhen Qin for their
   helps on this study.
CR Ahmadi MH, 2016, ENERG CONVERS MANAGE, V119, P422, DOI 10.1016/j.enconman.2016.04.062
   Ahmadi P, 2011, INT J GREENH GAS CON, V5, P1540, DOI 10.1016/j.ijggc.2011.08.011
   Ahmadi P, 2011, ENERGY, V36, P5886, DOI 10.1016/j.energy.2011.08.034
   Ahmadi P, 2011, APPL THERM ENG, V31, P2529, DOI 10.1016/j.applthermaleng.2011.04.018
   Ahmadi P, 2011, ENERG CONVERS MANAGE, V52, P2296, DOI 10.1016/j.enconman.2010.12.023
   Ahmadi P, 2010, ENERGY, V35, P5161, DOI 10.1016/j.energy.2010.07.050
   Al-Sharrah G, 2010, CHEM ENG SCI, V65, P1452, DOI 10.1016/j.ces.2009.10.015
   Al-Sulaiman FA, 2013, ENERG CONVERS MANAGE, V69, P199, DOI 10.1016/j.enconman.2012.12.030
   Al-Sulaiman FA, 2013, ENERG CONVERS MANAGE, V69, P209, DOI 10.1016/j.enconman.2012.12.032
   [Anonymous], 2017, INT RAT G20
   [Anonymous], 2008, DEFC2600CH11058 CAPS
   Babu BV, 2005, CHEM ENG SCI, V60, P4822, DOI 10.1016/j.ces.2005.02.073
   Bejan A., 1996, THERMAL DESIGN OPTIM
   Boundy B, 2011, BIOMASS ENERGY DATA
   Capstone Turbine Corporation, 2006, CAPST MOD C30 TECHN
   Cengel Y.A., 2011, THERMODYNAMICS ENG A
   Chang CT, 1996, CHEM ENG SCI, V51, P3951, DOI 10.1016/0009-2509(96)00232-1
   Chang H, 2006, CHEM ENG SCI, V61, P5355, DOI 10.1016/j.ces.2006.04.020
   Dincer I, 2013, EXERGY ENERGY ENV SU
   Energy Market Company Singapore, 2015, MARK UPD
   Gonca G, 2017, ENERG CONVERS MANAGE, V151, P32, DOI 10.1016/j.enconman.2017.08.065
   Gonca G, 2017, ENERGY, V124, P579, DOI 10.1016/j.energy.2017.02.096
   International Gas Union Program Committee D3, 2015, WORLD GAS C PAR
   Kanbur BB, 2018, PROCEEDINGS OF 2018 2ND INTERNATIONAL CONFERENCE ON GREEN ENERGY AND APPLICATIONS (ICGEA), P215, DOI 10.1109/ICGEA.2018.8356288
   Kanbur BB, 2018, J CLEAN PROD, V174, P1338, DOI 10.1016/j.jclepro.2017.11.046
   Kanbur BB, 2017, APPL ENERG, V204, P1148, DOI 10.1016/j.apenergy.2017.01.061
   Kanbur BB, 2017, RENEW SUST ENERG REV, V79, P1171, DOI 10.1016/j.rser.2017.05.161
   Kanbur BB, 2017, ENRGY PROCED, V105, P1910, DOI 10.1016/j.egypro.2017.03.559
   Kanbur BB, 2017, ENRGY PROCED, V105, P1902, DOI 10.1016/j.egypro.2017.03.558
   Kanbur BB, 2017, ENERGY, V129, P171, DOI 10.1016/j.energy.2017.04.071
   Kanbur BB, 2017, 2017 INTERNATIONAL CONFERENCE ON GREEN ENERGY AND APPLICATIONS (ICGEA 2017), P143, DOI 10.1109/ICGEA.2017.7925472
   Kaviri AG, 2012, ENERG CONVERS MANAGE, V58, P94, DOI 10.1016/j.enconman.2012.01.002
   Mathworks, 2014, MATL OPT TOOLB
   Mitra K, 2004, CHEM ENG SCI, V59, P385, DOI 10.1016/j.ces.2003.09.036
   Mokhatab S, 2013, HDB LIQUEFIED NATURA
   Moore R.L., 2010, INLEXT1018651
   Morosuk T, 2011, ENERGY, V36, P3771, DOI 10.1016/j.energy.2010.07.035
   Morosuk T, 2012, NATURAL GAS EXTRACTI, P235, DOI DOI 10.5772/51477
   Morosuk T, 2012, INT J ENERGY ENVIR E, V3, DOI 10.1186/2251-6832-3-1
   Radco Industries, 2014, XCELTHERMK MK1 HEAT
   Rajesh JK, 2001, CHEM ENG SCI, V56, P999, DOI 10.1016/S0009-2509(00)00316-X
   Reader GT, 1979, P 13 INT EN CONV ENG, V3, P1763
   Rokni M, 2014, ENERGY, V76, P19, DOI 10.1016/j.energy.2014.01.106
   Gomez MR, 2014, RENEW SUST ENERG REV, V38, P781, DOI 10.1016/j.rser.2014.07.029
   Rosen MA, 1999, INT J ENERG RES, V23, P1153, DOI 10.1002/(SICI)1099-114X(19991025)23:13<1153::AID-ER545>3.0.CO;2-Y
   Rosen MA, 2008, ENERG POLICY, V36, P128, DOI 10.1016/j.enpol.2007.09.006
   Sahoo PK, 2008, APPL THERM ENG, V28, P1580, DOI 10.1016/j.applthermaleng.2007.10.011
   SCHMIDT R, 1985, FLUID PHASE EQUILIBR, V19, P175, DOI 10.1016/0378-3812(85)87016-3
   SETZMANN U, 1991, J PHYS CHEM REF DATA, V20, P1061, DOI 10.1063/1.555898
   Span R, 2000, J PHYS CHEM REF DATA, V29, P1361, DOI 10.1063/1.1349047
   Tarafder A, 2005, CHEM ENG SCI, V60, P347, DOI 10.1016/j.ces.2004.07.120
   The Dow Chemical Company, 1997, DOWTH HEAT TRANSF FL
   Toffolo A, 2002, ENERGY, V27, P549, DOI 10.1016/S0360-5442(02)00009-9
   TSATSARONIS G, 1994, ENERGY, V19, P287, DOI 10.1016/0360-5442(94)90113-9
   United Nations, 2015, TRANSF OUR WORLD 203
NR 55
TC 0
Z9 0
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 429
EP 446
DI 10.1016/j.ces.2019.03.024
PG 18
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900035
DA 2020-05-12
ER

PT J
AU Liu, QX
   Sun, ZG
   Sun, YJ
   Chen, X
   Xi, G
AF Liu, Qi-xin
   Sun, Zhong-guo
   Sun, Yi-jie
   Chen, Xiao
   Xi, Guang
TI Numerical investigation of liquid dispersion by hydrophobic/hydrophilic
   mesh packing using particle method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid dispersion; Hydrophobic; Hydrophilic; Wettability; Surface area;
   Moving particle semi-implicit method
ID ROTATING PACKED-BED; MASS-TRANSFER; SEMIIMPLICIT METHOD; MPS METHOD;
   FLOW; INTENSIFICATION
AB Liquid dispersion in chemical processes is significant for increasing mass or heat transfer. A particle-based method, the moving particle semi-implicit (MPS) method, was employed in this study to simulate the process of liquid dispersion by mesh packing. The computational framework includes a designed inlet flow model, hydrophilic/hydrophobic surface boundary conditions, and a surface tension model. This study mainly focuses on the effect of hydrophobic/hydrophilic mesh packing on liquid dispersion performance. The mechanism of liquid dispersion is systematically investigated in basic situations as a liquid passing through a single wire, an orthogonal wire and a single aperture. The results indicate that hydrophobic and hydrophilic mesh packing have different effects on the formation of the free surface, which is the key to the mechanism of the liquid dispersion process. Hydrophobic mesh packing can disperse a liquid into several fine columns with detected droplets, which further develop into fine droplets, whereas hydrophilic mesh packing will guide a liquid to converge into a column at the bottom of the mesh packing. In addition, the surface area density and dispersion range of a liquid are quantitatively analyzed to illustrate liquid dispersion performance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Qi-xin; Sun, Zhong-guo; Sun, Yi-jie; Xi, Guang] Xi An Jiao Tong Univ, Sch Energy & Power Engn, Xian 710049, Shaanxi, Peoples R China.
   [Chen, Xiao] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Shaanxi, Peoples R China.
RP Sun, ZG (reprint author), Xi An Jiao Tong Univ, Sch Energy & Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM sun.zg@mail.xjtu.edu.cn
FU Natural Science Foundation of China (NSFC) ProjectNational Natural
   Science Foundation of China [51576154]
FX We thank De-lin Chai, Tong-sheng Wang, Kai Zhang, Yun-zhang Song, Ya-li
   Chen and Yong Zhang for helpful discussions. This work is supported by
   the Natural Science Foundation of China (NSFC) Project (No. 51576154).
CR Burns JR, 1996, CHEM ENG SCI, V51, P1347, DOI 10.1016/0009-2509(95)00367-3
   Chen X, 2019, OCEAN ENG, V171, P677, DOI 10.1016/j.oceaneng.2018.11.009
   Chen YS, 2006, IND ENG CHEM RES, V45, P6846, DOI 10.1021/ie060399l
   Gambaruto AM, 2015, J COMPUT PHYS, V302, P68, DOI 10.1016/j.jcp.2015.08.039
   Guo K, 2014, IND ENG CHEM RES, V53, P4052, DOI 10.1021/ie4029285
   Kon T, 2015, ISIJ INT, V55, P1284, DOI 10.2355/isijinternational.55.1284
   Kondo M, 2007, FEDSM 2007: PROCEEDINGS OF THE 5TH JOINT AMSE/JSME FLUIDS ENGINEERING SUMMER CONFERENCE VOL 1, PTS A AND B, P93
   Koshizuka S, 1996, NUCL SCI ENG, V123, P421, DOI 10.13182/NSE96-A24205
   Koshizuka S., 2018, FUNDAMENTALS FLUID S, P25, DOI DOI 10.1016/B978-0-12-812779-7.00002-3
   Lee BH, 2011, COMPUT METHOD APPL M, V200, P1113, DOI 10.1016/j.cma.2010.12.001
   Liu Y, 2017, CHEM ENG SCI, V170, P365, DOI 10.1016/j.ces.2017.01.033
   Luo Y, 2017, CHEM ENG SCI, V170, P347, DOI 10.1016/j.ces.2016.10.023
   Monaghan J. J, 1992, SMOOTHED PARTICLE HY
   Natsui S, 2014, CHEM ENG SCI, V111, P286, DOI 10.1016/j.ces.2014.02.038
   Rubio-Rubio M, 2018, INT J MULTIPHAS FLOW, V104, P206, DOI 10.1016/j.ijmultiphaseflow.2018.02.017
   Sang L, 2017, CHEM ENG SCI, V170, P355, DOI 10.1016/j.ces.2016.12.041
   Sang L, 2017, CHEM ENG SCI, V158, P429, DOI 10.1016/j.ces.2016.10.044
   Sun ZG, 2017, INT J HEAT MASS TRAN, V105, P90, DOI 10.1016/j.ijheatmasstransfer.2016.09.053
   Sun ZG, 2011, SCI CHINA PHYS MECH, V54, P1514, DOI 10.1007/s11433-011-4387-9
   Sun ZG, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3089587
   Sun ZG, 2009, CHEM ENG SCI, V64, P341, DOI 10.1016/j.ces.2008.10.034
   Tanaka M, 2010, J COMPUT PHYS, V229, P4279, DOI 10.1016/j.jcp.2010.02.011
   Wei G. E, 2001, CHINESE SCI B
   Xi G, 2018, J HYDRODYNAM, P79
   Xiang H, 2015, FLUID DYN RES, V47, DOI 10.1088/0169-5983/47/1/015511
   Xiong QG, 2013, COMPUT PHYS COMMUN, V184, P1701, DOI 10.1016/j.cpc.2013.02.021
   Xiong QG, 2011, CHEM ENG SCI, V66, P1859, DOI 10.1016/j.ces.2011.01.033
   Xiong QG, 2010, CHEM ENG SCI, V65, P5356, DOI 10.1016/j.ces.2010.06.035
   Xu XY, 2016, COMPUT PHYS COMMUN, V201, P43, DOI 10.1016/j.cpc.2015.12.016
   Yan ZY, 2012, IND ENG CHEM RES, V51, P10472, DOI 10.1021/ie202257t
   Yang XF, 2016, COAST ENG, V108, P56, DOI 10.1016/j.coastaleng.2015.11.007
   Zhang JP, 2017, CHEM ENG SCI, V170, P204, DOI 10.1016/j.ces.2017.03.058
   Zheng XH, 2016, CHEM ENG J, V285, P236, DOI 10.1016/j.cej.2015.09.083
NR 33
TC 2
Z9 2
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 447
EP 461
DI 10.1016/j.ces.2019.03.046
PG 15
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900036
DA 2020-05-12
ER

PT J
AU Kureck, H
   Govender, N
   Siegmann, E
   Boehling, P
   Radeke, C
   Khinast, JG
AF Kureck, Hermann
   Govender, Nicolin
   Siegmann, Eva
   Boehling, Peter
   Radeke, Charles
   Khinast, Johannes G.
TI Industrial scale simulations of tablet coating using GPU based DEM: A
   validation study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Simulation; Discrete elements; DEM; Particle shape; Bi-convex tablet;
   GPU
ID DISCRETE ELEMENT METHOD; CONTACT DETECTION ALGORITHMS; THEORETICAL
   DEVELOPMENTS; PARTICLES; MODEL; FLOW; POLYHEDRA; FRAMEWORK; SYSTEMS
AB The coating of tablets to prevent product degradation or control dissolution is a typical process in its production. Coating uniformity is critical for the quality of final product and batch acceptance. Therefore, the coating process needs to be optimized in order to achieve the desired uniformity and reduce manufacturing costs. Thus, understanding how process parameters such as spray properties, equipment geometry and tablet shape influence the coating process is critical for process optimization and approval by regulatory bodies. However this is a non-trivial task as obtaining information about the detailed processes in a tablet coater via experimental means is limited. Thus, computational modeling is the most feasible option to obtain information about the physical processes affecting the performance of tablet coaters. The most widely used computational method for such numerical modelling is the Discrete Element Method (DEM) where individual particles (tablets) are simulated. However, the computational cost of representing the typical shape of tablets is high for industrially relevant simulations. Thus tablet shape is typically approximated by simpler shapes such as spheres or multi spheres. Even with such simplifications, typical simulations take months to complete making it unfeasible for process optimization and design. In the last decade, the Graphical Processor Unit (GPU) has enabled large-scale simulations of tens of millions of spheres and millions of shaped particles using the XPS code. In this paper, we present an algorithm for modeling accurate bi-convex tablets that is tailored to the GPU. We firstly validate the algorithm and implementation against a number of experiments. Finally we perform a simulation of 20 million tablets in a drum coater to illustrate the usefulness of GPU computing for industrial coating applications. We found that the proposed method yields a good match against the lab scale experiments. For the industrial simulation the proposed method gave a more accurate result compared to the multi sphere approach while being significantly faster. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kureck, Hermann; Govender, Nicolin; Siegmann, Eva; Boehling, Peter; Radeke, Charles; Khinast, Johannes G.] Res Ctr Pharmaceut Engn GmbH, Graz, Austria.
   [Khinast, Johannes G.] Graz Univ Technol, Inst Proc & Particle Engn, Inffeldgasse 13, Graz, Austria.
RP Khinast, JG (reprint author), Graz Univ Technol, Inst Proc & Particle Engn, Inffeldgasse 13, Graz, Austria.
EM khinast@tugraz.at
OI govender, nicolin/0000-0002-5068-5429
FU Austrian COMET Program under the Austrian Federal Ministry of Transport,
   Innovation and Technology (BMVIT); Austrian Federal Ministry of Economy,
   Family and Youth (BMWFJ) under FFG [844606]; Province of Styria (Styrian
   Business Promotion Agency, SFG) [1.000.038.674]
FX Research Center Pharmaceutical Engineering is funded by the Austrian
   COMET Program under the auspices of the Austrian Federal Ministry of
   Transport, Innovation and Technology (BMVIT), the Austrian Federal
   Ministry of Economy, Family and Youth (BMWFJ) under FFG grant 844606 and
   by the Province of Styria (Styrian Business Promotion Agency, SFG grant
   1.000.038.674). COMET is managed by the Austrian Research Promotion
   Agency, FFG.; The authors want to thank Mr. Stefan Enzinger (RCPE GmbH),
   Dr Patrick Pizette (IMT Lille Douai) and Miss Salma Ben-Turkia (IMT
   Lille Douai) for their support.
CR Boehling P, 2017, EUR J PHARM SCI, V104, P72, DOI 10.1016/j.ejps.2017.03.031
   Boehling P, 2016, EUR J PHARM SCI, V93, P74, DOI 10.1016/j.ejps.2016.08.018
   Boehling P, 2016, EUR J PHARM SCI, V90, P14, DOI 10.1016/j.ejps.2015.12.022
   Bohling P, 2019, J PHARM SCI-US, V108, P538, DOI 10.1016/j.xphs.2018.10.016
   Borner M, 2016, POWDER TECHNOL, V295, P261, DOI 10.1016/j.powtec.2016.03.023
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Dreu R, 2016, EUR J PHARM BIOPHARM, V106, P97, DOI 10.1016/j.ejpb.2016.05.022
   Duran J., 1999, SANDS POWDERS GRAINS
   Ebrahimi M, 2017, ADV POWDER TECHNOL, V28, P2465, DOI 10.1016/j.apt.2017.05.009
   Feng YT, 2017, COMPUT METHOD APPL M, V315, P632, DOI 10.1016/j.cma.2016.11.001
   Feng Y. T., 2016, 7 INT C DISCR EL MET
   Freireich B, 2015, CHEM ENG SCI, V131, P197, DOI 10.1016/j.ces.2015.03.013
   Gan JQ, 2016, POWDER TECHNOL, V301, P1172, DOI 10.1016/j.powtec.2016.07.072
   Govender Nicolin, 2016, SoftwareX, V5, P62, DOI 10.1016/j.softx.2016.04.004
   Govender N., 2015, P INT C PART BAS MET
   Govender N., 2017, APPL MATH COMPUT
   Govender N., 2017, EPJ WEB C, V140
   Govender N, 2018, MINER ENG, V129, P71, DOI 10.1016/j.mineng.2018.09.019
   Govender N, 2018, ADV POWDER TECHNOL, V29, P2476, DOI 10.1016/j.apt.2018.06.028
   Govender N, 2018, CHEM ENG SCI, V188, P34, DOI 10.1016/j.ces.2018.05.011
   Govender N, 2015, MINER ENG, V79, P152, DOI 10.1016/j.mineng.2015.05.010
   Govender N, 2014, J COMPUT APPL MATH, V270, P386, DOI 10.1016/j.cam.2013.12.032
   Guo Y, 2012, POWDER TECHNOL, V228, P193, DOI 10.1016/j.powtec.2012.05.015
   He Y, 2018, POWDER TECHNOL, V333, P219, DOI 10.1016/j.powtec.2018.04.034
   Hohner D, 2012, POWDER TECHNOL, V226, P16, DOI 10.1016/j.powtec.2012.03.041
   Hohner D, 2011, POWDER TECHNOL, V208, P643, DOI 10.1016/j.powtec.2011.01.003
   Jajcevic D, 2013, CHEM ENG SCI, V98, P298, DOI 10.1016/j.ces.2013.05.014
   Ketchel J. S., 2005, P IDETC CIE
   Ketterhagen WR, 2011, INT J PHARMACEUT, V409, P137, DOI 10.1016/j.ijpharm.2011.02.045
   Kildashti K, 2018, CHEM ENG SCI, V177, P1, DOI 10.1016/j.ces.2017.11.004
   Kildashti K, 2018, POWDER TECHNOL, V326, P1, DOI 10.1016/j.powtec.2017.11.066
   Kodam M, 2012, CHEM ENG SCI, V69, P587, DOI 10.1016/j.ces.2011.11.011
   Kodam M, 2010, CHEM ENG SCI, V65, P5863, DOI 10.1016/j.ces.2010.08.007
   Kodam M, 2010, CHEM ENG SCI, V65, P5852, DOI 10.1016/j.ces.2010.08.006
   Kodam M, 2009, CHEM ENG SCI, V64, P3466, DOI 10.1016/j.ces.2009.04.025
   Kruggel-Emden H, 2008, POWDER TECHNOL, V188, P153, DOI 10.1016/j.powtec.2008.04.037
   Li CQ, 2015, POWDER TECHNOL, V286, P478, DOI 10.1016/j.powtec.2015.08.026
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   Mirtich B., 1995, I3D 95 P 1995 S INT
   Moore M., 1988, P 15 ANN C COMP GRAP
   Nassauer B, 2013, GRANUL MATTER, V15, P85, DOI 10.1007/s10035-012-0381-9
   Podlozhnyuk A, 2017, COMPUT PART MECH, V4, P101, DOI 10.1007/s40571-016-0131-6
   Radeke CA, 2010, CHEM ENG SCI, V65, P6435, DOI 10.1016/j.ces.2010.09.035
   Sanders J., 2010, CUDA BY EXAMPLE
   Schwager T, 2007, GRANUL MATTER, V9, P465, DOI 10.1007/s10035-007-0065-z
   Shigeto Y, 2011, PARTICUOLOGY, V9, P398, DOI 10.1016/j.partic.2011.04.002
   Siegmann E, 2017, CHEM-ING-TECH, V89, P995, DOI 10.1002/cite.201700004
   Smeets B, 2015, COMPUT METHOD APPL M, V290, P277, DOI 10.1016/j.cma.2015.03.004
   Song YX, 2006, POWDER TECHNOL, V161, P32, DOI 10.1016/j.powtec.2005.07.004
   STRONGE WJ, 2000, IMPACT MECH
   Thornton A, 2012, INT J MOD PHYS C, V23, DOI 10.1142/S0129183112400141
   Thornton C., 2015, GRANULAR DYNAMICS CO
   Toson P, 2018, INT J PHARMACEUT, V552, P288, DOI 10.1016/j.ijpharm.2018.09.032
   Toson P, 2017, POWDER TECHNOL, V313, P353, DOI 10.1016/j.powtec.2017.03.016
   Vidyapati V, 2013, IND ENG CHEM RES, V52, P13171, DOI 10.1021/ie303598e
   Walther JH, 2009, ENG COMPUTATION, V26, P688, DOI 10.1108/02644400910975478
   Wilke D. N., 2017, P 12 WORLD C STRUCT, P878
   Xua J, 2011, PARTICUOLOGY, V9, P446, DOI 10.1016/j.partic.2011.01.003
   Zhong WQ, 2016, POWDER TECHNOL, V302, P108, DOI 10.1016/j.powtec.2016.07.010
   Zhou ZY, 2011, IND ENG CHEM RES, V50, P9787, DOI 10.1021/ie200862n
NR 60
TC 7
Z9 7
U1 6
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 462
EP 480
DI 10.1016/j.ces.2019.03.029
PG 19
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900037
DA 2020-05-12
ER

PT J
AU John, TP
   Fonte, CP
   Kowalski, A
   Rodgers, TL
AF John, T. P.
   Fonte, C. P.
   Kowalski, A.
   Rodgers, T. L.
TI A comparison of power and flow characteristics between batch and in-line
   rotor-stator mixers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotor-stator; Mixing; Power number; Flow number; CFD
ID VELOCITY
AB Rotor-stator mixers are used in many industries to perform emulsification and de-agglomeration processes. Despite previous research, different modes of operation have not been compared in terms of flow and power characteristics. The aim of this study was to use CFD to investigate power and flow characteristics of a Silverson L5M mixer operating in batch and in-line mode. MRF was used along with the standard k - epsilon turbulence model for the simulations. Results suggest that batch mixers can be characterised in the same was as in-line mixers, and for a given mixing head design, the characterisation is independent of the mode of operation. A new way of the calculating flow number is proposed, which explains some discrepant results from previous studies. Overall, this work enhances our understanding of rotor-stator mixers and allows for better design choices of mixer. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [John, T. P.; Fonte, C. P.; Rodgers, T. L.] Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
   [Kowalski, A.] Unilever R&D, Port Sunlight Lab, Quarry Rd East, Wirral CH63 3JW, Merseyside, England.
RP John, TP (reprint author), Univ Manchester, Sch Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
EM thomas.john@manchester.ac.uk
OI Fonte, Claudio/0000-0001-9714-0779; John, Thomas/0000-0001-6687-0007
FU EPSRC industrial case awards; Unilever; EPSRC project The Centre in
   Advanced Fluid Engineering for Digital Manufacturing [EP/R00482X/1]
FX The authors would like to express their gratitude to the EPSRC
   industrial case awards and Unilever for funding the first authors PhD
   studies and EPSRC project The Centre in Advanced Fluid Engineering for
   Digital Manufacturing (EP/R00482X/1) for funding the other authors. The
   authors would also like to thank the workshop staff of The University of
   Manchesters School of Chemical Engineering and Analytical Science for
   their help with the modifications and maintenance of the equipment.
CR Atiemo-Obeng V. A, 2004, HDB IND MIXING SCI P, P479, DOI DOI 10.1002/0471451452.CH8
   Cooke M, 2012, AICHE J, V58, P1683, DOI 10.1002/aic.12703
   De Hert SC, 2017, CHEM ENG SCI, V167, P265, DOI 10.1016/j.ces.2017.04.020
   Hakansson A, 2018, PROCESSES, V6, DOI 10.3390/pr6040032
   Hakansson A, 2017, CAN J CHEM ENG, V95, P806, DOI 10.1002/cjce.22718
   Hall S, 2011, CAN J CHEM ENG, V89, P1040, DOI 10.1002/cjce.20556
   James J, 2017, CHEM ENG RES DES, V124, P313, DOI 10.1016/j.cherd.2017.06.020
   Jasinska M, 2015, CHEM ENG PROCESS, V91, P43, DOI 10.1016/j.cep.2015.03.015
   Kowalski AJ, 2011, CHEM ENG SCI, V66, P241, DOI 10.1016/j.ces.2010.10.010
   Kowalski AJ, 2009, CHEM ENG PROCESS, V48, P581, DOI 10.1016/j.cep.2008.04.002
   Malavasi S, 2012, FLOW MEAS INSTRUM, V28, P57, DOI 10.1016/j.flowmeasinst.2012.07.006
   Minnick BA, 2018, CHEM ENG RES DES, V136, P477, DOI 10.1016/j.cherd.2018.05.015
   Mortensen HH, 2018, CHEM ENG SCI, V177, P340, DOI 10.1016/j.ces.2017.11.037
   Mortensen HH, 2017, CHEM ENG RES DES, V121, P245, DOI 10.1016/j.cherd.2017.03.016
   Ozcan-Taskin G, 2011, CAN J CHEM ENG, V89, P1005, DOI 10.1002/cjce.20553
   Rielly C.D, 2009, COMPUTATIONAL FLUID
   Utomo A, 2009, CHEM ENG RES DES, V87, P533, DOI 10.1016/j.cherd.2008.12.011
   Utomo AT, 2008, CHEM ENG RES DES, V86, P1397, DOI 10.1016/j.cherd.2008.07.012
NR 18
TC 1
Z9 1
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 481
EP 490
DI 10.1016/j.ces.2019.03.015
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900038
DA 2020-05-12
ER

PT J
AU Moller, F
   Lavetty, C
   Schleicher, E
   Loschau, M
   Hampel, U
   Schubert, M
AF Moeller, Felix
   Lavetty, Craig
   Schleicher, Eckhard
   Loeschau, Martin
   Hampel, Uwe
   Schubert, Markus
TI Hydrodynamics, mixing and mass transfer in a pilot-scale bubble column
   with dense internals
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pilot-scale bubble column; Heat exchanger internals; Hydrodynamics;
   Liquid mixing; Mass transfer; Wire-mesh sensor
ID GAS-PHASE DISPERSION; WIRE-MESH SENSOR; CFD SIMULATIONS; HEAT-TRANSFER;
   LIQUID-PHASE; DESIGN; HOLDUP; PARAMETERS; REACTORS; ENTROPY
AB Bubble column reactors with exothermic reactions are often equipped with dense tube bundle heat exchangers. While there is some knowledge about the impact of such internals on hydrodynamics and mass transfer for narrow columns, its role in pilot-scale columns is less clear. In this paper we report on a study of hydrodynamics and mass transfer in a BCR of 4.2 m height and 0.392 m diameter. We investigated different tube arrangements with triangular and square pitch and tube diameters of 32 x 10(-3) m and 45 x 10(-3) m at the same cross-sectional coverage (similar to 25%). The column was operated at homogeneous and heterogeneous flow conditions. A customized three-layer wire-mesh sensor was utilized to visualize gas phase dynamics and liquid mixing characteristics in the column's cross-section. We found that sub-channel size is the most crucial geometric design parameter. Tracer mixing experiments revealed that internals reduce the mixing time due to the induction of large-scale liquid circulation. Mass transfer was studied with the oxygen stripping method. Here we found, that the effect of the internals on the gas-liquid mass transfer is almost negligible. Eventually, correlations for gas holdup, axial liquid dispersion and the volumetric gas-liquid mass transfer coefficient are given, which take the internals' geometry into account. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moeller, Felix; Lavetty, Craig; Schleicher, Eckhard; Hampel, Uwe; Schubert, Markus] Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
   [Loeschau, Martin] Teletron Rossendorf GmbH, Bautzner Landstr 45, D-01454 Grosserkmannsdorf, Germany.
   [Hampel, Uwe] Tech Univ Dresden, Chair Imaging Tech Energy & Proc Engn, D-01062 Dresden, Germany.
RP Moller, F; Schubert, M (reprint author), Helmholtz Zentrum Dresden Rossendorf, Inst Fluid Dynam, Bautzner Landstr 400, D-01328 Dresden, Germany.
EM felix.moeller@hzdr.de; m.schubert@hzdr.de
RI ; Hampel, Uwe/E-4065-2012
OI Schubert, Markus/0000-0002-6218-0989; Moller, Felix/0000-0001-6830-4455;
   Hampel, Uwe/0000-0002-7371-0148
FU European Research Council (ERC StG)European Research Council (ERC)
   [307360]
FX The authors gratefully acknowledge the European Research Council (ERC
   StG, No. 307360) for financial support.
CR AKITA K, 1973, IND ENG CHEM PROC DD, V12, P76, DOI 10.1021/i260045a015
   Al Mesfer MK, 2017, CHEM ENG SCI, V161, P228, DOI 10.1016/j.ces.2016.12.001
   Al Mesfer MK, 2016, CHEM ENG J, V300, P317, DOI 10.1016/j.cej.2016.04.075
   Baird M.H.I., 1975, CHEM ENG J, V9, P171, DOI DOI 10.1016/0300-9467(75)80010-4
   Baird MHI, 1998, CAN J CHEM ENG, V76, P370, DOI 10.1002/cjce.5450760305
   Berg S, 1993, GASGEHALTSVERTEILUNG
   Bernemann K, 1989, FLUIDDYNAMIK ZUM VER
   Besagni G, 2017, SCALE UP CRITERIA BU
   Beyer M, 2018, WIRE MESH SENSOR DAT
   Bhusare VH, 2017, CHEM ENG J, V317, P157, DOI 10.1016/j.cej.2017.01.128
   DECKWER WD, 1993, CHEM ENG SCI, V48, P889, DOI 10.1016/0009-2509(93)80328-N
   DECKWER WD, 1974, CHEM ENG SCI, V29, P2177, DOI 10.1016/0009-2509(74)80025-4
   DECKWER WD, 1978, CAN J CHEM ENG, V56, P43, DOI 10.1002/cjce.5450560107
   DECKWER WD, 1983, AICHE J, V29, P915, DOI 10.1002/aic.690290607
   DECKWER WD, 1992, BUBBLE COLUMN REACTO
   Doss A, 2017, CHEM ENG SCI, V171, P256, DOI 10.1016/j.ces.2017.05.019
   Forret A, 2003, CAN J CHEM ENG, V81, P360
   Furuya M, 2017, NUCL ENG DES
   George K. J. H., 2015, INVESTIGATIONS HYDRO
   George KJH, 2017, CHEM ENG SCI, V170, P297, DOI 10.1016/j.ces.2017.03.018
   Guan XP, 2017, CHEM ENG RES DES, V126, P109, DOI 10.1016/j.cherd.2017.08.019
   Guan XP, 2015, CHEM ENG RES DES, V102, P196, DOI 10.1016/j.cherd.2015.06.028
   Guan XP, 2014, IND ENG CHEM RES, V53, P16529, DOI 10.1021/ie502666y
   Guo XF, 2017, CHEM ENG SCI, V174, P311, DOI 10.1016/j.ces.2017.09.004
   Hamed M, 2012, HYDRODYNAMICS MIXING
   Han L, 2007, CHEM ENG SCI, V62, P131, DOI 10.1016/j.ces.2006.08.010
   HZDR Innovation, 2013, CLOCKBOX V5 CLOCKCON
   Jasim A, 2016, IMPACT HEAT EXCHANGI
   Jhawar AK, 2014, CHEM ENG RES DES, V92, P25, DOI 10.1016/j.cherd.2013.06.016
   Kagumba M., 2013, HEAT TRANSFER BUBBLE
   Kalaga DV, 2018, INT J CHEM REACT ENG, V16, DOI 10.1515/ijcre-2018-0012
   Kalaga DV, 2017, CHEM ENG SCI, V170, P332, DOI 10.1016/j.ces.2017.02.022
   Kipping R, 2017, CHEM ENG TECHNOL, V40, P1425, DOI 10.1002/ceat.201700005
   Kipping R, 2016, INT J MULTIPHAS FLOW, V85, P86, DOI 10.1016/j.ijmultiphaseflow.2016.05.017
   Krishna R, 2000, CHEM ENG J, V78, P43, DOI 10.1016/S1385-8947(99)00167-9
   Laborde-Boutet C, 2010, AICHE J, V56, P2397, DOI 10.1002/aic.12171
   Larachi F, 2006, CHEM ENG SCI, V61, P4195, DOI 10.1016/j.ces.2006.01.053
   Lau Y. M, 2018, INT J MULTIPH FLOW
   Li H, 2001, CAN J CHEM ENG, V79, P717, DOI 10.1002/cjce.5450790503
   Moller F, 2018, CHEM ENG SCI, V179, P265, DOI 10.1016/j.ces.2018.01.008
   Moller F, 2019, IND ENG CHEM RES
   Moller F, 2018, CHEM ENG RES DES
   Nedeltchev S., 2017, P 3 INT S MULT MULT
   Nedeltchev S, 2018, CHEM ENG J JPN
   Nedeltchev S, 2014, J CHEM ENG JPN, V47, P722, DOI 10.1252/jcej.13we362
   Nedeltchev S, 2013, CHEM ENG SCI, V100, P2, DOI 10.1016/j.ces.2013.03.039
   Nedeltchev S, 2009, CHEM ENG TECHNOL, V32, P1974, DOI 10.1002/ceat.200900336
   OHKI Y, 1970, CHEM ENG SCI, V25, P1, DOI 10.1016/0009-2509(70)85016-3
   Prasser HM, 1998, FLOW MEAS INSTRUM, V9, P111, DOI 10.1016/S0955-5986(98)00015-6
   Rollbusch P, 2015, CHEM ENG SCI, V126, P660, DOI 10.1016/j.ces.2014.11.061
   Rubio FC, 2004, CHEM ENG SCI, V59, P4369, DOI 10.1016/j.ces.2004.06.037
   SCHLUTER S, 1995, CHEM ENG PROCESS, V34, P157, DOI 10.1016/0255-2701(94)04002-8
   Schluter S, 1992, MODELLIERUNG SIMULAT
   SCHOUTEN JC, 1994, PHYS REV E, V49, P126, DOI 10.1103/PhysRevE.49.126
   Shah RK, 2003, FUNDAMENTALS HEAT EX
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Sharaf S, 2016, CHEM ENG J, V288, P489, DOI 10.1016/j.cej.2015.11.106
   Sultan A. J, 2018, INT J MULTIPH FLOW
   Sultan AJ, 2018, EXP THERM FLUID SCI, V98, P68, DOI 10.1016/j.expthermflusci.2018.05.005
   Sultan AJ, 2018, CHEM ENG SCI, V186, P1, DOI 10.1016/j.ces.2018.04.021
   Thulukkanam K., 2013, HEAT EXCHANGER DESIG
   WACHI S, 1990, CHEM ENG SCI, V45, P901, DOI 10.1016/0009-2509(90)85012-3
   Westermeyer-Benz H, 1992, WARMEUBERGANG GASGEH
   WILKINSON PM, 1992, AICHE J, V38, P544, DOI 10.1002/aic.690380408
   YAMASHITA F, 1987, J CHEM ENG JPN, V20, P204, DOI 10.1252/jcej.20.204
   Ylonen A. T., 2013, HIGH RESOLUTION FLOW
   Youssef A. A, 2010, FLUID DYNAMICS SCALU
   Youssef AA, 2014, CHEM ENG RES DES, V92, P1637, DOI 10.1016/j.cherd.2013.12.011
   Youssef AA, 2013, INT J CHEM REACT ENG, V11, DOI 10.1515/ijcre-2012-0023
   Youssef AA, 2009, IND ENG CHEM RES, V48, P8007, DOI 10.1021/ie900266q
NR 70
TC 1
Z9 1
U1 5
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 491
EP 507
DI 10.1016/j.ces.2019.03.001
PG 17
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900039
DA 2020-05-12
ER

PT J
AU Sandeep, KC
   Mohan, S
   Mandal, D
   Mahajani, S
AF Sandeep, K. C.
   Mohan, Sadhana
   Mandal, D.
   Mahajani, Sanjay
TI Determination of gas film mass transfer coefficient in a packed bed
   reactor for the catalytic combustion of hydrogen
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalytic combustion; Hydrogen oxidation; Mass transfer coefficient;
   Packed bed reactor; Hydrogen-air system; Palladium catalyst
ID NUMERICAL SIMULATIONS; KINETICS; RECOMBINATION; OXYGEN
AB The overall kinetics of catalytic combustion of hydrogen in air is decided by the contribution of the different resistances offered in individual steps such as external diffusion, internal diffusion and surface reaction. To estimate the contribution of external mass transfer resistance, empirical correlations in terms of dimensionless numbers viz., Sherwood number, particle Reynold's number, and Schmidt number are used in general. The Schmidt number for hydrogen in air is approximately 0.2 and most of the mass transfer correlations in packed bed reactors are valid for Schmidt number higher than 0.6, which corresponds to that of water vapour in the air. The external mass transfer correlations applicable for hydrogen-air system are scarce. In the present study, the external mass transfer effects were decoupled from internal diffusion and intrinsic reaction by conducting experiments with different particle Reynolds numbers in a packed bed batch reactor with complete recycle. Further, the system is theoretically modeled and the external film mass transfer coefficients were estimated at different particle Reynold's numbers using experimental data. Based on the experimental data, a new mass transfer correlation has been proposed to determine the gas film mass transfer coefficient of hydrogen in the air in packed bed reactors, in terms of conventional dimensionless numbers i.e., Sherwood number, Schmidt number, and particle Reynolds number. Further, the contribution of external mass transfer resistance on the overall reaction kinetics was also estimated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sandeep, K. C.; Mohan, Sadhana] Bhabha Atom Res Ctr, Heavy Water Div, Mumbai, Maharashtra, India.
   [Mandal, D.] Bhabha Atom Res Ctr, Alkali Mat & Met Div, Mumbai, Maharashtra, India.
   [Sandeep, K. C.; Mohan, Sadhana; Mandal, D.] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India.
   [Mahajani, Sanjay] Indian Inst Technol, Dept Chem Engn, Mumbai, Maharashtra, India.
RP Mahajani, S (reprint author), Indian Inst Technol, Dept Chem Engn, Mumbai, Maharashtra, India.
EM sanjaym@iitb.ac.in
OI Mandal, Dr D/0000-0002-9584-0496
CR Arnould F, 2001, 9 INT C NUCL ENG FRA
   Augier F, 2010, CHEM ENG SCI, V65, P1055, DOI 10.1016/j.ces.2009.09.059
   Chaubey R, 2013, RENEW SUST ENERG REV, V23, P443, DOI 10.1016/j.rser.2013.02.019
   Doraiswamy L. K, 2006, CATAL REV SCI ENG, V4940
   Dutta S, 2014, J IND ENG CHEM, V20, P1148, DOI 10.1016/j.jiec.2013.07.037
   DWIVEDI PN, 1977, IND ENG CHEM PROC DD, V16, P157, DOI 10.1021/i260062a001
   Faghri A., 2006, TRANSPORT PHENOMENA
   Fogler H.S., 2004, ELEMENTS CHEM REACTI
   Frantz J. F, 1962, CHEM ENG         SEP, P161
   Freund H, 2003, CHEM ENG SCI, V58, P903, DOI 10.1016/S0009-2509(02)00622-X
   Frossling N., 1938, Gerlands Beitrage zur Geophysik, V52, P170
   Guo G, 2001, CHEM ENG SCI, V56, P121, DOI 10.1016/S0009-2509(00)00413-9
   Gupta SK, 1995, NUMERICAL METHODS EN
   HARUTA M, 1981, INT J HYDROGEN ENERG, V6, P601, DOI 10.1016/0360-3199(81)90025-2
   Hoon Chew Yin, 2006, P 1 INT C NAT RES EN, V500-509
   JU CC, 1953, CHEM ENG PROG, V49, P141
   Kim KR, 2001, J IND ENG CHEM, V7, P116
   Lalik E, 2015, INT J HYDROGEN ENERG, V40, P16127, DOI 10.1016/j.ijhydene.2015.09.079
   Marin G. U. Y. B, 2014, ADV CHEM ENG
   MARTIN H, 1978, CHEM ENG SCI, V33, P913, DOI 10.1016/0009-2509(78)85181-1
   McCabe WL, 1993, UNIT OPERATIONS CHEM
   Ozdural AR, 2001, CHEM ENG SCI, V56, P3483, DOI 10.1016/S0009-2509(01)00049-5
   Rexwinkel G, 1997, CHEM ENG SCI, V52, P3995, DOI 10.1016/S0009-2509(97)00242-X
   Saint-Just J, 2016, WOODHEAD PUBL SER EN, P263, DOI 10.1016/B978-1-78242-363-8.00010-4
   Sandeep KC, 2017, INT J HYDROGEN ENERG, V42, P29300, DOI 10.1016/j.ijhydene.2017.10.023
   Sandeep KC, 2014, INT J HYDROGEN ENERG, V39, P17906, DOI 10.1016/j.ijhydene.2014.08.148
   SENGUPTA A, 1962, AICHE J, V8, P608
   THOENES D, 1958, CHEM ENG SCI, V8, P271, DOI 10.1016/0009-2509(58)85034-4
   UPADHYAY SN, 1975, J CHEM ENG DATA, V20, P20, DOI 10.1021/je60064a001
   WAKAO N, 1978, CHEM ENG SCI, V33, P1375, DOI 10.1016/0009-2509(78)85120-3
   WEEKMAN VW, 1974, AICHE J, V20, P833, DOI 10.1002/aic.690200502
   Wehinger GD, 2015, CHEM ENG SCI, V122, P197, DOI 10.1016/j.ces.2014.09.007
NR 32
TC 0
Z9 0
U1 2
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 508
EP 518
DI 10.1016/j.ces.2019.02.042
PG 11
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900040
DA 2020-05-12
ER

PT J
AU Khadaroo, SNBA
   Grassia, P
   Gouwanda, D
   Poh, PE
AF Khadaroo, Sabeeha N. B. A.
   Grassia, Paul
   Gouwanda, Darwin
   Poh, Phaik Eong
TI Is the dewatering of Palm Oil Mill Effluent (POME) feasible? Effect of
   temperature on POME's rheological properties and compressive behavior
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Palm oil mill effluent; Batch settling; Batch filtration; Compressive
   yield stress; Hindered settling function; Diffusivity function
ID PRESSURE FILTRATION; ANAEROBIC-DIGESTION; YIELD-STRESS; SUSPENSIONS;
   STRATEGIES; PREDICTION; THICKENERS; MODEL
AB The current treatment process of Palm Oil Mill Effluent (POME) has been a cause of concern over recent years as POME is known to cause greenhouse gas emission as well as water pollution. An alternative for POME treatment process optimization is to eliminate the conventional cooling ponds and introduce a dewatering device such as a thickener. The thickener will assist in the solid-liquid separation, removal of microbes and other impurities from the wastewater. The latter will contribute to making the anaerobic digesters used to treat POME more efficient by allowing a means of control on the digesters' load. However, to be able to design and predict the performance of the thickener unit; essential rheological properties of the suspension have to be determined. The rheological characteristics and the compressive behavior of POME have not been studied previously nor has the implementation of such a dewatering device in the POME treatment process. This paper attempts to bridge the gap on the rheological characteristics, the compressive behavior and the effect of temperature on the rheological properties of POME through batch settling and batch filtration experiments. Data such as the compressive yield stress, the hindered settling function, and the diffusivity function for POME have been extracted and evaluated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Khadaroo, Sabeeha N. B. A.; Gouwanda, Darwin; Poh, Phaik Eong] Monash Univ Malaysia, Sch Engn, Chem Engn Discipline, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
   [Grassia, Paul] Univ Strathclyde, Dept Chem & Proc Engn, James Weir Bldg,75 Montrose St, Glasgow G1 1XJ, Lanark, Scotland.
RP Poh, PE (reprint author), Monash Univ Malaysia, Sch Engn, Chem Engn Discipline, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia.
EM poh.phaik.eong@monash.edu
RI Poh, Phaik Eong/H-2335-2013
OI Poh, Phaik Eong/0000-0002-4215-5284; Grassia, Paul/0000-0001-5236-1850
FU Monash University MalaysiaMonash University; Royal Academy of
   Engineering under the Newton Research Collaboration Programme
   [NRCP1516/4/34]
FX The authors acknowledge financial support from Monash University
   Malaysia and the Royal Academy of Engineering under the Newton Research
   Collaboration Programme (Project NRCP1516/4/34).
CR Anderson NJ, 2002, WATER SCI TECHNOL, V46, P51
   Appels L, 2008, PROG ENERG COMBUST, V34, P755, DOI 10.1016/j.pecs.2008.06.002
   ASTM, 2000, TEST
   Aziz AAA, 2000, WATER SCI TECHNOL, V41, P9
   Carrere H, 2016, BIORESOURCE TECHNOL, V199, P386, DOI 10.1016/j.biortech.2015.09.007
   Choong YY, 2018, RENEW SUST ENERG REV, V82, P2993, DOI 10.1016/j.rser.2017.10.036
   de Kretser RG, 2001, AICHE J, V47, P1758, DOI 10.1002/aic.690470808
   Deniz V, 2015, PHYSICOCHEM PROBL MI, V51, P351, DOI 10.5277/ppmp150131
   Gladman B, 2006, KOREA-AUST RHEOL J, V18, P191
   Grassia P, 2008, CHEM ENG SCI, V63, P1971, DOI 10.1016/j.ces.2007.12.025
   Green MD, 1996, AICHE J, V42, P2308, DOI 10.1002/aic.690420820
   Green MD, 1998, IND ENG CHEM RES, V37, P4152, DOI 10.1021/ie970544i
   Harbour PJ, 2001, WATER SCI TECHNOL, V44, P191
   Hassan MA, 2005, WASTE TREAT FOOD PRO, P101, DOI DOI 10.1201/9781420037128.CH4
   Iskandar MJ, 2018, ENVIRON TECHNOL INNO, V9, P169, DOI 10.1016/j.eti.2017.11.003
   LANDMAN KA, 1994, ADV COLLOID INTERFAC, V51, P175, DOI 10.1016/0001-8686(94)80036-7
   LANDMAN KA, 1995, AICHE J, V41, P1687, DOI 10.1002/aic.690410709
   Landman KA, 1999, AICHE J, V45, P1875, DOI 10.1002/aic.690450905
   Lester DR, 2005, AICHE J, V51, P1158, DOI 10.1002/aic.10333
   Perlmutter B. A., 2015, SOLID LIQUID FILTRAT
   Raha S, 2005, POWDER TECHNOL, V155, P42, DOI 10.1016/j.powtec.2005.05.040
   Scales P., 2006, INTERFACE SCI TECHNO, V10, DOI [10.1016/S1573-4285(06)80082, DOI 10.1016/S1573-4285(06)80082]
   Skinner SJ, 2015, WATER RES, V82, P2, DOI 10.1016/j.watres.2015.04.045
   Stickland AD, 2005, AICHE J, V51, P2481, DOI 10.1002/aic.10501
   Stickland AD, 2008, CHEM ENG SCI, V63, P5283, DOI 10.1016/j.ces.2008.07.016
   Stickland AD, 2015, WATER RES, V82, P37, DOI 10.1016/j.watres.2015.04.004
   Tabassum S, 2015, J CLEAN PROD, V95, P148, DOI 10.1016/j.jclepro.2015.02.056
   Tan CK, 2017, MINER ENG, V105, P52, DOI 10.1016/j.mineng.2017.01.011
   Usher SP, 2009, CHEM ENG J, V151, P202, DOI 10.1016/j.cej.2009.02.027
   Usher SP, 2001, AICHE J, V47, P1561, DOI 10.1002/aic.690470709
   Usher SP, 2005, CHEM ENG J, V111, P253, DOI 10.1016/j.cej.2005.02.015
   Zhang Y, 2015, CHEM ENG SCI, V134, P297, DOI 10.1016/j.ces.2015.05.016
   Zhang Y, 2015, CHEM ENG SCI, V128, P54, DOI 10.1016/j.ces.2015.01.066
   Zhang Y, 2013, CHEM ENG SCI, V101, P346, DOI 10.1016/j.ces.2013.06.055
NR 34
TC 1
Z9 1
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 519
EP 528
DI 10.1016/j.ces.2019.03.051
PG 10
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900041
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Woo, Y
   Jeong, JH
   Lee, JW
   Park, J
   Cha, M
   Kim, D
   Yoo, K
   Yoon, JH
AF Woo, Yesol
   Jeong, Jae Hak
   Lee, Jong-Won
   Park, Jeasung
   Cha, Minjun
   Kim, Dongseon
   Yoo, Kyoungkeun
   Yoon, Ji-Ho
TI Thermodynamic stability and formation kinetics of CHClF2 hydrates in the
   presence of NiCl2
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas hydrate; Desalination; CHClF2; Phase equilibria; Formation kinetics
ID GAS HYDRATE; PHASE-EQUILIBRIA; ECONOMIC-EVALUATION; CARBON CAPTURE;
   WASTE-WATER; RECOVERY; METHANE; SYSTEM; NACL; REFRIGERANTS
AB A hydrate-based technology is suggested for the desalination of industrial effluents, especially electro-plating effluents including NiCl2. To decrease the required energy for operating a hydrate-based desalination (HBD) process, chlorodifluoromethane (CHClF2) was used as a guest for hydrate formation at relatively mild conditions. The phase equilibria of CHClF2 hydrates formed in aqueous NiCl2 solutions were investigated to identify the effect of NiCl2 on the thermodynamic stability of CHClF2 hydrates. The dissociation phase boundary of CHClF2 hydrates in the presence of NiCl2 was shifted to higher pressures and lower temperatures as the salinity of aqueous solutions increased. To confirm the feasibility of NiCl2 separation from wastewaters via the HBD process, X-ray diffraction and Raman spectroscopic measurements were performed. The results showed that the Ni2+ and Cl- ions did not participate in the hydrate framework, which revealed that the HBD process could be used to remove NiCl2 from effluents. The formation kinetics of CHClF2 hydrates were analyzed by a new kinetic model adopting transient time-dependent apparent rate constants, which significantly depends on the sub-cooling temperature and the concentration of NiCl2 in the aqueous solutions. Thermodynamic approximations regarding the Ni2+ and Cl- ion exclusion from the clathrate framework and the full occupancy of CHClF2 molecules in the large cages of structure I clathrate hydrate were confirmed by comparing the calculated Ni2+ concentrations in the liquid phase in equilibrium with CHClF2 clathrate hydrates with the experimental measurements. These results provide good information for separating metal ions from wastewater streams by HBD processes. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Woo, Yesol; Kim, Dongseon; Yoon, Ji-Ho] Korea Maritime & Ocean Univ, Ocean Sci & Technol OST Sch, Dept Convergence Study Ocean Sci & Technol, Busan 49112, South Korea.
   [Jeong, Jae Hak; Yoo, Kyoungkeun; Yoon, Ji-Ho] Korea Maritime & Ocean Univ, Dept Energy & Resources Engn, Busan 49112, South Korea.
   [Lee, Jong-Won] Kongju Natl Univ, Dept Environm Engn, Chungnam 31080, South Korea.
   [Park, Jeasung] Korea Inst Ind Technol KITECH, Intelligent Sustainable Mat R&D Grp, Chungnam 31056, South Korea.
   [Cha, Minjun] Kangwon Natl Univ, Dept Energy & Resources Engn, Chunchon 24341, South Korea.
   [Kim, Dongseon; Yoon, Ji-Ho] Korea Inst Ocean Sci & Technol, Marine Chem & Geochem Res Ctr, Busan 49111, South Korea.
RP Yoon, JH (reprint author), Korea Maritime & Ocean Univ, Ocean Sci & Technol OST Sch, Dept Convergence Study Ocean Sci & Technol, Busan 49112, South Korea.
EM jhyoon@kmou.ac.kr
RI Yoo, Kyoungkeun/X-8025-2019
FU Mid-career Research Program through the National Research Foundation of
   Korea (NRF) grant - Ministry of Science and ICT [2015003772]
FX This research was supported by the Mid-career Research Program
   (2015003772) through the National Research Foundation of Korea (NRF)
   grant founded by the Ministry of Science and ICT.
CR Ahn KH, 1999, DESALINATION, V122, P77, DOI 10.1016/S0011-9164(99)00029-6
   BARDUHN AJ, 1978, DESALINATION, V25, P151, DOI 10.1016/S0011-9164(00)88101-1
   Benvenuti T, 2014, SEP PURIF TECHNOL, V129, P106, DOI 10.1016/j.seppur.2014.04.002
   Berecz E, 1983, GAS HYDRATES
   Chan MK, 1996, J CHEM ENG DATA, V41, P1114
   Chu S, 2009, SCIENCE, V325, P1599, DOI 10.1126/science.1181637
   Chun MK, 1998, FLUID PHASE EQUILIBR, V150, P361, DOI 10.1016/S0378-3812(98)00336-7
   Chun MK, 2000, J CHEM ENG DATA, V45, P1150, DOI 10.1021/je000004j
   DAVIDSON DW, 1986, GEOCHIM COSMOCHIM AC, V50, P619, DOI 10.1016/0016-7037(86)90110-9
   Davy H., 1811, PHILOS T R SOC LONDO, V101, P155, DOI DOI 10.1098/RSTL.1811.0008
   ENGLEZOS P, 1987, CHEM ENG SCI, V42, P2647, DOI 10.1016/0009-2509(87)87015-X
   ENGLEZOS P, 1993, IND ENG CHEM RES, V32, P1251, DOI 10.1021/ie00019a001
   ENGLEZOS P, 1987, CHEM ENG SCI, V42, P2659, DOI 10.1016/0009-2509(87)87016-1
   Eslamimanesh A, 2011, CHEM ENG SCI, V66, P5439, DOI 10.1016/j.ces.2011.06.062
   Ganji H, 2007, FUEL, V86, P434, DOI 10.1016/j.fuel.2006.07.032
   Gibbins J, 2008, ENERG POLICY, V36, P4317, DOI 10.1016/j.enpol.2008.09.058
   Hammerschmidt EG, 1934, IND ENG CHEM, V26, P851, DOI 10.1021/ie50296a010
   Hashemi H, 2015, J CHEM THERMODYN, V82, P47, DOI 10.1016/j.jct.2014.10.017
   Hashemi H, 2014, J CHEM ENG DATA, V59, P3907, DOI 10.1021/je5007955
   Javanmardi J, 2005, APPL THERM ENG, V25, P1708, DOI 10.1016/j.applthermaleng.2004.10.009
   Javanmardi J, 2003, APPL THERM ENG, V23, P845, DOI 10.1016/S1359-4311(03)00023-1
   Kang SP, 2000, ENVIRON SCI TECHNOL, V34, P4397, DOI 10.1021/es001148l
   Karamoddin M, 2014, INT J REFRIG, V44, P66, DOI 10.1016/j.ijrefrig.2014.04.020
   Karamoddin M, 2014, J NAT GAS SCI ENG, V19, P46, DOI 10.1016/j.jngse.2014.04.013
   Karamoddin M, 2013, J CHEM THERMODYN, V65, P213, DOI 10.1016/j.jct.2013.06.001
   Kurniawan TA, 2006, CHEM ENG J, V118, P83, DOI 10.1016/j.cej.2006.01.015
   LEFEBVRE JH, 1992, J RAMAN SPECTROSC, V23, P243, DOI 10.1002/jrs.1250230502
   Linga P, 2007, J HAZARD MATER, V149, P625, DOI 10.1016/j.jhazmat.2007.06.086
   Maeda K, 2008, CHEM ENG PROCESS, V47, P2281, DOI 10.1016/j.cep.2008.01.002
   MERKE I, 1995, J MOL SPECTROSC, V173, P463, DOI 10.1006/jmsp.1995.1249
   Mohammadi A, 2014, CHEM ENG J, V237, P387, DOI 10.1016/j.cej.2013.09.026
   Ogawa T, 2006, APPL THERM ENG, V26, P2157, DOI 10.1016/j.applthermaleng.2006.04.003
   Park KN, 2011, DESALINATION, V274, P91, DOI 10.1016/j.desal.2011.01.084
   RIPMEESTER JA, 1987, NATURE, V325, P135, DOI 10.1038/325135a0
   Seo Y, 2015, ENVIRON SCI TECHNOL, V49, P6045, DOI 10.1021/acs.est.5b00866
   Silva PTD, 2006, J HAZARD MATER, V128, P39, DOI 10.1016/j.jhazmat.2005.07.026
   Sloan E. D., 1988, CLATHRATE HYDRATES N
   Snels M, 2001, J MOL SPECTROSC, V209, P1, DOI 10.1006/jmsp.2001.8403
   SOAVE G, 1972, CHEM ENG SCI, V27, P1197, DOI 10.1016/0009-2509(72)80096-4
   Song YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep21389
   *UNEP, 2000, MONTR PROT SUBST DEP
   Wittstruck T. A., 1961, J CHEM ENG DATA, V6, P343
   Woo Y, 2019, SEP PURIF TECHNOL, V209, P56, DOI 10.1016/j.seppur.2018.07.015
   ZareNezhad B, 2014, ENERG CONVERS MANAGE, V79, P289, DOI 10.1016/j.enconman.2013.12.030
   Zhang JS, 2007, IND ENG CHEM RES, V46, P6353, DOI 10.1021/ie070627r
   Zhong Y, 2000, CHEM ENG SCI, V55, P4175, DOI 10.1016/S0009-2509(00)00072-5
NR 46
TC 1
Z9 1
U1 5
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUL 20
PY 2019
VL 202
BP 529
EP 536
DI 10.1016/j.ces.2018.09.002
PG 8
WC Engineering, Chemical
SC Engineering
GA HS4ZP
UT WOS:000463879900042
DA 2020-05-12
ER

PT J
AU Taniguchi, M
   Ueda, Y
   Yagi, A
   Ikeda, S
   Endo, M
   Tomimatsu, T
   Nakayama, T
   Sekine, M
   Enomoto, T
   Kimura, T
AF Taniguchi, Mariko
   Ueda, Yutaka
   Yagi, Asami
   Ikeda, Sayaka
   Endo, Masayuki
   Tomimatsu, Takuji
   Nakayama, Tomio
   Sekine, Masayuki
   Enomoto, Takayuki
   Kimura, Tadashi
TI Cervical cancer screening rate differs by HPV vaccination status: An
   interim analysis
SO VACCINE
LA English
DT Article
DE Cervical cancer; Screening rate; HPV vaccine; Vaccination status
ID JAPANESE WOMEN; YOUNG; RISK
AB Background: The incidence of cervical cancer has been increasing, especially in younger generation, in Japan. The females born between 1994 and 1999, who achieved rates of HPV vaccination approaching 70%, have become the target of cervical cancer screening programs. Here, we have analyzed the cervical cancer screening rates among the vaccinated and unvaccinated women.
   Methods: The survey data for cervical cancer screening at age 20 in FY 2015 was derived from two cities, Toyonaka and Iwaki.
   Results: Among 2,727 females, in Toyonaka and Iwaki, who were born in FY 1995 and targeted in FY 2015 at age 20 for cervical cancer screening, their HPV vaccination rate was 64.2% (1,753/2,727). The screening rate was 6.4% (112/1,753) in the vaccinated and 3.9% (38/974) in the unvaccinated. This difference was statistically significant (p < 0.01).
   Conclusions: We have demonstrated that HPV-vaccinated females tended to be effectively protected from future cervical cancer than the unvaccinated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Taniguchi, Mariko; Ueda, Yutaka; Yagi, Asami; Endo, Masayuki; Tomimatsu, Takuji; Kimura, Tadashi] Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Ikeda, Sayaka] Int Univ Hlth & Werfare, Mita Hosp, Dept Gynecol, Minato Ku, 1-4-3 Mita, Tokyo 1088329, Japan.
   [Nakayama, Tomio] Natl Canc Ctr, Ctr Publ Hlth Sci, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Sekine, Masayuki; Enomoto, Takayuki] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.
RP Ueda, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ZVF03563@nifty.ne.jp
FU Health and Labor Sciences Research GrantMinistry of Health, Labour and
   Welfare, Japan [H29-024]
FX This study was supported by a Health and Labor Sciences Research Grant
   (H29-024).
CR Cancer Information Service National Cancer Center Japan, CANC REG STAT
   Egawa-Takata T, 2016, INT J CLIN ONCOL, V21, P962, DOI 10.1007/s10147-016-0970-4
   Ferlay J., 2013, GLOBOCAN 2012 V1 0 C
   Guo FJ, 2017, J WOMENS HEALTH, V26, P1114, DOI 10.1089/jwh.2017.6424
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Kudo R, 2016, INT J PATHOL CLIN RE, V2
   Kuroki H, 2012, J OBSTET GYNAECOL RE, V38, P35, DOI 10.1111/j.1447-0756.2011.01672.x
   Miura S, 2006, INT J CANCER, V119, P2713, DOI 10.1002/ijc.22195
   Onuki M, 2009, CANCER SCI, V100, P1312, DOI 10.1111/j.1349-7006.2009.01161.x
   Ueda Y, 2015, AM J OBSTET GYNECOL, V212, P405, DOI 10.1016/j.ajog.2014.11.037
   Ueda Y, 2015, J EPIDEMIOL, V25, P50, DOI 10.2188/jea.JE20140080
   World Health Organization, HUM PAP HPV CERV CAN
   Yagi A, 2019, CANCER RES, V79, P1252, DOI 10.1158/0008-5472.CAN-18-3109
   Yagi A, 2017, HUM VACC IMMUNOTHER, V13, P1700, DOI 10.1080/21645515.2017.1292190
   Yamaguchi M, 2018, PAPILLOMAVIRUS RES, V6, P6, DOI 10.1016/j.pvr.2018.05.002
NR 15
TC 0
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4424
EP 4426
DI 10.1016/j.vaccine.2019.06.064
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000004
PM 31272873
DA 2020-05-12
ER

PT J
AU Peyraud, N
   Zehrung, D
   Jarrahian, C
   Frivold, C
   Orubu, T
   Giersing, B
AF Peyraud, Nicolas
   Zehrung, Darin
   Jarrahian, Courtney
   Frivold, Collrane
   Orubu, Toritse
   Giersing, Birgitte
TI Potential use of microarray patches for vaccine delivery in low- and
   middle- income countries
SO VACCINE
LA English
DT Review
DE Microarray patches; Microneedle patches; Vaccine; Delivery; Product
   development
ID MICRONEEDLE PATCHES; INTRADERMAL DELIVERY; TRANSCUTANEOUS IMMUNIZATION;
   INACTIVATED POLIOVIRUS; SKIN VACCINATION; ACCEPTABILITY; ARRAYS; VIRUS;
   PAIN; TOLERABILITY
AB Microarray patches (MAPs), also referred to as microneedle patches, are a novel methodology that have the potential to overcome barriers to vaccine delivery in low- and middle-income countries (LMICs), and transform the way that vaccines are delivered within immunization programs. The World Health Organization's Initiative for Vaccine Research and its partners are working to understand how MAPs could ease vaccine delivery and increase equitable access to vaccines in LMICs. Global stakeholders have been engaged to evaluate technical, economic, and programmatic challenges; to validate assumptions where possible; and to propose areas of focus to facilitate future vaccine-MAP product development. This report summarizes those learnings. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Peyraud, Nicolas; Giersing, Birgitte] World Hlth Org, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland.
   [Peyraud, Nicolas] Medecins Sans Frontieres, Rue Lausanne 78, CH-2012 Geneva, Switzerland.
   [Zehrung, Darin; Jarrahian, Courtney; Frivold, Collrane] PATH, Seattle, WA 98121 USA.
   [Orubu, Toritse] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
RP Giersing, B (reprint author), World Hlth Org, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland.
EM giersingb@who.int
FU Bill & Melinda Gates FoundationGates Foundation; DFID
FX The authors thank Alan Fauconnier (WHO) and Pieter Neels (independent
   consultant) for their support with reviewing the regulatory pathways
   section. We would also like to thank Julian Hickling (independent
   consultant) for his review of this manuscript, and Marge Murray (PATH)
   for editing. PATH's contribution to this paper was supported by funding
   from the Bill & Melinda Gates Foundation and DFID.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P53
   [Anonymous], 2018, VIPS VACCINE INNOVAT
   [Anonymous], 2017, WKLY EPIDEMIOL REC 2, V92, P369
   Arya J, 2017, BIOMATERIALS, V128, P1, DOI 10.1016/j.biomaterials.2017.02.040
   Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019
   Arya JM, 2016, J CONTROL RELEASE, V239, P19, DOI 10.1016/j.jconrel.2016.08.012
   Bal SM, 2008, EUR J PHARM SCI, V35, P193, DOI 10.1016/j.ejps.2008.06.016
   Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]
   Burton SA, 2011, PHARM RES-DORDR, V28, P31, DOI 10.1007/s11095-010-0177-8
   Carey JB, 2014, SCI REP-UK, V4, DOI 10.1038/srep06154
   Chaiyakunapruk N, HEPATITIS B VACCINAT
   Chandrasekhar S, 2013, EXPERT OPIN DRUG DEL, V10, P1155, DOI 10.1517/17425247.2013.797405
   Corbett HJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013460
   Dellepiane N, 2015, VACCINE, V33, P52, DOI 10.1016/j.vaccine.2013.11.066
   Ding Z, 2011, PHARM RES-DORDR, V28, P145, DOI 10.1007/s11095-010-0093-y
   Durrheim DN, 2017, T ROY SOC TROP MED H, V111, P41, DOI 10.1093/trstmh/trx018
   Edens C, 2015, VACCINE, V33, P4683, DOI 10.1016/j.vaccine.2015.01.089
   Esser ES, 2016, J CONTROL RELEASE, V236, P47, DOI 10.1016/j.jconrel.2016.06.026
   Fernando GJP, 2018, VACCINE, V36, P3779, DOI 10.1016/j.vaccine.2018.05.053
   Fernando GJP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010266
   Giersing BK, 2017, VACCINE, V35, P6793, DOI 10.1016/j.vaccine.2017.04.063
   Gill HS, 2010, GENE THER, V17, P811, DOI 10.1038/gt.2010.22
   Gill HS, 2008, CLIN J PAIN, V24, P585, DOI 10.1097/AJP.0b013e31816778f9
   Griffin P, 2017, VACCINE, V35, P6676, DOI 10.1016/j.vaccine.2017.10.021
   Haq MI, 2009, BIOMED MICRODEVICES, V11, P35, DOI 10.1007/s10544-008-9208-1
   Hiraishi Y, 2011, VACCINE, V29, P2626, DOI 10.1016/j.vaccine.2011.01.042
   Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007
   Huang J, 2009, CLIN VACCINE IMMUNOL, V16, P719, DOI 10.1128/CVI.00447-08
   Jacoby E, 2015, VACCINE, V33, P4699, DOI 10.1016/j.vaccine.2015.03.062
   John Watkins, 2017, REGULAT RAPPORTEUR, V14
   Joyce JC, 2018, J INFECT DIS, V218, P124, DOI 10.1093/infdis/jiy139
   Kask AS, 2010, VACCINE, V28, P7483, DOI 10.1016/j.vaccine.2010.09.014
   Kaushik S, 2001, ANESTH ANALG, V92, P502, DOI 10.1213/00000539-200102000-00041
   Kim E, 2016, EBIOMEDICINE, V13, P315, DOI 10.1016/j.ebiom.2016.09.028
   Kines RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120797
   Kyu HH, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4111-4
   Lambert N, 2015, LANCET, V385, P2297, DOI 10.1016/S0140-6736(14)60539-0
   Leone M, 2017, PHARM RES-DORDR, V34, P2223, DOI 10.1007/s11095-017-2223-2
   Li JC, 2016, 29TH INTERNATIONAL SYMPOSIUM ON BALLISTICS, VOLS 1 AND 2, P2018
   Liu Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29135-w
   Lutton REM, 2015, DRUG DELIV TRANSL RE, V5, P313, DOI 10.1007/s13346-015-0237-z
   MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201
   Marshall S, 2017, VACCINE, V35, P4896, DOI 10.1016/j.vaccine.2017.07.083
   Marshall S, 2016, VACCINE, V34, P723, DOI 10.1016/j.vaccine.2015.12.002
   Matsuo K, 2012, J CONTROL RELEASE, V160, P495, DOI 10.1016/j.jconrel.2012.04.001
   McAllister DV, 2003, P NATL ACAD SCI USA, V100, P13755, DOI 10.1073/pnas.2331316100
   McCrudden MTC, 2015, DRUG DELIV TRANSL RE, V5, P3, DOI 10.1007/s13346-014-0211-1
   Mikszta JA, 2006, INFECT IMMUN, V74, P6806, DOI 10.1128/IAI.01210-06
   Moon S, 2013, VACCINE, V31, P3396, DOI 10.1016/j.vaccine.2012.11.027
   Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0
   Muller DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13011-0
   Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076
   Park S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205071
   PATH, 2017, EV MICR PATCH HUM FA
   Pattani A, 2012, J CONTROL RELEASE, V162, P529, DOI 10.1016/j.jconrel.2012.07.039
   Pearson FE, 2015, VACCINE, V33, P3248, DOI 10.1016/j.vaccine.2015.03.039
   Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003
   Poirier D, 2017, BIOMATERIALS, V145, P256, DOI 10.1016/j.biomaterials.2017.08.038
   Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504
   Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514
   Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304
   Prow TW, 2010, SMALL, V6, P1776, DOI 10.1002/smll.201000331
   Qiu YQ, 2016, DRUG DELIV, V23, P2391, DOI 10.3109/10717544.2014.992497
   Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Suh H, 2014, CLIN EXP VACCINE RES, V3, P42, DOI 10.7774/cevr.2014.3.1.42
   U.S. Food & Drug Administration, 2018, COMBINATION PRODUCT
   van der Maaden K, 2015, LANGMUIR, V31, P8654, DOI 10.1021/acs.langmuir.5b01262
   Wang BZ, 2014, J CONTROL RELEASE, V178, P1, DOI 10.1016/j.jconrel.2014.01.002
   Wang YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166038
   World Health Organization, 2018, WHO GLOB BENCHM TOOL
   World Health Organization, 2018, FULL PUBLIC HEALTH V
   World Health Organization, 2015, WHO MICROARRAY PATCH
   World Health Organization, 2017, REPL ANN 1 WHO TECHN, V924
   World Health Organization, WHOS VISION AND MISS
   World Health Organization, 2015, ANN 4 GUID PROC DAT
   World Health Organization, TRANSFORMING OUR WOR
   World Health Organization, 2017, WKLY EPIDEMIOL REC, V92, P53
   World Hlth Org, 2018, VACCINE, V36, P5500, DOI 10.1016/j.vaccine.2018.06.061
   Zehrung D, 2017, VACCINE, V35, P2265, DOI 10.1016/j.vaccine.2016.11.095
NR 80
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4427
EP 4434
DI 10.1016/j.vaccine.2019.03.035
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000005
PM 31262587
OA Other Gold
DA 2020-05-12
ER

PT J
AU Guillermet, E
   Alfa, DA
   Mai, LTP
   Subedi, M
   Demolis, R
   Giersing, B
   Jaillard, P
AF Guillermet, Elise
   Alfa, Daleb Abdoulaye
   Le Thi Phuong Mai
   Subedi, Madhusudan
   Demolis, Rachel
   Giersing, Birgitte
   Jaillard, Philippe
TI End-user acceptability study of the nanopatch (TM); a microarray patch
   (MAP) for child immunization in low and middle-income countries
SO VACCINE
LA English
DT Article
DE Attitude to health; Nanopatch; Microneedle; Immunization programs;
   Vaccine
ID DISSOLVING MICRONEEDLE PATCH; VACCINATION; TOLERABILITY; USABILITY
AB A promising new delivery technology, the microarray patch (MAPS) consists of an array of small solid coated or dissolvable needles, up to one mm in length, that administers a dry formulation of a vaccine or pharmaceutical. This study is not a real-life evaluation study but determines the anticipated acceptability of the Nanopatch (TM), a solid microarray patch device, in Benin, Nepal and Vietnam for vaccine delivery, and identifies factors that could improve the acceptability of the technology to increase measles immunization coverage.
   This study combined several evaluation methods, including simulation of vaccine administration on children and in-depth interviews with key stakeholders, healthcare workers, community health volunteers, caretakers, and community representatives.
   A total of 314 people participated in the study. The overall rate of total acceptability of the patch for child immunization was 92.7%. General opinions were very positive, providing clinical studies confirm that MAP administration is demonstrated to be painless, safe and effective for infectious disease prevention. The study participants were asked to consider the best strategy to introduce such vaccine delivery innovation. Firstly, delivery by skilled healthcare workers at the healthcare facilities will be preferred to establish the technology. Following this, administration by selected volunteers and outreach delivery may be possible, though under the supervision of skilled healthcare workers.
   This study's protocol received approval from the World Health Organization (WHO) Ethical Research Committee (ERC0002813) and the national IRB in Benin, Nepal and Vietnam. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guillermet, Elise; Jaillard, Philippe] Epilinks, St Genis Pouilly, France.
   [Alfa, Daleb Abdoulaye] Univ Abomey Calavi, Cotonou, Benin.
   [Le Thi Phuong Mai] Minist Hlth, Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
   [Subedi, Madhusudan] Tribhuvan Univ, Kirtipur, Nepal.
   [Demolis, Rachel] AMP Serv, Gennevilliers, France.
   [Giersing, Birgitte] World Hlth Org, Geneva, Switzerland.
RP Guillermet, E (reprint author), 994 Route Lac, F-74140 Chens Sur Leman, France.
EM eguillermet@epilinks.net; giersingb@who.int
FU World Health Organization (WHO), Department of Immunization, Vaccine and
   Biologicals; European Union's Seventh Programme for research,
   technological development and demonstrationEuropean Union (EU) [280873]
FX This study was funded by World Health Organization (WHO), Department of
   Immunization, Vaccine and Biologicals with support from a grant from the
   European Union's Seventh Programme for research, technological
   development and demonstration, under grant agreement No. 280873.
CR Agbenu E, 2014, INT J OCCUP ENV MED, V5, P9
   Arya J, 2017, BIOMATERIALS, V128, P1, DOI 10.1016/j.biomaterials.2017.02.040
   Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019
   Sartori AMC, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049006058
   De Coster I, 2015, VACCINE, V33, P3976, DOI 10.1016/j.vaccine.2015.06.030
   Donnelly RF, 2017, DRUG DISCOV TODAY, DOI [10.1016/j.drudis2017.10011, DOI 10.1016/J.DRUDIS2017.10011]
   Edens C, 2013, VACCINE, V31, P3403, DOI 10.1016/j.vaccine.2012.09.062
   Farag NH, 2018, VACCINE, V6, P36, DOI [10.10161/j.vaccine2018.06.011, DOI 10.10161/J.VACCINE2018.06.011]
   Fernando GJP, 2018, VACCINE, V36, P3779, DOI 10.1016/j.vaccine.2018.05.053
   Griffin P, 2017, VACCINE, V35, P6676, DOI 10.1016/j.vaccine.2017.10.021
   Guillermet E, 2015, PLOS ONE, DOI [10.1371/journalpone.0137797, DOI 10.1371/JOURNALPONE.0137797]
   Hanvoravongchai P, 2011, J INFECT DIS, V204, pS82, DOI 10.1093/infdis/jir091
   Hirobe S, 2013, PHARM RES-DORDR, V30, P2664, DOI 10.1007/s11095-013-1092-6
   Kahn AL, 2017, VACCINE, V35, P2214, DOI 10.1016/j.vaccine.2016.10.091
   Lee BY, 2015, VACCINE, V33, P4727, DOI 10.1016/j.vaccine.2015.02.076
   Lim J, 2016, OPER RES HEALTH CARE, V9, P40, DOI 10.1016/j.orhc.2016.02.003
   Marshall S, 2017, VACCINE, V35, P4896, DOI 10.1016/j.vaccine.2017.07.083
   Marshall S, 2016, VACCINE, V34, P723, DOI 10.1016/j.vaccine.2015.12.002
   Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   Pruss-Ustun A, 2003, WHO ENV BURDEN DIS S, V3
   Wong C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169030
NR 22
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4435
EP 4443
DI 10.1016/j.vaccine.2019.02.079
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000006
PM 30890383
DA 2020-05-12
ER

PT J
AU Williams, M
   Ewing, D
   Blevins, M
   Sun, PF
   Sundaram, AK
   Raviprakash, KS
   Porter, KR
   Sanders, JW
AF Williams, Maya
   Ewing, Dan
   Blevins, Maria
   Sun, Peifang
   Sundaram, Appavu K.
   Raviprakash, Kanakatte S.
   Porter, Kevin R.
   Sanders, John W.
TI Enhanced immunogenicity and protective efficacy of a tetravalent dengue
   DNA vaccine using electroporation and intradermal delivery
SO VACCINE
LA English
DT Article
DE DNA vaccine; Dengue; Electroporation; intradermal
ID INTRAMUSCULAR ELECTROPORATION; NEUTRALIZING ANTIBODIES;
   IMMUNE-RESPONSES; VIRUS; SAFETY; EXPRESSION
AB Phase 1 clinical trials with a DNA vaccine for dengue demonstrated that the vaccine is safe and well tolerated, however it produced less than optimal humoral immune responses. To determine if the immunogenicity of the tetravalent dengue DNA vaccine could be enhanced, we explored alternate, yet to be tested, methods of vaccine administration in non-human primates. Animals were vaccinated on days 0, 28 and 91 with either a low (1 mg) or high (5 mg) dose of vaccine by the intradermal or intramuscular route, using either needle-free injection or electroporation devices. Neutralizing antibody, IFN-gamma T cell and memory B cell responses were compared to a high dose group vaccinated with a needle-free intramuscular injection delivery device similar to what had been used in previous preclinical and clinical studies. All previously untested vaccination methodologies elicited improved immune responses compared to the high dose needle-free intramuscular injection delivery group. The highest neutralizing antibody responses were observed in the group that was vaccinated with the high dose formulation via intradermal electroporation. The highest IFN-gamma T cell responses were also observed in the high dose intradermal electroporation group and the CD8(+) T cells were the dominant contributors for the IFN gamma response. Memory B cells were detected for all four serotypes. More than a year after vaccination, groups were challenged with dengue-1 virus. Both the low and high dose intradermal electroporation groups had significantly fewer days of dengue-1 virus RNAemia compared to the control group. The results from this study demonstrate that using either an electroporation device and/or the intradermal route of delivery increases the immune response generated by this vaccine in non-human primates and should be explored in humans. (C) 2019 Published by Elsevier Ltd.
C1 [Williams, Maya; Porter, Kevin R.] Naval Med Res Ctr, Infect Dis Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
   [Ewing, Dan; Sun, Peifang; Sundaram, Appavu K.; Raviprakash, Kanakatte S.] Naval Med Res Ctr, Viral & Rickettsial Dis Dept, Silver Spring, MD USA.
   [Blevins, Maria; Sanders, John W.] Wake Forest Sch Med, Sect Infect Dis, Winston Salem, NC USA.
RP Williams, M (reprint author), Naval Med Res Ctr, Infect Dis Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
EM maya.williams1.mil@mail.mil
FU Joint Warfighter Medical Research Program [JW140050/W81XWH-15-2-0029]
FX This work was funded by the Joint Warfighter Medical Research Program
   JW140050/W81XWH-15-2-0029.
CR Babiuk S, 2004, J BIOTECHNOL, V110, P1, DOI 10.1016/j.jbiotec.2004.01.015
   Beckett CG, 2011, VACCINE, V29, P960, DOI 10.1016/j.vaccine.2010.11.050
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Cemazar M, 2007, CURR OPIN MOL THER, V9, P554
   Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274
   Danko JR, 2018, AM J TROP MED HYG, V98, P849, DOI 10.4269/ajtmh.17-0416
   Dobano C, 2007, VACCINE, V25, P6635, DOI 10.1016/j.vaccine.2007.06.036
   Elnekave M, 2011, EXPERT REV VACCINES, V10, P1169, DOI [10.1586/erv.11.66, 10.1586/ERV.11.66]
   Escoffre JM, 2009, MOL BIOTECHNOL, V41, P286, DOI 10.1007/s12033-008-9121-0
   Grant-Klein RJ, 2015, HUM VACC IMMUNOTHER, V11, P1991, DOI 10.1080/21645515.2015.1039757
   Hegazy-Hassan W, 2018, VACCINE
   Hooper JW, 2014, CLIN MICROBIOL INFEC, V20, P110, DOI 10.1111/1469-0691.12553
   Kalams SA, 2013, J INFECT DIS, V208, P818, DOI 10.1093/infdis/jit236
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Kitchener S, 2006, VACCINE, V24, P1238, DOI 10.1016/j.vaccine.2005.09.029
   Kochel T, 1997, VACCINE, V15, P547, DOI 10.1016/S0264-410X(97)00215-6
   Kochel TJ, 2000, VACCINE, V18, P3166, DOI 10.1016/S0264-410X(00)00105-5
   Kumar R, 2013, VACCINE, V31, P3140, DOI 10.1016/j.vaccine.2013.05.006
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Manoj S, 2004, CRIT REV CL LAB SCI, V41, P1, DOI 10.1080/10408360490269251
   Micozkadioglu H, 2007, RENAL FAILURE, V29, P285, DOI 10.1080/08860220601166263
   Mohammed AJ, 2010, NEW ENGL J MED, V362, P2351, DOI 10.1056/NEJMoa0909383
   Porter KR, 1998, ARCH VIROL, V143, P997, DOI 10.1007/s007050050348
   Raviprakash K, 2000, VACCINE, V18, P2426, DOI 10.1016/S0264-410X(99)00570-8
   Raviprakash K, 2000, J GEN VIROL, V81, P1659, DOI 10.1099/0022-1317-81-7-1659
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Raviprakash K, 2009, HUM VACCINES, V5, P520, DOI 10.4161/hv.5.8.9008
   Santiago GA, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002311
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Vien NC, 2008, T ROY SOC TROP MED H, V102, P294, DOI 10.1016/j.trstmh.2007.11.010
   Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4444
EP 4453
DI 10.1016/j.vaccine.2019.06.083
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000007
PM 31279565
DA 2020-05-12
ER

PT J
AU Briggs, L
   Fronek, P
   Quinn, V
   Wilde, T
AF Briggs, Lynne
   Fronek, Patricia
   Quinn, Val
   Wilde, Tracy
TI Perceptions of influenza and pneumococcal vaccine uptake by older
   persons in Australia
SO VACCINE
LA English
DT Article
DE Influenza; Pneumococcal disease; Immunisation program; Older adults;
   Australia
ID POLYSACCHARIDE VACCINE; HESITANCY; COVERAGE; PEOPLE; ADULTS
AB Background: Influenza and pneumococcal vaccinations reduce adverse health outcomes in older adults. The Australian National Immunisation Program (NIP) provides free seasonal influenza and pneumococcal vaccinations for adults >= 65 y. Guidelines recommend all adults >= 65 y receive one dose of 23-valent pneumococcal polysaccharide vaccine (23vPPV) regardless of their risk of invasive pneumococcal disease. However, the reported rate of vaccination against pneumococcal disease is much lower than seasonal influenza. Identifying and understanding the perspective of older people on vaccination is important to informing effective promotional strategies for this age group.
   Methods: Using a purposive and snowball recruitment strategy, 36 participants aged between 65 and 84 years of age were recruited in south-east Queensland and northern New South Wales. Face-to-face qualitative interviews conducted between July 2017 and January 2018 were recorded, transcribed and thematically analysed.
   Results: In this sample, the uptake of the influenza vaccine (n = 28, 78%) was greater than for the pneumococcal vaccine (n = 14, 39%). Five key themes identified were health practitioner influence; anti-vaccination influence; social responsibility; work-based vaccination; and perceptions of age. The influences on uptake were complex and multi-faceted.
   Conclusions: Findings provide new insights, in particular, the role of social responsibility, the long-term impact of workplace vaccinations, and how older people do not necessarily consider themselves old. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Briggs, Lynne; Fronek, Patricia; Quinn, Val; Wilde, Tracy] Griffith Univ, Sch Human Serv & Social Work, Gold Coast Campus,Parklands Dr, Southport, Qld 4222, Australia.
   [Fronek, Patricia] Griffith Univ, Law Futures Ctr, Nathan Campus,170 Kessels Rd, Nathan, Qld 4111, Australia.
RP Briggs, L (reprint author), Griffith Univ, Sch Human Serv & Social Work, Gold Coast Campus,Parklands Dr, Southport, Qld 4222, Australia.
EM l.briggs@griffith.edu.au; p.fronek@griffith.edu.au;
   v.quinn@griffith.edu.au; tracy.wilde@griffith.edu.au
RI Fronek, Patricia/M-5042-2015
OI Fronek, Patricia/0000-0002-0454-7148; Briggs, Lynne/0000-0002-0219-3323
FU Griffith UniversityGriffith University; Hong Kong Polytechnic University
   Collaboration Research Grant
FX This research was supported by a Griffith University and The Hong Kong
   Polytechnic University Collaboration Research Grant. BHC GUHKPK
   Briggs17.
CR Andrews RM, 2005, VACCINE, V23, P2756, DOI 10.1016/j.vaccine.2004.11.039
   Australian Bureau of Statistics, 2018, 3303 0 DEATHS DUE IN
   Australian Government Department of Health, 2018, IPD Q REP
   Australian Government Department of Health, 2017, 2017 INFL SEAS AUSTR
   Australian Government Department of Health, 2018, NAT IMM STRAT AUSTR
   Australian Government Department of Health, 2015, AUSTR IMM HDB
   Australian Institute of Health and Welfare, 2018, AUSTR HLTH SER, V16
   Australian Institute of Health and Welfare 2011, 2011, 2009 AD VACC SURV SU
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Burt S, 2018, INT J CLIN PHARM-NET, V40, P1519, DOI 10.1007/s11096-018-0738-1
   Chen C, 2018, VACCINE, V36, P6307, DOI 10.1016/j.vaccine.2018.08.084
   Denzin N., 2005, SAGE HDB QUALITATIVE, V3, P1, DOI DOI 10.1017/CBO9781107415324.004
   Dowera J, 2011, VACCINE, V29, P3031, DOI 10.1016/j.vaccine.2011.01.116
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dyda A, 2016, BMC INFECT DIS, V16
   Eilers R, 2014, PREV MED, V69, P224, DOI 10.1016/j.ypmed.2014.10.017
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Fontana A, 2000, HDB QUALITATIVE RES, V2, P645
   Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028
   Kriszner M, 2016, RES IDENTIFY IMMUNIS
   Kwong EWY, 2010, J ADV NURS, V66, P2297, DOI 10.1111/j.1365-2648.2010.05397.x
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lasser KE, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-49
   Laurence A, 2016, AUST NZ J PUBL HEAL, V40, P279, DOI 10.1111/1753-6405.12423
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   MacDougall DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009062
   MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109
   Menzies RI, 2017, MED J AUSTRALIA, V206, P1, DOI 10.5694/mja16.00811
   Moran A, 2019, VACCINE, V37, P705, DOI 10.1016/j.vaccine.2018.12.029
   Mui LWH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078210
   Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388
   Ochoa-Gondar O, 2014, CLIN INFECT DIS, V58, P909, DOI 10.1093/cid/ciu002
   Sabapathy D, 2014, PREV MED, V62, P155, DOI 10.1016/j.ypmed.2013.11.009
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Schneeberg A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-442
   Siu JY-m, 2018, GERONTOLOGIST
   Stephenson N, 2018, CRIT PUBLIC HEALTH, V28, P472, DOI 10.1080/09581596.2018.1446510
   Sullivan SG, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.43.17-00707
   Takashima M, 2019, RELATIVE EFFECTIVENE
   Therapeutic Goods Administration, 2011, PNEUMOVAX23 UPD REV
   Tsai YH, 2015, VACCINE, V33, P2897, DOI 10.1016/j.vaccine.2015.04.068
   Wheelock A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113503
NR 42
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4454
EP 4459
DI 10.1016/j.vaccine.2019.06.079
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000008
PM 31277956
DA 2020-05-12
ER

PT J
AU Klein, NP
   Block, SL
   Essink, B
   Barbi, S
   Smolenov, I
   Keshavan, P
AF Klein, Nicola P.
   Block, Stan L.
   Essink, Brandon
   Barbi, Silvia
   Smolenov, Igor
   Keshavan, Pavitra
TI Antibody persistence and booster response following MenACWY-CRM
   vaccination in children as assessed by two different assay methods
SO VACCINE
LA English
DT Article
DE Persistence; hSBA; rSBA; MenACWY-CRM; Meningococcal; Booster
ID MENINGOCOCCAL CONJUGATE VACCINE; NEISSERIA-MENINGITIDIS;
   IMMUNE-RESPONSE; COMPLEMENT; IMMUNOGENICITY; SEROGROUP; SAFETY;
   EPIDEMIOLOGY; CARRIAGE; BINDING
AB Background: The quadrivalent meningococcal conjugate vaccine MenACWY-CRM has been shown to be immunogenic and well-tolerated in infants and toddlers. We evaluated antibody persistence for up to 4 years after vaccination with MenACWY-CRM in the first years of life and response to a booster dose administered at 60 months of age.
   Methods: This was phase 3b, open-label, multicenter extension trial (NCT01148017). We assessed by hSBA and rSBA the persistence of antibody responses to serogroups ACWY in 203 healthy 60-month-olds receiving 4 doses of MenACWY-CRM during infancy (ACWY-4 group), or 2 doses at 12/13 and 15 months or 1 dose at 18 months of age (ACWY-2 group). We administered a MenACWY-CRM dose to 224 primed and 45 naive 60-month-olds and evaluated safety and antibody response 1 month later.
   Results: Antibody persistence measured by both assays was higher in primed than naive 60-month-olds. The percentages of primed children with hSBA titers >= 8 was low for serogroup A (6-25%) and moderate for serogroups C (27-43%), Y (69-74%) and W (56-69%). For all serogroups, hSBA antibody geometric mean titers (GMTs) tended to be higher in the ACWY-2 than the ACWY-4 group. Post-booster/single dose, >= 96% of primed and >= 73% of naive children had hSBA titers >= 8 against each serogroup, and hSBA GMTs were higher in primed children. The booster dose was well-tolerated and no safety concern was identified. We further assessed persistence using rSBA across different age groups and detected no overall correlation between rSBA and hSBA titers.
   Conclusions: Primary vaccination of infants/toddlers with MenACWY-CRM resulted in moderate antibody persistence against serogroups C, W and Y for up to 4 years after the last priming dose. Regardless of priming schedule, a MenACWY-CRM booster dose at 60 months of age induced a robust immune response against all serogroups and was well-tolerated in all children. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Klein, Nicola P.] Kaiser Permanente, Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
   [Block, Stan L.] Kentucky Pediat & Adult Res INC, 201 S 5th St, Bardstown, KY 40004 USA.
   [Essink, Brandon] Meridian Clin Res, 3323 N 107th St, Omaha, NE USA.
   [Barbi, Silvia; Smolenov, Igor] GSK, Hullenbergweg 81-87, NL-1101 CL Amsterdam, Netherlands.
   [Keshavan, Pavitra] GSK, Via Fiorentina 1, I-53100 Siena, Italy.
   [Smolenov, Igor] Moderna Therapeut, Cambridge, MA USA.
RP Barbi, S (reprint author), GSK, Hullenbergweg 81-87, NL-1101 CL Amsterdam, Netherlands.
EM Nicola.Klein@kp.org; bessink@mcrmed.com; silvia.x.barbi@gsk.com;
   pavitra.x.keshavan@gsk.com
OI Barbi, Silvia/0000-0002-3996-7361
FU Novartis Vaccines Division
FX The study was sponsored by the Novartis Vaccines Division; on 2 March
   2015 Novartis' non-influenza Vaccines Business was acquired by the
   GlaxoSmithKline group of companies. GlaxoSmithKline Biologicals SA took
   responsibility for all costs associated with the development and
   publishing of the present manuscript.
CR Ali O, 2015, J INFECT DIS, V212, P1298, DOI 10.1093/infdis/jiv211
   Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003
   Baxter R, 2014, J PEDIAT, V164, DOI [10.1016/lipeds.2014.02.0251409-15e4, DOI 10.1016/LIPEDS.2014.02.0251409-15E4]
   Baxter R, 2016, HUM VACC IMMUNOTHER, V12, P1300, DOI 10.1080/21645515.2015.1136040
   Baxter R, 2014, PEDIATR INFECT DIS J, V33, P1169, DOI 10.1097/INF.0000000000000438
   Block SL, 2015, VACCINE, V33, P2175, DOI 10.1016/j.vaccine.2015.02.049
   Booy R, 2019, HUM VACC IMMUNOTHER, V15, P470, DOI 10.1080/21645515.2018.1532248
   Borja-Tabora C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-116
   Borrow R, 2001, INFECT IMMUN, V69, P1568, DOI 10.1128/IAI.69.3.1568-1573.2001
   European Medicines Agency, MENV EPAR PROD INF
   Gill CJ, 2011, VACCINE, V30, P29, DOI 10.1016/j.vaccine.2011.10.068
   Gill CJ, 2010, HUM VACCINES, V6, P881, DOI 10.4161/hv.6.11.12849
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327
   Granoff DM, 2009, INFECT IMMUN, V77, P764, DOI 10.1128/IAI.01191-08
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Halperin SA, 2010, VACCINE, V28, P7865, DOI 10.1016/j.vaccine.2010.09.092
   Jackson LA, 2009, CLIN INFECT DIS, V49, pE1, DOI 10.1086/599117
   Jacobson RM, 2013, PEDIATR INFECT DIS J, V32, pE170, DOI 10.1097/INF.0b013e318279ac38
   Jafri RZ, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-17
   Keshavan P, 2018, EXPERT REV VACCINES, V17, P865, DOI 10.1080/14760584.2018.1521280
   Khatami A, 2012, VACCINE, V30, P2831, DOI 10.1016/j.vaccine.2012.02.046
   Klein NP, 2012, PEDIATR INFECT DIS J, V31, P64, DOI 10.1097/INF.0b013e31823dce5c
   Kristiansen PA, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0663-4
   Kristiansen PA, 2013, CLIN INFECT DIS, V56, P354, DOI 10.1093/cid/cis892
   Martinon-Torres F, 2016, J ADOLESCENT HEALTH, V59, pS12, DOI 10.1016/j.jadohealth.2016.03.041
   McIntosh EDG, 2015, VACCINE, V33, P4414, DOI 10.1016/j.vaccine.2015.07.019
   Pace D, 2012, VACCINE, V30, pB3, DOI 10.1016/j.vaccine.2011.12.062
   Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012
   Price GA, 2015, CLIN INFECT DIS, V61, pS554, DOI 10.1093/cid/civ504
   Reisinger KS, 2009, CLIN VACCINE IMMUNOL, V16, P1810, DOI 10.1128/CVI.00207-09
   Sabatini C, 2012, J Prev Med Hyg, V53, P116
   Seib KL, 2015, EXPERT REV VACCINES, V14, P841, DOI 10.1586/14760584.2015.1016915
   Tregnaghi M, 2014, INT J INFECT DIS, V26, P22, DOI 10.1016/j.ijid.2014.03.1390
   U. S. Food and Drug Administration, PACK INS MENV HIGHL
   Vesikari T, 2012, HUM VACC IMMUNOTHER, V8, P1892, DOI 10.4161/hv.22166
   World Health Organization, 2018, INV MEN DIS SER DIST
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4460
EP 4467
DI 10.1016/j.vaccine.2019.06.076
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000009
PM 31279564
OA Other Gold
DA 2020-05-12
ER

PT J
AU vom Steeg, LG
   Flores-Garcia, Y
   Zavala, F
   Klein, SL
AF vom Steeg, Landon G.
   Flores-Garcia, Yevel
   Zavala, Fidel
   Klein, Sabra L.
TI Irradiated sporozoite vaccination induces sex-specific immune responses
   and protection against malaria in mice
SO VACCINE
LA English
DT Article
DE Circumsporozoite protein; CSP; Estrogen; Gender; Plasmodium;
   Testosterone
ID GAMMA-INTERFERON; STERILE IMMUNITY; T-CELLS; ANTIBODIES; ESTROGEN;
   EFFICACY
AB In both preclinical animal studies and human clinical trials, adult females tend to develop greater adaptive immune responses than males following receipt of either viral or bacterial vaccines. While there is currently no approved malaria vaccine, several anti-sporozoite vaccines, including RTS,S/AS01 and attenuated sporozoite vaccines, are in development, but the impact of sex and age on their efficacy remains undefined. To examine sex differences in the efficacy of anti-sporozoite stage malaria vaccination, adult (10 weeks of age) or juvenile (11 days of age) male and female C3H mice were twice vaccinated with irradiated transgenic Plasmodium berghei sporozoites expressing the P. falciparum circumsporozoite (CSP) protein and 45 days post boost vaccination, mice were challenged with transgenic P. berghei via mosquito bite or intradermal challenge. Immunization with irradiated sporozoites resulted in greater protection against challenge in adult females, which was associated with greater anti-CSP antibody production and avidity, as well as greater hepatic, but not splenic, CD8(+) T cell IFNy production in adult females than adult males. No sex differences in adaptive immune responses or protection were observed in mice vaccinated prior to puberty, suggesting a role for sex steroid hormones. Depletion of testosterone in males increased, whereas rescue of testosterone decreased, anti-CSP antibody production, the number of antigen-specific CD8(+) T cells isolated from the liver, and protection following parasite challenge. Conversely, depletion of sex steroids in female mice did not alter vaccine induced responses or protection following challenge. These data suggest that elevated testosterone concentrations in males reduce adaptive immunity and contribute to sex differences in malaria vaccine efficacy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [vom Steeg, Landon G.; Flores-Garcia, Yevel; Zavala, Fidel; Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   [Klein, Sabra L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD USA.
RP Klein, SL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
EM sklein2@jhu.edu
OI Klein, Sabra/0000-0002-0730-5224
FU Johns Hopkins Malaria Research Institute
FX This work was supported by a pilot award from the Johns Hopkins Malaria
   Research Institute (SK).
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P33
   Bruna-Romero O, 2001, INT J PARASITOL, V31, P1499, DOI 10.1016/S0020-7519(01)00265-X
   Cernetich A, 2006, INFECT IMMUN, V74, P3190, DOI 10.1128/IAI.00008-06
   Cunningham M, 2011, CLIN REV ALLERG IMMU, V40, P66, DOI 10.1007/s12016-010-8203-5
   Espinosa DA, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0011-y
   Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
   GSK, 2016, EFF GSK BIOL CAN MAL
   Hoffman SL, 2015, VACCINE, V33, pD13, DOI 10.1016/j.vaccine.2015.07.091
   JAULIN C, 1992, INT IMMUNOL, V4, P945, DOI 10.1093/intimm/4.8.945
   Keitany GJ, 2014, INFECT IMMUN, V82, P5143, DOI 10.1128/IAI.02320-14
   Klein PW, 2008, GENDER MED, V5, P423, DOI 10.1016/j.genm.2008.10.001
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Klein SL, 2016, MBIO, V7, DOI 10.1128/mBio.00514-16
   Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8
   Lopes LN, 2016, MICROB PATHOGENESIS, V90, P7, DOI 10.1016/j.micpath.2015.10.020
   Migasena S, 1997, ACTA TROP, V67, P215, DOI 10.1016/S0001-706X(97)00061-2
   Nguyen DC, 2011, VACCINE, V29, P2515, DOI 10.1016/j.vaccine.2011.01.080
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   Plebanski M, 2017, TRENDS PARASITOL, V33, P154, DOI 10.1016/j.pt.2017.01.006
   Potluri T, 2017, MBIO, V8, DOI 10.1128/mBio.01868-17
   Purcell LA, 2008, VACCINE, V26, P4880, DOI 10.1016/j.vaccine.2008.07.017
   Reed RC, 1996, VACCINE, V14, P828, DOI 10.1016/0264-410X(95)00175-Z
   Robinson DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002149
   SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0
   Sugimoto CR, 2019, LANCET, V393, P550, DOI 10.1016/S0140-6736(18)32995-7
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   vom Steeg LG, 2016, AM J PHYSIOL-LUNG C, V311, pL1234, DOI 10.1152/ajplung.00352.2016
   Voysey M, 2016, VACCINE, V34, P1657, DOI 10.1016/j.vaccine.2016.02.036
   WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P39
   World Health Organization, 2015, GLOB TECHN STRAT MAL
   World Health Organization, 2017, WORLD MAL REP 2017
   Wunderlich F, 2002, STEROIDS, V67, P535, DOI 10.1016/S0039-128X(01)00175-1
   WUNDERLICH F, 1993, VACCINE, V11, P1097, DOI 10.1016/0264-410X(93)90068-9
   Wykes MN, 2009, EUR J IMMUNOL, V39, P2004, DOI 10.1002/eji.200939552
NR 36
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4468
EP 4476
DI 10.1016/j.vaccine.2019.06.075
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000010
PM 31262583
DA 2020-05-12
ER

PT J
AU Wang, CH
   Lu, JB
   Du, WX
   Wang, GZ
   Li, XG
   Shen, XB
   Su, C
   Yang, L
   Chen, BW
   Wang, JZ
   Xu, M
AF Wang, Chunhua
   Lu, Jinbiao
   Du, Weixin
   Wang, Guozhi
   Li, Xuguang
   Shen, Xiaobin
   Su, Cheng
   Yang, Lei
   Chen, Baowen
   Wang, Junzhi
   Xu, Miao
TI Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects
   guinea pigs from latent mycobacterium tuberculosis infection
SO VACCINE
LA English
DT Article
DE Mycobacterium tuberculosis; Subunit vaccine; Adjuvant; Immunogenicity;
   Protective efficacy; Latent tuberculosis infection
ID CALMETTE-GUERIN VACCINATION; CD8(+) T-CELLS; BCG VACCINE; MICE;
   PREVENTION; RESPONSES; EFFICACY; METAANALYSIS; EPIDEMIC; ANTIGENS
AB The high global burden of tuberculosis (TB) underscores the urgent need for an effective TB vaccine since the only licensed Bacillus Calmette-Guerin (BCG) vaccine is ineffective in preventing adult pulmonary TB and affords no protection against latent TB infection (LTBI). Herein we investigated the potential of Mycobacterium tuberculosis (Mtb) antigen proteins AEC comprised of Ag85b and ESAT6-CFP10 proteins in conjunction with aluminum (Al) and polyriboinosinic-polyribocytidylic acid (poly-IC) as a novel subunit vaccine against TB. The immunogenicity and protection induced by the adjuvanted vaccine were evaluated in two animal models. Mice vaccinated with AEC/Al/poly-IC exhibited significant antigen-specific humoral immune responses and cell-mediated immunity as determined by immunoassay and multicolor flow cytometric assay, and the protective effect of the vaccine was demonstrated in a guinea pig model of latent Mtb infection. Compared to the control group, the mean pathological scores and bacterial loads in lungs and spleens of AEC/Al/poly-IC-immunized guinea pigs were significantly reduced. These data indicate that the AEC/Al/poly-IC is highly immunogenic in mice and can effectively protect guinea pigs against latent Mtb infection; it may represent a promising candidate vaccine for the control of latent TB. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Chunhua; Lu, Jinbiao; Du, Weixin; Wang, Guozhi; Shen, Xiaobin; Su, Cheng; Yang, Lei; Chen, Baowen; Wang, Junzhi; Xu, Miao] Natl Inst Food & Drug Control, Div TB Vaccines, Beijing 102629, Peoples R China.
   [Wang, Chunhua] Chinese Acad Sci, Inst Proc Engn, Beijing 100190, Peoples R China.
   [Li, Xuguang] Hlth Canada, Ctr Biol Evaluat, Biol & Genet Therapies Directorate, Ottawa, ON, Canada.
RP Wang, JZ; Xu, M (reprint author), Natl Inst Food & Drug Control, 31 Huatuo Rd, Beijing 102629, Peoples R China.
EM wangjz@nifdc.org.cn; xumiaobj@126.com
OI Li, Xuguang (Sean)/0000-0003-1155-9128
FU China Mega-Project for Infectious Disease [2012ZX10004701003]
FX This study was supported by the grant from the China Mega-Project for
   Infectious Disease (2012ZX10004701003).
CR Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285
   Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370
   Achkar JM, 2018, CURR OPIN IMMUNOL, V53, P30, DOI 10.1016/j.coi.2018.04.004
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994
   Andersen P, 2014, COLD SPRING HARB PER, P4
   Baldwin SL, 1998, INFECT IMMUN, V66, P2951, DOI 10.1128/IAI.66.6.2951-2959.1998
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195
   Borrero R, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-S1-S13
   BREWER TF, 1995, CLIN INFECT DIS, V20, P126, DOI 10.1093/clinids/20.1.126
   Bungener L, 2008, VACCINE, V26, P2350, DOI 10.1016/j.vaccine.2008.02.063
   Chen L, 2010, FEMS IMMUNOL MED MIC, V59, P42, DOI 10.1111/j.1574-695X.2010.00660.x
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Feng CG, 1999, INFECT IMMUN, V67, P3242, DOI 10.1128/IAI.67.7.3242-3247.1999
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Floyd K, 2018, LANCET RESP MED, V6, P299, DOI 10.1016/S2213-2600(18)30057-2
   Gillard P, 2016, TUBERCULOSIS, V100, P118, DOI 10.1016/j.tube.2016.07.005
   Ginsberg AM, 1998, PUBLIC HEALTH REP, V113, P128
   Gong WP, 2018, HUM VACC IMMUNOTHER, V14, P1697, DOI 10.1080/21645515.2018.1458806
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530
   Kamath AB, 2004, J EXP MED, V200, P1479, DOI 10.1084/jem.20041690
   Kaufmann SHE, 2017, INT J INFECT DIS, V56, P263, DOI 10.1016/j.ijid.2016.10.018
   Kaufmann SHE, 2010, LANCET, V375, P2110, DOI 10.1016/S0140-6736(10)60393-5
   Kumar H, 2008, J IMMUNOL, V180, P683, DOI 10.4049/jimmunol.180.2.683
   Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035
   Lu JB, 2015, J MICROBIOL IMMUNOL, V48, P597, DOI 10.1016/j.jmii.2014.03.005
   [卢锦标 Lu Jinbiao], 2013, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V33, P900
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003
   Moschos SA, 2004, IMMUNOL CELL BIOL, V82, P628, DOI 10.1111/j.0818-9641.2004.01280.x
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176
   Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001
   ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210
   Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x
   Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200
   ROBERTS AD, 1995, IMMUNOLOGY, V85, P502
   Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643
   Skeiky YAW, 2004, J IMMUNOL, V172, P7618, DOI 10.4049/jimmunol.172.12.7618
   Smith SM, 2000, IMMUNOL CELL BIOL, V78, P325, DOI 10.1046/j.1440-1711.2000.00936.x
   Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373
   Hoang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080579
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.3.CO;2-W
   WHO, GLOB TUB REP 2018
   Xie HA, 2000, MODERN TUBERCULOSIS
   Zhu BD, 2018, RESPIROLOGY, V23, P359, DOI 10.1111/resp.13245
NR 51
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4477
EP 4484
DI 10.1016/j.vaccine.2019.06.078
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000011
PM 31266673
DA 2020-05-12
ER

PT J
AU Duralliu, A
   Matejtschuk, P
   Dubey, S
   Koroma, H
   Gubinelli, F
   Williams, DR
AF Duralliu, Arnold
   Matejtschuk, Paul
   Dubey, Sitara
   Koroma, Halima
   Gubinelli, Francesco
   Williams, Daryl R.
TI The influence of the closure format on the storage stability and
   moisture content of freeze-dried influenza antigen
SO VACCINE
LA English
DT Article
DE Freeze-drying; Moisture; Stability; Potency; Vials; Ampoules; Stopper;
   Vacuum oven
ID RADIAL-IMMUNODIFFUSION TECHNIQUE; HEMAGGLUTININ ANTIGEN; RESIDUAL
   MOISTURE; LYOPHILIZATION; VACCINES; HUMIDITY; ASSAY
AB Low moisture content is seen as crucial to achieving long term stability of freeze dried biologics and reference materials. Highly hygroscopic freeze-dried material are susceptible to moisture ingress over time which can lead to degradation and loss of biological potency. This study compared vials with unprocessed stoppers, vials with vacuum-oven dried stoppers and glass ampoules in order to determine the superior long term storage format in terms of moisture ingress and potency. B/Phuket influenza antigen was chosen as the model biological standard and the lyophilized antigen was stored at -20, 25 and 45 degrees C over a 1 year period. Ampoules had no significant moisture change across all storage temperatures as would be anticipated. Moisture content results at -20 degrees C showed no significant differences between ampoules, vials with vacuum-oven dried stoppers and vials with unprocessed stoppers over 12 months. Vials with vacuum-oven dried stoppers performed similarly to ampoules at -20 degrees C and 20 degrees C, but had a small increase in moisture content after 6 months at 45 degrees C. Vials with unprocessed stoppers preformed the worst and exhibited the largest moisture ingress after just 3 months at both 20 degrees C and 45 degrees C. Single radial immunodiffusion (SRD) potency assays showed at -20 degrees C and 20 degrees C there was no significant difference between all closure formats. At 45 degrees C there was a drop in potency for all closure formats, but ampoules and vials with vacuum-oven dried stoppers retained higher potency than vials with unprocessed stoppers. Thus, while ampoules are still considered to be the gold standard format for long term storage stability, using vials with vacuum-oven dried stoppers provides comparable stability and moisture integrity at -20 degrees C and 20 degrees C storage. (C) 2019 Published by Elsevier Ltd.
C1 [Duralliu, Arnold; Williams, Daryl R.] Imperial Coll London, Dept Chem Engn, Surfaces & Particle Engn Lab, London SW7 2AZ, England.
   [Matejtschuk, Paul] Natl Inst Biol Stand & Controls, Standardisat Sci, Blanche Lane, Potters Bar EN6 3QC, Herts, England.
   [Dubey, Sitara; Koroma, Halima; Gubinelli, Francesco] Natl Inst Biol Stand & Controls, Div Virol, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
RP Matejtschuk, P (reprint author), Natl Inst Biol Stand & Controls, Standardisat Sci, Blanche Lane, Potters Bar EN6 3QC, Herts, England.
EM Paul.Matejtschuk@nibsc.org
OI Matejtschuk, Paul/0000-0002-4646-800X
FU EPSRC Centre for Doctoral Training in Emergent Macromolecular Therapies,
   Department of Biochemical Engineering, at University College
   LondonEngineering & Physical Sciences Research Council (EPSRC); National
   Institute for Biological Standards and Control (NIBSC, UK)
FX This work was funded by EPSRC Centre for Doctoral Training in Emergent
   Macromolecular Therapies, Department of Biochemical Engineering, at
   University College London, in collaboration with National Institute for
   Biological Standards and Control (NIBSC, UK). We also thank the
   Influenza Group (NIBSC, UK) for supplying the influenza antigen
   preparations and Kiran Malik, Chinwe Duru and Ernest Ezeajughi
   (Standardisation Science) for providing training in some of the
   analytical techniques.
CR Breen ED, 2001, PHARMACEUT RES, V18, P1345, DOI 10.1023/A:1013054431517
   Choi Y, 2017, BIOLOGICALS, V50, P137, DOI 10.1016/j.biologicals.2017.08.001
   Corveleyn S, 1997, INT J PHARM, V159, P57, DOI 10.1016/S0378-5173(97)00263-9
   Donovan P D, 2007, PDA J Pharm Sci Technol, V61, P51
   Duralliu A, 2018, EUR J PHARM BIOPHARM, V127, P29, DOI 10.1016/j.ejpb.2018.02.003
   Engelhardt OG, 2018, VACCINE, V36, P4339, DOI 10.1016/j.vaccine.2018.05.076
   FORD AW, 1994, BIOLOGICALS, V22, P191, DOI 10.1006/biol.1994.1026
   GREIFF D, 1971, CRYOBIOLOGY, V8, P145, DOI 10.1016/0011-2240(71)90022-8
   HANCOCK BC, 1995, PHARMACEUT RES, V12, P799, DOI 10.1023/A:1016292416526
   HELD HR, 1977, J BIOL STAND, V5, P111, DOI 10.1016/0092-1157(77)90005-1
   House JA, 1996, DEV BIOL STAND, V87, P235
   HSU CC, 1992, DEV BIOLOGICALS, V74, P255
   Hubbard A, 2007, ANAL BIOANAL CHEM, V387, P2503, DOI 10.1007/s00216-006-0855-x
   LEMESTE M, 1985, J BIOL STAND, V13, P177, DOI 10.1016/S0092-1157(85)80001-9
   LIU WR, 1991, BIOTECHNOL BIOENG, V37, P177, DOI 10.1002/bit.260370210
   Matejtschuk P, 2005, BIOLOGICALS, V33, P63, DOI 10.1016/j.biologicals.2004.12.002
   Matejtschuk P., 2010, FREEZE DRYING LYOPHI, P317
   PIKAL MJ, 1992, DEV BIOLOGICALS, V74, P165
   Pikal MJ, 1992, DEV BIOL STAND, V74, P77
   Sasaki Hitoshi, 2010, PDA J Pharm Sci Technol, V64, P63
   SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P223
   Stohr Klaus, 2012, Methods Mol Biol, V865, P147, DOI 10.1007/978-1-61779-621-0_9
   Wang DD, 2016, COMPUTATIONAL BIOLOGY AND BIOINFORMATICS: GENE REGULATION GENE RNA PROTEIN EPIGENETICS, P233
   Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
   World Health Organization, 2006, WHO TECH REP SER, V932, P73
NR 26
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4485
EP 4490
DI 10.1016/j.vaccine.2019.06.070
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000012
PM 31277955
DA 2020-05-12
ER

PT J
AU Andrews, N
   Kent, A
   Amin-Chowdhury, Z
   Sheppard, C
   Fry, N
   Ramsay, M
   Ladhani, SN
AF Andrews, Nick
   Kent, Alison
   Amin-Chowdhury, Zahin
   Sheppard, Carmen
   Fry, Norman
   Ramsay, Mary
   Ladhani, Shamez N.
TI Effectiveness of the seven-valent and thirteen-valent pneumococcal
   conjugate vaccines in England: The indirect cohort design, 2006-2018
SO VACCINE
LA English
DT Article
DE Vaccine effectiveness; PCV13; PCV7; Pneumococcal conjugate vaccine;
   Waning; Invasive pneumococcal disease
ID DISEASE; WALES; IMMUNOGENICITY; VACCINATION; SCHEDULES; SEROTYPES;
   INFANTS
AB Background: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the UK childhood immunisation programme in 2006 and replaced with a 13-valent vaccine (PCV13) in 2010. Both vaccines led to rapid declines in vaccine-serotype invasive pneumococcal disease (IPD). Here, we assessed the long-term vaccine-effectiveness (VE) of both vaccines in England.
   Methods: Public Health England conducts enhanced national surveillance of IPD in England. VE against IPD was estimated using vaccine-serotype IPD cases and non-vaccine serotype IPD controls among vaccine-eligible children from September 2006 to June 2018 (the Broome method).
   Results: Vaccine history was available for 3421 IPD cases, including 1299 due to the additional PCV13 serotypes and the PCV13-related serotype 6C, 274 PCV7 serotypes and 1848 non-PCV13 serotypes. For the complete 2 + 1 schedule, both PCV7 and PCV13 showed high effectiveness against PCV7 serotypes with a combined VE of 92.0% (95%CI, 81.7-96.7). For the 2 + 1 schedule, PCV13 VE against the additional PCV13 serotypes plus 6C was 73.7% (31.1-89.9) compared to 90.0% (75.3 - 96.0) for PCV7 against PCV7 serotypes, although PCV13 VE increased to 84.8% (58.7-94.4) if serotype 3 was excluded; all 36 eligible serotype 3 IPD cases were fully-vaccinated with PCV13. Case numbers were low in older ages but there was evidence of waning, which was significant for serotype 19A for which there were sufficient numbers of cases for analysis.
   Conclusions: PCVs are highly effective in preventing vaccine-serotype IPD except for serotype 3 which has been increasing in incidence. Serotype 19A IPD has also persisted, likely due to a slightly lower VE and/or more rapid waning of protection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Andrews, Nick] Publ Hlth England, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England.
   [Kent, Alison; Ladhani, Shamez N.] St Georges Univ London, Paediat Infect Dis Res Grp, Cranmer Terrace, London SW17 0RE, England.
   [Amin-Chowdhury, Zahin; Ramsay, Mary; Ladhani, Shamez N.] Publ Hlth England, Immunisat & Countermeasures Div, 61 Colindale Ave, London NW9 5EQ, England.
   [Sheppard, Carmen; Fry, Norman] Publ Hlth England, Resp & Vaccine Preventable Bacterial Reference Un, London, England.
RP Ladhani, SN (reprint author), Publ Hlth England, Immunisat Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM shamez.ladhani@phe.gov.uk
RI ; ramsay, mary elizabeth/S-8281-2016
OI Amin-Chowdhury, Zahin/0000-0002-3106-992X; ramsay, mary
   elizabeth/0000-0002-7156-7640
CR Andrews N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028435
   Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0
   Hanquet G, 2018, THORAX
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Latasa P, 2017, VACCINE, V35, P5381, DOI 10.1016/j.vaccine.2017.07.089
   Miller E, 2011, VACCINE, V29, P9127, DOI 10.1016/j.vaccine.2011.09.112
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Oligbu G, 2017, CLIN INFECT DIS, V65, P1191, DOI 10.1093/cid/cix418
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Sings HL, 2018, CLIN INFECT DIS
   Southern J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195799
   Spijkerman J, 2013, JAMA-J AM MED ASSOC, V310, P930, DOI 10.1001/jama.2013.228052
   van Hoek AJ, 2014, VACCINE, V32, P4349, DOI 10.1016/j.vaccine.2014.03.017
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
NR 17
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4491
EP 4498
DI 10.1016/j.vaccine.2019.06.071
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000013
PM 31272872
DA 2020-05-12
ER

PT J
AU van Aalst, R
   Russo, EM
   Neupane, N
   Mahmud, SM
   Mor, V
   Wilschut, J
   Chit, A
   Postma, M
   Young-Xu, Y
AF van Aalst, Robertus
   Russo, Ellyn M.
   Neupane, Nabin
   Mahmud, Salaheddin M.
   Mor, Vincent
   Wilschut, Jan
   Chit, Ayman
   Postma, Maarten
   Young-Xu, Yinong
TI Economic assessment of a high-dose versus a standard-dose influenza
   vaccine in the US Veteran population: Estimating the impact on
   hospitalization cost for cardio-respiratory disease
SO VACCINE
LA English
DT Article
DE Influenza; High-dose vaccine; Economic assessment
ID SEASONAL INFLUENZA; HEALTH-CARE; ADULTS; OLDER; VA
AB Objective: To compare the economic impact of high-dose trivalent (HD) versus standard-dose trivalent (SD) influenza vaccination on direct medical costs for cardio-respiratory hospitalizations in adults aged 65 years or older enrolled in the United States (US) Veteran's Health Administration (VHA).
   Methods: Leveraging a relative vaccine effectiveness study of HD versus SD over five respiratory seasons (2010/11 through 2014/15), we collected cost data for healthcare provided to the same study population both at VHA and through Medicare services. Our economic assessment compared the costs of vaccination and hospital care for patients experiencing acute cardio-vascular or respiratory illness.
   Results: We analyzed 3.5 million SD and 158,636 HD person-seasons. The average cost of HD and SD vaccination was $23.48 (95% CI: $21.29 - $25.85) and $12.21 (95% CI: $11.49 - $13.00) per recipient, respectively, while the hospitalization rates for cardio-respiratory disease in HD and SD recipients were 0.114 (95% CI: 0.108-0.121) and 0.132 (95% CI: 0.132-0.133) per person-season, respectively. Attributing the average cost per hospitalization of $11,796 (95% CI: $11,685 - $11,907) to the difference in hospitalization rates, we estimated savings attributable to HD to be $202 (95% CI: $115 - $280) per vaccinated recipient.
   Conclusions: For the five-season period of 2010/11 through 2014/15, HD influenza vaccination was associated with net cost savings due to fewer hospitalizations, and therefore lower direct medical costs, for cardio-respiratory disease as compared to SD influenza vaccination in the senior US VHA population. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [van Aalst, Robertus; Postma, Maarten] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.
   [van Aalst, Robertus; Chit, Ayman] Sanofi Pasteur, Reg Epidemiol & Hlth Econ, Swiftwater, PA 18370 USA.
   [Russo, Ellyn M.; Neupane, Nabin; Young-Xu, Yinong] Vet Affairs Med Ctr, Clin Epidemiol Program, White River Jct, VT USA.
   [Mahmud, Salaheddin M.] Univ Manitoba, Dept Community Hlth Sci, Coll Med, Winnipeg, MB, Canada.
   [Mahmud, Salaheddin M.] Univ Manitoba, George & Fay Yee Ctr Healthcare Innovat, Winnipeg Reg Hlth Author, Winnipeg, MB, Canada.
   [Mor, Vincent] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
   [Mor, Vincent] Providence VA Med Ctr, Ctr Innovat Long Term Serv & Supports, Providence, RI USA.
   [Wilschut, Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.
   [Chit, Ayman] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
   [Postma, Maarten] Univ Groningen, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ PTE2, Groningen, Netherlands.
   [Postma, Maarten] Univ Groningen, Dept Econ Econometr & Finance, Fac Econ & Business, Groningen, Netherlands.
   [Young-Xu, Yinong] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA.
RP van Aalst, R (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.; van Aalst, R (reprint author), Sanofi Pasteur, Reg Epidemiol & Hlth Econ, Swiftwater, PA 18370 USA.
EM Rob.VanAalst@sanofi.com
RI van Aalst, Robertus/F-8207-2016
OI van Aalst, Robertus/0000-0003-3025-7811
FU Department of Veterans Affairs, VA Health Services Research and
   Development Service, VA Information Resource CenterUS Department of
   Veteran Affairs [SDR 02-237, 98-004]; Sanofi Pasteur, Inc., Swiftwater,
   PA, USA
FX Data analysis support provided by Yuliya Halchenko, MA; support for
   VA/CMS data provided by the Department of Veterans Affairs, VA Health
   Services Research and Development Service, VA Information Resource
   Center (Project Numbers SDR 02-237 and 98-004). This study was funded by
   a research grant from Sanofi Pasteur, Inc., Swiftwater, PA, USA.
CR Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252
   [Anonymous], 2018, AFF USDOV
   Arnold RJ, 2016, PHARMACOECONOMICS TH
   Association AH, 2016, UND MED MED FACT SHE
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790
   Lambert ND, 2012, EXPERT REV VACCINES, V11, P985, DOI [10.1586/erv.12.61, 10.1586/ERV.12.61]
   Lee J, OP FOR INF DISEASES2
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Nugent GN, 2004, MED CARE RES REV, V61, P495, DOI 10.1177/1077558704269795
   Petersen LA, 2010, HEALTH SERV RES, V45, P762, DOI 10.1111/j.1475-6773.2010.01107.x
   Shireman TI, 2019, J AM MED DIR ASS
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   West AN, 2016, J RURAL HEALTH, V32, P387, DOI 10.1111/jrh.12196
   West AN, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1069-8
   Wilcox RR, 2010, FUNDAMENTAL OF MODERN STATISTICAL METHODS: SUBSTANTIALLY IMPROVING POWER AND ACCURACY, SECOND EDITION, P1, DOI 10.1007/978-1-4419-5525-8
   Yinong YX, 2019, VACCINE, V37, P1484, DOI 10.1016/j.vaccine.2019.01.063
   Young-Xu Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169344
   Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4499
EP 4503
DI 10.1016/j.vaccine.2019.06.066
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000014
PM 31262590
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Hoes, J
   Knol, MJ
   Mollema, L
   Buisman, A
   de Melker, HE
   van der Klis, FRM
AF Hoes, J.
   Knol, M. J.
   Mollema, L.
   Buisman, A.
   de Melker, H. E.
   van der Klis, F. R. M.
TI Comparison of antibody response between boys and girls after infant and
   childhood vaccinations in the Netherlands
SO VACCINE
LA English
DT Article
DE Vaccine preventable diseases; Immunoglobulin G; Antibody level; Gender;
   Infant vaccination; Childhood booster
ID IMMUNE-RESPONSES; SEX-DIFFERENCES; MULTIPLEX IMMUNOASSAY; SERUM
   ANTIBODIES; RUBELLA; MEASLES; SEROPREVALENCE; DIPHTHERIA; TETANUS; MUMPS
AB Background: Infectious diseases can differ by sex in their incidence, prevalence, or severity of disease. These differences may be induced by sex-dependent immune responses and resulting protection, for example after vaccination. Therefore, this study aims to assess possible sex-differences in immunoglobulin levels (IgG) after infant and childhood vaccination.
   Methods: Data from a national cross-sectional serosurvey conducted in 2006/2007 were used (Pienter 2). We compared IgG levels against measles, mumps, rubella, diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b (Hib), and Neisseria meningitidis serogroup C (MenC) between girls and boys both short term (1 month to 1 year) and long term (1-3 year) after infant and childhood vaccinations, using linear regression analysis. Proportions of boys and girls reaching a protective IgG level were compared using Fishers exact test.
   Results: Differences in IgG were found at specific time points after vaccination against measles, mumps, rubella, MenC, and polio. The geometric mean concentration or titer (GMC/T) girls:boys ratios ranged between 1.10 for polio type 1 <1 year after the first childhood booster to 1.90 for MenC <1 year after infant vaccination, indicating higher antibody levels in girls. No significant differences were found between boys and girls for diphtheria, tetanus, pertussis, and Hib at either time point. Proportions with protective levels differed only at 1-3 years after infant vaccination for mumps (82.5% boys vs. 91.9% girls, p = 0.046), and at the same time point for MenC (7.0% boys vs. 18.2% girls, p = 0.015), and polio type 1 (87.8% boys vs. 95.9% girls, p = 0.047).
   Conclusion: Differences in IgG between boys and girls were generally small and not consistent, neither between pathogens nor within pathogens. If differences were observed, girls were favored over boys. On the whole, the results suggest that there are no major sex differences in protection from the studied pathogens in the Netherlands. (C) 2019 Published by Elsevier Ltd.
C1 [Hoes, J.; Knol, M. J.; Mollema, L.; de Melker, H. E.] Natl Inst Publ Hlth & Environm, Ctr Epidemiol & Surveillance Infect Dis, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [Buisman, A.; van der Klis, F. R. M.] Natl Inst Publ Hlth & Environm, Ctr Immunol Infect Dis & Vaccines, Ctr Infect Dis Control, Bilthoven, Netherlands.
RP Knol, MJ (reprint author), Natl Inst Publ Hlth & Environm RIVM, Antonie van Leeuwenhoeklaan 9, NL-3721 MA Bilthoven, Netherlands.
EM mirjam.knol@rivm.nl
FU Dutch Ministry of Health
FX This research was funded by the Dutch Ministry of Health, and was
   carried out in the framework of RIVM Strategic Programme (SPR), in which
   expertise and innovative projects prepare RIVM to respond to future
   issues in health and sustainability. The views expressed in this
   publication are those of the authors and not necessarily those of the
   funding agencies.
CR Baxter D, 2007, OCCUP MED-OXFORD, V57, P552, DOI 10.1093/occmed/kqm110
   Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054
   de Melker HE, 2003, VACCINE, V21, P716, DOI 10.1016/S0264-410X(02)00587-X
   de Voer RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012144
   de Voer RM, 2009, CLIN VACCINE IMMUNOL, V16, P433, DOI 10.1128/CVI.00364-08
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Flanagan KL, 2011, VACCINE, V29, P2349, DOI 10.1016/j.vaccine.2011.01.071
   GARENNE M, 1994, INT J EPIDEMIOL, V23, P632, DOI 10.1093/ije/23.3.632
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Jensen K., 2014, RANDOMIZED TRIAL EAR
   Kennedy RB, 2009, VACCINE, V27, P3319, DOI 10.1016/j.vaccine.2009.01.086
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Klein SL, 2016, NAT REV IMMUNOL
   Liston A, 2016, TRENDS IMMUNOL, V37, P637, DOI 10.1016/j.it.2016.08.002
   Mitchell LA, 1999, J MED MICROBIOL, V48, P1075, DOI 10.1099/00222615-48-12-1075
   Mollema L, 2014, EPIDEMIOL INFECT, V142, P1100, DOI 10.1017/S0950268813001532
   Mollema L., 2009, RENTER 2 PROJECT SEC
   Muenchhoff M, 2014, J INFECT DIS, V209, pS120, DOI 10.1093/infdis/jiu232
   Schurink-vantKlooster T. M., 2016, NATL IMMUNISATION PR
   Smits G, 2014, VACCINE, V32, P1890, DOI 10.1016/j.vaccine.2014.01.066
   Smits G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058234
   Smits GP, 2012, CLIN VACCINE IMMUNOL, V19, P396, DOI 10.1128/CVI.05537-11
   Steens A, 2010, VACCINE, V28, P7803, DOI 10.1016/j.vaccine.2010.09.036
   Swart EM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148605
   van der Klis FRM, 2009, NETH J MED, V67, P301
   Van der Maas N, 2014, EDITORIAL TEAM EDITO, V2006, P43
   van Gageldonk PGM, 2008, J IMMUNOL METHODS, V335, P79, DOI 10.1016/j.jim.2008.02.018
   van Lier A, 2012, EURO SURVEILL, V17
   van Lier E. A., 2015, IMMUNISATION COVERAG
   Voysey M, 2016, VACCINE, V34, P1657, DOI 10.1016/j.vaccine.2016.02.036
NR 30
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4504
EP 4510
DI 10.1016/j.vaccine.2019.06.055
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000015
PM 31279563
DA 2020-05-12
ER

PT J
AU Adrien, N
   Hyde, TB
   Gacic-Dobo, M
   Hombach, J
   Krishnaswamy, A
   Lambach, P
AF Adrien, Nedghie
   Hyde, Terri B.
   Gacic-Dobo, Marta
   Hombach, Joachim
   Krishnaswamy, Akshaya
   Lambach, Philipp
TI Differences between coverage of yellow fever vaccine and the first dose
   of measles-containing vaccine: A desk review of global data sources
SO VACCINE
LA English
DT Review
DE Yellow fever vaccine; Stock outs; Routine immunization coverage; Measles
   vaccine
AB Introduction: The strategy to Eliminate Yellow Fever Epidemics (EYE) is a global initiative that includes all countries with risk of yellow fever (YF) virus transmission. Of these, 40 countries (27 in Africa and 13 in the Americas) are considered high-risk and targeted for interventions to increase coverage of YF vaccine. Even though the World Health Organization (WHO) recommends that YF vaccine be given concurrently with the first dose of measles-containing vaccine (MCV1) in YF-endemic settings, estimated coverage for MCV1 and YF vaccine have varied widely. The objective of this study was to review global data sources to assess discrepancies in YF vaccine and MCV1 coverage and identify plausible reasons for these discrepancies.
   Methods: We conducted a desk review of data from 34 countries (22 in Africa, 12 in Latin America), from 2006 to 2016, with national introduction of YF vaccine and listed as high-risk by the EYE strategy. Data reviewed included procured and administered doses, immunization schedules, routine coverage estimates and reported vaccine stock-outs. In the 30 countries included in the comparitive analysis, differences greater than 3 percentage points between YF vaccine and MCV1 coverage were considered meaningful.
   Results: In America, there were meaningful differences (7-45%) in coverage of the two vaccines in 6 (67%) of the 9 countries. In Africa, there were meaningful differences (4-27%) in coverage of the two vaccines in 9 (43%) of the 21 countries. Nine countries (26%) reported MVC1 stock-outs while sixteen countries (47%) reported YF vaccine stock-outs for three or more years during 2006-2016.
   Conclusion: In countries reporting significant differences in coverage of the two vaccines, differences may be driven by different target populations and vaccine availability. However, these were not sufficient to completely explain observed differences. Further follow-up is needed to identify possible reasons for differences in coverage rates in several countries where these could not fully be explained. Published by Elsevier Ltd.
C1 [Adrien, Nedghie; Hyde, Terri B.; Krishnaswamy, Akshaya] US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS 24-2, Atlanta, GA 30329 USA.
   [Gacic-Dobo, Marta; Hombach, Joachim; Lambach, Philipp] WHO, Dept Immunizat Vaccines & Biol IVB, Geneva, Switzerland.
   [Krishnaswamy, Akshaya] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
RP Hyde, TB (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS 24-2, Atlanta, GA 30329 USA.
EM thyde@cdc.gov
OI Lambach, Philipp/0000-0003-0105-8899
FU World Health Organization's Initiative for Vaccine Research; World
   Health Organization Initiative for Vaccine Research
FX The development of the desk review was funded by a grant from the World
   Health Organization's Initiative for Vaccine Research. The authors would
   like to acknowledge the contributions of the US Centers for Disease
   Control and Prevention (US CDC), which provides financial support to the
   World Health Organization Initiative for Vaccine Research.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P193
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P33
   [Anonymous], 2018, GLOB STRAT ELIM YELL
   Barnett ED, 2007, CLIN INFECT DIS, V44, P850, DOI 10.1086/511869
   Barrett ADT, 2007, ANNU REV ENTOMOL, V52, P209, DOI 10.1146/annurev.ento.52.110405.091454
   Barrett ADT, 2018, SCIENCE, V361, P847, DOI 10.1126/science.aau8225
   Barrett ADT, 2016, NEW ENGL J MED, V375, P301, DOI 10.1056/NEJMp1606997
   Brown DW, 2017, WORLD J VACCINE, V7, P1, DOI [10.4236/wjv.2017.71001, DOI 10.4236/WJV.2017.71001]
   Burton AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038007
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   Casey Rebecca Mary, 2017, Pan Afr Med J, V27, P5, DOI 10.11604/pamj.supp.2017.27.3.12114
   Feldstein LR, 2017, MMWR-MORBID MORTAL W, V66, P1252, DOI 10.15585/mmwr.mm6645a3
   Garske T, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001638
   Gauri VK, PEYVAND IMMUNIZATION
   Heaton A, 2017, VACCINE, V35, P2272, DOI 10.1016/j.vaccine.2016.11.066
   Lydon P, 2017, VACCINE, V35, P2121, DOI 10.1016/j.vaccine.2016.12.071
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Paules CI, 2017, NEW ENGL J MED, V376, P1397, DOI 10.1056/NEJMp1702172
   Perry RT, 2013, MMWR-MORBID MORTAL W, V62, P27
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Strategic advisory group of experts on immunization, STRAT ADV GROUP EXP
   WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, P1109, DOI [10.1016/S1473-3099(17)30494-2, 10.1016/S1473-3099(16)30518-7]
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, P248, DOI 10.1016/S1473-3099(16)30588-6
   World Health Organization, 2016, GLOB STRAT ELIM YELL
   World Health Organization, 1998, YELL FEV TECHN CONS, P2
   World Health Organization, IMM VACC BIOL DAT ST
   Yen C, 2015, LANCET INFECT DIS, V15, P340, DOI 10.1016/S1473-3099(14)70999-5
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4511
EP 4517
DI 10.1016/j.vaccine.2019.06.063
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000016
PM 31266670
OA Green Accepted
DA 2020-05-12
ER

PT J
AU d'Offay, JM
   Fulton, RW
   Fishbein, M
   Eberle, R
   Dubovi, EJ
AF d'Offay, Jean M.
   Fulton, Robert W.
   Fishbein, Mark
   Eberle, R.
   Dubovi, Edward J.
TI Isolation of a naturally occurring vaccine/wild-type recombinant bovine
   herpesvirus type 1 (BoHV-1) from an aborted bovine fetus
SO VACCINE
LA English
DT Article
DE BoHV-1; Bovine herpesvirus type 1; Wild-type; Vaccine/wild-type
   recombinant; Vaccine-derived isolates; MLV viruses; SNP patterns
ID FIELD STRAINS; RESPIRATORY-DISEASE; GENETIC DIVERSITY; GENOMIC SEQUENCE;
   VIRUS; CATTLE; ALPHAHERPESVIRUSES; REACTIVATION; INFECTION; BLOOD
AB Bovine herpesvirus type 1 (BoHV-1) causes various disease syndromes in cattle including respiratory disease and abortions. During an investigation into the potential role of BoHV-1 modified-live vaccines (MLV) causing diseases in cattle, we performed whole genome sequencing on six BoHV-1 field strains isolated at Cornell Animal Health Diagnostic Center in the late 1970s. Three isolates (two respiratory and a fetal) were identified as vaccine-derived isolates, having SNP patterns identical to that of a previously sequenced MLV virus that exhibited a deleted US2 and truncated US1.67 genes. Two other isolates (a respiratory and a fetal) were categorized as wild-type (WT) viruses based on their unique SNP pattern that is distinct from MLV viruses. The sixth isolate from an aborted fetus was a recombinant virus with 62% of its genome exhibiting SNPs identical to one of the above-mentioned WT viruses also recovered from an aborted fetus. The remaining 38% consisted of two blocks of sequences derived from the MLV virus. The first block replaced the UL9-UL19 region, and the second vaccine-derived sequence block encompassed all the genes within the unique short region and the internal/terminal repeats containing the regulatory genes BICP4 and BICP22. This is confirmatory evidence that recombination between BoHV-1 MLV and WT viruses can occur under natural conditions and cause disease. It is important in that it underscores the potential for the glycoprotein E negative (gE(-)) marker vaccine used to eradicate BoHV-1 in some countries, to recombine with virulent field strains allowing them to capture the gE(-) marker, thereby endangering the control and eradication programs. Published by Elsevier Ltd.
C1 [d'Offay, Jean M.; Fulton, Robert W.; Eberle, R.] Oklahoma State Univ, Ctr Vet Hlth Sci, Dept Vet Pathobiol, 250 McElroy Hall, Stillwater, OK 74078 USA.
   [Fishbein, Mark] Oklahoma State Univ, Dept Plant Biol Ecol & Evolut, Phys Sci 301, Stillwater, OK 74078 USA.
   [Dubovi, Edward J.] Cornell Univ, Anim Hlth Diagnost Ctr, Ithaca, NY 14852 USA.
RP d'Offay, JM (reprint author), Oklahoma State Univ, Ctr Vet Hlth Sci, Dept Vet Pathobiol, 250 McElroy Hall, Stillwater, OK 74078 USA.
EM jean.doffay@okstate.edu
FU Center for Veterinary Health Sciences; Novartis Animal Health,
   Greensboro, NC; Endowed Chair
FX The research was supported by the Center for Veterinary Health Sciences,
   funds from the Endowed Chair for Dr. Robert Fulton, and a grant from
   Novartis Animal Health, Greensboro, NC.
CR Agnew-Crumpton R, 2016, INFECT GENET EVOL, V43, P67, DOI 10.1016/j.meegid.2016.05.023
   Chase CCL, 2017, VET MICROBIOL, V206, P69, DOI 10.1016/j.vetmic.2017.03.016
   d'Offay JM, 2016, ARCH VIROL, V161, P3269, DOI 10.1007/s00705-016-3026-1
   d'Offay JM, 2013, ARCH VIROL, V158, P1109, DOI 10.1007/s00705-012-1574-6
   Zajac MPD, 2009, J VIROL METHODS, V161, P75, DOI 10.1016/j.jviromet.2009.05.020
   DOFFAY JM, 1993, AM J VET RES, V54, P534
   Fuchs M, 1999, J CLIN MICROBIOL, V37, P2498, DOI 10.1128/JCM.37.8.2498-2507.1999
   Fujita K, 1998, ARCH VIROL, V143, P25, DOI 10.1007/s007050050265
   Fulton RW, 2016, VIRUS RES, V223, P115, DOI 10.1016/j.virusres.2016.06.017
   Fulton RW, 2015, VACCINE, V33, P549, DOI 10.1016/j.vaccine.2014.11.033
   Fulton RW, 2013, VACCINE, V31, P1471, DOI 10.1016/j.vaccine.2013.01.013
   Fulton Robert W., 2009, Animal Health Research Reviews, V10, P131, DOI 10.1017/S146625230999017X
   KATZ JB, 1990, VACCINE, V8, P286, DOI 10.1016/0264-410X(90)90060-Y
   KINTNER RL, 1995, ARCH VIROL, V140, P231, DOI 10.1007/BF01309859
   Lee SW, 2012, SCIENCE, V337, P188, DOI 10.1126/science.1217134
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Meurens F, 2004, J VIROL, V78, P9828, DOI 10.1128/JVI.78.18.9828-9836.2004
   Muylkens B, 2007, VET RES, V38, P181, DOI 10.1051/vetres:2006059
   Muylkens B, 2009, J VIROL, V83, P3127, DOI 10.1128/JVI.02474-08
   Newman RM, 2016, J VIROL, V89, P8219, DOI [10.1128/JVI.1303-1, DOI 10.1128/JVI.1303-1]
   Norberg P, 2015, J VIROL, V89, P7133, DOI 10.1128/JVI.00437-15
   NYAGA PN, 1979, COMP IMMUNOL MICROB, V2, P587, DOI 10.1016/0147-9571(79)90100-0
   O'Toole D, 2014, VET PATHOL, V51, P1051, DOI 10.1177/0300985814548515
   Pagamjav O, 2005, MICROBIOL IMMUNOL, V49, P167, DOI 10.1111/j.1348-0421.2005.tb03716.x
   Podaert KCK, 2019, J VIROL, V93, DOI 10.1128/JVI.02098-18
   SCHWYZER M, 1994, J GEN VIROL, V75, P1703, DOI 10.1099/0022-1317-75-7-1703
   Schynts F, 2003, J VIROL, V77, P12535, DOI 10.1128/JVI.77.23.12535-12542.2003
   Theil D, 2003, ANN NEUROL, V54, P678, DOI 10.1002/ana.10746
   Thiry E, 2005, REV MED VIROL, V15, P89, DOI 10.1002/rmv.451
   WHETSTONE CA, 1989, ARCH VIROL, V107, P27, DOI 10.1007/BF01313875
   Winkler MTC, 2000, J VIROL, V74, P5337, DOI 10.1128/JVI.74.11.5337-5346.2000
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4518
EP 4524
DI 10.1016/j.vaccine.2019.06.059
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000017
PM 31266667
DA 2020-05-12
ER

PT J
AU Bryden, GM
   Browne, M
   Rockloff, M
   Unsworth, C
AF Bryden, Gabrielle M.
   Browne, Matthew
   Rockloff, Matthew
   Unsworth, Carolyn
TI The privilege paradox: Geographic areas with highest socio-economic
   advantage have the lowest rates of vaccination
SO VACCINE
LA English
DT Article
DE Health psychology; Health promotion; Vaccine hesitancy; Vaccine refusal;
   Childhood immunisation; Childhood vaccination; 2016 Australian
   Population and Household; Census
ID MEASLES OUTBREAKS; HERD-IMMUNITY; NO JAB; HESITANCY; REFUSAL;
   UNDERIMMUNIZATION; DETERMINANTS; ASSOCIATION; EXEMPTIONS; PREDICTORS
AB The present study is the first to examine associations between area-level socio-demographic factors and uptake of vaccination among 5-year old children throughout Australia. A public-health focused ecological methodology was used that combined postcode-level socio-demographic variables from the 2016 Census with postcode-level vaccination data. Analyses included one-way analysis of variance and assessment of linear trends for each socio-demographic variable across five categories of vaccination rate; ranging from lowest (<= 90%) to highest (96.1-100%), as well as using vaccination rate as a continuous variable. Multiple regression analysis was also conducted using select indicators to predict vaccination rates in postcodes from major cities. The results of the univariate analyses showed that communities with lower rates of vaccination had relatively less disadvantage, and had relatively greater education and occupation status, as measured by SEIFA (ABS [4]). When we looked at the ASGS Remoteness Areas, we saw that the vaccination rates were lowest in postcodes from the major cities of Australia, and vaccination rates increased as communities became more remote. When the community is further refined to postcodes located in the major cities, and to the target group of parents/partners in a family with children aged 4-7, we found that postcodes with lower vaccination rates were characterised as having a relatively greater proportion of people with: a high education level (bachelor degree level or higher); having white-collar jobs as managers; having no religion, having people in the older age category (50-54); and conversely being unemployed. (C) 2019 Published by Elsevier Ltd.
C1 [Bryden, Gabrielle M.; Browne, Matthew; Rockloff, Matthew; Unsworth, Carolyn] Cent Queensland Univ, Sch Human Hlth & Social Sci, Univ Dr, Branyan, Qld 4670, Australia.
RP Browne, M (reprint author), Cent Queensland Univ, Sch Human Hlth & Social Sci, Univ Dr, Branyan, Qld 4670, Australia.
EM m.brown@cqu.edu.au
OI Browne, Matthew/0000-0002-2668-6229
FU Australian Commonwealth Government's Research Training Program/Research
   Training Scheme for a Research Higher Degree candidate; Australian
   GovernmentAustralian Government
FX This study was supported under the Australian Commonwealth Government's
   Research Training Program/Research Training Scheme for a Research Higher
   Degree candidate. We gratefully acknowledge the financial support
   provided by the Australian Government.
CR ABS, 2017, SIGN URB AR URB CTR, V4
   ABS, 2018, SOC IND AR SEIFA 201
   ABS, 2016, 2901 0 CENS POP HOUS
   AIHW, 2017, AUSTR HLTH 2016 RUR
   Atwell JE, 2013, PEDIATRICS, V132, P624, DOI 10.1542/peds.2013-0878
   Australian Government Department of Health, 2018, NAT IMM PROGR SCHED
   Bass PF III, 2015, PERTUSSIS MAKES NAST
   Beard Frank H, 2016, Med J Aust, V204, P275
   Bedford H, 2018, VACCINE, V36, P6556, DOI 10.1016/j.vaccine.2017.08.004
   Bird C, 2013, CAN MED ASSOC J, V185, pE393, DOI 10.1503/cmaj.109-4480
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562
   Browne M, 2014, EUR J SOC PSYCHOL, V44, P736, DOI 10.1002/ejsp.2059
   Bryden G., 2016, FOCUS ALTERNATIVE CO, V21, P58, DOI [10.1111/fct.12234, DOI 10.1111/FCT.12234]
   Bryden GM, 2018, VACCINE, V36, P1227, DOI 10.1016/j.vaccine.2017.12.068
   Corp I. B. M., 2017, IBM SPSS STAT WIND V
   Department of Health, 2018, CHILDH IMM COV WHAT
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Fisher H, 2014, J PUBLIC HEALTH-UK, V36, P36, DOI 10.1093/pubmed/fdt042
   Harding S, 2017, REPORT QUALITY 2016
   Henry KA, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4567-2
   Hull B, 2018, ANN IMMUNISATION COV
   Hull Brynley, 2003, N S W Public Health Bull, V14, P8, DOI 10.1071/NB03003
   Ingraham C., 2015, WASHINGTON POST
   Jain A, 2017, VACCINE, V35, P2315, DOI 10.1016/j.vaccine.2017.03.013
   Jansen VAA, 2003, SCIENCE, V301, P804, DOI 10.1126/science.1086726
   Kirby T, 2017, LANCET INFECT DIS, V17, P903, DOI 10.1016/S1473-3099(17)30459-0
   Kumar VM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-172
   Lamden KH, 2008, J PUBLIC HEALTH-UK, V30, P251, DOI 10.1093/pubmed/fdn036
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lieu TA, 2015, PEDIATRICS, V135, P280, DOI 10.1542/peds.2014-2715
   McIntosh EDG, 2016, J PEDIATR-US, V175, P248, DOI 10.1016/j.jpeds.2016.06.006
   McNutt LA, 2016, VACCINE, V34, P1733, DOI 10.1016/j.vaccine.2015.11.063
   Mulholland EK, 2008, B WORLD HEALTH ORGAN, V86, P399, DOI 10.2471/BLT.07.044545
   Onnela JP, 2016, SOC SCI MED, V153, P99, DOI 10.1016/j.socscimed.2016.01.024
   Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Rashid H, 2012, CURR OPIN INFECT DIS, V25, P243, DOI 10.1097/QCO.0b013e328352f727
   Reich JA, 2014, GENDER SOC, V28, P679, DOI 10.1177/0891243214532711
   Remes O, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1047
   Roggendorf H, 2012, MED MICROBIOL IMMUN, V201, P349, DOI 10.1007/s00430-012-0240-7
   Sanchez-Santos MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072656
   Sandford H, 2015, VACCINE, V33, P1218, DOI 10.1016/j.vaccine.2014.12.006
   Sedgwick P, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4773
   Sheerin D, 2017, EUR J IMMUNOL, V47, P2017, DOI 10.1002/eji.201746942
   Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187
   Tiley KS, 2018, VACCINE, V36, P6726, DOI 10.1016/j.vaccine.2018.09.032
   Warner EL, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0953-2
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   Yang YT, 2017, JAMA-J AM MED ASSOC, V317, P803, DOI 10.1001/jama.2017.0123
   Yang YT, 2016, AM J PUBLIC HEALTH, V106, P172, DOI 10.2105/AJPH.2015.302926
NR 53
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4525
EP 4532
DI 10.1016/j.vaccine.2019.06.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000018
PM 31262584
DA 2020-05-12
ER

PT J
AU Moser, MJ
   Hatta, Y
   Gabaglia, C
   Sanchez, A
   Dias, P
   Sarawar, S
   Kawaoka, Y
   Hatta, M
   Neumann, G
   Bilsel, P
AF Moser, Michael J.
   Hatta, Yasuko
   Gabaglia, Claudia
   Sanchez, Adriana
   Dias, Peter
   Sarawar, Sally
   Kawaoka, Yoshihiro
   Hatta, Masato
   Neumann, Gabriele
   Bilsel, Pamuk
TI Single-replication BM2SR vaccine provides sterilizing immunity and
   cross-lineage influenza B virus protection in mice
SO VACCINE
LA English
DT Article
DE Influenza vaccine; BM2-deficient; Single replication; Live influenza;
   Intranasal; Cross-lineage protection; Drifted; Hemagglutination
   inhibition; Influenza B
ID SEASONAL INFLUENZA; LIVE; CHILDREN; METAANALYSIS; PROTEIN; SAFETY; M2SR
AB t Both influenza A and B viruses cause outbreaks of seasonal influenza resulting in significant morbidity and mortality. There are two antigenically distinct lineages of influenza B virus, Yamagata lineage (YL) and Victoria lineage (VL). Since both B lineages have been co-circulating for years, more than 70% of influenza vaccines currently manufactured are quadrivalent consisting of influenza A (H1N1), influenza A (H3N2), influenza B (YL) and influenza B (VL) antigens. Although quadrivalent influenza vaccines tend to elevate immunity to both influenza B lineages, estimated overall vaccine efficacy against influenza B is still only around 42%. Thus, a more effective influenza B vaccine is needed.
   To meet this need, we generated BM2-deficient, single-replication (BM2SR) influenza B vaccine viruses that encode surface antigens from influenza B/Wisconsin/01/2010 (B/WI01, YL) and B/Brisbane/60/2008 (B/Bris60, VL) viruses. The BM2SR-WI01 and BM2SR-Bris60 vaccine viruses are replication-deficient in vitro and in vivo, and can only replicate in a cell line that expresses the complementing BM2 protein. Both BM2SR viruses were non-pathogenic to mice, and vaccinated animals showed elevated mucosal and serum antibody responses to both Yamagata and Victoria lineages in addition to cellular responses. Serum antibody responses included lineage-specific hemagglutinin inhibition antibody (HAI) responses as well as responses to the stem region of the hemagglutinin (HA). BM2SR vaccine viruses provided apparent sterilizing immunity to mice against intra- and inter-lineage drifted B virus challenge. The data presented here support the feasibility of BM2SR as a platform for next-generation trivalent influenza vaccine development. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Moser, Michael J.; Hatta, Yasuko; Bilsel, Pamuk] FluGen Inc, 597 Sci Dr, Madison, WI 53711 USA.
   [Gabaglia, Claudia; Sanchez, Adriana; Dias, Peter; Sarawar, Sally] Biomed Res Inst Southern Calif, Oceanside, CA 92056 USA.
   [Kawaoka, Yoshihiro; Hatta, Masato; Neumann, Gabriele] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Influenza Res Inst, Madison, WI 53711 USA.
   [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Div Virol,Dept Microbiol & Immunol, Tokyo 1088639, Japan.
   [Hatta, Masato] Univ Tokyo, Inst Med Sci, Int Res Ctr Infect Dis, Div Virol,Dept Special Pathogens, Tokyo 1088639, Japan.
RP Bilsel, P (reprint author), FluGen Inc, 597 Sci Dr, Madison, WI 53711 USA.
EM pbilsel@flugen.com
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI109925]
FX This work was supported, in part, by National Institutes of Health
   AI109925 to P.B. and S.S.
CR Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   Arunkumar GA, 2019, J VIROL, V93, DOI 10.1128/JVI.01696-18
   Belshe RB, 2010, VACCINE, V28, pD45, DOI 10.1016/j.vaccine.2010.08.028
   Belshe RB, 2010, VACCINE, V28, P2149, DOI 10.1016/j.vaccine.2009.11.068
   Beran J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-224
   Caini S, 2015, INFLUENZA OTHER RESP, V9, P3, DOI 10.1111/irv.12319
   Carter NJ, 2011, DRUGS, V71, P1591, DOI 10.2165/11206860-000000000-00000
   de Vries RD, 2018, J INFECT DIS, V217, P3, DOI 10.1093/infdis/jix546
   Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908
   Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17
   Esposito S, 2012, HUM VACC IMMUNOTHER, V8, P76, DOI 10.4161/hv.8.1.18809
   Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Hatta M, 2004, J VIROL, V78, P5576, DOI 10.1128/JVI.78.11.5576-5583.2004
   Hatta Y, 2017, VACCINE, V35, P4177, DOI 10.1016/j.vaccine.2017.06.039
   Hatta Y, 2011, VACCINE, V29, P2308, DOI 10.1016/j.vaccine.2011.01.023
   Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664
   Hoffmann E, 2002, P NATL ACAD SCI USA, V99, P11411, DOI 10.1073/pnas.172393399
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Kiseleva I, 2018, BIOMED RES INT, DOI 10.1155/2018/9695628
   Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007
   Laurie KL, 2018, J INFECT DIS, V217, P548, DOI 10.1093/infdis/jix509
   Liu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08165-y
   Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064
   Muralidharan A, 2018, BIOCHEM BIOPH RES CO, V502, P226, DOI 10.1016/j.bbrc.2018.05.148
   Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345
   Pebody R, 2013, EUROSURVEILLANCE, V18, DOI DOI 10.2807/ESE.18.05.20389-EN
   ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U
   Sarawar S, 2016, VACCINE, V34, P5090, DOI 10.1016/j.vaccine.2016.08.061
   Skowronski DM, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.5.18-00035
   Skowronski DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038929
   Skowronski DM, 2011, PEDIATR INFECT DIS J, V30, P833, DOI 10.1097/INF.0b013e31822db4dc
   Tennis P, 2011, VACCINE, V29, P4947, DOI 10.1016/j.vaccine.2011.04.113
   Tisa V, 2016, J Prev Med Hyg, V57, pE28
   Toback SL, 2012, EXPERT REV VACCINES, V11, P1293, DOI [10.1586/erv.12.108, 10.1586/ERV.12.108]
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   Valenciano M, 2013, EUROSURVEILLANCE, V18, P12
   van de Sandt CE, 2015, J GEN VIROL, V96, P2061, DOI 10.1099/vir.0.000156
   van de Witte S, 2018, VACCINE, V36, P6030, DOI 10.1016/j.vaccine.2018.04.043
   Vigil A, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.02269-17, 10.1128/aac.02269-17]
   Watanabe S, 2009, J VIROL, V83, P5947, DOI 10.1128/JVI.00450-09
   Xu T, 2006, AM J RESP CRIT CARE, V174, P1011, DOI 10.1164/rccm.200511-1751OC
   Young B, 2018, J INFECT DIS, V217, P731, DOI 10.1093/infdis/jix632
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4533
EP 4542
DI 10.1016/j.vaccine.2019.06.043
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000019
PM 31280945
OA Other Gold
DA 2020-05-12
ER

PT J
AU Parker, L
   Ritter, L
   Wu, W
   Maeso, R
   Bright, H
   Dibben, O
AF Parker, Lauren
   Ritter, Lydia
   Wu, Wen
   Maeso, Ruben
   Bright, Helen
   Dibben, Oliver
TI Haemagglutinin stability was not the primary cause of the reduced
   effectiveness of live attenuated influenza vaccine against A/H1N1pdm09
   viruses in the 2013-2014 and 2015-2016 seasons
SO VACCINE
LA English
DT Article
DE Influenza; Live attenuated influenza vaccine; Thermostability; pH
   stability; Haemagglutinin; 2009 pandemic A/H1N1 (A/H1N1pdm09); Vaccine
   effectiveness
ID CULTURE-CONFIRMED INFLUENZA; YOUNG-CHILDREN; UNITED-STATES; TEMPERATURE
   SENSITIVITY; RESPIRATORY-TRACT; MEMBRANE-FUSION; A VIRUS; ACID;
   EFFICACY; TRIVALENT
AB During the 2013-2014 influenza season, the quadrivalent live attenuated influenza vaccine (QLAIV), had lower than expected vaccine effectiveness (VE) against circulating A/H1N1pdm09 viruses in the USA. The underlying reason proposed for this was that the A/H1N1pdm09 vaccine strain, A/California/07/2009 (A/CA09), had a thermally unstable haemagglutinin (HA) protein. Consequently, a new A/H1N1pdm09 candidate strain, A/Bolivia/559/2013 (A/BOL13), was developed for inclusion in the 2015-2016 QLAIV. A key parameter for selection of A/BOL13 was its more thermostable HA phenotype compared with A/CA09. During the 2015-2016 season, QLAIV containing A/BOL13 was found in some studies to have improved, but still with suboptimal, VE against circulating A/H1N1pdm09 viruses and was not recommended for use by the CDC in the US market in the 2016-2017 influenza season. This suggested that improved HA thermostability had not entirely resolved the reduced VE observed. One hypothesis for this was that, by improving thermostability, the A/BOL13 HA protein had been over-stabilised, compromising its activation at the low endosomal pH required for successful viral entry. Here we demonstrate that, while the A/BOL13 HA protein is more stable than that of A/CA09, its thermal and pH stability were comparable with historically efficacious LAIV strains, suggesting that the HA had not been over-stabilised. Furthermore, studies simulating potential heat exposure during distribution by exposing QLAIV nasal sprayers to 33 degrees C for 4 h showed that, while remaining within product specification, A/CA09 viral potency was statistically decreased after 12 weeks at 2-8 degrees C. These data suggest that although unfavourable HA protein stability may have contributed to the reduced VE of A/CA09 in 2013-2014, it was unlikely to have affected A/BOL13 in 2015-2016. We conclude that HA stability was not the primary cause of the reduced effectiveness of LAIV against A/H1N1pdm09 viruses in the 2013-2014 and 2015-2016 seasons. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Parker, Lauren; Ritter, Lydia; Wu, Wen; Maeso, Ruben; Bright, Helen; Dibben, Oliver] AstraZeneca, Flu BPD, Liverpool, Merseyside, England.
   [Wu, Wen] Cambridge Data Sci, Barnet, England.
   [Maeso, Ruben] Seqirus Vaccines Ltd, Liverpool, Merseyside, England.
RP Parker, L (reprint author), AstraZeneca UK, Unit 6 Renaissance Way, Liverpool L24 9JW, Merseyside, England.
EM parkerla@medimmune.com
FU AstraZeneca UK Ltd.AstraZeneca
FX This study was supported by AstraZeneca UK Ltd.
CR Ambrose CS, 2008, INFLUENZA OTHER RESP, V2, P193, DOI 10.1111/j.1750-2659.2008.00056.x
   Ashkenazi S, 2006, PEDIATR INFECT DIS J, V25, P870, DOI 10.1097/01.inf.0000237829.66310.85
   Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368
   Caspard H, 2016, VACCINE, V34, P5066, DOI 10.1016/j.vaccine.2016.08.079
   Centers for Disease Control and Prevention, 2018, PREV STRAT SEAS INFL
   Chen ZY, 2010, J VIROL, V84, P44, DOI 10.1128/JVI.02106-09
   Cheng X, 2012, VIROLOGY, V432, P91, DOI 10.1016/j.virol.2012.06.002
   Costello DA, 2015, J VIROL, V89, P350, DOI 10.1128/JVI.01927-14
   Cotter CR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003831
   Department of Health and Human Services, 2012, CLIN REV SUPPL BIOL
   Edinger TO, 2014, J GEN VIROL, V95, P263, DOI 10.1099/vir.0.059477-0
   European Medicines Agency, 2013, ASS REP FLUENZ TETR
   European Medicines Agency, 2014, FLUENZ INFL VACC LIV
   Farnsworth A, 2011, VACCINE, V29, P1529, DOI 10.1016/j.vaccine.2010.12.120
   Feshchenko E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-77
   Fleming DM, 2006, PEDIATR INFECT DIS J, V25, P860, DOI 10.1097/01.inf.0000237797.14283.cf
   Galloway SE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003151
   Gaspard N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx111
   Gaymard A, 2016, CLIN MICROBIOL INFEC, V22, P975, DOI 10.1016/j.cmi.2016.07.007
   Giese S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060165
   Gould PS, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100269
   Grohskopf LA, 2018, MMWR-MORBID MORTAL W, V67, P643, DOI 10.15585/mmwr.mm6722a5
   HAYWOOD AM, 1986, J GEN VIROL, V67, P2813, DOI 10.1099/0022-1317-67-12-2813
   Hoffmann E, 2005, J VIROL, V79, P11014, DOI 10.1128/JVI.79.17.11014-11021.2005
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Huber Peter J, 2009, ROBUST STAT
   Jin H, 2003, VIROLOGY, V306, P18, DOI 10.1016/S0042-6822(02)00035-1
   Kingsley CN, 2017, J BIOL CHEM, V292, P21590, DOI 10.1074/jbc.M117.815043
   MAURERSTROH S, 2010, PLOS CURR, V2, DOI DOI 10.1371/JOURNAL.PCBI.1000867
   MCCONNELL JR, 2016, EUROSURVEILLANCE, V21, DOI DOI 10.1061/(ASCE)BE.1943-5592.0000846
   McLean HQ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3742
   McLean HQ, 2017, VACCINE, V35, P2685, DOI 10.1016/j.vaccine.2017.03.085
   O'Donnell CD, 2014, J VIROL, V88, P12374, DOI 10.1128/JVI.01107-14
   Pebody R, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.36.30013
   Penttinen PM, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.38.30350
   Public Health England, 2018, WINT 2018 19 FLU VAC
   Robertson JS, 2011, VACCINE, V29, P1836, DOI 10.1016/j.vaccine.2010.12.044
   RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2
   Russell CJ, 2014, CURR TOP MICROBIOL, V385, P93, DOI 10.1007/82_2014_393
   Russier M, 2016, P NATL ACAD SCI USA, V113, P1636, DOI 10.1073/pnas.1524384113
   SCHOLTISSEK C, 1985, VACCINE, V3, P215, DOI 10.1016/0264-410X(85)90109-4
   Singanayagam A, 2018, LANCET INFECT DIS, V18, pE25, DOI [10.1016/S1473-3099(17)30360-2, 10.1016/s1473-3099(17)30360-2]
   Tam JS, 2007, PEDIATR INFECT DIS J, V26, P619, DOI 10.1097/INF.0b013e31806166f8
   Vesikari T, 2006, PEDIATRICS, V118, P2298, DOI 10.1542/peds.2006-0725
   Wen F, 2018, J VIROL, V92
   Yang H, 2014, J VIROL, V88, P4828, DOI 10.1128/JVI.02278-13
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
NR 47
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4543
EP 4550
DI 10.1016/j.vaccine.2019.06.016
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000020
PM 31279567
OA Other Gold
DA 2020-05-12
ER

PT J
AU Dilokthornsakul, P
   Kengkla, K
   Saokaew, S
   Permsuwan, U
   Techasaensiri, C
   Chotpitayasunondh, T
   Chaiyakunapruk, N
AF Dilokthornsakul, Piyameth
   Kengkla, Kirati
   Saokaew, Surasak
   Permsuwan, Unchalee
   Techasaensiri, Chonnamet
   Chotpitayasunondh, Tawee
   Chaiyakunapruk, Nathorn
TI An updated cost-effectiveness analysis of pneumococcal conjugate vaccine
   among children in Thailand
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Cost-effectiveness analysis; Thailand
ID NONTYPABLE HAEMOPHILUS-INFLUENZAE; BUDGET IMPACT ANALYSIS;
   ECONOMIC-EVALUATION; INTRAVENOUS IMMUNOGLOBULIN; UTILITY ANALYSIS;
   PROTEIN-D; DISEASE; 10-VALENT; 7-VALENT; SURVEILLANCE
AB Background: A previous cost-effectiveness analysis (CEA) showed that Pneumococcal Conjugate Vaccine (PCV) 10 and PCV13 were not cost-effective for universal immunization among children in Thailand. Given recent changes in the evidence of efficacy, herd effects and price, a CEA of PCVs should be revisited. This study aimed to determine the cost-effectiveness of PCV10 and PCV13 compared to no PCV vaccination in Thai children.
   Material and methods: A Markov model was developed under a societal perspective with a lifetime horizon. Inputs were derived from a comprehensive literature review. Costs were calculated using the Thai National Electronic Database and converted to the year 2017 value. All costs and outcomes were discounted at a rate of 3%. The findings were reported as incremental cost-effectiveness ratios (ICERs) in Thai Baht (THB) per quality-adjusted life year (QALY) gained. Sensitivity analyses were performed. A cost-effectiveness acceptability curve was generated with the cost-effectiveness threshold of 160,000 THB/QALY.
   Results: Base-case analysis of 2 + 1 dose schedule and five-year protection, with no consideration of herd effect showed that 10ER for PCV10 was 170,437 THB/QALY, while ICER for PCV13 was 73,674 THB/QALY. With consideration of herd effect, both PCV10 and PCV13 had lower costs and higher QALYs compared to no PCV vaccination. Based on our probabilistic sensitivity analysis at willingness-to-pay of 160,000 THB/QALY, PCVI3 had 93% of being cost-effective, while 4.7% and 2.3%, for PCV10 and no PCV vaccination, respectively.
   Conclusion: At current prices, PCV13 is cost-effective, while PCV10 is not cost-effective in Thailand. When considering herd-effect, both PCV10 and PCV13 are cost-effective. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dilokthornsakul, Piyameth; Chaiyakunapruk, Nathorn] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Ctr Pharmaceut Outcomes Res, Phitsanulok, Thailand.
   [Kengkla, Kirati; Saokaew, Surasak] Univ Phayao, Sch Pharmaceut Sci, Ctr Hlth Outcomes Res & Therapeut Safety Cohorts, Phayao, Thailand.
   [Permsuwan, Unchalee] Chiang Mai Univ, Dept Pharmaceut Care, Fac Pharm, Chiang Mai, Thailand.
   [Techasaensiri, Chonnamet] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok, Thailand.
   [Chotpitayasunondh, Tawee] Childrens Hosp, Queen Sirikit Natl Inst Child Hlth, Minist Publ Hlth, Bangkok, Thailand.
   [Saokaew, Surasak; Chaiyakunapruk, Nathorn] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA.
   [Saokaew, Surasak] Univ Phayao, Sch Pharmaceut Sci, Unit Excellence Clin Outcomes Res & Innovat UNICO, Phayao, Thailand.
RP Dilokthornsakul, P; Chaiyakunapruk, N (reprint author), Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Ctr Pharmaceut Outcomes Res, Phitsanulok, Thailand.
EM piyamethd@nu.ac.th; nathorn.chaiyaku-napruk@monash.edu
RI ; Saokaew, Assoc. Prof. Dr. Surasak/J-6041-2015
OI permsuwan, unchalee/0000-0002-6909-2789; Dilokthornsakul,
   Piyameth/0000-0002-6981-1771; Saokaew, Assoc. Prof. Dr.
   Surasak/0000-0002-1382-0660
FU Pediatric Infectious Disease Society of Thailand; Pfizer (Thailand)
FX We would like to acknowledge the National Health Security Office for
   national data. This study is granted by Pediatric Infectious Disease
   Society of Thailand with support from Pfizer (Thailand).
CR Ansaldi F, 2011, HUM VACCINES, V7, P211, DOI 10.4161/hv.7.0.14602
   Artama M, 2018, CURR DRUG SAF, V13, P107, DOI 10.2174/1574886313666180406164151
   Baggett HC, 2009, CLIN INFECT DIS, V48, pS65, DOI 10.1086/596484
   Bamrungsawad N, 2016, CLIN DRUG INVEST, V36, P557, DOI 10.1007/s40261-016-0401-3
   Bamrungsawad N, 2015, PHARMACOECONOMICS, V33, P521, DOI 10.1007/s40273-015-0269-8
   Billings ME, 2016, PEDIATR INFECT DIS J, V35, P172, DOI 10.1097/INF.0000000000000955
   Bravo LC, 2009, VACCINE, V27, P7282, DOI 10.1016/j.vaccine.2009.04.046
   Briggs A.H., 2006, DECISION MODELLING H
   Center of Disease Control and Prevention, 2018, GLOB PNEUM DIS VACC
   Chaikledkaew U, 2009, THAILANDS NATL HLTH
   Chaiyakunapruk N., 2008, J MED ASS THAILAN S2, V91, P516
   Conklin L, 2014, PEDIATR INFECT DIS J, V33, pS109, DOI 10.1097/INF.0000000000000078
   Essential Medicines and. Technology Division (EMTD) Department of Medical Services Moll, 2018, HLTH TECHN ASS PROC
   Fitzwater SP, 2012, PEDIATR INFECT DIS J, V31, P501, DOI 10.1097/INF.0b013e31824de9f6
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290
   Jordan HT, 2009, INT J INFECT DIS, V13, P355, DOI 10.1016/j.ijid.2008.07.014
   Khwannimit Bodin, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P886
   Knol MJ, 2015, EMERG INFECT DIS, V21, P2040, DOI 10.3201/eid2111.140780
   Kotirum S, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00289
   Kulpeng W, 2013, VACCINE, V31, P2839, DOI 10.1016/j.vaccine.2013.03.047
   Leelahavarong P, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-209
   Lieu TA, 2002, AMBUL PEDIATR, V2, P358, DOI 10.1367/1539-4409(2002)002<0358:PVOFBA>2.0.CO;2
   Littlejohn ES, 2015, HUM VACC IMMUNOTHER, V11, P1828, DOI 10.1080/21645515.2015.1048937
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Mohara A, 2012, J COMP EFFECT RES, V1, P137, DOI [10.2217/cer.12.10, 10.2217/CER.12.10]
   Muangchana C, 2009, SE ASIAN J TROP MED, V40, P553
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Pavia M, 2009, PEDIATRICS, V123, pE1103, DOI 10.1542/peds.2008-3422
   Permsuwan Unchalee, 2014, Journal of the Medical Association of Thailand, V97, pS50
   Phongsamart W, 2014, HUM VACC IMMUNOTHER, V10, P1866, DOI 10.4161/hv.28675
   Pomat WS, 2019, CLIN INFECT DIS, V68, P1472, DOI 10.1093/cid/ciy743
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113
   Rhodes J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066038
   Riewpaiboon Arthorn, 2014, Journal of the Medical Association of Thailand, V97, pS127
   Sangmala P, 2014, ASIAN PAC J CANCER P, V15, P8993, DOI 10.7314/APJCP.2014.15.20.8993
   Saokaew S, 2016, PHARMACOECONOMICS, V34, P1211, DOI 10.1007/s40273-016-0439-3
   Shiri T, 2017, LANCET GLOB HEALTH, V5, pE51, DOI 10.1016/S2214-109X(16)30306-0
   Sucher AJ, 2011, ANN PHARMACOTHER, V45, P1516, DOI 10.1345/aph.1Q347
   Techathawat S, 2008, DIS CONTROL J, V34, P311
   Thavorncharoensap M, 2013, CLINICOECONOMIC OUTC, V5, P29, DOI 10.2147/CEOR.S38062
   Thongsri W, 2016, EXPERT REV PHARM OUT, V16, P525, DOI 10.1586/14737167.2016.1120672
   Tregnaghi MW, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001657
   Tricarico S, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0030-5
   Tyo KR, 2011, VACCINE, V29, P6686, DOI 10.1016/j.vaccine.2011.06.091
   Working group of Burden of Disease Project, 2007, BURD DIS INJ THAIL 2
   World Health Organization, PRIME STUD PCV REV I
   World Health Organization, 2008, EST HIB PNEUM DEATHS
   World Health Orgarnization, 2018, V3P VACC PROD PRIC P
   Wu DB, 2016, HUM VACC IMMUNOTHER, V12, P403, DOI 10.1080/21645515.2015.1067351
   Wu DBC, 2015, VACCINE, V33, P1633, DOI 10.1016/j.vaccine.2015.01.081
NR 53
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4551
EP 4560
DI 10.1016/j.vaccine.2019.06.015
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000021
PM 31280944
DA 2020-05-12
ER

PT J
AU Almudevar, A
   Kaur, R
   Pichichero, M
AF Almudevar, Anthony
   Kaur, Ravinder
   Pichichero, Michael
TI Statistical projection of post-vaccination antibody kinetics between
   dosing schedules
SO VACCINE
LA English
DT Article
DE Vaccines doses; Kinetics; Modeling
ID PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNOGENICITY; INFANTS; PROTECTION;
   SAFETY; ADULTS; MODEL; YOUNG; DECAY
AB Determining a recommended dosage schedule is a crucial component of vaccine administration, and is often subject to reassessment. Ideally, recommendations will be supported by multiple arm clinical trials. However, the considerable cost in both resources and time means that a method of predicting post vaccine humoral antibody levels associated with a hypothetical schedule using data collected from a currently implemented schedule would be of significant benefit to vaccination practice.
   In this paper we propose such a methodology, which permits statistical estimation of the population mean and standard deviation of log transformed antibody titers of various post-vaccination time points of a hypothetical schedule, using a longitudinal sample of antibody titers from an observed schedule. The method is based on the decomposition of humoral antibody kinetic history into distinct phases, for example, peak phase, decay phase and post-booster phase. The method is feasible because each phase has its own discernable kinetic laws. Of particular interest will be estimation of antibody levels immediately preceding a booster dose (typically the lowest level attained during the schedule), and the antibody levels following a booster dose. (C) 2019 Published by Elsevier Ltd.
C1 [Almudevar, Anthony] Univ Rochester, Dept Biostat & Computat Biol, 265 Crittenden Blvd,CU 420630, Rochester, NY 14642 USA.
   [Kaur, Ravinder; Pichichero, Michael] Rochester Gen Hosp, Res Inst, Ctr Infect Dis & Immunol, Rochester, NY 14621 USA.
RP Almudevar, A (reprint author), Univ Rochester, Dept Biostat & Computat Biol, 265 Crittenden Blvd,CU 420630, Rochester, NY 14642 USA.
EM Anthony_Almudevar@urmc.rochester.edu
FU  [R03 HD088909-02]
FX This study was funded by R03 HD088909-02 (PI: Kaur).
CR Almudevar A, 2017, IMMUNOL CELL BIOL, V95, P832, DOI 10.1038/icb.2017.55
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Broker M, 2016, HUM VACC IMMUNOTHER, V12, P664, DOI 10.1080/21645515.2015.1086048
   Conklin L, 2014, PEDIATR INFECT DIS J, V33, pS109, DOI 10.1097/INF.0000000000000078
   David MP, 2009, GYNECOL ONCOL, V115, pS1, DOI 10.1016/j.ygyno.2009.01.011
   Findlow H, 2016, HUM VACC IMMUNOTHER, V12, P226, DOI 10.1080/21645515.2015.1091908
   Fraser C, 2007, VACCINE, V25, P4324, DOI 10.1016/j.vaccine.2007.02.069
   Friedel V, 2014, EPIDEMIOL INFECT, V142, P2186, DOI 10.1017/S0950268813003178
   GESEMANN M, 1995, VACCINE, V13, P443, DOI 10.1016/0264-410X(94)00010-K
   Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7
   Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0
   Honorati MC, 1999, CLIN EXP IMMUNOL, V116, P121, DOI 10.1046/j.1365-2249.1999.00866.x
   Kaur R, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0181
   Kent A, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3945
   Kim DK, 2018, MMWR-MORBID MORTAL W, V67, P158, DOI 10.15585/mmwr.mm6705e3
   Lopez EL, 2015, PEDIATR INFECT DIS J, V34, P417, DOI 10.1097/INF.0000000000000605
   McCulloch CE, 2008, GENERALIZED LINEAR A
   Meites E., 2016, MMWR MORB MORTAL WKL, V65
   Mittal MK, 2013, PEDIATR EMERG CARE, V29, P1119, DOI 10.1097/PEC.0b013e3182a63125
   Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532
   Pichichero ME, 1997, PEDIATRICS, V100, P772, DOI 10.1542/peds.100.5.772
   Pichichero ME, 2016, J INFECT DIS, V213, P2014, DOI 10.1093/infdis/jiw053
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Plotkin SA, 2013, CLIN INFECT DIS, V56, P1458, DOI 10.1093/cid/cit048
   Shelly MA, 1997, INFECT IMMUN, V65, P242, DOI 10.1128/IAI.65.1.242-247.1997
   Spijkerman J, 2013, JAMA-J AM MED ASSOC, V310, P930, DOI 10.1001/jama.2013.228052
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   Tashani M, 2016, VACCINE, V34, P5929, DOI 10.1016/j.vaccine.2016.10.020
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4561
EP 4567
DI 10.1016/j.vaccine.2019.06.017
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000022
PM 31262582
DA 2020-05-12
ER

PT J
AU Fleming, JA
   Munthali, A
   Ngwira, B
   Kadzandira, J
   Jamili-Phiri, M
   Ortiz, JR
   Lambach, P
   Hombach, J
   Neuzil, KM
   Stepanchak, M
   Bhat, N
AF Fleming, Jessica A.
   Munthali, Alister
   Ngwira, Bagrey
   Kadzandira, John
   Jamili-Phiri, Monica
   Ortiz, Justin R.
   Lambach, Philipp
   Hombach, Joachim
   Neuzil, Kathleen M.
   Stepanchak, Maria
   Bhat, Niranjan
TI Maternal immunization in Malawi: A mixed methods study of community
   perceptions, programmatic considerations, and recommendations for future
   planning
SO VACCINE
LA English
DT Article
DE Maternal immunization; Malawi; Maternal tetanus toxoid and maternal
   influenza vaccine; Operational research
ID PREGNANT-WOMEN; INFLUENZA IMMUNIZATION; VACCINATION
AB Background: Safe, effective vaccines are given to pregnant women to protect their infants and/or themselves against certain infectious agents; however, apart from tetanus vaccination, maternal immunization in low- and middle-income countries (LMICs) remains low. Tetanus toxoid vaccine is integrated into antenatal care services in Malawi with high coverage and provides an opportunity to identify factors that facilitate successful immunization delivery to pregnant women in LMICs.
   Methods: PATH and the University of Malawi's Centre for Social Research conducted a mixed-methods study in 2015 to document community perceptions of maternal immunization, using tetanus vaccine as an example, and to identify factors perceived to be important to successfully introducing other maternal vaccines, such as influenza vaccine, in Malawi. We conducted 18 focus group discussions with pregnant and recently pregnant women and their family members and 76 semi-structured interviews with pregnant and recently pregnant women, community leaders, health workers, public health program managers, non-governmental partners, and policy makers.
   Results: We identified factors perceived to support the introduction of new maternal vaccines, including strong maternal vaccine acceptance in the community, an existing strategy for maternal tetanus vaccine delivery, and positive health workers' views about the introduction of additional maternal vaccines. Potential challenges to adoption and acceptance included identifying and tracking the target population and monitoring adverse events, and the need to ensure operational capacity of the health system to support the introduction and wide-scale use of an additional vaccine. For influenza vaccine specifically, additional challenges included limited awareness of influenza disease and its low prioritization among health needs.
   Conclusions: Lessons from the successful delivery of maternal tetanus immunization in Malawi may be informative for similar countries considering new vaccines for pregnant women or striving to optimize the delivery of those currently provided. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Fleming, Jessica A.; Neuzil, Kathleen M.; Bhat, Niranjan] PATH, Ctr Vaccine Innovat & Access, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
   [Munthali, Alister; Kadzandira, John; Jamili-Phiri, Monica] Univ Malawi, Ctr Social Res, POB 280, Zomba, Malawi.
   [Ngwira, Bagrey] Malawi Polytech, Private Bag 303, Blantyre 3, Malawi.
   [Ortiz, Justin R.; Lambach, Philipp; Hombach, Joachim] WHO, Initiat Vaccine Res, Appia 20, CH-1211 Geneva 27, Switzerland.
   [Stepanchak, Maria] Global Alliance Prevent Prematur & Stillbirth, 19009 33rd Ave W 200, Lynnwood, WA 98036 USA.
   [Ortiz, Justin R.; Neuzil, Kathleen M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, 55 W Baltimore S, Baltimore, MD 21201 USA.
   [Stepanchak, Maria] Seattle Childrens Hosp, 1900 9th Ave, Seattle, WA 98101 USA.
RP Fleming, JA (reprint author), PATH, Ctr Vaccine Innovat & Access, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
EM jfleming@path.org; amunthali@cc.ac.mw; mjamali@cc.ac.mw;
   JOrtiz@som.umaryland.edu; lambachp@who.int; hombachj@who.int;
   kneuzil@som.umaryland.edu; Maria.Stepanchak@seattlechildrens.org;
   nbhat@path.org
OI Ortiz, Justin/0000-0002-3138-5965
FU Bill & Melinda Gates Foundation through the World Health Organization
   (WHO) [OPP1084288]
FX This research was funded by the Bill & Melinda Gates Foundation through
   the World Health Organization (WHO), grant number OPP1084288. The
   authors would like to thank the research team in Malawi for support of
   this work, as well as the health staff, partners, and community members
   who graciously provided interviews. We also thank Mr. Glen Zinck for
   editorial support.
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P261
   [Anonymous], TET VACC WHO POS PAP
   [Anonymous], 2018, COMMUNICATION    APR
   [Anonymous], PERT VACC WHO POS PA
   [Anonymous], GLOB MAN SURV ADV EV
   Baleta AF, 2012, VACCINE, V30, pC66, DOI 10.1016/j.vaccine.2012.06.033
   Bisset KA, 2018, VACCINE, V36, P2751, DOI 10.1016/j.vaccine.2018.04.013
   Bollyky T, 2013, A REPORT OF THE SAFE
   Cassidy C, 2015, PHARMACOEPIDEM DR S, V24, P361, DOI 10.1002/pds.3754
   Chamberlain AT, 2017, SCIENCE, V358, P452, DOI 10.1126/science.aao4219
   Divala TH, 2016, AM J TROP MED HYG, V95, P915, DOI 10.4269/ajtmh.16-0243
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Dworkin SL, 2012, ARCH SEX BEHAV, V41, P1319, DOI 10.1007/s10508-012-0016-6
   Fleming JA, 2018, VACCINE, V36, P4054, DOI 10.1016/j.vaccine.2018.05.096
   Gkentzi D, 2017, ARCH DIS CHILD-FETAL, V102, pF456, DOI 10.1136/archdischild-2016-312341
   Ho A, 2016, LANCET, V387, P51
   Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052
   Lackritz E, 2017, MATERNAL IMMUNIZATIO
   Lin SM, 2018, CLIN EXP VACCINE RES, V7, P76, DOI 10.7774/cevr.2018.7.1.76
   McArthur-Lloyd A, 2016, ISSN GLOB HEAL COMMU, V2, P1, DOI [DOI 10.HTTPS://D0I.0RG/10.1080/23762004.2016.1205887, DOI 10.1080/23762004.2016.1205887]
   Myers KL, 2016, VACCINE, V34, P3942, DOI 10.1016/j.vaccine.2016.06.042
   Neuzil KM, 2016, CLIN VACCINE IMMUNOL, V23, P186, DOI 10.1128/CVI.00037-16
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Peterson I, 2016, J INFECT DIS, V214, P1700, DOI 10.1093/infdis/jiw426
   Sambala EZ, 2015, DISASTER MED PUBLIC, V9, P120, DOI 10.1017/dmp.2015.5
   Schoub BD, 2012, VACCINE, V30, pC35, DOI 10.1016/j.vaccine.2012.02.056
   Vandelaer J, 2003, VACCINE, V21, P3442, DOI 10.1016/S0264-410X(03)00347-5
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   Wong VWY, 2016, VACCINE, V34, P20, DOI 10.1016/j.vaccine.2015.11.020
   World Health Organization, 2018, CAUSALITY ASSESSMENT
   World Health Organization, 2018, VACCINE, V36, P3573
   World Health Organization, 2012, VACC INFL WHO POS PA
NR 32
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4568
EP 4575
DI 10.1016/j.vaccine.2019.06.020
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000023
PM 31319932
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Hong, DT
   Hien, ND
   Thao, PTP
   Anh, DD
   Mai, HH
   Huyen, DTT
   Huong, NL
   Phuong, BH
   Iijima, M
   Ito, T
   Nakayama, T
AF Duong Thi Hong
   Nguyen Dang Hien
   Pham Thi Phuong Thao
   Dang Duc Anh
   Hoang Hong Mai
   Dang Thi Thanh Huyen
   Nguyen Lien Huong
   Bui Huy Phuong
   Iijima, Makiko
   Ito, Takashi
   Nakayama, Tetsuo
TI Immunogenicity of the AIK-C measles vaccine in infants aged < 9 months
   in Vietnam
SO VACCINE
LA English
DT Article
DE Measles; AIK-C strain; Vietnam; Early immunization; Immunogenicity
ID EDMONSTON-ZAGREB; IMMUNIZATION; MORTALITY; TITER; SCHWARZ; 6-MONTH-OLD;
   EPIDEMIC; OUTBREAK; STANDARD; CHILDREN
AB Measles-associated deaths have been reported in infants <9 months during outbreaks. A cohort study was conducted on 210 infants aged 6-8 months to evaluate the immunogenicity and safety of the AIK-C measles vaccine containing 10(4.21) plaque-forming units (PFU)/0.5 mL produced in Vietnam. Paired serum samples were obtained from 196 subjects. Seropositivity was defined as >= 120 mIU/mL. The seroresponse rate was 173/196 (88.27%, 95% confidence interval (CI): 83.77-92.77%) with geometric mean titer (GMT) of 511 mIU/mL (95% CI: 688-880 mIU/mL), and no significant differences were observed by different age groups. Among 196 paired sera, they were categorized into four groups: 122 subjects <14 IU/mL, 28 subjects 14-<60 mIU/mL, 30 subjects 60-<120 mIU/mL, and 16 subjects >= 120 mIU/mL. The seroresponse rate was 112/122 (91.8%, 95% CI: 86.94-96.67%) with GMT (597 mIU/mL, 95% CI: 749-1002 mIU/mL) in the <14 mIU/L group. In the 14-<60 mIU/mL group, the seroresponse rate was 18/28 (64.29%) with 184 mIU/L of GMT and was significantly lower (p < 0.01) than that in the <14 mIU/mL group. In the 16 seropositive group, all subjects showed seroconversion (4-fold higher than before) with a higher GMT of 1078 mIU/mL. Local pain and itching at the injection site were observed in 8 subjects (3.8%) within 7 days of the vaccination. Regarding systemic adverse reactions, febrile illness >= 37.5 degrees C was observed in 14 subjects (6.7%). These results indicate that the AIK-C measles vaccine is effective and safe for infants aged 6-8 months and will contribute to reducing the number of measles-associated deaths in future outbreaks. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Duong Thi Hong; Dang Duc Anh; Hoang Hong Mai; Dang Thi Thanh Huyen; Nguyen Lien Huong] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
   [Nguyen Dang Hien; Pham Thi Phuong Thao] Ctr Res & Prod Vaccine & Biol, Hanoi, Vietnam.
   [Bui Huy Phuong] Hai Duong Ctr Dis Control, Hai Duong, Vietnam.
   [Iijima, Makiko] WHO Country Off, Hanoi, Vietnam.
   [Ito, Takashi; Nakayama, Tetsuo] Kitasato Inst Life Sci, Lab Viral Infect 2, Tokyo, Japan.
RP Nakayama, T (reprint author), Kitasato Inst Life Sci, Lab Viral Infect 2, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.
EM tetsuo-n@lisci.kitasato-u.ac.jp
FU World Health OrganizationWorld Health Organization [001]
CR AABY P, 1990, J INFECT DIS, V162, P1043, DOI 10.1093/infdis/162.5.1043
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   AABY P, 1993, J PEDIATR-US, V122, P904, DOI 10.1016/S0022-3476(09)90015-4
   Aaby Peter, 2003, Semin Pediatr Infect Dis, V14, P220, DOI 10.1016/S1045-1870(03)00037-2
   Biellik RJ, 2018, VACCINE, V36, P5645, DOI 10.1016/j.vaccine.2018.07.029
   BOLOTOVSKI VM, 1994, INT J EPIDEMIOL, V23, P1069, DOI 10.1093/ije/23.5.1069
   CHIKWEM JO, 1992, PUBLIC HEALTH, V106, P53, DOI 10.1016/S0033-3506(05)80329-4
   Cohen BJ, 2007, VACCINE, V26, P59, DOI 10.1016/j.vaccine.2007.10.046
   CUTTS FT, 1994, VACCINE, V12, P1311, DOI 10.1016/S0264-410X(94)80057-7
   *EXP PROGR IMM, 1992, WKLY EPIDEMIOL REC, V67, P357
   Gastanaduy PA, 2018, HUM VACC IMMUNOTHER, V14, P2222, DOI 10.1080/21645515.2018.1474310
   Hagan Jose E, 2018, MMWR Morb Mortal Wkly Rep, V67, P491, DOI 10.15585/mmwr.mm6717a3
   Hien ND, 2018, OPEN J PEDIAT, V8, P178
   Hien ND, 2011, E J MED, V16, P199
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Hai LT, 2016, EMERG INFECT DIS, V22, P687, DOI 10.3201/eid2204.151595
   MARKOWITZ LE, 1987, PEDIATR INFECT DIS J, V6, P809, DOI 10.1097/00006454-198709000-00001
   Moss WJ, 2011, J INFECT DIS, V204, pS47, DOI 10.1093/infdis/jir065
   Murakami H, 2008, B WORLD HEALTH ORGAN, V86, P948, DOI 10.2471/BLT.07.048579
   Nkrumah FK, 1998, B WORLD HEALTH ORGAN, V76, P353
   Nmor JC, 2011, INT J BIOL SCI, V7, P138, DOI 10.7150/ijbs.7.138
   Orenstein WA, 2018, VACCINE, V36, P35
   Pabst HF, 1999, VACCINE, V17, P1910, DOI 10.1016/S0264-410X(98)00472-1
   Phama VH, 2014, EBIOMEDICINE, V1, P133, DOI 10.1016/j.ebiom.2014.10.015
   Roberts L, 2015, SCIENCE, V348, P962, DOI 10.1126/science.348.6238.962
   Sasaki K, 1974, Kitasato Arch Exp Med, V47, P1
   Sniadack DH, 2011, J INFECT DIS, V204, pS476, DOI 10.1093/infdis/jir092
   Strebel PM, 2018, PLOTKINS VACCINES, P579, DOI DOI 10.1016/B978-0-323-35761-6.00037-7
   TIDJANI O, 1989, LANCET, V2, P1357
   Tsai HY, 1999, VIRAL IMMUNOL, V12, P343, DOI 10.1089/vim.1999.12.343
   van der Maas NAT, 2016, J INFECT DIS, V213, P1466, DOI 10.1093/infdis/jiv756
   WHO, GLOB MEASL RUB UPD
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4576
EP 4580
DI 10.1016/j.vaccine.2019.04.025
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000024
PM 31174936
DA 2020-05-12
ER

PT J
AU Yu, XY
   Chen, ZP
   Wang, SY
   Pan, HR
   Wang, ZF
   Zhang, QF
   Shen, LZ
   Zheng, XP
   Yan, CF
   Lu, M
   Chen, B
   Zheng, Y
   Zhang, J
   Lv, HK
   Huang, SJ
AF Yu, Xu-ya
   Chen, Zhi-ping
   Wang, Shen-yu
   Pan, Hui-rong
   Wang, Zhi-fang
   Zhang, Qiu-fen
   Shen, Ling-zhi
   Zheng, Xiao-ping
   Yan, Chuan-fu
   Lu, Mei
   Chen, Bo
   Zheng, Ya
   Zhang, Jun
   Lv, Hua-kun
   Huang, Shou-jie
TI Safety and immunogenicity of hepatitis E vaccine in elderly people older
   than 65 years
SO VACCINE
LA English
DT Article
DE Hepatitis E vaccine; Clinical trial; Elderly people; Safety;
   Immunogenicity
ID HPV VACCINE
AB Background: Hepatitis E virus (HEV) infection is a leading cause of acute hepatitis worldwide, and results in high morbidity and mortality rates among elderly people in China. The hepatitis E vaccine, Hecolin (R), has been shown to be safe and highly efficacious among healthy adults aged 16-65 years old. However, there is no data about Hecolin (R) vaccination in elderly people older than 65 years (y).
   Methods: An open-labeled, controlled trial was conducted to evaluate the safety and immunogenicity of Hecolin (R) among the elderly aged >65 y. A total of 601 eligible participants were enrolled. Among them, 200 elderly people aged >65 y and 201 adults aged 18-65 y were assigned to the Hecolin (R) groups and vaccinated at day 0, month 1 and month 6. Serum samples were collected for anti-HEV IgG determination at day 0 prior to immunization and at month 7. The remaining 200 elderly people aged >65 y were assigned to the safety control group and received no intervention but were instructed to report any adverse events that occurred during the whole study period in the same way as those in the Hecolin (R) groups.
   Results: After receiving 3 doses of Hecolin (R) with the standard schedule, most (96.7%) of the vaccinated elderly people aged >65 y seroconverted at one month after the final dose (month 7). At month 7, the geometric mean concentrations of anti-HEV IgG were 5.36 (95% CI, 3.88-7.41) and 19.65 (95% CI, 16.81-22.98) among the baseline seronegative and seropositive elderly, respectively. Of the vaccinated elderly, 97.3% (177/182) had anti-HEV IgG levels higher than 1.0 WU/ml at month 7. Hecolin (R) was very well tolerated in this population. No vaccine-related SAES were reported.
   Conclusions: Hecolin (R) is immunogenic and well tolerated in elderly people aged greater than 65 years. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Xu-ya; Pan, Hui-rong; Zhang, Qiu-fen] Xiamen Innovax Biotech Co Ltd, Xiamen 361022, Fujian, Peoples R China.
   [Chen, Zhi-ping; Wang, Shen-yu; Wang, Zhi-fang; Shen, Ling-zhi; Lv, Hua-kun] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China.
   [Zheng, Xiao-ping; Yan, Chuan-fu; Lu, Mei; Chen, Bo] Kaihua Ctr Dis Control & Prevent, Quzhou 324300, Peoples R China.
   [Zheng, Ya; Zhang, Jun; Huang, Shou-jie] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen 361005, Fujian, Peoples R China.
RP Lv, HK (reprint author), Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China.; Huang, SJ (reprint author), Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen 361005, Fujian, Peoples R China.
EM hklv@cdc.zj.cn; huangshoujie@xmu.edu.cn
CR Dalton HR, 2014, FUTURE MICROBIOL, V9, P1361, DOI 10.2217/fmb.14.89
   Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625
   Iversen OE, 2016, JAMA-J AM MED ASSOC, V316, P2411, DOI 10.1001/jama.2016.17615
   Li SW, 2015, HUM VACC IMMUNOTHER, V11, P908, DOI 10.1080/21645515.2015.1008870
   Bin Park S, 2012, NATURE, V491, P21, DOI 10.1038/491021a
   Rein DB, 2012, HEPATOLOGY, V55, P988, DOI 10.1002/hep.25505
   Ren X, 2017, EMERG INFECT DIS, V23, P276, DOI [10.3201/2302.161095, 10.3201/eid2302.161095]
   WHO, 2015, WEEKLY EPIDEMIOLOGIC
   WHO, 2010, GLOB PREV HEP E VIR
   Wu T, 2012, HUM VACC IMMUNOTHER, V8, P823, DOI 10.4161/hv.20042
   Zhang J, 2014, CLIN MICROBIOL INFEC, V20, pO397, DOI 10.1111/1469-0691.12419
   Zhang J, 2015, NEW ENGL J MED, V372, P914, DOI 10.1056/NEJMoa1406011
   Zhang X, 2016, VACCINE, V34, P5871, DOI 10.1016/j.vaccine.2016.10.045
   Zhu FC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087154
   Zhu FC, 2010, LANCET, V376, P895, DOI 10.1016/S0140-6736(10)61030-6
NR 15
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4581
EP 4586
DI 10.1016/j.vaccine.2019.04.006
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000025
PM 31262585
DA 2020-05-12
ER

PT J
AU Kamdem, AF
   Vidal, C
   Pazart, L
   Leroux, F
   Pugin, A
   Savet, C
   Deville, GSC
   Guillemot, D
   Massol, J
AF Kamdem, Arnaud Fotso
   Vidal, Chrystelle
   Pazart, Lionel
   Leroux, Franck
   Pugin, Aurore
   Savet, Caroline
   Deville, Geoffroy Sainte-Claire
   Guillemot, Didier
   Massol, Jacques
TI A case-control study of risk factors for intussusception among infants
   in eastern France after the introduction of the rotavirus vaccine
SO VACCINE
LA English
DT Article
DE Intussusception; Infants; Case-control study- rotavirus vaccine; Risk
   factors
ID CHILDREN; EPIDEMIOLOGY; GUIDELINES; IMMUNIZATION; MANAGEMENT; AUSTRALIA
AB Objective: The objective of the present study was to investigate the risk factors for intussusception (IS) among infants, including vaccination against rotavirus.
   Methods: Case-control study with systematic inclusion of all infants aged <1 year with suspected IS admitted to emergency departments in the eastern region of France between 1 April 2008 and 31 March 2012. All cases classed level 1 according to the Brighton classification were matched to 4 hospital controls. Two exposure windows were examined; exposure to the first dose of rotavirus vaccine in the 7 and in the 14 days prior to the occurrence of IS.
   Results: A total of 115 cases were matched with 457 controls. The average vaccination coverage rate over the 4 years of study was 8.6%. Rotavirus vaccine was not found to be significantly associated with the occurrence of IS in the 7 days (odds ratio (OR) not calculated; p = 0.99) and in the 14 days after administration of one dose vaccine (OR 1.33, 95% confidence interval (Cl) 0.14-12.82). Infant formula alone or combined with breastfeeding was associated with an excess risk of IS (OR 2.74, 95% CI 1.10-6.79). A history of gastroenteritis within 2 weeks prior to hospitalisation was also associated with an increased risk (OR 2.24, 95% CI 1.07-4.67).
   Conclusion: Our study indicates that infant formula alone or combined with breastfeeding is a risk factor for IS. A small, non-significant increase in the risk of IS was observed after rotavirus vaccination, although the low vaccine coverage rate likely precluded detection of a significant increase in risk. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kamdem, Arnaud Fotso] Besancon Univ Hosp, Dept Pediat Surg, F-25000 Besancon, France.
   [Vidal, Chrystelle; Pazart, Lionel; Leroux, Franck; Pugin, Aurore] Besancon Univ Hosp, INSERM CIC 1431, F-25000 Besancon, France.
   [Savet, Caroline; Deville, Geoffroy Sainte-Claire; Massol, Jacques] Transplantat Fdn, Phisquare Inst, F-75015 Paris, France.
   [Guillemot, Didier] INSERM, UMR 1181, B2PHI, F-75075 Paris, France.
   [Guillemot, Didier] Inst Pasteur, UMR 1181, B2PHI, F-75015 Paris, France.
   [Guillemot, Didier] Univ Versailles St Quentin, UMR 1181, B2PHI, F-78180 Montigny Le Bretonneux, France.
   [Guillemot, Didier] Hop Raymond Poincare, AP HP, F-92380 Garches, France.
RP Kamdem, AF (reprint author), Besancon Univ Hosp, Dept Pediat Surg, F-25000 Besancon, France.
EM afotsokamdem@chu-besancon.fr; C1vidal@chu-besancon.fr;
   lpazart@chu-besancon.fr; f1leroux@chu-besancon.fr;
   avivot@chu-besancon.fr; c1marmier@chu-besancon.fr;
   geoffroy.sainteclairedeville.ext@aixial.com;
   didier.guillemot@pasteur.fr; jacques.massol.ext@aixial.com
RI Guillemot, Didier/AAN-3051-2020
FU Sanofi Pasteur MSD; GlaxoSmithkline BiologicalsGlaxoSmithKline [109083]
FX This study was funded by grants from Sanofi Pasteur MSD and
   GlaxoSmithkline Biologicals (Study number: 109083).
CR Bahl R, 2009, J INFECT DIS, V200, pS277, DOI 10.1086/605045
   BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000
   Bines J, 2002, WHO V B 0219 2002
   Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016
   Bines JE, 2006, J PEDIATR-US, V149, P452, DOI 10.1016/j.jpeds.2006.04.010
   Bines JE, 2009, J INFECT DIS, V200, pS282, DOI 10.1086/605051
   Blanch AJM, 2007, EMERG MED AUSTRALAS, V19, P45, DOI 10.1111/j.1742-6723.2007.00923.x
   Bohning D, 2008, J AM STAT ASSOC, V103, P212, DOI 10.1198/016214507000000383
   Buettcher M, 2007, PEDIATRICS, V120, P473, DOI 10.1542/peds.2007-0035
   Buttery Jim P, 2014, Pediatr Infect Dis J, V33, P772, DOI 10.1097/INF.0000000000000359
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P1007
   Chen YE, 2005, ARCH DIS CHILD, V90, P1077, DOI 10.1136/adc.2005.074104
   El-Hodhod MA, 2008, EUR J CLIN MICROBIOL, V27, P879, DOI 10.1007/s10096-008-0506-6
   Guarino A, 2014, J PEDIATR GASTR NUTR, V59, P132, DOI 10.1097/MPG.0000000000000375
   Hook EB, 1995, EPIDEMIOL REV, V17, P243, DOI 10.1093/oxfordjournals.epirev.a036192
   Hsu HY, 1998, PEDIATR INFECT DIS J, V17, P893, DOI 10.1097/00006454-199810000-00009
   Jenke AC, 2011, J PEDIATR GASTR NUTR, V52, P446, DOI 10.1097/MPG.0b013e31820e1bec
   Johnson B, 2010, J PEDIATR GASTR NUTR, V51, P458, DOI 10.1097/MPG.0b013e3181d3273f
   Justice FA, 2006, J GASTROEN HEPATOL, V21, P842, DOI 10.1111/j.1440-1746.2005.04031.x
   Kamdem AF, 2017, EUR J PEDIATR, V176, P301, DOI 10.1007/s00431-016-2838-z
   Khumjui C, 2009, VACCINE, V27, pF116, DOI 10.1016/j.vaccine.2009.09.003
   Larson H. J., 2016, EBIOMEDICINE, DOI [10.1016/j.ebiom.2016.08.042, DOI 10.1016/J.EBI0M.2016.08.042]
   Leino T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0144812
   Lyngkaran N, 1988, J PEDIAT GASTROENTER, V7, P667
   Mansour AM, 2013, J INFECT DEV COUNTR, V7, P28, DOI 10.3855/jidc.2321
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Navarro OM, 2004, AM J ROENTGENOL, V182, P1169, DOI 10.2214/ajr.182.5.1821169
   Nylund CM, 2010, J PEDIATR-US, V156, P761, DOI 10.1016/j.jpeds.2009.11.026
   Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952
   Rha B, 2014, EXPERT REV VACCINES, V13, P1339, DOI 10.1586/14760584.2014.942223
   Rosillon D, 2015, PEDIATR INFECT DIS J, V34, P763, DOI 10.1097/INF.0000000000000715
   Samad L, 2013, VACCINE, V31, P4098, DOI 10.1016/j.vaccine.2013.06.084
   Velazquez F Raul, 2004, Pediatr Infect Dis J, V23, pS173, DOI 10.1097/01.inf.0000142467.50724.de
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
NR 36
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4587
EP 4593
DI 10.1016/j.vaccine.2019.02.053
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000026
PM 30851968
DA 2020-05-12
ER

PT J
AU Dale, LP
   White, L
   Mitchell, M
   Faulkner, G
AF Dale, Leila Pfaeffli
   White, Lauren
   Mitchell, Marc
   Faulkner, Guy
TI Smartphone app uses loyalty point incentives and push notifications to
   encourage influenza vaccine uptake
SO VACCINE
LA English
DT Article
DE Flu; Vaccine hesitancy; mHealth; Mobile; Phone; Behavioural economics;
   Geolocation
ID INTERVENTIONS; HESITANCY
AB Purpose: Carrot Rewards is a free, incentive-based, smartphone health app available in participating provinces in Canada. One feature of Carrot was designed to incentivize influenza vaccine education messages and encourage vaccine uptake for users in the province of British Columbia. This study aimed to evaluate the uptake of the Carrot Flu Campaign educational quiz and to determine if mobile "push" notifications, plus loyalty point incentives, resulted in users visiting a sponsored pharmacy to discuss and receive the influenza vaccine.
   Methods: The Carrot Flu Campaign delivered an in-app quiz, educating users on the importance of the influenza vaccine. Push notifications were then sent to users when they came within 200 m of a sponsored pharmacy. Those who visited the pharmacy collected bonus points and completed a follow up quiz tracking influenza vaccine behaviour. A sub-sample of users completed the Flu Campaign between their baseline and follow up Health Risk Assessment (HRA), a survey which asked about influenza vaccine uptake behaviour. Descriptive statistics were summarized.
   Results: A total of 38.1% (30,538/80,228) registered Carrot users completed the Flu Campaign quiz. Of those in participating cities (n = 21,469), 41% clicked on the map to show the nearest sponsored pharmacy and 78% enabled their smartphone's "locations" feature, allowing them to receive the push notifications. A small number of users spoke to a pharmacist (n = 96) and less than half reported receiving the influenza vaccine (38/96; 39.6%). From the HRA sub-sample (n = 3693), approximately 5% more users reported receiving the influenza vaccine during the 2017 influenza season compared to the previous year.
   Conclusions: Carrot Rewards used a novel delivery method to educate the general population and showed geolocation could be used to facilitate influenza vaccine uptake. Future iterations could tailor content to target those most at risk and should consider more robust evaluation methods to determine the app's effectiveness. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Dale, Leila Pfaeffli; Faulkner, Guy] Univ British Columbia, Sch Kinesiol, Vancouver, BC, Canada.
   [White, Lauren] Carrot Insights Inc, Toronto, ON, Canada.
   [Mitchell, Marc] Western Univ, Sch Kinesiol, London, ON, Canada.
RP Dale, LP (reprint author), Lower Mall Res Stn, Room 337,2259 Lower Mall, Vancouver, BC V6T 1Z4, Canada.
EM leila.dale@ubc.ca
FU Public Health Agency of Canada
FX The Carrot Rewards initiative has been made possible in part through
   funding from the Public Health Agency of Canada. The views expressed
   herein do not necessarily represent the views of the Public Health
   Agency of Canada and the British Columbia Ministry of Health. The
   authors also thank staff from the Public Health Agency of Canada, the
   British Columbia Ministry of Heath, the British Columbia Alliance for
   Healthy Living, Heart & Stroke Foundation of Canada, Diabetes Canada,
   and YMCA Canada for providing expert health content advice over the
   course of this project. The Public Health Agency of Canada and the
   British Columbia Ministry of Health reviewed the manuscript.
CR Atkins K, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009739
   Becker S, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3328
   Ben-Zeev D, 2015, ADM POLICY MENT HLTH, V42, P157, DOI 10.1007/s10488-014-0556-2
   Bruck P. A., 2012, BLED 2012 P, V2
   Buchan SA, 2017, CMAJ, V189
   Canadian radio-television and telecommunications commission, 2017, COMM MON REP 2016 TE
   Free C, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001363
   Frieden TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652
   Ghebrehewet S, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6258
   HealthlinkBC, 2017, IN INFL FLU VACC
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Jacobs MA, 2016, CURR OPIN PSYCHOL, V9, P33, DOI 10.1016/j.copsyc.2015.09.001
   Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040
   Jochelson K., 2007, PAYING PATIENT IMPRO
   Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Liu S, 2014, JMIR, V16
   Luz PM, 2017, VACCINE, V35, P5890, DOI 10.1016/j.vaccine.2017.08.078
   Mitchell M, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.7323
   Mitchell MS, 2013, AM J PREV MED, V45, P658, DOI 10.1016/j.amepre.2013.06.017
   Mitchell Marc Steven, 2014, J Med Internet Res, V16, pe179, DOI 10.2196/jmir.3701
   Nowalk MP, 2010, AM J PREV MED, V38, P237, DOI 10.1016/j.amepre.2009.11.011
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38
   Public Health Agency of Canada, 2008, OUTC NAT CONS C VACC, V34S2, P1
   Public Health Agency of Canada, 2017, INFL VACC UPT RES 20
   Public Health Agency of Canada, 2015, NAT HLTH LIF PLATF C
   Public Health Agency of Canada, 2017, PUBL FUND INFL VACC
   Public Health Agency of Canada, 2016, KNOW FLU FACTS
   Schick RS, 2017, PILOT FEASIBILITY ST, V4, P19
   Siegler AJ, 2017, JMIR PUBLIC HLTH SUR, V3
   Stedman-Smith M, 2017, WORKPLACE HEALTH SAF, V65, P21, DOI 10.1177/2165079916657107
   Thommes EW, 2017, HUM VACC IMMUNOTHER, V13, P867, DOI 10.1080/21645515.2016.1251537
NR 33
TC 3
Z9 3
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4594
EP 4600
DI 10.1016/j.vaccine.2018.04.018
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000027
PM 29699784
DA 2020-05-12
ER

PT J
AU Lecouturier, V
   Berry, C
   Saulnier, A
   Naville, S
   Manin, C
   Girerd-Chambaz, Y
   Crowe, JE
   Jackson, N
   Guy, B
AF Lecouturier, Valerie
   Berry, Catherine
   Saulnier, Aure
   Naville, Sophie
   Manin, Catherine
   Girerd-Chambaz, Yves
   Crowe, James E., Jr.
   Jackson, Nicholas
   Guy, Bruno
TI Characterization of recombinant yellow fever-dengue vaccine viruses with
   human monoclonal antibodies targeting key conformational epitopes
SO VACCINE
LA English
DT Article
DE Dengue; Vaccine; Antibodies; Human; Epitopes
ID NEUTRALIZING ANTIBODIES; TETRAVALENT; IMMUNOGENICITY; IDENTIFICATION;
   QUANTITATION; MATURATION; CHILDREN; EFFICACY; SAFETY
AB The recombinant yellow fever-17D-dengue virus, live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in several dengue-endemic countries. Although the vaccine provides protection against dengue, the level of protection differs by serotype and warrants further investigation. We characterized the antigenic properties of each vaccine virus serotype using highly neutralizing human monoclonal antibodies (hmAbs) that bind quaternary structure-dependent epitopes. Specifically, we monitored the binding of dengue virus-1 (DENY-1; 1F4), DENV-2 (2D22) or DENV-3 (5J7) serotype-specific or DENY-1-4 cross-reactive (1C19) hmAbs to the four chimeric yellow fever-dengue vaccine viruses (CYD-1-4) included in phase Ill vaccine formulations using a range of biochemical and functional assays (dot blot, ELISA, surface plasmon resonance and plaque reduction neutralization assays). In addition, we used the "classic" live, attenuated DENV-2 vaccine serotype, immature CYD-2 viruses and DENV-2 virus-like particles as control antigens for anti-serotype-2 reactivity. The CYD vaccine serotypes were recognized by each hmAbs with the expected specificity, moreover, surface plasmon resonance indicated a high functional affinity interaction with the CYD serotypes. In addition, the hmAbs provided similar protection against CYD and wild type dengue viruses in the in vitro neutralization assay. Overall, these findings demonstrate that the four CYD viruses used in clinical trials display key conformational and functional epitopes targeted by serotype-specific and/or cross-reactive neutralizing human antibodies. More specifically, we showed that CYD-2 displays serotype-specific epitopes present only on the mature virus. This indicates that the CYDTDV has the ability to elicit antibody specificities which are similar to those induced by the wild type DENY. Future investigations will be needed to address the nature of CYD-TDV-induced responses after vaccine administration, and how these laboratory markers relate to vaccine efficacy and safety. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Lecouturier, Valerie; Berry, Catherine; Saulnier, Aure; Naville, Sophie; Manin, Catherine; Girerd-Chambaz, Yves; Jackson, Nicholas; Guy, Bruno] Sanofi Pasteur, Res & Dev, Ave Marcel Merieux, F-69280 Marcy Letoile, France.
   [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
RP Lecouturier, V (reprint author), Sanofi Pasteur, Res & Dev, Ave Marcel Merieux, F-69280 Marcy Letoile, France.
EM valerie.lecouturier@sanofi.com; catherine.berry@sanofi.com;
   aure.saulnier@sanofi.com; sophie.naville@sanofi.com;
   catherine.manin@sanofi.com; yves.girerd-chambaz@sanofi.com;
   james.crowe@Vanderbilt.Edu; nicholas.jackson@sanofi.com;
   bruno.guy69@orange.fr
RI Crowe, James/B-5549-2009
OI Crowe, James/0000-0002-0049-1079; Girerd-Chambaz,
   Yves/0000-0002-5121-686X
FU Sanofi Pasteur
FX G. Sapparapu for providing the hmAbs, N. Nougarede for technical advice
   and helpful discussions, F. Boudet for critical review of the
   manuscript, F. Ronzon, Marie-Claire NicolaT and Aurelie Deliot for
   cryo-EM analysis of VLPs. Morine Cullell, Marie-Julie Diana, Damien
   Soulet, Nicolas Devard for viral neutralization and production of the
   immature CYD-2. Manuscript editing services were provided by Rebecca
   Hornby of in Science Communications, Springer Healthcare, and were
   funded by Sanofi Pasteur.
CR Arredondo-Garcia JL, 2018, CLIN MICROBIOL INFEC, V24, P755, DOI 10.1016/j.cmi.2018.01.018
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Byers Anthony M, 2015, Open Forum Infect Dis, V2, pofv172, DOI 10.1093/ofid/ofv172
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Coudeville L, 2016, VACCINE, V34, P6426, DOI 10.1016/j.vaccine.2016.08.050
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Fibriansah G, 2015, SCIENCE, V349, P88, DOI 10.1126/science.aaa8651
   Fibriansah G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7341
   Fibriansah G, 2014, EMBO MOL MED, V6, P358, DOI 10.1002/emmm.201303404
   Fibriansah G, 2013, J VIROL, V87, P7585, DOI 10.1128/JVI.00757-13
   Gailhardou S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004821
   Gallichotte EN, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006934
   GENTRY MK, 1982, AM J TROP MED HYG, V31, P548, DOI 10.4269/ajtmh.1982.31.548
   Guy B, 2016, ANNU REV MED, V67, P387, DOI 10.1146/annurev-med-091014-090848
   Guy B, 2015, VACCINE, V33, P7100, DOI 10.1016/j.vaccine.2015.09.108
   Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Harenberg A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004830
   Henein S, 2017, J INFECT DIS, V215, P351, DOI 10.1093/infdis/jiw576
   Hss AS, 2013, VACCINE, V31, P5814, DOI 10.1016/j.vaccine.2013.10.013
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   Lai CY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002451
   Mantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026
   Qiao M, 2011, AM J TROP MED HYG, V85, P724, DOI 10.4269/ajtmh.2011.10-0436
   Rabaa MA, 2017, ELIFE, V6, DOI [10.7554/eLife.24196, 10.7554/elife.24196]
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Smith DP, 2013, MBIO, V4, DOI 10.1128/mBio.00133-12
   Smith SA, 2014, J VIROL, V88, P12233, DOI 10.1128/JVI.00247-14
   Timiryasova TM, 2013, AM J TROP MED HYG, V88, P962, DOI 10.4269/ajtmh.12-0461
   Torresi J, 2015, VACCINE, V33, P5127, DOI 10.1016/j.vaccine.2015.08.008
   Tsai WY, 2013, J VIROL, V87, P12562, DOI 10.1128/JVI.00871-13
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Wang ZQ, 2013, J VIROL, V87, P8909, DOI 10.1128/JVI.00472-13
   Yu IM, 2008, SCIENCE, V319, P1834, DOI 10.1126/science.1153264
NR 36
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4601
EP 4609
DI 10.1016/j.vaccine.2018.04.065
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000028
PM 29706291
OA Other Gold
DA 2020-05-12
ER

PT J
AU Giambi, C
   Del Manso, M
   Dalla Zuanna, T
   Riccardo, F
   Bella, A
   Caporali, MG
   Baka, A
   Caks-Jager, N
   Melillo, T
   Mexia, R
   Petrovic, G
   Declich, S
   Ali, KA
   Dente, MG
   Lannazzo, S
   Kaic, B
   Napoli, C
   Panagiotopoulos, T
   Pereira, F
AF Giambi, Cristina
   Del Manso, Martina
   Dalla Zuanna, Teresa
   Riccardo, Flavia
   Bella, Antonino
   Caporali, Maria Grazia
   Baka, Agoritsa
   Caks-Jager, Nuska
   Melillo, Tanya
   Mexia, Ricardo
   Petrovic, Goranka
   Declich, Silvia
   Ali, Karam Adel
   Dente, Maria Grazia
   Lannazzo, Stefania
   Kaic, Bernard
   Napoli, Christian
   Panagiotopoulos, Takis
   Pereira, Filipa
CA CARE Working Grp Natl Immuniza
TI National immunization strategies targeting migrants in six European
   countries
SO VACCINE
LA English
DT Article
DE Migrants; Vaccination; Infectious diseases; Europe
ID VACCINATION; REFUGEES
AB Over the last three years an unprecedented flow of migrants arrived in Europe. There is evidence that vaccine preventable diseases have caused outbreaks in migrant holding centres. These outbreaks can be favored by a combination of factors including low immunization coverage, bad conditions that migrants face during their exhausting journey and overcrowding within holding facilities. In 2017, we conducted an online survey in Croatia, Greece, Italy, Malta, Portugal and Slovenia to explore the national immunization strategies targeting irregular migrants, refugees and asylum seekers. All countries stated that a national regulation supporting vaccination offer to migrants is available. Croatia, Italy, Portugal and Slovenia offer to migrant children and adolescents all vaccinations included in the National Immunization Plan; Greece and Malta offer only certain vaccinations, including those against diphtheria-tetanus-pertussis, poliomyelitis and measles-mumps-rubella. Croatia, Italy, Malta and Portugal also extend the vaccination offer to adults. All countries deliver vaccinations in holding centres and/or community health services, no one delivers vaccinations at entry site. Operating procedures that guarantee the migrants' access to vaccination at the community level are available only in Portugal. Data on administered vaccines is available at the national level in four countries: individual data in Malta and Croatia, aggregated data in Greece and Portugal. Data on vaccination uptake among migrants is available at national level only in Malta. Concluding, although diversified, strategies for migrant vaccination are in place in all the surveyed countries and generally in line with WHO and ECDC indications. Development of procedures to keep track of migrants' immunization data across countries, development of strategies to facilitate and monitor migrants' access to vaccinations at the community level and collection of data on vaccination uptake among migrants should be promoted to meet existing gaps. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Giambi, Cristina; Del Manso, Martina; Riccardo, Flavia; Bella, Antonino; Caporali, Maria Grazia; Declich, Silvia; Dente, Maria Grazia] Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Dalla Zuanna, Teresa] Univ Padua, Dept Cardiac Thorac & Vasc Sci & Publ Hlth, Via Loredan 18, I-35131 Padua, Italy.
   [Baka, Agoritsa] Hellen Ctr Dis Control & Prevent, 3-5 Agrafon Str, Maroussi 15123, Attica, Greece.
   [Caks-Jager, Nuska] Natl Inst Publ Hlth, Zalaska 29, Ljubljana 1000, Slovenia.
   [Melillo, Tanya] Minist Hlth, Infect Dis Prevent & Control Unit, 58 Emporium,C Debrockdorff St, Msida, Malta.
   [Mexia, Ricardo] Inst Nacl Saude Doutor Ricardo Jorge, Ave Padre Cruz, P-1649016 Lisbon, Portugal.
   [Petrovic, Goranka] Croatian Inst Publ Hlth, Rockefellerova 7, Zagreb 10000, Croatia.
   [Ali, Karam Adel] European Ctr Dis Prevent & Control, Stockholm, Sweden.
   [Lannazzo, Stefania] Minist Hlth, Rome, Italy.
   [Kaic, Bernard] Croatian Inst Publ Hlth, Zagreb, Croatia.
   [Napoli, Christian] Sapienza Univ, Rome, Italy.
   [Panagiotopoulos, Takis] Natl Sch Publ Hlth, Athens, Greece.
   [Pereira, Filipa] Directorate Gen Hlth, Lisbon, Portugal.
RP Giambi, C (reprint author), Ist Super Sanita, Viale Regina Elena 299, I-00161 Rome, Italy.
EM cristina.giambi@iss.it; martina.delmanso@iss.it;
   teresa.dallazuanna@studenti.unipd.it; flavia.riccardo@iss.it;
   antonino.bella@iss.it; mariagrazia.caporali@iss.it; baka@keelpno.gr;
   nuska.caks-jager@nijz.si; tanya.melillo@gov.mt;
   ricardo.mexia@insa.min-saude.pt; goranka.petrovic@hzjz.hr;
   silvia.declich@iss.it
RI Bella, Antonino/AAB-9943-2019; Mexia, Ricardo/O-7945-2014
OI Mexia, Ricardo/0000-0002-0511-7940; Declich, Silvia/0000-0002-5916-3889
FU EUEuropean Union (EU) [717217/CARE]
FX The study was conducted in the framework of the CARE ("Common Approach
   for REfugees and other migrants' health") project (717217/CARE) that
   received funding from the EU health Programme (2014-2020).
CR CARE, 2017, REP SURV IMM OFF TAR
   CARE, COMM DIS MON
   European Centre for Disease Prevention and Control, 2015, ECDC TECHN DOC INF D
   European Centre for Disease Prevention and Control, 2016, EP UPD MEASL AS SEEK
   European Centre for Disease Prevention and Control, 2015, SHORT AC PERT CONT V
   European Centre for Disease Prevention and Control, 2015, EXP OP PUBL HLTH NEE
   European Centre of Disease Prevention and Control, 2016, LETS TALK HES
   Fabiani M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166517
   Fondazione ISMU, 2017, VENT RAPP MIGR 2016
   Giambi C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14050459
   Haas EJ, 2014, INT HEALTH, V6, P203, DOI 10.1093/inthealth/ihu017
   International Organization for Migration. World Health Organization, 2014, TUB PREV CAR MIGR
   International Organization for Migration. World Health Organization, 2017, 2 GLOB CONS COL SRI
   Jones G, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.11.30167
   Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lesens O, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw042
   Meinel DM, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.08.010
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Prymula R, 2018, VACCINE, V36, P5385, DOI 10.1016/j.vaccine.2017.05.079
   Riccardo F, 2012, HEALTH POLICY, V105, P17, DOI 10.1016/j.healthpol.2012.02.004
   Rosano A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2549-9
   Semenza JC, 2016, EUR J PUBLIC HEALTH, V26, P372, DOI 10.1093/eurpub/ckw023
   Williams GA, 2016, SCAND J PUBLIC HEALT, V44, P6, DOI 10.1177/1403494815610182
   World Health Organization Regional Office for Europe, 2015, WHO UNHCR UNICEF JOI
NR 25
TC 5
Z9 5
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4610
EP 4617
DI 10.1016/j.vaccine.2018.01.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000029
PM 29426661
OA Other Gold
DA 2020-05-12
ER

PT J
AU Qazi, U
   Malik, S
   Raza, UA
   Saad, M
   Zeeshan, MF
   Anwar, S
AF Qazi, Umair
   Malik, Sidra
   Raza, Usman A.
   Saad, Maryam
   Zeeshan, Muhammad Fazal
   Anwar, Saeed
TI Compliance to timely vaccination in an Expanded Program on Immunization
   center of Pakistan
SO VACCINE
LA English
DT Article
DE Expanded program on immunization; Vaccination timeliness; Vaccination
   coverage; Pakistan
ID AGE-APPROPRIATE VACCINATION; UNITED-STATES; CHALLENGES; TIMELINESS;
   PERTUSSIS; REFUSAL; INFANTS; HEALTH
AB The importance of childhood immunization in prevention of highly fatal diseases and disability cannot be overemphasized. Pakistan has a national Expanded Program on Immunization but the compliance is far below the international benchmark for achieving a herd immunity. Monitoring the compliance to timely receipt of vaccinations is crucial to establishing and preventing disease and disability associated risk in children. There is little or no evidence that reports the timeliness of the vaccinations according to the EPI schedule in Peshawar. The primary objective of the study was to evaluate rate of Fully Immunized Children and to report compliance to the timeliness of vaccine specific schedule during the study period in the EPI center in the capital city of Peshawar, Khyber Pakhtunkhwa province of Pakistan. We collected consecutive retrospective data of the infants enrolled from June 2014 to December 2015 in one EPI center for our study. Out of the total 157 (n) children, fully immunized children (FIC) were 62 (39.5%) and only 19 (12.1%) were FIC with timely visits. Dropouts increased with successive vaccinations with highest for Measles 1 (42%). On-time vaccinations decreased over time, while the proportion of children receiving vaccination outside the ideal window period reaches as high as 46%. The study reports a low compliance to EPI schedule, and also highlights that immunization coverage is not a good indicator of age appropriate vaccinations. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Qazi, Umair; Malik, Sidra; Raza, Usman A.; Saad, Maryam; Zeeshan, Muhammad Fazal; Anwar, Saeed] Riphah Int Univ, Prime Inst Publ Hlth, Islamabad, Pakistan.
   [Raza, Usman A.] Univ Calif Berkeley, Sch Informat, Berkeley, CA 94720 USA.
   [Raza, Usman A.; Zeeshan, Muhammad Fazal; Anwar, Saeed] Riphah Int Univ, Peshawar Med Coll, Islamabad, Pakistan.
RP Qazi, U (reprint author), Riphah Int Univ, Prime Inst Publ Hlth, Islamabad, Pakistan.
EM uqazi@piph.prime.edu.pk
CR Ahmad F, 2010, ASSESSMENT IMMUNIZAT
   Ahmad Nisar, 1999, JPMA (Journal of the Pakistan Medical Association), V49, P301
   Ahmad S, 2013, J POSTGRADUATE MED I, V27
   Akmatov MK, 2008, VACCINE, V26, P3805, DOI 10.1016/j.vaccine.2008.05.031
   [Anonymous], GLOB VACC ACT PLAN 2
   [Anonymous], 2017, IMMUNIZATION COVERAG
   [Anonymous], 2017, PAKISTAN EXPANDED PR
   Babirye JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035432
   Bhutta Z, 2011, NATL NUTR SURVEY PAK
   Bhutta ZA, 2011, PAKISTAN NATL NUTR S
   CDC, 2016, INF IMM
   Control CID Prevention, 2010, REC IMM SCHED PERS A, V58
   Dannetun E, 2004, VACCINE, V22, P4228, DOI 10.1016/j.vaccine.2004.04.018
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   Dhs M, 2013, DEM HLTH SURV
   Fadnes LT, 2011, VACCINE, V29, P3564, DOI 10.1016/j.vaccine.2011.02.093
   Hyder AA, 2006, PUBLIC HEALTH, V120, P132, DOI 10.1016/j.puhe.2005.03.008
   Jacobson Vann JC, 2005, PATIENT REMINDER REC
   Kalim M, 2014, KJMS, V7, P263
   Kazi AM, LANCET GLOBAL HLTH, V5, pe377
   Khan I, 2015, GOMAL J MED SCI, V12
   Khan TM, 2016, VACCINE, V34, P2074, DOI 10.1016/j.vaccine.2016.03.008
   Masud T, 2012, EXPANDED PROGRAM IMM
   Muller O, 2016, GESUNDHEITSWESEN, V78, P227, DOI 10.1055/s-0035-1548854
   Murakami H, 2014, VACCINE, V32, P1382, DOI 10.1016/j.vaccine.2014.01.018
   Mushtaq MU, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-60
   Naeem Mohammad, 2011, J Ayub Med Coll Abbottabad, V23, P134
   Naeem Mohammad, 2011, J Ayub Med Coll Abbottabad, V23, P110
   Nips I, 2013, SECONDARY PAKISTAN D, V13
   Oliver-Williams C, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.7792
   Siddiqi Nazish, 2007, J Pak Med Assoc, V57, P391
   Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968
   Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012
   WHO, 2016, EXP PROGR IMM PAK
   WHO, 2016, IMM COV FACT SHEET
   WHO, 2015, IMM PRACT PRACT GUID
   WHO EMRO, 2017, EXP PROGR IMM
   WHO mA, SMALL INC IMPR VACC
   World Health Organization, 2017, IMM COV
   World Health Organization, 2016, WHO VACC PREV DIS MO
   World Health Organization, 2015, GLOB HLTH OBS GHO DA
NR 41
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4618
EP 4622
DI 10.1016/j.vaccine.2018.01.044
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000030
PM 29395529
DA 2020-05-12
ER

PT J
AU Beran, J
   Lattanzi, M
   Xie, F
   Moraschini, L
   Galgani, I
AF Beran, Jiri
   Lattanzi, Maria
   Xie, Fang
   Moraschini, Luca
   Galgani, Ilaria
TI Second five-year follow-up after a booster vaccination against
   tick-borne encephalitis following different primary vaccination
   schedules demonstrates at least 10 years antibody persistence
SO VACCINE
LA English
DT Article
DE Tick-borne encephalitis; Long-term persistence; Booster; Encepur; Adults
ID TBE VACCINATION; 0.5 ML; SAFETY; ADULTS; SEROPERSISTENCE;
   IMMUNOGENICITY; IMMUNIZATION; PROTECTION
AB Background: Tick borne encephalitis (TBE) endemic zones are expanding. We previously evaluated long term persistence of antibody 5 years after the first booster immunization following different primary immunization schedules with the polygeline-free inactivated TBE vaccine (TBEvac) in adults and adolescents. Here, we report anti-TBE virus (TBEV) antibody persistence from 6 to 10 years post-booster administration.
   Methods: This was a phase IV, open-label, single-center, second extension study (NCT01562444), conducted in Czechia. Healthy adults and adolescents >= 12 years who had received 3 different primary vaccination schedules (rapid, conventional and accelerated conventional) in the parent study and a booster dose before (12-18 months post-primary series completion) or at the beginning (3 years post-primary series completion) of the first extension study were screened and enrolled in this study. Blood samples were collected yearly and anti-TBEV antibody response was evaluated by neutralizing test (NT) antibody assays. Analysis was performed overall and per age strata: 15-49 years, >= 50 years, and >= 60 years.
   Results: Of 206 screened individuals, 191 completed the study. Overall, 90-100% of participants in the all-screened set and >= 97% in the per-protocol set had the clinically meaningful threshold of protection (NT titers >= 10) across all timepoints, regardless of the primary vaccination schedule. Overall, antibody geometric mean titers (GMTs) varied from 134 to 343 in the all-screened set. Older age groups showed overall lower GMTs, although GMTs remained higher than NT titers >= 10 up to year 10 in all groups.
   Conclusion: This study showed long-term persistence of anti-TBEV NT antibodies for up to 10 years after the first booster dose of TBEvac in all age groups, regardless of the primary vaccination schedule. (C) 2018 GSK. Published by Elsevier Ltd.
C1 [Beran, Jiri] Vaccinat & Travel Med Ctr, Tylovo Nabrezi 418-6, Hradec Kralove 50002, Czech Republic.
   [Beran, Jiri] Inst Postgrad Med Educ Prague, Dept Trop Travel Med & Immunizat, Ruska 2412-85, Prague 10000 10, Czech Republic.
   [Lattanzi, Maria; Moraschini, Luca; Galgani, Ilaria] GSK, Via Fiorentina 1, I-53100 Siena, Italy.
   [Xie, Fang] GSK Vaccines, 14200 Shady Grove Rd, Rockville, MD 20850 USA.
RP Galgani, I (reprint author), GSK, Via Fiorentina 1, I-53100 Siena, Italy.
EM jiri.beran@vakcinace.cz; maria.x.lattanzi@gsk.com; fang.z.xie@gsk.com;
   luca.x.moraschini@gsk.com; ilaria.x.galgani@gsk.com
FU Novartis Vaccines Division
FX The study was supported by the Novartis Vaccines Division; on 2 March
   2015 Novartis' non-influenza Vaccines Business was acquired by the GSK
   group of companies. GlaxoSmithKline Biologicals SA took responsibility
   for all costs associated with the development and publishing of the
   present manuscript.
CR Beran J, 2014, VACCINE, V32, P4275, DOI 10.1016/j.vaccine.2014.06.028
   Galgani I, 2017, EXPERT REV VACCINES, V16, P919, DOI 10.1080/14760584.2017.1358620
   Haglund M, 2003, VACCINE, V21, pS11, DOI 10.1016/S0264-410X(02)00811-3
   Hainz U, 2005, VACCINE, V23, P3232, DOI 10.1016/j.vaccine.2005.01.085
   Heinz FX, 2007, VACCINE, V25, P7559, DOI 10.1016/j.vaccine.2007.08.024
   Jilkova E, 2009, EXPERT OPIN BIOL TH, V9, P797, DOI 10.1517/14712590903066711
   Kaiser R, 1999, BRAIN, V122, P2067, DOI 10.1093/brain/122.11.2067
   Kerbo N., 2005, EUROSURVEILLANCE, V10, P2
   KLOCKMANN U, 1989, J BIOL STAND, V17, P331, DOI 10.1016/S0092-1157(89)80004-6
   Kollaritsch H, 2011, BACKGROUND DOCUMENT
   Kollaritsch H, 2012, EXPERT REV VACCINES, V11, P1103, DOI [10.1586/erv.12.86, 10.1586/ERV.12.86]
   Konior R, 2017, VACCINE, V35, P3607, DOI 10.1016/j.vaccine.2017.03.059
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Kunz C, 2003, VACCINE, V21, pS50, DOI 10.1016/S0264-410X(02)00813-7
   Kunze U, 2015, TICKS TICK-BORNE DIS, V6, P545, DOI 10.1016/j.ttbdis.2015.04.005
   Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4
   Litzba N, 2014, VECTOR-BORNE ZOONOT, V14, P149, DOI 10.1089/vbz.2012.1287
   Loew-Baselli A, 2009, HUM VACCINES, V5, P551, DOI 10.4161/hv.5.8.8571
   Plentz A, 2009, VACCINE, V27, P853, DOI 10.1016/j.vaccine.2008.11.082
   Randolph SE, 2010, VET PARASITOL, V167, P92, DOI 10.1016/j.vetpar.2009.09.011
   Schondorf I, 2007, VACCINE, V25, P1470, DOI 10.1016/j.vaccine.2006.10.028
   Suss J, 2008, EUROSURVEILLANCE, V13, P18916, DOI DOI 10.2807/ESE.13.26.18916-EN
   Zent O, 2005, J TRAVEL MED, V12, P85
   Zent O, 2004, VACCINE, V23, P312, DOI 10.1016/j.vaccine.2004.06.007
   Zent O, 2003, VACCINE, V21, P3584, DOI 10.1016/S0264-410X(03)00421-3
NR 25
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4623
EP 4629
DI 10.1016/j.vaccine.2017.12.081
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000031
PM 29397225
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tesema, B
   Zhao, JY
   Jiang, XP
   Liu, GQ
   Han, YG
   Wassie, T
AF Tesema, Birhanu
   Zhao, Jia-yu
   Jiang, Xun-ping
   Liu, Gui-qiong
   Han, Yan-guo
   Wassie, Teketay
TI Kisspeptin recombinant oral vaccine: A master gene vaccine inhibiting
   the reproductive physiology and behavior of ram lambs
SO VACCINE
LA English
DT Article
DE Kisspeptin; Recombinant vaccine; Reproductive physiology; Sexual
   behavior
ID GONADOTROPIN-RELEASING-HORMONE; ACTIVE IMMUNIZATION; GNRH; EXPRESSION;
   RESPONSES; IMMUNOCASTRATION; CHALLENGE; EPITOPES
AB The KISS1 gene product, kisspeptin, stimulates gonadotrophic steroid hormone (GNRH) neuronal signaling through the G-protein coupled receptor, kiss1r. Disturbance of this signaling pathway causes hypogonadotropic hypogonadism in mammals. As part of this cutting-edge research project, we analyzed the efficacy of an oral kisspeptin recombinant vaccine on the reproductive physiology and behavior of ram lambs. Ten 56-day old ram lambs were randomly divided into treatment and control groups to receive the experimental recombinant vaccines, C500/pKS-asd or C500/pVAX-asd (aspartate-beta semialdehyde dehydrogenase), respectively. The vaccines were orally administered at day 0, 28 and 56 and blood samples were taken and scrotal circumference data recorded at 14-day intervals (days 0, 14, 28, 42, 56, 70, and 84). At the end of the experimental period, day 98, sexual behaviors were assessed, scrotal circumferences were measured, and blood samples were collected. Testicular samples were also collected after the animals were sacrificed. Anti-kisspeptin antibody and testosterone serum levels were measured by indirect ELISA. Results demonstrated that the levels of anti-kisspeptin antibodies were significantly higher in the treatment group compared to controls (P < 0.05, P < 0.01 and P < 0.001). However, serum testosterone levels were lower in the treatment group (P < 0.01). Interestingly, vaccine administration contributed to a significant reduction (P < 0.01) in sexual behavior propensity. These results suggest that the kisspeptin recombinant oral vaccine regulates and inhibits the reproductive physiology and behavior of ram lambs. (C) 2017 Published by Elsevier Ltd.
C1 [Tesema, Birhanu; Zhao, Jia-yu; Jiang, Xun-ping; Liu, Gui-qiong; Han, Yan-guo; Wassie, Teketay] Huazhong Agr Univ, Coll Anim Sci & Technol, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Wuhan 430070, Hubei, Peoples R China.
RP Jiang, XP (reprint author), Huazhong Agr Univ, Coll Anim Sci & Technol, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Wuhan 430070, Hubei, Peoples R China.
EM xpjiang@mail.hzau.edu.cn
FU China National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China [NSFC-31772598]
FX This research was funded by the China National Natural Science
   Foundation of China NSFC-31772598.
CR AHREN C, 1993, VACCINE, V11, P929, DOI 10.1016/0264-410X(93)90380-G
   AKHTAR FB, 1985, J ENDOCRINOL, V104, P345, DOI 10.1677/joe.0.1040345
   Azizi A, 2010, VACCINE, V28, P4015, DOI 10.1016/j.vaccine.2010.04.018
   Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3
   Bliss SP, 2010, FRONT NEUROENDOCRIN, V31, P322, DOI 10.1016/j.yfrne.2010.04.002
   Celis G. J. P., 1987, Tecnica Pecuaria en Mexico, V25, P85
   Clarkson J, 2006, ENDOCRINOLOGY, V147, P5817, DOI 10.1210/en.2006-0787
   de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100
   ELMORE R G, 1976, Theriogenology, V6, P485, DOI 10.1016/0093-691X(76)90115-1
   Ferro VA, 2004, VET IMMUNOL IMMUNOP, V101, P73, DOI 10.1016/j.vetimm.2004.03.011
   Fromme B, 2003, ENDOCRINOLOGY, V144, P3262, DOI 10.1210/en.2002-221135
   Godfrey SI, 1996, ANIM REPROD SCI, V44, P41, DOI 10.1016/0378-4320(96)01479-0
   Gupta JC, 2004, PROTEIN EXPRES PURIF, V37, P1, DOI 10.1016/j.pep.2004.03.018
   Han YG, 2015, VACCINE, V33, P777, DOI 10.1016/j.vaccine.2014.12.054
   Hennessy DP, 1997, EAAP PUBLIC, P141
   Jang JH, 2006, J CONTROL RELEASE, V112, P120, DOI 10.1016/j.jconrel.2006.01.013
   JEFFCOATE IA, 1982, THERIOGENOLOGY, V18, P65, DOI 10.1016/0093-691X(82)90050-4
   Johan Turkstra, 2005, ACTIVE IMMUNIZATION
   Jones WR, 1983, IMMUNOLOGICAL FERTIL, P1
   Khan MAH, 2007, J VACCINE
   Khan MAH, 2008, VACCINE, V26, P1365, DOI 10.1016/j.vaccine.2007.12.052
   Kotiw M, 2012, CLIN VACCINE IMMUNOL, V19, P268, DOI 10.1128/CVI.05295-11
   LAND RB, 1973, NATURE, V241, P208, DOI 10.1038/241208a0
   Liang AX, 2008, VACCINE, V26, P2935, DOI 10.1016/j.vaccine.2008.03.036
   LUNSTRA DD, 1978, J ANIM SCI, V46, P1054
   Maruska KP, 2011, PHYSIOLOGY, V26, P412, DOI 10.1152/physiol.00032.2011
   Mastroeni P, 2000, INFECT IMMUN, V68, P46, DOI 10.1128/IAI.68.1.46-53.2000
   MELOEN RH, 1994, VACCINE, V12, P741, DOI 10.1016/0264-410X(94)90226-7
   MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547
   Monack DM, 2004, NAT REV MICROBIOL, V2, P747, DOI 10.1038/nrmicro955
   NOTTER DR, 1981, THERIOGENOLOGY, V15, P227, DOI 10.1016/S0093-691X(81)80011-8
   Pinilla L, 2012, PHYSIOL REV, V92, P1235, DOI 10.1152/physrev.00037.2010
   Rai J., 2004, J ANAT SOC INDIA, V53, P17
   Ramzan F, 2013, PROSTATE, V73, P690, DOI 10.1002/pros.22609
   RODRIGUEZ RE, 1989, ENDOCRINOLOGY, V124, P248, DOI 10.1210/endo-124-1-248
   Roseweir AK, 2009, HUM REPROD UPDATE, V15, P203, DOI 10.1093/humupd/dmn058
   SCHANBACHER BD, 1982, AM J PHYSIOL, V242, pE201
   Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322
   Stadnikov A A, 1996, Morfologiia, V110, P38
   Taylor MF, 1994, NEUROENDOCRINOLOGY, V59, P343
   Tsukamura H, 2011, THAI J VET MED, V41, P69
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Xu JS, 2004, J IMMUNOL METHODS, V289, P111, DOI 10.1016/j.jim.2004.04.004
   Yrlid U, 2000, FEMS IMMUNOL MED MIC, V27, P313, DOI 10.1016/S0928-8244(99)00209-6
NR 44
TC 5
Z9 5
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4630
EP 4636
DI 10.1016/j.vaccine.2017.09.001
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000032
PM 29097006
DA 2020-05-12
ER

PT J
AU Ren, D
   Almudevar, AL
   Murphy, TF
   Lafontaine, ER
   Campagnari, AA
   Luke-Marshall, N
   Pichichero, ME
AF Ren, Dabin
   Almudevar, Anthony L.
   Murphy, Timothy F.
   Lafontaine, Eric R.
   Campagnari, Anthony A.
   Luke-Marshall, Nicole
   Pichichero, Michael E.
TI Serum antibody response to Moraxella catarrhalis proteins in stringently
   defined otitis prone children
SO VACCINE
LA English
DT Article
DE Otitis prone; Nasopharyngeal colonization; Acute otitis media;
   Immunogenicity; Recombinant proteins; Carriage
ID STREPTOCOCCUS-PNEUMONIAE PROTEINS; NASOPHARYNGEAL COLONIZATION;
   HAEMOPHILUS-INFLUENZAE; VACCINE ANTIGENS; CELL GENERATION; MEDIA;
   IDENTIFICATION; CONTRIBUTE; ROCHESTER; ADULTS
AB Background: Moraxella catarrhalis (Mcat) is a frequent pathogen of acute otitis media (AOM) in young children. Here we prospectively assessed naturally-induced serum antibodies to four Mcat vaccine candidate proteins in stringently defined otitis prone (sOP) and non-otitis prone (NOP) children age 6-36 months old following nasopharyngeal (NP) colonization, at onset of AOM and convalescence from AOM.
   Methods: Serum IgG and IgM antibody against recombinant Mcat proteins, oligopeptide permease A (OppA), outer membrane protein (OMP) CD, hemagglutinin (Hag), and PilA Glade 2 (PilA2), were quantitated by ELISA.
   Results: During NP colonization by Mcat all four antigens were immunogenic in both sOP and NOP children. However, sOP children had lower antibody responses than NOP children across age 6-36 months, similar to our findings for protein vaccine candidates of Streptococcus pneumoniae (Spn) and Nontypeable Haemophilus influenzae (NTHi). sOP children displayed a later and lower peak of antibody rise than NOP children for all four antigens during NP colonization of Mcat. The age-dependent increase of antibody ranked as OppA > Hag5-9 > OMP CD > PilA2 in both sOP and NOP children. Lower serum antibody levels to the Mcat antigens were measured in sOP compared to NOP children at the onset of AOM. We did not find a consistent significant increase of antibody at the convalescence phase after an AOM. event.
   Conclusions: sOP children is a highly vulnerable population that mount lower serum antibody responses to Mcat candidate vaccine proteins compared to NOP children during asymptomatic NP carriage and at onset of AOM. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Ren, Dabin; Pichichero, Michael E.] Rochester Gen Hosp, Res Inst, 1425 Portland Ave, Rochester, NY 14621 USA.
   [Almudevar, Anthony L.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
   [Murphy, Timothy F.] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Clin & Translat Res Ctr, Buffalo, NY 14214 USA.
   [Lafontaine, Eric R.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
   [Campagnari, Anthony A.; Luke-Marshall, Nicole] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Microbiol & Immunol, Buffalo, NY 14214 USA.
RP Ren, D (reprint author), Rochester Gen Hosp, Res Inst, 1425 Portland Ave, Rochester, NY 14621 USA.
EM dabin.ren@rochesterregional.org
OI Murphy, Timothy/0000-0002-3496-2641
FU NIH/NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R03 A1113649, NIDCDRO1 08671]
FX This work was supported by the NIH/NIAID under Grant R03 A1113649 to
   Dabin Ren and NIDCDRO1 08671 to Michael E. Pichichero. The funder had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Basha S, 2015, CLIN EXP IMMUNOL, V182, P314, DOI 10.1111/cei.12660
   Basha S, 2014, EXPERT REV CLIN IMMU, V10, P1171, DOI 10.1586/1744666X.2014.942288
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Cameron A, 2010, MEDIA INT AUST, P90
   Casey JR, 2013, PEDIATR INFECT DIS J, V32, P805, DOI 10.1097/INF.0b013e31828d9acc
   Chonmaitree T, 2015, CLIN INFECT DIS, V60, P1, DOI 10.1093/cid/ciu714
   HEIKKINEN T, 1994, PEDIATR INFECT DIS J, V13, P659, DOI 10.1097/00006454-199407000-00016
   Heikkinen T, 2003, CLIN MICROBIOL REV, V16, P230, DOI 10.1128/CMR.16.2.230-241.2003
   ICH, 1994, VAL AN PROC TEXT MET
   Jones MM, 2014, INFECT IMMUN, V82, P4758, DOI 10.1128/IAI.02185-14
   Kaur R, 2011, PEDIATR INFECT DIS J, V30, P645, DOI 10.1097/INF.0b013e31821c2d8b
   Kaur R, 2011, VACCINE, V29, P1023, DOI 10.1016/j.vaccine.2010.11.055
   Khan MN, 2012, FEMS IMMUNOL MED MIC, V65, P439, DOI 10.1111/j.1574-695X.2012.00967.x
   Kirkham AS, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00497-16
   Koivunen P, 1999, PEDIATR INFECT DIS J, V18, P303, DOI 10.1097/00006454-199903000-00023
   LaFontaine ER, 2009, CLIN VACCINE IMMUNOL, V16, P653, DOI 10.1128/CVI.00460-08
   Luke-Marshall NR, 2011, GENE, V477, P19, DOI 10.1016/j.gene.2011.01.010
   Mathers K, 1999, PEDIATR INFECT DIS J, V18, P982, DOI 10.1097/00006454-199911000-00010
   Menon VJ, 2012, VACCINE, V30, P3136, DOI 10.1016/j.vaccine.2012.01.086
   Murphy TF, 2003, INFECT IMMUN, V71, P1288, DOI 10.1128/IAI.71.3.1288-1294.2003
   Pettigrew MM, 2008, EMERG INFECT DIS, V14, P1584, DOI 10.3201/eid1410.080119
   Pettigrew MM, 2011, J CLIN MICROBIOL, V49, P3750, DOI 10.1128/JCM.01186-11
   Pichichero ME, 2016, PEDIATR INFECT DIS J, V35, P1033, DOI 10.1097/INF.0000000000001217
   Pichichero ME, 2013, PEDIATR INFECT DIS J, V32, P1163, DOI 10.1097/INF.0b013e31829e887e
   Pichichero ME, 2013, PEDIATR CLIN N AM, V60, P391, DOI 10.1016/j.pcl.2012.12.007
   Pichichero ME, 2012, HUM VACC IMMUNOTHER, V8, P799, DOI 10.4161/hv.19820
   Pichichero ME, 2010, VACCINE, V28, P7184, DOI 10.1016/j.vaccine.2010.08.063
   Pinheiro J, 2017, LINEAR NONLINEAR MIX
   Ren DB, 2016, EXPERT OPIN THER TAR, V20, P19, DOI 10.1517/14728222.2015.1081686
   Ren D, 2015, VACCINE, V33, P5809, DOI 10.1016/j.vaccine.2015.09.023
   Ren DB, 2015, HUM VACC IMMUNOTHER, V11, P489, DOI 10.4161/21645515.2014.990861
   Ruckdeschel EA, 2008, INFECT IMMUN, V76, P1599, DOI 10.1128/IAI.01253-07
   Sharma SK, 2012, J INFECT DIS, V205, P1225, DOI 10.1093/infdis/jis179
   Sharma SK, 2011, J INFECT DIS, V204, P645, DOI 10.1093/infdis/jir340
   Thornton RB, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00556-16
   Verhoeven D, 2013, MED MICROBIOL IMMUN, V202, P295, DOI 10.1007/s00430-013-0293-2
   Weber CA, 2009, ADV DRUG DELIVER REV, V61, P965, DOI 10.1016/j.addr.2009.07.001
   Wiertsema SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049061
   Xu QF, 2016, PEDIATR INFECT DIS J, V35, P54, DOI 10.1097/INF.0000000000000949
   Xu QF, 2012, PEDIATR INFECT DIS J, V31, P638, DOI 10.1097/INF.0b013e31824ba6f7
   Yang M, 2011, INFECT IMMUN, V79, P846, DOI 10.1128/IAI.00314-10
NR 42
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4637
EP 4645
DI 10.1016/j.vaccine.2017.07.027
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000033
PM 28755833
DA 2020-05-12
ER

PT J
AU Dabanch, J
   Gonzalez, C
   Cerda, J
   Acevedo, J
   Calvo, M
   Diaz, E
   Endeiza, M
   Inostroza, J
   Rodriguez, J
   Saldana, A
   Santillana, S
   El Omeiri, N
   Bastias, M
AF Dabanch, Jeannette
   Gonzalez, Cecilia
   Cerda, Jaime
   Acevedo, Johanna
   Calvo, Mario
   Diaz, Eduardo
   Endeiza, Maria
   Inostroza, Jaime
   Rodriguez, Jaime
   Saldana, Adiela
   Santillana, Solange
   El Omeiri, Nathalie
   Bastias, Magdalena
TI Chile's National Advisory Committee on Immunization (CAVEI):
   Evidence-based recommendations for public policy decision-making on
   vaccines and immunization
SO VACCINE
LA English
DT Article
DE National Immunization Technical Advisory; Group; Evidence-based
   recommendations; Immunization decision-making; Immunization policy;
   Chile
AB A National Immunization Technical Advisory Group (NITAG) provides independent, evidence-based recommendations to the Ministry of Health for immunization programmes and policy formulation. In this article, we describe the structure, functioning and work processes of Chile's NITAG (CAVEI) and assess its functionality, quality of work processes and outputs, and integration of the committee into the Ministry of Health policy process using the Assessment tool for National Immunization Technical Advisory Groups. Among its strengths, CAVEI's administrative and work plasticity allows it to respond in a timely manner to the Ministry of Health's requests and proactively raise subjects for review. Representation of multiple areas of expertise within the committee makes CAVEI a robust and balanced entity for the development of evidence-based comprehensive recommendations. High ranking profile of the Secretariat structure furthers CAVEI's competences in policymaking and serves as a bridge between the committee and international initiatives in the field of immunizations. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Dabanch, Jeannette] Univ Chile, Hosp Clin, Santos Dumont 999, Santiago, Chile.
   [Gonzalez, Cecilia; Bastias, Magdalena] Minist Salud, Dept Inmunizac, Monjitas 565,p7, Santiago, Chile.
   [Cerda, Jaime] Pontificia Univ Catolica Chile, Fac Med, Dept Salud Publ, Diagonal Paraguay 362, Santiago, Chile.
   [Acevedo, Johanna] Minist Salud, Dept Epidemiol, Enrique Mac Iver 541, Santiago, Chile.
   [Calvo, Mario] Univ Austral Chile, Fac Med, Inst Med, Coronel Santiago Bueras 1003, Valdivia, Chile.
   [Diaz, Eduardo] Univ Chile, Fac Med, Av Independencia 1027, Santiago, Chile.
   [Endeiza, Maria] Clin Univ Los Andes, Av Plaza 2501, Santiago, Chile.
   [Inostroza, Jaime] Univ La Frontera, Fac Med, Ave Francisco Salazar 01145, Temuco, Chile.
   [Rodriguez, Jaime] Clin Alemana, Unidad Infectol Pediat, Av Vitacura 5951, Santiago, Chile.
   [Saldana, Adiela] Inst Salud Publ Chile, Farmacovigilancia Vacunas, Av Marathon 1000, Santiago, Chile.
   [Santillana, Solange] SEREMI Salud Reg Valparaiso, Melgarejo 669,Piso 6, Valparaiso, Chile.
   [El Omeiri, Nathalie] WHO, Dept Family Hlth Promot & Life Course PAHO, 525 23rd St NW, Washington, DC 20037 USA.
RP Bastias, M (reprint author), Minist Salud, Dept Inmunizac, Monjitas 565,Piso 7, Santiago 8320070, Chile.
EM bastiasmalu@gmail.com
OI Bastias, Magdalena/0000-0002-7298-4884
FU PAHO's Department of Family, Health Promotion and Life Course; United
   States Centers for Disease Control and Prevention (CDC), Global
   Immunization DivisionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA
FX We thank PAHO's Department of Family, Health Promotion and Life Course
   for facilitating this evaluation, the United States Centers for Disease
   Control and Prevention (CDC), Global Immunization Division, especially
   Abigail Sheffer and Kathy Cavallaro for their technical and financial
   support, the Argentinian Institute of Clinical and Effectiveness Health
   Policy, for their support during the evaluation (Juan Alonso, Maria
   Belizan and Daniel Jones), and the Global NITAGs Network, and its
   secretariat at the World Health Organization for their inputs and
   collaboration.
CR Blau J, 2013, VACCINE, V31, P2653, DOI 10.1016/j.vaccine.2013.01.047
   Centers for Disease Control and Prevention, 2018, ASS TOOL NAT IMM TEC
   Departamento de Estadisticas e Informacifin de Salud- Gobierno de Chile, 2009, IND BAS SAL 2009
   Departamento de Inmunizaciones, HIT VAC CHIL
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Health Policy and Institutional Development Unit of the Agence de Medecine Preventive, 2016, SIVAC EV TOOL NAT IM
   Mansilla C, 2017, REV PANAM SALUD PUBL, V41
   World Health Organization, 2018, NAT ADV COMM IMM
   World Health Organization Department of Immunization, 2018, GLOB VACC ACT PLAN M
NR 9
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4646
EP 4650
DI 10.1016/j.vaccine.2019.06.069
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000034
PM 31266668
OA Other Gold
DA 2020-05-12
ER

PT J
AU Torrijos, JLD
   Tuells, J
AF Duro Torrijos, Jose Luis
   Tuells, Jose
TI The beginnings of smallpox vaccination in Spain seen through the
   correspondence of Ignacio Maria Ruiz de Luzuriaga (1801-1802)
SO VACCINE
LA English
DT Article
DE Smallpox; Vaccine; Ruiz de Luzuriaga; Letters; Correspondence; Papers on
   the vaccine
ID SPREAD
AB Edward Jenner's discovery of the smallpox vaccine spread rapidly across Europe. In Spain, vaccinations first took place in December 1800 and the practice flourished upon the private initiative of doctors, surgeons, state officials and members of the nobility in different parts of the country. Ignacio Maria Ruiz de Luzuriaga, secretary of the Royal Academy of Medicine of Madrid, is considered in medical historiography as a key figure of the introduction of the smallpox vaccine in Spain. Ruiz de Luzuriaga had a major role as a disseminator of the Jennerian technique and as a distributor of the vaccine fluid. Given his prestige as a doctor and his position in the Royal Academy, he was commissioned to establish a scientific and academic corpus on preventive measures to foster their understanding, uptake and good practice among Spanish vaccinators. He also attempted to create a Central Vaccine Committee, such as that existing in other European countries. The Royal Academy kept records of his activity which have been filed and catalogued in a documentary set entitled 'Papeles sobre la vacuna' [Vaccine Papers]. This archive has not been studied in depth to date. These documents allow identifying a network of correspondents set up by Ruiz de Luzuriaga. He provided these correspondents with the vaccine and asked them to report back on the vaccination progress made in their municipalities. This correspondence provides an account of how the first immunisations in Spain unravelled, as well as of the initial concerns that accompanied the introduction of the vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Duro Torrijos, Jose Luis; Tuells, Jose] Univ Alicante, Catedra Balmis Vacunol, Campus San Vicente Raspeig, Alicante 03080, Spain.
RP Tuells, J (reprint author), Univ Alicante, Catedra Balmis Vacunol, Campus San Vicente Raspeig, Alicante 03080, Spain.
EM tuells@ua.es
RI Tuells, Jose/G-1015-2013
OI Tuells, Jose/0000-0003-1159-429X; Duro Torrijos, Jose
   Luis/0000-0002-2232-1492
FU Spanish Vaccination Foundation [FEV1-11PA]
FX This work is included in the framework of the research project `Papers
   on the vaccine' that received funding from the Spanish Vaccination
   Foundation (FEV1-11PA).
CR Balaguer Periguell E, 2003, NOMBRE NINOS REAL EX
   Bances D, 1802, TRATADO VACCINA VIRU
   Bazin H, 2008, HIST VACCINATIONS
   Bhattacharya S, 2009, B HIST MED, V83, P1, DOI 10.1353/bhm.0.0194
   Blasco Martinez L, 1991, THESIS
   BOWERS JZ, 1981, B HIST MED, V55, P17
   Canal Gabuti M, 1801, 1 INFORM DIRIGIDO SO
   Countess of Montijo, COMMUNICATION, P229
   Darmon P, 2001, B ACAD NAT MED PARIS, V185, P767, DOI 10.1016/S0001-4079(19)34520-0
   de oliveira Joao Francisco, COMMUNICATION, P93
   DUNBAR ROBERT G., 1941, BULL HISTORY MED, V10, P635
   Duro Torrijos JL, 2017, VACUNAS, V18, P26, DOI [10.1016/j.vacune2017.01.001, DOI 10.1016/J.VACUNE.2017.01.001]
   Duro Torrijos JL, 2014, THESIS
   Hernandez P, 1801, ORIGEN DESCUBRIMIENT
   Hopkins D. R., 1983, PRINCES PEASANTS SMA
   Jauregui Ignacio, COMMUNICATION, P113
   Jenner E, 1798, INQUIRY CAUSES EFFEC
   Leroy Alfonso, 1801, COMMUNICATION, P3
   Lopez Pinero Jose M, 1983, DICCIONARIO HIST CIE, VII
   Lopez Sanchez J, 1950, VIDA OBRA SABIO MED
   Luis Don, COMMUNICATION, P326
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Martinez V, 1802, TRATADO HIST PRACTIC
   MEYNELL E, 1995, SOC HIST MED, V8, P285, DOI 10.1093/shm/8.2.285
   Olague de Ros G, 1994, Dynamis, V14, P305
   Olague de Ros G, 2008, VACUNAS HIST ACTUALI, P19
   Olague de Ros G, 2004, ASCLEPIO, V56, P7, DOI [10.3989/ascLEpio.2004v56i1.70, DOI 10.3989/ASCLEPIO.2004.V56.I1.70]
   Romay T, 1805, MEMORIA INTRO PROGRE
   Rusnock A, 2009, B HIST MED, V83, P17, DOI 10.1353/bhm.0.0160
   Sanchez Granjel L, 1984, C EST VASC, P127
   Tisci C, 2003, MED STORIA, V3, P89
   Tomas Romay, COMMUNICATION, P119
   Tuells J, 2006, COLECCION BALMIS REA, P56
   Tuells J., 2013, VACUNAS, V14, P90, DOI [10.1016/j.vacun.2013.05.004, DOI 10.1016/J.VACUN.2013.05.004]
   Tuells J, 2012, VACUNAS, P128, DOI [10.1016/S1576-g/387(12)70052-I, DOI 10.1016/S1576-9887(12)70052-3]
   Tuells J, 2015, DYNAMIS, V35, P459, DOI 10.4321/S0211-95362015000200009
   Tuells J, 2012, VACCINE, V30, P5491, DOI 10.1016/j.vaccine.2012.06.059
   Usandizaga Soraluce M, 1964, EMINENTES MEDICOS VA
NR 38
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 26
PY 2019
VL 37
IS 32
BP 4651
EP 4657
DI 10.1016/j.vaccine.2019.05.088
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2MR
UT WOS:000483415000035
PM 31262586
DA 2020-05-12
ER

PT J
AU Majdinasab, A
   Yuan, QY
AF Majdinasab, Alireza
   Yuan, Qiuyan
TI Post-consumer cullet and potential engineering applications in North
   America
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Post-consumer cullet; Mixed-color cullet; Engineering applications; End
   markets; Collection; Economics
ID RECYCLED CRUSHED GLASS; ALKALI-SILICA REACTION; WASTE GLASS; FILTER
   MEDIUM; CONCRETE; AGGREGATE; POWDER; COLLECTION; MANAGEMENT; SINGLE
AB Waste glass cullet (WGC) recovered from almost all waste streams is contaminated with mixed-color sources of variable compositions. Consequently, over 60% of the cullet is discarded in landfills in North America. The present work provides an overview of the potential end markets for the cullet with a focus on collection systems, marketing strategies, safety and environmental issues as well as the economics of the target applications. Cullet can find major applications in construction industry as a substitute to natural aggregates integrated with different proportions of concrete to build pavements, and roads Cullet could be widely used in different applications due to its desirable physical, mechanical, and chemical properties. This makes cullet an appropriate alternative for natural resources. Although various applications discussed in this paper have well-established markets, low proportion of cullet has been implemented in those applications. This could be attributed to the higher preprocessing cost of cullet compared to the natural aggregates. Different measures are required by the governments to continue to develop the potential post-consumer markets for recycled cullet such as encouraging recycling of WGC and restricting the use of landfilling activities for WGC.
C1 [Majdinasab, Alireza; Yuan, Qiuyan] Univ Manitoba, Dept Civil Engn, Winnipeg, MB R3T 5V6, Canada.
RP Yuan, QY (reprint author), Univ Manitoba, Dept Civil Engn, Winnipeg, MB R3T 5V6, Canada.
EM qiuyan.yuan@umanitoba.ca
CR Abbassi A, 2008, APPL THERM ENG, V28, P450, DOI 10.1016/j.applthermaleng.2007.05.011
   ABCRC, 2014, ALB BEV CONT REC COR
   Adaway M, 2015, ELECTRON J STRUCT EN, V14, P116
   Afshinnia K, 2016, CONSTR BUILD MATER, V117, P263, DOI 10.1016/j.conbuildmat.2016.04.072
   Afshinnia K, 2015, CONSTR BUILD MATER, V81, P257, DOI 10.1016/j.conbuildmat.2015.02.041
   Andreola F, 2007, J EUR CERAM SOC, V27, P1623, DOI 10.1016/j.jeurceramsoc.2006.05.009
   Arnold G, 2008, NZ T AGENCY RES REP, V351, P40
   Bansal N.P., 2013, HDB GLASS PROPERTIES
   Blengini GA, 2012, WASTE MANAGE, V32, P1000, DOI 10.1016/j.wasman.2011.10.018
   Clean Washington Centre (CWC), 1993, GL932 CWC DAM MOOR I
   CM Consulting +, 2014, WHO PAYS WHAT AN BEV
   Corinaldesi V, 2005, WASTE MANAGE, V25, P197, DOI 10.1016/j.wasman.2004.12.009
   da Cruz NF, 2014, WASTE MANAGE, V34, P298, DOI 10.1016/j.wasman.2013.10.035
   Daigo I, 2018, RESOUR CONSERV RECY, V133, P375, DOI 10.1016/j.resconrec.2017.11.012
   DAY DE, 1970, AM CERAM SOC BULL, V49, P1038
   de Castro S, 2013, J CLEAN PROD, V41, P7, DOI 10.1016/j.jclepro.2012.09.021
   Dhir RK, 2009, MATER STRUCT, V42, P1451, DOI 10.1617/s11527-008-9465-8
   Disfani MM, 2011, WASTE MANAGE, V31, P2341, DOI 10.1016/j.wasman.2011.07.003
   Disfani MM, 2015, ENVIRON GEOTECH, V2, P269, DOI 10.1680/envgeo.13.00054
   Du HJ, 2017, CEMENT CONCRETE COMP, V75, P22, DOI 10.1016/j.cemconcomp.2016.10.010
   European Commission, 2015, ASS SEP COLL SCHEM 2
   FEVE, 2015, GLASS REC YEARS IMPR
   Fily-Pare I, 2013, USE RECYCLED GLASS S, P14
   Fitzgerald GC, 2012, RESOUR CONSERV RECY, V69, P50, DOI 10.1016/j.resconrec.2012.08.006
   Freestone IC, 2003, ARCHAEOMETRY, V45, P19, DOI 10.1111/1475-4754.00094
   FROSCH RA, 1989, SCI AM, V261, P144, DOI 10.1038/scientificamerican0989-144
   Glass Alliance Europe, 2016, EUR ALL GLASS IND
   hdr Engineering Inc, 1997, GLASS CULL UT CIV EN
   Horan NJ, 2007, WATER RES, V41, P253, DOI 10.1016/j.watres.2006.08.028
   Hurley J, 2003, GLASS RES DEV FINAL, P17
   Idir R, 2010, CONSTR BUILD MATER, V24, P1309, DOI 10.1016/j.conbuildmat.2009.12.030
   im N. L., 2014, MAT SCI FORUM, V803
   Imteaz MA, 2012, WASTE MANAGE RES, V30, P917, DOI 10.1177/0734242X12448512
   JOHNSTON CD, 1974, J TEST EVAL, V2, P344
   Klein J, 2015, 3D PRINT ADDIT MANUF, V2, P92, DOI 10.1089/3dp.2015.0021
   Kou SC, 2009, CEMENT CONCRETE COMP, V31, P107, DOI 10.1016/j.cemconcomp.2008.12.002
   Lakhan C, 2015, RESOURCES-BASEL, V4, P384, DOI 10.3390/resources4020384
   Lam CS, 2007, CEMENT CONCRETE COMP, V29, P616, DOI 10.1016/j.cemconcomp.2007.03.008
   Lantz D, 2008, RESOUR RECYCL, V12, P24
   Lee G, 2013, CONSTR BUILD MATER, V38, P638, DOI 10.1016/j.conbuildmat.2012.09.017
   Ling TC, 2013, RESOUR CONSERV RECY, V70, P25, DOI 10.1016/j.resconrec.2012.10.006
   Macfarlane A, 2002, GLASS WORLD HIST
   Mohajerani A, 2017, J CLEAN PROD, V166, P1, DOI 10.1016/j.jclepro.2017.07.250
   Mohajerani A, 2017, CONSTR BUILD MATER, V153, P69, DOI 10.1016/j.conbuildmat.2017.07.091
   Morawski C., 2009, UNDERSTANDING EC ENV, P3
   Nandy B, 2015, RESOUR CONSERV RECY, V101, P167, DOI 10.1016/j.resconrec.2015.05.012
   Naqvi SR, 2018, RESOUR CONSERV RECY, V136, P118, DOI 10.1016/j.resconrec.2018.04.013
   Nash PT, 1995, USE GLASS CULLET ROA
   NSW DECC, 2007, TRIAL REC GLASS PIP
   Obe R. K. D., 2018, SUSTAINABLE CONSTRUC
   Ooi PSK, 2008, TRANSP RES RECORD, P52, DOI 10.3141/2059-06
   Park SB, 2004, CEMENT CONCRETE RES, V34, P1145, DOI 10.1016/j.cemconres.2003.12.005
   PennDOT, 2005, STRAT REC PROGR FACT
   Rajabipour F, 2010, J MATER CIVIL ENG, V22, P1201, DOI 10.1061/(ASCE)MT.1943-5533.0000126
   Reddy KR, 1999, INT C SOL WAST TECHN, P1
   Rutledge Simon O., 2002, Journal of Environmental Engineering and Science, V1, P349, DOI 10.1139/s02-023
   Serpa D., 2015, ACI MAT J
   Soutar CA, 2000, ANN OCCUP HYG, V44, P3, DOI 10.1016/S0003-4878(99)00047-2
   Soyer E, 2010, CLEAN-SOIL AIR WATER, V38, P927, DOI 10.1002/clen.201000217
   Stantec Ltd, 2009, 176 CIF STANT LTD
   Stanworth J. E., 1950, PHYS PROPERTIES GLAS, V6
   SWHEC, 2005, SINGL STREAM COLL
   Teixeira J, 2004, EUR J OPER RES, V158, P543, DOI 10.1016/S0377-2217(03)00379-5
   Terro MJ, 2006, BUILD ENVIRON, V41, P633, DOI 10.1016/j.buildenv.2005.02.018
   Thomas C, 2005, MARKET STUDY RECYCLE
   Topcu IB, 2004, CEMENT CONCRETE RES, V34, P267, DOI 10.1016/j.cemconres.2003.07.003
   Tsai CL, 2013, J IND ECOL, V17, P129, DOI 10.1111/j.1530-9290.2012.00509.x
   Tucker EL, 2018, RESOUR CONSERV RECY, V129, P240, DOI 10.1016/j.resconrec.2017.10.025
   Ukwatta A, 2016, J CLEAN PROD, V119, P76, DOI 10.1016/j.jclepro.2016.01.094
   US EPA, 2015, ADV SUST MAT MAN FAC, P1, DOI DOI 10.1007/S13398-014-0173-7.2
   USEPA, 2001, DEP REF SYST, P57
   USEPA, 1992, EPA530SW90071A
   USEPA, 2014, MUN SOL WAST GEN REC
   Walls M, 2011, DEPOSIT REFUND SYSTE
   Woolverton A. B, 1996, THESIS
   WSDOT, 1997, WASH STAT DEP TRANSP
   Yamane J. K, 2014, STUDY IDENTIFY LOCAL
   Yuksel C, 2013, CEMENT CONCRETE COMP, V38, P57, DOI 10.1016/j.cemconcomp.2013.03.002
   Zheng K, 2013, WOOD PUBL SER CIVIL, P241, DOI 10.1533/9780857098993.2.241
   Zheng K, 2016, CEMENT CONCRETE COMP, V67, P30, DOI 10.1016/j.cemconcomp.2015.12.008
   Zhu HY, 2009, MATER STRUCT, V42, P485, DOI 10.1617/s11527-008-9396-4
NR 81
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 1
EP 9
DI 10.1016/j.reseonrec.2019.04.009
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700001
DA 2020-05-12
ER

PT J
AU Singh, RK
   Luthra, S
   Mangla, SK
   Uniyal, S
AF Singh, Rajesh Kr
   Luthra, Sunil
   Mangla, Sachin Kumar
   Uniyal, Surbhi
TI Applications of information and communication technology for sustainable
   growth of SMEs in India food industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food supply chain; Information communication technology; Resource
   management; Indian small and medium enterprises; Sustainable growth;
   Grey based; Decision-making trial and evaluation laboratory
ID SUPPLY CHAIN MANAGEMENT; CRITICAL SUCCESS FACTORS; E-PROCUREMENT;
   HONG-KONG; BIG DATA; TRACEABILITY; PERFORMANCE; BARRIERS; ADOPTION;
   SYSTEMS
AB Indian food sector is facing severe problem of wastage of about 30% of farm products due to inefficiency in operations of Small and Medium Enterprises (SMEs). The SMEs in Indian food sector are facing different challenges, such as financial issues, lack of technical skills and investment in the business etc. In this sense, several key factors can help food SMEs in reducing wastage of farm products and lowering energy consumption for sustainable growth. Thus, this paper tries to identify and analyse key factors for Information Communication Technology (ICT) applications for a sustainable growth of SMEs in Indian food sector. Grey based Decision Making Trial and Evaluation Laboratory technique was applied for analysis of factors. From findings, 'Government initiatives and policies', 'Public-private partnership', and 'Encouragement to ICT service provider' are topmost influential cause group factors. While, 'ICT integrated effective food supply chain', 'Coordination between different departments', and 'Collaboration and strategic alliances across supply chain' are highest influenced factors. Results suggests that 'Government policies and initiatives' are at the core of the efforts to upgrade food supply chain. As, Indian government is the largest customer of SMEs and controls various policy making aspects in food sector. Therefore, government has to take steps to encourage private and foreign investments as well as promote IT service providers and business environment related economic policies to improve competitiveness of Indian food sector. This work would help managers to develop efficient ICT applications for an effective sustainable growth of SMEs in their respective food supply chains.
C1 [Singh, Rajesh Kr] Management Dev Inst, Gurgaon 122007, Haryana, India.
   [Luthra, Sunil] State Inst Engn & Technol, Dept Mech Engn, Nilokheri, India.
   [Mangla, Sachin Kumar] Univ Plymouth, Plymouth Business Sch, Knowledge Management & Business Decis Making, Plymouth PL4 8AA, Devon, England.
   [Uniyal, Surbhi] Graph Era Univ, Dept Mech Engn, Dehra Dun 248002, Uttarakhand, India.
RP Mangla, SK (reprint author), Univ Plymouth, Plymouth Business Sch, Knowledge Management & Business Decis Making, Plymouth PL4 8AA, Devon, England.
EM rksdce@yahoo.com; sunilluthra1977@gmail.com; sachinmangl@gmail.com;
   surbhiuniyal@yahoo.com
RI Luthra, Sunil/D-4135-2014
OI Luthra, Sunil/0000-0001-7571-1331; KUMAR MANGLA,
   SACHIN/0000-0001-7166-5315
CR Adjei-Bamfo P, 2019, RESOUR CONSERV RECY, V142, P189, DOI 10.1016/j.resconrec.2018.12.001
   Aggarwal S, 2016, BRIT FOOD J, V118, P1085, DOI 10.1108/BFJ-08-2015-0274
   Ahumada O, 2009, EUR J OPER RES, V196, P1, DOI 10.1016/j.ejor.2008.02.014
   Akhtar P, 2016, INT J PROD ECON, V181, P392, DOI 10.1016/j.ijpe.2015.11.013
   Akhtar P, 2015, BRIT FOOD J, V117, P443, DOI 10.1108/BFJ-12-2013-0357
   Aung MM, 2014, FOOD CONTROL, V39, P172, DOI 10.1016/j.foodcont.2013.11.007
   Badia-Melis R, 2015, FOOD CONTROL, V57, P393, DOI 10.1016/j.foodcont.2015.05.005
   Bai CG, 2013, INT J PROD ECON, V146, P281, DOI 10.1016/j.ijpe.2013.07.011
   Balaji M, 2016, RESOUR CONSERV RECY, V114, P153, DOI 10.1016/j.resconrec.2016.07.016
   Barratt M, 2004, SUPPLY CHAIN MANAG, V9, P30, DOI 10.1108/13598540410517566
   Bernard AB, 2007, J ECON PERSPECT, V21, P105, DOI 10.1257/jep.21.3.105
   Bhagwat R, 2007, PROD PLAN CONTROL, V18, P283, DOI 10.1080/09537280701248578
   Bhandari D, 2019, RESOUR CONSERV RECY, V146, P156, DOI 10.1016/j.resconrec.2019.02.038
   Bhaskaran S, 2013, BRIT FOOD J, V115, P425, DOI 10.1108/00070701311314237
   Bhatt G, 2010, INFORM MANAGE-AMSTER, V47, P341, DOI 10.1016/j.im.2010.08.001
   Bonneau V., 2017, IND 4 0 AGR FOCUS IO
   Brand Equity, 2016, BRAND EQUITY
   Chang HH, 2013, SUPPLY CHAIN MANAG, V18, P34, DOI 10.1108/13598541311293168
   Chen KZ, 2015, CHINA AGR ECON REV, V7, P616, DOI 10.1108/CAER-02-2015-0016
   Cui L, 2019, J BUS RES, V98, P450, DOI 10.1016/j.jbusres.2018.03.031
   D & B Report, 2015, REP EM SMES IND OV I
   Dandage K, 2017, FOOD CONTROL, V71, P217, DOI 10.1016/j.foodcont.2016.07.005
   Dania WAP, 2018, J CLEAN PROD, V186, P851, DOI 10.1016/j.jclepro.2018.03.148
   Dora M, 2016, PROD PLAN CONTROL, V27, P1, DOI 10.1080/09537287.2015.1050477
   Dora M, 2015, TRENDS FOOD SCI TECH, V44, P272, DOI 10.1016/j.tifs.2015.03.008
   Dyerson R, 2009, Electronic Journal of Information Systems Evaluation, V12, P39
   Faisal M. N., 2016, Journal of Foodservice Business Research, V19, P171, DOI 10.1080/15378020.2016.1159894
   Faour-Klingbeil D, 2018, FOODS, V7, DOI 10.3390/foods7030033
   FICCI, 2010, SURV CHALL FOOD PROC
   Filipescu DA, 2009, ADV INT MARKETING, V20, P125, DOI 10.1108/S1474-7979(2009)0000020008
   Flynn BB, 2010, J OPER MANAG, V28, P58, DOI 10.1016/j.jom.2009.06.001
   Fritz M, 2009, INT J PROD ECON, V117, P317, DOI 10.1016/j.ijpe.2008.10.015
   Gabus A, 1972, WORLD PROBLEMS INVIT, P1
   Gaukler GM, 2010, J BUS IND MARK, V25, P572, DOI 10.1108/08858621011088301
   Ghadge A, 2017, IND MANAGE DATA SYST, V117, P1995, DOI 10.1108/IMDS-07-2016-0270
   Gong MF, 2018, RESOUR CONSERV RECY, V128, P155, DOI 10.1016/j.resconrec.2016.11.001
   Govindan K, 2018, INT J PROD ECON, V195, P419, DOI 10.1016/j.ijpe.2017.03.003
   Gunasekaran A, 2008, INT J PROD ECON, V113, P159, DOI 10.1016/j.ijpe.2007.04.012
   Halloran A, 2014, FOOD POLICY, V49, P294, DOI 10.1016/j.foodpol.2014.09.005
   Hendricks KB, 2007, J OPER MANAG, V25, P65, DOI 10.1016/j.jom.2006.02.002
   Hobbs J. E., 2005, CAN J AGR, V53, P757
   Hobbs JE, 2005, CAN J AGR ECON, V53, P47, DOI 10.1111/j.1744-7976.2005.00412.x
   Hsu CW, 2013, J CLEAN PROD, V56, P164, DOI 10.1016/j.jclepro.2011.09.012
   Jakhar SK, 2018, RESOUR CONSERV RECY, V139, P262, DOI 10.1016/j.resconrec.2018.08.019
   Jayaram J, 2014, INT J PROD ECON, V147, P472, DOI 10.1016/j.ijpe.2013.08.016
   Karipidis P, 2009, FOOD CONTROL, V20, P93, DOI 10.1016/j.foodcont.2008.02.008
   Kotsanopoulos KV, 2017, COMPR REV FOOD SCI F, V16, P760, DOI 10.1111/1541-4337.12293
   Kritchanchai D, 2004, IND MANAGE DATA SYST, V104, P384, DOI 10.1108/02635570410537471
   Kumar A, 2018, RESOUR CONSERV RECY, V131, P101, DOI 10.1016/j.resconrec.2017.12.024
   Kumar R, 2014, COMPET REV, V24, P414, DOI 10.1108/CR-06-2012-0016
   Kumar R, 2013, GLOB BUS REV, V14, P711, DOI 10.1177/0972150913501610
   Kumar S, 2011, SIMUL MODEL PRACT TH, V19, P2151, DOI 10.1016/j.simpat.2011.06.006
   Kumia S, 2015, J BUS RES, V68, P1906, DOI 10.1016/j.jbusres.2014.12.010
   Li Y, 2006, International Agri-Food Chains and Networks: Management and Organization, P163
   Luo W, 2018, PROG PHOTOVOLTAICS, V26, P859, DOI 10.1002/pip.3028
   Luthra S, 2018, ADV THE PRAC EMER MA, P209, DOI 10.1007/978-3-319-75013-2_16
   Luthra S, 2018, RESOUR CONSERV RECY, V138, P194, DOI 10.1016/j.resconrec.2018.07.005
   Luthra S, 2018, PROD PLAN CONTROL, V29, P705, DOI 10.1080/09537287.2018.1448126
   Luthra S, 2017, RESOUR CONSERV RECY, V125, P198, DOI 10.1016/j.resconrec.2017.02.018
   Mangina E, 2005, J FOOD ENG, V70, P403, DOI 10.1016/j.jfoodeng.2004.02.044
   Mangla SK, 2018, INT J PROD ECON, V203, P379, DOI 10.1016/j.ijpe.2018.07.012
   Mangla SK, 2016, J CLEAN PROD, V129, P608, DOI 10.1016/j.jclepro.2016.03.124
   Mangla SK, 2015, RESOUR CONSERV RECY, V104, P375, DOI 10.1016/j.resconrec.2015.01.001
   Manning L., 2004, British Food Journal, V106, P598, DOI 10.1108/00070700410553594
   Mathur A, 2012, PROD PLAN CONTROL, V23, P754, DOI 10.1080/09537287.2011.642150
   Maurya UK, 2015, IIMB MANAG REV, V27, P159, DOI 10.1016/j.iimb.2015.05.001
   Mishra N, 2017, PROD PLAN CONTROL, V28, P945, DOI 10.1080/09537287.2017.1336789
   Mohezar S, 2014, TRENDS FOOD SCI TECH, V38, P75, DOI 10.1016/j.tifs.2014.04.003
   Narula S. A., 2017, SUSTAIN CHALLENGES A, V212
   National Manufacturing Competitiveness Council, 2012, ENH FIRM LEV COMP IN
   Ngai EWT, 2008, INT J PROD ECON, V113, P223, DOI 10.1016/j.ijpe.2007.05.018
   NRAI, 2013, IND FOOD SERV REP
   O'Reilly S, 2015, INT J OPER PROD MAN, V35, P1362, DOI 10.1108/IJOPM-04-2014-0157
   Pan XF, 2018, COMPUT ECON, V52, P1139, DOI 10.1007/s10614-017-9745-x
   Pramatari K., 2015, SUPPLY CHAIN MANAG S, P183
   Pramatari K, 2007, SUPPLY CHAIN MANAG, V12, P210, DOI 10.1108/13598540710742527
   Rais M, 2014, NEHU J, V12, P37
   Rajesh R, 2015, COMPUT IND ENG, V87, P126, DOI 10.1016/j.cie.2015.04.028
   Raut RD, 2019, J CLEAN PROD, V215, P926, DOI 10.1016/j.jclepro.2019.01.139
   Regattieri A, 2007, J FOOD ENG, V81, P347, DOI 10.1016/j.jfoodeng.2006.10.032
   Ritchie B., 2000, MANAGE DECIS, V38, P575
   Riviera J. E., 2012, ENSURING SAFE FOODS
   Rueda X, 2017, J CLEAN PROD, V142, P2480, DOI 10.1016/j.jclepro.2016.11.026
   Saguy IS, 2014, TRENDS FOOD SCI TECH, V38, P136, DOI 10.1016/j.tifs.2014.05.006
   Sahay BS, 2006, SUPPLY CHAIN MANAG, V11, P15, DOI 10.1108/13598540610642439
   Sambamurthy V, 2003, MIS QUART, V27, P237
   Schroeder TC, 2012, FOOD POLICY, V37, P31, DOI 10.1016/j.foodpol.2011.10.005
   Shao J, 2016, J CLEAN PROD, V112, P3185, DOI 10.1016/j.jclepro.2015.10.113
   Sharma YK, 2019, MANAGE DECIS
   Shirani M., 2015, INT J SOCIAL BEHAV E, V9, P2761
   Singh Rajesh Kr, 2008, International Journal of Enterprise Network Management, V2, P248, DOI 10.1504/IJENM.2008.018780
   Singh RK, 2009, MANAG RES REV, V33, P54, DOI 10.1108/01409171011011562
   Singh RK, 2014, INT J INF SYST SUPPL, V7, P104, DOI 10.4018/ijisscm.2014070105
   Song ML, 2018, RESOUR CONSERV RECY, V129, P333, DOI 10.1016/j.resconrec.2016.08.005
   Song ML, 2018, MANAGE DECIS, V56, P188, DOI 10.1108/MD-04-2017-0375
   Song ML, 2017, ENVIRON SCI POLLUT R, V24, P1648, DOI 10.1007/s11356-016-7925-1
   Stefansson G., 2001, INT J SERVICES TECHN, V2, P187, DOI DOI 10.1504/IJSTM.2001.001599
   Su CM, 2016, J CLEAN PROD, V134, P469, DOI 10.1016/j.jclepro.2015.05.080
   Tatoglu E, 2016, INT J LOGIST-RES APP, V19, P181, DOI 10.1080/13675567.2015.1065802
   Thakkar J., 2009, MANAGEMENT RES NEWS, V32, P970, DOI DOI 10.1108/01409170910994178
   Thakkar J, 2013, PROD PLAN CONTROL, V24, P47, DOI 10.1080/09537287.2011.599119
   Thakur M, 2011, J FOOD ENG, V103, P417, DOI 10.1016/j.jfoodeng.2010.11.012
   Thakur V, 2019, J CLEAN PROD, V213, P847, DOI 10.1016/j.jclepro.2018.12.201
   Trienekens JH, 2012, ADV ENG INFORM, V26, P55, DOI 10.1016/j.aei.2011.07.007
   Tseng ML, 2018, RESOUR CONSERV RECY, V128, P118, DOI 10.1016/j.resconrec.2017.02.014
   Vaaland TI, 2007, SUPPLY CHAIN MANAG, V12, P20, DOI 10.1108/13598540710724374
   Verdouw CN, 2016, J FOOD ENG, V176, P128, DOI 10.1016/j.jfoodeng.2015.11.009
   Vickery SK, 2003, J OPER MANAG, V21, P523, DOI 10.1016/j.jom.2003.02.002
   Vlachos I, 2015, PROD PLAN CONTROL, V26, P1351, DOI 10.1080/09537287.2015.1049238
   Vlachos IP, 2014, EXPERT SYST APPL, V41, P5, DOI 10.1016/j.eswa.2013.07.006
   WTO, 2004, WORLD TRAD REP
   Xia XQ, 2015, J CLEAN PROD, V87, P811, DOI 10.1016/j.jclepro.2014.09.044
   Zhong R, 2017, IND MANAGE DATA SYST, V117, P2085, DOI 10.1108/IMDS-09-2016-0391
NR 113
TC 10
Z9 10
U1 21
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 10
EP 18
DI 10.1016/j.resconrec.2019.04.014
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700002
DA 2020-05-12
ER

PT J
AU Choi, JK
   Thangamani, D
   Kissock, K
AF Choi, Jun-Ki
   Thangamani, Dillip
   Kissock, Kelly
TI A systematic methodology for improving resource efficiency in small and
   medium-sized enterprises
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Resource efficiency; Sustainable manufacturing; Circular economy;
   Industrial resource assessment
ID ENERGY-EFFICIENCY; CIRCULAR ECONOMY; STREAMLINED LCA; INDICATORS;
   SUPPORT; FRAMEWORK; INDUSTRY; WASTE
AB This article offers a systematic and practical framework for identifying sustainable manufacturing practices from a resource efficiency perspective to assist small and medium-sized enterprises (SMEs) achieve industry-specific resource efficiency goals. It describes a tool called the Resource Efficiency Guidebook (REG) that combines a resource efficiency principle matrix and spreadsheet calculators to offer SMEs a systematic model for identifying and selecting industrial resource efficiency projects. REG contains assessment recommendations selected from industrial resource assessments performed in real manufacturing facilities. REG consists with six distinct resource categories where each category is accompanied by a list of common assessment recommendations (ARs). These ARs address specific improvements in resource efficiency and cost savings opportunities from across all genres of manufacturing industry. Each AR is accompanied by information containing all of the necessary calculations to re-produce the AR in another plant. Additionally, each resource category is accompanied by a set of best practices that explains the fundamentals of resource efficiency principles. This paper presents brief case studies to demonstrate the effectiveness of the REG for improving resource efficiency both economically and environmentally and discusses for the continued development of holistic and practical methods for assessing, developing and implementing resource efficiencies.
C1 [Choi, Jun-Ki; Kissock, Kelly] Univ Dayton, Mech & Aerosp Engn, Dayton, OH 45409 USA.
   [Choi, Jun-Ki; Kissock, Kelly] Univ Dayton, Ind Assessment Ctr, Dayton, OH 45409 USA.
   [Thangamani, Dillip] Midmark Corp, 675 Heathrow Dr, Lincolnshire, IL 60069 USA.
RP Choi, JK (reprint author), Univ Dayton, Mech & Aerosp Engn, Dayton, OH 45409 USA.
EM jchoi1@udayton.edu
FU US Department of EnergyUnited States Department of Energy (DOE)
FX We would like to express our gratitude to the US Department of Energy
   for supporting this work through the Industrial Assessment Center
   program. We acknowledge previous and current UD-IAC students for their
   contributions to this continuing effort and thank our industrial
   partners for their significant contributions.
CR Arena M, 2013, J CLEAN PROD, V41, P105, DOI 10.1016/j.jclepro.2012.09.031
   Argonne National Laboratory, 2006, DEV APPL GREET 2 7 T
   Balcazar N, 2010, REV ENVIRON SCI BIO, V9, P29, DOI 10.1007/s11157-010-9191-x
   Bunse K, 2011, J CLEAN PROD, V19, P667, DOI 10.1016/j.jclepro.2010.11.011
   Choi J.-K, 2009, QUEST SUSTAINABLE PR
   Choi J.-K., 2018, 25 CIRP LIF CYCL ENG
   Choi J.-K., 2013, IND ENERGY ASSESSMEN
   Choi JK, 2018, ENERG POLICY, V123, P289, DOI 10.1016/j.enpol.2018.08.066
   Choi JK, 2016, RESOUR CONSERV RECY, V107, P82, DOI 10.1016/j.resconrec.2015.12.007
   Cocca P, 2010, INT J PRODUCT PERFOR, V59, P186, DOI 10.1108/17410401011014258
   Corcelli F, 2018, RESOUR CONSERV RECY, V131, P313, DOI 10.1016/j.resconrec.2017.11.028
   da Cruz NF, 2014, RESOUR CONSERV RECY, V85, P1, DOI 10.1016/j.resconrec.2014.01.006
   Despeisse M, 2012, J CLEAN PROD, V31, P30, DOI 10.1016/j.jclepro.2012.02.027
   Di Maio F, 2017, RESOUR CONSERV RECY, V122, P163, DOI 10.1016/j.resconrec.2017.02.009
   Ellen MacArthur Foundation, 2013, CIRC EC OPP CONS GOO
   Espinoza LAT, 2018, RESOUR CONSERV RECY, V129, P120, DOI 10.1016/j.resconrec.2017.10.022
   European Commission, 2008, COM2008699 EUR COMM
   European Commission, 2015, RESOUR EFFIEICNCY GR, DOI [10.2873/232959.ET-01-15-921-EN-N, DOI 10.2873/232959.ET-01-15-921-EN-N]
   Fischer-Kowalski M, 2011, DECOUPLING NATURAL R
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Hernandez AG, 2018, RESOUR CONSERV RECY, V133, P132, DOI 10.1016/j.resconrec.2018.02.008
   Huysman S, 2017, RESOUR CONSERV RECY, V120, P46, DOI 10.1016/j.resconrec.2017.01.013
   Jayal AD, 2010, CIRP J MANUF SCI TEC, V2, P144, DOI 10.1016/j.cirpj.2010.03.006
   Joung CB, 2013, ECOL INDIC, V24, P148, DOI 10.1016/j.ecolind.2012.05.030
   Jovane F, 2008, CIRP ANN-MANUF TECHN, V57, P641, DOI 10.1016/j.cirp.2008.09.010
   King AM, 2006, SUSTAIN DEV, V14, P257, DOI 10.1002/sd.271
   Klinglmair M, 2017, RESOUR CONSERV RECY, V122, P1, DOI 10.1016/j.resconrec.2017.01.012
   Li H, 2018, RESOUR CONSERV RECY, V136, P389, DOI 10.1016/j.resconrec.2018.05.014
   Mann JG, 2003, RESOUR CONSERV RECY, V37, P175, DOI 10.1016/S0921-3449(02)00097-6
   Martinico-Perez MFG, 2018, RESOUR CONSERV RECY, V138, P74, DOI 10.1016/j.resconrec.2018.07.003
   McDonough W., 2010, CRADLE CRADLE REMAKI
   Pfaff M, 2018, RESOUR CONSERV RECY, V139, P205, DOI 10.1016/j.resconrec.2018.08.017
   Rahimifard S, 2010, CIRP ANN-MANUF TECHN, V59, P25, DOI 10.1016/j.cirp.2010.03.048
   Randar MH, 2016, APPL THERM ENG, V96, P217, DOI 10.1016/j.applthermaleng.2015.11.068
   Rastogi A, 2017, APPL ENERG, V205, P732, DOI 10.1016/j.apenergy.2017.08.149
   Safari F., 2015, International Journal of Recycling of Organic Waste in Agriculture, V4, P121, DOI 10.1007/s40093-015-0091-5
   Sarkar P, 2011, SUSTAINABLE MANUFACT, V54792, P943
   Seow Y, 2011, CIRP J MANUF SCI TEC, V4, P258, DOI 10.1016/j.cirpj.2011.03.007
   Smith L, 2012, INT J PROD ECON, V140, P227, DOI 10.1016/j.ijpe.2012.01.036
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Tanaka K, 2008, ENERG POLICY, V36, P2887, DOI 10.1016/j.enpol.2008.03.032
   Tanaka K, 2011, ENERG POLICY, V39, P6532, DOI 10.1016/j.enpol.2011.07.058
   U. S. Department of Energy, 2012, TRANSP EN DAT BOOK H, P31
   U. S. EPA, 2014, EN REC WAST MUN SOL
   UD-IAC, 2016, RES EFF GUID
   UNEP, 2011, PRE SME PROM RES EFF
   USCB, 2014, DET STAT IND US
   USDOC, 2014, SUST MAN
   Weinert N, 2011, CIRP ANN-MANUF TECHN, V60, P41, DOI 10.1016/j.cirp.2011.03.015
   Wu HY, 2015, J MATER CYCLES WASTE, V17, P637, DOI 10.1007/s10163-015-0404-9
   Zilahy G, 2004, J CLEAN PROD, V12, P311, DOI 10.1016/S0959-6526(03)00016-7
   Ziout A, 2013, CIRP J MANUF SCI TEC, V6, P59, DOI 10.1016/j.cirpj.2012.10.006
NR 52
TC 1
Z9 1
U1 2
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 19
EP 27
DI 10.1016/j.resconrec.2019.04.015
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700003
OA Bronze
DA 2020-05-12
ER

PT J
AU Ghadimi, P
   Wang, C
   Azadnia, AH
   Lim, MK
   Sutherland, JW
AF Ghadimi, Pezhman
   Wang, Chao
   Azadnia, Amir Hossein
   Lim, Ming K.
   Sutherland, John W.
TI Life cycle-based environmental performance indicator for the
   coal-to-energy supply chain: A Chinese case application
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Coal consumption and energy production; Coal-to-energy supply chain;
   Environmental performance indicator; Life cycle analysis; Fuzzy
   inference system
ID GREENHOUSE-GAS EMISSIONS; IMPACT ASSESSMENT; ELECTRICITY-GENERATION;
   SUSTAINABILITY ASSESSMENT; POWER; CONSUMPTION; LCA; IMPROVEMENT; OPTIONS
AB Coal consumption and energy production (CCEP) has received increasing attention since coal-fired power plants play a dominant role in the power sector worldwide. In China, coal is expected to retain its primary energy position over the next few decades. However, a large share of CO2 emissions and other environmental hazards, such as SO2 and NOx, are attributed to coal consumption. Therefore, understanding the environmental implications of the life cycle of coal from its production in coal mines to its consumption at coal-fired power plants is an essential task. Evaluation of such environmental burdens can be conducted using the life cycle assessment (LCA) tool. The main issues with the traditional LCA results are the lack of a numerical magnitude associated with the performance level of the obtained environmental burden values and the inherent uncertainty associated with the output results. This issue was addressed in this research by integrating the traditional LCA methodology with a weighted fuzzy inference system model, which is applied to a Chinese coal-to-energy supply chain system to demonstrate its applicability and effectiveness. Regarding the coal-to-energy supply chain under investigation, the CCEP environmental performance has been determined as "medium performance", with an indicator score of 39.15%. Accordingly, the decision makers suggested additional scenarios (redesign, equipment replacement, etc.) to improve the performance. A scenario-based analysis was designed to identify alternative paths to mitigate the environmental impact of the coal-to-energy supply chain. Finally, limitations and possible future work are discussed, and the conclusions are presented.
C1 [Ghadimi, Pezhman] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin, Ireland.
   [Ghadimi, Pezhman] Beijing Univ Technol, Beijing Dublin Int Coll, Beijing 100124, Peoples R China.
   [Wang, Chao] Beijing Univ Technol, Coll Econ & Management, Res Base Beijing Modern Mfg Dev, Beijing, Peoples R China.
   [Wang, Chao] Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA.
   [Wang, Chao] Boston Univ, Dept Phys, 590 Commonwealth Ave, Boston, MA 02215 USA.
   [Azadnia, Amir Hossein] Islamic Azad Univ, Ayatollah Amoli Branch, Dept Ind Engn, Amol, Iran.
   [Lim, Ming K.] Chongqing Univ, Coll Mech Engn, Chongqing, Peoples R China.
   [Lim, Ming K.] Coventry Univ, Ctr Business Soc, Coventry, W Midlands, England.
   [Sutherland, John W.] Purdue Univ, Environm & Ecol Engn, W Lafayette, IN 47907 USA.
RP Wang, C (reprint author), Beijing Univ Technol, Coll Econ & Management, Beijing 100124, Peoples R China.
EM chaowanghn@vip.163.com
RI Lim, Ming K/D-1476-2017
OI Lim, Ming K/0000-0003-0809-9431; Ghadimi, Pezhman/0000-0003-0153-9035;
   Wang, Chao/0000-0003-2076-9493
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [61603011, 61773029, 71772016]; Beijing Social
   Science Foundation [16JDGLC005]; International Postdoctoral Exchange
   Fellowship Program [20170016]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2015M580033]; Beijing
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2016ZZ-11]; International Research Cooperation Seed Fund of Beijing
   University of Technology, China [2018B22]; National Science
   FoundationNational Science Foundation (NSF) [PHY-1505000, CMMI-1125290,
   CHE-1213217]; DTRAUnited States Department of DefenseDefense Threat
   Reduction Agency [HDTRA1-14-1-0017]
FX This work has been supported in part by the National Natural Science
   Foundation of China (61603011, 61773029, and 71772016), Beijing Social
   Science Foundation (16JDGLC005), International Postdoctoral Exchange
   Fellowship Program (20170016), China Postdoctoral Science Foundation
   (2015M580033), Beijing Postdoctoral Science Foundation (2016ZZ-11), and
   International Research Cooperation Seed Fund of Beijing University of
   Technology, China (2018B22). We would like to express our gratitude
   toward Mr. Wable Jill and Ms. Anna Clapp for their invaluable time spent
   on proofreading this manuscript. Moreover, we gratefully acknowledge the
   discussions with and the support of Professor H. Eugene Stanley from
   Boston University. The Boston University Center for Polymer Studies is
   supported by National Science Foundation Grants PHY-1505000,
   CMMI-1125290, and CHE-1213217, and by DTRA Grant HDTRA1-14-1-0017.
CR Afrinaldi F, 2014, J CLEAN PROD, V67, P159, DOI 10.1016/j.jclepro.2013.12.010
   Agarski B, 2016, J CLEAN PROD, V112, P3256, DOI 10.1016/j.jclepro.2015.09.077
   Aguirre-Villegas HA, 2017, J CLEAN PROD, V157, P47, DOI 10.1016/j.jclepro.2017.03.232
   Apergis N, 2010, ENERG POLICY, V38, P1353, DOI 10.1016/j.enpol.2009.11.016
   Atilgan B, 2016, ENERGIES, V9, DOI 10.3390/en9010031
   Atilgan B, 2015, J CLEAN PROD, V106, P555, DOI 10.1016/j.jclepro.2014.07.046
   Awuah-Offei K, 2011, INT J LIFE CYCLE ASS, V16, P82, DOI 10.1007/s11367-010-0246-6
   Babbitt CW, 2005, J CLEAN PROD, V13, P903, DOI 10.1016/j.jclepro.2004.04.007
   Balaguera A, 2018, RESOUR CONSERV RECY, V132, P37, DOI 10.1016/j.resconrec.2018.01.003
   Benetto E, 2008, ENVIRON MODELL SOFTW, V23, P1461, DOI 10.1016/j.envsoft.2008.04.008
   Bian Z, 2010, MIN SCI TECHNOL CHIN, V20, P215, DOI DOI 10.1016/S1674-5264(09)60187-3
   Bovea MD, 2003, INT J PROD RES, V41, P593, DOI 10.1080/0020754021000033878
   Burchart-Korol D, 2016, SCI TOTAL ENVIRON, V562, P61, DOI 10.1016/j.scitotenv.2016.03.202
   Campbell R. J., 2013, INCREASING EFFICIENC
   Chang DY, 1996, EUR J OPER RES, V95, P649, DOI 10.1016/0377-2217(95)00300-2
   Cheng YP, 2011, INT J GREENH GAS CON, V5, P157, DOI 10.1016/j.ijggc.2010.07.007
   Cornelissen AMG, 2001, AGR ECOSYST ENVIRON, V86, P173, DOI 10.1016/S0167-8809(00)00272-3
   Cui XW, 2012, ENERGY, V45, P952, DOI 10.1016/j.energy.2012.06.063
   Ding N, 2017, RESOUR CONSERV RECY, V119, P47, DOI 10.1016/j.resconrec.2016.07.010
   DOE -National Energy Technology Laboratory, 2008, DOENETL20081329
   Dones R., 2007, ECOINVENT REPORT, V5
   Egilmez G, 2016, J CLEAN PROD, V129, P622, DOI 10.1016/j.jclepro.2016.03.111
   Fitzgerald BG, 2012, ECOL INDIC, V18, P371, DOI 10.1016/j.ecolind.2011.12.002
   Ghadimi P, 2012, J CLEAN PROD, V33, P10, DOI 10.1016/j.jclepro.2012.05.010
   Gonzalez B, 2002, RESOUR CONSERV RECY, V37, P61, DOI 10.1016/S0921-3449(02)00069-1
   Govindan K, 2018, INT J PROD ECON, V195, P419, DOI 10.1016/j.ijpe.2017.03.003
   Guereca LP, 2007, INT J LIFE CYCLE ASS, V12, P488, DOI 10.1065/lca2006.10.276
   Guo Y, 2018, RESOUR CONSERV RECY, V139, P387, DOI 10.1016/j.resconrec.2018.05.018
   He G, 2017, RESOUR CONSERV RECY, V121, P3, DOI 10.1016/j.resconrec.2016.11.003
   Hellweg S, 2014, SCIENCE, V344, P1109, DOI 10.1126/science.1248361
   Hossain MU, 2017, RESOUR CONSERV RECY, V120, P199, DOI 10.1016/j.resconrec.2016.12.012
   Jie Xu, 2013, Applied Mechanics and Materials, V367, P333, DOI 10.4028/www.scientific.net/AMM.367.333
   Khoshnevisan B, 2014, J CLEAN PROD, V73, P183, DOI 10.1016/j.jclepro.2013.09.057
   KIM T, 2016, SUSTAINABILITY-BASEL, V8, DOI DOI 10.3390/SU8040389
   Korre A, 2010, INT J GREENH GAS CON, V4, P289, DOI 10.1016/j.ijggc.2009.08.005
   Liu G, 2012, PROCEDIA ENGINEER, V49, P35, DOI 10.1016/j.proeng.2012.10.109
   Liu KFR, 2012, INT J LIFE CYCLE ASS, V17, P845, DOI 10.1007/s11367-012-0407-x
   Luo GF, 2017, ENERGIES, V10, DOI 10.3390/en10111855
   MAMDANI EH, 1974, P I ELECTR ENG, V121, P1585, DOI 10.1049/piee.1974.0328
   Mascle C, 2008, INT J PROD ECON, V112, P5, DOI 10.1016/j.ijpe.2006.08.016
   Memon FA, 2007, ENVIRON MONIT ASSESS, V129, P27, DOI 10.1007/s10661-006-9422-3
   Morais J, 2011, RESOUR CONSERV RECY, V55, P1109, DOI 10.1016/j.resconrec.2011.06.011
   Onat NC, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9050706
   Pell R, 2019, RESOUR CONSERV RECY, V142, P267, DOI 10.1016/j.resconrec.2018.11.022
   Rakotoson V, 2017, J CLEAN PROD, V168, P755, DOI 10.1016/j.jclepro.2017.09.055
   Schneider UA, 2011, AGR SYST, V104, P204, DOI 10.1016/j.agsy.2010.11.003
   Sengul H, 2016, J CLEAN PROD, V129, P478, DOI 10.1016/j.jclepro.2016.04.025
   Si H, 2010, INT J COAL GEOL, V81, P163, DOI 10.1016/j.coal.2009.11.004
   Singh B, 2015, RESOUR CONSERV RECY, V100, P49, DOI 10.1016/j.resconrec.2015.03.010
   Skone T., 2010, LIFE CYCLE ANAL INTE
   Spath PL, 1999, LIFE CYCLE ASSESSMEN
   Stamford L, 2012, INT J ENERG RES, V36, P1263, DOI 10.1002/er.2962
   State Administration of Coal Mine Safety of China, 2006, SPEC ID CLASS GASS M
   Su SS, 2017, RESOUR CONSERV RECY, V121, P156, DOI 10.1016/j.resconrec.2016.06.004
   Sun D, 2018, RESOUR CONSERV RECY, V129, P416, DOI 10.1016/j.resconrec.2016.09.021
   Tseng ML, 2018, RESOUR CONSERV RECY, V128, P118, DOI 10.1016/j.resconrec.2017.02.014
   United Nations, 2015, TRANSF OUR WORLD 203
   Vujic J, 2012, ENERGY, V45, P31, DOI 10.1016/j.energy.2012.02.011
   Wang C., 2011, THESIS BEIJING JIAOT
   Wang C, 2019, J CLEAN PROD, V206, P741, DOI 10.1016/j.jclepro.2018.09.172
   Wang C, 2014, J IND ENG MANAG-JIEM, V7, P311, DOI 10.3926/jiem.1053
   Weckenmann A, 2001, INT J LIFE CYCLE ASS, V6, P13, DOI 10.1007/BF02977589
   Whitaker M, 2012, J IND ECOL, V16, pS53, DOI 10.1111/j.1530-9290.2012.00465.x
   Widder S, 2011, SUSTAINABILITY ASSES
   World Wide Fund for Nature (WWF), 2016, LIV PLAN REP 2016
   Yang D, 2017, RESOUR CONSERV RECY, V119, P60, DOI 10.1016/j.resconrec.2016.06.017
   Yang Q, 2019, RESOUR CONSERV RECY, V141, P123, DOI 10.1016/j.resconrec.2018.10.016
   Yu SW, 2014, APPL ENERG, V114, P290, DOI 10.1016/j.apenergy.2013.09.062
   Zhou HR, 2019, RESOUR CONSERV RECY, V144, P74, DOI 10.1016/j.resconrec.2019.01.031
NR 69
TC 2
Z9 2
U1 7
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 28
EP 38
DI 10.1016/j.resconrec.2019.04.021
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700004
DA 2020-05-12
ER

PT J
AU Mavi, RK
   Fathi, A
   Saen, RF
   Mavi, NK
AF Mavi, Reza Kiani
   Fathi, Amirali
   Saen, Reza Farzipoor
   Mavi, Neda Kiani
TI Eco-innovation in transportation industry: A double frontier common
   weights analysis with ideal point method for Malmquist productivity
   index
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Eco-innovation; Environmental efficiency; Transportation; Data
   envelopment analysis; Double frontier; Common set of weights
ID DATA ENVELOPMENT ANALYSIS; EFFICIENCY ANALYSIS; ENVIRONMENTAL
   EFFICIENCY; ENERGY EFFICIENCY; DEA; PERFORMANCE; SUSTAINABILITY; GREEN;
   CHINA; DRIVERS
AB Transportation industry is one of the major contributors to the environmental pollution. Analyzing efficiency of this industry helps people and societies to enhance their awareness of its performance and develop managerial strategies. The need for sustainable development in transportation industry requires efficiency analysis over time. Malmquist productivity index (MPI) is a popular approach for performance evaluation during consecutive periods. This study offers a novel analysis and contribution to the knowledge of efficiency evaluation with DEA by (i) proposing a novel common set of weights model for double frontier DEA, (ii) dealing with undesirable outputs for efficiency analysis, and (iii) deriving a common set of weights for Malmquist productivity index using ideal point method. This paper investigates freight transportation in Iran to illustrate the applicability of the proposed CSW model. Developing CSW for MPI analysis to decompose overall efficiency into efficiency change and technical change enables decision makers to accurately trace the eco-innovation and environmental efficiency in this industry. Results show that majority of DMUs (except 4 DMUs) have experienced a constant or declining trend in terms of eco-innovation and environmental efficiency during 2014-2017.
C1 [Mavi, Reza Kiani] Edith Cowan Univ, Sch Business & Law, Markets & Serv Res Ctr, 270 Joondalup Dr, Joondalup, WA 6027, Australia.
   [Fathi, Amirali] Islamic Azad Univ, Dept Management, UAE Branch, Dubai, U Arab Emirates.
   [Saen, Reza Farzipoor] Islamic Azad Univ, Dept Ind Management, Karaj Branch, Fac Management & Accounting, Karaj, Iran.
   [Mavi, Neda Kiani] Edith Cowan Univ, Sch Business & Law, Joondalup, WA 6027, Australia.
RP Mavi, RK (reprint author), Edith Cowan Univ, Sch Business & Law, Markets & Serv Res Ctr, 270 Joondalup Dr, Joondalup, WA 6027, Australia.
EM r.kianimavi@ecu.edu.au; aafdba@gmail.com; farzipour@yahoo.com;
   n.kianimavi@ecu.edu.au
RI Saen, Reza Farzipoor/AAA-2089-2019; Fathi, Amirali/A-1081-2019; Saen,
   Reza Farzipoor/L-2958-2013
OI Saen, Reza Farzipoor/0000-0002-0851-6509; Fathi,
   Amirali/0000-0003-4127-2355
CR Alirezaee MR, 2010, INT T OPER RES, V17, P667, DOI 10.1111/j.1475-3995.2009.00759.x
   Amirteimoori A, 2007, APPL MATH COMPUT, V186, P10, DOI 10.1016/j.amc.2006.07.006
   Badiezadeh T, 2018, COMPUT OPER RES, V98, P284, DOI 10.1016/j.cor.2017.06.003
   Beltran-Esteve M, 2015, ENERG ECON, V51, P570, DOI 10.1016/j.eneco.2015.08.018
   Cainelli G, 2015, J CLEAN PROD, V94, P211, DOI 10.1016/j.jclepro.2015.02.008
   Carter CR, 2002, TRANSPORT RES E-LOG, V38, P37, DOI 10.1016/S1366-5545(01)00008-4
   CAVES DW, 1982, ECONOMETRICA, V50, P1393, DOI 10.2307/1913388
   Chang ICC, 2016, REG STUD, V50, P929, DOI 10.1080/00343404.2015.1108519
   Chang YT, 2013, ENERG POLICY, V58, P277, DOI 10.1016/j.enpol.2013.03.011
   CHARNES A, 1978, EUR J OPER RES, V2, P429, DOI 10.1016/0377-2217(78)90138-8
   COHEN WM, 1990, ADMIN SCI QUART, V35, P128, DOI 10.2307/2393553
   Cook WD, 2007, EUR J OPER RES, V178, P207, DOI 10.1016/j.ejor.2006.01.019
   Costantini V, 2016, J CLEAN PROD, V155, P1
   Cui Q, 2014, TRANSPORT RES D-TR E, V29, P1, DOI 10.1016/j.trd.2014.03.007
   den Hartog H, 2018, J CLEAN PROD, V181, P692, DOI 10.1016/j.jclepro.2018.02.003
   Djekic I, 2018, J CLEAN PROD, V180, P107, DOI 10.1016/j.jclepro.2018.01.185
   EIO, 2012, PAV WAY GREEN EC EC
   Environmental Protection Department HKSAR, 2004, AIR POLL GREENH GAS
   Fare R., 1992, J PROD ANAL, V1, P85, DOI DOI 10.1007/BF00158770
   FARRELL MJ, 1957, J R STAT SOC SER A-G, V120, P253, DOI 10.2307/2343100
   Fathi A, 2018, J CLEAN PROD, V184, P696, DOI 10.1016/j.jclepro.2018.02.256
   Florida R, 1996, CALIF MANAGE REV, V39, P80, DOI 10.2307/41165877
   Fussler C., 1996, ECOINNOVATION BREAKT
   Golany B., 1993, J PROD ANAL, V4, P419, DOI DOI 10.1007/BF01073549
   Gomez-Calvet R, 2016, COMPUT OPER RES, V66, P336, DOI 10.1016/j.cor.2015.07.018
   Guimaraes VDA, 2018, RENEW SUST ENERG REV, V93, P732, DOI 10.1016/j.rser.2018.05.015
   Gupta P., 2018, RESOUR POLICY, DOI [10.1016/j.resourpol.2018.04.007, DOI 10.1016/J.RESOURPOL.2018.04.007]
   Hemmelskamp J, 1999, INFLUENCE ENV POLICY
   Hojnik J, 2016, J CLEAN PROD, V133, P812, DOI 10.1016/j.jclepro.2016.06.002
   Holstein W, 2014, ENCY BRITANNICA
   Jaffe AB, 2003, HANDB ECON, V20, P461
   Jaffe AB, 2002, ENVIRON RESOUR ECON, V22, P41, DOI 10.1023/A:1015519401088
   Jahanshahloo GR, 2011, J OPER RES SOC, V62, P1796, DOI 10.1057/jors.2010.156
   Jahanshahloo GR, 2011, APPL MATH MODEL, V35, P218, DOI 10.1016/j.apm.2010.05.019
   Jang EK, 2015, SUSTAINABILITY-BASEL, V7, P12586, DOI 10.3390/su70912586
   Jansson J, 2017, J CLEAN PROD, V154, P176, DOI 10.1016/j.jclepro.2017.03.186
   Ji YB, 2010, STATA J, V10, P267, DOI 10.1177/1536867X1001000207
   Kao C, 2010, OMEGA-INT J MANAGE S, V38, P484, DOI 10.1016/j.omega.2009.12.005
   Kemp R., 2007, FINAL REPORT MEI PRO
   Kemp R, 1998, STUDIES TECHNOLOGY I
   Kemp R, 2008, CHEM IND-LONDON, P17
   Klemmer P., 1999, ENV INNOVATION INCEN
   Lapple D, 2015, FOOD POLICY, V51, P1, DOI 10.1016/j.foodpol.2014.11.003
   Lotfi FH, 2013, COMPUT IND ENG, V64, P631, DOI 10.1016/j.cie.2012.12.006
   Makui A., 2008, J IND SYSTEMS ENG, V1, P293
   Mavi RK, 2018, TRANSPORT POLICY, V72, P187, DOI 10.1016/j.tranpol.2018.03.010
   Mavi RK, 2019, TECHNOL FORECAST SOC, V144, P553, DOI 10.1016/j.techfore.2018.01.035
   Mavi RK, 2017, IADIS-INT J COMPUT S, V12, P133
   Mavi RK, 2013, J APPL MATH, DOI 10.1155/2013/906743
   OECD, 2009, SUST MAN EC FRAM PRA
   Omrani H, 2013, COMPUT IND ENG, V66, P1163, DOI 10.1016/j.cie.2013.07.023
   PARK J, 2017, SUSTAINABILITY-BASEL, V9, DOI DOI 10.3390/SU9010014
   Picazo-Tadeo AJ, 2011, J ENVIRON MANAGE, V92, P1154, DOI 10.1016/j.jenvman.2010.11.025
   PORTER ME, 1995, J ECON PERSPECT, V9, P97, DOI 10.1257/jep.9.4.97
   Rashidi K, 2015, ENERG ECON, V50, P18, DOI 10.1016/j.eneco.2015.04.018
   Rennings K, 2000, ECOL ECON, V32, P319, DOI 10.1016/S0921-8009(99)00112-3
   Rodriguez JA, 2017, J CLEAN PROD, V142, P2423, DOI 10.1016/j.jclepro.2016.11.033
   Saen Reza Farzipoor, 2009, International Journal of Procurement Management, V2, P180, DOI 10.1504/IJPM.2009.023406
   Seiford LM, 2002, EUR J OPER RES, V142, P16, DOI 10.1016/S0377-2217(01)00293-4
   Sueyoshi T, 2011, EUR J OPER RES, V211, P76, DOI 10.1016/j.ejor.2010.11.013
   Sun JS, 2013, APPL MATH MODEL, V37, P6301, DOI 10.1016/j.apm.2013.01.010
   Takamura Y., 2003, SOCIOECONOMIC PLANNI, V37, P85, DOI DOI 10.1016/S0038-0121(02)00049-6
   Tavana O.M., 2015, INT J APPL MANAGE SC, V7, P81
   THOMPSON RG, 1990, J ECONOMETRICS, V46, P93, DOI 10.1016/0304-4076(90)90049-Y
   Wang YM, 2007, J COMPUT APPL MATH, V206, P209, DOI 10.1016/j.cam.2006.06.012
   Wang YM, 2013, ECON MODEL, V33, P182, DOI 10.1016/j.econmod.2013.04.021
   Wang YM, 2011, MATH COMPUT MODEL, V54, P2760, DOI 10.1016/j.mcm.2011.06.064
   Wang YM, 2011, EXPERT SYST APPL, V38, P9122, DOI 10.1016/j.eswa.2011.01.004
   Wang YM, 2009, INT J PROD RES, V47, P6663, DOI 10.1080/00207540802314845
   Woo C, 2015, RENEW SUST ENERG REV, V47, P367, DOI 10.1016/j.rser.2015.03.070
   World Commission and Environment and Development (WCED), 1987, OUR COMMON FUTURE
   Wu J, 2016, TRANSPORT RES D-TR E, V48, P460, DOI 10.1016/j.trd.2015.08.001
   Yang FX, 2015, EUR J OPER RES, V247, P1003, DOI 10.1016/j.ejor.2015.07.029
   ZHANG Y, 2017, SUSTAINABILITY-BASEL, V9, DOI DOI 10.3390/SU9112085
   Zheng J, 2013, RES TRANSP BUS MANAG, V7, P4, DOI 10.1016/j.rtbm.2013.02.001
   Zhou GH, 2014, EXPERT SYST APPL, V41, P709, DOI 10.1016/j.eswa.2013.07.095
   Zhou P, 2007, ECOL ECON, V62, P291, DOI 10.1016/j.ecolecon.2006.12.020
   Ziolkowska JR, 2015, ENERG ECON, V51, P21, DOI 10.1016/j.eneco.2015.06.012
NR 78
TC 2
Z9 2
U1 10
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 39
EP 48
DI 10.1016/j.resconrec.2019.04.017
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700005
DA 2020-05-12
ER

PT J
AU Zhang, YP
   Zhao, HT
   Yu, YD
   Wang, T
   Zhou, WJ
   Jinag, J
   Chen, DJ
   Zhu, B
AF Zhang, Yupeng
   Zhao, Haotian
   Yu, Yadong
   Wang, Tao
   Zhou, Wenji
   Jinag, Jian
   Chen, Dingjiang
   Zhu, Bing
TI Copper in-use stocks accounting at the sub-national level in China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Copper; In-use stocks; Sub-national accounting; Bottom-up approach;
   China
ID SPATIAL CHARACTERIZATION; MATERIAL FLOW; METAL STOCKS; ALUMINUM
AB Copper in-use stocks play an important role in copper cycle. Investigating copper in-use stocks is essential to realize more efficient and sustainable utilization of copper resources. A systematic analysis at the sub-national level is still inadequate, especially for those sub-regions of the studied area. In order to fill the research gap, this study uses Chinads Sichuan Province as a case to assess copper in-use stock and its spatial distribution at the sub national level in China. Employing a bottom-up modelling approach, this study calculates the copper in-use stocks in Sichuan and its 21 prefectural sub-regions in 2014. Our results show that, 1) copper in-use stocks of the whole province were 1,891 Gg and the amount of in-use stocks per capita was 231%, which is far below the level of the developed countries and implies significant growth potential in the future. 2) Among all the categories calculated, residential buildings, non-residential buildings, automobiles, air conditioners, power substations, refrigerators, power transmission and distribution cables were the main reservoirs of copper and collectively took nearly 80% of the total stocks. Stocks per capita for the prefectural sub-regions in Sichuan are relatively close, ranged from 17.1 to 28.8 kg. 3) Distinction between rural and urban copper in-use stocks indicates Sichuanos rural copper stocks occupy an indispensable proportion. 4) The stocks density for prefectural regions varied from 149 kg/km(2) to 34,302 kg/km(2), indicating significant imbalance of spatial distribution characteristic and an unignorable intra-provincial disparity.
C1 [Zhang, Yupeng; Jinag, Jian; Chen, Dingjiang; Zhu, Bing] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
   [Zhao, Haotian] Tsinghua Univ, Dept Chem, Beijing 100084, Peoples R China.
   [Yu, Yadong] East China Univ Sci & Technol, Sch Business, Shanghai 200237, Peoples R China.
   [Wang, Tao] Tongji Univ, Circular Econ Res Inst, Shanghai 200433, Peoples R China.
   [Zhou, Wenji; Zhu, Bing] Int Inst Appl Syst Anal, Schlosspl 1, A-2361 Laxenburg, Austria.
RP Zhu, B (reprint author), Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
EM bingzhu@tsinghua.edu.cn
OI Yu, Yadong/0000-0003-4144-0208
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [41661144023, 71690244]
FX The National Natural Science Foundation of China (41661144023 and
   71690244) financially supports this study. We would like to thank Mr.
   Huajun Wang, Deputy Secretary-General of China Nonferrous Metals
   Industry Association, Ms. Yanhui Zhang, Deputy Secretary General of
   China National Resources Recycling Association, Professor Xu Ji from
   Sichuan University, Professor Shiqing Liu from Sichuan Academy of Social
   Sciences, Mr. Jun Chen from State Grid Sichuan Electric Power Company
   and Mr. Rui Pan from State Grid Chengdu Power Supply Company. We are
   also grateful for the informative discussion with experts at 2018
   International Conference on Resource Sustainability (Beijing, June 27,
   2018). Many thanks to four anonymous reviewers whose comments improved
   the presentation of our work.
CR [Anonymous], 2014, CHENGD AIRL FLEET DE
   Chen J., 2017, COMMUNICATION
   Chen WQ, 2015, ENVIRON SCI TECHNOL, V49, P3048, DOI 10.1021/es504353s
   China Electric Council (CEC), 2015, STAT COMP EL POW IND
   China Nonferrous Metals Industry Association (CNIA), 2015, STAT COMP NONF MET I
   Copper Development Association (CDA), 2009, COPP FACTS
   Daigo I, 2009, RESOUR CONSERV RECY, V53, P208, DOI 10.1016/j.resconrec.2008.11.010
   Department of Transportation of Sichuan Province (DTSP), 2015, SICH TRANSP YB
   Development Planning Division for Civil Aviation Administration of China (CACC), 2015, STAT DAT CIV AV CHIN
   Drakonakis K, 2007, RESOUR CONSERV RECY, V49, P406, DOI 10.1016/j.resconrec.2006.05.005
   Enerdata. eu, 2008, AV FLOOR AR PER CAP
   Fishman T, 2016, ENVIRON SCI TECHNOL, V50, P3729, DOI 10.1021/acs.est.5b05790
   Fishman T, 2015, ECOL ECON, V113, P76, DOI 10.1016/j.ecolecon.2015.03.001
   Gerst MD, 2008, ENVIRON SCI TECHNOL, V42, P7038, DOI 10.1021/es800420p
   Gloser S, 2013, ENVIRON SCI TECHNOL, V47, P6564, DOI 10.1021/es400069b
   Gordon RB, 2006, P NATL ACAD SCI USA, V103, P1209, DOI 10.1073/pnas.0509498103
   Guo Xue-yi, 2017, China Environmental Science, V37, P3464
   Han J, 2013, SUSTAIN SCI, V8, P553, DOI 10.1007/s11625-012-0196-y
   Hao H, 2017, CLEAN TECHNOL ENVIR, V19, P1509, DOI 10.1007/s10098-016-1325-6
   Jiang X. J., 2016, NONFERROUS MET SCI E, V7, P104, DOI [10.13264/J.CNKI.YSJSKX.2016.05.019, DOI 10.13264/J.CNKI.YSJSKX.2016.05.019]
   Li J. H., 2011, RES WASTE ELECT ELEC
   Lin L., 2013, RESHAPING EC GEOGRAP
   Liu W., 2017, COMMUNICATION
   Luo R. T., 2017, COMMUNICATION
   Melo MT, 1999, RESOUR CONSERV RECY, V26, P91, DOI 10.1016/S0921-3449(98)00077-9
   Ministry of Housing and Urban-Rural Development (MOHURD), 2015, STAND LIGHT DES URB
   Ministry of Housing and Urban-Rural Development (MOHURD), 2015, STAT COMM URB RUR CO
   Ministry of Railways of People's Republic of China (MOR), 2005, COPP COPP ALL CONT W
   Moura MCP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134135
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Muller DB, 2006, ECOL ECON, V59, P142, DOI 10.1016/j.ecolecon.2005.09.025
   National Bureau of Statistics of China (NBSC), 2015, NBSC CHIN STAT YB 20
   National Bureau of Statistics of China (NBSC), 1979, NBSC CHIN STAT YB 19
   National Development and Reform Commission (NDRC), 2018, PUBL ANN CONSTR NAT
   National Development and Reform Commission (NDRC), 2017, INSTR PROM BUILD RES
   National Development and Reform Commission (NDRC), 2017, LEAD ACT CIRC EC
   National Development and Reform Commission (NDRC), 2018, GUID PREP RES CIRC U
   Organisation for Economic Co-operation and Development (OECD), 2001, CONS DUR
   Organisation for Economic Co-operation and Development (OECD), 2003, URB
   Organisation for Economic Co-operation and Development (OECD), 2001, MACH EQ
   Pauliuk S, 2014, GLOBAL ENVIRON CHANG, V24, P132, DOI 10.1016/j.gloenvcha.2013.11.006
   Qiao B., 2012, CHINA METAL B, V9
   Ran Q. H., 2017, COMMUNICATION
   REW.ca, 2017, CAN ENJ 2 MOST LIV S
   Shanghai Bureau of Statistics (SBS), 2015, SBS SHANGH STAT YB 2
   Sichuan Provincial Bureau of Statistics (SPBS), 2015, SPBS SICH STAT YB 20
   Sichuan Provincial Department of Housing and Urban-Rural Development, 2018, 19 NAT C COMM PART C
   Sorme L., 2001, WATER AIR SOIL POLL, V1, P197
   Soulier M, 2018, J CLEAN PROD, V195, P435, DOI 10.1016/j.jclepro.2018.04.243
   Standardization Administration of the People's Republic of China (SAC), 2016, SPEC ROAD TRAFF SIGN
   Statistical Division of United Nations, 2000, HDB GEOGR INF SYST D
   Statistisches Bundesamt, 2014, INC CONS LIV COND
   The International Organization of Motor Vehicle Manufacturers (OICA), 2019, VEH US
   van Beers D, 2007, J CLEAN PROD, V15, P849, DOI 10.1016/j.jclepro.2006.06.022
   van Beers D, 2003, S AFR J SCI, V99, P61
   Wang H. J., 2017, COMMUNICATION
   Wang JL, 2010, J MATER CYCLES WASTE, V12, P66, DOI 10.1007/s10163-009-0271-3
   Wang T, 2015, RESOUR CONSERV RECY, V103, P205, DOI 10.1016/j.resconrec.2015.07.021
   World Bank, 2019, COUNTR PROF
   Xundao (Shen Zhen) Corp. Co. L, 2018, COMM CABL
   Xundao (Shen Zhen) Corp. Co. L, 2018, SYV SER COAX CABL
   Yan R. J., 2017, COMMUNICATION
   Yu K. L., 2016, J KOREA ORG RESOUR R, P42
   Zeltner C., 1999, SUSTAINABLE METAL MA
   Zhang C, 2017, ECOL ECON, V140, P265, DOI 10.1016/j.ecolecon.2017.04.021
   Zhang L, 2015, ENVIRON SCI TECHNOL, V49, P6430, DOI 10.1021/acs.est.5b00917
   Zhang L, 2014, RESOUR CONSERV RECY, V93, P134, DOI 10.1016/j.resconrec.2014.10.010
   Zhang L, 2012, J IND ECOL, V16, P191, DOI 10.1111/j.1530-9290.2011.00406.x
   Zhang Z., 2008, SPATIAL ANAL IN USE
NR 69
TC 0
Z9 0
U1 9
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 49
EP 60
DI 10.1016/j.resconrec.2019.04.010
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700006
DA 2020-05-12
ER

PT J
AU Paulo, PL
   Galbiati, AF
   Magalhaes, FJC
   Bernardes, FS
   Carvalho, GA
   Boncz, MA
AF Paulo, Paula Loureiro
   Galbiati, Adriana Farina
   Correa Magalhaes Filho, Fernando Jorge
   Bernardes, Fernando Silva
   Carvalho, Glauber Altrao
   Boncz, Marc Arpad
TI Evapotranspiration tank for the treatment, disposal and resource
   recovery of blackwater
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Design criteria; Ecotechnology; Natural system; Reuse; Sewage; Zero
   liquid discharge
ID WASTE-WATER EFFLUENT; ZERO-DISCHARGE; SYSTEMS; GREYWATER
AB The development of simple and safe solutions for sanitation systems is required to reach goal 6 of the United Nations Sustainable Development Goals. Source separation is an important step towards simplification of domestic sewage treatment, enabling the treatment and reuse of blackwater (BW) in more compact and decentralized systems. The Evapotranspiration tank (TEvap) is a natural, soil and plants-based hybrid system, being a combination of an in-built septic tank with a constructed wetland, used for BW recovery aiming at zero liquid discharge. The objective of this work was to describe the system dynamics and to evaluate criteria for design and operation, based on the evapotranspiration rate and performance. The study was based on a 1490 days-continuous run of a real scale TEvap. A design equation for sizing based on local climate conditions was proposed. The specific methanogenic activity was determined (0.047 kgCODIgTVS(-1)center dot d(-1)) and the applied biological loading rate was calculated. The results indicated that the TEvap could receive 740 L.d(-1) providing a COD removal of about 90%. However, the volumetric capacity of the TEvap combined with the routine in the household showed to be 87 L.d(-1) if zero liquid discharge was aimed. Understanding the routine of householders helps to decide whether to design the tank to cope with peak flows or to consider an infiltration trench for occasional overflow. When exposed to a peak flow, average COD removal was 75%. The slight accumulation of salts in the top soil did not affect the development of the plants.
C1 [Paulo, Paula Loureiro; Galbiati, Adriana Farina; Correa Magalhaes Filho, Fernando Jorge; Bernardes, Fernando Silva; Carvalho, Glauber Altrao; Boncz, Marc Arpad] Univ Fed Mato Grosso do Sul, Fac Engn Architecture & Urbanism & Geog, Av Costa e Silva S-N,Cidade Univ, BR-79070900 Campo Grande, MS, Brazil.
   [Correa Magalhaes Filho, Fernando Jorge] Univ Catolica Dom Bosco, Dept Sanit & Environm Engn, Jardim Seminario 6000, BR-79117900 Campo Grande, MS, Brazil.
RP Paulo, PL (reprint author), Univ Fed Mato Grosso do Sul, Fac Engn Architecture & Urbanism & Geog, Av Costa e Silva S-N,Cidade Univ, BR-79070900 Campo Grande, MS, Brazil.
EM paula.paulo@ufms.br; adriana.galbiati@gmail.com; fernando@ucdb.br;
   fernandosilvabernardes@gmail.com; glauber.altrao@gmail.com;
   marc.boncz@ufms.br
RI Filho, Fernando Jorge Correa Magalhaes/M-8015-2017; Paulo,
   Paula/G-3194-2012
OI Filho, Fernando Jorge Correa Magalhaes/0000-0001-5447-0137; Paulo,
   Paula/0000-0002-8091-6486
FU FUNDECT-MS, BrazilFundect [23/200.168/2007]
FX The work described in this paper was financially supported by
   FUNDECT-MS, Brazil, under Project no 23/200.168/2007.
CR Allen R., 2000, REF ET REFERENCE EVA
   APHA, 2012, STANDARD METHODS EXA, P1360, DOI DOI 10.5860/CHOICE.49-6910
   Aquino Sérgio F., 2007, Eng. Sanit. Ambient., V12, P192, DOI 10.1590/S1413-41522007000200010
   BARROSO L. B., 2011, ENGENHARIA AMBIENTAL, V8, P225
   Bieker S, 2010, WATER SCI TECHNOL, V61, P2905, DOI 10.2166/wst.2010.189
   Brouwer C., 1985, FAO IRRIGATION WATER
   Curneen S, 2016, ECOL ENG, V92, P199, DOI 10.1016/j.ecoleng.2016.03.032
   Curneen SJ, 2014, J ENVIRON MANAGE, V133, P153, DOI 10.1016/j.jenvman.2013.12.004
   Curneen S, 2015, WATER-SUI, V7, P2037, DOI 10.3390/w7052037
   de Graaff MS, 2010, WATER-SUI, V2, P101, DOI 10.3390/w2010101
   Esrey S., 1999, SANEAMIENTO ECOLOGIC
   Gregersen P, 2001, WATER SCI TECHNOL, V44, P407
   Guerra L. R. M., 2015, REV PROD DESENV, V1, P103
   Hargreaves G. H., 1985, Applied Engineering in Agriculture, V1, P96
   Istenic D, 2017, DESALIN WATER TREAT, V91, P260, DOI 10.5004/dwt.2017.21186
   Jantrania A. R., 2006, ADV ONSITE WASTEWATE
   Kadlec RH, 2005, WATER SCI TECHNOL, V51, P291
   Khurelbaatar G, 2017, ECOL ENG, V98, P82, DOI 10.1016/j.ecoleng.2016.10.010
   Macek P, 2007, FUNCT ECOL, V21, P478, DOI 10.1111/j.1365-2435.2007.01266.x
   Magalhaes FJC, 2018, J ENVIRON SCI HEAL A, V53, P493, DOI 10.1080/10934529.2017.1422954
   Montgomery DR, 2007, P NATL ACAD SCI USA, V104, P13268, DOI 10.1073/pnas.0611508104
   Palmquist H, 2005, SCI TOTAL ENVIRON, V348, P151, DOI 10.1016/j.scitotenv.2004.12.052
   Paulo P. L., 2018, CATALOSAN CATALOGUE
   Paulo PL, 2013, ECOL ENG, V50, P95, DOI 10.1016/j.ecoleng.2012.03.022
   Rosenqvist H, 1997, BIOMASS BIOENERG, V12, P1, DOI 10.1016/S0961-9534(96)00058-X
   Shi DC, 2005, PLANT SOIL, V271, P15, DOI 10.1007/s11104-004-1307-z
   TIESSEN H, 1994, NATURE, V371, P783, DOI 10.1038/371783a0
   Van Haandel A.C., 1994, ANAEROBIC SEWAGE TRE
   Venturi P, 1999, RENEW ENERG, V16, P1023, DOI 10.1016/S0960-1481(98)00363-2
   Vieira P., 2007, Water Science and Technology: Water Supply, V7, P193, DOI 10.2166/ws.2007.098
   World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), 2017, PROGR DRINK WAT SAN
   Wu SB, 2018, ENVIRON SCI TECHNOL, V52, P1693, DOI 10.1021/acs.est.8b00010
NR 32
TC 0
Z9 0
U1 9
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 61
EP 66
DI 10.1016/j.resconrec.2019.04.025
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700007
DA 2020-05-12
ER

PT J
AU Zhang, Q
   Wang, YJ
   Zhang, W
   Xu, J
AF Zhang, Qi
   Wang, Yujie
   Zhang, Wei
   Xu, Jin
TI Energy and resource conservation and air pollution abatement in China's
   iron and steel industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Co-benefits; Energy and resource conservation; Air pollution abatement;
   Iron and steel industry
ID CO2 EMISSIONS MITIGATION; EFFICIENCY IMPROVEMENT; REDUCTION; BENEFITS;
   POLLUTANTS; SECTOR; MODEL; COST; FLOW
AB China's iron and steel industry is one of the largest energy resource consumption and air pollutant emissions industries. In this study, a comprehensive assessment approach is established to evaluate the co-benefits of energy efficiency improvement, resource saving and air pollution abatement between 2015-2050. Five scenarios including the reference scenario, the structure adjustment scenario, the technologies improvement without end of -pipe measures scenario, the technologies improvement with EOP measures scenario and integrated scenario are developed for analysis. The modeling results demonstrate that scrap resource is enough to support production switching in all five scenarios. Energy resource consumption and air pollution emissions will decline step by step under the synergy effect of technology improvement and structure adjustment. The cumulative emission reductions of selected 35 energy efficiency technologies are 0.731 kg SO2/t, 0.535 kg NOx/t, 0.259 kg PM10/t and 0.579 kg AP(eq)/t at the discount rate of 15%. Sensitivity analysis shows that implementation rates and discount rates are the most critical factors.
C1 [Zhang, Qi; Wang, Yujie; Zhang, Wei; Xu, Jin] Northeastern Univ, Box 345,3-11 Wenhua Rd, Shenyang 110819, Liaoning, Peoples R China.
RP Zhang, Q (reprint author), Northeastern Univ, Box 345,3-11 Wenhua Rd, Shenyang 110819, Liaoning, Peoples R China.
EM zhangqi@smm.neu.edu.cn
OI ZHANG, Qi/0000-0003-1784-5934
FU National Key Research and Development Program [2016YFB0601305]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51874095]
FX This work was supported by the National Key Research and Development
   Program (Project No. 2016YFB0601305) and the National Natural Science
   Foundation of China (No.51874095). The authors gratefully acknowledge
   the reviewers and editors for their fruitful comments.
CR Burchart-Korol D, 2013, INT C MET MAT
   Bureau of International Recycling, 2013, STAINL STEEL SPEC AL
   Chen F, 2015, WATER AIR SOIL POLL, V226, DOI 10.1007/s11270-015-2316-7
   Chen WY, 2014, APPL ENERG, V136, P1174, DOI 10.1016/j.apenergy.2014.06.002
   Duflou JR, 2012, CIRP ANN-MANUF TECHN, V61, P587, DOI 10.1016/j.cirp.2012.05.002
   Flues F, 2015, J CLEAN PROD, V104, P250, DOI 10.1016/j.jclepro.2015.05.030
   Gu YF, 2015, J CLEAN PROD, V92, P274, DOI 10.1016/j.jclepro.2014.12.094
   Hartwig J, 2017, ENERGY, V124, P510, DOI 10.1016/j.energy.2017.02.077
   Hasanbeigi A., 2017, LBNL1007268
   Hasanbeigi A, 2013, ENERGY, V50, P315, DOI 10.1016/j.energy.2012.10.062
   He K, 2010, ENERGY, V35, P4265, DOI 10.1016/j.energy.2008.07.021
   Hernandez AG, 2018, RESOUR CONSERV RECY, V133, P132, DOI 10.1016/j.resconrec.2018.02.008
   Johansson MT, 2011, ENERGY, V36, P191, DOI 10.1016/j.energy.2010.10.053
   Li Y, 2014, APPL ENERG, V130, P603, DOI 10.1016/j.apenergy.2014.04.014
   Lin BQ, 2011, ENERG POLICY, V39, P3680, DOI 10.1016/j.enpol.2011.03.077
   [刘胜强 Liu Shengqiang], 2012, [环境科学与技术, Enuivonmental Science and Technology], V35, P168
   Lundgren J, 2013, APPL ENERG, V112, P431, DOI 10.1016/j.apenergy.2013.03.010
   Ma D, 2016, APPL ENERG, V162, P1225, DOI 10.1016/j.apenergy.2015.08.005
   Maddaloni A, 2015, APPL THERM ENG, V91, P638, DOI 10.1016/j.applthermaleng.2015.08.051
   Mao XQ, 2013, ENVIRON SCI TECHNOL, V47, P12002, DOI 10.1021/es4021316
   [毛显强 Mao Xianqiang], 2012, [环境科学学报, Acta Scientiae Circumstantiae], V32, P1253
   Meier A. K., 1982, THESIS
   Ministry of Ecology and Environment of People's Republic of China (MEEPRC), 2017, NAT ENV STAT B 2017
   Ministry of Industry and Information Technology, 2012, GUID ADV APPL EN SAV
   Ministry of Industry and Information Technology, 2011, 12 5 YEAR DEV PLAN I
   Moya JA, 2013, J CLEAN PROD, V52, P71, DOI 10.1016/j.jclepro.2013.02.028
   National Bureau of Statistics, 2015, CHIN STAT YB
   Rojas-Cardenas JC, 2017, J CLEAN PROD, V158, P335, DOI 10.1016/j.jclepro.2017.04.092
   Said A, 2013, APPL ENERG, V112, P765, DOI 10.1016/j.apenergy.2012.12.042
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Tan RP, 2018, ENERG ECON, V71, P213, DOI 10.1016/j.eneco.2018.02.019
   Wang C, 2017, APPL ENERG, V205, P1119, DOI 10.1016/j.apenergy.2017.08.125
   Wang CY, 2017, RESOUR CONSERV RECY, V124, P116, DOI 10.1016/j.resconrec.2017.04.014
   Wang K, 2016, SCI TOTAL ENVIRON, V559, P7, DOI 10.1016/j.scitotenv.2016.03.125
   Wang P, 2017, RESOUR CONSERV RECY, V117, P45, DOI 10.1016/j.resconrec.2015.07.009
   Wang P, 2014, RESOUR CONSERV RECY, V87, P191, DOI 10.1016/j.resconrec.2014.04.003
   Wang W, 2014, WORLD METALS, V2014, P3
   Wang Z, 2011, CHINA IRON STEEL SCR, V3, P21
   Wen ZG, 2014, J CLEAN PROD, V65, P120, DOI 10.1016/j.jclepro.2013.09.008
   World Steel Association (WSA), 2016, STEEL STAT YB 2016
   Worrell E, 2003, ENERGY, V28, P1081, DOI 10.1016/S0360-5442(03)00091-4
   Worrell E, 2001, ENERGY, V26, P513, DOI 10.1016/S0360-5442(01)00017-2
   Worrell E., 2010, LBNL4779E ERN ORL LA
   WSA, 2014, STEEL STAT YB 2014
   Wu XC, 2016, APPL ENERG, V184, P171, DOI 10.1016/j.apenergy.2016.09.094
   Wu XC, 2015, AEROSOL AIR QUAL RES, V15, P1422, DOI 10.4209/aaqr.2015.01.0029
   Wubbeke J, 2014, RESOUR CONSERV RECY, V87, P1, DOI 10.1016/j.resconrec.2014.03.004
   Xu B, 2016, ENERG POLICY, V88, P422, DOI 10.1016/j.enpol.2015.11.001
   Xu B, 2016, APPL ENERG, V161, P375, DOI 10.1016/j.apenergy.2015.10.039
   Xuan YN, 2017, RESOUR CONSERV RECY, V120, P186, DOI 10.1016/j.resconrec.2016.12.011
   Xuan YN, 2016, RESOUR CONSERV RECY, V109, P1, DOI 10.1016/j.resconrec.2016.02.003
   Yan Q, 2014, RES CHINA STEEL SCRA
   Yang H, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-137
   Yang X, 2013, APPL ENERG, V112, P1446, DOI 10.1016/j.apenergy.2013.03.040
   Zhang H, 2013, APPL ENERG, V112, P956, DOI 10.1016/j.apenergy.2013.02.019
   Zhang Q, 2018, APPL ENERG, V209, P251, DOI 10.1016/j.apenergy.2017.10.084
   Zhang Q, 2017, APPL ENERG, V191, P502, DOI 10.1016/j.apenergy.2017.01.072
   Zheng JJ, 2016, J CLEAN PROD, V114, P314, DOI 10.1016/j.jclepro.2015.07.011
NR 58
TC 2
Z9 2
U1 15
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 67
EP 84
DI 10.1016/j.resconrec.2019.04.018
PG 18
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700008
DA 2020-05-12
ER

PT J
AU Tao, Y
   Wen, ZG
   Xu, LN
   Zhang, X
   Tan, QL
   Li, HF
   Evans, S
AF Tao, Yuan
   Wen, Zongguo
   Xu, Lina
   Zhang, Xuan
   Tan, Qilu
   Li, Huifang
   Evans, Steve
TI Technology options: Can Chinese power industry reach the CO2 emission
   peak before 2030?
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Electric power industry; Emission peaks; Mitigation potential;
   Cost-benefit analysis
ID COST-BENEFIT-ANALYSIS; ENVIRONMENTAL KUZNETS CURVE; CARBON-DIOXIDE
   EMISSIONS; ELECTRICITY SECTOR; SCENARIO ANALYSIS; DECOMPOSITION
   ANALYSIS; ENERGY-CONSUMPTION; RENEWABLE ENERGY; DRIVING FACTORS;
   GENERATION
AB From the start of China's G20 presidency, China positions itself as a world leader in fighting climate change and emphasizes the wish to 'break a new path for growth'. China aims to peak carbon dioxide (CO2) emissions by 2030 and cut its greenhouse gas emissions per unit of gross domestic product by 60-65% from 2005 levels by 2030. The pledge is eagerly awaited as China aims to develop a low carbon economy through switching to alternatives to fossil fuels and being technologically energy-efficient. The power industry is the most important industrial sector while the biggest bottleneck for CO2 emission control in China. This paper develops a technologies -based bottom-up CO2 mitigation model to assess emission reduction potential of different technologies in the thermal power industry up to 2030. Using 2010 as the reference year, two macro-economic scenarios and four technological scenarios have been set to describe future policy measures for the period of 2015-2030. CO2 emission trends, reduction potentials and cost curves are demonstrated under different scenarios. The results show that the electric power industry can reach its CO2 emission peak by 2030 in the middle policy control scenario under macro-economic slow growth. Emissions would peak at 4.6 billion tonnes CO2-eq for the least cost scenario, which is 1.78 billion tones CO2-eq less than peak the BAU scenario in 2030. This is equivalent to the total CO2 emissions from 300 MW to 1000 MW coal-fired power plants with 5000 h in 30 provinces and municipalities of China in 2013. This research shows that the top four negative cost-beneficial technology options, 630 degrees C or 700 degrees C USC, small hydroelectricity, and nuclear power pressurized water reactor II and III, are the most preferable to be promoted to meet the CO2 emissions peak target in 2020 and 2030.
C1 [Tao, Yuan; Evans, Steve] Univ Cambridge, Dept Engn, Inst Mfg, 17 Charles Babbage Rd, Cambridge CB3 0FS, England.
   [Wen, Zongguo; Zhang, Xuan; Li, Huifang] Tsinghua Univ, Sch Environm, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China.
   [Xu, Lina] Shanxi Datong Univ, Business Sch, Datong 037009, Shanxi, Peoples R China.
   [Tan, Qilu] Natl Dev & Reform Commiss, Energy Res Inst, Beijing 100038, Peoples R China.
RP Wen, ZG (reprint author), Tsinghua Univ, Sch Environm, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China.
EM wenzg@tsinghua.edu.cn
FU "Thirteenth Five-Year" National Key Research and Development Program of
   China [2016YFB0601305]; National Science Fund for Distinguished Young
   Scholars of ChinaNational Natural Science Foundation of ChinaNational
   Science Fund for Distinguished Young Scholars [71825006]; National Basic
   Research Program of ChinaNational Basic Research Program of China
   [2010CB955903]; UK EPSRC Centre for Innovative Manufacturing in
   Industrial SustainabilityEngineering & Physical Sciences Research
   Council (EPSRC) [EP/I033351/1]
FX The authors gratefully acknowledge financial support from the
   "Thirteenth Five-Year" National Key Research and Development Program of
   China (2016YFB0601305), National Science Fund for Distinguished Young
   Scholars of China (71825006), National Basic Research Program of China
   (2010CB955903) the UK EPSRC Centre for Innovative Manufacturing in
   Industrial Sustainability (EP/I033351/1). This research project is part
   of the Research Center for Green Economy and Sustainable Development,
   Tsinghua University. We also appreciate the kind help of Dr Lihui Zhou
   and Junwei Ding from China Datang Cooperation.
CR Ackerman F, 2002, U PENN LAW REV, V150, P1553, DOI 10.2307/3312947
   Allen V. K, 1989, COST BENEFICIAL ANAL
   Ang BW, 2016, ENERG POLICY, V98, P170, DOI 10.1016/j.enpol.2016.08.027
   [Anonymous], 2015, CO2 EMISSIONS REDUCT
   Araujo C, 2016, APPL ENERG, V173, P124, DOI 10.1016/j.apenergy.2016.04.005
   Cai WJ, 2007, ENERG POLICY, V35, P6445, DOI 10.1016/j.enpol.2007.08.026
   Chinese National Bureau of Statistics, 2018, 9 15 INST CAP POW GE
   Clarke L, 2009, ENERG ECON, V31, pS64, DOI 10.1016/j.eneco.2009.10.013
   Dantas GD, 2017, RENEW SUST ENERG REV, V68, P997, DOI 10.1016/j.rser.2016.08.003
   Gonzalez PF, 2015, ENERG CONVERS MANAGE, V92, P459, DOI 10.1016/j.enconman.2014.12.083
   Gu BH, 2015, ENRGY PROCED, V75, P2436, DOI 10.1016/j.egypro.2015.07.210
   Guo Z, 2017, APPL ENERG, V185, P556, DOI 10.1016/j.apenergy.2016.10.132
   Hanak DP, 2014, FUEL, V134, P126, DOI 10.1016/j.fuel.2014.05.036
   Hu JF, 2012, ENERG POLICY, V45, P412, DOI 10.1016/j.enpol.2012.02.049
   IEA, 2015, CO2 EM FUEL COMB 201
   Iwai N, 2014, PROC CIRP, V15, P319, DOI 10.1016/j.procir.2014.06.076
   Karmellos M, 2016, ENERGY, V94, P680, DOI 10.1016/j.energy.2015.10.145
   Li FGN, 2017, APPL ENERG, V189, P89, DOI 10.1016/j.apenergy.2016.12.047
   Li YP, 2014, RENEW ENERG, V62, P31, DOI 10.1016/j.renene.2013.06.029
   Liddle B, 2015, GLOBAL ENVIRON CHANG, V31, P62, DOI 10.1016/j.gloenvcha.2014.10.016
   Liu QL, 2017, RESOUR CONSERV RECY, V122, P326, DOI 10.1016/j.resconrec.2017.03.008
   Liu XW, 2017, APPL ENERG, V189, P233, DOI 10.1016/j.apenergy.2016.12.057
   Lunz B, 2016, APPL ENERG, V171, P555, DOI 10.1016/j.apenergy.2016.03.087
   Mcelroy MB, 2010, FRONT ENVIRON SCI EN, V4, P2, DOI 10.1007/s11783-010-0005-8
   McKinsey & Company, 2018, PATHW LOW CARB EC VE
   Meng M, 2017, J CLEAN PROD, V142, P3101, DOI 10.1016/j.jclepro.2016.10.157
   Miao L, 2017, ECOL INDIC, V73, P29, DOI 10.1016/j.ecolind.2016.09.031
   National Development and Reform Commissions of China (NDRC), 2018, ENH ACT CLIM CHANG C
   Ozer B, 2013, ENERGY, V49, P395, DOI 10.1016/j.energy.2012.10.059
   Papendiek F, 2016, J CLEAN PROD, V112, P3643, DOI 10.1016/j.jclepro.2015.07.108
   Park NB, 2013, ENERG POLICY, V52, P288, DOI 10.1016/j.enpol.2012.09.021
   Pattupara R, 2016, APPL ENERG, V172, P152, DOI 10.1016/j.apenergy.2016.03.084
   Sardi J, 2017, APPL ENERG, V190, P453, DOI 10.1016/j.apenergy.2016.12.144
   Schill WP, 2015, APPL ENERG, V156, P185, DOI 10.1016/j.apenergy.2015.07.012
   Tan XC, 2016, APPL ENERG, V162, P1345, DOI 10.1016/j.apenergy.2015.06.071
   Treyer K, 2016, RENEW SUST ENERG REV, V55, P1234, DOI 10.1016/j.rser.2015.04.016
   Wang CJ, 2017, RENEW SUST ENERG REV, V67, P51, DOI 10.1016/j.rser.2016.09.006
   Wang Y, 2017, APPL ENERG, V190, P172, DOI 10.1016/j.apenergy.2016.12.109
   Weldu YW, 2017, J CLEAN PROD, V142, P2296, DOI 10.1016/j.jclepro.2016.11.047
   Wen ZG, 2008, ECOL ECON, V65, P356, DOI 10.1016/j.ecolecon.2007.07.007
   Wen ZG, 2014, INT J GREENH GAS CON, V28, P45, DOI 10.1016/j.ijggc.2014.06.013
   Wen ZG, 2014, ENERG ENVIRON-UK, V25, P635, DOI 10.1260/0958-305X.25.3-4.635
   Wu QL, 2016, ENERGIES, V9, DOI 10.3390/en9120988
   Yuan J., 2016, RESOUR CONSERV RECY, V129, P443, DOI DOI 10.1016/j.resconrec.2016.03.021
   Yuan J. H, 2016, ENERGIES, V9
   Yuan JH, 2014, ENERGY, V67, P27, DOI 10.1016/j.energy.2013.12.054
   Yuan JH, 2014, ENERG POLICY, V68, P508, DOI 10.1016/j.enpol.2014.01.019
   Zhang BY, 2016, ENRGY PROCED, V88, P119, DOI 10.1016/j.egypro.2016.06.034
   Zhang M, 2013, ENERG POLICY, V52, P159, DOI 10.1016/j.enpol.2012.10.013
   [张小丽 Zhang Xiaoli], 2018, [中国人口·资源与环境, China Population Resources and Environment], V28, P68
   Zhou GH, 2014, J CLEAN PROD, V83, P173, DOI 10.1016/j.jclepro.2014.06.047
   Zhu NP, 2016, ENRGY PROCED, V104, P203, DOI 10.1016/j.egypro.2016.12.035
   Zoundi Z, 2017, RENEW SUST ENERG REV, V72, P1067, DOI 10.1016/j.rser.2016.10.018
NR 53
TC 2
Z9 2
U1 12
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 85
EP 94
DI 10.1016/j.resconrec.2019.04.020
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700009
DA 2020-05-12
ER

PT J
AU Yilmaz, IH
   Abdulvahitoglu, A
AF Yilmaz, Ibrahim Halil
   Abdulvahitoglu, Asli
TI Evaluation of municipal solid waste options in Turkey: Scenarios for
   energy recovery, carbon mitigation and consequent financial strategies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Solid waste; Energy recovery; Carbon mitigation; Economy; Turkey
ID LIFE-CYCLE ASSESSMENT; ENVIRONMENTAL BENEFITS; MANAGEMENT STRATEGIES;
   BIOGAS PRODUCTION; ELECTRICITY; LANDFILL; SYSTEM; FEASIBILITY;
   POTENTIALS; IMPACT
AB Solid waste management is a challenging issue in Turkey not only due to population and economic growths but its adverse environmental impact, financial problems and technological obstacles, as well. The detailed evaluation of solid waste options is significant not to end up with issues such as shutting down the plants and stopping the investments which may cause serious environmental problems as a result of uncontrolled landfill gas emissions. This research presents a theoretical model for energy recovery from the municipal solid waste (MSW) in Turkey, and the consequent carbon mitigation scenarios and financial strategies regarding the adoption of European Union acquis, respectively. The model predicts the population growth compatible with the baseline scenario of Turkish Statistical Institute data and the MSW generation for each city of Turkey between 2004-2043. The three scenarios, namely open dump, landfill and incineration, are taken into consideration for greenhouse gas (GHG) emissions, energy recovery from emissions and economics subject to the Turkish environmental regulations towards the progress of this adoption. The aim of the research is to fulfill the literature gap by proposing practical formulations and realistic models for the mentioned scenarios and considering the energy, economy and ecology nexus based on the regional characteristics of solid waste systems as a consequence of adapting the Turkish MSW regulations and management. Results show that the maximum potential of electricity production is estimated to be 3461-13,450 GW h (0.40-1.56 GW/annum) in the landfill scenario while it is 1572-8386 GW h (0.17-0.96 GW/annum) in the incineration scenario. According to the nationwide projections, Turkey will have consumed the electricity of 437 TW h and 2236 TW h by 2023 and 2043, respectively. While the landfill scenario would meet 0.40-1.40% and 0.15-0.60% of the nationwide electricity production for the interested years, respectively; the incineration scenario would supply 0.06-0.34% and 0.07-0.38% of the nationwide electricity consumption. The maximum total savings for the landfill and incineration scenarios would range from 35.2-66.7 and 32.7-64.5 billion $, respectively in a time horizon at which the total amount of wastes for the corresponding scenarios are equivalent to each other. It is stressed that the landfill scenario would be better for lowering the GHG emissions in case of proper emission control.
C1 [Yilmaz, Ibrahim Halil] Adana Sci & Technol Univ, Dept Automot Engn, Adana, Turkey.
   [Abdulvahitoglu, Asli] Adana Sci & Technol Univ, Dept Mech Engn, Adana, Turkey.
RP Yilmaz, IH (reprint author), Adana Sci & Technol Univ, Dept Automot Engn, Adana, Turkey.
EM iyilmaz@adanabtu.edu.tr
RI Yilmaz, Ibrahim Halil/A-5967-2016
OI Yilmaz, Ibrahim Halil/0000-0001-7840-9162
CR Abdulvahitoglu A, 2018, INT ADV RES ENG J, V2, P117
   Abdulvahitoglu A, 2018, BIOFUELS-UK, V9, P95, DOI 10.1080/17597269.2016.1257319
   Agdag ON, 2009, WASTE MANAGE, V29, P456, DOI 10.1016/j.wasman.2008.01.012
   Akinci G, 2012, RESOUR CONSERV RECY, V58, P114, DOI 10.1016/j.resconrec.2011.11.005
   Akkoyunlu A, 2017, J HAZARD TOXIC RADIO, V21, DOI 10.1061/(ASCE)HZ.2153-5515.0000373
   Altan H.S, 2015, EFFECTS BIODEGRADABL
   Arikan E, 2017, J CLEAN PROD, V142, P403, DOI 10.1016/j.jclepro.2015.10.054
   Aydin N, 2017, ENRGY PROCED, V113, P111, DOI 10.1016/j.egypro.2017.04.031
   Ayodele TR, 2018, RESOUR CONSERV RECY, V134, P165, DOI 10.1016/j.resconrec.2018.03.017
   Banar M, 2008, ENVIRON ENG SCI, V25, P1213, DOI 10.1089/ees.2007.0164
   Baran B, 2016, RENEW ENERG, V90, P493, DOI 10.1016/j.renene.2015.12.070
   Budak F, 2008, J ENVIRON BIOL, V29, P923
   Christensen TH, 2009, WASTE MANAGE RES, V27, P707, DOI 10.1177/0734242X08096304
   DEE, 2017, NAT GREEN HOUS ACC F
   Deloitte, 2014, BIYOK ALUN CAG
   Demirbas A, 2006, ENERG SOURCE PART A, V28, P1127, DOI 10.1080/009083190910479
   Durmusoglu E, 2009, 3 INT S MBT MRF, P518
   EPA, 2005, LANDF GAS EM MOD V 3
   Erses AS, 2008, BIORESOURCE TECHNOL, V99, P5418, DOI 10.1016/j.biortech.2007.11.008
   Ersoy H, 2008, FRESEN ENVIRON BULL, V17, P932
   GHF, 2018, GUNCEL HURDA FIYATLA
   Hamzacebi C, 2014, ENERGY, V70, P165, DOI 10.1016/j.energy.2014.03.105
   IEA, 2016, EN POL LEA COUNTR TU
   *IPCC, 2006, IPCC GUID NAT GREENH
   Isik M. Z., 2012, International Journal of Physical Sciences, V7, P5815
   ITC, 2018, ITC INT SOL WAST MAN
   Johari A, 2012, RENEW SUST ENERG REV, V16, P2907, DOI 10.1016/j.rser.2012.02.005
   Kanat G, 2006, WASTE MANAGE, V26, P1384, DOI 10.1016/j.wasman.2005.12.010
   Kanat G, 2010, WASTE MANAGE, V30, P1737, DOI 10.1016/j.wasman.2010.01.036
   Lino FAM, 2010, RESOUR CONSERV RECY, V54, P916, DOI 10.1016/j.resconrec.2010.01.010
   Manfredi S, 2009, WASTE MANAGE RES, V27, P825, DOI 10.1177/0734242X09348529
   Mazzi A, 2017, ENVIRON IMPACT ASSES, V63, P59, DOI 10.1016/j.eiar.2016.11.004
   Melikoglu M, 2018, ENERGY STRATEG REV, V22, P188, DOI 10.1016/j.esr.2018.09.004
   Melikoglu M, 2013, RENEW SUST ENERG REV, V19, P52, DOI 10.1016/j.rser.2012.11.017
   Melikoglu M, 2013, RENEW ENERG, V50, P570, DOI 10.1016/j.renene.2012.07.032
   Metin E, 2003, WASTE MANAGE, V23, P425, DOI 10.1016/S0956-053X(03)00070-9
   MoEU, 2015, ENV INDICATORS
   MoEU, 2006, SOL WAST MAST PLAN F
   Nas SS, 2008, WASTE MANAGE, V28, P2435, DOI 10.1016/j.wasman.2007.09.039
   Oonk H, 2010, INNOV ENV TECHNOL, P1
   Ozbay I, 2015, POLISH J ENV STUD, V24
   Ozcan HK, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8101044
   Ozcan M, 2015, ENG SCI TECHNOL, V18, P178, DOI 10.1016/j.jestch.2014.10.003
   Ozturk HK, 2005, ENERGY, V30, P1003, DOI 10.1016/j.energy.2004.08.008
   Panepinto D, 2015, RESOUR CONSERV RECY, V97, P16, DOI 10.1016/j.resconrec.2015.02.002
   Rand T., 2000, MUNICIPAL SOLID WAST
   Ruth LA, 1998, PROG ENERG COMBUST, V24, P545, DOI 10.1016/S0360-1285(98)00011-2
   Saka K., 2017, INT J MANAGE APPL SC, V3, P79
   Saka K, 2016, 10 INT CLEAN EN S, P115
   Saka K, 2018, EUR J TECH, V8, P160
   Salihoglu G, 2010, J HAZARD MATER, V177, P42, DOI 10.1016/j.jhazmat.2009.11.096
   Sarptas H, 2015, 6 INT S MBT MRF, P1
   Scarlat N, 2015, RENEW SUST ENERG REV, V50, P1269, DOI 10.1016/j.rser.2015.05.067
   Scharff H, 2006, WASTE MANAGE, V26, P417, DOI 10.1016/j.wasman.2005.11.015
   Sel I, 2016, WASTE MANAGE, V56, P310, DOI 10.1016/j.wasman.2016.07.023
   SPO, 2009, EL MARK SUPPL SEC ST
   Taseli BK, 2007, RESOUR CONSERV RECY, V52, P119, DOI 10.1016/j.resconrec.2007.03.003
   Themelis NJ, 2007, RENEW ENERG, V32, P1243, DOI 10.1016/j.renene.2006.04.020
   Tinmaz E, 2006, WASTE MANAGE, V26, P307, DOI 10.1016/j.wasman.2005.06.005
   Tozlu A, 2016, RENEW SUST ENERG REV, V54, P809, DOI 10.1016/j.rser.2015.10.097
   Turan NG, 2009, WASTE MANAGE, V29, P465, DOI 10.1016/j.wasman.2008.06.004
   Leme MMV, 2014, RESOUR CONSERV RECY, V87, P8, DOI 10.1016/j.resconrec.2014.03.003
   WEC, 2016, WORLD EN RES WAST EN
   Yay ASE, 2015, J CLEAN PROD, V94, P284, DOI 10.1016/j.jclepro.2015.01.089
   Yilmaz I. H, 2017, 5 INT C SUST SOL WAS
   Yilmaz IH, 2018, J CLEAN PROD, V204, P511, DOI 10.1016/j.jclepro.2018.09.060
   Yilmaz IH, 2018, ENERG SOURCE PART B, V13, P46, DOI 10.1080/15567249.2017.1403498
   Yilmaz IH, 2012, DESALINATION, V291, P23, DOI 10.1016/j.desal.2012.01.022
   Zamorano M, 2007, RENEW SUST ENERG REV, V11, P909, DOI 10.1016/j.rser.2005.05.007
NR 69
TC 1
Z9 1
U1 5
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 95
EP 110
DI 10.1016/j.resconrec.2019.02.029
PG 16
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700010
DA 2020-05-12
ER

PT J
AU Oliver-Tomas, B
   Hitzl, M
   Owsianiak, M
   Renz, M
AF Oliver-Tomas, Borja
   Hitzl, Martin
   Owsianiak, Mikolaj
   Renz, Michael
TI Evaluation of hydrothermal carbonization in urban mining for the
   recovery of phosphorus from the organic fraction of municipal solid
   waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Advanced hydrochar; Low-ash solid fuel; Phosphorus extraction;
   Phosphorus fertilizer
ID SEWAGE-SLUDGE; AGRICULTURAL WASTE; FOOD WASTE; HYDROCHAR; BIOMASS;
   GENERATION; BIOCHAR; STREAMS; CARBONS; IMPACT
AB The organic fraction of municipal solid waste was identified as an alternative phosphorus resource: hydro thermal carbonization provided phosphorus-rich hydrochar. Two alternative valorization pathways can be considered for the latter: the use as a fertilizer or as solid fuel after phosphorus extraction. By means of life cycle assessment (LCA) the environmental impact of extracting phosphorus and using the hydrochar as solid fuel was evaluated. Therefore, in a first step, phosphorus extraction with nitric acid, hydrochloric acid and sulfuric acid was experimentally investigated on laboratory scale. Nitric acid proved to be the most suitable because it offered high extraction efficiency and improved solid fuel properties such as lower ash content and lower levels of chlorine and sulfur. In contrast, hydrochloric acid increased the chlorine content and sulfuric acid only replaced phosphate by sulfate, but did not reduce the ash content of hydrochar. Then phosphorus can be precipitated and used as fertilizer.
   Although technically feasible, LCA points out that the separate use of hydrochar and phosphorus represents an overall environmental burden for wide range of impact categories, including climate change and resource depletion. Therefore, other applications for phosphorus-rich hydrochars, like agriculture and horticulture, should be considered.
C1 [Oliver-Tomas, Borja; Hitzl, Martin] Ingelia SL, C Jaime Roig 19, Valencia 46010, Spain.
   [Owsianiak, Mikolaj] Tech Univ Denmark, Dept Management Engn, Div Quantitat Sustainabil Assessment, Bldg 116B, DK-2800 Lyngby, Denmark.
   [Oliver-Tomas, Borja; Renz, Michael] Univ Politecn Valencia, Inst Tecnol Quim UPV CSIC, CSIC, Ave Naranjos S-N, E-46022 Valencia, Spain.
RP Renz, M (reprint author), Univ Politecn Valencia, Inst Tecnol Quim UPV CSIC, CSIC, Ave Naranjos S-N, E-46022 Valencia, Spain.
EM mrenz@itq.upv.es
RI Owsianiak, Mikolaj/D-5370-2009; Renz, Michael/B-9361-2011
OI Owsianiak, Mikolaj/0000-0002-6834-6249; Renz,
   Michael/0000-0002-1101-9562
FU Spanish Ministry of Economy and Competiveness of the state programme
   "Research, Development and Innovation Oriented to the Challenges of
   Society" [RTC-2015-4017-3]
FX The authors are grateful for the financial support received from the
   Spanish Ministry of Economy and Competiveness under the RTC-2015-4017-3
   of the state programme "Research, Development and Innovation Oriented to
   the Challenges of Society"
CR [Anonymous], 2006, 14044 ISO
   Burguete P, 2016, GREEN CHEM, V18, P1051, DOI [10.1039/C5GC02296G, 10.1039/c5gc02296g]
   Busch D, 2013, ECOTOX ENVIRON SAFE, V97, P59, DOI 10.1016/j.ecoenv.2013.07.003
   Busch D, 2012, J ENVIRON QUAL, V41, P1023, DOI 10.2134/jeq2011.0122
   Cha JS, 2016, J IND ENG CHEM, V40, P1, DOI 10.1016/j.jiec.2016.06.002
   Cieslik B, 2017, J CLEAN PROD, V142, P1728, DOI 10.1016/j.jclepro.2016.11.116
   Dalias P, 2018, J ENVIRON CHEM ENG, V6, P6647, DOI 10.1016/j.jece.2018.10.042
   Desmidt E, 2015, CRIT REV ENV SCI TEC, V45, P336, DOI 10.1080/10643389.2013.866531
   Fornes F, 2017, J ENVIRON MANAGE, V191, P237, DOI 10.1016/j.jenvman.2017.01.026
   Funke A, 2010, BIOFUEL BIOPROD BIOR, V4, P160, DOI 10.1002/bbb.198
   Hauschild MZ, 2013, INT J LIFE CYCLE ASS, V18, P683, DOI 10.1007/s11367-012-0489-5
   Hitzl M, 2018, J ENVIRON CHEM ENG, V6, P7029, DOI 10.1016/j.jece.2018.10.064
   Hitzl M, 2015, CATAL TODAY, V257, P154, DOI 10.1016/j.cattod.2014.09.024
   Hu B, 2010, ADV MATER, V22, P813, DOI 10.1002/adma.200902812
   Idowu I, 2017, WASTE MANAGE, V69, P480, DOI 10.1016/j.wasman.2017.08.051
   International Organization for Standardization, 2016, 1722582016 ISOTS
   Kambo HS, 2015, RENEW SUST ENERG REV, V45, P359, DOI 10.1016/j.rser.2015.01.050
   Kempegowda RS, 2017, ENRGY PROCED, V120, P341, DOI 10.1016/j.egypro.2017.07.223
   Lang QQ, 2019, J ENVIRON MANAGE, V233, P440, DOI 10.1016/j.jenvman.2018.12.072
   Melia PM, 2017, CHEMOSPHERE, V186, P381, DOI 10.1016/j.chemosphere.2017.07.089
   Ottosen LM, 2013, CHEMOSPHERE, V91, P963, DOI 10.1016/j.chemosphere.2013.01.101
   Owsianiak M, 2018, GCB BIOENERGY, V10, P230, DOI 10.1111/gcbb.12484
   Owsianiak M, 2016, ACS SUSTAIN CHEM ENG, V4, P6783, DOI 10.1021/acssuschemeng.6b01732
   Smith AM, 2018, FUEL, V220, P546, DOI 10.1016/j.fuel.2018.01.143
   Titirici MM, 2007, CHEM MATER, V19, P4205, DOI 10.1021/cm0707408
   Titirici MM, 2012, ENERG ENVIRON SCI, V5, P6796, DOI 10.1039/c2ee21166a
   Wang TF, 2018, BIORESOURCE TECHNOL, V266, P275, DOI 10.1016/j.biortech.2018.06.093
   Weidema B. P., 2013, OVERVIEW METHDOLOGY
   Zhang LH, 2018, BIORESOURCE TECHNOL, V261, P10, DOI 10.1016/j.biortech.2018.03.089
   Zhang LH, 2017, BIORESOURCE TECHNOL, V230, P132, DOI 10.1016/j.biortech.2017.01.032
NR 30
TC 2
Z9 2
U1 12
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 111
EP 118
DI 10.1016/j.resconrec.2019.04.023
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700011
DA 2020-05-12
ER

PT J
AU Jiang, W
   Zhang, Z
   Deng, C
   Tang, X
   Feng, X
AF Jiang, Wei
   Zhang, Zhuang
   Deng, Chun
   Tang, Xu
   Feng, Xiao
TI Industrial park water system optimization with joint use of water
   utility sub-system
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Water system optimization; Superstructure; Industrial park; Mathematical
   model
ID PROPERTY INTEGRATION; GLOBAL OPTIMIZATION; NETWORKS; DESIGN; MANAGEMENT;
   MODEL; SUPERSTRUCTURE; DISCHARGE; OPTIONS; BATCH
AB This paper develops a new superstructure-based methodology for the synthesis of industrial park water system. The model includes sub-system of water utility, water-using and wastewater treatment for each single plant. It considers the single and inter-plant water integration and sharing strategy of water utility sub-system. The objective function is to minimize the partial annualized cost of the industrial park water system. Results show that all plants (i.e. Plants 1 and 2) in the industrial park can share a desalted water station in Plant 2. Because the water production ratio of desalted water station in Plant 2 is lower than that of Plant 1 and it indicates that the desalted water station in Plant 2 is with high efficiency to produce the same quality of desalted water. The cost can be decreased from 1.5 x 10(8) CNY/y (preliminary design) to 8.42 x 10(7) CNY/y (inter-plant optimization) with the flowrate reduction of water resource from 2694.954 t/h to 2045.184 t/h. It achieves the water minimization and effective joint use of water utility system.
C1 [Jiang, Wei; Zhang, Zhuang; Deng, Chun] China Univ Petr, State Key Lab Heavy Oil Proc, 18 Fuxue Rd, Beijing 102249, Peoples R China.
   [Tang, Xu] China Univ Petr, Sch Econ & Management, 18 Fuxue Rd, Beijing 102249, Peoples R China.
   [Feng, Xiao] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, 28 Xianning West Rd, Xian 710049, Shaanxi, Peoples R China.
RP Deng, C (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, 18 Fuxue Rd, Beijing 102249, Peoples R China.
EM chundeng@cup.edu.cn
OI Deng, Chun/0000-0003-0669-2805
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71673297, 21576287]; Science Foundation of China
   University of Petroleum, Beijing [2462018BJC003]
FX The authors thank National Natural Science Foundation of China (No.
   71673297 and 21576287) for supporting. The research is also supported by
   Science Foundation of China University of Petroleum, Beijing (No.
   2462018BJC003).
CR Aguilar-Oropeza G, 2019, IND ENG CHEM RES, V58, P2268, DOI 10.1021/acs.iecr.8b04419
   Alnouri SY, 2018, J CLEAN PROD, V171, P644, DOI 10.1016/j.jclepro.2017.09.236
   Alnouri SY, 2014, AICHE J, V60, P2853, DOI 10.1002/aic.14516
   Alnouri SY, 2014, CLEAN TECHNOL ENVIR, V16, P1637, DOI 10.1007/s10098-014-0739-2
   Aviso KB, 2014, PROCESS SAF ENVIRON, V92, P160, DOI 10.1016/j.psep.2012.12.001
   Aviso KB, 2010, CLEAN TECHNOL ENVIR, V12, P353, DOI 10.1007/s10098-009-0252-1
   Bishnu SK, 2014, IND ENG CHEM RES, V53, P8844, DOI 10.1021/ie5008932
   Boix M, 2012, J CLEAN PROD, V22, P85, DOI 10.1016/j.jclepro.2011.09.011
   Chen CL, 2010, COMPUT CHEM ENG, V34, P1522, DOI 10.1016/j.compchemeng.2010.02.024
   Chen CL, 2010, AICHE J, V56, P1845, DOI 10.1002/aic.12116
   Chew I., 2007, JOINT S CHEM MET ENG
   Chew IML, 2010, IND ENG CHEM RES, V49, P6439, DOI 10.1021/ie901802m
   Chew IML, 2009, CHEM ENG J, V153, P23, DOI 10.1016/j.cej.2009.05.026
   Chew IML, 2008, IND ENG CHEM RES, V47, P9485, DOI 10.1021/ie800072r
   Chew IML, 2009, J CLEAN PROD, V17, P1611, DOI 10.1016/j.jclepro.2009.08.005
   Deng C, 2018, J CLEAN PROD, V189, P878, DOI 10.1016/j.jclepro.2018.03.314
   Deng C, 2018, ACS SUSTAIN CHEM ENG, V6, P2302, DOI 10.1021/acssuschemeng.7b03754
   El-Halwagi MM, 2004, AICHE J, V50, P1854, DOI 10.1002/aic.10305
   Foo DCY, 2008, J ENVIRON MANAGE, V88, P253, DOI 10.1016/j.jenvman.2007.02.007
   Huang CH, 1999, IND ENG CHEM RES, V38, P2666, DOI 10.1021/ie990043s
   Liao ZW, 2007, IND ENG CHEM RES, V46, P4954, DOI 10.1021/ie061299i
   Liu L., 2018, COMPUTER AIDED CHEM, P1021
   Liu LL, 2018, COMPUT CHEM ENG, V108, P408, DOI 10.1016/j.compchemeng.2017.10.002
   Liu LL, 2017, COMPUT CHEM ENG, V104, P172, DOI 10.1016/j.compchemeng.2017.04.015
   Liu LL, 2016, COMPUT CHEM ENG, V91, P307, DOI 10.1016/j.compchemeng.2016.03.013
   Lopez-Morales CA, 2019, RESOUR CONSERV RECY, V140, P1, DOI 10.1016/j.resconrec.2018.09.001
   Lovelady EM, 2007, INT J ENVIRON POLLUT, V29, P274, DOI 10.1504/IJEP.2007.012807
   Lovelady EM, 2009, ENVIRON PROG SUSTAIN, V28, P265, DOI 10.1002/ep.10326
   Ponce-Ortega JM, 2011, AICHE J, V57, P2369, DOI 10.1002/aic.12444
   Ponce-Ortega JM, 2009, AICHE J, V55, P2329, DOI 10.1002/aic.11828
   Montastruc L, 2013, J CLEAN PROD, V43, P1, DOI 10.1016/j.jclepro.2012.12.039
   Napoles-Rivera F, 2010, CHEM ENG SCI, V65, P4363, DOI 10.1016/j.ces.2010.03.051
   Ng DKS, 2008, AICHE J, V54, P2624, DOI 10.1002/aic.11578
   OECD, 2012, OECD ENV OUTL 2050
   Olesen SG, 1996, PROCESS SAF ENVIRON, V74, P273, DOI 10.1205/095758296528626
   Ren KP, 2019, RESOUR CONSERV RECY, V143, P226, DOI 10.1016/j.resconrec.2019.01.003
   Rubio-Castro E, 2013, AICHE J, V59, P813, DOI 10.1002/aic.13874
   Rubio-Castro E, 2012, COMPUT CHEM ENG, V44, P58, DOI 10.1016/j.compchemeng.2012.05.004
   Spriggs D., 2004, 2004 AICHE SPRING NA, P2420
   Tan RR, 2011, PROCESS SAF ENVIRON, V89, P106, DOI 10.1016/j.psep.2010.11.004
   Tiu BTC, 2017, RESOUR CONSERV RECY, V119, P89, DOI 10.1016/j.resconrec.2016.06.005
   WANG YP, 1994, CHEM ENG SCI, V49, P981, DOI 10.1016/0009-2509(94)80006-5
   Zhao HP, 2016, J CLEAN PROD, V112, P4667, DOI 10.1016/j.jclepro.2015.07.130
NR 43
TC 2
Z9 2
U1 12
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 119
EP 127
DI 10.1016/j.resconrec.2019.04.005
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700012
DA 2020-05-12
ER

PT J
AU Brancoli, P
   Lundin, M
   Bolton, K
   Eriksson, M
AF Brancoli, Pedro
   Lundin, Magnus
   Bolton, Kim
   Eriksson, Mattias
TI Bread loss rates at the supplier-retailer interface-Analysis of risk
   factors to support waste prevention measures
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Bread; Retail; Take-back agreement; Waste prevention;
   Reasons
ID FOOD WASTE; PRODUCTS
AB This paper quantifies bread waste throughout the Swedish supply chain and investigates the loss rate of prepackaged bread products at the supplier-retailer interface. The goal is to understand the extent of bread waste in Sweden and to identify risk factors for high quantities of waste at the supplier-retailer interface, in order to provide information supporting waste prevention measures. The study uses primary data, in combination with national statistics and data from sustainability reports and the literature. Primary data were collected from 380 stores of a Swedish retail company and a bakery. Bread waste was calculated to be 80 410 tons/year in Sweden, the equivalent of 8.1 kg per person/year, and was found to be concentrated at households and in retail, specifically at the supplier-retailer interface. The results provide evidence that take-back agreements between suppliers and retailers, where the retailer only pays for sold products and the supplier bears the cost of the unsold products and their collection and treatment, are risk factors for high waste generation. Current business models may need to be changed to achieve a more sustainable bread supply chain with less waste.
C1 [Brancoli, Pedro; Lundin, Magnus; Bolton, Kim] Univ Boras, Swedish Ctr Resource Recovery, S-50190 Boras, Sweden.
   [Eriksson, Mattias] Swedish Univ Agr Sci, Dept Energy & Technol, Box 7032, S-75007 Uppsala, Sweden.
RP Brancoli, P (reprint author), Univ Boras, Swedish Ctr Resource Recovery, S-50190 Boras, Sweden.
EM pedro.brancoli@hb.se
RI Eriksson, Mattias/AAF-3553-2019; Brancoli, Pedro/P-2884-2019
OI Eriksson, Mattias/0000-0001-5586-0372; Brancoli,
   Pedro/0000-0002-0743-1335
FU Sparbanksstiftelsen Sjuharad
FX The authors are grateful for funding from Sparbanksstiftelsen Sjuharad.
CR Andersson T., 2012, FRAN HAGE MAGE EN ST
   Beretta C, 2013, WASTE MANAGE, V33, P764, DOI 10.1016/j.wasman.2012.11.007
   Brancoli P, 2017, RESOUR CONSERV RECY, V118, P39, DOI 10.1016/j.resconrec.2016.11.024
   Brook Lyndhurst ESA, 2012, HELPING CONSUMERS RE
   Brosowski A, 2016, BIOMASS BIOENERG, V95, P257, DOI 10.1016/j.biombioe.2016.10.017
   Cicatiello C, 2017, RESOUR CONSERV RECY, V125, P273, DOI 10.1016/j.resconrec.2017.06.010
   DLF Delfi HUI, 2018, DAGL
   Dutch Ministry of Economic Affairs A. a. l, 2014, PREV FOOD WAST OPT R
   EHI, 2011, NAHR LEB
   Eriksson M, 2017, RESOUR CONSERV RECY, V122, P83, DOI 10.1016/j.resconrec.2017.02.006
   Eriksson M, 2014, RESOUR CONSERV RECY, V83, P44, DOI 10.1016/j.resconrec.2013.11.011
   Eriksson M, 2012, RESOUR CONSERV RECY, V68, P14, DOI 10.1016/j.resconrec.2012.08.001
   Falasconi L, 2015, SUSTAINABILITY-BASEL, V7, P14745, DOI 10.3390/su71114745
   FAO, 2013, FOOD WAST FOOTPR IMP
   Garnett T, 2011, FOOD POLICY, V36, pS23, DOI 10.1016/j.foodpol.2010.10.010
   Garrone P, 2016, J CLEAN PROD, V137, P1076, DOI 10.1016/j.jclepro.2016.07.145
   Ghosh R, 2019, GLOB FOOD SECUR-AGR, V20, P1, DOI 10.1016/j.gfs.2018.10.002
   Hanssen O. J., 2011, INITIATIVES PREVENTI
   Hanssen OJ, 2016, RESOUR CONSERV RECY, V109, P146, DOI 10.1016/j.resconrec.2016.03.010
   Holweg C, 2016, INT J PHYS DISTR LOG, V46, P634, DOI 10.1108/IJPDLM-11-2014-0285
   Inkop Dagab, 2018, NUMBER CONVENIENCE S
   Ismatov A., 2015, SUSTAINABILITY IMPLI
   Jensen C., 2015, UPPFOLJNING ETAPPMAL
   Jensen C., 2017, UPPFOLJNING ETAPPMAL
   Katajajuuri JM, 2014, J CLEAN PROD, V73, P322, DOI 10.1016/j.jclepro.2013.12.057
   Kulikovskaja V, 2017, J INT FOOD AGRIBUS M, V29, P328, DOI 10.1080/08974438.2017.1350244
   Lebersorger S, 2014, WASTE MANAGE, V34, P1911, DOI 10.1016/j.wasman.2014.06.013
   Lewis H., 2017, FOOD WASTE OPPORTUNI
   Liljestrand K., 2016, REDUCING ENV IMPACT
   Livsmedelsverket Naturvardsverket Jordbruksverket, 2018, FLER GOR MER HANDL M
   Lyndhurst B, 2011, CONSUMER INSIGHT DAT
   Mena C, 2011, RESOUR CONSERV RECY, V55, P648, DOI 10.1016/j.resconrec.2010.09.006
   Moller H., 2014, REPORT REV FOOD WAST
   Mourad M, 2016, J CLEAN PROD, V126, P461, DOI 10.1016/j.jclepro.2016.03.084
   Ostergaard S., 2018, SUSTAINABILITY, V10, P1
   Ostergren K., 2014, P7KBBE20126311972 FU
   Polarbrod A. B., 2016, POLARBRODS HFILLBARH
   Redlingshofer B, 2017, J CLEAN PROD, V164, P703, DOI 10.1016/j.jclepro.2017.06.173
   Rohm H, 2017, FOODS, V6, DOI 10.3390/foods6120104
   SCB, 2018, STAT SWED POP STAT
   Schneider F., 2009, AUFKOMMEN VERWERTUNG
   Schroder J., 2017, DANSK SUPERMARKED GR
   Silvennoinen K, 2015, WASTE MANAGE, V46, P140, DOI 10.1016/j.wasman.2015.09.010
   SMED, 2015, UPPD MAT VERKS
   Statista, 2018, STAT CONS MARK OUTL
   Steinfeld H., 2006, LIVESTOCKS LONG SHAD
   Stenmarck A., 2016, ESTIMATES EUROPEAN F
   Stensgard A. E., 2016, FOOD WASTE NORWAY 20
   Sverige Avfall, 2017, SVENSK AVFALLSHANTER
   Tostivint C, 2016, FOOD WASTE QUANTIFIC
   USEPA, 2018, FOOD REC HIER
   van Donselaar K, 2006, INT J PROD ECON, V104, P462, DOI 10.1016/j.ijpe.2004.10.019
   van Woensel Tom, 2007, International Journal of Physical Distribution & Logistics Management, V37, P704, DOI 10.1108/09600030710840822
   Weegels P., 2010, FAST RETURN REUSING, P5
   Westoo A., 2018, MATAVFALL SVERIGE UP
   WRAP H Link Consumer Strategies Campden BRI, 2011, RED HOUSEH BAK WAST
   Xue L, 2017, ENVIRON SCI TECHNOL, V51, P6618, DOI 10.1021/acs.est.7b00401
NR 57
TC 1
Z9 1
U1 4
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 128
EP 136
DI 10.1016/j.resconrec.2019.04.027
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700013
DA 2020-05-12
ER

PT J
AU Cao, RJ
   Leng, Z
   Yu, HY
   Hsu, SC
AF Cao, Ruijun
   Leng, Zhen
   Yu, Huayuang
   Hsu, Shu-Chien
TI Comparative life cycle assessment of warm mix technologies in asphalt
   rubber pavements with uncertainty analysis
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Life cycle assessment; Uncertainty analysis; Asphalt rubber; Warm mix
   technologies
ID ENERGY-CONSUMPTION; CRUMB RUBBER; MANAGEMENT; MIXTURES; BINDERS; LCA
AB Asphalt rubber (AR) mixture has received growing attention in the past years because of its various advantages, such as potential energy recovery, excellent durability and lower tyre-road noise. However, its high construction temperature would result in increased energy consumption. As one of the solutions, warm mix asphalt (WMA) technologies can reduce the construction temperature with the assistance of various WMA additives, while the long-term environmental advantages still need to be explored. In this study, a life cycle assessment (LCA) framework incorporated with uncertainty analysis was built to identify the long-term energy-saving role of WMA technologies in AR pavement, and quantify the life cycle energy consumption of warm AR pavements built with three typical warm additives: organic wax, surfactant additive, and zeolite. The four uncertainty categories: material energy consumption, equipment energy consumption, mixing temperature reduction, and material transportation distance, were quantified and propagated through the Monte Carlo simulation. The results of this study showed a visible energy reduction due to usage of the WMA technologies during the material production stage. The importance of pavement roughness performance in the usage-stage energy contribution was signified, as the energy reduction benefits during the material production stage became insignificant when the usage stage was involved. In addition, by incorporating uncertainty analysis, more comprehensive information was provided for decision-making.
C1 [Cao, Ruijun; Leng, Zhen; Hsu, Shu-Chien] Hong Kong Polytech Univ, Dept Civil & Environm Engn, Hung Hom, Kowloon, Hong Kong, Peoples R China.
   [Yu, Huayuang] South China Univ Technol, Coll Civil Engn & Transportat, Guangzhou, Guangdong, Peoples R China.
RP Leng, Z (reprint author), Hong Kong Polytech Univ, Dept Civil & Environm Engn, Hung Hom, Kowloon, Hong Kong, Peoples R China.
EM ruijun.c.cao@connect.polyu.hk; zhen.leng@polyu.edu.hk;
   huayangyu@scut.edu.cn; mark.hsu@polyu.edu.hk
OI YU, Huayang/0000-0002-4051-4271; LENG, Zhen/0000-0002-7797-1134; Hsu,
   Shu-Chien/0000-0002-7232-9839
FU Research Institute for Sustainable Urban Development (RISUD) at the Hong
   Kong Polytechnic University
FX This study was conducted under the support of the Research Institute for
   Sustainable Urban Development (RISUD) at the Hong Kong Polytechnic
   University.
CR Akbarian M., 2012, MODEL BASED PAVEMENT
   American Association of State Highway and Transportation Officials (AASHTO), 2008, MECH EM PAV DES GUID
   [Anonymous], 2006, 35341 ISO
   [Anonymous], 2006, 14040 ISO
   [Anonymous], 2006, 14044 ISO
   Araujo JPC, 2014, TRANSPORT RES D-TR E, V32, P97, DOI 10.1016/j.trd.2014.07.006
   *ATH I, 2006, LIF CYCL PERSP CONCR
   Bartolozzi I., 2014, ENV ENG MANAGE J
   Berthiaume R, 1999, T CAN SOC MECH ENG, V23, P187
   Blengini GA, 2010, J CLEAN PROD, V18, P1021, DOI 10.1016/j.jclepro.2010.01.027
   Bryce JM, 2014, TRANSPORT RES D-TR E, V32, P435, DOI 10.1016/j.trd.2014.08.019
   Rubio MC, 2012, J CLEAN PROD, V24, P76, DOI 10.1016/j.jclepro.2011.11.053
   Celauro C., 2015, INT J LIFE CYCLE ASS, V34, P41, DOI DOI 10.1007/BF02978490
   Chatti K., 2012, ESTIMATING EFFECTS P
   Eurobitume, 2012, LIF CYCL INV BIT
   Farina A, 2017, RESOUR CONSERV RECY, V117, P204, DOI 10.1016/j.resconrec.2016.10.015
   Harm E., 2008, WARM MIX ASPHALT EUR
   Harvey J. T., 2016, PAVEMENT LIFE CYCLE
   Harvey J, 2014, GREEN ENERGY TECHNOL, P41, DOI 10.1007/978-3-662-44719-2_2
   Hassan M, 2010, INT J CONSTR ED RES, V6, P238, DOI DOI 10.1080/15578771.2010.507619
   Heijungs R, 2004, 9 INT C ENV MOD SOFT
   Hicks R. G, 2010, ASSESSMENT USE WARM
   Huijbregts M., 1998, INT J LIFE CYCLE ASS, V3, P273, DOI DOI 10.1007/BF02979835
   HUIJBREGTS MAJ, 1998, INT J LIFE CYCLE ASS, V3, P343, DOI DOI 10.1007/BF02979345
   Hurley G. C, 2009, OHIO FIELD TRIAL WAR
   Jiao X., 2015, INT J TRANSPORTATION, V4, P29, DOI DOI 10.1260/2046-0430.4.1.29
   Kristjansdottr O, 2007, TRANSP RES RECORD, P91, DOI 10.3141/2040-10
   Leng Z, 2018, TRANSPORTMETRICA A, V14, P562, DOI 10.1080/23249935.2017.1390707
   Leng Z, 2017, CONSTR BUILD MATER, V144, P291, DOI 10.1016/j.conbuildmat.2017.03.208
   Louhghalam A, 2017, J CLEAN PROD, V142, P956, DOI 10.1016/j.jclepro.2016.06.198
   Makela K., 1996, ENV ADAPTATION CONCR
   National Crushed Stone Association, 1977, FLEX PAV COST EST GU
   NCHRP (National Cooperative Highway Research Program), 2004, GUID MECH EMP DES NE
   Noshadravan A, 2013, TRANSPORT RES D-TR E, V25, P131, DOI 10.1016/j.trd.2013.10.002
   Prowell B., 2014, EFFECTS WMA PLANT EN, VII
   Rodriguez-Alloza AM, 2015, J CLEAN PROD, V90, P171, DOI 10.1016/j.jclepro.2014.11.035
   Santero NJ, 2011, RESOUR CONSERV RECY, V55, P801, DOI 10.1016/j.resconrec.2011.03.010
   Santos J, 2017, RESOUR CONSERV RECY, V116, P15, DOI 10.1016/j.resconrec.2016.08.025
   Stammer RE., 1995, ASSESSMENT ENERGY IM
   Stripple H., 2001, LIFE CYCLE ASSESSMEN
   *SWISS CTR LIF CYC, 2007, EC DAT
   Tatari O, 2012, RESOUR CONSERV RECY, V58, P18, DOI 10.1016/j.resconrec.2011.07.005
   Tufvesson LM, 2008, INT J LIFE CYCLE ASS, V13, P328, DOI 10.1007/s11367-008-0004-1
   Vidal R, 2013, RESOUR CONSERV RECY, V74, P101, DOI 10.1016/j.resconrec.2013.02.018
   Wang H., 2014, LIFE CYCLE ASSESSMEN
   Wang T., 2012, UCPRC LIFE CYCLE ASS
   Wang T, 2012, J CLEAN PROD, V33, P86, DOI 10.1016/j.jclepro.2012.05.001
   Weidema B.P., 1996, J CLEAN PROD, V4, P167, DOI DOI 10.1016/S0959-6526(96)00043-1
   Weidema B.P., 2013, OVERVIEW METHODOLOGY
   West R., 2014, ENG PROPERTIES FIELD
   Yu B, 2018, J CLEAN PROD, V189, P326, DOI 10.1016/j.jclepro.2018.04.068
   Yu B, 2018, INT J PAVEMENT ENG, V19, P519, DOI 10.1080/10298436.2016.1176166
   Yu H., 2017, APPL WARM ASPHALT RU
   Yu HY, 2018, CONSTR BUILD MATER, V175, P392, DOI 10.1016/j.conbuildmat.2018.04.218
   Yu HY, 2017, J CLEAN PROD, V141, P336, DOI 10.1016/j.jclepro.2016.09.043
   Yu HY, 2016, CONSTR BUILD MATER, V125, P168, DOI 10.1016/j.conbuildmat.2016.08.032
   Yu HY, 2016, CONSTR BUILD MATER, V111, P671, DOI 10.1016/j.conbuildmat.2016.02.066
   Yu JM, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8091495
   Zaabar I, 2010, TRANSPORT RES REC, P105, DOI 10.3141/2155-12
   Zapata P, 2005, J INFRASTRUCT SYST, V11, P9, DOI 10.1061/(ASCE)1076-0342(2005)11:1(9)
NR 60
TC 3
Z9 3
U1 15
U2 41
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 137
EP 144
DI 10.1016/j.resconrec.2019.04.031
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700014
DA 2020-05-12
ER

PT J
AU Du, JB
   Qiao, FX
   Yu, L
AF Du, Jianbang
   Qiao, Fengxiang
   Yu, Lei
TI Temporal characteristics and forecasting of PM2.5 concentration based on
   historical data in Houston, USA
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Air pollution; Time series analysis; PM2.5; Concentration factors;
   Temporal characteristics; Forecasting models
ID PARTICULATE MATTER PM2.5; AIR-POLLUTION; HYBRID MODEL; EMISSION; PM10;
   REGRESSION; EXPOSURE; DEPTH; CHINA; MASS
AB Urban PM2.5 has been recognized as a critical type of air pollutions that could damage the human respiratory system. Numerous studies have aimed to perform spatlotemporal assessment on diverse urban areas and proposed various PM2.5 forecasting models. Geographical variations and the inadequacy of hourly PM2.5 concentration forecasting are the main limitations of previous researches. The objectives of this paper are to elaborate the temporal characteristics of PM2.5 concentration of each geographic region in Houston, Texas, USA, from inland rural to coastal areas, and to build a forecasting model that could perform daily and hourly PM2.5 predictions. This research analyzed historical PM2.5 concentration data from 2008 to 2017 collected from five regions in Houston by the Texas Commission on Environmental Quality (TCEQ). Temporal characteristics calculation equations were provided. Analysis results revealed several important temporal characteristics of PM2.5 concentrations in Houston. The annual average daily PM2.5 concentration showed decreasing trends from 2008 to 2017. Higher PM2.5 concentration levels were observed in summer months than winter months. In downtown area the PM2.5 concentration levels were higher on weekdays than weekends. In rural, suburban, residential, and coastal areas the PM2.5 concentration levels were lower on weekdays than weekends. Moreover, PM(2.5 co)ncentration levels were significantly higher during traffic rush hours than other time intervals. The accuracy and precision of forecasting have been improved based on a combination of factors compared to the forecasting based solely on day-of-week factors (DWF), hourly concentration factors (HCF), and monthly concentration factors (MCF). Advantages of such combined forecasting include lowering calculation complexity and providing hourly concentration forecasting. Look-up tables for each temporal characteristic factor were provided that could be easily applied for further forecasting.
C1 [Du, Jianbang; Qiao, Fengxiang; Yu, Lei] Texas Southern Univ, Innovat Transportat Res Inst, 3100 Cleburne St, Houston, TX 77004 USA.
RP Du, JB (reprint author), Texas Southern Univ, Innovat Transportat Res Inst, 3100 Cleburne St, Houston, TX 77004 USA.
EM j.du7479@student.tsu.edu; fengxiang.qiao@tsu.edu; lei.yu@tsu.edu
FU National Science Foundation (NSF)National Science Foundation (NSF)
   [1137732]
FX The authors acknowledge that this research is supported in part by the
   National Science Foundation (NSF) under grants #1137732. The opinions,
   findings, and conclusions or recommendations expressed in this material
   are those of the author(s) and do not necessarily reflect the views of
   the funding agencies.
CR Allen D, 2004, STATE SCI AIR QUALIT
   Anderson JO, 2012, J MED TOXICOL, V8, P166, DOI 10.1007/s13181-011-0203-1
   Bateman A, 2011, RESOUR CONSERV RECY, V55, P1146, DOI 10.1016/j.resconrec.2011.07.004
   Blanchard C. L, 2012, J AIR WASTE MANAGE, V58, P1598
   Breysse PN, 2013, AIR QUAL ATMOS HLTH, V6, P333, DOI 10.1007/s11869-012-0181-8
   Dewitt H. L., 2018, AWMA 2018
   Du JB, 2018, ENVIRON ENG MANAG J, V17, P1237, DOI 10.30638/eemj.2018.123
   Dunea D, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121246
   Fan J, 2005, TEXAS J GEOPHYS RES, V110
   Flynn J, 2018, INVESTIGATION BACKGR
   Gao CK, 2019, RESOUR CONSERV RECY, V143, P184, DOI 10.1016/j.resconrec.2018.12.032
   Gasana J, 2012, ENVIRON RES, V117, P36, DOI 10.1016/j.envres.2012.05.001
   Hamra GB, 2014, ENVIRON HEALTH PERSP, V122, P906, DOI [10.1289/ehp.1408092, 10.1289/ehp/1408092]
   Hardin M, 1999, AEROSOLS CLIMATE CHA
   Hgac, 2017, PM25 HGAC HGB
   Johns DO, 2012, ENVIRON HEALTH PERSP, V120, P1238, DOI 10.1289/ehp.1204939
   Kis IM, 2016, RUD-GEOL-NAFT ZB, V31, P41
   Kloog I, 2012, ENVIRON SCI TECHNOL, V46, P11913, DOI 10.1021/es302673e
   Kulshrestha A, 2009, SCI TOTAL ENVIRON, V407, P6196, DOI 10.1016/j.scitotenv.2009.08.050
   Li Q, 2018, J POLLUT, V2
   Li W, 2017, RESOUR CONSERV RECY, V126, P162, DOI 10.1016/j.resconrec.2017.07.043
   Liu HY, 2018, ATMOSPHERE-BASEL, V9, DOI 10.3390/atmos9040150
   Liu YJ, 2014, AEROSOL AIR QUAL RES, V14, P954, DOI 10.4209/aaqr.2013.01.0023
   Ma L, 2019, RESOUR CONSERV RECY, V146, P441, DOI 10.1016/j.resconrec.2019.03.049
   Ma Z., 2015, ENV HLTH PERSPECT, V124, P184
   Matter P, 2014, STANDARDS TABLE HIST
   McKendry IG, 2002, J AIR WASTE MANAGE, V52, P1096, DOI 10.1080/10473289.2002.10470836
   Oakes M, 2014, ENVIRON INT, V69, P90, DOI 10.1016/j.envint.2014.03.030
   Omidvarborna H, 2015, RENEW SUST ENERG REV, V48, P635, DOI 10.1016/j.rser.2015.04.019
   Orru H, 2011, AIR QUAL ATMOS HLTH, V4, P247, DOI 10.1007/s11869-010-0075-6
   Perez P, 2008, ATMOS ENVIRON, V42, P8219, DOI 10.1016/j.atmosenv.2008.07.035
   Perkinson D. G, 1999, COMMUTING TEXAS PATT
   Querol X, 2004, ATMOS ENVIRON, V38, P6547, DOI 10.1016/j.atmosenv.2004.08.037
   Russell M, 2004, AEROSOL SCI TECH, V38, P14, DOI 10.1080/02786820390229318
   Smith RL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002914
   Stanek LW, 2011, ATMOS ENVIRON, V45, P5655, DOI 10.1016/j.atmosenv.2011.07.023
   Tai APK, 2010, ATMOS ENVIRON, V44, P3976, DOI 10.1016/j.atmosenv.2010.06.060
   TCEQ, 2018, 2018 ANN MON NETW PL
   Turpin BJ, 2001, AEROSOL SCI TECH, V35, P602, DOI 10.1080/02786820152051454
   USCB, 2017, MAP POP COUNT SUBD H
   Wang SJ, 2017, J CLEAN PROD, V142, P1800, DOI 10.1016/j.jclepro.2016.11.104
   Wei F, 1999, ENVIRON SCI TECHNOL, V33, P4188, DOI 10.1021/es9904944
   WILLMOTT CJ, 1982, B AM METEOROL SOC, V63, P1309, DOI 10.1175/1520-0477(1982)063<1309:SCOTEO>2.0.CO;2
   WILLMOTT CJ, 1985, J GEOPHYS RES-OCEANS, V90, P8995, DOI 10.1029/JC090iC05p08995
   Xiao QY, 2018, ENVIRON SCI TECHNOL, V52, P13260, DOI 10.1021/acs.est.8b02917
   Xiao ZM, 2011, AEROSOL AIR QUAL RES, V11, P873, DOI 10.4209/aaqr.2011.04.0052
   Yang WL, 2017, AEROSOL AIR QUAL RES, V17, P1610, DOI 10.4209/aaqr.2016.06.0220
   Zheng S, 2018, RESOUR CONSERV RECY, V137, P145, DOI 10.1016/j.resconrec.2018.06.004
   Zhou QP, 2014, SCI TOTAL ENVIRON, V496, P264, DOI 10.1016/j.scitotenv.2014.07.051
   Zumla A, 2015, LANCET GLOB HEALTH, V3, pE10, DOI 10.1016/S2214-109X(14)70361-4
NR 50
TC 4
Z9 4
U1 11
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 145
EP 156
DI 10.1016/j.resconrec.2019.04.024
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700015
DA 2020-05-12
ER

PT J
AU Pantini, S
   Giurato, M
   Rigamonti, L
AF Pantini, S.
   Giurato, M.
   Rigamonti, L.
TI A LCA study to investigate resource-efficient strategies for managing
   post-consumer gypsum waste in Lombardy region (Italy)
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Gypsum waste; Plasterboards; Recycling; Recycled gypsum; Waste
   management; Environmental assessment
ID LIFE-CYCLE ASSESSMENT; RECYCLED GYPSUM; MANAGEMENT
AB This study aimed at evaluating environmental sustainable solutions for managing the gypsum waste in Lombardy region (Italy), based on the Life Cycle Assessment (LCA) methodology. Primary data and information related to gypsum waste flows, recovery technologies and end-market of recycled materials were gathered to depict the whole recycling chain and to build up a life cycle inventory dataset specific for the geographical context under study. The LCA analysis of the current scenario allowed to identify strength and weak points of the regional system: up to date, most impacts are related to the recovery of gypsum waste by mixing with other mineral construction and demolition waste, which appeared as the prevalent option. Different alternative scenarios were hence analyzed by considering that all the gypsum waste is recycled in dedicated plants and by analyzing different end-uses of the recycled material. The focus was placed on four major sectors for which the use of recycled gypsum is technically feasible: plasterboard manufacturing, cement industry, disinfection of sewage sludge, and agriculture. For each analyzed end-use scenario, the potential market demand in Lombardy region as well as the technical requirements of the recycled gypsum were evaluated as key points in the LCA. Results from the impact assessment were used to provide recommendations for the regional government to move towards a more resource-efficient waste management.
C1 [Pantini, S.; Giurato, M.; Rigamonti, L.] Politecn Milan, Dept Civil & Environm Engn, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.
   [Pantini, S.; Rigamonti, L.] LEAP, MatER Resource Ctr, Via Nino Bixio 27-C, I-29121 Piacenza, Italy.
RP Pantini, S (reprint author), Politecn Milan, Dept Civil & Environm Engn, Piazza Leonardo da Vinci 32, I-20133 Milan, Italy.; Pantini, S (reprint author), LEAP, MatER Resource Ctr, Via Nino Bixio 27-C, I-29121 Piacenza, Italy.
EM sara.pantini@polimi.it
RI rigamonti, lucia/E-3943-2016
OI rigamonti, lucia/0000-0001-5468-9577; Giurato,
   Mattia/0000-0001-8476-4195
FU Regione LombardiaRegione Lombardia
FX The study was supported by Regione Lombardia. We thank ANPAR, ANCE, ARPA
   Lombardia, and the managers of the contacted recycling plants, quarries
   and manufacturers for the technical support and for having supplied
   primary data for the LCA.
CR AZTEC (Associazione Italiana Tecnico Economica Cemento), 2014, ANN REP 2014 IT LANG
   Bauer C., 2012, THESIS
   Biganzoli L, 2015, SCI TOTAL ENVIRON, V524, P361, DOI 10.1016/j.scitotenv.2015.04.041
   Blengini GA, 2010, J CLEAN PROD, V18, P1021, DOI 10.1016/j.jclepro.2010.01.027
   Borghi G, 2018, J CLEAN PROD, V184, P815, DOI 10.1016/j.jclepro.2018.02.287
   Butera S., 2011, P SARD 2011 13 INT W
   Chandara C, 2009, WASTE MANAGE, V29, P1675, DOI 10.1016/j.wasman.2008.11.014
   Codinho-Castro AP, 2012, WASTE MANAGE, V32, P153, DOI 10.1016/j.wasman.2011.08.019
   CRI, 2010, CONSTR REC IN CRI PO
   De Meester S, 2019, RESOUR CONSERV RECY, V142, P1, DOI 10.1016/j.resconrec.2018.10.015
   DUSAF (Destinazione d'Uso dei Suoli Agricoli e Forestali), 2010, REP US SUOL REG LOMB
   EC-JRC, 2010, ILCD HDB GEN GUID LI
   Ekvall T, 2007, WASTE MANAGE, V27, P989, DOI 10.1016/j.wasman.2007.02.015
   Erbs A, 2018, J CLEAN PROD, V183, P1314, DOI 10.1016/j.jclepro.2018.02.189
   European Commission (EC) JRC (Joint Research Center), 2011, REC LIF CYCL IMP ASS
   Finnveden G, 2009, J ENVIRON MANAGE, V91, P1, DOI 10.1016/j.jenvman.2009.06.018
   FRISCHKNECHT R., 2007, 3 SWISS CTR LIF CYCL
   Geraldo RH, 2017, J CLEAN PROD, V164, P288, DOI 10.1016/j.jclepro.2017.06.188
   Coelho LMG, 2018, RESOUR CONSERV RECY, V128, P438, DOI 10.1016/j.resconrec.2016.09.026
   GtoG Project, 2013, ENVBE001039 G G LIFE
   GtoG Project, 2013, LIF GYPS GYPS PROJ E
   GtoG Project, 2015, LIF GYPS GYPS PROJ E
   Jimenez Rivero A., 2015, INT J SUSTAIN POLICY, V11, P1, DOI DOI 10.18848/2325-1166/CGP/V11104/55358
   Rivero AJ, 2016, RESOUR CONSERV RECY, V108, P171, DOI 10.1016/j.resconrec.2016.01.014
   Jimenez-Rivero A., 2017, MATER CONSTRUCC, V67, P1
   Jimenez-Rivero A, 2017, J CLEAN PROD, V167, P1335, DOI 10.1016/j.jclepro.2017.05.068
   Kuttah D, 2015, TRANSP GEOTECH, V4, P28, DOI 10.1016/j.trgeo.2015.06.003
   Lam CM, 2018, J CLEAN PROD, V199, P840, DOI 10.1016/j.jclepro.2018.07.199
   Marcinkowski A., 2018, P 15 INT C MULT ASP, V1, P793
   Ndukwe I., 2016, RECYCLING, V1, P311, DOI [10.3390/recycling1030311, DOI 10.3390/RECYCLING1030311]
   Papailiopoulou N., 2018, J REMANUFACTURING, P1, DOI [10.1007/s13243-018-0062-x, DOI 10.1007/S13243-018-0062-X]
   Pedreno-Rojas MA, 2019, J CLEAN PROD, V215, P444, DOI 10.1016/j.jclepro.2019.01.053
   Rigamonti L, 2013, WASTE MANAGE RES, V31, P946, DOI 10.1177/0734242X13493957
   Suarez S, 2016, J CLEAN PROD, V117, P150, DOI 10.1016/j.jclepro.2016.01.044
   WRAP, 2008, TECHN REP LIF CYCL A
NR 35
TC 0
Z9 0
U1 7
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 157
EP 168
DI 10.1016/j.resconrec.2019.04.019
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700016
DA 2020-05-12
ER

PT J
AU Beretta, C
   Hellweg, S
AF Beretta, Claudio
   Hellweg, Stefanie
TI Potential environmental benefits from food waste prevention in the food
   service sector
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste reduction; Food service sector; LCA; Environmental impacts;
   SDG 12.3
ID FRESH-WATER; IMPACTS; LOSSES; CONSUMPTION; REDUCTION
AB Approximately 88 Mt of food are wasted every year in the European Union and are responsible for 15-16% of the environmental impact of its entire food value chain. The United Nations' Sustainable Development Goal (SDG) 12.3 demands per capita global food waste (FW) at the retail and consumer levels to be halved by 2030. This study aims to identify whether the SDG 12.3 is realistic and to assess the associated climate, biodiversity, and aggregated environmental benefits from FW prevention in the food service sector. The FW reduction potential is assessed in 13 case studies that implemented measures for reduction. We estimate status quo avoidable FW at 108 g/meal (13% of purchased food), causing 238 g CO2-eq/meal. FW reduction achieved in the case studies ranges from 32% of status quo in the education subsector to 62% in the business subsector. On average, a 38% decrease in FW amounts reduces climate impacts of FW by 41% and biodiversity impacts by 30%. In an extended reduction scenario, food services use 50% non-marketable vegetables that would otherwise be wasted throughout the food value chain. In combination, FW amounts are reduced by 70%. We conclude that the SDG 12.3 is realistic and can even be exceeded in the long term. Initial investments and political support are important to reach individual food services.
C1 [Beretta, Claudio; Hellweg, Stefanie] Swiss Fed Inst Technol, Inst Environm Engn, John von Neumann Weg 9, CH-8093 Zurich, Switzerland.
RP Beretta, C (reprint author), Swiss Fed Inst Technol, Inst Environm Engn, John von Neumann Weg 9, CH-8093 Zurich, Switzerland.
EM beretta@ifu.baug.ethz.ch
RI Hellweg, Stefanie/AAA-7756-2019
OI Hellweg, Stefanie/0000-0001-6376-9878
FU Swiss Federal Office for the Environment (FOEN)
FX ETH was supported by the Swiss Federal Office for the Environment
   (FOEN).
CR Andrini M, 2005, BIOGENE ABFALLE KENT
   BAFU, 2017, ZUST MASSN HAL UNPUB
   Baier U, 2014, 12 BAFU
   Baier U., 2007, BEWIRTSCHAFTUNG ORGA
   Bengoa X., 2015, WORLD FOOD LCA DATAB
   Beretta C, 2017, ENVIRON SCI TECHNOL, V51, P11165, DOI 10.1021/acs.est.6b06179
   Betz A, 2013, THESIS
   Blonk, 2016, AGR FOOTPR LCA FOOD
   Chaudhary A., 2016, ENV SCI TECHNOL
   Chaudhary A, 2015, ENVIRON SCI TECHNOL, V49, P9987, DOI 10.1021/acs.est.5b02507
   Dias-Ferreira C, 2015, WASTE MANAGE, V46, P146, DOI 10.1016/j.wasman.2015.09.025
   Ecoinvent, 2016, EC DAT
   Engstrom R, 2004, FOOD POLICY, V29, P203, DOI 10.1016/j.foodpol.2004.03.004
   Eriksson M, 2018, RESOUR CONSERV RECY, V130, P140, DOI 10.1016/j.resconrec.2017.11.030
   FAO, 2013, FOOD WAST FOOTPR IMP
   Frischknecht R, 2013, ENV STUDIES, V1330
   Garcia-Herrero I, 2018, FOOD POLICY, V80, P24, DOI 10.1016/j.foodpol.2018.08.007
   GastroSuisse, 2017, GASTROSUISSE BRANCH
   Goedkoop M, 2013, RECIPE 2008 LIFE CYC
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Gut F, 2018, COMMUNICATION
   Hrad M, 2015, ASSESSMENT FOOD WAST
   Hrad M., 2016, FOOD WASTE GENERATIO
   Kraut H, 2008, FOOD COMPOSITION NUT
   Kummu M, 2012, SCI TOTAL ENVIRON, V438, P477, DOI 10.1016/j.scitotenv.2012.08.092
   MILLENIUM ECOSYSTEM ASSESSMENT, 2005, EC HUM WELL BEING SY
   Oakdene H, 2013, OVERVIEW WASTE UK HO
   Pekcan G., 2006, HOUSEHOLD WASTAGE TU
   Pfister S, 2014, J CLEAN PROD, V73, P52, DOI 10.1016/j.jclepro.2013.11.031
   Pirani SI, 2016, J CLEAN PROD, V132, P129, DOI 10.1016/j.jclepro.2015.07.146
   Scherer L, 2016, ENVIRON SCI TECHNOL, V50, P7019, DOI 10.1021/acs.est.6b00740
   Scherhaufer S, 2018, WASTE MANAGE, V77, P98, DOI 10.1016/j.wasman.2018.04.038
   Silvennoinen K, 2015, WASTE MANAGE, V46, P140, DOI 10.1016/j.wasman.2015.09.010
   Steffen W, 2015, SCIENCE, V347, DOI 10.1126/science.1259855
   Stocker TF, 2014, CLIMATE CHANGE 2013: THE PHYSICAL SCIENCE BASIS, P1, DOI 10.1017/cbo9781107415324
   SVG, 2015, SVG SCHWEIZ VERB SPI
   Usubiaga A, 2018, J IND ECOL, V22, P574, DOI 10.1111/jiec.12695
   von Borstel T, 2017, ZWISCHENBILANZ 2017
   Waskow F, 2017, 2 NRW
NR 39
TC 4
Z9 4
U1 8
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 169
EP 178
DI 10.1016/j.resconrec.2019.03.023
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700017
DA 2020-05-12
ER

PT J
AU Nicholes, MJ
   Quested, TE
   Reynolds, C
   Gillick, S
   Parry, AD
AF Nicholes, Miranda J.
   Quested, Tom E.
   Reynolds, Christian
   Gillick, Sam
   Parry, Andrew D.
TI Surely you don't eat parsnip skins? Categorising the edibility of food
   waste
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Food waste; Edibility; Food behaviour; Questionnaire study; Behaviour
   and perception survey; Household behaviour
ID INTERVENTIONS; MANAGEMENT; DRIVERS; DESIGN
AB Food that is either wasted or lost, rather than being eaten, accounts for around a third of global food production and is linked to several environmental, economic and social issues. The reliable quantification of this wasted food is essential to monitor progress towards the United Nations' Sustainable Development Goal 12.3, which covers food loss and waste. Currently quantification of food waste is made difficult by many differing definitions, some of which require categorisation of food items into those parts considered edible and those considered inedible. Edibility is difficult to define as it is affected by cultural and social influences. This study presents a novel, easily-replicable, questionnaire-based methodology to categorise 'borderline' food items thrown away from households, e.g. parsnip skin, apple cores. The methodology captures self-reported information on what people eat (self-reported consumption) and their perceptions of edibility. Our results for the United Kingdom indicate that, for a given food 'part', there is divergence between individuals' responses to the survey questions: e.g. many people would 'never' eat carrot skins, whilst many others would 'always' eat them. Furthermore, there is a systematic difference between people's self-reported consumption and their perceptions of edibility. We suggest that both need to be considered to create a balanced categorisation of edible and inedible parts; we propose a method for incorporating both elements. Within this method, a threshold needs to be applied and the resultant classification, especially of those items close to this threshold, will inevitably be contentious. Despite this, the categorisation of what is considered edible using this methodology reflects the views of the majority of the population, facilitating the quantification of food waste. In addition, we envisage this methodology can be used to compare geographical differences and track changes over time with regard to edibility.
C1 [Nicholes, Miranda J.; Quested, Tom E.; Reynolds, Christian; Gillick, Sam; Parry, Andrew D.] Blenhe Court, Wrap, 19 George St, Banbury OX16 5BH, England.
   [Reynolds, Christian] Univ Sheffield, Sch Geog, Sheffield S10 2TN, S Yorkshire, England.
RP Quested, TE (reprint author), Blenhe Court, Wrap, 19 George St, Banbury OX16 5BH, England.
EM tom.quested@wrap.org.uk
RI Reynolds, Christian/L-2760-2015
OI Reynolds, Christian/0000-0002-1073-7394
FU UK Government's Department of Environment, Food and Rural Affairs
   (Defra)Department for Environment, Food & Rural Affairs (DEFRA);
   NERCNERC Natural Environment Research Council [NE/R007160/1]
FX This research was conducted as part of WRAP's wider work quantifying
   food waste, supported by funding from the UK Government's Department of
   Environment, Food and Rural Affairs (Defra). Christian Reynolds has
   funding from NERC to support an Innovation Placement at Waste &
   Resources Action Programme (WRAP) (Grant Ref: NE/R007160/1).
CR [Anonymous], 2016, ESTIMATES EUROPEAN F
   [Anonymous], 2017, SUST DEV GOALS REP
   [Anonymous], 2017, GUIDANCE INTERPRETIN
   Camovale E., 2000, TABELLE COMPOSIZIONE
   Chaboud G, 2017, GLOB FOOD SECUR-AGR, V12, P1, DOI 10.1016/j.gfs.2016.11.004
   De Laurentiis V, 2018, WASTE MANAGE, V77, P238, DOI 10.1016/j.wasman.2018.04.001
   Ericsson K. A., 1998, MIND CULT ACT, V5, P178, DOI DOI 10.1207/S15327884MCA0503_3
   Evans D., 2014, FOOD WASTE HOME CONS
   FAO, 2011, GLOBAL FOOD LOSSES F
   FUSIONS, 2016, FUS RED FOOD WAST SO
   Hebrok M, 2017, J CLEAN PROD, V151, P380, DOI 10.1016/j.jclepro.2017.03.069
   Koivupuro HK, 2012, INT J CONSUM STUD, V36, P183, DOI 10.1111/j.1470-6431.2011.01080.x
   Papargyropoulou E, 2014, J CLEAN PROD, V76, P106, DOI 10.1016/j.jclepro.2014.04.020
   Porpino G, 2016, J ASS CONSUMER RES, V1, P41, DOI DOI 10.1086/684528
   Public Health England, 2015, MCCANCE WIDD COMP FO
   R. R Core Team, 2017, LANG ENV STAT COMP
   Reynolds C, 2019, FOOD POLICY, V83, P7, DOI 10.1016/j.foodpol.2019.01.009
   Rimestad A. H, 2017, NORWEGIAN FOOD COMPO
   Romani S, 2018, APPETITE, V121, P215, DOI 10.1016/j.appet.2017.11.093
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Stancu V., 2018, CONSUMER FOOD WASTE
   Stockli S, 2018, RESOUR CONSERV RECY, V136, P445, DOI 10.1016/j.resconrec.2018.03.029
   Thyberg KL, 2016, RESOUR CONSERV RECY, V106, P110, DOI 10.1016/j.resconrec.2015.11.016
   United States Department of Agriculture Agricultural Research Service, 2015, USDA NAT NUTR DAT ST
   WRAP, 2013, HOUS FOOD DRINK WAST
   WRAP, 2008, THE FOOD WE WAST
   WRAP, 2014, HOUS FOOD DRINK WAST
   WRAP, 2018, HOUS FOOD WAST REST
   WRAP, 2009, HOUS FOOD DRINK WAST
   Wrap, 2015, HOUS FOOD WAST UK 20
NR 30
TC 2
Z9 2
U1 8
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 179
EP 188
DI 10.1016/j.resconrec.2019.03.004
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700018
DA 2020-05-12
ER

PT J
AU Heard, BR
   Bandekar, M
   Vassa, B
   Miller, SA
AF Heard, Brent R.
   Bandekar, Mayur
   Vassa, Benjamin
   Miller, Shelie A.
TI Comparison of life cycle environmental impacts from meal kits and
   grocery store meals
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE E-commerce; Food waste; Packaging; Supply chain management; Food
   retailing; Last-mile transportation
ID FOOD WASTE; CLIMATE-CHANGE; SUSTAINABILITY; RETAIL; SUPERMARKETS;
   CONSUMPTION; FRAMEWORK; BENEFITS; DELIVERY; ONLINE
AB Meal kits contain ingredients for cooking a meal that are pre-portioned, packaged, and delivered to a consumer's residence. Life cycle environmental impacts associated with climate change, acidification, eutrophication, land use, and water use are compared for five dinner recipes sourced as meal kits and through grocery store retailing. Inventory data are obtained from direct measurement of ingredients and packaging, supplemented with literature data for supply chain and production parameters. Results indicate that, on average, grocery meal greenhouse gas emissions are 33% higher than meal kits (8.1 kg CO(2)e/meal compared with 6.1 kg CO(2)e/meal kit). Other impact categories follow similar trends. A Monte Carlo analysis finds higher median emissions for grocery meals than meal kits for four out of five meals, occurring in 100% of model runs for two of five meals. Results suggest that meal kits' streamlined and direct-to-consumer supply chains (-1.05 kg CO(2)e/meal), reduced food waste (-0.86 kg CO(2)e/meal), and lower last-mile transportation emissions ( 0.45 kg CO(2)e/meal), appear to be sufficient to offset observed increases in packaging (0.17 kg CO(2)e/meal). Additionally, meal kit refrigeration packs present an average emissions decrease compared with retail refrigeration (-0.37 kg CO(2)e/meal). Meals with the largest environmental impact either contain red meat or are associated with large amounts of wasted food. The one meal kit with higher emissions is due to food mass differences rather than supply chain logistics. Meal kits are an evolving mode for food supply, and the environmental effects of potential changes to meal kit provision and grocery retailing are discussed.
C1 [Heard, Brent R.; Miller, Shelie A.] Univ Michigan, Sch Environm & Sustainabil, Ctr Sustainable Syst, 440 Church St, Ann Arbor, MI 48109 USA.
   [Bandekar, Mayur; Miller, Shelie A.] Univ Michigan, Program Environm, 440 Church St, Ann Arbor, MI 48109 USA.
   [Vassa, Benjamin] Univ Michigan, A Alfred Taubman Coll Architecture & Urban Planni, 2000 Bonisteel Blvd, Ann Arbor, MI 48109 USA.
RP Heard, BR (reprint author), Univ Michigan, Sch Environm & Sustainabil, Ctr Sustainable Syst, 440 Church St, Ann Arbor, MI 48109 USA.
EM brheard@umich.edu
RI ; Heard, Brent/P-7602-2016
OI Miller, Shelie/0000-0003-0379-3993; Heard, Brent/0000-0001-9761-2043
FU National Science Foundation Environmental Sustainability program [CBET
   1804287]
FX This work was supported by the National Science Foundation Environmental
   Sustainability program under Grant No. CBET 1804287. Any opinions,
   findings, and conclusions or recommendations expressed in this material
   are those of the author(s) and do not necessarily reflect the views of
   the National Science Foundation. The authors thank Alison Grantham and
   Hannah Koski from Blue Apron, LLC for their input and review of major
   assumptions. Blue Apron, LLC has not financially contributed to this
   project nor are there any conflicts of interest to declare.
CR Belavina E, 2017, MANAGE SCI, V63, P1781, DOI 10.1287/mnsc.2016.2430
   Bjorklund AE, 2002, INT J LIFE CYCLE ASS, V7, P64, DOI 10.1065/lca2001.12/071
   Brown JR, 2014, INT J LOGIST-RES APP, V17, P503, DOI 10.1080/13675567.2014.907397
   Butler K, 2017, MOTHER JONES
   Buzby J. C., 2014, EC INFORM B, DOI [10.2139/ssrn.2501659, DOI 10.2139/SSRN.2501659]
   Buzby JC, 2012, FOOD POLICY, V37, P561, DOI 10.1016/j.foodpol.2012.06.002
   Corrado S, 2017, J CLEAN PROD, V140, P847, DOI 10.1016/j.jclepro.2016.06.050
   Davis J, 2008, INT J LIFE CYCLE ASS, V13, P574, DOI 10.1007/s11367-008-0031-y
   Defra, 2008, FO405 DEFR
   Eriksson M, 2016, RESOUR CONSERV RECY, V107, P73, DOI 10.1016/j.resconrec.2015.11.022
   FAO Natural Resources and Management Department, 2013, AR429 FAO NAT RES MA
   Fenton K., 2017, UNPACKING SUSTAINABI
   Gallego-Schmid A, 2018, SCI TOTAL ENVIRON, V628-629, P979, DOI 10.1016/j.scitotenv.2018.02.128
   Giuseppe A, 2014, WASTE MANAGE, V34, P1306, DOI 10.1016/j.wasman.2014.02.018
   Goulias K., 2007, TRANSPORT RES REC, DOI 10.3141/1725-01
   Graham-Rowe E, 2014, RESOUR CONSERV RECY, V84, P15, DOI 10.1016/j.resconrec.2013.12.005
   Gunders D., 2012, WASTED AM IS LOSING
   Gustavsson J., 2011, GLOBAL FOOD LOSSES F
   Heard BR, 2016, ENVIRON SCI TECHNOL, V50, P12060, DOI 10.1021/acs.est.6b02740
   Heller MC, 2019, J IND ECOL, V23, P480, DOI 10.1111/jiec.12743
   Hottle TA, 2013, POLYM DEGRAD STABIL, V98, P1898, DOI 10.1016/j.polymdegradstab.2013.06.016
   Hou P, 2018, J CLEAN PROD, V201, P1052, DOI 10.1016/j.jclepro.2018.07.278
   Leach M, 2009, GROCERY STORE 50 ENE
   LIPTON J, 1995, REGUL TOXICOL PHARM, V21, P192, DOI 10.1006/rtph.1995.1024
   Lloyd SM, 2007, J IND ECOL, V11, P161, DOI 10.1162/jiec.2007.1136
   Lu L, 2018, AM J AGR ECON, V100, P1320, DOI 10.1093/ajae/aay056
   Marsh K, 2007, J FOOD SCI, V72, pR39, DOI 10.1111/j.1750-3841.2007.00301.x
   Matthews S.H., 2002, ENVIRON IMPACT ASSES, V22, P493, DOI DOI 10.1016/S0195-9255(02)00024-0
   Miller SA, 2015, ENVIRON SCI TECHNOL, V49, P3067, DOI 10.1021/es505217a
   Neff RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127881
   Nemecek T, 2016, INT J LIFE CYCLE ASS, V21, P607, DOI 10.1007/s11367-016-1071-3
   Niles MT, 2018, RENEW AGR FOOD SYST, V33, P297, DOI 10.1017/S1742170518000029
   Pan SL, 2017, IND MANAGE DATA SYST, V117, P1917, DOI 10.1108/IMDS-10-2016-0432
   Pelletier N, 2015, ENVIRON SCI TECHNOL, V49, P7515, DOI 10.1021/acs.est.5b00441
   Punakivi M., 2001, INT J PHYS DISTRIB, V31, P427, DOI DOI 10.1108/09600030110399423
   Rivera XCS, 2016, J CLEAN PROD, V112, P214, DOI 10.1016/j.jclepro.2015.07.111
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Schaubroeck T, 2018, J CLEAN PROD, V187, P672, DOI 10.1016/j.jclepro.2018.03.265
   Siikavirta H., 2002, J IND ECOL, V6, P83, DOI DOI 10.1162/108819802763471807
   Silvenius E, 2011, LIFE CYCLE SUSTAINAB, P359
   Sonesson U, 2005, AMBIO, V34, P414, DOI 10.1639/0044-7447(2005)034[0414:IPVHCA]2.0.CO;2
   Stancu V, 2016, APPETITE, V96, P7, DOI 10.1016/j.appet.2015.08.025
   Stein R, 2017, WIRED
   Stolaroff JK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02411-5
   The Nielsen Company, 2018, MEAL KIT MAN INN FOO
   Turner DA, 2015, RESOUR CONSERV RECY, V105, P186, DOI 10.1016/j.resconrec.2015.10.026
   U. S. Department of Energy, 2018, FUEL EC
   United Nations Environment Programme, 2016, 28 M PART MONTR PROT
   US Environmental Protection Agency, 2016, TRANS LOW GWP ALT CO
   USDA Economic Research Service, 2018, FOODAPS NAT HOUS FOO
   Venkat K., 2011, International Journal on Food System Dynamics, V2, P431
   Vermeulen SJ, 2012, ANNU REV ENV RESOUR, V37, P195, DOI 10.1146/annurev-environ-020411-130608
   Weber CL, 2010, J IND ECOL, V14, P754, DOI 10.1111/j.1530-9290.2010.00269.x
   Wiese A, 2012, TRANSPORT RES D-TR E, V17, P473, DOI 10.1016/j.trd.2012.05.007
   Wilson R., 2017, WHY SHAKEOUT MEAL KI
   Wygonik E., 2012, J TRANSPORTATION RES, V51, P111, DOI DOI 10.5399/0SU/JTRF.51.2.2926
   Yang XN, 2017, EUR J OPER RES, V263, P935, DOI 10.1016/j.ejor.2017.06.034
   Yrjola H., 2001, INT J PHYS DISTRIB, V31, P746, DOI DOI 10.1108/09600030110411419.YRJ0LA
NR 58
TC 2
Z9 2
U1 13
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 189
EP 200
DI 10.1016/j.resconrec.2019.04.008
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700019
DA 2020-05-12
ER

PT J
AU Liu, Y
   Feng, C
AF Liu, Ying
   Feng, Chao
TI What drives the fluctuations of "green" productivity in China's
   agricultural sector? A weighted Russell directional distance approach
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Agriculture; Green; Productivity growth; Factor decomposition; WRDDM;
   Global DEA
ID ENVIRONMENTALLY SENSITIVE PRODUCTIVITY; EFFICIENCY CHANGE; INDUSTRIAL
   SECTORS; ENERGY EFFICIENCY; CO2 EMISSIONS; TECHNOLOGICAL-PROGRESS;
   STRUCTURAL-CHANGE; ECONOMIC-REFORMS; STEEL-INDUSTRY; GROWTH
AB China is the most populous country in the world, and agriculture has played a large role in the country's remarkable economic achievements. However, the high levels of pollution and emissions from agriculture pose a threat to the nation's food and ecological security. Using a global weighted Russell distance function model, this paper attempts to provide strategies for the green development of China's agriculture by investigating the historical green total factor productivity. The results show that (1) during the sample period, China's agricultural green total factor productivity (AGTFP) showed a u-shaped trend, and the turning point was 2010. Technological progress in terms of agricultural output, energy use and pollutant treatment was the most powerful factor of growth after 2010, while the technological retrogression in terms of capital use was the main obstacle to growth. (2) Eastern China has the highest AGTFP, while western China has the highest AGTFP growth rate. This result indicates that eastern China is a leader in green agricultural development, while green agricultural development in western China is the most promising. The "mid-China collapse" occurred in the central China agricultural area. The collapse of the central region was mainly caused by a decline in pure technical efficiency; more specifically, the pure technical efficiency of fertilizer severely restricted the sustainable agricultural development of this area. (3) The provinces that have great spatial differences in terms of agricultural development and the driving factors of AGTFP can develop suitable green agricultural development strategies based on the results presented in this study.
C1 [Liu, Ying] Weifang Univ Sci & Technol, Ctr Agr Sage Culture Studies, Weifang 262700, Shandong, Peoples R China.
   [Feng, Chao] Chongqing Univ, Sch Econ & Business Adm, Chongqing 400030, Peoples R China.
RP Feng, C (reprint author), Chongqing Univ, Sch Econ & Business Adm, Chongqing 400030, Peoples R China.
EM littlefc@126.com
RI Feng, Chao/A-6705-2019
OI Feng, Chao/0000-0002-3568-7418
FU Social Science Planning Project of Chongqing [2018BS54]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities [2019CDSKXYJG0037]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [71633006]
FX We gratefully acknowledge the financial support from the Social Science
   Planning Project of Chongqing (No. 2018BS54), Fundamental Research Funds
   for the Central Universities (No. 2019CDSKXYJG0037), and National
   Natural Science Foundation of China (No. 71633006).
CR Balk BM, 2008, ECON THEOR, V35, P187, DOI 10.1007/s00199-007-0228-5
   Ball V.E., 2001, NEW DEV PRODUCTIVITY, P541
   Ball VE, 2004, J AGR RESOUR ECON, V29, P436
   Banos Carlos Pestana, 2012, OMEGA, V40, P1
   Cao KH, 2013, J DEV ECON, V104, P165, DOI 10.1016/j.jdeveco.2013.06.001
   Chambers RG, 1998, J OPTIMIZ THEORY APP, V98, P351, DOI 10.1023/A:1022637501082
   Chen P. C., 2014, NONRADIAL DIRECTIONA
   Chen PC, 2008, CHINA ECON REV, V19, P580, DOI 10.1016/j.chieco.2008.07.001
   Chen SY, 2014, ENERG ECON, V44, P89, DOI 10.1016/j.eneco.2014.04.002
   Coelli T., 2003, Journal of International Development, V15, P321, DOI 10.1002/jid.975
   COELLI TJ, 2000, AGR EC, V32, P115
   Del Gatto M, 2011, J ECON SURV, V25, P952, DOI 10.1111/j.1467-6419.2009.00620.x
   Diao PP, 2018, CHINA AGR ECON REV, V10, P293, DOI 10.1108/CAER-08-2015-0095
   Eroglu N. A., 2017, Anadolu Tarim Bilimleri Dergisi, V32, P35
   Fan SG, 2002, ECON DEV CULT CHANGE, V50, P819, DOI 10.1086/343136
   FAN SG, 1991, AM J AGR ECON, V73, P266, DOI 10.2307/1242711
   FARE R, 1994, AM ECON REV, V84, P66
   FARE R, 1989, REV ECON STAT, V71, P90
   Fare R, 2007, ENERGY, V32, P1055, DOI 10.1016/j.energy.2006.09.005
   Fei RL, 2016, TECHNOL FORECAST SOC, V109, P25, DOI 10.1016/j.techfore.2016.05.012
   Feng C, 2019, J CLEAN PROD, V225, P1105, DOI 10.1016/j.jclepro.2019.04.025
   Feng C, 2019, RESOUR POLICY, V60, P215, DOI 10.1016/j.resourpol.2018.12.006
   Feng C, 2018, J CLEAN PROD, V177, P837, DOI 10.1016/j.jclepro.2017.12.231
   Feng C, 2017, ECON MODEL, V64, P334, DOI 10.1016/j.econmod.2017.04.007
   Fujii H, 2015, REV DEV ECON, V19, P75, DOI 10.1111/rode.12123
   Fujii H, 2014, J BANK FINANC, V38, P41, DOI 10.1016/j.jbankfin.2013.09.022
   Fujii H, 2010, ENVIRON DEV ECON, V15, P485, DOI 10.1017/S1355770X10000173
   Hall RE, 1999, Q J ECON, V114, P83, DOI 10.1162/003355399555954
   Hsu S. H., 2003, AM AGR EC ASS ANN M, P27
   Jin SQ, 2002, AM J AGR ECON, V84, P916, DOI 10.1111/1467-8276.00043
   [赖斯芸 Lai Siyun], 2004, [清华大学学报. 自然科学版, Journal of Tsinghua University(Science and Technology)], V44, P1184
   Li K, 2015, CHINA ECON REV, V36, P279, DOI 10.1016/j.chieco.2015.09.008
   Li N, 2018, ENERGY, V164, P1145, DOI 10.1016/j.energy.2018.08.150
   Lin BQ, 2015, EUR J AGRON, V70, P33, DOI 10.1016/j.eja.2015.06.009
   LIN JYF, 1992, AM ECON REV, V82, P34
   Liu SW, 2015, AGR ECON-CZECH, V61, P522, DOI 10.17221/233/2014-AGRICECON
   Liu W, 2018, RESOUR CONSERV RECY, V139, P50, DOI 10.1016/j.resconrec.2018.07.017
   Liu Z, 2013, NATURE, V500, P143, DOI 10.1038/500143a
   Mao WN, 1997, CHINA ECON REV, V8, P157, DOI 10.1016/S1043-951X(97)90004-3
   MCMILLAN J, 1989, J POLIT ECON, V97, P781, DOI 10.1086/261628
   Pang B, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8060507
   Pastor JT, 2005, ECON LETT, V88, P266, DOI 10.1016/j.econlet.2005.02.013
   Rezek JP, 2004, J AGR RESOUR ECON, V29, P346
   Shen XB, 2017, RESOUR CONSERV RECY, V127, P21, DOI 10.1016/j.resconrec.2017.08.010
   Shen ZY, 2018, CHINA ECON REV, V51, P83, DOI 10.1016/j.chieco.2018.04.014
   Skevas I, 2018, EUR J OPER RES, V271, P250, DOI 10.1016/j.ejor.2018.04.050
   Song ML, 2018, ANN OPER RES, V270, P459, DOI 10.1007/s10479-016-2158-8
   Song ML, 2018, RESOUR CONSERV RECY, V128, P197, DOI 10.1016/j.resconrec.2016.08.015
   Song ML, 2018, EUR J OPER RES, V269, P51, DOI 10.1016/j.ejor.2017.03.073
   Song ML, 2017, RESOUR CONSERV RECY, V122, P261, DOI 10.1016/j.resconrec.2017.03.001
   Toma P, 2017, ECOL INDIC, V83, P132, DOI 10.1016/j.ecolind.2017.07.049
   Wang M, 2018, ENERG ECON, V76, P101, DOI 10.1016/j.eneco.2018.10.008
   Wang M, 2018, J CLEAN PROD, V202, P710, DOI 10.1016/j.jclepro.2018.08.152
   Wang ZH, 2015, APPL ENERG, V147, P617, DOI 10.1016/j.apenergy.2015.01.108
   Wang ZH, 2014, ENERGY, V74, P322, DOI 10.1016/j.energy.2014.06.082
   WEN GJ, 1993, ECON DEV CULT CHANGE, V42, P1, DOI 10.1086/452063
   Wu Y., 2009, CHINAS CAPITAL STOCK
   WU YR, 1995, J COMP ECON, V21, P207
   Yang ZH, 2018, ENERGIES, V11, DOI 10.3390/en11040853
   Zhang JX, 2018, RESOUR CONSERV RECY, V132, P269, DOI 10.1016/j.resconrec.2017.02.015
   Zhang JF, 2017, RESOUR CONSERV RECY, V125, P1, DOI 10.1016/j.resconrec.2017.05.007
   Zhu XH, 2018, RESOUR POLICY, V57, P1, DOI 10.1016/j.resourpol.2017.12.009
NR 62
TC 1
Z9 1
U1 12
U2 32
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 201
EP 213
DI 10.1016/j.resconrec.2019.04.013
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700020
DA 2020-05-12
ER

PT J
AU Zhao, SJ
   Song, QB
   Duan, HB
   Wen, ZG
   Wang, C
AF Zhao, Shujie
   Song, Qingbin
   Duan, Huabo
   Wen, Zongguo
   Wang, Chao
TI Uncovering the lifecycle GHG emissions and its reduction opportunities
   from the urban buildings: A case study of Macau
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE GHG emissions; Urban buildings; Life cycle assessment; Scenario analysis
ID ENERGY-CONSUMPTION; CARBON EMISSIONS; ENVIRONMENTAL IMPACTS;
   GREENHOUSE-GAS; CO2 EMISSIONS; CONSTRUCTION; WASTE; GENERATION;
   DEMOLITION; FOOTPRINT
AB The building sector has become the main source of implicit greenhouse gas(GHG)emissions worldwide, and Macau is no exception. However, as yet, there is a lack of work to quantify the GHG emissions and guide cities on how best to reduce emissions. By using the life cycle assessment method, this study is therefore designed to estimate the GHG emissions from urban buildings during the period of 1999-2016, to figure out the major contributors, and finally, to propose potential effective measures for GHG emissions reduction in Macau. The results show that total GHG emissions from buildings have grown quickly from 1.52 million metric tons (Mt) CO(2)e in 1999 to 5.91 Mt CO(2)e in 2016. The use phase contributes to most GHG emissions during the whole life stage, accounting for 65.75% of the total GHG emissions, followed by construction stage (33.72%). The unit GHG emissions in the construction stage is 1.47 (0.84-3.82) tons CO(2)e/m(2), while for the use stage, unit GHG emissions from resident and non-resident buildings in 2016 are up to 65.33 and 3316.37 CO(2)e/m(2)/year, respectively. It is noted that EoL stage has 'negative value', indicating that it could generally bring some environmental benefits due to materials recycling. e.g. In 2016, the environmental impacts and benefits in the EoL stage are 21.12 and 85.94 Kt CO(2)e, respectively. The gaming industry and clean electricity should be the key points of building GHG emission reduction in Macau. Further scenario analysis shows that the enforceable policies can slow down the growth rate of GHG emissions.
C1 [Zhao, Shujie; Song, Qingbin] Macau Univ Sci & Technol, Macau Environm Res Inst, Macau, Peoples R China.
   [Duan, Huabo] Shenzhen Univ, Coll Civil Engn, Shenzhen 518060, Peoples R China.
   [Wen, Zongguo] Tsinghua Univ, Sch Environm, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China.
   [Wang, Chao] Guangdong Univ Technol, Sch Mat & Energy, Guangdong Prov Key Lab Funct Soft Condensed Matte, Guangzhou 510006, Guangdong, Peoples R China.
RP Song, QB (reprint author), Macau Univ Sci & Technol, Macau Environm Res Inst, Macau, Peoples R China.; Duan, HB (reprint author), Shenzhen Univ, Coll Civil Engn, Shenzhen 518060, Peoples R China.
EM qbsong@must.edu.mo; huabo@szu.edu.cn
FU Foundation for Development of Science and Technology of Macau (FDCT)
   [0011/2018/A]; Research Grants for Macau University of Science and
   Technology [FRG-18-004-MERI]; Natural Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2017A030313438]
FX This work was supported by the Foundation for Development of Science and
   Technology of Macau (FDCT) (0011/2018/A), Research Grants for Macau
   University of Science and Technology (FRG-18-004-MERI), and Natural
   Science Foundation of Guangdong Province (2017A030313438).
CR Balaras CA, 2007, BUILD ENVIRON, V42, P1298, DOI 10.1016/j.buildenv.2005.11.001
   Beccali M, 2013, RENEW SUST ENERG REV, V27, P283, DOI 10.1016/j.rser.2013.05.040
   CBECS, 2012, COMM BUILD EN CONS S
   Cellura M, 2018, SCI TOTAL ENVIRON, V628-629, P1328, DOI 10.1016/j.scitotenv.2018.02.145
   Cellura M, 2017, RENEW SUST ENERG REV, V80, P733, DOI 10.1016/j.rser.2017.05.273
   Cellura M, 2013, RENEW ENERG, V60, P586, DOI 10.1016/j.renene.2013.06.019
   Chau CK, 2015, APPL ENERG, V143, P395, DOI 10.1016/j.apenergy.2015.01.023
   Chau CK, 2012, RESOUR CONSERV RECY, V61, P22, DOI 10.1016/j.resconrec.2012.01.001
   Chen WD, 2017, RESOUR CONSERV RECY, V117, P264, DOI 10.1016/j.resconrec.2016.10.008
   Chung SS, 2003, RESOUR CONSERV RECY, V37, P119, DOI 10.1016/S0921-3449(02)00075-7
   Dimoudi A, 2008, RESOUR CONSERV RECY, V53, P86, DOI 10.1016/j.resconrec.2008.09.008
   DSEC (Statistics and Census Service of Macau), 2017, CONSTR STAT 2000 201
   DSEC (Statistics and Census Service of Macau), 2017, EN STAT 2000 2017
   DSEC (Statistics and Census Service of Macau), 2017, CONSTR SECT SURV 200
   DSEC (Statistics and Census Service of Macau), 2017, MAC EXT MERCH TRAD S
   DSEC (Statistics and Census Service of Macau), 2017, YB STAT 1999 2016
   Duan HB, 2017, INT J LIFE CYCLE ASS, V22, P683, DOI 10.1007/s11367-016-1187-5
   Ecoinvent, 2019, EC DAT
   Hossain MU, 2019, RESOUR CONSERV RECY, V142, P10, DOI 10.1016/j.resconrec.2018.11.010
   IEA, 2008, WORLD EN OUTL
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Li JS, 2014, RENEW SUST ENERG REV, V34, P642, DOI 10.1016/j.rser.2014.03.038
   Lomas KJ, 2010, BUILD RES INF, V38, P1, DOI 10.1080/09613210903350937
   Ma JJ, 2017, BUILD ENVIRON, V117, P36, DOI 10.1016/j.buildenv.2017.03.005
   Mao RC, 2017, J CLEAN PROD, V166, P40, DOI 10.1016/j.jclepro.2017.07.173
   Marilyn A., 2008, RESIDENTIAL ENERGY C
   MEPU (Macau Environmental Protection Bureau), 2017, MAC ENV STAT REP 200
   NBS (National Bureau of Statistics of China), 2017, BEIJ STAT YB 2006 20
   ODES (Office for Development of the Energy Sector), 2014, RES REP ABSTR MAC EN
   Olivetti E, 2013, ENVIRON SCI TECHNOL, V47, P5208, DOI 10.1021/es3042934
   RECS, 2012, EN INF ADM
   SBS (Shanghai Bureau of Statistics), 2017, SHANGH STAT YB 2006
   Seo S, 2015, RESOUR CONSERV RECY, V105, P160, DOI 10.1016/j.resconrec.2015.10.024
   Song QB, 2018, INT J LIFE CYCLE ASS, V23, P1916, DOI 10.1007/s11367-017-1424-6
   Song QB, 2018, J CLEAN PROD, V194, P263, DOI 10.1016/j.jclepro.2018.05.148
   Song QB, 2018, J CLEAN PROD, V172, P2133, DOI 10.1016/j.jclepro.2017.11.206
   Song QB, 2018, RENEW SUST ENERG REV, V81, P2450, DOI 10.1016/j.rser.2017.06.051
   Song QB, 2017, RENEW SUST ENERG REV, V75, P504, DOI 10.1016/j.rser.2016.11.018
   Song QB, 2015, CLIMATIC CHANGE, V132, P615, DOI 10.1007/s10584-015-1449-4
   Standard for Building Carbon Emission Calculation, 2017, STAND BUILD CARB EM
   Tam WYV, 2018, J CLEAN PROD, V172, P4220, DOI 10.1016/j.jclepro.2017.11.130
   Thormark C, 2001, RESOUR CONSERV RECY, V33, P113, DOI 10.1016/S0921-3449(01)00078-7
   Tian Y., 2011, IEEE IC COMP COM NET
   Tumminia G, 2018, RENEW SUST ENERG REV, V92, P272, DOI 10.1016/j.rser.2018.04.059
   U. S. Environmental Protection Agency, 1995, 230R96006 US EPA
   UNEP, 2009, COMM CARB METR MEAS
   UNEP (United Nations Environment Programme), 2008, BUILD CLIM CHANG SUM
   Upton B, 2008, BIOMASS BIOENERG, V32, P1, DOI 10.1016/j.biombioe.2007.07.001
   Xu N., 2012, THESIS
   Yang XN, 2018, J CLEAN PROD, V183, P729, DOI 10.1016/j.jclepro.2018.02.070
   Ye H, 2011, ENERG BUILDINGS, V43, P147, DOI 10.1016/j.enbuild.2010.09.002
   Yu D., 2018, ENV SCI POLLUT R
   Yu DW, 2011, ENERG BUILDINGS, V43, P2638, DOI 10.1016/j.enbuild.2011.06.013
   Zheng LN, 2017, CONSTR BUILD MATER, V136, P405, DOI 10.1016/j.conbuildmat.2017.01.055
NR 54
TC 2
Z9 3
U1 11
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 214
EP 226
DI 10.1016/j.resconrec.2019.04.030
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700021
OA Bronze
DA 2020-05-12
ER

PT J
AU Dilkes-Hoffman, LS
   Pratt, S
   Laycock, B
   Ashworth, P
   Lant, PA
AF Dilkes-Hoffman, Leela Sarena
   Pratt, Steven
   Laycock, Bronwyn
   Ashworth, Peta
   Lant, Paul Andrew
TI Public attitudes towards plastics
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Plastic waste; Plastic in the ocean; Environmental issues; Reduce
   plastic use; Consumer attitude; Responsibility
ID ENVIRONMENTAL-IMPACT; CONSUMER ATTITUDES; CLIMATE-CHANGE; BEHAVIOR;
   PERSPECTIVE
AB Understanding and engaging the public is key for ensuring the success of government and industry initiatives aimed at addressing the problem of plastic waste. However, there has been little focus on documenting the general public's attitudes towards plastics. This study examines public beliefs and attitudes towards plastics in Australia and provides insight on a global level. The research was conducted using an online survey of a nationally representative sample (2518 respondents). Overall, the survey results indicate that the public view plastics as a serious environmental issue. Plastic in the ocean had the highest mean rating for seriousness out of nine environmental issues, followed by two other issues relating to plastic waste production and disposal. Whilst there was an association of plastics with food packaging and convenience, there was more of a negative association with the use of plastic overall. Eighty percent of respondents indicated a desire to reduce plastic use and the majority of respondents believe that paper and glass are more environmentally friendly packaging materials than plastics. However, the results showed that many respondents do not translate their aspiration to reduce plastic use into action. Overall, while a majority of the Australian public are concerned about plastics as an environmental issue, they place the bulk of the responsibility for reducing the use of disposable plastic on industry and government.
C1 [Dilkes-Hoffman, Leela Sarena; Pratt, Steven; Laycock, Bronwyn; Ashworth, Peta; Lant, Paul Andrew] Univ Queensland, Fac Engn Architecture & Informat Technol, Sch Chem Engn, St Lucia, Qld 4072, Australia.
RP Dilkes-Hoffman, LS (reprint author), Univ Queensland, Fac Engn Architecture & Informat Technol, Sch Chem Engn, St Lucia, Qld 4072, Australia.
EM l.dilkeshoffman@uq.net.au
RI Ashworth, Peta/AAC-7378-2019; Laycock, Bronwyn/B-7321-2016;
   Dilkes-Hoffman, Leela/H-8403-2017
OI Ashworth, Peta/0000-0003-4648-7531; Laycock,
   Bronwyn/0000-0002-0251-844X; Dilkes-Hoffman, Leela/0000-0003-4514-5839
FU Australian GovernmentAustralian Government; Westpac Bicentennial
   Foundation
FX LSDH thanks the Australian Government for the Research Training Program
   Scholarship stipend and tuition fee off set and the Westpac Bicentennial
   Foundation for the Future Leaders Scholarship held during this study.
   The authors would also like to extend thanks to Assoc./Prof. Maureen
   Hassall for initial discussions that helped to frame the work,
   Assoc./Prof. Kelly Fielding for reviewing the survey, and Michele
   Ferguson for advice on statistical analysis of the results.
CR Ari E, 2017, ENVIRON DEV SUSTAIN, V19, P1219, DOI 10.1007/s10668-016-9791-x
   Ashworth P, 2011, COMMUNICATION CLIMAT, P68, DOI [DOI 10.1088/1742-6596/304/1/012073, 10.1088/1742-6596/304/1/012073]
   Australian Bureau of Statistics, 2018, AUSTR DEM STAT
   Australian Bureau of Statistics, 2016, 2016 CENS QUICK STAT
   Babader A, 2016, EXPERT SYST APPL, V46, P417, DOI 10.1016/j.eswa.2015.10.025
   Barr S, 2001, ENVIRON PLANN A, V33, P2025, DOI 10.1068/a33225
   Best H, 2011, SOC SCI RES, V40, P917, DOI 10.1016/j.ssresearch.2010.12.001
   Boulstridge Emma, 2000, J COMMUNICATION MANA, V4, P355, DOI DOI 10.1108/EB023532
   Brooks AL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat0131
   Browne M. A, 2016, ACCUMULATION MICROPL, P9175
   Cheung TY, 2018, INT J SUST HIGHER ED, V19, P1038, DOI 10.1108/IJSHE-10-2017-0175
   Chilvers J, 2014, GLOBAL ENVIRON CHANG, V29, P165, DOI 10.1016/j.gloenvcha.2014.09.006
   Comrey A. L., 1992, 1 COURSE FACTOR ANAL
   Dauvergne P, 2018, GLOBAL ENVIRON CHANG, V51, P22, DOI 10.1016/j.gloenvcha.2018.05.002
   Department of Environment and Conservation NSW, 2017, WHO CAR ENV SURV ENV
   Dilkes-Hoffman LS, 2018, J CLEAN PROD, V180, P325, DOI 10.1016/j.jclepro.2018.01.169
   Ellen MacArthur Foundation, 2017, 6 CO AN MAJ STEP CIR
   Ellen MacArthur Foundation, 2018, GLOB COMM SIGN
   Ellen MacArthur Foundation, 2018, CO TAK MAJ STEP NEW
   European Commission, 2017, SPEC EUR 468 ATT EUR
   European Commission, 2018, EUR STRAT PLAST
   European Commission & European External Action Service, 2017, OUR OCEAN 2017 COMM
   Gall SC, 2015, MAR POLLUT BULL, V92, P170, DOI 10.1016/j.marpolbul.2014.12.041
   Gelcich S, 2014, P NATL ACAD SCI USA, V111, P15042, DOI 10.1073/pnas.1417344111
   Geyer R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700782
   Herbes C, 2018, J CLEAN PROD, V194, P203, DOI 10.1016/j.jclepro.2018.05.106
   Huffman AH, 2014, J ENVIRON PSYCHOL, V38, P262, DOI 10.1016/j.jenvp.2014.03.006
   Jambeck JR, 2015, SCIENCE, V347, P768, DOI 10.1126/science.1260352
   Khan F, 2019, RESOUR CONSERV RECY, V142, P49, DOI 10.1016/j.resconrec.2018.11.020
   Lorenzoni I, 2006, CLIMATIC CHANGE, V77, P73, DOI 10.1007/s10584-006-9072-z
   Moraes C, 2012, J MARKET MANAG-UK, V28, P103, DOI 10.1080/0267257X.2011.615482
   Nisbet MC, 2007, PUBLIC OPIN QUART, V71, P444, DOI 10.1093/poq/nfm031
   OECD, 2014, GREEN HOUS BEH OV 20, DOI [10.1787/9789264181373-en, DOI 10.1787/9789264181373-EN]
   Pahl S, 2017, NAT HUM BEHAV, V1, P697, DOI 10.1038/s41562-017-0204-4
   Pallant J., 2016, SPSS SURVIVAL MANUAL
   PlasticEurope, 2018, PLAST FACTS 2014 201, DOI [10.1016/j.marpolbul.2013.01.015, DOI 10.1016/J.MARPOLBUL.2013.01.015]
   Rahimi A, 2017, NAT REV CHEM, V1, DOI 10.1038/s41570-017-0046
   REA LM, 1997, DESIGNING CONDUCTING
   Saphores JDM, 2014, RESOUR CONSERV RECY, V92, P1, DOI 10.1016/j.resconrec.2014.08.010
   Sherry-Brennan F, 2010, ENERG POLICY, V38, P5311, DOI 10.1016/j.enpol.2009.03.037
   Tabachnick B.G., 2007, USING MULTIVARIATE S
   Tonglet M, 2004, RESOUR CONSERV RECY, V42, P27, DOI 10.1016/j.resconrec.2004.02.001
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   Williams H, 2011, J CLEAN PROD, V19, P43, DOI 10.1016/j.jclepro.2010.08.008
   World Economic Forum; Ellen MacArthur Foundation; McKinsey & Company, 2016, NEW PLAST EC RETH FU, DOI [10.1088/0953-8984/19/21/213202, DOI 10.1088/0953-8984/19/21/213202]
   World Factbook, 2019, WORLD FACTBOOK
   Yan T, 2008, ENCY SURVEY RES METH, P521, DOI [10.4135/9781412963947, DOI 10.4135/9781412963947]
   Zalasiewicz J, 2016, ANTHROPOCENE, V13, P4, DOI 10.1016/j.ancene.2016.01.002
   Zhang C, 2014, SURV RES METHODS-GER, V8, P127
NR 49
TC 7
Z9 7
U1 20
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD AUG
PY 2019
VL 147
BP 227
EP 235
DI 10.1016/j.resconrec.2019.05.005
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IC8DO
UT WOS:000471206700022
DA 2020-05-12
ER

PT J
AU Nusair, SD
   Ahmad, MI
AF Nusair, Shreen Deeb
   Ahmad, Mohammad Ibrahim
TI Toxicity of Vipera palaestinae venom and antagonistic effects of
   methanolic Check for leaf extract of Eryngium creticum lam
SO TOXICON
LA English
DT Article
DE Viper venoms; Eryngium; Lethal dose 50; Plant extracts; Interleukin-6;
   Tumor necrosis factor-alpha
ID SNAKE-VENOM; ADVERSE-REACTIONS; IN-VITRO; ANTIVENOM; ANTIOXIDANT;
   ALLERGENS; PROTEINS; A(2)
AB Vipera palaestinae is responsible for many venomous incidents in the Middle East. However, this species is not included in the antigenic pool of venoms for the production of the regionally available polyvalent antivenoms. In an attempt to develop a potential complementary altemative therapy for snakebite patients, this study is investigating the antagonistic effect of Eryngium creticum against V. palaestinae venom. In this context, the concentration of the venom as well as the electrophoretic profile, and the venom LD50 were determined by intraperitoneal injection (ip). The methanolic leaf extract was prepared, and its safety on rats was examined. Adult male Sprague-Dawley rats were divided into 8 groups (n = 6); G1-G3 were injected subplantar in the right hind paws with 2.5, 3.125, and 3.75 mg kg(-1) then 200 mg kg(-1) extract ip. G4-G6 were given the same venom dose with no extract, respectively. Controls were G7 that only had the extract ip, and G8 that was injected subplantar with PBS. The swollen paws were measured at Hour 0 (before injection), Hour 1, Hour 6, and Hour 24. IL-6 and TNF-alpha were measured in serum using ELISA. Histopathological changes were examined in paw sections. The pooled venom concentration was 176.93 +/- 35.81 mg ml(-1) revealed 10 protein bands (5-80 kDa), and the LD50 via ip rout was 6.56 mg kg(-1). Paw edema peaked at Hour 1. At Hour 6, edema in G1 was significantly reduced (p < 0.05) compared to G6, while at Hour 24 there was no significant difference between all groups including the controls. Treated animals in G1-G3 expressed IL-6 significantly lower (p < 0.001) than untreated G4-G6, respectively. Levels of TNF-alpha in G1 and G2 were significantly (p < 0.001) lower than G3-G6, while G5 and G6 were significantly (p < 0.001) higher than G1-G4. Histopathological changes showed intensifying edema, hemorrhage, and inflammation with incrementing venom doses. Sections from treated animals expressed less adverse changes compared to untreated animals. Together, the outcomes are encouraging future utilization of E. creticum as a supportive remedy for snakebite cases.
C1 [Nusair, Shreen Deeb] Jordan Univ Sci & Technol, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan.
   [Ahmad, Mohammad Ibrahim] Jordanian Pharmaceut Mfg Co, Res & Innovat Ctr, Amman, Jordan.
RP Nusair, SD (reprint author), Jordan Univ Sci & Technol, Fac Pharm, Dept Clin Pharm, POB 3030, Irbid 22110, Jordan.
EM sdnusair@just.edu.jo
FU Deanship of Research at Jordan University of Science and Technology
   [20180051]
FX This research was funded by the Deanship of Research at Jordan
   University of Science and Technology [grant No. 20180051].
CR Abu-Rabia Aref, 2005, Asian Pac J Cancer Prev, V6, P404
   AFIFI FU, 1990, J ETHNOPHARMACOL, V29, P43, DOI 10.1016/0378-8741(90)90096-C
   Afifi FU, 1996, ALEXANDRIA J PHARM S, V10, P195
   Ahmad MI, 2018, EMIR J FOOD AGR, V30, P654, DOI 10.9755/ejfa.2018.v30.i8.1765
   Alkofahi A, 1997, PHYTOTHER RES, V11, P540, DOI 10.1002/(SICI)1099-1573(199711)11:7<540::AID-PTR150>3.0.CO;2-9
   Almeida JR, 2016, TOXICON, V120, P147, DOI 10.1016/j.toxicon.2016.08.007
   Amr ZS, 2015, TOXINOLOGY, P251, DOI 10.1007/978-94-007-6386-9_55
   Amr ZS, 2011, VERTEBR ZOOL, V61, P179
   Boda F, 2018, TOXINS, V10, DOI 10.3390/toxins10070259
   Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515
   de Silva HA, 2016, BRIT J CLIN PHARMACO, V81, P446, DOI 10.1111/bcp.12739
   Dudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054
   Farhan Hussein, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS1217
   Felix-Silva J, 2017, TOXICON, V125, P74, DOI 10.1016/j.toxicon.2016.11.260
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Hamdan II, 2004, J ETHNOPHARMACOL, V93, P117, DOI 10.1016/j.jep.2004.03.033
   Hijazi A., 2015, J PHARM CHEM BIOL SC, V3, P262
   Hu YJ, 2017, TOXICON, V125, P13, DOI 10.1016/j.toxicon.2016.11.251
   JAGHABIR M, 1991, ARCH PHARM RES, V14, P295, DOI DOI 10.1007/BF02876873
   Khader M, 2010, J ETHNOPHARMACOL, V127, P319, DOI 10.1016/j.jep.2009.11.001
   Kikowska M, 2016, REV BRAS FARMACOGN, V26, P392, DOI 10.1016/j.bjp.2016.01.008
   Kupeli E, 2006, J ETHNOPHARMACOL, V107, P32, DOI 10.1016/j.jep.2006.02.005
   Leon G, 2013, TOXICON, V76, P63, DOI 10.1016/j.toxicon.2013.09.010
   Lepak MR, 2015, ANN PHARMACOTHER, V49, P145, DOI 10.1177/1060028014555711
   LOMONTE B, 1993, INFLAMMATION, V17, P93, DOI 10.1007/BF00916097
   Madero MF, 2009, INT ARCH ALLERGY IMM, V150, P307, DOI 10.1159/000222684
   Makki R, 2015, J NANOMED NANOTECHNO, V6, P1
   Manouchehri Sareh, 2016, Int J Hematol Oncol, V5, P27, DOI 10.2217/ijh-2015-0009
   Gutierrez JM, 2013, TOXICON, V62, P27, DOI 10.1016/j.toxicon.2012.09.006
   McCleary RJR, 2013, TOXICON, V62, P56, DOI 10.1016/j.toxicon.2012.09.008
   Nalbantsoy A, 2013, TOXICON, V65, P34, DOI 10.1016/j.toxicon.2012.12.017
   Nusair S., 2018, HUM EXP TOXICOL, V25
   Nusair SD, 2019, MUTAT RES-GEN TOX EN, V837, P34, DOI 10.1016/j.mrgentox.2018.09.006
   Nusair SD, 2017, WATER AIR SOIL POLL, V228, DOI 10.1007/s11270-017-3448-8
   Nusair SD, 2017, ENVIRON SCI POLLUT R, V24, P902, DOI 10.1007/s11356-016-7893-5
   Price JA, 2016, J INTERCULT ETHNOPHA, V5, P219, DOI 10.5455/jice.20160421070136
   Rima M, 2018, MOLECULES, V23, DOI 10.3390/molecules23102721
   da Silva ACR, 2016, MAR BIOTECHNOL, V18, P619, DOI 10.1007/s10126-016-9722-8
   Saad B, 2006, EVID-BASED COMPL ALT, V3, P433, DOI 10.1093/ecam/nel058
   Saenz MT, 1997, PHYTOTHER RES, V11, P380, DOI 10.1002/(SICI)1099-1573(199708)11:5<380::AID-PTR116>3.0.CO;2-#
   Sajon SR, 2017, J PHARMACOGN PHYTOCH, V6, P190
   Sunitha K, 2015, TOXICON, V98, P89, DOI 10.1016/j.toxicon.2015.02.014
   Toktas U., 2017, PLANTA MED, V4
   Venkatesan C, 2014, HUM EXP TOXICOL, V33, P336, DOI 10.1177/0960327113494901
   Xiao H, 2017, BIOMED RES INT, V2017, P10, DOI DOI 10.1016/j.inpa.2017.02.001
   Zeng FJ, 2017, CHIN J TRAUMATOL, V20, P299, DOI 10.1016/j.cjtee.2016.12.004
NR 46
TC 0
Z9 0
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 1
EP 8
DI 10.1016/j.toxicon.2019.05.006
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000001
PM 31095960
DA 2020-05-12
ER

PT J
AU Hou, SJ
   Liu, Y
   Tang, YQ
   Wu, MQ
   Guan, JW
   Li, XY
   Wang, Z
   Jiang, JY
   Deng, MC
   Duan, ZG
   Tang, X
   Han, XQ
   Jiang, LP
AF Hou, Shengjie
   Liu, Yuan
   Tang, Yaqin
   Wu, Mengqi
   Guan, Jianwu
   Li, Xianyao
   Wang, Zheng
   Jiang, Jinying
   Deng, Meichun
   Duan, Zhigui
   Tang, Xing
   Han, Xiaoqing
   Jiang, Liping
TI Anti-Toxoplasma gondii effect of two spider venoms in vitro and in vivo
SO TOXICON
LA English
DT Article
DE Spider venom; Toxoplasma gondii; Anti-Toxoplasma gondii; Invasion;
   Proliferation
ID PEPTIDE LYCOSIN-I; TOXOPLASMA-GONDII; SODIUM; PROLIFERATION; REPLICATION
AB Toxoplasma gondii (T. gondii) is an important pathogen that can cause serious public health problems. Currently, therapeutic drugs for toxoplasmosis present serious side effects, researches on more effective and novel substances with relatively low toxicity are urgently needed. Spider venoms comprise diverse novel pharmacological compounds. However, the anti-T. gondii activity of spider venoms remains largely unknown. This study was carried out to evaluate the anti-parasitic effect of spider venoms from Ornitoctonus huwena (HWVM) and Chilobrachys jingzhao (JZVM) against T. gondii tachyzoites in vitro and in vivo. Cytotoxic activity of HWVM and JZVM to HeLa cells was determined by MTT cell viability assays. Low doses (3.125, 6.25 and 12.5 mu g/mL) of HWVM and JZVM displayed low toxicity to HeLa cells. Trypan blue exclusion assay indicated that either of HWVM and JZVM affected the viability of tachyzoites in a time-dependent manner. Both spider venoms inhibited the invasion and proliferation of tachyzoites in vitro (p < 0.05). Moreover, Mice treated with HWVM after infection with 2 x 10(3) T. gondii tachyzoites showed a better survival rate than mice treated with saline alone (p < 0.05), while mice treated with JZVM did not. Our findings indicate that HWVM is a promising agent for the treatment of toxoplasmosis.
C1 [Hou, Shengjie; Liu, Yuan; Tang, Yaqin; Wu, Mengqi; Guan, Jianwu; Li, Xianyao; Han, Xiaoqing; Jiang, Liping] Cent S Univ, Xiangya Sch Med, Dept Parasitol, Changsha 410013, Hunan, Peoples R China.
   [Wang, Zheng] Cent S Univ, Xiangya Hosp 3, Dept Gen Surg 1, Changsha 410013, Hunan, Peoples R China.
   [Jiang, Jinying] Hunan Prov Maternal & Child Hlth Care Hosp, Dept Neonatol, Changsha 410013, Hunan, Peoples R China.
   [Deng, Meichun] Cent S Univ, Sch Life Sci, Dept Biochem, Changsha 410013, Hunan, Peoples R China.
   [Duan, Zhigui] Hunan Normal Univ, Coll Life Sci, Minist Educ, Key Lab Prot Chem & Dev Biol, Changsha 410081, Hunan, Peoples R China.
   [Tang, Xing] Hengyang Normal Univ, Coll Life Sci & Environm, Hengyang 421002, Hunan, Peoples R China.
RP Jiang, LP (reprint author), Cent S Univ, Xiangya Sch Med, Dept Parasitol, Changsha 410013, Hunan, Peoples R China.
EM jiangliping@csu.edu.cn
FU Hunan Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Hunan Province [2015JJ2192, 2017JJ2372]; Valuable
   Instrument and Equipment Fund of Central South University
   [CSUZC2019046]; China Postdoctoral Science Fund Project (first class)
   [2015M580704]; Central South University Teachers Research Fund
   [2014JSJJ027]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [31672290]; National Undergraduate
   Innovation Training Program of Central South University [201810533037]
FX The authors would like to thank Prof. Hongjuan Peng, Southern Medical
   University (Guangzhou, China), for providing the RH strain of T. gondii.
   This work was supported by Hunan Provincial Natural Science Foundation
   of China (grant numbers 2015JJ2192, 2017JJ2372); the Valuable Instrument
   and Equipment Fund of Central South University (CSUZC2019046); China
   Postdoctoral Science Fund Project (first class) (grant number
   2015M580704); Central South University Teachers Research Fund (grant
   number 2014JSJJ027); the National Natural Science Foundation of China
   (grant number 31672290) and National Undergraduate Innovation Training
   Program of Central South University (grant numbers 201810533037).
CR Adeyemi OS, 2018, PARASITOL RES, V117, P355, DOI 10.1007/s00436-017-5698-1
   Akef HM, 2018, TOXICOL RES-UK, V7, P381, DOI 10.1039/c8tx00022k
   Barbosa BF, 2008, CLIN EXP IMMUNOL, V151, P536, DOI 10.1111/j.1365-2249.2007.03583.x
   Barbosa BF, 2012, VET PARASITOL, V187, P44, DOI 10.1016/j.vetpar.2011.12.039
   Bastos LM, 2008, EXP PARASITOL, V120, P391, DOI 10.1016/j.exppara.2008.09.008
   Bende NS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5350
   Borges IP, 2016, TOXICON, V119, P84, DOI 10.1016/j.toxicon.2016.05.010
   Caldas LA, 2007, VET PARASITOL, V147, P210, DOI 10.1016/j.vetpar.2007.05.012
   Chen JJ, 2009, PEPTIDES, V30, P1042, DOI 10.1016/j.peptides.2009.02.018
   Chen JQ, 2005, TOXICON, V45, P15, DOI 10.1016/j.toxicon.2004.08.018
   De Leon-Nava MA, 2016, MAR DRUGS, V14, DOI 10.3390/md14040066
   Deng MC, 2009, NEUROPHARMACOLOGY, V57, P77, DOI 10.1016/j.neuropharm.2009.04.009
   Flegr J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090203
   Hao P, 2016, KOREAN J PARASITOL, V54, P139, DOI 10.3347/kjp.2016.54.2.139
   Jiang LP, 2014, PEPTIDES, V54, P9, DOI 10.1016/j.peptides.2014.01.001
   Jin L, 2016, J MED CHEM, V59, P1791, DOI 10.1021/acs.jmedchem.5b01264
   Kamau ET, 2012, ANTIMICROB AGENTS CH, V56, P5581, DOI 10.1128/AAC.00868-12
   Lee Sang-Bok, 2017, Brain Tumor Res Treat, V5, P34, DOI 10.14791/btrt.2017.5.1.34
   Leesombun A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156116
   Li XY, 2018, INFLAMM RES, V67, P455, DOI 10.1007/s00011-018-1138-7
   Liu Q, 2006, J BIOL CHEM, V281, P32861, DOI [10.1074/jbc.M606365200, 10.1074/jbc.M513542200]
   Lovett JL, 2002, J BIOL CHEM, V277, P25870, DOI 10.1074/jbc.M202553200
   Ma BB, 2018, PEPTIDES, V99, P108, DOI 10.1016/j.peptides.2017.12.011
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ning WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061049
   Peng K, 2002, J BIOL CHEM, V277, P47564, DOI 10.1074/jbc.M204063200
   Petersen E, 2007, SEMIN FETAL NEONAT M, V12, P214, DOI 10.1016/j.siny.2007.01.011
   Saez NJ, 2019, TOXICON, V158, P109, DOI 10.1016/j.toxicon.2018.11.298
   Sanfelice RA, 2017, ACTA TROP, V167, P208, DOI 10.1016/j.actatropica.2016.12.006
   Stewart RJ, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12685
   Strober W, 2001, Curr Protoc Immunol, VAppendix 3, p3B, DOI 10.1002/0471142735.ima03bs21
   Tan L, 2018, MICROBIOL RES, V216, P120, DOI 10.1016/j.micres.2018.08.012
   Tanaka T, 2010, IN VITRO CELL DEV-AN, V46, P560, DOI 10.1007/s11626-009-9271-9
   Tang YQ, 2019, EXP PARASITOL, V198, P17, DOI 10.1016/j.exppara.2019.01.009
   Teimouri A, 2018, INT J NANOMED, V13, P1341, DOI 10.2147/IJN.S158736
   Tenter AM, 2009, MEM I OSWALDO CRUZ, V104, P364, DOI 10.1590/S0074-02762009000200033
   Weiss LM, 2009, INT J PARASITOL, V39, P895, DOI 10.1016/j.ijpara.2009.02.004
   Xiao YC, 2007, TOXICON, V50, P507, DOI 10.1016/j.toxicon.2007.04.018
   Zhang XC, 2016, EXP PARASITOL, V165, P95, DOI 10.1016/j.exppara.2016.03.020
NR 39
TC 0
Z9 0
U1 1
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 9
EP 14
DI 10.1016/j.toxicon.2019.05.003
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000002
PM 31103717
DA 2020-05-12
ER

PT J
AU Ben Taheur, F
   Mansour, C
   Kouidhi, B
   Chaieb, K
AF Ben Taheur, Fadia
   Mansour, Chalbia
   Kouidhi, Bochra
   Chaieb, Kamel
TI Use of lactic acid bacteria for the inhibition of Aspergillus flavus and
   Aspergillus carbonarius growth and mycotoxin production
SO TOXICON
LA English
DT Article
DE A. flavus and A. carbonarius; Probiotics; LAB; Mycotoxins; Antifungal
   activity
ID ANTIFUNGAL ACTIVITY; IN-VITRO; LACTOBACILLUS-PLANTARUM; AFLATOXIN
   PRODUCTION; TOXIGENIC FUNGI; OCHRATOXIN; SPOILAGE; IDENTIFICATION;
   BIODEGRADATION; DETOXIFICATION
AB Almonds and peanuts are a rich source of proteins, vitamins and unsaturated fatty acids. However, they can be also contaminated by mycotoxigenic fungi; a reason that has enhanced to investigate efficient strategies of management of these fungal contaminations. Some Lactic acid bacteria have been proven capable of inhibiting growth and mycotoxin production in livestock and transform it into nontoxic derivatives. In this work, four lactic acid bacteria (LAB) were tested for their abilities to inhibit the growth and mycotoxin production of Aspergillus flavus and Aspergillus carbonarius. Antifungal activity was evaluated in agar medium as well as in almonds and peanuts. Results showed that LAB significantly inhibited Aspergillus flavus and Aspergillus carbonarius in agar medium but none of the strains were able to completely inhibit fungal growth. The highest fungal growth inhibition was obtained using L. kefiri FR7 (51.67% and 45.56% growth inhibition of A. flavus and A. carbonarius, respectively). The cell-free supernatants (CFS) from LAB reduced fungal growth with average growth inhibitions ranging from 13.33% to 40.56% and 12.78% to 37.78% for A. flavus and A. carbonarius, respectively. We noted also that cell-free supernatants at pH7 (CFS-pH7) from the entire tested LAB did not inhibit fungal growth. L. kefiri FR7 was the most effective strain in mycotoxin suppression with a reduction percentage reaching 97.22%, 95.27% and 75.26% for AFB1, AFB2 and OTA respectively. Moreover, the inoculation of L. kefiri FR7 in almonds artificially contaminated with A. flavus decrease 85.27% of AFB1 and 83.94% of AFB2 content after 7 days of incubation. On the other hand, application of L. kefiri FR7 in peanuts artificially contaminated with A. carbonarius reduced OTA content to 25%. Our study revealed the potential use and application of L. kefiri FR7 in the control of fungi growth and mycotoxins production in almonds and peanuts.
C1 [Ben Taheur, Fadia; Mansour, Chalbia; Chaieb, Kamel] Monastir Univ, Fac Pharm, Lab Anal Treatment & Valorizat Environm Pollutant, Monastir, Tunisia.
   [Kouidhi, Bochra] Taibah Univ, Coll Appl Med Sci, Med Lab Dept, Yanbu, Saudi Arabia.
   [Chaieb, Kamel] Jendouba Univ, Higher Inst Biotechnl Beja, Jendouba, Tunisia.
RP Kouidhi, B (reprint author), Taibah Univ, Fac Appl Med Sci, Med Lab Technol Dept, Yanbu, Saudi Arabia.
EM bochrak@yahoo.fr
CR Abdallah MF, 2018, J FOOD SCI, V83, P559, DOI 10.1111/1750-3841.14046
   Abrunhosa L, 2014, INT J FOOD MICROBIOL, V188, P45, DOI 10.1016/j.ijfoodmicro.2014.07.019
   Adebayo CO, 2011, FOOD CONTROL, V22, P1814, DOI 10.1016/j.foodcont.2011.04.013
   Akpo-Djenontin DOO, 2018, FOOD SCI NUTR, V6, P541, DOI 10.1002/fsn3.579
   Ammor S, 2006, FOOD CONTROL, V17, P454, DOI 10.1016/j.foodcont.2005.02.006
   Asurmendi P, 2014, J STORED PROD RES, V56, P33, DOI 10.1016/j.jspr.2013.11.002
   Belkacem-Hanfi N, 2014, BIOL CONTROL, V76, P52, DOI 10.1016/j.biocontrol.2014.05.001
   Ben Taheur F, 2016, MICROB PATHOGENESIS, V97, P213, DOI 10.1016/j.micpath.2016.06.018
   Ben Taheur F, 2016, MICROB PATHOGENESIS, V93, P158, DOI 10.1016/j.micpath.2016.02.006
   Brul S, 1999, INT J FOOD MICROBIOL, V50, P1, DOI 10.1016/S0168-1605(99)00072-0
   Chen YJ, 2015, INT J FOOD MICROBIOL, V211, P1, DOI 10.1016/j.ijfoodmicro.2015.06.021
   Cheong EYL, 2014, FOOD CONTROL, V46, P91, DOI 10.1016/j.foodcont.2014.05.011
   Cortes-Zavaleta O, 2014, INT J FOOD MICROBIOL, V173, P30, DOI 10.1016/j.ijfoodmicro.2013.12.016
   Cunha SC, 2018, FOOD CHEM TOXICOL, V114, P260, DOI 10.1016/j.fct.2018.02.039
   De Bellis P, 2015, TOXINS, V7, P5079, DOI 10.3390/toxins7124864
   Pereira GVD, 2016, LETT APPL MICROBIOL, V62, P96, DOI 10.1111/lam.12520
   De Muynck C, 2004, MICROBIOL RES, V159, P339, DOI 10.1016/j.micres.2004.07.002
   Elsanhoty RM, 2013, FOOD CONTROL, V33, P287, DOI 10.1016/j.foodcont.2013.03.002
   Gambacorta L, 2018, WORLD MYCOTOXIN J, V11, P159, DOI 10.3920/WMJ2017.2271
   Gerbaldo GA, 2012, FEMS MICROBIOL LETT, V332, P27, DOI 10.1111/j.1574-6968.2012.02570.x
   Gerez CL, 2013, BIOL CONTROL, V64, P231, DOI 10.1016/j.biocontrol.2012.10.009
   Grazioli B, 2006, INT J FOOD MICROBIOL, V111, pS93, DOI 10.1016/j.ijfoodmicro.2006.01.045
   Guimaraes A, 2018, INT J FOOD MICROBIOL, V264, P31, DOI 10.1016/j.ijfoodmicro.2017.10.025
   Ilavenil S, 2016, J SCI FOOD AGR, V96, P593, DOI 10.1002/jsfa.7128
   Jo EJ, 2016, FOOD CHEM, V194, P1102, DOI 10.1016/j.foodchem.2015.07.152
   Jogee PS, 2017, FOOD CONTROL, V71, P143, DOI 10.1016/j.foodcont.2016.06.036
   Kabak B, 2016, FOOD CHEM, V211, P8, DOI 10.1016/j.foodchem.2016.04.141
   Kachouri F, 2014, J FOOD PROTECT, V77, P1760, DOI 10.4315/0362-028X.JFP-13-360
   Le Lay C, 2016, FOOD CONTROL, V60, P247, DOI 10.1016/j.foodcont.2015.07.034
   Liu X, 2017, FOOD CONTROL, V82, P325, DOI 10.1016/j.foodcont.2017.07.012
   Luz C, 2018, FOOD CHEM TOXICOL, V112, P60, DOI 10.1016/j.fct.2017.12.030
   Oliveira PM, 2014, FOOD MICROBIOL, V37, P78, DOI 10.1016/j.fm.2013.06.003
   Oluwafemi F, 2010, TOXIN REV, V29, P115, DOI 10.3109/15569543.2010.512556
   Pitt JI, 2000, MED MYCOL, V38, P17, DOI 10.1080/mmy.38.s1.17.22
   Probst C, 2007, APPL ENVIRON MICROB, V73, P2762, DOI 10.1128/AEM.02370-06
   Radic B, 1997, TOXICOL LETT, V91, P105, DOI 10.1016/S0378-4274(97)03877-0
   Rodrigues P, 2012, FOOD RES INT, V48, P76, DOI 10.1016/j.foodres.2012.02.007
   Rouse S, 2008, J APPL MICROBIOL, V104, P915, DOI 10.1111/j.1365-2672.2007.03619.x
   Ruggirello M, 2019, FOOD RES INT, V115, P519, DOI 10.1016/j.foodres.2018.10.002
   Sadeghi A, 2019, BIOL CONTROL, V130, P70, DOI 10.1016/j.biocontrol.2018.09.017
   Sadeghi A, 2019, FOOD CONTROL, V95, P298, DOI 10.1016/j.foodcont.2018.08.013
   Saladino F, 2016, FOOD CONTROL, V67, P273, DOI 10.1016/j.foodcont.2016.03.012
   Sangmanee P, 2014, FOOD CONTROL, V40, P224, DOI 10.1016/j.foodcont.2013.12.005
   Sangsila A, 2016, FOOD CONTROL, V62, P187, DOI 10.1016/j.foodcont.2015.10.031
   Siahmoshteh F, 2017, INT J FOOD MICROBIOL, V254, P47, DOI 10.1016/j.ijfoodmicro.2017.05.011
   Soares C, 2010, WORLD MYCOTOXIN J, V3, P225, DOI 10.3920/WMJ2010.1216
   Su M, 2004, J SCI FOOD AGR, V84, P1119, DOI 10.1002/jsfa.1748
   Theumer MG, 2018, TOXICOL LETT, V287, P100, DOI 10.1016/j.toxlet.2018.02.007
   Tropcheva R, 2014, ANAEROBE, V28, P78, DOI 10.1016/j.anaerobe.2014.05.010
   Warth B, 2012, J AGR FOOD CHEM, V60, P9352, DOI 10.1021/jf302003n
   Zhu CY, 2015, FOOD CONTROL, V50, P125, DOI 10.1016/j.foodcont.2014.08.042
NR 51
TC 1
Z9 1
U1 9
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 15
EP 23
DI 10.1016/j.toxicon.2019.05.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000003
PM 31095961
DA 2020-05-12
ER

PT J
AU Wang, D
   Qu, JR
   Jiang, HY
   Jiang, Y
AF Wang, Di
   Qu, Jiaorong
   Jiang, Haiyue
   Jiang, Yu
TI The safety and efficacy of botulinum toxin for management of scars: A
   systematic review with meta-analysis and trial sequential analysis
SO TOXICON
LA English
DT Review
DE Botulinum toxin; Scars; Efficacy; Safety; Systematic review;
   Meta-analysis; Trial sequential analysis
ID FACIAL WOUNDS; DOUBLE-BLIND; SPLIT-SCAR; PREVENTION; INJECTION; FLAP
AB Scars can have a dramatic impact on patients' physical appearance and function. Injection of botulinum toxin has been used to prevent scar formation at the site of injury and to remodel scars that have already formed. The purpose of this review is to assess the safety and efficacy of botulinum toxin for scar management compared to placebo or no treatment.
   MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials and PubMed Central were searched. Nine randomized controlled trials comparing injections of botulinum toxin versus placebo or no treatment for individuals of any age with scars were included and were assessed by two independent review authors. Cochrane risk of bias was used to assess trial quality, sensitivity analyses was conducted and trial sequential analysis was employed to assess the risk of random error. Mean difference (MD), standardized mean difference (SMD) and 95% CI were calculated for continuous outcomes. Risk ratios (RR) and corresponding 95% confidence intervals (CI) were calculated for all dichotomous outcomes.
   The MD for the Vancouver scar scale (VSS) was -0.87 (95%CI, -1.73 to -0.02), and for the visual analogue scale (VAS) was 1.30 (95%0, 1.05 to 1.54). The SMD for scar width was -1.05 (95%Cl, -1.29 to -0.81). The safety of botulinum toxin therapy was evaluated by calculating adverse events and complications (RR 0.36; 95%CI, 0.09 to 1.45).
   Evidence from this study has documented the clinical benefits of botulinum toxin versus placebo or no treatment in the prevention and remodeling of scars. Injection of botulinum toxin is both safe and effective. Future studies should focus on the different doses needed and differences in effects between pre-surgical and post-surgical injection periods.
C1 [Wang, Di; Jiang, Haiyue] Chinese Acad Med Sci, Plast Surg Hosp, Peking Union Med Coll, 33 Badachu Rd, Beijing 100144, Peoples R China.
   [Qu, Jiaorong] Chinese Acad Med Sci, Natl Key Lab Med Mol Biol, Peking Union Med Coll, Inst Basic Med Sci, Beijing, Peoples R China.
   [Jiang, Yu] Chinese Acad Med Sci, Peking Union Med Coll, Sch Publ Hlth, Beijing, Peoples R China.
RP Jiang, HY (reprint author), Chinese Acad Med Sci, Plast Surg Hosp, Peking Union Med Coll, 33 Badachu Rd, Beijing 100144, Peoples R China.; Jiang, Y (reprint author), Chinese Acad Med Sci, Sch Publ Hlth, 9 DongDan SanTiao, Dongcheng Dist, Peoples R China.
EM jianghaiyue_psh@sina.com; jiangyu@pumc.edu.cn
OI Wang, Di/0000-0002-8904-2981
FU CAMS Innovation Fund for Medical Sciences [CAMS-I2M-1-007]; CAMS
   Innovation Fund for Medical Sciences (CIFMS) [2016-12M-2-006]; Capital
   Clinical Specialty Application Research Program [Z161100000516098]; PUMC
   Youth Fund [33320140171]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [33320140171]; PUMC Graduate Innovation Fund [2018-1002-02-20]
FX The review was supported by CAMS Innovation Fund for Medical Sciences
   (CAMS-I2M-1-007), CAMS Innovation Fund for Medical Sciences (CIFMS,
   2016-12M-2-006), Capital Clinical Specialty Application Research Program
   (Z161100000516098), PUMC Youth Fund and the Fundamental Research Funds
   for the Central Universities (No.33320140171), PUMC Graduate Innovation
   Fund (2018-1002-02-20). The authors have no financial interests in any
   of the products, devices or drugs mentioned in this manuscript.
CR Andersson KE, 2016, BASIC CLIN PHARMACOL, V119, P75, DOI 10.1111/bcpt.12577
   Baryza Mary Jo, 1995, Journal of Burn Care and Rehabilitation, V16, P535, DOI 10.1097/00004630-199509000-00013
   Caliskan E, 2016, EUR REV MED PHARMACO, V20, P1603
   Castelao M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003633.pub3
   Chang CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115690
   Chang CS, 2014, PLAST RECONSTR SURG, V134, P511, DOI 10.1097/PRS.0000000000000416
   Duncan JAL, 2006, PLAST RECONSTR SURG, V118, P909, DOI 10.1097/01.prs.0000232378.88776.b0
   Gadhia K, 2009, BRIT DENT J, V207, DOI 10.1038/sj.bdj.2009.813
   Gassner HG, 2000, PLAST RECONSTR SURG, V105, P1948, DOI 10.1097/00006534-200005000-00005
   Gassner HG, 2006, MAYO CLIN PROC, V81, P1023, DOI 10.4065/81.8.1023
   Gladstone HB, 2010, DERMAT RES PRACT, DOI 10.1155/2010/545796
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Hu L, 2018, PLAST RECONSTR SURG, V141, P646, DOI 10.1097/PRS.0000000000004110
   Huang W, 2000, J AM ACAD DERMATOL, V43, P249, DOI 10.1067/mjd.2000.105567
   Jeong HS, 2015, PLAST RECONSTR SURG, V136, p171E, DOI 10.1097/PRS.0000000000001438
   Johns MM, 2004, ANN OTO RHINOL LARYN, V113, P597, DOI 10.1177/000348940411300801
   Kerwin LY, 2014, INT J DERMATOL, V53, P922, DOI 10.1111/ijd.12436
   Kim YS, 2017, TOXINS, V9, DOI 10.3390/toxins9120403
   Kim YS, 2014, WOUND REPAIR REGEN, V22, P605, DOI 10.1111/wrr.12204
   Krusz JC, 2003, CEPHALALGIA, V23, P722
   Lee BJ, 2009, CLIN EXP OTORHINOLAR, V2, P20, DOI 10.3342/ceo.2009.2.1.20
   Lee SH, 2018, AESTHET PLAST SURG, V42, P530, DOI 10.1007/s00266-017-1008-7
   LI WH, 2014, CHIN J AESTH PLAST S, V25, P426
   Liu A, 2011, DERMATOL SURG, V37, P1740, DOI 10.1111/j.1524-4725.2011.02166.x
   Liu RK, 2010, PLAST RECONSTR SURG, V125, P1573, DOI 10.1097/PRS.0b013e3181d51404
   Morris CL, 2008, OPHTHAL PLAST RECONS, V24, P117, DOI 10.1097/IOP.0b013e318166dd2a
   Nathan CAO, 1999, LARYNGOSCOPE, V109, P855, DOI 10.1097/00005537-199906000-00002
   Omranifard M, 2016, ARCH PLAST SURG-APS, V43, P609, DOI 10.5999/aps.2016.43.6.609
   Ozkan SB, 2003, OPHTHALMIC SUR LA IM, V34, P391
   Park TH, 2015, ANN PLAS SURG, V74, P100, DOI 10.1097/SAP.0b013e31828d706f
   Prodromidou A, 2015, PLAST SURG-CHIR PLAS, V23, P260
   Richardson WS, 2003, SURG ENDOSC, V17, P696, DOI 10.1007/s00464-002-8628-x
   Strutton DR, 2004, J AM ACAD DERMATOL, V51, P241, DOI 10.1016/j.jaad.2003.12.040
   SULLIVAN T, 1990, Journal of Burn Care and Rehabilitation, V11, P256, DOI 10.1097/00004630-199005000-00014
   WANG XY, 2013, J PRACT DERMATOL, V5, P271
   Wang Y. H., 2015, INT EYE SCI, V15, P1103
   Wilson AM, 2006, PLAST RECONSTR SURG, V117, P1758, DOI 10.1097/01.prs.0000209944.45949.d1
   Xiao ZB, 2008, J PLAST RECONSTR AES, V61, P1128, DOI 10.1016/j.bjps.2008.05.003
   Xiao ZB, 2011, AESTHET PLAST SURG, V35, P802, DOI 10.1007/s00266-011-9690-3
   Xiao ZB, 2009, AESTHET PLAST SURG, V33, P409, DOI 10.1007/s00266-009-9334-z
   Zelken J, 2016, ANN PLAS SURG, V77, P535, DOI 10.1097/SAP.0000000000000625
   Zhang DZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151627
   Ziade M, 2013, J PLAST RECONSTR AES, V66, P209, DOI 10.1016/j.bjps.2012.09.012
NR 43
TC 1
Z9 1
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 24
EP 33
DI 10.1016/j.toxicon.2019.04.018
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000012
PM 31047933
DA 2020-05-12
ER

PT J
AU da Silva, AM
   da Fonseca, WL
   Neto, EDV
   Bisnetof, PF
   Contreras-Bernal, J
   Sachett, J
   Monteiro, WM
   Bernarde, PS
AF da Silva, Ageane Mota
   da Fonseca, Wirven Lima
   Valente Neto, Edgar de Araujo
   Bisnetof, Pedro Ferreira
   Contreras-Bernal, Jorge
   Sachett, Jacqueline
   Monteiro, Wuelton Marcelo
   Bernarde, Paulo Sergio
TI Envenomation by Micrurus annellatus bolivianus (Peters, 1871) coral
   snake in the western Brazilian Amazon
SO TOXICON
LA English
DT Review
DE Snakes; Elapidae; Coral snake; Micrurus annellatus bolivianus;
   Coagulopathy; Snakebite
ID FULVIUS-FULVIUS; VENOM; HERPETOFAUNA; ACRE
AB Bites by Micrurus snakes in Brazilian Amazon represent about 0.4% of snakebite registered in that area. There is not information available about the M. annellatus snakebites In this report, we describe a case of envenoming caused by Micrurus annellatus bolivianus recorded in the municipality of Cruzeiro do Sul, state of Acre, western Brazilian Amazon. On admission, the patient was suffering from mild pain, mild edema and paraesthesia restricted to the site of the bite, darkened vision and nausea. Laboratorial evaluation revealed unclottable blood which improved only after 3 days of follow-up. Envenoming was classified as moderate, and 50 ml of antielapid serum was administered. The next day after the incident, vital signs were normal and the patient had mild thrombocytopenia (133,000/mm3). The patient did not present any bleeding during the hospitalization. On the fourth day after admission, the patient was discharged alleging no complaints. The patient showed coagulopathy, a rare condition in cases of Micrurus bites. Some areas where there is a lack of knowledge on coral snakebites are listed in this manuscript.
C1 [da Silva, Ageane Mota] Inst Fed Acre, Campus Cruzeiro do Sul, Cruzeiro Do Sul, Acre, Brazil.
   [da Silva, Ageane Mota] Univ Fed Acre, Programa Posgrad Bionorte, Campus Univ,BR 364, Rio Branco, Acre, Brazil.
   [da Fonseca, Wirven Lima; Bernarde, Paulo Sergio] Univ Fed Acre, Lab Herpetol, Campus Floresta,Estr Canela Fina S-N, BR-69980000 Cruzeiro Do Sul, Acre, Brazil.
   [da Fonseca, Wirven Lima] Univ Fed Acre, Programa Posgrad Ecol & Manejo Recursos Nat, Rio Branco, Brazil.
   [Valente Neto, Edgar de Araujo] Hosp Reg Jurua, Cruzeiro Do Sul, Acre, Brazil.
   [Bisnetof, Pedro Ferreira] Univ Fed Amazonas, Programa Posgrad Zool, Manaus, Amazonas, Brazil.
   [Contreras-Bernal, Jorge; Sachett, Jacqueline; Monteiro, Wuelton Marcelo] Fundacao Med Trop Dr Heitor Vieira Dourado, Inst Pesquisa Clin Carlos Borborema, Manaus, Amazonas, Brazil.
   [Contreras-Bernal, Jorge; Sachett, Jacqueline; Monteiro, Wuelton Marcelo] Univ Estado Amazonas, Escola Super Saude, Manaus, Amazonas, Brazil.
RP Bernarde, PS (reprint author), Univ Fed Acre, Lab Herpetol, Campus Floresta,Estr Canela Fina S-N, BR-69980000 Cruzeiro Do Sul, Acre, Brazil.
EM snakebernarde@hotmail.com
RI ; Sachett, Jacqueline/I-5642-2017
OI Sergio Bernarde, Paulo/0000-0002-2191-7817; Sachett,
   Jacqueline/0000-0001-5723-9977; Lima, Wirven/0000-0002-2893-0627
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX We are grateful to the directors of the Jurua Regional Hospital of
   Cruzeiro do Sul for the permission for this research and the entire team
   of doctors, nurses, nursing assistants and other hospital staff for the
   support of this study. We would like to thank the funding provided by
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) - Finance Code 001.
CR Almeida P. C. R., 2016, COBRAS CORAIS BRASIL, P169
   BARROS ACS, 1994, TOXICON, V32, P445, DOI 10.1016/0041-0101(94)90296-8
   Bernarde P. S., 2017, SERPENTES ALTO JUNIA
   Bernarde PS, 2018, SALAMANDRA, V54, P249
   Bernarde PS, 2013, BIOTA NEOTROP, V13, P220, DOI 10.1590/S1676-06032013000100023
   Bernarde Paulo Sergio, 2012, Check List, V8, P516
   Bernarde PS, 2011, BIOTA NEOTROP, V11, P117, DOI 10.1590/S1676-06032011000300010
   Bucaretchi F, 2016, CLIN TOXICOL, V54, P222, DOI 10.3109/15563650.2015.1135337
   Canas CA, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0100-4
   Casais-e-Silva LL, 2016, TOXICOL LETT, V257, P60, DOI 10.1016/j.toxlet.2016.06.005
   Cavazos M. E. O., 2012, COMPLEMENTARY PEDIAT, V1, P123, DOI DOI 10.5772/34749
   Costa Henrique Caldeira, 2018, Herpetologia Brasileira, V7, P11
   da Sande Ministerio, 2001, MAN DIAGN TRAT AC AN, P120
   da Silva IM, 2018, TOXICON, V141, P51, DOI 10.1016/j.toxicon.2017.11.012
   da Silva NJ, 2001, COMP BIOCHEM PHYS C, V128, P425, DOI 10.1016/S1532-0456(00)00215-5
   Sousa JDD, 2018, AM J TROP MED HYG, V98, P1547, DOI 10.4269/ajtmh.17-0992
   Pardal PPD, 2010, REV INST MED TROP SP, V52, P333, DOI 10.1590/S0036-46652010000600009
   DIDISHEIM P, 1966, J AMER MED ASSOC, V198, P1299
   Feitosa DT, 2015, ZOOTAXA, V3974, P538, DOI 10.11646/zootaxa.3974.4.5
   Feitosa EL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132237
   Hayes WK, 2017, WILD ENVIRON MED, V28, P101, DOI 10.1016/j.wem.2017.03.006
   KITCHENS CS, 1987, JAMA-J AM MED ASSOC, V258, P1615, DOI 10.1001/jama.258.12.1615
   Malaque C.M.S., 2016, CRITICAL CARE TOXICO, P1, DOI 10.1007/978-3-319-20790-2
   Manock SR, 2008, T ROY SOC TROP MED H, V102, P1127, DOI 10.1016/j.trstmh.2008.03.026
   Melgarejo A.R., 2009, ANIMAIS PECONHENTOS, P42
   Oliveira FD, 2017, REV SOC BRAS MED TRO, V50, P365, DOI 10.1590/0037-8682-0408-2016
   Risk J. Y., 2016, COBRAS CORAIS BRASIL, p[382, 415]
   Roodt AR, 2013, REV INST MED TROP SP, V55, P13
   Salazar AM, 2011, TOXICON, V58, P35, DOI 10.1016/j.toxicon.2011.04.020
   Salazar E, 2018, TOXICON, V150, P212, DOI 10.1016/j.toxicon.2018.06.063
   Silva AM, 2015, J HUM GROWTH DEV, V25, P54, DOI [DOI 10.7322/JHGD.96768, 10.7322/JHGD.96768]
   Silva Jr N. J., 2016, COBRAS CORAIS BRASIL, V1, P369
   Strauch MA, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0148-9
   Tanaka G. D., 2016, TOXICON, V59-68, P117
   Vergara I, 2014, J PROTEOMICS, V105, P295, DOI 10.1016/j.jprot.2014.02.027
NR 35
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 34
EP 38
DI 10.1016/j.toxicon.2019.05.008
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000004
PM 31121172
DA 2020-05-12
ER

PT J
AU Sanz, L
   de Freitas-Lima, LN
   Quesada-Bernat, S
   Graca-de-Souza, VK
   Soares, AM
   Calderon, LD
   Calvete, JJ
   Caldeira, CAS
AF Sanz, Libia
   de Freitas-Lima, Lucas N.
   Quesada-Bernat, Sarai
   Graca-de-Souza, Viviane K.
   Soares, Andreimar M.
   Calderon, Leonardo de A.
   Calvete, Juan J.
   Caldeira, Cleopatra A. S.
TI Comparative venomics of Brazilian coral snakes: Micrurus frontalis,
   Micrurus spixii spixii, and Micrurus surinamensis
SO TOXICON
LA English
DT Article
DE Snake venom; 3FTx/PLA2 dichotomy; Venomics; Brazilian coral snakes;
   Genus Micrurus; Brazilian southern coral snake; Micrurus frontalis;
   Amazon coral snake; Micrurus spixii spixii; Aquatic coral snake;
   Micrurus surinamensis
ID COMPOSITIONAL PATTERNS; 3-FINGER TOXINS; TOXICITY; PROTEOME; PREY;
   SERPENTES; EVOLUTION; SELECTION; ELAPIDAE; PROTEINS
AB A comparative venom proteomic analysis of the Brazilian southern coral snake, M. frontalis, the Amazon coral snake M. spixii spixii, and the aquatic coral snake M. surinamensis is reported. Venoms from M. frontalis and M. s. spixii were composed mainly (> 90% of the total venom proteome) by 3FTxs and PLA(2)s in different proportions, and minor proteins from 2 to 5 protein families. Conversely, the aquatic coral snake expressed a streamlined (95%) 3FTx venom with low abundance (4.2%) of PLA(2) molecules. A compositional-lethal activity for natural prey correlation analysis suggests that M. surinamensis venom may has evolved under strong pressure to quickly immobilize aquatic prey. On the other hand, venoms from M. frontalis and M. s. spixii, whose diet consist mainly of amphisbaenians and colubrid snakes, may have been shaped through balancing selection. Our work provides strong evidence for the occurrence in M. frontalis venom, but not in those from M. s. spixi and M. surinamensis, of a KUN-PLA(2) complex homologue to heterodimeric venom toxins from some long-tailed monadal coral snakes that target acid-sensing receptors ASIC1 a/2 evoking pain. The M. frontalis protein would represent the first example of a KUN-PLA(2) heterodimer in a South American short-tailed triadal coral snake venom.
C1 [Sanz, Libia; Quesada-Bernat, Sarai; Calvete, Juan J.] CSIC, Lab Venom Evolut & Traslac, Valencia, Spain.
   [de Freitas-Lima, Lucas N.; Graca-de-Souza, Viviane K.; Soares, Andreimar M.] Ctr Univ Sao Lucas UniSL, R Alexandre Guimaraes 1927, Porto Velho, RO, Brazil.
   [de Freitas-Lima, Lucas N.; Graca-de-Souza, Viviane K.; Soares, Andreimar M.; Calderon, Leonardo de A.; Caldeira, Cleopatra A. S.] Fundacao Oswaldo Cruz Rondonia Fiocruz Rondonia, Ctr Estudos Biomol Aplicadas Saude CEBio, Porto Velho, RO, Brazil.
   [Soares, Andreimar M.; Calderon, Leonardo de A.; Caldeira, Cleopatra A. S.] Univ Fed Rondonia UNIR, Programa Posgrad Biol Expt PGBIOEXP, Porto Velho, RO, Brazil.
   [Soares, Andreimar M.; Calderon, Leonardo de A.; Caldeira, Cleopatra A. S.] Rede BIONORTE, Programa Posgrad Biodiversidade & Biotecnol, Porto Velho, RO, Brazil.
   [Soares, Andreimar M.] Epidemiol Amazonia Ocident INCT EpiAmO, Inst Nacl Ciencia & Tecnol, Porto Velho, RO, Brazil.
RP Calvete, JJ (reprint author), CSIC, Evolutionary & Translat Ven Lab, Valencia, Spain.; Calderon, LD; Caldeira, CAS (reprint author), UNIR, FIOCRUZ, Ctr Estudos Biomol Aplicadas Saude CEBio, Rua Beira 7671, BR-76820 Porto Velho, Rondonia, Brazil.
EM nflimalucas@gmail.com; squesada@ibv.csic.es;
   viviane.krominski@saolucas.edu.br; andreimarsoares@gmail.com;
   calderon@unir.br; jcalvete@ibv.csic.es; cleopatra@unir.br
RI Calvete, Juan J/K-9619-2014; da Silva Caldeira, Cleopatra
   Alves/L-8180-2019; Calderon, Leonardo/K-8515-2012
OI Calvete, Juan J/0000-0001-5026-3122; da Silva Caldeira, Cleopatra
   Alves/0000-0003-1670-5227; Quesada Bernat, Sarai/0000-0002-8757-4159;
   Calderon, Leonardo/0000-0003-2669-092X; Freitas,
   Lucas/0000-0001-7869-2391
FU Ministerio de Ciencia, Innovacion y Universidades, Madrid (Spain) [BFU
   2017-89103-P]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq/MCTIC)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES/MEC)CAPESSpanish Government; Fundacao
   Rondonia de Amparo ao Desenvolvimento das Acoes Cientificas e
   Tecnologicas de Pesquisa do Estado de Rondonia (FAPERO)
FX This study was partly supported by grant BFU 2017-89103-P from the
   Ministerio de Ciencia, Innovacion y Universidades, Madrid (Spain) to
   JJC. The authors wish to gratefully acknowledge the collaboration of Dr.
   Kayena Delaix Zaqueo in M. surinamensis venom extraction. Authors also
   express their gratitude to Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq/MCTIC), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES/MEC) and Fundacao Rondonia de Amparo ao
   Desenvolvimento das Acoes Cientificas e Tecnologicas de Pesquisa do
   Estado de Rondonia (FAPERO) for financial support. The authors thank the
   Program for Technological Development in Tools for Health-PDTIS-FIOCRUZ
   for the use of its facilities.
CR Aird SD, 2017, TOXINS, V9, DOI 10.3390/toxins9060187
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Baconguis I, 2014, CELL, V156, P717, DOI 10.1016/j.cell.2014.01.011
   Barlow A, 2009, P ROY SOC B-BIOL SCI, V276, P2443, DOI 10.1098/rspb.2009.0048
   Bohlen CJ, 2012, TOXICON, V60, P254, DOI 10.1016/j.toxicon.2012.04.336
   Bohlen CJ, 2011, NATURE, V479, P410, DOI 10.1038/nature10607
   Bucaretchi F, 2016, CLIN TOXICOL, V54, P222, DOI 10.3109/15563650.2015.1135337
   Calderon-Celis F, 2017, J PROTEOMICS, V164, P33, DOI 10.1016/j.jprot.2017.06.001
   Calvete JJ, 2014, EXPERT REV PROTEOMIC, V11, P315, DOI 10.1586/14789450.2014.900447
   Calvete JJ, 2013, TOXICON, V75, P44, DOI 10.1016/j.toxicon.2013.03.020
   Calvete JJ, 2011, EXPERT REV PROTEOMIC, V8, P739, DOI [10.1586/EPR.11.61, 10.1586/epr.11.61]
   CAMPBELL JA, 2004, VENOMOUS REPTILES W
   Chuman Y, 2000, TOXICON, V38, P449, DOI 10.1016/S0041-0101(99)00165-8
   Costa Henrique Caldeira, 2015, Herpetologia Brasileira, V4, P75
   Cuvier G., 1817, REPTILES POISSONS MO, V2
   da Cunha Osvaldo Rodrigues, 1993, Boletim do Museu Paraense Emilio Goeldi Serie Zoologia, V9, P1
   Da Silva J., 1993, HERP NAT HIST, V1, P37
   Da Silva Jr N. J., 2016, COBRAS CORAIS BRASIL, V169
   Da Silva Jr N. J., 1995, THESIS
   da Silva NJ, 1999, HERPETOL MONOGR, V13, P142, DOI 10.2307/1467062
   da Silva NJ, 2001, COMP BIOCHEM PHYS C, V128, P425, DOI 10.1016/S1532-0456(00)00215-5
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   Dashevsky D, 2018, J MOL EVOL, V86, P58, DOI 10.1007/s00239-017-9825-5
   Dumeril A. M. C., 1854, ERPETOLOGIE GEN HIST
   Eichberg S, 2015, EXPERT REV PROTEOMIC, V12, P557, DOI 10.1586/14789450.2015.1073590
   Fernandez J, 2015, TOXICON, V107, P217, DOI 10.1016/j.toxicon.2015.08.016
   GREENE HW, 1983, AM ZOOL, V23, P431
   Kini RM, 2010, TOXICON, V56, P855, DOI 10.1016/j.toxicon.2010.07.010
   Lippa E, 2019, J PROTEOMICS, V198, P177, DOI 10.1016/j.jprot.2019.01.007
   Llaurens V, 2017, MOL ECOL, V26, P2430, DOI 10.1111/mec.14051
   Lomonte B, 2016, TOXICON, V122, P7, DOI 10.1016/j.toxicon.2016.09.008
   Lynch VJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-2
   Margres MJ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-531
   Marques O.A.V., 1997, HERPETOLOGICAL NATUR, V5, P88
   Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1
   Olamendi-Portugal T, 2008, PROTEOMICS, V8, P1919, DOI 10.1002/pmic.200700668
   Olamendi-Portugal T, 2018, TOXICON, V153, P23, DOI 10.1016/j.toxicon.2018.08.003
   Passos P, 2005, ZOOTAXA, P1
   Rey-Suarez P, 2016, J PROTEOMICS, V136, P262, DOI 10.1016/j.jprot.2016.02.006
   Roze J. A., 1996, CORAL SNAKES AM BIOL, P340
   Sanz L, 2016, TOXINS, V8, DOI 10.3390/toxins8060178
   Savolainen O, 2013, NAT REV GENET, V14, P807, DOI 10.1038/nrg3522
   Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Schmidt K. P., 1943, Zoological Series Field Museum of Natural History, V24, P279
   Smith ES, 2018, J NEUROL, V265, P231, DOI 10.1007/s00415-017-8641-6
   Soares AM, 2014, TOXICON, V89, P91, DOI 10.1016/j.toxicon.2014.07.001
   Tanaka GD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000622
   Tasoulis T, 2017, TOXINS, V9, DOI 10.3390/toxins9090290
   Uetz P, 2016, REPTILE DATABASE
   Urdaneta AH, 2004, COMP BIOCHEM PHYS C, V138, P485, DOI 10.1016/j.cca.2004.08.018
   VANZOLINI PE, 1986, RELATORIO PESQUISA, V1, P1
   Vergara I, 2014, J PROTEOMICS, V105, P295, DOI 10.1016/j.jprot.2014.02.027
   Wagler J., 1824, ANIMALIA NOVA SIVE S, P75
   Wang BS, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1365-1
NR 54
TC 1
Z9 1
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 39
EP 45
DI 10.1016/j.toxicon.2019.05.001
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000005
PM 31091423
DA 2020-05-12
ER

PT J
AU Hunt, H
   Fraser, K
   Cave, NJ
   Gartrell, BD
   Petersen, J
   Roe, WD
AF Hunt, H.
   Fraser, K.
   Cave, N. J.
   Gartrell, B. D.
   Petersen, J.
   Roe, W. D.
TI Untargeted metabolic profiling of dogs with a suspected toxic
   mitochondrial myopathy using liquid chromatography-mass spectrometry
SO TOXICON
LA English
DT Article
DE Myopathy; Toxicity; Dogs; New Zealand; Mitochondria; Mass spectrometry
ID FATTY-ACID OXIDATION; SNAKEROOT AGERATINA-ALTISSIMA; SKELETAL-MUSCLE;
   KYNURENINE METABOLITES; PHOSPHOLIPID-SYNTHESIS; OMEGA-OXIDATION;
   BETA-OXIDATION; HAFF-DISEASE; LIVER; PLASMA
AB 'Go Slow myopathy' (GSM) is a suspected toxic myopathy in dogs that primarily occurs in the North Island of New Zealand, and affected dogs usually have a history of consuming meat, offal or bones from wild pigs (including previously frozen and/or cooked meat). Previous epidemiological and pathological studies on GSM have demonstrated that changes in mitochondrial structure and function are most likely caused by an environmental toxin that dogs are exposed to through the ingestion of wild pig. The disease has clinical, histological and biochemical similarities to poisoning in people and animals from the plant Ageratina altissima (white snakeroot). Aqueous and lipid extracts were prepared from liver samples of 24 clinically normal dogs and 15 dogs with GSM for untargeted liquid chromatography-mass spectrometry. Group-wise comparisons of mass spectral data revealed 38 features that were significantly different (FDR < 0.05) between normal dogs and those with GSM in aqueous extracts, and 316 significantly different features in lipid extracts. No definitive cause of the myopathy was identified, but alkaloids derived from several plant species were among the possible identities of features that were more abundant in liver samples from affected dogs compared to normal dogs. Mass spectral data also revealed that dogs with GSM have reduced hepatic phospholipid and sphingolipid concentrations relative to normal dogs. In addition, affected dogs had changes in the abundance of kynurenic acid, various dicarboxylic acids and N-acetylated branch chain amino acids, suggestive of mitochondrial dysfunction.
C1 [Hunt, H.; Cave, N. J.; Gartrell, B. D.; Roe, W. D.] Massey Univ, Sch Vet Sci, Palmerston North, New Zealand.
   [Fraser, K.] AgRes Grasslands Res Ctr, Food & Biobased Prod Grp, Food Nutr & Hlth Team, Palmerston North, New Zealand.
   [Petersen, J.] Norvet Serv Ltd, Okaihau, New Zealand.
RP Hunt, H (reprint author), Massey Univ, Sch Vet Sci, Palmerston North, New Zealand.
RI Fraser, Karl/V-6856-2019
OI Fraser, Karl/0000-0002-1136-4024; Gartrell, Brett/0000-0002-8062-9313
FU Palmerston North Medical Research Foundation, New Zealand
FX The authors would like to thank the dog owners and veterinarians for
   their assistance with sample collection. This research was supported by
   a grant from the Palmerston North Medical Research Foundation, New
   Zealand.
CR Asano N, 1997, EUR J BIOCHEM, V248, P296, DOI 10.1111/j.1432-1033.1997.00296.x
   Baran H, 2016, INT J TRYPTOPHAN RES, V9, P17, DOI [10.4137/IJTR.S37973, 10.4137/ijtr.s37973]
   Barton J, 2007, BIOL CONTROL, V40, P370, DOI 10.1016/j.biocontrol.2006.09.010
   Begriche K, 2011, J HEPATOL, V54, P773, DOI 10.1016/j.jhep.2010.11.006
   Beier Ross C., 1993, Natural Toxins, V1, P286, DOI 10.1002/nt.2620010506
   BONNER WA, 1962, TETRAHEDRON, V18, P1295, DOI 10.1016/0040-4020(62)80010-6
   Buchholz U, 2000, EMERG INFECT DIS, V6, P192, DOI 10.3201/eid0602.000215
   Chen YQ, 2009, INT J TRYPTOPHAN RES, V2, P1
   Cheville N. F., 2009, COMP CELLULAR BASIS, P181
   CHIEN KR, 1978, J BIOL CHEM, V253, P4809
   CHRISTENSEN WILLIAM I., 1965, ECON BOT, V19, P293, DOI 10.1007/BF02914317
   Dalziel JE, 2017, AM J PHYSIOL-GASTR L, V313, pG62, DOI 10.1152/ajpgi.00008.2017
   Davis TZ, 2016, RES VET SCI, V106, P29, DOI 10.1016/j.rvsc.2016.02.008
   Dewailly E, 1999, ENVIRON HEALTH PERSP, V107, P823, DOI 10.2307/3454581
   Fagone P, 2009, J LIPID RES, V50, pS311, DOI 10.1194/jlr.R800049-JLR200
   Forrest CM, 2003, ADV EXP MED BIOL, V527, P395
   Fraser K, 2013, FOOD RES INT, V53, P827, DOI 10.1016/j.foodres.2012.10.015
   FROMENTY B, 1990, J PHARMACOL EXP THER, V255, P1371
   FROMENTY B, 1995, PHARMACOL THERAPEUT, V67, P101, DOI 10.1016/0163-7258(95)00012-6
   FRY M, 1981, J BIOL CHEM, V256, P1874
   Fuertig R, 2016, BIOANALYSIS, V8, P1903, DOI 10.4155/bio-2016-0111
   FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x
   Gaillard Y, 1999, J CHROMATOGR B, V733, P181, DOI 10.1016/S0378-4347(99)00181-4
   Garvey SM, 2014, BIOGERONTOLOGY, V15, P217, DOI 10.1007/s10522-014-9492-5
   Gohil VM, 2009, J CELL BIOL, V184, P468, DOI 10.1083/jcb.200901127
   Gowda GAN, 2008, EXPERT REV MOL DIAGN, V8, P617, DOI 10.1586/14737159.8.5.617
   HAGENFELDT L, 1987, CLIN CHIM ACTA, V169, P77, DOI 10.1016/0009-8981(87)90395-0
   Hall RD, 2006, NEW PHYTOL, V169, P453, DOI 10.1111/j.1469-8137.2005.01632.x
   HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205
   Haukaas TH, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00017
   Hesselink RP, 2003, BBA-MOL BASIS DIS, V1637, P164, DOI 10.1016/S0925-4439(02)00229-6
   Hoene M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22218
   Holloway GP, 2006, J PHYSIOL-LONDON, V571, P201, DOI 10.1113/jphysiol.2005.102178
   Houtkooper RH, 2008, CELL MOL LIFE SCI, V65, P2493, DOI 10.1007/s00018-008-8030-5
   Howell C, 2008, CONSOLIDATED LIST EN
   Hunt H, 2018, NEW ZEAL VET J, V66, P199, DOI 10.1080/00480169.2018.1464974
   Hunt H., 2018, THESIS
   JELLUM E, 1986, SCAND J CLIN LAB INV, V46, P21
   Kamijo T, 1997, PEDIATR RES, V42, P569, DOI 10.1203/00006450-199711000-00002
   Karlikova R, 2016, VET J, V216, P125, DOI 10.1016/j.tvjl.2016.07.015
   Kato A, 2003, TETRAHEDRON-ASYMMETR, V14, P325, DOI 10.1016/S0957-4166(02)00799-1
   Kaushal V, 2001, TOXICON, V39, P615, DOI 10.1016/S0041-0101(00)00173-2
   KOGA J, 1995, TETRAHEDRON, V51, P7907, DOI 10.1016/0040-4020(95)00423-6
   Kompare M, 2008, SEMIN PEDIATR NEUROL, V15, P140, DOI 10.1016/j.spen.2008.05.008
   Korkmaz I, 2011, J EMERG MED, V41, P499, DOI 10.1016/j.jemermed.2008.03.045
   Lanza IR, 2009, METHOD ENZYMOL, V457, P349, DOI 10.1016/S0076-6879(09)05020-4
   Lee ST, 2010, J AGR FOOD CHEM, V58, P8560, DOI 10.1021/jf1012456
   LEWIS DC, 1987, J CULT GEOGR, V7, P51, DOI DOI 10.1080/08873638709478507
   Lu YW, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00003
   Lundsgaard AM, 2018, TRENDS ENDOCRIN MET, V29, P18, DOI 10.1016/j.tem.2017.10.011
   Majewski M, 2016, J PHYSIOL PHARMACOL, V67, P3
   Maurer HH, 2005, CLIN BIOCHEM, V38, P310, DOI 10.1016/j.clinbiochem.2005.01.014
   Meyerholtz KA, 2011, J VET DIAGN INVEST, V23, P775, DOI 10.1177/1040638711407899
   MOLYNEUX RJ, 1988, J NAT PROD, V51, P1198, DOI 10.1021/np50060a024
   MORTENSEN PB, 1992, BIOCHIM BIOPHYS ACTA, V1124, P71, DOI 10.1016/0005-2760(92)90128-I
   Norin T., 1971, ACTA CHEM SCAND, V25
   Ogier de Baulny H, 2002, Semin Neonatol, V7, P65
   OKAMOTO H, 1970, J BIOL CHEM, V245, P3603
   Peters RJB, 2010, TRAC-TREND ANAL CHEM, V29, P1250, DOI 10.1016/j.trac.2010.07.012
   Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395
   PREISS B, 1964, J BIOL CHEM, V239, P85
   Rahman MM, 2017, J SEP SCI, V40, P203, DOI 10.1002/jssc.201600889
   Ramesh A, 2004, J CHROMATOGR B, V802, P371, DOI 10.1016/j.jchromb.2003.12.016
   ROSE CL, 1959, J PHARMACOL EXP THER, V126, P179
   Sampson JN, 2013, CANCER EPIDEM BIOMAR, V22, P631, DOI 10.1158/1055-9965.EPI-12-1109
   SCHULTHEISS PC, 1995, VET HUM TOXICOL, V37, P452
   Sharma Om P., 1998, Natural Toxins, V6, P1, DOI 10.1002/(SICI)1522-7189(199802)6:1<1::AID-NT3>3.0.CO;2-E
   Shimomura Y, 2004, J NUTR, V134, p1583S, DOI 10.1093/jn/134.6.1583S
   SMITH LW, 1981, J NAT PROD, V44, P129, DOI 10.1021/np50014a001
   SOLOMON M, 1990, ARCH INTERN MED, V150, P683, DOI 10.1001/archinte.1990.00390150149028
   Sponseller BT, 2012, J VET INTERN MED, V26, P1012, DOI 10.1111/j.1939-1676.2012.00957.x
   SPRAUL MH, 1992, PHYTOCHEMISTRY, V31, P3109, DOI 10.1016/0031-9422(92)83455-8
   Srivastava A, 2017, ANAL BIOANAL CHEM, V409, P3757, DOI 10.1007/s00216-017-0317-7
   STEENBERGEN C, 1984, J MOL CELL CARDIOL, V16, P605, DOI 10.1016/S0022-2828(84)80625-2
   Tautenhahn R, 2012, ANAL CHEM, V84, P5035, DOI 10.1021/ac300698c
   TAYLOR DL, 1992, ANTIVIR CHEM CHEMOTH, V3, P273, DOI 10.1177/095632029200300504
   Thurberg BL, 2006, LAB INVEST, V86, P1208, DOI 10.1038/labinvest.3700484
   TODD FG, 1995, PHYTOCHEMISTRY, V39, P301, DOI 10.1016/0031-9422(94)00969-Z
   Torell F, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-017-1196-9
   TROPEA JE, 1989, BIOCHEMISTRY-US, V28, P2027, DOI 10.1021/bi00431a010
   Tsironi M, 2004, CAN MED ASSOC J, V171, P325, DOI 10.1503/cmaj.1031256
   Uriarte-Pueyo I, 2009, J AGR FOOD CHEM, V57, P11055, DOI 10.1021/jf902764n
   Valberg SJ, 2013, EQUINE VET J, V45, P419, DOI 10.1111/j.2042-3306.2012.00684.x
   van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142
   Vance JE, 2015, TRAFFIC, V16, P1, DOI 10.1111/tra.12230
   Wajner M, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20150240
   Wanders RJA, 2011, FEBS J, V278, P182, DOI 10.1111/j.1742-4658.2010.07947.x
   Want EJ, 2013, NAT PROTOC, V8, P17, DOI 10.1038/nprot.2012.135
   White J., 1985, AUSTR US POIS PLANTS, P411
   Wiswedel I, 2010, FREE RADICAL RES, V44, P135, DOI 10.3109/10715760903352841
   Wu AH, 2012, CLIN TOXICOL, V50, P733, DOI 10.3109/15563650.2012.713108
   WU CH, 1973, BIOCHEM PHARMACOL, V22, P2835
   Xia J, 2002, USING METABOANALYST
   Xu G, 2016, J CLIN ENDOCR METAB, V101, P5044, DOI 10.1210/jc.2016-1859
   Zhang B, 2012, INTERNAL MED, V51, P487, DOI 10.2169/internalmedicine.51.6786
   ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991
NR 96
TC 0
Z9 0
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 46
EP 55
DI 10.1016/j.toxicon.2019.05.007
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000006
PM 31102596
DA 2020-05-12
ER

PT J
AU De arco-Rodriguez, B
   Montealegre-Sanchez, L
   Solano-Redondo, L
   Castro-Herrera, F
   Ortega, JG
   Castillo, A
   Vargas-Zapata, C
   Jimenez-Charris, E
AF De arco-Rodriguez, Beatriz
   Montealegre-Sanchez, Leonel
   Solano-Redondo, Luis
   Castro-Herrera, Fernando
   Guillermo Ortega, Jose
   Castillo, Andres
   Vargas-Zapata, Carmina
   Jimenez-Charris, Eliecer
TI Phylogeny and toxicological assessments of two Porthidium lansbergii
   lansbergii morphotypes from the caribbean region of Colombia
SO TOXICON
LA English
DT Article
DE Snake venom; Porthidium lansbergii lansbergii; Color morphs;
   Toxinological comparison; Phylogenetic analysis
ID SNAKE-VENOM; BOTHROPS-ASPER; COSTA-RICA; PHOSPHOLIPASE A(2); COLOR
   PATTERN; VIPERIDAE; NEUTRALIZATION; PITVIPERS; METALLOPROTEINASE;
   DIVERSIFICATION
AB After a snakebite accident, species identification is of vital importance. However, the existence of intraspecific differences in the body coloration patterns of venomous snakes can generate confusion and delay a convenient and effective treatment. This is the situation for Porthidium lansbergii lansbergii from Colombia, for which two distinctive color morphs occur, and the relationship of these morphs with venom toxicity is unknown. Therefore, venom samples from specimens of these two morphs were collected from the Colombian Caribbean region, and their protein profiles compared. Likewise, their venom functional activities were evaluated in vitro and in vivo in BALB/C mice. Additionally, using sequences of the mitochondria] cytochrome b (Cyt-b) gene, the relationship between these Colombian P. lansbergii lansbergii morphotypes was investigated, and their phylogenetic positions were determined for the first time using Bayesian inference. Despite the noticeable coloration divergence between the individuals analyzed, similar protein profiles of their venoms were observed. Additionally, neither their lethality nor biochemical activities were notably different. In general, both venoms were highly proteolytic, lacked a coagulant effect in vitro, and extended the clotting time due to the action of venom components, such as disintegrins and proteases, that induce defibrination. These results agreed with the result of our phylogenetic analysis, suggesting that the two chromatic morphs do not represent isolated populations. The phylogenetic analyses also supported the currently recognized P. lansbergii lansbergii subspecies as a monophyletic complex. In conclusion, the results of this investigation suggest similar clinical manifestations regardless of body coloration after a P. lansbergii lansbergii envenomation, and pools can therefore be used for antivenom development, medical treatments, and further research efforts.
C1 [De arco-Rodriguez, Beatriz; Vargas-Zapata, Carmina] Univ Atlantico, Escuela Ciencias Basicas, Programa Biol, Grp Biol Nutr, Atlantico, Colombia.
   [Montealegre-Sanchez, Leonel; Jimenez-Charris, Eliecer] Univ Valle, Fac Salud, Grp Nutr, Cali, Colombia.
   [Solano-Redondo, Luis; Castro-Herrera, Fernando] Univ Valle, Fac Ciencias Nat & Exactas, Grp Lab Herpetol, Cali, Colombia.
   [Guillermo Ortega, Jose] Pontificia Univ Javeriana, Fac Ciencias Salud, Grp Invest Ciencias Basicas & Clin Salud, Cali, Colombia.
   [Castillo, Andres] Univ Valle, Fac Ciencias Nat & Exactas, Dept Biol, Cali, Colombia.
RP Jimenez-Charris, E (reprint author), Univ Valle, Fac Hlth, Nutr Grp, Calle 4B 36-00,Edificio 116, Cali 5002, Colombia.
EM eliecer.jimenez@correounivalle.edu.co
OI Jimenez Charris, Eliecer/0000-0001-6043-1521
FU School of Basic Sciences, Faculty of Health, Universidad del Valle
FX The authors thank Eliecer Jimenez Vargas and Raul Charris Morales for
   their help in the collection of venom samples. We also thank Mauricio
   Arango for his help in mouse manipulation. This work was supported by
   the School of Basic Sciences, Faculty of Health, Universidad del Valle.
CR Alape-Giron A, 2008, J PROTEOME RES, V7, P3556, DOI 10.1021/pr800332p
   Alencar LRV, 2016, MOL PHYLOGENET EVOL, V105, P50, DOI 10.1016/j.ympev.2016.07.029
   Barlow A, 2009, P ROY SOC B-BIOL SCI, V276, P2443, DOI 10.1098/rspb.2009.0048
   Bonilla Ana, 2010, Acta Biologica Venezuelica, V30, P35
   BRODIE ED, 1992, EVOLUTION, V46, P1284, DOI 10.1111/j.1558-5646.1992.tb01124.x
   Bryson RW, 2008, COPEIA, P172, DOI 10.1643/CH-07-043
   Butantan-British IBothrops/I Systematics Project, 2002, P111
   Calvete JJ, 2003, BIOCHEM J, V372, P725, DOI 10.1042/BJ20021739
   Calvete JJ, 2011, EXPERT REV PROTEOMIC, V8, P739, DOI [10.1586/EPR.11.61, 10.1586/epr.11.61]
   CAMPBELL JA, 2004, VENOMOUS REPTILES W
   Casewell NR, 2014, P NATL ACAD SCI USA, V111, P9205, DOI 10.1073/pnas.1405484111
   Castoe TA, 2005, MOL PHYLOGENET EVOL, V37, P881, DOI 10.1016/j.ympev.2005.05.013
   Cespedes N, 2010, J VENOM ANIM TOXINS, V16, P268, DOI 10.1590/S1678-91992010000200009
   CHIPPAUX JP, 1991, TOXICON, V29, P1279, DOI 10.1016/0041-0101(91)90116-9
   Chippindale PT, 1998, COPEIA, P883
   CHO WW, 1988, J AM CHEM SOC, V110, P5166, DOI 10.1021/ja00223a043
   Cisneros-Heredia Diego F., 2005, Check List, V1, P16
   Comejo-Escobar P., 2013, HERPETOTROPICOS, V9, P13
   Daltry JC, 1996, NATURE, V379, P537, DOI 10.1038/379537a0
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Fernandez J, 2010, BIOCHIMIE, V92, P273, DOI 10.1016/j.biochi.2009.12.006
   Finney DJ, 1971, STAT METHODS BIOL AS
   Flores-Padrón Diego, 2014, Saber, V26, P91
   Fuenmayor GR, 2005, CARIBB J SCI, V41, P346
   Galvis-Penuela P. A., 2011, RIOHACHA CORPOGUAJIR, V1, P822
   GENE JA, 1989, TOXICON, V27, P841, DOI 10.1016/0041-0101(89)90096-2
   Giron ME, 2018, TOXICON, V144, P23, DOI 10.1016/j.toxicon.2018.01.020
   Giron ME, 2011, TOXICON, V57, P608, DOI 10.1016/j.toxicon.2011.01.003
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   GUTIERREZ JM, 1985, TOXICON, V23, P887, DOI 10.1016/0041-0101(85)90380-0
   GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z
   GUTIERREZ JM, 1986, TOXICON, V24, P885, DOI 10.1016/0041-0101(86)90089-9
   Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9
   Hall AT, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hernandez Camacho J., 1992, DIVERSIDAD BIOL IBER, P45
   Hoede P., 2012, SPECIMEN VOUCHER ICP, V1160
   Holzer M, 1996, TOXICON, V34, P1149, DOI 10.1016/0041-0101(96)00057-8
   Infante-Rivero E., 2009, HERPETOTROPICOS, V5, P25
   Institute Clodomiro Picado, 1988, MAN PROC DET ACT TOX
   Jimenez-Charris E, 2016, TOXICON, V119, P289, DOI 10.1016/j.toxicon.2016.07.006
   Jimenez-Charris E, 2015, J PROTEOMICS, V114, P287, DOI 10.1016/j.jprot.2014.11.016
   Kopper RA, 2015, TOXICON, V101, P19, DOI 10.1016/j.toxicon.2015.04.013
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOMONTE B, 1993, INFLAMMATION, V17, P93, DOI 10.1007/BF00916097
   Lomonte B, 2014, J PROTEOMICS, V103, P137, DOI 10.1016/j.jprot.2014.03.034
   Lomonte B, 2012, J PROTEOMICS, V75, P1675, DOI 10.1016/j.jprot.2011.12.016
   Martinez-Romero G, 2013, TOXICON, V71, P84, DOI 10.1016/j.toxicon.2013.05.006
   Morgenstern D, 2013, TOXICON, V63, P120, DOI 10.1016/j.toxicon.2012.11.022
   OTERO RAFAEL, 2002, Iatreia, V15, P05
   Palumbi S.R., 1996, MOL SYSTEMATICS, P205, DOI DOI 10.1080/17451000.2014.902536
   Parkinson Christopher L., 2002, P93
   Ramos Jesús, 2010, Comunidad y Salud, V8, P025
   Ronquist F., 2005, MRBAYES VERSION 3 2
   Smyers Scott D., 2014, Herpetological Review, V45, P8
   THEAKSTON RDG, 1983, B WORLD HEALTH ORGAN, V61, P949
   Vargas A, 2011, ACTA SCI VET, V39
   Wang WJ, 2004, BIOCHEM BIOPH RES CO, V324, P224, DOI 10.1016/j.bbrc.2004.09.031
   Wuster W, 2005, MOL ECOL, V14, P1095, DOI 10.1111/j.1365-294X.2005.02471.x
   Wuster W, 2008, MOL PHYLOGENET EVOL, V49, P445, DOI 10.1016/j.ympev.2008.08.019
NR 61
TC 0
Z9 0
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 56
EP 65
DI 10.1016/j.toxicon.2019.05.010
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000007
PM 31129160
DA 2020-05-12
ER

PT J
AU Arak, H
   Torshizi, MAK
   Hedayati, M
   Rahimi, S
AF Arak, Homa
   Torshizi, Mohammad Amir Karimi
   Hedayati, Mehdi
   Rahimi, Shaban
TI Comparative evaluation of aflatoxin and mineral binding activity of
   molecular imprinted polymer designed for dummy template using in vitro
   and in vivo models
SO TOXICON
LA English
DT Article
DE Aflatoxin; Biochemical parameter; Duckling; Molecular imprinted polymer
ID SODIUM-CALCIUM ALUMINOSILICATE; ELECTROCHEMICAL SENSOR; SELECTIVE
   EXTRACTION; MONOLITHIC COLUMN; BROILER-CHICKENS; NATURAL ZEOLITE; B-1;
   PERFORMANCE; BENTONITE; EFFICACY
AB The amelioration of aflatoxicosis in ducklings was examined by feeding molecular imprinted polymer (MIP) synthesized to target the aflatoxin B-1 (AFB(1)) analog molecule [5, 7-dimethoxycoumarin (DMC)] as a smart and novel toxin binder in comparison to a commercial toxin binder (CTB). MIP was characterized with some techniques, such as scanning electron microscopy (SEM) and thermal gravimetric analysis (TGA) that showed morphology and thermal resistance of MIP, respectively. The SEM showed that more pores and big cavities were formed in the network of the MIP. TGA plots of MIP showed dehydration at temperatures of about 31 degrees C-200 degrees C and gradual decomposition until 300 degrees C. The in vitro and in vivo ability of MIP and CTB to adsorb some minerals (Ca, Cu, Mg, P and Zn) was evaluated. The in vivo efficacy of MIP as an aflatoxins (AFs) binder in duckling exposed to aflatoxin-contaminated feed from 4 to 18 d of age was also compared to that of the CTB. A total of 240 4-d-old ducklings were assigned to experimental diets. Each diet was replicated four times with 10 birds in each pen, and the initial body weight classes were considered as blocks. The experimental treatment diets included: 1-Control (basal diet without any additive or AFs), 2- MIP (5 g/kg diet), 3- CTB (5 g/kg diet), 4- AFs (0.2 mg/kg diet), 5- AFs + MIP (0.2 mg/kg + 5 g/kg diet), and 6- AFs + CTB (0.2 mg/kg + 5 g/kg diet). In vitro study may clearly reflect the possibility of adsorbing minerals by CTB as compared to MIP whilst the results were not confirmed by in vivo study and it seems that reduction in plasma levels of minerals is related to the adverse effects of AFs. Livers showed histopathological alterations, with bile-duct proliferation of all aflatoxin fed ducklings. Macroscopic study indicated liver of birds fed diets containing AFs showed abnormal signs including yellowish, friable and rounded shape without protective effect of MIP and CTB. The results obtained from in vivo study indicate the partial alleviation of the adverse effects of AFs in ducklings by dietary supplementation of MIP and CTB (5 g/kg) on plasma albumin, Zn, Mg and Ca.
C1 [Arak, Homa; Torshizi, Mohammad Amir Karimi; Rahimi, Shaban] Tarbiat Modares Univ, Fac Agr, Dept Poultry Sci, Tehran 14115336, Iran.
   [Hedayati, Mehdi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran 1985717413, Iran.
RP Torshizi, MAK (reprint author), Tarbiat Modares Univ, Fac Agr, Dept Poultry Sci, Tehran 14115336, Iran.
EM karimitm@modares.ac.ir
FU Vivan Group (Mashhad, Iran)
FX This research was partially supported by Vivan Group (Mashhad, Iran).
CR Ali WH, 2010, J CHROMATOGR A, V1217, P6668, DOI 10.1016/j.chroma.2010.04.071
   Aravind KL, 2003, POULTRY SCI, V82, P571, DOI 10.1093/ps/82.4.571
   Azizpour A, 2015, BRAZ J POULTRY SCI, V17, P7, DOI 10.1590/1516-635xSpecialIssueNutrition-PoultryFeedingAdditives007-014
   Baggiani C, 2008, ANALYST, V133, P719, DOI 10.1039/b711352h
   Batlokwa B. S., 2011, THESIS
   Bayram E, 2017, FOOD CHEM, V221, P829, DOI 10.1016/j.foodchem.2016.11.090
   Boudergue C., 2009, EFSA J, V6, P22, DOI [DOI 10.2903/SP.EFSA.2009.EN-22, 10.2903/sp.efsa.2009.EN-22]
   CAST, 2003, MYCOTOXINS RISKS IN
   Chen KJ, 2014, FOOD CHEM TOXICOL, V74, P91, DOI 10.1016/j.fct.2014.09.003
   Chen LX, 2016, CHEM SOC REV, V45, P2137, DOI 10.1039/c6cs00061d
   Chen X, 2016, POULTRY SCI, V95, P834, DOI 10.3382/ps/pev378
   Chen X, 2014, POULTRY SCI, V93, P2037, DOI 10.3382/ps.2014-03984
   Cigic IK, 2009, INT J MOL SCI, V10, P62, DOI 10.3390/ijms10010062
   De Angelis M, 2006, RES MICROBIOL, V157, P792, DOI 10.1016/j.resmic.2006.05.003
   Diaz-Bao M, 2016, J CHROMATOGR A, V1471, P51, DOI 10.1016/j.chroma.2016.10.022
   Eckhardt JC, 2014, BRIT POULTRY SCI, V55, P215, DOI 10.1080/00071668.2014.883065
   Fowler J. C., 2014, THESIS
   Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8
   IKEGWUONU FI, 1984, J APPL TOXICOL, V4, P241, DOI 10.1002/jat.2550040505
   Iskander AL, 2011, ANN AGRIC SCI, V56, P43, DOI 10.1016/j.aoas.2011.05.002
   Jard G, 2011, FOOD ADDIT CONTAM A, V28, P1590, DOI 10.1080/19440049.2011.595377
   Jiang MJ, 2015, TOXINS, V7, P3540, DOI 10.3390/toxins7093540
   Kececi T, 1998, BRIT POULTRY SCI, V39, P452, DOI 10.1080/00071669889051
   Kolkur S, 2017, ADV INTEL SYS RES, V137, P324
   Kostadinovic L., 2014, J PROCESS ENERGY AGR, V18, P44
   Kryscio DR, 2012, ACTA BIOMATER, V8, P461, DOI 10.1016/j.actbio.2011.11.005
   Kudupoje M. B., 2017, THESIS
   Kumar R, 2009, VET ARHIV, V79, P31
   Lei RL, 2014, ELECTROANAL, V26, P1004, DOI 10.1002/elan.201300640
   Li JJ, 2010, AGR SCI CHINA, V9, P449, DOI 10.1016/S1671-2927(09)60116-4
   Liang GH, 2018, J PHARMACEUT BIOMED, V149, P258, DOI 10.1016/j.jpba.2017.11.012
   Magnoli AP, 2011, POULTRY SCI, V90, P48, DOI 10.3382/ps.2010-00971
   McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S
   Monson MS, 2015, AGRICULTURE-BASEL, V5, P742, DOI 10.3390/agriculture5030742
   National Research Council, 1994, NUTRIENT REQUIREMENT
   Nemoto K, 2007, J AM CHEM SOC, V129, P13626, DOI 10.1021/ja0741426
   NEWBERNE PM, 1969, CANCER RES, V29, P236
   Ortatatli M, 2005, RES VET SCI, V78, P61, DOI 10.1016/j.rvsc.2004.06.006
   Panahi HA, 2014, J SEP SCI, V37, P691, DOI 10.1002/jssc.201301144
   Papaioannou DS, 2002, RES VET SCI, V72, P51, DOI 10.1053/rvsc.2001.0521
   Pasha TN, 2007, ANIM FEED SCI TECH, V132, P103, DOI 10.1016/j.anifeedsci.2006.03.014
   Ramos JJ, 1996, SMALL RUMINANT RES, V21, P233, DOI 10.1016/0921-4488(95)00835-7
   Rawal S, 2010, RES VET SCI, V89, P325, DOI 10.1016/j.rvsc.2010.04.011
   Razzaghi-Abyaneh M., 2013, AFLATOXINS RECENT AD
   Rosa CAR, 2001, POULTRY SCI, V80, P139, DOI 10.1093/ps/80.2.139
   Saleh ZA, 2007, INT DAIRY J, V17, P854, DOI 10.1016/j.idairyj.2006.09.014
   SAS Institute, 1990, SAS USERS GUIDE STAT
   Sehu A., 2007, DTSCH TIERARZTL WSCH, V114, P144, DOI [10.2377/0341-6593-114-144, DOI 10.2377/0341-6593-114-144]
   Semong O., 2017, MOL IMPR, V5, P1, DOI DOI 10.1515/MOLIM-2017-0001
   SHOTWELL OL, 1966, APPL MICROBIOL, V14, P425, DOI 10.1128/AEM.14.3.425-428.1966
   Sikiti P, 2014, J ENVIRON HEALTH SCI, V12, DOI 10.1186/2052-336X-12-82
   Solis-Cruz B, 2017, POLYMERS-BASEL, V9, DOI 10.3390/polym9100529
   Sun WQ, 2013, CHINESE J CATAL, V34, P1589, DOI 10.1016/S1872-2067(12)60624-X
   Szumski M, 2014, J CHROMATOGR A, V1364, P163, DOI 10.1016/j.chroma.2014.08.078
   Tengjaroenkul B., 2016, LIVEST RES RURAL DEV, V28, P12
   Thilsing T, 2006, J VET MED A, V53, P57, DOI 10.1111/j.1439-0442.2006.00798.x
   Wang CY, 2010, BIOMATERIALS, V31, P4944, DOI 10.1016/j.biomaterials.2010.02.073
   Wang FY, 2018, TOXINS, V10, DOI 10.3390/toxins10040131
   World Health Organization, 1994, IARC MONOGRAPHS ON T
   Yabusaki K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089627
   Yamaguchi T, 1999, RENAL FAILURE, V21, P453, DOI 10.3109/08860229909045184
   Yavuz O, 2017, BRAZ J POULTRY SCI, V19, P409, DOI 10.1590/1806-9061-2016-0349
   Yazdanpanah H, 2013, IRAN J PHARM RES, V12, P81
   Zaidi SA, 2017, BIOMATER SCI-UK, V5, P388, DOI 10.1039/c6bm00765a
   Zhao J, 2010, POULTRY SCI, V89, P2147, DOI 10.3382/ps.2009-00608
NR 65
TC 1
Z9 1
U1 9
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 66
EP 75
DI 10.1016/j.toxicon.2019.05.005
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000008
PM 31125619
DA 2020-05-12
ER

PT J
AU Moreira, DA
   Soares, RM
   Valente, RH
   Bebianno, MJ
   Rebelo, MF
AF Moreira, Daniel A.
   Soares, Raquel M.
   Valente, Richard H.
   Bebianno, Maria J.
   Rebelo, Mauro F.
TI Molecular effects of Microcystin-LA in tilapia (Oreochromis niloticus)
SO TOXICON
LA English
DT Article
DE Cyanotoxins; Protein phosphatase; Glutathione peroxidase; Gene
   expression
ID GLUTATHIONE-S-TRANSFERASE; PROTEIN PHOSPHATASE 2A; ZEBRAFISH
   DANIO-RERIO; FRESH-WATER FISHES; RIO-DE-JANEIRO; SALMO-TRUTTA L;
   OXIDATIVE STRESS; BROWN TROUT; BIOCHEMICAL-CHARACTERIZATION;
   CELL-EXTRACTS
AB Nile tilapia (Oreochromis niloticus) is a freshwater phytoplanktivorous fish species reported to accumulate and tolerate large amounts of cyanotoxins such as microcystins (MCs). The present study aimed to investigate molecular responses to the acute exposure of Nile tilapia to the Microcystin-LA analogue (MC-LA). Thus, the specimens were sublethally exposed to 1000 mu g kg(-1) of MC-LA for 12, 24, 48, and 96 h. Gene expression of PP1, PP2A, GST, GPX and actin was analyzed by quantitative PCR. The protein abundance profile of PP2A was determined by immunoblotting, while the integrity of its biological function was assessed by a phosphatase enzymatic assay. PP2A activity was significantly and strongly reduced by MC-LA. A resulting feedback mechanism significantly increased PP2A gene expression and protein abundance in all assessed times. However, a recovery of that phosphatase activity was not observed. In this study, the observed increase in GPX gene expression was the only response that could be directly related to the unknown factors associated to the fish survival to such high dose exposure.
C1 [Moreira, Daniel A.; Bebianno, Maria J.; Rebelo, Mauro F.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Environm Mol Biol, Rio De Janeiro, Brazil.
   [Soares, Raquel M.] Univ Fed Rio de Janeiro, Multidisciplinary Ctr Res Biol, NUMPEX BIO, Campus Duque Caxias, Duque De Caxias, RJ, Brazil.
   [Valente, Richard H.] Fundacao Oswaldo Cruz, Lab Toxinol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Bebianno, Maria J.] Univ Algarve, CIMA, Campus Gambelas, P-8000397 Faro, Portugal.
   [Moreira, Daniel A.] Fundacao Oswaldo Cruz, Grad Program Computat & Syst Biol, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Soares, RM (reprint author), Univ Fed Rio de Janeiro, Multidisciplinary Ctr Res Biol, NUMPEX BIO, Campus Duque Caxias, Duque De Caxias, RJ, Brazil.
EM rmsoares@xerem.ufrj.br
OI Valente, Richard Hemmi/0000-0002-6562-7571; Bebianno,
   Maria/0000-0003-1492-8566; Moreira, Daniel/0000-0002-9434-9582
FU Rio de Janeiro State Research Council [FAPERJ]Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/111.540/2008]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) fellowship from the Brazilian Ministry of
   EducationCAPES
FX This work was supported by grant E-26/111.540/2008 from the Rio de
   Janeiro State Research Council [FAPERJ]. Daniel Moreira was supported by
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   fellowship from the Brazilian Ministry of Education.
CR Best JH, 2001, FISH PHYSIOL BIOCHEM, V24, P171, DOI 10.1023/A:1014081827372
   Bury NR, 1996, ENVIRON TOXIC WATER, V11, P187, DOI 10.1002/(SICI)1098-2256(1996)11:3<187::AID-TOX3>3.0.CO;2-5
   Campos A, 2010, INT J MOL SCI, V11, P268, DOI 10.3390/ijms11010268
   Canadian Council on Animal Care (CCAC), 2010, CCAC GUID EUTH AN US, P1
   CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x
   CARMICHAEL WW, 1994, SCI AM, V270, P78, DOI 10.1038/scientificamerican0194-78
   Chen L., 2014, ENV TOXICOL, V31
   Chen L, 2017, ENVIRON SCI TECHNOL, V51, P596, DOI 10.1021/acs.est.6b03990
   Chen L, 2016, MINI-REV MED CHEM, V16, P1018, DOI 10.2174/1389557516666160219130407
   Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053949
   Chen Y, 2012, ENVIRON MONIT ASSESS, V184, P6775, DOI 10.1007/s10661-011-2457-0
   Chorus I., 1999, TOXIC CYANOBACTERIA, P400
   de Magalhaes VF, 2001, TOXICON, V39, P1077
   Ding WX, 2003, FEMS MICROBIOL LETT, V220, P1, DOI 10.1016/S0378-1097(03)00100-9
   Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005
   FERRIGNO P, 1993, MOL BIOL CELL, V4, P669
   Fischer WJ, 2005, TOXICOL APPL PHARM, V203, P257, DOI 10.1016/j.taap.2004.08.012
   Fischer WJ, 2000, TOXICOL APPL PHARM, V164, P73, DOI 10.1006/taap.1999.8861
   Fischer WJ, 2000, TOXICOL SCI, V54, P365, DOI 10.1093/toxsci/54.2.365
   Fu J, 2006, AQUAT TOXICOL, V80, P261, DOI 10.1016/j.aquatox.2006.09.003
   Fu WY, 2009, CHEM RES TOXICOL, V22, P41, DOI 10.1021/tx800396p
   Garcia CZ, 2012, NEOTROP ICHTHYOL, V10, P613, DOI 10.1590/S1679-62252012000300015
   Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Guo XC, 2015, ENVIRON SCI POLLUT R, V22, P19273, DOI 10.1007/s11356-015-5531-2
   Hao L, 2010, TOXICON, V55, P1378, DOI 10.1016/j.toxicon.2010.02.015
   He S, 2010, J BIOCHEM MOL TOXIC, V24, P293, DOI 10.1002/jbt.20338
   Hoeger SJ, 2005, TOXICOL APPL PHARM, V203, P231, DOI 10.1016/j.taap.2004.04.015
   HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8
   HONKANEN RE, 1990, J BIOL CHEM, V265, P19401
   Huang X., 2015, INVOLVEMENT OXIDATIV
   Jos A, 2005, AQUAT TOXICOL, V72, P261, DOI 10.1016/j.aquatox.2005.01.003
   Konishi T, 2005, BIOCHEM J, V388, P299, DOI 10.1042/BJ20041578
   Kotak BG, 1996, TOXICON, V34, P517, DOI 10.1016/0041-0101(96)00009-8
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Le Manach S, 2016, ENVIRON SCI TECHNOL, V50, P8324, DOI 10.1021/acs.est.6b01903
   Li GY, 2008, AQUAT TOXICOL, V88, P75, DOI 10.1016/j.aquatox.2008.03.007
   Li XY, 2003, TOXICON, V42, P85, DOI 10.1016/S0041-0101(03)00104-1
   Liang J, 2011, J ZHEJIANG UNIV-SC B, V12, P951, DOI 10.1631/jzus.B1100121
   Liang XF, 2007, J BIOCHEM MOL TOXIC, V21, P289, DOI 10.1002/jbt.20188
   Liao WQ, 2006, J BIOCHEM MOL TOXIC, V20, P114, DOI 10.1002/jbt.20125
   Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200
   MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E
   Malbrouck C, 2004, TOXICON, V44, P927, DOI 10.1016/j.toxicon.2004.09.003
   Malbrouck C, 2004, TOXICON, V43, P295, DOI 10.1016/j.toxicon.2003.12.007
   Malbrouck C, 2003, COMP BIOCHEM PHYS C, V135, P39, DOI 10.1016/S1532-0456(03)00047-4
   Malbrouck C, 2006, ENVIRON TOXICOL CHEM, V25, P72, DOI 10.1897/05-029R.1
   McLellan NL, 2017, TOXICOL RES-UK, V6, P391, DOI [10.1039/c7tx00043j, 10.1039/C7TX00043J]
   Mohamed ZA, 2003, ENVIRON TOXICOL, V18, P137, DOI 10.1002/tox.10111
   Molina R, 2005, TOXICON, V46, P725, DOI 10.1016/j.toxicon.2005.07.012
   Pflugmacher S, 1998, BBA-GEN SUBJECTS, V1425, P527, DOI 10.1016/S0304-4165(98)00107-X
   Prieto AI, 2006, AQUAT TOXICOL, V77, P314, DOI 10.1016/j.aquatox.2005.12.012
   Qiao Q, 2016, ENVIRON POLLUT, V219, P119, DOI 10.1016/j.envpol.2016.10.029
   R Core Team, 2008, R LANG ENV STAT COMP
   RODGER HD, 1994, J FISH DIS, V17, P177, DOI 10.1111/j.1365-2761.1994.tb00211.x
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045
   RUNNEGAR MT, 1993, AM J PHYSIOL, V265, pG224
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   Soares RA, 2004, AQUAT TOXICOL, V70, P1, DOI 10.1016/j.aquatox.2004.06.013
   Soares RM, 2006, ENVIRON TOXICOL, V21, P95, DOI 10.1002/tox.20160
   Tencalla F, 1997, TOXICON, V35, P583, DOI 10.1016/S0041-0101(96)00153-5
   TOIVOLA DM, 1994, FEBS LETT, V344, P175, DOI 10.1016/0014-5793(94)00382-3
   van Apeldoorn ME, 2007, MOL NUTR FOOD RES, V51, P7, DOI 10.1002/mnfr.200600185
   Vesterkvist PSM, 2012, TOXINS, V4, P1008, DOI 10.3390/toxins4111008
   Wang L, 2006, COMP BIOCHEM PHYS C, V144, P216, DOI 10.1016/j.cbpc.2006.08.009
   Wang MH, 2010, TOXICOL SCI, V113, P60, DOI 10.1093/toxsci/kfp248
   WICKSTROM ML, 1995, TOXICOL PATHOL, V23, P326, DOI 10.1177/019262339502300309
   WILLIAMS DE, 1995, TOXICON, V33, P125, DOI 10.1016/0041-0101(94)00154-Z
   Xie LQ, 2007, TOXICON, V49, P646, DOI 10.1016/j.toxicon.2006.11.004
   Xie LQ, 2004, ENVIRON POLLUT, V127, P431, DOI 10.1016/j.envpol.2003.08.011
   YOSHIZAWA S, 1990, J CANCER RES CLIN, V116, P609, DOI 10.1007/BF01637082
   Zhang H, 2008, FISH PHYSIOL BIOCHEM, V34, P307, DOI 10.1007/s10695-007-9189-7
   Zhang XZ, 2011, J APPL TOXICOL, V31, P561, DOI 10.1002/jat.1597
   Zhao M, 2006, AQUACULTURE, V261, P960, DOI 10.1016/j.aquaculture.2006.08.019
   Zikova A, 2010, J ENVIRON MONITOR, V12, P2276, DOI 10.1039/c0em00246a
   Zimba PV, 2001, J FISH DIS, V24, P41, DOI 10.1046/j.1365-2761.2001.00273.x
NR 77
TC 1
Z9 1
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 76
EP 82
DI 10.1016/j.toxicon.2019.05.002
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000009
PM 31121173
DA 2020-05-12
ER

PT J
AU Schaer, M
AF Schaer, Michael
TI Persistent pit viper envenomation in three dogs
SO TOXICON
LA English
DT Review
DE Persistent envenomation; Recurrent envenomation; Pit viper; Antivenom
ID RATTLESNAKE ENVENOMATION; IMMUNOGLOBULIN THERAPY; SNAKE; COAGULOPATHY;
   ANTIVENOMS; RECURRENCE; TRIAL; FAB
AB Introduction: North Central Florida is the home to several venomous snakes. The most clinically significant pit vipers include the Eastern Diamondback Rattlesnake, the Water Moccasin, and less commonly the Timber Rattlesnake. Many of the dogs and cats that become envenomated by these particular snakes have moderate to severe clinical signs requiring the use of antivenom in doses that can range from 1 to 20 vials with the average case requiring two vials. Oftentimes, the pet owners' financial limitations restrict the amount of antivenom that can be administered initially to severely envenomed cases. Most of these patients will become clinically stable after the first 48 hours of treatment, but there are rare instances where some patients will follow this same initial course, and then revert back to the initial signs of envenomation associated with delayed absorption of redistributed venom from other tissue sites in addition to the bite site. This report describes three dogs that showed signs of persistent and/or recurrent envenomation requiring additional doses of antivenom.
   Methods: The medical records of three dogs showing signs of persistent envenomation were reviewed by the author who was available and provided assistance during the course of the dogs' respective hospitalizations. The dog's signalment, time of year of the envenomation, clinical signs, treatment, and outcome are provided in each case.
   Results: Each of these three dogs showed severe signs of envenomation characterized by marked mental depression, prostration, hemorrhagic lymphedema, and evidence of prolonged coagulation times. Initial treatment in each consisted of intravenous crystalloid solution and polyvalent crotalid antivenom that exceeded the usual average dose as reported in the literature. After the coagulation test normalized during the first three days, all of them reverted to abnormal prolonged clotting times with signs of clinical deterioration requiring additional doses of antivenom. Clinical stability was eventually reached and all dogs survived to be discharged.
   Conclusions: The clinical course of the three dogs described in this study showed that veterinary patients can experience persistent envenomation in a similar manner as described in humans. It behooves the veterinary practitioner to be aware of this complication and to be prepared to extend antivenom treatment as deemed necessary.
C1 [Schaer, Michael] Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med,Diplomate AC, Dept Small Anim Internal Med,Diplomat ACVIM Small, Gainesville, FL 32608 USA.
RP Schaer, M (reprint author), Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med,Diplomate AC, Dept Small Anim Internal Med,Diplomat ACVIM Small, Gainesville, FL 32608 USA.
EM schaerm@ufl.edu
CR Armentano RA, 2014, J VET EMERG CRIT CAR, V24, P144, DOI 10.1111/vec.12139
   Armentano RA, 2011, J VET EMERG CRIT CAR, V21, P461, DOI 10.1111/j.1476-4431.2011.00677.x
   Boyer LV, 2013, TOXICON, V74, P101, DOI 10.1016/j.toxicon.2013.07.018
   Boyer LV, 1999, ARCH INTERN MED, V159, P706, DOI 10.1001/archinte.159.7.706
   Bush SP, 2013, TOXICON, V69, P29, DOI 10.1016/j.toxicon.2013.02.008
   Dart RC, 2001, ANN EMERG MED, V37, P181, DOI 10.1067/mem.2001.113372
   eClinpath.com, 2019, COAG ASS
   FIDLER HERBERT K., 1940, AMER JOUR PATH, V16, P355
   Gutierrez JM, 2003, CLIN PHARMACOKINET, V42, P721, DOI 10.2165/00003088-200342080-00002
   Gutierrez JM, 1998, TOXICON, V36, P1529, DOI 10.1016/S0041-0101(98)00145-7
   Katzenbach J. E., 2015, J SCI EDUC TECHNOL, P1
   Kitchens CS, 2008, J MED TOXICOL, V4, P180, DOI 10.1007/BF03161198
   Kota J, 2007, DRUG METAB DISPOS, V35, P2211, DOI 10.1124/dmd.107.015669
   Lavonas EJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-2
   Lavonas EJ, 2014, ANN EMERG MED, V63, P71, DOI 10.1016/j.annemergmed.2013.03.002
   McCown JL, 2009, J VET EMERG CRIT CAR, V19, P603, DOI 10.1111/j.1476-4431.2009.00487.x
   Mora J, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000318
   Paniagua D, 2017, TOXINOLOGY, P453, DOI 10.1007/978-94-007-6410-1_10
   Peterson ME, 2011, J VET EMERG CRIT CAR, V21, P335, DOI 10.1111/j.1476-4431.2011.00643.x
   Pritchard JC, 2014, J AM ANIM HOSP ASSOC, V50, P338, DOI 10.5326/JAAHA-MS-6131
   SCHAER M, 1984, COMP CONT EDUC PRACT, V6, P997
   Schaer M, 2015, J AM ANIM HOSP ASSOC, V51, P329, DOI 10.5326/JAAHA-MS-6234
   Seifert SA, 2001, ANN EMERG MED, V37, P189, DOI 10.1067/mem.2001.113135
   Stepien R. L., 2015, CLIN VET ADVISOR, P1110
   Yankin I., 2017, JFMS MED SURG, V3
NR 25
TC 0
Z9 0
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 83
EP 87
DI 10.1016/j.toxicon.2019.05.013
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000010
PM 31129161
DA 2020-05-12
ER

PT J
AU Singh, C
   Prakash, C
   Mishra, P
   Tiwari, KN
   Mishra, SK
   More, RS
   Kumar, V
   Singh, J
AF Singh, Chandrashekhar
   Prakash, Chandra
   Mishra, Pallavi
   Tiwari, Kavindra Nath
   Mishra, Sunil Kumar
   More, Raghunath Shahaji
   Kumar, Vijay
   Singh, Jasmeet
TI Hepatoprotective efficacy of Premna integrifolia L. leaves against
   aflatoxin B1-induced toxicity in mice
SO TOXICON
LA English
DT Article
DE Premna integrifolia; Aflatoxin B1; Hepatotoxicity; Oxidative stress;
   Apoptosis
ID INDUCED LIVER-INJURY; OXIDATIVE STRESS; HEPATOCELLULAR-CARCINOMA;
   INDUCED HEPATOTOXICITY; PROTECTIVE ROLE; IN-VITRO; ANTIOXIDANT; B-1;
   MECHANISMS; PATHWAY
AB The present study evaluated the hepatoprotective role of ethanol extract of P. integrifolia leaves (EEPL) on aflatoxin B1 (AFB1)-induced toxicity in mice. Mice were administered with AFB1 (0.1 mg/kg b. wt., orally) for 90 days, EEPL (400 and 600 mg/kg b. wt., orally) and silymarin (100 mg/kg b. wt., orally) in combination with AFB1. The study shows the protective effect of EEPL by the restoration of altered hematological indices and liver marker enzymes. Restoration of lipid peroxidation and glutathione content, along with activities of antioxidant enzymes, suggest amelioration of oxidative stress in AFB1-intoxicated mice. In addition, EEPL attenuated apoptosis and histopathological alterations in liver tissue. In conclusion, the current study suggests that EEPL protect mice liver against AFB1 toxicity by inhibiting oxidative stress and apoptosis. The protective activity of EEPL may be due to the enrichment of flavonoids (neohesperidin, apigenin-7-O-glucoside, catechin hydrate, cyanidin chloride, quercetin-3-galactoside, diosmin, genistein, malvin chloride, 4-hydroxy-3-methoxycinnamic acid, kaempferol-3-O-alpha-L-arabinoside, myricitrin, poncirin, vitexin and tiliroside) in the extract as identified by UPLC-QTOF-MS/MS.
C1 [Singh, Chandrashekhar; Mishra, Pallavi; Tiwari, Kavindra Nath] Banaras Hindu Univ, Dept Bot, MMV, Varanasi 221005, Uttar Pradesh, India.
   [Prakash, Chandra; Kumar, Vijay] Maharshi Dayanand Univ, Dept Biochem, Rohtak 124001, Haryana, India.
   [Mishra, Pallavi] Indian Inst Vegetable Res, Varanasi 221305, Uttar Pradesh, India.
   [Mishra, Sunil Kumar] Banaras Hindu Univ, Indian Inst Technol, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India.
   [More, Raghunath Shahaji] Banaras Hindu Univ, Inst Med Sci, Dept Anat, Varanasi 221005, Uttar Pradesh, India.
   [Singh, Jasmeet] Banaras Hindu Univ, Fac Ayurveda, Inst Med Sci, Dept Dravyagun, Varanasi 221005, Uttar Pradesh, India.
   [Prakash, Chandra] Jawaharlal Nehru Univ, Sch Life Sci, Neurobiol Lab, New Delhi 110067, India.
RP Tiwari, KN (reprint author), Banaras Hindu Univ, Dept Bot, MMV, Varanasi 221005, Uttar Pradesh, India.
EM kntiwaribhu@gmail.com
OI Prakash, Chandra/0000-0002-1435-1560
FU University Grants Commission (UGC), Government of India, New
   DelhiUniversity Grants Commission, India
FX Authors C. Singh and K.N. Tiwari would like to acknowledge University
   Grants Commission (UGC), Government of India, New Delhi for financial
   assistance. Advance Instrumentation Research Facility (AIRF), Jawaharlal
   Nehru University, New Delhi acknowledged for providing UPLC-QTOF-MS/MS
   facility.
CR Abdel-Wahhab MA, 2018, ENVIRON SCI POLLUT R, V25, P29144, DOI 10.1007/s11356-018-2921-2
   Abdulmajeed NA, 2011, ARAB J CHEM, V4, P1, DOI 10.1016/j.arabjc.2010.06.005
   Agnes VF, 2003, FOOD CHEM TOXICOL, V41, P119, DOI 10.1016/S0278-6915(02)00171-0
   Ali FEM, 2018, LIFE SCI, V207, P50, DOI 10.1016/j.lfs.2018.05.048
   Alm-Eldeen AA, 2017, BIOMED PHARMACOTHER, V87, P247, DOI 10.1016/j.biopha.2016.12.084
   Alm-Eldeen AA, 2015, TOXICOL IND HEALTH, V31, P1269, DOI 10.1177/0748233713491807
   An F, 2012, NEURAL REGEN RES, V7, P2565, DOI 10.3969/j.issn.1673-5374.2012.33.001
   Azad R, 2018, FITOTERAPIA, V131, P189, DOI 10.1016/j.fitote.2018.10.016
   Banu GS, 2009, INDIAN J CLIN BIOCHE, V24, P250, DOI 10.1007/s12291-009-0047-5
   Bender CE, 2012, P NATL ACAD SCI USA, V109, P4904, DOI 10.1073/pnas.1120680109
   Besaratinia A, 2009, GASTROENTEROLOGY, V137, P1127, DOI 10.1053/j.gastro.2009.06.002
   Bischoff K, 2018, VETERINARY TOXICOLOGY: BASIC AND CLINICAL PRINCIPLES, 3RD EDITION, P239, DOI 10.1016/B978-0-12-811410-0.00015-5
   Bose L. V., 2012, Journal of Pharmacy Research, V5, P3261
   Chauhan N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01748
   del Rio J. A., 2018, PHYTOCHEMICALS CITRU, P237
   Dianita R, 2017, PHARM BIOL, V55, P1715, DOI 10.1080/13880209.2017.1323225
   Domitrovic R, 2015, CHEM-BIOL INTERACT, V230, P21, DOI 10.1016/j.cbi.2015.01.030
   Dwivedi M., 2016, J RES TRADIT MED, V2, P56
   El-Nekeetya AA, 2014, TOXICOL REP, V1, P319, DOI 10.1016/j.toxrep.2014.05.014
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Eraslan G, 2017, ENVIRON SCI POLLUT R, V24, P27931, DOI 10.1007/s11356-017-0232-7
   FUCHS J, 1993, ARZNEIMITTELFORSCH, V43-1, P370
   Fukumoto LR, 2000, J AGR FOOD CHEM, V48, P3597, DOI 10.1021/jf000220w
   Ganesan K, 2017, ANN NY ACAD SCI, V1401, P102, DOI 10.1111/nyas.13446
   Gao JH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0595-y
   Goto T, 2012, MOL NUTR FOOD RES, V56, P435, DOI 10.1002/mnfr.201100458
   Gupta Rekha, 2011, Toxicol Int, V18, P94, DOI 10.4103/0971-6580.84259
   Hamid AS, 2013, ONCOL LETT, V5, P1087, DOI 10.3892/ol.2013.1169
   Huang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170109
   ITO Y, 1989, MUTAT RES, V222, P253, DOI 10.1016/0165-1218(89)90141-9
   Jaimez J, 2000, J CHROMATOGR A, V882, P1, DOI 10.1016/S0021-9673(00)00212-0
   Jain P, 2013, EUR J PHARM SCI, V50, P353, DOI 10.1016/j.ejps.2013.08.005
   Jang Y, 2018, PHYTOTHER RES, V32, P616, DOI 10.1002/ptr.6008
   Kashyap D, 2017, J FUNCT FOODS, V30, P203, DOI 10.1016/j.jff.2017.01.022
   KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4
   Kucera O, 2014, WORLD J GASTROENTERO, V20, P8364, DOI 10.3748/wjg.v20.i26.8364
   Liao SQ, 2014, BIOL TRACE ELEM RES, V162, P296, DOI 10.1007/s12011-014-0131-4
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Madrigal-Santillan E, 2014, WORLD J GASTROENTERO, V20, P14787, DOI 10.3748/wjg.v20.i40.14787
   Madunic J, 2018, CANCER LETT, V413, P11, DOI 10.1016/j.canlet.2017.10.041
   Majumder R, 2014, ADV BIO RES, V8, P29, DOI DOI 10.5829/ID0SI.ABR.2014.8.1.81138
   Mali PY, 2016, ANC SCI LIFE, V35, P132, DOI 10.4103/0257-7941.179864
   Massey TE, 2000, EXP LUNG RES, V26, P673, DOI 10.1080/01902140150216756
   Mogalli R, 2018, CYTOTECHNOLOGY, V70, P1519, DOI 10.1007/s10616-018-0242-4
   Munir AA, 1984, J ADELAIDE BOT GARD, V7, P1
   Niki E, 2005, BIOCHEM BIOPH RES CO, V338, P668, DOI 10.1016/j.bbrc.2005.08.072
   Palanisamy Sampathkumar, 2018, Pharmacognosy Journal, V10, P304, DOI 10.5530/pj.2018.2.53
   Prakash C, 2015, TOXICOL ENVIRON CHEM, V97, P1408, DOI 10.1080/02772248.2015.1102425
   Rajendran Rekha, 2010, Avicenna Journal of Medical Biotechnology, V2, P101
   Reiter E, 2009, MOL NUTR FOOD RES, V53, P508, DOI 10.1002/mnfr.200800145
   Rezaee-Khorasany A, 2019, J ETHNOPHARMACOL, V237, P286, DOI 10.1016/j.jep.2019.03.048
   Rotimi OA, 2017, TOXICOL REP, V4, P408, DOI 10.1016/j.toxrep.2017.07.006
   Rushing BR, 2019, FOOD CHEM TOXICOL, V124, P81, DOI 10.1016/j.fct.2018.11.047
   Saleh DO, 2014, CAN J PHYSIOL PHARM, V92, P965, DOI 10.1139/cjpp-2014-0192
   Singh C, 2018, BIOMED PHARMACOTHER, V107, P634, DOI 10.1016/j.biopha.2018.08.039
   Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706
   Taranu I, 2019, TOXICON, V162, P24, DOI 10.1016/j.toxicon.2019.02.020
   Towner RA, 2003, FREE RADICAL BIO MED, V35, P1330, DOI 10.1016/j.freeradbiomed.2003.08.002
   Vadivu R, 2009, J SCI RES, V1, P145, DOI DOI 10.3329/jsr.v1i1.1046
   Varga J, 2011, STUD MYCOL, P57, DOI 10.3114/sim.2011.69.05
   Venkatakrishnan K, 2018, FOOD FUNCT, V9, P1205, DOI 10.1039/c7fo01449j
   Vipin AV, 2017, BIOMED PHARMACOTHER, V91, P415, DOI 10.1016/j.biopha.2017.04.107
   Wang M, 2015, AM J CHINESE MED, V43, P241, DOI 10.1142/S0192415X15500160
   WILLS ED, 1966, BIOCHEM J, V99, P667, DOI 10.1042/bj0990667
   Witeska M, 2006, AQUACULT INT, V14, P141, DOI 10.1007/s10499-005-9020-3
   Xie WY, 2016, CHEM-BIOL INTERACT, V246, P11, DOI 10.1016/j.cbi.2016.01.004
   Yilmaz S, 2018, RES VET SCI, V119, P268, DOI 10.1016/j.rvsc.2018.07.007
   Yilmaz S, 2017, ADV CLIN EXP MED, V26, P907, DOI 10.17219/acem/66347
   Zhao L, 2016, J AGR FOOD CHEM, V64, P7291, DOI 10.1021/acs.jafc.6b02907
NR 69
TC 0
Z9 0
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2019
VL 166
BP 88
EP 100
DI 10.1016/j.toxicon.2019.05.014
PG 13
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA IH2KZ
UT WOS:000474325000011
PM 31125618
DA 2020-05-12
ER

PT J
AU Puffer, RC
   Sabbag, OD
   Logli, AL
   Spinner, RJ
   Rose, PS
AF Puffer, Ross C.
   Sabbag, Orlando D.
   Logli, Anthony L.
   Spinner, Robert J.
   Rose, Peter S.
TI Melorheostosis Causing Compression of Common Peroneal Nerve at Fibular
   Tunnel
SO WORLD NEUROSURGERY
LA English
DT Article
DE Compression; Hyperostosis; Melorheostosis; Nerve; Peroneal
ID SCLEROTOME
AB BACKGROUND: Melorheostosis is a bone hyperostosis disorder characterized flowing bone thought to occur in a sclerodermal distribution. These bony lesions often arise in soft tissues adjacent to joints. Pain arises from joint limitations and impingements, but diffuse pain can also occur.
   CASE DESCRIPTION: We present a case of a patient with symptomatic compression of the common peroneal nerve by an extraosseous hyperostotic tissue island in a patient with melorheostosis.
   CONCLUSIONS: Melorheostosis is a rare bone overgrowth syndrome that can to joint mobility limitations and pain. In specific locations, it can also lead to tethering and symptomatic compression of the peripheral nerves.
C1 [Puffer, Ross C.; Spinner, Robert J.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Sabbag, Orlando D.; Logli, Anthony L.; Spinner, Robert J.; Rose, Peter S.] Mayo Clin, Dept Orthoped, Rochester, MN 55905 USA.
RP Rose, PS (reprint author), Mayo Clin, Dept Orthoped, Rochester, MN 55905 USA.
EM rose.peter@mayo.edu
CR Abdullah S, 2014, SINGAP MED J, V55, pE54
   BIED JC, 1976, REV RHUM, V43, P193
   Byberg Sarah, 2018, J Med Case Rep, V12, P278, DOI 10.1186/s13256-018-1820-y
   Donath J, 2002, SKELETAL RADIOL, V31, P709, DOI 10.1007/s00256-002-0576-y
   Freyschmidt J, 2001, EUR RADIOL, V11, P474, DOI 10.1007/s003300000562
   Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453
   Hellemans Jan, 2006, Hum Mutat, V27, P290, DOI 10.1002/humu.9403
   Hollick RJ, 2010, BMJ CASE REP, V2010
   Ivanusic JJ, 2007, CLIN ANAT, V20, P956, DOI 10.1002/ca.20555
   Jha S, 2018, BONE, V117, P31, DOI 10.1016/j.bone.2018.09.005
   Jha S, 2019, J BONE MINER RES, V34, P145, DOI 10.1002/jbmr.3577
   Kang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03720-z
   Kotwal A, 2017, CURR OSTEOPOROS REP, V15, P335, DOI 10.1007/s11914-017-0375-y
   MURRAY RO, 1979, SKELETAL RADIOL, V4, P57, DOI 10.1007/BF00349329
   Saadallaoui Ben Hamida Kaouther, 2009, Tunis Med, V87, P204
   Shin S.J., 2015, JBJS CASE CONNECT, V5, pe401, DOI 10.2106/JBJS.CC.N.00159
   Slimani S, 2013, BMJ CASE REP, V2013
   Smith GC, 2017, PM&R, V9, P283, DOI 10.1016/j.pmrj.2016.07.530
   Vyskocil V, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0455-z
   Whyte MP, 2017, BONE, V101, P145, DOI 10.1016/j.bone.2017.04.010
   WYNNEDAVIES R, 1985, J BONE JOINT SURG BR, V67, P133
NR 21
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 1
EP 3
DI 10.1016/j.wneu.2019.04.208
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100131
PM 31051308
DA 2020-05-12
ER

PT J
AU Bohl, MA
   Leveque, JC
   Bayles, S
   Sethi, R
AF Bohl, Michael A.
   Leveque, Jean-Christophe
   Bayles, Stephen
   Sethi, Rajiv
TI Postoperative Development of Desmoid Tumor After Surgical Correction of
   Adult Spinal Deformity: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aggressive; Fibromatosis; Scoliosis; Spine
ID WINGLESS SIGNALING PATHWAY; CATENIN GENE CTNNB1; AGGRESSIVE
   FIBROMATOSIS; RADIATION-THERAPY; SURGERY; LAMINECTOMY; NECK; HEAD
AB BACKGROUND: Desmoid tumors are known to be rare and relatively slow growing with locally invasive histology and high recurrence rates. A rare subset of these tumors occurs adjacent to the spinal column after surgery. Since 1961, only 6 cases of postoperative paraspinal desmoid tumor have been reported. This report is the first to describe the occurrence of a paraspinal desmoid tumor after surgical correction of a spinal deformity.
   CASE DESCRIPTION: A 56-year-old woman with multiple sclerosis reported 2-3 years of progressively worsening mid and low back pain that was worse with standing and ambulation and almost completely relieved with lying flat. Standing anteroposterior scoliosis radiographs revealed a thoracolumbar spinal deformity, which was surgically corrected with a T4 pelvis spinal fixation and fusion. At her 2-year postoperative clinic visit the patient reported good improvement in her preoperative symptoms but felt a fullness in her right upper back and neck that was nontender. Magnetic resonance imaging revealed a large tumor in this region. The tumor was resected en bloc, and pathology noted a 14.5 cm x 8.7 cm x 4.2 cm mass with spindle cell proliferation and positive staining for beta-catenin (mutated gene found in 85% of desmoid tumors).
   CONCLUSIONS: This is the first report of a postoperative desmoid tumor after spinal deformity correction and the seventh reported case in the spine literature. All reported cases have been women aged 39-57 years. The patient will be followed closely with magnetic resonance imaging given the known high local recurrence rate of this tumor.
C1 [Bohl, Michael A.] St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
   [Bohl, Michael A.; Leveque, Jean-Christophe; Bayles, Stephen; Sethi, Rajiv] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA.
RP Bohl, MA (reprint author), St Josephs Hosp, Dept Neurosurg, Barrow Neurol Inst, Phoenix, AZ 85013 USA.; Bohl, MA (reprint author), Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA.
EM Michael.Bohl@bnaneuro.net
RI Leveque, Jean-Christophe/L-6367-2017
OI Leveque, Jean-Christophe/0000-0003-2465-444X
CR Avincsal OM, 2018, BALK MED J, V35, P278, DOI 10.4274/balkanmedj.2017.0509
   Ballo MT, 1999, J CLIN ONCOL, V17, P158, DOI 10.1200/JCO.1999.17.1.158
   Church J, 2005, DIS COLON RECTUM, V48, P1528, DOI 10.1007/s10350-005-0018-8
   Cohen S, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-28
   Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225
   Gega M, 2006, J CLIN ONCOL, V24, P102, DOI 10.1200/JCO.2005.02.1923
   GONATAS NK, 1961, ARCH PATHOL, V71, P214
   Guzey FK, 2006, J NEUROSURG-SPINE, V4, P338, DOI 10.3171/spi.2006.4.4.338
   Hendriks MP, 2013, HEAD NECK-J SCI SPEC, V35, pE246, DOI 10.1002/hed.23092
   Howe CR, 2011, SPINE, V36, P1397, DOI 10.1097/BRS.0b013e3181f453e2
   Jain Paresh, 2010, Ann R Coll Surg Engl, V92, pW19, DOI 10.1308/147870810X12822015504365
   Jelinek JA, 2001, INT J RADIAT ONCOL, V50, P121, DOI 10.1016/S0360-3016(00)01570-4
   KRAUS C, 1994, GENOMICS, V23, P272, DOI 10.1006/geno.1994.1493
   Latchford AR, 2006, BRIT J SURG, V93, P1258, DOI 10.1002/bjs.5425
   Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475
   Luo N, WORLD NEUROSURG
   Lynch JJ, 1999, J NEUROSURG, V90, P121, DOI 10.3171/spi.1999.90.1.0121
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Muller J., 1838, UEBER FEINEN BAU FOR
   NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0
   Nuyttens JJ, 2000, CANCER, V88, P1517, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1517::AID-CNCR3>3.0.CO;2-9
   PEIFER M, 1991, DEVELOPMENT, V111, P1029
   PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0
   Puvanesarajah Varun, 2013, Evid Based Spine Care J, V4, P137, DOI 10.1055/s-0033-1357356
   REITAMO JJ, 1982, AM J CLIN PATHOL, V77, P665
   Sakorafas GH, 2007, SURG ONCOL, V16, P131, DOI 10.1016/j.suronc.2007.07.009
   Schwab FJ, 2012, EUR SPINE J, V21, P2603, DOI 10.1007/s00586-012-2370-4
   Sevak S, 2012, SPINE, V37, pE456, DOI 10.1097/BRS.0b013e318232922a
   Sibley RK, 2001, ATLAS TUMOR PATHOL, P71
   Skubitz KM, 2017, MAYO CLIN PROC, V92, P947, DOI 10.1016/j.mayocp.2017.02.012
   Street JT, 2012, SPINE J, V12, P22, DOI 10.1016/j.spinee.2011.12.003
   Wang CP, 2006, HEAD NECK-J SCI SPEC, V28, P1008, DOI 10.1002/hed.20467
   Weiss SW, 2001, ENZINGER WEISSS SOFT, P227
   WYLER AR, 1973, J NEUROSURG, V39, P114, DOI 10.3171/jns.1973.39.1.0114
NR 34
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 4
EP 10
DI 10.1016/j.wneu.2019.04.201
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100132
PM 31051304
DA 2020-05-12
ER

PT J
AU Yokoya, S
   Hino, A
   Echigo, T
   Oka, H
AF Yokoya, Shigeomi
   Hino, Akihiko
   Echigo, Tadashi
   Oka, Hideki
TI Place-and-Clip Method for Fixing the Suture Thread in Deep-Brain
   Vascular Lesions: A Technical Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm clip; Narrow working space; Suture thread; Vascular injury
AB BACKGROUND: Intracranial vascular injury incurred during surgery must be repaired as quickly as possible. The standard repair procedure is surgical suturing. However, the narrow and deep working space may obstruct creating a knot with the suture thread.
   CASE DESCRIPTION: Resection of an olfactory groove meningioma was performed in a 73-year-old woman via the right lateral supraorbital approach. Tumor retraction caused an injury to the pericallosal artery. After temporary clipping of the vessel, a 10-0 nylon thread was placed on the vascular lesion and the end of the thread was fixed with an aneurysm clip.
   CONCLUSIONS: Fixing the suture thread with an aneurysm clip can be a rescue technique in suturing procedures on deeply located vascular lesions.
C1 [Yokoya, Shigeomi; Hino, Akihiko; Echigo, Tadashi; Oka, Hideki] Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
RP Yokoya, S (reprint author), Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
EM yokoya@ks.kyorin-u.ac.jp
CR Horiuchi T, 2013, NEUROSURG REV, V36, P133, DOI 10.1007/s10143-012-0398-x
NR 1
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 11
EP 13
DI 10.1016/j.wneu.2019.04.111
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100133
PM 31009785
DA 2020-05-12
ER

PT J
AU Yokota, H
   Noguchi, H
   Yokoyama, K
AF Yokota, Hiroshi
   Noguchi, Hiroshi
   Yokoyama, Kazuhiro
TI Epidermoid Cyst with Torcular Herophili Obstruction and Unusual Venous
   Drainage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diploic vein; Epidermoid cyst; Intracranial hypertension; Torcular
   herophili
ID OCCIPITAL BONE
AB BACKGROUND: An epidermoid cyst arising from diploic space in the skull can cause an intracranial mass effect with compression of the underlying venous sinuses.
   CASE DESCRIPTION: A 66-year-old woman came to us with a persistent headache and unsteadiness. Computed tomography demonstrated an occipital bone cystic lesion with an intracranial mass effect overlying the torcular herophili, with high-intensity findings in diffusion-weighted magnetic resonance imaging. Cerebral angiogram demonstrated obstruction of the torcular herophili with development of diploic venous drainage. The patient underwent removal of the lesion and a cranioplasty procedure. The diagnosis was torcular epidermoid cyst. The postoperative course was uneventful, and the symptoms were resolved.
   CONCLUSIONS: Development of diploic venous drainage contributed to avoidance of critical intracranial hypertension during slow growth of a torcular epidermoid cyst.
C1 [Yokota, Hiroshi; Noguchi, Hiroshi; Yokoyama, Kazuhiro] Higashiosaka City Gen Hosp, Dept Neurosurg, Higashiosaka, Osaka, Japan.
RP Yokota, H (reprint author), Higashiosaka City Gen Hosp, Dept Neurosurg, Higashiosaka, Osaka, Japan.
EM hyokota0001@gmail.com
CR Garcia-Gonzalez U, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09169
   GURIDI J, 1990, NEUROSURGERY, V27, P978, DOI 10.1227/00006123-199012000-00019
   Jaiswal AK, 2000, BRIT J NEUROSURG, V14, P225
   Lam CH, 2001, NEUROSURGERY, V48, P929, DOI 10.1097/00006123-200104000-00049
   Lee GYF, 2001, AUST NZ J SURG, V71, P385, DOI 10.1046/j.1440-1622.2001.02135.x
   RENGACHARY S, 1978, J NEUROSURG, V48, P475, DOI 10.3171/jns.1978.48.3.0475
   Tsutsumi S, 2014, AM J NEURORADIOL, V35, P1735, DOI 10.3174/ajnr.A4007
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 14
EP 17
DI 10.1016/j.wneu.2019.04.223
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100134
PM 31054339
DA 2020-05-12
ER

PT J
AU Chen, BY
   Chen, V
   Inam, S
   Yin, C
   Damodaran, O
AF Chen, Bi Yi
   Chen, Vivien
   Inam, Shafqat
   Yin, Charlotte
   Damodaran, Omprakash
TI Secondary Diffuse Choroid Plexus B-Cell Lymphoma: Case Report and Review
   of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chemotherapy; Intraventricular lymphoma; Secondary central nervous
   system lymphoma
ID CENTRAL-NERVOUS-SYSTEM; PRIMARY CNS LYMPHOMA; NON-HODGKINS-LYMPHOMA;
   INTRAVENOUS METHOTREXATE; RITUXIMAB; PROPHYLAXIS; INVOLVEMENT;
   RECURRENCE; DIAGNOSIS; TRIAL
AB BACKGROUND: Central nervous system (CNS) relapse is an uncommon complication of diffuse large B cell lymphoma and is associated with significant mortality and morbidity. It is becoming a more prevalent pathologic entity in the rituximab era. Our case provides insight into the pathophysiology, diagnosis, prevention, and management of secondary intraventricular CNS lymphomas.
   CASE DESCRIPTION: We report an unusual case of a 64-year-old man who presented with an isolated secondary CNS lymphoma involving the choroid plexus in a diffuse pattern. He initially presented with obstructive hydrocephalus from diffuse choroid plexus lesions and was commenced on systemic therapy after confirmation of diagnosis via samples obtained from an open biopsy.
   CONCLUSIONS: This case highlights the lack of high-quality evidence behind the use of high-dose intravenous methotrexate as CNS prophylaxis. The case provides additional insight into the pathophysiology of intraventricular CNS lymphomas and the importance of establishing a histopathologic diagnosis via an open biopsy before the administration of high-dose steroids.
C1 [Chen, Bi Yi; Chen, Vivien; Inam, Shafqat; Damodaran, Omprakash] Concord Gen Repatriat Hosp, Concord, Australia.
   [Yin, Charlotte] Royal North Shore Hosp, St Leonards, NSW, Australia.
RP Chen, BY (reprint author), Concord Gen Repatriat Hosp, Concord, Australia.
EM chen.m.biyi@gmail.com
CR Abramson JS, 2010, CANCER-AM CANCER SOC, V116, P4283, DOI 10.1002/cncr.25278
   Arkenau HT, 2007, ANN ONCOL, V18, P541, DOI 10.1093/annonc/mdl434
   Boehme V, 2009, BLOOD, V113, P3896, DOI 10.1182/blood-2008-10-182253
   Bromberg JE, 2013, HAEMATOLOGICA, V98, P808, DOI 10.3324/haematol.2012.070839
   del Rio MS, 2009, ONCOLOGIST, V14, P526, DOI 10.1634/theoncologist.2008-0236
   Deng LJ, 2013, INT J HEMATOL, V98, P664, DOI 10.1007/s12185-013-1458-x
   DeRosa P, 2014, J NEUROL SURG REP, V75, pE154, DOI 10.1055/s-0034-1378152
   Ferreri AJM, 2016, LANCET HAEMATOL, V3, pE217, DOI 10.1016/S2352-3026(16)00036-3
   Glantz MJ, 1998, J CLIN ONCOL, V16, P1561, DOI 10.1200/JCO.1998.16.4.1561
   HERMAN TS, 1979, CANCER, V43, P390, DOI 10.1002/1097-0142(197901)43:1<390::AID-CNCR2820430155>3.0.CO;2-U
   Herr MBP, 2014, BLOOD, V124, P5389
   Hollender A, 2002, ANN ONCOL, V13, P1099, DOI 10.1093/annonc/mdf175
   Kumar A, 2012, CANCER-AM CANCER SOC, V118, P2944, DOI 10.1002/cncr.26588
   LEVINE S, 1987, LAB INVEST, V56, P231
   McMillan A, 2005, BRIT J HAEMATOL, V131, P13, DOI 10.1111/j.1365-2141.2005.05703.x
   Pardridge WM, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-7
   Porter AB, 2008, ANN NEUROL, V63, P662, DOI 10.1002/ana.21366
   Ravichandran TP, 1998, NEURORADIOLOGY, V40, P522, DOI 10.1007/s002340050638
   Rubenstein JL, 2013, BLOOD, V121, P745, DOI 10.1182/blood-2012-07-440974
   Slone HW, 2005, AM J ROENTGENOL, V184, P1679, DOI 10.2214/ajr.184.5.01841679
   Soussain C, 2001, J CLIN ONCOL, V19, P742, DOI 10.1200/JCO.2001.19.3.742
   Spector R, 2015, EXP NEUROL, V267, P78, DOI 10.1016/j.expneurol.2015.02.032
   Suzuki M, 2015, J NEUROL SCI, V353, P179, DOI 10.1016/j.jns.2015.04.006
   Szczepanek D, 2018, NEUROL NEUROCHIR POL, V52, P410, DOI 10.1016/j.pjnns.2018.01.007
   Tai WM, 2011, ANN HEMATOL, V90, P809, DOI 10.1007/s00277-010-1150-7
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 18
EP 22
DI 10.1016/j.wneu.2019.04.203
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100135
PM 31048061
DA 2020-05-12
ER

PT J
AU Sriamornrattanakul, K
   Akharathammachote, N
AF Sriamornrattanakul, Kitiporn
   Akharathammachote, Nasaeng
TI Massive Epistaxis from Nontraumatic Cavernous Carotid Aneurysm Treated
   by High-Flow Bypass and Cervical Internal Carotid Artery Ligation: A
   Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid aneurysm; Cavernous carotid aneurysm; Cavernous segment of
   carotid artery aneurysm; Epistaxis; High-flow bypass
ID SINUS; REVASCULARIZATION; RUPTURE
AB BACKGROUND: Epistaxis is a rare presentation of the ruptured cavernous carotid aneurysm, especially the nontraumatic type. Both endovascular therapies and open surgeries have a role in the treatment with various outcomes, but the standard procedure is not well established. We report a successful high-flow bypass with cervical internal carotid artery ligation for aneurysm repair and review the related literature.
   CASE DESCRIPTION: An 81-year-old man presented with massive epistaxis from the left nostril. The epistaxis was controlled by nasal packing. A saccular aneurysm of the cavernous segment of the left internal carotid artery projecting into the sphenoid sinus was revealed using computed tomography angiography. We treated this patient with high-flow bypass with ligation of the cervical internal carotid artery. Immediate postoperative computed tomography angiography showed complete disappearance of the aneurysm. Nasal packing was removed without further bleeding. No neurological deficit or complications were detected in the postoperative period.
   CONCLUSIONS: In cases of massive or recurrent epistaxis without coagulopathy or nasal pathology, a cavernous carotid aneurysm should be considered. Immediate cessation of the bleeding is necessary. Flow-preservation bypass with proximal ligation of the parent artery is 1 of the effective procedures for the treatment of this condition with low morbidity.
C1 [Sriamornrattanakul, Kitiporn; Akharathammachote, Nasaeng] Navamindradhiraj Univ, Fac Med, Dept Surg, Div Neurosurg,Vajira Hosp, Bangkok, Thailand.
RP Sriamornrattanakul, K (reprint author), Navamindradhiraj Univ, Fac Med, Dept Surg, Div Neurosurg,Vajira Hosp, Bangkok, Thailand.
EM kitiporn6823@gmail.com
CR Akkari M, 2015, INTERV NEURORADIOL, V21, P660, DOI 10.1177/1591019915609164
   Chaboki H, 2004, HEAD NECK-J SCI SPEC, V26, P741, DOI 10.1002/hed.20081
   CHANDY MJ, 1989, J LARYNGOL OTOL, V103, P425, DOI 10.1017/S0022215100109156
   Davies A, 2011, J LARYNGOL OTOL, V125, P1070, DOI 10.1017/S0022215111002040
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Garg K, 2016, TURK NEUROSURG, V26, P357, DOI 10.5137/1019-5149.JTN.12598-14.1
   Honeybul S, 2006, J CLIN NEUROSCI, V13, P394, DOI 10.1016/j.jocn.2005.05.012
   Houkin K, 1999, J NEUROSURG, V90, P786, DOI 10.3171/jns.1999.90.4.0786
   INOUE T, 1990, NEUROSURGERY, V26, P903, DOI 10.1227/00006123-199006000-00001
   Ishishita Y, 2014, WORLD NEUROSURG, V82, P130, DOI 10.1016/j.wneu.2013.02.063
   Javedan SP, 2001, NEUROSURG CLIN N AM, V12, P541, DOI 10.1016/S1042-3680(18)30042-1
   Karkanevatos A, 2005, EUR ARCH OTO-RHINO-L, V262, P546, DOI 10.1007/s00405-004-0869-y
   Ko Jun Kyeung, 2017, NMC Case Rep J, V4, P43, DOI 10.2176/nmccrj.cr.2016-0137
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Lehmann P, 2009, EUR ARCH OTO-RHINO-L, V266, P767, DOI 10.1007/s00405-008-0743-4
   MAHMOUD NA, 1979, J LARYNGOL OTOL, V93, P629, DOI 10.1017/S0022215100087508
   Mizunari T, 2011, NEUROL MED-CHIR, V51, P113, DOI 10.2176/nmc.51.113
   Nomura M, 2010, NEUROL MED-CHIR, V50, P127, DOI 10.2176/nmc.50.127
   PRITZ MB, 1994, SURG NEUROL, V42, P293, DOI 10.1016/0090-3019(94)90395-6
   ROMANIUK CS, 1993, BRIT J RADIOL, V66, P942, DOI 10.1259/0007-1285-66-790-942
   Sriamornrattanakul Kitiporn, 2017, Asian J Neurosurg, V12, P382, DOI 10.4103/1793-5482.180930
   TEITELBAUM GP, 1995, NEURORADIOLOGY, V37, P334
NR 22
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 23
EP 28
DI 10.1016/j.wneu.2019.04.213
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100136
PM 31054341
DA 2020-05-12
ER

PT J
AU Molina, ES
   Di Somma, A
   Stummer, W
   Briganti, F
   Cavallo, LM
AF Molina, Eric Suero
   Di Somma, Alberto
   Stummer, Walter
   Briganti, Francesco
   Cavallo, Luigi Maria
TI Clinical Vasospasm After an Extended Endoscopic Endonasal Approach for
   Recurrent Pituitary Adenoma: Illustrative Case and Systematic Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebral vasospasm; Delayed cerebral ischemia; Extended endoscopic
ID CEREBRAL VASOSPASM; SUBARACHNOID HEMORRHAGE; TRANSSPHENOIDAL SURGERY;
   SYMPTOMATIC VASOSPASM; BALLOON ANGIOPLASTY; TUMOR REMOVAL; APOPLEXY;
   RESECTION; INFARCTION; ISCHEMIA
AB BACKGROUND: Cerebral vasospasm causing delayed cerebral ischemia after transsphenoidal surgery is a rare but life-threatening complication. Reports in the literature after extended endoscopic endonasal approach (EEEA) are scarce. Considering the progressive use of this technique during recent years, a better understanding of the potential adverse effects after this procedure is needed. The aim of this report was to systematically analyze the current literature and discuss management and causes for cerebral vasospasm after EEEA surgery.
   METHODS: We performed a systematic search of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and aimed to discuss relevant risk factors for cerebral vasospasm after extended transsphenoidal surgery.
   RESULTS: Thirty-four cases of delayed cerebral vasospasm after transsphenoidal surgery were identified. Among these, 4 were operated with an EEEA. We provide an extensive literature review and discuss causes and management of this delayed complication. We further present the case of a young woman who underwent resection for a large suprasellar recurrent pituitary adenoma. Surgery and initial postoperative course were uneventful. On the eighth postoperative day, the patient developed aphasia and brachiofacial paresis. Digital subtraction angiography (DSA) demonstrated cerebral vasospasm, and repeated intra-arterial nimodipine infusion was administrated. The patient recovered completely and was discharged without neurologic deficits.
   CONCLUSIONS: The threshold for DSA after unexplained neurologic deterioration after extended transsphenoidal surgery should be low, and cerebral vasospasm should be treated early and aggressively. Surgeons performing EEEA need to consider the possibility of this delayed complication.
C1 [Molina, Eric Suero; Stummer, Walter] Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
   [Di Somma, Alberto] Univ Barcelona, Dept Neurol Surg, Hosp Clin Barcelona, Barcelona, Spain.
   [Briganti, Francesco] Univ Naples Federico II, Dept Adv Biomed Sci, Unit Intervent Neuroradiol, Naples, Italy.
   [Cavallo, Luigi Maria] Univ Napoli Federico II, Div Neurosurg, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy.
RP Molina, ES (reprint author), Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
EM eric.suero@ukmuenster.de
RI Stummer, Walter/AAA-3319-2020; Stummer, Walter/AAF-9043-2019; Di Somma,
   Alberto/AAG-5690-2020
OI Di Somma, Alberto/0000-0002-3253-3448
CR AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037
   Ahmed SK, 2008, ACTA NEUROCHIR, V150, P1193, DOI 10.1007/s00701-008-0130-3
   Akutsu H, 2004, NEUROL MED-CHIR, V44, P479, DOI 10.2176/nmc.44.479
   Al-Zubaidi AS, 2005, SAUDI MED J, V26, P1153
   Alotaibi NM, 2013, J NEUROINTERV SURG, V5, P413, DOI 10.1136/neurintsurg-2012-010477
   Alzhrani G, 2018, WORLD NEUROSURG, V109, P233, DOI 10.1016/j.wneu.2017.09.192
   AOKI N, 1995, ACTA NEUROCHIR, V132, P53, DOI 10.1007/BF01404848
   Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147
   Banerjee C, 2015, PITUITARY, V18, P352, DOI 10.1007/s11102-014-0581-x
   BARROW DL, 1990, NEUROSURGERY, V27, P60, DOI 10.1227/00006123-199007000-00008
   Bejjani GK, 1999, SURG NEUROL, V52, P577, DOI 10.1016/S0090-3019(99)00108-1
   Bierer Joel, 2017, Surg Neurol Int, V8, P235, DOI 10.4103/sni.sni_192_16
   Bougaci N, 2017, NEUROCHIRURGIE, V63, P25, DOI 10.1016/j.neuchi.2016.12.002
   BOULLIN DJ, 1983, J NEUROSURG, V59, P231, DOI 10.3171/jns.1983.59.2.0231
   CAMP PE, 1980, NEUROSURGERY, V7, P382, DOI 10.1227/00006123-198010000-00012
   CARDOSO ER, 1983, SURG NEUROL, V20, P391, DOI 10.1016/0090-3019(83)90009-5
   Cervoni L, 1996, ITAL J NEUROL SCI, V17, P291, DOI 10.1007/BF01997789
   Chang SD, 1999, SURG NEUROL, V51, P521, DOI 10.1016/S0090-3019(97)00313-3
   Chong MY, 2014, PITUITARY, V17, P171, DOI 10.1007/s11102-013-0485-1
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Conti A, 2009, NEUROCRIT CARE, V10, P326, DOI 10.1007/s12028-009-9199-7
   DHAENS J, 1983, NEUROCHIRURGIE, V29, P401
   Douleh DG, 2018, CUREUS, V10, DOI 10.7759/cureus.2117
   DUFF TA, 1988, J NEUROSURG, V69, P593, DOI 10.3171/jns.1988.69.4.0593
   Ecker RD, 2003, NEUROSURGERY, V52, P706, DOI 10.1227/01.NEU.0000048482.27700.3B
   Eseonu CI, 2016, WORLD NEUROSURG, V92, P7, DOI 10.1016/j.wneu.2016.04.099
   Eskridge JM, 1998, NEUROSURGERY, V42, P510, DOI 10.1097/00006123-199803000-00016
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Friedman JA, 2001, J NEUROSURG, V95, P353, DOI 10.3171/jns.2001.95.2.0353
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700
   Hirschi RA, 2009, J NEUROSURG, V111, P252, DOI 10.3171/2008.9.JNS08729
   HYDEROWAN MD, 1983, SURG NEUROL, V20, P120, DOI 10.1016/0090-3019(83)90461-5
   Kamal R, 1999, NEUROL RES, V21, P796, DOI 10.1080/01616412.1999.11741017
   Karimnejad K, 2016, J CRANIOFAC SURG, V27, P988, DOI 10.1097/SCS.0000000000002672
   Kasliwal MK, 2008, NEUROL INDIA, V56, P81
   Kim EH, 2013, PITUITARY, V16, P260, DOI 10.1007/s11102-012-0415-7
   Kiser Tyree H, 2014, Hosp Pharm, V49, P923, DOI 10.1310/hpj4910-923
   Koutourousiou M, 2014, J NEUROSURG, V120, P1326, DOI 10.3171/2014.2.JNS13767
   KRAYENBUEHL H, 1960, Schweiz Med Wochenschr, V90, P961
   Lopes MBS, 2017, ACTA NEUROPATHOL, V134, P521, DOI 10.1007/s00401-017-1769-8
   Mansouri A, 2012, CAN J NEUROL SCI, V39, P767, DOI 10.1017/S0317167100015596
   MAWK JR, 1979, J NEUROSURG, V50, P229, DOI 10.3171/jns.1979.50.2.0229
   McGirt MJ, 2004, NEUROSURGERY, V54, P1369, DOI 10.1227/01.NEU.0000125016.37332.50
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nash R, 2016, ACTA NEUROCHIR, V158, P2105, DOI 10.1007/s00701-016-2956-4
   Nishioka H, 2001, BRIT J NEUROSURG, V15, P44, DOI 10.1080/02688690020024391
   Osterhage K, 2018, WORLD NEUROSURG, V110, P180, DOI 10.1016/j.wneu.2017.10.027
   Popugaev KA, 2011, NEUROL SCI, V32, P673, DOI 10.1007/s10072-011-0482-y
   POZZATI E, 1987, NEUROSURGERY, V20, P56, DOI 10.1227/00006123-198701000-00015
   Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537
   Puri AS, 2012, NEUROSURGERY, V71, P173, DOI 10.1227/NEU.0b013e31824aae21
   Ricarte IF, 2015, J STROKE CEREBROVASC, V24, pE271, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.005
   ROSENBAUM TJ, 1977, J NEUROSURG, V47, P599, DOI 10.3171/jns.1977.47.4.0599
   ROVIT RL, 1972, J NEUROSURG, V37, P280, DOI 10.3171/jns.1972.37.3.0280
   Shida N, 1998, NEUROL MED-CHIR, V38, P666, DOI 10.2176/nmc.38.666
   Smith D, 2004, CLIN ENDOCRINOL, V61, P273, DOI 10.1111/j.1365-2265.2004.02086.x
   SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120
   van der Jagt M, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1309-2
   von der Brelie C, 2017, WORLD NEUROSURG, V100, P504, DOI 10.1016/j.wneu.2016.12.110
   Wilkins R H, 1975, Surg Neurol, V4, P472
   ZABRAMSKI JM, 1986, NEUROSURGERY, V18, P1
   Zada G, 2011, J NEUROSURG, V114, P286, DOI 10.3171/2010.8.JNS10520
NR 63
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 29
EP 36
DI 10.1016/j.wneu.2019.04.046
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100137
PM 31003025
DA 2020-05-12
ER

PT J
AU Cucu, AI
   Costea, CF
   Perciaccante, A
   Carauleanu, A
   Turliuc, S
   Costachescu, B
   Poeata, I
   Turliuc, MD
AF Cucu, Andrei Ionut
   Costea, Claudia Florida
   Perciaccante, Antonio
   Carauleanu, Alexandru
   Turliuc, Serban
   Costachescu, Bogdan
   Poeata, Ion
   Turliuc, Mihaela Dana
TI The History of Arachne Through Historic Descriptions of Meningiomas with
   Hyperostosis: From Prehistory to the Present
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hyperostosis; Meningioma; Skull deformities
ID CRANIAL HYPEROSTOSIS; BONE-MASS; TUMOR; SEROTONIN; SKULL;
   CUSHING,HARVEY; ORIGIN; BASE; RISE
AB BACKGROUND: Intracranial meningiomas are brain tumors that have probably been known the longest, largely because of the occasional production of grotesque cranial deformities that have attracted the attention and interest of humankind. Because of the tendency of some intracranial meningiomas to cause skull deformation and thickening, these tumors have given rise to various speculations and theories related to their origin, starting in prehistoric times up to the present.
   METHODS: From the Steinheim skull and "pharaonic meningiomas" to the first meningioma monograph and the first explanations of Harvey Cushing regarding the mechanism of hyperostosis, this review aims to weave again the story of Arachne. We identify the main contributors who have tried to understand and explain the tendency of some of these tumors to cause hyperostosis or other skull bone involvements.
   CONCLUSIONS: The contribution of neurosurgeons or pathologists over the centuries is of undeniable importance and is the basis for understanding future molecular mechanisms.
C1 [Cucu, Andrei Ionut] Prof Dr N Oblu Emergency Clin Hosp, Neurosurg Clin, Iasi, Romania.
   [Costea, Claudia Florida] Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, Iasi, Romania.
   [Carauleanu, Alexandru] Grigore T Popa Univ Med & Pharm, Dept Obstet & Gynecol, Iasi, Romania.
   [Turliuc, Serban] Grigore T Popa Univ Med & Pharm, Dept Psychiat, Iasi, Romania.
   [Costachescu, Bogdan; Poeata, Ion; Turliuc, Mihaela Dana] Grigore T Popa Univ Med & Pharm, Dept Pharm, Iasi, Romania.
   [Perciaccante, Antonio] San Giovanni Dio Hosp, Dept Med, Gorizia, Italy.
RP Costea, CF (reprint author), Grigore T Popa Univ Med & Pharm, Dept Ophthalmol, Iasi, Romania.
EM costea10@yahoo.com
RI Costea, Claudia Florida/AAL-4352-2020; Cucu, Andrei Ionut/AAI-1078-2020
OI Perciaccante, Antonio/0000-0003-2743-7504
CR Abbott KH, 1939, B LOS ANGELES NEUROL, V4, P101
   Academie royale de chirurgie, 1819, MEM AC ROYAL CHIR
   Alpers BJ, 1932, ARCH NEURO PSYCHIATR, V28, P339, DOI 10.1001/archneurpsyc.1932.02240020091006
   ALRODHAN NRF, 1990, NEUROSURGERY, V26, P832, DOI 10.1227/00006123-199005000-00016
   ANDERSON T, 1992, MED HIST, V36, P207, DOI 10.1017/S0025727300055010
   Barthelemy EJ, 2016, J NEUROSURG, V125, P1283, DOI 10.3171/2015.10.JNS15877
   Berhouma M, 2013, CLIN NEUROL NEUROSUR, V115, P702, DOI 10.1016/j.clineuro.2012.08.005
   Bir SC, 2015, CLIN NEUROL NEUROSUR, V134, P75, DOI 10.1016/j.clineuro.2015.02.018
   Black PM, 1999, NEUROSURGERY, V45, P990, DOI 10.1097/00006123-199911000-00007
   BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587
   Brissaud E., 1903, REV NEUROL, V11, P537
   BROTHWELL D, 1972, WORLD ARCHAEOL, V4, P75, DOI 10.1080/00438243.1972.9979521
   Brothwell D., 1967, DIS ANTIQUITY
   Brothwell M, 2016, INT J PALEOPATHOL, V13, P65, DOI 10.1016/j.ijpp.2016.01.004
   Campillo D., 1991, INT J OSTEOARCHAEOL, V1, P225
   CASTELLANO F, 1952, J NEUROSURG, V9, P188, DOI 10.3171/jns.1952.9.2.0188
   Crell Hirsch A., 1876, ALLGEMEINE DTSCH BIO, V4, P587
   Cruveilhier J., 1829, ANATOMIE PATHOLOGIQU
   Cushing H, 1922, ARCH NEURO PSYCHIATR, V8, P139, DOI 10.1001/archneurpsyc.1922.02190140030003
   Czarnetzki A, 2003, LANCET, V362, P408, DOI 10.1016/S0140-6736(03)14044-5
   David AR, 2010, NAT REV CANCER, V10, P728, DOI 10.1038/nrc2914
   David R, 2008, LANCET, V372, P1802, DOI 10.1016/S0140-6736(08)61749-3
   de Saint-Maur PP, 2012, VIRCHOWS ARCH, V460, P109, DOI 10.1007/s00428-011-1162-2
   DEELEY TJ, 1983, CLIN RADIOL, V34, P597, DOI 10.1016/S0009-9260(83)80405-X
   Derome P J, 1978, Clin Neurosurg, V25, P435
   Echlin F, 1934, ARCH SURG-CHICAGO, V28, P357, DOI 10.1001/archsurg.1934.01170140137009
   Finger S, 2010, HDB CLIN NEUROLOGY, V95
   Finger S., 1994, ORIGINS NEUROSCIENCE
   FREEDMAN H, 1948, J NEUROPATH EXP NEUR, V7, P69, DOI 10.1097/00005072-194801000-00006
   Frost M, 2010, J BONE MINER RES, V25, P673, DOI 10.1002/jbmr.44
   GALLASSI A, 1953, Scalpel (Brux), V106, P1015
   Garcia-Albea E, 1999, REV NEUROLOGIA, V28, P430, DOI 10.33588/rn.2804.98391
   Garrison FH, 1929, INTRO HIST MED MED M
   GIUFFRE R, 1984, J NEUROSURG, V60, P47, DOI 10.3171/jns.1984.60.1.0047
   GUIDETTI B, 1983, SURG NEUROL, V20, P335, DOI 10.1016/0090-3019(83)90091-5
   HEICK A, 1993, ACTA NEUROL SCAND, V87, P243
   Herodotus, 1920, HERODOTUS
   Hussein K., 1951, B I EGYPTE, V32, P11
   Hussein K., 1947, ANN SERVICE ANTIQU S, V3, P257
   Jonsdottir B, 2003, AM J PHYS ANTHROPOL, V122, P232, DOI 10.1002/ajpa.10285
   Kaufman J., 1743, THESIS
   Kennedy F., 1920, NELSONS LOOSE LEAF L
   Kerr P Benjamin, 2005, Neurosurg Focus, V18, pe1
   KIM KS, 1983, AM J ROENTGENOL, V141, P1217, DOI 10.2214/ajr.141.6.1217
   Kompanje EJO, 2004, J NEURO-ONCOL, V67, P123, DOI 10.1023/B:NEON.0000021988.78895.9b
   Landow H, 1942, ARCH NEURO PSYCHIATR, V48, P518, DOI 10.1001/archneurpsyc.1942.02290100018002
   Laws ER, 1999, NEUROSURGERY, V45, P977, DOI 10.1097/00006123-199911000-00003
   Laws ER, 2019, MENINGIOMAS SKULL BA
   LJUNGGREN B, 1982, J NEUROSURG, V56, P471, DOI 10.3171/jns.1982.56.4.0471
   Loriaux DL, 2006, ENDOCRINOLOGIST, V16, P55, DOI 10.1097/01.ten.0000202534.83446.69
   Louis A., 1774, MEM ACAD R CHIR PARI, V5, P1
   MacCurdy GG, 1923, AM J PHYS ANTHROPOL, V6, P217, DOI 10.1002/ajpa.1330060302
   Macewen W., 1965, NEUROSURGICAL CLASSI
   Macewen W, 1881, LANCET, V118, P581, DOI 10.1016/S0140-6736(02)36340-2
   MAROON JC, 1994, J NEUROSURG, V80, P202, DOI 10.3171/jns.1994.80.2.0202
   Mastronardi L, 2009, NEUROSURG REV, V32, P381, DOI 10.1007/s10143-009-0206-4
   Matschke J, 2011, ANTICANCER RES, V31, P591
   Meningiomas Cushing H, 1938, THEIR CLASSIFICATION
   Mills CK, 1902, PHILA MED J, V9, P268
   MOODIE ROY L., 1926, ANN MED HIST, V8, P394
   NASU H., 1964, ACTA NEUROPATHOL, V3, P627
   Netsky MG, 1956, B HIST MED, V30, P465
   Novaro GF, 1891, B SCI MED BOLOGNA, V2, P63
   Okonkwo DO, 2009, MENINGIOMAS
   Oury F, 2010, GENE DEV, V24, P2330, DOI 10.1101/gad.1977210
   Oury F, 2010, M S-MED SCI, V26, P713, DOI 10.1051/medsci/2010268-9713
   Pahl W. M, 1987, HUM EVOL, V2, P329
   Parhon C, 1905, REV NEUROL-FRANCE, V13, P1017
   Paterniti S., 2015, AUSTIN NEUROSURG OPE, V2, P1030
   Patra DP, 2018, WORLD NEUROSURG, V118, P342, DOI 10.1016/j.wneu.2018.06.017
   Pecchioli Z., 1838, NUOVOV GIORN LETT SC, V36, P39
   Penfield WG, 1923, SURG GYNECOL OBSTET, V36, P657
   Phemister DB, 1923, ARCH SURG-CHICAGO, V6, P554, DOI 10.1001/archsurg.1923.01110180127004
   Pieper DR, 1999, NEUROSURGERY, V44, P742, DOI 10.1097/00006123-199904000-00028
   Plater F., 1614, OBSERVATIONUM HOMINI
   POMPILI A, 1982, SURG NEUROL, V17, P411, DOI 10.1016/S0090-3019(82)80006-2
   Priola SM, 2014, WORLD NEUROSURG, V82, P523, DOI 10.1016/j.wneu.2013.07.076
   Reichert F L, 1929, Cal West Med, V30, P183
   ROGERS L, 1949, BRIT J SURG, V36, P423, DOI 10.1002/bjs.18003614421
   Salzmann J., 1730, ACTA PHYSICOMEDICA A, V2, P225
   Salzmann J., 1730, ACTA PHYSICOMEDICA A, V2, P219
   Salzmann J., 1730, ACTA PHYSICOMEDICA A, V2, P222
   Sampath P, 2000, NEUROSURGERY, V46, P184
   Severinus Marcus Aurelius, 1646, MED EFFICACI
   Smith CMU, 2010, HDB CLIN NEUROLOGY H, V95
   Spiller WG, 1907, J AMER MED ASSOC, V49, P2059
   Spiller WG, 1899, T COLL PHYS, V21, P191
   Turliuc MD, 2018, WORLD NEUROSURG, V109, P365, DOI 10.1016/j.wneu.2017.10.041
   Vanzetti T., 1844, QUELQUES OBSERVATION
   Verhoeven V, 2019, ACTA CHIR BELG, V119, P254, DOI 10.1080/00015458.2018.1438561
   Virchow R, 1864, KRANKHAFTEN GESCHWUL
   Weber J, 2002, DEUT MED WOCHENSCHR, V127, P2757, DOI 10.1055/s-2002-36270
   WOLPOFF MH, 1999, PALEOANTHROPOLOGY
   Yadav VK, 2010, ANN NY ACAD SCI, V1192, P103, DOI 10.1111/j.1749-6632.2009.05312.x
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   York GK, 2010, HDB CLIN NEUROLOGY, V95
   Ziegler R., 1999, STUTTG BEITRG NATU C, V44, P24
   Zulch KJ, 1957, BRAIN TUMORS THEIR B
NR 98
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 37
EP 46
DI 10.1016/j.wneu.2019.04.199
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100138
PM 31048045
DA 2020-05-12
ER

PT J
AU Young, R
   Jiang, BW
   Theodore, N
AF Young, Robert
   Jiang, Bowen
   Theodore, Nicholas
TI Unusual Cause of Trigeminal Neuralgia: First Report of Intracranial
   Migration of Spinal Cord Stimulator
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cephalad migration; Spinal cord stimulation; Trigeminal neuralgia
ID REGIONAL PAIN SYNDROME; COST-EFFECTIVENESS; COMPLICATIONS; OUTCOMES;
   NERVE
AB BACKGROUND: Spinal cord stimulation has been shown to be an effective for some patients diagnosed with chronic pain and failed back syndrome. However, lead migration from the implantation site is a potential complication that may reduce treatment efficacy, produce unintended symptoms, and require invasive and costly surgical replacement or removal.
   CASE DESCRIPTION: A 71-year-old woman presented to the emergency department with diffuse headache and burning left-sided facial pain consistent with trigeminal neuralgia. She had a history of chronic regional pain syndrome that had been successfully treated for 8 years with a percutaneous spinal cord stimulator, and 2 weeks before presentation she had had the cervical lead replaced. Computed tomography demonstrated intradural and intracranial migration of the cervical lead, which had traversed along the left lateral aspect of the medulla and terminated at the pontomedullary junction The migrated cervical lead was removed surgically. At follow-up, her trigeminal pain had resolved.
   CONCLUSIONS: Although spinal cord stimulation has demonstrated effectiveness as a treatment for chronic pain, care must be taken to ensure that the spinal cord stimulator leads are properly placed within the epidural space and are firmly anchored to avoid migration. Intracranial migration of a spinal cord stimulator lead poses significant risks for injury to adjacent cortical structures and may produce pain syndromes including trigeminal neuralgia.
C1 [Young, Robert; Jiang, Bowen; Theodore, Nicholas] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Theodore, N (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM theodore@jhmi.edu
OI Theodore, Nicholas/0000-0001-5355-2683; Young,
   Robert/0000-0001-7190-8292
CR Babu R, 2013, NEUROMODULATION, V16, P418, DOI 10.1111/ner.12065
   Bendersky D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.06.012
   Burkett DJ, 2017, J NEUROIMAGING, V27, P539, DOI 10.1111/jon.12425
   Burton AW, 2004, NEUROMODULATION, V7, P242, DOI 10.1111/j.1094-7159.2004.04208.x
   Cameron T, 2004, J NEUROSURG, V100, P254, DOI 10.3171/spi.2004.100.3.0254
   Gazelka HM, 2015, NEUROMODULATION, V18, P123, DOI 10.1111/ner.12184
   Huang Ching-Tang, 2015, Acta Neurol Taiwan, V24, P63
   Jain S, 2018, BMJ CASE REP, V2018
   JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159
   Kemler MA, 2004, ANN NEUROL, V55, P13, DOI 10.1002/ana.10996
   Kemler MA, 2010, VALUE HEALTH, V13, P735, DOI 10.1111/j.1524-4733.2010.00744.x
   Kumar K, 2006, J NEUROSURG-SPINE, V5, P191, DOI 10.3171/spi.2006.5.3.191
   Kumar K, 2013, PAIN MED, V14, P1631, DOI 10.1111/pme.12146
   McGreevy K, 2012, PAIN PHYSICIAN, V15, pE79
   Mekhail NA, 2011, PAIN PRACT, V11, P148, DOI 10.1111/j.1533-2500.2010.00407.x
   Sears NC, 2011, NEUROMODULATION, V14, P312, DOI 10.1111/j.1525-1403.2011.00372.x
   Turner JA, 2004, PAIN, V108, P137, DOI 10.1016/j.pain.2003.12.016
NR 17
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 47
EP 49
DI 10.1016/j.wneu.2019.04.155
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100139
PM 31029815
DA 2020-05-12
ER

PT J
AU Kanematsu, R
   Hanakita, J
   Takahashi, T
   Tomita, Y
   Minami, M
AF Kanematsu, Ryo
   Hanakita, Junya
   Takahashi, Toshiyuki
   Tomita, Yosuke
   Minami, Manabu
TI An Acquired Cervical Dural Arteriovenous Fistula After Cervical Anterior
   Fusion: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior cervical discectomy and fusion (ACDE); Cervical anterior
   approach; Late operative complication; Postoperative DAVF; Spinal dural
   arteriovenous fistula (DAVF); Spinal surgery
ID ENDOVASCULAR TREATMENT; MALFORMATIONS; CLASSIFICATION; SHUNTS; SERIES;
   SPINE
AB BACKGROUND: Formation of a dural arteriovenous fistula (DAVF) after lumbar spine decompression in the lumbar spine has been reported as a late complication, but is extremely rare in the cervical spine.
   CASE DESCRIPTION: A 57-year-old man who underwent a C5-6, C6-7 anterior fusion 5 years previously for cervical myelopathy at another hospital presented with progressive gait disturbance and thermal hypoalgesia on the right side of the body. Magnetic resonance imaging showed flow voids in the spinal cord dorsally at the C4-7 level, which had not been detected before the initial operation. Digital subtraction angiography showed a fistulous connection at the C7 level between the perimedullary vein and a segmental artery from the right vertebral artery, which was diagnosed as a DAVF. Surgical interruption of the intradural draining vein with multilevel posterior cervical decompression was performed, and his symptoms improved.
   CONCLUSIONS: To the best of our knowledge, this is the first report of a DAVF developing atter multilevel anterior cervical discectomy and fusion. All the published cases of secondary DAVF, especially after spinal surgery, are reviewed.
C1 [Kanematsu, Ryo; Hanakita, Junya; Takahashi, Toshiyuki; Tomita, Yosuke; Minami, Manabu] Fujieda Heisei Mem Hosp, Spinal Disorders Ctr, Shizuoka, Japan.
RP Kanematsu, R (reprint author), Fujieda Heisei Mem Hosp, Spinal Disorders Ctr, Shizuoka, Japan.
EM ryo.knmt@gmail.com
CR Asakuno K, 2002, J NEUROSURG, V97, P375, DOI 10.3171/spi.2002.97.3.0375
   Bakker NA, 2015, NEUROSURGERY, V77, P137, DOI 10.1227/NEU.0000000000000727
   Bao YH, 1997, NEUROSURGERY, V40, P75, DOI 10.1097/00006123-199701000-00017
   Chuang NA, 2003, AM J NEURORADIOL, V24, P1901
   Di Chiro G, 1971, PROGRESS NEUROLOGICA, V4, P329
   Geibprasert S, 2008, STROKE, V39, P2783, DOI 10.1161/STROKEAHA.108.516757
   KENDALL BE, 1977, NEURORADIOLOGY, V13, P181, DOI 10.1007/BF00344211
   Khaldi Ahmad, 2009, Spine (Phila Pa 1976), V34, pE775, DOI 10.1097/BRS.0b013e3181ae4a52
   Kiyosue H, 2017, STROKE, V48, P3215, DOI 10.1161/STROKEAHA.117.019131
   Koch C, 2006, CURR OPIN NEUROL, V19, P69, DOI 10.1097/01.wco.0000200547.22292.11
   Krings T, 2009, AM J NEURORADIOL, V30, P639, DOI 10.3174/ajnr.A1485
   Lim SM, 2009, INTERV NEURORADIOL, V15, P466, DOI 10.1177/159101990901500417
   Miyachi S, 2011, INTERV NEURORADIOL, V17, P195, DOI 10.1177/159101991101700209
   MOURIER KL, 1993, NEUROSURGERY, V32, P885, DOI 10.1227/00006123-199306000-00001
   Murakami T, 2015, INTERV NEURORADIOL, V21, P249, DOI 10.1177/1591019915583212
   OLIVERO WC, 1993, J NEUROSURG, V79, P119, DOI 10.3171/jns.1993.79.1.0119
   Rangel-Castilla L, 2011, J NEUROSURG-SPINE, V15, P541, DOI 10.3171/2011.6.SPINE10695
   Rodesch G, 2002, NEUROSURGERY, V51, P374, DOI 10.1097/00006123-200208000-00013
   Ropper AE, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11344
   ROSENBLUM B, 1987, J NEUROSURG, V67, P795, DOI 10.3171/jns.1987.67.6.0795
   Sakaki T, 1996, J NEUROSURG, V84, P113, DOI 10.3171/jns.1996.84.1.0113
   Silva N, 2007, J NEUROSURG-SPINE, V6, P552, DOI 10.3171/spi.2007.6.6.6
   Spetzler RF, 2002, J NEUROSURG, V96, P145, DOI 10.3171/spi.2002.96.2.0145
   Steinmetz MP, 2004, NEUROSURGERY, V55, P77, DOI 10.1227/01.NEU.0000126878.95006.0F
   SYMON L, 1984, J NEUROSURG, V60, P238, DOI 10.3171/jns.1984.60.2.0238
   Takai K, 2015, J NEUROSURG-SPINE, V23, P526, DOI 10.3171/2014.11.SPINE14786
   Takai K, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1216
   TERADA T, 1994, J NEUROSURG, V80, P884, DOI 10.3171/jns.1994.80.5.0884
   Yoshino O, 1998, NEUROSURGERY, V42, P1387, DOI 10.1097/00006123-199806000-00126
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 50
EP 54
DI 10.1016/j.wneu.2019.04.202
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100140
PM 31054344
DA 2020-05-12
ER

PT J
AU Pizzuti, V
   di Russo, P
   Esposito, V
   Morace, R
AF Pizzuti, Valentina
   di Russo, Paolo
   Esposito, Vincenzo
   Morace, Roberta
TI Computed Tomography-Guided Posterolateral Transsacral Ala Approach to
   Presacral L5 Schwannoma: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative neurophysiologic monitoring; Minimally invasive;
   Posterolateral approach; Presacral schwannoma; Spinal navigation
AB BACKGROUND: Presacral schwannomas are rare tumors that may reach large size before becoming symptomatic. Total surgical removal has been considered the best treatment option Tumors arising from the presacral area are commonly managed through anterior approaches, whereas posterior approaches are used for pure intrasacral tumors or large lesions with both intrasacral and presacral extension, alone or in combination with anterior approaches.
   METHODS: We describe a quick and minimally invasive navigation-guided posterolateral approach to a right presacral L5 schwannoma. The lesion was microsurgically removed through high-speed drilling of the upper portion of the right sacral ala, under intraoperative neurophysiologic monitoring.
   RESULTS: The postoperative course was unremarkable, and the patient experienced improvement in his sensory disturbance. Postoperative magnetic resonance imaging and computed tomography scan showed the complete excision of the lesion and the removal of the upper sacral ala with preservation of the right L5-S1 articular complex. The histologic examination confirmed a schwannoma (World Health Organization grade I).
   CONCLUSIONS: The posterolateral transsacral ala approach may represent a minimally invasive option in the surgical management of presacral well-circumscribed benign tumors. Spinal navigation could be properly used to facilitate lesion exposure and to minimize the bone removal, The intraoperative neurophysiologic monitoring is an essential tool for the preservation of the lumbosacral nerve roots.
C1 [Pizzuti, Valentina; di Russo, Paolo; Esposito, Vincenzo; Morace, Roberta] IRCCS Neuromed, Dept Neurosurg, Pozzilli, IS, Italy.
   [Pizzuti, Valentina; Esposito, Vincenzo] Sapienza Univ, Dept Neurol & Psychiat, Rome, Italy.
RP di Russo, P (reprint author), IRCCS Neuromed, Dept Neurosurg, Pozzilli, IS, Italy.
EM p.dirusso.nch@gmail.com
CR Elnady B, 2017, INT ORTHOP, V41, P2535, DOI 10.1007/s00264-017-3570-7
   Jatal S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.04.07
   Klimo Paul Jr, 2003, Neurosurg Focus, V15, pE12
   Lee Byoung Hun, 2017, Korean J Spine, V14, P89, DOI 10.14245/kjs.2017.14.3.89
   Lee GYF, 2005, NEUROSURGERY, V57, DOI 10.1227/01.NEU.0000176705.42167.6F
   MAYO CW, 1953, P STAFF M MAYO CLIN, V28, P616
   Ogose A, 2001, SPINE, V26, P1817, DOI 10.1097/00007632-200108150-00020
   Ortolan EG, 1996, SPINE, V21, P522, DOI 10.1097/00007632-199602150-00023
   Pirris SM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E10
   Rapport RL, 1997, NEUROSURGERY, V40, P1087, DOI 10.1097/00006123-199705000-00040
   Rasmussen TB, 1940, ANN SURG, V111, P513, DOI 10.1097/00000658-194004000-00001
   Rousseau MA, 2005, EJSO, V31, P924, DOI 10.1016/j.ejso.2005.05.006
   Stephens M, 2018, WORLD NEUROSURG, V116, P362, DOI 10.1016/j.wneu.2018.05.212
   Sun W, 2016, ORTHOP SURG, V8, P162, DOI 10.1111/os.12245
   Tschugg A, 2016, J NEUROSURG-SPINE, V24, P385, DOI 10.3171/2015.7.SPINE15342
   Yin J, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2084-9
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 55
EP 61
DI 10.1016/j.wneu.2019.04.206
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100141
PM 31054349
DA 2020-05-12
ER

PT J
AU Chen, L
   Li, DH
   Lu, YH
   Hao, B
   Cao, YQ
AF Chen, Lei
   Li, De-heng
   Lu, Yun-he
   Hao, Bin
   Cao, Yi-qun
TI Preoperative Embolization Versus Direct Surgery of Meningiomas: A
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Blood loss; Complications; Direct surgery; Meningioma; Preoperative
   embolization; Surgical time
ID POLYVINYL-ALCOHOL PARTICLES; EFFICACY; COMPLICATIONS; SAFETY; RESECTION
AB BACKGROUND: Preoperative embolization (POE) of meningioma has been established to facilitate surgical resection, which may reduce intraoperative blood loss and surgical time. However, no consensus has been achieved in meningioma treatment and no meta-analysis has been conducted. The purpose of this study was to perform a systematic review and meta-analysis and provide evidence of the efficacy of meningioma treatment with POE and direct surgery.
   METHODS: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A systematic search was performed using PubMed and EMBASE. Meta-analysis was performed using the risk ratio of overall complication, mean difference (MD) of blood loss, and surgical time. The I-2 statistic was used to assess the heterogeneity.
   RESULTS: Eight studies (1 randomized controlled trial and 7 non-randomized controlled trials) were included, in which 510 patients met the inclusion criteria. We found that preoperative embolization for patients with meningioma did not increase the overall complication rate (risk ratio = 0.92, 95% confidence interval [CI] 0.61-1.38) and can significantly reduce intraoperative blood loss (MD = -65.10, 95% CI -124.76 to -20.82) and surgical time (MD = -38.48, 95% CI -64.03 to -12.93) compared with the control patients. No significant publication bias was observed.
   CONCLUSIONS: This meta-analysis supports the hypothesis that POE of meningioma is a useful adjunct in meningioma treatment. This technique helps reduce blood loss and surgical time during meningioma resection.
C1 [Cao, Yi-qun] Fudan Univ, Dept Neurosurg, Shanghai Canc Ctr, Shanghai, Peoples R China.
   Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China.
RP Cao, YQ (reprint author), Fudan Univ, Dept Neurosurg, Shanghai Canc Ctr, Shanghai, Peoples R China.
EM yiqun_fduscc@163.com
CR Aihara M, 2015, NEURORADIOLOGY, V57, P713, DOI 10.1007/s00234-015-1521-9
   Bendszus M, 2000, NEUROSURGERY, V47, P1306, DOI 10.1097/00006123-200012000-00008
   Bendszus M, 2005, AM J NEURORADIOL, V26, P1413
   Borg A, 2013, NEUROSURGERY, V73, P244, DOI 10.1227/NEU.0000000000000187
   Carli DFM, 2010, AM J NEURORADIOL, V31, P152, DOI 10.3174/ajnr.A1754
   Chun JY, 2002, NEUROSURGERY, V50, P1231, DOI 10.1097/00006123-200206000-00010
   DEAN BL, 1994, AM J NEURORADIOL, V15, P1675
   Fang QR, 2016, INT J NEUROSCI, V126, P1112, DOI 10.3109/00207454.2015.1134525
   Hirai T, 2004, AM J NEURORADIOL, V25, P74
   Ishihara H, 2015, INTERV NEURORADIOL, V21, P624, DOI 10.1177/1591019915590537
   Jo KI, 2016, CLIN RADIOL, V71, P335, DOI 10.1016/j.crad.2015.12.003
   Kallmes DF, 1997, NEURORADIOLOGY, V39, P877, DOI 10.1007/s002340050526
   Kominami S, 2012, INTERV NEURORADIOL, V18, P133, DOI 10.1177/159101991201800202
   Lacobucci M, 2017, DIAGN INTERV IMAG, V98, P307, DOI 10.1016/j.diii.2016.08.006
   Lee SSW, 2006, SURG PRACT, V10, P106, DOI 10.1111/j.1744-1633.2006.00309.x
   MACPHERSON P, 1991, NEURORADIOLOGY, V33, P334, DOI 10.1007/BF00587818
   MANELFE C, 1986, AM J NEURORADIOL, V7, P963
   Raper DMS, 2014, AM J NEURORADIOL, V35, P1798, DOI 10.3174/ajnr.A3919
   Shah AH, 2013, J NEUROSURG, V119, P364, DOI 10.3171/2013.3.JNS121328
   Singla A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13351
   Sluzewski M, 2013, AM J NEURORADIOL, V34, P727, DOI 10.3174/ajnr.A3311
   Suzuki K, 2017, J NEUROL SURG PART B, V78, P308, DOI 10.1055/s-0037-1598195
   Wu YM, 2009, CHINESE J RADIOL, V34, P245
NR 23
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 62
EP 68
DI 10.1016/j.wneu.2019.02.223
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100142
PM 30954743
DA 2020-05-12
ER

PT J
AU Nordmann, NJ
   Michael, AP
   Espinosa, JA
AF Nordmann, Nathan J.
   Michael, Alex P.
   Espinosa, Jose A.
TI Resolution of Symptomatic Lumbar Synovial Cyst After Traumatic Event
SO WORLD NEUROSURGERY
LA English
DT Article
DE Facet cyst; Lumbar; Radiculopathy; Resolution; Spine; Synovial cyst;
   Traumatic
ID DIAGNOSIS; MANAGEMENT
AB BACKGROUND: Synovial cysts are most commonly found in the lumbar spine and are associated with low back pain and radiculopathy. Frequent use of imaging modalities has led to an increase in intraspinal synovial cyst identification. Treatment typically ranges from conservative measures to surgical decompression, but spontaneous resolution has previously been reported. Here, we present the first report of symptomatic lumbar synovial cyst resolution after a traumatic fall.
   CASE DESCRIPTION: We present a case of a symptomatic synovial cyst between the fourth (L4) and fifth (L5) lumbar vertebrae identified on magnetic resonance imaging (MRI). The patient presented with right paramedian back pain and right-sided L5 radiculopathy. She underwent unsuccessful trials of antiinflammatory agents and physical therapy. Less than 1 year since initial diagnosis, the patient sustained a mechanic fall followed by resolution of prior symptoms. A subsequent lumbar MRI revealed complete resolution of the intraspinal synovial cyst.
   CONCLUSIONS: The diagnosis of synovial cysts are increasing in frequency due to their ease of identification with computed tomography and MRI. For cases of refractory pain and/or neurologic deficits, surgical decompression is usually necessary. In rare instances, synovial cysts may spontaneously regress or resolve secondary to other events. This is the first description of resolution after a traumatic fall. Due to limited data on this topic, this report may provide additional insight into the pathophysiology of synovial cyst formation and resolution.
C1 [Nordmann, Nathan J.; Michael, Alex P.; Espinosa, Jose A.] Southern Illinois Univ, Div Neurosurg, Sch Med, Springfield, IL 62702 USA.
RP Nordmann, NJ (reprint author), Southern Illinois Univ, Div Neurosurg, Sch Med, Springfield, IL 62702 USA.
EM nnordmann93@siumed.edu
OI Nordmann, Nathan/0000-0002-7106-8665
CR Apostolaki E, 2000, EUR RADIOL, V10, P615, DOI 10.1007/s003300050973
   Boviatsis EJ, 2008, EUR SPINE J, V17, P831, DOI 10.1007/s00586-007-0563-z
   Bydon A, 2010, SPINE J, V10, P820, DOI 10.1016/j.spinee.2010.04.010
   Campbell R, 2018, WORLD NEUROSURG, V119, pE502, DOI 10.1016/j.wneu.2018.07.190
   Choudhri Haroon Fiaz, 2006, Neurosurg Focus, V20, pE1
   Greenberg MS, 2016, HDB NEUROSURGERY
   Houten JK, 2003, J NEUROSURG, V99, P235, DOI 10.3171/spi.2003.99.2.0235
   HSU KY, 1995, SPINE, V20, P80, DOI 10.1097/00007632-199501000-00015
   Khan AM, 2006, EUR SPINE J, V15, P1176, DOI 10.1007/s00586-005-0009-4
   Maezawa Y, 2000, EUR SPINE J, V9, P85, DOI 10.1007/s005860050016
   MERCADER J, 1985, NEURORADIOLOGY, V27, P346, DOI 10.1007/BF00339570
   Pulhorn H, 2012, BRIT J NEUROSURG, V26, P123, DOI 10.3109/02688697.2011.595847
   Sinha P, 2016, J SURG CASE REP, V2016, prjw166
   Swartz PG, 2003, AM J NEURORADIOL, V24, P1261
   Trummer M, 2001, J NEUROL NEUROSUR PS, V70, P74, DOI 10.1136/jnnp.70.1.74
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 69
EP 71
DI 10.1016/j.wneu.2019.04.091
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100143
PM 31051307
DA 2020-05-12
ER

PT J
AU Yao, Y
   Lu, SS
   Li, DX
   Zhang, N
   Fei, XR
   Mei, JM
   Niu, CS
   Xia, CY
   Fu, XM
AF Yao, Yang
   Lu, Songsong
   Li, Dongxue
   Zhang, Nan
   Fei, Xiaorui
   Mei, Jiaming
   Niu, Chaoshi
   Xia, Chengyu
   Fu, Xianming
TI Retractorless Surgery for Giant Vestibular Schwannomas via the
   Retrosigmoid Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain injury; Retractorless surgery; Vestibular schwannoma
ID SURGICAL REMOVAL; BRAIN RETRACTION; BLOOD-FLOW
AB BACKGROUND: A fixed retractor is routinely used during surgery for vestibular schwannoma to maintain the surgical corridor; however, brain injuries can be caused by use of retractors. The aim of this study was to present strategies for retractorless surgery for giant vestibular schwannomas and compare retractorless surgery with traditional retractor-assisted surgery to illustrate feasibility and potentially superiority of retractorless surgery.
   METHODS: Clinical data of 61 patients with giant (>= 4 cm diameter) vestibular schwannomas undergoing craniotomy were retrospectively analyzed. Patients were divided into 2 cohorts: 1) 35 patients with traditional retractor surgery performed between June 2016 and July 2017; 2) 26 patients with retractorless surgery performed between June 2016 and July 2018. Duration of operation, intraoperative blood loss, extent of resection, rate of retention of facial nerve function, postoperative brain injury rate, intracranial infection rate, hospitalization time, and grade of facial nerve function were compared between the 2 groups.
   RESULTS: The incidence of postoperative brain injury Was 3.84% in the retractorless surgery group, which was significantly lower compared with the traditional retractor surgery group (22.86%) (P< 0.05). No significant differences were found regarding the other characteristics compared.
   CONCLUSIONS: Through appropriate comprehensive measures, retractorless surgery for giant vestibular schwannomas is an achievable goal. This procedure can reduce the incidence of postoperative brain injury with satisfactory tumor resection.
C1 [Yao, Yang] Shandong Univ, Jinan, Shandong, Peoples R China.
   [Yao, Yang; Lu, Songsong; Li, Dongxue; Zhang, Nan; Fei, Xiaorui; Mei, Jiaming; Niu, Chaoshi; Xia, Chengyu; Fu, Xianming] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC, Dept Neurosurg, Hefei, Anhui, Peoples R China.
   [Xia, Chengyu] Anhui Provi Hosp, Dept Neurosurg, Hefei, Anhui, Peoples R China.
RP Xia, CY (reprint author), Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC, Dept Neurosurg, Hefei, Anhui, Peoples R China.; Xia, CY (reprint author), Anhui Provi Hosp, Dept Neurosurg, Hefei, Anhui, Peoples R China.
EM docxiachengyu@163.com
OI Yao, Yang/0000-0003-0148-6519
CR ANDREWS R J, 1992, Neurological Research, V14, P12
   Charpiot A, 2010, ACTA OTO-LARYNGOL, V130, P1249, DOI 10.3109/00016481003762316
   HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202
   Huang X, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0805-6
   Giordano AI, 2012, ACTA OTORRINOLAR ESP, V63, P194, DOI 10.1016/j.otorri.2011.11.003
   Krayenbuhl N, 2011, NEUROSURGERY, V69, P344, DOI 10.1227/NEU.0b013e31821819a0
   Rosenorn J, 1989, Acta Neurol Scand Suppl, V120, P1
   ROSENORN J, 1985, J NEUROSURG, V63, P608, DOI 10.3171/jns.1985.63.4.0608
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Sato K, 2012, J PHYSIOL-LONDON, V590, P3277, DOI 10.1113/jphysiol.2012.230425
   Schatlo B, 2016, ACTA NEUROCHIR, V158, P229, DOI 10.1007/s00701-015-2684-1
   Silva J, 2012, WORLD NEUROSURG, V77, P731, DOI 10.1016/j.wneu.2011.08.019
   Spetzler RF, 2012, J NEUROSURG, V116, P291, DOI 10.3171/2011.8.JNS101896
   Sun H, 2016, J NEUROSURG SCI, V60, P54
   Tos M, 2004, ARCH OTOLARYNGOL, V130, P216, DOI 10.1001/archotol.130.2.216
   Wang X, 2017, CLIN NEUROL NEUROSUR, V155, P58, DOI 10.1016/j.clineuro.2017.02.018
   Xu W, 2002, ACTA NEUROCHIR, V144, P679, DOI 10.1007/s00701-002-0946-1
   Ye Xun, 2015, Zhonghua Yi Xue Za Zhi, V95, P1976
   Yu LH, 2015, WORLD NEUROSURG, V84, P1779, DOI 10.1016/j.wneu.2015.07.055
   Zhao Z H, 2017, Zhonghua Yi Xue Za Zhi, V97, P666, DOI 10.3760/cma.j.issn.0376-2491.2017.09.006
NR 20
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 72
EP 76
DI 10.1016/j.wneu.2019.04.132
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100144
PM 31026654
DA 2020-05-12
ER

PT J
AU Balestrino, A
   Secci, F
   Piatelli, G
   Morana, G
   Pavanello, M
   Pacetti, M
   Cama, A
   Consales, A
AF Balestrino, Alberto
   Secci, Francesca
   Piatelli, Gianluca
   Morana, Giovanni
   Pavanello, Marco
   Pacetti, Mattia
   Cama, Armando
   Consales, Alessandro
TI Pure Bilateral Lambdoid and Posterior Sagittal Synostosis (Mercedes-Benz
   Syndrome): Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bilateral lambdoid; Craniosynostosis; Mercedes-Benz syndrome;
   Multisutural craniosynostosis; Sagittal synostosys; Skull remodeling
ID CRANIOFACIAL DYSSYNOSTOSIS
AB BACKGROUND: Bilateral lambdoid and posterior sagittal synostosis is a rarely encountered multisutural craniosynostosis accounting for 0.3%-0.7% of all craniosynostoses. It has been named "Mercedes- Benz Syndrome" (MBS) because of the bone ridges that resemble the Mercedes-Benz logo. The typical head shape is usually described as anterior turricephaly combined with mild brachycephaly. We describe a case of pure MBS without involvement of other sutures. Since we believe that MBS is a different pathology when other sutures are involved, we will discuss our case with a review of the literature, including all reported cases of bilateral lambdoid and posterior sagittal synostosis with no other sutures involved but sagittal and bilateral lambdoid.
   CASE DESCRIPTION: A 3-month-old female baby came to our attention because of a turrycephalic appearance of the head. Findings of the neurologic examination were unremarkable. Computed tomography scan showed premature fusion of posterior third of sagittal suture and bilateral lambdoid suture. Magnetic resonance imaging did not show relevant intracranial abnormalities. She underwent sagittal decompression extended posteriorly below the lambdoid suture combined with biparietal decompression to obtain expansion of both parieto-frontal bones and posterior fossa. Post-operative course was uneventful. Follow-up at 3 months showed a good aesthetic result, and results of the neurologic examination were unremarkable.
   CONCLUSIONS: Pure MBS is a rare condition that unlike other multisutural complex craniosynostosis is rarely associated with genetic syndromes, has a low rate of associated intracranial anomalies, and has less need for more skull-remodeling surgery. The choice of the most suitable surgical procedure must be tailored on the patient, considering preoperative head appearance and eventually associated anomalies.
C1 [Balestrino, Alberto] Univ Genoa, Dept Neurosci DINOGMI, Div Neurosurg, Osped Policlin San Martino IST, Genoa, Italy.
   [Balestrino, Alberto; Secci, Francesca; Piatelli, Gianluca; Pavanello, Marco; Pacetti, Mattia; Cama, Armando; Consales, Alessandro] IRCCS Ist Giannina Gaslini Childrens Hosp, Div Neurosurg, Genoa, Italy.
   [Morana, Giovanni] IRCCS Ist Giannina Gaslini Childrens Hosp, Div Neuroradiol, Genoa, Italy.
RP Balestrino, A (reprint author), Univ Genoa, Dept Neurosci DINOGMI, Div Neurosurg, Osped Policlin San Martino IST, Genoa, Italy.; Balestrino, A (reprint author), IRCCS Ist Giannina Gaslini Childrens Hosp, Div Neurosurg, Genoa, Italy.
EM alberto.balestrino@gmail.com
RI Marco, Pavanello/K-2859-2019; Pacetti, Mattia/AAC-3306-2020; Morana,
   Giovanni/J-6134-2018
OI Marco, Pavanello/0000-0001-7312-0204; Pacetti,
   Mattia/0000-0001-6426-6164; Morana, Giovanni/0000-0001-8707-5969;
   Balestrino, Alberto/0000-0002-0233-1992
CR Al-Torki NA, 1998, AM J MED GENET, V79, P5
   Bermejo E, 2005, AM J MED GENET A, V132A, P41, DOI 10.1002/ajmg.a.30380
   Chivoret Nathalie, 2018, Surg Neurol Int, V9, P206, DOI 10.4103/sni.sni_454_17
   Chong S, 2016, J KOREAN NEUROSURG S, V59, P227, DOI 10.3340/jkns.2016.59.3.227
   Chumas PD, 1997, J NEUROSURG, V86, P177, DOI 10.3171/jns.1997.86.2.0177
   Colosimo C, 2005, PEDIAT NEURORADIOLOG, P1303
   Czerwinski M, 2011, PLAST RECONSTR SURG, V128, P955, DOI 10.1097/PRS.0b013e3182268ca6
   Hing AV, 2009, AM J MED GENET A, V149A, P1024, DOI 10.1002/ajmg.a.32782
   Lahidji SF, 2006, AM J MED GENET A, V140A, P1333, DOI 10.1002/ajmg.a.31268
   Moore MH, 1998, J CRANIOFAC SURG, V9, P417, DOI 10.1097/00001665-199809000-00003
   NEUHAUSER G, 1976, EUR J PEDIATR, V123, P15, DOI 10.1007/BF00497676
   Pillai S, 2013, CHILD NERV SYST, V29, P2117, DOI 10.1007/s00381-013-2155-z
   Rhodes JL, 2010, PLAST RECONSTR SURG, V125, P299, DOI 10.1097/PRS.0b013e3181c2a6aa
   Sloan GM, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.1.e2
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 77
EP 82
DI 10.1016/j.wneu.2019.04.117
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100145
PM 31009784
DA 2020-05-12
ER

PT J
AU Tyagi, G
   Bhat, DL
   Devi, BI
   Shukla, D
AF Tyagi, Gaurav
   Bhat, Dhananjaya L.
   Devi, Bhagavatula Indira
   Shukla, Dhaval
TI Multiple Remote Sequential Supratentorial Epidural Hematomas-An Unusual
   and Rare Complication After Posterior Fossa Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications of trapped fourth ventricle surgery; Epidural hematoma;
   Multiple EDH; Postoperative hemorrhage; Remote EDH; Sequential EDH;
   Supratentorial EDH infratentorial surgery
ID SITE INTRACRANIAL HEMORRHAGE; POSTOPERATIVE HEMORRHAGE; EXPLORATION;
   DEFICIENCY; DRAINAGE; SHUNT; RISK
AB BACKGROUND: Postoperative hemorrhage is a serious complication of intracranial surgery. Epidural hematomas (EDHs) are one of the common forms of bleeding after surgery, with <= 12% of patients requiring re-exploration. However, distant or remote site EDHs have been rare, in particular, those in a supratentorial location after infratentorial surgery.
   CASE DESCRIPTION: We report an unusual complication of surgery for fourth ventricular outlet obstruction. A young male patient developed multiple sequential supratentorial EDHs after posterior fossa surgery. He required 2 re-explorations after the primary surgery for evacuation of the EDHs within 24 hours. In the available data, we found only 28 such reported cases previously. Only 2 additional cases have been reported to have sequential EDHs after surgery. Various theories have been postulated, ranging from sudden intracranial pressure decompression, pin site hematoma, and shunt site bleeding due to dural stripping. None has been proven to definitively explain the complication.
   CONCLUSIONS: We wished to highlight this unusual complication of posterior fossa surgery, with an emphasis on rapid computed tomography scanning of the brain for patients in the early postoperative period with any neurological deterioration. Early radiological detection and timely intervention can be lifesaving.
C1 [Tyagi, Gaurav; Bhat, Dhananjaya L.; Devi, Bhagavatula Indira; Shukla, Dhaval] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
RP Devi, BI (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM bidevidr@gmail.com
OI Shukla, Dhaval/0000-0001-7613-1929
CR Avci E, 2010, NEUROL NEUROCHIR POL, V44, P609
   Borkar SA, 2013, BRIT J NEUROSURG, V27, P735, DOI 10.3109/02688697.2013.795521
   Brisman MH, 1996, NEUROSURGERY, V39, P1114, DOI 10.1097/00006123-199612000-00009
   Chung Ho-Jung, 2015, Brain Tumor Res Treat, V3, P132, DOI 10.14791/btrt.2015.3.2.132
   Desai VR, 2016, CUREUS, V8, DOI 10.7759/cureus.616
   DRIESEN W, 1974, ACTA NEUROCHIR, V30, P85, DOI 10.1007/BF01405757
   FISKIN RD, 1964, J NEUROSURG, V21, P58, DOI 10.3171/jns.1964.21.1.0058
   FRERA C, 1969, Acta Neurochirurgica, V20, P31, DOI 10.1007/BF01402236
   Fujimoto Y, 1999, NEUROSURG REV, V22, P226, DOI 10.1007/s101430050022
   Garg K, 2014, NEUROL INDIA, V62, P296, DOI 10.4103/0028-3886.137027
   Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF
   HAFT H, 1960, J NEUROSURG, V17, P49, DOI 10.3171/jns.1960.17.1.0049
   HARDERS A, 1985, ACTA NEUROCHIR, V74, P57, DOI 10.1007/BF01413279
   HIGAZI I, 1963, J NEUROSURG, V20, P527, DOI 10.3171/jns.1963.20.6.0527
   KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010
   KALIA KK, 1993, PEDIATR NEUROSURG, V19, P78, DOI 10.1159/000120704
   Lim JW, 2010, J PEDIATR NEUROSCI, V5, P79, DOI 10.4103/1817-1745.66674
   Naik V, 2011, NEUROL INDIA, V59, P172, DOI 10.4103/0028-3886.84368
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   Pandey P, 2008, CHILD NERV SYST, V24, P851, DOI 10.1007/s00381-007-0573-5
   Park SJ, 1997, J KOREAN NEUROSURG S, V26, P1123
   Schorstein J, 1942, J NEUROL PSYCHIATRY, V5, P142, DOI 10.1136/jnnp.5.3-4.142
   SENGUPTA RP, 1972, J NEUROL NEUROSUR PS, V35, P297, DOI 10.1136/jnnp.35.3.297
   TJAN TG, 1980, NEURORADIOLOGY, V19, P51
   Tondon A, 2004, J CLIN NEUROSCI, V11, P762, DOI 10.1016/j.jocn.2003.10.029
   Tsugane R, 1976, No Shinkei Geka, V4, P401
   Vrettou CS, 2010, ACTA NEUROCHIR, V152, P529, DOI 10.1007/s00701-009-0432-0
   Vupputuri R, 2014, J NEUROSCI RURAL PRA, V5, P199, DOI 10.4103/0976-3147.131688
   WEISS RM, 1964, J NEUROSURG, V21, P235, DOI 10.3171/jns.1964.21.3.0235
   WHISLER WW, 1965, J NEUROSURG, V23, P214, DOI 10.3171/jns.1965.23.2.0214
   Wolfsberger S, 2004, NEUROSURG REV, V27, P128, DOI 10.1007/s10143-003-0315-4
   Yu JL, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-015-0754-8
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 83
EP 90
DI 10.1016/j.wneu.2019.04.228
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100146
PM 31071445
DA 2020-05-12
ER

PT J
AU Chan, HM
   Loh, WNH
   Yeo, TT
   Teo, K
AF Chan, Hui-Minn
   Loh, Will Ne-Hooi
   Yeo, Tseng Tsai
   Teo, Kejia
TI Awake Craniotomy and Excision of a Diffuse Low-Grade Glioma in a
   Multilingual Patient: Neuropsychology and Language
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake craniotomy; Diffuse low-grade glioma; Electrostimulation;
   Language; Multilingual; Neuropsychology; Singapore
ID BILINGUAL PATIENTS; BRAIN; ORGANIZATION; LOCALIZATION; SYSTEM
AB BACKGROUND: Diffuse low-grade gliomas are a group of brain tumors that require an individualized and targeted therapeutic approach, such as awake craniotomy for surgical resection and intraoperative monitoring of speech and language functions.
   CASE DESCRIPTION: This case report presents a young, right-handed, Tamil-English-Malay multilingual man who underwent awake brain surgery for the excision of a diffuse low-grade glioma in the left frontal pars triangularis and opercularis region (i.e., Broca's area). Preoperative and postoperative neuropsychological assessments were conducted. Intraoperative language mapping was performed with electrostimulation.
   CONCLUSION: Awake craniotomy with speech and language monitoring allows a customized approach to the treatment and management of diffuse low-grade gliomas. Neuropsychological assessment and intraoperative findings are discussed in the context of functional reorganization and cortical representations of language.
C1 [Chan, Hui-Minn] Natl Univ Singapore Hosp, Dept Psychol Med, Singapore, Singapore.
   [Loh, Will Ne-Hooi] Natl Univ Singapore Hosp, Dept Anaesthesia, Singapore, Singapore.
   [Yeo, Tseng Tsai; Teo, Kejia] Natl Univ Singapore Hosp, Dept Neurosurg, Singapore, Singapore.
RP Chan, HM (reprint author), Natl Univ Singapore Hosp, Dept Psychol Med, Singapore, Singapore.
EM hui_minn_chan@nuhs.edu.sg
OI Chan, Hui Minn/0000-0003-1506-005X
CR Bello L, 2007, NEUROSURGERY, V60, P67, DOI 10.1227/01.NEU.0000249206.58601.DE
   Bello L, 2006, NEUROSURGERY, V59, P115, DOI 10.1227/01.NEU.0000219241.92246.FB
   Bhuvaneshwari B, 2011, S SE ASIAN PSYCHOLIN
   Chang EF, 2015, J NEUROSURG, V122, P250, DOI 10.3171/2014.10.JNS132647
   Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300
   Duffau H, 2014, DIAGN INTERV IMAG, V95, P945, DOI 10.1016/j.diii.2014.08.001
   Duffau H, 2004, CANCER-AM CANCER SOC, V100, P2622, DOI 10.1002/cncr.20297
   Duffau H, 2002, BRAIN, V125, P199, DOI 10.1093/brain/awf016
   Duffau H., 2014, DIFFUSE LOW GRADE GL
   Duffau H, 2015, NEURO-ONCOLOGY, V17, P332, DOI 10.1093/neuonc/nou153
   Giussani C, 2007, ACTA NEUROCHIR, V149, P1109, DOI 10.1007/s00701-007-1266-2
   HOWARD D, 1992, PYRAMIDS PALM TREES
   Kaplan EH, 2016, WINT SIMUL C PROC, P2, DOI 10.1109/WSC.2016.7822073
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lubrano V, 2012, J NEUROLINGUIST, V25, P567, DOI 10.1016/j.jneuroling.2011.08.002
   Lucas TH, 2004, J NEUROSURG, V101, P449, DOI 10.3171/jns.2004.101.3.0449
   Moritz-Gasser S, 2013, NEUROPSYCHOLOGIA, V51, P1814, DOI 10.1016/j.neuropsychologia.2013.06.007
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316
   Polczynska MM, 2016, NEUROPSYCHOLOGIA, V86, P167, DOI 10.1016/j.neuropsychologia.2016.04.030
   Randolph C, 2012, RBANS UPDATE REPEATA
   Soffietti R, 2010, EUR J NEUROL, V17, P1124, DOI 10.1111/j.1468-1331.2010.03151.x
   Talacchi A, 2013, FUNCT NEUROL, V28, P223, DOI 10.11138/FNeur/2013.28.3.223
   Tanji K, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00078
NR 24
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 91
EP 97
DI 10.1016/j.wneu.2019.04.181
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100147
PM 31059854
DA 2020-05-12
ER

PT J
AU Ono, I
   Satow, T
   Ito, Y
   Hamano, E
   Matsubara, H
   Kataoka, H
   Takahashi, JC
AF Ono, Isao
   Satow, Tetsu
   Ito, Yoshiro
   Hamano, Eika
   Matsubara, Hirofumi
   Kataoka, Hiroharu
   Takahashi, Jun C.
TI Case of latrogenic Vertebro-Vertebral Arteriovenous Fistula Treated by
   Combination o Double-Catheter and Balloon Anchoring Techniques
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon anchoring technique; Double-catheter technique;
   Vertebro-vertebral arteriovenous fistula
ID TRANSVENOUS EMBOLIZATION
AB Background: A case of high-flow cervical vertebro-vertebral arteriovenous fistula (VVAVF), which was occluded with detachable coils by the transarterial/transvenous double-catheter technique and balloon anchoring technique, is reported.
   Case Description: A 32-year-old male who had a history of dilated cardiomyopathy, heart failure, and arrhythmia under anticoagulation presented with a neck bruit after a right internal jugular vein puncture. A high-flow VVAVF between the right vertebral artery (VA) and vertebral vein (VV) was revealed by ultrasonography and angiography. To extirpate the shunt while preserving the right VA without using a stent to avoid antiplatelet therapy, the double-catheter technique was used to occlude the vein and shunt tightly, 1 catheter from the venous side and the other from the VA to the VV through the shunt. Finally, stabilization of the coil cage in the dilating VV was secured by placing a balloon distally as an anchor and successfully occluding the shunt with small amounts of coils only on the venous side. The shunt and cervical bruit disappeared immediately after the treatment, and no recurrence was observed.
   Conclusions: The double-catheter technique and balloon anchoring technique used in this case seem effective for transvenous embolization of VVAVF when preservation of the VA is desired.
C1 [Ono, Isao; Satow, Tetsu; Ito, Yoshiro; Hamano, Eika; Matsubara, Hirofumi; Kataoka, Hiroharu; Takahashi, Jun C.] Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Suita, Osaka, Japan.
RP Satow, T (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Suita, Osaka, Japan.
EM tetsus@ncvc.go.jp
OI Kataoka, Hiroharu/0000-0001-8507-7557
CR Baxter BW, 1998, AM J NEURORADIOL, V19, P1176
   Briganti F, 2004, MINIM INVAS NEUROSUR, V47, P386, DOI 10.1055/s-2004-830131
   Briganti F, 2013, NEURORADIOL J, V26, P339, DOI 10.1177/197140091302600315
   FUKAO S, 1995, NEURORADIOLOGY, V37, P400
   Gonzalez A, 2001, NEURORADIOLOGY, V43, P784, DOI 10.1007/s002340100586
   HALBACH VV, 1988, AM J ROENTGENOL, V150, P405, DOI 10.2214/ajr.150.2.405
   Ito Y, 2019, WORLD NEUROSURG, V122, P123, DOI 10.1016/j.wneu.2018.10.158
   Kai Y, 2001, ACTA NEUROCHIR, V143, P125, DOI 10.1007/s007010170116
   Merland J J, 1986, Ann Vasc Surg, V1, P73, DOI 10.1007/BF02732459
   Okata T, 2018, J NEUROENDOVASC THER, V12, P29
   Sadato A, 2003, NEUROL MED-CHIR, V43, P250, DOI 10.2176/nmc.43.250
   SHER MH, 1966, ANN SURG, V163, P408, DOI 10.1097/00000658-196603000-00013
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 98
EP 101
DI 10.1016/j.wneu.2019.04.236
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100148
PM 31075492
DA 2020-05-12
ER

PT J
AU Choi, DH
   Yoo, CJ
   Park, CW
   Kim, MJ
AF Choi, Dae Han
   Yoo, Chan Jong
   Park, Cheol Wan
   Kim, Myeong Jin
TI Idiopathic Pseudoaneurysm of External Carotid Artery with Delayed Facial
   Palsy After Covered Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; External carotid artery; Stent
ID ANEURYSM
AB BACKGROUND: Idiopathic pseudoaneurysms of the external carotid artery (ECA) between the internal maxillary artery and the facial artery are rare. Endovascular covered stenting is an alternative method for surgically challenging cases; however, movable and flexible vessels may prevent the maintenance of the stent.
   CASE DESCRIPTION: A 26-year-old woman presented with sudden swelling and pain of the left chin due to a pseudoaneurysm of the proximal ECA trunk. She had undergone endovascular covered stenting and suddenly developed facial palsy at postprocedural 1 week. Regrowth of the aneurysm and slippage of the stent were detected, and additional stenting was performed. Swelling and pain of the chin and neck and subsequently the facial palsy completely resolved, and the patient made a full recovery.
   CONCLUSIONS: The ECA aneurysm between the internal maxillary artery and facial artery may be more floating and changeable than any other portions of the ECA, and regrowth of the ECA aneurysm may cause delayed complication. In addition, knowledge of the mechanism is necessary to help in the endovascular treatment.
C1 [Choi, Dae Han; Yoo, Chan Jong; Park, Cheol Wan; Kim, Myeong Jin] Gachon Univ, Gil Med Ctr, Dept Neurosurg, Coll Med, Incheon, South Korea.
RP Kim, MJ (reprint author), Gachon Univ, Gil Med Ctr, Dept Neurosurg, Coll Med, Incheon, South Korea.
EM skymedi@gachon.ac.kr
OI Kim, Myeong Jin/0000-0001-5855-5533
CR Bhushan G, 2015, J ORAL MAXILLOFAC SU, V73
   Choi HC, 2018, J NEURORADIOLOGY, V45, P217, DOI 10.1016/j.neurad.2018.01.057
   Finsterer J, 2008, EUR ARCH OTO-RHINO-L, V265, P743, DOI 10.1007/s00405-008-0646-4
   Gatto Luana Antunes Maranha, 2017, Surg Neurol Int, V8, P270, DOI 10.4103/sni.sni_428_16
   Majumdar R, 2000, CLIN PEDIATR, V39, P440, DOI 10.1177/000992280003900716
   Nadig S, 2009, HEAD NECK-J SCI SPEC, V31, P136, DOI 10.1002/hed.20855
   Ni L, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005442
   Ogishima H, 2011, INVEST OPHTH VIS SCI, V52, P9710, DOI 10.1167/iovs.11-8160
   Rhee CS, 1999, OTOLARYNG HEAD NECK, V121, P158, DOI 10.1016/S0194-5998(99)70147-6
   Roob G, 1999, EUR NEUROL, V41, P3, DOI 10.1159/000007990
   Souldi H, 2016, INT J SURG CASE REP, V26, P170, DOI 10.1016/j.ijscr.2016.07.009
   Sullivan FM, 2007, NEW ENGL J MED, V357, P1598, DOI 10.1056/NEJMoa072006
   Wang DM, 2015, J VASC SURG, V61, P920, DOI 10.1016/j.jvs.2014.10.093
   Yuen JC, 2000, ANN PLAS SURG, V44, P656, DOI 10.1097/00000637-200044060-00015
   Zhang WG, 2019, J ELDER ABUSE NEGL, V31, P340, DOI 10.1080/08946566.2019.1652718
NR 15
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 102
EP 105
DI 10.1016/j.wneu.2019.04.265
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100149
PM 31078799
DA 2020-05-12
ER

PT J
AU Matsuo, S
   Komune, N
   Hayashi, D
   Amano, T
   Nakamizo, A
AF Matsuo, Satoshi
   Komune, Noritaka
   Hayashi, Daisuke
   Amano, Toshiyuki
   Nakamizo, Akira
TI Three-Piece Orbitozygomatic Craniotomy: Anatomical and Clinical Findings
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diamond threadwire saw; Orbitozygomatic craniotomy; Skull base; Surgical
   technique
ID INFERIOR ORBITAL FISSURE; ONE-PIECE; FACIAL-NERVE; SUPRAORBITAL
   APPROACH; MACCARTY KEYHOLE; DISSECTION; MUSCLE
AB OBJECTIVE: To describe the technical details of 3-piece orbitozygomatic (OZ) craniotomy using a diamond thread-wire saw as an alternative to cutting the orbital rim and zygoma.
   METHODS: The details of this procedure are presented cadaver dissection and a surgical case.
   RESULTS: Three-piece OZ craniotomy consists of 3 steps of bone flap elevation. First, the zygomatic arch is divided and reflected downward with the temporal muscle. This provides adequate exposure around the inferior orbital fissure with less skin flap retraction. In the second step, frontotemporal craniotomy is performed close to the skull base without the requirement for additional craniectomy. Finally, the superolateral wall of the orbital bone flap is elevated. Cutting the orbital rim and zygoma with a diamond threadwire saw allows reconstruction with a minimal bone gap.
   CONCLUSIONS: The herein-described 3-piece OZ craniotomy technique is simple and provides excellent brain exposure equivalent to that achieved by 1- and 2-piece OZ craniotomy while minimizing flap retraction and requiring less additional bone removal.
C1 [Matsuo, Satoshi; Komune, Noritaka; Hayashi, Daisuke; Amano, Toshiyuki; Nakamizo, Akira] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Matsuo, Satoshi] Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL 32611 USA.
   [Komune, Noritaka] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Fukuoka, Fukuoka, Japan.
RP Matsuo, S (reprint author), Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Neurosurg, Fukuoka, Fukuoka, Japan.; Matsuo, S (reprint author), Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL 32611 USA.
EM smatsuo1979@gmail.com
RI Matsuo, Satoshi/AAE-3849-2020
OI Matsuo, Satoshi/0000-0002-2052-0471
FU University of Florida FoundationUniversity of Florida
FX Part of this work was supported by the University of Florida Foundation.
CR ALMEFTY O, 1987, NEUROSURGERY, V21, P474, DOI 10.1227/00006123-198710000-00006
   Aziz KMA, 2002, ACTA NEUROCHIR, V144, P15, DOI 10.1007/s701-002-8270-1
   Bilbao CJ, 2013, OP TECH OTOLARYNGOL, V24, P229
   Campero A, 2008, ACTA NEUROCHIR, V150, P273, DOI 10.1007/s00701-007-1404-x
   Campero A, 2017, OPER NEUROSURG, V13, P622, DOI 10.1093/ons/opx047
   Campero A, 2010, NEUROSURGERY, V66, DOI 10.1227/01.NEU.0000348559.82835.21
   Conway JE, 2010, NEUROSURG REV, V33, P491, DOI 10.1007/s10143-010-0274-5
   Coscarella E, 2000, J NEUROSURG, V92, P877, DOI 10.3171/jns.2000.92.5.0877
   Davidge KM, 2010, NEUROSURGERY, V67, P120, DOI 10.1227/01.NEU.0000383132.34056.61
   HAKUBA A, 1986, SURG NEUROL, V26, P271, DOI 10.1016/0090-3019(86)90161-8
   JANE JA, 1982, NEUROSURGERY, V11, P537, DOI 10.1227/00006123-198210000-00016
   Jimbo H, 2011, J NEUROSURG, V114, P1386, DOI 10.3171/2010.8.JNS10294
   Kodera T, 2017, WORLD NEUROSURG, V97, P49, DOI 10.1016/j.wneu.2016.09.085
   Meybodi AT, 2017, WORLD NEUROSURG, V105, P359, DOI 10.1016/j.wneu.2017.05.124
   Oikawa S, 1996, J NEUROSURG, V84, P297, DOI 10.3171/jns.1996.84.2.0297
   PELLERIN P, 1984, NEUROSURGERY, V15, P715, DOI 10.1227/00006123-198411000-00016
   Poblete T, 2015, J NEUROSURG, V122, P1274, DOI 10.3171/2014.10.JNS142061
   SEKHAR LN, 1994, NEUROSURGERY, V35, P472, DOI 10.1227/00006123-199409000-00016
   Shimizu S, 2005, NEUROSURGERY, V57, P152, DOI 10.1227/01.NEU.0000163600.31460.D8
   Shimizu S, 2008, NEUROL MED-CHIR, V48, P191, DOI 10.2176/nmc.48.191
   Shimizu S, 2015, J NEUROL SURG PART B, V76, P459, DOI 10.1055/s-0035-1554903
   Shimizu S, 2011, SKULL BASE-INTERD AP, V21, P322, DOI 10.1055/s-0031-1284214
   Spiriev T, 2016, J NEUROL SURG PART B, V77, P199, DOI 10.1055/s-0035-1564590
   Tanriover N, 2006, NEUROSURGERY, V58, P229, DOI 10.1227/01.NEU.0000210010.46680.B4
   Tomita K, 1996, J BONE JOINT SURG AM, V78A, P1915, DOI 10.2106/00004623-199612000-00017
   Tubbs RS, 2010, NEUROSURGERY, V66, pONS230, DOI 10.1227/01.NEU.0000369650.69583.9C
   Wada Kojiro, 2015, Asian J Neurosurg, V10, P250, DOI 10.4103/1793-5482.161190
   Zabramski JM, 1998, J NEUROSURG, V89, P336, DOI 10.3171/jns.1998.89.2.0336
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 106
EP 113
DI 10.1016/j.wneu.2019.04.235
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100150
PM 31059850
DA 2020-05-12
ER

PT J
AU Dower, A
   Davies, MA
   Ghahreman, A
AF Dower, Ashraf
   Davies, Mark A.
   Ghahreman, Ali
TI Pathologic Basis of Lumbar Radicular Pain
SO WORLD NEUROSURGERY
LA English
DT Review
DE Lumbar disc; Pathology; Pathophysiology; Radicular pain; Sciatica
ID NERVE ROOT INJURY; EPIDURAL STEROID INJECTION; NUCLEUS PULPOSUS; DISC
   HERNIATION; INTERVERTEBRAL-DISK; BACK-PAIN; CAUDA-EQUINA; TRANSFORAMINAL
   INJECTION; RADICULOPATHY MODEL; CEREBROSPINAL-FLUID
AB BACKGROUND: Lumbar radicular pain is one of the most commonly encountered clinical syndromes; however, its underlying mechanistic basis, and its relation to the natural history of the disease, are poorly understood.
   METHODS: We revieved the available literature to explore the pathophysiology and natural history of lumbar radicular pain.
   RESULTS: Experimental observations have spawned distinctive, but not wally exclusive, pathophysiologic descriptions of radicular pain. These mechanisms include mechanical compression and inflammatory processes. In most cases, a complex interplay between these mechanisms is required to sustain the pain. However, when the dorsal root ganglion is mechanically deformed, sustained discharges causing pain can be evoked, leading to pain based on a purely mechanical basis. However, in other instances, previous sensitization of the nerve root by inflammatory processes is required.
   CONCLUSION: An understanding of these processes and the natural history of syndrome is important to developing therapeutic strategies.
C1 [Dower, Ashraf; Davies, Mark A.; Ghahreman, Ali] St George Hosp, Dept Neurosurg, Sydney, NSW, Australia.
   [Dower, Ashraf] Waikato Hosp, Dept Neurosurg, Hamilton, New Zealand.
   [Dower, Ashraf] Univ Sydney, Sch Med, Sydney, NSW, Australia.
   [Davies, Mark A.; Ghahreman, Ali] St George Private Hosp, Dept Neurosurg, Sydney, NSW, Australia.
   [Davies, Mark A.] Univ New South Wales, Dept Med, Sydney, NSW, Australia.
RP Dower, A (reprint author), St George Hosp, Dept Neurosurg, Sydney, NSW, Australia.; Dower, A (reprint author), Waikato Hosp, Dept Neurosurg, Hamilton, New Zealand.; Dower, A (reprint author), Univ Sydney, Sch Med, Sydney, NSW, Australia.
EM ashrafdower@gmail.com
CR Al-Khawaja Darweesh O, 2016, J Spine Surg, V2, P21, DOI 10.21037/jss.2016.01.05
   Aota Y, 2001, SPINE, V26, P2125, DOI 10.1097/00007632-200110010-00016
   Baumann N, 1998, ANN NY ACAD SCI, V845, P322, DOI 10.1111/j.1749-6632.1998.tb09684.x
   Benson RT, 2010, ANN ROY COLL SURG, V92, P147, DOI 10.1308/003588410X12518836438840
   BOBECHKO W P, 1965, J Bone Joint Surg Br, V47, P574
   BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013
   BOGDUK N, 1999, MED MANAGEMENT ACUTE
   Brisby H, 1999, SPINE, V24, P742, DOI 10.1097/00007632-199904150-00003
   Brisby H, 2002, SPINE, V27, P380, DOI 10.1097/00007632-200202150-00011
   Brisby H, 2002, EUR SPINE J, V11, P62, DOI 10.1007/s005860100306
   Burke JG, 2002, J BONE JOINT SURG BR, V84B, P196, DOI 10.1302/0301-620X.84B2.12511
   BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013
   Cavanaugh JM, 1994, T ORTHOP RES SOC, V19
   Celikoglu E, 2014, ACTA ORTHOP BELG, V80, P468
   Chen CY, 1997, SPINE, V22, P1057, DOI 10.1097/00007632-199705150-00002
   CIRIC I, 1980, J NEUROSURG, V53, P433, DOI 10.3171/jns.1980.53.4.0433
   Cotugno D., 1764, ISCHIAL NERVE
   de Castro I, 2005, ARQ NEURO-PSIQUIAT, V63, P701, DOI 10.1590/S0004-282X2005000400030
   DELAUCHECAVALLIER MC, 1992, SPINE, V17, P927, DOI 10.1097/00007632-199208000-00010
   DeLeo JA, 2002, SPINE, V27, P2526, DOI 10.1097/00007632-200211150-00026
   Devor M, 1996, LOW BACK PAIN: A SCIENTIFIC AND CLINICAL OVERVIEW, P187
   ELLENBERG MR, 1993, ARCH PHYS MED REHAB, V74, P3
   Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128
   ELVES MW, 1975, ORTHOP CLIN N AM, V6, P59
   Fardon D F, 2001, Spine (Phila Pa 1976), V26, pE93, DOI 10.1097/00007632-200103010-00006
   FRANSON RC, 1992, SPINE PHILA PA 197 S, V17, pS12
   FRASER RD, 1995, SPINE, V20, P710, DOI 10.1097/00007632-199503150-00012
   FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506
   GERTZBEIN SD, 1977, CLIN ORTHOP RELAT R, P68
   GERTZBEIN SD, 1977, CLIN ORTHOP RELAT R, P149
   GERTZBEIN SD, 1975, ORTHOP CLIN N AM, V6, P67
   Ghahreman A, 2011, PAIN MED, V12, P871, DOI 10.1111/j.1526-4637.2011.01116.x
   Ghahreman A, 2010, PAIN MED, V11, P1149, DOI 10.1111/j.1526-4637.2010.00908.x
   Gioia G, 1999, SPINE, V24, P1952, DOI 10.1097/00007632-199909150-00015
   Gosselin RD, 2010, NEUROSCIENTIST, V16, P519, DOI 10.1177/1073858409360822
   Gwak YS, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/2480689
   H Yoshizawa SN, 1996, INTRARADICULAR EDEMA
   Harrington JF, 2000, SPINE, V25, P929, DOI 10.1097/00007632-200004150-00006
   HEIKKILA JK, 1989, ANN MED, V21, P393, DOI 10.3109/07853898909149227
   Howe J., 1979, NEUROPHYSIOLOGICAL B, P647
   HOWE JF, 1977, PAIN, V3, P25, DOI 10.1016/0304-3959(77)90033-1
   JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201
   Kang JD, 1996, SPINE, V21, P271, DOI 10.1097/00007632-199602010-00003
   Kawakami M, 1998, CLIN ORTHOP RELAT R, P241
   Kawakami M, 1996, SPINE, V21, P2101, DOI 10.1097/00007632-199609150-00009
   Kawakami M, 1996, LOW BACK PAIN: A SCIENTIFIC AND CLINICAL OVERVIEW, P209
   Kim HJ, 2012, PAIN PHYSICIAN, V15, P415
   Kirita T, 2007, SPINE, V32, pE65, DOI 10.1097/01.brs.0000252202.85377.96
   KOJO I, 1986, ACTA NEUROL SCAND, V74, P383
   KOSTUIK JP, 1986, J BONE JOINT SURG AM, V68A, P386, DOI 10.2106/00004623-198668030-00011
   Levinson SR, 2012, MUSCLE NERVE, V46, P155, DOI 10.1002/mus.23314
   LINDAHL OLOV, 1951, ACTA ORTHOPAED SCAND, V20, P215, DOI 10.3109/17453675108991169
   MACKENZIE RA, 1975, J NEUROL NEUROSUR PS, V38, P865, DOI 10.1136/jnnp.38.9.865
   MAIGNE JY, 1992, SPINE, V17, P1071, DOI 10.1097/00007632-199209000-00010
   Marketos SG, 1999, SPINE, V24, P1381, DOI 10.1097/00007632-199907010-00018
   MCCARRON RF, 1987, SPINE, V12, P760, DOI 10.1097/00007632-198710000-00009
   Mcnab I., 1972, CERVICAL PAIN, P89
   MIXTER WJ, 1934, NEW ENGL J MED, V211, P210, DOI DOI 10.1056/NEJM193408022110506
   Ohmori K, 2001, SPINE, V26, P662, DOI 10.1097/00007632-200103150-00022
   OLMARKER K, 1994, SPINE, V19, P1803, DOI 10.1097/00007632-199408150-00003
   OLMARKER K, 1993, SPINE, V18, P1425
   OLMARKER K, 1995, SPINE, V20, P665, DOI 10.1097/00007632-199503150-00006
   Olmarker K, 1996, LOW BACK PAIN: A SCIENTIFIC AND CLINICAL OVERVIEW, P215
   OLMARKER K, 1989, SPINE, V14, P569, DOI 10.1097/00007632-198906000-00003
   PAL B, 1986, BRIT J RHEUMATOL, V25, P181
   Piperno M, 1997, SPINE, V22, P2061, DOI 10.1097/00007632-199709150-00001
   Porreca F, 1999, P NATL ACAD SCI USA, V96, P7640, DOI 10.1073/pnas.96.14.7640
   Rade M, 2017, SPINE, V42, P1117, DOI 10.1097/BRS.0000000000002235
   Rothman SM, 2007, BRAIN RES, V1181, P30, DOI 10.1016/j.brainres.2007.08.064
   Rothman SM, 2005, SPINE, V30, P2491, DOI 10.1097/01.brs.0000186316.38111.4b
   Rutkowski MA, 2002, DRUG NEWS PERSPECT, V15, P626, DOI 10.1358/dnp.2002.15.10.740239
   Rutkowski MD, 2002, SPINE, V27, P1604, DOI 10.1097/00007632-200208010-00003
   SAAL JA, 1990, SPINE, V15, P683, DOI 10.1097/00007632-199007000-00013
   SAAL JA, 1989, SPINE, V14, P431, DOI 10.1097/00007632-198904000-00018
   SAAL JS, 1990, SPINE, V15, P674, DOI 10.1097/00007632-199007000-00011
   Shieh SH, 2016, TAIWAN J OBSTET GYNE, V55, P525, DOI 10.1016/j.tjog.2016.06.013
   SMYTH MJ, 1958, J BONE JOINT SURG AM, V40, P1401, DOI 10.2106/00004623-195840060-00016
   Stafford MA, 2007, BRIT J ANAESTH, V99, P461, DOI 10.1093/bja/aem238
   SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6
   Takada Eiichi, 2001, J Orthop Surg (Hong Kong), V9, P1
   Takebayashi T, 2001, SPINE, V26, P940, DOI 10.1097/00007632-200104150-00018
   THELANDER U, 1992, SPINE, V17, P395, DOI 10.1097/00007632-199204000-00003
   Truumees E, 2015, CLIN ORTHOP RELAT R, V473, P1885, DOI 10.1007/s11999-014-3633-7
   WEBER H, 1993, SPINE, V18, P1433, DOI 10.1097/00007632-199309010-00006
   WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003
   WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003
   Winkelstein BA, 2004, J BIOMECH ENG-T ASME, V126, P258, DOI 10.1115/1.1695571
   Winkelstein BA, 2002, BRAIN RES, V956, P294, DOI 10.1016/S0006-8993(02)03560-6
   Winkelstein BA, 2001, J NEUROSCI METH, V111, P49, DOI 10.1016/S0165-0270(01)00445-9
   Yabuki S, 1998, SPINE, V23, P2517, DOI 10.1097/00007632-199812010-00006
   Zwart JA, 1998, ACTA NEUROL SCAND, V97, P41
NR 91
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 114
EP 121
DI 10.1016/j.wneu.2019.04.147
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100151
PM 31028982
DA 2020-05-12
ER

PT J
AU Ishiguro, T
   Satow, T
   Okada, A
   Hamano, E
   Ikeda, G
   Chikuie, H
   Koiso, T
   Hashimura, N
   Nishimura, M
   Takahashi, JC
AF Ishiguro, Taichi
   Satow, Tetsu
   Okada, Akihiro
   Hamano, Eika
   Ikeda, Go
   Chikuie, Hidekazu
   Koiso, Takao
   Hashimura, Naoki
   Nishimura, Masaki
   Takahashi, Jun C.
TI Spontaneous Persistent Primitive Trigeminal Artery-Cavernous Sinus
   Fistula Successfully Treated by Multipronged Coil Embolization: Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous sinus; Embolization; Fistulae; Multipronged; Persistent
   primitive trigeminal artery
ID TRANSVENOUS EMBOLIZATION; BALLOON
AB BACKGROUND: A spontaneous persistent primitive trigeminal artery-cavernous sinus fistula (PCF) is extremely rare. Until recently, endovascular treatment for PCF involving transarterial and/or transvenous coil embolization of the cavernous sinus (with/without the persistent trigeminal artery) was commonly performed. However, it may result in remaining shunt flow or exacerbation of cranial nerve palsy.
   CASE DESCRIPTION: A 51-year-old woman presented with headache and left abducens palsy. Digital subtraction angiography demonstrated a direct fistula between the cavernous segment of the persistent primitive trigeminal artery (PPTA) and posterosuperior compartment of the left cavernous sinus (CS). Three microcatheters were guided into the fistula as follows: 1) through the PPTA to the CS from the left internal carotid artery, 2) through the PPTA to the CS from the basilar artery, and 3) through the CS to the PPTA from the internal jugular vein. Using the double-catheter technique in a multidirectional fashion, shunt occlusion was achieved with a small number of coils. No signs of recurrence were observed during the follow-up period.
   CONCLUSIONS: The multipronged approach is safe and effective for embolization of a small tortuous artery and shunt segment to avoid incomplete shunt occlusion.
C1 [Ishiguro, Taichi; Satow, Tetsu; Okada, Akihiro; Hamano, Eika; Ikeda, Go; Chikuie, Hidekazu; Koiso, Takao; Hashimura, Naoki; Nishimura, Masaki; Takahashi, Jun C.] Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Osaka, Japan.
RP Satow, T (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Osaka, Japan.
EM tetsus@ncvc.go.jp
CR Alcala-Cerra Gabriel, 2012, Surg Neurol Int, V3, P111, DOI 10.4103/2152-7806.101798
   Bernstein K, 1998, AM J NEURORADIOL, V19, P1953
   Chan Y. L., 2006, Hong Kong Medical Journal, V12, P310
   Geibprasert S, 2008, ACTA NEUROCHIR, V150, P583, DOI 10.1007/s00701-008-1496-3
   Hurst RW, 1998, SKULL BASE SURG, V8, P225, DOI 10.1055/s-2008-1058188
   Ito Y, 2019, WORLD NEUROSURG, V122, P123, DOI 10.1016/j.wneu.2018.10.158
   KERBER CW, 1983, J NEUROSURG, V58, P611, DOI 10.3171/jns.1983.58.4.0611
   Masaryk TJ, 1999, AM J NEURORADIOL, V20, P1103
   Miller TR, 2015, J NEUROINTERV SURG, V7, P73, DOI 10.1136/neurintsurg-2013-010932
   Nishino K, 2008, J NEUROSURG, V109, P208, DOI 10.3171/JNS/2008/109/8/0208
   OHSHIRO S, 1993, NEUROSURGERY, V32, P144, DOI 10.1227/00006123-199301000-00025
   Oka Y, 2000, NEUROL MED-CHIR, V40, P61, DOI 10.2176/nmc.40.61
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P329, DOI 10.3109/00016925909171103
   Satow T, 2013, NEUROSURGERY, V73, P100, DOI 10.1227/NEU.0b013e31828ba578
   Tokunaga K, 2004, J NEUROSURG, V101, P697, DOI 10.3171/jns.2004.101.4.0697
   Yeh C-H, 2012, AJNR Am J Neuroradiol, V33, pE7, DOI 10.3174/ajnr.A2416
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 122
EP 126
DI 10.1016/j.wneu.2019.05.003
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100152
PM 31078800
OA Bronze
DA 2020-05-12
ER

PT J
AU Goethe, EA
   Youssef, M
   Patel, AJ
   Jalali, A
   Goodman, JC
   Mandel, JJ
AF Goethe, Eric A.
   Youssef, Michael
   Patel, Akash J.
   Jalali, Ali
   Goodman, J. Clay
   Mandel, Jacob J.
TI Recurrent Papillary Glioneuronal Tumor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Papillary glioneuronal tumor; Recurrent tumor
ID FEATURES; CDKN2A
AB BACKGROUND: Papillary glioneuronal tumors (PGNTs) are rare World Health Organization grade I neoplasms that are characterized by a benign course and excellent response to surgical resection. A few reports exist of tumors with more aggressive clinical and histologic features. In this report we detail the case of an unusually aggressive PGNT in a 67-year-old woman.
   CASE DESCRIPTION: The patient had a 3-year history of seizures and was diagnosed with a frontoparietal mass on imaging. She underwent subtotal resection with a histologic diagnosis of PGNT. Less than a year after surgery, the patient experienced recurrence of disease and underwent reresection and adjuvant radiation treatment. The patient's disease continued to progress despite radiation treatment, so adjuvant temozolomide was initiated. Molecular testing was performed and revealed a TERT promotor mutation, an FGFR3-TACC3 oncogenic fusion, and a copy number loss in CDKN2A/CDKN2B.
   CONCLUSIONS: PGNTs, while typically benign, can rarely recur after surgery. Molecular testing should be performed on all PGNTs to help possibly identify more aggressive tumors and potentially reveal novel treatment options.
C1 [Goethe, Eric A.; Mandel, Jacob J.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
   [Youssef, Michael] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
   [Patel, Akash J.; Jalali, Ali] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Goodman, J. Clay] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
RP Mandel, JJ (reprint author), Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
EM Jacob.mandel@bcm.edu
CR Ahmed AK, 2017, WORLD NEUROSURG, V107, P534, DOI 10.1016/j.wneu.2017.08.041
   Alvarez-Breckenridge C., 2017, ONCOL, V1, P5, DOI DOI 10.1038/s41698-017-0009-y
   Braun M, 2017, LEUKEMIA LYMPHOMA, V58, P1162, DOI 10.1080/10428194.2016.1228925
   Bridge JA, 2013, BRAIN PATHOL, V23, P121, DOI 10.1111/j.1750-3639.2012.00612.x
   Carangelo B, 2015, G CHIR, V36, P63, DOI 10.11138/gchir/2015.36.2.063
   Castro JC, 2019, NEUROCIRUGIA, V30, P144, DOI 10.1016/j.neucir.2018.04.003
   Delfau-Larue MH, 2015, BLOOD, V126, P604, DOI 10.1182/blood-2015-02-628792
   Demetriades AK, 2013, BRIT J NEUROSURG, V27, P401, DOI 10.3109/02688697.2012.741735
   Doxtader EE, 2018, DIAGN CYTOPATHOL, V46, P284, DOI 10.1002/dc.23885
   Frink RE, 2016, ONCOTARGET, V7, P31639, DOI 10.18632/oncotarget.9335
   Fujita Y, 2018, J SURG CASE REP, DOI 10.1093/jscr/rjy123
   Hou YH, 2019, ACTA NEUROPATHOL, V137, P837, DOI 10.1007/s00401-019-01969-2
   Ishizawa T, 2006, HUM PATHOL, V37, P627, DOI 10.1016/j.humpath.2005.12.014
   Javahery RJ, 2009, J NEUROSURG-PEDIATR, V3, P46, DOI 10.3171/2008.10.PEDS08242
   Lavrnic S, 2012, J NEUROL SURG PART A, V73, P224, DOI 10.1055/s-0032-1313636
   Li D, 2014, ACTA NEUROCHIR, V156, P627, DOI 10.1007/s00701-014-2023-y
   Mittal N, 2017, INTERDISCIP NEUROSUR, V7, P44, DOI 10.1016/j.inat.2016.11.010
   Momota H, 2015, NEUROPATHOLOGY, V35, P603, DOI 10.1111/neup.12215
   Pages M, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0264-5
   Tan WL, 2014, J COMPUT ASSIST TOMO, V38, P634, DOI 10.1097/RCT.0000000000000109
   Vaquero J, 2007, J NEURO-ONCOL, V83, P319, DOI 10.1007/s11060-007-9333-3
   Xiao H, 2011, J NEUROIMAGING, V21, P297, DOI 10.1111/j.1552-6569.2010.00478.x
   Yadav N, 2017, EUR J RADIOL, V97, P44, DOI 10.1016/j.ejrad.2017.10.004
   Zhao RJ, 2016, ACTA NEUROCHIR, V158, P695, DOI 10.1007/s00701-016-2744-1
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 127
EP 130
DI 10.1016/j.wneu.2019.04.266
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100153
PM 31078809
DA 2020-05-12
ER

PT J
AU Alattar, AA
   Bartek, J
   Chian, VL
   Mohammadi, AM
   Barnett, GH
   Sloan, A
   Chen, CC
AF Alattar, Ali A.
   Bartek, Jiri, Jr.
   Chian, Veronica L.
   Mohammadi, Alireza M.
   Barnett, Gene H.
   Sloan, Andrew
   Chen, Clark C.
TI Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring
   after Stereotactic Radiosurgery: A Systematic Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain metastases recurring after stereotactic radiosurgery; Laser
   interstitial thermal therapy; LITT; SLA; Stereotactic laser ablation
ID INTERSTITIAL THERMAL THERAPY; RADIATION NECROSIS; LUNG-CANCER;
   MANAGEMENT; LESIONS; OUTCOMES
AB BACKGROUND: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option.
   OBJECTIVE: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course.
   METHODS: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS.
   RESULTS: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%-100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1-2 days (range, 1-5 days), and most treated patients were discharged home (range, 59.5%-100%).
   CONCLUSION: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.
C1 [Alattar, Ali A.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Bartek, Jiri, Jr.] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Karolinska Inst, Dept Clin Neurosci & Med, Stockholm, Sweden.
   [Bartek, Jiri, Jr.] Rigshosp, Dept Neurosurg, Copenhagen, Denmark.
   [Chian, Veronica L.] Yale Med Sch, Dept Neurosurg, New Haven, CT USA.
   [Mohammadi, Alireza M.; Barnett, Gene H.] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
   [Mohammadi, Alireza M.; Barnett, Gene H.] Case Comprehens Canc Ctr, Cleveland, OH USA.
   [Sloan, Andrew] Univ Hosp Cleveland, Dept Neurosurg, Siedman Canc Ctr, Cleveland, OH 44106 USA.
   [Sloan, Andrew] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA.
   [Chen, Clark C.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Chen, CC (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM ccchen@umn.edu
RI Sloan, Andrew/AAE-9842-2020
FU UC San Diego School of Medicine
FX C.C. Chen has received honoraria from Monteris, MRI Interventions, and
   Varian Medical Systems; he is in a consulting advisory role to Tocagen;
   he is on the Speaker's Bureau for Varian Medical Systems; and has
   received research funding from Medtronic. This work was supported by a
   Clinical Research Fellowship from UC San Diego School of Medicine (to
   A.A.A).
CR Ahluwalia M, 2019, J NEUROSURG, V130, P804, DOI 10.3171/2017.11.JNS171273
   Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003
   Ali MA, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16227
   Arvold ND, 2016, NEURO-ONCOLOGY, V18, P1043, DOI 10.1093/neuonc/now127
   Barnett GH, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16319
   Brown DA, 2018, MAYO CLIN PROC, V93, P16, DOI 10.1016/j.mayocp.2017.08.023
   Carpentier A, 2008, NEUROSURGERY S1, V63
   Carpentier A, 2008, NEUROSURGERY, V63, P21, DOI [10.1227/01.NEU.0000311254.63848.72, 10.1227/01.neu.0000335007.07381.df]
   Carpentier A, 2011, LASER SURG MED, V43, P943, DOI 10.1002/lsm.21138
   Chaunzwa TL, 2018, NEUROSURGERY, V82, P56, DOI 10.1093/neuros/nyx142
   Christ Sebastian M, 2015, Surg Neurol Int, V6, pS355, DOI 10.4103/2152-7806.163315
   Del Rivero J, 2016, TRANSL LUNG CANCER R, V5, P727, DOI 10.21037/tlcr.2016.11.08
   Emens LA, 2017, EUR J CANCER, V81, P116, DOI 10.1016/j.ejca.2017.01.035
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Habboub G, 2017, J CLIN NEUROSCI, V35, P117, DOI 10.1016/j.jocn.2016.09.020
   Hawasli AH, 2013, NEUROSURGERY, V73, P1007, DOI 10.1227/NEU.0000000000000144
   Higuchi Yoshinori, 2018, Cancer Manag Res, V10, P1889, DOI 10.2147/CMAR.S116718
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040-8428(01)00179-2
   Jethwa PR, 2012, OPER NEUROSURG S, V71
   Kampinga HH, 2006, INT J HYPERTHER, V22, P191, DOI 10.1080/02656730500532028
   Koffer P, 2017, WORLD NEUROSURG, V104, P589, DOI 10.1016/j.wneu.2017.04.103
   McDuff SGR, 2013, J NEUROL NEUROSUR PS, V84, P1384, DOI 10.1136/jnnp-2013-305166
   Mckay WH, 2017, J NEUROSURG, V127, P148, DOI 10.3171/2016.5.JNS153051
   Moscetti L, 2007, CANCER-AM CANCER SOC, V109, P274, DOI 10.1002/cncr.22399
   Patel NV, 2013, LASER SURG MED, V45, P362, DOI 10.1002/lsm.22151
   Patel P, 2016, J NEUROSURG, V125, P853, DOI 10.3171/2015.7.JNS15244
   Pruitt R, 2017, J NEUROSURG, V126, P1238, DOI 10.3171/2016.3.JNS152147
   Rae Ali, 2016, Adv Radiat Oncol, V1, P294, DOI 10.1016/j.adro.2016.08.007
   Rao MS, 2014, NEUROSURGERY, V74, P658, DOI 10.1227/NEU.0000000000000332
   Rennert RC, 2018, WORLD NEUROSURG, V116, pE566, DOI 10.1016/j.wneu.2018.05.039
   Rennert RC, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16217
   Sawaya R, 1998, NEUROSURGERY, V42, P1044, DOI 10.1097/00006123-199805000-00054
   Schulze PC, 2004, ACTA NEUROCHIR, V146, P803, DOI 10.1007/s00701-004-0293-5
   Schwabe B, 1997, J COMPUT ASSIST TOMO, V21, P818, DOI 10.1097/00004728-199709000-00031
   Sharma M, 2016, EXPERT REV NEUROTHER, V16, P223, DOI 10.1586/14737175.2016.1135736
   Stockham AL, 2012, PROG NEUROL SURG, V25, P273, DOI 10.1159/000331200
   Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172
   Valiente M, 2018, TRENDS CANCER, V4, P176, DOI 10.1016/j.trecan.2018.01.003
   Venur VA, 2015, J CLIN ONCOL, V33
   Wang P, 2017, QUANT IMAGING MED SU, V7, P259, DOI 10.21037/qims.2017.03.05
   Wright J, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16233
NR 41
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 134
EP 142
DI 10.1016/j.wneu.2019.04.200
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100155
PM 31051303
DA 2020-05-12
ER

PT J
AU Aydoseli, A
   Ozgen, U
   Akgul, T
   Orhan, EK
   Achyamare, AE
   Can, H
   Karadag, C
AF Aydoseli, Aydin
   Ozgen, Utku
   Akgul, Turgut
   Orhan, Elif Kocasoy
   Achyamare, Ali Ekrem
   Can, Halil
   Karadag, Cihat
TI Subacute Traumatic Ascending Myelopathy in a 28-Year-Old Man: A Rare
   Case
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ascending myelopathy; Gunshot injury; Neurologic deterioration; Spinal
   cord edema
ID SPINAL-CORD-INJURY; POSTTRAUMATIC MYELOMALACIC MYELOPATHY; NEUROLOGIC
   DETERIORATION; APOPTOSIS; FEATURES
AB BACKGROUND: Subacute posttraumatic ascending myelopathy (SPAM) involves the rise in high signal intensity on T2-weighted images >= 4 vertebral segments above the initial injured site, and it usually occurs within the first few weeks after the injury. The pathophysiologic mechanisms of traumatic spinal cord damage are not clearly understood; however, there are some pathophysiologic processes such as arterial thrombosis, venous thrombosis, congestive ischemia, inflammatory or autoimmune reaction, and infection in the form of meningitis or myelitis that could lead to SPAM.
   CASE DESCRIPTION: We present a case of T7 fracture because of left shoulder gunshot injury and ascending myelopathy up to the C2 vertebra level, which occurred 1 week after the gunshot injury, without pretraumatic cervical injury or syringomyelia. Although control magnetic resonance imaging findings showed the second rise in the high signal intensity level of the spinal cord, T2-weighted signal intensity and cord edema decreased and the patient showed neurologic improvement.
   CONCLUSIONS: This was the first case in the literature that showed rise 2 times in high signal intensity level in the spinal cord because of gunshot injury. Inflammatory reactions and secondary injury processes might have led to neurologic deterioration and ascending myelopathy in our case; therefore, the patient may have shown neurologic improvement after methylprednisolone therapy because of its anti-inflammatory and antiedema effects. There is no clear evidence whether neurologic improvement is associated with steroid therapy or it is because of the natural course of SPAM.
C1 [Aydoseli, Aydin; Ozgen, Utku; Achyamare, Ali Ekrem] Istanbul Univ, Istanbul Med Fac, Dept Neurosurg, Istanbul, Turkey.
   [Akgul, Turgut] Istanbul Univ, Istanbul Med Fac, Dept Orthopaed & Traumatol, Istanbul, Turkey.
   [Orhan, Elif Kocasoy] Istanbul Univ, Istanbul Med Fac, Dept Neurol, Istanbul, Turkey.
   [Can, Halil] Biruni Univ, Dept Neurosurg, Med Hosp, Istanbul, Turkey.
   [Can, Halil] Biruni Univ, Dept Neurosurg, Istanbul, Turkey.
   [Karadag, Cihat] Univ Hosp Dusseldorf, Dept Neurosurg, Dusseldorf, Germany.
RP Ozgen, U (reprint author), Istanbul Univ, Istanbul Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM utkuozen3661@hotmail.com
RI Orhan, Elif Kocasoy/AAD-4657-2020; AKGUL, Turgut/AAC-7522-2020
OI ADIYAMAN, Ali Ekrem/0000-0002-4284-8611
CR Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18
   Aito S, 1999, SPINAL CORD, V37, P617, DOI 10.1038/sj.sc.3100872
   Al-Ghatany M, 2005, J NEUROSURG-SPINE, V2, P619, DOI 10.3171/spi.2005.2.5.0619
   Belanger E, 2000, J NEUROSURG, V93, P294, DOI 10.3171/spi.2000.93.2.0294
   Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73
   Dizdaroglu M, 2012, FREE RADICAL RES, V46, P382, DOI 10.3109/10715762.2011.653969
   FALCONE S, 1994, AM J NEURORADIOL, V15, P747
   Fehlings MG, 2011, J NEUROSURG-SPINE, V14, P570, DOI 10.3171/2010.4.SPINE1047
   Frankel H L, 1969, Paraplegia, V7, P111
   Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008
   Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483
   Kovanda TJ, 2014, J NEUROSURG-SPINE, V21, P454, DOI 10.3171/2014.5.SPINE13754
   Kumar A, 2010, EMERG RADIOL, V17, P249, DOI 10.1007/s10140-009-0832-8
   Kumar R, 2018, WORLD NEUROSURG, V113, pE345, DOI 10.1016/j.wneu.2018.02.033
   Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007
   LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9
   Lee TT, 1997, J NEUROSURG, V86, P624, DOI 10.3171/jns.1997.86.4.0624
   Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022
   Meagher TM, 2012, SPINAL CORD, V50, P638, DOI 10.1038/sc.2011.133
   Miller BA, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.11.058
   Okada S, 2014, SPINE J, V14, pE9, DOI 10.1016/j.spinee.2014.08.449
   Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149
   Planner AC, 2008, SPINAL CORD, V46, P140, DOI 10.1038/sj.sc.3102056
   QUENCER RM, 1983, RADIOLOGY, V146, P415, DOI 10.1148/radiology.146.2.6849087
   Schanne FAX, 2013, CALCIUM DEPENDENCE T, V206, P700
   Schmidt BJ, 2006, SPINAL CORD, V44, P322, DOI 10.1038/sj.sc.3101801
   VERNON JD, 1982, PARAPLEGIA, V20, P339, DOI 10.1038/sc.1982.64
   Visocchi M, 2003, ACTA NEUROCHIR, V145, P799, DOI 10.1007/s00701-003-0082-6
   Weinglass AB, 2008, ASSAY DRUG DEV TECHN, V6, P255, DOI 10.1089/adt.2008.125
   YABLON IG, 1989, SPINE, V14, P1084, DOI 10.1097/00007632-198910000-00010
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 143
EP 148
DI 10.1016/j.wneu.2019.04.168
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100156
PM 31042601
DA 2020-05-12
ER

PT J
AU Lichterman, BL
   Wong, SN
   Likhterman, LB
AF Lichterman, Boleslav L.
   Wong, Shun Ning
   Likhterman, Leonid B.
TI A Humanist Neurosurgeon: A Legacy of Dr. Roy Selby
SO WORLD NEUROSURGERY
LA English
DT Article
DE Humanism; Malaysia; Medical ethics; Neurosurgery history; Neurosurgery
   training; Roy Selby
AB The article is dedicated to the life and work of Dr. Roy Selby (1930-2002), an American neurosurgeon who founded neurosurgery in Malaysia. Dr. Selby stayed in Malaysia from July 1963 to May 1970. He opened the first neurosurgical department at the general hospital in Kuala Lumpur and established a training program under which Malaysian physicians and nurses were sent to neurosurgery centers in the United States and Canada. Some physicians came back and headed local neurosurgical units. On his return to the United States, Dr. Selby practiced neurosurgery until 1986, when he had to give it up due to the impact of progressive congestive heart failure. From 1986 to 1994, Dr. Selby taught graduate courses in the Department of Psychology at East Texas State University, Texarkana, Texas. He was a pioneer of spinal surgery and founded the Lumbar Spine Society. Dr. Selby was a world citizen neurosurgeon and advocated international standards of training in neurosurgery. From 1985 to 1994, he was chairman of the Archives Committee of the American Association of Neurological Surgeons. Dr. Selby serves as a model of a physician as a humanist.
C1 [Lichterman, Boleslav L.] Dept Humanities, Moscow, Russia.
   [Wong, Shun Ning] IM Sechenov First Moscow State Med Univ, Moscow, Russia.
   [Likhterman, Leonid B.] NN Burdenko Natl Med Res Ctr Neurosurg, Moscow, Russia.
RP Lichterman, BL (reprint author), Dept Humanities, Moscow, Russia.
EM litchterman@hotmail.com
CR American Humanist Society, 2019, DEF HUM
   [Anonymous], 1996, RETIRED SURG PUTS HE
   ARUMUGASAMY N, 1979, NEUROSURGERY, V5, P528, DOI 10.1227/00006123-197910000-00023
   BERGLAND RM, 1973, NEW ENGL J MED, V288, P1043, DOI 10.1056/NEJM197305172882004
   Cheah AF, 2003, TRIBUTE DATO N ARUMU
   Friedell MT, 1973, INT SURG, V58, P524
   Ghee LK, 2016, HIST MED HLTH MALAYS
   Gilbert T., 1996, TEXARKANA GAZET 0313
   Lichterman BL, 2007, NEUROSURGERY EMERGEN
   LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184
   Piatigorsky A., 2002, MEDITSYNSKAYA G 0215
   Raffiq A, 2015, MALAYS J MED SCI, V22, P5
   SELBY R, 1972, J NEUROSURG, V36, P225, DOI 10.3171/jns.1972.36.2.0225
   Selby R, 1973, Int Surg, V58, P536
   Selby R, 1973, Int Surg, V58, P524
   Selby R, 1973, Int Surg, V58, P523
   Selby R, 1973, Int Surg, V58, P444
   SELBY R, 1994, J NEURO-ONCOL, V18, P175, DOI 10.1007/BF01328951
   SELBY R, 1974, SURG NEUROL, V2, P326
   SELBY R, 1979, NEUROSURGERY, V5, P535, DOI 10.1227/00006123-197910000-00026
   SELBY R, 1983, SURG NEUROL, V19, P393, DOI 10.1016/0090-3019(83)90257-4
   Selby R., 1996, NEUROSURGERY
   Selby R., 1973, INT SURG, V64, P5
   Selby R., 1973, TROPICAL NEUROLOGY, P299
   SELBY RC, 1974, SURG NEUROL, V2, P165
   SELBY RC, 1973, J NEUROSURG, V38, P40, DOI 10.3171/jns.1973.38.1.0040
   Selby Roy C., 2002, ARKANSAS DEMOCRAT GA
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 149
EP 157
DI 10.1016/j.wneu.2019.04.178
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100157
PM 31042604
DA 2020-05-12
ER

PT J
AU Mohri, M
   Yamano, J
   Saito, K
   Nakada, M
AF Mohri, Masanao
   Yamano, Jun
   Saito, Katsuhiko
   Nakada, Mitsutoshi
TI Spinal Accessory Nerve Meningioma at the Foramen Magnum with Medullar
   Compression: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Foramen magnum; Meningioma; Spinal accessory nerve
AB BACKGROUND: Meningiomas that arise from the cranial nerve are rare. We present a case with an intradural extramedullary tumor at the foramen magnum originating from the spinal accessory nerve.
   CASE DESCRIPTION: The patient was a 69-year-old woman with dizziness and pain in the bilateral shoulder for 2 years. Neurologic examination revealed spinal accessory nerve palsy (difficult in raising the shoulder, deficit of 3/5) on the left side without further deficits. Magnetic resonance imaging showed medullar compression because of a left intradural extramedullary foramen magnum lesion dorsolateral to the medulla. Surgical exposure via a midline suboccipital approach with C1 laminectomy revealed that the lesion arises from the left accessory nerve without dural attachment. The tumor was resected without injury to the spinal accessory nerve, and histologic examination revealed that it was a meningothelial meningioma. The spinal accessory nerve palsy improved to 4 of 5 after 3 months after surgery.
   CONCLUSIONS: To our knowledge, this is the first report of an accessory nerve meningioma at the foramen magnum in which the spinal accessory nerve palsy appeared before operation and improved after tumor resection.
C1 [Mohri, Masanao; Yamano, Jun] Toyama City Hosp, Dept Neurosurg, Toyama, Japan.
   [Saito, Katsuhiko] Toyama City Hosp, Dept Pathol, Toyama, Japan.
   [Nakada, Mitsutoshi] Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
RP Mohri, M (reprint author), Toyama City Hosp, Dept Neurosurg, Toyama, Japan.
EM mmohri@tch.toyama.toyama.jp
CR Fujimoto Y, 2004, J NEURO-ONCOL, V68, P185, DOI 10.1023/B:NEON.0000027774.19801.af
   Hart AJ, 1998, J NEUROSURG, V88, P1104, DOI 10.3171/jns.1998.88.6.1104
   Kurokawa R, 2004, NEUROSURGERY, V54, P510, DOI 10.1227/01.NEU.0000103676.82231.91
   Liechty P, 2007, FOLIA NEUROPATHOL, V45, P23
   MEYER FB, 1984, J NEUROSURG, V61, P136, DOI 10.3171/jns.1984.61.1.0136
   Missori Paolo, 2017, Surg Neurol Int, V8, P187, DOI 10.4103/sni.sni_200_17
   NG THK, 1989, J NEUROSURG, V70, P646, DOI 10.3171/jns.1989.70.4.0646
   Tatagiba M, 2005, ACTA NEUROCHIR, V147, P909, DOI 10.1007/s00701-005-0520-8
   Thome C, 2003, ACTA NEUROCHIR, V145, P309, DOI 10.1007/s00701-002-1059-6
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 158
EP 161
DI 10.1016/j.wneu.2019.05.013
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100158
PM 31082561
DA 2020-05-12
ER

PT J
AU Amirjamshidi, A
   Abbasioun, K
   Ghassemi, B
   Hamidi, M
AF Amirjamshidi, Abbas
   Abbasioun, Kazem
   Ghassemi, Babak
   Hamidi, Mehrdokht
TI Solitary Metastasis of Adenocarcinoma of Submandibular Gland to Choroid
   Plexus in Cerebellopontine Angle: First Case Reported in Literature
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adenocarcinoma; Choroid plexus metastasis; Submandibular gland
ID CARCINOMA; HEAD
AB BACKGROUND: Adenocarcinoma of the salivary gland (AdCASG) is a rare and malignant tumor of the salivary glands. Albeit, metastatic lesions occur anecdotally in the choroid plexus and most rarely in the cerebellopontine angle (CPA). We report the first case of metastatic AdCASG to the choroid plexus of the lateral recess of the fourth ventricle located in CPA, emphasizing the clinical presentation and neuroradiologic findings.
   CASE DESCRIPTION: A 40-year-old man was referred with signs of increased intracranial pressure and a unilateral hearing problem. Magnetic resonance imaging showed a pear-shaped, vividly enhancing tumor in the left CPA. The tumor was a metastatic AdCASG. Gross total resection of the lesion was followed by a conventional radiotherapy lead in a 5-year tumor-free control interval.
   CONCLUSIONS: Metastatic lesions to the choroid plexus may show a pedunculated shape in magnetic resonance imaging. It is hypothesized that tumor seeding may occur through the veins, lymphatics, and nerve sheaths in the skull base region. Tissue specimen is necessary to confirm such rare pathology.
C1 [Amirjamshidi, Abbas] Sina Hosp, Dept Neurosurg, Tehran, Iran.
   [Abbasioun, Kazem; Ghassemi, Babak] Univ Tehran Med Sci, Arad Hosp, Dept Neurosurg, Tehran, Iran.
   [Hamidi, Mehrdokht] Univ Tehran Med Sci, Arad Hosp, Dept Pathol, Tehran, Iran.
RP Amirjamshidi, A (reprint author), Sina Hosp, Dept Neurosurg, Tehran, Iran.
EM abamirjamshidi@yahoo.com
OI amirjamshidi, abbas/0000-0002-5052-9485
CR Al-Anazi A, 2000, J NEUROSURG, V92, P506, DOI 10.3171/jns.2000.92.3.0506
   Arbelaez A, 1999, AM J NEURORADIOL, V20, P691
   Dudley RWR, 2015, J NEURO-ONCOL, V121, P201, DOI 10.1007/s11060-014-1628-6
   Escott EJ, 2001, RADIOGRAPHICS, V21, P625, DOI 10.1148/radiographics.21.3.g01ma19625
   FUKUI K, 1990, Neurologia Medico-Chirurgica, V30, P869, DOI 10.2176/nmc.30.869
   Hassaneen W, 2009, J NEURO-ONCOL, V91, P101, DOI 10.1007/s11060-008-9677-3
   Koeller KK, 2002, RADIOGRAPHICS, V22, P1473, DOI 10.1148/rg.226025118
   Leach JCD, 2004, J CLIN NEUROSCI, V11, P521, DOI 10.1016/j.jocn.2003.07.001
   MATSUDA M, 1991, SURG NEUROL, V36, P294, DOI 10.1016/0090-3019(91)90091-M
   Menon G, 2010, NEUROL INDIA, V58, P429, DOI 10.4103/0028-3886.66455
   Serrano-Arevalo ML, 2015, MED ORAL PATOL ORAL, V20, pE23, DOI 10.4317/medoral.19874
   Warren TA, 2016, J NEUROL SURG PART B, V77, P107, DOI 10.1055/s-0036-1579777
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 162
EP 164
DI 10.1016/j.wneu.2019.04.243
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100159
PM 31077898
DA 2020-05-12
ER

PT J
AU Wan, KR
   Kirollos, RW
   Lee, HY
   Low, DCY
   Ng, LP
   Seow, WT
   Low, SYY
AF Wan, Kai Rui
   Kirollos, Ramez W.
   Lee, Hwei Yee
   Low, David C. Y.
   Ng, Lee Ping
   Seow, Wan Tew
   Low, Sharon Y. Y.
TI Giant Aneurysm Arising from Anomalous Branch of the Middle Cerebral
   Artery in a Pediatric Patient: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intracranial aneurysm; Middle cerebral artery
ID INTRACRANIAL ANEURYSMS; CHILDREN; POPULATION; MANAGEMENT
AB BACKGROUND: Pediatric intracranial aneurysms are extremely rare. In this age group, cerebral vascular anomalies have been associated with the development of intracranial aneurysms.
   CASE DESCRIPTION: We present a case of a previously well 11-year-old boy presented with seizures secondary to a giant, unruptured, and partially thrombosed right middle cerebral artery (MCA) aneurysm. Extensive workup for underlying infective and autoimmune etiology was negative. Of interest, this vascular lesion was found to originate from an anomalous M2 branch, which ran an aberrant parallel course within the Sylvian fissure to the main and distally bifurcating MCA. The patient underwent successful surgical clipping and excision of the giant aneurysm.
   CONCLUSIONS: Because of the infrequency of the diagnosis, clinical pre-sentation, and its unique neurovascular anatomy, the management of this case is discussed in corroboration with current literature. In addition, highlighting this unusual case in an individual adds to the growing body of literature for better disease understanding, especially in the pediatric population.
C1 [Wan, Kai Rui; Kirollos, Ramez W.; Low, David C. Y.; Ng, Lee Ping; Seow, Wan Tew; Low, Sharon Y. Y.] KK Womens & Childrens Hosp, Neurosurg Serv, Singapore, Singapore.
   [Kirollos, Ramez W.; Low, David C. Y.; Seow, Wan Tew; Low, Sharon Y. Y.] Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.
   [Kirollos, Ramez W.; Low, David C. Y.; Seow, Wan Tew; Low, Sharon Y. Y.] SingHlth Duke NUS Neurosci Acad Clin Program, Singapore, Singapore.
   [Lee, Hwei Yee] Tan Tock Seng Hosp, Dept Pathol, Singapore, Singapore.
RP Low, SYY (reprint author), KK Womens & Childrens Hosp, Neurosurg Serv, Singapore, Singapore.; Low, SYY (reprint author), Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.; Low, SYY (reprint author), SingHlth Duke NUS Neurosci Acad Clin Program, Singapore, Singapore.
EM sharon.low.y.y@singhealth.com.sg
CR Aeron G, 2012, RADIOGRAPHICS, V32, P667, DOI 10.1148/rg.323105224
   Almefty K, 2014, WORLD NEUROSURG, V82, P40, DOI 10.1016/j.wneu.2013.03.064
   Ceylan S, 1998, NEUROSURG REV, V21, P189, DOI 10.1007/BF02389331
   Day AL, 2003, J NEUROSURG, V99, P228, DOI 10.3171/jns.2003.99.2.0228
   Deora H, 2017, PEDIATR NEUROSURG, V52, P313, DOI 10.1159/000477815
   Gemmete JJ, 2013, NEUROIMAG CLIN N AM, V23, P771, DOI 10.1016/j.nic.2013.03.018
   Ghali MGZ, 2018, WORLD NEUROSURG, V109, P418, DOI 10.1016/j.wneu.2017.09.150
   Pinto FCG, 2006, ARQ NEURO-PSIQUIAT, V64, P676, DOI 10.1590/S0004-282X2006000400031
   Goncalves VM, 2014, CASE REP MED, DOI 10.1155/2014/739862
   Huang J, 2005, SURG NEUROL, V63, P424, DOI 10.1016/j.surneu.2004.11.023
   Jian ZH, 2018, INT J CLIN EXP MED, V11, P6268
   Kong DS, 2008, ONCOL REP, V19, P639
   Koroknay-Pal P, 2012, STROKE, V43, P2091, DOI 10.1161/STROKEAHA.112.650077
   LaBorde DV, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.03.038
   Menshawi K, 2015, J STROKE, V17, P144, DOI 10.5853/jos.2015.17.2.144
   Park SH, 2008, J KOREAN NEUROSURG S, V44, P116, DOI 10.3340/jkns.2008.44.3.116
   Pruvot AS, 2016, NEUROCHIRURGIE, V62, P20, DOI 10.1016/j.neuchi.2013.06.004
   Ren HC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009947
   Requejo F, 2010, CHILD NERV SYST, V26, P1329, DOI 10.1007/s00381-010-1205-z
   Sekhar Laligam N, 2012, Clin Neurosurg, V59, P6
   Sorteberg A, 2013, CURR PEDIATR REV, V9, P343, DOI 10.2174/221155281120100005
   Uchiyama N, 2017, NEUROL MED-CHIR, V57, P261, DOI 10.2176/nmc.ra.2017-0043
   YAMAMOTO H, 1992, Neurologia Medico-Chirurgica, V32, P262, DOI 10.2176/nmc.32.262
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 165
EP 168
DI 10.1016/j.wneu.2019.05.012
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100160
PM 31082559
OA Bronze
DA 2020-05-12
ER

PT J
AU Lee, YL
   Kuo, JR
AF Lee, Yao-Lin
   Kuo, Jinn-Rung
TI Postobliteration Arteriovenous Malformation Mimicking Malignant Change
   30 Years After X-Knife Treatment-Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformation; Radiation-induced changes; Stereotactic
   radiosurgery; X-knife
ID RADIOSURGERY; EMBOLIZATION
AB BACKGROUND: Arteriovenous malformations (AVMs) are potentially dangerous vascular anomalies of the brain that can cause seizures or intracranial hemorrhage in patients if left untreated. Because full excision of these lesions is not always possible in deep or eloquent areas of the brain, radiosurgical advances have gone a long way in the control and treatment of AVMs. Postradiosurgery AVMs are followed closely via outpatient clinics with serial imaging every few months to assess AVM obliteration. Post X-knife treatment AVMs still carry with them some risk of rebleeding and even a chance of malignant transformation.
   CASE DESCRIPTION: In this article, we report a case of a post X-knife - (sic) arteriovenous malformation with the appearance of malignant change on magnetic resonance imaging and thallium-201 on follow-up 30 years after treatment. Imaging with magnetic resonance angiography showed obliteration of the lesion but progressive change in size with new soft tissue components, which suggests radiation-related secondary malignancy.
   CONCLUSIONS: Surgery was arranged, and pathology results indicate no malignant change.
C1 [Lee, Yao-Lin; Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Div Neurosurg, Dept Surg, Chimei Med Ctr, Tainan, Taiwan.
   [Kuo, Jinn-Rung] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
RP Kuo, JR (reprint author), Southern Taiwan Univ Sci & Technol, Div Neurosurg, Dept Surg, Chimei Med Ctr, Tainan, Taiwan.; Kuo, JR (reprint author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.
EM kuojinnrung@gmail.com
CR Bowden G, 2014, J NEUROSURG, V121, P637, DOI 10.3171/2014.5.JNS132244
   Ilyas A, 2018, J NEUROSURG, V128, P1354, DOI 10.3171/2016.12.JNS162478
   KIM KT, 1990, J NUCL MED, V31, P965
   Lawton MT, 2003, NEUROSURGERY, V52, P740, DOI 10.1227/01.NEU.0000053220.02268.9C
   LUESSENHOP AJ, 1960, JAMA-J AM MED ASSOC, V172, P1153, DOI 10.1001/jama.1960.63020110001009
   Parkhutik V, 2013, NEURORADIOLOGY, V55, P405, DOI 10.1007/s00234-012-1115-8
   Paul L, 2014, NEUROSURGERY, V75, P568, DOI 10.1227/NEU.0000000000000506
   Sheehan J, 2006, J NEUROSURG, V105, P325, DOI 10.3171/jns.2006.105.2.325
   SPETZLER RF, 1987, J NEUROSURG, V67, P17, DOI 10.3171/jns.1987.67.1.0017
   STEINER L, 1972, ACTA CHIR SCAND, V138, P459
   Yamamoto M, 1996, SURG NEUROL, V45, P110, DOI 10.1016/S0090-3019(96)80003-6
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 169
EP 173
DI 10.1016/j.wneu.2019.04.263
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100161
PM 31078806
OA Bronze
DA 2020-05-12
ER

PT J
AU Spille, DC
   Sporns, PB
   Hess, K
   Stummer, W
   Brokinkel, B
AF Spille, Dorothee Caecilia
   Sporns, Peter B.
   Hess, Katharina
   Stummer, Walter
   Brokinkel, Benjamin
TI Prediction of High-Grade Histology and Recurrence in Meningiomas Using
   Routine Preoperative Magnetic Resonance Imaging: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Grading; Magnetic resonance imaging; Meningioma; Prognosis
ID PERITUMORAL BRAIN EDEMA; INTRACRANIAL MENINGIOMAS; ATYPICAL MENINGIOMAS;
   CYSTIC MENINGIOMA; FEATURES; BENIGN; GROWTH; MRI; DIFFERENTIATION;
   CLASSIFICATION
AB OBJECTIVE: Estimating the risk of recurrence after surgery remains crucial during care of patients with meningioma. Numerous studies identified correlations of characteristics on routine preoperative magnetic resonance imaging (MRI) with postoperative recurrence or high-grade histology but showed partially inconclusive results.
   METHODS: A systematic review of the literature was performed about findings on preoperative MRI and their correlation with high-grade histology and recurrence. Quality of the included studies was analyzed using standardized Quality Assessment of Diagnostic Accuracy Studies criteria.
   RESULTS: Among the 35 studies included, quality of the series according to the Quality Assessment of Diagnostic Accuracy Studies criteria differed widely. Remarkably, MRI variables found to be associated with high-grade histology were commonly not consistently associated with prognosis and vice versa. Correlations of the tumor size, the peritumoral edema size, and contrast-enhancement of the tumor capsule with high-grade histology were controversial. In most studies, non-skull base tumor location, cyst formation, heterogenous contrast-enhancement, an irregular tumor shape, and disruption of the tumor/brain border but not intensity of the lesion on T2-weighted images, calcifications, or bone involvement were associated with grade II/III histology. Although tumor and edema size were usually found to correlate with recurrence, heterogenous contrast enhancement, cyst formation, intensity of the tumor on T2-weighted MRI, and enhancement of the tumor capsule were mostly not related with progression.
   CONCLUSIONS: Several mostly consistent but partially inconsistent variables associated with high-grade histology or prognosis were identified. Although standardized studies are needed to provide further clarification, consideration of these findings can help to improve estimation of prognosis and can therefore improve postoperative care in patients with meningioma.
C1 [Spille, Dorothee Caecilia; Stummer, Walter; Brokinkel, Benjamin] Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
   [Sporns, Peter B.] Univ Hosp Munster, Inst Clin Radiol, Munster, Germany.
   [Hess, Katharina] Univ Hosp Munster, Inst Neuropathol, Munster, Germany.
RP Spille, DC (reprint author), Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
EM dorotheecaecilia.spille@ukmuenster.de
RI Stummer, Walter/AAF-9043-2019; Stummer, Walter/AAA-3319-2020
OI Sporns, Peter Bernhard/0000-0002-3028-0539; Hess,
   Katharina/0000-0003-3922-6413; Brokinkel, Benjamin/0000-0003-3462-3479
CR Adeli Alborz, 2018, Oncotarget, V9, P35974, DOI 10.18632/oncotarget.26313
   Anthofer J, 2017, WORLD NEUROSURG, V104, P560, DOI 10.1016/j.wneu.2017.05.025
   Arita H, 2012, J NEURO-ONCOL, V107, P379, DOI 10.1007/s11060-011-0759-2
   Azizyan A, 2014, BIOMED RES INT, DOI 10.1155/2014/650939
   Bano S, 2013, ACTA RADIOL OPEN, V2, DOI 10.1177/2047981613512484
   Boukobza M, 2016, ACTA NEUROCHIR, V158, P1955, DOI 10.1007/s00701-016-2898-x
   Budohoski KP, 2018, ACTA NEUROCHIR, V160, P1813, DOI 10.1007/s00701-018-3593-x
   BUETOW MP, 1991, RADIOGRAPHICS, V11, P1087, DOI 10.1148/radiographics.11.6.1749851
   Chen TY, 2004, CLIN IMAG, V28, P10, DOI 10.1016/S0899-7071(03)00032-9
   Cornelius JF, 2013, ACTA NEUROCHIR, V155, P407, DOI 10.1007/s00701-012-1611-y
   Czyz M, 2017, NEUROSURGERY, V80, P300, DOI 10.1093/neuros/nyw030
   Fujimoto T, 2011, NEUROL MED-CHIR, V51, P415, DOI 10.2176/nmc.51.415
   GOLDSHER D, 1990, RADIOLOGY, V176, P447, DOI 10.1148/radiology.176.2.2367659
   Hale AT, 2018, J CLIN NEUROSCI, V48, P71, DOI 10.1016/j.jocn.2017.11.013
   Hashiba T, 2006, BRAIN TUMOR PATHOL, V23, P49, DOI 10.1007/s10014-006-0199-4
   Hess K, 2019, J NEUROSURG, V130, P789, DOI 10.3171/2017.11.JNS172265
   Hsu CC, 2010, J CLIN NEUROSCI, V17, P584, DOI 10.1016/j.jocn.2009.09.018
   Hwang WL, 2016, NEURO-ONCOLOGY, V18, P863, DOI 10.1093/neuonc/nov285
   Ibe M, 1996, CANCER-AM CANCER SOC, V78, P133, DOI 10.1002/(SICI)1097-0142(19960701)78:1<133::AID-CNCR19>3.0.CO;2-0
   Ildan F, 2007, SKULL BASE-INTERD AP, V17, P157, DOI 10.1055/s-2007-970554
   Jensen R, 2012, NEUROSURGERY, V71, P146, DOI 10.1227/NEU.0b013e3182567886
   Joo B, 2018, EUR RADIOL, V28, P331, DOI 10.1007/s00330-017-4962-1
   Juratli TA, 2017, ONCOTARGET, V8, P109228, DOI 10.18632/oncotarget.22650
   Kasuya H, 2006, NEUROSURG REV, V29, P293, DOI 10.1007/s10143-006-0039-3
   Katz LM, 2018, ACTA NEUROPATHOL, V135, P955, DOI 10.1007/s00401-018-1844-9
   Kawahara Y, 2012, J NEURO-ONCOL, V108, P147, DOI 10.1007/s11060-012-0809-4
   Ko C-C, 2018, J NEUROONCOL S1, V99, P307
   Lee EJ, 2017, J NEUROSURG, V127, P971, DOI 10.3171/2016.9.JNS161669
   Lee JW, 2009, EUR J NUCL MED MOL I, V36, P1574, DOI 10.1007/s00259-009-1133-x
   Li H, 2016, NEUROSURG REV, V39, P663, DOI 10.1007/s10143-016-0716-9
   Li H, 2016, WORLD NEUROSURG, V91, P89, DOI 10.1016/j.wneu.2016.03.079
   Lin BJ, 2014, J NEUROSURG, V121, P1201, DOI 10.3171/2014.7.JNS132359
   Liu H, 2016, J CRANIOFAC SURG, V27, pE229, DOI 10.1097/SCS.0000000000002361
   Louis DN, 2016, WHO CLASSIFICATION T
   Thenier-Villa J, 2017, NEUROL MED-CHIR, V57, P35, DOI 10.2176/nmc.oa.2016-0169
   Maiuri F, 1999, EUR J RADIOL, V31, P69, DOI 10.1016/S0720-048X(98)00083-7
   Mantle RE, 1999, J NEUROSURG, V91, P375, DOI 10.3171/jns.1999.91.3.0375
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
   Nakasu S, 1999, J NEUROSURG, V90, P455, DOI 10.3171/jns.1999.90.3.0455
   Nanda A, 2016, J CLIN NEUROSCI, V31, P112, DOI 10.1016/j.jocn.2016.02.021
   Nowak A, 2015, NEUROL NEUROCHIR POL, V49, P1, DOI 10.1016/j.pjnns.2014.11.003
   Pond JB, 2015, AM J NEURORADIOL, V36, P1253, DOI 10.3174/ajnr.A4309
   Qi ST, 2012, J NEUROSURG, V117, P645, DOI 10.3171/2012.6.JNS111987
   Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9
   Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377
   Sartor K, 1999, EUR RADIOL, V9, P1047, DOI 10.1007/s003300050790
   Schob S, 2016, TRANSL ONCOL, V9, P274, DOI 10.1016/j.tranon.2016.05.003
   SCHORNER W, 1990, NEURORADIOLOGY, V32, P12, DOI 10.1007/BF00593935
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Spille DC, 2016, WORLD NEUROSURG, V93, P346, DOI 10.1016/j.wneu.2016.06.055
   Todua F, 2012, Georgian Med News, P16
   Toh CH, 2008, AM J NEURORADIOL, V29, P1630, DOI 10.3174/ajnr.A1170
   Watanabe Y, 2013, EUR J RADIOL, V82, P658, DOI 10.1016/j.ejrad.2012.11.037
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   Wu QW, 2013, ASIAN PAC J CANCER P, V14, P6337, DOI 10.7314/APJCP.2013.14.11.6337
   Yashioka H, 1999, CANCER-AM CANCER SOC, V85, P936, DOI 10.1002/(SICI)1097-0142(19990215)85:4<936::AID-CNCR23>3.0.CO;2-J
NR 56
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 174
EP 181
DI 10.1016/j.wneu.2019.05.017
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100162
PM 31082555
OA Bronze
DA 2020-05-12
ER

PT J
AU Benyaich, Z
   Laghmari, M
   Lmejjati, M
   Aniba, K
   Ghannane, H
   Benali, SA
AF Benyaich, Zakariae
   Laghmari, Mehdi
   Lmejjati, Mohamed
   Aniba, Khalid
   Ghannane, Houssine
   Benali, Said Ait
TI Acute Lumbar Spinal Subdural Hematoma Inducing Paraplegia After Lumbar
   Spinal Manipulation: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cauda equina syndrome; Spinal manipulative therapy; Spinal subdural
   hematoma; Surgical decompression
ID IMAGING FINDINGS; RESOLUTION
AB BACKGROUND: Traumatic spinal subdural hematoma is an extremely rare occurrence that requires urgent investigation and most often prompt intervention. To our knowledge, this is the first reported case related to a spinal manipulative therapy.
   CASE DESCRIPTION: This report describes a case of traumatic lumbar subdual hematoma after a spinal manipulative therapy without any predisposing factor. A 23-year-old man was admitted to the emergency department for partial cauda equina syndrome after a spinal manipulation performed by a physiotherapist. Magnetic resonance imaging showed an acute spinal subdural hematoma at L2-L3 level with cauda equina compression. The patient underwent an emergency L2 laminectomy with evacuation of the hematoma. He recovered completely his neurologic functions after 1 week.
   CONCLUSION: Practitioners of spinal manipulations should be aware of spinal subdural hematoma as a possible complication. A rapid diagnosis with magnetic resonance imaging is mandatory, and emergency surgical decompression is usually the optimal treatment for spinal subdural hematomas with severe neurologic deficit.
C1 [Benyaich, Zakariae; Laghmari, Mehdi; Lmejjati, Mohamed; Aniba, Khalid; Ghannane, Houssine; Benali, Said Ait] Cadi Ayyad Univ Marrakech, Dept Neurosurg, Univ Hosp Ctr Marrakech, FMPM, Marrakech, Morocco.
RP Benyaich, Z (reprint author), Cadi Ayyad Univ Marrakech, Dept Neurosurg, Univ Hosp Ctr Marrakech, FMPM, Marrakech, Morocco.
EM zakariae.benyaich@gmail.com
OI Benyaich, Zakariae/0000-0002-3080-1373
CR Berhouma M, 2011, J CLIN NEUROSCI, V18, P569, DOI 10.1016/j.jocn.2010.07.127
   Cho DC, 2009, J SPINAL DISORD TECH, V22, P73, DOI 10.1097/BSD.0b013e31816d6546
   Cooper J, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.03.025
   EDELSON RN, 1974, ARCH NEUROL-CHICAGO, V31, P134, DOI 10.1001/archneur.1974.00490380082011
   Golden N, 2019, WORLD NEUROSURG, V123, P343, DOI 10.1016/j.wneu.2018.12.053
   Gordon WE, 2014, INTERDISCIP NEUROSUR, V1, P123, DOI 10.1016/j.inat.2014.09.003
   Hebert JJ, 2015, J MANIP PHYSIOL THER, V38, P677, DOI 10.1016/j.jmpt.2013.05.009
   Hung Kuo-Sheng, 2002, Spine (Phila Pa 1976), V27, pE534, DOI 10.1097/00007632-200212150-00024
   Izeki M, 2018, J ORTHOP SCI, V23, P857, DOI 10.1016/j.jos.2018.04.015
   JOHNSON PJ, 1991, ACTA NEUROCHIR, V113, P186, DOI 10.1007/BF01403207
   JUVONEN T, 1994, J TRAUMA, V36, P262, DOI 10.1097/00005373-199402000-00024
   Kim HY, 2010, J KOREAN NEUROSURG S, V47, P467, DOI 10.3340/jkns.2010.47.6.467
   Kim JH, 2011, J KOREAN NEUROSURG S, V49, P373, DOI 10.3340/jkns.2011.49.6.373
   Konitsiotis S, 2003, J NEUROL, V250, P1109, DOI 10.1007/s00415-003-0125-1
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   Krishnan P, 2016, BRIT J NEUROSURG, V30, P99, DOI 10.3109/02688697.2015.1071319
   Lee JL, 1996, J TRAUMA, V40, P654, DOI 10.1097/00005373-199604000-00026
   Manuel R, 2006, ACTA MEDICA PORT, V19, P455
   Mashiko R, 2006, NEUROL MED-CHIR, V46, P258, DOI 10.2176/nmc.46.258
   Maste P, 2014, SPINE, V39, pE1545, DOI 10.1097/BRS.0000000000000629
   Morris SF, 2004, J BONE JOINT SURG AM, V86A, P1768, DOI 10.2106/00004623-200408000-00022
   Pierce JL, 2018, RADIOGRAPHICS, V38, P1516, DOI 10.1148/rg.2018180099
   RADER JP, 1955, NEW ENGL J MED, V253, P374, DOI 10.1056/NEJM195509012530906
   RUSSELL NA, 1983, SURG NEUROL, V20, P133, DOI 10.1016/0090-3019(83)90464-0
   Singh DK, 2008, TURK NEUROSURG, V18, P324
   Song JY, 2011, KAOHSIUNG J MED SCI, V27, P473, DOI 10.1016/j.kjms.2011.06.009
   Sudo H, 2012, SPINE J, V12, P714, DOI 10.1016/j.spinee.2012.06.011
   VAZQUEZBARQUERO A, 1994, BRIT J NEUROSURG, V8, P739, DOI 10.3109/02688699409101190
   ZILKHA A, 1974, J NEUROSURG, V41, P627, DOI 10.3171/jns.1974.41.5.0627
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 182
EP 185
DI 10.1016/j.wneu.2019.05.002
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100163
PM 31078801
DA 2020-05-12
ER

PT J
AU Lu, VM
   Kaszuba, MC
   Murphy, ME
   Lanzino, G
   Daniels, DJ
AF Lu, Victor M.
   Kaszuba, Megan C.
   Murphy, Meghan E.
   Lanzino, Giuseppe
   Daniels, David J.
TI Near-Fatal Acute Giant Intracranial Aneurysm Rerupture In 7-Month-Old
   Infant
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fixed and dilated pupils; Giant aneurysm; Infant; Rebleed; Rerupture;
   Subarachnoid hemorrhage
ID ARTERIOVENOUS-MALFORMATIONS; CHILDREN; HEMORRHAGE; BRAIN
AB BACKGROUND: Aneurysm rerupture and bilateral fixed and dilated pupils (bFDPs) typically have a poor prognosis across all age groups. The synchronous occurrence of both features in the infantile demographic has not been previously reported.
   CASE DESCRIPTION: We describe the near-fatal clinical course of a 7-month-old infant who experienced an acute giant aneurysm rerupture with signs of bFDPs. The patient was rapidly managed with neurosurgical intervention and has achieved a favorable outcome 1 year later.
   CONCLUSIONS: This case highlights that survival of infants who present with intracranial aneurysmal rerupture and bFDPs is amenable to rapid neurosurgical intervention and should be remembered in clinical practice.
C1 [Lu, Victor M.; Kaszuba, Megan C.; Murphy, Meghan E.; Lanzino, Giuseppe; Daniels, David J.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
RP Daniels, DJ (reprint author), Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA.
EM daniels.david@mayo.edu
CR Buis DR, 2006, CHILD NERV SYST, V22, P1395, DOI 10.1007/s00381-006-0142-3
   CELLI P, 1984, SURG NEUROL, V22, P43, DOI 10.1016/0090-3019(84)90227-1
   CHADDUCK WM, 1995, CHILD NERV SYST, V11, P579, DOI 10.1007/BF00300996
   Clusmann H, 2001, J NEUROL NEUROSUR PS, V71, P175, DOI 10.1136/jnnp.71.2.175
   de Ribanpierre S, 2008, SWISS MED WKLY, V138, P59, DOI 2008/05/smw-11958
   Hoogmoed J, 2018, WORLD NEUROSURG, V119, pE568, DOI 10.1016/j.wneu.2018.07.212
   Huang J, 2005, SURG NEUROL, V63, P424, DOI 10.1016/j.surneu.2004.11.023
   HUMPHREYS RP, 1984, CHILD BRAIN, V11, P1
   Koehler PJ, 2015, J NEUROSURG, V122, P453, DOI 10.3171/2014.10.JNS14148
   KONDZIOLKA D, 1992, CAN J NEUROL SCI, V19, P40, DOI 10.1017/S0317167100042517
   Singhal A, 2011, J NEUROSURG-PEDIATR, V7, P462, DOI 10.3171/2011.2.PEDS10355
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 191
EP 195
DI 10.1016/j.wneu.2019.05.041
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100165
PM 31096028
DA 2020-05-12
ER

PT J
AU Neromyliotis, E
   Kalyvas, AV
   Drosos, E
   Komaitis, S
   Bartziotas, D
   Skandalakis, GP
   Stranjalis, G
   Koutsarnakis, C
AF Neromyliotis, Eleftherios
   Kalyvas, Aristotelis, V
   Drosos, Evangelos
   Komaitis, Spyridon
   Bartziotas, Dimitrios
   Skandalakis, Georgios P.
   Stranjalis, George
   Koutsarnakis, Christos
TI Spinal Atypical Rhabdoid Teratoid Tumor in an Adult Woman: Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atypical rhabdoid teratoid tumors; ATRT; Adult; Spinal
ID CENTRAL-NERVOUS-SYSTEM; TERATOID/RHABDOID TUMORS; CHILDHOOD; INFANCY;
   MEDULLOBLASTOMA; FEATURES; CNS
AB BACKGROUND: Atypical rhabdoid teratoid tumors are very rare embryonal tumors that typically affect children younger than 3 years old and are encountered intracranially.
   CASE DESCRIPTION: Here, we describe the case of a 19-year-old woman who presented with gait disturbances and coccydynia. Imaging revealed a cauda equina mass. The tumor was partially resected. Histology reported loss of SMARCB1/INI1 expression and therefore the diagnosis of atypical rhab doi d teratoid was established. The patient underwent radiation treatment, but within 3 months 2 relapses were manifested.
   CONCLUSIONS: Atypical rhabdoid teratoids are exceptionally rare in adults are seld..m found in spine; only 8 such cases have been reported in the medical literature. They are invariantly characterized by multiple relapses and dismal prognosis. The clinician must be attentive of leptomeningeal disseminations and 22q11 deletion-associated comorbidities.
C1 [Neromyliotis, Eleftherios; Kalyvas, Aristotelis, V; Drosos, Evangelos; Komaitis, Spyridon; Stranjalis, George; Koutsarnakis, Christos] Evangelismos Med Ctr, Dept Neurosurg, Athens, Greece.
   [Bartziotas, Dimitrios] Evangelismos Med Ctr, Dept Surg, Athens, Greece.
   [Neromyliotis, Eleftherios; Kalyvas, Aristotelis, V; Drosos, Evangelos; Komaitis, Spyridon; Stranjalis, George; Koutsarnakis, Christos] Univ Athens, Dept Neurosurg, Athens, Greece.
   [Neromyliotis, Eleftherios; Kalyvas, Aristotelis, V; Drosos, Evangelos; Komaitis, Spyridon; Skandalakis, Georgios P.; Stranjalis, George; Koutsarnakis, Christos] Athens Microneurosurg Lab, Athens, Greece.
RP Neromyliotis, E (reprint author), Evangelismos Med Ctr, Dept Neurosurg, Athens, Greece.; Neromyliotis, E (reprint author), Univ Athens, Dept Neurosurg, Athens, Greece.; Neromyliotis, E (reprint author), Athens Microneurosurg Lab, Athens, Greece.
EM neromiliotis@med.uoc.gr
RI Kalyvas, Aristotelis/AAI-4966-2020
OI Neromyliotis, Eleftherios/0000-0002-8729-6814
CR Amit Amit, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1439157
   Babgi M, 2018, PEDIATR NEUROSURG, V53, P254, DOI 10.1159/000488459
   Bambakidis NC, 2002, PEDIATR NEUROSURG, V37, P64, DOI 10.1159/000065107
   Biegel Jaclyn A, 2006, Neurosurg Focus, V20, pE11
   Bruch LA, 2001, HUM PATHOL, V32, P156, DOI 10.1053/hupa.2001.21572
   Burger PC, 1998, AM J SURG PATHOL, V22, P1083, DOI 10.1097/00000478-199809000-00007
   Chi SN, 2009, J CLIN ONCOL, V27, P385, DOI 10.1200/JCO.2008.18.7724
   Dardis C, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00247
   Geyer JR, 2005, J CLIN ONCOL, V23, P7621, DOI 10.1200/JCO.2005.09.095
   Ginn KF, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00114
   Gotti G, 2015, CHILD NERV SYST, V31, P1621, DOI 10.1007/s00381-015-2755-x
   Judkins AR, 2007, ADV ANAT PATHOL, V14, P335, DOI 10.1097/PAP.0b013e3180ca8b08
   Kanoto M, 2015, CLIN NEURORADIOL, V25, P55, DOI 10.1007/s00062-013-0282-2
   Lee IH, 2009, CLIN RADIOL, V64, P256, DOI 10.1016/j.crad.2008.09.007
   Li Luyuan, 2016, Surg Neurol Int, V7, P27, DOI 10.4103/2152-7806.178523
   McGinity Michael, 2017, Surg Neurol Int, V8, P34, DOI 10.4103/2152-7806.202132
   Meyers SP, 2006, AM J NEURORADIOL, V27, P962
   Oka H, 1999, NEUROL MED-CHIR, V39, P510, DOI 10.2176/nmc.39.510
   Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004
   Packer RJ, 2008, ARCH NEUROL-CHICAGO, V65, P1419, DOI 10.1001/archneur.65.11.1419
   Raisanen J, 2005, BRAIN PATHOL, V15, P23
   Rickert CH, 2001, CHILD NERV SYST, V17, P503, DOI 10.1007/s003810100496
   Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056
   Sinha P, 2015, EUR SPINE J, V24, pS472, DOI 10.1007/s00586-014-3445-1
   Toth G, 2011, GENE CHROMOSOME CANC, V50, P379, DOI 10.1002/gcc.20862
   Zarovnaya EL, 2007, J NEURO-ONCOL, V84, P49, DOI 10.1007/s11060-007-9339-x
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 196
EP 199
DI 10.1016/j.wneu.2019.05.007
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100166
PM 31082562
DA 2020-05-12
ER

PT J
AU Roessler, K
   Heynold, E
   Coras, R
   Lucking, H
   Buchfelder, M
AF Roessler, Karl
   Heynold, Elisabeth
   Coras, Roland
   Luecking, Hannes
   Buchfelder, Michael
TI Successful Surgery of Exophytic Brainstem Glioma Mimicking
   Cerebellar-Pontine Angle Tumor: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebellar-pontine angle; Complete resection; Pilocytic astrocytoma;
   Vestibular schwannoma hearing preservation
ID CEREBELLOPONTINE ANGLE; PILOCYTIC ASTROCYTOMA
AB BACKGROUND: Nontectal plate exophytic brainstem gliomas with pilocytic histology are rare and occur mainly in children. Because of their eloquent location, therapy usually consists of bioptic histologic verification and radio-therapy in case of progression.
   CASE DESCRIPTION: We report on a 43-year-old patient who presented with intermittent tinnitus and reduced hearing in his left ear, as well as a slight left-sided ataxia. Magnetic resonance imaging revealed a left-sided solid cystic cerebellar-pontine angle (CPA) tumor completely obliterating the CPA. Radiologically, a solid cystic vestibular schwannoma was diagnosed. Intraoperatively, a glossy-grayish, intensively bleeding tumor without any capsule or delineation to the brainstem or cranial nerves was resected using electrophysiologic monitoring. Postoperative histology revealed a pilocytic astrocytoma. Three months postoperatively, hearing was preserved (pure tone average-35 dB) and ataxia was equal to what it was preoperatively, gradually becoming better. Postoperative magnetic resonance scans demonstrated a complete resection of the tumor with completely restored brainstem contours.
   CONCLUSIONS: Exophytic brainstem gliomas may occur in the CPA and mimic vestibular schwannoma. Complete resection even with preserved hearing without neurologic deterioration may be feasible.
C1 [Roessler, Karl; Heynold, Elisabeth; Coras, Roland; Luecking, Hannes; Buchfelder, Michael] Univ Hosp Erlangen, Erlangen Univ Clin, Neurosurg Dept, Neuroradiol Dept, Erlangen, Germany.
RP Roessler, K (reprint author), Univ Hosp Erlangen, Erlangen Univ Clin, Neurosurg Dept, Neuroradiol Dept, Erlangen, Germany.
EM karl.roessler@uk-erlangen.de
OI Roessler, Karl/0000-0002-9249-8082
CR BEUTLER AS, 1995, NEUROSURGERY, V37, P125, DOI 10.1227/00006123-199507000-00019
   Dutta Gautam, 2017, Br J Neurosurg, P1, DOI 10.1080/02688697.2017.1419163
   Gass D, 2015, J NEURO-ONCOL, V122, P169, DOI 10.1007/s11060-014-1700-2
   KASANTIKUL V, 1980, ARCH OTOLARYNGOL, V106, P456
   KERNOHAN JW, 1948, J NEUROPATH EXP NEUR, V7, P349, DOI 10.1097/00005072-194810000-00001
   MILLEN SJ, 1985, AM J OTOL, V6, P503
   Mirone G, 2009, CHILD NERV SYST, V25, P247, DOI 10.1007/s00381-008-0690-9
   Recinos PF, 2007, PEDIATR NEUROSURG, V43, P192, DOI 10.1159/000098831
   SMIRNIOTOPOULOS JG, 1993, RADIOGRAPHICS, V13, P1131, DOI 10.1148/radiographics.13.5.8210595
   von Bueren AO, 2018, ACTA NEUROPATHOL, V136, P661, DOI 10.1007/s00401-018-1896-x
NR 10
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 202
EP 205
DI 10.1016/j.wneu.2019.05.053
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100168
PM 31100526
DA 2020-05-12
ER

PT J
AU Darbari, S
   Meena, RK
   Sawarkar, D
   Doddamani, RS
AF Darbari, Shaurya
   Meena, Rajesh Kumar
   Sawarkar, Dattaraj
   Doddamani, Ramesh Sharanappa
TI Optic Nerve Hemangioblastoma: Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hemangioblastoma; Optic nerve; VHL; Strawberry Red Spot; Arterial Spin
   Labelling
AB BACKGROUND: Hemangioblastomas of the optic nerve are very rare tumors. They occur in association with Von Hippel-Lindau (VHL) syndrome; however, sporadic occurrences have been reported. We describe here a case of optic nerve hemangioblastoma in the absence of VHL and review the pertinent literature.
   CASE DESCRIPTION: A 33-year-old woman presented with gradually progressive vision loss in the right eye. On examination, the visual acuity on the right was hand movement close to face in all quadrants. Color discrimination was impaired. Fundoscopy revealed optic atrophy and no other retinal pathology. There was relative afferent pupillary defect in the right eye. No neurocutaneous markers were found. Imaging revealed lesion isointense on T1, hyperintense on T2/fluid-attenuated inversion recovery, and showing relatively homogenous enhancement on postcontrast study. Multiple flow voids were seen in the intracranial part of the lesion. The proximal part of the intraorbital right optic nerve was enlarged and tortuous with distended optic nerve sheath. A right single-piece fronto-orbital craniotomy was done. A reddish lesion seen involving the right optic nerve just proximal to the chiasm with multiple vessels and a distinct feeding vessel was seen supplying the tumor. The lesion was excised and the optic nerve was sacrificed approximately 1 cm proximal to the chiasm. The postoperative course was uneventful.
   CONCLUSIONS: Conclusions: Optic nerve hemangioblastoma is a rare occurrence and a high level of suspicion is required preoperatively in the absence of VHL syndrome.
C1 [Darbari, Shaurya; Meena, Rajesh Kumar; Sawarkar, Dattaraj; Doddamani, Ramesh Sharanappa] All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
RP Doddamani, RS (reprint author), All India Inst Med Sci, Dept Neurosurg, New Delhi, India.
EM drsdramesh@gmail.com
CR Baggenstos M, 2008, J NEUROSURG, V109, P313, DOI 10.3171/JNS/2008/109/8/0313
   Barrett R, 2008, OPHTHALMOLOGY, V115, P2094, DOI 10.1016/j.ophtha.2008.06.003
   ECKSTEIN RP, 1981, PATHOLOGY, V13, P357, DOI 10.3109/00313028109081675
   Fard MA, 2014, NEURO-OPHTHALMOLOGY, V38, P254, DOI 10.3109/01658107.2014.944622
   Fons Martínez M.R., 2006, Arch Soc Esp Oftalmol, V81, P293
   Higashida T, 2007, NEUROL MED-CHIR, V47, P215, DOI 10.2176/nmc.47.215
   Hotta H, 1989, Neurol Med Chir (Tokyo), V29, P948, DOI 10.2176/nmc.29.948
   IN S, 1982, J NEUROSURG, V56, P426, DOI 10.3171/jns.1982.56.3.0426
   Kanno H, 2018, J KIDNEY CANCER VHL, V5, P1, DOI 10.15586/jkcvhl.2018.104
   Kato Kaoruko, 2004, No To Shinkei, V56, P711
   KERR DJ, 1995, NEUROSURGERY, V36, P573, DOI 10.1227/00006123-199503000-00017
   LAUTEN GJ, 1981, AM J NEURORADIOL, V2, P96
   McGrath LA, 2018, OCUL ONCOL PATHOL, V4, P370, DOI 10.1159/000486863
   NERAD JA, 1988, OPHTHALMOLOGY, V95, P398
   NOBILE S, 1951, Riv Neurol, V21, P506
   Pan J, 2015, CONT NEUROSURG, V37, P1
   Prabhu K, 2009, BRIT J NEUROSURG, V23, P561, DOI 10.1080/02688690902965964
   RUBIO A, 1994, HUM PATHOL, V25, P1249, DOI 10.1016/0046-8177(94)90044-2
   Schneider R., 1942, GRAEFES ARCH OPHTHAL, V145, P163
   Shima H, 2011, JPN J NEUROSURG, V20, P133
   Staub Blake N, 2014, Surg Neurol Int, V5, P33, DOI 10.4103/2152-7806.128430
   STEFANI FH, 1974, BRIT J OPHTHALMOL, V58, P823, DOI 10.1136/bjo.58.9.823
   Tanaka E, 1984, NIPPON GANKA KIYO, V35, p1390 
   Thomas RP, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-014-0333-2
   Turel MK, 2017, TURK NEUROSURG, V27, P827, DOI 10.5137/1019-5149.JTN.16680-15.1
   Verga P., 1930, RIV OTO NEURO OFTAL, V7, P101
   Zywicke H, 2012, CASE REP PATHOL, DOI 10.1155/2012/915408
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 211
EP 215
DI 10.1016/j.wneu.2019.04.224
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100171
PM 31054346
DA 2020-05-12
ER

PT J
AU Kayaci, S
   Cakir, T
   Dolgun, M
   Cakir, E
   Bozok, S
   Temiz, C
   Caglar, YS
AF Kayaci, Selim
   Cakir, Tayfun
   Dolgun, Muge
   Cakir, Ertugrul
   Bozok, Sahin
   Temiz, Cuneyt
   Caglar, Yusuf Sukru
TI Aortic Injury by Thoracic Pedicle Screw. When Is Aortic Repair Required?
   Literature Review and Three New Cases
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aortic injury; Aortic repair; Impingement; Pedicle screw; Thoracic
   vertebra
ID SPINAL INSTRUMENTATION; ENDOVASCULAR TREATMENT; DELAYED PRESENTATION;
   ABDOMINAL-AORTA; FALSE ANEURYSM; LUMBAR SPINE; PLACEMENT;
   PSEUDOANEURYSM; COMPLICATIONS; FIXATION
AB PURPOSE: Aortic injury by pedicle screw is rare but can cause serious complications. It has not been clearly determined when aortic repair is necessary in cases of screw impingement without perforation of the aortic wall. In this article, we review the treatment and clinical course of pedicle screw aortic impingement and attempt to clarify this issue.
   METHODS: Cases of aortic injury during thoracic screw procedures were found using a MEDLINE search and analyzed together with 3 new cases that we present.
   RESULTS: Nineteen cases collected from the literature and 3 new cases were included in the study. In 7 of the cases, aortic impingement by the pedicle screw was detected during postoperative follow-up (day 1) radiologic examinations. In the other cases, time to presentation of aortic impingement ranged between 2 weeks and 60 months after fixation. The main indications for thoracic spinal fixation were post-traumatic vertebral fracture and kyphoscoliosis/scoliosis. Repair of the aortic damage ranged from primary repair to stent and tube graft placement by the thoracic endovascular aortic repair method.
   CONCLUSIONS: In cases in which the screw impinges less than 5 mm into the aortic wall, hardware revision without aortic repair may be sufficient if recognized early and there are no sign of aortic leakage in vascular imaging. However, cases with more than 5 mm of screw impingement should undergo aortic repair first, even in the absence of aortic leakage, following by screw revision.
C1 [Kayaci, Selim; Cakir, Tayfun; Dolgun, Muge] Erzincan Univ, Fac Med, Dept Neurosurg, Erzincan, Turkey.
   [Cakir, Ertugrul] Karadeniz Tech Univ, Dept Neurosurg, Fac Med, Trabzon, Turkey.
   [Bozok, Sahin] Usak Univ, Fac Med, Dept Cardiovasc Surg, Usak, Turkey.
   [Temiz, Cuneyt] Celal Bayar Univ, Fac Med, Dept Neurosurg, Manisa, Turkey.
   [Caglar, Yusuf Sukru] Ankara Univ, Oept Neurosurg, Fac Med, Ankara, Turkey.
RP Kayaci, S (reprint author), Erzincan Univ, Fac Med, Dept Neurosurg, Erzincan, Turkey.
EM selim_kayaci@hotmail.com
RI Dolgun, Muge/O-7952-2018; Cakir, Tayfun/AAD-6595-2019; Bozok,
   Sahin/Q-1268-2018
OI Dolgun, Muge/0000-0002-7945-6902; CAKIR, TAYFUN/0000-0002-9979-9291;
   Bozok, Sahin/0000-0002-1256-5055
CR Andrassy J, 2006, J TRAUMA, V60, P765, DOI 10.1097/01.ta.0000210275.58266.24
   Borioni R, 1999, TEX HEART I J, V26, P312
   Brau Salvador A, 2004, Spine J, V4, P409, DOI 10.1016/j.spinee.2003.12.003
   Carmignani A, 2013, J CARDIAC SURG, V28, P163, DOI 10.1111/jocs.12052
   Catan H, 2007, EUR SPINE J, V16, P1203, DOI 10.1007/s00586-006-0281-y
   Chase CW, 1997, J VASC SURG, V25, P936, DOI 10.1016/S0741-5214(97)70226-X
   CHERRY JK, 1966, ARCH SURG-CHICAGO, V93, P404
   Choi JB, 2001, J TRAUMA, V50, P140, DOI 10.1097/00005373-200101000-00029
   Claiborne Paul, 2015, J Vasc Surg Cases, V1, P264, DOI 10.1016/j.jvsc.2015.09.001
   Clarke MJ, 2011, J NEUROSURG-SPINE, V15, P550, DOI 10.3171/2011.7.SPINE10267
   Colvard BD, 2012, J VASC SURG, V56, P201, DOI 10.1016/j.jvs.2011.12.084
   Di Silvestre M, 2007, SPINE, V32, P1655, DOI 10.1097/BRS.0b013e318074d604
   Dregelid E, 2007, J VASC SURG, V45, P1059, DOI 10.1016/j.jvs.2006.12.070
   Elliott MJ, 2007, J PEDIATR ORTHOPED, V27, P582, DOI 10.1097/01.bpb.0000279030.59150.13
   FACISZEWSKI T, 1995, SPINE, V20, P1592, DOI 10.1097/00007632-199507150-00007
   Falkensammer J, 2005, J VASC SURG, V42, P1010, DOI 10.1016/j.jvs.2005.07.011
   Faro FD, 2005, SPINE, V30, P2406, DOI 10.1097/01.brs.0000184587.25330.40
   Freyrie A, 2013, ANN VASC SURG, V27, P4991
   Han W, 2010, ORTHOPEDICS, V33
   Hinchliffe RJ, 2002, J ENDOVASC THER, V9, P590, DOI 10.1583/1545-1550(2002)009<0590:EEOARP>2.0.CO;2
   Hu HT, 2010, CARDIOVASC INTER RAD, V33, P1040, DOI [10.3724/SP.J.1016.2010.01040, 10.1007/s00270-009-9782-5]
   Huitema GC, 2007, SPINE, V32, P1259, DOI 10.1097/BRS.0b013e3180592c4a
   JENDRISAK MD, 1986, SURGERY, V99, P631
   Kakkos SK, 2008, J VASC SURG, V47, P1074, DOI 10.1016/j.jvs.2007.11.005
   Kim YJ, 2004, SPINE, V29, P333, DOI 10.1097/01.BRS.0000109983.12113.9B
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   Lagios K, 2015, CASE REP VASC MED, V2015
   Lopera JE, 2010, J TRAUMA, V69, P870, DOI 10.1097/TA.0b013e3181f0bd55
   Luther N, 2015, J SPINAL DISORD TECH, V28, pE298, DOI 10.1097/BSD.0b013e31828af33e
   Martin S, 2018, ANN VASC SURG, V48, DOI 10.1016/j.avsg.2017.10.021
   MATSUZAKI H, 1993, SPINE, V18, P2327, DOI 10.1097/00007632-199311000-00033
   Miller JS, 1998, J TRAUMA, V44, P214, DOI 10.1097/00005373-199801000-00034
   Minor ME, 2004, J VASC SURG, V39, P893, DOI 10.1016/j.jvs.2003.10.056
   Mitra A, 2004, PLAST RECONSTR SURG, V113, P206, DOI 10.1097/01.PRS.0000097440.15013.5C
   Papadoulas S, 2002, EUR J VASC ENDOVASC, V24, P189, DOI 10.1053/ejvs.2002.1682
   Pesenti S, 2014, ORTHOP TRAUMATOL-SUR, V100, P569, DOI 10.1016/j.otsr.2014.03.020
   Potter Michael Q, 2013, Evid Based Spine Care J, V4, P149, DOI 10.1055/s-0033-1357358
   Sasso RC, 2005, SPINE, V30, P670, DOI 10.1097/01.brs.0000155423.18218.75
   Schroder J, 2006, ZBL NEUROCHIR, V67, P123, DOI 10.1055/s-2006-942146
   Sevuk U, 2016, J CARDIAC SURG, V31, P220, DOI 10.1111/jocs.12718
   Smorgick Y, 2005, J SPINAL DISORD TECH, V18, P522, DOI 10.1097/01.bsd.0000154448.90707.a8
   Suk SI, 2001, SPINE, V26, P2049, DOI 10.1097/00007632-200109150-00022
   Tang JS, 2014, J BIOMED RES, V28, P228, DOI 10.7555/JBR.28.20130159
   Tong X, 2015, J FORMOS MED ASSOC, V114, P464, DOI 10.1016/j.jfma.2013.09.014
   Tschoeke SK, 2011, SPINE, V36, pE886, DOI 10.1097/BRS.0b013e318202e4d1
   Watanabe K, 2010, SPINE, V35, pE1064, DOI 10.1097/BRS.0b013e3181ed29c1
   Wegener B, 2008, EUR SPINE J, V17, pS351, DOI 10.1007/s00586-008-0715-9
   Wu H, 2010, CHIN J TRAUMATOL, V13, P201, DOI 10.3760/cma.j.issn.1008-1275.2010.04.002
   Yeh MW, 2005, J VASC SURG, V42, P1007, DOI 10.1016/j.jvs.2005.06.007
   Zietek Pawel, 2009, Chir Narzadow Ruchu Ortop Pol, V74, P377
NR 50
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 216
EP 224
DI 10.1016/j.wneu.2019.04.173
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100172
PM 31077895
DA 2020-05-12
ER

PT J
AU Gerosa, A
   Fanti, A
   Del Sette, B
   Bianco, A
   Cossandi, C
   Crobeddu, E
   Forgnone, S
   Fornaro, R
   Panzarasa, G
AF Gerosa, Andrea
   Fanti, Andrea
   Del Sette, Bruno
   Bianco, Andrea
   Cossandi, Christian
   Crobeddu, Emanuela
   Forgnone, Sara
   Fornaro, Riccardo
   Panzarasa, Gabriele
TI Posttraumatic Middle Meningeal Artery Pseudoaneurysm: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Clipping; Endovascular; Middle meningeal artery; MMA;
   Traumatic
ID TRAUMATIC PSEUDOANEURYSM; INTRACEREBRAL HEMORRHAGE; ANEURYSM; HEMATOMA;
   PATIENT; FISTULA; RUPTURE
AB BACKGROUND: Intracranial pseudoaneurysm is a rare entity, with few cases -Abed in the literature, and is mostly associated with a history of traumatic brain injury. Traumatic aneurysms comprise <1% of all intracranial aneurysms. In particular, middle meningeal artery (MMA) aneurysms are uncommon and usually caused by a skull fracture in the temporal region. About 40 traumatic MMA aneurysms are reported in the literature, and only 28 nontraumatic aneurysms are reported, usually related to high-flow conditions. The behavior of these aneurysms is largely unknown: both spontaneous resolution and aneurysm growth, leading to subsequent rupture, have been reported. Surgical and endovascular management are feasible for MMA aneurysms; however, the criterion standard treatment is not defined.
   CASE DESCRIPTION: We report the case of a traumatic pseudoaneurysm of the right MMA treated with an endovascular approach and provide a review of the literature.
   CONCLUSIONS: Aneurysms of the MMA are a rare entity that must be taken into account in the setting of a traumatic brain injury or predisposing factors. The diagnosis and aggressive treatment are mandatory, preventing the devastating consequences of their rupture. Endovascular and surgical techniques are well defined and available, even though there is not a demonstrated superiority in any of them.
C1 [Gerosa, Andrea] Osped Civile SS Antonio & Biagio & Cesare Arrigo, Alessandria, Italy.
   [Fanti, Andrea] Univ Pavia, Osped Papa Giovanni 23, Pavia, Italy.
   [Del Sette, Bruno; Bianco, Andrea; Cossandi, Christian; Crobeddu, Emanuela; Forgnone, Sara; Fornaro, Riccardo; Panzarasa, Gabriele] Osped Maggiore della Carita Novara, Novara, Italy.
RP Gerosa, A (reprint author), Osped Civile SS Antonio & Biagio & Cesare Arrigo, Alessandria, Italy.
EM andrea.gerosa@icloud.com
OI Gerosa, Andrea/0000-0003-3333-232X; Bianco, Andrea/0000-0002-8381-3861
CR Akyol C, 2009, BMJ CASE REP
   Akyuz M, 2010, TURK NEUROSURG, V20, P544, DOI 10.5137/1019-5149.JTN.1747-09.2
   Albert F K, 1989, Zentralbl Neurochir, V50, P153
   AULD AW, 1965, ARCH NEUROL-CHICAGO, V13, P369, DOI 10.1001/archneur.1965.00470040035005
   BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127
   BERK ME, 1961, BRIT J RADIOL, V34, P667, DOI 10.1259/0007-1285-34-406-667
   Bollati A, 1980, J Neurosurg Sci, V24, P89
   Borota Ljubisa, 1996, Neurologia Medico-Chirurgica, V36, P860, DOI 10.2176/nmc.36.860
   Bruneau M, 2002, SURG NEUROL, V57, P174, DOI 10.1016/S0090-3019(01)00668-1
   FLORES JS, 1986, NEUROSURGERY, V18, P200, DOI 10.1227/00006123-198602000-00016
   JIN K, 1981, BRAIN DEV-JPN, V3, P323, DOI 10.1016/S0387-7604(81)80055-1
   Kahara VJ, 1999, J NEUROSURG, V91, P518, DOI 10.3171/jns.1999.91.3.0518
   Kinoshita Y, 2004, NEUROL SURG TOKYO, V32, P1139
   Ko JH, 2014, INTERV NEURORADIOL, V20, P352, DOI 10.15274/NRJ-2014-10025
   Koebbe CJ, 2004, AM J NEURORADIOL, V25, P574
   Lama M, 2000, J Neurosurg Sci, V44, P39
   Lim DH, 2007, J KOREAN NEUROSURG S, V42, P416, DOI 10.3340/jkns.2007.42.5.416
   Marvin Eric, 2016, Surg Neurol Int, V7, pS23, DOI 10.4103/2152-7806.173564
   MEDER JF, 1992, J NEURORADIOLOGY, V19, P248
   PARK JW, 2017, KOREAN J NEUROTRAUMA, V13, P168, DOI DOI 10.12965/JER.1734948.474
   Park YS, 2010, J NEUROSURG, V113, P749, DOI 10.3171/2009.11.JNS09895
   RUMBAUGH CL, 1972, RADIOLOGY, V104, P81, DOI 10.1148/104.1.81
   SANCHIS JF, 1975, J NEUROL NEUROSUR PS, V38, P577, DOI 10.1136/jnnp.38.6.577
   Sandin JA, 1999, J NEUROSURG, V90, P951, DOI 10.3171/jns.1999.90.5.0951
   Settecase F, 2016, J NEUROSURG-PEDIATR, V17, P324, DOI 10.3171/2015.9.PEDS15267
   Srinivasan A, 2006, AM J NEURORADIOL, V27, P882
   Tsutsumi M, 2002, SURG NEUROL, V58, P325, DOI 10.1016/S0090-3019(02)00834-0
   ZINGESSER LH, 1965, BRIT J RADIOL, V38, P835, DOI 10.1259/0007-1285-38-455-835
NR 28
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 225
EP 229
DI 10.1016/j.wneu.2019.05.030
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100173
PM 31096023
DA 2020-05-12
ER

PT J
AU Silva, AHD
   Stevens, AR
   Joseph, J
   Albanese, E
AF Silva, Adikarige H. D.
   Stevens, Andrew R.
   Joseph, Jooly
   Albanese, Erminia
TI Multifocal Infratentorial Pilocytic Astrocytoma in an Adult Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Multifocal pilocytic astrocytoma; Multicentric pilocytic astrocytoma
ID LEPTOMENINGEAL DISSEMINATION; PROGNOSIS; TUMORS
AB BACKGROUND: Pilocytic astrocytoma is a benign glial tumor typically presenting in children. It is rare for adults to present with pilocytic astrocytoma and even less likely to manifest with multiple foci of lesions especially in nonoptic or hypothalamic locations.
   CASE DESCRIPTION: Our patient was a 37-year old man presenting with varied cranial neuropathies, cerebellar dysfunction, and long tract signs, with imaging demonstrating 3 discrete ill-defined contrast-enhancing lesions affecting the cerebellar peduncles, brainstem, and cervicomedullary junction. Neuronavigation-guided biopsy confirmed World Health Organization grade 1 pilocytic astrocytoma; the patient was treated with radiotherapy.
   CONCLUSIONS: To our knowledge, we believe this is the first reported case with multifocal infratentorial pilocytic astrocytoma on presentation in an adult patient in the absence of a prior history of associated risk factors such as neurofibromatosis 1 or chemoradiotherapeutic intervention.
C1 [Silva, Adikarige H. D.; Stevens, Andrew R.; Joseph, Jooly; Albanese, Erminia] Royal Stoke Univ Hosp, Dept Neurosurg, Stoke On Trent, Staffs, England.
RP Albanese, E (reprint author), Royal Stoke Univ Hosp, Dept Neurosurg, Stoke On Trent, Staffs, England.
EM erminia.albanese@uhnm.nhs.uk
CR BARNARD RO, 1987, CANCER, V60, P1519, DOI 10.1002/1097-0142(19871001)60:7<1519::AID-CNCR2820600719>3.0.CO;2-1
   Basheer A, 2017, NEUROSURGERY, V80, pE178, DOI 10.1093/neuros/nyw029
   BATZDORF U, 1963, J NEUROSURG, V20, P122, DOI 10.3171/jns.1963.20.2.0122
   Figueiredo EG, 2003, ARQ NEURO-PSIQUIAT, V61, P842, DOI 10.1590/S0004-282X2003000500025
   Forte D, 2018, WORLD NEUROSURG, V117, P172, DOI 10.1016/j.wneu.2018.06.011
   Jea A, 2010, J NEUROSURG-PEDIATR, V5, P149, DOI 10.3171/2009.9.PEDS09211
   Kanoke A, 2013, J NEUROSURG, V118, P854, DOI 10.3171/2012.9.JNS112353
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   MAMELAK AN, 1994, J NEUROSURG, V81, P24, DOI 10.3171/jns.1994.81.1.0024
   Morikawa M, 1997, SURG NEUROL, V48, P49, DOI 10.1016/S0090-3019(96)00366-7
   Ogura T, 2004, PEDIATR NEUROSURG, V40, P301, DOI 10.1159/000083744
   POLLACK IF, 1994, CANCER, V73, P2869, DOI 10.1002/1097-0142(19940601)73:11<2869::AID-CNCR2820731134>3.0.CO;2-I
   Sim KB, 1999, CHILD NERV SYST, V15, P477, DOI 10.1007/s003810050443
   Villarejo F, 2008, CHILD NERV SYST, V24, P203, DOI 10.1007/s00381-007-0449-8
   Xia JG, 2016, CLIN NEURORADIOL, V26, P341, DOI 10.1007/s00062-015-0370-6
NR 15
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 230
EP 233
DI 10.1016/j.wneu.2019.05.006
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100174
PM 31082554
OA Bronze
DA 2020-05-12
ER

PT J
AU Xin, X
   Zhang, Y
   Jin, T
   Liu, XX
AF Xin, Xin
   Zhang, Yong
   Jin, Tao
   Liu, Xinxin
TI Zero-Profile Implantation Combined with Miniscrew Fixation via Anterior
   Approach for Huge Teardrop Fracture of Axis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Axis fracture; Teardrop fracture; Treatment; Upper cervical spine;
   Zero-Profile
ID DROP FRACTURE; CERVICAL-SPINE; FUSION; INJURY; PLATE; TRAUMA; CORD
AB BACKGROUND: We present 3 case reports to share our experience and explore the safety and efficacy of treating huge teardrop fracture of the axis (HTDFA).
   CASE DESCRIPTION: Case 1: A 47-year-old man suffered from generalized pain after falling from a height. Case 2: A 39-year-old woman suffered facial contusions and lacerations during a car accident, and her neck was sore. Case 3: A 51-year-old woman was hit in the face during a car accident, and her neck was sore. These 3 patients had limited neck movement and no nerve injury, and their radiographs showed HTDFA. The patients were treated with Zero-Profile (Zero-P) implant placement combined with miniscrew fixation.
   CONCLUSIONS: The treatment of HTDFA by Zero-P implant placement combined with miniscrew fixation is effective and stable. The last follow-up examination of the patients showed that fusion had been achieved, and their neck pain had disappeared. Anterior reduction, diskectomy, and Zero-P implantation combined with miniscrew fixation can be used to treat HTDFA. Both avulsed teardrop fragment removal and C2-3 bone grafting lead to bone healing. This method is effective, safe, and simple for the treatment of HTDFA.
C1 [Xin, Xin; Zhang, Yong; Jin, Tao] Ankang Ctr Hosp, Dept Orthoped, Ankang, Peoples R China.
   [Liu, Xinxin] Xi An Jiao Tong Univ, Hong Hui Hosp, Magnet Resonance Imaging, Xian, Shaanxi, Peoples R China.
RP Liu, XX (reprint author), Xi An Jiao Tong Univ, Hong Hui Hosp, Magnet Resonance Imaging, Xian, Shaanxi, Peoples R China.
EM liuxinxinfly2008@163.com
CR Boran S, 2005, EUR J ORTHOP SURG TR, V15, P229
   Brembilla C, 2015, J NEUROL SURG PART A, V76, P13, DOI 10.1055/s-0034-1368092
   BURKE JT, 1989, SKELETAL RADIOL, V18, P335, DOI 10.1007/BF00361422
   Clavenna AL, 2012, SPINE J, V12, P157, DOI 10.1016/j.spinee.2012.01.011
   Deniz FE, 2007, TURK NEUROSURG, V17, P125
   HADLEY MN, 1985, NEUROSURGERY, V17, P281, DOI 10.1227/00006123-198508000-00006
   Hu Y, 2016, CLIN SPINE SURG, V29, pE49, DOI 10.1097/BSD.0b013e31828984f9
   Jiang T, 2017, J ORTHOP SCI, V22, P816, DOI 10.1016/j.jos.2017.06.007
   Kim TH, 2018, J KOREAN NEUROSURG S, V61, P574, DOI 10.3340/jkns.2018.0090
   Korres D S, 1994, Eur Spine J, V3, P151, DOI 10.1007/BF02190577
   Liu WJ, 2015, THER CLIN RISK MANAG, V11, DOI 10.2147/TCRM.S92511
   Maeda T, 2012, SPINE, V37, pE1560, DOI 10.1097/BRS.0b013e318272f345
   Martiniani M, 2013, EUR SPINE J, V22, pS951, DOI 10.1007/s00586-013-3008-x
   Morel E, 2009, ORTHOP TRAUMATOL-SUR, V95, P229, DOI 10.1016/j.otsr.2009.03.004
   Sander AL, 2013, AM J ROENTGENOL, V200, P618, DOI 10.2214/AJR.12.8748
   SCHNEIDER RC, 1956, J BONE JOINT SURG AM, V38, P985, DOI 10.2106/00004623-195638050-00003
   Scholz M, 2011, CLIN ORTHOP RELAT R, V469, P666, DOI 10.1007/s11999-010-1597-9
   Scholz M, 2009, SPINE, V34, P156, DOI 10.1097/BRS.0b013e31818ff9c4
   Ulrich C, 2001, EUR SPINE J, V10, P88, DOI 10.1007/s005860000233
   Watanabe M, 2011, J NEUROSURG-SPINE, V14, P710, DOI 10.3171/2011.1.SPINE10687
   Yang XB, 2015, SPINE, V40, pE1187, DOI 10.1097/BRS.0000000000001118
NR 21
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 235
EP 239
DI 10.1016/j.wneu.2019.04.242
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100175
PM 31077897
DA 2020-05-12
ER

PT J
AU Rothrock, RJ
   Li, AY
   Rumsey, J
   Fifi, JT
   Kellner, CP
   Roonprapunt, C
AF Rothrock, Robert J.
   Li, Adam Y.
   Rumsey, Jamie
   Fifi, Johanna T.
   Kellner, Christopher P.
   Roonprapunt, Chan
TI Aneurysmal Subarachnoid Hemorrhage with Spinal Subdural Hematoma: A Case
   Report and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anticoagulant; Cerebrospinal fluid drainage; Intracranial aneurysm;
   Spinal subdural hematoma; Subarachnoid hemorrhage
ID COMPLICATIONS
AB OBJECTIVE: Spinal subdural hematoma (S-SDH) rareiy occurs after aneurysmal subarachnoid hemorrhage (SAH). Little information is known regarding the management and prognosis of patients with both S-SDH and SAH. Here, we present an illustrative case and provide a systematic review of S-SDH in the setting of SAH.
   METHODS: A systematic literature review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines revealed 11 previous cases of concurrent intracranial SAH and spinal SDH, which are presented with our new reported case.
   RESULTS: Intracranial sources of spontaneous SAH included 8 aneurysms, 1 pseudoaneurysm, and 3 angiogram-negative cases. Hunt Hess grades ranged from 1 to 4, mean time between SAH and S-SDH was 5.8 days, and S-SDH presented most frequently in the lumbar spine. Eight patients showed significant to complete clinical recovery, 2 had continued plegia of the lower extremities, and 2 expired. Modified Rankin scores (mRS) ranged from 0 to 6, with mRS >2 for 4 of 12 patients. Patients with a poor clinical outcome (mRS >2) had an initially negative cerebral angiogram, earlier presentation with less time between SAH and S-SDH (0.8 vs. 7.6 days), use of antithrombotic medication, no diversion of cerebrospinal fluid, and cervical or thoracic S-SDH.
   CONCLUSION: S-SDH is uncommon in the setting of aneurysmal SAH; better outcomes are associated with lumbar location, delayed presentation, cerebrospinal fluid diversion, and lack of antithrombotic use. Conservative treatment may be sufficient in patients with delayed S-SDH and lack of significant neurologic deficits. More reported cases will allow greater understanding of this clinical entity.
C1 [Rothrock, Robert J.; Li, Adam Y.; Rumsey, Jamie; Fifi, Johanna T.; Kellner, Christopher P.; Roonprapunt, Chan] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Rothrock, RJ (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM RJRothrock@gmail.com
OI Li, Adam/0000-0001-7654-1469
CR Biesbroek JM, 2013, J NEUROL NEUROSUR PS, V84, P254, DOI 10.1136/jnnp-2011-302139
   Biesbroek JM, 2012, NEUROSURGERY, V71, P264, DOI 10.1227/NEU.0b013e318256c27d
   Choi DH, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.084
   Dardik A, 2002, J VASC SURG, V36, P47, DOI 10.1067/mva.2002.125022
   Domenicucci M, 1999, J NEUROSURG, V91, P65, DOI 10.3171/spi.1999.91.1.0065
   EARNEST F, 1984, AM J ROENTGENOL, V142, P247, DOI 10.2214/ajr.142.2.247
   Graffeo CS, 2017, NEUROCRIT CARE, V26, P109, DOI 10.1007/s12028-016-0327-x
   Grannan BL, 2014, J CLIN NEUROSCI, V21, P993, DOI 10.1016/j.jocn.2013.11.002
   Jung HS, 2015, J KOREAN NEUROSURG S, V57, P371, DOI 10.3340/jkns.2015.57.5.371
   Kim MS, 2007, NEUROL MED-CHIR, V47, P22, DOI 10.2176/nmc.47.22
   Kirsch EC, 2000, NEURORADIOLOGY, V42, P586, DOI 10.1007/s002340000331
   Kitchner J, 2012, NEUROLOGY, V78
   Kobayashi N, 2007, NEUROL INDIA, V55, P431, DOI 10.4103/0028-3886.33313
   Kocak A, 2009, TURK NEUROSURG, V19, P333
   Kreppel D, 2003, NEUROSURG REV, V26, P1, DOI 10.1007/s10143-002-0224-y
   KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287
   Lucas JW, 2012, NEUROSURGERY, V70, pE259, DOI 10.1227/NEU.0b013e31822ac0fb
   Marbacher S, 2010, ACTA NEUROCHIR, V152, P501, DOI 10.1007/s00701-009-0521-0
   Matsumoto H, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.03.020
   Mete A, 2012, TURK NEUROSURG, V22, P349, DOI 10.5137/1019-5149.JTN.3187-10.2
   NICHOLAS DS, 1988, J NEUROSURG, V69, P276, DOI 10.3171/jns.1988.69.2.0276
   Nozar A, 2002, INTERV NEURORADIOL, V8, P393, DOI 10.1177/159101990200800408
   Ovali GY, 2015, J NEUROIMAGING, V25, P668, DOI 10.1111/jon.12189
   Patil Vijaysinh Namdeo, 2016, Indian Heart J, V68 Suppl 2, pS22, DOI 10.1016/j.ihj.2016.05.012
   Penas ML, 2011, NEUROLOGIA, V26, P182, DOI 10.1016/j.nrl.2010.07.032
   Seizeur R, 2009, J CLIN NEUROSCI, V16, P842, DOI 10.1016/j.jocn.2008.09.003
   Subramaniam B, 2007, J CARDIOTHOR VASC AN, V21, P704, DOI 10.1053/j.jvca.2006.11.006
   Waldron JS, 2011, NEUROSURGERY, V68, pE835, DOI 10.1227/NEU.0b013e3182078099
   Yamaguchi S, 2003, SURG NEUROL, V59, P408, DOI 10.1016/S0090-3019(03)00016-8
   Yamauchi Takashi, 2004, Jpn J Thorac Cardiovasc Surg, V52, P466
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 240
EP 247
DI 10.1016/j.wneu.2019.05.069
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100176
PM 31103768
DA 2020-05-12
ER

PT J
AU Zagzoog, N
   Reddy, K
AF Zagzoog, Nirmeen
   Reddy, Kesava (Kesh)
TI Use of Minimally Invasive Tubular Retractors for Foramen Magnum
   Decompression of Chiari Malformation: A Technical Note and Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case study; Chiari malformation; Foramen magnum decompression; METRx;
   Minimally invasive surgery; Tubular retractors
ID SURGICAL-TREATMENT; I-MALFORMATION; DURAPLASTY; SYRINGOMYELIA
AB BACKGROUND: An intraoperative technique for foramen magnum decompression of Chiari malformation is presented. The technique uses minimal exposure tubular retractors attached to a flexible arm to keep the retractor in a fixed position, while allowing flexible angulation under fluoroscopic guidance.
   METHODS: Operations were performed between 2009 and 2018 on 22 patients with cerebellar tonsillar descent below the foramen magnum and a diagnosis of type I Chiari malformation. A linear durotomy was necessary, but only the outer layer of the dura was opened for some patients, which is less invasive than the traditional procedure where a durotomy is performed for both the inner and outer layers, and then a duraplasty is performed.
   RESULTS: The approach allowed access to a wide working area, minimized soft tissue exposure, and optimized extent of decompression. The postoperative imaging demonstrated satisfactory bony removal, and magnetic resonance imaging of the area with cerebrospinal (CSF) flow study showed good CSF flow across the foramen magnum. There was a low incidence of postoperative complications, and the average length of hospital stay was 1 day. For 19 of 22 cases, the symptoms completely resolved or markedly improved, and each of the patients who attended the last follow-up demonstrated syrinx resolution.
   CONCLUSIONS: Based on our experience with this technique, when used to assist in foramen magnum decompression of Chiari malformation I, the minimally invasive tubular retractor is a useful tool, providing the surgeon with enhanced visualization of the operative field, while reducing potential damage to tissue and optimizing surgical outcomes.
C1 [Zagzoog, Nirmeen; Reddy, Kesava (Kesh)] McMaster Univ, Dept Surg, Div Neurosurg, Hamilton, ON, Canada.
RP Zagzoog, N (reprint author), McMaster Univ, Dept Surg, Div Neurosurg, Hamilton, ON, Canada.
EM nirmeen.zagzoog@medportal.ca
CR Alden T D, 2001, Neurosurg Focus, V11, pE2
   Baisden Jamie, 2012, Surg Neurol Int, V3, pS232, DOI 10.4103/2152-7806.98580
   Batzdorf U, 2013, J NEUROSURG, V118, P232, DOI 10.3171/2012.10.JNS12305
   Duddy JC, 2014, BRIT J NEUROSURG, V28, P330, DOI 10.3109/02688697.2013.841847
   Durham SR, 2008, J NEUROSURG-PEDIATR, V2, P42, DOI 10.3171/PED/2008/2/7/042
   Fric R, 2016, ACTA NEUROCHIR, V158, P341, DOI 10.1007/s00701-015-2669-0
   Gandhi RH, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13163
   Greenfield JP, 2008, NEUROSURGERY, V63, P334, DOI [10.1227/01.NEU.0000334741.61745.72, 10.1227/01.neu.0000334741.61745.72]
   Hankinson T, 2011, CHILD NERV SYST, V27, P35, DOI 10.1007/s00381-010-1295-7
   Kim YB, 2007, J KOREAN NEUROSURG S, V42, P245, DOI 10.3340/jkns.2007.42.4.245
   Klekamp J, 2012, NEUROSURGERY, V71, P365, DOI 10.1227/NEU.0b013e31825c3426
   Mazzola CA, 2003, NEUROSURG FOCUS, V15, P1
   Mutchnick IS, 2010, J NEUROSURG-PEDIATR, V5, P474, DOI 10.3171/2010.1.PEDS09218
   Renee K, 2018, ENDOSCOPIC SPINE SUR, P299
   Sindou M, 2009, ADV TECH STAND NEURO, V34, P85, DOI 10.1007/978-3-211-78741-0_4
NR 15
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 248
EP 253
DI 10.1016/j.wneu.2019.04.094
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100177
PM 31048052
DA 2020-05-12
ER

PT J
AU Soltani, S
   Nogaro, MC
   Kieser, SCJ
   Wyatt, MC
   Kieser, DC
AF Soltani, Scheherezade
   Nogaro, Marie-Caroline
   Kieser, Sandra Colette Jacqueline
   Wyatt, Michael Charles
   Kieser, David Christopher
TI Spontaneous Spinal Epidural Hematomas in Pregnancy: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Decompression; Hematoma; Spine
ID PATIENT
AB BACKGROUND: Spontaneous spinal epidural hematomas (SSEH) are rare yet severe conditions. In pregnancy, this condition is challenging to diagnose and treat because of the risks to the mother and fetus. This study reviews the literature on SSEHs in pregnancy.
   METHODS: We performed a systematic review of the English literature on SSEHs from 1990 until 2018. Outcome measures were mode of presentation, risk factors, initial neurologic findings, diagnostic investigations, site and size of the SSEH, treatment, neurologic recovery, and survival.
   RESULTS: Fourteen publications (16 patients) were included. Two patients presented in the second trimester, with the remainder in the third trimester. All patients presented with back pain, and 15 subsequently developed spinal cord dysfunction. Magnetic resonance imaging (MRI) was performed in all cases. The cervicothoracic region was the most commonly affected, and the average hematoma size extended across 3.9 vertebral levels. All patients with neurologic dysfunction underwent surgical decompression. In women under 32 weeks' gestation, caesarean section was not routinely performed. In contrast, women of gestational age of 32 weeks or more underwent a caesarean section prior to spinal decompression. Women without neurologic dysfunction underwent a caesarean section and neurologic monitoring without decompression. All patients with abnormal neurology improved after surgery, except 1 patient. No patients died.
   CONCLUSIONS: In pregnancy, SSEHs typically present in the second or third trimesters with back pain, predominantly in the cervicothoracic region, followed by progressive neurologic dysfunction. MRI is diagnostic, and the treatment depends on the patient's neurologic dysfunction and gestational age.
C1 [Soltani, Scheherezade; Nogaro, Marie-Caroline] Oxford Univ Hosp NHS Fdn Trust, Dept Spinal Surg, Oxford, England.
   [Kieser, Sandra Colette Jacqueline] Univ Otago, Dept Radiol, Christchurch, New Zealand.
   [Wyatt, Michael Charles; Kieser, David Christopher] Univ Otago, Dept Orthopaed Surg & Musculoskeletal Med, Christchurch, New Zealand.
RP Kieser, DC (reprint author), Univ Otago, Dept Orthopaed Surg & Musculoskeletal Med, Christchurch, New Zealand.
EM kieserdavid@gmail.com
RI Wyatt, Michael C/M-9129-2015
OI Wyatt, Michael C/0000-0001-5283-2608
CR Aksay E, 2008, AM J EMERG MED, V26
   Aristedis Rovlias, 2017, Surg Neurol Int, V8, P182, DOI 10.4103/sni.sni_197_17
   Awad JN, 2005, J BONE JOINT SURG BR, V87B, P1248, DOI 10.1302/0301-620X.87B9.16518
   Bansal J, 2014, J CLIN DIAGN RES, V8, pRD6, DOI 10.7860/JCDR/2014/10415.5307
   Case AS, 2005, AM J OBSTET GYNECOL, V193, P875, DOI 10.1016/j.ajog.2005.03.015
   Deger SM, 2009, INTERNAL MED, V48, P2115, DOI 10.2169/internalmedicine.48.2335
   Doblar DD, 2005, INT J OBSTET ANESTH, V14, P256, DOI 10.1016/j.ijoa.2004.09.009
   Duffill J, 2000, J NEUROL NEUROSUR PS, V69, P816, DOI 10.1136/jnnp.69.6.816
   Endo T, 2014, SPINAL CORD, V52, P729, DOI 10.1038/sc.2014.53
   GROEN RJM, 1991, NEUROPEDIATRICS, V22, P225, DOI 10.1055/s-2008-1071446
   Hejazi N, 1998, NEUROL MED-CHIR, V38, P718, DOI 10.2176/nmc.38.718
   Hejazi N, 1998, NEUROL MED CHIR TOKY, V38, P723
   Hsieh Cheng-Fang, 2005, Acta Neurol Taiwan, V14, P201
   Huh J, 2016, ANESTH PAIN MED, V6
   Iwatsuki K, 2015, GLOB SPINE J, V5, pE44, DOI 10.1055/s-0034-1398489
   Jo YY, 2012, INT J OBSTET ANESTH, V21, P185, DOI 10.1016/j.ijoa.2011.12.008
   Liou KC, 2012, AM J EMERG MED, V30
   Masski G, 2004, INT J OBSTET ANESTH, V13, P103, DOI 10.1016/j.ijoa.2003.09.006
   Matsubara S, 2011, J OBSTET GYNAECOL RE, V37, P1466, DOI 10.1111/j.1447-0756.2010.01522.x
   Shima H, 2012, NAGOYA J MED SCI, V74, P207
   Steinmetz Michael P, 2003, Spine J, V3, P539
   Tada S, 2011, J OBSTET GYNAECOL RE, V37, P1734, DOI 10.1111/j.1447-0756.2011.01592.x
   Wang P, 2011, EUR SPINE J, V20, pS176, DOI 10.1007/s00586-010-1484-9
   Wulf H, 1996, CAN J ANAESTH, V43, P1260, DOI 10.1007/BF03013437
   Xian H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008473
   Yonekawa Y, 1975, Surg Neurol, V3, P327
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 254
EP 258
DI 10.1016/j.wneu.2019.05.050
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100178
PM 31102771
DA 2020-05-12
ER

PT J
AU Lechanoine, F
   Smirnov, M
   Armani-Franceschi, G
   Carneiro, P
   Cottier, P
   Destrieux, C
   Maldonado, IL
AF Lechanoine, Francois
   Smirnov, Mykyta
   Armani-Franceschi, Giulia
   Carneiro, Pedro
   Cottier, Philippe
   Destrieux, Christophe
   Maldonado, Igor Lima
TI Stereoscopic Images from Computed Tomography Angiograrns
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrovascular disorders; Computed tomography angiography;
   Computer-assisted three-dimensional imaging; Internal carotid artery;
   Middle cerebral artery; Stereoscopic vision; Three-dimensional image
ID ANEURYSM SURGERY; CEREBRAL-ARTERY; VIRTUAL-REALITY; SIMULATION; MODELS;
   3D; NEUROSURGEONS
AB OBJECTIVE: To present an adaptation of the anaglyph photography technique to be used with radiological images from computed tomography angiograms, enabling stereoscopic visualization of a patient's individual abnormal vascular anatomy for teaching, case discussion, or surgical planning purposes.
   METHODS: Traditional anaglyph procedures with actual objects yield 2 independent photographs, simulating the image perceived by each eye. Production of anaglyphs from angiograms involve 3 basic procedures: volume rendering, image capture, and image fusion. Volume renderings were reconstructed using a free, open-source DICOM (Digital Imaging and Communications in Medicine) reader. Subsequently, the virtual object was positioned to mimic the operator's angle of view, and different perspectives of the reconstructed volume could be obtained through exclusively horizontal rotation. The 2 images were then fused after their color composition was modified so that each eye would perceive only 1 image when using anaglyph glasses.
   RESULTS: Forty-three angiograms were reviewed for the purpose of this study and a total of 6 examinations were selected for illustration of the technique. Stereoscopic display was possible for all of them and in the 3 types of support tested: computer monitor, tablet, and smartphone screens.
   CONCLUSIONS: Anaglyph display of computed tomography angiograms is an effective and low-cost alternative for the stereoscopic visualization of a patient's individual intracranial vascular anatomy.
C1 [Lechanoine, Francois; Smirnov, Mykyta; Cottier, Philippe; Destrieux, Christophe; Maldonado, Igor Lima] Univ Tours, INSERM, UMR 1253, iBrain, Tours, France.
   [Lechanoine, Francois] CHU Grenoble Alpes, Neurosurg Dept, Grenoble, France.
   [Lechanoine, Francois] Univ Grenoble Alpes, Grenoble, France.
   [Armani-Franceschi, Giulia; Carneiro, Pedro] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   [Maldonado, Igor Lima] Univ Fed Bahia, Dept Biomorfol, Inst Ciencias Saude, Salvador, BA, Brazil.
   [Cottier, Philippe; Destrieux, Christophe; Maldonado, Igor Lima] CHRU Tours, Tours, France.
   [Maldonado, Igor Lima] Le Studium Loire Valley Inst Adv Studies, Orleans, France.
RP Maldonado, IL (reprint author), Univ Tours, INSERM, UMR 1253, iBrain, Tours, France.; Maldonado, IL (reprint author), Univ Fed Bahia, Dept Biomorfol, Inst Ciencias Saude, Salvador, BA, Brazil.; Maldonado, IL (reprint author), CHRU Tours, Tours, France.; Maldonado, IL (reprint author), Le Studium Loire Valley Inst Adv Studies, Orleans, France.
EM igorlimamaldonado@gmail.com
RI Smirnov, Mykyta/AAB-2647-2019; Maldonado, Igor/B-6806-2015; Destrieux,
   Christophe/K-1190-2012
OI Smirnov, Mykyta/0000-0002-9478-4787; Maldonado,
   Igor/0000-0001-6037-0407; Destrieux, Christophe/0000-0001-5348-8052
CR Abarca-Olivas J, 2014, NEUROCIRUGIA, V25, P1, DOI 10.1016/j.neucir.2013.02.009
   Abla AA, 2015, WORLD NEUROSURG, V83, P35, DOI 10.1016/j.wneu.2014.01.015
   Augusto M, 2013, ARQ BRAS NEUROCIR, V32, P211
   Rubino PA, 2014, WORLD NEUROSURG, V82, pE467, DOI 10.1016/j.wneu.2013.02.065
   Aversi-Ferreira TA, 2008, BIOSCI J, V24, P98
   Balogh A, 2004, J NEUROSURG, V100, P591, DOI 10.3171/jns.2004.100.4.0591
   Benet A, 2015, BIOMED RES INT, V2015, P1
   Brewster David, 1856, STEREOSCOPE ITS HIST
   Chaddad-Neto F, 2012, ARQ NEURO-PSIQUIAT, V70, P727, DOI 10.1590/S0004-282X2012000900015
   Davidson J M, 1898, Br Med J, V2, P1669
   Erbano BO, 2013, ACTA CIR BRAS, V28, P756, DOI 10.1590/S0102-86502013001100002
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Ferwerda JG, 1990, WORLD 3D
   Garcia-Ruiz MA, 2013, P CAN INT C ED CICE
   Gatesy SM, 2005, PALAEONTOL ELECTRON, V8, P814
   Getty DJ, 2007, J SOC INF DISPLAY, V15, P377, DOI 10.1889/1.2749323
   Murillo-Garcia FG, 2015, LANDSLIDES, V12, P277, DOI 10.1007/s10346-014-0473-1
   Gonzalo-Dominguez M, 2016, P 4 INT C TECHN EC E, P491
   Henn JS, 2002, J NEUROSURG, V96, P144, DOI 10.3171/jns.2002.96.1.0144
   Hubel D., 1979, SCI AM, P84
   Kimura T, 2009, NEUROSURGERY, V65, P719, DOI 10.1227/01.NEU.0000354350.88899.07
   Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep44301
   Magaldi MO, 2014, OPER NEUROSURG, V10, P592, DOI 10.1227/NEU.0000000000000553
   Mandel M, 2013, SENSORS-BASEL, V13, P6477, DOI 10.3390/s130506477
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   Muns Andrea, 2014, Surg Neurol Int, V5, P173, DOI 10.4103/2152-7806.146346
   Nam KW, 2012, HEALTHC INFORM RES, V18, P158, DOI 10.4258/hir.2012.18.3.158
   OSULLIVAN E, 1993, J ANAT, V182, P295
   Parraga RG, 2011, WORLD NEUROSURG, V75, P233, DOI 10.1016/j.wneu.2010.10.053
   Quintana LM, 2014, WORLD NEUROSURG, V82, pE417, DOI 10.1016/j.wneu.2013.03.002
   Randazzo Michael, 2016, Surg Neurol Int, V7, pS801
   Raymond J, 2007, AM J NEURORADIOL, V28, P401
   Ribas GC, 2001, J NEUROSURG, V95, P1057, DOI 10.3171/jns.2001.95.6.1057
   Ribas GC, 2006, REV MED SAO PAULO, V85, P78
   Rollmann W, 1853, ANN PHYS, V166, P186, DOI DOI 10.1002/ANDP.18531660914
   Ryan JR, 2016, WORLD NEUROSURG, V88, P175, DOI 10.1016/j.wneu.2015.12.102
   Sarnat HB, 1981, EVOLUTION NERVOUS SY
   Shimizu Satoru, 2006, Neurosurgery, V58, pE1000, DOI 10.1227/01.NEU.0000210247.37628.43
   Smith DM, 2007, PLAST RECONSTR SURG, V120, P1641, DOI 10.1097/01.prs.0000282452.22620.25
   Spiriev Toma, 2017, Surg Neurol Int, V8, P241, DOI 10.4103/sni.sni_419_16
   Wang L, 2018, J CLIN NEUROSCI, V50, P77, DOI 10.1016/j.jocn.2018.01.074
   Wolfgram DE, 1993, ADVENTURAS 3D
   Woods AJ, 2010, P SPIE STEREOSCOPIC, V7253, p0Q1
   Woods AJ, 2013, OPT ENG, V52, DOI 10.1117/1.OE.52.4.043203
   Wurm G, 2011, SURG INNOV, V18, P294, DOI 10.1177/1553350610395031
   Yatomi K, 2012, J NEUROL SURG PART A, V73, P397, DOI 10.1055/s-0032-1322592
   Yeung YY, 2004, P 4 INT FOR ED REF O, P1
   Zollhavarieh SM, 2014, ASJ, V11, P59
NR 48
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 259
EP 267
DI 10.1016/j.wneu.2019.04.257
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100179
PM 31078804
DA 2020-05-12
ER

PT J
AU Mikhail, M
   Mithani, K
   Ibrahim, GM
AF Mikhail, Mirriam
   Mithani, Karim
   Ibrahim, George M.
TI Presurgical and Intraoperative Augmented Reality in Neuro-Oncologic
   Surgery: Clinical Experiences and Limitations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Augmented reality; Neuro-oncology; Virtual reality
ID VIRTUAL-REALITY; CORTICOSPINAL TRACT; BRAIN-TUMORS; SYSTEM;
   NEURONAVIGATION; LOCALIZATION; DEFORMATION; INTEGRATION; SIMULATORS;
   NAVIGATION
AB Virtual reality (VR) and augmented reality (AR) represent novel adjuncts for neurosurgical planning in neuro-oncology. In addition to established use in surgical and medical training, VR/AR are gaining traction for clinical use preoperatively and intraoperatively. To understand the utility of VR/AR in the clinical setting, we conducted a literature search in Ovid MEDLINE and EMBASE with various search terms designed to capture the use of VR/AR in neurosurgical procedures for resection of cranial tumors. The search retrieved 302 articles, of which 35 were subjected to full-text review; 19 full-text articles were included in the review. Key findings highlighted by the individual authors were extracted and summarized into themes to present the value of VR/AR in the clinical setting. These studies included various VR/AR systems applied to surgeries involving heterogeneous pathologies and outcome measures. Overall, VR/AR were found to be qualitatively advantageous due to enhanced visualization of complex anatomy and improved intraoperative lesion localization. When these technologies were compared with existing neuronavigation systems, quantitative clinical benefits were also reported. The capacity to visualize three-dimensional images superimposed on patient anatomy is a potentially valuable tool in complex neurosurgical environments. Surgical limitations may be addressed through future advances in image registration and tracking as well as intraoperatively acquired imaging with the ability to yield real-time virtual models.
C1 [Mikhail, Mirriam; Mithani, Karim] Univ Toronto, Hosp Sick Children, Fac Med, Toronto, ON, Canada.
   [Ibrahim, George M.] Univ Toronto, Hosp Sick Children, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
RP Mikhail, M (reprint author), Univ Toronto, Hosp Sick Children, Fac Med, Toronto, ON, Canada.
EM mirriam.mikhail@gmail.com
CR Amidei C, 2015, NEURO-ONCOL PRACT, V2, P179, DOI 10.1093/nop/npv017
   Anil SM, 2007, MINIM INVAS NEUROSUR, V50, P65, DOI 10.1055/s-2007-982508
   Barone DG, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009685.pub2
   Besharati TL, 2015, J NEUROSURG, V123, P206, DOI DOI 10.3171/2014.9.JNS141001
   Chen JG, 2017, WORLD NEUROSURG, V106, P193, DOI [10.1016/j.WNEU.2017.06.146, 10.1016/j.wneu.2017.06.146]
   Chou B, 2006, OBSTET GYN CLIN N AM, V33, P283, DOI 10.1016/j.ogc.2006.01.007
   Chrastina J, 2012, J NEUROL SURG PART A, V75, P110
   D'Andrea G, 2012, NEUROSURG REV, V35, P401, DOI 10.1007/s10143-012-0373-6
   Dolati Parviz, 2015, Surg Neurol Int, V6, P172, DOI 10.4103/2152-7806.170023
   Drouin S, 2017, INT J COMPUT ASS RAD, V12, P363, DOI 10.1007/s11548-016-1478-0
   Ellaway R, 2010, MED TEACH, V32, P705, DOI [10.3109/0142159X.2010.505849, 10.3109/0142159X.2010.513223]
   Ferroli P, 2013, NEUROSURGERY, V72, pA54, DOI 10.1227/NEU.0b013e3182748ee8
   Finger T, 2017, ACTA NEUROCHIR, V159, P1033, DOI 10.1007/s00701-017-3152-x
   Freudenstein D, 2001, Comput Aided Surg, V6, P77, DOI 10.1002/igs.1011
   Gerard IJ, 2018, J MED IMAGING, V5, DOI 10.1117/1.JMI.5.2.021210
   Gerard IJ, 2015, WORKSH CLIN IM BAS P
   Hill DLG, 1998, NEUROSURGERY, V43, P514, DOI 10.1097/00006123-199809000-00066
   Inoue A, 2015, NEUROSURG REV, V38, P559, DOI 10.1007/s10143-015-0625-3
   Inoue D, 2013, J NEUROL SURG PART A, V74, P71, DOI 10.1055/s-0032-1333415
   Kapoor V, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0225-1
   Kin T, 2017, NEUROL MED-CHIR, V57, P513, DOI 10.2176/nmc.ra.2016-0320
   Lee MH, 2014, CHILD NERV SYST, V30, P1055, DOI 10.1007/s00381-014-2367-x
   Liberati A, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000100
   Lo CY, 2007, P ANN INT IEEE EMBS, P1326, DOI 10.1109/IEMBS.2007.4352542
   Low D, 2010, BRIT J NEUROSURG, V24, P69, DOI 10.3109/02688690903506093
   Ma Shunchang, 2014, Zhonghua Yi Xue Za Zhi, V94, P3562
   Masutani Y, 1998, Comput Aided Surg, V3, P239, DOI 10.1002/(SICI)1097-0150(1998)3:5<239::AID-IGS3>3.0.CO;2-B
   Maurer CR, 1998, IEEE T MED IMAGING, V17, P817, DOI 10.1109/42.736050
   Mazur T, 2018, WORLD NEUROSURG, V110, P414, DOI 10.1016/j.wneu.2017.11.132
   Meola A, 2017, NEUROSURG REV, V40, P537, DOI 10.1007/s10143-016-0732-9
   Nimsky C, 2001, SURG NEUROL, V56, P357, DOI 10.1016/S0090-3019(01)00628-0
   Okada T, 2006, RADIOLOGY, V240, P849, DOI 10.1148/radiol.2403050916
   Orringer DA, 2012, EXPERT REV MED DEVIC, V9, P491, DOI [10.1586/ERD.12.42, 10.1586/erd.12.42]
   Pan XD, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-79
   Parsons TD, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7040042
   Qiu TM, 2010, ACTA NEUROCHIR, V152, P1847, DOI 10.1007/s00701-010-0739-x
   Rennert RC, 2016, J NEURO-ONCOL, V130, P377, DOI 10.1007/s11060-016-2180-3
   Roder C, 2014, INT J COMPUT ASS RAD, V9, P551, DOI 10.1007/s11548-013-0952-1
   Rosahl SK, 2006, SKULL BASE-INTERD AP, V16, P59, DOI 10.1055/s-2006-931620
   Rotariu DH, 2017, TURK NEUROSURG, V27, P339, DOI 10.5137/1019-5149.JTN.16311-15.2
   Shan Q, 2017, PROCEDIA COMPUT SCI, V113, P400, DOI 10.1016/j.procs.2017.08.356
   Shuhaiber JH, 2004, ARCH SURG-CHICAGO, V139, P170, DOI 10.1001/archsurg.139.2.170
   Spetzger U, 2002, MINIM INVAS NEUROSUR, V45, P6, DOI 10.1055/s-2002-23583
   Stadie AT, 2009, MINIM INVAS NEUROSUR, V52, P9, DOI 10.1055/s-0028-1103305
   Stadie AT, 2013, NEUROSURGERY, V72, pA63, DOI 10.1227/NEU.0b013e318270d310
   Stadie AT, 2011, INT J COMPUT ASS RAD, V6, P565, DOI 10.1007/s11548-010-0529-1
   Stadie AT, 2008, J NEUROSURG, V108, P382, DOI 10.3171/JNS/2008/108/2/0382
   Stadlbauer A, 2009, ACTA NEUROCHIR, V151, P1061, DOI 10.1007/s00701-009-0378-2
   Sun GC, 2016, WORLD NEUROSURG, V96, P375, DOI 10.1016/j.wneu.2016.07.107
   Tagaytayan R, 2018, ARCH MED SCI, V14, P572, DOI 10.5114/aoms.2016.58690
   Watanabe E, 2016, WORLD NEUROSURG, V87, P399, DOI 10.1016/j.wneu.2015.11.084
   Widmann G, 2012, INT J MED ROBOT COMP, V8, P1, DOI 10.1002/rcs.441
   Yang DL, 2009, SURG NEUROL, V72, P682, DOI 10.1016/j.surneu.2009.07.040
   Zhang YQ, 2012, J CRANIOFAC SURG, V23, P1866, DOI 10.1097/SCS.0b013e31826bf22a
   Zhao Y, 2012, J CLIN NEUROSCI, V19, P255, DOI 10.1016/j.jocn.2011.03.041
NR 55
TC 0
Z9 0
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 268
EP 276
DI 10.1016/j.wneu.2019.04.256
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100180
PM 31103764
DA 2020-05-12
ER

PT J
AU Sun, W
   Li, GS
   Lai, ZH
   Lu, ZJ
   Lin, Y
   Peng, JD
   Huang, JC
   Hu, K
AF Sun, Wei
   Li, Guangsheng
   Lai, Zhaohui
   Lu, Zhijuan
   Lin, Ye
   Peng, Jidong
   Huang, Jinchang
   Hu, Kun
TI Subacute Combined Degeneration of the Spinal Cord and Hydrocephalus
   Associated with Vitamin B12 Deficiency
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anti-intrinsic factor; Atrophic gastritis; Cerebellum; Hydrocephalus;
   Neuroimaging; Subacute combined degeneration; Vitamin B12 deficiency
AB BACKGROUND: This study aimed to report the case of a patient who presented with depression, cognitive impairment, ataxic gait, and urinary incontinence associated with vitamin B12 deficiency.
   CASE DESCRIPTION: Serum vitamin B12 level was low in this patient, and anti-intrinsic factor antibody was positive. Neuroimaging revealed abnormal hyperintense signals in the cerebellum and dorsal and lateral columns of the spinal cord, and obstructive hydrocephalus. A biopsy of the stomach revealed chronic gastritis, intestinal metaplasia, and atrophy. After 3 months of initiating methylcobalamin therapy, significant improvement was noticed clinically, and brain magnetic resonance imaging was near to normal.
   CONCLUSIONS: This study was novel in reporting subacute combined degeneration of the spinal cord and hydrocephalus associated with vitamin B12 deficiency in adults.
C1 [Sun, Wei; Li, Guangsheng; Lai, Zhaohui; Lu, Zhijuan] Nanchang Univ, Affiliated Ganzhou Hosp, Dept Neurol, Ganzhou, Jiangxi, Peoples R China.
   [Lin, Ye] Nanchang Univ, Affiliated Ganzhou Hosp, Dept Gastroenterol, Ganzhou, Jiangxi, Peoples R China.
   [Peng, Jidong] Nanchang Univ, Affiliated Ganzhou Hosp, Dept Radiol, Ganzhou, Jiangxi, Peoples R China.
   [Huang, Jinchang] Nanchang Univ, Affiliated Ganzhou Hosp, Dept Pathol, Ganzhou, Jiangxi, Peoples R China.
   [Hu, Kun] Nanchang Univ, Affiliated Ganzhou Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
RP Li, GS (reprint author), Nanchang Univ, Affiliated Ganzhou Hosp, Dept Neurol, Ganzhou, Jiangxi, Peoples R China.
EM liguangsheng0016@163.com
CR Bergsneider M, 2008, NEUROSURGERY, V62, P643, DOI [10.1227/01.NEU.0000296954.22901.C6, 10.1227/01.neu.0000316269.82467.f7]
   Biancheri R, 2001, NEUROPEDIATRICS, V32, P14, DOI 10.1055/s-2001-12217
   Chakrabarty B, 2014, J CHILD NEUROL, V29, pNP161, DOI 10.1177/0883073813513498
   Coggins M, 1998, CLIN SCI, V94, P677
   Greitz Dan, 2006, Neuroradiol J, V19, P475
   HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001
   Lee R, 2003, HEMATOL ONCOL CLIN N, V17, P85, DOI 10.1016/S0889-8588(02)00090-4
   Morita S, 2003, J NEUROL SCI, V216, P183, DOI 10.1016/S0022-510X(03)00219-3
   Reynolds E, 2006, LANCET NEUROL, V5, P949, DOI 10.1016/S1474-4422(06)70598-1
   Scalabrino G, 2005, EXP NEUROL, V192, P463, DOI 10.1016/j.expneurol.2004.12.020
   Stabler S., 2006, CLIN HEMATOLOGY, P2242
   Stabler SP, 2013, NEW ENGL J MED, V368, P149, DOI [10.1056/NEJMcp1113996, 10.1056/NEJMc1304350]
   Toh BH, 2012, CLIN REV ALLERG IMMU, V42, P269, DOI 10.1007/s12016-010-8218-y
NR 13
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 277
EP 283
DI 10.1016/j.wneu.2019.05.008
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100181
PM 31082549
OA Bronze
DA 2020-05-12
ER

PT J
AU Zussman, BM
   Goldschmidt, E
   Faraji, AH
   Salvetti, DJ
   Jankowitz, BT
AF Zussman, Benjamin M.
   Goldschmidt, Ezequiel
   Faraji, Amir H.
   Salvetti, David J.
   Jankowitz, Brian T.
TI Middle Meningeal Artery Embolization for the Treatment of an Expanding
   Epidural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Epidural hematoma; Middle meningeal artery;
   Middle meningeal artery embolization
AB INTRODUCTION: Epidural hematomas (EHs) usually originate from traumatic injury to the middle meningeal artery (MMA). Although large Ells may need to be emergently evacuated, the management of smaller EHs is less clear, especially in the absence of significant mass effect or neurologic deficits. Endovascular treatment via MMA embolization for epidural hematomas has only been recently reported. Herein, we present a case whereby MMA embolization was performed to prevent further growth of an expanding, right-sided EH after a larger left EH was surgically evacuated.
   CASE DESCRIPTION: A 31-year-old male patient was brought to the emergency department after he was found down by the police at his house. He was initially conversant but quickly became obtunded within a few minutes. An initial scan showed bilateral (left larger than right) acute EHs, and the patient was taken to the operating room for a left craniotomy. Immediate postoperative imaging demonstrated an expanding right-sided EH. The patient was emergently taken to the endovascular suite and obvious contrast extravasation was noticed from the parietal branch of the MMA. The MMA was embolized via a transradial approach. Follow-up imaging revealed stable hematoma size without the need for additional surgery. The patient was discharged without any neurologic deficits.
   CONCLUSIONS: Herein, we report the successful endovascular treatment of an expanding EH following a contralateral craniotomy. Active bleeding of the MMA was observed via angiography and may predict further EH expansion. Endovascular exploration and possible treatment can be justified in patients with EH that do not have a clear surgical indication.
C1 [Zussman, Benjamin M.; Goldschmidt, Ezequiel; Faraji, Amir H.; Salvetti, David J.; Jankowitz, Brian T.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15261 USA.
RP Jankowitz, BT (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15261 USA.
EM jankbt@upmc.edu
CR Ban SP, 2018, RADIOLOGY, V286, P909, DOI 10.1148/radiol.2017170053
   CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004
   HAMILTON M, 1992, AM J NEURORADIOL, V13, P853
   Peres CMA, 2018, J NEUROSURG, V128, P1044, DOI 10.3171/2016.11.JNS161398
   Ross IB, 2009, J NEUROSURG, V110, P1247, DOI 10.3171/2008.7.JNS0883
   SAGHER O, 1992, AM J NEURORADIOL, V13, P860
   Srivatsan A, 2019, WORLD NEUROSURG, V122, P613, DOI 10.1016/j.wneu.2018.11.167
   Tempaku A, 2015, INTERV NEURORADIOL, V21, P366, DOI 10.1177/1591019915583224
   Waqas M, 2019, WORLD NEUROSURG, V126, P228, DOI 10.1016/j.wneu.2019.02.208
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 284
EP 286
DI 10.1016/j.wneu.2019.05.084
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100182
PM 31108255
DA 2020-05-12
ER

PT J
AU Takebayashi, K
   Kohara, K
   Miura, I
   Yuzurihara, M
   Kubota, M
   Kawamata, T
AF Takebayashi, Kento
   Kohara, Kotaro
   Miura, Isamu
   Yuzurihara, Masahito
   Kubota, Motoo
   Kawamata, Takakazu
TI Lumbar Ganglioneuroma from the Paravertebral Body Presenting in
   Continuity Between Intradural and Extradural Spaces
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ganglioneuroma; Lumbar; Paravertebral body
ID FILUM TERMINALE; PARAGANGLIOMA
AB BACKGROUND: Ganglioneuroma is a well-differentiated benign tumor that develops from the ganglion cells of the posterior mediastinum, retroperitoneum, cervical spine, and adrenal glands. The paravertebral body, in which the sympathetic trunk exists, is a common tumor site, and tumor sometimes invades the spinal canal through the intervertebral foramen. There have been no reports regarding tumors with intradural and extradural continuity. We report a paravertebral ganglioneuroma extending between the intradural and extradural spaces and its surgical treatment.
   CASE DESCRIPTION: A 33-year-old man was admitted to the hospital with progressive left lower limb numbness. A dumbbell-type tumor progressing to the spinal canal via the left intervertebral foramen from the paravertebral body at L1-2 was detected, and intradural calcified lesions were found. Pathologic examination of a computed tomography-guided biopsy sample revealed a ganglio-glioma. The extradural tumor was removed; however, the left lower limb pain gradually worsened. As complete block was observed on myelography, the intradural tumor was removed 8 months later. Intraoperative findings revealed that the intradural and extradural tumors were continuous through the L1 nerve root.
   CONCLUSIONS: This is the first known reported case of paravertebral ganglioneuroma presenting in continuity between the intradural and extradural spaces.
C1 [Takebayashi, Kento; Kohara, Kotaro; Miura, Isamu; Yuzurihara, Masahito; Kubota, Motoo] Kameda Med Ctr, Dept Spinal Surg, Chiba, Japan.
   [Takebayashi, Kento; Kohara, Kotaro; Miura, Isamu; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Takebayashi, K (reprint author), Kameda Med Ctr, Dept Spinal Surg, Chiba, Japan.; Takebayashi, K (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM tikurin0221@yahoo.co.jp
OI Miura, Isamu/0000-0001-5231-5862
CR Kang SH, 2018, EUR SPINE J, V27, pS520, DOI 10.1007/s00586-018-5568-2
   Kimura Shigeharu, 2002, Spine (Phila Pa 1976), V27, pE513, DOI 10.1097/00007632-200212010-00019
   Kulkarni AV, 1998, J NEUROSURG, V88, P324, DOI 10.3171/jns.1998.88.2.0324
   LERMAN RI, 1972, J NEUROSURG, V36, P652, DOI 10.3171/jns.1972.36.5.0652
   Okudera Y, 2014, J NEUROSURG-SPINE, V21, P270, DOI 10.3171/2014.4.SPINE121002
   Paasch C, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0953-y
   Przkora R, 2006, EUR SPINE J, V15, P363, DOI 10.1007/s00586-005-0964-9
   Qiu Y, 2007, SPINE, V32, pE326, DOI 10.1097/01.brs.0000261628.77342.ba
   Shankar GM, 2010, J NEUROSURG-SPINE, V12, P709, DOI 10.3171/2009.12.SPINE09482
   Sharma A, 1998, AM J ROENTGENOL, V170, P1650, DOI 10.2214/ajr.170.6.9609190
   Wang Z, 2016, CHIN NEUROSURG J, V2, P31
   Yang YH, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0823-7
   Yorita Kenji, 2014, J Med Case Rep, V8, P345, DOI 10.1186/1752-1947-8-345
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 289
EP 294
DI 10.1016/j.wneu.2019.05.065
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100184
PM 31102769
DA 2020-05-12
ER

PT J
AU Kuge, A
   Kondo, R
   Sato, S
   Mitobe, Y
   Saito, S
   Sonoda, Y
AF Kuge, Atsushi
   Kondo, Rei
   Sato, Shinji
   Mitobe, Yuta
   Saito, Shinjiro
   Sonoda, Yukihiko
TI Novel Burr Hole Dilator for Endoscopic Surgery for Intracranial
   Hemorrhagic Lesion: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burr hole surgery; Endoscopic neurosurgery; Minimally invasive; Novel
   burr hole dilator
ID HEMATOMA
AB OBJECTIVE: When performing burr hole endoscopic neurosurgery, it is necessary to get enough surgical corridor. We have used various instruments to extend burr hole size, but it was cumbersome to use so many tools.
   METHODS: In this report, we describe a novel instrument-a dilator attachment with a cordless handle to make it simple and safe to extend a burr hole. We developed this burr hole dilator attachment with blades on the side and an arc form on the bottom to prevent dural damage. It can be used to drill safely and efficiently. We describe some experiences of using this device.
   RESULTS: It is important to balance the maximization of operation range and surgical invasiveness for endoscopic neurosurgery. This new dilator for extending a burr hole is a safe, useful device to get enough surgical view and easily perform a surgical procedure in endoscopic surgery.
   CONCLUSIONS: Our dilator for expanding a burr hole improves the work of endoscopic surgery on intracranial hemorrhagic lesions.
C1 [Kuge, Atsushi] Yamagata City Hosp Saiseikan, Dept Emergency Med, Yamagata, Japan.
   [Kuge, Atsushi; Kondo, Rei; Sato, Shinji; Mitobe, Yuta; Saito, Shinjiro] Yamagata City Hosp Saiseikan, Dept Neurosurg, Yamagata, Japan.
   [Sonoda, Yukihiko] Yamagata Univ, Sch Med, Dept Neurosurg, Yamagata, Japan.
RP Kuge, A (reprint author), Yamagata City Hosp Saiseikan, Dept Emergency Med, Yamagata, Japan.; Kuge, A (reprint author), Yamagata City Hosp Saiseikan, Dept Neurosurg, Yamagata, Japan.
EM atsukuge@gmail.com
OI Sonoda, Yukihiko/0000-0001-7651-1374
CR AUER LM, 1989, J NEUROSURG, V70, P530, DOI 10.3171/jns.1989.70.4.0530
   Kuge A, 2017, ACUTE MED SURG, V4, P451, DOI 10.1002/ams2.295
   Nishihara T, 2007, CHILD NERV SYST, V23, P677, DOI 10.1007/s00381-007-0325-6
   Yokosuka K, 2015, J NEUROSURG, V123, P1065, DOI 10.3171/2014.10.JNS14915
NR 4
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 295
EP 298
DI 10.1016/j.wneu.2019.05.035
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100185
PM 31096032
DA 2020-05-12
ER

PT J
AU Ng, AL
   Rosenfeld, JV
   Di Ieva, A
AF Ng, Angela Li Ching
   Rosenfeld, Jeffrey, V
   Di Ieva, Antonio
TI Cranial Nerve Nomenclature: Historical Vignette
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial nerves; Eponyms; History of medicine; Nomenclature
ID ANATOMY; TERMINOLOGY; SYSTEM; GALEN; WORK; AD
AB The nomenclature of the 12 cranial nerves as we know it today was developed over a series of anatomic findings by some of history's most famous anatomists from Galen to Von Soemmerring. In this paper, we review the literature to present an overview of the remarkable historical journey that brought our forefathers to trace the pathway of individual cranial nerves from origin to destination. In particular, we discuss the evolution of the naming of the cranial nerves and highlight relevant eponymous descriptions. We also include some poignant illustrations of cranial nerves by ancient anatomists that set the scene to their discoveries. In reviewing this legacy, we summarize the important product of centuries of discoveries and investigations and the limitations of cranial nerve classification systems.
C1 [Ng, Angela Li Ching; Di Ieva, Antonio] Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Neurosurg Unit, Sydney, NSW, Australia.
   [Rosenfeld, Jeffrey, V] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia.
   [Rosenfeld, Jeffrey, V] Monash Univ, Dept Surg, Melbourne, Vic, Australia.
   [Rosenfeld, Jeffrey, V] Uniformed Serv Univ Hlth Sci, Dept Surg, F Edward Hebert Sch Med, Bethesda, MD 20814 USA.
RP Di Ieva, A (reprint author), Macquarie Univ, Fac Med & Hlth Sci, Dept Clin Med, Neurosurg Unit, Sydney, NSW, Australia.
EM antonio.diieva@mq.edu.au
OI Di Ieva, Antonio/0000-0002-5341-5416
CR Acar F, 2005, NEUROSURGERY, V56, P861, DOI 10.1227/01.NEU.0000156791.97198.58
   Alfieri A, 2010, ANN ANAT, V192, P139, DOI 10.1016/j.aanat.2010.02.004
   Aly I, 2016, INT J HIST PHIL MED, V6, P105
   Bast T., 1924, ANN MED HIST, V6, P69
   Brinkman RJ, 2017, J VOICE, V31, DOI 10.1016/j.jvoice.2015.12.019
   Carlson ML, 2017, OTOL NEUROTOL, V38, P1376, DOI 10.1097/MAO.0000000000001535
   Carmichael EA, 1933, BRAIN, V56, P109, DOI 10.1093/brain/56.2.109
   Cianci M., 1998, DRAWING 19052R, P19
   Clarke R, 1996, CHEM ENG-LONDON, P2
   Cogan DG, 1966, NEUROLOGY VISUAL SYS
   Costea CF, 2017, CHILD NERV SYST, V33, P1889, DOI 10.1007/s00381-017-3564-1
   Cowper W., 1698, ANATOMY HUMANE BODY
   Daneshfard B, 2016, J MED BIOGR, V24, P227, DOI 10.1177/0967772014529050
   Davis MC, 2014, CLIN ANAT, V27, P14, DOI 10.1002/ca.22345
   Di Ieva A, 2007, NEUROSURGERY, V60, P563, DOI 10.1227/01.NEU.0000249283.46514.93
   Di Ieva A, 2011, J NEUROSURG, V114, P1461, DOI 10.3171/2010.10.JNS101331
   Federative Committee on Anatomical Terminology, 1998, TERM AN INT AN TERM
   Flamm E., 1992, J NEUROSURG, V297, P285
   GOSS CM, 1966, AM J ANAT, V118, P327, DOI 10.1002/aja.1001180202
   HIERONS R, 1962, P ROY SOC MED, V55, P287, DOI 10.1177/003591576205500407
   Hildebrand R, 2005, ANAT EMBRYOL, V210, P337, DOI 10.1007/s00429-005-0027-3
   Hunt JR, 1909, J NERV MENT DIS, V36, P0321, DOI 10.1097/00005053-190906000-00001
   Hunter J., 1974, OBSERVATIONS CERTAIN
   Kaplan EL, 2009, WORLD J SURG, V33, P386, DOI 10.1007/s00268-008-9798-z
   Mayo H, 1822, ANATOMICAL PHYSL COM, P1
   Meckel JF, 1748, THESIS
   Mortazavi MM, 2013, CHILD NERV SYST, V29, P877, DOI 10.1007/s00381-012-1921-7
   ORAHILLY R, 1988, ACTA ANAT, V133, P3
   Pearce JMS, 2003, J NEUROL NEUROSUR PS, V74, P1688, DOI 10.1136/jnnp.74.12.1688
   Porzionato A, 2013, ANN ANAT, V195, P28, DOI 10.1016/j.aanat.2012.04.007
   Richardson WF, 2002, FABRIC HUMAN BODY TR
   Sanders Mark A, 2005, Anat Rec B New Anat, V282, P5, DOI 10.1002/ar.b.20046
   SHAW JP, 1992, CLIN ANAT, V5, P466
   Shoja MM, 2007, NEUROSURGERY, V61, P1325, DOI 10.1227/01.neu.0000306113.00916.7d
   Shoja MM, 2007, J ANAT, V210, P359, DOI 10.1111/j.1469-7580.2007.00711.x
   Shoja MM, 2014, CLIN ANAT, V27, P2, DOI 10.1002/ca.22365
   Simon F, 2011, ANN ANAT, V193, P447, DOI 10.1016/j.aanat.2011.04.012
   Simpson D, 2011, ANZ J SURG, V81, P905, DOI 10.1111/j.1445-2197.2011.05793.x
   Singer Charles trans, 1956, GALEN ANATOMICAL PRO
   Smith C, 2012, SAGES MANNUAL OF QUALITY, OUTCOMES AND PATIENT SAFETY, P41, DOI 10.1007/978-1-4419-7901-8_5
   Soemmerring S., 1778, BASE SKULL ORIGINS E
   Sonig A, 2013, J NEUROSURG, V119, P778, DOI 10.3171/2013.4.JNS121340
   Steinberg DA, 2002, SEMIN NEUROL, V22, P349, DOI 10.1055/s-2002-36756
   Swanson LW, 2015, NEUROANATOMICAL TERM
   Taglialagamba S., 2010, LEONARDO ANATOMY, P64
   Taylor J., 1738, MECH NEW TREATY ANAT
   Tubbs RS, 2007, CHILD NERV SYST, V23, P1225, DOI 10.1007/s00381-007-0368-8
   Vesalius Andreas, 1543, HUMANI CORPORIS FABR
   Vieussens R., 1685, UNIVERSAL NEUROGRAPH
   Willis T., 1666, CEREBRI ANATOME CUI
   Zago S, 2009, J NEUROL, V256, P1195, DOI 10.1007/s00415-009-5192-5
NR 51
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 299
EP 307
DI 10.1016/j.wneu.2019.05.036
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100186
PM 31100524
DA 2020-05-12
ER

PT J
AU Pizzinga, A
   Pindinello, I
   Artico, M
   Nicolai, A
   Taurone, S
   Santoro, A
AF Pizzinga, Annalisa
   Pindinello, Ivano
   Artico, Marco
   Nicolai, Alice
   Taurone, Samanta
   Santoro, Antonio
TI Francesco Durante and the First intracranial Tumor Successfully Operated
   on with Long Survival (1884)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Francesco Durante; Neurosurgery; Surgical procedure
ID SURGERY
AB Francesco Durante was born in Sicily, precisely Letojanni Gallodoro. He contributed to the history of neurosurgery in not only Italy but the whole world. In June 1884, he removed a left frontal meningioma, describing a personal technique of craniotomy with a discontinuous osteotangential section flap. It was the first such operation to be performed in any country after which the patient had a long survival. The important and pioneering contribution made by Durante to the history of neurosurgery is testified by his Treaty on Pathology and Surgical Therapy. Durante's procedure for craniotomy remained the best for several years. His contributions are still valid in medicine today, within not only the neurosurgical community but also other surgical disciplines, because he also developed innovative practices in the fields of oncology, general surgery, and orthopedics in addition to designing special surgical instruments.
C1 [Pizzinga, Annalisa] Sapienza Univ Rome, Fac Pharm & Med, Rome, Italy.
   [Pindinello, Ivano] Sapienza Univ Rome, Dept Drug Chem & Technol, Rome, Italy.
   [Artico, Marco; Nicolai, Alice; Taurone, Samanta] Sapienza Univ Rome, Dept Sensory Organs, Rome, Italy.
   [Santoro, Antonio] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
RP Taurone, S (reprint author), Sapienza Univ Rome, Dept Sensory Organs, Rome, Italy.
EM t.samanta@yahoo.it
CR Armocida G., 1993, F DURANTE
   Artico M, 1996, NEUROSURGERY, V39, P380, DOI 10.1097/00006123-199608000-00030
   Artico M, 2003, SURG NEUROL, V60, P71, DOI 10.1016/S0090-3019(03)00031-4
   Artico M, 1998, NEUROSURGERY, V42, P909, DOI 10.1097/00006123-199804000-00121
   Durand J L, 1997, Ann Chir Plast Esthet, V42, P75
   Durante F, 1887, LANCET, V130, P654, DOI 10.1016/S0140-6736(02)10289-3
   Durante F., 1895, TRATTATO PATOLOGIA T, VIII
   DURANTE F, 1885, B R ACCAD MED ROMA, V11, P247
   Falloppio G, 1964, RECONSTRUCTIVE PLAST, P564
   Goodrich JT, 2000, CHILD NERV SYST, V16, P669, DOI 10.1007/s003810000322
   Guidetti B, 1983, Surg Neurol, V20, P1, DOI 10.1016/0090-3019(83)90096-4
   GUIDETTI B, 1983, SURG NEUROL, V20, P335, DOI 10.1016/0090-3019(83)90091-5
   Maroon Joseph C, 2005, Neurosurg Focus, V19, pE1, DOI 10.3171/foc.2005.19.1.2
   Pare A., 1634, WORKS FAMOUS SURG AM
   Priola SM, 2014, WORLD NEUROSURG, V82, P523, DOI 10.1016/j.wneu.2013.07.076
   Sironi VA, 1986, CONTRIBUTO STORIA NE, P151
   Sterpetti AV, 2014, J NEUROL, V261, P2469, DOI 10.1007/s00415-014-7296-9
   STULA D, 1980, NEUROCHIRURGIA, V23, P41
   Tomasello F, 2006, NEUROSURGERY, V59, P389, DOI 10.1227/01.NEU.0000223444.18909.9A
   Triolo V, 1966, PHYSIS, VVIII, P199
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 308
EP 313
DI 10.1016/j.wneu.2019.05.054
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100187
PM 31100518
DA 2020-05-12
ER

PT J
AU Potts, MB
   Horbinski, CM
   Jahromi, BS
AF Potts, Matthew B.
   Horbinski, Craig M.
   Jahromi, Babak S.
TI Rapid Development of an Aneurysm at the Anastomotic Site of a
   Superficial Temporal Artery to Middle Cerebral Artery Bypass: Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anastomosis; Aneurysm; Middle cerebral artery; Pseudoaneurysm; Stroke;
   Superficial temporal artery
ID DE-NOVO ANEURYSM; EXTRACRANIAL-INTRACRANIAL BYPASS; INTRACEREBRAL
   HEMORRHAGE; RUPTURED ANEURYSM; SURGERY; PSEUDOANEURYSM
AB BACKGROUND: Direct extracranial to intracranial (EC-IC) bypass is a valuable treatment option for symptomatic occlusive cerebrovascular disease and complex intracranial aneurysms. Aneurysm formation at or near the anastomotic site is a rarely reported phenomenon, and the pathophysiology and appropriate management of such de novo aneurysms are not clear.
   CASE DESCRIPTION: Here we present the case of a superficial temporal to middle cerebral artery (STA-MCA) anastomosis that was complicated by aneurysm formation at the anastomotic site. This was treated with microsurgical clipping with preservation of the bypass. Pathologic analysis of the lesion was consistent with a pseudoaneurysm. We provide a literature review of this phenomenon, which is most often associated with low-flow STA-MCA bypasses, including review of the pathologic findings associated with it.
   CONCLUSION: Pseudoaneurysm formation at the site of an EC-IC bypass is a rare phenomenon that should be recognized and treated to prevent further growth and rupture.
C1 [Potts, Matthew B.; Horbinski, Craig M.; Jahromi, Babak S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Northwestern Mem Hosp, Chicago, IL 60611 USA.
   [Potts, Matthew B.; Jahromi, Babak S.] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Northwestern Mem Hosp, Chicago, IL 60611 USA.
   [Horbinski, Craig M.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Northwestern Mem Hosp, Chicago, IL 60611 USA.
RP Potts, MB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Northwestern Mem Hosp, Chicago, IL 60611 USA.; Potts, MB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Radiol, Northwestern Mem Hosp, Chicago, IL 60611 USA.
EM matthew.potts@northwestern.edu
CR Aoki T, 2012, NEUROSURGERY, V71, DOI 10.1227/NEU.0b013e318260ffcf
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   Eom KS, 2010, ACTA NEUROCHIR, V152, P1069, DOI 10.1007/s00701-009-0550-8
   Fein J M, 1985, Neurol Res, V7, P46
   FLEISCHER AS, 1979, SURG NEUROL, V12, P305
   Fukushima Yuta, 2015, Surg Neurol Int, V6, P41, DOI 10.4103/2152-7806.153709
   Hokari M, 2010, NEUROL MED-CHIR, V50, P1012, DOI 10.2176/nmc.50.1012
   Kalani MYS, 2015, WORLD NEUROSURG, V83, P345, DOI 10.1016/j.wneu.2014.10.013
   Kawahara I, 2013, CLIN NEUROL NEUROSUR, V115, P457, DOI 10.1016/j.clineuro.2012.05.044
   Kohno K, 1996, NEUROSURGERY, V38, P1051, DOI 10.1097/00006123-199605000-00041
   Kurokawa T, 2007, NEUROSURGERY, V61, P297, DOI 10.1227/01.neu.0000303983.19375.a3
   LANTOS G, 1984, J NEUROSURG, V60, P636, DOI 10.3171/jns.1984.60.3.0636
   LECLERCQ TA, 1980, J NEUROSURG, V52, P392, DOI 10.3171/jns.1980.52.3.0392
   Lykoudis EG, 2009, MICROSURG, V29, P293, DOI 10.1002/micr.20612
   Millesi M, 2015, J NEUROL SURG PART A, V76, P323, DOI 10.1055/s-0034-1376189
   MORGAN M, 1986, SURG NEUROL, V26, P277, DOI 10.1016/0090-3019(86)90162-X
   Nishimoto T, 2005, SURG NEUROL, V64, P261, DOI 10.1016/j.surneu.2004.09.041
   Nishizawa S, 2000, NEUROL MED-CHIR, V40, P408, DOI 10.2176/nmc.40.408
   PARENT AD, 1981, SURG NEUROL, V15, P229, DOI 10.1016/0090-3019(81)90151-8
   Pogorzelski Ryszard, 2014, Pol Przegl Chir, V86, P48, DOI 10.2478/pjs-2014-0009
   ROBERTSON JH, 1978, SURG NEUROL, V10, P241
   Sasaki T, 1996, J NEUROSURG, V85, P500, DOI 10.3171/jns.1996.85.3.0500
   Uchida Tatsuya, 2017, NMC Case Rep J, V4, P111, DOI 10.2176/nmccrj.cr.2017-0037
   Yokota H, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.05.075
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 314
EP 319
DI 10.1016/j.wneu.2019.05.108
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100188
PM 31125771
DA 2020-05-12
ER

PT J
AU Kuroda, N
   Inenaga, C
   Arai, Y
   Otsuki, Y
   Tanaka, T
AF Kuroda, Naoto
   Inenaga, Chikanori
   Arai, Yoshifumi
   Otsuki, Yoshiro
   Tanaka, Tokutaro
TI Cerebellar Metastasis of Unknown Primary Neuroendocrine Carcinoma:
   Report of Case Mimicking Hemangioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Cancer of unknown primary; Cerebellar metastasis;
   Neuroendocrine carcinoma; Neuroendocrine tumor
ID TUMORS; GUIDELINES; PET/CT; BRAIN
AB BACKGROUND: Neuroendocrine carcinoma (NEC) originates with neuroendocrine cells and is mainly found in the pancreas, lungs and gastrointestinal tract. We surgically treated a case of primary unknown NEC with only cerebral metastasis that mimicked hemangioblastoma. Recurrence was seen at the fornix, and no primary lesion had been identified as of 2 years after treatments despite careful examination.
   CASE DESCRIPTION: A 61-year-old man presented with dizziness. Past medical history included hypertension, dyslipidemia, hyperuricemia and colon polyp. We performed magnetic resonance imaging (MRI) to examine the cause of dizziness, revealing tumor with enhancement and peritumoral edema at the right cerebral lesion. Contrast-enhanced whole-body computed tomography (CT) showed no other lesions. We suspected hemangioblastoma from examinations and decided on surgical resection. Neuropathologically, the resected tumor was diagnosed as brain metastasis of NEC, but CT, fluorodeoxyglucose-positron emission tomography, gastrointestinal endoscopy, and somatostatin receptor scintigraphy all failed to reveal the primary lesion. As postoperative MRI showed enhancement around the resection cavity and at the right fornix, radiotherapy was performed. No other lesions were seen at 24 months post-operatively. We are continuing careful monitoring and no chemotherapy has been administered.
   CONCLUSIONS: We treated brain metastasis from NEC of unknown primary and mimicking hemangioblastoma using only local treatment. When an enhancing, single, solid tumor is seen in the cerebellum, brain metastasis from NEC of unknown primary is 1 differential diagnosis.
C1 [Kuroda, Naoto; Inenaga, Chikanori; Tanaka, Tokutaro] Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Naka Ku, Hamamatsu, Shizuoka, Japan.
   [Arai, Yoshifumi; Otsuki, Yoshiro] Seirei Hamamatsu Gen Hosp, Dept Pathol, Naka Ku, Hamamatsu, Shizuoka, Japan.
RP Kuroda, N (reprint author), Seirei Hamamatsu Gen Hosp, Dept Neurosurg, Naka Ku, Hamamatsu, Shizuoka, Japan.
EM h20ms-kuroda@jikei.ac.jp
OI Kuroda, Naoto/0000-0003-1977-4893
CR Akimoto J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1999-x
   Binderup T, 2010, J NUCL MED, V51, P704, DOI 10.2967/jnumed.109.069765
   Brehar F. M., 2013, ROMANIAN NEUROSURGER, V20, P159
   Kazmierczak PM, 2017, EUR RADIOL, V27, P1676, DOI 10.1007/s00330-016-4475-3
   Losa F, 2018, CLIN TRANSL ONCOL, V20, P89, DOI 10.1007/s12094-017-1807-y
   Maiuri F, 2004, J NEURO-ONCOL, V66, P327, DOI 10.1023/B:NEON.0000014517.56866.bc
   Mitry E, 1999, BRIT J CANCER, V81, P1351, DOI 10.1038/sj.bjc.6690325
   Nakano K, 2012, JPN J CLIN ONCOL, V42, P697, DOI 10.1093/jjco/hys085
   OLSEN JO, 1995, SEMIN NUCL MED, V25, P251, DOI 10.1016/S0001-2998(95)80014-X
   PATCHELL RA, 1986, NEUROLOGY, V36, P745, DOI 10.1212/WNL.36.6.745
   Pavel M, 2010, NEUROENDOCRINOLOGY, V91, P326, DOI 10.1159/000287277
   Prasad V, 2010, EUR J NUCL MED MOL I, V37, P67, DOI 10.1007/s00259-009-1205-y
   Sampathirao N, 2017, J NUCL MED TECHNOL, V45, P34, DOI 10.2967/jnmt.116.185777
   Tamura R, 2014, CASE REP NEUROL MED, DOI 10.1155/2014/295253
   Virgolini I, 2010, EUR J NUCL MED MOL I, V37, P2004, DOI 10.1007/s00259-010-1512-3
   Walter T, 2012, DIGEST LIVER DIS, V44, P95, DOI 10.1016/j.dld.2011.08.022
   Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 320
EP 323
DI 10.1016/j.wneu.2019.05.104
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100189
PM 31125774
DA 2020-05-12
ER

PT J
AU Yang, MJ
   Arkun, K
   Heilman, CB
AF Yang, Michael J.
   Arkun, Knarik
   Heilman, Carl B.
TI Tumor-to-Tumor Metastasis of Hepatocellular Carcinoma to Vestibular
   Schwannoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acoustic neuroma; Collision tumor; Metastatic hepatocellular carcinoma;
   Tumor-to-tumor metastasis; Vestibular schwannoma
ID BRAIN METASTASES; PROGNOSTIC-FACTORS; CANCER METASTASIS; MENINGIOMA;
   OUTCOMES
AB BACKGROUND: Intracranial metastasis is a common complication of systemic malignancy. A rare subset of intracranial masses constitutes tumor-totumor metastasis, in which an extracranial neoplasm hematogenously spreads to an existing intracranial lesion.
   CASE DESCRIPTION: Here we present the unique case of a 59-year-old man with known hepatocellular carcinoma who presented with acute headaches, double vision, vertigo, and gait instability in the context of 2 years of right-sided hearing loss. Head imaging showed a heterogeneous right cerebellopontine angle mass extending into the porus acousticus with adjacent cerebellar edema. Histopathologic analysis after resection found coexisting hepatocellular carcinoma within a vestibular schwannoma.
   CONCLUSIONS: Tumor-to-tumor metastasis is an important consideration in the diagnostic work-up and treatment of patients with known systemic malignancy who present with a new intracranial lesion. This pathologic entity could be missed if this patient were treated with single-fraction radiosurgery such as Gamma Knife.
C1 [Yang, Michael J.; Heilman, Carl B.] Tufts Med Ctr, Dept Neurosurg, Boston, MA 02111 USA.
   [Arkun, Knarik] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA.
RP Yang, MJ (reprint author), Tufts Med Ctr, Dept Neurosurg, Boston, MA 02111 USA.
EM MYang1@TuftsMedicalCenter.org
CR Bartelt S, 2004, WORLD J GASTROENTERO, V10, P3345, DOI 10.3748/wjg.v10.i22.3345
   BEST PV, 1963, J NEUROSURG, V20, P892, DOI 10.3171/jns.1963.20.10.0892
   BROOKS WH, 1972, J EXP MED, V136, P1631, DOI 10.1084/jem.136.6.1631
   Brooks WH, 1977, J NEUROSURG, V46, P467
   CHAMBERS PW, 1980, ARCH PATHOL LAB MED, V104, P350
   Choi HJ, 2009, J NEURO-ONCOL, V91, P307, DOI 10.1007/s11060-008-9713-3
   CROCKARD HA, 1988, NEUROSURGERY, V23, P382
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Frassanito P, 2011, ACTA NEUROCHIR, V153, P1989, DOI 10.1007/s00701-011-1126-y
   Fried BM, 1930, AM J PATHOL, V6, P0047
   Fukushima Y, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.10.031
   Graffeo CS, 2017, WORLD NEUROSURG, V98, P632, DOI 10.1016/j.wneu.2016.11.002
   Jiang XB, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-49
   Lanotte M, 2009, CLIN NEUROL NEUROSUR, V111, P87, DOI 10.1016/j.clineuro.2008.07.011
   LEBLANC RA, 1974, J NEUROSURG, V41, P614, DOI 10.3171/jns.1974.41.5.0614
   Lim S, 2014, J NEURO-ONCOL, V120, P199, DOI 10.1007/s11060-014-1546-7
   Lu JQ, 2009, J NEUROSURG, V110, P744, DOI 10.3171/2008.9.JNS08397
   Lua BK, 2012, KAOHSIUNG J MED SCI, V28, P397, DOI 10.1016/j.kjms.2012.02.007
   Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y
   Richter B, 2017, CLIN NEUROPATHOL, V36, P60, DOI 10.5414/NP300980
   Schmitt WR, 2013, J NEUROSURG, V118, P206, DOI 10.3171/2012.10.JNS12915
   Tang GC, 2007, ACTA NEUROCHIR, V149, P87, DOI 10.1007/s00701-006-1049-1
   WALLACH JB, 1959, ARCH NEUROL-CHICAGO, V1, P191, DOI 10.1001/archneur.1959.03840020065008
   WONG TW, 1962, J NEUROSURG, V19, P1088, DOI 10.3171/jns.1962.19.12.1088
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 324
EP 327
DI 10.1016/j.wneu.2019.05.106
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100190
PM 31125772
DA 2020-05-12
ER

PT J
AU Munich, SA
   Krishna, C
   Cress, MC
   Dhillon, GS
   Pollina, J
   Levy, EI
AF Munich, Stephan A.
   Krishna, Chandan
   Cress, Marshall C.
   Dhillon, Gurmeet S.
   Pollina, John
   Levy, Elad, I
TI Diagnosis and Endovascular Embolization of a Sacral Spinal Arteriovenous
   Fistula with "Holo-Spinal" Venous Drainage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous fistula; Artery of desproges-gotteron; Spine; Vascular
   malformation; Venous drainage
ID ARTERY
AB BACKGROUND: Spinal dural arteriovenous fistulas are the most common spinal vascular pathology, accounting for up to 70% of spinal vascular malformations. They most commonly present with insidious and progressive myelopathy and bowel, bladder, and sexual dysfunction. Although noninvasive imaging (e.g., magnetic resonance imaging, magnetic resonance angiography) may suggest the presence of a spinal arteriovenous fistula (AVF), the diagnosis requires confirmation with spinal angiography.
   CASE DESCRIPTION: A 65-year-old woman presented with progressive myelopathy. Traditional spinal angiography of the paired radicular arteries failed to demonstrate any vascular malformation. However, injection of the right internal iliac artery demonstrated an AVF arising from the artery of Desproges-Gofteron with retrograde venous drainage to the upper thoracic region.
   CONCLUSIONS: Selective transarterial catheterization and embolization with n-butyl cyanoacrylate resulted in complete occlusion of the AVF. Clinical improvement was also noted on postprocedural day 1. This case highlights the importance of internal iliac injections as a critical component of spinal angiography during an evaluation for vascular malformation.
C1 [Munich, Stephan A.; Krishna, Chandan; Cress, Marshall C.; Pollina, John; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.
   [Munich, Stephan A.; Krishna, Chandan; Cress, Marshall C.; Pollina, John; Levy, Elad, I] Kaleida Hlth, Dept Neurosurg, Gates Vasc Inst, Buffalo, NY 14210 USA.
   [Dhillon, Gurmeet S.] Proscan Radiol, Buffalo, NY USA.
   [Levy, Elad, I] Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
   [Krishna, Chandan] Mayo Clin, Dept Neurosurg, Scottsdale, AZ USA.
   [Cress, Marshall C.] Orlando Reg Med Ctr Inc, Dept Neurosurg, Orlando, FL USA.
RP Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Kaleida Hlth, Dept Neurosurg, Gates Vasc Inst, Buffalo, NY 14210 USA.; Levy, EI (reprint author), Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
EM elevy@ubas.com
CR Cohen JE, 2013, J NEUROSURG-PEDIATR, V11, P426, DOI 10.3171/2012.12.PEDS12363
   Desproges-Gotteron R., CONTRIBUTION ETUDE S
   GILBERTSON JR, 1995, AM J NEURORADIOL, V16, P2049
   HURST RW, 1995, NEUROLOGY, V45, P1309, DOI 10.1212/WNL.45.7.1309
   Jellema K, 2006, BRAIN, V129, P3150, DOI 10.1093/brain/awl220
   Jellema K, 2003, J NEUROL NEUROSUR PS, V74, P1438, DOI 10.1136/jnnp.74.10.1438
   Kataoka H, 2001, NEUROSURGERY, V48, P1224, DOI 10.1097/00006123-200106000-00004
   Krings T, 2009, AM J NEURORADIOL, V30, P639, DOI 10.3174/ajnr.A1485
   Krings T, 2007, NEUROIMAG CLIN N AM, V17, P57, DOI 10.1016/j.nic.2007.01.001
   Park SB, 2008, J KOREAN NEUROSURG S, V44, P364, DOI 10.3340/jkns.2008.44.6.364
   Saladino A, 2010, NEUROSURGERY, V67, P1350, DOI 10.1227/NEU.0b013e3181ef2821
   Schaat TJ, 2002, SPINE, V27, P893
   Su IC, 2013, NEURORADIOLOGY, V55, P1389, DOI 10.1007/s00234-013-1285-z
   Tubbs RS, 2011, J NEUROSURG-SPINE, V14, P529, DOI 10.3171/2010.11.SPINE10726
   van Dijk JMC, 2002, STROKE, V33, P1578, DOI 10.1161/01.STR.0000018009.83713.06
   Yen PPW, 2014, J NEUROSURG-SPINE, V21, P837, DOI 10.3171/2014.7.SPINE13797
   Zulch K J, 1970, Vasc Surg, V4, P116, DOI 10.1177/153857447000400206
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 328
EP 332
DI 10.1016/j.wneu.2019.05.099
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100191
PM 31121368
DA 2020-05-12
ER

PT J
AU Helou, E
   Sweid, A
   Tjoumakaris, S
   Herial, N
   Gooch, MR
   Rosenwasser, RH
   Jabbour, P
AF Helou, Elias
   Sweid, Ahmad
   Tjoumakaris, Stavropoula
   Herial, Nabeel
   Gooch, Michael R.
   Rosenwasser, Robert H.
   Jabbour, Pascal
TI Case Report of De Novo Cavernous Carotid Artery Aneurysm After an Acute
   Stroke Intervention for a Carotid Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid cavernous dissection; Carotid cavernous pseudoaneurysm;
   Embolization; Flow diversion
ID ISCHEMIC-STROKE; DISSECTION; AGE
AB BACKGROUND: Arterial dissections are a common cause of stroke in second decade-fourth decade patients, but may occur at any age. There are no previous reports of an intracranial carotid artery dissection that evolved spontaneously into both complications (i.e., stroke, pseudoaneurysm). To our knowledge, this is the first case of arterial dissection complicated by an occlusion and a pseudoaneurysm occurring at the same site.
   CASE DESCRIPTION: The patient is a 57-year-old woman who was found by a family member with complete right-side weakness and without the ability to communicate. On admission, her National Institutes of Health Stroke Scale score was 18 and her cerebral angiogram showed a left cavernous carotid occlusion. Mechanical thrombectomy failed to open the occlusion; therefore, an enterprise stent was deployed. Four weeks after the left internal carotid artery (ICA) stent placement, the patient presented with a complete ptosis of the left eye with minimally reactive pupil and a third nerve palsy. Computed tomography angiogram showed an 8-mm aneurysm of the left cavernous ICA. A cerebral angiogram was performed and showed a 10- x 7-mm cavernous pseudoaneurysm. The decision was made to treat the aneurysm with Pipeline-assisted coiling. The procedure went well without any complications.
   CONCLUSIONS: Intracranial dissection/occlusion is a frequent cause of brain infarction, especially in mid-adulthood. Clinical signs of subarachnoid hemorrhage, compressive nerve palsies, and epistaxis in a patient who had endovascular treatment for an intracranial arterial dissection occlusion should be considered as signs for pseudoaneurysm formation, and an angiography should be obtained as soon as possible.
C1 [Helou, Elias] Univ St Joseph, Dept Neurosurg, Beirut, Lebanon.
   [Sweid, Ahmad; Tjoumakaris, Stavropoula; Herial, Nabeel; Gooch, Michael R.; Rosenwasser, Robert H.; Jabbour, Pascal] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Sweid, Ahmad; Tjoumakaris, Stavropoula; Herial, Nabeel; Gooch, Michael R.; Rosenwasser, Robert H.; Jabbour, Pascal] Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
RP Jabbour, P (reprint author), Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.; Jabbour, P (reprint author), Jefferson Hosp Neurosci, Philadelphia, PA 19107 USA.
EM pascal.jabbour@jefferson.edu
OI Herial, Nabeel/0000-0002-5790-783X; Sweid, Ahmad/0000-0002-2652-2451
CR Ambekar Sudheer, 2014, Case Rep Vasc Med, V2014, P341748, DOI 10.1155/2014/341748
   BARR HWK, 1971, BRAIN, V94, P607, DOI 10.1093/brain/94.4.607
   Bejot Y, 2014, INT J STROKE, V9, P879, DOI 10.1111/ijs.12154
   BOGOUSSLAVSKY J, 1992, NEUROL CLIN, V10, P113
   BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P479, DOI 10.1001/archneur.1987.00520170009012
   Caplan LR, 2008, NAT CLIN PRACT NEURO, V4, P34, DOI 10.1038/ncpneuro0683
   Chalouhi N, 2014, STROKE, V45, P54, DOI 10.1161/STROKEAHA.113.003038
   CHAMBERS EF, 1981, AM J NEURORADIOL, V2, P405
   Chaves C, 2002, ARCH NEUROL-CHICAGO, V59, P977, DOI 10.1001/archneur.59.6.977
   Jacobson DM, 2001, NEUROLOGY, V56, P797, DOI 10.1212/WNL.56.6.797
   KUPERSMITH MJ, 1992, J NEUROSURG, V77, P690, DOI 10.3171/jns.1992.77.5.0690
   Patel PD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1742
   Satyarthee GD, 2004, J CLIN NEUROSCI, V11, P776, DOI 10.1016/j.jocn.2003.11.016
   Schievink WI, 2001, NEW ENGL J MED, V344, P898, DOI 10.1056/NEJM200103223441206
   Sridharan R, 2014, SINGAP MED J, V55, pE164
   Tomai F, 2017, JACC-CARDIOVASC INTE, V10, P622, DOI 10.1016/j.jcin.2016.12.276
   WANG AN, 1986, SURG NEUROL, V25, P77, DOI 10.1016/0090-3019(86)90120-5
NR 17
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 336
EP 339
DI 10.1016/j.wneu.2019.05.097
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100193
PM 31121371
DA 2020-05-12
ER

PT J
AU Laskay, NMB
   Estevez-Ordonez, D
   Atchley, TJ
   Amburgy, JW
   Harrigan, MR
AF Laskay, Nicholas M. B.
   Estevez-Ordonez, Dagoberto
   Atchley, Travis J.
   Amburgy, John W.
   Harrigan, Mark R.
TI Report of Spontaneous Internal Carotid Dissection it a Patient with
   Turner Syndrome with a Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Dissection; Internal carotid artery; Turner syndrome; Vasculopathy;
   Vertebral artery
ID VERTEBRAL ARTERY DISSECTION; AORTIC DISSECTION; MOYAMOYA-DISEASE;
   ABNORMALITIES; CHILDREN; WOMEN; VASCULOPATHY; COMMUNITY; WOMAN
AB BACKGROUND: Spontaneous isolated carotid artery (CA) or vertebral artery (VA) dissection in the absence of coarctation has rarely been reported in the literature. We report the case of a 20-year-old woman with Turner syndrome (TS) who developed an acute left middle cerebral artery territory ischemic stroke from a spontaneous left internal carotid artery (ICA) dissection. We also conducted a systematic review of the literature to identify prior studies establishing an association or other case reports of isolated CA or VA dissection in TS. We queried 5 databases: MEDLINE (PubMed), Scopus, Embase, Cochrane Central, and CINAHL EBSCO, We used a standardized search clause across databases. Inclusion and exclusion criteria were applied to articles retrieved. Studies were excluded based on title alone, abstract, or after vetting the data presented in the paper.
   CASE DESCRIPTION: Three case reports of patients with TS presenting with spontaneous intracranial and/or extracranial dissection of the ICA or VA were identified and included in this review.
   CONCLUSIONS: We present a case of bilateral spontaneous dissection of the ICA in a patient with TS. Only 3 reported cases of spontaneous extra- or intracranial dissection of the CA or VA were identified via a systematic review of the literature. Arterial dissection of the CA or VA, especially in absence of aortic coarctation, in individuals affected with TS suggest the possibility of systemic vasculopathy. More research is needed to establish a better understanding of the phenotypic effects of TS in macro- and microvascular structures.
C1 [Laskay, Nicholas M. B.; Estevez-Ordonez, Dagoberto; Atchley, Travis J.; Amburgy, John W.; Harrigan, Mark R.] Univ Alabama Birmingham, Dept Neurol Surg, Birmingham, AL 35294 USA.
RP Laskay, NMB (reprint author), Univ Alabama Birmingham, Dept Neurol Surg, Birmingham, AL 35294 USA.
EM nicholaslaskay@uabmc.edu
CR Ajimi Yasuhiko, 1992, Neurological Surgery, V20, P1021
   Baguet JP, 2005, HEART, V91, P1442, DOI 10.1136/hrt.2004.048371
   Barg N, 2014, NERVENARZT, V85, P747, DOI 10.1007/s00115-014-4081-z
   Bassetti C, 1996, STROKE, V27, P1804, DOI 10.1161/01.STR.27.10.1804
   Bettendorf M, 2006, J PEDIATR ENDOCR MET, V19, P149
   Bondy C A, 2007, Minerva Endocrinol, V32, P245
   Bondy CA, 2007, J CLIN ENDOCR METAB, V92, P10, DOI 10.1210/jc.2006-1374
   Bondy CA, 2009, HORM RES, V71, P52, DOI 10.1159/000178039
   COCKWELL A, 1991, J MED GENET, V28, P151, DOI 10.1136/jmg.28.3.151
   Davie CA, 2008, J NEUROL NEUROSUR PS, V79, P240, DOI 10.1136/jnnp.2007.116939
   Ducrocq X, 1999, REV NEUROL-FRANCE, V155, P575
   Dulac Y, 2008, ARCH CARDIOVASC DIS, V101, P485, DOI 10.1016/j.acvd.2008.05.007
   Elsheikh M, 2001, CLIN ENDOCRINOL, V55, P227, DOI 10.1046/j.1365-2265.2001.01321.x
   Fikar GR, 2000, CLIN PEDIATR, V39, P71, DOI 10.1177/000992280003900201
   Fuentes K, 2007, CEREBROVASC DIS, V24, P543, DOI 10.1159/000111221
   Fukuda I, 2009, ENDOCR J, V56, P983, DOI 10.1507/endocrj.K09E-141
   Gawlik A, 2014, EUR J ENDOCRINOL, V170, pR57, DOI 10.1530/EJE-13-0900
   GIROUD M, 1994, J NEUROL NEUROSUR PS, V57, P1443, DOI 10.1136/jnnp.57.11.1443
   Granger A, 2016, CLIN ANAT, V29, P638, DOI 10.1002/ca.22727
   Irioka T, 2011, NEUROL SCI, V32, P317, DOI 10.1007/s10072-010-0455-6
   Jagannath AD, 2010, AM J MED GENET A, V152A, P2085, DOI 10.1002/ajmg.a.33539
   Knop C, 2015, J PEDIATR ENDOCR MET, V28, P985, DOI 10.1515/jpem-2014-0180
   LANCMAN M, 1991, STROKE, V22, P269, DOI 10.1161/01.STR.22.2.269
   Lawson SA, 2014, J CLIN ENDOCR METAB, V99, pE2039, DOI 10.1210/jc.2014-1140
   Leys D, 1997, EUR NEUROL, V37, P3, DOI 10.1159/000117396
   Manjila S, 2014, J STROKE CEREBROVASC, V23, P1242, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.038
   Mimasaka S, 2007, PATHOL INT, V57, P219, DOI 10.1111/j.1440-1827.2007.02084.x
   Muscat P, 2001, J NEUROIMAGING, V11, P50, DOI 10.1111/j.1552-6569.2001.tb00010.x
   NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097
   Ostberg JE, 2005, J CLIN ENDOCR METAB, V90, P5161, DOI 10.1210/jc.2005-0677
   Sachdev V, 2008, J AM COLL CARDIOL, V51, P1904, DOI 10.1016/j.jacc.2008.02.035
   SCHIEVINK WI, 1994, NEW ENGL J MED, V330, P393, DOI 10.1056/NEJM199402103300604
   SCHIEVINK WI, 1993, STROKE, V24, P1678, DOI 10.1161/01.STR.24.11.1678
   Spengos K, 2006, EUR J NEUROL, V13, pE7, DOI 10.1111/j.1468-1331.2006.01417.x
   Turtle EJ, 2013, CLIN ENDOCRINOL, V78, P639, DOI 10.1111/cen.12104
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 340
EP 346
DI 10.1016/j.wneu.2019.05.029
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100194
PM 31096034
DA 2020-05-12
ER

PT J
AU Zhong, YX
   Lu, GF
   Chen, XL
   Cao, F
AF Zhong, Yu-Xin
   Lu, Guan-Feng
   Chen, Xiao-Lu
   Cao, Fei
TI Postoperative Guillain-Barre Syndrome, a Neurologic Complication that
   Must Not Be Overlooked: A Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acute inflammatory demyelinating polyradiculoneuropathy; Complications;
   Postoperative Guillain-Barre syndrome; Prognosis; Spine surgery
ID SENSORY AXONAL NEUROPATHY; PLASMA-EXCHANGE; RANDOMIZED-TRIAL; SURGERY;
   DIAGNOSIS; PATHOLOGY
AB BACKGROUND: Guillain-Barre syndrome (GBS) is an uncommon, yet life-threatening postoperative neuropathic complication that is easily neglected, and hence, timely treatment is not provided in the clinics. This review aims to summarize the clinical features of postoperative GBS, and thus, improve the understanding of postoperative GBS.
   METHODS: We reviewed the literature on postoperative GBS and assessed de-graphic information, clinical manifestation, operation, time of onset of postoperative GBS, and prognosis.
   RESULTS: A total of 33 cases of postoperative GBS were included in this study. The average age of patients with postoperative GBS was 46.9 years, and there was a peak in occurrence of GBS between ages 50 and 70 years. Men seemed more likely to have postoperative GBS than did women, with a ratio of 2.67:1. Progressive muscular weakness, present in 31 of the cases, was the most common presentation. Patients with spinal surgery were at further increased risk for GBS, and 84.8% of the patients with GBS had a good prognosis after prompt treatment.
   CONCLUSIONS: Surgery is probably a potential risk factor for the occurrence GBS. Early diagnosis and prompt treatment are imperative to reduce mortality.
C1 [Zhong, Yu-Xin; Lu, Guan-Feng; Chen, Xiao-Lu; Cao, Fei] Huazhong Univ Sci & Technol, Dept Neurol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
RP Cao, F (reprint author), Huazhong Univ Sci & Technol, Dept Neurol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM 2000xh0644@hust.edu.cn
CR Aldag M, 2017, CARDIOVASC J AFR, V28, pE4, DOI 10.5830/CVJA-2017-033
   Aluka KJ, 2009, JSLS-J SOC LAPAROEND, V13, P250
   Battaglia F, 2013, REV NEUROL-FRANCE, V169, P166, DOI 10.1016/j.neurol.2012.04.010
   Boghani Z, 2015, WORLD NEUROSURG, V84, P376, DOI 10.1016/j.wneu.2015.03.036
   Chen EY, 2017, J AM ACAD ORTHOP SUR, V25, P587, DOI 10.5435/JAAOS-D-16-00572
   Cheng J, 2011, J NEUROSURG-SPINE, V15, P605, DOI 10.3171/2011.8.SPINE1159
   Cicciu M, 2015, INT J CLIN EXP PATHO, V8, P7614
   Cingoz F, 2012, INTERACT CARDIOV TH, V15, P918, DOI 10.1093/icvts/ivs367
   Dahanukar S A, 1996, J Postgrad Med, V42, P12
   Dekutoski MB, 2010, SPINE, V35, pS9, DOI 10.1097/BRS.0b013e3181d830de
   Dowling JR, 2018, CASE REP ORTHOP, V2018
   Efron PA, 2018, SURGERY, V164, P178, DOI 10.1016/j.surg.2018.04.011
   Esperou H, 2000, INTENS CARE MED, V26, P1094, DOI 10.1007/s001340051323
   Fitzpatrick AM, 2011, J PERIPHER NERV SYST, V16, P84, DOI 10.1111/j.1529-8027.2011.00328.x
   Gensicke H, 2012, EUR J NEUROL, V19, P1239, DOI 10.1111/j.1468-1331.2012.03730.x
   Griffin JW, 1996, ANN NEUROL, V39, P17, DOI 10.1002/ana.410390105
   Halstead SK, 2008, BRAIN, V131, P1197, DOI 10.1093/brain/awm316
   Hekmat Manouchehr, 2016, Acta Med Iran, V54, P76
   Hendawi T, 2015, SPINE, V40, pE372, DOI 10.1097/BRS.0000000000000779
   Heyworth Benton E, 2011, HSS J, V7, P286
   HOGAN JC, 1992, INT J CARDIOL, V35, P427, DOI 10.1016/0167-5273(92)90248-2
   Huang SL, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.045
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736
   Hughes RAC, 1997, LANCET, V349, P225
   Jones GD, 1999, PAEDIATR ANAESTH, V9, P539, DOI 10.1046/j.1460-9592.1999.00396.x
   Juhasz-Pocsine K, 2007, NEUROLOGY, V68, P1843, DOI 10.1212/01.wnl.0000262768.40174.33
   Koc M, 2002, J INT MED RES, V30, P601, DOI 10.1177/147323000203000609
   Kuwabara S, 2004, DRUGS, V64, P597, DOI 10.2165/00003495-200464060-00003
   Landais Anne F, 2014, Surg Obes Relat Dis, V10, pe85, DOI 10.1016/j.soard.2014.02.019
   Masajtis-Zagajewska A, 2012, ANN TRANSPL, V17, P133
   Miscusi M, 2012, J NEUROSURG-SPINE, V17, P82, DOI 10.3171/2012.4.SPINE11932
   Nobile-Orazio E, 2018, LANCET NEUROL, V17, P483, DOI 10.1016/S1474-4422(18)30144-3
   Machado FCN, 2006, ARQ NEURO-PSIQUIAT, V64, P609, DOI 10.1590/S0004-282X2006000400017
   Rashid A, 2017, CUREUS, V9, DOI 10.7759/cureus.1393
   Raut MS, 2019, GEN THORAC CARDIOVAS, V67, P1087, DOI 10.1007/s11748-018-1002-2
   RENLUND DG, 1987, AM HEART J, V113, P844, DOI 10.1016/0002-8703(87)90736-8
   Rodriguez V, 2002, BONE MARROW TRANSPL, V29, P515, DOI 10.1038/sj.bmt.1703412
   Rudant J, 2018, NEUROLOGY, V91, pE1220, DOI 10.1212/WNL.0000000000006246
   Sahai N, 2017, EUR SPINE J, V26, pS6, DOI 10.1007/s00586-016-4577-2
   Schnaar RL, 2010, FEBS LETT, V584, P1741, DOI 10.1016/j.febslet.2009.10.011
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sheikh KA, 2005, ANN NEUROL, V57, P768, DOI 10.1002/ana.20482
   Son DW, 2011, J KOREAN NEUROSURG S, V50, P464, DOI 10.3340/jkns.2011.50.5.464
   Song W, 2012, NEUROL SCI, V33, P657, DOI 10.1007/s10072-011-0823-x
   Staff NP, 2010, BRAIN, V133, P2866, DOI 10.1093/brain/awq252
   Steger CM, 2012, CASE REP CARDIOL, DOI 10.1155/2012/506290
   STEINER I, 1985, NEUROLOGY, V35, P1473, DOI 10.1212/WNL.35.10.1473
   Subeq YM, 2009, J TRAUMA, V67, P132, DOI 10.1097/TA.0b013e318186253d
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705
   Wijdicks EFM, 2017, MAYO CLIN PROC, V92, P467, DOI 10.1016/j.mayocp.2016.12.002
   Willson MC, 2014, NEUROIMAG CLIN N AM, V24
   Yuki Nobuhiro, 2015, Brain Nerve, V67, P1341, DOI 10.11477/mf.1416200304
NR 54
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 347
EP 353
DI 10.1016/j.wneu.2019.04.239
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100195
PM 31059858
DA 2020-05-12
ER

PT J
AU da Costa, MDS
   Hardesty, DA
   Priddy, B
   Noiphithak, R
   Barbero, JMR
   Prevedello, DM
AF Silva da Costa, Marcos Devanir
   Hardesty, Douglas A.
   Priddy, Blake
   Noiphithak, Raywat
   Revuelta Barbero, Juan Manuel
   Prevedello, Daniel M.
TI Extended Supraorbital Approach with Modified Eyebrow Incision: Technical
   Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Eyebrow incision; Keyhole approach; Minimally invasive;
   Skull base; Supraorbital approach
ID ORBITOZYGOMATIC CRANIOTOMY; MENINGIOMAS; EXPERIENCE; ANTERIOR; TIPS
AB BACKGROUND: The extended supraorbital approach through a modified eyebrow incision is a minimally invasive variant of the frontotemporal or pterional approach that enriches a neurosurgeon's armamentarium for the treatment of pathologies lateral to the anterior clinoid process, by advancing laterally with frontal facial nerve branches monitoring. To demonstrate the steps of the approach, we studied 2 formalin-fixed and artery/vein silicone-injected adult cadaveric heads, and reviewed 1 of the 3 clinical cases operated on to illustrate the applicability of the approach.
   CLINICAL PRESENTATION: A 56-year-old woman presented with a history of seizures and a complaint of headache that started 2 months ago. She underwent an examination with brain magnetic resonance imaging that showed a dural-based lesion at the medial third of the lesser wing of sphenoid (which is consistent with meningioma). The patient underwent craniotomy with an extended supraorbital approach through a modified eyebrow incision that allowed Simpson grade II removal to be performed and good aesthetic outcome to be achieved.
   CONCLUSIONS: The extended supraorbital approach through a modified eyebrow incision is a minimally invasive approach that can add to a neurosurgeon's armamentarium and be used with microscopy, assisted by endoscope, or both to reach the anterior and middle cranial fossae.
C1 [Silva da Costa, Marcos Devanir] Univ Fed Sao Paulo, Dept Neurosurg, Sao Paulo, SP, Brazil.
   [Hardesty, Douglas A.; Noiphithak, Raywat; Revuelta Barbero, Juan Manuel; Prevedello, Daniel M.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Hardesty, Douglas A.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ USA.
   [Priddy, Blake] Ohio State Univ, Coll Med, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Noiphithak, Raywat] Thammasat Univ, Fac Med, Dept Surg, Div Neurosurg, Pathum Thani, Thailand.
   [Revuelta Barbero, Juan Manuel] Puerta de Hierro Univ Hosp, Dept Neurosurg, Madrid, Spain.
RP da Costa, MDS (reprint author), Univ Fed Sao Paulo, Dept Neurosurg, Sao Paulo, SP, Brazil.
EM marcoscostaneuro@gmail.com
OI Prevedello, Daniel/0000-0003-0214-2339; Revuelta-Barbero, J.
   Manuel/0000-0002-6426-2734; Noiphithak, Raywat/0000-0003-3866-4569;
   Silva da Costa, Marcos Devanir/0000-0003-3552-6347
CR ALMEFTY O, 1986, NEUROSURGERY, V19, P674
   Altay T, 2012, NEUROSURGERY, V71, P481, DOI 10.1227/NEU.0b013e318256c25a
   Berhouma M, 2011, ACTA NEUROCHIR, V153, P1949, DOI 10.1007/s00701-011-1089-z
   Chaddad-Neto F, 2016, ARQ NEURO-PSIQUIAT, V74, P228, DOI 10.1590/0004-282X20160024
   Chaddad-Neto F, 2012, ARQ NEURO-PSIQUIAT, V70, P727, DOI 10.1590/S0004-282X2012000900015
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2006, NEUROSURGERY, V59, P212, DOI 10.1227/01.NEU.0000223365.55701.F2
   Gazzeri R, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14203
   Igressa A, 2015, CLIN NEUROL NEUROSUR, V129, P27, DOI 10.1016/j.clineuro.2014.11.024
   Melamed I, 2005, MINIM INVAS NEUROSUR, V48, P259, DOI 10.1055/s-2005-915603
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Reisch R, 2014, J NEUROSURG, V121, P730, DOI 10.3171/2014.4.JNS13787
   Rigante L, 2015, J NEUROL SURG PART B, V76, P239, DOI 10.1055/s-0034-1543964
   Romani R, 2011, NEUROSURGERY, V68, P1632, DOI 10.1227/NEU.0b013e318214a840
   Romani R, 2009, NEUROSURGERY, V65, P39, DOI 10.1227/01.NEU.0000346266.69493.88
   van Lindert E, 1998, SURG NEUROL, V49, P481, DOI 10.1016/S0090-3019(96)00539-3
   Wilson DA, 2014, WORLD NEUROSURG, V82, pE243, DOI 10.1016/j.wneu.2013.02.002
   Zabramski JM, 1998, J NEUROSURG, V89, P336, DOI 10.3171/jns.1998.89.2.0336
NR 18
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 354
EP 359
DI 10.1016/j.wneu.2019.05.074
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100196
PM 31103767
DA 2020-05-12
ER

PT J
AU Ohshima, T
   Kawaguchi, R
   Miyachi, S
   Matsuo, N
AF Ohshima, Tomotaka
   Kawaguchi, Reo
   Miyachi, Shigeru
   Matsuo, Naoki
TI Traumatic Carotid-Cavernous Fistula Associated with Persistent Primitive
   Trigeminal Artery Successfully Treated Using In-Stent Coil Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Persistent primitive trigeminal artery; Stent;
   Traumatic carotid-cavernous fistula
AB BACKGROUND: Persistent primitive trigeminal artery (PPTA) is the most common type of fetal carotid-basilar persisting communication in adulthood; however, carotid-cavernous fistulas (CCFs) associated with PPTA are rare.
   CASE DESCRIPTION: An 84-year-old woman presented with traumatic CCF associated with PPTA manifesting as vascular bruit. Transarterial embolization was performed. Although a detachable coil was deployed at the fistula point, it was easy to migrate into the cavernous sinus because of the high-flow shunt. Therefore, a stent was deployed in the PPTA, and the inner lumen of the stent with a focus on the fistula point was occluded by using coils. Subsequently, the CCF completely disappeared.
   CONCLUSIONS: In-stent coil embolization was effective and reasonable for the high-flow CCF associated with the PPTA. This method reduced the number of coils required and operating time. However, careful preservation of perforators is needed.
C1 [Ohshima, Tomotaka; Miyachi, Shigeru] Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
   [Kawaguchi, Reo; Miyachi, Shigeru; Matsuo, Naoki] Aichi Med Univ, Dept Neurosurg, Nagakute, Aichi, Japan.
RP Ohshima, T (reprint author), Aichi Med Univ, Neuroendovasc Therapy Ctr, Nagakute, Aichi, Japan.
EM tmtkoh@gmail.com
CR CHENG WC, 1990, NEUROSURGERY, V27, P802, DOI 10.1227/00006123-199011000-00020
   Cook BE, 2000, J NEURO-OPHTHALMOL, V20, P264, DOI 10.1097/00041327-200020040-00012
   DEBRUN GM, 1988, AM J NEURORADIOL, V9, P749
   FLANDROY P, 1987, NEURORADIOLOGY, V29, P308, DOI 10.1007/BF00451777
   GUGLIELMI G, 1990, NEUROSURGERY, V27, P805, DOI 10.1227/00006123-199011000-00021
   Ishikawa O, 2019, J NEUROENDOVASC THER, V13, P38
   Kobayashi N, 2011, NEUROL MED-CHIR, V51, P37, DOI 10.2176/nmc.51.37
   McKenzie JD, 1996, AM J NEURORADIOL, V17, P280
   Osborn AG, 1999, DIAGNOSTIC CEREBRAL, P91
   Satow T, 2008, JPN J NEUROSURG TOKY, V17, P679
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 360
EP 364
DI 10.1016/j.wneu.2019.05.122
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100197
PM 31128309
DA 2020-05-12
ER

PT J
AU Bilos, LSK
   Kruljac, I
   Radosevio, JM
   Cacic, M
   Skoro, I
   Cerina, V
   Pecina, IH
   Vrkljan, M
AF Bilos, Lora Stanka Kirigin
   Kruljac, Ivan
   Radosevio, Jelena Marinkovio
   Cacic, Miroslav
   Skoro, Ivan
   Cerina, Vatroslav
   Pecina, Ivan Hrvoje
   Vrkljan, Milan
TI Empty Sella in the Making
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoplexy; Conservative; Empty sella; Nonfunctioning pituitary adenoma;
   Spontaneous remission
ID NONFUNCTIONING PITUITARY MACROADENOMA; SPONTANEOUS RESOLUTION;
   SPONTANEOUS REGRESSION; PRECIPITATING FACTORS; APOPLEXY; MANAGEMENT;
   ADENOMA; SURGERY
AB BACKGROUND: Pituitary apoplexy may occur when a large tumor compresses or outgrows its nutrient supply, resulting in ischemic necrosis and hemorrhage. Although once deemed a neurosurgical emergency, increasing evidence suggests that conservative management of pituitary apoplexy leads to favorable neuro-ophthalmologic and endocrinologic outcomes as well. Spontaneous remission after pituitary apoplexy has been described in functioning pituitary adenomas, but it is a rare occurrence in nonfunctioning tumors.
   CASE DESCRIPTION: We report a man that presented with pituitary apoplexy of a nonfunctioning pituitary macroadenoma that was managed conservatively and treated hormonally for hypopituitarism during a 2-year follow-up period, with serial neuroimaging demonstrating significant tumor volume reduction with almost complete resolution resulting in partial empty sella. In addition, a short literature review was performed pertaining to the management of pituitary anoplexy with emphasis on a more conservative approach.
   CONCLUSIONS: A subset of patients with pituitary apoplexy without altered consciousness and nonprogressive or mild ophthalmologic deficits may be managed conservatively; however, lifelong periodic assessment, preferably by a specialized multidisciplinary pituitary team, is essential until clinical outcomes become clear.
C1 [Bilos, Lora Stanka Kirigin; Kruljac, Ivan; Radosevio, Jelena Marinkovio; Cacic, Miroslav; Vrkljan, Milan] Univ Hosp Ctr Sestre Milosrdnice, Dept Endocrinol Diabetol & Metab Dis Mladen Sekso, Zagreb, Croatia.
   [Skoro, Ivan; Cerina, Vatroslav] Univ Hosp Ctr Sestre Milosrdnice, Dept Neurosurg, Zagreb, Croatia.
   [Pecina, Ivan Hrvoje] Univ Hosp Ctr Sestre Milosrdnice, Dept Radiol, Zagreb, Croatia.
RP Bilos, LSK (reprint author), Univ Hosp Ctr Sestre Milosrdnice, Dept Endocrinol Diabetol & Metab Dis Mladen Sekso, Zagreb, Croatia.
EM lora.s.kirigin@gmail.com
CR Albani A, 2016, INT J ENDOCRINOL, DOI 10.1155/2016/7951536
   Ayuk J, 2004, CLIN ENDOCRINOL, V61, P747, DOI 10.1111/j.1365-2265.2004.02162.x
   Bahar A, 2011, CASP J INTERN MED, V2, P201
   BILLS DC, 1993, NEUROSURGERY, V33, P602, DOI 10.1227/00006123-199310000-00007
   Biousse V, 2001, J NEUROL NEUROSUR PS, V71, P542, DOI 10.1136/jnnp.71.4.542
   Briet C, 2015, ENDOCR REV, V36, P622, DOI 10.1210/er.2015-1042
   Capatina C, 2015, EUR J ENDOCRINOL, V172, pR179, DOI 10.1530/EJE-14-0794
   Gruber A, 2006, BRIT J NEUROSURG, V20, P379, DOI 10.1080/02688690601046678
   Kachhara R, 2000, NEUROL INDIA, V48, P294
   Kameno K, 2016, INTERDISCIP NEUROSUR, V5, P45, DOI 10.1016/j.inat.2016.06.003
   Karamouzis I, 2018, HORM-INT J ENDOCRINO, V17, P551, DOI 10.1007/s42000-018-0082-9
   Kinoshita Y, 2014, CLIN ENDOCRINOL, V80, P720, DOI 10.1111/cen.12349
   Liu S, 2012, NEUROL INDIA, V60, P530, DOI 10.4103/0028-3886.103211
   MACCAGNAN P, 1995, J CLIN ENDOCR METAB, V80, P2190, DOI 10.1210/jc.80.7.2190
   Oldfield EH, 2015, J NEUROSURG, V122, P1444, DOI 10.3171/2014.10.JNS141720
   Rajasekaran S, 2011, CLIN ENDOCRINOL, V74, P9, DOI 10.1111/j.1365-2265.2010.03913.x
   Ranabir Salam, 2011, Indian J Endocrinol Metab, V15 Suppl 3, pS188, DOI 10.4103/2230-8210.84862
   Randeva HS, 1999, CLIN ENDOCRINOL, V51, P181, DOI 10.1046/j.1365-2265.1999.00754.x
   Schatz NJ, 2000, J NEURO-OPHTHALMOL, V20, P42, DOI 10.1097/00041327-200020010-00014
   Semple PL, 2007, NEUROSURGERY, V61, P956, DOI 10.1227/01.neu.0000303191.57178.2a
   Semple PL, 2005, NEUROSURGERY, V56, P65, DOI 10.1227/01.NEU.0000144840.55247.38
   Sibal Latika, 2004, Pituitary, V7, P157, DOI 10.1007/s11102-005-1050-3
   Wu ZB, 2007, CHINESE MED J-PEKING, V120, P2062, DOI 10.1097/00029330-200711020-00026
   Yoshino A, 2005, ACTA NEUROCHIR, V147, P253, DOI 10.1007/s00701-004-0443-9
   Zielinski G, 2013, ENDOKRYNOL POL, V64, P54
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 366
EP 370
DI 10.1016/j.wneu.2019.05.119
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100199
PM 31128314
DA 2020-05-12
ER

PT J
AU Chen, H
   Chen, RD
   Yang, HK
   Li, HE
   Wang, JH
   Yu, JS
AF Chen, Hao
   Chen, Rudong
   Yang, Hongkuan
   Li, Hue
   Wang, Junhong
   Yu, Jiasheng
TI Outcome of a Blood Blister-Like Aneurysm Treated by Clip-Reinforced
   Wrapping Technique Using Y-Shaped Temporalis Fascia for Perforator
   Protection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood blister-like aneurysm; Perforator; Temporalis fascia; Wrapping
ID INTERNAL CAROTID-ARTERY; PIPELINE EMBOLIZATION DEVICE; INTRACRANIAL
   ANEURYSMS; SUBARACHNOID HEMORRHAGE; SERIES; PSEUDOANEURYSMS; STRATEGIES
AB BACKGROUND: The optimal approach of blood blister-like aneurysms (BBAs) is debated. Wrapping has been reported to be an effective strategy, but artificial materials have often been used. In addition, perforator protection is difficult using this technique. In this case, we report a ruptured BBA of the left internal carotid artery (ICA) treated with a clip-reinforced wrapping technique using Y-shaped autologous temporalis fascia to protect the posterior communicating artery (PComA). The outcome was favorable.
   CASE DESCRIPTION: A 48-year-old woman was admitted for subarachnoid hemorrhage. Digital subtraction angiography (DSA) revealed a BBA located opposite the PComA origin. A frontotemporal craniotomy was performed. The temporalis fascia was isolated from the temporalis muscle, and then tailored into a Y shape for the PComA to pass through. The diseased segment and the BBA were then wrapped by the Y-shaped temporalis fascia circumferentially. Two clips were applied to the fascia to reinforce the wrapping to fit snugly enough around the parent artery subsequently. DSA and computed tomography angiography scan postoperation showed that the BBA had not recurred, the supraclinoid segment of the left ICA had reconstructed well, and the PComA was unobstructed. The patient recovered without any sequelae during the 1-year follow-up period.
   CONCLUSIONS: A clip-reinforced wrapping technique using Y-shaped temporalis fascia may be an effective method for treating BBAs located opposite the PComA origin. Long-term follow-up and large sample size studies, however, are necessary to validate this approach.
C1 [Chen, Hao; Chen, Rudong; Yang, Hongkuan; Li, Hue; Wang, Junhong; Yu, Jiasheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
RP Yu, JS (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
EM yujiasheng2000@sina.com
FU Natural Science Foundation of Hubei ProvinceNatural Science Foundation
   of Hubei Province [2018CFB458]
FX This work was supported by the Natural Science Foundation of Hubei
   Province (2018CFB458).
CR Beitzke M, 2013, J NEUROSURG, V119, P1009, DOI 10.3171/2013.6.JNS1373
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P1562, DOI 10.3174/ajnr.A3957
   Chalouhi N, 2014, NEUROSURGERY, V74, P527, DOI 10.1227/NEU.0000000000000309
   Cinar C, 2013, NEURORADIOLOGY, V55, P441, DOI 10.1007/s00234-013-1136-y
   COSSU M, 1993, NEUROSURGERY, V32, P344, DOI 10.1227/00006123-199303000-00002
   Deshmukh VR, 2006, NEUROSURGERY, V58, P434, DOI 10.1227/01.NEU.0000199158.02619.99
   Fang C, 2017, J NEUROINTERV SURG, V9, P963, DOI 10.1136/neurintsurg-2016-012662
   Guo YB, 2018, WORLD NEUROSURG, V109, P165, DOI 10.1016/j.wneu.2017.09.186
   Han MS, 2015, ACTA NEUROCHIR, V157, P1849, DOI 10.1007/s00701-015-2579-1
   Ishikawa T, 1997, NEUROSURGERY, V40, P403, DOI 10.1097/00006123-199702000-00038
   Ji TF, 2017, INT J MED SCI, V14, P390, DOI 10.7150/ijms.17979
   Joo SP, 2006, SURG NEUROL, V66, P424, DOI 10.1016/j.surneu.2006.01.024
   Kamijo K, 2010, J NEUROSURG, V113, P781, DOI 10.3171/2009.10.JNS09970
   Kim YB, 2014, YONSEI MED J, V55, P401, DOI 10.3349/ymj.2014.55.2.401
   Kubo Y, 2006, J NEUROSURG, V105, P785, DOI 10.3171/jns.2006.105.5.785
   Lee BH, 2009, J NEUROSURG, V110, P431, DOI 10.3171/2008.7.JNS08257
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Linfante I, 2017, J NEUROINTERV SURG, V9, P29, DOI 10.1136/neurintsurg-2016-012287
   Liu LX, 2019, WORLD NEUROSURG, V123, pE652, DOI 10.1016/j.wneu.2018.11.245
   McLaughlin N, 2012, NEUROCHIRURGIE, V58, P170, DOI 10.1016/j.neuchi.2012.02.025
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Mooney MA, 2015, OPER NEUROSURG, V11, P387, DOI 10.1227/NEU.0000000000000866
   Nerva JD, 2015, J NEUROINTERV SURG, V7, P210, DOI 10.1136/neurintsurg-2013-011047
   Ogawa A, 2000, NEUROSURGERY, V47, P578, DOI 10.1097/00006123-200009000-00008
   Pahl FH, 2016, WORLD NEUROSURG, V89, P376, DOI 10.1016/j.wneu.2016.01.025
   Perrini P, 2015, BRIT J NEUROSURG, V29, P785, DOI 10.3109/02688697.2015.1071320
   Peschillo S, 2016, AM J NEURORADIOL, V37, P856, DOI 10.3174/ajnr.A4606
   Safavi-Abbasi S, 2016, WORLD NEUROSURG, V90, P281, DOI 10.1016/j.wneu.2016.02.109
   Shin HS, 2003, YONSEI MED J, V44, P210, DOI 10.3349/ymj.2003.44.2.210
   Sim SY, 2014, J KOREAN NEUROSURG S, V56, P395, DOI 10.3340/jkns.2014.56.5.395
   Walsh KM, 2014, J NEUROINTERV SURG, V6, P184, DOI 10.1136/neurintsurg-2013-010648
NR 31
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 376
EP 380
DI 10.1016/j.wneu.2019.04.065
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100202
PM 30986585
DA 2020-05-12
ER

PT J
AU Dornbos, D
   Elder, JB
   Otero, JJ
   Baiocchi, RA
   Slone, HW
   Puduvalli, VK
   Giglio, P
AF Dornbos, David, III
   Elder, James B.
   Otero, Jose J.
   Baiocchi, Robert A.
   Slone, Hasel Wayne
   Puduvalli, Vinay K.
   Giglio, Pierre
TI Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with
   Clinicopathologic Correlation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dorsal column myelopathy; Intrathecal chemotherapy; Neuro-oncology
ID SUBACUTE COMBINED DEGENERATION; DORSAL COLUMN MYELOPATHY; METHOTREXATE;
   NEUROTOXICITY; DEXTROMETHORPHAN; HOMOCYSTEINE; CHILDREN
AB BACKGROUND: Myelopathy of the dorsal columns is a rare complication of intrathecal (IT) chemotherapy that occurs most frequently with IT methotrexate and cytarabine. This diagnosis is made with a combination of magnetic resonance imaging, somatosensory evoked potentials, and elevated cerebrospinal fluid (CSF) protein levels, particularly myelin basic protein.
   CASE DESCRIPTION: A 73-year-old man with blastic plasmacytoid dendritic cell neoplasm and known central nervous system involvement underwent standard treatment, including 5 doses of IT cytosine arabinoside. Following this, he had documented CSF clearance of disease. One year later, he developed progressive lower extremity weakness, numbness, and bowel/bladder dysfunction. Magnetic resonance imaging and repeat CSF analysis demonstrated recurrence, and he underwent further IT administration of methotrexate and cytarabine. CSF clearance of malignant cells was again established. However, weakness progressed to quadriplegia; loss of bowel/bladder control; and severe sensory loss, particularly vibration and proprioception. Repeat magnetic resonance imaging demonstrated high signal intensity in bilateral posterior columns. A lower thoracic spine dorsal column biopsy revealed cord destruction and diffuse macrophage infiltration with profound destruction of the neuropil.
   CONCLUSIONS: Although dorsal column myelopathy has previously been described in association with IT chemotherapy, this has solely been diagnosed on the basis of clinical examination, electrodiagnostic criteria, radiographic findings, and CSF analysis. This case provides a pathologic evaluation of an antemortem obtained specimen revealing diffuse macrophage infiltration and profound destruction of the neuropil. Whereas the mechanism underlying spinal cord toxicity following IT chemotherapy remains largely unknown, this case demonstrates a potentially macrophage-mediated process.
C1 [Dornbos, David, III; Elder, James B.; Puduvalli, Vinay K.; Giglio, Pierre] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Otero, Jose J.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA.
   [Baiocchi, Robert A.] Ohio State Univ, Wexner Med Ctr, Div Hematol, Dept Internal Med, Columbus, OH 43210 USA.
   [Slone, Hasel Wayne] Ohio State Univ, Wexner Med Ctr, Div Diagnost Radiol, Dept Radiol, Columbus, OH 43210 USA.
   [Puduvalli, Vinay K.; Giglio, Pierre] Ohio State Univ, Div Neurooncol, Comprehens Canc Ctr, Columbus, OH 43210 USA.
RP Dornbos, D (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
EM David.Dornbos@osumc.edu
RI Otero, Jose/AAI-4891-2020; Dornbos, David/AAF-5091-2019
OI Otero, Jose/0000-0003-0680-4520; 
CR Afshar M, 2014, PEDIATR NEUROL, V50, P625, DOI 10.1016/j.pediatrneurol.2014.01.048
   Bay A, 2005, J PEDIAT HEMATOL ONC, V27, P270, DOI 10.1097/01.mph.0000162527.85024.e9
   Counsel P, 2007, CLIN RADIOL, V62, P172, DOI 10.1016/j.crad.2006.09.005
   Drachtman RA, 2002, PEDIATR HEMAT ONCOL, V19, P319, DOI 10.1080/08880010290057336
   Gollard RP, 2013, J CLIN ONCOL, V31, pE327, DOI 10.1200/JCO.2012.45.4728
   Gosavi T, 2013, J CLIN NEUROSCI, V20, P1025, DOI 10.1016/j.jocn.2012.06.018
   Joseph PJ, 2014, J SPINAL CORD MED, V37, P107, DOI 10.1179/2045772312Y.0000000081
   Julia F, 2013, BRIT J DERMATOL, V169, P579, DOI 10.1111/bjd.12412
   Kawakami M, 2013, AM J HEMATOL, V88, P853, DOI 10.1002/ajh.23502
   Kishi S, 2003, J CLIN ONCOL, V21, P3084, DOI 10.1200/JCO.2003.07.056
   Lu CH, 2007, J NEUROIMAGING, V17, P184, DOI 10.1111/j.1552-6569.2007.00094.x
   Magge RS, 2015, BLOOD REV, V29, P93, DOI 10.1016/j.blre.2014.09.012
   Martin-Martin L, 2015, ONCOTARGET, V6, P19204, DOI 10.18632/oncotarget.4146
   Montejo C, 2019, CLIN CASE REP, V7, P638, DOI 10.1002/ccr3.2026
   Murata Ken-ya, 2015, J Med Case Rep, V9, P135, DOI 10.1186/s13256-015-0597-5
   Ng A., 2013, PM&R, V5, pS280
   Pinnix CC, 2017, AM J HEMATOL, V92, P155, DOI 10.1002/ajh.24611
   Quinn CT, 1997, J CLIN ONCOL, V15, P2800, DOI 10.1200/JCO.1997.15.8.2800
   Saito F, 2011, CASE REP NEUROL, V5, P110, DOI 10.1159/000351848
   Yi Y, 2015, J CHILD NEUROL, V30, P246, DOI 10.1177/0883073814527157
NR 20
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 381
EP 384
DI 10.1016/j.wneu.2019.05.123
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100203
PM 31128312
DA 2020-05-12
ER

PT J
AU Pedaballe, AR
   Mallepally, AR
   Tendon, V
   Sharma, A
   Chhabra, HS
AF Pedaballe, Ashok Reddy
   Mallepally, Abhinandan R.
   Tendon, Vikas
   Sharma, Arun
   Chhabra, Harvinder S.
TI An Unusual Case of Transdural Herniation of a Lumbar Intervertebral
   Disc: Diagnostic and Surgical Challenges
SO WORLD NEUROSURGERY
LA English
DT Article
DE Discectomy; Durotomy; Intradural herniation; Lumbar spine; Transdural
   herniation; Discectomy; Durotomy; Intradural herniation; Lumbar spine;
   Transdural herniation
AB BACKGROUND: Intradural lumbar disc herniation is rare, with an incidence of 0.3%-1%, but has been well reported in the literature. Transdural migration of the disc penetrating both ventral and dorsal dura is extremely rare, and there is a dearth of literature in the pathophysiology and surgical management of transdural herniation. Lack of knowledge on this type of presentation can cause intraoperative surprises and inadvertent cauda equina root injuries and lead to prolonged operative time. We report 1 such case, describe our surgical experience, and discuss the pathological mechanisms and signs.
   CASE DESCRIPTION: A 30-year-old woman presented to outpatient clinic with chronic cauda equina syndrome due to massive L4-L5 disc herniation. 14-15 decompression and transforaminal lumbar interbody fusion were planned. Unexpectedly, however, surgery revealed a transdural herniation, which was effectively managed with laminectomy, extension of durotomy, discectomy, repair of both dorsal and ventral dura, and interbody fusion, but at the expense of prolonged surgical time.
   CONCLUSIONS: Transdural herniation of a lumbar disc is very rare presentation. It can be effectively managed with laminectomy, extension of durotomy, discectomy and repair of both dorsal and ventral dura. It can be diagnosed by magnetic resonance imaging preoperatively only if read with suspicion of such presentation.
C1 [Pedaballe, Ashok Reddy; Mallepally, Abhinandan R.; Tendon, Vikas; Chhabra, Harvinder S.] Indian Spinal Injuries Ctr, Spine Unit, New Delhi, India.
   [Sharma, Arun] Indian Spinal Injuries Ctr, Dept Neurosurg, New Delhi, India.
RP Pedaballe, AR (reprint author), Indian Spinal Injuries Ctr, Spine Unit, New Delhi, India.
EM drashokreddy@gmail.com
CR Baikov ES, 2016, HIR POZVONOCNIKA, V13, P73
   Choi JY, 2007, SPINE J, V7, P111, DOI 10.1016/j.spinee.2006.02.025
   Dandy WE, 1942, J AMER MED ASSOC, V119, P474, DOI 10.1001/jama.1942.02830230008002
   Ducati LG, 2013, EUR SPINE J, V22, pS404, DOI 10.1007/s00586-012-2516-4
   Floeth Frank, 2012, Eur Spine J, V21 Suppl 4, pS453, DOI 10.1007/s00586-011-2073-2
   Han IH, 2009, J KOREAN NEUROSURG S, V46, P168, DOI 10.3340/jkns.2009.46.2.168
   Krajewski KL, 2013, SPINE, V38, pE763, DOI 10.1097/BRS.0b013e31828daa8c
   Mailleux P, 2015, J BELG SOC RADIOL, V99, P25, DOI 10.5334/jbr-btr.910
   REINA EG, 1994, SPINE, V19, P617, DOI 10.1097/00007632-199403000-00020
   Singh PK, 2012, ASIAN SPINE J, V6, P145, DOI 10.4184/asj.2012.6.2.145
   WASSERSTROM R, 1993, AM J NEURORADIOL, V14, P401
   YILDIZHAN A, 1991, ACTA NEUROCHIR, V110, P160, DOI 10.1007/BF01400685
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 385
EP 389
DI 10.1016/j.wneu.2019.05.103
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100204
PM 31121367
DA 2020-05-12
ER

PT J
AU Chen, KW
   Lin, YH
   Lee, CW
AF Chen, Kuo-Wei
   Lin, Yen-Heng
   Lee, Chung-Wei
TI Acute Posttraumatic Cerebral Venous Sinus Thrombosis-Induced Malignant
   Increased Intracranial Pressure Treated with Endovascular Dural Sinus
   Thrombectomy and Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural sinus stenting; Malignant increased intracranial hypertension;
   Posttraumatic cerebral venous sinus thrombosis
ID SKULL FRACTURE; HEAD-INJURY
AB BACKGROUND: Posttraumatic cerebral venous sinus thrombosis (CVST) is a major complication after head injury. Impaired venous outflow caused by CVST leads to increased intracranial pressure (IICP) refractory to medications and surgical decompression and often results in devastating consequences. Currently, there is no consensus on the treatment strategy.
   CASE DESCRIPTION: Here we report a case of posttraumatic CVST in a young male motorcyclist involved in a high-speed traffic accident. On admission, the patient immediately underwent decompressive hemicraniectomy. However, refractory malignant IICP developed within 24 hours after the operation. Computed tomography venography revealed compression of the right sigmoid sinus by the fractured temporal bone and extensive thrombosis toward the jugular bulb. Dural sinus thrombectomy and stenting were performed accordingly. After the procedure, IICP was alleviated immediately and the sedatives and medications were tapered off within days. The patient gradually recovered from deep comatose status and underwent cranioplasty 5 weeks later. Finally, the patient was discharged with only mild left wrist weakness.
   CONCLUSIONS: Acute cerebral sinus thrombosis caused by trauma may result in malignant IICP refractory to medications and surgical decompression. We have demonstrated that endovascular angioplasty and sinus stenting are effective in restoring venous outflow and reducing intracranial pressure. We have also demonstrated that appropriate and timely interventions are important to ensure quick and good recovery in patients with CVST.
C1 [Chen, Kuo-Wei] Natl Taiwan Univ, Hosp & Med Coll, Dept Traumatol, Taipei, Taiwan.
   [Lin, Yen-Heng; Lee, Chung-Wei] Natl Taiwan Univ, Hosp & Med Coll, Dept Med Imaging & Radiol, Taipei, Taiwan.
RP Lee, CW (reprint author), Natl Taiwan Univ, Hosp & Med Coll, Dept Med Imaging & Radiol, Taipei, Taiwan.
EM rad.chungweilee@gmail.com
OI LIN, YEN-HENG/0000-0003-4327-7432; LEE, CHUNG-WEI/0000-0002-3573-2506
CR Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565
   Bishop FS, 2009, J NEUROSURG, V111, P17, DOI 10.3171/2009.2.JNS08491
   D'Alise MD, 1998, SURG NEUROL, V49, P430, DOI 10.1016/S0090-3019(97)00182-1
   Daligic A, 2008, TURK NEUROSURG, V18, P70
   El Mekabaty A, 2017, J NEUROINTERV SURG, V9, P1228, DOI 10.1136/neurintsurg-2016-012803
   Frey JL, 1999, STROKE, V30, P489, DOI 10.1161/01.STR.30.3.489
   Fujii Y, 2009, J TRAUMA, V66, P1002, DOI 10.1097/TA.0b013e31819a0277
   Hersh DS, 2018, J NEUROSURG-PEDIATR, V21, P258, DOI 10.3171/2017.9.PEDS17311
   Hirata E, 2009, J CLIN NEUROSCI, V16, P725, DOI 10.1016/j.jocn.2008.07.071
   Kasner S E, 1998, J Stroke Cerebrovasc Dis, V7, P421, DOI 10.1016/S1052-3057(98)80126-2
   Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129
   Kuether TA, 1998, NEUROSURGERY, V42, P1166
   Kumpe DA, 2012, J NEUROSURG, V116, P538, DOI 10.3171/2011.10.JNS101410
   Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7
   Owler BK, 2003, J NEUROSURG, V98, P1045, DOI 10.3171/jns.2003.98.5.1045
   Rivkin MA, 2014, ACTA NEUROCHIR, V156, P999, DOI 10.1007/s00701-014-2025-9
   Slasky SE, 2017, J COMPUT ASSIST TOMO, V41, P891, DOI 10.1097/RCT.0000000000000620
   Xu K, 2015, INT J MED SCI, V12, P780, DOI 10.7150/ijms.12604
   Zhao X, 2008, J NEUROTRAUM, V25, P104, DOI 10.1089/neu.2007.0351
NR 19
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 393
EP 397
DI 10.1016/j.wneu.2019.05.105
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100206
PM 31125777
DA 2020-05-12
ER

PT J
AU Dubinski, D
AF Dubinski, Daniel
TI Ludwig Guttmann's Academic Relationship with Postwar Germany
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic rehabilitation; Cologne University; Emeritus professor;
   Friedrich Panse; Ludwig Guttmann; Postwar Germany
AB Sir Ludwig Guttmann's pioneering work in the treatment of spinal injury not only improved the care for patients with paraplegia up to now but revolutionized basic principles of neurorehabilitation. A wide selection of publications honors the personal and academic life of this singular German neurologist and neurosurgeon of Jewish descent. When the Nazis came into power, Guttmann was dismissed from his hospital workplace, humiliated, and later forced to leave Germany. Surprisingly, after the Second World War, the psychiatrist Friedrich Panse, who had been a member of the Nazi party, initiated Guttmann's academic rehabilitation up to his nomination as emeritus professor of Cologne University in 1964. The present article recounts the difficult academic restitution and poses the question why Guttmann sought to re-establish connections to Germany, a country that had expelled him so harshly some decades before.
C1 [Dubinski, Daniel] Goethe Univ, Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
RP Dubinski, D (reprint author), Goethe Univ, Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
EM danieldubinski@gmail.com
CR Eisenberg U, 2017, EXECRATED EXPATRIATE
   Forsbach R, 2012, NERVENARZT, V83, P329, DOI 10.1007/s00115-011-3390-8
   Friedlander S., 1977, YEARS PERSECUTION 19, V1
   Goodman Susan, 1986, SPIRIT STOKE MANDEVI
   Klee E., 2004, WHAT THEY DID WHAT T
   Meinecke F W, 1988, Unfallchirurgie, V14, P64
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 398
EP 402
DI 10.1016/j.wneu.2019.05.031
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100207
PM 31096031
DA 2020-05-12
ER

PT J
AU Bteich, F
   Kassab, C
   el Hage, G
   Mousse, R
   Abadjian, GA
   Bou-Nassif, R
AF Bteich, Fred
   Kassab, Cynthia
   el Hage, Giles
   Mousse, Ronald
   Abadjian, Gerard A.
   Bou-Nassif, Rabih
TI Atypical Presentation of Parietal Convexity Dural-Based Cavernous
   Hemangioma: A Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernoma; Chorea; Dural; Hemangioma
ID INTRACRANIAL MENINGIOMA; ANGIOMA; MIMICKING; MALFORMATION
AB BACKGROUND: Dural presentation of a cavernous hemangioma is a rare occurrence. Classically an intraparenchymal lesion with varying symptomatology including mostly headaches, seizures, and neurologic deficits depending on its location, a few cases have been reported along the convexity of the brain, even less eroding the calvaria, with none occasioning abnormal movements as the initial presentation.
   CASE DESCRIPTION: This is a case of a 67-year-old male who presented to the clinic for atypical progressive choreiform movements of the right side of his body and a soft subgaleal mass. Radiographic imaging showed a parietal tumor with intradural and extradural invasion mimicking a meningioma, which does not provide, given its location, a clear explanation of the symptoms. A craniotomy was performed on 29 January, 2018, during which the tumor was resected along with the invaded dura mater and calvaria.
   CONCLUSIONS: A pathology report was positive for cavernous hemangioma, an unexpected diagnosis based on the tumor's characteristics. After surgery, the patient recovered completely without residual symptoms, suggesting a compressive mass effect causing the atypical movement disorders.
C1 [Bteich, Fred; el Hage, Giles; Mousse, Ronald] Hotel Dieu de France Hosp, Neurosurg Dept, Achrafieh, Lebanon.
   [Bteich, Fred; el Hage, Giles; Mousse, Ronald; Bou-Nassif, Rabih] St Joseph Univ, Fac Med, Achrafieh, Lebanon.
   [Abadjian, Gerard A.] Hotel Dieu de France Hosp, Pathol Dept, Achrafieh, Lebanon.
   [Bou-Nassif, Rabih] St Joseph Hosp, Neurosurg Dept, Beirut, Lebanon.
   [Kassab, Cynthia] Univ Texas Houston, MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurosurg,Brain Tumor Immunol & Immunotherap, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [el Hage, Giles] CHUM, Montreal, PQ, Canada.
RP Bou-Nassif, R (reprint author), St Joseph Univ, Fac Med, Achrafieh, Lebanon.; Bou-Nassif, R (reprint author), St Joseph Hosp, Neurosurg Dept, Beirut, Lebanon.
EM rabih.bounassif@neurochirurgie.fr
CR Abhinav K, 2014, NEUROSURG FOCUS, V6, P668
   BARNETT GH, 1986, NEUROSURGERY, V18, P75, DOI 10.1227/00006123-198601000-00012
   Bhide A, 2018, INDIAN J NEUROSURG, V7, P280, DOI 10.1055/s-0038-1672355
   Boockvar JA, 2005, SURG NEUROL, V63, P178, DOI 10.1016/j.surneu.2004.03.012
   Cruz AS, 2016, CUREUS, V8, DOI 10.7759/cureus.560
   Di Vitantonio H, 2015, SURG NEUROL INT, V6
   Dubovoy AV, 2018, CHIN NEUROSURG J, V4, P17
   GhikaSchmid F, 1997, J NEUROL SCI, V146, P109, DOI 10.1016/S0022-510X(96)00290-0
   Gupta RK, 2016, J NEUROSCI RURAL PRA, V7, P615, DOI 10.4103/0976-3147.185508
   Hwang KJ, 2013, J NEUROL, V260, P2986, DOI 10.1007/s00415-013-7096-7
   Hwang S, 2009, ACTA NEUROCHIR, V151, P79, DOI 10.1007/s00701-008-0175-3
   Hyodo A, 2000, J NEUROSURG, V92, P503, DOI 10.3171/jns.2000.92.3.0503
   Ito J, 1978, No To Shinkei, V30, P737
   KUNISHIO K, 1986, Neurological Surgery, V14, P1487
   Labouge P, 2007, LANCET NEUROL, V6, P237, DOI 10.1016/S1474-4422(07)70053-4
   Lee AG, 1998, J NEURO-OPHTHALMOL, V18, P250
   LEWIS AI, 1994, NEUROSURGERY, V35, P498, DOI 10.1227/00006123-199409000-00019
   Li ZZ, 2018, J CLIN NEUROSCI, V58, P218, DOI 10.1016/j.jocn.2018.10.015
   MARTIN JP, 1957, BRAIN, V80, P1, DOI 10.1093/brain/80.1.1
   Massa-Micon B, 2000, SURG NEUROL, V53, P484, DOI 10.1016/S0090-3019(00)00202-0
   McKechnie S, 1998, J CLIN NEUROSCI, V5, P105, DOI 10.1016/S0967-5868(98)90217-X
   Morris Z, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3016
   Morrison L, 1993, GENEREVIEWS
   Murakami K, 2004, J CLIN NEUROSCI, V11, P430, DOI 10.1016/j.jocn.2003.05.010
   Nasi D, 2016, INT J SURG CASE REP, V22, P79, DOI 10.1016/j.ijscr.2016.03.041
   Nimjee Shahid M, 2006, Neurosurg Focus, V21, pe4
   Pelluru PK, 2017, NEUROL INDIA, V65, P1173, DOI 10.4103/neuroindia.NI_1151_15
   PERRY JR, 1993, CAN J NEUROL SCI, V20, P230
   Phillips LE, 2002, NEUROLOGY, V58, P1849, DOI 10.1212/WNL.58.12.1849
   Puca A, 2004, J NEUROSURG, V101, P1057, DOI 10.3171/jns.2004.101.6.1057
   Raychaudhuri R, 2005, SURG NEUROL, V63, P319, DOI 10.1016/j.surneu.2004.05.032
   REVUELTA R, 1994, NEUROSURG REV, V17, P309, DOI 10.1007/BF00306824
   Ryu HS, 2018, WORLD NEUROSURG, V110, P39, DOI 10.1016/j.wneu.2017.10.148
   Sakakibara Y, 2010, NEUROL MED-CHIR, V50, P328, DOI 10.2176/nmc.50.328
   Shen WC, 2000, J NEUROIMAGING, V10, P183, DOI 10.1111/jon2000103183
   Suzuki Kensuke, 1996, Neurologia Medico-Chirurgica, V36, P580, DOI 10.2176/nmc.36.580
   Terterov S, 2016, J NEUROSURG, V125, P167, DOI 10.3171/2015.6.JNS131105
   VOGLER R, 1995, AM J NEURORADIOL, V16, P773
   Wang X, 2016, BRIT J NEUROSURG, V30, P345, DOI 10.3109/02688697.2015.1096904
   Yonezawa Ushio, 2014, No Shinkei Geka, V42, P731
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 403
EP 407
DI 10.1016/j.wneu.2019.04.119
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100208
PM 31009776
DA 2020-05-12
ER

PT J
AU Moldovan, ID
   Agbi, C
   Kilty, S
   Alkherayf, F
AF Moldovan, Ioana D.
   Agbi, Charles
   Kilty, Shaun
   Alkherayf, Fahad
TI A Systematic Review of Prophylactic Antibiotic Use in Endoscopic
   Endonasal Transsphenoidal Surgery for Pituitary Lesions
SO WORLD NEUROSURGERY
LA English
DT Review
DE Antibiotic prophylaxis; Endonasal; Endoscopic; Perioperative; Pituitary
   lesions; Systematic review; Transsphenoidal surgery
ID SKULL BASE SURGERY; RISK-FACTORS; MENINGITIS; INFECTION; EFFICACY;
   REGIMEN; SERIES
AB BACKGROUND: The benefit of prophylactic antibiotic use in endoscopic endonasal transsphenoidal surgery (EETS) for pituitary lesions is controversial. Many surgeons administer antibiotics perioperatively not based on clear guidelines but to he safe. The purpose of this study was to determine if antibiotic prophylaxis use reduces the risk of infection (e.g., meningitis, sinusitis) within 30 days after the surgery in adult patients with pituitary lesions undergoing EETS.
   METHODS: A systematic review was performed to assess the effectiveness of perioperative antibiotic use in preventing infectious complications in patients undergoing EETS. Data sources included Ovid Databases, Scopus, PubMed, Cochrane Library, and Grey Literature. The inclusion criteria were randomized controlled trials, systematic reviews, observational studies, and case series of prophylactic antibiotic perioperative use for EETS. The study end points were the rates of meningitis and sinusitis as infectious complications after EETS.
   RESULTS: A total of 282 articles were identified by the initial literature search. Four studies met the inclusion criteria: 3 retrospective cohort and 1 prospective case series studies. All patients included in each study received different antibiotic regimens perioperatively. The quality of studies did not permit performance of a meta-analysis.
   CONCLUSIONS: Even though there are no clear practice guidelines regarding the antibiotic prophylaxis need in EETS, various antibiotic regimens have been used by surgeons. Our systematic review identified a limited number of published studies assessing this question, all observational. Randomized controlled trials are needed to evaluate the effectiveness of prophylactic antibiotic use in patients with pituitary lesions undergoing EETS.
C1 [Moldovan, Ioana D.; Agbi, Charles; Alkherayf, Fahad] Ottawa Hosp, Div Neurosurg, Dept Surg, Ottawa, ON, Canada.
   [Kilty, Shaun] Ottawa Hosp, Dept Otolaryngol Head & Neck Surg, Ottawa, ON, Canada.
   [Moldovan, Ioana D.; Kilty, Shaun; Alkherayf, Fahad] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
   [Agbi, Charles; Kilty, Shaun; Alkherayf, Fahad] Univ Ottawa, Ottawa, ON, Canada.
RP Moldovan, ID (reprint author), Ottawa Hosp, Div Neurosurg, Dept Surg, Ottawa, ON, Canada.; Moldovan, ID (reprint author), Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
EM imoldovan@ohri.ca
OI Moldovan, Ioana/0000-0002-4199-9581
CR [Anonymous], NEWCASTLE OTTAWA SCA
   Brown SM, 2007, LARYNGOSCOPE, V117, P1528, DOI 10.1097/MLG.0b013e3180caa177
   Gaillard S, 2014, WORLD NEUROSURG, V82, pS116, DOI 10.1016/j.wneu.2014.07.033
   Horowitz PM, 2016, OTOLARYNG CLIN N AM, V49, P227, DOI 10.1016/j.otc.2015.09.014
   Jin Y, 2018, WORLD NEUROSURG, V110, pE851, DOI 10.1016/j.wneu.2017.11.125
   Johans SJ, 2018, J CLIN NEUROSCI, V47, P249, DOI 10.1016/j.jocn.2017.10.036
   Kono Y, 2011, INFECT CONT HOSP EP, V32, P77, DOI 10.1086/657635
   Lai LT, 2014, J NEUROL SURG PART B, V75, P18, DOI 10.1055/s-0033-1353365
   Laws ER, 2014, WORLD NEUROSURG, V82, pS152, DOI 10.1016/j.wneu.2014.07.035
   Little AS, 2011, PITUITARY, V14, P335, DOI 10.1007/s11102-011-0299-y
   Little AS, 2011, PITUITARY, V14, P99, DOI 10.1007/s11102-010-0256-1
   Milanese L, 2017, WORLD NEUROSURG, V106, P912, DOI [10.1016/J.WNEU.2017.07.075, 10.1016/j.wneu.2017.07.075]
   Mortini P, 2005, NEUROSURGERY, V56, P1222, DOI 10.1227/01.NEU.0000159647.64275.9D
   Orlando R, 2007, SURG NEUROL, V68, P145, DOI 10.1016/j.surneu.2006.10.063
   Pagliano P, 2017, INFECTION, V45, P841, DOI 10.1007/s15010-017-1056-6
   Patel PN, 2018, OTOLARYNG HEAD NECK, V158, P783, DOI 10.1177/0194599817753610
   Rosen SAB, 2016, AM J RHINOL ALLERGY, V30, pE10, DOI 10.2500/ajra.2016.30.4298
   Shibao S, 2014, NEUROL MED-CHIR, V54, P1009, DOI 10.2176/nmc.oa.2014-0129
   Smith EJ, 2014, INT FORUM ALLERGY RH, V4, P1002, DOI 10.1002/alr.21395
   Somma T, 2015, CLIN NEUROL NEUROSUR, V139, P206, DOI 10.1016/j.clineuro.2015.10.007
   Theodros Debebe, 2015, CNS Oncol, V4, P411, DOI 10.2217/cns.15.21
   vanAken MO, 1997, CLIN INFECT DIS, V25, P852, DOI 10.1086/515533
   WHO, GLOB GUID PREV SURG
   Yadav YR, 2012, J NEUROSCI RURAL PRA, V3, P328, DOI 10.4103/0976-3147.102615
   Zada G, 2003, J NEUROSURG, V98, P350, DOI 10.3171/jns.2003.98.2.0350
   Zhang LQ, 2014, BIOMED RES-INDIA, V25, P437
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 408
EP 414
DI 10.1016/j.wneu.2019.05.082
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100209
PM 31108250
DA 2020-05-12
ER

PT J
AU Tarabay, A
   Rocca, A
   Maeder, P
   Simonin, A
   Messerer, M
   Deniel, RT
AF Tarabay, Antonio
   Rocca, Alda
   Maeder, Philippe
   Simonin, Alexandre
   Messerer, Mahmoud
   Deniel, Roy Thomas
TI Extra-Axial Cavernoma of the Cerebellopontine Angle: A Case Study and
   Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernoma; Cavernous hemangioma; Cavernous malformation;
   Cerebellopontine angle; Extra-axial cavernomas
ID MALFORMATION; HEMANGIOMA; MANAGEMENT; TUMORS; NERVE; BRAIN
AB BACKGROUND: Extra-axial cavernoma (EAC) at the cerebellopontine angle (CPA) is a rare clinical entity that can mimic radiologically several lesions encountered at this location. We report a case of EAC-CPA and present a review of the literature.
   METHODS: A PubMed research was conducted looking for EAC-CPA lesions described in literature. After reviewing all the relevant articles, the following data were extracted and organized into a single table: patients' symptoms, radiological characteristics, surgical procedure, histopathology, and outcome.
   RESULTS: Eighteen cases (including ours) were identified from these reports. Mean age at diagnosis was 42 with a male:female ratio of 2.6:1. The most commonly involved cranial nerves were the vestibulocochlear complex followed by the trigeminal nerve. The lesions were iso-to hypodense on computed tomography. On magnetic resonance imaging, the EAC-CPA can be solid or cystic. All lesions were approached using retrosigmoid craniotomies. Histologically, both intra- and extra-axial cavernomas are identical, consisting of devoid vascular sinusoids with endothelial lining. The outcome was favorable in 16/18 of the described cases. One case presented a worsened facial paresis and 1 patient died from excessive intraoperative bleeding and subsequent complications.
   CONCLUSIONS: Despite the fact that EAC-CPA are rarely encountered, it should be kept in mind in the list of differential diagnosis, preparing both the surgeon and anesthesiologist for the surgery of a vascular lesion. Specific radiological features, especially an associated developmental venous anomaly could point to the diagnosis.
C1 [Tarabay, Antonio; Rocca, Alda; Maeder, Philippe; Simonin, Alexandre; Messerer, Mahmoud; Deniel, Roy Thomas] CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland.
   [Maeder, Philippe; Messerer, Mahmoud; Deniel, Roy Thomas] CHU Vaudois, Dept Radiol, Lausanne, Switzerland.
RP Tarabay, A (reprint author), CHU Vaudois, Dept Neurosurg, Lausanne, Switzerland.
EM antonio.tarabay@chuv.ch
CR Albanese A, 2009, NEUROSURGERY, V64, pS135, DOI 10.1227/01.NEU.0000335654.56346.B6
   AWAD IA, 1993, NEUROSURGERY, V33, P179, DOI 10.1227/00006123-199308000-00001
   Beskonakli E, 2002, NEUROSURG REV, V25, P222, DOI 10.1007/s10143-002-0219-8
   Brunori A, 1996, SURG NEUROL, V46, P475, DOI 10.1016/S0090-3019(96)00153-X
   DALE AJD, 1968, MED CLIN N AM, V52, P789, DOI 10.1016/S0025-7125(16)32868-1
   Deshmukh VR, 2003, NEUROSURGERY, V53, P352, DOI 10.1227/01.NEU.0000073531.84342.C2
   Engh JA, 2010, OTOL NEUROTOL, V31, P294, DOI 10.1097/MAO.0b013e3181c34bf2
   Ferrante L, 1998, NEUROSURG REV, V21, P270, DOI 10.1007/BF01105784
   Ghanta Rajesh K, 2013, J Neurosci Rural Pract, V4, P210, DOI 10.4103/0976-3147.112772
   Heda S, 2018, BMJ CASE REP, V2018
   Hoshi M, 2000, NEUROL MED-CHIR, V40, P489, DOI 10.2176/nmc.40.489
   Huang HY, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-36
   IPLIKCIOGLU AC, 1986, NEUROSURGERY, V19, P641
   Kim M, 1997, NEUROSURGERY, V40, P187, DOI 10.1097/00006123-199701000-00041
   Kohan D, 1997, AM J OTOL, V18, P386
   Otani N, 2012, J CLIN NEUROSCI, V19, P1551, DOI 10.1016/j.jocn.2012.03.021
   Pollock BE, 2002, INT J RADIAT ONCOL, V52, P1002, DOI 10.1016/S0360-3016(01)02711-0
   Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050
   Sasani M, 2010, NEUROSURG QUART, V20, P23, DOI 10.1097/WNQ.0b013e3181cf8b19
   Stevenson CB, 2005, J NEUROSURG, V103, P931, DOI 10.3171/jns.2005.103.5.0931
   Vajramani GV, 1998, CLIN NEUROL NEUROSUR, V100, P133
   Wu B, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.12.087
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 415
EP 421
DI 10.1016/j.wneu.2019.05.034
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100210
PM 31128315
DA 2020-05-12
ER

PT J
AU Zaninovich, O
   Ramey, W
   Eldersveld, J
   Kasoff, WS
AF Zaninovich, Orel
   Ramey, Wyatt
   Eldersveld, Jordan
   Kasoff, Willard S.
TI Malignant Melanotic Schwannian Tumor Presenting with Spinal Cord
   Infarction Due to Occlusion of the Artery of Adamkiewicz: Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adamkiewicz infarction; Malignant melanotic schwannoma; Malignant
   melanotic schwannian tumor; Spinal tumor
ID SURGICAL DECOMPRESSION; CARNEY COMPLEX; INJURY; OUTCOMES
AB BACKGROUND: Malignant melanotic schwannian tumors (MMSTs) are rare Peripheral nerve sheath tumors that typically exhibit benign clinical presentation and histopathology but malignant long-term behavior.
   CASE DESCRIPTION: We report a case of a 22-year-old male with a T9-11 MMST who presented with acute paraplegia and complete loss of sacral function. Despite emergent decompression, he did not recover motor, sensory or bladder function, although bowel function did normalize.
   CONCLUSIONS: The anatomic location and rapid presentation of permanent deficits are suggestive of infarction of the spinal cord supplied by the artery of Adamkiewicz, a rare presentation of this disorder and of spinal schwannomas in general.
C1 [Zaninovich, Orel] Univ New Mexico Hosp, Dept Neurosurg, Albuquerque, NM USA.
   [Ramey, Wyatt; Kasoff, Willard S.] Univ Arizona, Coll Med, Dept Surg, Div Neurosurg, Tucson, AZ 85721 USA.
   [Eldersveld, Jordan] Banner Univ, Dept Pathol, Med Ctr, Tucson, AZ USA.
RP Kasoff, WS (reprint author), Univ Arizona, Coll Med, Dept Surg, Div Neurosurg, Tucson, AZ 85721 USA.
EM wkasoff@surgery.arizona.edu
OI Kasoff, Willard/0000-0003-3665-5554
CR Agaimy A, 2010, VIRCHOWS ARCH, V456, P411, DOI 10.1007/s00428-010-0886-8
   Agarwalla PK, 2016, NEUROSURGERY, V78, P142, DOI 10.1227/NEU.0000000000001010
   Chen DW, 2015, TURK NEUROSURG, V25, P326, DOI 10.5137/1019-5149.JTN.8153-13.0
   Chetty R, 2007, VIRCHOWS ARCH, V451, P717, DOI 10.1007/s00428-007-0453-0
   Culhaci Nil, 2003, Ann Diagn Pathol, V7, P254, DOI 10.1016/S1092-9134(03)00073-X
   DiBella C, 1997, J NEURO-ONCOL, V35, P149
   Er U, 2007, J CLIN NEUROSCI, V14, P676, DOI 10.1016/j.jocn.2006.03.010
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Jellema K, 2004, NEUROLOGY, V62, P1839, DOI 10.1212/01.WNL.0000125322.76322.6E
   Jug M, 2015, J NEUROTRAUM, V32, P1385, DOI 10.1089/neu.2014.3767
   Kusters-Vandevelde HVN, 2015, BRAIN PATHOL, V25, P209, DOI 10.1111/bpa.12241
   Kurtkaya-Yapicier O, 2003, HISTOL HISTOPATHOL, V18, P925, DOI 10.14670/HH-18.925
   LOWMAN RM, 1980, CANCER-AM CANCER SOC, V46, P391, DOI 10.1002/1097-0142(19800715)46:2<391::AID-CNCR2820460230>3.0.CO;2-C
   Izquierdo MAM, 2011, CYTOPATHOLOGY, V22, P60, DOI 10.1111/j.1365-2303.2010.00740.x
   Mattiassich G, 2017, J NEUROTRAUM, V34, P3362, DOI 10.1089/neu.2017.5132
   Melissano G, 2009, EUR J VASC ENDOVASC, V37, P395, DOI 10.1016/j.ejvs.2008.12.022
   MENNEMEYER RP, 1979, AM J SURG PATHOL, V3, P3, DOI 10.1097/00000478-197902000-00001
   Mohme M, 2017, NEUROSURG REV, V40, P377, DOI 10.1007/s10143-016-0790-z
   Nadeem M, 2017, CUREUS, V9, DOI 10.7759/cureus.1082
   New PW, 2012, EUR J NEUROL, V19, P1207, DOI 10.1111/j.1468-1331.2012.03702.x
   Prieto-Rodriguez M, 1998, DIAGN CYTOPATHOL, V19, P298, DOI 10.1002/(SICI)1097-0339(199810)19:4<298::AID-DC15>3.0.CO;2-I
   Shanmugam S, 2015, INDIAN J PATHOL MICR, V58, P368, DOI 10.4103/0377-4929.162903
   Shrier DA, INFARCTED SPINAL SCH
   Stillman MD, 2017, ARCH PHYS MED REHAB, V98, P1800, DOI 10.1016/j.apmr.2016.12.011
   Stratakis CA, 2016, REV ENDOCR METAB DIS, V17, P367, DOI 10.1007/s11154-016-9400-1
   Torres-Mora J, 2014, AM J SURG PATHOL, V38, P94, DOI 10.1097/PAS.0b013e3182a0a150
   Vallat-Decouvelaere AV, 1999, HISTOPATHOLOGY, V35, P558
   Zhang HY, 2005, CHINESE MED J-PEKING, V118, P1451
   Zonenshayn M, 2000, J NEUROSURG, V92, P241, DOI 10.3171/spi.2000.92.2.0241
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 422
EP 425
DI 10.1016/j.wneu.2019.04.267
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100211
PM 31108251
DA 2020-05-12
ER

PT J
AU Tan, D
   Daly, C
   Xenos, C
   Lai, LT
   Chandra, RV
AF Tan, Darius
   Daly, Christopher
   Xenos, Chris
   Lai, Leon T.
   Chandra, Ronil, V
TI Glioblastoma Presenting as Spontaneous Subarachnoid Hemorrhage:
   Technical Case Note of Combined Endovascular and Microsurgical
   Vision-Sparing Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular; Glioblastoma; Microsurgical; Subarachnoid hemorrhage
ID NEOPLASTIC CEREBRAL ANEURYSM
AB Background: Clinical utility of endovascular adjunct for tumor resection is well established, but its role in acute subarachnoid hemorrhage secondary to neoplastic pseudoaneurysm rupture has not been reported.
   Case Description: We discuss a 46-year-old patient presenting with a World Federation of Neurological Surgeons grade 1 subarachnoid hemorrhage from a ruptured posterior cerebral artery pseudoaneurysm due to glioblastoma tumor invasion.
   Conclusions: A combined targeted endovascular embolization with microsurgical resection to spare the calcarine artery was used to avoid disruption to the optic radiation fiber pathway.
C1 [Tan, Darius; Daly, Christopher; Xenos, Chris; Lai, Leon T.] Monash Univ, Dept Neurosurg, Melbourne, Vic, Australia.
   [Lai, Leon T.; Chandra, Ronil, V] Monash Univ, Dept Surg, Melbourne, Vic, Australia.
   [Chandra, Ronil, V] Monash Hlth, Dept Imaging, Neurointervent Radiol Unit, Melbourne, Vic, Australia.
RP Tan, D (reprint author), Monash Univ, Dept Neurosurg, Melbourne, Vic, Australia.
EM Darius.Tan@monashhealth.org
OI Chandra, Ronil/0000-0001-7555-2297
CR Ali Rushna, 2015, Surg Neurol Int, V6, P66, DOI 10.4103/2152-7806.155759
   ANDREWS BT, 1985, NEUROSURGERY, V17, P645, DOI 10.1227/00006123-198510000-00019
   BURTON C, 1970, NEW ENGL J MED, V282, P35, DOI 10.1056/NEJM197001012820109
   DECHIARA A, 1986, NEUROCHIRURGIA, V29, P58
   Ene CI, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.068
   HO KL, 1982, CANCER, V50, P2935, DOI 10.1002/1097-0142(19821215)50:12<2935::AID-CNCR2820501238>3.0.CO;2-Z
   Imai T, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.10.006
   Joki Tatsuhiro, 2013, No Shinkei Geka, V41, P37
   KOCHI N, 1984, J NEUROSURG, V60, P640, DOI 10.3171/jns.1984.60.3.0640
   Matsuda R, 2018, WORLD NEUROSURG, V120, P54, DOI 10.1016/j.wneu.2018.08.149
   MURATA J, 1993, NEUROSURGERY, V32, P124, DOI 10.1227/00006123-199301000-00019
   Przybylowski CJ, 2018, WORLD NEUROSURG, V116, pE371, DOI 10.1016/j.wneu.2018.04.208
   Reardon DA, 2011, J NATL COMPR CANC NE, V9, P414, DOI 10.6004/jnccn.2011.0038
   Rockswold G L, 1972, Minn Med, V55, P805
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Su YS, 2016, J CLIN NEUROSCI, V26, P26, DOI 10.1016/j.jocn.2015.10.019
   WONG G, 1983, J NEUROL NEUROSUR PS, V46, P449, DOI 10.1136/jnnp.46.5.449
   Yoon YS, 2008, ACTA NEUROCHIR, V150, P447, DOI 10.1007/s00701-008-1513-1
   Zheng J, 2015, CLIN NEUROL NEUROSUR, V128, P107, DOI 10.1016/j.clineuro.2014.11.010
NR 19
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 426
EP 430
DI 10.1016/j.wneu.2019.05.090
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100212
PM 31121373
DA 2020-05-12
ER

PT J
AU Tsukamoto, E
   Tanei, T
   Kato, T
   Naito, T
   Torii, J
   Ishii, K
   Hasegawa, T
AF Tsukamoto, Eisuke
   Tanei, Takafumi
   Kato, Takenori
   Naito, Takehiro
   Torii, Jun
   Ishii, Kazuki
   Hasegawa, Toshinori
TI Repeated Intracranial Hemorrhage After Delivery Induced by Coagulopathy
   Associated with Multiple Venous Malformations
SO WORLD NEUROSURGERY
LA English
DT Article
DE DIC; Intracranial hemorrhage; LIC; Multiple; Venous malformation
AB BACKGROUND: Venous malformations are classified as slow-flow vascular malformations. Coagulation abnormalities are known to be frequent among patients with venous malformations. We report a case of repeated intracranial hemorrhage after delivery, induced by coagulopathy associated with multiple venous malformations.
   CASE DESCRIPTION: A 28-year-old woman presented with left chronic subdural hematoma 1 month after successfully giving birth. She had a history of multiple venous malformations around the pubic region and hips. The hematoma was evacuated by burr hole surgery. Three hours later, her level of consciousness rapidly deteriorated and computed tomography showed acute epidural hematoma. The hematoma was removed immediately by craniotomy under general anesthesia. No bleeding points were apparent in the operative field. Continuous bleeding around the dura mater and subdural space were encountered, and hemostasis was not achieved by electrocoagulation. After using fresh frozen plasma, hemostasis was achieved. Level of consciousness and neurologic symptoms improved postoperatively. Magnetic resonance imaging revealed multiple venous malformations in bilateral lower extremities and the pelvis. Disseminated intravascular coagulopathy was diagnosed, and thrombo modulin and blood coagulation factor XIII were administered. She was discharged home without any neurologic deficits.
   CONCLUSIONS: The delivery activated localized intravascular coagulopathy in the venous malformations and induced chronic subdural hematoma. Surgical interventions then resulted in progression of the coagulopathy to disseminated intravascular coagulopathy, inducing acute epidural hematoma.
C1 [Tsukamoto, Eisuke; Tanei, Takafumi; Kato, Takenori; Naito, Takehiro; Torii, Jun; Ishii, Kazuki; Hasegawa, Toshinori] Komaki City Hosp, Dept Neurosurg, Komaki, Japan.
RP Tsukamoto, E (reprint author), Komaki City Hosp, Dept Neurosurg, Komaki, Japan.
EM torokeitai106@gmail.com
CR Brouillard P, 2003, CLIN GENET, V63, P340, DOI 10.1034/j.1399-0004.2003.00092.x
   Claes F, 2007, CLIN NEUROL NEUROSUR, V109, P520, DOI 10.1016/j.clineuro.2007.03.002
   Dompmartin A, 2008, ARCH DERMATOL, V144, P873, DOI 10.1001/archderm.144.7.873
   ENJOLRAS O, 1993, PEDIATR DERMATOL, V10, P311, DOI 10.1111/j.1525-1470.1993.tb00393.x
   Enjolras Odile, 1997, Journal of Dermatology (Tokyo), V24, P701
   Ernemann U, 2010, EUR J RADIOL, V75, P2, DOI 10.1016/j.ejrad.2010.04.009
   HIRASHIMA Y, 1983, Neurological Surgery, V11, P651
   KELLY GL, 1969, SURGERY, V65, P894
   Koenig MA, 2006, NEUROCRIT CARE, V5, P210, DOI 10.1385/NCC:5:3:210
   Kojima A, 2012, J STROKE CEREBROVASC, V21, DOI 10.1016/j.jstrokecerebrovasdis.2011.12.002
   Mazoyer E, 2008, ARCH DERMATOL, V144, P861, DOI 10.1001/archderm.144.7.861
   SUGIURA M, 1982, Neurological Surgery, V10, P295
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 434
EP 437
DI 10.1016/j.wneu.2019.05.089
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100215
PM 31121372
DA 2020-05-12
ER

PT J
AU Park, YJ
   Kim, SK
   Seo, HP
AF Park, Yong-Jin
   Kim, Sung-Kyu
   Seo, Hyoung-Peon
TI Ligament-Saving Laminoplasty for Intraspinal Tumor Excision: A Technical
   Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Laminoplasty; Spinal cord neoplasm; Thoracolumbar spine
ID CERVICAL LAMINECTOMY; LUMBAR; RECONSTRUCTION; SPINE
AB BACKGROUND: Various methods such as laminectomy, laminoplasty, and/or laminotomy can be used to remove intraspinal lesions. However, laminoplasty has generally been known to be able to prevent postoperative instability and deformity and avoid local scarring at operative site. We have described a new laminoplasty technique that can preserve the interspinous ligament during thoracolumbar intraspinal surgery.
   METHODS: Ten patients undergoing laminoplastic tumor excision were evaluated preoperatively and postoperatively with neurologic examinations, a pain visual analog scale, and the Oswestry Disability Index. Instability and fusion were evaluated with plain radiography and computed tomography. The operative time, complications, and hospital stay were also assessed.
   RESULTS: We assessed the data from 10 patients (12 disc levels with intradural extramedullary tumor who had undergone a ligament-saving laminoplasty procedure. Of the 10 tumors, 6 were schwannoma, 2 were meningioma, 1 was extra-adrenal paraganglioma, and 1 was metastatic adenocarcinoma. Spinal computed tomography was performed 6 months postoperatively. Complete union of the laminoplasty site was achieved for all 10 patients. The flexion-extension view of the plain radiograph was compared with the preoperative images to evaluate the stability of the operated level. No patient had range of motion limitation or instability.
   CONCLUSIONS: Ligament-saving laminoplasty can provide an appropriate surgical view and allow for anatomical reconstruction of the spinal posterior element after excision of spinal cord tumors. This procedure might offer an alternative to classic techniques for selected patients to preserve spinal biomechanical function.
C1 [Park, Yong-Jin; Kim, Sung-Kyu; Seo, Hyoung-Peon] Chonnam Natl Univ, Med Sch & Hosp, Dept Orthoped Surg, Gwangju, South Korea.
RP Seo, HP (reprint author), Chonnam Natl Univ, Med Sch & Hosp, Dept Orthoped Surg, Gwangju, South Korea.
EM osdrseo@gmail.com
OI Kim, Sung Kyu/0000-0002-0062-9373
CR Amhaz HH, 2009, PEDIATR NEUROSURG, V45, P151, DOI 10.1159/000209655
   Baisden J, 1999, SPINE, V24, P1283, DOI 10.1097/00007632-199907010-00003
   Bhimani AD, 2018, WORLD NEUROSURG, V117, pE290, DOI 10.1016/j.wneu.2018.06.014
   Chamoli U, 2015, P I MECH ENG H, V229, P812, DOI 10.1177/0954411915612503
   Elsberg CA, 1920, AM J MED SCI, V159, P194, DOI 10.1097/00000441-192002000-00002
   Fields MJ, 2000, SPINE, V25, P2925, DOI 10.1097/00007632-200011150-00015
   Franzini A, 2018, WORLD NEUROSURG, V114, P58, DOI [10.1016/J.WNEU.2018.03.026, 10.1016/j.wneu.2018.03.026]
   Hida S, 2006, EUR SPINE J, V15, P1292, DOI 10.1007/s00586-006-0099-7
   Jonsson B, 1997, SPINE, V22, P2938, DOI 10.1097/00007632-199712150-00017
   Miyakoshi N, 2018, BMC SURG, V18, DOI 10.1186/s12893-018-0372-9
   Miyakoshi N, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0066-5
   Morio Y, 2000, SPINE, V25, P190, DOI 10.1097/00007632-200001150-00008
   Park SB, 2009, J NEUROSURG-SPINE, V10, P603, DOI 10.3171/2009.2.SPINE08257
   RAIMONDI AJ, 1976, J NEUROSURG, V45, P555, DOI 10.3171/jns.1976.45.5.0555
   Wu CC, 2018, WORLD NEUROSURG, V112, pE125, DOI 10.1016/j.wneu.2017.12.171
NR 15
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 438
EP 443
DI 10.1016/j.wneu.2019.05.076
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100216
PM 31103766
DA 2020-05-12
ER

PT J
AU Kim, YS
   Kim, TS
   Yang, IC
   Joo, SP
AF Kim, You-Sub
   Kim, Tae-Sun
   Yang, In-Chul
   Joo, Sung-Pil
TI Staged, Combined Management of Ruptured Vertebral Artery Dissecting
   Aneurysms Involving the Posterior Inferior Cerebellar Artery: Report of
   4 Cases and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bypass; Embolization; Posterior inferior cerebellar artery; Vertebral
   artery dissecting aneurysms
ID SUBARACHNOID HEMORRHAGE
AB BACKGROUND: Ruptured vertebral artery dissecting aneurysms (VADAs) involving the posterior inferior cerebellar artery (PICA) are the most difficult to treat among variations of VADAs but require prompt treatment. The major challenge is to preserve the PICA while occluding the aneurysm. Despite advances in the management of ruptured VADAs involving the PICA, each treatment, whether it is combined or not, is associated with a significant degree of risk.
   CASE DESCRIPTION: This study presents 4 cases of ruptured VADAs involving the PICA that were successfully treated using a staged, combined method. Embolization of the rupture point in the acute stage was followed 3-4 weeks later by occlusion of the proximal vertebral artery (VA) and PICA origin after occipital artery-PICA bypass in the chronic stage.
   CONCLUSIONS: Although it is sometimes very difficult to determine the exact rupture point of VADAs, ruptures tend to occur at distal segments of a dissecting aneurysm presenting as bleb. Also, when planning a trapping of the VA, careful examination of angiography is needed to assess the contralateral VA and rupture point. Our staged and combined strategy may provide another valuable treatment option for treating VADAs involving the PICA with special emphasis on the safety and efficacy in our method.
C1 [Kim, You-Sub; Kim, Tae-Sun; Yang, In-Chul; Joo, Sung-Pil] Chonnam Natl Univ, Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
RP Kim, TS (reprint author), Chonnam Natl Univ, Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
EM taesun1963@yahoo.co.kr
CR AOKI N, 1990, STROKE, V21, P1628, DOI 10.1161/01.STR.21.11.1628
   Fine AD, 1999, J NEUROSURG, V91, P645, DOI 10.3171/jns.1999.91.4.0645
   Hamada J, 2003, J NEUROSURG, V99, P960, DOI 10.3171/jns.2003.99.6.0960
   JAMIESON KG, 1964, J NEUROSURG, V21, P781, DOI 10.3171/jns.1964.21.9.0781
   Kakino S, 2004, SURG NEUROL, V61, P185, DOI 10.1016/j.surneu.2003.06.001
   Lee JM, 2010, ACTA NEUROCHIR, V152, P1455, DOI 10.1007/s00701-010-0683-9
   MIZUTANI T, 1995, NEUROSURGERY, V36, P905, DOI 10.1227/00006123-199505000-00003
   Mizutani T, 2001, J NEUROSURG, V94, P712, DOI 10.3171/jns.2001.94.5.0712
   Murai T, 2001, Keio J Med, V50, P175
   Ota T, 2016, ACTA NEUROCHIR, V158, P1089, DOI 10.1007/s00701-016-2788-2
   Otawara Y, 2002, NEUROSURGERY, V50, P1372
   Ro A, 2013, J NEUROSURG, V119, P221, DOI 10.3171/2013.2.JNS121586
   Shi L, 2016, INT J MED SCI, V13, P540, DOI 10.7150/ijms.15233
   Yamada M, 2004, J NEUROSURG, V101, P25, DOI 10.3171/jns.2004.101.1.0025
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 444
EP 447
DI 10.1016/j.wneu.2019.05.146
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100217
PM 31132483
DA 2020-05-12
ER

PT J
AU Wu, L
   Ou, YW
   Liu, BY
   Liu, WM
AF Wu, Liang
   Ou, Yunwei
   Liu, Baiyun
   Liu, Weiming
TI Scalp Metastasis of Anaplastic Oligodendroglioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaplastic oligodendroglioma; Radiotherapy; Scalp metastasis; Surgical
   resection; Surgical seeding
ID SURGICAL PATHWAY
AB BACKGROUND: Scalp metastases from anaplastic oligodendroglioma (AO) are extremely rare and mostly involve intracranial recurrence or widely metastatic disease. Here we describe an exceptional case of histopathologically proven scalp metastasis of AO 6 years after surgical resection and postoperative adjuvant radiation.
   CASE DESCRIPTION: A 42-year-old woman presented with several months of progressive headache and dizziness. Preoperative magnetic resonance imaging (MRI) showed an irregular enhancing lesion in the left frontal lobe extending to the ependymal surface. Left frontal craniotomy was performed through a corona! approach, and gross total resection was achieved. Pathologic examination confirmed a World Health Organization grade III AO. The patient subsequently received 60 Gy of external beam radiotherapy in 30 fractions over 6 weeks. During 8 years of follow-up, the patient remained symptom free, and no evidence of intracranial recurrence was found. However, 6 years after intracranial tumor resection, the patient noticed a subcutaneous mass in her right frontal scalp, which was the site contralateral to her craniotomy. MRI revealed a homogeneously marked enhancing nodular lesion in the subcutaneous tissue of the right frontal scalp without intracranial recurrence. Gross total resection was performed, and the pathologic findings, which identified the mass as an AO, were consistent with those of the primary left frontal tumor.
   CONCLUSIONS: This study presents a rare case of long-term AO scalp metastasis without intracranial recurrence. lntraoperative seeding and longer survival for oligodendroglial tumors may cause this rare entity. Optimal surgical strategies and standard operative procedures can promote the prevention of iatrogenic seeding.
C1 [Wu, Liang; Ou, Yunwei; Liu, Baiyun; Liu, Weiming] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
RP Liu, WM (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM liuweimingnsok@sina.com
CR Amitendu S, 2012, J CLIN NEUROSCI, V19, P1511, DOI 10.1016/j.jocn.2011.08.040
   Forsyth TM, 2015, J CLIN NEUROSCI, V22, P1521, DOI 10.1016/j.jocn.2015.03.018
   Ginat DT, 2013, CLIN NEUROL NEUROSUR, V115, P461, DOI 10.1016/j.clineuro.2012.05.038
   Ginat DT, 2014, J NEURO-ONCOL, V118, P9, DOI 10.1007/s11060-014-1404-7
   Iloreta AMC, 2014, J NEUROL SURG REP, V75, pE246, DOI 10.1055/s-0034-1387184
   Krengli M, 2016, REP PRACT ONCOL RADI, V21, P407, DOI 10.1016/j.rpor.2016.02.005
   McLemore MS, 2012, AM J DERMATOPATH, V34, P214, DOI 10.1097/DAD.0b013e318230655c
   Merrell R, 2006, J NEURO-ONCOL, V80, P203, DOI 10.1007/s11060-006-9179-0
   Volavsek M, 2009, PATHOL RES PRACT, V205, P502, DOI 10.1016/j.prp.2008.11.003
   Woo Lho Hyoung, 2016, Brain Tumor Res Treat, V4, P160
NR 10
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 448
EP 451
DI 10.1016/j.wneu.2019.05.109
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100218
PM 31125773
DA 2020-05-12
ER

PT J
AU Neto, ARS
   Uruguay, ALR
   Paiva, DS
   Silva, ALP
   Godeiro, AHM
   Eberlin, LMN
AF Silva Neto, Angelo R.
   Uruguay, Ana Luiza R.
   Paiva, Damacio S.
   Silva, Alice L. P.
   Godeiro, Arthur H. M.
   Eberlin, Leticia M. N.
TI Neurogenic Bladder Dysfunction as Signal of Late Failure of Endoscopic
   Third Ventriculostomy in Child with Spina Bifida
SO WORLD NEUROSURGERY
LA English
DT Article
DE Long-term outcome; Neurogenic bladder; Pediatric hydrocephalus; Third
   ventriculostomy
ID HYDROCEPHALUS; MANAGEMENT
AB BACKGROUND: Endoscopic third ventriculostomy (ETV) is an option for hydrocephalus treatment in patients with myelomeningocele, mostly after a previous shunt dysfunction. Late failure of ETV is a rare event, traditionally associated with dramatic symptoms of intracranial hypertension. In patients with myelodysplasia and neurogenic bladder dysfunction, urodynamic deterioration can be a signal of neurologic worsening as a consequence of tethered cord or shunt problems.
   CASE DESCRIPTION: We describe here a rare case of a 12-year-old female patient with myelomeningocele and evidence of a failure 10 years after a previously successful ETV whose initial symptoms were worsening of urinary complaints. After 2 months, she was admitted to the emergency department with seizures and acute hydrocephalus and was shunted.
   CONCLUSIONS: Pediatric neurosurgeons must follow myelomeningocele patients with successful ETV for a long time and take care of subtle alterations of organic functions that have a close relationship with central nervous system integrity. A multidisciplinary approach can facilitate this strategy and avoid a tragic outcome.
C1 [Silva Neto, Angelo R.] Univ Fed Rio Grande do Norte, Pediat Neurosurg, Hosp Univ Onofre Lopes, Natal, RN, Brazil.
   [Silva Neto, Angelo R.; Uruguay, Ana Luiza R.; Paiva, Damacio S.; Silva, Alice L. P.; Godeiro, Arthur H. M.; Eberlin, Leticia M. N.] Univ Fed Rio Grande do Norte, Dept Integrated Med, Natal, RN, Brazil.
   [Silva Neto, Angelo R.] Santos Dumt Inst, Macaiba, Brazil.
RP Neto, ARS (reprint author), Univ Fed Rio Grande do Norte, Pediat Neurosurg, Hosp Univ Onofre Lopes, Natal, RN, Brazil.; Neto, ARS (reprint author), Univ Fed Rio Grande do Norte, Dept Integrated Med, Natal, RN, Brazil.; Neto, ARS (reprint author), Santos Dumt Inst, Macaiba, Brazil.
EM angelorsn@gmail.com
RI Neto, Angelo Silva/AAJ-6783-2020
OI Neto, Angelo Silva/0000-0002-3819-8951
CR Bowman RM, 2009, J NEUROSURG-PEDIATR, V3, P181, DOI 10.3171/2008.12.PEDS0874
   Cinalli G, 1999, Neurosurg Focus, V6, pe3
   Drake J, 2006, J NEUROSURG, V105, P118, DOI 10.3171/ped.2006.105.2.118
   Duru S, 2018, CHILD NERV SYST, V34, P1521, DOI 10.1007/s00381-018-3811-0
   Faggin R, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10303
   Feng HL, 2004, J NEUROSURG, V100, P626, DOI 10.3171/jns.2004.100.4.0626
   Kearns JT, 2013, CHILD NERV SYST, V29, P1589, DOI 10.1007/s00381-013-2136-2
   Marlin Arthur E, 2004, Neurosurg Focus, V16, pE4
   Panicker Jalesh N, 2010, Pract Neurol, V10, P178, DOI 10.1136/jnnp.2010.213892
   Stone SSD, 2014, J NEUROSURG-PEDIATR, V14, P439, DOI 10.3171/2014.7.PEDS14152
   Teo C, 1996, PEDIATR NEUROSURG, V25, P57, DOI 10.1159/000121098
   Wagner W, 2005, J NEUROSURG, V103, P43, DOI 10.3171/ped.2005.103.1.0043
   Waqar M, 2018, J CLIN NEUROSCI, V51, P6, DOI 10.1016/j.jocn.2018.02.012
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 454
EP 457
DI 10.1016/j.wneu.2019.05.138
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100220
PM 31132484
DA 2020-05-12
ER

PT J
AU Jaman, E
   Goldschmidt, E
   Algattas, H
   Wang, E
   Snyderman, CH
   Gardner, PA
AF Jaman, Emade
   Goldschmidt, Ezequiel
   Algattas, Hanna
   Wang, Eric
   Snyderman, Carl H.
   Gardner, Paul A.
TI Hormonal Fertility Therapy as Potential Risk Factor for Cerebrospinal
   Fluid Leak After Endoscopic Endonasal Surgery: Case Study and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE CSF leak; Endonasal endoscopic approach; Intracranial hypertension;
   Leuprolide
ID IDIOPATHIC INTRACRANIAL HYPERTENSION; SKULL-BASE RECONSTRUCTION; MODEL
AB BACKGROUND: Endoscopic endonasal approaches have been shown to be as effective as transcranial approaches for sinonasal malignancies involving the skull base. Although they are associated with less risk than an open cranial resection, cerebrospinal fluid (CSF) leaks remain a main concern. Some drugs can raise the intracranial pressure and exacerbate the risk of a postoperative CSF leak. In this case report, we present a 32-year-old woman who was treated via endoscopic endonasal approach for an olfactory neuroblastoma and later underwent fertility preservation treatment with leuprolide, which likely led to a delayed CSF leak.
   CASE DESCRIPTION: A 32-year-old woman diagnosed with a large invasive olfactory neuroblastoma underwent resection via an endonasal transcribriform approach and repair of skull base defect using a pericranial flap. Forty-seven days post operation the patient returned, presenting with a clear nasal discharge. Magnetic resonance imaging raised concern for focal flap necrosis, while computed tomography cisternogram revealed a defect in the pericranial flap. The defect was debrided and repaired; a postoperative lumbar drain was placed and showed an opening pressure of 26 cm of water. Discussion with the patient revealed that she received fertility preservation treatment with leuprolide followed by oocyte retrieval 32 days before presentation of her delayed CSF leak.
   CONCLUSIONS: Leuprolide or any drug that can potentially increase intracranial pressure should be held for 3 months after surgery or until after a skull base defect has fully healed.
C1 [Jaman, Emade] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Goldschmidt, Ezequiel; Algattas, Hanna; Snyderman, Carl H.; Gardner, Paul A.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
   [Wang, Eric; Snyderman, Carl H.; Gardner, Paul A.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
RP Gardner, PA (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.; Gardner, PA (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15260 USA.
EM gardpa@upmc.edu
CR Alexander J, 2013, J NEURO-OPHTHALMOL, V33, P310, DOI 10.1097/WNO.0b013e3182906881
   Boot JH, 1996, IRISH J MED SCI, V165, P60, DOI 10.1007/BF02942809
   Boughton B, 2001, LANCET ONCOL, V2, P591, DOI 10.1016/S1470-2045(01)00507-1
   Burkett JG, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0839-1
   FRAUNFELDER FT, 1995, JAMA-J AM MED ASSOC, V273, P773, DOI 10.1001/jama.1995.03520340027021
   Goldschmidt E, 2016, NEUROL RES, V38, P25, DOI 10.1080/01616412.2015.1122263
   Goldschmidt E, 2014, NEUROL RES, V36, P1040, DOI 10.1179/1743132814Y.0000000429
   Goldschmidt E, 2013, NEUROL RES, V35, P300, DOI 10.1179/1743132812Y.0000000136
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Lesny P, 1999, HUM REPROD, V14, P1953, DOI 10.1093/humrep/14.8.1953
   Mahajan Nalini, 2015, J Hum Reprod Sci, V8, P3, DOI 10.4103/0974-1208.153119
   Markey KA, 2016, J PAIN RES, V9, P223, DOI 10.2147/JPR.S80824
   Patel MR, 2010, NEUROSURGERY, V66, P506, DOI 10.1227/01.NEU.0000365620.59677.FF
   Perez MA, 2013, J NEURO-OPHTHALMOL, V33, P327, DOI 10.1097/WNO.0b013e318299c292
   Roxbury CR, 2016, OTOLARYNG CLIN N AM, V49, P153, DOI 10.1016/j.otc.2015.09.010
   Schlosser RJ, 2003, AM J RHINOL, V17, P191, DOI 10.1177/194589240301700403
   Stevens SM, 2018, LARYNGOSCOPE, V128, P248, DOI 10.1002/lary.26581
   Zwagerman NT, 2019, J NEUROSURG, V131, P1172, DOI 10.3171/2018.4.JNS172447
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 458
EP 463
DI 10.1016/j.wneu.2019.05.134
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100221
PM 31132487
DA 2020-05-12
ER

PT J
AU Xin, WQ
   Xin, QQ
   Yuan, Y
   Chen, S
   Gao, XL
   Zhao, Y
   Zhang, H
   Li, WK
   Yang, XY
AF Xin, Wen-qiang
   Xin, Qi-qiang
   Yuan, Yan
   Chen, Shi
   Gao, Xiang-liang
   Zhao, Yan
   Zhang, Hao
   Li, Wen-kui
   Yang, Xin-yu
TI Comparison of Flow Diversion and Coiling for the Treatment of Unruptured
   Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Review
DE Balloon-assisted coiling; Flow diversion; Meta-analysis; Stent-assisted
   coiling; Unruptured intracranial aneurysms
ID PIPELINE EMBOLIZATION DEVICE; STENT-ASSISTED COILING; ENDOVASCULAR
   TREATMENT; ARTERY ANEURYSMS; SINGLE-CENTER; OUTCOMES; COMPLICATIONS;
   EXPERIENCE; OCCLUSION; VISION
AB BACKGROUND: To systematically assess the efficacy and safety between flow diversion and coiling for patients with unruptured intracranial aneurysms.
   METHODS: Potential academic articles were identified from Cochrane Library, Medline, PubMed, EMBASE, ScienceDirect, and other databases. The time range we retrieved from was the inception of electronic databases to February 2019. Gray studies were identified from the references of included literature reports. STATA version 11.0 was used to analyze the pooled data.
   RESULTS: A total of 11 articles (10 retrospective studies and 1 prospective study) were involved in our study. The overall participants of the coiling group were 611, whereas 576 were in the flow diversion group. Our meta-analysis showed that flow diversion was preferable for unruptured intracranial aneurysms as its lower value of total cost per case (weighted mean difference, 5705.906; 95% confidence interval [CI], [4938.536, 6473236]; P < 0.001), fluoroscopy time per case (weighted mean difference, 25.786; 95% CI, 17.169-34.377; P < 0.001), and retreatment rates (odds ratio [OR], 7.127; 95% CI, [3.525, 14.410]; P < 0.001), at the same time, a higher rate of immediate completed occlusion (OR, 0.390; 95% CI, [0.224, 0.680]; P = 0.001) and follow-up completed occlusion (OR, 0.173; 95% CI, [0.080, 0.375]; P < 0.001) was demonstrated in the flow diversion group. There was no difference on intraoperative complication rates (P = 0.070), procedure-related mortality (P = 0.609) and rupture rates (P = 0.408), modified Rankin Scale (mRS) 0-2 at discharge (P = 0.077), and mRS 0-2 at follow-up (P = 0.484).
   CONCLUSIONS: The use of flow diversion for the treatment of unruptured intracranial aneurysms may reduce total cost per case, fluoroscopy time per case, retreatment rates, and increases immediate completed occlusion and follow-up completed occlusion rates without affecting the results of mRS and intraoperative complication.
C1 [Xin, Wen-qiang; Yuan, Yan; Chen, Shi; Gao, Xiang-liang; Zhao, Yan; Zhang, Hao; Li, Wen-kui; Yang, Xin-yu] Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Xin, Qi-qiang] Nanchang Univ, Sch Publ Hlth, Dept Prevent Med, Nanchang, Jiangxi, Peoples R China.
RP Yang, XY (reprint author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM tumeduxinyu@yeah.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570507]; Key Laboratory of Prevention and
   Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of
   Education, China [XN201814]
FX This work was supported by funding from the National Natural Science
   Foundation of China (no. 81570507, XYY) and the Open Project of Key
   Laboratory of Prevention and Treatment of Cardiovascular and
   Cerebrovascular Diseases of Ministry of Education, China (XN201814).
CR Adeeb N, 2017, WORLD NEUROSURG, V105, P206, DOI 10.1016/j.wneu.2017.05.104
   Ahn JH, 2014, AM J NEURORADIOL, V35, P2146, DOI 10.3174/ajnr.A3999
   Alderazi YJ, 2014, STROKE RES TREAT, V2014, DOI 10.1155/2014/415653
   Bodily KD, 2011, AM J NEURORADIOL, V32, P1232, DOI 10.3174/ajnr.A2478
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342
   Burrows AM, 2016, AM J NEURORADIOL, V37, P1866, DOI 10.3174/ajnr.A4835
   Byrne JV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012492
   Chalouhi N, 2017, NEUROSURGERY, V81, P92, DOI 10.1093/neuros/nyw070
   Chalouhi N, 2014, NEUROSURGERY, V74, P527, DOI 10.1227/NEU.0000000000000309
   Chalouhi N, 2014, J NEUROINTERV SURG, V6, P291, DOI 10.1136/neurintsurg-2013-010777
   Chalouhi N, 2013, STROKE, V44, P2150, DOI 10.1161/STROKEAHA.113.001785
   Chan T. T., 2011, Hong Kong Medical Journal, V17, P398
   Colby GP, 2015, J NEUROINTERV SURG, V7, P380, DOI 10.1136/neurintsurg-2014-011193
   Colby GP, 2013, J NEUROINTERV SURG, V5, P237, DOI 10.1136/neurintsurg-2012-010299
   Colby GP, 2012, NEUROSURGERY, V71, P944, DOI 10.1227/NEU.0b013e3182690b8b
   Cruz JP, 2013, AM J NEURORADIOL, V34, P271, DOI 10.3174/ajnr.A3380
   De Vries J, 2013, STROKE, V44, P1567, DOI 10.1161/STROKEAHA.111.000434
   Durst CR, 2014, AM J NEURORADIOL, V35, P2140, DOI 10.3174/ajnr.A4032
   Durst CR, 2016, J NEUROINTERV SURG, V8, P919, DOI 10.1136/neurintsurg-2015-011887
   El-Chalouhi N, 2014, WORLD NEUROSURG, V82, P696, DOI 10.1016/j.wneu.2013.02.089
   Inagawa T, 2009, ACTA NEUROCHIR, V151, P1623, DOI 10.1007/s00701-009-0479-y
   Lin N, 2015, ACTA NEUROCHIR, V157, P379, DOI 10.1007/s00701-014-2318-z
   Lubicz B, 2011, WORLD NEUROSURG, V76, P114, DOI 10.1016/j.wneu.2011.02.015
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Shapiro M, 2008, AM J NEURORADIOL, V29, P1777, DOI 10.3174/ajnr.A1216
   Signorelli F, 2018, WORLD NEUROSURG, V115, P234, DOI 10.1016/j.wneu.2018.04.143
   Silva MA, 2019, J NEUROSURG, V130, P1505, DOI 10.3171/2018.1.JNS171774
   Starke RM, 2014, J CLIN NEUROSCI, V21, P40, DOI 10.1016/j.jocn.2013.03.003
   Turfe ZA, 2015, J NEUROINTERV SURG, V7, P250, DOI 10.1136/neurintsurg-2014-011102
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Walcott BP, 2016, JAMA NEUROL, V73, P1002, DOI 10.1001/jamaneurol.2016.0609
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Xin WQ, 2019, WORLD NEUROSURG, V125, P74, DOI 10.1016/j.wneu.2019.01.118
   Zanaty M, 2014, STROKE, V45, P2656, DOI 10.1161/STROKEAHA.114.006247
NR 36
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 464
EP 472
DI 10.1016/j.wneu.2019.05.149
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100222
PM 31132489
DA 2020-05-12
ER

PT J
AU Van der Veken, J
   Mulcahy, MJ
   Harrington, TJ
   Assaad, NN
AF Van der Veken, Jom
   Mulcahy, Michael J.
   Harrington, Timothy J.
   Assaad, Nazih N.
TI Kinked Perforator Due to Clipping of Parent Vessel Aneurysm: Technical
   Note and Lessons Learned
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clipping; Kinked; Perforator
ID MIDDLE CEREBRAL-ARTERY
AB BACKGROUND: Adverse outcomes after aneurysm clipping can be potentially reversible, when managed appropriately.
   METHODS: This is a case report describing kinking of a perfactor due to clipping of parent vessel aneurysm.
   RESULTS: Complete recovery of a high-grade motor deficit was achieved after instant reintervention with application of smaller clips in combination with gelfoam soaked in papaverine.
   CONCLUSION: Use of evoked potentials and intraoperative digital subtraction angiography are recommended and may help in preclinical diagnosis. Knowledge of delayed perforator kinking as a complication may lead to a more rapid diagnosis and management.
C1 [Van der Veken, Jom; Mulcahy, Michael J.; Harrington, Timothy J.; Assaad, Nazih N.] Macquarie Univ, Australian Sch Adv Med, Dept Neurosurg, Sydney, NSW, Australia.
   [Harrington, Timothy J.] Royal North Shore Hosp, Dept Radiol, St Leonards, NSW, Australia.
RP Van der Veken, J (reprint author), Macquarie Univ, Australian Sch Adv Med, Dept Neurosurg, Sydney, NSW, Australia.
EM JVanDerVeken@mqneurosurgery.com
CR Choi HH, 2017, WORLD NEUROSURG, V108, P738, DOI 10.1016/j.wneu.2017.09.096
   Dashti R, 2007, SURG NEUROL, V67, P6, DOI 10.1016/j.surneu.2006.08.027
   Della Puppa A, 2018, WORLD NEUROSURG, V113, pE336, DOI 10.1016/j.wneu.2018.02.029
   Fong YW, 2018, WORLD NEUROSURG, V114, pE573, DOI 10.1016/j.wneu.2018.03.035
   Marbacher S, 2019, J NEUROSURG, V131, P64, DOI 10.3171/2018.1.JNS172253
   Motoyama Yasushi, 2016, Surg Neurol Int, V7, P8, DOI 10.4103/2152-7806.174602
   Rayan T, 2015, J NEUROSURG, V123, P472, DOI 10.3171/2014.9.JNS141547
   Ture U, 2000, J NEUROSURG, V92, P676, DOI 10.3171/jns.2000.92.4.0676
   UMANSKY F, 1985, J NEUROSURG, V62, P261, DOI 10.3171/jns.1985.62.2.0261
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 473
EP 476
DI 10.1016/j.wneu.2019.05.131
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100223
PM 31132497
DA 2020-05-12
ER

PT J
AU Kim, LH
   Chen, YR
AF Kim, Lily H.
   Chen, Yi-Ren
TI Risk Adjustment Instruments in Administrative Data Studies: A Primer for
   Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Review
DE Administrative data; Charlson Comorbidity Index; Clinical Classification
   Software; Elixhauser Comorbidity Index; Neurosurgery research; Pediatric
   Medical Complexity Algorithm; Risk adjustment tools
ID CHARLSON COMORBIDITY INDEX; IN-HOSPITAL MORTALITY; UNRUPTURED
   INTRACRANIAL ANEURYSMS; NATIONWIDE INPATIENT SAMPLE; TRAUMATIC
   BRAIN-INJURY; CARE RESOURCE USE; QUALITY-OF-LIFE; SURGICAL-TREATMENT;
   PERIOPERATIVE COMPLICATIONS; ELDERLY-PATIENTS
AB With the increasing interest in big data and health services research, use of administrative databases is becoming commonplace in health care studies, including in neurosurgery. Administrative data offer the unique advantage of accessing large amounts of information previously collected from a population-based sample with geographic diversity. When using administrative data sets, researchers can benefit from application of risk adjustment instruments, which help stratify patients and tailor the original sample for specific research questions. The Charlson Comorbidity Index and Elixhauser Comorbidity Index are 2 of the most common indices. The Pediatric Medical Complexity Algorithm and Clinical Classification Software are other promising tools. Understanding of these tools may assist neurosurgeons who wish to critically assess research findings relevant to their clinical practice. In this review, an overview is presented of risk adjustment tools commonly used in adult as well as pediatric populations and their history, uses, limitations, and applications in neurosurgical research are summarized.
C1 [Kim, Lily H.; Chen, Yi-Ren] Stanford Univ, Sch Med, Stanford Dept Neurosurg, Stanford, CA 94305 USA.
RP Kim, LH (reprint author), Stanford Univ, Sch Med, Stanford Dept Neurosurg, Stanford, CA 94305 USA.
EM lilyhkim@stanford.edu
CR Alshekhlee A, 2011, J STROKE CEREBROVASC, V20, P196, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.019
   Arrigo RT, 2011, SPINE, V36, pE1274, DOI 10.1097/BRS.0b013e318206cda3
   Arrigo RT, 2011, NEUROSURGERY, V68, P674, DOI 10.1227/NEU.0b013e318207780c
   Babu R, 2014, J NEUROSURG-SPINE, V21, P502, DOI 10.3171/2014.5.SPINE13283
   Balducci M, 2012, MED ONCOL, V29, P3478, DOI 10.1007/s12032-012-0263-3
   Bannay A, 2016, MED CARE, V54, P188, DOI 10.1097/MLR.0000000000000471
   Bartek J, 2015, WORLD NEUROSURG, V83, P673, DOI 10.1016/j.wneu.2015.01.022
   Bascom A, 2016, UROLOGY, V90, P184, DOI 10.1016/j.urology.2015.12.047
   Bekelis K, 2014, INT ANGIOL, V33, P58
   Bekelis K, 2014, SPINE J, V14, P1944, DOI 10.1016/j.spinee.2013.11.038
   Bekelis K, 2014, J NEUROINTERV SURG, V6, P556, DOI 10.1136/neurintsurg-2013-010884
   Bergqvist J, 2017, ACTA ONCOL, V56, P405, DOI 10.1080/0284186X.2016.1257864
   Berry JG, 2015, J PEDIATR-US, V167, P229, DOI 10.1016/j.jpeds.2015.04.068
   Bess S, 2014, SPINE, V39, P233, DOI 10.1097/BRS.0000000000000104
   Boogaarts HD, 2014, ACTA NEUROCHIR, V156, P1663, DOI 10.1007/s00701-014-2160-3
   Bouras T, 2010, J NEUROSURG-SPINE, V13, P329, DOI 10.3171/2010.3.SPINE09487
   Bowers CA, 2016, WORLD NEUROSURG, V96, P58, DOI 10.1016/j.wneu.2016.08.054
   Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x
   Cardin F, 2007, J CLIN GASTROENTEROL, V41, P257, DOI 10.1097/01.mcg.0000225611.48728.1e
   Cata JP, 2017, J CLIN NEUROSCI, V35, P82, DOI 10.1016/j.jocn.2016.10.006
   Chalmers D, 2015, INT BRAZ J UROL, V41, P661, DOI 10.1590/S1677-5538.IBJU.2014.0464
   Chan T, 2016, J PEDIATR-US, V177, P197, DOI 10.1016/j.jpeds.2016.06.035
   CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chi MJ, 2011, ARCH GERONTOL GERIAT, V52, P284, DOI 10.1016/j.archger.2010.04.017
   Chitale R, 2015, J SPINAL DISORD TECH, V28, P126, DOI 10.1097/BSD.0b013e318270dad7
   Chu CS, 2016, GEN HOSP PSYCHIAT, V38, P15, DOI 10.1016/j.genhosppsych.2015.08.006
   Chu YT, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-140
   Clough-Gorr KM, 2010, J CLIN ONCOL, V28, P380, DOI 10.1200/JCO.2009.23.5440
   Comin-Colet J, 2016, REV ESP CARDIOL, V69, P256, DOI 10.1016/j.rec.2015.07.030
   CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077
   Cook Curtiss B, 2006, Endocr Pract, V12, P363
   Davies BJ, 2009, UROLOGY, V73, P598, DOI 10.1016/j.urology.2008.09.080
   De Coster C, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-77
   Dea N, 2014, J NEUROSURG-SPINE, V21, P698, DOI 10.3171/2014.7.SPINE131007
   Derrington TM, 2015, MATERN CHILD HLTH J, V19, P2168, DOI 10.1007/s10995-015-1730-1
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   DHoore W, 1996, J CLIN EPIDEMIOL, V49, P1429, DOI 10.1016/S0895-4356(96)00271-5
   DHOORE W, 1993, METHOD INFORM MED, V32, P382
   Dobran Mauro, 2015, Asian J Neurosurg, V10, P207, DOI 10.4103/1793-5482.161192
   Dominick KL, 2005, ARTHRIT RHEUM-ARTHR, V53, P666, DOI 10.1002/art.21440
   Dowsey MM, 2015, OSTEOARTHR CARTILAGE, V23, P2141, DOI 10.1016/j.joca.2015.07.005
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   ELIXHAUSER A, 2015, CLIN CLASS SOFTW CCS
   Ening G, 2015, CLIN NEUROL NEUROSUR, V136, P89, DOI 10.1016/j.clineuro.2015.05.024
   Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6
   Fogerty MD, 2008, WOUND REPAIR REGEN, V16, P11, DOI 10.1111/j.1524-475X.2007.00327.x
   Folbert EC, 2017, OSTEOPOROSIS INT, V28, P269, DOI 10.1007/s00198-016-3711-7
   Foulongne E, 2013, NEUROCHIRURGIE, V59, P23, DOI 10.1016/j.neuchi.2012.09.005
   Fry DE, 2007, ANN SURG, V246, P875, DOI 10.1097/SLA.0b013e3180cc2e7a
   Fu KMG, 2010, NEUROSURGERY, V66, P42, DOI 10.1227/01.NEU.0000361999.29279.E6
   Gephart MGH, 2012, WORLD NEUROSURG, V78, P545, DOI 10.1016/j.wneu.2011.12.089
   Goldstein CL, 2015, SPINE J, V15, P1179, DOI 10.1016/j.spinee.2013.11.043
   Goz V, 2013, SPINE, V38, P1970, DOI 10.1097/BRS.0b013e3182a62527
   Greenberg JK, 2016, J NEUROSURG, V5, P1
   Grossman R, 2011, WORLD NEUROSURG, V75, P279, DOI 10.1016/j.wneu.2010.09.003
   Guan J, 2017, J NEUROSURG, V127, P96, DOI 10.3171/2016.7.JNS16975
   Guthery SL, 2004, J PEDIATR-US, V144, P589, DOI 10.1016/j.jpeds.2004.02.029
   Harhay MN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156532
   Hoegh V, 2016, SCAND J CARING SCI, V30, P507, DOI 10.1111/scs.12272
   Jette N, 2010, MED CARE, V48, P1105, DOI 10.1097/MLR.0b013e3181ef9d3e
   Junkkari A, 2017, EUR J NEUROL, V24, P58, DOI 10.1111/ene.13130
   Kalakoti P, 2015, NEUROSURG FOCUS, V38, P1
   Kelly AM, 2014, SPINE J, V14, P2905, DOI 10.1016/j.spinee.2014.04.016
   Klineberg E, 2016, SPINE, V41, P798
   Konglund A, 2013, ACTA NEUROCHIR, V155, P2263, DOI 10.1007/s00701-013-1872-0
   Kourtis AP, 2006, PEDIATRICS, V118, pE167, DOI 10.1542/peds.2005-2780
   Kronick R, 2000, HEALTH CARE FINANC R, V21, P29
   Kukreja S, 2015, CLIN NEUROL NEUROSUR, V136, P52, DOI 10.1016/j.clineuro.2015.05.015
   Kumar A, 2016, PHYS THER, V96, P232, DOI 10.2522/ptj.20150039
   Kurbasic Izeta, 2008, Acta Inform Med, V16, P159, DOI 10.5455/aim.2008.16.159-161
   Larcher A, 2016, CANC PROGNOSTICS HLT, P264
   Lee L, 2016, J NEUROSURG, V124, P546, DOI 10.3171/2014.12.JNS142053
   Lieffers JR, 2011, CANCER-AM CANCER SOC, V117, P1957, DOI 10.1002/cncr.25653
   Lim SW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169623
   Lin H.-B., 2014, BIOMED RES INT, V2014, P1
   Lin KB, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0248-x
   LIN TY, 2014, BIOMED RES INT, V14
   Liu JN, 2010, KIDNEY INT, V77, P141, DOI 10.1038/ki.2009.413
   Lix LM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-340
   Macki M, 2016, J NEUROL SCI, V361, P133, DOI 10.1016/j.jns.2015.12.035
   MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8
   MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X
   Marques WV, 2016, REV BRAS REUMATOL, V56, P14, DOI [10.1016/j.rbre.2015.07.009, 10.1016/j.rbr.2015.01.009]
   Mashhadinezhad H, 2012, TURK NEUROSURG, V22, P583, DOI 10.5137/1019-5149.JTN.5231-11.2
   McCarthy EP, 2000, MED CARE, V38, P868, DOI 10.1097/00005650-200008000-00010
   McGirt MJ, 2011, J NEUROSURG-SPINE, V14, P771, DOI 10.3171/2011.1.SPINE10571
   Meier U, 2013, NEUROSURGERY, V73, P1054, DOI 10.1227/NEU.0000000000000155
   Menendez ME, 2014, CLIN ORTHOP RELAT R, V472, P2878, DOI 10.1007/s11999-014-3686-7
   Mihailidis HG, 2017, ANZ J SURG, V87, P605, DOI 10.1111/ans.13885
   Missios S, 2014, NEUROMODULATION, V17, P451, DOI 10.1111/ner.12101
   Morris NA, 2016, NEUROCRIT CARE, V24, P226, DOI 10.1007/s12028-015-0178-x
   Mukherjee D, 2010, ARCH SURG-CHICAGO, V145, P247, DOI 10.1001/archsurg.2009.288
   Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021
   Murphy AJ, 2012, J SURG RES, V177, pE59, DOI 10.1016/j.jss.2012.04.018
   Myers RP, 2009, HEPATOLOGY, V49, P568, DOI 10.1002/hep.22676
   Newman WC, 2016, J NEUROSURG, V125, P713, DOI 10.3171/2015.8.JNS14553
   Okazaki T, 2016, WORLD NEUROSURG, V93, P336, DOI 10.1016/j.wneu.2016.06.070
   Patil CG, 2008, SPINE, V33, P1491, DOI 10.1097/BRS.0b013e318175d1bf
   Patil CG, 2012, WORLD NEUROSURG, V78, P640, DOI 10.1016/j.wneu.2011.10.042
   Pereira Andre F, 2015, Surg Neurol Int, V6, pS573, DOI 10.4103/2152-7806.169542
   Protopsaltis TS, 2015, J NEUROSURG-SPINE, V23, P153, DOI 10.3171/2014.11.SPINE1441
   Quail JM, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-146
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Rabbitts JA, 2015, J PAIN, V16, P1334, DOI 10.1016/j.jpain.2015.09.005
   Radovanovic D, 2014, HEART, V100, P288, DOI 10.1136/heartjnl-2013-304588
   Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb
   Ramey L, 2016, J AM MED DIR ASSOC, V17, P730, DOI 10.1016/j.jamda.2016.03.019
   Robinski M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157506
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8
   ROSENBAUM BP, 2017, CLIN SPINE SURG, V30, pE27
   Sansur CA, 2007, J NEUROSURG, V107, P998, DOI 10.3171/JNS-07/11/0998
   Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891
   Semrad TJ, 2007, J NEUROSURG, V106, P601, DOI 10.3171/jns.2007.106.4.601
   Sharabiani MTA, 2012, MED CARE, V50, P1109, DOI 10.1097/MLR.0b013e31825f64d0
   Shen Y, 2009, J NEUROSURG ANESTH, V21, P21, DOI 10.1097/ANA.0b013e31818b47e9
   Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693
   Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130
   Simon TD, 2014, PEDIATRICS, V133, pE1647, DOI 10.1542/peds.2013-3875
   Skovrlj B, 2014, SPINE, V39, pE1167, DOI 10.1097/BRS.0000000000000487
   Smith JS, 2015, J NEUROSURG-SPINE, V23, P349, DOI 10.3171/2014.12.SPINE14777
   Smith JS, 2014, J NEUROSURG-SPINE, V21, P994, DOI 10.3171/2014.9.SPINE131176
   Soroceanu A, 2015, J NEUROSURG-SPINE, V23, P656, DOI 10.3171/2015.3.SPINE14743
   Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee
   Specogna AV, 2014, STROKE, V45, P284, DOI 10.1161/STROKEAHA.113.003276
   Stukenborg GJ, 2001, MED CARE, V39, P727, DOI 10.1097/00005650-200107000-00009
   Sundararajan V, 2004, J CLIN EPIDEMIOL
   Tanenbaum JE, 2016, SPINE J
   Tehrani ASS, 2013, ACAD EMERG MED, V20, P689, DOI 10.1111/acem.12168
   Thompson BG, 2015, STROKE, V46, P2368, DOI 10.1161/STR.0000000000000070
   Thompson NR, 2015, MED CARE, V53, P374, DOI 10.1097/MLR.0000000000000326
   Tseng MC, 2009, J NEUROL SCI, V284, P52, DOI 10.1016/j.jns.2009.04.009
   Umegaki H, 2017, GERIATR GERONTOL INT, V17, P1623, DOI 10.1111/ggi.12943
   van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5
   Wang MY, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15180
   Wheeler Erlinda C, 2004, J Transcult Nurs, V15, P291, DOI 10.1177/1043659604268962
   Whitmore RG, 2014, SPINE J, V14, P31, DOI 10.1016/j.spinee.2013.03.011
   Wu CY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171667
   Yan Y, 2005, MED CARE, V43, P1073, DOI 10.1097/01.mlr.0000182477.29129.86
   Yoshihara H, 2014, SPINE J, V14, P1844, DOI 10.1016/j.spinee.2013.11.029
   Yu W, 2004, AM J MANAG CARE, V10, P909
   Yurkovich M, 2015, J CLIN EPIDEMIOL, V68, P3, DOI 10.1016/j.jclinepi.2014.09.010
   Zhu HF, 2008, NEUROLOGY, V71, P283, DOI 10.1212/01.wnl.0000318278.41347.94
   Zhu JS, 2012, ARCH OTOLARYNGOL, V138, P1120, DOI 10.1001/jamaoto.2013.720
NR 146
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 477
EP 500
DI 10.1016/j.wneu.2019.04.179
PG 24
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100224
PM 31048059
DA 2020-05-12
ER

PT J
AU Salehpour, F
   Shakeri, M
   Mirzaei, F
   Shokouhi, B
   Kazemzadeh, M
   Moghadasian, N
   Alavi, SAN
AF Salehpour, Firooz
   Shakeri, Moslem
   Mirzaei, Farhad
   Shokouhi, Behrooz
   Kazemzadeh, Mohammad
   Moghadasian, Nava
   Alavi, Seyed Ahmad Naseri
TI Cystic Degeneration of Cerebellar Tonsil 1 Year After Chiari I
   Malformation Surgery. A Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebellar tonsil; Chiari I malformation surgery
ID SYRINGOMYELIA; ASSOCIATION; CORD
AB BACKGROUND: Chiari malformation results from a bony structural anomaly of the skull base. The structural defect causes downward displacement of the cerebellar tonsils through the foramen magnum. The herniated tonsils block the normal flow of cerebrospinal fluid, which causes a wide spectrum of clinical symptoms.
   CASE REPORT: In May 2015, a 16-year-old girl was referred to our center because of a 1-year history of occipital headache, most often triggered by exercise and physical activity at school. She had experienced new-onset numbness in both hands, more severe on the right side, associated with some degrees of weakness. Eventually, an evaluation of her condition included magnetic resonance imaging in T1 and T2 sequences, which revealed a 20-mm downward migration of the cerebellar tonsils, associated with a cervical cord syrinx at the level of the fourth and fifth cervical vertebrae. The patient underwent posterior fossa decompression and C1 and partial C2 laminectomies. Postoperatively there were no complications, and the patient was discharged on day 3. Postoperatively, she experienced some improvement in her symptoms. After 2 months of routine outpatient follow-up, she was better, the headaches had subsided, she could resume some activities, and there was no paresis in her limbs.
   CONCLUSIONS: In cases of progressive symptoms of Chiari malformation, decompression is important and should be considered after shunt insertion to the hindbrain.
C1 [Salehpour, Firooz; Shakeri, Moslem; Mirzaei, Farhad; Alavi, Seyed Ahmad Naseri] Tabriz Univ Med Sci, Fac Med, Dept Neurosurg, Tabriz, Iran.
   [Shokouhi, Behrooz; Kazemzadeh, Mohammad; Moghadasian, Nava] Tabriz Univ Med Sci, Fac Med, Dept Pathol, Tabriz, Iran.
RP Alavi, SAN (reprint author), Tabriz Univ Med Sci, Fac Med, Dept Neurosurg, Tabriz, Iran.
EM dr.arsalan2010@gmail.com
RI Alavi, Seyed Ahmad Naseri/M-7909-2015
OI Alavi, Seyed Ahmad Naseri/0000-0002-3602-4966
CR Fernandez AA, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-S1-S1
   Deng XF, 2013, NEUROL MED-CHIR, V53, P847, DOI 10.2176/nmc.oa2012-0206
   DWORKIN GE, 1985, ARCH PHYS MED REHAB, V66, P329
   KLEKAMP J, 1995, ACTA NEUROCHIR, V137, P38, DOI 10.1007/BF02188778
   Langridge B, 2017, WORLD NEUROSURG, V104, P213, DOI 10.1016/j.wneu.2017.04.082
   Meadows J, 2000, J NEUROSURG, V92, P920, DOI 10.3171/jns.2000.92.6.0920
   Milhorat TH, 2009, SURG NEUROL, V72, P20, DOI 10.1016/j.surneu.2009.03.008
   Mortazavi MM, 2011, J NEUROSURG-PEDIATR, V7, P257, DOI 10.3171/2010.12.PEDS10579
   PILLAY PK, 1991, NEUROSURGERY, V28, P639, DOI 10.1227/00006123-199105000-00001
   Pueyrredon F, 2007, CHILD NERV SYST, V23, P427, DOI 10.1007/s00381-006-0252-y
   Sekula RF, 2011, NEUROL RES, V33, P232, DOI 10.1179/016164111X12962202723724
   Sgouros S, 1996, J NEUROSURG, V85, P197, DOI 10.3171/jns.1996.85.2.0197
   Stevenson CB, 2009, J NEUROSURG-PEDIATR, V4, P557, DOI 10.3171/2009.7.PEDS09174
   WATSON N, 1981, PARAPLEGIA, V19, P89, DOI 10.1038/sc.1981.20
   Woodward Josha A, 2018, Surg Neurol Int, V9, P88, DOI 10.4103/sni.sni_304_16
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 501
EP 505
DI 10.1016/j.wneu.2019.04.241
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100225
PM 31077896
DA 2020-05-12
ER

PT J
AU Tabano, A
   Restelli, F
   Pozzi, F
   Turri-Zanoni, M
   Veiceschi, P
   Cherubino, M
   Castelnuovo, P
   Locatelli, D
AF Tabano, Antonio
   Restelli, Francesco
   Pozzi, Fabio
   Turri-Zanoni, Mario
   Veiceschi, Pierlorenzo
   Cherubino, Mario
   Castelnuovo, Paolo
   Locatelli, Davide
TI The Helmet-Visor Pericranial Flap as a Viable Option for Anterior
   Cranial Base Reconstruction in Complex Oncologic Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranial base reconstruction; Pericranial flap; Skull base
   reconstruction; Superficial temporal artery; Vascularized pedicle
ID DURAL RECONSTRUCTION; SURGERY; FASCIA; BONE; MALIGNANCIES; OUTCOMES;
   ANATOMY; DISEASE
AB OBJECTIVE: To describe a novel bilaterally pedicled pericranial flap for anterior cranial base reconstruction after removal of complex frontobasal cancers extending to the frontal region, thus precluding the use of standard reconstructive techniques.
   METHODS: In selected oncologic cranial base surgeries,the use of the standard galea frontalis pericranial flap for reconstructive purposes may be precluded by tumor infiltration. In such cases, dura mater reconstruction and exclusion of frontal sinuses from the intracranial space can be performed using a large superficial temporal artery bilaterally pedicled pericranial flap obtained from both temporoparietal regions. Surgical technique, indication, contraindication, complications, and degree of resection are recorded to evaluate the efficacy of this surgical method.
   RESULTS: A 48-year-old man affected by a recurrence of frontbasal squamous cell carcinoma was surgically treated by combined transcranial and endoscopic endo-nasal resection. A large pericranial flap pedicled bilaterally on the parietal branches of the superficial temporal artery was obtained, transposed anteriorly, carefully watertight sutured to the dural defect, and used to exclude cranialized frontal sinuses as well. The reconstruction was successful, and the patient was discharged home on the tenth postoperative day without any complications and/or development of cerebrospinal fluid leak. Contrast-enhanced magnetic resonance imaging 3 months after surgery was clear from disease with consolidated surgical outcomes.
   CONCLUSIONS: This novel pericranial flap seems to be easily obtained and effective for anterior cranial base reconstruction when the use of a traditional galea frontalis flap is precluded for oncologic reasons and there are concerns for the possible development of contaminations and cerebrospinal fluid leaks.
C1 [Tabano, Antonio; Restelli, Francesco; Pozzi, Fabio; Veiceschi, Pierlorenzo; Locatelli, Davide] Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Div Neurosurg, Varese, Italy.
   [Turri-Zanoni, Mario; Castelnuovo, Paolo] Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Div Otorhinolaryngol, Varese, Italy.
   [Cherubino, Mario] Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Div Plast & Reconstruct Surg, Varese, Italy.
   [Pozzi, Fabio; Turri-Zanoni, Mario; Cherubino, Mario; Castelnuovo, Paolo; Locatelli, Davide] Univ Insubria, Head & Neck Surg & Forens Dissect Res Ctr, Dept Biotechnol & Life Sci, Varese, Italy.
RP Restelli, F (reprint author), Osped Circolo & Fdn Macchi, Dept Biotechnol & Life Sci, Div Neurosurg, Varese, Italy.
EM francesco.restelli91@gmail.com
RI Locatelli, Davide/AAH-5844-2020; Cherubino, Mario/N-1780-2019;
   Veiceschi, Pierlorenzo/AAA-3596-2019
OI Locatelli, Davide/0000-0003-1163-9611; Cherubino,
   Mario/0000-0003-1196-3075; Veiceschi, Pierlorenzo/0000-0002-0960-8712;
   Turri-Zanoni, Mario/0000-0002-3678-9088
CR Castelnuovo P, 2006, OPER TECH OTOLARYNGO, V17, P152
   Castelnuovo P, 2016, OTOLARYNG CLIN N AM, V49, P183, DOI 10.1016/j.otc.2015.09.012
   Castelnuovo P, 2014, WORLD NEUROSURG, V82, pS22, DOI 10.1016/j.wneu.2014.07.021
   Cavallo LM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.021
   Dallan I, 2015, WORLD NEUROSURG, V84, P97, DOI 10.1016/j.wneu.2015.02.034
   Devulapalli C, 2018, J CRANIOFAC SURG, V29, P2182, DOI 10.1097/SCS.0000000000004832
   Dixit PK, 2018, INT SURG J, V5, P2367
   Ducic Y, 2010, OPER TECH OTOLARYNGO, V21, P9
   Gagliardi F, 2017, WORLD NEUROSURG, V107, P477, DOI 10.1016/j.wneu.2017.08.022
   GOEL A, 1995, ACTA NEUROCHIR, V135, P203, DOI 10.1007/BF02187770
   GOEL A, 1994, BRIT J NEUROSURG, V8, P731, DOI 10.3109/02688699409101188
   Goel A, 1998, BRIT J NEUROSURG, V12, P254, DOI 10.1080/02688699845096
   GOEL A, 1995, BRIT J NEUROSURG, V9, P667
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Karligkiotis A, 2016, HEAD NECK-J SCI SPEC, V38, P1604, DOI 10.1002/hed.24481
   Karsidag S, 2009, J CRANIOFAC SURG, V20, P2248, DOI 10.1097/SCS.0b013e3181bf871b
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Kelly CP, 2005, PLAST RECONSTR SURG, V115, P1229, DOI 10.1097/01.PRS.0000156770.90333.66
   Kim J C, 2001, Arch Facial Plast Surg, V3, P170, DOI 10.1001/archfaci.3.3.170
   Leng LZ, 2008, NEUROSURGERY, V62, P342, DOI [10.1227/01.NEU.0000312720.93685.17, 10.1227/01.neu.0000326017.84315.1f]
   Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169
   Origitano TC, 2006, NEUROSURGERY, V58, P327, DOI 10.1227/01.NEU.0000192680.48095.BD
   Patel MR, 2010, NEUROSURGERY, V66, P506, DOI 10.1227/01.NEU.0000365620.59677.FF
   Patel SG, 2003, CANCER, V98, P1179, DOI 10.1002/cncr.11630
   Pinar YA, 2006, SURG RADIOL ANAT, V28, P248, DOI 10.1007/s00276-006-0094-z
   Rinehart GC, 1998, J CRANIOFAC SURG, V9, P65, DOI 10.1097/00001665-199801000-00014
   Sahnane N, 2019, INT J CANCER, V144, P1313, DOI 10.1002/ijc.31971
   Schijman E, 2004, CHILD NERV SYST, V5, P333
   Schwartz TH, 2008, NEUROSURGERY, V62, P991, DOI [10.1227/01.NEU.0000313231.81129.66, 10.1227/01.neu.0000325861.06832.06]
   Velasco-Torres HS, 2017, NEUROSURG REV, V40, P95, DOI 10.1007/s10143-016-0739-2
   Velasco-Torres HS, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.07.070
   Sekhar LN, 2001, NEUROSURGERY, V49, P749
   Song DL, 2002, CHINESE MED J-PEKING, V115, P552
   Takagi M, 2006, J CRANIOFAC SURG, V17, P584, DOI 10.1097/00001665-200605000-00035
   Tanaka S, 2010, NEUROEPIDEMIOLOGY, V34, P232, DOI 10.1159/000297747
   Than Khoi D, 2007, Neurosurgery, V60, pE773, DOI 10.1227/01.NEU.0000255400.46151.C3
   Turri-Zanoni M, 2018, WORLD NEUROSURG, V116, pE436, DOI 10.1016/j.wneu.2018.04.225
   Worm Paulo V, 2010, Surg Neurol Int, V1, P91, DOI 10.4103/2152-7806.74160
   Yoon SH, 2013, ARCH PLAST SURG-APS, V40, P341, DOI 10.5999/aps.2013.40.4.341
   Yoshioka N, 2005, NEUROSURGERY, V57, P11, DOI 10.1227/01.NEU.0000163477.85087.B1
   Zuniga MG, 2016, CURR OPIN OTOLARYNGO, V24, P75, DOI 10.1097/MOO.0000000000000223
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 506
EP 513
DI 10.1016/j.wneu.2019.05.136
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100226
PM 31132485
DA 2020-05-12
ER

PT J
AU Bobeff, EJ
   Sanchez-Viguera, C
   Arraez-Manrique, C
   Arraez-Sanchez, MA
AF Bobeff, Ernest Jan
   Sanchez-Viguera, Cristina
   Arraez-Manrique, Cinta
   Angel Arraez-Sanchez, Miguel
TI Suprasellar Epidermoid Cyst Case Report of Extended Endoscopic
   Transsphenoidal Resection and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Epidermoid cyst; Review; Suprasellar; Transsphenoidal
   endoscopic approach
ID RECURRENT ASEPTIC-MENINGITIS; SKULL BASE; ENDONASAL APPROACH; MOLLARETS
   MENINGITIS; CRANIAL BASE; TUMORS; SURGERY; INTRASELLAR; COMPLICATIONS;
   CRANIOTOMY
AB BACKGROUND: Suprasellar epidermoid cysts (SECs) constitute a large portion of so-called pearly tumors. Despite their insidious development and infiltration into vital neurovascular structures, they have a friable consistency, which particularly facilitates their resection; the only alternative to surgery is wait-and-see policy. We present a case of SEC in a patient with bitemporal hemianopia and no other significant symptoms and results of analysis of data on surgical treatment of 71 similar cases reported in the last 4 decades.
   CASE DESCRIPTION: A 29-year-old man presented with 1 year blurred vision. Bitemporal hemianopia was detected by perimetry. The patient was otherwise fit and well, with no significant past medical history. Magnetic resonance imaging showed an extra-axial suprasellar lesion with expansion toward the prepontine cistern, which showed restricted diffusion. The patient was operated on via a binostril endoscopic transtuberculum-transplanum endonasal approach. Pathologic examination confirmed the diagnosis of epidermoid cyst. The postoperative course was complicated by third cranial nerve palsy, rhinorrhea, which required reoperation, and diabetes insipidus. Otherwise, the patient made a good recovery and reported subjective improvement of visual acuity. Gradually, the left third cranial nerve function improved and there was neither any long-term complication nor recurrence on 6 months follow-up study.
   CONCLUSIONS: A suprasellar location frequently impedes the gross total resection of epidermoid cysts. Endoscopic endonasal approaches might be more effective in resection of lesions that do not extend laterally beyond the cranial nerves. The introduction of magnetic resonance imaging and surgical endoscopy were fundamental achievements in SEC management. There is a constant need for quality case reports on the management of these intracranial tumors.
C1 [Bobeff, Ernest Jan; Sanchez-Viguera, Cristina; Arraez-Manrique, Cinta; Angel Arraez-Sanchez, Miguel] Univ Malaga, Carlos Haya Univ Hosp, Dept Neurosurg, Malaga, Spain.
   [Bobeff, Ernest Jan] Med Univ Lodz, Barlicki Univ Hosp, Dept Neurosurg & Neurooncol, Lodz, Poland.
RP Bobeff, EJ (reprint author), Univ Malaga, Carlos Haya Univ Hosp, Dept Neurosurg, Malaga, Spain.; Bobeff, EJ (reprint author), Med Univ Lodz, Barlicki Univ Hosp, Dept Neurosurg & Neurooncol, Lodz, Poland.
EM ernestbobeff@gmail.com
CR ABRAMSON RC, 1989, NEUROSURGERY, V24, P574, DOI 10.1227/00006123-198904000-00014
   ACHARD JM, 1990, AM J MED, V89, P807, DOI 10.1016/0002-9343(90)90226-4
   ALBANESE V, 1982, SURG NEUROL, V18, P356, DOI 10.1016/0090-3019(82)90151-3
   Alves A M, 1970, Int Surg, V54, P239
   Aristegui FJ, 1998, PEDIATR NEUROL, V18, P156, DOI 10.1016/S0887-8994(97)00156-2
   BECKER WJ, 1984, CAN J NEUROL SCI, V11, P387, DOI 10.1017/S0317167100045777
   Beechar VB, 2018, NEUROSPINE, V15, P117, DOI 10.14245/ns.1836014.007
   Black HA, 1943, ARCH NEURO PSYCHIATR, V49, P214, DOI 10.1001/archneurpsyc.1943.02290140074006
   BOGGAN JE, 1983, J NEUROSURG, V58, P411, DOI 10.3171/jns.1983.58.3.0411
   BOLLAR A, 1989, NEUROCHIRURGIA, V32, P123
   Cappabianca P, 2008, NEUROSURGERY, V63, P240, DOI 10.1227/01.NEU.0000327038.09638.37
   Cavallo LM, 2007, J NEUROSURG, V107, P713, DOI 10.3171/JNS-07/10/0713
   Ceylan S, 2015, NEUROSURG REV, V38, P137, DOI 10.1007/s10143-014-0576-0
   Conrad J, 2016, J NEUROSURG, V125, P334, DOI 10.3171/2015.6.JNS142637
   Costa F, 2013, NEUROSURG QUART, V23, P108, DOI 10.1097/WNQ.0b013e318266c267
   CROSSLEY GH, 1990, AM J MED, V89, P805, DOI 10.1016/0002-9343(90)90225-3
   Cruveilhier J., 1829, ANATOMIE PATHOLOGIQU, P1
   Davies JM, 2013, J NEURO-ONCOL, V112, P307, DOI 10.1007/s11060-013-1065-y
   de Chadarevian J P, 1980, J Neuropathol Exp Neurol, V39, P661
   de Divitiis E, 2013, WORLD NEUROSURG, V80, P728, DOI 10.1016/j.wneu.2013.01.027
   Dehdashti AR, 2009, NEUROSURGERY, V64, P677, DOI 10.1227/01.NEU.0000339121.20101.85
   ELIASH A, 1983, CHILD BRAIN, V10, P414
   Esposito F, 2005, NEUROSURGERY, V56, P443
   Fomichev D, 2016, WORLD NEUROSURG, V96, P159, DOI 10.1016/j.wneu.2016.08.111
   Forbes JA, 2019, J NEUROSURG, V130, P1599, DOI 10.3171/2017.12.JNS172575
   Fox BD, 2009, J CLIN NEUROSCI, V16, P1101, DOI 10.1016/j.jocn.2008.04.033
   Gao BQ, 2007, PEDIATRICS, V120, pE220, DOI 10.1542/peds.2006-2053
   Goel A, 2010, J CLIN NEUROSCI, V17, P372, DOI 10.1016/j.jocn.2009.07.107
   GORMLEY WB, 1994, ACTA NEUROCHIR, V128, P115, DOI 10.1007/BF01400660
   Grahnke K, 2018, J NEUROL SURG PART B, V79, P445, DOI 10.1055/s-0037-1617431
   Grondin RT, 2007, CAN J NEUROL SCI, V34, P197, DOI 10.1017/S0317167100006041
   GROSSMAN A, 1985, CLIN ENDOCRINOL, V22, P679, DOI 10.1111/j.1365-2265.1985.tb03004.x
   HERMANS PE, 1972, AM J MED, V52, P128, DOI 10.1016/0002-9343(72)90014-9
   Huo C W, 2018, Surg Neurol Int, V9, P15, DOI 10.4103/sni.sni_269_17
   Jeswani S, 2016, J NEUROSURG, V124, P627, DOI 10.3171/2015.3.JNS142254
   Joseph V, 2005, BRIT J NEUROSURG, V19, P33, DOI 10.1080/02688690500089415
   Kwon TH, 2001, NEUROSURGERY, V49, P450, DOI 10.1097/00006123-200108000-00035
   Laufer I, 2007, J NEUROSURG, V106, P400, DOI 10.3171/jns.2007.106.3.400
   Laws ER, 2014, WORLD NEUROSURG, V82, pS152, DOI 10.1016/j.wneu.2014.07.035
   LEWIS AJ, 1983, J NEUROSURG, V59, P538, DOI 10.3171/jns.1983.59.3.0538
   Lynch Jose Carlos, 2014, Surg Neurol Int, V5, P163, DOI 10.4103/2152-7806.145764
   Mammis A, 2013, J NEUROL SURG PART A, V74, pE96, DOI 10.1055/s-0032-1328954
   Mann M, 1963, J Natl Med Assoc, V55, P18
   Margetis K, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.021
   Mascarenhas L, 2014, WORLD NEUROSURG, V82, P186, DOI 10.1016/j.wneu.2013.02.032
   McCoul ED, 2012, INT FORUM ALLERGY RH, V2, P258, DOI 10.1002/alr.21005
   Miller JD, 2017, J NEUROL SURG PART B, V78, P11, DOI 10.1055/s-0036-1583948
   Montaser AS, 2018, J NEUROL SURG PART B, V79, pS279, DOI 10.1055/s-0038-1624590
   MORI K, 1982, NEUROCHIRURGIA, V25, P138
   Mortazavi MM, 2015, CHILD NERV SYST, V31, P15, DOI 10.1007/s00381-014-2590-5
   Murad Mohammad Hassan, 2018, BMJ Evid Based Med, V23, P60, DOI 10.1136/bmjebm-2017-110853
   Nakassa ACI, 2018, J NEUROSURG, V128, P437, DOI 10.3171/2016.11.JNS161605
   OBRADOR S, 1969, J NEUROL NEUROSUR PS, V32, P450, DOI 10.1136/jnnp.32.5.450
   OGE K, 1991, NEUROCHIRURGIA, V34, P94
   PARIKH S, 1995, J NEURO-ONCOL, V24, P293, DOI 10.1007/BF01052846
   Prasad GL, 2017, WORLD NEUROSURG, V98, P870
   Rehman L, 2018, TURK NEUROSURG, V28, P763, DOI 10.5137/1019-5149.JTN.21095-17.0
   Ren XH, 2012, J NEUROSURG, V116, P611, DOI 10.3171/2011.10.JNS111462
   ROUX A, 1992, J NEUROSURG, V76, P528, DOI 10.3171/jns.1992.76.3.0528
   SADEH M, 1982, ARCH NEUROL-CHICAGO, V39, P250, DOI 10.1001/archneur.1982.00510160056013
   Schiefer TK, 2008, SURG NEUROL, V70, P584, DOI 10.1016/j.surneu.2007.12.021
   SCHUBIGER O, 1983, NEURORADIOLOGY, V24, P269, DOI 10.1007/BF00333179
   Stephenson ED, 2018, JAMA OTOLARYNGOL, V144, P923, DOI 10.1001/jamaoto.2018.1948
   Talacchi A, 1998, NEUROSURGERY, V42, P242, DOI 10.1097/00006123-199802000-00020
   Tuna H, 2008, J CLIN NEUROSCI, V15, P1154, DOI 10.1016/j.jocn.2007.07.004
   TYTUS JS, 1956, J NEUROL NEUROSUR PS, V19, P241, DOI 10.1136/jnnp.19.4.241
   Vaz-Guimaraes F, 2019, J NEUROSURG, V130, P368, DOI 10.3171/2017.7.JNS162783
   Watanabe T, 2011, NEUROL MED-CHIR, V51, P684, DOI 10.2176/nmc.51.684
   YAMAKAWA K, 1989, NEUROSURGERY, V24, P568, DOI 10.1227/00006123-198904000-00013
   YASARGIL MG, 1989, NEUROSURGERY, V24, P561
   Zada G, 2011, J NEUROSURG, V114, P286, DOI 10.3171/2010.8.JNS10520
NR 71
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 514
EP 526
DI 10.1016/j.wneu.2019.05.100
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100227
PM 31121364
DA 2020-05-12
ER

PT J
AU He, P
   Chen, W
   Qiu, XX
   Xi, YB
   Guan, H
   Xia, J
AF He, Pin
   Chen, Wei
   Qiu, Xi Xiong
   Xi, Yi Bin
   Guan, Hong
   Xia, Jun
TI A Rare High-Grade Glioma with a Histone H3 K27M Mutation in the
   Hypothalamus of an Adult Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult patient; Glioma; H3 K27M mutation; Hypothalamus
ID PROGNOSIS; GLIOBLASTOMA; MANAGEMENT; SUBGROUPS; H3F3A; TUMOR
AB BACKGROUND: Diffuse midline glioma H3 K27M mutant is a new tumor entity described in the revised 2016 World Health Organization classification. It is most frequently observed in children and develops in midline structures, including the brainstem, thalamus, and spine. We describe a rare diffuse midline glioma with an H3 K27M mutation arising in the hypothalamus of an adult.
   CASE DESCRIPTION: A 27-year-old woman was admitted to our department complaining of amenorrhea, polydipsia, and diuresis for the previous 3 months, and headache and lethargy for approximately 10 days. Computed tomography scan showed an oval isodense solid mass extending from the pituitary toward the suprasellar cistern. A gadolinium-enhanced magnetic resonance imaging (MRI) showed a strongly heterogeneous enhanced solid lesion and nonenhanced cystic lesion. The patient underwent surgery and chemoradiotherapy with temozolomide. Histologic and immunohistochemical analyses revealed H3 K27M-mutant diffuse midline glioma. The patient underwent another resection for a recurrent tumor 5 months after the first surgery. Three months after the second operation, the patient relapsed, with MRI revealing spinal cord and meningeal metastases; she died shortly afterward.
   CONCLUSIONS: Diffuse midline glioma with an H3 K27M mutation occurring in the hypothalamus of an adult is rare but should be considered in differential diagnoses. Because histone H3 K27M mutations are associated with aggressive clinical behavior and poor prognosis, molecular analyses should be used to determine the clinical and histopathologic features of such tumors. This will contribute to developing targeted drugs and gene therapy going forward.
C1 [He, Pin; Qiu, Xi Xiong; Xia, Jun] Shenzhen Univ, Hlth Sci Ctr, Affiliated Hosp 1, Dept Radiol, Shenzhen, Peoples R China.
   [Guan, Hong] Shenzhen Univ, Hlth Sci Ctr, Affiliated Hosp 1, Dept Pathol, Shenzhen, Peoples R China.
   [He, Pin; Qiu, Xi Xiong; Guan, Hong; Xia, Jun] Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China.
   [Chen, Wei] Tongji Univ, Sch Med, Dept Radiol, Tongji Hosp, Shanghai, Peoples R China.
   [Chen, Wei] Hubei Univ Med, Dept Radiol, Pingshan Dist Peoples Hosp, Shenzhen, Guangdong, Peoples R China.
   [Xi, Yi Bin] Fourth Mil Med Univ, Xijing Hosp, Dept Radiol, Xian, Shaanxi, Peoples R China.
RP Xia, J (reprint author), Shenzhen Univ, Hlth Sci Ctr, Affiliated Hosp 1, Dept Radiol, Shenzhen, Peoples R China.; Xia, J (reprint author), Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China.
EM xiajun@email.szu.edu.cn
OI chen, wei/0000-0003-4610-8490
FU Scientific Plan Program of Guangdong [2017A020215160]; Shenzhen
   Innovation Funding [JCYJ20170413161314734]
FX This work was supported by the Scientific Plan Program of Guangdong
   (2017A020215160) and Shenzhen Innovation Funding under Grant
   (JCYJ20170413161314734).
CR Aboian MS, 2017, AM J NEURORADIOL, V38, P795, DOI 10.3174/ajnr.A5076
   Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006
   Bozkurt SU, 2018, CHILD NERV SYST, V34, P107, DOI 10.1007/s00381-017-3633-5
   Castel D, 2015, ACTA NEUROPATHOL, V130, P815, DOI 10.1007/s00401-015-1478-0
   Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113
   Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0
   Ebrahimi A, 2019, J CANCER RES CLIN, V145, P839, DOI 10.1007/s00432-018-02836-5
   El Ahmadieh TY, 2019, WORLD NEUROSURG, V124, P87, DOI 10.1016/j.wneu.2018.12.147
   Gan HK, 2015, J CLIN NEUROSCI, V22, P1462, DOI 10.1016/j.jocn.2015.03.029
   Gessi M, 2016, ACTA NEUROPATHOL, V132, P635, DOI 10.1007/s00401-016-1608-3
   Karremann M, 2018, NEURO-ONCOLOGY, V20, P123, DOI 10.1093/neuonc/nox149
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Louis DN, 2018, ACTA NEUROPATHOL, V135, P639, DOI 10.1007/s00401-018-1826-y
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mallick S, 2016, J EGYPT NATL CANCER, V28, P199, DOI 10.1016/j.jnci.2016.07.001
   Meyronet D, 2017, NEURO-ONCOLOGY, V19, P1127, DOI 10.1093/neuonc/now274
   Mount CW, 2018, NAT MED, V24, P572, DOI 10.1038/s41591-018-0006-x
   Nakata S, 2017, BRAIN TUMOR PATHOL, V34, P113, DOI 10.1007/s10014-017-0288-6
   Ochs K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1328340
   Orillac C, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0361-0
   Picart T, 2018, J NEURO-ONCOL, V136, P555, DOI 10.1007/s11060-017-2682-7
   Pratt D, 2018, ACTA NEUROPATHOL, V135, P299, DOI 10.1007/s00401-018-1805-3
   Solomon DA, 2016, BRAIN PATHOL, V26, P569, DOI 10.1111/bpa.12336
   Upper A, 2019, WORLD NEUROSURG, V126, P223, DOI 10.1016/j.wneu.2019.03.025
   Venneti S, 2014, ACTA NEUROPATHOL, V128, P743, DOI 10.1007/s00401-014-1338-3
   Wang LM, 2018, HUM PATHOL, V78, P89, DOI 10.1016/j.humpath.2018.04.015
NR 26
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 527
EP 531
DI 10.1016/j.wneu.2019.04.172
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100228
PM 31048046
DA 2020-05-12
ER

PT J
AU Ghali, MGZ
   Srinivasan, VM
   Britz, GW
AF Ghali, Michael George Zaki
   Srinivasan, Visish M.
   Britz, Gavin W.
TI Maxillary Artery to Intracranial Bypass
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bypass; EC-IC; ICA; Maxillary; MCA; PCA; Revascularization; SCA; STA
ID MIDDLE CEREBRAL-ARTERY; SUPERFICIAL TEMPORAL ARTERY; INTERNAL
   CAROTID-ARTERY; GIANT SERPENTINE ANEURYSM; SAPHENOUS-VEIN GRAFTS;
   MICROSURGICAL ANATOMY; OPERATIVE TECHNIQUE; REVASCULARIZATION;
   MANAGEMENT; SURGERY
AB Cerebral revascularization is used in the treatment of complex aneurysms and acute and chronic cerebral occlusive disease. Although superficial temporal artery-middle cerebral artery remains the workhorse of extracranial-intracranial bypass, several approaches have been developed during the past half century. The maxillary artery has shown feasibility in cadaveric studies, and usefulness in living patients, for achieving successful surgical revascularization. Although technically challenging and unfamiliar, maxillary-intracranial bypass offers the advantages of higher flow, good caliber matching, shorter graft length, calvarial protection of the interposition graft, and versatility for revascularizing multiple intracranial targets, including the intracranial internal carotid, proximal and middle cerebral, posterior cerebral, and superior cerebellar arteries. We discuss and review the evolution of, operative approaches for, and clinical applications of maxillary artery to intracranial bypass.
C1 [Ghali, Michael George Zaki; Britz, Gavin W.] Houston Methodist Hosp, Dept Neurosurg, Houston, TX 77030 USA.
   [Srinivasan, Visish M.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Britz, GW (reprint author), Houston Methodist Hosp, Dept Neurosurg, Houston, TX 77030 USA.
EM gbritz@houstonmethodist.org
CR Abdulrauf SI, 2011, NEUROSURGERY, V68, P804, DOI 10.1227/NEU.0b013e3182093355
   Akiyama O, 2018, CLIN ANAT, V31, P724, DOI 10.1002/ca.22926
   Alvernia JE, 2017, ACTA NEUROCHIR, V159, P655, DOI 10.1007/s00701-017-3092-5
   Anson JA, 1996, J NEUROSURG, V84, P185, DOI 10.3171/jns.1996.84.2.0185
   Arbag H, 2005, ACTA OTO-LARYNGOL, V125, P999, DOI 10.1080/00016480510037933
   Arbag H, 2005, J LARYNGOL OTOL, V119, P519, DOI 10.1258/0022215054352153
   ASARI S, 1978, STROKE, V9, P461, DOI 10.1161/01.STR.9.5.461
   Asari S, 1977, No Shinkei Geka, V5, P261
   AUSMAN JI, 1979, SURG NEUROL, V12, P277
   AUSMAN JI, 1981, NEUROSURGERY, V9, P56, DOI 10.1227/00006123-198107000-00009
   Benet A, 2017, OPER NEUROSURG, V13, P280, DOI 10.1093/ons/opw010
   Berkovitz BKB, 2005, GRAYS ANATOMY, P519
   Bisson EF, 2008, NEUROSURGERY, V62, P1419, DOI [10.1227/01.NEU.0000297014.73587.1D, 10.1227/01.neu.0000333805.74832.ac]
   Britz GW, 2016, WORLD NEUROSURG, V85, P106, DOI [10.1016/J.WNEU.2015.08.004, 10.1016/j.wneu.2015.08.004]
   Buyukmumcu M, 2003, SURG RADIOL ANAT, V25, P368, DOI 10.1007/s00276-003-0150-x
   Cherian J, 2018, OPER NEUROSURG, V14, P288, DOI 10.1093/ons/opx119
   Coert BA, 2007, J NEUROSURG, V106, P855, DOI 10.3171/jns.2007.106.5.855
   Dacey RG, 2008, J NEUROSURG, V109, P559, DOI 10.3171/JNS/2008/109/9/0559
   DEOLIVEIRA E, 1995, ACTA NEUROCHIR, V136, P204, DOI 10.1007/BF01410627
   Eller JL, 2012, J NEUROL SURG PART B, V73, P48, DOI 10.1055/s-0032-1304556
   Evans JJ, 2004, NEUROSURGERY, V55, P1036, DOI 10.1227/01.NEU.0000140822.64362.C6
   Feng XQ, 2017, OPER NEUROSURG, V13, P246, DOI 10.1093/ons/opw006
   Feng XQ, 2016, OPER NEUROSURG, V12, P106, DOI 10.1227/NEU.0000000000001099
   FISCH UP, 1980, OTOLARYNG HEAD NECK, V88, P548, DOI 10.1177/019459988008800507
   Geibprasert S, 2009, AM J NEURORADIOL, V30, P1459, DOI 10.3174/ajnr.A1500
   GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560
   Gonzalez-Darder JM, 2011, NEUROCIRUGIA, V22, P429, DOI 10.4321/S1130-14732011000500004
   HADDAD GF, 1988, NEUROSURGERY, V23, P92, DOI 10.1227/00006123-198807000-00016
   HOPKINS LN, 1982, NEUROSURGERY, V10, P364, DOI 10.1227/00006123-198203000-00012
   HOPKINS LN, 1989, J NEUROSURG, V70, P207, DOI 10.3171/jns.1989.70.2.0207
   Ishikawa T, 2009, NEUROL MED-CHIR, V49, P553, DOI 10.2176/nmc.49.553
   Jafar JJ, 2002, NEUROSURGERY, V51, P138, DOI 10.1097/00006123-200207000-00021
   Joo W, 2013, CLIN ANAT, V26, P455, DOI 10.1002/ca.22202
   Kalani MYS, 2016, J CLIN NEUROSCI, V24, P151, DOI 10.1016/j.jocn.2015.08.007
   Kalani MYS, 2013, J CLIN NEUROSCI, V20, P887, DOI 10.1016/j.jocn.2012.09.007
   Kalani MYS, 2013, NEUROSURGERY, V72, P763, DOI 10.1227/NEU.0b013e3182870703
   Karabulut AK, 2001, ANN VASC SURG, V15, P548, DOI 10.1007/s10016-001-0027-6
   Kyoshima K, 2001, NEUROSURGERY, V48, P447, DOI 10.1097/00006123-200102000-00047
   Lawton MT, 2016, NEUROSURGERY, V79, P83, DOI 10.1227/NEU.0000000000001175
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Liu James K, 2003, Neurosurg Focus, V14, pe3
   Liu YL, 2017, ACTA NEUROCHIR, V159, P1693, DOI 10.1007/s00701-017-3101-8
   LOUGHEED WM, 1971, J NEUROSURG, V34, P114, DOI 10.3171/jns.1971.34.1.0114
   Lustig LR, 1998, SKULL BASE SURG, V8, P1, DOI 10.1055/s-2008-1058584
   Ma L, 2015, J CRANIOFAC SURG, V26, P544, DOI 10.1097/SCS.0000000000001521
   Maeda S, 2012, ANAT SCI INT, V87, P187, DOI 10.1007/s12565-012-0146-x
   Meybodi AT, 2017, WORLD NEUROSURG, V108, P973, DOI 10.1016/j.wneu.2017.08.135
   Meybodi AT, 2017, WORLD NEUROSURG, V107, P314, DOI 10.1016/j.wneu.2017.07.158
   Murray GM, 2001, J OROFAC PAIN, V15, P279
   Ng WH, 2001, J CLIN NEUROSCI, V8, P580, DOI 10.1054/jocn.2000.0812
   Nisanoglu V, 2006, HEART SURG FORUM, V9, pE807, DOI 10.1532/HSF98.20061070
   Nossek E, 2014, NEUROSURGERY, V75, P87, DOI 10.1227/NEU.0000000000000340
   Osborn AG, 1999, EXTERNAL CAROTID VAS, P31
   PAULLUS WS, 1977, J NEUROSURG, V47, P713, DOI 10.3171/jns.1977.47.5.0713
   PRETTERKLIEBER ML, 1991, ACTA ANAT, V142, P281
   Quinones-Hinojosa A, 2005, NEUROSURGERY, V57, P140, DOI 10.1227/01.NEU.0000163599.78896.F4
   Rhoton AL, 2002, NEUROSURGERY, V51, pS273, DOI 10.1227/01.NEU.0000028087.76279.41
   Rodriguez-Hernandez A, 2011, J NEUROSURG, V115, P387, DOI 10.3171/2011.3.JNS101413
   Russell SM, 2006, SURG NEUROL, V66, P285, DOI 10.1016/j.surneu.2006.03.029
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   SEGAL HD, 1977, J NEUROSURG, V46, P115, DOI 10.3171/jns.1977.46.1.0115
   SEKHAR LN, 1986, NEUROSURGERY, V19, P967, DOI 10.1227/00006123-198612000-00012
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   Shi XE, 2011, ACTA NEUROCHIR, V153, P1649, DOI 10.1007/s00701-011-1070-x
   Shi XG, 2015, NEUROSURG REV, V38, P109, DOI 10.1007/s10143-014-0571-5
   Sia SF, 2013, J CLIN NEUROSCI, V20, P1, DOI 10.1016/j.jocn.2012.05.007
   SUNDT TM, 1987, J NEUROSURG, V66, P172, DOI 10.3171/jns.1987.66.2.0172
   SUNDT TM, 1986, J NEUROSURG, V64, P169, DOI 10.3171/jns.1986.64.2.0169
   SUNDT TM, 1982, J NEUROSURG, V56, P205, DOI 10.3171/jns.1982.56.2.0205
   SUNDT TM, 1986, J NEUROSURG, V65, P439, DOI 10.3171/jns.1986.65.4.0439
   Takeuchi Satoru, 2015, Surg Neurol Int, V6, P95, DOI 10.4103/2152-7806.157949
   Ulku CH, 2004, ACTA OTO-LARYNGOL, V124, P858, DOI 10.1080/00016480410017477
   UMANSKY F, 1984, J NEUROSURG, V61, P458, DOI 10.3171/jns.1984.61.3.0458
   Ustun ME, 2004, NEUROSURGERY, V54, P667, DOI 10.1227/01.NEU.0000109553.72250.E0
   Vishteh AG, 1999, J NEUROSURG, V91, P346, DOI 10.3171/jns.1999.91.2.0346
   Vrionis FD, 1996, NEUROSURGERY, V39, P777, DOI 10.1097/00006123-199610000-00027
   Wang L, 2017, WORLD NEUROSURG, V108, P971, DOI 10.1016/j.wneu.2017.08.072
   Wang L, 2017, WORLD NEUROSURG, V105, P568, DOI 10.1016/j.wneu.2017.06.014
   Wang L, 2017, WORLD NEUROSURG, V104, P1004, DOI 10.1016/j.wneu.2017.01.134
   Wang L, 2017, WORLD NEUROSURG, V103, P395, DOI 10.1016/j.wneu.2017.04.055
   Wang L, 2017, NEUROSURG REV, V40, P319, DOI 10.1007/s10143-016-0778-8
   Wang L, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16252
   Wang Y, 2014, J STROKE CEREBROVASC, V23, P2573, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.024
   WORINGER E, 1963, NEURO-CHIR, V9, P181
   Yagmurlu K, 2017, WORLD NEUROSURG, V104, P1005, DOI 10.1016/j.wneu.2017.05.072
   Yagmurlu K, 2017, WORLD NEUROSURG, V100, P540, DOI 10.1016/j.wneu.2016.12.130
   Yasargil M G, 1977, Neurosurgery, V1, P22
   Yu Z, 2017, BRIT J NEUROSURG, V11, P1
   Yu ZT, 2017, J ULTRAS MED, V36, P439, DOI 10.7863/ultra.16.02011
   Yu ZT, 2016, NEUROL RES, V38, P420, DOI 10.1080/01616412.2016.1177931
   Zador Z, 2010, NEUROSURGERY, V66, P92, DOI 10.1227/01.NEU.0000362034.81037.FC
NR 91
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 532
EP 540
DI 10.1016/j.wneu.2019.03.015
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100229
PM 30974277
DA 2020-05-12
ER

PT J
AU Salaud, C
   Roualdes, V
   Thillays, F
   Martin, SA
   Buffenoir, K
AF Salaud, Celine
   Roualdes, Vincent
   Thillays, Francois
   Martin, Stephane Andre
   Buffenoir, Kevin
TI Trigeminal Ganglion Metastasis of Renal Clear Cell Carcinoma: Cases
   Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Renal clear cell carcinoma; Skull-based surgery; Trigeminal
   ganglion metastases
ID SKULL BASE METASTASIS
AB BACKGROUND: The trigeminal ganglion is an atypical site for metastasis, especially for renal clear cell carcinoma.
   CASE DESCRIPTION: We report 2 clinical cases of a 66-year-old man and a 58-year-old man with trigeminal symptoms. Both patients had a history of renal clear cell (RCC) that was considered to be cured at 6 and 9 years, respectively. Brain magnetic resonance imaging (MRI) showed a trigeminal ganglion lesion with increased gadolinium enhancement associated with petrous apex erosion. The main diagnostic hypothesis based on MRI was trigeminal schwannoma for both patients. One patient underwent subtotal removal, the other a biopsy. Histologic examinations resulted in the diagnosis of RCC metastasis. Body computed tomography revealed pancreatic metastasis for both but no renal recurrence. The patients were treated by local radiotherapy, and 1 of the patients had associated chemotherapy. We added to these clinical cases a literature review of skull base metastasis of RCC.
   Trigeminal ganglion metastasis of RCC is very rare and can persist until 10 years after the first RCC diagnosis. It seems that the best treatment is surgical removal. To date, the role of local radiotherapy is not demonstrated, and the prognosis seems to be poor.
   CONCLUSIONS: In the case of trigeminal symptoms, rapid tumoral growth on brain MRI, or a history of RCC, we think that a body computed tomography should be performed, and surgery should be considered.
C1 [Salaud, Celine; Roualdes, Vincent; Martin, Stephane Andre; Buffenoir, Kevin] Nantes Univ Hosp, Dept Neurotrauma Neurosurg, St Herblain, France.
   [Thillays, Francois] Inst Cancerol Ouest, Dept Radiotherapy, St Herblain, France.
RP Salaud, C (reprint author), Nantes Univ Hosp, Dept Neurotrauma Neurosurg, St Herblain, France.
EM celine.salaud@chu-nantes.fr
CR Agarwal A, 2015, NEURORADIOL J, V28, P36, DOI 10.15274/NRJ-2014-10117
   Ali O, 2018, EUR J RADIOL, V107, P134, DOI 10.1016/j.ejrad.2018.05.002
   Endo K, 2001, INTERNAL MED, V40, P924, DOI 10.2169/internalmedicine.40.924
   Fumino M, 1998, Hinyokika Kiyo, V44, P319
   Kachhara R, 2001, NEUROL MED-CHIR, V41, P360, DOI 10.2176/nmc.41.360
   MANI N, 2017, BMJ CASE REP, P111, DOI DOI 10.1016/B978-0-12-804409-4.00004-8
   Mendelson ZS, 2015, BRIT J NEUROSURG, V29, P430, DOI 10.3109/02688697.2014.987217
   Ogiwara T, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.03.019
   Okudo J, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/9184501
   Sagoh M, 1996, NEUROL SURG TOKYO, V24, P829
   Sepulveda I, 2013, CASE REP ONCOL, V6, P416, DOI 10.1159/000354575
   Tritschler P, 2014, CLIN NEURORADIOL, V24, P51, DOI 10.1007/s00062-012-0195-5
   Wang A, 2015, J NEUROL SURG REP, V76, pE282, DOI 10.1055/s-0035-1566125
   Wiechno P, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1217-1
   Xie HK, 2013, DEVICE CIRC SYST, P131
   Zhang WQ, 2018, WORLD J CLIN CASES, V6, P301, DOI 10.12998/wjcc.v6.i9.301
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 541
EP 546
DI 10.1016/j.wneu.2019.04.230
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100230
PM 31059855
DA 2020-05-12
ER

PT J
AU Della Pappa, GM
   Marchese, E
   Pedicelli, A
   Olivi, A
   Ricciardi, L
   Rapisarda, A
   Skrap, B
   Sabatino, G
   La Rocca, G
AF Della Pappa, Giuseppe Maria
   Marchese, Enrico
   Pedicelli, Alessandro
   Olivi, Alessandro
   Ricciardi, Luca
   Rapisarda, Alessandro
   Skrap, Benjamin
   Sabatino, Giovanni
   La Rocca, Giuseppe
TI Contrast-Enhanced Ultrasonography and Color Doppler: Guided
   Intraoperative Embolization of Intracranial Highly Vascularized Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Color Doppler; Contrast-enhanced ultrasonography;
   Hemangioblastoma; Intraoperative embolization; Ultrasonography; Brain
   tumor; Color Doppler; Contrast-enhanced ultrasonography;
   Hemangioblastoma; Intraoperative embolization; Ultrasonography
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; DURAL ARTERIOVENOUS-FISTULAS;
   PREOPERATIVE EMBOLIZATION; EFSUMB GUIDELINES; CLINICAL-PRACTICE;
   ULTRASOUND CEUS; DIRECT PUNCTURE; HEMANGIOPERICYTOMA; RECOMMENDATIONS;
   RESECTION
AB BACKGROUND: Preoperative embolization is often considered mandatory in highly vascularized brain tumors to contain blood loss. However, not all lesions are amenable to endovascular preoperative embolization. In the literature, cases of preoperative and intraoperative embolization are described only by arterial catheterization, whereas experiences of tumor embolization through direct puncture of the lesion are anecdotal; furthermore these cases lack an intraoperative control method to assess the effects of the embolizing procedure itself.
   METHODS: We describe the association of contrast enhanced ultrasonography (CEUS) and color Doppler ultrasonography (CDUS) to perform intraoperative embolization in an illustrative case of a posterior cranial fossa hemangioblastoma not amenable to a preoperative endovascular procedure. The combination of CEUS and CDUS was tested as an option for the intraoperative devascularization of tumors in which preoperative embolization is considered risky or not possible.
   RESULTS: The association of CEUS and CDUS provided real-time intraoperative data that directly guided the intraoperative embolization and provided reliable data about the hemodynamic effects produced after the direct injection of an embolizing agent. The technique offered a true real-time definition of the anatomic characteristics of the lesion and its relationships with the adjacent structures while distinguishing feeding from draining vessels.
   CONCLUSIONS: This technique has been proved to be a valuable tool in the surgical resection of highly vascularized tumors and in the treatment of intracranial and spinal vascular lesions and can be considered an option in those cases in which preoperative embolization is not possible. It is a feasible, modern, and cost-effective intraoperative imaging technique that allows identification of unexposed anatomic structures, hence minimizing surgical exposition and surgical manipulation.
C1 [Della Pappa, Giuseppe Maria; Marchese, Enrico; Olivi, Alessandro; Ricciardi, Luca; Rapisarda, Alessandro; Skrap, Benjamin; Sabatino, Giovanni; La Rocca, Giuseppe] Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.
   [Pedicelli, Alessandro] Univ Cattolica Sacro Cuore, Inst Neuroradiol, Rome, Italy.
   [Sabatino, Giovanni; La Rocca, Giuseppe] Mater Olbia Hosp, Neurosurg Unit, Olbia, Italy.
RP Della Pappa, GM (reprint author), Univ Cattolica Sacro Cuore, Inst Neurosurg, Rome, Italy.
EM giuseppe.larocca@policlinicogemelli.it
RI Rapisarda, Alessandro/AAF-3354-2019; La Rocca, Giuseppe/AAG-3922-2019;
   Pedicelli, Alessandro/M-2542-2018; Ricciardi, Luca/L-5405-2019; Pepa,
   Giuseppe Maria Della/AAC-1697-2019; Marchese, Enrico/J-2448-2012
OI La Rocca, Giuseppe/0000-0003-1830-4849; Pedicelli,
   Alessandro/0000-0002-2558-8838; Ricciardi, Luca/0000-0001-5110-8386;
   Pepa, Giuseppe Maria Della/0000-0001-8698-3359; SABATINO,
   Giovanni/0000-0002-4227-0434; Marchese, Enrico/0000-0001-8551-0357
CR Acerbi F, 2019, WORLD NEUROSURG, V125, P277, DOI 10.1016/j.wneu.2019.01.241
   Acerbi F, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1862
   Akinduro OO, 2018, WORLD NEUROSURG, V109, P182, DOI 10.1016/j.wneu.2017.09.147
   Ampie L, 2016, CLIN NEUROL NEUROSUR, V150, P143, DOI 10.1016/j.clineuro.2016.09.008
   Ampie L, 2016, J CLIN NEUROSCI, V24, P83, DOI 10.1016/j.jocn.2015.09.006
   Anderson Ian, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-205736
   Caroff J, 2017, J NEUROINTERV SURG, V9, P787, DOI 10.1136/neurintsurg-2017-012979
   Del Bene M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00576
   Della Pepa GM, 2018, ACTA NEUROCHIR, V160, P1873, DOI 10.1007/s00701-018-3628-3
   Della Pepa GM, 2018, ACTA NEUROCHIR, V160, P1259, DOI 10.1007/s00701-018-3541-9
   Della Pepa GM, 2018, WORLD NEUROSURG, V112, P138, DOI 10.1016/j.wneu.2018.01.101
   Della Pepa GM, 2017, NEUROSURGERY, V81, P315, DOI 10.1093/neuros/nyw175
   Della Pepa GM, 2011, ACTA NEUROCHIR, V153, P2255, DOI 10.1007/s00701-011-1113-3
   Ding D, 2013, INTERV NEURORADIOL, V19, P466, DOI 10.1177/159101991301900410
   Giovanni S, 2014, CLIN NEUROL NEUROSUR, V123, P50, DOI 10.1016/j.clineuro.2014.05.005
   Hao SY, 2013, J CLIN NEUROSCI, V20, P1269, DOI 10.1016/j.jocn.2012.12.008
   Ilunga-Mbuyamba E, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16040497
   Jung GS, 2016, CHILD NERV SYST, V32, P717, DOI 10.1007/s00381-015-2915-z
   Lekht I, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15570
   Lonser RR, 1998, J NEUROSURG, V88, P923, DOI 10.3171/jns.1998.88.5.0923
   Massimiliano V, 2015, INT J SURG CASE REP, V15, P57, DOI [10.1016/j.ijscr.2015.06.032, 10.1016/j.ijscr.2015.08.032]
   Prada F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18101
   Prada F, 2017, WORLD NEUROSURG, V100, DOI 10.1016/j.wneu.2017.01.045
   Prada F, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15573
   Prada F, 2015, BIOMED RES INT, DOI 10.1155/2015/925729
   Prada F, 2014, BIOMED RES INT, DOI 10.1155/2014/484261
   Prada F, 2014, NEUROSURGERY, V74, P542, DOI 10.1227/NEU.0000000000000301
   Ryttlefors M, 2016, J NEUROL SURG PART A, V77, P361, DOI 10.1055/s-0035-1551823
   Sabatino G, 2014, CLIN NEUROL NEUROSUR, V116, P20, DOI 10.1016/j.clineuro.2013.11.010
   Saliou G, 2017, NEUROCHIRURGIE, V63, P372, DOI 10.1016/j.neuchi.2016.01.004
   Scerrati A, 2014, CLIN NEUROL NEUROSUR, V124, P106, DOI 10.1016/j.clineuro.2014.06.032
   Sidhu PS, 2018, ULTRASCHALL MED, V39, pE2, DOI 10.1055/a-0586-1107
   Sidhu PS, 2018, ULTRASCHALL MED, V39, P154, DOI 10.1055/s-0044-101254
   Signorelli F, 2015, CLIN NEUROL NEUROSUR, V128, P123, DOI 10.1016/j.clineuro.2014.11.011
   Sultan A, 2016, INTERV NEURORADIOL, V22, P482, DOI 10.1177/1591019916633244
   Takeshima Y, 2015, EUR SPINE J, V24, pS585, DOI 10.1007/s00586-014-3755-3
   Tamura Y, 2012, ACTA NEUROCHIR, V154, P1407, DOI 10.1007/s00701-012-1421-2
   Yanez N, 2017, SURG NEUROL INT, V8, P164
NR 38
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 547
EP 555
DI 10.1016/j.wneu.2019.05.142
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100231
PM 31132498
DA 2020-05-12
ER

PT J
AU Pasini, A
   Donati, R
   Bramanti, B
   Salzni, L
   Gualdi-Russo, E
AF Pasini, Alba
   Donati, Roberta
   Bramanti, Barbara
   Salzni, Luciano
   Gualdi-Russo, Emanuela
TI New Evidence of Prehistoric Neurosurgery in Italy: The Case of Castello
   Del Tartaro
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deviant burial; Head injury; Italy; Neurosurgery; Prone burial; Recent
   Bronze Age; Trepanation
ID BRONZE-AGE; CRANIAL TREPANATION; SKULL; DEVIANCY
AB Archaeological evidence of trepanation during the European Bronze Age is numerous and testifies a wide application of neurosurgical practices during prehistory. In some particular cases, trepanation may be associated with other peculiar evidence concerning funerary practices. The aim of this paper is to present the case of a woman from the Recent Bronze Age site of Castello del Tartaro (Verona, Italy), who was buried in a prone position and whose skeletal remains presented evidence of probable frontal trepanation. The association between a deviant burial and trepanation could be of interest in better understanding the history and perception of neurosurgical practices during prehistory.
C1 [Pasini, Alba; Donati, Roberta; Bramanti, Barbara; Gualdi-Russo, Emanuela] Univ Ferrara, Dept Biomed & Specialty Surg Sci, Ferrara, Italy.
   [Salzni, Luciano] Superintendence Archaeol Heritage Veneto, Padua, Italy.
RP Bramanti, B (reprint author), Univ Ferrara, Dept Biomed & Specialty Surg Sci, Ferrara, Italy.
EM brmbbr@unife.it
RI Bramanti, Barbara/AAF-8542-2019
OI Bramanti, Barbara/0000-0002-5433-663X; Pasini, Alba/0000-0002-1658-7112
CR Acsadi Gy., 1970, HIST HUMAN LIFE SPAN
   Alusik T, 2015, WORLD NEUROSURG, V84, P214, DOI 10.1016/j.wneu.2015.02.010
   [Anonymous], 1980, J HUM EVOL, V9, P517
   Arcini C, 2009, CURRENT ARCHAEOLOGY, P30
   Arnott R., 2003, TREPANATION HIST DIS
   Aspock E., 2008, DEVIANT BURIAL ARCHA, P17
   Baggieri G, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P137
   Baggieri G, 2004, PALEOPATHOLOGY NEWSL, V125, P9
   Barbian LT, 2008, J FORENSIC SCI, V53, P263, DOI 10.1111/j.1556-4029.2007.00651.x
   Blake MR, 1918, J CTY LOUTH ARCHAEOL, V4, P217
   Brothwell Don R., 1981, DIGGING BONES EXCAVA
   Buikstra J, 1994, STANDARDS DATA COLLE
   Capasso L, 2002, LANCET, V359, P2206, DOI 10.1016/S0140-6736(02)09084-0
   Castillo-Robles J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33746-8
   Charlier P, 2014, ACTA MED-HIST ADRIAT, V12, P315
   de Divitiis E, 2013, WORLD NEUROSURG, V80, P821, DOI 10.1016/j.wneu.2013.01.069
   De Marinis R., 2003, NOTIZIE ARCHEOLOGICH, V11, P5
   de Pennery P., 1964, B SOC PREHISTORIQUE, V61, P124
   Donnabhain BO, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P79
   Erdal YS, 2011, INT J OSTEOARCHAEOL, V21, P505, DOI 10.1002/oa.1154
   Facchini E, 2003, HOMO, V53, P247, DOI 10.1078/0018-442X-00047
   Forte M., 1994, BOLOGNESE LOWLAND VI, P193
   Gardela L., 2015, ANALECTA ARCHAEO LOG, V10, P99
   Germana F, 1994, PREHISTORY LOWER BEL, P411
   Giot P-R, 1949, B MEM SOC ANTHRO PAR, V10, P59
   Giuffra V, 2017, INT J OSTEOARCHAEOL, V27, P745, DOI 10.1002/oa.2591
   Giuffra V, 2015, J ETHNOPHARMACOL, V160, P133, DOI 10.1016/j.jep.2014.11.042
   Goodrich JT, 2014, WORLD NEUROSURG, V81, P296, DOI 10.1016/j.wneu.2013.02.047
   Gross CG, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P307
   Guinto G, 2014, WORLD NEUROSURG, V81, P298, DOI 10.1016/j.wneu.2013.02.048
   Holck P., 1997, CREMATED BONES MED A, V1, P61
   Kimmerle EH, 2008, SKELETAL TRAUMA: IDENTIFICATION OF INJURIES RESULTING FROM HUMAN RIGHTS ABUSE AND ARMED CONFLICT, P1, DOI 10.1201/9781420009118
   Kirkup J, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P289
   Kushner DS, 2018, WORLD NEUROSURG, V114, P245, DOI [10.1016/J.WNEU.2018.03.143, 10.1016/j.wneu.2018.03.143]
   LOVEJOY CO, 1985, AM J PHYS ANTHROPOL, V68, P47, DOI 10.1002/ajpa.1330680105
   Lovell NC, 1997, YEARB PHYS ANTHROPOL, V40, P139
   Lv XL, 2013, WORLD NEUROSURG, V80, P897, DOI 10.1016/j.wneu.2012.08.009
   Mainardi S, 1994, BOLOGNESE LOWLAND VI, P213
   Malakootian M, 2019, INT J ENVIRON SCI TE, V16, P4275, DOI 10.1007/s13762-018-1836-2
   Gonzalez-Darder JM, 2017, NEUROCIRUGIA, V28, P28, DOI 10.1016/j.neucir.2016.04.003
   Martin G, 2003, TREPANATION: HISTORY, DISCOVERY, THEORY, P323
   Moghaddam N, 2015, INT J PALEOPATHOL, V11, P56, DOI 10.1016/j.ijpp.2015.08.002
   Mogliazza S, 2009, J ANTHROPOL SCI, V87, P187
   Moraitis K., 2006, FORENSIC SCI MED PAT, V2, P165
   Mountrakis C, 2011, MEDITERR ARCHAEOL AR, V11, P1
   Murphy E., 2008, DEVIANT BURIAL ARCHA
   Ortalli J., 2010, DEVIANT BURIALS ARCH, P23
   Ortner PJ, 2003, IDENTIFICATION PATHO
   Pancaldi P, 2010, DEVIANT BURIALS ARCH, P69
   Papagrigorakis MJ, 2014, WORLD NEUROSURG, V81, P431, DOI 10.1016/j.wneu.2013.01.044
   Pasini A, 2018, WORLD NEUROSURG, V113, P78, DOI 10.1016/j.wneu.2018.02.044
   Perego E, 2014, J MEDITERR ARCHAEOL, V27, P161, DOI 10.1558/jmea.v27i2.161
   Petrone P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124790
   Piombino-Mascali D, 2006, PREHISTORY NO ITALY, P555
   Riccomi G, 2017, WORLD NEUROSURG, V104, P9, DOI 10.1016/j.wneu.2017.04.160
   Roberts C, 2007, ARCHAEOLOGY DIS
   Salzani L, 2008, OPPEANO VECCHI NUOVI, P21
   Salzani L, 2015, STUDIES PREHISTORY E, P777
   Salzani L., 2005, BRONZE AGE NECROPOLI
   Saracino M, 2017, PREISTORIA ALPINA, V49, P73
   Sauer N., 1998, FORENSIC OSTEOLOGY A, P321
   Sauer NJ, 1984, HUMAN IDENTIFICATION, P177
   SHAY T, 1985, J ANTHROPOL ARCHAEOL, V4, P221, DOI 10.1016/0278-4165(85)90004-2
   Taylor A, 2008, DEVIANT BURIAL ARCHA, P91
   Tsoucalas G, 2017, WORLD NEUROSURG, V103, P501, DOI 10.1016/j.wneu.2017.04.022
   Tulumello G, 2018, WORLD NEUROSURG, V116, P116, DOI 10.1016/j.wneu.2018.05.058
   Ubelaker D.H., 1989, HUMAN SKELETAL REMAI
   Vasilyev SV, 2017, ACTA MED-HIST ADRIAT, V15, P67, DOI 10.31952/amha.15.1.4
   Verano JW, 2017, INT J PALEOPATHOL, V19, P111, DOI 10.1016/j.ijpp.2017.03.004
   Zamboni L, 2010, DEVIANT BURIALS ARCH, P147
NR 70
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 556
EP 561
DI 10.1016/j.wneu.2019.05.096
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100232
PM 31121362
DA 2020-05-12
ER

PT J
AU Attuati, L
   Zaed, I
   Morselli, C
   Pecchioli, G
   Fornari, M
   Picozzi, P
AF Attuati, Luca
   Zaed, Ismail
   Morselli, Carlotta
   Pecchioli, Guido
   Fornari, Maurizio
   Picozzi, Piero
TI Multimodal Management of Metastatic Malignant Meningiomas: The Role of
   Radiosurgery in Long-Term Local Control
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical meningiomas; Extracranial metastasis; Gamma Knife radiosurgery;
   Local recurrence; Malignant meningioma; Metastatic meningioma
ID INTRACRANIAL ANAPLASTIC MENINGIOMA; MULTIPLE PULMONARY METASTASES; GRADE
   2 MENINGIOMA; EXTRACRANIAL METASTASES; ATYPICAL MENINGIOMA; PLEURAL
   METASTASIS; BONE METASTASES; LUNG METASTASES; RECURRENT; RESECTION
AB BACKGROUND: Metastatic meningiomas (MMs) are rare (0.1 of 100 cases). Their treatment requires a multimodal approach, with surgery, radiotherapy, chemotherapy, and radiosurgery, which allows a long-term local control (LC) and an extension of free survival. In this study, the authors performed a review of the literature and reported 2 cases of patients affected by extracranial MMs, with long-term follow-up.
   CASE DESCRIPTION: Case 1: A 48-year-old woman was admitted for resection of an extra-axial falx lesion (meningioma G1). After 2 years, the lesion got a local recurrence, resected with a histologic diagnosis of meningioma G3. During the next 9 years, the patient underwent 5 Gamma Knife radiosurgery (GKRS) procedures for local recurrence. At 56 years, she was readmitted for a surgical local recurrence (histologic definition: anaplastic meningioma G3). At the age of 62, the patient underwent a right lobectomy for a lung mass (histologic diagnosis: anaplastic meningioma G3). After that, multiple lesions at soma L5 and adrenal gland were discovered and then monitored. Case 2: A 48-year-old woman was operated for a lesion involving torcular herophili (meningioma G2). After 3 years, a local recurrence requires GKRS combined with tamoxifen. In the next 7 years, she underwent 5 GKRS procedures for local recurrence. The patient also underwent chemotherapy with octreotide. At the age of 61, she discovered multiple lesions in both lungs, liver, and kidney. A hepatic biopsy showed anaplastic meningioma G3. Also this patient does not suffer from any neurologic or clinical deficits.
   CONCLUSIONS: LC in malignant meningioma is achievable through a multimodal approach; GKRS makes possible LC, but a novel aspect of these lesions is opened to discussion: the metastases. These reports show that multimodal treatment for MMs is an effective approach with good LC and improvement of overall survival. However, a long survival may allow systemic diffusion of the disease, in particular, when sagittal sinus is involved.
C1 [Attuati, Luca; Zaed, Ismail; Fornari, Maurizio; Picozzi, Piero] IRCCS Humanitas Clin & Res Hosp, Funct Radiosurg & Gamma Knife Unit, Dept Neurosurg, Milan, Italy.
   [Morselli, Carlotta] Sapienza Univ Rome, 0Epartment Neurosci, Rome, Italy.
   [Pecchioli, Guido] Azienda Osped Careggi, Dept Neurosurg, Florence, Italy.
RP Zaed, I (reprint author), IRCCS Humanitas Clin & Res Hosp, Funct Radiosurg & Gamma Knife Unit, Dept Neurosurg, Milan, Italy.
EM ismailzaed1@gmail.com
RI Zaed, Ismail/AAF-3433-2019
OI zaed, ismail/0000-0003-3506-4111; Attuati, Luca/0000-0002-4163-1779
CR Adlakha A, 1999, MAYO CLIN PROC, V74, P1129, DOI 10.4065/74.11.1129
   Alexandru D, 2011, CANCER-AM CANCER SOC, V117, P4506, DOI 10.1002/cncr.26065
   Asioli S, 2007, VIRCHOWS ARCH, V450, P591, DOI 10.1007/s00428-007-0392-9
   Baeesa SS, 2018, WORLD NEUROSURG, V120, P274, DOI 10.1016/j.wneu.2018.09.004
   Baisden BL, 1999, DIAGN CYTOPATHOL, V20, P291, DOI 10.1002/(SICI)1097-0339(199905)20:5<291::AID-DC8>3.0.CO;2-R
   Bhanusali DG, 2018, CUTIS, V101, P386
   Bloss HG, 2010, ACTA NEUROCHIR, V152, P99, DOI 10.1007/s00701-009-0556-2
   Boskos C, 2009, INT J RADIAT ONCOL, V75, P399, DOI 10.1016/j.ijrobp.2008.10.053
   Brennan C, 2010, BRIT J RADIOL, V83, pE259, DOI 10.1259/bjr/11276652
   CELLI P, 1992, NEUROSURGERY, V31, P1113, DOI 10.1227/00006123-199212000-00020
   Cerda-Nicolas M, 2003, J NEUROSURG, V98, P194, DOI 10.3171/jns.2003.98.1.0194
   Cho BR, 2017, BRIT J NEUROSURG, V31, P276, DOI 10.1080/02688697.2016.1244253
   Chohan MO, 2018, NEUROSURGERY, V82, P824, DOI 10.1093/neuros/nyx312
   Chua FHZ, 2016, J CLIN NEUROSCI, V33, P214, DOI 10.1016/j.jocn.2016.01.038
   Corniola Marco V, 2017, J Neurol Surg Rep, V78, pe129, DOI 10.1055/s-0037-1615808
   D'Aiuto M, 2005, ANN THORAC SURG, V80, P1129, DOI 10.1016/j.athoracsur.2004.02.146
   Dogan S, 2004, ZBL NEUROCHIR, V65, P141, DOI 10.1055/s-2004-816241
   Drummond KJ, 2000, J CLIN NEUROSCI, V7, P69, DOI 10.1054/jocn.1998.0153
   Du YR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0291-2
   Erman T, 2005, J NEURO-ONCOL, V74, P179, DOI 10.1007/s11060-004-3014-2
   Estanislau ES, 2009, ARQ NEURO-PSIQUIAT, V67, P730, DOI 10.1590/S0004-282X2009000400036
   Etienne-Mastroianni B, 2010, REV MAL RESPIR, V27, P764, DOI 10.1016/j.rmr.2010.06.017
   Fabi A, 2006, ANTICANCER RES, V26, P3835
   Figueroa BE, 1999, BRIT J RADIOL, V72, P513, DOI 10.1259/bjr.72.857.10505022
   Frydrychowicz C, 2015, NEUROPATHOLOGY, V35, P175, DOI 10.1111/neup.12177
   Fulkerson DH, 2008, CLIN NEUROL NEUROSUR, V110, P416, DOI 10.1016/j.clineuro.2007.12.025
   Gladin CR, 2007, J NEURO-ONCOL, V85, P81, DOI 10.1007/s11060-007-9386-3
   Hanakita S, 2013, J NEUROSURG, V119, P1410, DOI 10.3171/2013.8.JNS13343
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   HISHIMA T, 1995, PATHOL INT, V45, P617, DOI 10.1111/j.1440-1827.1995.tb03512.x
   Honda Y, 2017, MOL CLIN ONCOL, V7, P633, DOI 10.3892/mco.2017.1375
   Hutchins EB, 2004, CLIN NUCL MED, V29, P587, DOI 10.1097/01.rlu.0000135270.71585.72
   Ishibashi Hironori, 2008, Kyobu Geka, V61, P478
   JAASKELAINEN J, 1986, SURG NEUROL, V25, P233, DOI 10.1016/0090-3019(86)90233-8
   Kakkar A, 2016, BRAIN TUMOR PATHOL, V33, P228, DOI 10.1007/s10014-016-0250-z
   Kaminski JM, 2001, AM J CLIN ONCOL-CANC, V24, P579, DOI 10.1097/00000421-200112000-00010
   Kanthan R, 2013, ANN CLIN PATHOL, V1, P1001
   Kanzaki R, 2011, SURG TODAY, V41, P995, DOI 10.1007/s00595-010-4409-7
   Kessler RA, 2017, WORLD NEUROSURG, V101, P47, DOI 10.1016/j.wneu.2017.01.070
   Knoop M, 2004, DEUT MED WOCHENSCHR, V129, P1854, DOI 10.1055/s-2004-831348
   Kok DL, 2018, J CLIN NEUROSCI, V58, P224, DOI 10.1016/j.jocn.2018.09.005
   Kokubo M, 2000, J NEURO-ONCOL, V48, P51, DOI 10.1023/A:1006430102406
   Kovoor Jerry M E, 2002, Australas Radiol, V46, P65, DOI 10.1046/j.1440-1673.2002.00996.x
   Lambertz N, 2011, CLIN NEUROL NEUROSUR, V113, P592, DOI 10.1016/j.clineuro.2011.02.017
   Lanfranchi M, 2013, CLIN NUCL MED, V38, P668, DOI 10.1097/RLU.0b013e31829962ac
   Lee GC, 2009, J KOREAN NEUROSURG S, V45, P107, DOI 10.3340/jkns.2009.45.2.107
   Leemans J, 2016, ACTA CLIN BELG, V71, P107, DOI 10.1080/17843286.2015.1133002
   Ma J, 2014, WORLD NEUROSURG, V82, P757, DOI 10.1016/j.wneu.2014.05.026
   Mathiesen T, 2014, WORLD NEUROSURG, V81, P116, DOI 10.1016/j.wneu.2013.01.095
   Mindermann T, 2017, ACTA NEUROCHIR, V159, P2401, DOI 10.1007/s00701-017-3353-3
   Mukherjee Debraj, 2018, Asian J Neurosurg, V13, P98, DOI 10.4103/1793-5482.185057
   Murrah CP, 1996, ANN THORAC SURG, V61, P1823, DOI 10.1016/0003-4975(96)00064-1
   Nakaya M, 2019, J NEUROL SURG PART A, V80, P127, DOI 10.1055/s-0038-1669471
   Nakayama Y, 2014, ANN THORAC CARDIOVAS, V20, P410, DOI 10.5761/atcs.cr.11.01852
   Nanda A, 2016, J CLIN NEUROSCI, V31, P112, DOI 10.1016/j.jocn.2016.02.021
   Nishida N, 2016, J SPINAL CORD MED, V39, P484, DOI 10.1179/2045772315Y.0000000005
   Noel G, 2001, Cancer Radiother, V5, P217, DOI 10.1016/S1278-3218(01)00103-2
   Ocque R, 2014, ACTA CYTOL, V58, P1, DOI 10.1159/000355284
   OHTA M, 1994, CANCER, V74, P3176, DOI 10.1002/1097-0142(19941215)74:12<3176::AID-CNCR2820741217>3.0.CO;2-N
   Paix A, 2017, CANCER RADIOTHER, V21, P55, DOI 10.1016/j.canrad.2016.09.012
   Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M
   Press RH, 2014, INT J RADIAT ONCOL, V88, P1004, DOI 10.1016/j.ijrobp.2013.12.037
   Psaras T, 2009, CLIN NEUROPATHOL, V28, P453
   RAWAT B, 1995, NEURORADIOLOGY, V37, P38, DOI 10.1007/BF00588517
   Sabet A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-94
   SHUANGSHOTI S, 1970, CANCER-AM CANCER SOC, V26, P832, DOI 10.1002/1097-0142(197010)26:4<832::AID-CNCR2820260416>3.0.CO;2-S
   Surov A, 2013, J NEURO-ONCOL, V112, P323, DOI 10.1007/s11060-013-1074-x
   Taieb G, 2011, ARCH NEUROL-CHICAGO, V68, P388, DOI 10.1001/archneurol.2011.28
   TAYLOR BW, 1988, INT J RADIAT ONCOL, V15, P299, DOI 10.1016/S0360-3016(98)90008-6
   Teague SD, 2005, J THORAC IMAG, V20, P58, DOI 10.1097/01.rti.0000139388.80395.6e
   Teague SD, 2006, PET CLIN, V1, P289, DOI 10.1016/j.cpet.2006.09.004
   Thomas RZ, 2017, BJR CASE REP, V3, DOI 10.1259/bjrcr.20150092
   Travitzky M, 2003, ANTI-CANCER DRUG, V14, P247, DOI 10.1097/00001813-200303000-00009
   Vik Anne, 2006, Tidsskr Nor Laegeforen, V126, P2386
   Wang M, 2016, J INT MED RES, V44, P742, DOI 10.1177/0300060515618053
   Wang WH, 2016, WORLD NEUROSURG, V87, P557, DOI 10.1016/j.wneu.2015.10.021
   Yekeler Ensar, 2005, Diagn Interv Radiol, V11, P28
NR 77
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 562
EP 572
DI 10.1016/j.wneu.2019.05.058
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100233
PM 31102770
DA 2020-05-12
ER

EF